FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Vercruysse, T
   Boons, E
   Venken, T
   Vanstreels, E
   Voet, A
   Steyaert, J
   De Maeyer, M
   Daelemans, D
AF Vercruysse, Thomas
   Boons, Eline
   Venken, Tom
   Vanstreels, Els
   Voet, Arnout
   Steyaert, Jan
   De Maeyer, Marc
   Daelemans, Dirk
TI Mapping the Binding Interface between an HIV-1 Inhibiting Intrabody and
   the Viral Protein Rev
SO PLOS ONE
LA English
DT Article
ID RESONANCE ENERGY-TRANSFER; SMALL-MOLECULE INHIBITORS; NUCLEAR EXPORT;
   RESPONSE ELEMENT; TRANS-ACTIVATOR; IN-VIVO; HUMAN ASTROCYTES; TARGET
   SEQUENCE; GENE-EXPRESSION; RNA HELICASE
AB HIV-1 Rev is the key protein in the nucleocytoplasmic export and expression of the late viral mRNAs. An important aspect for its function is its ability to multimerize on these mRNAs. We have recently identified a llama single-domain antibody (Nb-190) as the first inhibitor targeting the Rev multimerization function in cells. This nanobody is a potent intracellular antibody that efficiently inhibits HIV-1 viral production. In order to gain insight into the Nb-190-Rev interaction interface, we performed mutational and docking studies to map the interface between the nanobody paratope and the Rev epitope. Alanine mutants of the hyper-variable domains of Nb-190 and the Rev multimerization domains were evaluated in different assays measuring Nb-190-Rev interaction or viral production. Seven residues within Nb-190 and five Rev residues are demonstrated to be crucial for epitope recognition. These experimental data were used to perform docking experiments and map the Nb-190-Rev structural interface. This Nb-190-Rev interaction model can guide further studies of the Nb-190 effect on HIV-1 Rev function and could serve as starting point for the rational development of smaller entities binding to the Nb190 epitope, aimed at interfering with protein-protein interactions of the Rev N-terminal domain.
C1 [Vercruysse, Thomas; Boons, Eline; Vanstreels, Els; Daelemans, Dirk] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.
   [Venken, Tom; Voet, Arnout; De Maeyer, Marc] Katholieke Univ Leuven, Dept Chem, Div Biochem Mol & Struct Biol, Louvain, Belgium.
   [Steyaert, Jan] Vrije Univ Brussel, Dept Mol Interact, Struct Biol Brussel Lab, Brussels, Belgium.
RP Daelemans, D (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.
EM dirk.daelemans@rega.kuleuven.be
RI Steyaert, Jan/H-4662-2011; Daelemans, Dirk/P-7923-2017
OI Steyaert, Jan/0000-0002-3825-874X; Daelemans, Dirk/0000-0001-7092-1153;
   voet, arnout/0000-0002-3329-2703
FU 'Instituut voor de Aanmoediging van Innovatie door Wetenschap en
   Technologie' (IWT); research council of the K.U. Leuven; 'Fonds voor
   Wetenschappelijk Onderzoek Vlaanderen' (FWO) [1.5.104.07, 1.5.165.10];
   Belgian Government under the framework of the Interuniversity Attraction
   Poles [I.A.P. P6/19]; K.U. Leuven Impulsfinanciering
FX Eline Boons was funded by a Ph.D grant of the 'Instituut voor de
   Aanmoediging van Innovatie door Wetenschap en Technologie' (IWT)
   (www.iwt.be). Tom Venken and Arnout Voet thank the research council of
   the K.U. Leuven for financial support. This work was further supported
   by the 'Fonds voor Wetenschappelijk Onderzoek Vlaanderen' (FWO) (grant
   1.5.104.07 and 1.5.165.10) (www.fwo.be), the Belgian Government under
   the framework of the Interuniversity Attraction Poles (I.A.P. P6/19),
   and the 'K.U. Leuven Impulsfinanciering'. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399
   AUER M, 1994, BIOCHEMISTRY-US, V33, P2988, DOI 10.1021/bi00176a031
   Christ F, 2010, NAT CHEM BIOL, V6, P442, DOI 10.1038/nchembio.370
   Costes SV, 2004, BIOPHYS J, V86, P3993, DOI 10.1529/biophysi.103.038422
   Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005
   Daelemans D, 2004, J BIOL CHEM, V279, P50167, DOI 10.1074/jbc.M407713200
   Daelemans D, 2002, P NATL ACAD SCI USA, V99, P14440, DOI 10.1073/pnas.212285299
   Daelemans D, 2006, CURR OPIN HIV AIDS, V1, P388, DOI 10.1097/01.COH.0000239851.22614.6a
   DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0
   Daugherty MD, 2008, MOL CELL, V31, P824, DOI 10.1016/j.molcel.2008.07.016
   Daugherty MD, 2010, NAT STRUCT MOL BIOL, V17, P1337, DOI 10.1038/nsmb.1902
   DiMattia MA, 2010, P NATL ACAD SCI USA, V107, P5810, DOI 10.1073/pnas.0914946107
   Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Fang JH, 2005, VIROLOGY, V336, P299, DOI 10.1016/j.virol.2005.03.017
   Fang JH, 2004, VIROLOGY, V330, P471, DOI 10.1016/j.virol.2004.09.039
   FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0
   Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2
   Fukuda M, 1997, NATURE, V390, P308
   Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Jain C, 2001, MOL CELL, V7, P603, DOI 10.1016/S1097-2765(01)00207-6
   JARVIS RA, 1973, IEEE T COMPUT, VC-22, P1025, DOI 10.1109/T-C.1973.223640                                                         
   KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436                                                          
   KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773
   Labute P, 2008, J COMPUT CHEM, V29, P1693, DOI 10.1002/jcc.20933
   Lefranc Marie-Paule, 2004, Methods Mol Biol, V248, P27
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Ludwig E, 1999, J VIROL, V73, P8279
   MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9                                                    
   MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488
   McNally JG, 2008, METHOD CELL BIOL, V85, P329, DOI 10.1016/S0091-679X(08)85014-5
   MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538
   NEUMANN M, 1995, J VIROL, V69, P2159
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s                                                               
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   Robertson-Anderson RM, 2011, J MOL BIOL, V410, P959, DOI 10.1016/j.jmb.2011.04.026
   Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723
   Van Neck T, 2008, BIOORGAN MED CHEM, V16, P9487, DOI 10.1016/j.bmc.2008.09.051
   Venken T, COMPUTATIONAL UNPUB
   Vercruysse T, 2011, RNA BIOL, V8, P316, DOI 10.4161/rna.8.2.13782
   Vercruysse T, 2010, J BIOL CHEM, V285, P21768, DOI 10.1074/jbc.M110.112490
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029                                                      
   Yin H, 2005, ANGEW CHEM INT EDIT, V44, P4130, DOI 10.1002/anie.200461786
   Zheng CH, 2007, BIOORGAN MED CHEM, V15, P6407, DOI 10.1016/j.bmc.2007.06.052
NR 50
TC 9
Z9 9
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2013
VL 8
IS 4
AR e60259
DI 10.1371/journal.pone.0060259
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 127RY
UT WOS:000317717300082
PM 23565213
OA gold
DA 2018-01-05
ER

PT J
AU Sagar, V
   Pilakka-Kanthikeel, SK
   Priestap, H
   Atluri, VSR
   Ding, H
   Guduru, R
   Khizroev, S
   Nair, MP
AF Sagar, Vidya
   Pilakka-Kanthikeel, S. K.
   Priestap, H.
   Atluri, V. S. R.
   Ding, H.
   Guduru, R.
   Khizroev, S.
   Nair, M. P.
TI MAGNETIC-NANO FORMULATION OF M-OPIOID RECEPTOR ANTAGONIST (CTOP) FOR
   TREATMENT OF MORPHINE-INDUCED NEUROPATHOGENESIS IN HIV INFECTION
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Sagar, Vidya; Pilakka-Kanthikeel, S. K.; Atluri, V. S. R.; Ding, H.; Guduru, R.; Khizroev, S.; Nair, M. P.] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Inst Neuroimmune Pharmacol,Dept Immunol, Miami, FL 33199 USA.
   [Priestap, H.] Florida Int Univ, Coll Arts & Sci, Dept Biol Sci, Miami, FL 33199 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2013
VL 8
IS 2
BP 432
EP 433
PG 2
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 163CA
UT WOS:000320312000150
DA 2018-01-05
ER

PT J
AU Nair, M
   Guduru, R
   Liang, P
   Hong, JM
   Sagar, V
   Khizroev, S
AF Nair, Madhavan
   Guduru, Rakesh
   Liang, Ping
   Hong, Jeongmin
   Sagar, Vidya
   Khizroev, Sakhrat
TI Externally controlled on-demand release of anti-HIV drug using
   magneto-electric nanoparticles as carriers
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; MAGNETIC NANOPARTICLES; DELIVERY; LIPOSOMES
AB Although highly active anti-retroviral therapy has resulted in remarkable decline in the morbidity and mortality in AIDS patients, inadequately low delivery of anti-retroviral drugs across the blood-brain barrier results in virus persistence. The capability of high-efficacy-targeted drug delivery and on-demand release remains a formidable task. Here we report an in vitro study to demonstrate the on-demand release of azidothymidine 5'-triphosphate, an anti-human immunodeficiency virus drug, from 30nm CoFe2O4@BaTiO3 magneto-electric nanoparticles by applying a low alternating current magnetic field. Magneto-electric nanoparticles as field-controlled drug carriers offer a unique capability of field-triggered release after crossing the blood-brain barrier. Owing to the intrinsic magnetoelectricity, these nanoparticles can couple external magnetic fields with the electric forces in drug-carrier bonds to enable remotely controlled delivery without exploiting heat. Functional and structural integrity of the drug after the release was confirmed in in vitro experiments with human immunodeficiency virus-infected cells and through atomic force microscopy, spectrophotometry, Fourier transform infrared and mass spectrometry studies.
C1 [Nair, Madhavan; Guduru, Rakesh; Hong, Jeongmin; Sagar, Vidya; Khizroev, Sakhrat] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol, Miami, FL 33174 USA.
   [Liang, Ping; Khizroev, Sakhrat] Univ Calif Riverside, Dept Elect Engn, Riverside, CA 92521 USA.
RP Khizroev, S (reprint author), Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Dept Immunol, Miami, FL 33174 USA.
EM khizroev@fiu.edu
FU National Science Foundation [005084-002]; National Institute of Health
   DA [027049]; Department of Defense Defense Microelectronics Activity
   [H94003-09-2-0904]
FX We acknowledge partial financial support from National Science
   Foundation award no. 005084-002, National Institute of Health DA no.
   027049 and Department of Defense Defense Microelectronics Activity under
   contract no. H94003-09-2-0904. We thank Luis Arroyo for his help with
   NMR measurements.
CR AYRE SG, 1989, MED HYPOTHESES, V29, P283, DOI 10.1016/0306-9877(89)90113-8
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651
   Corral-Flores V, 2010, ACTA MATER, V58, P764, DOI 10.1016/j.actamat.2009.09.054
   Derfus AM, 2007, ADV MATER, V19, P3932, DOI 10.1002/adma.200700091
   Eerenstein W, 2006, NATURE, V442, P759, DOI 10.1038/nature05023
   Hoare T, 2009, NANO LETT, V9, P3651, DOI 10.1021/nl9018935
   Hong JM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00624
   Litvinov J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037440
   McBain SC, 2008, INT J NANOMED, V3, P169
   Mocroft A, 2004, J ANTIMICROB CHEMOTH, V54, P10, DOI 10.1093/jac/dkh290
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Rovers SA, 2012, SOFT MATTER, V8, P1623, DOI 10.1039/c2sm06557f
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saxena S. K., 2012, SCIENCE, V337, P789
   SENYEI A, 1978, J APPL PHYS, V49, P3578, DOI 10.1063/1.325219
   SZEBENI J, 1990, AIDS RES HUM RETROV, V6, P691, DOI 10.1089/aid.1990.6.691
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Timko BP, 2010, ADV MATER, V22, P4925, DOI 10.1002/adma.201002072
   Tong R, 2012, J AM CHEM SOC, V134, P8848, DOI 10.1021/ja211888a
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Wang XW, 2009, AM J PATHOL, V174, P771, DOI 10.2353/ajpath.2009.080157
   Xie SH, 2011, NANOSCALE, V3, P3152, DOI 10.1039/c1nr10288e
NR 24
TC 70
Z9 70
U1 5
U2 91
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2013
VL 4
AR 1707
DI 10.1038/ncomms2717
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 143MR
UT WOS:000318872100064
PM 23591874
OA gold
DA 2018-01-05
ER

PT J
AU Bell, IR
   Schwartz, GE
   Boyer, NN
   Koithan, M
   Brooks, AJ
AF Bell, Iris R.
   Schwartz, Gary E.
   Boyer, Nancy N.
   Koithan, Mary
   Brooks, Audrey J.
TI Advances in integrative nanomedicine for improving infectious disease
   treatment in public health
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Nanomedicine; Drug delivery systems; Medicinal plants; Herbal medicine;
   Antioxidants; Homeopathy; Nanoparticles; Silica; Infectious disease
   treatment; Adaptation; Network medicine
ID POLYMERIC NANOPARTICLE FORMULATION; TIME-DEPENDENT SENSITIZATION; POROUS
   SILICA NANOPARTICLES; INFLUENZA-LIKE SYNDROMES; WATER-SOLUBLE COMPOUNDS;
   LOW-LEVEL FORMALDEHYDE; DRUG-DELIVERY SYSTEMS; BOVINE SERUM-ALBUMIN;
   IN-VITRO; SILVER NANOPARTICLES
AB Introduction: Infectious diseases present public health challenges worldwide. An emerging integrative approach to treating infectious diseases is using nanoparticle (NP) forms of traditional and alternative medicines. Advantages of nanomedicine delivery methods include better disease targeting, especially for intracellular pathogens, ability to cross membranes and enter cells, longer duration drug action, reduced side effects, and cost savings from lower doses.
   Methods: We searched Pubmed articles in English with keywords related to nanoparticles and nanomedicine. Nanotechnology terms were also combined with keywords for drug delivery, infectious diseases, herbs, antioxidants, homeopathy, and adaptation.
   Results: NPs are very small forms of material substances, measuring 1-100 nm along at least one dimension. Compared with bulk forms, NPs' large ratio of surface-area-to-volume confers increased reactivity and adsorptive capacity, with unique electromagnetic, chemical, biological, and quantum properties. Nanotechnology uses natural botanical agents for green manufacturing of less toxic NPs.
   Discussion: Nanoparticle herbs and nutriceuticals can treat infections via improved bioavailability and antiinflammatory, antioxidant, and immunomodulatory effects. Recent studies demonstrate that homeopathic medicines may contain source and/or silica nanoparticles because of their traditional manufacturing processes. Homeopathy, as a form of nanomedicine, has a promising history of treating epidemic infectious diseases, including malaria, leptospirosis and HIV/AIDS, in addition to acute upper respiratory infections. Adaptive changes in the host's complex networks underlie effects.
   Conclusions: Nanomedicine is integrative, blending modern technology with natural products to reduce toxicity and support immune function. Nanomedicine using traditional agents from alternative systems of medicine can facilitate progress in integrative public health approaches to infectious diseases. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Bell, Iris R.; Koithan, Mary] Univ Arizona, Coll Med, Dept Family & Community Med, Tucson, AZ 85719 USA.
   [Bell, Iris R.; Schwartz, Gary E.] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85719 USA.
   [Bell, Iris R.; Schwartz, Gary E.; Brooks, Audrey J.] Univ Arizona, Dept Psychol, Tucson, AZ 85719 USA.
   [Bell, Iris R.; Koithan, Mary] Univ Arizona, Coll Nursing, Tucson, AZ 85719 USA.
   [Bell, Iris R.; Schwartz, Gary E.; Koithan, Mary; Brooks, Audrey J.] Univ Arizona, Coll Med, Dept Med Integrat Med, Tucson, AZ 85719 USA.
   [Bell, Iris R.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85719 USA.
RP Bell, IR (reprint author), Univ Arizona, Coll Med, Dept Family & Community Med, 1450 North Cherry Ave,MS 245052, Tucson, AZ 85719 USA.
EM ibell@email.arizona.edu
FU National Center for Complementary and Alternative Medicine grant [T32
   AT01287]
FX This study was supported in part by National Center for Complementary
   and Alternative Medicine grant T32 AT01287 (PI: IRB)
CR Abbasi AR, 2012, ULTRASON SONOCHEM, V19, P540, DOI 10.1016/j.ultsonch.2011.08.002
   Adair BM, 2009, WIRES NANOMED NANOBI, V1, P405, DOI [10.1002/wnan.45, 10.1002/wnan.045]
   Ahmad Zahoor, 2006, Indian J Chest Dis Allied Sci, V48, P171
   Ahmad Z, 2008, EXPERT OPIN DRUG DEL, V5, P1323, DOI 10.1517/17425240802600662 
   Aickin M, 2005, J ALTERN COMPLEM MED, V11, P755, DOI 10.1089/acm.2005.11.755                                                         
   Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Al-Jamal WT, 2011, ACCOUNTS CHEM RES, V44, P1094, DOI 10.1021/ar200105p
   Al-Sadoon MK, 2012, CELL PHYSIOL BIOCHEM, V30, P653, DOI 10.1159/000341446
   Almeida JPM, 2011, NANOMEDICINE-UK, V6, P815, DOI [10.2217/nnm.11.79, 10.2217/NNM.11.79]
   Ambrogio MW, 2011, ACCOUNTS CHEM RES, V44, P903, DOI 10.1021/ar200018x
   Anick DJ, 2007, HOMEOPATHY, V96, P189, DOI 10.1016/j.homp.2007.03.005
   Anitha A, J BIOMATERIALS SCI P
   ANTELMAN SM, 1991, BRAIN RES, V566, P276, DOI 10.1016/0006-8993(91)91709-A                                                    
   Antelman SM, 1996, CRIT REV NEUROBIOL, V10, P101, DOI 10.1615/CritRevNeurobiol.v10.i1.50                                              
   Antelman SM, 2000, MOL PSYCHIATR, V5, P350, DOI 10.1038/sj.mp.4000721                                                           
   Antoniades Charalambos, 2010, Current Drug Delivery, V7, P303, DOI 10.2174/156720110793360586
   Armstead AL, 2011, INT J NANOMED, V6, P3281, DOI 10.2147/IJN.S27285
   Asano H, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/33/334209
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Baca HK, 2011, BBA-GEN SUBJECTS, V1810, P259, DOI 10.1016/j.bbagen.2010.09.005
   Bansal SS, 2011, CANCER PREV RES, V4, P1158, DOI 10.1158/1940-6207.CAPR-10-0006
   Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Barik TK, 2008, PARASITOL RES, V103, P253, DOI 10.1007/s00436-008-0975-7
   Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186                                                        
   Beg Sarwar, 2010, Recent Pat Drug Deliv Formul, V4, P245
   Bell IR, 2002, ARCH INTERN MED, V162, P133, DOI 10.1001/archinte.162.2.133
   Bell IR, 2013, HOMEOPATHY IN PRESS
   Bell IR, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-191
   Bell Iris R, 2013, Front Biosci (Schol Ed), V5, P685
   Bell IR, 2012, J ALTERN COMPLEM MED, V18, P445, DOI 10.1089/acm.2011.0931
   Bell IR, 2012, FORSCH KOMPLEMENTMED, V19, P15, DOI 10.1159/000335183
   Bellavite P, 2007, EVID-BASED COMPL ALT, V4, P149, DOI 10.1093/ecam/nel117
   Bellavite Paolo, 2011, Front Biosci (Schol Ed), V3, P1363
   Belton DJ, 2012, FEBS J, V279, P1710, DOI 10.1111/j.1742-4658.2012.08531.x
   Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029
   Bhakta G, 2005, BIOMATERIALS, V26, P2157, DOI 10.1016/j.biomaterials.2004.06.039
   Bhakta G, 2009, J BIOMED NANOTECHNOL, V5, P106, DOI 10.1166/jbn.2009.029
   Bharali DJ, 2007, ADV EXP MED BIOL, V601, P415
   Bhattacharyya Soumya Sundar, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P546
   Bhattacharyya SS, 2010, EXP BIOL MED, V235, P678, DOI 10.1258/ebm.2010.009338
   Bhattacharyya SS, 2008, EXP BIOL MED, V233, P1591, DOI 10.3181/0805-RM-181
   Bhatti M, 2008, INT J CANCER, V122, P1155, DOI 10.1002/ijc.23206
   Bisht S, 2005, INT J PHARMACEUT, V288, P157, DOI 10.1016/j.ijpharm.2004.07.035
   Bisht S, 2011, LAB INVEST, V91, P1383, DOI 10.1038/labinvest.2011.86
   Boericke W, 1927, POCKET MANUAL HOMEOP
   Bornhoft G., 2011, HOMEOPATHY HEALTHCAR
   Boyapalle S, 2012, J GLOB INFECT DIS, V4, P62, DOI 10.4103/0974-777X.93764
   Bracho G, 2010, HOMEOPATHY, V99, P156, DOI 10.1016/j.homp.2010.05.009
   Bronstein AC, 2009, CLIN TOXICOL, V47, P911, DOI 10.3109/15563650903438566
   Brumovsky PR, 2010, AUTON NEUROSCI-BASIC, V153, P106, DOI 10.1016/j.autneu.2009.07.006
   Burnett ME, 2011, PHOTODERMATOL PHOTO, V27, P58, DOI 10.1111/j.1600-0781.2011.00557.x
   Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690
   Cai Z, 2010, CURR DRUG METAB, V11, P197, DOI 10.2174/138920010791110836                                                      
   Calabrese EJ, 2008, AGEING RES REV, V7, P8, DOI 10.1016/j.arr.2007.07.001
   Calabrese EJ, 2007, TOXICOL APPL PHARM, V222, P122, DOI 10.1016/j.taap.2007.02.015
   Calabrese Edward J, 2005, Environ Pollut, V138, P379, DOI 10.1016/j.envpol.2004.10.001
   Calabrese EJ, 2011, J CELL COMMUN SIGNAL, V5, P25, DOI 10.1007/s12079-011-0119-1
   Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P980, DOI 10.1177/0960327110383625
   Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P531, DOI 10.1177/0960327110369857
   Calabrese EJ, 2010, HUM EXP TOXICOL, V29, P249, DOI 10.1177/0960327109363973
   Calabrese V, 2010, CURR PHARM DESIGN, V16, P877, DOI 10.2174/138161210790883615
   Calabrese V, 2008, NEUROCHEM RES, V33, P2444, DOI 10.1007/s11064-008-9775-9
   Calabrese V, 2012, BBA-MOL BASIS DIS, V1822, P753, DOI 10.1016/j.bbadis.2011.11.002
   Calabrese V, 2011, MOL ASPECTS MED, V32, P279, DOI 10.1016/j.mam.2011.10.007
   Camacho AI, 2011, VACCINE, V29, P8222, DOI 10.1016/j.vaccine.2011.08.121
   Cao G., 2011, NANOSTRUCTURES NANOM
   Cao X, 2012, ACTA BIOMATER, V8, P2104, DOI 10.1016/j.actbio.2012.02.011
   Cardoso MAT, 2011, INT J PHARMACEUT, V414, P1, DOI 10.1016/j.ijpharm.2011.04.045
   Caron V, 2011, CARBOHYD RES, V346, P2622, DOI 10.1016/j.carres.2011.09.004
   Chadwick S, 2010, ADV DRUG DELIVER REV, V62, P394, DOI 10.1016/j.addr.2009.11.012
   Chifiriuc MC, 2012, NANOSCALE RES LETT, V7, P209, DOI DOI 10.1186/1556-276X-7-209
   Chikramane PS, 2012, LANGMUIR, V28, P15864, DOI 10.1021/la303477s
   Chikramane PS, 2010, HOMEOPATHY, V99, P231, DOI 10.1016/j.homp.2010.05.006
   Choi HJ, 2012, PHYTOTHER RES, V26, P462, DOI 10.1002/ptr.3529
   Chonpathompikunlert P, 2012, NANOMEDICINE-UK, V7, P1029, DOI [10.2217/NNM.12.2, 10.2217/nnm.12.2]
   Moreira COC, 2012, HOMEOPATHY, V101, P74, DOI 10.1016/j.homp.2011.09.001
   Csermely P, 2001, TRENDS GENET, V17, P701, DOI 10.1016/S0168-9525(01)02495-7
   Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007                                                      
   Csermely P, 2008, NOVART FDN SYMP, V291, P137
   Csermely P, 2008, NOVART FDN SYMP, V291, P8
   Csermely Peter, 2008, Novartis Found Symp, V291, P45
   da Silva ER, 2012, EXP PARASITOL, V130, P183, DOI 10.1016/j.exppara.2012.01.015
   Daisy P, 2012, INT J NANOMED, V7, P1189, DOI 10.2147/IJN.S26650
   Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019
   Danesh-Bahreini MA, 2011, INT J NANOMED, V6, P835, DOI 10.2147/IJN.S16805
   Das S, 2013, COLLOID SURFACE B, V101, P325, DOI 10.1016/j.colsurfb.2012.07.008
   Dave SR, 2009, WIRES NANOMED NANOBI, V1, P583, DOI 10.1002/wnan.51
   DAVIDSON J, 1994, BR HOMOEOPATH J, V83, P78
   Debbage P, 2009, CURR PHARM DESIGN, V15, P153, DOI 10.2174/138161209787002870                                                      
   De Castro CL, 2002, SYNTHESIS FUNCTIONAL, P1
   Demangeat JL, 2010, J MOL LIQ, V155, P71, DOI 10.1016/j.molliq.2010.05.010
   Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034
   Demirovic D, EXPT GERONTOLOGY
   Deonarain MP, 2011, INNOVATIONS PHARM TE, P56
   Devi V Kusum, 2010, Pharmacogn Rev, V4, P27, DOI 10.4103/0973-7847.65322
   Diwan Manish, 2004, Current Drug Delivery, V1, P405, DOI 10.2174/1567201043334597
   Duceppe N, 2010, EXPERT OPIN DRUG DEL, V7, P1191, DOI 10.1517/17425247.2010.514604
   Elenkov IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104
   Elia V, 2007, HOMEOPATHY, V96, P163, DOI 10.1016/j,homp.2007.05.007
   Fang IJ, 2012, METHOD ENZYMOL, V508, P41, DOI 10.1016/B978-0-12-391860-4.00003-3
   Felippi CC, 2012, J BIOMED NANOTECHNOL, V8, P316, DOI 10.1166/jbn.2012.1379
   FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x                                              
   Fisher P, 2005, LANCET, V366, P2082, DOI 10.1016/S0140-6736(05)67879-8                                                   
   Fisher Peter, 2012, Front Biosci (Elite Ed), V4, P1669
   Fonnebo V, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-7
   Friese KH, 1997, INT J CLIN PHARM TH, V35, P296
   Ganesan S, 2012, ANTIVIR RES, V94, P258, DOI 10.1016/j.antiviral.2012.03.005
   Ghosh D, 2012, CHEM-BIOL INTERACT, V195, P206, DOI 10.1016/j.cbi.2011.12.004
   Ghosh D, 2010, CHEM-BIOL INTERACT, V186, P61, DOI 10.1016/j.cbi.2010.03.048
   Ghosh S, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-17
   Glatthaar-Saalmuller B, 2007, CAN J PHYSIOL PHARM, V85, P1084, DOI 10.1139/Y07-100
   Gnanadesigan M, 2011, ASIAN PAC J TROP MED, V4, P799, DOI 10.1016/S1995-7645(11)60197-1
   Gross T, 2008, J R SOC INTERFACE, V5, P259, DOI 10.1098/rsif.2007.1229
   Gwinn MR, 2006, ENVIRON HEALTH PERSP, V114, P1818
   Hadrup N, 2012, NEUROTOXICOLOGY, V33, P416, DOI 10.1016/j.neuro.2012.04.008
   Hahnemann S., 1843, ORGANON MED ART
   Haidvogl M, 2007, BMC COMPLEM ALTERN M, V2, P7
   HALE HB, 1969, ENVIRON RES, V2, P423, DOI 10.1016/0013-9351(69)90013-9                                                    
   Han LM, 2012, FITOTERAPIA, V83, P721, DOI 10.1016/j.fitote.2012.02.014
   Harhaji L, 2007, EUR J PHARMACOL, V568, P89, DOI 10.1016/j.ejphar.2007.04.041
   He S, 2011, J MICROENCAPSUL, V28, P183, DOI 10.3109/02652048.2010.544419
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hossu M, 2010, J PHOTOCH PHOTOBIO B, V99, P44, DOI 10.1016/j.jphotobiol.2010.02.002
   Huang S, 2009, CURR DRUG METAB, V10, P905, DOI 10.2174/138920009790274603                                                      
   Huang S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/37/375102
   Hueber AJ, 2009, AUTOIMMUNITY, V42, P368, DOI 10.1080/08916930902832298
   Iavicoli I, 2010, DOSE-RESPONSE, V8, P501, DOI 10.2203/dose-response.10-016.Iavicoli
   Ive EC, 2012, INT J MOL SCI, V13, P3979, DOI 10.3390/ijms13033979
   Ives JA, 2010, HOMEOPATHY, V99, P229, DOI 10.1016/j.homp.2010.08.009
   Ives JA, 2010, HOMEOPATHY, V99, P15, DOI 10.1016/j.homp.2009.11.006
   Jain AK, 2011, CRIT REV THER DRUG, V28, P1
   Jia L, 2005, CURR NANOSCI, V1, P237, DOI 10.2174/157341305774642939                                                      
   Kaehr B, 2012, P NATL ACAD SCI USA, V109, P17336, DOI 10.1073/pnas.1205816109
   Karatsoreos IN, 2011, TRENDS COGN SCI, V15, P576, DOI 10.1016/j.tics.2011.10.005
   Karpukhin AV, 2011, CELL BIOL INT, V35, P727, DOI 10.1042/CBI20100548
   Kaul G, 2011, INDIAN J MICROBIOL, V51, P124, DOI 10.1007/s12088-011-0147-9
   Kayne SB, 2008, HOMEOPATHIC PRACTICE
   Keck CM, 2006, EUR J PHARM BIOPHARM, V62, P3, DOI 10.1016/j.ejpb.2005.05.009
   Keijzer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026684
   Kim TH, 2012, J BIOMED MATER RES A, V100A, P1033, DOI 10.1002/jbm.a.34053
   Koithan M, 2012, FORSCH KOMPLEMENTMED, V19, P7, DOI 10.1159/000335181
   Koufaki M, 2009, CURR MED CHEM, V16, P4728, DOI 10.2174/092986709789878274                                                      
   Lam R, 2008, ACS NANO, V2, P2095, DOI 10.1021/nn800465x
   Laroui H, 2012, METHOD ENZYMOL, V509, P101, DOI 10.1016/B978-0-12-391858-1.00006-X
   Launay JC, 2006, AVIAT SPACE ENVIR MD, V77, P1230
   Lee JE, 2011, ACCOUNTS CHEM RES, V44, P893, DOI 10.1021/ar2000259
   Li CM, 2012, TOXICOL LETT, V209, P277, DOI 10.1016/j.toxlet.2012.01.004
   Li HL, 2009, J CONTROL RELEASE, V133, P238, DOI 10.1016/j.jconrel.2008.10.002
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Lira-Salazar G, 2006, HOMEOPATHY, V95, P223, DOI 10.1016/j.homp.2006.06.003
   Liu L, 2012, J PHARM SCI-US, V101, P2952, DOI 10.1002/jps.23225
   Liu TL, 2011, BIOMATERIALS, V32, P1657, DOI 10.1016/j.biomaterials.2010.10.035
   Liu Y, 2007, PHYS REV LETT, V98, P1
   Liu Y, 2009, J NANOSCI NANOTECHNO, V9, P6335, DOI 10.1166/jnn.2009.1320
   Lopes CM, 2010, PHARMAZIE, V65, P75, DOI 10.1691/ph.2010.9338
   Ludtke R, 2008, J CLIN EPIDEMIOL, V61, P1197, DOI 10.1016/j.jclinepi.2008.06.015
   Mansour HM, 2009, INT J NANOMED, V4, P299
   Mattson MP, 2008, AGEING RES REV, V7, P1, DOI 10.1016/j.arr.2007.08.007
   Mattson Mark P, 2007, Dose Response, V5, P174, DOI 10.2203/dose-response.07-004.Mattson
   McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.07t
   McEwen Bruce S, 2006, Dialogues Clin Neurosci, V8, P367
   McMillan J, 2011, PROG MOL BIOL TRANSL, V104, P563, DOI 10.1016/B978-0-12-416020-0.00014-0
   Meng XD, 2012, PHARMAZIE, V67, P161, DOI 10.1691/ph.2012.1086
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Merisko-Liversidge E, 2011, ADV DRUG DELIVER REV, V63, P427, DOI 10.1016/j.addr.2010.12.007
   Mihalik A, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002187
   Milgrom L R, 2001, Br Homeopath J, V90, P5, DOI 10.1038/sj.bhj.5800457
   Miroliaee AE, 2011, TOXICOL MECH METHOD, V21, P200, DOI 10.3109/15376516.2010.547887
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Mohamed BM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-29
   Montagnier L, 2009, INTERDISCIP SCI, V1, P81, DOI 10.1007/s12539-009-0036-7
   Morganti P, 2012, J NUTR HEALTH AGING, V16, P242, DOI 10.1007/s12603-011-0358-0
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Nair HB, 2010, BIOCHEM PHARMACOL, V80, P1833, DOI 10.1016/j.bcp.2010.07.021
   Napierska D, 2009, SMALL, V5, P846, DOI 10.1002/smll.200800461
   Nascarella MA, 2012, DOSE-RESPONSE, V10, P344, DOI 10.2203/dose-response.10-025.Nascarella
   Naser B, 2005, EVID-BASED COMPL ALT, V2, P69, DOI 10.1093/ecam/neh065
   Neves AR, 2012, CURR MED CHEM, V19, P1663
   Nnamani PO, 2011, J VECTOR DIS, V48, P224
   Nowrouzi Azin, 2010, Iran Biomed J, V14, P23
   Nune SK, 2009, J MATER CHEM, V19, P2912, DOI 10.1039/b822015h
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Papp R, 1998, BR HOM J, V87, P69
   Park EJ, 2009, TOXICOL LETT, V184, P18, DOI 10.1016/j.toxlet.2008.10.012
   Passagne I, 2012, TOXICOLOGY, V299, P112, DOI 10.1016/j.tox.2012.05.010
   Pattekari P, 2011, PHYS CHEM CHEM PHYS, V13, P9014, DOI 10.1039/c0cp02549f
   Pereira WKV, 2005, J INFECTION, V51, P157, DOI 10.1016/j.jinf.2004.09.009
   Perry Carole C., 2009, V47, P295
   Perry CC, 1998, CHEM COMMUN, P2587, DOI 10.1039/a807404f                                                                
   Petrilli V, 2007, JOINT BONE SPINE, V74, P571, DOI 10.1016/j.jbspin.2007.04.004
   Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002
   Philip D, 2010, PHYSICA E, V42, P1417, DOI 10.1016/j.physe.2009.11.081
   Pincus D, 2010, NONLIN DYNAM PSYCHOL, V14, P353
   Prakash DJ, 2010, PHARMACOGN RES, V2, P330, DOI 10.4103/0974-8490.75450
   Priyadarshini KA, 2012, PARASITOL RES, V111, P997, DOI 10.1007/s00436-012-2924-8
   Raffa V, 2010, MINIM INVASIV THER, V19, P127, DOI 10.3109/13645706.2010.481095
   Rakel D, 2012, INTEGRATIVE MED
   Ramachandran C, 2007, J ALTERN COMPLEM MED, V13, P403, DOI 10.1089/acm.2007.6292
   Ramchandani Nita M, 2010, Complement Ther Clin Pract, V16, P101, DOI 10.1016/j.ctcp.2009.09.008
   Ranjan A, 2012, FEMS MICROBIOL LETT, V332, P1, DOI 10.1111/j.1574-6968.2012.02566.x
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Rao ML, 2007, HOMEOPATHY, V96, P175, DOI 10.1016/j.homp.2007.03.009
   Rattan SIS, 2010, HUM EXP TOXICOL, V29, P551, DOI 10.1177/0960327110369858
   Reis CP, 2012, METHOD ENZYMOL, V508, P271, DOI 10.1016/B978-0-12-391860-4.00014-8
   Relaix S, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.061705
   Roduner E, 2006, CHEM SOC REV, V35, P583, DOI 10.1039/b502142c
   Roeska Kerstin, 2010, J Immune Based Ther Vaccines, V8, P6, DOI 10.1186/1476-8518-8-6
   Ruan BL, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-127
   Sandhu A, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/44/442001
   Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024
   Sayes CM, 2006, TOXICOL SCI, V92, P174, DOI 10.1093/toxsci/kfj197
   Schmiedel V, 2006, EXPLORE-NY, V2, P109, DOI 10.1016/j.explore.2005.12.008
   Seaton A, 2010, J R SOC INTERFACE, V7, pS119, DOI 10.1098/rsif.2009.0252.focus
   Seleem MN, 2009, ANTIMICROB AGENTS CH, V53, P4270, DOI 10.1128/AAC.00815-09
   Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2                                                   
   SHERR J, 1997, DYNAMIC PROVINGS, V1
   Shi ZL, 2010, J BIOMATER APPL, V25, P19, DOI 10.1177/0885328209339396
   Singare DS, 2010, INT J PHARMACEUT, V402, P213, DOI 10.1016/j.ijpharm.2010.09.041
   Singh N, 2009, BIOMATERIALS, V30, P3891, DOI 10.1016/j.biomaterials.2009.04.009
   Singh SK, 2011, EUR J PHARM BIOPHARM, V78, P441, DOI 10.1016/j.ejpb.2011.03.014
   Sinha MN, 2012, HOMEOPATHY, V101, P5, DOI 10.1016/j.homp.2011.08.003
   Song L, 2012, COLLOID SURFACE B, V94, P341, DOI 10.1016/j.colsurfb.2012.02.011
   Song MY, 2012, ENVIRON SCI TECHNOL, V46, P3457, DOI 10.1021/es2039008
   Sonkaew P, 2012, J AGR FOOD CHEM, V60, P5388, DOI 10.1021/jf301311g
   Sorg BA, 2004, BRAIN RES, V1008, P11, DOI 10.1016/j.brainres.2004.02.015
   Sorg BA, 2001, ANN NY ACAD SCI, V933, P57
   Sorg BA, 2001, BRAIN RES, V898, P314, DOI 10.1016/S0006-8993(01)02208-9
   Stern S, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100147
   Szalay MS, 2007, FEBS LETT, V581, P3675, DOI 10.1016/j.1ebsiet.2007.03.083
   Tafaghodi M, 2011, PARASITOL RES, V108, P1265, DOI 10.1007/s00436-010-2176-4
   Tai W, 2011, MUCOSAL IMMUNOL, V4, P197, DOI 10.1038/mi.2010.50
   Tang CY, 2011, COLLOID SURFACE B, V86, P189, DOI 10.1016/j.colsurfb.2011.03.041
   Tang M, 2010, J NANOSCI NANOTECHNO, V10, P8575, DOI 10.1166/jnn.2010.2482
   Tiuman TS, 2011, INT J INFECT DIS, V15, pE525, DOI 10.1016/j.ijid.2011.03.021
   Trichard M, 2005, Homeopathy, V94, P3, DOI 10.1016/j.homp.2004.11.021
   Ulery BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017642
   Ullman D, 2003, J ALTERN COMPLEM MED, V9, P133, DOI 10.1089/107555303321223008
   Upadhyay RP, 2011, INT J HIGH DILUTION, V10, P299
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Vaiserman AM, 2011, AGEING RES REV, V10, P413, DOI 10.1016/j.arr.2011.01.004
   Van Wijk R, 2010, HUM EXP TOXICOL, V29, P561, DOI 10.1177/0960327110369860
   Van Wijk Roeland, 2011, Front Biosci (Elite Ed), V3, P1128
   Vasquez A, 2004, P NATL ACAD SCI USA, V101, P17940
   Veeraapandian S, 2012, J BIOMED NANOTECHNOL, V8, P140, DOI 10.1166/jbn.2012.1356
   Verma S, 2009, INT J PHARMACEUT, V380, P216, DOI 10.1016/j.ijpharm.2009.07.005
   Vickers AJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001957.pub3
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   VITHOULKAS G, 1980, SCI HOMEOPATHY
   Wang TY, 2012, INT J PHARMACEUT, V436, P351, DOI 10.1016/j.ijpharm.2012.06.028
   Wiegant FAC, 2011, DOSE-RESPONSE, V9, P209, DOI 10.2203/dose-response.10-004.Wiegant
   Wiegant FAC, 1998, TOXICOLOGY, V127, P107, DOI 10.1016/S0300-483X(98)00035-3
   Winnik FM, ACCOUNTS CHEM RES
   Winter M, 2011, NANOTOXICOLOGY, V5, P326, DOI 10.3109/17435390.2010.506957
   Witt C., 2009, NEW DIRECTIONS HOMEO
   Witt CM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2158-5-115
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Yao P, 2009, OPT EXPRESS, V17, P11505, DOI 10.1364/OE.17.011505
   Zandi K, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-560
   Zhang HF, 2011, ENVIRON SCI TECHNOL, V45, P3725, DOI 10.1021/es103309n
   Zhu MT, 2012, SMALL, V8, P2841, DOI 10.1002/smll.201200381
   Zhu MT, 2012, SMALL, V8, P404, DOI 10.1002/smll.201101708
NR 261
TC 15
Z9 15
U1 2
U2 49
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-3820
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR
PY 2013
VL 5
IS 2
BP 126
EP 140
DI 10.1016/j.eujim.2012.11.002
PG 15
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 139XC
UT WOS:000318617300006
PM 23795222
OA green_accepted
DA 2018-01-05
ER

PT J
AU Niedzwiecki, DJ
   Iyer, R
   Borer, PN
   Movileanu, L
AF Niedzwiecki, David J.
   Iyer, Raghuvaran
   Borer, Philip N.
   Movileanu, Liviu
TI Sampling a Biomarker of the Human Immunodeficiency Virus across a
   Synthetic Nanopore
SO ACS NANO
LA English
DT Article
DE nanobiotechnology; biosensors; single-molecule detection; single-channel
   electrical recordings; chemical kinetics; protein-RNA interactions
ID HIV-1 NUCLEOCAPSID PROTEIN; SOLID-STATE NANOPORES; SEQUENCE-SPECIFIC
   DETECTION; RECOGNITION ELEMENT; SINGLE POLYPEPTIDE; FORCE SPECTROSCOPY;
   DNA-POLYMERASE; ZINC-FINGERS; SL3 RNA; MOLECULE
AB One primary goal in nanobiotechnology is designing new methodologies for molecular biomedical diagnosis at stages much earlier than currently possible and without use of expensive reagents and sophisticated equipment. In this work, we show the proof of principle for single-molecule detection of the nucleocapsid protein 7 (NCp7), a protein biomarker of the HIV-1 virus, using synthetic nanopores and the resistive-pulse technique. The biosensing mechanism relied upon specific interactions between NCp7 and aptamers of stem-loop 3 (513) in the packaging domain of the retroviral RNA genome. One critical step of this study was the choice of the optimal size of the nanopores for accurate, label-free determinations of the dissociation constant of the NCp7 protein-SL3 RNA aptamer complex. Therefore, we systematically investigated the NCp7 protein-SL3 RNA aptamer complex employing two categories of nanopores in a silicon nitride membrane: (i) small, whose internal diameter was smaller than 6 nm, and (ii) large, whose internal diameter was in the range of 7 to 15 nm. Here, we demonstrate that only the use of nanopores with an internal diameter that is smaller than or comparable with the largest cross-sectional size of the NCp7-SL3 aptamer complex enables accurate measurement of the dissociation constant between the two interacting partners. Notably, this determination can be accomplished without the need for prior nanopore functionalization. Moreover, using small solid-state nanopores, we demonstrate the ability to detect drug candidates that inhibit the binding interactions between NCp7 and 513 RNA by using a test case of N-ethylmaleimide.
C1 [Niedzwiecki, David J.; Movileanu, Liviu] Syracuse Univ, Dept Phys, Syracuse, NY 13244 USA.
   [Iyer, Raghuvaran; Borer, Philip N.] Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.
   [Borer, Philip N.; Movileanu, Liviu] Syracuse Univ, Struct Biol Biochem & Biophys Program, Syracuse, NY 13244 USA.
   [Movileanu, Liviu] Syracuse Univ, Syracuse Biomat Inst, Syracuse, NY 13244 USA.
RP Movileanu, L (reprint author), Syracuse Univ, Dept Phys, Syracuse, NY 13244 USA.
EM lmovilea@physics.syr.edu
FU National Science Foundation-Materials Research Science and Engineering
   Centers (MRSEC) program [DMR-0520404]; National Science Foundation
   [ECS-0335765]; National Institutes of Health [R01 GM088403]
FX We are grateful to J. Grazul, M. Thomas, and J. Treichler for their help
   during the early stages of this work. We also thank colleagues in the
   Movileanu and Borer laboratories for stimulating discussions. Nanopores
   were made at the Electron Microscopy Facility of the Cornell Center for
   Materials Research (CCMR) with support from the National Science
   Foundation-Materials Research Science and Engineering Centers (MRSEC)
   program (DMR-0520404). The preparation of the silicon nitride membranes
   was performed at the Cornell Nano-Scale Facility, a member of the
   National Nanotechnology Infrastructure Network (NNIN), which is
   supported by the National Science Foundation (Grant ECS-0335765). This
   work is funded in part by grants from the National Science Foundation
   (DMR-1006332) and the National Institutes of Health (R01 GM088403) to
   on.
CR Abelow AE, 2010, CHEM COMMUN, V46, P7984, DOI 10.1039/c0cc02649b
   Arrondo J. L., 2006, ADV TECHNIQUES BIOPH
   Atas E, 2012, ELECTROPHORESIS, V33, P3437, DOI 10.1002/elps.201200266
   Athavale SS, 2010, BIOCHEMISTRY-US, V49, P3525, DOI 10.1021/bi901279e
   Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038
   Benner S, 2007, NAT NANOTECHNOL, V2, P718, DOI 10.1038/nnano.2007.344
   Bezrukov SM, 2000, J MEMBRANE BIOL, V174, P1, DOI 10.1007/s002320001026                                                           
   Bikwemu R, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/45/454117
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Chertova EN, 1998, BIOCHEMISTRY-US, V37, P17890, DOI 10.1021/bi980907y
   CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   Cruceanu M, 2006, NUCLEIC ACIDS RES, V34, P593, DOI 10.1093/nar/gkj458
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Dekker C, 2007, NAT NANOTECHNOL, V2, P209, DOI 10.1038/nnano.2007.27
   Ding S, 2009, ANAL CHEM, V81, P6649, DOI 10.1021/ac9006705
   Dorvel B, 2009, NUCLEIC ACIDS RES, V37, P4170, DOI 10.1093/nar/gkp317
   Dudko OK, 2007, BIOPHYS J, V92, P4188, DOI 10.1529/biophysj.106.102855
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Gu LQ, 2010, ANALYST, V135, P441, DOI 10.1039/b907735a
   Gu LQ, 2003, P NATL ACAD SCI USA, V100, P15498, DOI 10.1073/pnas.2531778100
   Hagan N, 2003, BIOCHEMISTRY-US, V42, P10736, DOI 10.1021/bi0348922
   Han A, 2008, ANAL CHEM, V80, P4651, DOI 10.1021/ac7025207
   Hornblower B, 2007, NAT METHODS, V4, P315, DOI 10.1038/NMETH1021
   Jenkins LMM, 2005, J MED CHEM, V48, P2847, DOI 10.1021/jm0492195
   Kawano R, 2011, J AM CHEM SOC, V133, P8474, DOI 10.1021/ja2026085
   Kleefen A, 2010, NANO LETT, V10, P5080, DOI 10.1021/nl1033528
   Kowalczyk SW, 2010, NANO LETT, V10, P1414, DOI 10.1021/nl100271c
   LINIAL ML, 1990, CURR TOP MICROBIOL, V157, P125
   Majd S, 2010, CURR OPIN BIOTECH, V21, P439, DOI 10.1016/j.copbio.2010.05.002
   Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171
   Mohammad MM, 2008, EUR BIOPHYS J BIOPHY, V37, P913, DOI 10.1007/s00249-008-0309-9
   Mohammad MM, 2008, J AM CHEM SOC, V130, P4081, DOI 10.1021/ja710787a
   Mohammad MM, 2012, J AM CHEM SOC, V134, P9521, DOI 10.1021/ja3043646
   Movileanu L, 2005, BIOPHYS J, V89, P1030, DOI 10.1529/biophysj.104.057406
   Movileanu L, 2003, BIOPHYS J, V85, P897, DOI 10.1016/S0006-3495(03)74529-9                                                   
   Movileanu L, 2008, SOFT MATTER, V4, P925, DOI 10.1039/b719850g
   Movileanu L, 2009, TRENDS BIOTECHNOL, V27, P333, DOI 10.1016/j.tibtech.2009.02.008
   MUTHUKUMAR M, 1989, MACROMOLECULES, V22, P1937, DOI 10.1021/ma00194a070                                                             
   Niedzwiecki DJ, 2012, BIOPHYS J, V103, P2115, DOI 10.1016/j.bpj.2012.10.008
   Niedzwiecki DJ, 2010, J AM CHEM SOC, V132, P10816, DOI 10.1021/ja1026858
   Osaki T, 2009, ANAL CHEM, V81, P9866, DOI 10.1021/ac901732z
   Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n
   RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0                                                                
   Rotem D, 2012, J AM CHEM SOC, V134, P2781, DOI 10.1021/ja2105653
   Shim JW, 2008, J PHYS CHEM B, V112, P8354, DOI 10.1021/jp0775911
   Shim JW, 2009, NUCLEIC ACIDS RES, V37, P972, DOI 10.1093/nar/gkn968
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Singer A, 2010, NANO LETT, V10, P738, DOI 10.1021/nl100058y
   Smeets RMM, 2008, P NATL ACAD SCI USA, V105, P417, DOI 10.1073/pnas.0705349105
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Soskine M, 2012, NANO LETT, V12, P4895, DOI 10.1021/nl3024438
   Spiering A, 2011, NANO LETT, V11, P2978, DOI 10.1021/nl201541y
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   Tabard-Cossa V, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/30/305505
   Tabard-Cossa V, 2009, ACS NANO, V3, P3009, DOI 10.1021/nn900713a
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   Wanunu M, 2011, ACS NANO, V5, P9345, DOI 10.1021/nn203764j
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P160, DOI [10.1038/nnano.2009.379, 10.1038/NNANO.2009.379]
   Wei RS, 2012, NAT NANOTECHNOL, V7, P257, DOI [10.1038/nnano.2012.24, 10.1038/NNANO.2012.24]
   Wolfe AJ, 2007, J AM CHEM SOC, V129, P14034, DOI 10.1021/ja0749340
   Wong CTA, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2723088
   Yang L., 2008, THESIS SYRACUSE U
   Yusko EC, 2011, NAT NANOTECHNOL, V6, P253, DOI 10.1038/nnano.2011.12
NR 67
TC 33
Z9 33
U1 6
U2 96
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD APR
PY 2013
VL 7
IS 4
BP 3341
EP 3350
DI 10.1021/nn400125c
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 133MU
UT WOS:000318143300049
PM 23445080
OA green_accepted
DA 2018-01-05
ER

PT J
AU Niedzwiecki, DJ
   Iyer, R
   Borer, PN
   Movileanu, L
AF Niedzwiecki, David J.
   Iyer, Raghuvaran
   Borer, Philip N.
   Movileanu, Liviu
TI Sampling a Biomarker of the Human Immunodeficiency Virus across a
   Synthetic Nanopore (vol 7, pg 3341, 2013)
SO ACS NANO
LA English
DT Correction
FU NIGMS NIH HHS [R01 GM088403]
CR Niedzwiecki DJ, 2013, ACS NANO, V7, P3341, DOI 10.1021/nn400125c
NR 1
TC 2
Z9 2
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD APR
PY 2013
VL 7
IS 4
BP 3731
EP 3731
DI 10.1021/nn401345w
PG 1
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 133MU
UT WOS:000318143300093
PM 23541219
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gan, N
   Du, XW
   Cao, YT
   Hu, FT
   Li, TH
   Jiang, QL
AF Gan, Ning
   Du, Xiaowen
   Cao, Yuting
   Hu, Futao
   Li, Tianhua
   Jiang, Qianli
TI An Ultrasensitive Electrochemical Immunosensor for HIV p24 Based on
   Fe3O4@SiO2 Nanomagnetic Probes and Nanogold Colloid-Labeled
   Enzyme-Antibody Copolymer as Signal Tag
SO MATERIALS
LA English
DT Article
DE Fe3O4@SiO2 magnetic beads; nanogold-labeled EnVision antibody enzyme
   complex; HIV p24; signal amplification; electrochemical immunosensor
ID MODIFIED ELECTRODE; ANTIGEN; IMMUNOASSAY; NANOPARTICLES; BIOSENSOR;
   COMPLEX; CHITOSAN; SERUM; ASSAY
AB An ultrasensitive portable electrochemical immunosensor for human immunodeficiency virus p24 (HIV p24) antigen detection has been developed, whereby the detection sensitivity was 1000 times higher than that of the ELISA method. Firstly, a novel HRP enzyme-antibody copolymer (EV-p24 Ab2) was synthesized through an EnVision regent (EV, a dextrin amine skeleton anchoring more than 100 molecules of HRP and 15 molecules of anti IgG), then incubated in the secondary antibody of p24. Secondly, the copolymer was immobilized on the gold nanocolloids (AuNPs) to fabricate a novel signal tag (AuNPs/EV-p24 Ab2). Subsequently, a sandwich-type immunoreaction would take place between the capture probe (silicon dioxide-coated magnetic Fe3O4 nanoparticles (MNPs) labeled with the primary p24 antibody (MNPs-p24 Ab1)), p24 (different concentrations) and the signal tag [AuNPs/EV-p24 Ab2)] to form the immunocomplex. Finally, the immunocomplex was absorbed on the surface of screen printed carbon electrode (SPCE) by a magnet and immersed in the o-hydroxyl phenol (HQ) and H2O2. The large amounts of HRP on the signal tag can catalyze the oxidation of HQ by H2O2, which can induce an amplified reductive current. Moreover, the capture probe could improve the accumulation ability of p24 and facilitate its separation from the substrate through the magnet. Under optimal conditions, the proposed immunoassay exhibited good sensitivity to p24 within a certain concentration range from 0.001 to 10.00 ng/mL, with a detection limit of 0.5 pg/mL (S/N = 3). The proposed method can be used for real-time and early detection of HIV-infected people.
C1 [Gan, Ning; Du, Xiaowen; Cao, Yuting; Hu, Futao; Li, Tianhua] Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
   [Jiang, Qianli] Southern Med Univ, Nanfang Hosp, Dept Lab Med, Guangzhou 510515, Guangdong, Peoples R China.
RP Gan, N (reprint author), Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
EM ganning@nbu.edu.cn; duxiaowen@126.com; caoyuting@nbu.edu.cn;
   hufutao@nbu.edu.cn; litianhua@nbu.edu.cn; jiangqianlid@yahoo.cn
FU National Natural Science Foundation of China [30901367]; Natural Science
   Foundation of Zhejiang province and Ningbo [LY12C20004, Y201223074,
   2012C37012, Y3110478, 2011A610018, 2011A610006, 2011C23126]; Ningbo
   University
FX This work was supported by the National Natural Science Foundation of
   China (No. 30901367), the Natural Science Foundation of Zhejiang
   province and Ningbo (LY12C20004, Y201223074, 2012C37012, Y3110478,
   2011A610018, 2011A610006, 2011C23126), and the K.C. Wong Magna Fund in
   Ningbo University.
CR Bi S, 2009, CHEM-EUR J, V15, P4704, DOI 10.1002/chem.200801722
   Biancotto A, 2009, J VIROL METHODS, V157, P98, DOI 10.1016/j.jviromet.2008.11.013
   Chang CC, 2010, ANAL CHEM, V82, P1207, DOI 10.1021/ac901797j
   Cui RJ, 2008, ADV FUNCT MATER, V18, P2197, DOI 10.1002/adfm.200701340
   de la Escosura-Muniz A, 2009, ANAL CHEM, V81, P10268, DOI 10.1021/ac902087k
   Feng JJ, 2005, ANAL BIOCHEM, V342, P280, DOI 10.1016/j.ab.2005.04.040                                                        
   Fu ZF, 2006, J IMMUNOL METHODS, V312, P61, DOI 10.1016/j.jim.2006.02.006
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Jie GF, 2008, BIOSENS BIOELECTRON, V23, P1896, DOI 10.1016/j.bios.2008.02.028
   Kammerer U, 2001, J HISTOCHEM CYTOCHEM, V49, P623, DOI 10.1177/002215540104900509                                                      
   Kannangai R, 2001, J CLIN VIROL, V22, P41, DOI 10.1016/S1386-6532(01)00170-6                                                   
   Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002
   Kivuyo SL, 2011, INT J STD AIDS, V22, P719, DOI 10.1258/ijsa.2009.009382
   Kaur J., 2011, J FUZZY SET VALUED A, V2011, P1
   Lai CW, 2008, SMALL, V4, P218, DOI 10.1002/smll.200700283
   Loh KS, 2008, SENSORS-BASEL, V8, P5775, DOI 10.3390/s8095775
   Okochi M, 2005, BIOTECHNOL BIOENG, V90, P14, DOI 10.1002/bit.20313
   Plumere N, 2012, J COLLOID INTERF SCI, V368, P208, DOI 10.1016/j.jcis.2011.10.070
   Spacek LA, 2011, INT J STD AIDS, V22, P310, DOI 10.1258/ijsa.2009.009363
   Suwansa-Ard S, 2008, ELECTROANAL, V20, P308, DOI 10.1002/elan.200704063
   Tang DP, 2006, J PHYS CHEM B, V110, P11640, DOI 10.1021/jp060950s
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Tshishi TA, 2007, IMMUNO-ANAL BIOL SPE, V22, P190, DOI 10.1016/j.immbio.2007.02.005
   Wu YF, 2009, ANAL CHEM, V81, P1600, DOI 10.1021/ac802345z
   Xiong P, 2012, MATERIALS, V5, P2757, DOI 10.3390/ma5122757
   Xu X, 2011, INT J ENV RES PUB HE, V8, P1258, DOI 10.3390/ijerph8041258
   Zheng L, 2012, MOLECULES, V17, P5988, DOI 10.3390/molecules17055988
   Zhou KF, 2010, ELECTROCHIM ACTA, V55, P3055, DOI 10.1016/j.electacta.2010.01.035
NR 28
TC 30
Z9 30
U1 3
U2 107
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1996-1944
J9 MATERIALS
JI Materials
PD APR
PY 2013
VL 6
IS 4
BP 1255
EP 1269
DI 10.3390/ma6041255
PG 15
WC Materials Science, Multidisciplinary
SC Materials Science
GA 131TE
UT WOS:000318018200003
PM 28809208
OA gold
DA 2018-01-05
ER

PT J
AU Mella-Raipan, JA
   Lagos, CF
   Recabarren-Gajardo, G
   Espinosa-Bustos, C
   Romero-Parra, J
   Pessoa-Mahana, H
   Iturriaga-Vasquez, P
   Pessoa-Mahana, CD
AF Mella-Raipan, Jaime A.
   Lagos, Carlos F.
   Recabarren-Gajardo, Gonzalo
   Espinosa-Bustos, Christian
   Romero-Parra, Javier
   Pessoa-Mahana, Hernan
   Iturriaga-Vasquez, Patricio
   David Pessoa-Mahana, Carlos
TI Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of
   2-Pyridylbenzimidazoles-A New Family of High Affinity CB1 Cannabinoid
   Ligands
SO MOLECULES
LA English
DT Article
DE cannabinoid; CB1 receptor; binding; docking; 3D-QSAR
ID HUMAN-IMMUNODEFICIENCY-VIRUS-(I) PROTEASE INHIBITORS; MOLECULAR-FIELD
   ANALYSIS; ENDOCANNABINOID SYSTEM; RECEPTOR; PHARMACOLOGY; DERIVATIVES;
   AGONISTS; ANALOGS; SERIES; ANTAGONIST
AB A series of novel 2-pyridylbenzimidazole derivatives was rationally designed and synthesized based on our previous studies on benzimidazole 14, a CB1 agonist used as a template for optimization. In the present series, 21 compounds displayed high affinities with K-i values in the nanomolar range. JM-39 (compound 39) was the most active of the series (K-iCB1 = 0.53 nM), while compounds 31 and 44 exhibited similar affinities to WIN 55212-2. CoMFA analysis was performed based on the biological data obtained and resulted in a statistically significant CoMFA model with high predictive value (q(2) = 0.710, r(2) = 0.998, r(pred)(2) = 0.823).
C1 [Mella-Raipan, Jaime A.] Univ Valparaiso, Dept Quim & Bioquim, Fac Ciencias, Valparaiso, Chile.
   [Lagos, Carlos F.; Recabarren-Gajardo, Gonzalo; Espinosa-Bustos, Christian; Romero-Parra, Javier; David Pessoa-Mahana, Carlos] Pontificia Univ Catolica Chile, Dept Farm, Fac Quim, Santiago 22, Chile.
   [Pessoa-Mahana, Hernan] Univ Chile, Dept Quim Organ & Fis Quim, Fac Quim & Ciencias Farmaceut, Santiago, Chile.
   [Iturriaga-Vasquez, Patricio] Univ Chile, Fac Ciencias, Dept Quim, Santiago, Chile.
RP Pessoa-Mahana, CD (reprint author), Pontificia Univ Catolica Chile, Dept Farm, Fac Quim, Casilla 306, Santiago 22, Chile.
EM cpessoa@uc.cl
OI Espinosa-Bustos, Christian/0000-0001-6038-8439; Lagos, Carlos
   F./0000-0002-5432-9747; Recabarren, Gonzalo/0000-0002-7763-7830
FU FONDECYT [1100493, 1100542]
FX Financial support under FONDECYT Projects 1100493 and 1100542 to CDPM
   and PIV is gratefully acknowledged. CFL, CEB and JRP are CONICYT PhD
   fellows. CFL thanks OpenEye Scientific Software and Inteligand for
   academic software licenses. S. D. G.
CR Araya KA, 2007, EUR J PHARMACOL, V572, P32, DOI 10.1016/j.ejphar.2007.06.013
   Bahrami K, 2008, J ORG CHEM, V73, P6835, DOI 10.1021/jo8010232
   Ballesteros J. A., 1995, METH NEUROSCI, V25, P366, DOI DOI 10.1016/S1043-9471(05)80049-7
   Blaazer AR, 2011, EUR J MED CHEM, V46, P5086, DOI 10.1016/j.ejmech.2011.08.021
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   CHO SJ, 1995, J MED CHEM, V38, P1060, DOI 10.1021/jm00007a003
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   COMPTON DR, 1992, J PHARMACOL EXP THER, V263, P1118
   CRAMER RD, 1988, J AM CHEM SOC, V110, P5959, DOI 10.1021/ja00226a005
   DEVANE WA, 1988, MOL PHARMACOL, V34, P605
   Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
   Diaz P, 2008, J MED CHEM, V51, P4932, DOI 10.1021/jm8002203
   Feig M, 2004, J COMPUT CHEM, V25, P265, DOI 10.1002/jcc.10378
   Felder CC, 1998, J PHARMACOL EXP THER, V284, P291
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2                                                    
   Gasteiger J., 1980, TETRAHEDRON LETT, V19, P3181
   Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1                                                   
   Gonzalez A, 2008, BIOORGAN MED CHEM, V16, P4378, DOI 10.1016/j.bmc.2008.02.070
   Gonzalez A, 2011, MEDCHEMCOMM, V2, P160, DOI 10.1039/c0md00258e
   HUFFMAN JW, 1994, BIOORG MED CHEM LETT, V4, P563, DOI 10.1016/S0960-894X(01)80155-4
   Rohde J., 2011, [No title captured], Patent No. [WO2011100324A1, 2011100324, 2011/100324]
   Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772
   Liao SY, 2008, QSAR COMB SCI, V27, P740, DOI 10.1002/qsar.200730154
   Lozano-Ondoua AN, 2010, LIFE SCI, V86, P646, DOI 10.1016/j.lfs.2010.02.014
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0                                                                
   OPREA TI, 1994, J MED CHEM, V37, P2206, DOI 10.1021/jm00040a013
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Padgett LW, 2005, LIFE SCI, V77, P1767, DOI 10.1016/j.lfs.2005.05.020
   Palmer SL, 2002, CHEM PHYS LIPIDS, V121, P3, DOI 10.1016/S0009-3084(02)00143-3                                                   
   Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3
   Pertwee RG, 1999, CURR MED CHEM, V6, P635
   Pessoa-Mahana D, 2010, J BRAZIL CHEM SOC, V21, P63, DOI 10.1590/S0103-50532010000100011
   RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6                                                   
   SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306
   SALI A, 1995, MOL MED TODAY, V1, P270
   Sharkey KA, 2007, EUR J NEUROSCI, V25, P2773, DOI 10.1111/j.1460-9568.2007.05521.x
   Tam J, 2012, CELL METAB, V16, P167, DOI 10.1016/j.cmet.2012.07.002
   Thakur GA, 2006, METH MOLEC MED, V123, P113
   Trotter BW, 2011, BIOORG MED CHEM LETT, V21, P2354, DOI 10.1016/j.bmcl.2011.02.082
   Vasquez D, 2007, J CHIL CHEM SOC, V52, P1281, DOI 10.4067/S0717-97072007000400002
   WALLER CL, 1993, J MED CHEM, V36, P4152, DOI 10.1021/jm00078a003
   Watson C, 2011, BIOORG MED CHEM LETT, V21, P4284, DOI 10.1016/j.bmcl.2011.05.063
   Yan L, 2010, J MED CHEM, V53, P4028, DOI 10.1021/jm100023j
   Makriyannis A., 2001, WO Patent, Patent No. 200128557
NR 44
TC 9
Z9 9
U1 2
U2 40
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD APR
PY 2013
VL 18
IS 4
BP 3972
EP 4001
DI 10.3390/molecules18043972
PG 30
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 131TV
UT WOS:000318020100024
PM 23558540
OA gold
DA 2018-01-05
ER

PT J
AU Eidahl, JO
   Crowe, BL
   North, JA
   McKee, CJ
   Shkriabai, N
   Feng, L
   Plumb, M
   Graham, RL
   Gorelick, RJ
   Hess, S
   Poirier, MG
   Foster, MP
   Kvaratskhelia, M
AF Eidahl, Jocelyn O.
   Crowe, Brandon L.
   North, Justin A.
   McKee, Christopher J.
   Shkriabai, Nikoloz
   Feng, Lei
   Plumb, Matthew
   Graham, Robert L.
   Gorelick, Robert J.
   Hess, Sonja
   Poirier, Michael G.
   Foster, Mark P.
   Kvaratskhelia, Mamuka
TI Structural basis for high-affinity binding of LEDGF PWWP to
   mononucleosomes
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID GROWTH-FACTOR; HIV-1 INTEGRASE; IN-VITRO; LENTIVIRAL INTEGRATION;
   RECOMBINANT HISTONES; CHROMATIN-BINDING; DNA INTEGRATION; DOMAIN;
   PROTEINS; IDENTIFICATION
AB Lens epithelium-derived growth factor (LEDGF/p75) tethers lentiviral preintegration complexes (PICs) to chromatin and is essential for effective HIV-1 replication. LEDGF/p75 interactions with lentiviral integrases are well characterized, but the structural basis for how LEDGF/p75 engages chromatin is unknown. We demonstrate that cellular LEDGF/p75 is tightly bound to mononucleosomes (MNs). Our proteomic experiments indicate that this interaction is direct and not mediated by other cellular factors. We determined the solution structure of LEDGF PWWP and monitored binding to the histone H3 tail containing trimethylated Lys36 (H3K36me3) and DNA by NMR. Results reveal two distinct functional interfaces of LEDGF PWWP: a well-defined hydrophobic cavity, which selectively interacts with the H3K36me3 peptide and adjacent basic surface, which non-specifically binds DNA. LEDGF PWWP exhibits nanomolar binding affinity to purified native MNs, but displays markedly lower affinities for the isolated H3K36me3 peptide and DNA. Furthermore, we show that LEDGF PWWP preferentially and tightly binds to in vitro reconstituted MNs containing a tri-methyl-lysine analogue at position 36 of H3 and not to their unmodified counterparts. We conclude that cooperative binding of the hydrophobic cavity and basic surface to the cognate histone peptide and DNA wrapped in MNs is essential for high-affinity binding to chromatin.
C1 [Eidahl, Jocelyn O.; McKee, Christopher J.; Shkriabai, Nikoloz; Feng, Lei; Plumb, Matthew; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA.
   [Eidahl, Jocelyn O.; McKee, Christopher J.; Shkriabai, Nikoloz; Feng, Lei; Plumb, Matthew; Kvaratskhelia, Mamuka] Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA.
   [Crowe, Brandon L.; Foster, Mark P.] Ohio State Univ, Dept Chem & Biochem, Columbus, OH 43210 USA.
   [North, Justin A.; Poirier, Michael G.] Ohio State Univ, Dept Phys, Columbus, OH 43210 USA.
   [Graham, Robert L.; Hess, Sonja] CALTECH, Beckman Inst, Proteome Explorat Lab, Pasadena, CA 91125 USA.
   [Gorelick, Robert J.] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, SAIC Frederick Inc, Frederick, MD 21702 USA.
RP Kvaratskhelia, M (reprint author), Ohio State Univ, Coll Pharm, 500 W 12Th Ave, Columbus, OH 43210 USA.
EM kvaratskhelia.1@osu.edu
RI Graham, Robert/A-7857-2010; Foster, Mark/F-6332-2012; Poirier,
   Michael/B-5378-2012; Hess, Sonja/K-4842-2013
OI Foster, Mark/0000-0001-9645-7491; Hess, Sonja/0000-0002-5904-9816
FU National Institutes of Health [AI062520, GM103368, GM077234]; National
   Cancer Institute, National Institutes of Health [HHSN261200800001E];
   SAIC-Frederick, Inc.
FX National Institutes of Health [AI062520 and GM103368 to M. K., GM077234
   to M. P. F.]; National Cancer Institute, National Institutes of Health
   [under contract HHSN261200800001E with SAIC-Frederick, Inc. (to R. J.
   G.)]. The content of this publication does not necessarily reflect the
   views or policies of the Department of Health and Human Services, nor
   does mention of trade names, commercial products, or organizations imply
   endorsement by the U. S. Government. Funding for open access charge:
   National Institutes of Health [GM103368].
CR Bahrami A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000307
   Botbol YR, 2008, NUCLEIC ACIDS RES, V36, P1237, DOI 10.1093/nar/gkm1127
   Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506921402
   Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200
   Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329
   Daniels T, 2005, PROSTATE, V62, P14, DOI 10.1002/pros.20112
   Daugaard M, 2007, CANCER RES, V67, P2559, DOI 10.1158/0008-5472.CAN-06-4121
   Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Ferris AL, 2010, P NATL ACAD SCI USA, V107, P3135, DOI 10.1073/pnas.0914142107
   Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q
   Gijsbers R, 2011, J BIOL CHEM, V286, P41812, DOI 10.1074/jbc.M111.255711
   Gijsbers R, 2010, MOL THER, V18, P552, DOI 10.1038/mt.2010.36
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305                                                 
   Guntert Peter, 2004, Methods Mol Biol, V278, P353
   Hare S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000515
   Hare S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000259
   Johnson Bruce A, 2004, Methods Mol Biol, V278, P313
   Lee JE, 2011, MOL CELL PROTEOMICS, V10, pM110, DOI DOI 10.1074/MCP.M110.006460
   Llano M, 2006, SCIENCE, V314, P461, DOI 10.1126/science.1132319
   Llano M, 2006, J MOL BIOL, V360, P760, DOI 10.1016/j.jmb.2006.04.073
   Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494
   Luger K, 1997, NATURE, V389, P251
   Luger K, 1999, METH MOL B, V119, P1
   Lukasik SM, 2006, PROTEIN SCI, V15, P314, DOI 10.1110/ps.051751706
   Manohar M, 2009, J BIOL CHEM, V284, P23312, DOI 10.1074/jbc.M109.003202
   Mckee CJ, 2009, METHODS, V47, P304, DOI 10.1016/j.ymeth.2008.10.023
   McNeely M, 2011, J MOL BIOL, V410, P811, DOI 10.1016/j.jmb.2011.03.073
   Meehan AM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000522
   Nameki N, 2005, PROTEIN SCI, V14, P756, DOI 10.1110/ps.04975305
   Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717
   PRUSS D, 1994, J BIOL CHEM, V269, P25031
   PRYCIAK PM, 1992, EMBO J, V11, P291
   Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759
   Qiu Y, 2012, BIOCHEM J, V442, P527, DOI 10.1042/BJ20111885
   RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7
   Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9                                                   
   Schnitzler G.R, 2000, CURR PROTOC MOL BIOL, P212521
   SHEN Y, 2009, J BIOMOL NMR, V44, P213, DOI DOI 10.1007/S10858-009-9333-Z
   Shun MC, 2007, GENE DEV, V21, P1767, DOI 10.1101/gad.1565107
   Shun MC, 2008, J VIROL, V82, P11555, DOI 10.1128/JVI.01561-08
   Simon MD, 2007, CELL, V128, P1003, DOI 10.1016/j.cell.2006.12.041
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   Turlure F, 2006, NUCLEIC ACIDS RES, V34, P1653, DOI 10.1093/nar/gkl052
   Vandegraaff N, 2006, VIROLOGY, V346, P415, DOI 10.1016/j.virol.2005.11.022
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Vezzoli A, 2010, NAT STRUCT MOL BIOL, V17, P617, DOI 10.1038/nsmb.1797
   Wang GP, 2007, GENOME RES, V17, P1186, DOI 10.1101/gr.6286907
   Wu H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018919
   Yang J, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-101
NR 52
TC 77
Z9 77
U1 0
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD APR
PY 2013
VL 41
IS 6
BP 3924
EP 3936
DI 10.1093/nar/gkt074
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 132JJ
UT WOS:000318063400043
PM 23396443
OA gold
DA 2018-01-05
ER

PT J
AU Vigant, F
   Lee, J
   Hollmann, A
   Tanner, LB
   Ataman, ZA
   Yun, T
   Shui, GH
   Aguilar, HC
   Zhang, D
   Meriwether, D
   Roman-Sosa, G
   Robinson, LR
   Juelich, TL
   Buczkowski, H
   Chou, SW
   Castanho, MARB
   Wolf, MC
   Smith, JK
   Banyard, A
   Kielian, M
   Reddy, S
   Wenk, MR
   Selke, M
   Santos, NC
   Freiberg, AN
   Jung, ME
   Lee, B
AF Vigant, Frederic
   Lee, Jihye
   Hollmann, Axel
   Tanner, Lukas B.
   Ataman, Zeynep Akyol
   Yun, Tatyana
   Shui, Guanghou
   Aguilar, Hector C.
   Zhang, Dong
   Meriwether, David
   Roman-Sosa, Gleyder
   Robinson, Lindsey R.
   Juelich, Terry L.
   Buczkowski, Hubert
   Chou, Sunwen
   Castanho, Miguel A. R. B.
   Wolf, Mike C.
   Smith, Jennifer K.
   Banyard, Ashley
   Kielian, Margaret
   Reddy, Srinivasa
   Wenk, Markus R.
   Selke, Matthias
   Santos, Nuno C.
   Freiberg, Alexander N.
   Jung, Michael E.
   Lee, Benhur
TI A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target
   Virus-Cell Fusion
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEMBRANE-FUSION; ENVELOPED VIRUSES;
   UP-CONVERSION; MODEL SYSTEMS; FLUORESCENCE; PHOTOINACTIVATION;
   INHIBITOR; ENTRY; NANOPARTICLES
AB LJ001 is a lipophilic thiazolidine derivative that inhibits the entry of numerous enveloped viruses at non-cytotoxic concentrations (IC50 <= 0.5 mu M), and was posited to exploit the physiological difference between static viral membranes and biogenic cellular membranes. We now report on the molecular mechanism that results in LJ001's specific inhibition of virus-cell fusion. The antiviral activity of LJ001 was light-dependent, required the presence of molecular oxygen, and was reversed by singlet oxygen (O-1(2)) quenchers, qualifying LJ001 as a type II photosensitizer. Unsaturated phospholipids were the main target modified by LJ001-generated O-1(2). Hydroxylated fatty acid species were detected in model and viral membranes treated with LJ001, but not its inactive molecular analog, LJ025. O-1(2)-mediated allylic hydroxylation of unsaturated phospholipids leads to a trans-isomerization of the double bond and concurrent formation of a hydroxyl group in the middle of the hydrophobic lipid bilayer. LJ001-induced O-1(2)-mediated lipid oxidation negatively impacts on the biophysical properties of viral membranes (membrane curvature and fluidity) critical for productive virus-cell membrane fusion. LJ001 did not mediate any apparent damage on biogenic cellular membranes, likely due to multiple endogenous cytoprotection mechanisms against phospholipid hydroperoxides. Based on our understanding of LJ001's mechanism of action, we designed a new class of membrane-intercalating photosensitizers to overcome LJ001's limitations for use as an in vivo antiviral agent. Structure activity relationship (SAR) studies led to a novel class of compounds (oxazolidine-2,4-dithiones) with (1) 100-fold improved in vitro potency (IC50<10 nM), (2) red-shifted absorption spectra (for better tissue penetration), (3) increased quantum yield (efficiency of O-1(2) generation), and (4) 10-100-fold improved bioavailability. Candidate compounds in our new series moderately but significantly (p <= 0.01) delayed the time to death in a murine lethal challenge model of Rift Valley Fever Virus (RVFV). The viral membrane may be a viable target for broad-spectrum antivirals that target virus-cell fusion.
C1 [Vigant, Frederic; Ataman, Zeynep Akyol; Robinson, Lindsey R.; Wolf, Mike C.; Lee, Benhur] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.
   [Lee, Jihye; Jung, Michael E.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90024 USA.
   [Hollmann, Axel; Castanho, Miguel A. R. B.; Santos, Nuno C.] Univ Lisbon, Fac Med, Inst Mol Med, P-1699 Lisbon, Portugal.
   [Tanner, Lukas B.; Wenk, Markus R.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117595, Singapore.
   [Tanner, Lukas B.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn NGS, Singapore 117548, Singapore.
   [Yun, Tatyana; Juelich, Terry L.; Smith, Jennifer K.; Freiberg, Alexander N.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Shui, Guanghou] Natl Univ Singapore, Inst Life Sci, Singapore 117548, Singapore.
   [Aguilar, Hector C.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.
   [Zhang, Dong; Selke, Matthias] Calif State Univ Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90032 USA.
   [Meriwether, David; Reddy, Srinivasa] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
   [Roman-Sosa, Gleyder; Kielian, Margaret] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA.
   [Buczkowski, Hubert; Banyard, Ashley] Anim Hlth & Vet Labs Agcy, Wildlife Zoonoses & Vector Borne Dis Res Grp, Weybridge, Surrey, England.
   [Chou, Sunwen] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Chou, Sunwen] VA Med Ctr, Portland, OR USA.
   [Wenk, Markus R.] Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117548, Singapore.
   [Wenk, Markus R.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Wenk, Markus R.] Univ Basel, Basel, Switzerland.
RP Vigant, F (reprint author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA.
EM bleebhl@ucla.edu
RI Buczkowski, Hubert/E-1786-2011; sebastianovitsch, stepan/G-8507-2013;
   Santos, Nuno/N-7248-2013; Wenk, Markus/D-1441-2014; Hollmann,
   Axel/J-4931-2013; APHA, Staff publications/E-6082-2010; Lee,
   Benhur/A-8554-2016; Banyard, Ashley/C-7998-2011
OI Santos, Nuno/0000-0002-0580-0475; Lee, Benhur/0000-0003-0760-1709;
   Banyard, Ashley/0000-0002-1286-9825; Castanho,
   Miguel/0000-0001-7891-7562; Hollmann, Axel/0000-0002-8060-2997; FCCN,
   Bogus/0000-0001-6282-8004; FCCN, Bogus/0000-0003-1034-3552
FU NIH [U01 AI070495, U01 AI082100, R01 AI069317, U54 AI065359, AI075647];
   NIH-NIGMS [5SC1GM084776]; Fundaca para a Ciencia e a Tecnologia -
   Ministerio da Educaca e Ciencia (Portugal) [PTDC/SAU-BEB/099142/2008,
   SFRH/BPD/72037/2010]; Veterans Affairs research funds
FX This work was supported by NIH grants U01 AI070495, U01 AI082100, R01
   AI069317, U54 AI065359 (PSWRCE) (to BL), AI075647 (to MK), NIH-NIGMS
   5SC1GM084776 (to DZ and MS), and by Fundaca para a Ciencia e a
   Tecnologia - Ministerio da Educaca e Ciencia (Portugal) project
   PTDC/SAU-BEB/099142/2008 (to NCS) and fellowship SFRH/BPD/72037/2010 (to
   AH) and Veterans Affairs research funds (SC). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aguilar HC, 2006, J VIROL, V80, P4878, DOI 10.1128/JVI.80.10.4878-4889.2006
   Aguilar HC, 2010, J VIROL, V84, P8033, DOI 10.1128/JVI.00469-10
   Ayuyan AG, 2006, BIOPHYS J, V91, P2172, DOI 10.1529/biophysj.106.087387
   Bernstein ZP, 2008, CURR HIV RES, V6, P152, DOI 10.2174/157016208783885001
   Bonavia A, 2011, P NATL ACAD SCI USA, V108, P6739, DOI 10.1073/pnas.1017142108
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658                                                      
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3
   Chiu SW, 1999, BIOPHYS J, V76, P1939, DOI 10.1016/S0006-3495(99)77353-4                                                   
   Costa L, 2012, VIRUSES, P1034
   Davis B, 2008, J BIOL CHEM, V283, P6428, DOI 10.1074/jbc.M709970200
   De Clercq E, 2004, NAT REV MICROBIOL, V2, P704, DOI 10.1038/nrmicro975
   Floyd RA, 2004, ANTIVIR RES, V61, P141, DOI 10.1016/j.antiviral.2003.11.004
   FOOTE CS, 1984, METHOD ENZYMOL, V105, P36
   Franquelim HG, 2008, J AM CHEM SOC, V130, P6215, DOI 10.1021/ja711247n
   Gerl MJ, 2012, J CELL BIOL, V196, P213, DOI 10.1083/jcb.201108175
   Girotti AW, 2008, FREE RADICAL BIO MED, V44, P956, DOI 10.1016/j.freeradbiomed.2007.12.004
   Hirayama J, 1997, PHOTOCHEM PHOTOBIOL, V66, P697, DOI 10.1111/j.1751-1097.1997.tb03209.x                                              
   Hoffmann HH, 2011, P NATL ACAD SCI USA, V108, P5777, DOI 10.1073/pnas.1101143108
   Idris NM, 2012, NAT MED, V18, P1580, DOI 10.1038/nm.2933
   Kesel AJ, 2011, EUR J MED CHEM, V46, P1656, DOI 10.1016/j.ejmech.2011.02.014
   Krishnamoorthy G, 2005, PHOTOCHEM PHOTOBIOL, V81, P924, DOI 10.1562/2004-11-23-RA-378R1.1
   Kubin A, 2005, CURR PHARM DESIGN, V11, P233, DOI 10.2174/1381612053382287
   KUBISTA M, 1994, ANALYST, V119, P417, DOI 10.1039/an9941900417
   Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773
   Lai SW, 2010, PHOTOCHEM PHOTOBIOL, V86, P1414, DOI 10.1111/j.1751-1097.2010.00809.x
   LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015                                                             
   LENARD J, 1993, P NATL ACAD SCI USA, V90, P158, DOI 10.1073/pnas.90.1.158
   Liao MF, 2005, J CELL BIOL, V171, P111, DOI 10.1016/jcb.200507075
   Martin CSS, 2009, TRENDS MICROBIOL, V17, P514, DOI 10.1016/j.tim.2009.08.002
   Matos PM, 2010, BBA-BIOMEMBRANES, V1798, P1999, DOI 10.1016/j.bbamem.2010.07.012
   Melikyan GB, 2010, P NATL ACAD SCI USA, V107, P17069, DOI 10.1073/pnas.1012748107
   Meriwether D, 2011, J LIPID RES, V52, P1795, DOI 10.1194/jlr.M016741
   Moor ACE, 1997, PHOTOCHEM PHOTOBIOL, V65, P465, DOI 10.1111/j.1751-1097.1997.tb08591.x
   NAGLE JF, 1988, BIOCHIM BIOPHYS ACTA, V942, P1, DOI 10.1016/0005-2736(88)90268-4
   NORTH J, 1993, J PHOTOCH PHOTOBIO B, V17, P99, DOI 10.1016/1011-1344(93)80002-Q
   Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1
   Rider TH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022572
   Sanford KW, 2012, J CLIN APHERESIS, V27, P126, DOI 10.1002/jca.21217
   Santos NC, 1998, BIOCHEMISTRY-US, V37, P8674, DOI 10.1021/bi9803933
   Santos NC, 2003, BBA-BIOMEMBRANES, V1612, P123, DOI 10.1016/S0005-2736(03)00112-3
   Shui GH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019731
   Solheim BG, 2008, TRANSFUS APHER SCI, V39, P75, DOI 10.1016/j.transci.2008.05.003
   St Vincent MR, 2010, P NATL ACAD SCI USA, V107, P17339, DOI 10.1073/pnas.1010026107
   Veiga S, 2004, BIOCHEM J, V377, P107, DOI 10.1042/BJ20031350
   Vieira CR, 2008, J PEPT SCI, V14, P448, DOI 10.1002/psc.1006
   Vigant F, 2010, CHEM BIOL, V17, P1049, DOI 10.1016/j.chembiol.2010.10.002
   Wang F, 2011, NAT MATER, V10, P968, DOI [10.1038/nmat3149, 10.1038/NMAT3149]
   Wang F, 2010, NATURE, V463, P1061, DOI 10.1038/nature08777
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]
   Wilen CB, 2012, ADV EXP MED BIOL, V726, P223, DOI 10.1007/978-1-4614-0980-9_10
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Zasloff M, 2011, P NATL ACAD SCI USA, V108, P15978, DOI 10.1073/pnas.1108558108
   Zhang L, 2012, J CELL BIOL, V196, P315, DOI 10.1083/jcb.201107058
NR 56
TC 32
Z9 32
U1 1
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2013
VL 9
IS 4
AR e1003297
DI 10.1371/journal.ppat.1003297
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 132MN
UT WOS:000318072700038
PM 23637597
OA gold
DA 2018-01-05
ER

PT J
AU Kimura, S
   Hase, K
   Ohno, H
AF Kimura, Shunsuke
   Hase, Koji
   Ohno, Hiroshi
TI The molecular basis of induction and formation of tunneling nanotubes
SO CELL AND TISSUE RESEARCH
LA English
DT Review
DE Tunneling nanotubes; M-Sec/TNFaip2/B94; Rho small GTPase family; Exocyst
   complex; HIV Nef
ID MEMBRANE NANOTUBES; EXOCYST COMPLEX; GAP-JUNCTIONS; VIRUS TYPE-1;
   T-CELLS; MITOCHONDRIAL TRANSFER; EXTENSIONS CYTONEMES; HUMAN
   NEUTROPHILS; P12(I) PROTEIN; CUTTING EDGE
AB Tunneling nanotubes (TNTs) and associated structures are recently recognized structures for intercellular communication. They are F-actin-containing thin protrusions of the plasma membrane of a cell and allow a direct physical connection to the plasma membranes of remote cells. TNTs and associated structures serve as mediators for intercellular transfer of organelles as well as membrane components and cytoplasmic molecules. Moreover, several pathogens have been shown to exploit these structures to spread among cells. Because of their contribution to normal cellular functions and importance in pathological conditions, studies on TNTs and related structures have accelerated over the past few years. These studies have revealed key molecules for their induction and/or formation; HIV Nef and M-Sec can induce the formation of TNTs in coordination with the remodeling of the actin cytoskeleton and vesicle trafficking.
C1 [Kimura, Shunsuke] Hokkaido Univ, Grad Sch Med, Lab Histol & Cytol, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
   [Kimura, Shunsuke; Ohno, Hiroshi] RIKEN, Res Ctr Allergy & Immunol, Lab Epithelial Immunobiol, Yokohama, Kanagawa 2300045, Japan.
   [Hase, Koji] Univ Tokyo, Inst Med Sci, Int R&D Ctr MucoVac, Lab Mucosal Barriol, Tokyo 1088639, Japan.
   [Hase, Koji] RIKEN, Res Ctr Allergy & Immunol, Lab Bioenvironm Epigenet, Yokohama, Kanagawa 2300045, Japan.
   [Hase, Koji] Japan Sci & Technol Agcy, PRESTO, Tokyo 1020075, Japan.
   [Ohno, Hiroshi] Yokohama City Univ, Grad Sch Nanobiosci, Dept Supramol Biol, Div Immunobiol, Yokohama, Kanagawa 2300045, Japan.
RP Ohno, H (reprint author), Yokohama City Univ, Grad Sch Nanobiosci, Dept Supramol Biol, Div Immunobiol, 1-7-29 Suehiro, Yokohama, Kanagawa 2300045, Japan.
EM ohno@rcai.riken.jp
RI Kimura, Shunsuke/D-7093-2012; Ohno, Hiroshi/L-7899-2014
OI Kimura, Shunsuke/0000-0001-9408-2884; Ohno, Hiroshi/0000-0001-8776-9661
CR Aggarwal A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002762
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Arkwright PD, 2011, CELL RES, V20, P72
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Eugenin EA, 2003, J IMMUNOL, V170, P1320, DOI 10.4049/jimmunol.170.3.1320                                                     
   Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x
   Fukumoto R, 2007, J VIROL, V81, P9088, DOI 10.1128/JVI.02703-06
   Fukumoto R, 2009, BLOOD, V113, P3726, DOI 10.1182/blood-2008-04-146928
   Galkina SI, 2012, BIOCH BIOPHYS ACTA
   Galkina SI, 2011, FEMS IMMUNOL MED MIC, V61, P114, DOI 10.1111/j.1574-695X.2010.00754.x
   Galkina SI, 2010, CELL ADHES MIGR, V4, P32, DOI 10.4161/cam.4.1.10314
   Galkina SI, 2009, FEMS IMMUNOL MED MIC, V56, P162, DOI 10.1111/j.1574-695X.2009.00560.x
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   He B, 2009, CURR OPIN CELL BIOL, V21, P537, DOI 10.1016/j.ceb.2009.04.007
   Hung CH, 2007, CELL HOST MICROBE, V1, P121, DOI 10.1016/j.chom.2007.03.004
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Jin RS, 2005, EMBO J, V24, P2064, DOI 10.1038/sj.emboj.7600699
   KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003
   Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Liu J, 2012, CURR BIOL
   Lokar M, 2010, PROTOPLASMA, V246, P81, DOI 10.1007/s00709-010-0143-7
   Luchetti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035766
   Martinez AD, 2002, BRAIN RES, V943, P191, DOI 10.1016/S0006-8993(02)02621-5                                                   
   Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728
   Mukerji J, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-33
   Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200                                                          
   Nikolic DS, 2011, BLOOD, V118, P4841, DOI 10.1182/blood-2010-09-305417
   Nobile C, 2010, J VIROL, V84, P2282, DOI 10.1128/JVI.02230-09
   Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122
   Onfelt B, 2004, J IMMUNOL, V173, P1511, DOI 10.4049/jimmunol.173.3.1511                                                     
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Oviedo-Orta E, 2004, BBA-BIOMEMBRANES, V1662, P102, DOI 10.1016/j.bbamem.2003.10.021
   Pasquier J, 2012, J BIOL CHEM, V287, P7374, DOI 10.1074/jbc.M111.312157
   Ranzinger J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029537
   Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150                                                        
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Rustom A, 2009, ANN NY ACAD SCI, V1178, P129, DOI 10.1111/j.1749-6632.2009.04997.x
   Saito T, 2006, CURR OPIN IMMUNOL, V18, P305, DOI 10.1016/j.coi.2006.03.014
   SAKSELA K, 1995, EMBO J, V14, P484
   SARMA V, 1992, J IMMUNOL, V148, P3302
   Scott G, 2002, J CELL SCI, V115, P1441
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Sowinski S, 2011, METHODS, V53, P27, DOI 10.1016/j.ymeth.2010.04.002
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725
   Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720
   Twiss JL, 2009, TRENDS CELL BIOL, V19, P236, DOI 10.1016/j.tcb.2009.02.007
   Van Prooyen N, 2010, P NATL ACAD SCI USA, V107, P20738, DOI 10.1073/pnas.1009635107
   Veranic P, 2008, BIOPHYS J, V95, P4416, DOI 10.1529/biophysj.108.131375
   Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147
   Watkins SC, 2005, IMMUNITY, V23, P309, DOI 10.1016/j.immuni.2005.08.009
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Yasuda K, 2011, AGING-US, V3, P597, DOI 10.18632/aging.100341                                                           
   Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507
NR 67
TC 22
Z9 23
U1 0
U2 38
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD APR
PY 2013
VL 352
IS 1
BP 67
EP 76
DI 10.1007/s00441-012-1518-1
PG 10
WC Cell Biology
SC Cell Biology
GA 110XY
UT WOS:000316482200007
PM 23229356
DA 2018-01-05
ER

PT J
AU Togami, H
   Shimura, K
   Okamoto, M
   Yoshikawa, R
   Miyazawa, T
   Matsuoka, M
AF Togami, Hiroaki
   Shimura, Kazuya
   Okamoto, Munehiro
   Yoshikawa, Rokusuke
   Miyazawa, Takayuki
   Matsuoka, Masao
TI Comprehensive In Vitro Analysis of Simian Retrovirus Type 4
   Susceptibility to Antiretroviral Agents
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITORS; LANGURS
   SEMNOPITHECUS-ENTELLUS; IMMUNE-DEFICIENCY SYNDROME; TO-CELL SPREAD;
   DRUG-RESISTANCE; NONNUCLEOSIDE INHIBITORS; RHESUS-MONKEYS; HTLV-I;
   INFECTION
AB Simian retrovirus type 4 (SRV-4), a simian type D retrovirus, naturally infects cynomolgus monkeys, usually without apparent symptoms. However, some infected monkeys presented with an immunosuppressive syndrome resembling that induced by simian immunodeficiency virus infection. Antiretrovirals with inhibitory activity against SRV-4 are considered to be promising agents to combat SRV-4 infection. However, although some antiretrovirals have been reported to have inhibitory activity against SRV-1 and SRV-2, inhibitors with anti-SRV-4 activity have not yet been studied. In this study, we identified antiretroviral agents with anti-SRV-4 activity from a panel of anti-human immunodeficiency virus (HIV) drugs using a robust in vitro luciferase reporter assay. Among these, two HIV reverse transcriptase inhibitors, zidovudine (AZT) and tenofovir disoproxil fumarate (TDF), potently inhibited SRV-4 infection within a submicromolar to nanomolar range, which was similar to or higher than the activities against HIV-1, Moloney murine leukemia virus, and feline immunodeficiency virus. In contrast, nonnucleoside reverse transcriptase inhibitors and protease inhibitors did not exhibit any activities against SRV-4. Although both AZT and TDF effectively inhibited cell-free SRV-4 transmission, they exhibited only partial inhibitory activities against cell-to-cell transmission. Importantly, one HIV integrase strand transfer inhibitor, raltegravir (RAL), potently inhibited single-round infection as well as cell-free and cell-to-cell SRV-4 transmission. These findings indicate that viral expansion routes impact the inhibitory activity of antiretrovirals against SRV-4, while only RAL is effective in suppressing both the initial SRV-4 infection and subsequent SRV-4 replication.
C1 [Togami, Hiroaki; Shimura, Kazuya; Matsuoka, Masao] Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto 606, Japan.
   [Okamoto, Munehiro] Kyoto Univ, Primate Res Inst, Sect Wildlife Div, Ctr Human Evolut Modeling Res, Inuyama, Aichi 484, Japan.
   [Yoshikawa, Rokusuke; Miyazawa, Takayuki] Kyoto Univ, Inst Virus Res, Lab Signal Transduct, Kyoto 606, Japan.
RP Shimura, K (reprint author), Kyoto Univ, Inst Virus Res, Lab Virus Control, Kyoto 606, Japan.
EM kshimura@virus.kyoto-u.ac.jp
OI SHIMURA, Kazuya/0000-0001-7819-5184; Matsuoka, Masao/0000-0002-0473-754X
FU JSPS KAKENHI [24791021, 24300153]
FX This work was supported in part by a JSPS KAKENHI grant-in-aid for young
   scientists (B) to K. S. (grant number 24791021) and a grant-in-aid for
   scientific research (B) to M.O. (grant number 24300153).
CR Auwerx J, 2004, MOL PHARMACOL, V65, P244, DOI 10.1124/mol.65.1.244
   Balzarini J, 2000, PHARMACOL THERAPEUT, V87, P175, DOI 10.1016/S0163-7258(00)00050-4
   Beck-Engeser GB, 2009, P NATL ACAD SCI USA, V106, P20865, DOI 10.1073/pnas.0908074106
   Canducci F, 2009, AIDS, V23, P455, DOI 10.1097/QAD.0b013e328323da60
   CDC-KUPRI, 2010, PRIMATE RES, V26, P69
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Cyranoski D, 2010, NATURE, V466, P302, DOI 10.1038/466302a
   DAHLBERG JE, 1987, P NATL ACAD SCI USA, V84, P2469, DOI 10.1073/pnas.84.8.2469
   DANIEL MD, 1984, SCIENCE, V223, P602, DOI 10.1126/science.6695172
   De Clercq E, 2005, NAT REV DRUG DISCOV, V4, P928, DOI 10.1038/nrd1877
   De Clercq E, 2009, REV MED VIROL, V19, P287, DOI 10.1002/rmv.624
   Fransen S, 2009, J VIROL, V83, P11440, DOI 10.1128/JVI.01168-09
   GAO Q, 1992, J VIROL, V66, P12
   Hara M, 2005, MICROBES INFECT, V7, P126, DOI 10.1016/j.micinf.2004.08.021
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   HENRICKSON RV, 1984, LAB ANIM SCI, V34, P140
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Ikeda T, 2004, J VIROL, V78, P11563, DOI 10.1128/JVI.78.21.11563-11573.2004
   Johnson Victoria A, 2011, Top Antivir Med, V19, P156
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   KATO N, 1995, BIOCHEM BIOPH RES CO, V206, P863, DOI 10.1006/bbrc.1995.1123
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Koh Y, 2011, J VIROL, V85, P3677, DOI 10.1128/JVI.02541-10
   Lerche NW, 2001, J VIROL, V75, P1783, DOI 10.1128/JVI.75.4.1783-1789.2001
   Lewis MG, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-21
   Li B, 2000, VIRUS GENES, V21, P241, DOI 10.1023/A:1008104000920
   LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157                                                       
   MARX PA, 1984, SCIENCE, V223, P1083, DOI 10.1126/science.6695196
   MARX PA, 1985, J VIROL, V56, P571
   Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111
   MATSUSHITA S, 1987, J CLIN INVEST, V80, P394, DOI 10.1172/JCI113085
   MAUL DH, 1988, J VIROL, V62, P1768
   Miyazato P, 2006, J VIROL, V80, P10683, DOI 10.1128/JVI.01009-06
   Montiel NA, 2010, J MED PRIMATOL, V39, P303, DOI 10.1111/j.1600-0684.2010.00412.x
   Nandi JS, 2006, VIRUS GENES, V33, P107, DOI 10.1007/s11262-005-0032-x
   Nandi JS, 2000, VIROLOGY, V277, P6, DOI 10.1006/viro.2000.0567
   Nandi JS, 2003, VIROLOGY, V311, P192, DOI 10.1016/S0042-6822(03)00187-9
   NORTH TW, 1989, ANTIMICROB AGENTS CH, V33, P915, DOI 10.1128/AAC.33.6.915                                                            
   Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065
   Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292
   Piliero PJ, 2004, JAIDS-J ACQ IMM DEF, V37, pS2, DOI 10.1097/01.qai.0000137001.40505.56
   Powell SK, 1999, J VIROL, V73, P8813
   Quan YD, 1998, J MOL BIOL, V277, P237, DOI 10.1006/jmbi.1997.1592
   Ray AS, 2005, AIDS REV, V7, P113
   Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699
   Ren JS, 2008, VIRUS RES, V134, P157, DOI 10.1016/j.virusres.2007.12.018
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   Rosenblum LL, 2001, ANTIVIR CHEM CHEMOTH, V12, P91, DOI 10.1177/095632020101200202                                                      
   Sakuma R, 2010, VIROLOGY, V397, P1, DOI 10.1016/j.virol.2009.11.013
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Shafer RW, 2006, J INFECT DIS, V194, pS51, DOI 10.1086/505356                                                                  
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398                                                          
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Smith RA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-70
   Snasel J, 2005, FEBS J, V272, P203, DOI 10.1111/j.1432-1033.2004.04386.x
   Tailor CS, 1999, J VIROL, V73, P4470
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653
   TSAI CC, 1989, ANTIMICROB AGENTS CH, V33, P1908, DOI 10.1128/AAC.33.11.1908                                                          
   TSAI CC, 1988, AIDS RES HUM RETROV, V4, P359, DOI 10.1089/aid.1988.4.359
   Tsurutani N, 2000, J VIROL, V74, P4795, DOI 10.1128/JVI.74.10.4795-4806.2000
   White JA, 2009, J VIROL METHODS, V162, P148, DOI 10.1016/j.jviromet.2009.07.030
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Zao CL, 2011, ARCH VIROL, V156, P2053, DOI 10.1007/s00705-011-1068-y
   Zao CL, 2010, VIROLOGY, V405, P390, DOI 10.1016/j.virol.2010.06.028
   Zhu YQ, 1996, ANTIMICROB AGENTS CH, V40, P1983
NR 68
TC 3
Z9 4
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD APR
PY 2013
VL 87
IS 8
BP 4322
EP 4329
DI 10.1128/JVI.03208-12
PG 8
WC Virology
SC Virology
GA 113MC
UT WOS:000316671000018
PM 23365453
OA gold
DA 2018-01-05
ER

PT J
AU Hirobe, S
   Okada, N
   Nakagawa, S
AF Hirobe, Sachiko
   Okada, Naoki
   Nakagawa, Shinsaku
TI Transcutaneous vaccines - current and emerging strategies
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE adjuvant; clinical study; microneedle; skin; transcutaneous vaccination
ID EPIDERMAL POWDER IMMUNIZATION; TRANSDERMAL DRUG-DELIVERY; HEAT-LABILE
   TOXIN; DISSOLVING MICRONEEDLE ARRAY; LOW-FREQUENCY ULTRASOUND; CYTOTOXIC
   T-LYMPHOCYTES; HIV-1 DNA VACCINE; INFLUENZA-A VIRUS; IMMUNE-RESPONSES;
   ANTIBODY-RESPONSES
AB Introduction: Vaccination, which is the major fundamental prophylaxis against illness and death from infectious disease, has greatly contributed to the global improvement of human health. However, the disadvantages of conventional injection systems hamper the delivery of vaccination technologies to developing countries. The imminent practice of easy-to-use vaccination methods is expected to overcome certain issues associated with injectable vaccinations. One innovative method is the transcutaneous immunization (TCI) system.
   Areas covered: Two major strategies for TCI are discussed in this review. One is to promote antigen permeation of the skin barrier by patch systems or nanoparticles. The other is the delivery of antigens into the skin by electroporation and microneedles in order to physically overcome the skin barrier. Moreover, adjuvant development for TCI is discussed.
   Expert opinion: Many different approaches have been developed for TCI, which have the potential to be effective, easy-to-use and painless methods of vaccination. However, in practical terms, the guidelines concerning the manufacturing processes and clinical trial evaluation of the procedures have not kept pace with the development of these novel formulations. The accumulation of information regarding skin characteristics and the properties of TCI devices will help refine TCI system development guidelines and thus lead to the improvement of transcutaneous vaccination.
C1 [Hirobe, Sachiko; Okada, Naoki; Nakagawa, Shinsaku] Osaka Univ, Grad Sch Pharmaceut Sci, Lab Biotechnol & Therapeut, Suita, Osaka 5650871, Japan.
RP Okada, N (reprint author), Osaka Univ, Grad Sch Pharmaceut Sci, Lab Biotechnol & Therapeut, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.
EM okada@phs.osaka-u.ac.jp; nakagawa@phs.osaka-u.ac.jp
FU National Institute of Biomedical Innovation (NIBIO); Ministry of Health,
   Labour and Welfare; Ministry of Education, Culture, Sports, Science and
   Technology of Japan
FX Our studies mentioned in this review were conducted in collaboration
   with CosMED Pharmaceutics Co. Ltd., Nara Medical University, Osaka
   University Graduate School of Medicine, and The Research Foundation for
   Microbial Diseases of Osaka University. Our work was supported by the
   National Institute of Biomedical Innovation (NIBIO), the Ministry of
   Health, Labour and Welfare, and the Ministry of Education, Culture,
   Sports, Science and Technology of Japan.
CR Aboud S, 2010, CLIN VACCINE IMMUNOL, V17, P1124, DOI 10.1128/CVI.00008-10
   Anjuere F, 2003, J IMMUNOL, V170, P1586, DOI 10.4049/jimmunol.170.3.1586                                                     
   Azad Neelam, 2006, Current Drug Delivery, V3, P137, DOI 10.2174/156720106776359249
   Bal SM, 2011, VACCINE, V29, P4025, DOI 10.1016/j.vaccine.2011.03.039
   Bal SM, 2010, PHARM RES-DORDR, V27, P1837, DOI 10.1007/s11095-010-0182-y
   Bal SM, 2010, J CONTROL RELEASE, V142, P374, DOI 10.1016/j.jconrel.2009.11.018
   Banks SL, 2008, PHARM RES-DORDR, V25, P1677, DOI 10.1007/s11095-008-9578-3
   Barry BW, 2004, NAT BIOTECHNOL, V22, P165, DOI 10.1038/nbt0204-165                                                             
   Beignon AS, 2002, IMMUNOLOGY, V105, P204, DOI 10.1046/j.0019-2805.2001.01357.x
   Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555
   Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x
   Braun RP, 2008, HUM VACCINES, V4, P36, DOI 10.4161/hv.4.1.4876                                                             
   Campbell CC, 1997, FEMS IMMUNOL MED MIC, V18, P325, DOI 10.1016/S0928-8244(97)00065-5                                                   
   Cassaday RD, 2007, CLIN CANCER RES, V13, P540, DOI 10.1158/1078-0432.CCR-06-2039
   Celli S, 2011, NAT MED, V17, P744, DOI 10.1038/nm.2376
   Chen D, 2002, AIDS RES HUM RETROV, V18, P715, DOI 10.1089/088922202760072348                                                      
   Chen DX, 2003, VACCINE, V21, P2830, DOI 10.1016/S0264-410X(03)00175-0
   Chen DX, 2001, J VIROL, V75, P11630, DOI 10.1128/JVI.75.23.11630-11640.2001
   Chen XF, 2009, J CONTROL RELEASE, V139, P212, DOI 10.1016/j.jconrel.2009.06.029
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818
   Cristillo AD, 2008, BIOCHEM BIOPH RES CO, V366, P29, DOI 10.1016/j.bbrc.2007.11.052
   Dahlan A, 2009, INT J PHARMACEUT, V379, P139, DOI 10.1016/j.ijpharm.2009.06.011
   Dahlan A, 2009, INT J PHARM, V368, P123, DOI 10.1016/j.ijpharm.2008.10.014
   Davis SP, 2004, J BIOMECH, V37, P1155, DOI 10.1016/j.jbiomech.2003.12.010
   Dincer Z, 2006, EXP TOXICOL PATHOL, V57, P351, DOI 10.1016/j.etp.2006.03.014
   Ding Z, 2009, J CONTROL RELEASE, V136, P71, DOI 10.1016/j.jconrel.2009.01.025
   Ding Z, 2009, PHARM RES-DORD, V26, P1635, DOI 10.1007/s11095-009-9874-6
   Donnelly RF, 2010, DRUG DELIV, V17, P187, DOI 10.3109/10717541003667798
   Drape RJ, 2006, VACCINE, V24, P4475, DOI 10.1016/j.vaccine.2005.08.012
   El Maghraby GMM, 2004, INT J PHARM, V276, P143, DOI 10.1016/j.ijpharm.2004.02.024
   Epstein JE, 2002, HUM GENE THER, V13, P1551, DOI 10.1089/10430340260201644
   Frech SA, 2005, VACCINE, V23, P946, DOI 10.1016/j.vaccine.2004.06.036
   Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9
   Gill HS, 2007, PHARM RES, V24, P1369, DOI 10.1007/s11095-007-9286-4
   Gill HS, 2007, J CONTROL RELEASE, V117, P227, DOI 10.1016/j.jconrel.2006.10.017
   Glenn G M, 1999, Expert Opin Investig Drugs, V8, P797, DOI 10.1517/13543784.8.6.797
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014                                                                   
   Glenn GM, 2007, INFECT IMMUN, V75, P2163, DOI 10.1128/IAI.01740-06
   Gockel CM, 2000, MOL IMMUNOL, V37, P537, DOI 10.1016/S0161-5890(00)00074-2
   Gupta PN, 2005, INT J PHARM, V293, P73, DOI 10.1016/j.ijpharm.2004.12.022
   Haque A, 2007, ANN BIOL CLIN-PARIS, V65, P125
   Henry S, 1998, J PHARM SCI, V87, P922, DOI 10.1021/js980042+                                                               
   Hirao LA, 2008, VACCINE, V26, P440, DOI 10.1016/j.vaccine.2007.10.041
   Hirobe S, 2012, VACCINE, V30, P1847, DOI 10.1016/j.vaccine.2011.12.130
   Hooper JW, 2007, VACCINE, V25, P1814, DOI 10.1016/j.vaccine.2006.11.017
   Ishii Y, 2008, J CONTROL RELEASE, V131, P113, DOI 10.1016/j.jconrel.2008.07.025
   Ito Y, 2006, EUR J PHARM SCI, V29, P82, DOI 10.1016/j.ejps.2006.05.011
   Ito Y, 2006, J DRUG TARGET, V14, P255, DOI 10.1080/10611860600785080
   Jain S, 2005, J PHARM PHARMACOL, V57, P1177, DOI 10.1211/jpp.57.9.0012
   Johnston D, 2006, VACCINE, V24, P1958, DOI 10.1016/j.vaccine.2005.10.045
   Jones JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008032
   Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061
   Kahlon R, 2003, VACCINE, V21, P2890, DOI 10.1016/S0264-410X(03)00141-5
   Kelly K, 2008, VACCINE, V26, P1344, DOI 10.1016/j.vaccine.2007.12.041
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Kersten G, 2007, EXPERT OPIN DRUG DEL, V4, P459, DOI 10.1517/17425247.4.5.459
   Kim YC, 2012, ADV DRUG DELIVER REV, V64, P1547, DOI 10.1016/j.addr.2012.04.005
   Kim YC, 2011, PHARM RES-DORDR, V28, P135, DOI 10.1007/s11095-010-0134-6
   Kim YC, 2010, J CONTROL RELEASE, V142, P187, DOI 10.1016/j.jconrel.2009.10.013
   Kohli AK, 2004, INT J PHARM, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038
   Laurent PE, 2007, VACCINE, V25, P8833, DOI 10.1016/j.vaceine.2007.10.020
   Leppin A, 2009, INT J BEHAV MED, V16, P7, DOI 10.1007/s12529-008-9002-8
   Levine MM, 2003, NAT MED, V9, P99, DOI 10.1038/nm0103-99
   Macklin MD, 1998, J VIROL, V72, P1491
   Manning BM, 2001, EXP GERONTOL, V37, P107, DOI 10.1016/S0531-5565(01)00157-7
   Martanto W, 2006, J CONTROL RELEASE, V112, P357, DOI 10.1016/j.jconrel.2006.02.017
   Martanto W, 2006, PHARM RES, V23, P104, DOI 10.1007/s11095-005-8498-8
   Mathers AR, 2006, IMMUNOL RES, V36, P127, DOI 10.1385/IR:36:1:127                                                             
   Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040                                                         
   Matsuo K, 2012, J CONTROL RELEASE, V161, P10, DOI 10.1016/j.jconrel.2012.01.033
   Matsuo K, 2012, J CONTROL RELEASE, V160, P495, DOI 10.1016/j.jconrel.2012.04.001
   Matsuo K, 2011, BIOL PHARM BULL, V34, P1835, DOI 10.1248/bpb.34.1835                                                             
   Matsuo K, 2011, BIOL PHARM BULL, V34, P586, DOI 10.1248/bpb.34.586                                                              
   Matsuo K, 2011, J CONTROL RELEASE, V149, P15, DOI 10.1016/j.jconrel.2010.05.012
   Mattheolabakis G, 2010, INT J PHARMACEUT, V385, P187, DOI 10.1016/j.ijpharm.2009.10.033
   McAllister DV, 2003, P NATL ACAD SCI USA, V100, P13755, DOI 10.1073/pnas.2331316100
   McKenzie R, 2007, VACCINE, V25, P3684, DOI 10.1016/j.vaccine.2007.01.043
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131                                                                   
   Metz M, 2008, IMMUNOBIOLOGY, V213, P251, DOI 10.1016/j.imbio.2007.10.017
   Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415
   Mishra D, 2008, EUR J PHARM SCI, V33, P424, DOI 10.1016/j.ejps.2008.01.015
   Miyano T, 2005, BIOMED MICRODEVICES, V7, P185, DOI 10.1007/s10544-005-3024-7
   Mutyambizi K, 2009, CELL MOL LIFE SCI, V66, P831, DOI 10.1007/s00018-008-8470-y
   Nagpal K, 2010, CHEM PHARM BULL, V58, P1423, DOI 10.1248/cpb.58.1423                                                             
   Nestle FO, 2007, J CLIN INVEST, V117, P2382, DOI 10.1172/JC133349
   Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718
   Ozaki T, 2005, VIRAL IMMUNOL, V18, P373, DOI 10.1089/vim.2005.18.373
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Paul A, 1995, EUR J IMMUNOL, V25, P3521, DOI 10.1002/eji.1830251248
   Paul A, 1998, VACCINE, V16, P188, DOI 10.1016/S0264-410X(97)00185-0
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Prausnitz MR, 2009, CURR TOP MICROBIOL, V333, P369, DOI 10.1007/978-3-540-92165-3_18
   PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504
   Prego C, 2010, VACCINE, V28, P2607, DOI 10.1016/j.vaccine.2010.01.011
   Prymula R, 2012, ADV THER, V29, P41, DOI 10.1007/s12325-011-0090-5
   REIHSNER R, 1995, MED ENG PHYS, V17, P304, DOI 10.1016/1350-4533(95)90856-7
   Roberts LK, 2005, VACCINE, V23, P4867, DOI 10.1016/j.vaccine.2005.05.026
   ROUGIER A, 1990, ARCH DERMATOL RES, V282, P498, DOI 10.1007/BF00371943
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Seya T, 2006, EVID-BASED COMPL ALT, V3, P31, DOI 10.1093/ecam/nek010
   SEYA T, 2006, EVID-BASED COMPL ALT, V3, P133
   Shaker DS, 2007, MOL THER, V15, P2037, DOI 10.1038/sj.mt.6300286
   Sugita K, 2007, CLIN EXP IMMUNOL, V147, P176, DOI 10.1111/j.1365-2249.2006.03258.x
   Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182
   Tezel A, 2005, VACCINE, V23, P3800, DOI 10.1016/j.vaccine.2005.02.027
   Thissen M R T M, 2006, J Drugs Dermatol, V5, P461
   Tierney R, 2003, J INFECT DIS, V188, P753, DOI 10.1086/377287
   UNICEF's work on immunisation, 1976, [No title captured], Patent No. [1976964482, 3 1976; 964: 482]
   Valadas E, 2005, EUR J RADIOL, V55, P154, DOI 10.1016/j.ejrad.2005.04.013
   Valladeau J, 2005, SEMIN IMMUNOL, V17, P273, DOI 10.1016/j.smim.2005.05.009
   Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077
   van der Maaden K, 2012, J CONTROL RELEASE, V161, P645, DOI 10.1016/j.jconrel.2012.01.042
   VANBEVER R, 1994, PHARMACEUT RES, V11, P1657, DOI 10.1023/A:1018930425591                                                         
   Verbaan FJ, 2008, J CONTROL RELEASE, V128, P80, DOI 10.1016/j.jconrel.2008.02.009
   Vogt A, 2008, J IMMUNOL, V180, P1482, DOI 10.4049/jimmunol.180.3.1482                                                     
   Vogt A, 2006, J INVEST DERMATOL, V126, P1316, DOI 10.1038/sj.jid.5700226
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Weaver J C, 1995, Methods Mol Biol, V55, P3
   Widera G, 2006, VACCINE, V24, P1653, DOI 10.1016/j.vaccine.2005.09.049
   Williams J, 2000, VACCINE, V18, P1939, DOI 10.1016/S0264-410X(99)00446-6
   Yagi H, 2006, CANCER RES, V66, P10136, DOI 10.1158/0008-5472.CAN-06-1029
   Zhao YL, 2006, VACCINE, V24, P1282, DOI 10.1016/j.vaccine.2005.09.035
   Zhu JZ, 2008, MOL IMMUNOL, V45, P3238, DOI 10.1016/j.molimm.2008.02.028
   Zhu QY, 2009, P NATL ACAD SCI USA, V106, P7968, DOI 10.1073/pnas.0812652106
NR 126
TC 11
Z9 11
U1 0
U2 47
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD APR
PY 2013
VL 10
IS 4
BP 485
EP 498
DI 10.1517/17425247.2013.760542
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 106FK
UT WOS:000316128100006
PM 23316778
DA 2018-01-05
ER

PT J
AU Wang, C
   Shi, WG
   Cai, LF
   Lu, L
   Wang, Q
   Zhang, TH
   Li, JL
   Zhang, ZQ
   Wang, K
   Xu, L
   Jiang, XF
   Jiang, SB
   Liu, KL
AF Wang, Chao
   Shi, Weiguo
   Cai, Lifeng
   Lu, Lu
   Wang, Qian
   Zhang, Tianhong
   Li, Jinglai
   Zhang, Zhenqing
   Wang, Kun
   Xu, Liang
   Jiang, Xifeng
   Jiang, Shibo
   Liu, Keliang
TI Design, Synthesis, and Biological Evaluation of Highly Potent Small
   Molecule-Peptide Conjugates as New HIV-1 Fusion Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUBSTITUTED PYRROLE DERIVATIVES; 6-HELIX
   BUNDLE FORMATION; GP41 COILED-COIL; TARGETING GP41; ENTRY INHIBITORS;
   MEDIATED FUSION; IN-VITRO; CORE; ENFUVIRTIDE
AB The small molecule fusion inhibitors N-(4-carboxy-3-hydroxyphenyl)-2,5-dimethylpyrrole (NB-2) and N-(3-carboxy-4-hydroxyphenyl)-2,S-dimethylpyrrole (A(12)) target a hydrophobic pocket of HIV-1 gp41 and have moderate anti-HIV-1 activity. In this paper, we report the design, synthesis, and structure-activity relationship of a group of hybrid molecules in which the pocket-binding domain segment of the C34 peptide was replaced with NB-2 and A(12) derivatives. In addition, the synergistic effect between the small molecule and peptide moieties was analyzed, and lead compounds with a novel scaffold were discovered. We found that either the nonpeptide or peptide part alone showed weak activity against HIV-1-mediated cell-cell fusion, but the conjugates properly generated a strong synergistic effect. Among them, conjugates Aoc-beta Ala-P26 and Noc-beta Ala-P26 exhibited a low nanomolar IC50 in the cell-cell fusion assay and effectively inhibited T20-sensitive and -resistant HIV-1 strains. Furthermore, the new molecules exhibited better stability against proteinase K digestion than T20 and C34.
C1 [Wang, Chao; Shi, Weiguo; Cai, Lifeng; Zhang, Tianhong; Li, Jinglai; Zhang, Zhenqing; Wang, Kun; Xu, Liang; Jiang, Xifeng; Liu, Keliang] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Shanghai Med Coll, Minist Educ, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Shanghai Med Coll, Minist Hlth, Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   [Lu, Lu; Wang, Qian; Jiang, Shibo] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China.
RP Liu, KL (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM shibojiang@fudan.edu.cn; keliangliu55@126.com
RI Lu, Lu/K-7070-2014; Wang, Chao/J-3250-2015; Jiang, Shibo/L-4500-2014
OI Wang, Chao/0000-0002-7673-0638; Lu, Lu/0000-0002-2255-0391
FU National Science Foundation of China [81072581, 81273560]; National
   Science and Technology Major Project of China grant [2012ZX09301003]
FX This research was supported, in part, by grants from the National
   Science Foundation of China (81072581 and 81273560) and a National
   Science and Technology Major Project of China grant (2012ZX09301003).
CR Ashkenazi A, 2011, EUR BIOPHYS J BIOPHY, V40, P349, DOI 10.1007/s00249-010-0666-z
   Balogh E, 2009, J AM CHEM SOC, V131, P2821, DOI 10.1021/ja8094558
   Cai LF, 2007, ANTIMICROB AGENTS CH, V51, P2388, DOI 10.1128/AAC.00150-07
   Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Cai LF, 2009, ANTIMICROB AGENTS CH, V53, P2444, DOI 10.1128/AAC.00150-09
   CASE DA, 2004, AMBER 8
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Ferrer M, 1999, NAT STRUCT BIOL, V6, P953
   Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103
   Gallo SA, 2001, BIOCHEMISTRY-US, V40, P12231, DOI 10.1021/bi0155596
   Gochin M, 2010, ACS CHEM BIOL, V6, P267, DOI 10.1021/cb100368d
   Gochin M, 2011, CURR TOP MED CHEM, V11, P3022, DOI 10.2174/156802611798808488                                                      
   He YX, 2008, P NATL ACAD SCI USA, V105, P16332, DOI 10.1073/pnas.0807335105
   Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004
   Jiang SB, 2002, CURR PHARM DESIGN, V8, P563
   Jiang SB, 2011, J MED CHEM, V54, P572, DOI 10.1021/jm101014v
   Liu K, 2008, J MED CHEM, V51, P7843, DOI 10.1021/jm800869t
   Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200
   Liu SW, 2007, CURR PHARM DESIGN, V13, P143, DOI 10.2174/138161207779313722
   Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013
   Liu SW, 2003, J BIOMOL SCREEN, V8, P685, DOI 10.1177/1087057103259155
   Lu L, 2012, BBA-BIOMEMBRANES, V1818, P2950, DOI 10.1016/j.bbamem.2012.07.020
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Mink M, 2005, J VIROL, V79, P12447, DOI 10.1128/JVI.79.19.12447-12454.2005
   Mo HM, 2004, VIROLOGY, V329, P319, DOI 10.1016/j.virol.2004.08.025
   Naider F, 2009, CURR OPIN STRUC BIOL, V19, P473, DOI 10.1016/j.sbi.2009.07.003
   Naito T, 2009, ANTIMICROB AGENTS CH, V53, P1013, DOI 10.1128/AAC.01211-08
   Pan CG, 2010, J FORMOS MED ASSOC, V109, P94, DOI 10.1016/S0929-6646(10)60029-0
   Pang W, 2008, VIROLOGY, V377, P80, DOI 10.1016/j.virol.2008.04.013
   Tan JJ, 2011, MED CHEM, V7, P309
   Teixeira C, 2008, BIOORGAN MED CHEM, V16, P3039, DOI 10.1016/j.bmc.2007.12.034
   Wang C, 2004, BIOORGAN MED CHEM, V12, P4403, DOI 10.1016/j.bmc.2004.06.012
   Wang Y, 2010, BIOORG MED CHEM LETT, V20, P189, DOI 10.1016/j.bmcl.2009.10.139
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Xu Y, 2006, J COMB CHEM, V8, P531, DOI 10.1021/cc0600167
   Zhou GF, 2000, BIOORGAN MED CHEM, V8, P2219, DOI 10.1016/S0968-0896(00)00155-3                                                   
   Zhou GY, 2010, BIOORG MED CHEM LETT, V20, P1500, DOI 10.1016/j.bmcl.2010.01.111
NR 41
TC 19
Z9 19
U1 2
U2 51
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 28
PY 2013
VL 56
IS 6
BP 2527
EP 2539
DI 10.1021/jm3018964
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 118NM
UT WOS:000317032200029
PM 23458727
DA 2018-01-05
ER

PT J
AU Fuentes-Paniagua, E
   Pena-Gonzalez, CE
   Galan, M
   Gomez, R
   de la Mata, FJ
   Sanchez-Nieves, J
AF Fuentes-Paniagua, Elena
   Pena-Gonzalez, Cornelia E.
   Galan, Marta
   Gomez, Rafael
   Javier de la Mata, F.
   Sanchez-Nieves, Javier
TI Thiol-Ene Synthesis of Cationic Carbosilane Dendrons: a New Family of
   Synthons
SO ORGANOMETALLICS
LA English
DT Article
ID STABILIZED GOLD NANOPARTICLES; CLICK CHEMISTRY; EFFECTIVE CARRIERS;
   DENDRIMER 2G-NN16; BUILDING-BLOCKS; DRUG-DELIVERY; GENE DELIVERY; HIV;
   BIOCOMPATIBILITY; MACROMOLECULES
AB A variety of neutral and cationic carbosilane dendrons containing a wide range of active groups, such as -N-3, -OH, -NH2, and -SH, at the focal points were synthesized from carbosilane vinyl dendrons BrG(n)V(m) from generations 1-3 by substitution of the bromine atom at the focal point and functionalization of the vinyl groups via thiol-ene click chemistry with HS(CH2)(2)NMe2 center dot HCl. These dendritic wedges were characterized by NMR, MS, and elemental analysis.
C1 [Fuentes-Paniagua, Elena; Pena-Gonzalez, Cornelia E.; Galan, Marta; Gomez, Rafael; Javier de la Mata, F.; Sanchez-Nieves, Javier] Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, E-28871 Alcala De Henares, Madrid, Spain.
   [Fuentes-Paniagua, Elena; Gomez, Rafael; Javier de la Mata, F.; Sanchez-Nieves, Javier] Univ Alcala de Henares, Networking Res Ctr Bioengn Biomat & Nanomed CIBER, E-28871 Alcala De Henares, Madrid, Spain.
RP Gomez, R (reprint author), Univ Alcala de Henares, Dept Quim Organ & Quim Inorgan, Campus Univ, E-28871 Alcala De Henares, Madrid, Spain.
RI De la Mata, F. Javier/K-1649-2014; Gomez Ramirez, Rafael/K-1216-2014;
   Sanchez-Nieves, Javier/J-9260-2014
OI De la Mata, F. Javier/0000-0003-0418-3935; Gomez Ramirez,
   Rafael/0000-0001-6448-2414; Sanchez-Nieves, Javier/0000-0003-0410-2285;
   Pena Gonzalez, Cornelia E./0000-0002-9049-8804
FU MINECO [CTQ2011-23245]; Consortium NANODENDMED (CAM) [S2011/BMD-2351];
   University of Alcala [UAH2011/EXP-037]; CIBER-BBN; Instituto de Salud
   Carlos III; European Regional Development Fund; Ministerio de Educacion
   y Ciencia (Spain); Ministerio de Educacion Superior, Ciencia y
   Tecnologia (Dominican Republic)
FX This work was supported by the grants CTQ2011-23245 (MINECO) and
   Consortium NANODENDMED ref S2011/BMD-2351 (CAM) awarded to R.G. and
   UAH2011/EXP-037 (University of Alcala) awarded to F.J.d.l.M. This study
   was also supported by the CIBER-BBN financed by the Instituto de Salud
   Carlos III, with assistance from the European Regional Development Fund.
   E.F.-P. and M.G. acknowledge the Ministerio de Educacion y Ciencia
   (Spain), and C.E.P.-G. acknowledges the Ministerio de Educacion
   Superior, Ciencia y Tecnologia (Dominican Republic), for a fellowship.
CR Andres R, 2005, EUR J INORG CHEM, P3742, DOI 10.1002/ejic.200500182
   Arnaiz E, 2012, MOL PHARMACEUT, V9, P433, DOI 10.1021/mp200542j
   Astruc D, 2010, CHEM REV, V110, P1857, DOI 10.1021/cr900327d
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Berna M, 2006, BIOMACROMOLECULES, V7, P146, DOI 10.1021/bm050480s
   Caminade AM, 2006, EUR J INORG CHEM, P887, DOI 10.1002/ejic.200500893
   Carlmark A, 2009, CHEM SOC REV, V38, P352, DOI 10.1039/b711745k
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Cho TJ, 2011, CHEM MATER, V23, P2665, DOI 10.1021/cm200591h
   Chonco L, 2012, J CONTROL RELEASE, V161, P949, DOI 10.1016/j.jconrel.2012.04.050
   Cuadrado I, 1999, ADV DENDR MACROMOL, V3, P151
   Daniel MC, 2003, J AM CHEM SOC, V125, P2617, DOI 10.1021/ja021325d
   Daniel MC, 2001, CHEM COMMUN, P2000, DOI 10.1039/b106805a
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dutta T, 2010, NANOMED-NANOTECHNOL, V6, P25, DOI 10.1016/j.nano.2009.05.005
   Finn MG, 2010, CHEM SOC REV, V39, P1231, DOI 10.1039/c003740k
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Gras R, 2012, BIOMATERIALS, V33, P4002, DOI 10.1016/j.biomaterials.2012.02.018
   Gras R, 2012, MOL PHARMACEUT, V9, P102, DOI 10.1021/mp200305u
   Grayson SM, 2001, CHEM REV, V101, P3819, DOI 10.1021/cr990116h
   Hardy JG, 2009, ORG BIOMOL CHEM, V7, P789, DOI 10.1039/b818469k
   Hecht S, 2001, ANGEW CHEM INT EDIT, V40, P74, DOI 10.1002/1521-3773(20010105)40:1<74::AID-ANIE74>3.0.CO;2-C
   Heegaard PMH, 2010, BIOCONJUGATE CHEM, V21, P405, DOI 10.1021/bc900290d
   Jiang GH, 2007, MATER LETT, V61, P278, DOI 10.1016/j.matlet.2006.04.110
   Jimenez JL, 2012, J DRUG DELIV SCI TEC, V22, P75, DOI 10.1016/S1773-2247(12)50007-9                                                   
   Joshi N, 2008, CURR TOP MED CHEM, V8, P1225, DOI 10.2174/156802608785849067
   Kang T, 2010, CHEM COMMUN, V46, P1556, DOI 10.1039/b921598k
   Kim MK, 2001, CHEM COMMUN, P667, DOI 10.1039/b100575h                                                                
   Krupkova A, 2010, MACROMOLECULES, V43, P4511, DOI 10.1021/ma100315w
   Liang LY, 2011, COORDIN CHEM REV, V255, P2933, DOI 10.1016/j.ccr.2011.06.028
   Love A. B., 2010, POLYM CHEM, V1, P17
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Medina SH, 2009, CHEM REV, V109, P3141, DOI 10.1021/cr900174j
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Mori T, 2005, TETRAHEDRON, V61, P2751, DOI 10.1016/j.tet.2005.01.090
   Newkome GR, 2010, CHEM REV, V110, P6338, DOI 10.1021/cr900341m
   Newkome G. R., 2001, DENDRIMERS DENDRONS
   Nishikawa K, 2005, J INFECT DIS, V191, P2097, DOI 10.1086/430388                                                                  
   Nunez R, 2006, ORG LETT, V8, P4549, DOI 10.1021/ol061767k
   Nwe K, 2009, CANCER BIOTHER RADIO, V24, P289, DOI 10.1089/cbr.2008.0626
   Oka H, 2008, BIOORG MED CHEM LETT, V18, P4405, DOI 10.1016/j.bmcl.2008.06.101
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Ortega P, 2008, ORG BIOMOL CHEM, V6, P3264, DOI 10.1039/b809569h
   Ortega P, 2011, ORG BIOMOL CHEM, V9, P5238, DOI 10.1039/c1ob05321c
   Paleos CM, 2008, CURR TOP MED CHEM, V8, P1204, DOI 10.2174/156802608785848996                                                      
   Pan JZ, 2012, TETRAHEDRON, V68, P2943, DOI 10.1016/j.tet.2012.02.040
   Rasines B, 2012, DALTON T, V41, P12733, DOI 10.1039/c2dt31099f
   Rasines B, 2012, NEW J CHEM, V36, P360, DOI 10.1039/c1nj20374f
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Rissing C, 2008, ORGANOMETALLICS, V27, P5394, DOI 10.1021/om8003527
   Rissing C, 2009, ORGANOMETALLICS, V28, P3167, DOI 10.1021/om9001395
   Rolland O, 2009, NEW J CHEM, V33, P1809, DOI 10.1039/b901054h
   Sakamoto JI, 2009, BIOORGAN MED CHEM, V17, P5451, DOI 10.1016/j.bmc.2009.06.036
   Sanchez-Nieves J., 2010, TETRAHEDRON, P9203
   Schluter AD, 2000, ANGEW CHEM INT EDIT, V39, P864, DOI 10.1002/(SICI)1521-3773(20000303)39:5<864::AID-ANIE864>3.0.CO;2-E               
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Smith DK, 2008, CURR TOP MED CHEM, V8, P1187, DOI 10.2174/156802608785849030
   Takahashi T, 2007, BIOCONJUGATE CHEM, V18, P1163, DOI 10.1021/bc070014v
   Twyman LJ, 2002, CHEM SOC REV, V31, P69, DOI 10.1039/b107812g
   Uliniuc A, 2012, CELL CHEM TECHNOL, V46, P1
   van Heerbeek R, 2006, ORG BIOMOL CHEM, V4, P211, DOI 10.1039/b514583j
   Vigo S, 2012, J ORGANOMET CHEM, V717, P88, DOI 10.1016/j.jorganchem.2012.07.032
   Villaraza AJL, 2010, CHEM REV, V110, P2921, DOI 10.1021/cr900232t
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Yamada A, 2006, TETRAHEDRON, V62, P5074, DOI 10.1016/j.tet.2006.03.042
   Yokoyama S, 2003, TOP CURR CHEM, V228, P205, DOI 10.1007/b11012
NR 66
TC 27
Z9 27
U1 2
U2 49
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0276-7333
J9 ORGANOMETALLICS
JI Organometallics
PD MAR 25
PY 2013
VL 32
IS 6
BP 1789
EP 1796
DI 10.1021/om301217g
PG 8
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
SC Chemistry
GA 114WN
UT WOS:000316773800030
DA 2018-01-05
ER

PT J
AU Zhang, JC
   Yang, KN
   Zhang, HS
   Liang, XJ
AF Zhang Jinchao
   Yang Kangning
   Zhang Haisong
   Liang Xingjie
TI Application Status and Prospect of Carbon-Based Nanomaterials in
   Biomedical Field
SO PROGRESS IN CHEMISTRY
LA Chinese
DT Article
DE carbon-based nanomaterials; carbon nanotubes; fullerene; graphene;
   nanodiamond
ID MRI CONTRAST AGENTS; NANO-GRAPHENE OXIDE; TUMOR-BEARING MICE; NEURAL
   STEM-CELLS; PHOTODYNAMIC THERAPY; IN-VITRO; DRUG-DELIVERY; FULLERENE
   C-60; GENE-DELIVERY; NEUROPROTECTIVE AGENTS
AB Nanomaterials have become a new type of materials with a rapid development of nanotechnology. Nanomaterials have unique physical and chemical properties such as small size effect, large surface area, high reactivity, and quantum effects. These features make the nanoscience as one of the three pillars of the world science. Carbon-based nanomaterials are an important part of nanomaterials, they include carbon nanotubes, fullerene, graphene, nanodiamond and their derivatives. Due to their unique physical and chemical properties, carbon-based nanomaterials have broad applications in the biomedical field. In addition, with the industrialization of nanotechnology,, various forms of carbon-based nanomaterials have come into human life in different ways, and the biosafety is increasingly attracting attention of scientists around the world. This article reviews the potential applications of all four types of carbon-based nanomaterials in the biomedical field including tissue engineering, drug/gene carrier, biological imaging, cancer treatment, anti-HIV/anti-bacterial activity, and biological sensing. In addition, the biosafety issue is also reviewed. Finally, we discuss the need for future research. Specifically, we identify the most important research topics, which urgently need to be studied.
C1 [Zhang Jinchao; Yang Kangning] Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Baoding 071002, Peoples R China.
   [Liang Xingjie] CAS Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
   [Zhang Haisong] Hebei Univ, Affiliated Hosp, Baoding 071000, Peoples R China.
RP Zhang, JC (reprint author), Hebei Univ, Coll Chem & Environm Sci, Chem Biol Key Lab Hebei Prov, Baoding 071002, Peoples R China.
EM jczhang6970@yahoo.com.cn; liangxj@nanoctr.cn
CR Akhavan O, 2010, ACS NANO, V4, P5731, DOI 10.1021/nn101390x
   Bao HQ, 2011, SMALL, V7, P1569, DOI 10.1002/smll.201100191
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Chen WH, 2011, ACS APPL MATER INTER, V3, P4085, DOI 10.1021/am2009647
   Choi JH, 2007, NANO LETT, V7, P861, DOI 10.1021/nl062306v
   Chow E K, 2011, SCI TRANSL MED, V3, P1
   Cui DX, 2005, TOXICOL LETT, V155, P73, DOI 10.1016/j.toxlet.2004.08.015
   Dan Z G, 2009, J PHARM PRACTICE, V27, P167
   Dong HQ, 2010, SCI CHINA CHEM, V53, P2265, DOI 10.1007/s11426-010-4114-9
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Dugan LL, 1996, NEUROBIOL DIS, V3, P129, DOI 10.1006/nbdi.1996.0013
   Erlanger BF, 2001, NANO LETT, V1, P465, DOI 10.1021/nl015570r
   Feng LZ, 2011, NANOSCALE, V3, P1252, DOI 10.1039/c0nr00680g
   Friedman S H, 1993, J AM CHEM SOC, V115, P6505
   Gao LZ, 2006, CHEMBIOCHEM, V7, P239, DOI 10.1002/cbic.200500227
   Ghosh S, 2009, ACS NANO, V3, P2667, DOI 10.1021/nn900368b
   Godal A, 2006, J ENVIRON PATHOL TOX, V25, P109, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.60                                  
   Grausova L, 2009, DIAM RELAT MATER, V18, P578, DOI 10.1016/j.diamond.2008.10.024
   Heller DA, 2005, ADV MATER, V17, P2793, DOI 10.1002/adma.200500477                                                          
   Hu WB, 2010, ACS NANO, V4, P4317, DOI 10.1021/nn101097v
   Huang HD, 2011, TRAC-TREND ANAL CHEM, V30, P1109, DOI 10.1016/j.trac.2011.03.014
   Huang H, 2007, NANO LETT, V7, P3305, DOI 10.1021/nl071521o
   Huang P, 2011, THERANOSTICS, V1, P240, DOI 10.7150/thno/v01p0240
   Iijima S, 1991, MAT SCI ENG C, V354, P56
   Iwamoto Y, 2006, CHEM COMMUN, P4805, DOI 10.1039/b614305
   Jan E, 2007, NANO LETT, V7, P1123, DOI 10.1021/nl0620132
   Jiang G C, 2005, THESIS HUAZHONG U SC
   Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F
   Kalbacova M, 2010, CARBON, V48, P4323, DOI 10.1016/j.carbon.2010.07.045
   Kam NWS, 2009, NANO LETT, V9, P273, DOI 10.1021/nl802859a
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Kato H, 2003, J AM CHEM SOC, V125, P4391, DOI 10.1021/ja027555+
   Kellermann N, 2004, ANGEW CHEM, V116, P3019
   Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Leeuw TK, 2007, NANO LETT, V7, P2650, DOI 10.1021/nl0710452
   Li MX, 2005, CHINESE J ANAL CHEM, V33, P1211
   Li XM, 2012, BIOMATERIALS, V33, P4818, DOI 10.1016/j.biomaterials.2012.03.045
   Li Y, 2011, J FUZHOU U NATURAL S, V5, P781
   Liang XJ, 2010, P NATL ACAD SCI USA, V107, P7449, DOI 10.1073/pnas.0909707107
   LIU AH, 2006, J FUNCT MAT, V8, P1322
   Liu DD, 2010, ACS NANO, V4, P2185, DOI 10.1021/nn901479w
   Liu J H, 2010, ACS APPL MATER INTER, V2, P1348
   [刘凯敏 LIU KaiMin], 2007, [应用化学, Chinese Journal of Applied Chemistry], V24, P90
   Liu K P, 2011, THESIS LANZHOU U
   Liu KP, 2011, J MATER CHEM, V21, P12034, DOI 10.1039/c1jm10749f
   Liu Y, 2005, ANGEW CHEM INT EDIT, V44, P4782, DOI 10.1002/anie.200500042
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Liu Z, 2008, CANCER RES, V68, P6652, DOI 10.1158/0008-5472.CAN-08-1468
   Lu C H, 2010, CHEM COMMUN, P3116
   Lu X, 2004, CHEM J CHINESE U, V25, P697
   Ma H B, 2011, MAT REV B, V25, P19
   [马万顺 Ma Wanshun], 2010, [生物物理学报, Acta Biophysica Sinica], V26, P638
   Manus LM, 2010, NANO LETT, V10, P484, DOI 10.1021/nl903264h
   Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005
   Marrs B, 2006, J BIOMED MATER RES A, V77A, P269, DOI 10.1002/jbm.a.30651
   Martin R, 2010, ACS NANO, V4, P65, DOI 10.1021/nn901616c
   Meng J, 2011, NANOSCALE, V3, P4713, DOI 10.1039/c1nr10898k
   Mikawa M, 2001, BIOCONJUGATE CHEM, V12, P510, DOI 10.1021/bc000136m
   Mohanty N, 2008, NANO LETT, V8, P4469, DOI 10.1021/nl802412n
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Ou Z M, 2009, ACTA OPTICAL SINIC S, VS1, P181
   Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437
   Partha R, 2008, ACS NANO, V2, P1950, DOI 10.1021/nn800422k
   Rancan F, 2007, BIOCONJUGATE CHEM, V18, P1078, DOI 10.1021/bc0603337
   Robinson JT, 2011, J AM CHEM SOC, V133, P6825, DOI 10.1021/ja2010175
   Rui M M, 2010, P NATL ACAD SCI USA, V107, P5339
   Ruiz ON, 2011, ACS NANO, V5, P8100, DOI 10.1021/nn202699t
   Schrand AM, 2007, DIAM RELAT MATER, V16, P2118, DOI 10.1016/j.diamond.2007.07.020
   Schrand AM, 2007, J PHYS CHEM B, V111, P2, DOI 10.1021/jp066387v
   Shen AJ, 2012, J BIOMED MATER RES A, V100A, P2499, DOI 10.1002/jbm.a.34148
   Shi JL, 2011, ACTA CHIM SINICA, V69, P2015
   Sitharaman B, 2008, MOL PHARMACEUT, V5, P567, DOI 10.1021/mp700106w
   Sun XM, 2008, NANO RES, V1, P203, DOI 10.1007/s12274-008-8021-8
   Tang ZW, 2010, SMALL, V6, P1205, DOI 10.1002/smll.201000024
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Vandrovcova M, 2008, PHYS STATUS SOLIDI A, V205, P2252, DOI 10.1002/pssa.200879730
   Venkatesan N, 2005, BIOMATERIALS, V26, P7154, DOI 10.1016/j.biiomaterials.2005.05.012
   Wang C C, 2006, ACTA CHIM SINICA, V13, P1355
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   Wang X, 2009, THESIS SHANGHAI JIAO
   Chen B P, 2006, CHINESE J CURRENT TR, V4, P961
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Yang XY, 2008, J PHYS CHEM C, V112, P17554, DOI 10.1021/jp806751k
   Yao L, 2011, CHEM J CHINESE U, V44, P885
   Ye B, 2009, CARCINO GENESIS TERA, V1, P6
   Yin F, 2007, CHINESE J ANAL CHEM, V35, P1021
   Yin JJ, 2008, MOL PHARMACOL, V74, P1132, DOI 10.1124/mol.108.048348
   Yudoh K, 2009, INT J NANOMED, V4, P217
   Yudoh K, 2009, INT J NANOMED, V4, P233
   Zhang DW, 2010, METHODS MOL BIOL, V625, P41, DOI 10.1007/978-1-60761-579-8_5
   Zhang LM, 2011, SMALL, V7, P460, DOI 10.1002/smll.201001522
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhang P, 2011, J MATER CHEM, V21, P7755, DOI 10.1039/c1jm10813a
   Zhang WD, 2011, NANOSCALE, V3, P2636, DOI 10.1039/c1nr10239g
   Zhang XY, 2011, CARBON, V49, P986, DOI 10.1016/j.carbon.2010.11.005
   Zhang XQ, 2009, ACS NANO, V3, P2609, DOI 10.1021/nn900865g
   Zhang X Y, 2011, THESIS TAIYUAN U TEC
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
   Zhang ZH, 2006, CLIN CANCER RES, V12, P4933, DOI 10.1158/1078-0432.CCR-05-2831
   Zhao W, 2009, J CLIN REHABILITATIV, V13, P9237
   Zhou F F, 2009, CHINESE J LASERS, V10, P2676
   Zhou GQ, 2010, J NANOSCI NANOTECHNO, V10, P8597, DOI 10.1166/jnn.2010.2486
   Zhou N, 2010, CHINESE J ANAL CHEM, V3, P301
   zhou X P, 2011, THESIS SHANXI U
   Zhu S., 2011, CHEM COMMUN, P6858
   ZHU XS, 2008, CHIN J ENVIRON SCI, V29, P855
NR 108
TC 4
Z9 7
U1 2
U2 66
PU CHINESE ACAD SCIENCES
PI BEIJING
PA NO. 33 BEISIHUANXILU,  ZHONGGUANCUN, BEIJING 100080, PEOPLES R CHINA
SN 1005-281X
J9 PROG CHEM
JI Prog. Chem.
PD MAR 24
PY 2013
VL 25
IS 2-3
BP 397
EP 408
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA 122MA
UT WOS:000317321000020
DA 2018-01-05
ER

PT J
AU Esseghaier, C
   Ng, A
   Zourob, M
AF Esseghaier, Chiheb
   Ng, Andy
   Zourob, Mohammed
TI A novel and rapid assay for HIV-1 protease detection using magnetic bead
   mediation
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE HIV-1 protease; Magnetic bead-peptide; Biosensor; Impedance
   spectroscopy; Surface plasmon resonance
ID SURFACE-PLASMON RESONANCE; BIOSENSOR TECHNOLOGY; MOLECULAR RECOGNITION;
   INHIBITORS; SENSORS; STABILIZATION; KINETICS; ANTIBODY; COMPLEX; BINDING
AB A simple sensing assay was established for label-free detection of HIV-1 protease. HIV-1 protease peptide substrate conjugated to magnetic beads via its N-terminus is directly fixed onto the sensor gold surface through the sulphur atom of cysteine. Surface plasmon resonance (SPR) was used to study the peptide substrate cleavage efficiency of the protease with magnetic beads of different sizes (1 mu m and 30 nm). Cyclic voltammetry and faradic impedance spectroscopy were employed in order to characterize the functionalized gold electrode. It was found that the nano-sized beads are a more efficient sensing probe for the protease. Electrochemical biosensing showed a gradual decrease in charge transfer resistance after injection of the HIV-1 protease. The experimental data established a detection limit of 10 pg/ml, as well as demonstrated a drug screening assay. This HIV-1 protease biosensor represents a new detection approach which will lead to low-cost point-of-care devices for sensitive HIV-1 diagnosis, as well as high-throughput drug screening platforms. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Esseghaier, Chiheb; Ng, Andy; Zourob, Mohammed] INRS EMT, Varennes, PQ J3X 1S2, Canada.
RP Zourob, M (reprint author), INRS EMT, Varennes, PQ J3X 1S2, Canada.
EM zourob@emt.inrs.ca
RI Arumugam, Thirumagal/C-3408-2014; Ng, Andy/I-3060-2016; Spackova,
   Barbora/G-6707-2014
OI Ng, Andy/0000-0003-3257-0801; Spackova, Barbora/0000-0002-8442-5641
FU NSERC; NanoQuebec
FX The authors would like to extend a special gratitude to NSERC and
   NanoQuebec for funding. The authors would like to acknowledge Dr. Irina
   Statekina for her help in fabricating the chips and device prototype.
CR Alterman M, 2001, EUR J PHARM SCI, V13, P203, DOI 10.1016/S0928-0987(01)00109-9                                                   
   Batt CA, 2007, SCIENCE, V316, P1579, DOI 10.1126/science.1140729
   Bianchi N, 1997, CLIN DIAGN VIROL, V8, P199, DOI 10.1016/S0928-0197(97)00025-1
   Darfeuille F, 2002, BIOCHEMISTRY-US, V41, P12186, DOI 10.1021/bi025974d
   Glaser RW, 1996, J IMMUNOL METHODS, V189, P1, DOI 10.1016/0022-1759(95)00221-9
   Hahn S, 2005, BIOELECTROCHEMISTRY, V67, P151, DOI 10.1016/j.bioelechem.2004.07.006
   Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097                                                          
   Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9
   Homola J, 2008, CHEM REV, V108, P462, DOI 10.1021/cr068107d
   Iqbal SS, 2000, BIOSENS BIOELECTRON, V15, P549, DOI 10.1016/S0956-5663(00)00108-1                                                   
   Iribe M.S.A.Y., 2007, HDB BIOSENSORS BIOCH
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Kerman K., 2004, MEAS SCI TECHNOL, V15, P1
   Kim SJ, 2002, BIOCHEM BIOPH RES CO, V291, P925, DOI 10.1006/bbrc.2002.6521
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Markgren PO, 2002, J MED CHEM, V45, P5430, DOI 10.1021/jm0208370
   Markgren PO, 2001, ANAL BIOCHEM, V291, P207, DOI 10.1006/abio.2001.5025
   Martinez JL, 2008, SCIENCE, V321, P365, DOI 10.1126/science.1159483
   Mitchell J, 2010, SENSORS-BASEL, V10, P7323, DOI 10.3390/s100807323
   Mitchell JS, 2005, ANAL BIOCHEM, V343, P125, DOI 10.1016/j.ab.2005.05.001
   MONTAGNIER L, 1987, ANN INST PASTEUR VIR, V138, P3, DOI 10.1016/S0769-2617(87)80068-0                                                   
   Nair TM, 2000, NUCLEIC ACIDS RES, V28, P1935, DOI 10.1093/nar/28.9.1935                                                           
   Ota A, 1998, HYBRIDOMA, V17, P471, DOI 10.1089/hyb.1998.17.471
   Rich RL, 2003, TRENDS MICROBIOL, V11, P124, DOI 10.1016/S0966-842X(03)00025-8
   Roos H, 1998, J MOL RECOGNIT, V11, P204, DOI 10.1002/(SICI)1099-1352(199812)11:1/6<204::AID-JMR424>3.0.CO;2-T
   SALYERS AA, 2002, BACTERIAL PATHOGENES
   Taubes G, 2008, SCIENCE, V321, P356, DOI 10.1126/science.321.5887.356
   Tran L.D., 2011, MAT SCI ENG C, V31, P477
   UNAIDS/ WHO, 2009, UNAIDS WHO AIDS EP U
   Yang HW, 2001, IMMUNOBIOLOGY, V203, P778, DOI 10.1016/S0171-2985(01)80006-1                                                   
   Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051
NR 31
TC 17
Z9 18
U1 2
U2 142
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAR 15
PY 2013
VL 41
BP 335
EP 341
DI 10.1016/j.bios.2012.08.049
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 079SA
UT WOS:000314191300048
PM 23017677
DA 2018-01-05
ER

PT J
AU Liu, BR
   Huang, YW
   Lee, HJ
AF Liu, Betty R.
   Huang, Yue-Wern
   Lee, Han-Jung
TI Mechanistic studies of intracellular delivery of proteins by
   cell-penetrating peptides in cyanobacteria
SO BMC MICROBIOLOGY
LA English
DT Article
DE Cell-penetrating peptide (CPP); Endocytosis; Green fluorescent protein
   (GFP); Macropinocytosis; Protein transduction; Red fluorescent protein
   (RFP)
ID HUMAN IMMUNODEFICIENCY VIRUS; SYNECHOCYSTIS-SP PCC-6803; PLANT-CELLS;
   SYNECHOCOCCUS-ELONGATUS; PLASMA-MEMBRANE; QUANTUM DOTS; TAT PROTEIN;
   TRANSDUCTION; GENE; TRANSPORT
AB Background: The plasma membrane plays an essential role in selective permeability, compartmentalization, osmotic balance, and cellular uptake. The characteristics and functions of cyanobacterial membranes have been extensively investigated in recent years. Cell-penetrating peptides (CPPs) are special nanocarriers that can overcome the plasma membrane barrier and enter cells directly, either alone or with associated cargoes. However, the cellular entry mechanisms of CPPs in cyanobacteria have not been studied.
   Results: In the present study, we determine CPP-mediated transduction efficiency and internalization mechanisms in cyanobacteria using a combination of biological and biophysical methods. We demonstrate that both Synechocystis sp. PCC 6803 and Synechococcus elongatus PCC 7942 strains of cyanobacteria possess red autofluorescence. Green fluorescent protein (GFP), either alone or noncovalently associated with a CPP comprised of nine arginine residues (R9/GFP complexes), entered cyanobacteria. The ATP-depleting inhibitor of classical endocytosis, N-ethylmaleimide (NEM), could block the spontaneous internalization of GFP, but not the transduction of R9/GFP complexes. Three specific inhibitors of macropinocytosis, cytochalasin D (CytD), 5-(N-ethyl-N-isopropyl)-amiloride (EIPA), and wortmannin, reduced the efficiency of R9/GFP complex transduction, indicating that entry of R9/GFP complexes involves macropinocytosis. Both the 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) and membrane leakage analyses confirmed that R9/GFP complexes were not toxic to the cyanobacteria, nor were the endocytic and macropinocytic inhibitors used in these studies.
   Conclusions: In summary, we have demonstrated that cyanobacteria use classical endocytosis and macropinocytosis to internalize exogenous GFP and CPP/GFP proteins, respectively. Moreover, the CPP-mediated delivery system is not toxic to cyanobacteria, and can be used to investigate biological processes at the cellular level in this species. These results suggest that both endocytic and macropinocytic pathways can be used for efficient internalization of regular protein and CPP-mediated protein delivery in cyanobacteria, respectively.
C1 [Liu, Betty R.; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
   [Huang, Yue-Wern] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO 65409 USA.
RP Lee, HJ (reprint author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien 97401, Taiwan.
EM hjlee@mail.ndhu.edu.tw
FU National Science Council of Taiwan [NSC 101-2811-B-259-001, NSC
   101-2320-B-259-002-MY3]; National Institutes of Health [R15EB009530]
FX We thank Dr. Hsiu-An Chu (Academia Sinica, Taipei, Taiwan) for provision
   of cyanobacteria, Dr. Michael B. Elowitz (California Institute of
   technology, CA, USA) for the pQE8-GFP plasmid, and Core Instrument
   Center (National Health Research Institutes, Miaoli, Taiwan) for the TCS
   SP5 II confocal system. We are grateful to Dr. Robert S. Aronstam
   (Missouri University of Science and Technology, USA) for editing the
   manuscript. This work was supported by the Postdoctoral Fellowship NSC
   101-2811-B-259-001 from the National Science Council of Taiwan (BRL),
   the Award Number R15EB009530 from the National Institutes of Health
   (YWH), and the Grant Number NSC 101-2320-B-259-002-MY3 from the National
   Science Council of Taiwan (HJL).
CR Adav SS, 2010, BIOTECHNOL ADV, V28, P255, DOI 10.1016/j.biotechadv.2009.08.006
   Balasubramanian L, 2011, BIOTECHNOL APPL BIOC, V58, P220, DOI 10.1002/bab.31
   Chang M, 2005, ELECTROPHORESIS, V26, P3062, DOI 10.1002/elps.200500041
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060
   Crosthwaite SK, 2011, ESSAYS BIOCHEM, V49, P37, DOI 10.1042/BSE0490037
   Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hajek J, 2012, CRYOBIOLOGY, V64, P215, DOI 10.1016/j.cryobiol.2012.02.002
   HANSEN SH, 1995, J BIOL CHEM, V270, P28425
   Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326                                                           
   Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x
   Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006
   Huang F, 2004, MOL CELL PROTEOMICS, V3, P586, DOI 10.1074/mcp.MCP200
   Karapetyan NV, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1127, DOI 10.1134/S0006297907100100
   Karnauchov I, 1997, EUR J BIOCHEM, V249, P497, DOI 10.1111/j.1432-1033.1997.t01-1-00497.x                                          
   Koksharova OA, 2002, APPL MICROBIOL BIOT, V58, P123, DOI 10.1007/s00253-001-0864-9
   Kroth PG, 2002, INT REV CYTOL, V221, P191
   Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012
   Li JF, 2010, ANTICANCER RES, V30, P2193
   Li J, 2007, PHYCOLOGIA, V46, P593, DOI 10.2216/07-11.1
   Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019
   Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637
   Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6
   Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053
   LIU BR, 2013, ADV STUD BIOL, V5, P11
   Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151
   Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6
   LIU MJ, 2013, ADV STUD BIOL, V5, P71
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Ma DX, 2011, INT J PHARMACEUT, V419, P200, DOI 10.1016/j.ijpharm.2011.08.001
   Machado IMP, 2012, J BIOTECHNOL, V162, P50, DOI 10.1016/j.jbiotec.2012.03.005
   Madani F., 2011, J BIOPHYS, V2011, DOI DOI 10.1155/2011/414729
   Mellerick DM, 2004, J NEUROBIOL, V60, P308, DOI 10.1002/neu.20020
   Nanbo A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001121
   Nazarenko LV, 2003, MICROBIOL-SGM, V149, P1147, DOI 10.1099/mic.0.26074-0
   Ruffing AM, 2012, BIOTECHNOL BIOENG, V109, P2190, DOI 10.1002/bit.24509
   Ruffing Anne M, 2011, Bioeng Bugs, V2, P136, DOI 10.4161/bbug.2.3.15285
   Sato M., 2004, MICROBIOL CULT COLL, V20, P53
   Schulze K, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-118
   SHESTAKOV SV, 1970, MOL GEN GENET, V107, P372, DOI 10.1007/BF00441199
   Stamatakis K, 2001, BBA-BIOENERGETICS, V1506, P172, DOI 10.1016/S0005-2728(01)00192-X                                                   
   Tillich UM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049467
   Toyomasu T, 2007, P NATL ACAD SCI USA, V104, P3084, DOI 10.1073/pnas.0608426104
   Tunnemann Gisela, 2008, J Pept Sci, V14, P469, DOI 10.1002/psc.968
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Zeder M, 2010, APPL ENVIRON MICROB, V76, P1615, DOI 10.1128/AEM.02232-09
NR 59
TC 16
Z9 17
U1 1
U2 44
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD MAR 14
PY 2013
VL 13
AR 57
DI 10.1186/1471-2180-13-57
PG 9
WC Microbiology
SC Microbiology
GA 139YM
UT WOS:000318621200001
PM 23497160
OA gold
DA 2018-01-05
ER

PT J
AU Gajbhiye, V
   Ganesh, N
   Barve, J
   Jain, NK
AF Gajbhiye, Virendra
   Ganesh, Narayanan
   Barve, Jaya
   Jain, Narendra K.
TI Synthesis, characterization and targeting potential of zidovudine loaded
   sialic acid conjugated-mannosylated poly(propyleneimine) dendrimers
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE HIV; Macrophage targeting; Zidovudine; Dendrimer; Dual targeting
ID MONOCYTES/MACROPHAGES IN-VITRO; INFECTION; TRANSMISSION; MACROPHAGES;
   MONOCYTES; INVITRO; AGENTS
AB The present investigation was aimed at exploring dual targeting of anti-HIV drug, zidovudine (ZDV) via sialic acid conjugated-mannosylated poly(propyleneimine) (PPI) dendritic nano-constructs. Fourth generation PPI dendrimers, sialic acid conjugated PPI dendrimers (SPPI), mannose conjugated PPI dendrimers (MPPI) and dual ligand system i.e. sialic acid conjugated-mannosylated PPI dendrimers (SMPPI) were synthesized and characterized by FT-IR and H-1 NMR spectroscopies and were further confirmed by size exclusion chromatography and differential scanning calorimetry. Various parameters like drug loading, pH dependent in vitro release, hemolytic toxicity, macrophage uptake and cytotoxicity concerning PPI, SPPI, MPPI and SMPPI dendrimers were evaluated. ZDV loaded SMPPI, SPPI and MPPI have shown reduced hemolytic toxicity, cytotoxicity and in vitro drug release at pH 7.4. Extremely significant (P<0.001) increase in cellular uptake of ZDV by macrophage cells was observed in case of SMPPI as compared to PPI and free drug. The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards sialoadhesin and carbohydrate receptors. The drug concentration in lymph nodes was increased to about 28 times in case of SMPPI (1335 +/- 17.6 ng/g) as compared to free drug (48 +/- 5.8 ng/g) at 6th hr. The results suggested that such dual ligand dendritic system (SMPPI) hold potential to enhance biocompatibility and site specific delivery of antiretroviral drug, ZDV. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Gajbhiye, Virendra; Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
   [Ganesh, Narayanan; Barve, Jaya] JawaharLal Nehru Canc Hosp & Res Ctr, Dept Res, Bhopal, MP, India.
RP Gajbhiye, V (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
EM cme_virendra@yahoo.co.in; jnarendr@yahoo.-co.in
FU UGC (New Delhi)
FX Virendra Gajbhiye acknowledges New Zealand Pharmaceuticals Ltd, (New
   Zealand) for benevolent gift of sialic acid and UGC (New Delhi) for SRF.
CR Alcorn J, 2002, ANTIMICROB AGENTS CH, V46, P1831, DOI 10.1128/AAC.46.6.1831-1836.2002
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Gajbhiye V., 2009, EURO J MED CHEM, V44, P155
   Gajbhiye V, 2008, CURR NANOSCI, V4, P267, DOI 10.2174/157341308785161136                                                      
   Gajbhiye V, 2007, CURR PHARM DESIGN, V13, P415, DOI 10.2174/138161207780162999
   Gajbhiye V, 2011, BIOMATERIALS, V32, P6213, DOI 10.1016/j.biomaterials.2011.04.057
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   KESSON AM, 1994, J LEUKOCYTE BIOL, V56, P241
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   ROTHI RJG, 1986, J TOXICOL ENV HLTH, V17, P221
   United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2009, AIDS EP UPD GLOB SUM, P6
   Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
NR 19
TC 27
Z9 27
U1 2
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD MAR 12
PY 2013
VL 48
IS 4-5
BP 668
EP 679
DI 10.1016/j.ejps.2012.12.027
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 119HB
UT WOS:000317087300010
PM 23298577
DA 2018-01-05
ER

PT J
AU Freedman, KJ
   Bastian, AR
   Chaiken, I
   Kim, MJ
AF Freedman, Kevin J.
   Bastian, Arangassery R.
   Chaiken, Irwin
   Kim, Min Jun
TI Solid-State Nanopore Detection of Protein Complexes: Applications in
   Healthcare and Protein Kinetics
SO SMALL
LA English
DT Article
DE protein complexes; HIV detection; point-of-care diagnostics; gp120;
   antibodies
ID SINGLE-MOLECULE; GP120; INTERACTOME; FABRICATION; DISEASE; BINDING;
   MODELS; FORCE; HIV-1
AB Protein conjugation provides a unique look into many biological phenomena and has been used for decades for molecular recognition purposes. In this study, the use of solid-state nanopores for the detection of gp120-associated complexes are investigated. They exhibit monovalent and multivalent binding to anti-gp120 antibody monomer and dimers. In order to investigate the feasibility of many practical applications related to nanopores, detection of specific protein complexes is attempted within a heterogeneous protein sample, and the role of voltage on complexed proteins is researched. It is found that the electric field within the pore can result in unbinding of a freely translocating protein complex within the transient event durations measured experimentally. The strong dependence of the unbinding time with voltage can be used to improve the detection capability of the nanopore system by adding an additional level of specificity that can be probed. These data provide a strong framework for future protein-specific detection schemes, which are shown to be feasible in the realm of a real-world' sample and an automated multidimensional method of detecting events.
C1 [Freedman, Kevin J.] Drexel Univ, Dept Chem & Biol Engn, Philadelphia, PA 19104 USA.
   [Bastian, Arangassery R.; Kim, Min Jun] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
   [Bastian, Arangassery R.; Chaiken, Irwin] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Kim, Min Jun] Drexel Univ, Dept Mech Engn & Mech, Philadelphia, PA 19104 USA.
RP Kim, MJ (reprint author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA.
EM mkim@coe.drexel.edu
FU National Science Foundation Graduate Research Fellowship [2010095296];
   HFSP [RGY0075/2009-C]
FX This material is based upon work supported by the National Science
   Foundation Graduate Research Fellowship under Grant ID No. 2010095296
   and the HFSP young investigator award (RGY0075/2009-C). The authors
   would like to especially thank Anmiv Prabhu for help with drilling the
   nanopores used in this work. Figure 2 was corrected on March 11, 2013.
CR Appiah LT, 2009, AIDS PATIENT CARE ST, V23, P365, DOI 10.1089/apc.2008.0224
   BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575
   Bonanno LM, 2007, LANGMUIR, V23, P5817, DOI 10.1021/la063659c
   Chaurasia G, 2007, NUCLEIC ACIDS RES, V35, pD590, DOI 10.1093/nar/gkl817
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Dudko OK, 2007, BIOPHYS J, V92, P4188, DOI 10.1529/biophysj.106.102855
   Eteshola E, 2001, SENSOR ACTUAT B-CHEM, V72, P129, DOI 10.1016/S0925-4005(00)00640-7
   Firnkes M, 2010, NANO LETT, V10, P2162, DOI 10.1021/nl100861c
   Freedman KJ, 2011, ANAL CHEM, V83, P5137, DOI 10.1021/ac2001725
   Greenwald Jeffrey L, 2006, Curr Infect Dis Rep, V8, P125, DOI 10.1007/s11908-006-0008-6
   Han A, 2008, ANAL CHEM, V80, P4651, DOI 10.1021/ac7025207
   Ito T, 2001, TRENDS BIOTECHNOL, V19, pS23, DOI 10.1016/S0167-7799(01)01790-5
   Kantor R, 2004, AIDS, V18, P1503, DOI 10.1097/01.aids.0000131358.29586.6b
   Kapanidis AN, 2009, TRENDS BIOCHEM SCI, V34, P234, DOI 10.1016/j.tibs.2009.01.008
   Kasianowicz JJ, 2001, ANAL CHEM, V73, P2268, DOI 10.1021/ac000958c
   Kerndt PR, 2009, AIDS BEHAV, V13, P1037, DOI 10.1007/s10461-009-9580-8
   Kim MJ, 2006, ADV MATER, V18, P3149, DOI 10.1002/adma.200601191
   Koliski P., 2011, ELECTROPHORESIS, V32, P2044
   Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037
   Martin-Garcia J, 2005, J VIROL, V79, P6703, DOI 10.1128/JVI.79.11.6703-6713.2005
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Nazem A., 2011, NANOTECHNOLOGY SEC I, V1, P169, DOI [10.5640/insc.0104169, DOI 10.5640/INSC.0104169]
   Nazem A, 2008, J ALZHEIMERS DIS, V13, P199
   Oukhaled A, 2011, ACS NANO, V5, P3628, DOI 10.1021/nn1034795
   Oukhaled G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.158101
   Pedone D, 2009, ANAL CHEM, V81, P9689, DOI 10.1021/ac901877z
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Pushkarev D, 2009, NAT BIOTECHNOL, V27, P847, DOI 10.1038/nbt.1561
   Siwy Z, 2005, J AM CHEM SOC, V127, P5000, DOI 10.1021/ja043910f
   Storm AJ, 2003, NAT MATER, V2, P537, DOI 10.1038/nmat941
   Sugase K, 2007, NATURE, V447, P1021, DOI 10.1038/nature05858
   Talaga DS, 2009, J AM CHEM SOC, V131, P9287, DOI 10.1021/ja901088b
   Veigel C, 2011, NAT REV MOL CELL BIO, V12, P163, DOI 10.1038/nrm3062
   Wei RS, 2012, NAT NANOTECHNOL, V7, P257, DOI [10.1038/nnano.2012.24, 10.1038/NNANO.2012.24]
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Workman S, 2009, J VIROL METHODS, V160, P14, DOI 10.1016/j.jviromet.2009.04.003
   Yoo PD, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S4-S22
   Yusko EC, 2011, NAT NANOTECHNOL, V6, P253, DOI 10.1038/nnano.2011.12
NR 38
TC 23
Z9 24
U1 2
U2 65
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1613-6810
J9 SMALL
JI Small
PD MAR 11
PY 2013
VL 9
IS 5
BP 750
EP 759
DI 10.1002/smll.201201423
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 101IX
UT WOS:000315769700016
PM 23074081
DA 2018-01-05
ER

PT J
AU Koppers-Lalic, D
   Hogenboom, MM
   Middeldorp, JM
   Pegtel, DM
AF Koppers-Lalic, Danijela
   Hogenboom, Marye M.
   Middeldorp, Jaap M.
   Pegtel, D. Michiel
TI Virus-modified exosomes for targeted RNA delivery; A new approach in
   nanomedicine
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Exosomes; MicroRNA; Genetic-transfer; Virus; Gene-therapy
ID MEMBRANE-FUSION PROTEINS; IN-VIVO DELIVERY; GENE DELIVERY;
   MULTIVESICULAR ENDOSOMES; MICRORNA BIOGENESIS; CATIONIC LIPOSOMES;
   MAMMALIAN-CELLS; HIV-1 INFECTION; SIRNA DELIVERY; DRUG-DELIVERY
AB A major goal in biomedical research is to clinically reverse the cause of disease rather than treating the symptoms. Gene therapy has the potential to meet this goal and the discovery of RNA interference (RNAi) has lead to a new class of highly selective therapeutics. However, initial enthusiasm is reduced due to safety concerns associated with virus-based delivery vectors that are used for in vivo delivery.
   Viral vectors for siRNA delivery into target cells are used because of their high target specificity and delivery efficacy (endosomal escape). Recent discoveries suggest that a specialized form of nano-sized lipid vesicles called exosomes can incorporate and transport functional RNAs into target cells and may serve as an attractive alternative. Evidence is accumulating that most pluricellular organisms sustain exosome-based communications via inter-cellular exchange of mRNA and miRNAs between cells. We discovered that viruses have found ways to exploit this communication pathway and we argue here that adaptations of exosomes imposed by viruses maybe exploited for superior delivery of RNA in vivo. We discuss recent discoveries in exosome biogenesis their physical properties, targeting and delivery strategies and how the knowledge of exosome production in virus infected cells could propel their entry into clinical settings. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Koppers-Lalic, Danijela; Hogenboom, Marye M.; Middeldorp, Jaap M.; Pegtel, D. Michiel] Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Med Ctr, NL-1117 HV Amsterdam, Netherlands.
RP Pegtel, DM (reprint author), Vrije Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Med Ctr, Boelelaan, NL-1117 HV Amsterdam, Netherlands.
EM d.pegtel@vumc.nl
RI Pegtel, Dirk/M-8393-2015
OI Pegtel, Dirk/0000-0002-7357-4406; Middeldorp, Jaap/0000-0002-0765-4125
FU Netherlands Organization for Scientific Research (NWO-Veni); Association
   for International Cancer Research (UK) [AICR 11-0157]
FX This project is supported by research grants from the Netherlands
   Organization for Scientific Research (NWO-Veni) to D.M.P. and the
   Association for International Cancer Research (AICR 11-0157, UK) to
   D.K.L.
CR Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807
   Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180
   Barreto A, 2010, VIRAL IMMUNOL, V23, P595, DOI 10.1089/vim.2009.0113
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5                                                   
   Bedi D, 2011, NANOMED-NANOTECHNOL, V7, P315, DOI 10.1016/j.nano.2010.10.004
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Borel Florie, 2011, J RNAi Gene Silencing, V7, P434
   Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774
   BRENNECKE J, 2005, PLOS BIOL, V3, P85, DOI DOI 10.1371/J0URNAL.PBI0.0030085
   Brown MD, 2001, INT J PHARM, V229, P1, DOI 10.1016/S0378-5173(01)00861-4
   Bundy BC, 2008, BIOTECHNOL BIOENG, V100, P28, DOI 10.1002/bit.21716
   Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493
   Campbell Tamika D, 2008, Ethn Dis, V18, pS2
   Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493
   Cho YW, 2003, J PHARM PHARMACOL, V55, P721, DOI 10.1211/0022357021206
   daSilva LLP, 2009, J VIROL, V83, P6578, DOI 10.1128/JVI.00548-09
   Dass CR, 2006, J CONTROL RELEASE, V113, P155, DOI 10.1016/j.jconrel.2006.04.009
   Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f
   Dominska M, 2010, J CELL SCI, V123, P1183, DOI 10.1242/jcs.066399
   Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044
   Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663                                                      
   DUMASWALA UJ, 1984, TRANSFUSION, V24, P490, DOI 10.1046/j.1537-2995.1984.24685066807.x
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121                                                        
   Fang Y, 2007, PLOS BIOL, V5, P1267, DOI 10.1371/journal.pbio.0050158
   Flanagan J, 2003, J GEN VIROL, V84, P1871, DOI 10.1099/vir.0.18944-0
   Friedrich I, 2004, SEMIN CANCER BIOL, V14, P223, DOI 10.1016/j.semcancer.2004.04.001
   Gibbings D, 2010, TRENDS CELL BIOL, V20, P491, DOI 10.1016/j.tcb.2010.06.001
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Huckriede A, 2005, VACCINE, V23, pS26, DOI 10.1016/j.vaccine.2005.04.026
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Hurley JH, 2008, CURR OPIN CELL BIOL, V20, P4, DOI 10.1016/j.ceb.2007.12.002
   Izquierdo-Useros N, 2011, CELL MICROBIOL, V13, P10, DOI 10.1111/j.1462-5822.2010.01542.x
   Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006
   Johnstone RM, 2006, BLOOD CELL MOL DIS, V36, P315, DOI 10.1016/j.bcmd.2005.12.001
   Johnstone RM, 2005, BLOOD CELL MOL DIS, V34, P214, DOI 10.1016/j.bcmd.2005.03.002
   Kaneda Yasufumi, 2011, Cold Spring Harb Protoc, V2011, P1281, DOI 10.1101/pdb.prot065748
   Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973
   Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005
   Keryer-Bibens C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-283
   Kielian M, 2006, NAT REV MICROBIOL, V4, P67, DOI 10.1038/nrmicro1326
   Kielian M, 2006, VIROLOGY, V344, P38, DOI 10.1016/j.virol.2005.09.036
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kuate S, 2007, VIROLOGY, V362, P26, DOI 10.1016/j.virol.2006.12.011
   Lakhal S, 2011, BIOESSAYS, V33, P737, DOI 10.1002/bies.201100076
   Liu YP, 2009, MOL THER, V17, P1712, DOI 10.1038/mt.2009.176
   Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498
   Madrid R, 2005, J BIOL CHEM, V280, P5032, DOI 10.1074/jbc.M401202200
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Marsh M, 2008, SCIENCE, V319, P1191, DOI 10.1126/science.1155750
   Masciopinto F, 2004, EUR J IMMUNOL, V34, P2834, DOI 10.1002/eji.200424887
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Meckes DG, 2011, J VIROL, V85, P12844, DOI 10.1128/JVI.05853-11
   Middeldorp JM, 2008, SEMIN CANCER BIOL, V18, P388, DOI 10.1016/j.semcancer.2008.10.004
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Nemerow GR, 1999, MICROBIOL MOL BIOL R, V63, P725
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   Pegtel DM, 2011, BBA-GENE REGUL MECH, V1809, P715, DOI 10.1016/j.bbagrm.2011.08.002
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004
   Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8                                                   
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Rana S, 2011, BIOCHEM SOC T, V39, P559, DOI 10.1042/BST0390559
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161                                                          
   Ruiss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025294
   Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2
   Seow Y, 2009, MOL THER, V17, P767, DOI 10.1038/mt.2009.41
   Shankar P, 2005, JAMA-J AM MED ASSOC, V293, P1367, DOI 10.1001/jama.293.11.1367
   Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/vir.O.18346-O
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x
   Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x
   Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105
   Temchura VV, 2008, VACCINE, V26, P3662, DOI 10.1016/j.vaccine.2008.04.069
   Temme S, 2010, J IMMUNOL, V184, P236, DOI 10.4049/jimmunol.0902192
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Touze A, 2001, J GEN VIROL, V82, P3005, DOI 10.1099/0022-1317-82-12-3005                                                    
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vallhov H, 2011, J IMMUNOL, V186, P73, DOI 10.4049/jimmunol.1001145
   van den Boorn JG, 2011, NAT BIOTECHNOL, V29, P325, DOI 10.1038/nbt.1830
   Van Dommelen SM, 2011, J CONTROL RELEASE, V161, P635
   Verweij FJ, 2011, EMBO J, V30, P2115, DOI 10.1038/emboj.2011.123
   von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1                                                   
   Waehler R, 2007, NAT REV GENET, V8, P573, DOI 10.1038/nrg2141
   Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
   Zhang Y, 2010, INT J PHARMACEUT, V390, P198, DOI 10.1016/j.ijpharm.2010.01.035
   Zidi I, 2012, MED ONCOL, V29, P1384, DOI 10.1007/s12032-011-9942-8
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339
NR 103
TC 50
Z9 51
U1 6
U2 100
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAR
PY 2013
VL 65
IS 3
BP 348
EP 356
DI 10.1016/j.addr.2012.07.006
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 122NF
UT WOS:000317324100005
PM 22820525
DA 2018-01-05
ER

PT J
AU Zhang, T
   Zhang, C
   Agrahari, V
   Murowchick, JB
   Oyler, NA
   Youan, BBC
AF Zhang, Tao
   Zhang, Chi
   Agrahari, Vivek
   Murowchick, James B.
   Oyler, Nathan A.
   Youan, Bi-Botti C.
TI Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres
   intended for HIV prevention
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE pH-sensitive; Mucoadhesive; Tenofovir; Spray drying; HIV/AIDS
   microbicide
ID TARGETED PARTICLES; DRUG-DELIVERY; NANOPARTICLES; POWDER; MODEL; SEMEN;
   ACCEPTABILITY; OPTIMIZATION; FORMULATION; DAPIVIRINE
AB Purpose: To develop spray dried mucoadhesive and pH-sensitive microspheres (MS) based on polymethacrylate salt intended for vaginal delivery of tenofovir (a model HIV microbicide) and assess their critical biological responses.
   Methods: The formulation variables and process parameters are screened and optimized using a 2(4-1) fractional factorial design. The MS are characterized for size, zeta potential, yield, encapsulation efficiency, Carr's index, drug loading, in vitro release, cytotoxicity, inflammatory responses and mucoadhesion.
   Results: The optimal MS formulation has an average size of 4.73 mu m, zeta potential of -26.3 mV, 68.9% yield, encapsulation efficiency of 88.7%, Carr's index of 28.3 and drug loading of 2% (w/w). The MS formulation release 91.7% of its payload in the presence of simulated human semen. At a concentration of 1 mg/ml, the MS are noncytotoxic to vaginal endocervical/epithelial cells and Lactobacillus crispatus when compared to control media. There is also no statistically significant level of inflammatory cytokine (IL1-alpha, IL-1 beta, IL-6, IL-8, and IP-10) release triggered by these MS. Their percent mucoadhesion is 2-fold higher than that of 1% HEC gel formulation.
   Conclusion: These data suggest the promise of using such MS as an alternative controlled microbicide delivery template by intravaginal route for HIV prevention. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Zhang, Tao; Agrahari, Vivek; Youan, Bi-Botti C.] Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, Kansas City, MO 64108 USA.
   [Zhang, Chi; Oyler, Nathan A.] Univ Missouri, Dept Chem, Kansas City, MO 64110 USA.
   [Murowchick, James B.] Univ Missouri, Dept Geosci, Kansas City, MO 64110 USA.
RP Youan, BBC (reprint author), Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, 2464 Charlotte, Kansas City, MO 64108 USA.
EM youanb@mail.umkc.edu
RI Zhang, Tao/G-1312-2014; Murowchick, James/R-5493-2017
OI Murowchick, James/0000-0003-2987-0352
FU National Institute of Allergy And Infectious Diseases [R01AI087304]
FX The work presented was supported by Award Number R01AI087304 from the
   National Institute of Allergy And Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy And
   Infectious Diseases or the National Institutes of Health. The authors
   would like to thank Dr. Vladimir Dusevich (Director, Electron Microscopy
   Facility, School of Dentistry, University of Missouri-Kansas City, MO)
   for the electron microscopy, and Fairview Farm Meat Co. (Topeka, KS) for
   providing the porcine vaginal tissue.
CR Agrahari V, 2012, AAPS PHARMSCITECH, V13, P202, DOI 10.1208/s12249-011-9735-6
   Altini L, 2010, CONTRACEPTION, V82, P563, DOI 10.1016/j.contraception.2010.04.019
   Chevanan N, 2010, BIORESOURCE TECHNOL, V101, P207, DOI 10.1016/j.biortech.2009.07.083
   Christie RJ, 2009, BIOCONJUGATE CHEM, V20, P476, DOI 10.1021/bc800367e
   Cilurzo F, 2005, EUR J PHARM SCI, V24, P355, DOI 10.1016/j.ejps.2004.11.010
   Cilurzo F, 2003, J CONTROL RELEASE, V88, P43, DOI 10.1016/S0168-3659(02)00459-5
   Clark MR, 2011, INT J PHARMACEUT, V413, P10, DOI 10.1016/j.ijpharm.2011.04.004
   D'Cruz OJ, 2005, TOXICOL PATHOL, V33, P465, DOI 10.1080/01926230590959866
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   Degussa, 2011, EUDRAGIT L 100 EUDRA
   DERRINGER G, 1980, J QUAL TECHNOL, V12, P214
   FHI, 2011, VOICE HIV PREV TRIAL
   Fichorova RN, 1999, BIOL REPROD, V60, P508, DOI 10.1095/biolreprod60.2.508                                                      
   Fichorova RN, 2005, ANTIMICROB AGENTS CH, V49, P323, DOI 10.1128/ACC.49.1.323-335.2005
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Gallagher W., 2011, FTIR ANAL PROTEIN ST
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Genc MR, 2004, EUR J OBSTET GYN R B, V116, P152, DOI 10.1016/j.ejogrb.2004.02.010
   Gonnissen Y, 2008, EUR J PHARM BIOPHARM, V68, P277, DOI 10.1016/j.ejpb.2007.05.004
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hamdy S, 2011, CURR DRUG DELIV, V8, P261, DOI 10.2174/156720111795256101                                                      
   Hung RW, 2011, CURR DRUG DELIV, V8, P274
   Jankower L., 1989, CONTROLLED RELEASE F
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   JORGENSON JH, 1999, MANUAL CLIN MICROBIO
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   Mahalingam A, 2011, BIOMATERIALS, V32, P8343, DOI 10.1016/j.biomaterials.2011.05.001
   Mbopi-Keou FX, 2010, CONTRACEPTION, V81, P79, DOI 10.1016/j.contraception.2009.07.002
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mohammadi G, 2010, J PHARM PHARM SCI, V13, P152, DOI 10.18433/J3JG61                                                                 
   Morrow KM, 2008, AIDS BEHAV, V12, P272, DOI 10.1007/s10461-007-9266-z
   Nekkanti V, 2009, DRUG DEV IND PHARM, V35, P1219, DOI 10.1080/03639040902882264
   Newman AW, 2003, DRUG DISCOV TODAY, V8, P898, DOI 10.1016/S1359-6446(03)02832-0                                                   
   Nielsen LS, 1998, EUR J PHARM SCI, V6, P231, DOI 10.1016/S0928-0987(97)10004-5                                                   
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Patterson JE, 2005, J PHARM SCI-US, V94, P1998, DOI 10.1002/jps.20424
   Ren YC, 2008, DRUG DEV IND PHARM, V34, P984, DOI [10.1080/03639040802154913, 10.1080/03639040802154913 ]
   STEVENSSIMON C, 1994, SEX TRANSM DIS, V21, P168, DOI 10.1097/00007435-199405000-00007
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2011, UNAIDS REP GLOB AIDS
   UNAIDS/WHO, 2011, GLOB HIV AIDS RESP E, P229
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 50
TC 20
Z9 20
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD MAR
PY 2013
VL 97
IS 3
BP 334
EP 346
DI 10.1016/j.antiviral.2012.12.019
PG 13
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 127OX
UT WOS:000317709400016
PM 23274788
OA green_accepted
DA 2018-01-05
ER

PT J
AU Damhorst, GL
   Watkins, NN
   Bashir, R
AF Damhorst, Gregory L.
   Watkins, Nicholas N.
   Bashir, Rashid
TI Micro- and Nanotechnology for HIV/AIDS Diagnostics in Resource-Limited
   Settings
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Global health; human immunodeficiency virus (HIV)/acquired immune
   deficiency syndrome (AIDS); micro- and nanotechnology; point-of-care
   (PoC) diagnostics
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE ACTIVITY; HIV-1
   VIRAL LOAD; PLATFORM IMAGE CYTOMETER; REAL-TIME PCR; ACTIVE
   ANTIRETROVIRAL THERAPY; POLYMERASE CHAIN-REACTION; BLOOD
   MONONUCLEAR-CELLS; CAPSID P24 ANTIGEN; HUMAN CD4(+) CELLS
AB Thirty-four million people are living with HIV worldwide, a disproportionate number of whom live in resource-limited settings. Proper clinical management of AIDS, the disease caused by HIV, requires regular monitoring of both the status of the host's immune system and levels of the virus in their blood. Therefore, more accessible technologies capable of performing a CD4+ T cell count and HIV viral load measurement in settings where HIV is most prevalent are desperately needed to enable better treatment strategies and ultimately quell the spread of the virus within populations. This review discusses micro- and nanotechnology solutions to performing these key clinical measurements in resource-limited settings.
C1 [Damhorst, Gregory L.] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
   [Damhorst, Gregory L.; Watkins, Nicholas N.; Bashir, Rashid] Univ Illinois, Micro & Nanotechnol Lab, Urbana, IL 61801 USA.
   [Watkins, Nicholas N.] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA.
RP Bashir, R (reprint author), Univ Illinois, Dept Elect & Comp Engn, Dept Bioengn, 1406 W Green St, Urbana, IL 61801 USA.
EM gdamhor2@illinois.edu; watkins7@illinois.edu; rbashir@illinois.edu
OI Damhorst, Gregory/0000-0002-2237-1713
CR Aberg JA, 2009, CLIN INFECT DIS, V49, P651, DOI 10.1086/605292
   Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Bae SY, 2009, CYTOM PART B-CLIN CY, V76B, P345, DOI 10.1002/cyto.b.20470
   Barlow KL, 1997, J CLIN MICROBIOL, V35, P2846
   Beck M, 2012, LAB CHIP, V12, P167, DOI 10.1039/c1lc20565j
   Bonard D, 2003, JAIDS-J ACQ IMM DEF, V34, P267, DOI 10.1097/00126334-200311010-00002
   Boyle DS, 2012, TRENDS BIOTECHNOL, V30, P45, DOI 10.1016/j.tibtech.2011.06.015
   Braun J, 2003, AIDS, V17, P331, DOI 10.1097/01.aids.0000042974.95433.ec
   Bremer JW, 1996, J PEDIATR-US, V129, P198, DOI 10.1016/S0022-3476(96)70243-3
   CASSOL S, 1994, J CLIN MICROBIOL, V32, P2641
   Cassol S, 1997, J CLIN MICROBIOL, V35, P2795
   CDC, 2010, HIV TEST BAS CONS
   Chen GD, 2010, ANAL CHEM, V82, P723, DOI 10.1021/ac9024522
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Cheng X, 2007, LAB CHIP, V7, P746, DOI 10.1039/b705082h
   Cheng XH, 2009, LAB CHIP, V9, P1357, DOI 10.1039/b818813k
   Chin CD, 2012, LAB CHIP, V12, P2118, DOI 10.1039/c2lc21204h
   Christopherson C, 2000, J CLIN MICROBIOL, V38, P630
   de la Rica R, 2012, NAT NANOTECHNOL, V7, P821, DOI [10.1038/NNANO.2012.186, 10.1038/nnano.2012.186]
   De Rossi A, 2010, NEW MICROBIOL, V33, P293
   Delamare C, 1997, J ACQ IMMUN DEF SYND, V15, P121, DOI 10.1097/00042560-199706010-00004                                                
   Desire N, 2001, J CLIN MICROBIOL, V39, P1303, DOI 10.1128/JCM.39.4.1303-1310.2001                                                 
   Ekstrand DHL, 1996, BIOTECHNOL APPL BIOC, V23, P95
   Epstein FH, 1993, NEW ENGL J MED, V328, P327
   Fiscus SA, 2007, J CLIN MICROBIOL, V45, P2274, DOI 10.1128/JCM.00813-07
   Furtado M. R., 1995, CHANGES VIRAL MRNA E
   Garrido C, 2009, J CLIN MICROBIOL, V47, P1031, DOI 10.1128/JCM.02099-08
   Gibellini D, 2008, J INFECTION, V56, P219, DOI 10.1016/j.jinf.2008.01.001
   Gohring JT, 2010, SENSORS-BASEL, V10, P5798, DOI 10.3390/s100605798
   Greengrass V, 2009, JAIDS-J ACQ IMM DEF, V52, P387, DOI 10.1097/QAI.0b013e3181b05f62
   Greengrass VL, 2009, J CLIN MICROBIOL, V47, P3011, DOI 10.1128/JCM.00805-09
   Gurkan UA, 2011, LAB CHIP, V11, P3979, DOI 10.1039/c1lc20487d
   Hatzakis AE, 2004, AIDS, V18, P2261, DOI 10.1097/00002030-200411190-00006
   Herbert S, 2012, SEX TRANSM INFECT, V88, P413, DOI 10.1136/sextrans-2012-050507
   Holmes D, 2010, ANAL CHEM, V82, P1455, DOI 10.1021/ac902568p
   Holmes D, 2009, LAB CHIP, V9, P2881, DOI 10.1039/b910053a
   Iqbal HS, 2007, J MED MICROBIOL, V56, P1611, DOI 10.1099/jmm.0.47456-0
   Jangam S. R., 2012, BIOSENS BIOELECTRON, P69
   Jangam SR, 2009, J CLIN MICROBIOL, V47, P2363, DOI 10.1128/JCM.r00092-09
   Jani IV, 2011, AIDS, V25, P807, DOI 10.1097/QAD.0b013e328344f424
   Jani IV, 2011, 6 IAS C HIV PATH TRE
   Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005
   Jiang XQ, 2010, BIOSENS BIOELECTRON, V25, P1622, DOI 10.1016/j.bios.2009.11.024
   Johannessen A, 2009, CLIN INFECT DIS, V49, P976, DOI 10.1086/605502
   Jokerst JV, 2010, ANAL CHEM, V82, P1571, DOI 10.1021/ac901743u
   Jokerst JV, 2008, LAB CHIP, V8, P2079, DOI 10.1039/b817116e
   Kiesel P, 2011, CYTOM PART A, V79A, P317, DOI 10.1002/cyto.a.21042
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Kostrikis LG, 2002, J VIROL, V76, P10099, DOI 10.1128/JVI.76.20.10099-10108.2002
   Krantz EM, 2011, JAIDS-J ACQ IMM DEF, V57, P396, DOI 10.1097/QAI.0b013e318221c62a
   Labbett W, 2009, J CLIN MICROBIOL, V47, P3266, DOI 10.1128/JCM.00715-09
   Larson B., 2012, PLOS ONE, V7, P1
   Lee HH, 2010, J INFECT DIS, V201, pS65, DOI 10.1086/650385
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Lee SH, 2008, LAB CHIP, V8, P2121, DOI 10.1039/b811131f
   Li X, 2007, CYTOM PART B-CLIN CY, V72B, P397, DOI 10.1002/cyto.b.20165
   Li X, 2007, CLIN VACCINE IMMUNOL, V14, P412, DOI 10.1128/CVI.00372-06
   Lombart JP, 2005, AIDS, V19, P1273, DOI 10.1097/01.aids.0000180098.58017.48
   Malmsten A, 2005, J MED VIROL, V76, P291, DOI 10.1002/jmv.20360
   Malmsten A, 2003, J MED VIROL, V71, P347, DOI 10.1002/jmv.10492
   Malnati MS, 2008, NAT PROTOC, V3, P1240, DOI 10.1038/nprot.2008.108
   Manabe Y. C., 2012, PLOS ONE, V7, P1
   Mao XL, 2009, LAB CHIP, V9, P1583, DOI 10.1039/b820138b
   MICHAEL NL, 1995, J VIROL, V69, P1868
   Mine M, 2009, J VIROL METHODS, V159, P93, DOI 10.1016/j.jviromet.2009.03.008
   Mishra N., 2004, P NSTI NAN C TRAD SH, P228
   Mishra NN, 2005, BIOSENS BIOELECTRON, V21, P696, DOI 10.1016/j.bios..2005.01.011
   Moon S., 2011, PLOS ONE, V6, P1
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Moroney SM, 2006, J MICROBIOL METH, V65, P350, DOI 10.1016/j.mimet.2005.08.003
   Mtapuri-Zinyowera S, 2010, JAIDS-J ACQ IMM DEF, V55, P1, DOI 10.1097/QAI.0b013e3181e93071
   Mwaba P, 2003, LANCET, V362, P2067, DOI 10.1016/S0140-6736(03)15103-3
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   National Institute of Allergy and Infectious Diseases, 2010, REL HUM IMM VIR ACQ
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Parpia ZA, 2010, JAIDS-J ACQ IMM DEF, V55, P413, DOI 10.1097/QAI.0b013e3181f1afbc
   Pasternak AO, 2008, J CLIN MICROBIOL, V46, P2206, DOI 10.1128/JCM.00055-08
   Pasternak AO, 2010, AIDS, V24, P1641, DOI 10.1097/QAD.0b013e32833b3171
   Pasternak A. O., 2009, PLOS ONE, V4, P1
   Peterson T., 2011, PCR HIV TEST
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Re MC, 2010, CLIN MICROBIOL INFEC, V16, P640, DOI 10.1111/j.1469-0691.2009.02826.x
   Respess RA, 2005, J CLIN MICROBIOL, V43, P506, DOI 10.1128/JCM.43.1.506-508.2005
   Robertus J, 2010, CHEM SOC REV, V39, P354, DOI 10.1039/b906608j
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Rohrman B. A., 2012, PLOS ONE, V7, P1
   SAKSELA K, 1995, ANN INTERN MED, V123, P641, DOI 10.7326/0003-4819-123-9-199511010-00001
   SCHUTZBANK TE, 1995, J CLIN MICROBIOL, V33, P2036
   Shen F, 2011, J AM CHEM SOC, V133, P17705, DOI 10.1021/ja2060116
   Sivapalasingam S, 2005, J CLIN MICROBIOL, V43, P3793, DOI 10.1128/JCM.43.8.3793-3796.2005
   Soares RS, 2011, J VIROL METHODS, V175, P38, DOI 10.1016/j.jviromet.2011.04.012
   Steegen K, 2007, J VIROL METHODS, V146, P178, DOI 10.1016/j.jviromet.2007.06.019
   Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005
   Stewart P, 2010, J CLIN VIROL, V49, P198, DOI 10.1016/j.jcv.2010.07.022
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Tang W, 2010, J INFECT DIS, V201, pS46, DOI 10.1086/650388
   Tanriverdi S, 2010, J INFECT DIS, V201, pS52, DOI 10.1086/650387
   Thorslund S, 2008, BIOMED MICRODEVICES, V10, P851, DOI 10.1007/s10544-008-9199-y
   Thorslund S, 2007, SENSOR ACTUAT B-CHEM, V123, P847, DOI 10.1016/j.snb.2006.10.034
   UN, 2012, MILL DEV GOALS REP
   UNAIDS (Joint United Nations Programme on HIV/AIDS), 2012, UNAIDS WORLD AIDS DA
   Klein R., 2007, 3 NEW HIV ASS APPR
   U.S. Food and Drug Administration, 2010, VACC BLOOD BIOL APPR
   U.S. Food and Drug Administration, 2011, COMPL LIST DON SCREE
   van Berkel C, 2011, LAB CHIP, V11, P1249, DOI 10.1039/c0lc00587h
   Vermund S. H., 2013, CHALLENGES INFECT DI, P3
   Wang JH, 2013, BIOSENS BIOELECTRON, V41, P484, DOI 10.1016/j.bios.2012.09.011
   Wang JH, 2011, MICROFLUID NANOFLUID, V10, P531, DOI 10.1007/s10404-010-0687-z
   Wang S., 2010, DEFENSE, V7666
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang YN, 2008, LAB CHIP, V8, P309, DOI 10.1039/b713932b
   Wang ZK, 2010, ANAL CHEM, V82, P36, DOI 10.1021/ac902144w
   Watkins N, 2009, LAB CHIP, V9, P3177, DOI 10.1039/b912214a
   Watkins NN, 2011, LAB CHIP, V11, P1437, DOI 10.1039/c0lc00556h
   Weidner J, 2011, J VIROL METHODS, V172, P22, DOI 10.1016/j.jviromet.2010.12.008
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
   WHO/UNAIDS/UNICEF, 2011, GLOB HIV AIDS RESP E
   Willyard C, 2007, NAT MED, V13, P1131, DOI 10.1038/nm1007-1131
   Wu XD, 2008, ELECTROPHORESIS, V29, P2754, DOI 10.1002/elps.200700912
   Wu XD, 2008, LAB CHIP, V8, P1943, DOI 10.1039/b804319a
   Ymeti A, 2007, CYTOM PART A, V71A, P132, DOI 10.1002/cyto.a.20375
   Yun H, 2010, LAB CHIP, V10, P3243, DOI 10.1039/c0lc00041h
   Zachariah R, 2011, TROP MED INT HEALTH, V16, P37, DOI 10.1111/j.1365-3156.2010.02669.x
   Zanchetta M, 2006, J INFECT DIS, V193, P1718, DOI 10.1086/504264
   ZELLA D, 1995, CLIN DIAGN VIROL, V3, P155, DOI 10.1016/0928-0197(94)00029-T                                                    
   Zhu H, 2008, COLLOID SURFACE B, V64, P260, DOI 10.1016/j.colsurfb.2008.02.010
NR 129
TC 10
Z9 10
U1 2
U2 27
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
EI 1558-2531
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD MAR
PY 2013
VL 60
IS 3
BP 715
EP 726
DI 10.1109/TBME.2013.2244894
PG 12
WC Engineering, Biomedical
SC Engineering
GA 115KL
UT WOS:000316810900017
PM 23512111
DA 2018-01-05
ER

PT J
AU Giacalone, G
   Bochot, A
   Fattal, E
   Hillaireau, H
AF Giacalone, Giovanna
   Bochot, Amelie
   Fattal, Elias
   Hillaireau, Herve
TI Drug-Induced Nanocarrier Assembly as a Strategy for the Cellular
   Delivery of Nucleotides and Nucleotide Analogues
SO BIOMACROMOLECULES
LA English
DT Article
ID ANTICANCER NUCLEOSIDE ANALOGS; CONTAINING LIPOSOMES; CHITOSAN; CARRIERS;
   NANOCAPSULES; TRIPHOSPHATE; FORMULATIONS; MACROPHAGES
AB The natural nucleotide adenosine triphosphate (ATP) and nucleotide analogues such as azidothymidine triphosphate (AZT-TP) display important pharmacological activities for the treatment of ischemia and HIV infections, respectively. Their clinical use is, however, limited mostly due to their hydrophilicity, which highly restricts their diffusion into the target cells. Few nanocarriers have been proposed to address the challenge of ATP/AZT-TP cellular delivery, but the loading efficiency, preparation complexity, and efficient cellular delivery remain important barriers to their development. In this study, we propose an original, straightforward and versatile design of nucleotide and nucleotide analogue nanocarriers based on the natural polysaccharide chitosan (CS). We show that the drugs ATP and AZT-TP can induce ionotropic gelation of CS, leading to CS/ATP and CS/AZT-TP nanoparticles with high drug entrapment efficiency and loading rate-up to 44%. Such nanocarriers release ATP and AZT-TP in physiological media and allow an efficient in vitro cellular delivery of these molecules down to the cell cytoplasm.
C1 [Hillaireau, Herve] Univ Paris 11, Inst Galien Paris Sud, Chatenay Malabry, France.
   CNRS, UMR 8612, Chatenay Malabry, France.
RP Hillaireau, H (reprint author), Univ Paris 11, Inst Galien Paris Sud, Chatenay Malabry, France.
EM herve.hillaireau@u-psud.fr
RI Hillaireau, Herve/U-7781-2017
OI Hillaireau, Herve/0000-0002-0628-7618
CR Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4                 
   Chaib S, 2003, LIVER INT, V23, P379, DOI 10.1034/j.1478-3231.2003.00863.x                                                
   CHAUDRY IH, 1990, ANN NY ACAD SCI, V603, P130
   Chaudry I. H., 1990, ANN NY ACAD SCI, V603, P140
   Galmarini CM, 2010, INT J PHARMACEUT, V395, P281, DOI 10.1016/j.ijpharm.2010.05.028
   Garcia-Fuentes M, 2012, J CONTROL RELEASE, V161, P496, DOI 10.1016/j.jconrel.2012.03.017
   Hillaireau H, 2007, INT J PHARM, V331, P148, DOI 10.1016/j.ijpharm.2006.10.031
   Hillaireau H, 2009, J DRUG DELIV SCI TEC, V19, P385, DOI 10.1016/S1773-2247(09)50081-0                                                   
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Horcajada P, 2010, NAT MATER, V9, P172, DOI [10.1038/nmat2608, 10.1038/NMAT2608, 10.1038/NMAT260B]
   Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004
   Kohli E, 2007, J CONTROL RELEASE, V121, P19, DOI 10.1016/j.jconrel.2007.04.007
   Koppensteiner H, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-82
   Korb V, 2008, CRIT REV THER DRUG, V25, P305, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i4.10                                    
   Muzzarelli RAA, 1998, ANAL BIOCHEM, V260, P255, DOI 10.1006/abio.1998.2705
   Neveux N, 2000, J HEPATOL, V33, P68, DOI 10.1016/S0168-8278(00)80161-0                                                   
   Rodriguez JF, 2000, ANTIMICROB AGENTS CH, V44, P3097, DOI 10.1128/AAC.44.11.3097-3100.2000
   Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
NR 19
TC 19
Z9 19
U1 1
U2 51
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD MAR
PY 2013
VL 14
IS 3
BP 737
EP 742
DI 10.1021/bm301832v
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 105DB
UT WOS:000316044700018
PM 23351139
DA 2018-01-05
ER

PT J
AU Xiang, DS
   Zheng, AH
   Luo, M
   Ji, XH
   He, ZK
AF Xiang DongShan
   Zheng AiHua
   Luo Ming
   Ji XingHu
   He ZhiKe
TI Graphene oxide and molecular beacons-based multiplexed DNA detection by
   synchronous fluorescence analysis
SO SCIENCE CHINA-CHEMISTRY
LA English
DT Article
DE multiplexed DNA; molecular beacons; synchronous fluorescence analysis;
   graphene oxide
ID REAL-TIME PCR; NANOPARTICLE PROBES; PROTEIN-DETECTION; CLINICAL-SAMPLES;
   ASSAY; SEQUENCE; PLATFORM
AB We have developed a multiplexed DNA detection method based on graphene oxide (GO) and molecular beacons (MBs) by synchronous fluorescence analysis, demonstrated it by an oligonucleotide sequence of wild-type HBV (T1) and a reverse-transcription oligonucleotide sequence of the RNA fragment of HIV (T2) as a model system. In the absence of targets DNA, FAM-tagged free MB probes (P-HBV) and ROX-tagged free MB probes (P-HIV) are adsorbed on GO via pi-pi interactions between DNA nucleobases and nucleosides, and the pi-rich GO brings the fluorophores of MB and GO into close proximity. And then, the fluorescence of fluorophores is quenched by GO. But in the presence of targets DNA, P-HBV and P-HIV hybridize with their targets DNA resulting in the formation of double-stranded DNA (dsDNA), causing the separation of P-HBV and P-HIV from the surface of GO and the recovery of the fluorescence of fluorophores (FAM and ROX) simultaneously. The simultaneous detection of T1 and T2 can be realized by measuring fluorescence signals of FAM and ROX, respectively. Under the optimum conditions, the fluorescence intensities of two dyes all exhibit good linear dependence on their target DNA concentration in the range of 5x10(-11)-5x10(-9) M. The detection limit of T1 is 3x10(-11) M (3 sigma), and that of T2 is 2x10(-11) M. Compared with other methods for DNA detection based on GO, the proposed method has some advantages including higher selectivity and shorter analytical time.
C1 [Xiang DongShan; Zheng AiHua; Luo Ming; Ji XingHu; He ZhiKe] Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol & Med, Minist Educ, Wuhan 430072, Peoples R China.
   [Xiang DongShan] Hubei Univ Nationalities, Sch Chem & Environm Engn, Enshi 445000, Peoples R China.
RP He, ZK (reprint author), Wuhan Univ, Coll Chem & Mol Sci, Key Lab Analyt Chem Biol & Med, Minist Educ, Wuhan 430072, Peoples R China.
EM zhkhe@whu.edu.cn
FU National Key Scientific Program-Nanoscience and Nanotechnology
   [2011CB933600]; National Natural Science Foundation of China [21075093];
   Science Fund for Creative Research Groups of NSFC [20921062]
FX This work was supported by the National Key Scientific
   Program-Nanoscience and Nanotechnology (2011CB933600), the National
   Natural Science Foundation of China (21075093), and the Science Fund for
   Creative Research Groups of NSFC (20921062).
CR Bao HQ, 2011, SMALL, V7, P1569, DOI 10.1002/smll.201100191
   Brunner J, 2004, J AM CHEM SOC, V126, P13626, DOI 10.1021/ja047252a
   Casson N, 2008, J CLIN MICROBIOL, V46, P1491, DOI 10.1128/JCM.02302-07
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P680
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Huang PJJ, 2012, SMALL, V8, P977, DOI 10.1002/smll.201102156
   Kunduru V, 2010, NANOMED-NANOTECHNOL, V6, P642, DOI 10.1016/j.nano.2010.03.002
   Li F, 2012, CHEM COMMUN, V48, P127, DOI 10.1039/c1cc15694b
   Li JWJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn033
   Liu JB, 2011, SCI CHINA CHEM, V54, P1157, DOI 10.1007/s11426-011-4350-7
   Liu XQ, 2012, ACS NANO, V6, P3553, DOI 10.1021/nn300598q
   Lotan Y, 2009, BJU INT, V103, P1368, DOI 10.1111/j.1464-410X.2009.08360.x
   Mao S, 2011, NANO RES, V4, P921, DOI 10.1007/s12274-011-0148-3
   Mao S, 2010, ADV MATER, V22, P3521, DOI 10.1002/adma.201000520
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Ohishi Y, 2008, HEPATOLOGY, V48, P853, DOI 10.1002/hep.22382
   Schenk T, 2009, J CLIN MICROBIOL, V47, P1428, DOI 10.1128/JCM.02080-08
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Sun WL, 2011, ANAL METHODS-UK, V3, P2472, DOI 10.1039/c1ay05521f
   Swearingen CB, 2005, ANAL CHEM, V77, P442, DOI 10.1021/ac0401016
   Teles FRR, 2008, TALANTA, V77, P606, DOI 10.1016/j.talanta.2008.07.024
   Wallet F, 2010, CLIN MICROBIOL INFEC, V16, P774, DOI 10.1111/j.1469-0691.2009.02940.x
   Wang J, 2011, ANAL CHEM, V83, P3528, DOI 10.1021/ac200236r
   Wang X, 2012, ANAL METHODS-UK, V4, P360, DOI 10.1039/c2ay05827h
   Wen HY, 2012, SMALL, V8, P760, DOI 10.1002/smll.201101613
   Wu M, 2011, LANGMUIR, V27, P2731, DOI 10.1021/la1037926
   Yang CYJ, 2005, J AM CHEM SOC, V127, P12772, DOI 10.1021/ja053482t
   Zhang P, 2001, ANGEW CHEM INT EDIT, V40, P402, DOI 10.1002/1521-3773(20010119)40:2<402::AID-ANIE402>3.3.CO;2-9
   Zhou DM, 2011, SCI CHINA CHEM, V54, P1277, DOI 10.1007/s11426-011-4337-4
   Zhu NN, 2003, ANAL CHIM ACTA, V481, P181, DOI 10.1016/S0003-2670(03)00123-5
NR 31
TC 8
Z9 9
U1 2
U2 100
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7291
J9 SCI CHINA CHEM
JI Sci. China-Chem.
PD MAR
PY 2013
VL 56
IS 3
BP 380
EP 386
DI 10.1007/s11426-012-4767-7
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 089DW
UT WOS:000314890600017
DA 2018-01-05
ER

PT J
AU Liu, Y
   Timani, K
   Ou, X
   Broxmeyer, HE
   He, JJ
AF Liu, Ying
   Timani, Khalid
   Ou, Xuan
   Broxmeyer, Hal E.
   He, Johnny J.
TI C-MYC Controlled TIP110 Protein Expression Regulates OCT4 mRNA Splicing
   in Human Embryonic Stem Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID PLURIPOTENT; BLASTOCYST; DEATH; LIFE
AB We reported previously that HIV-1 the Tat-interacting protein of 110 kDa (TIP110; P110(NRB)/SART3/p110) is important in regulation of hematopoiesis, and in maintaining pluripotent factor (NANOG, OCT4, and SOX2) expression in and pluripotency of human embryonic stem cells (hESCs). Here we show that TIP110 expression in hESCs line H9 and embryonal carcinoma cell line NT-2 is regulated by C-MYC expression in ESCs through an E box present in the TIP110 promoter region. Through up-and down-modulation of expression, TIP110 induces OCT4 exon 1a inclusion and exon 1b skipping in our OCT4 minigene model. Thus, TIP110 expression in ESCs regulates alternative splicing of OCT4, an event required for pluripotency of ESCs.
C1 [Liu, Ying; Timani, Khalid; He, Johnny J.] Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Anat, Ft Worth, TX 76092 USA.
   [Ou, Xuan; Broxmeyer, Hal E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN USA.
RP Liu, Y (reprint author), Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Anat, Ft Worth, TX 76092 USA.
EM ying.liu@unthsc.edu
OI Timani, Khalid/0000-0002-4862-9348
FU Public Health Service Grants from the National Institutes of Health [R01
   HL 056416, R01 HL 67384, P01 DK090948]
FX These studies were supported by Public Health Service Grants from the
   National Institutes of Health: R01 HL 056416, R01 HL 67384, and P01
   DK090948 to H.E.B.
CR Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530
   Bell M, 2002, EMBO J, V21, P2724, DOI 10.1093/emboj/21.11.2724
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670
   Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611
   Liu Y, 2008, EXP HEMATOL, V36, P947, DOI 10.1016/j.exphem.2008.06.005
   Liu Y, 2012, STEM CELLS DEV, V21, P829, DOI 10.1089/scd.2011.0512
   Liu Y, 2011, BLOOD, V117, P5643, DOI 10.1182/blood-2010-12-325332
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Rossant J, 2007, REPROD FERT DEVELOP, V19, P111, DOI 10.1071/RD06125
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   TAKEDA J, 1992, NUCLEIC ACIDS RES, V20, P4613, DOI 10.1093/nar/20.17.4613
   Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217
   Yamanaka Y, 2006, DEV DYNAM, V235, P2301, DOI 10.1002/dvdy.20844
   Zeng FY, 2004, DEV BIOL, V272, P483, DOI 10.1016/j.ydbio.2004.05.018
NR 17
TC 11
Z9 13
U1 0
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAR
PY 2013
VL 22
IS 5
DI 10.1089/scd.2012.0271
PG 6
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 090JM
UT WOS:000314975300001
PM 23088399
OA green_published
DA 2018-01-05
ER

PT J
AU Guillen, G
   Aguilar, JC
   Duenas, S
   Hermida, L
   Iglesias, E
   Penton, E
   Lobaina, Y
   Lopez, M
   Mussachio, A
   Falcon, V
   Alvarez, L
   Martinez, G
   Gil, L
   Valdes, I
   Izquierdo, A
   Lazo, L
   Marcos, E
   Guzman, G
   Muzio, V
   Herrera, L
AF Guillen, G.
   Aguilar, J. C.
   Duenas, S.
   Hermida, L.
   Iglesias, E.
   Penton, E.
   Lobaina, Y.
   Lopez, M.
   Mussachio, A.
   Falcon, V.
   Alvarez, L.
   Martinez, G.
   Gil, L.
   Valdes, I.
   Izquierdo, A.
   Lazo, L.
   Marcos, E.
   Guzman, G.
   Muzio, V.
   Herrera, L.
TI Virus-like particles as nanovaccine candidates
SO ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE VLPs; hepatitis; HBV; HCV; human immunodeficiency virus; Th1
AB The existing vaccines are mainly limited to the microorganisms we are able to culture and produce and/or to those whose killing is mediated by humoral response (antibody mediated). It has been more difficult to develop vaccines capable of inducing a functional cellular response needed to prevent or cure chronic diseases. New strategies should be taken into account in the improvement of cell-based immune responses in order to prevent and control the infections and eventually clear the virus. Preclinical and clinical results with vaccine candidates developed as a vaccine platform based on virus-like particles (VLPs) evidenced their ability to stimulate mucosal as well as systemic immunity. Particles based on envelope, membrane or nucleocapsid microbial proteins induce a strong immune response after nasal or parenteral administration in mice, non-human primates and humans. In addition, the immune response obtained was modulated in a Th1 sense. The VLPs were also able to immunoenhance the humoral and cellular immune responses against several viral pathogens. Studies in animals and humans with nasal and systemic formulations evidenced that it is possible to induce functional immune response against HBV, HCV, HIV and dengue virus.
C1 [Guillen, G.; Aguilar, J. C.; Duenas, S.; Hermida, L.; Iglesias, E.; Penton, E.; Lobaina, Y.; Lopez, M.; Mussachio, A.; Falcon, V.; Alvarez, L.; Martinez, G.; Gil, L.; Valdes, I.; Izquierdo, A.; Lazo, L.; Marcos, E.; Guzman, G.; Muzio, V.; Herrera, L.] Ctr Ingn Genet & Biotecnol, Havana 10600, Cuba.
RP Guillen, G (reprint author), Ctr Ingn Genet & Biotecnol, Ave 31-158 & 190,POB 6162, Havana 10600, Cuba.
EM gerardo.guillen@cigb.edu.cu
CR Acosta-Rivero N, 2005, AM J INFECT DIS, V1, P66, DOI 10.3844/ajidsp.2005.66.72
   Acosta-Rivero N, 2009, BIOL RES, V42, P41, DOI [10.4067/S0716-97602009000100005, /S0716-97602009000100005]
   Alvarez-Lajonchere L, 2012, INT REV IMMUNOL, V31, P223, DOI 10.3109/08830185.2012.680552
   Alvarez-Lajonchere L, 2009, HUM VACCINES, V5, P568, DOI 10.4161/hv.5.8.8572                                                             
   Antonis AFG, 2006, VACCINE, V24, P5481, DOI 10.1016/j.vaccine.2006.03.089
   Bernard L, 2008, ANTIVIR RES, V80, P194, DOI 10.1016/j.antiviral.2008.06.005
   Chen YP, 1996, J VIROL, V70, P8765
   Chin JFL, 2007, MICROBES INFECT, V9, P1, DOI 10.1016/j.micinf.2006.09.009
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Dell K, 2006, VACCINE, V24, P2238, DOI 10.1016/j.vaccine.2005.11.060
   Duenas-Carrera S, 2004, BIOTECHNOL APPL BIOC, V39, P249, DOI 10.1042/BA200301129                                                             
   Duenas-Carrera Santiago, 1999, Biotecnologia Aplicada, V16, P226
   Gil L, 2012, J GEN VIROL, V93, P1204, DOI 10.1099/vir.0.037721-0
   Gil L, 2009, INT IMMUNOL, V21, P1175, DOI 10.1093/intimm/dxp082
   Hermida L, 2006, VACCINE, V24, P3165, DOI 10.1016/j.vaccine.2006.01.036
   Hermida L, 2004, BIOTECHNOL APPL BIOC, V39, P107, DOI 10.1042/BA20030039
   Hermida L, 2004, J VIROL METHODS, V115, P41, DOI 10.1016/j.jviromet.2003.09.024
   Huis CK, 2005, INT J MED SCI, V2, P24
   Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004
   Iglesias E, 2006, IMMUNOL CELL BIOL, V84, P174, DOI 10.1111/j.1440-1711.2005.01408.x
   IGLESIAS E, 2001, J BIOCH MOL BIOL BIO, V5, P109
   Iglesias E, 2008, CURR HIV RES, V6, P452, DOI 10.2174/157016208785861186                                                      
   Iglesias E, 2012, INT IMMUNOPHARMACOL, V12, P487, DOI 10.1016/j.intimp.2011.12.026
   Izquierdo A, 2012, ANTIVIR RES, V95, P1, DOI 10.1016/j.antiviral.2012.04.006
   Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040
   Lobaina Y, 2005, MOL IMMUNOL, V42, P289, DOI 10.1016/j.molimm.2004.09.005
   Martinez-Donato G, 2010, BIOTECHNOL APPL BIOC, V56, P111, DOI 10.1042/BA20090216
   Pol S, 2006, EXPERT REV VACCINES, V5, P707, DOI 10.1586/14760584.5.5.707
   Riedl P, 2002, EUR J IMMUNOL, V32, P1709, DOI 10.1002/1521-4141(200206)32:6<1709::AID-IMMU1709>3.0.CO;2-D
   Riedl P, 2002, J IMMUNOL, V168, P4951, DOI 10.4049/jimmunol.168.10.4951                                                    
   Valdes I, 2009, VACCINE, V27, P995, DOI 10.1016/j.vaccine.2008.11.106
   Valdes I, 2011, CLIN VACCINE IMMUNOL, V18, P455, DOI 10.1128/CVI.00382-10
   Valdes I, 2009, VIROLOGY, V394, P249, DOI 10.1016/j.virol.2009.08.029
   Young SL, 2006, VACCINE, V24, P5406, DOI 10.1016/j.vaccine.2006.03.052
NR 34
TC 2
Z9 3
U1 0
U2 5
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 2043-6254
EI 2043-6262
J9 ADV NAT SCI-NANOSCI
JI Adv. Nat. Sci.-Nanosci Nanotechnol
PD MAR
PY 2013
VL 4
IS 1
AR 015005
DI 10.1088/2043-6262/4/1/015005
PG 4
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA V41HZ
UT WOS:000209538600007
OA gold
DA 2018-01-05
ER

PT J
AU Kawasuji, T
   Johns, BA
   Yoshida, H
   Weatherhead, JG
   Akiyama, T
   Taishi, T
   Taoda, Y
   Mikamiyama-Iwata, M
   Murai, H
   Kiyama, R
   Fuji, M
   Tanimoto, N
   Yoshinaga, T
   Seki, T
   Kobayashi, M
   Sato, A
   Garvey, EP
   Fujiwara, T
AF Kawasuji, Takashi
   Johns, Brian A.
   Yoshida, Hiroshi
   Weatherhead, Jason G.
   Akiyama, Toshiyuki
   Taishi, Teruhiko
   Taoda, Yoshiyuki
   Mikamiyama-Iwata, Minako
   Murai, Hitoshi
   Kiyama, Ryuichi
   Fuji, Masahiro
   Tanimoto, Norihiko
   Yoshinaga, Tomokazu
   Seki, Takahiro
   Kobayashi, Masanori
   Sato, Akihiko
   Garvey, Edward P.
   Fujiwara, Tamio
TI Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic
   Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID SOCIETY-USA PANEL; ANTIRETROVIRAL TREATMENT; STRAND TRANSFER;
   ACTIVE-SITE; RALTEGRAVIR; ELVITEGRAVIR; RESISTANCE; INFECTION; BINDING;
   RECOMMENDATIONS
AB This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties. We report herein a series of bicyclic carbamoyl pyridone analogues to address conformational issues from our initial SAR studies. This modification of the core unit succeeded to deliver low nanomolar potency in standard antiviral assays. An additional hydroxyl substituent on the bicyclic scaffold provides remarkable improvement of antiviral efficacies against clinically relevant resistant viruses. These findings led to additional cyclic tethering of the naked hydroxyl group resulting in tricyclic carbamoyl pyridone inhibitors to address remaining issues and deliver potential clinical candidates. The tricyclic carbamoyl pyridone derivatives described herein served as the immediate leads in molecules to the next generation integrase inhibitor dolutegravir which is currently in late stage clinical evaluation.
C1 [Kawasuji, Takashi; Yoshida, Hiroshi; Akiyama, Toshiyuki; Taishi, Teruhiko; Taoda, Yoshiyuki; Mikamiyama-Iwata, Minako; Murai, Hitoshi; Kiyama, Ryuichi; Fuji, Masahiro; Tanimoto, Norihiko; Yoshinaga, Tomokazu; Seki, Takahiro; Kobayashi, Masanori; Sato, Akihiko; Fujiwara, Tamio] Shionogi & Co Ltd, Shionogi Pharmaceut Res Ctr, Toyonaka, Osaka 5610825, Japan.
   [Johns, Brian A.; Weatherhead, Jason G.; Garvey, Edward P.] GlaxoSmithKline Res & Dev Ltd, Infect Dis Therapeut Area Unit, Res Triangle Pk, NC 27709 USA.
RP Kawasuji, T (reprint author), Shionogi & Co Ltd, Shionogi Pharmaceut Res Ctr, 3-1-1 Futaba Cho, Toyonaka, Osaka 5610825, Japan.
EM takashi.kawasuji@shionogi.co.jp
CR Adams JL, 2012, CURR OPIN HIV AIDS, V7, P390, DOI 10.1097/COH.0b013e328356e91c
   Bacchi A, 2011, J MED CHEM, V54, P8407, DOI 10.1021/jm200851g
   Bacchi A, 2011, MOL PHARMACEUT, V8, P507, DOI 10.1021/mp100343x
   Blanco JL, 2011, J INFECT DIS, V203, P1204, DOI 10.1093/infdis/jir025
   Cohen C., 2010, 17 C RETR OPP INF SA
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Elion R, 2010, 50 INT C ANT AG CHEM
   Garrido C, 2012, ANTIMICROB AGENTS CH, V56, P2873, DOI 10.1128/AAC.06170-11
   Goethals O, 2008, J VIROL, V82, P10366, DOI 10.1128/JVI.00470-08
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   Hazuda DJ, 2012, CURR OPIN HIV AIDS, V7, P383, DOI 10.1097/COH.0b013e3283567309
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hazuda D. J., 2003, ADV ANTIVIRAL DRUG D, V4, P63
   Hightower KE, 2011, ANTIMICROB AGENTS CH, V55, P4552, DOI 10.1128/AAC.00157-11
   Johns BA, 2008, EXPERT OPIN THER PAT, V18, P1225, DOI 10.1517/13543770802500450
   Kawasuji T, 2006, BIOORGAN MED CHEM, V14, P8420, DOI 10.1016/j.bmc.2006.08.043
   Kawasuji T, 2012, J MED CHEM, V55, P8735, DOI 10.1021/jm3010459
   Kobayashi M, 2011, ANTIMICROB AGENTS CH, V55, P813, DOI 10.1128/AAC.01209-10
   Long YQ, 2004, J MED CHEM, V47, P2561, DOI 10.1021/jm030559k
   Marcelin AG, 2009, CURR OPIN HIV AIDS, V4, P531, DOI 10.1097/COH.0b013e328331d4b1
   Marinello J, 2008, BIOCHEMISTRY-US, V47, P9345, DOI 10.1021/bi800791q
   Molina JM, 2012, LANCET INFECT DIS, V12, P27, DOI 10.1016/S1473-3099(11)70249-3
   Nachega J. B., 2012, 19 INT AIDS C WASH D
   Pendri A, 2011, EXPERT OPIN THER PAT, V21, P1173, DOI 10.1517/13543776.2011.586631
   Rowley M, 2008, PROGR MED CHEM, V46, P1, DOI 10.1016/S0079-6468(07)00001-X
   Sato M, 2009, J MED CHEM, V52, P4869, DOI 10.1021/jm900460z
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
NR 30
TC 32
Z9 33
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 14
PY 2013
VL 56
IS 3
BP 1124
EP 1135
DI 10.1021/jm301550c
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 093HK
UT WOS:000315182100042
PM 23316884
DA 2018-01-05
ER

PT J
AU Wang, MY
   He, HJ
   Turko, IV
   Phinney, KW
   Wang, LL
AF Wang, Meiyao
   He, Hua-Jun
   Turko, Illarion V.
   Phinney, Karen W.
   Wang, Lili
TI Quantifying the Cluster of Differentiation 4 Receptor Density on Human T
   Lymphocytes Using Multiple Reaction Monitoring Mass Spectrometry
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID FLOW-CYTOMETRY; CD4 EXPRESSION; QUANTIFICATION; PROTEIN; QUANTITATION;
   IMMUNOFLUORESCENCE; STANDARD; ANTIBODY; RANGE; CELLS
AB Cluster of differentiation 4 (CD4) is an important glycoprotein containing four extracellular domains, a transmembrane portion and a short intracellular tail. It locates on the surface of various types of immune cells and performs a critical role in multiple cellular functions such as signal amplification and activation of T cells. It is well-known as a clinical cell surface protein marker for study of HIV progression and for defining the T helper cell population in immunological applications. Moreover, CD4 protein has been used as a biological calibrator for quantification of other surface and intracellular proteins. However, flow cytometry, the conventional method of quantification of the CD4 density on the T cell surface depends on antibodies and has suffered from variables such as antibody clones, the fluorophore and conjugation chemistries, the fixation conditions, and the flow cytometric quantification methods used. In this study, we report the development of a highly reproducible nano liquid chromatography-multiple reaction monitoring mass spectrometry-based quantitative method to quantify the CD4 receptor density in units of copy number per cell on human CD4+ T cells. The method utilizes stable isotope-labeled full-length standard CD4 as an internal standard to measure endogenous CD4 directly, without the use of antibodies. The development of the mass spectrometry-based approach of CD4 protein quantification is important as a complementary strategy to validate the analysis from the cytometry-based conventional method. It also provides new support for quantitative understanding and advanced characterization of CD4 on CD4+ T cells.
C1 [Wang, Meiyao; Turko, Illarion V.] Univ Maryland, Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.
   [Wang, Meiyao; Turko, Illarion V.; Phinney, Karen W.] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
   [He, Hua-Jun; Wang, Lili] NIST, Biosyst & Biomat Div, Gaithersburg, MD 20899 USA.
RP Wang, MY (reprint author), Univ Maryland, Inst Biosci & Biotechnol Res, Rockville, MD 20850 USA.
EM meiyaow@umd.edu; lili.wang@nist.gov
RI Wang, Meiyao/F-6133-2012
CR Brun V, 2009, J PROTEOMICS, V72, P740, DOI 10.1016/j.jprot.2009.03.007
   Davis KA, 1998, CYTOMETRY, V33, P197, DOI 10.1002/(SICI)1097-0320(19981001)33:2<197::AID-CYTO14>3.0.CO;2-P                
   Estess P, 1990, CURRENT RES PROTEIN, P499
   Fortin T, 2009, MOL CELL PROTEOMICS, V8, P1006, DOI 10.1074/mcp.M800238-MCP200
   Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913                                                      
   Gratama JW, 1998, CYTOMETRY, V33, P166, DOI 10.1002/(SICI)1097-0320(19981001)33:2<166::AID-CYTO11>3.0.CO;2-S
   Heudi O, 2008, ANAL CHEM, V80, P4200, DOI 10.1021/ac800205s
   Hoffman RA, 1993, CLIN FLOW CYTOMETRY, P469
   Hultin LE, 1998, CYTOMETRY, V33, P123, DOI 10.1002/(SICI)1097-0320(19981001)33:2<123::AID-CYTO6>3.0.CO;2-K
   ISOBE M, 1986, P NATL ACAD SCI USA, V83, P4399, DOI 10.1073/pnas.83.12.4399
   KAWAMURA I, 1989, J VIROL, V63, P3748
   Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61
   Larbi A, 2006, CELL SIGNAL, V18, P1017, DOI 10.1016/j.cellsig.2005.08.016
   Liao WL, 2008, ANAL BIOCHEM, V377, P55, DOI 10.1016/j.ab.2008.03.016
   PONCELET P, 1991, RES IMMUNOL, V142, P291, DOI 10.1016/0923-2494(91)90078-W
   Remily-Wood ER, 2012, J MASS SPECTROM, V47, P188, DOI 10.1002/jms.2053
   Serke S, 1998, CYTOMETRY, V33, P179, DOI 10.1002/(SICI)1097-0320(19981001)33:2<179::AID-CYTO12>3.0.CO;2-R
   Wang L, 2008, CYTOM PART A, V73A, P279, DOI 10.1002/cyto.a.20507
   Wang L, 2007, CYTOM PART B-CLIN CY, V72B, P442, DOI 10.1002/cyto.b.20354
   Wang LL, 2012, CYTOM PART A, V81A, P567, DOI 10.1002/cyto.a.22060
   Wang L, 2011, CYTOM PART B-CLIN CY, V80B, P51, DOI 10.1002/cyto.b.20541
   Wang MY, 2012, ANAL CHEM, V84, P5186, DOI 10.1021/ac300587v
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
NR 23
TC 3
Z9 3
U1 3
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD FEB 5
PY 2013
VL 85
IS 3
BP 1773
EP 1777
DI 10.1021/ac3031306
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 086IA
UT WOS:000314676100074
PM 23286534
DA 2018-01-05
ER

PT J
AU Ren, JG
   Zou, MJ
   Gao, P
   Wang, Y
   Cheng, G
AF Ren, Jungang
   Zou, Meijuan
   Gao, Ping
   Wang, Yue
   Cheng, Gang
TI Tissue distribution of borneol-modified ganciclovir-loaded solid lipid
   nanoparticles in mice after intravenous administration
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Solid lipid nanoparticles; Borneol; Ganciclovir; Pharmacokinetics;
   Tissue distribution; Brain-targeting
ID 80-COATED POLYBUTYLCYANOACRYLATE NANOPARTICLES; HIV-INFECTED PATIENTS;
   IN-VITRO; ORAL BIOAVAILABILITY; DRUG-DELIVERY; NON-STEALTH; BRAIN;
   PHARMACOKINETICS; DOXORUBICIN; PACLITAXEL
AB The main purpose of this research was to prepare borneol-modified and non-bomeol ganciclovir-loaded solid lipid nanoparticles (SLNs) to study whether borneol could enhance the transport of ganciclovir (GCV) incorporated in SLN to the brain in mice after their intravenous administration. Ganciclovir injection (GCV-inj) was selected as a control. The SLNs were prepared using a modified microemulsion method. Pharmacokinetic and biodistribution studies were conducted in kunming mice after intravenous administration of GCV-inj, GCV solid lipid nanoparticles without bomeol (GCV-SLN), and three types of GCV solid lipid nanoparticles containing different ratios of borneol (GCVb-SLN). It was found that, in plasma, the area under the concentration-time curve (AUC(0 similar to t)) for GCVb-SLN and GCV-SLN was greater than that for the GCV-inj. In the brain, the AUC(0 similar to t) of GCVb-SLN was significantly increased compared with that of a GCV-inj and GCV-SLN. In the other mouse tissues, the peak concentration of GCV achieved was always lower after the injection of any of the four types of SLN than after the commercial injection. These results indicate that GCV-SLN modified with borneol enhances the transport of ganciclovir to the brain. Therefore, SLN modified with borneol is a potential delivery system for transporting drugs to the central nervous system (CNS). (C) 2012 Elsevier B.V. All rights reserved.
C1 [Ren, Jungang; Zou, Meijuan; Gao, Ping; Wang, Yue; Cheng, Gang] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China.
   [Ren, Jungang] Harbin Univ Commerce, Sch Pharm, Harbin, Heilongjiang, Peoples R China.
RP Cheng, G (reprint author), Shenyang Pharmaceut Univ, Sch Pharm, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China.
EM chenggang63@hotmail.com
CR Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098                                                         
   Asano-Mori Y, 2006, J ANTIMICROB CHEMOTH, V57, P1004, DOI 10.1093/jac/dk1089
   ASHTON WT, 1982, BIOCHEM BIOPH RES CO, V108, P1716, DOI 10.1016/S0006-291X(82)80109-5
   BAILER AJ, 1988, J PHARMACOKINET BIOP, V16, P303, DOI 10.1007/BF01062139
   Begley DJ, 2004, PHARMACOL THERAPEUT, V104, P29, DOI 10.1016/j.pharmthera.2004.08.001
   Bekerman T, 2004, J PHARM SCI-US, V93, P1264, DOI 10.1002/jps.20057
   Bummer PM, 2004, CRIT REV THER DRUG, V21, P1
   Cai Z, 2008, J DRUG TARGET, V16, P178, DOI 10.1080/10611860701794395 
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Chen DB, 2001, CHEM PHARM BULL, V49, P1444, DOI 10.1248/cpb.49.1444
   Chen HB, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/1/015101
   Dai JP, 2009, J ORAL PATHOL MED, V38, P276, DOI 10.1111/j.1600-0714.2008.00738.x
   de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237
   Doijad RC, 2008, INDIAN J PHARM SCI, V70, P203, DOI 10.4103/0250-474X.41456
   FLETCHER C, 1986, CLIN PHARMACOL THER, V40, P281, DOI 10.1038/clpt.1986.177                                                           
   FLETCHER CV, 1989, DICP ANN PHARMAC, V23, P5, DOI 10.1177/106002808902300101                                                      
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gao CY, 2010, J PHARM PHARMACOL, V62, P360, DOI [10.1211/jpp/62.03.0011, 10.1211/jpp.62.03.0011]
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4
   Hu LD, 2010, AAPS PHARMSCITECH, V11, P582, DOI 10.1208/s12249-010-9410-3
   Igartua M, 2002, INT J PHARM, V233, P149, DOI 10.1016/S0378-5173(01)00936-X
   Katlama C, 1997, GENITOURIN MED, V73, P169
   Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077
   LASKIN OL, 1987, AM J MED, V83, P201, DOI 10.1016/0002-9343(87)90685-1
   LIEBMANN J, 1993, LANCET, V342, P1428, DOI 10.1016/0140-6736(93)92789-V
   LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488
   Lu Y, 2011, J ZHEJIANG UNIV-SC B, V12, P143, DOI 10.1631/jzus.B1000121
   Luo Y, 2006, J CONTROL RELEASE, V114, P53, DOI 10.1016/j.jconrel.2006.05.010
   Marshall Beth C, 2009, Paediatr Drugs, V11, P309, DOI 10.2165/11316080-000000000-00000
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Mouly S, 2001, BRIT J CLIN PHARMACO, V51, P557, DOI 10.1046/j.0306-5251.2001.01389.x
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   PALESTINE AG, 1988, REV INFECT DIS, V10, pS515
   Schwarz C, 1999, J MICROENCAPSUL, V16, P205, DOI 10.1080/026520499289185
   Shah KA, 2009, J BIOMED NANOTECHNOL, V5, P396, DOI 10.1166/jbn.2009.1048
   SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368
   SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404
   Suresh G, 2007, AAPS PHARMSCITECH, V8
   Tirucherai Giridhar S, 2003, AAPS PharmSciTech, V4, pE45
   Veerareddy PR, 2004, DRUGS TODAY, V40, P133, DOI 10.1358/dot.2004.40.2.799425
   Wang Y, 2006, DRUG DELIV, V13, P189, DOI 10.1080/10717540500315930
   Wu CJ, 2006, PHARMAZIE, V61, P783
   Xiao YY, 2008, J CHROMATOGR SCI, V46, P395, DOI 10.1093/chromsci/46.5.395                                                       
   Xiao YY, 2007, INT J PHARMACEUT, V337, P74, DOI 10.1016/j.ijpharm.2006.12.034
   Xu XF, 2011, PLANTA MED, V77, P1600, DOI 10.1055/s-0030-1270998
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
   Zara GP, 2002, J DRUG TARGET, V10, P327, DOI 10.1080/10611860290031868
NR 50
TC 7
Z9 15
U1 3
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD FEB
PY 2013
VL 83
IS 2
BP 141
EP 148
DI 10.1016/j.ejpb.2012.10.018
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 105BU
UT WOS:000316041400003
PM 23201052
DA 2018-01-05
ER

PT J
AU Zhong, P
   Agosto, LM
   Munro, JB
   Mothes, W
AF Zhong, Peng
   Agosto, Luis M.
   Munro, James B.
   Mothes, Walther
TI Cell-to-cell transmission of viruses
SO CURRENT OPINION IN VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VIROLOGICAL SYNAPSES; MEMBRANE NANOTUBES;
   DENDRITIC CELLS; ANIMAL VIRUSES; SPREAD; HIV-1; INFECTION; TYPE-1; ENTRY
AB The life cycle of most viruses involves the release of particles into the extracellular space. Consequently, the study of virus egress as well as virus entry has focused almost exclusively on the biology of cell-free virus. However, cell-free virus spread is often very inefficient. Specific barriers, either located in the donor cell or in the target cell, prevent efficient spread by the cell-free mode. In contrast, viral spread by direct cell cell contact is largely unaffected by most of these barriers resulting in preferential spread by cell-to-cell transmission. Virus cell-to-cell transmission allows an efficient coordination of several steps of the viral life cycle. It often involves complex inter-cellular adhesion, cellular polarity and intra-cellular trafficking. Because virus cell-to-cell transmission can involve transmission through zones of tight cell cell contact that are resistant to neutralizing antibodies and reach a high local particle concentration, cell-to-cell transmission can contribute to the pathogenesis of viral infections.
C1 [Zhong, Peng; Agosto, Luis M.; Munro, James B.; Mothes, Walther] Yale Univ, Sch Med, Dept Microbial Pathogenesis, New Haven, CT 06536 USA.
RP Mothes, W (reprint author), Yale Univ, Sch Med, Dept Microbial Pathogenesis, 295 Congress Ave, New Haven, CT 06536 USA.
EM walther.mothes@yale.edu
FU NIH [R01s CA098727, AI084096]; Cancer Research Institute postdoctoral
   fellowship; China Scholarship Council-Yale World Scholars in the
   Biomedical Sciences
FX We thank Ari Helenius for discussions. This work was supported by the
   NIH R01s CA098727 and AI084096 to WM, a Cancer Research Institute
   postdoctoral fellowship to JBM, and a fellowship from the China
   Scholarship Council-Yale World Scholars in the Biomedical Sciences to
   PZ.
CR Abela IA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002634
   Aggarwal A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002762
   Aubert M, 2009, J VIROL, V83, P6171, DOI 10.1128/JVI.02163-08
   BLACK FL, 1955, J IMMUNOL, V74, P236
   Burckhardt CJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000621
   Casartelli N, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000955
   Celestino M, 2012, J VIROL, V86, P6688, DOI 10.1128/JVI.07037-11
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Dale BM, 2011, CELL HOST MICROBE, V10, P551, DOI 10.1016/j.chom.2011.10.015
   Davis DM, 2008, NAT REV MOL CELL BIO, V9, P431, DOI 10.1038/nrm2399
   Del Portillo A, 2011, J VIROL, V85, P7169, DOI 10.1128/JVI.00231-11
   Dodding MP, 2009, CELL HOST MICROBE, V6, P536, DOI 10.1016/j.chom.2009.10.011
   Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7                                                   
   Ganesh L, 2004, J VIROL, V78, P11980, DOI 10.1128/JVI.78.21.11980-11987.2004
   Gordon-Alonso M, 2006, J IMMUNOL, V177, P5129, DOI 10.4049/jimmunol.177.8.5129                                                     
   GUPTA P, 1989, J VIROL, V63, P2361
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Jin J, 2011, J VIROL, V85, P7672, DOI 10.1128/JVI.00409-11
   Jin J, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000163
   Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Jolly C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002226
   Jolly C, 2010, J VIROL, V84, P12185, DOI 10.1128/JVI.01447-10
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003
   Kuhl BD, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-115
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Lidke DS, 2005, J CELL BIOL, V170, P619, DOI 10.1083/jcb.200503140                                                           
   Lucas WJ, 2006, VIROLOGY, V344, P169, DOI 10.1016/j.virol.2005.09.026
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Mazurov D, 2011, J VIROL, DOI [10.1128/JVI.06993-06911, DOI 10.1128/JVI.06993-06911]
   Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   McDonald D, 2010, VIRUSES-BASEL, V2, P1404, DOI 10.3390/v2081704
   MERZ DC, 1980, J EXP MED, V151, P275, DOI 10.1084/jem.151.2.275                                                           
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Moore J P, 1995, AIDS, V9 Suppl A, pS117
   Mori K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028178
   Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10
   Murooka TT, 2012, NATURE
   Nikolic DS, 2011, BLOOD, V118, P4841, DOI 10.1182/blood-2010-09-305417
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   Permanyer M, 2012, J VIROL, V86, P8773, DOI 10.1128/JVI.01044-12
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   Platt EJ, 2010, J VIROL, V84, P3106, DOI 10.1128/JVI.01958-09
   Richardson MW, 2008, J VIROL, V82, P11117, DOI 10.1128/JVI.01046-08
   Roizman B, 2001, FIELDS VIROLOGY, V1, P1123
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q                                                    
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Sattentau QJ, 2011, CURR OPIN VIROL, V1, P396, DOI 10.1016/j.coviro.2011.09.004
   Sewald X, 2012, NAT COMMUN IN PRESS
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sherer NM, 2010, J VIROL, V84, P3248, DOI 10.1128/JVI.02155-09
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Smith GA, 2001, P NATL ACAD SCI USA, V98, P3466, DOI 10.1073/pnas.061029798
   Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Thoulouze MI, 2011, TRENDS MICROBIOL, V19, P257, DOI 10.1016/j.tim.2011.03.002
   van der Schaar HM, 2007, J VIROL, V81, P12019, DOI 10.1128/JVI.00300-07
   van der Schaar HM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000244
   Vasiliver-Shamis G, 2009, J VIROL, V83, P11341, DOI 10.1128/JVI.01440-09
   Weng J, 2009, J VIROL, V83, P7467, DOI 10.1128/JVI.00163-09
   Yakimovich A, 2012, J VIROL, V86, P10123, DOI 10.1128/JVI.01102-12
   Zhong P, 2012, PLOS ONE IN PRESS
NR 67
TC 60
Z9 60
U1 0
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD FEB
PY 2013
VL 3
IS 1
BP 44
EP 50
DI 10.1016/j.coviro.2012.11.004
PG 7
WC Virology
SC Virology
GA 101FE
UT WOS:000315759800007
PM 23219376
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chandran, H
   Rangnekar, A
   Shetty, G
   Schultes, EA
   Reif, JH
   LaBean, TH
AF Chandran, Harish
   Rangnekar, Abhijit
   Shetty, Geetha
   Schultes, Erik A.
   Reif, John H.
   LaBean, Thomas H.
TI An autonomously self-assembling dendritic DNA nanostructure for target
   DNA detection
SO BIOTECHNOLOGY JOURNAL
LA English
DT Article
DE DNA sequence detection; Hybridization cascade; Molecular self-assembly;
   Nanobiotechnology; Nucleic acids
ID NANOPARTICLES
AB There is a growing need for sensitive and reliable nucleic acid detection methods that are convenient and inexpensive. Responsive and programmable DNA nanostructures have shown great promise as chemical detection systems. Here, we describe a DNA detection system employing the triggered self-assembly of a novel DNA dendritic nanostructure. The detection protocol is executed autonomously without external intervention. Detection begins when a specific, single-stranded target DNA strand (T) triggers a hybridization chain reaction (HCR) between two, distinct DNA hairpins (alpha and beta). Each hairpin opens and hybridizes up to two copies of the other. In the absence of T, alpha and beta are stable and remain in their poised, closed-hairpin form. In the presence of T, a hairpins are opened by toe-hold mediated strand-displacement, each of which then opens and hybridizes two beta hairpins. Likewise, each opened beta hairpin can open and hybridize two a hairpins. Hence, each layer of the growing dendritic nanostructure can in principle accommodate an exponentially increasing number of cognate molecules, generating a high molecular weight nanostructure. This HCR system has minimal sequence constraints, allowing reconfiguration for the detection of arbitrary target sequences. Here, we demonstrate detection of unique sequence identifiers of HIV and Chlamydia pathogens.
C1 [Chandran, Harish; Reif, John H.] Duke Univ, Dept Comp Sci, Durham, NC 27706 USA.
   [Rangnekar, Abhijit; LaBean, Thomas H.] N Carolina State Univ, Dept Mat Sci & Engn, Raleigh, NC 27606 USA.
   [Shetty, Geetha] Texas A&M Hlth Sci Ctr, Coll Med Scott & White, Inst Regenerat Med, Temple, TX USA.
   [Schultes, Erik A.] Leiden Univ, Med Ctr, Leiden, Netherlands.
RP LaBean, TH (reprint author), N Carolina State Univ, Dept Mat Sci & Engn, EB 1 Room 3030,911 Partners Way, Raleigh, NC 27606 USA.
EM thlabean@ncsu.edu
RI LaBean, Thomas/G-2859-2011
OI LaBean, Thomas/0000-0002-6739-2059; Schultes, Erik/0000-0001-8888-635X;
   Rangnekar, Abhijit/0000-0002-5562-4035
FU NSF [CCF-1141847]; NSF EMT [CCF-0829797, CCF-0829798]; NSF-CCF
   [0829749]; AFSOR [FA9550-08-1-0188]
FX The authors would like to thank Peng Yin for helpful discussions
   regarding the research described here. Financial support was provided by
   NSF CCF-1141847, NSF EMT CCF-0829797: NSF EMT CCF-0829798, NSF-CCF
   0829749, and AFSOR Contract FA9550-08-1-0188.
CR Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101
   Girjes AA, 1999, RES MICROBIOL, V150, P483, DOI 10.1016/S0923-2508(99)00108-4                                                   
   Green SJ, 2006, BIOPHYS J, V91, P2966, DOI 10.1529/biophysj.106.084681
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Omabegho T, 2009, SCIENCE, V324, P67, DOI 10.1126/science.1170336
   Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o
   Sherman WB, 2004, NANO LETT, V4, P1203, DOI 10.1021/nl049527q
   Tian T., 2004, J AM CHEM SOC, V126, P11410
   Yin P, 2008, NATURE, V451, P318, DOI 10.1038/nature06451
   Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524                                                                
   Zhang DY, 2007, SCIENCE, V318, P1121, DOI 10.1126/science.1148532
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 13
TC 24
Z9 24
U1 1
U2 78
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1860-6768
J9 BIOTECHNOL J
JI Biotechnol. J.
PD FEB
PY 2013
VL 8
IS 2
SI SI
BP 221
EP 227
DI 10.1002/biot.201100499
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 086AR
UT WOS:000314655900008
PM 22965937
DA 2018-01-05
ER

PT J
AU Chiappetta, DA
   Hocht, C
   Opezzo, JAW
   Sosnik, A
AF Chiappetta, Diego A.
   Hocht, Christian
   Opezzo, Javier A. W.
   Sosnik, Alejandro
TI Intranasal administration of antiretroviral-loaded micelles for
   anatomical targeting to the brain in HIV
SO NANOMEDICINE
LA English
DT Article
DE anatomical targeting to the brain; CNS; efavirenz-loaded micelles; HIV;
   reservoirs; intranasal administration
ID CENTRAL-NERVOUS-SYSTEM; IMMUNODEFICIENCY-VIRUS-INFECTION; SOLID LIPID
   NANOPARTICLES; P-GLYCOPROTEIN; DRUG-DELIVERY; COPOLYMER MICELLES;
   POLYMERIC MICELLES; PLA NANOPARTICLES; EFAVIRENZ; TRANSPORT
AB Aim: To investigate the intranasal administration of poly(ethylene oxide) poly(propylene oxide) polymeric micelles loaded with high payloads of the first-line antiretroviral drug efavirenz for targeting to the CNS. Methods & materials: The effect of micellar size and composition and drug payload was assessed, employing simple micelles made of a highly hydrophilic copolymer, poloxamer F127, loaded with 20 mg/ml drug and mixed micelles containing 75% of a poloxamine of intermediate hydrophobicity, T904, and 25% F127 loaded with 20 and 30 mg/ml drug. F127 confers high physical stability, while T904 substantially improves the encapsulation capacity of the micelles. Results: The bioavailability of the drug in the CNS was increased fourfold and the relative exposure index (ratio between the area under the curve in the CNS and plasma) was increased fivefold with respect to the same system administered intravenously. Conclusion: These findings demonstrate the potential of this scalable and cost-viable strategy to address the HIV sanctuary in the CNS.
C1 [Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Grp Biomat & Nanotechnol Improved Med BIONMED, Dept Pharmaceut Technol, Fac Pharm & Biochem, Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Natl Sci Res Council CONICET, Buenos Aires, DF, Argentina.
   [Hocht, Christian; Opezzo, Javier A. W.] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmacol, Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Grp Biomat & Nanotechnol Improved Med BIONMED, Dept Pharmaceut Technol, Fac Pharm & Biochem, 956 Junin St,6th Floor,CP 1113, Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
FU University of Buenos Aires [UBACyT 20020090200016, 20020100300088];
   CONICET [PIP0220]
FX The authors thank the University of Buenos Aires (Grants UBACyT
   20020090200016 and 20020100300088) and the CONICET (Grant PIP0220) for
   financial support. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Balani SK, 1999, DRUG METAB DISPOS, V27, P141
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Cheng QY, 2008, BIOPHARM DRUG DISPOS, V29, P431, DOI 10.1002/bdd.621
   Chiappetta DA, 2010, CURR HIV RES, V8, P23
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Cook-Easterwood J, 2007, EXP NEUROL, V205, P506, DOI 10.1016/j.expneurol.2007.03.007
   Crews L, 2009, INT J MOL SCI, V10, P1045, DOI 10.3390/ijms10031045
   Csajka C, 2003, CLIN PHARMACOL THER, V73, P20, DOI 10.1067/mcp.2003.22
   Cuestas ML, 2012, BIOORG MED CHEM LETT, V22, P6577, DOI 10.1016/j.bmcl.2012.09.012
   Cuestas ML, 2011, MOL PHARMACEUT, V8, P1152, DOI 10.1021/mp2000132
   Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011
   De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011
   de Lange ECM, 1999, ADV DRUG DELIVER REV, V36, P211, DOI 10.1016/S0169-409X(98)00089-1                                                   
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Dhanda D.S., 2005, DRUG DELIV TECHNOL, V5, P64
   Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Fabbiani M, 2009, J ANTIMICROB CHEMOTH, V64, P109, DOI 10.1093/jac/dkp132
   Gaucher G, 2010, EUR J PHARM BIOPHARM, V76, P147, DOI 10.1016/j.ejpb.2010.06.007
   Gazzard BG, 2006, HIV AIDS EUROPE MOVI, P101
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Grovit-Ferbas K, 2010, IMMUNOL RES, V48, P40, DOI 10.1007/s12026-010-8166-x
   Hocht Christian, 2004, Curr Drug Discov Technol, V1, P269, DOI 10.2174/1570163043334848
   Hocht C, 2007, NEUROSCI LETT, V413, P168, DOI 10.1016/j.neulet.2006.11.075
   Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022764
   Jain R, 2010, NANOMEDICINE-UK, V5, P575, DOI [10.2217/nnm.10.28, 10.2217/NNM.10.28]
   KABANOV AV, 1995, MACROMOLECULES, V28, P2303, DOI 10.1021/ma00111a026                                                             
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kurkalli BGS, 2010, CURR STEM CELL RES T, V5, P49, DOI 10.2174/157488810790442831
   Liu JB, 2005, J CONTROL RELEASE, V103, P481, DOI 10.1016/j.jconrel.2004.12.013
   Lo CL, 2007, BIOMATERIALS, V28, P1225, DOI 10.1016/j.biomaterials.2006.09.050
   Lopez-Cortes LF, 2005, JAIDS-J ACQ IMM DEF, V39, P551
   Mainardes RM, 2010, INT J PHARMACEUT, V395, P266, DOI 10.1016/j.ijpharm.2010.05.020
   Marzolini C, 2001, AIDS, V15, P1193, DOI 10.1097/00002030-200106150-00023
   Maurin MB, 2002, PHARMACEUT RES, V19, P517, DOI 10.1023/A:1015160132290
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Nath A, 2006, CURR OPIN NEUROL, V19, P358, DOI 10.1097/01.wco.0000236614.51592.ca                                              
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Padowski JM, 2010, J PHARM SCI-US, V99, P3226, DOI 10.1002/jps.22070
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Peroni RN, 2010, PRESENTED AT FIRST W
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j,jconrel.2006.10.015
   Prinsen BHCMT, 2004, CLIN CHIM ACTA, V347, P1, DOI 10.1016/j.cccn.2004.04.005
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Shaik N, 2007, DRUG METAB DISPOS, V35, P2076, DOI 10.1124/dmd.107.017723
   Shaik N, 2009, J PHARM SCI-US, V98, P4170, DOI 10.1002/jps.21723
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Smith PF, 2005, ANTIMICROB AGENTS CH, V49, P3558, DOI 10.1128/AAC.49.8.3558-3561.2005
   Sosnik A, 2005, TISSUE ENG, V11, P1807, DOI 10.1089/ten.2005.11.1807                                                        
   Sosnik A, 2005, BIOMATERIALS, V26, P7425, DOI 10.1016/j.biomaterials.2005.05.086
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001
   Van Rie A, 2008, PEDIATRICS, V122, pE123, DOI 10.1542/peds.2007-2558
   van Rooy I, 2011, PHARM RES-DORDR, V28, P456, DOI 10.1007/s11095-010-0291-7
   Vivithanaporn P, 2011, EXPERT REV ANTI-INFE, V9, P371, DOI [10.1586/eri.10.179, 10.1586/ERI.10.179]
   Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Zhang QZ, 2006, J DRUG TARGET, V14, P281, DOI 10.1080/10611860600721051
NR 79
TC 31
Z9 31
U1 0
U2 24
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD FEB
PY 2013
VL 8
IS 2
BP 223
EP 237
DI 10.2217/NNM.12.104
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 087VD
UT WOS:000314791200017
PM 23173734
DA 2018-01-05
ER

PT J
AU Ferreira, SA
   Gama, FM
   Vilanova, M
AF Ferreira, Silvia A.
   Gama, Francisco M.
   Vilanova, Manuel
TI Polymeric nanogels as vaccine delivery systems
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Adjuvants; Delivery systems; Polymeric nanogels; Vaccines
ID N-TRIMETHYL CHITOSAN; POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES; HUMORAL
   IMMUNE-RESPONSES; HUMAN DENDRITIC CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CD4 T-CELLS; IN-VIVO; HEPATITIS-B; BIODEGRADABLE NANOPARTICLES; DNA
   VACCINES
AB Polymeric nanogels find a relevant field of application in the formulation of a new generation of therapeutic and preventive vaccines, aiming at the fine-tuned modulation of the immune response. Intrinsic properties of polymeric nanogels, such as material chemistry, size and shape, surface charge, and hydrophobicity or hydrophilicity, may be determining factors in shaping the induced immune response. These materials can thus work as synthetic adjuvants, which can also be conjugated with immunostimulants. Polymeric nanogels protect vaccine antigens from degradation in vivo and, surface-conjugated with antibodies or specific ligands, could increase active targeting specificity. This review covers the recent published data concerning the modulation of innate and adaptive immune responses by engineered polymeric nanogels and their potential application as delivery systems in vaccination.
C1 [Ferreira, Silvia A.; Gama, Francisco M.] Univ Minho, Inst Biotechnol & Bioengn, Ctr Biol Engn, P-4710057 Braga, Portugal.
   [Vilanova, Manuel] Univ Porto, ICBAS, IMFF Dept Imunofisiol & Farmacol, Lab Imunol Mario Arala Chaves, P-4100 Oporto, Portugal.
   [Vilanova, Manuel] IBMC, Oporto, Portugal.
RP Gama, FM (reprint author), Univ Minho, Inst Biotechnol & Bioengn, Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.
EM fmgama@deb.uminho.pt
RI Vilanova, Manuel/D-2127-2013; Ferreira, Silvia/B-4161-2014; Gama,
   Miguel/I-3140-2015
OI Vilanova, Manuel/0000-0001-7007-306X; Gama, Miguel/0000-0002-5655-0015
FU International Iberian Nanotechnology Laboratory (INL)
FX S.A. Ferreira is the recipient of a fellowship from International
   Iberian Nanotechnology Laboratory (INL).
CR Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Amidi M, 2006, J CONTROL RELEASE, V111, P107, DOI 10.1016/j.conrel.2005.11.014
   Amidi M, 2007, VACCINE, V25, P144, DOI 10.1016/j.vaccine.2006.06.086
   Amidi M, 2010, ADV DRUG DELIVER REV, V62, P59, DOI 10.1016/j.addr.2009.11.009
   Andersson J, 2002, J IMMUNOL, V168, P5786, DOI 10.4049/jimmunol.168.11.5786                                                    
   Aoki M, 2009, VACCINE, V27, P6854, DOI 10.1016/j.vaccine.2009.09.018
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Bal SM, 2011, EUR J PHARM SCI, V45, P475
   Bal SM, 2010, J CONTROL RELEASE, V142, P374, DOI 10.1016/j.jconrel.2009.11.018
   Bandyopadhyay A, 2011, BIOMATERIALS, V32, P3094, DOI 10.1016/j.biomaterials.2010.12.054
   Beaudette TT, 2009, MOL PHARMACEUT, V6, P1160, DOI 10.1021/mp900038e
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   Bivas-Benita M, 2009, VACCINE, V27, P4010, DOI 10.1016/j.vaccine.2009.04.033
   Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]
   Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029
   Borges O, 2008, EUR J PHARM BIOPHARM, V69, P405, DOI 10.1016/j.ejpb.2008.01.019
   Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004
   Broos S, 2010, VACCINE, V28, P5075, DOI 10.1016/j.vaccine.2010.05.004
   Brunner R, 2010, IMMUNOL LETT, V128, P29, DOI 10.1016/j.imlet.2009.10.005
   Calvo-Calle JM, 2006, INFECT IMMUN, V74, P6929, DOI 10.1128/IAI.01151-06
   Caputo A, 2009, VACCINE, V27, P3605, DOI 10.1016/j.vaccine.2009.03.047
   Carcaboso AM, 2004, VACCINE, V22, P1423, DOI 10.1016/j.vaccine.2003.10.020
   Chadwick S, 2009, EXPERT OPIN BIOL TH, V9, P427, DOI [10.1517/14712590902849224, 10.1517/14712590902849224 ]
   Chen F, 2008, INT J PHARM, V349, P226, DOI 10.1016/j.ijpharm.2007.07.035
   Cheng R, 2011, J CONTROL RELEASE, V152, P2, DOI 10.1016/j.jconrel.2011.01.030
   Cherif MS, 2011, VACCINE, V29, P9038, DOI 10.1016/j.vaccine.2011.09.031
   Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014
   Cohen JA, 2009, BIOCONJUGATE CHEM, V20, P111, DOI 10.1021/bc800338n
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   Cruz LJ, 2011, BIOMATERIALS, V32, P6791, DOI 10.1016/j.biomaterials.2011.04.082
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Cu Y., 2008, MOL PHARM, V6, P173
   Danesh-Bahreini MA, 2011, INT J NANOMED, V6, P835, DOI 10.2147/IJN.S16805
   Dash M, 2011, PROG POLYM SCI, V36, P981, DOI 10.1016/j.progpolymsci.2011.02.001
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034
   Disis ML, 2011, CANCER IMMUNOL IMMUN, V60, P433, DOI 10.1007/s00262-010-0960-8
   Disis ML, 2009, LANCET, V373, P673, DOI 10.1016/S0140-6736(09)60404-9
   Diwan M, 2002, J CONTROL RELEASE, V85, P247, DOI 10.1016/S0168-3659(02)00275-4
   Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Doshi N, 2009, ADV FUNCT MATER, V19, P3843, DOI 10.1002/adfm.200901538
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Florindo HF, 2009, BIOMATERIALS, V30, P879, DOI 10.1016/j.biomaterials.2008.10.035
   Gu XG, 1998, CANCER RES, V58, P3385
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035
   Hamdy S, 2007, J BIOMED MATER RES A, V81A, P652, DOI 10.1002/jbm.a.31019
   Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021
   Han RL, 2011, J BIOMED MATER RES A, V96A, P142, DOI 10.1002/jbm.a.32860
   Harandi AM, 2010, VACCINE, V28, P2363, DOI 10.1016/j.vaccine.2009.12.084
   Hasegawa K, 2006, CLIN CANCER RES, V12, P1921, DOI 10.1158/1078-0432.CCR-05-1900
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Hu YH, 2009, BIOMACROMOLECULES, V10, P756, DOI 10.1021/bm801199z
   Huang YB, 2000, J CONTROL RELEASE, V65, P63, DOI 10.1016/S0168-3659(99)00233-3                                                   
   Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604
   Ingolotti M, 2010, EXPERT REV VACCINES, V9, P747, DOI 10.1586/ERV.10.57
   Jelley-Gibbs DM, 2000, J IMMUNOL, V165, P5017, DOI 10.4049/jimmunol.165.9.5017                                                     
   Jiang L, 2007, J GENE MED, V9, P253, DOI 10.1002/jgm.1017
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kageyama S, 2008, CANCER SCI, V99, P601, DOI 10.1111/j.1349-7006.2007.00705.x
   Kanchan V, 2007, BIOMATERIALS, V28, P5344, DOI 10.1016/j.biomaterials.2007.08.015
   Kawabata R, 2007, INT J CANCER, V120, P2178, DOI 10.1002/ijc.22583
   Khatri K, 2008, INT J PHARM, V354, P235, DOI 10.1016/j.ijpharm.2007.11.027
   Kim H, 2010, ADV FUNCT MATER, V20, P3925, DOI 10.1002/adfm.201000021
   Kitano S, 2006, CLIN CANCER RES, V12, P7397, DOI 10.1158/1078-0432.CCR-06-1546
   Kumar M, 2002, HUM GENE THER, V13, P1415, DOI 10.1089/10430340260185058
   Kurosaki T, 2012, PHARM RES-DORDR, V29, P483, DOI 10.1007/s11095-011-0571-x
   Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102
   Kwon YJ, 2005, J CONTROL RELEASE, V105, P199, DOI 10.1016/j.jconrel.2005.02.027
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lee PW, 2010, BIOMATERIALS, V31, P2425, DOI 10.1016/j.biomaterials.2009.11.100
   Leroux-Roels G, 2010, VACCINE, V28, pC25, DOI 10.1016/j.vaccine.2010.07.021
   LI GP, 2009, CELL MOL IMMUNOL, V6, P45
   Liang Ming Tao, 2006, Current Drug Delivery, V3, P379
   Lingnau K, 2002, VACCINE, V20, P3498, DOI 10.1016/S0264-410X(02)00343-2                                                   
   Lofthouse S, 2002, ADV DRUG DELIVER REV, V54, P863, DOI 10.1016/S0169-409X(02)00073-X
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI [10.1586/erm.09.15, 10.1586/ERM.09.15]
   Mangal S, 2011, VACCINE, V29, P4953, DOI 10.1016/j.vaccine.2011.04.112
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Matsuo K, 2007, BIOCHEM BIOPH RES CO, V362, P1069, DOI 10.1016/j.bbrc.2007.08.112
   Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004
   Mishra B, 2010, NANOMED-NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Nguyen DN, 2009, ADV MATER, V21, P847, DOI 10.1002/adma.200801478
   Oh JK, 2010, CAN J CHEM, V88, P173, DOI 10.1139/V09-158
   Oh JK, 2009, PROG POLYM SCI, V34, P1261, DOI 10.1016/j.progpolymsci.2009.08.001
   Okamoto S, 2007, VACCINE, V25, P8270, DOI 10.1016/j.vaccine.2007.09.051
   Okamoto S, 2009, VACCINE, V27, P5896, DOI 10.1016/j.vaccine.2009.07.037
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Prego C, 2010, VACCINE, V28, P2607, DOI 10.1016/j.vaccine.2010.01.011
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, J APPL PHYSIOL, V101, P1162, DOI 10.1152/japplphysiol.00389.2006
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Renaudet O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011216
   Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326
   Roy K, 1999, NAT MED, V5, P387
   Sarti F, 2011, BIOMATERIALS, V32, P4052, DOI 10.1016/j.biomaterials.2011.02.011
   Sayin B, 2008, INT J PHARMACEUT, V363, P139, DOI 10.1016/j.ijpharm.2008.06.029
   Sayin B, 2009, EUR J PHARM SCI, V38, P362, DOI 10.1016/j.ejps.2009.08.010
   Schenten D, 2011, ADV IMMUNOL, V109, P87, DOI 10.1016/B978-0-12-387664-5.00003-0
   Scholl I, 2004, CLIN EXP ALLERGY, V34, P315, DOI 10.1111/j.1365-2222.2004.01884.x
   Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372
   Shakweh M, 2005, EUR J PHARM BIOPHARM, V61, P1, DOI 10.1016/j.ejpb.2005.04.006
   Sharma S, 2009, J PHARM SCI-US, V98, P812, DOI 10.1002/jps.21493
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Shiku H, 2000, CANCER CHEMOTH PHARM, V46, pS77, DOI 10.1007/s002800000179
   Shuaibu MN, 2011, VACCINE, V29, P3239, DOI 10.1016/j.vaccine.2011.02.033
   Shukla GC, 2011, ACS NANO, V5, P3405, DOI 10.1021/nn200989r
   Singh J, 2006, METHODS, V38, P96, DOI 10.1016/j.ymeth.2005.11.003
   Skwarczynski M, 2011, CURR DRUG DELIV, V8, P282, DOI 10.2174/156720111795256192                                                      
   Slutter B, 2010, VACCINE, V28, P6282, DOI 10.1016/j.vaccine.2010.06.121
   Slutter B, 2010, J CONTROL RELEASE, V143, P207, DOI 10.1016/j.jconrel.2010.01.007
   Slutter B, 2009, J CONTROL RELEASE, V138, P113, DOI 10.1016/j.jconrel.2009.05.011
   Standley SM, 2007, BIOCONJUGATE CHEM, V18, P77, DOI 10.1021/bc060165i
   Su XF, 2011, MOL PHARMACEUT, V8, P774, DOI 10.1021/mp100390w
   Swartz MA, 2008, SEMIN IMMUNOL, V20, P147, DOI 10.1016/j.smim.2007.11.007
   Toda M, 2010, ACS APPL MATER INTER, V2, P1107, DOI 10.1021/am900891h
   Uenaka Akiko, 2007, Cancer Immun, V7, P9
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Uto T, 2011, BIOMATERIALS, V32, P5206, DOI 10.1016/j.biomaterials.2011.03.052
   Uto T, 2009, IMMUNOL LETT, V125, P46, DOI 10.1016/j.imlet.2009.05.008
   Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x
   van der Burg SH, 2006, ADV DRUG DELIVER REV, V58, P916, DOI 10.1016/j.addr.2005.11.003
   Verheul RJ, 2011, J CONTROL RELEASE, V156, P46, DOI 10.1016/j.jconrel.2011.07.014
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2                                                   
   Vila A, 2004, J CONTROL RELEASE, V98, P231, DOI 10.1016/j.jconrel.2004.04.026
   Vila A, 2004, EUR J PHARM BIOPHARM, V57, P123, DOI 10.1016/j.ejpb.2003.09.006
   Vila A, 2002, POLYM ADVAN TECHNOL, V13, P851, DOI 10.1002/pat.280
   Wada H, 2008, INT J CANCER, V123, P2362, DOI 10.1002/ijc.23810
   Wang C, 2004, NAT MATER, V3, P190, DOI 10.1038/nmat1075
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Weber C, 2009, J BIOMED MATER RES A, V93A, P1322
   Wendorf J, 2008, HUM VACCINES, V4, P44, DOI 10.4161/hv.4.1.4886                                                             
   Westwood A, 2006, VACCINE, V24, P1736, DOI 10.1016/j.vaccine.2005.10.021
   Xiang SD, 2010, WIRES NANOMED NANOBI, V2, P205, DOI 10.1002/wnan.88
   Xu W, 2004, VACCINE, V22, P3603, DOI 10.1016/j.vaccine.2004.03.033
   Yamaguchi S, 2010, CANCER IMMUNOL IMMUN, V59, P759, DOI 10.1007/s00262-009-0796-2
   Yang Jun, 2010, Chin J Cancer, V29, P359
   Yang XR, 2009, INT J PHARMACEUT, V375, P123, DOI 10.1016/j.ijpharm.2009.03.032
   Yoo JW, 2010, MACROMOL RAPID COMM, V31, P142, DOI 10.1002/marc.200900592
   Yoshikawa T, 2008, VACCINE, V26, P1303, DOI 10.1016/j.vaccine.2007.12.037
   Yue H, 2010, EUR J PHARM SCI, V41, P650, DOI 10.1016/j.ejps.2010.09.006
   Zeng WG, 2001, VACCINE, V19, P3843, DOI 10.1016/S0264-410X(01)00152-9
NR 150
TC 30
Z9 31
U1 6
U2 61
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD FEB
PY 2013
VL 9
IS 2
BP 159
EP 173
DI 10.1016/j.nano.2012.06.001
PG 15
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 088YL
UT WOS:000314873700002
PM 22772049
DA 2018-01-05
ER

PT J
AU Yolamanova, M
   Meier, C
   Shaytan, AK
   Vas, V
   Bertoncini, CW
   Arnold, F
   Zirafi, O
   Usmani, SM
   Muller, JA
   Sauter, D
   Goffinet, C
   Palesch, D
   Walther, P
   Roan, NR
   Geiger, H
   Lunov, O
   Simmet, T
   Bohne, J
   Schrezenmeier, H
   Schwarz, K
   Standker, L
   Forssmann, WG
   Salvatella, X
   Khalatur, PG
   Khokhlov, AR
   Knowles, TPJ
   Weil, T
   Kirchhoff, F
   Munch, J
AF Yolamanova, Maral
   Meier, Christoph
   Shaytan, Alexey K.
   Vas, Virag
   Bertoncini, Carlos W.
   Arnold, Franziska
   Zirafi, Onofrio
   Usmani, Shariq M.
   Mueller, Janis A.
   Sauter, Daniel
   Goffinet, Christine
   Palesch, David
   Walther, Paul
   Roan, Nadia R.
   Geiger, Hartmut
   Lunov, Oleg
   Simmet, Thomas
   Bohne, Jens
   Schrezenmeier, Hubert
   Schwarz, Klaus
   Staendker, Ludger
   Forssmann, Wolf-Georg
   Salvatella, Xavier
   Khalatur, Pavel G.
   Khokhlov, Alexei R.
   Knowles, Tuomas P. J.
   Weil, Tanja
   Kirchhoff, Frank
   Muench, Jan
TI Peptide nanofibrils boost retroviral gene transfer and provide a rapid
   means for concentrating viruses
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID ENHANCE HIV-INFECTION; LENTIVIRAL VECTORS; ENVELOPE GLYCOPROTEIN;
   FIBRONECTIN FRAGMENTS; HEMATOPOIETIC-CELLS; AMYLOID FIBRILS;
   TRANSDUCTION; EFFICIENCY; LYMPHOCYTES; LEUKEMIA
AB Inefficient gene transfer and low virion concentrations are common limitations of retroviral transduction(1). We and others have previously shown that peptides derived from human semen form amyloid fibrils that boost retroviral gene delivery by promoting virion attachment to the target cells(2-8). However, application of these natural fibril-forming peptides is limited by moderate efficiencies, the high costs of peptide synthesis, and variability in fibril size and formation kinetics. Here, we report the development of nanofibrils that self-assemble in aqueous solution from a 12-residue peptide, termed enhancing factor C (EF-C). These artificial nanofibrils enhance retroviral gene transfer substantially more efficiently than semen-derived fibrils or other transduction enhancers. Moreover, EF-C nanofibrils allow the concentration of retroviral vectors by conventional low-speed centrifugation, and are safe and effective, as assessed in an ex vivo gene transfer study. Our results show that EF-C fibrils comprise a highly versatile, convenient and broadly applicable nanomaterial that holds the potential to significantly facilitate retroviral gene transfer in basic research and clinical applications.
C1 [Yolamanova, Maral; Arnold, Franziska; Zirafi, Onofrio; Usmani, Shariq M.; Mueller, Janis A.; Sauter, Daniel; Goffinet, Christine; Palesch, David; Kirchhoff, Frank; Muench, Jan] Univ Ulm, Med Ctr, Inst Mol Virol, D-89081 Ulm, Germany.
   [Meier, Christoph; Weil, Tanja] Univ Ulm, Inst Organ Chem Macromol Chem 3, D-89081 Ulm, Germany.
   [Shaytan, Alexey K.; Khalatur, Pavel G.; Khokhlov, Alexei R.] Univ Ulm, Inst Polymer Sci, D-89069 Ulm, Germany.
   [Shaytan, Alexey K.] Moscow MV Lomonosov State Univ, Fac Biol, Moscow 119991, Russia.
   [Vas, Virag; Geiger, Hartmut] Univ Ulm, Med Ctr, Dept Dermatol & Allerg Dis, D-89081 Ulm, Germany.
   [Bertoncini, Carlos W.; Salvatella, Xavier] ICREA, Barcelona 08028, Spain.
   [Bertoncini, Carlos W.; Salvatella, Xavier] Inst Res Biomed, Joint BSC IRB Res Programme Computat Biol, Barcelona 08028, Spain.
   [Walther, Paul] Univ Ulm, Cent Electron Microscopy Facil, D-89069 Ulm, Germany.
   [Roan, Nadia R.] Univ Calif San Francisco, Dept Urol, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA.
   [Lunov, Oleg; Simmet, Thomas] Univ Ulm, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany.
   [Bohne, Jens] Hannover Med Sch, Inst Virol, D-30625 Hannover, Germany.
   [Schrezenmeier, Hubert; Schwarz, Klaus] Univ Ulm, Inst Transfus Med, D-89081 Ulm, Germany.
   [Schrezenmeier, Hubert; Schwarz, Klaus] Gemeinnutzige GmbH, DRK Blood Serv Baden Wurttemberg Hessen, Inst Clin Transfus Med & Immunogenet Ulm, D-89081 Ulm, Germany.
   [Staendker, Ludger; Forssmann, Wolf-Georg] Hannover Med Sch, Clin Immunol, Peptide Res Grp, D-30625 Hannover, Germany.
   [Khalatur, Pavel G.] Russian Acad Sci, AN Nesmeyanov Inst Organoelement Cpds, Moscow 119991, Russia.
   [Khokhlov, Alexei R.] Moscow MV Lomonosov State Univ, Fac Phys, Moscow 119991, Russia.
   [Knowles, Tuomas P. J.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.
RP Yolamanova, M (reprint author), Univ Ulm, Med Ctr, Inst Mol Virol, Meyerhofstr 1, D-89081 Ulm, Germany.
EM jan.muench@uni-ulm.de
RI Khokhlov, Alexei/E-9233-2011; Lunov, Oleg/H-1387-2014; Meier,
   Christoph/G-2779-2012; Salvatella, Xavier/C-7337-2008; Shaytan,
   Alexey/D-7306-2012
OI Lunov, Oleg/0000-0003-2922-8896; Meier, Christoph/0000-0002-2974-1422;
   Salvatella, Xavier/0000-0002-8371-4185; Shaytan,
   Alexey/0000-0003-0312-938X; Vas, Virag/0000-0002-9722-8188; Usmani,
   Shariq/0000-0002-6462-1098; Khalatur, Pavel/0000-0001-5480-5531
FU AIDS Research and Reference Program; German Research Foundation; ICREA
FX The authors thank S. Liu for support in the initial phase of the project
   and D. Krnavek and M. Schlaier for expert technical assistance. The
   authors also thank W. Mothes for providing the MLV GAG-UP plasmid, B.
   Bohm for Bon cells, J. von Einem for HFF cells, the AIDS Research and
   Reference Program for U87-MG and TZM-bl cells, and N. Landau for CEMx-M7
   (CEMx174 5.25 M7) cells. This work was supported by a grant from the
   German Research Foundation to J.M. Molecular simulations were performed
   using the resources of Moscow University Supercomputing Center.
CR Arnold F, 2012, J VIROL, V86, P1244, DOI 10.1128/JVI.06121-11
   Cerf E, 2009, BIOCHEM J, V421, P415, DOI 10.1042/BJ20090379
   CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8
   Dalhaimer P, 2003, MACROMOLECULES, V36, P6873, DOI 10.1021/ma034120d
   Dull T, 1998, J VIROL, V72, P8463
   Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876
   Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193                                                      
   KAPLAN M. M., 1967, J VIROL, V1, P145
   Kim KA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-55
   Knowles TP, 2007, SCIENCE, V318, P1900, DOI 10.1126/science.1150057
   Knowles TPJ, 2011, NAT NANOTECHNOL, V6, P469, DOI [10.1038/nnano.2011.102, 10.1038/NNANO.2011.102]
   KOEFFLER HP, 1980, BLOOD, V56, P344
   Kustikova OS, 2007, BLOOD, V109, P1897, DOI 10.1182/blood-2006-08-044156
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Leyva FJ, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-13
   Makin OS, 2005, FEBS J, V272, P5950, DOI 10.1111/j.1742-4658.2005.05025.x
   MANNING JS, 1971, APPL MICROBIOL, V22, P1162
   Matrai J, 2010, MOL THER, V18, P477, DOI 10.1038/mt.2009.319
   Millington M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006461
   Munch J, 2007, CELL, V131, P1059, DOI 10.1016/j.cell.2007.10.014
   Pollok KE, 1998, J VIROL, V72, P4882
   Roan NR, 2011, CELL HOST MICROBE, V10, P541, DOI 10.1016/j.chom.2011.10.010
   Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08
   Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042
   Schambach A, 2006, GENE THER, V13, P1524, DOI 10.1038/sj.gt.3302807
   Schambach A, 2006, MOL THER, V13, P391, DOI 10.1016/j.ymthe.2005.08.012
   Shaytan AK, 2011, ACS NANO, V5, P6894, DOI 10.1021/nn2011943
   Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37
   Wurm M, 2011, BIOL CHEM, V392, P887, DOI 10.1515/BC.2011.085
   Wurm M, 2010, J GENE MED, V12, P137, DOI 10.1002/jgm.1429
NR 30
TC 54
Z9 54
U1 3
U2 66
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD FEB
PY 2013
VL 8
IS 2
BP 130
EP 136
DI 10.1038/NNANO.2012.248
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 093GD
UT WOS:000315178800022
PM 23334171
DA 2018-01-05
ER

PT J
AU Tiwari, S
   Nair, MPN
   Saxena, SK
AF Tiwari, Sneham
   Nair, Madhavan P. N.
   Saxena, Shailendra K.
TI Latest trends in drugs of abuse - HIV infection and neuroAIDS
SO FUTURE VIROLOGY
LA English
DT Article
DE alcohol; cocaine; drug abuse; HIV; methamphetamine; morphine; neuroAIDS;
   tobacco
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BLOOD-BRAIN-BARRIER; LC-MS/MS METHOD;
   CONCURRENT DETERMINATION; NICOTINE METABOLITES; CIRCULATING PLATELET;
   OXIDATIVE STRESS; 5'-TRIPHOSPHATE; NANOFORMULATION; MODULATION
AB Symposium on Drugs of Abuse - HIV Infection and NeuroAIDS: A Global Perspective, during the 3rd World Congress on Biotechnology Hyderabad, India, 13-15 September 2012 Drug abuse and co-occurring infections are associated with significant morbidity and mortality. In particular, HIV infection is associated with serious neurological complications, including neuroAIDS. Therefore, on 13-15 September 2012, the OMICS Group (USA) and Shailendra K Saxena (Centre for Cellular and Molecular Biology, India) hosted a symposium titled: Drugs of Abuse - HIV Infection and NeuroAIDS: A Global Perspective' that was cochaired by Jag H Khalsa and Jeymohan Joseph of the NIH, MD, USA, at the 3rd World Congress on Biotechnology, in Hyderabad, India. Renowned scientists from India and the USA highlighted a number of issues, including the epidemiology, causes and underlying pathophysiological mechanisms of neuroAIDS, impact on health, and designing new treatment modalities (e.g., nanotherapeutics) for the treatment of neurological disorders.
C1 [Tiwari, Sneham; Saxena, Shailendra K.] CSIR Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Nair, Madhavan P. N.] Florida Int Univ, Coll Med, Miami, FL 33199 USA.
RP Saxena, SK (reprint author), CSIR Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.
OI Saxena, Shailendra K/0000-0003-2856-4185
FU Council of Scientific and Industrial Research (CSIR-CCMB), India; NIH
   [R37DA025576, R01MH085259]
FX The authors are grateful to Council of Scientific and Industrial
   Research (CSIR-CCMB), India, for the encouragement and support for this
   work. SK Saxena and MPN Nair are supported by NIH grants R37DA025576 and
   R01MH085259. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Ande A, 2012, DRUG ALCOHOL DEPEN, V125, P49, DOI 10.1016/j.drugalcdep.2012.03.015
   Anderson E, 2002, JAIDS, V31, pS43, DOI 10.1097/01.QAI.0000027931.48986.D8
   Chang L, 1999, AM J PSYCHIAT, V156, P716
   CHANG SL, 1995, BRAIN RES, V679, P89, DOI 10.1016/0006-8993(95)00210-H
   Chang SL, 2007, J VIROL, V81, P8406, DOI 10.1128/JVI.00155-07
   Chang SL, 2012, J NEUROIMMUNE PHARM, V7, P332, DOI 10.1007/s11481-011-9324-1
   Chen SL, 2012, J NEUROIMMUNE PHARM, V7, P444, DOI 10.1007/s11481-011-9337-9
   Dutta R, 2012, CURR HIV RES, V10, P469, DOI 10.2174/157016212802138805
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Heesch CM, 2000, HEART, V83, P688, DOI 10.1136/heart.83.6.688
   Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810
   Jin MY, 2012, J NEUROIMMUNE PHARM, V7, P289, DOI 10.1007/s11481-011-9283-6
   Kass MD, 2010, J NEUROIMMUNE PHARM, V5, P566, DOI 10.1007/s11481-010-9221-z
   Kiyatkin EA, 2009, INT REV NEUROBIOL, V88, P65, DOI 10.1016/S0074-7742(09)88004-5
   Molina PE, 2008, ALCOHOL CLIN EXP RES, V32, P138, DOI 10.1111/j.1530-0277.2007.00549.x
   Molina PE, 2011, J NEUROIMMUNE PHARM, V6, P516, DOI 10.1007/s11481-011-9301-8
   Nath A, 2002, J INFECT DIS, V186, pS193, DOI 10.1086/344528                                                                  
   Ocasio FM, 2004, J NEUROIMMUNOL, V149, P90, DOI 10.1016/j.jneuroim.2003.12.016
   Revel FG, 2011, P NATL ACAD SCI USA, V108, P8485, DOI 10.1073/pnas.1103029108
   Roy S, 2011, J NEUROIMMUNE PHARM, V6, P442, DOI 10.1007/s11481-011-9292-5
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813
   Samikkannu T, 2010, J NEUROVIROL, V16, P255, DOI 10.3109/13550284.2010.497809
   Saxena SK, 2012, SCIENCE, V337, P798, DOI 10.1126/science.337.6096.798
   Singh MV, 2012, J VIROL METHODS, V181, P170, DOI 10.1016/j.jviromet.2012.02.005
   UNODC (UN Office on Drugs and Crime), 2012, WORLD DRUG REP 2012
   Yao HH, 2011, J NEUROSCI, V31, P5942, DOI 10.1523/JNEUROSCI.5618-10.2011
   Yao HH, 2011, BLOOD, V117, P2538, DOI 10.1182/blood-2010-10-313593
NR 28
TC 7
Z9 7
U1 0
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
J9 FUTURE VIROL
JI Future Virol.
PD FEB
PY 2013
VL 8
IS 2
BP 121
EP 127
DI 10.2217/FVL.12.134
PG 7
WC Virology
SC Virology
GA 086GX
UT WOS:000314673200007
PM 23626655
OA green_accepted
DA 2018-01-05
ER

PT J
AU Elsaid, KA
   Ferreira, L
   Truong, T
   Liang, A
   Machan, J
   D'Souza, GG
AF Elsaid, K. A.
   Ferreira, L.
   Truong, T.
   Liang, A.
   Machan, J.
   D'Souza, G. G.
TI Pharmaceutical nanocarrier association with chondrocytes and cartilage
   explants: influence of surface modification and extracellular matrix
   depletion
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Cell-penetrating peptide; Cartilage; Nanocarriers; Osteoarthritis
ID HUMAN IMMUNODEFICIENCY VIRUS; ARTICULAR-CARTILAGE; TAT PEPTIDE;
   MULTIFUNCTIONAL NANOCARRIERS; INTRAARTICULAR INJECTION; INTRACELLULAR
   DELIVERY; CANCER-THERAPY; OSTEOARTHRITIS; NANOPARTICLES; PROTEOGLYCAN
AB Objective: To evaluate cartilage diffusion and isolated chondrocyte association of micelles and liposomes and to determine the effect of cell-penetrating peptide (CPP) surface functionalization and extracellular matrix depletion on chondrocyte association and cartilage diffusion, respectively.
   Methods: Rhodamine-labeled micelles and liposomes were incubated with bovine chondrocytes and cell-associated fluorescence was quantified using flow cytometry. Rhodamine-labeled CPP-modified micelles and liposomes were incubated with chondrocytes and cell-associated fluorescence was compared to unmodified nanocarriers. Rhodamine-labeled micelles and liposomes were incubated with bovine cartilage explants for 1, 2 and 4 h and cartilage-associated fluorescence was compared across groups. Cartilage explants were treated with interleukin-1 alpha (IL-1 alpha) or with 0.25% trypsin. Rhodamine-labeled micelles and liposomes were incubated with control, IL-1 and trypsin-treated explants and cartilage-associated fluorescence was compared across groups.
   Results: Chondrocyte-associated fluorescence following treatment with micelles was significantly higher (P < 0.001) than fluorescence in the cells treated with liposomes while there was no difference between cell-associated fluorescence in the liposomes-treated and untreated controls. CPP-modified nanocarriers exhibited a significant increase in chondrocyte association compared to unmodified nanocarriers (P < 0.001). Micelles exhibited a time and concentration-dependent diffusion in cartilage explants while liposomes showed no diffusion. Following IL-1 and trypsin treatments, micelle diffusion in articular cartilage was significantly higher (P < 0.001) than their diffusion in untreated explants.
   Conclusion: Micelles exhibit superior association with isolated chondrocytes compared to liposomes. Surface modification with a CPP enhances chondrocyte association of both nanocarriers. 15 nm diameter micelles are better than 138 nm diameter liposomes in penetrating articular cartilage and extracellular matrix depletion enhances micelle penetration. (C) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Elsaid, K. A.; Ferreira, L.; Truong, T.; Liang, A.; D'Souza, G. G.] Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   [Machan, J.] Rhode Isl Hosp, Providence, RI 02903 USA.
RP Elsaid, KA (reprint author), Massachusetts Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 179 Longwood Ave, Boston, MA 02115 USA.
EM khaled.elsaid@mcphs.edu
OI Machan, Jason/0000-0003-2048-4914; Elsaid, Khaled/0000-0002-8925-4255
FU NIH/NIAMS [R15 AR061722-01]
FX This work is supported by NIH/NIAMS R15 AR061722-01 to ME and GD.
CR Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev.bioeng-071811-150124, 10.1146/annurev-bioeng-071811-150124]
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   Chevalier X, 2009, ARTHRIT RHEUM-ARTHR, V61, P344, DOI 10.1002/art.24096
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Flannery CR, 2010, CURR DRUG TARGETS, V11, P614
   FOONG WC, 1988, J PHARM PHARMACOL, V40, P464, DOI 10.1111/j.2042-7158.1988.tb05278.x                                              
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gerwin N, 2006, ADV DRUG DELIVER REV, V58, P226, DOI 10.1016/j.addr.2006.01.018
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Jabr-Milane L, 2008, J CONTROL RELEASE, V130, P121, DOI 10.1016/j.jconrel.2008.04.016
   Jabr-Milane LS, 2008, CANCER TREAT REV, V34, P592, DOI 10.1016/j.ctrv.2008.04.003
   Jay GD, 2000, J RHEUMATOL, V27, P594
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Juliano RL, 2006, ANN NY ACAD SCI, V1082, P18, DOI 10.1196/annals.1348.011
   Kozaci LD, 1997, ARTHRITIS RHEUM, V40, P164, DOI 10.1002/art.1780400121
   Larsen NE, 2011, J BIOMED MAT RES B
   Le Graverand-Gastineau MPH, 2010, CURR DRUG TARGETS, V11, P528
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Loeser RF, 2012, ARTHRITIS RHEUM-US, V64, P1697, DOI 10.1002/art.34453
   Lotz MK, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3046
   Mort John S., 2007, V135, P201
   OWEN SG, 1994, BRIT J CLIN PHARMACO, V38, P349, DOI 10.1111/j.1365-2125.1994.tb04365.x                                              
   Salo EN, 2012, OSTEOARTHR CARTILAGE, V20, P117, DOI 10.1016/j.joca.2011.11.016
   Sarma AV, 2001, J ORTHOP RES, V19, P671, DOI 10.1016/S0736-0266(00)00064-4
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015
   Torzilli PA, 1997, J BIOMECH, V30, P895, DOI 10.1016/S0021-9290(97)00059-6
   TORZILLI PA, 1993, MED BIOL ENG COMPUT, V31, pS93, DOI 10.1007/BF02446656
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   van den Hoven JM, 2011, MOL PHARMACEUT, V8, P1002, DOI 10.1021/mp2000742
   Vugmeyster Y, 2012, AAPS J, V14, P97, DOI 10.1208/s12248-011-9315-4
NR 33
TC 3
Z9 3
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD FEB
PY 2013
VL 21
IS 2
BP 377
EP 384
DI 10.1016/j.joca.2012.11.011
PG 8
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 086FF
UT WOS:000314668800015
PM 23186944
OA gold
DA 2018-01-05
ER

PT J
AU Kamanna, K
   Aneja, R
   Duffy, C
   Kubinski, P
   Moreira, DR
   Bailey, LD
   McFadden, K
   Schon, A
   Holmes, A
   Tuzer, F
   Contarino, M
   Freire, E
   Chaiken, IM
AF Kamanna, Kantharaju
   Aneja, Rachna
   Duffy, Caitlin
   Kubinski, Pamela
   Moreira, Diogo Rodrigo
   Bailey, Lauren D.
   McFadden, Karyn
   Schoen, Arne
   Holmes, Andrew
   Tuzer, Ferit
   Contarino, Mark
   Freire, Ernesto
   Chaiken, Irwin M.
TI Non-natural Peptide Triazole Antagonists of HIV-1 Envelope gp120
SO CHEMMEDCHEM
LA English
DT Article
DE antiviral agents; calorimetry; HIV entry inhibitors; peptides; surface
   plasmon resonance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENTRY INHIBITORS; FUSION INHIBITORS; DUAL
   ANTAGONIST; MEMBRANE-FUSION; PHAGE DISPLAY; TYPE-1; RECEPTOR;
   ENFUVIRTIDE; RESISTANCE
AB We investigated the derivation of non-natural peptide triazole dual receptor site antagonists of HIV-1 Env gp120 to establish a pathway for developing peptidomimetic antiviral agents. Previously we found that the peptide triazole HNG-156 [R-I-N-N-I-X-W-S-E-A-M-M-CONH2, in which X=ferrocenyltriazole-Pro (FtP)] has nanomolar binding affinity to gp120, inhibits gp120 binding to CD4 and the co-receptor surrogate mAb 17b, and has potent antiviral activity in cell infection assays. Furthermore, truncated variants of HNG-156, typified by UM-24 (Cit-N-N-I-X-W-S-CONH2) and containing the critical central stereospecific LX-LW cluster, retain the functional characteristics of the parent peptide triazole. In the current work, we examined the possibility of replacing natural with unnatural residue components in UM-24 to the greatest extent possible. The analogue with the critical hot spot residue Trp?6 replaced with L-3-benzothienylalanine (Bta) (KR-41), as well as a completely non-natural analogue containing D-amino acid substitutions outside the central cluster (KR-42, DCit-DN-DN-DI-X-Bta-DS-CONH2), retained the dual receptor site antagonism/antiviral activity signature. The results define differential functional roles of subdomains within the peptide triazole and provide a structural basis for the design of metabolically stable peptidomimetic inhibitors of HIV-1 Env gp120.
C1 [Kamanna, Kantharaju; Aneja, Rachna; Duffy, Caitlin; Kubinski, Pamela; Moreira, Diogo Rodrigo; Bailey, Lauren D.; McFadden, Karyn; Holmes, Andrew; Tuzer, Ferit; Contarino, Mark; Chaiken, Irwin M.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA.
   [Schoen, Arne; Freire, Ernesto] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
RP Kamanna, K (reprint author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,New Coll Bldg,Room 11302, Philadelphia, PA 19102 USA.
EM irwin.chaiken@drexelmed.edu
FU National Institute of General Medical Sciences (NIGMS) [5P01GM056550]
FX This study was supported by the National Institute of General Medical
   Sciences (NIGMS), grant number 5P01GM056550.
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Bastian AR, 2011, CHEMMEDCHEM, V6, P1335, DOI 10.1002/cmdc.201100177
   Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i
   Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Choi WT, 2012, BIOCHEMISTRY-US, V51, P7078, DOI 10.1021/bi2016712
   Cocklin S, 2007, J VIROL, V81, P3645, DOI 10.1128/JVI.01778-06
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215
   Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9                                                            
   Dwyer JJ, 2007, P NATL ACAD SCI USA, V104, P12772, DOI 10.1073/pnas.0701478104
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eggink D, 2010, CURR PHARM DESIGN, V16, P3716, DOI 10.2174/138161210794079218
   Engelman A, 2012, NAT REV MICROBIOL, V10, P279, DOI 10.1038/nrmicro2747
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Ferrer M, 1999, J VIROL, V73, P5795
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Francis JN, 2012, BIOCONJUGATE CHEM, V23, P1252, DOI 10.1021/bc300076f
   Gopi H, 2008, J MED CHEM, V51, P2638, DOI 10.1021/jm070814r
   Gopi H, 2009, J MOL RECOGNIT, V22, P169, DOI 10.1002/jmr.892
   Gopi HN, 2006, CHEMMEDCHEM, V1, P54, DOI 10.1002/cmdc.200500037
   Greenberg ML, 2004, J ANTIMICROB CHEMOTH, V54, P333, DOI 10.1093/jac/dkh330
   Harris A, 2011, P NATL ACAD SCI USA, V108, P11440, DOI 10.1073/pnas.1101414108
   Hertje M, 2010, CHEMMEDCHEM, V5, P1825, DOI 10.1002/cmdc.201000292
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Liu D, 2007, J VIROL, V81, P11489, DOI 10.1128/JVI.02845-06
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   McFadden K, 2012, ANTIMICROB AGENTS CH, V56, P1073, DOI 10.1128/AAC.05555-11
   Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1
   Pancera M, 2005, J VIROL, V79, P9954, DOI 10.1128/JVI.79.15.9954-9969.2005
   Perry CM, 2010, DRUGS, V70, P1189, DOI 10.2165/11203940-000000000-00000
   Ray N, 2007, J VIROL, V81, P3240, DOI 10.1128/JVI.02413-06
   Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854                                                   
   Scibek JJ, 2002, ANAL BIOCHEM, V307, P258, DOI 10.1016/S0003-2697(02)00043-X
   Shafer RW, 2008, AIDS REV, V10, P67
   Shino T, 2006, BIOCHEMISTRY-US, V45, P1106, DOI 10.1021/bi0518038
   Teixeira C, 2011, EUR J MED CHEM, V46, P979, DOI 10.1016/j.ejmech.2011.01.046
   Tuzer F, 2013, PROTEINS, V81, P271, DOI 10.1002/prot.24184
   Umashankara M, 2010, CHEMMEDCHEM, V5, P1871, DOI 10.1002/cmdc.201000222
   Welch BD, 2007, P NATL ACAD SCI USA, V104, P16828, DOI 10.1073/pnas.0708109104
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6                                                   
   Yost R, 2009, AM J HEALTH-SYST PH, V66, P715, DOI 10.2146/ajhp080206
NR 46
TC 4
Z9 4
U1 0
U2 21
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD FEB
PY 2013
VL 8
IS 2
BP 322
EP 328
DI 10.1002/cmdc.201200422
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 079LU
UT WOS:000314172700015
PM 23239505
OA green_accepted
DA 2018-01-05
ER

PT J
AU Seremeta, KP
   Chiappetta, DA
   Sosnik, A
AF Seremeta, Katia P.
   Chiappetta, Diego A.
   Sosnik, Alejandro
TI Poly(epsilon-caprolactone), Eudragit (R) RS 100 and
   poly(epsilon-caprolactone)/Eudragit (R) RS 100 blend submicron particles
   for the sustained release of the antiretroviral efavirenz
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE HIV infection; Antiretrovirals; Efavirenz-loaded
   poly(epsilon-caprolactone); Eudragit (R) RS 100 and
   poly(epsilon-caprolactone)/Eudragit (R) RS 100 blend submicron
   particles; Drug delivery systems; Controlled release in vitro
ID IMMUNODEFICIENCY-VIRUS-INFECTION; CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY;
   HIV-1 INFECTION; P-GLYCOPROTEIN; POLYMERIC NANOPARTICLES; INTRANASAL
   DELIVERY; COPOLYMER MICELLES; BLOCK-COPOLYMERS; BRAIN
AB The design of simple and scalable drug delivery systems to target the central nervous system (CNS) could represent a breakthrough in the addressment of the HIV-associated neuropathogenesis. The intranasal (i.n.) route represents a minimally invasive strategy to surpass the blood-brain barrier, though it demands the use of appropriate nanocarriers bearing high drug payloads and displaying sufficiently long residence time. The present work explored the development of submicron particles made of poly(epsilon-caprolactone) (PCL), Eudragit (R) RS 100 (RS a copolymer of ethylacrylate, methylmethacrylate and methacrylic acid esterified with quaternary ammonium groups) and their blends, loaded with the first-choice antiretroviral efavirenz (EFV) as an approach to fine tune the particle size and the release kinetics. Particles displaying hydrodynamic diameters between 90 and 530 nm were obtained by two methods: nanoprecipitation and emulsion/solvent diffusion/evaporation. In general, the former resulted in smaller particles and narrower size distributions. The encapsulation efficiency was greater than 94%, the drug weight content approximately 10% and the yield in the 72.5-90.0% range. The highly positive surface (>+30 mV) rendered the suspensions physically stable for more than one month. In vitro release assays indicated that the incorporation of the poly(methacrylate) into the composition reduced the burst effect and slowed the release rate down with respect to pure poly(epsilon-caprolactone) particles. The analysis of the release profile indicated that, in all cases, the kinetics adjusted well to the Higuchi model with R-adj(2) values >0.9779. These findings suggested that the release was mainly controlled by diffusion. In addition, when data were analyzed by the Korsmeyer-Peppas model, n values were in the 0.520-0.587 range, indicating that the drug release was accomplished by the combination of two phenomena: diffusion and polymer chain relaxation. Based on ATR/FT-IR analysis that investigated drug/polymer matrix interactions, the potential role of the hydrophobic interactions of C-F groups of EFV with carbonyl groups in the backbone of PCL and poly(methacrylate) could be ruled out. The developed EFV-loaded particles appear as a useful platform to investigate the intranasal administration to increase the bioavailability in the CNS. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Seremeta, Katia P.; Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, RA-1113 Buenos Aires, DF, Argentina.
   [Seremeta, Katia P.; Chiappetta, Diego A.; Sosnik, Alejandro] Consejo Nacl Invest Cient & Tecn, Natl Sci Res Council, RA-1033 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Fac Pharm & Biochem, Dept Pharmaceut Technol, Grp Biomat & Nanotechnol Improved Med BIONIMED, 956 Junin St,6th Floor, RA-1113 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
OI Seremeta, Katia/0000-0001-6302-7073
FU UBA [UBACyT 20020090200189]; CONICET [PIP0220]
FX KPS thanks a Ph.D. scholarship of CONICET. DAC and AS are staff members
   of CONICET. The work was partially supported by grants of UBA (UBACyT
   20020090200189) and CONICET (PIP0220). Authors thank Dr. Romina J.
   Glisoni for technical assistance in ATR/FT-IR analysis.
CR Al-Ghananeem AM, 2010, J DRUG TARGET, V18, P381, DOI 10.3109/10611860903483396
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Aungst BJ, 1999, ADV DRUG DELIVER REV, V39, P105, DOI 10.1016/S0169-409X(99)00022-8
   Balimane PV, 1999, ADV DRUG DELIVER REV, V39, P183, DOI 10.1016/S0169-409X(99)00026-5                                                   
   Basarkar A, 2009, PHARM RES-DORD, V26, P72, DOI 10.1007/s11095-008-9710-4
   Bastakoti BP, 2011, COLLOID SURFACE B, V88, P734, DOI 10.1016/j.colsurfb.2011.08.009
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   陈建海, 1997, 生物医学工程学杂志, V14, P334
   Chen Y, 2008, BIOORGAN MED CHEM, V16, P5914, DOI 10.1016/j.bmc.2008.04.064
   Chernysheva YV, 2003, MENDELEEV COMMUN, P65, DOI 10.1070/MC2003v013n02ABEH001690
   Chiappetta D.A., NANOMEDICINE UK IN P
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Cohn D, 2006, BIOMATERIALS, V27, P1718, DOI 10.1016/j.biomaterials.2005.10.035
   Cook-Easterwood J, 2007, EXP NEUROL, V205, P506, DOI 10.1016/j.expneurol.2007.03.007
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   Crews L, 2009, INT J MOL SCI, V10, P1045, DOI 10.3390/ijms10031045
   Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011
   Dean M, 2001, J LIPID RES, V42, P1007
   Delaney M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-S1-S6                                                       
   Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924
   Eidi H, 2010, INT J PHARMACEUT, V396, P156, DOI 10.1016/j.ijpharm.2010.06.006
   Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001
   Gotelli GA, 2011, J APPL POLYM SCI, V121, P1321, DOI 10.1002/app.33664
   Grovit-Ferbas K, 2010, IMMUNOL RES, V48, P40, DOI 10.1007/s12026-010-8166-x
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Hanson LR, 2007, J NEUROIMMUNE PHARM, V2, P81, DOI 10.1007/s11481-006-9039-x
   Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630
   Hoffart V, 2002, DRUG DEV IND PHARM, V28, P1091, DOI 10.1081/DDC-120014576
   Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022764
   Javadzadeh Y, 2010, COLLOID SURFACE B, V81, P498, DOI 10.1016/j.colsurfb.2010.07.047
   Kumar N, 2001, ADV DRUG DELIVER REV, V53, P23, DOI 10.1016/S0169-409X(01)00219-8
   Lince F, 2008, J COLLOID INTERF SCI, V322, P505, DOI 10.1016/j.jcis.2008.03.033
   Lopedota A, 2009, EUR J PHARM BIOPHARM, V72, P509, DOI 10.1016/j.ejpb.2009.02.013
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Moretton MA, 2010, COLLOID SURFACE B, V79, P467, DOI 10.1016/j.colsurfb.2010.05.016
   Nath A, 2006, CURR OPIN NEUROL, V19, P358, DOI 10.1097/01.wco.0000236614.51592.ca                                              
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Park S, 2005, J PHARMACOL EXP THER, V312, P1249, DOI 10.1124/jpet.104.076216
   Pawar D, 2010, AAPS J, V12, P130, DOI 10.1208/s12248-009-9169-1
   Peralta G, 2008, ENFERM INFEC MICR CL, V26, P150, DOI 10.1157/13116752                                                                
   Peroni RN, 2011, BIOCHEM PHARMACOL, V82, P1227, DOI 10.1016/j.bcp.2011.07.081
   Perrin DE, 1997, DRUG TARG D, V7, P63
   Puga AM, 2012, ACTA BIOMATER, V8, P1507, DOI 10.1016/j.actbio.2011.12.020
   Rao JP, 2011, PROG POLYM SCI, V36, P887, DOI 10.1016/j.progpolymsci.2011.01.001
   Rathbone MJ, 2002, J CONTROL RELEASE, V85, P61, DOI 10.1016/S0168-3659(02)00272-9
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Collet B., 1989, J PHARM SCI, V78, P781
   Romanelli F, 2006, CURR PHARM DESIGN, V12, P1121, DOI 10.2174/138161206776055868
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Cossu A., 2011, NANOSCALE RES LETT, V28, P260
   Schaffazick SR, 2008, EUR J PHARM BIOPHARM, V69, P64, DOI 10.1016/j.ejpb.2007.11.010
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shaik N, 2009, J PHARM SCI-US, V98, P4170, DOI 10.1002/jps.21723
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Song KC, 2006, COLLOID SURFACE A, V276, P162, DOI 10.1016/j.colsurfa.2005.10.064
   Sosnik A, 2003, POLYMER, V44, P7033, DOI 10.1016/j.polymer.2003.09.012
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Sun HF, 2006, BIOMATERIALS, V27, P1735, DOI 10.1016/j.biomaterials.2005.09.019
   Mupuala A., 2008, PEDIATRICS, V122, P123
   Vivithanaporn P, 2011, EXPERT REV ANTI-INFE, V9, P371, DOI [10.1586/eri.10.179, 10.1586/ERI.10.179]
   Wang J, 2006, J CONTROL RELEASE, V113, P31, DOI 10.1016/j.jconrel.2006.03.011
   [Anonymous], AIDS EPIDEMIC UPDATE
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Kosachenco B.G., 2012, CATHETER CARDIOVASC
   Zhao J, 2007, BIOMATERIALS, V28, P1414, DOI 10.1016/j.biomaterials.2006.10.012
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
NR 71
TC 36
Z9 36
U1 0
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD FEB 1
PY 2013
VL 102
BP 441
EP 449
DI 10.1016/j.colsurfb.2012.06.038
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 067NI
UT WOS:000313301200064
PM 23010128
DA 2018-01-05
ER

PT J
AU Choi, JH
   Kang, SR
   Kim, H
   Um, SH
   Shin, K
   Choi, JW
   Oh, BK
AF Choi, Jin-Ha
   Kang, So-Ra
   Kim, Heesuk
   Um, Soong Ho
   Shin, Kwanwoo
   Choi, Jeong-Woo
   Oh, Byung-Keun
TI Dye-Doped Silica Nanoparticle with HIV-1 TAT Peptide for Bioimaging
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Dye-Doped Silica Nanoparticle; Cell Penetrating Peptide; HIV-1 TAT
   Peptide; Bioimaging; Fluorescein Isothiocyanate
ID DELIVERY; CELLS
AB Multifunctional silica nanoparticles for bioimaging and drug delivery have progressively been developed as novel modalities for cancer diagnosis and treatment. In this study, we synthesized fluorescein isothiocyanate (FITC) doped silica nanoparticle coated with 3-aminopropyl trimethoxysilane (APTS). Additionally, the surface of this silica nanoparticle was modified with HIV-1 trans-activating transcriptional activator (HIV-1 TAT) peptide. The HIV-1 TAT peptide (cell-penetrating peptide) is able to deliver cargos such as oligonucleotides and proteins across the plasma membrane of living cells. This study demonstrates the feasibility of TAT peptide coated silica nanoparticle as a potential carrier for bioimaging and drug delivery.
C1 [Choi, Jin-Ha; Kang, So-Ra; Choi, Jeong-Woo; Oh, Byung-Keun] Sogang Univ, Dept Chem & Biomol Engn, Seoul 121742, South Korea.
   [Um, Soong Ho] Sungkyunkwan Univ, Dept Chem Engn, Suwon 440746, Gyeonggi Do, South Korea.
   [Kim, Heesuk; Shin, Kwanwoo] Sogang Univ, Dept Chem, Seoul 121742, South Korea.
RP Oh, BK (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 1 Shinsu Dong, Seoul 121742, South Korea.
OI Shin, Kwanwoo/0000-0002-7563-8581
FU National Research Foundation; Ministry of Education, Science and
   Technology, Korea; Ministryof Land, Transport and Maritime Affairs;
   Sogang University [201114007]; PET Converging Research Center
FX This research was supported by the Nuclear R&D program through the
   National Research Foundation funded by the Ministry of Education,
   Science and Technology, Korea. and by a part of the project titled
   "Development of Sustainable Remediation Technology for Marine
   Contaminated Sediments" funded by the Ministryof Land, Transport and
   Maritime Affairs, and by Sogang University Research Grant of 2011
   (201114007). Kwanwoo Shin acknowledged a financial support from PET
   Converging Research Center.
CR FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Monde Q., 2001, ANALYST, V126, P1274
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Rao KS, 2005, J COLLOID INTERF SCI, V289, P125, DOI 10.1016/j.jcis.2005.02.019
   Smith JE, 2006, TRAC-TREND ANAL CHEM, V25, P848, DOI 10.1016/j.trac.2006.03.008
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Wang L, 2006, ANAL CHEM, V78, P646, DOI 10.1021/ac0693619                                                               
NR 7
TC 14
Z9 14
U1 3
U2 48
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD FEB
PY 2013
VL 9
IS 2
BP 291
EP 294
DI 10.1166/jbn.2013.1542
PG 4
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA 079SH
UT WOS:000314192000017
PM 23627057
DA 2018-01-05
ER

PT J
AU Vasilyeva, SV
   Silnikov, VN
   Shatskaya, NV
   Levina, AS
   Repkova, MN
   Zarytova, VF
AF Vasilyeva, Svetlana V.
   Silnikov, Vladimir N.
   Shatskaya, Natalia V.
   Levina, Asya S.
   Repkova, Marina N.
   Zarytova, Valentina F.
TI SiO2 nanoparticles as platform for delivery of nucleoside triphosphate
   analogues into cells
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE SiO2 nanoparticles; Nucleoside triphosphates; 'Click' chemistry;
   Delivery into cells; Substrate properties
ID CLICK CHEMISTRY; ALIPHATIC POLYESTERS; ANTICANCER DRUGS; GENE-TRANSFER;
   DERIVATIVES; 5'-TRIPHOSPHATES; MECHANISM; BIOLOGY; AGENTS
AB A system for delivery of analogues of 2'-deoxyribonucleoside triphosphate (dNTP) based on SiO2 nanoparticles was proposed. A simple and versatile method was developed for the preparation of SiO2-dNTP conjugates using the 'click'-reaction between premodified nanoparticles containing the azido groups and dNTP containing the alkyne-modified gamma-phosphate group. The substrate properties of SiO2-dNTP were tested using Klenow fragment and HIV reverse transcriptase. Nucleoside triphosphates being a part of the SiO2-dNTP nanocomposites were shown to be incorporated into the growing DNA chain. The rate of polymerization with the use of SiO2-dNTP or common dNTP in case of HIV reverse transcriptase differed insignificantly. It was shown by confocal microscopy that the proposed SiO2-dNTP nanocomposites bearing the fluorescent label penetrate into cells and even into cellular nuclei. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Vasilyeva, Svetlana V.; Silnikov, Vladimir N.; Levina, Asya S.; Repkova, Marina N.; Zarytova, Valentina F.] Inst Chem Biol & Fundamental Med, Novosibirsk 630090, Russia.
   [Shatskaya, Natalia V.] Inst Cytol & Genet, Novosibirsk 630090, Russia.
RP Vasilyeva, SV (reprint author), Inst Chem Biol & Fundamental Med, Lavrentev Ave 8, Novosibirsk 630090, Russia.
EM svetlana2001@gmail.com
RI Levina, Asya/G-4230-2013; Repkova, Marina/G-4305-2013; Zarytova,
   Valentina/G-3526-2013; Vasilyeva, Svetlana/A-6819-2014; Silnikov,
   Vladimir /H-1118-2013
OI Vasilyeva, Svetlana/0000-0002-3551-2458; 
FU RFBR [11-04-01408-a]
FX Authors thank S. I. Baiborodin for the assistance in the use of confocal
   fluorescent microscopy and F. V. Tuzikov for the assistance in the
   analysis of the size of nanoparticles. The work was supported by RFBR
   Grant no. 11-04-01408-a.
CR Alagarsamy V, 2007, CHEM BIOL DRUG DES, V70, P158, DOI 10.1111/j.1747-0285.2007.00544.x
   ALVAREZ R, 1994, J MED CHEM, V37, P4185, DOI 10.1021/jm00050a015
   Atherton E., 1985, J CHEM SOC P1, V10, P2065
   Aufort M, 2008, BIOORG MED CHEM LETT, V18, P1195, DOI 10.1016/j.bmcl.2007.11.111
   BABKINA GT, 1975, BIOORG KHIM+, V1, P611
   BASHFORD CL, 1986, J BIOL CHEM, V261, P9300
   Canham L. T., 1995, ADV MATER, V1033, P7
   Chen M, 2005, EXP CELL RES, V305, P51, DOI 10.1016/j.yexcr.2004.12.021
   De Clercq E, 2004, REV MED VIROL, V14, P289, DOI 10.1002/rmv.439
   Hofheinz RD, 2005, ANTI-CANCER DRUG, V16, P691, DOI 10.1097/01.cad.0000167902.53039.5a
   Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009
   Kolb H. C., 2004, ANGEW CHEM INT EDIT, V2001, P40
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   Lee LV, 2003, J AM CHEM SOC, V125, P9588, DOI 10.1021/ja0302836
   Lee RJ, 2006, MOL CANCER THER, V5, P1639, DOI 10.1158/1535-7163.MCT-06-CO2
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Morris-Natschke SL, 2003, CURR PHARM DESIGN, V9, P1441, DOI 10.2174/1381612033454702
   Neu M, 2005, J GENE MED, V7, P992, DOI 10.1002/jgm.773
   Neumeyer A, 2011, NANOMED-NANOTECHNOL, V7, P410, DOI 10.1016/j.nano.2010.12.007
   Park JH, 2009, NAT MATER, V8, P331, DOI [10.1038/NMAT2398, 10.1038/nmat2398]
   Parrish B, 2005, J AM CHEM SOC, V127, P7404, DOI 10.1021/ja050310n                                                               
   Parrish B, 2007, BIOCONJUGATE CHEM, V18, P263, DOI 10.1021/bc060201d
   Paunesku T, 2003, NAT MATER, V2, P343, DOI 10.1038/nmat875
   Perez-Balderas F., 2003, ORG LETT, V5, P1951
   Seo TS, 2003, J ORG CHEM, V68, P609, DOI 10.1021/jo026615r
   Tiera MJ, 2006, CURR GENE THER, V6, P59, DOI 10.2174/156652306775515510                                                      
   Tuzikov FV, 1996, BIOPOLYMERS, V38, P131, DOI 10.1002/(SICI)1097-0282(199602)38:2<131::AID-BIP1>3.0.CO;2-W
   Tuzikov F. V., 2002, MED SCI MONITOR, V8, pMT79
   Vasilyeva SV, 2011, NUCLEOS NUCLEOT NUCL, V30, P753, DOI 10.1080/15257770.2011.595379
   Vinogradov SV, 2007, EXPERT OPIN DRUG DEL, V4, P5, DOI 10.1517/17425247.4.1.5
   Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x
   Zhang ZY, 2000, BIOCONJUGATE CHEM, V11, P805, DOI 10.1021/bc000018z
NR 32
TC 8
Z9 8
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD FEB 1
PY 2013
VL 21
IS 3
BP 703
EP 711
DI 10.1016/j.bmc.2012.11.057
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 072TX
UT WOS:000313696900013
PM 23280146
DA 2018-01-05
ER

PT J
AU Joyce, MG
   Kanekiyo, M
   Xu, L
   Biertumpfel, C
   Boyington, JC
   Moquin, S
   Shi, W
   Wu, XL
   Yang, YP
   Yang, ZY
   Zhang, BS
   Zheng, AQ
   Zhou, TQ
   Zhu, J
   Mascola, JR
   Kwong, PD
   Nabel, GJ
AF Joyce, M. Gordon
   Kanekiyo, Masaru
   Xu, Ling
   Biertuempfel, Christian
   Boyington, Jeffrey C.
   Moquin, Stephanie
   Shi, Wei
   Wu, Xueling
   Yang, Yongping
   Yang, Zhi-Yong
   Zhang, Baoshan
   Zheng, Anqi
   Zhou, Tongqing
   Zhu, Jiang
   Mascola, John R.
   Kwong, Peter D.
   Nabel, Gary J.
TI Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural
   Malleability, and Crystal Structure with Antibody VRC-PG04
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; CD4
   BINDING-SITE; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEIN;
   CD4-BINDING SITE; EPITOPE; BROAD; INFECTION; RECEPTOR
AB The outer domain of the HIV-1 gp120 envelope glycoprotein contains the epitope for broadly neutralizing antibodies directed to the CD4-binding site, many of which are able to neutralize over 90% of circulating HIV-1 isolates. While the outer domain is conformationally more stable than other portions of the HIV-1 envelope, efforts to express the outer domain as an immunogen for eliciting broadly neutralizing antibodies have not been successful, potentially because natural outer domain variants do not bind strongly to antibodies such as VRC01. In this study, we optimized the antigenic properties of the HIV-1 Env outer domain to generate OD4.2.2, from the KER2018 strain of clade A HIV-1, enabling it to bind antibodies such as VRC01 with nanomolar affinity. The crystal structure of OD4.2.2 in complex with VRC-PG04 was solved at 3.0-angstrom resolution and compared to known crystal structures including (i) the structure of core gp120 bound by VRC-PG04 and (ii) a circularly permutated version of the outer domain in complex with antibody PGT128. Much of the VRC-PG04 epitope was preserved in the OD4.2.2 structure, though with altered N and C termini conformations. Overall, roughly one-third of the outer domain structure appeared to be fixed in conformation, independent of alterations in termini, clade, or ligand, while other portions of the outer domain displayed substantial structural malleability. The crystal structure of OD4.2.2 with VRC-PG04 provides atomic-level details for an HIV-1 domain recognized by broadly neutralizing antibodies and insights relevant to the rational design of an immunogen that could elicit such antibodies by vaccination.
C1 [Joyce, M. Gordon; Kanekiyo, Masaru; Xu, Ling; Biertuempfel, Christian; Boyington, Jeffrey C.; Moquin, Stephanie; Shi, Wei; Wu, Xueling; Yang, Yongping; Yang, Zhi-Yong; Zhang, Baoshan; Zheng, Anqi; Zhou, Tongqing; Zhu, Jiang; Mascola, John R.; Kwong, Peter D.; Nabel, Gary J.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Kwong, PD (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM pdkwong@nih.gov; gnabel@nih.gov
RI Zhou, Tongqing/A-6880-2010
OI Zhou, Tongqing/0000-0002-3935-4637; Biertumpfel,
   Christian/0000-0002-7528-6547
FU Intramural Research Program of the National Institutes of Health
   (National Institute of Allergy and Infectious Diseases); U.S. Department
   of Energy, Basic Energy Sciences, Office of Science [W-31-109Eng-38]
FX Support for this work was provided by the Intramural Research Program of
   the National Institutes of Health (National Institute of Allergy and
   Infectious Diseases). Use of sector 22 (SER-CAT) at the Advanced Photon
   Source was supported by the U.S. Department of Energy, Basic Energy
   Sciences, Office of Science, under contract number W-31-109Eng-38.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203
   Berkower I, 2008, VIROLOGY, V377, P330, DOI [10.1016/j.virol.2008.03.040, 10.1016/j.virol.2008.0:3.040]
   Bricogne G., 2011, BUSTER VERSION 2 10
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Grundner C, 2005, VIROLOGY, V331, P33, DOI 10.1016/j.virol.2004.09.022
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   HO DD, 1991, J VIROL, V65, P489
   KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873                                                       
   Kang Y, 2009, VACCINE, V27, P5120, DOI 10.1016/j.vaccine.2009.06.037
   Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19                                                             
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860
   Li Ming-qiang, 2007, Harm Reduct J, V4, P8, DOI 10.1186/1477-7517-4-8
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Li YX, 2011, J VIROL, V85, P8954, DOI 10.1128/JVI.00754-11
   Lynch RM, 2012, J VIROL, V86, P7588, DOI 10.1128/JVI.00734-12
   Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340                                                        
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   MOORE JP, 1995, J VIROL, V69, P101
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Pietzsch J, 2010, J EXP MED, V207, P1995, DOI 10.1084/jem.20101176
   POSNER MR, 1991, J IMMUNOL, V146, P4325
   Quinnan GV, 1999, AIDS RES HUM RETROV, V15, P561, DOI 10.1089/088922299311088
   VUJCIC LK, 1995, AIDS RES HUM RETROV, V11, P783, DOI 10.1089/aid.1995.11.783
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wu L, 2006, VACCINE, V24, P4995, DOI 10.1016/j.vaccine.2006.03.083
   Wu L, 2009, J VIROL, V83, P5077, DOI 10.1128/JVI.02600-08
   Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532
   Wu XL, 2009, J VIROL, V83, P10892, DOI 10.1128/JVI.01142-09
   Yang XZ, 2004, J VIROL, V78, P12975, DOI 10.1128/JVI.78.23.12975-12986.2004
   Zhang MY, 2004, J VIROL, V78, P9233, DOI 10.1128/JVI.78.17.9233-9242.2004
   Zhang MY, 2003, J IMMUNOL METHODS, V283, P17, DOI 10.1016/j.jim.2003.07.003
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
   ZWART G, 1991, VIROLOGY, V181, P481, DOI 10.1016/0042-6822(91)90880-K
NR 43
TC 23
Z9 23
U1 0
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2013
VL 87
IS 4
BP 2294
EP 2306
DI 10.1128/JVI.02717-12
PG 13
WC Virology
SC Virology
GA 078BB
UT WOS:000314072000035
PM 23236069
OA gold
DA 2018-01-05
ER

PT J
AU Syed, S
   Zubair, A
   Frieri, M
AF Syed, Saad
   Zubair, Adeel
   Frieri, Marianne
TI Immune Response to Nanomaterials: Implications for Medicine and
   Literature Review
SO CURRENT ALLERGY AND ASTHMA REPORTS
LA English
DT Review
DE Nanomaterials; Reactive oxygen species; Nuclear factor-kappa B; NF-kappa
   B pathway; Advances; Allergy; Immunology; Immune response
ID NF-KAPPA-B; WALLED CARBON NANOTUBES; DRUG-DELIVERY SYSTEMS; IN-VITRO;
   OXIDATIVE STRESS; GOLD NANOPARTICLES; MAGNETIC NANOPARTICLES; SILVER
   NANOPARTICLES; SILICA NANOPARTICLES; STEALTH CHARACTER
AB Nanomaterials, substances below 100 nm, are increasingly used in medical diagnosis and treatment every day. The use of such materials has helped deliver drugs across the blood-brain barrier, alleviate allergy symptoms, specifically target cancer or HIV cells, and more. However, the tunable characteristics of such materials have not been perfected. The different materials, sizes, shapes, and structures have different responses on the body. This paper will investigate the successful treatments made with nanoparticles and some general health effects. A review of the literature revealed an inflammatory response and an increased production of reactive oxidative species (ROS) to be common immune responses to nanomaterial use. The mechanisms by which the inflammatory response and ROS production occur will also be discussed.
C1 [Frieri, Marianne] Nassau Univ Med Ctr, Dept Med, Div Allergy Immunol, E Meadow, NY 11554 USA.
   [Frieri, Marianne] Nassau Univ Med Ctr, NSLIJ Hlth Care Syst, E Meadow, NY 11554 USA.
RP Frieri, M (reprint author), Nassau Univ Med Ctr, Dept Med, Div Allergy Immunol, 2201 Hempstead Turnpike, E Meadow, NY 11554 USA.
EM saad914@yahoo.com; az1698@gmail.com; mfrieri@numc.edu
CR Aitken RJ, 2006, OCCUP MED-OXFORD, V56, P300, DOI 10.1093/occmed/kq1051
   Arora S, 2008, TOXICOL LETT, V179, P93, DOI 10.1016/j.toxlet.2008.04.009
   Bailon P, 2009, EXPERT OPIN DRUG DEL, V6, P1, DOI [10.1517/17425240802650568 , 10.1517/17425240802650568]
   Balasubramanian SK, 2010, BIOMATERIALS, V31, P2034, DOI 10.1016/j.biomaterials.2009.11.079
   Barillet S, 2010, J NANOPART RES, V12, P61, DOI 10.1007/s11051-009-9694-y
   Buzea C, 2007, BIOINTERPHASES, V2, pMR17, DOI 10.1116/1.2815690
   Canal C, 2012, J PHARM PHARM SCI, V15, P197, DOI 10.18433/J3X884                                                                 
   Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m
   Chompoosor A, 2010, SMALL, V6, P2246, DOI 10.1002/smll.201000463
   Circu M, 2009, FREE RADIC BIOL MED, V48, P749
   Crouzier D, 2010, TOXICOLOGY, V272, P39, DOI 10.1016/j.tox.2010.04.001
   Cuenya BR, 2010, THIN SOLID FILMS, V518, P3127, DOI 10.1016/j.tsf.2010.01.018
   Deng X, 2007, CARBON, V45, P1419, DOI 10.1016/j.carbon.2007.03.035
   des Rieux A, 2005, EUR J PHARM SCI, V25, P455, DOI 10.1016/j.ejps.2005.04.015
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Downs TR, 2012, MUTAT RES-GEN TOX EN, V745, P38, DOI 10.1016/j.mrgentox.2012.03.012
   Dzhindzhikhashvili M, 2011, ALLERGY ASTHMA PROC, V11, P1
   Fievez V, 2009, EUR J PHARM BIOPHARM, V73, P16, DOI 10.1016/j.ejpb.2009.04.009
   Foldbjerg R, 2011, ARCH TOXICOL, V85, P743, DOI 10.1007/s00204-010-0545-5
   Forman HJ, 2007, FREE RADICAL BIO MED, V42, P926, DOI 10.1016/j.freeradbiomed.2007.01.011
   Frieri M., 2011, CURRENT ALLERGY ASTH, V12, P25
   Frieri M., 1999, FOOD HYPERSENSITIVIT, P39
   Frieri M, 2012, J NEPHROL
   Frieri M, 2010, CLIN IMMUNOL
   Frieri M, 2007, ALLERGY ASTHMA PROC, V28, P614, DOI 10.2500/aap.2007.28.2952
   Frisella PD, 2011, AM J RHINOL ALLERGY, V25, P231, DOI 10.2500/ajra.2011.25.3629
   Gao T, 2005, CHEM MATER, V17, P887, DOI 10.1021/cm0485456
   Garnett MC, 2006, OCCUP MED-OXFORD, V56, P307, DOI 10.1093/occmed/kql052
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225                                                
   Halliwell B, 2007, FREE RADICAL BIO MED, P1
   Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002
   Hamman JH, 2010, MAR DRUGS, V8, P1305, DOI 10.3390/md8041305
   Hansen SF, 2010, WIRES NANOMED NANOBI, V2, P441, DOI 10.1002/wnan.99
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13
   Heng BC, 2011, ARCH TOXICOL, V85, P1517, DOI 10.1007/s00204-011-0722-1
   Inoue K, 2010, FREE RADICAL BIO MED, V48, P924, DOI 10.1016/j.freeradbiomed.2010.01.013
   Jain TK, 2008, MOL PHARM, V5, P316, DOI 10.1021/mp7001285
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kah JCY, 2009, J DRUG TARGET, V17, P181, DOI 10.1080/10611860802582442
   Kalgaonkar S, 2009, J NUTR BIOCHEM, V20, P304, DOI 10.1016/j.jnutbio.2008.04.003
   Kandasamy R, 2010, INT IMMUNOPHARMACOL, V10, P218, DOI 10.1016/j.intimp.2009.11.003
   Kim B, 2010, NEW ENGL J MED, V36, P2434
   Kim S, 2009, TOXICOL IN VITRO, V23, P1076, DOI 10.1016/j.tiv.2009.06.001
   Klimek L, 2011, CLIN EXP ALLERGY, V41, P1305, DOI 10.1111/j.1365-2222.2011.03783.x
   Lee S, 2011, BIOMATERIALS, V32, P9434, DOI 10.1016/j.biomaterials.2011.08.042
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910
   Lipka J, 2010, BIOMATERIALS, V31, P6574, DOI 10.1016/j.biomaterials.2010.05.009
   Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c
   Liu AH, 2012, ADV MATER RES-SWITZ, V345, P287, DOI 10.4028/www.scientific.net/AMR.345.287
   Liu ZG, 2009, INT ARCH ALLERGY IMM, V150, P221, DOI 10.1159/000222674
   Lonkar P, 2011, INT J CANCER, V128, P1999, DOI 10.1002/ijc.25815
   Luo Z., 2011, COLLOID POLYM SCI, V290, P141
   Mahajan SD, 2011, PATHOLOG RES INT
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mahler GJ, 2012, NAT NANOTECHNOL, V7, P264, DOI [10.1038/nnano.2012.3, 10.1038/NNANO.2012.3]
   Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966
   Mansur A, 2000, ALLERGY ASTHMA PROC, V21, P145, DOI 10.2500/108854100778148936                                                      
   Mansur A, 2000, ANN ALLERG ASTHMA IM, V84, P583, DOI 10.1016/S1081-1206(10)62407-6                                                   
   Masamune A, 2009, GUT, V58, P550, DOI 10.1136/gut.2008.154401
   Mikhaylov G, 2011, NAT NANOTECHNOL, V6, P594, DOI [10.1038/NNANO.2011.112, 10.1038/nnano.2011.112]
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Napierska D, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-39
   Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x                                                
   Nelson AM, 2011, J INVEST DERMATOL, V132, pS135
   Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017
   Nishanth RP, 2011, NANOTOXICOLOGY, V5, P502, DOI 10.3109/17435390.2010.541604
   Pan YH, 2009, J STRUCT BIOL, V166, P22, DOI 10.1016/j.jsb.2008.12.001
   Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655
   Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37
   Poplawski T, 2009, CHEM-BIOL INTERACT, V180, P69, DOI 10.1016/j.cbi.2009.02.001
   Powers KW, 2007, NANOTOXICOLOGY, V1, P42, DOI 10.1080/17435390701314902
   Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2
   Pujalte I, 2011, PART FIBRE TOXICOL, V3, P8
   Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913
   Romoser AA, 2012, TOXICOL LETT, V210, P293, DOI 10.1016/j.toxlet.2012.01.022
   Saltan N, 2011, INT J NANOMED, V6, P477, DOI 10.2147/IJN.S16803
   Sanhai WR, 2008, NAT NANOTECHNOL, V3, P242, DOI 10.1038/nnano.2008.114
   Sarkar A, 2011, TOXICOLOGY, V290, P209
   Sayes CM, 2007, NANO LETT, V7, P2399, DOI 10.1021/nl0710710
   Schipper ML, 2008, NAT NANOTECHNOL, V3, P216, DOI 10.1038/nnano.2008.68
   Shah NB, 2012, MOL PHARM
   Shahzad G, 2011, GASTROENTEROLOGY, V2011
   Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001
   Simko M, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-42
   Sitrin RG, 1998, J IMMUNOL, V161, P1462
   Song WH, 2010, TOXICOL LETT, V199, P389, DOI 10.1016/j.toxlet.2010.10.003
   Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149
   Teste B, 2011, LAB CHIP, V11, P4207, DOI 10.1039/c1lc20809h
   Thurnherr T, 2011, TOXICOL LETT, V200, P176, DOI 10.1016/j.toxlet.2010.11.012
   Toyama T, 2011, CONTACT DERMATITIS, V59, P122
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Yamashita K, 2011, NAT NANOTECHNOL, V6, P321, DOI [10.1038/nnano.2011.41, 10.1038/NNANO.2011.41]
   Yang RH, 2007, ENVIRON HEALTH PERSP, V115, P1339, DOI 10.1289/ehp.10290
   Yang ST, 2008, SMALL, V4, P940, DOI 10.1002/smll.200700714
   Yin R, 2010, ACUTE LUNG INFLAMMAT
   Yoshida M, 2008, ACS NANO, V2, P1101, DOI 10.1021/nn800332g
   Zhou D, 2010, NAT NANOTECHNOL, V6, P39
NR 103
TC 26
Z9 26
U1 1
U2 125
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1529-7322
J9 CURR ALLERGY ASTHM R
JI Curr. Allergy Asthma Rep.
PD FEB
PY 2013
VL 13
IS 1
BP 50
EP 57
DI 10.1007/s11882-012-0302-3
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA 070OC
UT WOS:000313517900007
PM 22941559
DA 2018-01-05
ER

PT J
AU Chen, YP
   Chen, CT
   Hung, Y
   Chou, CM
   Liu, TP
   Liang, MR
   Chen, CT
   Mou, CY
AF Chen, Yi-Ping
   Chen, Chien-Tsu
   Hung, Yann
   Chou, Chih-Ming
   Liu, Tsang-Pai
   Liang, Ming-Ren
   Chen, Chao-Tsen
   Mou, Chung-Yuan
TI A New Strategy for Intracellular Delivery of Enzyme Using Mesoporous
   Silica Nanoparticles: Superoxide Dismutase
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; RESPONSIVE CONTROLLED-RELEASE;
   MESENCHYMAL STEM-CELLS; TAT-MEDIATED DELIVERY; CU,ZN-SUPEROXIDE
   DISMUTASE; DRUG-DELIVERY; PC12 CELLS; PROTEIN; TRANSDUCTION; ACTIVATION
AB We developed mesoporous silica nanoparticle (MSN) as a multifunctional vehicle for enzyme delivery. Enhanced transmembrane delivery of a superoxide dismutase (SOD) enzyme embedded in MSN was demonstrated. Conjugation of the cell-penetrating peptide derived from the human immunodeficiency virus 1 (HIV) transactivator protein (TAT) to mesoporous silica nanoparticle is shown to be an effective way to enhance transmembrane delivery of nanoparticles for intracellular and molecular therapy. Cu,Zn-superoxide dismutase (SOD) is a key antioxidant enzyme that detoxifies intracellular reactive oxygen species, ROS, thereby protecting cells from oxidative damage. In this study, we fused a human Cu,Zn-SOD gene with TAT in a bacterial expression vector to produce a genetic in-frame His-tagged TAT-SOD fusion protein. The His-tagged TAT-SOD fusion protein was expressed in E. coli using IPTG induction and purified using FMSN-Ni-NTA. The purified TAT-SOD was conjugated to FITC-MSN forming FMSN-TAT-SOD. The effectiveness of FMSN-TAT-SOD as an agent against ROS was investigated, which included the level of ROS and apoptosis after free radicals induction and functional recovery after ROS damage. Confocal microscopy on live unfixed cells and flow cytometry analysis showed characteristic nonendosomal distribution of FMSN-TAT-SOD. Results suggested that FMSN-TAT-SOD may provide a strategy for the therapeutic delivery of antioxidant enzymes that protect cells from ROS damage.
C1 [Chen, Yi-Ping; Hung, Yann; Liang, Ming-Ren; Chen, Chao-Tsen; Mou, Chung-Yuan] Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan.
   [Chen, Chien-Tsu; Chou, Chih-Ming] Taipei Med Univ, Dept Biochem, Taipei 106, Taiwan.
   [Liu, Tsang-Pai] Mackay Mem Hosp, Dept Surg, Div Gen Surg, Taipei 106, Taiwan.
   [Liu, Tsang-Pai] Mackay Med Nursing & Management Coll, Taipei 106, Taiwan.
RP Mou, CY (reprint author), Natl Taiwan Univ, Dept Chem, Taipei 106, Taiwan.
EM cymou@ntu.du.tw
OI MOU, CHUNG-YUAN/0000-0001-7060-9899
FU National Science Council of Taiwan through the National Nanotechnology
   Program
FX This work was supported by the National Science Council of Taiwan
   through the National Nanotechnology Program. We thank Mr. Si-Han Wu, Dr.
   Fan-Ching Chien, and Prof. Peilin Chen for technical help.
CR Babu P, 2007, BIOCONJUGATE CHEM, V18, P146, DOI 10.1021/bc060204q
   Bindokas VP, 1996, J NEUROSCI, V16, P1324
   Chou CM, 2005, ANN NY ACAD SCI, V1042, P303, DOI 10.1196/annals.1338.053
   Chuang CY, 2011, ARCH TOXICOL, V85, P209, DOI 10.1007/s00204-010-0585-x
   Chung EJ, 2012, INVEST OPHTH VIS SCI, V53, P379, DOI 10.1167/iovs.11-8491
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Coupland PG, 2009, INTEGR BIOL, V1, P318, DOI 10.1039/b822569a
   Crowe J, 1996, Methods Mol Biol, V58, P491
   Dube KN, 2012, CURR PHARM DESIGN, V18, P799
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P339, DOI 10.1016/j.freeadbiomed.2004.04.036
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Feve AP, 2012, CNS NEUROL DISORD-DR, V11, P450
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525                                             
   Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815
   Guignet EG, 2004, NAT BIOTECHNOL, V22, P440, DOI 10.1038/nbt954
   Hoffmann F, 2006, J NANOSCI NANOTECHNO, V6, P265, DOI 10.1166/jnn.2006.001
   Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05-4288fje
   Jeong HJ, 2012, MOL CELLS, V33, P471, DOI 10.1007/s10059-012-2255-8
   Kalkanidis M, 2006, METHODS, V40, P20, DOI 10.1016/j.ymeth.2006.05.018
   Kashio A, 2012, GENE THER, V19, P1141, DOI 10.1038/gt.2011.204
   Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l
   Lee JA, 2009, EXP MOL MED, V41, P629, DOI 10.3858/emm.2009.41.9.069
   Li C, 2004, CATAL REV, V46, P419, DOI 10.1081/CR-200036734
   Li X, 1999, J NEURAL TRANSM, V106, P1, DOI 10.1007/s007020050137
   Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g
   Lin YS, 2005, CHEM MATER, V17, P4570, DOI 10.1021/cm051014c
   Lin YC, 2011, CHEM-EUR J, V17, P13059, DOI 10.1002/chem.201101540
   Liu Lihong, 2008, Biomaterials, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Lu F, 2009, SMALL, V5, P1408, DOI 10.1002/smll.200900005
   MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x
   Mendez J, 2012, BIOCONJUGATE CHEM, V23, P698, DOI 10.1021/bc200301a
   Messner UK, 1999, KIDNEY INT, V55, P2322, DOI 10.1046/j.1523-1755.1999.00473.x
   PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0                                                                
   Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m
   Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536
   Slowing II, 2007, J AM CHEM SOC, V129, P8845, DOI 10.1021/ja0719780
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Sun XX, 2011, J AM CHEM SOC, V133, P18554, DOI 10.1021/ja2080168
   Torney F, 2007, NAT NANOTECHNOL, V2, P295, DOI 10.1038/nnano.2007.108
   Tusell JM, 2005, GLIA, V49, P52, DOI 10.1002/glia.20095
   Vallet-Regi M, 2006, CHEM-EUR J, V12, P5934, DOI 10.1002/chem.200600226
   VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779
   Vucic S, 2009, CURR MOL MED, V9, P255, DOI 10.2174/156652409787847173                                                      
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wu SH, 2011, CHEM COMMUN, V47, P9972, DOI 10.1039/c1cc11760b
   Yang WL, 1998, NEUROCHEM RES, V23, P47, DOI 10.1023/A:1022497319548
NR 48
TC 65
Z9 67
U1 11
U2 318
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JAN 30
PY 2013
VL 135
IS 4
BP 1516
EP 1523
DI 10.1021/ja3105208
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 083VE
UT WOS:000314492500055
PM 23289802
DA 2018-01-05
ER

PT J
AU Soltani, F
   Sankian, M
   Hatefi, A
   Ramezani, M
AF Soltani, Fatemeh
   Sankian, Mojtaba
   Hatefi, Arash
   Ramezani, Mohammad
TI Development of a novel histone H1-based recombinant fusion peptide for
   targeted non-viral gene delivery
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Recombinant peptides; Non-viral gene delivery systems; Targeted
   delivery; Cancer gene therapy
ID THERAPY; CANCER; TRANSPORT; EFFICIENT; DNA; NANOCARRIERS; POLYMERS;
   VECTORS; NUCLEUS; SYSTEMS
AB In this study a new multifunctional recombinant gene delivery system (vector) was developed for targeted gene delivery to ZR-75-1 breast cancer cells. The vector backbone contained multiple domains including: (1) two tandem repeating units of truncated histone H1 to condense pDNA, (2) a model cell targeting peptide to target ZR-75-1 cells, (3) a pH-responsive synthetic fusogenic peptide, KALA, to destabilize endosomal membrane, and (4) a nuclear localization signal from human immunodeficiency virus to enhance translocation of pDNA toward the cell nucleus.
   The vectors were cloned and expressed in Escherichia coli BL21 (DE3) followed by purification with Ni-NTA affinity chromatography. They were then characterized using physicochemical and in vitro biological methods to evaluate the gene transfer efficiency and vector multifunctionality. The results demonstrated that the recombinant vector bearing all four functional domains had the highest rate of gene transfection efficiency as compared to the vectors which lacked one or more functional motifs. Beside the ability to target, the developed multifunctional vector was able to disrupt endosomal membranes, reach cell nucleus by utilizing microtubules and transfect efficiently while showing no detectable toxicity. (C) 2012 Elsevier B. V. All rights reserved.
C1 [Soltani, Fatemeh; Ramezani, Mohammad] Mashhad Univ Med Sci, Sch Pharm, Dept Biotechnol, Pharmaceut Res Ctr, Mashhad, Iran.
   [Sankian, Mojtaba] Mashhad Univ Med Sci, Sch Med, Immunol Res Ctr, Immunobiochem Lab, Mashhad, Iran.
   [Hatefi, Arash] Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ USA.
RP Ramezani, M (reprint author), Mashhad Univ Med Sci, Sch Pharm, Dept Biotechnol, Pharmaceut Res Ctr, Mashhad, Iran.
EM ahatefi@pharmacy.rutgers.edu; ramezanim@mums.ac.ir
OI Soltani, Fatemeh/0000-0002-8219-9919
FU Mashhad University of Medical Sciences, Mashhad, Iran; Iranian
   Nanotechnology Initiative
FX This work was funded by Mashhad University of Medical Sciences, Mashhad,
   Iran. The financial support by the Iranian Nanotechnology Initiative is
   gratefully acknowledged. This work was part of F. Soltani's PhD thesis.
CR Bharath S.M., 2002, BIOCHEMISTRY-US, V41, P7617
   BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972
   Canine BF, 2010, ADV DRUG DELIVER REV, V62, P1524, DOI 10.1016/j.addr.2010.04.001
   Canine BF, 2009, J CONTROL RELEASE, V138, P188, DOI 10.1016/j.jconrel.2009.04.017
   Dane KY, 2006, J IMMUNOL METHODS, V309, P120, DOI 10.1016/j.jim.2005.11.021
   El-Aneed A, 2004, J CONTROL RELEASE, V94, P1, DOI 10.1016/j.jconrel.2003.09.013
   Escriou V, 2003, ADV DRUG DELIVER REV, V55, P295, DOI 10.1016/S0169-409X(02)00184-9
   Ghandehari H, 2010, ADV DRUG DELIVER REV, V62, P1403, DOI 10.1016/j.addr.2010.07.007
   Giacca M, 2012, J CONTROL RELEASE, V161, P377, DOI 10.1016/j.jconrel.2012.04.008
   Hatefi A, 2006, J GENE MED, V8, P468, DOI 10.1002/jgm.872
   Hattori Y, 2010, YAKUGAKU ZASSHI, V130, P917, DOI 10.1248/yakushi.130.917                                                         
   Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420
   Kaouass M, 2006, J CONTROL RELEASE, V113, P245, DOI 10.1016/j.jconrel.2006.04.013
   Khan Saifur Rahman, 2012, Recent Pat DNA Gene Seq, V6, P2
   Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1                                                   
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Megeed Z, 2002, ADV DRUG DELIVER REV, V54, P1075, DOI 10.1016/S0169-409X(02)00063-7                                                   
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   O'Rorke S, 2010, PROG POLYM SCI, V35, P441, DOI 10.1016/j.progpolymsci.2010.01.005
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Suh JH, 2004, BIOTECHNOL PROGR, V20, P598, DOI 10.1021/bp034251y
   Uherek C, 2000, ADV DRUG DELIVER REV, V44, P153, DOI 10.1016/S0169-409X(00)00092-2
   Vercauteren D, 2012, J CONTROL RELEASE, V161, P566, DOI 10.1016/j.jconrel.2012.05.020
   Wagstaff KM, 2007, BIOCHEM J, V406, P185, DOI 10.1042/BJ20070505                                                              
   WANG CY, 1984, BIOCHEMISTRY-US, V23, P4409, DOI 10.1021/bi00314a026
   Wang YH, 2009, J CONTROL RELEASE, V137, P46, DOI [10.1016/j.conrel.2009.03.005, 10.1016/j.jconrel.2009.03.005]
   Warnock JN, 2011, METHODS MOL BIOL, V737, P1, DOI 10.1007/978-1-61779-095-9_1
   Wu TL, 2011, ADV DRUG DELIVER REV, V63, P671, DOI 10.1016/j.addr.2011.05.005
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
NR 34
TC 9
Z9 9
U1 2
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JAN 30
PY 2013
VL 441
IS 1-2
BP 307
EP 315
DI 10.1016/j.ijpharm.2012.11.027
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 077UQ
UT WOS:000314054200037
PM 23200954
DA 2018-01-05
ER

PT J
AU Kuhne, MR
   Mulvey, T
   Belanger, B
   Chen, S
   Pan, C
   Chong, CL
   Cao, F
   Niekro, W
   Kempe, T
   Henning, KA
   Cohen, LJ
   Korman, AJ
   Cardarelli, PM
AF Kuhne, Michelle R.
   Mulvey, Tanya
   Belanger, Blake
   Chen, Sharline
   Pan, Chin
   Chong, Colin
   Cao, Fei
   Niekro, Wafa
   Kempe, Tom
   Henning, Karla A.
   Cohen, Lewis J.
   Korman, Alan J.
   Cardarelli, Pina M.
TI BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis
   In Vitro and Shows Antitumor Activity In Vivo in Hematologic
   Malignancies
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC
   PROGENITORS; MULTIPLE-MYELOMA; OVARIAN-CANCER; BREAST-CANCER;
   TUMOR-GROWTH; CELLS; EXPRESSION; HIV-1
AB Purpose: CXCR4 has been identified as a prognostic marker for acute myeloid leukemia (AML) and other malignancies. We describe the development and characterization of a fully human antibody to CXCR4 and its application for therapy of AML, non-Hodgkin lymphoma (NHL), chronic lymphoid leukemia (CLL), and multiple myeloma.
   Experimental Design: Human transgenic mice were immunized with CXCR4-expressing cells, and antibodies reactive with CXCR4 were analyzed for apoptosis induction and ability to interfere with CXCL12-induced migration and calcium flux. In vivo efficacy was determined in multiple AML, NHL, and multiple myeloma xenograft tumors in severe combined immunodeficient mice.
   Results: BMS-936564/MDX-1338 is a fully human IgG4 monoclonal antibody that specifically recognizes human CXCR4. In vitro studies show that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 binding to CXCR4-expressing cells, and inhibits CXCL12-induced migration and calcium flux with low nanomolar EC50 values. When given as monotherapy, MDX-1338 exhibits antitumor activity in established tumors including AML, NHL, and multiple myeloma xenograft models. In addition, we show that MDX-1338 induced apoptosis on a panel of cell lines and propose that antibody-induced apoptosis is one of the mechanisms of tumor growth inhibition.
   Conclusions: BMS-936564/MDX-1338 is a potent CXCR4 antagonist which is efficacious as monotherapy in tumor-bearing mice and is currently in phase I for the treatment of relapsed/refractory AML, NHL, CLL, and multiple myeloma. Clin Cancer Res; 19(2); 357-66. (C)2012 AACR.
C1 [Kuhne, Michelle R.; Mulvey, Tanya; Belanger, Blake; Chen, Sharline; Pan, Chin; Chong, Colin; Cao, Fei; Cardarelli, Pina M.] Bristol Myers Squibb, BDC, Dept Cell Biol & Physiol, Redwood City, CA 94063 USA.
   [Niekro, Wafa; Kempe, Tom] BDC, Dept Hybridoma, Redwood City, CA USA.
   [Henning, Karla A.; Korman, Alan J.] BDC, Dept Discovery Res, Redwood City, CA USA.
   [Cohen, Lewis J.] Bristol Myers Squibb, Discovery Med & Clin Pharmacol, Lawrenceville, NJ USA.
RP Cardarelli, PM (reprint author), Bristol Myers Squibb, BDC, Dept Cell Biol & Physiol, 700 Bay Rd, Redwood City, CA 94063 USA.
EM pina.cardarelli@bms.com
CR Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857
   ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood-2008-10-186668
   Beider K, 2011, EXP HEMATOL, V39, P282, DOI 10.1016/j.exphem.2010.11.010
   Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Corvaia N, 2011, P 102 ANN M AM ASS C
   Dar A, 2011, LEUKEMIA, V25, P1286, DOI 10.1038/leu.2011.62
   Di Salvo J, 2000, EUR J PHARMACOL, V409, P143, DOI 10.1016/S0014-2999(00)00846-3
   Garg H, 2006, J LEUKOCYTE BIOL, V79, P351, DOI 10.1189/jlb.0805430
   Guleng B, 2005, CANCER RES, V65, P5864, DOI 10.1158/0008-5472.CAN-04-3833
   Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282                                                          
   Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8                                                   
   Hiller DJ, 2011, SURGERY, V150, P459, DOI 10.1016/j.surg.2011.07.005
   Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Liu Z, 2011, DIABETOLOGIA, V54, P2067, DOI 10.1007/s00125-011-2181-x
   LOETSCHER M, 1994, J BIOL CHEM, V269, P232
   Marechal R, 2009, BRIT J CANCER, V100, P1444, DOI 10.1038/sj.bjc.6605020
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745                                                        
   Mohle R, 1998, BLOOD, V91, P4523
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Ottaiano A, 2006, CLIN CANCER RES, V12, P2795, DOI 10.1158/1078-0432.CCR-05-2142
   Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908
   Porvasnik S, 2009, PROSTATE, V69, P1460, DOI 10.1002/pros.21008
   Richert MM, 2009, ONCOL REP, V21, P761, DOI 10.3892/or_00000282
   Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143
   Spano JP, 2004, ANN ONCOL, V15, P613, DOI 10.1093/annonc/mdh136
   Spoo AC, 2007, BLOOD, V109, P786, DOI 10.1182/blood-2006-05-024844
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693
   Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311
   Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
   Fetzer OS, 2011, Svenson Sinventors; Cerulean Pharma Inc., assignee. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods publication date. United States patent, Patent No. [US20120052097, 6794132, US6794132]
   [Anonymous], 2011, Clinical Trials.gov-NCT01374503, Patent No. [20120052097, US20120052097]
NR 37
TC 78
Z9 81
U1 0
U2 21
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 15
PY 2013
VL 19
IS 2
BP 357
EP 366
DI 10.1158/1078-0432.CCR-12-2333
PG 10
WC Oncology
SC Oncology
GA 073JN
UT WOS:000313739400007
PM 23213054
OA gold
DA 2018-01-05
ER

PT J
AU Sen, M
   Yolacan, B
   Guven, O
AF Sen, Murat
   Yolacan, Burcu
   Guven, Olgun
TI A comprehensive study on the size exclusion chromatography of
   kappa-carrageenan for the identification of after-peaks
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE size exclusion chromatography; kappa-carrageenan; after-peaks
ID MOLECULAR-WEIGHT CARRAGEENANS; RADIATION-INDUCED DEGRADATION; ANTI-HIV
   ACTIVITY; DEGRADED CARRAGEENAN; POLYSACCHARIDES
AB Aqueous size exclusion chromatography (SEC) of polysaccharides in general and carrageenans in particular is complicated by a number of factors. The chromatograms of carrageenans which are sulfated anionic natural polymers contain a number of after-peaks depending on the occlusion, adsorption, or association of various ionic species either naturally present or evolved during their processing. A systematic SEC analysis of after-peaks appearing in the chromatograms was made to identify the species responsible for their formation. The five after-peaks constantly appearing in the aqueous (0.1M NaNO3) SEC of kappa-carrageenan are attributed to sulfate, chloride, and nitrate anions whereas the first three and the fourth are due to divalent cations, mostly, and the fifth appears to result from the unknown impurities. (C) 2012 Wiley Periodicals, Inc. J. Appl. Polym. Sci., 2012
C1 [Sen, Murat; Yolacan, Burcu; Guven, Olgun] Hacettepe Univ, Dept Chem, TR-06800 Ankara, Turkey.
RP Sen, M (reprint author), Hacettepe Univ, Dept Chem, TR-06800 Ankara, Turkey.
EM msen@hacettepe.edu.tr
RI SEN, MURAT/G-9303-2013
FU Hacettepe University [02 G 105]; Academy of Sciences of Turkey;
   International Atomic Energy Agency [14475/R02]
FX The authors gratefully acknowledge the support provided by the Hacettepe
   University Research Funding through 02 G 105 Infrastructure Project. OG
   appreciates the support of the Academy of Sciences of Turkey and the
   International Atomic Energy Agency through Research Contract No.
   14475/R02.
CR Aranilla C. T., 1999, RADIAT PHYS CHEM, V55, P127
   DELAHUNTY T, 1987, FOOD CHEM TOXICOL, V25, P113, DOI 10.1016/0278-6915(87)90143-8
   Karlsson A, 1999, CARBOHYD POLYM, V38, P7, DOI 10.1016/S0144-8617(98)00085-X
   Knutsen SH, 2001, CARBOHYD RES, V331, P101, DOI 10.1016/S0008-6215(00)00324-4
   Kume T, 2002, RADIAT PHYS CHEM, V63, P625, DOI 10.1016/S0969-806X(01)00558-8                                                   
   Kurata M., 1989, POLYM HDB, pV11/22
   MARCUS AJ, 1989, J PHARM PHARMACOL, V41, P423, DOI 10.1111/j.2042-7158.1989.tb06493.x                                              
   Meunier V, 1999, MACROMOLECULES, V32, P2610, DOI 10.1021/ma981319v
   MORRIS ER, 1980, J MOL BIOL, V138, P349, DOI 10.1016/0022-2836(80)90291-0
   Nagasawa N, 2000, POLYM DEGRAD STABIL, V69, P279, DOI 10.1016/S0141-3910(00)00070-7                                                   
   PATIER P, 1995, PLANT SCI, V110, P27, DOI 10.1016/0168-9452(95)04182-T
   Relleve L, 2005, POLYM DEGRAD STABIL, V87, P403, DOI 10.1016/j.polymdegradstab.2004.09.003
   Sen M, 2007, NUCL INSTRUM METH B, V265, P429, DOI 10.1016/j.nimb.2007.09.033
   Smidsrod O., 1982, CARBOHYD POLYM, V2, P270
   Te Nijenhuis K., 1997, ADV POLYM SCI, V130, P203
   Tobacman JK, 2001, MED HYPOTHESES, V56, P589, DOI 10.1054/mehy.2000.1208
   Tobacman JK, 2001, ENVIRON HEALTH PERSP, V109, P983, DOI 10.2307/3454951
   Ueda K, 1998, MACROMOLECULES, V31, P675, DOI 10.1021/ma970846w
   Villanueva RD, 2004, FOOD HYDROCOLLOID, V18, P283, DOI 10.1016/S0268-005X(03)00084-5
   Lai Vivian M. F., 2000, FOOD CHEM, V68, P319
   Yamada T, 1997, CARBOHYD POLYM, V32, P51, DOI 10.1016/S0144-8617(96)00128-2
   Yamada T, 2000, CARBOHYD POLYM, V41, P115, DOI 10.1016/S0144-8617(99)00083-1                                                   
NR 22
TC 1
Z9 1
U1 1
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD JAN 5
PY 2013
VL 127
IS 1
BP 494
EP 499
DI 10.1002/app.37758
PG 6
WC Polymer Science
SC Polymer Science
GA 017MP
UT WOS:000309594400061
DA 2018-01-05
ER

PT J
AU Gao, GF
   Wieczorek, L
   Peachman, KK
   Polonis, VR
   Alving, CR
   Rao, M
   Rao, VB
AF Gao, Guofen
   Wieczorek, Lindsay
   Peachman, Kristina K.
   Polonis, Victoria R.
   Alving, Carl R.
   Rao, Mangala
   Rao, Venigalla B.
TI Designing a Soluble Near Full-length HIV-1 gp41 Trimer
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROXIMAL EXTERNAL REGION; BROADLY
   NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODY;
   TYPE-1 ENVELOPE; INTEGRIN ALPHA(4)BETA(7); CONFORMATIONAL-CHANGES;
   IMMUNODOMINANT DOMAIN; MEMBRANE-FUSION
AB The HIV-1 envelope spike is a trimer of heterodimers composed of an external glycoprotein gp120 and a transmembrane glycoprotein gp41. gp120 initiates virus entry by binding to host receptors, whereas gp41 mediates fusion between viral and host membranes. Although the basic pathway of HIV-1 entry has been extensively studied, the detailed mechanism is still poorly understood. Design of gp41 recombinants that mimic key intermediates is essential to elucidate the mechanism as well as to develop potent therapeutics and vaccines. Here, using molecular genetics and biochemical approaches, a series of hypotheses was tested to overcome the extreme hydrophobicity of HIV-1 gp41 and design a soluble near full-length gp41 trimer. The two long heptad repeat helices HR1 and HR2 of gp41 ectodomain were mutated to disrupt intramolecular HR1-HR2 interactions but not intermolecular HR1-HR1 interactions. This resulted in reduced aggregation and improved solubility. Attachment of a 27-amino acid foldon at the C terminus and slow refolding channeled gp41 into trimers. The trimers appear to be stabilized in a prehairpin-like structure, as evident from binding of a HR2 peptide to exposed HR1 grooves, lack of binding to hexa-helical bundle specific NC-1 mAb, and inhibition of virus neutralization by broadly neutralizing antibodies 2F5 and 4E10. Fusion to T4 small outer capsid protein, Soc, allowed display of gp41 trimers on the phage nanoparticle. These approaches for the first time led to the design of a soluble gp41 trimer containing both the fusion peptide and the cytoplasmic domain, providing insights into the mechanism of entry and development of gp41-based HIV-1 vaccines.
C1 [Gao, Guofen; Rao, Venigalla B.] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.
   [Wieczorek, Lindsay; Peachman, Kristina K.] Henry M Jackson Fdn Adv Mil Med, US Mil HIV Res Program, Silver Spring, MD 20910 USA.
   [Polonis, Victoria R.; Alving, Carl R.; Rao, Mangala] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.
RP Rao, VB (reprint author), Catholic Univ Amer, Dept Biol, 620 Michigan Ave NE, Washington, DC 20064 USA.
EM rao@cua.edu
OI Rao, Venigalla/0000-0002-0777-6587
FU National Institutes of Health [R01AI02725 (NIAID)]
FX This work was supported in part by National Institutes of Health Grant
   R01AI02725 (NIAID).
CR Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566
   Barbato G, 2003, J MOL BIOL, V330, P1101, DOI 10.1016/S0022-2836(03)00611-9
   Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bianchi E, 2010, P NATL ACAD SCI USA, V107, P10655, DOI 10.1073/pnas.1004261107
   Boutwell CL, 2010, J INFECT DIS, V202, pS309, DOI 10.1086/655653
   Brunel FM, 2006, J VIROL, V80, P1680, DOI 10.1128/JVI.80.4.1680-1687.2006
   Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Chakrabarti BK, 2011, J VIROL, V85, P8217, DOI 10.1128/JVI.00756-11
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004
   Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d
   Fokine A, 2004, P NATL ACAD SCI USA, V101, P6003, DOI 10.1073/pnas.0400444101
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815
   GNANN JW, 1987, J VIROL, V61, P2639
   Greenberg M, 2004, REV MED VIROL, V14, P321, DOI 10.1002/rmv.440
   Hager-Braun C, 2006, J IMMUNOL, V176, P7471, DOI 10.4049/jimmunol.176.12.7471                                                    
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4
   Jiang S, 1998, J VIROL, V72, P10213
   Kim M, 2007, VACCINE, V25, P5102, DOI 10.1016/j.vaccine.2006.09.071
   Kwong PD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007278
   Li Q, 2007, J MOL BIOL, V370, P1006, DOI 10.1016/j.jmb.2007.05.008
   Li Q, 2006, J MOL BIOL, V363, P577, DOI 10.1016/j.jmb.2006.08.049
   Lorizate M, 2006, J MOL BIOL, V360, P45, DOI 10.1016/j.jmb.2006.04.056
   Maltez Fernando, 2011, Curr Opin HIV AIDS, V6 Suppl 1, pS21, DOI 10.1097/01.COH.0000410238.80894.81
   Mascola JR, 1999, J VIROL, V73, P4009
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   MATHIESEN T, 1989, IMMUNOLOGY, V67, P1
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   Meadows DC, 2006, CHEMMEDCHEM, V1, P16, DOI 10.1002/cmdc.200500026
   Melchers M, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-48
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   MUSTER T, 1993, J VIROL, V67, P6642
   Nelson JK, 2008, IEEE T DIELECT EL IN, V15, P1, DOI 10.1109/T-DEI.2008.4446730                                                      
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Peachman KK, 2012, CLIN VACCINE IMMUNOL, V19, P11, DOI 10.1128/CVI.05376-11
   Pejchal R, 2010, CURR PHARM DESIGN, V16, P3744, DOI 10.2174/138161210794079173
   Phogat S, 2007, CURR PHARM DESIGN, V13, P213, DOI 10.2174/138161207779313632                                                      
   Polonis VR, 2008, VIROLOGY, V375, P315, DOI 10.1016/j.virol.2008.02.007
   Qin L, 2010, J MOL BIOL, V395, P728, DOI 10.1016/j.jmb.2009.10.007
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   ROBINSON WE, 1990, J VIROL, V64, P5301
   ROBINSON WE, 1991, J VIROL, V65, P4169
   Sathaliyawala T, 2006, J VIROL, V80, P7688, DOI 10.1128/JVI.00235-06
   Scholz C, 2005, J MOL BIOL, V345, P1229, DOI 10.1016/j.jmb.2004.10.091
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   Tsumoto K, 2004, BIOTECHNOL PROGR, V20, P1301, DOI 10.1021/bp0498793
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2010, CURR OPIN IMMUNOL, V22, P358, DOI 10.1016/j.coi.2010.02.012
   Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018233
   WANG JJG, 1986, P NATL ACAD SCI USA, V83, P6159, DOI 10.1073/pnas.83.16.6159
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 69
TC 10
Z9 10
U1 0
U2 44
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN 4
PY 2013
VL 288
IS 1
BP 234
EP 246
DI 10.1074/jbc.M112.424432
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 066CJ
UT WOS:000313197200023
PM 23184960
OA gold
DA 2018-01-05
ER

PT J
AU Raveendran, S
   Poulose, AC
   Yoshida, Y
   Maekawa, T
   Kumar, DS
AF Raveendran, Sreejith
   Poulose, Aby C.
   Yoshida, Yasuhiko
   Maekawa, Toru
   Kumar, D. Sakthi
TI Bacterial exopolysaccharide based nanoparticles for sustained drug
   delivery, cancer chemotherapy and bioimaging
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Mauran; Sustained release; Bacterial polysaccharides; Extremophiles;
   Chitosan; Cancer therapy and bioimaging; Halomonas
ID HALOMONAS-MAURA; SULFATED POLYSACCHARIDES; PARTICLES; CARRIERS; SYSTEMS;
   ACID; HIV; PH
AB introduction of a novel biocompatible, stable, biomaterial for drug delivery application remains always challenging. In the present study, we report the synthesis of an extremophilic bacterial sulfated polysaccharide based nanoparticle as a stable biocompatible material for drug delivery, evaluation of anticancer efficacy and bioimaging. Mauran (MR), the sulfated exopolysaccharide extracted from a moderately halophilic bacterium, Halomonas maura was used for the synthesis of nanoparticles along with chitosan (CH). MR/CH nanoparticles were synthesized by simple polyelectrolyte complexation of anionic MR and cationic CH. The MR/CH hybrid nanoparticles formed were ranging between 30 and 200 nm in diameter with an overall positive zeta potential of 27.5 +/- 5 mV and was found to be stable under storage in solution for at least 8 weeks. In vitro drug release studies showed a sustained and prolonged delivery of 5-fluorouracil (5FU) for 10-12 days from MR/CH nanoparticles under three different pHs of 4.5, 6.9 and 7.4 respectively. Cytotoxicity assay revealed that MR/CH nanoparticles were non-cytotoxic towards normal cells and toxic to cancer cells. Also, 5FU loaded MR/CH nanoparticles were found more effective than free 5FU in its sustained and controlled manner of killing breast adenocarcinoma cells. Fluorescein isothiocyanate (FITC) labeled MR/CH nanoparticles were used for cell binding and uptake studies; thereby demonstrating the application of dye tagged MR/CH nanoparticles for safe and nontoxic mode of live cellular imaging. We report the introduction of an extremophilic bacterial polysaccharide, MR, for the first time as a novel biocompatible and stable biomaterial to the world of nanotechnology, pharmaceutics and biomedical technology. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Raveendran, Sreejith; Poulose, Aby C.; Yoshida, Yasuhiko; Maekawa, Toru; Kumar, D. Sakthi] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
RP Kumar, DS (reprint author), Toyo Univ, Grad Sch Interdisciplinary New Sci, Bionano Elect Res Ctr, Kawagoe, Saitama 3508585, Japan.
EM sakthi@toyo.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT),
   Japan; programme of the strategic research foundation at private
   universities [S1101017]
FX Sreejith Raveendran and Aby C. Poulose would like to acknowledge their
   sincere gratitude to the Ministry of Education, Culture, Sports, Science
   and Technology (MEXT), Japan for the financial support under the
   Monbukagakusho fellowship during the research. Also, part of this study
   has been supported by a grant for the programme of the strategic
   research foundation at private universities S1101017, organized by the
   MEXT, Japan since April 2012.
CR Arad M. S., 2010, CURR OPIN BIOTECH, V21, P358
   Argandona M, 2005, FEMS MICROBIOL LETT, V244, P69, DOI 10.1016/j.femsle.2005.01.019
   Arias S, 2003, EXTREMOPHILES, V7, P319, DOI 10.1007/s00792-003-0325-8
   Bakkialakshmi S, 2011, J PHARM SCI RES, V3, P1326
   Bhumkar R. D., 2006, AAPS PHARMSCITECH, V7
   Bouchotroch S, 2001, INT J SYST EVOL MICR, V51, P1625, DOI 10.1099/00207713-51-5-1625                                                      
   Calvo C, 1998, J IND MICROBIOL BIOT, V20, P205, DOI 10.1038/sj.jim.2900513
   Cheng JJ, 2009, PROCESS BIOCHEM, V44, P453, DOI 10.1016/j.procbio.2008.12.012
   Dev A, 2010, CARBOHYD POLYM, V80, P833, DOI 10.1016/j.carbpol.2009.12.040
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017                                                             
   Dunne M, 2000, BIOMATERIALS, V21, P1659, DOI 10.1016/S0142-9612(00)00040-5
   Ge Y., 2006, NANOSCALE RES LETT, V4, P287
   Gomez-Ordonez E, 2011, FOOD HYDROCOLLOID, V25, P1514, DOI 10.1016/j.foodhyd.2011.02.009
   Grenha A, 2010, J BIOMED MATER RES A, V92A, P1265, DOI 10.1002/jbm.a.32466
   HOSOYA M, 1991, ANTIMICROB AGENTS CH, V35, P2515, DOI 10.1128/AAC.35.12.2515                                                          
   Huang LL, 2010, CARBOHYD POLYM, V80, P168, DOI 10.1016/j.carbpol.2009.11.007
   Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X                                                   
   Lin YH, 2009, BIOMATERIALS, V30, P3332, DOI 10.1016/j.biomaterials.2009.02.036
   Liu ZG, 2007, J BIOMED MATER RES A, V83A, P806, DOI 10.1002/jbm.a.31407
   Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001
   Llamas I, 2006, ANTON LEEUW INT J G, V89, P395, DOI 10.1007/s10482-005-9043-9
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   McCarron PA, 2000, J PHARM PHARMACOL, V52, P1451, DOI 10.1211/0022357001777658
   Nair K Lekha, 2011, Int J Nanomedicine, V6, P1685, DOI 10.2147/IJN.S20165
   Nichols CM, 2005, MICROB ECOL, V49, P578, DOI 10.1007/s00248-004-0093-8
   QUESADA E, 1990, INT J SYST BACTERIOL, V40, P261, DOI 10.1099/00207713-40-3-261                                                       
   Rougeaux H, 1996, CARBOHYD POLYM, V31, P237, DOI 10.1016/S0144-8617(96)00079-3
   Santo VE, 2010, J SUPERCRIT FLUID, V54, P320, DOI 10.1016/j.supflu.2010.05.021
   Sivabalan M, 2011, PHARM GLOBALE IJCP, V2, P1
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Toshihiko T., 2003, TRENDS GLYCOSCI GLYC, V15, P29
   Xu T, 2007, MAT SCI ENG C-BIO S, V27, P579, DOI 10.1016/j.msec.2006.05.029
NR 32
TC 23
Z9 25
U1 3
U2 97
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JAN 2
PY 2013
VL 91
IS 1
BP 22
EP 32
DI 10.1016/j.carbpol.2012.07.079
PG 11
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 026DH
UT WOS:000310253800004
PM 23044101
DA 2018-01-05
ER

PT J
AU Gidwani, M
   Singh, AV
AF Gidwani, Meeta
   Singh, Ajay V.
TI Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in
   vivo and in vitro Models, Opportunities and Challenges
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Nanoparticles; Blood Brain Barrier; polysorbate 80; TEER; Endothelial
   Cells
ID 80-COATED POLYBUTYLCYANOACRYLATE NANOPARTICLES; SOLID LIPID
   NANOPARTICLES; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES; CAPILLARY
   ENDOTHELIAL-CELLS; TREAT ALZHEIMERS-DISEASE; BOVINE SERUM-ALBUMIN;
   POLY(N-BUTYLCYANOACRYLATE) NANOPARTICLES; PHARMACOLOGICAL-ACTIVITY;
   ALLOY NANOPARTICLES; TARGETED DELIVERY
AB The blood brain barrier (BBB) maintains homeostasis by regulating the transport of chemicals at the brain interface. However, it is also one of the largest obstacles for drug delivery to the central nervous system (CNS). The utilization of nanoparticles as drug delivery vehicles is one potential solution to overcome this barrier. This review highlights the characteristics of the BBB that inhibit the passage of drugs to the brain, evaluates the efficiency of current in vitro models to mimic the BBB, and discusses the use of nanoparticles in both in vivo and in vitro models to enhance drug permeability across the barrier. In addition, this review describes factors that influence the passage of nanoparticles (type of polymers and surfactant coating, nanoparticle size) across the barrier. Protein opsonization and phagocytic activity of the reticuloendothelial system limits the amount of drug delivered to the brain, and this article summarizes methods to circumvent these issues. This paper also reviews literature covering opportunities and challenges provided with current applications of nanoparticle drug delivery systems for diseases of the brain, including cancer, HIV, and Alzheimer's disease.
C1 [Gidwani, Meeta; Singh, Ajay V.] Rensselaer Polytech Inst, Dept Biomed Engn, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12180 USA.
RP Singh, AV (reprint author), Rensselaer Polytech Inst, Dept Biomed Engn, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12180 USA.
EM singha8@rpi.edu
FU Biomedical Engineering department at Rensselaer Polytechnic Institute
   (RPI)
FX The authors gratefully acknowledge the Biomedical Engineering department
   at Rensselaer Polytechnic Institute (RPI) for financial support.
   Furthermore, we thank Dr. Ryan Gilbert for helpful discussions and
   technical assistance.
CR Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X
   Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098                                                         
   Angelova A, 2007, INT J PHARM, V344, P1, DOI 10.1016/j.ijpharm.2007.06.031
   ARMSTRONG BK, 1989, J CONTROL RELEASE, V10, P27, DOI 10.1016/0168-3659(89)90015-1
   Avadi MR, 2010, NANOMED-NANOTECHNOL, V6, P58, DOI 10.1016/j.nano.2009.04.007
   Bodzioch M, 1999, NAT GENET, V22, P347
   BORCHARD G, 1994, INT J PHARM, V110, P29, DOI 10.1016/0378-5173(94)90372-7                                                    
   BOWMAN PD, 1983, ANN NEUROL, V14, P396, DOI 10.1002/ana.410140403                                                           
   BROADWELL RD, 1982, SCIENCE, V217, P164, DOI 10.1126/science.7089551
   Brown RC, 2003, J CELL SCI, V116, P693, DOI 10.1242/jcs.00264
   BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243                                                  
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Champion JA, 2007, J CONTROL RELEASE, V121, P3, DOI 10.1016/j.jconrel.2007.03.022
   Chen ZJJ, 2004, FASEB J, V18, P1129, DOI 10.1096/fj.03-1490fje
   CHIUEH CC, 1978, BRAIN RES, V145, P291, DOI 10.1016/0006-8993(78)90863-6
   Cui ZR, 2005, EUR J PHARM BIOPHARM, V59, P263, DOI 10.1016/j.ejpb.2004.07.009
   Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3
   Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877
   DEHOUCK MP, 1990, J NEUROCHEM, V54, P1798, DOI 10.1111/j.1471-4159.1990.tb01236.x
   Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017
   Friden PM, 1997, J CONTROL RELEASE, V46, P117, DOI 10.1016/S0168-3659(96)01580-5
   Gaillard PJ, 2001, EUR J PHARM SCI, V12, P215, DOI 10.1016/S0928-0987(00)00123-8                                                   
   Gao KP, 2006, INT J PHARM, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040
   Gaumet M, 2008, EUR J PHARM BIOPHARM, V69, P1, DOI 10.1016/j.ejpb.2007.08.001
   Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70
   Gomes I, 2004, NEUROCHEM RES, V29, P441, DOI 10.1023/B:NERE.0000013749.65266.a2                                              
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Greene DL, 1996, J PHARMACOL EXP THER, V277, P1366
   GRIEB P, 1985, J APPL PHYSIOL, V58, P1929
   HANIG JP, 1972, EUR J PHARMACOL, V18, P79, DOI 10.1016/0014-2999(72)90134-3
   Hassan S, 2014, J NANOSCI NANOTECHNO, V14, P402, DOI 10.1166/jnn.2014.8747
   He PL, 2007, ANAL CHEM, V79, P8024, DOI 10.1021/ac070772e
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Jordan A, 1999, J MAGN MAGN MATER, V201, P413, DOI 10.1016/S0304-8853(99)00088-8
   KOBILER D, 1989, BRAIN RES, V496, P314, DOI 10.1016/0006-8993(89)91079-2
   Koffie RM, 2011, P NATL ACAD SCI USA, V108, P18837, DOI 10.1073/pnas.1111405108
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2014, J TAIWAN INST CHEM E, V45, P755, DOI 10.1016/j.jtice.2013.09.024
   Kuo YC, 2014, INT J PHARMACEUT, V465, P132, DOI 10.1016/j.ijpharm.2014.02.008
   Kwan P, 2005, EPILEPSIA, V46, P224, DOI 10.1111/j.0013-9580.2005.31904.x
   Kwok PCL, 2014, CURR PHARM DESIGN, V20, P474, DOI 10.2174/13816128113199990400                                                    
   LANGERMAN L, 1995, J PHARMACOL TOXICOL, V34, P23, DOI 10.1016/1056-8719(94)00077-H
   Li YP, 2001, J CONTROL RELEASE, V71, P287, DOI 10.1016/S0168-3659(01)00235-8
   Lippmann ES, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-2
   Liu HL, 2010, P NATL ACAD SCI USA, V107, P15205, DOI 10.1073/pnas.1003388107
   Liu Z, 2008, P NATL ACAD SCI USA, V105, P1410, DOI 10.1073/pnas.0707654105
   Lou H, 2007, ONCOGENE, V26, P1357, DOI 10.1038/sj.onc.1210200
   Mohamed M. S., 2013, BIOCHIM BIOPHYS ACTA, V1840, P1657
   Mykhaylyk O, 2001, J MAGN MAGN MATER, V225, P241, DOI 10.1016/S0304-8853(00)01264-6
   Nakagawa S, 2007, CELL MOL NEUROBIOL, V27, P687, DOI 10.1007/s10571-007-9195-4
   Nakagawa S, 2009, NEUROCHEM INT, V54, P253, DOI 10.1016/j.neuint.2008.12.002
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90
   PARDRIDGE WM, 1979, J CLIN INVEST, V64, P145, DOI 10.1172/JCI109433
   Perri re N., 2007, BRAIN RES, V1150, P1
   Pulfer SK, 1999, J NEURO-ONCOL, V41, P99, DOI 10.1023/A:1006137523591                                                         
   Ramge P, 2000, EUR J NEUROSCI, V12, P1931, DOI 10.1046/j.1460-9568.2000.00078.x
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Rousselle C, 2003, J PHARMACOL EXP THER, V306, P371, DOI 10.1124/jpet.102.048520
   Roux F, 2005, CELL MOL NEUROBIOL, V25, P41, DOI 10.1007/s10571-004-1376-9
   RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725
   Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699                                                               
   SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7
   Schroder U, 1996, BRAIN RES, V710, P121, DOI 10.1016/0006-8993(95)01375-X                                                    
   Schroeder U, 1998, J PHARM SCI, V87, P1305, DOI 10.1021/js980084y
   Schroeder U, 1998, PEPTIDES, V19, P777, DOI 10.1016/S0196-9781(97)00474-9
   Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002
   Shi ZL, 2006, BIOMATERIALS, V27, P2440, DOI 10.1016/j.biomaterials.2005.11.036
   Singh AV, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/47/475101
   Singh AV, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/11/115028
   Singh AV, 2009, COLLOID SURFACE B, V69, P239, DOI 10.1016/j.colsurfb.2008.11.021
   Singh AV, 2014, ACS NANO, V8, P2196, DOI 10.1021/nn405253d
   Singh AV, 2012, MATER DESIGN, V36, P829, DOI 10.1016/j.matdes.2011.01.061
   Singh AV, 2011, MAT SCI ENG C-MATER, V31, P892, DOI 10.1016/j.msec.2011.02.006
   Singh AV, 2010, CURR NANOSCI, V6, P577
   Singh AV, 2010, CURR NANOSCI, V6, P365
   Singh AV, 2013, J BIOMED MATER RES A, V101, P3019, DOI 10.1002/jbm.a.34586
   Singh AV, 2013, J BIOMED MATER RES A, V101, P2994, DOI 10.1002/jbm.a.34601
   Singh AV, 2005, J MATER CHEM, V15, P5115, DOI 10.1039/b510398c
   Singh A.V., 2012, AUTOIMMUNE DIS, V2012
   Singh A.V., 2010, J BIONANOSCI
   Sun WQ, 2004, BIOMATERIALS, V25, P3065, DOI 10.1016/j.biomaterials.2003.09.087
   Tamaru M, 2014, INT J PHARMACEUT, V465, P77, DOI 10.1016/j.ijpharm.2014.02.016
   Thode K, 1997, PHARMACEUT RES, V14, P905, DOI 10.1023/A:1012104017761
   Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015
   Urich E., 2013, SCI REP, V3
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Visser CC, 2005, EUR J PHARM SCI, V25, P299, DOI 10.1016/j.ejps.2005.03.008
   Voigt N., 2014, EUR J PHARM BIOPHARM
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Wang Q, 2005, INT J PHARMACEUT, V288, P349, DOI 10.1016/j.ijpharm.2004.10.007
   Wilson B, 2008, EUR J PHARM BIOPHARM, V70, P75, DOI 10.1016/j.ejpb.2008.03.009
   Wilson B, 2008, BRAIN RES, V1200, P159, DOI 10.1016/j.brainres.2008.01.039
   Wilson B, 2010, NANOMED-NANOTECHNOL, V6, P144, DOI 10.1016/j.nano.2009.04.001
   Yang SC, 1999, J CONTROL RELEASE, V59, P299, DOI 10.1016/S0168-3659(99)00007-3
   Zhang C, 2014, INT J PHARMACEUT, V461, P192, DOI 10.1016/j.ijpharm.2013.11.049
   Zhang Q, 2001, INT J PHARM, V218, P75, DOI 10.1016/S0378-5173(01)00614-7
NR 106
TC 10
Z9 10
U1 4
U2 31
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2013
VL 14
IS 14
BP 1201
EP 1212
PG 12
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AK5DI
UT WOS:000338444200008
DA 2018-01-05
ER

PT J
AU Hood, JL
   Jallouk, AP
   Campbell, N
   Ratner, L
   Wickline, SA
AF Hood, Joshua L.
   Jallouk, Andrew P.
   Campbell, Nancy
   Ratner, Lee
   Wickline, Samuel A.
TI Cytolytic nanoparticles attenuate HIV-1 infectivity
SO ANTIVIRAL THERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SOLUBLE CD4; IN-VIVO; MELITTIN;
   NEUTRALIZATION; CELLS; MICROBICIDE; SENSITIVITY; RESISTANCE; PEPTIDES
AB Background: We investigated whether cytolytic melittin peptides could inhibit HIV-1 infectivity when carried in a nanoparticle construct that might be used as a topical vaginal virucide. Free melittin and melittin-loaded nanoparticles were prepared and compared for cytotoxicity and their ability to inhibit infectivity by CXCR4 and CCR5 tropic HIV-1 strains.
   Methods: TZM-bl reporter cells expressing luciferase under the control of the HIV-1 promoter were incubated with HIV-1 NLHX (CXCR4) or HIV-1 NLYU2 (CCR5) viral strains and different doses of soluble CD4 (positive control) or free melittin to determine infectivity and viability. Melittin-loaded nanoparticles were formulated and different doses tested against VK2 vaginal epithelial cells to determine cell viability. Based on VK2 viability, melittin nanoparticles were tested for prevention of CXCR4 and CCR5 tropic HIV-1 infectivity and viability of TZM-bl reporter cells. Low-speed centrifugation was used to compare the ability of blank non-melittin nanoparticles and melittin nanoparticles to capture CCR5 tropic HIV-1.
   Results: As expected, the soluble CD4 positive control inhibited CXCR4 (50% inhibitory concentration [IC50] 3.7 mu g/ml) and CCR5 (IC50 0.03 mu g/ml) tropic HIV-1 infectivity. Free melittin doses < 2 mu M were not cytotoxic and were highly effective in reducing HIV-1 infectivity for both CXCR4 and CCR5 strains in TZM-bl reporter cells, while VK2 vaginal cell viability was adversely affected at all free melittin doses tested. However, VK2 cell viability was not affected at any dose of melittin-loaded nanoparticles. Melittin nanoparticles safely and significantly decreased CXCR4 (IC50 2.4 mu M and IC90 6.9 mu M) and CCR5 (IC50 3.6 mu M and IC90 11.4 mu M) strain infectivity of TZM-bl reporter cells. Furthermore, melittin nanoparticles captured more HIV-1 than blank nanoparticles.
   Conclusions: These data illustrate the first proof-of-concept for therapeutic and safe nanoparticle-mediated inhibition of HIV-1 infectivity. Future investigations appear warranted to explore the antiviral prophylactic potential of melittin nanoparticles to capture, disrupt and prevent initial infection with HIV-1 or potentially other enveloped viruses.
C1 [Hood, Joshua L.; Jallouk, Andrew P.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Med, Div Cardiol,Consortium Translat Res Adv Imaging &, St Louis, MO 63110 USA.
   [Campbell, Nancy; Ratner, Lee] Washington Univ, Sch Med, Dept Med, Div Oncol & Infect Dis, St Louis, MO 63110 USA.
RP Hood, JL (reprint author), Washington Univ, Sch Med, Dept Med, Div Cardiol,Consortium Translat Res Adv Imaging &, St Louis, MO 63110 USA.
EM jhood@dom.wustl.edu
OI Hood, Joshua/0000-0003-3998-4118
FU Bill & Melinda Gates Foundation Grand Challenges Explorations
   [OPP1024642]
FX This research was supported by the Bill & Melinda Gates Foundation Grand
   Challenges Explorations grant number OPP1024642 'Fusogenic nanoparticles
   for combined anti-HIV/contraception'. JLH and SAW devised the
   experiments, reviewed and interpreted experimental data, and wrote and
   edited the manuscript. APJ and NC performed experiments, and LR assisted
   in experimental protocol development, data review, interpretation of
   results and manuscript preparation.
CR Agrawal-Gamse C, 2009, J VIROL, V83, P11005, DOI 10.1128/JVI.01238-09
   ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056
   Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007
   DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574                                                         
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Dey B, 2003, J VIROL, V77, P2859, DOI 10.1128/JVI.77.5.2859-2865.2003
   ESSER AF, 1979, P NATL ACAD SCI USA, V76, P5843, DOI 10.1073/pnas.76.11.5843
   Harmon B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000956
   Hurt CB, 2011, CLIN INFECT DIS, V53, P1265, DOI 10.1093/cid/cir684
   KENNEDY PE, 1993, VIROLOGY, V192, P375, DOI 10.1006/viro.1993.1047
   KLEIN DH, 1992, BIOMAT ARTIF CELL IM, V20, P859, DOI 10.3109/10731199209119731                                                       
   Maher S, 2008, BIOCHEM PHARMACOL, V75, P1104, DOI 10.1016/j.bcp.2007.10.029
   ORLOFF SL, 1993, J VIROL, V67, P1461
   Owada T, 2001, J VIROL METHODS, V94, P15, DOI 10.1016/S0166-0934(01)00262-2
   Ownby CL, 1997, TOXICON, V35, P67, DOI 10.1016/S0041-0101(96)00078-5                                                   
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   SCHUTTEN M, 1995, SCAND J IMMUNOL, V41, P18, DOI 10.1111/j.1365-3083.1995.tb03528.x
   Shaposhnikova VV, 1997, FEBS LETT, V410, P285, DOI 10.1016/S0014-5793(97)00578-4
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   SULLIVAN N, 1995, J VIROL, V69, P4413
   Tu WC, 2008, TOXICON, V52, P318, DOI 10.1016/j.toxicon.2008.06.007
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731                                                      
   Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481
   WESTERVELT P, 1992, J VIROL, V66, P2577
NR 25
TC 44
Z9 47
U1 2
U2 58
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2013
VL 18
IS 1
BP 95
EP 103
DI 10.3851/IMP2346
PG 9
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 287XP
UT WOS:000329575900011
PM 22954649
DA 2018-01-05
ER

PT J
AU Drappier, C
   Oliveira, H
   Sandre, O
   Ibarboure, E
   Combet, S
   Garanger, E
   Lecommandoux, S
AF Drappier, Charlotte
   Oliveira, Hugo
   Sandre, Olivier
   Ibarboure, Emmanuel
   Combet, Sophie
   Garanger, Elisabeth
   Lecommandoux, Sebastien
TI Self-assembled core-shell micelles from peptide-b-polymer molecular
   chimeras towards structure-activity relationships
SO FARADAY DISCUSSIONS
LA English
DT Article
ID BLOCK-COPOLYMERS; CELLULAR UPTAKE; TAT PEPTIDE; HIV-1 TAT; SCATTERING;
   MECHANISM; DELIVERY; DESIGN; NANOPARTICLES; CYTOTOXICITY
AB The aim of this contribution is to design, produce and characterize size-tuneable core-shell micelles from amphiphilic Tat-b-poly(trimethylene carbonate) (Tat-b-PTMC) molecular chimeras, and to explore their biological properties. Because the extensive characterization of nanomaterials is a pre-requisite to understand and rationalize their ensuing properties, we present a detailed description of Tat-b-PTMC micelles thanks to light scattering, AFM imaging and small angle neutron scattering analyses. In vitro, Tat-b-PTMC micelles were found to be rapidly and efficiently internalized by HeLa cells, with cellular uptake kinetics being mostly related to Tat peptide content and, to a lesser extent, to nanoparticle size. We also demonstrated that, after a first membrane-binding step, Tat-b-PTMC micelles were taken up by cells via an energy-dependent endocytotic process.
C1 [Drappier, Charlotte; Oliveira, Hugo; Sandre, Olivier; Ibarboure, Emmanuel; Garanger, Elisabeth; Lecommandoux, Sebastien] Univ Bordeaux, ENSCBP, F-33607 Pessac, France.
   [Drappier, Charlotte; Oliveira, Hugo; Sandre, Olivier; Ibarboure, Emmanuel; Garanger, Elisabeth; Lecommandoux, Sebastien] CNRS, LCPO, UMR 5629, F-33607 Pessac, France.
   [Drappier, Charlotte; Garanger, Elisabeth] Inst Europeen Chim & Biol, F-33607 Pessac, France.
   [Combet, Sophie] CEA Saclay, CEA, CNRS, Lab Leon Brillouin,UMR 12, F-91191 Gif Sur Yvette, France.
RP Garanger, E (reprint author), Univ Bordeaux, ENSCBP, 16 Ave Pey Berland, F-33607 Pessac, France.
EM e.garanger@iecb.u-bordeaux.fr
OI Oliveira, Hugo/0000-0002-9715-8052; Lecommandoux,
   Sebastien/0000-0003-0465-8603
FU Aquitaine region council; CNRS; MENRT; CPER/FEDER
FX We particularly thank Alain Menelle from Laboratoire Leon Brillouin for
   providing us access to the PACE spectrometer during the annual training
   to neutron scattering techniques (Fan du LLB/Orphee). We are very
   grateful to Martin Teichmann from IECB for the access to his cell
   culture facility. We also greatly thank Julie Thevenot from LCPO for the
   synthesis of PEG-b-PTMC block copolymers, and Sabrina Rousseau from UMS
   3033 at IECB for her help with FACS experiments. Aquitaine region
   council, CNRS, MENRT and CPER/FEDER are gratefully acknowledged for
   financial support. We also thank the program RNP "Precision Polymers
   Materials" P2M from ESF.
CR Borner HG, 2009, PROG POLYM SCI, V34, P811, DOI 10.1016/j.progpolymsci.2009.05.001
   Brulet A, 2007, J APPL CRYSTALLOGR, V40, P165, DOI 10.1107/S0021889806051442
   Cai CH, 2011, CHEM COMMUN, V47, P11189, DOI 10.1039/c1cc12683k
   Carlsen A, 2009, CURR OPIN COLLOID IN, V14, P329, DOI 10.1016/j.cocis.2009.04.007
   Debaisieux S, 2012, TRAFFIC, V13, P355, DOI 10.1111/j.1600-0854.2011.01286.x
   Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972
   Drappier C, 2013, POLYM CHEM-UK, V4, P2011, DOI 10.1039/c2py21044d
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuks G, 2011, CHEM SOC REV, V40, P2475, DOI 10.1039/c0cs00085j
   Garanger E, 2012, ANGEW CHEM INT EDIT, V51, P3060, DOI 10.1002/anie.201107734
   Gauthier MA, 2008, CHEM COMMUN, P2591, DOI 10.1039/b719689j
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Jain S, 2003, SCIENCE, V300, P460, DOI 10.1126/science.1082193                                                         
   Kadlecova Z, 2012, BIOMACROMOLECULES, V13, P3127, DOI 10.1021/bm300930j
   Klok HA, 2009, MACROMOLECULES, V42, P7990, DOI 10.1021/ma901561t
   KUNZ D, 1983, COLLOID POLYM SCI, V261, P635, DOI 10.1007/BF01415033                                                              
   Lutz JF, 2008, PROG POLYM SCI, V33, P1, DOI 10.1016/j.progpolymsci.2007.07.005
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Marsden HR, 2009, MACROMOL BIOSCI, V9, P939, DOI 10.1002/mabi.200900057
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Moghimi SM, 2005, MOL THER, V11, P990, DOI 10.1016/j.mythe.2005.02.010
   Nederberg F, 2007, BIOMACROMOLECULES, V8, P153, DOI 10.1021/bm060795n
   Pedersen JS, 1997, ADV COLLOID INTERFAC, V70, P171, DOI 10.1016/S0001-8686(97)00312-6                                                   
   Reynhout IC, 2009, ACCOUNTS CHEM RES, V42, P681, DOI 10.1021/ar800143a
   Rodriguez-Hernandez J, 2005, PROG POLYM SCI, V30, P691, DOI 10.1016/j.progpolymsci.2005.04.002
   Rosler A, 2001, ADV DRUG DELIVER REV, V53, P95, DOI 10.1016/S0169-409X(01)00222-8
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Sanson C, 2010, LANGMUIR, V26, P2751, DOI 10.1021/la902786t
   Shi JJ, 2011, ACCOUNTS CHEM RES, V44, P1123, DOI 10.1021/ar200054n
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
NR 34
TC 8
Z9 8
U1 2
U2 21
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-6640
EI 1364-5498
J9 FARADAY DISCUSS
JI Faraday Discuss.
PY 2013
VL 166
BP 83
EP 100
DI 10.1039/c3fd00098b
PG 18
WC Chemistry, Physical
SC Chemistry
GA 284GW
UT WOS:000329305100005
PM 24611270
DA 2018-01-05
ER

PT S
AU Montenegro, C
   Leguizamon, A
   Quiroga, D
   Rojas, C
AF Montenegro, C.
   Leguizamon, A.
   Quiroga, D.
   Rojas, C.
GP IEEE
TI Design, simulation and characterization of microfluidic system for human
   immunodeficiency virus detection
SO 2013 PAN AMERICAN HEALTH CARE EXCHANGES (PAHCE)
SE Pan American Health Care Exchanges
LA Spanish
DT Proceedings Paper
CT 8th Pan American Health Care Exchanges Conference (PAHCE)
CY APR 29-MAY 04, 2013
CL Medellin, COLOMBIA
SP IEEE Morelos Mexico EMB Chapter, IEEE Colombia Sect, IEEE LA EMB Chapter, Univ Antioquia, Univ Pontificia Bolivariana, Escuela Ingn Antioquia, USM Materialise, EMCO, GBarco, Medinistros, AMAREY, Smart Management Choice, Colcafe, Revista Semana, Medellin Convent Bur
DE biotechnology; microfluidics; nanotechnology; simulation
AB Development of a specialized fluidic microsystem for HIV diagnosis from the reaction dependent of the affinity antigen-antibody. Based on knowledge about virus detection in laboratory, we pretend to decrease time spent to obtain results. In a first phase, this device will have a filtering zone, provided of small canals, causing that only specific cells could reach the next phase of membrane destruction for virus extraction; finally, specialized chemical sensors will react with these compounds, and it will show a colored signal to indicate diagnosis.
C1 [Montenegro, C.; Leguizamon, A.; Quiroga, D.] Univ Manuela Beltran, Grp Invest, Programa Ingn Biomed, Bogota, Colombia.
   [Rojas, C.] Univ Manuela Beltran, Ingn Biomed, Vicerrect Investigac, Bogota, Colombia.
RP Montenegro, C (reprint author), Univ Manuela Beltran, Grp Invest, Programa Ingn Biomed, Bogota, Colombia.
CR Alvarez Maria del Carmen Castilla, ATS SERVICIO GALLEGO, V2
   Biddle Margaret M., 2001, INTRO SAMS SELF ASSE, P1
   Bolufer Pascual, AUGE MICROFLUIDICA
   Buttgenbach S., 2011, DESING MANUFACTURING
   Valcarcel Cases M., 1988, TECNICAS ANALITICAS
   Chen X, 2008, SENSOR ACTUAT B-CHEM, V130, P216, DOI 10.1016/j.snb.2007.07.126
   Lapizco-Encinas BH, 2008, REV MEX ING QUIM, V7, P205
   Maltezos G, 2011, BIOMED MICRODEVICES, V13, P143, DOI 10.1007/s10544-010-9479-1
   Mohamed Gad-el-hak, 2001, MEMS HDB
   Pachon Jeronimo, INFECCION VIH GUIA P
   Pamme N, 2007, LAB CHIP, V7, P1644, DOI 10.1039/b712784g
   Bioing, TRANSDUCTORES SENSOR
NR 12
TC 0
Z9 0
U1 0
U2 3
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2327-8161
BN 978-1-4673-6257-3; 978-1-4673-6254-2
J9 PANAM HEALT CARE
PY 2013
PG 6
WC Medical Informatics
SC Medical Informatics
GA BJK67
UT WOS:000328694600087
DA 2018-01-05
ER

PT J
AU Bhatt, MA
   Messer, A
   Kordower, JH
AF Bhatt, Mansi A.
   Messer, Anne
   Kordower, Jeffrey H.
TI Can Intrabodies Serve as Neuroprotective Therapies for Parkinson's
   Disease? Beginning Thoughts
SO JOURNAL OF PARKINSONS DISEASE
LA English
DT Article
DE Alpha-synuclein; intrabodies; nanobodies; Parkinson's disease
ID ALPHA-SYNUCLEIN OLIGOMERS; AMYLOID FIBRIL FORMATION; ANTIBODY-BINDING
   SITES; A-BETA COMPONENT; IN-VITRO; HUNTINGTONS-DISEASE; MUTANT
   HUNTINGTIN; PRECURSOR PROTEIN; INDUCED TOXICITY; TRANSGENIC MICE
AB Misfolded proteins and subsequent protein aggregation appears to underlie a significant fraction of neurodegenerative diseases including Parkinson's disease. One of the neuropathological hallmarks of Parkinson's disease is the presence of alpha-syn containing intracellular inclusions known as Lewy bodies and Lewy neurites. Intrabodies are antibody fragments that have been engineered to be expressed intracellularly. They can be directed towards specific target antigens present in various subcellular locations, and have shown promise in cancer, HIV, autoimmune diseases, and Huntington's disease. More recently they have been shown to modulate abnormalities caused by aggregated alpha-syn in cell culture. This mini-review mainly focuses on summarizing structural and cellular effects of intrabodies shown to have affinity for different forms of alpha-synuclein (monomeric, oligomeric and fibrillar), as well as those exhibiting affinity for particular residues of alpha-synuclein (e.g., the NAC region, C terminal region).
C1 [Bhatt, Mansi A.] Dept Pharmacol, Chicago, IL USA.
   [Kordower, Jeffrey H.] Rush Univ, Med Ctr, Chicago, IL 60611 USA.
   [Messer, Anne] SUNY Albany, NY State Dept Hlth, Wadsworth Ctr, Albany, NY 12222 USA.
   [Messer, Anne] SUNY Albany, Dept Biomed Sci, Albany, NY USA.
   [Messer, Anne] Regenerat Res Fdn, Neural Stem Cell Inst, Rensselaer, NY USA.
RP Kordower, JH (reprint author), Rush Univ, Med Ctr, Dept Neurol Sci, 1735 West Harrison St, Chicago, IL 60611 USA.
EM Jeffrey_kordower@rush.edu
FU NINDS NIH HHS [R01 NS053912, R21 NS073415]
CR Barkhordarian H, 2006, PROTEIN ENG DES SEL, V19, P497, DOI 10.1093/protein/gzl036
   Bartels T, 2011, NATURE, V477, P107, DOI 10.1038/nature10324
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bezard E, 2011, MOVEMENT DISORD, V26, P993, DOI 10.1002/mds.23696
   Buell AK, 2010, J PHYS CHEM B, V114, P10925, DOI 10.1021/jp101579n
   Campbell BCV, 2000, NEUROBIOL DIS, V7, P192, DOI 10.1006/nbdi.2000.0286
   Chartier A, 2009, HUM MOL GENET, V18, P1849, DOI 10.1093/hmg/ddp101
   Chu YP, 2012, BRAIN, V135, P2058, DOI 10.1093/brain/aws133
   Chu YP, 2009, NEUROBIOL DIS, V35, P385, DOI 10.1016/j.nbd.2009.05.023
   Chu YP, 2006, J COMP NEUROL, V494, P495, DOI 10.1002/cne.20828
   Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7
   Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s
   Collier TJ, 2011, NAT REV NEUROSCI, V12, P359, DOI 10.1038/nrn3039
   Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311
   Cookson M.R., 2009, MOL NEURODEGENER, V4
   Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624
   Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599
   De Genst EJ, 2010, J MOL BIOL, V402, P326, DOI 10.1016/j.jmb.2010.07.001
   El-Agnaf OMA, 2006, FASEB J, V20, P419, DOI 10.1096/fj.03-1449com
   Ellisdon AM, 2007, J MOL BIOL, V368, P595, DOI 10.1016/j.jmb.2007.02.058
   Emadi S, 2007, J MOL BIOL, V368, P1132, DOI 10.1016/j.jmb.2007.02.089
   Emadi S, 2009, J BIOL CHEM, V284, P11048, DOI 10.1074/jbc.M806559200
   Eriksen JL, 2003, NEURON, V40, P453, DOI 10.1016/S0896-6273(03)00684-6
   Eslamboli A, 2007, BRAIN, V130, P799, DOI 10.1093/brain/awl382
   Fauvet B, 2012, J BIOL CHEM, V287, P15345, DOI 10.1074/jbc.M111.318949
   Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074                                                                
   FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283
   Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748
   Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619                                                         
   Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200                                                          
   Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564                                                                
   Greenbaum EA, 2005, J BIOL CHEM, V280, P7800, DOI 10.1074/jbc.M411638200
   GRIFFITHS AD, 1994, EMBO J, V13, P3245
   Groot AJ, 2008, CELL ONCOL, V30, P397, DOI 10.3233/CLO-2008-0442
   Guilliams T, 2013, J MOL BIOL, V425, P2397, DOI 10.1016/j.jmb.2013.01.040
   Habicht G, 2007, P NATL ACAD SCI USA, V104, P19232, DOI 10.1073/pnas.0703793104
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   Hoehn MM, 2001, NEUROLOGY, V57, pS11
   Hsu LJ, 1998, J NEUROCHEM, V71, P338
   Huston JS, 1996, ADV PROTEIN CHEM, V49, P329, DOI 10.1016/S0065-3233(08)60493-3
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879                                                         
   IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X                                                    
   Joshi SN, 2012, MABS-AUSTIN, V4, P686, DOI 10.4161/mabs.21696
   Kalia LV, 2013, ANN NEUROL, V73, P155, DOI 10.1002/ana.23746
   Kalia LV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014695
   Karpinar DP, 2009, EMBO J, V28, P3256, DOI 10.1038/emboj.2009.257
   Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799                                                          
   Knowles TPJ, 2007, P NATL ACAD SCI USA, V104, P10016, DOI 10.1073/pnas.0610659104
   Kourtis N, 2011, EMBO J, V30, P2520, DOI 10.1038/emboj.2011.162
   Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106
   Kvam E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005727
   Kwok JBJ, 2004, ANN NEUROL, V55, P329, DOI 10.1002/ana.10826
   Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0
   Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a                                                                 
   Lo A. S. -Y., 2008, V181, P343
   Lynch SM, 2008, J MOL BIOL, V377, P136, DOI 10.1016/j.jmb.2007.11.096
   Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199
   Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010                                                    
   Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265
   Messer A, 2013, NEUROTHERAPEUTICS, V10, P447, DOI 10.1007/s13311-013-0193-6
   Messer A, 2009, EXPERT OPIN BIOL TH, V9, P1189, DOI 10.1517/14712590903176387
   Miller TW, 2005, MOL THER, V12, P394, DOI 10.1016/j.ymthe.2005.04.003
   Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777
   Outeiro TF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001867
   Paxinou E, 2001, J NEUROSCI, V21, P8053
   Periquet M, 2007, J NEUROSCI, V27, P3338, DOI 10.1523/JNEUROSCI.0285-07.2007
   Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045                                                   
   Putcha P, 2010, J PHARMACOL EXP THER, V332, P849, DOI 10.1124/jpet.109.158436
   Roovers RC, 2007, CURR OPIN MOL THER, V9, P327
   Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0
   Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897                                                          
   Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278                                                         
   Snyder-Keller A, 2010, J NEUROPATH EXP NEUR, V69, P1078, DOI 10.1097/NEN.0b013e3181f530ec
   Southwell AL, 2009, J NEUROSCI, V29, P13589, DOI 10.1523/JNEUROSCI.4286-09.2009
   Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744
   Tetzlaff JE, 2008, J BIOL CHEM, V283, P17962, DOI 10.1074/jbc.M802283200
   Tsika E, 2010, J NEUROSCI, V30, P3409, DOI 10.1523/JNEUROSCI.4977-09.2010
   Tyedmers J, 2010, NAT REV MOL CELL BIO, V11, P777, DOI 10.1038/nrm2993
   Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200                                                          
   Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2
   Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j
   Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860
   Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364                                                        
   Wang CE, 2008, J CELL BIOL, V181, P803, DOI 10.1083/jcb.200710158
   Wang W, 2011, P NATL ACAD SCI USA, V108, P17797, DOI 10.1073/pnas.1113260108
   White DA, 2009, FEBS LETT, V583, P2587, DOI 10.1016/j.febslet.2009.06.008
   Winner B, 2011, P NATL ACAD SCI USA, V108, P4194, DOI 10.1073/pnas.1100976108
   Wolfgang WJ, 2005, P NATL ACAD SCI USA, V102, P11563, DOI 10.1073/pnas.0505321102
   Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795
   Zhou C, 2004, MOL THER, V10, P1023, DOI 10.1016/j.ymthe.2004.08.019
   Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0                                                   
   [Anonymous], 1984, LANCET, V1, P167
NR 95
TC 2
Z9 2
U1 0
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1877-7171
EI 1877-718X
J9 J PARKINSON DIS
JI J. Parkinsons Dis.
PY 2013
VL 3
IS 4
BP 581
EP 591
DI 10.3233/JPD-130252
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 270PY
UT WOS:000328332100011
PM 24270241
DA 2018-01-05
ER

PT J
AU Hitzbleck, M
   Delamarche, E
AF Hitzbleck, Martina
   Delamarche, Emmanuel
TI Reagents in microfluidics: an 'in' and 'out' challenge
SO CHEMICAL SOCIETY REVIEWS
LA English
DT Review
ID DIP-PEN NANOLITHOGRAPHY; HIGH-PERFORMANCE IMMUNOASSAYS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; ATOMIC-FORCE
   MICROSCOPY; DRUG-DELIVERY SYSTEMS; BIO-NANO-CHIP; CONTROLLED-RELEASE;
   HYDROGEL MICROPARTICLES; SAMPLE PREPARATION
AB Microfluidic devices are excellent at downscaling chemical and biochemical reactions and thereby can make reactions faster, better and more efficient. It is therefore understandable that we are seeing these devices being developed and used for many applications and research areas. However, microfluidic devices are more complex than test tubes or microtitre plates and the integration of reagents into them is a real challenge. This review looks at state-of-the-art methods and strategies for integrating various classes of reagents inside microfluidics and similarly surveys how reagents can be released inside microfluidics. The number of methods used for integrating and releasing reagents is surprisingly large and involves reagents in dry and liquid forms, directly-integrated reagents or reagents linked to carriers, as well as active, passive and hybrid release methods. We also made a brief excursion into the field of drug release and delivery. With this review, we hope to provide a large number of examples of integrating and releasing reagents that can be used by developers and users of microfluidics for their specific needs.
C1 [Hitzbleck, Martina; Delamarche, Emmanuel] IBM Res Zurich, CH-8803 Ruschlikon, Switzerland.
RP Delamarche, E (reprint author), IBM Res Zurich, Saumerstr 4, CH-8803 Ruschlikon, Switzerland.
EM emd@zurich.ibm.com
RI Delamarche, Emmanuel/G-6342-2013
OI Delamarche, Emmanuel/0000-0002-8753-8895
FU European Union [278720]
FX We thank our colleagues Robert Lovchik and Janick Stucki for their help,
   Michel Despont and Walter Riess for their continuous support, Prof.
   Janos Voros (ETHZ) and Govind Kaigala for discussions and advice on the
   manuscript. We are grateful to our partners within the EU project 'Chips
   for Life' (www.chips4life.eu) for discussions and providing insight into
   the manufacturing of diagnostic devices. We acknowledge funding from the
   European Union Seventh Framework Programme under grant agreement no.
   278720.
CR Abe K, 2010, ANAL BIOANAL CHEM, V398, P885, DOI 10.1007/s00216-010-4011-2
   Abi-Samra K, 2011, LAB CHIP, V11, P723, DOI 10.1039/c0lc00160k
   An HZ, 2012, ADV MATER, V24, P3838, DOI 10.1002/adma.201200214
   Andersson H, 2003, SENSOR ACTUAT B-CHEM, V92, P315, DOI 10.1016/S0925-4005(03)00266-1
   Appleyard DC, 2011, ANAL CHEM, V83, P193, DOI 10.1021/ac1022343
   Arrabito G, 2012, ANAL CHEM, V84, P5450, DOI 10.1021/ac300621z
   Austin J, 2011, METHODS MOL BIOL, V785, P379, DOI 10.1007/978-1-61779-286-1_25
   Azek F, 2000, ANAL BIOCHEM, V284, P107, DOI 10.1006/abio.2000.4692
   Bally M, 2010, LAB CHIP, V10, P372, DOI 10.1039/b916071j
   BASSOUS E, 1977, APPL PHYS LETT, V31, P135, DOI 10.1063/1.89587
   Beck M, 2012, LAB CHIP, V12, P167, DOI 10.1039/c1lc20565j
   Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474
   Bernard A, 1998, LANGMUIR, V14, P2225, DOI 10.1021/la980037l                                                               
   Biehl M, 2008, IEEE SENS J, V8, P593, DOI 10.1109/JSEN.2008.918919
   BioDot, 2013, ZX1010 PALTF
   Boden R, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/7/075036
   Bong KW, 2010, LANGMUIR, V26, P8008, DOI 10.1021/la904903g
   Capretto L, 2011, TOP CURR CHEM, V304, P27, DOI 10.1007/128_2011_150
   Carrilho E, 2009, ANAL CHEM, V81, P5990, DOI 10.1021/ac900847g
   Cederquist KB, 2010, WIRES NANOMED NANOBI, V2, P578, DOI 10.1002/wnan.96
   Chan EM, 2005, J AM CHEM SOC, V127, P13854, DOI 10.1021/ja051381p
   Chapin SC, 2011, ANAL CHEM, V83, P7179, DOI 10.1021/ac201618k
   Chen CF, 2009, LAB CHIP, V9, P3511, DOI 10.1039/b912014a
   Chen DF, 2010, BIOMED MICRODEVICES, V12, P705, DOI 10.1007/s10544-010-9423-4
   Chin CD, 2012, LAB CHIP, V12, P2118, DOI 10.1039/c2lc21204h
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Choi JW, 2002, LAB CHIP, V2, P27, DOI [10.1039/b107540n, 10.1039/b1077540n]
   Choi K, 2012, ANNU REV ANAL CHEM, V5, P413, DOI 10.1146/annurev-anchem-062011-143028
   Choi NW, 2012, ANAL CHEM, V84, P9370, DOI 10.1021/ac302128u
   Choi S, 2010, BIOMICROFLUIDICS, V4, DOI 10.1063/1.3486609
   Chronis N, 2007, NAT METHODS, V4, P727, DOI 10.1038/NMETH1075
   Crank J., 1980, MATH DIFFUSION
   de Lange V, 2011, ACS APPL MATER INTER, V3, P50, DOI 10.1021/am100849f
   Deegan RD, 1997, NATURE, V389, P827, DOI 10.1038/39827                                                                   
   Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779
   Delaney JT, 2009, SOFT MATTER, V5, P4866, DOI 10.1039/b909878j
   Delehanty James B, 2004, Methods Mol Biol, V264, P135
   Desbois L, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.4758460
   Di Risio S, 2007, MACROMOL RAPID COMM, V28, P1934, DOI 10.1002/marc.200700226
   Dimatrix, 2013, MAT PRINT DMP 2800
   Du N, 2011, BIOSENS BIOELECTRON, V28, P251, DOI 10.1016/j.bios.2011.07.027
   Du WB, 2009, LAB CHIP, V9, P2286, DOI 10.1039/b908978k
   DuBose A. J., 2013, NUCLEIC ACIDS RES, V1, P1
   Dudia A, 2008, NANO LETT, V8, P1105, DOI 10.1021/nl073211b
   Duncanson WJ, 2012, LAB CHIP, V12, P2135, DOI 10.1039/c2lc21164e
   Erickson D, 2004, ANAL CHIM ACTA, V507, P11, DOI 10.1016/j.aca.2003.09.019
   Eteshola E, 2001, SENSOR ACTUAT B-CHEM, V72, P129, DOI 10.1016/S0925-4005(00)00640-7
   Fan R, 2008, NAT BIOTECHNOL, V26, P1373, DOI 10.1038/nbt.1507
   Fiddes LK, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3687381
   Focke M, 2010, LAB CHIP, V10, P3210, DOI 10.1039/c0lc00161a
   Focke M, 2010, LAB CHIP, V10, P1365, DOI 10.1039/c001195a
   Foley J, 2005, LANGMUIR, V21, P11296, DOI 10.1021/la0518142
   FOLKMAN J, 1964, J Surg Res, V4, P139, DOI 10.1016/S0022-4804(64)80040-8
   Franzesi GT, 2006, J AM CHEM SOC, V128, P15064, DOI 10.1021/ja065867x
   Fridley GE, 2012, LAB CHIP, V12, P4321, DOI 10.1039/c2lc40785j
   Fu E, 2011, ANAL CHEM, V83, P7941, DOI 10.1021/ac201950g
   Fu E, 2010, LAB CHIP, V10, P918, DOI 10.1039/b919614e
   Fujie T, 2012, BIOMED MICRODEVICES, V14, P1069, DOI 10.1007/s10544-012-9698-8
   Gao YL, 2005, ANAL CHIM ACTA, V543, P109, DOI 10.1016/j.aca.2005.04.032
   Garcia E, 2004, LAB CHIP, V4, P78, DOI 10.1039/b308914b
   Gervais L, 2011, ADV MATER, V23, pH151, DOI 10.1002/adma.201100464
   Gervais L, 2009, LAB CHIP, V9, P3330, DOI 10.1039/b906523g
   GeSiM, 2013, NAN
   GeSiM, 2013, MICR PRINT
   Gielen F, 2010, ANAL CHEM, V82, P7509, DOI 10.1021/ac101557g
   Gijs MAM, 2004, MICROFLUID NANOFLUID, V1, P22, DOI 10.1007/s10404-004-0010-y
   Gijs MAM, 2010, CHEM REV, V110, P1518, DOI 10.1021/cr9001929
   Govindarajan AV, 2012, LAB CHIP, V12, P174, DOI 10.1039/c1lc20622b
   Gunther A, 2006, LAB CHIP, V6, P1487, DOI 10.1039/b609851g
   Gupta P, 2002, DRUG DISCOV TODAY, V7, P569, DOI 10.1016/S1359-6446(02)02255-9
   Haaheim J, 2008, SCANNING, V30, P137, DOI 10.1002/sca.20098
   Haeberle S, 2007, LAB CHIP, V7, P1094, DOI 10.1039/b706364b
   HamiltonRobotics, 2013, NIMBUS LIQ HANDL WOR
   HARLAND RS, 1988, PHARMACEUT RES, V5, P488, DOI 10.1023/A:1015913207052                                                         
   Heij B., 2003, SENSOR ACTUAT A-PHYS, V103, P88
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hitzbleck M, 2013, ADV MATER, V25, P2672, DOI 10.1002/adma.201204854
   Hitzbleck M, 2013, MICROMACHINES-BASEL, V4, P1, DOI 10.3390/mi4010001
   Hitzbleck M, 2012, LAB CHIP, V12, P1972, DOI 10.1039/c2lc00015f
   Hitzbleck M, 2011, LAB CHIP, V11, P2680, DOI 10.1039/c1lc20282k
   Hoffmann J, 2010, LAB CHIP, V10, P1480, DOI 10.1039/b926139g
   Horak D, 2013, J BIOMED MATER RES A, V101, P23, DOI 10.1002/jbm.a.34297
   Hossain SMZ, 2009, ANAL CHEM, V81, P5474, DOI 10.1021/ac900660p
   Hu M, 2007, J MICROELECTROMECH S, V16, P786, DOI 10.1109/JMEMS.2007.892911
   Huang PL, 2012, IEEE T IND ELECTRON, V59, P1578, DOI 10.1109/TIE.2011.2160135
   Ikami M, 2010, LAB CHIP, V10, P3335, DOI [10.1039/c0lc00241k, 10.1039/c01c00241k]
   Iverson BD, 2008, MICROFLUID NANOFLUID, V5, P145, DOI 10.1007/s10404-008-0266-8
   Jang MJ, 2012, BIOCHIP J, V6, P107, DOI 10.1007/s13206-012-6201-9
   Jia GY, 2007, COLLOID SURFACE B, V58, P52, DOI 10.1016/j.colsurfb.2007.03.007
   Jokerst JV, 2011, SMALL, V7, P613, DOI 10.1002/smll.201002089
   Juncker D, 2005, NAT MATER, V4, P622, DOI 10.1038/nmat1435
   Juncker D, 2002, ANAL CHEM, V74, P6139, DOI 10.1021/ac0261449
   Kaigala GV, 2011, LANGMUIR, V27, P5686, DOI 10.1021/la2003639
   Kim D, 2007, LAB CHIP, V7, P193, DOI 10.1039/b612995a
   Kim J, 2009, LAB CHIP, V9, P606, DOI 10.1039/b807915c
   Kirk JT, 2011, LAB CHIP, V11, P1372, DOI 10.1039/c0lc00313a
   Koga H, 2012, J MATER CHEM, V22, P11591, DOI 10.1039/c2jm30759f
   Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046
   KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628                                                                
   Kusnezow W, 2006, MOL CELL PROTEOMICS, V5, P1681, DOI 10.1074/mcp.T500035-MCP200
   LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0
   Lee BS, 2009, LAB CHIP, V9, P1548, DOI 10.1039/b820321k
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Lenhert S, 2007, SMALL, V3, P71, DOI 10.1002/smll.200600431
   Li HY, 2011, LAB CHIP, V11, P528, DOI [10.1039/c0lc00291g, 10.1039/c01c00291g]
   Li MS, 2012, ANGEW CHEM INT EDIT, V51, P5497, DOI 10.1002/anie.201201822
   Li X., 2006, DESIGN CONTROLLED RE
   Li X, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3687398
   Lim CT, 2007, BIOSENS BIOELECTRON, V22, P1197, DOI 10.1016/j.bios.2006.06.005
   Lim JA, 2008, ADV FUNCT MATER, V18, P229, DOI 10.1002/adfm.200700859
   Lin CH, 2004, ELECTROPHORESIS, V25, P4058, DOI 10.1002/elps.200406172
   Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x
   Liu CC, 2009, LAB CHIP, V9, P768, DOI 10.1039/b814322f
   Liu RH, 2004, SENSOR ACTUAT B-CHEM, V98, P328, DOI 10.1016/j.snb.2003.09.037
   Liu WS, 2010, ANAL CHEM, V82, P3276, DOI 10.1021/ac100044c
   Liu YJ, 2003, ANAL BIOCHEM, V317, P76, DOI 10.1016/S0003-2697(03)00051-4
   Lovchik RD, 2009, J MICROMECH MICROENG, V19, DOI 10.1088/0960-1317/19/11/115006
   Luk VN, 2012, PROTEOMICS, V12, P1310, DOI 10.1002/pmic.201100608
   Luo YQ, 2008, LAB CHIP, V8, P694, DOI 10.1039/b800606g
   MacBeath G, 2000, SCIENCE, V289, P1760
   Malaquin L, 2007, LANGMUIR, V23, P11513, DOI 10.1021/la700852c
   Mandal S, 2009, LAB CHIP, V9, P2924, DOI 10.1039/b907826f
   MANZ A, 1990, SENSOR ACTUAT B-CHEM, V1, P244, DOI 10.1016/0925-4005(90)80209-I                                                    
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Martinez AW, 2008, LAB CHIP, V8, P2146, DOI 10.1039/b811135a
   McKenzie KG, 2009, LAB CHIP, V9, P3543, DOI 10.1039/b913806d
   Meister A, 2009, NANO LETT, V9, P2501, DOI 10.1021/nl901384x
   Microfluidic ChipShop, 2010, LAB ON A CHIP CAT
   microdrop Technologies GmbH, 2013, DISP HEADS
   Millipore, 2008, RAP LAT FLOW TEST ST
   Moerman R, 2001, ANAL CHEM, V73, P2183, DOI 10.1021/ac001041g
   Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031
   Ng J. K. K., 2011, BIOSENSORS HLTH ENV
   Ng JK, 2008, BIOSENS BIOELECTRON, V23, P803, DOI 10.1016/j.bios.2007.08.026
   Ngom B, 2010, ANAL BIOANAL CHEM, V397, P1113, DOI 10.1007/s00216-010-3661-4
   Nie ZH, 2010, LAB CHIP, V10, P3163, DOI [10.1039/c0lc00237b, 10.1039/c01c00237b]
   Nilsson J, 2009, ANAL CHIM ACTA, V649, P141, DOI 10.1016/j.aca.2009.07.017
   Nosworthy NJ, 2009, BIOMACROMOLECULES, V10, P2577, DOI 10.1021/bm900523m
   Oh KW, 2006, J MICROMECH MICROENG, V16, pR13, DOI 10.1088/0960-1317/16/5/R01
   Park JM, 2007, LAB CHIP, V7, P557, DOI 10.1039/b616112
   Park S, 2012, SENSORS-BASEL, V12, P8426, DOI 10.3390/s120608426
   Pelton R, 2009, TRAC-TREND ANAL CHEM, V28, P925, DOI 10.1016/j.trac.2009.05.005
   PEPPAS NA, 1983, J BIOMED MATER RES, V17, P1079, DOI 10.1002/jbm.820170615
   Pernodet N, 1997, ELECTROPHORESIS, V18, P55, DOI 10.1002/elps.1150180111                                                         
   Phillips CO, 2012, LANGMUIR, V28, P9878, DOI 10.1021/la300867m
   Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661
   Plieva FM, 2008, IND ENG CHEM RES, V47, P4131, DOI 10.1021/ie071406o
   Pregibon DC, 2007, SCIENCE, V315, P1393, DOI 10.1126/science.1134929
   Prescott JH, 2006, NAT BIOTECHNOL, V24, P437, DOI 10.1038/nbt1199
   N. Products, 2000, NAT BIOTECHNOL, V18, P110
   Qiu XB, 2011, BIOMED MICRODEVICES, V13, P809, DOI 10.1007/s10544-011-9551-5
   Rahimi S, 2011, BIOMED MICRODEVICES, V13, P267, DOI 10.1007/s10544-010-9491-5
   Raj J, 2009, BIOSENS BIOELECTRON, V24, P2654, DOI 10.1016/j.bios.2009.01.026
   Ramachandran S., 2006, DISTR DIAGN HOM HEAL, P16
   Ramadan Q, 2013, LAB CHIP, V13, P196, DOI 10.1039/c2lc40845g
   Ren L, 2012, BIOSENS BIOELECTRON, V35, P147, DOI 10.1016/j.bios.2012.02.034
   Riegger L, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/4/045021
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Roper MG, 2005, ANAL CHEM, V77, P3887, DOI 10.1021/ac050756m
   Rupcich N, 2003, CHEM MATER, V15, P1803, DOI 10.1021/cm030028k
   Ryoo HI, 2011, LAB CHIP, V11, P378, DOI 10.1039/c0lc00448k
   Salaita K, 2007, NAT NANOTECHNOL, V2, P145, DOI 10.1038/nnano.2007.39
   Saliba AE, 2010, P NATL ACAD SCI USA, V107, P14524, DOI 10.1073/pnas.1001515107
   Santini JT, 1999, NATURE, V397, P335
   Satarkar NS, 2008, J CONTROL RELEASE, V130, P246, DOI 10.1016/j.jconrel.2008.06.008
   Schumacher S, 2012, LAB CHIP, V12, P464, DOI 10.1039/c1lc20693a
   Sedgwick H, 2008, J R SOC INTERFACE, V5, pS123, DOI [10.1098/rsif.2008.0169.focus, 10.1098/rsif.2008.0169]
   Shim WB, 2006, J AGR FOOD CHEM, V54, P9728, DOI 10.1021/jf0620057
   Shin YH, 2010, ANGEW CHEM INT EDIT, V49, P9689, DOI 10.1002/anie.201004654
   Shoffner MA, 1996, NUCLEIC ACIDS RES, V24, P375, DOI 10.1093/nar/24.2.375
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0                                                   
   Singh M, 2010, ADV MATER, V22, P673, DOI 10.1002/adma.200901141
   Sista R, 2008, LAB CHIP, V8, P2091, DOI 10.1039/b814922d
   Sithigorngul P, 2007, J MICROBIOL METH, V71, P256, DOI 10.1016/j.mimet.2007.09.012
   Sivagnanam V, 2009, MICROELECTRON ENG, V86, P1404, DOI 10.1016/j.mee.2008.11.087
   Soppimath KS, 2002, DRUG DEV IND PHARM, V28, P957, DOI 10.1081/DDC-120006428
   Soussan E, 2009, ANGEW CHEM INT EDIT, V48, P274, DOI 10.1002/anie.200802453
   Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977                                                       
   Srinivas RL, 2011, ANAL CHEM, V83, P9138, DOI 10.1021/ac202335u
   Staples M, 2010, WIRES NANOMED NANOBI, V2, P400, DOI 10.1002/wnan.93
   Steinert CP, 2009, BIOMED MICRODEVICES, V11, P755, DOI 10.1007/s10544-009-9289-5
   Stevens DY, 2008, LAB CHIP, V8, P2038, DOI 10.1039/b811158h
   Stevenson CL, 2012, ADV DRUG DELIVER REV, V64, P1590, DOI 10.1016/j.addr.2012.02.005
   Stiefel P, 2012, NANO LETT, V12, P4219, DOI 10.1021/nl3018109
   Stucki J., 2012, P MICROTAS C, P1927
   Tan JL, 2002, LANGMUIR, V18, P519, DOI 10.1021/la011351+
   Tan SN, 2010, ANAL CHEM, V82, P8844, DOI 10.1021/ac1015062
   Tan WH, 2007, P NATL ACAD SCI USA, V104, P1146, DOI 10.1073/pnas.0606625104
   Tecan, 2013, HP D300 DIG DISP
   TERRY SC, 1979, IEEE T ELECTRON DEV, V26, P1880, DOI 10.1109/T-ED.1979.19791
   Thermo Scientific, 2013, CV2000 AUT LIQ HANDL
   Thermo Scientific, 2013, HYDR DT PIP WORKST
   Thoma K, 1999, EUR J PHARM BIOPHARM, V47, P39, DOI 10.1016/S0939-6411(98)00086-1
   Thompson JA, 2010, J CHROMATOGR B, V878, P228, DOI 10.1016/j.jchromb.2009.08.050
   Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163
   Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996
   TOVEY ER, 1989, J BIOCHEM BIOPH METH, V19, P169, DOI 10.1016/0165-022X(89)90024-9
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u                                                               
   Verch T, 2012, BIOANALYSIS, V4, P177, DOI [10.4155/bio.11.301, 10.4155/BIO.11.301]
   Verpoorte E, 2003, LAB CHIP, V3, p60N, DOI 10.1039/b313217j
   Vilkner T, 2004, ANAL CHEM, V76, P3373, DOI 10.1021/ac040063q
   von Muhlen MG, 2010, ANAL CHEM, V82, P1905, DOI 10.1021/ac9027356
   Vreeland WN, 2003, ANAL CHEM, V75, P6906, DOI 10.1021/ac034850j
   Wang CH, 2011, LAB CHIP, V11, P1521, DOI 10.1039/c0lc00430h
   Wang GF, 2010, ANNU REV ANAL CHEM, V3, P387, DOI 10.1146/annurev.anchem.111808.073644
   Wang J, 2000, NUCLEIC ACIDS RES, V28, P3011, DOI 10.1093/nar/28.16.3011
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Weibel DB, 2006, CURR OPIN CHEM BIOL, V10, P584, DOI 10.1016/j.cbpa.2006.10.016
   Weigl B, 2008, LAB CHIP, V8, P1999, DOI 10.1039/b811314a
   Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346                                                    
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   WHO, 2008, ACC QUAL ASS DIAGN
   Wise D. L., 2000, HDB PHARM CONTROLLED
   Wong RC, 2009, LATERAL FLOW IMMUNOASSAY, P1, DOI 10.1007/978-1-59745-240-3
   Wu CC, 2011, SMALL, V7, P989, DOI 10.1002/smll.201001749
   Xia H. M., 2010, SIMTECH TECH REP, V11, P228
   Xia H, 2012, BIOMED MICRODEVICES, V14, P67, DOI 10.1007/s10544-011-9586-7
   Xu GL, 2010, LAB CHIP, V10, P3103, DOI 10.1039/c005265e
   Xu H, 2009, ANAL CHEM, V81, P669, DOI 10.1021/ac8020592
   Xu J, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/6/065020
   Xu ZR, 2008, LAB CHIP, V8, P1658, DOI 10.1039/b805774e
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yamada M, 2004, ANAL CHEM, V76, P895, DOI 10.1021/ac0350007
   Yobas L, 2009, BIOMED MICRODEVICES, V11, P1279, DOI 10.1007/s10544-009-9347-z
   Zeta Corporation, 2013, LAT FLOW
   Zhang CS, 2007, BIOTECHNOL ADV, V25, P483, DOI 10.1016/j.biotechadv.2007.05.003
   Zhang R, 2008, CHEM COMMUN, P1317, DOI 10.1039/b717932d
   Zhang W, 2011, J COLLOID INTERF SCI, V353, P143, DOI 10.1016/j.jcis.2010.09.029
   Zheng CH, 2012, LAB CHIP, V12, P2487, DOI [10.1039/c2lc40145b, 10.1039/c21c40145b]
   Zhou GN, 2012, ANAL CHEM, V84, P7736, DOI 10.1021/ac301082d
   Ziegler J, 2008, ANAL CHEM, V80, P1763, DOI 10.1021/ac702160x
   Zimmermann M, 2009, BIOMED MICRODEVICES, V11, P1, DOI 10.1007/s10544-008-9187-2
   Zubtsov DA, 2007, ANAL BIOCHEM, V368, P205, DOI 10.1016/j.ab.2007.04.040
   May K., 1997, <IT>US Pat</IT>., Patent No. [US5622871, 5622871]
   Campbell R. L., 1987, <IT>US Pat.</IT>, Patent No. [US4703017, 4703017]
   Rosenstein R. W., 1989, <IT>US Pat</IT>., Patent No. [US4855240, 4855240]
NR 237
TC 39
Z9 40
U1 6
U2 132
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0306-0012
EI 1460-4744
J9 CHEM SOC REV
JI Chem. Soc. Rev.
PY 2013
VL 42
IS 21
BP 8494
EP 8516
DI 10.1039/c3cs60118h
PG 23
WC Chemistry, Multidisciplinary
SC Chemistry
GA 232JK
UT WOS:000325489600013
PM 23925517
DA 2018-01-05
ER

PT J
AU Xiang, DX
   Zheng, Y
   Duan, W
   Li, X
   Yin, JJ
   Shigdar, S
   O'Connor, ML
   Marappan, M
   Zhao, XJ
   Miao, YQ
   Xiang, B
   Zheng, CL
AF Xiang, Dongxi
   Zheng, Yang
   Duan, Wei
   Li, Xiujing
   Yin, Jianjian
   Shigdar, Sarah
   O'Connor, Michael Liam
   Marappan, Manju
   Zhao, Xiaojuan
   Miao, Yingqiu
   Xiang, Bin
   Zheng, Conglong
TI Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by
   silver nanoparticles in vitro and in vivo
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE silver nanoparticles; influenza virus; H3N2; antiviral activity
ID HEMAGGLUTININ; H1N1; EXPERIENCE; ENVELOPE; PROTEIN; MICE
AB Silver nanoparticles (AgNPs) have attracted much attention as antimicrobial agents and have demonstrated efficient inhibitory activity against various viruses, including human immunodeficiency virus, hepatitis B virus, and Tacaribe virus. In this study, we investigated if AgNPs could have antiviral and preventive effects in A/Human/Hubei/3/2005 (H3N2) influenza virus infection. Madin-Darby canine kidney cells infected with AgNP-treated H3N2 influenza virus showed better viability (P, 0.05 versus influenza virus control) and no obvious cytopathic effects compared with an influenza virus control group and a group treated with the solvent used for preparation of the AgNPs. Hemagglutination assay indicated that AgNPs could significantly inhibit growth of the influenza virus in Madin-Darby canine kidney cells (P< 0.01 versus the influenza virus control). AgNPs significantly reduced cell apoptosis induced by H3N2 influenza virus at three different treatment pathways (P<0.05 versus influenza virus control). H3N2 influenza viruses treated with AgNPs were analyzed by transmission electron microscopy and found to interact with each other, resulting in destruction of morphologic viral structures in a time-dependent manner in a time range of 30 minutes to 2 hours. In addition, intranasal AgNP administration in mice significantly enhanced survival after infection with the H3N2 influenza virus. Mice treated with AgNPs showed lower lung viral titer levels and minor pathologic lesions in lung tissue, and had a marked survival benefit during secondary intranasal passage in vivo. These results provide evidence that AgNPs have beneficial effects in preventing H3N2 influenza virus infection both in vitro and in vivo, and demonstrate that AgNPs can be used as potential therapeutics for inhibiting outbreaks of influenza.
C1 [Xiang, Dongxi; Duan, Wei; Shigdar, Sarah; O'Connor, Michael Liam; Marappan, Manju] Deakin Univ, Sch Med, Waurn Ponds, Vic 3217, Australia.
   [Zheng, Yang] Osaka Univ, Dept Pharmacol, Osaka, Japan.
   [Li, Xiujing; Yin, Jianjian; Miao, Yingqiu; Zheng, Conglong] Dalian Univ, Coll Med, Dept Biol, Dalian 116012, Liaoning, Peoples R China.
   [Zhao, Xiaojuan] Qingdao Cent Hosp, Dept Obstet & Gynecol, Qingdao, Shandong, Peoples R China.
   [Xiang, Bin] Dalian Univ, Coll Med, Dept Oral Med, Dalian 116012, Liaoning, Peoples R China.
   [Xiang, Bin] Dalian Univ, Coll Med, Med Res Ctr, Dalian 116012, Liaoning, Peoples R China.
RP Xiang, DX (reprint author), Deakin Univ, Sch Med, Waurn Ponds, Vic 3217, Australia.
EM dxiang@deakin.edu.au
RI Duan, Wei/A-5181-2015
OI Duan, Wei/0000-0001-5782-9184
FU National Natural Science Foundation of China [30870681]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (30870681). We thank Professor Xu-lin Chen (Wuhan
   Institute of Virology, Chinese Academy of Sciences) for kindly providing
   the A/Human/Hubei/3/2005 (H3N2) influenza virus used in this work.
CR Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Boni MF, 2006, P R SOC B, V273, P1307, DOI 10.1098/rspb.2006.3466
   BRADLEY DE, 1962, J GEN MICROBIOL, V29, P503, DOI 10.1099/00221287-29-3-503                                                       
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0                                                                
   DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583                                                              
   ECKERT EA, 1967, SCIENCE, V158, P527, DOI 10.1126/science.158.3800.527-b
   ECKERT EDWARD A., 1967, J VIROL, V1, P920
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Haidari M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021444
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Li HD, 2013, EUR J APPL PHYSIOL, V113, P1555, DOI 10.1007/s00421-012-2584-5
   Li WY, 2011, ARCH VIROL, V156, P1979, DOI 10.1007/s00705-011-1087-8
   Li Y, 2006, J HOSP INFECT, V62, P58, DOI 10.1016/i.jhin.2005.04.015
   Lu L, 2008, ANTIVIR THER, V13, P253
   Lynch JP, 2007, SEMIN RESP CRIT CARE, V28, P144, DOI 10.1055/s-2007-976487
   Mori Y, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-93
   Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157
   Peyre M, 2009, EPIDEMIOL INFECT, V137, P1, DOI 10.1017/S0950268808001039
   Poland GA, 2009, CLIN INFECT DIS, V48, P1254, DOI 10.1086/598989
   Radyukhin V, 2008, ARCH VIROL, V153, P1977, DOI 10.1007/s00705-008-0214-7
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347
   Tharakaraman K, 2013, SCI REP-UK, V3, DOI 10.1038/srep01822
   Trefry JC, 2013, J BIOMED NANOTECHNOL, V9, P1624, DOI 10.1166/jbn.2013.1659
   Tyler WJ, 2007, J NEUROSCI, V27, P9427, DOI 10.1523/JNEUROSCI.0664-07.2007
   WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0
   Wilson JC, 2003, CURR DRUG TARGETS, V4, P389, DOI 10.2174/1389450033491019
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Yoo DG, 2012, J MED FOOD, V15, P855, DOI 10.1089/jmf.2012.0017
NR 30
TC 28
Z9 30
U1 1
U2 26
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 4103
EP 4113
DI 10.2147/IJN.S53622
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 244KB
UT WOS:000326385900001
PM 24204140
OA gold
DA 2018-01-05
ER

PT J
AU Hu, J
   Wang, L
   Li, F
   Han, YL
   Lin, M
   Lu, TJ
   Xu, F
AF Hu, Jie
   Wang, Lin
   Li, Fei
   Han, Yu Long
   Lin, Min
   Lu, Tian Jian
   Xu, Feng
TI Oligonucleotide-linked gold nanoparticle aggregates for enhanced
   sensitivity in lateral flow assays
SO LAB ON A CHIP
LA English
DT Article
ID OF-CARE DIAGNOSTICS; STRIP BIOSENSOR; GLOBAL HEALTH; POINT;
   HYBRIDIZATION; TECHNOLOGIES; DEVICES; FUTURE
AB Lateral flow assays (LFAs) as rapid analytical techniques promise to be widely used in point-of-care (POC) diagnostics because of their affordability and simplicity. However, LFAs still suffer from low sensitivity in detection of various biomarkers, e. g., nucleic acids. In this study, we developed a simple and general one-step signal amplification strategy, which employed oligonucleotide-linked gold nanoparticle (AuNP) aggregates to enhance the sensitivity in nucleic acid lateral flow (NALF) assays. Using a nucleic acid sequence of human immunodeficiency virus type 1 (HIV-1) as a model analyte, we observed that the detection limit of the developed NALF assay was 0.1 nM, which was improved by 2.5-fold compared with that of a non-signal amplification approach. The methodology described here could be used to detect a broad range of nucleic acids, and the general signal amplification approach could be potentially adopted in other types of LFAs.
C1 [Hu, Jie; Wang, Lin; Han, Yu Long; Lin, Min; Xu, Feng] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
   [Hu, Jie; Wang, Lin; Li, Fei; Han, Yu Long; Lin, Min; Lu, Tian Jian; Xu, Feng] Xi An Jiao Tong Univ, Bioinspired Engn & Biomech Ctr, Xian 710049, Peoples R China.
   [Li, Fei] Xi An Jiao Tong Univ, Sch Sci, Dept Chem, Xian 710049, Peoples R China.
RP Lu, TJ (reprint author), Xi An Jiao Tong Univ, Bioinspired Engn & Biomech Ctr, Xian 710049, Peoples R China.
EM tjlu@mail.xjtu.edu.cn; fengxu@mail.xjtu.edu.cn
RI Xu, Feng/C-7430-2011; Lu, Tian Jian/E-6063-2016; Xu, Feng/H-4468-2011
OI Xu, Feng/0000-0003-4351-0222
FU National 111 Project of China [B06024]; Major International Joint
   Research Program of China [11120101002]; Chinese Ministry of Education
   [313045]; South Wisdom Valley Innovative Research Team Program;
   International Science & Technology Cooperation Program of China
   [2013DFG02930]; Fundamental Research Funds for the Central Universities;
   China Postdoctoral Science Foundation [2013M532054]; China Young
   1000-Talent Program; Program for New Century Excellent Talents in
   University [NCET-12-0437]
FX This work was financially supported by the National 111 Project of China
   (B06024), the Major International Joint Research Program of China
   (11120101002), the Key (Key grant) Project of Chinese Ministry of
   Education (313045), South Wisdom Valley Innovative Research Team
   Program, International Science & Technology Cooperation Program of China
   (2013DFG02930), the Fundamental Research Funds for the Central
   Universities, and China Postdoctoral Science Foundation funded project
   (2013M532054). FX was also partially supported by the China Young
   1000-Talent Program and Program for New Century Excellent Talents in
   University (NCET-12-0437).
CR Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Choi DH, 2010, BIOSENS BIOELECTRON, V25, P1999, DOI 10.1016/j.bios.2010.01.019
   Craw P, 2012, LAB CHIP, V12, P2469, DOI [10.1039/c2lc40100b, 10.1039/c21c40100b]
   Dineva MA, 2005, J CLIN MICROBIOL, V43, P4015, DOI 10.1128/JCM.43.8.4015.4021.2005
   Figeys D., 2000, ANAL CHEM, V72, p330A
   Glynou K, 2003, ANAL CHEM, V75, P4155, DOI 10.1021/ac034256+
   Gubala V, 2012, ANAL CHEM, V84, P487, DOI 10.1021/ac2030199
   He YQ, 2011, BIOSENS BIOELECTRON, V26, P2018, DOI 10.1016/j.bios.2010.08.079
   Hill HD, 2006, NAT PROTOC, V1, P324, DOI 10.1038/nprot.2006.51
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Li X, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3687398
   Liu CY, 2011, ANAL CHEM, V83, P6778, DOI 10.1021/ac201462d
   Liu J., 2006, ANGEW CHEM INT EDIT, V45, P7959
   Mao X, 2009, ANAL CHEM, V81, P1660, DOI 10.1021/ac8024653
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Mazumdar D, 2010, CHEM COMMUN, V46, P1416, DOI 10.1039/b917772h
   Niemz A, 2011, TRENDS BIOTECHNOL, V29, P240, DOI 10.1016/j.tibtech.2011.01.007
   Nilghaz A, 2012, LAB CHIP, V12, P209, DOI 10.1039/c1lc20764d
   Parolo C, 2013, CHEM SOC REV, V42, P450, DOI 10.1039/c2cs35255a
   Parolo C, 2013, BIOSENS BIOELECTRON, V40, P412, DOI 10.1016/j.bios.2012.06.049
   Pelton R, 2009, TRAC-TREND ANAL CHEM, V28, P925, DOI 10.1016/j.trac.2009.05.005
   Rappuoli R, 2004, NAT MED, V10, P1177, DOI 10.1038/nm1129
   Rohrman BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045611
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Sylvestre JP, 2004, J PHYS CHEM B, V108, P16864, DOI 10.1021/jp047134+
   Tang D, 2009, BIOSENS BIOELECTRON, V25, P514, DOI 10.1016/j.bios.2009.07.030
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Zhang DY, 2012, NAT CHEM, V4, P208, DOI [10.1038/NCHEM.1246, 10.1038/nchem.1246]
NR 31
TC 54
Z9 56
U1 5
U2 57
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PY 2013
VL 13
IS 22
BP 4352
EP 4357
DI 10.1039/c3lc50672j
PG 6
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 238LA
UT WOS:000325946800012
PM 24056409
DA 2018-01-05
ER

PT J
AU Parthasarathi, V
   Thilagavathi, G
AF Parthasarathi, V
   Thilagavathi, G.
TI Developing antiviral surgical gown using nonwoven fabrics for health
   care sector
SO AFRICAN HEALTH SCIENCES
LA English
DT Article
DE Surgical gown; antiviral gown; Tri laminate; nonwoven; care uniform
ID SURFACE-TENSION
AB Background: Healthcare workers' uniforms including surgical gowns are used as barriers to eliminate the risk of infection for both doctor and patient. The prevalence of human immunodeficiency virus, hepatitis B and C viruses in the patient population is very common.
   Objectives: To develop antiviral surgical gown comprising of Polypropylene nonwoven as outer layer, Polytetrafluroethylene (PTFE) film as middle layer and polyester nonwoven as inner layer and the surgical gown with a basic weight of 70 g/m(2).
   Methods: The titanium dioxide (TiO2) nano dispersion was prepared with methylene blue and urea as a reacting medium. These nano particles have an average size of 9 nm which was revealed by High resolution transmission electron microscope. The nonwoven fabric pore size was characterised by using digital image analyzer. The polypropylene nonwoven fabrics were treated with nano dispersion by pad-dry-cure method and trilaminate fabric was formed using fusing machine. The presence of nano particle on the surface of the non woven fabric was confirmed by Scanning Electron microscope.
   Results: The trilaminate surgical gown has passed ASTM 1671 viral penetration test which is mandatory for healthcare facilities. The average pore size of inner, middle and outer layer were found as 0.187, 0.4 and 0.147 micron respectively. The tensile strength of the trilaminate fabric in both machine and cross direction was 145 N and 94 N respectively. The tearing strength of the trilaminate fabric in direction I and II was 10 N and 4 N respectively. The hydrostatic and index puncture resistance of the trilaminate fabric was 2930 mmwc and 58.8 N respectively. The moisture vapour permeability of the fabric was exhibited as 585.7 g/m(2)/day.
   Conclusion: The surgical gown exhibits antiviral property which can protect the health care people from human immunodeficiency virus.
C1 [Parthasarathi, V; Thilagavathi, G.] PSG Coll Technol, Dept Fash Technol, Coimbatore 641004, Tamil Nadu, India.
RP Parthasarathi, V (reprint author), PSG Coll Technol, Dept Fash Technol, Coimbatore 641004, Tamil Nadu, India.
EM sarathi_vp@hotmail.com
CR Association Operating Room Nurses, 1993, ASS OPERATING ROOM N, V57, P554
   Azouni MA, 2001, J COLLOID INTERF SCI, V239, P509, DOI 10.1006/jcis.2001.7568
   Barbara J, 2002, INFECT CONTROL TODAY, V1, P3234
   Belkin N. L., 1993, TECHNICAL TEXTILES I, V1, P22
   Lickfield, 2001, INT FIBRE J, V3, P42
   McCullough EA, 1993, J NONWOVEN RES, V4, P14
   McCullough EA, 1995, AM J INFECT CONTROL, V21, P368
   Phongikaroon S, 2005, J CHEM ENG DATA, V50, P1602, DOI 10.1021/je050074w
   Rigby AJ, 1993, TEXTILE HORIZONS, V2, P12
   Rutala WA, 2001, INFECT CONT HOSP EP, V22, P248, DOI 10.1086/501895
   Unsal E, 2005, J APPL POLYM SCI, V97, P282, DOI 10.1002/app.21716
   Zhang X, 2003, B ENVIRON CONTAM TOX, V70, P652, DOI 10.1007/s00128-003-0034-0
   [Anonymous], 1995, FED REG, V5, P23042
   [Anonymous], 2011, AVERAGE LENGTH STAY
NR 14
TC 2
Z9 2
U1 0
U2 21
PU MAKERERE UNIV, FAC MED
PI KAMPALA
PA PO BOX 7072, KAMPALA, 00000, UGANDA
SN 1680-6905
EI 1729-0503
J9 AFR HEALTH SCI
JI Afr. Health Sci.
PY 2013
VL 13
IS 2
BP 327
EP 332
DI 10.4314/ahs.v13i2.18
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 235DI
UT WOS:000325695600019
PM 24235931
OA gold
DA 2018-01-05
ER

PT J
AU Avti, PK
   Kakkar, A
AF Avti, Pramod K.
   Kakkar, Ashok
TI Dendrimers as anti-inflammatory agents
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Dendrimers; Nanocarriers; Anti-inflammatory agents; Cyclooxygenase
   (COX-2); Inducible nitric oxide synthase (iNOS); Pro-inflammatory
   cytokines
ID CAPSID PROTEIN; IN-VITRO; POLY(AMIDOAMINE) DENDRIMERS; DENDRITIC
   MACROMOLECULES; MOLECULAR ARCHITECTURE; CAPPED DENDRIMERS; HUMAN
   MONOCYTES; ENERGY-TRANSFER; HIV-1; POLYMERS
AB Dendrimers constitute an intriguing class of macromolecules which find applications in a variety of areas including biology. These hyperbranched macromolecules with tailored backbone and surface groups have been extensively investigated as nanocarriers for gene and drug delivery, by molecular encapsulation or covalent conjugation. Dendrimers have provided an excellent platform to develop multivalent and multifunctional nanoconjugates incorporating a variety of functional groups including drugs which are known to be anti-inflammatory agents. Recently, dendrimers have been shown to possess anti-inflammatory properties themselves. This unexpected and intriguing discovery has provided an additional impetus in designing novel active pharmaceutical agents. In this review, we highlight some of the recent developments in the field of dendrimers as nanoscale anti-inflammatory agents.
C1 [Avti, Pramod K.] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   [Avti, Pramod K.] Ecole Polytech, Inst Biomed Engn, Montreal, PQ H3C 3A7, Canada.
   [Avti, Pramod K.; Kakkar, Ashok] McGill Univ, Dept Chem, Fac Sci, Montreal, PQ H3A 0B8, Canada.
RP Kakkar, A (reprint author), McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada.
EM ashok.kakkar@mcgill.ca
RI Avti, Pramod/D-5303-2012
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Fonds de Recherche Nature et Technologie Quebec (FQRNT)
FX We would like to thank the Natural Sciences and Engineering Research
   Council of Canada (NSERC) and Fonds de Recherche Nature et Technologie
   Quebec (FQRNT) for financial support.
CR Adronov A, 2000, J AM CHEM SOC, V122, P1175, DOI 10.1021/ja993272e                                                               
   Archut A, 1998, J AM CHEM SOC, V120, P12187, DOI 10.1021/ja9822409                                                               
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   BUHLEIER E, 1978, SYNTHESIS-STUTTGART, P155
   Castonguay A, 2011, CHEM COMMUN, V47, P12146, DOI 10.1039/c1cc15354d
   Chauhan AS, 2009, BIOMACROMOLECULES, V10, P1195, DOI 10.1021/bm9000298
   Chauhan AS, 2004, J DRUG TARGET, V12, P575, DOI 10.1080/10611860400010655
   Cheng YY, 2005, EUR J MED CHEM, V40, P1188, DOI 10.1016/j.ejmech.2005.06.010
   Clayton R, 2011, BIOCONJUGATE CHEM, V22, P2186, DOI 10.1021/bc200331v
   Dernedde J, 2010, P NATL ACAD SCI USA, V107, P19679, DOI 10.1073/pnas.1003103107
   Domenech R, 2010, BIOMACROMOLECULES, V11, P2069, DOI 10.1021/bm100432x
   Ehrchen J, 2007, BLOOD, V109, P1265, DOI 10.1182/blood-2006-02-001115
   Espinosa E, 2001, MICROBES INFECT, V3, P645, DOI 10.1016/S1286-4579(01)01420-4
   Fischer M, 1999, ANGEW CHEM INT EDIT, V38, P884, DOI DOI 10.1002/SICI)1521-3773(19990401)38:7<884::AID-ANIE884>3.0.CO
   FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834
   Fruchon S, 2009, J LEUKOCYTE BIOL, V85, P553, DOI 10.1189/jlb.0608371
   Garzon MT, 2004, PROTEIN SCI, V13, P1512, DOI 10.1110/ps.03555304
   Gilat SL, 1999, ANGEW CHEM INT EDIT, V38, P1422, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1422::AID-ANIE1422>3.0.CO;2-V
   Griffe L, 2007, ANGEW CHEM INT EDIT, V46, P2523, DOI 10.1002/anie.200604651
   HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027                                                             
   Hayder M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002212
   HOURANI R., 2011, TETRAHEDRON LETT, V51, P3792
   Hourani R, 2010, MACROMOL RAPID COMM, V31, P947, DOI 10.1002/marc.200900712
   HULT A., 2003, ENCY POLYM SCI TECHN, P722
   JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226                                                   
   JANSEN JFGA, 1995, J AM CHEM SOC, V117, P4417, DOI 10.1021/ja00120a032                                                             
   Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004
   Kensinger RD, 2004, BIOCONJUGATE CHEM, V15, P349, DOI 10.1021/bc034156a
   Kolhe P, 2003, INT J PHARM, V259, P143, DOI 10.1016/S0378-5173(03)00225-4
   Milhem OM, 2000, INT J PHARM, V197, P239, DOI 10.1016/S0378-5173(99)00463-9
   MORALES-SERNA J.A., 2010, EUR J ORG CHEM, V14, P2657
   MOUREY TH, 1992, MACROMOLECULES, V25, P2401, DOI 10.1021/ma00035a017                                                             
   Neibert K, 2013, MOL PHARMACEUT, V10, P2502, DOI 10.1021/mp4000508
   Neira JL, 2009, FEBS J, V276, P6110, DOI 10.1111/j.1742-4658.2009.07314.x
   Perez-Anes A, 2010, BIOORGAN MED CHEM, V18, P242, DOI 10.1016/j.bmc.2009.10.058
   Portevin D, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-82
   Poupot M, 2006, FASEB J, V20, P2339, DOI 10.1096/fj.06-5742com
   Rele SM, 2005, J AM CHEM SOC, V127, P10132, DOI 10.1021/ja0511974
   Rupp R, 2007, INT J NANOMED, V2, P561
   Schluter AD, 2000, ANGEW CHEM INT EDIT, V39, P864, DOI 10.1002/(SICI)1521-3773(20000303)39:5<864::AID-ANIE864>3.0.CO;2-E               
   Sharma A, 2011, MACROMOLECULES, V44, P521, DOI 10.1021/ma102354k
   Sharma A, 2011, BIOMATERIALS, V32, P1419, DOI 10.1016/j.biomaterials.2010.10.025
   Soliman GM, 2011, CHEM COMMUN, V47, P9572, DOI 10.1039/c1cc11981h
   Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tomalia DA, 1984, 1 SPSJ INT POL C SOC, P65
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   WIWATTANAPATAPEE R., 1999, P INT S CONTR REL BI, V26, P145
NR 50
TC 5
Z9 5
U1 0
U2 10
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PY 2013
VL 49
SI SI
BP 57
EP 65
DI 10.1590/S1984-82502013000700006                                         
          
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 224UL
UT WOS:000324915100006
OA gold
DA 2018-01-05
ER

PT S
AU Chan, CPY
   Mak, WC
   Cheung, KY
   Sin, KK
   Yu, CM
   Rainer, TH
   Renneberg, R
AF Chan, Cangel Pui Yee
   Mak, Wing Cheung
   Cheung, Kwan Yee
   Sin, King Keung
   Yu, Cheuk Man
   Rainer, Timothy H.
   Renneberg, Reinhard
BE Cooks, RG
   Pemberton, JE
TI Evidence-Based Point-of-Care Diagnostics: Current Status and Emerging
   Technologies
SO ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, VOL 6
SE Annual Review of Analytical Chemistry
LA English
DT Article; Book Chapter
DE acute coronary syndrome; heart failure; human immunodeficiency virus;
   microfluidics; POC; tuberculosis
ID DRUG-RESISTANT TUBERCULOSIS; DECOMPENSATED HEART-FAILURE; BRAIN
   NATRIURETIC PEPTIDE; PAPER-BASED MICROFLUIDICS; ACUTE CORONARY
   SYNDROMES; LAB-ON-PAPER; MYOCARDIAL-INFARCTION; LIQUID-CRYSTALS;
   MYCOBACTERIUM-TUBERCULOSIS; EMERGENCY-DEPARTMENT
AB Point-of-care (POC) diagnostics brings tests nearer to the site of patient care. The turnaround time is short, and minimal manual interference enables quick clinical management decisions. Growth in POC diagnostics is being continuously fueled by the global burden of cardiovascular and infectious diseases. Early diagnosis and rapid initiation of treatment are crucial in the management of such patients. This review provides the rationale for the use of POC tests in acute coronary syndrome, heart failure, human immunodeficiency virus, and tuberculosis. We also consider emerging technologies that are based on advanced nanomaterials and microfluidics, improved assay sensitivity, miniaturization in device design, reduced costs, and high-throughput multiplex detection, all of which may shape the future development of POC diagnostics.
C1 [Chan, Cangel Pui Yee; Rainer, Timothy H.] Chinese Univ Hong Kong, Accident & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China.
   [Yu, Cheuk Man] Chinese Univ Hong Kong, Div Cardiol, Dept Med & Therapeut, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
   [Mak, Wing Cheung] Linkoping Univ, Dept Phys Chem & Biol, Biosensors & Bioelect Ctr, S-58183 Linkoping, Sweden.
   [Cheung, Kwan Yee] Linkoping Univ, Dept Clin & Expt Med, Integrat Regenerat Med Ctr, S-58183 Linkoping, Sweden.
   [Sin, King Keung; Renneberg, Reinhard] Hong Kong Univ Sci & Technol, Dept Chem, Kowloon, Hong Kong, Peoples R China.
RP Chan, CPY (reprint author), Chinese Univ Hong Kong, Accident & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China.
EM thrainer@cuhk.edu.hk; chrenneb@ust.hk
RI Yu, Cheuk-man/P-3747-2015; Rainer, Timothy/I-2591-2013
OI Rainer, Timothy/0000-0003-3355-3237; Mak, Wing
   Cheung/0000-0003-3274-6029
CR Abe K, 2008, ANAL CHEM, V80, P6928, DOI 10.1021/ac800604v
   Abe K, 2010, ANAL BIOANAL CHEM, V398, P885, DOI 10.1007/s00216-010-4011-2
   Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4                                                   
   Anand IS, 2003, CIRCULATION, V107, P1278, DOI 10.1161/01.CIR.0000054164.99881.00
   Apple FS, 2006, CLIN CHIM ACTA, V370, P191, DOI 10.1016/j.cca.2006.02.011
   Asati A, 2009, ANGEW CHEM INT EDIT, V48, P2308, DOI 10.1002/anie.200805279
   Harrison DJ, 1998, P MU TAS 98 WORKSH, P231
   Batz HG, 2011, LAB FREE TUBERCULOSI
   Bhalla Vikas, 2004, Congest Heart Fail, V10, P3, DOI 10.1111/j.1527-5299.2004.03310.x
   Bi XY, 2010, BIOSENS BIOELECTRON, V26, P107, DOI 10.1016/j.bios.2010.05.018
   Blankenberg S, 2006, CIRCULATION, V114, P201, DOI 10.1161/CIRCULATIONAHA.105.590927
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847
   Boyd FM, 1999, AIDS CARE, V11, P21, DOI 10.1080/09540129948171                                                          
   Branson BM, 2003, J LAB MED, V27, P288
   Bruzewicz DA, 2008, ANAL CHEM, V80, P3387, DOI 10.1021/ac702605a
   Carrilho E, 2009, ANAL CHEM, V81, P7091, DOI 10.1021/ac901071p
   Caruso F, 2000, LANGMUIR, V16, P1485, DOI 10.1021/la991161n                                                               
   Centres for Disease Control and Prevention, 2008, FDA APPR RAP HIV ANT
   Cent. Dis. Control Prevent, 2001, REV GUID HIV COUNS T
   Cent. Dis. Control Prevent, 1998, UPD HIV COUNS TEST U
   Chan CPY, 2007, ANAL CHIM ACTA, V584, P7, DOI 10.1016/j.aca.2006.11.025
   Chan CPY, 2004, J IMMUNOL METHODS, V295, P111, DOI 10.1016/j.jim.2004.09.016
   Chan CPY, 2004, ANAL CHEM, V76, P3638, DOI 10.1021/ac0353740                                                               
   Chen CH, 2012, ANAL BIOCHEM, V421, P321, DOI 10.1016/j.ab.2011.11.007
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Chitnis G, 2011, LAB CHIP, V11, P1161, DOI [10.1039/c0lc00512f, 10.1039/c01c00512f]
   Delaney JL, 2011, ANAL CHEM, V83, P1300, DOI 10.1021/ac102392t
   Delaney KP, 2011, CLIN INFECT DIS, V52, P257, DOI 10.1093/cid/ciq068
   Denny N, 2011, 0019 PRIM CAR DIAGN
   Dhingra N., 2006, MAKING SAFE BLOOD AV
   Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309
   Ding N, 2010, ANAL CHEM, V82, P5897, DOI 10.1021/ac100597s
   Dungchai W, 2011, ANALYST, V136, P77, DOI 10.1039/c0an00406e
   Dungchai W, 2009, ANAL CHEM, V81, P5821, DOI 10.1021/ac9007573
   Fitzgerald P, 2011, ACAD EMERG MED, V18, P487, DOI 10.1111/j.1553-2712.2011.01068.x
   Gandhi NR, 2010, LANCET, V375, P1830, DOI 10.1016/S0140-6736(10)60410-2
   Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260
   Ge L, 2012, BIOMATERIALS, V33, P1024, DOI 10.1016/j.biomaterials.2011.10.065
   Gupta VK, 1998, SCIENCE, V279, P2077, DOI 10.1126/science.279.5359.2077                                                   
   Hartono D, 2009, ADV FUNCT MATER, V19, P3574, DOI 10.1002/adfm.200901020
   Heifets LB, 1999, INT J TUBERC LUNG D, V3, P564
   Hillemann D, 2009, J CLIN MICROBIOL, V47, P1767, DOI 10.1128/JCM.00081-09
   Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONHA.105.167586
   Hutchinson AB, 2006, AIDS, V20, P1597, DOI 10.1097/01.aids.0000238405.93249.16
   Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064
   Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1
   Jt. U.N. Progr. HIV AIDS, 2007, AIDS EP UPD 2007
   Kjellgren H, 2006, CARBOHYD POLYM, V65, P453, DOI 10.1016/j.carbpol.2006.02.005
   Klasner SA, 2010, ANAL BIOANAL CHEM, V397, P1821, DOI 10.1007/s00216-010-3718-4
   Laperche S, 2009, TRANSFUSION, V49, P1600, DOI 10.1111/j.1537-2995.2009.02239.x
   Lawn SD, 2012, LANCET INFECT DIS, V12, P201, DOI 10.1016/S1473-3099(11)70251-1
   Lee BS, 2009, LAB CHIP, V9, P1548, DOI 10.1039/b820321k
   Lee-Lewandrowski E, 2003, ARCH PATHOL LAB MED, V127, P456
   Leung V, 2010, COLLOID SURFACE A, V364, P16, DOI 10.1016/j.colsurfa.2010.04.008
   Li X, 2010, CELLULOSE, V17, P649, DOI 10.1007/s10570-010-9401-2
   Li X, 2010, COLLOID SURFACE B, V76, P564, DOI 10.1016/j.colsurfb.2009.12.023
   Li X, 2008, ANAL CHEM, V80, P9131, DOI 10.1021/ac801729t
   Ling DI, 2008, EUR RESPIR J, V32, P1165, DOI 10.1183/09031936.00061808
   Lowe AM, 2012, CHEM MATER, V24, P746, DOI 10.1021/cm202632m
   Lowe AM, 2010, ACS APPL MATER INTER, V2, P722, DOI 10.1021/am900753v
   Luk YY, 2004, J AM CHEM SOC, V126, P9024, DOI 10.1021/ja0398565
   Maisel AS, 2008, J AM COLL CARDIOL, V52, P534, DOI 10.1016/j.jacc.2008.05.010
   Mak WC, 2011, BIOSENS BIOELECTRON, V26, P3148, DOI 10.1016/j.bios.2010.12.016
   Mak WC, 2005, ANAL CHEM, V77, P2835, DOI 10.1021/ac0485051
   Mak WC, 2004, ELECTROANAL, V16, P156, DOI 10.1002/elan.200302927
   Martinez AW, 2007, ANGEW CHEM INT EDIT, V46, P1318, DOI 10.1002/anie.200603817
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Martinez AW, 2008, P NATL ACAD SCI USA, V105, P19606, DOI 10.1073/pnas.0810903105
   McDonnell B, 2009, CLIN BIOCHEM, V42, P549, DOI 10.1016/j.clinbiochem.2009.01.019
   Migliori GB, 2007, EUROSURVEILLANCE, V12
   Mion MM, 2007, CLIN BIOCHEM, V40, P1245, DOI 10.1016/j.clinbiochem.2007.07.018
   Morgan M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-62
   Morrow DA, 2004, AM HEART J, V148, P739, DOI 10.1016/j.ahj.2004.05.024
   Natl. Inst. Health Clin. Excell, 2010, NAT I HLTH CLIN EXC
   Nie ZH, 2010, LAB CHIP, V10, P3163, DOI [10.1039/c0lc00237b, 10.1039/c01c00237b]
   Noh H, 2010, ANAL CHEM, V82, P8071, DOI 10.1021/ac1005537
   Olkkonen J, 2010, ANAL CHEM, V82, P10246, DOI 10.1021/ac1027066
   Pai M, 2009, CLIN CHEST MED, V30, P701, DOI 10.1016/j.ccm.2009.08.016
   Pai NP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000367
   Pai NP, 2012, LANCET INFECT DIS, V12, P373, DOI 10.1016/S1473-3099(11)70368-1
   Pai NP, 2009, WOMENS HEALTH, V5, P55, DOI 10.2217/17455057.5.1.55
   Pai NP, 2008, PLOS MED, V5, P768, DOI 10.1371/journal.pmed.0050092
   Park J, 2012, ANAL CHEM, V84, P2133, DOI 10.1021/ac203163u
   Parsons LM, 2004, FRONT BIOSCI-LANDMRK, V9, P2086, DOI 10.2741/1290                                                                    
   Peacock WF, 2007, CARDIOLOGY, V107, P44, DOI 10.1159/000093612
   Pham MX, 2004, AM HEART J, V148, P776, DOI 10.1016/j.ahj.2004.03.058
   Ren L, 2012, BIOSENS BIOELECTRON, V35, P147, DOI 10.1016/j.bios.2012.02.034
   Renaud B, 2008, ACAD EMERG MED, V15, P216, DOI 10.1111/j.1553-2712.2008.00069.x
   Rezk AR, 2012, LAB CHIP, V12, P773, DOI 10.1039/c2lc21065g
   Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46
   Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Schilling KM, 2012, ANAL CHEM, V84, P1579, DOI 10.1021/ac202837s
   Schumacher S, 2012, LAB CHIP, V12, P464, DOI 10.1039/c1lc20693a
   Seydack M, 2005, BIOSENS BIOELECTRON, V20, P2454, DOI 10.1016/j.bios.2004.11.003
   Shah NS, 2007, EMERG INFECT DIS, V13, P380, DOI 10.3201/eid1303.061400                                                          
   Sin KK, 2006, ANAL BIOANAL CHEM, V384, P638, DOI 10.1007/s00216-005-0245-9
   Singer AJ, 2005, ANN EMERG MED, V45, P587, DOI 10.1016/j.annemergmed.2004.11.020
   Sivakumar S, 2009, ADV FUNCT MATER, V19, P2260, DOI 10.1002/adfm.200900399
   Song SY, 2012, ANAL BIOCHEM, V420, P139, DOI 10.1016/j.ab.2011.09.012
   Song YJ, 2011, ADV MATER, V23, P4215, DOI 10.1002/adma.201101853
   Steingart KR, 2007, PLOS MED, V4, P1041, DOI 10.1371/journal.pmed.0040202
   Storrow AB, 2007, POINT CARE, V6, P215, DOI 10.1097/poc.0b013e31809f8e34                                                    
   Sturenburg E, 2009, DTSCH ARZTEBL INT, V106, P48, DOI 10.3238/arztebl.2009.0048
   Tagny CT, 2008, TRANSFUSION, V48, P1256, DOI 10.1111/j.1537-2995.2008.01697.x
   Than M, 2011, LANCET, V377, P1077, DOI 10.1016/S0140-6736(11)60310-3
   Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397
   Trau D, 2002, ANAL CHEM, V74, P5480, DOI 10.1021/ac0200522
   Trau D, 2003, BIOSENS BIOELECTRON, V18, P1491, DOI 10.1016/S0956-5663(03)00119-2
   Tudos AJ, 2001, LAB CHIP, V1, P83, DOI 10.1039/b106958f
   Vella SJ, 2012, ANAL CHEM, V84, P2883, DOI 10.1021/ac203434x
   Wang SM, 2012, BIOSENS BIOELECTRON, V31, P212, DOI 10.1016/j.bios.2011.10.019
   Wei F, 2009, CLIN CANCER RES, V15, P1
   Wei H, 2008, ANAL CHEM, V80, P2250, DOI 10.1021/ac702203f
   World Health Organ, 2009, NEW LAB DIAGN TOOLS
   WHO UNAIDS and UNICEF, 2011, PROGR REP 2011 GLOB
   World Health Organisation, 2004, RAP HIV TESTS GUID U
   World Health Organization, 2010, POL STAT FLUOR LIGHT
   World Health Organization, 2005, WORLD HLTH REP 2005
   World Health Organ, 2012, TUB FACT SHEET 104
   World Health Organ, 2008, DIAGN EV SER, V2
   World Health Organ, 2010, GLOB REP SURV RESP M
   World Health Organ, 2012, FACT SHEET 317 CARD
   World Health Organization, 2011, POL STAT AUT REAL TI
   World Health Organ, 2011, POL STAT COMM SER TE
   WHO, 2012, GLOB REP RES INF DIS
   Xu Q, 2010, CLIN CHIM ACTA, V411, P1781, DOI 10.1016/j.cca.2010.07.033
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yan JX, 2012, CHEM-EUR J, V18, P4938, DOI 10.1002/chem.201102855
   Yang ZQ, 2010, ADV FUNCT MATER, V20, P2098, DOI 10.1002/adfm.201000367
   Zhao WA, 2008, LAB CHIP, V8, P1988, DOI 10.1039/b814043j
   [Anonymous], 2007, LANCET, V370, P361
NR 132
TC 48
Z9 48
U1 5
U2 81
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 1936-1327
BN 978-0-8243-4406-1
J9 ANNU REV ANAL CHEM
JI Annu. Rev. Anal. Chem.
PY 2013
VL 6
BP 191
EP 211
DI 10.1146/annurev-anchem-062012-092641
PG 21
WC Chemistry, Analytical; Spectroscopy
SC Chemistry; Spectroscopy
GA BGR34
UT WOS:000323887500010
PM 23527548
DA 2018-01-05
ER

PT B
AU Belda, FJ
   Caballero, S
   Diez, JM
   Otegui, M
   Figueras, FJ
   Vinent, A
   Gajardo, R
   Jorquera, JI
AF Belda, F. J.
   Caballero, S.
   Diez, J. M.
   Otegui, M.
   Figueras, F. J.
   Vinent, A.
   Gajardo, R.
   Jorquera, J., I
BE Etzioni, A
   Gambineri, E
TI Study of Planova (TM) 20N nanofiltration as applied to Flebogamma (R)
   DIF
SO PROCEEDINGS OF THE 15TH MEETING OF THE EUROPEAN SOCIETY
   IMMUNODEFICIENCIES (ESID)
LA English
DT Proceedings Paper
CT 15th Biannual Meeting of the
   European-Society-for-Primary-Immunodeficiency (ESID)
CY OCT 03-06, 2012
CL Florence, ITALY
SP European Soc Primary Immunodeficiency (ESID), Int Nursing Grp Immunodeficiencies (INGID), Int Patient Org Primary Immunodeficiencies (IPOPI)
DE nanofiltration; Planova (TM) 20N; intravenous immunoglobulins;
   Flebogamma (R) DIF
AB Introduction: A safe therapy with intravenous immunoglobulins (IVIG) coming from human plasma is used to treat patients with immunodeficiencies. Flebogamma (R) DIF is an IVIG produced by Grifols which safety is enhanced by its 20 nm nanofiltration process.
   Objective: The purpose of these studies was to determine the capacity of Flebogamma (R) DIF 20 nm nanofiltration step to eliminate spiked relevant and/or model viruses.
   Methods: Laboratory scale studies were conducted to establish the capacity of nanofiltration process down to 20 nm pore size (Planova (TM) 20N), from Grifols' Flebogamma (R) DIF production process, to inactivate/remove spiked viruses. Down-scale spiking laboratory experiments, validated for equivalence to the industrial-scale nanofiltration process were performed. Relevant and models viruses of different size were used for Human Immunodeficiency virus (HIV), Herpesvirus and Hepatitis B, Hepatitis C, West Nile Virus (WNV), Hepatitis A and B19 virus.
   Results: The reduction capacity (log(10)) achieved for the different relevant and models viruses were >= 4.81 for HIV-1, >= 4.63 for PRV, >= 4.67 for BVDV, >= 3.63 for WNV, >= 5.92 for EMCV and 4.61 for PPV.
   Conclusions Nanofiltration process down to 20 nm in IVIG was effective to inactivate/remove a wide range of relevant and model viruses of various sizes. This nanofiltration step increases the safety margin of Flebogamma (R) DIF and contributes together with the combination of other methods (precipitations, low pH, pasteurization and SD treatment) to eliminate potential pathogens, with very different mechanisms of action.
C1 [Belda, F. J.; Caballero, S.; Diez, J. M.; Otegui, M.; Figueras, F. J.; Vinent, A.; Gajardo, R.; Jorquera, J., I] Inst Grifols SA, Res & Dev Area, Barcelona, Spain.
RP Belda, FJ (reprint author), Inst Grifols SA, Res & Dev Area, Barcelona, Spain.
EM paco.belda@grifols.com; santiago.caballero@grifols.com;
   josemaria.diez@grifols.com; magdalena.otegui@grifols.com;
   fran.figueras@grifols.com; andrea.vinent@grifols.com;
   rodrigo.gajardo@grifols.com; juanignacio.jorquera@grifols.com
CR Caballero S, 2010, BIOLOGICALS, V38, P486, DOI 10.1016/j.biologicals.2010.02.008
   [Anonymous], 1996, CPMPBWP26895
   [Anonymous], 2001, CPMPICH29595
   [Anonymous], 2012, EMACHMPBWP7062712010
   Heimburger N, 1989, Curr Stud Hematol Blood Transfus, P23
   Menconi MC, 2009, TRANSFUSION MED, V19, P213, DOI 10.1111/j.1365-3148.2009.00931.x
NR 6
TC 0
Z9 0
U1 0
U2 1
PU MEDIMOND S R L
PI 40128 BOLOGNA
PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY
BN 978-88-7587-666-1
PY 2013
BP 5
EP 8
PG 4
WC Immunology
SC Immunology
GA BGW36
UT WOS:000324375200002
DA 2018-01-05
ER

PT J
AU Tang, HY
   Yin, LC
   Kim, KH
   Cheng, JJ
AF Tang, Haoyu
   Yin, Lichen
   Kim, Kyung Hoon
   Cheng, Jianjun
TI Helical poly(arginine) mimics with superior cell-penetrating and
   molecular transporting properties
SO CHEMICAL SCIENCE
LA English
DT Article
ID PERMEABLE MINIATURE PROTEINS; NONVIRAL GENE DELIVERY; IN-VITRO; PEPTIDE;
   ARGININE; SIRNA; DOMAIN; INTERNALIZATION; NANOPARTICLES; TRANSFECTION
AB Poly(arginine) mimics bearing long hydrophobic side chains adopt a stable helical conformation and exhibit helix-related cell-penetrating properties. Elongating the polypeptide backbone length and increasing side chain hydrophobicity further increase the helicities of poly(arginine) mimics. These helical poly(arginine) mimics show superior cell membrane permeability up to two orders of magnitude higher than that of HIV-TAT peptide and excellent DNA and siRNA delivery efficiencies in various mammalian cells.
C1 [Tang, Haoyu; Yin, Lichen; Kim, Kyung Hoon; Cheng, Jianjun] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA.
RP Cheng, JJ (reprint author), Univ Illinois, Dept Mat Sci & Engn, 1304 West Green St, Urbana, IL 61801 USA.
EM jianjunc@illinois.edu
RI Tang, Haoyu/D-9983-2014
OI Tang, Haoyu/0000-0001-7095-9688
FU NSF [CHE-1153122]; NIH [1DP2OD007246, 1R21EB013379]
FX J.C. acknowledges support from the NSF (CHE-1153122) and the NIH (NIH
   Director's New Innovator Award 1DP2OD007246 and 1R21EB013379).
CR Cooley CB, 2009, J AM CHEM SOC, V131, P16401, DOI 10.1021/ja907363k
   Daniels DS, 2007, J AM CHEM SOC, V129, P14578, DOI 10.1021/ja0772445
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Drappier C, 2013, POLYM CHEM-UK, V4, P2011, DOI 10.1039/c2py21044d
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Engler AC, 2009, ANGEW CHEM INT EDIT, V48, P9334, DOI 10.1002/anie.200904070
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Gabrielson NP, 2012, ANGEW CHEM INT EDIT, V51, P1143, DOI 10.1002/anie.201104262
   Geihe EI, 2012, P NATL ACAD SCI USA, V109, P13171, DOI 10.1073/pnas.1211361109
   HAYAKAWA T, 1969, B CHEM SOC JPN, V42, P1937, DOI 10.1246/bcsj.42.1937                                                            
   HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015
   Hsu T, 2011, P NATL ACAD SCI USA, V108, P15816, DOI 10.1073/pnas.1016152108
   Jewell CM, 2011, ANGEW CHEM INT EDIT, V50, P12312, DOI 10.1002/anie.201104514
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kolonko EM, 2008, J AM CHEM SOC, V130, P5626, DOI 10.1021/ja8001716
   Kolonko EM, 2009, J AM CHEM SOC, V131, P7327, DOI 10.1021/ja809284s
   Kolusheva S, 2000, BIOCHEMISTRY-US, V39, P15851, DOI 10.1021/bi000570b
   Kondo E, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1952
   Kwon EJ, 2010, MOL PHARMACEUT, V7, P1260, DOI 10.1021/mp1000668
   Lattig-Tunnemann G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1459
   Law M, 2008, BIOTECHNOL PROGR, V24, P957, DOI [10.1002/btpr.13, 10.1021/bp.13]
   Lu H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1209
   Mandal D, 2011, ANGEW CHEM INT EDIT, V50, P9633, DOI 10.1002/anie.201102572
   Mano M, 2007, J PEPT SCI, V13, P301, DOI 10.1002/psc.842
   McLendon PM, 2010, MOL PHARMACEUT, V7, P738, DOI 10.1021/mp900282e
   McNaughton BR, 2009, P NATL ACAD SCI USA, V106, P6111, DOI 10.1073/pnas.0807883106
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m
   Naik RJ, 2011, J BIOL CHEM, V286, P18982, DOI 10.1074/jbc.M111.227793
   Pace CN, 1998, BIOPHYS J, V75, P422
   Patil KM, 2012, J AM CHEM SOC, V134, P7196, DOI 10.1021/ja210026m
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Ruzza P, 2004, J PEPT SCI, V10, P423, DOI 10.1002/psc.558
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Smith BA, 2008, J AM CHEM SOC, V130, P2948, DOI 10.1021/ja800074v
   Som A, 2012, ANGEW CHEM INT EDIT, V51, P980, DOI 10.1002/anie.201104624
   Som A, 2011, ANGEW CHEM INT EDIT, V50, P6147, DOI 10.1002/anie.201101535
   Sun PN, 2008, J DRUG TARGET, V16, P668, DOI 10.1080/10611860802201381 
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Zhang K, 2008, BIOCONJUGATE CHEM, V19, P1880, DOI 10.1021/bc800160b
   Zhao X, 2010, J CONTROL RELEASE, V144, P46, DOI 10.1016/j.jconrel.2010.01.022
NR 48
TC 52
Z9 52
U1 5
U2 67
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
J9 CHEM SCI
JI Chem. Sci.
PY 2013
VL 4
IS 10
BP 3839
EP 3844
DI 10.1039/c3sc51328a
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 210ON
UT WOS:000323843500008
PM 25400902
OA green_accepted
DA 2018-01-05
ER

PT S
AU Fu, JX
   Hu, Y
   Zhou, LC
   Lim, MY
   Goleb, M
   Zhan, QW
   Ou-Yang, HD
AF Fu, Jinxin
   Hu, Yi
   Zhou, Liangcheng
   Lim, Min Yao
   Goleb, Melissa
   Zhan, Qiwen
   Ou-Yang, H. Daniel
BE Buranasiri, P
   Sumriddetchkajorn, S
TI Mapping two-dimension trapping potential of nanoparticles in an optical
   trap
SO ICPS 2013: INTERNATIONAL CONFERENCE ON PHOTONICS SOLUTIONS
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT 1st International Conference on Photonics Solutions (ICPS)
CY MAY 26-28, 2013
CL Pattaya, THAILAND
SP Opt Soc, Natl Elect & Comp Technol Ctr, King Mongkuts Inst Technol Ladkrabang, Fac Sci, SPIE
DE Optical trapping; optical bottle; cylindrical vector beam; nanoparticles
ID CYLINDRICAL VECTOR BEAMS; MANIPULATION; FORCE
AB Combining confocal microscopy and optical tweezers, we map out the spatial distribution of the particle concentrations of quantum dots, fluorescent HIV pseudo virus particles and polystyrene nanospheres in an optical trap. By analyzing the Boltzmann distribution of local particle concentrations, we obtain the two-dimension single particle trapping potential profile at the center of the optical trap in the direction perpendicular to the beam propagation. We compare the trapping potential energies of pseudo HIV vesicles and same-sized polystyrene spheres. We also compare the trapping potential energy of polystyrene spheres of a focused Gaussian beam and two modes of cylindrical vector beams.
C1 [Fu, Jinxin; Hu, Yi; Zhou, Liangcheng; Lim, Min Yao; Ou-Yang, H. Daniel] Lehigh Univ, Dept Phys, Bethlehem, PA 18015 USA.
RP Fu, JX (reprint author), Lehigh Univ, Dept Phys, Bldg 16, Bethlehem, PA 18015 USA.
EM hdo0@lehigh.edu
CR Ashkin A, 2000, IEEE J SEL TOP QUANT, V6, P841, DOI 10.1109/2944.902132
   Berg-Sorensen K, 2004, REV SCI INSTRUM, V75, P594, DOI 10.1063/1.1645654
   Donato MG, 2012, OPT LETT, V37, P3381, DOI 10.1364/OL.37.003381
   Florin EL, 1998, APPL PHYS A-MATER, V66, pS75, DOI 10.1007/s003390051103
   Grier DG, 2003, NATURE, V424, P810, DOI 10.1038/nature01935
   Hu Y., BIOPHOTONICS UNPUB
   Huang L, 2012, OPT LETT, V37, P1694, DOI 10.1364/OL.37.001694
   Jauffred L, 2008, NANO LETT, V8, P3376, DOI 10.1021/nl801962f
   Junio J, 2011, OPT LETT, V36, P1497, DOI 10.1364/OL.36.001497
   Junio J, 2010, SOLID STATE COMMUN, V150, P1003, DOI 10.1016/j.ssc.2010.01.018
   Ling L., 2010, J APPL PHYS, V108
   McCann LI, 1999, NATURE, V402, P785, DOI 10.1038/45492                                                                   
   Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1                                                   
   Zhan QW, 2009, ADV OPT PHOTONICS, V1, P1, DOI 10.1364/AOP.1.000001
   Zhan QW, 2002, OPT EXPRESS, V10, P324, DOI 10.1364/OE.10.000324
NR 15
TC 0
Z9 0
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-9745-1
J9 PROC SPIE
PY 2013
VL 8883
AR UNSP 88830J
DI 10.1117/12.2027057
PG 5
WC Optics; Physics, Applied
SC Optics; Physics
GA BGO26
UT WOS:000323618100019
DA 2018-01-05
ER

PT J
AU Yang, SD
   Chen, YF
   Gu, KE
   Dash, A
   Sayre, CL
   Davies, NM
   Ho, EA
AF Yang, Sidi
   Chen, Yufei
   Gu, Kaien
   Dash, Alicia
   Sayre, Casey L.
   Davies, Neal M.
   Ho, Emmanuel A.
TI Novel intravaginal nanomedicine for the targeted delivery of saquinavir
   to CD4(+) immune cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE nanoparticles; saquinavir; antibody conjugation; intravaginal gel;
   HIV/AIDS; microbicide
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIBODY-CONJUGATED NANOPARTICLES;
   ANTIRETROVIRAL DRUG-DELIVERY; PRODUCT P-GLYCOPROTEIN; IN-VITRO;
   POLYMERIC NANOPARTICLES; INTRACELLULAR DELIVERY; LIPID NANOPARTICLES;
   HIV TRANSMISSION; T-CELLS
AB The goal of this study was to develop and characterize an intravaginal nanomedicine for the active targeted delivery of saquinavir (SQV) to CD4(+) immune cells as a potential strategy to prevent or reduce HIV infection. The nanomedicine was formulated into a vaginal gel to provide ease in self-administration and to enhance retention within the vaginal tract. SQV-encapsulated nanoparticles (SQV-NPs) were prepared from poly(lactic-co-glycolic acid) (PLGA) and conjugated to antihuman anti-CD4 antibody. Antibody-conjugated SQV-NPs (Ab-SQV-NPs) had an encapsulation efficiency (EE%) of 74.4% +/- 3.7% and an antibody conjugation efficiency (ACE%) of 80.95% +/- 1.10%. Over 50% of total loaded SQV was released from NPs over 3 days. NPs were rapidly taken up by Sup-T1 cells, with more than a twofold increase in the intracellular levels of SQV when delivered by Ab-SQV-NPs in comparison to controls 1 hour post-treatment. No cytotoxicity was observed when vaginal epithelial cells were treated for 24 hours with drug-free Ab-NPs (1,000 mu g/mL), 1% HEC placebo gel (200 mg/mL), or 1% HEC gel loaded with drug-free Ab-NPs (5 mg NPs/g gel, 200 mg/mL of gel mixture). Overall, we described an intravaginal nanomedicine that is nontoxic and can specifically deliver SQV into CD4(+) immune cells. This platform may demonstrate potential utility in its application as postexposure prophylaxis for the treatment or reduction of HIV infection, but further studies are required.
C1 [Yang, Sidi; Chen, Yufei; Gu, Kaien; Dash, Alicia; Sayre, Casey L.; Davies, Neal M.; Ho, Emmanuel A.] Univ Manitoba, Fac Pharm, Winnipeg, MB R3E 0T5, Canada.
   [Yang, Sidi; Chen, Yufei; Gu, Kaien; Dash, Alicia; Ho, Emmanuel A.] Univ Manitoba, Lab Drug Delivery & Biomat, Winnipeg, MB R3E 0T5, Canada.
RP Ho, EA (reprint author), Univ Manitoba, Fac Pharm, Lab Drug Delivery & Biomat, Apotex Ctr, 750 McDermot Ave Room 329, Winnipeg, MB R3E 0T5, Canada.
EM emmanuel_ho@umanitoba.ca
RI Davies, Neal/J-5811-2013; Chen, Yufei/R-7259-2016
OI Chen, Yufei/0000-0002-5782-3556; Sayre, Casey/0000-0002-1820-7689; Ho,
   Emmanuel/0000-0003-4729-9970
FU Manitoba Health Research Council; Dr Paul HT Thorlakson Foundation Fund;
   Faculty of Graduate Studies International Graduate Student Entrance
   Scholarship; Manitoba Health Research Council Graduate Studentship
FX This work was supported in part by grants awarded to Dr Emmanuel A Ho
   from the Manitoba Health Research Council and the Dr Paul HT Thorlakson
   Foundation Fund. Sidi Yang is grateful for the financial support
   received from the Faculty of Graduate Studies International Graduate
   Student Entrance Scholarship, and Yufei Chen is grateful for the
   financial support received from the Manitoba Health Research Council
   Graduate Studentship. The authors are grateful to Dr Xiaochen Gu for
   providing us access to his rheometer and Franz cells. The authors would
   also like to thank Deborah Chan for her help with the nanoparticle
   preparation.
CR Alsenz J, 1998, PHARMACEUT RES, V15, P423, DOI 10.1023/A:1011924314899
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   Arruebo M, 2009, J NANOMATER, DOI 10.1155/2009/439389
   Bicho A, 2010, INT J PHARMACEUT, V399, P80, DOI 10.1016/j.ijpharm.2010.08.005
   Bining N, 1997, J GERONTOL A-BIOL, V52, pB137, DOI 10.1093/gerona/52A.3.B137                                                       
   Campolongo MJ, 2009, NAT MATER, V8, P447, DOI 10.1038/nmat2456
   Ceric F, 2005, J ELECTRON MICROSC, V54, P479, DOI 10.1093/jmicro/dfh106
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900                                                            
   Crotts G, 1998, J MICROENCAPSUL, V15, P699, DOI 10.3109/02652049809008253
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Date AA, 2012, ANTIVIR RES, V96, P430, DOI 10.1016/j.antiviral.2012.09.015
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Eagling VA, 2002, XENOBIOTICA, V32, P1, DOI 10.1080/00498250110085845
   Endsley AN, 2012, JAIDS-J ACQ IMM DEF, V61, P417, DOI 10.1097/QAI.0b013e3182653c1f
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Flens MJ, 1996, AM J PATHOL, V148, P1237
   Gandapu U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023388
   Garg AB, 2009, ANTIVIR CHEM CHEMOTH, V19, P143
   Geldenhuys W, 2011, J DRUG TARGET, V19, P837, DOI 10.3109/1061186X.2011.589435
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Huisman MT, 2001, MOL PHARMACOL, V59, P806
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Joag SV, 1997, J VIROL, V71, P4016
   Kamel S, 2008, EXPRESS POLYM LETT, V2, P758, DOI 10.3144/expresspolymlett.2008.90
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kranz H, 2000, J PHARM SCI, V89, P1558
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   LARSSON PG, 1991, EUR J OBSTET GYN R B, V38, P39, DOI 10.1016/0028-2243(91)90205-Y
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Merrill DP, 1997, J INFECT DIS, V176, P265, DOI 10.1086/517263
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074
   Mumper RJ, 2009, DRUG DEV IND PHARM, V35, P515, DOI 10.1080/03639040802488097
   Musumeci T, 2006, INT J PHARM, V325, P172, DOI 10.1016/j.ijpharm.2006.06.023
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parker R, 2002, AM J PUBLIC HEALTH, V92, P343, DOI 10.2105/AJPH.92.3.343                                                           
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Peer D, 2010, J CONTROL RELEASE, V148, P63, DOI 10.1016/j.jconrel.2010.06.029
   Rao JP, 2011, PROG POLYM SCI, V36, P887, DOI 10.1016/j.progpolymsci.2011.01.001
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Rohan LC, 2010, PLOS ONE, V5
   SEHGAL D, 1994, ANAL BIOCHEM, V218, P87, DOI 10.1006/abio.1994.1144                                                          
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Smith Stephen M, 2004, Retrovirology, V1, P16, DOI 10.1186/1742-4690-1-16
   THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300                                                            
   THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   UNAIDS, 2011, UNAIDS 2011 WORLD AI
   Valentin A, 2010, AIDS RES HUM RETROV, V26, P79, DOI 10.1089/aid.2009.0044
   Vella S, 1998, CLIN PHARMACOKINET, V34, P189, DOI 10.2165/00003088-199834030-00002                                                
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   World Health Organization, 2009, WOMEN AND HEALTH: TODAY'S EVIDENCE TOMORROW'S AGENDA, P1
   Yang J, 2007, J MATER CHEM, V17, P2695, DOI 10.1039/b702538f
   Yang LL, 2009, SMALL, V5, P235, DOI 10.1002/smll.200800714
   Youle Mike, 2003, J Int Assoc Physicians AIDS Care (Chic), V2, P102, DOI 10.1177/154510970300200302
   Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007
NR 69
TC 17
Z9 17
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 2847
EP 2858
DI 10.2147/IJN.S46958
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 196XE
UT WOS:000322809900001
PM 23966779
OA gold
DA 2018-01-05
ER

PT J
AU Khan, AA
   Mudassir, J
   Mohtar, N
   Darwis, Y
AF Khan, Arshad Ali
   Mudassir, Jahanzeb
   Mohtar, Noratiqah
   Darwis, Yusrida
TI Advanced drug delivery to the lymphatic system: lipid-based
   nanoformulations
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE lymphatic system; blood circulation; solid lipid nanoparticles;
   nanostructured lipid carriers
ID CELL LUNG-CANCER; ENHANCED ORAL BIOAVAILABILITY; FLOW BLOCKING APPROACH;
   NANOPARTICLES SLN; CARRIERS NLC; FORMULATION DEVELOPMENT; ENGINEERED
   LIPOSOMES; LINEAR CORRELATION; LIPOPHILIC DRUGS; PEYERS-PATCHES
AB The delivery of drugs and bioactive compounds via the lymphatic system is complex and dependent on the physiological uniqueness of the system. The lymphatic route plays an important role in transporting extracellular fluid to maintain homeostasis and in transferring immune cells to injury sites, and is able to avoid first-pass metabolism, thus acting as a bypass route for compounds with lower bioavailability, ie, those undergoing more hepatic metabolism. The lymphatic route also provides an option for the delivery of therapeutic molecules, such as drugs to treat cancer and human immunodeficiency virus, which can travel through the lymphatic system. Lymphatic imaging is useful in evaluating disease states and treatment plans for progressive diseases of the lymph system. Novel lipid-based nanoformulations, such as solid lipid nanoparticles and nanostructured lipid carriers, have unique characteristics that make them promising candidates for lymphatic delivery. These formulations are superior to colloidal carrier systems because they have controlled release properties and provide better chemical stability for drug molecules. However, multiple factors regulate the lymphatic delivery of drugs. Prior to lymphatic uptake, lipid-based nanoformulations are required to undergo interstitial hindrance that modulates drug delivery. Therefore, uptake and distribution of lipid-based nanoformulations by the lymphatic system depends on factors such as particle size, surface charge, molecular weight, and hydrophobicity. Types of lipid and concentration of the emulsifier are also important factors affecting drug delivery via the lymphatic system. All of these factors can cause changes in intermolecular interactions between the lipid nanoparticle matrix and the incorporated drug, which in turn affects uptake of drug into the lymphatic system. Two lipid-based nanoformulations, ie, solid lipid nanoparticles and nanostructured lipid carriers, have been administered via multiple routes (subcutaneous, pulmonary, and intestinal) for targeting of the lymphatic system. This paper provides a detailed review of novel lipid-based nanoformulations and their lymphatic delivery via different routes, as well as the in vivo and in vitro models used to study drug transport in the lymphatic system. Physicochemical properties that influence lymphatic delivery as well as the advantages of lipid-based nanoformulations for lymphatic delivery are also discussed.
C1 [Khan, Arshad Ali; Mudassir, Jahanzeb; Mohtar, Noratiqah; Darwis, Yusrida] Univ Sains Malaysia, Sch Pharmaceut Sci, Minden 11800, Penang, Malaysia.
RP Darwis, Y (reprint author), Univ Sains Malaysia, Sch Pharmaceut Sci, Minden 11800, Penang, Malaysia.
EM yusrida@usm.my
FU Universiti Sains Malaysia [304/PFarmasi/6312023]
FX The authors would like to thank the Universiti Sains Malaysia for
   providing a short-term grant (304/PFarmasi/6312023) to support this
   work. The authors would also like to thank Miss Safia Akhtar for
   technical assistance.
CR Bargoni A, 1998, PHARMACEUT RES, V15, P745, DOI 10.1023/A:1011975120776
   Beg S, 2012, AAPS PHARMSCITECH, V13, P1416, DOI 10.1208/s12249-012-9865-5
   Beier R, 1998, AM J PHYSIOL-GASTR L, V275, pG130
   BOCCI V, 1986, EXPERIENTIA, V42, P432, DOI 10.1007/BF02118644
   Boyd M, 2004, J PHARMACOL TOX MET, V49, P115, DOI 10.1016/j.vascn.2003.11.004
   Cai S, 2008, J SURG RES, V147, P247, DOI 10.1016/j.jss.2008.02.048
   Cai S, 2011, ADV DRUG DELIVER REV, V63, P901, DOI 10.1016/j.addr.2011.05.017
   Tran Cao HS, 2011, ADV DRUG DELIV REV, V63
   Cavalli R, 2003, J PHARM SCI, V92, P1085, DOI 10.1002/jps.10368
   Cavalli R, 2000, PHARMACOL RES, V42, P541, DOI 10.1006/phrs.2000.0737
   Chalikwar SS, 2012, COLLOID SURFACE B, V97, P109, DOI 10.1016/j.colsurfb.2012.04.027
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   CHARMAN WNA, 1986, INT J PHARM, V34, P175, DOI 10.1016/0378-5173(86)90027-X
   Chen HM, 1998, ADV DRUG DELIVER REV, V34, P339, DOI 10.1016/S0169-409X(98)00047-7
   Chen XQ, 1996, NAT MED, V2, P1033
   Chen Y, 2008, BIOL PHARM BULL, V31, P118, DOI 10.1248/bpb.31.118
   Choi SH, 2008, EUR J PHARM BIOPHARM, V68, P545, DOI 10.1016/j.ejpb.2007.07.011
   Clark R, 1998, ONCOLOGY-NY, V12, P647
   Clogston JD, 2011, METHODS MOL BIOL, V697, P63, DOI 10.1007/978-1-60327-198-1_6
   Cohen MS, 2011, ADV DRUG DELIVER REV, V63, P865, DOI 10.1016/j.addr.2011.05.013
   Dahan A, 2005, EUR J PHARM SCI, V24, P381, DOI 10.1016/j.ejps.2004.12.006
   Dahan A, 2008, J CONTROL RELEASE, V129, P1, DOI 10.1016/j.jconrel.2008.03.021
   DAHLBACK B, 1981, ARCH MICROBIOL, V128, P267, DOI 10.1007/BF00422527
   Dixit AR, 2010, AAPS PHARMSCITECH, V11, P314, DOI 10.1208/s12249-010-9385-0
   Edwards GA, 2001, ADV DRUG DELIVER REV, V50, P45, DOI 10.1016/S0169-409X(01)00148-X
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   Frenkel V, 2006, ACAD RADIOL, V13, P469, DOI 10.1016/j.acra.2005.08.024
   Gershkovich P, 2005, EUR J PHARM SCI, V26, P394, DOI 10.1016/j.ejps.2005.07.011
   HAQUE AK, 1991, J THORAC IMAG, V7, P9, DOI 10.1097/00005382-199112000-00004                                                
   Harivardhan R.L., 2005, J CONTROL RELEASE, V105, P185, DOI DOI 10.1016/J.JCONREL.2005.02.028
   Hauss DJ, 1998, J PHARM SCI, V87, P164, DOI 10.1021/js970300n
   HAWLEY AE, 1995, ADV DRUG DELIVER REV, V17, P129, DOI 10.1016/0169-409X(95)00045-9
   Holm R, 2004, INT J PHARMACEUT, V272, P189, DOI 10.1016/j.ijpharm.2003.12.017
   Holm R, 2003, EUR J PHARM SCI, V20, P91, DOI 10.1016/S0928-0987(03)00174-X
   Holm R, 2012, EUR J PHARM BIOPHARM, V81, P281, DOI 10.1016/j.ejpb.2012.03.005
   Iqbal J, 2009, AM J PHYSIOL-ENDOC M, V296, pE1183, DOI 10.1152/ajpendo.90899.2008
   Jacobs C, 2000, INT J PHARM, V196, P161, DOI 10.1016/S0378-5173(99)00412-3                                                   
   JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58                                               
   Jaques PA, 2000, INHAL TOXICOL, V12, P715
   Jenning V, 2000, INT J PHARM, V199, P167, DOI 10.1016/S0378-5173(00)00378-1
   Jeong YI, 2008, J PHARM SCI-US, V97, P1268, DOI 10.1002/jps.21103
   Kagan L, 2007, EUR J PHARM BIOPHARM, V67, P759, DOI 10.1016/j.ejpb.2007.04.002
   Kaminskas LM, 2011, ADV DRUG DELIVER REV, V63, P890, DOI 10.1016/j.addr.2011.05.016
   Karpf DM, 2006, J PHARM SCI-US, V95, P45, DOI 10.1002/jps.20431
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Khoo SM, 2003, PHARMACEUT RES, V20, P1460, DOI 10.1023/A:1025718513246
   Khoo SM, 2001, J PHARM SCI, V90, P1599, DOI 10.1002/jps.1110
   Kojima N, 2008, J CONTROL RELEASE, V129, P26, DOI 10.1016/j.jconrel.2008.03.023
   Kommuru TR, 2001, INT J PHARM, V212, P233, DOI 10.1016/S0378-5173(00)00614-1
   LANGENBACK EG, 1990, J APPL PHYSIOL, V69, P1302
   Latimer P, 2009, EXP BIOL MED, V234, P1244, DOI 10.3181/0901-RM-8
   Lawson KA, 2004, CANCER CHEMOTH PHARM, V54, P421, DOI 10.1007/s00280-004-0817-y
   Lespine A, 2006, EUR J PHARM SCI, V27, P37, DOI 10.1016/j.ejps.2005.08.003
   Li XR, 2010, AAPS PHARMSCITECH, V11, P672, DOI 10.1208/s12249-010-9432-x
   Liggins RT, 2000, BIOMATERIALS, V21, P1959, DOI 10.1016/S0142-9612(00)00080-6
   Ling R, 2005, J DRUG TARGET, V13, P137, DOI 10.1080/10611860400027725
   Ling SSN, 2006, DRUG DEV IND PHARM, V32, P335, DOI 10.1080/03639040500519102
   Liu J, 2006, LUNG CANCER, V51, P377, DOI 10.1016/j.lungcan.2005.11.006
   Liu J, 2007, BIOMATERIALS, V28, P3236, DOI 10.1016/j.biomaterials.2007.03.022
   Lu HX, 2007, CANCER CHEMOTH PHARM, V59, P175, DOI 10.1007/s00280-006-0256-z
   Luo GP, 2010, INT J PHARMACEUT, V385, P150, DOI 10.1016/j.ijpharm.2009.10.014
   MAINCENT P, 1992, PHARMACEUT RES, V9, P1534, DOI 10.1023/A:1015895804597
   McAllaster JD, 2011, ADV DRUG DELIVER REV, V63, P867, DOI 10.1016/j.addr.2011.05.014
   McCarter MD, 2004, SURGERY, V135, P121, DOI 10.1016/S0039-6060(03)00342-8
   McIntire GL, 1998, J PHARM SCI, V87, P1466, DOI 10.1021/js980060r
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Miteva DO, 2010, CIRC RES, V106, P920, DOI 10.1161/CIRCRESAHA.109.207274
   Mogh SM, 2008, BBA-BIOMEMBRANES, V1778, P51, DOI 10.1016/j.bbamem.2007.08.033
   Moghimi SM, 1999, ADV DRUG DELIVER REV, V37, P295, DOI 10.1016/S0169-409X(98)00099-4                                                   
   Muchow M, 2011, DRUG DEV IND PHARM, V37, P8, DOI 10.3109/03639045.2010.489559
   Muller RH, 2007, ADV DRUG DELIVER REV, V59, P375, DOI 10.1016/j.addr.2007.05.002
   Muller RH, 2002, INT J PHARM, V242, P121, DOI 10.1016/S0378-5173(02)00180-1
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller RH, 2002, ADV DRUG DELIV REV, V54, P131, DOI 10.1016/S0169-409X(02)00118-7
   Muller R.H., 2000, HDB PHARM CONTROLLED
   Muranishi S, 1997, J CONTROL RELEASE, V46, P157, DOI 10.1016/S0168-3659(96)01588-X
   MYERS RA, 1992, INT J PHARM, V80, P51, DOI 10.1016/0378-5173(92)90261-Y
   Nune SK, 2011, ADV DRUG DELIVER REV, V63, P876, DOI 10.1016/j.addr.2011.05.020
   O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annone/mdh097
   O'Driscoll CM, 2008, ADV DRUG DELIVER REV, V60, P617, DOI 10.1016/j.addr.2007.10.012
   O'Driscoll CM, 2002, EUR J PHARM SCI, V15, P405, DOI 10.1016/S0928-0987(02)00051-9
   O'Driscol CM, 1992, LYMPHATIC TRANSPORT
   Onizuka M, 1997, J PHYSIOL-LONDON, V503, P223, DOI 10.1111/j.1469-7793.1997.223bi.x
   Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   Paliwal R, 2009, NANOMED-NANOTECHNOL, V5, P184, DOI 10.1016/j.nano.2008.08.003
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   PATEL HM, 1992, CRIT REV THER DRUG, V9, P39
   PATEL HM, 1984, BIOCHIM BIOPHYS ACTA, V801, P76, DOI 10.1016/0304-4165(84)90214-9
   Porter CJH, 1997, CRIT REV THER DRUG, V14, P333
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, P61, DOI 10.1016/S0169-409X(01)00151-X
   Porter CJH, 1997, ADV DRUG DELIVER REV, V25, P71, DOI 10.1016/S0169-409X(96)00492-9
   Rao DA, 2010, J PHARM SCI-US, V99, P2018, DOI 10.1002/jps.21970
   Sanjula B, 2009, J DRUG TARGET, V17, P249, DOI 10.1080/10611860902718672
   Saupe A, 2005, BIO-MED MATER ENG, V15, P393
   Seeballuck F, 2004, PHARM RES, V21, P2320, DOI 10.1007/s11095-004-7684-4                                                       
   Seeballuck F, 2003, PHARMACEUT RES, V20, P1085, DOI 10.1023/A:1024422625596                                                         
   Segrave AM, 2004, J PHARMACOL EXP THER, V309, P1085, DOI 10.1124/jpet.103.063289
   SIMON L, 1995, J DRUG TARGET, V3, P51, DOI 10.3109/10611869509015932                                                       
   Singh B, 2011, DRUG DELIV, V18, P599, DOI 10.3109/10717544.2011.604686
   Sleeman JP, 2006, LYMPHOLOGY, V39, P62
   Sleeman JP, 2000, RECENT RES CANCER, V157, P55
   Sun MH, 2011, EUR J PHARM SCI, V43, P132, DOI 10.1016/j.ejps.2011.04.011
   TAKADA K, 1986, J PHARMACOBIO-DYNAM, V9, P156
   TAKAKURA Y, 1987, INT J PHARM, V37, P145, DOI 10.1016/0378-5173(87)90019-6
   TAKAKURA Y, 1984, CANCER RES, V44, P2505
   Takakura Y, 1992, LYMPHATIC TRANSPORT
   Thakkar H, 2011, J PHARM BIOALLIED SC, V3, P442, DOI 10.4103/0975-7406.84463
   Trevaskis NL, 2008, ADV DRUG DELIVER REV, V60, P702, DOI 10.1016/j.addr.2007.09.007
   Uner M, 2006, PHARMAZIE, V61, P375
   Videira MA, 2002, J DRUG TARGET, V10, P607, DOI 10.1080/1061186021000054933
   Videira M, 2012, NANOMED-NANOTECHNOL, V8, P1208, DOI 10.1016/j.nano.2011.12.007
   Walker JE, 2009, ALCOHOL CLIN EXP RES, V33, P357, DOI 10.1111/j.1530-0277.2008.00844.x
   Wells JM, 2008, NAT REV MICROBIOL, V6, P349, DOI 10.1038/nrmicro1840
   WHITE DG, 1991, INT J PHARM, V69, P169, DOI 10.1016/0378-5173(91)90221-9
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Wu HF, 2011, EUR J PHARM SCI, V42, P348, DOI 10.1016/j.ejps.2010.12.010
   Yanez JA, 2011, ADV DRUG DELIVER REV, V63, P923, DOI 10.1016/j.addr.2011.05.019
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
   Yao Jing, 2008, J Pharm Pharm Sci, V11, P22
   YOSHIKAWA H, 1981, INT J PHARM, V8, P291
   Yuan H, 2007, COLLOID SURFACE B, V58, P157, DOI 10.1016/j.colsurfb.2007.03.002
   Zangemeister-Wittke U, 1999, CELL MOL LIFE SCI, V55, P1585, DOI 10.1007/s000180050398
   Zara GP, 2002, J PHARM SCI, V91, P1324, DOI 10.1002/jps.10129
   Zhou L, 2012, PHARMAZIE, V67, P304, DOI 10.1691/ph.2012.1108
   Zhuang CY, 2010, INT J PHARMACEUT, V394, P179, DOI 10.1016/j.ijpharm.2010.05.005
NR 127
TC 58
Z9 60
U1 1
U2 79
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 2733
EP 2744
DI 10.2147/IJN.S41521
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 188SP
UT WOS:000322214200001
PM 23926431
OA gold
DA 2018-01-05
ER

PT S
AU Ramage, G
   Williams, C
AF Ramage, Gordon
   Williams, Craig
BE Sariaslani, S
   Gadd, GM
TI The Clinical Importance of Fungal Biofilms
SO ADVANCES IN APPLIED MICROBIOLOGY, VOL 84
SE Advances in Applied Microbiology
LA English
DT Review; Book Chapter
ID CANDIDA-ALBICANS BIOFILMS; CENTRAL VENOUS CATHETER;
   ANTIFUNGAL-DRUG-RESISTANCE; VENTILATOR-ASSOCIATED PNEUMONIA;
   ASPERGILLUS-FUMIGATUS BIOFILM; ANTIBIOTIC LOCK TECHNIQUE;
   CRYPTOCOCCUS-NEOFORMANS BIOFILMS; SILVER COLLOIDAL NANOPARTICLES;
   PROSTHETIC VALVE ENDOCARDITIS; HUMAN-IMMUNODEFICIENCY-VIRUS
AB Fungal biofilms have become an increasingly important clinical problem. The widespread use of antibiotics, frequent use of indwelling medical devices, and a trend toward increased patient immunosuppression have resulted in a creation of opportunity for clinically important yeasts and molds to form biofilms. This review will discuss the diversity and importance of fungal biofilms in the context of clinical medicine, provide novel insights into the clinical management of fungal biofilm infection, present evidence why these structures are recalcitrant to antifungal therapy, and discuss how our knowledge and understanding may lead to novel therapeutic intervention.
C1 [Ramage, Gordon] Univ Glasgow, Infect & Immun Res Grp, Glasgow Dent Sch, Sch Med,Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.
   [Williams, Craig] Univ West Scotland, Inst Healthcare Associated Infect, Sch Hlth Nursing & Midwifery, Glasgow, Lanark, Scotland.
RP Ramage, G (reprint author), Univ Glasgow, Infect & Immun Res Grp, Glasgow Dent Sch, Sch Med,Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.
EM gordon.ramage@glasgow.ac.uk
CR Abad-Diaz-De-Cerio A., 2013, MED MYCOLOGY
   Agirbashi H, 2008, JPN J INFECT DIS, V61, P130
   Ajesh K, 2012, MYCOPATHOLOGIA, V174, P409, DOI 10.1007/s11046-012-9575-2
   Akins RA, 2005, MED MYCOL, V43, P285, DOI 10.1080/13693780500138971
   Al-Dhaheri RS, 2008, ANTIMICROB AGENTS CH, V52, P1884, DOI 10.1128/AAC.01473-07
   Al-Fattani MA, 2004, ANTIMICROB AGENTS CH, V48, P3291, DOI 10.1128/AAC.48.9.3291-3297.2004
   Al-Fattani MA, 2006, J MED MICROBIOL, V55, P999, DOI 10.1099/jmm.0.46569-0
   Albertson GD, 1996, ANTIMICROB AGENTS CH, V40, P2835
   Albuquerque P, 2012, MED MYCOL, V50, P337, DOI 10.3109/13693786.2011.652201
   Amin R, 2010, CHEST, V137, P171, DOI 10.1378/chest.09-1103
   Anaissie EJ, 2002, CLIN INFECT DIS, V35, pE86, DOI 10.1086/342305
   Anderson JB, 2005, NAT REV MICROBIOL, V3, P547, DOI 10.1038/nrmicrol179
   Andes D, 2004, INFECT IMMUN, V72, P6023, DOI 10.1128/IAI.72.10.6023-6031.2004
   Andes DR, 2012, CLIN INFECT DIS, V54, P1110, DOI 10.1093/cid/cis021
   Angel-Moreno A, 2005, J Infect, V51, pe85, DOI 10.1016/j.jinf.2004.08.034
   Ariani N, 2012, BIOFOULING, V28, P583, DOI 10.1080/08927014.2012.698614
   ARNOW P M, 1991, American Journal of Medicine, V90, P128, DOI 10.1016/0002-9343(91)90518-3
   Arslan SG, 2008, J ORAL PATHOL MED, V37, P26, DOI 10.1111/j.1600-0714.2007.00574.x
   Aslam S, 2011, INT J ARTIF ORGANS, V34, P752, DOI 10.5301/ijao.5000024
   Bachmann SP, 2002, ANTIMICROB AGENTS CH, V46, P3591, DOI 10.1128/AAC.46.11.3591-3596.2002
   Baillie GS, 2000, J ANTIMICROB CHEMOTH, V46, P397, DOI 10.1093/jac/46.3.397
   Baillie GS, 1998, ANTIMICROB AGENTS CH, V42, P1900
   Baillie GS, 1998, ANTIMICROB AGENTS CH, V42, P2146
   Bakaletz LO, 2007, PEDIATR INFECT DIS J, V26, pS17, DOI 10.1097/INF.0b013e318154b273
   Bamford CV, 2009, INFECT IMMUN, V77, P3696, DOI 10.1128/IAI.00438-09
   Bandara HMHN, 2009, J MED MICROBIOL, V58, P1623, DOI 10.1099/jmm.0.012989-0
   Banerjee U, 1997, J MED VET MYCOL, V35, P139
   Bauters TGM, 2001, MED MYCOL, V39, P379, DOI 10.1080/714031041
   Beauvais A, 2007, CELL MICROBIOL, V9, P1588, DOI 10.1111/j.1462-5822.2007.00895.x
   Beauvais A, 2009, FEMS YEAST RES, V9, P411, DOI 10.1111/j.1567-1364.2009.00482.x
   Beikler T, 2011, PERIODONTOL 2000, V55, P87, DOI 10.1111/j.1600-0757.2010.00360.x
   BENOIT JL, 1995, CLIN INFECT DIS, V21, P1286, DOI 10.1093/clinids/21.5.1286
   BERKOWITZ ID, 1979, MEDICINE, V58, P430, DOI 10.1097/00005792-197911000-00003                                                
   Bink A, 2011, ANTIMICROB AGENTS CH, V55, P4033, DOI 10.1128/AAC.00280-11
   Bizerra FC, 2008, FEMS YEAST RES, V8, P442, DOI 10.1111/j.1567-1364.2007.00347.x
   Blackwood RA, 2011, PEDIATR INFECT DIS J, V30, P1105, DOI 10.1097/INF.0b013e31822c84a4
   Blyth CC, 2010, MED MYCOL, V48, pS37, DOI 10.3109/13693786.2010.500627
   Boase S, 2011, INT FORUM ALLERGY RH, V1, P340, DOI 10.1002/alr.20066
   Boland JM, 2011, MYCOSES, V54, P354, DOI 10.1111/j.1439-0507.2010.01884.x
   Bonhomme J, 2011, MOL MICROBIOL, V80, P995, DOI 10.1111/j.1365-2958.2011.07626.x
   Branski LK, 2009, SURG INFECT, V10, P389, DOI 10.1089/sur.2009.024
   BRAUN DK, 1994, AM J KIDNEY DIS, V24, P864, DOI 10.1016/S0272-6386(12)80683-4                                                   
   Bruns S, 2010, PROTEOMICS, V10, P3097, DOI 10.1002/pmic.201000129
   Buckler BS, 2008, PEDIATR INFECT DIS J, V27, P762, DOI 10.1097/INF.0b013e318170b68b
   Bueid A, 2010, J ANTIMICROB CHEMOTH, V65, P2116, DOI 10.1093/jac/dkq279
   Buess M, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-237
   Bugli F., 2012, ANTIMICROBIAL AGENTS, V57, P1275
   Buijssen KJDA, 2012, HEAD NECK-J SCI SPEC, V34, P863, DOI 10.1002/hed.21833
   Busscher HJ, 1997, APPL ENVIRON MICROB, V63, P3810
   Canabarro A., 2012, J PERIODONTAL RES
   Cannizzo FT, 2007, MED MYCOL, V45, P357, DOI 10.1080/13693780701225767
   Cannon RD, 2007, MICROBIOL-SGM, V153, P3211, DOI 10.1099/mic.0.2007/010405-0
   Cannon RD, 2009, CLIN MICROBIOL REV, V22, P291, DOI 10.1128/CMR.00051-08
   Cao YY, 2005, ANTIMICROB AGENTS CH, V49, P584, DOI 10.1128/AAC.49.2.584-589.2005
   CARLSON E, 1982, INFECT IMMUN, V38, P921
   Carlson RP, 2008, J BIOMAT SCI-POLYM E, V19, P1035, DOI 10.1163/156856208784909372
   Carson CF, 2006, CLIN MICROBIOL REV, V19, P50, DOI 10.1128/CMR.19.1.50-62.2006
   Caserta RA, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-234
   Castagnola E, 2005, PEDIATR INFECT DIS J, V24, P747, DOI 10.1097/01.inf.0000172929.23419.cb
   Cateau E, 2008, J ANTIMICROB CHEMOTH, V62, P153, DOI 10.1093/jac/dkn160
   Cateau E, 2011, INT J ANTIMICROB AG, V37, P380, DOI 10.1016/j.ijantimicag.2010.12.016
   CECCHIN E, 1984, AM J KIDNEY DIS, V4, P280, DOI 10.1016/S0272-6386(84)80105-5                                                   
   Cetrulo CL, 2012, MICROSURG, V32, P144, DOI 10.1002/micr.20956
   Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001
   Chassot F, 2008, CONTRACEPTION, V77, P355, DOI 10.1016/j.contraception.2008.01.007
   Chi ZM, 2010, APPL MICROBIOL BIOT, V86, P1227, DOI 10.1007/s00253-010-2483-9
   Chotirmall SH, 2010, CHEST, V138, P1186, DOI 10.1378/chest.09-2996
   Chowdhary A, 2013, MYCOSES, V56, P1, DOI 10.1111/j.1439-0507.2012.02190.x
   Cimon B, 2000, EUR J CLIN MICROBIOL, V19, P53, DOI 10.1007/s100960050011
   Coco BJ, 2008, ORAL MICROBIOL IMMUN, V23, P377, DOI 10.1111/j.1399-302X.2008.00439.x
   Cornely OA, 2012, CLIN MICROBIOL INFEC, V18, P19, DOI 10.1111/1469-0691.12039
   Coulthwaite L, 2007, BRIT J BIOMED SCI, V64, P180, DOI 10.1080/09674845.2007.11732784                                                  
   Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370
   Cowen LE, 2008, NAT REV MICROBIOL, V6, P187, DOI 10.1038/nrmicro1835
   Cugini C, 2007, MOL MICROBIOL, V65, P896, DOI 10.1111/j.1365-2958.2007.05840.x
   Curvale-Fauchet N, 2004, MYCOSES, V47, P491, DOI 10.1111/j.1439-0507.2004.01047.x
   Cushion MT, 2009, EUKARYOT CELL, V8, P197, DOI 10.1128/EC.00202-08
   D'Antonio D, 2004, EUR J CLIN MICROBIOL, V23, P787, DOI 10.1007/s10096-004-1207-4
   Dai WeiWei, 2011, Dermatol Online J, V17, P5
   Damman CJ, 2012, AM J GASTROENTEROL, V107, P1452, DOI 10.1038/ajg.2012.93
   Davis LE, 2002, EMERG INFECT DIS, V8, P376, DOI 10.3201/eid0804.010103                                                          
   de Carvalho FG, 2006, ARCH ORAL BIOL, V51, P1024, DOI 10.1016/j.archoralbio.2006.06.001
   De Prijck K, 2010, MYCOPATHOLOGIA, V169, P167, DOI 10.1007/s11046-009-9242-4
   De Vos MM, 2006, J MICROBIOL METH, V64, P420, DOI 10.1016/j.mimet.2005.07.004
   DEBEER D, 1994, BIOTECHNOL BIOENG, V44, P636, DOI 10.1002/bit.260440510                                                           
   Deelstra JJ, 2013, J ARTHROPLASTY, V28, pe375
   Delhaes L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036313
   Delisle MS, 2011, CAN RESPIR J, V18, P131, DOI 10.1155/2011/827692                                                             
   Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943
   Di Bonaventura G, 2006, ANTIMICROB AGENTS CH, V50, P3269, DOI 10.1128/AAC.00556-06
   Ding C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028151
   Dongari-Bagtzoglou A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007967
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002
   Dowd SE, 2011, J WOUND CARE, V20, P40, DOI 10.12968/jowc.2011.20.1.40                                                      
   Dumitru R, 2004, ANTIMICROB AGENTS CH, V48, P2350, DOI 10.1128/AAC.48.7.2350-2354.2004
   Dusane DH, 2008, LETT APPL MICROBIOL, V47, P374, DOI 10.1111/j.1472-765X.2008.02440.x
   Dutronc H, 2010, SCAND J INFECT DIS, V42, P890, DOI 10.3109/00365548.2010.498023
   Ebbens FA, 2009, CURR OPIN OTOLARYNGO, V17, P43, DOI 10.1097/MOO.0b013e32831de91e
   Ebbens FA, 2009, CURR ALLERGY ASTHM R, V9, P114, DOI 10.1007/s11882-009-0017-2
   Ell SR, 1996, J LARYNGOL OTOL, V110, P240
   Ellis ME, 2001, CLIN INFECT DIS, V32, P50, DOI 10.1086/317550
   Elving GJ, 2001, J BIOMED MATER RES, V58, P421
   Enjalbert B, 2005, EUKARYOT CELL, V4, P1203, DOI 10.1128/EC.4.7.1203-1210.2005
   Escande W, 2011, ANN THORAC SURG, V91, pE92, DOI 10.1016/j.athoracsur.2011.01.102
   Falcone M, 2009, MEDICINE, V88, P160, DOI 10.1097/MD.0b013e3181a693f8
   Fanning S, 2012, EUKARYOT CELL, V11, P896, DOI 10.1128/EC.00103-12
   Fanning S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002585
   Fauvart M, 2011, J MED MICROBIOL, V60, P699, DOI 10.1099/jmm.0.030932-0
   Fazli M, 2009, J CLIN MICROBIOL, V47, P4084, DOI 10.1128/JCM.01395-09
   Feldman M, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-6
   Finkel JS, 2011, NAT REV MICROBIOL, V9, P109, DOI 10.1038/nrmicro2475
   Foreman A, 2011, LARYNGOSCOPE, V121, P1085, DOI 10.1002/lary.21438
   Fortun J, 2012, J INFECTION, V65, P64, DOI 10.1016/j.jinf.2012.02.011
   Fox PM, 2012, J PLAST RECONSTR AES, V65, pE286, DOI 10.1016/j.bjps.2012.04.049
   Gajer P, 2012, SCI TRANSL MED, V4
   Gangell C, 2011, CLIN INFECT DIS, V53, P425, DOI 10.1093/cid/cir399
   Ganguly S, 2011, EUKARYOT CELL, V10, P1448, DOI 10.1128/EC.05196-11
   Garzoni C, 2007, EUR J CLIN MICROBIOL, V26, P915, DOI 10.1007/s10096-007-0386-1
   Ghannoum MA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000713
   Gibson J, 2009, APPL ENVIRON MICROB, V75, P504, DOI 10.1128/AEM.01037-08
   Golmia R, 2011, SEMIN ARTHRITIS RHEU, V40, P580, DOI 10.1016/j.semarthrit.2010.07.007
   GOODMAN JS, 1983, J RHEUMATOL, V10, P494
   GOTTLIEB K, 1993, GASTROINTEST ENDOSC, V39, P413, DOI 10.1016/S0016-5107(93)70118-2                                                   
   Grimoud AM, 2005, ORAL DIS, V11, P163, DOI 10.1111/j.1601-0825.2005.01074.x                                                
   Grosjean P, 2007, EUR ARCH OTO-RHINO-L, V264, P461, DOI 10.1007/s00405-007-0281-5
   Guo F.-J., 2012, ANTON LEEUW INT J G, V103, P737
   Gutierrez-Correa M, 2012, APPL BIOCHEM BIOTECH, V167, P1235, DOI 10.1007/s12010-012-9555-5
   Hall-Stoodley L, 2012, FEMS IMMUNOL MED MIC, V65, P127, DOI 10.1111/j.1574-695X.2012.00968.x
   Hamet M, 2012, INTENS CARE MED, V38, P1272, DOI 10.1007/s00134-012-2584-2
   Harding MW, 2009, TRENDS MICROBIOL, V17, P475, DOI 10.1016/j.tim.2009.08.007
   Harriott MM, 2010, MICROBIOL-SGM, V156, P3635, DOI 10.1099/mic.0.039354-0
   Harriott MM, 2009, ANTIMICROB AGENTS CH, V53, P3914, DOI 10.1128/AAC.00657-09
   Hawser S, 1996, J MED VET MYCOL, V34, P407
   Hawser SP, 1998, J MED MICROBIOL, V47, P253, DOI 10.1099/00222615-47-3-253                                                       
   HEFFNER DK, 1978, AM J CLIN PATHOL, V70, P420
   Hogan DA, 2004, MOL MICROBIOL, V54, P1212, DOI 10.1111/j.1365-2958.2004.04349.x
   Hogan DA, 2002, SCIENCE, V296, P2229, DOI 10.1126/science.1070784
   Holmes AR, 2006, ORAL SURG ORAL MED O, V102, P488, DOI 10.1016/j.tripleo.2005.10.052
   Honraet K, 2005, J CLIN MICROBIOL, V43, P770, DOI 10.1128/JCM.43.2.770-777.2005
   Hornby JM, 2001, APPL ENVIRON MICROB, V67, P2982, DOI 10.1128/AEM.67.7.2982-2992.2001
   Hsu C. C., 2012, MED MYCOLOGY
   Humphreys G, 2011, J ANTIMICROB CHEMOTH, V66, P2556, DOI 10.1093/jac/dkr350
   Jakubovics NS, 2010, MOL ORAL MICROBIOL, V25, P4, DOI 10.1111/j.2041-1014.2009.00563.x
   Janagond Anand, 2012, Indian J Med Microbiol, V30, P229, DOI 10.4103/0255-0857.96704
   Jayshree RS, 2006, J MED MICROBIOL, V55, P961, DOI 10.1099/jmm.0.46394-0
   Jeloka TK, 2011, PERITON DIALYSIS INT, V31, P211, DOI 10.3747/pdi.2010.00099
   Johannsson B, 2009, DIAGN MICR INFEC DIS, V64, P76, DOI 10.1016/j.diagmicrobio.2009.01.005
   JOHNSON DC, 1994, PEDIATR INFECT DIS J, V13, P930, DOI 10.1097/00006454-199410000-00015
   Jose A, 2010, J PROSTHODONT, V19, P252, DOI 10.1111/j.1532-849X.2009.00561.x
   Joyner PM, 2010, ORG BIOMOL CHEM, V8, P5486, DOI 10.1039/c0ob00579g
   Kaneko Y, 2010, MED MYCOL, V48, P606, DOI 10.3109/13693780903426721
   Kania RE, 2010, BIOFOULING, V26, P519, DOI 10.1080/08927014.2010.489238
   Karkas A, 2012, EUROPEAN ARCH OTORHI, V270, P893
   Kauffman CA, 2011, CLIN INFECT DIS, V52, pS452, DOI 10.1093/cid/cir111
   Keir J, 2011, J LARYNGOL OTOL, V125, P331, DOI 10.1017/S0022215111000016
   Kelesidis T, 2010, SCAND J INFECT DIS, V42, P12, DOI 10.3109/00365540903253510
   Khot PD, 2006, ANTIMICROB AGENTS CH, V50, P3708, DOI 10.1128/AAC.00997-06
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Klaerner HG, 1997, J SURG RES, V70, P161, DOI 10.1006/jsre.1997.5110
   Ko KS, 2010, J KOREAN MED SCI, V25, P1722, DOI 10.3346/jkms.2010.25.12.1722
   KOMSHIAN SV, 1989, REV INFECT DIS, V11, P379
   Kondori N, 2011, J CLIN MICROBIOL, V49, P1004, DOI 10.1128/JCM.01899-10
   Kraneveld EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042770
   Kruppa M, 2004, EUKARYOT CELL, V3, P1062, DOI 10.1128/EC.3.4.1062-1065.2004
   Krzossok S, 2004, CLIN NEPHROL, V62, P66
   KRZYWDA EA, 1995, INFECT CONT HOSP EP, V16, P596
   Kucharikova S, 2011, J MED MICROBIOL, V60, P1261, DOI 10.1099/jmm.0.032037-0
   Kucharikova S, 2010, ANTIMICROB AGENTS CH, V54, P4474, DOI 10.1128/AAC.00697-10
   Kuhn DM, 2002, ANTIMICROB AGENTS CH, V46, P1773, DOI 10.1128/AAC.46.6.1773-1780.2002
   Kuhn DM, 2002, INFECT IMMUN, V70, P878, DOI 10.1128/IAI.70.2.878-888.2002
   Kuhn DM, 2003, J CLIN MICROBIOL, V41, P506, DOI 10.1128/JCM.41.1.506-508.2003
   Kumamoto CA, 2005, P NATL ACAD SCI USA, V102, P5576, DOI 10.1073/pnas.0407097102
   Kumamoto CA, 2011, CURR OPIN MICROBIOL, V14, P386, DOI 10.1016/j.mib.2011.07.015
   LaFleur MD, 2006, ANTIMICROB AGENTS CH, V50, P3839, DOI 10.1128/AAC.00684-06
   LaFleur MD, 2010, ANTIMICROB AGENTS CH, V54, P39, DOI 10.1128/AAC.00860-09
   Langer Philip, 2003, Am J Orthop (Belle Mead NJ), V32, P402
   Lass-Florl C, 2003, INT J ANTIMICROB AG, V21, P229, DOI 10.1016/S0924-8579(02)00189-9
   LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991                                                
   Lazzell AL, 2009, J ANTIMICROB CHEMOTH, V64, P567, DOI 10.1093/jac/dkp242
   Leake J L, 2009, J Wound Care, V18, P103
   Leake J.L., 2009, J WOUND CARE, V18, P108
   Leake J. L., 2009, J WOUND CARE, V18, P106
   Leclair LW, 2010, MED MYCOL, V48, pS125, DOI 10.3109/13693786.2010.521522
   Lee Sang Wook, 2010, Korean J Urol, V51, P216, DOI 10.4111/kju.2010.51.3.216
   Lepak A, 2006, ANTIMICROB AGENTS CH, V50, P1311, DOI 10.1128/AAC.50.4.1311-1319.2006
   Lermann U, 2008, MICROBIOL-SGM, V154, P3281, DOI 10.1099/mic.0.2008/022525-0
   Lewis K, 2008, CURR TOP MICROBIOL, V322, P107
   Lewis K, 2010, ANNU REV MICROBIOL, V64, P357, DOI 10.1146/annurev.micro.112408.134306
   Li F, 2007, EUKARYOT CELL, V6, P931, DOI 10.1128/EC.00049-07
   Lifshitz DA, 1999, J ENDOUROL, V13, P735, DOI 10.1089/end.1999.13.735
   Liu G, 2009, PEDIATR RES, V66, P600, DOI 10.1203/PDR.0b013e3181bd5bf8
   Lopez-Ribot JL, 1999, ANTIMICROB AGENTS CH, V43, P1621
   Sato FRL, 2010, J AM DENT ASSOC, V141, P1231, DOI 10.14219/jada.archive.2010.0050                                                 
   Loussert C, 2010, CELL MICROBIOL, V12, P405, DOI 10.1111/j.1462-5822.2009.01409.x
   Ma B, 2012, ANNU REV MICROBIOL, V66, P371, DOI 10.1146/annurev-micro-092611-150157
   Macfarlane S, 2007, J APPL MICROBIOL, V102, P1187, DOI 10.1111/j.1365-2672.2007.03287.x
   Macfarlane S, 2008, J CLIN GASTROENTEROL, V42, pS142, DOI 10.1097/MCG.0b013e31816207df
   Mansur AJ, 1996, CLIN INFECT DIS, V22, P380, DOI 10.1093/clinids/22.2.380                                                        
   Martin TJ, 2005, INT J PEDIATR OTORHI, V69, P1503, DOI 10.1016/j.ijporl.2005.04.012
   Martinez LR, 2006, ANTIMICROB AGENTS CH, V50, P1021, DOI 10.1128/AAC.50.3.1021-1033.2006
   Martinez LR, 2010, J INFECT DIS, V201, P1436, DOI 10.1086/651558
   Martinez LR, 2010, BIOMATERIALS, V31, P669, DOI 10.1016/j.biomaterials.2009.09.087
   Martinez-Pajares JD, 2010, J MED MICROBIOL, V59, P367, DOI 10.1099/jmm.0.012799-0
   MARTINS M, 2011, MYCOSES, V55, P80
   Martins M, 2010, MYCOPATHOLOGIA, V169, P323, DOI 10.1007/s11046-009-9264-y
   Mason KL, 2012, INFECT IMMUN, V80, P3371, DOI 10.1128/IAI.00449-12
   Mateus C, 2004, ANTIMICROB AGENTS CH, V48, P3358, DOI 10.1128/AAC.48.9.3358-3366.2004
   McMillan A, 2011, COLLOID SURFACE B, V86, P58, DOI 10.1016/j.colsurfb.2011.03.016
   Meurman JH, 2005, EUR J ORAL SCI, V113, P188, DOI 10.1111/j.1600-0722.2005.00191.x
   Mignogna MD, 2011, INT J INFECT DIS, V15, pE533, DOI 10.1016/j.ijid.2011.02.005
   Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165
   Mitchell KF, 2013, ANTIMICROB AGENTS CH, V57, P1918, DOI 10.1128/AAC.02378-12
   Monteiro DR, 2011, BIOFOULING, V27, P711, DOI 10.1080/08927014.2011.599101
   Monteiro DR, 2012, J PROSTHODONT, V21, P7, DOI 10.1111/j.1532-849X.2011.00772.x
   Monteiro DR, 2012, J APPL MICROBIOL, V114, P1175
   Morales DK, 2010, MOL MICROBIOL, V78, P1379, DOI 10.1111/j.1365-2958.2010.07414.x
   Morschhauser J, 2010, FUNGAL GENET BIOL, V47, P94, DOI 10.1016/j.fgb.2009.08.002
   Mowat E, 2008, MED MYCOL S1, V47, pS120
   Mowat E, 2008, J ANTIMICROB CHEMOTH, V62, P1281, DOI 10.1093/jac/dkn402
   Mowat E, 2010, FEMS MICROBIOL LETT, V313, P96, DOI 10.1111/j.1574-6968.2010.02130.x
   Muller FMC, 2011, MED MYCOL, V49, pS96, DOI 10.3109/13693786.2010.502190
   Mukherjee PK, 2003, INFECT IMMUN, V71, P4333, DOI 10.1128/IAI.71.84333-4340.2003
   Mukherjee PK, 2009, INT J ANTIMICROB AG, V33, P149, DOI 10.1016/j.ijantimicag.2008.07.030
   Murzyn A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012050
   Naglik J, 2004, CELL MICROBIOL, V6, P915, DOI 10.1111/j.1462-5822.2004.00439.x
   Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003
   Naglik JR, 2006, J MED MICROBIOL, V55, P1323, DOI 10.1099/jmm.0.46737-0
   Naglik JR, 2008, MICROBIOL-SGM, V154, P3266, DOI 10.1099/mic.0.2008/022293-0
   Nailis H, 2010, RES MICROBIOL, V161, P284, DOI 10.1016/j.resmic.2010.02.004
   Nam KY, 2011, J ADV PROSTHODONT, V3, P20, DOI 10.4047/jap.2011.3.1.20
   Navarathna DHMLP, 2007, INFECT IMMUN, V75, P1609, DOI 10.1128/IAI.01182-06
   Negri M, 2012, EUR J CLIN MICROBIOL, V31, P1399, DOI 10.1007/s10096-011-1455-z
   Nett J, 2007, ANTIMICROB AGENTS CH, V51, P510, DOI 10.1128/AAC.01056-06
   Nett JE, 2011, EUKARYOT CELL, V10, P1660, DOI 10.1128/EC.05126-11
   Nett JE, 2011, J CLIN MICROBIOL, V49, P1426, DOI 10.1128/JCM.02273-10
   Nett JE, 2010, INFECT IMMUN, V78, P3650, DOI 10.1128/IAI.00480-10
   Nett JE, 2010, ANTIMICROB AGENTS CH, V54, P3505, DOI 10.1128/AAC.00227-10
   Nett JE, 2010, J INFECT DIS, V202, P171, DOI 10.1086/651200
   Nett JE, 2009, J INFECT DIS, V200, P307, DOI 10.1086/599838
   Newton A.V., 1962, BRIT DENT J, P357
   Niimi K, 2006, ANTIMICROB AGENTS CH, V50, P1148, DOI 10.1128/AAC.50.4.1148-1155.2006
   Niimi M, 2010, ODONTOLOGY, V98, P15, DOI 10.1007/s10266-009-0118-3
   Ninomiya K, 2012, BIOL PHARM BULL, V35, P861, DOI 10.1248/bpb.35.861
   Nobile CJ, 2006, CELL MICROBIOL, V8, P1382, DOI 10.1111/j.1462-5822.2006.00761.x
   Nobile CJ, 2012, CELL, V148, P126, DOI 10.1016/j.cell.2011.10.048
   Nobile CJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000133
   Nucci M, 2010, CLIN INFECT DIS, V51, P295, DOI 10.1086/653935
   O'Grady NP, 2011, CLIN INFECT DIS, V52, pE162, DOI 10.1093/cid/cir257
   ODDS FC, 1988, CANDIDA CANDIDOSIS
   Oliveira C, 2012, PEDIATRICS, V129, P318, DOI 10.1542/peds.2011-1602
   Onyewu C, 2003, ANTIMICROB AGENTS CH, V47, P956, DOI 10.1128/AAC.47.3.956-964.2003
   Ozdemir H, 2011, MYCOSES, V54, pE647, DOI 10.1111/j.1439-0507.2010.01964.x
   PAIGE C, 1987, WESTERN J MED, V147, P333
   Pammi M, 2013, PEDIAT INFECT DIS J
   Pannanusorn S, 2012, MYCOSES, V56, P264
   Papi M, 2012, MICROSC MICROANAL, V18, P1088, DOI 10.1017/S1431927612001067
   Park KH, 2010, CLIN MICROBIOL INFEC, V16, P742, DOI 10.1111/j.1469-0691.2009.02926.x
   Percival SL, 2005, INFECT CONT HOSP EP, V26, P515, DOI 10.1086/502577
   Pereira-Cenci T, 2008, J APPL ORAL SCI, V16, P86, DOI 10.1590/S1678-77572008000200002
   Perumal P, 2007, ANTIMICROB AGENTS CH, V51, P2454, DOI 10.1128/AAC.01237-06
   Peters BM, 2013, ANTIMICROB AGENTS CH, V57, P74, DOI 10.1128/AAC.01599-12
   Peters BM, 2012, CLIN MICROBIOL REV, V25, P193, DOI 10.1128/CMR.00013-11
   Peters BM, 2010, FEMS IMMUNOL MED MIC, V59, P493, DOI 10.1111/j.1574-695X.2010.00710.x
   Pettit RK, 2010, MED MYCOL, V48, P421, DOI [10.3109/13693780903136879, 10.1080/13693780903136879]
   Piddock LJV, 2006, NAT REV MICROBIOL, V4, P629, DOI 10.1038/nrmicro1464
   Pieroni K. P., 2012, PEDIATR INFECT DIS J, V32, P289
   Pihet M, 2009, MED MYCOL, V47, P387, DOI 10.1080/13693780802609604
   Pini G, 2005, MYCOSES, V48, P45, DOI 10.1111/j.1439-0507.2004.01062.x
   PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101
   Pulcrano G, 2012, FEMS YEAST RES, V12, P430, DOI 10.1111/j.1567-1364.2012.00792.x
   Puri S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046020
   Raad I, 2007, ANTIMICROB AGENTS CH, V51, P78, DOI 10.1128/AAC.00154-06
   Rajendran R, 2013, EUKARYOT CELL, V12, P420, DOI 10.1128/EC.00287-12
   Rajendran R, 2011, ANTIMICROB AGENTS CH, V55, P2092, DOI 10.1128/AAC.01189-10
   Rajendran R, 2010, MYCOPATHOLOGIA, V170, P229, DOI 10.1007/s11046-010-9319-0
   Ramage G, 2001, ANTIMICROB AGENTS CH, V45, P2475, DOI 10.1128/AAC.45.9.2475-2479.2001
   Ramage G, 2004, ORAL SURG ORAL MED O, V98, P53, DOI 10.1016/j.tripleo.2003.04.002
   Ramage G, 2002, APPL ENVIRON MICROB, V68, P5459, DOI 10.1128/AEM.68.11.5459-5463.2002
   Ramage G, 2002, J ANTIMICROB CHEMOTH, V49, P973, DOI [10.1093/jac/dkf049, 10.1093/jac.dkf049]
   Ramage G, 2002, FEMS MICROBIOL LETT, V214, P95, DOI 10.1016/S0378-1097(02)00853-4
   Ramage G, 2012, INT J MICROBIOL, V2012, DOI DOI 10.1155/2012/528521
   Ramage G, 2007, MYCOPATHOLOGIA, V164, P301, DOI 10.1007/s11046-007-9068-x
   Ramage G, 2006, FEMS YEAST RES, V6, P979, DOI 10.1111/j.1567-1364.2006.00117.x
   Ramage G, 2013, ANTIMICROB AGENTS CH, V57, P2369, DOI 10.1128/AAC.02344-12
   Ramage G, 2012, J PROSTHODONT, V21, P516, DOI 10.1111/j.1532-849X.2012.00865.x
   Ramage G, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00220
   Ramage G, 2012, MYCOPATHOLOGIA, V174, P11, DOI 10.1007/s11046-012-9522-2
   Ramage G, 2011, FEMS MICROBIOL LETT, V324, P89, DOI 10.1111/j.1574-6968.2011.02381.x
   Ramage G, 2011, ORAL SURG ORAL MED O, V111, P456, DOI 10.1016/j.tripleo.2010.10.043
   Ramage G, 2009, CRIT REV MICROBIOL, V35, P340, DOI 10.3109/10408410903241436
   Rautemaa R, 2007, J ANTIMICROB CHEMOTH, V60, P889, DOI 10.1093/jac/dkm299
   Rautemaa R, 2011, CRIT REV MICROBIOL, V37, P328, DOI 10.3109/1040841X.2011.585606
   REDDING S, 1994, CLIN INFECT DIS, V18, P240, DOI 10.1093/clinids/18.2.240                                                        
   Reddy BT, 2002, SCAND J INFECT DIS, V34, P143, DOI 10.1080/00365540110026895
   REID G, 1992, J UROLOGY, V148, P1592, DOI 10.1016/S0022-5347(17)36976-8                                                   
   Reis LJ, 2005, CLIN INFECT DIS, V41, P752, DOI 10.1086/432580
   REX JH, 1995, CLIN INFECT DIS, V21, P994, DOI 10.1093/clinids/21.4.994                                                        
   Richardson M, 2009, CLIN MICROBIOL INFEC, V15, P2, DOI 10.1111/j.1469-0691.2009.02972.x
   Robbins N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002257
   Robertson EJ, 2012, APPL ENVIRON MICROB, V78, P7977, DOI 10.1128/AEM.01953-12
   Rodrigues L, 2006, FEMS IMMUNOL MED MIC, V46, P107, DOI 10.1111/j.1574-695X.2005.00006.x
   Rodrigues L, 2004, APPL MICROBIOL BIOT, V66, P306, DOI 10.1007/s00253-004-1674-7
   Rombaux P., 1996, Rhinology (Utrecht), V34, P237
   Rosenblatt WB, 1997, PLAST RECONSTR SURG, V99, P1470, DOI 10.1097/00006534-199704001-00059                                                
   Ruan SY, 2009, CLIN INFECT DIS, V49, pE11, DOI 10.1086/599614
   Rukayadi Y., 2012, PHYTOTHERAPY RES
   Sa HS, 2012, DIAGN MICR INFEC DIS, V73, P376, DOI 10.1016/j.diagmicrobio.2012.05.005
   Salim N, 2013, INT J ANTIMICROB AG, V41, P193, DOI 10.1016/j.ijantimicag.2012.09.006
   SAMARANAYAKE LP, 1986, J ORAL PATHOL MED, V15, P386, DOI 10.1111/j.1600-0714.1986.tb00646.x
   Sanglard D, 2003, MOL MICROBIOL, V48, P959, DOI 10.1046/j.1365-2958.2003.03495.x
   Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405                                                      
   Sardi JCO, 2013, J MED MICROBIOL, V62, P10, DOI 10.1099/jmm.0.045054-0
   Sardi Janaina C O, 2010, J Oral Sci, V52, P177
   Sayed S. I., 2012, J INDIAN MED ASSOC, V110, P180
   Sayed Suhail I, 2012, Ear Nose Throat J, V91, pE19
   Schinabeck MK, 2004, ANTIMICROB AGENTS CH, V48, P1727, DOI 10.1128/AAC.48.5.1727-1732.2004
   Seidler MJ, 2008, ANTIMICROB AGENTS CH, V52, P4130, DOI 10.1128/AAC.00234-08
   Seneviratne CJ, 2010, PROTEOMICS, V10, P1444, DOI 10.1002/pmic.200900611
   Serban Raluca Ioana, 2010, Rev Med Chir Soc Med Nat Iasi, V114, P1077
   Seth AK, 2012, J SURG RES, V178, P330, DOI 10.1016/j.jss.2012.06.048
   Shapiro RS, 2011, MICROBIOL MOL BIOL R, V75, P213, DOI 10.1128/MMBR.00045-10
   Sherry L, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00116
   Short DPG, 2011, J CLIN MICROBIOL, V49, P4264, DOI 10.1128/JCM.05468-11
   Shuford JA, 2006, J INFECT DIS, V194, P710, DOI 10.1086/506452
   Sibley CD, 2008, P NATL ACAD SCI USA, V105, P15070, DOI 10.1073/pnas.0804326105
   Sibley CD, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000184
   Silva S, 2011, FEMS MICROBIOL REV, V36, P288, DOI DOI 10.1111/J.1574-6976.2011.00278.X
   Silva S, 2011, J ORAL PATHOL MED, V40, P421, DOI 10.1111/j.1600-0714.2010.00981.x
   Silva S, 2009, MED MYCOL, V47, P681, DOI 10.3109/13693780802549594
   Silverman RJ, 2010, INFECT IMMUN, V78, P4644, DOI 10.1128/IAI.00685-10
   Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627
   Singh R, 2011, MICROBIOL-SGM, V157, P2611, DOI 10.1099/mic.0.048504-0
   Singh SD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000532
   Singhal D, 2011, AM J RHINOL ALLERGY, V25, P219, DOI 10.2500/ajra.2011.25.3622
   Siqueira JF, 2004, ORAL SURG ORAL MED O, V97, P632, DOI 10.1016/j.tripleo.2003.12.022
   Siqueira VM, 2011, INT J ENV RES PUB HE, V8, P456, DOI 10.3390/ijerph8020456
   Sobel JD, 2011, CLIN INFECT DIS, V52, pS433, DOI 10.1093/cid/cir109
   Won Song J., 2008, MED MYCOL, V42, P1
   Steinbach WJ, 2007, NAT REV MICROBIOL, V5, P418, DOI 10.1038/nrmicro1680
   Stonecypher K, 2010, CRIT CARE NURS Q, V33, P339, DOI 10.1097/CNQ.0b013e3181f649a6
   Taff HT, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002848
   Taff HT, 2012, MED MYCOL, V50, P214, DOI 10.3109/13693786.2011.580016
   TCHEKMEDYIAN NS, 1986, AM J MED SCI, V291, P419, DOI 10.1097/00000441-198606000-00009                                                
   Tobudic S, 2010, MYCOSES, V53, P208, DOI 10.1111/j.1439-0507.2009.01690.x
   Tre-Hardy M, 2008, INT J ANTIMICROB AG, V31, P329, DOI 10.1016/j.ijantimicag.2007.12.005
   Trevisani L, 2005, DIGEST DIS SCI, V50, P463, DOI 10.1007/s10620-005-2459-2
   Tumbarello M, 2012, PLOS ONE, V7
   Tumbarello M, 2007, J CLIN MICROBIOL, V45, P1843, DOI 10.1128/JCM.00131-07
   Uppuluri P, 2008, ANTIMICROB AGENTS CH, V52, P1127, DOI 10.1128/AAC.01397-07
   Uppuluri P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000828
   VALDIVIESO M, 1976, CANCER, V38, P1750, DOI 10.1002/1097-0142(197610)38:4<1750::AID-CNCR2820380450>3.0.CO;2-3
   Vediyappan G, 2010, ANTIMICROB AGENTS CH, V54, P2096, DOI 10.1128/AAC.01638-09
   Viale P, 2001, CLIN INFECT DIS, V33, P1947, DOI 10.1086/323554                                                                  
   Wada M, 1998, J ARTHROPLASTY, V13, P479, DOI 10.1016/S0883-5403(98)90019-5
   Wallner M., 2012, HERZ
   Walraven CJ, 2013, ANTIMICROB AGENTS CH, V57, P1, DOI 10.1128/AAC.01351-12
   Walsh TJ, 1997, J MED VET MYCOL, V35, P133
   WALSH TJ, 1986, NEUROSURGERY, V18, P373, DOI 10.1227/00006123-198603000-00025                                                
   WALTER EB, 1990, SOUTHERN MED J, V83, P837, DOI 10.1097/00007611-199007000-00027                                                
   Wang XR, 2012, J NAT PROD, V75, P707, DOI 10.1021/np2009994
   Wang XR, 2012, ORG BIOMOL CHEM, V10, P2044, DOI 10.1039/c2ob06856g
   Warkentien T, 2012, CLIN INFECT DIS, V55, P1441, DOI 10.1093/cid/cis749
   White TC, 1997, ANTIMICROB AGENTS CH, V41, P1482
   Williams DW, 2011, PERIODONTOL 2000, V55, P250, DOI 10.1111/j.1600-0757.2009.00338.x
   Wolcott RD, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-226
   Wu CY, 2007, J ANTIMICROB CHEMOTH, V60, P706, DOI 10.1093/jac/dkm262                                                              
   Xie ZH, 2012, J INFECT DIS, V206, P1936, DOI 10.1093/infdis/jis607
   Yang SP, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-10
   Yao M, 2001, ANN OTO RHINOL LARYN, V110, P377, DOI 10.1177/000348940111000415                                                      
   Yeater KM, 2007, MICROBIOL-SGM, V153, P2373, DOI 10.1099/mic.0.2007/006163-0
   YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002                                                
   YOUNKIN S, 1984, J BONE JOINT SURG AM, V66A, P142, DOI 10.2106/00004623-198466010-00023                                                
   Yu LH, 2012, ANTIMICROB AGENTS CH, V56, P770, DOI 10.1128/AAC.05290-11
   Zhao X, 2006, MICROBIOL-SGM, V152, P2287, DOI 10.1099/mic.0.28959-0
NR 374
TC 19
Z9 19
U1 2
U2 41
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-2164
BN 978-0-12-407800-0
J9 ADV APPL MICROBIOL
JI Adv. Appl. Microbiol.
PY 2013
VL 84
BP 27
EP 83
DI 10.1016/B978-0-12-407673-0.00002-3
PG 57
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA BFP97
UT WOS:000320924000002
PM 23763758
DA 2018-01-05
ER

PT J
AU Xu, XHN
   Wen, ZY
   Brownlow, WJ
AF Xu, Xiao-Hong Nancy
   Wen, Zhaoyang
   Brownlow, William J.
TI Ultrasensitive analysis of binding affinity of HIV receptor and
   neutralizing antibodies using solution-phase electrochemiluminescence
   assay
SO JOURNAL OF ELECTROANALYTICAL CHEMISTRY
LA English
DT Article
DE Electrochemiluminescence; Binding constant; Binding affinity; HIV
   receptors; CD4; gp120-CD4
ID ELECTROGENERATED CHEMILUMINESCENT DETECTION; ALKANEBISPHOSPHONATE
   THIN-FILM; OPTICAL NANOSCOPY PHOTON; BICINCHONINIC ACID; DNA; CD4;
   IMMOBILIZATION; IMMUNOASSAYS; ENVELOPE; VACCINES
AB Binding of a few ligand molecules with its receptors on cell surface can initiate cellular signaling transduction pathways, and trigger viral infection of host cells. HIV-1 infects host T-cells by binding its viral envelope protein (gp120) with its receptor (a glycoprotein, CD4) on T cells. Primary strategies to prevent and treat HIV infection is to develop therapies (e.g., neutralizing antibodies) that can block specific binding of CD4 with gp120. The infection often leads to the lower counts of CD4 cells, which makes it an effective biomarker to monitor the AIDS progression and treatment. Despite research over decades, quantitative assays for effective measurements of binding affinities of protein-protein (ligand-receptor, antigen-antibody) interactions remains highly sought. Solid-phase electrochemiluminescence (ECL) immunoassay has been commonly used to capture analytes from the solution for analysis, which involves immobilization of antibody on solid surfaces (micron-sized beads), but it cannot quantitatively measure binding affinities of molecular interactions. In this study, we have developed solution-phase ECL assay with a wide dynamic range (0-2 nM) and high sensitivity and specificity for quantitative analysis of CD4 at femtomolar level and their binding affinity with gp120 and monoclonal antibodies (MABs). We found that binding affinities of CD4 with gp120 and MAB (Q4120) are 9.5 x 10(8) and 1.2 x 10(9) M-1, respectively. The results also show that MAB (Q4120) of CD4 can completely block the binding of gp120 with CD4, while MAB (17b) of gp120 can only partially block their interaction. This study demonstrates that the solution-phase ECL assay can be used for ultrasensitive and quantitative analysis of binding affinities of protein-protein interactions in solution for better understating of protein functions and identification of effective therapies to block their interactions. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Xu, Xiao-Hong Nancy; Wen, Zhaoyang; Brownlow, William J.] Old Dominion Univ, Dept Chem & Biochem, Norfolk, VA 23529 USA.
RP Xu, XHN (reprint author), Old Dominion Univ, Dept Chem & Biochem, Norfolk, VA 23529 USA.
EM xhxu@odu.edu
FU NIH [R21-RR15057, R01GM076440, 3R01GM764401-4S1]; Old Dominion Summer
   Fellowship; Dominion Scholar Fellowship
FX This work is supported in part by NIH (R21-RR15057; R01GM076440;
   3R01GM764401-4S1), Old Dominion Summer Fellowship (Brownlow) and
   Dominion Scholar Fellowship (Wen). We thank NIH AIDS Reagent Program for
   providing us with all related proteins and antibodies.
CR ATKINS PW, 1982, PHYSICAL CHEM, P823
   Bard A. J., 2004, ELECTROGENERATED CHE, P1
   BARD AJ, 1980, ELECTROCHEMICAL METH, P488
   Bard A. J., 2000, ENCY ANAL CHEM APPL, P9842
   BLACKBURN GF, 1991, CLIN CHEM, V37, P1534
   BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243
   Carter MT, 1990, BIOCONJUGATE CHEM, V1, P257, DOI 10.1021/bc00004a005
   Cicala C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S2
   Cludts I, 2010, CYTOKINE, V50, P129, DOI 10.1016/j.cyto.2010.01.001
   Cosa G, 2001, PHOTOCHEM PHOTOBIOL, V73, P585, DOI 10.1562/0031-8655(2001)073<0585:PPOFDD>2.0.CO;2
   Debad JD, 2004, MG ELEC CH, P359
   Huang T, 2012, NANOSCALE, V4, P2797, DOI 10.1039/c2nr11739h
   Huang T, 2011, NANOSCALE, V3, P3567, DOI 10.1039/c1nr10182j
   Huang T, 2008, J AM CHEM SOC, V130, P17095, DOI 10.1021/ja8068853
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Montefiori DC, 2009, CURR OPIN HIV AIDS, V4, P347, DOI 10.1097/COH.0b013e32832f4a4d
   RODRIGUEZ M, 1990, ANAL CHEM, V62, P2658, DOI 10.1021/ac00223a002
   Roundhill D. M., 1994, PHOTOCHEMISTRY PHOTO
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   TUSZYNSKI GP, 1990, ANAL BIOCHEM, V184, P189, DOI 10.1016/0003-2697(90)90032-5
   XU XH, 1995, J AM CHEM SOC, V117, P2627, DOI 10.1021/ja00114a027                                                             
   XU XH, 1994, J AM CHEM SOC, V116, P8386, DOI 10.1021/ja00097a064
   Xu XHN, 2001, ANALYST, V126, P1285, DOI 10.1039/b104180k
   Zu Y.-B., 2007, NEW FRONTIERS ULTRAS, P235
   Zamani M, 2010, CLIN EXP DERMATOL, V35, P521, DOI 10.1111/j.1365-2230.2009.03667.x
   Xu X.-H., 1996, Australian Patent, Patent No. 703344
   Bard A. J., 1996, Biosensor for and method of electrogenerated chemiluminescent detection of nucleic acid adsorbed to a solid surface, Patent No. [WO9606946A1, 9606946]
NR 30
TC 4
Z9 4
U1 1
U2 14
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1572-6657
J9 J ELECTROANAL CHEM
JI J. Electroanal. Chem.
PD JAN 1
PY 2013
VL 688
SI SI
BP 53
EP 60
DI 10.1016/j.jelechem.2012.08.004
PG 8
WC Chemistry, Analytical; Electrochemistry
SC Chemistry; Electrochemistry
GA 120GM
UT WOS:000317158800011
PM 23565071
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mehendale, R
   Joshi, M
   Patravale, V
AF Mehendale, Rujuta
   Joshi, Medha
   Patravale, Vandana
TI Nanomedicines for Treatment of Viral Diseases
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE nanocarriers; viral diseases; nanoparticles; targated drug delivery
ID SOLID LIPID NANOPARTICLES; HUMAN-IMMUNODEFICIENCY-VIRUS;
   BLOOD-BRAIN-BARRIER; IN-VIVO EVALUATION; NANOFORMULATED ANTIRETROVIRAL
   DRUG; POLY PROPYLENEIMINE DENDRIMER; ANTI-HIV ACTIVITY; POLYMERIC
   NANOPARTICLES; SILVER NANOPARTICLES; DELIVERY-SYSTEMS
AB Viral diseases affect millions of people worldwide, with a high impact on human health and socioeconomic development. More than 40 million people are affected with human immunodeficiency virus (HIV) alone. This review discusses the various nanocarriers (e.g., liposomes, solid lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, etc.) based on approaches that have been applied in the literature and in the clinic to combat the different challenges faced by the antiviral therapy. The recent developments in smart delivery technologies (e.g., immunoliposomes) targeting delivery to the lectin receptors and cell-penetrating peptides for site-specific delivery of antiviral agents at the viral reservoirs are also been discussed.
C1 [Mehendale, Rujuta; Patravale, Vandana] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Bombay 400019, Maharashtra, India.
   [Joshi, Medha] Midwestern Univ, Dept Pharmaceut Sci, Chicago Coll Pharm, Downers Grove, IL 60515 USA.
RP Patravale, V (reprint author), Inst Chem Technol, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Bombay 400019, Maharashtra, India.
EM vb.patravale@ictmumbai.edu.in
OI Joshi, Medha/0000-0002-0280-0349
CR Agarwal A, 2008, J PHARM PHARMACOL, V60, P671, DOI 10.1211/jpp.60.6.0001
   Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Ali MM, 2008, CHEM-EUR J, V14, P7250, DOI 10.1002/chem.200800402
   Allam A. N., 2011, ASIAN J PHARM BIOL R, V1, P28
   Amoozgar Z, 2012, WIRES NANOMED NANOBI, V4, P219, DOI 10.1002/wnan.1157
   Anton N, 2008, J CONTROL RELEASE, V128, P185, DOI 10.1016/j.jconrel.2008.02.007
   BAPAT N, 1992, DRUG DEV IND PHARM, V18, P65, DOI 10.3109/03639049209043684                                                       
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Barnard DL, 1997, ANTIVIR RES, V34, P27, DOI 10.1016/S0166-3542(96)01019-4
   Behrens I, 2002, PHARMACEUT RES, V19, P1185, DOI 10.1023/A:1019854327540
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Borges O, 2007, EUR J PHARM SCI, V32, P278, DOI 10.1016/j.ejps.2007.08.005
   Borgmann K, 2011, AIDS RES HUM RETROV, V27, P853, DOI [10.1089/aid.2010.0295, 10.1089/AID.2010.0295]
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Bronshtein T, 2011, J CONTROL RELEASE, V151, P139, DOI 10.1016/j.jconrel.2011.02.023
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chepurnov AA, 2003, ACTA TROP, V87, P315, DOI 10.1016/S0001-706X(03)00120-7
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   CHONN A, 1991, J IMMUNOL, V146, P4234
   Clark MA, 2001, ADV DRUG DELIVER REV, V50, P81, DOI 10.1016/S0169-409X(01)00149-1
   Clayton R, 2007, J VIROL METHODS, V139, P17, DOI 10.1016/j.jviromet.2006.08.017
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   De Jaeghere F, 2000, J CONTROL RELEASE, V68, P291, DOI 10.1016/S0168-3659(00)00272-8
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dev A, 2010, CARBOHYD POLYM, V80, P833, DOI 10.1016/j.carbpol.2009.12.040
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Dhaliwal S, 2008, AAPS J, V10, P322, DOI 10.1208/s12248-008-9039-2
   Donovan BW, 2000, ANTIVIR CHEM CHEMOTH, V11, P41, DOI 10.1177/095632020001100104                                                      
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006                                               
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Fadeel B, 2010, ADV DRUG DELIVER REV, V62, P362, DOI 10.1016/j.addr.2009.11.008
   Fang JY, 2008, EUR J PHARM BIOPHARM, V70, P633, DOI 10.1016/j.ejpb.2008.05.008
   FLASHER D, 1994, BBA-BIOMEMBRANES, V1194, P185, DOI 10.1016/0005-2736(94)90219-4                                                    
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949                                                         
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   Galdiero S, 2011, MOLECULES, V16, P8894, DOI 10.3390/molecules16108894
   Gandapu U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023388
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Gazumyan A, 2000, CURR PHARM DESIGN, V6, P525, DOI 10.2174/1381612003400704                                                        
   Gilbert BE, 1996, SEMIN PEDIAT INFECT, V7, P148
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gong YH, 2002, ANTIVIR RES, V55, P319, DOI 10.1016/S0166-3542(02)00054-2
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Gupta NK, 2011, VACCINE, V29, P9026, DOI 10.1016/j.vaccine.2011.09.033
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   HANDJANIVILA RM, 1979, INT J COSMETIC SCI, V1, P303, DOI 10.1111/j.1467-2494.1979.tb00224.x
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Hasanovic A, 2009, J PHARM PHARMACOL, V61, P1609, DOI 10.1211/jpp/61.12.0004
   Hashim F, 2010, DRUG DELIV, V17, P282, DOI 10.3109/10717541003706257
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Izquierdo P, 2002, LANGMUIR, V18, P26, DOI 10.1021/la010808c
   Jain K, 2010, INT J PHARMACEUT, V394, P122, DOI 10.1016/j.ijpharm.2010.04.027
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Jones T, 2008, AM AC DERM ANN M FEB
   Joshi MD, 2009, EUR J PHARM BIOPHARM, V71, P161, DOI 10.1016/j.ejpb.2008.09.003
   Joung Y, PHARM RES, P1
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   Khalil NM, 2011, EXPERT OPIN DRUG DEL, V8, P95, DOI 10.1517/17425247.2011.543673
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   KOFF WC, 1985, ANTIVIR RES, V5, P179, DOI 10.1016/0166-3542(85)90050-6                                                    
   Konda SD, 2002, INVEST RADIOL, V37, P199, DOI 10.1097/00004424-200204000-00005
   Kroll RA, 1998, NEUROSURGERY, V43, P879, DOI 10.1097/00006123-199810000-00090                                                
   Kubo T, 2000, INT J ONCOL, V17, P309
   Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2011, COLLOID SURFACE B, V88, P682, DOI 10.1016/j.colsurfb.2011.07.060
   Kuo YC, 2011, INT J PHARMACEUT, V416, P365, DOI 10.1016/j.ijpharm.2011.06.037
   Kuo YC, 2009, INT J PHARM, V365, P206, DOI 10.1016/j.ijpharm.2008.08.050
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Lai F, 2007, INT J NANOMED, V2, P419
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Landers JJ, 2002, J INFECT DIS, V186, P1222, DOI 10.1086/344316
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lembo David, 2010, Antiviral Chemistry & Chemotherapy, V21, P53, DOI 10.3851/IMP1684
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lu L, 2008, ANTIVIR THER, V13, P253
   Macri RV, 2009, BIOORGAN MED CHEM, V17, P3162, DOI 10.1016/j.bmc.2009.02.055
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Matteucci ML, 2000, VET RADIOL ULTRASOUN, V41, P100, DOI 10.1111/j.1740-8261.2000.tb01462.x
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   MEIJER DKF, 1992, ANTIVIR RES, V18, P215, DOI 10.1016/0166-3542(92)90058-D
   Mintzer MA, 2011, CHEM SOC REV, V40, P173, DOI 10.1039/b901839p
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   Moon HI, VET MICROBIOL
   Mukherjee B, 2007, INT J NANOMED, V2, P213
   Munyendo WL, 2012, BIOMOLECULES, V2, P187, DOI 10.3390/biom2020187
   Muzzalupo R, 2011, EUR J PHARM BIOPHARM, V79, P28, DOI 10.1016/j.ejpb.2011.01.020
   NORLEY SG, 1987, INVEST OPHTH VIS SCI, V28, P591
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Oka H, 2009, BIOORGAN MED CHEM, V17, P5465, DOI 10.1016/j.bmc.2009.06.035
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   PEYMAN GA, 1987, RETINA-J RET VIT DIS, V7, P227, DOI 10.1097/00006982-198707040-00005
   PHILLIPS NC, 1992, RES IMMUNOL, V143, P205, DOI 10.1016/S0923-2494(92)80167-J
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Pollock S, 2010, P NATL ACAD SCI USA, V107, P17176, DOI 10.1073/pnas.1009445107
   Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169-409X(00)00133-2                                                   
   Powers DC, 1997, MECH AGEING DEV, V93, P179, DOI 10.1016/S0047-6374(96)01809-X
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Reis CP, 2006, NANOMED-NANOTECHNOL, V2, P8, DOI 10.1016/j.nano.2005.12.003
   Ren GG, 2009, INT J ANTIMICROB AG, V33, P587, DOI 10.1016/j.ijantimicag.2008.12.004
   Resnik DB, 2007, CONTEMP CLIN TRIALS, V28, P433, DOI 10.1016/j.cct.2006.11.001
   Reuter JD, 1999, BIOCONJUGATE CHEM, V10, P271, DOI 10.1021/bc980099n
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Rojo J, 2004, J ANTIMICROB CHEMOTH, V54, P579, DOI 10.1093/jac/dkh399
   Rokhade AP, 2007, CARBOHYD POLYM, V67, P605, DOI 10.1016/j.carbpol.2006.07.001
   Rollinger JM, 2008, J MED CHEM, V51, P842, DOI 10.1021/jm701494b
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sawada H, 2007, J FLUORINE CHEM, V128, P1416, DOI 10.1016/j.jfluchem.2007.05.023
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHREIER H, 1994, J CONTROL RELEASE, V30, P1, DOI 10.1016/0168-3659(94)90039-6                                                    
   Schwarz JC, INT J PHARM
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shegokar R, 2011, PHARMAZIE, V66, P408, DOI 10.1691/ph.2011.0317
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Shegokar R, 2011, NANOMED-NANOTECHNOL, V7, P333, DOI 10.1016/j.nano.2010.10.012
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Stulzer HK, 2008, CARBOHYD POLYM, V73, P490, DOI 10.1016/j.carbpol.2007.12.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tang ESK, 2003, INT J PHARM, V265, P103, DOI 10.1016/S0378-5173(03)00408-3
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Uchegbu IF, 1998, INT J PHARM, V172, P33, DOI 10.1016/S0378-5173(98)00169-0                                                   
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Wan L, 2007, PHARM RES, V24, P2110, DOI 10.1007/s11095-007-9402-5
   Wang W, 2006, CHEM BIOL DRUG DES, V68, P314, DOI 10.1111/j.1747-0285.2006.00454.x
   Wang X, 2011, CHEM COMMUN, V47, P8620, DOI 10.1039/c1cc12981c
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xie Fang-ming, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P657
   Xu ZP, 2006, CHEM ENG SCI, V61, P1027, DOI 10.1016/j.ces.2005.06.019
   You J, 2011, COLLOID SURFACE B, V85, P161, DOI 10.1016/j.colsurfb.2011.02.023
   Zhang XG, 2008, J ZHEJIANG UNIV-SC B, V9, P506, DOI 10.1631/jzus.B0820047
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
NR 169
TC 12
Z9 12
U1 1
U2 41
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0743-4863
EI 2162-660X
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2013
VL 30
IS 1
BP 1
EP 49
PG 49
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 121NI
UT WOS:000317251100001
PM 23510109
DA 2018-01-05
ER

PT J
AU Limban, C
   Grumezescu, AM
   Chirea, M
   Matei, L
   Chifiriuc, MC
AF Limban, Carmen
   Grumezescu, Alexandru Mihai
   Chirea, Mariana
   Matei, Lilia
   Chifiriuc, Mariana Carmen
TI Antimicrobial Potential of Benzamides and Derived Nanosystems for
   Controlling in vitro Biofilm Development on Medical Devices
SO CURRENT ORGANIC CHEMISTRY
LA English
DT Article
DE Benzamides; Thiourea derivatives; Magnetic nanoparticles; Anti-biofilm
   properties; Quorum sensing inhibitors
ID THIOUREA DERIVATIVES; ANTIBACTERIAL ACTIVITIES; SULFONAMIDE MOIETIES;
   ANTI-HIV; AGENTS; UREA; NANOPARTICLES; PARTICLES; COMPLEXES; LIGANDS
AB The aim of this paper is to review the antimicrobial activity of thiourea derivatives against planktonic and adherent bacterial and fungal strains, as well as to show how nanotechnology could improve the intrinsic antimicrobial activity of the novel substances, by obtaining biocompatible nanocomposites based on magnetite nanoparticles and newly synthesized 2-((4-ethylphenoxy)methyl)-N-(alkylphenylcarbamothioyl) benzamides, which proved increased resistance to microbial colonization or inhibited the development of already existent biofilms, revealing a great potential for biomedical applications.
C1 [Limban, Carmen] Carol Davila Univ Med & Pharm, Dept Pharmaceut Chem, Bucharest 020956, Romania.
   [Grumezescu, Alexandru Mihai] Univ Politehn Bucuresti, Dept Sci & Engn Oxid Mat & Nanomat, Fac Appl Chem & Mat Sci, Bucharest 011061, Romania.
   [Chirea, Mariana] Univ Porto, Fac Ciencias, P-4169007 Oporto, Portugal.
   [Matei, Lilia; Chifiriuc, Mariana Carmen] S Nicolau Inst Virol, Bucharest, Romania.
   [Matei, Lilia; Chifiriuc, Mariana Carmen] Univ Bucharest, Fac Biol, Dept Microbiol, Bucharest 060101, Romania.
RP Chirea, M (reprint author), Univ Porto, Fac Ciencias, CIQ-UP L4,Rua Campo Alegre 687, P-4169007 Oporto, Portugal.
EM mariana.chirea@fc.up.pt
RI Chifiriuc, Mariana Carmen/F-9136-2016; Limban, Carmen/O-9187-2014;
   CHIREA, MARIANA/C-8600-2014
OI Chifiriuc, Mariana Carmen/0000-0001-6098-1857; CHIREA,
   MARIANA/0000-0001-6881-9432; Matei, Lilia/0000-0003-4479-655X
FU UE-FISCDI Ideas Project [154/2011]; FCT of Portugal
   [SFRH/BPD/39294/2007]
FX The authors acknowledge the financial support of the UE-FISCDI Ideas
   Project no. 154/2011. M.C. acknowledges financial support from FCT of
   Portugal, fellowship number SFRH/BPD/39294/2007.
CR Abdel-Rahman HM, 2007, J ENZYM INHIB MED CH, V22, P57, DOI 10.1080/14756360600991082
   Al-Masoudi NA, 2010, ARKIVOC, P185
   Alagarsamy V, 2004, BIOL PHARM BULL, V27, P652, DOI 10.1248/bpb.27.652
   Andronescu E, 2012, BIOINTERFACE RES APP, V2, P332
   Andronescu E, 2010, J MATER SCI-MATER M, V21, P2237, DOI 10.1007/s10856-010-4076-7
   Arslan H, 2009, MOLECULES, V14, P519, DOI 10.3390/molecules14010519
   Baier J, 2012, BIOINTERFACE RES APP, V2, P339
   Chen SP, 2005, CARBOHYD POLYM, V60, P33, DOI 10.1016/j.carbpol.2004.11.020
   Chifiriuc MC, 2012, NANOSCALE RES LETT, V7, P209, DOI DOI 10.1186/1556-276X-7-209
   Cikla P, 2010, MARMARA PHARM J, V14, P13, DOI 10.12991/201014460
   Cunha S, 2007, MONATSH CHEM, V138, P511, DOI 10.1007/s00706-007-0600-y
   Desai AD, 2007, INDIAN J CHEM B, V46, P1169
   Dogruer DS, 2010, TURK J CHEM, V34, P57, DOI 10.3906/kim-0904-27
   Dong A, 2011, ACS APPL MATER INTER, V3, P4228, DOI 10.1021/am200864p
   Dong HC, 2011, BIOMACROMOLECULES, V12, P1305, DOI 10.1021/bm200031v
   Estrela Andreia Bergamo, 2010, Pharmaceuticals (Basel), V3, P1374
   Fuks L., 2010, TRANSITION MET CHEM
   Grumezescu AM, 2011, BIOINTERFACE RES APP, V1, P229
   Grumezescu AM, 2011, BIOINTERFACE RES APP, V1, P160
   Grumezescu AM, 2011, IEEE T NANOBIOSCI, V10, P269, DOI 10.1109/TNB.2011.2178263
   Grumezescu A.M., 2012, LETT APPL NANOBIOSCI, V1, P56
   Grumezescu AM, 2012, LETT APPL NANOBIOSCI, V1, P31
   Gulkok Y, 2012, TURK J CHEM, V36, P279, DOI 10.3906/kim-1106-54
   Hasegawa H., 1993, US Pat, Patent No. [5,190,961, 5190961]
   Isab AA, 2010, POLYHEDRON, V29, P1251, DOI 10.1016/j.poly.2009.12.037
   Jadhav S., 2010, RASAYAN J CHEM, V3, P27
   Karakus S, 2002, FARMACO, V57, P577, DOI 10.1016/S0014-827X(02)01252-1
   Kayser H, 2001, PEST MANAG SCI, V57, P975, DOI 10.1002/ps.360
   Ke SY, 2006, ARKIVOC, P63
   Keche AP, 2012, BIOORG MED CHEM LETT, V22, P3445, DOI 10.1016/j.bmcl.2012.03.092
   Kima H.J., 2012, RADIAT PHYS CHEM, V81, P1612
   Kumar S, 2007, HORTIC SCI, V34, P77
   Kurt G, 2009, CHEM PAP, V63, P548, DOI 10.2478/s11696-009-0055-1
   Liav A, 2008, BIOORG MED CHEM LETT, V18, P2649, DOI 10.1016/j.bmcl.2008.03.033
   Limban C, 2011, MOLECULES, V16, P7593, DOI 10.3390/molecules16097593
   Limban C, 2009, REV CHIM-BUCHAREST, V60, P657
   Lohray VB, 2005, PURE APPL CHEM, V77, P195, DOI 10.1351/pac200577010195
   Mantle MD, 2011, INT J PHARMACEUT, V417, P173, DOI 10.1016/j.ijpharm.2010.11.035
   Medeiros SF, 2011, INT J PHARMACEUT, V403, P139, DOI 10.1016/j.ijpharm.2010.10.011
   Mihaiescu DE, 2012, LETT APPL NANOBIOSCI, V1, P45
   Mishra A, 2009, EUR J MED CHEM, V44, P4404, DOI 10.1016/j.ejmech.2009.06.001
   Modi K.N., 2011, INT J DRUG DEV RES, V3, P334
   Park H, 2004, BIOORG MED CHEM LETT, V14, P787, DOI 10.1016/j.bmcl.2003.11.019
   PATEL NB, 2011, INT J BIOL CHEM, V5, P37, DOI DOI 10.3923/ijbc.2011.37.45
   Patel RB, 2007, J BRAZIL CHEM SOC, V18, P312, DOI 10.1590/S0103-50532007000200011
   Pathak AK, 2011, E-J CHEM, V8, P240, DOI 10.1155/2011/820718                                                             
   Peikov VT, 1999, J MAGN MAGN MATER, V193, P307, DOI 10.1016/S0304-8853(98)00514-9
   Ramadas K, 1998, PESTIC SCI, V52, P145, DOI 10.1002/(SICI)1096-9063(199802)52:2<145::AID-PS677>3.0.CO;2-J
   Reddy N. S., 2011, INT J ORG CHEM, V1, P167
   Rizwana B., 2012, International Journal of ChemTech Research, V4, P464
   Saeed A., 2008, PHARM CHEM J, V42, P191, DOI DOI 10.1007/S11094-008-0094-X
   Saeed A, 2009, J FLUORINE CHEM, V130, P1028, DOI 10.1016/j.jfluchem.2009.09.003
   Saeed S, 2010, EUR J CHEM, V1, P200, DOI DOI 10.5155/EURJCHEM.1.3.200-205.120
   Sarmah K. N., 2012, INT J COMPUT ENG RES, V2, P289
   Sarmah K. N., 2011, ARCH APPL SCI RES, V3, P428
   Sarmah K.N., 2011, CHEM MAT RES, V1, P1
   Saviuc C, 2011, BIOINTERFACE RES APP, V1, P31
   Schweiger C, 2011, INT J PHARMACEUT, V408, P130, DOI 10.1016/j.ijpharm.2010.12.046
   Selvam S, 2012, INT J PHARMACEUT, V434, P366, DOI 10.1016/j.ijpharm.2012.04.069
   Struga M, 2010, ARCH PHARM RES, V33, P47, DOI 10.1007/s12272-010-2223-9
   Struga M, 2009, EUR J MED CHEM, V44, P4960, DOI 10.1016/j.ejmech.2009.08.013
   Subhasree R.S., 2012, LETT APPL NANOBIOSCI, V1, P2
   Tokuyama R, 2001, CHEM PHARM BULL, V49, P353, DOI 10.1248/cpb.49.353                                                              
   WALCHSHOFER N, 1990, J PHARM SCI, V79, P606, DOI 10.1002/jps.2600790713
   Wang H., 2011, INT J PHARMACEUT, V430, P343
   YAMAGUCHI K, 1990, J APPL PHYS, V67, P4493, DOI 10.1063/1.344892
NR 66
TC 7
Z9 7
U1 1
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1385-2728
J9 CURR ORG CHEM
JI Curr. Org. Chem.
PD JAN
PY 2013
VL 17
IS 2
BP 162
EP 175
DI 10.2174/1385272811317020013                                             
          
PG 14
WC Chemistry, Organic
SC Chemistry
GA 121VU
UT WOS:000317273500012
DA 2018-01-05
ER

PT J
AU Shiang, YC
   Ou, CM
   Chen, SJ
   Ou, TY
   Lin, HJ
   Huang, CC
   Chang, HT
AF Shiang, Yen-Chun
   Ou, Chung-Mao
   Chen, Shih-Ju
   Ou, Ting-Yu
   Lin, Han-Jia
   Huang, Chih-Ching
   Chang, Huan-Tsung
TI Highly efficient inhibition of human immunodeficiency virus type 1
   reverse transcriptase by aptamers functionalized gold nanoparticles
SO NANOSCALE
LA English
DT Article
ID TARGETED CANCER-THERAPY; DRUG-RESISTANCE; HIV-1 PROTEASE; NUCLEIC-ACIDS;
   DNA APTAMERS; C VIRUS; CELLS; ENTRY; ASSAY; NANOTECHNOLOGY
AB We have developed aptamer (Apt)-conjugated gold nanoparticles (Apt-Au NPs, 13 nm in diameter) as highly effective inhibitors for human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT). Two Apts, RT1t49 (Apt(pol)) and ODN 93 (Apt(RH)), which recognize the polymerase and RNase H regions of HIV-1 RT, are used to conjugate Au NPs to prepare Apt(pol)-Au NPs and Apt(RH)-Au NPs, respectively. In addition to DNA sequence, the surface density of the aptamers on Au NPs (nApt-Au NPs; n is the number of aptamer molecules on each Au NP) and the linker length number (T-m; m is the base number of the deoxythymidine linker) between the aptamer and Au NPs play important roles in determining their inhibition activity. A HIV-lentiviral vector-based antiviral assay has been applied to determine the inhibitory effect of aptamers or Apt-Au NPs on the early stages of their replication cycle. The nucleasestable G-quadruplex structure of 40Apt(RH)-T-45-Au NPs shows inhibitory efficiency in the retroviral replication cycle with a decreasing infectivity (40.2%).
C1 [Shiang, Yen-Chun; Ou, Chung-Mao; Chen, Shih-Ju; Chang, Huan-Tsung] Natl Taiwan Univ, Dept Chem, Taipei 10617, Taiwan.
   [Ou, Ting-Yu; Lin, Han-Jia; Huang, Chih-Ching] Natl Taiwan Ocean Univ, Inst Biosci & Biotechnol, Keelung 20224, Taiwan.
   [Ou, Ting-Yu; Lin, Han-Jia; Huang, Chih-Ching] Natl Taiwan Ocean Univ, Ctr Excellence Marine Bioenvironm & Biotechnol CM, Keelung 20224, Taiwan.
RP Lin, HJ (reprint author), Natl Taiwan Ocean Univ, Inst Biosci & Biotechnol, 2 Pei Ning Rd, Keelung 20224, Taiwan.
EM hanjia@ntou.edu.tw; changht@ntu.edu.tw
RI Chang, Huan-Tsung/C-1183-2011
OI Chang, Huan-Tsung/0000-0002-5393-1410; Huang,
   Chih-Ching/0000-0002-0363-1129
FU National Science Council of Taiwan [NSC 101-2113-M-002-002-MY3];
   National Health Research Institutes (Taiwan) [NHRI-EX100-10047NI]
FX This study was supported by the National Science Council of Taiwan under
   contract NSC 101-2113-M-002-002-MY3 and the National Health Research
   Institutes (Taiwan) under contract NHRI-EX100-10047NI.
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Arnold BA, 1998, BIOTECHNIQUES, V25, P98
   Bamrungsap S, 2012, ACS NANO, V6, P3974, DOI 10.1021/nn3002328
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Bodles-Brakhop AM, 2008, EXPERT REV VACCINES, V7, P1085, DOI 10.1586/14760584.7.7.1085
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Buff MCR, 2010, NUCLEIC ACIDS RES, V38, P2111, DOI 10.1093/nar/gkp1148
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033
   Cerchia L, 2010, TRENDS BIOTECHNOL, V28, P517, DOI 10.1016/j.tibtech.2010.07.005
   Chen LQ, 2010, J PHYS CHEM B, V114, P3655, DOI 10.1021/jp9104618
   Chen T, 2011, NANOSCALE, V3, P546, DOI 10.1039/c0nr00646g
   Choi SJ, 2000, ANAL BIOCHEM, V281, P95, DOI 10.1006/abio.2000.4529                                                          
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Cihlar T, 2009, ANTIMICROB AGENTS CH, V53, P150, DOI 10.1128/AAC.01183-08
   Clapham PR, 2002, J GEN VIROL, V83, P1809, DOI 10.1099/vir.0.18313-0
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1
   Du Y, 2011, ANALYST, V136, P493, DOI 10.1039/c0an00557f
   Du Y, 2010, ANAL CHEM, V82, P1556, DOI 10.1021/ac902566u
   ENUSTUN BV, 1963, J AM CHEM SOC, V85, P3317, DOI 10.1021/ja00904a001                                                             
   Famulok M, 2011, ACCOUNTS CHEM RES, V44, P1349, DOI 10.1021/ar2000293
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gao HL, 2012, BIOMATERIALS, V33, P6264, DOI 10.1016/j.biomaterials.2012.05.020
   Giljohann DA, 2007, NANO LETT, V7, P3818, DOI [10.1021/nl072471q, 10.1021/nl07247lq]
   Girard MP, 2011, VACCINE, V29, P6191, DOI 10.1016/j.vaccine.2011.06.085
   Gopinath SCB, 2007, ARCH VIROL, V152, P2137, DOI 10.1007/s00705-007-1014-1
   Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801
   He XX, 2011, NANOSCALE, V3, P2936, DOI 10.1039/c0nr00913j
   He XX, 2003, J AM CHEM SOC, V125, P7168, DOI 10.1021/ja034450d
   Hetherington S, 2001, CLIN THER, V23, P1603, DOI 10.1016/S0149-2918(01)80132-6                                                   
   Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297
   Hsu CL, 2011, CHEM-EUR J, V17, P10994, DOI 10.1002/chem.201101081
   Huang CC, 2008, ANAL CHEM, V80, P1497, DOI 10.1021/ac701998f
   Jiao PF, 2011, CURR MED CHEM, V18, P2086
   Kearney M, 2008, AIDS, V22, P497, DOI 10.1097/QAD.0b013e3282f29478
   Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812
   Kim D, 2010, ACS NANO, V4, P3689, DOI 10.1021/nn901877h
   Kim JK, 2012, BIOMATERIALS, V33, P207, DOI 10.1016/j.biomaterials.2011.09.023
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kissel JD, 2007, AIDS RES HUM RETROV, V23, P699, DOI 10.1089/aid.2006.0262
   Kissel JD, 2007, NUCLEIC ACIDS RES, V35, P5039, DOI 10.1093/nar/gkm420
   Krebs JF, 2008, BIOCONJUGATE CHEM, V19, P185, DOI 10.1021/bc700284y
   Lee JH, 2010, ADV DRUG DELIVER REV, V62, P592, DOI 10.1016/j.addr.2010.03.003
   Lever AML, 2006, INT J HEMATOL, V84, P23, DOI 10.1532/IJH97.06112
   Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375
   Li N, 2008, NUCLEIC ACIDS RES, V36, P6739, DOI 10.1093/nar/gkn775
   Lin TE, 2011, BIOSENS BIOELECTRON, V29, P204, DOI 10.1016/j.bios.2011.08.020
   Lisziewicz J, 2013, NANOMED-NANOTECHNOL, V9, P28, DOI 10.1016/j.nano.2012.05.012
   Liu GD, 2009, ANAL CHEM, V81, P10013, DOI 10.1021/ac901889s
   Liu JM, 2011, J ANAL ATOM SPECTROM, V26, P1191, DOI 10.1039/c0ja00232a
   Liu J, 2012, ANAL BIOANAL CHEM, V402, P187, DOI 10.1007/s00216-011-5414-4
   Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081
   Lovatt A, 1999, J VIROL METHODS, V82, P185, DOI 10.1016/S0166-0934(99)00111-1
   Lu WT, 2010, ACS NANO, V4, P1739, DOI 10.1021/nn901742q
   Luo YL, 2011, ACS NANO, V5, P7796, DOI 10.1021/nn201592s
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Menendez JA, 2002, BREAST CANCER RES TR, V72, P203, DOI 10.1023/A:1014968415759
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Mescalchin A, 2011, MOLECULES, V16, P1271, DOI 10.3390/molecules16021271
   Miyoshi D, 2008, BIOCHIMIE, V90, P1040, DOI 10.1016/j.biochi.2008.02.009
   Nair BG, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/45/455102
   Raviv SM, 2008, J THROMB HAEMOST, V6, P1764, DOI 10.1111/j.1538-7836.2008.03106.x
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Scourfield A, 2011, EXPERT REV ANTI-INFE, V9, P1001, DOI [10.1586/eri.11.125, 10.1586/ERI.11.125]
   Seferos DS, 2009, NANO LETT, V9, P308, DOI 10.1021/nl802958f
   Shukoor MI, 2012, ACS APPL MATER INTER, V4, P3007, DOI 10.1021/am300374q
   Soontornworajit B, 2011, ANAL BIOANAL CHEM, V399, P1591, DOI 10.1007/s00216-010-4559-x
   Steinstraesser L, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-2
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Sturmer M, 2009, MED MICROBIOL IMMUN, V198, P147, DOI 10.1007/s00430-009-0117-6
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tanimoto S, 2008, CHEM COMMUN, P5767, DOI 10.1039/b811726h
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   TAYLOR PB, 1994, J BIOL CHEM, V269, P6325
   Thiel KW, 2009, OLIGONUCLEOTIDES, V19, P209, DOI 10.1089/oli.2009.0199
   Virno A, 2007, BIOORGAN MED CHEM, V15, P5710, DOI 10.1016/j.bmc.2007.06.008
   Wang W, 2011, BIOSENS BIOELECTRON, V26, P3110, DOI 10.1016/j.bios.2010.10.034
   Wang YY, 2010, LANGMUIR, V26, P10025, DOI 10.1021/la100139p
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Xiao ZY, 2012, ACS NANO, V6, P696, DOI 10.1021/nn204165v
   Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479
   Yang L, 2011, ADV DRUG DELIVER REV, V63, P1361, DOI 10.1016/j.addr.2011.10.002
   Zaitseva M, 2010, BIOPHYS CHEM, V146, P1, DOI 10.1016/j.bpc.2009.09.011
   Zhang M, 2012, CHEM COMMUN, V48, P5488, DOI 10.1039/c2cc31626a
   Zheng GF, 2008, J AM CHEM SOC, V130, P9644, DOI 10.1021/ja803035p
NR 90
TC 19
Z9 20
U1 3
U2 52
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2013
VL 5
IS 7
BP 2756
EP 2764
DI 10.1039/c3nr33403a
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 106CV
UT WOS:000316120100027
PM 23429884
DA 2018-01-05
ER

PT J
AU Balakrishnan, KR
   Anwar, G
   Chapman, MR
   Nguyen, T
   Kesavaraju, A
   Sohn, LL
AF Balakrishnan, Karthik R.
   Anwar, George
   Chapman, Matthew R.
   Trongtuong Nguyen
   Kesavaraju, Anand
   Sohn, Lydia L.
TI Node-pore sensing: a robust, high-dynamic range method for detecting
   biological species
SO LAB ON A CHIP
LA English
DT Article
ID SOLID-STATE NANOPORES; RESISTIVE-PULSE TECHNIQUE; SINGLE-MOLECULE;
   MONONUCLEAR-CELLS; COULTER-COUNTER; ALPHA-HEMOLYSIN; SENSORS; DNA;
   IDENTIFICATION; AMPLIFICATION
AB Resistive-pulse sensing (RPS), which is based on measuring the current pulse produced when a single particle transits a pore or channel, is an extremely versatile technique used to determine the size and concentration of cells and viruses and to detect single molecules. A major challenge to RPS is dynamic range: smaller particles in a heterogeneous sample can go undetected because of low signal-to-noise ratios (SNRs) and the fact that the pore size must be commensurate with that of the largest particles. Here, we describe a fundamentally different pore that provides an unprecedented dynamic detection range, from tens of nanometers to several microns in size, without the need for pre-sorting or filtration. Because of its unique geometry - nodes inserted along the channel - our pore produces distinct electronic signatures that overcome low SNRs. We demonstrate the power of our device by directly detecting and enumerating human immunodeficiency virus (HIV) in human plasma.
C1 [Balakrishnan, Karthik R.; Anwar, George; Sohn, Lydia L.] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
   [Chapman, Matthew R.] Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA.
   [Trongtuong Nguyen] Univ Calif Berkeley, Berkeley, CA 94720 USA.
   [Kesavaraju, Anand] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.
RP Sohn, LL (reprint author), Univ Calif Berkeley, Dept Mech Engn, 5118 Etcheverry Hall,Mail Stop 1740, Berkeley, CA 94720 USA.
EM sohn@me.berkeley.edu
OI Chapman, Matthew/0000-0002-2645-1294
FU Berkeley-Siemens Center of Knowledge Interchange; Siemens Corporate
   Technology; National Defense Science and Engineering Graduate Fellowship
   (NDSEG)
FX We thank J. Uzgiris and S. Pandit for helpful discussions and assistance
   with the viral-detection experiments, J. Hack for data analysis
   assistance, and E. Jabart, M. Chambers, and V. Tuminelli for helpful
   discussions. This research was funded by the Berkeley-Siemens Center of
   Knowledge Interchange and Siemens Corporate Technology. K. B. is
   supported by a National Defense Science and Engineering Graduate
   Fellowship (NDSEG).
CR Balakrishnan K, 2012, LAB METHODS CELL BIO, V112, P369
   Bayley H, 2000, CHEM REV, V100, P2575, DOI 10.1021/cr980099g
   Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038
   BELL J, 1989, AIDS RES HUM RETROV, V5, P87, DOI 10.1089/aid.1989.5.87                                                           
   BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Bryan AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029866
   Carbonaro A, 2005, LAB CHIP, V5, P1155, DOI 10.1039/b504827c
   Carbonaro A, 2008, LAB CHIP, V8, P1478, DOI 10.1039/b801929k
   Clarke J, 2009, NAT NANOTECHNOL, V4, P265, DOI [10.1038/nnano.2009.12, 10.1038/NNANO.2009.12]
   Comandini UV, 1997, J VIROL METHODS, V69, P171, DOI 10.1016/S0166-0934(97)00153-5                                                   
   CRAINE K, 1967, J CLIN PATHOL, V20, P913, DOI 10.1136/jcp.20.6.913
   DEBLOIS RW, 1970, REV SCI INSTRUM, V41, P909, DOI 10.1063/1.1684724
   DEBLOIS RW, 1977, J VIROL, V23, P227
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   GOLIBERSUCH D C, 1973, Biophysical Journal, V13, P265
   GREGG EC, 1965, BIOPHYS J, V5, P393, DOI 10.1016/S0006-3495(65)86724-8                                                   
   Gu LQ, 2001, SCIENCE, V291, P636, DOI 10.1126/science.291.5504.636                                                    
   Hall AR, 2010, NAT NANOTECHNOL, V5, P874, DOI [10.1038/nnano.2010.237, 10.1038/NNANO.2010.237]
   Harms ZD, 2011, ANAL CHEM, V83, P9573, DOI 10.1021/ac202358t
   HART C, 1988, LANCET, V2, P596
   HIRSCH J, 1968, J LIPID RES, V9, P110
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   KUBITSCHEK HE, 1958, NATURE, V182, P234, DOI 10.1038/182234a0
   KWOK S, 1987, J VIROL, V61, P1690
   Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037
   Rincon-Restrepo M, 2011, NANO LETT, V11, P746, DOI 10.1021/nl1038874
   Rodriguez AT, 2006, J AM CHEM SOC, V128, P9276, DOI 10.1021/ja061380c
   Saleh OA, 2003, P NATL ACAD SCI USA, V100, P820, DOI 10.1073/pnas.0337563100
   Saleh OA, 2003, NANO LETT, V3, P37, DOI 10.1021/nl0255202
   Saleh OA, 2001, REV SCI INSTRUM, V72, P4449, DOI 10.1063/1.1419224
   SIMMONDS P, 1990, J VIROL, V64, P864
   Smeets RMM, 2008, P NATL ACAD SCI USA, V105, P417, DOI 10.1073/pnas.0705349105
   Sun L, 2000, J AM CHEM SOC, V122, P12340, DOI 10.1021/ja002429w
   Wang HY, 2011, ANAL CHEM, V83, P1746, DOI 10.1021/ac1029874
   Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]
   Wanunu M, 2007, NANO LETT, V7, P1580, DOI 10.1021/nl070462b
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wanunu M, 2009, NANO LETT, V9, P3498, DOI 10.1021/nl901691v
   Wei RS, 2010, SMALL, V6, P1406, DOI 10.1002/smll.201000253
   Wu XD, 2008, ELECTROPHORESIS, V29, P2754, DOI 10.1002/elps.200700912
   Wu YF, 2012, BIOMED MICRODEVICES, V14, P739, DOI 10.1007/s10544-012-9655-6
   Xie P, 2012, NAT NANOTECHNOL, V7, P119, DOI [10.1038/nnano.2011.217, 10.1038/NNANO.2011.217]
   Ying YL, 2011, CHEM COMMUN, V47, P5690, DOI 10.1039/c0cc05787h
   Zhe J, 2007, J MICROMECH MICROENG, V17, P304, DOI 10.1088/0960-1317/17/2/017
   Zhou KM, 2011, J AM CHEM SOC, V133, P1618, DOI 10.1021/ja108228x
NR 46
TC 13
Z9 13
U1 2
U2 43
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
J9 LAB CHIP
JI Lab Chip
PY 2013
VL 13
IS 7
BP 1302
EP 1307
DI 10.1039/c3lc41286e
PG 6
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA 100HI
UT WOS:000315688500012
PM 23386180
DA 2018-01-05
ER

PT J
AU Drappier, C
   Wirotius, AL
   Bathany, K
   Ibarboure, E
   Condassamy, O
   Garanger, E
   Lecommandoux, S
AF Drappier, Charlotte
   Wirotius, Anne-Laure
   Bathany, Katell
   Ibarboure, Emmanuel
   Condassamy, Olivia
   Garanger, Elisabeth
   Lecommandoux, Sebastien
TI Biofunctional micellar nanoparticles from peptide-b-polymer chimeras
SO POLYMER CHEMISTRY
LA English
DT Article
ID INTRACELLULAR DRUG-DELIVERY; CELL-PENETRATING PEPTIDES;
   SYNTHETIC-POLYMER; BLOCK-COPOLYMERS; TAT PEPTIDE; PROTEIN; MEMBRANE;
   SIRNA; HIV-1; SPECTROSCOPY
AB We describe the precision synthesis and characterization of amphiphilic peptide-b-polymer chimeras encoding, at the molecular level, self-assembly properties and biological functions, presently cell membrane penetrating motifs (Tat peptide). Self-assembled micellar nanoparticles obtained from a series of Tat-b-poly(trimethylene carbonate) (Tat-b-PTMC) chimeras with tunable hydrophilic fractions were finely characterized in order to establish chimera-nanoparticle structure relationships. Well-defined nanoparticles with diameters ranging from 22 to 40 nm could be obtained by direct self-assembly in buffer.
C1 [Drappier, Charlotte; Wirotius, Anne-Laure; Ibarboure, Emmanuel; Condassamy, Olivia; Garanger, Elisabeth; Lecommandoux, Sebastien] Univ Bordeaux, CNRS, UMR 5629, LCPO, F-33607 Pessac, France.
   [Drappier, Charlotte; Garanger, Elisabeth] IECB, F-33607 Pessac, France.
   [Bathany, Katell] Univ Bordeaux, CNRS, UMR 5248, CBMN,PGF, F-33076 Bordeaux, France.
RP Garanger, E (reprint author), Univ Bordeaux, CNRS, UMR 5629, LCPO, 16 Ave Pey Berland, F-33607 Pessac, France.
EM e.garanger@iecb.u-bordeaux.fr; lecommandoux@enscbp.fr
RI Lecommandoux, Sebastien/B-9536-2011
OI Lecommandoux, Sebastien/0000-0003-0465-8603
CR Abramkin S, 2012, DALTON T, V41, P3001, DOI 10.1039/c2dt12024k
   Bakkour Y, 2012, POLYM CHEM-UK, V3, P2006, DOI 10.1039/c2py20054f
   Becker ML, 2005, BIOMACROMOLECULES, V6, P220, DOI 10.1021/bm049551y
   Borner HG, 2009, PROG POLYM SCI, V34, P811, DOI 10.1016/j.progpolymsci.2009.05.001
   Carlsen A, 2009, CURR OPIN COLLOID IN, V14, P329, DOI 10.1016/j.cocis.2009.04.007
   Christian NA, 2007, BIOCONJUGATE CHEM, V18, P31, DOI 10.1021/bc0601267
   Danial M, 2012, BIOMACROMOLECULES, V13, P1438, DOI 10.1021/bm300150q
   Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuks G, 2011, CHEM SOC REV, V40, P2475, DOI 10.1039/c0cs00085j
   Garanger E, 2012, ANGEW CHEM INT EDIT, V51, P3060, DOI 10.1002/anie.201107734
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hentschel J, 2008, MACROMOLECULES, V41, P1073, DOI 10.1021/ma8000934
   Holowka EP, 2007, NAT MATER, V6, P52, DOI 10.1038/nmat1794
   Huang J, 2012, J AM CHEM SOC, V134, P119, DOI 10.1021/ja209676p
   Jain S, 2003, SCIENCE, V300, P460, DOI 10.1126/science.1082193                                                         
   Johnson CS, 1999, PROG NUCL MAG RES SP, V34, P203, DOI 10.1016/S0079-6565(99)00003-5
   Kanazawa T, 2012, EUR J PHARM BIOPHARM, V81, P470, DOI 10.1016/j.ejpb.2012.04.021
   Kim Y, 2012, BIOMACROMOLECULES, V13, P3418, DOI 10.1021/bm301351e
   Klok HA, 2009, MACROMOLECULES, V42, P7990, DOI 10.1021/ma901561t
   Krpetic Z, 2011, ACS NANO, V5, P5195, DOI 10.1021/nn201369k
   Lutz JF, 2008, PROG POLYM SCI, V33, P1, DOI 10.1016/j.progpolymsci.2007.07.005
   Lutz JF, 2007, AUST J CHEM, V60, P410, DOI 10.1071/CH07052
   Meszynska A, 2012, CHEM COMMUN, V48, P3887, DOI 10.1039/c2cc30233k
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Nam HY, 2011, BIOMATERIALS, V32, P5213, DOI 10.1016/j.biomaterials.2011.03.058
   Nam YS, 2002, BIOTECHNOL LETT, V24, P2093, DOI 10.1023/A:1021373731787
   Pounder RJ, 2008, CHEM COMMUN, P5158, DOI 10.1039/b809167f
   Rabotyagova OS, 2011, BIOMACROMOLECULES, V12, P269, DOI 10.1021/bm100928x
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reynhout IC, 2009, ACCOUNTS CHEM RES, V42, P681, DOI 10.1021/ar800143a
   Rodriguez-Hernandez J, 2005, PROG POLYM SCI, V30, P691, DOI 10.1016/j.progpolymsci.2005.04.002
   Rosler A, 2001, ADV DRUG DELIVER REV, V53, P95, DOI 10.1016/S0169-409X(01)00222-8
   Sanson C, 2010, SOFT MATTER, V6, P1722, DOI 10.1039/b924617g
   Sanson C, 2011, ACS NANO, V5, P1122, DOI 10.1021/nn102762f
   Sanson C, 2010, LANGMUIR, V26, P2751, DOI 10.1021/la902786t
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schatz C, 2009, ANGEW CHEM INT EDIT, V48, P2572, DOI 10.1002/anie.200805895
   Singha NK, 2011, BIOMACROMOLECULES, V12, P2908, DOI 10.1021/bm200469a
   Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028
   ten Cate MGJ, 2007, MACROMOL CHEM PHYSIC, V208, P1437, DOI 10.1002/macp.200600666
   Upadhyay KK, 2010, BIOMATERIALS, V31, P2882, DOI 10.1016/j.biomaterials.2009.12.043
   van Dongen SFM, 2010, ANGEW CHEM INT EDIT, V49, P7213, DOI 10.1002/anie.201002655
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vladimir P T., 2008, ADV DRUG DELIVERY RE, V60, P548
   Xiong XB, 2011, ACS NANO, V5, P5202, DOI 10.1021/nn2013707
   Xu XD, 2012, POLYM CHEM-UK, V3, P2479, DOI 10.1039/c2py20299a
   Yoon YR, 2008, CHEM COMMUN, P1892, DOI 10.1039/b719868j
NR 50
TC 9
Z9 9
U1 0
U2 44
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9954
J9 POLYM CHEM-UK
JI Polym. Chem.
PY 2013
VL 4
IS 6
BP 2011
EP 2018
DI 10.1039/c2py21044d
PG 8
WC Polymer Science
SC Polymer Science
GA 093BW
UT WOS:000315167700031
DA 2018-01-05
ER

PT J
AU Leleux, J
   Roy, K
AF Leleux, Jardin
   Roy, Krishnendu
TI Micro and Nanoparticle-Based Delivery Systems for Vaccine Immunotherapy:
   An Immunological and Materials Perspective
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Review
ID TOLL-LIKE-RECEPTORS; HUMAN DENDRITIC CELLS; ENHANCED IMMUNE-RESPONSE;
   PATTERN-RECOGNITION RECEPTORS; ANTIGEN-PRESENTING CELLS; IN-VITRO
   RELEASE; NF-KAPPA-B; PARTICLE-SIZE; INNATE IMMUNITY; CHITOSAN
   NANOPARTICLES
AB The development and widespread application of vaccines has been one of the most significant achievements of modern medicine. Vaccines have not only been instrumental in controlling and even eliminating life-threatening diseases like polio, measles, diphtheria, etc., but have also been immensely powerful in enhancing the worldwide outlook of public health over the past century. Despite these successes, there are still many complex disorders (e. g., cancer, HIV, and other emerging infectious diseases) for which effective preventative or therapeutic vaccines have been difficult to develop. This failure can be attributed primarily to our inability to precisely control and modulate the highly complex immune memory response, specifically the cellular response. Dominated by B and T cell maturation and function, the cellular response is primarily initiated by potent immunostimulators and antigens. Efficient and targeted delivery of these immunomodulatory and immunostimulatory molecules to appropriate cells is key to successful development of next generation vaccine formulations. Over the past decade, particulate carriers have emerged as an attractive means for enhancing the delivery efficacy and potency of vaccines and associated immunomodulatory molecules. Specifically, polymer-based micro and nanoparticles are being extensively studied for a wide variety of applications. In this review, we discuss the immunological fundamentals for developing effective vaccines and how materials and material properties can be exploited to improve these therapies. Particular emphasis is given to polymer-based particles and how the route of administration of particulate systems affects the phenotype and robustness of an immune response. Comparison of various strategies and recent advancements in the field are discussed along with insights into current limitations and future directions.
C1 [Leleux, Jardin] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA.
   [Roy, Krishnendu] Univ Texas Austin, Dept Biomed Engn, Cockrell Family Chair Engn Excellence, Austin, TX 78712 USA.
RP Roy, K (reprint author), Univ Texas Austin, Dept Biomed Engn, Cockrell Family Chair Engn Excellence, BME 5-202B,C0800,1 Univ Stn, Austin, TX 78712 USA.
EM kroy@mail.utexas.edu
CR Ackerman ME, 2012, ANNU REV MED, V63, P113, DOI 10.1146/annurev-med-050310-085221
   Ahire VJ, 2007, DRUG DEV IND PHARM, V33, P1112, DOI 10.1080/03639040701377847
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Akira S, 2011, PHILOS T R SOC B, V366, P2748, DOI 10.1098/rstb.2011.0106
   ALBERTS B, 2002, MOL BIOL CELL
   ALLEMANN E, 1993, PHARMACEUT RES, V10, P1732, DOI 10.1023/A:1018970030327
   Almeria B, 2010, J COLLOID INTERF SCI, V343, P125, DOI 10.1016/j.jcis.2009.10.002
   Alpar HO, 2005, ADV DRUG DELIVER REV, V57, P411, DOI 10.1016/j.addr.2004.09.004
   Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016
   Arca HC, 2009, EXPERT REV VACCINES, V8, P937, DOI [10.1586/erv.09.47, 10.1586/ERV.09.47]
   Astete CE, 2006, J BIOMAT SCI-POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Batista-Duharte A, 2011, TOXICOL LETT, V203, P97, DOI 10.1016/j.toxlet.2011.03.001
   Beaudette TT, 2009, MOL PHARMACEUT, V6, P1160, DOI 10.1021/mp900038e
   Behera T, 2011, INT IMMUNOPHARMACOL, V11, P907, DOI 10.1016/j.intimp.2011.02.002
   Berg J. M., 2002, BIOCHEMISTRY
   Borges O, 2006, J CONTROL RELEASE, V114, P348, DOI 10.1016/j.jconrel.2006.06.011
   Brannon-Peppas L, 2007, PHARM RES, V24, P618, DOI 10.1007/s11095-006-9208-x
   Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203
   Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7
   Chadwick S, 2010, ADV DRUG DELIVER REV, V62, P394, DOI 10.1016/j.addr.2009.11.012
   Champion JA, 2008, PHARM RES-DORDR, V25, P1815, DOI 10.1007/s11095-008-9562-y
   Chiellini F, 2008, NANOMEDICINE-UK, V3, P367, DOI 10.2217/17435889.3.3.367
   Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014
   Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623
   Chu VT, 2011, SCAND J IMMUNOL, V73, P508, DOI 10.1111/j.1365-3083.2011.02544.x
   Chua BY, 2012, MOL PHARMACEUT, V9, P81, DOI 10.1021/mp200264m
   Coester C, 2006, EUR J PHARM BIOPHARM, V62, P306, DOI 10.1016/j.ejpb.2005.09.009
   Combadiere B, 2008, COMP IMMUNOL MICROB, V31, P293, DOI 10.1016/j.cimid.2007.07.015
   Costantino HR, 2004, J PHARM SCI-US, V93, P2624, DOI 10.1002/jps.20078
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Dang JM, 2006, ADV DRUG DELIVER REV, V58, P487, DOI 10.1016/j.addr.2006.03.001
   De Geest BG, 2012, ANGEW CHEM INT EDIT, V51, P3862, DOI 10.1002/anie.201200048
   De Haes W, 2010, MOL THER, V18, P1408, DOI 10.1038/mt.2010.82
   De Temmerman ML, 2012, J CONTROL RELEASE, V158, P233, DOI 10.1016/j.jconrel.2011.10.029
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   De Temmerman ML, 2011, BIOMACROMOLECULES, V12, P1283, DOI 10.1021/bm101559w
   Debache K, 2011, PARASITE IMMUNOL, V33, P81, DOI 10.1111/j.1365-3024.2010.01255.x
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9
   Dunne A, 2011, CURR OPIN PHARMACOL, V11, P404, DOI 10.1016/j.coph.2011.03.004
   Fischer S, 2009, J DRUG TARGET, V17, P652, DOI 10.1080/10611860903119656
   Florindo HF, 2008, VACCINE, V26, P4168, DOI 10.1016/j.vaccine.2008.05.074
   Florindo HF, 2009, BIOMATERIALS, V30, P879, DOI 10.1016/j.biomaterials.2008.10.035
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Fuller DH, 2006, METHODS, V40, P86, DOI 10.1016/j.ymeth.2006.05.022
   Garcia F, 2004, OBSTET GYNECOL, V103, P317, DOI 10.1097/01.AOG.0000110246.93627.17
   Garlepp MJ, 1995, CLIN EXP IMMUNOL, V102, P614
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225                                                
   Ghosh TK, 2007, INT IMMUNOPHARMACOL, V7, P1111, DOI 10.1016/j.intimp.2007.04.006
   Ghosn B, 2010, OLIGONUCLEOTIDES, V20, P163, DOI 10.1089/oli.2010.0235
   Gombotz WR, 1998, ADV DRUG DELIVER REV, V31, P267, DOI 10.1016/S0169-409X(97)00124-5
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   Gupta NK, 2011, VACCINE, V29, P9026, DOI 10.1016/j.vaccine.2011.09.033
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Haining WN, 2004, J IMMUNOL, V173, P2578, DOI 10.4049/jimmunol.173.4.2578                                                     
   Harandi AM, 2009, EXPERT REV VACCINES, V8, P293, DOI 10.1586/14760584.8.3.293
   Heffernan MJ, 2009, BIOMATERIALS, V30, P910, DOI 10.1016/j.biomaterials.2008.10.034
   Heffernan MJ, 2005, BIOCONJUGATE CHEM, V16, P1340, DOI 10.1021/bc050176w
   Heuking S, 2012, J PHARM SCI-US, V101, P1166, DOI 10.1002/jps.23017
   Higgins Sarah C, 2010, Curr Infect Dis Rep, V12, P4, DOI 10.1007/s11908-009-0080-9
   Hilleman MR, 2000, VACCINE, V18, P1436, DOI 10.1016/S0264-410X(99)00434-X
   Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1079/pnas.1016933101
   Hori Y, 2008, BIOMATERIALS, V29, P3671, DOI 10.1016/j.biomaterials.2008.05.033
   Hori Y, 2009, ACTA BIOMATER, V5, P969, DOI 10.1016/j.actbio.2008.11.019
   Hu YH, 2009, BIOMACROMOLECULES, V10, P756, DOI 10.1021/bm801199z
   Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604
   Hunter Z, 2011, VACCINE, V29, P4584, DOI 10.1016/j.vaccine.2011.04.051
   Hunter Z, 2009, VACCINE, V28, P403, DOI 10.1016/j.vaccine.2009.10.035
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Igartua M, 1998, J CONTROL RELEASE, V56, P63, DOI 10.1016/S0168-3659(98)00077-7
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718
   Ito K, 2003, MOL IMMUNOL, V39, P847, DOI 10.1016/S0161-5890(03)00024-5
   Jabbal-Gill I, 2010, J DRUG TARGET, V18, P771, DOI 10.3109/1061186X.2010.523790
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Jain AK, 2010, INT J PHARMACEUT, V387, P253, DOI 10.1016/j.ijpharm.2009.12.013
   Jain S, 2005, BIOMACROMOLECULES, V6, P2590, DOI 10.1021/bm0503221
   Jewell CM, 2011, P NATL ACAD SCI USA, V108, P15745, DOI 10.1073/pnas.1105200108
   Jilek S, 2004, PHARM RES, V21, P1240, DOI 10.1023/B:PHAM.0000033012.16152.5d                                              
   Jilek S, 2005, ADV DRUG DELIVER REV, V57, P377, DOI 10.1016/j.addr.2004.09.010
   Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6
   Jones KS, 2008, BIOTECHNOL PROGR, V24, P807, DOI [10.1002/btpr.10, 10.1021/bp.10]
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kabelitz D, 2007, CURR OPIN IMMUNOL, V19, P1, DOI 10.1016/j.coi.2006.11.018
   Kang ML, 2009, BIOTECHNOL ADV, V27, P857, DOI 10.1016/j.biotechadv.2009.06.007
   Kasturi SP, 2005, BIOMATERIALS, V26, P6375, DOI 10.1016/j.biomaterials.2005.03.043
   Kasturi SP, 2006, J CONTROL RELEASE, V113, P261, DOI 10.1016/j.jcornel.2006.04.006
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Katare YK, 2005, INT J PHARM, V301, P149, DOI 10.1016/j.ijpharm.2005.05.028
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914
   Khatri K, 2008, INT J PHARM, V354, P235, DOI 10.1016/j.ijpharm.2007.11.027
   Klinman DA, 2004, VACCINE, V22, P2881, DOI 10.1016/j.vaccine.2003.12.020
   KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X
   Kohli AK, 2004, INT J PHARM, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038
   Kuo-Haller P, 2010, MOL PHARMACEUT, V7, P1585, DOI 10.1021/mp100009e
   Kushwah R, 2011, IMMUNOLOGY, V133, P409, DOI 10.1111/j.1365-2567.2011.03457.x
   Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102
   Kwon YJ, 2005, MOL PHARMACEUT, V2, P83, DOI 10.1021/mp0498953
   Lai RPJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035083
   Lauring AS, 2010, NAT BIOTECHNOL, V28, P573, DOI 10.1038/nbt.1635
   Lee PW, 2008, BIOMATERIALS, V29, P742, DOI 10.1016/j.biomaterials.2007.10.034
   Lee YH, 2010, J CONTROL RELEASE, V145, P58, DOI 10.1016/j.jconrel.2010.03.014
   Liard C, 2012, J INVEST DERMATOL, V132, P615, DOI 10.1038/jid.2011.346
   Lin L, 2004, EUR J IMMUNOL, V34, P1483, DOI 10.1002/eji.200324736
   Lin ML, 2008, IMMUNOL CELL BIOL, V86, P353, DOI 10.1038/icb.2008.3
   Ludewig B, 2001, J IMMUNOL, V166, P3678, DOI 10.4049/jimmunol.166.6.3678                                                     
   Mackay I. R., 2001, NEW ENGL J MED, V345, P1042
   Macklin MD, 1998, J VIROL, V72, P1491
   Macpherson AJ, 2012, IMMUNOL REV, V245, P132, DOI 10.1111/j.1600-065X.2011.01072.x
   Mallapragada SK, 2008, INT J PHARMACEUT, V364, P265, DOI 10.1016/j.ijpharm.2008.06.030
   Malyala P, 2008, J PHARM SCI-US, V97, P1155, DOI 10.1002/jps.21065
   Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004
   Masihi KN, 2000, INT J ANTIMICROB AG, V14, P181, DOI 10.1016/S0924-8579(99)00161-2                                                   
   Mata E, 2011, EUR J PHARM SCI, V44, P32, DOI 10.1016/j.ejps.2011.05.015
   MCCARTHY RE, 1977, IMMUNOLOGY, V32, P963
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5                                                   
   Merodio M, 2001, EUR J PHARM SCI, V12, P251, DOI 10.1016/S0928-0987(00)00169-X                                                   
   Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264-410X(00)00170-5                                                   
   Mohaghegh M, 2011, PHARM DEV TECHNOL, V16, P36, DOI 10.3109/10837450903479962
   Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012
   Mottram PL, 2007, MOL PHARMACEUT, V4, P73, DOI 10.1021/mp060096p
   Mueller M, 2011, INT J CANCER, V129, P407, DOI 10.1002/ijc.25914
   Mui B, 2001, J PHARMACOL EXP THER, V298, P1185
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Munier S, 2005, COLLOID SURFACE B, V43, P163, DOI 10.1016/j.colsurfb.2005.05.001
   Murillo M, 2002, J CONTROL RELEASE, V85, P237, DOI 10.1016/S0168-3659(02)00276-6
   Murphy K., 2007, JANEWAYS IMMUNOBIOLO
   Murthy N, 2003, P NATL ACAD SCI USA, V100, P4995, DOI 10.1073/pnas.0930644100
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Naz RK, 2012, J REPROD IMMUNOL, V93, P1, DOI 10.1016/j.jri.2011.09.005
   Nettey H, 2006, J MICROENCAPSUL, V23, P632, DOI 10.1080/02652040600776564
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269
   O'Hagan DT, 2001, BIOMOL ENG, V18, P69, DOI 10.1016/S1389-0344(01)00101-0                                                   
   Ofokansi K, 2010, EUR J PHARM BIOPHARM, V76, P1, DOI 10.1016/j.ejpb.2010.04.008
   OHAGAN DT, 1989, VACCINE, V7, P421, DOI 10.1016/0264-410X(89)90156-4
   Osorio F, 2011, IMMUNITY, V34, P651, DOI 10.1016/j.immuni.2011.05.001
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003
   Pechenkin M.A., 2011, J BIOEQUIV AVAILAB, V3, P244
   PERESWETOFFMORATH L, 1995, INT J PHARM, V124, P37, DOI 10.1016/0378-5173(95)00070-Y
   Peyre M, 2004, VACCINE, V22, P2430, DOI 10.1016/j.vaccine.2003.11.068
   Pietrocola G, 2011, INT J ARTIF ORGANS, V34, P799, DOI 10.5301/ijao.5000030
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Rafati H, 1997, J CONTROL RELEASE, V43, P89, DOI 10.1016/S0168-3659(96)01475-7                                                   
   Raghuwanshi D, 2012, MOL PHARMACEUT, V9, P946, DOI 10.1021/mp200553x
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0                                                   
   Ruben FL, 2001, CLIN INFECT DIS, V32, P170, DOI 10.1086/317553
   Salvador A, 2012, VACCINE, V30, P589, DOI 10.1016/j.vaccine.2011.11.057
   Samuelsen M, 2009, SCAND J IMMUNOL, V69, P421, DOI 10.1111/j.1365-3083.2009.02244.x
   Saxena V, 2004, INT J PHARM, V278, P293, DOI 10.1016/j.ijpharm.2004.03.032
   Schliehe C, 2011, J IMMUNOL, V187, P2112, DOI 10.4049/jimmunol.1002084
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Semete B, 2010, TOXICOL APPL PHARM, V249, P158, DOI 10.1016/j.taap.2010.09.002
   Senti G, 2009, CURR OPIN ALLERGY CL, V9, P537, DOI 10.1097/ACI.0b013e3283310ff7
   Sethi S, 2011, VIRULENCE, V2, P316, DOI 10.4161/viru.2.4.16142
   Sexton A, 2009, ACS NANO, V3, P3391, DOI 10.1021/nn900715g
   Sharma S, 2012, J PHARM SCI-US, V101, P233, DOI 10.1002/jps.22763
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Sheets EE, 2003, AM J OBSTET GYNECOL, V188, P916, DOI 10.1067/mob.2003.256
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Singh A, 2011, J CONTROL RELEASE, V155, P184, DOI 10.1016/j.jconrel.2011.06.008
   Singh A, 2009, BIOMATERIALS, V30, P5187, DOI 10.1016/j.biomaterials.2009.06.001
   Singh A, 2008, MOL THER, V16, P2011, DOI 10.1038/mt.2008.206
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Slutter B, 2010, VACCINE, V28, P6282, DOI 10.1016/j.vaccine.2010.06.121
   Slutter B, 2009, J CONTROL RELEASE, V138, P113, DOI 10.1016/j.jconrel.2009.05.011
   Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6                                                   
   Spychaj T, 1996, MACROMOL SYMP, V110, P191, DOI 10.1002/masy.19961100114                                                        
   Standley SM, 2007, BIOCONJUGATE CHEM, V18, P77, DOI 10.1021/bc060165i
   Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6                                                   
   Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839
   Sudheesh MS, 2011, DRUG DELIV, V18, P320, DOI 10.3109/10717544.2010.549525
   Swartz MA, 2008, SEMIN IMMUNOL, V20, P147, DOI 10.1016/j.smim.2007.11.007
   Tabassi SAS, 2008, INT J PHARM, V360, P12, DOI 10.1016/j.ijpharm.2008.03.036
   Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615
   Tafaghodi M, 2011, EXP PARASITOL, V129, P107, DOI 10.1016/j.exppara.2011.07.007
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8                                                   
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   Tayade PT, 2004, AAPS PHARMSCI, V6, DOI 10.1208/ps060112                                                                
   Temmerman M.-L., 2011, PHARM RES, V28, P1765
   Uddin AN, 2009, J DRUG TARGET, V17, P553, DOI 10.1080/10611860903067301
   Vajdy M, 2004, IMMUNOL CELL BIOL, V82, P617, DOI 10.1111/j.1440-1711.2004.01288.x
   van der Lubben IM, 2001, EUR J PHARM SCI, V14, P201, DOI 10.1016/S0928-0987(01)00172-5                                                   
   van der Lubben IM, 2001, ADV DRUG DELIVER REV, V52, P139, DOI 10.1016/S0169-409X(01)00197-1                                                   
   Verheul RJ, 2011, J CONTROL RELEASE, V156, P46, DOI 10.1016/j.jconrel.2011.07.014
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2                                                   
   Villemejane J, 2009, BRIT J PHARMACOL, V157, P207, DOI 10.1111/j.1476-5381.2009.00032.x
   von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407                                                     
   Waeckerle-Men Y, 2006, VACCINE, V24, P1847, DOI 10.1016/j.vaccine.2005.10.032
   Wanakule P, 2012, CURR DRUG METAB, V13, P42, DOI 10.2174/138920012798356880                                                      
   Wang DQ, 1999, J CONTROL RELEASE, V57, P9, DOI 10.1016/S0168-3659(98)00099-6
   Weber C, 2010, J BIOMED MATER RES A, V93A, P1322, DOI 10.1002/jbm.a.32605
   Wen ZS, 2011, MAR DRUGS, V9, P1038, DOI 10.3390/md9061038
   WRIGHT AK, 1975, BIOPHYS J, V15, P137, DOI 10.1016/S0006-3495(75)85797-3                                                   
   Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016
   Xie H, 2005, INFECT IMMUN, V73, P828, DOI 10.1028/IAI.73.2.828-833.2005
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yang D, 2009, J BIOMED MATER RES A, V90A, P411, DOI 10.1002/jbm.a.32096
   Yeboah KG, 2009, J MICROENCAPSUL, V26, P166, DOI [10.1080/02652040802211717, 10.1080/02652040802211717 ]
   Zepp F, 2010, VACCINE, V28, pC14, DOI 10.1016/j.vaccine.2010.07.020
   Zhang XQ, 2007, J PHARM SCI-US, V96, P3283, DOI 10.1002/jps.20978
   Zhao K, 2011, VACCINE, V29, P8549, DOI 10.1016/j.vaccine.2011.09.029
   Zheng XL, 2010, AAPS J, V12, P519, DOI 10.1208/s12248-010-9213-1
   Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154
NR 218
TC 68
Z9 69
U1 9
U2 170
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2192-2640
EI 2192-2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JAN
PY 2013
VL 2
IS 1
SI SI
BP 72
EP 94
DI 10.1002/adhm.201200268
PG 23
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
SC Engineering; Science & Technology - Other Topics; Materials Science
GA 092LC
UT WOS:000315121900006
PM 23225517
DA 2018-01-05
ER

PT J
AU Dorvel, B
   Damhorst, G
   Chan, V
   Shim, J
   Banerjee, S
   Cvetkovic, C
   Raman, R
   Bashir, R
AF Dorvel, Brian
   Damhorst, Gregory
   Chan, Vincent
   Shim, Jiwook
   Banerjee, Shouvik
   Cvetkovic, Caroline
   Raman, Ritu
   Bashir, Rashid
TI A gold nanoparticle assay for HIV viral load quantification
SO NANOMEDICINE
LA English
DT News Item
C1 [Dorvel, Brian; Damhorst, Gregory] Univ Illinois, Dept Biophys & Computat Biol, Urbana, IL 61801 USA.
   [Dorvel, Brian; Damhorst, Gregory; Chan, Vincent; Shim, Jiwook; Banerjee, Shouvik; Cvetkovic, Caroline; Raman, Ritu; Bashir, Rashid] Univ Illinois, Micro & Nanotechnol Lab, Urbana, IL 61801 USA.
   [Chan, Vincent; Cvetkovic, Caroline; Raman, Ritu; Bashir, Rashid] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.
   [Shim, Jiwook; Bashir, Rashid] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA.
   [Banerjee, Shouvik] Univ Illinois, Dept Mat Sci & Engn, Urbana, IL 61801 USA.
RP Bashir, R (reprint author), Univ Illinois, Micro & Nanotechnol Lab, Urbana, IL 61801 USA.
EM rbashir@illinois.edu
RI Shim, Jiwook/H-3810-2013
OI Shim, Jiwook/0000-0003-4088-2557
NR 0
TC 0
Z9 0
U1 1
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JAN
PY 2013
VL 8
IS 1
BP 14
EP 14
PG 1
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 084YS
UT WOS:000314577800009
DA 2018-01-05
ER

PT J
AU De Haes, W
   Rejman, J
   Pollard, C
   Merlin, C
   Vekemans, M
   Florence, E
   De Smedt, SC
   Grooten, J
   Vanham, G
   De Koker, S
   Van Gulck, E
AF De Haes, Winni
   Rejman, Joanna
   Pollard, Charlotte
   Merlin, Celine
   Vekemans, Marc
   Florence, Eric
   De Smedt, Stefaan C.
   Grooten, Johan
   Vanham, Guido
   De Koker, Stefaan
   Van Gulck, Ellen
TI Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells
   to stimulate HIV-specific immune responses
SO NANOMEDICINE
LA English
DT Article
DE cationic lipid; dendritic cell; HIV-1; immunostimulation; immunotherapy;
   mRNA delivery; nanoparticle
ID CYTOTOXIC T-LYMPHOCYTES; DNA VACCINES; ANTIRETROVIRAL THERAPY; GENE
   DELIVERY; IN-VITRO; VACCINATION; NEF; INDUCTION; SYSTEM; MICROPARTICLES
AB Aim: Cationic lipids (Lipofectamine (TM) [Invitrogen, Merelbeke, Belgium] and 1,2-dioleoyl-3-trimethylammonium-propane/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and polymers (jetPEI (TM) and in vivo-jetPEI (TM) [Polyplus-transfection, Illkirch, France]) were evaluated for their potential to deliver mRNA to monocyte-derived dendritic cells. Materials & methods: Lipoplexes and polyplexes, containing mRNA encoding GFP or Gag protein, were incubated with human monocyte-derived dendritic cells and transfection efficiencies were assessed by flow cytometry. Results: Lipofectamine was by far the most efficient in mRNA delivery, therefore it was used in further experiments. Incubation of monocyte-derived dendritic cells isolated from HIV-1-positive donors with mRNA encoding Gag protein complexed to Lipofectamine resulted in 50% transfection. Importantly, coculture of these Gag-transfected dendritic cells with autologous T cells induced an over tenfold expansion of IFN-gamma- and IL-2-secreting CD4(+) and CD8(+) T cells. Conclusion: Cationic lipid-mediated mRNA delivery may be a useful tool for therapeutic vaccination against HIV-1. This approach can be applied to develop vaccination strategies for other infectious diseases and cancer.
C1 [De Haes, Winni; Pollard, Charlotte; Merlin, Celine; Vekemans, Marc; Florence, Eric; Vanham, Guido; Van Gulck, Ellen] Inst Trop Med Antwerp, B-2000 Antwerp, Belgium.
   [Rejman, Joanna; Pollard, Charlotte; De Smedt, Stefaan C.; Grooten, Johan; De Koker, Stefaan] Univ Ghent, B-9052 Ghent, Belgium.
   [Vanham, Guido] Univ Antwerp, Fac Pharmaceut Vet & Biomed Sci, Antwerp, Belgium.
   [Vanham, Guido] Vrije Univ Brussel, Fac Med & Pharmacol, Brussels, Belgium.
RP De Haes, W (reprint author), Inst Trop Med Antwerp, Natl Str 155, B-2000 Antwerp, Belgium.
EM wdehaes@itg.be
OI De Smedt, Stefaan/0000-0002-8653-2598; Florence,
   Eric/0000-0002-7004-9120
FU Inter-University Attraction Poles (IUAP) [P6/41]; Fund for Scientific
   Research Flanders (FWO) [G.0226.10]; Secondary Research Funding
   Institute of Tropical Medicine (SOFI-B); European Vaccines; Microbicides
   Enterprise (Europrise) [037611]
FX This work was supported by grants from Inter-University Attraction Poles
   (IUAP; P6/41 of the Belgian government), Fund for Scientific Research
   Flanders (FWO; project no. G.0226.10), Secondary Research Funding
   Institute of Tropical Medicine (SOFI-B) and European Vaccines and
   Microbicides Enterprise (Europrise; contract no. 037611). W De Haes is a
   predoctoral fellow of the Agency for Innovation by Science and
   Technology in Flanders. The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript apart from those disclosed.
CR Aline F, 2009, VACCINE, V9, P536
   Allard SD, 2008, VACCINE, V26, P3735, DOI 10.1016/j.vaccine.2008.04.077
   Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bojak A, 2002, INTERVIROLOGY, V45, P275, DOI 10.1159/000067919
   Chassin D, 1999, EUR J IMMUNOL, V29, P196, DOI 10.1002/(SICI)1521-4141(199901)29:01<196::AID-IMMU196>3.3.CO;2-W
   CONRY RM, 1995, CANCER RES, V55, P1397
   De Haes W, 2010, MOL THER, V18, P1408, DOI 10.1038/mt.2010.82
   De Keersmaecker B, 2011, J LEUKOCYTE BIOL, V89, P989, DOI 10.1189/jlb.0810466
   De Rose R, 2008, ADV MATER, V20, P4698, DOI 10.1002/adma.200801826
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Deretic V, 2009, CURR OPIN IMMUNOL, V21, P53, DOI 10.1016/j.coi.2009.02.002
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Espuelas S, 2005, MOL IMMUNOL, V42, P721, DOI 10.1016/j.molimm.2004.09.022
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Hawkins T, 2010, ANTIVIR RES, V85, P201, DOI 10.1016/j.antiviral.2009.10.016
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209                                                          
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kreiter S, 2011, CANCER RES, V71, P6132, DOI 10.1158/0008-5472.CAN-11-0291
   Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lorenzi JCC, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-77
   LU D, 1994, CANCER GENE THER, V1, P245
   MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749
   O'Hagan DT, 2004, IMMUNOL REV, V199, P191, DOI 10.1111/j.0105-2896.2004.00153.x                                                
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Pascolo Steve, 2008, V183, P221
   Ponsaerts P, 2002, LEUKEMIA, V16, P1324, DOI 10.1038/sj.leu.2402511
   Read ML, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni085
   Rejman J, 2010, J CONTROL RELEASE, V147, P385, DOI 10.1016/j.jconrel.2010.07.124
   Remaut K, 2007, MAT SCI ENG R, V58, P117, DOI 10.1016/j.mser.2007.06.001
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Roesler E, 2009, J ALLERGY CLIN IMMUN, V124, P1070, DOI 10.1016/j.jaci.2009.06.036
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   Routy JP, 2010, CLIN IMMUNOL, V134, P140, DOI 10.1016/j.clim.2009.09.009
   Scheel B, 2006, EUR J IMMUNOL, V36, P2807, DOI 10.1002/eji.2006.35910
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Van Gulck ER, 2008, J VIROL, V82, P3561, DOI 10.1128/JVI.02080-07
   Van Gulck ERA, 2006, BLOOD, V107, P1818, DOI 10.1182/blood-2005-01-0339
   Van Lint S, 2012, CANCER RES, V72, P1661, DOI 10.1158/0008-5472.CAN-11-2957
   Van Nuffel An M T, 2010, Methods Mol Biol, V629, P405, DOI 10.1007/978-1-60761-657-3_27
   Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49
   Van Tendeloo VF, 2010, P NATL ACAD SCI USA, V107, P13824, DOI 10.1073/pnas.1008051107
   Van Gulck E., 2011, AIDS, V26, pF1
   Yamamoto A, 2009, EUR J PHARM BIOPHARM, V71, P484, DOI 10.1016/j.ejpb.2008.09.016
   Yoshikawa T, 2008, GENE THER, V15, P1321, DOI 10.1038/gt.2008.85
   Yu H, 2007, VACCINE, V25, P1701, DOI 10.1016/j.vaccine.2006.11.046
NR 48
TC 7
Z9 7
U1 0
U2 27
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD JAN
PY 2013
VL 8
IS 1
BP 77
EP 87
DI 10.2217/NNM.12.97
PG 11
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 084YS
UT WOS:000314577800016
PM 22891862
DA 2018-01-05
ER

PT J
AU MacEwan, SR
   Chilkoti, A
AF MacEwan, Sarah R.
   Chilkoti, Ashutosh
TI Harnessing the power of cell-penetrating peptides: activatable carriers
   for targeting systemic delivery of cancer therapeutics and imaging
   agents
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID MULTIFUNCTIONAL POLYMERIC MICELLE; ACIDIC SOLID TUMORS; HIV-1 TAT
   PEPTIDE; DRUG-DELIVERY; IN-VIVO; MOLECULAR TRANSPORTERS; RICH PEPTIDES;
   PHARMACEUTICAL NANOCARRIERS; INTRACELLULAR TRAFFICKING; ANTIMICROBIAL
   PEPTIDES
AB Targeted delivery of cancer therapeutics and imaging agents aims to enhance the accumulation of these molecules in a solid tumor while avoiding uptake in healthy tissues. Tumor-specific accumulation has been pursued with passive targeting by the enhanced permeability and retention effect, as well as with active targeting strategies. Active targeting is achieved by functionalization of carriers to allow specific interactions between the carrier and the tumor environment. Functionalization of carriers with ligands that specifically interact with overexpressed receptors on cancer cells represents a classic approach to active tumor targeting. Cell-penetrating peptides (CPPs) provide a non-specific and receptor-independent mechanism to enhance cellular uptake that offers an exciting alternative to traditional active targeting approaches. While the non-specificity of CPP-mediated internalization has the intriguing potential to make this approach applicable to a wide range of tumor types, their promiscuity is, however, a significant barrier to their clinical utility for systemically administered applications. Many approaches have been investigated to selectively turn on the function of systemically delivered CPP-functionalized carriers specifically in tumors to achieve targeted delivery of cancer therapeutics and imaging agents. (C) 2012 Wiley Periodicals, Inc.
C1 [MacEwan, Sarah R.; Chilkoti, Ashutosh] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Chilkoti, Ashutosh] Duke Univ, Ctr Biol Inspired Mat & Mat Syst, Durham, NC USA.
RP Chilkoti, A (reprint author), Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
EM Chilkoti@duke.edu
OI MacEwan, Sarah/0000-0002-4365-6232
FU NIH [R01EB007205]; NSF's Research Triangle MRSEC [NSF DMR-1121107]
FX This work was supported by the NIH through Grant R01EB007205 (A. C.) and
   by a graduate fellowship from the NSF's Research Triangle MRSEC (NSF
   DMR-1121107) (S.M.).
CR Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Brandt F, 2010, DERMATOL SURG, V36, P2111, DOI 10.1111/j.1524-4725.2010.01711.x
   Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Choi JM, 2006, NAT MED, V12, P574, DOI 10.1038/nm1385
   Choi Y, 2011, BIOCONJUGATE CHEM, V22, P1576, DOI 10.1021/bc200126k
   Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   DEXTER DL, 1986, J CLIN ONCOL, V4, P244, DOI 10.1200/JCO.1986.4.2.244                                                        
   Dreher MR, 2008, J AM CHEM SOC, V130, P687, DOI 10.1021/ja0764862
   Falk MH, 2001, INT J HYPERTHER, V17, P1, DOI 10.1080/02656730150201552                                                       
   Fink-Retter A, 2007, ONCOL REP, V18, P299
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Flynn CR, 2010, J PHARM SCI-US, V99, P3100, DOI 10.1002/jps.22087
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Goun EA, 2006, BIOCONJUGATE CHEM, V17, P787, DOI 10.1021/bc0503216
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   Harris TJ, 2008, SMALL, V4, P1307, DOI 10.1002/smll.200701319
   Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100
   Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Huang YZ, 2010, CURR PHARM DESIGN, V16, P2369, DOI 10.2174/138161210791920441                                                      
   Ifediba MA, 2010, BIOCONJUGATE CHEM, V21, P803, DOI 10.1021/bc900488e
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jones S, 2010, CHEM BIOL, V17, P735, DOI 10.1016/j.chembiol.2010.05.018
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kawamoto S, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3555531
   Kerkis A, 2006, IUBMB LIFE, V58, P7, DOI 10.1080/15216540500494508
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Khalil Ikramy A, 2008, Int J Pharm, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Koren E, 2012, J CONTROL RELEASE, V160, P264, DOI 10.1016/j.jconrel.2011.12.002
   Kuai R, 2010, MOL PHARM
   Kuai R, 2011, MOL PHARMACEUT, V8, P2151, DOI 10.1021/mp200100f
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Lehto T, 2012, EXPERT OPIN DRUG DEL, V9, P823, DOI 10.1517/17425247.2012.689285
   Levi J, 2010, J AM CHEM SOC, V132, P11264, DOI 10.1021/ja104000a
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Li YT, 2009, J BIOMED MATER RES A, V91A, P209, DOI 10.1002/jbm.a.32204
   Liu JR, 2010, NEUROPATH APPL NEURO, V36, P211, DOI 10.1111/j.1365-2990.2009.01047.x
   MacEwan SR, 2012, NANO LETT, V12, P3322, DOI 10.1021/nl301529p
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284
   Marks JR, 2011, J AM CHEM SOC, V133, P8995, DOI 10.1021/ja2017416
   Massodi I, 2005, J CONTROL RELEASE, V108, P396, DOI 10.1016/j.jcornel.2005.08.007
   Miyaji Y, 2011, DRUG METAB DISPOS, V39, P1946, DOI 10.1124/dmd.111.040725
   Mok H, 2009, LANGMUIR, V25, P1645, DOI 10.1021/la803542v
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802                                                     
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Ni Chonghaile Triona, 2011, Science, V334, P1129, DOI 10.1126/science.1206727
   Oh E, 2011, ACS NANO, V5, P6434, DOI 10.1021/nn201624c
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Parker N, 2005, ANAL BIOCHEM, V338, P284, DOI 10.1016/j.ab.2004.12.026
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   Roemer RB, 1999, ANNU REV BIOMED ENG, V1, P347, DOI 10.1146/annurev.bioeng.1.1.347
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556
   Sadler K, 2002, BIOCHEMISTRY-US, V41, P14150, DOI 10.1021/bi026661l
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawant RR, 2009, INT J PHARMACEUT, V374, P114, DOI 10.1016/j.ijpharm.2009.02.022
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Shamay Y, 2011, BIOMATERIALS, V32, P1377, DOI 10.1016/j.biomaterials.2010.10.029
   SKIPPER HE, 1971, CANCER, V28, P1479, DOI 10.1002/1097-0142(197112)28:6<1479::AID-CNCR2820280622>3.0.CO;2-M
   Som A, 2011, ANGEW CHEM INT EDIT, V50, P6147, DOI 10.1002/anie.201101535
   Splith K, 2010, BIOCONJUGATE CHEM, V21, P1288, DOI 10.1021/bc100089z
   Svensen N, 2012, TRENDS PHARMACOL SCI, V33, P186, DOI 10.1016/j.tips.2012.02.002
   Taniguchi K, 2008, CANCER SCI, V99, P929, DOI 10.1111/j.1349-7006.2008.00782.x
   Torchilin V, 2009, EUR J PHARM BIOPHARM, V71, P431, DOI 10.1016/j.ejpb.2008.09.026
   van Duijnhoven SMJ, 2011, J NUCL MED, V52, P279, DOI 10.2967/jnumed.110.082503
   Vezenkov LL, 2010, BIOCONJUGATE CHEM, V21, P1850, DOI 10.1021/bc1002086
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Watkins GA, 2009, BIOORGAN MED CHEM, V17, P653, DOI 10.1016/j.bmc.2008.11.078
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2005, ORG LETT, V7, P4815, DOI 10.1021/ol051496y
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Zhang W, 2011, BIOCONJUGATE CHEM, V22, P1410, DOI 10.1021/bc200138d
   Zhu L, 2012, ACS NANO, V6, P3491, DOI 10.1021/nn300524f
NR 93
TC 29
Z9 31
U1 2
U2 84
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD JAN-FEB
PY 2013
VL 5
IS 1
BP 31
EP 48
DI 10.1002/wnan.1197
PG 18
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 090NY
UT WOS:000314987200003
PM 22977001
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mancuso, M
   Jiang, L
   Cesarman, E
   Erickson, D
AF Mancuso, Matthew
   Jiang, Li
   Cesarman, Ethel
   Erickson, David
TI Multiplexed colorimetric detection of Kaposi's sarcoma associated
   herpesvirus and Bartonella DNA using gold and silver nanoparticles
SO NANOSCALE
LA English
DT Article
ID DEFICIENCY SYNDROME AIDS; BACILLARY ANGIOMATOSIS; HOMOSEXUAL MEN;
   PROBES; HUMAN-HERPESVIRUS-8; PROTEIN; VIRUS; POLYNUCLEOTIDES;
   SEROPREVALENCE; NANOSTRUCTURES
AB Kaposi's sarcoma (KS) is an infectious cancer occurring most commonly in human immunodeficiency virus (HIV) positive patients and in endemic regions, such as Sub-Saharan Africa, where KS is among the top four most prevalent cancers. The cause of KS is the Kaposi's sarcoma-associated herpesvirus (KSHV, also called HHV-8), an oncogenic herpesvirus that while routinely diagnosed in developed nations, provides challenges to developing world medical providers and point-of-care detection. A major challenge in the diagnosis of KS is the existence of a number of other diseases with similar clinical presentation and histopathological features, requiring the detection of KSHV in a biopsy sample. In this work we develop an answer to this challenge by creating a multiplexed one-pot detection system for KSHV DNA and DNA from a frequently confounding disease, bacillary angiomatosis. Gold and silver nanoparticle aggregation reactions are tuned for each target and a multi-color change system is developed capable of detecting both targets down to levels between 1 nM and 2 nM. The system developed here could later be integrated with microfluidic sample processing to create a final device capable of solving the two major challenges in point-of-care KS detection.
C1 [Mancuso, Matthew] Cornell Univ, Dept Biomed Engn, Ithaca, NY 14853 USA.
   [Jiang, Li; Erickson, David] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA.
   [Cesarman, Ethel] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA.
RP Erickson, D (reprint author), Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA.
EM de54@cornell.edu
RI Mancuso, Matthew/B-4637-2012
FU Clinical and Translational Science Center under NIH [UL1 RR 024996];
   National Science Foundation Graduate Research Fellowship [DGE-0707428];
   National Science Foundation [ECS-0335765]; Nanobiotechnology Center
   (NBTC), an STC Program of the National Science Foundation [ECS-9876771]
FX This work was funded in part by the Clinical and Translational Science
   Center under NIH grant UL1 RR 024996. M. Mancuso would like to
   acknowledge a National Science Foundation Graduate Research Fellowship
   under Grant no. DGE-0707428. This work was performed in part at the
   Cornell NanoScale Facility, a member of the National Nanotechnology
   Infrastructure Network, which is supported by the National Science
   Foundation (Grant ECS-0335765) and at the Nanobiotechnology Center
   (NBTC), an STC Program of the National Science Foundation under
   Agreement no. ECS-9876771.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389                                                          
   Arlett JL, 2011, NAT NANOTECHNOL, V6, P203, DOI 10.1038/nnano.2011.44
   Aslan K, 2005, ANAL CHEM, V77, P2007, DOI 10.1021/ac0484880
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BERGER TG, 1989, ARCH DERMATOL, V125, P1543, DOI 10.1001/archderm.125.11.1543                                                    
   Butler LM, 2009, J INFECT DIS, V200, P430, DOI 10.1086/600103
   Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102
   Caldwell BD, 1996, J AM PODIAT MED ASSN, V86, P260, DOI 10.7547/87507315-86-6-260                                                       
   Centers for Disease Control and Prevention, 1982, MMWR-MORBID MORTAL W, V31, P300
   Centers for Disease Control and Prevention, 1982, MMWR-MORBID MORTAL W, V31, P294
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879                                                         
   Chen CK, 2010, BIOSENS BIOELECTRON, V25, P1922, DOI 10.1016/j.bios.2010.01.005
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Daniel WL, 2009, J AM CHEM SOC, V131, P6362, DOI 10.1021/ja901609k
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Eltom MA, 2002, J NATL CANCER I, V94, P1204
   Ferlay J, 2011, CANC INCIDENCE MORTA
   FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2                                                   
   Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837
   GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823                                                         
   Hao EC, 2002, J AM CHEM SOC, V124, P15182, DOI 10.1021/ja028336r
   He J, 1998, J INFECT DIS, V178, P1787, DOI 10.1086/314512                                                                  
   Hill HD, 2006, NAT PROTOC, V1, P324, DOI 10.1038/nprot.2006.51
   HYMES KB, 1981, LANCET, V2, P598
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541
   Kalluri JR, 2009, ANGEW CHEM, V121, P9848
   Koehler JE, 1997, NEW ENGL J MED, V337, P1876, DOI 10.1056/NEJM199712253372603                                                     
   Liu MZ, 2005, J PHYS CHEM B, V109, P22192, DOI 10.1021/jp054808n
   Mandal S, 2009, LAB CHIP, V9, P2924, DOI 10.1039/b907826f
   Martinez A. W., 2009, ANAL CHEM, V82, P3, DOI DOI 10.1021/AC9013989
   Martro E, 2004, J MED VIROL, V72, P126, DOI 10.1002/jmv.10548
   Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888
   Millstone JE, 2006, ADV FUNCT MATER, V16, P1209, DOI 10.1002/adfm.200600066
   Minhas V, 2008, AM J EPIDEMIOL, V168, P311, DOI 10.1093/aje/kwn125
   Mudanyali O, 2012, LAB CHIP, V12, P2678, DOI [10.1039/c2lc40235a, 10.1039/c21c40235a]
   Murphy CJ, 2006, INORG CHEM, V45, P7544, DOI 10.1021/ic0519382
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Nam JM, 2002, J AM CHEM SOC, V124, P3820, DOI 10.1021/ja0178766
   Nguyen HQ, 2008, AIDS, V22, P937, DOI 10.1097/QAD.0b013e3282ff6275
   PITCHENIK AE, 1983, ANN INTERN MED, V98, P277, DOI 10.7326/0003-4819-98-3-277
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k                                                               
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Shen L, 2012, LAB CHIP, V12, P4240, DOI [10.1039/c2lc40741, 10.1039/c2lc40741h]
   Storhoff JJ, 2004, NAT BIOTECHNOL, V22, P883, DOI 10.1038/nbt977
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229
   TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z                                                    
   Tappero JW, 1997, NEW ENGL J MED, V337, P1888, DOI 10.1056/NEJM199712253372605                                                     
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Thompson DG, 2008, ANAL CHEM, V80, P2805, DOI 10.1021/ac702403w
   Veigas B, 2012, LAB CHIP, V12, P4802, DOI 10.1039/c2lc40739f
   von Muhlen MG, 2010, ANAL CHEM, V82, P1905, DOI 10.1021/ac9027356
   Yanik AA, 2011, P NATL ACAD SCI USA, V108, P11784, DOI 10.1073/pnas.1101910108
   Zhang J, 2009, ANGEW CHEM INT EDIT, V48, P7787, DOI 10.1002/anie.200903380
   Zheng GF, 2010, NANO LETT, V10, P3179, DOI 10.1021/nl1020975
   Zhou J, 2008, LANGMUIR, V24, P10407, DOI 10.1021/la800961j
NR 57
TC 33
Z9 34
U1 2
U2 76
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2013
VL 5
IS 4
BP 1678
EP 1686
DI 10.1039/c3nr33492a
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 083PM
UT WOS:000314477300054
PM 23340972
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wiktor, M
   Morin, S
   Sass, HJ
   Kebbel, F
   Grzesiek, S
AF Wiktor, Maciej
   Morin, Sebastien
   Sass, Hans-Juergen
   Kebbel, Fabian
   Grzesiek, Stephan
TI Biophysical and structural investigation of bacterially expressed and
   engineered CCR5, a G protein-coupled receptor
SO JOURNAL OF BIOMOLECULAR NMR
LA English
DT Article
DE CCR5; G protein-coupled receptor; Expression in E. coli; NMR; Homology
   modeling
ID MUSCARINIC ACETYLCHOLINE-RECEPTOR; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY;
   ESCHERICHIA-COLI; OPIOID RECEPTOR; BOVINE RHODOPSIN; HIV-1 INFECTION;
   SMALL-MOLECULE; GPCR; PURIFICATION
AB The chemokine receptor CCR5 belongs to the class of G protein-coupled receptors. Besides its role in leukocyte trafficking, it is also the major HIV-1 coreceptor and hence a target for HIV-1 entry inhibitors. Here, we report Escherichia coli expression and a broad range of biophysical studies on E. coli-produced CCR5. After systematic screening and optimization, we obtained 10 mg of purified, detergent-solubilized, folded CCR5 from 1L culture in a triply isotope-labeled (H-2/N-15/C-13) minimal medium. Thus the material is suitable for NMR spectroscopic studies. The expected alpha-helical secondary structure content is confirmed by circular dichroism spectroscopy. The solubilized CCR5 is monodisperse and homogeneous as judged by transmission electron microscopy. Interactions of CCR5 with its ligands, RANTES and MIP-1 beta were assessed by surface plasmon resonance yielding K-D values in the nanomolar range. Using size exclusion chromatography, stable monomeric CCR5 could be isolated. We show that cysteine residues affect both the yield and oligomer distribution of CCR5. HSQC spectra suggest that the transmembrane domains of CCR5 are in equilibrium between several conformations. In addition we present a model of CCR5 based on the crystal structure of CXCR4 as a starting point for protein engineering.
C1 [Wiktor, Maciej; Morin, Sebastien; Sass, Hans-Juergen; Grzesiek, Stephan] Univ Basel, Focal Area Struct Biol & Biophys, Biozentrum, CH-4056 Basel, Switzerland.
   [Kebbel, Fabian] Univ Basel, Biozentrum, Ctr Cellular Imaging & NanoAnalyt C CINA, CH-4058 Basel, Switzerland.
RP Grzesiek, S (reprint author), Univ Basel, Focal Area Struct Biol & Biophys, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.
EM stephan.grzesiek@unibas.ch
OI Grzesiek, Stephan/0000-0003-1998-4225; Morin,
   Sebastien/0000-0003-4426-326X
FU EU; SNF [31-109,712]; SystemsX.ch (C-CINA)
FX We thank Prof. A. Arseniev for providing the plasmids pET28F10 and
   pMT10H10 and Prof. A. Spang for the plasmid pCA528, Dr. Paul Jeno and
   Suzanne Moes for mass spectrometry analysis as well as Dr. Marcel
   Blommers, Dr. Lukasz Skora and Prof. Sebastian Hiller for stimulating
   discussions. This work was supported by the EU FP7 Combined Highly
   Active Anti-Retroviral Microbicides (CHAARM), SNF Grant 31-109,712 and
   SystemsX.ch (C-CINA).
CR Abramoff MD, 2004, J BIOPHOTONICS INT, V11, P36
   Attrill H, 2009, PROTEIN EXPRES PURIF, V64, P32, DOI 10.1016/j.pep.2008.10.001
   Balistreri CR, 2007, ANN NY ACAD SCI, V1100, P162, DOI 10.1196/annals.1395.014
   Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8
   Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200
   Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661                                                         
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902                                                        
   Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723                                                         
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dodevski I, 2011, J MOL BIOL, V408, P599, DOI 10.1016/j.jmb.2011.02.051
   Duncan SR, 2005, J MED GENET, V42, P205, DOI 10.1136/jmg.2004.025346
   Filmore D., 2004, MOD DRUG DISCOV, V7, P24
   Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256
   Furukawa H, 2000, J BIOCHEM-TOKYO, V127, P151, DOI 10.1093/oxfordjournals.jbchem.a022577                                           
   Gaertner H, 2008, P NATL ACAD SCI USA, V105, P17706, DOI 10.1073/pnas.0805098105
   Gautier A, 2008, ANGEW CHEM INT EDIT, V47, P7297, DOI 10.1002/anie.200802783
   Gottschalk G., 1986, BACTERIAL METABOLISM
   Granier S, 2012, NATURE, V485, P400, DOI 10.1038/nature11111
   Haga K, 2012, NATURE, V482, P547, DOI 10.1038/nature10753
   Hanson MA, 2012, SCIENCE, V335, P851, DOI 10.1126/science.1215904
   Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027
   HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5
   HUTNER S. H., 1950, PROC AMER PHIL SOC, V94, P152
   Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772
   Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Krepkiy D, 2006, PROTEIN EXPRES PURIF, V49, P60, DOI 10.1016/j.pep.2006.03.002
   Kruse AC, 2012, NATURE, V482, P552, DOI 10.1038/nature10867
   Lebon G, 2011, NATURE, V474, P521, DOI 10.1038/nature10136
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Lemay J, 2005, NAT IMMUNOL, V6, P535, DOI 10.1038/ni0605-535a
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Lusso P, 2011, FASEB J, V25, P1230, DOI 10.1096/fj.10-167627
   Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954
   Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m
   Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653
   Navratilova I, 2006, ANAL BIOCHEM, V353, P278, DOI 10.1016/j.ab.2006.03.049
   Navratilova I, 2005, ANAL BIOCHEM, V339, P271, DOI 10.1016/j.ab.2004.12.017
   Navratilova I, 2011, ACS MED CHEM LETT, V2, P549, DOI 10.1021/ml2000017
   Nisius L, 2008, PROTEIN EXPRES PURIF, V61, P155, DOI 10.1016/j.pep.2008.06.001
   Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007d
   Otten R, 2010, J AM CHEM SOC, V132, P2952, DOI 10.1021/ja907706a
   Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739                                                    
   Park SH, 2012, NATURE, V491, P779, DOI 10.1038/nature11580
   Park SH, 2011, BIOCHEMISTRY-US, V50, P2371, DOI 10.1021/bi101568j
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366
   Petrovskaya LE, 2010, BIOCHEMISTRY-MOSCOW+, V75, P881, DOI 10.1134/S0006297910070102
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325
   Reckel S, 2011, ANGEW CHEM INT EDIT, V50, P11942, DOI 10.1002/anie.201105648
   Ren H., 2009, PLOS ONE, V4, P1
   Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226                                                               
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Sastry M, 2011, J BIOMOL NMR, V50, P197, DOI 10.1007/s10858-011-9506-4
   Shibata Y, 2009, J MOL BIOL, V390, P262, DOI 10.1016/j.jmb.2009.04.068
   Shimamura T, 2011, NATURE, V475, P65, DOI 10.1038/nature10236
   Stenkamp RE, 2008, ACTA CRYSTALLOGR D, V64, P902, DOI 10.1107/S0907444908017162
   Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867
   Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8                                                   
   Tian CL, 2005, J AM CHEM SOC, V127, P8010, DOI 10.1021/ja05116115
   Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101
   Weiss HM, 2002, EUR J BIOCHEM, V269, P82, DOI 10.1046/j.0014-2956.2002.02618.x
   Werner K, 2008, J BIOMOL NMR, V40, P49, DOI 10.1007/s10858-007-9205-3
   White SH, 2004, PROTEIN SCI, V13, P1948, DOI 10.1110/ps.04712004
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939
NR 70
TC 6
Z9 6
U1 0
U2 23
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-2738
J9 J BIOMOL NMR
JI J. Biomol. NMR
PD JAN
PY 2013
VL 55
IS 1
BP 79
EP 95
DI 10.1007/s10858-012-9688-4
PG 17
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA 077TK
UT WOS:000314050700008
PM 23229639
DA 2018-01-05
ER

PT J
AU Janssen, KPF
   Knez, K
   Spasic, D
   Lammertyn, J
AF Janssen, Kris P. F.
   Knez, Karel
   Spasic, Dragana
   Lammertyn, Jeroen
TI Nucleic Acids for Ultra-Sensitive Protein Detection
SO SENSORS
LA English
DT Review
DE nucleic acid; biosensor; protein; biomarker; PCR; aptamer
ID ROLLING-CIRCLE AMPLIFICATION; BIOGENIC MAGNETOSOME NANOPARTICLES;
   AFFINITY APTAMER AMPLIFICATION; PROXIMITY LIGATION ASSAYS;
   POLYMERASE-CHAIN-REACTION; IN-VITRO SELECTION; HIV-1 TAT PROTEIN;
   IMMUNO-PCR; ULTRASENSITIVE DETECTION; SIGNAL AMPLIFICATION
AB Major advancements in molecular biology and clinical diagnostics cannot be brought about strictly through the use of genomics based methods. Improved methods for protein detection and proteomic screening are an absolute necessity to complement to wealth of information offered by novel, high-throughput sequencing technologies. Only then will it be possible to advance insights into clinical processes and to characterize the importance of specific protein biomarkers for disease detection or the realization of "personalized medicine". Currently however, large-scale proteomic information is still not as easily obtained as its genomic counterpart, mainly because traditional antibody-based technologies struggle to meet the stringent sensitivity and throughput requirements that are required whereas mass-spectrometry based methods might be burdened by significant costs involved. However, recent years have seen the development of new biodetection strategies linking nucleic acids with existing antibody technology or replacing antibodies with oligonucleotide recognition elements altogether. These advancements have unlocked many new strategies to lower detection limits and dramatically increase throughput of protein detection assays. In this review, an overview of these new strategies will be given.
C1 [Janssen, Kris P. F.; Knez, Karel; Spasic, Dragana; Lammertyn, Jeroen] Katholieke Univ Leuven, Fac Bioingn Wetenschappen, MeBioS Biosensor Grp, Louvain, Belgium.
RP Lammertyn, J (reprint author), Katholieke Univ Leuven, Fac Bioingn Wetenschappen, MeBioS Biosensor Grp, Louvain, Belgium.
EM kris.janssen@biw.kuleuven.be; karel.knez@biw.kuleuven.be;
   dragana.spasic@biw.kuleuven.be; jeroen.lammertyn@biw.kuleuven.be
FU Fund for Scientific Research Flanders [FWO G.0997.11];
   EFRO-Interreg-NanosensEU; EU-FP7 MAREX; KULeuven-IOF-Nanodiag; IMI
   RAPP-ID; IWT-VIS Sensors for Food
FX The authors would like to thank the Fund for Scientific Research
   Flanders (FWO G.0997.11), EFRO-Interreg-NanosensEU, EU-FP7 MAREX, IMI
   RAPP-ID, IWT-VIS Sensors for Food and KULeuven-IOF-Nanodiag for
   financial support.
CR Akter F, 2011, ANAL BIOCHEM, V416, P174, DOI 10.1016/j.ab.2011.05.004
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Ansong Charles, 2008, Briefings in Functional Genomics & Proteomics, V7, P50, DOI 10.1093/bfgp/eln010
   Baird GS, 2010, AM J CLIN PATHOL, V134, P529, DOI 10.1309/AJCPFU4CG2WGJJKS
   Baner J, 1998, NUCLEIC ACIDS RES, V26, P5073, DOI 10.1093/nar/26.22.5073                                                          
   Bini A, 2007, ANAL CHEM, V79, P3016, DOI 10.1021/ac070096g
   Brody E, 2012, J MOL BIOL, V422, P595, DOI 10.1016/j.jmb.2012.06.021
   Ceyhan B, 2006, SMALL, V2, P1251, DOI 10.1002/smll.200600282
   Cheglakov Z, 2008, ANGEW CHEM INT EDIT, V47, P126, DOI 10.1002/anie.200703688
   Cheglakov Z, 2007, ORG BIOMOL CHEM, V5, P223, DOI 10.1039/b615450f
   Cho EJ, 2009, ANNU REV ANAL CHEM, V2, P241, DOI 10.1146/annurev.anchem.1.031207.112851
   Cho M, 2010, P NATL ACAD SCI USA, V107, P15373, DOI 10.1073/pnas.1009331107
   Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1                                                   
   CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0
   Darmanis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025583
   Darmanis S, 2010, MOL CELL PROTEOMICS, V9, P327, DOI 10.1074/mcp.M900248-MCP200
   Di Giusto DA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni063
   Di Giusto DA, 2004, J BIOL CHEM, V279, P46483, DOI 10.1074/jbc.M408037200
   Diamandis EP, 2010, J NATL CANCER I, V102, P1462, DOI 10.1093/jnci/djq306
   ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X
   Famulok M, 2011, ACCOUNTS CHEM RES, V44, P1349, DOI 10.1021/ar2000293
   FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641
   Fischer NO, 2008, ANAL BIOCHEM, V373, P121, DOI 10.1016/j.ab.2007.09.035
   Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473
   Fredriksson S, 2007, NAT METHODS, V4, P327, DOI 10.1038/NMETH1020
   Furukawa K, 2008, BIOORG MED CHEM LETT, V18, P4562, DOI 10.1016/j.bmcl.2008.07.040
   Gokulrangan G, 2005, ANAL CHEM, V77, P1963, DOI 10.1021/ac0483926
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   Goluch ED, 2006, LAB CHIP, V6, P1293, DOI 10.1039/b606294f
   Gstaiger M, 2009, NAT REV GENET, V10, P617, DOI 10.1038/nrg2633
   Gullberg M, 2004, P NATL ACAD SCI USA, V101, P8420, DOI 10.1073/pnas.0400552101
   Gullberg M, 2003, CURR OPIN BIOTECH, V14, P82, DOI 10.1016/S0958-1669(02)00011-3
   Guo YC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl260
   Gusev Y, 2001, AM J PATHOL, V159, P63, DOI 10.1016/S0002-9440(10)61674-4
   Hasegawa H, 2008, SENSORS-BASEL, V8, P1090, DOI 10.3390/s8021090                                                                
   HENDRICKSON ER, 1995, NUCLEIC ACIDS RES, V23, P522, DOI 10.1093/nar/23.3.522                                                            
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Huang CC, 2005, ANAL CHEM, V77, P5735, DOI 10.1021/ac050957q
   Janssen KPF, 2012, ANAL BIOANAL CHEM, V404, P2073, DOI 10.1007/s00216-012-6252-8
   Janssen KPF, 2011, ANAL METHODS-UK, V3, P2156, DOI 10.1039/c1ay05124e
   Jhaveri S, 2000, NAT BIOTECHNOL, V18, P1293, DOI 10.1038/82414
   Kamali-moghaddam M., 2010, BMC NEUROSCI, V11, P1
   Keeney TR, 2009, JALA-J ASSOC LAB AUT, V14, P360, DOI 10.1016/j.jala.2009.05.003
   Landegren U, 2012, ANAL CHEM, V84, P1824, DOI 10.1021/ac2032222
   Lee SJ, 2008, ANAL CHEM, V80, P2867, DOI 10.1021/ac800050a
   Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532
   Li J, 2012, ANAL CHEM, V84, P5309, DOI 10.1021/ac3006186
   Liao SQ, 2010, BIOCONJUGATE CHEM, V21, P2183, DOI 10.1021/bc100032v
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Liu J., 2005, ANGEW CHEM INT EDIT, V45, P90
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P7955, DOI 10.1002/anie.200603106
   Lundberg M, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr424
   Malou N, 2011, TRENDS MICROBIOL, V19, P295, DOI 10.1016/j.tim.2011.03.004
   Mao CB, 2009, ANGEW CHEM INT EDIT, V48, P6790, DOI 10.1002/anie.200900231
   Mason JT, 2006, NAT BIOTECHNOL, V24, P555, DOI 10.1038/nbt1201
   McGregor LM, 2010, J AM CHEM SOC, V132, P15522, DOI 10.1021/ja107677q
   Mehan M., 2011, COMPLEMENT THERAP SE, V734, P283
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Nakamura C, 2001, MOL CRYST LIQ CRYST, V371, P369, DOI 10.1080/10587250108024762                                                       
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Niemeyer CM, 2005, TRENDS BIOTECHNOL, V23, P208, DOI 10.1016/j.tibtech.2005.02.006
   Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553                                                          
   Nong RY, 2012, EXPERT REV PROTEOMIC, V9, P21, DOI [10.1586/EPR.11.78, 10.1586/epr.11.78]
   Goransson J., 2012, PLOS ONE, V7
   Ostroff R. M., 2010, PLOS ONE, V5
   Picotti P, 2009, CELL, V138, P795, DOI 10.1016/j.cell.2009.05.051
   Pinto A, 2012, ACS CHEM BIOL, V7, P359, DOI 10.1021/cb2003835
   Pollet J, 2012, ANALYST, V137, P5710, DOI 10.1039/c2an36201e
   Pollet J, 2009, BIOSENS BIOELECTRON, V25, P864, DOI 10.1016/j.bios.2009.08.045
   Qiu LP, 2011, ANAL CHEM, V83, P3050, DOI 10.1021/ac103274j
   Ren J, 2001, ANN NY ACAD SCI, V945, P116
   Rittie L, 2008, J CELL COMMUN SIGNAL, V2, P25, DOI 10.1007/s12079-008-0026-2
   Saha K, 2012, CHEM REV, V112, P2739, DOI 10.1021/cr2001178
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800                                        
   Sassolas A, 2011, BIOSENS BIOELECTRON, V26, P3725, DOI 10.1016/j.bios.2011.02.031
   Sassolas A, 2011, ANALYST, V136, P257, DOI 10.1039/c0an00281j
   Schallmeiner E, 2007, NAT METHODS, V4, P135, DOI 10.1038/nmeth974
   Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197
   Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359
   Shao WP, 2003, J BIOMED BIOTECHNOL, P299, DOI 10.1155/S1110724303209268                                                       
   Sims PW, 2000, ANAL BIOCHEM, V281, P230, DOI 10.1006/abio.2000.4578                                                          
   Snyder M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.32
   Sooter LJ, 2001, BIOL CHEM, V382, P1327, DOI 10.1515/BC.2001.165
   Stoeva SI, 2006, J AM CHEM SOC, V128, P8378, DOI 10.1021/ja0613106
   Strehlitz B, 2008, SENSORS-BASEL, V8, P4296, DOI 10.3390/s8074296
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tran DT, 2011, BIOSENS BIOELECTRON, V26, P2987, DOI 10.1016/j.bios.2010.11.053
   Turner DJ, 2011, ANAL CHEM, V83, P666, DOI 10.1021/ac102666n
   van Weemen BK, 2005, CLIN CHEM, V51, P2226, DOI 10.1373/clinchem.2005.059626                                                    
   Vaught JD, 2010, J AM CHEM SOC, V132, P4141, DOI 10.1021/ja908035g
   Verschoor ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013565
   Wacker R, 2007, BIOCHEM BIOPH RES CO, V357, P391, DOI 10.1016/j.bbrc.2007.03.156
   Wang JL, 2009, BIOSENS BIOELECTRON, V25, P124, DOI 10.1016/j.bios.2009.06.016
   Wang XL, 2004, ANAL CHEM, V76, P5605, DOI 10.1021/ac0494228
   Wei H, 2007, CHEM COMMUN, P3735, DOI 10.1039/b707642h
   Wiltshire S, 2000, CLIN CHEM, V46, P1990
   Wu ZS, 2010, ANAL CHEM, V82, P2221, DOI 10.1021/ac901794w
   Xue LY, 2012, ANAL CHEM, V84, P3507, DOI 10.1021/ac2026783
   Xue LY, 2010, CHEM COMMUN, V46, P7373, DOI 10.1039/c0cc02038a
   YALOW RS, 1960, J CLIN INVEST, V39, P1157, DOI 10.1172/JCI104130
   Yang LT, 2008, ANAL BIOCHEM, V380, P164, DOI 10.1016/j.ab.2008.05.018
   Yates JR, 2009, ANNU REV BIOMED ENG, V11, P49, DOI 10.1146/annurev-bioeng-061008-124934
   Yoshida Y, 2009, ANAL BIOANAL CHEM, V395, P1089, DOI 10.1007/s00216-009-3041-0
   Zhang HQ, 2008, J AM CHEM SOC, V130, P34, DOI 10.1021/ja0778747
   Zhang HQ, 2012, ANAL CHEM, V84, P877, DOI 10.1021/ac203207g
   Zhang HQ, 2006, ANGEW CHEM INT EDIT, V45, P1576, DOI 10.1002/anie.200503345
   Zhang ZZ, 2012, ANAL CHEM, V84, P1623, DOI 10.1021/ac2029002
   Zheng DM, 2012, ANAL CHEM, V84, P3554, DOI 10.1021/ac300690r
   ZHOU H, 1993, NUCLEIC ACIDS RES, V21, P6038, DOI 10.1093/nar/21.25.6038
   Zhou HP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-r28                                                         
   Zhou XM, 2012, ANALYST, V137, P1963, DOI 10.1039/c2an00020b
   Zichi D, 2008, CURR OPIN CHEM BIOL, V12, P78, DOI 10.1016/j.cbpa.2008.01.016
NR 115
TC 16
Z9 16
U1 7
U2 180
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1424-8220
J9 SENSORS-BASEL
JI Sensors
PD JAN
PY 2013
VL 13
IS 1
BP 1353
EP 1384
DI 10.3390/s130101353
PG 32
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 077JV
UT WOS:000314024800077
PM 23337338
OA gold
DA 2018-01-05
ER

PT J
AU Mukherjee, N
   Ahammed, S
   Bhadra, S
   Ranu, BC
AF Mukherjee, Nirmalya
   Ahammed, Sabir
   Bhadra, Sukalyan
   Ranu, Brindaban C.
TI Solvent-free one-pot synthesis of 1,2,3-triazole derivatives by the
   'Click' reaction of alkyl halides or aryl boronic acids, sodium azide
   and terminal alkynes over a Cu/Al2O3 surface under ball-milling
SO GREEN CHEMISTRY
LA English
DT Article
ID COPPER NANOPARTICLES; 1,4-DISUBSTITUTED 1,2,3-TRIAZOLES; MULTICOMPONENT
   SYNTHESIS; CYCLOADDITION REACTION; HUISGEN CYCLOADDITION;
   CATALYTIC-SYSTEM; ACTIVATED CARBON; HIV-1 PROTEASE; IONIC LIQUIDS;
   CHEMISTRY
AB A one-pot procedure for the synthesis of 1,2,3-triazole derivatives by a three-component coupling of alkyl (benzyl) halides or aryl boronic acids, sodium azide and terminal alkynes over copper(II) sulfate supported on alumina (Cu/Al2O3) under ball-milling in the absence of any solvent and additive has been developed. The product was isolated by simple washing of the crude reaction residue with ethanol followed by evaporation of the solvent. No chromatographic purification is required. The catalyst is recycled for subsequent reactions. The azides are produced in situ and thus this procedure avoids the handling of hazardous azides. This protocol offers broad scope for access to a variety of diversely substituted 1,2,3-triazoles. The use of no hazardous organic solvent, the use of ball-milling, and cost efficiency, recyclability of the catalyst up to eight runs without appreciable loss of activity and high yields of products make this procedure greener.
C1 [Mukherjee, Nirmalya; Ahammed, Sabir; Bhadra, Sukalyan; Ranu, Brindaban C.] Indian Assoc Cultivat Sci, Dept Organ Chem, Kolkata 700032, India.
RP Mukherjee, N (reprint author), Indian Assoc Cultivat Sci, Dept Organ Chem, Kolkata 700032, India.
EM ocbcr@iacs.res.in
OI MUKHERJEE, NIRMALYA/0000-0002-6755-2235
FU DST, New Delhi [SR/S2/JCB-11/2008]; CSIR [01(2365)/10/EMR-II]; CSIR;
   DST, New Delhi
FX We are pleased to acknowledge financial support from DST, New Delhi in
   the form of the award of J. C. Bose National Fellowships to B. C. R.
   (Grant no. SR/S2/JCB-11/2008) and CSIR [Grant no. 01(2365)/10/EMR-II].
   S. A. and S. B. are also thankful to CSIR for their fellowships. We
   thank Dr T. K. Paine of our Institute for his help in getting the EPR
   spectrum, and Nanoscience Project Unit at LACS, funded by DST, New Delhi
   for XPS.
CR Ahammed S, 2012, TETRAHEDRON, V68, P10542, DOI 10.1016/j.tet.2012.08.046
   Alonso F, 2011, ORG BIOMOL CHEM, V9, P6385, DOI 10.1039/c1ob05735a
   Alonso F, 2010, ADV SYNTH CATAL, V352, P3208, DOI 10.1002/adsc.201000637
   Alvarez J. G., 2010, GREEN CHEM, V12, P2127
   Appukkuttan P, 2004, ORG LETT, V6, P4223, DOI 10.1021/ol048341v
   Aucagne V, 2006, ORG LETT, V8, P4505, DOI 10.1021/ol061657d
   Baig RBN, 2012, GREEN CHEM, V14, P625, DOI 10.1039/c2gc16301b
   Bhadra S, 2010, J ORG CHEM, V75, P8533, DOI 10.1021/jo101916e
   Bhadra S, 2010, J ORG CHEM, V75, P4864, DOI 10.1021/jo100755g
   Bhadra S, 2009, ADV SYNTH CATAL, V351, P2369, DOI 10.1002/adsc.200900358
   Bock VD, 2005, EUR J ORG CHEM, P51, DOI 10.1002/ejoc.200500483
   Buckley BR, 2010, CHEM-EUR J, V16, P6278, DOI 10.1002/chem.201000447
   Chassaing S, 2007, ORG LETT, V9, P883, DOI 10.1021/ol0631152
   Chatterjee T, 2012, TETRAHEDRON LETT, V53, P4142, DOI 10.1016/j.tetlet.2012.05.127
   Cintas P, 2010, NAT PROTOC, V5, P607, DOI 10.1038/nprot.2010.1
   Fann W.-Q., 1996, COMPREHENSIVE HETERO, V4, P1
   Gerard B, 2006, TETRAHEDRON, V62, P6405, DOI 10.1016/j.tet.2006.04.025
   Giffin MJ, 2008, J MED CHEM, V51, P6263, DOI 10.1021/jm800149m
   Girard C, 2006, ORG LETT, V8, P1689, DOI 10.1021/ol060283l
   Hernandez JG, 2011, TETRAHEDRON, V67, P6953, DOI 10.1016/j.tet.2011.06.042
   Hudson R, 2012, GREEN CHEM, V14, P622, DOI 10.1039/c2gc16421c
   HUISGEN R, 1989, PURE APPL CHEM, V61, P613, DOI 10.1351/pac198961040613                                                         
   HUISGEN R, 1965, CHEM BER-RECL, V98, P4014, DOI 10.1002/cber.19650981228                                                        
   Huisgen R, 1963, ANGEW CHEM INT EDIT, V2, P565, DOI DOI 10.1002/ANIE.196305651
   James SL, 2012, CHEM SOC REV, V41, P413, DOI 10.1039/c1cs15171a
   Jin T, 2011, ADV SYNTH CATAL, V353, P3095, DOI 10.1002/adsc.201100760
   Kaboudin B, 2012, ORG BIOMOL CHEM, V10, P4543, DOI 10.1039/c2ob25061f
   Kim JY, 2010, CHEM COMMUN, V46, P439, DOI 10.1039/b917781g
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kumar BSPA, 2012, TETRAHEDRON LETT, V53, P4595, DOI 10.1016/j.tetlet.2012.06.077
   Ladouceur S, 2011, SYNTHESIS-STUTTGART, P3604, DOI 10.1055/s-0030-1260256
   Lipshutz BH, 2006, ANGEW CHEM INT EDIT, V45, P8235, DOI 10.1002/anie.200603726
   Marra A, 2008, J ORG CHEM, V73, P2458, DOI 10.1021/jo7026454
   Miao T, 2008, SYNTHESIS-STUTTGART, P363, DOI 10.1055/s-2008-1032037
   Molteni G, 2006, NEW J CHEM, V30, P1137, DOI 10.1039/b604297j
   Namitharan K, 2009, CHEM-EUR J, V15, P2755, DOI 10.1002/chem.200802384
   Pachon LD, 2005, ADV SYNTH CATAL, V347, P811, DOI 10.1002/adsc.200404383
   Pressly ED, 2011, J POLYM SCI POL CHEM, V49, P814, DOI 10.1002/pola.24504
   Quader S, 2007, J ORG CHEM, V72, P1962, DOI 10.1021/jo0620967
   Raut D, 2009, CATAL COMMUN, V10, P1240, DOI 10.1016/j.catcom.2009.01.027
   Rodriguez B, 2007, ADV SYNTH CATAL, V349, P2213, DOI 10.1002/adsc.200700252
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Sarkar A, 2008, J PHYS CHEM C, V112, P3334, DOI 10.1021/jp077603i
   Schimdt R., 2011, CHEM-EUR J, V17, P8129
   Scott SO, 2011, DALTON T, V40, P12117, DOI 10.1039/c1dt10551e
   Shao CW, 2011, J ORG CHEM, V76, P6832, DOI 10.1021/jo200869a
   Sharghi H, 2009, ADV SYNTH CATAL, V351, P207, DOI 10.1002/adsc.200800612
   Shin JA, 2012, J ORG CHEM, V77, P4117, DOI 10.1021/jo3000095
   Siemsen P, 2000, ANGEW CHEM INT EDIT, V39, P2632, DOI [10.1002/1521-3773(20000804)39:152632:AID-ANIE26323.0. CO, DOI 10.1002/1521-3773(20000804)39:15<2632::AID-ANIE2632>3.0.CO;2-F]
   Stolle A, 2011, CHEM SOC REV, V40, P2317, DOI 10.1039/c0cs00195c
   Szuppa T, 2010, GREEN CHEM, V12, P1288, DOI 10.1039/c002819c
   Tao CZ, 2007, TETRAHEDRON LETT, V48, P3525, DOI 10.1016/j.tetlet.2007.03.107
   Thorwirth R, 2011, SYNLETT, P2200, DOI 10.1055/s-0030-1261179
   Thorwirth R, 2011, CHEM COMMUN, V47, P4370, DOI 10.1039/c0cc05657j
   Thorwirth R, 2010, CHEM-EUR J, V16, P13236, DOI 10.1002/chem.201001702
   Thorwirth R, 2010, GREEN CHEM, V12, P985, DOI 10.1039/c000674b
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Tullberg E, 2004, J ORGANOMET CHEM, V689, P3778, DOI 10.1016/j.jorganchem.2004.06.045
   Wang L, 2010, GREEN CHEM LETT REV, V3, P121, DOI 10.1080/17518251003591771
   Whiting M, 2006, ANGEW CHEM INT EDIT, V45, P1435, DOI 10.1002/anie.200502161
   Yan JC, 2010, SYNTHESIS-STUTTGART, P447, DOI 10.1055/s-0029-1217111
   Zhang Z, 2004, CHEM LETT, V33, P168, DOI 10.1246/cl.2004.168
   Zhao YB, 2006, TETRAHEDRON LETT, V47, P1545, DOI 10.1016/j.tetlet.2006.01.004
NR 63
TC 78
Z9 78
U1 4
U2 76
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2013
VL 15
IS 2
BP 389
EP 397
DI 10.1039/c2gc36521a
PG 9
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA 079QH
UT WOS:000314185900016
DA 2018-01-05
ER

PT J
AU Shen, Y
   Liu, YY
   Zhu, G
   Fang, H
   Huang, YH
   Jiang, XY
   Wang, ZL
AF Shen, Yue
   Liu, Yingyi
   Zhu, Guang
   Fang, Hao
   Huang, Yunhui
   Jiang, Xingyu
   Wang, Zhong L.
TI Patterned polymer nanowire arrays as an effective protein immobilizer
   for biosensing and HIV detection
SO NANOSCALE
LA English
DT Article
ID MICROFLUIDIC CHANNELS; DNA MICROARRAYS; CANCER-RESEARCH; FABRICATION;
   MEMBRANES; CHIPS; IMMUNOASSAYS; MICROBEADS; PROTEOMICS; MONOLITHS
AB We report an array of polymeric nanowires for effectively immobilizing biomolecules on biochips owing to the large surface area. The nanowires were fabricated in predesigned patterns using an inductively coupled plasma (ICP) etching process. Microfluidic biochips integrated using the substrates with arrays of nanowires and polydimethylsiloxane channels have been demonstrated to be effective for detecting antigens, and a detection limit of antigens at 0.2 mu g mL(-1) has been achieved, which is improved by a factor of 50 compared to that based on flat substrates without the nanowires. In addition, the high sensitivity for clinical detection of human immunodeficiency virus (HIV) antibody has also been demonstrated, showing a 20 times enhancement in fluorescent signal intensity between the samples with positive and negative HIV.
C1 [Shen, Yue; Zhu, Guang; Fang, Hao; Wang, Zhong L.] Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.
   [Shen, Yue; Huang, Yunhui] Huazhong Univ Sci & Technol, Coll Mat Sci & Engn, Wuhan 430074, Hubei, Peoples R China.
   [Liu, Yingyi; Jiang, Xingyu] Chinese Acad Sci, Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
RP Jiang, XY (reprint author), Chinese Acad Sci, Natl Ctr Nanosci & Technol, Beijing 100190, Peoples R China.
EM xingyujiang@nanoctr.cn; zlwang@gatech.edu
RI Huang, Yunhui/C-3752-2014; Wang, Zhong Lin/E-2176-2011
OI Wang, Zhong Lin/0000-0002-5530-0380; Jiang, Xingyu/0000-0002-5008-4703
FU NSF; BES DOE; NSFC [51202076]; MOST; Chinese Academy of Sciences
   [KJCX2-YW-M13]
FX The research was supported by NSF, BES DOE, NSFC (51202076), MOST, and
   the Knowledge Innovation Program of the Chinese Academy of Sciences
   (Grant no. KJCX2-YW-M13).
CR Barbulovic-Nad I, 2006, CRIT REV BIOTECHNOL, V26, P237, DOI 10.1080/07388550600978358
   de Jong J, 2006, LAB CHIP, V6, P1125, DOI 10.1039/b603275c
   de Jong J, 2005, LAB CHIP, V5, P1240, DOI 10.1039/b509280a
   Fang H, 2009, J PHYS CHEM C, V113, P16571, DOI 10.1021/jp907072z
   Guschin D, 1997, ANAL BIOCHEM, V250, P203, DOI 10.1006/abio.1997.2209
   Jiang XY, 2003, J AM CHEM SOC, V125, P5294, DOI 10.1021/ja034566
   Jo E, 2011, J POLYM SCI POL PHYS, V49, P89, DOI 10.1002/polb.22147
   Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.0.CO;2-5
   Kallioniemi OP, 2001, ANN MED, V33, P142, DOI 10.3109/07853890109002069                                                       
   Kondabagil KR, 2001, J MICROBIOL BIOTECHN, V11, P907
   Lee Y, 2011, J MATER CHEM, V21, P4476, DOI 10.1039/c0jm03881d
   Lilliehorn T, 2005, SENSOR ACTUAT B-CHEM, V106, P851, DOI 10.1016/j.snb.2004.07.003
   Liu YY, 2009, ELECTROPHORESIS, V30, P3269, DOI 10.1002/elps.200900128
   Mikhailovich V, 2008, BIOESSAYS, V30, P673, DOI 10.1002/bies.20781
   Morber JR, 2009, ADV MATER, V21, P2072, DOI 10.1002/adma.200803648
   Ng AHC, 2010, ANAL BIOANAL CHEM, V397, P991, DOI 10.1007/s00216-010-3678-8
   Rohr T, 2001, ELECTROPHORESIS, V22, P3959, DOI 10.1002/1522-2683(200110)22:18<3959::AID-ELPS3959>3.0.CO;2-5
   Rusmini F, 2007, BIOMACROMOLECULES, V8, P1775, DOI 10.1021/bm061197b
   Srinivas PR, 2001, CLIN CHEM, V47, P1901
   Stoughton RB, 2005, ANNU REV BIOCHEM, V74, P53, DOI 10.1146/annurev.biochem.74.082803.133212
   Templin MF, 2003, PROTEOMICS, V3, P2155, DOI 10.1002/pmic.200300600
   von Eggeling F, 2001, ELECTROPHORESIS, V22, P2898, DOI 10.1002/1522-2683(200108)22:14<2898::AID-ELPS2898>3.0.CO;2-A
   Walter G, 2000, CURR OPIN MICROBIOL, V3, P298, DOI 10.1016/S1369-5274(00)00093-X
   Weigl BH, 2003, ADV DRUG DELIVER REV, V55, P349, DOI 10.1016/S0169-409X(02)00223-5
   Yang DY, 2009, BIOMACROMOLECULES, V10, P3335, DOI 10.1021/bm900955p
   Yang DY, 2008, ADV MATER, V20, P4770, DOI 10.1002/adma.200801302
   Yu C, 2000, ELECTROPHORESIS, V21, P120, DOI 10.1002/(SICI)1522-2683(20000101)21:1<120::AID-ELPS120>3.0.CO;2-H               
   Zhang Q, 2006, ELECTROPHORESIS, V27, P4943, DOI 10.1002/elps.200600024
   Zhu H, 2000, NAT GENET, V26, P283
NR 29
TC 8
Z9 9
U1 3
U2 78
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
J9 NANOSCALE
JI Nanoscale
PY 2013
VL 5
IS 2
BP 527
EP 531
DI 10.1039/c2nr33069e
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 069HP
UT WOS:000313426200010
PM 23223639
DA 2018-01-05
ER

PT J
AU Zhen, X
   Wang, X
   Xie, C
   Wu, W
   Jiang, XQ
AF Zhen, Xu
   Wang, Xin
   Xie, Chen
   Wu, Wei
   Jiang, Xiqun
TI Cellular uptake, antitumor response and tumor penetration of
   cisplatin-loaded milk protein nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE Casein; Protein nanoparticles; Drug delivery; Multicellular tumor
   spheroids; Tumor penetration
ID ALBUMIN-BOUND PACLITAXEL; DRUG-DELIVERY SYSTEMS; HIV-1 TAT PROTEIN;
   MULTICELLULAR SPHEROIDS; POLYMERIC MICELLES; CASEIN MICELLES;
   CREMOPHOR-FREE; SOLID TUMORS; IN-VIVO; TRANSGLUTAMINASE
AB The casein nanoparticles cross-linked by transglutaminase were prepared, and cisplatin (CDDP), as a model antitumor drug, was loaded into the casein nanoparticles. These nanoparticles were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and zeta potential. The uptake and penetration of nanoparticles in 2- and 3-dimensional SH-SY5Y cells were examined at 37 degrees C and 4 degrees C. The in vivo biodistribution of the nanoparticles was investigated using near-infrared fluorescence (NIRF) imaging and ion-coupled plasma mass spectrometry (ICP-MS). The antitumor effect of CDDP-loaded nanoparticles was evaluated on hepatic H22 tumor-bearing mice model via intravenous administration. It is found that the obtained nanoparticles showed spherical shape with the size of 257 nm, and drug loading content of 10%. These CDDP-loaded casein nanoparticles have the extraordinary capabilities to penetrate cell membrane barriers, target tumor and inhibit tumor growth. The tumor growth inhibition of CDDP-loaded nanoparticles is 1.5-fold higher than that of free CDDP. Further, the penetration examination of the CDDP-loaded casein nanoparticles in the tumor tissue demonstrated that the nanoparticles had the ability to penetrate the tumor and deliver CDDP to the tumor more deeply and affect the cells far from the vasculature. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Jiang, Xiqun] Nanjing Univ, Coll Chem & Chem Engn, Lab Mesoscop Chem, Nanjing 210093, Jiangsu, Peoples R China.
   Nanjing Univ, Coll Chem & Chem Engn, Dept Polymer Sci & Engn, Nanjing 210093, Jiangsu, Peoples R China.
RP Jiang, XQ (reprint author), Nanjing Univ, Coll Chem & Chem Engn, Lab Mesoscop Chem, Nanjing 210093, Jiangsu, Peoples R China.
EM jiangx@nju.edu.cn
RI Jiang,  Xiqun/I-8128-2014
FU National Natural Science Foundation of China [51033002, 51273090]
FX This study was supported by National Natural Science Foundation of China
   (No. 51033002 and 51273090).
CR Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371
   Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299
   Bachar M, 2012, J CONTROL RELEASE, V160, P164, DOI 10.1016/j.jconrel.2012.01.004
   Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634
   Ding D, 2012, ACS APPL MATER INTER, V4, P1838, DOI 10.1021/am300138z
   Ding D, 2011, ACS NANO, V5, P2520, DOI 10.1021/nn102138u
   Ding D, 2011, EUR J PHARM BIOPHARM, V79, P142, DOI 10.1016/j.ejpb.2011.01.008
   Elzoghby AO, 2012, J CONTROL RELEASE, V157, P168, DOI 10.1016/j.jconrel.2011.07.031
   Elzoghby AO, 2011, J CONTROL RELEASE, V153, P206, DOI 10.1016/j.jconrel.2011.02.010
   Hamilton G, 1998, CANCER LETT, V131, P29, DOI 10.1016/S0304-3835(98)00198-0
   Hawkins MJ, 2008, ADV DRUG DELIVER REV, V60, P876, DOI 10.1016/j.addr.2007.08.044
   He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843
   Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715
   Kim TH, 2010, BIOMATERIALS, V31, P7386, DOI 10.1016/j.biomaterials.2010.06.004
   Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875
   Lammel AS, 2010, BIOMATERIALS, V31, P4583, DOI 10.1016/j.biomaterials.2010.02.024
   Liu CJ, 2011, SOFT MATTER, V7, P11526, DOI 10.1039/c1sm06388j
   Liu CJ, 2010, CHEM COMMUN, V46, P7566, DOI 10.1039/c0cc02370a
   Liu Y, 2000, NAT MED, V6, P1380
   Livney YD, 2010, CURR OPIN COLLOID IN, V15, P73, DOI 10.1016/j.cocis.2009.11.002
   Lundin P, 2008, BIOCONJUGATE CHEM, V19, P2535, DOI 10.1021/bc800212j
   Margus H, 2012, MOL THER, V20, P525, DOI 10.1038/mt.2011.284
   McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242
   MOTOKI M, 1987, AGR BIOL CHEM TOKYO, V51, P993, DOI 10.1080/00021369.1987.10868166                                                  
   Netti PA, 2000, CANCER RES, V60, P2497
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Nishiyama N, 1999, LANGMUIR, V15, P377, DOI 10.1021/la980572l                                                               
   Shapira A, 2010, NANOMED-NANOTECHNOL, V6, P547, DOI 10.1016/j.nano.2010.01.003
   Smiddy MA, 2006, J DAIRY SCI, V89, P1906, DOI 10.3168/jds.S0022-0302(06)72258-5                                               
   Sparreboom A, 2005, CLIN CANCER RES, V11, P4136, DOI 10.1158/1078-0432.CCR-04-2291                                                   
   Teixeira LSM, 2012, BIOMATERIALS, V33, P1281, DOI 10.1016/j.biomaterials.2011.10.067
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Zeiger E, 2005, MUTAT RES-REV MUTAT, V589, P136, DOI 10.1016/j.mrrev.2005.01.001
   Zhu ZS, 2011, BIOMATERIALS, V32, P9525, DOI 10.1016/j.biomaterials.2011.08.072
NR 34
TC 52
Z9 52
U1 17
U2 355
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2013
VL 34
IS 4
BP 1372
EP 1382
DI 10.1016/j.biomaterials.2012.10.061
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 065NS
UT WOS:000313155800050
PM 23158934
DA 2018-01-05
ER

PT J
AU Ionov, M
   Ciepluch, K
   Klajnert, B
   Glinska, S
   Gomez-Ramirez, R
   de la Mata, FJ
   Munoz-Fernandez, MA
   Bryszewska, M
AF Ionov, Maksim
   Ciepluch, Karol
   Klajnert, Barbara
   Glinska, Slawa
   Gomez-Ramirez, Rafael
   Javier de la Mata, Francisco
   Angeles Munoz-Fernandez, Maria
   Bryszewska, Maria
TI Complexation of HIV derived peptides with carbosilane dendrimers
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Carbosilane dendrimers; HIV derived peptides; Nano-complex formation;
   Characterization; Stability
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL INTERFERING RNA;
   LOCKED-IN-DENDRIMERS; DENDRITIC CELLS; LIPID-MEMBRANES; SERUM-ALBUMIN;
   DELIVERY; OLIGONUCLEOTIDES; BIOCOMPATIBILITY; DENDRIPLEXES
AB Dendrimers have been proposed as new carriers for selected HIV-1 peptides. This paper reports on the complexation behaviour of the three HIV-derived-peptides: Gp160, NH-EIDNYTNTIYTLLEE-COOH; P24, NH-DTINEEAAEW-COOH and Nef, NHGMDDPEREVLEWRFDSRLAF-COOH with second generation cationic carbosilane dendrimers (CBD) branched with carbon-silicon bonds (CBD-CS) or oxygen-silicon bonds (CBD-OS). Studies on the formation of complexes between HIV peptides and CBDs by fluorescence polarization, zeta-potential, electrophoresis and transmission electron microscopy have shown that both studied dendrimers form complexes with HIV peptides. At a molar ratio of (2.5-3):1 (dendrimer:peptide), the complexes formed were in the size range of 180-275 nm and with significant positive surface charge. The results suggest that interactions between dendrimers and HIV peptides have electrostatic nature due to the negative charge of peptides backbone and positive charge of dendrimer functional groups. Dendriplex stability depended on the type of studied dendrimers. Time of peptides release from the complexes ranged from 1 (CBD-OS) to similar to 36 (CBD-CS) h. Basing on the obtained results, we propose that the water-soluble cationic carbosilane dendrimers can be considered for delivery of HIV peptides to dendritic cells. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Ionov, Maksim; Ciepluch, Karol; Klajnert, Barbara; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, PL-90236 Lodz, Poland.
   [Glinska, Slawa] Univ Lodz, Lab Electron Microscopy, Fac Biol & Environm Protect, PL-90236 Lodz, Poland.
   [Gomez-Ramirez, Rafael; Javier de la Mata, Francisco] Univ Alcala de Henares, CIBER BBN Alcala de Henares, Dept Quim Inorgan, Alcala De Henares 99775, Spain.
   [Angeles Munoz-Fernandez, Maria] Gen Hosp Univ Gregorio Maranon, CIBER BBN, Lab InmunoBiol Mol, Madrid, Spain.
RP Ionov, M (reprint author), Univ Lodz, Dept Gen Biophys, Pomorska St 141-143, PL-90236 Lodz, Poland.
EM maksion@biol.uni.lodz.pl
RI Gomez Ramirez, Rafael/K-1216-2014; Klajnert-Maculewicz,
   Barbara/J-4574-2014; De la Mata, F. Javier/K-1649-2014
OI Gomez Ramirez, Rafael/0000-0001-6448-2414; Klajnert-Maculewicz,
   Barbara/0000-0003-3459-8947; De la Mata, F. Javier/0000-0003-0418-3935;
   Bryszewska, Maria/0000-0003-4676-3743;
   Munoz-Fernandez/0000-0002-0813-4500
FU DEN-PEPTHIV [PS09102669]; FIS [PI08222]; CIBER-BBN; 
   [1/EuroNanoMed/2010]
FX Studies were funded by project No1/EuroNanoMed/2010, DEN-PEPTHIV
   PS09102669, FIS (PI08222), CIBER-BBN.
CR Adamczak M, 2012, COLLOID SURFACE B, V90, P211, DOI 10.1016/j.colsurfb.2011.10.028
   Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Domenech R, 2010, BIOMACROMOLECULES, V11, P2069, DOI 10.1021/bm100432x
   El-Ridy MS, 2011, DRUG DEV IND PHARM, V37, P1491, DOI 10.3109/03639045.2011.587431
   Gardikis K, 2011, J NANOSCI NANOTECHNO, V11, P3764, DOI 10.1166/jnn.2011.3847
   Gardikis K, 2010, COLLOID SURFACE B, V81, P11, DOI 10.1016/j.colsurfb.2010.06.010
   Gardikis K, 2010, J PHARM SCI-US, V99, P3561, DOI 10.1002/jps.22121
   Gras R, 2009, PHARM RES-DORD, V26, P577, DOI 10.1007/s11095-008-9776-z
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Hou S, 2008, COLLOID SURFACE B, V62, P151, DOI 10.1016/j.colsurfb.2007.09.032
   Huang XL, 2005, J VIROL, V79, P3052, DOI 10.1128/JVI.79.5.3052-3062.2005
   Ionov M, 2012, BBA-BIOMEMBRANES, V1818, P2209, DOI 10.1016/j.bbamem.2012.04.019
   Ionov M, 2011, COLLOID SURFACE B, V82, P8, DOI 10.1016/j.colsurfb.2010.07.046
   Ionov M, 2010, J THERM ANAL CALORIM, V99, P741, DOI 10.1007/s10973-009-0405-9
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Lesniak W, 2005, NANO LETT, V5, P2123, DOI 10.1021/nl051077u
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177
   Ofek P, 2010, FASEB J, V24, P3122, DOI 10.1096/fj.09-149641
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Padamwar MN, 2011, J LIPOSOME RES, V21, P324, DOI 10.3109/08982104.2011.575380
   Pastor E, 2011, COLLOID SURFACE B, V88, P601, DOI 10.1016/j.colsurfb.2011.07.049
   Pion M, 2010, BIOMATERIALS, V31, P8749, DOI 10.1016/j.biomaterials.2010.07.093
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Sekowski S, 2009, COLLOID SURFACE B, V69, P95, DOI 10.1016/j.colsurfb.2008.11.006
   Shcharbin D, 2009, J CONTROL RELEASE, V135, P186, DOI 10.1016/j.jconrel.2009.01.015
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   Shcharbin D, 2011, COLLOID SURFACE B, V83, P388, DOI 10.1016/j.colsurfb.2010.11.009
   Smoluchowski M., 1921, HDB ELECT MAGNETISMU, P366
   Sze A, 2003, J COLLOID INTERF SCI, V261, P402, DOI 10.1016/S0021-9797(03)00142-5
   Tan QY, 2010, DRUG DELIV, V17, P28, DOI 10.3109/10717540903508953
   VanCompernolle SE, 2005, J VIROL, V79, P11598, DOI 10.1128/JVI.79.18.11598-11606.2005
   Vasumathi V, 2010, MACROMOLECULES, V43, P8264, DOI 10.1021/ma1012495
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wrobel D, 2011, BBA-MOL CELL BIOL L, V1811, P221, DOI 10.1016/j.bbalip.2010.11.007
NR 37
TC 17
Z9 17
U1 2
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD JAN 1
PY 2013
VL 101
BP 236
EP 242
DI 10.1016/j.colsurfb.2012.07.011
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 068ZS
UT WOS:000313405300037
PM 23010025
DA 2018-01-05
ER

PT J
AU Zhang, J
   Wu, XY
   Yang, WJ
   Chen, JH
   Fu, FF
AF Zhang, Jing
   Wu, XiaoYan
   Yang, WeiJuan
   Chen, JingHua
   Fu, FengFu
TI Ultra-sensitive electrochemical detection of single nucleotide
   polymorphisms based on an electrically controllable magnetic gold
   electrode
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DNA DETECTION; BIOSENSOR; NANOPARTICLES;
   IMMUNOASSAY; PROBES; GENE
AB A novel controllable magnetic electrochemical biosensor for the ultra-sensitive detection of single nucleotide polymorphisms (SNPs) of trace HIV-related salivary DNA is first described here based on a home-made electrically controllable magnetic gold electrode (ECM-GE).
C1 [Chen, JingHua] Fujian Med Univ, Fac Pharm, Fuzhou 350004, Fujian, Peoples R China.
   [Zhang, Jing] Fujian Agr & Forestry Univ, Fac Life Sci, Fuzhou 350002, Fujian, Peoples R China.
   [Zhang, Jing; Wu, XiaoYan; Yang, WeiJuan; Fu, FengFu] Fuzhou Univ, Dept Chem, Key Lab Anal & Detect Food Safety MOE & Fujian Pr, Fuzhou 350108, Fujian, Peoples R China.
RP Chen, JH (reprint author), Fujian Med Univ, Fac Pharm, Fuzhou 350004, Fujian, Peoples R China.
EM cjh_huaxue@126.com; fengfu@fzu.edu.cn
FU National Key Technologies R & D Program of China [2012BAD29B06]; NSFC
   [41240035, 21105012, 21205015]; National Science Foundation of Fujian
   Province [2012J01035, 2011Y0016, 2011J01028]
FX The work was supported by the National Key Technologies R & D Program of
   China (No. 2012BAD29B06), NSFC (41240035, 21105012, 21205015), National
   Science Foundation of Fujian Province (2012J01035, 2011Y0016,
   2011J01028).
CR Candotti D, 2004, J VIROL METHODS, V118, P39, DOI [10.1016/S0166-0934(04)00019-9, 10.1016/j.jviromet.2004.01.017]
   Cash KJ, 2009, ANAL CHEM, V81, P656, DOI 10.1021/ac802011d
   Chen JH, 2010, BIOSENS BIOELECTRON, V26, P144, DOI 10.1016/j.bios.2010.05.033
   Do J, 2008, LAB CHIP, V8, P542, DOI 10.1039/b715569g
   Grossmann TN, 2008, ANGEW CHEM INT EDIT, V47, P7119, DOI 10.1002/anie.200801355
   Hodinka RL, 1998, CLIN DIAGN LAB IMMUN, V5, P419
   Inouye M, 2005, P NATL ACAD SCI USA, V102, P11606, DOI 10.1073/pnas.0502078102
   Koets M, 2009, BIOSENS BIOELECTRON, V24, P1893, DOI 10.1016/j.bios.2008.09.023
   Li D, 2007, CHEM COMMUN, P3544, DOI 10.1039/b704731b
   Liang Y, 2007, TALANTA, V72, P443, DOI 10.1016/j.talanta.2006.11.002
   Loaiza OA, 2008, ANAL CHEM, V80, P8239, DOI 10.1021/ac801319b
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Ozkan-Ariksoysal D, 2008, ANAL CHEM, V80, P588, DOI 10.1021/ac071407q
   Panke O, 2007, BIOSENS BIOELECTRON, V22, P2656, DOI 10.1016/j.bios.2006.10.033
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Shiddiky MJA, 2010, J AM CHEM SOC, V132, P10053, DOI 10.1021/ja1021365
   von Lode P, 2005, CLIN BIOCHEM, V38, P591, DOI 10.1016/j.clinbiochem.2005.03.008
   Wabuyele MB, 2005, ANAL CHEM, V77, P7810, DOI 10.1021/ac0514671
   Warsinke A, 2009, ANAL BIOANAL CHEM, V393, P1393, DOI 10.1007/s00216-008-2572-0
   [Anonymous], 2009, UNAIDS PUBL
   Wu CK, 2011, ANALYST, V136, P2106, DOI 10.1039/c1an15061h
   Zetola NM, 2007, INFECT DIS CLIN N AM, V21, P19, DOI 10.1016/j.idc.2007.01.008
   Zhang J, 2011, BIOSENS BIOELECTRON, V26, P4053, DOI 10.1016/j.bios.2011.03.029
   Zhang J, 2010, CHEM COMMUN, V46, P6986, DOI 10.1039/c0cc02080j
   Zhang J, 2009, BIOSENS BIOELECTRON, V25, P815, DOI 10.1016/j.bios.2009.08.032
NR 25
TC 13
Z9 14
U1 1
U2 40
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2013
VL 49
IS 10
BP 996
EP 998
DI 10.1039/c2cc37783g
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 064FW
UT WOS:000313059300013
PM 23258110
DA 2018-01-05
ER

PT J
AU Ren, JT
   Wang, JH
   Wang, J
   Wang, EK
AF Ren, Jiangtao
   Wang, Jiahai
   Wang, Jin
   Wang, Erkang
TI Colorimetric Enantiorecognition of Oligopeptide and Logic Gate
   Construction Based on DNA Aptamer-Ligand-Gold Nanoparticle Interactions
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE aptamers; enantioselectivity; gold nanoparticles; logic gates;
   oligopeptides
ID AMINO-ACIDS; INDICATOR DISPLACEMENT; CHIRAL RECOGNITION; HIV-1 ENTRY;
   VASOPRESSIN; BINDING; ENANTIOSELECTIVITY; NUCLEATION; SEPARATION;
   PEPTIDES
AB At the gate: Colorimetric enantiorecognition of one oligopeptide was realized by virtue of a D-enantiomer specific DNA aptamer as chiral selector and unmodified gold nanoparticles as indicator. Oligopeptide enantiomers as inputs were introduced into colorimetric logic gates, which have the potential for enantiorecognition of oligopeptides (see figure). This system may lead to a better understanding of chiral recognition for information processing in natural systems.
C1 [Ren, Jiangtao; Wang, Jiahai; Wang, Jin; Wang, Erkang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.
   [Ren, Jiangtao] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Wang, Jiahai] SUNY Stony Brook, Dept Chem & Phys, Stony Brook, NY 11794 USA.
RP Wang, J (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.
EM jin.wang.1@stonybrook.edu; ekwang@ciac.jl.cn
RI Wang, JiaHai/C-5539-2012
OI Wang, JiaHai/0000-0002-4846-7561
FU National Natural Science Foundation of China [21190040, 21075210]; 973
   Project [2009CB930100, 2010CB933600]; National Science Foundation
FX This work was supported by the National Natural Science Foundation of
   China (No. 21190040 and 21075210) and the 973 Project (2009CB930100 and
   2010CB933600) and the National Science Foundation.
CR Bi S., 2010, ANGEW CHEM, V122, P4540
   Bi S, 2010, ANGEW CHEM INT EDIT, V49, P4438, DOI 10.1002/anie.201000840
   Choi Y, 2007, ANGEW CHEM, V119, P721
   Choi Y, 2007, ANGEW CHEM INT EDIT, V46, P707, DOI 10.1002/anie.200603735
   Czerwenka C, 2002, ANAL CHEM, V74, P5658, DOI 10.1021/ac0203721
   Du Y, 2012, CHEM COMMUN, V48, P799, DOI 10.1039/c1cc15303j
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Fu YZ, 2012, CHEM COMMUN, V48, P2322, DOI 10.1039/c2cc17301h
   Ghosh SK, 2007, CHEM REV, V107, P4797, DOI 10.1021/cr0680282
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Jana NR, 2001, CHEM MATER, V13, P2313, DOI 10.1021/cm000662n
   Kasprzyk-Hordern B, 2010, CHEM SOC REV, V39, P4466, DOI 10.1039/c000408c
   Kim YS, 2010, BIOORGAN MED CHEM, V18, P3467, DOI 10.1016/j.bmc.2010.03.074
   Kolpashchikov DM, 2005, J AM CHEM SOC, V127, P11348, DOI 10.1021/ja051362f
   Leung D, 2008, J AM CHEM SOC, V130, P12318, DOI 10.1021/ja803806c
   Liu JW, 2009, CHEM REV, V109, P1948, DOI 10.1021/cr030183i
   Lu HA, 2011, ANAL METHODS-UK, V3, P488, DOI 10.1039/c0ay00489h
   Michaud M, 2003, J AM CHEM SOC, V125, P8672, DOI 10.1021/ja034483t
   Muramatsu S, 2006, J AM CHEM SOC, V128, P3764, DOI 10.1021/ja057604t
   Null EL, 2010, ANALYST, V135, P419, DOI 10.1039/b921267a
   NUZZO RG, 1983, J AM CHEM SOC, V105, P4481, DOI 10.1021/ja00351a063                                                             
   POPENOE EA, 1952, J AM CHEM SOC, V74, P3713, DOI 10.1021/ja01134a528                                                             
   Qin HX, 2012, ANAL CHIM ACTA, V712, P127, DOI 10.1016/j.aca.2011.10.044
   Ren JT, 2012, BIOSENS BIOELECTRON, V35, P401, DOI 10.1016/j.bios.2012.03.028
   Ruta J, 2007, ANAL CHEM, V79, P4716, DOI 10.1021/ac070469d
   Schug KA, 2005, CHEM REV, V105, P67, DOI 10.1021/cr040603j
   Staden R.I. Stefan-van, 2007, SENSOR ACTUAT B-CHEM, V120, P399
   Szacilowski K, 2008, CHEM REV, V108, P3481, DOI 10.1021/cr068403q
   TAYLOR SP, 1953, J BIOL CHEM, V205, P45
   Nguyen T, 2011, SENSOR ACTUAT B-CHEM, V154, P59, DOI 10.1016/j.snb.2009.10.032
   Thomson F., 2010, ENCY PSYCHOPHARMACOL, P151
   Urata H, 2007, BIOCHEM BIOPH RES CO, V360, P459, DOI 10.1016/j.bbrc.2007.06.075
   Wan H, 2000, J CHROMATOGR A, V875, P43, DOI 10.1016/S0021-9673(99)01209-1
   WARD DN, 1957, P SOC EXP BIOL MED, V96, P568
   Ward TJ, 2012, ANAL CHEM, V84, P626, DOI 10.1021/ac202892w
   Wei WL, 2011, CHEM SCI, V2, P2050, DOI 10.1039/c1sc00308a
   Welch BD, 2010, J VIROL, V84, P11235, DOI 10.1128/JVI.01339-10
   Williams KP, 1997, P NATL ACAD SCI USA, V94, P11285, DOI 10.1073/pnas.94.21.11285
   Xu XW, 2011, CHEM COMMUN, V47, P9435, DOI 10.1039/c1cc13459k
   Yin BC, 2012, CHEM COMMUN, V48, P1248, DOI 10.1039/c1cc15639j
   Zhang LP, 2012, ANAL CHIM ACTA, V717, P127, DOI 10.1016/j.aca.2011.12.037
   Zhou M., 2012, ANGEW CHEM, V124, P2740
   Zhou M, 2012, ANGEW CHEM INT EDIT, V51, P2686, DOI 10.1002/anie.201107068
   Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200
   Zhu JB, 2011, BIOMATERIALS, V32, P7318, DOI 10.1016/j.biomaterials.2011.06.040
   Zhu X, 2011, CHEM COMMUN, V47, P9080, DOI 10.1039/c1cc12734a
NR 46
TC 21
Z9 23
U1 8
U2 171
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0947-6539
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD JAN
PY 2013
VL 19
IS 2
BP 478
EP 482
DI 10.1002/chem.201202430
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 065PQ
UT WOS:000313161200008
PM 23233391
DA 2018-01-05
ER

PT J
AU Rahman, MA
   Hussain, A
   Hussain, MS
   Mirza, MA
   Iqbal, Z
AF Rahman, Md. Akhlaquer
   Hussain, Arshad
   Hussain, Md. Sarfaraj
   Mirza, Mohd. Aamir
   Iqbal, Zeenat
TI Role of excipients in successful development of
   self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS)
SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
LA English
DT Review
DE Self-emulsifying/microemulsifying drug delivery systems (SEDDS/SMEDDS);
   lipophilic drugs; excipient; surfactant; P-glycoprotein (P-gp); oral
   delivery; oral bioavailability
ID IMPROVED ORAL BIOAVAILABILITY; LONG-CHAIN TRIGLYCERIDES; SOFT-GELATIN
   CAPSULES; WATER-SOLUBLE DRUGS; VITAMIN-E-TPGS; FREQUENCY
   DIELECTRIC-SPECTROSCOPY; INTESTINAL LYMPHATIC TRANSPORT; SOLID LIPID
   NANOPARTICLES; IN-VIVO BIOAVAILABILITY; HIV PROTEASE INHIBITOR
AB The oral delivery of hydrophobic drug presents a major challenge because of the low aqueous solubility of such compounds. Self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS), which are isotropic mixtures of oils, surfactants, solvents and co-solvents/surfactants, can be used for the design of formulations in order to improve the oral absorption of highly lipophilic drug compounds. The efficiency of oral absorption of said drug from such type of formulation depends on many formulation-related parameters, such as surfactant concentration, oil/surfactant ratio, polarity of the emulsion, droplet size and charge, all of which in essence determine the self-emulsification ability. Thus, only very specific pharmaceutical excipient combinations will lead to efficient self-emulsifying systems. With the growing interest in this field, there is an increasing need for guidelines in excipient selection to obtain effective delivery system with improved bioavailability.
   The aim of this review is to present the recent approaches in selecting the most appropriate lipid system(s); methods for its characterization and role of various excipients for improved delivery of dosage form.
C1 [Rahman, Md. Akhlaquer; Hussain, Arshad; Hussain, Md. Sarfaraj] Integral Univ, Fac Pharm, Lucknow 226026, Uttar Pradesh, India.
   [Mirza, Mohd. Aamir; Iqbal, Zeenat] Fac Pharm, Dept Pharmaceut, New Delhi, India.
RP Rahman, MA (reprint author), Integral Univ, Fac Pharm, Lucknow 226026, Uttar Pradesh, India.
EM rahmanpharma@gmail.com
FU University Grant Commission (UGC), Government of India
FX One of the authors, Md. A. Rahman is highly grateful to the University
   Grant Commission (UGC), Government of India for providing financial
   assistance in the form of Maulana Azad National Fellowship (MANF). There
   is no declaration of interest.
CR AMIDON GL, 1995, PHARMACEUT RES, V12, P413, DOI 10.1023/A:1016212804288
   Anderson B.D., 1999, B TECH GATTEFOSSE, V92, P11
   ANGELL CA, 1984, J PHYS CHEM-US, V88, P4593, DOI 10.1021/j150664a031                                                             
   ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U
   Attama AA, 2003, INT J PHARM, V262, P23, DOI 10.1016/S0378-5173(03)00315-6
   Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
   AUNGST BJ, 1993, J PHARM SCI, V82, P979, DOI 10.1002/jps.2600821002
   Aungst BJ, 1994, B T GATTEFOSSE, V87, P49
   Bansal T, 2008, CRIT REV THER DRUG, V25, P63, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i1.20                                    
   BENAMEUR H, 2006, B TECH GATTEFOSSE, P63
   Benet LZ, 2001, ADV DRUG DELIVER REV, V50, pS3, DOI 10.1016/S0169-409X(01)00178-8
   Bolzinger-Thevenin MA, 1999, LANGMUIR, V15, P2307, DOI 10.1021/la9804278                                                               
   Brubach JB, 2007, INT J PHARM, V336, P248, DOI 10.1016/j.ijpharm.2006.11.057
   Brubach JB, 2004, J PHYS CHEM B, V108, P17721, DOI 10.1021/jp047989m
   Burcham DL, 1997, BIOPHARM DRUG DISPOS, V18, P737, DOI 10.1002/(SICI)1099-081X(199711)18:8<737::AID-BDD59>3.0.CO;2-9
   Buss N, 2001, BRIT J CLIN PHARMACO, V52, P255, DOI 10.1046/j.0306-5251.2001.01452.x
   Caliph SM, 2000, J PHARM SCI, V89, P1073, DOI 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO;2-V                        
   Cao YC, 2004, J PHARM SCI-US, V93, P2768, DOI 10.1002/jps.20126
   Cardiello PG, 2003, JAIDS-J ACQ IMM DEF, V32, P375, DOI 10.1097/00126334-200304010-00005
   CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251                                             
   Chambin O, 2005, DRUG DEV IND PHARM, V31, P527, DOI 10.1080/03639040500215750
   Chambin O, 2004, INT J PHARM, V278, P79, DOI 10.1016/j.ijpharm.2004.02.033
   CHARMAN SA, 1992, PHARMACEUT RES, V9, P87, DOI 10.1023/A:1018987928936                                                         
   CHARMAN WNA, 1986, INT J PHARM, V33, P155, DOI 10.1016/0378-5173(86)90049-9
   CHERVINSKY DS, 1993, ANTICANCER RES, V13, P93
   Chiu YY, 2003, PHARMACEUT RES, V20, P749, DOI 10.1023/A:1023481418576
   Choy YW, 2005, INT J PHARM, V299, P55, DOI 10.1016/j.ijpharm.2005.04.030
   Christensen JO, 2004, EUR J PHARM SCI, V23, P287, DOI 10.1016/j.ejps.2004.08.003
   Collnot EM, 2007, MOL PHARM, V4, P465, DOI 10.1021/mp060121r
   CONSTANTINIDES PP, 1995, PHARMACEUT RES, V12, P1561, DOI 10.1023/A:1016268311867
   Corswant CV, 1997, LANGMUIR, V13, P5061
   CRAIG DQM, 1995, INT J PHARM, V114, P103, DOI 10.1016/0378-5173(94)00222-Q
   CRAIG DQM, 1993, INT J PHARM, V96, P147, DOI 10.1016/0378-5173(93)90222-2
   Craig DQM, 1993, B TECH GATTEFOSSE, V86, P21
   Crowley KJ, 2002, J PHARM SCI, V91, P492, DOI 10.1002/jps.10028
   Cuine JF, 2008, J PHARM SCI-US, V97, P995, DOI 10.1002/jps.21246
   Curry R, 2001, 1 IAS C HIV PATH TRE
   Devani M, 2004, J PHARM PHARMACOL, V56, P307, DOI 10.1211/0022357022872
   Devani MJ, 2005, INT J PHARM, V300, P76, DOI 10.1016/j.ijpharm.2005.05.011
   Dintaman JM, 1999, PHARMACEUT RES, V16, P1550, DOI 10.1023/A:1015000503629
   Father I, 2001, J PHARM SCI, V90, P987
   Feinberg J, 2000, 40 INT C ANT AG CHEM
   Fernandez S, 2007, BBA-MOL CELL BIOL L, V1771, P633, DOI 10.1016/j.bbalip.2007.02.009
   Fischl MA, 1997, J ACQ IMMUN DEF SYND, V15, P28, DOI 10.1097/00042560-199705010-00005                                                
   Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5
   Gao P, 2003, J PHARM SCI-US, V92, P2386, DOI 10.1002/jps.10511
   GARGOURI Y, 1986, BIOCHIM BIOPHYS ACTA, V879, P419, DOI 10.1016/0005-2760(86)90234-1
   Gershanik T, 1996, Pharm Dev Technol, V1, P147, DOI 10.3109/10837459609029889
   Gershanik T, 1998, PHARMACEUT RES, V15, P863, DOI 10.1023/A:1011968313933                                                         
   Gershanik T, 2000, EUR J PHARM BIOPHARM, V50, P179, DOI 10.1016/S0939-6411(00)00089-8
   Gibson L, 2007, ORAL LIPID BASED FOR, P43
   GREENBERG S, 1990, J CLIN PHARMACOL, V30, P596, DOI 10.1002/j.1552-4604.1990.tb01862.x                                              
   GREENBERGER NJ, 1966, J CLIN INVEST, V45, P217, DOI 10.1172/JCI105334
   Grove M, 2006, EUR J PHARM SCI, V28, P233, DOI 10.1016/j.ejps.2006.02.005
   Gursoy N, 2003, J PHARM SCI-US, V92, P2411, DOI 10.1002/jpd.10501
   Gursoy RN, 2004, BIOMED PHARMACOTHER, V58, P173, DOI 10.1016/j.biopha.2004.02.001
   Hantzschel D, 1999, PHYS CHEM CHEM PHYS, V1, P5703, DOI 10.1039/a907015j
   Hauss DJ, 1998, J PHARM SCI, V87, P164, DOI 10.1021/js970300n
   Hauss D.J., 2007, ORAL LIPID BASED FOR, p[1, 43]
   Hirai M, 1999, J PHYS CHEM SOLIDS, V60, P1359, DOI 10.1016/S0022-3697(99)00113-4                                                   
   Holm R, 2003, EUR J PHARM SCI, V20, P91, DOI 10.1016/S0928-0987(03)00174-X
   Hong JY, 2006, J CONTROL RELEASE, V110, P332, DOI 10.1016/j.jconrel.2005.10.002
   Humberstone AJ, 1996, J PHARM SCI, V85, P525, DOI 10.1021/js950472p
   Jackson M., 1987, PHYSL GASTROINTESTIN, V2, P1597
   Jannin V, 2008, ADV DRUG DELIVER REV, V60, P734, DOI 10.1016/j.addr.2007.09.006
   Jenning V, 2000, J CONTROL RELEASE, V66, P115, DOI 10.1016/S0168-3659(99)00223-0
   Julianto T, 2000, INT J PHARM, V200, P53, DOI 10.1016/S0378-5173(00)00337-9                                                   
   Kang BK, 2004, INT J PHARM, V274, P65, DOI 10.1016/j.ijpharm.2003.12.028
   KARARLI TT, 1992, PHARMACEUT RES, V9, P888, DOI 10.1023/A:1015896731545
   Kawakami K, 2002, J CONTROL RELEASE, V81, P65, DOI 10.1016/S0168-3659(02)00049-4
   Khan N, 2003, J CONTROL RELEASE, V93, P355, DOI 10.1016/j.jconrel.2003.09.006
   Khoo SM, 1998, INT J PHARM, V167, P155, DOI 10.1016/S0378-5173(98)00054-4
   Khoo SM, 1999, PHARM SCI, V1, pS
   Kim HJ, 2000, DRUG DEV IND PHARM, V26, P523, DOI 10.1081/DDC-100101263                                                           
   Kim JY, 2000, INT J PHARM, V194, P81, DOI 10.1016/S0378-5173(99)00367-1
   Kim KH, 2002, ENCY PHARM TECHNOLOG, P886
   KISHI H, 1984, BIOMEDICAL CLIN ASPE, P131
   KIYASU JY, 1952, J BIOL CHEM, V199, P415
   Kobayashi Y, 2000, INT J PHARM, V193, P137, DOI 10.1016/S0378-5173(99)00315-4
   Kohli K, 2010, DRUG DISCOV TODAY, V15, P958, DOI 10.1016/j.drudis.2010.08.007
   Kommuru TR, 2001, INT J PHARM, V212, P233, DOI 10.1016/S0378-5173(00)00614-1
   KOVARIK JM, 1994, J PHARM SCI, V83, P444, DOI 10.1002/jps.2600830336
   Kurowski M, 2003, HIV Med, V4, P94, DOI 10.1046/j.1468-1293.2003.00143.x
   Lawrence MJ, 2000, ADV DRUG DELIVER REV, V45, P89, DOI 10.1016/S0169-409X(00)00103-4
   Lo YL, 1998, ANTICANCER RES, V18, P3005
   MacGregor KJ, 1997, ADV DRUG DELIVER REV, V25, P33, DOI 10.1016/S0169-409X(96)00489-9
   MALCOLMSON C, 1993, J PHARM PHARMACOL, V45, P141, DOI 10.1111/j.2042-7158.1993.tb03700.x                                              
   Martignoni M, 2004, CHEM-BIOL INTERACT, V151, P1, DOI 10.1016/j.cbi.2004.10.002
   Matsuoka K, 2002, BBA-MOL CELL BIOL L, V1580, P200, DOI 10.1016/S1388-1981(01)00204-9
   Meinzer A, 1995, B T GATTEFOSSE, V88, P21
   MUELLER EA, 1994, PHARMACEUT RES, V11, P301, DOI 10.1023/A:1018923912135
   MYERS RA, 1992, INT J PHARM, V78, P217, DOI 10.1016/0378-5173(92)90374-B                                                    
   Myers RA, 1992, INT J PHARMACEUT, V80, P511
   Nakamura N, 1999, J DISPER SCI TECHNOL, V20, P535, DOI 10.1080/01932699908943806
   Nazzal S, 2002, INT J PHARM, V235, P247, DOI 10.1016/S0378-5173(02)00003-0
   Odeberg JM, 2003, EUR J PHARM SCI, V20, P375, DOI 10.1016/j.ejps.2003.08.005
   PALIN KJ, 1986, INT J PHARM, V33, P99, DOI 10.1016/0378-5173(86)90043-8
   PARKER WO, 1993, COLLOID SURFACE A, V72, P275, DOI 10.1016/0927-7757(93)80476-U                                                    
   POCOCK DME, 1974, LIPIDS, V9, P374, DOI 10.1007/BF02532054                                                              
   POELMA FGJ, 1990, PHARMACEUT RES, V7, P392, DOI 10.1023/A:1015827624296
   Porter CJH, 2008, ADV DRUG DELIVER REV, V60, P673, DOI 10.1016/j.addr.2007.10.014
   Porter CJH, 2007, NAT REV DRUG DISCOV, V6, P231, DOI 10.1038/nrd2197
   Porter CJH, 2004, PHARM RES, V21, P1405, DOI 10.1023/B:PHAM.0000036914.22132.cc
   Porter CJH, 2001, ADV DRUG DELIVER REV, V50, pS127, DOI 10.1016/S0169-409X(01)00182-X
   Porter CJH, 1997, ADV DRUG DELIVER REV, V25, P71, DOI 10.1016/S0169-409X(96)00492-9
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   Pouton CW, 1997, ADV DRUG DELIVER REV, V25, P47, DOI 10.1016/S0169-409X(96)00490-5                                                   
   Rahman MA, 2011, CURR DRUG DELIV, V8, P330
   Rajebahadur M, 2006, DRUG DELIV, V13, P201, DOI 10.1080/10717540500316094
   REISS H, 1975, J COLLOID INTERF SCI, V53, P61, DOI 10.1016/0021-9797(75)90035-1                                                    
   Ritschel WA, 1996, CLIN TRANSPLANT, V10, P364
   Robinson J., 1996, B TECHNIQUE GATTEFOS, P11
   Roche Registration LTD, 2002, INV SAQ HARD GEL CAP
   Roche Registration LTD, 2002, FORT SAQ SOFT GEL CA
   ROWINSKY EK, 1992, SEMIN ONCOL, V19, P646
   Schick M. J. E., 1977, NONIONIC SURFACTANTS, V1
   Schwendener RA, 1996, J CANCER RES CLIN, V122, P723, DOI 10.1007/BF01209119                                                              
   Sek L, 2006, J PHARM PHARMACOL, V58, P809, DOI 10.1211/jpp.58.6.0011
   Sek L, 2001, J PHARMACEUT BIOMED, V25, P651, DOI 10.1016/S0731-7085(00)00528-8
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   SERAJUDDIN ATM, 1988, J PHARM SCI, V77, P414, DOI 10.1002/jps.2600770512                                                          
   Sha XY, 2005, EUR J PHARM SCI, V24, P477, DOI 10.1016/j.ejps.2005.01.001
   SHAH NH, 1994, INT J PHARM, V106, P15, DOI 10.1016/0378-5173(94)90271-2
   Shen HR, 2006, J PHARM PHARMACOL, V58, P1183, DOI 10.1211/jpp.58.9.0004
   Singh B, 2009, CRIT REV THER DRUG, V26, P427, DOI 10.1615/CritRevTherDrugCarrierSyst.v26.i5.10                                    
   STELLA V, 1978, J PHARM SCI, V67, P1375, DOI 10.1002/jps.2600671011
   Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23
   Stuart JWTC, 1999, AIDS, V13, pF53
   Subramanian N, 2004, BIOL PHARM BULL, V27, P1993, DOI 10.1248/bpb.27.1993
   SWENSON ES, 1992, ADV DRUG DELIVER REV, V8, P39
   TOGUCHI H, 1990, CHEM PHARM BULL, V38, P2792, DOI 10.1248/cpb.38.2792                                                             
   TOKUMURA T, 1987, J PHARM SCI, V76, P286, DOI 10.1002/jps.2600760404
   TRULL AK, 1994, TRANSPLANT P, V26, P2977
   Tuleu C, 2004, J PHARM SCI-US, V93, P1495, DOI 10.1002/jps.20068
   VONDERSCHER J, 1994, TRANSPLANT P, V26, P2925
   Vyas SP, 2002, TARGETED CONTROLLED, P291
   Wadke D. A., 1989, PHARM DOSAGE FORMS T, V1, P1
   WAKERLY MG, 1986, ACS SYM SER, V311, P242
   WASHINGTON C, 1990, INT J PHARM, V66, P1, DOI 10.1016/0378-5173(90)90379-I
   Wei LL, 2005, DRUG DEV IND PHARM, V31, P785, DOI 10.1080/03639040500216428
   WELLING PG, 1977, J PHARMACOKINET BIOP, V5, P291, DOI 10.1007/BF01061694                                                              
   Woo JS, 2003, PHARMACEUT RES, V20, P24, DOI 10.1023/A:1022286422439
   Wu W, 2006, EUR J PHARM BIOPHARM, V63, P288, DOI 10.1016/j.ejpb.2005.12.005
   Yang SC, 2004, PHARM RES, V21, P261, DOI 10.1023/B:PHAM.0000016238.44452.f1
   Yap SP, 2004, INT J PHARM, V281, P67, DOI 10.1016/j.ijpharm.2004.05.015
   Yeni P, 2003, JAIDS-J ACQ IMM DEF, V34, pS91, DOI 10.1097/00126334-200309011-00014
   Yu L, 1999, PHARMACEUT RES, V16, P1812, DOI 10.1023/A:1018939006780                                                         
   Zhang YC, 2001, CLIN PHARMACOKINET, V40, P159, DOI 10.2165/00003088-200140030-00002
NR 149
TC 24
Z9 31
U1 7
U2 85
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0363-9045
J9 DRUG DEV IND PHARM
JI Drug Dev. Ind. Pharm.
PD JAN
PY 2013
VL 39
IS 1
BP 1
EP 19
DI 10.3109/03639045.2012.660949
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 058US
UT WOS:000312660800001
PM 22372916
DA 2018-01-05
ER

PT J
AU Lisziewicz, J
   Toke, ER
AF Lisziewicz, Julianna
   Toke, Eniko R.
TI Nanomedicine applications towards the cure of HIV
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Review
DE HIV vaccine; HIV eradication; Memory T cells; Drug development
ID ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-LIKE PARTICLES; DENDRITIC CELLS;
   IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; RESIDUAL VIREMIA; DNA
   VACCINES; T-CELLS; NANOPARTICLES; INFECTION
AB Combination antiretroviral therapy (cART) successfully suppresses HIV replication. However, daily and lifelong treatment is necessary to manage patient illness because cART neither eradicates infected cells from reservoirs nor reconstitutes HIV-specific immunity that could kill infected cells. Toward the cure of HIV, different nanomedicine classes have been developed with the following disease-modifying properties: to eradicate the virus by activation of latently infected CD4+ T-cells and reservoirs flushing; to kill the infected cells in the reservoirs by boosting of HIV-specific T cells; and to prevent infection by the use of microbicides with improved epithelial penetration and drug half-life. Preclinical and clinical trials consistently demonstrated that DermaVir, the most advanced nanomedicine, induces long-lasting memory T-cell responses and reduces viral load in comparison with placebo. DermaVir and the nanomedicine pipelines have the potential to improve the health of HIV-infected people at lower costs, to decrease antiretroviral drug exposure, and to contribute to the cure of HIV/AIDS. From the Clinical Editor: Despite the leaps and bounds in the development of antiretroviral therapy, HIV remains a significant public health challenge. In this review, applications of nanomedicine-based technologies are discussed in the context of HIV treatment, including virus elimination by activation of latently infected CD4+ T-cells; infected cell elimination in the reservoirs by boosting HIV-specific T cells, and by preventing infection by the use of microbicides with improved epithelial penetration and drug half-life. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Lisziewicz, Julianna; Toke, Eniko R.] Genet Immun Kft, H-1045 Budapest, Hungary.
   [Lisziewicz, Julianna] Genet Immun Inc, Mclean, VA USA.
RP Lisziewicz, J (reprint author), Genet Immun Kft, Berlini Utca 47-49, H-1045 Budapest, Hungary.
EM lisziewj@geneticimmunity.com
FU National Office for Research and Technology (NKTH) in Hungary [HIKC05,
   DVCLIN01]
FX Dr. Julianna Lisziewicz holds shares in Genetic Immunity. This work was
   supported by grants: HIKC05 and DVCLIN01 of the National Office for
   Research and Technology (NKTH) in Hungary.
CR Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bauer J, 2001, J INVEST DERMATOL, V116, P313, DOI 10.1046/j.1523-1747.2001.01247.x                                                
   BLATTNER W, 1988, SCIENCE, V241, P515, DOI 10.1126/science.3399881
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907                                                     
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Casazza JP, 2001, J VIROL, V75, P6508, DOI 10.1128/JVI.75.14.6508-6516.2001
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   CHRISTENSEN ND, 1994, J GEN VIROL, V75, P2271, DOI 10.1099/0022-1317-75-9-2271
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Diebold SS, 1999, J BIOL CHEM, V274, P19087, DOI 10.1074/jbc.274.27.19087                                                        
   Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106
   Fairman J, 2009, HUM VACCINES, V5, P141, DOI 10.4161/hv.5.3.6589                                                             
   Fuller DH, 2006, METHODS, V40, P86, DOI 10.1016/j.ymeth.2006.05.022
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Gallo RC, 2002, SCIENCE, V298, P1728, DOI 10.1126/science.1078050
   Gandhi RT, 2011, PLOS MED, V7, P1
   Grabovac V, 2007, DRUG DEV IND PHARM, V33, P767, DOI 10.1080/03639040601050163
   Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706
   Han XZ, 2009, CYTOTECHNOLOGY, V60, P63, DOI 10.1007/s10616-009-9215-y
   Hatano H, 2011, J INFECT DIS, V203, P894
   Hildesheim A, 2007, JAMA-J AM MED ASSOC, V298, P743, DOI 10.1001/jama.298.7.743
   Holtgrave DR, 2005, INT J STD AIDS, V16, P777, DOI 10.1258/095646205774988109
   Kalams SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029231
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kish-Catalone T, 2007, AIDS RES HUM RETROV, V23, P33, DOI 10.1089/aid.2006.0076
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lisziewicz J, 2010, EUR J NANOMED
   Lisziewicz J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035416
   Lorincz O., 2011, NANOMEDICIN IN PRESS
   Losina E, 2009, CLIN INFECT DIS, V49, P1570, DOI 10.1086/644772
   Ma Xiaowei, 2010, AAPS J, V12, P272, DOI 10.1208/s12248-010-9187-z
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   MARTIN SJ, 1993, AIDS, V7, P1315, DOI 10.1097/00002030-199310000-00003
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Mavigner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007658
   McMahon D, 2010, CLIN INFECT DIS, V50, P912, DOI 10.1086/650749
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Natz E, 2011, RATIONAL DESIGN FORM, P109
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Pornpattananangkul D, 2010, ACS NANO, V4, P1935, DOI 10.1021/nn9018587
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Rodriguez B, 2010, 18 INT AIDS C VIENN
   Rupp R, 2007, INT J NANOMED, V2, P561
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Shan L, 2012, IMMUNITY, V36, P1
   Shen L, 2008, J ALLERGY CLIN IMMUN, V122, P22, DOI 10.1016/j.jaci.2008.05.033
   Somogyi E, 2011, VACCINE, V29, P744, DOI 10.1016/j.vaccine.2010.11.019
   Spearman P, 2011, J INFECT DIS, V203, P1165, DOI 10.1093/infdis/jiq175
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
   Tomalia DA, 2009, J NANOPART RES, V11, P1251, DOI 10.1007/s11051-009-9632-z
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wang YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021547
   Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016
NR 76
TC 23
Z9 24
U1 4
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JAN
PY 2013
VL 9
IS 1
BP 28
EP 38
DI 10.1016/j.nano.2012.05.012
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 064CA
UT WOS:000313047300005
PM 22659241
DA 2018-01-05
ER

PT J
AU Yeung, KS
   Qiu, ZL
   Yin, ZW
   Trehan, A
   Fang, HQ
   Pearce, B
   Yang, Z
   Zadjura, L
   D'Arienzo, CJ
   Riccardi, K
   Shi, PY
   Spicer, TP
   Gong, YF
   Browning, MR
   Hansel, S
   Santone, K
   Barker, J
   Coulter, T
   Lin, PF
   Meanwell, NA
   Kadow, JF
AF Yeung, Kap-Sun
   Qiu, Zhilei
   Yin, Zhiwei
   Trehan, Ashok
   Fang, Haiquan
   Pearce, Bradley
   Yang, Zheng
   Zadjura, Lisa
   D'Arienzo, Celia J.
   Riccardi, Keith
   Shi, Pei-Yong
   Spicer, Timothy P.
   Gong, Yi-Fei
   Browning, Marc R.
   Hansel, Steven
   Santone, Kenneth
   Barker, Jonathan
   Coulter, Thomas
   Lin, Ping-Fang
   Meanwell, Nicholas A.
   Kadow, John F.
TI Inhibitors of HIV-1 attachment. Part 8: The effect of C7-heteroaryl
   substitution on the potency, and in vitro and in vivo profiles of
   indole-based inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 attachment inhibitors; Indole glyoxamide; Heterocycles; Ligand
   efficiency; Lipophilic ligand efficiency
ID MEDICINAL CHEMISTRY; DRUG DISCOVERY; PATTERNS; ENVELOPE; BINDING; ENTRY
AB As part of the SAR profiling of the indole-oxoacetic piperazinyl benzamide class of HIV-1 attachment inhibitors, substitution at the C7 position of the lead 4-fluoroindole 2 with various 5- and 6-membered heteroaryl moieties was explored. Highly potent (picomolar) inhibitors of pseudotyped HIV-1 in a primary, cell-based assay were identified and select examples were shown to possess nanomolar inhibitory activity against M-and T-tropic viruses in cell culture. These C7-heteroaryl-indole analogs maintained the ligand efficiency (LE) of 2 and were also lipophilic efficient as measured by LLE and LELP. Pharmacokinetic studies of this class of inhibitor in rats showed that several possessed substantially improved IV clearance and half-lives compared to 2. Oral exposure in the rat correlated with membrane permeability as measured in a Caco-2 assay where the highly permeable 1,2,4-oxadiazole analog 13 exhibited the highest exposure. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Yeung, Kap-Sun; Qiu, Zhilei; Yin, Zhiwei; Trehan, Ashok; Fang, Haiquan; Pearce, Bradley; Yang, Zheng; Zadjura, Lisa; D'Arienzo, Celia J.; Riccardi, Keith; Shi, Pei-Yong; Spicer, Timothy P.; Gong, Yi-Fei; Browning, Marc R.; Hansel, Steven; Santone, Kenneth; Lin, Ping-Fang; Meanwell, Nicholas A.; Kadow, John F.] Bristol Myers Squibb Res & Dev, Wallingford, CT 06492 USA.
   [Barker, Jonathan; Coulter, Thomas] Evotec UK Ltd, Abingdon OX14 4SA, Oxon, England.
RP Yeung, KS (reprint author), Bristol Myers Squibb Res & Dev, 5 Res Pkwy,POB 5100, Wallingford, CT 06492 USA.
EM kapsun.yeung@bms.com
CR Bostrom J, 2012, J MED CHEM, V55, P1817, DOI 10.1021/jm2013248
   Dalvie DK, 2002, CHEM RES TOXICOL, V15, P269, DOI 10.1021/tx015574b
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Doms RW, 2000, GENE DEV, V14, P2677, DOI 10.1101/gad.833300                                                              
   Goldberg K, 2012, MEDCHEMCOMM, V3, P600, DOI 10.1039/c2md20054f
   Hanna GJ, 2011, ANTIMICROB AGENTS CH, V55, P722, DOI 10.1128/AAC.00759-10
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Kadow J. F, 2011, 241 ACS NAT M EXP AN
   Kadow J, 2006, CURR OPIN INVESTIG D, V7, P721
   Kadow JF, 2012, TOP MED CHEM SER, V8, P105, DOI 10.1007/978-3-642-28965-1
   Kadow JF, 2012, J MED CHEM, V55, P2048, DOI 10.1021/jm201218m
   Keseru GM, 2009, NAT REV DRUG DISCOV, V8, P203, DOI 10.1038/nrd2796
   Laurence C, 2009, J MED CHEM, V52, P4073, DOI 10.1021/jm801331y
   Leeson PD, 2007, NAT REV DRUG DISCOV, V6, P881, DOI 10.1038/nrd2445
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Meanwell NA, 2009, BIOORG MED CHEM LETT, V19, P5136, DOI 10.1016/j.bmcl.2009.07.027
   Meanwell NA, 2009, BIOORG MED CHEM LETT, V19, P1977, DOI 10.1016/j.bmcl.2009.02.040
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Nettles R, 2011, 18 C RETR OPP INF BO
   Nettles RE, 2012, J INFECT DIS, V206, P1002, DOI 10.1093/infdis/jis432
   Taiwo B, 2010, J ANTIMICROB CHEMOTH, V65, P1100, DOI 10.1093/jac/dkq096
   Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o
   Wang T, 2009, J MED CHEM, V52, P7778, DOI 10.1021/jm900843g
   Wang T, 2009, BIOORG MED CHEM LETT, V19, P5140, DOI 10.1016/j.bmcl.2009.07.076
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Yeung K.-S., 2012, BIOORG MED IN PRESS, P22
   Wallace O.B., 2003, U.S. Patent, Patent No. [6,573,262, 6573262]
NR 28
TC 14
Z9 14
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 1
PY 2013
VL 23
IS 1
BP 203
EP 208
DI 10.1016/j.bmcl.2012.10.117
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 053JO
UT WOS:000312267700035
PM 23200249
DA 2018-01-05
ER

PT J
AU Kesteleyn, B
   Amssoms, K
   Schepens, W
   Hache, G
   Verschueren, W
   Van De Vreken, W
   Rombauts, K
   Meurs, G
   Sterkens, P
   Stoops, B
   Baert, L
   Austin, N
   Wegner, J
   Masungi, C
   Dierynck, I
   Lundgren, S
   Jonsson, D
   Parkes, K
   Kalayanov, G
   Wallberg, H
   Rosenquist, A
   Samuelsson, B
   Van Emelen, K
   Thuring, JW
AF Kesteleyn, Bart
   Amssoms, Katie
   Schepens, Wim
   Hache, Geerwin
   Verschueren, Wim
   Van De Vreken, Wim
   Rombauts, Klara
   Meurs, Greet
   Sterkens, Patrick
   Stoops, Bart
   Baert, Lieven
   Austin, Nigel
   Wegner, Jorg
   Masungi, Chantal
   Dierynck, Inge
   Lundgren, Stina
   Jonsson, Daniel
   Parkes, Kevin
   Kalayanov, Genadiy
   Wallberg, Hans
   Rosenquist, Asa
   Samuelsson, Bertil
   Van Emelen, Kristof
   Thuring, Jan Willem
TI Design and synthesis of HIV-1 protease inhibitors for a long-acting
   injectable drug application
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV/AIDS; HIV Protease; Protease inhibitor; Long-acting formulation;
   Nanosuspension
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HYDROXYETHYLENE DIPEPTIDE ISOSTERES;
   ANTIVIRAL ACTIVITY; POTENT; ANALOGS; RESISTANCE; ADHERENCE; THERAPY
AB The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R-3) at the para-position of the P1' benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R-1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC(50)s on wildtype HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Kesteleyn, Bart; Amssoms, Katie; Schepens, Wim; Hache, Geerwin; Verschueren, Wim; Van De Vreken, Wim; Rombauts, Klara; Meurs, Greet; Sterkens, Patrick; Stoops, Bart; Baert, Lieven; Austin, Nigel; Wegner, Jorg; Masungi, Chantal; Dierynck, Inge; Van Emelen, Kristof; Thuring, Jan Willem] Janssen Infect Dis, B-2340 Beerse, Belgium.
   [Lundgren, Stina; Jonsson, Daniel; Parkes, Kevin; Kalayanov, Genadiy; Wallberg, Hans; Rosenquist, Asa; Samuelsson, Bertil] Medivir AB, SE-14122 Huddinge, Sweden.
RP Kesteleyn, B (reprint author), Janssen Infect Dis, Turnhoutseweg 30, B-2340 Beerse, Belgium.
EM bkestele@its.jnj.com
CR ALTERI E, 1993, ANTIMICROB AGENTS CH, V37, P2087, DOI 10.1128/AAC.37.10.2087                                                          
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
   Bold G, 1998, J MED CHEM, V41, P3387, DOI 10.1021/jm970873c
   Capraro HG, 1996, ARCH PHARM, V329, P273, DOI 10.1002/ardp.19963290602
   Cheng Y, 2002, BIOORG MED CHEM LETT, V12, P2419, DOI 10.1016/S0960-894X(02)00424-9
   Cozens RM, 1996, ANTIVIR CHEM CHEMOTH, V7, P294, DOI 10.1177/095632029600700602                                                      
   DAVIS FA, 1990, J ORG CHEM, V55, P3715, DOI 10.1021/jo00299a007
   Elan Drug Technologies, 2008, NAN TECHN TECHN FOC
   EVANS BE, 1985, J ORG CHEM, V50, P4615, DOI 10.1021/jo00223a037
   Fogarty L, 2002, PATIENT EDUC COUNS, V46, P93, DOI 10.1016/S0738-3991(01)00219-1
   GHOSH AK, 1991, J ORG CHEM, V56, P6500, DOI 10.1021/jo00023a009
   HUNGATE RW, 1991, TETRAHEDRON LETT, V32, P6851, DOI 10.1016/0040-4039(91)80423-4                                                    
   Johnson Victoria A, 2011, Top Antivir Med, V19, P156
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Kuppens Tom, 2004, Drug Discov Today Technol, V1, P269, DOI 10.1016/j.ddtec.2004.11.004
   LIN JH, 1992, J PHARMACOL EXP THER, V263, P105
   LYLE TA, 1991, J MED CHEM, V34, P1228, DOI 10.1021/jm00107a051                                                             
   Martinez-Cajas JL, 2007, ANTIVIR RES, V76, P203, DOI 10.1016/j.antiviral.2007.06.010
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rathbun CR, 2005, CLIN THER, V27, P199
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   THOMPSON WJ, 1992, J MED CHEM, V35, P1685, DOI 10.1021/jm00088a003                                                             
   Tsantrizos YS, 2008, ACCOUNTS CHEM RES, V41, P1252, DOI 10.1021/ar8000519
   VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050
   Degoey D. A., 2005, U.S. Patent, Patent No. [U.S. 20,050,148,623, 20050148623]
NR 26
TC 6
Z9 6
U1 2
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 1
PY 2013
VL 23
IS 1
BP 310
EP 317
DI 10.1016/j.bmcl.2012.10.095
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 053JO
UT WOS:000312267700057
PM 23177258
DA 2018-01-05
ER

PT J
AU Connell, BJ
   Lortat-Jacob, H
AF Connell, Bridgette J.
   Lortat-Jacob, Hugues
TI Human immunodeficiency virus and heparan sulfate: from attachment to
   entry inhibition
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE heparan sulfate; glycosaminoglycan; CCR5/CXCR4; gp120; V3 loop;
   co-receptor binding site; HIV-1; attachment and entry inhibition
AB By targeting cells that provide protection against infection, HIV-1 causes acquired immunodeficiency syndrome. Infection starts when gp120, the viral envelope glycoprotein, binds to CD4 and to a chemokine receptor usually CCR5 or CXCR4. As many microorganisms, HIV-1 also interacts with heparan sulfate (HS), a complex group of cell surface associated anionic polysaccharides. It has been thought that this binding, occurring at a step prior to CD4 recognition, increases infectivity by pre-concentrating the virion particles at the cell surface. Early work, dating from before the identification of CCR5 and CXCR4, showed that a variety of HS mimetics bind to the gp120 V3 loop through electrostatic interactions, compete with cell surface associated HS to bind the virus and consequently, neutralize the infectivity of a number of T-cell line-adapted HIV-1 strains. However, progress made to better understand HIV-1 attachment and entry, coupled with the recent identification of additional gp120 regions mediating HS recognition, have considerably modified this view. Firstly, theV3 loop from CXCR4-using viruses is much more positively charged compared to those using CCR5. HS inhibition of cell attachment is thus restricted to CXCR4-using viruses (such as T-cell line-adapted HIV-1). Secondly, studies aiming at characterizing the gp120/HS complex revealed that HS binding was far more complex than previously thought: in addition to the V3 loop of CXCR4 tropic gp120, HS interacts with several other cryptic areas of the protein, which can be induced upon CD4 binding, and are conserved amongst CCR5 and CXCR4 viruses. In view of these data, this review will detail the present knowledge on HS binding to HIV-1, with regards to attachment and entry processes. It will discuss the perspective of targeting the gp120 co-receptor binding site with HS mimetic compounds, a strategy that recently gave rise to entry inhibitors that work in the low nanomolar range, independently of co-receptor usage.
C1 [Connell, Bridgette J.; Lortat-Jacob, Hugues] Univ Grenoble Alpes, Inst Biol Struct, Grenoble, France.
   [Connell, Bridgette J.; Lortat-Jacob, Hugues] CNRS, Inst Biol Struct, Grenoble, France.
   [Connell, Bridgette J.; Lortat-Jacob, Hugues] CEA, Direct Sci Vivant, Inst Biol Struct, Grenoble, France.
RP Lortat-Jacob, H (reprint author), Inst Biol Struct, 71 Ave Martyrs, F-38000 Grenoble, France.
EM hugues.lortat-jacob@ibs.fr
FU Agence National de la Recherche sur le SIDA (ANRS), Sidaction; Agence
   Nationale de la Recherche [ANR-10-EMMA-0012]
FX Our research described in this review was supported by the Agence
   National de la Recherche sur le SIDA (ANRS), Sidaction, and the Agence
   Nationale de la Recherche (ANR-10-EMMA-0012 grant). We apologize for
   failing to cite work that may have been relevant but was omitted due to
   space limitations. The authors thank K. Arien and G. Vanham for helpful
   discussions, and their collaborators (F. Arenzana-Seisdedos, F. Baleux,
   D. Bonnaffe, P. Clayette, E. Crublet, Q. Sattentau, and R. Vives) that
   have, in one way or another, contributed to the research described here.
CR Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003
   BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742                                                          
   Baleux F, 2009, NAT CHEM BIOL, V5, P743, DOI 10.1038/nchembio.207
   Banks WA, 2004, NEUROSCIENCE, V128, P143, DOI 10.1016/j.neuroscience.2004.06.021
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bartlett AH, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001367
   Bartolini B, 2003, ANTIVIR RES, V58, P139, DOI 10.1016/S0166-3542(02)00209-7                                                   
   Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI [10.1128/JVI.76.21.10791-10800.2002, DOI 10.1128/JVI.76.21.10791-10800.2002]
   Basu A, 2007, J VIROL, V81, P3933, DOI 10.1128/JVI.02622-06
   BATINIC D, 1992, J BIOL CHEM, V267, P6664
   Bear JS, 2006, VIROLOGY, V347, P183, DOI 10.1016/j.virol.2005.11.034
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bobardt MD, 2004, J VIROL, V78, P6567, DOI 10.1128/JVI.78.12.6567-6584.2004
   Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6                                                   
   Bobardt MD, 2007, J VIROL, V81, P395, DOI 10.1128/JVI.01303-06
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   Bomsel M, 2003, NAT REV MOL CELL BIO, V4, P57, DOI 10.1038/nrm1005
   Bucior I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002616
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   Ceballos A, 2009, J EXP MED, V206, P2717, DOI 10.1084/jem.20091579
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Connell BJ, 2012, CHEM BIOL, V19, P131, DOI 10.1016/j.chembiol.2011.12.009
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   Crublet E, 2008, J BIOL CHEM, V283, P15193, DOI 10.1074/jbc.M800066200
   Cruz L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068379
   Duchesne L, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001361
   Fadnes B, 2012, GLYCOCONJUGATE J, V29, P513, DOI 10.1007/s10719-012-9427-9
   FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544                                                          
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x
   Germi R, 2002, J MED VIROL, V68, P206, DOI 10.1002/jmv.10196
   Goetz R, 2013, NAT REV MOL CELL BIO, V14, P166, DOI 10.1038/nrm3528
   Greiner VJ, 2011, BIOCHIMIE, V93, P1647, DOI 10.1016/j.biochi.2011.05.033
   Harrop HA, 1998, GLYCOBIOLOGY, V8, P131, DOI 10.1093/glycob/8.2.131
   Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171                                                         
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hu YP, 2011, NAT CHEM, V3, P557, DOI 10.1038/nchem.1073
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Hulst MM, 2000, J VIROL, V74, P9553, DOI 10.1128/JVI.74.20.9553-9561.2000
   Ibrahim J, 1999, VIRUS RES, V60, P159, DOI 10.1016/S0168-1702(99)00018-0
   ITO M, 1987, ANTIVIR RES, V7, P361, DOI 10.1016/0166-3542(87)90018-0
   Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005
   Kalia M, 2009, J VIROL, V83, P12714, DOI 10.1128/JVI.00717-09
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Klimstra WB, 1998, J VIROL, V72, P7357
   Kobayashi K, 2010, J BIOL CHEM, V285, P1716, DOI 10.1074/jbc.M109.021576
   Kreuger J, 2012, J HISTOCHEM CYTOCHEM, V60, P898, DOI 10.1369/0022155412464972
   Kumar RB, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-25
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lambert S, 2009, BLOOD, V113, P5176, DOI 10.1182/blood-2008-04-150342
   Lebrun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032421
   Lee E, 2006, ANTIVIR RES, V69, P31, DOI 10.1016/j.antiviral.2005.08.006
   Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4
   Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Longarela OL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058340
   Lortat-Jacob H, 1996, J BIOL CHEM, V271, P16139, DOI 10.1074/jbc.271.27.16139                                                        
   Lortat-Jacob H, 2009, CURR OPIN STRUC BIOL, V19, P543, DOI 10.1016/j.sbi.2009.09.003
   Mandl CW, 2001, J VIROL, V75, P5627, DOI 10.1128/JVI.75.12.5627-5637.2001
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Mulloy B, 2012, HDB EXP PHARM, V207, P77, DOI DOI 10.1007/978-3-642-23056-1_5
   Nazli A, 2013, J IMMUNOL, V191, P4246, DOI 10.4049/jimmunol.1301482
   Norman MU, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000169
   Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x                                              
   PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Poiesi C, 2008, VIRUS RES, V132, P25, DOI 10.1016/j.virusres.2007.10.006
   Qu XX, 2012, DEVELOPMENT, V139, P2730, DOI 10.1242/dev.079236
   RIDER CC, 1994, BIOCHEMISTRY-US, V33, P6974, DOI 10.1021/bi00188a029
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   RODERIQUEZ G, 1995, J VIROL, V69, P2233
   Rueda P, 2012, CIRCULATION, V126, P1882, DOI 10.1161/CIRCULATIONAHA.112.113290
   Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200
   Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029
   Saidi H, 2009, AIDS RES HUM RETROV, V25, P497, DOI 10.1089/aid.2008.0156
   Salanga CL, 2011, EXP CELL RES, V317, P590, DOI 10.1016/j.yexcr.2011.01.004
   Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001
   Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952
   Sarris M, 2012, CURR BIOL, V22, P2375, DOI 10.1016/j.cub.2012.11.018
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shaw G, 2012, COLD SPRING HARB PER, V2, DOI DOI 10.1101/CSHPERSPECT.A006965
   Sherer NM, 2010, J VIROL, V84, P3248, DOI 10.1128/JVI.02155-09
   Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6                                                   
   Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x
   Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1                                                   
   Sureau C, 2013, HEPATOLOGY, V57, P985, DOI 10.1002/hep.26125
   Tilton JC, 2010, ANTIVIR RES, V85, P91, DOI 10.1016/j.antiviral.2009.07.022
   Tiwari V, 2012, GLYCOBIOLOGY, V22, P1402, DOI 10.1093/glycob/cws106
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Urbinati C, 2008, MOLECULES, V13, P2758, DOI 10.3390/molecules13112758
   Vidricaire G, 2007, J INFECT DIS, V195, P1461, DOI 10.1086/515576
   Vives RR, 2006, CURR GENE THER, V6, P35, DOI 10.2174/156652306775515565                                                      
   Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200
   Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200
   Walker SJ, 2002, J VIROL, V76, P6909, DOI 10.1128/JVI.76.14.69069-6918.2002
   Weiss RA, 2002, IUBMB LIFE, V53, P201, DOI 10.1080/15216540290098927
   Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982
   Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0
   Wu ZW, 2003, J INFECT DIS, V188, P1473, DOI 10.1086/379248                                                                  
NR 104
TC 35
Z9 36
U1 3
U2 11
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2013
VL 4
AR UNSP 385
DI 10.3389/fimmu.2013.00385
PG 12
WC Immunology
SC Immunology
GA V38WS
UT WOS:000209374100375
PM 24312095
OA gold
DA 2018-01-05
ER

PT J
AU Xu, G
   Mahajan, S
   Roy, I
   Yong, KT
AF Xu, Gaixia
   Mahajan, Supriya
   Roy, Indrajit
   Yong, Ken-Tye
TI Theranostic quantum dots for crossing blood brain barrier in vitro and
   providing therapy of HIV-associated encephalopathy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE theranostic quantum dots; HIV-associated encephalopathy; in vitro blood
   brain barrier model; nanomedicine; drug delivery
ID SEMICONDUCTOR NANOCRYSTALS; P-GLYCOPROTEIN; DRUG-DELIVERY; MODEL;
   PERMEABILITY; CELLS; CNS; NANOPARTICLES; DISORDERS; CHEMISTRY
AB The blood brain barrier (BBB) is a complex physiological checkpoint that restricts the free diffusion of circulating molecules from the blood into the central nervous system. Delivering of drugs and other active agents across the BBB is one of the major technical challenges faced by scientists and medical practitioners. Therefore, development of novel methodologies to address this challenge holds the key for both the diagnosis and treatment of brain diseases, such as HIV-associated encephalopathy. Bioconjugated quantum dots (QDs) are excellent fluorescent probes and nano-vectors, being designed to transverse across the BBB and visualize drug delivery inside the brain. This paper discusses the use of functionalized QDs for crossing the blood brain barrier and treating brain disease. We highlight the guidelines for using in vitro BBB models for brain disease studies. The theranostic QDs offers a strategy to significantly improve the effective dosages of drugs to transverse across the BBB and orientate to the targets inside the brain.
C1 [Xu, Gaixia] Shenzhen Univ, Coll Optoelect Engn, Key Lab Optoelect Dev & Syst, Minist Educ, Shenzhen, Guangdong, Peoples R China.
   [Mahajan, Supriya] SUNY Buffalo, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY USA.
   [Roy, Indrajit] Univ Delhi, Dept Chem, New Delhi, India.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore.
RP Yong, KT (reprint author), Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore.
EM ktyong@ntu.edu.sg
FU National Basic Research Program of China [2012CB85802]; National Natural
   Science Foundation of China [61235012]; Technological and Scientific
   Innovation Project of Guangdong Educational Commission [2012KJCX0094]
FX This research was supported by National Basic Research Program of China
   (2012CB85802), National Natural Science Foundation of China (61235012),
   and Technological and Scientific Innovation Project of Guangdong
   Educational Commission (2012KJCX0094),
CR Abbott NJ, 2012, EPILEPSIA, V53, P1, DOI 10.1111/j.1528-1167.2012.03696.x
   Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x                                                
   Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Banks WA, 1999, J NEUROVIROL, V5, P538, DOI 10.3109/13550289909021284                                                       
   Banks WA, 2006, CURR HIV RES, V4, P259, DOI 10.2174/157016206777709447                                                      
   Berger JR, 2004, FRONT BIOSCI, V9, P2680, DOI 10.2741/1427
   Bharali DJ, 2005, J AM CHEM SOC, V127, P11364, DOI 10.1021/ja051455x
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   BRADBURY MWB, 1993, EXP PHYSIOL, V78, P453, DOI 10.1113/expphysiol.1993.sp003698                                                
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Cucullo L, 2005, CURR OPIN DRUG DISC, V8, P89
   Cucullo L, 2002, BRAIN RES, V951, P243, DOI 10.1016/S0006-8993(02)03167-0                                                   
   Cucullo L, 2011, J CEREBR BLOOD F MET, V31, P767, DOI 10.1038/jcbfm.2010.162
   Davis SS, 1997, TRENDS BIOTECHNOL, V15, P217, DOI 10.1016/S0167-7799(97)01036-6                                                   
   de Lange ECM, 2012, CURR PHARM BIOTECHNO, V13, P2319
   Erickson MA, 2012, NEUROIMMUNOMODULAT, V19, P121, DOI 10.1159/000330247
   Erogbogbo F, 2008, ACS NANO, V2, P873, DOI 10.1021/nn700319z
   Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69
   Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071                                                               
   Hardman R, 2006, ENVIRON HEALTH PERSP, V114, P165, DOI 10.1289/ehp.8284
   Hedi M., 2000, J AM CHEM SOC, V122, P12142, DOI [10.1021/ia002535y, DOI 10.1021/JA002535Y]
   Hilderbrand SA, 2010, CURR OPIN CHEM BIOL, V14, P71, DOI 10.1016/j.cbpa.2009.09.029
   Jain KK, 2012, NANOMEDICINE-UK, V7, P1225, DOI 10.2217/nnm.12.86
   JOO F, 1993, NEUROCHEM INT, V23, P499, DOI 10.1016/0197-0186(93)90098-P
   Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077
   Kubitschko S, 1997, ANAL BIOCHEM, V253, P112, DOI 10.1006/abio.1997.2337                                                          
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Liu LW, 2013, ANALYST, V138, P6144, DOI 10.1039/c3an01030a
   Lucey DW, 2005, CHEM MATER, V17, P3754, DOI 10.1021/cm050110a
   Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23
   Mahajan SD, 2012, METHOD ENZYMOL, V509, P41, DOI 10.1016/B978-0-12-391858-1.00003-4
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Mukhtar M, 2000, J HUMAN VIROL, V3, P324
   Naik P, 2012, J PHARM SCI-US, V101, P1337, DOI 10.1002/jps.23022
   Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126
   Pardridge WM, 2012, METHOD ENZYMOL, V503, P269, DOI 10.1016/B978-0-12-396962-0.00011-2
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Pinaud F, 2010, NAT METHODS, V7, P275, DOI [10.1038/NMETH.1444, 10.1038/nmeth.1444]
   Prasad P. N., 2004, INTRO BIOPHOTONICS, DOI [10.1002/0471465380, DOI 10.1002/0471465380]
   Qian J, 2007, J PHYS CHEM B, V111, P6969, DOI 10.1021/jp070620n
   RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725
   Santaguida S, 2006, BRAIN RES, V1109, P1, DOI 10.1016/j.brainres.2006.06.027
   Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4
   Stanness KA, 1996, NEUROTOXICOLOGY, V17, P481
   Stanness KA, 1999, NEUROREPORT, V10, P3725, DOI 10.1097/00001756-199912160-00001
   Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015
   Sun HY, 2003, ADV DRUG DELIVER REV, V55, P83, DOI 10.1016/S0169-409X(02)00172-2                                                   
   Titus MA, 1999, CELL MOL LIFE SCI, V56, P181, DOI 10.1007/s000180050420
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u                                                               
   Uyeda HT, 2005, J AM CHEM SOC, V127, P3870, DOI 10.1021/ja044031w
   Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022
   Won H. S., 2009, PROG NEUROBIOL, V87, P133, DOI [10.1016/j.pneurobio.2008.09.009, DOI 10.1016/J.PNEUROBIO.2008.09.009]
   Xu G, 2008, BIOCONJUGATE CHEM, V19, P1179, DOI 10.1021/bc700477u
   Xu YX, 2011, CHEM COMMUN, V47, P1524, DOI 10.1039/c0cc03501g
   Yong KT, 2010, INTEGR BIOL-UK, V2, P121, DOI 10.1039/b916663g
   Yong KT, 2009, J MATER CHEM, V19, P4655, DOI 10.1039/b817667c
   Yong KT, 2009, ACS NANO, V3, P502, DOI 10.1021/nn8008933
NR 63
TC 19
Z9 21
U1 3
U2 31
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PY 2013
VL 4
AR 140
DI 10.3389/fphar.2013.00140
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AX6CS
UT WOS:000347011700138
PM 24298256
OA gold
DA 2018-01-05
ER

PT J
AU Knopik-Skrocka, A
   Sniegowska, A
AF Knopik-Skrocka, Agnieszka
   Sniegowska, Agata
TI PARTICIPATION OF MEMBRANE NANOTUBES IN INTERCELLULAR COMMUNICATION
SO POSTEPY BIOLOGII KOMORKI
LA Polish
DT Article
DE membrane nanotubes; intercellular communication; organelle transport;
   signal transduction; transmission of pathogens
AB A few years ago a so far unknown type of intercellular connections between animal cells, involved in their communication was discovered. Due to its specific nano-architecture, these connections were named tunneling nanotubes or membrane nanotubes. Nanotubes ensure the transfer of both membrane and cytosolic cellular components, including organelles. They also participate in calcium signal transduction and apoptosis signal. The length of the distance at which cells contact via nano tubes reaches several hundred micrometers. The published data suggest that nanotubes have heterogenous structure. Among them, there are nanotubes which provide direct contact of the cytoplasm in connected cells (open-ended structure), and those, in which the transport requires overcoming a barrier, which is the cell membrane (close-ended structure). An important finding in the study of membrane nanotubes was demonstrating the ability of these connections of the transmission of pathogens, such as HIV, or abnormal form of PrP prion protein. In addition, nanotubes mediate a transport of MDR protein, involved in resistance of cancer cells to chemotherapy. It means that this type of cell connection may play an important role in the pathomechanism of AIDS, prion as well as cancer diseases.
C1 [Knopik-Skrocka, Agnieszka; Sniegowska, Agata] Uniwersytet Adama Mickiewicza Poznaniu, Zaklad Biol Komorki, Inst Biol Eksperymentalnej, Poznan, Poland.
RP Knopik-Skrocka, A (reprint author), Adam Mickiewicz Univ, Zaklad Biol Komorki, Inst Biol Eksperymentalnej, Ul Umultowska 89, PL-61614 Poznan, Poland.
EM askro@amu.edu.pl
CR Abel MP, 2011, BIOINTERPHASES, V6, P22, DOI 10.1116/1.3567416
   Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279
   Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009
   Arkwright PD, 2010, CELL RES, V20, P72, DOI 10.1038/cr.2009.112
   Baluska F, 2004, TRENDS CELL BIOL, V14, P404, DOI 10.1016/j.tcb.2004.07.001
   Belting M, 2008, J CELL BIOL, V183, P1187, DOI 10.1083/jcb.200810038
   Brundin P, 2010, NAT REV MOL CELL BIO, V11, P301, DOI 10.1038/nrm2873
   Bukoreshtliev NV, 2009, FEBS LETT, V583, P1481, DOI 10.1016/j.febslet.2009.03.065
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Cselenyak A, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-29
   Daubeuf S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008716
   Domhan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021283
   Dubey GP, 2011, CELL, V144, P590, DOI 10.1016/j.cell.2011.01.015
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Goligorsky MS, 2009, CURR OPIN HEMATOL, V16, P215, DOI 10.1097/MOH.0b013e32832a07bd
   Gongadze E, 2011, INT J NANOMED, V6, P1801, DOI 10.2147/IJN.S21755
   Gordon-Alonso M, 2010, CELL HEALTH CYTOSKEL, V2, P33
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Guescini M, 2012, EXP CELL RES, V318, P603, DOI 10.1016/j.yexcr.2012.01.005
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   He KM, 2011, CARDIOVASC RES, V92, P39, DOI 10.1093/cvr/cvr189
   He KM, 2010, ACS NANO, V4, P3015, DOI 10.1021/nn1002198
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Hodneland E, 2006, CYTOM PART A, V69A, P961, DOI 10.1002/cyto.a.20302
   Hurtig J., 2010, REV NANOMED NANOBIOT, V2, P260
   Kabaso D, 2012, BIOELECTROCHEMISTRY, V87, P204, DOI 10.1016/j.bioelechem.2012.02.009
   Kabaso D, 2012, J BIOMECH, V45, P231, DOI 10.1016/j.jbiomech.2011.10.039
   Kadiu I, 2011, J NEUROIMMUNE PHARM, V6, P658, DOI 10.1007/s11481-011-9298-z
   Kadiu I, 2011, J PROTEOME RES, V10, P3225, DOI 10.1021/pr200262q
   Kimura S, 2012, EXP CELL RES, V318, P1699, DOI 10.1016/j.yexcr.2012.05.013
   Langevin C, 2010, BIOCHEM J, V431, P189, DOI 10.1042/BJ20100698
   Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3
   Lokar M, 2012, INT J NANOMED, V7, P1891, DOI 10.2147/IJN.S28723
   Lokar M, 2010, PROTOPLASMA, V246, P81, DOI 10.1007/s00709-010-0143-7
   Lou Emil, 2012, Commun Integr Biol, V5, P399, DOI 10.4161/cib.20569
   Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093
   Luchetti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035766
   Marzo L, 2012, FRONT PHYSIOL, V3, P1
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   McGowan M., 2011, J CELL MOL BIOL, V9, P11
   Mi L., 2011, J BIOMATER NANOBIOTE, V2, P173
   Nakamura K, 2011, J BIOL CHEM, V286, P20710, DOI 10.1074/jbc.M110.213538
   Niu XL, 2009, J CELL SCI, V122, P600, DOI 10.1242/jcs.031427
   Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Pasquier J, 2012, J BIOL CHEM, V287, P7374, DOI 10.1074/jbc.M111.312157
   Pasquier J, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-5
   Patschan S, 2008, AM J PHYSIOL-RENAL, V294, pF100, DOI 10.1152/ajprenal.00261.2007
   Plotnikov EY, 2010, EXP CELL RES, V316, P2447, DOI 10.1016/j.yexcr.2010.06.009
   Rechavi O, 2009, FEBS LETT, V583, P1792, DOI 10.1016/j.febslet.2009.03.014
   Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010
   Roda-Navarro P, 2007, FASEB J, V21, P1636, DOI 10.1096/fj.06-7488rev
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Rustom A, 2009, ANN NY ACAD SCI, V1178, P129, DOI 10.1111/j.1749-6632.2009.04997.x
   Schiller C, 2013, HUM IMMUNOL, V74, P412, DOI 10.1016/j.humimm.2012.11.026
   Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416,9.1.105
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Simons K, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004697
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Smith IF, 2011, BIOPHYS J, V100, pL37, DOI 10.1016/j.bpj.2011.03.007
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Sowinski S, 2011, METHODS, V53, P27, DOI 10.1016/j.ymeth.2010.04.002
   Stinchcombe JC, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-45
   Su B, 2008, CURR ALZHEIMER RES, V5, P525, DOI 10.2174/156720508786898451                                                      
   Takahashi A, 2013, J CELL BIOCHEM, V114, P1238, DOI 10.1002/jcb.24433
   Veranic P, 2008, BIOPHYS J, V95, P4416, DOI 10.1529/biophysj.108.131375
   Wang XL, 2010, J APPL PHYS, V107, DOI 10.1063/1.3358007
   Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147
   Wang ZG, 2012, ACS NANO, V6, P10033, DOI 10.1021/nn303729r
   Wittig D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033195
   Yao J, 2009, AM J PHYSIOL-RENAL, V296, pF939, DOI 10.1152/ajprenal.90612.2008
   Yasuda K, 2011, AGING-US, V3, P597, DOI 10.18632/aging.100341                                                           
   Yasuda K, 2010, AM J PATHOL, V176, P1685, DOI 10.2353/ajpath.2010.091071
   Zani BG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008930
   Zhao HX, 2011, CURR OPIN CELL BIOL, V23, P14, DOI 10.1016/j.ceb.2010.10.005
NR 80
TC 0
Z9 0
U1 0
U2 0
PU POLSKIE TOWARZYSTWO ANATOMICZNE
PI WARSAW
PA CENTRUM MEDYCZNE KSZTALCENIA PODYPLOMOWEGO, UL. MARYMONCKA 99, WARSAW,
   POLAND
SN 0324-833X
EI 2080-2218
J9 POSTEPY BIOL KOMORKI
JI Postepy Biol. Komorki
PY 2013
VL 40
IS 2
BP 321
EP 343
PG 23
WC Biology; Cell Biology
SC Life Sciences & Biomedicine - Other Topics; Cell Biology
GA V45PM
UT WOS:000209828500009
DA 2018-01-05
ER

PT J
AU das Neves, J
   Sarmento, B
   Amiji, M
   Bahia, MF
AF das Neves, Jose
   Sarmento, Bruno
   Amiji, Mansoor
   Bahia, Maria Fernanda
TI Development and validation of a HPLC method for the assay of dapivirine
   in cell-based and tissue permeability experiments
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Microbicides; Liquid chromatography; Box-Behnken design; Method
   validation; Polymeric nanoparticles; Diphenylamine
ID REVERSE-TRANSCRIPTASE INHIBITORS; IN-VITRO EVALUATION; VAGINAL
   MICROBICIDE; POLYMERIC NANOPARTICLES; INTRAVAGINAL RING; HIV
   MICROBICIDE; OPTIMIZATION; DELIVERY; TMC120; SAFETY
AB Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is being currently used for the development of potential anti-HIV microbicide formulations and delivery systems. A new high-performance liquid chromatography (HPLC) method with UV detection was developed for the assay of this drug in different biological matrices, namely cell lysates, receptor media from permeability experiments and homogenates of mucosal tissues. The method used a reversed-phase C18 column with a mobile phase composed of trifluoroacetic acid solution (0.1%, v/v) and acetonitrile in a gradient mode. Injection volume was 50 mu L and the flow rate 1 mL/min. The total run time was 12 min and UV detection was performed at 290 nm for dapivirine and the internal standard (IS) diphenylamine. A Box-Behnken experimental design was used to study different experimental variables of the method, namely the ratio of the mobile phase components and the gradient time, and their influence in responses such as the retention factor, tailing factor, and theoretical plates for dapivirine and the IS, as well as the peak resolution between both compounds. The optimized method was further validated and its usefulness assessed for in vitro and ex vivo experiments using dapivirine or dapivirine-loaded nanoparticles. The method showed to be selective, linear, accurate and precise in the range of 0.02-1.5 mu g/mL. Other chromatographic parameters, namely carry-over, lower limit of quantification (0.02 mu g/mL), limit of detection (0.006 mu g/mL), recovery (equal or higher than 90.7%), and sample stability at different storage conditions, were also determined and found adequate for the intended purposes. The method was successfully used for cell uptake assays and permeability studies across cell monolayers and pig genital mucosal tissues. Overall, the proposed method provides a simple, versatile and reliable way for studying the behavior of dapivirine in different biological matrices and assessing its potential as an anti-HIV microbicide drug. (C) 2012 Elsevier B.V. All rights reserved.
C1 [das Neves, Jose; Sarmento, Bruno; Bahia, Maria Fernanda] Univ Porto, Fac Pharm, Lab Pharmaceut Technol, LTF CICF, P-4050313 Oporto, Portugal.
   [das Neves, Jose; Sarmento, Bruno] CESPU, Inst Super Ciencias Saude N, Dept Pharmaceut Sci, CICS, P-4585116 Gandra, Portugal.
   [Sarmento, Bruno] NEWTherapies Grp, INEB Inst Engn Biomed, P-4150180 Oporto, Portugal.
   [Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP das Neves, J (reprint author), Univ Porto, Fac Pharm, Lab Pharmaceut Technol, LTF CICF, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.
EM j.dasneves@gmail.com
RI das Neves, Jose/J-8369-2013; Sarmento, Bruno/J-6265-2013; Amiji,
   Mansoor/A-4365-2014
OI das Neves, Jose/0000-0002-2317-2759; Sarmento,
   Bruno/0000-0001-5763-7553; Amiji, Mansoor/0000-0001-6170-881X
FU Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BD/43393/2008]
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia, Portugal for financial support (grant SFRH/BD/43393/2008).
   The authors express their gratitude to Marta Salgueirinho at Carneiro &
   Salgueirinho, Lda., Trofa, Portugal, for providing pig vaginal and
   rectal mucosa samples.
CR Akil A., 2012, 2012 INT MICR C SYDN
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Awotwe-Otoo D, 2012, J PHARMACEUT BIOMED, V62, P61, DOI 10.1016/j.jpba.2012.01.002
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   de Aragdo NM, 2005, TALANTA, V67, P1007, DOI 10.1016/j.talanta.2005.04.066
   European Medicines Agency, 2011, GUID BIOAN METH VAL
   Ferreira SLC, 2007, ANAL CHIM ACTA, V597, P179, DOI 10.1016/j.aca.2007.07.011
   Food and Drug Administration, 2001, GUID IND BIOAN METH
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gupta J, 2011, CURR PHARM ANAL, V7, P21, DOI 10.2174/157341211794708703                                                      
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   International Partnership for Microbicides, 1 EFF TRIAL MICR RIN
   Jespers VA, 2007, JAIDS-J ACQ IMM DEF, V44, P154, DOI 10.1097/QAI.0b013e31802bb35f
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   LoBrutto R., 2007, HPLC PHARM SCI, P455
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   Microbicide Trials Network, ASPIRE STUD PREV INF
   Nel AA, 2009, AIDS, V23, P1531, DOI 10.1097/QAD.0b013e32832c413d
   Nel AM, 2010, JAIDS-J ACQ IMM DEF, V55, P161, DOI 10.1097/QAI.0b013e3181e3293a
   Neue UD, 2005, J CHROMATOGR A, V1063, P35, DOI 10.1016/j.chroma.2004.11.096
   Nuttall JP, 2008, ANTIMICROB AGENTS CH, V52, P909, DOI 10.1128/AAC.00330-07
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Shin HS, 2002, J CHROMATOGR B, V769, P177, DOI 10.1016/S1570-0232(02)00007-7
   Sonnergaard JM, 2006, INT J PHARM, V321, P12, DOI 10.1016/j.ijpharm.2006.06.001
   Torrens M, 1998, DRUG ALCOHOL DEPEN, V52, P193, DOI 10.1016/S0376-8716(98)00096-9                                                   
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Vidal J., 1999, ANAL CHEM, V71, P2672
   Woolfson AD, 2010, INT J PHARMACEUT, V388, P136, DOI 10.1016/j.ijpharm.2009.12.042
   Zhou Y, 2009, J CHROMATOGR A, V1216, P7013, DOI 10.1016/j.chroma.2009.08.058
NR 36
TC 9
Z9 9
U1 0
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD DEC 12
PY 2012
VL 911
BP 76
EP 83
DI 10.1016/j.jchromb.2012.10.034
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 057ON
UT WOS:000312573000013
PM 23217310
DA 2018-01-05
ER

PT J
AU Zheng, J
   Jiao, AL
   Yang, RH
   Li, HM
   Li, JS
   Shi, ML
   Ma, C
   Jiang, Y
   Deng, L
   Tan, WH
AF Zheng, Jing
   Jiao, Anli
   Yang, Ronghua
   Li, Huimin
   Li, Jishan
   Shi, Muling
   Ma, Cheng
   Jiang, Ying
   Deng, Li
   Tan, Weihong
TI Fabricating a Reversible and Regenerable Raman-Active Substrate with a
   Biomolecule-Controlled DNA Nanomachine
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID SURFACE-ENHANCED RAMAN; SERS HOT-SPOTS; SINGLE-MOLECULE; GOLD
   NANOPARTICLES; SPECTROSCOPY; SCATTERING; SILVER; APTAMER;
   OLIGONUCLEOTIDES; AMPLIFICATION
AB A DNA configuration switch is designed to fabricate a reversible and regenerable Raman-active substrate. The substrate is composed of a Au film and a hairpin-shaped DNA strand (hot-spot-generation probes, HSGPs) labeled with dye-functionalized silver nanoparticles (AgNPs). Another ssDNA that recognizes a specific trigger is used as an antenna. The HSGPs are immobilized on the Au film to draw the dye-functionalized AgNPs close to the Au surface and create an intense electromagnetic field. Hybridization of HSGP with the two arm segments of the antenna forms a triplex-stem structure to separate the dye-functionalized AgNPs from the Au surface, quenching the Raman signal. Interaction with its trigger releases the antenna from the triplex-stem structure, and the hairpin structure of the HSGP is restored, creating an effective "off-on" Raman signal switch. Nucleic acid sequences associated with the HIV-1 US long terminal repeat sequences and ATP are used as the triggers. The substrate shows excellent reversibility, reproducibility, and controllability of surface-enhanced Raman scattering (SERS) effects, which are significant requirements for practical SEAS sensor applications.
C1 [Zheng, Jing; Jiao, Anli; Yang, Ronghua; Li, Huimin; Li, Jishan; Shi, Muling; Ma, Cheng; Jiang, Ying; Deng, Li; Tan, Weihong] Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Mol Sci & Biomed Lab, Coll Biol,Coll Chem & Chem Engn, Changsha 410082, Hunan, Peoples R China.
   [Tan, Weihong] Univ Florida, UF Genet Inst, Shands Canc Ctr, Dept Physiol & Funct Genom, Gainesville, FL 32611 USA.
   [Tan, Weihong] Univ Florida, Dept Chem, Ctr Res Bio Nano Interface, Gainesville, FL 32611 USA.
   [Tan, Weihong] Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA.
RP Yang, RH (reprint author), Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Mol Sci & Biomed Lab, Coll Biol,Coll Chem & Chem Engn, Changsha 410082, Hunan, Peoples R China.
EM yangrh@pku.edu.cn; tan@chem.ufl.edu
RI Tan, Weihong/A-5412-2008
OI Tan, Weihong/0000-0002-8066-1524
FU NSFC [21005026, 21135001]; DFMEC [20100151120008, 20110161110006]; '973'
   National Key Basic Research Program [2011CB911000]; Foundation for
   Innovative Research Groups of NSFC [21221003]; U.S. National Institutes
   of Health [GM066137, GM079359, CA133086]; China National Instrumentation
   Program [2011YQ03012412]; special fund of Chongqing Key Laboratory
FX The work was supported by NSFC (21005026 and 21135001), DFMEC
   (20100151120008, 20110161110006), and '973' National Key Basic Research
   Program (2011CB911000), and the Foundation for Innovative Research
   Groups of NSFC (Grant 21221003). It is also supported by grants awarded
   by the U.S. National Institutes of Health (GM066137, GM079359, and
   CA133086), by China National Instrumentation Program 2011YQ03012412, and
   by the special fund of Chongqing Key Laboratory.
CR ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   Aldaye FA, 2008, SCIENCE, V321, P1795, DOI 10.1126/science.1154533
   Bonham AJ, 2007, J AM CHEM SOC, V129, P14572, DOI 10.1021/ja0767837
   Braun G, 2007, J AM CHEM SOC, V129, P6378, DOI 10.1021/ja070514z
   Cao C. Y., 2002, SCIENCE, V297, P1536
   Cao YC, 2003, J AM CHEM SOC, V125, P14676, DOI 10.1021/ja0366235
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Fleischmann M., 1974, J CHEM PHYS LETT, V26, P163, DOI DOI 10.1016/0009-2614(74)85388-1
   Graham D, 2008, NAT NANOTECHNOL, V3, P548, DOI 10.1038/nnano.2008.189
   HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033
   Jiang J, 2003, J PHYS CHEM B, V107, P9964, DOI 10.1021/jp034632u
   Kang T, 2010, NANO LETT, V10, P1189, DOI 10.1021/nl1000086
   Kang T, 2009, J PHYS CHEM C, V113, P7492, DOI 10.1021/jp809391c
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Kim NH, 2011, ADV MATER, V23, P4152, DOI 10.1002/adma.201101847
   Kim NH, 2010, NANO LETT, V10, P4181, DOI 10.1021/nl102495j
   Kneipp J, 2005, ANAL CHEM, V77, P2381, DOI 10.1021/ac050109v
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Lee SJ, 2006, J AM CHEM SOC, V128, P2200, DOI 10.1021/ja0578350
   Li JF, 2010, NATURE, V464, P392, DOI 10.1038/nature08907
   Moskovits M, 2002, TOP APPL PHYS, V82, P215
   Qian XM, 2008, J AM CHEM SOC, V130, P14934, DOI 10.1021/ja8062502
   Rycenga M, 2011, ANGEW CHEM INT EDIT, V50, P5473, DOI 10.1002/anie.201101632
   SALUNKHE M, 1992, J AM CHEM SOC, V114, P8768, DOI 10.1021/ja00049a003                                                             
   Shafer-Peltier KE, 2003, J AM CHEM SOC, V125, P588, DOI 10.1021/ja028255v
   Sharma J, 2009, SCIENCE, V323, P112, DOI 10.1126/science.1165831
   Shegai T, 2009, J AM CHEM SOC, V131, P14390, DOI 10.1021/ja904480r
   STACY AM, 1983, CHEM PHYS LETT, V102, P365, DOI 10.1016/0009-2614(83)87057-2
   Urata H, 2007, BIOCHEM BIOPH RES CO, V360, P459, DOI 10.1016/j.bbrc.2007.06.075
   Wei KK, 2012, ANAL CHEM, V84, P908, DOI 10.1021/ac201712k
   Xu HX, 2000, PHYS REV E, V62, P4318, DOI 10.1103/PhysRevE.62.4318
   Yan J, 2012, ANAL CHEM, V84, P9139, DOI 10.1021/ac301809e
   Zhang ZL, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3573827
   Zheng J, 2011, ANAL CHEM, V83, P6586, DOI 10.1021/ac201314y
NR 35
TC 65
Z9 65
U1 25
U2 254
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 12
PY 2012
VL 134
IS 49
BP 19957
EP 19960
DI 10.1021/ja308875r
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 054NR
UT WOS:000312351000002
PM 23190376
OA green_accepted
DA 2018-01-05
ER

PT J
AU Goudanavar, P
   Krishna, AT
   Hiremath, D
   Udupi, R
AF Goudanavar, Prakash
   Krishna, A. Thandava
   Hiremath, Doddayya
   Udupi, Rajgopal
TI Design and Characterization of Nanoparticulate Drug Delivery System
   Containing the Antiviral Drug Stavudine
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE In-vitro release; Nanoparticles; Stability study; Stavudine
AB Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome (AIDS). Stavudine nanoparticles for oral delivery were prepared by emulsion droplet coalescence method, emulsion cross linking method, and double emulsion method. The prepared nanoparticles were characterized for particle size and the surface morphology, results revealed that nanoparticles were found to be discrete and spherical with the mean size range of 119.9-69.9 nm. Encapsulation efficiency was in the range of 28.9 to 60.9 %. The drug content was uniform and reproducible in each batch of nanoparticles. FTIR and DSC studies revealed no interactions between drug and excipients. In-vitro release profiles indicated that, irrespective of the polymer used, increase in concentration has drastically retarded, the release of stavudine. The mechanism of drug release was Non-Fickian diffusion controlled first order kinetics for optimized formulation. Stability studies indicated that, the prepared nanoparticle remained more stable at room temperature after one month.
C1 [Goudanavar, Prakash; Krishna, A. Thandava; Hiremath, Doddayya; Udupi, Rajgopal] NET Pharm Coll, Dept Pharmaceut, Raichur 584103, Karnataka, India.
RP Goudanavar, P (reprint author), NET Pharm Coll, Dept Pharmaceut, Raichur 584103, Karnataka, India.
EM pgoudanavar01@gmail.com
CR Jain NK, 2001, ADV CONTROLLED NOVEL
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Liu Chenguang, 2007, Journal of Ocean University of China, V6, P237, DOI 10.1007/s11802-007-0237-9
   Sivabalan M, 2011, PHARM GLOBALE IJCP, V1
NR 4
TC 0
Z9 0
U1 0
U2 4
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326-2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PD DEC
PY 2012
VL 31
IS 10
BP 1518
EP 1522
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 173NN
UT WOS:000321086300024
DA 2018-01-05
ER

PT J
AU Ribeiro-Viana, R
   Sanchez-Navarro, M
   Luczkowiak, J
   Koeppe, JR
   Delgado, R
   Rojo, J
   Davis, BG
AF Ribeiro-Viana, Renato
   Sanchez-Navarro, Macarena
   Luczkowiak, Joanna
   Koeppe, Julia R.
   Delgado, Rafael
   Rojo, Javier
   Davis, Benjamin G.
TI Virus-like glycodendrinanoparticles displaying quasi-equivalent nested
   polyvalency upon glycoprotein platforms potently block viral infection
SO NATURE COMMUNICATIONS
LA English
DT Article
ID LECTIN DC-SIGN; EBOLA-VIRUS; MULTIVALENT SYSTEMS; TERMINAL ALKYNES;
   IMMUNE-RESPONSE; DENDRITIC CELLS; Q-BETA; PROTEIN; HIV-1; DENDRIMERS
AB Ligand polyvalency is a powerful modulator of protein-receptor interactions. Host-pathogen infection interactions are often mediated by glycan ligand-protein interactions, yet its interrogation with very high copy number ligands has been limited to heterogenous systems. Here we report that through the use of nested layers of multivalency we are able to assemble the most highly valent glycodendrimeric constructs yet seen (bearing up to 1,620 glycans). These constructs are pure and well-defined single entities that at diameters of up to 32nm are capable of mimicking pathogens both in size and in their highly glycosylated surfaces. Through this mimicry these glyco-dendri-protein-nano-particles are capable of blocking (at picomolar concentrations) a model of the infection of T-lymphocytes and human dendritic cells by Ebola virus. The high associated polyvalency effects (beta>10(6), beta/N similar to 10(2)-10(3)) displayed on an unprecedented surface area by precise clusters suggest a general strategy for modulation of such interactions.
C1 [Ribeiro-Viana, Renato; Sanchez-Navarro, Macarena; Koeppe, Julia R.; Davis, Benjamin G.] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England.
   [Ribeiro-Viana, Renato; Rojo, Javier] Univ Seville, CSIC, IIQ, Glycosyst Lab, Seville 41092, Spain.
   [Luczkowiak, Joanna; Delgado, Rafael] Hosp 12 Octubre Imas12, Inst Invest, Mol Microbiol Lab, Madrid 28041, Spain.
RP Delgado, R (reprint author), Hosp 12 Octubre Imas12, Inst Invest, Mol Microbiol Lab, Madrid 28041, Spain.
EM rdelgado.hdoc@salud.madrid.org; javier.rojo@iiq.csic.es;
   ben.davis@chem.ox.ac.uk
RI Delgado, Rafael/C-4910-2016; Davis, Benjamin/C-5281-2011; Ribeiro-Viana,
   Renato/A-5935-2017; Rojo, Javier/A-2801-2015; Sanchez-Navarro,
   Macarena/H-9862-2015
OI Delgado, Rafael/0000-0002-6912-4736; Davis,
   Benjamin/0000-0002-5056-407X; Ribeiro-Viana, Renato/0000-0001-6603-4770;
   Rojo, Javier/0000-0003-3173-3437; Sanchez-Navarro,
   Macarena/0000-0002-0159-2381; Luczkowiak, Joanna/0000-0001-6950-9372
FU MICINN of Spain [CTQ2008-01694, CTQ2011-23410]; EU RTN CARMUSYS
   [PITN-GA-2008-213592]; Instituto de Salud Carlos III [FIS PI080806,
   PI1101580]; Fundacion para la Investigacion y Prevencion del SIDA [FIPSE
   36749]; European FEDER funds; Centers for Disease Control and
   Prevention, Atlanta, GA; TSRI, La Jolla, CA; EPSRC LSI Platform
FX We acknowledge the financial support by the MICINN of Spain
   CTQ2008-01694 and CTQ2011-23410, the EU RTN CARMUSYS
   (PITN-GA-2008-213592), Instituto de Salud Carlos III (FIS PI080806 and
   PI1101580) and Fundacion para la Investigacion y Prevencion del SIDA
   (FIPSE 36749) and the European FEDER funds. We thank Professors A.
   Sanchez (Centers for Disease Control and Prevention, Atlanta, GA) and
   M.G. Finn (TSRI, La Jolla, CA) for providing Zaire Ebola Virus
   glycoprotein and p75m/Q beta plasmids, respectively. MSN thanks
   Fundacion Ramon Areces for funding, BGD is a Royal Society Wolfson
   Research Merit Award recipient and is supported by an EPSRC LSI Platform
   grant.
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Andre S, 1999, GLYCOBIOLOGY, V9, P1253, DOI 10.1093/glycob/9.11.1253                                                        
   Andreini M, 2011, ORG BIOMOL CHEM, V9, P5778, DOI 10.1039/c1ob05573a
   Arce E, 2003, BIOCONJUGATE CHEM, V14, P817, DOI 10.1021/bc034008k
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Borrok MJ, 2007, J AM CHEM SOC, V129, P12780, DOI 10.1021/ja072944v
   Camponovo J, 2009, J ORG CHEM, V74, P5071, DOI 10.1021/jo900554b
   CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1
   Chalker JM, 2011, ACCOUNTS CHEM RES, V44, P730, DOI 10.1021/ar200056q
   CRICK FHC, 1956, NATURE, V177, P473, DOI 10.1038/177473a0
   Davis BG, 2001, CHEM COMMUN, P351, DOI 10.1039/b009184g                                                                
   de Bakker BI, 2007, CHEMPHYSCHEM, V8, P1473, DOI 10.1002/cphc.200700169
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P17107, DOI 10.1073/pnas.1002717107
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Golmohammadi R, 1996, STRUCTURE, V4, P543, DOI 10.1016/S0969-2126(96)00060-3
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1
   Greatrex BW, 2009, TETRAHEDRON, V65, P2939, DOI 10.1016/j.tet.2009.02.018
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   HE JL, 1995, J VIROL, V69, P6705
   Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068
   Kostiainen MA, 2006, ANGEW CHEM INT EDIT, V45, P3538, DOI 10.1002/anie.200504540                                                          
   KOZLOVSKA TM, 1993, GENE, V137, P133, DOI 10.1016/0378-1119(93)90261-Z
   Lasala F, 2003, ANTIMICROB AGENTS CH, V47, P3970, DOI 10.1128/AAC.47.12.3970-3972.2003
   Luczkowiak J, 2011, BIOCONJUGATE CHEM, V22, P1354, DOI 10.1021/bc2000403
   Mammen M., 1998, ANGEW CHEM INT ED, V37
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Mitchell DA, 2007, TETRAHEDRON-ASYMMETR, V18, P1502, DOI 10.1016/j.tetasy.2007.06.003
   Neyrolles O, 2006, TRENDS MICROBIOL, V14, P383, DOI 10.1016/j.tim.2006.07.007
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Ortega-Munoz M, 2006, ADV SYNTH CATAL, V348, P2410, DOI 10.1002/adsc.200600254
   Prost LR, 2012, ACS CHEM BIOL, V7, P1603, DOI 10.1021/cb300260p
   Puig-Kroger A, 2000, J IMMUNOL, V165, P4338, DOI 10.4049/jimmunol.165.8.4338                                                     
   Reina JJ, 2007, CHEMMEDCHEM, V2, P1030, DOI 10.1002/cmdc.200700047
   Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634                                                     
   Rendle PM, 2004, J AM CHEM SOC, V126, P4750, DOI 10.1021/ja031698u
   Robinson MA, 2004, P NATL ACAD SCI USA, V101, P14527, DOI 10.1073/pnas.0303574101
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Sanchez-Navarro M, 2010, DRUG NEWS PERSPECT, V23, P557, DOI 10.1358/dnp.2010.23.9.1437246
   Sato M, 2004, J AM CHEM SOC, V126, P14013, DOI 10.1021/ja0464261
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4
   Strable E, 2008, BIOCONJUGATE CHEM, V19, P866, DOI 10.1021/bc700390r
   Tabarani G, 2009, J BIOL CHEM, V284, P21229, DOI 10.1074/jbc.M109.021204
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Van H. J. C. M., 2000, J AM CHEM SOC, V122, P1282
   Van Kasteren SI, 2007, NAT PROTOC, V2, P3185, DOI 10.1038/nprot.2007.430
   van Kasteren SI, 2007, NATURE, V446, P1105, DOI 10.1038/nature05757
   van KY, 2003, NAT REV IMMUNOL, V3, P697, DOI [10.1038/nri1182, DOI 10.1038/NRI1182]
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255                                                       
   Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034
NR 53
TC 52
Z9 52
U1 3
U2 73
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC
PY 2012
VL 3
AR 1303
DI 10.1038/ncomms2302
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 109HH
UT WOS:000316356700070
PM 23250433
OA green_published
DA 2018-01-05
ER

PT J
AU Torchilin, VP
AF Torchilin, Vladimir P.
TI Multifunctional nanocarriers
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nanomedicine; Pharmaceutical carriers; Drug delivery; Drug targeting;
   Long-circulating drug carriers; Imaging; Intracellular drug delivery;
   Liposomes; Micelles; Polymeric nanoparticles
ID STERICALLY STABILIZED LIPOSOMES; HUMAN-IMMUNODEFICIENCY-VIRUS; LARGE
   UNILAMELLAR LIPOSOMES; PH-SENSITIVE LIPOSOMES; PEGYLATED
   POLYCYANOACRYLATE NANOPARTICLES; POLY(ETHYLENE GLYCOL)-GRAFTED
   LIPOSOMES; GADOLINIUM-LABELED LIPOSOMES; CONTRAST ENHANCEMENT AGENTS;
   RECEPTOR-TARGETED DELIVERY; LONG-CIRCULATING LIPOSOMES
AB Currently used pharmaceutical nanocarriers, such as liposomes, micelles, nanoemulsions, polymeric nanoparticles and many others demonstrate a broad variety of useful properties, such as longevity in the blood allowing for their accumulation in pathological areas with compromised vasculature; specific targeting to certain disease sites due to various targeting ligands attached to the surface of the nanocarriers; enhanced intracellular penetration with the help of surface-attahced cell-penetrating molecules; contrast properties due to the carrier loading with various contrast materials allowing for direct carrier visualization in vivo; stimuli-sensitivity allowing for drug release from the carriers under certain physiological conditions, and others. Some of those pharmaceutical carriers have already made their way into clinic, while others are still under preclinical development. What could be seen much more rare, however, are the pharmaceutical nanocarriers combining several from the listed abilities. Long-circulating immunoliposomes capable of prolonged residence in the blood and specific target recognition represent one of few examples of this kind. At the same time, the enginnering of multifunctional pharmaceutical nanocarriers combinig several useful preoperties in one particle can significantly enhance the efficacy of many therapeutic and diagnostic protocols. This paper considers current status and possible future directions in the emerging area of multifunctional nanocarriers with primary attention on the combination of such properties as longevity, targetability, intracellular penetration and contrast loading. (C) 2012 Elsevier B.V. All rights reserved.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Mugar Bldg,Room 312,360 Huntington Ave, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR ALLEN TM, 1995, ADV DRUG DELIVER REV, V16, P267, DOI 10.1016/0169-409X(95)00029-7
   ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7                                                    
   ALLEN TM, 1992, CANCER RES, V52, P2431
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   Alonso MJ, 2004, BIOMED PHARMACOTHER, V58, P168, DOI 10.1016/j.biopha.2004.01.007
   Asai T, 2002, FEBS LETT, V520, P167, DOI 10.1016/S0014-5793(02)02821-1
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Balthasar S, 2005, BIOMATERIALS, V26, P2723, DOI 10.1016/j.biomaterials.2004.07.047
   Barsky D, 1992, MAGN RESON MED, V21, P1
   BENHAR I, 1994, P NATL ACAD SCI USA, V91, P12051, DOI 10.1073/pnas.91.25.12051                                                        
   Bernkop-Schnurch A, 2001, CRIT REV THER DRUG, V18, P459
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3
   BOGDANOV AA, 1988, FEBS LETT, V231, P381, DOI 10.1016/0014-5793(88)80854-8                                                    
   BOMAN NL, 1994, CANCER RES, V54, P2830
   Boomer JA, 1999, CHEM PHYS LIPIDS, V99, P145, DOI 10.1016/S0009-3084(99)00033-X
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0
   Choi H, 2004, ACAD RADIOL, V11, P996, DOI 10.1016/j.acra.2004.04.018
   Choi Y, 2005, CELL CYCLE, V4, P669, DOI 10.4161/cc.4.5.1684
   CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   Cohen S, 1996, MICROPARTICULATE SYS
   Dagar S, 2003, J CONTROL RELEASE, V91, P123, DOI 10.1016/S0168-3659(03)00242-6
   DAVIS SS, 1993, J CONTROL RELEASE, V24, P157, DOI 10.1016/0168-3659(93)90175-5
   DeFrees SA, 1996, J AM CHEM SOC, V118, P6101, DOI 10.1021/ja954122g                                                               
   Delgado AD, 2000, J BIOMAT SCI-POLYM E, V11, P1395, DOI 10.1163/156856200744309                                                         
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derycke ASL, 2002, INT J ONCOL, V20, P181
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   DUNNICK JK, 1975, J NUCL MED, V16, P483
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006
   ENOCH HG, 1979, P NATL ACAD SCI USA, V76, P145, DOI 10.1073/pnas.76.1.145
   Ewer MS, 2004, SEMIN ONCOL, V31, P161, DOI 10.1053/j.seminoncol.2004.08.006
   FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   GABIZON A, 1992, BIOCHIM BIOPHYS ACTA, V1103, P94, DOI 10.1016/0005-2736(92)90061-P
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949                                                         
   Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124                                                               
   GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B                                                    
   Catane R, 1994, CANCER RES, V54, P987
   Gaspar MM, 1996, CANCER CHEMOTH PHARM, V38, P373, DOI 10.1007/s002800050497                                                           
   GEISERT EE, 1995, NEUROSCI LETT, V184, P40, DOI 10.1016/0304-3940(94)11163-D
   Gijsens Antoon, 2002, International Journal of Cancer, V101, P78, DOI 10.1002/ijc.10548
   Glogard C, 2002, INT J PHARM, V233, P131, DOI 10.1016/S0378-5173(01)00935-8
   GRANT CWM, 1989, MAGNET RESON MED, V11, P236, DOI 10.1002/mrm.1910110211
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Gregoriadis G., 1988, LIPOSOMES DRUG CARRI
   Guo X, 2001, BIOCONJUGATE CHEM, V12, P291, DOI 10.1021/bc000110v
   Gupta AK, 2004, J MATER SCI-MATER M, V15, P493, DOI 10.1023/B:JMSM.0000021126.32934.20                                              
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   HARPER GR, 1991, BIOMATERIALS, V12, P695, DOI 10.1016/0142-9612(91)90119-U
   Hatakeyama H, 2004, INT J PHARM, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025
   HEATH TD, 1980, BIOCHIM BIOPHYS ACTA, V599, P42, DOI 10.1016/0005-2736(80)90055-3
   HEEREMANS JLM, 1995, THROMB HAEMOSTASIS, V73, P488
   HIRANO K, 1985, J PHARM SCI, V74, P915, DOI 10.1002/jps.2600740902                                                          
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   HUANG SK, 1994, CANCER RES, V54, P2186
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Hwang K. J., 1987, LIPOSOMES BIOPHYSICS, P109
   Iinuma H, 2002, INT J CANCER, V99, P130, DOI 10.1002/ijc.10242
   Illum L, 1983, J PHARM SCI, V72, P1086
   Illum L, 2001, PHARMACEUT RES, V18, P640, DOI 10.1023/A:1011081210142
   Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254
   JAMSHAID M, 1988, INT J PHARM, V48, P125, DOI 10.1016/0378-5173(88)90255-4                                                    
   Jeong JH, 2003, BIOCONJUGATE CHEM, V14, P473, DOI 10.1021/bc025632k
   Joshee N, 2002, HUM GENE THER, V13, P1991, DOI 10.1089/10430340260355392
   KABALKA GW, 1991, MAGN RESON IMAGING, V9, P373, DOI 10.1016/0730-725X(91)90425-L                                                    
   KABALKA GW, 1991, MAGNET RESON MED, V19, P406, DOI 10.1002/mrm.1910190231
   Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w
   Kamps JAAM, 2000, J DRUG TARGET, V8, P235, DOI 10.3109/10611860008997902                                                       
   Kato K, 2004, BIOTECHNOL PROGR, V20, P897, DOI 10.1021/bp0342093
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Kellam B, 2003, CHEM SOC REV, V32, P327, DOI 10.1039/b211643j
   KHAW BA, 1991, J NUCL MED, V32, P1742
   KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   Klibanov A.L, 1998, LONG CIRCULATING LIP, P269
   Klibanov Alexander L., 2003, P231
   Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78                                                     
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10                                    
   KRAUSE HJ, 1985, INT J PHARM, V27, P145, DOI 10.1016/0378-5173(85)90064-X
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   KUNG VT, 1986, BIOCHIM BIOPHYS ACTA, V862, P435, DOI 10.1016/0005-2736(86)90247-6
   Lasic D, 1995, STEALTH LIPOSOMES
   LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2003, J CONTROL RELEASE, V91, P103, DOI 10.1016/S0168-3659(03)00239-6
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Leroux JC, 2001, J CONTROL RELEASE, V72, P71, DOI 10.1016/S0168-3659(01)00263-2                                                   
   LESERMAN LD, 1980, NATURE, V288, P602, DOI 10.1038/288602a0
   Lestini BJ, 2002, J CONTROL RELEASE, V78, P235, DOI 10.1016/S0168-3659(01)00505-3                                                   
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   LISZIEWICZ J, 1995, GENE THER, V2, P218
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X
   Lu YJ, 2002, CANCER IMMUNOL IMMUN, V51, P153, DOI 10.1007/s00262-002-0266-6
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   Lukyanov AN, 2004, J CONTROL RELEASE, V94, P187, DOI 10.1016/j.jconrel.2003.10.008
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863
   MARTIN FJ, 1982, J BIOL CHEM, V257, P286
   Marty C, 2005, METH MOLEC MED, V109, P389
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   MARUYAMA K, 1991, CHEM PHARM BULL, V39, P1620
   MARUYAMA K, 1994, INT J PHARM, V111, P103, DOI 10.1016/0378-5173(94)90407-3
   MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   MOGHIMI SM, 1991, INT J PHARM, V68, P121, DOI 10.1016/0378-5173(91)90134-A
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Monsky WL, 1999, CANCER RES, V59, P4129
   Morawski AM, 2005, CURR OPIN BIOTECH, V16, P89, DOI 10.1016/j.copbio.2004.11.001
   Muller M, 2003, J BIOMED MATER RES A, V66A, P55, DOI 10.1002/jbm.a.10502
   Muller R, 1991, CARRIERS CONTROLLED
   Murad KT, 1999, BLOOD, V93, P2121
   NAPER DH, 1983, POLYM STABILIZATION
   NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y
   Ni S, 2002, ANTICANCER RES, V22, P2131
   Nobs L, 2004, J PHARM SCI-US, V93, P1980, DOI 10.1002/jps.20098
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Ogris M, 2001, AAPS PHARMSCI, V3, part. no.
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Paleos CM, 2004, BIOMACROMOLECULES, V5, P524, DOI 10.1021/bm030068h
   Pan XQ, 2003, PHARMACEUT RES, V20, P417, DOI 10.1023/A:1022656105022
   PANG SNJ, 1993, J AM COLL TOXICOL, V12, P429
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Park EK, 2005, BIOMATERIALS, V26, P1053, DOI 10.1016/j.biomaterials.2004.04.008
   Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7
   Patel H, 1990, TARGETING DRUGS OPTI, P87
   PATEL HM, 1984, BIOCHIM BIOPHYS ACTA, V801, P76, DOI 10.1016/0304-4165(84)90214-9
   Peer D, 2004, INT J CANCER, V108, P780, DOI 10.1002/ijc.11615
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Phillips WT, 1995, HANDB PHARM TOX, P149
   Pollard H, 2001, J GENE MED, V3, P153, DOI 10.1002/jgm.160
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Pooga M, 1998, FASEB J, V12, P67
   PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014-5793(92)80655-Z
   Powel G.M., 1980, HDB WATER SOLUBLE GU, P1
   Putz B., 1994, Journal of Liposome Research, V4, P771, DOI 10.3109/08982109409018599
   Raffaghello L, 2003, CANCER LETT, V197, P151, DOI 10.1016/S0304-3835(03)00097-1
   RANUCCI E, 1994, MACROMOL CHEM PHYSIC, V195, P3469, DOI 10.1002/macp.1994.021951015                                                     
   Rolland A., 1993, PHARM PARTICULATE CA
   Rose PG, 2005, ONCOLOGIST, V10, P205, DOI 10.1634/theoncologist.10-3-205                                                  
   Roth JA, 1998, SEMIN ONCOL, V25, P33
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Roux E, 2004, J CONTROL RELEASE, V94, P447, DOI 10.1016/j.jconrel.2003.10.024
   Roux E, 2002, INT J PHARM, V242, P25, DOI 10.1016/S0378-5173(02)00183-7                                                   
   Roux E, 2002, J PHARM SCI, V91, P1795, DOI 10.1002/jps.10172
   RUBAS W, 1986, INT J CANCER, V37, P149, DOI 10.1002/ijc.2910370123
   RUBEN S, 1989, J VIROL, V63, P1
   Sakurai F, 2000, J CONTROL RELEASE, V66, P255, DOI 10.1016/S0168-3659(99)00280-1
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Sapra P, 2002, CANCER RES, V62, P7190
   SARTORE L, 1994, J BIOACT COMPAT POL, V9, P411, DOI 10.1177/088391159400900404
   Sawant R.M, 2005, P 32 INT S CONTR REL
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689                                                        
   Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwendener R, 1990, INVEST RADIOL, V23, P922
   Schwendener R. A., 1994, Journal of Liposome Research, V4, P837, DOI 10.3109/08982109409018603
   Scott MD, 2004, TRANSFUS CLIN BIOL, V11, P40, DOI 10.1016/j.tracli.2003.12.005
   Scott MD, 1998, CURR PHARM DESIGN, V4, P423
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   Shalaev EY, 1999, BBA-BIOMEMBRANES, V1419, P229, DOI 10.1016/S0005-2736(99)00068-1
   Sheff D, 2004, ADV DRUG DELIVER REV, V56, P927, DOI 10.1016/j.addr.2003.11.005
   Shi GF, 2002, J CONTROL RELEASE, V80, P309, DOI 10.1016/S0168-3659(02)00017-2
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   SIOMI H, 1990, J VIROL, V64, P1803
   STANIMIROVIC DB, 1994, NEUROCHEM RES, V19, P1473, DOI 10.1007/BF00968993
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Stephenson SM, 2003, ANTICANCER RES, V23, P3341
   Sudimack JJ, 2002, BBA-BIOMEMBRANES, V1564, P31, DOI 10.1016/S0005-2736(02)00399-1
   Sullivan DC, 2004, MOL IMAGING, V3, P364, DOI 10.1162/1535350042973526
   Takeuchi H, 1999, EUR J PHARM BIOPHARM, V48, P123, DOI 10.1016/S0939-6411(99)00029-6
   Tan PH, 2003, J GENE MED, V5, P311, DOI 10.1002/jgm.358
   Tang FX, 1999, BIOCONJUGATE CHEM, V10, P791, DOI 10.1021/bc990016i                                                               
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   TILCOCK C, 1989, RADIOLOGY, V171, P77, DOI 10.1148/radiology.171.1.2928549                                                 
   Tilcock C, 1993, LIPOSOME TECHNOLOGY, V2, P65
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin V, 1993, PHOSPHOLIPID HDB, P293
   Torchilin V P, 1997, Q J Nucl Med, V41, P141
   Torchilin V P, 1985, Crit Rev Ther Drug Carrier Syst, V2, P65
   Torchilin Vladimir P., 1995, Journal of Liposome Research, V5, P795, DOI 10.3109/08982109509012682
   Torchilin Vladimir P., 2003, P193
   Torchilin Vladimir P., 2000, Current Pharmaceutical Biotechnology, V1, P183, DOI 10.2174/1389201003378960
   Torchilin Vladimir P., 1996, Journal of Liposome Research, V6, P99, DOI 10.3109/08982109609037204
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P181, DOI 10.1016/0005-2736(94)90025-6
   Torchilin VP, 2002, BIOMEDICAL ASPECTS OF DRUG TARGETING, P3
   TORCHILIN VP, 1995, ADV DRUG DELIVER REV, V16, P141, DOI 10.1016/0169-409X(95)00022-Y                                                    
   TORCHILIN VP, 1995, J PHARM SCI, V84, P1049, DOI 10.1002/jps.2600840904
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   TORCHILIN VP, 1982, FEBS LETT, V138, P117, DOI 10.1016/0014-5793(82)80408-0                                                    
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Torchilin VP, 1999, CHEMTECH, V29, P27
   TORCHILIN VP, 1992, FASEB J, V6, P2716
   Torchilin VP, 1997, ADV DRUG DELIVER REV, V24, P301, DOI 10.1016/S0169-409X(96)00472-3
   TORCHILIN VP, 1980, BIOCHIM BIOPHYS ACTA, V602, P511, DOI 10.1016/0005-2736(80)90330-2                                                    
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin VP, 2001, BIOMATERIALS, V22, P3035, DOI 10.1016/S0142-9612(01)00050-3                                                   
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torchilin VP, 1998, J MICROENCAPSUL, V15, P1, DOI 10.3109/02652049809006831                                                       
   Torchilin V.P, 1995, HANDB PHARM TOX, P403
   Torchilin VP., 1984, LIPOSOME TECHNOLOGY, V3, P75
   Torchilin V.P, 1991, IMMOBILIZED ENZYMES, P206
   Torchilin V.P, 1995, STEALTH LIPOSOMES, P225
   TORCHILIN VP, 1995, HDB TARGETED DELIVER
   Torchilin V. P., 1993, J LIPOSOME RES, V3, P201
   Torchilin V.P, 2000, P 27 INT S CONTR REL, P217
   Trubetskoy Vladimir S., 1994, Journal of Liposome Research, V4, P961, DOI 10.3109/08982109409018613
   TRUBETSKOY VS, 1995, ADV DRUG DELIVER REV, V16, P311, DOI 10.1016/0169-409X(95)00032-3
   TRUBETSKOY VS, 1995, MAGN RESON IMAGING, V13, P31, DOI 10.1016/0730-725X(94)00083-F
   Trubetskoy VS, 1996, ACAD RADIOL, V3, P232, DOI 10.1016/S1076-6332(96)80448-X                                                   
   Trubetskoy VS, 1996, STP PHARMA SCI, V6, P79
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Turk MJ, 2002, BBA-BIOMEMBRANES, V1559, P56, DOI 10.1016/S0005-2736(01)00441-2
   UNGER E, 1990, INVEST RADIOL, V25, P638, DOI 10.1097/00004424-199006000-00004                                                
   UNGER EC, 1989, RADIOLOGY, V171, P81, DOI 10.1148/radiology.171.1.2928550                                                 
   van Vlerken Lilian E, 2006, Expert Opin Drug Deliv, V3, P205, DOI 10.1517/17425247.3.2.205
   Varga CM, 2000, BIOTECHNOL BIOENG, V70, P593, DOI 10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang J, 2005, J DRUG TARGET, V13, P73, DOI 10.1080/10611860400011935
   Wartlick H, 2004, J DRUG TARGET, V12, P461, DOI 10.1080/10611860400010697
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8
   WEISSIG V, 1990, PHARMAZIE, V45, P849
   Gregoriadis G, 1992, LIPOSOME TECHNOLOGY, V3, P231
   Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820
   WOODLE MC, 1994, BIOCONJUGATE CHEM, V5, P493, DOI 10.1021/bc00030a001                                                             
   WOODLE MC, 1992, INT J PHARMACEUT, V88, P327, DOI 10.1016/0378-5173(92)90331-U                                                    
   WOODLE MC, 1993, CHEM PHYS LIPIDS, V64, P249, DOI 10.1016/0009-3084(93)90069-F
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Xu L, 2002, MOL CANCER THER, V1, P337
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yessine MA, 2004, ADV DRUG DELIVER REV, V56, P999, DOI 10.1016/j.addr.2003.10.039
   YOSHIOKA H, 1991, BIOMATERIALS, V12, P861, DOI 10.1016/0142-9612(91)90075-L
   YUAN F, 1995, CANCER RES, V55, P3752
   Zalipsky S, 1997, BIOCONJUGATE CHEM, V8, P111, DOI 10.1021/bc9600832                                                               
   ZALIPSKY S, 1995, ADV DRUG DELIVER REV, V16, P157, DOI 10.1016/0169-409X(95)00023-Z
   Zalipsky S, 1998, NATO ADV SCI I A-LIF, V300, P131
   Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n                                                               
   Zhang F, 2001, J BIOMAT SCI-POLYM E, V12, P515, DOI 10.1163/156856201300194252
   Zhang JX, 2004, PHARMACOL RES, V49, P185, DOI 10.1016/j.phrs.2003.09.003
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 264
TC 156
Z9 161
U1 9
U2 219
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC
PY 2012
VL 64
SU S
BP 302
EP 315
DI 10.1016/j.addr.2012.09.031
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 058EK
UT WOS:000312616700027
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Gajewicz, A
   Rasulev, B
   Dinadayalane, TC
   Urbaszek, P
   Puzyn, T
   Leszczynska, D
   Leszczynski, J
AF Gajewicz, Agnieszka
   Rasulev, Bakhtiyor
   Dinadayalane, Tandabany C.
   Urbaszek, Piotr
   Puzyn, Tomasz
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI Advancing risk assessment of engineered nanomaterials: Application of
   computational approaches
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nanomaterials; Nanoparticles; Nanodescriptors; Quantum-chemical methods;
   Nano-QSAR; Toxicity
ID METAL-OXIDE NANOPARTICLES; WALL CARBON NANOTUBES; QUANTITATIVE
   STRUCTURE-PROPERTY; TITANIUM-DIOXIDE NANOPARTICLES; FULLERENE C-60
   SOLUBILITY; IN-VITRO CYTOTOXICITY; HIV-1 PR INHIBITORS; LINE ENTRY
   SYSTEM; ORGANIC-SOLVENTS; OPTIMAL DESCRIPTORS
AB Nanotechnology that develops novel materials at size of 100 nm or less has become one of the most promising areas of human endeavor. Because of their intrinsic properties, nanoparticles are commonly employed in electronics, photovoltaic, catalysis, environmental and space engineering, cosmetic industry and - finally - in medicine and pharmacy. In that sense, nanotechnology creates great opportunities for the progress of modem medicine. However, recent studies have shown evident toxicity of some nanoparticles to living organisms (toxicity), and their potentially negative impact on environmental ecosystems (ecotoxicity). Lack of available data and low adequacy of experimental protocols prevent comprehensive risk assessment The purpose of this review is to present the current state of knowledge related to the risks of the engineered nanoparticles and to assess the potential of efficient expansion and development of new approaches, which are offered by application of theoretical and computational methods, applicable for evaluation of nanomaterials. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Rasulev, Bakhtiyor; Dinadayalane, Tandabany C.; Leszczynski, Jerzy] Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
   [Gajewicz, Agnieszka; Urbaszek, Piotr; Puzyn, Tomasz] Univ Gdansk, Fac Chem, Inst Environm & Human Hlth Protect, Lab Environm Chemometr, PL-80952 Gdansk, Poland.
   [Leszczynska, Danuta] Jackson State Univ, Dept Civil & Environm Engn, Interdisciplinary Ctr Nanotox, Jackson, MS 39217 USA.
RP Leszczynski, J (reprint author), Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Ctr Nanotox, 1400 JR Lynch St, Jackson, MS 39217 USA.
EM jerzy@icnanotox.org
RI Rasulev, Bakhtiyor/A-3030-2008
OI Rasulev, Bakhtiyor/0000-0002-7845-4884; Dinadayalane, Tandabany
   C./0000-0002-5007-6615; Gajewicz, Agnieszka/0000-0001-7702-210X; Puzyn,
   Tomasz/0000-0003-0449-8339
FU NSF CREST Interdisciplinary Nanotoxicity Center NSF-CREST [HRD-0833178];
   NSF-EPSCoR [362492-190200-01\NSFEPS-0903787]; Department of Defense
   through the U. S. Army Engineer Research and Development Center,
   Vicksburg, MS [W912HZ-06-C-0057]; 711 HPW/RHP [FA8650-10-2-6062];
   Foundation for Polish Science; Polish Ministry of Science and Higher
   Education [DS/8180-4-0171-12]; European Social Fund; State Budget and
   the Pomorskie Voivodeship Budget according to the Operational Programme
   Human Capital, Priority VIII, Action 8.2, Under-action 8.22: 'Regional
   Innovation Strategy'
FX The authors thank the support of the NSF CREST Interdisciplinary
   Nanotoxicity Center NSF-CREST - Grant # HRD-0833178; NSF-EPSCoR Award #:
   362492-190200-01\NSFEPS-0903787; the Department of Defense through the
   U. S. Army Engineer Research and Development Center, Vicksburg, MS for
   funding of High Performance Computational Design of Novel Materials
   (HPCDNM) - Contract # W912HZ-06-C-0057.; This material is based on
   research sponsored by 711 HPW/RHP under agreement number
   FA8650-10-2-6062. The U.S. Government is authorized to reproduce and
   distribute reprints for Governmental purposes notwithstanding any
   copyright notation thereon. The views and conclusions contained herein
   are those of the authors and should not be interpreted as necessarily
   representing the official policies or endorsements, either expressed or
   implied, of 711 HPW/RHP or the U.S. Government.; T.P. thanks the
   Foundation for Polish Science for a fellowship under the 'FOCUS 2010'
   Program. This work was supported by the Polish Ministry of Science and
   Higher Education (grant no. DS/8180-4-0171-12). A.G. thanks the European
   Social Fund, the State Budget and the Pomorskie Voivodeship Budget
   according to the Operational Programme Human Capital, Priority VIII,
   Action 8.2, Under-action 8.22: 'Regional Innovation Strategy' for
   granting her with a fellowship in frame of the project "InnoDoktorant -
   Scholarships for PhD students, IVth edition".
CR Abraham MH, 2000, J CHEM SOC PERK T 2, P281, DOI 10.1039/a907461i                                                                
   ABRAHAM MH, 1993, J CHEM SOC CHEM COMM, P1863, DOI 10.1039/c39930001863                                                            
   Accelrys Software Inc, 2012, DISC STUD MOD ENV RE
   Agasti SS, 2010, ADV DRUG DELIVER REV, V62, P316, DOI 10.1016/j.addr.2009.11.004
   Aillon KL, 2009, ADV DRUG DELIVER REV, V61, P457, DOI 10.1016/j.addr.2009.03.010
   Aitken R.J., 2004, 274 I OCC MED
   Akkurt F, 2009, FULLER NANOTUB CAR N, V17, P616, DOI 10.1080/15363830903291374
   Allen MJ, 2010, CHEM REV, V110, P132, DOI 10.1021/cr900070d
   Aoshima H, 2009, J TOXICOL SCI, V34, P555, DOI 10.2131/jts.34.555                                                              
   Artiles MS, 2011, ADV DRUG DELIVER REV, V63, P1352, DOI 10.1016/j.addr.2011.07.005
   Aruoja V, 2009, SCI TOTAL ENVIRON, V407, P1461, DOI 10.1016/j.scitotenv.2008.10.053
   Asare N, 2012, TOXICOLOGY, V291, P65, DOI 10.1016/j.tox.2011.10.022
   Asharani PV, 2011, NANOTOXICOLOGY, V5, P43, DOI 10.3109/17435390.2010.489207
   Asharani PV, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/25/255102
   Auffan M, 2006, ENVIRON SCI TECHNOL, V40, P4367, DOI 10.1021/es060691k
   Bai W, 2010, J NANOPART RES, V12, P1645, DOI 10.1007/s11051-009-9740-9
   Barnard AS, 2009, NAT NANOTECHNOL, V4, P332, DOI 10.1038/nnano.2009.126
   Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Ben-Moshe T, 2010, CHEMOSPHERE, V81, P387, DOI 10.1016/j.chemosphere.2010.07.007
   Benn TM, 2011, ENVIRON POLLUT, V159, P1334, DOI 10.1016/j.envpol.2011.01.018
   BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0
   Bianco A, 2011, CHEM COMMUN, V47, P10182, DOI 10.1039/c1cc13011k
   Blinova I, 2010, ENVIRON POLLUT, V158, P41, DOI 10.1016/j.envpol.2009.08.017
   Bonnefoi MS, 2010, CRIT REV TOXICOL, V40, P893, DOI 10.3109/10408444.2010.506640
   Borm Paul J A, 2006, Part Fibre Toxicol, V3, P11, DOI 10.1186/1743-8977-3-11
   Borm PJA, 2002, INHAL TOXICOL, V14, P311, DOI 10.1080/08958370252809086
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Braydich-Stolle LK, 2009, J NANOPART RES, V11, P1361, DOI 10.1007/s11051-008-9523-8
   Bylaska E.J., 2006, NEWCHEM COMPUTATIONA
   Cagin T, 1999, J NANOPART RES, V1, P51, DOI 10.1023/A:1010009630519
   Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104
   Chang YL, 2011, TOXICOL LETT, V200, P201, DOI 10.1016/j.toxlet.2010.11.016
   Chen HW, 2006, FASEB J, V20, P2393, DOI 10.1096/fj.06-6485fje
   Chen M, 2005, EXP CELL RES, V305, P51, DOI 10.1016/j.yexcr.2004.12.021
   Chen Y, 2004, TOXICOL IND HEALTH, V20, P21, DOI 10.1191/0748233704th190oa
   Chen Z, 2006, TOXICOL LETT, V163, P109, DOI 10.1016/j.toxlet.2005.10.003
   Cho WS, 2009, TOXICOL APPL PHARM, V236, P16, DOI 10.1016/j.taap.2008.12.023
   Choi BG, 2010, ACS NANO, V4, P2910, DOI 10.1021/nn100145x
   Choi O, 2008, ENVIRON SCI TECHNOL, V42, P4583, DOI 10.1021/es703238h
   Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875
   Constantin C, 2010, NANOMEDICINE-UK, V5, P307, DOI [10.2217/nnm.09.111, 10.2217/NNM.09.111]
   Cook SM, 2010, J HAZARD MATER, V176, P367, DOI 10.1016/j.jhazmat.2009.11.039
   Cormode DP, 2010, ADV DRUG DELIVER REV, V62, P329, DOI 10.1016/j.addr.2009.11.005
   Cui DX, 2005, TOXICOL LETT, V155, P73, DOI 10.1016/j.toxlet.2004.08.015
   Danauskas SM, 2001, J CHEM INF COMP SCI, V41, P419, DOI 10.1021/ci000140s
   Das A., 2010, NANOTECHNOLOGY, V21
   Dinadayalane TC, 2010, STRUCT CHEM, V21, P1155, DOI 10.1007/s11224-010-9670-2
   Dinadayalane T.C., 2012, HDB COMPUTATIONAL CH, P793
   Donaldson Ken, 2003, Ann Ist Super Sanita, V39, P405
   Donaldson Ken, 2005, Part Fibre Toxicol, V2, P10
   Dreher KL, 2004, TOXICOL SCI, V77, P3, DOI 10.1093/toxsci/kfh041
   Duch MC, 2011, NANO LETT, V11, P5201, DOI 10.1021/nl202515a
   Duffin R, 2007, INHAL TOXICOL, V19, P849, DOI 10.1080/08958370701479323
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Edelstein A. S., 1998, NANOMATERIALS SYNTHE
   Ellegaard-Jensen L, 2012, ECOTOX ENVIRON SAFE, V80, P216, DOI 10.1016/j.ecoenv.2012.03.003
   Ema M, 2011, REGUL TOXICOL PHARM, V61, P276, DOI 10.1016/j.yrtph.2011.08.007
   [Anonymous], 2006, APPR EX METH ASS POT, P2006
   Fadeel B, 2010, ADV DRUG DELIVER REV, V62, P362, DOI 10.1016/j.addr.2009.11.008
   Fahmy B, 2009, TOXICOL IN VITRO, V23, P1365, DOI 10.1016/j.tiv.2009.08.005
   Federici G, 2007, AQUAT TOXICOL, V84, P415, DOI 10.1016/j.aquatox.2007.07.009
   Flunt R., 1997, ORG REACTIONS, V31, P21
   Fourches D, 2010, ACS NANO, V4, P5703, DOI 10.1021/nn1013484
   Franklin NM, 2007, ENVIRON SCI TECHNOL, V41, P8484, DOI 10.1021/es071445r
   Frisch M. J., 2004, GAUSSIAN 03
   Fubini B, 2010, NANOTOXICOLOGY, V4, P347, DOI 10.3109/17435390.2010.509519
   Fujita K, 2009, TOXICOL LETT, V191, P109, DOI 10.1016/j.toxlet.2009.08.011
   Gajewicz A, 2011, NANOSCI NANOTECHNOL, V1, P53, DOI DOI 10.2174/2210681211101010053
   Gao HJ, 2003, NANO LETT, V3, P471, DOI 10.1021/nl025967a
   GastroPLUS, 2012, GASTROPLUS
   Gleiche M., 2006, NANOFORUM REPORT
   Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949
   Goodarzi M, 2010, FLUID PHASE EQUILIBR, V293, P130, DOI 10.1016/j.fluid.2010.02.025
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   Gordon MS, 2005, THEORY AND APPLICATIONS OF COMPUTATIONAL CHEMISTRY: THE FIRST FORTY YEARS, P1167, DOI 10.1016/B978-044451719-7/50084-6
   GORDON T, 1992, AM IND HYG ASSOC J, V53, P503
   Green C. J., 2011, NANOTECHNOLOGY REV E
   Han XL, 2011, TOXICOLOGY, V287, P99, DOI 10.1016/j.tox.2011.06.011
   Hansen CM, 2004, CARBON, V42, P1591, DOI 10.1016/j.carbon.2004.02.011
   Heinlaan M, 2008, CHEMOSPHERE, V71, P1308, DOI 10.1016/j.chemosphere.2007.11.047
   Hoet P. H., 2004, J NANOBIOTECHNOL, V2, P12, DOI DOI 10.1186/1477-3155-2-12
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864                                                        
   Horie M, 2012, CHEM RES TOXICOL, V25, P605, DOI 10.1021/tx200470e
   Horie M, 2010, TOXICOL IN VITRO, V24, P1629, DOI 10.1016/j.tiv.2010.06.003
   Hu XK, 2009, SCI TOTAL ENVIRON, V407, P3070, DOI 10.1016/j.scitotenv.2009.01.033
   Huang JC, 2005, FLUID PHASE EQUILIBR, V237, P186, DOI 10.1016/j.fluid.2005.09.005
   Hussain SM, 2005, TOXICOL IN VITRO, V19, P975, DOI 10.1016/j.tiv.2005.06.034
   IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0                                                                
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Ispas C, 2009, ENVIRON SCI TECHNOL, V43, P6349, DOI 10.1021/es9010543
   Ivask A, 2010, ANAL BIOANAL CHEM, V398, P701, DOI 10.1007/s00216-010-3962-7
   Jensen F., 1999, INTRO COMPUTATIONAL
   Jeong SW, 2009, J ENVIRON MONITOR, V11, P1595, DOI 10.1039/b907658a
   Jiang JK, 2009, J NANOPART RES, V11, P77, DOI 10.1007/s11051-008-9446-4
   Johnson RR, 2009, NANO LETT, V9, P537, DOI 10.1021/nl802645d
   Jung JH, 2010, ANGEW CHEM INT EDIT, V49, P5708, DOI 10.1002/anie.201001428
   Karlsson HL, 2008, CHEM RES TOXICOL, V21, P1726, DOI 10.1021/tx800064j
   Kasemets K, 2009, TOXICOL IN VITRO, V23, P1116, DOI 10.1016/j.tiv.2009.05.015
   Katritzky AR, 2001, J CHEM INF COMP SCI, V41, P679, DOI 10.1021/ci000134w
   Katritzky A.R., 2005, CODESSA PROCOMPREHEN
   Kayat J, 2011, NANOMED-NANOTECHNOL, V7, P40, DOI 10.1016/j.nano.2010.06.008
   Kim JS, 2006, TOXICOL SCI, V89, P338, DOI 10.1093/toxsci/kfj027
   Klimisch HJ, 1997, REGUL TOXICOL PHARM, V25, P1, DOI 10.1006/rtph.1996.1076
   Kraszewski S, 2010, ACS NANO, V4, P4158, DOI 10.1021/nn100723r
   Kreyling WG, 2004, J AEROSOL MED, V17, P140, DOI 10.1089/0894268041457147                                                        
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Kumari M, 2011, J HAZARD MATER, V190, P613, DOI 10.1016/j.jhazmat.2011.03.095
   Kuz'min VE, 2005, J MOL MODEL, V11, P457, DOI 10.1007/s00894-005-0237-x
   Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015
   Lam CW, 2006, CRIT REV TOXICOL, V36, P189, DOI 10.1080/10408440600570233
   Leszczynski J, 2010, NAT NANOTECHNOL, V5, P633, DOI 10.1038/nnano.2010.182
   Li M, 2011, ENVIRON SCI TECHNOL, V45, P1977, DOI 10.1021/es102624t
   Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000
   Li T, 2010, ANAL BIOANAL CHEM, V398, P689, DOI 10.1007/s00216-010-3915-1
   Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o
   Lindberg HK, 2009, TOXICOL LETT, V186, P166, DOI 10.1016/j.toxlet.2008.11.019
   Linkov I, 2008, NANOMED-NANOTECHNOL, V4, P167, DOI 10.1016/j.nano.2008.01.001
   Linkov I, 2009, J NANOPART RES, V11, P513, DOI 10.1007/s11051-008-9514-9
   Liu HX, 2005, J PHYS CHEM B, V109, P20565, DOI 10.1021/jp052223n
   Liu JZ, 2008, CHEM RES TOXICOL, V21, P459, DOI 10.1021/tx700392b
   Liu KP, 2011, J MATER CHEM, V21, P12034, DOI 10.1039/c1jm10749f
   Liu Z, 2011, MATER TODAY, V14, P316, DOI 10.1016/S1369-7021(11)70161-4
   Long TC, 2006, ENVIRON SCI TECHNOL, V40, P4346, DOI 10.1021/es060589n
   Lu FS, 2009, ADV MATER, V21, P139, DOI 10.1002/adma.200801491
   Lubick N, 2008, ENVIRON SCI TECHNOL, V42, P8617, DOI 10.1021/es8026314
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   Lux Research, 2008, NAN STAT MARK Q3 200
   Magrez A, 2006, NANO LETT, V6, P1121, DOI 10.1021/nl060162e
   Majestic BJ, 2010, INT J OCCUP ENV HEAL, V16, P488, DOI 10.1179/107735210799160048                                                      
   Makarucha AJ, 2011, EUR BIOPHYS J BIOPHY, V40, P103, DOI 10.1007/s00249-010-0651-6
   Makitra RG, 2003, RUSS J GEN CHEM+, V73, P1227, DOI 10.1023/B:RUGC.0000007645.77987.b4                                              
   Mananghaya M, 2012, J NANOTECHNOL, DOI 10.1155/2012/780815
   Marcus Y, 2001, J PHYS CHEM B, V105, P2499, DOI 10.1021/jp0023720
   Martin D, 2010, LETT DRUG DES DISCOV, V7, P587, DOI 10.2174/157018010792062759                                                      
   Mauri A, 2006, MATCH-COMMUN MATH CO, V56, P237
   Maynard AD, 2006, NATURE, V444, P267, DOI 10.1038/444267a
   Medina C, 2007, BRIT J PHARMACOL, V150, P552, DOI 10.1038/sj.bjp.0707130
   Miyawaki J, 2008, ACS NANO, V2, P213, DOI 10.1021/nn700185t
   Mohammadpour E, 2011, Journal of Applied Sciences, V11, P1653, DOI 10.3923/jas.2011.1653.1657
   Monajjemi M, 2012, J CLUST SCI, V23, P259, DOI 10.1007/s10876-011-0426-y
   Monthioux M, 2006, CARBON, V44, P1621, DOI 10.1016/j.carbon.2006.03.019
   Moore MN, 2006, ENVIRON INT, V32, P967, DOI 10.1016/j.envint.2006.06.014
   Morimoto Y, 2010, J OCCUP HEALTH, V52, P325, DOI 10.1539/joh.R10003
   Mortimer M, 2010, TOXICOLOGY, V269, P182, DOI 10.1016/j.tox.2009.07.007
   Moss OR, 2006, INHAL TOXICOL, V18, P711, DOI 10.1080/08958370600747770
   Mukherjee P, 2010, ADV DRUG DELIVER REV, V62, P283, DOI 10.1016/j.addr.2009.11.001
   Muller J, 2006, CARBON, V44, P1048, DOI 10.1016/j.carbon.2005.10.019
   Murdock RC, 2008, TOXICOL SCI, V101, P239, DOI 10.1093/toxsci/kfm240
   Murphy FA, 2011, AM J PATHOL, V178, P2587, DOI 10.1016/j.ajpath.2011.02.040
   Murr LE, 2005, MATER CHARACT, V55, P50, DOI 10.1016/j.matchar.2005.02.008
   Mutlu GM, 2010, NANO LETT, V10, P1664, DOI 10.1021/nl9042483
   Navarro E, 2008, ENVIRON SCI TECHNOL, V42, P8959, DOI 10.1021/es801785m
   Navarro E, 2008, ECOTOXICOLOGY, V17, P372, DOI 10.1007/s10646-008-0214-0
   Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Nirmala R, 2011, J BIOMED NANOTECHNOL, V7, P342, DOI 10.1166/jbn.2011.1292
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   O'Brien N, 2008, HUM ECOL RISK ASSESS, V14, P568, DOI 10.1080/10807030802074261
   Obata S, 2011, J PHYS CHEM C, V115, P19659, DOI 10.1021/jp2072809
   Oberdorster G, 2012, ENVIRON HEALTH PERSP, V120, pA13, DOI 10.1289/ehp.1104320
   Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339
   Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73
   Oberdorster Gunter, 2005, Part Fibre Toxicol, V2, P8, DOI 10.1186/1743-8977-2-8
   OECD, 2012, SER SAF MAN NAN, V33
   OECD, 2007, GUID DOC VAL QUANT S, P154
   OECD, 2010, GUID MAN TEST MAN NA
   Oh WK, 2010, SMALL, V6, P872, DOI 10.1002/smll.200902074
   Oprea T.I., 1994, DRUG DES DISCOVERY, V12, P29
   Ormsby JL, 2004, J ORG CHEM, V69, P4287, DOI 10.1021/jo035589+
   Panessa-Warren BJ, 2006, J PHYS-CONDENS MAT, V18, pS2185, DOI 10.1088/0953-8984/18/33/S34
   Panessa-Warren BJ, 2008, INT J NANOTECHNOL, V5, P55, DOI 10.1504/IJNT.2008.016549
   Parashar UK, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/41/415104
   Partha R, 2009, INT J NANOMED, V4, P261
   Paur HR, 2011, J AEROSOL SCI, V42, P668, DOI 10.1016/j.jaerosci.2011.06.005
   Penn A, 2005, ENVIRON HEALTH PERSP, V113, P956, DOI 10.1289/ehp.7661
   Peters K, 2004, J MATER SCI-MATER M, V15, P321, DOI 10.1023/B:JMSM.0000021095.36878.1b
   Petrova T, 2011, J NANOPART RES, V13, P3235, DOI 10.1007/s11051-011-0238-x
   Pitkethly MJ, 2004, MATER TODAY, V7, P20, DOI 10.1016/S1369-7021(04)00627-3                                                   
   Poater A., 2007, 2 NAN C VEN IT
   Poggi MA, 2004, ANAL CHEM, V76, P3429, DOI 10.1021/ac0400818
   Posgai R, 2011, CHEMOSPHERE, V85, P34, DOI 10.1016/j.chemosphere.2011.06.040
   Pourbasheer E, 2011, FULLER NANOTUB CAR N, V19, P585, DOI 10.1080/1536383X.2010.504952
   Powers KW, 2007, NANOTOXICOLOGY, V1, P42, DOI 10.1080/17435390701314902
   Puzyn T, 2006, CHEMOSPHERE, V62, P1817, DOI 10.1016/j.chemosphere.2005.07.055
   Puzyn T., 2010, RECENT ADV QSAR STUD
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   Puzyn T, 2009, SMALL, V5, P2494, DOI 10.1002/smll.200900179
   Qu ZW, 2006, J PHYS CHEM B, V110, P8998, DOI 10.1021/jp056607p
   QUINA FH, 1995, J PHYS CHEM-US, V99, P11708, DOI 10.1021/j100030a014                                                             
   Rasulev B., 2007, FED AN CHEM SPECT S
   Reddy KM, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2742324
   Rehn B, 2003, TOXICOL APPL PHARM, V189, P84, DOI 10.1016/S0041-008X(03)00092-9
   Riediker M., 2011, COMPENDIUM PROJECTS
   Rispoli F, 2010, J HAZARD MATER, V180, P212, DOI 10.1016/j.jhazmat.2010.04.016
   Rivera Gil P, 2010, ACS NANO, V4, P5527, DOI 10.1021/nn1025687
   Russell William M. S, 1959, PRINCIPLES HUMANE EX
   Sanchez VC, 2012, CHEM RES TOXICOL, V25, P15, DOI 10.1021/tx200339h
   Sasidharan A, 2011, NANOSCALE, V3, P2461, DOI 10.1039/c1nr10172b
   Savolainen K, 2010, TOXICOLOGY, V269, P92, DOI 10.1016/j.tox.2010.01.013
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Schaeublin NM, 2012, LANGMUIR, V28, P3248, DOI 10.1021/la204081m
   Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b
   Schinwald A, 2012, ACS NANO, V6, P736, DOI 10.1021/nn204229f
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Schrand AM, 2010, WIRES NANOMED NANOBI, V2, P544, DOI 10.1002/wnan.103
   Jaguar, 2011, JAG VERS 7 8
   [Anonymous], 2012, SCHROD SUIT 2012
   Schultz TW, 2003, J MOL STRUC-THEOCHEM, V622, P1, DOI 10.1016/S0166-1280(02)00614-0
   Schwarz J. A., 1999, SURFACES NANOPARTICL
   Schwerha JJ, 2010, J OCCUP ENVIRON MED, V52, P943, DOI 10.1097/JOM.0b013e3181dc6c52
   [Anonymous], 2012, THEOR CHEM
   Scown TM, 2010, CRIT REV TOXICOL, V40, P653, DOI 10.3109/10408444.2010.494174
   [Anonymous], 2011, AUT 4 0
   Sharma V, 2011, J NANOSCI NANOTECHNO, V11, P3782, DOI 10.1166/jnn.2011.4250
   Simeon TM, 2005, INT J QUANTUM CHEM, V105, P429, DOI 10.1002/qua.20718
   Simon-Deckers A, 2009, ENVIRON SCI TECHNOL, V43, P8423, DOI 10.1021/es9016975
   Sinha N, 2005, IEEE T NANOBIOSCI, V4, P180, DOI 10.1109/TNB.2005.850478
   Sivaraman N, 2001, J CHEM INF COMP SCI, V41, P1067, DOI 10.1021/ci010003a
   Skaltsas T, 2011, MICROPOR MESOPOR MAT, V143, P451, DOI 10.1016/j.micromeso.2011.03.038
   SMITH AL, 1996, P ELECTROCHEM SOC, V96, P53
   Song MY, 2012, ENVIRON SCI TECHNOL, V46, P3457, DOI 10.1021/es2039008
   Stewart J. P., 2009, MOPAC2009
   Suarez-Martinez I, 2012, CARBON, V50, P741, DOI 10.1016/j.carbon.2011.11.002
   Sun WM, 2011, J PHYS CHEM C, V115, P3220, DOI 10.1021/jp108812z
   Thill A, 2006, ENVIRON SCI TECHNOL, V40, P6151, DOI 10.1021/es060999b
   THOMAS ER, 1982, J CHEM ENG DATA, V27, P399, DOI 10.1021/je00030a010                                                             
   Tian FR, 2006, TOXICOL IN VITRO, V20, P1202, DOI 10.1016/j.tiv.2006.03.008
   Titov AV, 2010, ACS NANO, V4, P229, DOI 10.1021/nn9015778
   Todeschini R., 2000, HDB MOL DESCRIPTORS
   TOPLISS JG, 1972, J MED CHEM, V15, P1066, DOI 10.1021/jm00280a017
   Toropov AA, 2008, CARBON MATER-CHEM PH, V1, P337
   Toropov AA, 2006, BIOORGAN MED CHEM, V14, P3923, DOI 10.1016/j.bmc.2006.01.038
   Toropov AA, 2005, INDIAN J CHEM A, V44, P1545
   Toropov AA, 2005, J SERB CHEM SOC, V70, P669, DOI 10.2298/JSC0504669T                                                             
   Toropov AA, 2001, J MOL STRUC-THEOCHEM, V538, P287, DOI 10.1016/S0166-1280(00)00713-2                                                   
   Toropov A.A., 2007, 4 INT S REC ADV ENV, pPB
   Toropov A.A, 2012, CORAL SEA SOFTWARE
   Toropov A, 2006, COMPUT BIOL CHEM, V30, P434, DOI 10.1016/j.compbiolchem.2006.09.003
   Toropov AA, 2008, CHEM PHYS LETT, V457, P332, DOI 10.1016/j.cplett.2008.04.013
   Toropov Andrey A, 2007, Curr Drug Discov Technol, V4, P77
   Toropov AA, 2007, MATER LETT, V61, P4777, DOI 10.1016/j.matlet.2007.03.026
   Toropov AA, 2007, CHEM PHYS LETT, V444, P209, DOI 10.1016/j.cplett.2007.07.024
   Toropov AA, 2007, CHEM PHYS LETT, V441, P119, DOI 10.1016/j.cplett.2007.04.094
   Toropov AA, 2007, COMPUT BIOL CHEM, V31, P127, DOI 10.1016/j.compbiolchem.2007.02.002
   Toropov AA, 2007, COMPUT BIOL CHEM, V31, P57, DOI 10.1016/j.compbiolchem.2007.01.003
   Toropov AA, 2009, J MATH CHEM, V46, P1232, DOI 10.1007/s10910-008-9514-0
   Toropova AP, 2011, CHEM BIOL DRUG DES, V77, P343, DOI 10.1111/j.1747-0285.2011.01109.x
   Toropova AP, 2011, MOL DIVERS, V15, P249, DOI 10.1007/s11030-010-9245-6
   Torrens F, 2005, NANOTECHNOLOGY, V16, pS181, DOI 10.1088/0957-4484/16/5/009
   Tran C.L, 2011, J NANOPART RES, P1
   Tran N, 2010, INT J NANOMED, V5, P277
   [Anonymous], 2011, SYBYL 8 0
   Troshin PA, 2009, ADV FUNCT MATER, V19, P779, DOI 10.1002/adfm.200801189
   Tsuji JS, 2006, TOXICOL SCI, V89, P42, DOI 10.1093/toxsci/kfi339
   Uo M, 2011, DENT MATER J, V30, P245, DOI 10.4012/dmj.2010-039
   van der Jagt K., 2004, 21405 JRC EUR
   Venkataraman S, 2011, ADV DRUG DELIVER REV, V63, P1228, DOI 10.1016/j.addr.2011.06.016
   Vidal D, 2005, J CHEM INF MODEL, V45, P386, DOI 10.1021/ci0496797
   Wang J, 2011, NANOMEDICINE-UK, V6, P1605, DOI [10.2217/NNM.11.141, 10.2217/nnm.11.141]
   Wang JL, 2006, J CHEM INF MODEL, V46, P801, DOI 10.1021/ci050402w
   Wang K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671-010-9751-6
   Wang ZY, 2011, ENVIRON SCI TECHNOL, V45, P6018, DOI 10.1021/es200790x
   Wiesner MR, 2006, ENVIRON SCI TECHNOL, V40, P4336, DOI 10.1021/es062726m
   Win-Shwe TT, 2011, INT J MOL SCI, V12, P6267, DOI 10.3390/ijms12096267
   Worle-Knirsch JM, 2006, NANO TODAY, V1, P48, DOI 10.1016/S1748-0132(06)70148-7
   Worth A.P., 2010, RECENT ADV QSAR STUD
   Wu JH, 2009, TOXICOL LETT, V191, P1, DOI 10.1016/j.toxlet.2009.05.020
   Wu J, 2011, ACS NANO, V5, P4476, DOI 10.1021/nn103530b
   Wu YT, 2006, CHEM REV, V106, P4843, DOI 10.1021/cr050554q
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Xia XR, 2011, ACS NANO, V5, P9074, DOI 10.1021/nn203303c
   Xia XR, 2010, NAT NANOTECHNOL, V5, P671, DOI [10.1038/nnano.2010.164, 10.1038/NNANO.2010.164]
   Yamakoshi Y, 2003, J AM CHEM SOC, V125, P12803, DOI 10.1021/ja0355574
   Yang ST, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/39/395101
   Yang XY, 2010, AQUAT TOXICOL, V100, P202, DOI 10.1016/j.aquatox.2009.08.011
   Yokel RA, 2011, J OCCUP MED TOXICOL, V6, DOI 10.1186/1745-6673-6-7
   Yokoyama A, 2005, NANO LETT, V5, P157, DOI 10.1021/nl0484752
   Yuan JF, 2011, TOXICOL LETT, V207, P213, DOI 10.1016/j.toxlet.2011.09.014
   Zhang LM, 2010, SMALL, V6, P537, DOI 10.1002/smll.200901680
   Zhang YB, 2007, J NANOSCI NANOTECHNO, V7, P497, DOI 10.1166/jnn.2007.125
   Zhang YB, 2010, ACS NANO, V4, P3181, DOI 10.1021/nn1007176
   Zhao XC, 2012, ENVIRON INT, V40, P244, DOI 10.1016/j.envint.2011.12.003
   Zhao YH, 2001, J PHARM SCI-US, V90, P749, DOI 10.1002/jps.1031
   Zhu SQ, 2006, MAR ENVIRON RES, V62, pS5, DOI 10.1016/j.marenvres.2006.04.059
   Zhu XS, 2009, J NANOPART RES, V11, P67, DOI 10.1007/s11051-008-9426-8
   Zuo G, 2011, J PHYS CHEM C, V115, P23323, DOI 10.1021/jp208967t
   [Anonymous], 2009, ANAL NANOTECHNOLOGY
NR 291
TC 87
Z9 88
U1 9
U2 222
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC
PY 2012
VL 64
IS 15
BP 1663
EP 1693
DI 10.1016/j.addr.2012.05.014
PG 31
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 063UC
UT WOS:000313026500002
PM 22664229
DA 2018-01-05
ER

PT J
AU Date, AA
   Shibata, A
   Goede, M
   Sanford, B
   La Bruzzo, K
   Belshan, M
   Destache, CJ
AF Date, Abhijit A.
   Shibata, Annemarie
   Goede, Michael
   Sanford, Bridget
   La Bruzzo, Krista
   Belshan, Michel
   Destache, Christopher J.
TI Development and evaluation of a thermosensitive vaginal gel containing
   raltegravir plus efavirenz loaded nanoparticles for HIV prophylaxis
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Raltegravir; Efavirenz; Pre-exposure prophylaxis; Nanoparticles; HIV;
   Thermosensitive gel
ID TOPICAL MICROBICIDES; DOUBLE-BLIND; IN-VITRO; INFECTION; PREVENTION;
   FORMULATIONS; DISPOSITION; METABOLISM; EXPRESSION; WOMEN
AB The objective of this investigation was to develop a thermosensitive vaginal gel containing raltegravir + efavirenz loaded PLGA nanoparticles (RAL+EFV-NPs) for pre-exposure prophylaxis of HIV. RAL+EFV-NPs were fabricated using a modified emulsion-solvent evaporation method and characterized for size and zeta potential. The average size and surface charge of RAL+EFV-NP were 81.8 +/- 6.4 nm and -23.18 +/- 7.18 mV respectively. The average encapsulation efficiency of raltegravir and efavirenz was 55.5% and 98.2% respectively. Thermosensitive vaginal gel containing RAL+EFV-NPs was successfully prepared using a combination of Pluronic F127 (20% w/v) and Pluronic F68 (1% w/v). Incorporation RAL+EFV-NPs in the gel did not result in nanoparticle aggregation and RAL+EFV-NPs containing gel showed thermogelation at 32.5 degrees C. The RAL+EFV-NPs were evaluated for inhibition of HIV-1(NL4-3) using TZM-bl indicator cells. The EC90 of RAL+EFV-NPs was lower than raltegravir + efavirenz (RAL+EFV) solution but did not reach significance. Compared to control HeLa cells without any treatment, RAL+EFV-NPs or blank gel were not cytotoxic for 14 days in vitro. The intracellular levels of efavirenz in RAL+EFV-NPs treated HeLa cells were above the EC90 for 14 days whereas raltegravir intracellular concentrations were eliminated within 6 days. Transwell experiments of NPs-in-gel demonstrated rapid transfer of fluorescent nanoparticles from the gel and uptake in HeLa cells within 30 min. These data demonstrate the potential of antiretroviral NP-embedded vagina gels for long-term vaginal pre-exposure prophylaxis of heterosexual HIV-1 transmission. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Date, Abhijit A.; Goede, Michael; Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Shibata, Annemarie; La Bruzzo, Krista] Creighton Univ, Dept Biol, Omaha, NE 68178 USA.
   [Sanford, Bridget; Belshan, Michel] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Date, Abhijit/0000-0001-6617-882X; Destache,
   Christopher/0000-0001-7923-3939
FU National Institute of Health [1R56AI095115-01]; Creighton University;
   National Institute of General Medical Sciences [8 P30 GM103509-03];
   NIH-INBRE;  [5RO1AI080348]
FX This work was supported by National Institute of Health grants
   1R56AI095115-01 and a Clinical Translational Science Award from
   Creighton University (to C.J.D.), 5RO1AI080348 (to M.B.), a grant from
   the National Institute of General Medical Sciences (8 P30 GM103509-03),
   NIH-INBRE grant and Creighton University Presidents Grant (to A.S.). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams JL, 2012, BEST PRACT RES CL OB, V26, P451, DOI 10.1016/j.bpobgyn.2012.01.004
   Aka-Any-Grah A, 2010, EUR J PHARM BIOPHARM, V76, P296, DOI 10.1016/j.ejpb.2010.07.004
   Baloglu E, 2011, J PHARM PHARMACOL, V63, P1274, DOI 10.1111/j.2042-7158.2011.01315.x
   Bumpus NN, 2006, J PHARMACOL EXP THER, V318, P345, DOI 10.1124/jpet.106.102525
   Clavel C, 2011, ANTIMICROB AGENTS CH, V55, P3018, DOI 10.1128/AAC.01460-10
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dezzutti CS, 2012, J ANTIMICROB CHEMOTH, V67, P2139, DOI 10.1093/jac/dks173
   Ensign L. M., 2012, SCI TRANSL MED, V4, P138, DOI DOI 10.1126/SCITRANSLMED.3003453
   FARIN FM, 1995, CARCINOGENESIS, V16, P1670
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Friend DR, 2010, PHARM DEV TECHNOL, V15, P562, DOI 10.3109/10837450903369879
   Garcia-Lerma JG, 2010, TRENDS PHARMACOL SCI, V31, P74, DOI 10.1016/j.tips.2009.10.009
   Iwamoto M, 2008, J CLIN PHARMACOL, V48, P209, DOI 10.1177/0091270007310382
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kassahun K, 2007, DRUG METAB DISPOS, V35, P1657, DOI 10.1124/dmd.107.016196
   Kelly CG, 2011, J INTERN MED, V270, P509, DOI 10.1111/j.1365-2796.2011.02454.x
   Kiser PF, 2012, J PHARM SCI-US, V101, P1852, DOI 10.1002/jps.23089
   Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334
   Maurin MB, 2002, PHARMACEUT RES, V19, P517, DOI 10.1023/A:1015160132290
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   Moss DM, 2012, ANTIMICROB AGENTS CH, V56, P3020, DOI 10.1128/AAC.06407-11
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Nakamura A, 2008, DRUG METAB DISPOS, V36, P1461, DOI 10.1124/dmd.108.021428
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Rodriguez-Antona C, 2003, MOL PHARMACOL, V63, P1180, DOI 10.1124/mol.63.5.1180
   Roy S, 2001, ANTIMICROB AGENTS CH, V45, P1671, DOI 10.1128/AAC.45.6.1671-1681.2001
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Shibata A., AIDS HUM RETROVIRUSE
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Tanaka R, 2008, ANTIMICROB AGENTS CH, V52, P782, DOI 10.1128/AAC.01613-06
   Warner L, 2009, J INFECT DIS, V199, P59, DOI 10.1086/595569
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
NR 33
TC 30
Z9 31
U1 0
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD DEC
PY 2012
VL 96
IS 3
BP 430
EP 436
DI 10.1016/j.antiviral.2012.09.015
PG 7
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 056UY
UT WOS:000312518100019
PM 23041201
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dereuddre-Bosquet, N
   Morellato-Castillo, L
   Brouwers, J
   Augustijns, P
   Bouchemal, K
   Ponchel, G
   Ramos, OHP
   Herrera, C
   Stefanidou, M
   Shattock, R
   Heyndrickx, L
   Vanham, G
   Kessler, P
   Le Grand, R
   Martin, L
AF Dereuddre-Bosquet, Nathalie
   Morellato-Castillo, Laurence
   Brouwers, Joachim
   Augustijns, Patrick
   Bouchemal, Kawthar
   Ponchel, Gilles
   Ramos, Oscar H. P.
   Herrera, Carolina
   Stefanidou, Martha
   Shattock, Robin
   Heyndrickx, Leo
   Vanham, Guido
   Kessler, Pascal
   Le Grand, Roger
   Martin, Loic
TI MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and
   Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques
SO PLOS PATHOGENS
LA English
DT Article
ID ENVELOPE GLYCOPROTEIN; SIVMAC251 INFECTION; RHESUS MACAQUES; CD4;
   NEUTRALIZATION; GP120; ENTRY; MINIPROTEIN; PROTECTION; INHIBITORS
AB In complement to an effective vaccine, development of potent anti-HIV microbicides remains an important priority. We have previously shown that the miniCD4 M48U1, a functional mimetic of sCD4 presented on a 27 amino-acid stable scaffold, inhibits a broad range of HIV-1 isolates at sub-nanomolar concentrations in cellular models. Here, we report that M48U1 inhibits efficiently HIV-1(Ba-L) in human mucosal explants of cervical and colorectal tissues. In vivo efficacy of M48U1 was evaluated in nonhuman primate (NHP) model of mucosal challenge with SHIV162P3 after assessing pharmacokinetics and pharmacodynamics of a miniCD4 gel formulation in sexually matured female cynomolgus macaques. Among 12 females, half were treated with hydroxyethylcellulose-based gel (control), the other half received the same gel containing 3 mg/g of M48U1, one hour before vaginal route challenge with 10 AID(50) of SHIV162P3. All control animals were infected with a peak plasma viral load of 10(5)-10(6) viral RNA (vRNA) copies per mL. In animals treated with miniCD4, 5 out of 6 were fully protected from acquisition of infection, as assessed by qRT-PCR for vRNA detection in plasma, qPCR for viral DNA detection in PBMC and lymph node cells. The only infected animal in this group had a delayed peak of viremia of one week. These results demonstrate that M48U1 miniCD4 acts in vivo as a potent entry inhibitor, which may be considered in microbicide developments.
C1 [Dereuddre-Bosquet, Nathalie; Le Grand, Roger] CEA, Div Immunovirol, iMETI, Fontenay Aux Roses, France.
   [Dereuddre-Bosquet, Nathalie; Le Grand, Roger] Univ Paris 11, UMRE01, Orsay, France.
   [Morellato-Castillo, Laurence; Ramos, Oscar H. P.; Kessler, Pascal; Martin, Loic] CEA, iBiTecS, Serv Ingn Mol Prot, Gif Sur Yvette, France.
   [Brouwers, Joachim; Augustijns, Patrick] Katholieke Univ Leuven, Louvain, Belgium.
   [Bouchemal, Kawthar; Ponchel, Gilles] Univ Paris Sud, Fac Pharm, Chatenay Malabry, France.
   [Herrera, Carolina; Shattock, Robin] Univ London Imperial Coll Sci Technol & Med, Fac Med, Infect Dis Sect, London, England.
   [Stefanidou, Martha] Albert Einstein Coll Med, Dept Pediat & Microbiol Immunol, Bronx, NY 10467 USA.
   [Heyndrickx, Leo; Vanham, Guido] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Heyndrickx, Leo; Vanham, Guido] Univ Antwerp, B-2020 Antwerp, Belgium.
RP Dereuddre-Bosquet, N (reprint author), CEA, Div Immunovirol, iMETI, Fontenay Aux Roses, France.
EM loic.martin@cea.fr
RI Ramos, Oscar/E-1862-2013; Brouwers, Joachim/B-3602-2012
OI Ramos, Oscar/0000-0002-5788-4500; Brouwers, Joachim/0000-0003-1478-6174
FU French National Research Agency (ANR); ANRS (French National Agency for
   Research on AIDS and Viral Hepatitis; European Microbicide Project
   (EMPRO-FP6) Program; European Combined Highly Active Retroviral
   Microbicides (CHAARM-FP7) Program [242135]
FX This work was funded by the French National Research Agency (ANR). We
   also thank the ANRS (French National Agency for Research on AIDS and
   Viral Hepatitis - www.anrs.fr) for the financial support to the ANRS NHP
   working group. This work was also partially supported by grants from the
   European Microbicide Project (EMPRO-FP6) and the European Combined
   Highly Active Retroviral Microbicides (CHAARM-FP7 - Grant agreement
   no242135 -www.chaarm.eu) Programs. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aarnink A, 2011, IMMUNOGENETICS, V63, P267, DOI 10.1007/s00251-010-0504-6
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Bourry O, 2009, AIDS, V23, P447, DOI 10.1097/QAD.0b013e328321302d
   Grupping K, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-36
   Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karlsson I, 2007, J VIROL, V81, P13444, DOI 10.1128/JVI.01466-07
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Mannioui A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-106
   Martin G, 2011, J BIOL CHEM, V286, P21706, DOI 10.1074/jbc.M111.232272
   Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768
   Mee ET, 2009, IMMUNOGENETICS, V61, P327, DOI 10.1007/s00251-009-0369-8
   O'Connor SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000524
   Stricher F, 2008, J MOL BIOL, V382, P510, DOI 10.1016/j.jmb.2008.06.069
   Van Herrewege Y, 2008, J ANTIMICROB CHEMOTH, V61, P818, DOI 10.1093/jac/dkn042
   Veazey RS, 2010, J INFECT DIS, V202, P739, DOI 10.1086/655661
   Veazey RS, 2009, J INFECT DIS, V199, P1525, DOI 10.1086/598685
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Vermeire K, 2008, CURR HIV RES, V6, P246, DOI 10.2174/157016208784324958
   Vita C, 1999, P NATL ACAD SCI USA, V96, P13091, DOI 10.1073/pnas.96.23.13091
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
NR 25
TC 27
Z9 28
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2012
VL 8
IS 12
AR e1003071
DI 10.1371/journal.ppat.1003071
PG 8
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 062GJ
UT WOS:000312907100026
PM 23236282
OA gold
DA 2018-01-05
ER

PT J
AU Atas, E
   Singer, A
   Meller, A
AF Atas, Evrim
   Singer, Alon
   Meller, Amit
TI DNA sequencing and bar-coding using solid-state nanopores
SO ELECTROPHORESIS
LA English
DT Review
DE DNA sequencing; Genotyping; Nanopore; Optical readout; PNA
ID PEPTIDE NUCLEIC-ACIDS; ANTIRETROVIRAL TREATMENT; STRAND INVASION;
   GAMMA-PNAS; B-DNA; SINGLE; MOLECULES; RESOLUTION; SENSORS; DIAGNOSTICS
AB Nanopores have emerged as a prominent single-molecule analytic tool with particular promise for genomic applications. In this review, we discuss two potential applications of the nanopore sensors: First, we present a nanopore-based single-molecule DNA sequencing method that utilizes optical detection for massively parallel throughput. Second, we describe a method by which nanopores can be used as single-molecule genotyping tools. For DNA sequencing, the distinction among the four types of DNA nucleobases is achieved by employing a biochemical procedure for DNA expansion. In this approach, each nucleobase in each DNA strand is converted into one of four predefined unique 16-mers in a process that preserves the nucleobase sequence. The resulting converted strands are then hybridized to a library of four molecular beacons, each carrying a unique fluorophore tag, that are perfect complements to the 16-mers used for conversion. Solid-state nanopores are then used to sequentially remove these beacons, one after the other, leading to a series of photon bursts in four colors that can be optically detected. Single-molecule genotyping is achieved by tagging the DNA fragments with ?-modified synthetic peptide nucleic acid probes coupled to an electronic characterization of the complexes using solid-state nanopores. This method can be used to identify and differentiate genes with a high level of sequence similarity at the single-molecule level, but different pathology or response to treatment. We will illustrate this method by differentiating the pol gene for two highly similar human immunodeficiency virus subtypes, paving the way for a novel diagnostics platform for viral classification.
C1 [Atas, Evrim; Singer, Alon; Meller, Amit] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Meller, Amit] Technion Israel Inst Technol, Fac Biomed Engn, Haifa, Israel.
RP Meller, A (reprint author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
EM ameller@bu.edu
OI Meller, Amit/0000-0001-7082-0985
FU National Institutes of Health [R01 HG-005871]; National Science
   Foundation [PHY-0646637]
FX The authors acknowledge A. Squires for careful editing and commenting on
   the manuscript. Financial support from National Institutes of Health
   award R01 HG-005871 and National Science Foundation awards PHY-0646637
   are acknowledged.
CR Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5                                                   
   Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Chenna V, 2008, CHEMBIOCHEM, V9, P2388, DOI 10.1002/cbic.200800441
   Cherf GM, 2012, NAT BIOTECHNOL, V30, P344, DOI 10.1038/nbt.2147
   Deamer DW, 2002, ACCOUNTS CHEM RES, V35, P817, DOI 10.1021/ar000138m
   Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986
   Fuller CW, 2009, NAT BIOTECHNOL, V27, P1013, DOI 10.1038/nbt.1585
   Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764
   Gulick R. M., 2010, J ACQUIR IMMUNE D S1, V55, pS43
   Gulick RM, 2010, JAIDS-J ACQ IMM DEF, V55, pS43, DOI 10.1097/QAI.0b013e3181f9c09e
   Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427
   He GF, 2009, J AM CHEM SOC, V131, P12088, DOI 10.1021/ja900228j
   Healy K, 2007, NANOMEDICINE-UK, V2, P459, DOI 10.2217/17435889.2.4.459
   Kaittanis C, 2010, ADV DRUG DELIVER REV, V62, P408, DOI 10.1016/j.addr.2009.11.013
   Karkare S, 2006, APPL MICROBIOL BIOT, V71, P575, DOI 10.1007/s00253-006-0434-2
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   Kim MJ, 2006, ADV MATER, V18, P3149, DOI 10.1002/adma.200601191
   Kuhn H., 2010, ARTIF DNA PNA XNA, V1, P45, DOI 10.4161/adna.1.1.12444
   Lee HS, 2007, ADV MATER, V19, P4189, DOI 10.1002/adma.200701119
   Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037
   Liu Yu-Tsueng, 2008, Infectious Disorders - Drug Targets, V8, P183
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Manrao EA, 2012, NAT BIOTECHNOL, V30, P349, DOI 10.1038/nbt.2171
   McNally B, 2008, NANO LETT, V8, P3418, DOI 10.1021/nl802218f
   McNally B, 2010, NANO LETT, V10, P2237, DOI 10.1021/nl1012147
   Meller A, 2001, PHYS REV LETT, V86, P3435, DOI 10.1103/PhysRevLett.86.3435
   Miller MB, 2009, CLIN MICROBIOL REV, V22, P611, DOI 10.1128/CMR.00019-09
   Milos PM, 2009, EXPERT REV MOL DIAGN, V9, P659, DOI 10.1586/ERM.09.50
   Nam SW, 2009, NANO LETT, V9, P2044, DOI 10.1021/nl900309s
   Nielsen PE, 2010, CHEM BIODIVERS, V7, P786, DOI 10.1002/cbdv.201000005
   Phillips KM, 2005, NUCLEIC ACIDS RES, V33, P5829, DOI 10.1093/nar/gki895
   Rapireddy S, 2007, J AM CHEM SOC, V129, P15596, DOI 10.1021/ja074886j
   Rodenburg CM, 2001, AIDS RES HUM RETROV, V17, P161, DOI 10.1089/08892220150217247
   Rosenstein JK, 2012, NAT METHODS, V9, P487, DOI [10.1038/NMETH.1932, 10.1038/nmeth.1932]
   Sahu B, 2011, J ORG CHEM, V76, P5614, DOI 10.1021/jo200482d
   Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325
   Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389
   Singer A, 2012, NANO LETT, V12, P1722, DOI 10.1021/nl300372a
   Singer A, 2010, NANO LETT, V10, P738, DOI 10.1021/nl100058y
   Soni V. G., 2010, REV SCI INSTRUM, V81
   Storm AJ, 2003, NAT MATER, V2, P537, DOI 10.1038/nmat941
   Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004
   Venkatesan BM, 2011, NAT NANOTECHNOL, V6, P615, DOI [10.1038/nnano.2011.129, 10.1038/NNANO.2011.129]
   Wanunu M., 2009, NAT NANOTECHNOL, V5, P160
   Wanunu M, 2008, BIOPHYS J, V95, P4716, DOI 10.1529/biophysj.108.140475
   Wanunu M, 2009, NANO LETT, V9, P3498, DOI 10.1021/nl901691v
   Xie P, 2012, NAT NANOTECHNOL, V7, P119, DOI [10.1038/nnano.2011.217, 10.1038/NNANO.2011.217]
   Zhang N, 2010, J INFECT DIS, V201, pS42, DOI 10.1086/650389
NR 49
TC 15
Z9 15
U1 1
U2 95
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0173-0835
J9 ELECTROPHORESIS
JI Electrophoresis
PD DEC
PY 2012
VL 33
IS 23
SI SI
BP 3437
EP 3447
DI 10.1002/elps.201200266
PG 11
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 051VY
UT WOS:000312157200005
PM 23109189
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kalinin, S
   Peulen, T
   Sindbert, S
   Rothwell, PJ
   Berger, S
   Restle, T
   Goody, RS
   Gohlke, H
   Seidel, CAM
AF Kalinin, Stanislav
   Peulen, Thomas
   Sindbert, Simon
   Rothwell, Paul J.
   Berger, Sylvia
   Restle, Tobias
   Goody, Roger S.
   Gohlke, Holger
   Seidel, Claus A. M.
TI A toolkit and benchmark study for FRET-restrained high-precision
   structural modeling
SO NATURE METHODS
LA English
DT Article
ID SINGLE-MOLECULE FRET; RESONANCE ENERGY-TRANSFER; MULTIPARAMETER
   FLUORESCENCE DETECTION; PROBABILITY-DISTRIBUTION ANALYSIS; HIV-1
   REVERSE-TRANSCRIPTASE; NANO-POSITIONING SYSTEM; DNA; COMPLEX; DYNAMICS;
   SPECTROSCOPY
AB We present a comprehensive toolkit for Forster resonance energy transfer (FRET)-restrained modeling of biomolecules and their complexes for quantitative applications in structural biology. A dramatic improvement in the precision of FRET-derived structures is achieved by explicitly considering spatial distributions of dye positions, which greatly reduces uncertainties due to flexible dye linkers. The precision and confidence levels of the models are calculated by rigorous error estimation. The accuracy of this approach is demonstrated by docking a DNA primer-template to HIV-1 reverse transcriptase. The derived model agrees with the known X-ray structure with an r.m.s. deviation of 0.5 angstrom. Furthermore, we introduce FRET-guided 'screening' of a large structural ensemble created by molecular dynamics simulations. We used this hybrid approach to determine the formerly unknown configuration of the flexible single-strand template overhang.
C1 [Kalinin, Stanislav; Peulen, Thomas; Sindbert, Simon; Rothwell, Paul J.; Berger, Sylvia; Seidel, Claus A. M.] Univ Dusseldorf, Lehrstuhl Mol Phys Chem, D-40225 Dusseldorf, Germany.
   [Rothwell, Paul J.; Restle, Tobias; Goody, Roger S.] Max Planck Inst Mol Physiol, D-44139 Dortmund, Germany.
   [Restle, Tobias] Med Univ Lubeck, Inst Mol Med, D-23538 Lubeck, Germany.
   [Gohlke, Holger] Univ Dusseldorf, Inst Pharmazeut & Med Chem, D-40225 Dusseldorf, Germany.
RP Kalinin, S (reprint author), Univ Dusseldorf, Lehrstuhl Mol Phys Chem, D-40225 Dusseldorf, Germany.
EM stanislav.kalinin@uni-duesseldorf.de; cseidel@hhu.de
RI Goody, Roger/J-8845-2014; Seidel, Claus/A-3682-2012
OI Goody, Roger/0000-0002-0772-0444; Seidel, Claus/0000-0002-5171-149X
FU Volkswagen Foundation [I/74470]; Max-Planck Society; German Federal
   Ministry of Education and Research (BMBF) [0311865]; German Science
   Foundation [SPP 1258, SE 1195/12-2]; 'Fit for Excellence' initiative of
   HHU; International Helmholtz Research School of Biophysics and Soft
   Matter (IHRS BioSoft); NRW Research School of Biological Structures in
   Molecular Medicine and Biotechnology (BioStruct)
FX We dedicate this paper to the memory of our brilliant colleague, Robert
   M. Clegg, a pioneer in the application of FRET in the life sciences and
   a remarkable human being. We would like to thank E. Schweinberger, O.
   Kensch and B. M. Wohrl for assistance with the experiments, E. Haustein
   for analytical software, H. Sanabria for help with data visualization
   and A. Scheidig for helpful discussions. We acknowledge financial
   support from the Volkswagen Foundation (to R. S. G. and C. A. M. S.;
   grant no. I/74470), Max-Planck Society (to R. S. G.), German Federal
   Ministry of Education and Research (BMBF) (BioFuture grant no. 0311865)
   and German Science Foundation within SPP 1258 (grant no. SE 1195/12-2)
   (to C. A. M. S.) and 'Fit for Excellence' initiative of HHU (to H. G.).
   T. P. thanks the International Helmholtz Research School of Biophysics
   and Soft Matter (IHRS BioSoft), and S. S. thanks the NRW Research School
   of Biological Structures in Molecular Medicine and Biotechnology
   (BioStruct) for scholarships.
CR Andrecka J, 2008, P NATL ACAD SCI USA, V105, P135, DOI 10.1073/pnas.0703815105
   Antonik M, 2006, J PHYS CHEM B, V110, P6970, DOI 10.1021/jp057257+
   Balci H, 2011, BIOPHYS J, V101, P976, DOI 10.1016/j.bpj.2011.07.010
   Best RB, 2007, P NATL ACAD SCI USA, V104, P18964, DOI 10.1073/pnas.0709567104
   Boura E, 2011, P NATL ACAD SCI USA, V108, P9437, DOI 10.1073/pnas.1101763108
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Brunger AT, 2011, J STRUCT BIOL, V173, P497, DOI 10.1016/j.jsb.2010.09.004
   Cai Q, 2007, BIOPHYS J, V93, P2110, DOI 10.1529/biophysj.107.109439
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Choi UB, 2010, NAT STRUCT MOL BIOL, V17, P318, DOI 10.1038/nsmb.1763
   DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1                                                   
   Dolghih E, 2007, J PHOTOCH PHOTOBIO A, V190, P321, DOI 10.1016/j.jphotochem.2006.11.009
   EFRON B, 1986, ANN STAT, V14, P1301, DOI 10.1214/aos/1176350145                                                          
   Eggeling C, 2001, J BIOTECHNOL, V86, P163, DOI 10.1016/S0168-1656(00)00412-0
   Felekyan S, 2012, CHEMPHYSCHEM, V13, P1036, DOI 10.1002/cphc.201100897
   Gotte M, 2010, BBA-PROTEINS PROTEOM, V1804, P1202, DOI 10.1016/j.bbapap.2009.07.020
   Gopich IV, 2003, J PHYS CHEM B, V107, P5058, DOI 10.1021/jp027481o
   Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264
   Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522
   Hoefling M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019791
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Isaksson M, 2007, PHYS CHEM CHEM PHYS, V9, P1941, DOI 10.1039/b614817d
   Kalinin S, 2008, J PHYS CHEM B, V112, P8361, DOI 10.1021/jp711942q
   Knight JL, 2005, BIOPHYS J, V88, P925, DOI 10.1529/biophysj.104.050187
   Lakowicz JR, 2006, PRINCIPLES FLUORESCE
   Lyskov S, 2008, NUCLEIC ACIDS RES, V36, pW233, DOI 10.1093/nar/gkn216
   Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   McCann JJ, 2011, STRUCTURE, V19, P810, DOI 10.1016/j.str.2011.02.017
   Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0
   Merchant KA, 2007, P NATL ACAD SCI USA, V104, P1528, DOI 10.1073/pnas.0607097104
   Muschielok A, 2008, NAT METHODS, V5, P965, DOI 10.1038/nmeth.1259
   Muschielok A, 2011, J PHYS CHEM B, V115, P11927, DOI 10.1021/jp2060377
   Nir E, 2006, J PHYS CHEM B, V110, P22103, DOI 10.1021/jp063483n
   Olofsson M, 2006, PHYS CHEM CHEM PHYS, V8, P3130, DOI 10.1039/b601313a
   PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006
   Peletskaya EN, 2004, J VIROL, V78, P3387, DOI 10.1128/JVI.78.7.3387-3397.2004
   Rothwell PJ, 2003, P NATL ACAD SCI USA, V100, P1655, DOI 10.1073/pnas.0434003100
   Rothwell P.J., 2002, THESIS U DORTMUND
   Sabir T, 2011, J AM CHEM SOC, V133, P1188, DOI 10.1021/ja108626w
   Sakon JJ, 2010, NAT METHODS, V7, P203, DOI [10.1038/nmeth.1421, 10.1038/NMETH.1421]
   Santoso Y, 2010, CHEMPHYSCHEM, V11, P2209, DOI 10.1002/cphc.201000129
   Sindbert S, 2011, J AM CHEM SOC, V133, P2463, DOI 10.1021/ja105725e
   Sisamakis E, 2010, METHOD ENZYMOL, V475, P455, DOI 10.1016/S0076-6879(10)75018-7
   Soong TT, 2004, FUNDAMENTALS PROBABI
   STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131                                             
   Tokuriki N, 2009, SCIENCE, V324, P203, DOI 10.1126/science.1169375
   Upadhyay AK, 2010, MOL CELL BIOCHEM, V338, P19, DOI 10.1007/s11010-009-0316-x
   van Dijk M, 2010, NUCLEIC ACIDS RES, V38, P5634, DOI 10.1093/nar/gkq222
   VanBeek DB, 2007, BIOPHYS J, V92, P4168, DOI 10.1529/biophysj.106.092650
   van der Meer B. W., 1994, RESONANCE ENERGY TRA
   Wozniak AK, 2008, P NATL ACAD SCI USA, V105, P18337, DOI 10.1073/pnas.0800977105
NR 52
TC 125
Z9 127
U1 6
U2 106
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1548-7091
J9 NAT METHODS
JI Nat. Methods
PD DEC
PY 2012
VL 9
IS 12
BP 1218
EP U129
DI 10.1038/NMETH.2222
PG 10
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 050ZL
UT WOS:000312093500028
PM 23142871
DA 2018-01-05
ER

PT J
AU Wunderlich, S
   Haase, A
   Merkert, S
   Beier, J
   Schwanke, K
   Schambach, A
   Glage, S
   Gohring, G
   Curnow, EC
   Martin, U
AF Wunderlich, Stephanie
   Haase, Alexandra
   Merkert, Sylvia
   Beier, Jennifer
   Schwanke, Kristin
   Schambach, Axel
   Glage, Silke
   Goehring, Gudrun
   Curnow, Eliza C.
   Martin, Ulrich
TI Induction of Pluripotent Stem Cells from a Cynomolgus Monkey Using a
   Polycistronic Simian Immunodeficiency Virus-Based Vector,
   Differentiation Toward Functional Cardiomyocytes, and Generation of
   Stably Expressing Reporter Lines
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID HUMAN DENDRITIC CELLS; TRIM5-ALPHA RESTRICTION FACTOR; SOMATIC-CELLS;
   LENTIVIRUS VECTORS; HIV-1 REPLICATION; EPITHELIAL-CELLS; DEFINED MEDIUM;
   PRIMATE MODEL; GENE-TRANSFER; IPS CELLS
AB Induced pluripotent stem cells (iPSCs) represent a novel cell source for regenerative therapies. Many emerging iPSC-based therapeutic concepts will require preclinical evaluation in suitable large animal models. Among the large animal species frequently used in preclinical efficacy and safety studies, macaques show the highest similarities to humans at physiological, cellular, and molecular levels. We have generated iPSCs from cynomolgus monkeys (Macaca fascicularis) as a segue to regenerative therapy model development in this species. Because typical human immunodeficiency virus type 1 (HIV-1)-based lentiviral vectors show poor transduction of simian cells, a simian immunodeficiency virus (SIV)-based vector was chosen for efficient transduction of cynomolgus skin fibroblasts. A corresponding polycistronic vector with codon-optimized reprogramming factors was constructed for reprogramming. Growth characteristics as well as cell and colony morphology of the resulting cynomolgus iPSCs (cyiPSCs) were demonstrated to be almost identical to cynomolgus embryonic stem cells (cyESCs), and cyiPSCs expressed typical pluripotency markers including OCT4, SOX2, and NANOG. Furthermore, differentiation in vivo and in vitro into derivatives of all three germ layers, as well as generation of functional cardiomyocytes, could be demonstrated. Finally, a highly efficient technique for generation of transgenic cyiPSC clones with stable reporter expression in undifferentiated cells as well as differentiated transgenic cyiPSC progeny was developed to enable cell tracking in recipient animals. In conclusion, our data indicate that cyiPSCs represent a valuable cell source for establishment of macaque-based allogeneic and autologous preclinical cell transplantation models for various fields of regenerative medicine.
C1 [Wunderlich, Stephanie; Haase, Alexandra; Merkert, Sylvia; Beier, Jennifer; Schwanke, Kristin; Martin, Ulrich] Hannover Med Sch, Dept Cardiothorac Transplantat & Vasc Surg, Leibniz Res Labs Biotechnol & Artificial Organ LE, D-30625 Hannover, Germany.
   [Schambach, Axel] Hannover Med Sch, Dept Expt Hematol, D-30625 Hannover, Germany.
   [Glage, Silke] Hannover Med Sch, Inst Lab Anim Sci, D-30625 Hannover, Germany.
   [Goehring, Gudrun] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany.
   [Curnow, Eliza C.] Washington Natl Primate Res Ctr, Seattle, WA 98121 USA.
RP Martin, U (reprint author), Hannover Med Sch, Dept Cardiothorac Transplantat & Vasc Surg, Leibniz Res Labs Biotechnol & Artificial Organ LE, D-30625 Hannover, Germany.
EM martin.ulrich@mh-hannover.de
RI Martin, Ulrich/F-4888-2017
OI Martin, Ulrich/0000-0003-1058-4540
FU German Federal Ministry of Education and Research [01GN0816]; Excellence
   Cluster 'REBIRTH'
FX The authors are grateful to R. Chen, M. Tomala, and T. Scheper for
   providing recombinant bFGF, A. Kirschning and G. Drager for providing
   Y-27632, Francois-Loic Cossett and Didier Negre, Ecole Normale
   Superieure de Lyon, France for providing the SIVmac-vector
   pSIV<INF>RMES</INF>GAE, and Covance for providing us skin biopsies from
   cynomolgous monkeys. This work was supported by the German Federal
   Ministry of Education and Research (01GN0816) as well as by the
   Excellence Cluster 'REBIRTH'.
CR Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503
   Authier Simon, 2007, Journal of Pharmacological and Toxicological Methods, V56, P122, DOI 10.1016/j.vascn.2007.03.011
   Banach K, 2003, AM J PHYSIOL-HEART C, V284, pH2114, DOI 10.1152/ajpheart.01106.2001
   Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599
   Bjugstad KB, 2008, EXP NEUROL, V211, P362, DOI 10.1016/j.expneurol.2008.01.025
   Champeroux Pascal, 2009, Journal of Pharmacological and Toxicological Methods, V59, P73, DOI 10.1016/j.vascn.2008.11.001
   Chan AWS, 2010, CELL REPROGRAM, V12, P509, DOI 10.1089/cell.2010.0019
   Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499
   Deleidi M, 2011, STEM CELLS, V29, P1052, DOI 10.1002/stem.662
   Doevendans PA, 1998, CARDIOVASC RES, V39, P34, DOI 10.1016/S0008-6363(98)00073-X                                                   
   Emborg ME, 2008, CELL TRANSPLANT, V17, P383
   Esteban MA, 2009, J BIOL CHEM, V284, P17634, DOI 10.1074/jbc.M109.008938
   Ezashi T, 2009, P NATL ACAD SCI USA, V106, P10993, DOI 10.1073/pnas.0905284106
   Gandolfi F, 2011, THERIOGENOLOGY, V75, P1416, DOI 10.1016/j.theriogenology.2011.01.026
   Gruh I, 2005, BIOTECHNIQUES, V38, P530, DOI 10.2144/05384BM02                                                               
   Haase A, 2009, CELL STEM CELL, V5, P434, DOI 10.1016/j.stem.2009.08.021
   Halbach MD, 2003, CELL PHYSIOL BIOCHEM, V13, P271, DOI 10.1159/000074542
   Hanazono Y, 2003, TRENDS CARDIOVAS MED, V13, P106, DOI 10.1016/S1050-1738(02)00253-0                                                   
   Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028
   Ikeda H, 2007, AM J PHYSIOL-GASTR L, V293, pG911, DOI 10.1152/ajpgi.00210.2007
   KNOERZER W, 1989, GENE, V75, P21, DOI 10.1016/0378-1119(89)90379-X
   LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505
   Lee AS, 2011, J BIOL CHEM, V286, P32697, DOI 10.1074/jbc.M111.235739
   Liang HM, 2010, CELL PHYSIOL BIOCHEM, V25, P459, DOI 10.1159/000303051
   Liebsch M, 2011, ARCH TOXICOL, V85, P841, DOI 10.1007/s00204-011-0718-x
   Liu HS, 2008, CELL STEM CELL, V3, P587, DOI 10.1016/j.stem.2008.10.014
   Liu YX, 2006, BIOCHEM BIOPH RES CO, V346, P131, DOI 10.1016/j.bbrc.2006.05.086
   Luo JS, 2011, STEM CELLS DEV, V20, P1669, DOI 10.1089/scd.2011.0127
   Mangeot PE, 2002, MOL THER, V5, P283, DOI 10.1006/mthe.2002.0541
   Mangeot PE, 2000, J VIROL, V74, P8307, DOI 10.1128/JVI.74.18.8307-8315.2000
   Mauritz C, 2008, CIRCULATION, V118, P507, DOI 10.1161/CIRCULATIONAHA.108.778795
   Munk C, 2002, P NATL ACAD SCI USA, V99, P13843, DOI 10.1073/pnas.212400099
   Nakayama EE, 2006, VIROLOGY, V350, P158, DOI 10.1016/j.virol.2006.03.035
   Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3
   Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292
   Okahara-Narita J, 2012, PRIMATES, V53, P205, DOI 10.1007/s10329-011-0283-1
   Okamoto S, 2011, INVEST OPHTH VIS SCI, V52, P8785, DOI 10.1167/iovs.11-8129
   Olmer R, 2010, STEM CELL RES, V5, P51, DOI 10.1016/j.scr.2010.03.005
   OMURA Y, 1970, T NEW YORK ACAD SCI, V32, P874, DOI 10.1111/j.2164-0947.1970.tb02987.x                                              
   Owens CA, 2003, J VIROL, V77, P726, DOI 10.1128/JVI.77.1.726-731.2003
   Palecek J, 2011, ORG BIOMOL CHEM, V9, P5503, DOI 10.1039/c1ob05332a
   Papapetrou EP, 2009, P NATL ACAD SCI USA, V106, P12759, DOI 10.1073/pnas.0904825106
   Perron MJ, 2007, J VIROL, V81, P2138, DOI 10.1128/JVI.02318-06
   Rahm N, 2011, J VIROL, V85, P4173, DOI 10.1128/JVI.00075-11
   RAKUSAN K, 1994, CARDIOVASC RES, V28, P969, DOI 10.1093/cvr/28.7.969
   Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104
   Roitberg BZ, 2006, J NEUROSURG, V105, P96, DOI 10.3171/jns.2006.105.1.96                                                       
   Sakuma R, 2007, GENE THER, V14, P185, DOI 10.1038/sj.gt.3302852
   Schwanke K, 2006, STEM CELLS, V24, P1423, DOI 10.1634/stemcells.2005-0380
   Schwanke U, 2006, J CLIN APHERESIS, V21, P153, DOI 10.1002/jca.20077
   Shimada H., 2011, MOL REPROD DEV, V77, P2
   STOKER ME, 1982, ANAT REC, V202, P187, DOI 10.1002/ar.1092020203
   Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103
   Suemori H, 2001, DEV DYNAM, V222, P273, DOI 10.1002/dvdy.1191                                                               
   SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710
   Szymczak AL, 2005, EXPERT OPIN BIOL TH, V5, P627, DOI 10.1517/14712598.5.5.627
   Tabar V, 2008, NAT MED, V14, P379, DOI 10.1038/nm1732
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024                                                      
   Tanaka T, 2009, BIOCHEM BIOPH RES CO, V385, P497, DOI 10.1016/j.bbrc.2009.05.073
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   van Laake LW, 2008, CIRC RES, V102, P1008, DOI 10.1161/CIRCRESAHA.108.175505
   Warlich E, 2011, MOL THER, V19, P782, DOI 10.1038/mt.2010.314
   Wessels A, 2003, PHYSIOL GENOMICS, V15, P165, DOI 10.1152/physiolgenomics.00033.2003
   Wesselschmidt RL, 2011, METHODS MOL BIOL, V767, P3, DOI 10.1007/978-1-61779-201-4_1
   Wunderlich S, 2008, HUM GENE THER, V19, P39, DOI 10.1089/hum.2006.0180
   Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894
   Yu JY, 2007, SCIENCE, V318, P1917, DOI [10.1126/science.1151526, 10.1126/science.1172482]
   Zhang F, 2011, TISSUE ENG PART B-RE, V17, P115, DOI [10.1089/ten.teb.2010.0549, 10.1089/ten.TEB.2010.0549]
   Zhong BN, 2011, MOL THER, V19, P1667, DOI 10.1038/mt.2011.51
   Zhu FF, 2011, DIABETOLOGIA, V54, P2325, DOI 10.1007/s00125-011-2246-x
NR 70
TC 6
Z9 8
U1 0
U2 16
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD DEC
PY 2012
VL 14
IS 6
BP 471
EP 484
DI 10.1089/cell.2012.0041
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA 047RI
UT WOS:000311857800003
PM 23194451
OA green_published
DA 2018-01-05
ER

PT J
AU Vijayakumar, S
   Ganesan, S
AF Vijayakumar, S.
   Ganesan, S.
TI Gold Nanoparticles as an HIV Entry Inhibitor
SO CURRENT HIV RESEARCH
LA English
DT Article
DE Gold nanoparticle; cytotoxic; broad - spectrum; immune system; viral
   inhibition; HIV-1
ID GLYCOPROTEIN; BIOLOGY; TROPISM; AIDS; CD4
AB Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay. The 50% cytotoxicity concentration, IC50 of gold nanoparticles was found to be 1.12 +/- 0.05 mg/ml. M-tropic, T-tropic, dual tropic and resistant isolates were inhibited by gold nanoparticles and their inhibition concentration ranged from 0.05 to 0.12 mg/ml. The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion. In this study, the gold nanoparticles were used to analyze their mode of antiviral activity and the experimental results showed that they inhibit the viral entry by binding with gp120 and prevent CD4 attachment. These properties of gold nanoparticles make them as an effective antiviral inhibitor.
C1 [Vijayakumar, S.] Sri Ramakrishna Inst Technol, Dept Phys, Coimbatore 641010, Tamil Nadu, India.
   [Ganesan, S.] Govt Coll Technol, Dept Phys, Coimbatore 641013, Tamil Nadu, India.
RP Vijayakumar, S (reprint author), Sri Ramakrishna Inst Technol, Dept Phys, Coimbatore 641010, Tamil Nadu, India.
EM vijaysk.research@gmail.com
CR BarreSinoussi F, 1996, LANCET, V348, P31, DOI 10.1016/S0140-6736(96)09058-7
   Bhattacharya J, 2007, NANOMED-NANOTECHNOL, V3, P14, DOI 10.1016/j.nano.2006.10.159
   Borkow G., 2005, Current Drug Targets - Infectious Disorders, V5, P3, DOI 10.2174/1568005053174645
   CHAVDA SC, 1994, J GEN VIROL, V75, P3249, DOI 10.1099/0022-1317-75-11-3249
   Coffin J. M., 1992, RETROVIRIDAE, P19
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0
   El-Sayed IH, 2005, NANO LETT, V5, P829, DOI 10.1021/nl050074e
   El-Ansary A, 2009, J TOXICOL, P1
   Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880
   FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617
   Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Keele BF, 2006, SCIENCE, V313, P523, DOI 10.1126/science.1126531
   Khalil H, 2004, LANGMUIR, V20, P6896, DOI 10.1021/la0497402
   Lara H.H., 2010, J BIOTECHNOL, P8, DOI DOI 10.1186/1477-3155-8-1
   LEKUTIS C, 1992, J ACQ IMMUN DEF SYND, V5, P78
   Levy JA, 1996, NEW ENGL J MED, V335, P1528, DOI 10.1056/NEJM199611143352011                                                     
   McDonnell GE, 1999, CLIN MICROBIOL REV, V12, P111
   Molen KH, 1979, J CANCER RES CLIN, V94, P81
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482                                                   
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Shankar SS, 2005, J NANOSCI NANOTECHNO, V5, P1721, DOI 10.1166/jnn.2005.192
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Spira S, 2003, J ANTIMICROB CHEMOTH, V51, P229, DOI 10.1093/jac/dkg079
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Zussman, 2003, AIDS, V17, P653
NR 27
TC 16
Z9 16
U1 0
U2 20
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD DEC
PY 2012
VL 10
IS 8
BP 643
EP 646
DI 10.2174/157016212803901383                                              
          
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 037LL
UT WOS:000311106100003
PM 22954307
DA 2018-01-05
ER

PT J
AU Ahmed, AHAM
   Brocchini, S
   Croft, SL
AF Ahmed, Abeer H. A. Mohamed
   Brocchini, Stephen
   Croft, Simon L.
TI Recent advances in development of amphotericin B formulations for the
   treatment of visceral leishmaniasis
SO CURRENT OPINION IN INFECTIOUS DISEASES
LA English
DT Review
DE amphotericin B; drug delivery system; visceral leishmaniasis
ID AZAR DERMAL LEISHMANIASIS; FUNCTIONALIZED CARBON NANOTUBES; HIV-INFECTED
   PATIENTS; SECONDARY PROPHYLAXIS; COMBINATION THERAPIES; BEARING
   EMULSOMES; LIPID COMPLEX; IN-VITRO; EFFICACY; TOXICITY
AB Purpose of review
   Amphotericin B (AmpB) is considered the first-line treatment for visceral leishmaniasis in areas in which resistance to antimony is prevalent. This review describes recent advances in clinically available and novel drug delivery systems of AmpB to treat visceral leishmaniasis.
   Recent findings
   Over the past two decades, lipid-based AmpB formulations developed to tackle the toxicity of AmpB have been used clinically for the treatment of visceral leishmaniasis. Liposomal AmpB (AmBisome) has been the most successful lipid formulation, and recent clinical studies on visceral leishmaniasis have shown the potential of single-dose AmBisome treatment as well as its use in short course combinations with other antileishmanial drugs. Current research is focussed on the development of more stable and affordable nonlipid formulations of AmpB. Although a diverse range of nonlipid-based AmpB formulations have been evaluated, none have yet reached the clinic.
   Summary
   Liposomal AmpB (AmBisome) has become a standard treatment, by intravenous infusion, for visceral leishmaniasis and the basis for new short course treatments. There have been extensive efforts to develop new AmpB formulations on the basis of polymers, lipids or physical aggregates of AmpB to replace the costly lipid-based formulations. However, no nonlipid-based AmpB delivery systems have yet reached the clinic.
C1 [Ahmed, Abeer H. A. Mohamed; Croft, Simon L.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England.
   [Ahmed, Abeer H. A. Mohamed; Brocchini, Stephen] UCL Sch Pharm, Dept Pharmaceut, London, England.
RP Croft, SL (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM simon.croft@lshtm.ac.uk
CR Mohamed Ahmed A, 2010, AMB POLYGLUTAMIC ACI
   Mohamed Ahmed A, 2011, THESIS U LONDON LOND
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530
   Burgess BL, 2010, INT J PHARMACEUT, V399, P148, DOI 10.1016/j.ijpharm.2010.07.057
   Chappuis F., 2007, NAT REV MICROBIOL, pS7, DOI DOI 10.1038/NRMICRO1748
   Chen H, 2008, LANGMUIR, V24, P5213, DOI 10.1021/la703570m
   CLARK JM, 1991, ANTIMICROB AGENTS CH, V35, P615, DOI 10.1128/AAC.35.4.615                                                            
   Croft SL, 2011, CLIN MICROBIOL INFEC, V17, P1478, DOI 10.1111/j.1469-0691.2011.03630.x
   Das S, 2009, THER CLIN RISK MANAG, V5, P117
   Espada R, 2008, INT J PHARMACEUT, V361, P64, DOI 10.1016/j.ijpharm.2008.05.013
   Gradoni L, 2008, TROP MED INT HEALTH, V13, P1272, DOI 10.1111/j.1365-3156.2008.02144.x
   Guffanti M, 2008, AM J TROP MED HYG, V79, P715
   Gupta S, 2007, J DRUG TARGET, V15, P437, DOI 10.1080/10611860701453836
   Gupta S, 2007, J DRUG TARGET, V15, P206, DOI 10.1080/10611860701195395
   Jadhav MP, 2010, J POSTGRAD MED, V56, P14, DOI 10.4103/0022-3859.65276
   Kravetz MH, 1961, MED INTELL, V265, P183
   Les K, 2010, CONTR DRUG REL CRS A
   Li C, 2008, ADV DRUG DELIVER REV, V60, P886, DOI 10.1016/j.addr.2007.11.009
   Lopez-Velez R, 2004, J ANTIMICROB CHEMOTH, V53, P540, DOI 10.1093/jac/dkh084
   Manandhar KD, 2008, J ANTIMICROB CHEMOTH, V62, P376, DOI 10.1093/jac/dkn189
   Manfredi R, 2008, INT J ANTIMICROB AG, V31, P590, DOI 10.1016/j.ijantimicag.2008.02.007
   Meheus F, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000818
   Molina I, 2007, J ANTIMICROB CHEMOTH, V60, P837, DOI 10.1093/jac/dkm294
   Mondal D, 2011, CURR OPIN INFECT DIS, V24, P418, DOI 10.1097/QCO.0b013e32834a8ba1
   Mondal S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000764
   Moon S, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-39
   Mueller M, 2007, T ROY SOC TROP MED H, V101, P19, DOI 10.1016/j.trstmh.2006.02.005
   Musa AM, 2005, ANN TROP MED PARASIT, V99, P563, DOI 10.1179/136485905X514127
   Nahar M, 2009, PHARM RES-DORD, V26, P2588, DOI 10.1007/s11095-009-9973-4
   Nahar M, 2008, NANOMED-NANOTECHNOL, V4, P252, DOI 10.1016/j.nano.2008.03.007
   Nelson KG, 2006, ANTIMICROB AGENTS CH, V50, P1238, DOI 10.1128/AAC.50.4.1238-1244.2006
   Nicoletti S, 2010, BIOORGAN MED CHEM, V18, P2559, DOI 10.1016/j.bmc.2010.02.043
   Nicoletti S, 2009, INT J ANTIMICROB AG, V33, P441, DOI 10.1016/j.ijantimicag.2008.10.013
   Olliaro P, 2009, TROP MED INT HEALTH, V14, P918, DOI 10.1111/j.1365-3156.2009.02306.x
   Olson JA, 2008, ANTIMICROB AGENTS CH, V52, P259, DOI 10.1128/AAC.00870-07
   PATTERSON TF, 1989, J INFECT DIS, V159, P717, DOI 10.1093/infdis/159.4.717                                                        
   Paz-Ares L, 2008, BRIT J CANCER, V98, P1608, DOI 10.1038/sj.bjc.6604372
   Prajapati VK, 2012, J INFECT DIS, V205, P333, DOI 10.1093/infdis/jir735
   Prajapati VK, 2011, J ANTIMICROB CHEMOTH, V66, P874, DOI 10.1093/jac/dkr002
   PROFFITT RT, 1991, J ANTIMICROB CHEMOTH, V28, P49, DOI 10.1093/jac/28.suppl_B.49                                                       
   Rihl Markus, 2006, J Infect, V53, pe25, DOI 10.1016/j.jinf.2005.09.015
   Ritmeijer K, 2011, CLIN INFECT DIS, V53, pE152, DOI 10.1093/cid/cir674
   Romero L. A., 2008, EXPERT OPIN DRUG DEL, V5, P805
   Rybak-Smith MJ, 2011, ADV DRUG DELIVER REV, V63, P1031, DOI 10.1016/j.addr.2011.05.012
   Sanchez-Brunete JA, 2004, J DRUG TARGET, V12, P453, DOI 10.1080/10611860400006596
   Savic R, 2006, LANGMUIR, V22, P3570, DOI 10.1021/la0531998
   Sedlak M, 2009, MINI-REV MED CHEM, V9, P1306, DOI 10.2174/138955709789878178                                                      
   Sinha PK, 2011, CLIN INFECT DIS, V53, pE91, DOI 10.1093/cid/cir521
   Sundar S, 2006, CLIN INFECT DIS, V42, P608, DOI 10.1086/500138
   Sundar S, 2009, AM J TROP MED HYG, V80, P700
   Sundar S, 2011, LANCET, V377, P477, DOI 10.1016/S0140-6736(10)62050-8
   Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627
   ter Horst R, 2008, CLIN INFECT DIS, V46, P1702, DOI 10.1086/587899
   Tiyaboonchai W, 2007, INT J PHARMACEUT, V329, P142, DOI 10.1016/j.ijpharm.2006.08.013
   Vakil R, 2006, LANGMUIR, V22, P9723, DOI 10.1021/la061408y
   van Etten EWM, 2000, ANTIMICROB AGENTS CH, V44, P1598, DOI 10.1128/AAC.44.6.1598-1603.2000
   Wasan EK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000913
   WHO, 2010, WHO TECH REP SER, V949, P1
   WHO (World Health Organization), 2011, ACC WORK OV GLOB IMP, P1
   WHO, COSTS MED CURR US TR
   Yanamandra U, 2011, INTERNAL MED, V50, P2855, DOI 10.2169/internalmedicine.50.5617
   Yoo BK, 2006, BIOL PHARM BULL, V29, P1700, DOI 10.1248/bpb.29.1700
NR 63
TC 2
Z9 2
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7375
J9 CURR OPIN INFECT DIS
JI Curr. Opin. Infect. Dis.
PD DEC
PY 2012
VL 25
IS 6
BP 695
EP 702
DI 10.1097/QCO.0b013e328359eff2
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 036MU
UT WOS:000311031200011
DA 2018-01-05
ER

PT J
AU Endsley, AN
   Ho, RJY
AF Endsley, Aaron N.
   Ho, Rodney J. Y.
TI Enhanced Anti-HIV Efficacy of Indinavir After Inclusion in CD4-Targeted
   Lipid Nanoparticles
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE targeted drug delivery; HIV; CD4; nanoparticles
ID LYMPH-NODES; GELATIN NANOPARTICLES; TARGETED DELIVERY; VIRAL LOAD;
   REPLICATION; LOCALIZATION; SUPPRESSION; DIDANOSINE; RESERVOIRS;
   REDUCTION
AB Background: Combination drug therapy has reduced plasma HIV to undetectable levels; however, drug-sensitive virus persists in patients' lymphoid tissue. We have reported significant lymphoid tissue drug localization with indinavir-associated lipid nanoparticles (LNPs). Our current objective is to evaluate whether additional enhancement is achievable by targeting these particles to CD4(+)-HIV host cells.
   Methods: We characterized 2 peptide-coated (CD4-BP2 and CD4-BP4) drug-associated LNPs and demonstrated CD4-cell specificity. Drug-associated LNPs expressing polyethyleneglycol were exposed on HIV-2-infected cells under dynamic conditions that emulated lymph node physiology for 15, 30, and 60 minutes at concentrations from 0 to 25 mu M and evaluated for antiviral activity and cell-associated drug concentrations. The specificity of CD4-mediated enhancement of indinavir LNPs antiviral activity was evaluated by blocking with anti-CD4 antibody.
   Results: Inclusion of CD4-binding peptides on LNPs enhanced antiviral activity for all incubation conditions, compared with control particles or soluble drug (eg, 60 minutes exposure, EC50 = 0.12-0.13 vs. 0.46 mu M for targeted nanoparticles vs. soluble drug). The CD4-BP4 peptide exhibited higher efficiency in eliciting antiviral activity than CD4-BP2-coated particles (EC50 = 7.5 mu M vs. >25 mu M at 15 minutes drug exposure). This enhancement seems to be driven by CD4 availability and cell-associated indinavir concentrations, as blocking of CD4 significantly ablated indinavir efficacy in targeted particles and indinavir concentrations reflected the observed anti-HIV activity.
   Conclusions: We constructed CD4-targeted LNPs that provide selective binding and efficient delivery of indinavir to CD4(+)-HIV host cells. Inclusion of polyethyleneglycol in LNPs would minimize immune recognition of peptides. The enhancement of anti-HIV effects is effective even under limited time exposure.
C1 [Endsley, Aaron N.; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
FU NIH [AI77390, RR00166, RR025014]; Milo Gibaldi endowment
FX Supported in part by NIH grants AI77390, RR00166, and RR025014.; The
   author R.J.Y.H. is also supported by the Milo Gibaldi endowment.
CR Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Duzgunes N, 1999, MOL MEMBR BIOL, V16, P111, DOI 10.1080/096876899294832                                                         
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   MCCALLUS DE, 1992, VIRAL IMMUNOL, V5, P163, DOI 10.1089/vim.1992.5.163
   Paintsil Elijah, 2009, AIDS Res Ther, V6, P5, DOI 10.1186/1742-6405-6-5
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001                                                
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Tedla N, 1999, CLIN EXP IMMUNOL, V117, P92
   Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Zeidan A, 2009, EXPERT OPIN BIOL TH, V9, P111, DOI [10.1517/14712590802586058, 10.1517/14712590802586058 ]
NR 22
TC 13
Z9 13
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2012
VL 61
IS 4
BP 417
EP 424
DI 10.1097/QAI.0b013e3182653c1f
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 037DU
UT WOS:000311083200006
PM 22743598
OA gold
DA 2018-01-05
ER

PT J
AU Zhan, P
   Li, X
   Li, ZY
   Chen, XW
   Tian, Y
   Chen, WM
   Liu, XY
   Pannecouque, C
   De Clercq, E
AF Zhan, Peng
   Li, Xiao
   Li, Zhenyu
   Chen, Xuwang
   Tian, Ye
   Chen, Wenmin
   Liu, Xinyong
   Pannecouque, Christophe
   De Clercq, Erik
TI Structure-based bioisosterism design, synthesis and biological
   evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1
   NNRTIs
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV reverse transcriptase; NNRTIs; Heterocycle; Synthesis; Anti-HIV-1
   activity; SAR; 1,2,4-Triazine; Structure-based bioisosterism strategy
ID REVERSE-TRANSCRIPTASE INHIBITORS; NONNUCLEOSIDE INHIBITORS; COLORIMETRIC
   ASSAY; DRUG DESIGN; THIOACETANILIDES; STRATEGIES; DISCOVERY; MUTANT;
   AIDS
AB The development of new HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the possibility of generating novel chemical entities of increased potency. Previous investigations in our laboratory resulted in the discovery of several novel series of arylazolylthioacetanilides as potent NNRTIs. In this study, based on the structure-based bioisosterism strategy, novel 1,2,4-triazin-6-yl thioacetamide derivatives were designed, synthesized and evaluated for their anti-HIV activity in MT-4 cells. Among them, the most promising compound was 8b15 with double-digit nanomolar activity against wild-type HIV-1 (EC50 = 0.018 +/- 0.007 mu M) and moderate activity against the double mutant strain RES056 (EC50 = 3.3 +/- 0.1 mu M), which indicated that 1,2,4-triazin-6-yl thioacetamide can be used as a novel scaffold to develop a new class of potent NNRTIs active against both wild-type and drug-resistant HIV-1 strains. In addition, preliminary structure-activity relationship (SAR) and molecular modeling results are also briefly discussed, which provide some useful information for the further design of novel NNRTIs. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
C1 [Zhan, Peng; Li, Xiao; Li, Zhenyu; Chen, Xuwang; Tian, Ye; Chen, Wenmin; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Educ Minist China, Key Lab Chem Biol, Jinan 250012, Shandong, Peoples R China.
   [Zhan, Peng; Li, Xiao; Li, Zhenyu; Chen, Xuwang; Tian, Ye; Chen, Wenmin; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China.
   [Pannecouque, Christophe; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Sch Pharmaceut Sci, Educ Minist China, Key Lab Chem Biol, 44 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC) [81102320, 30873133,
   30772629, 30371686]; NSFC for International Cooperation [30910103908];
   Research Fund for the Doctoral Program of Higher Education of China
   [20110131130005, 20110131120037]; Independent Innovation Foundation of
   Shandong University (IIFSDU) [2010GN044]; Shandong Postdoctoral
   Innovation Science Research Special Program [201002023]; China
   Postdoctoral Science Foundation [20100481282, 2012T50584]; KU Leuven
   [GOA 10/014]
FX The financial support from the National Natural Science Foundation of
   China (NSFC No.81102320, No.30873133, No.30772629, No.30371686), Key
   Project of NSFC for International Cooperation (No.30910103908), Research
   Fund for the Doctoral Program of Higher Education of China
   (No.20110131130005, 20110131120037), Independent Innovation Foundation
   of Shandong University (IIFSDU, No.2010GN044), Shandong Postdoctoral
   Innovation Science Research Special Program (No.201002023), China
   Postdoctoral Science Foundation funded project (No.20100481282,
   2012T50584) and KU Leuven (GOA 10/014) is gratefully acknowledged.
CR Baraldi PG, 2007, BIOORGAN MED CHEM, V15, P2514, DOI 10.1016/j.bmc.2007.01.055
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   De La Rosa M, 2006, BIOORG MED CHEM LETT, V16, P4444, DOI 10.1016/j.bmcl.2006.06.048
   FITT JJ, 1977, J ORG CHEM, V42, P2639, DOI 10.1021/jo00435a027
   Gagnon A, 2007, BIOORG MED CHEM LETT, V17, P4437, DOI 10.1016/j.bmcl.2007.06.012
   Gagnon A, 2009, BIOORG MED CHEM LETT, V19, P1199, DOI 10.1016/j.bmcl.2008.12.074
   Li DY, 2012, J MED CHEM, V55, P3595, DOI 10.1021/jm200990c
   Lima LMA, 2005, CURR MED CHEM, V12, P23, DOI 10.2174/0929867053363540                                                        
   Miyoshi I., 1982, GANN MONOGR, V28, P219
   Moyle Graeme, 2010, Antimicrob Agents Chemother, V54, P3170, DOI 10.1128/AAC.00268-10
   Muraglia E, 2006, BIOORG MED CHEM LETT, V16, P2748, DOI 10.1016/j.bmcl.2006.02.024
   O'Meara JA, 2007, BIOORG MED CHEM LETT, V17, P3362, DOI 10.1016/j.bmcl.2007.03.097
   Olesen P H, 2001, Curr Opin Drug Discov Devel, V4, P471
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q                                                               
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   SUZUKI K, 1993, J VIROL METHODS, V44, P189, DOI 10.1016/0166-0934(93)90054-U
   Suzuki T, 2009, BIOORG MED CHEM LETT, V19, P3072, DOI 10.1016/j.bmcl.2009.04.016
   TAYLOR EC, 1985, J HETEROCYCLIC CHEM, V22, P409, DOI 10.1002/jhet.5570220238                                                         
   Wang ZW, 2006, BIOORG MED CHEM LETT, V16, P4174, DOI 10.1016/j.bmcl.2006.05.096
   Wu J., 2003, MOLECULES, V2007, P12
   Zhan P., 2011, MED RES REV
   ZHAN P, 2009, MED CHEM RES, V19, P652
   Zhan P., 2012, ARCH PHARM RES, V1037, P35
   Zhan P., 2011, EXPERT OPIN THER PAT, V5, P717
   Zhan P., 2009, MINI-REV MED CHEM, V1014, P9
   Zhan P, 2008, BIOORG MED CHEM LETT, V18, P5368, DOI 10.1016/j.bmcl.2008.09.055
   Zhan P, 2011, EUR J MED CHEM, V46, P5039, DOI 10.1016/j.ejmech.2011.08.011
   Zhan P, 2010, CHEM BIODIVERS, V7, P1717, DOI 10.1002/cbdv.200900197
   Zhan P, 2009, CURR MED CHEM, V16, P3903, DOI 10.2174/092986709789178019                                                      
   Zhan P, 2009, EUR J MED CHEM, V44, P4648, DOI 10.1016/j.ejmech.2009.06.037
   Zhan P, 2009, BIOORGAN MED CHEM, V17, P6374, DOI 10.1016/j.bmc.2009.07.027
   Zhan P, 2009, BIOORGAN MED CHEM, V17, P5920, DOI 10.1016/j.bmc.2009.07.004
   Zhan P, 2009, BIOORGAN MED CHEM, V17, P5775, DOI 10.1016/j.bmc.2009.07.028
   Zhan P, 2009, CURR MED CHEM, V16, P2876, DOI 10.2174/092986709788803231                                                      
   Zhao HY, 2009, DRUG DISCOV TODAY, V14, P516, DOI 10.1016/j.drudis.2009.02.008
NR 37
TC 22
Z9 22
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 1
PY 2012
VL 22
IS 23
BP 7155
EP 7162
DI 10.1016/j.bmcl.2012.09.062
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 030PR
UT WOS:000310583100034
PM 23084898
DA 2018-01-05
ER

PT J
AU Craparo, EF
   Bondi, ML
AF Craparo, Emanuela Fabiola
   Bondi, Maria Luisa
TI Application of polymeric nanoparticles in immunotherapy
SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Review
DE antigen; dendritic cells; immunotherapy; polymeric nanoparticles
ID HUMAN DENDRITIC CELLS; POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES;
   HEPATITIS-B ANTIGEN; BIODEGRADABLE NANOPARTICLES; IMMUNE-RESPONSES;
   VACCINE DELIVERY; HIV-1 P24; IN-VIVO; CHITOSAN NANOPARTICLES;
   CANCER-IMMUNOTHERAPY
AB Purpose of review
   The purpose of the present review is to underline the importance of nanoparticulate carriers, such as polymeric nanoparticles, in the future development of safe and effective formulation in the field of immunotherapy against infectious diseases and cancer.
   Recent findings
   Polymeric nanoparticles can modulate the immune response, that is, by targeting antigens to dendritic cells that possess a crucial role in initiating immune responses, and might be potentially useful in immunotherapy.
   Summary
   In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of infectious diseases and cancer. Polymeric nanoparticles are particularly adept at facilitating immunotherapeutic approaches because they can be engineered to have different physical properties, encapsulated agents, and surface ligands. Moreover, these systems are administrable for all routes, are capable of being actively taken up by dendritic cells and have shown promising potential in systemic and mucosal immunotherapy. Here, some recent findings on these systems, in their potential applications for infectious and cancer immunotherapy, are reported.
C1 [Bondi, Maria Luisa] CNR, Ist Studio Mat Nanostrutturati UOS Palermo, I-90146 Palermo, Italy.
   [Craparo, Emanuela Fabiola] Univ Palermo, Dipartimento Sci & Tecnol Mol & Biomol STEMBIO, Lab Biocompatible Polymers, Palermo, Italy.
RP Bondi, ML (reprint author), CNR, Ist Studio Mat Nanostrutturati UOS Palermo, Via Ugo Malfa 153, I-90146 Palermo, Italy.
EM marialuisa.bondi@ismn.cnr.it
OI BONDI', MARIA LUISA/0000-0002-2674-1654
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Alshamsan A, 2010, MOL PHARMACEUT, V7, P1643, DOI 10.1021/mp100067u
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Bal SM, 2012, EUR J PHARM SCI, V45, P475, DOI 10.1016/j.ejps.2011.10.003
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Baxevanis CN, 2009, CRIT REV CL LAB SCI, V46, P167, DOI 10.1080/10408360902937809
   Bharali DJ, 2008, NANOMED-NANOTECHNOL, V4, P311, DOI 10.1016/j.nano.2008.05.006
   Borges O, 2007, EUR J PHARM SCI, V32, P278, DOI 10.1016/j.ejps.2007.08.005
   Bourquin C, 2008, J IMMUNOL, V181, P2990, DOI 10.4049/jimmunol.181.5.2990                                                     
   Broos S, 2010, VACCINE, V28, P5075, DOI 10.1016/j.vaccine.2010.05.004
   Byrne JD, 2008, ADV DRUG DELIVER REV, V60, P1615, DOI 10.1016/j.addr.2008.08.005
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Esparza I, 2012, J BIOMED BIOTECHNOL, V2012
   Elamanchili P, 2007, J IMMUNOTHER, V30, P378, DOI 10.1097/CJI.0b013e31802cf3e3
   Fievez V, 2009, EUR J PHARM BIOPHARM, V73, P16, DOI 10.1016/j.ejpb.2009.04.009
   Flanary S, 2009, BIOCONJUGATE CHEM, V20, P241, DOI 10.1021/bc800317a
   Garcia-Contreras L, 2008, P NATL ACAD SCI USA, V105, P4656, DOI 10.1073/pnas.0800043105
   Goforth R, 2009, CANCER IMMUNOL IMMUN, V58, P517, DOI 10.1007/s00262-008-0574-6
   Gomez S, 2009, J IMMUNOL METHODS, V348, P1, DOI 10.1016/j.jim.2009.06.005
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Hamasaki T, 2010, CLIN VACCINE IMMUNOL, V17, P748, DOI 10.1128/CVI.00505-09
   Hamdy S, 2008, VACCINE, V26, P5046, DOI 10.1016/j.vaccine.2008.07.035
   Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021
   Heit A, 2007, EUR J IMMUNOL, V37, P2063, DOI 10.1002/eji.200737169
   Holzer M, 2009, EUR J PHARM BIOPHARM, V72, P428, DOI 10.1016/j.ejpb.2009.02.002
   Jahnisch H, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/517493
   Kim J, 2011, NANO TODAY, V6, P466, DOI 10.1016/j.nantod.2011.08.005
   Klippstein R, 2010, NANOMED-NANOTECHNOL, V6, P523, DOI 10.1016/j.nano.2010.01.001
   Kohli AK, 2004, INT J PHARM, V275, P13, DOI 10.1016/j.ijpharm.2003.10.038
   Krishnamachari Y, 2011, PHARM RES-DORDR, V28, P215, DOI 10.1007/s11095-010-0241-4
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Lori F, 2007, CURR MED CHEM, V14, P1911
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Matsuo K, 2010, BIOL PHARM BULL, V33, P2003, DOI 10.1248/bpb.33.2003
   Minigo G, 2007, VACCINE, V25, P1316, DOI 10.1016/j.vaccine.2006.09.086
   Molavi L, 2010, MOL PHARMACEUT, V7, P364, DOI 10.1021/mp900145g
   Muttil P, 2010, AAPS J, V12, P330, DOI 10.1208/s12248-010-9192-2
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Pic E, 2010, MOL IMAGING BIOL, V12, P394, DOI 10.1007/s11307-009-0288-y
   Prasad S, 2011, NANOMED-NANOTECHNOL, V7, P1, DOI 10.1016/j.nano.2010.07.002
   Prokop A, 2008, J PHARM SCI-US, V97, P3518, DOI 10.1002/jps.21270
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Rytting E, 2008, EXPERT OPIN DRUG DEL, V5, P629, DOI [10.1517/17425247.5.6.629 , 10.1517/17425240802141568]
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Scholl I, 2006, IMMUNOL ALLERGY CLIN, V26, P349, DOI 10.1016/j.iac.2006.02.007
   Scholl I, 2004, CLIN EXP ALLERGY, V34, P315, DOI 10.1111/j.1365-2222.2004.01884.x
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Sheng WY, 2011, PHARM RES-DORDR, V28, P200, DOI 10.1007/s11095-010-0258-8
   Slutter B, 2009, J CONTROL RELEASE, V138, P113, DOI 10.1016/j.jconrel.2009.05.011
   Solbrig CM, 2007, MOL PHARMACEUT, V4, P47, DOI 10.1021/mp060107e
   Steinman RM, 2008, IMMUNITY, V29, P319, DOI 10.1016/j.immuni.2008.08.001
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Thapa P, 2009, VACCINE, V27, P3484, DOI 10.1016/j.vaccine.2009.01.047
   Waeckerle-Men Y, 2006, VACCINE, V24, P1847, DOI 10.1016/j.vaccine.2005.10.032
   Waeckerle-Men Y, 2005, ADV DRUG DELIVER REV, V57, P475, DOI 10.1016/j.addr.2004.09.007
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Zhang ZP, 2011, BIOMATERIALS, V32, P3666, DOI 10.1016/j.biomaterials.2011.01.067
   Zwiorek K, 2008, PHARM RES, V25, P551, DOI 10.1007/s11095-007-9410-5
NR 75
TC 12
Z9 12
U1 1
U2 44
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-4050
EI 1473-6322
J9 CURR OPIN ALLERGY CL
JI Curr. Opin. Allergy Clin. Immunol.
PD DEC
PY 2012
VL 12
IS 6
BP 658
EP 664
DI 10.1097/ACI.0b013e3283588c57
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 029TY
UT WOS:000310520100013
PM 23095912
DA 2018-01-05
ER

PT J
AU de la Rica, R
   Stevens, MM
AF de la Rica, Roberto
   Stevens, Molly M.
TI Plasmonic ELISA for the ultrasensitive detection of disease biomarkers
   with the naked eye
SO NATURE NANOTECHNOLOGY
LA English
DT Article
ID BIOMIMETIC CRYSTALLIZATION; P24 ANTIGEN; PROTEINS; NANOPARTICLES;
   SENSITIVITY; BLOOD
AB In resource-constrained countries, affordable methodologies for the detection of disease biomarkers at ultralow concentrations can potentially improve the standard of living(1,2). However, current strategies for ultrasensitive detection often require sophisticated instruments that may not be available in laboratories with fewer resources(3-11). Here, we circumvent this problem by introducing a signal generation mechanism for biosensing that enables the detection of a few molecules of analyte with the naked eye. The enzyme label of an enzyme-linked immunosorbent assay (ELISA) controls the growth of gold nanoparticles and generates coloured solutions with distinct tonality when the analyte is present. Prostate specific antigen (PSA) and HIV-1 capsid antigen p24 were detected in whole serum at the ultralow concentration of 1x10(-18) g ml(-1). p24 was also detected with the naked eye in the sera of HIV-infected patients showing viral loads undetectable by a gold standard nucleic acid-based test.
C1 [de la Rica, Roberto] Univ London Imperial Coll Sci Technol & Med, Dept Mat, Dept Bioengn, London SW7 2AZ, England.
   Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 2AZ, England.
RP de la Rica, R (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Mat, Dept Bioengn, Exhibit Rd, London SW7 2AZ, England.
EM roberto.delarica@gmail.com; m.stevens@imperial.ac.uk
RI de la Rica, Roberto/F-9430-2014
OI de la Rica, Roberto/0000-0002-5750-1469
FU Engineering and Physical Sciences Research Council (EPSRC); European
   Research Council (ERC); European Community
FX The authors thank G. S. Cooke and S. Kaye (Faculty of Medicine, Imperial
   College London) for the kind gift of human samples containing different
   viral loads. M. M. S. thanks the Engineering and Physical Sciences
   Research Council (EPSRC) and the European Research Council (ERC)
   starting investigator grant 'Naturale' for funding. This research was
   supported by a Marie Curie Intra European Fellowship within the 7th
   European Community Framework Programme (R. R.). The monoclonal antibody
   to HIV-1 p24 from S. Zolla-Pazner was provided by the Centre for AIDS
   Reagents, National Institute for Biological Standards and Control
   (NIBSC, a centre of the UK Health Protection Agency).
CR Aili D, 2009, SMALL, V5, P2445, DOI 10.1002/smll.200900530
   Chen S, 2011, NANO LETT, V11, P1826, DOI 10.1021/nl2006092
   de la Rica R, 2008, ANGEW CHEM INT EDIT, V47, P5415, DOI 10.1002/anie.200801181
   de la Rica R, 2011, ANGEW CHEM INT EDIT, V50, P5703, DOI 10.1002/anie.201008189
   de La Rica R, 2010, ANGEW CHEM INT EDIT, V49, P1447, DOI 10.1002/anie.200906200
   de la Rica R, 2009, ANAL CHEM, V81, P7732, DOI 10.1021/ac901210f
   Engelbrekt C, 2009, J MATER CHEM, V19, P7839, DOI 10.1039/b911111e
   Fan R, 2008, NAT BIOTECHNOL, V26, P1373, DOI 10.1038/nbt.1507
   Kowalczyk B., 2009, ANGEW CHEM INT EDIT, V49, P5737
   Laromaine A, 2007, J AM CHEM SOC, V129, P4156, DOI 10.1021/ja0706504
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Patton JC, 2008, CLIN VACCINE IMMUNOL, V15, P388, DOI 10.1128/CVI.00265-07
   Pejoux C, 2010, SMALL, V6, P999, DOI 10.1002/smll.200902121
   Qu WS, 2011, ANGEW CHEM INT EDIT, V50, P3442, DOI 10.1002/anie.201006025
   Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641
   Rodriguez-Lorenzo L, 2012, NAT MATER, V11, P604, DOI [10.1038/NMAT3337, 10.1038/nmat3337]
   Rodriguez-Lorenzo L, 2009, J AM CHEM SOC, V131, P4616, DOI 10.1021/ja809418t
   Tabakman M. N, 2011, NATURE COMMUN, V2, P466
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Thaxton CS, 2009, P NATL ACAD SCI USA, V106, P18437, DOI 10.1073/pnas.0904719106
NR 20
TC 279
Z9 280
U1 54
U2 491
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1748-3387
J9 NAT NANOTECHNOL
JI Nat. Nanotechnol.
PD DEC
PY 2012
VL 7
IS 12
BP 821
EP 824
DI 10.1038/NNANO.2012.186
PG 4
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 049SM
UT WOS:000312003700018
PM 23103935
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Jung, S
   Swamy, BY
   Moon, JB
   Kim, DH
   Chung, I
AF Jung, Sungmo
   Swamy, B. Yerri
   Moon, Jin-Bok
   Kim, Dong-Hyun
   Chung, Ildoo
TI Anti-AIDS Active Polyrotaxane-AZT Conjugates with Bioactive Bulky
   Stoppers and Their Nanoparticles
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE 3 '-Azido-3 '-deoxythymidine; AIDS; drug delivery systems;
   nanoparticles; polyrotaxanes
ID PLACEBO-CONTROLLED TRIAL; ANTITUMOR ACTIVITIES; INCLUSION COMPLEXES;
   AZIDOTHYMIDINE AZT; CURDLAN SULFATE; AQUEOUS-MEDIA; VIRUS INVITRO;
   DOUBLE-BLIND; ZIDOVUDINE; HIV
AB New anti-HIV active agents, polyrotaxane-AZT conjugates with various bioactive bulky stoppers such as 3'-azido-3'-deoxythymidine (AZT) and tocopherol and their nanoparticles were synthesized and characterized. The degree of AZT substitution of the conjugates was calculated from ELEM. ANAL and ranged from 1.8 to 5.9, respectively. The in vitro antiviral activity of these conjugates was determined and used to evaluate their potential applications in anti-AIDS drugs. The in vitro anti-HIV activities indicate that the synthesized polyrotaxane-AZT conjugates and their nanoparticles against HIV-1 and HIV-2 strains were more potent inhibitors than free AZT, with reduced cytotoxicities against uninfected MT-4 cells. The effect of the conjugates against HIV-1 and HIV-2 strains increased with decreasing particle size. (C) 2012 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 50: 4895-4901, 2012
C1 [Jung, Sungmo; Swamy, B. Yerri; Chung, Ildoo] Pusan Natl Univ, Dept Polymer Sci & Engn, Pusan 609735, South Korea.
   [Moon, Jin-Bok] Kyungnam Coll Univ Informat & Technol, Dept Shoe Fash Ind, Pusan 617701, South Korea.
   [Kim, Dong-Hyun] Catholic Univ Pusan, Dept Radiol Sci, Coll Hlth Sci, Pusan 609757, South Korea.
RP Chung, I (reprint author), Pusan Natl Univ, Dept Polymer Sci & Engn, Pusan 609735, South Korea.
EM idchung@pusan.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [2012-0002454]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (No. 2012-0002454).
CR AOKI T, 1991, AIDS RES HUM RETROV, V7, P409, DOI 10.1089/aid.1991.7.409
   BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4
   BALZARINI J, 1987, MOL PHARMACOL, V32, P162
   Banerjee T, 2002, INT J PHARM, V243, P93, DOI 10.1016/S0378-5173(02)00267-3
   BARRY M, 1994, BRIT J CLIN PHARMACO, V37, P7, DOI 10.1111/j.1365-2125.1994.tb04231.x                                              
   CHENG YC, 1987, J BIOL CHEM, V262, P2187
   Chung I, 2006, J POLYM SCI POL CHEM, V44, P295, DOI 10.1002/pola.21101
   Chung ID, 2000, J POLYM SCI POL CHEM, V38, P4272, DOI 10.1002/1099-0518(20001201)38:23<4272::AID-POLA130>3.0.CO;2-1                   
   Chung ID, 2005, CHEM COMMUN, P1046, DOI 10.1039/b416591h
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401                                                     
   HAO Z, 1988, MOL PHARMACOL, V34, P431
   Jung EY, 2000, J POLYM SCI POL CHEM, V38, P1247, DOI 10.1002/(SICI)1099-0518(20000415)38:8<1247::AID-POLA8>3.0.CO;2-F
   Kawaguchi Y, 2000, ORG LETT, V2, P1353, DOI 10.1021/ol0055667                                                               
   KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49                                                            
   Lacy C. F., 2007, DRUG INFORM HDB, P1812
   LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383
   LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804                                                         
   Milonaki Y, 2012, J POLYM SCI POL CHEM, V50, P1226, DOI 10.1002/pola.25888
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   Miyauchi M, 2005, J AM CHEM SOC, V127, P2034, DOI 10.1021/ja042840
   Montassier P, 1997, INT J PHARM, V153, P199, DOI 10.1016/S0378-5173(97)00104-X
   Muschin T, 2011, J POLYM SCI POL CHEM, V49, P3241, DOI 10.1002/pola.24738
   Nakashima H., 1989, ANTIVIR RES, V11, P234
   Ooya T, 2005, SCI TECHNOL ADV MAT, V6, P447, DOI 10.1016/j.stam.2005.03.015
   PanZhou XR, 1997, ANTIMICROB AGENTS CH, V41, P2502
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Silion M, 2011, J POLYM SCI POL CHEM, V49, P1730, DOI 10.1002/pola.24581
   Thomas NS, 2003, EUR J PHARM SCI, V18, P71, DOI 10.1016/S0928-0987(02)00242-7
   Villaverde J, 2005, CHEMOSPHERE, V60, P656, DOI 10.1016/j.chemosphere.2005.01.030
   Xu YC, 2012, J POLYM SCI POL CHEM, V50, P1216, DOI 10.1002/pola.25886
   Zhang XY, 2012, J POLYM SCI POL CHEM, V50, P2293, DOI 10.1002/pola.26000
NR 34
TC 5
Z9 5
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-624X
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD DEC 1
PY 2012
VL 50
IS 23
BP 4895
EP 4901
DI 10.1002/pola.26317
PG 7
WC Polymer Science
SC Polymer Science
GA 030AG
UT WOS:000310539400013
DA 2018-01-05
ER

PT J
AU Blumenthal, R
   Durell, S
   Viard, M
AF Blumenthal, Robert
   Durell, Stewart
   Viard, Mathias
TI HIV Entry and Envelope Glycoprotein-mediated Fusion
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL MEMBRANE-FUSION; GP41 CYTOPLASMIC
   TAIL; INFLUENZA HEMAGGLUTININ; CELL-FUSION; T-CELLS; GP120 CORE;
   CONFORMATIONAL-CHANGES; TYPE-1 VIRIONS; PORE FORMATION
AB HIV entry involves binding of the trimeric viral envelope glycoprotein (Env) gp120/gp41 to cell surface receptors, which triggers conformational changes in Env that drive the membrane fusion reaction. The conformational landscape that the lipids and Env navigate en route to fusion has been examined by biophysical measurements on the microscale, whereas electron tomography, x-rays, and NMR have provided insights into the process on the nanoscale and atomic scale. However, the coupling between the lipid and protein pathways that give rise to fusion has not been resolved. Here, we discuss the known and unknown about the overall HIV Env-mediated fusion process.
C1 [Blumenthal, Robert; Viard, Mathias] NCI, Nanobiol Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
   [Durell, Stewart] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
   [Viard, Mathias] SAIC Frederick Inc, Basic Sci Program, CCRNP, Frederick Natl Lab, Frederick, MD 21702 USA.
RP Blumenthal, R (reprint author), NCI, Nanobiol Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
EM blumenthalr@mail.nih.gov
FU National Institutes of Health from NCI [HHSN261200800001E]; National
   Institutes of Health Intramural Research Program of NCI, Center for
   Cancer Research, Frederick National Lab; National Institutes of Health
   Intramural AIDS Targeted Antiviral Program (IATAP); NIAID Intramural
   Biodefense Research Program
FX This was supported, in whole or in part, by National Institutes of
   Health Contract HHSN261200800001E from NCI; the National Institutes of
   Health Intramural Research Program of NCI, Center for Cancer Research,
   Frederick National Lab; and grants from the National Institutes of
   Health Intramural AIDS Targeted Antiviral Program (IATAP) and the NIAID
   Intramural Biodefense Research Program. This is the first article in the
   Thematic Minireview Series on Understanding Human Immunodeficiency
   Virus-Host Interactions at the Biochemical Level.
CR Ashkenazi A, 2011, FASEB J, V25, P2156, DOI 10.1096/fj.10-175752
   Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004
   Barrero-Villar M, 2009, J CELL SCI, V122, P103, DOI 10.1242/jcs.035873
   Berger EA, 1997, AIDS, V11, pS3
   Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+
   Blumenthal R, 2002, CHEM PHYS LIPIDS, V116, P39, DOI 10.1016/S0009-3084(02)00019-1
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Cavrois M, 2004, VIROLOGY, V328, P36, DOI 10.1016/j.virol.2004.07.015
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan R, 2008, J VIROL, V82, P11228, DOI 10.1128/JVI.00981-08
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369                                                          
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   Chien MP, 2008, FASEB J, V22, P1179, DOI 10.1096/fj.07-9576com
   CLAVEL F, 1994, J VIROL, V68, P1179
   Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005
   Dale BM, 2011, CELL HOST MICROBE, V10, P551, DOI 10.1016/j.chom.2011.10.015
   Dimitrov AS, 2007, BIOCHEMISTRY-US, V46, P1398, DOI 10.1021/bi062245f
   Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d
   Do Kwon Y, 2012, P NATL ACAD SCI USA, V109, P5663, DOI 10.1073/pnas.1112391109
   Dobrowsky TM, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000855
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   Finnegan CM, 2007, J VIROL, V81, P5294, DOI 10.1128/JVI.02553-06
   Finnegan CM, 2006, ANTIVIR RES, V69, P116, DOI 10.1016/j.antiviral.2005.11.002
   Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1079/pnas.0402874101
   Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002
   Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5
   Garcia-Exposito L, 2011, MOL BIOL CELL, V22, P1148, DOI 10.1091/mbc.E10-08-0722
   Garg H, 2007, J BIOL CHEM, V282, P16899, DOI 10.1074/jbc.M701701200
   Garg H, 2011, CURR TOP MED CHEM, V11, P2947, DOI 10.2174/156802611798808479                                                      
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Gordon-Alonso M, 2012, MOL BIOL CELL, V23, P2253, DOI 10.1091/mbc.E11-12-1003
   HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0
   Harmon B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000956
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   HUANG MJ, 1995, J VIROL, V69, P6810
   Iyengar S, 1998, J VIROL, V72, P5251
   Jacobs A, 2007, J BIOL CHEM, V282, P32406, DOI 10.1074/jbc.M705577200
   Jimenez-Baranda S, 2007, NAT CELL BIOL, V9, P838, DOI 10.1038/ncb1610
   Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404                                                           
   Karatekin E, 2003, BIOPHYS J, V84, P1734, DOI 10.1016/S0006-3495(03)74981-9                                                   
   KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1
   Klasse PJ, 2007, VIROLOGY, V369, P245, DOI 10.1016/j.virol.2007.06.044
   Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200                                                          
   Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1                                                   
   Kozlov MM, 2002, TRAFFIC, V3, P256, DOI 10.1034/j.1600-0854.2002.030403.x
   Kozlovsky Y, 2002, BIOPHYS J, V82, P882, DOI 10.1016/S0006-3495(02)75450-7                                                   
   Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898                                                          
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lai AL, 2012, J MOL BIOL, V418, P3, DOI 10.1016/j.jmb.2012.02.010
   Lai WH, 2011, AIDS RES HUM RETROV, V27, P1013, DOI 10.1089/aid.2010.0259
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Lorizate M, 2009, J BIOL CHEM, V284, P22238, DOI 10.1074/jbc.M109.029256
   LOWY RJ, 1995, EXP CELL RES, V216, P411, DOI 10.1006/excr.1995.1052                                                          
   LOWY RJ, 1990, P NATL ACAD SCI USA, V87, P1850, DOI 10.1073/pnas.87.5.1850
   Magnus C, 2009, J VIROL, V83, P1523, DOI 10.1128/JVI.01764-08
   Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573
   Markosyan RM, 2005, MOL BIOL CELL, V16, P5502, DOI 10.1091/mcb.E05-06-0496
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995                                                           
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Munoz-Barroso I, 1999, J VIROL, V73, P6089
   Pace MJ, 2011, J VIROL, V85, P644, DOI 10.1128/JVI.01851-10
   Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107
   Raviv Y, 2002, VIROLOGY, V293, P243, DOI 10.1006/viro.2001.1237
   Rawat SS, 2004, J VIROL, V78, P7360, DOI 10.1128/JVI.78.14.7360-7368.2004
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Richard JP, 2011, BIOCHEM J, V440, P185, DOI 10.1042/BJ20111243
   Schaeffer E, 2004, J VIROL, V78, P1375, DOI 10.1128/JVI.78.3.1375-1383.2004
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Takenawa T, 2010, P JPN ACAD B-PHYS, V86, P509, DOI 10.2183/pjab.86.509
   Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797
   Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002
   Viard M, 2008, BIOCHEMISTRY-US, V47, P1977, DOI 10.1021/bi701920f
   Vieira CR, 2010, CHEM BIOL, V17, P766, DOI 10.1016/j.chembiol.2010.05.023
   Vorster PJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.182238
   WALKER BD, 1987, P NATL ACAD SCI USA, V84, P8120, DOI 10.1073/pnas.84.22.8120
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   White TA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001249
   WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580
   Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005
   Yang L, 2002, SCIENCE, V297, P1877, DOI 10.1126/science.1074354
   Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005
   Yoder A, 2008, CELL, V134, P782, DOI 10.1016/j.cell.2008.06.036
   Yu DY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000633
   ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885                                                          
NR 100
TC 79
Z9 79
U1 2
U2 60
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 30
PY 2012
VL 287
IS 49
BP 40841
EP 40849
DI 10.1074/jbc.R112.406272
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 048CK
UT WOS:000311887600002
PM 23043104
OA gold
DA 2018-01-05
ER

PT J
AU Hansen, MB
   van Gaal, E
   Minten, I
   Storm, G
   van Hest, JCM
   Lowik, DWPM
AF Hansen, Morten B.
   van Gaal, Ethlinn
   Minten, Inge
   Storm, Gert
   van Hest, Jan C. M.
   Lowik, Dennis W. P. M.
TI Constrained and UV-activatable cell-penetrating peptides for
   intracellular delivery of liposomes
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Cell penetrating peptide; Liposomes; Peptide amphiphiles; Activatable
   cellular transduction
ID HUMAN IMMUNODEFICIENCY VIRUS; LABILE ANCHOR GROUPS; DRUG-DELIVERY;
   TRIGGERED RELEASE; PHARMACEUTICAL NANOCARRIERS; SENSITIVE LIPOSOMES;
   THERMOSENSITIVE LIPOSOMES; CYTOSOLIC DELIVERY; LOW-TEMPERATURE;
   REMOTE-CONTROL
AB Herein we report on the development of a novel method of constraining a cell-penetrating peptide, which can be used to trigger transport of liposomes into cells upon in this case radiation with UV-light. A cell-penetrating peptide, which was modified on both termini with an alkyl chain, was anchored to the liposomal surface in a constrained and deactivated form. Since one of the two alkyl chains was connected to the peptide via a UV-cleavable linker, disconnection of this alkyl chain upon irradiation led to the exposure of the cell-penetrating peptide, and mediated the transport of the entire liposome particle into cells. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hansen, Morten B.; Minten, Inge; van Hest, Jan C. M.; Lowik, Dennis W. P. M.] Radboud Univ Nijmegen, Inst Mol & Mat, Dept Organ Chem, NL-6525 AJ Nijmegen, Netherlands.
   [van Gaal, Ethlinn; Storm, Gert] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3584 CG Utrecht, Netherlands.
   [Storm, Gert] Univ Twente, Fac Sci & Technol, MIRA Inst Biomed Technol & Tech Med, NL-7500 AE Enschede, Netherlands.
RP Lowik, DWPM (reprint author), Radboud Univ Nijmegen, Inst Mol & Mat, Dept Organ Chem, Heyendaalseweg 135, NL-6525 AJ Nijmegen, Netherlands.
EM d.lowik@science.ru.nl
RI Lowik, Dennis/D-6913-2012; Storm, Gert/O-8696-2016; van Hest,
   Jan/D-5625-2012
OI Lowik, Dennis/0000-0002-9284-837X; van Hest, Jan/0000-0001-7973-2404
CR ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   Angelos S, 2007, J PHYS CHEM C, V111, P6589, DOI 10.1021/jp0707211
   Antipina MN, 2011, ADV DRUG DELIVER REV, V63, P716, DOI 10.1016/j.addr.2011.03.012
   Azagarsamy MA, 2009, J AM CHEM SOC, V131, P14184, DOI 10.1021/ja906162u
   BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y
   BREIPOHL G, 1989, INT J PEPT PROT RES, V34, P262
   Caldorera-Moore M, 2010, EXPERT OPIN DRUG DEL, V7, P479, DOI 10.1517/17425240903579971
   Carling CJ, 2010, ANGEW CHEM INT EDIT, V49, P3782, DOI 10.1002/anie.201000611
   Chaloin L, 2001, BIOCONJUGATE CHEM, V12, P691, DOI 10.1021/bc000125t
   Chandra B, 2006, ORG BIOMOL CHEM, V4, P1730, DOI 10.1039/b518359f
   Collins L, 2010, ACS NANO, V4, P2856, DOI 10.1021/nn901414q
   Davis SC, 1998, BIOCONJUGATE CHEM, V9, P783, DOI 10.1021/bc980047y
   Dhar S, 2008, J AM CHEM SOC, V130, P11467, DOI 10.1021/ja803036e
   Dromi S, 2007, CLIN CANCER RES, V13, P2722, DOI 10.1158/1078-0432.CCR-06-2443
   Elegbede AI, 2008, J AM CHEM SOC, V130, P10633, DOI 10.1021/ja801548g
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x                                              
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Foged C, 2007, J LIPOSOME RES, V17, P191, DOI 10.1080/08982100701530373
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz MM, 2007, PHARM RES, V24, P2040, DOI 10.1007/s11095-007-9338-9
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   Giri S, 2005, ANGEW CHEM INT EDIT, V44, P5038, DOI 10.1002/anie.200501819
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Jabr-Milane L, 2008, J CONTROL RELEASE, V130, P121, DOI 10.1016/j.jconrel.2008.04.016
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6                                                    
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   Kocer A, 2005, SCIENCE, V309, P755, DOI 10.1126/science.1114760
   Koning GA, 2010, PHARM RES-DORDR, V27, P1750, DOI 10.1007/s11095-010-0154-2
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Lee HB, 2004, J ORG CHEM, V69, P701, DOI 10.1021/jo034167x
   Li ZG, 2003, LANGMUIR, V19, P6381, DOI 10.1021/la034188m
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Mizukami S, 2010, J AM CHEM SOC, V132, P9524, DOI 10.1021/ja102167m
   Muggia F M, 2001, Curr Oncol Rep, V3, P156, DOI 10.1007/s11912-001-0016-5
   Nguyen TD, 2007, J AM CHEM SOC, V129, P626, DOI 10.1021/ja065485r
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Patel K, 2008, J AM CHEM SOC, V130, P2382, DOI 10.1021/ja0772086
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316
   Sarko D, 2010, MOL PHARMACEUT, V7, P2224, DOI 10.1021/mp100223d
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   Shamay Y, 2011, BIOMATERIALS, V32, P1377, DOI 10.1016/j.biomaterials.2010.10.029
   Smith B, 2011, J CONTROL RELEASE, V153, P187, DOI 10.1016/j.jconrel.2011.04.005
   Song YY, 2009, J AM CHEM SOC, V131, P4230, DOI 10.1021/ja810130h
   SPECTOR AA, 1969, J LIPID RES, V10, P56
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X
   STUBER W, 1989, INT J PEPT PROT RES, V34, P215
   Suzuki R, 2009, J CONTROL RELEASE, V133, P198, DOI 10.1016/j.jconrel.2008.10.015
   SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194
   Tardi PG, 1996, J DRUG TARGET, V4, P129, DOI 10.3109/10611869609015970
   Taylor SK, 2009, ANGEW CHEM INT EDIT, V48, P4394, DOI 10.1002/anie.200900499
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   van Dongen SFM, 2010, ANGEW CHEM INT EDIT, V49, P7213, DOI 10.1002/anie.201002655
   Versluis F, 2009, J AM CHEM SOC, V131, P13186, DOI 10.1021/ja9026264
   Vivero-Escoto JL, 2009, J AM CHEM SOC, V131, P3462, DOI 10.1021/ja900025f
   Vriezema DM, 2003, ANGEW CHEM INT EDIT, V42, P772, DOI 10.1002/anie.200390204                                                          
   Wagstaff KM, 2007, MOL THER, V15, P721, DOI 10.1038/mt.sj.6300093
   Xiong RL, 2010, J FLUORESC, V20, P551, DOI 10.1007/s10895-009-0579-3
   Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z
   YATVIN MB, 1978, SCIENCE, V202, P1290, DOI 10.1126/science.364652                                                          
   Yukawa H, 2010, BIOMATERIALS, V31, P4094, DOI 10.1016/j.biomaterials.2010.01.134
   Zalipsky S, 1997, BIOCONJUGATE CHEM, V8, P111, DOI 10.1021/bc9600832                                                               
NR 73
TC 35
Z9 37
U1 3
U2 103
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2012
VL 164
IS 1
BP 87
EP 94
DI 10.1016/j.jconrel.2012.10.008
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 062UF
UT WOS:000312947400010
PM 23085152
DA 2018-01-05
ER

PT J
AU Ball, C
   Krogstad, E
   Chaowanachan, T
   Woodrow, KA
AF Ball, Cameron
   Krogstad, Emily
   Chaowanachan, Thanyanan
   Woodrow, Kim A.
TI Drug-Eluting Fibers for HIV-1 Inhibition and Contraception
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED INFECTIONS;
   SHOCK-SYNDROME TOXIN-1; GLYCEROL MONOLAURATE; VAGINAL RINGS; IN-VITRO;
   TOPICAL MICROBICIDES; CONTROLLED-RELEASE; SOLID DISPERSIONS; EXPLANT
   CULTURE
AB Multipurpose prevention technologies (MPTs) that simultaneously prevent sexually transmitted infections (STIs) and unintended pregnancy are a global health priority. Combining chemical and physical barriers offers the greatest potential to design effective MPTs, but integrating both functional modalities into a single device has been challenging. Here we show that drug-eluting fiber meshes designed for topical drug delivery can function as a combination chemical and physical barrier MPT. Using FDA-approved polymers, we fabricated nanofiber meshes with tunable fiber size and controlled degradation kinetics that facilitate simultaneous release of multiple agents against HIV-1, HSV-2, and sperm. We observed that drug-loaded meshes inhibited HIV-1 infection in vitro and physically obstructed sperm penetration. Furthermore, we report on a previously unknown activity of glycerol monolaurate (GML) to potently inhibit sperm motility and viability. The application of drug-eluting nanofibers for HIV-1 prevention and sperm inhibition may serve as an innovative platform technology for drug delivery to the lower female reproductive tract.
C1 [Ball, Cameron; Krogstad, Emily; Chaowanachan, Thanyanan; Woodrow, Kim A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
RP Woodrow, KA (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
EM woodrow@u.washington.edu
FU United States National Institutes of Health (NIH) [5U54HD042454];
   University of Washington; Creative and Novel Ideas in HIV Research award
   [AI027767]; NIH [AI094412, AI098648]; NSF Graduate Research Fellowships
FX Collection of human semen samples from volunteers was performed at the
   University of Washington Male Fertility Laboratory and was supported by
   an United States National Institutes of Health (NIH) grant to J. Amory
   (5U54HD042454). The research was supported by funding to K.A.W. from the
   University of Washington, the Creative and Novel Ideas in HIV Research
   award (AI027767), and by partial support from NIH grants AI094412 and
   AI098648. C.B. and E.K. are partially supported by NSF Graduate Research
   Fellowships.
CR Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424                                                                  
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   Auras R, 2010, POLY LACTIC ACID SYN
   Baeten JM, 2007, CLIN INFECT DIS, V45, P360, DOI 10.1086/519432
   Ballagh SA, 2008, CONTRACEPTION, V77, P130, DOI 10.1016/j.contraception.2007.10.003
   Blish CA, 2011, AM J REPROD IMMUNOL, V65, P302, DOI 10.1111/j.1600-0897.2010.00930.x
   Boulmedarat L, 2005, J PHARM SCI-US, V94, P1300, DOI 10.1002/jps.20350
   Cui WG, 2006, BIOMACROMOLECULES, V7, P1623, DOI 10.1021/bm060057z
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047
   Forbes CJ, 2011, J CONTROL RELEASE, V156, P161, DOI 10.1016/j.jconrel.2011.08.006
   Free MJ, 1996, CONTRACEPTION, V53, P221, DOI 10.1016/0010-7824(96)00041-8
   Friend DR, 2010, ANTIVIR RES, V88, pS47, DOI 10.1016/j.antiviral.2010.09.005
   Garg S, 2010, ANTIVIR RES, V88, pS19, DOI 10.1016/j.antiviral.2010.09.010
   Glasier A, 2006, LANCET, V368, P1595, DOI 10.1016/S0140-6736(06)69478-6
   Graver MA, 2011, ANN CLIN MICROB ANTI, V10, DOI 10.1186/1476-0711-10-8
   Ham AS, 2012, PHARM RES-DORDR, V29, P1897, DOI 10.1007/s11095-012-0715-7
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Han YA, 2007, CONTRACEPTION, V76, P132, DOI 10.1016/j.contraception.2007.04.006
   Herrera C, 2009, ANTIMICROB AGENTS CH, V53, P1797, DOI 10.1128/AAC.01096-08
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kieweg SL, 2006, J BIOMECH ENG-T ASME, V128, P540, DOI 10.1115/1.2206198
   Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831
   Lin YC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007499
   Major I, 2010, IEEE ENG MED BIO, P1089, DOI 10.1109/IEMBS.2010.5627333
   Malcolm K, 2003, J CONTROL RELEASE, V91, P355, DOI 10.1016/S0168-3659(03)00260-8
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Malcolm RK, 2005, J ANTIMICROB CHEMOTH, V56, P954, DOI 10.1093/jac/dki326
   Minnis AM, 2005, SEX TRANSM INFECT, V81, P193, DOI 10.1136/sti.2003.007153
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Notari S, 2009, IUBMB LIFE, V61, P470, DOI 10.1002/iub.181
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Patton DL, 1999, AM J OBSTET GYNECOL, V180, P1080, DOI 10.1016/S0002-9378(99)70598-3
   Peterson ML, 2006, BIOCHEMISTRY-US, V45, P2387, DOI 10.1021/bi051992u
   Platt EJ, 1998, J VIROL, V72, P2855
   PROJAN SJ, 1994, J BACTERIOL, V176, P4204, DOI 10.1128/jb.176.14.4204-4209.1994                                                
   Ratner B D, 1996, BIOMATERIALS SCI INT
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Saxena BB, 2004, CONTRACEPTION, V70, P213, DOI 10.1016/j.contraception.2004.02.015
   Schlievert PM, 2008, ANTIMICROB AGENTS CH, V52, P4448, DOI 10.1128/AAC.00989-08
   SCHLIEVERT PM, 1992, ANTIMICROB AGENTS CH, V36, P626, DOI 10.1128/AAC.36.3.626                                                            
   Schwartz JL, 2008, CONTRACEPTION, V78, P237, DOI 10.1016/j.contraception.2008.04.118
   Singer R, 2011, J VIROL, V85, P5504, DOI 10.1128/JVI.02422-10
   Strandberg KL, 2010, ANTIMICROB AGENTS CH, V54, P597, DOI 10.1128/AAC.01151-09
   Szentivanyi A, 2011, ADV DRUG DELIVER REV, V63, P209, DOI 10.1016/j.addr.2010.12.002
   Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08
   Teo Wee-Eong, 2006, Biotechnology Journal, V1, P918, DOI 10.1002/biot.200600044
   Teo WE, 2011, SCI TECHNOL ADV MAT, V12, DOI 10.1088/1468-6996/12/1/013002
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Vetter SM, 2005, ANTIMICROB AGENTS CH, V49, P1302, DOI 10.1128/AAC.49.4.1302-1305.2005
   Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231
   Watts DH, 1999, J INFECT DIS, V180, P426, DOI 10.1086/314881
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   WHO, 2010, WHO LAB MAN EX PROC
   Yohe ST, 2012, J AM CHEM SOC, V134, P2016, DOI 10.1021/ja211148a
   Yu DG, 2010, INT J PHARMACEUT, V400, P158, DOI 10.1016/j.ijpharm.2010.08.010
   Yu DG, 2010, AAPS PHARMSCITECH, V11, P809, DOI 10.1208/s12249-010-9438-4
   Zidovetzki R, 2007, BBA-BIOMEMBRANES, V1768, P1311, DOI 10.1016/j.bbamen.2007.03.026
   [Anonymous], 2012, CAMI MULTIPURPOSE PR, P1
NR 62
TC 26
Z9 26
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2012
VL 7
IS 11
AR e49792
DI 10.1371/journal.pone.0049792
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 057YW
UT WOS:000312601700019
PM 23209601
OA gold
DA 2018-01-05
ER

PT J
AU Lattanzi, L
   Federico, M
AF Lattanzi, Laura
   Federico, Maurizio
TI A strategy of antigen incorporation into exosomes: Comparing
   cross-presentation levels of antigens delivered by engineered exosomes
   and by lentiviral virus-like particles
SO VACCINE
LA English
DT Article
DE Exosomes; Cross-presentation; Virus-like particles; Nef; Vesicular
   stomatitis virus-G protein
ID RESPONSE IN-VITRO; LIPID RAFTS; NEF INCREASES; T-CELLS; PROTEIN; HIV;
   EXPRESSION; INFECTIVITY; GENERATION; INDUCTION
AB Among strategies aimed at developing new nanoparticle-based vaccines, exosomes hold much promise. They are nanovesicles released by basically all eukaryotic cell types originating from intraluminal vesicles which accumulate in multivesicular bodies. Exosomes have immunogenic properties whose strength correlates with the amounts of associated antigens. Engineering antigens to target them in exosomes represents the last frontier in terms of nanoparticle-based vaccines. Here we report a new method to incorporate protein antigens in exosomes relying on the unique properties; of a mutant of the HIV-1 Nef protein, Nef(mut). This is a biologically inactive mutant we found incorporating into exosomes at high levels also when fused at its C-terminus with foreign proteins. We compared both biochemical and antigenic properties of Nef(mut) exosomes with those of previously characterized Nef(mut) -based lentiviral virus-like particles (VLPs). We found that exosomes incorporate Nef(mut) and fusion protein derivatives with similar efficiency of VLPs. When an envelope fusion protein was associated with both exosomes and VLPs to favor cross-presentation of associated antigens. Nef(mut) and its derivatives incorporated in exosomes were cross-presented at levels at least similar to what observed when the antigens were delivered by engineered VLPs. This occurred despite exosomes entered target cells with an apparent lower efficiency than VLPs. The unique properties of HIV-1 Nef(mut) in terms of exosome incorporation efficiency, carrier of foreign antigens, and lack of anti-cellular effects open the way toward the development of a flexible, safe, cost-effective exosome-based CD8(+) T cell vaccine platform. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Federico, Maurizio] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
   [Lattanzi, Laura] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy.
RP Federico, M (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM maurizio.federico@iss.it
RI Federico, Maurizio/J-5867-2016
OI Federico, Maurizio/0000-0003-4154-1025; Lattanzi,
   Laura/0000-0001-6998-4827
FU AIDS national project of the Ministry of Health, Rome, Italy
FX This work was supported by grants from the AIDS national project of the
   Ministry of Health, Rome, Italy. We thank A. Cosma, CEA, Service
   d'Immuno-Virologie, Institut des Maladies Emergentes et Therapies
   Innovantes, Fontenay-aux-Roses, France, Department of Microbiology and
   immunology, and C. J. Dembek, Institute of Virology, Helmholtz Zentrum
   Munchen, German Research Center for Environmental Health, Neuherberg,
   Germany, for kindly providing HLA-B7, -B35 and -Cw7 B-LCLs and
   Nef-specific CD8<SUP>+</SUP> T cell clones. We also are grateful to P.
   van der Bruggen, Ludwig Institute for Cancer Research, Brussels,
   Belgium, for providing the HLA-A.01 B-LCLs and the MAGE-A3 specific CD8+
   T cell clone, and to P. di Bonito, Department of Infectious, Parasitic
   and Immunomediated Diseases, Istituto Superiore di Sanita, Rome, Italy,
   for providing both Nef<SUP>mut</SUP> and Nef<SUP>mut</SUP> Delta Stop
   vectors. We are indebted to Guendalina Luswergh-Fornari for her
   excellent editorial assistance, and to Pietro Arciero for technical
   support.
CR Alessandrini L, 2000, J GEN VIROL, V81, P2905, DOI 10.1099/0022-1317-81-12-2905                                                    
   Alexander M, 2004, J VIROL, V78, P1685, DOI 10.1128/JVI.78.4.1685-1696.2004
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Buonaguro L, 2005, J VIROL, V79, P7059, DOI 10.1128/JVI.79.11.7059-7067.2005
   Chaput N, 2010, SEMIN IMMUNOPATHOL, V33, P419
   Delcayre A, 2005, BLOOD CELL MOL DIS, V35, P158, DOI 10.1016/j.bcmd.2005.07.003
   DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677                                                              
   Di Bonito P, 2009, VIROLOGY, V395, P45, DOI 10.1016/j.virol.2009.09.012
   Escudier B., 2005, J TRANSL MED, DOI [DOI 10.1186/1479-5876-3-10, 10.1186/1479-5876-3-1015740633]
   Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x
   Foster JL, 2011, J NEUROIMMUNE PHARM, V6, P230, DOI 10.1007/s11481-011-9262-y
   GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921
   Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929
   Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   Hartman ZC, 2011, VACCINE, V29, P9361, DOI 10.1016/j.vaccine.2011.09.133
   Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004
   Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Segura MM, 2010, METHODS MOL BIOL, V614, P39, DOI 10.1007/978-1-60761-533-0_2
   Morse Michael A, 2005, J Transl Med, V3, P9, DOI 10.1186/1479-5876-3-9
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Muratori C, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-52
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Peretti S, 2005, MOL THER, V12, P1185, DOI 10.1016/j.ymthe.2005.06.474
   Rabesandratana H, 1998, BLOOD, V91, P2573
   Ruiss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025294
   Russo V, 2001, J CANC, V2, P329
   Sistigu A, 2011, VACCINE, V29, P3465, DOI 10.1016/j.vaccine.2011.02.059
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Sparacio S, 2001, MOL THER, V3, P602, DOI 10.1006/mthe.2001.0296
   Tan A, 2010, INT J NANOMED, V5, DOI 10.2147/IJN.S13402
   VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7                                                   
   Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394
   Zhang JM, 2010, TUMORI, V96, P452
   Zhang Y, 2010, INT J ONCOL, V36, P133, DOI 10.3892/ijo_00000484
   Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8                                                   
   Zheng YH, 2003, P NATL ACAD SCI USA, V100, P8460, DOI 10.1073/pnas.1437453100
NR 38
TC 15
Z9 15
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 26
PY 2012
VL 30
IS 50
BP 7229
EP 7237
DI 10.1016/j.vaccine.2012.10.010
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 056XB
UT WOS:000312523600021
PM 23099330
DA 2018-01-05
ER

PT J
AU Raghuwanshi, D
   Mishra, V
   Suresh, MR
   Kaur, K
AF Raghuwanshi, Dharmendra
   Mishra, Vivek
   Suresh, Mavanur R.
   Kaur, Kamaljit
TI A simple approach for enhanced immune response using engineered
   dendritic cell targeted nanoparticles
SO VACCINE
LA English
DT Article
DE Dendritic cells; DEC-205 receptor; PLGA nanoparticles; Bifunctional
   fusion protein; Ovalbumin; Vaccine delivery
ID ANTIGEN-PRESENTING CELLS; IN-VIVO; T-CELLS; MONOCLONAL-ANTIBODY; DEC-205
   RECEPTOR; HIV GAG; MHC-I; DELIVERY; VACCINES; PROTEIN
AB In this study, we demonstrate a simple strategy for enhanced immune response using a two-component dendritic cell (DC) targeted antigen delivery system. One component consists of a recombinant bifunctional fusion protein (bfFp) used for DC targeting, whereas, the other component is made of biotinylated PLGA nanoparticles that encapsulate the antigen. The fusion protein (bfFp) made of a truncated core-streptavidin fused to anti-DEC-205 single chain antibody (scFv) was mixed with ovalbumin-loaded biotinylated NPs that were formulated using biotin-PEG (2000)-PLGA, and the combination, bfFp functionalized NPs was used for DC targeted antigen delivery. In vitro DC uptake studies revealed a 2-fold higher receptor-mediated uptake of bfFp functionalized NPs when compared to non-targeted NPs. Immunization of the mice with the bfFp functionalized NPs in conjunction with DC maturation stimulus (anti-CD40 mAb) enhanced OVA-specific IgG and IgG subclass responses. Splenocytes of these mice secreted significantly higher levels of Th1 (IFN-gamma and IL-2) cytokines upon ex vivo restimulation with OVA. The promising outcomes of the bfFp functionalized DC targeted system support its use as a versatile vaccine delivery system for the design of monovalent or polyvalent vaccines. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Raghuwanshi, Dharmendra; Mishra, Vivek; Suresh, Mavanur R.; Kaur, Kamaljit] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
RP Kaur, K (reprint author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
EM kkaur@ualberta.ca
FU Canadian institute of Health and Research (CIHR); Canadian Commonwealth
   Scholarship Program (CCSP); DBT, Govt. of India
FX This work was supported by funding from the Canadian institute of Health
   and Research (CIHR) for grant support to M.R.S. D.R. would like to thank
   Canadian Commonwealth Scholarship Program (CCSP) for the financial
   support during graduate studies. V.M. would like to thank DBT, Govt. of
   India, for Overseas Associateship Award.
CR Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bandyopadhyay A, 2011, BIOMATERIALS, V32, P3094, DOI 10.1016/j.biomaterials.2010.12.054
   Basu S, 2009, P NATL ACAD SCI USA, V106, P7957, DOI 10.1073/pnas.0902857106
   Birkholz K, 2010, BLOOD, V116, P2277, DOI 10.1182/blood-2010-02-268425
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
   Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104
   Caminschi I, 2008, BLOOD, V112, P3264, DOI 10.1182/blood-2008-05-155176
   Cheong C, 2010, BLOOD, V116, P3828, DOI 10.1182/blood-2010-06-288068
   Cruz LJ, 2011, BIOMATERIALS, V32, P6791, DOI 10.1016/j.biomaterials.2011.04.082
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   Demangel C, 2001, INFECT IMMUN, V69, P2456, DOI 10.1128/IAI.69.4.2456-2461.2001
   Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9
   Do Y, 2008, EUR J IMMUNOL, V38, P20, DOI 10.1002/eji.200737799
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Essa S, 2011, INT J PHARMACEUT, V411, P178, DOI 10.1016/j.ijpharm.2011.02.039
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Goforth R, 2009, CANCER IMMUNOL IMMUN, V58, P517, DOI 10.1007/s00262-008-0574-6
   Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021
   Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769
   He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259                                                    
   Idoyaga J, 2008, J IMMUNOL, V180, P3647, DOI 10.4049/jimmunol.180.6.3647                                                     
   INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109                                                          
   Jain S, 2011, EXPERT REV VACCINES, V10, P1731, DOI [10.1586/ERV.11.126, 10.1586/erv.11.126]
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Johansen P, 2007, EXPERT REV VACCINES, V6, P471, DOI 10.1586/14760584.6.4.471
   Johnson TS, 2008, CLIN CANCER RES, V14, P8169, DOI 10.1158/1078-0432.CCR-08-1474
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Lahoud MH, 2011, J IMMUNOL, V187, P842, DOI 10.4049/jimmunol.1101176
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673                                                           
   Mahnke K, 2007, CELL IMMUNOL, V250, P1, DOI 10.1016/j.cellimm.2008.01.004
   Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012
   Moon JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031472
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pandit S, 2007, J MICROENCAPSUL, V24, P539, DOI 10.1080/02652040701443700
   Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021
   Pereira CF, 2007, J IMMUNOTHER, V30, P705, DOI 10.1097/CJI.0b013e31812e6256                                                    
   Raghuwanshi D, 2012, MOL PHARMACEUT, V9, P946, DOI 10.1021/mp200553x
   Ramakrishna V, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-5
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Shan XQ, 2009, COLLOID SURFACE B, V72, P303, DOI 10.1016/j.colsurfb.2009.04.017
   Shortman K, 2009, EXP MOL MED, V41, P61, DOI 10.3858/emm.2009.41.2.008
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615
   Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318
   Thomas C, 2011, MOL PHARMACEUT, V8, P405, DOI 10.1021/mp100255c
   Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x
   Unger WWJ, 2011, CURR OPIN IMMUNOL, V23, P131, DOI 10.1016/j.coi.2010.11.011
   Wang WW, 2009, MOL PHARMACEUT, V6, P158, DOI 10.1021/mp800111a
   Weiss B, 2007, BIOCONJUGATE CHEM, V18, P1087, DOI 10.1021/bc060342f
   Zhang ZP, 2011, BIOMATERIALS, V32, P3666, DOI 10.1016/j.biomaterials.2011.01.067
NR 54
TC 19
Z9 20
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 26
PY 2012
VL 30
IS 50
BP 7292
EP 7299
DI 10.1016/j.vaccine.2012.09.036
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 056XB
UT WOS:000312523600030
PM 23022399
DA 2018-01-05
ER

PT J
AU Roy, U
   McMillan, J
   Alnouti, Y
   Gautum, N
   Smith, N
   Balkundi, S
   Dash, P
   Gorantla, S
   Martinez-Skinner, A
   Meza, J
   Kanmogne, G
   Swindells, S
   Cohen, SM
   Mosley, RL
   Poluektova, L
   Gendelman, HE
AF Roy, Upal
   McMillan, JoEllyn
   Alnouti, Yazen
   Gautum, Nagsen
   Smith, Nathan
   Balkundi, Shantanu
   Dash, Prasanta
   Gorantla, Santhi
   Martinez-Skinner, Andrea
   Meza, Jane
   Kanmogne, Georgette
   Swindells, Susan
   Cohen, Samuel M.
   Mosley, R. Lee
   Poluektova, Larisa
   Gendelman, Howard E.
TI Pharmacodynamic and Antiretroviral Activities of Combination
   Nanoformulated Antiretrovirals in HIV-1-Infected Human Peripheral Blood
   Lymphocyte-Reconstituted Mice
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INTERLEUKIN-2-RECEPTOR GAMMA-CHAIN; MAJOR
   HISTOCOMPATIBILITY COMPLEX; RESOURCE-LIMITED SETTINGS; CNS
   DRUG-DELIVERY; MURINE MODEL; MOUSE MODEL; T-CELLS; HIV; MACROPHAGES
AB Lack of adherence, inaccessibility to viral reservoirs, long-term drug toxicities, and treatment failures are limitations of current antiretroviral therapy (ART). These limitations lead to increased viral loads, medicine resistance, immunocompromise, and comorbid conditions. To this end, we developed long-acting nanoformulated ART (nanoART) through modifications of existing atazanavir, ritonavir, and efavirenz suspensions in order to establish cell and tissue drug depots to achieve sustained antiretroviral responses. NanoART's abilities to affect immune and antiviral responses, before or following human immunodeficiency virus type 1 infection were tested in nonobese severe combined immune-deficient mice reconstituted with human peripheral blood lymphocytes. Weekly subcutaneous injections of drug nanoformulations at doses from 80 mg/kg to 250 mg/kg, 1 day before and/or 1 and 7 days after viral exposure, elicited drug levels that paralleled the human median effective concentration, and with limited toxicities. NanoART treatment attenuated viral replication and preserved CD4(+) Tcell numbers beyond that seen with orally administered native drugs. These investigations bring us one step closer toward using long-acting antiretrovirals in humans.
C1 [Roy, Upal; McMillan, JoEllyn; Smith, Nathan; Balkundi, Shantanu; Dash, Prasanta; Gorantla, Santhi; Martinez-Skinner, Andrea; Kanmogne, Georgette; Mosley, R. Lee; Poluektova, Larisa; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Coll Med, Omaha, NE 68198 USA.
   [Swindells, Susan] Univ Nebraska Med Ctr, Dept Internal Med, Coll Med, Omaha, NE 68198 USA.
   [Cohen, Samuel M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Coll Med, Omaha, NE 68198 USA.
   [Meza, Jane] Univ Nebraska Med Ctr, Dept Biostat, Coll Publ Hlth, Omaha, NE 68198 USA.
   [Alnouti, Yazen; Gautum, Nagsen] Univ Nebraska Med Ctr, Dept Pharmacal Sci, Coll Pharm, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Coll Med, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Roy, Upal/0000-0002-0325-567X; Poluektova, Larisa/0000-0001-7339-8732
FU National Institutes of Health [1P01 DA028555, 2R01 NS034239, 2R37
   NS36126, P01 NS31492, P20RR 15635, P01MH64570, P01 NS43985]; Baxter
   Healthcare
FX This work was supported by the National Institutes of Health (grant
   numbers 1P01 DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR
   15635, P01MH64570, and P01 NS43985 [to H. E. G.]) and by a research
   grant from Baxter Healthcare.
CR AIDSinfo Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG HIV 1
   Balkundi S, 2010, J VIS EXP, P2460
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Batrakova EV, 2011, EXPERT OPIN DRUG DEL, V8, P415, DOI 10.1517/17425247.2011.559457
   Batrakova EV, 2010, J CONTROL RELEASE, V143, P290, DOI 10.1016/j.jconrel.2010.01.004
   Berges BK, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-65
   Best BM, 2009, AIDS, V23, P83, DOI 10.1097/QAD.0b013e328317a702
   Braithwaite RS, 2006, J ANTIMICROB CHEMOTH, V58, P1036, DOI 10.1093/jac/dk1386
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790
   Broder Michael S, 2011, J Med Econ, V14, P167, DOI 10.3111/13696998.2011.554932
   Chesney MA, 1999, AIDS, V13, pS271
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   GENDELMAN HE, 1994, ADV NEUROIMMUNOL, V4, P189, DOI 10.1016/S0960-5428(06)80256-1
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gendelman HE, 2008, J NEUROIMMUNE PHARM, V3, P58, DOI 10.1007/s11481-008-9103-9
   Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7
   Gorantla S, 2005, J VIROL, V79, P2124, DOI 10.1128/JVI.79.4.2124-2132.2005
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Gorantla S, 2010, J IMMUNOL, V184, P7082, DOI 10.4049/jimmunol.1000438
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Huff-Rousselle M, 2007, Glob Public Health, V2, P184, DOI 10.1080/17441690601063299
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   King MA, 2009, CLIN EXP IMMUNOL, V157, P104, DOI 10.1111/j.1365-2249.2009.03933.x
   Lopez-Cortes LF, 2005, JAIDS-J ACQ IMM DEF, V39, P551
   MOSIER DE, 1993, SCIENCE, V260, P689, DOI 10.1126/science.8097595
   Mosier DE, 1995, J CLIN IMMUNOL, V15, p130S
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Ohbo K, 1996, BLOOD, V87, P956
   Pino S, 2010, METHODS MOL BIOL, V602, P105, DOI 10.1007/978-1-60761-058-8_7
   Poluektova L, 2004, J IMMUNOL, V172, P7610, DOI 10.4049/jimmunol.172.12.7610                                                    
   Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941                                                     
   Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000                                                 
   Stoddart CA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000655
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   [WHO] World Health Organization, ANT THER HIV INF AD
   Wood E, 2005, AIDS, V19, P1189, DOI 10.1097/01.aids.0000176219.48484.f1
NR 42
TC 33
Z9 33
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 15
PY 2012
VL 206
IS 10
BP 1577
EP 1588
DI 10.1093/infdis/jis395
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 025UI
UT WOS:000310220000014
PM 22811299
OA gold
DA 2018-01-05
ER

PT J
AU Hu, YW
   Li, FH
   Han, DX
   Wu, TS
   Zhang, QX
   Niu, L
   Bao, Y
AF Hu, Yuwei
   Li, Fenghua
   Han, Dongxue
   Wu, Tongshun
   Zhang, Qixian
   Niu, Li
   Bao, Yu
TI Simple and label-free electrochemical assay for signal-on DNA
   hybridization directly at undecorated graphene oxide
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Graphene oxide; DNA; Label-free; Impedimetric detection; Signal-on
ID MOLECULAR BEACON; METHYLENE-BLUE; CARBON; SHEETS; GOLD; AMPLIFICATION;
   SENSITIVITY; ADSORPTION; MONOLAYERS; SURFACES
AB Exploring graphene oxide (GO), DNA hybridization detection usually relies on either GO decoration or DNA sequences labeling. The former endows GO with desired chemical, optical, and biological properties. The latter adopts labeled molecules to indicate hybridization. In the present work, we propose a simple, label-free DNA assay using undecorated GO directly as the sensing platform. GO is anchored on diazonium functionalized electrode through electrostatic attraction, hydrogen bonding or epoxy ring-opening. The pi-pi stacking interaction between hexagonal cells of GO and DNA base rings facilitates DNA immobilization. The adsorbed DNA sequence is specially designed with two parts, including immobilization sequence and probe sequence. In the absence of target, the two sequences lie nearly flat on GO platform. In the presence of target, probe hybridizes with it to form double helix DNA, which 'stands' on GO. While the immobilization sequence part remains 'lying' on GO surface. Hence, DNA hybridization induces GO interfacial property changes, including negative charge and conformational transition from 'lying' ssDNA to 'standing' dsDNA. These changes are monitored by electrochemical impedance spectroscopy and adopted as the analytical signal. This strategy eliminates the requirement for GO decoration or DNA labeling, representing a comparatively simple and effective way. Finally, the principle is applied to the detection of conserved sequence of the human immunodeficiency virus 1 pol gene fragment. The dynamic detection range is from 1.0 x 10(-12) to 1.0 x 10(-6) M with detection limit of 1.1 x 10(-13) M with 3 sigma. And the sequences with double- or four-base mismatched are readily distinguishable. In addition, this strategy may hold great promise for potential applications from DNA biosensing to nanostructure framework construction based on the versatile DNA self-assembly. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hu, Yuwei; Li, Fenghua; Han, Dongxue; Wu, Tongshun; Zhang, Qixian; Niu, Li; Bao, Yu] Chinese Acad Sci, Changchun Inst Appl Chem, Engn Lab Modern Analyt Tech, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
   [Hu, Yuwei; Niu, Li] Jilin Univ, Coll Chem, Changchun 130012, Peoples R China.
RP Han, DX (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, Engn Lab Modern Analyt Tech, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
EM dxhan@ciac.j1.cn; ybao@ciac.j1.cn
FU NSFC, China [21175130, 21105096]; Department of Science and Techniques
   of Jilin Province [201215091]
FX The authors are most grateful to the NSFC, China (no. 21175130 and no.
   21105096) and Department of Science and Techniques of Jilin Province
   (no. 201215091) for their financial support.
CR Akca S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018442
   Balapanuru J, 2010, ANGEW CHEM INT EDIT, V49, P6549, DOI 10.1002/anie.201001004
   Bonanni A, 2012, TRAC-TREND ANAL CHEM, V37, P12, DOI 10.1016/j.trac.2012.02.011
   Bonanni A, 2012, CHEM-EUR J, V18, P1668, DOI 10.1002/chem.201102850
   Bonanni A, 2011, ACS NANO, V5, P2356, DOI 10.1021/nn200091p
   Chen CP, 2009, ANAL CHEM, V81, P36, DOI 10.1021/ac800986q
   Chen Y, 2011, CHEM COMMUN, V47, P12798, DOI 10.1039/c1cc14902d
   Dijksma M, 2002, LANGMUIR, V18, P3105, DOI 10.1021/la010898l
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Dubuisson E, 2011, ANAL CHEM, V83, P2452, DOI 10.1021/ac102431d
   Farjami E, 2010, ANALYST, V135, P1443, DOI 10.1039/c0an00049c
   Freeman R, 2011, J AM CHEM SOC, V133, P11597, DOI 10.1021/ja202639m
   Fujii S, 2010, J AM CHEM SOC, V132, P10034, DOI 10.1021/ja101265r
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Giovanni M, 2012, ANALYST, V137, P580, DOI 10.1039/c1an15910k
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Hu YW, 2010, CHEM-EUR J, V16, P1992, DOI 10.1002/chem.200901870
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Hu YW, 2012, BIOMATERIALS, V33, P1097, DOI 10.1016/j.biomaterials.2011.10.045
   Hu YW, 2011, BIOSENS BIOELECTRON, V26, P4355, DOI 10.1016/j.bios.2011.04.037
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Kang T, 2010, NANO LETT, V10, P1189, DOI 10.1021/nl1000086
   Kim H, 2011, BIOCONJUGATE CHEM, V22, P2558, DOI 10.1021/bc200397j
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Kurkina T, 2011, ANGEW CHEM INT EDIT, V50, P3710, DOI 10.1002/anie.201006806
   Lee K, 2007, ANGEW CHEM INT EDIT, V46, P4667, DOI 10.1002/anie.200700419
   Lehr J, 2011, J PHYS CHEM C, V115, P6629, DOI 10.1021/jp111838r
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u
   Li F, 2010, NANOSCALE, V2, P1021, DOI 10.1039/b9nr00401g
   Li J, 2003, NANO LETT, V3, P597, DOI 10.1021/nl0340677
   Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878
   Liu GZ, 2011, LANGMUIR, V27, P4176, DOI 10.1021/la104373v
   LIU YC, 1995, J AM CHEM SOC, V117, P11254, DOI 10.1021/ja00150a024                                                             
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Lu CH, 2010, CHEM-EUR J, V16, P4889, DOI 10.1002/chem.200903071
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Rawson F.J., 2012, NANO LETT, DOI http://dx.doi.org/10.1021/nl03780d
   Shiigi H, 2005, J AM CHEM SOC, V127, P3280, DOI 10.1021/ja0445793
   Song B, 2010, CHEMPHYSCHEM, V11, P585, DOI 10.1002/cphc.200900743
   Star A, 2006, P NATL ACAD SCI USA, V103, P921, DOI 10.1073/pnas.0504146103
   Tang LAL, 2010, J AM CHEM SOC, V132, P10976, DOI 10.1021/ja104017y
   Wang J, 2004, J AM CHEM SOC, V126, P3010, DOI 10.1021/ja031723w
   Yan YM, 2005, CHEM MATER, V17, P3457, DOI 10.1021/cm0504182
   Yang WR, 2002, ELECTROANAL, V14, P1299, DOI 10.1002/1521-4109(200210)14:18<1299::AID-ELAN1299>3.0.CO;2-Y
   Yeung CL, 2010, ADV FUNCT MATER, V20, P2657, DOI 10.1002/adfm.201000411
   Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235
   Zhou M, 2009, ANAL CHEM, V81, P5603, DOI 10.1021/ac900136z
NR 49
TC 48
Z9 49
U1 0
U2 114
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD NOV 13
PY 2012
VL 753
BP 82
EP 89
DI 10.1016/j.aca.2012.09.038
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 036WN
UT WOS:000311063100011
PM 23107140
DA 2018-01-05
ER

PT J
AU Dash, PK
   Gendelman, HE
   Roy, U
   Balkundi, S
   Alnouti, Y
   Mosley, RL
   Gelbard, HA
   McMillan, J
   Gorantla, S
   Poluektova, LY
AF Dash, Prasanta K.
   Gendelman, Howard E.
   Roy, Upal
   Balkundi, Shantanu
   Alnouti, Yazen
   Mosley, Rodney L.
   Gelbard, Harris A.
   McMillan, JoEllyn
   Gorantla, Santhi
   Poluektova, Larisa Y.
TI Long-acting nanoformulated antiretroviral therapy elicits potent
   antiretroviral and neuroprotective responses in HIV-1-infected humanized
   mice
SO AIDS
LA English
DT Article
DE central nervous system; drug biodistribution; HIV-associated
   neurocognitive disorders; humanized mice; HIV-1; nanoformulated
   antiretroviral therapy
ID PROGRESSIVE HIV-1 INFECTION; ATAZANAVIR-RITONAVIR; DRUG-DELIVERY;
   REGIMEN SIMPLIFICATION; MOUSE; MODEL; PHARMACOKINETICS; MACROPHAGES;
   SUPPRESSION; LIMITATIONS
AB Objectives: Long-acting nanoformulated antiretroviral therapy (nanoART) with improved pharmacokinetics, biodistribution and limited systemic toxicities will likely improve drug adherence and access to viral reservoirs.
   Design: Atazanavir and ritonavir crystalline nanoART were formulated in a poloxamer-188 excipient by high-pressure homogenization. These formulations were evaluated for antiretroviral and neuroprotective activities in humanized NOD/scid-IL-2Rg(c)(null) (NSG) mice.
   Methods: NanoART-treated NSG mice were evaluated for drug biodistribution, pharmacodynamics and toxicity. CD34(+) human hematopoietic stem cells were transplanted at birth in replicate NSG mice. The mice were infected with HIV-1(ADA) at 5 months of age. Eight weeks later, the infected animals were treated with weekly subcutaneous injections of nanoformulated ATV and RTV. Peripheral viral load, CD4(+) T-cell counts and lymphoid and brain histopathology and immunohistochemistry tests were performed.
   Results: NanoART treatments by once-a-week injections reduced viral loads more than 1000-fold and protected CD4(+) T-cell populations. This paralleled high ART levels in liver, spleen and blood that were in or around the human minimal effective dose concentration without notable toxicities. Importantly, examination of infected brain subregions showed that nanoART elicited neuroprotective responses with detectable increases in microtubule-associated protein-2, synaptophysin and neurofilament expression when compared to untreated virus-infected animals. Therapeutic interruptions produced profound viral rebounds.
   Conclusion: Long-acting nanoART has translational potential with sustained and targeted efficacy and with limited systemic toxicities. Such success in drug delivery and distribution could improve drug adherence and reduce viral resistance in infected people. (c) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Dash, Prasanta K.; Gendelman, Howard E.; Roy, Upal; Balkundi, Shantanu; Mosley, Rodney L.; McMillan, JoEllyn; Gorantla, Santhi; Poluektova, Larisa Y.] Univ Nebraska Med Ctr, Coll Med, Ctr Neurodegenerat Disorders, Omaha, NE USA.
   [Alnouti, Yazen] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE USA.
   [Gelbard, Harris A.] Univ Rochester, Sch Med & Dent, Dept Neurol, Ctr Neural Dev & Dis,Child Neurol Div, Rochester, NY 14642 USA.
   [Dash, Prasanta K.; Gendelman, Howard E.; Roy, Upal; Balkundi, Shantanu; Mosley, Rodney L.; McMillan, JoEllyn; Gorantla, Santhi; Poluektova, Larisa Y.] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE USA.
RP Gendelman, HE (reprint author), 985880 Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Poluektova, Larisa/0000-0001-7339-8732; Roy, Upal/0000-0002-0325-567X
FU National Institutes of Health [1P01 DA028555, 2R01 NS034239, 2R37
   NS36126, P01 NS31492, P20RR 15635, P30 MH062261, P01 NS43985,
   P01MH64570]; Baxter Healthcare
FX The work was supported by the National Institutes of Health grants 1P01
   DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635, P30
   MH062261, P01 NS43985 (HEG) and P01MH64570 (HAG and HEG) and from a
   research grant from Baxter Healthcare.
CR Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Bartlett JA, 2009, LANCET INFECT DIS, V9, P637, DOI 10.1016/S1473-3099(09)70227-0
   Berges BK, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-65
   Boffito M, 2011, ANTIMICROB AGENTS CH, V55, P4218, DOI 10.1128/AAC.01747-10
   Choi A, 2010, AM J KIDNEY DIS, V56, P872, DOI 10.1053/j.ajkd.2010.05.019
   Choudhary SK, 2009, J VIROL, V83, P8254, DOI 10.1128/JVI.00580-09
   Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324
   Dash PK, 2011, J NEUROSCI, V31, P3148, DOI 10.1523/JNEUROSCI.5473-10.2011
   Felmlee MA, 2008, DRUG METAB DISPOS, V36, P435, DOI 10.1124/dmd.107.018838
   Foreman O, 2011, VET PATHOL, V48, P495, DOI 10.1177/0300985810378282
   Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06
   Gorantla S, 2012, J NEUROIMMUNE PHARM, V7, P352, DOI 10.1007/s11481-011-9335-y
   Gorantla S, 2012, TRENDS NEUROSCI, V35, P197, DOI 10.1016/j.tins.2011.12.006
   Gorantla S, 2010, AM J PATHOL, V177, P2938, DOI 10.2353/ajpath.2010.100536
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Jain R, 2006, CURR PHARM DESIGN, V12, P1065, DOI 10.2174/138161206776055813                                                      
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kanmogne GD, 2012, INT J NANOMED, V7, P2373, DOI 10.2147/IJN.S29454
   Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679
   Kuypers DRJ, 2009, DRUG AGING, V26, P715, DOI 10.2165/11316480-000000000-00000
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P541, DOI [10.2217/nnm.09.37, 10.2217/NNM.09.37]
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941                                                     
   Roy U, J INFECT DI IN PRESS
   Sato K, 2011, EXP BIOL MED, V236, P977, DOI 10.1258/ebm.2011.010294
   Stoddart CA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000655
   Swindells S, 2006, JAMA-J AM MED ASSOC, V296, P806, DOI 10.1001/jama.296.7.806                                                          
   Swindells S, 2011, J INFECT DIS, V204, P669, DOI 10.1093/infdis/jir370
   Taiwo B, 2010, DRUGS, V70, P1629, DOI 10.2165/11538020-000000000-00000
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wilkin TJ, 2009, J INFECT DIS, V199, P866, DOI 10.1086/597119
NR 35
TC 52
Z9 52
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 13
PY 2012
VL 26
IS 17
BP 2135
EP 2144
DI 10.1097/QAD.0b013e328357f5ad
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 032WQ
UT WOS:000310750800002
PM 22824628
OA gold
DA 2018-01-05
ER

PT J
AU Mandal, M
   Zhu, ZN
   Cumming, JN
   Liu, XX
   Strickland, C
   Mazzola, RD
   Caldwell, JP
   Leach, P
   Grzelak, M
   Hyde, L
   Zhang, Q
   Terracina, G
   Zhang, LL
   Chen, X
   Kuvelkar, R
   Kennedy, ME
   Favreau, L
   Cox, K
   Orth, P
   Buevich, A
   Voig, J
   Wang, HW
   Kazakevich, I
   McKittrick, BA
   Greenlee, W
   Parker, EM
   Stamford, AW
AF Mandal, Mihirbaran
   Zhu, Zhaoning
   Cumming, Jared N.
   Liu, Xiaoxiang
   Strickland, Corey
   Mazzola, Robert D.
   Caldwell, John P.
   Leach, Prescott
   Grzelak, Michael
   Hyde, Lynn
   Zhang, Qi
   Terracina, Giuseppe
   Zhang, Lili
   Chen, Xia
   Kuvelkar, Reshma
   Kennedy, Matthew E.
   Favreau, Leonard
   Cox, Kathleen
   Orth, Peter
   Buevich, Alexei
   Voig, Johannes
   Wang, Hongwu
   Kazakevich, Irina
   McKittrick, Brian A.
   Greenlee, William
   Parker, Eric M.
   Stamford, Andrew W.
TI Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid
   Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor
   a Bioactive Conformation
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID GAMMA-SECRETASE INHIBITOR; X-RAY CRYSTALLOGRAPHY; ALZHEIMERS-DISEASE;
   PRECURSOR PROTEIN; HIV-1 PROTEASE; POTENT INHIBITORS; CRYSTAL-STRUCTURE;
   LEAD GENERATION; DRUG DISCOVERY; HUMAN BRAIN
AB On the basis of our observation that the biaryl substituent of iminopyrimidinone 7 must be in a pseudoaxial conformation to occupy the contiguous S1-S3 subsites of BACE1, we have designed a novel fused bicyclic iminopyrimidinc ne scaffold intended to favor this bioactive conformation. Strategic incorporation of a nitrogen atom in the new constrained ring allowed us to develop SAR around the S2' binding pocket and ultimately resulted in analogues with low nanomolar potency for BACE1. In particular, optimization of the prime side substituent led to major improvements in potency by displacement of two conserved water molecules from a region near S2'. Further optimization of the pharmacokinetic properties of this fused pyrrolidine series, in conjunction with facile access to a rat pharmacodynamic model, led to identification of compound 43, which is an orally active, brain penetrant inhibitor that reduces A beta(40) in the plasma, CSF, and cortex of rats in a dose-dependent manner.
C1 [Mandal, Mihirbaran; Zhu, Zhaoning; Cumming, Jared N.; Liu, Xiaoxiang; Mazzola, Robert D.; Caldwell, John P.; McKittrick, Brian A.; Greenlee, William; Stamford, Andrew W.] Merck Res Labs, Dept Med Chem, Kenilworth, NJ 07033 USA.
   [Leach, Prescott; Grzelak, Michael; Hyde, Lynn; Zhang, Qi; Terracina, Giuseppe; Zhang, Lili; Chen, Xia; Kuvelkar, Reshma; Kennedy, Matthew E.; Parker, Eric M.] Merck Res Labs, Dept Neurosci, Kenilworth, NJ 07033 USA.
   [Buevich, Alexei] Merck Res Labs, Dept Analyt Chem, Kenilworth, NJ 07033 USA.
   [Kazakevich, Irina] Merck Res Labs, Dept Basic Pharmaceut Sci, Kenilworth, NJ 07033 USA.
   [Favreau, Leonard; Cox, Kathleen] Merck Res Labs, Dept Exploratory Drug Metab, Kenilworth, NJ 07033 USA.
RP Mandal, M (reprint author), Merck Res Labs, Dept Med Chem, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
EM mihirbaran.mandal@merck.com
FU U.S. Department of Energy, Office of Science, Office of Basic Energy
   Sciences [DE-AC02-06CH11357]
FX We thank T.-M.Chan for his help in compound characterization, Drs. Jim
   Tata and Ann Weber for their strong support, and Dr. Eric Gilbert for
   helpful feedback on the manuscript. Use of the IMCA-CAT beamline 17-ID
   (or 17-BM) at the Advanced Photon Source was supported by the companies
   of the Industrial Macromolecular Crystallography Association through a
   contract with Hauptman-Woodward Medical Research Institute. Use of the
   Advanced Photon Source was supported by the U.S. Department of Energy,
   Office of Science, Office of Basic Energy Sciences, under Contract No.
   DE-AC02-06CH11357.
CR Archer HA, 2006, ANN NEUROL, V60, P145, DOI 10.1002/ana.20889
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Barrow JC, 2008, J MED CHEM, V51, P6259, DOI 10.1021/jm800914n
   Bateman RJ, 2009, ANN NEUROL, V66, P48, DOI 10.1002/ana.21623
   Baxter E. W., 2007, J MED CHEM, V50, P4162
   Bold G, 1998, J MED CHEM, V41, P3387, DOI 10.1021/jm970873c
   Bullock R, 2006, ALZ DIS ASSOC DIS, V20, P23, DOI 10.1097/01.wad.0000201847.29836.a5                                              
   Chein RJ, 2010, ORG LETT, V12, P132, DOI 10.1021/ol9025364
   Cheng Y, 2011, J MED CHEM, V54, P5836, DOI 10.1021/jm200544q
   Cole DC, 2006, J MED CHEM, V49, P6158, DOI 10.1021/jm0607451
   Congreve M, 2007, J MED CHEM, V50, P1124, DOI 10.1021/jm061197u
   Cumming JN, 2008, BIOORG MED CHEM LETT, V18, P3236, DOI 10.1016/j.bmcl.2008.04.050
   Cumming JN, 2012, BIOORG MED CHEM LETT, V22, P2444, DOI 10.1016/j.bmcl.2012.02.013
   Carlson C., 2011, ALZHEIMERS DEMENT, V7, P396
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   DEAN WD, 1993, J ORG CHEM, V58, P7916, DOI 10.1021/jo00079a044                                                             
   Didziapetris R, 2003, J DRUG TARGET, V11, P391, DOI 10.1080/10611860310001648248
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   Dorsey BD, 2000, J MED CHEM, V43, P3386, DOI 10.1021/jm9903848
   Edwards PD, 2007, J MED CHEM, V50, P5912, DOI 10.1021/jm070829p
   Fleisher AS, 2008, ARCH NEUROL-CHICAGO, V65, P1031, DOI 10.1001/archneur.65.8.1031
   Geschwindner S, 2007, J MED CHEM, V50, P5903, DOI 10.1021/jm070825k
   Ghosh AK, 2000, J AM CHEM SOC, V122, P3522, DOI 10.1021/ja000300g                                                               
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994                                                         
   Hardy John, 2006, Current Alzheimer Research, V3, P71, DOI 10.2174/156720506775697098
   Hom R. K., 2003, J MED CHEM, V46, P1799
   Horn RK, 2004, J MED CHEM, V47, P158
   Hull M, 2006, DRUGS, V66, P2075
   Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811
   Iserloh U, 2008, BIOORG MED CHEM LETT, V18, P414, DOI 10.1016/j.bmcl.2007.10.116
   Iserloh U, 2008, BIOORG MED CHEM LETT, V18, P418, DOI 10.1016/j.bmcl.2007.10.053
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Korczyn AD, 2008, ALZHEIMERS DEMENT, V4, P176, DOI 10.1016/j.jalz.2007.11.008
   Korfmacher WA, 2001, RAPID COMMUN MASS SP, V15, P335, DOI 10.1002/rcm.235
   Kuo YM, 1996, J BIOL CHEM, V271, P4077
   Lam PYS, 1998, TETRAHEDRON LETT, V39, P2941, DOI 10.1016/S0040-4039(98)00504-8                                                   
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448
   Lu K, 2011, BIOORG MED CHEM LETT, V21, P5310, DOI 10.1016/j.bmcl.2011.07.020
   Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9
   Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059
   Maibaum J, 2007, J MED CHEM, V50, P4832, DOI 10.1021/jm070316i
   Maillard MC, 2007, J MED CHEM, V50, P776, DOI 10.1021/jm061242y
   Makhey VD, 1998, PHARMACEUT RES, V15, P1160, DOI 10.1023/A:1011971303880
   Malamas MS, 2010, J MED CHEM, V53, P1146, DOI 10.1021/jm901414e
   Malamas MS, 2009, J MED CHEM, V52, P6314, DOI 10.1021/jm9006752
   McConlogue L., 2007, J BIOL CHEM, V282, P8589
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Murray CW, 2007, J MED CHEM, V50, P1116, DOI 10.1021/jm0611962
   Nordberg A, 2006, ALZ DIS ASSOC DIS, V20, pS12, DOI 10.1097/01.wad.0000213804.59187.2d
   Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9                                                   
   Rodrigues CMP, 2001, BIOCHEM BIOPH RES CO, V281, P468, DOI 10.1006/bbrc.2001.4370
   RUBAS W, 1993, PHARMACEUT RES, V10, P113, DOI 10.1023/A:1018937416447
   Schellenberg GD, 2012, ACTA NEUROPATHOL
   [Anonymous], SCHROD MOD SOFTW
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741
   Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29
   Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1
   Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114
   Stamford AW, 2012, ACS MED CHEM LETT, V3, P897, DOI 10.1021/ml3001165
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tariot PN, 2003, ALZ DIS ASSOC DIS, V17, pS105, DOI 10.1097/00002093-200307004-00005                                                
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735                                                    
   Wang H, 2008, J NEUROSCI, V28, P8677, DOI 10.1523/JNEUROSCI.2440-08.2008
   Wang YS, 2010, J MED CHEM, V53, P942, DOI 10.1021/jm901472u
   Webb RL, 2010, J MED CHEM, V53, P7490, DOI 10.1021/jm901885s
   Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341
   Wolfe JP, 2000, J ORG CHEM, V65, P1144, DOI 10.1021/jo9916986                                                               
   Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107                                                                  
   Zhu ZN, 2010, J MED CHEM, V53, P951, DOI 10.1021/jm901408p
NR 72
TC 29
Z9 29
U1 2
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 8
PY 2012
VL 55
IS 21
BP 9331
EP 9345
DI 10.1021/jm301039c
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 033CE
UT WOS:000310769500026
PM 22989333
DA 2018-01-05
ER

PT J
AU Koenderman, AHL
   ter Hart, HGJ
   Prins-de Nijs, IMM
   Bloem, J
   Stoffers, S
   Kempers, A
   Derksen, GJ
   Al, B
   Dekker, L
   Over, J
AF Koenderman, A. H. L.
   ter Hart, H. G. J.
   Prins-de Nijs, I. M. M.
   Bloem, J.
   Stoffers, S.
   Kempers, A.
   Derksen, G. J.
   Al, B.
   Dekker, L.
   Over, J.
TI Virus safety of plasma products using 20 nm instead of 15 nm filtration
   as virus removing step
SO BIOLOGICALS
LA English
DT Article
DE Plasma derivatives; Virus removing filtration
ID IMMUNE GLOBULIN; RESIDUAL RISK; VIRAL SAFETY; HEPATITIS-B; FACTOR-IX;
   NANOFILTRATION; HIV; ELIMINATION; INFECTIONS; LIQUID
AB During the manufacture of human plasma derivatives, a series of complementary measures are undertaken to prevent transmission of blood-borne viruses. Virus filtration using 15 nm (Planova15N) filters has successfully been implemented in manufacturing processes for various plasma derivatives primarily because virus filtration is a technique, mild for proteins, that can effectively remove even small non-lipid-enveloped viruses, such as HAV and parvovirus B19. However, the use of 15 nm filters has limitations with regard to protein capacity of the filters and the process flow, resulting in an expensive manufacturing step. Therefore, studies were performed to test whether the use of 20 nm (Planova20N) filters, having different characteristics compared to 15 nm filters, can be an alternative for the use of 15 nm filters.
   It is shown that 20 nm filtration can be an alternative for 15 nm filtration. However, the virus removal capacity of the 20 nm filters depends on the plasma product that is filtered. Therefore, an optimisation study must be performed with regard to process parameters such as pressure, pH and protein concentration for each plasma product. In this study, using optimised conditions, the virus removal capacity of 20 nm filters appears to be comparable or even better when compared to that of 15 nm filters. (C) 2012 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
C1 [Koenderman, A. H. L.; ter Hart, H. G. J.; Prins-de Nijs, I. M. M.; Bloem, J.; Stoffers, S.; Kempers, A.; Derksen, G. J.; Over, J.] Sanquin Blood Supply, Div Plasma Prod, Prod Dev, NL-1006 AD Amsterdam, Netherlands.
   [Al, B.; Dekker, L.] Sanquin Blood Supply, Pharmaceut Serv, NL-1006 AD Amsterdam, Netherlands.
RP Koenderman, AHL (reprint author), Sanquin Blood Supply, Div Plasma Prod, Prod Dev, POB 9190, NL-1006 AD Amsterdam, Netherlands.
EM a.koenderman@sanquin.nl
CR Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129                                                          
   Burnouf T, 2007, TRANSFUS MED REV, V21, P101, DOI 10.1016/j.tmrv.2006.11.001
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   Caballero S, 2010, BIOLOGICALS, V38, P486, DOI 10.1016/j.biologicals.2010.02.008
   Chiavetta JA, 2003, CAN MED ASSOC J, V169, P767
   Dwyre DM, 2011, VOX SANG, V100, P92, DOI 10.1111/j.1423-0410.2010.01426.x
   [Anonymous], 2012, CPMPBWP2697062712010
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   Hongo-Hirasaki T, 2011, BIOTECHNOL PROGR, V27, P162, DOI 10.1002/btpr.533
   Mauser-Bunschoten EP, 2011, HAEMOPHILIA, V17, P439, DOI 10.1111/j.1365-2516.2010.02453.x
   Menconi MC, 2009, TRANSFUSION MED, V19, P213, DOI 10.1111/j.1365-3148.2009.00931.x
   Pillonel J, 2004, TRANSFUS CLIN BIOL, V11, P81, DOI 10.1016/j.tracli.2004.02.004
   Roberts PL, 2010, BIOLOGICALS, V38, P303, DOI 10.1016/j.biologicals.2009.12.006
   Soluk L, 2008, AM J THER, V15, P435, DOI 10.1097/MJT.0b013e318160c1b7
   Terpstra FG, 2007, BIOLOGICALS, V35, P173, DOI 10.1016/j.biologicals.2006.08.005
   Terpstra FG, 2006, VOX SANG, V90, P21, DOI 10.1111/j.1423-0410.2005.00710.x
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   von Bonsdorff L, 2001, BIOLOGICALS, V29, P27, DOI 10.1006/biol.2001.0273
   Yamaguchi K, 2007, J MEMBRANE SCI, V298, P99, DOI 10.1016/j.memsci.2007.04.009
   Yunoki M, 2008, VOX SANG, V95, P94, DOI 10.1111/j.1423-0410.2008.01078.x
   Yunoki M, 2008, BIOLOGICALS, V36, P27, DOI 10.1016/j.biologicals.2007.04.005
   Yunoki M, 2010, BIOLOGICALS, V38, P311, DOI 10.1016/j.biologicals.2009.10.018
   [Anonymous], 1996, CPMBBWP26895
NR 24
TC 4
Z9 5
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
J9 BIOLOGICALS
JI Biologicals
PD NOV
PY 2012
VL 40
IS 6
BP 473
EP 481
DI 10.1016/j.biologicals.2012.07.010
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA 044CJ
UT WOS:000311596700012
PM 22901944
DA 2018-01-05
ER

PT J
AU Liu, L
   Ye, Q
   Wu, YJ
   Hsieh, WY
   Chen, CL
   Shen, HH
   Wang, SJ
   Zhang, HS
   Hitchens, TK
   Ho, C
AF Liu, Li
   Ye, Qing
   Wu, Yijen
   Hsieh, Wen-Yuan
   Chen, Chih-Lung
   Shen, Hsin-Hsin
   Wang, Shian-Jy
   Zhang, Haosen
   Hitchens, T. Kevin
   Ho, Chien
TI Tracking T-cells in vivo with a new nano-sized MRI contrast agent
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Immune response; Cellular MRI; Nanoparticle; Regenerative medicine; Rat
   heart-lung transplant model
ID IRON-OXIDE PARTICLES; CARDIAC ALLOGRAFT-REJECTION; MAGNETIC-RESONANCE;
   PROTAMINE SULFATE; CELLULAR MRI; IMMUNE CELLS; ORGAN; NANOPARTICLES;
   MACROPHAGES; ASSAY
AB Non-invasive in vivo tracking of T-cells by magnetic resonance imaging (MRI) can lead to a better understanding of many pathophysiological situations, including AIDS, cancer, diabetes, graft rejection. However, an efficient MRI contrast agent and a reliable technique to track non-phagocytic T-cells are needed. We report a novel superparamagnetic nano-sized iron-oxide particle, IOPC-NH2 series particles, coated with polyethylene glycol (PEG), with high transverse relaxivity (250 s(-1) mM(-1)), thus useful for MRI studies. IOPC-NH2 particles are the first reported magnetic particles that can label rat and human T-cells with over 90% efficiency, without using transfection agents, HIV-1 transactivator peptide, or electroporation. IOPC-NH2 particles do not cause any measurable effects on T-cell properties. Infiltration of IOPC-NH2-labeled T-cells can be detected in a rat model of heart-lung transplantation by in vivo MRI. IOPC-NH2 is potentially valuable contrast agents for labeling a variety of cells for basic and clinical cellular MRI studies, e.g., cellular therapy.
C1 [Liu, Li; Ye, Qing; Wu, Yijen; Zhang, Haosen; Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA.
   [Hsieh, Wen-Yuan; Chen, Chih-Lung; Shen, Hsin-Hsin] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu, Taiwan.
   [Wang, Shian-Jy] Ind Technol Res Inst, Mat & Chem Res Labs, Hsinchu, Taiwan.
RP Ho, C (reprint author), Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA.
EM chienho@andrew.cmu.edu
RI Ho, Chien/O-6112-2016
OI Ho, Chien/0000-0002-4094-9232; Liu, Li/0000-0003-2493-3086
FU National Institutes of Health [R01HL-081349, P41EB-001977]; American
   Heart Association [10POST3010016]
FX This work is supported by research grants from the National Institutes
   of Health (R01HL-081349 and P41EB-001977 for C. H.) and a Postdoctoral
   Fellowship granted by the American Heart Association (10POST3010016 for
   L.L.).
CR Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655
   Bin Na H, 2007, CHEM COMMUN, P5167, DOI 10.1039/b712721a
   Bulte JWM, 2009, AM J ROENTGENOL, V193, P314, DOI 10.2214/AJR.09.3107
   Chang WH, 2008, Patent application, Patent No. [P54960092wo, 54960092]
   Chen CL, 2011, MOL IMAGING BIOL, V13, P825, DOI 10.1007/s11307-010-0430-x
   Chen CL, 2003, J IMMUNOL, V170, P528, DOI 10.4049/jimmunol.170.1.528                                                      
   Chung SK, 2008, INT J PHARM, V354, P16, DOI 10.1016/j.ijpharm.2007.08.016
   De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701                                                                   
   Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1                                                   
   Ho C, 2004, CURR PHARM BIOTECHNO, V5, P551, DOI 10.2174/1389201043376535
   Hu FQ, 2010, CHEM COMMUN, V46, P73, DOI 10.1039/b916562b
   Hu FQ, 2009, J PHYS CHEM C, V113, P20855, DOI 10.1021/jp907216g
   Janjic JM, 2008, J AM CHEM SOC, V130, P2832, DOI 10.1021/ja077388j
   Jun YW, 2008, ANGEW CHEM INT EDIT, V47, P5122, DOI 10.1002/anie.200701674
   Kircher MF, 2003, CANCER RES, V63, P6838
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Mahmoudi M, 2011, CHEM REV, V111, P253, DOI 10.1021/cr1001832
   Minchin RF, 2010, ENDOCRINOLOGY, V151, P474, DOI 10.1210/en.2009-1012
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Qiao J, 2011, PLOS ONE, P6
   Riemer J, 2004, ANAL BIOCHEM, V331, P370, DOI 10.1016/j.ab.2004.03.049
   SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151
   Schlesinger N, 2011, NAT REV DRUG DISCOV, V10, P17, DOI 10.1038/nrd3349
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2
   Shapiro EM, 2007, CONTRAST MEDIA MOL I, V2, P147, DOI 10.1002/cmmi.134
   Tang KS, 2011, MAGN RESON MED, V65, P1564, DOI 10.1002/mrm.22843
   Thorek DLJ, 2008, BIOMATERIALS, V29, P3583, DOI 10.1016/j.biomaterials.2008.05.015
   Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519                                                    
   Wang LJ, 2009, NANOMEDICINE-UK, V4, P305, DOI [10.2217/nnm.09.6, 10.2217/NNM.09.6]
   Wu H, 2008, ANGEW CHEM INT EDIT, V47, P3730, DOI 10.1002/anie.200800434
   Wu YL, 2011, CURR CARDIOVASC IMAG, V4, DOI 10.1007/s12410-010-9055-3
   Wu YL, 2009, JACC-CARDIOVASC IMAG, V2, P731, DOI 10.1016/j.jcmg.2009.01.013
   Wu YJL, 2004, METHOD ENZYMOL, V386, P73
   Wu YL, 2006, P NATL ACAD SCI USA, V103, P1852, DOI 10.1073/pnas.0507198103
   Ye Q, 2008, CIRCULATION, V118, P149, DOI 10.1161/CIRCULATIONAHA.107.746354
   YEH TC, 1993, MAGNET RESON MED, V30, P617, DOI 10.1002/mrm.1910300513
   YEH TC, 1995, MAGNET RESON MED, V33, P200, DOI 10.1002/mrm.1910330209
NR 37
TC 14
Z9 15
U1 0
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
EI 1549-9642
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD NOV
PY 2012
VL 8
IS 8
BP 1345
EP 1354
DI 10.1016/j.nano.2012.02.017
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 028NH
UT WOS:000310428600013
PM 22406186
OA green_accepted
DA 2018-01-05
ER

PT J
AU Yu, S
   Zhao, G
AF Yu, S.
   Zhao, G.
TI Development of Polyphenols as HIV-1 Integrase Inhibitors: a Summary and
   Perspective
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE AIDS; HIV-1; integrase; inhibitors; mechanism; drug resistance;
   polyphenols; 1,5-DCQA; SAR; computer-aided drug design; evolution;
   perspective
ID HUMAN-IMMUNODEFICIENCY-VIRUS; L-CHICORIC ACID; SITE BINDING MODES;
   TYPE-1 INTEGRASE; IN-VITRO; 1,5-DICAFFEOYLQUINIC ACID; BIOLOGICAL
   EVALUATION; POTENT INHIBITORS; ACTIVE-SITE; STYRYLQUINOLINE DERIVATIVES
AB Raltegravir, the only drug targeting the integration step in HIV-1 life cycle, makes beta-ketoenol integrase (IN) strand transfer inhibitor (STI) gain a definitive place in the treatment of HIV-1 infection. However, the emergence of viral strains resistant to beta-ketoenol STI demands a continued effort toward the discovery of novel IN inhibitors interfering with HIV-1 IN in a mechanistically different manner. Polyphenols, among the most developed IN inhibitors, exhibit a different mechanism of action compared with beta-ketoenol STI. Some of them exhibit strong IN inhibitory activity and anti-viral activity at nanomolar level and 1,5-DCQA has been in phase II clinical trial in China. It is undoubted that this kind of compounds are attractive candidates for future inhibitor design, as they should be effective against STI resistant viral strains and display synergistic effect when combined with the current existing STI. However, almost all reviews about IN inhibitors have been focused on beta-ketoenol STI, while the thorough evolution and general structure-activity relationship (SAR) summaries of polyphenols as IN inhibitors had never been specially discussed. In this review, we provide a comprehensive report of the nearly twenty years development of polyphenols as IN inhibitors: summarizing general SAR and suggesting the orientation for further research. Compilation of such data will prove beneficial in developing a novel generation of IN inhibitors.
C1 [Yu, S.; Zhao, G.] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R China.
RP Zhao, G (reprint author), Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R China.
EM guisenzhao@sdu.edu.cn
FU National Natural Science Foundation of China [20872082, 21072115]
FX This work was supported by the National Natural Science Foundation of
   China (No20872082 and No21072115).
CR Agapkina J, 2004, EUR J BIOCHEM, V271, P205, DOI 10.1046/j.1432-1033.2003.03921.x
   Al-Mawsawi LQ, 2007, FEBS LETT, V581, P1151, DOI 10.1016/j.febslet.2007.02.023
   Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1
   Bailly F, 2005, BIOORG MED CHEM LETT, V15, P5053, DOI 10.1016/j.bmcl.2005.07.091
   Bailly F, 2005, CURR MED CHEM, V12, P1811, DOI 10.2174/0929867054367239
   Bailly F, 2004, BIOORGAN MED CHEM, V12, P5611, DOI 10.1016/j.bmc.2004.07.066
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Beare KD, 2012, CURR MED CHEM, V19, P1177
   Bernard C, 2004, BIOORG MED CHEM LETT, V14, P2473, DOI 10.1016/j.bmcl.2004.03.005
   Blanco JL, 2011, J INFECT DIS, V203, P1204, DOI 10.1093/infdis/jir025
   Bodiwala HS, 2011, BIOORGAN MED CHEM, V19, P1256, DOI 10.1016/j.bmc.2010.12.031
   Bonnenfant S, 2004, J VIROL, V78, P5728, DOI 10.1128/JVI.78.11.5728-5736.2004
   Buolamwini JK, 2002, J MED CHEM, V45, P841, DOI 10.1021/jm010399h
   Burger DM, 2010, EXPERT OPIN DRUG MET, V6, P1151, DOI 10.1517/17425255.2010.513383
   BURKE TR, 1995, J MED CHEM, V38, P4171, DOI 10.1021/jm00021a006
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   Charvat TT, 2006, BIOORGAN MED CHEM, V14, P4552, DOI 10.1016/j.bmc.2006.02.030
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   Cotelle P, 2011, EXPERT OPIN THER PAT, V21, P1799, DOI 10.1517/13543776.2011.624272
   Crosby DC, 2010, J MED CHEM, V53, P8161, DOI 10.1021/jm1010594
   Dayam R, 2008, MED RES REV, V28, P118, DOI 10.1002/med.20116
   De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A                          
   De Luca L, 2011, MINI-REV MED CHEM, V11, P714, DOI 10.2174/138955711796268787                                                      
   Deng JX, 2007, CURR PHARM DESIGN, V13, P129, DOI 10.2174/138161207779313687                                                      
   Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85                                                             
   Di Francesco ME, 2008, BIOORG MED CHEM LETT, V18, P2709, DOI 10.1016/j.bmcl.2008.03.017
   Didierjean J, 2005, ANTIMICROB AGENTS CH, V49, P4884, DOI 10.1128/AAC.49.12.4884-4894.2005
   Dubois M, 2008, J MED CHEM, V51, P2575, DOI 10.1021/jm7011134
   Dupont R, 2001, BIOORG MED CHEM LETT, V11, P3175, DOI 10.1016/S0960-894X(01)00658-8                                                   
   Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8
   Fan X, 2011, BIOORGAN MED CHEM, V19, P4935, DOI 10.1016/j.bmc.2011.06.058
   Farnet CM, 1998, ANTIMICROB AGENTS CH, V42, P2245
   FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399                                                          
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   Fisher TE, 2007, BIOORG MED CHEM LETT, V17, P6511, DOI 10.1016/j.bmcl.2007.09.086
   Garvey EP, 2008, ANTIMICROB AGENTS CH, V52, P901, DOI 10.1128/AAC.01218-07
   Goethals O, 2008, J VIROL, V82, P10366, DOI 10.1128/JVI.00470-08
   Gupta P, 2011, MOL DIVERS, V15, P733, DOI 10.1007/s11030-011-9304-7
   Hare S, 2010, P NATL ACAD SCI USA, V107, P20057, DOI 10.1073/pnas.1010246107
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 1997, J VIROL, V71, P7005
   Healy EF, 2009, J MOL GRAPH MODEL, V27, P584, DOI 10.1016/j.jmgm.2008.09.011
   Ho CC, 2005, J ANTIMICROB CHEMOTH, V56, P372, DOI 10.1093/jac/dki244
   Hombrouck A, 2008, ANTIMICROB AGENTS CH, V52, P2069, DOI 10.1128/AAC.00911-07
   Hwang DJ, 2001, BIOORGAN MED CHEM, V9, P1429, DOI 10.1016/S0968-0896(01)00013-X                                                   
   Jiang F, 2010, CLIN IMMUNOL, V137, P347, DOI 10.1016/j.clim.2010.08.007
   Jin HL, 2006, BIOORG MED CHEM LETT, V16, P3989, DOI 10.1016/j.bcml.2006.05.016
   Kim SN, 2000, BIOORG MED CHEM LETT, V10, P1879, DOI 10.1016/S0960-894X(00)00355-3                                                   
   King PJ, 2003, VIROLOGY, V306, P147, DOI 10.1016/S0042-6822(02)00042-9                                                   
   Kobayashi M, 2008, ANTIVIR RES, V80, P213, DOI 10.1016/j.antiviral.2008.06.012
   Lee JY, 2003, BIOORG MED CHEM LETT, V13, P4331, DOI 10.1016/j.bmcl.2003.09.046
   Lee SU, 2007, EUR J MED CHEM, V42, P1309, DOI 10.1016/j.ejmech.2007.02.016
   Lee-Huang S, 2007, BIOCHEM BIOPH RES CO, V354, P872, DOI 10.1016/j.bbrc.2007.01.071
   Lee-Huang S, 2007, BIOCHEM BIOPH RES CO, V354, P879, DOI 10.1016/j.bbrc.2007.01.058
   Lenz JCC, 2011, EXPERT OPIN INV DRUG, V20, P537, DOI 10.1517/13543784.2011.562189
   LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839
   Li XA, 2011, VIROLOGY, V411, P194, DOI 10.1016/j.virol.2010.12.008
   Lin ZW, 1999, J MED CHEM, V42, P1401, DOI 10.1021/jm980531m
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu JL, 2010, BIOMED CHROMATOGR, V24, P935, DOI 10.1002/bmc.1388
   Luo ZG, 2010, MINI-REV MED CHEM, V10, P1046
   Maertens GN, 2010, NATURE, V468, P326, DOI 10.1038/nature09517
   Marchand C, 2009, CURR TOP MED CHEM, V9, P1016, DOI 10.2174/156802609789630910                                                      
   Maurin C, 2006, BIOORGAN MED CHEM, V14, P2978, DOI 10.1016/j.bmc.2005.12.039
   Maurin C, 2010, BIOORGAN MED CHEM, V18, P5194, DOI 10.1016/j.bmc.2010.05.059
   MAZUMDER A, 1995, BIOCHEM PHARMACOL, V49, P1165, DOI 10.1016/0006-2952(95)98514-A
   Mazumder A, 1997, J MED CHEM, V40, P3057, DOI 10.1021/jm970190x
   McDougall B, 1998, ANTIMICROB AGENTS CH, V42, P140
   Meadows DC, 2007, BIOORGAN MED CHEM, V15, P1127, DOI 10.1016/j.bmc.2006.10.017
   Meadows DC, 2006, CHEMMEDCHEM, V1, P959, DOI 10.1002/cmdc.200600040
   Meadows DC, 2005, J MED CHEM, V48, P4526, DOI 10.1021/jm049171v
   Mekouar K, 1998, J MED CHEM, V41, P2846, DOI 10.1021/jm980043e
   Moreira RFA, 2001, ARCH LATINOAM NUTR, V51, P95
   Mouscadet JF, 2010, DRUG RESIST UPDATE, V13, P139, DOI 10.1016/j.drup.2010.05.001
   Nair V, 2007, REV MED VIROL, V17, P277, DOI 10.1002/rmv.539
   Neamati N, 1997, MOL PHARMACOL, V52, P1041
   Nicklaus MC, 1997, J MED CHEM, V40, P920, DOI 10.1021/jm960596u
   Pace P, 2007, J MED CHEM, V50, P2225, DOI 10.1021/jm070027u
   Parejo I, 2004, ANAL CHIM ACTA, V512, P271, DOI 10.1016/j.aca.2004.02.053
   Petersen M, 2003, PHYTOCHEMISTRY, V62, P121, DOI 10.1016/S0031-9422(02)00513-7
   Petrocchi A, 2007, BIOORG MED CHEM LETT, V17, P350, DOI 10.1016/j.bmcl.2006.10.054
   Pluymers W, 2000, MOL PHARMACOL, V58, P641
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Powderly WG, 2010, J ANTIMICROB CHEMOTH, V65, P2485, DOI 10.1093/jac/dkq350
   Prada N, 2010, EXPERT OPIN INV DRUG, V19, P1087, DOI 10.1517/13543784.2010.501078
   Queffelec C, 2008, BIOORG MED CHEM LETT, V18, P4736, DOI 10.1016/j.bmcl.2008.06.063
   Queffelec C, 2008, EUR J MED CHEM, V43, P2268, DOI 10.1016/j.ejmech.2007.12.013
   Ramkumar K, 2010, MED RES REV, V30, P890, DOI 10.1002/med.20194
   REDDY ACP, 1994, FOOD CHEM TOXICOL, V32, P279
   Reinke RA, 2004, VIROLOGY, V326, P203, DOI 10.1016/J.VIROL.2004.06.005
   Reinke RA, 2002, J MED CHEM, V45, P3669, DOI 10.1021/jm010359d
   Ribeiro AJM, 2012, J AM CHEM SOC, V134, P13436, DOI 10.1021/ja304601k
   Robinson WE, 1998, ANTIVIR RES, V39, P101
   Robinson WE, 1996, P NATL ACAD SCI USA, V93, P6326, DOI 10.1073/pnas.93.13.6326
   Robinson WE, 1996, MOL PHARMACOL, V50, P846
   Sahu KK, 2008, ACTA CHIM SLOV, V55, P138
   Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4
   Sechi Mario, 2004, Antiviral Chemistry & Chemotherapy, V15, P67
   Semenova EA, 2006, MOL PHARMACOL, V69, P1454, DOI 10.1124/mol.105.020321
   Serrao E, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-25
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Singh SB, 2003, J IND MICROBIOL BIOT, V30, P721, DOI 10.1007/s10295-003-0101-x
   SOICKE H, 1988, PLANTA MED, P175
   Supuran CT, 2004, MINI-REV MED CHEM, V4, P189, DOI 10.2174/1389557043487402                                                        
   Tchertanov L, 2007, J MED CHEM, V50, P1133, DOI 10.1021/jm061375j
   Tewtrakul S, 2007, PHYTOTHER RES, V21, P1092, DOI 10.1002/ptr.2252
   Tintori C, 2007, J CHEM INF MODEL, V47, P1536, DOI 10.1021/ci700078n
   Vajragupta O, 2005, BIOORG MED CHEM LETT, V15, P3364, DOI 10.1016/j.bmcl.2005.05.032
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180
   Wang P, 2009, BIOORG MED CHEM LETT, V19, P4574, DOI 10.1016/j.bmcl.2009.06.100
   [魏振满 WEI Zhen-man], 2010, [中国新药杂志, Chinese Journal New Drugs], V19, P106
   Wills T, 2012, EXPERT OPIN INV DRUG, V21, P395, DOI 10.1517/13543784.2012.658914
   Xia CN, 2008, BIOORG MED CHEM LETT, V18, P6553, DOI 10.1016/j.bmcl.2008.10.046
   Xu YW, 2003, BIOORGAN MED CHEM, V11, P3589, DOI 10.1016/S0968-0896(03)00372-9
   Yang B, 2006, J PHARMACEUT BIOMED, V40, P417, DOI 10.1016/j.jpba.2005.06.037
   Yang B, 2005, DRUG METAB DISPOS, V33, P930, DOI 10.1124/dmd.104.002154
   Yoshimoto M, 2002, BIOSCI BIOTECH BIOCH, V66, P2336, DOI 10.1271/bbb.66.2336
   Neamati N., 2012, J ENZYME IN IN PRESS
   Yuan HB, 2002, BIOORGAN MED CHEM, V10, P4169, DOI 10.1016/S0968-0896(02)00332-2                                                   
   Zhao GS, 2007, MINI-REV MED CHEM, V7, P707
   Zhao H, 1997, J MED CHEM, V40, P1186, DOI 10.1021/jm960449w
   Zhao XZ, 2008, J MED CHEM, V51, P251, DOI 10.1021/jm070715d
   Zhao XZ, 2009, BIOORGAN MED CHEM, V17, P5318, DOI 10.1016/j.bmc.2009.05.008
   Zhao XZ, 2009, BIOORG MED CHEM LETT, V19, P2714, DOI 10.1016/j.bmcl.2009.03.122
   Zhu K, 1999, J VIROL, V73, P3309
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o                                                               
NR 127
TC 7
Z9 7
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD NOV
PY 2012
VL 19
IS 32
BP 5536
EP 5561
DI 10.2174/092986712803833236                                              
          
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 030VS
UT WOS:000310598800013
PM 22934810
DA 2018-01-05
ER

PT J
AU Ashkenazi, A
   Viard, M
   Unger, L
   Blumenthal, R
   Shai, Y
AF Ashkenazi, Avraham
   Viard, Mathias
   Unger, Linor
   Blumenthal, Robert
   Shai, Yechiel
TI Sphingopeptides: dihydrosphingosine-based fusion inhibitors against
   wild-type and enfuvirtide-resistant HIV-1
SO FASEB JOURNAL
LA English
DT Article
DE viral envelope protein; sphingolipids
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MEMBRANE-FUSION; CELL-CELL FUSION;
   ENVELOPE GLYCOPROTEIN; MEDIATED FUSION; LIPID RAFTS; COILED-COIL; GP41;
   PEPTIDE; CHOLESTEROL
AB Understanding the structural organization of lipids in the cell and viral membranes is essential for elucidating mechanisms of viral fusion that lead to entry of enveloped viruses into their host cells. The HIV lipidome shows a remarkable enrichment in dihydrosphingomyelin, an unusual sphingolipid formed by a dihydrosphingosine backbone. Here we investigated the ability of dihydrosphingosine to incorporate into the site of membrane fusion mediated by the HIV envelope (Env) protein. Dihydrosphingosine as well as cholesterol, fatty acid, and tocopherol was conjugated to highly conserved, short HIV-1 Env-derived peptides with no antiviral activity otherwise. We showed that dihydrosphingosine exclusively endowed nanomolar antiviral activity to the peptides (IC50 as low as 120 nM) in HIV-1 infection on TZM-bl cells and on Jurkat T cells, as well as in the cell-cell fusion assay. These sphingopeptides were active against enfuvirtide-resistant and wild-type CXCR4 and CCR5 tropic HIV strains. The anti-HIV activity was determined by both the peptides and their dihydrosphingosine conjugate. Moreover, their mode of action involved accumulation in the cells and viruses and binding to membranes enriched in sphingomyelin and cholesterol. The data suggest that sphingopeptides are recruited to the HIV membrane fusion site and provide a general concept in developing inhibitors of sphingolipid-mediated biological systems.-Ashkenazi, A., Viard, M., Unger, L., Blumenthal, R., Shai, Y. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 26, 4628-4636 (2012). www.fasebj.org
C1 [Ashkenazi, Avraham; Unger, Linor; Shai, Yechiel] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
   [Viard, Mathias; Blumenthal, Robert] NCI, Nanobiol Program, Ctr Canc Res, Frederick Natl Lab, Frederick, MD 21701 USA.
   [Viard, Mathias] SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res Nanobiol Program, Frederick Natl Lab, Frederick, MD USA.
RP Shai, Y (reprint author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
EM yechiel.shai@weizmann.ac.il
FU Israel Science Foundation; Frederick National Laboratory; National
   Cancer Institute; U.S. National Institutes of Health [HHSN26120080001E]
FX The authors thank Batya Zarmi for her valuable help with peptide
   purification and Winfried Weissenhorn for providing the recent
   3-dimensional structure of gp41. This study was supported by the Israel
   Science Foundation (to Y. S.) and in part by federal funds (to R. B.)
   from the Frederick National Laboratory, National Cancer Institute, U.S.
   National Institutes of Health (contract HHSN26120080001E). The content
   of this publication does not necessarily reflect the views or policies
   of the U. S. Department of Health and Human Services, nor does mention
   of trade names, commercial products, or organizations imply endorsement
   by the U. S. government. Y. S. is the incumbent of the Harold S. and
   Harriet B. Brady Professorial Chair in Cancer Research.
CR Ablan S, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-104
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428.12437.2004
   BENEFRAIM I, 1993, BIOCHEMISTRY-US, V32, P2371, DOI 10.1021/bi00060a031
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Buzon V, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000880
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Chien MP, 2008, FASEB J, V22, P1179, DOI 10.1096/fj.07-9576com
   Choi KS, 2005, J VIROL, V79, P9862, DOI 10.1128/JVI.79.15.9862-9871.2005
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Epand RM, 2003, BIOPHYS J, V84, P3102, DOI 10.1016/S0006-3495(03)70035-6                                                   
   Finnegan CM, 2007, J VIROL, V81, P5294, DOI 10.1128/JVI.02553-06
   Finnegan CM, 2004, P NATL ACAD SCI USA, V101, P15452, DOI 10.1079/pnas.0402874101
   Finzi A, 2010, MOL CELL, V37, P656, DOI 10.1016/j.molcel.2010.02.012
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006
   Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5
   Garg H, 2007, J BIOL CHEM, V282, P16899, DOI 10.1074/jbc.M701701200
   Goni FM, 2006, BBA-BIOMEMBRANES, V1758, P1902, DOI 10.1016/j.bbamem.2006.09.011
   Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967
   Hetru C, 2000, BIOCHEM J, V345, P653, DOI 10.1042/0264-6021:3450653
   Holguin A, 2007, AIDS RES HUM RETROV, V23, P1067, DOI 10.1089/aid.2006.0256
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Kuikka M, 2001, BIOPHYS J, V80, P2327, DOI 10.1016/S0006-3495(01)76203-0                                                   
   Lev N, 2007, J MOL BIOL, V374, P220, DOI 10.1016/j.jmb.2007.09.008
   Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200
   Medigeshi GR, 2008, J VIROL, V82, P5212, DOI 10.1128/JVI.00008-08
   Melikyan GB, 2006, J VIROL, V80, P3249, DOI 10.1128/JV.80.7.3249-3258.2006
   MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Rawat SS, 2006, GLYCOCONJUGATE J, V23, P189, DOI 10.1007/s10719-006-7924-4
   Rawat SS, 2005, BIOSCIENCE REP, V25, P329, DOI 10.1007/s10540-005-2894-5
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977
   Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015
   Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.22356210100
   Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002
   Viard Mathias, 2004, Glycoconj J, V20, P213
   Vieira CR, 2010, CHEM BIOL, V17, P766, DOI 10.1016/j.chembiol.2010.05.023
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Wexler-Cohen Y, 2007, FASEB J, V21, P3677, DOI 10.1096/fj.07-8582com
   Wexler-Cohen Y, 2010, FASEB J, V24, P4196, DOI 10.1096/fj.09-151704
   Wexler-Cohen Y, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000509
   WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331                                             
NR 56
TC 19
Z9 19
U1 1
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD NOV
PY 2012
VL 26
IS 11
BP 4628
EP 4636
DI 10.1096/fj.12-215111
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 030MG
UT WOS:000310574200024
PM 22872679
OA green_published
DA 2018-01-05
ER

PT J
AU Katata, L
   Tshweu, L
   Naidoo, S
   Kalombo, L
   Swai, H
AF Katata, Lebogang
   Tshweu, Lesego
   Naidoo, Saloshnee
   Kalombo, Lonji
   Swai, Hulda
TI Design and formulation of nano-sized spray dried efavirenz-part I:
   influence of formulation parameters
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Spray dried; Polycaprolactone; Efavirenz; Nanoparticles; Taguchi method
ID NANOPARTICLES; TAGUCHI; RELEASE; OPTIMIZATION; THERAPY; VIVO
AB Efavirenz (EFV) is one of the first-line antiretroviral drugs recommended by the World Health Organisation for treating HIV. It is a hydrophobic drug that suffers from low aqueous solubility (4 mu g/mL), which leads to a limited oral absorption and low bioavailability. In order to improve its oral bioavailability, nano-sized polymeric delivery systems are suggested. Spray dried polycaprolactone-efavirenz (PCL-EFV) nanoparticles were prepared by the double emulsion method. The Taguchi method, a statistical design with an L-8 orthogonal array, was implemented to optimise the formulation parameters of PCL-EFV nanoparticles. The types of sugar (lactose or trehalose), surfactant concentration and solvent (dichloromethane and ethyl acetate) were chosen as significant parameters affecting the particle size and polydispersity index (PDI). Small nanoparticles with an average particle size of less than 254 +/- 0.95 nm in the case of ethyl acetate as organic solvent were obtained as compared to more than 360 +/- 19.96 nm for dichloromethane. In this study, the type of solvent and sugar were the most influencing parameters of the particle size and PDI. Taguchi method proved to be a quick, valuable tool in optimising the particle size and PDI of PCL-EFV nanoparticles. The optimised experimental values for the nanoparticle size and PDI were 217 +/- 2.48 nm and 0.093 +/- 0.02.
C1 [Katata, Lebogang; Tshweu, Lesego; Naidoo, Saloshnee; Kalombo, Lonji; Swai, Hulda] CSIR, Ctr Polymers & Composites, ZA-0001 Brummeria Pretoria, South Africa.
   [Tshweu, Lesego] Univ Johannesburg, Fac Sci, Dept Appl Chem, ZA-2006 Auckland Pk, South Africa.
RP Katata, L (reprint author), CSIR, Ctr Polymers & Composites, POB 395,Meiring Naude Rd, ZA-0001 Brummeria Pretoria, South Africa.
EM lebzakate@yahoo.com
FU CSIR Young Researcher's Fund; South African Department of Science and
   Technology
FX The authors would like to thank CSIR Young Researcher's Fund and South
   African Department of Science and Technology for providing financial
   support for the work presented in this paper. Dr James Wesley-Smith is
   acknowledged for the TEM analysis of the nanoparticles.
CR Bendell A., 1989, TAGUCHI METHODS APPL
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Heng K, 2009, J NANOPART RES, V12, P1743
   Ilium L., 1982, INT J PHARMACEUT, V12, P135
   Jahanshahi M, 2008, J APPL STAT, V35, P1345, DOI 10.1080/02664760802382426
   Kateb B, 2011, NEUROIMAGE, V54, pS106, DOI 10.1016/j.neuroimage.2010.01.105
   Kho K, 2010, POWDER TECHNOL, V203, P432, DOI 10.1016/j.powtec.2010.06.003
   Kim KD, 2007, COLLOID SURFACE A, V311, P170, DOI 10.1016/j.colsurfa.2007.06.017
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   Lee SH, 2011, INT J PHARMACEUT, V403, P192, DOI 10.1016/j.ijpharm.2010.10.012
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011                                                
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Palmieri GF, 1997, DRUG DEV IND PHARM, V23, P1069, DOI 10.3109/03639049709150495                                                       
   Pan American Health Organization, 2011, PED GUID, P1
   Giddam AK, 2010, INT J PHARM PHARM SC, V2, P35
   Santos-Magalhaes NS, 2010, ADV DRUG DELIVER REV, V62, P560, DOI 10.1016/j.addr.2009.11.024
   Schubert MA, 2005, EUR J PHARM BIOPHARM, V61, P77, DOI 10.1016/j.ejpb.2005.03.006
   Semete B, 2010, SMART BIOMO IN PRESS
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Shah LK, 2006, PHARM RES, V23, P11
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Varshosaz J, 2009, AAPS PHARMSCITECH, V10, P158, DOI 10.1208/s12249-009-9191-8
   WORLD HEALTH ORGANIZATION (WHO), 2010, ANT THER HIV INF AD
NR 29
TC 7
Z9 7
U1 1
U2 24
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD NOV
PY 2012
VL 14
IS 11
AR 1247
DI 10.1007/s11051-012-1247-0
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 030ZG
UT WOS:000310608100014
DA 2018-01-05
ER

PT J
AU Musumeci, D
   Montesarchio, D
AF Musumeci, Domenica
   Montesarchio, Daniela
TI Polyvalent nucleic acid aptamers and modulation of their activity: a
   focus on the thrombin binding aptamer
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE Aptamers; Thrombin; Polyvalent interactions; Nanoparticles; Drug-active
   reversal agents
ID QUADRUPLEX-FORMING OLIGONUCLEOTIDES; FUNCTIONALIZED GOLD NANOPARTICLES;
   ENDOTHELIAL GROWTH-FACTOR; IRON-OXIDE NANOPARTICLES; STRANDED-DNA
   MOLECULES; IN-VITRO SELECTION; ANTI-HIV ACTIVITY; BIVALENT APTAMER;
   HIGH-AFFINITY; CANCER-THERAPY
AB Nucleic acid-based aptamers can be selected from combinatorial libraries of synthetic oligonucleotides to bind, with affinity and specificity similar to antibodies, a wide range of biomedically relevant targets. Compared to protein therapeutics, aptamers exhibit significant advantages in terms of size, non-immunogenicity and wide synthetic accessibility. Various chemical modifications have been introduced in the natural oligonucleotide backbone of aptamers in order to increase their half-life, as well as their pharmacological properties. Very effective alternative approaches, devised in order to improve both the aptamer activity and stability, were based on the design of polyvalent aptamers, able to establish multivalent interactions with the target: thus, multiple copies of an aptamer can be assembled on the same molecular- or nanomaterial-based scaffold. In the present review, the thrombin binding aptamers (TBAs) are analyzed as a model system to study multiple-aptamer constructs aimed at improving their anticoagulation activity in terms of binding to the target and stability to enzymatic degradation. Indeed - even if the large number of chemically modified TBAs investigated in the last 20 years has led to encouraging results - a significant progress has been obtained only recently with bivalent or engineered dendritic TBA aptamers, or assemblies of TBAs on nanoparticles and DNA nanostructures. Furthermore, the modulation of the aptamers activity by means of tailored drug-active reversal agents, especially in the field of anticoagulant aptamers, as well as the reversibility of the TBA activity through the use of antidotes, such as porphyrins, complementary oligonucleotides or of external stimuli, are discussed. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Musumeci, Domenica; Montesarchio, Daniela] Univ Naples Federico II, Dipartimento Sci Chim, I-80126 Naples, Italy.
RP Musumeci, D (reprint author), Univ Naples Federico II, Dipartimento Sci Chim, Via Cintia 21,Complesso Univ Monte St Angelo, I-80126 Naples, Italy.
EM domymusu@alice.it
FU AIRC, Italian Association for Cancer Research [11947]; MIUR [prot.
   2009J54YAP_002]
FX AIRC, Italian Association for Cancer Research (grant no. 11947) and MIUR
   (PRIN prot. 2009J54YAP_002) are gratefully acknowledged for financial
   support.
CR Agarwal T, 2011, BIOCHIMIE, V93, P1694, DOI 10.1016/j.biochi.2011.05.036
   Arosio D, 2011, BIOCONJUGATE CHEM, V22, P664, DOI 10.1021/bc100448r
   Avino A, 2012, CURR PHARM DESIGN, V18, P2036, DOI 10.2174/138161212799958387                                                      
   Baldrich E, 2005, ANAL BIOCHEM, V341, P194, DOI 10.1016/j.ab.2005.02.031
   Bamrungsap S, 2012, ACS NANO, V6, P3974, DOI 10.1021/nn3002328
   Basnar B, 2006, ANAL CHEM, V78, P3638, DOI 10.1021/ac052289e
   Becker RC, 2010, THROMB HAEMOSTASIS, V103, P586, DOI 10.1160/TH09-10-0716
   Becker RC, 2009, CURR OPIN MOL THER, V11, P707
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Bompiani KM, 2012, J THROMB HAEMOST, V10, P870, DOI 10.1111/j.1538-7836.2012.04679.x
   Bonifacio L, 2008, INT J MOL SCI, V9, P422, DOI 10.3390/ijms9030422                                                             
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Bromberg L, 2012, LANGMUIR, V28, P4548, DOI 10.1021/la205127x
   Bucci EM, 2007, NUCLEOS NUCLEOT NUCL, V26, P1047, DOI 10.1080/15257770701509602
   Buff MCR, 2010, NUCLEIC ACIDS RES, V38, P2111, DOI 10.1093/nar/gkp1148
   Chen T, 2011, NANOSCALE, V3, P546, DOI 10.1039/c0nr00646g
   Cho EJ, 2009, ANNU REV ANAL CHEM, V2, P241, DOI 10.1146/annurev.anchem.1.031207.112851
   Chow LMC, 2009, CURR PHARM DESIGN, V15, P659, DOI 10.2174/138161209787315576                                                      
   Cohen MG, 2010, CIRCULATION, V122, P614, DOI 10.1161/CIRCULATIONAHA.109.927756
   Coppola T, 2008, BIOORGAN MED CHEM, V16, P8244, DOI 10.1016/j.bmc.2008.07.040
   Cui Y, 2004, J MEMBRANE BIOL, V202, P137, DOI 10.1007/s00232-004-0725-4
   D'Onofrio J, 2008, BIOCONJUGATE CHEM, V19, P607, DOI 10.1021/bc7003395
   D'Onofrio J, 2007, BIOCONJUGATE CHEM, V18, P1194, DOI 10.1021/bc070062f
   de la Osa JP, 2006, CHEMBIOCHEM, V7, P46, DOI 10.1002/cbic.200500281
   Di Cera E, 2007, J THROMB HAEMOST, V5, P196
   Di Cera E, 2008, MOL ASPECTS MED, V29, P203, DOI 10.1016/j.mam.2008.01.001
   Di Fabio G, 2011, CHEM COMMUN, V47, P2363, DOI 10.1039/c0cc04751a
   Di Giusto DA, 2004, J BIOL CHEM, V279, P46483, DOI 10.1074/jbc.M408037200
   Dollins CM, 2008, CHEM BIOL, V15, P675, DOI 10.1016/j.chembiol.2008.05.016
   Donalisio M, 2010, ANTIMICROB AGENTS CH, V54, P4290, DOI 10.1128/AAC.00471-10
   Dua P, 2011, METHODS, V54, P215, DOI 10.1016/j.ymeth.2011.02.002
   Dyke CK, 2006, CIRCULATION, V114, P2490, DOI 10.1161/CIRUCLATIONAHA.106.668434
   Eaton BE, 1997, BIOORGAN MED CHEM, V5, P1087, DOI 10.1016/S0968-0896(97)00044-8                                                   
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0                                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Endsley AN, 2012, AAPS J, V14, P225, DOI 10.1208/s12248-012-9329-6
   Esposito V, 2007, NUCLEOS NUCLEOT NUCL, V26, P1145, DOI 10.1080/15257770701526978
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Farokhzad OC, 2006, EXPERT OPIN DRUG DEL, V3, P311, DOI 10.1517/17425247.3.3.311
   Ge L, 2012, LANGMUIR, V28, P707, DOI 10.1021/la203954x
   Gestwicki JE, 2000, CHEM BIOL, V7, P583, DOI 10.1016/S1074-5521(00)00002-8                                                   
   Gestwicki JE, 2002, J AM CHEM SOC, V124, P14922, DOI 10.1021/ja027184x
   Gindy ME, 2009, EXPERT OPIN DRUG DEL, V6, P865, DOI 10.1517/17425240902932908
   Goji S, 2011, J NUCLEIC ACIDS, DOI 10.4061/2011/316079
   Gold L, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a003582
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2                                                    
   GRIFFIN LC, 1993, BLOOD, V81, P3271
   Gupta N, 2011, BIOCONJUGATE CHEM, V22, P1473, DOI 10.1021/bc200091c
   He GX, 1998, J MED CHEM, V41, P2234, DOI 10.1021/jm970434d                                                               
   He GX, 1998, J MED CHEM, V41, P4224, DOI 10.1021/jm970766i
   Healy JM, 2004, PHARM RES, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Heckel A, 2005, J AM CHEM SOC, V127, P822, DOI 10.1021/ja043285e
   Heckel A, 2006, ANGEW CHEM INT EDIT, V45, P6748, DOI 10.1002/anie.200602346
   Hotoda H, 1998, J MED CHEM, V41, P3655, DOI 10.1021/jm970658w                                                               
   Hsu CL, 2012, RSC ADV, V2, P1577, DOI 10.1039/c1ra00344e
   Hsu CL, 2011, CHEM-EUR J, V17, P10994, DOI 10.1002/chem.201101081
   Huang YF, 2008, ANAL CHEM, V80, P567, DOI 10.1021/ac702322j
   Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x
   Huntington JA, 2003, TRENDS PHARMACOL SCI, V24, P589, DOI 10.1016/j.tips.2003.09.002
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Jensen TB, 2011, BIOORGAN MED CHEM, V19, P4739, DOI 10.1016/j.bmc.2011.06.087
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Joachimi A, 2007, J AM CHEM SOC, V129, P3036, DOI 10.1021/ja0677822
   Joshi A, 2008, CHEM-EUR J, V14, P7738, DOI 10.1002/chem.200800278
   Kamikawa TL, 2010, BIOSENS BIOELECTRON, V26, P1346, DOI 10.1016/j.bios.2010.07.047
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Kelly JA, 1996, J MOL BIOL, V256, P417, DOI 10.1006/jmbi.1996.0097
   Kim Y, 2008, P NATL ACAD SCI USA, V105, P5664, DOI 10.1073/pnas.0711803105
   Kim Y, 2010, CHEM-ASIAN J, V5, P56, DOI 10.1002/asia.200900421
   KRAWCZYK SH, 1995, NUCLEOS NUCLEOT, V14, P1109, DOI 10.1080/15257779508012546
   Lee JH, 2010, ADV DRUG DELIVER REV, V62, P592, DOI 10.1016/j.addr.2010.03.003
   Li F, 2010, BIOORG MED CHEM LETT, V20, P6577, DOI 10.1016/j.bmcl.2010.09.035
   LI WX, 1994, BLOOD, V83, P677
   Liao YJ, 2012, LANGMUIR, V28, P8944, DOI 10.1021/la204651t
   Lin PH, 2011, COLLOID SURFACE B, V88, P552, DOI 10.1016/j.colsurfb.2011.07.032
   Lin Y, 1996, NUCLEIC ACIDS RES, V24, P3407, DOI 10.1093/nar/24.17.3407
   LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229
   Luganini A, 2011, ANTIMICROB AGENTS CH, V55, P3231, DOI 10.1128/AAC.00149-11
   Lundblad RL, 2005, PLATELETS, V16, P373, DOI 10.1080/09537100500123568
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Mallikaratchy PR, 2011, NUCLEIC ACIDS RES, V39, P2458, DOI 10.1093/nar/gkq996
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165
   Marathias VM, 1999, NUCLEIC ACIDS RES, V27, P2860, DOI 10.1093/nar/27.14.2860
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martino L, 2006, NUCLEIC ACIDS RES, V34, P6653, DOI 10.1093/nar/gkl915
   Mayer G, 2009, CHEMBIOCHEM, V10, P654, DOI 10.1002/cbic.200800814
   McNamara JO, 2008, J CLIN INVEST, V118, P376, DOI 10.1172/JCI33365
   Medley CD, 2011, ANAL CHEM, V83, P727, DOI 10.1021/ac102263v
   Milano G, 2010, MOL BIOSYST, V6, P553, DOI 10.1039/b915680a
   Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902                                                          
   Muller J, 2008, J THROMB HAEMOST, V6, P2105, DOI 10.1111/j.1538-7836.2008.03162.x
   Muller J, 2007, CHEMBIOCHEM, V8, P2223, DOI 10.1002/cbic.200700535
   Musumeci D, 2007, NUCLEOS NUCLEOT NUCL, V26, P1447, DOI 10.1080/15257770701542330
   Musumeci D, 2012, BIOCONJUGATE CHEM, V23, P382, DOI 10.1021/bc200305t
   Musumeci D, 2011, MOL BIOSYST, V7, P1742, DOI 10.1039/c1mb05009e
   Nagatoishi S, 2007, BIOCHEM BIOPH RES CO, V352, P812, DOI 10.1016/j.bbrc.2006.11.088
   Nagatoishi S, 2011, BIOCHIMIE, V93, P1231, DOI 10.1016/j.biochi.2011.03.013
   Nair BG, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/45/455102
   Nallagatla SR, 2009, J COMB CHEM, V11, P364, DOI 10.1021/cc800178m
   Ni X, 2011, CURR MED CHEM, V18, P4206, DOI 10.2174/092986711797189600                                                      
   Nimjee SM, 2006, MOL THER, V14, P408, DOI 10.1016/j.ymthe.2006.04.006
   Nimjee SM, 2012, MOL THER, V20, P391, DOI 10.1038/mt.2011.226
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Nirnjee SM, 2005, TRENDS CARDIOVAS MED, V15, P41
   Oney S, 2007, OLIGONUCLEOTIDES, V17, P265, DOI 10.1089/oli.2007.0089
   Oney S, 2009, NAT MED, V15, P1224, DOI 10.1038/nm.1990
   PABORSKY LR, 1993, J BIOL CHEM, V268, P20808
   Padmanabhan K, 1996, ACTA CRYSTALLOGR D, V52, P272, DOI 10.1107/S0907444995013977
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Pagano B, 2008, BIOPHYS J, V94, P562, DOI 10.1529/biophysj.107.117382
   Paleos CM, 2010, EXPERT OPIN DRUG DEL, V7, P1387, DOI 10.1517/17425247.2010.534981
   Papp I, 2011, CHEMBIOCHEM, V12, P887, DOI 10.1002/cbic.201000776
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Pasternak A, 2011, NUCLEIC ACIDS RES, V39, P1155, DOI 10.1093/nar/gkq823
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Peng CG, 2007, NUCLEIC ACIDS RES, V35, P4977, DOI 10.1093/nar/gkm520
   Peng XH, 2008, INT J NANOMED, V3, P311
   Peng XM, 2007, CURR TOP MED CHEM, V7, P363, DOI 10.2174/156802607779941251                                                      
   Pinto A, 2012, ACS CHEM BIOL, V7, P359, DOI 10.1021/cb2003835
   Plank C, 2011, ADV DRUG DELIVER REV, V63, P1300, DOI 10.1016/j.addr.2011.08.002
   Pozmogova GE, 2010, B EXP BIOL MED+, V150, P180, DOI 10.1007/s10517-010-1099-5
   Pu Y, 2010, ANAL BIOANAL CHEM, V397, P3225, DOI 10.1007/s00216-010-3715-7
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0                                                    
   Rangnekar A., 2011, NANOMEDICINE, V8, P673
   Raviv SM, 2008, J THROMB HAEMOST, V6, P1764, DOI 10.1111/j.1538-7836.2008.03106.x
   Ringquist S, 1998, CYTOMETRY, V33, P394, DOI 10.1002/(SICI)1097-0320(19981201)33:4<394::AID-CYTO2>3.0.CO;2-0
   Rohrbach F, 2012, CHEMBIOCHEM, V13, P631, DOI 10.1002/cbic.201200015
   Rotem D, 2012, J AM CHEM SOC, V134, P2781, DOI 10.1021/ja2105653
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   Russo Krauss I, 2011, NUCLEIC ACIDS RES, V39, P7858, DOI 10.1093/nar/gkr522
   Sacca B, 2005, NUCLEIC ACIDS RES, V33, P1182, DOI 10.1093/nar/gki257
   Santulli-Marotto S, 2003, CANCER RES, V63, P7483
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   Seferos DS, 2009, NANO LETT, V9, P308, DOI 10.1021/nl802958f
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Shiang YC, 2011, ANGEW CHEM INT EDIT, V50, P7660, DOI 10.1002/anie.201101718
   Shiang YC, 2010, ADV FUNCT MATER, V20, P3175, DOI 10.1002/adfm.201000642
   Smirnov I, 2000, BIOCHEMISTRY-US, V39, P1462, DOI 10.1021/bi9919044
   Sofou S, 2007, NANOMEDICINE-UK, V2, P711, DOI 10.2217/17435889.2.5.711
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   Taira K, 2011, J NUCLEIC ACIDS, DOI 10.4061/2011/103872
   Tan WH, 2011, TRENDS BIOTECHNOL, V29, P634, DOI 10.1016/j.tibtech.2011.06.009
   Tang ZW, 2009, CLIN CHEM, V55, P813, DOI 10.1373/clinchem.2008.113514
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275                                                          
   Thierry Benjamin, 2009, Current Drug Delivery, V6, P391
   Tian L, 2009, BIOCHEMISTRY-US, V48, P264, DOI 10.1021/bi801630b
   Torres-Chavolla E, 2009, BIOSENS BIOELECTRON, V24, P3175, DOI 10.1016/j.bios.2008.11.010
   TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854                                                        
   Tucker WO, 2012, CURR PHARM DESIGN, V18, P2014
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   Uehara S, 2008, B CHEM SOC JPN, V81, P1485, DOI 10.1246/bcsj.81.1485
   Vance D, 2008, BIOTECHNOL BIOENG, V101, P429, DOI 10.1002/bit.22056
   Vance D, 2009, ADV DRUG DELIVER REV, V61, P931, DOI 10.1016/j.addr.2009.06.002
   Virno A, 2007, BIOORGAN MED CHEM, V15, P5710, DOI 10.1016/j.bmc.2007.06.008
   Wang AZ, 2008, CHEMMEDCHEM, V3, P1311, DOI 10.1002/cmdc.200800091
   Wang J, 2009, CHEMBIOCHEM, V10, P2171, DOI 10.1002/cbic.200900408
   WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003
   Wang RE, 2011, CURR MED CHEM, V18, P4126
   Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399
   Wolberg AS, 2007, BLOOD REV, V21, P131, DOI 10.1016/j.blre.2006.11.001
   WU QY, 1992, J BIOL CHEM, V267, P24408
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Xiao ZY, 2012, ACS NANO, V6, P3670, DOI 10.1021/nn301869z
   Xiao ZY, 2012, ACS NANO, V6, P696, DOI 10.1021/nn204165v
   Yang L, 2011, ADV DRUG DELIVER REV, V63, P1361, DOI 10.1016/j.addr.2011.10.002
   Yigit MV, 2008, BIOCONJUGATE CHEM, V19, P412, DOI 10.1021/bc7003928
   Yu CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024077
   Zaitseva M, 2010, BIOPHYS CHEM, V146, P1, DOI 10.1016/j.bpc.2009.09.011
   Zavyalova E, 2011, CURR MED CHEM, V18, P3343, DOI 10.2174/092986711796504727                                                      
   Zhang SJ, 2009, BIOORG MED CHEM LETT, V19, P6978, DOI 10.1016/j.bmcl.2009.10.045
   Zhou J, 2008, CHEM BIOL, V15, P644, DOI 10.1016/j.chembiol.2008.07.004
NR 178
TC 41
Z9 41
U1 5
U2 130
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD NOV
PY 2012
VL 136
IS 2
BP 202
EP 215
DI 10.1016/j.pharmthera.2012.07.011
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 029LC
UT WOS:000310496100007
PM 22850531
DA 2018-01-05
ER

PT J
AU Underwood, MR
   Johns, BA
   Sato, A
   Martin, JN
   Deeks, SG
   Fujiwara, T
AF Underwood, Mark R.
   Johns, Brian A.
   Sato, Akihiko
   Martin, Jeffrey N.
   Deeks, Steven G.
   Fujiwara, Tamio
TI The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1
   Variants Isolated From Raltegravir-Treated Adults
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE Dolutegravir; DTG; S/GSK1349572; integrase inhibitor; raltegravir
   resistance; UCSF SCOPE cohort
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PATIENTS FAILING RALTEGRAVIR;
   CROSS-RESISTANCE PROFILE; ANTIRETROVIRAL THERAPY; SUSCEPTIBILITY;
   S/GSK1349572; MUTATIONS; EVOLUTION
AB Background: Dolutegravir (DTG, S/GSK1349572) is an integrase inhibitor with low nanomolar potency. Susceptibility to dolutegravir and raltegravir was determined for raltegravir-resistant clinical isolates.
   Methods: Genotypic and phenotypic susceptibility to integrase inhibitors was examined using 39 clinical isolate samples obtained from 18 adults who had exhibited incomplete viral suppression on a raltegravir-based regimen.
   Results: Of 39 samples evaluated, 30 had genotypic and phenotypic resistance to raltegravir. All samples lacking raltegravir resistance retained complete susceptibility to dolutegravir. Of the 30 samples with genotypic evidence of raltegravir resistance, the median level of phenotypic resistance to raltegravir was high (median fold change in inhibitory concentration at 50%, >81; range, 3.7 to >87), while the level of resistance to dolutegravir was close to that of wild-type variants (median fold change, 1.5; range, 0.9-19.0). Longitudinal samples from 5 subjects collected during long-term failure of raltegravir revealed time-dependent general decreases in phenotypic susceptibility to raltegravir, with minimal changes in phenotypic susceptibility to dolutegravir. The median fold change to dolutegravir for isolates containing changes at G140S + Q148H, G140S + Q148R, T97A + Y143R, and N155H (thus including raltegravir signature resistance codons) were 3.75, 13.3, 1.05, and 1.37, respectively.
   Conclusions: Dolutegravir retained in vitro activity against clinical isolates obtained from subjects who failed raltegravir-based therapy at near wild-type levels for variants containing the Y143 and N155 resistance mutations. Isolates with Q148 plus additional integrase mutations possessed a broader range of and more reduced susceptibility to dolutegravir.
C1 [Underwood, Mark R.; Johns, Brian A.] GlaxoSmithKline, Med Discovery & Dev, Infect Dis Therapy Area Unit, Res Triangle Pk, NC 27709 USA.
   [Sato, Akihiko] Shionogi & Co Ltd, Med Res Labs, Osaka, Japan.
   [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Deeks, Steven G.] San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA.
   [Fujiwara, Tamio] Shionogi & Co Ltd, Global Dev, Osaka, Japan.
RP Underwood, MR (reprint author), GlaxoSmithKline, Med Discovery & Dev, Infect Dis Therapy Area Unit, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM mark.r.underwood@gsk.com
FU National Institutes of Health [P30 AI027763, UL1 RR024131, R24
   AI067039]; Shionogi-ViiV Healthcare LLC.
FX Supported by the National Institutes of Health Grants P30 AI027763, UL1
   RR024131, and R24 AI067039 and by Shionogi-ViiV Healthcare LLC.
CR Al-Mawsawi LQ, 2011, CHEMMEDCHEM, V6, P228, DOI 10.1002/cmdc.201000443
   Bar-Magen T, 2010, J VIROL, V84, P9210, DOI 10.1128/JVI.01164-10
   Canducci F, 2011, J INFECT DIS, V204, P1811, DOI 10.1093/infdis/jir636
   Canducci F, 2009, AIDS, V23, P455, DOI 10.1097/QAD.0b013e328323da60
   Ceccherini-Silberstein F, 2009, AIDS REV, V11, P17
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Deanda FG, 2010, ANTIVIR THER, V15, pA73
   DeAnda FG, 2010, 50 INT C ANT AG CHEM
   Fransen S, 2005, 12 C RETR OPP INF FE
   Fransen S, 2009, 16 C RETR OPP INF FE
   Fransen S, 2009, J VIROL, V83, P11440, DOI 10.1128/JVI.01168-09
   Goethals O, 2008, J VIROL, V82, P10366, DOI 10.1128/JVI.00470-08
   Goethals O, 2010, VIROLOGY, V402, P338, DOI 10.1016/j.virol.2010.03.034
   Hare S, 2011, MOL PHARMACOL, V80, P565, DOI 10.1124/mol.111.073189
   Hatano H, 2010, JAIDS-J ACQ IMM DEF, V54, P389, DOI 10.1097/QAI.0b013e3181c42ea4
   Kobayashi M, 2011, ANTIMICROB AGENTS CH, V55, P813, DOI 10.1128/AAC.01209-10
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   Metifiot M, 2010, VIRUSES-BASEL, V2, P1347, DOI 10.3390/v2071347
   Min S, 2011, AIDS, V25, P1737, DOI 10.1097/QAD.0b013e32834a1dd9
   Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Seki T, 2010, 17 C RETR OPP INF FE
   van Lunzen J, 2012, LANCET INFECT DIS, V12, P111, DOI 10.1016/S1473-3099(11)70290-0
   Van Wesenbeeck L, 2011, ANTIMICROB AGENTS CH, V55, P321, DOI 10.1128/AAC.01733-09
NR 24
TC 52
Z9 53
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD NOV 1
PY 2012
VL 61
IS 3
BP 297
EP 301
DI 10.1097/QAI.0b013e31826bfd02
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 029TR
UT WOS:000310519300011
PM 22878423
OA gold
DA 2018-01-05
ER

PT J
AU Toropov, AA
   Toropova, AP
   Benfenati, E
   Gini, G
   Puzyn, T
   Leszczynska, D
   Leszczynski, J
AF Toropov, Andrey A.
   Toropova, Alla P.
   Benfenati, Emilio
   Gini, Giuseppina
   Puzyn, Tomasz
   Leszczynska, Danuta
   Leszczynski, Jerzy
TI Novel application of the CORAL software to model cytotoxicity of metal
   oxide nanoparticles to bacteria Escherichia coli
SO CHEMOSPHERE
LA English
DT Article
DE QSAR; CORAL software; Cytotoxicity to bacterium Escherichia coli; Metal
   oxide nanoparticle
ID HIV-1 PR INHIBITORS; DESCRIPTORS QSAR ANALYSIS; QUANTITATIVE STRUCTURE;
   BALANCE; NANO
AB Convenient to apply and available on the Internet software CORAL (http://www.insilico.eu/CORAL)has been used to build up quantitative structure-activity relationships (QSAR) for prediction of cytotoxicity of metal oxide nanoparticles to bacteria Escherichia coli (minus logarithm of concentration for 50% effect pEC50). In this study six random splits of the data into the training and test set were examined. It has been shown that the CORAL provides a reliable tool that could be used to build up a QSAR of the pEC50. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Toropov, Andrey A.; Toropova, Alla P.; Benfenati, Emilio] Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy.
   [Gini, Giuseppina] Politecn Milan, Dept Elect & Informat, I-20133 Milan, Italy.
   [Puzyn, Tomasz] Univ Gdansk, Lab Environm Chemometr, Fac Chem, PL-80952 Gdansk, Poland.
   [Leszczynska, Danuta] Jackson State Univ, Dept Civil & Environm Engn, Interdisciplinary Nanotox Ctr, Jackson, MS 39217 USA.
   [Leszczynski, Jerzy] Jackson State Univ, Dept Chem & Biochem, Interdisciplinary Nanotox Ctr, Jackson, MS 39217 USA.
RP Toropov, AA (reprint author), Ist Ric Farmacol Mario Negri, Via La Masa 19, I-20156 Milan, Italy.
EM andrey.toropov@marionegri.it
OI Toropova, Alla/0000-0002-4194-9963; Puzyn, Tomasz/0000-0003-0449-8339;
   Toropov, Andrey/0000-0001-6864-6340
FU OSIRIS; NSF CREST Interdisciplinary Nanotoxicity Center NSF-CREST
   [HRD-0833178]; NSF-EPSCoR Award [362492-190200-01/NSFEPS-0903787];
   Department of Defense through the U.S. Army Engineer Research and
   Development Center, Vicksburg, MS through the contract: High Performance
   Computational Design of Novel Materials (HPCDNM) [W912 HZ-06-C-0057]
FX The authors thank for support of the OSIRIS, the NSF CREST
   Interdisciplinary Nanotoxicity Center NSF-CREST - Grant # HRD-0833178;
   NSF-EPSCoR Award #: 362492-190200-01/NSFEPS-0903787; and the Department
   of Defense through the U.S. Army Engineer Research and Development
   Center, Vicksburg, MS. for generous support through the contract: High
   Performance Computational Design of Novel Materials (HPCDNM) - Contract
   #W912 HZ-06-C-0057.
CR Afantitis A, 2011, EUR J MED CHEM, V46, P497, DOI 10.1016/j.ejmech.2010.11.029
   Balaban AT, 2005, BIOORG MED CHEM LETT, V15, P3966, DOI 10.1016/j.bmcl.2005.05.136
   Basak SC, 2011, DRUG DEVELOP RES, V72, P225, DOI 10.1002/ddr.20428
   Bhhatarai B, 2010, MOL INFORM, V29, P511, DOI 10.1002/minf.201000011
   Cosentino U, 2000, CHEMOMETR INTELL LAB, V52, P183, DOI 10.1016/S0169-7439(00)00092-7                                                   
   Das K.Ch., 2010, CHEM PHYS LETT, V497, P140
   Duchowicz PR, 2011, CHEMOMETR INTELL LAB, V105, P27, DOI 10.1016/j.chemolab.2010.10.007
   Enoch SJ, 2008, CHEMOSPHERE, V71, P1225, DOI 10.1016/j.chemosphere.2007.12.011
   Furtula B, 2011, J CHEMOMETR, V25, P87, DOI 10.1002/cem.1342
   Ivanciuc T, 2006, MOL DIVERS, V10, P133, DOI 10.1007/s11030-005-9003-3
   Katritzky AR, 2010, EUR J MED CHEM, V45, P5183, DOI 10.1016/j.ejmech.2010.08.033
   Leszczynski J, 2010, NAT NANOTECHNOL, V5, P633, DOI 10.1038/nnano.2010.182
   Mitra I, 2010, MOL SIMULAT, V36, P1067, DOI 10.1080/08927022.2010.503326
   Puzyn T, 2011, NAT NANOTECHNOL, V6, P175, DOI [10.1038/nnano.2011.10, 10.1038/NNANO.2011.10]
   RANDIC M, 1991, CHEMOMETR INTELL LAB, V10, P213, DOI 10.1016/0169-7439(91)80051-Q                                                    
   Tetko I.V., 2008, J INORG BIOCHEM, V102, P1224
   Toropov AA, 2010, EUR J MED CHEM, V45, P1387, DOI 10.1016/j.ejmech.2009.12.037
   Toropov AA, 2010, J COMPUT CHEM, V31, P381, DOI 10.1002/jcc.21333
   Toropova AP, 2010, J MATH CHEM, V48, P959, DOI 10.1007/s10910-010-9719-x
   Toropova A.P., 2011, MOL DIVERS, V105, P249
NR 20
TC 51
Z9 52
U1 3
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
J9 CHEMOSPHERE
JI Chemosphere
PD NOV
PY 2012
VL 89
IS 9
BP 1098
EP 1102
DI 10.1016/j.chemosphere.2012.05.077
PG 5
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 013UN
UT WOS:000309331500011
PM 22704203
DA 2018-01-05
ER

PT J
AU Sun, Y
   Zhang, ZW
   Grigoryants, VM
   Myers, WK
   Liu, F
   Earle, KA
   Freed, JH
   Scholes, CP
AF Sun, Yan
   Zhang, Ziwei
   Grigoryants, Vladimir M.
   Myers, William K.
   Liu, Fei
   Earle, Keith A.
   Freed, Jack H.
   Scholes, Charles P.
TI The Internal Dynamics of Mini c TAR DNA Probed by Electron Paramagnetic
   Resonance of Nitroxide Spin-Labels at the Lower Stem, the Loop, and the
   Bulge
SO BIOCHEMISTRY
LA English
DT Article
ID HIV-1 NUCLEOCAPSID PROTEIN; PAIR DISTANCE DISTRIBUTIONS;
   ROTATIONAL-DYNAMICS; TIKHONOV REGULARIZATION; REVERSE TRANSCRIPTION;
   STRAND TRANSFER; NUCLEIC-ACIDS; RNA STRUCTURE; PULSED ESR; SPECTROSCOPY
AB Electron paramagnetic resonance (EPR) at 236.6 and 9.5 GHz probed the tumbling of nitroxide spin probes in the lower stem, in the upper loop, and near the bulge of mini c TAR DNA. High-frequency 236.6 GHz EPR, not previously applied to spin-labeled oligonucleotides, was notably sensitive to fast, anisotropic, hindered local rotational motion of the spin probe, occurring approximately about the NO nitroxide axis. Labels attached to the 2'-aminocytidine sugar in the mini c TAR DNA showed such anisotropic motion, which was faster in the lower stem, a region previously thought to be partially melted. More flexible labels attached to phosphorothioates at the end of the lower stem tumbled isotropically in mini c TAR DNA, mini TAR RNA, and psi(3) RNA, but at 5 degrees C, the motion became more anisotropic for the labeled RNAs, implying more order within the RNA lower stems. As observed by 9.5 GHz EPR, the slowing of nanosecond motions of large segments of the oligonucleotide was enhanced by increasing the ratio of the nucleocapsid protein NCp7 to mini c TAR DNA from 0 to 2. The slowing was most significant at labels in the loop and near the bulge. At a 4:1 ratio of NCp7 to mini c TAR DNA, all labels reported tumbling times of >5 ns, indicating a condensation of NCp7 and TAR DNA. At the 4:1 ratio, pulse dipolar EPR spectroscopy of bilabels attached near the 3' and 5' termini showed evidence of an NCp7-induced increase in the 3'-5' end-to-end distance distribution and a partially melted stem.
C1 [Sun, Yan; Grigoryants, Vladimir M.; Myers, William K.; Liu, Fei; Scholes, Charles P.] SUNY Albany, Dept Chem, Albany, NY 12222 USA.
   [Zhang, Ziwei; Freed, Jack H.] Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA.
   [Zhang, Ziwei; Freed, Jack H.] Cornell Univ, ACERT, Ithaca, NY 14853 USA.
   [Earle, Keith A.] SUNY Albany, Dept Phys, Albany, NY 12222 USA.
RP Scholes, CP (reprint author), SUNY Albany, Dept Chem, 1400 Washington Ave, Albany, NY 12222 USA.
EM cps14@albany.edu
OI Myers, William/0000-0001-5935-9112
FU NIGMS NIH HHS [R01 GM066253, P41 GM103521, GM066253-01A1,
   3R01GM06625304S1, P41GM103521]; NCRR NIH HHS [P41 RR016292, P41RR016292]
CR Avilov SV, 2009, BIOCHEMISTRY-US, V48, P2422, DOI 10.1021/bi8022366
   Barnes JP, 1997, REV SCI INSTRUM, V68, P2838, DOI 10.1063/1.1148205
   Bazzi A, 2011, NUCLEIC ACIDS RES, V39, P3903, DOI 10.1093/nar/gkq1290
   Bennati M, 2005, REP PROG PHYS, V68, P411, DOI 10.1088/0034-4885/68/2/R05
   Borbat PP, 2007, METHOD ENZYMOL, V423, P52, DOI 10.1016/S0076-6879(07)23003-4
   Borbat PP, 2001, SCIENCE, V291, P266, DOI 10.1126/science.291.5502.266
   Borbat PP, 1997, J MAGN RESON, V127, P155, DOI 10.1006/jmre.1997.1201
   Budil DE, 1996, J MAGN RESON SER A, V120, P155, DOI 10.1006/jmra.1996.0113
   Cai Q, 2007, BIOPHYS J, V93, P2110, DOI 10.1529/biophysj.107.109439
   Cai Q, 2006, NUCLEIC ACIDS RES, V34, P4722, DOI 10.1093/nar/gkl546
   Chiang YW, 2005, J MAGN RESON, V177, P184, DOI 10.1016/j.jmr.2005.07.021
   Chiang YW, 2005, J MAGN RESON, V172, P279, DOI 10.1016/j.jmr.2004.10.012
   Cosa G, 2006, J PHYS CHEM B, V110, P2419, DOI 10.1021/jp054189i
   Cosa G, 2004, BIOPHYS J, V87, P2759, DOI 10.1529/biophysj.104.043083
   Darlix JL, 2011, J MOL BIOL, V410, P565, DOI 10.1016/j.jmb.2011.03.037
   Deweerd K, 2001, BIOCHEMISTRY-US, V40, P15846, DOI 10.1021/bi011414n
   Dzikovski B, 2006, J MAGN RESON, V179, P273, DOI 10.1016/j.jmr.2005.12.015
   Earle KA, 1999, APPL MAGN RESON, V16, P247, DOI 10.1007/BF03161937                                                              
   Earle K. A, 2005, MAGN RESON CHEM, V43, pS256
   Earle K. A., 2006, ADV ESR METHODS POLY
   Edwards TE, 2005, CHEM BIOL, V12, P329, DOI 10.1016/j.chembiol.2005.01.012
   Edwards TE, 2002, BIOCHEMISTRY-US, V41, P14843, DOI 10.1021/bi026299a
   Edwards TE, 2002, CHEM BIOL, V9, P699, DOI 10.1016/S1074-5521(02)00150-3
   Edwards TE, 2001, J AM CHEM SOC, V123, P1527, DOI 10.1021/ja005649i
   Fisher CK, 2008, J PHYS CHEM B, V112, P16815, DOI 10.1021/jp806188j
   Freed JH, 2000, ANNU REV PHYS CHEM, V51, P655, DOI 10.1146/annurev.physchem.51.1.655                                               
   Getz M, 2007, BIOPOLYMERS, V86, P384, DOI 10.1002/bip.20765
   Grant GPG, 2008, BIOCHEM BIOPH RES CO, V371, P451, DOI 10.1016/j.bbrc.2008.04.088
   Grant GPG, 2009, J AM CHEM SOC, V131, P3136, DOI 10.1021/ja808217s
   Grigoryants VM, 2000, BIOPHYS J, V78, P2702, DOI 10.1016/S0006-3495(00)76814-7                                                   
   Grigoryants V.M., 2006, PROTEIN STRUCTURES M, P47
   Guo J., 1997, J VIROL, V71, P5178
   Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4
   Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i
   Karim CB, 2004, P NATL ACAD SCI USA, V101, P14437, DOI 10.1073/pnas.0402801101
   Karim CB, 2007, NAT PROTOC, V2, P42, DOI 10.1038/nprot.2007.2
   Liang ZC, 1999, J PHYS CHEM B, V103, P6384, DOI 10.1021/jp9907746                                                               
   Liu HW, 2007, P NATL ACAD SCI USA, V104, P5261, DOI 10.1073/pnas.0700166104
   Pitt SW, 2005, ANGEW CHEM INT EDIT, V44, P3412, DOI 10.1002/anie.200500075
   POLIMENO A, 1995, J PHYS CHEM-US, V99, P10995, DOI 10.1021/j100027a047                                                             
   Popova AM, 2009, BIOCHEMISTRY-US, V48, P8540, DOI 10.1021/bi900860w
   Price EA, 2007, BIOPOLYMERS, V87, P40, DOI 10.1002/bip.20769
   Qin PZ, 2003, BIOCHEMISTRY-US, V42, P6772, DOI 10.1021/bi027222p
   Qin PZ, 2001, BIOCHEMISTRY-US, V40, P6929, DOI 10.1021/bi010294g
   Sun XY, 2007, NUCLEIC ACIDS RES, V35, P1698, DOI 10.1093/nar/gkm020
   Theimer CA, 1998, J MOL BIOL, V279, P545, DOI 10.1006/jmbi.1998.1812                                                          
   TIRADO MM, 1980, J CHEM PHYS, V73, P1986, DOI 10.1063/1.440288
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   Vo MN, 2006, J MOL BIOL, V363, P244, DOI 10.1016/j.jmb.2006.08.039
   Vo MN, 2009, J MOL BIOL, V386, P773, DOI 10.1016/j.jmb.2008.12.073
   Vo MN, 2009, J MOL BIOL, V386, P789, DOI 10.1016/j.jmb.2008.12.070
   Xi XM, 2008, BIOCHEMISTRY-US, V47, P10099, DOI 10.1021/bi800602e
   Zargarian L, 2009, NUCLEIC ACIDS RES, V37, P4043, DOI 10.1093/nar/gkp297
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
   Zhang Q, 2009, RNA, V15, P1941, DOI 10.1261/rna.1806909
   Zhang ZW, 2008, BIOPOLYMERS, V89, P1125, DOI 10.1002/bip.21064
   Zhang ZW, 2010, J PHYS CHEM B, V114, P5503, DOI 10.1021/jp910606h
NR 58
TC 4
Z9 4
U1 1
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 30
PY 2012
VL 51
IS 43
BP 8530
EP 8541
DI 10.1021/bi301058q
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 029GX
UT WOS:000310483900006
PM 23009298
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chojnacki, J
   Staudt, T
   Glass, B
   Bingen, P
   Engelhardt, J
   Anders, M
   Schneider, J
   Muller, B
   Hell, SW
   Krausslich, HG
AF Chojnacki, Jakub
   Staudt, Thorsten
   Glass, Baerbel
   Bingen, Pit
   Engelhardt, Johann
   Anders, Maria
   Schneider, Jale
   Mueller, Barbara
   Hell, Stefan W.
   Kraeusslich, Hans-Georg
TI Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by
   Fluorescence Nanoscopy
SO SCIENCE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN INCORPORATION; GP41
   CYTOPLASMIC TAIL; INFLUENZA-VIRUS; TYPE-1; VIRIONS; FUSION; ENV;
   ORGANIZATION; TOMOGRAPHY
AB Human immunodeficiency virus type 1 (HIV-1) buds from the cell as an immature particle requiring subsequent proteolysis of the main structural polyprotein Gag for morphological maturation and infectivity. Visualization of the viral envelope (Env) glycoprotein distribution on the surface of individual HIV-1 particles with stimulated emission depletion (STED) superresolution fluorescence microscopy revealed maturation-induced clustering of Env proteins that depended on the Gag-interacting Env tail. Correlation of Env surface clustering with the viral entry efficiency revealed coupling between the viral interior and exterior: Rearrangements of the inner protein lattice facilitated the alteration of the virus surface in preparation for productive entry. We propose that Gag proteolysis-dependent clustering of the sparse Env trimers on the viral surface may be an essential aspect of HIV-1 maturation.
C1 [Chojnacki, Jakub; Glass, Baerbel; Anders, Maria; Mueller, Barbara; Kraeusslich, Hans-Georg] Univ Heidelberg, Dept Infect Dis, D-69120 Heidelberg, Germany.
   [Staudt, Thorsten; Bingen, Pit; Engelhardt, Johann; Schneider, Jale; Hell, Stefan W.] German Canc Res Ctr, Opt Nanoscopy Div, D-69120 Heidelberg, Germany.
   [Staudt, Thorsten; Bingen, Pit; Engelhardt, Johann; Schneider, Jale; Hell, Stefan W.] BIOQUANT, D-69120 Heidelberg, Germany.
   [Hell, Stefan W.] Max Planck Inst Biophys Chem, Dept NanoBiophoton, D-37077 Gottingen, Germany.
RP Krausslich, HG (reprint author), Univ Heidelberg, Dept Infect Dis, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.
EM hans-georg.kraeusslich@med.uni-heidelberg.de
FU German Research Foundation (DFG)
FX We are grateful to J. Mak (Burnet Institute, Melbourne) for purified
   recombinant HIV-1 Gag and to P. Guardado-Calves (Institut Pasteur,
   Paris) for monomeric and trimeric Env gp140. We thank L. Castillo for
   purified recombinant HIV-1 CA, V. Bosch (DKFZ Heidelberg) for HIV-1
   gp120 and CD4 antisera as well as HIV-1 Env expression plasmids, R. Doms
   (University of Pennsylvania) for SupT1R5 cells, C. Aiken (Vanderbilt
   University Medical Center) for infectious HIV-1 variant plasmids, and T.
   Hope (Northwestern University Chicago) for the eGFP. Vpr construct.
   H.-G.K. is an investigator of the Excellence Cluster CellNetworks funded
   by the German Research Foundation (DFG). S.W.H. holds a patent on STED
   microscopy in several European countries and the United States, which
   has been licensed to Leica, a microscope manufacturer.
CR Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   CHENG RH, 1995, CELL, V80, P621
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   Cosson P, 1996, EMBO J, V15, P5783
   de Marco A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001215
   Endress T, 2008, EUR BIOPHYS J BIOPHY, V37, P1291, DOI 10.1007/s00249-008-0322-z
   Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715
   Freed EO, 1996, J VIROL, V70, P341
   Harris A, 2006, P NATL ACAD SCI USA, V103, P19123, DOI 10.1073/pnas.0607614103
   HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3
   HELL SW, 1994, OPT LETT, V19, P780, DOI 10.1364/OL.19.000780                                                            
   Holtkotte D, 2006, AIDS RES HUM RETROV, V22, P57, DOI 10.1089/aid.2006.22.57
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200                                                          
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004
   Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343
   ROBEN P, 1994, J VIROL, V68, P4821
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Trkola A, 1996, J VIROL, V70, P1100
   WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I
   Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004
   Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.26334931100
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 26
TC 98
Z9 101
U1 9
U2 75
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD OCT 26
PY 2012
VL 338
IS 6106
BP 524
EP 528
DI 10.1126/science.1226359
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 025NH
UT WOS:000310195800057
PM 23112332
DA 2018-01-05
ER

PT J
AU Trigilio, J
   Antoine, TE
   Paulowicz, I
   Mishra, YK
   Adelung, R
   Shukla, D
AF Trigilio, James
   Antoine, Thessicar E.
   Paulowicz, Ingo
   Mishra, Yogendra K.
   Adelung, Rainer
   Shukla, Deepak
TI Tin Oxide Nanowires Suppress Herpes Simplex Virus-1 Entry and
   Cell-to-Cell Membrane Fusion
SO PLOS ONE
LA English
DT Article
ID 3-O-SULFATED HEPARAN-SULFATE; TYPE-1; NANOPARTICLES; PERFORMANCE;
   INHIBITION; INFECTION; SPREAD
AB The advent of nanotechnology has ushered in the use of modified nanoparticles as potential antiviral agents against diseases such as herpes simplex virus 1 and 2 (HSV-1) (HSV-2), human immunodeficiency virus (HIV), monkeypox virus, and hepatitis B virus. Here we describe the application of tin oxide (SnO2) nanowires as an effective treatment against HSV-1 infection. SnO2 nanowires work as a carrier of negatively charged structures that compete with HSV-1 attachment to cell bound heparan sulfate (HS), therefore inhibiting entry and subsequent cell-to-cell spread. This promising new approach can be developed into a novel form of broad-spectrum antiviral therapy especially since HS has been shown to serve as a cellular co-receptor for a number of other viruses as well, including the respiratory syncytial virus, adeno-associated virus type 2, and human papilloma virus.
C1 [Trigilio, James; Antoine, Thessicar E.; Shukla, Deepak] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60607 USA.
   [Antoine, Thessicar E.; Shukla, Deepak] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA.
   [Paulowicz, Ingo; Mishra, Yogendra K.; Adelung, Rainer] Univ Kiel, Dept Engn, Inst Mat Sci, Kiel, Germany.
RP Shukla, D (reprint author), Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60607 USA.
EM dshukla@uic.edu
RI Mishra, Yogendra/G-6241-2010
OI Mishra, Yogendra/0000-0002-8786-9379; Shukla, Deepak/0000-0002-3039-6953
FU National Institutes of Health [RO1 AI057860, AI081869]; AvH foundation;
   DFG [SFB-855 A5]; Heisenberg Professorship; inflammation at interfaces
   cluster
FX This work was supported by National Institutes of Health grants RO1
   AI057860 and AI081869 to D. Shukla. YKM acknowledges a grant from AvH
   foundation, RA gratefully acknowledges the funds from DFG from SFB-855
   A5, and a Heisenberg Professorship, and support from the inflammation at
   interfaces cluster. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Clement C, 2006, J CELL BIOL, V174, P1009, DOI 10.1083/jcb.200509155
   Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000
   Desai P, 1998, J VIROL, V72, P7563
   Gurlo A, 2011, NANOSCALE, V3, P154, DOI 10.1039/c0nr00560f
   HEROLD BC, 1991, J VIROL, V65, P1090
   Karasneh GA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-481
   Legarra A, 2008, GENETICS, V180, P611, DOI 10.1534/genetics.108.088575
   Mecklenburg M, 2012, ADV MATER, V24, P3486, DOI 10.1002/adma.201200491
   Mishra YK, 2011, ANTIVIR RES, V92, P305, DOI 10.1016/j.antiviral.2011.08.017
   Novak N, 2005, CLIN EXP IMMUNOL, V142, P405, DOI 10.1111/j.1365-2249.2005.02927.x
   O'Donnell CD, 2009, J BIOL CHEM, V284, P29654, DOI 10.1074/jbc.M109.037960
   Roller RJ, 1997, J VIROL, V71, P5805
   Salameh Sarah, 2012, Open Virol J, V6, P1, DOI 10.2174/1874357901206010001
   Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6                                                   
   Tiwari V, 2005, J VIROL, V79, P13173, DOI 10.1128/JVI.79.20.13173-13179.2005
   Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0
   Tiwari V., 2012, GLYCOBIOLOGY
   Tiwari V, 2009, BIOCHEM BIOPH RES CO, V390, P382, DOI 10.1016/j.bbrc.2009.08.174
   van Lint AL, 2007, VIROLOGY, V368, P227, DOI 10.1016/j.virol.2007.08.030
   WUDUNN D, 1989, J VIROL, V63, P52
   Zhe R, 2008, ARCH VIROL, V153, P1401, DOI 10.1007/s00705-008-0110-1
   Kaps S., 2011, Deutsches Patentamt, Patent No. [DE2011/000282, 2011000282, DE2011000282]
NR 25
TC 14
Z9 14
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e48147
DI 10.1371/journal.pone.0048147
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026VC
UT WOS:000310310200152
PM 23110193
OA gold
DA 2018-01-05
ER

PT J
AU Arjmandi, N
   Van Roy, W
   Lagae, L
   Borghs, G
AF Arjmandi, Nima
   Van Roy, Willem
   Lagae, Liesbet
   Borghs, Gustaaf
TI Measuring the Electric Charge and Zeta Potential of Nanometer-Sized
   Objects Using Pyramidal-Shaped Nanopores
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SOLID-STATE NANOPORES; MOLECULE MASS-SPECTROMETRY; ELECTROPHORETIC
   MOBILITY; SUBMICRON PARTICLES; COULTER-COUNTER; IONIC-STRENGTH; DNA;
   TRANSLOCATION; NANOPARTICLES; VIRUSES
AB Nanometer-scale pores are capable of detecting the size and concentration of nanometer-sized analytes at low concentrations upon analyzing their translocation through the pore, in small volumes and over a short time without labeling. Here, we present a simple, widely applicable, robust, and precise method to measure the zeta-potential of different nano-objects using nanopores. Zeta-potential i.e., a quantity that represents electrical charge in nanocolloids, is an important property in manufacturing of pharmaceuticals, inks, foams, cosmetics, and food. Its use is also imperative in understanding basic properties of complex dispersions including blood, living organisms, and their interaction with the environment. The characterization methods for zeta-potential are limited. Using the nanopore technique, the zeta-potential and the charge of nanoparticles can be measured independently of other parameters, such as particle size. This simple method is based on measuring the duration of the translocation of analytes through a nanopore as a function of applied voltage. A simple analytical model has been developed to extract the zeta-potential. This method is able to detect and differentiate nanometer-sized objects of similar size; it also enables the direct and precise quantitative measurement of their zeta-potential. We have applied this method to a wide range of different nanometer-sized particles and compared the results with values measured by commercially available tools. Furthermore, potential capability of this method in detection and characterization of virions is shown by measuring the low zeta-potential of HIV and EBV viruses.
C1 [Arjmandi, Nima; Van Roy, Willem; Lagae, Liesbet; Borghs, Gustaaf] IMEC, B-3001 Louvain, Belgium.
   [Arjmandi, Nima; Lagae, Liesbet; Borghs, Gustaaf] Katholieke Univ Leuven, Dept Phys & Astron, B-3001 Louvain, Belgium.
RP Arjmandi, N (reprint author), IMEC, Kapeldreef 75, B-3001 Louvain, Belgium.
EM Arjmandi@imec.be
CR Ai Y, 2011, PHYS CHEM CHEM PHYS, V13, P4060, DOI 10.1039/c0cp02267e
   Albert B., 1994, J MOL BIOL CELL
   Albrecht T, 2011, ACS NANO, V5, P6714, DOI 10.1021/nn202253z
   Ambjornsson T, 2002, J CHEM PHYS, V117, P4063, DOI 10.1063/1.1486208
   Arjmandi N., 2012, P NAN C LANZ SPAIN
   Arjmandi N, 2012, MICROFLUID NANOFLUID, V12, P17, DOI 10.1007/s10404-011-0843-0
   Arjmandi N, 2009, J VAC SCI TECHNOL B, V27, P1915, DOI 10.1116/1.3167367
   Bacri L, 2011, J PHYS CHEM B, V115, P2890, DOI 10.1021/jp200326w
   Belyi VA, 2006, P NATL ACAD SCI USA, V103, P17174, DOI 10.1073/pnas.0608311103
   Berne B.J., 2000, DYNAMIC LIGHT SCATTE
   Bockris J. O., 1998, MODERN ELECTROCHEMIS
   Bondoc LL, 1998, J IND MICROBIOL BIOT, V20, P317
   Bowen WR, 1998, NAT BIOTECHNOL, V16, P785, DOI 10.1038/nbt0898-785                                                             
   Castellanos A, 2003, J PHYS D APPL PHYS, V36, P2584, DOI 10.1088/0022-3727/36/20/023                                                     
   Chang H, 2004, NANO LETT, V4, P1551, DOI 10.1021/nl049267c
   Chang H, 2006, BIOMED MICRODEVICES, V8, P263, DOI 10.1007/s10544-006-9144-x
   Clarke J, 2009, NAT NANOTECHNOL, V4, P265, DOI [10.1038/nnano.2009.12, 10.1038/NNANO.2009.12]
   DEBLOIS RW, 1977, J COLLOID INTERF SCI, V61, P323, DOI 10.1016/0021-9797(77)90395-2
   Dekker C, 2007, NAT NANOTECHNOL, V2, P209, DOI 10.1038/nnano.2007.27
   DOSRAMOS JG, 1989, J COLLOID INTERF SCI, V133, P302, DOI 10.1016/S0021-9797(89)80039-6                                                   
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Dubbeldam JLA, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.010801
   Dukhin S. S., 1974, ELECT PHENOMENASURFA
   Fraikin JL, 2011, NAT NANOTECHNOL, V6, P308, DOI [10.1038/nnano.2011.24, 10.1038/NNANO.2011.24]
   Franzman MA, 2010, J AM CHEM SOC, V132, P4060, DOI 10.1021/ja100249m
   Freedman KJ, 2011, ANAL CHEM, V83, P5137, DOI 10.1021/ac2001725
   GIDDINGS JC, 1993, SCIENCE, V260, P1456, DOI 10.1126/science.8502990                                                         
   Hall AR, 2011, NANO LETT, V11, P2446, DOI 10.1021/nl200873w
   Hamley I. W., 2005, BLOCK COPOLYMERS SOL
   HENRICKSON SE, 2000, J PHYS REV LETT, V85, P3057
   Houpaniemi I., 2006, J CHEM PHYS, V125
   Hunter RJ, 2001, FDN COLLOID SCI
   Ito T, 2004, ACCOUNTS CHEM RES, V37, P937, DOI 10.1021/ar040108+
   Ito T, 2004, LANGMUIR, V20, P6940, DOI 10.1021/la049524t
   Ito T, 2003, ANAL CHEM, V75, P2399, DOI 10.1021/ac023072v
   Jans H., 2010, NANOTECHNOLOGY, V21
   Keyser UF, 2006, NAT PHYS, V2, P473, DOI 10.1038/nphys344
   Kox R, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/33/335703
   Lan WJ, 2011, ANAL CHEM, V83, P3840, DOI 10.1021/ac200312n
   Loeb A. L., 1961, J ELECTROCHEM SOC, V108, p269C
   LYKLEMA J, 1961, J COLL SCI IMP U TOK, V16, P501, DOI 10.1016/0095-8522(61)90029-0
   Masliyah J. H., 2006, ELECTROKINETIC COLLO
   Nohynek GJ, 2007, CRIT REV TOXICOL, V37, P251, DOI 10.1080/10408440601177780
   OBRIEN RW, 1978, J CHEM SOC FARAD T 2, V74, P1607, DOI 10.1039/f29787401607                                                            
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   PIERCE JS, 1974, J VIROL, V13, P1030
   Reiner JE, 2010, P NATL ACAD SCI USA, V107, P12080, DOI 10.1073/pnas.1002194107
   Roberts GS, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2734968
   Robertson JWF, 2007, P NATL ACAD SCI USA, V104, P8207, DOI 10.1073/pnas.0611085104
   Schaldach CM, 2006, J COLLOID INTERF SCI, V294, P1, DOI 10.1016/j.jcis.2005.06.082
   Seaman GVF, 2001, ELECTROPHORESIS, V22, P373, DOI 10.1002/1522-2683(200102)22:3<373::AID-ELPS373>3.0.CO;2-8
   Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325
   Smeets RMM, 2006, NANO LETT, V6, P89, DOI 10.1021/nl052107w
   Sperling RA, 2007, J PHYS CHEM C, V111, P11552, DOI 10.1021/jp070999d
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   Tabard-Cossa V, 2009, ACS NANO, V3, P3009, DOI 10.1021/nn900713a
   Tamaki E, 2006, J CHROMATOGR A, V1137, P256, DOI 10.1016/j.chroma.2006.10.097
   Tas NR, 2004, APPL PHYS LETT, V85, P3274, DOI 10.1063/1.1804602
   van Dorp S, 2009, NAT PHYS, V5, P347, DOI 10.1038/NPHYS1230
   Venkatesan BM, 2011, NAT NANOTECHNOL, V6, P615, DOI [10.1038/nnano.2011.129, 10.1038/NNANO.2011.129]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Willmott G., 2010, J PHYS CONDENS MATT, V22
   Wong CTA, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2723088
NR 63
TC 48
Z9 48
U1 3
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 16
PY 2012
VL 84
IS 20
BP 8490
EP 8496
DI 10.1021/ac300705z
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 020JQ
UT WOS:000309805200011
PM 22901005
DA 2018-01-05
ER

PT J
AU Pellis, M
   Pardon, E
   Zolghadr, K
   Rothbauer, U
   Vincke, C
   Kinne, J
   Dierynck, I
   Hertogs, K
   Leonhardt, H
   Messens, J
   Muyldermans, S
   Conrath, K
AF Pellis, Mireille
   Pardon, Els
   Zolghadr, Kourosh
   Rothbauer, Ulrich
   Vincke, Cecile
   Kinne, Joerg
   Dierynck, Inge
   Hertogs, Kurt
   Leonhardt, Heinrich
   Messens, Joris
   Muyldermans, Serge
   Conrath, Katja
TI A bacterial-two-hybrid selection system for one-step isolation of
   intracellularly functional Nanobodies
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Bacterial-two-hybrid; Intrabody; Nanobody
ID DOMAIN ANTIBODY FRAGMENTS; GREEN FLUORESCENT PROTEIN; COMPLEMENTATION
   ASSAY; CHAIN ANTIBODIES; LIVING CELLS; VISUALIZATION; IDENTIFICATION;
   PURIFICATION; RECOGNITION; TECHNOLOGY
AB Camel single-domain antibody fragments or Nanobodies, are practical in a wide range of applications. Their unique biochemical and biophysical properties permit an intracellular expression and antigen targeting. The availability of an efficient intracellular selection step would immediately identify the best intracellularly performing functional antibody fragments. Therefore, we assessed a bacterial-two-hybrid system to retrieve such Nanobodies. With GFP as an antigen we demonstrate that antigen-specific Nanobodies of sub-micromolar affinity and stability above 30 kJ/mol at a titer of 10(-4) can be retrieved in a single-step selection. This was further proven practically by the successful recovery from an 'immune' library of multiple stable, antigen-specific Nanobodies of good affinity for HIV-1 integrase or nucleoside hydrolase. The sequence diversity, intrinsic domain stability, antigen-specificity and affinity of these binders compare favorably to those that were retrieved in parallel by phage display pannings. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Pellis, Mireille; Vincke, Cecile; Muyldermans, Serge; Conrath, Katja] Vrije Univ Brussel, Lab Cellular & Mol Immunol, B-1050 Brussels, Belgium.
   [Pellis, Mireille; Pardon, Els; Vincke, Cecile; Messens, Joris; Muyldermans, Serge; Conrath, Katja] VIB, Dept Biol Struct, Brussels, Belgium.
   [Pardon, Els; Messens, Joris] Vrije Univ Brussel, Lab Struct Biol Brussels, B-1050 Brussels, Belgium.
   [Zolghadr, Kourosh; Rothbauer, Ulrich] ChromoTek GmbH, D-82152 Martinsried, Germany.
   [Kinne, Joerg] Cent Vet Res Lab, Dubai, U Arab Emirates.
   [Dierynck, Inge; Hertogs, Kurt] Tibotec, B-2800 Mechelen, Belgium.
   [Leonhardt, Heinrich] Univ Munich, Biozentrum, Dept Biol 2, D-82152 Planegg Martinsried, Germany.
RP Muyldermans, S (reprint author), Vrije Univ Brussel, Lab Cellular & Mol Immunol, Pl Laan 2, B-1050 Brussels, Belgium.
EM svmuylde@vub.ac.be
RI Messens, Joris/K-5856-2016; Leonhardt, Heinrich/B-2791-2014;
   Muyldermans, Serge/C-6418-2016
OI Messens, Joris/0000-0002-2128-8264; Muyldermans,
   Serge/0000-0002-3678-3575
FU Instituut voor de aanmoediging van Innovatie door Wetenschap en
   Technologie in Vlaanderen (IWT); FWO-Vlaanderen; VIB; Vrije Universiteit
   Brussel (GOA OZR); EU [241481]
FX We thank Khadija Wahni and Sarah Haesaerts for the technical support to
   produce the recombinant proteins used in this study. M.P. acknowledges
   the financial support from the Instituut voor de aanmoediging van
   Innovatie door Wetenschap en Technologie in Vlaanderen (IWT). This work
   was financed by FWO-Vlaanderen, VIB, Vrije Universiteit Brussel (GOA &
   OZR) and by EU-project AFFINOMICS (241481).
CR Ben Abderrazek R, 2011, PROTEIN ENG DES SEL, V24, P727, DOI 10.1093/protein/gzr037
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001
   da Silva FA, 2004, J MOL BIOL, V340, P525, DOI 10.1016/j.jmb.2004.04.062
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   der Maur Adrian Auf, 2002, Journal of Biological Chemistry, V277, P45075
   DESCHAMPS JR, 1995, PROTEIN EXPRES PURIF, V6, P555, DOI 10.1006/prep.1995.1073
   Dolk E, 2005, APPL ENVIRON MICROB, V71, P442, DOI 10.1128/AEM.71.1.442-450.2005
   Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0                                                                
   Dufner P, 2006, TRENDS BIOTECHNOL, V24, P523, DOI 10.1016/j.tibtech.2006.09.004
   Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602
   Ewert S, 2004, METHODS, V34, P184, DOI 10.1016/j.ymeth.2004.04.007
   Flajnik MF, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001120
   Govaert J, 2012, J BIOL CHEM, V287, P1970, DOI 10.1074/jbc.M111.242818
   Hu JC, 2000, METHODS, V20, P80, DOI 10.1006/meth.1999.0908
   Koch H, 2006, J MOL BIOL, V357, P427, DOI 10.1016/j.jmb.2005.12.043
   Mossner E, 2001, J MOL BIOL, V308, P115, DOI 10.1006/jmbi.2001.4575
   Muyldermans S, 2009, VET IMMUNOL IMMUNOP, V128, P178, DOI 10.1016/j.vetimm.2008.10.299
   Nygrem P.A., 2003, CURR OPIN CHEM BIOL, V7, P683
   Portner-Taliana A, 2000, J IMMUNOL METHODS, V238, P161, DOI 10.1016/S0022-1759(00)00145-9
   Rahbarizadeh F, 2004, HYBRIDOMA HYBRIDOM, V23, P151, DOI 10.1089/1536859041224334
   Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685
   Rothbauer U, 2006, NAT METHODS, V3, P887, DOI 10.1038/NMETH953
   Saerens D, 2005, J MOL BIOL, V352, P597, DOI 10.1016/j.jmb.2005.07.038
   Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x
   Tsukamoto T, 2000, NAT CELL BIOL, V2, P871
   van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8
   Vascotto F, 2005, J IMMUNOL METHODS, V301, P31, DOI 10.1016/j.jim.2005.03.011
   Versees W, 2001, J MOL BIOL, V307, P1363, DOI 10.1006/jmbi.2001.4548
   Visintin M, 2004, J IMMUNOL METHODS, V290, P135, DOI 10.1016/j.jim.2004.04.014
   Visintin M, 2002, J MOL BIOL, V317, P73, DOI 10.1006/jmbi.2001.5392
   Zolghadr K, 2008, MOL CELL PROTEOMICS, V7, P2279, DOI 10.1074/mcp.M700548-MCP200
NR 32
TC 22
Z9 22
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD OCT 15
PY 2012
VL 526
IS 2
SI SI
BP 114
EP 123
DI 10.1016/j.abb.2012.04.023
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 006RL
UT WOS:000308836400005
PM 22583807
DA 2018-01-05
ER

PT J
AU Belletti, D
   Tosi, G
   Forni, F
   Gamberini, MC
   Baraldi, C
   Vandelli, MA
   Ruozi, B
AF Belletti, Daniela
   Tosi, Giovanni
   Forni, Flavio
   Gamberini, Maria Cristina
   Baraldi, Cecilia
   Vandelli, Maria Angela
   Ruozi, Barbara
TI Chemico-physical investigation of tenofovir loaded polymeric
   nanoparticles
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE PMPA; Nps; PLGA; CH; Raman spectra; DSC analysis
ID CHITOSAN NANOPARTICLES; SOLVENT EVAPORATION; DISOPROXIL FUMARATE; DRUG
   RELEASE; MICROSPHERES; DIFFUSION; MECHANISM; DELIVERY
AB Tenofovir (PMPA), an acyclic nucleoside phosphonate analog, is one of the most important drugs used for the HIV treatment. Unfortunately, several adverse reactions are related to its i.v. administration owing to the saturation of an anionic renal transporter. In order to improve the drug administration, the PMPA was embedded into a new type of nanocarriers based on poly-(D,L-lactide-co-glycolide) (PLGA) and/or chitosan (CH). The strategies for the preparation of nanoparticles (Nps) with a more efficient drug loading respect to the one reported in the literature for PMPA nanoencapsulation were investigated. CH was added in the first inner emulsion or in the external phase during the second emulsion of water/oil/water (W/O/W) Nps. The addition of CH in the first inner emulsion was the most promising technique. The Nps have a Z-average of 230 nm, a Z-potential of -3 mV and an EE% of 15 that was 2.5-3 times higher than that obtained with PLGA Nps or CH Nps. In vitro release studies showed a limited control on drug release in phosphate buffer (pH 7.4) while an initial burst effect followed by a slow drug release was observed in acidic receiving phase (pH 4.6). These results suggest the PLGA/CH Nps should be an effective and attractive anti-HIV drug carrier to study the cellular uptake and drug delivery on target cells such as macrophages. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Belletti, Daniela; Tosi, Giovanni; Forni, Flavio; Vandelli, Maria Angela; Ruozi, Barbara] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, TE FAR TI Grp, I-41100 Modena, Italy.
   [Gamberini, Maria Cristina; Baraldi, Cecilia] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, Analyt Sect, I-41100 Modena, Italy.
RP Ruozi, B (reprint author), Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, TE FAR TI Grp, Via Campi 183, I-41100 Modena, Italy.
EM daniela.belletti@unimore.it; giovanni.tosi@unimore.it;
   flavio.forni@unimore.it; mariacristina.gamberini@unimore.it;
   cecilia.baraldi@unimore.it; mariaangela.vandelli@unimore.it;
   barbara.ruozi@unimore.it
RI Tosi, Giovanni/D-4547-2011; Forni, Flavio/D-5492-2015; Baraldi,
   Cecilia/D-3151-2015; Gamberini, Maria Cristina/D-3175-2015; Vandelli,
   Maria Angela/D-5497-2015; Ruozi, Barbara/D-5500-2015
OI Tosi, Giovanni/0000-0001-8318-667X; Forni, Flavio/0000-0001-5974-6286;
   Baraldi, Cecilia/0000-0003-3823-7823; Gamberini, Maria
   Cristina/0000-0002-7591-2886; Vandelli, Maria
   Angela/0000-0003-1462-8133; Ruozi, Barbara/0000-0002-2400-9910;
   Belletti, Daniela/0000-0003-2872-445X
CR Badiou S, 2006, J INFECTION, V52, P335, DOI 10.1016/j.jinf.2005.07.020
   BODMEIER R, 1987, PHARMACEUT RES, V4, P465, DOI 10.1023/A:1016419303727
   Chakravarthi SS, 2011, INT J PHARMACEUT, V409, P111, DOI 10.1016/j.ijpharm.2011.02.034
   Cicconi P, 2004, INT J ANTIMICROB AG, V24, P284, DOI 10.1016/j.ijantimicag.2004.04.005
   Cihlar T, 2001, NUCLEOS NUCLEOT NUCL, V20, P641, DOI 10.1081/NCN-100002341
   De Clercq Eric, 2003, Expert Rev Anti Infect Ther, V1, P21, DOI 10.1586/14787210.1.1.21
   FORNI F, 1990, INT J PHARM, V60, P83, DOI 10.1016/0378-5173(90)90293-D
   Fung HB, 2002, CLIN THER, V24, P1515, DOI 10.1016/S0149-2918(02)80058-3
   Gallant JE, 2003, CLIN INFECT DIS, V37, P944, DOI 10.1086/378068
   Ghaderi R, 1996, INT J PHARM, V141, P205, DOI 10.1016/0378-5173(96)04639-X
   Giola M, 2005, INT J INFECT DIS, V9, P228, DOI 10.1016/j.ijid.2004.09.010
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   JOSHI DP, 1979, ANAL CHIM ACTA, V104, P153, DOI 10.1016/S0003-2670(01)83825-3                                                   
   KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9
   Lim LY, 1997, DRUG DEV IND PHARM, V23, P981, DOI 10.3109/03639049709149150                                                       
   Malik Amyn, 2005, J Infect, V51, pE61, DOI 10.1016/j.jinf.2004.08.031
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Messai I, 2006, COLLOID SURFACE A, V278, P188, DOI 10.1016/j.colsurfa.2005.12.018
   Mundargi RC, 2008, CARBOHYD POLYM, V71, P42, DOI 10.1016/j.carbpol.2007.05.013
   Naik AB, 2010, J PHOTOCH PHOTOBIO A, V214, P145, DOI 10.1016/j.jphotochem.2010.06.018
   Papadimitriou S, 2008, CARBOHYD POLYM, V73, P44, DOI 10.1016/j.carbpol.2007.11.007
   PEPPAS NA, 1980, J MEMBRANE SCI, V7, P241, DOI 10.1016/S0376-7388(00)80471-8                                                   
   PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110
   PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6
   Qaqish RB, 1999, CARBOHYD POLYM, V38, P99, DOI 10.1016/S0144-8617(98)00109-X                                                   
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Rosca ID, 2004, J CONTROL RELEASE, V99, P271, DOI 10.1016/j.jconrel.2004.07.007
   Ruozi B, 2005, EUR J PHARM SCI, V25, P81, DOI 10.1016/j.ejps.2005.01.020
   Schooley RT, 2002, AIDS, V16, P1257, DOI 10.1097/00002030-200206140-00008
   SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398                                                          
   Tahara K, 2009, INT J PHARMACEUT, V382, P198, DOI 10.1016/j.ijpharm.2009.07.023
   Vey E, 2011, POLYM DEGRAD STABIL, V96, P1882, DOI 10.1016/j.polymdegradstab.2011.07.011
   Viread, 2011, TEN DIS FUM PACK INS
   Wainberg MA, 1999, ANTIVIR THER, V4, P87
   Williams John, 2006, J Infect, V52, pe107, DOI 10.1016/j.jinf.2005.07.014
   Wilson B, 2010, NANOMED-NANOTECHNOL, V6, P144, DOI 10.1016/j.nano.2009.04.001
   Yang R, 2009, INT J PHARMACEUT, V371, P142, DOI 10.1016/j.ijpharm.2008.12.007
   Zhang K, 2011, CARBOHYD POLYM, V83, P60, DOI 10.1016/j.carbpol.2010.07.021
   Zheng CH, 2004, BIOCHEM BIOPH RES CO, V323, P1321, DOI 10.1016/j.bbrc.2004.09.007
NR 40
TC 17
Z9 17
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 15
PY 2012
VL 436
IS 1-2
BP 753
EP 763
DI 10.1016/j.ijpharm.2012.07.070
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 003GS
UT WOS:000308597600083
PM 22884838
DA 2018-01-05
ER

PT J
AU Wilson, SM
   Schmutzler, BS
   Brittain, JM
   Dustrude, ET
   Ripsch, MS
   Pellman, JJ
   Yeum, TS
   Hurley, JH
   Hingtgen, CM
   White, FA
   Khanna, R
AF Wilson, Sarah M.
   Schmutzler, Brian S.
   Brittain, Joel M.
   Dustrude, Erik T.
   Ripsch, Matthew S.
   Pellman, Jessica J.
   Yeum, Tae-Sung
   Hurley, Joyce H.
   Hingtgen, Cynthia M.
   White, Fletcher A.
   Khanna, Rajesh
TI Inhibition of Transmitter Release and Attenuation of
   Anti-retroviral-associated and Tibial Nerve Injury-related Painful
   Peripheral Neuropathy by Novel Synthetic Ca2+ Channel Peptides
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GATED CALCIUM-CHANNELS; GENE-RELATED PEPTIDE; N-TYPE; MICROSCALE
   THERMOPHORESIS; SYNAPTIC-TRANSMISSION; BETA-SUBUNIT; KNEE-JOINT;
   PROTEIN; BINDING; NEURONS
AB N-type Ca2+ channels (CaV2.2) are a nidus for neurotransmitter release and nociceptive transmission. However, the use of CaV2.2 blockers in pain therapeutics is limited by side effects resulting from inhibition of the physiological functions of CaV2.2 within the CNS. We identified an anti-nociceptive peptide (Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L., Liu, N., Xiong, W., Ripsch, M. S., Wang, Y., Fehrenbacher, J. C., Fitz, S. D., Khanna, M., Park, C. K., Schmutzler, B. S., Cheon, B. M., Due, M. R., Brustovetsky, T., Ashpole, N. M., Hudmon, A., Meroueh, S. O., Hingtgen, C. M., Brustovetsky, N., Ji, R. R., Hurley, J. H., Jin, X., Shekhar, A., Xu, X. M., Oxford, G. S., Vasko, M. R., White, F. A., and Khanna, R. (2011) Suppression of inflammatory and neuropathic pain by uncoupling CRMP2 from the presynaptic Ca2+ channel complex. Nat. Med. 17, 822-829) derived from the axonal collapsin response mediator protein 2 (CRMP2), a protein known to bind and enhance CaV2.2 activity. Using a peptide tiling array, we identified novel peptides within the first intracellular loop (CaV2.2(388-402), "L1") and the distal C terminus (CaV1.2(2014-2028) "Ct-dis") that bound CRMP2. Microscale thermophoresis demonstrated micromolar and nanomolar binding affinities between recombinant CRMP2 and synthetic L1 and Ct-dis peptides, respectively. Co-immunoprecipitation experiments showed that CRMP2 association with CaV2.2 was inhibited by L1 and Ct-dis peptides. L1 and Ct-dis, rendered cell-penetrant by fusion with the protein transduction domain of the human immunodeficiency virus TAT protein, were tested in in vitro and in vivo experiments. Depolarization-induced calcium influx in dorsal root ganglion (DRG) neurons was inhibited by both peptides. Ct-dis, but not L1, peptide inhibited depolarization-stimulated release of the neuropeptide transmitter calcitonin gene-related peptide in mouse DRG neurons. Similar results were obtained in DRGs from mice with a heterozygous mutation of Nf1 linked to neurofibromatosis type 1. Ct-dis peptide, administered intraperitoneally, exhibited antinociception in a zalcitabine (2'-3'-dideoxycytidine) model of AIDS therapy-induced and tibial nerve injury-related peripheral neuropathy. This study suggests that CaV peptides, by perturbing interactions with the neuromodulator CRMP2, contribute to suppression of neuronal hypersensitivity and nociception.
C1 [Schmutzler, Brian S.; Pellman, Jessica J.; Hingtgen, Cynthia M.; Khanna, Rajesh] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Wilson, Sarah M.; Brittain, Joel M.; Dustrude, Erik T.; Hurley, Joyce H.; Hingtgen, Cynthia M.; White, Fletcher A.; Khanna, Rajesh] Indiana Univ Sch Med, Program Med Neurosci, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA.
   [Ripsch, Matthew S.; Yeum, Tae-Sung; White, Fletcher A.] Indiana Univ Sch Med, Dept Anesthesia, Indianapolis, IN 46202 USA.
   [Hurley, Joyce H.; Khanna, Rajesh] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Hingtgen, Cynthia M.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA.
   [Khanna, Rajesh] Sophia Therapeut LLC, Indianapolis, IN 46202 USA.
RP Khanna, R (reprint author), 950 W Walnut St,R2 Rm 478, Indianapolis, IN 46202 USA.
EM khanna5@iu.edu
RI White, Fletcher/F-3203-2015
OI White, Fletcher/0000-0002-8408-9262; Khanna, Rajesh/0000-0002-9066-2969
FU National Institutes of Health (NIH), NCRR of the Indiana Clinical and
   Translational Sciences Institute [RR025761]; NIH, NINDS [NS049136-06];
   NIH, NIDA [DA026040-04]; Indiana State Department of Health
   [A70-9-079138]; American Heart Association [SDG5280023]; Department of
   Defense [NF1000099]; Ralph W. and Grace M. Showalter Foundation; Indiana
   University Biomedical Committee [2286501]; Indiana Clinical and
   Translational Sciences Institute; Elwert Award in Medicine; Paul and
   Carole Stark Fellowship; Children's Tumor Foundation; Larry Kays Medical
   Neuroscience Fellowship
FX This work was supported, in whole or in part, by National Institutes of
   Health (NIH), NCRR, Project Development Team Grant RR025761 in support
   of the Indiana Clinical and Translational Sciences Institute (to R. K);
   NIH, NINDS, Grant NS049136-06 (to F. A. W.); and NIH, NIDA, Grant
   DA026040-04 (to F. A. W.). This work was also supported by a Clinical
   and Translational Sciences Award from the Indiana State Department of
   Health Spinal Cord and Brain Injury Fund (A70-9-079138 to R. K.),
   American Heart Association National Scientist Development Grant
   SDG5280023 (to R. K.), Department of Defense Congressionally Directed
   Military Medical Research and Development Program Neurofibromatosis New
   Investigator Award NF1000099 (to R. K.), a Ralph W. and Grace M.
   Showalter Foundation grant (to R. K.), Indiana University Biomedical
   Committee Research Support Funds Grant 2286501 (to R. K), a Research
   Inventions and Scientific Commercialization grant (to R. K.) from the
   Indiana Clinical and Translational Sciences Institute, and the Elwert
   Award in Medicine (to R. K.).; Supported in part by a Paul and Carole
   Stark Fellowship.; Supported by a Young Investigator's Award from the
   Children's Tumor Foundation.; Supported by a Larry Kays Medical
   Neuroscience Fellowship.
CR Almagor L, 2012, J NEUROSCI, V32, P7602, DOI 10.1523/JNEUROSCI.5727-11.2012
   Altier C, 2007, J NEUROSCI, V27, P6363, DOI 10.1523/JNEUROSCI.0307-07.2007
   Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8
   BOWERSOX SS, 1992, J CARDIOVASC PHARM, V20, P756, DOI 10.1097/00005344-199211000-00011
   Bowersox SS, 1996, J PHARMACOL EXP THER, V279, P1243
   Brittain JM, 2012, CHANNELS, V6, P94, DOI 10.4161/chan.19415
   Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455
   Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345
   Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951
   Bucci G, 2011, J PHYSIOL-LONDON, V589, P3085, DOI 10.1113/jphysiol.2010.204735
   Chan Allen W, 2007, Channels (Austin), V1, P11
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chen JJ, 1996, PEPTIDES, V17, P31, DOI 10.1016/0196-9781(95)02091-8
   Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821                                                              
   Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280
   Cizkova D, 2002, EXP BRAIN RES, V147, P456, DOI 10.1007/s00221-002-1217-3
   DeWaard M, 1997, NATURE, V385, P446
   DODGE FA, 1967, J PHYSIOL-LONDON, V189, pP90
   Favereaux A, 2011, EMBO J, V30, P3830, DOI 10.1038/emboj.2011.249
   Fossat P, 2010, J NEUROSCI, V30, P1073, DOI 10.1523/JNEUROSCI.3145-09.2010
   Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0
   Hingtgen CM, 2006, NEUROSCIENCE, V137, P637, DOI 10.1016/j.neuroscience.2005.09.030
   JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353
   Jimenez-Andrade JM, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-10
   Joseph EK, 2004, PAIN, V107, P147, DOI 10.1016/j.pain.2003.10.010
   Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838
   Li B, 2004, MOL PHARMACOL, V66, P761
   MALMBERG AB, 1994, J NEUROSCI, V14, P4882
   Manceur AP, 2009, MOL THER, V17, P500, DOI 10.1038/mt.2008.271
   Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453
   McGivern Joseph G, 2007, Neuropsychiatr Dis Treat, V3, P69, DOI 10.2147/nedt.2007.3.1.69
   Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3                                                   
   Neugebauer V, 1996, NEUROSCIENCE, V71, P1095, DOI 10.1016/0306-4522(95)00473-4
   Neugebauer V, 1996, J NEUROPHYSIOL, V76, P3740
   Patrakitkomjorn S, 2008, J BIOL CHEM, V283, P9399, DOI 10.1074/jbc.M708206200
   Pavlidis P, 2003, BIOINFORMATICS, V19, P295, DOI 10.1093/bioinformatics/19.2.295
   Piekarz AD, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-54
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0
   Ripsch MS, 2012, TRANSL NEUROSCI, V3, P1, DOI 10.2478/s13380-012-0002-4
   Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349
   Schmidtko A, 2010, LANCET, V375, P1569, DOI 10.1016/S0140-6736(10)60354-6
   SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0
   Sluka KA, 1997, PAIN, V71, P157, DOI 10.1016/S0304-3959(97)03354-X
   Snutch Terrance P, 2005, NeuroRx, V2, P662, DOI 10.1602/neurorx.2.4.662
   Souza AH, 2008, PAIN, V140, P115, DOI 10.1016/j.pain.2008.07.014
   Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200
   Tedford HW, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-6
   van den Bogaart G, 2012, J BIOL CHEM, V287, P16447, DOI 10.1074/jbc.M112.343418
   Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588
   Vanegas H, 2000, PAIN, V85, P9, DOI 10.1016/S0304-3959(99)00241-9                                                   
   Wang YY, 2010, TRANSL NEUROSCI, V1, P106, DOI 10.2478/v10134-010-0025-8
   Wang YY, 2011, TRANSL NEUROSCI, V2, P13, DOI 10.2478/s13380-011-0002-9
   Wang YY, 2011, ACS CHEM NEUROSCI, V2, P317, DOI 10.1021/cn200024z
   Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801
   White DM, 1998, BRAIN RES, V801, P50, DOI 10.1016/S0006-8993(98)00539-3
   Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093
   Wilson SM, 2011, CHANNELS, V5, P447, DOI 10.4161/chan.5.5.17363
   Winquist RJ, 2005, BIOCHEM PHARMACOL, V70, P489, DOI 10.1016/j.bcp.2005.04.035
   Zamponi GW, 2009, BRAIN RES REV, V60, P84, DOI 10.1016/j.brainresrev.2008.12.021
   Zillner K, 2012, METHODS MOL BIOL, V815, P241, DOI 10.1007/978-1-61779-424-7_18
NR 61
TC 25
Z9 26
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 12
PY 2012
VL 287
IS 42
BP 35065
EP 35077
DI 10.1074/jbc.M112.378695
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 022OF
UT WOS:000309968000018
PM 22891239
OA gold
DA 2018-01-05
ER

PT J
AU Chen, X
   Hong, CY
   Lin, YH
   Chen, JH
   Chen, GN
   Yang, HH
AF Chen, Xian
   Hong, Cheng-Yi
   Lin, Ya-Hui
   Chen, Jing-Hua
   Chen, Guo-Nan
   Yang, Huang-Hao
TI Enzyme-Free and Label-Free Ultrasensitive Electrochemical Detection of
   Human Immunodeficiency Virus DNA in Biological Samples Based on
   Long-Range Self-Assembled DNA Nanostructures
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID ROLLING-CIRCLE AMPLIFICATION; HYBRIDIZATION CHAIN-REACTION;
   SEQUENCE-SPECIFIC DETECTION; AMPLIFIED DETECTION; CHRONOCOULOMETRIC DNA;
   NUCLEIC-ACIDS; GOLD; BIOSENSORS; COMPLEX; SENSOR
AB Biosensors based on nanomaterials have been used for detection of various biological molecules with high sensitivity and selectivity. Herein, we developed a simple and ultrasensitive electrochemical DNA biosensor using long-range self-assembled DNA nanostructures as carriers for signal amplification, which can achieve an impressive detection limit of S aM human immunodeficiency virus (HIV) DNA even in complex biological samples. In this study, we designed two auxiliary probes. A cascade of hybridization events between the two auxiliary probes can lead to long-range self-assembly and form micrometer-long one-dimensional DNA nanostructures. In the presence of target DNA, each copy of the target can act as a trigger to connect a DNA nanostructure to a capture probe on the electrode surface. Then, a great amount of redox indicator [Ru(NH3)(6)](3+) can be electrostatically bound to the DNA nanostructures and eventually result in significantly amplified electrochemical signals.
C1 [Chen, Xian; Hong, Cheng-Yi; Lin, Ya-Hui; Chen, Jing-Hua; Chen, Guo-Nan; Yang, Huang-Hao] Fuzhou Univ, Coll Chem & Chem Engn, Key Lab Anal & Detect Technol Food Safety MOE, Fujian Prov Key Lab Anal & Detect Technol Food Sa, Fuzhou 350108, Peoples R China.
   [Chen, Jing-Hua] Fujian Med Univ, Fac Pharm, Dept Pharmaceut Anal, Fuzhou 350004, Peoples R China.
RP Chen, JH (reprint author), Fuzhou Univ, Coll Chem & Chem Engn, Key Lab Anal & Detect Technol Food Safety MOE, Fujian Prov Key Lab Anal & Detect Technol Food Sa, Fuzhou 350108, Peoples R China.
EM cjh_huaxue@126.com; hhyang@fio.org.cn
FU National Basic Research Program of China [2010CB732403]; National
   Natural Science Foundation of China [21125524, 21105012]; Program for
   New Century Excellent Talents in University of China [09-0014]; Program
   for Changjiang Scholars and Innovative Research Team in University
   [IRT1116]; National Science Foundation of Fujian Province [2010J06003]
FX The authors gratefully acknowledge the financial support from the
   National Basic Research Program of China (No. 2010CB732403), the
   National Natural Science Foundation of China (No. 21125524, No.
   21105012), the Program for New Century Excellent Talents in University
   of China (09-0014), the Program for Changjiang Scholars and Innovative
   Research Team in University (No. IRT1116), and the National Science
   Foundation of Fujian Province (No. 2010J06003).
CR Beyer S, 2005, NANO LETT, V5, P719, DOI 10.1021/nl050155a
   Chen JH, 2010, CHEM COMMUN, V46, P5939, DOI 10.1039/c0cc00748j
   Chen X, 2011, CHEM COMMUN, V47, P12116, DOI 10.1039/c1cc15695k
   Cheng YQ, 2009, ANGEW CHEM INT EDIT, V48, P3268, DOI 10.1002/anie.200805665
   Christian AT, 2001, P NATL ACAD SCI USA, V98, P14238, DOI 10.1073/pnas.251383598                                                          
   COMPTON J, 1991, NATURE, V350, P91, DOI 10.1038/350091a0
   Cui DX, 2008, ANAL CHEM, V80, P7996, DOI 10.1021/ac800992m
   Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Hu KC, 2008, ANAL CHEM, V80, P9124, DOI 10.1021/ac8017197
   Huang J, 2011, ANGEW CHEM INT EDIT, V50, P401, DOI 10.1002/anie.201005375
   Huang Y, 2009, J AM CHEM SOC, V131, P2478, DOI 10.1021/ja808700d
   Lao RJ, 2005, ANAL CHEM, V77, P6475, DOI 10.1021/ac050911x
   Lepage PH, 2011, ANAL CHEM, V83, P8086, DOI 10.1021/ac200713f
   Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u
   Li H, 2010, ANAL CHEM, V82, P5477, DOI 10.1021/ac101193e
   Li JS, 2010, ANAL CHEM, V82, P2811, DOI 10.1021/ac100336n
   Li J, 2012, BIOSENS BIOELECTRON, V36, P142, DOI 10.1016/j.bios.2012.04.003
   Liu DS, 2011, NPG ASIA MATER, V3, P109, DOI 10.1038/asiamat.2011.147
   Lu CH, 2011, ANAL CHEM, V83, P7276, DOI 10.1021/ac200617k
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Lubin AA, 2010, ACCOUNTS CHEM RES, V43, P496, DOI 10.1021/ar900165x
   Niazov T, 2004, NANO LETT, V4, P1683, DOI 10.1021/nl0491428
   Pei H, 2010, ADV MATER, V22, P4754, DOI 10.1002/adma.201002767
   Peng YF, 2011, ANAL CHEM, V83, P820, DOI 10.1021/ac102370s
   Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/NNANO.2011.187, 10.1038/nnano.2011.187]
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SEEMAN NC, 1982, J THEOR BIOL, V99, P237, DOI 10.1016/0022-5193(82)90002-9
   Seeman NC, 2005, TRENDS BIOCHEM SCI, V30, P119, DOI 10.1016/j.tibs.2005.01.007
   Shimron S, 2012, ANAL CHEM, V84, P1042, DOI 10.1021/ac202643y
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Teller C, 2010, TRENDS BIOTECHNOL, V28, P619, DOI 10.1016/j.tibtech.2010.09.005
   Wanekaya AK, 2006, ELECTROANAL, V18, P533, DOI 10.1002/elan.200503449
   Wang F, 2011, J AM CHEM SOC, V133, P17149, DOI 10.1021/ja2076789
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Wu J, 2010, ANAL CHEM, V82, P8830, DOI 10.1021/ac101474k
   Xia F, 2010, J AM CHEM SOC, V132, P14346, DOI 10.1021/ja104998m
   Xiao Y, 2007, NAT PROTOC, V2, P2875, DOI 10.1038/nprot.2007.413
   Xiao Y, 2009, J AM CHEM SOC, V131, P15311, DOI 10.1021/ja905068s
   Yin BC, 2012, CHEM COMMUN, V48, P4208, DOI 10.1039/c2cc30997a
   Yin BC, 2010, ANAL CHEM, V82, P8272, DOI 10.1021/ac101761q
   Zhang J, 2007, NAT PROTOC, V2, P2888, DOI 10.1038/nprot.2007.419
   Zhang J, 2006, J AM CHEM SOC, V128, P8575, DOI 10.1021/ja061521a
   Zhang YL, 2009, ANAL CHEM, V81, P1982, DOI 10.1021/ac802512d
   Zhao WA, 2006, ANGEW CHEM INT EDIT, V45, P2409, DOI 10.1002/anie.2006000061
   Zhou M, 2011, ACCOUNTS CHEM RES, V44, P1232, DOI 10.1021/ar200096g
NR 46
TC 91
Z9 92
U1 6
U2 196
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 2
PY 2012
VL 84
IS 19
BP 8277
EP 8283
DI 10.1021/ac3017828
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 016BV
UT WOS:000309493200030
PM 22950631
DA 2018-01-05
ER

PT J
AU Fitzgerald, W
   Grivel, JC
AF Fitzgerald, W.
   Grivel, J. -C.
TI A universal nanoparticle cell secretion capture assay for the study of
   HIV-1-positive tissues
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Fitzgerald, W.; Grivel, J. -C.] NICHD, NIH, Bethesda, MD USA.
EM grivelj@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 32
EP 32
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200075
DA 2018-01-05
ER

PT J
AU Cruz, LJ
   Rueda, F
   Tacken, P
   Albericio, F
   Torensma, R
   Figdor, CG
AF Cruz, Luis J.
   Rueda, Felix
   Tacken, Paul
   Albericio, Fernando
   Torensma, Ruurd
   Figdor, Carl G.
TI Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in
   vivo targeting to dendritic cells
SO NANOMEDICINE
LA English
DT Review
DE carrier conjugates; cross-reactivity; delivery vehicle; HIV-1;
   immunogenicity; nanoparticle; specific ligands; synthetic peptide
   vaccines; targeting; V3 loop
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REGULATORY T-CELLS; MHC CLASS-I; ACTIVE
   ANTIRETROVIRAL THERAPY; TOLL-LIKE RECEPTORS; PBL-SCID MICE; DC-SIGN;
   IMMUNE-RESPONSES; HIV-1-INFECTED PATIENTS; DISEASE PROGRESSION
AB Current retroviral treatments have reduced AIDS to a chronic disease for most patients. However, given drug-related side effects, the emergence of drug-resistant strains and the persistence of viral replication, the development of alternative treatments is a pressing need. This review focuses on recent developments in HIV immunotherapy treatments, with particular emphasis on current vaccination strategies for optimizing the induction of an effective immune response by the recruitment of dendritic cells. In addition to cell-based therapies, targeted strategies aiming to deliver synthetic HIV peptides to dendritic cell-specific receptors in vivo will be discussed.
C1 Radboud Univ Nijmegen, Dept Tumor Immunol, Nijmegen Ctr Mol Life Sci, Ctr Med, NL-6525 ED Nijmegen, Netherlands.
   Networking Ctr Bioengn Biomat & ManoMed, Inst Res Biomed & CIBER BBN, Barcelona 08028, Spain.
   Univ Kwazulu Natal, Sch Chem, ZA-4041 Durban, South Africa.
   Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain.
RP Cruz, LJ (reprint author), Radboud Univ Nijmegen, Dept Tumor Immunol, Nijmegen Ctr Mol Life Sci, Ctr Med, NL-6525 ED Nijmegen, Netherlands.
RI Figdor, Carl/A-4232-2010; Torensma, Ruurd/H-3830-2015
OI Torensma, Ruurd/0000-0002-0143-5626; Albericio,
   Fernando/0000-0002-8946-0462; Torensma, Ruurd/0000-0002-0555-7903;
   Figdor, Carl/0000-0002-2366-9212
CR Abdel-Motal UM, 2009, VACCINE, V27, P3072, DOI 10.1016/j.vaccine.2009.03.019
   Alexaki A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000215
   Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010
   Andre F, 2004, J IMMUNOL, V172, P2126, DOI 10.4049/jimmunol.172.4.2126                                                     
   Andrieu JM, 2007, J INTERN MED, V261, P123, DOI 10.1111/j.1365-2796.2006.01738.x
   Angin M, 2012, J INFECT DIS, V205, P1495, DOI 10.1093/infdis/jis236
   Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C                     
   Barouch DH, 2010, NAT MED, V16, P319, DOI 10.1038/nm.2089
   Berzofsky JA, 2004, J CLIN INVEST, V114, P450, DOI 10.1172/JCI200422674
   BERZOFSKY JA, 1991, FASEB J, V5, P2412
   Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Bozzacco L, 2010, EUR J IMMUNOL, V40, P36, DOI 10.1002/eji.200939748
   Brave A, 2009, VACCINE, V27, P184, DOI 10.1016/j.vaccine.2008.10.041
   Breckpot K, 2010, J VIROL, V84, P5627, DOI 10.1128/JVI.00014-10
   Brown K, 2003, J IMMUNOL, V171, P6875, DOI 10.4049/jimmunol.171.12.6875                                                    
   Chaput N, 2005, EXPERT OPIN BIOL TH, V5, P737, DOI 10.1517/14712598.5.6.737
   Coren LV, 2008, RETROVIROLOGY, V16, P50
   Cruz LJ, 2004, BIOCONJUGATE CHEM, V15, P1110, DOI 10.1021/bc049944u
   Cruz LJ, 2004, BIOCONJUGATE CHEM, V15, P112, DOI 10.1021/bc034119j
   Cruz LJ, 2001, J PEPT SCI, V7, P511, DOI 10.1002/psc.336                                                                 
   CRUZ LJ, 2001, LETT PEPT SCI, V7, P229
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Cruz LJ, 2009, INT IMMUNOPHARMACOL, V9, P1452, DOI 10.1016/j.intimp.2009.08.026
   Cruz Luis J., 2000, Biotecnologia Aplicada, V17, P35
   Datta SAK, 2011, J VIROL, V85, P4111, DOI 10.1128/JVI.00006-11
   De Haes W, 2010, MOL THER, V18, P1408, DOI 10.1038/mt.2010.82
   De Keersmaecker B, 2011, J LEUKOCYTE BIOL, V89, P989, DOI 10.1189/jlb.0810466
   de Souza MS, 2012, J IMMUNOL, V188, P5166, DOI 10.4049/jimmunol.1102756
   Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6                                                   
   Dittmer U, 2008, VIRAL IMMUNOL, V21, P459, DOI 10.1089/vim.2008.0046
   Domingo P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013896
   Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.14053
   Duval M, 2008, J VIROL, V82, P4671, DOI 10.1128/JVI.02499-07
   Egan MA, 2004, AIDS RES HUM RETROV, V20, P794, DOI 10.1089/0889222041725244
   Elahi S, 2011, NAT MED, V17, P989, DOI 10.1038/nm.2422
   Equils O, 2003, J IMMUNOL, V170, P5159, DOI 10.4049/jimmunol.170.10.5159                                                    
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Fanales-Belasio E, 2002, DNA CELL BIOL, V21, P599, DOI 10.1089/104454902760330138                                                      
   Fantuzzi L, 2004, J VIROL, V78, P9763, DOI 10.1128/JVI.78.18.9763-9772.2004
   Flamar A, 2009, RETROVIROLOGY S3, V6, P286
   Forthal DN, 2007, J IMMUNOL, V178, P6596, DOI 10.4049/jimmunol.178.10.6596                                                    
   Foxall RB, 2011, AIDS, V25, P1961, DOI 10.1097/QAD.0b013e32834b3554
   Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618
   French MA, 2010, AIDS, V24, P1983, DOI 10.1097/QAD.0b013e32833c1ce0
   Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200
   Garcia F, 2011, VACCINE, V29, P6454, DOI 10.1016/j.vaccine.2011.07.043
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838                                                     
   Gieseler RK, 2004, SCAND J IMMUNOL, V59, P415, DOI 10.1111/j.0300-9475.2004.01431.x                                                
   Gilbert PB, 2005, J INFECT DIS, V191, P666, DOI 10.1086/428405
   Gilboa E, 2004, IMMUNOL REV, V199, P251, DOI 10.1111/j.0105-2896.2004.00139.x                                                
   Goldstein G, 2010, VACCINE, V28, P1008, DOI 10.1016/j.vaccine.2009.10.129
   GrasMasse H, 1997, VACCINE, V15, P1568, DOI 10.1016/S0264-410X(97)00079-0                                                   
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778
   Grousson J, 1998, CELL BIOL TOXICOL, V14, P345, DOI 10.1023/A:1007585707853
   Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0
   Hart M K, 1995, Pharm Biotechnol, V6, P821
   Hattori Y, 2004, BIOCHEM BIOPH RES CO, V317, P992, DOI 10.1016/j.bbrc.2004.03.141
   Haynes BF, 2011, TRENDS MOL MED, V17, P108, DOI 10.1016/j.molmed.2010.10.008
   He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259                                                    
   Hedley SJ, 2006, GENE THER, V13, P88, DOI 10.1038/sj.gt.3302603
   Huang XL, 2003, J INFECT DIS, V187, P315, DOI 10.1086/346054
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108
   Iglesias E, 2005, MOL IMMUNOL, V42, P99, DOI 10.1016/j.molimm.2004.06.038
   Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822
   Jacobs JFM, 2007, BIOL DENDRITIC CELLS
   Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751
   Jin HT, 2011, BMB REP, V44, P217, DOI 10.5483/BMBRep.2011.44.4.217
   Jin X, 2009, VACCINE, V27, P7080, DOI 10.1016/j.vaccine.2009.09.060
   Joffre OP, 2010, EUR J IMMUNOL, V40, P1255, DOI 10.1002/eji.201040419
   Jones T, 2010, CURR OPIN INVEST DR, V11, P964
   Joshi MD, 2011, INT J PHARMACEUT, V416, P426, DOI 10.1016/j.ijpharm.2011.02.055
   Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199
   Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338
   Kappes John C., 2001, Somatic Cell and Molecular Genetics, V26, P147, DOI 10.1023/A:1021082815013
   Kasper MR, 2003, J VIROL, V77, P3041, DOI 10.1128/JVI.77.5.3041-3049.2003
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Korokhov N, 2005, CANCER BIOL THER, V4, P239
   Lapenta C, 2003, J EXP MED, V198, P361, DOI 10.1081/jem.20021924
   Leitner T., 1996, HUMAN RETROVIRUS AID, P11128
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Levy Y, 2005, AIDS, V19, P279
   Li M, 2012, PROTEOMICS, V12, P2203, DOI 10.1002/pmic.201100376
   Li W, 2011, J VIROL, V85, P13342, DOI 10.1128/JVI.00120-11
   Li XB, 2005, ARCH IMMUNOL THER EX, V53, P329
   Liu GW, 2007, IMMUNOLOGY, V122, P149, DOI 10.1111/j.1365-2567.2007.02651.x                                                
   Loof N, 2009, RETROVIROLOGY S3, V6, P046
   Lu L, 2008, VACCINE, V26, P845, DOI 10.1016/j.vaccine.2007.11.022
   Lu S, 2008, HUM VACCINES, V4, P449, DOI 10.4161/hv.4.6.6179                                                             
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806
   Macatangay Bernard J. C., 2010, HIV Therapy, V4, P639, DOI 10.2217/HIV.10.51
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martinon F, 2009, RETROVIROLOGY S3, V6, P346
   Mendez-Lagares G, 2012, J INFECT DIS, V205, P1501, DOI 10.1093/infdis/jis230
   Mitchell DA, 2000, J CLIN INVEST, V106, P1065, DOI 10.1172/JCI11405                                                                
   Montefiori DC, 2012, J INFECT DIS, V206, P431, DOI 10.1093/infdis/jis367
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12
   Moreno-Fernandez ME, 2011, BLOOD, V117, P5372, DOI 10.1182/blood-2010-12-323162
   Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532
   Moron G, 2004, TRENDS IMMUNOL, V25, P92, DOI 10.1016/j.it.2003.11.008
   Nanjundappa RH, 2011, VACCINE, V29, P3538, DOI 10.1016/j.vaccine.2011.02.095
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477                                                    
   Ortiz-Stern A, 2003, IMMUNOL LETT, V90, P137, DOI 10.1016/j.imlet.2003.09.004
   Palmisano L, 2011, ANN I SUPER SANITA, V47, P44, DOI 10.4415/ANN_11_01_10
   Pantophlet R, 2008, VIROLOGY, V381, P251, DOI 10.1016/j.virol.2008.08.032
   Pasquier B, 2005, IMMUNITY, V22, P31, DOI 10.1016/j.immuni.2004.11.017
   Patham B, 2011, CURR MED CHEM, V18, P3987, DOI 10.2174/092986711796957194                                                      
   Perez LG, 2009, J VIROL, V83, P7397, DOI 10.1128/JVI.00656-09
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Presicce P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028118
   Presicce P, 2012, AIDS, V26, P263, DOI 10.1097/QAD.0b013e32834ed8df
   Qin XL, 2011, J CELL BIOCHEM, V112, P3515, DOI 10.1002/jcb.23318
   Rapaka RR, 2007, J IMMUNOL, V178, P3702, DOI 10.4049/jimmunol.178.6.3702                                                     
   RESNICK DA, 1995, J VIROL, V69, P2406
   Rinaldo CR, 2008, J INT MED, V265, P138
   Rios Cesar Mauricio Rueda, 2012, Open Virol J, V6, P49, DOI 10.2174/1874357901206010049
   Romain G, 2012, EUR J IMMUNOL, V42, P2019, DOI 10.1002/eji.201242478
   Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2                                                   
   Rosenberg ES, 2010, PLOS ONE, V5
   RUBINSTEIN A, 1995, AIDS, V9, P243
   Rudolf MP, 2001, J IMMUNOL, V166, P5917, DOI 10.4049/jimmunol.166.10.5917                                                    
   Salmon-Ceron D, 2010, AIDS, V24, P2211, DOI 10.1097/QAD.0b013e32833ce566
   Schilling R, 2006, VACCINE, V24, P4648, DOI 10.1016/j.vaccine.2005.08.050
   Schlosser E, 2008, VACCINE, V26, P1626, DOI 10.1016/j.vaccine.2008.01.030
   Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240                                                     
   Serre K, 2003, METHOD ENZYMOL, V373, P100
   Smith AD, 1998, J VIROL, V72, P651
   Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445
   Spaner DE, 2007, LEUKEMIA, V21, P53, DOI 10.1038/sj.leu.2404456
   Spearman P, 2009, VACCINE, V27, P243, DOI 10.1016/j.vaccine.2008.10.051
   Steinman RM, 2005, ADV EXP MED BIOL, V560, P83
   Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Tacken PJ, 2006, IMMUNOBIOLOGY, V211, P599, DOI 10.1016/j.imbio.2006.05.021
   Tacken PJ, 2011, BLOOD, V118, P6836, DOI 10.1182/blood-2011-07-367615
   Tacken PJ, 2011, SEMIN IMMUNOL, V23, P12, DOI 10.1016/j.smim.2011.01.001
   Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318
   Tang J, 2011, VACCINE, V30, P1071
   Tanzi E, 2006, J MED VIROL, V78, P440, DOI 10.1002/jmv.20559
   Thammavongsa V, 2009, IMMUNOGENETICS, V61, P703, DOI 10.1007/s00251-009-0399-2
   Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046
   Tillman BW, 2000, CANCER RES, V60, P5456
   Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6
   Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317                                                           
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   Vollbrecht T, 2012, AIDS, V26, pF31, DOI 10.1097/QAD.0b013e328354b43f
   Wallace PK, 2001, J IMMUNOL METHODS, V248, P183, DOI 10.1016/S0022-1759(00)00351-3
   Wang XC, 2008, EUR J IMMUNOL, V38, P3226, DOI 10.1002/eji.200838285
   Weiss L, 2010, P NATL ACAD SCI USA, V107, P10632, DOI 10.1073/pnas.1000027107
   Whiteside TL, 2009, CLIN VACCINE IMMUNOL, V16, P233, DOI 10.1128/CVI.00066-08
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   Wingard JB, 2008, EUR J IMMUNOL, V38, P1310, DOI 10.1002/eji.200738069
   Wu L, 2006, VACCINE, V24, P4995, DOI 10.1016/j.vaccine.2006.03.083
   Xin KQ, 2003, BLOOD, V102, P223, DOI 10.1182/blood-2003-01-0110
   Xu HB, 2010, J IMMUNOL, V185, P7340, DOI 10.4049/jimmunol.1001642
   Yamanaka T, 1997, AIDS RES HUM RETROV, V13, P317, DOI 10.1089/aid.1997.13.317
   Yang L, 2008, NAT BIOTECHNOL, V26, P326, DOI 10.1038/nbt1390
   Yang OO, 2002, J VIROL, V76, P1626, DOI 10.1128/JVI.76.4.1626-1631.2002
   Yoshida A, 2003, J VIROL, V77, P8719, DOI 10.1128/JVI.77.16.8719-8728.2003
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037966
   Zhang MY, 2008, J VIROL, V82, P6869, DOI 10.1128/JVI.00033-08
   Zhou YL, 2002, J IMMUNOTHER, V25, P289, DOI 10.1097/01.CJI.0000018683.88942.4B
   zur Wiesch JS, 2011, J VIROL, V85, P1287, DOI 10.1128/JVI.01758-10
NR 169
TC 3
Z9 3
U1 0
U2 28
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD OCT
PY 2012
VL 7
IS 10
BP 1591
EP 1610
DI 10.2217/NNM.12.131
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 028LU
UT WOS:000310424600020
PM 23148541
DA 2018-01-05
ER

PT J
AU Briz, V
   Serramia, MJ
   Madrid, R
   Hameau, A
   Caminade, AM
   Majoral, JP
   Munoz-Fernandez, MA
AF Briz, V.
   Serramia, M. J.
   Madrid, R.
   Hameau, A.
   Caminade, Anne-Marie
   Majoral, J. P.
   Munoz-Fernandez, M. A.
TI Validation of a Generation 4 Phosphorus-Containing Polycationic
   Dendrimer for Gene Delivery Against HIV-1
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Nanomedicine; phosphorus dendrimer; HIV; oligodeoxynucleotides; siRNA
   and gene therapy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL INTERFERING RNA; HUMAN T-CELLS;
   CARBOSILANE DENDRIMERS; SIRNA DELIVERY; OLIGONUCLEOTIDES; REPLICATION;
   INFECTION; PROTEINS; SEQUENCE
AB Gene therapy, in which oligomeric genetic material is carried into cells by nano-sized gene delivery vehicles to interfere with gene expression, represents a promising approach for preventive therapy against HIV/AIDS pandemic. Herein, we evaluate the usefulness of a phosphorus-containing dendrimer G(4)(NH+Et2Cl-)(96) as a delivery agent of ODNs and siRNAs. G4(NH+Et2Cl-)(96) formed stable complexes with ODNs or siRNAs and exhibited very low cytotoxicity in Sup T1 cells or PBMC. Functional validation was performed by using specific siRNA against HIV-1 Nef, siNEF to interfere in HIV-1 replication. G(4)(NH+Et2Cl-)(96)/siNEF dendriplex showed a high efficiency in Nef silencing. Furthermore, in vitro treatment of HIV-infected PBMC with G(4)(NH(+)Et2Cl(-))(96)/siNEF dendriplex significantly reduced the viral replication. Our results prove the usefulness of phosphorus-containing dendrimers to deliver and transfect siRNA into CD4-T cells as a potential alternative therapy in the HIV-1 infection.
C1 [Briz, V.; Serramia, M. J.; Madrid, R.; Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, IiSGM, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Hameau, A.; Caminade, Anne-Marie; Majoral, J. P.] CNRS, Chim Coordinat Lab, F-31077 Toulouse 04, France.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, IiSGM, Lab Inmunobiol Mol, C Doctor Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@salud.madrid.org
RI Caminade, Anne-Marie/E-2819-2015
OI Caminade, Anne-Marie/0000-0001-8487-3578;
   Munoz-Fernandez/0000-0002-0813-4500; Madrid Gonzalez,
   Ricardo/0000-0002-1350-9864
FU Red Tematica de Investigacion Cooperativa Sanitaria ISCIII [RED RIS
   RD06/0006/0035]; Fondo de Investigacion Sanitaria (INTRASALUD)
   [PI09/02029, PS09102669]; INDISNET [S-2011-BMD2332]; MAMF [FIPSE
   240800/09]; Sara Borrell FIS program [CD09/00433]; CNRS; MNT ERA-Net
   [NAN2007-31198-E, NAN2007-31135-E]
FX This work was supported in part by grants from Red Tematica de
   Investigacion Cooperativa Sanitaria ISCIII (RED RIS RD06/0006/0035);
   Fondo de Investigacion Sanitaria (INTRASALUD 2009; PI09/02029;
   PS09102669); INDISNET S-2011-BMD2332; FIPSE 240800/09 by MAMF; V. B is
   supported by Sara Borrell FIS program (CD09/00433). A. H. A.-M. C. and
   J.P. M. thank the CNRS for financial support as well MNT ERA-Net:
   NAN2007-31198-E, NAN2007-31135-E EuroNanoMed, DENPEPTHIV; and COST
   action: TD0802 both groups.
CR Blais JC, 2000, ANAL CHEM, V72, P5097, DOI 10.1021/ac0003854
   CHESEBRO B, 1992, J VIROL, V66, P6547
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hernandez-Lopez JL, 2008, THIN SOLID FILMS, V516, P1256, DOI 10.1016/j.tsf.2007.05.049
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Krishna TR, 2006, ANGEW CHEM INT EDIT, V45, P4645, DOI 10.1002/anie.200601246
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Maksimenko AV, 2003, J GENE MED, V5, P61, DOI 10.1002/jgm.319
   Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104
   Pushker R, 2010, J VIROL, V84, P3644, DOI 10.1128/JVI.01959-09
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Richter SN, 2009, CURR MED CHEM, V16, P267, DOI 10.2174/092986709787002646                                                      
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Slany M, 1996, TETRAHEDRON LETT, V37, P9053, DOI 10.1016/S0040-4039(96)02123-5                                                   
   Slany M, 1997, INORG CHEM, V36, P1939, DOI 10.1021/ic961258m                                                               
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   Turner JJ, 2006, BBA-BIOMEMBRANES, V1758, P290, DOI 10.1016/j.bbamem.2005.10.013
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Weber ND, 2012, J CONTROL RELEASE, V157, P55, DOI 10.1016/j.jconrel.2011.09.059
   Yin JY, 2006, J IMMUNOL METHODS, V312, P1, DOI 10.1016/j.jim.2006.01.023
NR 28
TC 24
Z9 24
U1 1
U2 31
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD OCT
PY 2012
VL 19
IS 29
BP 5044
EP 5051
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 022QR
UT WOS:000309976900014
PM 22963636
DA 2018-01-05
ER

PT J
AU de las Cuevas, N
   Garcia-Gallego, S
   Rasines, B
   de la Mata, FJ
   Guijarro, LG
   Munoz-Fernandez, MA
   Gomez, R
AF de las Cuevas, N.
   Garcia-Gallego, S.
   Rasines, B.
   de la Mata, F. J.
   Guijarro, L. G.
   Munoz-Fernandez, M. A.
   Gomez, R.
TI In Vitro Studies of Water-Stable Cationic Carbosilane Dendrimers As
   Delivery Vehicles for Gene Therapy Against HIV and Hepatocarcinoma
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Dendrimer; carbosilane; oligonucleotides; siRNA; drug delivery; gene
   therapy; transfection agent; HIV; cancer
ID PHOSPHORUS-CONTAINING DENDRIMERS; INSULIN-RECEPTOR SUBSTRATE-4;
   DENDRITIC MACROMOLECULES; DRUG-DELIVERY; ANTISENSE OLIGONUCLEOTIDES;
   BIOCOMPATIBILITY; POLYMERS; ORGANOSILICON; GLYCEROL; CARRIERS
AB Here we present a synthetic procedure for water-stable carbosilane dendrimers containing ammonium groups at the periphery of type Gn-{[Si(CH2)(3)N+(Me)(Et)CH2CH2N+Me3](x) (CF3SO3-)(y)} which have been used as non-viral vectors for transfecting different types of nucleic acids against two different medical problems, HIV and hepatocarcinoma. These systems have shown to be non-toxic in both PBMC and HepG2 cell lines under the experimental conditions and are able to form nanoconjugates with nucleic acids perfectly stable over time and in a wide range of pH values, which leads to the conclusion that the interaction between dendrimer and nucleic acid is very strong. In addition, a high degree of transfection using these nanoconjugates has been observed, ranging from 70-90% depending on the generation and in the particular case of PBMC transfection with anti-HIV oligonucleotides. However, besides of the good properties shown by the dendrimers here prepared as transfecting agents, only moderate effect was observed in functional experiments for hepatocarcinoma, as a result of the strong interaction between dendrimer and nucleic acid. Nevertheless, it is important to mention that an IRS-4 knock-down of 40% in HepG2 achieves an analogous degree of cell sensitization to cancer treatment, which may represent a major advance in the hepatocarcinoma treatment when appropriate dendrimers as transfection agents are used.
C1 [Guijarro, L. G.] Univ Alcala de Henares, Dept Bioquim & Biol Mol, E-28871 Alcala De Henares, Spain.
   [de las Cuevas, N.; Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid, Spain.
   [Garcia-Gallego, S.; Rasines, B.; de la Mata, F. J.; Guijarro, L. G.; Gomez, R.] Univ Alcala de Henares, Dept Quim Inorgan, E-28871 Alcala De Henares, Spain.
RP Guijarro, LG (reprint author), Univ Alcala de Henares, Dept Quim Inorgan, Campus Univ,Edificio Farm, E-28871 Alcala De Henares, Spain.
EM rafael.gomez@uah.es
RI Gomez Ramirez, Rafael/K-1216-2014; De la Mata, F. Javier/K-1649-2014;
   Rasines, Beatriz/H-4309-2015
OI Gomez Ramirez, Rafael/0000-0001-6448-2414; De la Mata, F.
   Javier/0000-0003-0418-3935; Garcia Gallego, Sandra/0000-0001-6112-0450;
   Munoz-Fernandez/0000-0002-0813-4500
FU Fondos de Investigacion Sanitaria (FIS) of Ministerio de Sanidad y
   Consumo [PI061479]; Red RIS [RD06-0006-0035]; FIPSE [24632/07]; MNT-ERA
   NET [NAN2007-31198-E, NAN2007-31135-E]; Fundacion Caja Navarra and
   Comunidad de Madrid [S-SAL-0159-2006]; Fondos de Investigacion Sanitaria
   (FIS) [PI080222]; NANODENDMED [S2011/BMD2351]; CIBER-BBN; VI National R
   D i Plan; Iniciativa Ingenio; Consolider Program; CIBER Actions;
   Instituto de Salud Carlos III; European Regional Development Fund;
   Consejer a de Educacion de la Comunidad de Madrid; Fondo Social Europeo;
    [SAF 2008-05355];  [CCG07-UAH/BIO-2085];  [S2010/BMD-2423]
FX This work has been supported by grants from Fondos de Investigacion
   Sanitaria (FIS) of Ministerio de Sanidad y Consumo (PI061479), Red RIS
   RD06-0006-0035, FIPSE (24632/07), MNT-ERA NET 2007 (NAN2007-31198-E),
   Fundacion Caja Navarra and Comunidad de Madrid (S-SAL-0159-2006) to M.
   A. M.-F.. MNT-ERA NET 2007 (NAN2007-31135-E), Fondos de Investigacion
   Sanitaria (FIS) (PI080222) and NANODENDMED S2011/BMD2351(CM) to
   Universidad de Alcala. It has also been supported by CIBER-BBN as an
   initiative funded by VI National R & D & i Plan 2008-2011, Iniciativa
   Ingenio 2010, Consolider Program, CIBER Actions and financed by the
   Instituto de Salud Carlos III with assistance from the European Regional
   Development Fund. Also, we thank Dr. Santiago Ropero, Dr. Miguel Angel
   Lasuncion, Dr. Pilar Sancho, and Dr. M<SUP>a</SUP> Jose Carmena, for
   kindly providing us with some cell lines. This work was supported by
   grants from the Consejer a de Educacion de la Comunidad de Madrid and
   Fondo Social Europeo (F. S. E.). Further support was given by SAF
   2008-05355, CCG07-UAH/BIO-2085 and S2010/BMD-2423.
CR Berh J.P., 1993, ACCOUNTS CHEM RES, V26, P274
   Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Boysen MMK, 2003, EUR J ORG CHEM, P4376, DOI 10.1002/ejoc.200300413
   Caminade AM, 2005, PROG POLYM SCI, V30, P491, DOI 10.1016/j.progpolymsci.2005.01.001
   Carter B.J., 1998, VIRAL VECTORS GENE A, V5a, P397
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Crooke S T, 1997, Adv Pharmacol, V40, P1, DOI 10.1016/S1054-3589(08)60136-2
   Cuadrado I, 1999, ADV DENDR MACROMOL, V3, P151
   Cuevas EP, 2007, J HEPATOL, V46, P1089, DOI 10.1016/j.jhep.2007.01.031
   Cuevas EP, 2009, J CELL BIOCHEM, V108, P1292, DOI 10.1002/jcb.22359
   Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245
   Estefand R., 2001, DRUG DISCOV TODAY, V6, P427
   Frechet J. M. J., 2002, DENDRIMERS OTHER DEN
   Frey H., 2002, REV MOL BIOTECHNOL, V90, P257, DOI DOI 10.1016/S1389-0352(01)00063-0
   Fuchs S, 2004, CHEM-EUR J, V10, P1167, DOI 10.1002/chem.200305386
   Garcia-Merino I., 2009, RETROVIROLOGY, P6
   Haag R, 2000, J AM CHEM SOC, V122, P2954, DOI 10.1021/ja994363e                                                               
   Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314                                                     
   HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027                                                             
   Hernandez-Breijo B, 2011, WORLD J GASTROENTERO, V17, P3899, DOI 10.3748/wjg.v17.i34.3899
   Liu MJ, 1999, PHARM SCI TECHNOL TO, V2, P393, DOI 10.1016/S1461-5347(99)00203-5                                                   
   Liu MJ, 2000, J CONTROL RELEASE, V65, P121, DOI 10.1016/S0168-3659(99)00245-X
   Liu MJ, 1999, J POLYM SCI POL CHEM, V37, P3492, DOI 10.1002/(SICI)1099-0518(19990901)37:17<3492::AID-POLA7>3.0.CO;2-0
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Merino S, 2001, CHEM-EUR J, V7, P3095, DOI 10.1002/1521-3765(20010716)7:14<3095::AID-CHEM3095>3.0.CO;2-S                   
   Neerman MF, 2004, INT J PHARM, V281, P129, DOI 10.1016/j.ijpharm.2004.04.023
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Perrin D. D., 1988, PURIFICATION LAB CHE
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Rasines B, 2009, DALTON T, P8704, DOI 10.1039/b909955g
   Roush W, 1997, SCIENCE, V276, P1192, DOI 10.1126/science.276.5316.1192                                                   
   Rubinstein R., 2003, POLYM PHYS
   SEYFERTH D, 1994, ORGANOMETALLICS, V13, P2682, DOI 10.1021/om00019a026                                                             
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001                                                             
   VANDERMADE AW, 1993, ADV MATER, V5, P466, DOI 10.1002/adma.19930050613                                                        
   VANDERMADE AW, 1992, J CHEM SOC CHEM COMM, P1400, DOI 10.1039/c39920001400                                                            
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Verma M.I., 2000, MOL THER, V2, P415
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Zabner J, 1997, ADV DRUG DELIVER REV, V27, P17, DOI 10.1016/S0169-409X(97)00019-7
   ZHOU LL, 1993, MACROMOLECULES, V26, P963, DOI 10.1021/ma00057a013                                                             
NR 43
TC 16
Z9 16
U1 2
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD OCT
PY 2012
VL 19
IS 29
BP 5052
EP 5061
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 022QR
UT WOS:000309976900015
PM 22963627
DA 2018-01-05
ER

PT J
AU Park, JY
   Kim, JH
   Kim, YM
   Jeong, HJ
   Kim, DW
   Park, KH
   Kwon, HJ
   Park, SJ
   Lee, WS
   Ryu, YB
AF Park, Ji-Young
   Kim, Jang Hoon
   Kim, Young Min
   Jeong, Hyung Jae
   Kim, Dae Wook
   Park, Ki Hun
   Kwon, Hyung-Jun
   Park, Su-Jin
   Lee, Woo Song
   Ryu, Young Bae
TI Tanshinones as selective and slow-binding inhibitors for SARS-CoV
   cysteine proteases
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Tanshinone; SARS-CoV; 3CL(pro); PLpro; Slow-binding inhibitor
ID RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE;
   SALVIA-MILTIORRHIZA; DEUBIQUITINATING ENZYME; 3C-LIKE PROTEASE;
   CLINICAL-USE; VIRUS; PURIFICATION; EXPRESSION; DISCOVERY
AB In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CL(pro) and PLpro, viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tanshinones are good inhibitors of both cysteine proteases. However, their activity was slightly affected by subtle changes in structure and targeting enzymes. All isolated compounds (1-7) act as time dependent inhibitors of PLpro, but no improved inhibition was observed following preincubation with the 3CL(pro). In a detail kinetic mechanism study, all of the tanshinones except rosmariquinone (7) were identified as noncompetitive enzyme isomerization inhibitors. However, rosmariquinone (7) showed a different kinetic mechanism through mixed-type simple reversible slow-binding inhibition. Furthermore, tanshinone I (5) exhibited the most potent nanomolar level inhibitory activity toward deubiquitinating (IC50 = 0.7 mu M). Additionally, the inhibition is selective because these compounds do not exert significant inhibitory effects against other proteases including chymotrysin, papain, and HIV protease. These findings provide potential inhibitors for SARS-CoV viral infection and replication. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Park, Ji-Young; Kim, Jang Hoon; Kim, Young Min; Jeong, Hyung Jae; Kwon, Hyung-Jun; Park, Su-Jin; Lee, Woo Song; Ryu, Young Bae] KRIBB, Infect Control Res Ctr, Korea Res Inst Biosci & Biotechnol, Jeongeup 580185, South Korea.
   [Kim, Dae Wook; Park, Ki Hun] Gyeongsang Natl Univ, Grad Sch, Div Appl Life Sci, IALS,BK Program 21, Jinju 660701, South Korea.
   [Park, Ji-Young] Chonnam Natl Univ, Sch Biol Sci & Biotechnol, Kwangju 500757, South Korea.
RP Lee, WS (reprint author), KRIBB, Infect Control Res Ctr, Korea Res Inst Biosci & Biotechnol, Jeongeup 580185, South Korea.
EM wslee@kribb.re.kr; ybryu@kribb.re.kr
FU National Research Foundation; Korea government (MEST) [2012-0001110];
   KRIBB Research Initiative Program, Republic of Korea
FX This research was supported by National Research Foundation Grant
   founded by Korea government (MEST) (No. 2012-0001110) and KRIBB Research
   Initiative Program, Republic of Korea.
CR Abd-Elazem IS, 2002, ANTIVIR RES, V55, P91, DOI 10.1016/S0166-3542(02)00011-6
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Castillo-Yanez FJ, 2006, FOOD CHEM, V99, P252, DOI 10.1016/j.foodchem.2005.06.052
   Chou CY, 2008, BIOCHEM PHARMACOL, V75, P1601, DOI 10.1016/j.bcp.2008.01.005
   Chou K., 2003, BIOCHEM BIOPH RES CO, V308, P48
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jvc.2004.02.009
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Donnelly A. C., 2003, J GERONTOL B-PSYCHOL, V361, P1761
   Ghosh A. K., 2006, ANNU REP MED CHEM, V41, P184
   Ghosh AK, 2009, J MED CHEM, V52, P5228, DOI 10.1021/jm900611t
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Li SW, 2011, J GEN VIROL, V92, P1127, DOI 10.1099/vir.0.028936-0
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Ma ZJ, 2009, RAPID COMMUN MASS SP, V23, P2857, DOI 10.1002/rcm.4195
   MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ryu Y. B., 2010, BIOORGAN MED CHEM, V1873, P20
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Shie JJ, 2005, J MED CHEM, V48, P4469, DOI 10.1021/jm050184y
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Sun HF, 2003, PROTEIN EXPRES PURIF, V32, P302, DOI 10.1016/j.pep.2003.08.016
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Wang BQ, 2010, J MED PLANTS RES, V4, P2813
   Wu CY, 2004, P NATL ACAD SCI USA, V101, P10012, DOI 10.1073/pnas.0403596101
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
NR 30
TC 14
Z9 15
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD OCT 1
PY 2012
VL 20
IS 19
BP 5928
EP 5935
DI 10.1016/j.bmc.2012.07.038
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 009XP
UT WOS:000309059000022
PM 22884354
DA 2018-01-05
ER

PT J
AU Zahid, M
   Robbins, PD
AF Zahid, Maliha
   Robbins, Paul D.
TI Protein Transduction Domains: Applications for Molecular Medicine
SO CURRENT GENE THERAPY
LA English
DT Review
DE Protein transduction domains; NF-kappa B; cancer; gene delivery; imaging
ID NF-KAPPA-B; PEPTIDE-MEDIATED TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS;
   CONJUGATED QUANTUM DOTS; MESENCHYMAL STEM-CELLS; CELLULAR UPTAKE; GENE
   DELIVERY; CANCER-CELLS; IN-VIVO; PERMEABLE PEPTIDES
AB Protein transduction domains (PTD) or cell penetrating peptides (CTPs) are small peptides able to carry proteins, peptides, nucleic acid, and nanoparticles, including viral particles, across the cellular membranes into cells. In general, PTDs can be classified into 3 types: cationic peptides of 6-12 amino acids in length, comprised predominantly of arginine, ornithine and/or lysine residues; hydrophobic peptides such as leader sequences of secreted growth factors and cytokines; and cell-type specific peptides, identified by screening of peptide phage display libraries. These three types of transduction peptides have many different applications including delivery of therapeutic proteins and drugs, delivery of fluorescent or radioactive compounds for imaging, and improving uptake of DNA, RNA and even viral particles. Here we review the potential applications of protein transduction domains.
C1 [Robbins, Paul D.] Scripps Florida, Dept Metab & Aging, Jupiter, FL USA.
   [Zahid, Maliha] Univ Pittsburgh, Dept Dev Biol, Pittsburgh, PA 15260 USA.
   [Zahid, Maliha] Excela Hlth Cardiol, Greensburg, PA USA.
RP Zahid, M (reprint author), Scripps Res Inst, Dept Metab & Aging, 130 Scripps Way, Jupiter, FL USA.
EM probbins@scripps.edu
CR Araki D, 2010, UROLOGY, V75, P813, DOI 10.1016/j.urology.2009.10.002
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Chamarthy SP, 2004, MOL IMMUNOL, V41, P741, DOI 10.1016/j.molimm.2004.04.022
   Cheng CJ, 2012, MOL PHARMACEUT, V9, P1481, DOI 10.1021/mp300081s
   Dave SH, 2007, J IMMUNOL, V179, P7852, DOI 10.4049/jimmunol.179.11.7852                                                    
   Delfin DA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-68
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   Eto Y, 2009, PEPTIDES, V30, P1548, DOI 10.1016/j.peptides.2009.05.017
   Ezzat K, 2012, J CONTROL RELEASE, V162, P1, DOI 10.1016/j.jconrel.2012.06.006
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabrielson NP, 2012, MOL THER, V29
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Harada H, 2002, CANCER RES, V62, P2013
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kashiwagi H, 2007, ANN SURG ONCOL, V14, P1763, DOI 10.1245/s10434-006-9298-z
   Katterle Y, 2004, BRIT J CANCER, V90, P230, DOI 10.1038/sj.bjc.6601506
   Kim HY, 2011, BIOMATERIALS, V32, P5262, DOI 10.1016/j.biomaterials.2011.03.074
   Kwon MK, 2008, MOL CANCER THER, V7, P1514, DOI 10.1158/1535-7163.MCT-07-2009
   Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685
   Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   Mi ZB, 2003, MOL THER, V8, P295, DOI 10.1016/S1525-016(03)00181-3
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nicklin SA, 2000, CIRCULATION, V102, P231
   Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107
   Peterson JM, 2011, MOL MED, V17, P508, DOI 10.2119/molmed.2010.00263
   Prantner Andrew M, 2003, Mol Imaging, V2, P333, DOI 10.1162/153535003322750673
   Rajagopalan R, 2007, J GENE MED, V9, P275, DOI 10.1002/jgm.1014
   Reay DP, 2011, NEUROBIOL DIS, V43, P598, DOI 10.1016/j.nbd.2011.05.008
   Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Schott JW, 2011, CURR GENE THER, V11, P382
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Takenobu T, 2002, MOL CANCER THER, V1, P1043
   Tas SW, 2009, CURR GENE THER, V9, P160, DOI 10.2174/156652309788488569                                                      
   Tiera MJ, 2011, CURR GENE THER, V11, P288
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543
   Youn JI, 2008, CANCER GENE THER, V15, P703, DOI 10.1038/cgt.2008.45
   Zahid M, 2011, METHODS MOL BIOL, V683, P277, DOI 10.1007/978-1-60761-919-2_20
   Zahid M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012252
NR 50
TC 8
Z9 8
U1 2
U2 38
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
J9 CURR GENE THER
JI Curr. Gene Ther.
PD OCT
PY 2012
VL 12
IS 5
BP 374
EP 380
DI 10.2174/156652312802762527                                              
          
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 004PX
UT WOS:000308694700004
PM 22920684
DA 2018-01-05
ER

PT J
AU Green, LA
   Kim, C
   Gupta, SK
   Rajashekhar, G
   Rehman, J
   Clauss, M
AF Green, Linden Ann
   Kim, Chul
   Gupta, Samir K.
   Rajashekhar, Gangaraju
   Rehman, Jalees
   Clauss, Matthias
TI Pentoxifylline Reduces Tumor Necrosis Factor-alpha and HIV-Induced
   Vascular Endothelial Activation
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID NF-KAPPA-B; ACUTE MYOCARDIAL-INFARCTION; CELL-ADHESION MOLECULE-1;
   IMMUNODEFICIENCY-VIRUS-INFECTION; PROTEIN-KINASE PATHWAY; P38 MAP
   KINASE; ANTIRETROVIRAL THERAPY; TNF-ALPHA; INFLAMMATORY RESPONSE;
   CARDIOVASCULAR RISK
AB Untreated HIV infection is associated with endothelial dysfunction and subsequent cardiovascular disease, likely due to both direct effects of the virus and to indirect effects of systemic inflammation on the vasculature. We have recently shown that treatment with the antiinflammatory agent pentoxifylline (PTX) improved in vivo endothelial function and reduced circulating levels of the inflammatory markers vascular cell adhesion molecule-1 (VCAM-1) and interferon-gamma-induced protein (IP-10) in HIV-infected patients. To delineate the mechanisms underlying this therapeutic effect, we tested whether clinically relevant concentrations of PTX suppress VCAM-1 or IP-10 release in cultivated human lung microvascular endothelial cells. Indeed, we found that tumor necrosis factor (TNF)-alpha-induced VCAM-1 was reduced with concentrations of PTX in the low nanomolar range, comparable to plasma levels in PTX-treated groups. We also investigated the effect of HIV proteins and found that HIV transactivator of transcription (HIV-Tat) and HIV-envelope-derived recombinant gp120 enhanced TNF-alpha-induced VCAM-1 gene expression in lung microvascular and coronary macrovascular endothelial cells, respectively. In addition, PTX and a NF-kappa B-specific inhibitor reduced this enhanced VCAM-1 gene induction in microvascular and macrovascular endothelial cells. These results provide novel insights in how the antiinflammatory agent PTX can directly reduce HIV-associated proinflammatory endothelial activation, which may underlie vascular dysfunction and coronary vascular diseases.
C1 [Clauss, Matthias] Indiana Univ Sch Med, Indiana Ctr Vasc Biol & Med ICVBM, VA Med Ctr, Indianapolis, IN 46202 USA.
   [Green, Linden Ann; Kim, Chul; Rajashekhar, Gangaraju; Clauss, Matthias] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN USA.
   [Gupta, Samir K.] Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN USA.
   [Rajashekhar, Gangaraju] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN USA.
   [Rehman, Jalees] Univ Illinois, Dept Med, Cardiol Sect, Chicago, IL USA.
   [Rehman, Jalees] Univ Illinois, Dept Pharmacol, Chicago, IL USA.
RP Clauss, M (reprint author), Indiana Univ Sch Med, Indiana Ctr Vasc Biol & Med ICVBM, VA Med Ctr, C 3108,1481 W 10th St, Indianapolis, IN 46202 USA.
EM mclauss@iupui.edu
RI Rehman, Jalees/J-8258-2012; Gangaraju, Rajashekhar/I-6620-2013
OI Rehman, Jalees/0000-0002-2787-9292; Gangaraju,
   Rajashekhar/0000-0003-3337-1329
FU National Institutes of Health [R01 HL095149]; Indiana University
   Research Support Funds Program
FX This research was supported by grants from the National Institutes of
   Health (R01 HL095149) and the Indiana University Research Support Funds
   Program.
CR Afessa B, 2000, CHEST, V118, P138, DOI 10.1378/chest.118.1.138
   Agouridakis P, 2002, RESPIR RES, V3, DOI 10.1186/rr193                                                                   
   ARDITI M, 1991, PEDIATR INFECT DIS J, V10, P450, DOI 10.1097/00006454-199106000-00007
   Baker JV, 2011, EUR HEART J, V32, P945, DOI 10.1093/eurheartj/ehq483
   BASARAN Y, 1993, ANGIOLOGY, V44, P332, DOI 10.1177/000331979304400411
   Bowie AG, 2000, J IMMUNOL, V165, P7180, DOI 10.4049/jimmunol.165.12.7180                                                    
   Chen YM, 2003, BRIT J PHARMACOL, V138, P950, DOI 10.1038/sj.bjp.0705088
   Chi D, 2000, ENDOTHELIUM-NEW YORK, V7, P223, DOI 10.3109/10623320009072210                                                       
   Clauss M, 2001, BLOOD, V97, P1321, DOI 10.1182/blood.V97.5.1321
   Dansky HM, 2001, ARTERIOSCL THROM VAS, V21, P1662, DOI 10.1161/hq1001.096625
   Dhawan S, 1997, BLOOD, V90, P1535
   DIAZ PT, 1992, ANN INTERN MED, V116, P124, DOI 10.7326/0003-4819-116-2-124
   Dohgu S, 2008, EXP NEUROL, V210, P740, DOI 10.1016/j.expneurol.2007.12.028
   El-Sadr WM, 2008, ANN INTERN MED, V149, P289, DOI 10.7326/0003-4819-149-5-200809020-00003
   Feldman ED, 2006, ANN SURG ONCOL, V13, P125, DOI 10.1245/ASO.2006.03.038
   Freiberg MS, 2011, CIRC-CARDIOVASC QUAL, V4, P425, DOI 10.1161/CIRCOUTCOMES.110.957415
   Fu J, 2008, MED CHEM, V4, P597, DOI 10.2174/157340608786242106                                                      
   Futakuchi M, 2004, CANCER SCI, V95, P18, DOI 10.1111/j.1349-7006.2004.tb03165.x
   GATTEGNO L, 1995, CELL ADHES COMMUN, V3, P179, DOI 10.3109/15419069509081285                                                       
   Gupta SK, 2008, AIDS, V22, P653, DOI 10.1097/QAD.0b013e3282f470d2
   Gupta SK, 2010, AIDS, V24, P1377, DOI 10.1097/QAD.0b013e3283396024
   Gupta SK, 2008, 15 C RETR OPP INF
   Hasebe Y, 2000, INVEST OPHTH VIS SCI, V41, P2774
   Hoie EB, 2004, BIOL PHARM BULL, V27, P1670, DOI 10.1248/bpb.27.1670                                                             
   Jaruga B, 2004, AM J PHYSIOL-GASTR L, V287, pG1044, DOI 10.1152/ajpgi.00184.2004
   Ji Q, 2004, ANN CLIN LAB SCI, V34, P427
   Jiang J, 2010, CARDIOVASC RES, V87, P366, DOI 10.1093/cvr/cvq013
   Jong E, 2010, THROMB HAEMOSTASIS, V104, P1228, DOI 10.1160/TH10-04-0233
   Koga M, 2007, HYPERTENS RES, V30, P259, DOI 10.1291/hypres.30.259                                                           
   KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854
   Li JCB, 2007, IMMUNOLOGY, V121, P337, DOI 10.1111/j.1365-2567.2007.02580.x
   Lucas R, 1997, EUR J IMMUNOL, V27, P1719, DOI 10.1002/eji.1830270719                                                          
   Mehta NJ, 2000, CHEST, V118, P1133, DOI 10.1378/chest.118.4.1133
   Nikolopoulou A, 2008, INT J CARDIOL, V130, P246, DOI 10.1016/j.ijcard.2007.08.052
   Obel N, 2007, CLIN INFECT DIS, V44, P1625, DOI 10.1086/518285
   Petrache I, 2008, THORAX, V63, P463, DOI 10.1136/thx.2007.079111
   Postadzhiyan AS, 2008, CLIN BIOCHEM, V41, P126, DOI 10.1016/j.clinbiochem.2007.09.001
   Rajan S, 2008, J CELL BIOCHEM, V105, P477, DOI 10.1002/jcb.21845
   Rajashekhar G, 2007, PHYSIOL GENOMICS, V31, P104, DOI 10.1152/physiolgenomics.00157.2006
   Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003
   Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609
   Schwarz JBK, 2009, CIRC RES, V104, P189, DOI 10.1161/CIRCRESAHA.108.182683
   Silvestro A, 2005, THROMB HAEMOSTASIS, V93, P559, DOI 10.1160/TH04-07-0440
   Skiest DJ, 2007, J INFECT DIS, V195, P1426, DOI 10.1086/512681
   Taha H, 2009, J PHYSIOL PHARMACOL, V60, P3
   Toborek M, 2003, J NEUROCHEM, V84, P169, DOI 10.1046/j.1471-4159.2003.01543.x
   Torriani FJ, 2008, J AM COLL CARDIOL, V52, P569, DOI 10.1016/j.jacc.2008.04.049
   TOZAWA K, 1995, CANCER RES, V55, P4162
   Triant VA, 2007, J CLIN ENDOCR METAB, V92, P2506, DOI 10.1210/jc.2006-2190
   VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375                                                          
   Zhang M, 2005, BIOCHEM BIOPH RES CO, V327, P57, DOI 10.1016/j.bbrc.2004.11.131
   Zhang YM, 2009, FASEB J, V23, P1358, DOI 10.1096/fj.08-110296
NR 52
TC 8
Z9 8
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2012
VL 28
IS 10
BP 1207
EP 1215
DI 10.1089/aid.2011.0385
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 013TV
UT WOS:000309329700006
PM 22463742
OA green_published
DA 2018-01-05
ER

PT J
AU Lee, M
   Guo, JP
   Schwab, C
   McGeer, EG
   McGeer, PL
AF Lee, Moonhee
   Guo, Jian-Ping
   Schwab, Claudia
   McGeer, Edith G.
   McGeer, Patrick L.
TI Selective inhibition of the membrane attack complex of complement by low
   molecular weight components of the aurin tricarboxylic acid synthetic
   complex
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE C5b-9; Complement C9 protein; Alzheimer's disease; Macular degeneration;
   Paroxysmal nocturnal hemoglobinuria
ID PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; AMYLOID PRECURSOR PROTEIN; ANTI-HIV
   ACTIVITIES; AURINTRICARBOXYLIC ACID; ALZHEIMERS-DISEASE; TRANSGENIC
   MICE; C6 DEFICIENCY; NEUROFIBRILLARY TANGLES; PLAQUE-FORMATION;
   IMMUNIZATION
AB Complement plays a vital role in both the innate and adaptive immune systems. It recognizes a target, opsonizes it, generates anaphylatoxins, and directly kills cells through the membrane attack complex (MAC). This final function, which assembles C5b-9(n) on viable cell surfaces, can kill host cells through bystander lysis. Here we identify for the first time compounds that can inhibit bystander lysis while not interfering with the other essential functions of complement. We show that aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), and aurin hexacarboxylic acid (AHA), block the addition of C9 to C5b-8 so that the MAC cannot form. These molecules inhibit hemolysis of human, rat, and mouse red cells with a half maximal inhibitory concentration (IC50) in the nanomolar range. When given orally to Alzheimer disease type B6SJL-Tg mice, they inhibit MAC formation in serum and improve memory retention. On autopsy, they show no evidence of harm to any organ. Aurin tricarboxylic acid, aurin quadracarboxylic acid, and aurin hexacarboxylic acid may be effective therapeutic agents in Alzheimer disease and other degenerative disorders where self damage from the MAC occurs. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Lee, Moonhee; Guo, Jian-Ping; Schwab, Claudia; McGeer, Edith G.; McGeer, Patrick L.] Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada.
RP McGeer, PL (reprint author), Univ British Columbia, Kinsmen Lab Neurol Res, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
EM mcgeerpl@interchange.ubc.ca
FU Pacific Alzheimer Research Foundation
FX This research was supported by the Pacific Alzheimer Research
   Foundation. The authors are grateful to the Centre for Drug Research and
   Development (CDRD) for making their library of compounds available for
   screening and for help with carrying out the mass spectrographic
   analysis. The authors are also grateful to Dr. Jennifer Love of the
   Chemistry Department, University of British Columbia for help with mass
   spectrographic analysis and interpretation of the data, and to the
   Department of Chemistry and Raymond Anderson and David Williams of the
   Earth and Ocean Sciences Department for help with column separation of
   ATA derivatives.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   CUSHMAN M, 1991, J MED CHEM, V34, P337, DOI 10.1021/jm00105a053
   CUSHMAN M, 1992, J ORG CHEM, V57, P7241, DOI 10.1021/jo00052a045
   CUSHMAN M, 1990, TETRAHEDRON, V46, P1491, DOI 10.1016/S0040-4020(01)81957-8
   EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397                                                              
   GONZALEZ RG, 1979, BIOCHIM BIOPHYS ACTA, V562, P534, DOI 10.1016/0005-2787(79)90116-3
   Heisig G.B., 1941, ORG SYN COL, V1, P54
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2
   HUSLER T, 1995, J BIOL CHEM, V270, P3483
   JOSEPH R, 1993, BRAIN RES, V625, P244, DOI 10.1016/0006-8993(93)91065-Z
   Kawamata T., 1992, AM J PATHOL, V140, P697
   Kira R, 1998, HUM GENET, V102, P605, DOI 10.1007/s004390050749                                                           
   Kojima T, 1998, J IMMUNOL, V161, P3762
   Lee M, 2011, GLIA, V59, P152, DOI 10.1002/glia.21087
   Matsuno H, 1998, THROMB HAEMOSTASIS, V79, P865
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGeer PL, 2003, NEUROBIOL AGING, V24, P391, DOI 10.1016/S0197-4580(02)00157-4
   MCGEER PL, 1989, NEUROSCI LETT, V107, P341, DOI 10.1016/0304-3940(89)90843-4                                                    
   Miklossy J, 2008, OPEN PATHOL J, V2, P86
   MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341
   Nakashima S, 2002, J IMMUNOL, V169, P4620, DOI 10.4049/jimmunol.169.8.4620                                                     
   Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8                                              
   Owens MR, 1996, THROMB RES, V81, P177, DOI 10.1016/0049-3848(95)00234-0
   Parham KL, 2007, MOL IMMUNOL, V44, P2756, DOI 10.1016/j.molimm.2006.11.022
   Rameix-Welti MA, 2007, EUR J IMMUNOL, V37, P1377, DOI 10.1002/eji.200636812
   Regan RF, 1995, BRAIN RES, V705, P188, DOI 10.1016/0006-8993(95)01170-6
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124                                                                   
   Schmiedt W, 1998, ARTERIOSCL THROM VAS, V18, P1790, DOI 10.1161/01.ATV.18.11.1790                                                       
   Schwab C, 1996, BRAIN RES, V707, P196, DOI 10.1016/0006-8993(95)01257-5                                                    
   Schwab C, 2004, EXP NEUROL, V188, P52, DOI 10.1016/j.expneurol.2004.03.016
   Shen Y, 2001, NEUROSCI LETT, V305, P165, DOI 10.1016/S0304-3940(01)01842-0
   TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T                                                    
   Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003
   WANG P, 1992, J ORG CHEM, V57, P3861, DOI 10.1021/jo00040a027                                                             
   Wu GX, 2009, CIRC RES, V104, P550, DOI 10.1161/CIRCRESAHA.108.191361
   Wu GS, 2003, XENOTRANSPLANTATION, V10, P214, DOI 10.1034/j.1399-3089.2003.01088.x
   Wyss-Coray T, 2002, P NATL ACAD SCI USA, V99, P10837, DOI 10.1073/pnas.162350199
   Yamada T., 1992, ACTA NEUROPATHOL, V84, P101
   YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707                                                     
   Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5
   YASUHARA O, 1994, BRAIN RES, V652, P346, DOI 10.1016/0006-8993(94)90246-1
   Zhu ZB, 1998, CLIN EXP IMMUNOL, V111, P91
NR 49
TC 13
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD OCT
PY 2012
VL 33
IS 10
BP 2237
EP 2246
DI 10.1016/j.neurobiolaging.2011.12.005
PG 10
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 996LG
UT WOS:000308088500001
PM 22217416
DA 2018-01-05
ER

PT J
AU Ng, HI
   Fernando, GJP
   Kendall, MAF
AF Ng, Hwee-Ing
   Fernando, Germain J. P.
   Kendall, Mark A. F.
TI Induction of potent CD8(+) T cell responses through the delivery of
   subunit protein vaccines to skin antigen-presenting cells using densely
   packed microprojection arrays
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Needle-free vaccine; Dose sparing; Adjuvant; Microneedle; Transdermal;
   CTL
ID HEPATITIS-B-VACCINE; IMMUNE-RESPONSES; IN-VITRO; TARGETED DELIVERY;
   INFLUENZA VACCINATION; CPG OLIGONUCLEOTIDES; BACTERIAL-DNA; C VIRUS;
   PEPTIDE; IMMUNIZATION
AB The generation of both antibody and CD8(+) T cell responses against pathogens is considered important for many advanced vaccines for diseases including tuberculosis, HIV and malaria. However, most current vaccines are delivered into muscle by the needle and syringe method and induce protection via humoral (antibody) immune responses. In this paper, we test the hypothesis that delivering a model subunit protein antigen (ovalbumin) to the skin's abundant immune cell population using a densely packed microprojection array (Nanopatch) enhances CD8(+) T cell responses. We found that the Nanopatch significantly enhanced the CD8(+) T cell responses when compared to intramuscular delivery of both antigen-only and adjuvanted cases (Quil-A and CpG; separately). To our knowledge, this is the first published study demonstrating significantly improved CD8(+) T cell responses achieved by delivering subunit vaccines to the skin's abundant immune cell population. Successfully replicating these findings in humans could significantly advance the reach of vaccines. (C) 2012 Elsevier B. V. All rights reserved.
C1 [Ng, Hwee-Ing; Fernando, Germain J. P.; Kendall, Mark A. F.] Univ Queensland, D2G2, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
   [Kendall, Mark A. F.] Univ Queensland, Diamantina Inst, Brisbane, Qld 4102, Australia.
RP Kendall, MAF (reprint author), Univ Queensland, D2G2, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
EM m.kendall@uq.edu.au
RI Fernando, Germain/C-3733-2009; Ng, Hwee Ing/D-6515-2016; Kendall,
   Mark/M-4122-2017
OI Fernando, Germain/0000-0003-3260-0548; Ng, Hwee Ing/0000-0001-6519-1942;
   
FU National Health and Medical Research Council of Australia [569726,
   631720]; Australian Research Council [DP1093281]; Queensland Smart State
   Scheme
FX The NPs were manufactured in the ANFF facility at the University of
   Queensland, Brisbane, Australia. We would like to thank Chelsea Stewart
   and others at the Biological Research Facility in the Australian
   Institute for Bioengineering and Nanotechnology at The University of
   Queensland for animal care. We thank Clare Primiero and Jin Zhang for
   assistance with the ELISPOT assays, and Sally Yukiko for help with the
   coating of the NPs. We also thank Prof. Lars Nielsen for his assistance
   on statistical analyses. This work was supported by the National Health
   and Medical Research Council of Australia (Grants ID# 569726 & ID#
   631720), the Australian Research Council Future Fellowship (MAFK), the
   Australian Research Council Grant (ID# DP1093281) and the Queensland
   Smart State Scheme.
CR Alarcon JB, 2007, CLIN VACCINE IMMUNOL, V14, P375, DOI 10.1138/CVI.00387-06
   Arora A, 2008, INT J PHARMACEUT, V364, P227, DOI 10.1016/j.ijpharm.2008.08.032
   Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878                                                     
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498
   Borja-Cabrera GP, 2004, VACCINE, V22, P2234, DOI 10.1016/j.vaccine.2003.11.039
   BORROW P, 1994, J VIROL, V68, P6103
   Byers DE, 1999, J IMMUNOL, V163, P3022
   Castro-Diaz N, 2012, VACCINE, V30, P388, DOI 10.1016/j.vaccine.2011.10.080
   Cevc G, 2010, J CONTROL RELEASE, V141, P277, DOI 10.1016/j.jconrel.2009.10.016
   Chen XF, 2012, J CONTROL RELEASE, V158, P78, DOI 10.1016/j.jconrel.2011.10.026
   Chen XF, 2011, ADV FUNCT MATER, V21, P464, DOI 10.1002/adfm.201000966
   Chen X, 2011, J CONTROL RELEASE, V152, P349, DOI 10.1016/j.jconrel.2011.02.026
   Chen XF, 2010, J CONTROL RELEASE, V148, P327, DOI 10.1016/j.jconrel.2010.09.001
   Chen XF, 2009, J CONTROL RELEASE, V139, P212, DOI 10.1016/j.jconrel.2009.06.029
   Chen XF, 2008, 2008 INTERNATIONAL CONFERENCE ON NANOSCIENCE AND NANOTECHNOLOGY, P105, DOI 10.1109/ICONN.2008.4639257
   Coles RM, 2002, J IMMUNOL, V168, P834, DOI 10.4049/jimmunol.168.2.834                                                      
   Corbett HJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013460
   Crichton ML, 2010, BIOMATERIALS, V31, P4562, DOI 10.1016/j.biomaterials.2010.02.022
   Deacon B, 2006, J ANXIETY DISORD, V20, P946, DOI 10.1016/j.janxdis.2006.01.004
   Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548
   Fernando GJP, 2012, J CONTROL RELEASE, V159, P215, DOI 10.1016/j.jconrel.2012.01.030
   Fernando GJP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010266
   Fernando GJP, 1998, SCAND J IMMUNOL, V47, P459
   FERNANDO GJP, 1995, VACCINE, V13, P1460, DOI 10.1016/0264-410X(95)00029-Z
   Fernando GJP, 1998, J IMMUNOL, V161, P2421
   Fernando GJP, 2002, EUR J IMMUNOL, V32, P1541, DOI 10.1002/1521-4141(200206)32:6<1541::AID-IMMU1541>3.0.CO;2-S
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Gao FG, 2002, CANCER RES, V62, P6438
   Gregor C., 2009, J CONTROL RELEASE, V141, P277
   Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8
   He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06
   Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Jenkins D, 2012, RSC ADV, V2, P3490, DOI 10.1039/c2ra20153d
   KARCH H, 1983, J IMMUNOL, V131, P6
   Kask AS, 2010, VACCINE, V28, P7483, DOI 10.1016/j.vaccine.2010.09.014
   Kendall Mark A F, 2010, Handb Exp Pharmacol, P193, DOI 10.1007/978-3-642-00477-3_7
   Kensil CR, 1996, CRIT REV THER DRUG, V13, P1
   Kim M, 2006, INT IMMUNOL, V18, P435, DOI 10.1093/intimm/dxh383
   Kim YC, 2010, J CONTROL RELEASE, V142, P187, DOI 10.1016/j.jconrel.2009.10.013
   Klinman DM, 2009, ADV DRUG DELIVER REV, V61, P248, DOI 10.1016/j.addr.2008.12.012
   Koch MD, 2002, J ANXIETY DISORD, V16, P511, DOI 10.1016/S0887-6185(02)00170-6
   Koutsonanos DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004773
   Kreijtz JHCM, 2007, VACCINE, V25, P612, DOI 10.1016/j.vaccine.2006.08.036
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Levine MM, 2004, NAT IMMUNOL, V5, P460, DOI 10.1038/ni0504-465
   LIPFORD GB, 1994, VACCINE, V12, P73, DOI 10.1016/0264-410X(94)90013-2
   Liu T, 2000, J EXP MED, V191, P1459, DOI 10.1084/jem.191.9.1459
   MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153
   Matsumoto K, 2004, J NATL CANCER I, V96, P1611, DOI 10.1093/jnci/dhj301
   Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728
   Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7                                                   
   Narayan S, 2007, EUR J IMMUNOL, V37, P406, DOI 10.1002/eji.200535688
   NEWMAN MJ, 1992, J IMMUNOL, V148, P2357
   Prow TW, 2010, SMALL, V6, P1776, DOI 10.1002/smll.201000331
   Pruss-Ustun A, 2005, AM J IND MED, V48, P482, DOI 10.1002/aijm.20230
   Raphael AP, 2010, SMALL, V6, P1785, DOI 10.1002/smll.201000326
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Sablan BP, 2012, VACCINE, V30, P2689, DOI 10.1016/j.vaccine.2012.02.001
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Siegrist CA, 2004, VACCINE, V23, P615, DOI 10.1016/j.vaccine.2004.07.014
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   SKIDMORE BJ, 1976, J EXP MED, V143, P143, DOI 10.1084/jem.143.1.143                                                           
   Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373
   Stittelaar KJ, 2000, VACCINE, V18, P2482, DOI 10.1016/S0264-410X(00)00026-8                                                   
   Tu WW, 2010, J VIROL, V84, P6527, DOI 10.1128/JVI.00519-10
   Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077
   Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200
   Widera G, 2006, VACCINE, V24, P1653, DOI 10.1016/j.vaccine.2005.09.049
   Wong P, 2003, ANNU REV IMMUNOL, V21, P29, DOI 10.1146/annurev.immunol.21.120601.141114
   Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099
   Yu H, 2004, J GEN VIROL, V85, P1533, DOI 10.1099/vir.0.79821-0
   Zhao K, 2011, VACCINE, V29, P6670, DOI 10.1016/j.vaccine.2011.06.100
   Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045
NR 77
TC 18
Z9 18
U1 2
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 28
PY 2012
VL 162
IS 3
BP 477
EP 484
DI 10.1016/j.jconrel.2012.07.024
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 029PD
UT WOS:000310506900001
PM 22841796
DA 2018-01-05
ER

PT J
AU Ekiert, DC
   Kashyap, AK
   Steel, J
   Rubrum, A
   Bhabha, G
   Khayat, R
   Lee, JH
   Dillon, MA
   O'Neil, RE
   Faynboym, AM
   Horowitz, M
   Horowitz, L
   Ward, AB
   Palese, P
   Webby, R
   Lerner, RA
   Bhatt, RR
   Wilson, IA
AF Ekiert, Damian C.
   Kashyap, Arun K.
   Steel, John
   Rubrum, Adam
   Bhabha, Gira
   Khayat, Reza
   Lee, Jeong Hyun
   Dillon, Michael A.
   O'Neil, Ryann E.
   Faynboym, Aleksandr M.
   Horowitz, Michael
   Horowitz, Lawrence
   Ward, Andrew B.
   Palese, Peter
   Webby, Richard
   Lerner, Richard A.
   Bhatt, Ramesh R.
   Wilson, Ian A.
TI Cross-neutralization of influenza A viruses mediated by a single
   antibody loop
SO NATURE
LA English
DT Article
ID POTENT NEUTRALIZATION; CRYSTAL-STRUCTURE; STRUCTURAL BASIS;
   BINDING-SITE; HEMAGGLUTININ; EPITOPE; HIV-1; RECOGNITION; SYSTEM; BROAD
AB Immune recognition of protein antigens relies on the combined interaction of multiple antibody loops, which provide a fairly large footprint and constrain the size and shape of protein surfaces that can be targeted. Single protein loops can mediate extremely high-affinity binding, but it is unclear whether such a mechanism is available to antibodies. Here we report the isolation and characterization of an antibody called C05, which neutralizes strains from multiple subtypes of influenza A virus, including H1, H2 and H3. X-ray and electron microscopy structures show that C05 recognizes conserved elements of the receptor-binding site on the haemagglutinin surface glycoprotein. Recognition of the haemagglutinin receptor-binding site is dominated by a single heavy-chain complementarity-determining region 3 loop, with minor contacts from heavy-chain complementarity-determining region 1, and is sufficient to achieve nanomolar binding with a minimal footprint. Thus, binding predominantly with a single loop can allow antibodies to target small, conserved functional sites on otherwise hypervariable antigens.
C1 [Ekiert, Damian C.; Bhabha, Gira; Khayat, Reza; Lee, Jeong Hyun; Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   [Kashyap, Arun K.; Dillon, Michael A.; O'Neil, Ryann E.; Faynboym, Aleksandr M.; Horowitz, Michael; Horowitz, Lawrence; Bhatt, Ramesh R.] Sea Lane Biotechnol, Mountain View, CA 94043 USA.
   [Steel, John; Palese, Peter] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Rubrum, Adam; Webby, Richard] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.
   [Lerner, Richard A.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Wilson, IA (reprint author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM ramesh.bhatt@sealanebio.com; wilson@scripps.edu
RI Ward, Andrew/F-9203-2014
OI Ward, Andrew/0000-0001-7153-3769; Palese, Peter/0000-0002-0337-5823;
   Ekiert, Damian/0000-0002-2570-0404
FU National Institutes of Health (NIH) [P01AI058113]; Achievement Rewards
   for College Scientists Foundation [GM080209]; NIH Molecular Evolution
   Training Program; Skaggs Institute; Northeast Biodefense Center
   [U54-AI057158-Lipkin]; National Institute of Allergy and Infectious
   Diseases (NIAID) [U01AI070373]; Center for Research on Influenza
   Pathogenesis NIAID [HHSN266200700010C]; DOE Office of Biological and
   Environmental Research; NIH, National Center for Research Resources,
   Biomedical Technology Program; National Institute of General Medical
   Sciences (NIGMS); National Cancer Institute [Y1-CO-1020]; NIGMS
   [Y1-GM-1104]; US Department of Energy, Basic Energy Sciences, Office of
   Science [DE-AC02-06CH11357]; NIH though the P41 program at the National
   Center for Research Resources [RR017573]; NIH [U54 GM094586]
FX We thank H. Tien and D. Marciano for automated crystal screening, the
   staff of the Advanced Photon Source (APS) GM/CA-CAT and Stanford
   Synchrotron Radiation Lightsource (SSRL) BL11-1 for beamline support, X.
   Dai and R. Stanfield for assistance with data collection and processing,
   M. Hothorn for assistance with ITC experiments, J. Paulson and D. Burton
   for comments and discussion, A. Estelles and R. Briante, L. Xu, S. Wang
   and D. Corn for technical support and P. Foremanfor assistance with
   animal study design. This project was funded in part by National
   Institutes of Health (NIH) grant P01AI058113 (I. A. W.), a predoctoral
   fellowship from the Achievement Rewards for College Scientists
   Foundation (D. C. E.), grant GM080209 from the NIH Molecular Evolution
   Training Program (D. C. E.), the Skaggs Institute (I. A. W.), a career
   development fellowship from the Northeast Biodefense Center
   (U54-AI057158-Lipkin) (J. S.), National Institute of Allergy and
   Infectious Diseases (NIAID) grant U01AI070373 (R. W.), and Center for
   Research on Influenza Pathogenesis NIAID contract HHSN266200700010C (P.
   P.). Portions of this research were carried out at the SSRL, a national
   user facility operated by Stanford University on behalf of the US
   Department of Energy (DOE), Office of Basic Energy Sciences. The SSRL
   Structural Molecular Biology Program is supported by the DOE Office of
   Biological and Environmental Research and by the NIH, National Center
   for Research Resources, Biomedical Technology Program, and the National
   Institute of General Medical Sciences (NIGMS). The GM/CA-CAT 23-ID-B
   beamline has been funded in whole or in part with federal funds from the
   National Cancer Institute (Y1-CO-1020) and NIGMS (Y1-GM-1104). Use of
   the APS was supported by the US Department of Energy, Basic Energy
   Sciences, Office of Science, under contract no. DE-AC02-06CH11357. The
   electron microscopy data presented here was collected at the National
   Resource for Automated Molecular Microscopy, which is supported by the
   NIH though the P41 program (RR017573) at the National Center for
   Research Resources. The JCSG is supported by NIH grant U54 GM094586. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of NIGMS or the NIH. This is
   publication 21421 from The Scripps Research Institute.
CR Abhinandan KR, 2008, MOL IMMUNOL, V45, P3832, DOI 10.1016/j.molimm.2008.05.022
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07
   Barbey-Martin C, 2002, VIROLOGY, V294, P70, DOI 10.1006/viro.2001.1320
   Brown PH, 2004, J MOL BIOL, V337, P857, DOI 10.1016/j.jmb.2004.01.041
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Corti D, 2010, J CLIN INVEST, V120, P1663, DOI 10.1172/JCI41902
   de Wildt RMT, 1999, J MOL BIOL, V294, P701, DOI 10.1006/jmbi.1999.3289                                                          
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617
   Fleury D, 1999, NAT STRUCT BIOL, V6, P530, DOI 10.1038/9299
   Fleury D, 1998, NAT STRUCT BIOL, V5, P119, DOI 10.1038/nsb0298-119
   Fleury D, 2000, PROTEINS, V40, P572
   Fodor E, 1999, J VIROL, V73, P9679
   Hensley SE, 2009, SCIENCE, V326, P734, DOI 10.1126/science.1178258
   Hohn M, 2007, J STRUCT BIOL, V157, P47, DOI 10.1016/j.jsb.2006.07.003
   Kashyap AK, 2008, P NATL ACAD SCI USA, V105, P5986, DOI 10.1073/pnas.0801367105
   Kashyap AK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000990
   Krause JC, 2011, MBIO, V2, DOI 10.1128/mBio.00345-10
   Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003
   Lander GC, 2009, J STRUCT BIOL, V166, P95, DOI 10.1016/j.jsb.2009.01.002
   Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McLellan JS, 2011, NATURE, V480, P336, DOI 10.1038/nature10696
   Mindell JA, 2003, J STRUCT BIOL, V142, P334, DOI 10.1016/S1047-8477(03)00069-8
   MIYAZAKI J, 1989, GENE, V79, P269
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   Ohshima N, 2011, J VIROL, V85, P11048, DOI 10.1128/JVI.05397-11
   OKUNO Y, 1993, J VIROL, V67, P2552
   Pancera M, 2010, J VIROL, V84, P8098, DOI 10.1128/JVI.00966-10
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Pejchal R, 2010, P NATL ACAD SCI USA, V107, P11483, DOI 10.1073/pnas.1004600107
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8
   Smith T, 1996, BRIT MED J, V312, P383
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942
   Voss NR, 2009, J STRUCT BIOL, V166, P205, DOI 10.1016/j.jsb.2009.01.004
   Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517
   Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108
   Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59
   Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352
   Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430
   Yoshida R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000350
   Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819
NR 50
TC 152
Z9 154
U1 1
U2 51
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD SEP 27
PY 2012
VL 489
IS 7417
BP 526
EP +
DI 10.1038/nature11414
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 011LT
UT WOS:000309167100042
PM 22982990
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Heffernan, C
   Sumer, H
   Guillemin, GJ
   Manuelpillai, U
   Verma, PJ
AF Heffernan, Corey
   Sumer, Huseyin
   Guillemin, Gilles J.
   Manuelpillai, Ursula
   Verma, Paul J.
TI Design and Screening of a Glial Cell-Specific, Cell Penetrating Peptide
   for Therapeutic Applications in Multiple Sclerosis
SO PLOS ONE
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LYMPHOCYTIC CHORIOMENINGITIS
   VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; ANTENNAPEDIA HOMEODOMAIN;
   RECOMBINANT PROTEINS; IMPROVES DELIVERY; FUSION PROTEIN; TAT PROTEIN;
   SPINAL-CORD; 3RD HELIX
AB Multiple Sclerosis (MS) is an autoimmune, neurodegenerative disease of the central nervous system (CNS) characterized by demyelination through glial cell loss. Current and proposed therapeutic strategies to arrest demyelination and/or promote further remyelination include: (i) modulation of the host immune system; and/or (ii) transplantation of myelinating/stem or progenitor cells to the circulation or sites of injury. However, significant drawbacks are inherent with both approaches. Cell penetrating peptides (CPP) are short amino acid sequences with an intrinsic ability to translocate across plasma membranes, and theoretically represent an attractive vector for delivery of therapeutic peptides or nanoparticles to glia to promote cell survival or remyelination. The CPPs described to date are commonly non-selective in the cell types they transduce, limiting their therapeutic application in vivo. Here, we describe a theoretical framework for design of a novel CPP sequence that selectively transduces human glial cells (excluding non-glial cell types), and conduct preliminary screens of purified, recombinant CPPs with immature and matured human oligodendrocytes and astrocytes, and two non-glial cell types. A candidate peptide, termed TD2.2, consistently transduced glial cells, was significantly more effective at transducing immature oligodendrocytes than matured progeny, and was virtually incapable of transducing two non-glial cell types: (i) human neural cells and (ii) human dermal fibroblasts. Time-lapse confocal microscopy confirms trafficking of TD2.2 (fused to EGFP) to mature oligodendrocytes 3-6 hours after protein application in vitro. We propose selectivity of TD2.2 for glial cells represents a new therapeutic strategy for the treatment of glial-related disease, such as MS.
C1 [Heffernan, Corey; Sumer, Huseyin; Verma, Paul J.] Monash Univ, Monash Inst Med Res, Ctr Reprod & Dev, Reprogramming & Stem Cell Lab, Clayton, Vic, Australia.
   [Manuelpillai, Ursula] Monash Univ, Monash Inst Med Res, Ctr Reprod & Dev, Placental Stem Cell Lab, Clayton, Vic, Australia.
   [Guillemin, Gilles J.] Univ New S Wales, Dept Pharmacol, Sydney, NSW, Australia.
   [Verma, Paul J.] S Australian Res & Dev Ind, Turretfield Res Ctr, Rosedale, SA, Australia.
RP Verma, PJ (reprint author), Monash Univ, Monash Inst Med Res, Ctr Reprod & Dev, Reprogramming & Stem Cell Lab, Clayton, Vic, Australia.
EM Paul.Verma@monash.edu
OI Guillemin, Gilles/0000-0001-8105-4470; Sumer,
   Huseyin/0000-0001-9413-5579
FU Victorian Government's Operational Infrastructure Support Program;
   Australian Stem Cell Centre iPS Program Grant; Harold Mitchell
   Foundation; Australian National Health & Medical Research Council
   (NHMRC); NHMRC Grant [606473]
FX This project was supported by the Victorian Government's Operational
   Infrastructure Support Program, and funded by Australian Stem Cell
   Centre iPS Program Grant and Harold Mitchell Foundation. Personal
   postgraduate funding for CH and research support for GJG was provided by
   Australian National Health & Medical Research Council (NH&MRC). UM
   supported by NH&MRC Grant #606473. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aktas Y, 2005, BIOCONJUGATE CHEM, V16, P1503, DOI 10.1021/bc050217o
   Axtell RC, 2010, NAT MED, V16, P406, DOI 10.1038/nm.2110
   Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279
   Benn SC, 2005, J NEUROCHEM, V95, P1118, DOI 10.1111/j.1471-4159.2005.03459.x
   BORROW P, 1992, J VIROL, V66, P7270
   BOWIE JU, 1989, J BIOL CHEM, V264, P7596
   Buntinx M, 2003, J NEUROCYTOL, V32, P25, DOI 10.1023/A:1027324230923                                                         
   Chian RJ, 2009, BRAIN RES, V1287, P1, DOI 10.1016/j.brainres.2009.06.066
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600
   Goyal A, 2000, BIOCHEM J, V345, P247, DOI 10.1042/0264-6021:3450247                                                       
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Heffernan C, 2012, STEM CELLS IN PRESS
   Heffernan C, 2010, REPROD FERT DEVELOP, V22, P1022, DOI 10.1071/RD09265
   Huang JK, 2011, NAT NEUROSCI, V14, P45, DOI 10.1038/nn.2702
   Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025
   Johansson HJ, 2011, METHODS MOL BIOL, V683, P233, DOI 10.1007/978-1-60761-919-2_17
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103
   Larsen KE, 2006, BRAIN RES, V1120, P1, DOI 10.1016/j.brainres.2006.08.079
   Lim C. K., 2007, INT C SER, V1304, P213, DOI [10.1016/j.ics.2007.07.011, DOI 10.1016/J.ICS.2007.07.011]
   Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5
   Maginnis MS, 2009, SEMIN CANCER BIOL, V19, P261, DOI 10.1016/j.semcancer.2009.02.013
   McCandless EE, 2009, J IMMUNOL, V183, P613, DOI 10.4049/jimmunol.0802258
   MCLAURIN J, 1995, J NEUROBIOL, V26, P283, DOI 10.1002/neu.480260212
   Milward E, 2008, J NEUROIMMUNOL, V193, P140, DOI 10.1016/j.jneuroim.2007.11.001
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206                                                           
   Pan CY, 2010, MOL BIOL REP, V37, P2117, DOI 10.1007/s11033-009-9680-6
   Rambukkana A, 2003, P NATL ACAD SCI USA, V100, P16071, DOI 10.1073/pnas.2232366100
   Ravichandran V, 2006, PROTEOMICS, V6, P5628, DOI 10.1002/pmic.200600261
   Ren ZH, 2011, J NEUROSCI, V31, P8329, DOI 10.1523/JNEUROSCI.1028-11.2011
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Sgambato A, 2003, AM J PATHOL, V162, P849, DOI 10.1016/S0002-9440(10)63881-3
   Song JH, 2006, J NEUROSCI, V26, P3299, DOI 10.1523/JNEUROSCI.5572-05.2006
   Stork R, 2007, PROTEIN ENG DES SEL, V20, P569, DOI 10.1093/protein/gzm061
   Sullivan BM, 2011, P NATL ACAD SCI USA, V108, P2969, DOI 10.1073/pnas.1019304108
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418                                                        
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
NR 44
TC 4
Z9 4
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2012
VL 7
IS 9
AR e45501
DI 10.1371/journal.pone.0045501
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 016YP
UT WOS:000309556100052
PM 23049807
OA gold
DA 2018-01-05
ER

PT J
AU Rohrman, BA
   Leautaud, V
   Molyneux, E
   Richards-Kortum, RR
AF Rohrman, Brittany A.
   Leautaud, Veronica
   Molyneux, Elizabeth
   Richards-Kortum, Rebecca R.
TI A Lateral Flow Assay for Quantitative Detection of Amplified HIV-1 RNA
SO PLOS ONE
LA English
DT Article
ID RESOURCE-LIMITED SETTINGS; VIRAL LOAD ASSAY; P24 ANTIGEN; ANTIRETROVIRAL
   THERAPY; MOLECULAR DIAGNOSTICS; AMPLIFICATION; INFECTION
AB Although the accessibility of HIV treatment in developing nations has increased dramatically over the past decade, viral load testing to monitor the response of patients receiving therapy is often unavailable. Existing viral load technologies are often too expensive or resource-intensive for poor settings, and there is no appropriate HIV viral load test currently available at the point-of-care in low resource settings. Here, we present a lateral flow assay that employs gold nanoparticle probes and gold enhancement solution to detect amplified HIV RNA quantitatively. Preliminary results show that, when coupled with nucleic acid sequence based amplification (NASBA), this assay can detect concentrations of HIV RNA that match the clinically relevant range of viral loads found in HIV patients. The lateral flow test is inexpensive, simple and rapid to perform, and requires few resources. Our results suggest that the lateral flow assay may be integrated with amplification and sample preparation technologies to serve as an HIV viral load test for low-resource settings.
C1 [Rohrman, Brittany A.; Leautaud, Veronica; Richards-Kortum, Rebecca R.] Rice Univ, Dept Bioengn, Houston, TX 77251 USA.
   [Molyneux, Elizabeth] Queen Elizabeth Cent Hosp, Coll Med, Dept Paediat, Blantyre, Malawi.
RP Richards-Kortum, RR (reprint author), Rice Univ, Dept Bioengn, Houston, TX 77251 USA.
EM rkortum@rice.edu
RI Richards-Kortum, Rebecca/P-4074-2014
OI Richards-Kortum, Rebecca/0000-0003-2347-9467
FU National Institute of Allergy and Infectious Diseases [R21AI087104];
   Nanobiology Interdisciplinary Graduate Training Program (NIH) [T32
   EB009379]
FX The project described was supported by Award Number R21AI087104 from the
   National Institute of Allergy and Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy and
   Infectious Diseases or the National Institutes of Health. This work was
   also funded in part by the Nanobiology Interdisciplinary Graduate
   Training Program (NIH Grant No. T32 EB009379). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asiello PJ, 2011, LAB CHIP, V11, P1420, DOI 10.1039/c0lc00666a
   Carter D. J., 2007, NUCL ACIDS RES, V35, pe74
   COMPTON J, 1991, NATURE, V350, P91, DOI 10.1038/350091a0
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, GUID US ANT AG HIV 1, P1
   [Anonymous], 2006, GUID US ANT AG HIV 1
   Dimov IK, 2008, LAB CHIP, V8, P2071, DOI 10.1039/b812515e
   Ellerbee AK, 2009, ANAL CHEM, V81, P8447, DOI 10.1021/ac901307q
   Fields B., 2007, FIELDS VIROLOGY
   Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417
   Fu E, 2011, ANAL CHEM, V83, P7941, DOI 10.1021/ac201950g
   Fu E, 2010, SENSOR ACTUAT B-CHEM, V149, P325, DOI 10.1016/j.snb.2010.06.024
   Fu E, 2010, LAB CHIP, V10, P918, DOI 10.1039/b919614e
   Gupta S, 2007, ANAL CHEM, V79, P3810, DOI 10.1021/ac062341m
   He YQ, 2011, BIOSENS BIOELECTRON, V26, P2018, DOI 10.1016/j.bios.2010.08.079
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   LaBarre P, 2011, PLOS ONE, V6, P8
   Lee HH, 2010, J INFECT DIS, V201, pS65, DOI 10.1086/650385
   Lee SH, 2008, LAB CHIP, V8, P2121, DOI 10.1039/b811131f
   Li X, 2010, ANAL BIOANAL CHEM, V396, P495, DOI 10.1007/s00216-009-3195-9
   Liu CC, 2011, LAB CHIP, V11, P2686, DOI 10.1039/c1lc20345b
   Martinez AW, 2010, LAB CHIP, V10, P2499, DOI [10.1039/c0lc00021c, 10.1039/c01c00021c]
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Moore DM, 2008, JAIDS-J ACQ IMM DEF, V49, P477, DOI 10.1097/QAI.0b013e318186eb18
   Parpia ZA, 2010, JAIDS-J ACQ IMM DEF, V55, P413, DOI 10.1097/QAI.0b013e3181f1afbc
   Respess RA, 2005, J CLIN MICROBIOL, V43, P506, DOI 10.1128/JCM.43.1.506-508.2005
   Stewart P, 2010, J CLIN VIROL, V49, P198, DOI 10.1016/j.jcv.2010.07.022
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   WHO UNAIDS UNICEF, 2009, UN ACC SCAL PRIOR HI
   Yu JH, 2011, LAB CHIP, V11, P1286, DOI 10.1039/c0lc00524j
   Zhu HY, 2011, LAB CHIP, V11, P315, DOI [10.1039/c0lc00358a, 10.1039/c01c00358a]
NR 34
TC 53
Z9 53
U1 2
U2 63
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2012
VL 7
IS 9
AR e45611
DI 10.1371/journal.pone.0045611
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014RG
UT WOS:000309392800068
PM 23029134
OA gold
DA 2018-01-05
ER

PT J
AU Sato, Y
   Morimoto, K
   Kubo, T
   Yanagihara, K
   Seyama, T
AF Sato, Yuichiro
   Morimoto, Kinjiro
   Kubo, Takanori
   Yanagihara, Kazuyoshi
   Seyama, Toshio
TI High Mannose-Binding Antiviral Lectin PFL from Pseudomonas fluorescens
   Pf0-1 Promotes Cell Death of Gastric Cancer Cell MKN28 via Interaction
   with alpha 2-Integrin
SO PLOS ONE
LA English
DT Article
ID OSCILLATORIA-AGARDHII; SERRA AGGLUTININ; IN-VITRO; INTEGRIN;
   GLYCOSYLATION; SPECIFICITY; ADHESION; VIRUSES; GLYCANS; ALGAE
AB Novel anti-HIV lectin family which shows a strict binding specificity for high mannose glycans has been found in lower organisms. The bacterial orthologue has been identified in the genome of Pseudomonas fluorescens Pf0-1 and the gene coding a putative lectin was cloned, expressed in Escherichia coli and purified by one step gel filtration. Glycan array screening of the recombinant lectin, termed PFL, has revealed that PFL preferentially recognizes high mannose glycans with alpha 1-3 Man that was highly exposed at the D2 position. In contrast, masking of this alpha 1-3 Man with alpha 1-2 Man dramatically impaired lectin-carbohydrate interactions. Reducing terminal disaccharide, GlcNAc-GlcNAc of high mannose glycans was also essential for PFL-binding. PFL showed a potent anti-influenza virus activity by inhibiting the virus entry into cells at doses of low nanomolar concentration. At micromolar concentration or higher, PFL showed a cytotoxicity accompanying loss of the cell adhesion against human gastric cancer MKN28 cells. The cell surface molecule to which PFL bound was coprecipitated with biotin-labeled PFL and identified as integrin alpha 2 by peptide mass fingerprinting using MALDI-TOF mass spectrometry. Intriguingly, upon treatment with exogenous PFL, integrin alpha 2 on the cell surface underwent rapid internalization to the cytoplasm and accumulated to perinuclear region, together with the bound PFL. The resulting loss of cell adherence would trigger a signaling pathway that induced anoikis-like cell death. These events were effectively inhibited by pretreatment of PFL with mannnan, indicating the involvement of high mannose glycans on PFL-induced cell death that was triggered by PFL-integrin alpha 2 interactions.
C1 [Sato, Yuichiro; Morimoto, Kinjiro] Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Hiroshima, Japan.
   [Kubo, Takanori; Yanagihara, Kazuyoshi; Seyama, Toshio] Yasuda Womens Univ, Fac Pharm, Dept Life Sci, Hiroshima, Japan.
RP Sato, Y (reprint author), Yasuda Womens Univ, Fac Pharm, Dept Med Pharm, Hiroshima, Japan.
EM sato-y@yasuda-u.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [24790101]
FX This research was supported in part by a Grant-in-Aid for Young
   Scientists (B) from the Japan Society for the Promotion of Science
   (JSPS) (Grant number 24790101). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Balzarini Jan, 2007, Antiviral Chemistry & Chemotherapy, V18, P1
   Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001
   Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509
   Chisholm JRM, 1996, NATURE, V381, P382, DOI 10.1038/381382a0                                                                
   Fukuda Y, 2006, ANTI-CANCER DRUG, V17, P943, DOI 10.1097/01.cad.0000224458.13651.b4
   Gu JG, 2009, BIOL PHARM BULL, V32, P780, DOI 10.1248/bpb.32.780                                                              
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200
   Koharudin LMI, 2011, J BIOL CHEM, V286, P1588, DOI 10.1074/jbc.M110.173278
   Liao WR, 2003, J IND MICROBIOL BIOT, V30, P433, DOI 10.1007/s10295-003-0068-7
   Litynska A, 2002, ACTA BIOCHIM POL, V49, P491
   Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83
   MirShekari SY, 1997, J BIOL CHEM, V272, P4027, DOI 10.1074/jbc.272.7.4027                                                          
   Omokawa Y, 2010, INT J PHARMACEUT, V389, P157, DOI 10.1016/j.ijpharm.2010.01.033
   Parret AHA, 2005, APPL ENVIRON MICROB, V71, P5197, DOI 10.1128/AEM.71.9.5197-5207.2005
   Petrossian K, 2007, ACTA HISTOCHEM, V109, P491, DOI 10.1016/j.acthis.2007.05.004
   Pochec E, 2003, BBA-MOL CELL RES, V1643, P113, DOI 10.1016/j.bbamcr.2003.10.004
   Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3
   Rintanen N, 2012, MOL BIOL CELL, V23, P448, DOI 10.1091/mbc.E11-06-0548
   Sanchez-Ruderisch H, 2011, CELL DEATH DIFFER, V18, P806, DOI 10.1038/cdd.2010.148
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Sato Y, 2011, J BIOL CHEM, V286, P19446, DOI 10.1074/jbc.M110.216655
   Sato Y, 2011, BIOCHEM BIOPH RES CO, V405, P291, DOI 10.1016/j.bbrc.2011.01.031
   Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200
   Silby MW, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r51
   Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000
   Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315
NR 28
TC 14
Z9 15
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 20
PY 2012
VL 7
IS 9
AR e45922
DI 10.1371/journal.pone.0045922
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014PT
UT WOS:000309388900111
PM 23029318
OA gold
DA 2018-01-05
ER

PT J
AU Yu, NY
   Hagan, MF
AF Yu, Naiyin
   Hagan, Michael F.
TI Simulations of HIV Capsid Protein Dimerization Reveal the Effect of
   Chemistry and Topography on the Mechanism of Hydrophobic Protein
   Association
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; C-TERMINAL DOMAIN; ASSEMBLY KINETICS;
   WATER MODELS; LIQUID WATER; FORCE-FIELD; FREE-ENERGY; SURFACES;
   DEPENDENCE; INTERFACES
AB Recent work has shown that the hydrophobic protein surfaces in aqueous solution sit near a drying transition. The tendency for these surfaces to expel water from their vicinity leads to self-assembly of macromolecular complexes. In this article, we show with a realistic model for a biologically pertinent system how this phenomenon appears at the molecular level. We focus on the association of the C-terminal domain (CA-C) of the human immunodeficiency virus capsid protein. By combining all-atom simulations with specialized sampling techniques, we measure the water density distribution during the approach of two CA-C proteins as a function of separation and amino acid sequence in the interfacial region. The simulations demonstrate that CA-C protein-protein interactions sit at the edge of a dewetting transition and that this mesoscopic manifestation of the underlying liquid-vapor phase transition can be readily manipulated by biology or protein engineering to significantly affect association behavior. Although the wild-type protein remains wet until contact, we identify a set of in silico mutations, in which three hydrophilic amino acids are replaced with nonpolar residues, that leads to dewetting before association. The existence of dewetting depends on the size and relative locations of substituted residues separated by nanometer length scales, indicating long-range cooperativity and a sensitivity to surface topography. These observations identify important details that are missing from descriptions of protein association based on buried hydrophobic surface area.
C1 [Yu, Naiyin; Hagan, Michael F.] Brandeis Univ, Martin Fisher Sch Phys, Waltham, MA 02254 USA.
RP Hagan, MF (reprint author), Brandeis Univ, Martin Fisher Sch Phys, Waltham, MA 02254 USA.
EM hagan@brandeis.edu
RI Hagan, Michael/N-2177-2014
OI Hagan, Michael/0000-0002-9211-2434
FU National Institute Of Allergy And Infectious Diseases [R01AI080791]
FX This work was supported by award No. R01AI080791 from the National
   Institute Of Allergy And Infectious Diseases. Computational resources
   were provided by the National Science Foundation through TeraGrid
   computing resources (LONI Queenbee and SDSC Trestles) and the Brandeis
   HPCC. We are most grateful to Patrick Varilly for providing us with a
   patch to perform INDUS sampling in GROMACS, to David Chandler for
   comments on manuscript, and to Francesco Pontiggia for insightful
   discussions.
CR Acharya H, 2010, FARADAY DISCUSS, V146, P353, DOI 10.1039/b927019a
   Alcaraz LA, 2008, FEBS J, V275, P3299, DOI 10.1111/j.1742-4658.2008.06478.x
   Alcaraz LA, 2007, BIOPHYS J, V93, P1264, DOI 10.1529/biophysj.106.101089
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Berne BJ, 2009, ANNU REV PHYS CHEM, V60, P85, DOI 10.1146/annurev.physchem.58.032806.104445
   Bjelkmar P, 2010, J CHEM THEORY COMPUT, V6, P459, DOI 10.1021/ct900549r
   Bocanegra R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023877
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Carambassis A, 1998, PHYS REV LETT, V80, P5357, DOI 10.1103/PhysRevLett.80.5357                                                     
   Ceres P, 2002, BIOCHEMISTRY-US, V41, P11525, DOI 10.1021/bi0261645
   Chandler D, 2005, NATURE, V437, P640, DOI 10.1038/nature04162
   Cheng YK, 1998, NATURE, V392, P696
   Christenson HK, 2001, ADV COLLOID INTERFAC, V91, P391, DOI 10.1016/S0001-8686(00)00036-1                                                   
   Dahirel V, 2011, P NATL ACAD SCI USA, V108, P11530, DOI 10.1073/pnas.1105315108
   deBerg M, 2008, COMPUTATIONAL GEOMET
   del Alamo M, 2005, J MOL BIOL, V345, P893, DOI 10.1016/j.jmb.2004.10.086
   del Alamo M, 2003, J BIOL CHEM, V278, P27923, DOI 10.1074/jbc.M304466200
   EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0
   Endres D, 2002, BIOPHYS J, V83, P1217, DOI 10.1016/S0006-3495(02)75245-4                                                   
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004
   Giovambattista N, 2008, P NATL ACAD SCI USA, V105, P2274, DOI 10.1073/pnas.0708088105
   Hagan MF, 2006, BIOPHYS J, V91, P42, DOI 10.1529/biophysj.105.076851
   Hagan MF, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3635775
   Hagan MF, 2010, BIOPHYS J, V98, P1065, DOI 10.1016/j.bpj.2009.11.023
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   HORTON N, 1992, PROTEIN SCI, V1, P169
   Hua L, 2009, J PHYS CHEM C, V113, P5244, DOI 10.1021/jp8088758
   Huang DM, 2000, P NATL ACAD SCI USA, V97, P8324, DOI 10.1073/pnas.120176397
   Hummer G, 1998, PHYS REV LETT, V80, P4193, DOI 10.1103/PhysRevLett.80.4193                                                     
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Jack RL, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.021119
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kegel WK, 2004, BIOPHYS J, V86, P3905, DOI 10.1529/biophysj.104.040055
   Koishi T., 2005, J CHEM PHYS, V123
   Krone MG, 2008, J AM CHEM SOC, V130, P11066, DOI 10.1021/ja8017303
   Kuiken C, 2010, HIV SEQUENCE COMPEND
   KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812                                                           
   Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6
   LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226                                                                
   Lidon-Moya MC, 2005, PROTEIN SCI, V14, P2387, DOI 10.1110/ps.041324305
   Liu P, 2005, NATURE, V437, P159, DOI 10.1038/nature03926
   Lum K, 1999, J PHYS CHEM B, V103, P4570, DOI 10.1021/jp984327m                                                               
   Mateu MG, 2009, FEBS J, V276, P6098, DOI 10.1111/j.1742-4658.2009.07313.x
   Mateu MG, 2002, J MOL BIOL, V318, P519, DOI 10.1016/S0022-2836(02)00091-8
   Mittal J, 2010, FARADAY DISCUSS, V146, P341, DOI 10.1039/b925913a
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805                                                           
   Mora T, 2011, J STAT PHYS, V144, P268, DOI 10.1007/s10955-011-0229-4
   Nguyen HD, 2007, NANO LETT, V7, P338, DOI 10.1021/nl062449h
   Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359
   Paravastu AK, 2008, P NATL ACAD SCI USA, V105, P18349, DOI 10.1073/pnas.0806270105
   PARKER JL, 1994, J PHYS CHEM-US, V98, P8468, DOI 10.1021/j100085a029                                                             
   Patel AJ, 2012, J PHYS CHEM B, V116, P2498, DOI 10.1021/jp2107523
   Patel AJ, 2011, J STAT PHYS, V145, P265, DOI 10.1007/s10955-011-0269-9
   Patel AJ, 2010, J PHYS CHEM B, V114, P1632, DOI 10.1021/jp909048f
   Pornillos O, 2011, NATURE, V469, P424, DOI 10.1038/nature09640
   Pornillos O, 2010, J MOL BIOL, V401, P985, DOI 10.1016/j.jmb.2010.06.042
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Rapaport DC, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/10/104115
   Rodier F, 2005, PROTEINS, V60, P36, DOI 10.1002/prot.20478
   Sachse C, 2008, P NATL ACAD SCI USA, V105, P7462, DOI 10.1073/pnas.0712290105
   SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1016/S0022-2836(95)80064-6
   SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294
   Stillinger FH, 1973, J SOLUTION CHEM, V2, P141, DOI 10.1007/BF00651970                                                              
   von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003
   Vulevic B, 1997, BIOPHYS J, V72, P1357, DOI 10.1016/S0006-3495(97)78782-4                                                   
   Worthylake DK, 1999, ACTA CRYSTALLOGR D, V55, P85, DOI 10.1107/S0907444998007689
   Yu X, 2009, BIOMACROMOLECULES, V10, P390, DOI 10.1021/bm801151r
   Zhang JY, 2009, MINI-REV MED CHEM, V9, P510, DOI 10.2174/138955709787847958                                                      
   Zhou RH, 2004, SCIENCE, V305, P1605, DOI 10.1126/science.1101176
   Zlotnick A, 2003, VIROLOGY, V315, P269, DOI 10.1016/S0042-6822(03)00586-5
NR 76
TC 8
Z9 8
U1 2
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD SEP 19
PY 2012
VL 103
IS 6
BP 1363
EP 1369
DI 10.1016/j.bpj.2012.08.016
PG 7
WC Biophysics
SC Biophysics
GA 009HV
UT WOS:000309017800029
PM 22995509
OA gold
DA 2018-01-05
ER

PT J
AU Andrieux-Meyer, I
   Calmy, A
   Cahn, P
   Clayden, P
   Raguin, G
   Katlama, C
   Vitoria, M
   Levin, A
   Lynch, S
   Goemaere, E
   Ford, N
AF Andrieux-Meyer, Isabelle
   Calmy, Alexandra
   Cahn, Pedro
   Clayden, Polly
   Raguin, Gilles
   Katlama, Christine
   Vitoria, Marco
   Levin, Andrew
   Lynch, Sharonann
   Goemaere, Eric
   Ford, Nathan
TI Preferred antiretroviral drugs for the next decade of scale up
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Editorial Material
DE Antiretroviral therapy; regimen sequencing; treatment optimization
ID RESOURCE-LIMITED SETTINGS; INCOME COUNTRIES; LIFE EXPECTANCY; THERAPY;
   METAANALYSIS; TENOFOVIR; SAFETY; COHORT
AB Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings.
C1 [Andrieux-Meyer, Isabelle; Calmy, Alexandra; Lynch, Sharonann; Ford, Nathan] Med Sans Frontieres, Geneva, Switzerland.
   [Calmy, Alexandra] Hop Univ Geneve, Geneva, Switzerland.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
   [Clayden, Polly] HIV I Base, London, England.
   [Raguin, Gilles] Esther, Paris, France.
   [Raguin, Gilles] St Antoine Hosp, Dept Infect Dis, Paris, France.
   [Katlama, Christine] Grp Hosp Pitie Salpetriere, F-75634 Paris, France.
   [Katlama, Christine] SOLTHIS, Paris, France.
   [Vitoria, Marco] WHO, Dept HIV AIDS Antiretroviral Treatment & HIV Care, CH-1211 Geneva, Switzerland.
   [Levin, Andrew] Clinton Hlth Access Initiat, New York, NY USA.
   [Goemaere, Eric] Med Sans Frontieres, Cape Town, South Africa.
   [Ford, Nathan] Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa.
RP Ford, N (reprint author), Med Sans Frontieres, Geneva, Switzerland.
EM Nathan.Ford@msf.org
CR Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Calmy A, 2004, AIDS, V18, P2353
   Clayden P, 2012, 2012 PIPELINE REPORT
   ClinicalTrials.gov, SAFETY AND EFFICACY
   Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681
   Crawford KW, 2012, LANCET INFECT DIS, V12, P550, DOI 10.1016/S1473-3099(12)70134-2
   Ford N, 2011, AIDS, V25, P2301, DOI 10.1097/QAD.0b013e32834cdb71
   Ford N, 2010, CURR OPIN HIV AIDS, V5, P38, DOI 10.1097/COH.0b013e3283339b41
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Kranzer K, 2011, TROP MED INT HEALTH, V16, P1297, DOI 10.1111/j.1365-3156.2011.02828.x
   Renaud-Thery F, 2011, INT J TUBERC LUNG D, V16, P6
   Lynch S, 2012, SCIENCE, V337, P298, DOI 10.1126/science.1225702
   Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438
   Mills EJ, 2011, ANN INTERN MED, V155, P209, DOI 10.7326/0003-4819-155-4-201108160-00358
   MSF, 2011, ANTIRETROVIRAL SEQUE
   MSF/UNAIDS, 2012, CLOSER TO HOME DELIV
   US Food and Drugs Administration, 2012, ANTIRETROVIRAL DRUGS
   World Health Organization, 2011, SHORT TERM PRIORITIE
   WHO, 2012, TECHNICAL UPDATE ON
   World Health Organisation (WHO), 2011, PROGRESS REPORT 2011
   WHO, 2011, CONSULTATION THE STR
   WHO/UNAIDS, 2011, THE TREATMENT 2 0 FR
NR 22
TC 7
Z9 7
U1 0
U2 1
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD SEP 18
PY 2012
VL 15
AR 17986
DI 10.7448/IAS.15.2.17986
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 025RR
UT WOS:000310210800001
PM 23010379
OA gold
DA 2018-01-05
ER

PT J
AU Climent, N
   Munier, S
   Pique, N
   Garcia, F
   Pavot, V
   Leon, A
   Primard, C
   Miralles, L
   Rovira, C
   Casanova, V
   McCormick, P
   Gatell, JM
   Verrier, B
   Gallart, T
AF Climent, N.
   Munier, S.
   Pique, N.
   Garcia, F.
   Pavot, V.
   Leon, A.
   Primard, C.
   Miralles, L.
   Rovira, C.
   Casanova, V.
   McCormick, P.
   Gatell, J. M.
   Verrier, B.
   Gallart, T.
TI Loading dendritic cells from HIV-1 infected patients with PLA-p24
   nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell
   responses
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Climent, N.; Garcia, F.; Leon, A.; Miralles, L.; Rovira, C.; Gatell, J. M.; Gallart, T.] Hosp Clin Barcelona, Barcelona, Spain.
   [Munier, S.; Pavot, V.; Primard, C.; Verrier, B.] FRE3310 CNRS UCBL, Inst Biol & Chim Prot, Lyon, France.
   [Pique, N.] U Barcelona, Fac Pharm, Dept Microbiol & Parasitol, Barcelona, Spain.
   [Casanova, V.; McCormick, P.] Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Barcelona, Spain.
RI Leon, Agathe/K-9851-2015
OI Leon, Agathe/0000-0002-1198-5090; McCormick, Peter/0000-0002-2225-5181
NR 0
TC 0
Z9 0
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR P247
DI 10.1186/1742-4690-9-S2-P247
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100320
OA gold
DA 2018-01-05
ER

PT J
AU Hanson, MC
   Mata-Fink, J
   Abraham, W
   Wittrup, KD
   Irvine, DJ
AF Hanson, M. C.
   Mata-Fink, J.
   Abraham, W.
   Wittrup, K. D.
   Irvine, D. J.
TI Shaping humoral responses against mini-libraries of HIV env antigens via
   lipid nanoparticle vaccine delivery
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Hanson, M. C.; Mata-Fink, J.; Abraham, W.] MIT, Cambridge, MA 02139 USA.
   [Wittrup, K. D.] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
   [Irvine, D. J.] Howard Hughes Med Inst, Chevy Chase, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR O63
DI 10.1186/1742-4690-9-S2-O63
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100064
OA gold
DA 2018-01-05
ER

PT J
AU Pavot, V
   Rochereau, N
   Lahaye, V
   Genin, C
   Perouzel, E
   Lioux, T
   Primard, C
   Delair, T
   Paul, S
   Verrier, B
AF Pavot, V.
   Rochereau, N.
   Lahaye, V.
   Genin, C.
   Perouzel, E.
   Lioux, T.
   Primard, C.
   Delair, T.
   Paul, S.
   Verrier, B.
TI Induction of HIV mucosal immunity at distal sites after encapsulation of
   NOD1 and NOD2 ligands in biodegradable nanocarriers
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Pavot, V.; Lahaye, V.; Primard, C.; Verrier, B.] IBCP CNRS, Lyon, France.
   [Rochereau, N.; Genin, C.; Paul, S.] GIMAP, St Etienne, France.
   [Perouzel, E.; Lioux, T.] Cayla Invivogen, Toulouse, France.
   [Delair, T.] Univ Lyon IMP, Lyon, France.
NR 0
TC 0
Z9 0
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR P194
DI 10.1186/1742-4690-9-S2-P194
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100267
OA gold
DA 2018-01-05
ER

PT J
AU Pejawar-Gaddy, S
   Kovacs, J
   Barouch, D
   Chen, B
   Irvine, D
AF Pejawar-Gaddy, S.
   Kovacs, J.
   Barouch, D.
   Chen, B.
   Irvine, D.
TI Design of lipid nanoparticle delivery agents for multivalent display of
   recombinant Env trimers in HIV vaccination
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Pejawar-Gaddy, S.; Irvine, D.] MIT, Boston, MA USA.
   [Kovacs, J.; Barouch, D.; Chen, B.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR O10
DI 10.1186/1742-4690-9-S2-O10
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100011
OA gold
DA 2018-01-05
ER

PT J
AU Rao, V
AF Rao, V.
TI The emptied bacteriophage T4 head: a novel nanoparticle vehicle to
   simultaneously deliver HIV-1 antigens and genes into dendritic cells
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Rao, V.] Catholic Univ Amer, Washington, DC 20064 USA.
NR 0
TC 0
Z9 0
U1 2
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR P324
DI 10.1186/1742-4690-9-S2-P324
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100397
OA gold
DA 2018-01-05
ER

PT J
AU Zwick, MB
   Leaman, D
AF Zwick, M. B.
   Leaman, D.
TI Purification of chemically fixed HIV-1 spikes for oriented display on
   nanoparticles
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Zwick, M. B.; Leaman, D.] Scripps Res Inst, La Jolla, CA 92037 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD SEP 13
PY 2012
VL 9
SU 2
AR P347
DI 10.1186/1742-4690-9-S2-P347
PG 1
WC Virology
SC Virology
GA 015UO
UT WOS:000309472100420
OA gold
DA 2018-01-05
ER

PT J
AU Nogues, C
   Leh, H
   Lautru, J
   Delelis, O
   Buckle, M
AF Nogues, Claude
   Leh, Herve
   Lautru, Joseph
   Delelis, Olivier
   Buckle, Malcolm
TI Efficient Antifouling Surface for Quantitative Surface Plasmon Resonance
   Based Biosensor Analysis
SO PLOS ONE
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; GOLD NANOPARTICLES; PROTEIN ADSORPTION; HIV-1
   INTEGRASE; MODEL SYSTEM; DNA; BINDING; HYBRIDIZATION; OLIGONUCLEOTIDES;
   LIGANDS
AB Non-specific binding to biosensor surfaces is a major obstacle to quantitative analysis of selective retention of analytes at immobilized target molecules. Although a range of chemical antifouling monolayers has been developed to address this problem, many macromolecular interactions still remain refractive to analysis due to the prevalent high degree of nonspecific binding. In this manuscript we explore the dynamic process of the formation of self-assembled monolayers and optimize physical and chemical properties thus reducing considerably non-specific binding while maintaining the integrity of the immobilized biomolecules. As a result, analysis of specific binding of analytes to immobilized target molecules is significantly facilitated.
C1 [Nogues, Claude; Leh, Herve; Delelis, Olivier; Buckle, Malcolm] CNRS, ENS Cachan, LBPA, Cachan, France.
   [Lautru, Joseph] ENS Cachan, Inst Alembert, Cachan, France.
RP Nogues, C (reprint author), CNRS, ENS Cachan, LBPA, Cachan, France.
EM buckle@lbpa.ens-cachan.fr
FU Eurotransbio financed project [Qubis ETB-2006-066]; CONCOURS NATIONAL
   aide a la creation d'entreprise de technologies innovantes du ministere
   de l'Enseignement superieur et de OSEO/ANVAR (Agence Nationale de la
   Valorisation de la Recherche); Association National pour la Recherche
   Scientifique (ANRS) [ANR-06-PCVI-0015-04 IMFOVIR]; Centre National de la
   Recherche Francaise (CNRS)
FX This work was supported by: 1) Eurotransbio financed project (Qubis
   ETB-2006-066). http://www.eurotransbio.eu; 2) CONCOURS NATIONAL 2008
   aide a la creation d'entreprise de technologies innovantes du ministere
   de l'Enseignement superieur et de OSEO/ANVAR (Agence Nationale de la
   Valorisation de la Recherche). http://www.oseo.fr/; 3) Association
   National pour la Recherche Scientifique (ANRS) for support of the
   ANR-06-PCVI-0015-04 IMFOVIR. http://www.agence-nationale-recherche.fr;
   4) Centre National de la Recherche Francaise (CNRS).
   http://www.cnrs.fr/. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bouffartigues E, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm030
   Bouffartigues E, 2007, NAT STRUCT MOL BIOL, V14, P441, DOI 10.1038/nsmb1233
   Buckle M, 1996, P NATL ACAD SCI USA, V93, P889, DOI 10.1073/pnas.93.2.889                                                           
   Caumont A, 1999, FEBS LETT, V455, P154, DOI 10.1016/S0014-5793(99)00859-5
   COFFIN JM, 1997, RETROVIRUSES
   Delelis O, 2008, J BIOL CHEM, V283, P27838, DOI 10.1074/jbc.M803257200
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j
   Halperin A, 2006, J PHYS-CONDENS MAT, V18, pS463, DOI 10.1088/0953-8984/18/18/S01
   Harder P, 1998, J PHYS CHEM B, V102, P426, DOI 10.1021/jp972635z                                                               
   Harris JM, 1992, POLYETHYLENE GLYCOL, P408
   Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586                                                               
   Herrwerth S, 2003, J AM CHEM SOC, V125, P9359, DOI 10.1021/ja034820y
   Hucknall A, 2009, ADV MATER, V21, P2441, DOI 10.1002/adma.200900383
   Lahiri J, 1999, LANGMUIR, V15, P7186, DOI 10.1021/la9815650                                                               
   Lahiri J, 1999, ANAL CHEM, V71, P777, DOI 10.1021/ac980959t                                                               
   Nogues C, 2004, PHYS CHEM CHEM PHYS, V6, P4459, DOI 10.1039/b410862k
   Nogues C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012152
   Peled D, 2008, LANGMUIR, V24, P11842, DOI 10.1021/la801437n
   Peled D, 2010, J PHYS CHEM B, V114, P8581, DOI 10.1021/jp104533q
   Pertsin AJ, 1998, J PHYS CHEM B, V102, P4918, DOI 10.1021/jp9806617                                                               
   Petrovykh DY, 2003, J AM CHEM SOC, V125, P5219, DOI 10.1021/ja029450c
   PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032
   Smolov M, 2006, FEBS J, V273, P1137, DOI 10.1111/j.1742-4658.2006.05139.x
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Storhoff JJ, 2002, P SOC PHOTO-OPT INS, V4937, P1, DOI 10.1117/12.476069
   Xu J, 2005, J AM CHEM SOC, V127, P13227, DOI 10.1021/ja052352h
NR 27
TC 8
Z9 8
U1 0
U2 40
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 12
PY 2012
VL 7
IS 9
AR e44287
DI 10.1371/journal.pone.0044287
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005GJ
UT WOS:000308738500043
PM 22984487
OA gold
DA 2018-01-05
ER

PT J
AU Geall, AJ
   Verma, A
   Otten, GR
   Shaw, CA
   Hekele, A
   Banerjee, K
   Cu, Y
   Beard, CW
   Brito, LA
   Krucker, T
   O'Hagan, DT
   Singh, M
   Mason, PW
   Valiante, NM
   Dormitzer, PR
   Barnett, SW
   Rappuoli, R
   Ulmer, JB
   Mandl, CW
AF Geall, Andrew J.
   Verma, Ayush
   Otten, Gillis R.
   Shaw, Christine A.
   Hekele, Armin
   Banerjee, Kaustuv
   Cu, Yen
   Beard, Clayton W.
   Brito, Luis A.
   Krucker, Thomas
   O'Hagan, Derek T.
   Singh, Manmohan
   Mason, Peter W.
   Valiante, Nicholas M.
   Dormitzer, Philip R.
   Barnett, Susan W.
   Rappuoli, Rino
   Ulmer, Jeffrey B.
   Mandl, Christian W.
TI Nonviral delivery of self-amplifying RNA vaccines
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE vaccine platform; SAM vaccine; respiratory syncytial virus; HIV
ID RESPIRATORY SYNCYTIAL VIRUS; MESSENGER-RNA; DNA VACCINES; ALPHAVIRUS
   VECTORS; VACCINATION TRIAL; DIRECT-INJECTION; SIRNA DELIVERY;
   GENE-TRANSFER; IN-VIVO; IMMUNITY
AB Despite more than two decades of research and development on nucleic acid vaccines, there is still no commercial product for human use. Taking advantage of the recent innovations in systemic delivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine. Here we show that nonviral delivery of a 9-kb self-amplifying RNA encapsulated within an LNP substantially increased immunogenicity compared with delivery of unformulated RNA. This unique vaccine technology was found to elicit broad, potent, and protective immune responses, that were comparable to a viral delivery technology, but without the inherent limitations of viral vectors. Given the many positive attributes of nucleic acid vaccines, our results suggest that a comprehensive evaluation of nonviral technologies to deliver self-amplifying RNA vaccines is warranted.
C1 [Geall, Andrew J.; Verma, Ayush; Otten, Gillis R.; Shaw, Christine A.; Hekele, Armin; Banerjee, Kaustuv; Cu, Yen; Beard, Clayton W.; Brito, Luis A.; O'Hagan, Derek T.; Singh, Manmohan; Mason, Peter W.; Valiante, Nicholas M.; Dormitzer, Philip R.; Barnett, Susan W.; Rappuoli, Rino; Ulmer, Jeffrey B.; Mandl, Christian W.] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA.
   [Krucker, Thomas] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
RP Geall, AJ (reprint author), Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA.
EM andrew.geall@novartis.com
RI Verma, Ayush/H-1217-2012
FU HIV Vaccine Research and Design Grant [5P01AI066287]
FX We thank the RNA Vaccine Platform Team at Novartis Vaccines and
   Diagnostics and, in particular, Jacob Archer, Mithra Rothfeder, and
   Avishek Nandi for their assistance in producing the RNA and DNA for
   these studies; Michelle Chan for coordinating the delivery of
   formulations for the animal studies; Alison Curtis and Melissa Sackal
   for their assistance in conducting the bioluminescence studies in mice;
   Christine Dong Lee for conducting the RSV-F immunogenicity studies in
   mice and running the corresponding immunological assays; Kate Broderick
   (Inovio, San Diego) for providing on-site training using the Elgen DNA
   Delivery System; Tina Scalzo and Melissa Sackal for conducting the ELISA
   and lung titer assays in the cotton rat study; Giuseppe Palladino and
   his serology team; and James Monroe and Kristian Friedrich for assisting
   in the respiratory syncytial virus neutralization assay. Funding for the
   HIV studies was provided by HIV Vaccine Research and Design Grant
   5P01AI066287.
CR Atkins Gregory J., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000859
   Barnett SW, 2010, J VIROL, V84, P5975, DOI 10.1128/JVI.02533-09
   Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135
   Dupuis M, 2000, J IMMUNOL, V165, P2850, DOI 10.4049/jimmunol.165.5.2850                                                     
   Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102                                                     
   Heyes J, 2005, J CONTROL RELEASE, V107, P276, DOI 10.1016/j.jconrel.2005.06.014
   Jeffs LB, 2005, PHARM RES, V22, P362, DOI 10.1007/s11095-004-1873-z
   JOHANNING FW, 1995, NUCLEIC ACIDS RES, V23, P1495, DOI 10.1093/nar/23.9.1495
   Johansson DX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029732
   Jones KL, 2007, BIOTECHNIQUES, V43, P675, DOI 10.2144/000112593
   Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101                                                         
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749
   Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285
   Pascolo Steve, 2008, V183, P221
   Perri S, 2003, J VIROL, V77, P10394, DOI 10.1128/JVI.77.19.10394-10403.2003
   Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4
   Piggott JM, 2009, MOL MED REP, V2, P753, DOI 10.3892/mmr_00000168
   PRINCE GA, 1985, J VIROL, V55, P517
   Probst Jochen, 2006, Genet Vaccines Ther, V4, P4, DOI 10.1186/1479-0556-4-4
   Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085
   Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360
   Rittig SM, 2011, MOL THER, V19, P990, DOI 10.1038/mt.2010.289
   Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Smerdou C, 1999, CURR OPIN MOL THER, V1, P244
   Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108
   Tao WK, 2011, MOL THER, V19, P567, DOI 10.1038/mt.2010.282
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   Weide B, 2008, J IMMUNOTHER, V31, P180, DOI 10.1097/CJI.0b013e31815ce501
   Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068
   Weiss R, 2012, EXPERT REV VACCINES, V11, P55, DOI [10.1586/erv.11.168, 10.1586/ERV.11.168]
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wilson KD, 2007, INT IMMUNOPHARMACOL, V7, P1064, DOI 10.1016/j.intimp.2007.04.002
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Zimmer G, 2010, VIRUSES-BASEL, V2, P413, DOI 10.3390/v2020413
NR 40
TC 119
Z9 121
U1 0
U2 33
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 4
PY 2012
VL 109
IS 36
BP 14604
EP 14609
DI 10.1073/pnas.1209367109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 007TZ
UT WOS:000308912600064
PM 22908294
OA gold
DA 2018-01-05
ER

PT J
AU Azizi, K
   Sohrabinia, A
AF Azizi, Khaled
   Sohrabinia, Ali
TI A DFT study on the interaction between adsorbed silver on C-60 and
   disulfide bond
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE C-60 fullerene; Silver atom; Disulfide bond; DMDS; HIV-1/gp 120
ID DENSITY-FUNCTIONAL THEORY; CORRELATION-ENERGY; HYDROGEN STORAGE;
   AB-INITIO; NANOPARTICLES; VIRUS; BINDING; REPLICATION; INHIBITION;
   FULLERENES
AB Adsorption of a silver atom on the surface of Buckyball (C-60) was investigated using density functional theory (DFT). The Ag atom tends to occupy the bridge site over C-C bond in pentagon-hexagon ring junction with the binding energy of -3833 kcal mol(-1). The capability of destroying S-S bond by both a single silver atom and the silver atom adsorbed on C-60 was also investigated by DFT calculations using dimethyl disulfide as the molecular model. The results of the natural bond orbital (NBO) and population analysis indicate that the cleavage of the S S bond effectively occurs by the silver atom adsorbed on C-60. Since denaturation of disulfide bonds of envelope glycoprotein (gp) 120 is a key step in the prevention of the spread of HIV-1, the development of the proposed study is promised to HIV-1 research field. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Azizi, Khaled; Sohrabinia, Ali] Univ Kurdistan, Dept Chem, Sanandaj, Iran.
RP Azizi, K (reprint author), Univ Kurdistan, Dept Chem, Sanandaj, Iran.
EM k.azizi@uok.ac.ir
CR Bakry R, 2007, INT J NANOMED, V2, P639
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Barbouche R, 2003, J BIOL CHEM, V278, P3131, DOI 10.1074/jbc.M205467200
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913                                                                
   Chamberlain TW, 2011, CHEM-EUR J, V17, P668, DOI 10.1002/chem.201001288
   Chandrakumar KRS, 2008, NANO LETT, V8, P13, DOI 10.1021/nl071456i
   Da Ros T, 1999, CHEM COMMUN, P663
   De Almeida WB, 2005, J BRAZIL CHEM SOC, V16, P345, DOI 10.1590/S0103-50532005000300008
   Denis PA, 2005, J CHEM THEORY COMPUT, V1, P900, DOI 10.1021/ct0500702
   Elechiguerra J.L., 2005, J NANOBIOTECHNOL, V3, P1477
   FRISCH MJ, 1998, GAUSSIAN 98
   Han JG, 2001, CHEM PHYS, V263, P255, DOI 10.1016/S0301-0104(00)00381-5
   HAY PJ, 1985, J CHEM PHYS, V82, P270, DOI 10.1063/1.448799
   Hobza P., 1988, INTERMOLECULAR COMPL
   Huang WJ, 2003, TRIBOL INT, V36, P163, DOI 10.1016/S0301-679X(02)00130-5                                                   
   Kaneti J, 2002, J PHYS CHEM A, V106, P11197, DOI 10.1021/jp020994a
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Kumar A, 2008, NAT MATER, V7, P236, DOI 10.1038/nmat2099
   Lan JH, 2008, J PHYS CHEM C, V112, P5598, DOI 10.1021/jp711754h
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   LEKUTIS C, 1992, J ACQ IMMUN DEF SYND, V5, P78
   Liau SY, 1997, LETT APPL MICROBIOL, V25, P279, DOI 10.1046/j.1472-765X.1997.00219.x                                                
   Lide D.R., 2003, CRC HDB CHEM PHYS, V84
   Loboda O, 2009, FULLER NANOTUB CAR N, V17, P457, DOI 10.1080/15363830903008141
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mastro M.A., 2009, MED CHEM RES, V19, P1074
   McDonnell G, 2007, ANTISEPSIS DISINFECT
   Nanda KK, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.106102
   Ozcan M, 2008, ACTA PHYS-CHIM SIN, V24, P1387, DOI 10.1016/S1872-1508(08)60059-5
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Sinclair JP, 1997, BIODRUGS, V8, P128, DOI 10.2165/00063030-199708020-00006                                                
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun Q, 2006, J AM CHEM SOC, V128, P9741, DOI 10.1021/ja058330c
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   VANDUIJNEVELDT FB, 1994, CHEM REV, V94, P1873, DOI 10.1021/cr00031a007                                                             
   Wang L.S., 1997, STRUCTURE PROPERTIES
   Wilson L. J., 1999, Electrochemical Society Interface, V8, P24
   Yoon M., 2009, J CHEM PHYS, V131, P64707
NR 41
TC 1
Z9 1
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD SEP
PY 2012
VL 38
BP 354
EP 359
DI 10.1016/j.jmgm.2012.06.003
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA 068UX
UT WOS:000313392800036
PM 23085174
DA 2018-01-05
ER

PT J
AU Meher, BR
   Wang, YX
AF Meher, Biswa Ranjan
   Wang, Yixuan
TI Binding of Single walled carbon nanotube to WT and mutant HIV-1
   proteases: Analysis of flap dynamics and binding mechanism
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE Single walled carbon nanotube (SWCNT); Molecular dynamics; Binding
   energy; MM-PBSA; HIV-1 protease inhibitor; Flap dynamics
ID DRUG-RESISTANT MUTANTS; ORALLY BIOAVAILABLE INHIBITOR; RESOLUTION
   CRYSTAL-STRUCTURES; MOLECULAR-DYNAMICS; FULLERENE DERIVATIVES;
   WILD-TYPE; FREE-ENERGY; POTENT; FLEXIBILITY; AMPRENAVIR
AB Most of the currently treated HIV-1 protease (HIV-PR) inhibitors have been prone to suffer from the mutations associated drug resistance. Therefore, it is necessary to search for potent alternatives against the drug resistance. In the current study we have tested the single-walled carbon nanotube (SWCNT) as an inhibitor in wild type (WT) as well as in three primary mutants (I50V(PR), V82A(PR) and I84V(PR)) of the HIV-1-PR through docking the SWCNT in the active site region, and then performed all-atom MD simulations for the complexes. The conformational dynamics of HIV-PR with a 20 ns trajectory reveals that the SWCNT can effectively bind to the HIV-1-PR active site and regulate the flap dynamics such as maintaining the flap-flap closed. To gain an insight into the binding affinity, we also performed the MM-PBSA based binding free energy calculations for the four HIV-PR/SWCNT complexes. It was observed that, although the binding between the SWCNT and the HIV-PR decreases due to the mutations, the SWCNTs bind to the HIV-PRs 3-5 folds stronger than the most potent HIV-1-PR inhibitor, TMC114. Remarkably, the significant interactions with binding energy higher than 1 kcal/mol focus on the flap and active regions, which favors closing flap-flap and deactivating the active residues of the HIV-PR. The flap dynamics and binding strength information for HIV-PR and SWCNTs can help design SWCNT-based HIV-1-PR inhibitors. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Meher, Biswa Ranjan; Wang, Yixuan] Albany State Univ, Dept Nat Sci, Computat Chem Lab, Albany, GA 31705 USA.
RP Wang, YX (reprint author), Albany State Univ, Dept Nat Sci, Computat Chem Lab, Albany, GA 31705 USA.
EM ywang@asurams.edu
FU National Institute of General Medical of the National Institute of
   Health [SC3GM082324]; American Recovery and Reinvestment Act
   [3SC3GM082324-02S1]; Pittsburgh Supercomputing Center, NCSA-Teragrid
   [CHE100117]
FX This work was supported by the National Institute of General Medical of
   the National Institute of Health (SC3GM082324), the American Recovery
   and Reinvestment Act (3SC3GM082324-02S1). The authors thank Pittsburgh
   Supercomputing Center, NCSA-Teragrid for providing the computational
   facilities to carry out the work in the form of a startup grant
   (CHE100117) to BRM.
CR Alcaro S, 2009, J CHEM INF MODEL, V49, P1751, DOI 10.1021/ci900012k
   Aruksakunwong O, 2007, CURR COMPUT-AID DRUG, V3, P201, DOI 10.2174/157340907781695431                                                      
   Bayly C. I., 1993, J PHYS CHEM, V97
   Benyamini H, 2006, BIOCONJUGATE CHEM, V17, P378, DOI 10.1021/bc050299g
   Berendsen H.J.C., 1984, J CHEM PHYS, V81, P7
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Case D. A., 2010, AMBER 11
   CHEN ZG, 1994, J BIOL CHEM, V269, P26344
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Compain P, 2010, ANGEW CHEM INT EDIT, V49, P5753, DOI 10.1002/anie.201002802
   Dewar M. J. S., 1985, J AM CHEM SOC, V107
   Essmann U., 1995, J CHEM PHYS, V103, P17, DOI DOI 10.1063/1
   Freedberg DI, 1998, J AM CHEM SOC, V120, P7916, DOI 10.1021/ja981206r                                                               
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hou TJ, 2007, J MED CHEM, V50, P1177, DOI 10.1021/jm0609162
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024
   Innocenti A, 2010, BIOORGAN MED CHEM, V18, P2822, DOI 10.1016/j.bmc.2010.03.026
   Jorgensen WL, 1983, J CHEM PHYS, V79, P10, DOI 10.1063/1.445869
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   Kar P, 2012, J COMPUT AID MOL DES, V26, P215, DOI 10.1007/s10822-012-9550-5
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c
   Li DC, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3148022
   Mahalingam B, 2004, EUR J BIOCHEM, V271, P1516, DOI 10.1111/j.1432-1033.2004.04060.x
   Mashino T, 2001, FULLERENE SCI TECHN, V9, P191, DOI 10.1081/FST-100102966                                                           
   Meher BR, 2012, J PHYS CHEM B, V116, P1884, DOI 10.1021/jp2074804
   Meng XM, 2007, J ENZYM INHIB MED CH, V22, P293, DOI 10.1080/14756360601114270
   Meng XM, 2006, CHINESE SCI BULL, V51, P2550, DOI 10.1007/s11434-006-2142-9
   Mongan J, 2004, J COMPUT CHEM, V25, P2038, DOI 10.1002/jcc.20139
   Muzammil S, 2007, J VIROL, V81, P5144, DOI 10.1128/JVI.02706-06
   Ohtaka H, 2002, PROTEIN SCI, V11, P1908, DOI 10.1110/ps.0206402
   Onufriev A, 2000, J PHYS CHEM B, V104, P3712, DOI 10.1021/jp994072s                                                               
   Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702
   Piana S, 2002, J MOL BIOL, V319, P567, DOI 10.1016/S0022-2836(02)00301-7
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Shen CH, 2010, FEBS J, V277, P3699, DOI 10.1111/j.1742-4658.2010.07771.x
   Stoica I, 2008, J AM CHEM SOC, V130, P2639, DOI 10.1021/ja0779250
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   Tie YF, 2007, PROTEINS, V67, P232, DOI 10.1002/prot.21304
   Tzoupis H, 2011, J COMPUT AID MOL DES, V25, P959, DOI 10.1007/s10822-011-9475-4
   Ueng TH, 1999, FULLERENE SCI TECHN, V7, P681, DOI 10.1080/10641229909351370                                                       
   Wang YF, 2007, J MED CHEM, V50, P4509, DOI 10.1021/jm070482q
   Wang YX, 1996, BIOCHEMISTRY-US, V35, P9945, DOI 10.1021/bi961268z
   Wolff DJ, 2002, ARCH BIOCHEM BIOPHYS, V399, P130, DOI 10.1006/abbi.2002.2766
   Wu EL, 2008, CHEM-EUR J, V14, P8704, DOI 10.1002/chem.200800277
   Yang ST, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/39/395101
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   Zoete V, 2002, J MOL BIOL, V315, P21, DOI 10.1006/jmbi.2001.5173
NR 54
TC 8
Z9 8
U1 4
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD SEP
PY 2012
VL 38
BP 430
EP 445
DI 10.1016/j.jmgm.2012.10.001
PG 16
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA 068UX
UT WOS:000313392800046
PM 23142620
OA green_accepted
DA 2018-01-05
ER

PT J
AU Carvalho, ALM
   Cunha, CP
   Cruz, ETL
   da Silva, JA
   Lira, AAM
   de Santana, DP
AF Carvalho, Andre L. M.
   Cunha, Clemilton P.
   Cruz, Emison T. L.
   da Silva, Jose A.
   Lira, Ana A. M.
   de Santana, Davi. P.
TI Spectrophotometric Determination of Zidovudine-Loaded Microemulsion and
   Application in Assay of In Vitro Release Kinetics
SO LATIN AMERICAN JOURNAL OF PHARMACY
LA English
DT Article
DE HIV; Nanotechnology; Quality Control; Transdermal
ID DRUG-DELIVERY; VALIDATION
AB This work aimed at developing a method for quantification of zidovudine (AZT) in microemulsion system and samples derived from in vitro release kinetics. The samples were quantified by UV spectrophotometry at 266 nm wavelength. The method was linear between 4 and 25 mu g/mL, the coefficient of correlation (R-2) was 0.9998; it showed coefficient of variation below 5 % in intra-run and inter-run precision. The recovery was obtained with values close to the 100 % of theoretical at three different concentrations using ethanol as the solvent. In vitro release kinetics was evaluated in Franz cell set with pre-collection set at 6 h interval. The method is suitable for zidovudine quantification in samples of microemulsion systems evaluated using relatively low cost solvents and no complex extraction techniques.
C1 [Carvalho, Andre L. M.; Cunha, Clemilton P.; Cruz, Emison T. L.] Dept Bioquim & Farmacol, BR-64049550 Teresina, Piaui, Brazil.
   [da Silva, Jose A.] Programa Posgrad Ciencias Farmaceut PPGCF, BR-58100001 Campina Grande, Paraiba, Brazil.
   [Lira, Ana A. M.] Curso Farm, Dept Fisiol, BR-49100000 Aracaju, Sergipe, Brazil.
   [Carvalho, Andre L. M.; de Santana, Davi. P.] Nucleo Desenvolvimento Farmaceut & Cosmet NUDFAC, BR-50740520 Recife, PE, Brazil.
RP Carvalho, ALM (reprint author), Dept Bioquim & Farmacol, Campus Minist Petronio Portela S-N, BR-64049550 Teresina, Piaui, Brazil.
EM aluismenezes@yahoo.com.br
OI Lira, Ana/0000-0003-3451-9049
FU Research Foundation of the State of Piaui (PAPEPI); National Counsel of
   Technological and Scientific Development (CNPQ)
FX We acknowledge the Pharmaceutical Laboratory of Pemambuco State (LAFEPE)
   for donating the drug and the Research Foundation of the State of Piaui
   (PAPEPI) and National Counsel of Technological and Scientific
   Development (CNPQ) for their financial support.
CR Basavaiah K, 2007, INDIAN J CHEM TECHN, V14, P200
   Basavaiah K, 2007, J CHEM, V4, P173
   Carvalho FC, 2009, CHROMATOGRAPHIA, V69, P207, DOI 10.1365/s10337-009-1015-1
   Cornelio R, 2007, LAT AM J PHARM, V26, P883
   Formariz T.P., 2005, BRAZ J PHARM SCI, V41, P301
   Diefenbach ICF, 2008, LAT AM J PHARM, V27, P612
   Heuschkel S, 2008, J PHARM SCI-US, V97, P603, DOI 10.1002/jps.20995
   International Conference on Harmonization, 2005, GUIND IND Q2B R1 VAL
   Kantarci G, 2007, AAPS PHARMSCITECH, V8
   Lefebvre I, 2007, J CHROMATOGR B, V858, P2, DOI 10.1016/j.jchromb.2007.07.028
   Liu C. H, 2012, COLLOID SURFACE A, V353, P149
   Martins Maria Rita Fernandes Morais, 2002, Rev. Bras. Cienc. Farm., V38, P33, DOI 10.1590/S1516-93322002000100004
   McClements DJ, 2012, SOFT MATTER, V8, P1719, DOI 10.1039/c2sm06903b
   BRASIL Ministerio da Saude, PROT ASS FARM DST AI
   Narishetty STK, 2005, J CONTROL RELEASE, V102, P59, DOI 10.1016/j.jconrel.2004.09.016
   Narishetty STK, 2004, J CONTROL RELEASE, V95, P367, DOI 10.1016/j.jconrel.2003.11.022
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Oliveira Anselmo Gomes de, 2004, Quím. Nova, V27, P131, DOI 10.1590/S0100-40422004000100023
   Ribani M, 2004, QUIM NOVA, V27, P771, DOI 10.1590/S0100-40422004000500017
   Santos JV, 2008, LAT AM J PHARM, V27, P303
   Silva J. A, 2009, REV BRAS FARM, V90, P245
   SILVA J. A., 2010, REV CIENC BASICA APL, V31, P125
   Suwanpidokkul N, 2004, AAPS PHARMSCITECH, V5
   [Anonymous], 2010, FARMACOPEIA BRASILEI
NR 24
TC 1
Z9 1
U1 0
U2 0
PU COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
PI LA PLATA
PA DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA
SN 0326-2383
J9 LAT AM J PHARM
JI Lat. Am. J. Pharm.
PD SEP
PY 2012
VL 31
IS 7
BP 1052
EP 1056
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 045RA
UT WOS:000311713300019
DA 2018-01-05
ER

PT J
AU Moody, IS
   Verde, SC
   Overstreet, CM
   Robinson, WE
   Weiss, GA
AF Moody, Issa S.
   Verde, Shawn C.
   Overstreet, Cathie M.
   Robinson, W. Edward, Jr.
   Weiss, Gregory A.
TI In vitro evolution of an HIV integrase binding protein from a library of
   C-terminal domain gamma S-crystallin variants
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV integrase; Phage display; Binding proteins; Enzyme inhibitors; Drug
   resistance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DNA STRAND TRANSFER; TYPE-1 INTEGRASE; EYE
   LENS; INHIBITOR; RALTEGRAVIR; REPLICATION; MUTATIONS; ELVITEGRAVIR;
   ANTIBODIES
AB A protein without natural binding functions was engineered to bind HIV-1 integrase. Phage display selections applied a library of variants based on the C-terminal domain of the eye lens protein human gamma S-crystallin. Multiple loop regions were altered to encode libraries with approximate to 3.6 x 10(11) different variants. A crystallin variant, termed integrase binding protein-10 (IBP-10), inhibits integrase catalysis with nano-molar K-i values. IBP-10 interacts with the integrase C-terminal domain and inhibits integrase substrate affinity. This allosteric mechanism allows IBP-10 to inhibit drug-resistant integrase variants. The results demonstrate the applicability of the crystallin scaffold for the discovery of binding partners and enzyme inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Verde, Shawn C.; Robinson, W. Edward, Jr.] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
   [Moody, Issa S.; Overstreet, Cathie M.; Weiss, Gregory A.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
   [Weiss, Gregory A.] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA.
RP Robinson, WE (reprint author), Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
EM ewrobins@uci.edu; gweiss@uci.edu
FU University of California Multi-Campus Research Program, through the
   California Center for Anti-Viral Drug Discovery; NIH through an
   NCI-supported Cancer Biology Training grant [5 T32 CA09054]; Minority
   Biomedical Research Science [GM-55246]; Minority Health and Health
   Disparities International Research Training programs [MD-01485]
FX The authors gratefully acknowledge support from the University of
   California Multi-Campus Research Program, through the California Center
   for Anti-Viral Drug Discovery. The authors also thank Brenda R.
   McDougall for her invaluable technical support. This work was also
   supported by the NIH through an NCI-supported Cancer Biology Training
   grant (5 T32 CA09054), the Minority Biomedical Research Science
   (GM-55246), and the Minority Health and Health Disparities International
   Research Training (MD-01485) programs.
CR Al-Mawsawi LQ, 2011, CHEMMEDCHEM, V6, P228, DOI 10.1002/cmdc.201000443
   AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354
   Baldanti F, 2010, J MED VIROL, V82, P116, DOI 10.1002/jmv.21651
   BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935
   Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200
   da Silva D., 2010, J ANTIMICROB CHEMO, V6, P1262
   DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0
   Desjobert C., 2004, BIOCHEMISTY, V134, P39
   Ebersbach H, 2007, J MOL BIOL, V372, P172, DOI 10.1016/j.jmb.2007.06.045
   Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0
   ENGELMAN A, 1993, EMBO J, V12, P3269
   ENGELMAN A, 1995, J VIROL, V69, P2729
   ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C
   Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007
   Huang J, 2008, P NATL ACAD SCI USA, V105, P6578, DOI 10.1073/pnas.0801097105
   Kobayashi M, 2008, ANTIVIR RES, V80, P213, DOI 10.1016/j.antiviral.2008.06.012
   Koide A, 1998, J MOL BIOL, V284, P1141, DOI 10.1006/jmbi.1998.2238
   LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818                                                         
   Lewin S.R., 2011, AIDS, V7, P885
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Marchand C, 2009, CURR TOP MED CHEM, V9, P1016, DOI 10.2174/156802609789630910                                                      
   Marinello J, 2008, BIOCHEMISTRY-US, V47, P9345, DOI 10.1021/bi800791q
   Murase K, 2003, CHEM BIOL, V10, P161, DOI 10.1016/S1074-5521(03)00025-5
   Pandey Krishan K, 2008, Retrovirology (Auckl), V2, P11
   Pingen M, 2011, J ANTIMICROB CHEMOTH, V66, P1467, DOI 10.1093/jac/dkr157
   Puras Lutzke Ramon A., 1995, Proceedings of the National Academy of Sciences of the United States of America, V92, P11456
   Purkiss AG, 2002, J BIOL CHEM, V277, P4199, DOI 10.1074/jbc.M110083200
   Ramcharan J., 2006, RETROVIROLOGY, P3
   Reinke RA, 2004, VIROLOGY, V326, P203, DOI 10.1016/J.VIROL.2004.06.005
   RICCHETTI M, 1990, EMBO J, V9, P1583
   Sandstrom K, 2003, PROTEIN ENG, V16, P691, DOI 10.1093/protein/gzg086
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Sidhu S. S., 2004, PHAGE DISPLAY PRACTI, P27
   Sinha D, 1998, Mol Vis, V4, P8
   Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9
   Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Sun H, 2005, J MED GENET, V42, P706, DOI 10.1136/jmg.2004.028274
   UNAIDS, 2008, REP GLOB HIV AIDS EP, P45
   Wenk M, 2000, BIOPHYS CHEM, V86, P95, DOI 10.1016/S0301-4622(00)00161-7                                                   
   Wilkinson TA, 2009, J BIOL CHEM, V284, P7931, DOI 10.1074/jbc.M806241200
NR 49
TC 1
Z9 1
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2012
VL 22
IS 17
BP 5584
EP 5589
DI 10.1016/j.bmcl.2012.07.008
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 995WV
UT WOS:000308046400045
PM 22858140
OA green_accepted
DA 2018-01-05
ER

PT J
AU Andreani, T
   Macedo, AS
   Ferreira, SF
   Silva, AM
   Rosmaninho, A
   Souto, EB
AF Andreani, Tatiana
   Macedo, Ana Sofia
   Ferreira, Sandra F.
   Silva, Amelia M.
   Rosmaninho, Aristoteles
   Souto, Eliana B.
TI Topical Targeting Therapies for Sexually Transmitted Diseases
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Sexual transmitted diseases; nanotechnology; diagnostics; prevention;
   topical therapy
ID SOLID LIPID NANOPARTICLES; NEISSERIA-GONORRHOEAE; CHLAMYDIAL INFECTIONS;
   DENDRIMER MICROBICIDE; DRUG-DELIVERY; AMPLICOR PCR; SPL7013 GEL;
   PREVENTION; HIV; PENCICLOVIR
AB The past years have witnessed a persistent deterioration of sexual health, especially among young adults. The most concerning problems are sexually transmitted diseases and non-planned pregnancies that cost millions of dollars in healthcare. Sexually transmitted diseases are usually represented by cutaneous signs which may provide a portal of entry for the transmission of other infections, such as HIV. Skin is a widely used route of delivery of drugs locally, and also potentially promising pathway for systemic targeting. Skin contributes to the physical and chemical protection of the body, providing an important barrier against topical drug administration. However, it may be overcome by nanotechnology-based systems, especially in skin diseases, reducing the side effects. Different approaches have been focused on nanotechnology, not only in the treatment of sexually transmitted diseases, but also in diagnostics and prevention of these infections. The present paper highlights recent advances in the nanotechnology-based systems for the diagnostic, prevention and topical treatment of sexually transmitted diseases.
C1 [Andreani, Tatiana; Macedo, Ana Sofia; Ferreira, Sandra F.; Souto, Eliana B.] UFP, Fac Hlth Sci, Dept Pharmaceut Technol, P-4200150 Oporto, Portugal.
   [Andreani, Tatiana; Silva, Amelia M.] Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, Vila Real, Portugal.
   [Andreani, Tatiana; Silva, Amelia M.] Ctr Res & Technol Agroenvironm & Biol Sci, Vila Real, Portugal.
   [Rosmaninho, Aristoteles] Hosp Santo Antonio, Dept Dermatol, CHP EPE, Oporto, Portugal.
   [Souto, Eliana B.] Univ Tras Os Montes & Alto Douro, IBB, CGB, UTAD, Vila Real, Portugal.
RP Souto, EB (reprint author), UFP, Fac Hlth Sci, Dept Pharmaceut Technol, Rua Carlos da Maia 296, P-4200150 Oporto, Portugal.
EM eliana@ufp.edu.pt
RI Silva, Amelia/J-7128-2013
OI Silva, Amelia/0000-0002-7524-9914; Souto, Eliana B./0000-0002-9737-6017;
   Andreani, Tatiana/0000-0002-3794-8159
FU Fundacao para a Ciencia e Tecnologia for Tatiana Andreani
   [SFRH/BD/60640/2009]
FX The financial support received from Fundacao para a Ciencia e Tecnologia
   for Tatiana Andreani (SFRH/BD/60640/2009). FCT is also acknowledged
   under the reference ERA-Eula/002/2009.
CR Abu Salah K, 2010, SENSORS-BASEL, V10, P963, DOI 10.3390/s100100963
   Abu-Salah KM, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/715295
   Alex MRA, 2011, EUR J PHARM SCI, V42, P11, DOI 10.1016/j.ejps.2010.10.002
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Andrei G, 2004, ANTIVIR RES, V61, P181, DOI 10.1016/j.antiviral.2003.10.003
   Ansari AA, 2009, ANALYST, V134, P997, DOI 10.1039/b817562d
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Bassiri M, 1997, J CLIN MICROBIOL, V35, P2556
   Brown TJ, 1999, J AM ACAD DERMATOL, V41, P511, DOI 10.1016/S0190-9622(99)80045-0
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Calugi C, 2011, EXPERT OPIN THER PAT, V21, P381, DOI 10.1517/13543776.2011.551116
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   *COORD COMM GLOB H, 2005, PLOS MED, V2, pE25, DOI DOI 10.1371/JOURNAL.PMED.0020025
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   DARBY G, 1994, J INT MED RES, V22, pA33
   De M, 2008, ADV MATER, V20, P4225, DOI 10.1002/adma.200703183
   Dizon D.S., 2011, QUESTIONS ANSWERS HU
   El Maghraby G M, 2008, Eur J Pharm Sci, V34, P203, DOI 10.1016/j.ejps.2008.05.002
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Harris P.S., 1997, CURRENT PROBLEMS DER, V9, P209
   Hasanovic A, 2010, EUR J PHARM BIOPHARM, V75, P148, DOI 10.1016/j.ejpb.2010.03.014
   Hauck TS, 2010, ADV DRUG DELIVER REV, V62, P438, DOI 10.1016/j.addr.2009.11.015
   Jain S, 2011, DRUG DELIV TRANSL RE, V1, P395, DOI 10.1007/s13346-011-0036-0
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Jenning V, 2001, J MICROENCAPSUL, V18, P149
   Jung C, 2011, BIOSENS BIOELECTRON, V26, P1953, DOI 10.1016/j.bios.2010.07.088
   Jung YL, 2010, BIOSENS BIOELECTRON, V25, P1941, DOI 10.1016/j.bios.2010.01.010
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kirjavainen M, 1999, J CONTROL RELEASE, V58, P207, DOI 10.1016/S0168-3659(98)00152-7
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Lara H.H., 2010, J NANOBIOTECHNOL, V13, P8
   LEE VHL, 1988, CRIT REV THER DRUG, V5, P69
   Liang CH, 2009, CHEM PHYS LIPIDS, V158, P81, DOI 10.1016/j.chemphyslip.2009.01.006
   Lv QZ, 2009, INT J PHARMACEUT, V372, P191, DOI 10.1016/j.ijpharm.2009.01.014
   Manavi K, 2006, BEST PRACT RES CL OB, V20, P941, DOI 10.1016/j.bpobgyn.2006.06.003
   Meng JN, 2011, EUR J PHARM SCI, V44, P57, DOI 10.1016/j.ejps.2011.06.007
   Mukenge-Tshibaka L, 2000, J CLIN MICROBIOL, V38, P4076
   Munusamy P, 2009, MAT SCI ENG C-MATER, V29, P2313, DOI 10.1016/j.msec.2009.05.020
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   O'Farrell N, 2006, INT J NANOMED, V1, P451, DOI 10.2147/nano.2006.1.4.451
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Paavonen J, 2004, INT CONGR SER, V1266, P277, DOI 10.1016/j.ics.2004.01.114
   Paraskevaidis E, 2004, CANCER TREAT REV, V30, P205, DOI 10.1016/j.ctrv.2003.07.008
   Pragya S., 2008, CLIN EXP MED, V8, P207
   Pontinha ADR, 2011, PHYS CHEM CHEM PHYS, V13, P5227, DOI 10.1039/c0cp02377a
   ROJANASAKUL Y, 1992, PHARMACEUT RES, V9, P1029, DOI 10.1023/A:1015802427428
   Rupp R, 2007, INT J NANOMED, V2, P561
   Schafer-Korting M, 2007, ADV DRUG DELIVER REV, V59, P427, DOI 10.1016/j.addr.2007.04.006
   Sendid B, 2007, J MED MICROBIOL, V56, P495, DOI 10.1099/jmm.0.46715-0
   Severson J.L., 1999, CURRENT PROBLEMS DER, V11, P60
   Severy LJ, 2005, AIDS BEHAV, V9, P121, DOI 10.1007/s10461-005-1687-y
   Singh R, 2011, BIOSENS BIOELECTRON, V26, P2967, DOI 10.1016/j.bios.2010.11.047
   Singh R, 2010, J BIOTECHNOL, V150, P357, DOI 10.1016/j.jbiotec.2010.09.935
   SOBEL JD, 1993, CLIN OBSTET GYNECOL, V36, P153, DOI 10.1097/00003081-199303000-00021
   Souto EB, 2009, METHOD ENZYMOL, V464, P105, DOI 10.1016/S0076-6879(09)64006-4
   Tang JF, 2010, DIAGN MICR INFEC DIS, V67, P122, DOI 10.1016/j.diagmicrobio.2010.01.009
   Taylor R. F., 1996, HDB CHEM BIOL SENSOR
   Techakehakij W, 2008, VACCINE, V26, P6258, DOI 10.1016/j.vaccine.2008.09.036
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Tian J, 2007, CHEMMEDCHEM, V2, P129, DOI 10.1002/cmdc.200600171
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Toti US, 2011, BIOMATERIALS, V32, P6606, DOI 10.1016/j.biomaterials.2011.05.038
   Tymchuk CN, 2008, EXPERT OPIN DRUG SAF, V7, P1, DOI [10.1517/14740338.7.1.1, 10.1517/14740338.7.1.1 ]
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   UNAIDS, 2010, UNAIDS REP GLOB AIDS, P4
   *UNAIDS, 2008, JOINT UN PROGR HIV A
   Wang J, 2000, NUCLEIC ACIDS RES, V28, P3011, DOI 10.1093/nar/28.16.3011
   Weller S. C., 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]
   Wells MA, 2012, NANOTOXICOLOGY, V6, P837, DOI 10.3109/17435390.2011.625131
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yu H., 1997, SCI CLIN APPL MAGNET
   Zhao WA, 2008, J AM CHEM SOC, V130, P3610, DOI 10.1021/ja710241b
   Zhu WW, 2008, INT J PHARMACEUT, V360, P184, DOI 10.1016/j.ijpharm.2008.04.008
NR 76
TC 1
Z9 1
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
EI 1875-6786
J9 CURR NANOSCI
JI Curr. Nanosci.
PD SEP
PY 2012
VL 8
IS 4
BP 486
EP 490
DI 10.2174/157341312801784348                                              
          
PG 5
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 027XN
UT WOS:000310387500003
DA 2018-01-05
ER

PT J
AU Maly, J
   Pedziwiatr-Werbicka, E
   Maly, M
   Semeradtova, A
   Appelhans, D
   Danani, A
   Zaborski, M
   Klajnert, B
   Bryszewska, M
AF Maly, J.
   Pedziwiatr-Werbicka, E.
   Maly, M.
   Semeradtova, A.
   Appelhans, D.
   Danani, A.
   Zaborski, M.
   Klajnert, B.
   Bryszewska, M.
TI Highly Organized Self-Assembled Dendriplexes Based on Poly(propylene
   imine) Glycodendrimer and Anti-HIV Oligodeoxynucleotides
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Antisense therapy; atomic force microscopy; dendriplexes; molecular
   modeling; nanofibers; PPI dendrimers; self-assembling; dynamic light
   scattering; anti-HIV therapy; drug delivery
ID SOLUBLE CARBOSILANE DENDRIMERS; GENE TRANSFECTION; IN-VITRO; DELIVERY;
   DNA; OLIGONUCLEOTIDES; THERAPY; BINDING; CELLS; VIVO
AB Dendrimers are artificial polymeric macromolecules which are widely considered to be a promising tool for future gene therapy applications. They have been used as efficient delivery vehicles for antisense oligonucleotides targeting the interior of cells. We demonstrate that dendriplexes formed from anti-HIV oligodeoxynucleotides ANTI-TAR, GEM91, and SREV in complex with generation 4 maltose (PPI-Mal G4) and maltotriose (PPI-Mal-III G4) modified poly(propylene imine) dendrimers are able to self-assemble into highly organized 1D and 3D nanostructures. The resulting nanostructures were characterized by fluorescence methods, laser Doppler electrophoresis, dynamic light scattering (DLS), atomic force microscopy (AFM) and molecular modeling. The results show that ANTI-TAR and GEM 91 dendriplexes self-assemble into fibrils with length scales up to several hundreds of nm. SREV, on the contrary, forms quadrilateral-like 3D nanostructures. A good correlation between the various experimental methods and molecular modeling indicates the formation of those nanostructures in solution. Space symmetry of the oligonucleotides and the resulting dendriplex monomeric units are probably the most important factors which influence the way of self-assembling.
C1 [Maly, J.; Maly, M.; Semeradtova, A.] Univ JE Purkyne, Usti Nad Labem 40096, Czech Republic.
   [Pedziwiatr-Werbicka, E.; Klajnert, B.; Bryszewska, M.] Univ Lodz, Dept Gen Biophys, PL-90236 Lodz, Poland.
   [Maly, M.; Danani, A.] Univ Appl Sci So Switzerland, Lab Appl Math & Phys LAMFI, CH-6928 Manno, Switzerland.
   [Appelhans, D.] Leibniz Inst Polymer Res Dresden, D-01069 Dresden, Germany.
   [Zaborski, M.] Tech Univ Lodz, Inst Polymer & Dye Technol, PL-90924 Lodz, Poland.
RP Maly, J (reprint author), Dept Biol PrF UJEP, Ceske Mladeze 8, Usti Nad Labem 40001, Czech Republic.
EM malyjalga@seznam.cz
RI Maly, Marek/H-5757-2015; Maly, Jan/B-6434-2011; Klajnert-Maculewicz,
   Barbara/J-4574-2014; Umlauf, Ursula/D-3356-2014
OI Maly, Marek/0000-0002-5930-563X; Maly, Jan/0000-0002-7022-2157;
   Klajnert-Maculewicz, Barbara/0000-0003-3459-8947; Bryszewska,
   Maria/0000-0003-4676-3743; Pedziwiatr-Werbicka,
   Elzbieta/0000-0001-7943-2612
FU project "Biological properties and biomedical applications of
   dendrimers"; EU European Regional Development Fund; COST action
   [TD0802]; Czech national Cost project [OC10053]; Swiss project "MULTI";
   DECS - Canton Ticino; USI; Grant Agency of Czech Academy of Sciences
   (GAAV CR) [KAN 200520702]; Internal Grant Agency of UJEP
FX This research was partly supported by project "Biological properties and
   biomedical applications of dendrimers" operated within the Foundation
   for Polish Science Team Programme co-financed by the EU European
   Regional Development Fund and COST action TD0802, M. M. acknowledges
   Czech national Cost project OC10053, M. M. and A. D. acknowledges Swiss
   project "MULTI" sponsored by DECS - Canton Ticino and USI, J.M.
   acknowledges project KAN 200520702 of the Grant Agency of Czech Academy
   of Sciences (GAAV CR) and project of Internal Grant Agency of UJEP.
CR Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Case D. A., 2010, AMBER 11
   Chen W, 2000, LANGMUIR, V16, P15, DOI 10.1021/la981429v                                                               
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Evans HM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.075501
   Fischer M, 2010, BIOMACROMOLECULES, V11, P1314, DOI 10.1021/bm100101s
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Ju R., 2011, CHEM COMMUN, P47
   Klajnert B, 2008, CHEM-EUR J, V14, P7030, DOI 10.1002/chem.200800342
   Loup C, 1999, CHEM-EUR J, V5, P3644, DOI 10.1002/(SICI)1521-3765(19991203)5:12<3644::AID-CHEM3644>3.0.CO;2-I
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Maly J, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/38/385101
   Mkandawire M, 2009, J BIOPHOTONICS, V2, P596, DOI 10.1002/jbio.200910002
   Ohsaki M, 2002, BIOCONJUGATE CHEM, V13, P510, DOI 10.1021/bc015525a
   Paleos CM, 2010, EXPERT OPIN DRUG DEL, V7, P1387, DOI 10.1517/17425247.2010.534981
   Pedziwiatr E, 2009, J FLUORESC, V19, P267, DOI 10.1007/s10895-008-0412-4
   Pedziwiatr-Werbicka E, 2012, J BIOMED NANOTECHNOL, V8, P57, DOI 10.1166/jbn.2012.1369
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   Pietsch T, 2011, SMALL, V7, P221, DOI 10.1002/smll.201001461
   Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/NNANO.2011.187, 10.1038/nnano.2011.187]
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Sitterberg J, 2010, EUR J PHARM BIOPHARM, V74, P2, DOI 10.1016/j.ejpb.2009.09.005
   Stofik M, 2009, BIOSENS BIOELECTRON, V24, P1918, DOI 10.1016/j.bios.2008.09.028
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Tan SJ, 2011, NAT NANOTECHNOL, V6, P268, DOI [10.1038/NNANO.2011.49, 10.1038/nnano.2011.49]
   TOMALIA DA, 1986, MACROMOLECULES, V19, P2466, DOI 10.1021/ma00163a029                                                             
   Vijayanathan V, 2002, BIOCHEMISTRY-US, V41, P14085, DOI 10.1021/bi0203987
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wang P, 2008, ADV MATER, V20, P1381, DOI 10.1002/adma.200701669
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Zinselmeyer BH, 2003, J CONTROL RELEASE, V91, P201, DOI 10.1016/S0168-3659(03)00234-7
   [Anonymous], 1976, ZAGADNIENIA BIOFIZYK, V1, P17
NR 33
TC 10
Z9 10
U1 3
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD SEP
PY 2012
VL 19
IS 27
BP 4708
EP 4719
DI 10.2174/092986712803306457                                              
          
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 019EB
UT WOS:000309718800018
PM 22834818
DA 2018-01-05
ER

PT J
AU Lu, W
AF Lu, Wei
TI Adsorptive-Mediated Brain Delivery Systems
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Review
DE Adsorptive-mediated transcytosis (AMT); blood-brain barrier (BBB);
   cationized protein; nanoparticle; toxicity
ID ACCELERATED BLOOD CLEARANCE; CONJUGATED PEGYLATED NANOPARTICLES; HIV-1
   TAT PROTEIN; VASCULAR-PERMEABILITY; ARGININE-VASOPRESSIN; REPEATED
   INJECTIONS; BARRIER TRANSPORT; PLA NANOPARTICLES; GENE DELIVERY; CNS
   DELIVERY
AB The blood-brain barrier (BBB), which impedes drug penetration into the central nervous system, is composed of specific structures formed by brain capillary endothelial cells and sheathed by astrocytic end-feet through basement membrane. Many brain drug delivery strategies have focused on adsorptive-mediated transcytosis (AMT), which is triggered by electrostatic interaction between cationic molecules and anionic microdomains on the cytoplasm membrane of the brain capillary endothelial cells. AMT-based drug delivery to the brain can be achieved by using cationic proteins and basic oligopeptides such as cell-penetrating peptides as targetors. Large therapeutic molecules such as neuropeptides and proteins or even drug-encapsulated vectors such as liposomes and nanoparticles can be allowed to access brain parenchyma through AMT when conjugated with these cationic targetors. In this review, I briefly discuss adsorptive-mediated brain delivery systems that may provide physiologic-based strategies for enhanced delivery of therapeutic substances through the BBB.
C1 Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.
RP Lu, W (reprint author), Univ Rhode Isl, Coll Pharm, Dept Biomed & Pharmaceut Sci, 41 Lower Coll Rd, Kingston, RI 02881 USA.
EM weilu@uri.edu
CR ADLER SG, 1983, J CLIN INVEST, V71, P487, DOI 10.1172/JCI110793
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3
   Boiardi A, 1999, CANCER CHEMOTH PHARM, V43, P178, DOI 10.1007/s002800050881
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BURBACH JPH, 1983, J BIOL CHEM, V258, P1487
   BURBACH JPH, 1989, METHOD ENZYMOL, V168, P385
   COLEY HM, 1993, BIOCHEM PHARMACOL, V46, P1317, DOI 10.1016/0006-2952(93)90094-D
   Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071
   Dong YC, 2004, BIOMATERIALS, V25, P2843, DOI 10.1016/j.biomaterials.2003.09.055
   Drin G, 2002, AAPS PHARMSCI, V4
   Girod J, 1999, J NEUROCHEM, V73, P2002
   Hawkins CJ, 2004, VITAM HORM, V67, P427
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Hirate K, 1997, BEHAV BRAIN RES, V83, P205, DOI 10.1016/S0166-4328(97)86070-6                                                   
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   HUANG JT, 1984, J NEUROPATH EXP NEUR, V43, P489, DOI 10.1097/00005072-198409000-00004
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Ishida T, 2006, J CONTROL RELEASE, V112, P15, DOI 10.1016/j.jconrel.2006.01.005
   Ishida T, 2005, J CONTROL RELEASE, V105, P305, DOI 10.1016/j.jconrel.2005.04.003
   Ishida T, 2003, J CONTROL RELEASE, V88, P35, DOI 10.1016/S0168-3659(02)00462-5
   Ishida T, 2003, INT J PHARM, V255, P167, DOI 10.1016/S0378-5173(03)00085-1
   Ishida T, 2002, CELL MOL BIOL LETT, V7, P286
   Ishida T, 2006, J CONTROL RELEASE, V115, P243, DOI 10.1016/j.jconrel.2006.08.001
   KANG YS, 1994, PHARMACEUT RES, V11, P1257, DOI 10.1023/A:1018982125649                                                         
   KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214
   Laverman P, 2001, J PHARMACOL EXP THER, V298, P607
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   Liu Lihong, 2008, Biomaterials, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Lu W, 2005, INT J PHARM, V295, P247, DOI 10.1016/j.ijpharm.2005.01.043
   Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027
   Lu W, 2007, INT J CANCER, V120, P420, DOI 10.1002/ijc.22296
   Lu W, 2007, J CONTROL RELEASE, V118, P38, DOI 10.1016/j.jconrel.2006.11.015
   Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008-5472.CAN-06-2354
   MANN DA, 1991, EMBO J, V10, P1733
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   MUCKERHEIDE A, 1987, J IMMUNOL, V138, P833
   Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861
   NAGY Z, 1983, LAB INVEST, V49, P662
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90
   PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V255, P893
   PARDRIDGE WM, 1987, BIOCHEM BIOPH RES CO, V146, P307, DOI 10.1016/0006-291X(87)90726-1
   Plard JP, 1999, COLLOID SURFACE B, V16, P173, DOI 10.1016/S0927-7765(99)00068-5                                                   
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Saad SY, 2001, PHARMACOL RES, V43, P211, DOI 10.1006/phrs.2000.0769
   Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z
   Schnyder A, 2005, J DRUG TARGET, V13, P325, DOI 10.1080/10611860500206674
   SHIMURA T, 1991, J PHARMACOL EXP THER, V258, P459
   STRAUSBAUGH LJ, 1987, BRAIN RES, V409, P221, DOI 10.1016/0006-8993(87)90705-0
   Tanabe S, 1999, PHARMACOL BIOCHEM BE, V63, P549, DOI 10.1016/S0091-3057(99)00034-9
   TERASAKI T, 1991, PHARMACEUT RES, V8, P815, DOI 10.1023/A:1015882924470
   Thole M, 2002, J DRUG TARGET, V10, P337, DOI 10.1080/10611860290031840
   TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x
   TRIGUERO D, 1991, J PHARMACOL EXP THER, V258, P186
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vajkoczy P, 2000, J NEURO-ONCOL, V50, P99, DOI 10.1023/A:1006474832189                                                         
   VEHASKARI VM, 1984, J CLIN INVEST, V73, P1053, DOI 10.1172/JCI111290
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   VORBRODT AW, 1989, J NEUROCYTOL, V18, P359, DOI 10.1007/BF01190839
   Working PK, 1999, J PHARMACOL EXP THER, V289, P1128
   Xie YL, 2006, BEHAV BRAIN RES, V173, P76, DOI 10.1016/j.bbr.2006.06.001
   Xu F, 2009, J DRUG TARGET, V17, P423, DOI 10.1080/10611860902963013
   YUAN F, 1994, CANCER RES, V54, P4564
   Zhang Y, 2004, COLLOID POLYM SCI, V282, P1323, DOI 10.1007/s00396-004-1068-5
NR 67
TC 13
Z9 16
U1 1
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD SEP
PY 2012
VL 13
IS 12
BP 2340
EP 2348
DI 10.2174/138920112803341851                                              
          
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 018LI
UT WOS:000309661600005
PM 23016640
DA 2018-01-05
ER

PT J
AU Gunzenhauser, J
   Olivier, N
   Pengo, T
   Manley, S
AF Gunzenhaeuser, Julia
   Olivier, Nicolas
   Pengo, Thomas
   Manley, Suliana
TI Quantitative Super-Resolution Imaging Reveals Protein Stoichiometry and
   Nanoscale Morphology of Assembling HIV-Gag Virions
SO NANO LETTERS
LA English
DT Article
DE Super-resolution imaging; protein assembly; protein counting; HIV-Gag
ID MICROSCOPY; VIRUS; PARTICLES; CELLS
AB The HIV structural protein Gag assembles to form spherical particles of radius similar to 70 nm. During the assembly process, the number of Gag proteins increases over several orders of magnitude from a few at nucleation to thousands at completion. The challenge in studying protein assembly lies in the fact that current methods such as standard fluorescence or electron microscopy techniques cannot access all stages of the assembly process in a cellular context. Here, we demonstrate an approach using super-resolution fluorescence imaging that permits quantitative morphological and molecular counting analysis over a wide range of protein cluster sizes. We applied this technique to the analysis of hundreds of HIV-Gag clusters at the cellular plasma membrane, thus elucidating how different fluorescent labels can change the assembly of virions.
C1 [Gunzenhaeuser, Julia; Olivier, Nicolas; Pengo, Thomas; Manley, Suliana] Ecole Polytech Fed Lausanne, Lab Expt Biophys, Lausanne, Switzerland.
RP Manley, S (reprint author), Ecole Polytech Fed Lausanne, Lab Expt Biophys, Lausanne, Switzerland.
RI Manley, Suliana/D-3818-2012
OI Manley, Suliana/0000-0002-4755-4778; Pengo, Thomas/0000-0002-9632-918X;
   Olivier, Nicolas/0000-0001-9042-5456
FU European Research Council under the European Community [243016];
   Brazilian Swiss Joint Research Program
FX We wish to thank Harald Hess for the PeakSelector software, George
   Patterson for the kind gift of plasmid mEos2, Joerg Wiedenmann for the
   gift of tdEos plasmids and purified proteins, Daniel Blair for the
   clustering algorithm, and Vinoth Sundar Rajan for additional experiments
   during the review process. The research leading to these results has
   received funding from the European Research Council under the European
   Community's Seventh Framework Programme/ERC Grant Agreement
   243016-PALMassembly. T.P. also received support from the Brazilian Swiss
   Joint Research Program.
CR Annibale P, 2010, J PHYS CHEM LETT, V1, P1506, DOI 10.1021/jz1003523
   Annibale P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022678
   Baddeley D, 2010, MICROSC MICROANAL, V16, P64, DOI 10.1017/S143192760999122X
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Briggs JAG, 2006, J MOL BIOL, V355, P157, DOI 10.1016/j.jmb.2005.10.025
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   HOSHEN J, 1976, PHYS REV B, V14, P3438, DOI 10.1103/PhysRevB.14.3438                                                        
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435
   McKinney SA, 2009, NAT METHODS, V6, P131, DOI [10.1038/NMETH.1296, 10.1038/nmeth.1296]
   Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
NR 21
TC 34
Z9 34
U1 1
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD SEP
PY 2012
VL 12
IS 9
BP 4705
EP 4710
DI 10.1021/nl3021076
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 002YW
UT WOS:000308576000048
PM 22906128
DA 2018-01-05
ER

PT J
AU Xu, X
   Wang, X
   Li, Y
   Wang, YH
   Yang, L
AF Xu, Xue
   Wang, Xia
   Li, Yan
   Wang, Yonghua
   Yang, Ling
TI A large-scale association study for nanoparticle C60 uncovers mechanisms
   of nanotoxicity disrupting the native conformations of DNA/RNA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATIONS; DIELECTRIC MEDIUM; PAIR POTENTIALS; DNA
   RECOGNITION; CARBON NANOTUBE; RNA; C-60; DISTRIBUTIONS; REPLICATION;
   STABILITY
AB Nano-scale particles have attracted a lot of attention for its potential use in medical studies, in particular for the diagnostic and therapeutic purposes. However, the toxicity and other side effects caused by the undesired interaction between nanoparticles and DNA/RNA are not clear. To address this problem, a model to evaluate the general rules governing how nanoparticles interact with DNA/RNA is demanded. Here by, use of an examination of 2254 native nucleotides with molecular dynamics simulation and thermodynamic analysis, we demonstrate how the DNA/RNA native structures are disrupted by the fullerene (C60) in a physiological condition. The nanoparticle was found to bind with the minor grooves of double-stranded DNA and trigger unwinding and disrupting of the DNA helix, which indicates C60 can potentially inhibit the DNA replication and induce potential side effects. In contrast to that of DNA, C60 only binds to the major grooves of RNA helix, which stabilizes the RNA structure or transforms the configuration from stretch to curl. This finding sheds new light on how C60 inhibits reverse transcription as HIV replicates. In addition, the binding of C60 stabilizes the structures of RNA riboswitch, indicating that C60 might regulate the gene expression. The binding energies of C60 with different genomic fragments varies in the range of -56 to -10 kcal mol(-1), which further verifies the role of nanoparticle in DNA/RNA damage. Our findings reveal a general mode by which C60 causes DNA/RNA damage or other toxic effects at a systematic level, suggesting it should be cautious to handle these nanomaterials in various medical applications.
C1 [Xu, Xue; Wang, Xia; Wang, Yonghua] NW A&F Univ, Coll Life Sci, Ctr Bioinformat, Yangling 712100, Shaanxi, Peoples R China.
   [Li, Yan] Dalian Univ Technol, Sch Chem Engn, Dalian 116024, Liaoning, Peoples R China.
   [Yang, Ling] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China.
RP Wang, YH (reprint author), NW A&F Univ, Coll Life Sci, Ctr Bioinformat, Yangling 712100, Shaanxi, Peoples R China.
EM yh_wang@nwsuaf.edu.cn
FU High-Performance Computing Platform of Northwest AF University; National
   Natural Science Foundation of China [31170796]; Northwest AF University;
   National Natural Science Foundation of China (NSFC)
FX High-Performance Computing Platform of Northwest A&F University, and is
   financially supported by the National Natural Science Foundation of
   China [31170796] and also the Fund of Northwest A&F University. Funding
   for open access charge: The National Natural Science Foundation of China
   (NSFC) is an organization directly affiliated to the State Council for
   the management of the National Natural Science Fund. And Northwest A&F
   University manages the Fund of Northwest A&F University.
CR BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Berk H., 1997, J COMPUT CHEM, V18, P1463
   Calvaresi M, 2010, ACS NANO, V4, P2283, DOI 10.1021/nn901809b
   Calzolai L, 2010, NANO LETT, V10, P3101, DOI 10.1021/nl101746v
   Chargaff E, 1955, NUCL ACIDS CHEM BIOL
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701                                                           
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n                                                               
   HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K
   Hess H, 2007, ACS NANO, V1, P390, DOI 10.1021/nn700407v
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695                                                        
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Lu CR, 2010, J MOL BIOL, V404, P803, DOI 10.1016/j.jmb.2010.09.059
   Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949                                                                    
   Montange RK, 2008, ANNU REV BIOPHYS, V37, P117, DOI 10.1146/annurev.biophys.37.032807.130000
   NEIDLE S, 1999, OXFORD HDB NUCL ACID
   OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225                                             
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196                                                     
   Richter S, 2002, P NATL ACAD SCI USA, V99, P7928, DOI 10.1073/pnas.122119999
   Rohs R, 2009, NATURE, V461, P1248, DOI 10.1038/nature08473
   Roxbury D, 2011, J AM CHEM SOC, V133, P13545, DOI 10.1021/ja204413v
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Toulme JJ, 2001, PROG NUCLEIC ACID RE, V69, P1, DOI 10.1016/S0079-6603(01)69043-3
   Tse WC, 2004, CHEM BIOL, V11, P1607, DOI 10.1016/j.chembiol.2003.08.012
   Tu XM, 2009, NATURE, V460, P250, DOI 10.1038/nature08116
   Xiao ZT, 2011, J PHYS CHEM C, V115, P21546, DOI 10.1021/jp204017u
   Xu X, 2012, SOFT MATTER, V8, P2915, DOI 10.1039/c2sm06811g
   Yakovchuk P, 2006, NUCLEIC ACIDS RES, V34, P564, DOI 10.1093/nar/gkj454
   Zhao XC, 2005, BIOPHYS J, V89, P3856, DOI 10.1529/biophysj.105.064410
   Zuo GH, 2010, ACS NANO, V4, P7508, DOI 10.1021/nn101762b
NR 34
TC 18
Z9 19
U1 0
U2 52
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD SEP
PY 2012
VL 40
IS 16
BP 7622
EP 7632
DI 10.1093/nar/gks517
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 008LZ
UT WOS:000308959800011
PM 22661584
OA gold
DA 2018-01-05
ER

PT J
AU Sakkhachornphop, S
   Barbas, CF
   Keawvichit, R
   Wongworapat, K
   Tayapiwatana, C
AF Sakkhachornphop, Supachai
   Barbas, Carlos F., III
   Keawvichit, Rassamee
   Wongworapat, Kanlaya
   Tayapiwatana, Chatchai
TI Zinc Finger Protein Designed to Target 2-Long Terminal Repeat Junctions
   Interferes with Human Immunodeficiency Virus Integration
SO HUMAN GENE THERAPY
LA English
DT Article
ID CHAIN VARIABLE FRAGMENTS; INHIBIT EARLY STAGES; VIRAL LIFE-CYCLE; CD4(+)
   T-CELLS; TYPE-1 INTEGRASE; INTRACELLULAR EXPRESSION; HIV-1 REPLICATION;
   IN-VITRO; ANTIRETROVIRAL THERAPY; SUBSTRATE-SPECIFICITY
AB Integration of the human immunodeficiency virus type 1 (HIV-1) genome into the host chromosome is a vital step in the HIV life cycle. The highly conserved cytosine-adenine (CA) dinucleotide sequence immediately upstream of the cleavage site is crucial for integrase (IN) activity. As this viral enzyme has an important role early in the HIV-1 replication cycle, interference with the IN substrate has become an attractive strategy for therapeutic intervention. We demonstrated that a designed zinc finger protein (ZFP) fused to green fluorescent protein (GFP) targets the 2-long terminal repeat (2-LTR) circle junctions of HIV-1 DNA with nanomolar affinity. We report now that 2LTRZFP-GFP stably transduced into 293T cells interfered with the expression of vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral red fluorescent protein (RFP), as shown by the suppression of RFP expression. We also used a third-generation lentiviral vector and pCEP4 expression vector to deliver the 2LTRZFP-GFP transgene into human T-lymphocytic cells, and a stable cell line for long-term expression studies was selected for HIV-1 challenge. HIV-1 integration and replication were inhibited as measured by Alu-gag real-time PCR and p24 antigen assay. In addition, the molecular activity of 2LTRZFP-GFP was evaluated in peripheral blood mononuclear cells. The results were confirmed by Alu-gag real-time PCR for integration interference. We suggest that the expression of 2LTRZFP-GFP limited viral integration on intracellular immunization, and that it has potential for use in HIV gene therapy in the future.
C1 [Sakkhachornphop, Supachai; Tayapiwatana, Chatchai] Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Div Clin Immunol, Chiang Mai 50200, Thailand.
   [Sakkhachornphop, Supachai; Keawvichit, Rassamee; Wongworapat, Kanlaya] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50200, Thailand.
   [Barbas, Carlos F., III] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Barbas, Carlos F., III] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   [Barbas, Carlos F., III] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Tayapiwatana, Chatchai] Chiang Mai Univ, Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Fac Associated Med Sci,Biomed Technol Res Unit, Chiang Mai 50200, Thailand.
RP Tayapiwatana, C (reprint author), Chiang Mai Univ, Fac Associated Med Sci, Dept Med Technol, Div Clin Immunol, Chiang Mai 50200, Thailand.
EM chatchai.t@cmu.ac.th
FU Thailand Research Fund through the Royal Golden Jubilee Ph.D. program
   [PHD/0112/2550]; Fogarty AIDS International Research and Training
   Program; Johns Hopkins University; National Center for Genetic
   Engineering and Biotechnology (BIOTEC) of the National Science and
   Technology Development Agency of Thailand; U.S. National Institutes of
   Health grant [GM065059]
FX The authors thank Dr. Beatriz Gonzalez Alonso and Roberta Fuller for
   technical assistance, the Faculty of Allied Health Sciences at
   Chulalongkorn University in Bangkok for performing the confocal imaging
   experiments, and Dr. Bruce G. Weniger for editorial suggestions. This
   work was supported by the Thailand Research Fund through the Royal
   Golden Jubilee Ph.D. program (grant number PHD/0112/2550), Fogarty AIDS
   International Research and Training Program, Johns Hopkins University,
   the National Center for Genetic Engineering and Biotechnology (BIOTEC)
   of the National Science and Technology Development Agency of Thailand,
   and U.S. National Institutes of Health grant GM065059 (C.F.B.). The
   authors thank the National Research University Project under Thailand's
   Office of the Higher Education Commission for partial financial support.
CR Agosto LM, 2007, VIROLOGY, V368, P60, DOI 10.1016/j.virol.2007.06.001
   Balakrishnan M, 1997, J VIROL, V71, P1025
   BARBOSA P, 1994, AIDS RES HUM RETROV, V10, P53, DOI 10.1089/aid.1994.10.53
   Bohjanen PR, 1996, NUCLEIC ACIDS RES, V24, P3733, DOI 10.1093/nar/24.19.3733
   Bugreev DV, 2003, BIOCHEMISTRY-US, V42, P9235, DOI 10.1021/bi0300480
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Charpentier C, 2008, HIV MED, V9, P765, DOI 10.1111/j.1468-1293.2008.00628.x
   Chen LF, 2007, MED J AUSTRALIA, V186, P146
   COHLI H, 1994, ANTISENSE RES DEV, V4, P19
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   Delelis O, 2009, NUCLEIC ACIDS RES, V37, P1193, DOI 10.1093/nar/gkn1050
   Deprez E, 2004, MOL PHARMACOL, V65, P85, DOI 10.1124/mol.65.1.85                                                             
   DONEHOWER LA, 1984, P NATL ACAD SCI-BIOL, V81, P6461, DOI 10.1073/pnas.81.20.6461
   Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200                                                          
   Dull T, 1998, J VIROL, V72, P8463
   Evering TH, 2008, EXPERT OPIN INV DRUG, V17, P413, DOI [10.1517/13543784.17.3.413, 10.1517/13543784.17.3.413 ]
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Grant Philip, 2008, J HIV Ther, V13, P36
   Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004
   Hicks C, 2009, CLIN INFECT DIS, V48, P931, DOI 10.1086/597290
   JURRIAANS S, 1992, J GEN VIROL, V73, P1537, DOI 10.1099/0022-1317-73-6-1537
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   Katzman M, 1996, J VIROL, V70, P9069
   KIM SY, 1989, J VIROL, V63, P3708
   Gupta RK, 2007, INT J ANTIMICROB AG, V29, P510, DOI 10.1016/j.ijantimicag.2007.01.003
   LAFEMINA RL, 1991, J VIROL, V65, P5624
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Levy J. A., 2007, HIV PATHOGENESIS AID, P77
   LevyMintz P, 1996, J VIROL, V70, P8821
   Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893
   LIEM SE, 1993, HUM GENE THER, V4, P625, DOI 10.1089/hum.1993.4.5-625                                                        
   Liszewski MK, 2009, METHODS, V47, P254, DOI 10.1016/j.ymeth.2009.01.002
   Lu XB, 2004, J VIROL, V78, P7079, DOI 10.1128/JVI.78.13.7079-7088.2004
   MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889
   MARCHETTI A, 1995, J VIROL, V69, P1932
   Mbisa Jean L, 2011, Infect Drug Resist, V4, P65, DOI 10.2147/IDR.S7775
   O'Doherty U, 2002, J VIROL, V76, P10942, DOI 10.1128/JVI.76.21.10942-10950.2002
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PAUZA CD, 1990, VIROLOGY, V179, P886
   PAUZA CD, 1994, VIROLOGY, V205, P470, DOI 10.1006/viro.1994.1667                                                          
   Ramezani A, 2002, FRONT BIOSCI, V7, pA29, DOI 10.2741/ramezani
   REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838                                                           
   Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699
   Sakkhachornphop S, 2009, PROTEIN SCI, V18, P2219, DOI 10.1002/pro.233
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Segal DJ, 2004, J BIOL CHEM, V279, P14509, DOI 10.1074/jbc.M400349200
   Shaheen F, 1996, J VIROL, V70, P3392
   SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119
   Staunstrup NH, 2009, MOL THER, V17, P1205, DOI 10.1038/mt.2009.10
   Su K, 2009, METHODS, V47, P269, DOI 10.1016/j.ymeth.2009.01.001
   Tamhane Mayur, 2008, AIDS Res Ther, V5, P16, DOI 10.1186/1742-6405-5-16
   Tan WJ, 2004, J VIROL, V78, P1301, DOI 10.1128/JVI.78.3.1301-1313.2004
   Tesio M, 2008, STEM CELLS, V26, P1620, DOI 10.1634/stemcells.2008-0161
   Tewari D, 2003, J GENE MED, V5, P182, DOI 10.1002/jgm.336
   VANDENENT FMI, 1994, J VIROL, V68, P7825
   Vercruysse T, 2010, J BIOL CHEM, V285, P21768, DOI 10.1074/jbc.M110.112490
   VINK C, 1991, J VIROL, V65, P4636
   VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S
   WHITCOMB JM, 1990, J VIROL, V64, P4903
   YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0
   YOSHINAGA T, 1995, J VIROL, V69, P3233
   Zufferey R, 1998, J VIROL, V72, P9873
NR 63
TC 10
Z9 10
U1 0
U2 7
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD SEP
PY 2012
VL 23
IS 9
BP 932
EP 942
DI 10.1089/hum.2011.124
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 007VM
UT WOS:000308916500003
PM 22429108
OA green_published
DA 2018-01-05
ER

PT J
AU Bezerra, AG
   Barison, A
   Oliveira, VS
   Foti, L
   Krieger, MA
   Dhalia, R
   Viana, IFT
   Schreiner, WH
AF Bezerra, A. G., Jr.
   Barison, A.
   Oliveira, V. S.
   Foti, L.
   Krieger, M. A.
   Dhalia, R.
   Viana, I. F. T.
   Schreiner, W. H.
TI The mechanism of cysteine detection in biological media by means of
   vanadium oxide nanoparticles
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Cysteine; Glutathione; Protein; Vanadate; NMR
ID CARBON-PASTE ELECTRODE; GOLD NANOPARTICLES; PROTEIN; SENSOR;
   HOMOCYSTEINE; DIAGNOSIS; P24
AB We report on the interaction of vanadate nanoparticles, produced using the laser ablation in liquids synthesis, with cysteine in biological molecules. Cysteine is a very important amino acid present in most proteins, but also because cysteine and the tripeptide glutathione are the main antioxidant molecules in our body system. Detailed UV-Vis absorption spectra and dynamic light scattering measurements were done to investigate the detection of cysteine in large biological molecules. The intervalence band of the optical absorption spectra shows capability for quantitative cysteine sensing in the mu M range in biological macromolecules. Tests included cytoplasmic repetitive antigen and flagellar repetitive antigen proteins of the Trypanosoma cruzi protozoa, as well as the capsid p24 proteins from Human Immunodeficiency Virus type 1 and type 2. Detailed NMR measurements for hydrogen, carbon, and vanadium nuclei show that cysteine in contact with the vanadate looses hydrogen of the sulphydryl side chain, while the vanadate is reduced. The subsequent detachment of two deprotonated molecules to form cystine and the slow return to the vanadate complete the oxidation-reduction cycle. Therefore, the vanadate acts as a charge exchanging catalyst on cysteine to form cystine. The NMR results also indicate that the nanoparticles are not formed by the common orthorhombic V2O5 form.
C1 [Oliveira, V. S.; Schreiner, W. H.] Univ Fed Parana, Dept Fis, Ctr Politecn, BR-81531880 Curitiba, Parana, Brazil.
   [Bezerra, A. G., Jr.] Univ Tecnol Fed Parana, Dept Acad Fis, BR-80230010 Curitiba, Parana, Brazil.
   [Barison, A.] Univ Fed Parana, Dept Quim, Ctr Politecn, BR-81531880 Curitiba, Parana, Brazil.
   [Foti, L.; Krieger, M. A.] Fundacao Oswaldo Cruz, Inst Biol Mol Parana, BR-81350010 Curitiba, Parana, Brazil.
   [Dhalia, R.; Viana, I. F. T.] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, BR-50670420 Recife, PE, Brazil.
RP Schreiner, WH (reprint author), Univ Fed Parana, Dept Fis, Ctr Politecn, BR-81531880 Curitiba, Parana, Brazil.
EM wido@fisica.ufpr.br
RI Viana, Isabelle/M-4435-2017; Saude Publica, Inct/J-9544-2013; Ginane
   Bezerra-Jr, Arandi/I-9233-2017
OI Viana, Isabelle/0000-0003-4648-6635; Ginane Bezerra-Jr,
   Arandi/0000-0002-5145-5131
FU CPqD-Centro de Pesquisa e Desenvolvimento em Telecomunicacoes;
   CNPq-Conselho de Desenvolvimento Cientifico e Tecnologico
FX We acknowledge the support of CPqD-Centro de Pesquisa e Desenvolvimento
   em Telecomunicacoes and CNPq-Conselho de Desenvolvimento Cientifico e
   Tecnologico, Brazilian agencies.
CR Amendola V, 2009, PHYS CHEM CHEM PHYS, V11, P3805, DOI 10.1039/b900654k
   Baptista P, 2008, ANAL BIOANAL CHEM, V391, P943, DOI 10.1007/s00216-007-1768-z
   Celestino-Santos W, 2011, J NANOSCI NANOTECHNO, V11, P4702, DOI 10.1166/jnn.2011.4194
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Crans DC, 2009, COORDIN CHEM REV, V253, P2178, DOI 10.1016/j.ccr.2009.01.031
   Forster Susan M., 2003, Clinical Medicine (London), V3, P203
   Ji HM, 2009, ELECTROCHIM ACTA, V54, P7429, DOI 10.1016/j.electacta.2009.07.076
   KRIEGER MA, 1992, AM J TROP MED HYG, V46, P427, DOI 10.4269/ajtmh.1992.46.427                                                       
   Lim IIS, 2007, LANGMUIR, V23, P826, DOI 10.1021/la062334t
   Lu C, 2007, CHEM COMMUN, P3871, DOI 10.1039/b708603b
   Ly TD, 2004, J VIROL METHODS, V122, P185, DOI 10.1016/j.jviromet.2004.08.018
   MACARA IG, 1980, BIOCHIM BIOPHYS ACTA, V629, P95, DOI 10.1016/0304-4165(80)90268-8
   Maduraiveeran G, 2011, J NANOPART RES, V13, P4267, DOI 10.1007/s11051-011-0372-5
   Pontoni G, 2000, AMINO ACIDS, V19, P469, DOI 10.1007/s007260070024
   Quig D, 1998, Altern Med Rev, V3, P262
   Ramasarma T., 2003, Proceedings of the Indian National Science Academy Part B Biological Sciences, V69, P649
   Netto LES, 2007, COMP BIOCHEM PHYS C, V146, P180, DOI 10.1016/j.cbpc.2006.07.014
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   Tang SX, 2010, CLIN VACCINE IMMUNOL, V17, P1244, DOI 10.1128/CVI.00066-10
   Teixeira MFS, 2005, SENSOR ACTUAT B-CHEM, V106, P619, DOI 10.1016/j.snb.2004.07.031
   Thiagarajan S, 2010, J NANOSCI NANOTECHNO, V10, P702, DOI 10.1166/jnn.2010.1810
   WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471
   Wriedt H.A., 1989, B ALLOY PHASE DIAGRA, V10, P271, DOI DOI 10.1007/BF02877512
   Zhang M, 2007, J AM CHEM SOC, V129, P10322, DOI 10.1021/ja073140i
NR 24
TC 4
Z9 4
U1 3
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD SEP
PY 2012
VL 14
IS 9
AR 1123
DI 10.1007/s11051-012-1123-y
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 998GP
UT WOS:000308225800052
DA 2018-01-05
ER

PT J
AU Yu, DD
   Ruangchaithaweesuk, S
   Yao, L
   Xu, SJ
AF Yu, Dindi
   Ruangchaithaweesuk, Songtham
   Yao, Li
   Xu, Shoujun
TI Detecting molecules and cells labeled with magnetic particles using an
   atomic magnetometer
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Molecular imaging; Magnetic particles; Atomic magnetometry; Remnant
   magnetization; Cellular imaging
ID BREAST-CANCER; NANOPARTICLES; TIME; IMMUNOASSAY; TEMPERATURE;
   MICROSCOPY; RESOLUTION; TRACKING; BINDING; ASSAYS
AB The detection of magnetically labeled molecules and cells involves three essential parameters: sensitivity, spatial resolution, and molecular specificity. We report on the use of atomic magnetometry and its derivative techniques to achieve high performance in terms of all these parameters. With a sensitivity of 80 fT/root Hz for dc magnetic fields, we show that 7,000 streptavidin-conjugated magnetic microparticles magnetized by a permanent magnet produce a magnetic field of 650 pT; this result predicts that a single such particle can be detected during one second of signal averaging. Spatial information is obtained using a scanning magnetic imaging scheme. The spatial resolution is 20 mu m with a detection distance of more than 1 cm; this distance is much longer than that in previous reports. The molecular specificity is achieved using force-induced remnant magnetization spectroscopy, which currently uses an atomic magnetometer for detection. As an example, we perform measurement of magnetically labeled human CD4+ T cells, whose count in the blood is the diagnostic criterion for human immunodeficiency virus infection. Magnetic particles that are specifically bound to the cells are resolved from nonspecifically bound particles and quantitatively correlate with the number of cells. The magnetic particles have an overall size of 2.8 mu m, with a magnetic core in nanometer regime. The combination of our techniques is predicted to be useful in molecular and cellular imaging.
C1 [Yu, Dindi; Ruangchaithaweesuk, Songtham; Yao, Li; Xu, Shoujun] Univ Houston, Dept Chem, Houston, TX 77204 USA.
RP Xu, SJ (reprint author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.
EM sxu7@uh.edu
FU US National Science Foundation [ECCS-1028328]; Texas Center for
   Superconductivity at the University of Houston; GEAR Grant
FX Support from the US National Science Foundation (ECCS-1028328) is
   acknowledged. This study is supported in part by the Texas Center for
   Superconductivity at the University of Houston and a GEAR Grant.
CR Acosta V, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.053404
   Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598
   Bouchard LS, 2009, P NATL ACAD SCI USA, V106, P4085, DOI 10.1073/pnas.0813019106
   Budker D, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.043403
   Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924
   Chemla YR, 2000, P NATL ACAD SCI USA, V97, P14268, DOI 10.1073/pnas.97.26.14268                                                        
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   d'Ettorre G, 2011, AIDS RES HUM RETROV, V27, P355, DOI 10.1089/aid.2010.0342
   Dang HB, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3491215
   Debbage P, 2008, HISTOCHEM CELL BIOL, V130, P845, DOI 10.1007/s00418-008-0511-y
   Fong LE, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1884025
   Garcia NC, 2010, OPT LETT, V35, P661, DOI 10.1364/OL.35.000661
   Gleich B, 2005, NATURE, V435, P1214, DOI 10.1038/nature03808
   Goodwill PW, 2011, IEEE T MED IMAGING, V30, P1581, DOI 10.1109/TMI.2011.2125982
   Haun JB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002048
   Heim E, 2009, J MAGN MAGN MATER, V321, P1628, DOI 10.1016/j.jmmm.2009.02.101
   Holmberg A, 2005, ELECTROPHORESIS, V26, P501, DOI 10.1002/elps.200410070
   Horng HE, 2005, IEEE T APPL SUPERCON, V15, P668, DOI 10.1109/TASC.2005.849995
   Kominis IK, 2003, NATURE, V422, P596, DOI 10.1038/nature01484
   Leigh DR, 2005, CYTOM PART A, V66A, P103, DOI 10.1002/cyto.a.20155
   Leuschner C, 2006, BREAST CANCER RES TR, V99, P163, DOI 10.1007/s10549-006-9199-7
   Margolis DM, 2011, AIDS RES HUM RETROV, V27, P347, DOI 10.1089/aid.2011.0017
   Maser D, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3626505
   Misra RDK, 2008, MATER SCI TECH-LOND, V24, P1011, DOI 10.1179/174328408X341690
   Nan XL, 2008, CHEMPHYSCHEM, V9, P707, DOI 10.1002/cphc.200700839
   Nikitin MP, 2009, J MAGN MAGN MATER, V321, P1658, DOI 10.1016/j.jmmm.2009.02.108
   Osterfeld SJ, 2008, P NATL ACAD SCI USA, V105, P20637, DOI 10.1073/pnas.0810822105
   Pannetier M, 2004, SCIENCE, V304, P1648, DOI 10.1126/science.1096841
   Picot J, 2012, CYTOTECHNOLOGY, V64, P109, DOI 10.1007/s10616-011-9415-0
   Saar BG, 2010, ANGEW CHEM INT EDIT, V49, P5476, DOI 10.1002/anie.201000900
   Seltzer SJ, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.051407
   Shah V, 2007, NAT PHOTONICS, V1, P649, DOI 10.1038/nphoton.2007.201
   SHAPIRO HM, 2003, PRACTICAL FLOW CYTOM
   Shi H, 2011, P NATL ACAD SCI USA, V108, P3900, DOI 10.1073/pnas.1016197108
   Sivagnanam V, 2010, LANGMUIR, V26, P6091, DOI 10.1021/la9045572
   Vigneault F, 2011, J VIROL, V85, P3015, DOI 10.1128/JVI.01846-10
   Xu SJ, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2336087
   Yang SY, 2008, BIOSENS BIOELECTRON, V24, P855, DOI 10.1016/j.bios.2008.07.019
   Yao L, 2011, ANGEW CHEM INT EDIT, V50, P4407, DOI 10.1002/anie.201007297
   Yao L, 2010, ANGEW CHEM INT EDIT, V49, P7493, DOI 10.1002/anie.201002830
   Yao L, 2009, ANGEW CHEM INT EDIT, V48, P5679, DOI 10.1002/anie.200902114
   Ye T, 2009, PHOTOCHEM PHOTOBIOL, V85, P631, DOI 10.1111/j.1751-1097.2008.00514.x
   Yezhelyev MV, 2006, LANCET ONCOL, V7, P657, DOI 10.1016/S1470-2045(06)70793-8
NR 43
TC 3
Z9 3
U1 0
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
EI 1572-896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD SEP
PY 2012
VL 14
IS 9
AR 1135
DI 10.1007/s11051-012-1135-7
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 998GP
UT WOS:000308225800062
DA 2018-01-05
ER

PT J
AU Reynolds, JL
   Law, WC
   Mahajan, SD
   Aalinkeel, R
   Nair, B
   Sykes, DE
   Yong, KT
   Hui, R
   Prasad, PN
   Schwartz, SA
AF Reynolds, Jessica L.
   Law, Wing Cheung
   Mahajan, Supriya D.
   Aalinkeel, Ravikumar
   Nair, Bindukumar
   Sykes, Donald E.
   Yong, Ken-Tye
   Hui, Rui
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Nanoparticle Based Galectin-1 Gene Silencing, Implications in
   Methamphetamine Regulation of HIV-1 Infection in Monocyte Derived
   Macrophages
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE Macrophage; HIV-1; Galectin-1; Goldnanorod; siRNA
ID BLOOD-BRAIN-BARRIER; IMMUNODEFICIENCY-VIRUS-INFECTION; IMMATURE
   DENDRITIC CELLS; CENTRAL-NERVOUS-SYSTEM; GOLD NANOPARTICLES; T-CELLS;
   MONONUCLEAR PHAGOCYTES; VIRAL PERSISTENCE; HOST; EXPRESSION
AB Galectin-1, an adhesion molecule, is expressed in macrophages and implicated in human immunodeficiency virus (HIV-1) viral adsorption. In this study, we investigated the effects of methamphetamine on galectin-1 production in human monocyte derived macrophages (MDM) and the role of galectin-1 in methamphetamine potentiation of HIV-1 infection. Herein we show that levels of galectin-1 gene and protein expression are significantly increased by methamphetamine. Furthermore, concomitant incubation of MDM with galectin-1 and methamphetamine facilitates HIV-1 infection compared to galectin-1 alone or methamphetamine alone. We utilized a nanotechnology approach that uses gold nanorod (GNR)-galectin-1 siRNA complexes (nanoplexes) to inhibit gene expression for galectin-1. Nanoplexes significantly silenced gene expression for galectin-1 and reversed the effects of methamphetamine on galectin-1 gene expression. Moreover, the effects of methamphetamine on HIV-1 infection were attenuated in the presence of the nanoplex in MDM.
C1 [Reynolds, Jessica L.; Mahajan, Supriya D.; Aalinkeel, Ravikumar; Nair, Bindukumar; Sykes, Donald E.; Schwartz, Stanley A.] SUNY Buffalo, Innovat Ctr, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY 14203 USA.
   [Law, Wing Cheung; Hui, Rui; Prasad, Paras N.] SUNY Buffalo, Inst Lasers & Biophoton, Dept Chem, Amherst, NY 14203 USA.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore.
RP Reynolds, JL (reprint author), SUNY Buffalo, Innovat Ctr, Dept Med, Div Allergy Immunol & Rheumatol, 640 Ellicott St, Buffalo, NY 14203 USA.
EM jlr8@buffalo.edu
OI Law, Wing Cheung/0000-0003-3855-6170
FU National Institutes of Health [K01DA024577, R01AI085569, R21DA030108];
   Kaleida Health Foundation
FX This work was supported by the National Institutes of Health.;
   K01DA024577 (JR); R01AI085569 (SAS); R21DA030108 (SM); Kaleida Health
   Foundation (SAS)
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Airoldi M, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/467154
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   BARONDES SH, 1994, J BIOL CHEM, V269, P20807
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Buch S, 2011, J NEUROIMMUNE PHARM, V6, P503, DOI 10.1007/s11481-011-9297-0
   Buckner CM, 2006, J NEUROIMMUNE PHARM, V1, P160, DOI 10.1007/s11481-006-9017-3
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Chiariotti Lorenzo, 2004, Glycoconjugate Journal, V19, P441
   Ciborowski P, 2007, VIROLOGY, V363, P198, DOI 10.1016/j.virol.2007.01.013
   Ciborowski P, 2006, CURR HIV RES, V4, P279, DOI 10.2174/157016206777709474
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736                                                           
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Endharti AT, 2005, EUR J IMMUNOL, V35, P86, DOI 10.1002/eji.200425340                                                           
   Eugenin EA, 2006, J NEUROSCI, V26, P1098, DOI 10.1523/JNEUROSCI.3863-05.2006
   Fortin JF, 1998, J VIROL, V72, P2105
   Gaskill PJ, 2009, AM J PATHOL, V175, P1148, DOI 10.2353/ajpath.2009.081067
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GENDELMAN HE, 1988, ANN NEUROL, V23, pS78, DOI 10.1002/ana.410230721                                                           
   Gilbert C, 2007, J VIROL, V81, P7672, DOI 10.1128/JVI.02810-06
   Gonzalez E, 2002, P NATL ACAD SCI USA, V99, P13795, DOI 10.1073/pnas.202357499
   Gordon S, 2011, EUR J IMMUNOL, V41, P2470, DOI 10.1002/eji.201141988
   Hamamoto DT, 2009, ORAL DIS, V15, P27, DOI 10.1111/j.1601-0825.2008.01459.x
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   Howard KA, 2009, MOL THER, V17, P162, DOI 10.1038/mt.2008.220
   Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818                                                              
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kalasinsky KS, 2001, FORENSIC SCI INT, V116, P163, DOI 10.1016/S0379-0738(00)00368-6                                                   
   Klette KL, 2005, J ANAL TOXICOL, V29, P669, DOI 10.1093/jat/29.7.669                                                            
   Kraft-Terry SD, 2011, J PROTEOME RES, V10, P2852, DOI 10.1021/pr200124j
   Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/endo.138.10.5566
   Laroui H, 2011, BIOMATERIALS, V32, P1218, DOI 10.1016/j.biomaterials.2010.09.062
   Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32
   Liang H, 2008, AM J PATHOL, V172, P1617, DOI 10.2353/ajpath.2008.070971
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Mahajan SD, 2005, CLIN IMMUNOL, V115, P323, DOI 10.1016/j.clim.2005.02.004
   Mahajan SD, 2012, IMMUNOL INVEST, V41, P337, DOI 10.3109/08820139.2011.604863
   Mariani SA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-S1-S8
   Martinez D, 2007, NEUROIMAG CLIN N AM, V17, P539, DOI 10.1016/j.nic.2007.07.004
   Martinez LR, 2009, J INFECT DIS, V200, P131, DOI 10.1086/599328
   Masamune A, 2006, AM J PHYSIOL-GASTR L, V290, pG729, DOI 10.1152/ajpgi.00511.2005
   Mercier S, 2008, VIROLOGY, V371, P121, DOI 10.1016/j.virol.2007.09.034
   Mimi H, 2012, J CONTROL RELEASE, V158, P123, DOI 10.1016/j.jconrel.2011.10.035
   Morefield KM, 2011, ADDICTION, V106, P1293, DOI 10.1111/j.1360-0443.2011.03399.x
   Nawroth I, 2010, RADIOTHER ONCOL, V97, P143, DOI 10.1016/j.radonc.2010.09.010
   Nikoobakht B, 2002, PHOTOCHEM PHOTOBIOL, V75, P591, DOI 10.1562/0031-8655(2002)075<0591:TQOCQD>2.0.CO;2                                 
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Ouellet M, 2005, J IMMUNOL, V174, P4120, DOI 10.4049/jimmunol.174.7.4120                                                     
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Prasad P. N., 2004, INTRO BIOPHOTONICS
   Purohit V, 2011, MOL NEUROBIOL, V44, P102, DOI 10.1007/s12035-011-8195-z
   Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P557, DOI 10.1590/S0100-879X1999000500009
   Rabinovich GA, 1999, IMMUNOLOGY, V97, P100
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Reynolds JL, 2007, BBA-PROTEINS PROTEOM, V1774, P433, DOI 10.1016/j.bbapap.2007.02.001
   Reynolds JL, 2012, J IMMUNOL, V188, P3757, DOI 10.4049/jimmunol.1102276
   Ricardo-Dukelow M, 2007, J NEUROIMMUNOL, V185, P37, DOI 10.1016/j.jneuroim.2007.01.004
   Romagnani P, 2000, EUR CYTOKINE NETW, V11, P510
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X                                                   
   Roth MD, 2005, J LEUKOCYTE BIOL, V78, P1198, DOI 10.1189/jlb.0405219
   Schepers RJF, 2003, CLIN CHEM, V49, P121, DOI 10.1373/49.1.121
   Secchiero P, 2000, J IMMUNOL, V164, P4018, DOI 10.4049/jimmunol.164.8.4018                                                     
   Sokolov K, 2003, CANCER RES, V63, P1999
   St-Pierre C, 2012, ANTIMICROB AGENTS CH, V56, P154, DOI 10.1128/AAC.05595-11
   St-Pierre C, 2011, J VIROL, V85, P11742, DOI 10.1128/JVI.05351-11
   St-Pierre C, 2010, METHOD ENZYMOL, V480, P267, DOI 10.1016/S0076-6879(10)80013-8
   Takayasu T, 1995, J Clin Forensic Med, V2, P25, DOI 10.1016/1353-1131(95)90036-5
   Talloczy Z, 2008, PLOS PATHOG, DOI 10.1371/annotation/bd02ad26-a081-4c61-88c2-ebda285b8bca
   Tipton DA, 2009, TOXICOL IN VITRO, V24, P921
   Tokatlian T, 2010, WIRES NANOMED NANOBI, V2, P305, DOI 10.1002/wnan.81
   Toussi SS, 2009, AIDS RES HUM RETROV, V25, P1117, DOI 10.1089/aid.2008.0282
   Trikha S, 2011, J BIOL CHEM, V286, P36086, DOI 10.1074/jbc.M111.240762
   Wey SP, 2008, TOXICOL LETT, V181, P157, DOI 10.1016/j.toxlet.2008.07.015
   Williams KC, 2002, ANNU REV NEUROSCI, V25, P537, DOI 10.1146/annurev.neuro.25.112701.142822                                          
   Wu DT, 2000, J NEUROVIROL, V6, pS82
NR 78
TC 17
Z9 17
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD SEP
PY 2012
VL 7
IS 3
BP 673
EP 685
DI 10.1007/s11481-012-9379-7
PG 13
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 989JL
UT WOS:000307556000019
PM 22689223
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mateu, MG
AF Mateu, Mauricio G.
TI Mechanical properties of viruses analyzed by atomic force microscopy: A
   virological perspective
SO VIRUS RESEARCH
LA English
DT Review
DE Atomic force microscopy; Virus; Capsid; Mechanical properties;
   Elasticity; Conformational stability and dynamics
ID PARVOVIRUS MINUTE VIRUS; HERPES-SIMPLEX-VIRUS; TOBACCO-MOSAIC-VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL CAPSIDS; CRYOELECTRON TOMOGRAPHY;
   FUNCTIONAL IMPLICATIONS; 3-DIMENSIONAL STRUCTURE; SINGLE BIOMOLECULES;
   MOLECULAR-DYNAMICS
AB The advent of nanoscience and nanotechnology and the development of atomic force microscopy and other single-molecule techniques are leading to a renewed look at viruses from the point of view of the physical sciences. As any other solid-state object, virus particles are endowed with mechanical properties such as elasticity or brittleness. Emerging studies on virus mechanics may facilitate the engineering of the physical properties of viruses to improve their potential application in nanotechnology, and may be also relevant to understand virus biology. Viruses are subject to internal and external forces, and as evolving entities they may have selectively adapted their mechanical behavior to resist, or even use, those forces. This article adopts the perspective of structural and molecular virology to review the results obtained to date, using the atomic force microscope, on the mechanical properties of virus particles, their molecular determinants, and possible biological implications. (c) 2012 Elsevier B.V. All rights reserved.
C1 Univ Autonoma Madrid, CSIC UAM, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
RP Mateu, MG (reprint author), Univ Autonoma Madrid, CSIC UAM, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.
EM mgarcia@cbm.uam.es
OI G. Mateu, Mauricio/0000-0002-2915-1529
FU Spanish Ministerio de Ciencia e Innovacion (MICINN) [BIO2009-10092];
   Comunidad de Madrid (CM) [S-2009/MAT/1467]; Fundacion Ramon Areces
FX I gratefully acknowledge Dr. P.J. de Pablo for collaboration, advice,
   discussions and reading of the manuscript; Profs. J. Gomez-Herrero and
   J.M. Almendral for collaboration and support; Drs. M. Castellanos and R.
   Perez and P.J.P. Carrillo for excellent work on virus mechanics, and
   M.C. also for discussions and reading of the manuscript; A.
   Rodriguez-Huete and M.A. Fuertes for great experimental assistance; and
   Dr. C. Carrasco and M. Hernando-Perez for collaboration and advice. M.C.
   and M.A.F. kindly provided figures and some references. This work is
   funded by grants from the Spanish Ministerio de Ciencia e Innovacion
   (MICINN) (BIO2009-10092) and Comunidad de Madrid (CM) (S-2009/MAT/1467),
   and by an institutional grant from Fundacion Ramon Areces. M.G.M. is an
   associate member of the Institute for Biocomputation and Physics of
   Complex Systems, Zaragoza, Spain.
CR Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3                                                   
   Ahadi A, 2009, J PHYS CHEM B, V113, P3370, DOI 10.1021/jp8089352
   Alegre-Cebollada J, 2010, J BIOL CHEM, V285, P18961, DOI 10.1074/jbc.R109.011932
   Allison DP, 2010, WIRES NANOMED NANOBI, V2, P618, DOI 10.1002/wnan.104
   Arkhipov A, 2009, BIOPHYS J, V97, P2061, DOI 10.1016/j.bpj.2009.07.039
   Baclayon M, 2011, NANO LETT, V11, P4865, DOI 10.1021/nl202699r
   Baclayon M, 2010, MOL CELL PROTEOMICS, V9, P1678, DOI 10.1074/mcp.R110.001461
   BARO AM, 1985, NATURE, V315, P253, DOI 10.1038/315253a0
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BINNIG G, 1982, HELV PHYS ACTA, V55, P726
   Briggs JAG, 2011, J MOL BIOL, V410, P491, DOI 10.1016/j.jmb.2011.04.021
   Buenemann M, 2007, P NATL ACAD SCI USA, V104, P9925, DOI 10.1073/pnas.0611472104
   Buenemann M, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.051924
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Carrasco C, 2011, BIOPHYS J, V100, P1100, DOI 10.1016/j.bpj.2011.01.008
   Carrasco C, 2009, P NATL ACAD SCI USA, V106, P5475, DOI 10.1073/pnas.0810095106
   Carrasco C, 2008, P NATL ACAD SCI USA, V105, P4150, DOI 10.1073/pnas.0708017105
   Carreira A, 2004, J BIOL CHEM, V279, P6517, DOI 10.1074/jbc.M307662200
   Carrillo-Tripp M, 2009, NUCLEIC ACIDS RES, V37, pD436, DOI 10.1093/nar/gkn840
   Casjens S, 1985, VIRUS STRUCTURE ASSE
   CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1
   Castellanos M., 2012, P NATL ACAD IN PRESS
   Castellanos M, 2012, BIOPHYS J, V102, P2615, DOI 10.1016/j.bpj.2012.04.026
   Chiu W, 1997, STRUCTURAL BIOL VIRU
   Chiu W., 2003, ADV PROTEIN CHEM, V64
   Cieplak M, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3276287
   Clare DK, 2010, J STRUCT BIOL, V171, P303, DOI 10.1016/j.jsb.2010.06.011
   Cordova A, 2003, BIOPHYS J, V85, P70, DOI 10.1016/S0006-3495(03)74455-5                                                   
   Cuellar JL, 2010, J GEN VIROL, V91, P2449, DOI 10.1099/vir.0.021212-0
   de Pablo PJ, 2011, METHODS MOL BIOL, V783, P197, DOI 10.1007/978-1-61779-282-3_11
   de Pablo PJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.098101
   de Pablo PJ, 1998, APPL PHYS LETT, V73, P3300, DOI 10.1063/1.122751
   Dedeo MT, 2011, PROG MOL BIOL TRANSL, V103, P353, DOI 10.1016/B978-0-12-415906-8.00002-9
   Douglas T, 2006, SCIENCE, V312, P873, DOI 10.1126/science.1123223
   Dryden KA, 2006, MOL CELL, V22, P843, DOI 10.1016/j.molcel.2006.05.025
   Dufrene YF, 2002, J BACTERIOL, V184, P5205, DOI 10.1128/JB.184.19.5205-5213.2002
   Dufrene Y. F., 2007, PFLUGERS ARCH, V456, P237
   Eghiaian F., 2009, BIOPHYS J, V96, p15a
   Evilevitch A, 2003, P NATL ACAD SCI USA, V100, P9292, DOI 10.1073/pnas.1233721100
   Evilevitch A, 2011, J MOL BIOL, V405, P18, DOI 10.1016/j.jmb.2010.10.039
   Falvo MR, 1997, BIOPHYS J, V72, P1396, DOI 10.1016/S0006-3495(97)78786-1                                                   
   Ferreon ACM, 2011, BBA-PROTEINS PROTEOM, V1814, P1021, DOI 10.1016/j.bbapap.2011.01.011
   Firtel M, 1995, MICRON, V26, P347, DOI 10.1016/0968-4328(95)00012-7
   Fisher TE, 2000, NAT STRUCT BIOL, V7, P719
   Forman JR, 2007, CURR OPIN STRUC BIOL, V17, P58, DOI 10.1016/j.sbi.2007.01.006
   Forster F, 2005, P NATL ACAD SCI USA, V102, P4729, DOI 10.1073/pnas.0409178102
   Freddolino PL, 2006, STRUCTURE, V14, P437, DOI 10.1016/j.str.2005.11.014
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Gelbart WM, 2009, SCIENCE, V323, P1682, DOI 10.1126/science.1170645
   Gibbons MM, 2008, BIOPHYS J, V95, P3640, DOI 10.1529/biophysj.108.136176
   Gibbons MM, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.031901
   Gladnikoff M, 2008, BIOPHYS J, V94, P320, DOI 10.1529/biophysj.107.114579
   Gladnikoff M, 2009, BIOPHYS J, V97, P2419, DOI 10.1016/j.bpj.2009.08.016
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   Guerin T, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.061911
   HABERLE W, 1992, ULTRAMICROSCOPY, V42, P1161, DOI 10.1016/0304-3991(92)90418-J
   Hansma HG, 1998, CURR OPIN CHEM BIOL, V2, P579, DOI 10.1016/S1367-5931(98)80086-0
   Harris A, 2006, P NATL ACAD SCI USA, V103, P19123, DOI 10.1073/pnas.0607614103
   Hartschuh RD, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.021907
   Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123
   Hinterdorfer P, 2006, NAT METHODS, V3, P347, DOI 10.1038/NMETH871
   Horber JKH, 2003, SCIENCE, V302, P1002, DOI 10.1126/science.1067410
   Huang RK, 2011, J MOL BIOL, V408, P541, DOI 10.1016/j.jmb.2011.01.016
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Ivanovska I, 2007, P NATL ACAD SCI USA, V104, P9603, DOI 10.1073/pnas.0703166104
   Ivanovska IL, 2011, P NATL ACAD SCI USA, V108, P12611, DOI 10.1073/pnas.1105586108
   Johnson JE, 2003, ADV PROTEIN CHEM, V64, P197
   Johnson JE, 2010, CURR OPIN STRUC BIOL, V20, P210, DOI 10.1016/j.sbi.2010.01.004
   Katan AJ, 2011, CELL, V147, P979, DOI 10.1016/j.cell.2011.11.017
   Kienberger F, 2006, ACCOUNTS CHEM RES, V39, P29, DOI 10.1021/ar050084m
   Kirmizis D, 2010, INT J NANOMED, V5, P137
   Klug A, 1999, PHILOS T ROY SOC B, V354, P531, DOI 10.1098/rstb.1999.0404                                                          
   Klug WS, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.228101
   Knobler CM, 2009, ANNU REV PHYS CHEM, V60, P367, DOI 10.1146/annurev.physchem.59.032607.093728
   Kol N, 2007, BIOPHYS J, V92, P1777, DOI 10.1529/biophysj.106.093914
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Kontou M, 2005, J VIROL, V79, P10931, DOI 10.1128/JVI.79.17.10931-10943.2005
   Kurland NE, 2012, MICRON, V43, P116, DOI 10.1016/j.micron.2011.07.017
   Kuznetsov YG, 2001, J GEN VIROL, V82, P2025, DOI 10.1099/0022-1317-82-9-2025                                                     
   Kuznetsov YG, 2011, MICROBIOL MOL BIOL R, V75, P268, DOI 10.1128/MMBR.00041-10
   LANDAU L D, 1986, COURSE THEORETICAL P, V7
   Lander G. C., 2008, STRUCTURE, V16, P1339
   Lata R, 2000, CELL, V100, P253, DOI 10.1016/S0092-8674(00)81563-9                                                   
   Li S, 2011, BIOPHYS J, V100, P637, DOI 10.1016/j.bpj.2010.12.3701
   Liashkovich I, 2008, J CELL SCI, V121, P2287, DOI 10.1242/jcs.032284
   Liu J, 2010, METHOD ENZYMOL, V483, P267, DOI 10.1016/S0076-6879(10)83014-9
   Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000
   Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1028/JVI.76.14.7049-7059.2002
   Malkin Alexander J, 2005, Methods Mol Biol, V292, P85
   Maroto B, 2004, J VIROL, V78, P10685, DOI 10.1128/jvi.78.19.10685-10694.2004
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   Mateu MG, 2011, PROTEIN ENG DES SEL, V24, P53, DOI 10.1093/protein/gzq069
   Mateu MG, 2009, FEBS J, V276, P6098, DOI 10.1111/j.1742-4658.2009.07313.x
   May ER, 2011, BIOPHYS J, V100, pL59, DOI 10.1016/j.bpj.2011.04.026
   McPherson A, 2011, METHODS MOL BIOL, V736, P171, DOI 10.1007/978-1-61779-105-5_12
   Miao YL, 2010, J PHYS CHEM B, V114, P11181, DOI 10.1021/jp102314e
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Moloney M, 2004, ULTRAMICROSCOPY, V100, P163, DOI 10.1016/j.ultramic.2003.12.011
   Morais MC, 2005, MOL CELL, V18, P149, DOI 10.1016/j.molcel.2005.03.013
   Moreno-Herrero F, 2002, APPL PHYS LETT, V81, P2620, DOI 10.1063/1.1509856
   Morozov AY, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.041925
   NAMBA K, 1986, SCIENCE, V231, P1401, DOI 10.1126/science.3952490
   Neuman KC, 2008, NAT METHODS, V5, P491, DOI 10.1038/NMETH.1218
   Newcomb WW, 2000, J VIROL, V74, P1663, DOI 10.1128/JVI.74.4.1663-1673.2000
   NEWCOMB WW, 1991, J VIROL, V65, P613
   Nguyen TT, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.051923
   Oberhauser AF, 2008, J BIOL CHEM, V283, P6617, DOI 10.1074/jbc.R700050200
   Parot P, 2007, J MOL RECOGNIT, V20, P418, DOI 10.1002/jmr.857
   Perez R, 2011, J MOL BIOL, V413, P32, DOI 10.1016/j.jmb.2011.08.020
   Plevka P, 2011, J VIROL, V85, P4822, DOI 10.1128/JVI.02598-10
   Powell SK, 2000, NAT BIOTECHNOL, V18, P1279, DOI 10.1038/82391                                                                   
   Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287
   Purohit PK, 2005, BIOPHYS J, V88, P851, DOI 10.1529/biophysj.104.047134
   Rankl C, 2008, P NATL ACAD SCI USA, V105, P17778, DOI 10.1073/pnas.0806451105
   Rapaport DC, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.186101
   Reddy VS, 2005, ADV VIRUS RES, V64, P45, DOI 10.1016/S0065-3527(05)64003-1
   Reguera J, 2004, P NATL ACAD SCI USA, V101, P2724, DOI 10.1073/pnas.0307748101
   Riolobos L, 2006, J MOL BIOL, V357, P1026, DOI 10.1016/j.jmb.2006.01.019
   Roos WH, 2007, CELL MOL LIFE SCI, V64, P1484, DOI 10.1007/s00018-007-6451-1
   Roos WH, 2010, NAT PHYS, V6, P733, DOI 10.1038/NPHYS1797
   Roos WH, 2010, BIOPHYS J, V99, P1175, DOI 10.1016/j.bpj.2010.05.033
   Roos WH, 2012, P NATL ACAD SCI USA, V109, P2342, DOI 10.1073/pnas.1109590109
   Roos WH, 2011, METHODS MOL BIOL, V783, P251, DOI 10.1007/978-1-61779-282-3_14
   Roos WH, 2009, ADV MATER, V21, P1187, DOI 10.1002/adma.200801709
   Roos WH, 2009, P NATL ACAD SCI USA, V106, P9673, DOI 10.1073/pnas.0901514106
   Schmatulla A, 2007, J MICROSC-OXFORD, V225, P264, DOI 10.1111/j.1365-2818.2007.01741.x
   Serena PA, 2009, PHYS STATUS SOLIDI C, V6, P2128, DOI 10.1002/pssc.200881738
   Siber A, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011919
   Singh S, 2003, J BIOL CHEM, V278, P18249, DOI 10.1074/jbc.M211408200
   Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581
   Speir JA, 2006, J VIROL, V80, P3582, DOI 10.1128/JVI.80.7.3582-3591.2006
   SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6
   Stockley P. G., 2010, EMERGING TOPICS PHYS
   Tama F, 2005, J MOL BIOL, V345, P299, DOI 10.1016/j.jmb.2004.10.054
   TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420
   Uetrecht C, 2008, P NATL ACAD SCI USA, V105, P9216, DOI 10.1073/pnas.0800406105
   Valle N., 2006, PARVOVIRUSES, P291
   Vliegenthart GA, 2006, BIOPHYS J, V91, P834, DOI 10.1529/biophysj.106.081422
   Wikoff WR, 2000, SCIENCE, V289, P2129, DOI 10.1126/science.289.5487.2129
   Wilts BD, 2010, BIOPHYS J, V98, p656A, DOI 10.1016/j.bpj.2009.12.3597                                                      
   Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5
   Yang F, 2000, NAT STRUCT BIOL, V7, P230
   Zandi R, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.021917
   Zhao Y, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.031914
   Zhou ZH, 2000, SCIENCE, V288, P877, DOI 10.1126/science.288.5467.877
   Zink M, 2010, BIOPHYS J, V98, P687, DOI 10.1016/j.bpj.2009.10.047
   Zink M, 2009, BIOPHYS J, V96, P1350, DOI 10.1016/j.bpj.2008.11.028
   AgbandjeMckenna M, 2011, RSC BIOMOL SCI, P1
NR 148
TC 42
Z9 43
U1 2
U2 66
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
J9 VIRUS RES
JI Virus Res.
PD SEP
PY 2012
VL 168
IS 1-2
BP 1
EP 22
DI 10.1016/j.virusres.2012.06.008
PG 22
WC Virology
SC Virology
GA 991JW
UT WOS:000307698300001
PM 22705418
DA 2018-01-05
ER

PT J
AU Wang, XF
   Kurihara, S
   Hasegawa, M
   Ruslinda, AR
   Kawarada, H
AF Wang, Xianfen
   Kurihara, Shinichiro
   Hasegawa, Masataka
   Ruslinda, A. Rahim
   Kawarada, Hiroshi
TI High Priority of Nanocrystalline Diamond as a Biosensing Platform
SO JAPANESE JOURNAL OF APPLIED PHYSICS
LA English
DT Article
ID HYDROGEN-TERMINATED DIAMOND; SINGLE-CRYSTAL DIAMOND; THIN-FILMS;
   SURFACE; FUNCTIONALIZATION; WETTABILITY; ENERGY
AB Here we report the performance of surface functionalized diamond surfaces as biosensing platform for human immunodeficiency virus transactivator of transcription (HIV-Tat) peptide detection. Comparative investigations were conducted on nanocrystalline diamond (NCD) and polycrystalline diamond (PCD) films. Scanning electron microscopy (SEM) images revealed the morphology differences between NCD and PCD films. X-ray photoelectron spectroscopy (XPS) data showed that functional components and corresponding coverages, demonstrating denser carboxyl acid groups and fluorinated groups on NCD than that PCD films after UV/ozone and fluorine plasma treatment respectively. Contact angle results showed the differences in surface wettability and free energy between functionalized NCD and PCD biosensors. Fluorescence observations confirmed that higher biosensing performance can be obtained on NCD biosensors with high sensitivity selectivity, and stability. The NCD films with denser surface coverages of functionalizations made NCD films much more priority as an effective biosensing candidate than PCD films. (C) 2012 The Japan Society of Applied Physics
C1 [Wang, Xianfen; Kurihara, Shinichiro; Ruslinda, A. Rahim; Kawarada, Hiroshi] Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan.
   [Hasegawa, Masataka] Natl Inst Adv Ind & Technol AIST, Nanotube Res Ctr, Tsukuba, Ibaraki 3058565, Japan.
RP Wang, XF (reprint author), Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan.
EM xianfen.wang@gmail.com
RI A.Rahim, Ruslinda/K-7078-2014; Kawarada, Hiroshi/L-6486-2017
OI A.Rahim, Ruslinda/0000-0002-3511-9509; 
FU Global Center of Excellence (GCOE) Research from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan; Japan Society
   for the Promotion of Science (JSPS) [23246069]; Chinese government for
   the China Scholarship Council Award
FX This work was supported by a Grant-in-Aid from a Global Center of
   Excellence (GCOE) Research from the Ministry of Education, Culture,
   Sports, Science and Technology, Japan and a Grant-in-Aid for Fundamental
   Research A (23246069) from the Japan Society for the Promotion of
   Science (JSPS). Xianfen Wang gratefully appreciates the Chinese
   government for the China Scholarship Council Award.
CR Ang PK, 2009, ADV FUNCT MATER, V19, P109, DOI 10.1002/adfm.200800770
   Chong KF, 2007, LANGMUIR, V23, P5615, DOI 10.1021/la070037y
   CLARK DT, 1973, J POLYM SCI POL CHEM, V11, P389, DOI 10.1002/pol.1973.170110207                                                      
   Colombo E, 2011, DIAM RELAT MATER, V20, P793, DOI 10.1016/j.diamond.2011.03.032
   Ferro S, 2005, CARBON, V43, P1191, DOI 10.1016/j.carbon.2004.12.012
   Hartl A, 2008, LANGMUIR, V24, P9898, DOI 10.1021/la8014139
   Hartl A, 2004, NAT MATER, V3, P736, DOI 10.1038/nmat1204
   Hernando J, 2007, DIAM RELAT MATER, V16, P138, DOI 10.1016/j.diamond.2006.04.005
   Kawarada H, 1996, SURF SCI REP, V26, P205, DOI 10.1016/S0167-5729(97)80002-7
   Liu Y, 2004, CHEM MATER, V16, P3924, DOI 10.1021/cm048875q
   Nakamura T, 2006, DIAM RELAT MATER, V15, P678, DOI 10.1016/j.diamond.2005.10.030
   Nebel CE, 2006, DIAM RELAT MATER, V15, P1107, DOI 10.1016/j.diamond.2005.11.041
   Ohtani B, 1998, CHEM LETT, P953, DOI 10.1246/cl.1998.953                                                             
   Ostrovskaya L, 2007, DIAM RELAT MATER, V16, P2109, DOI 10.1016/j.diamond.2007.07.026
   Ostrovskaya L, 2002, DIAM RELAT MATER, V11, P845, DOI 10.1016/S0925-9635(01)00636-7                                                   
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815                                                      
   PATE BB, 1986, SURF SCI, V165, P83, DOI 10.1016/0039-6028(86)90665-5                                                    
   Popov C, 2009, DIAM RELAT MATER, V18, P895, DOI 10.1016/j.diamond.2009.02.004
   Riedel M, 2004, DIAM RELAT MATER, V13, P746, DOI 10.1016/j.diamond.2003.11.094
   Ruslinda AR, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3643067
   Salvadori MC, 2010, DIAM RELAT MATER, V19, P324, DOI 10.1016/j.diamond.2010.01.002
   Song KS, 2006, ANAL CHIM ACTA, V573, P3, DOI 10.1016/j.aca.2006.04.051
   Strother T, 2002, LANGMUIR, V18, P968, DOI 10.1021/la0112561
   Szunerits S, 2008, J SOLID STATE ELECTR, V12, P1205, DOI 10.1007/s10008-007-0473-3
   Torrengo S, 2011, DIAM RELAT MATER, V20, P990, DOI 10.1016/j.diamond.2011.05.014
   Tsugawa K, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.125460
   Wang XF, 2012, DIAM RELAT MATER, V24, P146, DOI 10.1016/j.diamond.2011.12.033
   Wang XF, 2011, DIAM RELAT MATER, V20, P1319, DOI 10.1016/j.diamond.2011.08.011
   Yang NJ, 2009, ADV FUNCT MATER, V19, P887, DOI 10.1002/adfm.200801392
   Yang WS, 2002, NAT MATER, V1, P253, DOI 10.1038/nmat779
   Zhou YL, 2008, ANAL CHEM, V80, P4141, DOI 10.1021/ac702417x
NR 31
TC 2
Z9 2
U1 1
U2 12
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0021-4922
EI 1347-4065
J9 JPN J APPL PHYS
JI Jpn. J. Appl. Phys.
PD SEP
PY 2012
VL 51
IS 9
AR 090125
DI 10.1143/JJAP.51.090125
PG 7
WC Physics, Applied
SC Physics
GA 001WB
UT WOS:000308489700025
OA gold
DA 2018-01-05
ER

PT J
AU Wahome, N
   Pfeiffer, T
   Ambiel, I
   Yang, YK
   Keppler, OT
   Bosch, V
   Burkhard, P
AF Wahome, Newton
   Pfeiffer, Tanya
   Ambiel, Ina
   Yang, Yongkun
   Keppler, Oliver T.
   Bosch, Valerie
   Burkhard, Peter
TI Conformation-specific Display of 4E10 and 2F5 Epitopes on
   Self-assembling Protein Nanoparticles as a Potential HIV Vaccine
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE membrane proximal external region (MPER); repetitive antigen display;
   self-assembling protein nanoparticle (SAPN)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROXIMAL EXTERNAL REGION; BROADLY
   NEUTRALIZING ANTIBODIES; HUMAN MONOCLONAL-ANTIBODIES; PEPTIDE
   NANOPARTICLES; ECTODOMAIN REGION; TYPE-1 GP41; MEMBRANE; DESIGN; TARGET
AB The self-assembling protein nanoparticle (SAPN) is an antigen-presenting system that has been shown to be suitable for use as a vaccine platform. The SAPN scaffold is based on the principles of icosahedral symmetry, beginning from a monomeric chain that self-assembles into an ordered oligomeric state. The monomeric chain contains two covalently linked a-helical coiled-coil domains, an N-terminal de novo-designed pentameric tryptophan zipper and a C-terminal de novo-designed trimeric leucine zipper, which assemble along the internal symmetry axes of an icosahedron. In this study, we incorporated the membrane proximal external region (MPER) of HIV-1 gp41 from HXB2 into the N-terminal pentamer, referred to as MPER-SAPN, attempting to reproduce the a-helical state of the 4E10 epitope while maintaining a structurally less-constrained 2F5 epitope. SpragueDawley rats were immunized with MPER-SAPNs, and their sera were analyzed for induced humoral anti-HIV-1 responses. We show that high membrane proximal external region-specific titers can be raised via the repetitive antigen display of MPER on the SAPN without the need for adjuvant. However, none of the sera displayed a detectable neutralizing activity against HIV-1. Thus, 4E10- and 2F5-like neutralizing antibodies could not be elicited by MPER conformationally restrained in the SAPN context.
C1 [Wahome, Newton; Yang, Yongkun; Burkhard, Peter] Univ Connecticut, Mol & Cell Biol Dept, Storrs, CT 06250 USA.
   [Wahome, Newton; Yang, Yongkun; Burkhard, Peter] Univ Connecticut, Inst Mat Sci, Storrs, CT 06250 USA.
   [Pfeiffer, Tanya; Bosch, Valerie] Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Infekt & Krebs, D-69120 Heidelberg, Germany.
   [Ambiel, Ina; Keppler, Oliver T.] Univ Klinikum Heidelberg, Dept Infektiol, D-69120 Heidelberg, Germany.
RP Burkhard, P (reprint author), Univ Connecticut, Mol & Cell Biol Dept, 97 N Eagleville Rd, Storrs, CT 06250 USA.
EM v.bosch@dkfz-heidelberg.de; peter.burkhard@uconn.edu
FU University of Connecticut Research Foundation; Deutsches
   Krebsforschungszentrum; German Centre for Infection Research, University
   of Heidelberg
FX The work was financially supported by the University of Connecticut
   Research Foundation (P. B.), the Deutsches Krebsforschungszentrum (V.
   B.) and by the German Centre for Infection Research, University of
   Heidelberg (O.T.K.). P. B. hold shares in the company Alpha-O Peptides
   the owner of the relevant IP.
CR Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Apellaniz B, 2009, BIOCHEMISTRY-US, V48, P5320, DOI 10.1021/bi900504t
   Bosch V, 2009, VACCINE, V27, P2202, DOI 10.1016/j.vaccine.2009.02.014
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Burkhard P, 2002, J MOL BIOL, V318, P901, DOI 10.1016/S0022-2836(02)00114-6
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   CHESEBRO B, 1988, J VIROL, V62, P3779
   Ebensen T, 2009, ADV EXP MED BIOL, V655, P171, DOI 10.1007/978-1-4419-1132-2_13
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Goffinet C, 2007, P NATL ACAD SCI USA, V104, P1015, DOI 10.1073/pnas.0607414104
   Guenaga J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016074
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   Hinz A, 2009, VIROLOGY, V390, P221, DOI 10.1016/j.virol.2009.05.015
   Hoxie JA, 2010, ANNU REV MED, V61, P135, DOI 10.1146/annurev.med.60.042507.164323
   Julien JP, 2010, J VIROL, V84, P4136, DOI 10.1128/JVI.02357-09
   Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957
   Keppler OT, 2002, J EXP MED, V195, P719, DOI 10.1084/jem.20011549
   Liu J, 2009, BIOCHEMISTRY-US, V48, P2915, DOI 10.1021/bi802303b
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   Matyas GR, 2009, AIDS, V23, P2069, DOI 10.1097/QAD.0b013e32832faea5
   O'Rourke SM, 2009, J VIROL, V83, P7728, DOI 10.1128/JVI.00688-09
   Ofek G, 2010, P NATL ACAD SCI USA, V107, P17880, DOI 10.1073/pnas.1004728107
   Ofek G, 2010, J VIROL, V84, P2955, DOI 10.1128/JVI.02257-09
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Raman S., 2009, OPEN NANOMED J, V2, P15, DOI DOI 10.2174/1875933500902010015
   Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007
   Ruprecht C, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-S3-P65                                                      
   Scherer EM, 2010, P NATL ACAD SCI USA, V107, P1529, DOI 10.1073/pnas.0909680107
   Schroeder U, 2009, J MOL BIOL, V386, P1368, DOI 10.1016/j.jmb.2008.11.023
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107
   Verkoczy L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007215
   Vishwanathan SA, 2008, J VIROL, V82, P5118, DOI 10.1128/JVI.00305-08
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Zolla-Pazner Susan, 2005, Human Antibodies, V14, P69
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2005, AIDS, V19, P1725, DOI 10.1097/01.aids.0000189850.83322.41
NR 39
TC 40
Z9 40
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD SEP
PY 2012
VL 80
IS 3
BP 349
EP 357
DI 10.1111/j.1747-0285.2012.01423.x
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 977MD
UT WOS:000306664800001
PM 22650354
OA gold
DA 2018-01-05
ER

PT J
AU Sun, WC
   Fletcher, D
   van Heeckeren, RC
   Davis, PB
AF Sun, Wenchao
   Fletcher, David
   van Heeckeren, Rolf Christiaan
   Davis, Pamela B.
TI Non-covalent ligand conjugation to biotinylated DNA nanoparticles using
   TAT peptide genetically fused to monovalent streptavidin
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Non-viral gene therapy; polylysine-PEG block copolymer; ligand
   conjugation; biotin-streptavidin interaction; monovalent streptavidin
ID IN-VIVO; MAMMALIAN-CELLS; PROTEIN TRANSDUCTION; FUSION PROTEIN; GENE
   DELIVERY; LIPID RAFT; COMPLEXES; BINDING; SYSTEM; VITRO
AB DNA nanoparticles (DNA NPs), which self-assemble from DNA plasmids and poly-l-lysine (pLL)-polyethylene glycol (PEG) block copolymers, transfect several cell types in vitro and in vivo with minimal toxicity and immune response. To further enhance the gene transfer efficiency of DNA NP and control its tropism, we established a strategy to efficiently attach peptide ligands to DNA NPs. The non-covalent biotin-streptavidin (SA) interaction was used for ligand conjugation to overcome problems associated with covalent conjugation methods. A fusion protein of SA with the HIV-1 TAT peptide was cloned, expressed, purified and attached to biotinylated DNA NPs. A modified SA system with tetrameric structure but monovalent biotin binding capacity was adopted and shown to reduce the aggregation of biotinylated DNA NPs compared to neutravidin. Compared to unmodified DNA NPs, TAT modified DNA NPs significantly enhanced in vitro gene transfer, particularly at low DNA concentrations. Studies of cellular uptake and cellular distribution of the DNA NPs indicated that attaching TAT enhanced binding of DNA NPs to cell surface but not internalization at high DNA concentrations. In vivo studies showed that TAT modified DNA NPs mediated equal level of gene transfer to the mouse airways via the luminal route compared to unmodified DNA NPs.
C1 [Sun, Wenchao; Davis, Pamela B.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.
   [Sun, Wenchao; Fletcher, David; van Heeckeren, Rolf Christiaan; Davis, Pamela B.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA.
RP Davis, PB (reprint author), Case Western Reserve Univ, Sch Med, Dept Biochem, 2109 Adelbert Rd,BRB 113, Cleveland, OH 44106 USA.
EM pbd@cwru.edu
RI Sun, Wenchao/H-7738-2017
OI Sun, Wenchao/0000-0003-4306-2896
FU National Institutes of Health [R01DK058318, R21DK084371, P30DK27651]
FX This research was supported by the National Institutes of Health Grants
   R01DK058318, R21DK084371, and P30DK27651.
CR Albarran B, 2005, PROTEIN ENG DES SEL, V18, P147, DOI 10.1093/protein/gzi014
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Boylan NJ, 2012, J CONTROL RELEASE, V157, P72, DOI 10.1016/j.jconrel.2011.08.031
   Breitz HB, 1999, CANCER BIOTHER RADIO, V14, P381, DOI 10.1089/cbr.1999.14.381
   Chen X, 2008, MOL THER, V16, P333, DOI 10.1038/sj.mt.6300365
   Chen XG, 2011, MOL THER, V19, P93, DOI 10.1038/mt.2010.214
   Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   Howarth M, 2006, NAT METHODS, V3, P267, DOI 10.1038/NMETH861
   Howarth M, 2008, NAT PROTOC, V3, P534, DOI 10.1038/nprot.2008.20
   Huang ZH, 2005, MOL THER, V11, P409, DOI 10.1016/j.ymthe.2004.10.013
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kakimoto S, 2010, BIOMED PHARMACOTHER, V64, P296, DOI 10.1016/j.biopha.2009.06.017
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255                                                        
   Kwok KY, 1999, J PHARM SCI, V88, P996, DOI 10.1021/js990072s
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   Meyer DL, 2001, PROTEIN SCI, V10, P491, DOI 10.1110/ps.19901
   PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3
   Peetla C, 2009, MOL PHARMACEUT, V6, P1311, DOI 10.1021/mp900011h
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Rimann M, 2008, BIOCONJUGATE CHEM, V19, P548, DOI 10.1021/bc7003439
   Schultz J, 2000, CANCER RES, V60, P6663
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Sun WC, 2010, J CONTROL RELEASE, V146, P118, DOI 10.1016/j.jconrel.2010.04.031
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Toro A, 2006, J CLIN INVEST, V116, P2717, DOI 10.1172/JC125052
   Townsend SA, 2007, BIOMATERIALS, V28, P5176, DOI 10.1016/j.biomaterials.2007.08.011
   Ward CM, 2002, J GENE MED, V4, P536, DOI 10.1002/jgm.296
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Yurek DM, 2009, MOL THER, V17, P641, DOI 10.1038/mt.2009.2
   Ziady AG, 2003, MOL THER, V8, P936, DOI 10.1016/j.ymthe.2003.07.007
   Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002
NR 36
TC 3
Z9 4
U1 1
U2 22
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PD SEP
PY 2012
VL 20
IS 8
BP 678
EP 690
DI 10.3109/1061186X.2012.712128
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 980YB
UT WOS:000306929000004
PM 22845840
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dong, HH
   Liu, JL
   Zhu, H
   Ou, CY
   Xing, WG
   Qiu, MF
   Zhang, GY
   Xiao, Y
   Yao, J
   Pan, PL
   Jiang, Y
AF Dong, Huahuang
   Liu, Jianli
   Zhu, Hong
   Ou, Chin-Yih
   Xing, Wenge
   Qiu, Maofeng
   Zhang, Guiyun
   Xiao, Yao
   Yao, Jun
   Pan, Pinliang
   Jiang, Yan
TI Two types of nanoparticle-based bio-barcode amplification assays to
   detect HIV-1 p24 antigen
SO VIROLOGY JOURNAL
LA English
DT Article
DE Human immunodeficiency viruses; Bio-barcode amplification; p24 detection
ID RESOURCE-LIMITED SETTINGS; REAL-TIME-PCR; ULTRASENSITIVE DETECTION;
   VIRUS-INFECTION; IMMUNO-PCR; RNA; DIAGNOSIS; PROTEIN; PLASMA; LOAD
AB Background: HIV-1 p24 antigen is a major viral component of human immunodeficiency virus type 1 (HIV-1) which can be used to identify persons in the early stage of infection and transmission of HIV-1 from infected mothers to infants. The detection of p24 is usually accomplished by using an enzyme-linked immunosorbent assay (ELISA) with low detection sensitivity. Here we report the use of two bio-barcode amplification (BCA) assays combined with polymerase chain reaction (PCR) and gel electrophoresis to quantify HIV-1 p24 antigen.
   Method: A pair of anti-p24 monoclonal antibodies (mAbs) were used in BCA assays to capture HIV-1 p24 antigen in a sandwich format and allowed for the quantitative measurement of captured p24 using PCR and gel electrophoresis. The first 1 G12 mAb was coated on microplate wells or magnetic microparticles (MMPs) to capture free p24 antigens. Captured p24 in turn captured 1D4 mAb coated gold nanoparticle probes (GNPs) containing double-stranded DNA oligonucleotides. One strand of the oligonucleotides was covalently immobilized whereas the unbound complimentary bio-barcode DNA strand could be released upon heating. The released bio-barcode DNA was amplified by PCR, electrophoresed in agarose gel and quantified.
   Results: The in-house ELISA assay was found to quantify p24 antigen with a limit of detection (LOD) of 1,000 pg/ml and a linear range between 3,000 and 100,000 pg/ml. In contrast, the BCA-based microplate method yielded an LOD of 1 pg/ml and a linear detection range from 1 to 10,000 pg/ml. The BCA-based MMP method yielded an LOD of 0.1 pg/ml and a linear detection range from 0.1 to 1,000 pg/ml.
   Conclusions: When combined with PCR and simple gel electrophoresis, BCA-based microplate and MMPs assays can be used to quantify HIV-1 p24 antigen. These methods are 3-4 orders of magnitude more sensitive than our in-house ELISA-based assay and may provide a useful approach to detect p24 in patients newly infected with HIV.
C1 [Dong, Huahuang; Xing, Wenge; Qiu, Maofeng; Zhang, Guiyun; Xiao, Yao; Yao, Jun; Pan, Pinliang; Jiang, Yan] Chinese Ctr Dis Control & Prevent, Natl HIV HCV Reference Lab, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.
   [Liu, Jianli; Zhu, Hong] Beijing Exit & Entry Inspect & Quarantine Bur, HIV Cent Confirmatory Lab, Beijing, Peoples R China.
   [Ou, Chin-Yih] US Ctr Dis Control & Prevent, Global AIDS Program, China Off, Beijing, Peoples R China.
RP Jiang, Y (reprint author), Chinese Ctr Dis Control & Prevent, Natl HIV HCV Reference Lab, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.
EM jiangyan03@263.net
FU Twelfth Five Projects of National Science and Technology fund from the
   Ministry of Science and Technology of China [2012ZX10001001-002]
FX The authors would like to thank Lingzhang Meng, Hui Zhang, Xiuhua Lv,
   Lijian Pei, Jun Tao, Zengqiang Wang, Xingmei Li and Serena Fuller for
   their valuable assistance with preparation of experimental materials.
   This study was funded by the Twelfth Five Projects of National Science
   and Technology fund from the Ministry of Science and Technology of China
   (grant no: 2012ZX10001001-002).
CR ALLAIN JP, 1986, LANCET, V2, P1233
   Bao YP, 2006, ANAL CHEM, V78, P2055, DOI 10.1021/ac051798d
   Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN
   Chen LY, 2009, J IMMUNOL METHODS, V346, P64, DOI 10.1016/j.jim.2009.05.007
   Daskalakis Demetre, 2011, Top Antivir Med, V19, P18
   Feugate JE, 2002, J CELL BIOL, V156, P161, DOI 10.1083/jcb.200103062
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Finnegan J, 2009, J TROP PEDIATRICS, V55, P216, DOI 10.1093/tropej/fmp056
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   George E, 2007, J CLIN MICROBIOL, V45, P3416, DOI 10.1128/JCM.01314-07
   Ho PS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-13
   Jennings C, 2005, J CLIN MICROBIOL, V43, P5950, DOI 10.1128/JCM.43.12.5950-5956.2005
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Nam JM, 2005, ANAL CHEM, V77, P6985, DOI 10.1021/ac0513764
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Oh BK, 2006, SMALL, V2, P103, DOI 10.1002/smll.200500260
   Prado JG, 2004, J CLIN MICROBIOL, V42, P1620, DOI 10.1128/JCM.42.4.1620-1625.2004
   Pruvost M, 2005, BIOTECHNIQUES, V38, P569, DOI 10.2144/05384ST03
   Respess RA, 2005, J CLIN MICROBIOL, V43, P506, DOI 10.1128/JCM.43.1.506-508.2005
   Ribas SG, 2003, J VIROL METHODS, V113, P29, DOI 10.1016/S0166-0934(03)00219-2
   Rouet F, 2005, J CLIN MICROBIOL, V43, P2709, DOI 10.1128/JCM.43.6.2709-2717.2005
   Schupbach J, 1996, AIDS, V10, P1085
   Sivapalasingam S, 2005, J CLIN MICROBIOL, V43, P3793, DOI 10.1128/JCM.43.8.3793-3796.2005
   Stoeva SI, 2006, J AM CHEM SOC, V128, P8378, DOI 10.1021/ja0613106
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Thaxton CS, 2009, P NATL ACAD SCI USA, V106, P18437, DOI 10.1073/pnas.0904719106
   Thaxton CS, 2005, ANAL CHEM, V77, P8174, DOI 10.1021/ac0514265
   Wen J, 2010, J BIOL CHEM, V285, P11023, DOI 10.1074/jbc.M109.085381
NR 30
TC 9
Z9 9
U1 2
U2 54
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD AUG 31
PY 2012
VL 9
AR 180
DI 10.1186/1743-422X-9-180
PG 7
WC Virology
SC Virology
GA 037RR
UT WOS:000311124700001
PM 22935171
OA gold
DA 2018-01-05
ER

PT J
AU Sun, LQ
   Zhu, L
   Qian, KD
   Qin, BJ
   Huang, L
   Chen, CH
   Lee, KH
   Xie, L
AF Sun, Lian-Qi
   Zhu, Lei
   Qian, Keduo
   Qin, Bingjie
   Huang, Li
   Chen, Chin Ho
   Lee, Kuo-Hsiung
   Xie, Lan
TI Design, Synthesis, and Preclinical Evaluations of Novel 4-Substituted
   1,5-Diarylanilines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase
   Inhibitor (NNRTI) Drug Candidates
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; RILPIVIRINE; ETRAVIRINE; DISCOVERY; RESISTANT;
   TMC125
AB Twenty-one new 4-substituted diarylaniline compounds (DAANs) (series 13, 14, and 15) were designed, synthesized, and evaluated against wildtype and drug resistant HIV-1 viral strains. As a result, approximately a dozen new DAANs showed high potency with low nano- to subnanomolar EC50 values ranging from 0.2 to 10 nM. The three most promising compounds 14e, 14h, and 15h exhibited high potency against wild-type and drug-resistant viral strains with EC50 values at the subnanomolar level (0.29-0.87 nM) and were comparable to or more potent than the new NNRTI drug riplivirine (2) in the same assays. Drug like physicochemical property assessments revealed that the most active DAANs (EC50 < 10 nM) have better aqueous solubility (>1-90 mu g/mL at pH 7.4 and pH 2) and metabolic stability in vitro than 2, as well as desirable log P values (<5) and polar surface areas (PSA) (<140 A(2)). These promising results warrant further development of this novel compound class as potential potent anti-AIDS clinical trial candidates.
C1 [Sun, Lian-Qi; Qin, Bingjie; Xie, Lan] Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Zhu, Lei; Huang, Li; Chen, Chin Ho] Duke Univ, Med Ctr, Surg Oncol Res Facil, Durham, NC 27710 USA.
   [Qian, Keduo; Lee, Kuo-Hsiung] Univ N Carolina, UNC Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC 27599 USA.
   [Lee, Kuo-Hsiung] China Med Univ & Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.
RP Xie, L (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Tai Ping Rd, Beijing 100850, Peoples R China.
EM lanxieshi@yahoo.com
OI Huang, Li/0000-0001-5659-4053
FU National Natural Science Fund of China (NSFC) [30930106]; U.S. NIH
   grants [AI65310, AI33066]
FX This investigation was supported by Grant 30930106 from the National
   Natural Science Fund of China (NSFC) awarded to L.X. and by U.S. NIH
   grants awarded to C.H.C. (Grant AI65310) and K.-H.L. (Grant AI33066).
CR Azijn H, 2010, ANTIMICROB AGENTS CH, V54, P718, DOI 10.1128/AAC.00986-09
   Dang Z, 2009, J MED CHEM, V52, P7887, DOI 10.1021/jm9004253
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p
   Fauci AS, 2011, SCIENCE, V333, P13, DOI 10.1126/science.1209751
   Fulco PP, 2009, PHARMACOTHERAPY, V29, P281, DOI 10.1592/phco.29.3.281
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Kaufmann GR, 2000, CURR OPIN MICROBIOL, V3, P508, DOI 10.1016/S1369-5274(00)00131-4
   Kerns E. H., 2008, DRUG LIKE PROPERTIES, P65
   Piersanti G, 2007, ORG BIOMOL CHEM, V5, P2567, DOI 10.1039/b707599e
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Shattock RJ, 2011, SCIENCE, V333, P42, DOI 10.1126/science.1206399
   Tian XT, 2010, J MED CHEM, V53, P8287, DOI 10.1021/jm100738d
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
NR 17
TC 33
Z9 36
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 23
PY 2012
VL 55
IS 16
BP 7219
EP 7229
DI 10.1021/jm3007678
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 992BB
UT WOS:000307748800019
PM 22856541
OA green_accepted
DA 2018-01-05
ER

PT J
AU Yan, M
   Liang, M
   Wen, J
   Liu, Y
   Lu, YF
   Chen, ISY
AF Yan, Ming
   Liang, Min
   Wen, Jing
   Liu, Yang
   Lu, Yunfeng
   Chen, Irvin S. Y.
TI Single siRNA Nanocapsules for Enhanced RNAi Delivery
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID LIPID-LIKE MATERIALS; IN-VIVO; LENTIVIRAL VECTORS; HIV-1 INFECTION;
   NANOPARTICLES; CELLS; GENE; MICE; POLYPLEXES; EXPRESSION
AB Synthetic siRNA has been considered as a highly promising therapeutic agent for human diseases. However, clinical use of siRNA has been hampered by instability in the body and inability to deliver sufficient RNA interference compounds to the tissues or cells. To address this challenge, we present here a single siRNA nanocapsule delivery technology, which is achieved by encapsulating a single siRNA molecule within a degradable polymer nanocapsule with a diameter around 20 nm and positive surface charge. As proof-of-concept, since CCR5 is considered a major silencing target of HIV therapy, CCR5-siRNA. nanocapsules were delivered into 293T cells and successfully downregulated the CCRS RNA fused with mCherry reporter RNA. In the absence of human serum, nanocapsules and lipofectamine silenced expression of CCR5-mCherry expression to 8% and 15%, respectively. Such nanocapsules maintain the integrity of siRNA inside even after incubation with ribonuclease and serum for 1 h; under the same conditions, siRNA is degraded in the native form or when formulated with lipofectamine. In the presence of serum, CCR5-siRNA nanocapsules knocked down CCR5-mCherry expression to less than 15% while siRNAs delivered through lipofectamine slightly knocked down the expression to 55%. In summary, this work provides a novel platform for siRNA delivery that can be developed for therapeutic purposes.
C1 [Liu, Yang; Lu, Yunfeng] Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA 90095 USA.
   [Yan, Ming; Liu, Yang; Lu, Yunfeng] Univ Calif Los Angeles, Calif NanoSyst Inst CNSI, Los Angeles, CA 90095 USA.
   [Yan, Ming; Liang, Min; Wen, Jing; Chen, Irvin S. Y.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
RP Lu, YF (reprint author), Univ Calif Los Angeles, Dept Biomol & Chem Engn, Los Angeles, CA 90095 USA.
EM luucla@ucla.edu; syuchen@mednet.ucla.edu
FU UCLA CNSI; UCLA AIDS Institute; UCLA Center for AIDS Research [AI28697]
FX This work was supported by a seed fund from UCLA CNSI, postdoc
   fellowship award and mentorship award from UCLA AIDS Institute and the
   UCLA Center for AIDS Research (AI28697).
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Akinc A, 2009, MOL THER, V17, P872, DOI 10.1038/mt.2009.36
   An DS, 2007, P NATL ACAD SCI USA, V104, P13110, DOI 10.1073/pnas.0705474104
   An DS, 2006, MOL THER, V14, P494, DOI 10.1016/j.ymthe.2006.05.015
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Broderick JA, 2011, GENE THER, V18, P1104, DOI 10.1038/gt.2011.50
   Cheng K, 2009, MOL PHARMACEUT, V6, P649, DOI 10.1021/mp900094j
   Cho SW, 2009, ADV FUNCT MATER, V19, P3112, DOI 10.1002/adfm.200900519
   DeRouchey J, 2008, BIOMACROMOLECULES, V9, P724, DOI 10.1021/bm7011482
   Dohmen C, 2012, ACS NANO, V6, P5198, DOI 10.1021/nn300960m
   Gary DJ, 2011, ACS NANO, V5, P3493, DOI 10.1021/nn102540y
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lee JS, 2009, NANO LETT, V9, P2402, DOI 10.1021/nl9009793
   Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989
   Li MJ, 2003, MOL THER, V8, P196, DOI 10.1016/S1525-0016(03)00165-5
   Liang M, 2009, J GENE MED, V11, P185, DOI 10.1002/jgm.1290
   Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106
   Mahon KP, 2010, BIOCONJUGATE CHEM, V21, P1448, DOI 10.1021/bc100041r
   Manavella PA, 2012, P NATL ACAD SCI USA, V109, P2461, DOI 10.1073/pnas.1200169109
   Meyer M, 2008, J AM CHEM SOC, V130, P3272, DOI 10.1021/ja710344v
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497
   Miyata K, 2012, CHEM SOC REV, V41, P2562, DOI 10.1039/c1cs15258k
   Nguyen DN, 2012, P NATL ACAD SCI USA, V109, pE797, DOI 10.1073/pnas.1121423109
   Schroeder A, 2010, J INTERN MED, V267, P9, DOI 10.1111/j.1365-2796.2009.02189.x
   Shimizu H, 2010, J AM SOC NEPHROL, V21, P622, DOI 10.1681/ASN.2009030295
   Shimizu S, 2010, BLOOD, V115, P1534, DOI 10.1182/blood-2009-04-215855
   Siegwart DJ, 2011, P NATL ACAD SCI USA, V108, P12996, DOI 10.1073/pnas.1106379108
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Timko BP, 2011, ANNU REV MATER RES, V41, P1, DOI 10.1146/annurev-matsci-062910-100359
   Van Stry M, 2012, J VIROL, V86, P4151, DOI 10.1128/JVI.05303-11
   Wagner E, 2012, ACCOUNTS CHEM RES, V45, P1005, DOI 10.1021/ar2002232
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
NR 36
TC 25
Z9 25
U1 8
U2 76
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD AUG 22
PY 2012
VL 134
IS 33
BP 13542
EP 13545
DI 10.1021/ja304649a
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 991KD
UT WOS:000307699000003
PM 22866878
OA green_accepted
DA 2018-01-05
ER

PT J
AU Steinbach, JM
   Weller, CE
   Booth, CJ
   Saltzman, WM
AF Steinbach, Jill M.
   Weller, Caroline E.
   Booth, Carmen J.
   Saltzman, W. Mark
TI Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital
   infection
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE siRNA; HSV-2; Nanoparticle; Drug delivery; Microbicide
ID HERPES-SIMPLEX VIRUS-2; DRUG-DELIVERY SYSTEMS; IN-VIVO; HIV PREVENTION;
   TRANSMISSION; MICROBICIDES; TYPE-2; MICE; STRATEGIES; PROTECTS
AB Effective, low-cost, and safe treatments for sexually transmitted viral infections are urgently needed. Here, we show for the first time that intravaginal administration with nanoparticles of poly(lactic-co-glycolic acid) (PLGA) encapsulating short interfering RNA (siRNA) molecules is effective for prevention of genital HSV-2 infections in mice. PLGA nanoparticles (NPs) were designed to interfere with HSV-2 infection by siRNA-mediated knockdown of nectin, a host cell protein. NPs were characterized in vitro to determine the optimal formulation based on siRNA loading, controlled release profile, and mRNA knockdown. Mice inoculated intravaginally with a lethal dose of HSV-2, and treated with PLGA NPs, showed increased survival from similar to 9 days (in untreated mice) to >28 days (in PLGA NP treated mice) - the longest survival ever observed with siRNA treatment in this mouse model. This work provides proof-of-concept that topical administration of NPs containing siRNA against a pathologically relevant host cell target can knockdown the gene in tissue and improve survival after HSV-2 infection. Furthermore, this system provides a safe delivery platform that employs materials that are already approved by the FDA and can be modified to enhance delivery of other microbicides. (C) 2012 Elsevier B. V. All rights reserved.
C1 [Steinbach, Jill M.; Weller, Caroline E.; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA.
   [Booth, Carmen J.] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06510 USA.
RP Saltzman, WM (reprint author), Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA.
EM mark.saltzman@yale.edu
FU NIH NIAID [F32AI093056-01A1]; Yale Proteomics and Genomics Training
   Fellowship [NIH T32-HG003198]; NIH [R01 EB000487]
FX Funded by an NIH NIAID Postdoctoral Fellowship (F32AI093056-01A1) and
   Yale Proteomics and Genomics Training Fellowship (NIH T32-HG003198) to
   JMS and NIH R01 EB000487 to WMS. We thank Nha Duong for help with Fig. 1
   and Young-Eun Seo for technical assistance. We also thank Dr. Akiko
   Iwasaki for her generous donation of the HSV-2 virus stock.
CR Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Conwell CC, 2008, MOL THER, V16, P370, DOI 10.1038/sj.mt.6300356
   Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001
   Corrigan OI, 2009, EUR J PHARM SCI, V37, P477, DOI 10.1016/j.ejps.2009.04.004
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   Dasgupta G, 2009, EXPERT REV VACCINES, V8, P1023, DOI 10.1586/ERV.09.60
   Duvvuri S, 2006, PHARM RES, V23, P215, DOI 10.1007/s11095-005-9042-6
   Eszterhas SK, 2011, INFECT DIS REP, V3, P52, DOI 10.1081/idr2011.e11
   Fernandez-Romero JA, 2012, ANTIMICROB AGENTS CH, V56, P358, DOI 10.1128/AAC.05461-11
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Katakowski J.A., 2006, DISCOV MED, V11, P124
   Kaushic C, 2003, J VIROL, V77, P4558, DOI 10.1128/JVI.77.8.4558-4565.2003
   Khazanov E, 2006, J GENE MED, V8, P998, DOI 10.1002/jgm.933
   Koelle DM, 2008, ANNU REV MED, V59, P381, DOI 10.1146/annurev.med.59.061606.095540
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Linehan MM, 2004, J VIROL, V78, P2530, DOI 10.1128/JVI.78.5.2530-2536.2004
   Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128
   Macmillan L, 2007, FEMS IMMUNOL MED MIC, V49, P46, DOI 10.1111/j.1574-695X.2006.00165.x
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   OVERALL JC, 1975, INFECT IMMUN, V11, P476
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Parr MB, 2003, J NEUROVIROL, V9, P594, DOI 10.1080/13550280390246499
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   SPANG AE, 1983, J VIROL, V45, P332
   Tobian AAR, 2009, CURR OPIN HIV AIDS, V4, P294, DOI 10.1097/COH.0b013e32832c1881
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Wheeler L.A., J CLIN INVEST, V121, P2401
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu SY, 2011, J CONTROL RELEASE, V155, P418, DOI 10.1016/j.jconrel.2011.02.002
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964
   Yim KC, 2005, J VIROL, V79, P14632, DOI 10.1128/JVI.79.23.14632-14639.2005
   Zhang YJ, 2006, MOL THER, V14, P336, DOI 10.1016/j.ymthe.2006.04.001
   [Anonymous], 2007, NAT MED, V13, P518
NR 34
TC 47
Z9 48
U1 0
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 20
PY 2012
VL 162
IS 1
BP 102
EP 110
DI 10.1016/j.jconrel.2012.06.008
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 992IP
UT WOS:000307769200012
PM 22705461
OA green_accepted
DA 2018-01-05
ER

PT J
AU Shlyakhtenko, LS
   Lushnikov, AY
   Miyagi, A
   Li, M
   Harris, RS
   Lyubchenko, YL
AF Shlyakhtenko, Luda S.
   Lushnikov, Alexander Y.
   Miyagi, Atsushi
   Li, Ming
   Harris, Reuben S.
   Lyubchenko, Yuri L.
TI Nanoscale Structure and Dynamics of ABOBEC3G Complexes with
   Single-Stranded DNA
SO BIOCHEMISTRY
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; APOBEC3G CATALYTIC DOMAIN; CYTIDINE DEAMINASE;
   BIOMOLECULAR PROCESSES; CRYSTAL-STRUCTURE; RESTRICTION; HIV-1;
   HYPERMUTATION; SPECIFICITY; INFECTION
AB The DNA cytosine deaminase APOBEC3G (A3G) is capable of blocking retrovirus replication by editing viral cDNA and impairing reverse transcription. However, the biophysical details of this host-pathogen interaction are unclear. We applied atomic force microscopy (AFM) and hybrid DNA substrates to investigate properties of A3G bound to single-stranded DNA (ssDNA). Hybrid DNA substrates included ssDNA with 5' or 3' ends attached to DNA duplexes (tail-DNA) and gap-DNA substrates, in which ssDNA is flanked by two double-stranded fragments. We found that A3G binds with similar efficiency to the 5' and 3' substrates, suggesting that ssDNA polarity is not an important factor. Additionally, we observed that A3G binds the single-stranded region of the gap-DNA substrates with the same efficiency as tail-DNA. These results demonstrate that single-stranded DNA ends are not needed for A3G binding. The protein stoichiometry does not depend on the ssDNA substrate type, but the ssDNA length modulates the stoichiometry of A3G in the complex. We applied single-molecule high-speed AFM to directly visualize the dynamics of A3G in the complexes. We were able to visualize A3G sliding and protein association-dissociation events. During sliding, A3G translocated over a 69-nucleotide ssDNA segment in <1 s. Association-dissociation events were more complex, as dimeric A3G could dissociate from the template as a whole or undergo a two-step process with monomers capable of sequential dissociation. We conclude that A3G monomers, dimers, and higher-order oligomers can bind ssDNA substrates in a manner independent of strand polarity and availability of free ssDNA ends.
C1 [Shlyakhtenko, Luda S.; Lushnikov, Alexander Y.; Miyagi, Atsushi; Lyubchenko, Yuri L.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
   [Li, Ming; Harris, Reuben S.] Univ Minnesota, Mason Canc Ctr, Dept Biochem Mol Biol & Biophys, Inst Mol Virol,Ctr Genome Engn, Minneapolis, MN 55455 USA.
RP Lyubchenko, YL (reprint author), Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, COP 1012,986025 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM ylyubchenko@unmc.edu
FU National Institutes of Health [P01-GM091743, R01-GM096039]; U.S.
   Department of Energy [DE-FG02-08ER64579]; National Science Foundation
   [EPS-1004094]; Nebraska Research Initiative
FX The work was supported by the National Institutes of Health (Grants
   P01-GM091743 and R01-GM096039), U.S. Department of Energy Grant
   DE-FG02-08ER64579, the National Science Foundation (Grant EPS-1004094),
   and the Nebraska Research Initiative.
CR Albin JS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001343
   Ando T, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/6/062001
   Autore F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011515
   Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086
   Chelico L, 2009, NAT STRUCT MOL BIOL, V16, P455
   Chelico L, 2008, J BIOL CHEM, V283, P13780, DOI 10.1074/jbc.M801004200
   Chelico L, 2010, J BIOL CHEM, V285, P16195, DOI 10.1074/jbc.M110.107987
   Chelico L, 2009, NAT STRUCT MOL BIOL, V16, P454, DOI 10.1038/nsmb0509-454
   Chen KM, 2008, NATURE, V452, P116, DOI 10.1038/nature06638
   Feng YQ, 2011, J BIOL CHEM, V286, P11415, DOI 10.1074/jbc.M110.199604
   Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200
   Harjes E, 2009, J MOL BIOL, V389, P819, DOI 10.1016/j.jmb.2009.04.031
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   Holden LG, 2008, NATURE, V456, P121, DOI 10.1038/nature07357
   Hultquist JF, 2011, J VIROL, V85, P11220, DOI 10.1128/JVI.05238-11
   Huthoff H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000330
   Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05
   Li M, 2012, ACS CHEM BIOL, V7, P506, DOI 10.1021/cb200440y
   Lyubchenko YL, 2011, METHODS, V54, P274, DOI 10.1016/j.ymeth.2011.02.001
   Lyubchenko YL, 2009, METHODS, V47, P206, DOI 10.1016/j.ymeth.2008.09.002
   Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185
   McDougall WM, 2011, BIOCHEM BIOPH RES CO, V412, P612, DOI 10.1016/j.bbrc.2011.08.009
   Miyagi A, 2011, BIOCHEMISTRY-US, V50, P7901, DOI 10.1021/bi200946z
   Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Nowarski R, 2008, NAT STRUCT MOL BIOL, V15, P1059, DOI 10.1038/nsmb.1495
   Nowarski R, 2012, BLOOD, V120, P366, DOI 10.1182/blood-2012-01-402123
   Roberts SA, 2012, MOL CELL, V46, P424, DOI 10.1016/j.molcel.2012.03.030
   Schumacher AJ, 2008, J VIROL, V82, P2652, DOI 10.1128/JVI.02391-07
   Senavirathne G, 2012, J BIOL CHEM, V287, P15826, DOI 10.1074/jbc.M112.342790
   Shandilya SMD, 2010, STRUCTURE, V18, P28, DOI 10.1016/j.str.2009.10.016
   Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200
   Shlyakhtenko LS, 2012, BIOCHEMISTRY-US, V51, P1500, DOI 10.1021/bi201863z
   Shlyakhtenko LS, 2011, J BIOL CHEM, V286, P3387, DOI 10.1074/jbc.M110.195685
   Shlyakhtenko LS, 2009, BIOCHEMISTRY-US, V48, P7842, DOI 10.1021/bi900977t
   Shlyakhtenko LS, 2009, J BIOL CHEM, V284, P20956, DOI 10.1074/jbc.M109.028977
   Suzuki Y, 2011, BIOPHYS J, V101, P2992, DOI 10.1016/j.bpj.2011.09.064
   Uchihashi T, 2011, METHODS MOL BIOL, V736, P285, DOI 10.1007/978-1-61779-105-5_18
   Yamamoto D, 2010, METHOD ENZYMOL, V475, P541, DOI 10.1016/S0076-6879(10)75020-5
NR 39
TC 26
Z9 26
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 14
PY 2012
VL 51
IS 32
BP 6432
EP 6440
DI 10.1021/bi300733d
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 988GY
UT WOS:000307478700016
PM 22809226
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chonco, L
   Pion, M
   Vacas, E
   Rasines, B
   Maly, M
   Serramia, MJ
   Lopez-Fernandez, L
   De la Mata, J
   Alvarez, S
   Gomez, R
   Munoz-Fernandez, MA
AF Chonco, L.
   Pion, M.
   Vacas, E.
   Rasines, B.
   Maly, M.
   Serramia, M. J.
   Lopez-Fernandez, L.
   De la Mata, J.
   Alvarez, S.
   Gomez, R.
   Munoz-Fernandez, M. A.
TI Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker
   profile
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Dendrimer; Microbicide; Anti-HIV activity; Biocompatibility; Molecular
   modeling
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; SEXUAL
   TRANSMISSION; TOPICAL MICROBICIDES; EPITHELIAL-CELLS; FORCE-FIELD;
   VAGINAL GEL; PRO 2000; PREVENTION; INFECTION
AB Researchers have been working hard for more than 20 years to develop safe and effective microbicides to empower women to better control their own sexual life and to protect themselves against HIV and other sexually transmitted infections (STIs). Microbicide classes include moderately specific macromolecular anionic polymers that block HIV and other STIs, and HIV specific drugs that inhibit viral entry and reverse transcription. Based on innovative nanotechnology design, we showed a novel water-soluble anionic carbosilane dendrimer (2G-S16) as a propitious molecule against HIV-infection. A state-of-the-art research was accomplished that focused on biomedical cutting-edge techniques such as in vitro and in vivo cytotoxicity assays performed on female rabbit genital tracts, simulate in vitro model of vaginal epithelium in order to evaluate HIV transmission blockade through the monolayer, complete gene expression profiling experiment to study deregulated genes after 2G-S16 exposition, molecular dynamics simulation of 2G-S16 molecule against principal proteins of HIV particles and pro- and anti-inflammatory cytokine profile study. Therefore, a high-throughput study and detailed analysis of the results were achieved in this article. We provided promising outcomes to encourage 2G-S16 as a hopeful microbicide. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Chonco, L.; Pion, M.; Vacas, E.; Serramia, M. J.; Lopez-Fernandez, L.; Alvarez, S.; Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain.
   [Chonco, L.; Pion, M.; Vacas, E.; Serramia, M. J.; Lopez-Fernandez, L.; Alvarez, S.; Munoz-Fernandez, M. A.] Hosp Gen Univ Gregorio Maranon, Plataforma Lab, Madrid 28007, Spain.
   [Rasines, B.; De la Mata, J.; Gomez, R.] Univ Alcala De Henares, Dpto Quim Inorgan, Madrid 28871, Spain.
   [Maly, M.] Univ JE Purkyne, Fac Sci, Usti Nad Labem 40096, Czech Republic.
   [Maly, M.] Univ Appl Sci So Switzerland, Lab Appl Math & Phys LAMFI, CH-6928 Manno, Switzerland.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, C Dr Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@salud.madrid.org
RI Pion, Marjorie/D-8139-2012; Chonco, Louis/Q-5399-2017; Chonco,
   Louis/E-2011-2013; Rasines, Beatriz/H-4309-2015; Maly,
   Marek/H-5757-2015; Gomez Ramirez, Rafael/K-1216-2014; De la Mata, F.
   Javier/K-1649-2014
OI Pion, Marjorie/0000-0002-6406-747X; Chonco, Louis/0000-0002-0577-692X;
   Maly, Marek/0000-0002-5930-563X; Gomez Ramirez,
   Rafael/0000-0001-6448-2414; De la Mata, F. Javier/0000-0003-0418-3935;
   Pion, Marjorie/0000-0003-1828-4745; Munoz-Fernandez/0000-0002-0813-4500;
   Lopez-Fernandez, Luis/0000-0003-3964-5837
FU FIS [INTRASALUD PI09/02029, P509102669]; Red RIS [RD06/0006/0035];
   INDISNET [S-2011-BMD2332]; FIPSE [240800/09]; MAMF; Czech national Cost
   project [OC10053]; Swiss project "MULTI"; DECS-Canton Ticino; USI; Cost
   action [TD0802]
FX This work was supported by grants from FIS (INTRASALUD PI09/02029,
   P509102669) Red RIS (RD06/0006/0035), INDISNET S-2011-BMD2332 and FIPSE
   240800/09 by MAMF. MM thanks the Czech national Cost project OC10053,
   and Swiss project "MULTI" sponsored by DECS-Canton Ticino and USI for
   financial support as well Cost action TD0802 for supporting both groups.
CR Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   CHARNEAU P, 1994, VIROLOGY, V205, P247, DOI 10.1006/viro.1994.1640
   Chonco L, 2007, ORG BIOMOL CHEM, V5, P1886, DOI 10.1039/b703989a
   Cohen CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016258
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gali Y, 2010, J VIROL METHODS, V165, P186, DOI 10.1016/j.jviromet.2010.01.018
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Gordon MS, 2005, THEORY AND APPLICATIONS OF COMPUTATIONAL CHEMISTRY: THE FIRST FORTY YEARS, P1167, DOI 10.1016/B978-044451719-7/50084-6
   Granich R, 2010, CURR OPIN HIV AIDS, V5, P298, DOI 10.1097/COH.0b013e32833a6c32
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gras R, 2009, PHARM RES-DORD, V26, P577, DOI 10.1007/s11095-008-9776-z
   Guenthner PC, 2005, INFECT IMMUN, V73, P4155, DOI 10.1128/IAI.73.7.4155-4160.2005
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   KARIM QA, 2010, AIDS RES HUM RETRO S, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Karim SSA, 2010, INDIAN J MED RES, V132, P656
   Keller MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008781
   LII JH, 1991, J COMPUT CHEM, V12, P186, DOI 10.1002/jcc.540120208                                                           
   Jimenez JL, 2012, NEW J CHEM, V36, P299, DOI 10.1039/c1nj20396g
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mertenskoetter T, 2011, EUR J MED RES, V16, P1
   Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867
   MEYLAN PRA, 1994, ANTIMICROB AGENTS CH, V38, P2910, DOI 10.1128/AAC.38.12.2910                                                          
   Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4                                                   
   Munier CML, 2011, DRUGS, V71, P387, DOI 10.2165/11585400-000000000-00000
   Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
   Omar RF, 2011, INT J INFECT DIS, V15, pE656, DOI 10.1016/j.ijid.2011.05.001
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pirrone V, 2011, ANTIVIR RES, V90, P168, DOI 10.1016/j.antiviral.2011.03.176
   Price CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024095
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Reina JJ, 2010, FUTURE MED CHEM, V2, P1141, DOI 10.4155/FMC.10.203
   Rupp R, 2007, INT J NANOMED, V2, P561
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Shaunak Sunil, 2004, Discov Med, V4, P464
   Smyth GK., 2005, BIOINFORMATICS COMPU
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Vannucci L, 2003, INT J ONCOL, V23, P285
   Vermeire K, 2008, CURR HIV RES, V6, P246, DOI 10.2174/157016208784324958
   Vzorov AN, 2005, VIROLOGY, V332, P89, DOI 10.1016/j.virol.2004.10.044
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wu XW, 2003, CHEM PHYS LETT, V381, P512, DOI 10.1016/j.cplett.2003.10.013
   YAHI N, 1994, J BIOL CHEM, V269, P24349
NR 60
TC 53
Z9 53
U1 4
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 10
PY 2012
VL 161
IS 3
BP 949
EP 958
DI 10.1016/j.jconrel.2012.04.050
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 996IB
UT WOS:000308077000029
PM 22652549
DA 2018-01-05
ER

PT J
AU Gong, R
   Wang, YP
   Ying, TL
   Dimitrov, DS
AF Gong, Rui
   Wang, Yanping
   Ying, Tianlei
   Dimitrov, Dimiter S.
TI Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact
   Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
SO PLOS ONE
LA English
DT Article
ID INTERNATIONAL IMMUNOGENETICS DATABASE; BINDING-SITE; CH2 DOMAINS; HUMAN
   IGG1; THERAPEUTIC ANTIBODIES; MOLECULAR RECOGNITION;
   INCREASED-STABILITY; PROTEIN SCAFFOLDS; CRYSTAL-STRUCTURE; RECEPTOR
AB Libraries based on an isolated human immunoglobulin G1 (IgG1) constant domain 2 (CH2) have been previously diversified by random mutagenesis. However, native isolated CH2 is not very stable and the generation of many mutations could lead to an increase in immunogenicity. Recently, we demonstrated that engineering an additional disulfide bond and removing seven N-terminal residues results in an engineered antibody domain (eAd) (m01s) with highly increased stability and enhanced binding to human neonatal Fc receptor (FcRn) (Gong et al, JBC, 2009 and 2011). We and others have also previously shown that grafting of the heavy chain complementarity region 3 (CDR-H3 (H3)) onto cognate positions of the variable domain leads to highly diversified libraries from which a number of binders to various antigens have been selected. However, grafting of H3s to non-cognate positions in constant domains results in additional residues at the junctions of H3s and the CH2 framework. Here we describe a new method based on multi-step PCR that allows the precise replacement of loop FG (no changes in its flanking sequences) by human H3s from another library. Using this method and limited mutagenesis of loops BC and DE we generated an eAd phage-displayed library. Panning of this library against an HIV-1 gp41 MPER peptide resulted in selection of a binder, m2a1, which neutralized HIV-1 isolates from different clades with modest activity and retained the m01s capability of binding to FcRn. This result provides a proof of concept that CH2-based antigen binders that also mimic to certain extent other functions of full-size antibodies (binding to FcRn) can be generated; we have previously hypothesized that such binders can be made and coined the term nanoantibodies (nAbs). Further studies in animal models and in humans will show how useful nAbs could be as therapeutics and diagnostics.
C1 [Gong, Rui; Wang, Yanping; Ying, Tianlei; Dimitrov, Dimiter S.] NIH, Prot Interact Grp, Frederick Natl Lab Canc Res, Frederick, MD USA.
   [Wang, Yanping] SAIC Frederick Inc, Frederick, MD USA.
RP Gong, R (reprint author), NIH, Prot Interact Grp, Frederick Natl Lab Canc Res, Frederick, MD USA.
EM gongr@mail.nih.gov
FU National Institutes of Health (NIH); NIH, National Cancer Institute
   (NCI), Center for Cancer Research; NCI, NIH [N01-CO-12400]; U.S.
   Government
FX This work was supported by the Intramural AIDS Targeted Antiviral
   Program (IATAP), National Institutes of Health (NIH) to DSD, and by the
   Intramural Research Program of the NIH, National Cancer Institute (NCI),
   Center for Cancer Research. This project has been funded in whole or in
   part with federal funds from the NCI, NIH, under contract N01-CO-12400.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; SAIC-Frederick,
   Inc. is a wholly owned subsidiary of Science Applications International
   Corporation and operates exclusively under a single, long-term contract
   to the National Cancer Institute, part of the U.S. National Institutes
   of Health. All funding is derived from the U.S. Government. This does
   not alter the authors' adherence to all the PLoS ONE policies on sharing
   data and materials.
CR Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127
   Caravella J, 2010, CURR OPIN CHEM BIOL, V14, P520, DOI 10.1016/j.cbpa.2010.06.175
   Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94
   Chen WZ, 2008, P NATL ACAD SCI USA, V105, P17121, DOI 10.1073/pnas.0805297105
   Chen WZ, 2008, J MOL BIOL, V382, P779, DOI 10.1016/j.jmb.2008.07.054
   Chen WZ, 2010, MOL IMMUNOL, V47, P912, DOI 10.1016/j.molimm.2009.09.039
   Chen Weizao, 2009, V525, P81, DOI 10.1007/978-1-59745-554-1_4
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dimitrov DS, 2010, MABS-AUSTIN, V2, P347, DOI 10.4161/mabs.2.3.11779                                                          
   Dimitrov Dimiter S., 2009, V525, P1, DOI 10.1007/978-1-59745-554-1_1
   Dimitrov DS, 2009, MABS, V1, P26, DOI 10.4161/mabs.1.1.7480                                                           
   Feige MJ, 2004, J MOL BIOL, V344, P107, DOI 10.1016/j.jmb.2004.09.033
   Feng Y, 2011, PROTEIN EXPRES PURIF, V79, P66, DOI 10.1016/j.pep.2011.03.012
   Gebauer M, 2009, CURR OPIN CHEM BIOL, V13, P245, DOI 10.1016/j.cbpa.2009.04.627
   Gehlsen KR, 2012, MABS-AUSTIN, V4, P466, DOI 10.4161/mabs.20652
   Gill DS, 2006, CURR OPIN BIOTECH, V17, P653, DOI 10.1016/j.copbio.2006.10.003
   Gong R, 2012, BIODRUGS, V26, P143, DOI 10.2165/11631400-000000000-00000
   Gong R, 2011, J BIOL CHEM, V286, P27288, DOI 10.1074/jbc.M111.254219
   Gong R, 2009, J BIOL CHEM, V284, P14203, DOI 10.1074/jbc.M900769200
   Hackel BJ, 2008, J MOL BIOL, V381, P1238, DOI 10.1016/j.jmb.2008.06.051
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178                                                     
   Julien JP, 2008, J MOL BIOL, V384, P377, DOI 10.1016/j.jmb.2008.09.024
   Kiefer F, 2009, NUCLEIC ACIDS RES, V37, pD387, DOI 10.1093/nar/gkn750
   Lefranc Marie-Paule, 2004, In Silico Biology, V4, P17
   Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838
   Lefranc MP, 2005, NUCLEIC ACIDS RES, V33, pD593, DOI 10.1093/nar/gki065
   Lefranc MP, 2003, NUCLEIC ACIDS RES, V31, P307, DOI 10.1093/nar/gkg085
   Lefranc MP, 2001, NUCLEIC ACIDS RES, V29, P207, DOI 10.1093/nar/29.1.207
   Lefranc MP, 1999, NUCLEIC ACIDS RES, V27, P209, DOI 10.1093/nar/27.1.209
   Lefranc MP, 2005, SILICO BIOL, V5, P45
   Martin WL, 2001, MOL CELL, V7, P867, DOI 10.1016/S1097-2765(01)00230-1
   Mezo AR, 2010, J BIOL CHEM, V285, P27694, DOI 10.1074/jbc.M110.120667
   Nicely NI, 2010, NAT STRUCT MOL BIOL, V17, P1492, DOI 10.1038/nsmb.1944
   Peitsch M. C., 1995, NAT BIOTECHNOL, V13, P658, DOI DOI 10.1038/NBT0795-658
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Regan L, 2003, P NATL ACAD SCI USA, V100, P3553, DOI 10.1073/pnas.0830651100
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Ruiz M, 2000, NUCLEIC ACIDS RES, V28, P219, DOI 10.1093/nar/28.1.219
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097                                                          
   Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957
   Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200
   Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.0.CO;2-9
   Skerra A, 2007, CURR OPIN BIOTECH, V18, P295, DOI 10.1016/j.copbio.2007.04.010
   von Minckwitz G, 2005, BREAST CANCER RES, V7, pR617, DOI 10.1186/bcr1264
   Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V387, P387, DOI 10.1016/j.bbrc.2009.07.044
   Yeung YA, 2009, J IMMUNOL, V182, P7663, DOI 10.4049/jimmunol.0804182
   Zhang MY, 2004, J MOL BIOL, V335, P209, DOI 10.1016/j.jmb.2003.09.055
   Zhu ZY, 2011, J VIROL, V85, P11401, DOI 10.1128/JVI.05312-11
NR 54
TC 14
Z9 15
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2012
VL 7
IS 8
AR e42288
DI 10.1371/journal.pone.0042288
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 987SL
UT WOS:000307437900027
PM 22879932
OA gold
DA 2018-01-05
ER

PT J
AU Akhlaghi, Y
   Kompany-Zareh, M
   Hormozi-Nezhad, MR
AF Akhlaghi, Yousef
   Kompany-Zareh, Mohsen
   Hormozi-Nezhad, Mohammad Reza
TI Multiway Investigation of Interaction between Fluorescence Labeled DNA
   Strands and Unmodified Gold Nanoparticles
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RESONANCE ENERGY-TRANSFER; RANK 2ND-ORDER CALIBRATION; RESTRICTED-TUCKER
   MODELS; 3-MODE FACTOR-ANALYSIS; OLIGONUCLEOTIDE PROBES; COLORIMETRIC
   DETECTION; QUANTUM DOTS; PARAFAC; SEQUENCES; FRET
AB The single stranded DNA can be adsorbed on the negatively charged surface of gold nanoparticles (AuNPs), but the rigid structure of double stranded DNA prevents it from adsorption. Signal of a tagged single stranded DNA will be quenched by the plasmon effect of the AuNP surface after its adsorption. This phenomenon has been used to study the DNA hybridization and interactions of two complementary 21mer oligonucleotides each tagged with a different fluorescent dye in the presence of 13 nm gold nanoparticles. The DNA strands used in this study belong to the genome of HIV. The obtained rank deficient three-way fluorescence data sets were resolved by both PARAFAC and restricted Tucker3 models. This is the first successful application of a multiway chemometric technique to analyze multidimensional nanobiological data. The restricted Tucker3 showed a better performance compared to PARAFAC in resolving the data sets. The advantages of restricted Tucker3 analysis over the unrestricted one, i.e., the limited rotational freedom (more unique results) and better interpretability of the obtained results, were experienced in this study. The resolved excitation, emission, and concentration profiles and specially fluorescence resonance energy transfer (FRET) profiles obtained by restricted Tucker3 were chemically more meaningful than those obtained from PARAFAC.
C1 [Akhlaghi, Yousef; Kompany-Zareh, Mohsen] IASBS, Dept Chem, Zanjan 4513766731, Iran.
   [Hormozi-Nezhad, Mohammad Reza] Sharif Univ Technol, Dept Chem, Tehran 111559516, Iran.
   [Hormozi-Nezhad, Mohammad Reza] Sharif Univ Technol, Inst Nanosci & Nanotechnol, Tehran, Iran.
RP Kompany-Zareh, M (reprint author), IASBS, Dept Chem, Zanjan 4513766731, Iran.
EM kompanym@iasbs.ac.ir
CR Adams NM, 2012, LANGMUIR, V28, P1068, DOI 10.1021/la2028862
   Al Attar HA, 2009, BIOMACROMOLECULES, V10, P1077, DOI 10.1021/bm801194n
   Algar WR, 2007, ANAL CHIM ACTA, V581, P193, DOI 10.1016/j.aca.2006.08.026
   ALGAR WR, 2008, LANGMUIR, V25, P633
   Andersson CA, 2000, CHEMOMETR INTELL LAB, V52, P1, DOI 10.1016/S0169-7439(00)00071-X
   Bahram M, 2007, ANAL CHIM ACTA, V584, P397, DOI 10.1016/j.aca.2006.11.070
   Bro R, 2003, J CHEMOMETR, V17, P274, DOI 10.1002/cem.801
   Bro R, 2009, J CHEMOMETR, V23, P324, DOI 10.1002/cem.1206
   CARROLL JD, 1970, PSYCHOMETRIKA, V35, P283, DOI 10.1007/BF02310791                                                              
   Chen H, 2012, ANALYST, V137, P153, DOI 10.1039/c1an15805h
   Chen H, 2011, J CHEMOMETR, V25, P20, DOI 10.1002/cem.1340
   Cheng YN, 2011, ANAL CHEM, V83, P1307, DOI 10.1021/ac102463c
   Dong HF, 2010, ANAL CHEM, V82, P5511, DOI 10.1021/ac100852z
   Du H, 2003, J AM CHEM SOC, V125, P4012, DOI 10.1021/ja0290781
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762                                                                   
   Epstein JR, 2002, ANAL CHIM ACTA, V469, P3, DOI 10.1016/S0003-2670(02)00030-2                                                   
   Gao F, 2011, ANALYST, V136, P3973, DOI 10.1039/c1an15287d
   GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008                                                             
   Harshman R. A., 1970, UCLA WORKING PAPERS, V16, P1
   Jiang GX, 2009, ACS NANO, V3, P4127, DOI 10.1021/nn901324y
   Kiers HAL, 1998, J CHEMOMETR, V12, P125, DOI 10.1002/(SICI)1099-128X(199803/04)12:2<125::AID-CEM504>3.0.CO;2-D               
   Kiers HAL, 1997, PSYCHOMETRIKA, V62, P251, DOI 10.1007/BF02295279                                                              
   Kompany-Zareh M, 2012, ANAL CHIM ACTA, V723, P18, DOI 10.1016/j.aca.2012.02.028
   Li H, 2007, RNA, V13, P2034, DOI 10.1261/rna.138807
   Li HX, 2005, ANAL CHEM, V77, P6229, DOI 10.1021/ac050921y
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li HX, 2004, J AM CHEM SOC, V126, P10958, DOI 10.1021/ja048749n
   Li HX, 2004, ANAL CHEM, V76, P5414, DOI 10.1021/ac049173n
   Marras SAE, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf121
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Nelson EM, 2011, LANGMUIR, V27, P1770, DOI [10.1021/la102613f, 10.1021/la1026131f]
   Ray PC, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/37/375504
   Ray PC, 2006, J PHYS CHEM B, V110, P20745, DOI 10.1021/jp0651211
   Rinnan A, 2005, CHEMOMETR INTELL LAB, V76, P91, DOI 10.1016/j.chemolab.2004.09.009
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Sepulveda B, 2009, NANO TODAY, V4, P244, DOI 10.1016/j.nantod.2009.04.001
   Smilde A., 2004, MULTIWAY ANAL APPL C
   SMILDE AK, 1994, J CHEMOMETR, V8, P21, DOI 10.1002/cem.1180080104                                                          
   SMILDE AK, 1994, ANAL CHEM, V66, P3345, DOI 10.1021/ac00092a010
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Tan YN, 2011, ANAL CHEM, V83, P4251, DOI 10.1021/ac200525a
   Ten Berge JMF, 1999, LINEAR ALGEBRA APPL, V294, P169, DOI 10.1016/S0024-3795(99)00057-9                                                   
   Thygesen LG, 2004, CHEMOMETR INTELL LAB, V71, P97, DOI 10.1016/j.chemolab.2003.12.012
   TUCKER LR, 1966, PSYCHOMETRIKA, V31, P279, DOI 10.1007/BF02289464                                                              
NR 44
TC 20
Z9 20
U1 2
U2 68
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD AUG 7
PY 2012
VL 84
IS 15
BP 6603
EP 6610
DI 10.1021/ac3008576
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 984AG
UT WOS:000307159200050
PM 22779697
DA 2018-01-05
ER

PT J
AU Christ, F
   Shaw, S
   Demeulemeester, J
   Desimmie, BA
   Marchand, A
   Butler, S
   Smets, W
   Chaltin, P
   Westby, M
   Debyser, Z
   Pickford, C
AF Christ, Frauke
   Shaw, Stephen
   Demeulemeester, Jonas
   Desimmie, Belete A.
   Marchand, Arnaud
   Butler, Scott
   Smets, Wim
   Chaltin, Patrick
   Westby, Mike
   Debyser, Zeger
   Pickford, Chris
TI Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase
   Block HIV Replication and Modulate Integrase Multimerization
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; COACTIVATOR P75; STRAND
   TRANSFER; DNA-BINDING; VIRAL-DNA; RALTEGRAVIR; ELVITEGRAVIR; REVEALS;
   ASSAY
AB Targeting the HIV integrase (HIV IN) is a clinically validated approach for designing novel anti-HIV therapies. We have previously described the discovery of a novel class of integration inhibitors, 2-(quinolin-3-yl)acetic acid derivatives, blocking HIV replication at a low micromolar concentration through binding in the LEDGF/p75 binding pocket of HIV integrase, hence referred to as LEDGINs. Here we report the detailed characterization of their mode of action. The design of novel and more potent analogues with nanomolar activity enabled full virological evaluation and a profound mechanistic study. As allosteric inhibitors, LEDGINs bind to the LEDGF/p75 binding pocket in integrase, thereby blocking the interaction with LEDGF/p75 and interfering indirectly with the catalytic activity of integrase. Detailed mechanism-of-action studies reveal that the allosteric mode of inhibition is likely caused by an effect on HIV-1 integrase oligomerization. The multimodal inhibition by LEDGINs results in a block in HIV integration and in a replication deficiency of progeny virus. The allosteric nature of LEDGINs leads to synergy in combination with the clinically approved active site HIV IN strand transfer inhibitor (INSTI) raltegravir, and cross-resistance profiling proves the distinct mode of action of LEDGINs and INSTIs. The allosteric nature of inhibition and compatibility with INSTIs underline an interest in further (clinical) development of LEDGINs.
C1 [Shaw, Stephen; Butler, Scott; Westby, Mike; Pickford, Chris] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England.
   [Christ, Frauke; Demeulemeester, Jonas; Desimmie, Belete A.; Chaltin, Patrick; Debyser, Zeger] Katholieke Univ Leuven, Mol Virol & Gene Therapy VCTB 5, Louvain, Belgium.
   [Marchand, Arnaud; Smets, Wim; Chaltin, Patrick] CISTIM Leuven Vzw, CISTIM, Louvain, Belgium.
RP Pickford, C (reprint author), Pfizer Ltd, Sandwich CT13 9NJ, Kent, England.
EM zeger.debyser@med.kuleuven.be; chris.pickford@theresearchnetwork.co.uk
RI Demeulemeester, Jonas/J-6130-2014
OI Demeulemeester, Jonas/0000-0002-2660-2478
FU CellCoVir SBO from the Flemish IWT [60813]; FWO [G.0530.08]; EC grant
   THING [HEALTH-F3-2008-201032]
FX Research was funded by a CellCoVir SBO grant (no. 60813) from the
   Flemish IWT, FWO grant G.0530.08, EC grant THING
   (HEALTH-F3-2008-201032), and the Research Fund and IOF Program of the KU
   Leuven. F.C. is an IOF fellow, J.D. is a doctoral fellow for the FWO,
   and B.A.D. is a DBOF fellow of KU Leuven.
CR ADACHI A, 1986, J VIROL, V59, P284
   Blair WS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001220
   Bruno R, 2003, 17 INT AIDS C MEX CI, V17, P2674
   Busschots K, 2005, J BIOL CHEM, V280, P17841, DOI 10.1074/jbc.M411681200
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Cherepanov P, 2005, P NATL ACAD SCI USA, V102, P17308, DOI 10.1073/pnas.0506921402
   Cherepanov P, 2004, J BIOL CHEM, V279, P48883, DOI 10.1074/jbc.M406307200
   Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200
   Christ F, 2010, NAT CHEM BIOL, V6, P442, DOI 10.1038/nchembio.370
   Corbau R, 2010, ANTIMICROB AGENTS CH, V54, P4451, DOI 10.1128/AAC.01455-09
   De Rijck J, 2006, J VIROL, V80, P11498, DOI 10.1128/JVI.00801-06
   Demeulemeester J, 2012, J BIOMOL SCREEN, V17, P618, DOI 10.1177/1087057111436343
   Desimmie BA, MOL THER IN PRESS
   Desimmie BA, 2012, LANCET INFECT DIS, V12, P3, DOI 10.1016/S1473-3099(11)70277-8
   Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Garrido C, 2011, ANTIVIR RES, V90, P164, DOI 10.1016/j.antiviral.2011.03.178
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hayouka Z, 2007, P NATL ACAD SCI USA, V104, P8316, DOI 10.1073/pnas.0700781104
   Hombrouck A, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030047
   Johnson EN, 2008, ASSAY DRUG DEV TECHN, V6, P327, DOI 10.1089/adt.2007.113
   Kessl JJ, 2012, J BIOL CHEM, V287, P16801, DOI 10.1074/jbc.M112.354373
   Kessl JJ, 2011, NUCLEIC ACIDS RES, V39, P9009, DOI 10.1093/nar/gkr581
   Kessl JJ, 2009, MOL PHARMACOL, V76, P824, DOI 10.1124/mol.109.058883
   Lewinski MK, 2006, PLOS PATHOG, V2, P611, DOI 10.1371/journal.ppat.0020060
   Llano M, 2006, SCIENCE, V314, P461, DOI 10.1126/science.1132319
   Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200
   Malet I, 2008, ANTIMICROB AGENTS CH, V52, P1351, DOI 10.1128/AAC.01228-07
   Margot NA, 2005, ANTIVIR THER, V10, P343
   Marinello J, 2008, BIOCHEMISTRY-US, V47, P9345, DOI 10.1021/bi800791q
   McNeely M, 2011, J MOL BIOL, V410, P811, DOI 10.1016/j.jmb.2011.03.073
   Molina JM, 2012, LANCET INFECT DIS, V12, P27, DOI 10.1016/S1473-3099(11)70249-3
   Murray JM, 2007, AIDS, V21, P2315, DOI 10.1097/QAD.0b013e3282f12377                                                    
   Neamati N., 2011, WILEY SERIES DRUG DI
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Schrijvers R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002558
   Shimura K, 2008, J VIROL, V82, P764, DOI 10.1128/JVI.01534-07
   Shun MC, 2007, GENE DEV, V21, P1767, DOI 10.1101/gad.1565107
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Tintori C, 2012, BIOORG MED CHEM LETT, V22, P3109, DOI 10.1016/j.bmcl.2012.03.064
   Tsiang M, 2012, J BIOL CHEM, V287, P21189, DOI 10.1074/jbc.M112.347534
   Vandekerckhove L, 2006, J VIROL, V80, P1886, DOI 10.1128/JVI.80.4.1886-1896.2006
   Vanegas M, 2005, J CELL SCI, V118, P1733, DOI 10.1242/jcs.02299
   Wang GP, 2007, GENOME RES, V17, P1186, DOI 10.1101/gr.6286907
   Zeier Michele D., 2011, Infectious Disorders - Drug Targets, V11, P98
   Zolopa AR, 2010, J INFECT DIS, V201, P814, DOI 10.1086/650698
NR 49
TC 85
Z9 87
U1 0
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2012
VL 56
IS 8
BP 4365
EP 4374
DI 10.1128/AAC.00717-12
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 979NI
UT WOS:000306826300041
PM 22664975
OA gold
DA 2018-01-05
ER

PT J
AU Zhu, Q
   Talton, J
   Zhang, GF
   Cunningham, T
   Wang, ZJ
   Waters, RC
   Kirk, J
   Eppler, B
   Klinman, DM
   Sui, YJ
   Gagnon, S
   Belyakov, IM
   Mumper, RJ
   Berzofsky, JA
AF Zhu, Qing
   Talton, James
   Zhang, Guofeng
   Cunningham, Tshaka
   Wang, Zijian
   Waters, Robert C.
   Kirk, James
   Eppler, Baerbel
   Klinman, Dennis M.
   Sui, Yongjun
   Gagnon, Susan
   Belyakov, Igor M.
   Mumper, Russell J.
   Berzofsky, Jay A.
TI Large intestine-targeted, nanoparticle-releasing oral vaccine to control
   genitorectal viral infection
SO NATURE MEDICINE
LA English
DT Article
ID IN-VIVO EVALUATION; T-CELL RESPONSES; DRUG-DELIVERY; PROTECTS MICE;
   RECTAL MUCOSA; MACAQUES; IMMUNIZATION; HIV; COMPARTMENTALIZATION;
   TECHNOLOGIES
AB Both rectal and vaginal mucosal surfaces serve as transmission routes for pathogenic microorganisms. Vaccination through large intestinal mucosa, previously proven protective for both of these mucosal sites in animal studies, can be achieved successfully by direct intracolorectal (i.c.r.) administration, but this route is clinically impractical. Oral vaccine delivery seems preferable but runs the risk of the vaccine's destruction in the upper gastrointestinal tract. Therefore, we designed a large intestine-targeted oral delivery with pH-dependent microparticles containing vaccine nanoparticles, which induced colorectal immunity in mice comparably to colorectal vaccination and protected against rectal and vaginal viral challenge. Conversely, vaccine targeted to the small intestine induced only small intestinal immunity and provided no rectal or vaginal protection, demonstrating functional compartmentalization within the gut mucosal immune system. Therefore, using this oral vaccine delivery system to target the large intestine, but not the small intestine, may represent a feasible new strategy for immune protection of rectal and vaginal mucosa.
C1 [Zhu, Qing; Cunningham, Tshaka; Sui, Yongjun; Gagnon, Susan; Belyakov, Igor M.; Berzofsky, Jay A.] NCI, Vaccine Branch, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Zhu, Qing] AF Gen Hosp, Dept Oncol, Beijing, Peoples R China.
   [Zhang, Guofeng] Natl Inst Biomed Imaging & Bioengn, Lab Bioengn & Phys Sci, US Natl Inst Hlth, Bethesda, MD USA.
   [Wang, Zijian] Jingmeng Res Ctr, Beijing, Peoples R China.
   [Klinman, Dennis M.] NCI, Expt Immunol Lab, Ctr Canc Res, Frederick, MD 21701 USA.
   [Belyakov, Igor M.] Univ Michigan, Sch Med, Michigan Nanotechnol Inst Med & Biol Sci, Ann Arbor, MI USA.
   [Belyakov, Igor M.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
   [Mumper, Russell J.] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC USA.
RP Zhu, Q (reprint author), NCI, Vaccine Branch, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA.
EM qing20892@gmail.com; berzofsj@mail.nih.gov
FU Intramural Research Program of NIH; National Cancer Institute; Center
   for Cancer Research; Intramural AIDS Targeted Antiviral Program;
   National Natural Science Foundation of China [31170872]; Collaborative
   Research and Development Agreement with Nanotherapeutics Inc
FX We thank B. Moss and P. Earl (US National Institutes of Health (NIH))
   for generously providing vPE16, G. Cohen (University of Pennsylvania)
   for vaccinia antibodies, the NIH Tetramer Facility for tetramer P18-I10
   and BEI Resources for vaccinia recombinant proteins. We also thank J.
   Hooper, D. Johnson, M. Dobrovolskaia, B. Zolnik, J. Gao and X. Liu for
   professional comments and help, and J. FitzGerald for electron
   microscopy. We appreciate Z. Xia, D. Pendleton, D. Li and L. Smith for
   their technical and secretarial assistance. This research was supported
   by the Intramural Research Program of NIH, the National Cancer
   Institute, the Center for Cancer Research and the Intramural AIDS
   Targeted Antiviral Program, a grant from the National Natural Science
   Foundation of China (31170872), and a Collaborative Research and
   Development Agreement with Nanotherapeutics Inc.
CR Belyakov IM, 2007, J IMMUNOL, V178, P7211, DOI 10.4049/jimmunol.178.11.7211                                                    
   Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102                                                                 
   Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320
   Bott C, 2004, ALIMENT PHARM THERAP, V20, P347, DOI 10.1111/j.1365-2036.2004.02033.x
   Boyer JD, 2007, P NATL ACAD SCI USA, V104, P18648, DOI 10.1073/pnas.0709198104
   Cole ET, 2002, INT J PHARM, V231, P83, DOI 10.1016/S0378-5173(01)00871-7
   Critchfield JW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003577
   Cronkhite RI, 2004, VACCINE, V22, P2106, DOI 10.1016/j.vaccine.2003.12.012
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10
   Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004
   Gururajan M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000863
   Han M, 2009, J PHARM SCI-US, V98, P2626, DOI 10.1002/jps.21627
   Hooper JW, 2003, VIROLOGY, V306, P181, DOI 10.1016/S0042-6822(02)00038-7
   Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096
   Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767
   Manicassamy S, 2009, SEMIN IMMUNOL, V21, P185, DOI 10.1016/j.smim.2009.05.005
   McConnell EL, 2008, VACCINE, V26, P639, DOI 10.1016/j.vaccine.2007.11.071
   Miller CJ, 1996, NAT MED, V2, P751, DOI 10.1038/nm0796-751
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267
   Price GE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013162
   Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399
   Schellekens RCA, 2008, J CONTROL RELEASE, V132, P91, DOI 10.1016/j.jconrel.2008.08.008
   Schiffer Joshua T, 2010, Proc Natl Acad Sci U S A, V107, P18973, DOI 10.1073/pnas.1006614107
   Shang LM, 2008, GASTROENTEROLOGY, V135, P529, DOI 10.1053/j.gastro.2008.04.020
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778                                                     
   Zhu Q, 2008, MUCOSAL IMMUNOL, V1, P78, DOI 10.1038/mi.2007.3
   Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105
   Zhu Q, 2010, J CLIN INVEST, V120, P607, DOI 10.1172/JCI39293
NR 32
TC 67
Z9 68
U1 3
U2 79
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2012
VL 18
IS 8
BP 1291
EP +
DI 10.1038/nm.2866
PG 22
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 988DU
UT WOS:000307469300037
PM 22797811
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hu, XM
   Zhang, MJ
   Leak, RK
   Gan, Y
   Li, PY
   Gao, YQ
   Chen, J
AF Hu, Xiaoming
   Zhang, Meijuan
   Leak, Rehana K.
   Gan, Yu
   Li, Peiying
   Gao, Yanqin
   Chen, Jun
TI Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cell penetrating peptide; TAT protein transduction domains; blood brain
   barrier; stroke; neuroprotection
ID CELL-PENETRATING PEPTIDE; FOCAL CEREBRAL-ISCHEMIA; VECTOR-MEDIATED
   STRATEGY; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS; KINASE-C-DELTA;
   POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; HUMAN IMMUNODEFICIENCY VIRUS;
   MEMBRANE-PERMEABLE PEPTIDES; NEURONAL PRECURSOR CELLS
AB Stroke is a devastating disease with few therapeutic options. Despite our growing understanding of the critical mechanistic events in post-stroke brain injury, the clinical translation of these findings has been less effective. A monumental hurdle to the field has been the inability of many systemically applied therapies to efficiently cross the blood brain barrier (BBB) and enter brain cells. Over the last two decades, however, significant technological achievements have overcome this obstacle to facilitate central nervous system (CNS) drug delivery. Noninvasive drug carriers, especially cell penetrating peptide (CPP) show great potential to deliver neurotherapeutics across the BBB for the treatment of ischemic brain injury. This review begins with a brief introduction to the BBB in relation to drug delivery and then provides an overview of the development of drug carriers for neurotherapeutics, with a focus on CPP-mediated transduction. We discuss recent advances and limitations in this field, as well as mechanisms underlying CPP-mediated brain targeting. We also summarize the application of CPPs in stroke research. Continuing modifications and improvements of CPPs are expected to enhance both their feasibility in clinical stroke management and their specificity towards particular cell types.
C1 [Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
   [Hu, Xiaoming; Zhang, Meijuan; Gan, Yu; Li, Peiying; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.
   [Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China.
   [Hu, Xiaoming; Gan, Yu; Li, Peiying; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China.
   [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA.
   [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
EM yqgao@shmu.edu.cn; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU American Heart Association [10POST4150028]; National Institutes of
   Health/NINDS Grants [NS36736, NS43802, NS56118, NS45048]; Chinese
   Natural Science Foundation grants [30670642, 30870794, 81020108021]
FX XIAOMING HU is supported by a grant (10POST4150028) from the American
   Heart Association. JUN CHEN is supported by National Institutes of
   Health/NINDS Grants NS36736, NS43802, NS56118, and NS45048. YANQIN GAO
   is supported by Chinese Natural Science Foundation grants 30670642,
   30870794, and 81020108021. We thank Pat Strickler for excellent
   secretarial support.
CR Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873
   Achilefu S, 2003, J MED CHEM, V46, P3403, DOI 10.1021/jm030081k
   Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108
   Alves ID, 2010, BBA-BIOMEMBRANES, V1798, P2231, DOI 10.1016/j.bbamem.2010.02.009
   An JJ, 2008, FEBS J, V275, P1296, DOI 10.1111/j.1742-4658.2008.06291.x
   Andaloussi SE, 2006, NUCLEIC ACIDS RES, V39, P3972
   ARNHEITER H, 1988, EMBO J, V7, P1315
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x
   Backman CM, 2006, MOL CELL ENDOCRINOL, V252, P160, DOI 10.1016/j.mce.2006.03.013
   Baek SK, 2011, J NEURO-ONCOL, V104, P439, DOI 10.1007/s11060-010-0511-3
   Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001
   Bates E, 2008, NY TIMES        1026, V117, P886
   Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007
   Berger C, 2007, J IMMUNOL METHODS, V323, P65, DOI 10.1016/j.jim.2007.02.009
   Biju KC, 2010, MOL THER, V18, P1536, DOI 10.1038/mt.2010.107
   Binder C, 2011, J GENE MED, V13, P158, DOI 10.1002/jgm.1548
   Boado RJ, J PHARM EXP THER, V333, P961
   Boado RJ, 2008, BIOTECHNOL BIOENG, V100, P387, DOI 10.1002/bit.21764
   Boado RJ, 2010, BIOTECHNOL BIOENG, V105, P627, DOI 10.1002/bit.22576
   Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911
   Bright R, 2007, BRAIN RES, V1144, P146, DOI 10.1016/j.brainres.2007.01.113
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.040691101
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526                                                        
   Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208                                                         
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   BROWNSON EA, 1994, J PHARMACOL EXP THER, V270, P675
   Cai B, 2011, EXP NEUROL, V227, P224, DOI 10.1016/j.expneurol.2010.11.009
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cardozo AK, 2007, BBA-BIOMEMBRANES, V1768, P2222, DOI 10.1016/j.bbamem.2007.06.003
   Carrigan CN, 2005, ANAL BIOCHEM, V341, P290, DOI 10.1016/j.ab.2005.03.026
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Chaloin L, 1997, BIOCHEMISTRY-US, V36, P11179, DOI 10.1021/bi9708491
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Cho JH, 2008, NEUROCHEM INT, V52, P659, DOI 10.1016/j.neuint.2007.08.013
   Choi SH, 2005, MOL CELLS, V20, P401
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8
   Della-Morte D, 2011, NEUROSCI LETT, V487, P158, DOI 10.1016/j.neulet.2010.10.013
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Dietz GPH, 2006, BRAIN RES, V1082, P61, DOI 10.1016/j.brainres.2006.01.083
   Doeppner TR, 2010, NEUROBIOL DIS, V40, P265, DOI 10.1016/j.nbd.2010.05.033
   Doeppner TR, 2009, J CEREBR BLOOD F MET, V29, P1187, DOI 10.1038/jcbfm.2009.44
   Doeppner TR, 2009, NEUROBIOL DIS, V34, P87, DOI 10.1016/j.nbd.2008.12.013
   Drin G, 2002, AAPS PHARMSCI, V4
   Du LT, 2011, HUM MOL GENET, V20, P3151, DOI 10.1093/hmg/ddr217
   Duchardt F, 2009, J BIOL CHEM, V284, P36099, DOI 10.1074/jbc.M109.036426
   Dykstra CM, 2009, J NEUROPATH EXP NEUR, V68, P823, DOI 10.1097/NEN.0b013e3181ac6b70
   Ehrenreich H, 2002, MOL MED, V8, P495
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2007, BIOCHEM J, V407, P285, DOI 10.1042/BJ20070507
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Eum WS, 2004, FREE RADICAL BIO MED, V37, P1656, DOI 10.1016/j.freeradbiomed.2004.07.028
   Falanga A, 2011, NANOMED-NANOTECHNOL, V7, P925, DOI 10.1016/j.nano.2011.04.009
   Fan YF, 2006, NEUROCHEM INT, V48, P50, DOI 10.1016/j.neuint.2005.07.008
   Fan YF, 2007, J CEREBR BLOOD F MET, V27, P719, DOI 10.1038/sj.jcbfm.9600373
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Flinterman M, 2009, MOL THER, V17, P334, DOI 10.1038/mt.2008.256
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fu AL, 2010, BRAIN RES, V1360, P193, DOI 10.1016/j.brainres.2010.09.009
   Fu AL, 2004, NEUROSCI LETT, V368, P258, DOI 10.1016/j.neulet.2004.05.116
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gao YQ, 2010, STROKE, V41, P166, DOI 10.1161/STROKEAHA.109.561852
   Gelperina SE, 2002, TOXICOL LETT, V126, P131, DOI 10.1016/S0378-4274(01)00456-8
   Gou XC, 2011, J DRUG TARGET, V19, P86, DOI 10.3109/10611861003733961
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grunwald J, 2009, BIOCONJUGATE CHEM, V20, P1531, DOI 10.1021/bc900081e
   Guegan C, 2006, NEUROBIOL DIS, V22, P177, DOI 10.1016/j.nbd.2005.10.014
   Harwig S S, 1995, J Pept Sci, V1, P207, DOI 10.1002/psc.310010308
   Hearst SM, 2011, NEUROSCIENCE, V197, P369, DOI 10.1016/j.neuroscience.2011.09.025
   Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015
   Huang RQ, 2006, CHEM PHARM BULL, V54, P1254, DOI 10.1248/cpb.54.1254                                                             
   Hwang IK, 2005, FREE RADICAL BIO MED, V39, P392, DOI 10.1016/j.freeradbiomed.2005.03.027
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Jha D, 2011, BIOCONJUGATE CHEM, V22, P319, DOI 10.1021/bc100045s
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kawamoto S, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3555531
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356
   Kilic U, 2003, STROKE, V34, P1304, DOI 10.1161/01.STR.0000066869.45310.50
   Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016
   Kim DW, 2011, BMB REP, V44, P647, DOI 10.5483/BMBRep.2011.44.10.647
   Kim DW, 2010, FREE RADICAL BIO MED, V48, P969, DOI 10.1016/j.freeradbiomed.2010.01.023
   Kim DW, 2009, FREE RADICAL BIO MED, V47, P941, DOI 10.1016/j.freeradbiomed.2009.06.036
   Kim DW, 2005, MOL CELLS, V19, P88
   Kim JA, 2006, J CEREBR BLOOD F MET, V26, P209, DOI 10.1038/sj.jcbfm.9600181
   Kim W, 2012, NEUROCHEM RES, V37, P307, DOI 10.1007/s11064-011-0613-0
   Ko YT, 2009, GENE THER, V16, P52, DOI 10.1038/gt.2008.135
   Kobayashi N, 2010, PROTEIN PEPTIDE LETT, V17, P1480, DOI 10.2174/0929866511009011480                                                     
   Koponen S, 2000, J CEREBR BLOOD F MET, V20, P93, DOI 10.1097/00004647-200001000-00013                                                
   KORDOWER JH, 1994, P NATL ACAD SCI USA, V91, P9077, DOI 10.1073/pnas.91.19.9077
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kurakhmaeva KB, 2009, J DRUG TARGET, V17, P564, DOI 10.1080/10611860903112842
   Lee YJ, 2011, BBA-GEN SUBJECTS, V1810, P752, DOI 10.1016/j.bbagen.2011.05.013
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Liddelow SA, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-2
   Lin SY, 2009, EXP NEUROL, V217, P361, DOI 10.1016/j.expneurol.2009.03.021
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   Loscher W, 2005, NEURORX, V2, P86, DOI 10.1007/BF03206645
   Lu JZ, 2011, BIOTECHNOL BIOENG, V108, P1954, DOI 10.1002/bit.23118
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Meng H, 2007, J AM CHEM SOC, V129, P15615, DOI 10.1021/ja075373f
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nagel F, 2008, J NEUROCHEM, V105, P853, DOI 10.1111/j.1471-4159.2007.05204.x
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Namanja HA, 2009, BIOCHEM BIOPH RES CO, V388, P672, DOI 10.1016/j.bbrc.2009.08.056
   Neundorf I, 2008, BIOCONJUGATE CHEM, V19, P1596, DOI 10.1021/bc800149f
   NEUWELT EA, 1987, J NEURO-ONCOL, V4, P195, DOI 10.1007/BF00150611
   Niarchos DK, 2006, PEPTIDES, V27, P2661, DOI 10.1016/j.peptides.2006.05.021
   Nijboer CH, 2010, BRAIN BEHAV IMMUN, V24, P812, DOI 10.1016/j.bbi.2009.09.008
   Nijboer CH, 2009, STROKE, V40, P3362, DOI 10.1161/STROKEAHA.109.560250
   Oehlke J, 2004, EUR J BIOCHEM, V271, P3043, DOI 10.1111/j.1432-1033.2004.04236.x
   Pardridge WM, 1999, PHARM SCI TECHNOL TO, V2, P49, DOI 10.1016/S1461-5347(98)00117-5                                                   
   PEREZ F, 1992, J CELL SCI, V102, P717
   Pooga M, 1998, FASEB J, V12, P67
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Pujals S, 2008, CHEMMEDCHEM, V3, P296, DOI 10.1002/cmdc.200700267
   QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8
   Qin Y, 2011, INT J PHARMACEUT, V419, P85, DOI 10.1016/j.ijpharm.2011.07.021
   Qu HY, 2008, EUR J PHARMACOL, V594, P93, DOI 10.1016/j.ejphar.2008.06.109
   Radis-Baptista G, 2008, J MED CHEM, V51, P7041, DOI 10.1021/jm8009475
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rapoport M, 2011, J MOL MED, V89, P161, DOI 10.1007/s00109-010-0693-3
   Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947
   Repici M, 2007, NEUROSCIENCE, V150, P40, DOI 10.1016/j.neuroscience.2007.08.021
   Rhee M, 2006, J BIOL CHEM, V281, P1233, DOI 10.1074/jbc.M509813200
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rousselle C, 2003, J PHARMACOL EXP THER, V306, P371, DOI 10.1124/jpet.102.048520
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rousselle C, 2002, J DRUG TARGET, V10, P309, DOI 10.1080/10611860290031886
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sheng JW, 2009, BIOCHEM BIOPH RES CO, V382, P236, DOI 10.1016/j.bbrc.2008.11.139
   Sheng M, 2001, J CELL SCI, V114, P1251
   Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497
   Shimohata T, 2007, STROKE, V38, P375, DOI 10.1161/01.STR.0000254616.78387.ee
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106
   Sokolov Y, 1999, BBA-BIOMEMBRANES, V1420, P23, DOI 10.1016/S0005-2736(99)00086-3
   Song BW, 2002, J PHARMACOL EXP THER, V301, P605, DOI 10.1124/jpet.301.2.605                                                          
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Sun HS, 2008, STROKE, V39, P2544, DOI 10.1161/STROKEAHA.107.506048
   Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Ulbrich K, 2009, EUR J PHARM BIOPHARM, V71, P251, DOI 10.1016/j.ejpb.2008.08.021
   Vazquez J, 2003, HYPERTENSION, V41, P751, DOI 10.1161/01.HYP.0000047878.13793.41
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HY, 2010, BIOMATERIALS, V31, P2874, DOI 10.1016/j.biomaterials.2009.12.042
   Wang Q, 2008, ANESTHESIOLOGY, V108, P1071, DOI 10.1097/ALN.0b013e318173f66b
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wiegler K, 2008, CEREBROVASC DIS, V26, P360, DOI 10.1159/000151639
   Wilson B, 2008, BRAIN RES, V1200, P159, DOI 10.1016/j.brainres.2008.01.039
   Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254
   Xia HM, 2011, BIOMATERIALS, V32, P9888, DOI 10.1016/j.biomaterials.2011.09.004
   Yamano S, 2011, J CONTROL RELEASE, V152, P278, DOI 10.1016/j.jconrel.2011.02.004
   Ye NH, 2011, LIFE SCI, V89, P868, DOI 10.1016/j.lfs.2011.09.015
   Yin W, 2006, NEUROBIOL DIS, V21, P358, DOI 10.1016/j.nbd.2005.07.015
   Youn JI, 2008, CANCER GENE THER, V15, P703, DOI 10.1038/cgt.2008.45
   Yune TY, 2008, FREE RADICAL BIO MED, V45, P1190, DOI 10.1016/j.freeradbiomed.2008.07.016
   Zhang C, 2010, EXP CLIN ENDOCR DIAB, V118, P31, DOI 10.1055/s-0029-1202273
   Zhang F, 2006, J NEUROSCI RES, V83, P1241, DOI 10.1002/jnr.20816
   Zhang Y, 2001, STROKE, V32, P1378, DOI 10.1161/01.STR.32.6.1378                                                        
   Zhao KS, 2005, BIOCHEM PHARMACOL, V70, P1796, DOI 10.1016/j.bcp.2005.08.022
NR 188
TC 5
Z9 5
U1 0
U2 37
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD AUG
PY 2012
VL 18
IS 25
BP 3704
EP 3720
DI 10.2174/138161212802002715                                              
          
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 993OR
UT WOS:000307869600012
PM 22574984
DA 2018-01-05
ER

PT J
AU Chen, BD
   Yang, CL
   Wang, MS
   Ma, XG
AF Chen Bao-Dong
   Yang Chuan-Lu
   Wang Mei-Shan
   Ma Xiao-Guang
TI Dynamic mechanism for encapsulating two HIV replication inhibitor
   peptides with carbon nanotubes
SO CHINESE PHYSICS B
LA English
DT Article
DE molecular dynamics simulation; drug delivery; peptide-CNT interaction;
   spontaneous encapsulation; conformational change
ID MOLECULAR-DYNAMICS; TAGGED PEPTIDE; SIMULATION; PROTEINS; WATER
AB Encapsulation of biomolecules inside a carbon nanotube (CNT) has attracted great interest because it could enable the delivery of nanoscale pharmaceutical drugs with CNT-based devices. Using a molecular dynamics simulation, we investigate the dynamic process by which human immunodeficiency virus (HIV) replication inhibitor peptides (HRIPs) are encapsulated in a water solution contained inside a CNT. The van der Waals attraction between the HRIPs and the CNT and the root-mean-square deviation are used to analyse the evolution of the encapsulation. It is found that the interaction between the HRIPs and the CNT is the main driving force for the encapsulation process, which does not cause an obvious conformational change to the HRIPs.
C1 [Chen Bao-Dong; Yang Chuan-Lu; Wang Mei-Shan; Ma Xiao-Guang] Ludong Univ, Sch Phys & Optoelect Engn, Yantai 264025, Peoples R China.
RP Yang, CL (reprint author), Ludong Univ, Sch Phys & Optoelect Engn, Yantai 264025, Peoples R China.
EM yangchuanlu@263.net
RI Yang, Chuan-Lu/K-3052-2013; Ma, Xiao Guang/A-8683-2012
OI Yang, Chuan-Lu/0000-0001-9138-3075; Ma, Xiao Guang/0000-0002-7935-499X
FU Natural Science Foundation of Shandong Province of China [ZR2011AL010];
   National Natural Science Foundation of China [NSFC-10974078,
   NSFC-11174117]
FX Project supported by the Natural Science Foundation of Shandong Province
   of China (Grant No. ZR2011AL010) and the National Natural Science
   Foundation of China (Grant Nos. NSFC-10974078 and NSFC-11174117).
CR Bao WX, 2006, ACTA PHYS SIN-CH ED, V55, P3552
   Chen BD, MOL PHYS IN PRESS
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dhar S, 2008, J AM CHEM SOC, V130, P11467, DOI 10.1021/ja803036e
   Gao HJ, 2003, NANO LETT, V3, P471, DOI 10.1021/nl025967a
   Hilder TA, 2008, MICRO NANO LETT, V3, P41, DOI 10.1049/mnl:20080008
   Hirschfelder J. O., 1964, MOL THEORY GASES LIQ
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kang Y, 2008, J PHYS CHEM B, V112, P4801, DOI 10.1021/jp711392g
   Kang Y, 2010, J PHYS CHEM B, V114, P2869, DOI 10.1021/jp905995s
   Kang Y, 2009, BIOMATERIALS, V30, P2807, DOI 10.1016/j.biomaterials.2009.01.024
   Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015
   Li R, 2011, ACTA PHYS SIN-CH ED, V60
   Lin Y, 2004, J MATER CHEM, V14, P527, DOI 10.1039/b314481j
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Meng LJ, 2009, ACTA PHYS SIN-CH ED, V58, P7781
   Pei QX, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2981798
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   TSANG SC, 1995, CHEM COMMUN, V17, P1803
   Veetil JV, 2007, BIOTECHNOL PROGR, V23, P517, DOI 10.1021/bp0602395
   Walther JH, 2001, J PHYS CHEM B, V105, P9980, DOI 10.1021/jp011344u
   Wang Y, 2003, ACTA PHYS SIN-CH ED, V52, P3120
   Xie YH, 2005, MATER LETT, V59, P971, DOI 10.1016/j.matlet.2004.10.079
   Yang ZY, 2007, ENG ANAL BOUND ELEM, V31, P402, DOI 10.1016/j.enganabound.2006.07.012
   Yang ZY, 2006, MAT SCI ENG A-STRUCT, V423, P84, DOI 10.1016/j.msea.2005.10.078
NR 27
TC 4
Z9 4
U1 0
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1674-1056
J9 CHINESE PHYS B
JI Chin. Phys. B
PD AUG
PY 2012
VL 21
IS 8
AR 083103
DI 10.1088/1674-1056/21/8/083103
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 988OY
UT WOS:000307501600023
DA 2018-01-05
ER

PT J
AU Belmiloud, Y
   Ouraghi, M
   Brahimi, M
   Benaboura, A
   Charqaoui, D
   Tangour, B
AF Belmiloud, Y.
   Ouraghi, M.
   Brahimi, M.
   Benaboura, A.
   Charqaoui, D.
   Tangour, B.
TI Theoretical Study of the Anti-Human Immuno-Deficiency Virus TIBO
   Molecule Confined Into Carbon Nanotubes
SO JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE
LA English
DT Article
DE Carbon Nanotube; Anti-HIV; Inhibitor Non-Nucleosidic of Inverse
   Transcriptase; TIBO; Butterfly Conformation; Virus Mutation
ID HIV-1 REVERSE-TRANSCRIPTASE; NONNUCLEOSIDE INHIBITORS; PAMAM DENDRIMERS;
   DRUG-DELIVERY; 8-CL TIBO; BETA-RING; TYPE-1; DERIVATIVES; BINDING;
   REPLICATION
AB This work deals with the butterfly conformation control of the anti-HIV TIBO molecule confined into carbon nanotubes (CNT). This theoretical study concerns the variation of some pertinent conformation descriptors such as butterfly angle, wingspan, volume, dipole moment, solvation energy and confinement energy versus carbon nanotube diameters. Obtained results show that it is possible to describe the configurations of actual drugs as 8-Cl or 9-Cl TIBO as the parent molecule TIBO encapsulated in an adequate CNT. Our approach indicates that drug confinement inside CNTs may be a promising way to use a same drug in order to fellow HIV virus mutations.
C1 [Belmiloud, Y.; Brahimi, M.; Tangour, B.] Univ Sci & Tech Houari Boumediene, Fac Chim, Lab Physicochim Theor & Chim Informat, Bab Ezzouar 16111, Alger, Algeria.
   [Belmiloud, Y.] Univ Mhamed Bougara, Boumerdes, Algeria.
   [Ouraghi, M.; Benaboura, A.] Univ Sci & Tech Houari Boumediene, Fac Chim, Lab Synth Macromol & Thioorgan Macromol, Bab Ezzouar 16111, Alger, Algeria.
   [Ouraghi, M.] Univ Sci & Tech Houari Boumediene, Fac Phys, Ctr Rech Sci & Tech Anal Physicochim CRAPC, Bab Ezzouar 16111, Alger, Algeria.
   [Charqaoui, D.] Univ Cadi Ayyad, Dept Chim, Fac Sci Semlalia, Marrakech 40001, Morocco.
   [Tangour, B.] Univ Tunis El Manar, Tunis 1092, Tunisia.
RP Tangour, B (reprint author), Univ Sci & Tech Houari Boumediene, Fac Chim, Lab Physicochim Theor & Chim Informat, BP 32 Elalia, Bab Ezzouar 16111, Alger, Algeria.
CR Agarwal A, 2009, BIOMATERIALS, V30, P3588, DOI 10.1016/j.biomaterials.2009.03.016
   Agrawal P, 2007, BIOMATERIALS, V28, P3349, DOI 10.1016/j.biomaterials.2007.04.004
   ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001                                                             
   ALTHAUS IW, 1994, BIOCHEM PHARMACOL, V47, P2017, DOI 10.1016/0006-2952(94)90077-9
   Arnold E., 1996, DRUG DES DISCOVERY, V29, P13
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   Barreca ML, 1999, BIOORGAN MED CHEM, V7, P2283, DOI 10.1016/S0968-0896(99)00181-9
   Belmiloud Y., 2008, BIOSCIENCES BIOTECHN, V5, P507
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   Chauhan AS, 2003, J CONTROL RELEASE, V90, P335, DOI 10.1016/S0168-3659(03)00200-1
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   Eriksson MAL, 1999, J MED CHEM, V42, P868, DOI 10.1021/jm980277y                                                               
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Garg R, 1999, CHEM REV, V99, P3525, DOI 10.1021/cr9703358                                                               
   GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   Gupta U, 2007, J PHARM PHARM SCI, V10, P358
   Gupta U, 2006, NANOMED-NANOTECHNOL, V2, P66, DOI 10.1016/j.nano.2006.04.002
   Hampel S, 2008, NANOMEDICINE-UK, V3, P175, DOI 10.2217/17435889.3.2.175
   Hemmateenejad B, 2007, J IRAN CHEM SOC, V4, P481, DOI 10.1007/BF03247236                                                              
   Hemmateenejad B, 2005, J MOL STRUC-THEOCHEM, V732, P39, DOI 10.1016/j.theochem.2005.07.015
   [Anonymous], HYP 7 5 WIND
   Jingshan R., 1995, STRUCTURE, V3, P915
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Larder B.A., 1993, INHIBITORS HIV REVER, P205
   Mager P P, 1996, Drug Des Discov, V14, P241
   Mager PP, 1996, EUR J MED CHEM, V31, P701, DOI 10.1016/0223-5234(96)85879-X
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   Mui W., 1992, MED CHEM, V35, P201
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SCHAFER W, 1993, J MED CHEM, V36, P726, DOI 10.1021/jm00058a009
   Singh P, 2008, BIOCONJUGATE CHEM, V19, P2239, DOI 10.1021/bc800125u
   Smith MBK, 2000, PROTEIN ENG, V13, P413, DOI 10.1093/protein/13.6.413
   Smith RH, 1998, J MED CHEM, V41, P5272, DOI 10.1021/jm9804174                                                               
   Tekade RK, 2009, CHEM REV, V109, P49, DOI 10.1021/cr068212n
   Wang LX, 2010, J MOL STRUC-THEOCHEM, V940, P76, DOI 10.1016/j.theochem.2009.10.013
   WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423                                             
   Yanai T, 2004, CHEM PHYS LETT, V393, P51, DOI 10.1016/j.cplett.2004.06.011
NR 46
TC 13
Z9 13
U1 0
U2 8
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1546-1955
J9 J COMPUT THEOR NANOS
JI J. Comput. Theor. Nanosci.
PD AUG
PY 2012
VL 9
IS 8
BP 1101
EP 1108
DI 10.1166/jctn.2012.2150
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 979ZB
UT WOS:000306862300016
DA 2018-01-05
ER

PT J
AU Li, N
   Yu, MH
   Deng, LD
   Yang, J
   Dong, AJ
AF Li, Ning
   Yu, Meihua
   Deng, Liandong
   Yang, Jun
   Dong, Anjie
TI Thermosensitive hydrogel of hydrophobically-modified methylcellulose for
   intravaginal drug delivery
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article
ID VAGINAL MICROBICIDES; HIV TRANSMISSION; IN-VITRO; PREVENTION; GEL;
   THERMOGELATION; NANOPARTICLES; CHITOSAN; RELEASE; SYSTEMS
AB Hydrogels with the advantages of prolonging drug release and administration convenience are necessary for intravaginal drug delivery to prevent sexual transmission of human immunodeficiency virus and other vaginal infections. In this study, the thermosensitive hydrogel of methylcellulose modified by stearic acid (MCS) were evaluated in the presence of NaCl and phosphates, which exhibited sol-to-gel transition performance at body temperature or even lower. The in vitro cytotoxicity and in vivo mucosal irritation were investigated and the results showed that MCS hydrogel possessed good biocompatibility similar with hydroxyethyl cellulose (HEC) gel. Significantly, the release studies revealed that MCS hydrogel could control tenofovir sustained release for 10 h without burst release, longer than that from HEC gel or poloxamer 407 hydrogel. Therefore, MCS thermosensitive hydrogel would be a promising carrier for intravaginal delivery of antiviral drugs for long time controlled release.
C1 [Li, Ning; Yu, Meihua; Deng, Liandong; Dong, Anjie] Tianjin Univ, Sch Chem Engn & Technol, Dept Polymer Sci & Technol, Tianjin 300072, Peoples R China.
   [Yang, Jun] Nankai Univ, Coll Life Sci, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China.
RP Dong, AJ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Dept Polymer Sci & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China.
EM ajdong@tju.edu.cn
FU National High Technology Research and Development Program of China (863)
   [2009AA03Z313]; National Grand Program on Key Infectious Disease Control
   [2008ZX10001-015-10]
FX This work was supported by a grant from the National High Technology
   Research and Development Program of China (863) (2009AA03Z313) and
   National Grand Program on Key Infectious Disease Control
   (2008ZX10001-015-10).
CR Aranha CC, 2008, CYTOKINE, V43, P63, DOI 10.1016/j.cyto.2008.04.005
   Bilensoy E, 2006, AAPS PHARMSCITECH, V7, P1
   Bourinbaiar AS, 2006, CURR PHARM DESIGN, V12, P2017, DOI 10.2174/138161206777442119
   Brown TJ, 1999, J AM ACAD DERMATOL, V41, P511, DOI 10.1016/S0190-9622(99)80045-0
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   Desbrieresa J, 2000, POLYMER, V41, P2451
   Feeney M, 2009, J MATER SCI-MATER M, V20, P1081, DOI 10.1007/s10856-008-3665-1
   Gaetano F.D., 2005, J MATER SCI-MATER M, V16, P261
   Hirrien M, 1998, POLYMER, V39, P6251, DOI 10.1016/S0032-3861(98)00142-6                                                   
   Hussain A, 2005, J CONTROL RELEASE, V103, P301, DOI 10.1016/j.jconrel.2004.11.034
   Ji QX, 2009, J MATER SCI-MATER M, V20, P1603, DOI 10.1007/s10856-009-3729-x
   Kang YM, 2011, BIOMATERIALS, V32, P4556, DOI 10.1016/j.biomaterials.2011.03.007
   Kenneth HM, 2006, AIDS, V20, P543
   KNUTH K, 1993, ADV DRUG DELIVER REV, V11, P137, DOI 10.1016/0169-409X(93)90030-8                                                    
   Krishnan S, 2008, ANN NY ACAD SCI, V1136, P101, DOI 10.1196/annals.1425.013
   Lee SC, 2005, J BIOACT COMPAT POL, V20, P5, DOI 10.1177/0883911505049652
   Lisa CR, 2009, AAPS J, V11, P78
   Liu J, 2007, J MATER SCI-MATER M, V18, P2205, DOI 10.1007/s10856-007-3010-0
   Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Schwartz JL, 2007, CONTRACEPTION, V75, P136, DOI 10.1016/j.contraception.2006.09.003
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   UN AIDS/WHO, 2010, AIDS EP JUL 2010
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   Vermani K., 2000, PSTT, V3, P359, DOI [10.1016/S1461-5347(00)00296-0, DOI 10.1016/S1461-5347(00)00296-0]
   Weber J, 2005, PLOS MED, V2, P392, DOI 10.1371/journal.pmed.0020142
   Xu Y, 2005, POLYMER, V46, P7410, DOI 10.1016/j.polymer.2005.05.128
   Yool J-W, 2010, INT J PHARMACEUT, V403, P262
   Zhou WJ, 2011, J MATER SCI-MATER M, V22, P1221, DOI 10.1007/s10856-011-4304-9
NR 31
TC 9
Z9 11
U1 4
U2 59
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD AUG
PY 2012
VL 23
IS 8
BP 1913
EP 1919
DI 10.1007/s10856-012-4664-9
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 976LT
UT WOS:000306586900008
PM 22569735
DA 2018-01-05
ER

PT J
AU Eissenstat, M
   Guerassina, T
   Gulnik, S
   Afonina, E
   Silva, AM
   Ludtke, D
   Yokoe, H
   Yu, B
   Erickson, J
AF Eissenstat, Michael
   Guerassina, Tanya
   Gulnik, Sergei
   Afonina, Elena
   Silva, Abelardo M.
   Ludtke, Douglas
   Yokoe, Hiroko
   Yu, Betty
   Erickson, John
TI Enamino-oxindole HIV protease inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Oxindole; HIV; Protease; Inhibitors; Resistance
ID STRUCTURE-BASED DESIGN; BIOLOGICAL EVALUATION; POTENT; DISCOVERY;
   INDOLINONES; SELECTION; MUTANTS
AB We have designed and synthesized a series of HIV protease inhibitors (PIs) with enamino-oxindole substituents optimized to interact with the S2' subsite of the HIV protease binding pocket. Several of these inhibitors have sub-nanomolar K-i and antiviral IC50 in the low nM range against WT HIV and against a panel of multi-drug resistant (MDR) strains. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Eissenstat, Michael; Guerassina, Tanya; Gulnik, Sergei; Afonina, Elena; Silva, Abelardo M.; Ludtke, Douglas; Yokoe, Hiroko; Yu, Betty; Erickson, John] Sequoia Pharmaceut Inc, Gaithersburg, MD 20878 USA.
RP Eissenstat, M (reprint author), Sequoia Pharmaceut Inc, 267 Kentlands Blvd,905, Gaithersburg, MD 20878 USA.
EM eissenst@comcast.net
CR Bouchikhi F, 2008, EUR J MED CHEM, V43, P2316, DOI 10.1016/j.ejmech.2008.01.010
   Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d
   DeLano Warren, PYMOL MOL GRAPHICS S
   Friedrichsen W, 2000, ADV HETEROCYCL CHEM, V76, P85, DOI 10.1016/S0065-2725(00)76004-1
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002                                                             
   Ghosh AK, 1996, J MED CHEM, V39, P3278, DOI 10.1021/jm960128k
   Gulnik SV, 2008, ANTIVIR THER, V13, pA35
   Gulnik SV, 2008, CURR OPIN HIV AIDS, V3, P633, DOI 10.1097/COH.0b013e328313911d
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092
   Kodama E, 1996, ANTIVIR RES, V31, P159, DOI 10.1016/0166-3542(96)06966-5
   Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c
   Kumar SP, 2011, EUR J MED CHEM, V46, P927, DOI 10.1016/j.ejmech.2011.01.008
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Park SJ, 2004, B KOR CHEM SOC, V25, P349
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Roth GJ, 2009, J MED CHEM, V52, P4466, DOI 10.1021/jm900431g
   SARGES R, 1989, J MED CHEM, V32, P437, DOI 10.1021/jm00122a025
   Sassatelli M, 2006, EUR J MED CHEM, V41, P709, DOI 10.1016/j.ejmech.2006.03.021
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   Turk D., P 1996 M INT UN CRYS
   Wang YF, 2007, J MED CHEM, V50, P4509, DOI 10.1021/jm070482q
   Williams J W, 1979, Methods Enzymol, V63, P437
   Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
   Tahri A., 2004, International Patent Application, Patent No. [2004016619, WO 2004016619]
   Erickson J.W., 2003, International Patent Application, Patent No. [WO 2003057173, 2003057173]
   Eissenstat M., 2005, International Patent Application, Patent No. [WO 2005087728, 2005087728]
   Wigerinck P.T.B.P., 2001, International Patent Application, Patent No. [WO 2001025240, 2001025240]
   [Anonymous], 1999, Latest label information for PREZISTA (darunavir ethanolate), Patent No. [9967254, WO9967254]
NR 32
TC 6
Z9 6
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2012
VL 22
IS 15
BP 5078
EP 5083
DI 10.1016/j.bmcl.2012.05.120
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 975BG
UT WOS:000306481100033
PM 22749283
DA 2018-01-05
ER

PT J
AU Gibaud, S
   Attivi, D
AF Gibaud, Stephane
   Attivi, David
TI Microemulsions for oral administration and their therapeutic
   applications
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE bioavailability; microemulsion; nanoemulsion; self-emulsifying system
ID DRUG-DELIVERY SYSTEMS; RAMIPRIL NANOEMULSION FORMULATION; PH-SENSITIVE
   NANOPARTICLES; LIPID-BASED FORMULATIONS; WATER-SOLUBLE DRUG;
   CYCLOSPORINE-A; IN-VIVO; ARTIFICIAL MEMBRANE; CLINICAL PHARMACOKINETICS;
   MULTIDRUG-RESISTANCE
AB Introduction: The microemulsion concept was introduced in 1943 by Hoar and Schulman. Self-microemulsifying drug delivery systems (S(M)EDDS) are much more recent and can be described as isotropic solutions of oils and surfactants that form oil-in-water O/W microemulsions when they are poured into an aqueous medium. When they are presented as soft capsules for oral delivery, S(M)EDDS have the ability to considerably improve the intestinal absorption of agents that are incorporated into the S(M)EDDS. Forty percent of newly discovered drug candidates have little or no water solubility and therefore have low and/or variable bioavailability profiles. Many of these drugs are good candidates for formulation into S(M)EDDS.
   Areas covered: This paper describes the preparation and assessment of these formulations and their current applications. The characterisation of this type of formulation has improved, and in vitro models (Caco-2 cell cultures, Ussing chambers, the everted sac technique, etc.) can be used for screening different formulations. It describes also marketed formulations (i.e., cyclosporin and saquinavir S(M)EDDS) and some other formulations.
   Expert opinion: Actual applications of S(M)EDDS remain rare. The first drug marketed as a S(M)EDDS was cyclosporin, and it had significantly improved bioavailability compared with the conventional solution. In the last decade, several S(M)EDDS loaded with antiviral drugs (e. g., ritonavir, saquinavir) were tested for treatment of HIV infection, but the relative improvement in clinical benefit was not significant. The S(M)EDDS formulation of Norvir (R) (soft capsules) has been withdrawn in some countries.
C1 [Gibaud, Stephane] Univ Lorraine, CITHEFOR EA 3452, Fac Pharm, F-54000 Nancy, France.
   [Gibaud, Stephane; Attivi, David] Ctr Hosp Neufchateau, F-88300 Neufchateau, France.
RP Gibaud, S (reprint author), Univ Lorraine, CITHEFOR EA 3452, Fac Pharm, 5 Rue Albert Lebrun, F-54000 Nancy, France.
EM stephane.gibaud@univ-lorraine.fr
OI GIBAUD, Stephane/0000-0003-3594-0601
CR ABOOFAZELI R, 1995, INT J PHARM, V125, P107, DOI 10.1016/0378-5173(95)00125-3
   Agueros M, 2009, EUR J PHARM SCI, V38, P405, DOI 10.1016/j.ejps.2009.09.010
   Aliabadi HM, 2005, BIOMATERIALS, V26, P7251, DOI 10.1016/j.biomaterials.2005.05.042
   Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013
   Ankola DD, 2010, J R SOC INTERFACE, V7, pS475, DOI 10.1098/rsif.2010.0046.focus
   Araya H, 2006, DRUG METAB PHARMACOK, V21, P45, DOI 10.2133/dmpk.21.45                                                              
   Attivi D, 2011, ACT PHARM HOSP, V7, P39
   Attivi D, 2010, DRUG DEV IND PHARM, V36, P421, DOI 10.3109/03639040903225083
   BELLOCQ AM, 1982, J COLLOID INTERF SCI, V89, P427, DOI 10.1016/0021-9797(82)90194-1                                                    
   BEVERIDGE T, 1981, CURR THER RES CLIN E, V30, P5
   Brime B, 2003, J ANTIMICROB CHEMOTH, V52, P103, DOI 10.1093/jac/dkg266
   CHARMAN SA, 1992, PHARMACEUT RES, V9, P87, DOI 10.1023/A:1018987928936                                                         
   Chen BP, 1997, FORMULARY, V32, P795
   [陈丽华 Chen Lihua], 2011, [中国药学杂志, Chinese Pharmaceutical Journal], V46, P40
   Chen MCM, 2005, BIOTECHNOL PROGR, V21, P1297, DOI 10.1021/bp050030b
   Chen XX, 2008, PHARM RES-DORDR, V25, P1511, DOI 10.1007/s11095-007-9517-8
   Chinsangaram J, 2012, ANTIMICROB AGENTS CH
   CHOO LiM JONG, 2011, [Applied Chemistry for Engineering, 공업화학], V22, P416
   Chouksey R, 2011, INT J PHARM PHARM SC, V3, P147
   COON JS, 1991, CANCER RES, V51, P897
   Dai JD, 2004, INT J PHARM, V280, P229, DOI 10.1016/j.ijpharm.2004.05.006
   DANIELSSON I, 1981, COLLOID SURFACE, V3, P391, DOI 10.1016/0166-6622(81)80064-9                                                    
   Date AA, 2007, INT J PHARM, V329, P166, DOI 10.1016/j.ijpharm.2006.08.038
   DREWE J, 1992, BRIT J CLIN PHARMACO, V34, P60, DOI 10.1111/j.1365-2125.1992.tb04108.x                                              
   El-Shabouri MH, 2002, INT J PHARM, V249, P101, DOI 10.1016/S0378-5173(02)00461-1                                                   
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Fanucchi Michael, 2006, Treat Respir Med, V5, P181, DOI 10.2165/00151829-200605030-00004
   Fatouros Dimitrios G, 2007, Ther Clin Risk Manag, V3, P591
   Florence AT, 2004, J DRUG TARGET, V12, P65, DOI 10.1080/10611860410001693706
   FREY FJ, 1988, CLIN PHARMACOL THER, V43, P55, DOI 10.1038/clpt.1988.11                                                            
   Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X
   Gershanik T, 1998, PHARMACEUT RES, V15, P863, DOI 10.1023/A:1011968313933                                                         
   GHOSH PK, 2006, AAPS PHARMSCITECH, V7, DOI DOI 10.1208/PT070377
   Goddeeris C, 2007, EUR J PHARM BIOPHARM, V66, P173, DOI 10.1016/j.ejpb.2006.10.005
   GREVEL J, 1986, EUR J CLIN PHARMACOL, V31, P211, DOI 10.1007/BF00606661
   Griffin BT, 2006, J PHARM PHARMACOL, V58, P917, DOI 10.1211/jpp.58.7.0006
   Grove M, 2006, EUR J PHARM SCI, V28, P233, DOI 10.1016/j.ejps.2006.02.005
   Gui SY, 2008, PHARMAZIE, V63, P516, DOI 10.1691/ph.2008.8018
   Guo J, 2005, DRUG DELIV, V12, P35, DOI 10.1080/10717540590889691
   Guo JX, 2001, INT J PHARM, V216, P17, DOI 10.1016/S0378-5173(00)00680-3
   Gupta A, 2011, RES J PHARM SCI BIOT, V1, P51
   Han DH, 2010, CHEM PHARM BULL, V58, P11, DOI 10.1248/cpb.58.11                                                               
   He L, 2003, INT J PHARM, V250, P45, DOI 10.1016/S0378-5173(02)00478-7
   Heo MY, 2005, ARCH PHARM RES, V28, P604, DOI 10.1007/BF02977766
   Hoar TP, 1943, NATURE, V152, P102, DOI 10.1038/152102a0
   Hu LD, 2011, DRUG DELIV, V18, P90, DOI 10.3109/10717544.2010.522613
   Hugen PWH, 2002, PHARM WORLD SCI, V24, P83, DOI 10.1023/A:1016121100568                                                         
   Italia JL, 2007, J CONTROL RELEASE, V119, P197, DOI 10.1016/j.jconrel.2007.02.004
   KAHAN BD, 1989, NEW ENGL J MED, V321, P1725
   Kang BK, 2004, INT J PHARM, V274, P65, DOI 10.1016/j.ijpharm.2003.12.028
   Kansy M, 1998, J MED CHEM, V41, P1007, DOI 10.1021/jm970530e                                                               
   Kanwar JR, 2011, CURR MED CHEM, V18, P2079
   Karasulu HY, 2008, EXPERT OPIN DRUG DEL, V5, P119, DOI 10.1517/17425247.5.1.119
   Khandavilli S, 2007, J INVEST DERMATOL, V127, P154, DOI 10.1038/sj.jid.5700485
   King KM, 2009, JOURNAL, V16, P8
   KOVARIK JM, 1994, THER DRUG MONIT, V16, P232, DOI 10.1097/00007691-199406000-00002
   KOVARIK JM, 1994, J PHARM SCI, V83, P444, DOI 10.1002/jps.2600830336
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Lai J, 2010, INT J NANOMED, V5, P13
   Lee EJ, 2001, INT J PHARM, V218, P125, DOI 10.1016/S0378-5173(01)00621-4                                                   
   Lee EH, 2008, ANESTHESIOLOGY, V109, P436, DOI 10.1097/ALN.0b013e318182a486
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Liu C, 2006, DRUG DEV IND PHARM, V32, P115, DOI 10.1080/03639040500388573
   Lu JL, 2008, EUR J PHARM BIOPHARM, V69, P899, DOI 10.1016/j.ejpb.2008.02.023
   MALENKOV AG, 1967, EXP CELL RES, V48, P307, DOI 10.1016/0014-4827(67)90356-4
   Mandal S, 2011, SA PHARM J INC PHARM, V78, P44
   Surjyanarayan M, 2009, INT J PHARM TECH RES, V1, P1442
   Masungi C, 2008, PHARMAZIE, V63, P194, DOI 10.1691/ph.2008.7327
   MEHTA MU, 1988, BRIT J CLIN PHARMACO, V25, P579, DOI 10.1111/j.1365-2125.1988.tb03348.x                                              
   Michaud LB, 2000, DRUG SAFETY, V23, P401, DOI 10.2165/00002018-200023050-00005
   MORGAN T, 1994, CLIN PHARMACOKINET, V26, P335, DOI 10.2165/00003088-199426050-00002                                                
   MUELLER EA, 1994, PHARMACEUT RES, V11, P301, DOI 10.1023/A:1018923912135
   Muller RH, 2006, INT J PHARM, V317, P82, DOI 10.1016/j.ijpharm.2006.02.045
   Muellertz A, 2010, J PHARM PHARMACOL, V62, P1622, DOI 10.1111/j.2042-7158.2010.01107.x
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Nazar MF, 2009, AAPS PHARMSCITECH, V10, P1286, DOI 10.1208/s12249-009-9328-9
   NEUGEBAUER G, 1987, Journal of Cardiovascular Pharmacology, V10, pS85
   NICHOLS J, 1960, P SOC EXP BIOL MED, V104, P539
   Ning X, 2011, DRUG DEV IND PHARM, V37, P727, DOI 10.3109/03639045.2010.538061
   O'Driscoll CM, 2002, EUR J PHARM SCI, V15, P405, DOI 10.1016/S0928-0987(02)00051-9
   Osipow LI, 1963, J SOC COSMET CHEM, V14, P277
   PAL R, 1994, COLLOID SURFACE A, V84, P141, DOI 10.1016/0927-7757(93)02711-M                                                    
   Paolino D, 2002, INT J PHARM, V244, P21, DOI 10.1016/S0378-5173(02)00295-8
   Patel V, 2010, IRAN J PHARM RES, V9, P327
   Patil Pradeep, 2007, Acta Pharmaceutica (Zagreb), V57, P111, DOI 10.2478/v10007-007-0009-5
   Perez EA, 2007, SEMIN ONCOL, V34, pS1
   Porter CJH, 1997, ADV DRUG DELIVER REV, V25, P71, DOI 10.1016/S0169-409X(96)00492-9
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928-0987(00)00167-6
   PRINCE LM, 1967, J COLLOID INTERF SCI, V23, P165, DOI 10.1016/0021-9797(67)90099-9
   PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002                                                
   RIEHM H, 1972, CANCER RES, V32, P1195
   Saffoon N, 2011, J APPL PHARM SCI, V1, P13
   Santos-Magalhaes NS, 2000, INT J PHARM, V208, P71, DOI 10.1016/S0378-5173(00)00546-9                                                   
   Schrijvers Dirk, 2005, Future Oncol, V1, P829, DOI 10.2217/14796694.1.6.829
   SCHULMAN JH, 1961, ANN NY ACAD SCI, V92, P366, DOI 10.1111/j.1749-6632.1961.tb44987.x                                              
   SCHULMAN JH, 1959, J PHYS CHEM-US, V63, P1677, DOI 10.1021/j150580a027                                                             
   Sha XY, 2005, EUR J PHARM SCI, V24, P477, DOI 10.1016/j.ejps.2005.01.001
   Shafiq S, 2007, J BIOMED NANOTECHNOL, V3, P28, DOI 10.1166/jbn.2007.008
   Shafiq S, 2007, EUR J PHARM BIOPHARM, V66, P227, DOI 10.1016/j.ejpb.2006.10.014
   Shah NM, 2006, J NANOSCI NANOTECHNO, V6, P2967, DOI 10.1166/jnn.2006.403
   SHAH NH, 1994, INT J PHARM, V106, P15, DOI 10.1016/0378-5173(94)90271-2
   SHARMA US, 1995, J PHARM SCI, V84, P1223, DOI 10.1002/jps.2600841015
   Spernath A, 2006, ADV COLLOID INTERFAC, V128, P47, DOI 10.1016/j.cis.2006.11.016
   TRULL AK, 1995, BRIT J CLIN PHARMACO, V39, P627, DOI 10.1111/j.1365-2125.1995.tb05722.x                                              
   TRULL AK, 1993, LANCET, V341, P433, DOI 10.1016/0140-6736(93)93025-V                                                    
   VENKATARAMANAN R, 1985, SEMIN LIVER DIS, V5, P357, DOI 10.1055/s-2008-1040633
   WALLACE EZ, 1961, NEW ENGL J MED, V265, P1088, DOI 10.1056/NEJM196111302652204                                                     
   Wang XQ, 2004, J CONTROL RELEASE, V97, P421, DOI 10.1016/j.jconrel.2004.03.003
   Wei LL, 2005, DRUG DEV IND PHARM, V31, P785, DOI 10.1080/03639040500216428
   Weiss J, 2005, HDB FOOD ANAL CHEM W, P631
   Wong SM, 2006, INT J PHARM, V317, P61, DOI 10.1016/j.ijpharm.2006.03.001
   Yang SC, 2004, PHARM RES, V21, P261, DOI 10.1023/B:PHAM.0000016238.44452.f1
   Yin YM, 2009, J CONTROL RELEASE, V140, P86, DOI 10.1016/j.jconrel.2009.08.015
   Yong CS, 2005, DRUG DEV IND PHARM, V31, P615, DOI 10.1080/03639040500216113
   Zheng JY, 2006, INT J PHARM, V307, P209, DOI 10.1016/j.ijpharm.2005.10.007
   ZORDANNUDO T, 1993, CANCER RES, V53, P5994
   Brossard D, 2010, Methods for making a formulation and use thereof for administering polar drugs, Patent No. [WO2010067035A1, 2010067035]
   Batung F, 2010, Self-microemulsifying mitotane composition, Patent No. [WO20101136952, 20101136952]
NR 119
TC 19
Z9 20
U1 1
U2 40
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD AUG
PY 2012
VL 9
IS 8
BP 937
EP 951
DI 10.1517/17425247.2012.694865
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 976SE
UT WOS:000306604000005
PM 22663249
DA 2018-01-05
ER

PT J
AU Singh, R
   Verma, R
   Sumana, G
   Srivastava, AK
   Sood, S
   Gupta, RK
   Malhotra, BD
AF Singh, Renu
   Verma, Rachna
   Sumana, G.
   Srivastava, Avanish Kumar
   Sood, Seema
   Gupta, Rajinder K.
   Malhotra, B. D.
TI Nanobiocomposite platform based on polyaniline-iron oxide-carbon
   nanotubes for bacterial detection
SO BIOELECTROCHEMISTRY
LA English
DT Article
DE Electrochemical genosensor; Neisseria gonorrhoeae; Sexually transmitted
   disease; Nanocomposite; Nucleic acid hybridization
ID SEXUALLY-TRANSMITTED-DISEASE; CONDUCTING POLYMERS; DNA BIOSENSOR;
   COMPOSITES; NANOPARTICLES; FABRICATION; ELECTRODES; PARTICLES; FILMS
AB The nanocomposite based on polyaniline (PANI)-iron oxide nanoparticles (nFe(3)O(4)) and multi walled carbon-nanotubes (CNT) has been fabricated onto indium tin oxide (ITO) coated glass plate via facile electrochemical synthesis of polyaniline in presence of nFe(3)O(4) (similar to 20 nm) and CNT (20-80 nm in diameter). The results of transmission electron microscopic studies show evidence of coating of PANI and nFe(3)O(4) onto the CNT. The PANI-nFe(3)O(4)-CNT/ITO nanoelectrode has been characterized by Fourier transform infrared spectroscopy, X-ray diffraction and scanning electron microscopy studies. The biotinylated nucleic acid probe sequence consisting of 20 bases has been immobilized onto PANI-nFe(3)O(4)-CNT/ITO nanoelectrode using biotin-avidin coupling. It is shown that the PANI-nFe(3)O(4)-CNT platform based biosensor can be used to specifically detect bacteria (N. gonorrhoeae) at minute concentration as low as (1 x 10(-19) M) indicating high sensitivity within 45 s of hybridization time at 298 K by differential pulse voltammetry using methylene blue as electroactive indicator. This bacterial sensor has also been tested with 4 positive and 4 negative PCR amplicons of gonorrhoea affected patient samples. The results of these studies have implications towards the fabrication of a handheld device for Neisseria gonorrhoeae detection that may perhaps result in a decrease in the human immunodeficiency virus infections. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Singh, Renu; Sumana, G.; Srivastava, Avanish Kumar; Malhotra, B. D.] CSIR, Dept Sci & Technol, Ctr Biomol Elect, Biomed Instrumentat Sect,Natl Phys Lab, New Delhi 110012, India.
   [Verma, Rachna; Sood, Seema] All India Inst Med Sci, Dept Microbiol, New Delhi 110002, India.
   [Gupta, Rajinder K.] Guru Gobind Singh Indraprastha Univ, Sch Biotechnol, Delhi 110075, India.
   [Malhotra, B. D.] Delhi Technol Univ, Dept Biotechnol, Delhi 110042, India.
RP Malhotra, BD (reprint author), CSIR, Dept Sci & Technol, Ctr Biomol Elect, Biomed Instrumentat Sect,Natl Phys Lab, Dr KS Krishnan Marg, New Delhi 110012, India.
EM bansi.malhotra@gmail.com
RI malhotra, bansi/E-8921-2012
OI malhotra, bansi/0000-0002-0957-2684
FU Council of Scientific and Industrial Research (CSIR), India; Department
   of Science & Technology (DST) [DST/TSG/ME/2008/18, GAP-070932];
   CSIR-EMPOWER [OLP-102232]; Department of Biotechnology, Govt. of India
   [DBT/GAP070832]
FX The authors thank Director, National Physical Laboratory, New Delhi,
   India for the facilities. Renu Singh is thankful to the Council of
   Scientific and Industrial Research (CSIR), India for the award of Senior
   Research Fellowship. The authors thank Dr. K. N. Sood and Jay Tawale,
   NPL for SEM measurements. We thank Dr. Kavita Arora, Ms. Anu Singh, Dr.
   V.K. Sharma, Professor and Head, Dermatology, AIIMS, Dr. J.C.
   Samantaray, Professor and Head and Dr. Arti Kapil, Professor,
   Microbiology, AIIMS, Dr. Manju Bala, Senior Microbiologist, Safdarjang
   hospital, New Delhi for the useful discussions. We acknowledge the
   financial support received from Department of Science & Technology (DST)
   [DST/TSG/ME/2008/18 and GAP-070932], CSIR-EMPOWER project (OLP-102232)
   and Department of Biotechnology, Govt. of India (DBT/GAP070832).
CR Balasubramanian K, 2006, ANAL BIOANAL CHEM, V385, P452, DOI 10.1007/s00216-006-0314-8
   Cates W, 1999, SEX TRANSM DIS, V26, pS2, DOI 10.1097/00007435-199904001-00002                                                
   Cruz-Silva R, 2004, POLYMER, V45, P4711, DOI 10.1016/j.polymer.2004.05.007
   Ding HJ, 2008, J PHYS CHEM B, V112, P9289, DOI 10.1021/jp8016997
   Du CS, 2006, NANOTECHNOLOGY, V17, P5314, DOI 10.1088/0957-4484/17/21/005
   Gao M, 2003, ELECTROANAL, V15, P1089, DOI 10.1002/elan.200390131
   Hu XG, 2006, J PHYS CHEM B, V110, P853, DOI 10.1021/jp055834o
   Hu X.G., 2007, LANGMUIR, V23, P6353
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Jiang KY, 2003, NANO LETT, V3, P275, DOI 10.1021/nl025914t
   Kang MS, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/8/085701
   Kim B, 2004, LANGMUIR, V20, P8239, DOI 10.1021/la049424n
   Kryszewski M, 1998, SYNTHETIC MET, V94, P99, DOI 10.1016/S0379-6779(97)04152-0
   Li CS, 2006, CARBON, V44, P2021, DOI 10.1016/j.carbon.2006.01.033
   Liao JC, 2007, J MOL DIAGN, V9, P158, DOI 10.2353/jmoldx.2007.060052
   Lin YH, 2004, NANO LETT, V4, P191, DOI 10.1021/nl0347233
   Liu FJ, 2008, SYNTHETIC MET, V158, P767, DOI 10.1016/j.synthmet.2008.05.001
   Lu XF, 2005, NANOTECHNOLOGY, V16, P1660, DOI 10.1088/0957-4484/16/9/043
   Mathur RB, 2008, COMPOS SCI TECHNOL, V68, P1608, DOI 10.1016/j.compscitech.2008.02.020
   O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631
   Philip B, 2005, POLYM BULL, V53, P127, DOI 10.1007/s00289-004-0321-x
   Qu LT, 2006, J AM CHEM SOC, V128, P5523, DOI 10.1021/ja060296u
   Shan Y, 2007, MATER CHEM PHYS, V103, P206, DOI 10.1016/j.matchemphys.2007.02.038
   Singh R, 2011, BIOSENS BIOELECTRON, V26, P2967, DOI 10.1016/j.bios.2010.11.047
   Singh R, 2010, THIN SOLID FILMS, V519, P1135, DOI 10.1016/j.tsf.2010.08.057
   Singh R, 2010, J BIOTECHNOL, V150, P357, DOI 10.1016/j.jbiotec.2010.09.935
   Singh R, 2010, J MOL RECOGNIT, V23, P472, DOI 10.1002/jmr.1014
   Singh R, 2009, BIOSENS BIOELECTRON, V24, P2232, DOI 10.1016/j.bios.2008.11.030
   Taufik S, 2011, INT J ELECTROCHEM SC, V6, P1880
   Wang J, 2005, ELECTROANAL, V17, P7, DOI 10.1002/elan.200403113
   Wang SG, 2003, BIOCHEM BIOPH RES CO, V311, P572, DOI 10.1016/j.bbrc.2003.10.031
   Xuan SH, 2008, J PHYS CHEM C, V112, P18804, DOI 10.1021/jp807124z
   Yan XB, 2007, J PHYS CHEM C, V111, P4125, DOI 10.1021/jp0651844
   Yu YJ, 2005, SYNTHETIC MET, V150, P271, DOI 10.1016/j.synthmet.2005.02.011
   Zengin H, 2002, ADV MATER, V14, P1480, DOI 10.1002/1521-4095(20021016)14:20<1480::AID-ADMA1480>3.0.CO;2-O                  
   Zhang MG, 2004, ANAL CHEM, V76, P5045, DOI 10.1021/ac049519u
   Zhu L, 2008, SENSORS-BASEL, V8, P5649, DOI 10.3390/s8095649
NR 37
TC 22
Z9 24
U1 0
U2 45
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1567-5394
J9 BIOELECTROCHEMISTRY
JI Bioelectrochemistry
PD AUG
PY 2012
VL 86
BP 30
EP 37
DI 10.1016/j.bioelechem.2012.01.005
PG 8
WC Biochemistry & Molecular Biology; Biology; Biophysics; Electrochemistry
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Biophysics; Electrochemistry
GA 950GW
UT WOS:000304638600004
PM 22306338
DA 2018-01-05
ER

PT J
AU Barnaby, SN
   Sarker, NH
   Tsiola, A
   Banerjee, IA
AF Barnaby, Stacey N.
   Sarker, Nazmul H.
   Tsiola, Areti
   Banerjee, Ipsita A.
TI Biomimetic formation of chicoric-acid-directed luminescent silver
   nanodendrites
SO NANOTECHNOLOGY
LA English
DT Article
ID WALLED CARBON NANOTUBES; SHAPE CONTROL; DENDRITIC NANOSTRUCTURES; METAL
   NANOPARTICLES; PHENOLIC-COMPOUNDS; VAPOR-DEPOSITION; HIV-1 INTEGRASE;
   NANOTREES; GROWTH; NANOCRYSTALS
AB In this work, we report the formation of well-defined silver nanodendrites via biomineralization under mild conditions in a single step, in the presence of the plant phytohormone chicoric acid (CA), a well-known HIV-I integrase inhibitor. CA played a dual role as reductant as well as directed the growth of the nanodendrites, which were found to grow primarily in the [111] and [200] directions. In addition to the formation of highly ordered hierarchical structures, the formed Ag nanodendrites were found to exhibit luminescence, as observed by confocal microscopy. This study not only demonstrates a new method for the preparation of luminescent silver nanodendrites using a simple, environmentally friendly biological method, but also indicates the ability of CA, a potent HIV-integrase inhibitor, to interact with silver ions which may shed light on its potential for additional biomedical and biosensor applications.
C1 [Barnaby, Stacey N.; Sarker, Nazmul H.; Banerjee, Ipsita A.] Fordham Univ, Dept Chem, Bronx, NY 10458 USA.
   [Tsiola, Areti] CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA.
RP Barnaby, SN (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM banerjee@fordham.edu
FU Office Fordham University Faculty Research Grant; Fordham University
   Summer Science Internship program
FX This work was conducted in part using equipment from the Queens College
   Facilities for Imaging, Cell and Molecular Biology. The financial
   support provided by the Dean's Office Fordham University Faculty
   Research Grant is acknowledged (IB). SB and NS thank the Fordham
   University Summer Science Internship program for financial support.
CR Aguirre CM, 2009, NANO LETT, V9, P1457, DOI 10.1021/nl8033152
   Aslan K, 2005, ANAL BIOANAL CHEM, V382, P926, DOI 10.1007/s00216-005-3195-3
   Bali R, 2010, IND ENG CHEM RES, V49, P12762, DOI 10.1021/ie101600m
   Bohren CF, 1983, ABSORPTION SCATTERIN
   Brown S, 2000, J MOL BIOL, V299, P725, DOI 10.1006/jmbi.2000.3682
   Charlton A J, 2000, J CHEM SOC P2, V29, P317
   Cheng CW, 2010, ACS APPL MATER INTER, V2, P1824, DOI 10.1021/am100270b
   Colfen H, 2003, ANGEW CHEM INT EDIT, V42, P2350, DOI 10.1002/anie.200200562
   Dick KA, 2004, J CRYST GROWTH, V272, P131, DOI 10.1016/j.jcrysgro.2004.09.004
   Dick KA, 2004, NAT MATER, V3, P380, DOI 10.1038/nmat1133
   Dong J, 2007, P NATL ACAD SCI USA, V104, P13313, DOI 10.1073/pnas.0702669104
   Fan FR, 2009, CRYST GROWTH DES, V9, P2335, DOI 10.1021/cg801231p
   Fang JX, 2007, CRYST GROWTH DES, V7, P864, DOI 10.1021/cg0604879
   Fazary AE, 2009, J CHEM ENG DATA, V54, P35, DOI 10.1021/je800441u
   Feldheim DL, 2007, ACS NANO, V1, P154, DOI 10.1021/nn7002019
   Fu Y, 2008, LANGMUIR, V24, P3429, DOI 10.1021/la702673p
   Gardea-Torresdey JL, 2003, LANGMUIR, V19, P1357, DOI 10.1021/la020835i
   Giljohann DA, 2010, ANGEW CHEM INT EDIT, V49, P3280, DOI 10.1002/anie.200904359
   Goritz M, 2005, J AM CHEM SOC, V127, P18016, DOI 10.1021/ja056463s
   Gulley-Stahl H, 2010, ENVIRON SCI TECHNOL, V44, P4116, DOI 10.1021/es902040u
   Guo Z, 2011, LANGMUIR, V27, P6193, DOI 10.1021/la104979x
   Haes AJ, 2004, J PHYS CHEM B, V108, P109, DOI 10.1021/jp0361327
   Hasobe T, 2006, J PHYS CHEM B, V110, P25477, DOI 10.1021/jp064845u
   Hider RC, 2001, METHOD ENZYMOL, V335, P190
   Hu JQ, 2005, ADV MATER, V17, P971, DOI 10.1002/adma.200401789
   Huang T, 2010, LANGMUIR, V26, P7582, DOI 10.1021/la904393n
   Huang Y, 2005, NANO LETT, V5, P1429, DOI 10.1021/nl050795d
   Imai H, 2005, CRYST GROWTH DES, V5, P1073, DOI 10.1021/cg0496585
   Jacob JA, 2008, LANGMUIR, V24, P528, DOI 10.1021/la702073r
   Jung YJ, 2001, CARBON, V39, P2195, DOI 10.1016/S0008-6223(01)00041-0                                                   
   Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l
   Kai D, 2011, J MATER ENG PERFORM, V21, P353
   Kawasaki JK, 2011, NANO LETT, V11, P781, DOI 10.1021/nl1039956
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Kerker M, 1969, SCATTERING LIGHT OTH
   Kotal A, 2010, LANGMUIR, V26, P6576, DOI 10.1021/la903923q
   Leopoldini M, 2004, J PHYS CHEM A, V108, P4916, DOI 10.1021/jp037247d
   Li HB, 2011, J ALLOY COMPD, V509, P2111, DOI 10.1016/j.jallcom.2010.10.159
   Licini G, 2003, ANGEW CHEM INT EDIT, V42, P4572, DOI 10.1002/anie.200301668
   Lim R, 2009, SCIENCE, V324, P1302
   Lin ZW, 1999, J MED CHEM, V42, P1401, DOI 10.1021/jm980531m
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Liu F, 2010, PHYS SCRIPTA, VT139, DOI 10.1088/0031-8949/2010/T139/014074
   Liu JW, 2007, CARBON, V45, P681, DOI 10.1016/j.carbon.2006.11.026
   Lofton C, 2005, ADV FUNCT MATER, V15, P1197, DOI 10.1002/adfm.200400091
   Lu LT, 2008, J MATER CHEM, V18, P2453, DOI 10.1039/b801800f
   McDonald M, 1996, J AGR FOOD CHEM, V44, P599, DOI 10.1021/jf950459q
   Meng GW, 2005, P NATL ACAD SCI USA, V102, P7074, DOI 10.1073/pnas.0502098102
   Mie G, 1908, ANN PHYS, V25, P377
   Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695
   Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479
   Mouxing F.U., 2006, CHINESE J CHEM ENG, V14, P114, DOI DOI 10.1016/S1004-9541(06)60046-3
   Mukherjee P, 2001, NANO LETT, V1, P515, DOI 10.1021/nl0155274
   Naik RR, 2002, NAT MATER, V1, P169, DOI 10.1038/nmat758
   Nakayama M, 1999, ANAL SCI, V15, P259, DOI 10.2116/analsci.15.259                                                          
   Nam KT, 2008, ACS NANO, V2, P1480, DOI 10.1021/nn800018n
   Nandwana V, 2007, J PHYS CHEM C, V111, P4185, DOI 10.1021/jp068330e
   Otte MA, 2010, ACS NANO, V4, P349, DOI 10.1021/nn901024e
   Penn RL, 1998, SCIENCE, V281, P969, DOI 10.1126/science.281.5379.969                                                    
   Risveden K, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/5/055102
   Robinson WE, 1998, ANTIVIR RES, V39, P101
   Sarikaya M, 1999, P NATL ACAD SCI USA, V96, P14183, DOI 10.1073/pnas.96.25.14183                                                        
   Scher EC, 2003, PHILOS T ROY SOC A, V361, P241, DOI 10.1098/rsta.2002.1126
   Shibuya M, 2009, CHEM PHYS LETT, V473, P126, DOI 10.1016/j.cplett.2009.03.043
   Song YJ, 2004, J AM CHEM SOC, V126, P635, DOI 10.1021/ja037474t
   Stampfer C, 2006, NANO LETT, V6, P1449, DOI 10.1021/nl0606527
   Sun SH, 2007, CHEM-EUR J, V13, P9087, DOI 10.1002/chem.200700448
   Tao AR, 2008, SMALL, V4, P310, DOI 10.1002/smll.200701295
   Teng F, 2010, J CRYST GROWTH, V312, P3493, DOI 10.1016/j.jcrysgro.2010.09.005
   Teranishi T, 2000, J INORG ORGANOMET P, V10, P145, DOI 10.1023/A:1009476128466                                                         
   Wang DL, 2003, NAT MATER, V2, P355, DOI 10.1038/nmat908
   Wang XQ, 2002, CHEM COMMUN, P1300, DOI 10.1039/b203185j
   Wei GD, 2003, CHEM MATER, V15, P4436, DOI 10.1021/cm034628v
   Wen XG, 2006, LANGMUIR, V22, P4836, DOI 10.1021/la060267x
   Xiao JP, 2001, ADV MATER, V13, P1887, DOI 10.1002/1521-4095(200112)13:24<1887::AID-ADMA1887>3.0.CO;2-2                    
   Yang LB, 2009, MATER RES BULL, V44, P1270, DOI 10.1016/j.materresbull.2009.01.002
   Yang XA, 2010, CHEM COMMUN, V46, P8818, DOI 10.1039/c0cc03280h
   Yao WT, 2006, J PHYS CHEM B, V110, P11704, DOI 10.1021/jp060164n
   Yao ZY, 2007, CARBON, V45, P1566, DOI 10.1016/j.carbon.2007.02.030
   Yoosaf K, 2007, J PHYS CHEM C, V111, P12839, DOI 10.1021/jp073923q
   Zheng JF, 2008, MATER LETT, V62, P4069, DOI 10.1016/j.matlet.2008.05.013
   Zhou J, 2002, CHEM PHYS LETT, V365, P505, DOI 10.1016/S0009-2614(02)01456-2
   Zhou Y, 1999, ADV MATER, V11, P850, DOI 10.1002/(SICI)1521-4095(199907)11:10<850::AID-ADMA850>3.0.CO;2-Z
NR 83
TC 3
Z9 3
U1 0
U2 18
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD JUL 27
PY 2012
VL 23
IS 29
AR 294011
DI 10.1088/0957-4484/23/29/294011
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 968IT
UT WOS:000305972900012
PM 22744213
DA 2018-01-05
ER

PT J
AU Parai, MK
   Huggins, DJ
   Cao, H
   Nalam, MNL
   Ali, A
   Schiffer, CA
   Tidor, B
   Rana, TM
AF Parai, Maloy Kumar
   Huggins, David J.
   Cao, Hong
   Nalam, Madhavi N. L.
   Ali, Akbar
   Schiffer, Celia A.
   Tidor, Bruce
   Rana, Tariq M.
TI Design, Synthesis, and Biological and Structural Evaluations of Novel
   HIV-1 Protease Inhibitors To Combat Drug Resistance
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DEAD-END ELIMINATION; X-RAY; BINDING;
   DISCOVERY; SUBSTRATE; TMC114; POTENT; THERAPY; ENERGY
AB A series of new HIV-1 protease inhibitors (PIs) were designed using a general strategy that combines computational structure-based design with substrate-envelope constraints. The PIs incorporate various alcohol-derived P2 carbamates with acyclic and cyclic heteroatomic functionalities into the (R)-hydroxyethylamine isostere. Most of the new PIs show potent binding affinities against wild-type HIV-1 protease and three multidrug resistant (MDR) variants. In particular, inhibitors containing the 2,2-dichloroacetamide, pyrrolidinone, imidazolidinone, and oxazolidinone moieties at P2 are the most potent with K-i values in the picomolar range. Several new PIs exhibit nanomolar antiviral potencies against patient-derived wild-type viruses from HIV-1 clades A, B, and C and two MDR variants. Crystal structure analyses of four potent inhibitors revealed that carbonyl groups of the new P2 moieties promote extensive hydrogen bond interactions with the invariant Asp29 residue of the protease. These structure activity relationship findings can be utilized to design new Pis with enhanced enzyme inhibitory and antiviral potencies.
C1 [Parai, Maloy Kumar; Rana, Tariq M.] Sanford Burnham Med Res Inst, Program RNA Biol, La Jolla, CA 92037 USA.
   [Huggins, David J.; Tidor, Bruce] MIT, Dept Biol Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Huggins, David J.; Tidor, Bruce] MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA.
   [Cao, Hong; Ali, Akbar; Rana, Tariq M.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Chem Biol Program, Worcester, MA 01605 USA.
RP Rana, TM (reprint author), Sanford Burnham Med Res Inst, Program RNA Biol, La Jolla, CA 92037 USA.
EM trana@sanfordburnham.org
OI Huggins, David/0000-0003-1579-2496
FU National Institutes of General Medical Sciences of the NIH [GM066524,
   GM082209, AI41404, A143198]; U.S. Department of Energy, Basic Energy
   Sciences, Office of Science [DE-AC02-06CH11357]; National Institutes of
   Health, National Center for Research Resources [RR007707]
FX This research was supported in part by grants from the National
   Institutes of General Medical Sciences of the NIH (Grants GM066524,
   GM082209, AI41404, A143198). We thank Kaneka USA for their generous
   gifts of chiral epoxides, Ellen A. Nalivaika for providing the wild-type
   and MDR HIV-1 proteases, the AIDS Research and Reference Reagent Program
   (NIAD, NIH) for reference protease inhibitors, Monogram Biosciences for
   antiviral testing, and members of the Rana, Tidor, and Schiffer
   laboratories for helpful discussions, particularly Dr. Huricha Baigude
   for his help in HPLC data collection. In addition, we thank Kuan Hung
   Lin for his help in the refinement of the wild-type protease complex of
   13c and Shivender Shandilya for collecting the data on complexes of 13f,
   13g, and 14j with the wild-type protease at BioCARS beamline of the
   Advanced Photon Source, Argonne National Laboratory, IL. Use of the
   Advanced Photon Source for X-ray data collection was supported by the
   U.S. Department of Energy, Basic Energy Sciences, Office of Science,
   under Contract DE-AC02-06CH11357. Use of the BioCARS Sector 14 was
   supported by the National Institutes of Health, National Center for
   Research Resources, under Grant RR007707.
CR Ali A, 2006, J MED CHEM, V49, P7342, DOI 10.1021/jm060666p
   Ali A, 2010, J MED CHEM, V53, P7699, DOI 10.1021/jm1008743
   Altman MD, 2008, J AM CHEM SOC, V130, P6099, DOI 10.1021/ja076558p
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
   Bissantz C, 2010, J MED CHEM, V53, P5061, DOI 10.1021/jm100112j
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Freire E, 2008, DRUG DISCOV TODAY, V13, P869, DOI 10.1016/j.drudis.2008.07.005
   Ghosh AK, 2008, J MED CHEM, V51, P6021, DOI 10.1021/jm8004543
   Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m
   Ghosh AK, 2011, J MED CHEM, V54, P622, DOI 10.1021/jm1012787
   GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104
   GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407
   GRECO WR, 1979, J BIOL CHEM, V254, P2104
   Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007
   He GX, 2011, MEDCHEMCOMM, V2, P1093, DOI 10.1039/c1md00147g
   Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450                                                          
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+
   Kangas E, 1998, J CHEM PHYS, V109, P7522, DOI 10.1063/1.477375
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   King NM, 2002, PROTEIN SCI, V11, P418, DOI 10.1110/ps.25502
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c
   KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P2773, DOI 10.1073/pnas.88.7.2773
   Leach AR, 1998, PROTEINS, V33, P227, DOI 10.1002/(SICI)1097-0134(19981101)33:2<227::AID-PROT7>3.0.CO;2-F                 
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035
   MOMANY FA, 1992, J COMPUT CHEM, V13, P888, DOI 10.1002/jcc.540130714
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Nalam MNL, 2010, J VIROL, V84, P5368, DOI 10.1128/JVI.02531-09
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405                                                           
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7
   SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   Surleraux DLNG, 2005, J MED CHEM, V48, P1965, DOI 10.1021/jm049454m
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   Tickle I.J., 1999, IUCR99 COMPUTING SCH
   Waters L, 2007, INT J CLIN PRACT, V61, P983, DOI 10.1111/j.1742-1241.2007.01383.x
   Wu TD, 2003, J VIROL, V77, P4836, DOI 10.1128/JVI.77.8.4836-4847.2003
NR 50
TC 19
Z9 20
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 26
PY 2012
VL 55
IS 14
BP 6328
EP 6341
DI 10.1021/jm300238h
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 978SA
UT WOS:000306764600007
PM 22708897
OA green_accepted
DA 2018-01-05
ER

PT J
AU La Regina, G
   Coluccia, A
   Brancale, A
   Piscitelli, F
   Famiglini, V
   Cosconati, S
   Maga, G
   Samuele, A
   Gonzalez, E
   Clotet, B
   Schols, D
   Este, JA
   Novellino, E
   Silvestri, R
AF La Regina, Giuseppe
   Coluccia, Antonio
   Brancale, Andrea
   Piscitelli, Francesco
   Famiglini, Valeria
   Cosconati, Sandro
   Maga, Giovanni
   Samuele, Alberta
   Gonzalez, Emmanuel
   Clotet, Bonaventura
   Schols, Dominique
   Este, Jose A.
   Novellino, Ettore
   Silvestri, Romano
TI New Nitrogen Containing Substituents at the Indole-2-carboxamide Yield
   High Potent and Broad Spectrum Indolylarylsulfone HIV-1 Non-Nucleoside
   Reverse Transcriptase Inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID INDOLYL ARYL SULFONES; RESISTANCE MUTATIONS; ANTI-HIV-1 ACTIVITY;
   DRUG-RESISTANCE; WILD-TYPE; DERIVATIVES; DISCOVERY; INFECTION; DESIGN;
   VIRUS
AB New indolylarylsulfone (IAS) derivatives bearing nitrogen containing substituents at the indole-2-carboxamide inhibited the HIV-1 WT in MT-4 cells at low nanomolar concentrations. In particular, compound 9 was uniformly effective against the mutant Y181C, Y188L, and K103N HIV-1 strains; it was highly active against the multidrug resistant mutant IRLL98 HIV-1 strain bearing the K101Q, Y181C, and G190A mutations conferring resistance to NVP, DLV, and EFV and several HIV-1 clades A in PBMC.
C1 [La Regina, Giuseppe; Coluccia, Antonio; Piscitelli, Francesco; Famiglini, Valeria; Silvestri, Romano] Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy.
   [Brancale, Andrea] CNR, Ist Chim Biomol, I-00185 Rome, Italy.
   [Brancale, Andrea] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales.
   [Maga, Giovanni; Samuele, Alberta] CNR, Inst Mol Genet IGM CNR, I-27100 Pavia, Italy.
   [Gonzalez, Emmanuel; Clotet, Bonaventura; Este, Jose A.] Univ Autonoma Barcelona, IrsiCaixa, Hosp Univ Germans Trias & Pujol, Badalona 08916, Spain.
   [Schols, Dominique] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   [Novellino, Ettore] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   [Cosconati, Sandro] Univ Naples 2, Dipartimento Sci Ambientali, I-81100 Caserta, Italy.
RP Silvestri, R (reprint author), Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM romano.silvestri@uniroma1.it
RI Schols, Dominique/S-9057-2017; Este, Jose/B-5509-2008; Brancale,
   Andrea/N-9445-2014; La Regina, Giuseppe/I-2161-2012
OI Schols, Dominique/0000-0003-3256-5850; Este, Jose/0000-0002-1436-5823;
   Brancale, Andrea/0000-0002-9728-3419; La Regina,
   Giuseppe/0000-0003-3252-1161; Silvestri, Romano/0000-0003-2489-0178;
   Cosconati, Sandro/0000-0002-8900-0968; Novellino,
   Ettore/0000-0002-2181-2142; /0000-0002-7940-8206
FU Istituto Pasteur-Fondazione Cenci Bolognetti [2009]; Finanziaria Laziale
   di Sviluppo (FILAS) [2010]; Spanish MICINN [BFU2009-06958,
   SAF201021617-C02]; K.U. Leuven (GOA) [10/014, PE/10/018]; FWO [G.485.08]
FX We are indebted to Istituto Pasteur-Fondazione Cenci Bolognetti (grant
   2009), Finanziaria Laziale di Sviluppo (FILAS, grant 2010), and the
   Spanish MICINN (projects BFU2009-06958 and SAF201021617-C02) for
   financial support. This work was supported by the K.U. Leuven (GOA no.
   10/014 and PE/10/018) and the FWO (no. G.485.08), and we are grateful to
   S. Claes and E. Fonteyn for excellent technical assistance. A.C. thanks
   Istituto Pasteur-Fondazione Cenci Bolognetti for his Borsa di Studio per
   Ricerche in Italia.
CR Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   Cortez KJ, 2011, VIRUSES-BASEL, V3, P347, DOI 10.3390/v3040347
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Haubrich R, 2008, NAT REV DRUG DISCOV, V7, P287, DOI 10.1038/nrd2563
   Howkins T., 2010, ANTIVIR RES, V85, P201
   La G. Regina, 2010, ANTIVIR CHEM CHEMOTH, V20, P231
   La Regina R, 2011, J MED CHEM, V54, P1587
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Piscitelli F, 2009, J MED CHEM, V52, P1922, DOI 10.1021/jm801470b
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2006, J MED CHEM, V49, P3172, DOI 10.1021/jm0512490
   Silvestri R, 2004, J MED CHEM, V47, P3892, DOI 10.1021/jm031147e
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   World Health Organisation (WHO), 2011, PROGRESS REPORT 2011
NR 17
TC 23
Z9 23
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 26
PY 2012
VL 55
IS 14
BP 6634
EP 6638
DI 10.1021/jm300477h
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 978SA
UT WOS:000306764600035
PM 22712652
DA 2018-01-05
ER

PT J
AU Pearce, TR
   Shroff, K
   Kokkoli, E
AF Pearce, Timothy R.
   Shroff, Kamlesh
   Kokkoli, Efrosini
TI Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery
SO ADVANCED MATERIALS
LA English
DT Review
DE peptides; lipid nanoparticles; liposomes; cancer; drug delivery
ID FIBRONECTIN-MIMETIC PEPTIDE; EPIDERMAL-GROWTH-FACTOR; CELL-ADHESION
   MOLECULE; HUMAN IMMUNODEFICIENCY VIRUS; FUSION COAT PROTEIN;
   BREAST-CANCER CELLS; IN-VIVO; TUMOR-CELLS; INTRACELLULAR DELIVERY;
   LIPOSOMAL DOXORUBICIN
AB Encapsulating anticancer drugs in nanoparticles has proven to be an effective mechanism to alter the pharmacokinetic and pharmacodynamic profiles of the drugs, leading to clinically useful cancer therapeutics like Doxil and DaunoXome. Underdeveloped tumor vasculature and lymphatics allow these first-generation nanoparticles to passively accumulate within the tumor, but work to create the next-generation nanoparticles that actively participate in the tumor targeting process is underway. Lipid nanoparticles functionalized with targeting peptides are among the most often studied. The goal of this article is to review the recently published literature of targeted nanoparticles to highlight successful designs that improved in vivo tumor therapy, and to discuss the current challenges of designing these nanoparticles for effective in vivo performance.
C1 [Shroff, Kamlesh; Kokkoli, Efrosini] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.
   [Pearce, Timothy R.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
RP Kokkoli, E (reprint author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.
EM kokkoli@umn.edu
RI Kokkoli, Efrosini/J-1656-2015; Shroff, Kamlesh/I-2512-2012
OI Kokkoli, Efrosini/0000-0001-7783-0158; Shroff,
   Kamlesh/0000-0001-5730-9779
FU CAREER award [NSF/CBET-0846274]
FX This work was supported by the CAREER award NSF/CBET-0846274.
CR Accardo A, 2010, MOL BIOSYST, V6, P878, DOI 10.1039/b923147a
   Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   American Cancer Society, 2011, CANC FACT FIG 2011
   Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018
   Atchison NA, 2010, LANGMUIR, V26, P14081, DOI 10.1021/la101264h
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525
   Blanco E, 2011, CANCER SCI, V102, P1247, DOI 10.1111/j.1349-7006.2011.01941.x
   Bogdanowich-Knipp SJ, 1999, J PEPT RES, V53, P530, DOI 10.1034/j.1399-3011.1999.00052.x
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471                                                              
   Chang DK, 2009, J BIOL CHEM, V284, P12905, DOI 10.1074/jbc.M900280200
   Chang DK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004171
   Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4
   Chen XA, 2010, J CONTROL RELEASE, V145, P17, DOI 10.1016/j.jconrel.2010.03.007
   Choi CHJ, 2011, P NATL ACAD SCI USA, V108, P6656, DOI 10.1073/pnas.1103573108
   Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI [10.1038/nbt1340, 10.1038/nbtl340]
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   Colombo G, 2002, J BIOL CHEM, V277, P47891, DOI 10.1074/jbc.M207500200
   Dai WB, 2010, J DRUG TARGET, V18, P254, DOI 10.3109/10611860903353354
   Demirgoz D, 2008, LANGMUIR, V24, P13518, DOI 10.1021/la801961r
   Demirgoz D, 2009, SOFT MATTER, V5, P2011, DOI 10.1039/b814217c
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Du HR, 2011, MOL PHARMACEUT, V8, P1224, DOI 10.1021/mp200039s
   Dubey PK, 2010, J DRUG TARGET, V18, P373, DOI 10.3109/10611860903483388
   Ellis LM, 2003, AM SURGEON, V69, P3
   Falciani C, 2011, CHEMMEDCHEM, V6, P678, DOI 10.1002/cmdc.201000463
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Filmore D., 2004, MODERN DRUG DISCOVER, V7, P4
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Garg A, 2011, CURR PHARM BIOTECHNO, V12, P1135, DOI 10.2174/138920111796117328                                                      
   Garg A, 2009, INT J PHARM, V366, P201, DOI 10.1016/j.ijpharm.2008.09.016
   GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151
   Goutayer M, 2010, EUR J PHARM BIOPHARM, V75, P137, DOI 10.1016/j.ejpb.2010.02.007
   Grange C, 2010, CANCER RES, V70, P2180, DOI 10.1158/0008-5472.CAN-09-2821
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gross-Goupil M, 2012, CURR UROL REP, V13, P16, DOI 10.1007/s11934-011-0232-y
   Guo NH, 1997, J PEPT RES, V50, P210
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hallahan D, 2003, CANCER CELL, V3, P63, DOI 10.1016/S1535-6108(02)00238-6
   Han Z, 2008, NAT MED, V14, P343, DOI 10.1038/nm1691
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9                                                   
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843
   He XF, 2011, MOL PHARMACEUT, V8, P430, DOI 10.1021/mp100266g
   He YN, 2010, INT J NANOMED, V5, P697
   Helbok A, 2012, NANOMED-NANOTECHNOL, V8, P112, DOI 10.1016/j.nano.2011.04.012
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Herringson TP, 2011, INT J PHARMACEUT, V411, P206, DOI 10.1016/j.ijpharm.2011.03.044
   Herringson TP, 2011, J DRUG TARGET, V19, P681, DOI 10.3109/1061186X.2010.536984
   Herringson TP, 2009, J CONTROL RELEASE, V139, P229, DOI 10.1016/j.jconrel.2009.06.034
   Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003                                                
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Jayanna PK, 2010, NANOMED-NANOTECHNOL, V6, P538, DOI 10.1016/j.nano.2010.01.005
   Jensen M, 2007, CANCER LETT, V258, P9, DOI 10.1016/j.canlet.2007.09.004
   Jia YF, 2004, CANCER RES, V64, P8674, DOI 10.1158/0008-5472.CAN-04-0069
   Jiang JA, 2010, EUR J PHARM BIOPHARM, V76, P170, DOI 10.1016/j.ejpb.2010.06.011
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kang MJ, 2011, CHEM PHARM BULL, V59, P109, DOI 10.1248/cpb.59.109                                                              
   Katanasaka Y, 2010, INT J CANCER, V127, P2685, DOI 10.1002/ijc.25276
   Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100
   Khan IU, 2008, ANTI-CANCER AGENT ME, V8, P186
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kokkoli E, 2006, SOFT MATTER, V2, P1015, DOI 10.1039/b608929a
   Krebs LJ, 2000, CANCER RES, V60, P4194
   Kuai R, 2011, MOL PHARMACEUT, V8, P2151, DOI 10.1021/mp200100f
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101
   Leamon CP, 2003, BIOCONJUGATE CHEM, V14, P738, DOI 10.1021/bc020089t
   Li W, 2011, EUR J RADIOL, V80, P598, DOI 10.1016/j.ejrad.2011.01.051
   Liu XY, 2010, INT J MED SCI, V7, P197
   Loi M, 2010, J CONTROL RELEASE, V145, P66, DOI 10.1016/j.jconrel.2010.03.015
   LoRusso PM, 2011, CLIN CANCER RES, V17, P5774, DOI 10.1158/1078-0432.CCR-11-0972
   Lowery A, 2011, J CONTROL RELEASE, V150, P117, DOI 10.1016/j.jconrel.2010.11.006
   Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06
   Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
   Mai JH, 2009, J CONTROL RELEASE, V139, P174, DOI 10.1016/j.jconrel.2009.06.024
   Mamasheva Elina, 2011, Mol Pharm, V8, P2224, DOI 10.1021/mp200079y
   Marchio S, 2004, CANCER CELL, V5, P151, DOI 10.1016/S1535-6108(04)00025-X                                                   
   Mardilovich A, 2006, LANGMUIR, V22, P3259, DOI 10.1021/la052756n
   Markwalder R, 1999, CANCER RES, V59, P1152
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Meng SY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/41/415103
   Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200
   Missirlis D, 2010, MOL PHARMACEUT, V7, P2173, DOI 10.1021/mp100193h
   MOGHIMI SM, 1991, BIOCHEM BIOPH RES CO, V177, P861, DOI 10.1016/0006-291X(91)91869-E
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Morisco A, 2011, BIOPOLYMERS, V96, P88, DOI 10.1002/bip.21491
   Mulder WJM, 2009, ANGIOGENESIS, V12, P17, DOI 10.1007/s10456-008-9124-2
   Mulder WJM, 2006, NANO LETT, V6, P1, DOI 10.1021/nl051935m
   Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007
   Murase Y, 2010, CANCER LETT, V287, P165, DOI 10.1016/j.canlet.2009.06.008
   Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5
   Negussie AH, 2010, J CONTROL RELEASE, V143, P265, DOI 10.1016/j.jconrel.2009.12.031
   Oku N, 2002, ONCOGENE, V21, P2662, DOI 10.1038/sj/onc/1205347
   OLSEN JO, 1995, SEMIN NUCL MED, V25, P251, DOI 10.1016/S0001-2998(95)80014-X
   Oumzil K, 2011, J CONTROL RELEASE, V151, P123, DOI 10.1016/j.jconrel.2011.02.008
   Pangburn TO, 2012, SOFT MATTER, V8, P4449, DOI 10.1039/c2sm06922a
   Pangburn TO, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3160763
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Park JH, 2010, P NATL ACAD SCI USA, V107, P981, DOI 10.1073/pnas.0909565107
   Partanen J, 1999, CURR TOP MICROBIOL, V237, P159
   Pasqualini R, 2000, CANCER RES, V60, P722
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Pinedo H., 2006, DRUGS AFFECTING GROW
   Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165
   Rivera-Fillat MP, 2010, J PEPT SCI, V16, P315, DOI 10.1002/psc.1241
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Safra T, 2003, ONCOLOGIST, V8, P17
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Schally AV, 2001, FRONT NEUROENDOCRIN, V22, P248, DOI 10.1006/frne.2001.0217                                                          
   Schluep T, 2009, P NATL ACAD SCI USA, V106, P11394, DOI 10.1073/pnas.0905487106
   Schroeder A, 2010, J INTERN MED, V267, P9, DOI 10.1111/j.1365-2796.2009.02189.x
   Schroeder JE, 2007, J CONTROL RELEASE, V124, P28, DOI 10.1016/j.jconrel.2007.08.028
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Shroff K, 2012, LANGMUIR, V28, P4729, DOI 10.1021/la204466g
   Shroff K, 2012, LANGMUIR, V28, P1858, DOI 10.1021/la203322t
   Smith CJ, 2005, NUCL MED BIOL, V32, P733, DOI 10.1016/j.nucmelbio.2005.05.005
   Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d                                                               
   Sofou S, 2008, EXPERT OPIN DRUG DEL, V5, P189, DOI 10.1517/17425247.5.2.189
   Song SX, 2009, FASEB J, V23, P1396, DOI 10.1096/fj.08-117002
   Stubblefield MD, 2009, CANC REHABILITATION
   Takara K, 2010, INT J PHARMACEUT, V396, P143, DOI 10.1016/j.ijpharm.2010.05.002
   Terada T, 2006, J DRUG TARGET, V14, P536, DOI 10.1080/10611860600849498
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tournaire R, 2004, EMBO REP, V5, P262, DOI 10.1038/sj.embor.7400100
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060
   Volante M, 2008, MOL CELL ENDOCRINOL, V286, P219, DOI 10.1016/j.mce.2007.12.002
   Wang J, 2011, SMALL, V7, P1919, DOI 10.1002/smll.201100442
   Wang T, 2010, MOL PHARMACEUT, V7, P1149, DOI 10.1021/mp1000229
   Wang T, 2010, NANOMEDICINE-UK, V5, P563, DOI 10.2217/NNM.10.30
   Wang XH, 2011, J PHARM SCI-US, V100, P1196, DOI 10.1002/jps.22348
   Wang ZJ, 2011, IUBMB LIFE, V63, P659, DOI 10.1002/iub.485
   WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628
   Xu J, 2010, NATL VITAL STAT REPO
   YAMAMURA K, 1993, SEMIN CANCER BIOL, V4, P259
   Yan Z., 2011, J CONTROL RELEASE, V157, P118
   Yan ZQ, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/41/415103
   Yauch RL, 2012, CURR OPIN GENET DEV, V22, P45, DOI 10.1016/j.gde.2012.01.003
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
   Zhang JL, 2010, MOL PHARMACEUT, V7, P1159, DOI 10.1021/mp1000235
   Zhang N., 2010, CRITICAL REV THERAPE, V27, P371
   Zhang YF, 2010, EUR J PHARM BIOPHARM, V74, P467, DOI 10.1016/j.ejpb.2010.01.002
   Zhao H, 2009, J DRUG TARGET, V17, P10, DOI 10.1080/10611860802368966 
NR 156
TC 95
Z9 95
U1 3
U2 136
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD JUL 24
PY 2012
VL 24
IS 28
SI SI
BP 3803
EP 3822
DI 10.1002/adma.201200832
PG 20
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 975BH
UT WOS:000306481200006
PM 22674563
DA 2018-01-05
ER

PT J
AU Nakayama, Y
AF Nakayama, Yasuhide
TI Hyperbranched Polymeric "Star Vectors" for Effective DNA or siRNA
   Delivery
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; GENE DELIVERY; RADICAL
   POLYMERIZATION; COATING MATERIAL; VIVO; TRANSFECTION; COPOLYMERS;
   POLYETHYLENIMINE; PHOTOCHEMISTRY
AB Although gene therapy offers an attractive strategy for treating inherited disorders, current techniques using viral and nonviral delivery systems have not yielded many successful results in clinical trials. Viral vectors such as retroviruses, lentiviruses, and adenoviruses deliver genes efficiently; however, the possibility of negative outcomes from viral transformation cannot be completely ruled out In contrast, various types of nonviral vectors are attracting considerable attention because they are easier to handle and induce weak immune responses.
   Cationic polymers, such as polyethylenimine (PEI) and poly(N,N-dimethylaminopropyl acrylamide) (PDMAPAAm), can generate nanoparticles through the formation of polyion complexes, "polyplexes" with DNA. These nonviral systems offer many advantages over viral systems. The primary obstacle to implementing these cationic polymers in an effective gene therapy remains their comparatively inefficient gene transfection in vivo.
   We describe four strategies for the development of hyperbranched star vectors (SVs) for enhancing DNA or siRNA delivery. The molecular design was performed by living radical polymerization in which the chain length can be controlled by photoirradiation and solution conditions, including concentrations of the monomer or iniferter (a molecule that serves as a combination of initiator, transfer agent, and terminator). The branch composition is controlled by the types of monomers that are added stepwise. In our first strategy, we prepared a series of only cationic PDMAPAAm-based SVs with no brandies or 3, 4, or 6 branching numbers. These SVs could form polyion complexes (polyplexes) by mixing with DNA only in aqueous solution. The relative gene expression activity of the delivered DNA increased according to the degree of branching In addition, increasing the molecular weight of SVs and narrowing their polydispersity index (PDI) Improved their activity. For targeting DNA delivery to the specific cells, we modified the SV with ligands. Interestingly, the SV could adsorb the RGD peptide, making gene transfer possible in endothelial cells which are usually refractory to such treatments. The peptide was added to the polyplex solution without covalent derivatization to the SV. me introduction of additional branching by cross-linking using iniferter-incluced coupling reactions further improved gene transfection activity. After block copolymerization of PDMAPAAm-based SVs with a nonionic monomer (DMAAm), the blocked SVs (BSVs) produced polyplexes with DNA that had excellent colloidal stability for 1 month, leading to efficient in vitro and In vivo gene delivery. Moreover, BSVs served as carriers for siRNA delivery. BSVs enhanced siRNA-mediated gene silencing in mouse liver and lung. As an alternative approach, we developed a novel gene transfection method in which the polyplexes were kept in contact with their deposition surface by thermoresponsive blocking of the W. This strategy was more effective than reverse transfection and the conventional transfection methods in solution.
C1 Natl Cerebral & Cardiovasc Ctr, Res Inst, Div Med Engn & Mat, Suita, Osaka 5658565, Japan.
RP Nakayama, Y (reprint author), Natl Cerebral & Cardiovasc Ctr, Res Inst, Div Med Engn & Mat, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.
EM nakayama@ri.ncvc.go.jp
CR Banerjee P, 2004, BIOCONJUGATE CHEM, V15, P960, DOI 10.1021/bc0342128
   Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499
   Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2
   Bielinska AU, 2000, BIOMATERIALS, V21, P877, DOI 10.1016/S0142-9612(99)00229-X
   Brodbeck WG, 2002, P NATL ACAD SCI USA, V99, P10287, DOI 10.1073/pnas.162124199
   Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Erfle H, 2007, NAT PROTOC, V2, P392, DOI 10.1038/nprot.2006.483
   Gosselin MA, 2001, BIOCONJUGATE CHEM, V12, P989, DOI 10.1021/bc0100455
   GRAINGER DW, 1989, J BIOMED MATER RES, V23, P979, DOI 10.1002/jbm.820230903
   Ishikawa A, 2008, BIOCONJUGATE CHEM, V19, P558, DOI 10.1021/bc700385r
   Iwai R., 2012, BIOCONJUGAT IN PRESS
   Kichise T, 2002, APPL ENVIRON MICROB, V68, P2411, DOI 10.1128/AEM.68.5.2411-2419.2002
   Kim WJ, 2005, J CONTROL RELEASE, V106, P224, DOI 10.1016/j.jconrel.2005.04.016
   Kircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
   Kumashiro Y, 2010, ANN BIOMED ENG, V38, P1977, DOI 10.1007/s10439-010-0035-1
   Kurisawa M, 2000, J CONTROL RELEASE, V69, P127, DOI 10.1016/S0168-3659(00)00297-2
   Kurowska-Latallo J.F., 1996, P NATL ACAD SCI USA, V93, P4897
   LEE JH, 1989, J BIOMED MATER RES, V23, P351, DOI 10.1002/jbm.820230306                                                           
   LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0                                                                
   Matsuda T, 2003, BIOMATERIALS, V24, P4517, DOI 10.1016/S0142-9612(03)00344-2
   Mizoguchi I, 2005, BIOCHEM BIOPH RES CO, V338, P1499, DOI 10.1016/j.bbrc.2005.10.112
   Mori T, 2009, BIOCONJUGATE CHEM, V20, P1262, DOI 10.1021/bc9001294
   Nagasaki T, 2003, BIOCONJUGATE CHEM, V14, P513, DOI 10.1021/bc0256603
   Nakayama Y, 1996, MACROMOLECULES, V29, P8622, DOI 10.1021/ma9606014                                                               
   Nakayama Y, 2002, LANGMUIR, V18, P2601, DOI 10.1021/la011415g
   Nakayama Y, 1999, LANGMUIR, V15, P5560, DOI 10.1021/la981581x                                                               
   Nakayama Y, 1999, BIOMATERIALS, V20, P963, DOI 10.1016/S0142-9612(98)00252-X
   Nakayama Y, 2007, BIOCONJUGATE CHEM, V18, P2037, DOI 10.1021/bc070045q
   Nakayama Y, 2007, LANGMUIR, V23, P8206, DOI 10.1021/1a700323m
   Nakayama Yasuhide, 2005, Current Drug Delivery, V2, P53, DOI 10.2174/1567201052772825
   Nakayama Y, 2011, BIOCONJUGATE CHEM, V22, P193, DOI 10.1021/bc100267z
   Nakayama Y, 2008, POLYM J, V40, P1060, DOI 10.1295/polymj.PJ2008132
   Nemoto Y, 2008, J POLYM SCI POL CHEM, V46, P4505, DOI 10.1002/pola.22787
   Nemoto Y, 2009, BIOCONJUGATE CHEM, V20, P2293, DOI 10.1021/bc900283h
   Nemoto Y, 2008, BIOCONJUGATE CHEM, V19, P2513, DOI 10.1021/bc800003t
   Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836
   Ohya Shoji, 2004, J Artif Organs, V7, P181
   OTSU T, 1982, MAKROMOL CHEM-RAPID, V3, P133
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Rouslahti E., 1996, ANNU REV CELL DEV BI, V12, P697
   Taguchi T, 2004, BIOCHEM BIOPH RES CO, V320, P18, DOI 10.1016/j.bbrc.2004.05.126
   Umeda Mariko, 2005, Current Drug Delivery, V2, P207, DOI 10.2174/1567201054367986
   Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175
   WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33                                                           
   Zanta MA, 1997, BIOCONJUGATE CHEM, V8, P839, DOI 10.1021/bc970098f                                                               
   Zhong ZY, 2005, BIOMACROMOLECULES, V6, P3440, DOI 10.1021/bm050505n
   Zhou YM, 2005, P ANN INT IEEE EMBS, P501, DOI 10.1109/IEMBS.2005.1616457
   Zhou YM, 2007, J CONTROL RELEASE, V123, P239, DOI 10.1016/j.jconrel.2007.08.026
NR 49
TC 39
Z9 40
U1 5
U2 135
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD JUL 17
PY 2012
VL 45
IS 7
BP 994
EP 1004
DI 10.1021/ar200220t
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 974NH
UT WOS:000306441900006
PM 22353143
DA 2018-01-05
ER

PT J
AU Nakase, I
   Akita, H
   Kogure, K
   Graslund, A
   Langel, U
   Harashima, H
   Futaki, S
AF Nakase, Ikuhiko
   Akita, Hidetaka
   Kogure, Kentaro
   Graslund, Astrid
   Langel, Ulo
   Harashima, Hideyoshi
   Futaki, Shiroh
TI Efficient Intracellular Delivery of Nucleic Acid Pharmaceuticals Using
   Cell-Penetrating Peptides
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID ARGININE-RICH PEPTIDES; MEMBRANE-ASSOCIATED PROTEOGLYCANS; NANO DEVICE
   MEND; INTERNALIZATION MECHANISMS; GENE DELIVERY; PLASMA-MEMBRANE; SIRNA
   DELIVERY; TAT PEPTIDE; IN-VIVO; MACROPINOCYTOSIS
AB Over the last 20 years, researchers have designed or discovered peptides that can permeate membranes and deliver exogenous molecules inside a cell. These peptides, known as cell-penetrating peptides (CPPs), typically consist of 6-30 residues, including HIV TAT peptide, penetratin, oligoarginine, transportan, and TP10. Through chemical conjugation or noncovalent complex formation, these structures successfully deliver bioactive and membrane-impermeable molecules into cells. CPPs have also gained attention as an attractive vehicle for the delivery of nucleic add pharmaceuticals (NAPs), including genes/plasmids, short oligonucleotides, and small interference RNAs and their analogues, due to their high internalization efficacy, low cytotoxicity, and flexible structural design.
   In this Account, we survey the potential of CPPs for the design and optimization of NAP delivery systems. First, we describe the impact of the N-terminal stearylation of CPPs. Endocytic pathways make a major contribution to the cellular uptake of NAPS. Stearylation at the N-terminus of CPPs with stearyl-octaarginine (R8), stearyl-(RxR)(4), and stearyl-TP10 prompts the formation of a self-assembled core shell nanoparticle with NAPS, a compact structure that promotes cellular uptake. Researchers have designed modifications such as the addition of trifluoromethylquinoline moieties to lysine residues to destabilize endosomes, as exemplified by PepFect 6, and these changes further improve biological responsiveness. Alternatively, stearylation also allows implantation of CPPs onto the surface of liposomes. This feature facilitates "programmed packaging" to establish multifunctional envelope-type nanodevices (MEND). The R8-MEND showed high transfection efficiency comparable to that of adenovirus in non-dividing cells.
   Understanding the cellular uptake mechanisms of CPPs will further improve CPP-mediated NAP delivery. The cellular uptake of CPPs and their NAP complex involves various types of endocytosis. Macropinocytosis, a mechanism which is also activated in response to stimuli such as growth factors or viruses, is a primary pathway for arginine-rich CPPs because high cationic charge density promotes this endocytic pathway. The use of larger endosomes (known as macropinosomes) rather than clathrin- or caveolae-mediated endocytosis has been reported in macropinocytosis which would also facilitate the endocytosis of NAP nanoparticles into cells.
C1 [Nakase, Ikuhiko; Futaki, Shiroh] Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.
   [Akita, Hidetaka; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan.
   [Kogure, Kentaro] Kyoto Pharmaceut Univ, Dept Biophys Chem, Kyoto 6078414, Japan.
   [Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs Nat Sci, S-10691 Stockholm, Sweden.
   [Langel, Ulo] Stockholm Univ, Dept Neurochem, S-10692 Stockholm, Sweden.
RP Futaki, S (reprint author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Swedish Research Council; Swedish Foundation for Strategic Research;
   VINNOVA [MDB09-0015]; Japan Science, Technology Agency (JST)
FX This work was supported in part by Grants-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan (to I.N., H.A., K.K., H.H., and S.F.). This study was also
   supported by the Swedish Research Council, the Swedish Foundation for
   Strategic Research and VINNOVA (Project No. MDB09-0015) (to U.L. and
   A.G.), and Strategic Japanese-Swedish Cooperative Programme on
   "Multidisciplinary BIO" from Japan Science, Technology Agency (JST) and
   VINNOVA (to S.F.).S.F
CR Akita H, 2010, J CONTROL RELEASE, V143, P311, DOI 10.1016/j.jconrel.2010.01.012
   Akita H, 2009, BIOMATERIALS, V30, P2940, DOI 10.1016/j.biomaterials.2009.02.009
   Crombez L, 2011, METHODS MOL BIOL, V764, P59, DOI 10.1007/978-1-61779-188-8_4
   Crombez L, 2011, METHODS MOL BIOL, V683, P349, DOI [10.1007/978-1-60751-919-2_25, 10.1007/978-1-60761-919-2_25]
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Dupont E, 2011, METHODS MOL BIOL, V683, P21, DOI 10.1007/978-1-60761-919-2_2
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   EI-Sayed A., 2008, J BIOL CHEM, V283, P23450
   El Andaloussi S., 2011, NUCLEIC ACIDS RES, V39, P3972, DOI DOI 10.1093/NAR/GKQ1299
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Guterstam P, 2009, BBA-BIOMEMBRANES, V1788, P2509, DOI 10.1016/j.bbamem.2009.09.014
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Hatakeyama H, 2011, BIOMATERIALS, V32, P4306, DOI 10.1016/j.biomaterials.2011.02.045
   Hatakeyama H, 2011, ADV DRUG DELIVER REV, V63, P152, DOI 10.1016/j.addr.2010.09.001
   Inomata K, 2009, NATURE, V458, P106, DOI 10.1038/nature07839
   Jones AT, 2008, INT J PHARMACEUT, V354, P34, DOI 10.1016/j.ijpharm.2007.10.046
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Khalil Ikramy A, 2008, Int J Pharm, V354, P39, DOI 10.1016/j.ijpharm.2007.12.003
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kogure K, 2008, ADV DRUG DELIVER REV, V60, P559, DOI 10.1016/j.addr.2007.10.007
   Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Mann A, 2011, MOL PHARMACEUT, V8, P1729, DOI 10.1021/mp2000814
   Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2008, ADV DRUG DELIVER REV, V60, P598, DOI 10.1016/j.addr.2007.10.006
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Nakase I, 2009, MOL THER, V17, P1868, DOI 10.1038/mt.2009.192
   Oskolkov N, 2011, INT J PEPT RES THER, V17, P147, DOI 10.1007/s10989-011-9252-1
   Perret F, 2005, J AM CHEM SOC, V127, P1114, DOI 10.1021/ja043633c
   Pooga M, 1998, FASEB J, V12, P67
   REzzat K., 2011, NUCLEIC ACIDS RES, V39, P5284
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Sakai N, 2005, CHEMBIOCHEM, V6, P114, DOI 10.1002/cbic.200400256
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Swanson JA, 2008, NAT REV MOL CELL BIO, V9, P639, DOI 10.1038/nrm2447
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Tanaka K, 2011, CHEM PHARM BULL, V59, P202, DOI 10.1248/cpb.59.202
   Tanaka K, 2010, INT J PHARMACEUT, V398, P219, DOI 10.1016/j.ijpharm.2010.07.038
   Tonges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016
   Zuber G, 2001, ADV DRUG DELIVER REV, V52, P245, DOI 10.1016/S0169-409X(01)00213-7
   Langel U, 2011, METHODS MOL BIOL, V683, P1, DOI 10.1007/978-1-60761-919-2
NR 57
TC 137
Z9 138
U1 4
U2 191
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD JUL 17
PY 2012
VL 45
IS 7
BP 1132
EP 1139
DI 10.1021/ar200256e
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 974NH
UT WOS:000306441900019
PM 22208383
DA 2018-01-05
ER

PT J
AU Kumar, AB
   Anderson, JM
   Melendez, AL
   Manetsch, R
AF Kumar, Arun Babu
   Anderson, Jordan Micheal
   Melendez, Anthony Lester
   Manetsch, Roman
TI Synthesis and structure-activity relationship studies of
   1,3-disubstituted 2-propanols as BACE-1 inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE BACE-1; beta-Secretase; 1,3-Disubstituted 2-propanol; Small molecule
   inhibitor; Blood-brain barrier; Cathepsin D; HEA; Hydroxyethylamines
ID BETA-SECRETASE INHIBITORS; ALZHEIMERS-DISEASE; PROTEASE INHIBITORS;
   CRYSTAL-STRUCTURE; HIV-1 PROTEASE; DESIGN; PREDICTION; THERAPEUTICS;
   BRAIN; AMINE
AB A library of 1,3-disubstituted 2-propanols was synthesized and evaluated as low molecular weight probes for beta-secretase inhibition. By screening a library of 121 1,3-disubstituted 2-propanol derivatives, we identified few compounds inhibiting the enzyme at low micromolar concentrations. The initial hits were optimized to yield a potent BACE-1 inhibitor exhibiting an IC50 constant in the nanomolar range. Exploration of the pharmacological properties revealed that these small molecular inhibitors possessed a high selectivity over cathepsin D and desirable physicochemical properties beneficial to cross the blood-brain barrier. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Kumar, Arun Babu; Anderson, Jordan Micheal; Melendez, Anthony Lester; Manetsch, Roman] Univ S Florida, Dept Chem, Tampa, FL 33620 USA.
RP Manetsch, R (reprint author), Univ S Florida, Dept Chem, CHE 205,4202 E Fowler Ave, Tampa, FL 33620 USA.
EM manetsch@usf.edu
FU University of South Florida
FX Funding was provided by the University of South Florida.
CR Asso V, 2008, CHEMMEDCHEM, V3, P1530, DOI 10.1002/cmdc.200800162
   BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796
   Barrow JC, 2007, CHEMMEDCHEM, V2, P995, DOI 10.1002/cmdc.200700038
   Bertini S, 2011, BIOORG MED CHEM LETT, V21, P6657, DOI 10.1016/j.bmcl.2011.09.064
   Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x
   Clark DE, 2003, DRUG DISCOV TODAY, V8, P927, DOI 10.1016/S1359-6446(03)02827-7
   De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218
   Dohnalek J, 2002, J MED CHEM, V45, P1432, DOI 10.1021/jm010979e
   Ghosh AK, 1998, J ORG CHEM, V63, P6146, DOI 10.1021/jo980159i                                                               
   Ghosh AK, 2008, NEUROTHERAPEUTICS, V5, P399, DOI 10.1016/j.nurt.2008.05.007
   GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4                                                   
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994                                                         
   Hills ID, 2007, CURR OPIN DRUG DISC, V10, P383
   Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150                                                    
   Hong L, 2002, NEUROBIOL AGING, V23, pS108
   Ioakimidis L, 2008, QSAR COMB SCI, V27, P445, DOI 10.1002/qsar.200730051
   Jonsdottir SO, 2005, BIOINFORMATICS, V21, P2145, DOI 10.1093/bioinformatics/bti314
   Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456                                                          
   Lobell M, 2003, J PHARM SCI, V92, P360, DOI 10.1002/jps.10282
   Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059
   Maillard MC, 2007, J MED CHEM, V50, P776, DOI 10.1021/jm061242y
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   Probst GD, 2010, BIOORG MED CHEM LETT, V20, P6034, DOI 10.1016/j.bmcl.2010.08.070
   Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317
   Sasaki H, 2010, BIOORG MED CHEM LETT, V20, P4558, DOI 10.1016/j.bmcl.2010.06.021
   Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r
   Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248                                       
   Truong AP, 2010, BIOORG MED CHEM LETT, V20, P6231, DOI 10.1016/j.bmcl.2010.08.102
   TUCKER TJ, 1992, J MED CHEM, V35, P2525, DOI 10.1021/jm00092a002                                                             
   Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x
   Wu YJ, 2009, BIOORG MED CHEM LETT, V19, P2654, DOI 10.1016/j.bmcl.2009.03.144
   Xu WJ, 2009, BIOORG MED CHEM LETT, V19, P3188, DOI 10.1016/j.bmcl.2009.04.113
NR 32
TC 12
Z9 12
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 15
PY 2012
VL 22
IS 14
BP 4740
EP 4744
DI 10.1016/j.bmcl.2012.05.072
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 970AU
UT WOS:000306101300049
PM 22727644
DA 2018-01-05
ER

PT J
AU Ramana, LN
   Sharma, S
   Sethuraman, S
   Ranga, U
   Krishnan, UM
AF Ramana, Lakshmi Narashimhan
   Sharma, Shilpee
   Sethuraman, Swaminathan
   Ranga, Udaykumar
   Krishnan, Uma Maheswari
TI Investigation on the stability of saquinavir loaded liposomes:
   Implication on stealth, release characteristics and cytotoxicity
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE PEGylated liposomes; Non-PEGylated liposomes; Saquinavir
ID POLY PROPYLENEIMINE DENDRIMER; BLOOD-BRAIN-BARRIER; MECHANISMS;
   STAVUDINE; TRANSPORT; HYDRATION; DELIVERY; AGENTS
AB Although anti-retroviral therapy is the most efficient disease management strategy for HIV-AIDS, its applications are limited by several factors including the low bioavailability and first pass metabolism of the drugs. Nanocarriers such as liposomes have been developed to circumvent some of these problems. We report here preparation of novel liposome formulations for efficient delivery of anti-retroviral drugs to mammalian cells in culture. The liposomes were prepared and surface was modified using poly (ethylene glycol). Encapsulation efficiency of the anti-retroviral drug saquinavir was found to be approximately 33% and also exhibited sustained release of the drug. Although PEGylated liposomes were more stable in protein-supplemented media, had better colloidal stability and exhibited lesser sonochemical stability due to lower cavitation threshold. The cell viability studies using Jurkat T-cells revealed that the PEGylated liposomes loaded with saquinavir were less cytotoxic as compared to the non-PEGylated liposomes or free drug confirming the potential of the liposomes as a sustained drug-release system. The drug delivery potential of the liposomes loaded with Alexa flour 647 was evaluated using Jurkat T-cells and flow cytometry showing uptake upto 74%. Collectively, our data demonstrate efficient targeting of mammalian cells using novel liposome formulations with insignificant levels of cytotoxicity. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Krishnan, Uma Maheswari] SASTRA Univ, Ctr Nanotechnol & Adv Biomat CeNTAB, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
   [Sharma, Shilpee; Ranga, Udaykumar] Jawaharlal Nehru Ctr Adv Sci Res, HIV AIDS Lab, Mol Biol & Genet Unit, Bangalore, Karnataka, India.
RP Krishnan, UM (reprint author), SASTRA Univ, Ctr Nanotechnol & Adv Biomat CeNTAB, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
EM umakrishnan@sastra.edu
OI sharma, shilpee/0000-0003-4645-9442
FU ICMR [35/9/2009-BMS]; JNCASR
FX The authors acknowledge financial support from ICMR (no. 35/9/2009-BMS),
   SASTRA University for infrastructural support and JNCASR.
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   Anuradha S., 2011, BIOMED MATER, V6, P1
   ASHAN F, 2002, J CONTROL RELEASE, V79, P29
   Covreur PV. C., 2006, PHARM RES, V23, P1417
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   El Maghraby GMM, 2005, INT J PHARMACEUT, V292, P179, DOI 10.1016/j.ijpharm.2004.11.037
   FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274                                                         
   Gabriele B., 1993, BIOCHIM BIOPHYS ACTA, V1146, P157
   Gupta U, 2006, BIOMACROMOLECULES, V7, P649, DOI 10.1021/bm050802s
   HEE HD, 2006, EUR J PHARM BIOPHARM, V62, P110
   Heiati H., 2008, INT J PHARMACEUT, V351, P271
   Jagannathan S., 2003, BIOPHYS J, V85, P3087
   Jie G., 2009, INT J PHARMACEUT, V374, P145
   Jubo L., 2006, CANCER CHEMOTH PHARM, V58, P306
   Kaname H., 2006, CHEM PHARM BULL, V54, P80
   KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654                                                          
   Katragadda A, 2000, CELL MOL BIOL LETT, V5, P483
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Lakshmi R.N., 2010, J BIOMED SCI, V17, P57
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481                                                           
   Margherita V., 2010, OPEN DRUG DELIVERY J, V4, P55
   OKADA N, 1982, IMMUNOLOGY, V45, P115
   Paola M., 2007, EUR J PHARM BIOPHARM, V67, P86
   Sabin J, 2006, EUR PHYS J E, V20, P401, DOI 10.1140/epje/i2006-10029-9
   Howard Temin M., 1988, REV INFECT DIS, V10, P399
   Tirosh O, 1998, BIOPHYS J, V74, P1371, DOI 10.1016/S0006-3495(98)77849-X                                                   
   Tove E.J., 2010, EUR J PHARM BIOPHARM, V47, P327
   Tove E.J., 2010, EUR J PHARM BIOPHARM, V42, P380
   Umesh G., 2010, ADV DRUG DELIV REV, V62, P478
   Vitas AI, 1996, ANTIMICROB AGENTS CH, V40, P146
   Vono M, 2010, OPEN DRUG DELIV, V4, P55
   Yang T., 2007, INT J PHARMACEUT, V338, P316
   Yan-le H., 2005, ARCH PHARM RES, V28, P626
NR 36
TC 19
Z9 20
U1 0
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 15
PY 2012
VL 431
IS 1-2
BP 120
EP 129
DI 10.1016/j.ijpharm.2012.04.054
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 945BB
UT WOS:000304246700016
PM 22569226
DA 2018-01-05
ER

PT J
AU Montesinos, RN
   Beduneau, A
   Pellequer, Y
   Lamprecht, A
AF Montesinos, Rita Nieto
   Beduneau, Arnaud
   Pellequer, Yann
   Lamprecht, Alf
TI Delivery of P-glycoprotein substrates using chemosensitizers and
   nanotechnology for selective and efficient therapeutic outcomes
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE P-glycoprotein; Drug efflux; P-gp modulators; Nanocarriers; Drug
   delivery strategies
ID BLOOD-BRAIN-BARRIER; MEDIATED MULTIDRUG-RESISTANCE; PHASE-I TRIAL;
   VALSPODAR PSC 833; ZOSUQUIDAR TRIHYDROCHLORIDE LY335979;
   POLYCAPROLACTONE DIBLOCK COPOLYMERS; CO-ENCAPSULATING DOXORUBICIN; DRUG
   EFFLUX TRANSPORTERS; ACUTE MYELOID-LEUKEMIA; ANTI-HIV DRUGS
AB As a result of its broad substrate specificity and critical localization in excretory and barrier function tissues, P-glycoprotein (P-gp) plays major roles in the pharmacokinetics, safety and efficacy profiles of numerous drugs. P-gp is often responsible for the failure of many chemical treatments against cancer, immunosuppressive, infectious and neurodegenerative diseases. Among the therapeutic approaches to circumvent P-gp function, advances in the design of new chemical P-gp modulators to interact specifically with P-gp have yielded few clinical successful reports. Members of a class of components that were initially developed as surface active agents showed promising results with regard to the modulation of P-gp. These components include surfactants and amphiphilic co-polymers. Alternatively, colloidal systems were developed to facilitate drug uptake in resistant cells. This approach is based on the encapsulation of drugs, which masks them from the biological environment and prevents their transport by P-gp using the surfactants released from the nanocarrier. Likewise, a novel and synergistic strategy is currently being explored and involves nanocarrier-mediated transport and controlled release of both P-gp substrates and P-gp modulators. In this review, we discuss recent results obtained by direct modulation with chemosensitizers and the available nanotechnology to modulate P-gp function. In this manuscript, we also discuss unexplored pathways for future therapies. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Montesinos, Rita Nieto; Beduneau, Arnaud; Pellequer, Yann; Lamprecht, Alf] Univ Franche Comte, Lab Pharmaceut Engn, F-25000 Besancon, France.
   [Lamprecht, Alf] Univ Bonn, Lab Pharmaceut Technol & Biopharmaceut, Bonn, Germany.
RP Montesinos, RN (reprint author), Univ Franche Comte, Lab Pharmaceut Engn, 19 Rue Ambroise Pare, F-25000 Besancon, France.
EM rita.nieto_montesinos@univ-fcomte.fr
RI Nieto Montesinos, Rita Milagros/M-5488-2017
OI Nieto Montesinos, Rita Milagros/0000-0002-5671-4593
FU region of Franche-Comte
FX The authors gratefully thank the region of Franche-Comte for financial
   support.
CR Abraham J, 2009, CLIN CANCER RES, V15, P3574, DOI 10.1158/1078-0432.CCR-08-0938
   Akhtar N, 2011, EXPERT OPIN THER PAT, V21, P561, DOI 10.1517/13543776.2011.561784
   Alakhov V, 2001, EXPERT OPIN BIOL TH, V1, P583, DOI 10.1517/14712598.1.4.583                                                        
   Alakhova DY, 2010, J CONTROL RELEASE, V142, P89, DOI 10.1016/j.jconrel.2009.09.026
   Ambudkar SV, 2006, EUR J PHARM SCI, V27, P392, DOI 10.1016/j.ejps.2005.10.010
   Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361
   Anderson BD, 2006, DRUG METAB DISPOS, V34, P653, DOI 10.1124/dmd.105.006536
   Anderson GD, 2007, EPILEPSIA, V48, P2372, DOI 10.1111/j.1528-1167.2007.01260_3.x                                              
   Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370                                                    
   Aye ILMH, 2009, CHEM-BIOL INTERACT, V180, P327, DOI 10.1016/j.cbi.2009.04.012
   Bansal T, 2009, DRUG DISCOV TODAY, V14, P1067, DOI 10.1016/j.drudis.2009.07.010
   BARTLETT NL, 1994, J CLIN ONCOL, V12, P835, DOI 10.1200/JCO.1994.12.4.835                                                       
   Batrakova EV, 2004, PHARM RES, V21, P2226, DOI 10.1007/s11095-004-7675-5
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Batrakova EV, 1998, PHARMACEUT RES, V15, P1525, DOI 10.1023/A:1011942814300                                                         
   BENSON AB, 1985, CANCER TREAT REP, V69, P795
   BERMAN E, 1995, LEUKEMIA, V9, P1631
   Binichathlan Z, 2010, EUR J PHARM BIOPHARM, V75, P90, DOI 10.1016/j.ejpb.2010.03.010
   CAIRO MS, 1989, CANCER RES, V49, P1063
   Callaghan R, 2006, FEBS LETT, V580, P1056, DOI 10.1016/j.febslet.2005.11.083
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Chen BA, 2008, INT J NANOMED, V3, P277
   Chi KN, 2005, INVEST NEW DRUG, V23, P311, DOI 10.1007/s10637-005-1439-x
   Choo EF, 2006, J PHARMACOL EXP THER, V317, P1012, DOI 10.1124/jpet.105.099648
   Colabufo NA, 2010, J MED CHEM, V53, P1883, DOI 10.1021/jm900743c
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   Dabholkar RD, 2006, INT J PHARM, V315, P148, DOI 10.1016/j.ijpharm.2006.02.018
   Dai CL, 2007, CANCER CHEMOTH PHARM, V60, P741, DOI 10.1007/s00280-007-0420-0
   de Klerk OL, 2009, INT J NEUROPSYCHOPH, V12, P895, DOI 10.1017/S1461145709009894
   Demeule M, 2001, INT J CANCER, V93, P62, DOI 10.1002/ijc.1306                                                                
   denOuden D, 1996, LEUKEMIA, V10, P1930
   deVerdiere AC, 1997, BRIT J CANCER, V76, P198, DOI 10.1038/bjc.1997.362
   Dietzmann Knut, 1994, Zentralblatt fuer Pathologie, V140, P149
   Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747
   Du J, 2009, MOL PHARMACEUT, V6, P905, DOI 10.1021/mp800218q
   DUDEJA PK, 1995, ARCH BIOCHEM BIOPHYS, V319, P309, DOI 10.1006/abbi.1995.1298
   Fischer V, 1998, DRUG METAB DISPOS, V26, P802
   Fracasso PM, 2005, BRIT J CANCER, V93, P46, DOI 10.1038/sj.bjc.6602653
   Fracasso PM, 2004, CLIN CANCER RES, V10, P7220, DOI 10.1158/1078-0432.CCR-04-0452                                                   
   Friedenberg WR, 2006, CANCER, V106, P830, DOI 10.1002/cncr.21666
   Fu LW, 2004, CANCER CHEMOTH PHARM, V53, P349, DOI 10.1007/s00280-003-0742-5
   Garcion E, 2006, MOL CANCER THER, V5, P1710, DOI 10.1158/1535-7163.MCT-06-0289
   Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X
   Germann UA, 1997, ANTI-CANCER DRUG, V8, P125, DOI 10.1097/00001813-199702000-00004
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   GOLDBERG H, 1988, BIOCHEM BIOPH RES CO, V152, P552, DOI 10.1016/S0006-291X(88)80073-1
   Goren D, 2000, CLIN CANCER RES, V6, P1949
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Hennessy M, 2007, PHARMACOL RES, V55, P1, DOI 10.1016/j.phrs.2006.10.007
   Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668                                                         
   Ho GT, 2003, GUT, V52, P759, DOI 10.1136/gut.52.5.759                                                            
   HOLLT V, 1992, BIOCHEM PHARMACOL, V43, P2601, DOI 10.1016/0006-2952(92)90149-D
   HYAFIL F, 1993, CANCER RES, V53, P4595
   Immordino ML, 2004, J CONTROL RELEASE, V100, P331, DOI 10.1016/j.jconrel.2004.09.001
   JAFFREZOU JP, 1991, J BIOL CHEM, V266, P19858
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   KABANOV AV, 1992, BIOCHEM INT, V26, P1035
   Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3                                                   
   Kaminski WE, 2006, BBA-MOL BASIS DIS, V1762, P510, DOI 10.1016/j.bbadis.2006.01.011
   Kelly RJ, 2011, CLIN CANCER RES, V17, P569, DOI 10.1158/1078-0432.CCR-10-1725
   Kemper EM, 2004, CANCER CHEMOTH PHARM, V53, P173, DOI 10.1007/s00280-003-0720-y
   Kerb R, 2006, CANCER LETT, V234, P4, DOI 10.1016/j.canlet.2005.06.051
   Kobayashi T, 2007, INT J PHARM, V329, P94, DOI 10.1016/j.ijpharm.2006.08.039
   Koziara JM, 2004, J CONTROL RELEASE, V99, P259, DOI 10.1016/j.jconrel.2004.07.006
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7                                                   
   Krishna R, 1999, CLIN CANCER RES, V5, P2939
   Krishna R, 2000, INT J CANCER, V85, P131, DOI 10.1002/(SICI)1097-0215(20000101)85:1<131::AID-IJC23>3.3.CO;2-I
   Krishna R, 1997, CANCER RES, V57, P5246
   Kruijtzer CMF, 2002, J CLIN ONCOL, V20, P2943, DOI 10.1200/JCO.2002.12.116
   Kuppens IELM, 2007, CLIN CANCER RES, V13, P3276, DOI 10.1158/1078-0432.CCR-06-2414
   Kurnik D, 2008, ANESTHESIOLOGY, V109, P1092, DOI 10.1097/ALN.0b013e31818d8f28
   Lamprecht A, 2006, J CONTROL RELEASE, V112, P208, DOI 10.1016/j.jconrel.2006.02.014
   Lancet JE, 2009, LEUKEMIA RES, V33, P1055, DOI 10.1016/j.leukres.2008.09.015
   Letrent SP, 1998, PHARMACEUT RES, V15, P599, DOI 10.1023/A:1011938112599
   Levine DH, 2008, METHODS, V46, P25, DOI 10.1016/j.ymeth.2008.05.006
   Lhomme C, 2008, J CLIN ONCOL, V26, P2674, DOI 10.1200/JCO.2007.14.9807
   Liscovitch M, 2002, DRUGS, V5, P349
   Lo YI, 2003, J CONTROL RELEASE, V90, P37, DOI 10.1016/S0168-3659(03)00163-9
   Lo YL, 2001, J CONTROL RELEASE, V76, P1, DOI 10.1016/S0168-3659(01)00406-0
   Lo YL, 2001, ANTICANCER RES, V21, P445
   Loo TW, 2008, ARCH BIOCHEM BIOPHYS, V476, P51, DOI 10.1016/j.abb.2008.02.025
   Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006
   Ma P, 2009, J BIOMED NANOTECHNOL, V5, P151, DOI 10.1166/jbn.2009.1021
   Malingre MM, 2001, BRIT J CANCER, V84, P42, DOI 10.1054/bjoc.2000.1543
   Marcelletti JF, 2009, LEUKEMIA RES, V33, P769, DOI 10.1016/j.leukres.2008.09.020
   Maupas C, 2011, INT J PHARMACEUT, V411, P136, DOI 10.1016/j.ijpharm.2011.03.056
   McDevitt CA, 2007, PHARMACOL THERAPEUT, V113, P429, DOI 10.1016/j.pharmthera.2006.10.003
   Miller DW, 1997, BIOCONJUGATE CHEM, V8, P649, DOI 10.1021/bc970118d
   Mistry P, 2001, CANCER RES, V61, P749
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Morschhauser F, 2007, LEUKEMIA LYMPHOMA, V48, P708, DOI 10.1080/10428190701190169
   Munic V, 2010, EUR J PHARM SCI, V41, P86, DOI 10.1016/j.ejps.2010.05.016
   Myer MS, 1999, ONCOL REP, V6, P217
   Narasaki F, 1997, CANCER CHEMOTH PHARM, V40, P425, DOI 10.1007/s002800050681
   Newman MJ, 2000, CANCER RES, V60, P2964
   Nornoo AO, 2008, INT J PHARM, V349, P108, DOI 10.1016/j.ijpharm.2007.07.042
   Pang ZQ, 2010, MOL PHARMACEUT, V7, P1995, DOI 10.1021/mp100277h
   Patel NR, 2011, INT J PHARMACEUT, V416, P296, DOI 10.1016/j.ijpharm.2011.05.082
   Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021
   Planting AST, 2005, CANCER CHEMOTH PHARM, V55, P91, DOI 10.1007/s00280-004-0854-6
   Rago RP, 2003, CANCER CHEMOTH PHARM, V51, P297, DOI 10.1007/s00280-003-0573-4
   RAMU A, 1984, CANCER RES, V44, P4392
   Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900
   Rapposelli S, 2009, CURR TOP MED CHEM, V9, P209, DOI 10.2174/156802609787521544                                                      
   Rege BD, 2002, EUR J PHARM SCI, V16, P237, DOI 10.1016/S0928-0987(02)00055-6
   Roe M, 1999, BIOORG MED CHEM LETT, V9, P595, DOI 10.1016/S0960-894X(99)00030-X                                                   
   RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4                                                    
   SALTZ L, 1994, CANCER, V74, P2757, DOI 10.1002/1097-0142(19941115)74:10<2757::AID-CNCR2820741004>3.0.CO;2-O            
   De Juan BS, 2006, J DRUG TARGET, V14, P614, DOI 10.1080/10611860600866872
   Sandler A, 2004, CLIN CANCER RES, V10, P3265, DOI 10.1158/1078-0432.CCR-03-0644
   Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4
   Seetharaman S, 1998, J NEUROCHEM, V70, P1151
   Seiden MV, 2002, GYNECOL ONCOL, V86, P302, DOI 10.1006/gyno.2002.6762
   Shono Y, 2004, J PHARM SCI-US, V93, P877, DOI 10.1002/jps.20017
   SLATE DL, 1995, ANTICANCER RES, V15, P811
   SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9
   Smith AJ, 2000, J BIOL CHEM, V275, P23530
   Soma CE, 2000, BIOMATERIALS, V21, P1
   Song XR, 2010, J PHARM SCI-US, V99, P4874, DOI 10.1002/jps.22200
   Song XR, 2009, EUR J PHARM SCI, V37, P300, DOI 10.1016/j.ejps.2009.02.018
   Sparreboom A, 1999, ANTI-CANCER DRUG, V10, P719, DOI 10.1097/00001813-199909000-00005
   Spiegl-Kreinecker S, 2002, J NEURO-ONCOL, V57, P27, DOI 10.1023/A:1015735815111
   Storch CH, 2007, BIOCHEM PHARMACOL, V73, P1573, DOI 10.1016/j.bcp.2007.01.027
   Strazza M, 2011, BRAIN RES, V1399, P96, DOI 10.1016/j.brainres.2011.05.015
   THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300                                                            
   TSURUO T, 1981, CANCER RES, V41, P1967
   TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G
   Uhr M, 2000, NEUROPSYCHOPHARMACOL, V22, P380, DOI 10.1016/S0893-133X(99)00095-0
   Valle JW, 2011, INVEST NEW DRUG, V29, P1029, DOI 10.1007/s10637-010-9399-1
   van Zuylen L, 2000, CLIN CANCER RES, V6, P1365
   van Zuylen L, 2002, EUR J CANCER, V38, P1090, DOI 10.1016/S0959-8049(02)00035-7
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   VERWEIJ J, 1991, BRIT J CANCER, V64, P361, DOI 10.1038/bjc.1991.307
   WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302                                                           
   Wang HC, 2006, EUR J PHARM BIOPHARM, V62, P44, DOI 10.1016/j.ejpb.2005.06.004
   Wang JC, 2005, BIOL PHARM BULL, V28, P822, DOI 10.1248/bpb.28.822                                                              
   Wang T, 2010, MOL PHARMACEUT, V7, P1007, DOI 10.1021/mp1001125
   Wang X, 2011, ACS NANO, V5, P6184, DOI 10.1021/nn200739q
   Wong HL, 2006, J CONTROL RELEASE, V116, P275, DOI 10.1016/j.jconrel.2006.09.007
   WOODCOCK DM, 1992, BRIT J CANCER, V66, P62, DOI 10.1038/bjc.1992.217
   Wu J, 2007, J PHARM PHARM SCI, V10, P350
   Yague E, 2007, CANCER RES, V67, P1130, DOI 10.1158/0008-5472.CAN-06-2574
   Zastre J, 2004, PHARM RES, V21, P1489, DOI 10.1023/B:PHAM.0000036925.45002.a2
   Zastre J, 2002, EUR J PHARM BIOPHARM, V54, P299, DOI 10.1016/S0939-6411(02)00119-4
   Zastre J, 2007, J PHARM SCI-US, V96, P864, DOI 10.1002/jps.20785
   Zhang ZP, 2006, BIOMATERIALS, V27, P4025, DOI 10.1016/j.biomaterials.2006.03.006
   Zhu SJ, 2009, EUR J PHARM SCI, V37, P573, DOI 10.1016/j.ejps.2009.05.001
   Zhu XM, 2005, ANTICANCER RES, V25, P1953
NR 148
TC 47
Z9 48
U1 1
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUL 10
PY 2012
VL 161
IS 1
BP 50
EP 61
DI 10.1016/j.jconrel.2012.04.034
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 965TL
UT WOS:000305790100006
DA 2018-01-05
ER

PT J
AU Freisz, S
   Mezher, J
   Hafirassou, L
   Wolff, P
   Nomine, Y
   Romier, C
   Dumas, P
   Ennifar, E
AF Freisz, Severine
   Mezher, Joelle
   Hafirassou, Lamine
   Wolff, Philippe
   Nomine, Yves
   Romier, Christophe
   Dumas, Philippe
   Ennifar, Eric
TI Sequence and structure requirements for specific recognition of HIV-1
   TAR and DIS RNA by the HIV-1 Vif protein
SO RNA BIOLOGY
LA English
DT Article
DE HIV; biophysics; RNA-protein interactions; microcalorimetry
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DIMERIZATION INITIATION SITE; ISOTHERMAL
   TITRATION CALORIMETRY; CYTIDINE DEAMINASE APOBEC3H; VIRAL INFECTIVITY
   FACTOR; ANTIVIRAL ACTIVITY; GENOMIC-RNA; RESTRICTION FACTORS; SOR GENE;
   CBF-BETA
AB The HIV-1 Vif protein plays an essential role in the regulation of the infectivity of HIV-1 virion and in vivo pathogenesis. Vif neutralizes the human DNA-editing enzyme APOBEC 3 protein, an antiretroviral cellular factor from the innate immune system, allowing the virus to escape the host defense system. It was shown that Vif is packaged into viral particles through specific interactions with the viral genomic RNA. Conserved and structured sequences from the 5'-noncoding region, such as the Tat-responsive element (TAR) or the genomic RNA dimerization initiation site (DIS), are primary binding sites for Vif. In the present study we used isothermal titration calorimetry to investigate sequence and structure determinants important for Vif binding to short viral RNA corresponding to TAR and DIS stem-loops. We showed that Vif specifically binds TAR and DIS in the low nanomolar range. In addition, Vif primarily binds the TAR UCU bulge, but not the apical loop. Determinants for Vif binding to the DIS loop-loop complex are likely more complex and involve the self-complementary loop together with the upper part of the stem. These results suggest that Tat-TAR inhibitors or DIS small molecule binders might be also effective to disturb Vif-TAR and Vif-DIS binding in order to reduce Vif packaging into virions.
C1 [Freisz, Severine; Mezher, Joelle; Hafirassou, Lamine; Wolff, Philippe; Dumas, Philippe; Ennifar, Eric] Univ Strasbourg, Inst Biol Mol & Cellulaire, CNRS, Architecture & Reactivite ARN, Strasbourg, France.
   [Nomine, Yves] Univ Strasbourg, Ecole Biotechnol Strasbourg, Inst Rech, Equipe Oncoprot, Illkirch Graffenstaden, France.
   [Romier, Christophe] Univ Strasbourg, CNRS, INSERM, Dept Biol & Genom Struct,IGBMC, Illkirch Graffenstaden, France.
RP Ennifar, E (reprint author), Univ Strasbourg, Inst Biol Mol & Cellulaire, CNRS, Architecture & Reactivite ARN, Strasbourg, France.
EM e.ennifar@ibmc.u-strasbg.fr
RI Nomine, Yves/P-8670-2016
OI Romier, Christophe/0000-0002-3680-935X
FU "Agence Nationale de Recherche sur le SIDA" (ANRS)
FX This work was supported by the "Agence Nationale de Recherche sur le
   SIDA" (ANRS to E. E.). S. F. is an ANRS fellow. J.M. is a
   SIDACTION/Fondation Pierre Berge fellow.
CR Auclair JR, 2007, PROTEINS, V69, P270, DOI 10.1002/prot.21471
   Barraud P, 2008, CURR HIV RES, V6, P91, DOI 10.2174/157016208783885056                                                      
   Bergeron JR, 2010, PLOS PATHOG, V6
   Bernacchi S, 2005, J BIOL CHEM, V280, P40112, DOI 10.1074/jbc.M503230200
   Bernacchi S, 2007, NUCLEIC ACIDS RES, V35, P7128, DOI 10.1093/nar/gkm856
   Bernacchi S, 2007, J BIOL CHEM, V282, P26361, DOI 10.1074/jbc.M703122200
   Bernacchi S, 2011, NUCLEIC ACIDS RES, V39, P2404, DOI 10.1093/nar/gkq979
   Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06
   Bishop KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000231
   Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057
   Burnouf D, 2012, J AM CHEM SOC, V134, P559, DOI 10.1021/ja209057d
   Campoy Adrian Velazquez, 2005, Biophysical Chemistry, V115, P115
   Chiu YL, 2008, ANNU REV IMMUNOL, V26, P317, DOI 10.1146/annurev.immunol.26.021607.090350
   Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034
   Dang Y, 2008, J BIOL CHEM, V283, P11606, DOI 10.1074/jbc.M707586200
   Dang Y, 2006, J VIROL, V80, P10522, DOI 10.1128/JVI.01123-06
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000
   Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005
   Donahue JP, 2008, VIROLOGY, V377, P49, DOI 10.1016/j.virol.2008.04.017
   Ennifar E, 2006, NUCLEIC ACIDS RES, V34, P2328, DOI 10.1093/nar/gkl317
   Ennifar E, 2006, J MOL BIOL, V356, P771, DOI 10.1016/j.jmb.2005.12.022
   Ennifar E, 1999, STRUCT FOLD DES, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7
   Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P2671, DOI 10.1093/nar/gkg350
   Ennifar E, 2003, J BIOL CHEM, V278, P2723, DOI 10.1074/jbc.M205726200
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   Ennifar E, 2007, BIOCHIMIE, V89, P1195, DOI 10.1016/j.biochi.2007.03.003
   Ennifar E, 2007, RNA, V13, P1445, DOI 10.1261/rna.408507
   Ennifar E, 2010, NUCLEIC ACIDS RES, V38, P5807, DOI 10.1093/nar/gkq344
   Feig AL, 2009, METHOD ENZYMOL, V468, P409, DOI 10.1016/S0076-6879(09)68019-8
   FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453
   Freisz S, 2008, ANGEW CHEM INT EDIT, V47, P4110, DOI 10.1002/anie.200800726
   GABUZDA DH, 1992, J VIROL, V66, P6489
   Gallerano D, 2011, AMINO ACIDS, V40, P981, DOI 10.1007/s00726-010-0725-x
   GALLO R, 1988, NATURE, V333, P504, DOI 10.1038/333504a0
   Hagan NA, 2007, J MOL BIOL, V365, P396, DOI 10.1016/j.mb.2006.09.081
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   Henriet S, 2005, J MOL BIOL, V354, P55, DOI 10.1016/j.jmb.2005.09.025
   Henriet S, 2009, MICROBIOL MOL BIOL R, V73, P211, DOI 10.1128/MMBR.00040-08
   Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004
   Hultquist JF, 2012, J VIROL, V86, P2874, DOI 10.1128/JVI.06950-11
   Jager S, 2012, NATURE, V481, P371, DOI 10.1038/nature10693
   Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005
   Khan MA, 2002, J VIROL, V76, P9112, DOI 10.1128/JVI.76.18.9112-9123.2002
   Lalonde MS, 2011, PLOS PATHOG, V7
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Marcsisin SR, 2011, J MOL BIOL, V410, P1008, DOI 10.1016/j.jmb.2011.04.053
   Marcsisin SR, 2010, J MOL BIOL, V402, P892, DOI 10.1016/j.jmb.2010.08.026
   Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4                                                   
   Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946
   Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3                                                   
   Mercenne G, 2010, NUCLEIC ACIDS RES, V38, P633, DOI 10.1093/nar/gkp1009
   Miller JH, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-81
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686                                                        
   Nguyen KL, 2004, VIROLOGY, V319, P163, DOI 10.1016/j.virol.2003.11.021
   OhAinle M, 2006, J VIROL, V80, P3853, DOI 10.1128/JVI.80.8.3853-3862.2006
   Opi S, 2007, J VIROL, V81, P8236, DOI 10.1128/JVI.02694-06
   Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903
   Paul I, 2006, P NATL ACAD SCI USA, V103, P18475, DOI 10.1073/pnas.0604150103
   Romier C, 2006, ACTA CRYSTALLOGR D, V62, P1232, DOI 10.1107/S0907444906031003
   ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365
   Salim NN, 2009, METHODS, V47, P198, DOI 10.1016/j.ymeth.2008.09.003
   Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001
   SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244
   Stenglein MD, 2006, J BIOL CHEM, V281, P16837, DOI 10.1074/jbc.M602367200
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246
   Wissing S, 2010, MOL ASPECTS MED, V31, P383, DOI 10.1016/j.mam.2010.06.001
   Yang B, 2003, J BIOL CHEM, V278, P6596, DOI 10.1074/jbc.M210164200
   Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200                                                          
   Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121                                                        
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
   Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000                                                
   Zhang WY, 2012, NATURE, V481, P376, DOI 10.1038/nature10718
   Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004
NR 85
TC 4
Z9 5
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD JUL
PY 2012
VL 9
IS 7
BP 966
EP 977
DI 10.4161/rna.20483
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 982XM
UT WOS:000307078700008
PM 22767258
OA gold
DA 2018-01-05
ER

PT J
AU Elhaes, H
   Osman, O
   Ibrahim, M
AF Elhaes, Hanan
   Osman, Osama
   Ibrahim, Medhat
TI Interaction of Nano Structure Material with Heme Molecule: Modelling
   Approach
SO JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE
LA English
DT Article
DE PM3; C-60; AM1; Fullerene Epoxide; Vibrational Spectra
ID HIV-1 PROTEASE INHIBITORS; ELECTRONIC-PROPERTIES; COMPUTATIONAL NOTES;
   C-60; FULLERENE; DERIVATIVES; SILICON
AB As the emerging utilization of nano materials, their possible interactions with living cells must be of concern. The present work is dedicated to study the possible interaction between C-60 epoxides (C-60-O) and hemoglobin. A model for crystal structure and vibrational spectra of fullerene and its epoxides are introduced on the basis of AM1 semiemperical quantum mechanical method. Results indicate the possibility for fullerene epoxide to interact with heme molecule. CO, CO2 interaction with heme is carried out for comparison. Results indicate that the interaction of C-60-O with heme is more likely to happen as adsorb state and complex. This interaction affects the role of heme molecule as gas transporter.
C1 [Elhaes, Hanan] Ain Shams Univ, Dept Phys, Fac Women Arts Sci & Educ, Cairo 11757, Egypt.
   [Osman, Osama; Ibrahim, Medhat] Natl Res Ctr, Dept Spect, Cairo 12311, Egypt.
RP Elhaes, H (reprint author), Ain Shams Univ, Dept Phys, Fac Women Arts Sci & Educ, Cairo 11757, Egypt.
OI Osman, Osama/0000-0002-9977-3964; IBRAHIM, Medhat/0000-0002-9698-0837
CR CHASE B, 1992, J PHYS CHEM-US, V96, P4262, DOI 10.1021/j100190a029
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DONALDSON K, 2000, WORKSH INH ENV OCC I, P523
   Dunford R, 1997, FEBS LETT, V418, P87, DOI 10.1016/S0014-5793(97)01356-2
   Elhaes H, 2010, J COMPUT THEOR NANOS, V7, P536, DOI 10.1166/jctn.2010.1390
   Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8
   Fujita K, 2009, TOXICOLOGY, V258, P47, DOI 10.1016/j.tox.2009.01.005
   Hameed AJ, 2007, J MOL STRUC-THEOCHEM, V809, P131, DOI 10.1016/j.theochem.2007.01.021
   Ibrahim M, 2005, CHINESE J PHYS, V43, P915
   Ibrahim M., 2008, ECLET QUIM, V30, P21
   Ibrahim M, 2006, CHINESE J PHYS, V44, P432
   Ibrahim M, 2010, J COMPUT THEOR NANOS, V7, P224, DOI 10.1166/jctn.2010.1350
   Ibrahim M, 2010, SPECTROCHIM ACTA A, V75, P702, DOI 10.1016/j.saa.2009.11.042
   Ibrahim M, 2008, J COMPUT THEOR NANOS, V5, P2247, DOI 10.1166/jctn.2008.1127
   Ibrahim M, 2009, J COMPUT THEOR NANOS, V6, P574, DOI 10.1166/jctn.2009.1074
   Ibrahim M, 2009, J COMPUT THEOR NANOS, V6, P80, DOI 10.1166/jctn.2009.1009
   Ibrahim M, 2009, J COMPUT THEOR NANOS, V6, P85, DOI 10.1166/jctn.2009.1010
   Jalbout AF, 2008, J ORGANOMET CHEM, V693, P216, DOI 10.1016/j.jorganchem.2007.09.036
   Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P168
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Shinohara N, 2009, TOXICOL LETT, V191, P289, DOI 10.1016/j.toxlet.2009.09.012
   Xu Z, 2010, J HAZARD MATER, V180, P375, DOI 10.1016/j.jhazmat.2010.04.042
NR 22
TC 4
Z9 4
U1 0
U2 2
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1546-1955
J9 J COMPUT THEOR NANOS
JI J. Comput. Theor. Nanosci.
PD JUL
PY 2012
VL 9
IS 7
BP 901
EP 905
DI 10.1166/jctn.2012.2114
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 979ZA
UT WOS:000306862200001
DA 2018-01-05
ER

PT J
AU Koren, E
   Torchilin, VP
AF Koren, Erez
   Torchilin, Vladimir P.
TI Cell-penetrating peptides: breaking through to the other side
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
DE cell-penetrating peptides; nanocarrier; drug delivery; transfection
ID HUMAN IMMUNODEFICIENCY VIRUS; DRUG-DELIVERY SYSTEMS; TAT-FUSION
   PROTEINS; IN-VIVO; GENE DELIVERY; PHARMACEUTICAL NANOCARRIERS;
   INTRACELLULAR DELIVERY; TUMOR-CELLS; MULTIFUNCTIONAL LIPOSOMES;
   TRANSFECTION EFFICIENCY
AB Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the intracellular delivery of a large variety of cargoes through the cell membrane. Intracellular delivery of plasmid DNA (pDNA), oligonucleotides, small interfering RNAs (siRNAs), proteins and peptides, contrast agents, drugs, as well as various nanoparticulate pharmaceutical carriers (e.g., liposomes, micelles) has been demonstrated both in vitro and in vivo. This review focuses on the peptide-based strategy for intracellular delivery of CPP-modified nanocarriers to deliver small molecule drugs or DNA. In addition, we discuss the rationales for the design of 'smart' pharmaceutical nanocarriers in which the cell-penetrating properties are hidden until triggered by exposure to appropriate environmental conditions (e.g., a particular pH, temperature, or enzyme level), applied local microwave, ultrasound, or radiofrequency radiation.
C1 [Koren, Erez; Torchilin, Vladimir P.] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, 312 Mugar Life Sci Bldg,360 Huntington Ave, Boston, MA 02115 USA.
EM erezkoren@gmail.com; v.torchilin@neu.edu
FU National Institutes of Health [RO1 CA121838, RO1 CA128486]
FX This work was supported by National Institutes of Health grants RO1
   CA121838 and RO1 CA128486 to V.P. Torchilin. W.C. Hartner is gratefully
   acknowledged for his help during preparation of this manuscript.
CR Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Desai P, 2010, MOL MEMBR BIOL, V27, P247, DOI 10.3109/09687688.2010.522203
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grunwald J, 2009, BIOCONJUGATE CHEM, V20, P1531, DOI 10.1021/bc900081e
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Gupta B, 2007, ONCOL RES, V16, P351
   Han L, 2010, HUM GENE THER, V21, P417, DOI 10.1089/hum.2009.087
   Hatakeyama H, 2011, ADV DRUG DELIVER REV, V63, P152, DOI 10.1016/j.addr.2010.09.001
   Henriques ST, 2008, J PEPT SCI, V14, P482, DOI 10.1002/psc.1003
   Herbig ME, 2005, BIOPHYS J, V89, P4056, DOI 10.1529/biophysj.105.068692
   Hudecz F, 2005, MED RES REV, V25, P679, DOI 10.1002/med.20034
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Jiang QY, 2011, BIOMATERIALS, V32, P7253, DOI 10.1016/j.biomaterials.2011.06.015
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Juliano RL, 2006, ANN NY ACAD SCI, V1082, P18, DOI 10.1196/annals.1348.011
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kale AA, 2010, METHODS MOL BIOL, V605, P213, DOI 10.1007/978-1-60327-360-2_15
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Kono K, 2011, BIOMATERIALS, V32, P1387, DOI 10.1016/j.biomaterials.2010.10.050
   Koren E., 2012, J CONTROL RELEASE
   Koren E, 2011, DRUG DELIV, V18, P377, DOI 10.3109/10717544.2011.567310
   Kuai R, 2011, MOL PHARMACEUT, V8, P2151, DOI 10.1021/mp200100f
   Langel U., 2007, HDB CELL PENETRATING
   Lebleu B, 2008, ADV DRUG DELIVER REV, V60, P517, DOI 10.1016/j.addr.2007.09.002
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindberg S, 2011, THER DELIV, V2, P71, DOI 10.4155/TDE.10.78
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Meyer-Losic F, 2008, CLIN CANCER RES, V14, P2145, DOI 10.1158/1078-0432.CCR-07-4580
   MOULTON HM, 2008, RSC BIOMOLEC SCI, P43
   Nguyen J, 2008, J GENE MED, V10, P1236, DOI 10.1002/jgm.1255
   Nguyen QT, 2010, P NATL ACAD SCI USA, V107, P4317, DOI 10.1073/pnas.0910261107
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oh E, 2011, ACS NANO, V5, P6434, DOI 10.1021/nn201624c
   Omata D, 2011, MOL PHARMACEUT, V8, P2416, DOI 10.1021/mp200353m
   Palm-Apergi C, 2011, METHODS MOL BIOL, V683, P339, DOI 10.1007/978-1-60761-919-2_24
   Petersen S, 2011, J PHYS CHEM C, V115, P5152, DOI 10.1021/jp1093614
   Pooga M, 1998, FASEB J, V12, P67
   Pujals S, 2007, BIOCHEM SOC T, V35, P794, DOI 10.1042/BST0350794                                                              
   Rahmat D, 2012, BIOMATERIALS, V33, P2321, DOI 10.1016/j.biomaterials.2011.11.046
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   RYSER HJP, 1965, SCIENCE, V150, P501, DOI 10.1126/science.150.3695.501
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Sawant RR, 2009, INT J PHARMACEUT, V374, P114, DOI 10.1016/j.ijpharm.2009.02.022
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Torchilin V, 2008, MULTIFUNCTIONAL PHAR
   Torchilin V, 2012, ADV DEL SCI TECHNOL, P289, DOI 10.1007/978-1-4614-0881-9_11
   Torchilin V, 2009, EUR J PHARM BIOPHARM, V71, P431, DOI 10.1016/j.ejpb.2008.09.026
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Verdurmen WPR, 2011, CHEM BIOL, V18, P1000, DOI 10.1016/j.chembiol.2011.06.006
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Yezhelyev MV, 2008, J AM CHEM SOC, V130, P9006, DOI 10.1021/ja800086u
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 81
TC 268
Z9 273
U1 15
U2 182
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD JUL
PY 2012
VL 18
IS 7
BP 385
EP 393
DI 10.1016/j.molmed.2012.04.012
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 976ZM
UT WOS:000306625900005
PM 22682515
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Cramer, S
   Rempe, R
   Galla, HJ
AF Cramer, S.
   Rempe, R.
   Galla, H-J.
TI Exploiting the Properties of Biomolecules for Brain Targeting of
   Nanoparticulate Systems
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Adsorptive-mediated endocytosis; brain; carbohydrates; cell-penetrating
   peptides; lectins; liposomes; nanoparticles; receptor-mediated
   endocytosis
ID CENTRAL-NERVOUS-SYSTEM; SELF-ASSEMBLED NANOPARTICLES; GROWTH-FACTOR
   RECEPTOR; IN-VITRO MODEL; LOW-DENSITY-LIPOPROTEIN;
   HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY SYSTEM; TRIMETHYL CHITOSAN
   CHLORIDE; SOLID LIPID NANOPARTICLES; DNA-LOADED NANOPARTICLES
AB The main obstacle in the treatment of central nervous system diseases is represented by a limited passage of diagnostic and therapeutic agents across the blood-brain barrier, which separates the blood stream from the cerebral parenchyma and maintains the homeostasis of the brain. The growing knowledge about the brain capillary endothelium and the discovery of specific mechanisms for the uptake of substances enables the development of various strategies to enhance the drug delivery rate into the brain. Among the different strategies, nanoparticles are promising candidates for drug delivery to the brain due to their potential in encapsulating drugs and thereby disguising their permeation limiting characteristics. Furthermore a surface functionalization of many nanoparticles can easily be achieved allowing the active targeting of nanoparticles to the brain. For this non-invasive approach, the surface functionalization of nanoparticles with biomolecules has shown promising potential for effective drug delivery to the brain.
   This review indexes the main classes of biomolecules used for the surface functionalization of nanoparticles and discusses their potential as drug delivery systems for an enhanced passage of diagnostic and therapeutic agents into the brain parenchyma.
C1 [Cramer, S.; Rempe, R.; Galla, H-J.] Univ Munster, Dept Biochem, D-48149 Munster, Germany.
RP Galla, HJ (reprint author), Univ Munster, Dept Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.
EM gallah@uni-muenster.de
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Agyare EK, 2008, PHARM RES-DORDR, V25, P2674, DOI 10.1007/s11095-008-9688-y
   Aktas Y, 2005, INT J PHARM, V298, P378, DOI 10.1016/j.ijpharm.2005.03.027
   Alam MI, 2010, EUR J PHARM SCI, V40, P385, DOI 10.1016/j.ejps.2010.05.003
   Alizadeh D, 2010, NANOMED-NANOTECHNOL, V6, P382, DOI 10.1016/j.nano.2009.10.001
   Allen DD, 2006, LIFE SCI, V78, P1029, DOI 10.1016/j.lfs.2005.06.004
   ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986
   ARTURSSON P, 1994, PHARMACEUT RES, V11, P1358, DOI 10.1023/A:1018967116988
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Begley DJ, 2004, PHARMACOL THERAPEUT, V104, P29, DOI 10.1016/j.pharmthera.2004.08.001
   Bell RD, 2007, J CEREBR BLOOD F MET, V27, P909, DOI 10.1038/sj.jcbfm.9600419
   BERGMANN P, 1984, CLIN SCI, V67, P35, DOI 10.1042/cs0670035                                                               
   BICKEL U, 1993, P NATL ACAD SCI USA, V90, P2618, DOI 10.1073/pnas.90.7.2618
   Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3
   Binkowski-Machut C, 2006, BIOORG MED CHEM LETT, V16, P1784, DOI 10.1016/j.bmcl.2006.01.031
   Bisht S, 2009, WIRES NANOMED NANOBI, V1, P415, DOI [10.1002/wnan.43, 10.1002/wnan.043]
   Bredel M, 1999, CLIN CANCER RES, V5, P1786
   BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6                                                   
   BROADWELL RD, 1989, ACTA NEUROPATHOL, V79, P117, DOI 10.1007/BF00294368                                                              
   Cao Y, 2006, J CLIN ONCOL, V24, P1228, DOI 10.1200/JCO.2005.04.7233
   Chavanpatil MD, 2007, MOL PHARM, V4, P730, DOI 10.1021/mp070024d
   Chen XG, 2003, J AGR FOOD CHEM, V51, P3135, DOI 10.1021/jf0208482
   Chrai SS, 2001, BIOPHARM-APPL T BIO, V14, P10
   Ciofani G, 2008, BIOMED MICRODEVICES, V10, P131, DOI 10.1007/s10544-007-9118-7
   Cirpanli Y, 2011, INT J PHARMACEUT, V403, P201, DOI 10.1016/j.ijpharm.2010.10.015
   Cirpanli Y, 2009, EUR J PHARM BIOPHARM, V73, P82, DOI 10.1016/j.ejpb.2009.04.013
   Clark DE, 2001, COMB CHEM HIGH T SCR, V4, P477
   Cornford Eain M, 2005, NeuroRx, V2, P27, DOI 10.1007/BF03206640
   CORNFORD EM, 1992, CANCER RES, V52, P138
   Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013
   Costantino L, 2006, BIOMATERIALS, V27, P4635, DOI 10.1016/j.biomaterials.2006.04.026
   Czub J, 2007, BBA-BIOMEMBRANES, V1768, P2616, DOI 10.1016/j.bbamem.2007.06.017
   Dale O, 2006, J PHARM PHARMACOL, V58, P909, DOI 10.1211/jpp.58.7.0005
   Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006
   DeGiovanni C, 1996, CANCER RES, V56, P3898
   Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x                                                
   Demeule M, 2008, J PHARMACOL EXP THER, V324, P1064, DOI 10.1124/jpet.107.131318
   Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x
   Pereira de Oliveira M., 2005, PHARM RES, V22, P1898, DOI DOI 10.1007/S11095-005-7147-6
   Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j
   DiMeco F, 2002, J NEUROSURG, V97, P1173, DOI 10.3171/jns.2002.97.5.1173
   Dorner L, 2011, J CLIN NEUROSCI, V18, P347, DOI 10.1016/j.jocn.2010.05.036
   Douglas KL, 2005, J BIOMAT SCI-POLYM E, V16, P43, DOI 10.1163/1568562052843339
   Du J, 2009, MOL PHARMACEUT, V6, P905, DOI 10.1021/mp800218q
   Dufes C, 2004, INT J PHARMACEUT, V285, P77, DOI 10.1016/j.ijpharm.2004.07.020
   DUFFY KR, 1988, METABOLISM, V37, P136, DOI 10.1016/S0026-0495(98)90007-5
   Dutta S, 1998, J PHARM PHARMACOL, V50, P37, DOI 10.1111/j.2042-7158.1998.tb03302.x                                              
   Eavarone DA, 2000, J BIOMED MATER RES, V51, P10, DOI 10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
   Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/endo.142.4.8084
   Erdlenbruch B, 2003, BRIT J PHARMACOL, V139, P685, DOI 10.1038/sj.bjp.0705302
   Ernst R, 2010, FEBS J, V277, P540, DOI 10.1111/j.1742-4658.2009.07485.x
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017
   Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011
   FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260
   FRANK HJL, 1985, DIABETES, V34, P728, DOI 10.2337/diabetes.34.8.728
   FRANK HJL, 1981, DIABETES, V30, P757, DOI 10.2337/diabetes.30.9.757
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fujita M, 2007, J CONTROL RELEASE, V122, P356, DOI 10.1016/j.jconrel.2007.05.032
   GALLIS HA, 1990, REV INFECT DIS, V12, P308
   Gan CW, 2010, BIOMATERIALS, V31, P7748, DOI 10.1016/j.biomaterials.2010.06.053
   Gao XL, 2008, BIOCONJUGATE CHEM, V19, P2189, DOI 10.1021/bc8002698
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   Geninatti C., 2006, J MED CHEM, V49, P4926
   Gil ES, 2009, BIOMACROMOLECULES, V10, P505, DOI 10.1021/bm801026k
   Girois SB, 2005, EUR J CLIN MICROBIOL, V24, P119, DOI 10.1007/s10096-005-1281-2
   GLICK RP, 1989, NEUROSURGERY, V24, P791, DOI 10.1227/00006123-198906000-00001                                                
   Gong W, 2011, BIOL PHARM BULL, V34, P1058, DOI 10.1248/bpb.34.1058                                                             
   Grabrucker AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017851
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREINACHER A, 1995, THROMB HAEMOSTASIS, V74, P886
   Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022
   Hall W.A, 1991, J NEUROSURG, V74, P941
   Hatakeyama H, 2004, INT J PHARM, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025
   He H, 2011, BIOMATERIALS, V32, P478, DOI 10.1016/j.biomaterials.2010.09.002
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Huang RQ, 2007, J BIOMED SCI, V14, P121, DOI 10.1007/s11373-006-9121-7
   Huang RQ, 2010, J NEUROL SCI, V290, P123, DOI 10.1016/j.jns.2009.09.032
   Huang RQ, 2009, J CEREBR BLOOD F MET, V29, P1914, DOI 10.1038/jcbfm.2009.104
   Huang SX, 2011, BIOMATERIALS, V32, P6832, DOI 10.1016/j.biomaterials.2011.05.064
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047
   Hyung Park J, 2006, BIOMATERIALS, V27, P119
   Iqbal U, 2010, BRIT J CANCER, V103, P1606, DOI 10.1038/sj.bjc.6605937
   Jallouli Y, 2007, INT J PHARMACEUT, V344, P103, DOI 10.1016/j.ijpharm.2007.06.023
   Janes KA, 2001, J CONTROL RELEASE, V73, P255, DOI 10.1016/S0168-3659(01)00294-2                                                   
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   JEGADEN D, 1993, INT ARCH OCC ENV HEA, V64, P527, DOI 10.1007/BF00381103                                                              
   Jeong YI, 2008, J PHARM SCI-US, V97, P1268, DOI 10.1002/jps.21103
   Jeong YI, 2006, J PHARM SCI-US, V95, P2348, DOI 10.1002/jps.20586
   Ji B, 2006, LIFE SCI, V78, P851, DOI 10.1016/j.lfs.2005.05.085
   Ji BQ, 2001, DRUG DELIV, V8, P13
   Kakkar V, 2011, FOOD CHEM TOXICOL, V49, P2906, DOI 10.1016/j.fct.2011.08.006
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   KATSURAYA K, 1994, CARBOHYD RES, V260, P51, DOI 10.1016/0008-6215(94)80021-9                                                    
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   KAYYALI R, 1994, FEBS LETT, V344, P221, DOI 10.1016/0014-5793(94)00378-5
   Keane MM, 1999, CANCER RES, V59, P734
   Khalifa A, 1997, NUCL MED COMMUN, V18, P17, DOI 10.1097/00006231-199701000-00005
   Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356
   Kim JH, 2006, J CONTROL RELEASE, V111, P228, DOI 10.1016/j.jconrel.2005.12.013
   Kim K, 2005, BIOMACROMOLECULES, V6, P1154, DOI 10.1021/bm049305m
   Kotze AF, 1998, J CONTROL RELEASE, V51, P35, DOI 10.1016/S0168-3659(97)00154-5                                                   
   Kratzer I, 2007, J CONTROL RELEASE, V117, P301, DOI 10.1016/j.jconrel.2006.11.020
   Krauland AH, 2006, INT J PHARMACEUT, V307, P270, DOI 10.1016/j.ijphann.2005.10.016
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kuhr F, 2010, NEUROPEPTIDES, V44, P145, DOI 10.1016/j.npep.2009.12.004
   KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214
   Lalancette-Hebert M, 2010, MOL PHARMACEUT, V7, P1183, DOI 10.1021/mp1000372
   Lamprecht A, 2006, J CONTROL RELEASE, V112, P208, DOI 10.1016/j.jconrel.2006.02.014
   Lawrenson JG, 2000, J ANAT, V196, P55, DOI 10.1046/j.1469-7580.2000.19610055.x
   LEAMON CP, 1992, J BIOL CHEM, V267, P24966
   LEAMON CP, 1993, J BIOL CHEM, V268, P24847
   Lee HJ, 2000, J PHARMACOL EXP THER, V292, P1048
   Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9
   Leitner VM, 2003, EUR J PHARM BIOPHARM, V56, P207, DOI 10.1016/S0939-6411(03)00061-4
   LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022                                                             
   Lewis JS, 1997, CLIN THER, V19, P187, DOI 10.1016/S0149-2918(97)80110-5
   LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0
   Liu CG, 2005, J AGR FOOD CHEM, V53, P437, DOI 10.1021/jf040188w
   Liu LB, 2008, J NEUROSCI RES, V86, P1153, DOI 10.1002/jnr.21558
   Liu Lihong, 2008, Biomaterials, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Liu XL, 2011, PHARM RES-DORDR, V28, P962, DOI 10.1007/s11095-010-0303-7
   Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481                                                           
   Lohbach C, 2006, J NANOSCI NANOTECHNO, V6, P3303, DOI 10.1166/jnn.2006.476
   Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728
   LOSSINSKY AS, 1995, J NEUROCYTOL, V24, P795, DOI 10.1007/BF01191215
   Lu W, 2005, INT J PHARM, V295, P247, DOI 10.1016/j.ijpharm.2005.01.043
   Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027
   Mahoney MJ, 1996, J PHARM SCI, V85, P1276, DOI 10.1021/js9601602
   Maletinska L, 2000, CANCER RES, V60, P2300
   Mao SR, 2005, BIOMATERIALS, V26, P6343, DOI 10.1016/j.biomaterials.2005.03.036
   Mao SR, 2006, J PHARM SCI-US, V95, P1035, DOI 10.1002/jps.20520
   Markert S, 2008, ANTICANCER RES, V28, P3567
   Marquet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022598
   MATHIESON PW, 1990, NEW ENGL J MED, V323, P250, DOI 10.1056/NEJM199007263230407                                                     
   Mehvar Reza, 2003, Current Pharmaceutical Biotechnology, V4, P283, DOI 10.2174/1389201033489685
   Mei D, 2008, EUR J PHARM BIOPHARM, V70, P874, DOI 10.1016/j.ejpb.2008.06.031
   Menei P, 1999, CANCER, V86, P325, DOI 10.1002/(SICI)1097-0142(19990715)86:2<325::AID-CNCR17>3.0.CO;2-S
   Menendez JA, 2001, EUR J CANCER, V37, P402, DOI 10.1016/S0959-8049(00)00408-1
   Menendez JA, 2006, EUR J CANCER, V42, P2425, DOI 10.1016/j.ejca.2005.10.016
   MEZA I, 1982, J CELL BIOCHEM, V18, P407, DOI 10.1002/jcb.1982.240180403
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Mishima K, 2003, NEUROPHARMACOLOGY, V44, P541, DOI 10.1016/S0028-3908(02)00408-2
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X                                                   
   Molnar E, 2010, BIOMACROMOLECULES, V11, P2880, DOI 10.1021/bm100577x
   Monnaert V, 2004, J PHARMACOL EXP THER, V311, P1115, DOI 10.1124/jpet.104.071845
   Monnaert V, 2004, J PHARMACOL EXP THER, V310, P745, DOI 10.1124/jpet.104.067512
   Moos T, 2001, J NEUROCHEM, V79, P119, DOI 10.1046/j.1471-4159.2001.00541.x                                                
   MORONI MC, 1992, J BIOL CHEM, V267, P2714
   MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851
   MUCKERHEIDE A, 1987, J IMMUNOL, V138, P833
   Murtas S, 2005, J BIOMAT SCI-POLYM E, V16, P829, DOI 10.1163/1568562054255718
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Na K, 2003, J CONTROL RELEASE, V87, P3, DOI 10.1016/S0168-3659(02)00345-0
   Nagamatsu S, 1996, BIOCHEM J, V319, P477, DOI 10.1042/bj3190477                                                               
   Nagpal K, 2010, CHEM PHARM BULL, V58, P1423, DOI 10.1248/cpb.58.1423                                                             
   Nikanjam M, 2007, INT J PHARM, V328, P86, DOI 10.1016/j.ijpharm.2006.07.046
   OCRANT I, 1990, ENDOCRINOLOGY, V127, P1260, DOI 10.1210/endo-127-3-1260                                                         
   Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4
   Pan D, 2008, J AM CHEM SOC, V130, P9186, DOI 10.1021/ja801482d
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan WH, 2004, J CELL SCI, V117, P5071, DOI 10.1242/jcs.01381
   Pang ZQ, 2008, J CONTROL RELEASE, V128, P120, DOI 10.1016/j.jconrel.2008.03.007
   PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V255, P893
   PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66
   Parikh T, 2010, EUR J PHARM BIOPHARM, V74, P442, DOI 10.1016/j.ejpb.2009.11.001
   Park JH, 2004, J CONTROL RELEASE, V95, P579, DOI 10.1016/j.jconrel.2003.12.020
   Park JS, 2006, J CONTROL RELEASE, V115, P37, DOI 10.1016/j.jconrel.2006.07.011
   Pen A, 2007, GLIA, V55, P559, DOI 10.1002/glia.20481
   Pillay S, 2009, INT J PHARMACEUT, V382, P277, DOI 10.1016/j.ijpharm.2009.08.021
   Pinarbasli O, 2009, PHARMAZIE, V64, P436, DOI 10.1691/ph.2009.8374
   Polt R, 2005, MED RES REV, V25, P557, DOI 10.1002/med.20039
   Qin Y, 2010, J DRUG TARGET, V18, P536, DOI 10.3109/10611861003587235
   Qu XZ, 2006, BIOMACROMOLECULES, V7, P3452, DOI 10.1021/bm0604000
   RAHMAN A, 1992, J NATL CANCER I, V84, P1909, DOI 10.1093/jnci/84.24.1909
   Re F, 2010, J BIOTECHNOL, V156, P341
   Rempe R, 2011, BIOCHEM BIOPH RES CO, V406, P64, DOI 10.1016/j.bbrc.2011.01.110
   Reukov V, 2011, BIOTECHNOL BIOENG, V108, P243, DOI 10.1002/bit.22958
   Roger M., 2011, INT J PHARMACEUT, V423, P63
   ROSS JF, 1994, CANCER, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
   Saboktakin MR, 2011, INT J BIOL MACROMOL, V49, P747, DOI 10.1016/j.ijbiomac.2011.07.006
   SAITO H, 1991, CARBOHYD RES, V217, P181, DOI 10.1016/0008-6215(91)84128-2
   Salgado AJ, 2010, MACROMOL BIOSCI, V10, P1130, DOI 10.1002/mabi.201000005
   SASAKI T, 1979, EUR J CANCER, V15, P211, DOI 10.1016/0014-2964(79)90062-8                                                    
   Saul JM, 2003, J CONTROL RELEASE, V92, P49, DOI 10.1016/S0168-3659(03)00295-5
   Schipper NGM, 1997, PHARMACEUT RES, V14, P923, DOI 10.1023/A:1012160102740
   Schirmacher A, 2000, BIOELECTROMAGNETICS, V21, P338, DOI 10.1002/1521-186X(200007)21:5<338::AID-BEM2>3.3.CO;2-H
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Selvi BR, 2008, NANO LETT, V8, P3182, DOI 10.1021/nl801503m
   Shao K, 2010, J CONTROL RELEASE, V147, P118, DOI 10.1016/j.jconrel.2010.06.018
   Smith JM, 2005, BIOMATERIALS, V26, P3269, DOI 10.1016/j.biomaterials.2004.06.020
   SMITH KR, 1989, PHARMACEUT RES, V6, P466, DOI 10.1023/A:1015960205409                                                         
   Son YJ, 2003, J CONTROL RELEASE, V91, P135, DOI 10.1016/S0168-3659(03)00231-1
   STEVEN AC, 1983, J CELL BIOL, V97, P1714, DOI 10.1083/jcb.97.6.1714
   Storm PB, 2002, J NEURO-ONCOL, V56, P209, DOI 10.1023/A:1015003232713                                                         
   Sugimoto Y, 2003, MOL CANCER THER, V2, P105
   Sun XM, 2004, ANGEW CHEM INT EDIT, V43, P597, DOI 10.1002/anie.200352386
   Tahara K, 2011, EUR J PHARM BIOPHARM, V77, P84, DOI 10.1016/j.ejpb.2010.11.002
   Tahara K, 2009, INT J PHARMACEUT, V382, P198, DOI 10.1016/j.ijpharm.2009.07.023
   TAKADA G, 1982, TOHOKU J EXP MED, V136, P219, DOI 10.1620/tjem.136.219
   Talukder MJR, 2003, J VET MED SCI, V65, P957, DOI 10.1292/jvms.65.957
   Thole M, 2002, J DRUG TARGET, V10, P337, DOI 10.1080/10611860290031840
   Tilloy S, 2006, BIOORG MED CHEM LETT, V16, P2154, DOI 10.1016/j.bmcl.2006.01.049
   Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022
   Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008
   Tosi G., J CONTROL RELEASE, V145, P49
   Towner RA, 2010, TISSUE ENG PT A, V16, P357, DOI 10.1089/ten.TEA.2009.0233
   TRIGUERO D, 1989, P NATL ACAD SCI USA, V86, P4761, DOI 10.1073/pnas.86.12.4761
   TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x
   Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1007/BF03206642
   Ulbrich K, 2011, INT J PHARMACEUT, V406, P128, DOI 10.1016/j.ijpharm.2010.12.023
   Ulbrich K, 2009, EUR J PHARM BIOPHARM, V71, P251, DOI 10.1016/j.ejpb.2008.08.021
   ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0
   UMEZAWA F, 1988, BIOCHEM BIOPH RES CO, V153, P1038, DOI 10.1016/S0006-291X(88)81333-0                                                   
   Uner M, 2007, INT J NANOMED, V2, P289
   van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889                                                       
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Verreault M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-124
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   VORBRODT AW, 1986, J HISTOCHEM CYTOCHEM, V34, P251, DOI 10.1177/34.2.3753715                                                            
   Wang SL, 2010, INT J PHARMACEUT, V386, P249, DOI 10.1016/j.ijpharm.2009.11.002
   Wang XM, 2008, EUR J PHARM BIOPHARM, V70, P735, DOI 10.1016/j.ejpb.2008.07.005
   Wang ZH, 2010, BIOMATERIALS, V31, P908, DOI 10.1016/j.biomaterials.2009.09.104
   Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x                                              
   Weber EL, 2005, NEURO-ONCOLOGY, V7, P84, DOI 10.1215/S1152851704000614                                                       
   Wee S, 1998, ADV DRUG DELIVERY RE, V4, P267, DOI DOI 10.1016/S0169-409X(97)00124-5
   WEITMAN SD, 1992, CANCER RES, V52, P3396
   Wen ZY, 2011, J CONTROL RELEASE, V151, P131, DOI 10.1016/j.jconrel.2011.02.022
   Werle M, 2006, J CONTROL RELEASE, V111, P41, DOI 10.1016/j.cornel.2005.11.011
   Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79
   Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200
   WIESSNER JH, 1982, BIOCHIM BIOPHYS ACTA, V689, P490, DOI 10.1016/0005-2736(82)90307-8                                                    
   Wilson B, 2009, J NEUROSCI METH, V177, P427, DOI 10.1016/j.jneumeth.2008.10.036
   Wu DF, 1999, PHARMACEUT RES, V16, P415, DOI 10.1023/A:1018829920158
   Wu G, 2006, MOL CANCER THER, V5, P52, DOI 10.1158/1535-7163.MCT-05-0325
   Xiang JJ, 2003, J GENE MED, V5, P803, DOI 10.1002/jgm.419
   Xie H, 2011, BIOMATERIALS, V32, P495, DOI 10.1016/j.biomaterials.2010.09.024
   Xin HL, 2011, BIOMATERIALS, V32, P4293, DOI 10.1016/j.biomaterials.2011.02.044
   Yamamoto M, 1997, CANCER RES, V57, P2799
   Ying X, 2011, PHARMACOLOGY, V87, P105, DOI 10.1159/000323222
   Ying X, 2010, J CONTROL RELEASE, V141, P183, DOI 10.1016/j.jconrel.2009.09.020
   Zhang J, 2007, NANOMED-NANOTECHNOL, V3, P258, DOI 10.1016/j.nano.2007.08.002
   Zhang L, 2009, AAPS J, V11, P693, DOI 10.1208/s12248-009-9151-y
   Zhang Y, 2002, J GENE MED, V4, P183, DOI 10.1002/jgm.255
   Zhao H, 2010, J INT MED RES, V38, P957, DOI 10.1177/147323001003800322                                                      
   Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207
   Zhao XB, 2008, EXPERT OPIN DRUG DEL, V5, P309, DOI [10.1517/17425247.5.3.309, 10.1517/17425247.5.3.309 ]
NR 252
TC 5
Z9 5
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD JUL
PY 2012
VL 19
IS 19
BP 3163
EP 3187
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 967ZD
UT WOS:000305945800006
PM 22612701
DA 2018-01-05
ER

PT J
AU Marchionni, I
   Beaumont, M
   Maccaferri, G
AF Marchionni, Ivan
   Beaumont, Michael
   Maccaferri, Gianmaria
TI The chemokine CXCL12 and the HIV-1 envelope protein gp120 regulate
   spontaneous activity of Cajal-Retzius cells in opposite directions
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID HIPPOCAMPAL-FORMATION; INTRINSIC EFFICACY; POTASSIUM CHANNELS;
   NEURONAL-ACTIVITY; RECEPTOR CXCR4; REELER MICE; FACTOR-I; EXPRESSION;
   MOUSE; CONNECTIONS
AB Key points The CXC chemokine ligand 12 (CXCL12) modulates spontaneous firing of CajalRetzius cells via the CXC chemokine receptor 4 (CXCR4). However, the underlying mechanism(s) are poorly understood. CXCR4 also binds the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein 120 (gp120), but the functional effects of this interaction on CajalRetzius cell excitability remain unknown. We show that CXCL12 reduces spontaneous firing in CajalRetzius cells by opening a BK-type calcium-activated potassium conductance, whereas gp120 increases their excitability via a calcium- and chloride-dependent mechanism. Our data suggest that, depending on the use of CXCL12 or gp120 as ligands, partial agonism at the CXCR4 receptor generates calcium responses of different strengths, which lead to the recruitment of either calcium-activated potassium or chloride channels. We propose that HIV infection disrupts a signalling pathway important for the regulation of the excitability of CajalRetzius cells, and alters their functions. Abstract Activation of the CXC chemokine receptor 4 (CXCR4) in CajalRetzius cells by CXC chemokine ligand 12 (CXCL12) is important for controlling their excitability. CXCR4 is also a co-receptor for the glycoprotein 120 (gp120) of the envelope of the human immunodeficiency virus type 1 (HIV-1), and binding of gp120 to CXCR4 may produce pathological effects. In order to study CXCR4-dependent modulation of membrane excitability, we recorded in cell-attached configuration spontaneous action currents from hippocampal stratum lacunosum-moleculare CajalRetzius cells of the CXCR4-EGFP mouse. CXCL12 (50 nm) powerfully inhibited firing independently of synaptic transmission, suggesting that CXCR4 regulates an intrinsic conductance. This effect was prevented by conditioning slices with BAPTA-AM (200 mu m), and by blockers of the BK calcium-dependent potassium channels (TEA (1 mm), paxilline (10 mu m) and iberiotoxin (100 nm)). In contrast, exposure to gp120 (pico- to nanomolar range, alone or in combination with soluble cluster of differentiation 4 (CD4)), enhanced spontaneous firing frequency. This effect was prevented by the CXCR4 antagonist AMD3100 (1 mu m) and was absent in EGFP-negative stratum lacunosum-moleculare interneurons. Increased excitability was prevented by treating slices with BAPTA-AM or bumetanide, suggesting that gp120 activates a mechanism that is both calcium- and chloride-dependent. In conclusion, our results demonstrate that CXCL12 and gp120 modulate the excitability of CajalRetzius cells in opposite directions. We propose that CXCL12 and gp120 either generate calcium responses of different strength or activate distinct pools of intracellular calcium, leading to agonist-specific responses, mediated by BK channels in the case of CXCL12, and by a chloride-dependent mechanism in the case of gp120.
C1 [Marchionni, Ivan; Beaumont, Michael; Maccaferri, Gianmaria] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA.
RP Maccaferri, G (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Physiol, 303 E Chicago Ave,Tarry Blg Rm 5-707, Chicago, IL 60611 USA.
EM g-maccaferri@northwestern.edu
FU National Institute of Neurological Disorders and Stroke (NINDS)
   [NS064135]
FX We thank Drs Richard Miller and Marco Martina for comments on a previous
   version of the manuscript and discussion. This work was supported by the
   National Institute of Neurological Disorders and Stroke (NINDS)
   (NS064135, G.M.).
CR Abraham H, 2004, HIPPOCAMPUS, V14, P385, DOI 10.1002/hipo.10180
   Abraham H, 2003, HIPPOCAMPUS, V13, P715, DOI 10.1002/hipo.10125
   Achilles K, 2007, J NEUROSCI, V27, P8616, DOI 10.1523/JNEUROSCI.5041-06.2007
   Aguilo A, 1999, J NEUROSCI, V19, P10856
   Ahuja S, 2009, TRENDS PHARMACOL SCI, V30, P494, DOI 10.1016/j.tips.2009.06.003
   Alcantara S, 1998, J NEUROSCI, V18, P7779
   Andrade AL, 2010, J PHYSIOL-LONDON, V588, P1499, DOI 10.1113/jphysiol.2010.187609
   Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200
   Bodner A, 2003, J NEUROIMMUNOL, V140, P1, DOI 10.1016/S0165-5728(03)00162-0
   Borrell V, 1999, EXP NEUROL, V156, P268, DOI 10.1006/exnr.1999.7022
   Borrell V, 2006, NAT NEUROSCI, V9, P1284, DOI 10.1038/nn1764
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518
   Chameau P, 2009, P NATL ACAD SCI USA, V106, P7227, DOI 10.1073/pnas.0810764106
   Chowdhury TG, 2010, FRONT NEUROANAT, V40, P10
   Clarke WP, 1998, TRENDS PHARMACOL SCI, V19, P270, DOI 10.1016/S0165-6147(97)01138-3
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   DELRIO JA, 1995, CEREB CORTEX, V5, P13, DOI 10.1093/cercor/5.1.13
   DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0
   Derer P, 2001, J COMP NEUROL, V440, P136, DOI 10.1002/cne.1375                                                                
   Drakew A, 1998, NEUROSCIENCE, V82, P1079
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   Drummond GB, 2009, J PHYSIOL-LONDON, V587, P713, DOI 10.1113/jphysiol.2008.167387
   Dwinell MB, 2004, AM J PHYSIOL-GASTR L, V286, pG844, DOI 10.1152/ajpgi.00112.2003
   Epstein LG, 1999, J LEUKOCYTE BIOL, V65, P453
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Florio T, 2006, MOL PHARMACOL, V69, P539, DOI 10.1124/mol.105.015255
   Frotscher M, 2003, CEREB CORTEX, V13, P634, DOI 10.1093/cercor/13.6.634
   Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2                                                   
   FULLER CM, 1994, J BIOL CHEM, V269, P26642
   Garcia NVD, 2011, NATURE, V472, P351, DOI 10.1038/nature09865
   Guyon A, 2007, J MOL ENDOCRINOL, V38, P365, DOI 10.1677/JME-06-0013
   Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341
   Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8                                                   
   Hevner RF, 2003, DEV BRAIN RES, V141, P39, DOI 10.1016/S0165-3806(02)00641-7
   IMAMOTO K, 1994, NEUROSCI RES, V20, P101, DOI 10.1016/0168-0102(94)90027-2
   Ina A, 2007, EUR J NEUROSCI, V26, P615, DOI 10.1111/j.1460-9568.2007.05703.x
   Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11
   IWATSUKI N, 1985, J MEMBRANE BIOL, V86, P139, DOI 10.1007/BF01870780
   Janusonis S, 2004, J NEUROSCI, V24, P1652, DOI 10.1523/JNEUROSCI.4651-03.2004
   Khan MZ, 2004, AIDS RES HUM RETROV, V20, P1063, DOI 10.1089/aid.2004.20.1063
   Kleemann P, 2008, N-S ARCH PHARMACOL, V378, P261, DOI 10.1007/s00210-008-0313-8
   Lacor PN, 2000, P NATL ACAD SCI USA, V97, P3556, DOI 10.1073/pnas.050589597
   Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x
   LO TM, 1992, BRAIN RES, V594, P189, DOI 10.1016/0006-8993(92)91125-X
   Maccaferri G, 2011, J PHYSIOL-LONDON, V589, P1885, DOI 10.1113/jphysiol.2010.201079
   Marchionni I, 2010, J PHYSIOL-LONDON, V588, P2859, DOI 10.1113/jphysiol.2010.190868
   Medina I, 1999, EUR J NEUROSCI, V11, P1167, DOI 10.1046/j.1460-9568.1999.00550.x                                                
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500                                                        
   Mienville JM, 1998, J PHYSIOL-LONDON, V512, P809, DOI 10.1111/j.1469-7793.1998.809bd.x                                                
   Mienville JM, 1999, J NEUROSCI, V19, P1636
   Mienville JM, 1999, CEREB CORTEX, V9, P776, DOI 10.1093/cercor/9.8.776                                                          
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175
   OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1
   Oh SB, 2001, J NEUROSCI, V21, P5027
   OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251
   OMRI B, 1994, INT IMMUNOL, V6, P377, DOI 10.1093/intimm/6.3.377                                                          
   Paredes MF, 2006, J NEUROSCI, V26, P9404, DOI 10.1523/JNEUROSCI.2575-06.2006
   Pozas E, 2008, BRAIN RES, V1239, P85, DOI 10.1016/j.brainres.2008.08.058
   Qian X, 2006, J GEN PHYSIOL, V128, P389, DOI 10.1085/jgp.200609486
   Radnikow G, 2002, J NEUROSCI, V22, P6908
   Rychert J, 2010, AIDS RES HUM RETROV, V26, P1139, DOI 10.1089/aid.2009.0290
   SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2                                                    
   Schonemeier B, 2008, J COMP NEUROL, V510, P207, DOI 10.1002/cne.21780
   Soda T, 2003, J NEUROSCI, V23, P6272
   Sodickson DL, 1996, J NEUROSCI, V16, P6374
   Soriano E, 2005, NEURON, V46, P389, DOI 10.1016/j.neuron.2005.04.019
   Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300
   Stoltenburg G, 1991, Verh Dtsch Ges Pathol, V75, P191
   Stumm RK, 2003, J NEUROSCI, V23, P5123
   Stumm RK, 2002, J NEUROSCI, V22, P5865
   Super H, 1998, J NEUROSCI, V18, P4616
   Tinnes S, 2011, FASEB J, V25, P1002, DOI 10.1096/fj.10-168294
   Tiveron MC, 2010, J NEUROIMMUNOL, V224, P72, DOI 10.1016/j.jneuroim.2010.05.011
   Tran PB, 2005, J NEUROIMMUNOL, V160, P68, DOI 10.1016/j.jneuroim.2004.11.001
   Womack MD, 2002, EUR J NEUROSCI, V16, P1214, DOI 10.1046/j.1460-9568.2002.02171.x
   Xu CS, 2011, GLIA, V59, P997, DOI 10.1002/glia.21171
NR 79
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD JUL
PY 2012
VL 590
IS 13
BP 3185
EP 3202
DI 10.1113/jphysiol.2011.224873
PG 18
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 965VX
UT WOS:000305796600020
PM 22473778
OA gold
DA 2018-01-05
ER

PT J
AU Lehto, T
   Kurrikoff, K
   Langel, U
AF Lehto, Taavi
   Kurrikoff, Kaido
   Langel, Ulo
TI Cell-penetrating peptides for the delivery of nucleic acids
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE cell-penetrating peptide; gene delivery; nanoparticle; oligonucleotide
   delivery; siRNA delivery
ID ARGININE-RICH PEPTIDES; SPLICE-CORRECTING OLIGONUCLEOTIDES; CONJUGATED
   MORPHOLINO OLIGOMERS; DUCHENNE MUSCULAR-DYSTROPHY; SMALL INTERFERING
   RNA; DEFICIENT MDX MICE; HIV-1 TAT PROTEIN; GENE DELIVERY;
   MAMMALIAN-CELLS; ANTISENSE OLIGONUCLEOTIDES
AB Introduction: Different gene therapy approaches have gained extensive interest lately and, after many initial hurdles, several promising approaches have reached to the clinics. Successful implementation of gene therapy is heavily relying on finding efficient measures to deliver genetic material to cells. Recently, non-viral delivery of nucleic acids and their analogs has gained significant interest. Among non-viral vectors, cell-penetrating peptides (CPPs) have been extensively used for the delivery of nucleic acids both in vitro and in vivo.
   Areas covered: In this review we will discuss recent advances of CPP-mediated delivery of nucleic acid-based cargo, concentrating on the delivery of plasmid DNA, splice-correcting ONs, and small-interfering RNAs.
   Expert opinion: CPPs have proved their potential as carriers for nucleic acids. However, similarly to other non-viral vectors, CPPs require further development, as efficient systemic delivery is still seldom achieved. To achieve this, CPPs should be modified with entities that would allow better endosomal escape, targeting of specific tissues and cells, and shielding agents that increase the half-life of the vehicles. Finally, to understand the clinical potential of CPPs, they require more thorough investigations in clinically relevant disease models and in pre-clinical and clinical studies.
C1 [Lehto, Taavi; Kurrikoff, Kaido; Langel, Ulo] Univ Tartu, Inst Technol, Mol Biotechnol Lab, EE-50411 Tartu, Estonia.
   [Langel, Ulo] Stockholm Univ, Dept Neurochem, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden.
RP Lehto, T (reprint author), Univ Tartu, Inst Technol, Mol Biotechnol Lab, Nooruse 1, EE-50411 Tartu, Estonia.
EM tlehto@ut.ee
RI Kurrikoff, Kaido/D-1518-2010; Lehto, Taavi/B-7798-2010
OI Kurrikoff, Kaido/0000-0002-5161-8930; 
FU Swedish Research Council (VR-NT); Cancerfoundation, Sweden; EU through
   European Regional Development Fund through Center of Excellence in
   Chemical Biology, Estonia; Estonian Government [SF0180027s08]
FX This work was supported by the Swedish Research Council (VR-NT); by
   Cancerfoundation, Sweden; by the EU through the European Regional
   Development Fund through the Center of Excellence in Chemical Biology,
   Estonia; by the targeted financing SF0180027s08 from the Estonian
   Government.
CR Abes R, 2008, NUCLEIC ACIDS RES, V36, P6343, DOI 10.1093/nar/gkn541
   Abes S, 2007, NUCLEIC ACIDS RES, V35, P4495, DOI 10.1093/nar/gkm418
   Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   Andaloussi SEL, 2011, METHODS MOL BIOL, V683, P361, DOI 10.1007/978-1-60761-919-2_26
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654
   Brasseur R, 2010, BBA-BIOMEMBRANES, V1798, P2177, DOI 10.1016/j.bbamem.2010.09.001
   Burrer R, 2007, J VIROL, V81, P5637, DOI 10.1128/JVI.02360-06
   Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005
   Edinger D, 2011, WIRES NANOMED NANOBI, V3, P33, DOI 10.1002/wnan.97
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2
   El Andaloussi S., 2011, NUCLEIC ACIDS RES, V39, P3972, DOI DOI 10.1093/NAR/GKQ1299
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   Ezzat K, 2012, FASEB J, V26, P1172, DOI 10.1096/fj.11-191536
   Ezzat K, 2011, NUCLEIC ACIDS RES, V39, P5284, DOI 10.1093/nar/gkr072
   Ezzat K, 2010, CURR PHARM DESIGN, V16, P1167, DOI 10.2174/138161210790963832                                                      
   Fletcher S, 2007, MOL THER, V15, P1587, DOI 10.1038/sj.mt.6300245
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Fujita T, 2008, J CONTROL RELEASE, V129, P124, DOI 10.1016/j.jconrel.2008.04.010
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Govindarajan S, 2012, BIOMATERIALS, V33, P2570, DOI 10.1016/j.biomaterials.2011.12.003
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Hassane FS, 2011, J CONTROL RELEASE, V153, P163, DOI 10.1016/j.jconrel.2011.04.013
   Hatakeyama H, 2009, J CONTROL RELEASE, V139, P127, DOI 10.1016/j.jconrel.2009.06.008
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Ivanova GD, 2008, NUCLEIC ACIDS RES, V36, P6418, DOI 10.1093/nar/gkn671
   Jearawiriyapaisarn N, 2008, MOL THER, V16, P1624, DOI 10.1038/mt.2008.120
   Jearawiriyapaisarn N, 2010, CARDIOVASC RES, V85, P444, DOI 10.1093/cvr/cvp335
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Kaiser J, 2011, SCIENCE, V334, P29, DOI 10.1126/science.334.6052.29
   Kay MA, 2011, NAT REV GENET, V12, P316, DOI 10.1038/nrg2971
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Kole R, 2012, NAT REV DRUG DISCOV, V2011, P125
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lehto T, 2011, PROG MOL BIOL TRANSL, V104, P397, DOI 10.1016/B978-0-12-416020-0.00010-3
   Lehto T, 2011, MOL THER, V19, P1457, DOI 10.1038/mt.2011.10
   Lehto T, 2010, J CONTROL RELEASE, V141, P42, DOI 10.1016/j.jconrel.2009.08.028
   Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Mae M, 2009, EXPERT OPIN DRUG DEL, V6, P1195, DOI 10.1517/17425240903213688
   Mae M, 2009, J CONTROL RELEASE, V134, P221, DOI 10.1016/j.jconrel.2008.11.025
   Maeda H, 2011, ADV DRUG DELIVER REV, V63, P129, DOI 10.1016/j.addr.2010.05.001
   McClorey G, 2006, GENE THER, V13, P1373, DOI 10.1038/sj.gt.3302800
   Meyer Martin, 2006, Expert Opin Drug Deliv, V3, P563, DOI 10.1517/17425247.3.5.563
   Michiue H, 2009, CANCER BIOL THER, V8, P2306
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510                                                          
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moulton HM, 2007, BIOCHEM SOC T, V35, P826, DOI 10.1042/BST0350826                                                              
   Moulton HM, 2003, ANTISENSE NUCLEIC A, V13, P31, DOI 10.1089/108729003764097322
   Moulton HM, 2009, ANN NY ACAD SCI, V1175, P55, DOI 10.1111/j.1749-6632.2009.04976.x
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nakamura Y, 2007, J CONTROL RELEASE, V119, P360, DOI 10.1016/j.jconrel.2007.03.010
   Nakase I, 2011, ACC CHEM RE IN PRESS
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Ogris M, 2011, HUM GENE THER, V22, P799, DOI 10.1089/hum.2011.065
   Oskolkov N, 2011, INT J PEPT RES THER, V17, P147, DOI 10.1007/s10989-011-9252-1
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Pooga M, 1998, FASEB J, V12, P67
   Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167
   Read SP, 2010, J GENE MED, V12, P86, DOI 10.1002/jgm.1415
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rydstrom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025924
   Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Svasti S, 2009, P NATL ACAD SCI USA, V106, P1205, DOI 10.1073/pnas.0812436106
   Tonges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Trabulo S, 2008, J GENE MED, V10, P1210, DOI 10.1002/jgm.1247
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HY, 2010, J CONTROL RELEASE, V155, P26
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Whitney MA, 2011, NAT BIOTECHNOL, V29, P352, DOI 10.1038/nbt.1764
   Wolf Y, 2006, BIOCHEMISTRY-US, V45, P14944, DOI 10.1021/bi0606896
   Wood MJA, 2010, BRAIN, V133, P957, DOI 10.1093/brain/awq002
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Yin HF, 2010, MOL THER, V18, P1822, DOI 10.1038/mt.2010.151
   Yin HF, 2009, HUM MOL GENET, V18, P4405, DOI 10.1093/hmg/ddp395
   Yin H, 2008, HUM MOL GENET, V17, P3909, DOI 10.1093/hmg/ddn293
NR 100
TC 63
Z9 64
U1 4
U2 59
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2012
VL 9
IS 7
BP 823
EP 836
DI 10.1517/17425247.2012.689285
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 961PK
UT WOS:000305478200008
PM 22594635
DA 2018-01-05
ER

PT J
AU Ham, AS
   Rohan, LC
   Boczar, A
   Yang, L
   Buckheit, KW
   Buckheit, RW
AF Ham, Anthony S.
   Rohan, Lisa Cencia
   Boczar, Ashlee
   Yang, Lu
   Buckheit, Karen W.
   Buckheit, Robert W., Jr.
TI Vaginal Film Drug Delivery of the Pyrimidinedione IQP-0528 for the
   Prevention of HIV Infection
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE films; formulation; HIV; microbicides; pyrimidinedione
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PHASE-I SAFETY; CELLULOSE SULFATE;
   TOPICAL MICROBICIDES; ACCEPTABILITY; TRANSMISSION; WOMEN; GEL; SERIES
AB Polymeric quick-dissolving films were developed as a solid dosage topical microbicide formulation for the vaginal delivery of the highly potent and non-toxic, dual-acting HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) pyrimidinedione, IQP-0528.
   Formulated from approved excipients, a polyvinyl alcohol (PVA) based film was manufactured via solvent casting methods. The film formulations were evaluated based upon quantitative physicochemical evaluations defined by a Target Product Profile (TPP)
   Films dosed with 0.1% (w/w) of IQP-0528 disintegrated within 10 min with over 50% of drug released and near 100% total drug released after 30 min. The IQP-0528 films were found to be non-toxic in in vitro CEM-SS and PBMC cell-based assays and biologically active with sub-nanomolar efficacy against HIV-1 infection. In a 12 month stability protocol, the IQP-0528 films demonstrated no significant degradation at International Conference on Harmonization (ICH) recommended standard (25A degrees C/65% relative humidity (R.H.)) and accelerated (40A degrees C/75% R.H.) environmental conditions.
   Based on the above evaluations, a vaginal film formulation has been identified as a potential solid dosage form for the vaginal delivery of the topical microbicide candidate IQP-0528.
C1 [Ham, Anthony S.; Boczar, Ashlee; Yang, Lu; Buckheit, Karen W.; Buckheit, Robert W., Jr.] ImQuest BioSci Inc, Frederick, MD 21704 USA.
   [Rohan, Lisa Cencia] Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
RP Ham, AS (reprint author), ImQuest BioSci Inc, 7340 Execut Way,Suite R, Frederick, MD 21704 USA.
EM aham@imquestbio.com
FU NIAID NIH HHS [R21 AI088586]
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Buckheit Robert W. Jr., 2007, Antiviral Chemistry & Chemotherapy, V18, P259
   Buckheit RW, 2008, ANTIMICROB AGENTS CH, V52, P225, DOI 10.1128/AAC.00972-07
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   El-Sadr WM, 2006, AIDS, V20, P1109, DOI 10.1097/01.aids.0000226950.72223.5f                                             
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   Harrison PF, 2003, CLIN INFECT DIS, V36, P1290, DOI 10.1086/374834
   Holt BY, 2006, J WOMENS HEALTH, V15, P281, DOI 10.1089/jwh.2006.15.281                                                         
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Linhares IM, 2011, AM J OBSTET GYNECOL, V204
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Malonza IM, 2005, AIDS, V19, P2157, DOI 10.1097/01.aids.0000194797.59046.8f
   CK Mauk, 1997, CONTRACEPTION, V56, P89
   Mayer KH, 2001, CLIN INFECT DIS, V32, P476, DOI 10.1086/318496
   MCCORMACK S, 2010, LANCET, V276, P1329
   Mizrahi Boaz, 2008, Recent Pat Drug Deliv Formul, V2, P108, DOI 10.2174/187221108784534126
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Pool R, 2000, Cult Health Sex, V2, P197, DOI 10.1080/136910500300804
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Schwartz JL, 2006, CONTRACEPTION, V74, P133, DOI 10.1016/j.contraception.2006.02.008
   TURPIN J, 2002, EXPERT OPIN INV DRUG, V11, P1007, DOI DOI 10.1517/13543784.11.8.1077
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Watson Buckheit Karen, 2011, Antimicrob Agents Chemother, V55, P5243, DOI 10.1128/AAC.05237-11
   Watson KM, 2008, ANTIMICROB AGENTS CH, V52, P2787, DOI 10.1128/AAC.01657-07
   Yehia Soad A., 2009, Current Drug Delivery, V6, P17
NR 29
TC 34
Z9 34
U1 0
U2 14
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUL
PY 2012
VL 29
IS 7
BP 1897
EP 1907
DI 10.1007/s11095-012-0715-7
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 958FN
UT WOS:000305222000017
PM 22392331
OA green_accepted
DA 2018-01-05
ER

PT J
AU Trefry, JC
   Wooley, DP
AF Trefry, John C.
   Wooley, Dawn P.
TI Rapid assessment of antiviral activity and cytotoxicity of silver
   nanoparticles using a novel application of the tetrazolium-based
   colorimetric assay
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Inhibitory concentration 50; Tetrazolium salts; Antiviral agents; Metal
   nanoparticles; Silver
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; LENTIVIRUS VECTOR; CELLS;
   REDUCTION; CULTURE; HIV-1; PROLIFERATION; TOXICITY; FUSION
AB This study centers on the development of a new screening: tool for simultaneously evaluating the antiviral and cytotoxic properties of antiviral agents against an HIV-1-based, pseudotyped virus particle engineered to encode antibiotic resistance. The traditional colony-forming-unit assay for quantifying this type of virus was impractical as a screening tool due to the cumbersome nature of the setup and high costs in labor and supplies. Therefore, a smaller-scale and higher-throughput means of scoring antiviral activity was successfully developed and used to evaluate a specific batch of 25-nm silver nanoparticles (AgNPs). The new assay employed a unique application of the traditional cell proliferation/cytotoxicity test that is based on the chemical 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, which produces a colorimetric readout. The AgNPs showed a half maximal inhibitory concentration against the virus of 11.2 +/- 0.6 mu g/ml (p < 0.0001) with no significant toxicity against the cells. Because the virus was engineered to undergo only the first half of its replication cycle, the observed AgNP inhibition must have occurred at one of the early stages of infection. Overall, the new assay was very efficient and will be useful for testing different viral pseudotypes, screening different types of nanomaterials, and investigating other antiviral agents. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wooley, Dawn P.] Wright State Univ, Dept Neurosci Cell Biol & Physiol, Dayton, OH 45435 USA.
   [Trefry, John C.] Wright State Univ, Biomed Sci PhD Program, Dayton, OH 45435 USA.
RP Wooley, DP (reprint author), Wright State Univ, Dept Neurosci Cell Biol & Physiol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.
EM john.c.trefry.ctr@us.army.mil; dawn.wooley@wright.edu
FU Wright State University; Ohio Board of Regents
FX The authors thank Dr. Katherine J.D.A. Excoffon and Mary K. Leonard for
   critical reading of the manuscript. The Ohio Board of Regents and the
   Biomedical Sciences Ph.D. Program at Wright State University supported
   this study.
CR Bernas T, 2002, CYTOMETRY, V47, P236, DOI 10.1002/cyto.10080
   Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
   BRADLEY DE, 1962, J GEN MICROBIOL, V29, P503, DOI 10.1099/00221287-29-3-503                                                       
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Cronin J, 2005, CURR GENE THER, V5, P387, DOI 10.2174/1566523054546224
   da Costa AO, 1999, BIOCELL, V23, P65
   Dini L, 2011, NANOMATER NANOTECHNO, V1, P58
   DISTEFANO DJ, 1995, J VIROL METHODS, V55, P199, DOI 10.1016/0166-0934(95)00057-2                                                    
   El Badawy AM, 2010, ENVIRON SCI TECHNOL, V44, P1260, DOI 10.1021/es902240k
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Evanoff DD, 2005, CHEMPHYSCHEM, V6, P1221, DOI 10.1002/cphc.200500113
   Heldt CL, 2006, J VIROL METHODS, V135, P56, DOI [10.1016/j.jviromet.2006.01.022, 10.1016/j.j.viromet.2006.01.022]
   Huang KJ, 2005, J VIROL METHODS, V124, P95, DOI 10.1016/j.jviromet.2004.11.010
   Huang KT, 2004, BIOTECHNIQUES, V37, P406
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kim VN, 1998, J VIROL, V72, P811
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-38
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-30
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x                                             
   Lu L, 2008, ANTIVIR THER, V13, P253
   Lu XM, 2009, ANNU REV PHYS CHEM, V60, P167, DOI 10.1146/annurev.physchem.040808.090434
   Mehrbod P, 2009, DARU, V17, P88
   Monteiro-Riviere NA, 2009, TOXICOL APPL PHARM, V234, P222, DOI 10.1016/j.taap.2008.09.030
   Morones JR, 2007, LANGMUIR, V23, P8180, DOI 10.1021/1a7008336
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pabbruwe MB, 2005, BIOTECHNOL LETT, V27, P1451, DOI 10.1007/s10529-005-1308-x
   Patel MI, 2005, BIOTECHNOL LETT, V27, P805, DOI 10.1007/s10529-005-5803-x
   Seiler Andrea E. M., 2006, V329, P371
   STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Trefry JC, 2010, J AM CHEM SOC, V132, P10970, DOI 10.1021/ja103809c
   Xiang DX, 2011, J VIROL METHODS, V178, P137, DOI 10.1016/j.jviromet.2011.09.003
   Yonezawa A, 2005, J VIROL, V79, P918, DOI 10.1128/JVI.79.2.918-926.2005
   Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001
   Zufferey R, 1998, J VIROL, V72, P9873
NR 38
TC 6
Z9 6
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUL
PY 2012
VL 183
IS 1
BP 19
EP 24
DI 10.1016/j.jviromet.2012.03.014
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 950FE
UT WOS:000304634200004
PM 22465243
DA 2018-01-05
ER

PT J
AU Chen, XW
   Zhan, P
   Liu, X
   Cheng, ZH
   Meng, CC
   Shao, SY
   Pannecouque, C
   De Clercq, E
   Liu, XY
AF Chen, Xuwang
   Zhan, Peng
   Liu, Xin
   Cheng, Ziheng
   Meng, Caicai
   Shao, Siyuan
   Pannecouque, Christophe
   De Clercq, Erik
   Liu, Xinyong
TI Design, synthesis, anti-HIV evaluation and molecular modeling of
   piperidine-linked amino-triazine derivatives as potent non-nucleoside
   reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1; NNRTIs; Piperidine; Triazine; Antiviral activity; SAR; Molecular
   modeling
ID RESISTANT MUTANT VIRUSES; COLORIMETRIC ASSAY; BROAD POTENCY; DAPY
   ANALOGS; DISCOVERY; NNRTIS; DIARYLPYRIMIDINES; AIDS; SAR
AB A novel series of piperidine-linked amino-triazine derivatives were designed, synthesized and evaluated for in vitro anti-HIV activity as non-nucleoside reverse transcriptase inhibitors on the basis of our previous work. Screening results indicated that most compounds showed excellent activity against wild-type HIV-1 with EC50 values in low nanomolar concentration range (especially compound 6b3, EC50 = 4.61 nM, SI = 5945) and high activity against K103N/Y181C resistant mutant strain of HIV-1 with EC50 values in low micromolar concentration range. In addition, preliminary structure-activity relationship and molecular modeling of these new analogs were detailed in this manuscript. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
C1 [Chen, Xuwang; Zhan, Peng; Liu, Xin; Meng, Caicai; Shao, Siyuan; Liu, Xinyong] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China.
   [Cheng, Ziheng] Shandong Univ, Marine Coll, Weihai 264209, Shandong, Peoples R China.
   [Pannecouque, Christophe; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC) [81102320, 30873133,
   30772629, 30371686]; NSFC [30910103908]; Research Fund for the Doctoral
   Program of Higher Education of China [20110131130005, 20110131120037];
   Independent Innovation Foundation of Shandong University (IIFSDU)
   [2010GN044]; Shandong Postdoctoral Innovation Science Research Special
   Program [201002023]; China Postdoctoral Science Foundation
   [20100481282]; KU Leuven [GOA 10/014]
FX The financial support from the National Natural Science Foundation of
   China (NSFC Nos. 81102320, 30873133, 30772629, 30371686), Key Project of
   NSFC for International Cooperation (No. 30910103908), Research Fund for
   the Doctoral Program of Higher Education of China (Nos. 20110131130005,
   20110131120037), Independent Innovation Foundation of Shandong
   University (IIFSDU, No. 2010GN044), Shandong Postdoctoral Innovation
   Science Research Special Program (No. 201002023), China Postdoctoral
   Science Foundation funded project (No. 20100481282) and KU Leuven (GOA
   10/014) is gratefully acknowledged. We thank K. Erven, K. Uyttersprot
   and C. Heens for technical assistance with the HIV assays.
CR Chen XW, 2012, EUR J MED CHEM, V51, P60, DOI 10.1016/j.ejmech.2012.02.019
   Chen XW, 2011, CURR MED CHEM, V18, P359, DOI 10.2174/092986711794839142                                                      
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   D'Aquila Richard T, 2003, Top HIV Med, V11, P92
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   Feng XQ, 2010, BIOORGAN MED CHEM, V18, P2370, DOI 10.1016/j.bmc.2010.03.007
   Feng XQ, 2009, CHEMMEDCHEM, V4, P219, DOI 10.1002/cmdc.200800334
   Gu SX, 2011, BIOORGAN MED CHEM, V19, P7093, DOI 10.1016/j.bmc.2011.10.002
   Gu SX, 2011, BIOORGAN MED CHEM, V19, P5117, DOI 10.1016/j.bmc.2011.07.023
   Heeres J, 2005, J MED CHEM, V48, P1910, DOI 10.1021/jm040829e
   Hirschel B, 1998, NEW ENGL J MED, V338, P906, DOI 10.1056/NEJM199803263381310
   Kertesz DJ, 2010, BIOORG MED CHEM LETT, V20, P4215, DOI 10.1016/j.bmcl.2010.05.040
   Leftheris K, 2004, J MED CHEM, V47, P6283, DOI 10.1021/jm049521d
   Liang YH, 2010, BIOORGAN MED CHEM, V18, P4601, DOI 10.1016/j.bmc.2010.05.036
   Liang YH, 2009, CHEMMEDCHEM, V4, P1537, DOI 10.1002/cmdc.200900212
   Miller CD, 2011, DRUG TODAY, V47, P5, DOI 10.1358/dot.2011.47.1.1583188
   Miyoshi I., 1982, GANN MONOGR, V28, P219
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Qin BJ, 2010, J MED CHEM, V53, P4906, DOI 10.1021/jm1002952
   Ren J, 2008, J MED CHEM, V51, P5000, DOI 10.1021/jm8004493
   Romines KR, 2006, J MED CHEM, V49, P727, DOI 10.1021/jm0506701
   Tang GZ, 2010, BIOORG MED CHEM LETT, V20, P6020, DOI 10.1016/j.bmcl.2010.08.068
   Tian XT, 2010, J MED CHEM, V53, P8287, DOI 10.1021/jm100738d
   Tian XT, 2009, BIOORG MED CHEM LETT, V19, P5482, DOI 10.1016/j.bmcl.2009.07.080
   Udier-Blagovic M, 2003, J AM CHEM SOC, V125, P6016, DOI 10.1021/ja034308c
   Wuest JD, 2009, TETRAHEDRON, V65, P7393, DOI 10.1016/j.tet.2009.07.026
   Zacharie B, 2010, J MED CHEM, V53, P1138, DOI 10.1021/jm901403r
   Zeng ZS, 2010, CHEMMEDCHEM, V5, P837, DOI 10.1002/cmdc.201000045
   Zhan P, 2009, BIOORGAN MED CHEM, V17, P5920, DOI 10.1016/j.bmc.2009.07.004
   Zhang ZJ, 2007, ANTIMICROB AGENTS CH, V51, P429, DOI 10.1128/AAC.01032-06
NR 32
TC 30
Z9 30
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 15
PY 2012
VL 20
IS 12
BP 3856
EP 3864
DI 10.1016/j.bmc.2012.04.030
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 948EN
UT WOS:000304486500020
PM 22591854
DA 2018-01-05
ER

PT J
AU Breuer, S
   Chang, MW
   Yuan, JY
   Torbett, BE
AF Breuer, Sebastian
   Chang, Max W.
   Yuan, Jinyun
   Torbett, Bruce E.
TI Identification of HIV-1 Inhibitors Targeting the Nucleocapsid Protein
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID RNA PACKAGING SIGNAL; VIRUS TYPE-1 GAG; STEM-LOOP SL2; GENOMIC RNA;
   2-MERCAPTOBENZAMIDE THIOESTERS; ACYL TRANSFER; NMR STRUCTURE; ZINC
   FINGERS; IN-VITRO; PSI
AB The HIV-1 nucleocapsid (NC) is a RNA/DNA binding protein encoded within the Gag polyprotein, which is critical for the selection and chaperoning of viral genomic RNA during virion assembly. RNA/DNA binding occurs through a highly conserved zinc-knuckle motif present in NC. Given the necessity of NC viral RNA/DNA interaction for viral replication, identification of compounds that disrupt the NC-RNA/DNA interaction may have value as an antiviral strategy. To identify small molecules that disrupt NC viral RNA/DNA binding, a high-throughput fluorescence polarization assay was developed and a library of 14 400 diverse, druglike compounds was screened. Compounds that disrupted NC binding to a fluorescence-labeled DNA tracer were next evaluated by differential scanning fluorimetry to identify compounds that must bind to NC or Gag to impart their effects. Two compounds were identified that inhibited NC DNA interaction, specifically bound NC with nanomolar affinity, and showed modest anti-HIV-1 activity in ex vivo cell assays.
C1 [Breuer, Sebastian; Chang, Max W.; Yuan, Jinyun; Torbett, Bruce E.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
RP Torbett, BE (reprint author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM betorbet@scripps.edu
OI Chang, Max/0000-0002-4526-489X
FU NIH [1 P01 GM083658, 1 R01 HL091219]; NIH from CFAR [1 P30 AI036214]; 
   [2T32AI007354];  [CHRP-F09-SRI-205]
FX We are grateful to Drs. Hugh Rosen, Steven Brown, and Jacqueline Lohse
   for providing valuable technical expertise with the high-throughput
   screening platform at The Scripps Research Molecular Screening Center,
   The Scripps Research Institute, La Jolla, CA. We thank Sheryll Espinola
   and Dr. Ingo H. Engels from the Genomics Institute of the Novartis
   Research Foundation, La Jolla, CA, for their expertise in SRU BIND assay
   technology. Karen Crain is thanked for helping with the cell culture
   experiments. M.G. Finn is gratefully thanked for his helpful discussions
   of chemical properties of the identified compounds. Drs. Christopher
   Aiken and Norman Chen, Vanderbilt University, Nashville, TN, gratefully
   provided bevirimat. The studies were supported by NIH Grants 1 P01
   GM083658 (B.E.T.) and 1 R01 HL091219 (B.E.T.) and NIH core support from
   CFAR, Grant 1 P30 AI036214. J.Y. is supported by Grant 2T32AI007354, and
   S.B. is supported by Grant CHRP-F09-SRI-205. This is internal
   publication MEM no. 21430 from The Scripps Research Institute.
CR Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Arthur LO, 1998, AIDS RES HUM RETROV, V14, pS311
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bolton EE, 2010, ANN REP COMP CHEM, V4, P217, DOI 10.1016/S1574-1400(08)00012-1
   Breuer S, 2011, BIOCHEMISTRY-US, V50, P4371, DOI 10.1021/bi200031m
   Chan LL, 2008, ACS CHEM BIOL, V3, P437, DOI 10.1021/cb800057j
   Chertova EN, 1998, BIOCHEMISTRY-US, V37, P17890, DOI 10.1021/bi980907y
   Cruceanu M, 2006, ANAL BIOCHEM, V358, P159, DOI 10.1016/j.ab.2006.08.037
   Darlix JL, 2007, ADV PHARMACOL, V55, P299, DOI 10.1016/S1054-3589(07)55009-X
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   de Rocquigny H, 2008, MINI-REV MED CHEM, V8, P24
   Dietz J, 2008, CHEMMEDCHEM, V3, P749, DOI 10.1002/cmdc.200700194
   Druillennec S, 1999, BIOORG MED CHEM LETT, V9, P627, DOI 10.1016/S0960-894X(99)00052-9
   Druillennec S, 1999, P NATL ACAD SCI USA, V96, P4886, DOI 10.1073/pnas.96.9.4886                                                          
   Feng YX, 1999, J VIROL, V73, P4251
   Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577
   Hill MK, 2002, J VIROL, V76, P11245, DOI 10.1128/JVI.76.22.11245-11253.2002
   Jenkins LMM, 2007, J AM CHEM SOC, V129, P11067, DOI 10.1021/ja071254o
   Jenkins LMM, 2010, NAT CHEM BIOL, V6, P887, DOI 10.1038/NCHEMBIO.456
   Jenkins LMM, 2005, J MED CHEM, V48, P2847, DOI 10.1021/jm0492195
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   KAPLAN AH, 1993, J VIROL, V67, P4050
   Kenakin T, 1997, PHARM ANAL DRUG RECE
   LEVER AML, 1991, BIOCHEM SOC T, V19, P963, DOI 10.1042/bst0190963                                                              
   Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100
   Liang C, 2002, J VIROL, V76, P11729, DOI 10.1128/JVI.76.22.11729-11737.2002
   Mark-Danieli M, 2005, J VIROL, V79, P7756, DOI 10.1128/JVI.79.12.7756-7767.2005
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398
   Muriaux D, 2010, RNA BIOL, V7, P744, DOI 10.4161/rna.7.6.14065
   Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Ohishi M, 2011, NUCLEIC ACIDS RES, V39, P3404, DOI 10.1093/nar/gkq1314
   Raja C, 2006, BIOCHEMISTRY-US, V45, P9254, DOI 10.1021/bi052560m
   RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194
   Roldan A, 2004, J BIOL CHEM, V279, P39886, DOI 10.1074/jbc.M405632200
   Shvadchak V, 2009, BIOCHIMIE, V91, P916, DOI 10.1016/j.biochi.2009.04.014
   Stephen AG, 2002, BIOCHEM BIOPH RES CO, V296, P1228, DOI 10.1016/S0006-291X(02)02063-6
   Turconi S, 2001, J BIOMOL SCREEN, V6, P275
   Turpin Jim A, 2003, Expert Rev Anti Infect Ther, V1, P97, DOI 10.1586/14787210.1.1.97
   Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103
   Warui DM, 2009, J MED CHEM, V52, P5462, DOI 10.1021/jm900599v
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 44
TC 22
Z9 22
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 14
PY 2012
VL 55
IS 11
BP 4968
EP 4977
DI 10.1021/jm201442t
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 959ZJ
UT WOS:000305356400006
PM 22587465
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kailasa, SK
   Wu, HF
AF Kailasa, Suresh Kumar
   Wu, Hui-Fen
TI Functionalized quantum dots with dopamine dithiocarbamate as the matrix
   for the quantification of efavirenz in human plasma and as affinity
   probes for rapid identification of microwave tryptic digested proteins
   in MALDI-TOF-MS
SO JOURNAL OF PROTEOMICS
LA English
DT Article; Proceedings Paper
CT 2nd International Congress on Analytical Proteomics
CY JUL 18-20, 2011
CL Ourense, SPAIN
DE Functionalized QDs; Small molecules; Proteins; MALDI-TOF-MS
ID DESORPTION/IONIZATION MASS-SPECTROMETRY;
   ASSISTED-LASER-DESORPTION/IONIZATION; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   HIGH-RESOLUTION DETECTION; DESORPTION-IONIZATION; CONCENTRATING PROBES;
   PEPTIDE ANALYSIS; HIV DRUGS; SALDI-MS; NANOPARTICLES
AB Functionalized quantum dots with dopamine dithiocarbamate (QDs-DDTC) were utilized for the first time as an efficient material for the quantification of efavirenz in human plasma of HIV infected patients and rapid identification of microwave tryptic digest proteins (cytochrome c, lysozyme and BSA) by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The synthesized QDs-DDTC was characterized by using spectroscopic (UV-visible, FT-IR and H-1 NMR) and microscopic (SEM and TEM) techniques. Functionalized QDs-DDTC exhibited a high desorption/ionization efficiency for the rapid quantification of small molecules (efavirenz, tobramycin and aspartame) at low-mass region. QDs-DDTC has well ability to trap target species, and capable to transfer laser energy for efficient desorption/ionization of analytes with background-free detection. The use of QDs-DDTC as a matrix provided good linearity for the quantification of small molecules (R-2=similar to 0.9983), with good reproducibility (RSD <10%), in the analysis of efavirenz in the plasma of HIV infected patients by the standard addition method. We also demonstrated that the use of functionalized QDs-DDTC as affinity probes for the rapid identification of microwave tryptic digested proteins (cytochrome c, lysozyme and BSA) by MALDI-TOF-MS. QDs-DDTC-based MALDI-TOF-MS approach provides simplicity, rapidity, accuracy, and precision for the determination of efavirenz in human plasma of HIV infected patients and rapid identification of microwave tryptic digested proteins. This new material presents a marked advance in the development of matrix-free mass spectrometric methods for the rapid and precise quantitative determination of a variety of molecules. This article is part of a Special Issue entitled: Proteomics: The clinical link. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Kailasa, Suresh Kumar; Wu, Hui-Fen] Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung 80424, Taiwan.
   [Kailasa, Suresh Kumar; Wu, Hui-Fen] Natl Sun Yat Sen Univ, Ctr Nanosci & Nanotechnol, Kaohsiung 80424, Taiwan.
   [Kailasa, Suresh Kumar] SV Natl Inst Technol, Dept Appl Chem, Surat 395007, India.
   [Wu, Hui-Fen] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan.
RP Wu, HF (reprint author), Natl Sun Yat Sen Univ, Dept Chem, Kaohsiung 80424, Taiwan.
CR Aamoutse R.E., 2003, DRUGS, V63, P741
   Arakawa R, 2010, ANAL SCI, V26, P1229, DOI 10.2116/analsci.26.1229                                                         
   Banerjee S, 2009, J PHYS CHEM C, V113, P9659, DOI 10.1021/jp9019574
   Bao HM, 2008, J PROTEOME RES, V7, P5339, DOI 10.1021/pr800572e
   Biswas S, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/23/235226
   Bose AK, 2002, J AM SOC MASS SPECTR, V13, P839, DOI 10.1016/S1044-0305(02)00387-2                                                   
   Castellana ET, 2007, NANO LETT, V7, P3023, DOI 10.1021/nl071469w
   Chen JY, 2011, ANAL BIOANAL CHEM, V399, P377, DOI 10.1007/s00216-010-4375-3
   Chen WY, 2006, ANAL BIOANAL CHEM, V386, P699, DOI 10.1007/s00216-006-0427-0
   Chen YC, 1998, J CHROMATOGR A, V826, P77, DOI 10.1016/S0021-9673(98)00726-2
   Chiang CK, 2010, NANOMED-NANOTECHNOL, V6, P530, DOI 10.1016/j.nano.2010.01.006
   Chiu TC, 2007, RECENT PAT NANOTECH, V1, P99
   Clarke SJ, 2006, NAT MATER, V5, P409, DOI 10.1038/nmat1631
   Cohen LH, 2002, ANAL BIOANAL CHEM, V373, P571, DOI 10.1007/s00216-002-1321-z
   Dale MJ, 1996, ANAL CHEM, V68, P3321, DOI 10.1021/ac960558i
   Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828
   Dong XL, 2010, ANAL CHEM, V82, P6208, DOI 10.1021/ac101022m
   Droste JAH, 2003, THER DRUG MONIT, V25, P393, DOI 10.1097/00007691-200306000-00023
   Dubois F, 2007, J AM CHEM SOC, V129, P482, DOI 10.1021/ja067742y
   Gerber JG, 2003, J CLIN VIROL, V27, P117, DOI 10.1016/S1386-6532(03)00033-7
   Juan HF, 2005, PROTEOMICS, V5, P840, DOI 10.1002/pmic.200401056
   KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028
   Ke YT, 2010, TALANTA, V83, P178, DOI 10.1016/j.talanta.2010.09.003
   Li Yan, 2007, J Proteome Res, V6, P3849, DOI 10.1021/pr070132s
   Lopez-Ferrer D, 2005, J PROTEOME RES, V4, P1569, DOI 10.1021/pr050112v
   Mann M, 2001, TRENDS BIOCHEM SCI, V26, P54, DOI 10.1016/S0968-0004(00)01726-6
   McLean JA, 2005, J AM CHEM SOC, V127, P5304, DOI 10.1021/ja043907w
   Notari S, 2006, J CHROMATOGR B, V833, P109, DOI 10.1016/j.jchromb.2006.02.010
   Notari S, 2006, J CHROMATOGR B, V831, P258, DOI 10.1016/j.jchromb.2005.12.016
   Qiao L, 2008, ANGEW CHEM INT EDIT, V47, P2646, DOI 10.1002/anie.200703876
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Shrivas K, 2009, PROTEOMICS, V9, P2656, DOI 10.1002/pmic.200800772
   Stephenson JL, 2002, CURR OPIN BIOTECH, V13, P57, DOI 10.1016/S0958-1669(02)00285-9
   SUNNER J, 1995, ANAL CHEM, V67, P4335, DOI 10.1021/ac00119a021                                                             
   TANAKA K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI DOI 10.1002/RCM.1290020802
   Turapov OA, 2008, ANAL CHEM, V80, P6093, DOI 10.1021/ac702527b
   van Kampen JJA, 2007, J CHROMATOGR B, V847, P38, DOI 10.1016/j.jchromb.2006.10.001
   Watanabe T, 2008, J MASS SPECTROM, V43, P1063, DOI 10.1062/jms.1385
   Wei J, 1999, NATURE, V399, P243, DOI 10.1038/20400                                                                   
   Wu HF, 2010, TALANTA, V82, P540, DOI 10.1016/j.talanta.2010.05.026
   Zhu ZJ, 2009, ANALYST, V134, P2183, DOI 10.1039/b910428c
   Zou HF, 2002, ANGEW CHEM INT EDIT, V41, P646, DOI 10.1002/1521-3773(20020215)41:4<646::AID-ANIE646>3.3.CO;2-9
NR 42
TC 20
Z9 20
U1 1
U2 59
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-3919
J9 J PROTEOMICS
JI J. Proteomics
PD JUN 6
PY 2012
VL 75
IS 10
BP 2924
EP 2933
DI 10.1016/j.jprot.2011.12.008
PG 10
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 958UK
UT WOS:000305266000015
PM 22202183
DA 2018-01-05
ER

PT J
AU Mohammad, MM
   Iyer, R
   Howard, KR
   McPike, MP
   Borer, PN
   Movileanu, L
AF Mohammad, Mohammad M.
   Iyer, Raghuvaran
   Howard, Khalil R.
   McPike, Mark P.
   Borer, Philip N.
   Movileanu, Liviu
TI Engineering a Rigid Protein Tunnel for Biomolecular Detection
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID COLI OUTER-MEMBRANE; HIV-1 NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE;
   ION-CHANNEL; SL3 RNA; FHUA; TRANSLOCATION; TRANSPORT; NANOPORE; STATES
AB One intimidating challenge in protein nanopore-based technologies is designing robust protein scaffolds that remain functionally intact under a broad spectrum of detection conditions. Here, we show that an extensively engineered bacterial ferric hydroxamate uptake component A (FhuA), a beta-barrel membrane protein, functions as a robust protein tunnel for the sampling of biomolecular events. The key implementation in this work was the coupling of direct genetic engineering with a refolding approach to produce an unusually stable protein nanopore. More importantly, this nanostructure maintained its stability under many experimental circumstances, some of which, including low ion concentration and highly acidic aqueous phase, are normally employed to gate, destabilize, or unfold beta-barrel membrane proteins. To demonstrate these advantageous traits, we show that the engineered FhuA-based protein nanopore functioned as a sensing element for examining the proteolytic activity of an enzyme at highly acidic pH and for determining the kinetics of protein-DNA aptamer interactions at physiological salt concentration.
C1 [Mohammad, Mohammad M.; Movileanu, Liviu] Syracuse Univ, Dept Phys, Syracuse, NY 13244 USA.
   [Iyer, Raghuvaran; Borer, Philip N.] Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.
   [Howard, Khalil R.; Borer, Philip N.; Movileanu, Liviu] Syracuse Univ, Struct Biol Biochem & Biophys Program, Syracuse, NY 13244 USA.
   [McPike, Mark P.; Borer, Philip N.] AptaMatrix Inc, Syracuse, NY 13205 USA.
   [Movileanu, Liviu] Syracuse Univ, Syracuse Biomat Inst, Syracuse, NY 13244 USA.
RP Movileanu, L (reprint author), Syracuse Univ, Dept Phys, 201 Phys Bldg, Syracuse, NY 13244 USA.
EM lmovilea@physics.syr.edu
FU U.S. National Science Foundation [DMR-1006332, DGE-1068780]; National
   Institutes of Health [R01 GM088403, R01 GM032691, R44 GM076811]
FX We thank Andreas Matouschek for the generous gift of pb<INF>2</INF>-Ba
   plasmids, and Stewart Loh and Bert van den Berg for constructive
   comments on the manuscript. We are also grateful to David J.
   Niedzwieciki for single-channel experiments with dextran and to Tatyana
   Konyakhina for electrophysiology data with alpha HL and the NCp7
   aptamers. This work was funded by the U.S. National Science Foundation
   Grants DMR-1006332 (L.M.) and DGE-1068780 (IGERT Program), and the
   National Institutes of Health grants R01 GM088403 (L.M.), R01 GM032691
   (P.N.B.), and R44 GM076811 (M.P.M.).
CR Athavale SS, 2010, BIOCHEMISTRY-US, V49, P3525, DOI 10.1021/bi901279e
   Athavale S. S, 2010, THESIS SYRACUSE U SY
   Bayley H, 2000, CHEM REV, V100, P2575, DOI 10.1021/cr980099g
   Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038
   BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5                                                   
   Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Braun M, 2002, EUR J BIOCHEM, V269, P4948, DOI 10.1046/j.1432-1033.2002.03195.x
   Braun T, 2009, NAT NANOTECHNOL, V4, P179, DOI [10.1038/NNANO.2008.398, 10.1038/nnano.2008.398]
   Braun V, 2009, J BACTERIOL, V191, P3431, DOI 10.1128/JB.00106-09
   Burgess NK, 2008, J BIOL CHEM, V283, P26748, DOI 10.1074/jbc.M802754200
   Butler TZ, 2008, P NATL ACAD SCI USA, V105, P20647, DOI 10.1073/pnas.0807514106
   Chen M, 2008, P NATL ACAD SCI USA, V105, P6272, DOI 10.1073/pnas.0711561105
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Derrington IM, 2010, P NATL ACAD SCI USA, V107, P16060, DOI 10.1073/pnas.1001831107
   Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215
   Ferguson AD, 2001, STRUCTURE, V9, P707, DOI 10.1016/S0969-2126(01)00631-1
   Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956                                                              
   Hall AR, 2010, NAT NANOTECHNOL, V5, P874, DOI [10.1038/nnano.2010.237, 10.1038/NNANO.2010.237]
   Howorka S, 2009, CHEM SOC REV, V38, P2360, DOI 10.1039/b813796j
   Huang SH, 2002, NAT STRUCT BIOL, V9, P301, DOI 10.1038/nsb772
   Jones RGA, 2002, J IMMUNOL METHODS, V263, P57, DOI 10.1016/S0022-1759(02)00031-5
   Kang XF, 2005, ANGEW CHEM INT EDIT, V44, P1495, DOI 10.1002/anie.200461885
   KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4                                                   
   Killmann H, 1996, J BACTERIOL, V178, P6913, DOI 10.1128/jb.178.23.6913-6920.1996                                                
   Kleinschmidt JH, 1999, BIOCHEMISTRY-US, V38, P4996, DOI 10.1021/bi9824644
   KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233
   Krantz BA, 2005, SCIENCE, V309, P777, DOI 10.1126/science.1113380
   Langer R, 1998, NATURE, V392, P5
   LINIAL ML, 1990, CURR TOP MICROBIOL, V157, P125
   Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6                                                   
   Maglia G, 2009, NANO LETT, V9, P3831, DOI 10.1021/nl9020232
   Majd S, 2010, CURR OPIN BIOTECH, V21, P439, DOI 10.1016/j.copbio.2010.05.002
   Mohammad MM, 2008, J AM CHEM SOC, V130, P4081, DOI 10.1021/ja710787a
   Mohammad MM, 2011, J BIOL CHEM, V286, P8000, DOI 10.1074/jbc.M110.197723
   Mohammad MM, 2010, J PHYS CHEM B, V114, P8750, DOI 10.1021/jp101311s
   Movileanu L, 2009, TRENDS BIOTECHNOL, V27, P333, DOI 10.1016/j.tibtech.2009.02.008
   Olasagasti F, 2010, NAT NANOTECHNOL, V5, P798, DOI [10.1038/nnano.2010.177, 10.1038/NNANO.2010.177]
   Paoletti AC, 2002, BIOCHEMISTRY-US, V41, P15423, DOI 10.1021/bi026307n
   Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057
   Shin SH, 2002, ANGEW CHEM INT EDIT, V41, P3707, DOI 10.1002/1521-3773(20021004)41:19<3707::AID-ANIE3707>3.0.CO;2-5
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]
   Wendell D, 2009, NAT NANOTECHNOL, V4, P765, DOI [10.1038/nnano.2009.259, 10.1038/NNANO.2009.259]
   Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752
   Zhao QT, 2009, J AM CHEM SOC, V131, P6324, DOI 10.1021/ja9004893
NR 46
TC 56
Z9 57
U1 5
U2 63
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUN 6
PY 2012
VL 134
IS 22
BP 9521
EP 9531
DI 10.1021/ja3043646
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 952ZZ
UT WOS:000304837800077
PM 22577864
OA green_accepted
DA 2018-01-05
ER

PT J
AU Liu, J
   Gray, WD
   Davis, ME
   Luo, Y
AF Liu, Jie
   Gray, Warren D.
   Davis, Michael E.
   Luo, Ying
TI Peptide- and saccharide-conjugated dendrimers for targeted drug
   delivery: a concise review
SO INTERFACE FOCUS
LA English
DT Review
DE dendrimer; ligand; drug delivery; targeting; binding
ID HUMAN IMMUNODEFICIENCY VIRUS; MACROMOLECULE SUGAR BALLS; PAMAM
   DENDRIMERS; BIOLOGICAL EVALUATION; BINDING-PROPERTIES; PHAGE DISPLAY;
   FUNCTIONAL GLYCOMICS; SIRNA DELIVERY; ALPHA-THIOSIALODENDRIMERS;
   POLYAMIDOAMINE DENDRIMER
AB Dendrimers comprise a category of branched materials with diverse functions that can be constructed with defined architectural and chemical structures. When decorated with bioactive ligands made of peptides and saccharides through peripheral chemical groups, dendrimer conjugates are turned into nanomaterials possessing attractive binding properties with the cognate receptors. At the cellular level, bioactive dendrimer conjugates can interact with cells with avidity and selectivity, and this function has particularly stimulated interests in investigating the targeting potential of dendrimer materials for the design of drug delivery systems. In addition, bioactive dendrimer conjugates have so far been studied for their versatile capabilities to enhance stability, solubility and absorption of various types of therapeutics. This review presents a brief discussion on three aspects of the recent studies to use peptide-and saccharide-conjugated dendrimers for drug delivery: (i) synthesis methods, (ii) cell-and tissue-targeting properties and (iii) applications of conjugated dendrimers in drug delivery nanodevices. With more studies to elucidate the structure-function relationship of ligand-dendrimer conjugates in transporting drugs, the conjugated dendrimers hold promise to facilitate targeted delivery and improve drug efficacy for discovery and development of modern pharmaceutics.
C1 [Liu, Jie; Gray, Warren D.; Luo, Ying] Peking Univ, Dept Biomed Engn, Coll Engn, Beijing 100871, Peoples R China.
   [Davis, Michael E.] Emory Univ, Div Cardiol, Sch Med, Atlanta, GA 30322 USA.
   [Gray, Warren D.; Davis, Michael E.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA.
   [Davis, Michael E.] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30322 USA.
   [Luo, Ying] Guangzhou Int Business Incubator, Natl Engn Lab Regenerat & Implantable Med Devices, Guangzhou 510663, Guangdong, Peoples R China.
RP Luo, Y (reprint author), Peking Univ, Dept Biomed Engn, Coll Engn, Room 206,Fangzheng Bldg,298 Chengfu Rd, Beijing 100871, Peoples R China.
EM ying.luo@pku.edu.cn
RI Luo, Ying/A-9920-2012
OI Luo, Ying/0000-0001-9834-9419
FU National High-Tech R&D Programme of China [2009AA03Z314]; Beijing
   Natural Science Foundation [7102088]; Whitaker International Fellowship;
   GT-Emory-PKU
FX The research was supported by National High-Tech R&D Programme of China
   (project no. 2009AA03Z314), the Beijing Natural Science Foundation
   (Project no. 7102088), a Whitaker International Fellowship for W.D.G.,
   and the GT-Emory-PKU Coulter Seed grant.
CR Agashe HB, 2006, J PHARM PHARMACOL, V58, P1491, DOI 10.1211/jpp.58.11.0010
   Agrawal P, 2007, BIOMATERIALS, V28, P3349, DOI 10.1016/j.biomaterials.2007.04.004
   Alexandridis P, 2011, CHEM ENG TECHNOL, V34, P15, DOI 10.1002/ceat.201000335
   Almutairi A, 2009, P NATL ACAD SCI USA, V106, P685, DOI 10.1073/pnas.0811757106
   Andre S, 1999, GLYCOBIOLOGY, V9, P1253, DOI 10.1093/glycob/9.11.1253                                                        
   Aoi K, 1997, TETRAHEDRON, V53, P15415, DOI 10.1016/S0040-4020(97)00970-8
   AOI K, 1995, MACROMOLECULES, V28, P5391, DOI 10.1021/ma00119a037                                                             
   Appeldoorn CCM, 2005, TETRAHEDRON-ASYMMETR, V16, P361, DOI 10.1016/j.tetasy.2004.11.014
   Arima H, 2006, J CONTROL RELEASE, V116, P64, DOI 10.1016/j.jconrel.2006.08.026
   Assa-Munt N, 2001, BIOCHEMISTRY-US, V40, P2373, DOI 10.1021/bi002101f
   Baek MG, 2002, BIOORGAN MED CHEM, V10, P11, DOI 10.1016/S0968-0896(01)00248-6
   Bastings MMC, 2011, J AM CHEM SOC, V133, P6636, DOI 10.1021/ja110700x
   Benito JM, 2004, J AM CHEM SOC, V126, P10355, DOI 10.1021/ja047864v
   Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820
   Bhadra D, 2005, INT J PHARM, V295, P221, DOI 10.1016/j.ijpharm.2005.01.026
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Boswell CA, 2008, MOL PHARMACEUT, V5, P527, DOI 10.1021/mp800022a
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Campidelli S, 2006, J AM CHEM SOC, V128, P12544, DOI 10.1021/ja063697i
   Carlescu I, 2009, MED CHEM RES, V18, P477, DOI 10.1007/s00044-008-9139-7
   Chabre YM, 2008, CURR TOP MED CHEM, V8, P1237, DOI 10.2174/156802608785848987                                                      
   Chabre YM, 2010, ADV CARBOHYD CHEM BI, V63, P165, DOI 10.1016/S0065-2318(10)63006-5
   Chen HY, 2004, IEEE J SEL TOP QUANT, V10, P10, DOI 10.1109/JSTQE.2004.824101
   Chen X, 2009, J AM CHEM SOC, V131, P890, DOI 10.1021/ja807334b
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Clayton R, 2011, BIOCONJUGATE CHEM, V22, P2186, DOI 10.1021/bc200331v
   Comelli EM, 2006, GLYCOBIOLOGY, V16, P117, DOI 10.1093/glycob/cwj048
   D'Emanuele A, 2005, ADV DRUG DELIVER REV, V57, P2147, DOI 10.1016/j.addr.2005.09.012
   Darbre T, 2008, CURR TOP MED CHEM, V8, P1286, DOI 10.2174/156802608785849058
   de Paz JL, 2007, CHEM BIOL, V14, P879, DOI 10.1016/j.chembiol.2007.07.007
   Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x
   Dijkgraaf I, 2007, ORG BIOMOL CHEM, V5, P935, DOI 10.1039/b615940k
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Dutta T, 2010, NANOMED-NANOTECHNOL, V6, P25, DOI 10.1016/j.nano.2009.05.005
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Frechet JMJ, 2002, P NATL ACAD SCI USA, V99, P4782, DOI 10.1073/pnas.082013899
   Ghosh S, 2009, NANOSCALE RES LETT, V4, P937, DOI 10.1007/s11671-009-9339-1
   Godula K, 2010, J AM CHEM SOC, V132, P9963, DOI 10.1021/ja103009d
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Han L, 2010, HUM GENE THER, V21, P417, DOI 10.1089/hum.2009.087
   Heiden TCK, 2007, TOXICOL APPL PHARM, V225, P70, DOI 10.1016/j.taap.2007.07.009
   Helms BA, 2009, J AM CHEM SOC, V131, P11683, DOI 10.1021/ja902285m
   Hill E, 2007, BIOCONJUGATE CHEM, V18, P1756, DOI 10.1021/bc0700234
   Hook AL, 2010, BIOMATERIALS, V31, P187, DOI 10.1016/j.biomaterials.2009.09.037
   Huang SX, 2011, BIOMATERIALS, V32, P6832, DOI 10.1016/j.biomaterials.2011.05.064
   Hunter AC, 2006, ADV DRUG DELIVER REV, V58, P1523, DOI 10.1016/j.addr.2006.09.008
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Jin ZH, 2010, BIOL PHARM BULL, V33, P370, DOI 10.1248/bpb.33.370                                                              
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Ke WL, 2009, BIOMATERIALS, V30, P6976, DOI 10.1016/j.biomaterials.2009.08.049
   Kesharwani P, 2011, CURR DRUG TARGETS, V12, P1478, DOI 10.2174/138945011796818135                                                      
   Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367-5931(00)00153-8
   Kihara F, 2002, BIOCONJUGATE CHEM, V13, P1211, DOI 10.1021/bc025557d
   Kim JK, 2010, J DENT RES, V89, P1433, DOI 10.1177/0022034510384870
   Kobayashi H, 2005, ADV DRUG DELIVER REV, V57, P2271, DOI 10.1016/j.addr.2005.09.016
   Kojima C, 2009, J AM CHEM SOC, V131, P6052, DOI 10.1021/ja809639c
   Kolhatkar RB, 2007, BIOCONJUGATE CHEM, V18, P2054, DOI 10.1021/bc0603889
   Kukowska-Latallo JF, 2005, CANCER RES, V65, P5317, DOI 10.1158/0008-5472.CAN-04-3921
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Lagnoux D, 2005, CHEM-EUR J, V11, P3941, DOI 10.1002/chem.200401294
   Landers JJ, 2002, J INFECT DIS, V186, P1222, DOI 10.1086/344316
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430                                                         
   Lempens EHM, 2011, BIOCONJUGATE CHEM, V22, P397, DOI 10.1021/bc100403e
   Li Yiwen, 2007, Curr Drug Discov Technol, V4, P246, DOI 10.2174/157016307783220503
   Li Z, 2009, MOL PHARM, V7, P94, DOI DOI 10.1021/MP9001415
   Li ZM, 2010, J NANOSCI NANOTECHNO, V10, P4859, DOI 10.1166/jnn.2010.2217
   Lindhorst TK, 1996, ANGEW CHEM INT EDIT, V35, P1953, DOI 10.1002/anie.199619531                                                          
   Liu JF, 2011, INT J NANOMED, V6, P59, DOI 10.2147/IJN.S14601
   Liu J, 2012, BIOCONJUGATE CHEM, V23, P174, DOI 10.1021/bc200433s
   Liu XP, 2012, POLYM CHEM-UK, V3, P310, DOI 10.1039/c1py00404b
   Liu Y, 2009, J AM CHEM SOC, V131, P2798, DOI 10.1021/ja8100227
   Llinares M, 1997, CHEM COMMUN, P2119, DOI 10.1039/a703679e                                                                
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Luo D, 2002, MACROMOLECULES, V35, P3456, DOI 10.1021/ma0106346
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Mangold SL, 2005, ORG BIOMOL CHEM, V3, P2354, DOI 10.1039/b417789d
   Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417
   Martin AL, 2009, J AM CHEM SOC, V131, P734, DOI 10.1021/ja807220u
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   McNerny DQ, 2009, BIOCONJUGATE CHEM, V20, P1853, DOI 10.1021/bc900217h
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Medina SH, 2011, BIOMATERIALS, V32, P4118, DOI 10.1016/j.biomaterials.2010.11.068
   Mihov G, 2005, BIOCONJUGATE CHEM, V16, P283, DOI 10.1021/bc049839k
   Mintzer MA, 2011, CHEM SOC REV, V40, P173, DOI 10.1039/b901839p
   Mukherjee SP, 2010, TOXICOL IN VITRO, V24, P169, DOI 10.1016/j.tiv.2009.09.014
   Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739
   Myung JH, 2011, ANGEW CHEM INT EDIT, V50, P11769, DOI 10.1002/anie.201105508
   Niederhafner P, 2008, J PEPT SCI, V14, P2, DOI 10.1002/psc.931
   Ortega-Munoz M, 2007, ORG BIOMOL CHEM, V5, P2291, DOI 10.1039/b706331h
   Ozawa C, 2007, TETRAHEDRON, V63, P9685, DOI 10.1016/j.tet.2007.07.023
   Page D, 1997, BIOCONJUGATE CHEM, V8, P714, DOI 10.1021/bc970126u
   Pan BF, 2007, CANCER RES, V67, P8156, DOI 10.1158/0008-5472.CAN-06-4762
   Pan BF, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/12/125101
   Pan MF, 2006, J COLLOID INTERF SCI, V297, P151, DOI 10.1016/j.jcis.2005.09.068
   Pandita D, 2011, BIOMACROMOLECULES, V12, P472, DOI 10.1021/bm1012647
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7
   Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785
   Peters D, 2009, P NATL ACAD SCI USA, V106, P9815, DOI 10.1073/pnas.0903369106
   Petrenko VA, 2008, EXPERT OPIN DRUG DEL, V5, P825, DOI [10.1517/17425247.5.8.825, 10.1517/17425247.5.8.825 ]
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Pini A, 2005, ANTIMICROB AGENTS CH, V49, P2665, DOI 10.1128/AAC.49.7.2665-2672.2005
   Potyrailo R, 2011, ACS COMB SCI, V13, P579, DOI 10.1021/co200007w
   Prieto MJ, 2006, INT J PHARMACEUT, V326, P160, DOI 10.1016/j.ijpharm.2006.05.068
   Raman R, 2006, GLYCOBIOLOGY, V16, p82R, DOI 10.1093/glycob/cwj080
   RAO C, 1994, J AM CHEM SOC, V116, P6975, DOI 10.1021/ja00094a078
   Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
   Rojo J, 2004, CHEMBIOCHEM, V5, P291, DOI 10.1002/cbic.200300726
   Roy R, 2003, TRENDS GLYCOSCI GLYC, V15, P291, DOI 10.4052/tigg.15.291                                                             
   Sakamoto JI, 2009, BIOORGAN MED CHEM, V17, P5451, DOI 10.1016/j.bmc.2009.06.036
   Sashiwa H, 2001, MACROMOLECULES, V34, P3211, DOI 10.1021/ma001534n
   Sashiwa H, 2000, MACROMOLECULES, V33, P6913, DOI 10.1021/ma0005769
   Sato N, 2001, MAGNET RESON MED, V46, P1169, DOI 10.1002/mrm.1314
   Sebestik J, 2011, AMINO ACIDS, V40, P301, DOI 10.1007/s00726-010-0707-z
   Shan J, 2007, CHEM COMMUN, P4580, DOI 10.1039/b707740h
   SHAO J, 1995, J AM CHEM SOC, V117, P3893, DOI 10.1021/ja00119a001                                                             
   Shi XY, 2009, BIOPOLYMERS, V91, P936, DOI 10.1002/bip.21279
   Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3
   Stasko NA, 2007, BIOMACROMOLECULES, V8, P3853, DOI 10.1021/bm7008203
   Sun Y., 2005, COLLOIDS SURF PHYSIC, V259, P89, DOI [10.1016/j.colsurfa.2005.02.009, DOI 10.1016/J.COLSURFA.2005.02.009]
   Sun YP, 2001, CHEM MATER, V13, P2864, DOI 10.1021/cm0100691
   Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529                                                        
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Thompson JP, 1997, GLYCOCONJUGATE J, V14, P837, DOI 10.1023/A:1018590021762
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   Tosh DK, 2010, BIOCONJUGATE CHEM, V21, P372, DOI 10.1021/bc900473v
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Waite CL, 2011, BIOTECHNOL BIOENG, V108, P2999, DOI 10.1002/bit.23255
   Waite CL, 2009, BIOCONJUGATE CHEM, V20, P1908, DOI 10.1021/bc900228m
   Waite CL, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-38
   Welsh DJ, 2011, ORG BIOMOL CHEM, V9, P4795, DOI 10.1039/c1ob05241a
   Woller EK, 2001, BIOMACROMOLECULES, V2, P1052, DOI 10.1021/bm015560k
   Wood KC, 2008, BIOCONJUGATE CHEM, V19, P403, DOI 10.1021/bc700408r
   Wu P., 2008, ANGEW CHEM, V120, P5100, DOI DOI 10.1002/ANGE.200705363
   Yang H, 2008, J MATER SCI-MATER M, V19, P1991, DOI 10.1007/s10856-007-3278-0
   Yang H, 2007, INT J NANOMED, V2, P89, DOI 10.2147/nano.2007.2.1.89
   Zanini D, 1996, J ORG CHEM, V61, P7348, DOI 10.1021/jo961047z                                                               
   Zanini D, 1997, J AM CHEM SOC, V119, P2088, DOI 10.1021/ja963874n                                                               
   Zanini D, 1998, J ORG CHEM, V63, P3486, DOI 10.1021/jo972061u                                                               
   Zhou YY, 2009, MACROMOL BIOSCI, V9, P1090, DOI 10.1002/mabi.200900110
NR 148
TC 32
Z9 33
U1 0
U2 77
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2042-8898
EI 2042-8901
J9 INTERFACE FOCUS
JI Interface Focus
PD JUN 6
PY 2012
VL 2
IS 3
BP 307
EP 324
DI 10.1098/rsfs.2012.0009
PG 18
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 930AI
UT WOS:000303107300005
PM 23741608
OA gold
DA 2018-01-05
ER

PT J
AU Hormozi-Nezhad, MR
   Seyedhosseini, E
   Robatjazi, H
AF Hormozi-Nezhad, M. R.
   Seyedhosseini, E.
   Robatjazi, H.
TI Spectrophotometric determination of glutathione and cysteine based on
   aggregation of colloidal gold nanoparticles
SO SCIENTIA IRANICA
LA English
DT Article
DE Gold nanoparticle; Amino acids; Cysteine; Glutathione; Colorimetric
   detection
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; HIV-INFECTION;
   WHEY PROTEINS; CHEMISTRY; ELECTRODE
AB We report herein the development of a highly sensitive colorimetric method for the determination of cysteine and glutathione, based on aggregation of the citrate capped gold nanoparticles (Au NPs). This was exploited from high affinity of low-molecular-weight aminothiols towards the Au NPs surface, which could induce displacement of the citrate shell by the thiolate shell of target molecules, resulting in aggregation of the NPs through intermolecular electrostatic interaction or hydrogen-bonding. As a result of aggregation, which can be affected by the ionic strength, pH and concentration of Au NPs, the plasmon band at around 521 nm decreases gradually, along with formation of a new red shifted band. The calibration curves, which are derived from the intensity ratios of absorbance at-640 nm and 650 nm for cysteine and glutathione, respectively, to the original wavelength of 521 nm, display a linear relation in the range of 1 x 10(-6)-100 x 10(-6) M cysteine and 5 x 10(-6)-200 x 10(-6) M glutathione. The obtained detection limits (3 sigma) were 2.1 x 10(-6) M and 3.3 x 10(-6) M for determination of cysteine and glutathione, respectively. (c) 2012 Sharif University of Technology. Production and hosting by Elsevier B.V. All rights reserved.
C1 [Hormozi-Nezhad, M. R.; Seyedhosseini, E.; Robatjazi, H.] Sharif Univ Technol, Dept Chem, Tehran 111559516, Iran.
   [Hormozi-Nezhad, M. R.] Sharif Univ Technol, Inst Nanosci & Nanotechnol, Tehran 111559516, Iran.
RP Hormozi-Nezhad, MR (reprint author), Sharif Univ Technol, Dept Chem, Tehran 111559516, Iran.
EM hormozi@sharif.edu
FU Sharif University of Technology Research Council
FX This work was supported by Sharif University of Technology Research
   Council. The authors wish to express their gratitude for the support of
   this
CR Adair JC, 2001, NEUROLOGY, V57, P1515, DOI 10.1212/WNL.57.8.1515                                                           
   Andrew M., 2007, ANAL CHEM, V79, P8769
   Bakirdere S, 2010, ANAL CHIM ACTA, V680, P41, DOI 10.1016/j.aca.2010.09.023
   BOUNOUS G, 1991, CANCER LETT, V57, P91, DOI 10.1016/0304-3835(91)90200-2
   BRAY TM, 1994, BIOCHEM PHARMACOL, V47, P2113, DOI 10.1016/0006-2952(94)90246-1
   Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a
   Cagla Ozkilic Anil, 2006, Journal of Basic and Clinical Physiology and Pharmacology, V17, P245
   Chiang NC, 2009, RAPID COMMUN MASS SP, V23, P3063, DOI 10.1002/rcm.4221
   Droge W, 1997, FASEB J, V11, P1077
   Ghosh SK, 2004, J PHYS CHEM B, V108, P13963, DOI 10.1021/jp047021q
   Hulst H.C.V.d., 1981, LIGHT SCATTERING SMA, P397
   JULIUS M, 1994, J CLIN EPIDEMIOL, V47, P1021, DOI 10.1016/0895-4356(94)90117-1
   Kim GJ, 2011, ORG LETT, V13, P2799, DOI 10.1021/ol200967w
   Kimling J, 2006, J PHYS CHEM B, V110, P15700, DOI 10.1021/jp061667w
   Kuster A, 2008, ANAL BIOANAL CHEM, V390, P1403, DOI 10.1007/s00216-007-1799-5
   Liang SC, 2002, ANAL CHIM ACTA, V451, P211, DOI 10.1016/S0003-2670(01)01409-X                                                   
   Liu J., 2004, J FLURESC, V14, P931
   Marzal P.C., 2006, CLIN CHIM ACTA, V371, P152
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431                                             
   Micke P, 2001, EUR J CLIN INVEST, V31, P171, DOI 10.1046/j.1365-2362.2001.00781.x
   Mocanu U., 2009, COLLOID SURF A, V338, P93
   Oh E, 2005, J AM CHEM SOC, V127, P3270, DOI 10.1021/ja0433323
   Perlman I, 1940, J BIOL CHEM, V133, P651
   Potesil D, 2005, J CHROMATOGR A, V1084, P134, DOI 10.1016/j.chroma.2005.06.019
   Safavi A, 2009, ANAL CHEM, V81, P7538, DOI 10.1021/ac900501j
   Shahrokhian S, 2001, ANAL CHEM, V73, P5972, DOI 10.1021/ac010541m
   Staal FJT, 1998, EUR J CLIN INVEST, V28, P194
   Su KH, 2003, NANO LETT, V3, P1087, DOI 10.1021/nl034197f
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   WITSCHI A, 1992, EUR J CLIN PHARMACOL, V43, P667, DOI 10.1007/BF02284971                                                              
   Xu F, 2002, ANAL BIOANAL CHEM, V372, P791, DOI 10.1007/s00216-002-1255-5
   Xu Q, 2011, MICROCHIM ACTA, V173, P323, DOI 10.1007/s00604-011-0562-y
   Yang P, 2008, MICROCHIM ACTA, V163, P263, DOI 10.1007/s00604-008-0006-5
   Zhao WA, 2008, J AM CHEM SOC, V130, P3610, DOI 10.1021/ja710241b
NR 34
TC 27
Z9 28
U1 3
U2 56
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1026-3098
J9 SCI IRAN
JI Sci. Iran.
PD JUN
PY 2012
VL 19
IS 3
BP 958
EP 963
DI 10.1016/j.scient.2012.04.018
PG 6
WC Engineering, Multidisciplinary
SC Engineering
GA 013RM
UT WOS:000309323000078
DA 2018-01-05
ER

PT J
AU Lee, J
   Yun, KS
   Choi, CS
   Shin, SH
   Ban, HS
   Rhim, T
   Lee, SK
   Lee, KY
AF Lee, Jangwook
   Yun, Kyoung-Soo
   Choi, Chang Seon
   Shin, Seung-Hwa
   Ban, Hong-Seok
   Rhim, Taiyoun
   Lee, Sang Kyung
   Lee, Kuen Yong
TI T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan
   Nanoparticles
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID GENE DELIVERY; RNA INTERFERENCE; DNA NANOPARTICLES; HIV-1 INFECTION;
   SYSTEMS; APOPTOSIS; THERAPY; CARRIER
AB The intracellular delivery of small interfering RNA (siRNA) plays a key role in RNA interference (RNA and provides an emerging technique to treat various diseases, including infectious diseases. Chitosan has frequently been used in gene delivery applications, including siRNA delivery. However, studies regarding the modification of chitosan with antibodies specifically targeting T cells are lacking. We hypothesized that chitosan nanoparticles modified with T cell-specific antibodies would be useful for delivering siRNA to T cells. CD7-specific single-chain antibody (scFvCD7) was chemically conjugated to chitosan by carbodiimide chemistry, and nanoparticles were prepared by a complex coacervation method in the presence of siRNA. The mean diameter and zeta potential of the scFvCD7-chitosan/siRNA nanoparticles were approximately 320 nm and +17 mV, respectively, and were not significantly influenced by the coupling of antibody to chitosan. The cellular association of antibody-conjugated nanoparticles to CD4+ T cell lines as well as gene silencing efficiency in the cells was significantly improved compared to nonmodified chitosan nanoparticles. This approach to introducing T cell-specific antibody to chitosan nanoparticles may find useful applications for the treatment of various infectious diseases.
C1 [Lee, Kuen Yong] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.
   Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea.
RP Lee, KY (reprint author), Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.
EM sangkyunglee@hanyang.ac.kr; leeky@hanyang.ac.kr
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [20110017959]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (No. 20110017959).
CR Ackerson CJ, 2006, J AM CHEM SOC, V128, P2635, DOI 10.1021/ja0555668
   Andersen MO, 2008, BIOMATERIALS, V29, P506, DOI 10.1016/j.biomaterials.2007.10.003
   Anderson J, 2003, AIDS RES HUM RETROV, V19, P699, DOI 10.1089/088922203322280928
   Bremer E, 2005, CANCER RES, V65, P3380, DOI 10.1158/0008-5472.CAN-04-2756                                                   
   Christensen LV, 2006, BIOCONJUGATE CHEM, V17, P1233, DOI 10.1021/bc0602026
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142-9612(02)00507-0                                                   
   Davis ME, 2002, CURR OPIN BIOTECH, V13, P128, DOI 10.1016/S0958-1669(02)00294-X
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Hashida M, 1998, J CONTROL RELEASE, V53, P301, DOI 10.1016/S0168-3659(97)00263-0
   Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010
   Ilium L., 1998, PHARM RES, V15, P1326, DOI DOI 10.1023/A:1011929016601
   Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021
   Kumar MNVR, 2004, CHEM REV, V104, P6017, DOI 10.1021/cr030441b
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lee DW, 2009, J CONTROL RELEASE, V139, P146, DOI 10.1016/j.jconrel.2009.06.018
   Lee KY, 1998, J CONTROL RELEASE, V51, P213, DOI 10.1016/S0168-3659(97)00173-9
   Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6
   Li SD, 2007, J CONTROL RELEASE, V123, P181, DOI 10.1016/j.jconrel.2007.09.004
   Liu XD, 2007, BIOMATERIALS, V28, P1280, DOI 10.1016/j.biomaterials.2006.11.004
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Manjunath N, 2006, TRENDS IMMUNOL, V27, P328, DOI 10.1016/j.it.2006.05.006
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004
   Martinez MA, 2002, TRENDS IMMUNOL, V23, P559, DOI 10.1016/S1471-4906(02)02328-1
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Park TG, 2006, ADV DRUG DELIVER REV, V58, P467, DOI 10.1016/j.addr.2006.03.007
   Park YK, 2000, J CONTROL RELEASE, V69, P97, DOI 10.1016/S0168-3659(00)00298-4                                                   
   Peipp M, 2002, CANCER RES, V62, P2848
   Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148
   Rojanarata T, 2008, PHARM RES-DORDR, V25, P2807, DOI 10.1007/s11095-008-9648-6
   Schaffert D, 2008, GENE THER, V15, P1131, DOI 10.1038/gt.2008.105
   Shankar P, 2005, JAMA-J AM MED ASSOC, V293, P1367, DOI 10.1001/jama.293.11.1367
   Somia N, 2000, NAT REV GENET, V1, P91, DOI 10.1038/35038533
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Tan ML, 2009, J PHARM PHARMACOL, V61, P3, DOI 10.1211/jpp/61.01.0002
NR 36
TC 34
Z9 34
U1 4
U2 50
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUN
PY 2012
VL 23
IS 6
BP 1174
EP 1180
DI 10.1021/bc2006219
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 959ZV
UT WOS:000305358700010
PM 22607555
DA 2018-01-05
ER

PT J
AU Lin, CM
   Lu, TY
AF Lin, Chun-Mao
   Lu, Tan-Yi
TI C-60 Fullerene Derivatized Nanoparticles and their Application to
   Therapeutics
SO RECENT PATENTS ON NANOTECHNOLOGY
LA English
DT Article
DE Antioxidant; apoptosis; autophagy; blood brain barrier (BBB);
   cytotoxicity; fullerene; fulleropyrrolidine-xanthine dyad; fullerene
   dyad; graphene; nanomedicine; nanoparticle; nanotechnology;
   neurodegenerative disease; neuroprotective; PEG-C-60-3; PTX-C-60-2
ID BETA-AMYLOID PEPTIDE; BLOOD-BRAIN-BARRIER; IN-VIVO; RAT-BRAIN;
   POLY(BUTYLCYANOACRYLATE) NANOPARTICLES; FUNCTIONALIZED FULLERENES;
   SOLUBLE PENDANT; GENE-TRANSFER; ACID C-60; CELLS
AB Fullerenes can be formed into many new materials and devices. They have a wide range of applications in medicine, electronics, biomaterials, and energy production. An overview of the nanostructure and the physical and chemical characteristics of fullerene-drug derivatives is given. The biological behavior of fullerene derivatives shows their potential to medical application fields because C-60 is rapidly absorbed by tissues and is excreted through urinary tract and enterons, which reveals low toxicity in vitro and in vivo studies. Nanomedicine has become one of the most promising areas of nanotechnology, while many have claimed its therapeutic use against cancer, human immunodeficiency virus (HIV), and neurodegenerative disorders. Water-soluble C-60 fullerene derivatives that come from chemical modification largely enhance the biological efficacy. The blood-brain barrier (BBB) is a physical barrier composed of endothelial tight junctions that restrict the paracellular permeability. A major challenge facing neuropharmacology is to find compounds that can be delivered into the brain through the bloodstream. Fullerene C-60 was demonstratively able to cross the BBB by hybridizing a biologically active moiety dyad, which provides a promising clue as a pharmacological therapy of neural disorders.
C1 [Lin, Chun-Mao; Lu, Tan-Yi] Taipei Med Univ, Sch Med, Taipei 11031, Taiwan.
   [Lin, Chun-Mao] Taipei Med Univ Hosp, Orthoped Res Ctr, Taipei, Taiwan.
RP Lu, TY (reprint author), Taipei Med Univ, Sch Med, 250 Wuxing St, Taipei 11031, Taiwan.
EM dannyt_ylu@yahoo.com.tw
FU Center of Excellence for Clinical Trial and Research in Neuroscience,
   Taiwan [DOH99-TD-B-111-003]
FX This study was supported by the grants from the Center of Excellence for
   Clinical Trial and Research in Neuroscience (DOH99-TD-B-111-003),
   Taiwan.
CR Aldersey-Williams Hugh, 1995, MOST BEAUTIFUL MOL D
   Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   Bakry R, 2007, INT J NANOMED, V2, P639
   Bezmel'nitsyn V. N., 1998, Physics-Uspekhi, V41, P1091, DOI 10.1070/PU1998v041n11ABEH000502
   Bisaglia M, 2000, J NEUROCHEM, V74, P1197
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Chen YW, 2004, AM J PHYSIOL-REG I, V287, pR21, DOI 10.1152/ajpregu.00310.2003
   Da Ros T, 2001, CROAT CHEM ACTA, V74, P743
   Drummond DC, 1999, PHARMACOL REV, V51, P691
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Edwin LC, 2011, J EXP CLIN MED, V3, P1
   Feng LZ, 2011, NANOMEDICINE-UK, V6, P317, DOI [10.2217/nnm.10.158, 10.2217/NNM.10.158]
   Feuerstein I, 2006, J AM SOC MASS SPECTR, V17, P1203, DOI 10.1016/j.jasms.2006.04.032
   Fletcher JS, 2006, ANAL CHEM, V78, P1827, DOI 10.1021/ac051624w
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Friese A, 2000, EUR J PHARM BIOPHARM, V49, P103, DOI 10.1016/S0939-6411(99)00073-9
   Gause C, FULLERENE NANOMEDICI
   Geckeler KE, 1999, POLYM INT, V48, P743
   GECKELER KE, 1993, J AM CHEM SOC, V115, P3850, DOI 10.1021/ja00062a091                                                             
   GECKELER KE, 1994, TRENDS POLYM SCI, V2, P355
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Gharbi N, 2005, NANO LETT, V5, P2578, DOI 10.1021/nl051866b
   Harada-Shiba M, 2002, GENE THER, V9, P407, DOI 10.1038/sj.gt/3301665
   Hizume Y, 2010, J AM CHEM SOC, V132, P6628, DOI 10.1021/ja1014713
   Huang ST, 2008, BIOORGAN MED CHEM, V16, P8619, DOI 10.1016/j.bmc.2008.08.004
   Huang ST, 2008, BIOORG MED CHEM LETT, V18, P99, DOI 10.1016/j.bmcl.2007.11.004
   Huang YL, 1998, EUR J BIOCHEM, V254, P38, DOI 10.1046/j.1432-1327.1998.2540038.x                                              
   Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009
   Kabanov AV, 2007, PROG POLYM SCI, V32, P1054, DOI 10.1016/j.progpolymsei.2007.05.014
   Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P181
   Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P168
   Kotelnikova RA, 2003, J NANOPART RES, V5, P561, DOI 10.1023/B:NAN0.0000006070.61144.93
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Lao F, 2009, ACS NANO, V3, P3358, DOI 10.1021/nn900912n
   Lee CM, 2011, NANOMED-NANOTECHNOL, V7, P107, DOI 10.1016/j.nano.2010.06.009
   Li QN, 2001, CHINESE SCI BULL, V46, P1615, DOI 10.1007/BF02900619                                                              
   Lin AMY, 1999, J NEUROCHEM, V72, P1634, DOI 10.1046/j.1471-4159.1999.721634.x
   Lin AMY, 2002, NEUROSCI RES, V43, P317, DOI 10.1016/S0168-0102(02)00056-1
   Liu B, 1996, CHEM COMMUN, P1241, DOI 10.1039/cc9960001241                                                            
   Lu TY, 2011, J FOOD DRUG ANAL, V19, P151
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Modi G, 2009, PROG NEUROBIOL, V88, P272, DOI 10.1016/j.pneurobio.2009.05.002
   Mori T, 2006, TOXICOLOGY, V225, P48, DOI 10.1016/j.tox.2006.05.001
   Moussa F, 1996, FULLERENE SCI TECHN, V4, P21, DOI 10.1080/10641229608001534                                                       
   Moussa F, 1997, P ELECTROCHEM SOC, V5, P332
   Mroz P, 2007, FREE RADICAL BIO MED, V43, P711, DOI 10.1016/j.freeradbiomed.2007.05.005
   Nakamura E, 2003, ACCOUNTS CHEM RES, V36, P807, DOI 10.1021/ar030027y
   Nguyen HK, 2000, GENE THER, V7, P126, DOI 10.1038/sj.gt.3301052                                                           
   Nishizawa T, 2009, CHEM COMMUN, P2469, DOI 10.1039/b902060h
   Oishi M, 2007, J MATER CHEM, V17, P3720, DOI 10.1039/b706973a
   Pardridge William M, 2005, NeuroRx, V2, P3
   PATIL AO, 1993, POLYM BULL, V30, P187, DOI 10.1007/BF00296848                                                              
   Willi P, 2011, TRENDS BIOMATER ARTI, V25, P91
   Qiao R, 2007, NANO LETT, V7, P614, DOI 10.1021/nl062515f
   Rainer M, 2006, RAPID COMMUN MASS SP, V20, P2954, DOI 10.1002/rcm.2673
   Rancan F, 2002, J PHOTOCH PHOTOBIO B, V67, P157, DOI 10.1016/S1011-1344(02)00320-2                                                   
   RUOFF RS, 1993, J PHYS CHEM-US, V97, P3379, DOI 10.1021/j100115a049
   Sagman Uri, 2002, APPL COMMERCIAL PR 4
   Satoh M, 1997, EUR J PHARMACOL, V327, P175, DOI 10.1016/S0014-2999(97)89658-6
   Sharma R, 2009, NSTI NANOTECH, V2, P150
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Sitharaman B, 2008, MOL PHARMACEUT, V5, P567, DOI 10.1021/mp700106w
   Steiniger SCJ, 2004, INT J CANCER, V109, P759, DOI 10.1002/ijc.20048
   Straface E, 1999, FEBS LETT, V454, P335, DOI 10.1016/S0014-5793(99)00812-1
   Sun YP, 1996, CHEM COMMUN, P2699, DOI 10.1039/cc9960002699                                                            
   SUZUKI T, 1992, J AM CHEM SOC, V114, P7301, DOI 10.1021/ja00044a055                                                             
   Tegos GP, 2005, CHEM BIOL, V12, P1127, DOI 10.1016/j.chembiol.2005.08.014
   Tong J, 2011, BIOMATERIALS, V32, P3654, DOI 10.1016/j.biomaterials.2011.01.068
   TSUCHIYA T, 1995, BIOCHEM BIOPH RES CO, V206, P885, DOI 10.1006/bbrc.1995.1126
   Tykhomyrov AA, 2008, TOXICOLOGY, V246, P158, DOI 10.1016/j.tox.2008.01.005
   Vallant RM, 2007, ANAL CHEM, V79, P8144, DOI 10.1021/ac0712392
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   Wong-Ekkabut J, 2008, NAT NANOTECHNOL, V3, P363, DOI 10.1038/nnano.2008.130
   YAMAGO S, 1995, CHEM BIOL, V2, P385, DOI 10.1016/1074-5521(95)90219-8                                                    
   Kepley CL, 2011, Patent No. [US 2011251158 A1, 2011251158]
   Chiang LY, 1999, Patent No. [US5994410 (A), 5994410]
   Michael G, 2010, Patent No. [US2010144868 A1, 2010144868]
   Dugan LL, 2010, Patent No. [US2010297070 A1, 2010297070]
   Kirpatrick L, 2011, Patent No. [CA2762524 A1, 2762524]
   Chung BH, 2011, Patent No. [KR20110120224 A, 20110120224]
   Rasnetsov LD, 2006, Patent No. [US2006122276 A1, 2006122276]
   Petrik VI, 2006, Patent No. [US2006134096 A1, 2006134096]
NR 85
TC 19
Z9 20
U1 4
U2 69
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1872-2105
EI 2212-4020
J9 RECENT PAT NANOTECH
JI Recent Pat. Nanotechnology
PD JUN
PY 2012
VL 6
IS 2
BP 105
EP 113
DI 10.2174/187221012800270135                                              
          
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 947QO
UT WOS:000304444800003
PM 22455733
DA 2018-01-05
ER

PT J
AU das Neves, J
   Michiels, J
   Arien, KK
   Vanham, G
   Amiji, M
   Bahia, MF
   Sarmento, B
AF das Neves, Jose
   Michiels, Johan
   Arien, Kevin K.
   Vanham, Guido
   Amiji, Mansoor
   Bahia, Maria Fernanda
   Sarmento, Bruno
TI Polymeric Nanoparticles Affect the Intracellular Delivery,
   Antiretroviral Activity and Cytotoxicity of the Microbicide Drug
   Candidate Dapivirine
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cell uptake; HIV/AIDS; microbicides; nanotechnology;
   poly(epsilon-caprolactone)
ID REVERSE-TRANSCRIPTASE INHIBITORS; IN-VITRO EVALUATION; HIV-NEGATIVE
   WOMEN; DENDRITIC CELLS; POSTEXPOSURE PROPHYLAXIS; INTRAVAGINAL RING;
   TARGETED DELIVERY; T-CELLS; PREVENTION; SYSTEMS
AB To assess the intracellular delivery, antiretroviral activity and cytotoxicity of poly(epsilon-caprolactone) (PCL) nanoparticles containing the antiretroviral drug dapivirine.
   Dapivirine-loaded nanoparticles with different surface properties were produced using three surface modifiers: poloxamer 338 NF (PEO), sodium lauryl sulfate (SLS) and cetyl trimethylammonium bromide (CTAB). The ability of nanoparticles to promote intracellular drug delivery was assessed in different cell types relevant for vaginal HIV transmission/microbicide development. Also, antiretroviral activity of nanoparticles was determined in different cell models, as well as their cytotoxicity.
   Dapivirine-loaded nanoparticles were readily taken up by different cells, with particular kinetics depending on the cell type and nanoparticles, resulting in enhanced intracellular drug delivery in phagocytic cells. Different nanoparticles showed similar or improved antiviral activity compared to free drug. There was a correlation between increased antiviral activity and increased intracellular drug delivery, particularly when cell models were submitted to a single initial short-course treatment. PEO-PCL and SLS-PCL nanoparticles consistently showed higher selectivity index values than free drug, contrasting with high cytotoxicity of CTAB-PCL.
   These results provide evidence on the potential of PCL nanoparticles to affect toxicity and activity of dapivirine, depending on surface engineering. Thus, this formulation approach may be a promising strategy for the development of next generation microbicides.
C1 [das Neves, Jose; Bahia, Maria Fernanda; Sarmento, Bruno] Univ Porto, Fac Pharm, LTF CICF, Lab Pharmaceut Technol, P-4050047 Oporto, Portugal.
   [Michiels, Johan; Arien, Kevin K.; Vanham, Guido] Inst Trop Med, Dept Microbiol, Virol Unit, B-2000 Antwerp, Belgium.
   [Vanham, Guido] Univ Antwerp, Fac Pharmacol Biomed & Vet Sci, Dept Biomed Sci, B-2020 Antwerp, Belgium.
   [Vanham, Guido] Univ Brussels, Fac Med & Pharmacol, Brussels, Belgium.
   [Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   [Sarmento, Bruno] Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, CICS, Gandra, Portugal.
RP das Neves, J (reprint author), Univ Porto, Fac Pharm, LTF CICF, Lab Pharmaceut Technol, Rua Anibal Cunha 164, P-4050047 Oporto, Portugal.
EM j.dasneves@gmail.com
RI Amiji, Mansoor/A-4365-2014; Sarmento, Bruno/J-6265-2013; das Neves,
   Jose/J-8369-2013
OI Amiji, Mansoor/0000-0001-6170-881X; Sarmento, Bruno/0000-0001-5763-7553;
   das Neves, Jose/0000-0002-2317-2759
FU Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BD/43393/2008];
   Fund for Scientific Research Flanders (FWO); Agence Nationale de
   Recherches sur le SIDA et les hepatites virales (ANRS); EU
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia, Portugal for financial support (grant SFRH/BD/43393/2008).
   Kevin K. Arien and Guido Vanham are supported by research grants from
   the Fund for Scientific Research Flanders (FWO), the Agence Nationale de
   Recherches sur le SIDA et les hepatites virales (ANRS), and EU-FP7
   CHAARM. Dapivirine was originally developed by Tibotec Pharmaceuticals
   and was licensed to the International Partnership for Microbicides under
   a royalty-free agreement for the development of vaginal microbicides. We
   express our gratitude to Jing Xu for SEM imaging at the Nanomaterials
   Characterization Facility, Northeastern University.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   ARBELOA FL, 1988, J CHEM SOC FARAD T 2, V84, P1903, DOI 10.1039/f29888401903                                                            
   Arien KK, 2011, REV MED VIROL, V21, P110, DOI 10.1002/rmv.684
   Arien KK, 2010, FUTURE MICROBIOL, V5, P1621, DOI 10.2217/FMB.10.129
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   Cavrois M, 2007, PLOS PATHOG, V3, P38, DOI 10.1371/journal.ppat.0090004
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   das Neves J, 2011, EXPERT OPIN DRUG DEL, V8, P1085, DOI 10.1517/17425247.2011.586334
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J, 2010, J PHARMACEUT BIOMED, V52, P167, DOI 10.1016/j.jpba.2010.01.007
   das Neves J, 2010, TRENDS MICR FORM WOR
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Frenkel YV, 2005, J MED CHEM, V48, P1974, DOI 10.1021/jm049439i
   Freshney R. I., 2010, CULTURE ANIMAL CELLS, P365
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Gali Y, 2010, J VIROL METHODS, V165, P186, DOI 10.1016/j.jviromet.2010.01.018
   Gamsiz DE, 2008, BIOTECHNOL BIOENG, V101, P1072, DOI 10.1002/bit.21958
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Harush-Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p
   Harush-Frenkel O, 2008, CRIT REV THER DRUG, V25, P485, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i6.10                                    
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Heyndrickx L, 2008, J VIROL METHODS, V148, P166, DOI 10.1016/j.jviromet.2007.11.009
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Kanemura Y, 2002, J NEUROSCI RES, V69, P869, DOI 10.1002/jnr.10377
   Kashuba AD, 2010, 18 INT AIDS C VIENN
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26
   Montefiori D.C., 2005, CURR PROTOC IMMUNOL, V12, P11, DOI DOI 10.1002/0471142735.IM1211S64
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Nel AA, 2009, AIDS, V23, P1531, DOI 10.1097/QAD.0b013e32832c413d
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08
   Sinha VR, 2004, INT J PHARM, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Tajalli H, 2009, SPECTROCHIM ACTA A, V72, P697, DOI 10.1016/j.saa.2008.09.033
   Terrazas-Aranda Katty, 2007, Antiviral Chemistry & Chemotherapy, V18, P141
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P337, DOI 10.1128/AAC.48.1.337-339.2004
   Van Herrewege Y, 2002, AIDS RES HUM RETROV, V18, P1091, DOI 10.1089/088922202320567833
   Vanham G, 2000, AIDS, V14, P2299, DOI 10.1097/00002030-200010200-00011                                                
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Woolfson AD, 2006, INT J PHARM, V325, P82, DOI 10.1016/j.ijpharm.2006.06.026
NR 55
TC 39
Z9 39
U1 0
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUN
PY 2012
VL 29
IS 6
BP 1468
EP 1484
DI 10.1007/s11095-011-0622-3
PG 17
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 943JQ
UT WOS:000304117700005
PM 22072053
DA 2018-01-05
ER

PT J
AU Kapur, N
   Thakral, D
   Durgapal, H
   Panda, SK
AF Kapur, N.
   Thakral, D.
   Durgapal, H.
   Panda, S. K.
TI Hepatitis E virus enters liver cells through receptor-dependent
   clathrin-mediated endocytosis
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE clathrin-mediated endocytosis; competitive binding assay; hepatitis E
   virus; hepatitis E virus entry; virus-like particle
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SURFACE HEPARAN-SULFATE;
   HERPES-SIMPLEX-VIRUS; READING FRAME 2; CAPSID PROTEIN; ENVELOPE
   GLYCOPROTEIN; STRUCTURAL PROTEINS; CULTURE-SYSTEM; INSECT CELLS;
   FULL-LENGTH
AB . We investigated the virushost interaction for hepatitis E virus (HEV) by performing competitive binding assays using in vitro assembled virus-like particles (VLPs). We used Escherichia coli expressed native capsid protein (pORF2) and its mutants with an attached Gly(5)-Ala (linker) reporter [enhanced green fluorescent protein (EGFP)/firefly luciferase (Fluc)]. Transmission electron microscopy and nanoparticle tracking showed near uniform particles of approximately 3035 nm in diameter for pORF2 VLPs and 60100 nm for reporter-linked VLPs. Binding of reporter-linked full-length (1660aa) and N-terminal truncated (?1112aa) pORF2 VLPs to Huh7 cell surfaces was found to be specific with 1.92 +/- 0.065 x 105 sites per cell. Saturation binding indicated an equilibrium dissociation constant (Kd) of 121.1 +/- 23.83 and 123.8 +/- 16.15 nm for pORF2-linker-EGFP and pORF2-linker-Fluc VLPs respectively. A similar binding pattern was observed for ?1112aa pORF2-linker-EGFP and ?1112aa pORF2-linker-Fluc VLPs with Kd values of 123.6 +/- 10.60 and 135.6 +/- 16.19 nm respectively. The affinity (log Ki) of pORF2 binding on Huh7 cells in the presence of EGFP-tagged and Fluc-tagged pORF2 VLPs was found to be approximately 2.0. However, no VLP formation or binding was observed with refolded C-terminal truncated (?458660aa) pORF2. We investigated HEV internalization using fluorescent VLPs (EGFP-VLPs), which showed vesicle-mediated uptake starting at 5 min post-incubation. The uptake of VLPs could be stopped by inhibitors for clathrin-dependent endocytosis, but not by caveosome inhibitors. No binding and uptake of EGFP-VLPs were observed on non-hepatic cell lines (HeLa and SiHa). These findings suggest that HEV attaches to the host cell via a specific high affinity receptor and enters the cytoplasm by clathrin-mediated endocytosis.
C1 [Kapur, N.; Thakral, D.; Durgapal, H.; Panda, S. K.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
RP Panda, SK (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
EM subrat@gmail.com
FU Department of Biotechnology, Ministry of science and Technology,
   Government of India; Council of Scientific and Industrial Research
   (CSIR), Government of India
FX This study was funded by a grant in aid project to Prof. S.K. Panda from
   Department of Biotechnology, Ministry of science and Technology,
   Government of India. Neeraj Kapur and Deepshi Thakral are recipients of
   fellowship from Council of Scientific and Industrial Research (CSIR),
   Government of India. We sincerely thank Mr Anil Kundalia and Mr Ashutosh
   (Labindia, India) for their constant support and assistance with Leica
   confocal microscope. We gratefully acknowledge the help of Mr Rajesh
   Pathania (Senior Technical Officer) and Mr Sandeep Arya (Technical
   Assistant), Electron microscopy facility, AIIMS, for conducting this
   work. We also thank Mr Jeremy Warren for timely analysis of VLPs by
   'NanoSight'.
CR Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200
   BRADLEY JR, 1993, J IMMUNOL, V150, P5544
   Byrnes Andrew P., 1998, Journal of Virology, V72, P7349
   CARL M, 1994, CLIN DIAGN LAB IMMUN, V1, P253
   Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Charpilienne A, 2001, J BIOL CHEM, V276, P29361, DOI 10.1074/jbc.M101935200
   Chen XJS, 2001, J MOL BIOL, V307, P173, DOI 10.1006/jmbi.2000.4464
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Chung CS, 1998, J VIROL, V72, P1577
   Gilbert L, 2004, BIOCHEM BIOPH RES CO, V313, P878, DOI 10.1016/j.bbrc.2003.11.176
   Gilbert L, 2006, J NANOBIOTECHNOL, V4, P1
   Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x                                          
   Guu TSY, 2009, P NATL ACAD SCI USA, V106, P12992, DOI 10.1073/pnas.0904848106
   Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2
   Jameel S, 1996, J VIROL, V70, P207
   Kalia M, 2009, J VIROL, V83, P12714, DOI 10.1128/JVI.00717-09
   Kanesashi SN, 2003, J GEN VIROL, V84, P1899, DOI 10.1099/vir.0.19067-0
   KRAWCZYNSKI K, 1993, HEPATOLOGY, V17, P932, DOI 10.1002/hep.1840170525
   Krusat T, 1997, ARCH VIROL, V142, P1247, DOI 10.1007/s007050050156
   Panda SK, 2007, REV MED VIROL, V17, P151, DOI 10.1002/rmv.522
   Li F, 1997, J MED VIROL, V52, P289, DOI 10.1002/(SICI)1096-9071(199707)52:3<289::AID-JMV10>3.0.CO;2-E
   Li SW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000537
   Li SW, 2005, J BIOL CHEM, V280, P3400, DOI 10.1074/jbc.M410361200
   Li TC, 1997, J VIROL, V71, P7207
   Li TC, 2005, J VIROL, V79, P12999, DOI 10.1128/JVI.79.20.12999-13006.2005
   MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8
   Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662
   Mandl CW, 2001, J VIROL, V75, P5627, DOI 10.1128/JVI.75.12.5627-5637.2001
   MARION PL, 1980, J VIROL, V33, P795
   MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031
   MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9
   Mondor I, 1998, J VIROL, V72, P3623
   Moria M, 2011, VIRUS RES, V161, P59
   Muratori C, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-52
   Oganesyan N, 2004, PHARMAGENOMICS, V4, P22
   Okamoto H, 2011, VIRUS RES, V161, P65, DOI 10.1016/j.virusres.2011.01.015
   Okamoto H, 2011, REV MED VIROL, V21, P18, DOI 10.1002/rmv.678
   PANDA SK, 1995, J CLIN MICROBIOL, V33, P2653
   Panda SK, 2000, J VIROL, V74, P2430, DOI 10.1128/JVI.74.5.2430-2437.2000
   Peng S, 1999, J Tongji Med Univ, V19, P170
   PURDY MA, 1993, SEMIN VIROL, V4, P319, DOI 10.1006/smvy.1993.1029
   Reyes G R, 1993, Arch Virol Suppl, V7, P15
   Robinson RA, 1998, PROTEIN EXPRES PURIF, V12, P75, DOI 10.1006/prep.1997.0817
   SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X                                                    
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x                                              
   SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273
   Shukla P, 2011, P NATL ACAD SCI USA, V108, P2438, DOI 10.1073/pnas.1018878108
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005
   Takahashi M, 2007, J CLIN MICROBIOL, V45, P3671, DOI 10.1128/JCM.01086-07
   TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9                                                    
   Tanaka T, 2007, J GEN VIROL, V88, P903, DOI 10.1099/vir.0.82535-0
   Tanaka T, 2009, J CLIN MICROBIOL, V47, P1906, DOI 10.1128/JCM.00629-09
   Thakral D, 2005, J GEN VIROL, V86, P1189, DOI 10.1099/vir.0.80705-0
   Tong Yu-pin, 2003, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V17, P258
   Tong Yupin, 2002, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V16, P23
   Torresi J, 1997, J VIROL METHODS, V69, P81, DOI 10.1016/S0166-0934(97)00142-0
   Torresi J, 1999, J GEN VIROL, V80, P1185, DOI 10.1099/0022-1317-80-5-1185                                                     
   Touze A, 1998, NUCLEIC ACIDS RES, V26, P1317, DOI 10.1093/nar/26.5.1317                                                           
   TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369                                                        
   Tyagi S, 2001, BIOCHEM BIOPH RES CO, V286, P214, DOI 10.1006/bbrc.2001.5256
   Worm HC, 2002, MICROBES INFECT, V4, P657, DOI 10.1016/S1286-4579(02)01584-8
   WUDUNN D, 1989, J VIROL, V63, P52
   Xiaofang L., 2001, J BIOMED BIOTECHNOL, V1, P122, DOI [10.1155/S1110724301000262, DOI 10.1155/S1110724301000262]
   Xing L, 1999, VIROLOGY, V265, P35, DOI 10.1006/viro.1999.0005                                                          
   Yamada K, 2009, J GEN VIROL, V90, P457, DOI 10.1099/vir.0.007559-0
   Yamashita T, 2009, P NATL ACAD SCI USA, V106, P12986, DOI 10.1073/pnas.0903699106
   Zafrullah M, 1999, J VIROL, V73, P4074
   Zheng ZZ, 2010, J GEN VIROL, V91, P1728, DOI 10.1099/vir.0.019323-0
NR 70
TC 22
Z9 22
U1 0
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD JUN
PY 2012
VL 19
IS 6
BP 436
EP 448
DI 10.1111/j.1365-2893.2011.01559.x
PG 13
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 939ZE
UT WOS:000303858900008
PM 22571906
DA 2018-01-05
ER

PT J
AU Block, O
   Mitra, A
   Novotny, L
   Dykes, C
AF Block, Olivia
   Mitra, Anirban
   Novotny, Lukas
   Dykes, Carrie
TI A rapid label-free method for quantitation of human immunodeficiency
   virus type-1 particles by nanospectroscopy
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HIV-1; Nanospectroscopy; Virus particles
ID DRUG-RESISTANT MUTANTS; CD4(+) T-CELLS; REPLICATION-COMPETENT; HIV-1;
   ASSAY; NANOPARTICLES; SENSITIVITY; PROTEASE; VIRIONS; IMPACT
AB Infection of cells with human immunodeficiency virus type-1 (HIV-1) results in the production of both infectious and non-infectious virions. At present, several assays are available for the quantitation of virus particles based on the presence of either viral capsid protein or nucleic acid. However, the ability to detect the total number of virus particles, both infectious and non-infectious, has been an elusive goal that would advance the study of virus assembly and egress. A rapid optical detection scheme for real-time label-free quantitation of HIV-1 virus particles was developed. Virions produced in cell cultures transfected transiently were evaluated with a nanospectroscopic assay. Quantitation with the optical detection scheme correlated with routine conventional assays. Nanospectroscopy can be used for the detection of both infectious and non-infectious, wild type and mutant strains of HIV-1 in solution at concentrations as low as 7 x 10(10) particles/mI, requiring volumes as small as 2 mu I per assay, and in significantly less time than standard techniques. This assay provides a rapid, reliable system for quantifying virus particles in solution and could be applied to the study of viral particle production in cell culture. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Dykes, Carrie] Univ Rochester, Med Ctr, Dept Med, Div Infect Dis,Sch Med & Dent, Rochester, NY 14642 USA.
   [Novotny, Lukas] Univ Rochester, Inst Opt, Rochester, NY 14642 USA.
   [Mitra, Anirban; Novotny, Lukas] Dept Phys & Astron, Rochester, NY USA.
RP Dykes, C (reprint author), Univ Rochester, Med Ctr, Dept Med, Div Infect Dis,Sch Med & Dent, Box 689,601 Elmwood Ave, Rochester, NY 14642 USA.
EM carrie_dykes@urmc.rochester.edu
FU National Institutes of Health [R01-AI-041387, R21-A1085543-01A1];
   University of Rochester Developmental Center for AIDS Research (D-CFAR)
   [P30 AI-078498]
FX We would like to acknowledge Dr. John Lesoine and Steve Person for help
   in fabrication of the nanofluidic channels. We would like to acknowledge
   the University of Rochester Electron microscopy core for help imaging
   the virus samples. This study was supported by National Institutes of
   Health Grants R01-AI-041387 to C.D. and R21-A1085543-01A1 to L.N., and
   the University of Rochester Developmental Center for AIDS Research
   (D-CFAR) P30 AI-078498.
CR Bennett AE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000591
   Bhatta D, 2011, BIOSENS BIOELECTRON, V30, P78, DOI 10.1016/j.bios.2011.08.031
   BOURINBAIAR AS, 1994, ACTA VIROL, V38, P59
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Chen SH, 2009, IEEE T NANOBIOSCI, V8, P120, DOI 10.1109/TNB.2008.2011733
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   DIMITROV DS, 1993, J VIROL, V67, P2182
   Driskell JD, 2011, ANALYST, V136, P3083, DOI 10.1039/c1an15303j
   Dykes C, 2001, VIROLOGY, V285, P193, DOI 10.1006/viro.2001.0920
   Dykes C, 2006, J CLIN MICROBIOL, V44, P1930, DOI 10.1128/JCM.02415-05
   Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5
   Freed EO, 2003, TRENDS MICROBIOL, V11, P56, DOI 10.1016/S0966-842X(02)00013-6
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   HIGGINS JR, 1986, J CLIN MICROBIOL, V24, P424
   HUANG MJ, 1995, J VIROL, V69, P6810
   KIMPTON J, 1992, J VIROL, V66, P2232
   Leutenegger CM, 2001, AIDS RES HUM RETROV, V17, P243, DOI 10.1089/088922201750063160                                                      
   Lu T, 2011, P NATL ACAD SCI USA, V108, P5976, DOI 10.1073/pnas.1017962108
   Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x
   Mitra A, 2010, ACS NANO, V4, P1305, DOI 10.1021/nn901889v
   Niikura K, 2009, BIOCONJUGATE CHEM, V20, P1848, DOI 10.1021/bc900255x
   O'Connell KA, 2011, P NATL ACAD SCI USA, V108, pE689, DOI 10.1073/pnas.1108866108
   OSTER G, 1950, J GEN PHYSIOL, V33, P445, DOI 10.1085/jgp.33.5.445
   Piekna-Przybylska D, 2011, VIROLOGY, V410, P368, DOI 10.1016/j.virol.2010.11.026
   Richman D.D., 2009, SCIENCE, V323, P1394
   SARNGADHARAN MG, 1984, SCIENCE, V224, P506, DOI 10.1126/science.6324345                                                         
   Takasaki T, 1997, ARCH VIROL, V142, P375, DOI 10.1007/s007050050083
   Taylor N, 2009, ANTIVIR THER, V14, P1189, DOI 10.3851/IMP1427
NR 28
TC 8
Z9 8
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2012
VL 182
IS 1-2
BP 70
EP 75
DI 10.1016/j.jviromet.2012.03.012
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 940NP
UT WOS:000303900600010
PM 22460038
OA green_accepted
DA 2018-01-05
ER

PT J
AU Cruz, LJ
   Tacken, PJ
   Pots, JM
   Torensma, R
   Buschow, SI
   Figdor, CG
AF Cruz, Luis J.
   Tacken, Paul J.
   Pots, Jeanette M.
   Torensma, Ruurd
   Buschow, Sonja I.
   Figdor, Carl G.
TI Comparison of antibodies and carbohydrates to target vaccines to human
   dendritic cells via DC-SIGN
SO BIOMATERIALS
LA English
DT Article
DE Antigenicity; Drug delivery; Immune response; Immunostimulation;
   Nanoparticle
ID C-TYPE LECTIN; IN-VIVO; MYCOBACTERIUM-TUBERCULOSIS; CROSS-PRESENTATION;
   IMMUNE-RESPONSES; ANTIGEN UPTAKE; RECEPTOR; HIV-1; DEGRADATION;
   ACTIVATION
AB Vaccine efficacy is improved upon specific delivery to professional antigen (Ag) presenting cells, such as dendritic cells (DCs). Antigenicity and adjuvanticity of vaccine components can be enhanced by encapsulation within nanoparticle (NP) vaccine carriers that are targeted to the human DC-specific C-type lectin receptor DC-SIGN. Here we used two strategies to target vaccines components to DC-SIGN: 1) carbohydrates as natural receptor ligands and 2) receptor-specific antibodies (Abs). To determine the optimal targeting strategy, we coated NP vaccines harboring MHC class I or II-restricted Ags and the TLR ligands (TLRLs) poly I:C and resiquimod with either the DC-SIGN ligands Lewis-X (Le(x)), mannosylated lipoarabinomannan (ManLAM), glycosylated HIV protein gp120, or three distinct DC-SIGN Abs. Although, because of their lower MW, surface coating of NP vaccines with carbohydrates resulted in a higher number of surface molecules per NP than coating with Abs, NP vaccines carrying Abs were more effectively bound and internalized by human DCs than carriers harboring Le(x), ManLAM or gp120. Furthermore. NP vaccines harboring TLRLs triggered significant induction of DC maturation markers when compared to those without TLRLs, irrespective of the targeting moiety. Ab- and gp120-mediated targeting induced equally high levels of proinflammatory cytokines and increased presentation of the MHC class I-restricted epitope. By contrast, presentation of the MHC class II-restricted epitope was more efficient upon Ab-mediated targeting than when using gp120. Le(x) or ManLAM. From these findings we conclude that receptor-specific Abs are more effective than carbohydrates for DC-targeted vaccination strategies. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Cruz, Luis J.; Tacken, Paul J.; Pots, Jeanette M.; Torensma, Ruurd; Buschow, Sonja I.; Figdor, Carl G.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6525 GA Nijmegen, Netherlands.
RP Figdor, CG (reprint author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, Postbox 9101, NL-6500 HB Nijmegen, Netherlands.
EM c.figdor@ncmls.ru.nl
RI Buschow, Sonja/F-3777-2010; Figdor, Carl/A-4232-2010; Torensma,
   Ruurd/H-3830-2015
OI Torensma, Ruurd/0000-0002-0143-5626; Torensma,
   Ruurd/0000-0002-0555-7903; Figdor, Carl/0000-0002-2366-9212; Buschow,
   Sonja/0000-0002-7907-8315
FU Marie Curie Research Training Network EU [MRTN-CT-2006-035946];
   Netherlands Organisation for Scientific Research (NWO, Spinoza Prize);
   NIH, NIAID [HHSN266200400091C]
FX The authors wish to thank the technicians of the NCMLS Tumor Immunology
   Department's Clinical DC Group for their assistance. This work was
   supported by a Marie Curie Research Training Network EU grant
   Immunonamap (MRTN-CT-2006-035946) and The Netherlands Organisation for
   Scientific Research (NWO, Spinoza Prize). ManLAM was received as a part
   of NIH, NIAID contract No. HHSN266200400091C "Tuberculosis Vaccine
   Testing and Research Materials" awarded to Colorado State University.
CR Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134
   Belizaire R, 2009, P NATL ACAD SCI USA, V106, P17463, DOI 10.1073/pnas.0908583106
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
   Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971
   Cambi A, 2007, NANO LETT, V7, P970, DOI 10.1021/nl0700503
   Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039
   Cruz LJ, 2011, BIOMATERIALS, V32, P6791, DOI 10.1016/j.biomaterials.2011.04.082
   Cruz LJ, 2011, MOL PHARMACEUT, V8, P520, DOI 10.1021/mp100356k
   Cruz LJ, 2010, J CONTROL RELEASE, V144, P118, DOI 10.1016/j.jconrel.2010.02.013
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778
   Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769
   Hodges A, 2007, NAT IMMUNOL, V8, P569, DOI 10.1038/ni1470
   Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002
   HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673
   Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004
   Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532
   Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283
   Pitarque S, 2005, BIOCHEM J, V392, P615, DOI 10.1042/BJ20050709
   Sanchez-Navarro M, 2010, DRUG NEWS PERSPECT, V23, P557, DOI 10.1358/dnp.2010.23.9.1437246
   Schaefer M, 2008, J IMMUNOL, V180, P6836, DOI 10.4049/jimmunol.180.10.6836                                                    
   Schreibelt G, 2010, BLOOD, V116, P564, DOI 10.1182/blood-2009-11-251884
   Singh SK, 2009, MOL IMMUNOL, V47, P164, DOI 10.1016/j.molimm.2009.09.026
   Tacken PJ, 2008, J IMMUNOL, V180, P7687, DOI 10.4049/jimmunol.180.11.7687                                                    
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Tacken PJ, 2011, BLOOD, V118, P4111, DOI 10.1182/blood-2011-04-346957
   Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318
   Tacken PJ, 2011, BLOOD, DOI [10.1182Iblood201107367615, DOI 10.1183/BLOOD201107367615]
   Tel J, 2010, J IMMUNOL, V184, P4276, DOI 10.4049/jimmunol.0903286
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   Tsuji T, 2011, J IMMUNOL, V186, P1218, DOI 10.4049/jimmunol.1000808
   Yang JH, 2004, J FLUORESC, V14, P275, DOI 10.1023/B:JOFL.0000024559.47422.9d
NR 34
TC 36
Z9 36
U1 0
U2 28
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2012
VL 33
IS 16
BP 4229
EP 4239
DI 10.1016/j.biomaterials.2012.02.036
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 929WL
UT WOS:000303096300021
PM 22410170
DA 2018-01-05
ER

PT J
AU Endsley, AN
   Ho, RJY
AF Endsley, Aaron N.
   Ho, Rodney J. Y.
TI Design and Characterization of Novel Peptide-Coated Lipid Nanoparticles
   for Targeting Anti-HIV Drug to CD4 Expressing Cells
SO AAPS JOURNAL
LA English
DT Article
DE CD4 targeting; HIV; lipid nanoparticle; peptide; targeted drug delivery
ID LYMPH-NODES; ANTIRETROVIRAL THERAPY; GELATIN NANOPARTICLES; VIRAL LOAD;
   DELIVERY; INDINAVIR; REPLICATION; LOCALIZATION; SUPPRESSION; DIDANOSINE
AB Human immunodeficiency virus (HIV) persists in lymph nodes and lymphoid tissues even during aggressive drug treatment, likely due to insufficient drug concentrations at this site. Therefore, to eliminate this residual virus, methods that enhance lymph node drug concentrations are currently being evaluated. Although enhanced drug concentrations in tissue have been achieved with drug-associated lipid nanoparticles, targeting these particles to CD4(+) cells may provide specific delivery of drug to HIV target cells and further enhance drug efficacy. We have evaluated four candidate peptides with reported binding specificity to CD4 for anchoring on lipid nanoparticle preparations previously shown to localize in lymph nodes. Terminal cysteine containing candidate peptides were conjugated to lipid nanoparticles through maleimide-linked phopholipids for targeting to CD4 cells. Using fluorescently labeled lipid nanoparticle binding to cells with varying degree of CD4 expression (CEMx174, Molt-4, Jurkat, and Ramos), we indentified two peptide sequences that provided CD4 selectivity to nanoparticles. These two peptide candidates on lipid nanoparticles bound to cells corresponding to the degree of CD4 expression and in a peptide dose dependent manner. Further, binding of these targeted lipid nanoparticles was CD4 specific, as pre-exposure of CD4(+) cells to anti-CD4 antibodies or free peptides inhibited the binding interactions. These results indicate targeting of lipid nanoparticles for specific binding to CD4 can be accomplished by tagging CD4 binding peptides with peptides, and these results provide a basis for further evaluation of this targeted delivery system to enhance antiviral drug delivery to CD4(+) HIV host cells, particularly those in lymph nodes and lymphoid tissues.
C1 [Endsley, Aaron N.; Ho, Rodney J. Y.] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
FU NIH [AI77390, NS39178, RR00166]; NIH through the Institute of
   Translational Health Sciences [1UL1-RR025014]
FX This study is supported in part by NIH grants AI77390, NS39178, and
   RR00166, and 1UL1-RR025014 through the Institute of Translational Health
   Sciences.
CR Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707
   Casset F, 2003, BIOCHEM BIOPH RES CO, V307, P198, DOI 10.1016/S0006-291X(03)01131-8
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Duzgunes N, 1999, MOL MEMBR BIOL, V16, P111, DOI 10.1080/096876899294832                                                         
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Hong YL, 1999, AIDS RES HUM RETROV, V15, P1667, DOI 10.1089/088922299309702                                                         
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Roge BT, 2004, HIV MED, V5, P344, DOI 10.1111/j.1468-1293.2004.00233.x                                                
   Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001                                                
   SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Tedla N, 1999, CLIN EXP IMMUNOL, V117, P92
   WHO, 2009, GLOB SUMM AIDS EP 11
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Yoon V, 2010, CURR MED CHEM, V17, P741, DOI 10.2174/092986710790514499                                                      
   ZANOTTO C, 1995, VIROLOGY, V206, P807, DOI 10.1006/viro.1995.1003
NR 28
TC 9
Z9 9
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PD JUN
PY 2012
VL 14
IS 2
BP 225
EP 235
DI 10.1208/s12248-012-9329-6
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 926EU
UT WOS:000302814900009
PM 22391788
OA green_published
DA 2018-01-05
ER

PT J
AU Singh, DK
   Lara, HH
AF Singh, Dinesh K.
   Lara, Humberto H.
TI Inhibition of cell-associated HIV-1 by silver nanoparticles
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Singh, Dinesh K.; Lara, Humberto H.] Winston Salem State Univ, Winston Salem, NC USA.
EM singhd@wssu.edu
OI Lara, Humberto H/0000-0003-4854-9839
NR 0
TC 4
Z9 4
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 25
PY 2012
VL 9
SU 1
AR O1
DI 10.1186/1742-4690-9-S1-O1
PG 1
WC Virology
SC Virology
GA 015UN
UT WOS:000309472000026
OA gold
DA 2018-01-05
ER

PT J
AU Martinelli, N
   Hartlieb, B
   Usami, Y
   Sabin, C
   Dordor, A
   Miguet, N
   Avilov, SV
   Ribeiro, EA
   Gottlinger, H
   Weissenhorn, W
AF Martinelli, Nicolas
   Hartlieb, Bettina
   Usami, Yoshiko
   Sabin, Charles
   Dordor, Aurelien
   Miguet, Nolwenn
   Avilov, Sergiy V.
   Ribeiro, Euripedes A., Jr.
   Goettlinger, Heinrich
   Weissenhorn, Winfried
TI CC2D1A Is a Regulator of ESCRT-III CHMP4B
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE CC2D1A; Freud-1; Aki-1; Lgd; ESCRT
ID C2 DOMAIN PROTEIN; NF-KAPPA-B; STRUCTURAL BASIS; MENTAL-RETARDATION;
   HELICAL STRUCTURES; PLASMA-MEMBRANE; CELL-DIVISION; PATHWAY;
   CYTOKINESIS; FILAMENTS
AB Endosomal sorting complexes required for transport (ESCRTs) regulate diverse processes ranging from receptor sorting at endosomes to distinct steps in cell division and budding of some enveloped viruses. Common to all processes is the membrane recruitment of ESCRT-III that leads to membrane fission. Here, we show that CC2D1A is a novel regulator of ESCRT-III CHMP4B function. We demonstrate that CHMP4B interacts directly with CC2D1A and CC2D1B with nanomolar affinity by forming a 1:1 complex. Deletion mapping revealed a minimal CC2D1A-CHMP4B binding construct, which includes a short linear sequence within the third DM14 domain of CC2D1A. The CC2D1A binding site on CHMP4B was mapped to the N-terminal helical hairpin. Based on a crystal structure of the CHMP4B helical hairpin, two surface patches were identified that interfere with CC2D1A interaction as determined by surface plasmon resonance. Introducing these mutations into a C-terminal truncation of CHMP4B that exerts a potent dominant negative effect on human immunodeficiency virus type 1 budding revealed that one of the mutants lost this effect completely. This suggests that the identified CC2D1A binding surface might be required for CHMP4B polymerization, which is consistent with the finding that CC2D1A binding to CHMP4B prevents CHMP4B polymerization in vitro. Thus, CC2D1A might act as a negative regulator of CHMP4B function. (C) 2012 Published by Elsevier Ltd.
C1 [Martinelli, Nicolas; Hartlieb, Bettina; Sabin, Charles; Dordor, Aurelien; Miguet, Nolwenn; Avilov, Sergiy V.; Ribeiro, Euripedes A., Jr.; Weissenhorn, Winfried] Univ Grenoble 1, EMBL, CNRS, UVHCI,UMI 3265, F-38042 Grenoble 9, France.
   [Usami, Yoshiko; Goettlinger, Heinrich] Univ Massachusetts, Sch Med, Program Mol Med, Program Gene Funct & Express, Worcester, MA 01605 USA.
   [Avilov, Sergiy V.] Grenoble Outstn, European Mol Biol Lab, F-38042 Grenoble 9, France.
RP Weissenhorn, W (reprint author), Univ Grenoble 1, EMBL, CNRS, UVHCI,UMI 3265, 6 Rue Jules Horowitz, F-38042 Grenoble 9, France.
EM weissenhorn@embl.fr
RI Avilov, Sergiy/A-2904-2012
FU Agence Nationale de la Recherche [ANR-08-BLAN-0271-01]; Deutsche
   Forschungsgemeinschaft (DFG) [SPP1175]; National Institute of Allergy
   and Infectious Diseases [R37AI029873]; European Molecular Biology
   Organization; Region Rhone-Alpes (Cluster 10 infectiologie)
FX This work was supported by the Agence Nationale de la Recherche
   (ANR-08-BLAN-0271-01) and the Deutsche Forschungsgemeinschaft (DFG)
   (SPP1175) (W.W.), the National Institute of Allergy and Infectious
   Diseases (R37AI029873 to H.G.), a postdoctoral fellowship from the
   European Molecular Biology Organization (B.H.) and a PhD fellowship from
   the Region Rhone-Alpes (Cluster 10 infectiologie) (N.M.). We thank Dr.
   T. Klein (Heinrich Heine Universitat, Dusseldorf) for the lgd cDNA
   clone. We acknowledge the Partnership for Structural Biology
   (http://www.psb-grenoble.eu) for access to the common platforms
   including the crystallization facility (J. Marquez), the biophysical
   platform (M. Jamin) and the European Synchrotron Radiation Facility for
   beam time and assistance during data collection. The HIV-1 p24
   monoclonal antibody (183-H12-5C) (provided by Drs. Bruce Chesebro and
   Kathy Wehrly) was obtained through the AIDS Research and Reference
   Reagent Program, Division of AIDS, National Institute of Allergy and
   Infectious Diseases, National Institutes of Health.
CR Bajorek M, 2009, NAT STRUCT MOL BIOL, V16, P754, DOI 10.1038/nsmb.1621
   Bieniasz PD, 2009, CELL HOST MICROBE, V5, P550, DOI 10.1016/j.chom.2009.05.015
   Bodon G, 2011, J BIOL CHEM, V286, P40276, DOI 10.1074/jbc.M111.283671
   Carlton JG, 2008, P NATL ACAD SCI USA, V105, P10541, DOI 10.1073/pnas.0802008105
   Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422
   CCP4, 1994, ACTA CRYSTALLOGR D, V50, P157
   Chang CH, 2011, J BIOL CHEM, V286, P7043, DOI 10.1074/jbc.M110.164632
   CHESEBRO B, 1992, J VIROL, V66, P6547
   Childress JL, 2006, CURR BIOL, V16, P2228, DOI 10.1016/j.cub.2006.09.031
   Dordor A, 2011, FUTURE MICROBIOL, V6, P1159, DOI [10.2217/fmb.11.100, 10.2217/FMB.11.100]
   Elia N, 2011, P NATL ACAD SCI USA, V108, P4846, DOI 10.1073/pnas.1102714108
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Fyfe I, 2011, J BIOL CHEM, V286, P34262, DOI 10.1074/jbc.M111.266411
   Gallagher CM, 2006, DEV CELL, V11, P641, DOI 10.1016/j.devcel.2006.09.014
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2                                                   
   Gerard FCA, 2007, BIOCHEMISTRY-US, V46, P10328, DOI 10.1021/bi7007799
   Ghazi-Tabatabai S, 2008, STRUCTURE, V16, P1345, DOI 10.1016/j.str.2008.06.010
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305                                                 
   Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847
   Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031
   Hao Q, 2004, J APPL CRYSTALLOGR, V37, P498, DOI 10.1107/S0021889804008696
   Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015
   Hurley JH, 2008, CURR OPIN CELL BIOL, V20, P4, DOI 10.1016/j.ceb.2007.12.002
   Hurley JH, 2010, NAT REV MOL CELL BIO, V11, P556, DOI 10.1038/nrm2937
   Im YJ, 2009, DEV CELL, V17, P234, DOI 10.1016/j.devcel.2009.07.008
   Jaekel R, 2006, DEV CELL, V11, P655, DOI 10.1016/j.devcel.2006.09.019
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Kieffer C, 2008, DEV CELL, V15, P62, DOI 10.1016/j.devcel.2008.05.014
   Lata S, 2008, SCIENCE, V321, P1354, DOI 10.1126/science.1161070
   Lata S, 2008, J MOL BIOL, V378, P818, DOI 10.1016/j.jmb.2008.03.030
   Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042
   LESLIE AGW, 1992, NEWSLETT PROTEIN CRY, V26
   Martin-Serrano J, 2011, NAT REV MICROBIOL, V9, P519, DOI 10.1038/nrmicro2596
   Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406
   McCullough J, 2008, P NATL ACAD SCI USA, V105, P7687, DOI 10.1073/pnas.0801567105
   McDonald B, 2009, J CELL SCI, V122, P2167, DOI 10.1242/jcs.028308
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Morita E, 2010, P NATL ACAD SCI USA, V107, P12889, DOI 10.1073/pnas.1005938107
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Muziol T, 2006, DEV CELL, V10, P821, DOI 10.1016/j.devcel.2006.03.013
   Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08
   Nakamura A, 2010, BIOCHEM BIOPH RES CO, V393, P872, DOI 10.1016/j.bbrc.2010.02.103
   Nakamura A, 2009, J CELL BIOL, V187, P607, DOI 10.1083/jcb.200906019
   Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869
   Obita T, 2007, NATURE, V449, P735, DOI 10.1038/nature06171
   Ou XM, 2003, J NEUROSCI, V23, P7415
   Panjikar S, 2005, ACTA CRYSTALLOGR D, V61, P449, DOI 10.1107/S0907444905001307
   Peel S, 2011, TRENDS BIOCHEM SCI, V36, P199, DOI 10.1016/j.tibs.2010.09.004
   Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263
   Pires R, 2009, STRUCTURE, V17, P843, DOI 10.1016/j.str.2009.04.007
   Rogaeva A, 2007, J NEUROSCI RES, V85, P2833, DOI 10.1002/jnr.21277
   Rogaeva A, 2007, EUR J NEUROSCI, V26, P965, DOI 10.1111/j.1460-9568.2007.05727.x
   Saksena S, 2009, CELL, V136, P97, DOI 10.1016/j.cell.2008.11.013
   Samson RY, 2008, SCIENCE, V322, P1710, DOI 10.1126/science.1165322
   Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678
   Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662                                                   
   Sheldrick G. M., 2001, INT TABLES CRYSTALLO, P247
   Shim S, 2007, TRAFFIC, V8, P1068, DOI 10.1111/j.1600-0854.2007.00584.x                                                
   Solomons J, 2011, STRUCTURE, V19, P1149, DOI 10.1016/j.str.2011.05.011
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   Stuchell-Brereton MD, 2007, NATURE, V449, P740, DOI 10.1038/nature06172
   Szewczyk B., 2011, INT J NEUROPSYCHOPH, V13, P1089
   Teis D, 2008, DEV CELL, V15, P578, DOI 10.1016/j.devcel.2008.08.013
   Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072
   Tsang HTH, 2006, GENOMICS, V88, P333, DOI 10.1016/j.ygeno.2006.04.003
   Tsang HTH, 2009, HUM MOL GENET, V18, P3805, DOI 10.1093/hmg/ddp324
   Usami Y, 2009, BIOCHEM SOC T, V37, P181, DOI 10.1042/BST0370181
   Vaccari T, 2009, J CELL SCI, V122, P2413, DOI 10.1242/jcs.046391
   von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1                                                   
   Weiss ER, 2011, J MOL BIOL, V410, P525, DOI 10.1016/j.jmb.2011.04.055
   Xiao JY, 2009, MOL BIOL CELL, V20, P3514, DOI 10.1091/mbc.E09-05-0403
   Zamborlini A, 2006, P NATL ACAD SCI USA, V103, P19140, DOI 10.1073/pnas.0603788103
   Zhao M, 2010, J BIOL CHEM, V285, P24372, DOI 10.1074/jbc.M109.100057
NR 77
TC 21
Z9 21
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD MAY 25
PY 2012
VL 419
IS 1-2
BP 75
EP 88
DI 10.1016/j.jmb.2012.02.044
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 937VK
UT WOS:000303690900006
PM 22406677
OA green_accepted
DA 2018-01-05
ER

PT J
AU Nair, BG
   Fukuda, T
   Mizuki, T
   Hanajiri, T
   Maekawa, T
AF Nair, Baiju G.
   Fukuda, Takahiro
   Mizuki, Toru
   Hanajiri, Tatsuro
   Maekawa, Toru
TI Intracellular trafficking of superparamagnetic iron oxide nanoparticles
   conjugated with TAT peptide: 3-dimensional electron tomography analysis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Nanoparticles; Internalisation; Cell penetrating peptides; Endocytic
   pathways; Transmission electron microscopy; 3-D tomography
ID CELL-PENETRATING PEPTIDES; CRYOELECTRON TOMOGRAPHY; GOLD NANOPARTICLES;
   DELIVERY; MEMBRANE; ORGANIZATION; CYTOPLASM
AB Internalisation of nanoparticles conjugated with cell penetrating peptides is a promising approach to various drug delivery applications. Cell penetrating peptides such as transactivating transcriptional activator (TAT) peptides derived from HIV-1 proteins are effective intracellular delivery vectors for a wide range of nanoparticles and pharmaceutical agents thanks to their amicable ability to enter cells and minimum cytotoxicity. Although different mechanisms of intracellular uptake and localisation have been proposed for TAT conjugated nanoparticles, it is necessary to visualise the particles on a 3-D plane in order to investigate the actual intracellular uptake and localisation. Here, we study the intracellular localisation and trafficking of TAT peptide conjugated superparamagnetic ion oxide nanoparticles (TAT-SPIONs) using 3-D electron tomography. 3-D tomograms clearly show the location of TAT-SPIONs in a cell and their slow release from the endocytic vesicles into the cytoplasm. The present methodology may well be utilised for further investigations of the behaviours of nanoparticles in cells and eventually for the development of nano drug delivery systems. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Nair, Baiju G.; Fukuda, Takahiro; Mizuki, Toru; Hanajiri, Tatsuro; Maekawa, Toru] Toyo Univ, Bionano Elect Res Ctr, Saitama 3508585, Japan.
RP Maekawa, T (reprint author), Toyo Univ, Bionano Elect Res Ctr, Saitama 3508585, Japan.
EM maekawa@toyo.jp
OI Mizuki, Toru/0000-0003-2744-881X; Nair, Baiju/0000-0002-1616-8807
FU  [S1101017]
FX Part of the present study has been supported by a Grant for the
   Strategic Development of Advanced Science and Technology S1101017
   organised by the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT), Japan, since April 2011.
CR Al-Jamal KT, 2011, NANOSCALE, V3, P2627, DOI 10.1039/c1nr10080g
   Bartz R, 2011, BIOCHEM J, V435, P475, DOI 10.1042/BJ20101021
   Baumeister W, 2002, CURR OPIN STRUC BIOL, V12, P679, DOI 10.1016/S0959-440X(02)00378-0
   Ben-Harush K., 2010, J CELL SCI, V1, P7
   Bertorelle F, 2006, LANGMUIR, V22, P5385, DOI 10.1021/la052710u
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Gao JH, 2009, NANO TODAY, V4, P37, DOI 10.1016/j.nantod.2008.10.009
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P1, DOI 10.1016/B978-0-12-370501-3.00001-1
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hoenger A, 2009, CURR OPIN CELL BIOL, V21, P89, DOI 10.1016/j.ceb.2008.12.003
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Iwasaki K, 2010, CURR OPIN STRUC BIOL, V20, P632, DOI 10.1016/j.sbi.2010.08.007
   Jung JJ, 2010, ANGEW CHEM INT EDIT, V49, P103, DOI 10.1002/anie.200905126
   Kobayashi T, 2011, BIOTECHNOL J, V6, P1342, DOI 10.1002/biot.201100045
   Krpetic Z, 2011, ACS NANO, V5, P5195, DOI 10.1021/nn201369k
   McIntosh R, 2005, TRENDS CELL BIOL, V15, P43, DOI 10.1016/j.tcb.2004.11.009
   Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184                                                         
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P16883, DOI 10.1073/pnas.1108795108
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Nair BG, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/45/455102
   Peng L., 2010, STRUCTURE, V13, P47
   Porter AE, 2007, NAT NANOTECHNOL, V2, P713, DOI 10.1038/nnano.2007.347
   Porter AE, 2007, ENVIRON SCI TECHNOL, V41, P3012, DOI 10.1021/es062541f
   Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046
   Schrand M.A., 2010, NAT PROTOC, V5, P744
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Sougrat R., 2007, PLOS PATHOG, V4, pe63
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Vacha R, 2011, NANO LETT, V11, P5391, DOI 10.1021/nl2030213
   Varkouhi A.K., 2011, J CONTROL RELEASE, V10, P220
   Wang C, 2011, BIOMATERIALS, V32, P1110, DOI 10.1016/j.biomaterials.2010.09.069
   Wilhelm C, 2002, LANGMUIR, V18, P8148, DOI 10.1021/la0257337
   Yu J, 2009, J MATER CHEM, V19, P1265, DOI 10.1039/b816157g
   Yuan HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013495
NR 37
TC 11
Z9 14
U1 0
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 18
PY 2012
VL 421
IS 4
BP 763
EP 767
DI 10.1016/j.bbrc.2012.04.080
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 957NB
UT WOS:000305168600022
PM 22546557
DA 2018-01-05
ER

PT J
AU Wong, HL
   Wu, XY
   Bendayan, R
AF Wong, Ho Lun
   Wu, Xiao Yu
   Bendayan, Reina
TI Nanotechnological advances for the delivery of CNS therapeutics
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Central nervous system; Nanomedicine; Nanotechnology; Drug delivery;
   Blood-brain barrier; Brain targeting
ID BLOOD-BRAIN-BARRIER; SOLID LIPID NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM;
   ENDOTHELIAL-CELL LINE; RECEPTOR-MEDIATED DELIVERY; EFFLUX
   TRANSPORT-SYSTEMS; EFFICIENT GENE DELIVERY; IN-VITRO MODELS; OF-THE-ART;
   DRUG-DELIVERY
AB Effective non-invasive treatment of neurological diseases is often limited by the poor access of therapeutic agents into the central nervous system (CNS). The majority of drugs and biotechnological agents do not readily permeate into brain parenchyma due to the presence of two anatomical and biochemical dynamic barriers: the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Therefore, one of the most significant challenges facing CNS drug development is the availability of effective brain targeting technology. Recent advances in nanotechnology have provided promising solutions to this challenge. Several nanocarriers ranging from the more established systems, e.g. polymeric nanoparticles, solid lipid nanopartides, liposomes, micelles to the newer systems, e.g. dendrimers, nanogels, nanoemulsions and nanosuspensions have been studied for the delivery of CNS therapeutics. Many of these nanomedicines can be effectively transported across various in vitro and in vivo BBB models by endocytosis and/or transcytosis, and demonstrated early preclinical success for the management of CNS conditions such as brain tumors, HIV encephalopathy, Alzheimer's disease and acute ischemic stroke. Future development of CNS nanomedicines need to focus on increasing their drug-trafficking performance and specificity for brain tissue using novel targeting moieties, improving their BBB permeability and reducing their neurotoxicity. (c) 2011 Elsevier B.V. All rights reserved.
C1 [Wu, Xiao Yu; Bendayan, Reina] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 2S2, Canada.
   [Wong, Ho Lun] Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA.
RP Bendayan, R (reprint author), Univ Toronto, Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON M5S 2S2, Canada.
EM r.bendayan@utoronto.ca
FU Ontario HIV treatment Network (OHTN), Ministry of Health of Ontario;
   Canadian Institutes of Health Research [MOP-56976]; OHTN
FX Dr. Reina Bendayan is a recipient of a Career Scientist Award from the
   Ontario HIV treatment Network (OHTN), Ministry of Health of Ontario.
   This work is supported by operating grants from the Canadian Institutes
   of Health Research (MOP-56976) and OHTN, awarded to Dr. Bendayan.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x                                                
   Abulrob A, 2008, MOL IMAGING, V7, P248, DOI 10.2310/7290.2008.00025
   Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
   Anda T., 1995, DRUG DELIV SYST, V10, P425
   Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002
   Batrakova EV, 2003, J PHARMACOL EXP THER, V304, P845, DOI 10.1124/jpet.102.043307
   Batrakova EV, 1999, PHARMACEUT RES, V16, P1366, DOI 10.1023/A:1018990706838                                                         
   Bendayan R, 2002, MICROSC RES TECHNIQ, V57, P365, DOI 10.1002/jemt.10090
   Bendayan R, 2006, J HISTOCHEM CYTOCHEM, V54, P1159, DOI 10.1369/jhc.5A6870.2006
   Bertrand N, 2010, METHODS MOL BIOL, V605, P545, DOI 10.1007/978-1-60327-360-2_36
   Betbeder D, 2000, PHARM RES-DORDR, V17, P743, DOI 10.1023/A:1007594602449
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   Brioschi AM, 2009, PROG BRAIN RES, V180, P193, DOI 10.1016/S0079-6123(08)80011-8
   Buckner JC, 2007, MAYO CLIN PROC, V82, P1271, DOI 10.4065/82.10.1271                                                              
   Cai B, 2011, EXP NEUROL, V227, P224, DOI 10.1016/j.expneurol.2010.11.009
   Camenisch G, 1998, EUR J PHARM SCI, V6, P313, DOI 10.1016/S0928-0987(97)10019-7
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chen PY, 2010, NEURO-ONCOLOGY, V12, P1050, DOI 10.1093/neuonc/noq054
   Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8                                                   
   COHEN BE, 1972, NATURE, V236, P173, DOI 10.1038/236173a0
   Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013
   Costantino L, 2009, PROG BRAIN RES, V180, P35, DOI 10.1016/S0079-6123(08)80003-9
   CRONE C, 1965, J PHYSIOL-LONDON, V181, P103, DOI 10.1113/jphysiol.1965.sp007748                                                  
   Cui ZR, 2005, EUR J PHARM BIOPHARM, V59, P263, DOI 10.1016/j.ejpb.2004.07.009
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Dallas S, 2004, J PHARMACOL EXP THER, V309, P1221, DOI 10.1124/jpet.103.063966
   Dallas S, 2006, PHARMACOL REV, V58, P140, DOI 10.1124/pr.58.2.3
   Das D, 2005, J PHARM SCI-US, V94, P1343, DOI 10.1002/jps.20357
   DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665
   de Boer AG, 2003, ANNU REV PHARMACOL, V43, P629, DOI 10.1146/annurev.pharmtox.43.100901.140204                                       
   de Lange ECM, 2004, ADV DRUG DELIVER REV, V56, P1793, DOI 10.1016/j.addr.2004.07.009
   Dechy-Cabaret O, 2004, CHEM REV, V104, P6147, DOI 10.1021/cr040002s
   Deeken JF, 2007, CLIN CANCER RES, V13, P1663, DOI 10.1158/1078-0432.CCR-06-2854
   Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x
   Deng CX, 2011, THER DELIV, V2, P137, DOI 10.4155/TDE.10.107
   Deng XY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/11/115101
   Desai A, 2008, J PHARM SCI-US, V97, P2745, DOI 10.1002/jps.21182
   Desormeaux A, 1998, J DRUG TARGET, V6, P1
   Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Eavarone DA, 2000, J BIOMED MATER RES, V51, P10, DOI 10.1002/(SICI)1097-4636(200007)51:1<10::AID-JBM2>3.0.CO;2-R
   Elder A, 2006, ENVIRON HEALTH PERSP, V114, P1172, DOI 10.1289/ehp.9030
   Enerson BE, 2006, J CEREBR BLOOD F MET, V26, P959, DOI 10.1038/sj.jcbfm.9600249
   Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005
   Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017
   Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0                                                   
   Fisher JL, 2007, NEUROL CLIN, V25, P867, DOI 10.1016/j.ncl.2007.07.002
   Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158
   Fortin D, 2007, CANCER-AM CANCER SOC, V109, P751, DOI 10.1002/cncr.22450
   FRESTA M, 1994, J PHARM PHARMACOL, V46, P974, DOI 10.1111/j.2042-7158.1994.tb03252.x                                              
   Gao KP, 2006, INT J PHARM, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040
   Gao XL, 2007, J CONTROL RELEASE, V121, P156, DOI 10.1016/j.jconrel.2007.05.026
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   Garcel Aude, 2010, International Journal of Biomedical Nanoscience and Nanotechnology, V1, P133, DOI 10.1504/IJBNN.2010.034650
   Garcia-Alloza M, 2004, NEUROMOL MED, V6, P65, DOI 10.1385/NMM:6:1:065
   Garcion E, 2006, MOL CANCER THER, V5, P1710, DOI 10.1158/1535-7163.MCT-06-0289
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   GARNER C, 1992, BRAIN RES, V591, P137, DOI 10.1016/0006-8993(92)90988-L                                                    
   Goldstein LB, 2007, CIRCULATION, V116, P1504, DOI 10.1161/CIRCULATIONAHA.106.670885
   GONATAS NK, 1984, J CELL BIOL, V99, P1379, DOI 10.1083/jcb.99.4.1379
   Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527
   Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292
   Groothuis DR, 1997, J NEUROVIROL, V3, P387, DOI 10.3109/13550289709031185                                                       
   Hartig W, 2003, NEUROSCI LETT, V338, P174, DOI 10.1016/S0304-3940(02)01399-X
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   He H, 2011, BIOMATERIALS, V32, P478, DOI 10.1016/j.biomaterials.2010.09.002
   Heart Disease and Stroke Statistics, 2011, CIRCULATION, V123, pe18
   Hu KL, 2011, INT J PHARMACEUT, V415, P273, DOI 10.1016/j.ijpharm.2011.05.062
   Huang GH, 2008, INT J PHARM, V355, P314, DOI 10.1016/j.ijpharm.2007.12.013
   Huang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
   Hussain SM, 2006, TOXICOL SCI, V92, P456, DOI 10.1093/toxsci/kfl020
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Huwyler J, 1997, J PHARMACOL EXP THER, V282, P1541
   Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026
   Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046
   Hynynen K, 2008, ADV DRUG DELIVER REV, V60, P1209, DOI 10.1016/j.addr.2008.03.010
   Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022764
   Invernici G, 2011, RECENT PAT ANTI-CANC, V6, P58, DOI 10.2174/157489211793979990
   Juan QL, 2009, NEUROSCI LETT, V450, P172, DOI 10.1016/j.neulet.2008.10.080
   Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
   Kabanov AV, 2003, J CONTROL RELEASE, V91, P75, DOI 10.1016/S0168-3659(03)00211-6
   Kakinuma K, 1996, INT J HYPERTHER, V12, P157, DOI 10.3109/02656739609023698
   Kanazawa T, 2011, PHARM RES-DORDR, V28, P2130, DOI 10.1007/s11095-011-0440-7
   Kerwin BA, 2008, J PHARM SCI-US, V97, P2924, DOI 10.1002/jps.21190
   Kim DH, 2006, BIOMATERIALS, V27, P3031, DOI 10.1016/j.biomaterials.2005.12.021
   Kim HR, 2007, BIOMACROMOLECULES, V8, P793, DOI 10.1021/bm060711a
   Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103
   Kis O, 2010, TRENDS PHARMACOL SCI, V31, P22, DOI 10.1016/j.tips.2009.10.001
   Kogan MJ, 2006, NANO LETT, V6, P110, DOI 10.1021/nl0516862
   Koukourakis MI, 2000, ACTA ONCOL, V39, P207
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   KUMAGAI AK, 1987, J BIOL CHEM, V262, P15214
   Kumar M, 2008, INT J PHARM, V358, P285, DOI 10.1016/j.ijpharm.2008.03.029
   Kumar M, 2008, J DRUG TARGET, V16, P806, DOI [10.1080/10611860802476504, 10.1080/10611860802476504 ]
   Kumar VV, 2003, CURR MED CHEM, V10, P1297, DOI 10.2174/0929867033457458
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Kusuhara H, 2001, DRUG DISCOV TODAY, V6, P206, DOI 10.1016/S1359-6446(00)01643-3
   Kusuhara H, 2001, DRUG DISCOV TODAY, V6, P150, DOI 10.1016/S1359-6446(00)01632-9
   Kusuhara H., 2005, NEURORX, V2, P73, DOI 10.1007/BF03206644
   Lamprecht A, 2006, J CONTROL RELEASE, V112, P208, DOI 10.1016/j.jconrel.2006.02.014
   Lee CW, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3116710
   Lee YJ, 2006, J PHARMACOL EXP THER, V316, P647, DOI 10.1124/jpet.105.088328
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Liu G, 2009, PROG BRAIN RES, V180, P97, DOI 10.1016/S0079-6123(08)80005-2
   Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699
   Lockman PR, 2003, J CONTROL RELEASE, V93, P271, DOI 10.1016/j.jconrel.2003.08.006
   Long TC, 2006, ENVIRON SCI TECHNOL, V40, P4346, DOI 10.1021/es060589n
   Loscher W, 2005, NAT REV NEUROSCI, V6, P591, DOI 10.1038/nrn1728
   Lu W, 2007, J CONTROL RELEASE, V118, P38, DOI 10.1016/j.jconrel.2006.11.015
   Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008-5472.CAN-06-2354
   Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014
   Mamot C, 2005, CANCER RES, V65, P11631, DOI 10.1158/0008-5472.CAN-05-1093
   Marsh JN, 2007, NANOMEDICINE-UK, V2, P533, DOI 10.2217/17435889.2.4.533
   Marushima A, 2011, NEUROSURGERY, V68, P1418, DOI 10.1227/NEU.0b013e31820c02d9
   McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Mistry A, 2009, INT J PHARMACEUT, V379, P146, DOI 10.1016/j.ijpharm.2009.06.019
   Modi G, 2010, ANN NY ACAD SCI, V1184, P154, DOI 10.1111/j.1749-6632.2009.05108.x
   Mora M, 2002, PHARMACEUT RES, V19, P1430, DOI 10.1023/A:1020440229102
   Mori N, 1995, BRAIN RES, V703, P184, DOI 10.1016/0006-8993(95)01095-5
   Muller RH, 1997, PHARMACEUT RES, V14, P458, DOI 10.1023/A:1012043315093
   NEUWELT EA, 1984, NEUROSURGERY, V15, P362, DOI 10.1227/00006123-198409000-00011                                                
   Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995
   Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597
   Ohtsuki S, 2007, PHARM RES, V24, P1745, DOI 10.1007/s11095-007-9374-5
   Pandita D, 2011, AAPS PHARMSCITECH, V12, P712, DOI 10.1208/s12249-011-9636-8
   Pang ZQ, 2008, J CONTROL RELEASE, V128, P120, DOI 10.1016/j.jconrel.2008.03.007
   Pardridge William M, 2005, NeuroRx, V2, P3
   Pardridge WM, 2010, J DRUG TARGET, V18, P157, DOI 10.3109/10611860903548354
   Pisanic TR, 2007, BIOMATERIALS, V28, P2572, DOI 10.1016/j.biomaterials.2007.01.043
   Priano L, 2004, MOVEMENT DISORD, V19, P937, DOI 10.1002/mds.20054
   Priano L, 2007, J NANOSCI NANOTECHNO, V7, P3596, DOI 10.1166/jnn.2007.809
   Priano L, 2011, EUR J PHARM BIOPHARM, V79, P135, DOI 10.1016/j.ejpb.2011.02.009
   Prieto P, 2004, ATLA-ALTERN LAB ANIM, V32, P37
   Raymond SB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002175
   Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947
   Rempe R, 2011, BIOCHEM BIOPH RES CO, V406, P64, DOI 10.1016/j.bbrc.2011.01.110
   Ribeiro MMB, 2010, MINI-REV MED CHEM, V10, P263, DOI 10.2174/138955710791185082                                                      
   Ronaldson PT, 2008, GLIA, V56, P1711, DOI 10.1002/glia.20725
   Ronaldson PT, 2008, J NEUROCHEM, V106, P1298, DOI 10.1111/j.1471-4159.2008.05479.x
   Ronaldson PT, 2006, MOL PHARMACOL, V70, P1087, DOI 10.1124/mol.106.025973
   Ronaldson PT, 2010, MOL PHARMACOL, V77, P644, DOI 10.1124/mol.109.059410
   The Royal Society & The Royal Academy of Engineering, 2004, NAN NAN OPP UNC, P25
   SABATIER JM, 1991, J VIROL, V65, P961
   SALAHUDDIN TS, 1988, NEUROPATH APPL NEURO, V14, P467, DOI 10.1111/j.1365-2990.1988.tb01338.x                                              
   Salama NN, 2005, J PHARM SCI-US, V94, P1216, DOI 10.1002/jps.20344
   Saul JM, 2003, J CONTROL RELEASE, V92, P49, DOI 10.1016/S0168-3659(03)00295-5
   Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P11, DOI 10.1046/j.1440-1681.1999.02986.x
   Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Segal MB, 2000, CELL MOL NEUROBIOL, V20, P183, DOI 10.1023/A:1007045605751                                                         
   Shi NY, 2001, P NATL ACAD SCI USA, V98, P12754, DOI 10.1073/pnas.221450098
   Shubar HM, 2009, J DRUG TARGET, V17, P257, DOI 10.1080/10611860902718680
   Shuhendler AJ, 2011, ACS NANO, V5, P1958, DOI 10.1021/nn103024b
   Shuhendler AJ, 2010, BREAST CANCER RES TR, V119, P255, DOI 10.1007/s10549-008-0271-3
   Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086
   Soni S, 2006, J DRUG TARGET, V14, P87, DOI 10.1080/10611860600635608
   Soni V., 2005, AM J DRUG DELIV, V3, P155
   Sood RR, 2008, J CEREBR BLOOD F MET, V28, P431, DOI 10.1038/sj.jcbfm.9600534
   SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68                                               
   Strome EM, 2007, MOL IMAGING BIOL, V9, P186, DOI 10.1007/s11307-007-0093-4
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   Takamiya M, 2011, J NEUROSCI RES, V89, P1125, DOI 10.1002/jnr.22622
   Tian XH, 2011, INT J NANOMED, V6, P445, DOI 10.2147/IJN.S16570
   Tin-Tin-Win-Shwe, 2006, Toxicology Letters (Shannon), V163, P153, DOI 10.1016/j.toxlet.2005.10.006
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022
   UMEZAWA F, 1988, BIOCHEM BIOPH RES CO, V153, P1038, DOI 10.1016/S0006-291X(88)81333-0                                                   
   van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889                                                       
   van der Sandt ICJ, 2001, PHARMACEUT RES, V18, P587, DOI 10.1023/A:1011016923346
   Veiseh O, 2009, CANCER RES, V69, P6200, DOI 10.1158/0008-5472.CAN-09-1157
   Vergoni AV, 2009, NANOMED-NANOTECHNOL, V5, P369, DOI 10.1016/j.nano.2009.02.005
   Vinogradov S, 1999, COLLOID SURFACE B, V16, P291, DOI 10.1016/S0927-7765(99)00080-6                                                   
   Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r
   Visser CC, 2004, J DRUG TARGET, V12, P145, DOI 10.1080/10611860410001701706
   Voinea M, 2002, VASC PHARMACOL, V39, P13, DOI 10.1016/S1537-1891(02)00165-9
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004
   Wang JY, 2009, NEUROTOXICOLOGY, V30, P926, DOI 10.1016/j.neuro.2009.09.005
   Webb Murray S, 2007, Recent Pat Drug Deliv Formul, V1, P185, DOI 10.2174/187221107782331593
   Weksler BB, 2005, FASEB J, V19, P1872
   Wilhelm I, 2011, ACTA NEUROBIOL EXP, V71, P113
   Wong HL, 2004, J PHARM SCI-US, V93, P1993, DOI 10.1002/jps.20100
   Wong HL, 2006, NANOTECHNOLOGY CANC, P714
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Wong HL, 2006, J CONTROL RELEASE, V116, P275, DOI 10.1016/j.jconrel.2006.09.007
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wu DF, 1997, J CLIN INVEST, V100, P1804, DOI 10.1172/JCI119708                                                               
   Xiang JJ, 2003, J GENE MED, V5, P803, DOI 10.1002/jgm.419
   Xue HY, 2011, BIOMATERIALS, V32, P2662, DOI 10.1016/j.biomaterials.2010.12.029
   Xue HY, 2011, ACS NANO, V5, P7034, DOI 10.1021/nn201659z
   Yang H, 2010, PHARM RES-DORDR, V27, P1759, DOI 10.1007/s11095-010-0141-7
   Yang SC, 1999, PHARMACEUT RES, V16, P751, DOI 10.1023/A:1018888927852
   Yurek D., NANOPARTICLE GENE TH
   Zara GP, 2002, J DRUG TARGET, V10, P327, DOI 10.1080/10611860290031868
   Zara GP, 1999, PHARMACOL RES, V40, P281, DOI 10.1006/phrs.1999.0509
   Zastre JA, 2009, J NEUROSCI RES, V87, P1023, DOI 10.1002/jnr.21898
   Zhang QZ, 2006, J DRUG TARGET, V14, P281, DOI 10.1080/10611860600721051
   Zhang QZ, 2004, INT J PHARM, V275, P85, DOI 10.1016/j.ijpharm.2004.01.039
   Zhang XB, 2003, J DRUG TARGET, V11, P117, DOI 10.1080/1061186031000115150
   Zhang XB, 2009, J NEUROIMMUNE PHARM, V4, P35, DOI 10.1007/s11481-008-9119-1
   Zhang Y, 2002, J GENE MED, V4, P183, DOI 10.1002/jgm.255
   Zhang Y, 2003, HUM GENE THER, V14, P1, DOI 10.1089/10430340360464660
   Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003
NR 208
TC 150
Z9 155
U1 9
U2 150
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAY 15
PY 2012
VL 64
IS 7
BP 686
EP 700
DI 10.1016/j.addr.2011.10.007
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 943OA
UT WOS:000304132500009
PM 22100125
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Vandermeulen, G
   Athanasopoulos, T
   Trundley, A
   Foster, K
   Preat, V
   Yanez-Munoz, RJ
   Dickson, G
AF Vandermeulen, Gaelle
   Athanasopoulos, Takis
   Trundley, Anita
   Foster, Keith
   Preat, Veronique
   Yanez-Munoz, Rafael J.
   Dickson, George
TI Highly potent delivery method of gp160 envelope vaccine combining
   lentivirus-like particles and DNA electrotransfer
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE VLP; Electroporation; Electrotransfer; HIV vaccine; DNA vaccine
ID VIRUS-LIKE PARTICLES; INFLAMMATORY DENDRITIC CELLS; VESICULAR
   STOMATITIS-VIRUS; SKELETAL-MUSCLE; NALP3 INFLAMMASOME; HIV VACCINES;
   T-CELL; IMMUNIZATION; TYPE-1; IMMUNOGENICITY
AB Particulate antigen assemblies in the nanometer range and DNA plasmids are particularly interesting for designing vaccines. We hypothesised that a combination of these approaches could result in a new delivery method of gp160 envelope HIV-1 vaccine which could combine the potency of virus-like particles (VLPs) and the simplicity of use of DNA vaccines. Characterisation of lentivirus-like particles (lentiVLPs) by western blot, dynamic light scattering and electron microscopy revealed that their protein pattern, size and structure make them promising candidates for HIV-1 vaccines. Although all particles were similar with regard to size and distribution, they clearly differed in p24 capsid protein content suggesting that Rev may be required for particle maturation and Gag processing. In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combination of gp160 and VSV-G envelopes did not influence the magnitude of the immune response but the combination of lentiVLPs with Alum adjuvant resulted in a more potent response. Interestingly, the strongest immune response was obtained when plasmids encoding lentiVLPs were co-delivered to mice muscles by electrotransfer, suggesting that lentiVLPs were efficiently produced in vivo or the packaging genes mediate an adjuvant effect. DNA electrotransfer of plasmids encoding lentivirus-like particles offers many advantages and appears therefore as a promising delivery method of HIV-1 vaccines. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Vandermeulen, Gaelle; Athanasopoulos, Takis; Trundley, Anita; Foster, Keith; Yanez-Munoz, Rafael J.; Dickson, George] Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.
   [Vandermeulen, Gaelle; Preat, Veronique] Catholic Univ Louvain, Louvain Drug Res Inst, B-1200 Brussels, Belgium.
RP Dickson, G (reprint author), Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.
EM g.dickson@rhul.ac.uk
RI Vandermeulen, Gaelle/A-4074-2011
OI Vandermeulen, Gaelle/0000-0002-8696-9642
FU Grand Challenges Explorations programs; EU [222878]; EU (PERSIST)
   [222878]; EU (EVA Centre); NIBSC, UK (AVIP) [LSHP-CT-2004-503487]
FX G. Vandermeulen and A. Trundley were supported by Grand Challenges
   Explorations programs and T. Athanasopoulos by the Collaboration for
   AIDS Vaccine Discovery. The authors thank Michael Hollinshead for his
   help with electron microscopy image acquisition. Work in R.J.
   Yanez-Munoz's laboratory was supported by the 7th EU Framework Programme
   (PERSIST project, grant agreement no. 222878). The monoclonal antibody
   to HIV-1 gp160/gp120 (ARP301) from R. Daniels and M. Aymard, the 4E10
   monoclonal antibody (ARP3239) from Polymun Scientific GmbH and the
   monoclonal antibody to HIV-1 p24 (ARP3243.3) from Quattromed LtD were
   provided by the EU Programme EVA Centre for AIDS Reagents, NIBSC, UK
   (AVIP Contract Number LSHP-CT-2004-503487).
CR Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Blair DA, 2011, J IMMUNOL, V187, P2310, DOI 10.4049/jimmunol.1100363
   Blissenbach M, 2010, J VIROL, V84, P6598, DOI 10.1128/JVI.02264-09
   Bloquel C, 2004, J GENE MED, V6, pS11, DOI 10.1002/jgm.508
   Brandt S, 2007, PLOS PATHOG, V3, P518, DOI 10.1371/journal.ppat.0030054
   Brave A, 2007, MOL THER, V15, P1724, DOI 10.1038/sj.mt.6300235
   Buonaguro L, 2007, VACCINE, V25, P5968, DOI 10.1016/j.vaccine.2007.05.052
   Chiarella P, 2008, EXPERT OPIN BIOL TH, V8, P1645, DOI [10.1517/14712590802472606, 10.1517/14712598.8.11.1645 ]
   CHRYSTIE IL, 1988, J MED VIROL, V25, P281, DOI 10.1002/jmv.1890250305
   Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4
   Doan LX, 2005, REV MED VIROL, V15, P75, DOI 10.1002/rmv.449
   Duerr A, 2006, CLIN INFECT DIS, V43, P500, DOI 10.1086/505979
   Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306
   GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329
   Goto N, 1997, VACCINE, V15, P1364, DOI 10.1016/S0264-410X(97)00054-6
   Harris K, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-251
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755                                                     
   Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Kuate S, 2006, VIROLOGY, V351, P133, DOI 10.1016/j.virol.2006.03.009
   Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019
   LeBlanc JJ, 2008, J VIROL, V82, P2570, DOI 10.1128/JVI.01717-07
   Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x
   Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Marsac D, 2002, J VIROL, V76, P7544, DOI 10.1128/JVI.76.15.7544-7553.2002
   Mascola JR, 2010, ANNU REV IMMUNOL, V28, P413, DOI 10.1146/annurev-immunol-030409-101256
   McBurney SP, 2009, VACCINE, V27, P4337, DOI 10.1016/j.vaccine.2009.04.032
   McMahon JM, 2001, GENE THER, V8, P1264, DOI 10.1038/sj.gt.3301522
   Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262                                                          
   Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004
   Muratori C, 2010, METHODS MOL BIOL, V614, P111, DOI 10.1007/978-1-60761-533-0_7
   Peut V, 2007, J VIROL, V81, P13125, DOI 10.1128/JVI.01408-07
   Quan FS, 2007, VACCINE, V25, P3841, DOI 10.1016/j.vaccine.2007.01.107
   Rasmussen RA, 2006, VACCINE, V24, P2324, DOI 10.1016/j.vaccine.2005.11.063
   Sailaja G, 2007, VIROLOGY, V362, P331, DOI 10.1016/j.virol.2006.12.014
   Sanders RW, 2011, EXPERT REV VACCINES, V10, P1117, DOI [10.1586/ERV.11.97, 10.1586/erv.11.97]
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Scheerlinck JPY, 2008, DRUG DISCOV TODAY, V13, P882, DOI 10.1016/j.drudis.2008.06.016
   Swartz MA, 2001, ADV DRUG DELIVER REV, V50, P3, DOI 10.1016/S0169-409X(01)00150-8
   Tagliamonte M, 2011, VACCINE, V29, P4913, DOI 10.1016/j.vaccine.2011.05.004
   Urcuqui-Inchima S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016686
   Vandermeulen G, 2007, J CONTROL RELEASE, V124, P81, DOI 10.1016/j.jconrel.2007.08.010
   Visciano ML, 2011, VACCINE, V29, P4903, DOI 10.1016/j.vaccine.2011.05.005
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
NR 48
TC 4
Z9 4
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 10
PY 2012
VL 159
IS 3
BP 376
EP 383
DI 10.1016/j.jconrel.2012.01.035
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 955FD
UT WOS:000305001600010
PM 22310089
DA 2018-01-05
ER

PT J
AU Baumgartel, V
   Muller, B
   Lamb, DC
AF Baumgaertel, Viola
   Mueller, Barbara
   Lamb, Don C.
TI Quantitative Live-Cell Imaging of Human Immunodeficiency Virus (HIV-1)
   Assembly
SO VIRUSES-BASEL
LA English
DT Review
DE HIV; assembly; fluorescence; microscopy; ESCRT; live-cell imaging
ID FLUORESCENCE CORRELATION SPECTROSCOPY; SINGLE-PARTICLE TRACKING;
   INTERNAL-REFLECTION FLUORESCENCE; LASER-SCANNING MICROSCOPE; GAG-GAG
   INTERACTIONS; PLASMA-MEMBRANE; ENERGY-TRANSFER; FLUCTUATION
   SPECTROSCOPY; LOCALIZATION MICROSCOPY; NANOSCALE RESOLUTION
AB Advances in fluorescence methodologies make it possible to investigate biological systems in unprecedented detail. Over the last few years, quantitative live-cell imaging has increasingly been used to study the dynamic interactions of viruses with cells and is expected to become even more indispensable in the future. Here, we describe different fluorescence labeling strategies that have been used to label HIV-1 for live cell imaging and the fluorescence based methods used to visualize individual aspects of virus-cell interactions. This review presents an overview of experimental methods and recent experiments that have employed quantitative microscopy in order to elucidate the dynamics of late stages in the HIV-1 replication cycle. This includes cytosolic interactions of the main structural protein, Gag, with itself and the viral RNA genome, the recruitment of Gag and RNA to the plasma membrane, virion assembly at the membrane and the recruitment of cellular proteins involved in HIV-1 release to the nascent budding site.
C1 [Mueller, Barbara] Univ Heidelberg Hosp, Dept Infect Dis, D-69120 Heidelberg, Germany.
   [Baumgaertel, Viola; Lamb, Don C.] Univ Munich, Ctr NanoSci CeNS, Dept Chem, D-81377 Munich, Germany.
   [Baumgaertel, Viola; Lamb, Don C.] Univ Munich, Ctr Integrated Prot Sci, Munich CIPSM, D-81377 Munich, Germany.
   [Lamb, Don C.] Univ Illinois, Dept Phys, Urbana, IL 61820 USA.
RP Muller, B (reprint author), Univ Heidelberg Hosp, Dept Infect Dis, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.
EM viola.baumgaertel@cup.uni-muenchen.de;
   barbara.mueller@med.uni-heidelberg.de; d.lamb@lmu.de
RI Lamb, Don/G-9501-2014
OI Lamb, Don/0000-0002-0232-1903
FU Deutsche Forschungsgemeinschaft [MU885/4-2, SPP1175, LA1971/1-2]; EU;
   Ludwig-Maximilians-University Munich (LMUinnovativ BioImaging Network)
FX We gratefully acknowledge the financial support of the Deutsche
   Forschungsgemeinschaft (grant MU885/4-2 and Schwerpunktprogramm SPP1175,
   LA1971/1-2), the EU (7th framework, grant HIV-ACE) the Excellence
   Cluster Nanosystems Initiative Munich (NIM) and the
   Ludwig-Maximilians-University Munich (LMUinnovativ BioImaging Network).
CR Andresen M, 2008, NAT BIOTECHNOL, V26, P1035, DOI 10.1038/nbt.1493
   Arhel N, 2006, NAT METHODS, V3, P817, DOI 10.1038/nmeth931
   Axelrod D, 2003, METHOD ENZYMOL, V361, P1
   AXELROD D, 1984, ANNU REV BIOPHYS BIO, V13, P247, DOI 10.1146/annurev.bb.13.060184.001335
   Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982
   Baumgartel V., 2011, NAT CELL BIOL, P469
   Baumgartel V., 2012, FLUORESCENT PROTEINS, P280
   Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Blanchet F, 2011, CURR OPIN HIV AIDS, V6, P391, DOI 10.1097/COH.0b013e328349b0a0
   Briggs JAG, 2011, J MOL BIOL, V410, P491, DOI 10.1016/j.jmb.2011.04.021
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067
   Dale BM, 2011, CELL HOST MICROBE, V10, P551, DOI 10.1016/j.chom.2011.10.015
   Datta SAK, 2011, J MOL BIOL, V406, P205, DOI 10.1016/j.jmb.2010.11.051
   Davies BA, 2010, MOL BIOL CELL, V21, P3396, DOI 10.1091/mbc.E10-06-0512
   Derdowski A, 2004, J VIROL, V78, P1230, DOI 10.1128/JVI.78.3.1230-1242.2004
   Digman MA, 2005, BIOPHYS J, V89, P1317, DOI 10.1529/biophysj.105.062836
   Digman MA, 2008, BIOPHYS J, V94, P2320, DOI 10.1529/biophysj.107.114645
   Digman MA, 2011, ANNU REV PHYS CHEM, V62, P645, DOI 10.1146/annurev-physchem-032210-103424
   Digman MA, 2009, MICROSC RES TECHNIQ, V72, P323, DOI 10.1002/jemt.20655
   Digman MA, 2009, BIOPHYS J, V96, P707, DOI 10.1016/j.bpj.2008.09.051
   Dupont A, 2011, NANOSCALE, V3, P4532, DOI 10.1039/c1nr10989h
   Eckhardt M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022007
   ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102                                                      
   Endress T, 2008, EUR BIOPHYS J BIOPHY, V37, P1291, DOI 10.1007/s00249-008-0322-z
   Fabrikant G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000575
   Fogarty KH, 2011, BIOPHYS J, V100, P1587, DOI 10.1016/j.bpj.2011.02.008
   FORSTER T, 1946, NATURWISSENSCHAFTEN, V33, P166, DOI 10.1007/BF00585226                                                              
   FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55
   Godinez WJ, 2009, MED IMAGE ANAL, V13, P325, DOI 10.1016/j.media.2008.12.004
   Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269                                                    
   Grotjohann T, 2011, NATURE, V478, P204, DOI 10.1038/nature10497
   Haller C, 2008, BIOL CHEM, V389, P1253, DOI 10.1515/BC.2008.143
   Hell SW, 2004, CURR OPIN NEUROBIOL, V14, P599, DOI 10.1016/j.conb.2004.08.015
   HELL SW, 1994, OPT LETT, V19, P780, DOI 10.1364/OL.19.000780                                                            
   Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   Hogue IB, 2011, J VIROL, V85, P9749, DOI 10.1128/JVI.00743-11
   Hogue IB, 2009, J VIROL, V83, P7322, DOI 10.1128/JVI.02545-08
   Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Hurley JH, 2010, CRIT REV BIOCHEM MOL, V45, P463, DOI 10.3109/10409238.2010.502516
   Ivanchenko S., 2011, SUPRAMOLECULAR STRUC, V10, P1
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896
   Jin J, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000163
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2011, NAT CELL BIOL, V13, P394, DOI 10.1038/ncb2207
   Jouvenet N, 2009, P NATL ACAD SCI USA, V106, P19114, DOI 10.1073/pnas.0907364106
   Jun SM, 2011, STRUCTURE, V19, P1573, DOI 10.1016/j.str.2011.09.006
   Keller PJ, 2008, SCIENCE, V322, P1065, DOI 10.1126/science.1162493
   Keppler A, 2004, P NATL ACAD SCI USA, V101, P9955, DOI 10.1073/pnas.0401923101
   Kolin DL, 2007, CELL BIOCHEM BIOPHYS, V49, P141, DOI 10.1007/s12013-007-9000-5
   Kukulski W, 2011, J CELL BIOL, V192, P111, DOI 10.1083/jcb.201009037
   Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100
   Langelier C, 2006, J VIROL, V80, P9465, DOI 10.1128/JVI.01049-06
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   Larson DR, 2003, J CELL BIOL, V162, P1233, DOI 10.1083/jcb.200303200
   Lehmann M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002456
   Lu K, 2011, J MOL BIOL, V410, P609, DOI 10.1016/j.jmb.2011.04.029
   MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103
   MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705
   Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176
   Martin-Serrano J, 2011, NAT REV MICROBIOL, V9, P519, DOI 10.1038/nrmicro2596
   Meijering E, 2009, SEMIN CELL DEV BIOL, V20, P894, DOI 10.1016/j.semcdb.2009.07.004
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Morita E, 2011, CELL HOST MICROBE, V9, P235, DOI 10.1016/j.chom.2011.02.004
   Mothes W, 2010, J VIROL, V84, P8360, DOI 10.1128/JVI.00443-10
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Muriaux D, 2010, RNA BIOL, V7, P744, DOI 10.4161/rna.7.6.14065
   Ono A, 2010, BIOL CELL, V102, P335, DOI 10.1042/BC20090165
   PETERSEN NO, 1993, BIOPHYS J, V65, P1135, DOI 10.1016/S0006-3495(93)81173-1                                                   
   Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812
   Querido E, 2008, METHOD CELL BIOL, V85, P273
   Rein A, 2011, TRENDS BIOCHEM SCI, V36, P373, DOI 10.1016/j.tibs.2011.04.001
   Rossow MJ, 2010, NAT PROTOC, V5, P1761, DOI 10.1038/nprot.2010.122
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Ruthardt N, 2011, MOL THER, V19, P1199, DOI 10.1038/mt.2011.102
   Saffarian S, 2008, BIOPHYS J, V94, P2333, DOI 10.1529/biophysj.107.117234
   Saksena S, 2009, CELL, V136, P97, DOI 10.1016/j.cell.2008.11.013
   Santi PA, 2011, J HISTOCHEM CYTOCHEM, V59, P129, DOI 10.1369/0022155410394857
   SAXTON MJ, 1994, BIOPHYS J, V67, P2110, DOI 10.1016/S0006-3495(94)80694-0                                                   
   SAXTON MJ, 1995, BIOPHYS J, V69, P389, DOI 10.1016/S0006-3495(95)79911-8                                                   
   SAXTON MJ, 1993, BIOPHYS J, V64, P1766, DOI 10.1016/S0006-3495(93)81548-0                                                   
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Sergeev M, 2006, BIOPHYS J, V91, P3884, DOI 10.1529/biophysj.106.091181
   Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037
   Shi XK, 2010, NANOSCOPY AND MULTIDIMENSIONAL OPTICAL FLUORESCENCE MICROSCOPY
   STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719
   Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509                                                
   Verveer PJ, 2007, NAT METHODS, V4, P311, DOI 10.1038/NMETH1017
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   Weiss ER, 2011, J MOL BIOL, V410, P525, DOI 10.1016/j.jmb.2011.04.055
   Wiedenmann J, 2009, IUBMB LIFE, V61, P1029, DOI 10.1002/iub.256
   Willig KI, 2006, NAT METHODS, V3, P721, DOI 10.1038/NMETH922
   Wiseman PW, 1999, BIOPHYS J, V76, P963, DOI 10.1016/S0006-3495(99)77260-7                                                   
   Wollert T, 2010, NATURE, V464, P864, DOI 10.1038/nature08849
   Wollert T, 2009, NATURE, V458, P172, DOI 10.1038/nature07836
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   Wu PH, 2010, BIOPHYS J, V98, P2822, DOI 10.1016/j.bpj.2010.03.020
   Yoon JW, 2008, BIOPHYS J, V94, P4932, DOI 10.1529/biophysj.107.116285
NR 103
TC 13
Z9 13
U1 0
U2 28
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAY
PY 2012
VL 4
IS 5
BP 777
EP 799
DI 10.3390/v4050777
PG 23
WC Virology
SC Virology
GA 965XT
UT WOS:000305801700008
PM 22754649
OA gold
DA 2018-01-05
ER

PT J
AU Nicol, MQ
   Ligertwood, Y
   Bacon, MN
   Dutia, BM
   Nash, AA
AF Nicol, Marlynne Q.
   Ligertwood, Yvonne
   Bacon, Matthew N.
   Dutia, Bernadette M.
   Nash, Anthony A.
TI A novel family of peptides with potent activity against influenza A
   viruses
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article
ID ANTIVIRAL PEPTIDE; INHIBITION; INFECTION; ENFUVIRTIDE; PROTEIN; FUSION;
   SYSTEM; ENTRY; MICE
AB The emergence of drug-resistant strains of influenza virus has catalysed a search for new antiviral agents to supplement or replace existing drugs. Following the success of the human immunodeficiency virus entry blocker Enfuvirtide, there has been a resurgence of interest in peptide-based antivirals. In this paper, we report on the discovery of a novel family of peptides (FluPep, FP) that function as inhibitors of influenza A virus infection. The prototype peptide (FP1, also known as Tkip) interacts with haemagglutinin and inhibits the binding of the virus to cell membranes. Using a plaque-reduction assay, we have demonstrated that a variety of influenza A virus subtypes (including H1N1, H3N2 and H5N1) are inhibited by FluPep and its derivatives at nanomolar concentrations. By truncating FluPep we have identified a minimal sequence of 6 aa that binds to haemagglutinin and inhibits infection. Using a mouse model of intranasal influenza virus infection, we observed potent inhibition of virus infection when peptide is given at the time of virus administration. These data indicate that FluPep is a highly effective anti-influenza agent with the potential to translate to the clinic.
C1 [Nash, Anthony A.] Univ Edinburgh, Roslin Inst, Easter Bush EH25 9RG, Scotland.
   Univ Edinburgh, Royal Dick Sch Vet Studies, Easter Bush EH25 9RG, England.
RP Nash, AA (reprint author), Univ Edinburgh, Roslin Inst, Easter Bush EH25 9RG, Scotland.
EM tony.nash@ed.ac.uk
FU Interdisciplinary Centre for Human and Avian Influenza Research
   (ICHAIR); BBSRC ISPG; BBSRC [BBSRC BB/FOF/324]
FX This work was funded by the Interdisciplinary Centre for Human and Avian
   Influenza Research (ICHAIR) with a grant to Scottish Higher Education
   Funding Council, BBSRC ISPG funding and a BBSRC follow-on-fund (BBSRC
   BB/FOF/324). The authors would like to thank Professor Wendy Barclay,
   Imperial College, London, UK and Dr David Jackson, University of St
   Andrews, St Andrews, UK for providing viruses used in these experiments,
   Dr Gerald Barry for carrying out the SFV assays and Professor Mark
   Bradley, Professor of High-Throughput Chemical Biology, School of
   Chemistry, University of Edinburgh, UK.
CR Ahmed CM, 2009, J VIROL, V83, P1402, DOI 10.1128/JVI.01138-08
   Altmann SE, 2009, VIROLOGY, V388, P248, DOI 10.1016/j.virol.2009.03.023
   Bai FW, 2007, J VIROL, V81, P2047, DOI 10.1128/JVI.01840-06
   Budge PJ, 2004, J ANTIMICROB CHEMOTH, V54, P299, DOI 10.1093/jac/dkh355
   Cheng G, 2008, P NATL ACAD SCI USA, V105, P3088, DOI 10.1073/pnas.0712380105
   Cooper DA, 2004, LANCET INFECT DIS, V4, P426, DOI 10.1016/S1473-3099(04)01058-8                                                   
   Howard W, 2007, AVIAN DIS, V51, P393, DOI 10.1637/7645-050906R1.1
   Jing XH, 2008, P NATL ACAD SCI USA, V105, P10967, DOI 10.1073/pnas.0804958105
   Jones JC, 2006, J VIROL, V80, P11960, DOI [10.1128/JVI.01678-06, 10.1128/JVI.01678.06]
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Mujtaba MG, 2005, J IMMUNOL, V175, P5077, DOI 10.4049/jimmunol.175.8.5077                                                     
   Sleeman K, 2010, ANTIMICROB AGENTS CH, V54, P2517, DOI 10.1128/AAC.01739-09
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Triana-Baltzer GB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007788
NR 14
TC 25
Z9 25
U1 0
U2 21
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-1317
J9 J GEN VIROL
JI J. Gen. Virol.
PD MAY
PY 2012
VL 93
BP 980
EP 986
DI 10.1099/vir.0.038679-0
PN 5
PG 7
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 951QX
UT WOS:000304736200007
PM 22258859
OA gold
DA 2018-01-05
ER

PT J
AU Zheng, L
   Jia, LY
   Li, B
   Situ, B
   Liu, QL
   Wang, Q
   Gan, N
AF Zheng, Lei
   Jia, Liyong
   Li, Bo
   Situ, Bo
   Liu, Qinlan
   Wang, Qian
   Gan, Ning
TI A Sandwich HIV p24 Amperometric Immunosensor Based on a Direct Gold
   Electroplating-Modified Electrode
SO MOLECULES
LA English
DT Article
DE HIV; p24; sandwich amperometric immunosensor; direct electroplating
ID GLASSY-CARBON ELECTRODE; ELECTROCHEMICAL IMMUNOSENSOR; NANOCOMPOSITE
AB Acquired immune deficiency syndrome (AIDS) is a severe communicable immune deficiency disease caused by the human immune deficiency virus (HIV). The analysis laboratory diagnosis of HIV infection is a crucial aspect of controlling AIDS. The p24 antigen, the HIV-1 capsid protein, is of considerable diagnostic interest because it is detectable several days earlier than host-generated HIV antibodies following HIV exposure. We present herein a new sandwich HIV p24 immunosensor based on directly electroplating an electrode surface with gold nanoparticles using chronoamperometry, which greatly increased the conductivity and reversibility of the electrode. Under optimum conditions, the electrochemical signal showed a linear relationship with the concentration of p24, ranging from 0.01 ng/mL to 100 ng/mL (R > 0.99), and the detection limit was 0.008 ng/mL. Compared with ELISA, this method increased the sensitivity by more than two orders of magnitude (the sensitivity of ELISA for p24 is about 1 ng/mL). This immunosensor may be broadly applied to clinical samples, being distinguished by its ease of use, mild reaction conditions, guaranteed reproducibility, and good anti-interference ability.
C1 [Zheng, Lei; Jia, Liyong; Li, Bo; Situ, Bo; Liu, Qinlan; Wang, Qian] So Med Univ, Nanfang Hosp, Clin Lab Ctr, Guangzhou 510515, Guangdong, Peoples R China.
   [Jia, Liyong; Gan, Ning] Ningbo Univ, Fac Mat Sci & Chem Engn, State Key Lab Base Novel Funct Mat & Preparat Sci, Ningbo 315211, Zhejiang, Peoples R China.
RP Wang, Q (reprint author), So Med Univ, Nanfang Hosp, Clin Lab Ctr, Guangzhou 510515, Guangdong, Peoples R China.
EM nfyyzl@163.com; jialiyong@126.com; boli198777@163.com; drstb@126.com;
   liuqinlan1206@163.com; wangqian@fimmu.com; ganning@nbu.edu.cn
FU National Natural Science Foundation of China [20805024]; Science and
   Technology Program of Guangdong Province [2010A030300006,
   2008A050200006]; Science and Technology Project of Ningbo [2009D10010,
   2011A610018]; Wong K.C megna foundation in Ningbo University; Natural
   Science Foundation of Guangdong Province [S2011010003840]
FX We appreciate the support of the National Natural Science Foundation of
   China (20805024), the Science and Technology Program of Guangdong
   Province (2010A030300006, 2008A050200006), Science and Technology
   Project of Ningbo (2009D10010,2011A610018); Wong K.C megna foundation in
   Ningbo University and the Natural Science Foundation of Guangdong
   Province (S2011010003840).
CR Ahirwal GK, 2010, BIOSENS BIOELECTRON, V25, P2016, DOI 10.1016/j.bios.2010.01.029
   Branson BM, 2010, JAIDS-J ACQ IMM DEF, V55, pS102, DOI 10.1097/QAI.0b013e3181fbca44
   Che X, 2010, J COLLOID INTERF SCI, V345, P174, DOI 10.1016/j.jcis.2010.01.033
   Chen HA, 2010, ANAL BIOCHEM, V403, P36, DOI 10.1016/j.ab.2010.04.011
   Chen XJ, 2010, BIOSENS BIOELECTRON, V25, P1130, DOI 10.1016/j.bios.2009.09.038
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Gerasimov JY, 2010, CHEM COMMUN, V46, P395, DOI 10.1039/b919070h
   Huang KJ, 2010, ANAL CHIM ACTA, V659, P102, DOI 10.1016/j.aca.2009.11.023
   Liu GZ, 2011, BIOSENS BIOELECTRON, V26, P3660, DOI 10.1016/j.bios.2011.02.026
   Malhotra R, 2010, ANAL CHEM, V82, P3118, DOI 10.1021/ac902802b
   Ning N., 2010, CHINESE J ANAL CHEM, V38, P1556
   Ran XQ, 2010, COLLOID SURFACE B, V79, P421, DOI 10.1016/j.colsurfb.2010.05.012
   Tang JA, 2010, BIOSENS BIOELECTRON, V25, P2657, DOI 10.1016/j.bios.2010.04.039
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Wei Q., 2010, SENSOR ACTUAT B-CHEM, V153, P256
   Wei Q, 2010, BIOSENS BIOELECTRON, V26, P627, DOI 10.1016/j.bios.2010.07.012
   Wei Q, 2010, BIOSENS BIOELECTRON, V26, P723, DOI 10.1016/j.bios.2010.06.052
   Wei Q, 2010, SENSOR ACTUAT B-CHEM, V149, P314, DOI 10.1016/j.snb.2010.06.008
   Yang GM, 2009, ANAL CHIM ACTA, V644, P72, DOI 10.1016/j.aca.2009.04.021
   Yang MH, 2010, BIOSENS BIOELECTRON, V26, P560, DOI 10.1016/j.bios.2010.07.040
   Zhao GY, 2011, ANAL BIOCHEM, V408, P53, DOI 10.1016/j.ab.2010.08.039
   Zhuo Y, 2011, BIOSENS BIOELECTRON, V26, P2188, DOI 10.1016/j.bios.2010.09.033
NR 22
TC 31
Z9 32
U1 1
U2 39
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD MAY
PY 2012
VL 17
IS 5
BP 5988
EP 6000
DI 10.3390/molecules17055988
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 949PH
UT WOS:000304587600093
PM 22609788
OA gold
DA 2018-01-05
ER

PT J
AU Chen, XW
   Zhan, P
   Pannecouque, C
   Balzarini, J
   De Clercq, E
   Liu, XY
AF Chen, Xuwang
   Zhan, Peng
   Pannecouque, Christophe
   Balzarini, Jan
   De Clercq, Erik
   Liu, Xinyong
TI Synthesis and biological evaluation of piperidine-substituted triazine
   derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1; NNRTIs; Piperidine; Triazine; AIDS; SAR
ID RESISTANT MUTANT VIRUSES; COLORIMETRIC ASSAY; BROAD POTENCY;
   DIARYLTRIAZINES; ETRAVIRINE; DISCOVERY; SERIES; AIDS
AB A novel series of piperidine-substituted triazine derivatives have been synthesized and evaluated for anti-HIV activities in MT-4 cells. Most compounds displayed extremely promising activity against wildtype HIV-1 with EC50 values in low nanomolar concentration, better than that of Nevirapine, Delavirdine, Zidovudine and Dideoxycitidine, and higher potency towards the resistant mutant strain K103N/Y181C than that of Nevirapine and Delavirdine. Selected compounds were also assayed against reverse transcriptase with lower IC50 values than that of Nevirapine. The structure-activity relationship (SAR) of these novel structural congeners was also discussed. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Chen, Xuwang; Zhan, Peng; Liu, Xinyong] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China.
   [Pannecouque, Christophe; Balzarini, Jan; De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC) [81102320, 30873133,
   30772629, 30371686]; NSFC for International Cooperation [30910103908];
   Research Fund for the Doctoral Program of Higher Education of China
   [20110131130005, 20110131120037, 070422083]; Independent Innovation
   Foundation of Shandong University (IIFSDU) [2010GN044]; Shandong
   Postdoctoral Innovation Science Research Special Program [201002023];
   China Postdoctoral Science Foundation [20100481282]
FX The financial support from the National Natural Science Foundation of
   China (NSFC No. 81102320, No. 30873133, No. 30772629 and No. 30371686),
   Key Project of NSFC for International Cooperation (No. 30910103908),
   Research Fund for the Doctoral Program of Higher Education of China (No.
   20110131130005, 20110131120037 and No. 070422083), Independent
   Innovation Foundation of Shandong University (IIFSDU, No. 2010GN044),
   Shandong Postdoctoral Innovation Science Research Special Program (No.
   201002023) and China Postdoctoral Science Foundation funded project (No.
   20100481282) is gratefully acknowledged.
CR Chen XW, 2011, CURR MED CHEM, V18, P359, DOI 10.2174/092986711794839142                                                      
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Kertesz DJ, 2010, BIOORG MED CHEM LETT, V20, P4215, DOI 10.1016/j.bmcl.2010.05.040
   Kumar A, 2009, BIOORG MED CHEM LETT, V19, P6996, DOI 10.1016/j.bmcl.2009.10.010
   Liu B, 2010, BIOORG MED CHEM LETT, V20, P6592, DOI 10.1016/j.bmcl.2010.09.034
   Ma X.-D., 2011, CHEMMEDCHEM, V12, P2225
   Miller CD, 2011, DRUG TODAY, V47, P5, DOI 10.1358/dot.2011.47.1.1583188
   Miyoshi I., 1982, GANN MONOGR, V28, P219
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   Sax Paul E, 2008, AIDS Clin Care, V20, P17
   Scholler-Gyure M, 2008, BRIT J CLIN PHARMACO, V66, P508, DOI 10.1111/j.1365-2125.2008.03214.x
   Seminari E, 2008, EXPERT REV ANTI-INFE, V6, P427, DOI 10.1586/14787210.6.4.427
   SUZUKI K, 1993, J VIROL METHODS, V44, P189, DOI 10.1016/0166-0934(93)90054-U
   Tang GZ, 2010, BIOORG MED CHEM LETT, V20, P6020, DOI 10.1016/j.bmcl.2010.08.068
   UNAIDS, 2010, GLOB AIDS REP 2010
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Wuest JD, 2009, TETRAHEDRON, V65, P7393, DOI 10.1016/j.tet.2009.07.026
   Xiong YZ, 2008, EUR J MED CHEM, V43, P1230, DOI 10.1016/j.ejmech.2007.08.001
   Zacharie B, 2010, J MED CHEM, V53, P1138, DOI 10.1021/jm901403r
   Zhan P, 2011, EUR J MED CHEM, V46, P5039, DOI 10.1016/j.ejmech.2011.08.011
   Zhan P, 2009, EUR J MED CHEM, V44, P4648, DOI 10.1016/j.ejmech.2009.06.037
NR 25
TC 34
Z9 34
U1 0
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAY
PY 2012
VL 51
BP 60
EP 66
DI 10.1016/j.ejmech.2012.02.019
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 945QU
UT WOS:000304291900006
PM 22405288
DA 2018-01-05
ER

PT J
AU Dash, P
   Gorantla, S
   Roy, U
   Balkundi, S
   Knibbe, J
   McMillan, J
   Gelbard, H
   Poluektova, L
   Gendelman, H
AF Dash, Prasanta
   Gorantla, Santhi
   Roy, Upal
   Balkundi, Shantanu
   Knibbe, Jaclyn
   McMillan, JoEllyn
   Gelbard, Harris
   Poluektova, Larisa
   Gendelman, Howard
TI Long-acting nanoformulated anti-retroviral drugs are neuroprotective in
   HIV-1 infected humanized mice brains
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
C1 [Dash, Prasanta; Gorantla, Santhi; Roy, Upal; Balkundi, Shantanu; Knibbe, Jaclyn; McMillan, JoEllyn; Poluektova, Larisa; Gendelman, Howard] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Gelbard, Harris] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.
EM pdash@unmc.edu
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD MAY
PY 2012
VL 18
SU 1
MA P60
BP 29
EP 29
PG 1
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 948FA
UT WOS:000304487800061
DA 2018-01-05
ER

PT J
AU Reynolds, J
   Law, WC
   Mahajan, S
   Nair, B
   Schwartz, S
AF Reynolds, Jessica
   Law, Wing Cheung
   Mahajan, Supriya
   Nair, Bindukumar
   Schwartz, Stanley
TI Development of a biodegradable nanoparticle for co-delivery of mu opioid
   receptor siRNA and Saquinavir: therapeutic potential for HIV-1 positive
   drug users
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Meeting Abstract
C1 [Reynolds, Jessica; Law, Wing Cheung; Mahajan, Supriya; Nair, Bindukumar; Schwartz, Stanley] SUNY Buffalo, Buffalo, NY 14260 USA.
EM jlr8@buffalo.edu
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD MAY
PY 2012
VL 18
SU 1
MA P184
BP 90
EP 91
PG 2
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 948FA
UT WOS:000304487800185
DA 2018-01-05
ER

PT J
AU Niu, YH
   Bai, G
   Wu, HF
   Wang, RSE
   Qiao, Q
   Padhee, S
   Buzzeo, R
   Cao, CH
   Cai, JF
AF Niu, Youhong
   Bai, Ge
   Wu, Haifan
   Wang, Rongsheng E.
   Qiao, Qiao
   Padhee, Shruti
   Buzzeo, Robert
   Cao, Chuanhai
   Cai, Jianfeng
TI Cellular Translocation of a gamma-AApeptide Mimetic of Tat Peptide
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE gamma-AApeptides; cellular uptake; peptidomimetics; Tat; cell
   penetrating peptide (CPP)
ID PENETRATING PEPTIDES; BETA-PEPTIDE; DELIVERY; PROTEIN; CELLS;
   TRANSACTIVATOR; TRANSDUCTION; FOLDAMERS; DESIGN
AB Cell-penetrating peptides including the trans-activating transcriptional activator (Tat) from HIV-1 have been used as carriers for intracellular delivery of a myriad of cargoes including drugs, molecular probes, DNAs and nanoparticles. Utilizing fluorescence flow cytometry and confocal fluorescence microscopy, we demonstrate that a gamma-AApeptide mimetic of Tat (48-57) can cross the cell membranes and enter the cytoplasm and nucleus of cells, with efficiency comparable to or better than that of Tat peptide (48-57). Deletion of the four side chains of the gamma-AApeptide attenuates translocation capability. We also establish that the gamma-AApeptide is even less toxic than the Tat peptide against mammalian cells. In addition to their low toxicity, gamma-AApeptides are resistant to protease degradation, which may prove to be advantageous over alpha-peptides for further development of molecular transporters for intracellular delivery.
C1 [Cao, Chuanhai] USF Coll Pharm, Tampa, FL 33613 USA.
   [Niu, Youhong; Bai, Ge; Wu, Haifan; Wang, Rongsheng E.; Qiao, Qiao; Padhee, Shruti; Cai, Jianfeng] Univ S Florida, Dept Chem, Tampa, FL 33620 USA.
   [Buzzeo, Robert] Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
RP Cao, CH (reprint author), USF Coll Pharm, 4001 E Fletcher Ave, Tampa, FL 33613 USA.
EM ccao@health.usf.edu; jianfengcai@usf.edu
RI Wu, Haifan/O-1935-2013; Wu, Haifan/F-8818-2014
OI Wu, Haifan/0000-0002-2050-9950; Wu, Haifan/0000-0002-2050-9950; Hill,
   Robert/0000-0002-7220-9626
FU USF
FX This work is supported by USF start-up fund.
CR Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Gius DR, 1999, CANCER RES, V59, P2577
   Goodman CM, 2007, NAT CHEM BIOL, V3, P252, DOI 10.1038/nchembio876
   Horne WS, 2008, ACCOUNTS CHEM RES, V41, P1399, DOI 10.1021/ar800009n
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kitchens KM, 2008, MOL PHARM, V5, P364, DOI 10.1021/mp700089s
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Niu YH, 2011, ORG BIOMOL CHEM, V9, P6604, DOI 10.1039/c1ob05738c
   Niu YH, 2011, NEW J CHEM, V35, P542, DOI 10.1039/c0nj00943a
   PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Rueping M, 2002, CHEMBIOCHEM, V3, P257, DOI 10.1002/1439-7633(20020301)3:2/3<257::AID-CBIC257>3.0.CO;2-S                    
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Trehin R, 2004, BIOCHEM J, V382, P945, DOI 10.1042/BJ20040238                                                              
   Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v
   Vezenkov LL, 2010, BIOCONJUGATE CHEM, V21, P1850, DOI 10.1021/bc1002086
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
NR 19
TC 17
Z9 17
U1 2
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2012
VL 9
IS 5
BP 1529
EP 1534
DI 10.1021/mp300070w
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 941KC
UT WOS:000303961100048
PM 22413929
DA 2018-01-05
ER

PT J
AU Federico, M
AF Federico, Maurizio
TI From virus-like particles to engineered exosomes for a new generation of
   vaccines
SO FUTURE VIROLOGY
LA English
DT Review
DE antigen delivery; CTL immunity; exosome; lentivirus; Nef; vaccine;
   virus-like particle
ID CELLULAR IMMUNE-RESPONSES; TUMOR-DERIVED EXOSOMES; INFLUENZA-VIRUS;
   NEUTRALIZING ANTIBODIES; IN-VITRO; RELEASE PATHWAY; DENDRITIC CELLS;
   PROTECT MICE; INDUCTION; HIV
AB Over the last two decades, virus-like particles (VLPs) have been the focus of countless investigations on innovative vaccines. The number of monotypic, multipartite and chimeric VLP-based vaccines proposed have increased even further in the last few years as part of the continuous effort to improve the safety, efficacy and cost-effectiveness of immunogens. As compared with monomer- or subunit-based vaccines, VLPs show several advantages in terms of potency of the elicited immune responses. Chimeric VLPs are quite flexible tools to accommodate foreign peptides, cell proteins and nonself-assembling viral products. However, their use often meets with still unresolved hurdles such as induction of undesired immune responses, neutralization by pre-existing immunity and complex methods of production. Among strategies aimed at developing new nanoparticle-based vaccines, exosomes hold much promise. They are nanovesicles constitutively released by eukaryotic cells that originate from intraluminal vesicles accumulating in multivesicular bodies. Exosomes have immunogenic properties, the strength of which correlates with the amounts of associated antigens. Engineering antigens of interest to target them in exosomes represents the last frontier in terms of nanoparticle-based vaccines.
C1 Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
RP Federico, M (reprint author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.
EM maurizio.federico@iss.it
FU Italian Ministry of Health, Rome, Italy [3H/27, 3H/28, 3H/29]
FX This work was supported by grants (3H/27, 3H/28 and 3H/29) from the
   National AIDS Program from the Italian Ministry of Health, Rome, Italy.
   The author has no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624
   Ashiru O, 2010, CANCER RES, V70, P481, DOI 10.1158/0008-5472.CAN-09-1688
   Bhatnagar S, 2007, J BIOL CHEM, V282, P25779, DOI 10.1074/jbc.M702277200
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014                                                           
   Brown SD, 2009, BIOCHEMISTRY-US, V48, P11155, DOI 10.1021/bi901306p
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Buonaguro L, 2005, J VIROL, V79, P7059, DOI 10.1128/JVI.79.11.7059-7067.2005
   Buseyne F, 2001, NAT MED, V7, P344, DOI 10.1038/85493
   Caldeira JD, 2010, VACCINE, V28, P4384, DOI 10.1016/j.vaccine.2010.04.049
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Chackerian B, 2010, HUM VACCINES, V6, P926, DOI [10.4161/hv.6.11.12655, 10.4161/hv.7.1.12655]
   Chaput N, 2010, SEMIN IMMUNOPATHOL, V33, P419
   Chazal N, 2003, MICROBIOL MOL BIOL R, V67, P226, DOI 10.1128/MMBR.67.2.226-237.2003
   Dai S, 2008, MOL THER, V16, P782, DOI 10.1038/mt.2008.1
   de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871
   Delcayre A, 2005, BLOOD CELL MOL DIS, V35, P158, DOI 10.1016/j.bcmd.2005.07.003
   Deml L, 1997, VIROLOGY, V235, P10, DOI 10.1006/viro.1997.8669
   Di Bonito P, 2009, VIROLOGY, V395, P45, DOI 10.1016/j.virol.2009.09.012
   El-Kamary SS, 2010, J INFECT DIS, V202, P1649, DOI 10.1086/657087
   Escudier B., 2005, J TRANSL MED, DOI [DOI 10.1186/1479-5876-3-10, 10.1186/1479-5876-3-1015740633]
   Fang Y, 2007, PLOS BIOL, V5, pE158
   Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x
   Flanagan J, 2003, J GEN VIROL, V84, P1871, DOI 10.1099/vir.0.18944-0
   Foster JL, 2011, J NEUROIMMUNE PHARM, V6, P230, DOI 10.1007/s11481-011-9262-y
   Garrone P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002330
   Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929
   Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.183143100
   Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   Hartman ZC, 2011, VACCINE, V29, P9361, DOI 10.1016/j.vaccine.2011.09.133
   Herbst-Kralovetz M, 2010, EXPERT REV VACCINES, V9, P299, DOI 10.1586/ERV.09.163
   Kattenbeck B, 1997, J GEN VIROL, V78, P2489, DOI 10.1099/0022-1317-78-10-2489                                                    
   Keryer-Bibens C, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-283
   Khurana S, 2011, J VIROL, V85, P10945, DOI 10.1128/JVI.05406-11
   Kim SH, 2006, MOL THER, V13, P289, DOI 10.1016/j.ymthe.2005.09.015
   Kim SH, 2005, J IMMUNOL, V174, P6440, DOI 10.4049/jimmunol.174.10.6440                                                    
   Klamp T, 2011, CANCER RES, V71, P516, DOI 10.1158/0008-5472.CAN-10-2292
   Krishnamachari Y, 2011, PHARM RES-DORDR, V28, P215, DOI 10.1007/s11095-010-0241-4
   Lamparski HG, 2002, J IMMUNOL METHODS, V270, P211, DOI 10.1016/S0022-1759(02)00330-7
   Lee DH, 2011, VACCINE, V29, P4003, DOI 10.1016/j.vaccine.2011.03.067
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Liu YV, 2011, VACCINE, V29, P6606, DOI 10.1016/j.vaccine.2011.06.111
   Ma YM, 2011, J VIROL, V85, P2942, DOI 10.1128/JVI.02332-10
   Marsac D, 2002, J VIROL, V76, P7544, DOI 10.1128/JVI.76.15.7544-7553.2002
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150
   McGinnes LW, 2011, J VIROL, V85, P366, DOI 10.1128/JVI.01861-10
   McGinnes LW, 2010, J VIROL, V84, P4513, DOI 10.1128/JVI.01931-09
   Segura MM, 2010, METHODS MOL BIOL, V614, P39, DOI 10.1007/978-1-60761-533-0_2
   Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075
   Montefiori DC, 2001, J VIROL, V75, P5879, DOI 10.1128/JVI.75.13.5879-5890.2001                                                
   Mori Y, 2008, TRAFFIC, V9, P1728, DOI 10.1111/j.1600-0854.2008.00796.x
   Morse Michael A, 2005, J Transl Med, V3, P9, DOI 10.1186/1479-5876-3-9
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Ohtaki N, 2010, VACCINE, V28, P6588, DOI 10.1016/j.vaccine.2010.07.055
   Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152
   Peretti S, 2005, MOL THER, V12, P1185, DOI 10.1016/j.ymthe.2005.06.474
   Pushko P, 2011, VACCINE, V29, P5911, DOI 10.1016/j.vaccine.2011.06.068
   Quan FS, 2011, J INFECT DIS, V204, P987, DOI 10.1093/infdis/jir474
   Quan FS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009161
   Rohn TA, 2011, J IMMUNOL, V186, P1769, DOI 10.4049/jimmunol.1000030
   Roy P, 2009, ADV EXP MED BIOL, V655, P145, DOI 10.1007/978-1-4419-1132-2_11
   Ruiss R, 2011, J VIROL, V85, P13105, DOI 10.1128/JVI.05598-11
   Ruiss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025294
   Simons K, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004697
   Sistigu A, 2011, VACCINE, V29, P3465, DOI 10.1016/j.vaccine.2011.02.059
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Spohn G, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-146
   Szajnik M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011469
   Tan A, 2010, INT J NANOMED, V5, DOI 10.2147/IJN.S13402
   Tan Ming, 2010, J VIROL, V85, P753
   Tang XC, 2011, VIRAL IMMUNOL, V24, P311, DOI 10.1089/vim.2011.0016
   Tumban E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023310
   Usami Y, 2001, BIOCH SOC T 1, V37, P181
   Velasquez LS, 2011, VACCINE, V29, P5221, DOI 10.1016/j.vaccine.2011.05.027
   Walpita P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018437
   Warfield KL, 2011, J INFECT DIS, V204, pS1053, DOI 10.1093/infdis/jir346
   Wu CY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009784
   Xie YF, 2010, CANCER BIOTHER RADIO, V25, P21, DOI 10.1089/cbr.2009.0714
   Xiu FM, 2007, J MOL MED, V85, P511, DOI 10.1007/s00109-006-0154-1
   Yang CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022517
   Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988                                                           
   Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3
   Zhang JM, 2010, TUMORI, V96, P452
   Zhang S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-333
   Zhang Y, 2010, INT J ONCOL, V36, P133, DOI 10.3892/ijo_00000484
NR 87
TC 1
Z9 1
U1 2
U2 26
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0794
J9 FUTURE VIROL
JI Future Virol.
PD MAY
PY 2012
VL 7
IS 5
BP 473
EP 482
DI 10.2217/FVL.12.29
PG 10
WC Virology
SC Virology
GA 935WM
UT WOS:000303552900010
DA 2018-01-05
ER

PT J
AU Dong, MX
   Lu, L
   Li, HT
   Wang, XH
   Lu, H
   Jiang, SB
   Dai, QY
AF Dong, Ming-xin
   Lu, Lu
   Li, Haitao
   Wang, Xiaohua
   Lu, Hong
   Jiang, Shibo
   Dai, Qiu-yun
TI Design, synthesis, and biological activity of novel 1,4-disubstituted
   piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry
   inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CCR5 receptor antagonist; Anti-HIV-1; SAR
ID SMALL-MOLECULE CCR5; TAK-220; INFECTION; DISCOVERY; DRUGS
AB A series of novel 1,4-disubstituted piperidine/piperazine derivatives were designed, synthesized and evaluated for their in vitro activities against HIV-1 Bal (R5) infection in CEMX174 5.25M7 cells. A majority of these compounds showed potent anti-HIV-1 activities with IC50 at nanomolar levels. N-(4-Fluoro-benzyl)piperazine analog B07 hydrochloride exhibited potency against HIV-1 activity similar to that of TAK-220 hydrochloride, but it had much better water solubility (25 mg/ml in phosphate sodium buffer at 25 degrees C) and oral bioavailability (56%) than TAK-220 hydrochloride (a solubility of 2 mg/ml and oral bioavailability of 1.4%). These results suggest that B07 hydrochloride may serve as a better lead for the development of new anti-HIV-1 therapies or microbicides for treatment and prevent of HIV-1 infection. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lu, Lu; Lu, Hong; Jiang, Shibo] Fudan Univ, Shanghai Med Coll, Inst Pathogen Microbiol, MOE MOH Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
   [Dong, Ming-xin; Li, Haitao; Wang, Xiaohua; Dai, Qiu-yun] Beijing Inst Biotechnol, Beijing 100071, Peoples R China.
   [Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.
RP Jiang, SB (reprint author), Fudan Univ, Shanghai Med Coll, Inst Pathogen Microbiol, MOE MOH Key Lab Med Mol Virol, Shanghai 200032, Peoples R China.
EM sjiang@nybloodcenter.org; qy_dai@yahoo.com
RI Jiang, Shibo/L-4500-2014; 董, 铭心/H-1760-2015; Lu, Lu/K-7070-2014
OI 董, 铭心/0000-0001-8623-0146; Lu, Lu/0000-0002-2255-0391
FU key National Science and Technology Program-'Major New Drug Development
   During the 11th Five-Year Period of China [2009ZX09103-628]; Natural
   Science Foundation of China [81102373, 81173098]
FX We thank Dr. Xinbo Jiang from GenScript USA Inc. for the tests of
   inhibitory activity of human ERG channels, Prof. Zhengqing Zhang from
   Beijing Institute of Toxicology and Pharmacology for the determination
   of pharmacokinetics. This work was supported by the key National Science
   and Technology Program-'Major New Drug Development During the 11th
   Five-Year Period of China' (2009ZX09103-628) to Q.Y.D. and by Grants
   from the Natural Science Foundation of China #81102373 to D.M.X. and
   #81173098 to S.J.
CR Dong MX, 2010, EUR J MED CHEM, V45, P4096, DOI 10.1016/j.ejmech.2010.05.070
   Imamura S, 2006, J MED CHEM, V49, P2784, DOI 10.1021/jm051034q
   Katchman AN, 2006, J PHARMACOL EXP THER, V316, P1098, DOI 10.1124/jpet.105.093393
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Lederman MM, 2006, JAMA-J AM MED ASSOC, V296, P815, DOI 10.1001/jama.296.7.815
   Liu T, 2010, MINI-REV MED CHEM, V10, P1277, DOI 10.2174/13895575110091277                                                       
   Lu H, 2006, AIDS RES HUM RETROV, V22, P411, DOI 10.1089/aid.2006.22.411
   Nishikawa M, 2005, ANTIMICROB AGENTS CH, V49, P4708, DOI 10.1128/AAC.49.11.4708-4715.2005
   Pearlstein R, 2003, J MED CHEM, V46, P2017, DOI 10.1021/jm0205651
   Price DA, 2006, BIOORG MED CHEM LETT, V16, P4633, DOI 10.1016/j.bmcl.2006.06.012
   Takashima K, 2005, ANTIMICROB AGENTS CH, V49, P3474, DOI 10.1128/AAC.49.8.3474-3482.2005
   Yap YG, 2000, BRIT MED J, V320, P1158, DOI 10.1136/bmj.320.7243.1158                                                       
   Long Y.Q., [No title captured], Patent No. [WO09052708, 09052708]
   Roche, PCT Int. Appl., Patent No. [WO2005121145, 2005121145]
NR 14
TC 14
Z9 17
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 1
PY 2012
VL 22
IS 9
BP 3284
EP 3286
DI 10.1016/j.bmcl.2012.03.019
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 928EN
UT WOS:000302964300049
PM 22464131
DA 2018-01-05
ER

PT J
AU Radi, M
   Pagano, M
   Franchi, L
   Castagnolo, D
   Schenone, S
   Casaluce, G
   Zamperini, C
   Dreassi, E
   Maga, G
   Samuele, A
   Gonzalo, E
   Clotet, B
   Este, JA
   Botta, M
AF Radi, Marco
   Pagano, Mafalda
   Franchi, Luigi
   Castagnolo, Daniele
   Schenone, Silvia
   Casaluce, Gianni
   Zamperini, Claudio
   Dreassi, Elena
   Maga, Giovanni
   Samuele, Alberta
   Gonzalo, Encarna
   Clotet, Bonaventura
   Este, Jose A.
   Botta, Maurizio
TI Synthesis, Biological Activity, and ADME Properties of Novel
   S-DABOs/N-DABOs as HIV Reverse Transcriptase Inhibitors
SO CHEMMEDCHEM
LA English
DT Article
DE ADME; antiviral agents; lead optimization; NNRTIs; reverse transcriptase
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MEMBRANE PERMEATION ASSAY; NONNUCLEOSIDE
   INHIBITORS; MICROBICIDE; INFECTION; FAMILY; TRANSMISSION; OPTIMIZATION;
   ABSORPTION; PREVENTION
AB Previous studies aimed at exploring the SAR of C2-functionalized S-DABOs demonstrated that the substituent at this position plays a key role in the inhibition of both wild-type RT and drug-resistant enzymes, particularly the K103N mutant form. The introduction of a cyclopropyl group led us to the discovery of a potent inhibitor with picomolar activity against wild-type RT and nanomolar activity against many key mutant forms such as K103N. Despite its excellent antiviral profile, this compound suffers from a suboptimal ADME profile typical of many S-DABO analogues, but it could, however, represent a promising candidate as an anti-HIV microbicide. In the present work, a new series of S-DABO/N-DABO derivatives were synthesized to obtain additional SAR information on the C2-position and in particular to improve ADME properties while maintaining a good activity profile against HIV-1 RT. In vitro ADME properties (PAMPA permeation, water solubility, and metabolic stability) were also experimentally evaluated for the most interesting compounds to obtain a reliable indication of their plasma levels after oral administration.
C1 [Radi, Marco; Pagano, Mafalda; Franchi, Luigi; Castagnolo, Daniele; Casaluce, Gianni; Zamperini, Claudio; Dreassi, Elena; Botta, Maurizio] Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   [Schenone, Silvia] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   [Maga, Giovanni; Samuele, Alberta] IGM CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Gonzalo, Encarna; Clotet, Bonaventura; Este, Jose A.] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab IrsiCaixa, Badalona 08916, Spain.
   [Botta, Maurizio] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.
RP Botta, M (reprint author), Univ Siena, Dipartimento Farmaco Chim Tecnol, Via Alcide de Gasperi 2, I-53100 Siena, Italy.
EM botta.maurizio@gmail.com
RI Dreassi, Elena/B-5728-2012; Castagnolo, Daniele /C-2796-2014; Este,
   Jose/B-5509-2008
OI Dreassi, Elena/0000-0001-8987-940X; Castagnolo, Daniele
   /0000-0002-7517-5732; Este, Jose/0000-0002-1436-5823; Radi,
   Marco/0000-0002-0874-6697
FU European Union ("CHAARM") [HEALTHF3-2009-242135]; European Union
   ("THINC") [HEALTH-2007-2.3.2-1]; National AIDS Program [40H26]; MICINN
   [SAF2010-216117-C02]
FX This work was supported by the European Union ("CHAARM" Collaborative
   Project, grant number HEALTHF3-2009-242135 and "THINC" Collaborative
   Project, grant number HEALTH-2007-2.3.2-1) to M.B., the National AIDS
   Program Grant 40H26 to G.M., and MICINN project SAF2010-216117-C02 to
   B.C.
CR Adams J, 2010, ANN PHARMACOTHER, V44, P157, DOI 10.1345/aph.1M359
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   Avdeef A., 2000, LOGP2000 2 LIP S LAU, P305
   Buckheit RW, 2010, ANTIVIR RES, V85, P142, DOI 10.1016/j.antiviral.2009.10.013
   Castagnolo D, 2009, SYNLETT, P2093, DOI 10.1055/s-0029-1217700
   D'Cruz OJ, 2006, J ANTIMICROB CHEMOTH, V57, P411, DOI 10.1093/jac/dki464
   D'Cruz OJ, 2006, J ENZYM INHIB MED CH, V21, P329, DOI 10.1080/14756360600774413
   D'Cruz OJ, 2006, CURR HIV RES, V4, P329, DOI 10.2174/157016206777709519
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Di L, 2005, CURR OPIN DRUG DISC, V8, P495
   Fernandez-Romero JA, 2007, SEX TRANSM DIS, V34, P9, DOI 10.1097/01.olq.0000223287.46097.4b
   Fletcher P, 2009, ANTIMICROB AGENTS CH, V53, P487, DOI 10.1128/AAC.01156-08
   Gonzalez-Ortega E, 2011, ANTIVIR RES, V92, P479, DOI 10.1016/j.antiviral.2011.10.010
   Hossain MM, 2006, J VIROL, V80, P4440, DOI 10.1128/JVI.80.9.4440-4446.2006
   Kansy M, 1998, J MED CHEM, V41, P1007, DOI 10.1021/jm970530e                                                               
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   Mertenskoetter T, 2011, EUR J MED RES, V16, P1
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Muller S, 1996, SYNLETT, P521
   Nawrozkij MB, 2008, J MED CHEM, V51, P4641, DOI 10.1021/jm800340w
   Olsen JS, 2011, FUTURE MED CHEM, V3, P2101, DOI [10.4155/FMC.11.153, 10.4155/fmc.11.153]
   Petricci E, 2006, ARKIVOC, P452
   Radi M, 2008, CHEMMEDCHEM, V3, P573, DOI 10.1002/cmdc.200700198
   Radi M, 2011, SYNLETT, P1997, DOI 10.1055/s-0030-1261174
   Radi M, 2011, J MED CHEM, V54, P2610, DOI 10.1021/jm1012819
   Radi M, 2009, ORG BIOMOL CHEM, V7, P2841, DOI 10.1039/b906445a
   Radi M, 2009, J MED CHEM, V52, P840, DOI 10.1021/jm801330n
   Samuele A, 2010, ANTIVIR RES, V86, P268, DOI 10.1016/j.antiviral.2010.03.008
   Samuele A, 2009, ANTIVIR RES, V81, P47, DOI 10.1016/j.antiviral.2008.09.008
   Sugano K, 2001, J BIOMOL SCREEN, V6, P189, DOI 10.1177/108705710100600309                                                      
   Sweeney ZK, 2008, CURR OPIN DRUG DISC, V11, P458
   Wabnitz TC, 2003, ORG LETT, V5, P2141, DOI 10.1021/ol034596h
   Wohnsland F, 2001, J MED CHEM, V44, P923, DOI 10.1021/jm001020e
   Yu M, 2011, CURR MED CHEM, V18, P2376, DOI 10.2174/092986711795843209                                                      
   Zhan P., 2011, MED RES REV, DOI [10.1002/med.20241, DOI 10.1002/MED.20241]
   Botta M., 2007, [No title captured], Patent No. [WO/2007/043094, 2007043094]
NR 37
TC 11
Z9 11
U1 1
U2 10
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1860-7179
J9 CHEMMEDCHEM
JI ChemMedChem
PD MAY
PY 2012
VL 7
IS 5
BP 883
EP 896
DI 10.1002/cmdc.201200056
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 931CP
UT WOS:000303192300014
PM 22419605
DA 2018-01-05
ER

PT J
AU Lorincz, O
   Toke, ER
   Somogyi, E
   Horkay, F
   Chandran, PL
   Douglas, JF
   Szebeni, J
   Lisziewicz, J
AF Lorincz, Orsolya
   Toke, Eniko R.
   Somogyi, Eszter
   Horkay, Ferenc
   Chandran, Preethi L.
   Douglas, Jack F.
   Szebeni, Janos
   Lisziewicz, Julianna
TI Structure and biological activity of pathogen-like synthetic
   nanomedicines
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Vaccine; Immunotherapy; Immunity; DermaVir
ID GENE DELIVERY; COMPLEMENT ACTIVATION; POTENTIAL BARRIER; CATIONIC
   LIPIDS; PLASMID DNA; IN-VITRO; COMPLEXES; HYPERSENSITIVITY;
   POLYETHYLENIMINE; DERMAVIR
AB Here we characterize the structure, stability and intracellular mode of action of DermaVir nanomedicine that is under clinical development for the treatment of HIV/AIDS. This nanomedicine comprises pathogen-like pDNA/PEIm nanoparticles (NPs) having the structure and function resembling spherical viruses that naturally evolved to deliver nucleic acids to the cells. Atomic force microscopy demonstrated spherical 100 - 200 nm NPs with a smooth polymer surface protecting the pDNA in the core. Optical absorption determined both the NP structural stability and biological activity relevant to their ability to escape from the endosome and release the pDNA at the nucleus. Salt, pH and temperature influence nanomedicine shelf-life and intracellular stability. This approach facilitates the development of diverse polyplex nanomedicines where the delivered pDNA-expressed antigens induce immune responses to kill infected cells.
   From the Clinical Editor: The authors investigated DermaVir nanomedicine comprised of pathogen-like pDNA/PEIm nanoparticles with structure and function resembling spherical viruses. DermaVir delivery of pDNA expresses antigens that induce immune responses to kill HIV infected cells. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lorincz, Orsolya; Toke, Eniko R.; Somogyi, Eszter; Lisziewicz, Julianna] Genet Immun Kft, H-1045 Budapest, Hungary.
   [Horkay, Ferenc; Chandran, Preethi L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Tissue Biophys & Biomimet, Program Pediat Imaging & Tissue Sci, NIH, Bethesda, MD USA.
   [Douglas, Jack F.] NIST, Div Polymers, Gaithersburg, MD 20899 USA.
   [Szebeni, Janos] Bay Zoltan Fdn Appl Res, Nanomed Res & Educ Ctr, H-1089 Budapest, Hungary.
   [Szebeni, Janos] Semmelweis Univ, H-1089 Budapest, Hungary.
   [Lisziewicz, Julianna] Genet Immun LLC, Mclean, VA USA.
RP Lisziewicz, J (reprint author), Genet Immun Kft, Berlini U 47-49, H-1045 Budapest, Hungary.
EM lisziewj@geneticimmunity.com
FU NICHD, NIH; NKTH [CARPA777];  [HIKC05];  [DVCLIN01]
FX Dr. Julianna Lisziewicz holds shares in Genetic Immunity. This work was
   supported by grants: HIKC05 and DVCLIN01 announced by the National
   Office for Research and Technology (NKTH) in Hungary. Ferene Horkay and
   Preethi L. Chandran acknowledge the support of the Intramural Research
   Program of the NICHD, NIH. Janos Szebeni acknowledges the grant supports
   FP7 "Anticarb," NKTH CARPA777.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Bruewer M, 2005, FASEB J, V19, P923, DOI 10.1096/fj.04-3260com
   Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374
   Remy J., 1998, ADV DRUG DELIV REV, V30, P85
   Eliyahu H, 2006, BIOMATERIALS, V27, P1646, DOI 10.1016/j.biomaterials.2005.09.005
   Garcea RL, 2004, CURR OPIN BIOTECH, V15, P513, DOI 10.1016/j.copbio.2004.10.002
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Han XZ, 2009, CYTOTECHNOLOGY, V60, P63, DOI 10.1007/s10616-009-9215-y
   Hughes ME, 2007, NANO LETT, V7, P1191, DOI 10.1021/nl062906u
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Jeong JH, 2007, PROG POLYM SCI, V32, P1239, DOI 10.1016/j.progpolymsci.2007.05.019
   Kleemann E, 2004, J CONTROL RELEASE, V100, P437, DOI 10.1016/j.jconrel.2004.09.005
   Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lisziewicz J, 2008, 15 C RETR OPP INF BO
   Lobo BA, 2001, ARCH BIOCHEM BIOPHYS, V386, P95, DOI 10.1006/abbi.2000.2196
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Merkel OM, 2011, BIOMATERIALS, V32, P4936, DOI 10.1016/j.biomaterials.2011.03.035
   Natz E, 2011, GENE VACCINES, P127
   Park JJ, 2010, LANGMUIR, V26, P4822, DOI 10.1021/la903581w
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Somogyi E, 2011, VACCINE, V29, P744, DOI 10.1016/j.vaccine.2010.11.019
   Srinivasachari S, 2006, J AM CHEM SOC, V128, P8172
   STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Szebeni J, 2000, J LIPOSOME RES, V10, P467, DOI 10.3109/08982100009031112
   Szebeni J, 1998, J NATL CANCER I, V90, P300, DOI 10.1093/jnci/90.4.300                                                           
   Szebeni J, 1999, CIRCULATION, V99, P2302
   Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
   Tomac S, 1996, J AM CHEM SOC, V118, P5544, DOI 10.1021/ja960495l                                                               
   vanLunzen J., 2010, 18 INT AIDS C VIENN
   Wan L, 2009, J PHYS CHEM B, V113, P13735, DOI 10.1021/jp901835u
   Zekany L, 1991, COMPUTATION METHODS
   Zuber G, 2001, ADV DRUG DELIVER REV, V52, P245, DOI 10.1016/S0169-409X(01)00213-7
   Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9
NR 40
TC 18
Z9 18
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD MAY
PY 2012
VL 8
IS 4
BP 497
EP 506
DI 10.1016/j.nano.2011.07.013
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 930QI
UT WOS:000303153800014
PM 21839051
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tian, Y
   Zhan, P
   Rai, D
   Zhang, JY
   De Clercq, E
   Liu, XY
AF Tian, Ye
   Zhan, Peng
   Rai, Diwakar
   Zhang, Jiyan
   De Clercq, Erik
   Liu, Xinyong
TI Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one
   Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase
   Inhibitors
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE HIV; AIDS; 1,3-Thiazolidin-4-ones; HIV-1 NNRTIs; Antiviral; Drug design
ID ANTI-HIV; BIOLOGICAL-ACTIVITY; RT INHIBITORS; POSITIONAL ADAPTABILITY;
   STRUCTURAL FEATURES; MEDICINAL CHEMISTRY; ANTI-HIV-1 AGENTS; DRUG
   DESIGN; BENZIMIDAZOLES; THIAZOLIDIN-4-ONES
AB Derived from the structure of 1H,3H-thiazolo[3,4-a]benzimidazoles (TBZs), 2,3-diaryl-1,3-thiazolidin-4-one derivatives became a novel class of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Under the guidance of continuous structure-activity relationship (SAR) analysis and molecular modeling, various structural modifications were carried out on nearly all the positions of the thiazolidin-4-one nucleus. Some of the derivatives proved to be highly effective against HIV-1 replication at 10-40 nanomolar concentration ranges with minimal cytotoxicities. In this article, the whole development of 2,3-diaryl-1,3-thiazolidin-4-one series from the discoveries to recent advances, their panoramic SAR studies and binding modes based on molecular modeling were reviewed, and also some enlightenments for further investigation were presented.
C1 [Tian, Ye; Zhan, Peng; Rai, Diwakar; Zhang, Jiyan; Liu, Xinyong] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China.
   [De Clercq, Erik] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Liu, XY (reprint author), Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
EM xinyongl@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC) [30873133, 30772629,
   30371686]; NSFC for International Cooperation [30910103908]; Research
   Fund for the Doctoral Program of Higher Education of China [070422083];
   Independent Innovation Foundation of Shandong University (IIFSDU)
   [2010GN044]; Shangdong Postdoctoral Innovation Science Research Special
   Program [201002023]; China Postdoctoral Science Foundation [20100481282]
FX The financial support from the National Natural Science Foundation of
   China (NSFC No. 30873133, No. 30772629, No. 30371686), Key Project of
   NSFC for International Cooperation (No. 30910103908), Research Fund for
   the Doctoral Program of Higher Education of China (No. 070422083),
   Independent Innovation Foundation of Shandong University (IIFSDU, No.
   2010GN044), Shangdong Postdoctoral Innovation Science Research Special
   Program (No. 201002023) and China Postdoctoral Science Foundation funded
   project (No. 20100481282) is gratefully acknowledged.
CR Balzarini J, 2007, EUR J MED CHEM, V42, P993, DOI 10.1016/j.ejmech.2007.01.003
   Balzarini J, 2009, EUR J MED CHEM, V44, P303, DOI 10.1016/j.ejmech.2008.02.039
   Barreca Maria Letizia, 2003, Farmaco (Lausanne), V58, P259, DOI 10.1016/S0014-827X(03)00024-7
   Barreca ML, 2005, J MED CHEM, V48, P3433, DOI 10.1021/jm049279a
   Barreca ML, 1999, BIOORGAN MED CHEM, V7, P2283, DOI 10.1016/S0968-0896(99)00181-9
   Barreca ML, 2002, J MED CHEM, V45, P5410, DOI 10.1021/jm020977+
   Barreca ML, 2001, BIOORG MED CHEM LETT, V11, P1793, DOI 10.1016/S0960-894X(01)00304-3
   Brown N, 2006, MINI-REV MED CHEM, V6, P1217, DOI 10.2174/138955706778742768                                                      
   Chen H, 2009, BIOORGAN MED CHEM, V17, P3980, DOI 10.1016/j.bmc.2009.04.024
   Chimirri A., 2001, Antiviral Chemistry and Chemotherapy, V12, P169
   Chimirri A, 1999, ANTIVIR CHEM CHEMOTH, V10, P211, DOI 10.1177/095632029901000405                                                      
   CHIMIRRI A, 1991, FARMACO, V46, P925
   CHIMIRRI A, 1991, FARMACO, V46, P817
   Chimirri A, 1998, ANTIVIR CHEM CHEMOTH, V9, P431, DOI 10.1177/095632029800900507                                                      
   Chimirri A, 1997, ANTIVIR CHEM CHEMOTH, V8, P363, DOI 10.1177/095632029700800409                                                      
   Chimirri A, 1997, FARMACO, V52, P673
   Chimirri A, 2000, HETEROCYCLES, V53, P613, DOI 10.3987/COM-99-8784                                                             
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   Huang FL, 2008, ANTIMICROB AGENTS CH, V52, P4300, DOI 10.1128/AAC.00363-08
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   Lamoureux G, 2010, CURR MED CHEM, V17, P2967, DOI 10.2174/092986710792065027                                                      
   McMartin C, 1997, J COMPUT AID MOL DES, V11, P333, DOI 10.1023/A:1007907728892                                                         
   Morningstar ML, 2007, J MED CHEM, V50, P4003, DOI 10.1021/jm060103d
   Murugesan V, 2011, BIOORGAN MED CHEM, V19, P6919, DOI 10.1016/j.bmc.2011.09.018
   Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q                                                               
   Pauwels R, 2006, ANTIVIR RES, V71, P77, DOI 10.1016/j.antiviral.2006.05.007
   Pitta E, 2010, LETT DRUG DES DISCOV, V7, P228, DOI 10.2174/157018010790945869                                                      
   Prabhakar YS, 2005, COMB CHEM HIGH T SCR, V8, P431, DOI 10.2174/1386207054546531
   Prabhakar YS, 2004, QSAR COMB SCI, V23, P234, DOI 10.1002/qsar.200330854
   Rao A, 2004, ANTIVIR RES, V63, P79, DOI 10.1016/j.antiviral.2004.03.004
   Rao A, 2002, FARMACO, V57, P747, DOI 10.1016/S0014-827X(02)01268-5
   Rao A, 2002, FARMACO, V57, P819, DOI 10.1016/S0014-827X(02)01300-9                                                   
   Rao Angela, 2003, Farmaco (Lausanne), V58, P115, DOI 10.1016/S0014-827X(02)00024-1
   Rao Angela, 2004, Farmaco (Lausanne), V59, P33, DOI 10.1016/j.farmac.2003.09.001
   Rawal RK, 2008, CHEM BIOL DRUG DES, V72, P147, DOI 10.1111/j.1747-0285.2008.00683.x
   Rawal RK, 2007, MED CHEM, V3, P355
   Rawal RK, 2007, BIOORGAN MED CHEM, V15, P3134, DOI 10.1016/j.bmc.2007.02.044
   Rawal RK, 2007, QSAR COMB SCI, V26, P398, DOI 10.1002/qsar.200630040
   Rawal RK, 2007, BIOORGAN MED CHEM, V15, P1725, DOI 10.1016/j.bcm.2006.12.003
   Rawal RK, 2008, EUR J MED CHEM, V43, P2800, DOI 10.1016/j.ejmech.2007.12.015
   Rawal RK, 2005, BIOORGAN MED CHEM, V13, P6771, DOI 10.1016/j.bmc.2005.07.063
   Rawal RK, 2005, COMB CHEM HIGH T SCR, V8, P439, DOI 10.2174/1386207054546496
   Roth T, 1997, J MED CHEM, V40, P4199, DOI 10.1021/jm970096g
   Roy K, 2005, QSAR COMB SCI, V24, P579, DOI 10.1002/qsar.200430901
   SCHAFER W, 1993, J MED CHEM, V36, P726, DOI 10.1021/jm00058a009
   Seminari E, 2008, EXPERT REV ANTI-INFE, V6, P427, DOI 10.1586/14787210.6.4.427
   Smith MBK, 2003, J MED CHEM, V46, P1940, DOI 10.1021/jm020271f
   Tavel JA, 1999, CLIN INFECT DIS, V28, P643, DOI 10.1086/515179                                                                  
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   U.S. Food and Drug Administration, FDA APPR NEW HIV TRE
   Viegas-Junior C, 2007, CURR MED CHEM, V14, P1829
   Zhan P., 2011, MED RES REV, DOI [10.1002/med.20241, DOI 10.1002/MED.20241]
   Zhan P, 2009, CURR MED CHEM, V16, P3903, DOI 10.2174/092986709789178019                                                      
NR 56
TC 19
Z9 19
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAY
PY 2012
VL 19
IS 13
BP 2026
EP 2037
DI 10.2174/092986712800167383                                              
          
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 928UT
UT WOS:000303012900004
PM 22429098
DA 2018-01-05
ER

PT J
AU Mufhandu, HT
   Gray, ES
   Madiga, MC
   Tumba, N
   Alexandre, KB
   Khoza, T
   Wibmer, CK
   Moore, PL
   Morris, L
   Khati, M
AF Mufhandu, Hazel T.
   Gray, Elin S.
   Madiga, Maphuti C.
   Tumba, Nancy
   Alexandre, Kabamba B.
   Khoza, Thandeka
   Wibmer, Constantinos Kurt
   Moore, Penny L.
   Morris, Lynn
   Khati, Makobetsa
TI UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of
   Human Immunodeficiency Virus Type 1 Subtype C
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NEUTRALIZES R5 STRAINS; MONOCLONAL-ANTIBODIES; BINDING-SITE;
   STRUCTURAL-CHARACTERIZATION; ENVELOPE GLYCOPROTEIN; HIV-1
   NEUTRALIZATION; CD4-BINDING SITE; FUSION INHIBITOR; RECEPTOR-BINDING;
   ENV CLONES
AB Entry of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by the virion surface envelope (Env) glycoproteins, making it a desirable target for antiretroviral entry inhibitors. We previously isolated a family of gp120 binding RNA aptamers and showed that they neutralized the infectivity of HIV-1. In this study, we assessed the activity of a shortened synthetic derivative of the B40 aptamer, called UCLA1, against a large panel of HIV-1 subtype C viruses. UCLA1 tightly bound to a consensus HIV-1 subtype C gp120 and neutralized isolates of the same subtype with 50% inhibitory concentrations (IC(50)s) in the nanomolar range. The aptamer had little toxicity in tests with cell lines and primary cells. Furthermore, it exhibited high therapeutic indices, suggesting that it may be effective at very low doses. Mapping of UCLA1 binding sites on gp120 revealed eight amino acid residues that modulated neutralization resistance. This included residues within the coreceptor binding site, at the base of the V3 loop, and in the bridging sheet within the conserved V1/V2 stem-loop of gp120. The aptamer was also shown to have synergistic effects with T20, a gp41 fusion inhibitor, and IgG1b12 (b12), an anti-CD4 binding site monoclonal antibody. These results suggest that UCLA1 may be suitable for development as a potent HIV-1 entry inhibitor.
C1 [Mufhandu, Hazel T.; Khoza, Thandeka; Khati, Makobetsa] CSIR, Biosci Unit, ZA-0001 Pretoria, South Africa.
   [Gray, Elin S.; Madiga, Maphuti C.; Tumba, Nancy; Alexandre, Kabamba B.; Wibmer, Constantinos Kurt; Moore, Penny L.; Morris, Lynn] Natl Inst Communicable Dis, AIDS Virus Res Unit, Johannesburg, South Africa.
   [Morris, Lynn] Univ Witwatersrand, Johannesburg, South Africa.
   [Khati, Makobetsa] Groote Schuur Hosp, Dept Med, ZA-7925 Cape Town, South Africa.
   [Khati, Makobetsa] Univ Cape Town, ZA-7925 Cape Town, South Africa.
RP Khati, M (reprint author), CSIR, Biosci Unit, ZA-0001 Pretoria, South Africa.
EM mkhati@csir.co.za
OI Wibmer, Constantinos Kurt/0000-0003-2329-2280; Moore,
   Penny/0000-0001-8719-4028; Gray, Elin/0000-0002-8613-3570
FU South African Department of Science and Technology (DST); Council for
   Scientific and Industrial Research (CSIR); Young Researcher
   Establishment Fund (YREF) [2007 029]; Poliomyelitis Research Foundation
   [08/37]; Wits Medical Faculty Research Endowment Fund [001 410 MUFH011
   TS]; NIH [5U01AI066734-03]
FX This work was supported by the South African Department of Science and
   Technology (DST) and a Council for Scientific and Industrial Research
   (CSIR) Parliamentary Grant. Hazel Mufhandu was funded by The Young
   Researcher Establishment Fund (YREF 2007 029), the Poliomyelitis
   Research Foundation (08/37), the Wits Medical Faculty Research Endowment
   Fund (001 410 MUFH011 TS), and a CSIR Ph.D. studentship. The authors
   acknowledge the generous donation of aptamer UCLA1 by Ian McGowan,
   William James, and Brian Sproat under the NIH Aptamer Microbicide
   Program, grant 5U01AI066734-03.
CR Alexandre KB, 2010, VIROLOGY, V402, P187, DOI 10.1016/j.virol.2010.03.021
   Alexandre KB, 2011, J VIROL, V85, P9039, DOI 10.1128/JVI.02675-10
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Bures R, 2000, AIDS RES HUM RETROV, V16, P2019, DOI 10.1089/088922200750054756
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   Cilliers T, 2003, J VIROL, V77, P4449, DOI 10.1128/JVI.77.7.4449-4456.2003
   Cohen C, 2008, VIROLOGY, V381, P46, DOI 10.1016/j.virol.2008.08.025
   Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001                                                
   de Campos WRL, 2009, ANTIMICROB AGENTS CH, V53, P3056, DOI 10.1128/AAC.01502-08
   Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Dey AK, 2005, RNA, V11, P873, DOI 10.1261/rna.7205405
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Gray ES, 2007, J VIROL, V81, P6187, DOI 10.1128/JVI.00239-07
   Gray ES, 2007, J VIROL, V81, P10769, DOI 10.1128/JVI.01106-07
   Gray ES, 2009, J VIROL, V83, P8925, DOI 10.1128/JVI.00758-09
   Gray ES, 2006, PLOS MED, V3, P1023, DOI 10.1371/journal.pmed.0030255
   Honnen WJ, 2007, J VIROL, V81, P1424, DOI 10.1128/JVI.02054-06
   Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698                                                                  
   Joubert MK, 2010, BIOCHEMISTRY-US, V49, P5880, DOI 10.1021/bi100301k
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624
   Montefiori DC, 2004, EVALUATING NEUTRALIZ, V12
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Moore MD, 2011, J BIOL CHEM, V286, P2526, DOI 10.1074/jbc.M110.178426
   Nagashima KA, 2001, J INFECT DIS, V183, P1121, DOI 10.1086/319284                                                                  
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   Osztie E, 2001, AM J NEURORADIOL, V22, P818
   Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003
   Pinter A, 2005, J VIROL, V79, P6909, DOI 10.1128//JVI.79.11.6909-6917.2005
   Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Sayer N, 2002, BIOCHEM BIOPH RES CO, V293, P924, DOI 10.1016/S0006-291X(02)00308-X
   Schols D, 2006, ANTIVIR RES, V71, P216, DOI 10.1016/j.antiviral.2006.04.009
   Tremblay CL, 2000, J ACQ IMMUN DEF SYND, V25, P99, DOI 10.1097/00126334-200010010-00001
   Van Harmelen JH, 1999, AIDS RES HUM RETROV, V15, P395
   Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373
   Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746
   Wang W, 2009, CHINESE J ANAL CHEM, V37, P454, DOI 10.1016/S1872-2040(08)60092-4                                                   
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Zhou J, 2010, OLIGONUCLEOTIDES, V21, P1
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2011, METHODS, V54, P284, DOI 10.1016/j.ymeth.2010.12.039
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
   Zwick MB, 2001, J VIROL, V75, P12198, DOI 10.1128/JVI.75.24.12198-12208.2001                                              
NR 59
TC 13
Z9 16
U1 0
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAY
PY 2012
VL 86
IS 9
BP 4989
EP 4999
DI 10.1128/JVI.06893-11
PG 11
WC Virology
SC Virology
GA 925RD
UT WOS:000302777800024
PM 22379083
OA gold
DA 2018-01-05
ER

PT J
AU Benedetti, F
   Berti, F
   Budal, S
   Campaner, P
   Dinon, F
   Tossi, A
   Argirova, R
   Genova, P
   Atanassov, V
   Hinkov, A
AF Benedetti, Fabio
   Berti, Federico
   Budal, Sara
   Campaner, Pietro
   Dinon, Francesca
   Tossi, Alessandro
   Argirova, Radka
   Genova, Petia
   Atanassov, Vasil
   Hinkov, Anton
TI Synthesis and Biological Activity of Potent HIV-1 Protease Inhibitors
   Based on Phe-Pro Dihydroxyethylene Isosteres
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STEREOSELECTIVE-SYNTHESIS; DIPEPTIDE
   ISOSTERES; ASPARTIC PROTEASE; BINDING MECHANISM; ABT-378 LOPINAVIR;
   DESIGN; DISCOVERY; ALPHA; DIOLS
AB Peptidomimetic inhibitors of HIV-1 PR are still a key resource in the fight against AIDS. Here we describe the synthesis and biological activity of HIV-1 PR inhibitors based on four novel dihydroxyethylene isosteres of the Phe-Pro and Pro-Pro dipeptides. The isosteres, containing four stereogenic centers, were synthesized in high yield and excellent stereoselectivity via the cyclization of epoxy amines derived from alpha-amino acids. The inhibitors were assembled by coupling the isosteres with suitable flanking groups and were screened against recombinant HIV PR showing activities in the subnanomolar to micromolar range. Two Phe-Pro-based inhibitors active at the nanomolar level were further investigated: both inhibitors combine the ability to suppress HIV-1 replication in infected MT-2 cells with low cytotoxicity against the same cells, thereby displaying a high therapeutic index. These results demonstrate the potential of the new Phe-Pro dihydroxyethylene isostere as a core unit of powerful HIV-1 PR inhibitors.
C1 [Benedetti, Fabio; Berti, Federico; Budal, Sara; Campaner, Pietro; Dinon, Francesca] Univ Trieste, Dept Chem & Pharmaceut Sci, I-34127 Trieste, Italy.
   [Tossi, Alessandro] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy.
   [Argirova, Radka; Genova, Petia] Natl Ctr Infect & Parasit Dis, Dept Virol, Sofia 1233, Bulgaria.
   [Atanassov, Vasil] St Kliment Ohridski Sofia Univ, Lab Bioocordinat & Bioanalyt Chem, Sofia, Bulgaria.
   [Hinkov, Anton] St Kliment Ohridski Sofia Univ, Fac Chem & Pharm, Sofia, Bulgaria.
RP Benedetti, F (reprint author), Univ Trieste, Dept Chem & Pharmaceut Sci, Via Giorgieri 1, I-34127 Trieste, Italy.
EM benedett@units.it; fberti@units.it
RI Benedetti, Fabio/G-4787-2012
OI Benedetti, Fabio/0000-0002-8773-7413; Tossi,
   Alessandro/0000-0001-9087-5764
FU Ministry of University and Research (MIUR Rome-Italy); University of
   Trieste
FX We thank Ministry of University and Research (MIUR Rome-Italy) for
   financial support (PRIN project) and the University of Trieste for
   partially supporting P.C. and F.D. (Ph.D. fellowships). The MT-2 cell
   line was a gift from Dr. Sylvie Liu, Imperial College, Faculty of
   Medicine, London, UK. The H9/HTLV III B line was a gift from Dr. R Gallo
   (NIH, Bethesda, MD).
CR Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
   Armbruster J, 1998, ANGEW CHEM INT EDIT, V37, P2242, DOI 10.1002/(SICI)1521-3773(19980904)37:16<2242::AID-ANIE2242>3.0.CO;2-0            
   Beaulieu PL, 2000, J MED CHEM, V43, P1094, DOI 10.1021/jm990336n                                                               
   Benedetti F, 2004, ORG LETT, V6, P1017, DOI 10.1021/ol0499147
   Benedetti F, 1997, J ORG CHEM, V62, P9348, DOI 10.1021/jo971202p                                                               
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Broglia RA, 2006, PROTEINS, V62, P928, DOI 10.1002/prot.20849
   BUDT KH, 1995, BIOORGAN MED CHEM, V3, P559, DOI 10.1016/0968-0896(95)00069-S
   Chen XQ, 2003, BIOORG MED CHEM LETT, V13, P3657, DOI 10.1016/j.bmcl.2003.08.043
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Copeland R, 2000, ENZYMES PRACTICAL IN
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   De Clercq E, 2009, REV MED VIROL, V19, P287, DOI 10.1002/rmv.624
   Dieter RK, 1996, J ORG CHEM, V61, P4180, DOI 10.1021/jo960153y                                                               
   DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027                                                             
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Frecer V, 2008, J MOL GRAPH MODEL, V27, P376, DOI 10.1016/j.jmgm.2008.06.006
   FURFINE ES, 1992, BIOCHEMISTRY-US, V31, P7886, DOI 10.1021/bi00149a020                                                             
   GEMAL AL, 1981, J AM CHEM SOC, V103, P5454, DOI 10.1021/ja00408a029                                                             
   Geremia S, 2006, CHEMMEDCHEM, V1, P186, DOI 10.1002/cmdc.200500063
   Ghosh AK, 2007, BIOORGAN MED CHEM, V15, P7576, DOI 10.1016/j.bmc.2007.09.010
   Gurjar MK, 1997, TETRAHEDRON, V53, P4769, DOI 10.1016/S0040-4020(97)00160-9                                                   
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317                                                                  
   Hinkov A, 2010, CR ACAD BULG SCI, V63, P1455
   Hoffman RV, 2002, J ORG CHEM, V67, P1045, DOI 10.1021/jo010270f
   Hosur T.M.V., 1994, J AM CHEM SOC, V116, P847
   IBUKA T, 1993, J ORG CHEM, V58, P1207, DOI 10.1021/jo00057a038                                                             
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   Ishima R, 2008, PROTEINS, V70, P1408, DOI 10.1002/prot.21632
   Kammermeier B, 1996, CHEM-EUR J, V2, P307, DOI 10.1002/chem.19960020312                                                        
   KEMPF DJ, 1992, J ORG CHEM, V57, P5692, DOI 10.1021/jo00047a023                                                             
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003
   KOSKINEN AMP, 1993, SYNLETT, P501
   MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231
   Mossman T., 1989, J IMMUNOL METHODS, V65, P55, DOI DOI 10.1016/0022-1759(83)90303-4
   Muhlman A, 2001, J MED CHEM, V44, P3407, DOI 10.1021/jm0011171
   [Anonymous], 2010, ASS GUID MAN VERS 6
   Northrop DB, 2001, ACCOUNTS CHEM RES, V34, P790, DOI 10.1021/ar000184m
   Pietrucci F, 2009, J AM CHEM SOC, V131, P11811, DOI 10.1021/ja903045y
   Ramu E, 2009, TETRAHEDRON-ASYMMETR, V20, P2201, DOI 10.1016/j.tetasy.2009.09.003
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Rodriguez AC, 2004, TETRAHEDRON-ASYMMETR, V15, P1847, DOI 10.1016/j.tetasy.2004.05.005
   RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006
   Sham HL, 2002, BIOORG MED CHEM LETT, V12, P1185, DOI 10.1016/S0960-894X(02)00134-8                                                   
   Smith R, 1996, NAT STRUCT BIOL, V3, P946, DOI 10.1038/nsb1196-946
   Steuber H, 2010, CURR TOP MED CHEM, V10, P323, DOI 10.2174/156802610790725470                                                      
   Stoner EJ, 2000, ORG PROCESS RES DEV, V4, P264, DOI 10.1021/op990202j
   Takeuchi Y, 1999, HETEROCYCLES, V51, P1869, DOI 10.3987/COM-99-8564                                                             
   Tossi A, 2000, EUR J BIOCHEM, V267, P1715, DOI 10.1046/j.1432-1327.2000.01164.x
   Wachtmeister J, 2000, TETRAHEDRON, V56, P3219, DOI 10.1016/S0040-4020(00)00220-9
   Weber B, 1999, SYNTHESIS-STUTTGART, P1593
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8
NR 58
TC 8
Z9 8
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 26
PY 2012
VL 55
IS 8
BP 3900
EP 3910
DI 10.1021/jm3001136
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 930VV
UT WOS:000303173600023
PM 22458611
DA 2018-01-05
ER

PT J
AU Mukerji, J
   Olivieri, KC
   Misra, V
   Agopian, KA
   Gabuzda, D
AF Mukerji, Joya
   Olivieri, Kevin C.
   Misra, Vikas
   Agopian, Kristin A.
   Gabuzda, Dana
TI Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role
   for exocyst complex proteins in mediating enhancement of intercellular
   nanotube formation
SO RETROVIROLOGY
LA English
DT Article
DE HIV; Nef; Exocyst complex; Intercellular nanotubes; Pak2 kinase;
   Fluorescence confocal microscopy
ID VIRUS TYPE-1 NEF; NF-KAPPA-B; T-CELLS; P21-ACTIVATED KINASE-2;
   INFECTED-CELLS; LIPID RAFTS; IMMUNOLOGICAL SYNAPSE; MULTIVESICULAR
   BODIES; DENDRITIC CELLS; IN-VIVO
AB Background: HIV-1 Nef protein contributes to pathogenesis via multiple functions that include enhancement of viral replication and infectivity, alteration of intracellular trafficking, and modulation of cellular signaling pathways. Nef stimulates formation of tunneling nanotubes and virological synapses, and is transferred to bystander cells via these intercellular contacts and secreted microvesicles. Nef associates with and activates Pak2, a kinase that regulates T-cell signaling and actin cytoskeleton dynamics, but how Nef promotes nanotube formation is unknown.
   Results: To identify Nef binding partners involved in Pak2-association dependent Nef functions, we employed tandem mass spectrometry analysis of Nef immunocomplexes from Jurkat cells expressing wild-type Nef or Nef mutants defective for the ability to associate with Pak2 (F85L, F89H, H191F and A72P, A75P in NL4-3). We report that wild-type, but not mutant Nef, was associated with 5 components of the exocyst complex (EXOC1, EXOC2, EXOC3, EXOC4, and EXOC6), an octameric complex that tethers vesicles at the plasma membrane, regulates polarized exocytosis, and recruits membranes and proteins required for nanotube formation. Additionally, Pak2 kinase was associated exclusively with wild-type Nef. Association of EXOC1, EXOC2, EXOC3, and EXOC4 with wild-type, but not mutant Nef, was verified by co-immunoprecipitation assays in Jurkat cells. Furthermore, shRNA-mediated depletion of EXOC2 in Jurkat cells abrogated Nef-mediated enhancement of nanotube formation. Using bioinformatic tools, we visualized protein interaction networks that reveal functional linkages between Nef, the exocyst complex, and the cellular endocytic and exocytic trafficking machinery.
   Conclusions: Exocyst complex proteins are likely a key effector of Nef-mediated enhancement of nanotube formation, and possibly microvesicle secretion. Linkages revealed between Nef and the exocyst complex suggest a new paradigm of exocyst involvement in polarized targeting for intercellular transfer of viral proteins and viruses.
C1 [Mukerji, Joya; Olivieri, Kevin C.; Misra, Vikas; Agopian, Kristin A.; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Mukerji, Joya; Agopian, Kristin A.; Gabuzda, Dana] Harvard Univ, Sch Med, Div Med Sci Program Virol, Boston, MA USA.
   [Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol Microbiol, Boston, MA USA.
RP Gabuzda, D (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
EM dana_gabuzda@dfci.harvard.edu
FU NIH [R21 AI73415, R21 AI77464, DP1 DA028994]; Harvard University Center
   for AIDS Research; DFCI/Harvard Cancer Center;  [T32 AG00222];  [T32
   AI007386]
FX We thank Stefanie Sowinski, Mathew Sowa, Wei Guo, Edward Manser, Michael
   Farzan, Thomas M. Roberts, Kai Wucherpfennig, Etienne Gagnon, Ross
   Tomaino, David Cureton, Lai Ding, Jeffrey Teigler, Daniel Tom, Lisa
   Cameron, Megan Mefford, Alexander Holman, Andres Finzi, Hillel Haim, and
   the Gabuzda Lab for advice and discussions, Ross Tomaino for mass
   spectrometry and data analysis, Lai Ding and Daniel Tom for expert
   confocal imaging support, and Peter Schow and Kimberley Lowe for FACS.
   This work was supported by NIH grants R21 AI73415, R21 AI77464, and DP1
   DA028994. pHAGE was obtained from the Harvard Gene Therapy Initiative
   plasmid repository. J.M. was supported in part by T32 AG00222. K.C.O.
   was supported in part by T32 AI007386. Core facilities were supported by
   Harvard University Center for AIDS Research, and DFCI/Harvard Cancer
   Center grants. Confocal microscopy images were collected by J.M. at the
   Harvard NeuroDiscovery Center Optical Imaging Core Facility.
CR Agopian K, 2006, J VIROL, V80, P3050, DOI 10.1128/JVI.80.6.3050-3061.2006
   Alexander M, 2004, J VIROL, V78, P1685, DOI 10.1128/JVI.78.4.1685-1696.2004
   Ali SA, 2010, AIDS RES HUM RETROV, V26, P173, DOI 10.1089/aid.2009.0068
   ARHEL N, 2010, CURRT TOP MICROBIOL, V339, P147
   Arhel N, 2009, J CLIN INVEST, V119, P2965, DOI 10.1172/JCI38994
   Arold S, 1997, STRUCTURE, V5, P1361, DOI 10.1016/S0969-2126(97)00286-4
   Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000                                              
   Balasubramanian N, 2010, CURR BIOL, V20, P75, DOI 10.1016/j.cub.2009.11.016
   Baldari CT, 2010, CURR OPIN CELL BIOL, V22, P75, DOI 10.1016/j.ceb.2009.10.010
   Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5
   Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235                                                     
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Brown A, 1999, J VIROL, V73, P9899
   Campbell TD, 2008, ETHNIC DIS, V18, P14
   Chaudhry A, 2008, TRAFFIC, V9, P1925, DOI 10.1111/j.1600-0854.2008.00802.x
   Chu PC, 2004, J IMMUNOL, V172, P7324, DOI 10.4049/jimmunol.172.12.7324                                                    
   Costa LJ, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-33
   Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277
   daSilva LLP, 2009, J VIROL, V83, P6578, DOI 10.1128/JVI.00548-09
   Fackler OT, 2007, NAT REV IMMUNOL, V7, P310, DOI 10.1038/nri2041
   Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8                                                   
   Fenard D, 2005, J IMMUNOL, V175, P6050, DOI 10.4049/jimmunol.175.9.6050                                                     
   Fielding AB, 2005, EMBO J, V24, P3389, DOI 10.1038/sj.emboj.7600803
   Fortin JF, 2004, J BIOL CHEM, V279, P39520, DOI 10.1074/jbc.M407477200
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   Gousset K, 2009, PRION, V3, P94, DOI 10.4161/pri.3.2.8917                                                            
   Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755
   Greenway A, 1996, J VIROL, V70, P6701
   Griffiths GM, 2010, J CELL BIOL, V189, P397, DOI 10.1083/jcb.201002027
   Haller C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001212
   Haller C, 2008, BIOL CHEM, V389, P1253, DOI 10.1515/BC.2008.143
   Haller C, 2006, J BIOL CHEM, V281, P19618, DOI 10.1074/jbc.M513802200
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990
   He B, 2009, CURR OPIN CELL BIOL, V21, P537, DOI 10.1016/j.ceb.2009.04.007
   Hertzog M, 2011, BIOCHEM J, V433, P403, DOI 10.1042/BJ20101214
   Hyrcza MD, 2007, J VIROL, V81, P3477, DOI 10.1128/JVI.01552-06
   Izquierdo-Useros N, 2009, BLOOD, V113, P2732, DOI 10.1182/blood-2008-05-158642
   Jackson PK, 2009, CELL, V138, P222, DOI 10.1016/j.cell.2009.07.008
   Jager S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719
   Janardhan A, 2004, PLOS BIOL, V2, P65, DOI 10.1371/journa.pbio.020006
   Jin YJ, 2005, J IMMUNOL, V175, P3157, DOI 10.4049/jimmunol.175.5.3157                                                     
   Konig R, 2008, CELL, V135, P49, DOI 10.1016/j.cell.2008.07.032
   Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004
   Lenassi M, 2010, TRAFFIC, V11, P110, DOI 10.1111/j.1600-0854.2009.01006.x
   Lim KH, 2010, MOL CELL BIOL, V30, P508, DOI 10.1128/MCB.00916-08
   Lindwasser OW, 2008, J VIROL, V82, P1166, DOI 10.1128/JVI.01874-07
   Linnemann T, 2002, VIROLOGY, V294, P246, DOI 10.1006/viro.2002.1365
   Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200
   Madrid R, 2005, J BIOL CHEM, V280, P5032, DOI 10.1074/jbc.M401202200
   Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200
   Munson M, 2006, NAT STRUCT MOL BIOL, V13, P577, DOI 10.1038/nsmb1097
   Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009
   Ndolo T, 2006, VIROLOGY, V353, P374, DOI 10.1016/j.virol.2006.06.008
   Olivieri KC, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-64
   Peterlin BM, 2006, NAT IMMUNOL, V7, P229, DOI 10.1038/ni0306-229
   Peterlin BM, 2003, NAT REV IMMUNOL, V3, P97, DOI 10.1038/nri998
   Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984
   Piguet V, 2000, NAT CELL BIOL, V2, P163
   Pulkkinen K, 2004, J VIROL, V78, P12773, DOI 10.1128/JVI.78.23.12773-12780.2004
   Rauch S, 2008, J VIROL, V82, P2918, DOI 10.1128/JVI.02185-07
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001
   RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5                                                    
   Roeth JF, 2006, MICROBIOL MOL BIOL R, V70, P548, DOI 10.1128/MMBR.00042-05
   Rudnicka D, 2009, NAT IMMUNOL, V10, P933, DOI 10.1038/ni0909-933
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167                                                         
   Shelton MN, 2012, J VIROL, V86, P406, DOI 10.1128/JVI.05720-11
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3                                                   
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042
   Sowinski S, 2010, METHODS, V53, P27
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Stumptner-Cuvelette P, 2003, MOL BIOL CELL, V14, P4857, DOI 10.1091/mbc.E03-04-0211
   Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Tuosto L, 2003, EUR J IMMUNOL, V33, P2186, DOI 10.1002/eji.200323682
   Van den Broeke C, 2010, TRENDS CELL BIOL, V20, P160, DOI 10.1016/j.tcb.2009.12.005
   VENNY, VENNY INTERACTIVE TO
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394
   Wei BL, 2003, CURR HIV RES, V1, P41, DOI 10.2174/1570162033352057                                                        
   Wilson AA, 2008, AM J RESP CELL MOL, V39, P133, DOI 10.1165/rcmb.2007-0133OC
   Witte V, 2008, J IMMUNOL, V181, P8425, DOI 10.4049/jimmunol.181.12.8425                                                    
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Yeung ML, 2009, J BIOL CHEM, V284, P19463, DOI 10.1074/jbc.M109.010033
   Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272
   Zhang XM, 2004, J BIOL CHEM, V279, P43027, DOI 10.1074/jbc.M402264200
   Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035
   Zhou HL, 2008, CELL HOST MICROBE, V4, P495, DOI 10.1016/j.chom.2008.10.004
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
   Zuo XF, 2006, NAT CELL BIOL, V8, P1383, DOI 10.1038/ncb1505
   Zuo XF, 2009, MOL BIOL CELL, V20, P2522, DOI 10.1091/mbc.E08-07-0772
   2010, NUCL ACIDS RES, V38, pD142
NR 94
TC 36
Z9 36
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD APR 25
PY 2012
VL 9
AR 33
DI 10.1186/1742-4690-9-33
PG 16
WC Virology
SC Virology
GA 967HP
UT WOS:000305897800001
PM 22534017
OA gold
DA 2018-01-05
ER

PT J
AU Kawabata, A
   Baoum, A
   Ohta, N
   Jacquez, S
   Seo, GM
   Berkland, C
   Tamura, M
AF Kawabata, Atsushi
   Baoum, Abdulgader
   Ohta, Naomi
   Jacquez, Stephanie
   Seo, Gwi-Moon
   Berkland, Cory
   Tamura, Masaaki
TI Intratracheal Administration of a Nanoparticle-Based Therapy with the
   Angiotensin II Type 2 Receptor Gene Attenuates Lung Cancer Growth
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TAT PROTEIN; CELL-PROLIFERATION;
   ADENOVIRUS VECTORS; DELIVERY; EXPRESSION; APOPTOSIS; BREAST; DEATH; MICE
AB Targeted gene delivery, transfection efficiency, and toxicity concerns remain a challenge for effective gene therapy. In this study, we dimerized the HIV-1 TAT peptide and formulated a nanoparticle vector (dTAT NP) to leverage the efficiency of this cell-penetrating strategy for tumor-targeted gene delivery in the setting of intratracheal administration. Expression efficiency for dTAT NP-encapsulated luciferase or angiotensin II type 2 receptor (AT2R) plasmid DNA (pDNA) was evaluated in Lewis lung carcinoma (LLC) cells cultured in vitro or in vivo in orthotopic tumor grafts in syngeneic mice. In cell culture, dTAT NP was an effective pDNA transfection vector with negligible cytotoxicity. Transfection efficiency was further increased by addition of calcium and glucose to dTAT/pDNA NP. In orthotopic tumor grafts, immunohistochemical analysis confirmed that dTAT NP successfully delivered pDNA to the tumor, where it was expressed primarily in tumor cells along with the bronchial epithelium. Notably, gene expression in tumor tissues persisted at least 14 days after intratracheal administration. Moreover, bolus administration of dTAT NP-encapsulated AT2R or TNF-related apoptosis-inducing ligand (TRAIL) pDNA markedly attenuated tumor growth. Taken together, our findings offer a preclinical proof-of-concept for a novel gene delivery system that offers an effective intratracheal strategy for administering lung cancer gene therapy. Cancer Res; 72(8); 2057-67. (C) 2012 AACR.
C1 [Kawabata, Atsushi; Ohta, Naomi; Jacquez, Stephanie; Seo, Gwi-Moon; Tamura, Masaaki] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA.
   [Baoum, Abdulgader; Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.
   [Baoum, Abdulgader; Berkland, Cory] Univ Kansas, Dept Petr Engn, Lawrence, KS 66045 USA.
RP Tamura, M (reprint author), Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA.
EM mtamura@vet.k-state.edu
OI Ohta, Naomi/0000-0001-5790-3137
FU Kansas State University (KSU) Terry C. Johnson Center for Basic Cancer
   Research; KSU College of Veterinary Medicine; Kansas State Legislative
   Appropriation; The Institute for Advancing Medical Innovation at The
   University of Kansas; NIH [P20 RR017686, P20 RR016475, 5P20RR015563];
   Kansas Bioscience Authority; Savara Pharmaceuticals
FX C. Berkland has Commercial Research Grant and Ownership Interest
   (including patents) from Savara Pharmaceuticals. No potential conflicts
   of interest were disclosed by the other authors.; This work was
   supported in part by the Kansas State University (KSU) Terry C. Johnson
   Center for Basic Cancer Research, KSU College of Veterinary Medicine
   Dean's fund, Kansas State Legislative Appropriation, The Institute for
   Advancing Medical Innovation at The University of Kansas and NIH grants
   P20 RR017686, P20 RR016475, 5P20RR015563 and Kansas Bioscience Authority
   collaborative cancer research grant. In addition, Savara Pharmaceuticals
   is gratefully acknowledged for providing financial support for portions
   of this work.
CR Antus B., 2000, Acta Physiologica Hungarica, V87, P5
   Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
   Baoum A, 2009, PHARM RES, V12, P2619
   Baoum A, 2011, INT J PHARM     0812
   Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254
   Benihoud K, 1999, CURR OPIN BIOTECH, V10, P440, DOI 10.1016/S0958-1669(99)00007-5                                                   
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Booth NL, 2009, CANCER IMMUNOL IMMUN, V58, P1229, DOI 10.1007/s00262-008-0637-8
   Doi C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-67
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102                                              
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395
   Hassani Z, 2005, J GENE MED, V7, P198, DOI 10.1002/jgm.659
   Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040
   Hope MJ, 1998, MOL MEMBR BIOL, V15, P1, DOI 10.3109/09687689809027512
   Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422                                                     
   Kanehira T, 2005, CANCER RES, V65, P7660, DOI 10.1158/0008-5472.CAN-05-0275
   Kedinger V, 2011, MOL CANCER, V4, P34
   Li S, 2000, GENE THER, V7, P31, DOI 10.1038/sj.gt.3301110
   Liu Q, 2003, GENE THER, V10, P935, DOI 10.1038/sj.gt.3302036
   Mani K, 2007, MOL CANCER THER, V6, P782, DOI 10.1158/1535-7163.MCT-06-0370
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244                                                   
   Matsuzuka T, 2010, LUNG CANCER, V70, P28, DOI 10.1016/j.lungcan.2010.01.003
   Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026
   Ogris M, 2002, DRUG DISCOV TODAY, V7, P479, DOI 10.1016/S1359-6446(02)02243-2
   Peeters MJTFDV, 1996, HUM GENE THER, V7, P1693, DOI 10.1089/hum.1996.7.14-1693
   Pickel L, 2010, CANCER BIOL THER, V9, P277, DOI 10.4161/cbt.9.4.10643
   Ragusa A, 2007, IEEE T NANOBIOSCI, V6, P319, DOI 10.1109/TNB.2007.908996
   Shekhar MPV, 2001, CANCER RES, V61, P1320
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x
   STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710
   Takagi T, 2002, CARCINOGENESIS, V23, P1235, DOI 10.1093/carcin/23.7.1235
   Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647
   Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8
   TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   vanRoozendaal KEP, 1996, INT J CANCER, V65, P120, DOI 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156
   YEI SP, 1994, GENE THER, V1, P192
NR 46
TC 41
Z9 42
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2012
VL 72
IS 8
BP 2057
EP 2067
DI 10.1158/0008-5472.CAN-11-3634
PG 11
WC Oncology
SC Oncology
GA 927KH
UT WOS:000302905700017
PM 22389453
OA gold
DA 2018-01-05
ER

PT J
AU Reynolds, JL
   Law, WC
   Mahajan, SD
   Aalinkeel, R
   Nair, B
   Sykes, DE
   Mammen, MJ
   Yong, KT
   Hui, R
   Prasad, PN
   Schwartz, SA
AF Reynolds, Jessica L.
   Law, Wing Cheung
   Mahajan, Supriya D.
   Aalinkeel, Ravikumar
   Nair, Bindukumar
   Sykes, Donald E.
   Mammen, Manoj J.
   Yong, Ken-Tye
   Hui, Rui
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Morphine and Galectin-1 Modulate HIV-1 Infection of Human
   Monocyte-Derived Macrophages
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID BLOOD MONONUCLEAR PHAGOCYTES; IMMATURE DENDRITIC CELLS; GOLD
   NANOPARTICLES; T-CELLS; EXPRESSION; RECEPTOR; CHEMOKINE; REPLICATION;
   PROMOTES; STABILIZATION
AB Morphine is a widely abused, addictive drug that modulates immune function. Macrophages are a primary reservoir of HIV-1; therefore, they play a role in the development of this disease, as well as impact the overall course of disease progression. Galectin-1 is a member of a family of beta-galactoside-binding lectins that are soluble adhesion molecules and that mediate direct cell-pathogen interactions during HIV-1 viral adhesion. Because the drug abuse epidemic and the HIV-1 epidemic are closely interrelated, we propose that increased expression of galectin-1 induced by morphine may modulate HIV-1 infection of human monocyte-derived macrophages (MDMs). In this article, we show that galectin-1 gene and protein expression are potentiated by incubation with morphine. Confirming previous studies, morphine alone or galectin-1 alone enhance HIV-1 infection of MDMs. Concomitant incubation with exogenous galectin-1 and morphine potentiated HIV-1 infection of MDMs. We used a nanotechnology approach that uses gold nanorod-galectin-1 small interfering RNA complexes (nanoplexes) to inhibit gene expression for galectin-1. We found that nanoplexes silenced gene expression for galectin-1, and they reversed the effects of morphine on galectin-1 expression. Furthermore, the effects of morphine on HIV-1 infection were reduced in the presence of the nanoplex. The Journal of Immunology, 2012, 188: 3757-3765.
C1 [Reynolds, Jessica L.] SUNY Buffalo, Innovat Ctr, Div Allergy Immunol & Rheumatol, Dept Med, Buffalo, NY 14203 USA.
   [Law, Wing Cheung; Hui, Rui; Prasad, Paras N.] SUNY Buffalo, Dept Chem, Inst Lasers & Biophoton, Buffalo, NY 14260 USA.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore 639798, Singapore.
RP Reynolds, JL (reprint author), SUNY Buffalo, Innovat Ctr, Div Allergy Immunol & Rheumatol, Dept Med, 640 Ellicott St, Buffalo, NY 14203 USA.
EM jlr8@buffalo.edu
OI Mammen, Manoj/0000-0003-0343-3234; Law, Wing Cheung/0000-0003-3855-6170
FU National Institutes of Health [K01DA024577, R01AI085569, R21DA030108];
   Kaleida Health Foundation
FX This work was supported by National Institutes of Health Grants
   K01DA024577 (to J.L.R.), R01AI085569 (to S. A. S.), and R21DA030108 (to
   S. D. M.) and the Kaleida Health Foundation (to S.A.S.).
CR Almkvist J, 2002, GLYCOCONJUGATE J, V19, P575, DOI 10.1023/B:GLYC.0000014088.21242.e0
   Avdoshina V, 2010, GLIA, V58, P1630, DOI 10.1002/glia.21035
   Balkundi S, 2010, J VIS EXP, DOI [10.3791/2460, DOI 10.3791/2460]
   BARONDES SH, 1994, J BIOL CHEM, V269, P20807
   Barrionuevo P, 2007, J IMMUNOL, V178, P436, DOI 10.4049/jimmunol.178.1.436                                                      
   Beagles K, 2004, MOL PHARMACOL, V65, P437, DOI 10.1124/mol.65.2.437                                                            
   Bergamaschi A, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-31
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Brandt B, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.1
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Chang SL, 2012, J NEUROIMMUNE PHARM, V7, P332, DOI 10.1007/s11481-011-9324-1
   Chiariotti Lorenzo, 2004, Glycoconjugate Journal, V19, P441
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Elola MT, 2005, J BIOMED SCI, V12, P13, DOI 10.1007/s11373-004-8169-5
   Endharti AT, 2005, EUR J IMMUNOL, V35, P86, DOI 10.1002/eji.200425340                                                           
   Fortin JF, 1998, J VIROL, V72, P2105
   Gaskill PJ, 2009, AM J PATHOL, V175, P1148, DOI 10.2353/ajpath.2009.081067
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Gieseke F, 2010, BLOOD, V116, P3770, DOI 10.1182/blood-2010-02-270777
   Gilbert C, 2007, J VIROL, V81, P7672, DOI 10.1128/JVI.02810-06
   Guo CJ, 2002, J INVEST MED, V50, P435, DOI 10.1136/jim-50-06-03
   Hamamoto DT, 2009, ORAL DIS, V15, P27, DOI 10.1111/j.1601-0825.2008.01459.x
   Herbein G, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-33
   Ho WZ, 2003, J PHARMACOL EXP THER, V307, P1158, DOI 10.1124/jpet.103.056697
   Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/endo.138.10.5566
   Li Y, 2003, PEDIATR RES, V54, P282, DOI 10.1203/01.PDR.0000074973.83826.4C
   Liang H, 2008, AM J PATHOL, V172, P1617, DOI 10.2353/ajpath.2008.070971
   Liu Fu-Tong, 2002, Expert Opin Ther Targets, V6, P461, DOI 10.1517/14728222.6.4.461
   Mahajan SD, 2005, CLIN IMMUNOL, V115, P323, DOI 10.1016/j.clim.2005.02.004
   Mahajan SD, 2002, J IMMUNOL, V169, P3589, DOI 10.4049/jimmunol.169.7.3589                                                     
   Martin JL, 2010, AM J PATHOL, V176, P786, DOI 10.2353/ajpath.2010.090457
   Mercier S, 2008, VIROLOGY, V371, P121, DOI 10.1016/j.virol.2007.09.034
   Ouellet M, 2005, J IMMUNOL, V174, P4120, DOI 10.4049/jimmunol.174.7.4120                                                     
   PETERSON PK, 1994, J NEUROIMMUNOL, V50, P167, DOI 10.1016/0165-5728(94)90043-4
   Peterson PK, 2004, J NEUROIMMUNOL, V147, P123, DOI 10.1016/j.jneuroim.2003.10.026
   PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006
   Prasad P. N., 2004, INTRO BIOPHOTONICS
   Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P557, DOI 10.1590/S0100-879X1999000500009
   Rabinovich GA, 1999, IMMUNOLOGY, V97, P100
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Reynolds JL, 2007, BBA-PROTEINS PROTEOM, V1774, P433, DOI 10.1016/j.bbapap.2007.02.001
   Reynolds JL, 2006, AM J INFECT DIS, V2, P49, DOI 10.3844/ajidsp.2006.49.57
   Romagnani P, 2000, EUR CYTOKINE NETW, V11, P510
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X                                                   
   Romagnani S., 2000, ANN ALLERG ASTHMA IM, V85, P21
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P18
   Roth MD, 2005, J LEUKOCYTE BIOL, V78, P1198, DOI 10.1189/jlb.0405219
   SCHWEITZER C, 1991, RES VIROLOGY, V142, P189, DOI 10.1016/0923-2516(91)90056-9
   Scott Ken, 2004, Glycoconjugate Journal, V19, P467
   Secchiero P, 2000, J IMMUNOL, V164, P4018, DOI 10.4049/jimmunol.164.8.4018                                                     
   Sokolov K, 2003, CANCER RES, V63, P1999
   St-Pierre C, 2010, METHOD ENZYMOL, V480, P267, DOI 10.1016/S0076-6879(10)80013-8
   Toussi SS, 2009, AIDS RES HUM RETROV, V25, P1117, DOI 10.1089/aid.2008.0282
   Trikha S, 2011, J BIOL CHEM, V286, P36086, DOI 10.1074/jbc.M111.240762
   VanderLaan JW, 1996, INT J IMMUNOPHARMACO, V18, P401, DOI 10.1016/S0192-0561(96)00011-2
   Vojdani Z, 2010, ARCH IRAN MED, V13, P294, DOI 010134/AIM.008
NR 58
TC 8
Z9 8
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2012
VL 188
IS 8
BP 3757
EP 3765
DI 10.4049/jimmunol.1102276
PG 9
WC Immunology
SC Immunology
GA 923TD
UT WOS:000302641400022
PM 22430735
OA gold
DA 2018-01-05
ER

PT J
AU Miyauchi, K
   Urano, E
   Takizawa, M
   Ichikawa, R
   Komano, J
AF Miyauchi, Kosuke
   Urano, Emiko
   Takizawa, Mari
   Ichikawa, Reiko
   Komano, Jun
TI Therapeutic potential of HIV protease-activable CASP3
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; APOPTOSIS; GENE; TRANSDUCTION;
   ACTIVATION; REGULATOR; CASPASE-3; PR55(GAG); CELLS; FLIP
AB Development of a therapeutic application of CASP3/caspase 3/CPP32, an executor of apoptosis, has been challenging because regulation of its activation is complicated. This study aimed to inhibit cancer cell growth and human immunodeficiency virus type 1 (HIV-1) propagation through a CASP3 mutant, CASP3*, activable by HIV-1-encoded aspartate protease. Active CASP3* was delivered to leukemic cells using a protein transduction vehicle, the lentivirus-like nanoparticle (LENA), which should contain thousands of CASP3*-Gag protein molecules and release the activated CASP3* into the target cell cytoplasm. CASP3*-LENA induced apoptosis in various types of leukemic cells. In addition to being effective against leukemic cells, constitutive expression of CASP3* restricted HIV-1 propagation in SUP-T1 cells. The attenuation of HIV-1 replication in SUP-T1/CASP3* cells was attributed to the elimination of HIV-1-infected cells by apoptosis. These data suggest that CASP3* has therapeutic potential against both lymphoid malignancies and HIV-1 infection.
C1 [Miyauchi, Kosuke; Urano, Emiko; Takizawa, Mari; Ichikawa, Reiko; Komano, Jun] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan.
RP Komano, J (reprint author), Osaka Prefectural Inst Publ Hlth, Dept Infect Dis, Higashinari Ku, 3-69 Nakamachi,1 Chome, Osaka 5370025, Japan.
EM ajkomano@nih.go.jp
FU Japan Health Science Foundation; Japanese Ministry of Health, Labor, and
   Welfare [H18-AIDS-W-003]; Japanese Ministry of Education, Culture,
   Sports, Science and Technology [18689014, 18659136]
FX This work was supported by the Japan Health Science Foundation, the
   Japanese Ministry of Health, Labor, and Welfare (H18-AIDS-W-003 to JK),
   and the Japanese Ministry of Education, Culture, Sports, Science and
   Technology (18689014 and 18659136 to JK).
CR Aoki T, 2011, GENE THER, V18, P936, DOI 10.1038/gt.2011.38
   Aoki T, 2010, GENE THER, V17, P1124, DOI 10.1038/gt.2010.61
   Azran Inbal, 2004, Retrovirology, V1, P20, DOI 10.1186/1742-4690-1-20
   Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009
   Cam L, 2005, J GENE MED, V7, P30, DOI 10.1002/jgm.636
   Charoenthongtrakul S., 2011, J VIROL, V85, P6955
   Cohen GM, 1997, BIOCHEM J, V326, P1
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Komano J, 2004, MOL BIOL CELL, V15, P5197, DOI 10.1091/mbc.E04-04-0279
   Krueger A, 2006, BLOOD, V107, P3933, DOI 10.1182/blood-2005-06-2567                                                      
   Mitsuyasu RT, 2009, NAT MED, V15, P285, DOI 10.1038/nm.1932
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Okamoto K, 2006, GENES CELLS, V11, P177, DOI 10.1111/j.1365-2443.2006.00927.x
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Shimizu S, 2007, AIDS, V21, P575, DOI 10.1097/QAD.0b013e32801424a5                                                    
   Urano E, 2008, J GEN VIROL, V89, P3144, DOI 10.1099/vir.0.2008/004820-0
   Wagner R, 2000, HUM GENE THER, V11, P2403, DOI 10.1089/104303400750038507
   Walters J, 2009, BIOCHEM J, V424, P335, DOI 10.1042/BJ20090825
   Yamabe K, 1999, GENE THER, V6, P1952, DOI 10.1038/sj.gt.3301041                                                           
NR 19
TC 3
Z9 3
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 11
PY 2012
VL 2
AR 359
DI 10.1038/srep00359
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 922PC
UT WOS:000302559000002
PM 22496955
OA gold
DA 2018-01-05
ER

PT J
AU Pattani, A
   McKay, PF
   Curran, RM
   McCaffrey, J
   Gupta, PN
   Lowry, D
   Kett, VL
   Shattock, RJ
   McCarthy, HO
   Malcolm, RK
AF Pattani, Aditya
   McKay, Paul F.
   Curran, Rhonda M.
   McCaffrey, Joanne
   Gupta, Prem N.
   Lowry, Deborah
   Kett, Vicky L.
   Shattock, Robin J.
   McCarthy, Helen O.
   Malcolm, R. Karl
TI Molecular investigations into vaginal immunization with HIV gp41
   antigenic construct H4A in a quick release solid dosage form
SO VACCINE
LA English
DT Article
DE HIV; Mucosal vaccination; Vaginal vaccination; Quick release; gp41
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; FEMALE GENITAL-TRACT;
   IMMUNE-RESPONSES; MUCOSAL IMMUNIZATION; SECRETING CELLS; AIDS VACCINE;
   INFECTION; ANTIBODIES; INDUCTION; MICE
AB A robust vaginal immune response is considered essential for an effective prophylactic vaccine that prevents transmission of HIV and other sexually acquired diseases. Considerable attention has recently focused on the potential of vaginally administered vaccines as a means to induce such local immunity. However, the potential for vaccination at this site remains in doubt as the vaginal mucosa is generally considered to have low immune inductive potential. In the current study, we explored for the first time the use of a quick release, freeze-dried, solid dosage system for practical vaginal administration of a protein antigen. These solid dosage forms overcome the common problem associated with leakage and poor retention of vaginally administered antigen solutions. Mice were immunized vaginally with H4A, an HIV gp41 envelope based recombinant protein, using quick release, freeze-dried solid rods, and the immune responses compared to a control group immunized via subcutaneous H4A injection. Vaginally immunized mice failed to elicit robust immune responses. Our detailed investigations, involving cytokine analysis, the stability of H4A in mouse cervicovaginal lavage, and elucidation of the state of H4A protein in the immediate-release dosage form, revealed that antigen instability in vaginal fluid, the state of the antigen in the dosage form, and the cytokine profile induced are all likely to have contributed to the observed lack of immunogenicity. These are important factors affecting vaginal immunization and provide a rational basis for explaining the typically poor and variable elicitation of immunity at this site, despite the presence of immune responsive cells within the vaginal mucosae. In future mucosal vaccine studies, a more explicit focus on antigen stability in the dosage form and the immune potential of available antigen-responsive cells is recommended. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Pattani, Aditya; Curran, Rhonda M.; McCaffrey, Joanne; Gupta, Prem N.; Lowry, Deborah; Kett, Vicky L.; McCarthy, Helen O.; Malcolm, R. Karl] Queens Univ Belfast, Ctr Med Biol, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland.
   [McKay, Paul F.] St Georges Univ London, Div Cellular & Mol Med, Ctr Infect, London SW17 0RE, England.
   [McKay, Paul F.; Shattock, Robin J.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis, Div Med, London W2 1PG, England.
RP Malcolm, RK (reprint author), Queens Univ Belfast, Ctr Med Biol, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM k.malcolm@qub.ac.uk
RI Kett, Vicky/D-2276-2010
OI Kett, Vicky/0000-0002-6250-6053; McKay, Paul/0000-0001-5195-6254
FU European Community [201038]; EuroNeut-41; Sir Joseph Hotung Foundation
FX Funding for this work was provided by European Community's Seventh
   Framework Programme (FP7/2007-2013) under grant agreement no. 201038.
   H4A antigen was designed by Prof. Pedro Luis Mateo Alarcon, Dr.
   Francisco Conejero-Lara and Dr. Irene Lague Fernandez at the University
   of Granada, Spain. AP is supported by EuroNeut-41 and PMK is supported
   by the Sir Joseph Hotung Foundation. The authors thank Dr. Raphaelle El
   Habib, Sanofi-Pasteur (coordinator Euroeneut-41 consortium), Marie
   Gaelle Roger, PX'Therapeutics (for providing the H4A protein), Dr.
   Manish Umrethia, Mr. Stephen Lloyd and Mr. Kun-Hung Chen at QUB for
   their help.
CR Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Bernstein DI, 2000, VACCINE, V18, P1351, DOI 10.1016/S0264-410X(99)00416-8                                                   
   Black CA, 2000, J IMMUNOL, V165, P5077, DOI 10.4049/jimmunol.165.9.5077                                                     
   Brange J., 2000, PHARM FORMULATION DE, P89
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   Cranage MP, 2010, MUCOSAL IMMUNOL, V3, P57, DOI 10.1038/mi.2009.110
   Cranage MP, 2011, VACCINE, V29, P1421, DOI 10.1016/j.vaccine.2010.12.034
   CROOME RJ, 1953, J APPL CHEM, V3, P280
   Curran RM, 2009, VACCINE, V27, P6791, DOI 10.1016/j.vaccine.2009.08.088
   Donnelly L, VACCINE, V29, P4512
   Eriksson K, 1998, INFECT IMMUN, V66, P5889
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   Grant AD, 2001, BRIT MED J, V322, P1475, DOI 10.1136/bmj.322.7300.1475                                                       
   Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036
   Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kiyono H, 1995, ADV DRUG DELIVER REV, V18, P23, DOI 10.1016/0169-409X(95)00049-D
   Kohtaro F, 2005, MUCOSAL IMMUNOLOGY, P539
   Kozlowski PA, 1997, INFECT IMMUN, V65, P1387
   Lamptey P, 2002, POPUL BULL, V57, P3
   Lamptey PR, 2002, BRIT MED J, V324, P207, DOI 10.1136/bmj.324.7331.207                                                        
   LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702
   Liu XS, 2002, IMMUNOL CELL BIOL, V80, P21, DOI 10.1046/j.1440-1711.2002.01051.x                                                
   MATSUMOTO R, 1989, IMMUNOLOGY, V66, P32
   Medaglini D, 1997, VACCINE, V15, P1330, DOI 10.1016/S0264-410X(97)00026-1
   Mestecky J, 2005, VACCINE, V23, P1800, DOI 10.1016/j.vaccine.2004.11.009
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847
   Ruane TD, 2011, FRONT IMMUNOL, P2
   Russell MW, 2002, MICROBES INFECT, V4, P667, DOI 10.1016/S1286-4579(02)01585-X
   Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5
   Sonoda E, 2009, J IMMUNOL, V182, P14
   Strober W, 2005, MUCOSAL IMMUNOLOGY, V1, P583
   Telang C, 2003, PHARMACEUT RES, V20, P660, DOI 10.1023/A:1023263203188                                                         
   THAPAR MA, 1990, IMMUNOLOGY, V70, P121
   Tudor D, 2009, MUCOSAL IMMUNOL, V2, P412, DOI 10.1038/mi.2009.89
   Uehling DT, 2001, J INFECT DIS, V183, pS81, DOI 10.1086/318839                                                                  
   Umrethia M, 2010, J PHARMACEUT BIOMED, V51, P1175, DOI 10.1016/j.jpba.2009.12.004
   UNAIDS, 2010, GLOB REP UNAIDS REP
   Wang B, 1997, VACCINE, V15, P821
   Wassen L, 1996, SCAND J IMMUNOL, V44, P408, DOI 10.1046/j.1365-3083.1996.d01-320.x                                              
   Wassen L, 2005, CLIN DIAGN LAB IMMUN, V12, P447, DOI 10.1128/CDLI.12.3.447-452.2005
   Wu HY, 2000, INFECT IMMUN, V68, P5539, DOI 10.1128/IAI.68.10.5539-5545.2000
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
NR 46
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 5
PY 2012
VL 30
IS 17
BP 2778
EP 2785
DI 10.1016/j.vaccine.2012.02.004
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 928YO
UT WOS:000303028600011
PM 22361120
DA 2018-01-05
ER

PT J
AU Sankar, V
   Keerthi, LM
   Parmar, N
AF Sankar, V
   Keerthi, Madhura L.
   Parmar, Nilaykumar
TI Formation and In-vitro Evaluation of Zidovudine-Lamivudine Nanoparticles
SO INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH
LA English
DT Article
DE HIV; Nanoparticles; Emulsion Polymerization method; In vitro release;
   Stability study
AB Human immunodeficiency Virus infection and Acquired immune Deficiency Syndrome commonly referred to as HIV/AIDS which have emerged as being the most serious and challenging public health problems in the world. Zidovudine-Lamivudine nanoparticles were prepared by emulsion polymerization in a continous aqueous phase with different polymers ply(lactic-co-glycolic acid) PLGA (50:50), Poly(lactic acid) PLA, Poly (methyl methacrylate) PMMA, Methylmethacrylate-Sulfopropylmethacrylate (MMA-SPM).
   The particle size and the surface morphology results revealed that PLGA nanoparticles (NPs) were smooth spherical with a size ranging from 58-224 nm. The drug content in lyophilized PLGAs was found to be 51.67% (Zidovudine) 58.33% (Lamivudine) and no drug loss was found after storage for 1 month at room temperature. In vitro release studies revealed that the rate of drug of drug release from PLGA NPs was 95.38% in 10 h with zidovudine, and 97.37% in 10 h with lamivudine which was slower when compared to MMA-SPM, PLA and PMM NPs. The rate of drug release from MMA-SPM NPs was 64.33% in 10 h with zidovudine and 95.43% in 10 h with lamivudine. Acute toxicity studies in mice revealed that the dose administered does not induce mortality in test animal.
C1 [Sankar, V; Keerthi, Madhura L.; Parmar, Nilaykumar] PSG Coll Pharm, Dept Pharmaceut, Coimbatore 641004, Tamil Nadu, India.
RP Sankar, V (reprint author), PSG Coll Pharm, Dept Pharmaceut, Coimbatore 641004, Tamil Nadu, India.
EM sansunv@yahoo.co.in
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   Basu SK, 2008, TROP J PHARM RES, V7, P1033
   Breunig S, 2008, EUR J PHARM SCI, V68, P112
   Fatiha Challata B, 2005, BIOMATERIALS, V267, P260
   Fallouh Al Khouri, 2000, INT J PHARMACEUT, V8, P35
   Jain NK, 2001, ADV CONTROLLED NOVEL
   Kumaresh S. ?S., 2001, J CONTROL RELEASE, V70, P1
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Liu F, 1989, ACTA PHARMACOL SIN, V24, P372
   Maria Palmira Daflon Gremia O, 2008, PHARM NANOTECHNOLOGY, V2, P43
   Vyas SP, 2002, TARGETED CONTROLLED
NR 11
TC 2
Z9 2
U1 0
U2 1
PU ASSOC PHARMACEUTICAL TEACHERS INDIA
PI BANGALORE
PA AL-AMEEN COLL PHARMACY, OPP LALBACH MAIN GATE, HOSUR MAIN RD, BANGALORE,
   560 027, INDIA
SN 0019-5464
J9 INDIAN J PHARM EDUC
JI Indian J. Pharm. Educ. Res.
PD APR-JUN
PY 2012
VL 46
IS 2
BP 192
EP 196
PG 5
WC Education, Scientific Disciplines; Pharmacology & Pharmacy
SC Education & Educational Research; Pharmacology & Pharmacy
GA 018GW
UT WOS:000309649300014
DA 2018-01-05
ER

PT J
AU Arnaiz, B
   Martinez-Avila, O
   Falcon-Perez, JM
   Penades, S
AF Arnaiz, Blanca
   Martinez-Avila, Olga
   Falcon-Perez, Juan M.
   Penades, Soledad
TI Cellular Uptake of Gold Nanoparticles Bearing HIV gp120 Oligomannosides
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; HUMAN DENDRITIC CELLS; HAMSTER OVARY
   CELLS; LECTIN DC-SIGN; T-CELLS; INTRAVAGINAL INOCULATION; SELECTIVE
   RECOGNITION; TARGETING PROPERTIES; VIRAL DISSEMINATION; STRUCTURAL BASIS
AB Dendritic cells are the most potent of the professional antigen-presenting cells which display a pivotal role in the generation and regulation of adaptive immune responses against HIV-1. The migratory nature of dendritic cells is subverted by HIV-1 to gain access to lymph nodes where viral replication occurs. Dendritic cells express several calcium-dependent C-type lectin receptors including dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN), which constitute a major receptor for HIV-1. DC-SIGN recognizes N-linked high-mannose glycan clusters on HIV gp120 through multivalent and Ca2+-dependent protein carbohydrate interactions. Therefore, mimicking the cluster presentation of oligomannosides from the virus surface is a strategic approach for carbohydrate-based microbicides. We have shown that gold nanoparticles (mannoGNPs) displaying multiple copies of structural motifs (di-, tri-, tetra-, penta-, or heptaoligomanosides) of the N-linked high-mannose glycan of viral gp120 are efficient inhibitors of DC-SIGN-mediated trans-infection of human T cells. We have now prepared the corresponding fluorescent-labeled glyconanoparticles (FITC-mannoGNPs) and studied their uptake by DC-SIGN expressing Burkitt lymphoma cells (Raji DC-SIGN cell line) and monocyte-derived immature dendritic cells (iDCs) by flow cytometry and confocal laser scanning microscopy. We demonstrate that the 1.8 nm oligomannoside coated nanoparticles are endocytosed following both DC-SIGN-dependent and -independent pathways and part of them colocalize with DC-SIGN in early endosomes. The blocking and sequestration of DC-SIGN receptors by mannoGNPs could explain their ability to inhibit HIV-1 trans-infection of human T cells in vitro.
C1 [Arnaiz, Blanca; Martinez-Avila, Olga; Penades, Soledad] CIC BiomaGUNE, Lab Glyconanotechnol, Biofunct Nanomat Unit, San Sebastian 20009, Spain.
   [Arnaiz, Blanca; Martinez-Avila, Olga; Penades, Soledad] Biomed Res Networking Ctr Bioengn Biomat & Nanome, San Sebastian 20009, Spain.
   [Falcon-Perez, Juan M.] CIBERehd, Basque Fdn Sci, IKERBASQUE, Bizkaia 48160, Spain.
   [Falcon-Perez, Juan M.] CIBERehd, CIC BioGUNE, Metabol Unit, Bizkaia 48160, Spain.
RP Penades, S (reprint author), CIC BiomaGUNE, Lab Glyconanotechnol, Biofunct Nanomat Unit, P Miramon 182, San Sebastian 20009, Spain.
EM spenades@cicbiomagune.es
RI Mahapatra, Indrani/D-7506-2011; Falcon-Perez, Juan/F-5920-2011;
   biomaGUNE, CIC/J-9136-2014
OI biomaGUNE, CIC/0000-0001-7690-0660; Falcon-Perez, Juan
   M/0000-0003-3133-0670
FU Spanish Ministry of Science and Innovation [CTQ2011-27268]; EU;
   Department of Industry and Innovation of the Basque Country Government;
   EC FP6/7 Europrise Network of Excellence; AVIP; NGIN consortia; Bill and
   Melinda Gates GhRC-CAVD
FX This work was supported by the Spanish Ministry of Science and
   Innovation (grant CTQ2011-27268), the EU (grant CHAARM), and the
   Department of Industry and Innovation of the Basque Country Government
   (grant ETORTER). The reagent ARP971 GM-CSF Recombinant and gp120 from
   the HIV-1 CNS4 clone (repository reference ARP683) were obtained from
   the Programme EVA Centre for AIDS Reagents, NIBSC, UK, supported by the
   EC FP6/7 Europrise Network of Excellence, AVIP and NGIN consortia, and
   the Bill and Melinda Gates GhRC-CAVD Project and was donated by
   Invitrogen. We thank Dr. J. M. Cardenas, director of the Basque Centre
   for Transfusions and Human Tissue for the access to blood samples from
   healthy donors.
CR Adams EW, 2008, CHEMBIOCHEM, V9, P294, DOI 10.1002/cbic.200700310
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Cambi A, 2007, NANO LETT, V7, P970, DOI 10.1021/nl0700503
   Cambi A, 2009, EUR J IMMUNOL, V39, P1923, DOI 10.1002/eji.200939351
   Cavrois M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000051
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cho EC, 2011, NAT NANOTECHNOL, V6, P385, DOI [10.1038/nnano.2011.58, 10.1038/NNANO.2011.58]
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005
   Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221
   DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2
   Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179
   Espuelas S, 2008, BIOCONJUGATE CHEM, V19, P2385, DOI 10.1021/bc8002524
   Falcon-Perez JM, 2005, J CELL SCI, V118, P5243, DOI 10.1242/jcs.02633
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200
   FUCHS R, 1989, J BIOL CHEM, V264, P2212
   Garber KCA, 2010, CHEM COMMUN, V46, P6747, DOI 10.1039/c0cc00830c
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784
   Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000
   Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212
   Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Nazarian R, 2003, P NATL ACAD SCI USA, V100, P8770, DOI 10.1073/pnas.1532040100
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018
   Rieger J, 2009, BIOMACROMOLECULES, V10, P651, DOI 10.1021/bm801492c
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Shan MM, 2007, PLOS PATHOG, V3, P1637, DOI 10.1371/journal.ppat.0030169
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   SJOBACK R, 1995, SPECTROCHIM ACTA A, V51, pL7, DOI 10.1016/0584-8539(95)01421-P
   Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215
   Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482
   Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129
   Verma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Wattendorf U, 2008, LANGMUIR, V24, P11790, DOI 10.1021/la801085d
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m
   Zinchuk V, 2008, CURR PROTOC CELL BIO, DOI [10.1002/0471143030.cb0419s39, DOI 10.1002/0471143030.CB0419S39]
NR 52
TC 53
Z9 54
U1 1
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD APR
PY 2012
VL 23
IS 4
BP 814
EP 825
DI 10.1021/bc200663r
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 927BG
UT WOS:000302881300016
PM 22433013
DA 2018-01-05
ER

PT J
AU Parboosing, R
   Maguire, GEM
   Govender, P
   Kruger, HG
AF Parboosing, Raveen
   Maguire, Glenn E. M.
   Govender, Patrick
   Kruger, Hendrik G.
TI Nanotechnology and the Treatment of HIV Infection
SO VIRUSES-BASEL
LA English
DT Review
DE Nanotechnology; HIV; antiretroviral agents; nanomedicine; nanoparticles
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SOLID LIPID NANOPARTICLES; DRUG-DELIVERY
   SYSTEMS; BLOOD-BRAIN-BARRIER; SMALL-INTERFERING RNA; STERICALLY
   STABILIZED LIPOSOMES; POLY PROPYLENEIMINE DENDRIMER; BLOCK-COPOLYMER
   MICELLES; IN-VIVO EVALUATION; OF-THE-ART
AB Suboptimal adherence, toxicity, drug resistance and viral reservoirs make the lifelong treatment of HIV infection challenging. The emerging field of nanotechnology may play an important role in addressing these challenges by creating drugs that possess pharmacological advantages arising out of unique phenomena that occur at the "nano" scale. At these dimensions, particles have physicochemical properties that are distinct from those of bulk materials or single molecules or atoms. In this review, basic concepts and terms in nanotechnology are defined, and examples are provided of how nanopharmaceuticals such as nanocrystals, nanocapsules, nanoparticles, solid lipid nanoparticles, nanocarriers, micelles, liposomes and dendrimers have been investigated as potential anti-HIV therapies. Such drugs may, for example, be used to optimize the pharmacological characteristics of known antiretrovirals, deliver anti-HIV nucleic acids into infected cells or achieve targeted delivery of antivirals to the immune system, brain or latent reservoirs. Also, nanopharmaceuticals themselves may possess anti-HIV activity. However several hurdles remain, including toxicity, unwanted biological interactions and the difficulty and cost of large-scale synthesis of nanopharmaceuticals.
C1 [Parboosing, Raveen] Univ KwaZulu Natal, Natl Hlth Lab Serv, Dept Virol, Inkosi Albert Luthuli Cent Hosp, ZA-4091 Durban, South Africa.
   [Maguire, Glenn E. M.; Kruger, Hendrik G.] Univ KwaZulu Natal, Sch Chem, ZA-4001 Durban, South Africa.
   [Govender, Patrick] Univ KwaZulu Natal, Sch Biochem Genet & Microbiol, ZA-4001 Durban, South Africa.
RP Parboosing, R (reprint author), Univ KwaZulu Natal, Natl Hlth Lab Serv, Dept Virol, Inkosi Albert Luthuli Cent Hosp, 5th Floor Lab Bldg,800 Bellair Rd, ZA-4091 Durban, South Africa.
EM parboosingr@ukzn.ac.za; Maguireg@ukzn.ac.za; Govenderpt@ukzn.ac.za;
   Kruger@ukzn.ac.za
RI Maguire, Glenn/C-5591-2013; Govender, Patrick/I-6795-2012; Kruger,
   Gert/B-1687-2009
OI Maguire, Glenn/0000-0002-9135-5370; Govender,
   Patrick/0000-0002-9131-590X; Kruger, Gert/0000-0003-0606-2053;
   Parboosing, Raveen/0000-0002-5476-1011
FU Discovery Foundation; National Research Foundation [GUN 48505]; Aspen
   Pharmacare; University of KwaZulu-Natal; K-Rith; MRC (SA)
FX A Discovery Foundation Academic Fellowship Award to R. Parboosing made
   this work possible. We thank Asokaran Rajh for the illustrations in
   Figure 2. We acknowledge the support of the National Research Foundation
   (GUN 48505), Aspen Pharmacare, K-Rith, MRC (SA) and the University of
   KwaZulu-Natal.
CR Aggarwal P, 2009, ADV DRUG DELIVER REV, V61, P428, DOI 10.1016/j.addr.2009.03.009
   Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Aitken RJ, 2006, OCCUP MED-OXFORD, V56, P300, DOI 10.1093/occmed/kq1051
   Akhtar S, 2000, ADV DRUG DELIVER REV, V44, P3, DOI 10.1016/S0169-409X(00)00080-6
   Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   AZoNano, NAN DENDR PROP FUT A
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
   Bawa R, 2010, EUR J NANOMED, V3, P34, DOI 10.3884/0003.1.9
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   Bekkara-Aounallah F, 2008, ADV FUNCT MATER, V18, P3715, DOI 10.1002/adfm.200800705
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383
   Borges AR, 2010, VIROLOGY, V408, P80, DOI 10.1016/j.virol.2010.09.004
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   BRAUNWALD E, 2001, HARRISONS PRINCIPLES
   Brown MD, 2001, INT J PHARM, V229, P1, DOI 10.1016/S0378-5173(01)00861-4
   Buchanan CM, 2008, BIOMACROMOLECULES, V9, P305, DOI 10.1021/bm700827h
   Buhro WE, 2003, NAT MATER, V2, P138, DOI 10.1038/nmat844                                                                 
   Caron J, 2010, BIOORG MED CHEM LETT, V20, P2761, DOI 10.1016/j.bmcl.2010.03.070
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, NANOMED-NANOTECHNOL, V7, P624, DOI 10.1016/j.nano.2011.01.017
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, CURR HIV RES, V8, P223, DOI 10.2174/157016210791111142
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Chrai S.S., 2002, PHARM TECH, V26, P28
   Chrastina A, 2011, WIRES NANOMED NANOBI, V3, P421, DOI 10.1002/wnan.143
   Clarke J.R., 2000, AIDS REV, V2, P15
   Clayton R, 2009, ANTIVIR RES, V84, P142, DOI 10.1016/j.antiviral.2009.08.003
   Clayton R, 2011, BIOCONJUGATE CHEM, V22, P2186, DOI 10.1021/bc200331v
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   Crowe SM, 2006, CURR OPIN HIV AIDS, V1, P129, DOI 10.1097/01.COH.0000209583.89952.9d
   Croy SR, 2006, CURR PHARM DESIGN, V12, P4669, DOI 10.2174/138161206779026245
   Dahl V, 2010, ANTIVIR RES, V85, P286, DOI 10.1016/j.antiviral.2009.09.016
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   de Martimprey H, 2009, EUR J PHARM BIOPHARM, V71, P490, DOI 10.1016/j.ejpb.2008.09.024
   Pereira de Oliveira M., 2005, PHARM RES, V22, P1898, DOI DOI 10.1007/S11095-005-7147-6
   Desmaele D., 2012, J CONTR REL IN PRESS, DOI [10.1016/j.jconrel.2011.1007.1038, DOI 10.1016/J.JCONREL.2011.1007.1038]
   DESORMEAUX A, 1994, AIDS, V8, P1545, DOI 10.1097/00002030-199411000-00005                                                
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dinauer N, 2004, J CONTROL RELEASE, V96, P497, DOI 10.1016/j.jconrel.02.020
   Dorman N, 2001, HIV Med, V2, P114, DOI 10.1046/j.1468-1293.2001.00052.x
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Duzgunes N, 2001, NUCLEOS NUCLEOT NUCL, V20, P515, DOI 10.1081/NCN-100002327
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   [Anonymous], 1 INT WORKSH NAN 201
   Farokhzad OC, 2008, EXPERT OPIN DRUG DEL, V5, P927, DOI [10.1517/17425240802370043, 10.1517/17425247.5.9.927 ]
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fattal E, 2009, BRIT J PHARMACOL, V157, P179, DOI 10.1111/j.1476-5381.2009.00148.x
   Fattal E, 2008, INT J PHARMACEUT, V364, P237, DOI 10.1016/j.ijpharm.2008.06.011
   Feinberg MB, 1996, LANCET, V348, P239, DOI 10.1016/S0140-6736(96)06231-9
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Fields B., 2007, FIELDS VIROLOGY
   Fischer HC, 2007, CURR OPIN BIOTECH, V18, P565, DOI 10.1016/j.copbio.2007.11.008
   FLASHER D, 1994, BBA-BIOMEMBRANES, V1194, P185, DOI 10.1016/0005-2736(94)90219-4                                                    
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Fu AH, 2007, NANO LETT, V7, P179, DOI 10.1021/nl0626434
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Garg M, 2007, AAPS PHARMSCITECH, V8
   Goldberg M, 2007, J BIOMAT SCI-POLYM E, V18, P241, DOI 10.1163/156856207779996931
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Han SQ, 2010, CARBOHYD POLYM, V80, P1111, DOI 10.1016/j.carbpol.2010.01.031
   Harvie P, 1996, ANTIMICROB AGENTS CH, V40, P225
   HARVIE P, 1995, AIDS, V9, P701, DOI 10.1097/00002030-199507000-00006
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Heiati H, 1997, INT J PHARM, V146, P123, DOI 10.1016/S0378-5173(96)04782-5
   Heiati H, 1998, INT J PHARM, V174, P71, DOI 10.1016/S0378-5173(98)00236-1
   Hillaireau H, 2006, INT J PHARM, V324, P37, DOI 10.1016/j.ijpharm.2006.07.006
   Hillaireau H, 2006, J CONTROL RELEASE, V116, P346, DOI 10.1016/j.jconrel.2006.09.016
   Howard KA, 2009, ADV DRUG DELIVER REV, V61, P710, DOI 10.1016/j.addr.2009.04.001
   Hughes MD, 2001, DRUG DISCOV TODAY, V6, P303, DOI 10.1016/S1359-6446(00)00326-3
   Jaaskelainen I, 2002, MINI-REV MED CHEM, V2, P307, DOI 10.2174/1389557023405891
   Jabr-Milane L, 2008, J CONTROL RELEASE, V130, P121, DOI 10.1016/j.jconrel.2008.04.016
   Jain Subheet, 2008, Current Drug Delivery, V5, P275, DOI 10.2174/156720108785915078
   Juliano R, 2009, MOL PHARMACEUT, V6, P686, DOI 10.1021/mp900093r
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kayser O, 2005, CURR PHARM BIOTECHNO, V6, P3
   Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294                                                      
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kinman L, 2006, JAIDS-J ACQ IMM DEF, V42, P155, DOI 10.1097/01.qai.0000214822.33905.87                                              
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Kiser JJ, 2008, CURR OPIN HIV AIDS, V3, P330, DOI 10.1097/COH.0b013e3282fbaa6b
   Konopka K, 1998, BBA-BIOMEMBRANES, V1372, P55, DOI 10.1016/S0005-2736(98)00046-7
   Koo OM, 2005, NANOMED-NANOTECHNOL, V1, P193, DOI 10.1016/j.nano.2005.06.004
   Kovochich M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018270
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   Kroto H.W., 2010, ENCY BRITANNICA DELU
   Kuo YC, 2008, INT J PHARM, V351, P271, DOI 10.1016/j.ijpharm.2007.09.020
   Kuo YC, 2007, INT J PHARM, V340, P143, DOI 10.1016/j.ijpharm.2007.03.012
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Kwon GS, 2006, DRUG DEVELOP RES, V67, P15, DOI 10.1002/ddr.20063
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lines MG, 2008, J ALLOY COMPD, V449, P242, DOI 10.1016/j.jallcom.2006.02.082
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   Lu MG, 2010, ACS NANO, V4, P6303, DOI 10.1021/nn1018818
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Ma Xiaowei, 2010, AAPS J, V12, P272, DOI 10.1208/s12248-010-9187-z
   Macri RV, 2009, BIOORGAN MED CHEM, V17, P3162, DOI 10.1016/j.bmc.2009.02.055
   Mahajan S.D., 2011, PATHOLOG RES INT, V2011
   Mainardes RM, 2009, J PHARM SCI-US, V98, P257, DOI 10.1002/jps.21406
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Marsden MD, 2009, J ANTIMICROB CHEMOTH, V63, P7, DOI 10.1093/jac/dkn455
   Mason TG, 2006, J PHYS-CONDENS MAT, V18, pR635, DOI 10.1088/0953-8984/18/41/R01
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   McNeil SE, 2011, METHODS MOL BIOL, V697, P3, DOI 10.1007/978-1-60327-198-1_1
   Medepalli K.K., 2008, ADV NANOMATERIALS BI
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074
   Muller RH, 2011, EUR J PHARM BIOPHARM, V78, P1, DOI 10.1016/j.ejpb.2011.01.007
   Muthu MS, 2009, NANOMEDICINE-UK, V4, P105, DOI 10.2217/17435889.4.1.105
   Nie SM, 2010, NANOMEDICINE-UK, V5, P523, DOI 10.2217/NNM.10.23
   Niemeyer C. M., 2004, NANOBIOTECHNOLOGY CO
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Ochekpe NA, 2009, TROP J PHARM RES, V8, P275
   Ochekpe NA, 2009, TROP J PHARM RES, V8, P265
   Ojewole E, 2008, EUR J PHARM BIOPHARM, V70, P697, DOI 10.1016/j.ejpb.2008.06.020
   Ozpolat B, 2010, J INTERN MED, V267, P44, DOI 10.1111/j.1365-2796.2009.02191.x
   Palmer S, 2011, J INTERN MED, V270, P550, DOI 10.1111/j.1365-2796.2011.02457.x
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Picraux T., 2010, ENCY BRITANNICA DELU
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Pomerantz RJ, 2003, HIV CLIN TRIALS, V4, P137, DOI 10.1310/80JH-148K-NADQ-U927
   Pozniak AL, 2010, AIDS, V24, P55, DOI 10.1097/QAD.0b013e32833032ed
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Reyes-Darias JA, 2008, CURR HIV RES, V6, P500, DOI 10.2174/157016208786501454
   Sanhai WR, 2008, NAT NANOTECHNOL, V3, P242, DOI 10.1038/nnano.2008.114
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Sarin H, 2010, J ANGIOGENES RES, V2, P1
   Sathigari S, 2009, AAPS PHARMSCITECH, V10, P81, DOI 10.1208/s12249-008-9180-3
   Schrijvers R, 2011, LANCET, V378, P201, DOI 10.1016/S0140-6736(11)60992-6
   Schulz MJ, 2009, ENG MED BIOL, P1
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Singha Kaushik, 2011, Oligonucleotides, V21, P133, DOI 10.1089/nat.2011.0293
   Sonza S, 2001, AIDS PATIENT CARE ST, V15, P511, DOI 10.1089/108729101753205676                                                      
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Spitzenberger TJ, 2007, J CEREBR BLOOD F MET, V27, P1033, DOI 10.1038/sj.jcbfm.9600414
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tabarani G, 2006, FEBS LETT, V580, P2402, DOI 10.1016/j.febslet.2006.03.061
   Tegart G., 2001, P 2 INT C TECHN FOR
   Torchilin V.P., 2006, NANOPARTICULATES DRU, p[xxix, 724]
   United States National Nanotechnology Initiative, NAN 101 WHAT IS IT I
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z                          
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wan Li, 2006, AIDS Res Ther, V3, P12, DOI 10.1186/1742-6405-3-12
   Wang W, 2006, CHEM BIOL DRUG DES, V68, P314, DOI 10.1111/j.1747-0285.2006.00454.x
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Williams D, 2008, BIOMATERIALS, V29, P1737, DOI 10.1016/j.biomaterials.2008.01.003
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   WU HB, 2007, ACTA PHARM SIN, V42, P538
   Yang DW, 1996, ANTIVIR RES, V31, P95, DOI 10.1016/0166-3542(96)00957-6                                                    
   Zhang JX, 2009, RECENT PAT NANOTECH, V3, P225, DOI 10.2174/187221009789177803
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   Schinazi R.F., 2001, US Patent App., Patent No. [20,030/036,562, 20030036562]
NR 189
TC 37
Z9 37
U1 6
U2 64
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD APR
PY 2012
VL 4
IS 4
BP 488
EP 520
DI 10.3390/v4040488
PG 33
WC Virology
SC Virology
GA 932AL
UT WOS:000303261200004
PM 22590683
OA gold
DA 2018-01-05
ER

PT J
AU Peng, YP
   Wu, JL
   Wang, JH
   Li, WM
   Yu, SJ
AF Peng, Yunping
   Wu, Junlin
   Wang, Jihua
   Li, Wenmei
   Yu, Shujuan
TI Study and evaluation of Wondfo rapid diagnostic kit based on nano-gold
   immunochromatography assay for diagnosis of Plasmodium falciparum
SO PARASITOLOGY RESEARCH
LA English
DT Article
ID MALARIA; MICROSCOPY; PCR
AB Malaria has been recognized as a human disease for thousands of years and remains one of the most common diseases affecting humans worldwide. Therefore, a method for rapidly detecting Plasmodium falciparum is necessary and useful. We have developed Wondfo rapid diagnostic kit based on nano-gold immunochromatography assay for the detection of P. falciparum in patient specimen. In the present study, we demonstrated the sensitivity and specificity of the rapid diagnostic kit in which nano-gold labeling techniques and the monoclonal antibodies against histidine-rich protein-2 of P. falciparum were used to establish two-antibody sandwich immunochromatographic assay for detecting P. falciparum. By using microscopic examination of blood smears as control, the sensitivity, specificity, and feasibility of Wondfo rapid diagnostic kit was determined in the prompt and accurate diagnosis of malaria. In this study, 1,558 blood samples were collected from outpatient clinics in China and detected by both Wondfo kit and microscopic examination. The Wondfo kit did not show cross-reaction with microfilaria, Toxoplasma gondii, and other parasites in the blood. The patient samples positive for rheumatoid factor, HIV, tuberculosis, and syphilis did not show false positivity when testing with Wondfo kit. The detection sensitivity and specificity of Wondfo rapid diagnostic kit were 95.49% and 99.53%, respectively. These results indicate that our rapid diagnostic assay may be useful for detecting P. falciparum in patient specimen.
C1 [Wu, Junlin] Guangdong Inst Microbiol, Guangzhou 510070, Guangdong, Peoples R China.
   [Peng, Yunping; Li, Wenmei; Yu, Shujuan] S China Univ Technol, Sch Food & Bioengn, Guangzhou 510006, Guangdong, Peoples R China.
   [Peng, Yunping; Wang, Jihua; Li, Wenmei] Guangzhou Wondfo Biotech Co Ltd, Guangzhou 510643, Guangdong, Peoples R China.
RP Wu, JL (reprint author), Guangdong Inst Microbiol, Guangzhou 510070, Guangdong, Peoples R China.
EM microwjl@yahoo.com
CR Ashley EA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-241
   Hanscheid T, 2002, TRENDS PARASITOL, V18, P395, DOI 10.1016/S1471-4922(02)02348-6
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   Huang SH, 2006, CLIN CHIM ACTA, V373, P139, DOI 10.1016/j.cca.2006.05.026
   Mboera LEG, 2006, ANN TROP MED PARASIT, V100, P115, DOI 10.1179/136485906X78571
   Murray CK, 2009, INTERDISCIP PERSPECT, V1
   Nicastri E, 2009, AM J TROP MED HYG, V80, P712
   Reyburn H., 2004, BMJ-BRIT MED J, V329, P2121, DOI [10.1136/ bmj.38251.658229.55, DOI 10.1136/BMJ.38251.658229.55]
   WHO, 2010, MAL RAP DIAGN TEST P
   [Anonymous], 2010, WHO GUID TREATM MAL
   Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119
   Wu Ying-song, 2005, Di Yi Jun Yi Da Xue Xue Bao, V25, P761
NR 12
TC 9
Z9 11
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
J9 PARASITOL RES
JI Parasitol. Res.
PD APR
PY 2012
VL 110
IS 4
BP 1421
EP 1425
DI 10.1007/s00436-011-2643-6
PG 5
WC Parasitology
SC Parasitology
GA 926EQ
UT WOS:000302814500013
PM 21922236
DA 2018-01-05
ER

PT J
AU Svensen, N
   Walton, JGA
   Bradley, M
AF Svensen, Nina
   Walton, Jeffrey G. A.
   Bradley, Mark
TI Peptides for cell-selective drug delivery
SO TRENDS IN PHARMACOLOGICAL SCIENCES
LA English
DT Review
ID HUMAN IMMUNODEFICIENCY VIRUS; ADVANCED SOLID TUMORS; VIVO PHAGE DISPLAY;
   IN-VIVO; PENETRATING PEPTIDE; PHASE-II; ENDOTHELIAL-CELLS; HOMING
   PEPTIDE; PHENOTYPIC HETEROGENEITY; GLIOBLASTOMA-MULTIFORME
AB The ability to target specific cell types to achieve optimal distribution of therapeutic entities into diseased tissues, while limiting possible adverse off-target effects, has long been a goal of many research groups and pharmaceutical organizations. This review focuses on peptidic tissue-specific biomarkers that allow peptides to act as homing devices for specific tissue types or organs, with a focus on homing peptides (HPs) and cell-penetrating homing peptides (CPHPs). These HPs, in addition to promoting cellular uptake, can deliver a variety of cargos (drugs, oligonucleotides and nanoparticles) into cells. Two such peptides that have entered clinical trials are the tumor-homing peptide asparagine-glycine-arginine (NGR) (fused to human tumor necrosis factor), which selectively binds CD13, an aminopeptidase that is overexpressed on tumor blood vessels, and cyclo[Arg-Gly-Asp-D-Phe-(NMeVal)] (cRGD, cilengitide), an anti-angiogenic agent that targets the alpha(v)beta(3) and alpha(v)beta(5) integrins.
C1 [Svensen, Nina; Walton, Jeffrey G. A.; Bradley, Mark] Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland.
RP Bradley, M (reprint author), Univ Edinburgh, Sch Chem, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.
EM mark.bradley@ed.ac.uk
CR Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Ali M, 2011, NUCL MED BIOL, V38, P751, DOI 10.1016/j.nucmedbio.2011.01.007
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998
   Burg MA, 1999, CANCER RES, V59, P2869
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   Cho C. H., 2011, Homing peptide for tumor vasculature, Patent No. [WO/2011/011976, 2011011976]
   Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132
   DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   Eskens FALM, 2003, EUR J CANCER, V39, P917, DOI 10.1016/S0959-8049(03)00057-1
   Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998
   Fink K., 2010, ASCO ANN M
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gelain F, 2011, ACS NANO, V5, P1845, DOI 10.1021/nn102663a
   Gerlag DM, 2001, ARTHRITIS RES, V3, P357, DOI 10.1186/ar327                                                                   
   Gilbert MR, 2012, J NEURO-ONCOL, V106, P147, DOI 10.1007/s11060-011-0650-1
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gregorc V, 2009, BRIT J CANCER, V101, P219, DOI 10.1038/sj.bjc.6605162
   Gregorc V, 2010, J CLIN ONCOL, V28, P2604, DOI 10.1200/JCO.2009.27.3649
   Gregorc V, 2010, EUR J CANCER, V46, P198, DOI 10.1016/j.ejca.2009.10.005
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Haubner R., 1997, ANGEW CHEM INT EDIT, V36, P1374
   Hoffinan J. A., 2004, PHAGE DISPLAY PRACTI, P171
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Jhoti H, 2007, STRUCTURE BASED DRUG
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kim Y, 2006, BIOCHEMISTRY-US, V45, P9434, DOI 10.1021/bi060264j
   Krogsgaard-Larsen P., 2002, TXB DRUG DESIGN DISC
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Laakkonen P, 2010, INTEGR BIOL-UK, V2, P326, DOI 10.1039/c0ib00013b
   Liu Y, 2007, MOL PHARM, V4, P435, DOI 10.1021/mp060122j
   MacDonald TJ, 2008, J CLIN ONCOL, V26, P919, DOI 10.1200/JCO.2007.14.1812
   Mae M, 2009, INT J PEPT RES THER, V15, P11, DOI 10.1007/s10989-008-9156-x
   Manish G, 2011, RES J CHEM SCI, V1, P135
   Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84
   Martin Irene, 2010, Pharmaceuticals (Basel), V3, P1456
   Mi ZB, 2003, MOL THER, V8, P295, DOI 10.1016/S1525-016(03)00181-3
   Mier W, 2003, ANGEW CHEM INT EDIT, V42, P1968, DOI 10.1002/anie.200219978
   Myrberg H, 2008, BIOCONJUGATE CHEM, V19, P70, DOI 10.1021/bc0701139
   Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651                                                                   
   Pasqualini R, 2000, CANCER RES, V60, P722
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   Pi YB, 2011, BIOMATERIALS, V32, P6324, DOI 10.1016/j.biomaterials.2011.05.017
   Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599
   Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008
   Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593                                                        
   Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder EL, 2005, CANCER RES, V65, P10646, DOI 10.1158/0008-5472.CAN-05-0118
   Stupp R, 2007, J CLIN ONCOL, V25, P1459, DOI 10.1200/JCO.2006.09.7139
   Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057
   Svensen N, 2011, CHEM BIOL, V18, P1284, DOI 10.1016/j.chembiol.2011.07.017
   Svensen N, 2011, ANGEW CHEM INT EDIT, V50, P6133, DOI 10.1002/anie.201101804
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Trabulo Sara, 2010, Pharmaceuticals (Basel), V3, P961
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wang B, 2005, WILEY SER DRUG DISC, P1, DOI 10.1002/0471475734
   Wong ET, 1999, J CLIN ONCOL, V17, P2572, DOI 10.1200/JCO.1999.17.8.2572                                                      
   Yoneda Y., 2008, BIOORG MED CHEM LETT, P1632
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316                                                          
   Zhang LL, 2006, CANCER RES, V66, P5696, DOI 10.1158/0008-5472.CAN-05-3876
   Zhang LL, 2005, CIRCULATION, V112, P1601, DOI 10.1161/CIRCULATIONAHA.104.529537
   Zhou NM, 2002, J BIOL CHEM, V277, P17476, DOI 10.1074/jbc.M202063200
NR 70
TC 100
Z9 107
U1 3
U2 117
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0165-6147
J9 TRENDS PHARMACOL SCI
JI Trends Pharmacol. Sci.
PD APR
PY 2012
VL 33
IS 4
BP 186
EP 192
DI 10.1016/j.tips.2012.02.002
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 929XW
UT WOS:000303100000003
PM 22424670
DA 2018-01-05
ER

PT J
AU Jimenez-Mancilla, N
   Ferro-Flores, G
   Ocampo-Garcia, B
   Luna-Gutierrez, M
   Ramirez, FD
   Pedraza-Lopez, M
   Torres-Garcia, E
AF Jimenez-Mancilla, Nallely
   Ferro-Flores, Guillermina
   Ocampo-Garcia, Blanca
   Luna-Gutierrez, Myrna
   De Maria Ramirez, Flor
   Pedraza-Lopez, Martha
   Torres-Garcia, Eugenio
TI Multifunctional Targeted Radiotherapy System for Induced Tumours
   Expressing Gastrin-releasing Peptide Receptors
SO CURRENT NANOSCIENCE
LA English
DT Article
DE Lu-177-gold nanoparticles; radiolabelled gold nanoparticles;
   radiolabelled Lys(3)-bombesin-Tat(49-57); targeted radiotherapy;
   Tc-99m-gold nanoparticles
ID TC-99M-LABELED GOLD NANOPARTICLES; RADIONUCLIDE THERAPY; THERMAL
   THERAPY; TAT PEPTIDE; DOSIMETRY; MICE; CONJUGATION; BIOKINETICS;
   NUCLEUS; CELLS
AB The gastrin-releasing peptide receptor (GRP-r) is overexpressed in breast and prostate cancer, and Lys(3)-bombesin is a peptide that binds with high affinity to the GRP-r. HIV Tat(49-57) is a cell-penetrating peptide that reaches the DNA. In cancer cells, Lu-177 shows efficient cross-fire effect, while Tc-99m that is internalised to cancer cell nuclei acts as an effective system of targeted radiotherapy because of the Auger and IC electron emissions near the DNA. The aim of this research was to prepare a multifunctional system of Lu-177-and Tc-99m-labelled gold nanoparticles (AuNPs) that were conjugated to Tat(49-57)-Lys(3)-bombesin (Tat-BN) and to evaluate the radiation absorbed dose to GRP receptor-positive PC3 tumours that were induced in mice. Cys-Gly-Cys-Tat-BN (CGC-Tat-BN), 1,4,7,10-tetraazacyclododecane-N,N',N '',N'''-tetraacetic-Gly-Gly-Cys (DOTA-GGC) and hydrazinonicotinyl-Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr-(ol) (HYNIC-TOC) peptides were conjugated to AuNPs to prepare a multifunctional system by means of a spontaneous reaction of the thiol groups of cysteine. TEM, UV-Vis, XPS and Far-IR spectroscopy techniques demonstrated that AuNPs were functionalised with peptides through interactions with the -SH groups. The Tc-99m labelling was performed via the HYNIC-TOC ligand, and the Lu-177 labelling was performed through DOTA-GGC. The radiochemical purity was 96 +/- 2%. The Lu-177-absorbed dose per injected activity that was delivered to the PC3 tumours was 7.9 Gy/MBq, and the Tc-99m-absorbed dose that was delivered to the nuclei was 0.53 Gy/MBq. The Lu-177/Tc-99m-AuNP-Tat-BN system showed properties suitable for a targeted radionuclide therapy of tumours expressing GRP receptors due to the energy deposition from beta-emissions and the Auger and IC electron emissions near the DNA.
C1 [Ferro-Flores, Guillermina] Inst Nacl Invest Nucl, Dept Mat Radiactivos, Ocoyoacac 52750, Estado De Mexic, Mexico.
   [Jimenez-Mancilla, Nallely; Luna-Gutierrez, Myrna; Torres-Garcia, Eugenio] Univ Autonoma Estado Mexico, Mexico City, DF, Mexico.
   [Pedraza-Lopez, Martha] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
RP Ferro-Flores, G (reprint author), Inst Nacl Invest Nucl, Dept Mat Radiactivos, Carretera Mexico Toluca S-N, Ocoyoacac 52750, Estado De Mexic, Mexico.
EM ferro_flores@yahoo.com.mx
RI Torres-Garcia, Eugenio/B-3234-2016
OI Torres-Garcia, Eugenio/0000-0001-8355-3927; Ocampo-Garcia, Blanca
   E./0000-0002-5831-8412; FERRO-FLORES, GUILLERMINA/0000-0003-0296-7605;
   Luna-Gutierrez, Myrna Alejandra/0000-0002-4082-3816; Jimenez-Mancilla,
   Nallely Patricia/0000-0001-9480-4621
FU Mexican National Council of Science and Technology
   [CONACYT-SEP-CB-2010-01-150942]
FX This study was supported by the Mexican National Council of Science and
   Technology (CONACYT-SEP-CB-2010-01-150942). There are no conflicts of
   interest.
CR Bakker WH, 2006, Q J NUCL MED MOL IM, V50, P265
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Buchegger F, 2006, EUR J NUCL MED MOL I, V33, P1352, DOI 10.1007/s00259-006-0187-2
   Chanda N, 2010, P NATL ACAD SCI USA, V107, P8760, DOI 10.1073/pnas.1002143107
   Cornelissen B, 2008, NUCL MED BIOL, V35, P101, DOI 10.1016/j.nucmedbio.2007.09.007
   Costantini DL, 2008, CANCER BIOTHER RADIO, V23, P3, DOI 10.1089/cbr.2007.0430
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Elbialy N, 2010, J BIOMED NANOTECHNOL, V6, P687, DOI 10.1166/jbn.2010.1166
   Elfeky SA, 2011, CURR NANOSCI, V7, P1028
   Ferro-Flores G, 2006, NUCL MED COMMUN, V27, P371, DOI 10.1097/01.mnm.0000202863.52046.7f                                              
   Ferro-Flores G, 2010, APPL RADIAT ISOTOPES, V68, P2274, DOI 10.1016/j.apradiso.2010.06.014
   Ferro-Flores G, 2008, ADV DRUG DELIVER REV, V60, P1389, DOI 10.1016/j.addr.2008.04.008
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Huang X, 2007, LASER SURG MED, V39, P747, DOI 10.1002/lsm.20577
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Jadzinsky PD, 2007, SCIENCE, V318, P430, DOI 10.1126/science.1148624
   Kato HS, 2002, J PHYS CHEM B, V106, P9655, DOI 10.1021/jp020968c
   Kogan MJ, 2007, NANOMEDICINE-UK, V2, P287, DOI 10.2217/17435889.2.3.287
   Levy R, 2004, J AM CHEM SOC, V126, P10076, DOI 10.1021/ja0487269
   Mendoza-Sanchez AN, 2010, J BIOMED NANOTECHNOL, V6, P375, DOI 10.1166/jbn.2010.1132
   Miller WH, 2005, CANCER BIOTHER RADIO, V20, P436, DOI 10.1089/cbr.2005.20.436                                                         
   Morales-Avila E, 2011, BIOCONJUGATE CHEM, V22, P913, DOI 10.1021/bc100551s
   Ocampo-Garcia B, 2011, NUCL MED COMMUN, V32, P1095, DOI 10.1097/MNM.0b013e32834acf33
   Ocampo-Garcia BE, 2011, NUCL MED BIOL, V38, P1, DOI 10.1016/j.nucmedbio.2010.07.007
   Olmedo I, 2008, BIOCONJUGATE CHEM, V19, P1154, DOI 10.1021/bc800016y
   Panigone S, 2006, Q J NUCL MED MOL IM, V50, P310
   Petroski J, 2009, J ORGANOMET CHEM, V694, P1138, DOI 10.1016/j.jorganchem.2008.11.057
   Porta F, 2007, MAT SCI ENG B-SOLID, V140, P187, DOI 10.1016/j.mseb.2007.03.019
   Pujatti PB, 2011, Q J NUCL MED MOL IM, V55, P310
   Rodriguez-Cortes J, 2007, RADIAT EFF DEFECT S, V162, P791, DOI 10.1080/10420150701482568
   Santos-Cuevas CL, 2008, NUCL MED COMMUN, V29, P741, DOI 10.1097/MNM.0b013e3282ffb45c
   Santos-Cuevas CL, 2011, NUCL MED COMMUN, V32, P303, DOI 10.1097/MNM.0b013e328341b27f
   Santos-Cuevas CL, 2009, INT J PHARMACEUT, V375, P75, DOI 10.1016/j.ijpharm.2009.04.018
   Surujpaul PP, 2008, BIOPHYS CHEM, V138, P83, DOI 10.1016/j.bpc.2008.09.005
   Tavares AAS, 2010, MED PHYS, V37, P3551, DOI 10.1118/1.3451117
   Wang H, 2011, CURR NANOSCI, V7, P874, DOI 10.2174/157341311798220682                                                      
NR 36
TC 6
Z9 6
U1 2
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
J9 CURR NANOSCI
JI Curr. Nanosci.
PD APR
PY 2012
VL 8
IS 2
BP 193
EP 201
DI 10.2174/157341312800167678                                              
          
PG 9
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 925RQ
UT WOS:000302779300002
DA 2018-01-05
ER

PT J
AU Xu, LG
   Liu, Y
   Chen, ZY
   Li, W
   Liu, Y
   Wang, LM
   Liu, Y
   Wu, XC
   Ji, YL
   Zhao, YL
   Ma, LY
   Shao, YM
   Chen, CY
AF Xu, Ligeng
   Liu, Ye
   Chen, Zhiyun
   Li, Wei
   Liu, Ying
   Wang, Liming
   Liu, Yong
   Wu, Xiaochun
   Ji, Yinglu
   Zhao, Yuliang
   Ma, Liying
   Shao, Yiming
   Chen, Chunying
TI Surface-Engineered Gold Nanorods: Promising DNA Vaccine Adjuvant for
   HIV-1 Treatment
SO NANO LETTERS
LA English
DT Article
DE Gold nanorod; surface chemistry; adjuvant; DNA vaccine; HIV-1
ID POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES; AT-PT NANOSTRUCTURES; GENE
   DELIVERY; CELLULAR-IMMUNITY; DENDRITIC CELLS; INDUCTION; RESPONSES;
   CYTOTOXICITY; IMMUNIZATION; COMBINATION
AB With the intense international response to the AIDS pandemic, HIV vaccines have been extensively investigated but have failed due to issues of safety or efficacy in humans. Adjuvants for HIV/AIDS vaccines are under intense research but a rational design approach is still lacking. Nanomaterials represent an obvious opportunity in this field due to their unique physicochemical properties. Gold nanostructures are being actively studied as a promising and versatile platform for biomedical application. Herein, we report novel surface-engineered gold nanorods (NRs) used as promising DNA vaccine adjuvant for HIV treatment. We have exploited the effects of surface chemistry on the adjuvant activity of the gold nanorod by placing three kinds of molecules, that is, cetyltrimethylammonium bromide (CTAB), poly(diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) on the surface of the nanorod. These PDDAC- or PEI-modified Au NRs can significantly promote cellular and humoral immunity as well as T cell proliferation through activating antigen-presenting cells if compared to naked HIV-1 Env plasmid DNA treatment in vivo. These findings have shed light on the rational design of low-toxic nanomaterials as a versatile platform for vaccine nanoadjuvants/delivery systems.
C1 [Wu, Xiaochun; Ji, Yinglu] Natl Ctr Nanosci & Technol China, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing 100190, Peoples R China.
   [Xu, Ligeng; Chen, Zhiyun; Liu, Ying; Wang, Liming; Zhao, Yuliang; Chen, Chunying] Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
   [Liu, Ye; Liu, Yong; Ma, Liying; Shao, Yiming] Natl Ctr AIDS STD Control & Prevent China CDC, Beijing 102206, Peoples R China.
   [Li, Wei; Wang, Liming; Zhao, Yuliang] Chinese Acad Sci, Inst High Energy Phys, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100049, Peoples R China.
RP Wu, XC (reprint author), Natl Ctr Nanosci & Technol China, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing 100190, Peoples R China.
EM wuxc@nanoctr.cn; chenchy@nanoctr.cn
RI Wang, Liming/A-6924-2012; Xu, Ligeng/F-9844-2013
OI Wang, Liming/0000-0003-1382-9195; Xu, Ligeng/0000-0003-4946-2567
FU Ministry of Science and Technology of China [2011CB933401, 2011CB932802,
   2010CB93404]; Natural Science Foundation of China [31070854]; Major
   National ST Program [2012ZX10001-008]; Chinese Academy of Sciences
FX The authors acknowledge the financial support by the Ministry of Science
   and Technology of China as the National Basic Research Programs
   (2011CB933401, 2011CB932802, and 2010CB93404), the Natural Science
   Foundation of China (31070854), the Major National S&T Program
   (2012ZX10001-008), and the Knowledge Innovation Program of the Chinese
   Academy of Sciences. The authors are indebted to Dr. Ann Motten,
   NIEHS/NIH, for critical reading of the manuscript.
CR Borges O, 2008, EUR J PHARM BIOPHARM, V69, P405, DOI 10.1016/j.ejpb.2008.01.019
   Brownlie A, 2004, INT J PHARM, V274, P41, DOI 10.1016/j.ijpharm.2003.12.029
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Carney RP, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1338
   Chakravarthy KV, 2010, P NATL ACAD SCI USA, V107, P10172, DOI 10.1073/pnas.0914561107
   Chen CC, 2006, J AM CHEM SOC, V128, P3709, DOI 10.1021/ja0570180
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Diwan Manish, 2004, Current Drug Delivery, V1, P405, DOI 10.2174/1567201043334597
   Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633                                                      
   EDELMAN R, 1992, AIDS RES HUM RETROV, V8, P1409
   Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000
   Feng LL, 2008, CHEM-EUR J, V14, P9764, DOI 10.1002/chem.200800544
   Florindo HF, 2009, BIOMATERIALS, V30, P879, DOI 10.1016/j.biomaterials.2008.10.035
   Gao YX, 2007, J ANAL ATOM SPECTROM, V22, P856, DOI 10.1039/b703323k
   Garzon MR, 2005, VACCINE, V23, P1384, DOI 10.1016/j.vaccine.2004.09.009
   Ge CC, 2011, P NATL ACAD SCI USA, V108, P16968, DOI 10.1073/pnas.1105270108
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   Guo R., 2010, LANGMUIR, V26, P5423
   Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7
   He WW, 2011, BIOMATERIALS, V32, P1139, DOI 10.1016/j.biomaterials.2010.09.040
   Huang HC, 2009, ACS NANO, V3, P2941, DOI 10.1021/nn900947a
   Hunsaker BD, 2001, VET IMMUNOL IMMUNOP, V79, P1, DOI 10.1016/S0165-2427(01)00244-6
   Jen CP, 2004, LANGMUIR, V20, P1369, DOI 10.1021/la036154k
   Jo JI, 2008, EUR J PHARM BIOPHARM, V68, P90, DOI 10.1016/j.ejpb.2007.04.021
   Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707
   Joint United Nations Programme on HIV/AIDS, 2010, UNAIDS REP GLOB AIDS
   Kapsenberg M.L., 1998, ENCY IMMUNOLOGY, P1379
   Kobayashi S, 2009, BIOCONJUGATE CHEM, V20, P953, DOI 10.1021/bc800530v
   Li YF, 2011, SMALL, V7, P2965, DOI 10.1002/smll.201101059
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Lu L, 2008, NATURE, V455, P609, DOI 10.1038/455609a
   Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mancini-Bourgine M, 2004, HEPATOLOGY, V40, P874, DOI 10.1002/hep.20408
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
   Mumper RJ, 2001, MOL BIOTECHNOL, V19, P79, DOI 10.1385/MB:19:1:079
   Nikoobakht B, 2003, CHEM MATER, V15, P1957, DOI 10.1021/cm0207321
   Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774
   Parris K, 2003, ALTERN MED REV, V8, P223
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Qiu Y, 2010, BIOMATERIALS, V31, P7606, DOI 10.1016/j.biomaterials.2010.06.051
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519                                                         
   Rea JC, 2009, ACTA BIOMATER, V5, P903, DOI 10.1016/j.actbio.2008.10.003
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Uto T, 2011, BIOMATERIALS, V32, P5206, DOI 10.1016/j.biomaterials.2011.03.052
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   Wendorf J., 2008, HUM VACCINES, V1, P44
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   Wilsonl KD, 2009, J GENE MED, V11, P14, DOI 10.1002/jgm.1267
   Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001
   Zhao YL, 2008, NAT NANOTECHNOL, V3, P191, DOI 10.1038/nnano.2008.77
NR 54
TC 125
Z9 130
U1 11
U2 171
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD APR
PY 2012
VL 12
IS 4
BP 2003
EP 2012
DI 10.1021/nl300027p
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 922CO
UT WOS:000302524600044
PM 22372996
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Alais, S
   Soto-Rifo, R
   Balter, V
   Gruffat, H
   Manet, E
   Schaeffer, L
   Darlix, JL
   Cimarelli, A
   Raposo, G
   Ohlmann, T
   Leblanc, P
AF Alais, Sandrine
   Soto-Rifo, Ricardo
   Balter, Vincent
   Gruffat, Henri
   Manet, Evelyne
   Schaeffer, Laurent
   Darlix, Jean Luc
   Cimarelli, Andrea
   Raposo, Graca
   Ohlmann, Theophile
   Leblanc, Pascal
TI Functional mechanisms of the cellular prion protein (PrPC) associated
   anti-HIV-1 properties
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Prion; PrPC; HIV-1; Restriction factor; Anti-viral; RNA; Translation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRESS-INDUCIBLE PROTEIN-1; OXIDATIVE
   STRESS; NUCLEOCAPSID PROTEIN; TUNNELING NANOTUBES; SIGNAL-TRANSDUCTION;
   HIV-1 RELEASE; NUCLEIC-ACID; IN-VITRO; T-CELLS
AB The cellular prion protein PrPC/CD230 is a GPI-anchor protein highly expressed in cells from the nervous and immune systems and well conserved among vertebrates. In the last decade, several studies suggested that PrPC displays antiviral properties by restricting the replication of different viruses, and in particular retroviruses such as murine leukemia virus (MuLV) and the human immunodeficiency virus type 1 (HIV-1). In this context, we previously showed that PrPC displays important similarities with the HIV-1 nucleocapsid protein and found that PrPC expression in a human cell line strongly reduced HIV-1 expression and virus production. Using different PrPC mutants, we report here that the anti-HIV-1 properties are mostly associated with the amino-terminal 24-KRPKP-28 basic domain. In agreement with its reported RNA chaperone activity, we found that PrPC binds to the viral genomic RNA of HIV-1 and negatively affects its translation. Using a combination of biochemical and cell imaging strategies, we found that PrPC colocalizes with the virus assembly machinery at the plasma membrane and at the virological synapse in infected T cells. Depletion of PrPC in infected T cells and microglial cells favors HIV-1 replication, confirming its negative impact on the HIV-1 life cycle.
C1 [Schaeffer, Laurent; Leblanc, Pascal] Univ Lyon, LBMC, CNRS UMR 5239, ENS,HCL,Ecole Normale Super Lyon, F-69007 Lyon, France.
   [Alais, Sandrine; Soto-Rifo, Ricardo; Balter, Vincent; Gruffat, Henri; Manet, Evelyne; Schaeffer, Laurent; Darlix, Jean Luc; Cimarelli, Andrea; Ohlmann, Theophile; Leblanc, Pascal] Univ Lyon, F-69000 Lyon, France.
   [Alais, Sandrine; Soto-Rifo, Ricardo; Gruffat, Henri; Manet, Evelyne; Darlix, Jean Luc; Cimarelli, Andrea; Ohlmann, Theophile; Leblanc, Pascal] INSERM, U758, Human Virol Dept, F-69007 Lyon, France.
   [Balter, Vincent] CNRS, UMR 5276, Lab Geol Lyon, Lyon, France.
   [Raposo, Graca] Inst Curie, CNRS, UMR144, PICT IBiSA, F-75005 Paris, France.
RP Leblanc, P (reprint author), Univ Lyon, LBMC, CNRS UMR 5239, ENS,HCL,Ecole Normale Super Lyon, F-69007 Lyon, France.
EM Pascal.Leblanc@ens-lyon.fr
RI Soto Rifo, Ricardo/I-2850-2013; ohlmann, Theophile/M-4463-2014; Ohlmann,
   Theophile/H-6522-2016; sourisseau, marion/M-7542-2014; Gruffat,
   Henri/I-2407-2016
OI Soto Rifo, Ricardo/0000-0003-0945-2970; ohlmann,
   Theophile/0000-0002-2001-8916; Manet, Evelyne/0000-0001-7619-9982
FU CNRS; INSERM; GIS-Prion; ANRS; Conycit
FX We thank Ramanujan Hegde, David Harris, Paul Bieniasz, David Westaway,
   Jeremy Luban, Serge Benichou, Didier Trono and Hybridolab for kindly
   providing biological materials. We thank Olivier Schwartz, Clarisse
   Berlioz-Torrent and Renaud Mahieux for materials, discussions and help.
   We thank Robin Buckland and Jenny T. Miller for carefully reading the
   manuscript. We acknowledge the PLATIM microscope platform at ENS Lyon
   (SFR Biosciences Gerland-Lyon Sud UMS34444/US8, France). This work was
   supported by the CNRS, INSERM and GIS-Prion. RSR and TO received grant
   support from ANRS and Conycit. We thank the ANR program EXOPRION (to PL
   and GR) for its essential contribution to the definitive version of this
   work.
CR ADACHI A, 1986, J VIROL, V59, P284
   Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7
   Alais S, 2008, BIOL CELL, V100, P603, DOI 10.1042/BC20080025
   Ballerini C, 2006, J IMMUNOL, V176, P7254, DOI 10.4049/jimmunol.176.12.7254                                                    
   Campana V, 2007, J BIOL CHEM, V282, P22747, DOI 10.1074/jbc.M701468200
   Caruso P, 2009, VIROLOGY, V385, P343, DOI 10.1016/j.virol.2008.12.005
   Chakrabarti O, 2009, CELL, V137, P1136, DOI 10.1016/j.cell.2009.03.042
   Chakrabarti O, 2009, TRENDS BIOCHEM SCI, V34, P287, DOI 10.1016/j.tibs.2009.03.001
   Corley SM, 2008, BIOINFORM BIOL INSIG, V2, P383
   Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979
   Deshmane SL, 2009, J BIOL CHEM, V284, P11364, DOI 10.1074/jbc.M809266200
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200
   Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544
   Gendron K, 2011, NUCLEIC ACIDS RES, V39, P902, DOI 10.1093/nar/gkq885
   Goggin K, 2008, BBA-MOL CELL RES, V1783, P479, DOI 10.1016/j.bbamcr.2007.10.008
   Gomes MPB, 2008, PRION, V2, P64, DOI 10.4161/pri.2.2.6988                                                            
   Goujon C, 2008, J VIROL, V82, P12335, DOI 10.1128/JVI.01181-08
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Grenier C, 2006, J NEUROCHEM, V97, P1456, DOI 10.1111/j.1471-4159.2006.03837.x
   Griffiths RE, 2007, BLOOD, V110, P4518, DOI 10.1182/blood-2007-04-085183
   Guo MX, 2008, BIOCHEM BIOPH RES CO, V365, P154, DOI 10.1016/j.bbrc.2007.10.160
   Hamard-Peron E, 2010, J VIROL, V84, P503, DOI 10.1128/JVI.01134-09
   Isaacs JD, 2006, CLIN EXP IMMUNOL, V146, P1, DOI 10.1111/j.1365-2249.2006.03194.x
   Kang SW, 2006, CELL, V127, P999, DOI 10.1016/j.cell.2006.10.032
   Kupzig S, 2003, TRAFFIC, V4, P694, DOI 10.1034/j.1600-0854.2003.00129.x                                                
   Leblanc P, 2004, J MOL BIOL, V337, P1035, DOI 10.1016/j.jmb.2004.02.007
   Leblanc P, 2006, EMBO J, V25, P2674, DOI 10.1038/sj.emboj.7601162
   Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007
   Lindl KA, 2007, NEUROPATH APPL NEURO, V33, P658, DOI 10.1111/j.1365-2990.2007.00866.x
   Lotscher M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001158
   Manuelidis L, 2007, J CELL BIOCHEM, V100, P897, DOI 10.1002/jcb.21090
   Mattei V, 2004, FEBS LETT, V560, P14, DOI 10.1016/S0014-5793(04)00029-8
   Mehrpour M, 2010, CANCER LETT, V290, P1, DOI 10.1016/j.canlet.2009.07.009
   Miyazawa K, 2010, J CELL BIOCHEM, V111, P239, DOI 10.1002/jcb.22723
   Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X
   Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925
   MULLER WEG, 1992, BIOCHIM BIOPHYS ACTA, V1139, P32, DOI 10.1016/0925-4439(92)90079-3
   Nakamura Y, 2003, J GEN VIROL, V84, P3495, DOI 10.1099/vir.0.19222-0
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nandi PK, 2004, J MOL BIOL, V344, P827, DOI 10.1016/j.jmb.2004.09.080
   Nandi PK, 1999, ARCH VIROL, V144, P1751, DOI 10.1007/s007050050702
   Neil S, 2009, J INTERF CYTOK RES, V29, P569, DOI 10.1089/jir.2009.0077
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Nicolini A, 2001, J NEUROCHEM, V79, P713, DOI 10.1046/j.1471-4159.2001.00568.x
   Nikles D, 2005, J VIROL, V79, P4033, DOI 10.1128/JVI.79.7.4033-4042.2005
   Orsi A, 2006, J BIOL CHEM, V281, P30431, DOI 10.1074/jbc.M605320200
   Pasupuleti M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007358
   Perez-Caballero D, 2009, CELL, V139, P499, DOI 10.1016/j.cell.2009.08.039
   Pocernich CB, 2005, BRAIN RES REV, V50, P14, DOI 10.1016/j.brainresrev.2005.04.002
   Price TO, 2005, BRAIN RES, V1045, P57, DOI 10.1016/j.brainres.2005.03.031
   Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363
   Rane NS, 2008, DEV CELL, V15, P359, DOI 10.1016/j.devcel.2008.06.015
   Rane NS, 2010, J CELL BIOL, V188, P515, DOI 10.1083/jcb.200911115
   Ricci EP, 2008, RNA, V14, P1443, DOI 10.1261/rna.813608
   Roberts TK, 2010, AM J PATHOL, V177, P1848, DOI 10.2353/ajpath.2010.091006
   Roffe M, 2010, P NATL ACAD SCI USA, V107, P13147, DOI 10.1073/pnas.1000784107
   Ronaldson PT, 2008, J NEUROCHEM, V106, P1298, DOI 10.1111/j.1471-4159.2008.05479.x
   Rudnicka D, 2009, J VIROL, V83, P6234, DOI 10.1128/JVI.00282-09
   Sakudo A, 2005, BIOCHEM BIOPH RES CO, V326, P600, DOI 10.1016/j.bbrc.2004.11.092
   Schrock Y, 2009, FEBS LETT, V583, P389, DOI 10.1016/j.febslet.2008.12.038
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06
   Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200
   Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje
   Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344
   Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001
   Walters KA, 2006, PLOS PATHOG, V2, P591, DOI 10.1371/journal.ppat.0020059
   Watts JC, 2009, PLOS PATHOG, V5, DOI DOI 10.1371/JOURNAL.PPAT.1000608
   Watts JC, 2007, BBA-MOL BASIS DIS, V1772, P654, DOI 10.1016/j.bbadis.2007.05.001
   Weiss S, 1997, J VIROL, V71, P8790
   Young R, 2009, FEBS LETT, V583, P3296, DOI 10.1016/j.febslet.2009.09.027
   Zafar S, 2011, J PROTEOME RES, V10, P3123, DOI 10.1021/pr2001989
   Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325
   Zhang CC, 2006, P NATL ACAD SCI USA, V103, P2184, DOI 10.1073/pnas.0510577103
NR 75
TC 4
Z9 4
U1 1
U2 10
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD APR
PY 2012
VL 69
IS 8
BP 1331
EP 1352
DI 10.1007/s00018-011-0879-z
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 918OD
UT WOS:000302258700007
PM 22076653
DA 2018-01-05
ER

PT J
AU Zhang, XK
   Zhang, X
   Wang, FS
AF Zhang, Xinke
   Zhang, Xue
   Wang, Fengshan
TI Intracellular transduction and potential of Tat PTD and its analogs:
   from basic drug delivery mechanism to application
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE mechanism; systemic delivery; targeted systems; Tat PTD; topical
   delivery
ID CELL-PENETRATING PEPTIDES; HEPARAN-SULFATE PROTEOGLYCANS; FOCAL
   CEREBRAL-ISCHEMIA; ARGININE-RICH PEPTIDES; ACIDIC SOLID TUMORS; IN-VIVO;
   PROTEIN TRANSDUCTION; MEDIATED DELIVERY; PLASMA-MEMBRANE; PHARMACEUTICAL
   NANOCARRIERS
AB Introduction: It has been 20 years since the discovery of the membrane-translocating property of the HIV-1 transactivator of transcription (Tat) protein. The Tat protein transduction domain (Tat PTD) is a very promising tool for non-invasive cellular import of cargos and has been successfully applied to in vitro and in vivo delivery of different therapeutic agents for the treatment of many diseases. A growing number of reports on Tat PTD-mediated delivery have extensively revealed the mechanisms involved. Yet, due to the varied conditions used, the reports on the internalization mode of Tat PTD-cargo chimera are often varied.
   Areas covered: This article reviews the possible intracellular trafficking mechanisms of Tat PTD including its binding, cellular entry process, and the roles of participants of the cell membrane. The therapeutic applications via local administration, such as those for the treatment of skin, ocular, cardiac and cerebral diseases, are also reviewed. In addition, some novel systems built by different groups are elucidated, which are utilized to overcome the poor targeting efficiency of Tat PTD for the treatment of CNS diseases, cancer and other diseases via systemic administration.
   Expert opinion: With the development of targeting factors, such as antibodies, some cell targeting peptides and novel polymers, Tat PTD is expected to play a more efficient and/or better tolerated therapeutic role in the drug delivery field.
C1 [Zhang, Xinke; Wang, Fengshan] Shandong Univ, Inst Biochem & Biotechnol Drugs, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Xue] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77225 USA.
RP Wang, FS (reprint author), Shandong Univ, Inst Biochem & Biotechnol Drugs, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China.
EM fswang@sdu.edu.cn
FU Graduate Independent Innovation Foundation of Shandong University
FX The authors state no conflict of interest. This work was funded by
   Graduate Independent Innovation Foundation of Shandong University.
CR Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b
   Amand HL, 2011, BBA-BIOMEMBRANES, V1808, P1860, DOI 10.1016/j.bbamem.2011.03.011
   Arthanari Y, 2010, J CONTROL RELEASE, V145, P272, DOI 10.1016/j.jconrel.2010.04.011
   BATES E, 2008, CIRCULATION, V117, P886
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817
   Bitler BG, 2010, RECENT PAT ANTI-CANC, V5, P99, DOI 10.2174/157489210790936252                                                      
   Blondeau P, 2007, CHEM SOC REV, V36, P198, DOI 10.1039/b603089k
   Boisguerin P, 2011, J CONTROL RELEASE, V156, P146, DOI 10.1016/j.jconrel.2011.07.037
   Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006
   Brasseur R, 2010, BBA-BIOMEMBRANES, V1798, P2177, DOI 10.1016/j.bbamem.2010.09.001
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Brooks NA, 2010, BBA-REV CANCER, V1805, P25, DOI 10.1016/j.bbcan.2009.09.004
   Bruyninckx WJ, 2001, BLOOD, V97, P3251, DOI 10.1182/blood.V97.10.3251
   Butko P, 2007, BIOCH US, V46, P3888
   Cai B, 2011, EXP NEUROL, V227, P224, DOI 10.1016/j.expneurol.2010.11.009
   Dietz G. P., 2011, EXP NEUROL, V227, P224
   Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165
   Dietz GPH, 2010, CURR PHARM BIOTECHNO, V11, P167, DOI 10.2174/138920110790909731                                                      
   Doeppner TR, 2010, NEUROBIOL DIS, V40, P265, DOI 10.1016/j.nbd.2010.05.033
   Doeppner TR, 2010, EXP NEUROL, V223, P548, DOI 10.1016/j.expneurol.2010.02.001
   Doeppner TR, 2009, J CEREBR BLOOD F MET, V29, P1187, DOI 10.1038/jcbfm.2009.44
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Eiriksdottir E, 2010, BIOCONJUGATE CHEM, V21, P1662, DOI 10.1021/bc100174y
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Futaki S, 2007, BIOCH US, V46, P492
   Futaki S, 2008, ADV DRUG DELIV REV, V60, P598
   Giacca M, 2005, ADV DRUG DELIV REV, V57, P597
   Gillmeister MP, 2011, BIOCONJUGATE CHEM, V22, P556, DOI 10.1021/bc900445g
   Harada H, 2002, CANCER RES, V62, P2013
   Harada Hiroshi, 2006, Breast Cancer, V13, P16, DOI 10.2325/jbcs.13.16
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1
   Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767                                                              
   Howl J, 2009, EXPERT OPIN THER PAT, V19, P1329, DOI 10.1517/17530050902824829
   Huang M, 2002, PHARMACEUT RES, V19, P1488, DOI 10.1023/A:1020404615898
   Huang YZ, 2010, CURR PHARM DESIGN, V16, P2369, DOI 10.2174/138161210791920441                                                      
   Inoue M, 2004, INT J ONCOL, V25, P713
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Jones AT, 2007, J CELL MOL MED, V11, P670, DOI 10.1111/j.1582-4934.2007.00062.x
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Kale AA, 2007, J DRUG TARGET, V15, P538, DOI 10.1080/10611860701498203
   Kawamoto S, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3555531
   Kichler A, 2006, BBA-BIOMEMBRANES, V1758, P301, DOI 10.1016/j.bbamem.2006.02.005
   Kwon YM, 2008, EXPERT OPIN DRUG DEL, V5, P1255, DOI 10.1517/17425240802498059 
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Lee ES, 2008, J CONTROL RELEASE, V129, P228, DOI 10.1016/j.jconrel.2008.04.024
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Li YT, 2009, J BIOMED MATER RES A, V91A, P209, DOI 10.1002/jbm.a.32204
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Metzler B, 2008, CIRCULATION, V118, pE80, DOI 10.1161/CIRCULATIONAHA.108.772772
   Miyaji Y, 2011, DRUG METAB DISPOS, V39, P1946, DOI 10.1124/dmd.111.040725
   Nagel F, 2008, J NEUROCHEM, V105, P853, DOI 10.1111/j.1471-4159.2007.05204.x
   Naik SS, 2005, J CONTROL RELEASE, V101, P35, DOI 10.1016/j.jconrel.2004.07.020
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nam HY, 2011, BIOMATERIALS, V32, P5213, DOI 10.1016/j.biomaterials.2011.03.058
   Noguchi H, 2010, CELL TRANSPLANT, V19, P649, DOI 10.3727/096368910X508744
   Ohta Y, 2008, J NEUROSCI RES, V86, P3028, DOI 10.1002/jnr.21747
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Raagel H, 2010, BBA-BIOMEMBRANES, V1798, P2240, DOI 10.1016/j.bbamem.2010.02.013
   Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]
   RAUB TJ, 1986, EXP CELL RES, V165, P92, DOI 10.1016/0014-4827(86)90535-5
   Repici M, 2006, ADV EXP MED BIOL, V588, P145
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rullo A, 2011, BIOPOLYMERS, V95, P722, DOI 10.1002/bip.21641
   Sawant R, 2011, METHODS MOL BIOL, V683, P431, DOI 10.1007/978-1-60761-919-2_31
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Schorderet DF, 2005, CLIN EXP OPHTHALMOL, V33, P628, DOI 10.1111/j.1442-9071.2005.01108.x                                                
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sethuraman VA, 2008, PHARM RES, V25, P657, DOI 10.1007/s11095-007-9480-4
   Sethuraman VA, 2007, J CONTROL RELEASE, V118, P216, DOI 10.1016/j.jconrel.2006.12.008
   Simon MJ, 2011, ANN BIOMED ENG, V39, P394, DOI 10.1007/s10439-010-0144-x
   Simon MJ, 2010, NEUROSCI LETT, V486, P1, DOI 10.1016/j.neulet.2010.09.029
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Su YC, 2010, BIOCHEMISTRY-US, V49, P6009, DOI 10.1021/bi100642n
   Ter-Avetisyan G, 2009, J BIOL CHEM, V284, P3370, DOI 10.1074/jbc.M805550200
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2005, J CONTROL RELEASE, V109, P77, DOI 10.1016/j.jconrel.2005.09.032
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang Y, 2010, J CELL MOL MED, V14, P1998, DOI 10.1111/j.1582-4934.2009.00786.x
   Wender PA, 2005, ADV DRUG DELIV REV, V57, P495
   Yang ST, 2010, BIOPHYS J, V99, P2525, DOI 10.1016/j.bpj.2010.08.029
   Yonezawa Tomo, 2009, Recent Pat DNA Gene Seq, V3, P96
   Zhang XP, 2009, MOL PHARMACEUT, V6, P836, DOI 10.1021/mp800121f
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Ziegler A, 2008, ADV DRUG DELIVER REV, V60, P580, DOI 10.1016/j.addr.2007.10.005
   Ziegler A, 2008, BIOPHYS J, V94, P2142, DOI 10.1529/biophysj.107.113472
NR 100
TC 20
Z9 28
U1 1
U2 24
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD APR
PY 2012
VL 9
IS 4
BP 457
EP 472
DI 10.1517/17425247.2012.663351
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 912XW
UT WOS:000301835800008
PM 22432469
DA 2018-01-05
ER

PT J
AU Dash, PK
   Gorantla, S
   Roy, U
   Knibbe, J
   Balkundi, S
   McMillan, J
   Gelbard, HA
   Poluektova, LY
   Gendelman, HE
AF Dash, P. K.
   Gorantla, S.
   Roy, U.
   Knibbe, J.
   Balkundi, S.
   McMillan, J.
   Gelbard, H. A.
   Poluektova, L. Y.
   Gendelman, H. E.
TI Efficacy and Safety Tests of Long-acting Nanoformulated Anti-retroviral
   Drugs in HIV-1 Infected Humanized Mice
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Dash, P. K.; Gorantla, S.; Roy, U.; Knibbe, J.; Balkundi, S.; McMillan, J.; Poluektova, L. Y.; Gendelman, H. E.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gelbard, H. A.] Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, New York, NY 14642 USA.
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2012
VL 7
SU 1
BP S35
EP S35
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 918YY
UT WOS:000302288800069
DA 2018-01-05
ER

PT J
AU Dash, PK
   Gorantla, S
   Roy, U
   Knibbe, J
   Balkundi, S
   McMillan, J
   Gelbard, HA
   Poluektova, LY
   Gendelman, HE
AF Dash, P. K.
   Gorantla, S.
   Roy, U.
   Knibbe, J.
   Balkundi, S.
   McMillan, J.
   Gelbard, H. A.
   Poluektova, L. Y.
   Gendelman, H. E.
TI Efficacy and Safety Tests of Long-acting Nanoformulated Anti-Retroviral
   Drugs in HIV-1 Infected Humanized Mice.
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Dash, P. K.; Gorantla, S.; Roy, U.; Knibbe, J.; Balkundi, S.; McMillan, J.; Poluektova, L. Y.; Gendelman, H. E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gelbard, H. A.] Univ Rochester, Sch Med & Dent, Ctr Neural Dev & Dis, Rochester, NY 14642 USA.
RI ROY, UPAL/C-6126-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2012
VL 7
SU 1
BP S14
EP S14
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 918YY
UT WOS:000302288800006
DA 2018-01-05
ER

PT J
AU Liu, Y
   Lee, MR
   Timani, K
   He, JJ
   Broxmeyer, HE
AF Liu, Ying
   Lee, Man-Ryul
   Timani, Khalid
   He, Johnny J.
   Broxmeyer, Hal E.
TI Tip110 Maintains Expression of Pluripotent Factors in and Pluripotency
   of Human Embryonic Stem Cells
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID TAT-INTERACTING PROTEIN; SELF-RENEWAL; 110 KDA; OCT-4; DIFFERENTIATION;
   KNOCKDOWN; NANOG
AB HIV-1 Tat-interacting protein of 110 kDa [Tip110; p110(nrb)/SART3/p110] is an RNA binding nuclear protein implicated in regulation of HIV-1 gene and host gene transcription, pre-mRNA splicing, and cancer immunology. Recently, we demonstrated a role for Tip110 in regulation of hematopoiesis. Here, we show that TIP110 is also expressed in human embryonic stem cells (hESCs) and expression was decreased with differentiation of these ESCs. TIP110 was found, through up-and down-modulation of expression of Tip110, to be important in maintaining pluripotent factor (NANOG, OCT4, and SOX2) expression in and pluripotency of hESCs, although the mechanisms involved and whether the Tip110 effects are direct remain to be determined.
C1 [Liu, Ying; Lee, Man-Ryul; Timani, Khalid; He, Johnny J.; Broxmeyer, Hal E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [He, Johnny J.] Indiana Univ Sch Med, Ctr AIDS Res, Indianapolis, IN 46202 USA.
RP Liu, Y (reprint author), UNT Hlth Sci Ctr, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM ying.liu@unthsc.edu; hbroxmey@iupui.edu
OI Timani, Khalid/0000-0002-4862-9348
FU Public Health Service [R01 HL56416, R01 HL67384]; National Institutes of
   Health [P01 DK90948]
FX These studies were supported by Public Health Service Grants R01 HL56416
   and R01 HL67384, and by P01 DK90948 from the National Institutes of
   Health to Hal E. Broxmeyer.
CR Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Broxmeyer HE, 2011, BLOOD, V117, P4733
   Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930
   Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580
   Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005
   Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225                                                      
   Liu Y, 2004, J BIOL CHEM, V279, P21766, DOI 10.1074/jbc.M314321200
   Liu Y, 2002, J BIOL CHEM, V277, P23854, DOI 10.1047/jbc.M200773200
   Liu Y, 2011, BLOOD, V117, P5643, DOI 10.1182/blood-2010-12-325332
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Matin MM, 2004, STEM CELLS, V22, P659, DOI 10.1634/stemcells.22-5-659                                                      
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125
   Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271                                                      
   Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9<722::AID-BIES5>3.3.CO;2-O
NR 16
TC 16
Z9 17
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD APR
PY 2012
VL 21
IS 6
BP 829
EP 833
DI 10.1089/scd.2011.0512
PG 5
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 918BB
UT WOS:000302222700001
PM 22132941
OA green_published
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Cahn, P
   Qazi, S
   D'Cruz, O
AF Uckun, Fatih M.
   Cahn, Pedro
   Qazi, Sanjive
   D'Cruz, Osmond
TI Stampidine as a promising antiretroviral drug candidate for pre-exposure
   prophylaxis against sexually transmitted HIV/AIDS
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE AIDS; human immunodeficiency virus-1; nucleoside reverse transcriptase
   inhibitor; pre-exposure prophylaxis; reverse transcriptase
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITOR; ANTI-HIV
   AGENT; TENOFOVIR DISOPROXIL FUMARATE; RANDOMIZED CONTROLLED-TRIAL;
   IN-VIVO PHARMACOKINETICS; GMP-GRADE STAMPIDINE; HUMANIZED BLT MICE;
   VAGINAL GEL; PHOSPHATE DERIVATIVES
AB Introduction: Pre-exposure prophylaxis (PrEP) is an evolving new approach to prevention of sexually transmitted HIV-1 that employs antiretroviral (ARV) agents prior to potential HIV-1 exposure in an attempt to reduce the likelihood of HIV-1 infection postexposure. The identification of new ARV agents with potent activity against multidrug-resistant HIV remains an unmet and urgent challenge in the field of PrEP.
   Areas covered: This article reviews the preclinical and early clinical activity and safety profile of stampidine, a novel antiretroviral (ARV) drug candidate that exhibits remarkable subnanomolar to low nanomolar in vitro antiretroviral potency against genotypically and phenotypically nucleoside reverse transcriptase inhibitor (NRTI)-resistant primary clinical HIV isolates, nonnucleoside RT-resistant HIV-1 isolates. Stampidine has a favorable pharmaco-kinetic profile in mice, rats, dogs and cats with 25 or 50 mg/kg tolerable dose levels yielding micromolar plasma concentrations that are 1000-fold higher than its in vitro IC50 value against HIV. Stampidine has a favorable, safety profile in mice, rats, dogs and cats and it showed significant in vivo ARV activity in HIV-infected Hu-PBL-SCID mice as well as FIV-infected domestic cats. Furthermore, it did not cause any maternal toxicity, developmental toxicity or teratogenicity in rabbits treated at 10 - 40 mg/kg/day dose levels. In a recently completed first-in-human Phase I clinical trial, stampidine did not cause dose-limiting toxicity at single dose levels ranging from 5 to 25 mg/kg.
   Expert opinion: The favorable safety and activity profile of stampidine warrants its further development as a promising next-generation PrEP candidate to prevent the sexual transmission of HIV-1. The discovery of stampidine as a potent antiretroviral agent represents a significant step forward in the development of effective therapeutic as well as preventive strategies against HIV/AIDS.
C1 [Uckun, Fatih M.; Qazi, Sanjive; D'Cruz, Osmond] Childrens Hosp Los Angeles, Dev Therapeut Program, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA.
   [Uckun, Fatih M.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90027 USA.
   [Uckun, Fatih M.; Qazi, Sanjive; D'Cruz, Osmond] Paradigm Pharmaceut, St Paul, MN 55455 USA.
   [Cahn, Pedro] Univ Buenos Aires, Dept Med, Sch Med, Buenos Aires, DF, Argentina.
   [Cahn, Pedro] Hosp Juan A Fernandez, Infect Dis Unit, Buenos Aires, DF, Argentina.
   [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina.
RP Uckun, FM (reprint author), Childrens Hosp Los Angeles, Dev Therapeut Program, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA.
FU Children's Hospital Los Angeles
FX The authors received funding from the institutional funds of Children's
   Hospital Los Angeles. The authors have no competing interests to declare
   and have received no funding in preparation of the manuscript.
CR AIDS Vaccine Advocacy Coalition, GLOB ADV HIV PREV ON
   Anderson PL, 2011, J ANTIMICROB CHEMOTH, V66, P240, DOI 10.1093/jac/dkq447
   AVERT (AIDS Education & Research Trust), POST PROPH PREEXP PR
   Baeten J, 2011, 6 IAS C HIV PATH TRE
   Blackard JT, 2002, CLIN INFECT DIS, V34, P1108, DOI 10.1086/339547                                                                  
   Brenner B, 2004, AIDS, V18, P1653, DOI 10.1097/01.aids.0000131377.28694.04
   Cahn P., 2012, J AIDS CLIN RES, V03, P1, DOI [10.4172/2155-6113.1000138, DOI 10.4172/2155-6113.1000138]
   Calmy A, 2009, J INFECT DIS, V200, P1746, DOI 10.1086/644785
   Campbell MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005690
   CDC, 2011, RES FEM PREP CLIN TR
   CDC, 2011, PREEXP PROPH PREP
   Celum C, 2012, CURR OPIN INFECT DIS, V25, P51, DOI 10.1097/QCO.0b013e32834ef5ef
   Chen CL, 2002, DRUG METAB DISPOS, V30, P1523, DOI 10.1124/dmd.30.12.1523
   Chen CL, 2001, DRUG METAB DISPOS, V29, P1035
   Cheung PK, 2004, AIDS REV, V6, P107
   Cohen MS, 2002, CURR CLIN TOPICS INF, V22, P214
   D'Cruz OJ, 2006, ARZNEIMITTEL-FORSCH, V56, P159
   D'Cruz OJ, 2001, BIOL REPROD, V64, P51, DOI 10.1095/biolreprod64.1.51
   D'Cruz OJ, 2008, CURR OPIN INVEST DR, V9, P152
   Das K, 2009, J BIOL CHEM, V284, P35092, DOI 10.1074/jbc.M109.022525
   De Clercq E, 2012, BIOCHEM PHARMACOL, V83, P567, DOI 10.1016/j.bcp.2011.10.016
   Denton PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008829
   Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016
   Dolling D, 2012, HIV MED, V13, P309, DOI 10.1111/j.1468-1293.2011.00968.x
   DuMez D, 2006, ARZNEIMITTEL-FORSCH, V56, P136
   Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474
   [Anonymous], FEM PREP JUN 2011 UP
   Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028
   Garcia-Lerma JG, 2010, TRENDS PHARMACOL SCI, V31, P74, DOI 10.1016/j.tips.2009.10.009
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gurney KB, 2005, J VIROL, V79, P5762, DOI 10.1128/JVI.79.9.5762-5773.2005
   Hachiya A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016242
   Halpern V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003784
   Hemelaar J, 2006, AIDS, V20, P13, DOI DOI 10.1097/01.AIDS.0000247564.73009.BC
   Howell Alexandra L, 2005, Curr HIV/AIDS Rep, V2, P35
   Hurt CB, 2011, CLIN INFECT DIS, V53, P1265, DOI 10.1093/cid/cir684
   Jhaveri Malhar A, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P328, DOI 10.1177/1545109710376595
   Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9
   Kelesidis Theodoros, 2011, Curr HIV/AIDS Rep, V8, P94, DOI 10.1007/s11904-011-0078-4
   Kohler JJ, 2011, LAB INVEST, V91, P852, DOI 10.1038/labinvest.2011.48
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   Lampe MA, 2011, AM J OBSTET GYNECOL, V204, DOI DOI 10.1016/J.AJ0G.2011.02.026
   Liegler T, 2011, 18 C RETR OPP INF CR
   Mayer KH, 2010, JAIDS-J ACQ IMM DEF, V55, pS122, DOI 10.1097/QAI.0b013e3181fbcb4c
   McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0
   Microbicide Trials Network, MTN003
   Moyle GJ, 2000, AIDS, V14, P1292, DOI 10.1097/00002030-200006160-00037                                                
   Moyle GJ, 2005, J INFECT DIS, V191, P866, DOI 10.1086/428096                                                                  
   Myers GM, 2011, AIDS PATIENT CARE ST, V25, P63, DOI 10.1089/apc.2010.0222
   Naswa Smriti, 2011, Indian J Sex Transm Dis, V32, P1, DOI 10.4103/0253-7184.81246
   Neff CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015257
   NIH News, 2011, NIH NEWS        1125
   Paraskevis D, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-49
   Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174
   Peeters M, 2000, AIDS RES HUM RETROV, V16, P315, DOI 10.1089/088922200309197                                                         
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Peterson L, 2007, PLOS ONE, V2, pe1312, DOI 10.1371/journal.pone.0001312
   Richardson BA, 2001, SEX TRANSM DIS, V28, P394, DOI 10.1097/00007435-200107000-00006
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Smith DM, 2006, VIROLOGY, V355, P1, DOI 10.1016/j.virol.2006.08.009
   Smith DM, 2005, AIDS, V19, P1251, DOI 10.1097/01.aids.0000180095.12276.ac                                             
   Steain Megan C, 2004, Sex Health, V1, P239, DOI 10.1071/SH04024
   Subbarao S, 2006, J INFECT DIS, V194, P904, DOI 10.1086/507306
   TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197
   Uckun FM, 2007, ARZNEIMITTEL-FORSCH, V57, P112
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P193
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P121
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P176
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P117
   Uckun FM, 2005, ARZNEIMITTEL-FORSCH, V55, P223
   Uckun FM, 2004, ARZNEIMITTEL-FORSCH, V54, P69
   Uckun FM, 2003, ARZNEIMITTEL-FORSCH, V53, P357
   Uckun FM, 2003, ANTIMICROB AGENTS CH, V47, P1233, DOI 10.1128/AAC.47.4.1233-1240.2003
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3613, DOI 10.1128/AAC.46.11.3613-3616.2002
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Van Damme L, 2002, LANCET, V360, P971, DOI 10.1016/S0140-6736(02)11079-8                                                   
   Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957
   Van Rompay KKA, 2006, JAIDS-J ACQ IMM DEF, V43, P6, DOI 10.1097/01.qai.0000224972.60339.7c
   Venkatachalam TK, 1998, BIOORG MED CHEM LETT, V8, P3121, DOI 10.1016/S0960-894X(98)00547-2
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P445
   Vigano A, 2007, CLIN DRUG INVEST, V27, P573, DOI 10.2165/00044011-200727080-00006
   White KL, 2004, ANTIMICROB AGENTS CH, V48, P992, DOI 10.1128/AAC.48.3.992-1003.2004
   Wolf K, 2003, ANTIMICROB AGENTS CH, V47, P3478, DOI 10.1128/AAC.47.11.3478-3484.2003
   Yirrell DL, 2002, AIDS, V16, P279, DOI 10.1097/00002030-200201250-00018
   Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502                                                     
NR 88
TC 3
Z9 3
U1 0
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3784
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD APR
PY 2012
VL 21
IS 4
BP 489
EP 500
DI 10.1517/13543784.2012.664635
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 907ZE
UT WOS:000301458700007
PM 22360744
DA 2018-01-05
ER

PT J
AU Sharghi, H
   Aberi, M
   Doroodmand, MM
AF Sharghi, Hashem
   Aberi, Mahdi
   Doroodmand, Mohammad Mahdi
TI One-pot synthesis of 2-arylbenzimidazole, 2-arylbenzothiazole and
   2-arylbenzoxazole derivatives using vanadium(IV)-salen complex as
   homogeneous catalyst and vanadium(IV)-salen complex nanoparticles
   immobilized onto silica as a heterogeneous nanocatalyst
SO JOURNAL OF THE IRANIAN CHEMICAL SOCIETY
LA English
DT Article
DE Vanadium(IV)-salen complexes; Nanoparticle heterogeneous catalyst;
   Benzimidazole; Benzothiazole; Benzoxazole
ID SCHIFF-BASE COMPLEXES; HIV-1 REVERSE-TRANSCRIPTASE; CARBON-NITROGEN
   BONDS; 2-SUBSTITUTED BENZIMIDAZOLES; MANNICH REACTION; RECOVERABLE
   CATALYSTS; HYDROGEN-PEROXIDE; ACTIVATED CARBON; DNA-BINDING;
   ENANTIOSELECTIVE EPOXIDATION
AB The efficient synthesis of 2-arylbenzimidazole, 2-arylbenzothiazole and 2-arylbenzoxazole derivatives is described by condensation of aryl aldehydes and o-phenylenediamines, 2-aminothiophenol and 2-aminophenol in a single pot using a catalytic amount of vanadium(IV)-salen complex or vanadium-salen nanoparticles supported on silica (5.0 mol%) in excellent isolated yields. The immobilized catalyst was characterized by powder X-ray diffraction, scanning electron microscopy, atomic force microscopy, transmission electron microscopy, inductively coupled plasma analysis, thermogravimetric instrument for analysis of nitrogen adsorption and FT-IR spectroscopy.
C1 [Sharghi, Hashem; Aberi, Mahdi; Doroodmand, Mohammad Mahdi] Shiraz Univ, Dept Chem, Shiraz 71454, Iran.
   [Doroodmand, Mohammad Mahdi] Shiraz Univ, Nanotechnol Res Inst, Shiraz 71454, Iran.
RP Sharghi, H (reprint author), Shiraz Univ, Dept Chem, Shiraz 71454, Iran.
EM shashem@susc.ac.ir
FU Shiraz University Research Council
FX We gratefully acknowledge the support of this work by the Shiraz
   University Research Council. We are also grateful to Mr. H. Sajedian
   Fard and Mr. M. S. Darvish Tafvizi for their helpful cooperation.
CR Alagille D, 2005, TETRAHEDRON LETT, V46, P1349, DOI 10.1016/j.tetlet.2004.12.111
   Alloum A. B., 2003, TETRAHEDRON LETT, V44, P5935, DOI DOI 10.1016/S0040-4039(03)01387-X
   Alvarez HM, 2007, CATAL COMMUN, V8, P1336, DOI 10.1016/j.catcom.2006.11.021
   Austen SC, 2001, J HETEROCYCLIC CHEM, V38, P979, DOI 10.1002/jhet.5570380427                                                         
   Bahrami K, 2008, J ORG CHEM, V73, P6835, DOI 10.1021/jo8010232
   Bahrami K, 2007, SYNTHESIS-STUTTGART, P547, DOI 10.1055/s-2007-965878
   Bahrami K, 2009, SYNLETT, P569, DOI 10.1055/s-0028-1087911
   Baleizao C, 2004, TETRAHEDRON, V60, P10461, DOI 10.1016/j.tet.2004.08.077
   Baleizao C, 2006, CHEM REV, V106, P3987, DOI 10.1021/cr050973n
   BATHINI Y, 1990, CHEM RES TOXICOL, V3, P268, DOI 10.1021/tx00015a013
   Beaulieu PL, 2003, SYNTHESIS-STUTTGART, P1683
   Belokon Y, 1997, J CHEM SOC PERK T 1, P1293, DOI 10.1039/a608097i                                                                
   BHATNAGAR I, 1968, TETRAHEDRON, V24, P1293, DOI 10.1016/0040-4020(68)88080-9                                                    
   Caballero V, 2009, J MOL CATAL A-CHEM, V308, P41, DOI 10.1016/j.molcata.2009.03.024
   Chakraborti AK, 2007, GREEN CHEM, V9, P1335, DOI 10.1039/b710414f
   Chen YX, 2008, ANGEW CHEM INT EDIT, V47, P9330, DOI 10.1002/anie.200803381
   CHIKASHITA H, 1987, B CHEM SOC JPN, V60, P737, DOI 10.1246/bcsj.60.737                                                             
   Choi SJ, 2006, BIOORGAN MED CHEM, V14, P1229, DOI 10.1016/j.bmc.2005.09.051
   Cozzi PG, 2003, ANGEW CHEM INT EDIT, V42, P2895, DOI 10.1002/anie.200351230
   Curini M, 2004, SYNLETT, P1832, DOI 10.1055/s-2004-829555
   DEVOS DE, 2000, CATALYST IMMOBILIZAT
   Du LH, 2007, SYNTHESIS-STUTTGART, P675, DOI 10.1055/s-2007-965922
   DUBEY PK, 1979, INDIAN J CHEM B, V18, P428
   Easmon J, 2006, J MED CHEM, V49, P6343, DOI 10.1021/jm060232u
   ELSHEIKH MI, 1981, J ORG CHEM, V46, P3256, DOI 10.1021/jo00329a022                                                             
   GEORGE B, 1977, J ORG CHEM, V42, P441, DOI 10.1021/jo00423a011                                                             
   Gladysz JA, 2002, CHEM REV, V102, P3215, DOI 10.1021/cr020068s
   Gladysz JA, 2001, PURE APPL CHEM, V73, P1319, DOI 10.1351/pac200173081319                                                         
   Gogol P, 2006, TETRAHEDRON LETT, V47, P79, DOI 10.1016/j.tetlet.2005.10.134
   Gomes MDT, 1996, CATAL LETT, V42, P213, DOI 10.1007/BF00810691
   Grobler JA, 2007, J BIOL CHEM, V282, P8005, DOI 10.1074/jbc.M608274200
   Harapanhalli RS, 1996, J MED CHEM, V39, P4804, DOI 10.1021/jm9602672                                                               
   Hasaninejad A, 2009, PHOSPHORUS SULFUR, V184, P147, DOI 10.1080/10426500802080931
   Heravi MM, 2008, CATAL COMMUN, V9, P504, DOI 10.1016/j.catcom.2007.03.011
   Hranjec M, 2007, J MED CHEM, V50, P5696, DOI 10.1021/jmo70876h
   Huang ST, 2006, BIOORGAN MED CHEM, V14, P6106, DOI 10.1016/j.bmc.2006.05.007
   Itoh T, 2004, HETEROCYCLES, V63, P2769
   JACOBSEN EN, 1991, J AM CHEM SOC, V113, P7063, DOI 10.1021/ja00018a068                                                             
   Jain SL, 2008, ADV SYNTH CATAL, V350, P1479, DOI 10.1002/adse.200800264
   Ji SJ, 2006, DYES PIGMENTS, V70, P246, DOI 10.1016/j.dyepig.2005.03.007
   KATSAROS N, 1982, TRANSIT METAL CHEM, V7, P72, DOI 10.1007/BF00618185                                                              
   Katsuki T, 1996, J MOL CATAL A-CHEM, V113, P87, DOI 10.1016/S1381-1169(96)00106-9                                                   
   Kawashita Y, 2003, ORG LETT, V5, P3713, DOI 10.1021/ol035393w
   Kawashita Y, 2006, TETRAHEDRON LETT, V47, P4231, DOI 10.1016/j.tetlet.2006.04.019
   Kobayashi H, 2008, J MOL CATAL A-CHEM, V294, P43, DOI 10.1016/j.molcata.2008.07.019
   Kodomari M, 2004, SYNTHETIC COMMUN, V34, P3029, DOI 10.1081/SCC-200026663
   Kozlov YN, 2007, J PHYS CHEM A, V111, P7736, DOI 10.1021/jp0700884
   Kumar A, 2010, MOL DIVERS, V14, P331, DOI 10.1007/s11030-009-9170-8
   Lee KJ, 2001, CAN J CHEM, V79, P1556, DOI 10.1139/cjc-79-11-1556                                                          
   Lima LF, 2005, REACT KINET CATAL L, V84, P69, DOI 10.1007/s11144-005-0192-7                                                       
   Lin SN, 2005, TETRAHEDRON LETT, V46, P4315, DOI 10.1016/j.tetlet.2005.04.101
   Loos D, 1999, MOLECULES, V4, P81, DOI 10.3390/40400081                                                                
   Maruyama K, 1996, J ORG CHEM, V61, P3342, DOI 10.1021/jo950944k                                                               
   Maurya MR, 2006, DALTON T, P3561, DOI 10.1039/b600822d
   Maurya MR, 2010, INORG CHEM, V49, P6586, DOI 10.1021/ic1004209
   Mckee ML, 2008, BIOORGAN MED CHEM, V16, P1775, DOI 10.1016/j.bmc.2007.11.019
   McMorn P, 2004, CHEM SOC REV, V33, P108, DOI 10.1039/b200387m
   Miller JA, 2002, ANGEW CHEM INT EDIT, V41, P2953, DOI 10.1002/1521-3773(20020816)41:16<2953::AID-ANIE2953>3.0.CO;2-2                  
   Morningstar ML, 2007, J MED CHEM, V50, P4003, DOI 10.1021/jm060103d
   Mortimer CG, 2006, J MED CHEM, V49, P179, DOI 10.1021/jm050942k
   Mukhopadhyay C, 2007, HETEROCYCLES, V71, P1837, DOI 10.3987/COM-07-11079                                                            
   Nagata K, 2003, HETEROCYCLES, V61, P93
   Navarrete-Vazquez G, 2006, BIOORG MED CHEM LETT, V16, P4169, DOI 10.1016/j.bmcl.2006.05.082
   Oksuzoglu E, 2007, MED CHEM RES, V16, P1, DOI 10.1007/s00044-007-9005-z
   PASQUALI M, 1979, INORG CHEM, V18, P2401, DOI 10.1021/ic50199a014                                                             
   PATZOLD F, 1992, SYNTHETIC COMMUN, V22, P281, DOI 10.1080/00397919208021304
   Pereira C, 2008, J MOL CATAL A-CHEM, V283, P5, DOI 10.1016/j.molcata.2007.11.034
   PERRY RJ, 1993, J ORG CHEM, V58, P7016, DOI 10.1021/jo00077a019                                                             
   Rasmussen K, 2007, NEUROPSYCHOPHARMACOL, V32, P786, DOI 10.1038/sj.npp.1301239
   Ravi V, 2007, CHEM PHARM BULL, V55, P1254, DOI 10.1248/cpb.55.1254
   Razus AC, 2007, DYES PIGMENTS, V74, P26, DOI 10.1016/j.dyepig.2006.01.041
   Sadeghi S, 2004, SENSOR ACTUAT B-CHEM, V98, P174, DOI 10.1016/j.snb.2003.10.005
   Saito B, 2001, TETRAHEDRON LETT, V42, P3873, DOI 10.1016/S0040-4039(01)00590-1                                                   
   Shamsipur M, 2001, ANAL CHEM, V73, P2869, DOI 10.0121/ac001449d
   Shamsipur M, 2001, ANAL CHIM ACTA, V450, P37, DOI 10.1016/S0003-2670(01)01380-0                                                   
   Shamsipur M, 2007, ELECTROANAL, V19, P1661, DOI 10.1002/elan.200703902
   Sharghi H, 2004, SYNTHESIS-STUTTGART, P2900, DOI 10.1055/s-2004-831253
   Sharghi H, 2011, J IRAN CHEM SOC, V8, pS89, DOI 10.1007/BF03254285                                                              
   Sharghi H, 2003, B CHEM SOC JPN, V76, P137, DOI 10.1246/bcsj.76.137                                                             
   Sharghi H, 2010, J IRAN CHEM SOC, V7, P275, DOI 10.1007/BF03245889                                                              
   Sharghi H, 1999, B CHEM SOC JPN, V72, P1525, DOI 10.1246/bcsj.72.1525                                                            
   Sharghi H, 2008, ADV SYNTH CATAL, V350, P2380, DOI 10.1002/adsc.200800317
   Sharghi H, 2008, SYNTHETIC COMMUN, V38, P1128, DOI 10.1080/00397910701863657
   Sharghi H, 2008, CAN J CHEM, V86, P426, DOI 10.1139/V08-026
   Sharghi H, 2007, HETEROCYCLES, V71, P1601, DOI 10.3987/COM-07-11044                                                            
   Sharghi H, 2010, ADV SYNTH CATAL, V352, P3031, DOI 10.1002/adsc.201000319
   Sharghi H, 2008, EUR J ORG CHEM, P4126, DOI 10.1002/ejoc.200800351
   Sharghi H, 2010, HELV CHIM ACTA, V93, P435, DOI 10.1002/hlca.200900226                                                          
   Sharghi H, 2010, CAN J CHEM, V88, P14, DOI 10.1139/V09-141
   Sharghi H, 2009, ADV SYNTH CATAL, V351, P2391, DOI 10.1002/adsc.200900353
   Sharghi H, 2009, SYNTHETIC COMMUN, V39, P860, DOI 10.1080/00397910802431214
   Sharghi H, 2009, ADV SYNTH CATAL, V351, P207, DOI 10.1002/adsc.200800612
   Sharghi H, 2008, CAN J CHEM, V86, P1044, DOI 10.1139/V08-153
   SHIHADA AF, 1974, Z ANORG ALLG CHEM, V408, P9, DOI 10.1002/zaac.19744080103                                                        
   SINGH MP, 1992, CHEM RES TOXICOL, V5, P597, DOI 10.1021/tx00029a003
   Singh MP, 2000, SYNTHESIS-STUTTGART, P1380
   STEPHENS FF, 1949, J CHEM SOC, P2971, DOI 10.1039/jr9490002971                                                            
   Tamura Y, 2003, TETRAHEDRON LETT, V44, P3301, DOI 10.1016/S0040-4039(03)00609-9
   TERASHIMA M, 1982, SYNTHESIS-STUTTGART, P484, DOI 10.1055/s-1982-29847                                                            
   Trivedi R, 2006, J MOL CATAL A-CHEM, V245, P8, DOI 10.1016/j.molcata.2005.09.025
   Van Zandt MC, 2005, J MED CHEM, V48, P3141, DOI 10.1021/jm0492094
   VANDENEYNDE JJ, 1995, TETRAHEDRON, V51, P5813, DOI 10.1016/0040-4020(95)00252-4                                                    
   Velusamy S, 2003, EUR J ORG CHEM, P3913, DOI 10.1002/ejoc.200300324
   Verner E, 2001, J MED CHEM, V44, P2753, DOI 10.1021/0100638
   Weidner-Wells MA, 2001, BIOORG MED CHEM LETT, V11, P1545, DOI 10.1016/S0960-894X(01)00024-5
   Xin L., 1999, WUHAN U J NAT SCI, V4, P355
   YADAGIRI B, 1990, SYNTHETIC COMMUN, V20, P955, DOI 10.1080/00397919008052798
   Yang SA, 2005, J CRYST GROWTH, V280, P60, DOI 10.1016/j.jcrysgro.2005.03.046
   Zhang HD, 2008, J CATAL, V256, P226, DOI 10.1016/j.jcat.2008.03.013
   Zhao JQ, 2008, J INORG ORGANOMET P, V18, P441, DOI 10.1007/s10904-008-9221-0
NR 110
TC 21
Z9 21
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1735-207X
J9 J IRAN CHEM SOC
JI J. Iran Chem. Soc.
PD APR
PY 2012
VL 9
IS 2
SI SI
BP 189
EP 204
DI 10.1007/s13738-011-0045-4
PG 16
WC Chemistry, Multidisciplinary
SC Chemistry
GA 912FQ
UT WOS:000301780500012
DA 2018-01-05
ER

PT J
AU Usha, V
   Hobrath, JV
   Gurcha, SS
   Reynolds, RC
   Besra, GS
AF Usha, Veeraraghavan
   Hobrath, Judith V.
   Gurcha, Sudagar S.
   Reynolds, Robert C.
   Besra, Gurdyal S.
TI Identification of Novel Mt-Guab2 Inhibitor Series Active against M.
   tuberculosis
SO PLOS ONE
LA English
DT Article
ID INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; GENE-DISRUPTED MICE;
   MONOPHOSPHATE DEHYDROGENASE; IMP DEHYDROGENASE; CRYSTAL-STRUCTURE;
   MYCOBACTERIUM-TUBERCULOSIS; MYCOPHENOLIC-ACID; IN-VIVO;
   BORRELIA-BURGDORFERI; DRUG DISCOVERY
AB Tuberculosis (TB) remains a leading cause of mortality worldwide. With the emergence of multidrug resistant TB, extensively drug resistant TB and HIV-associated TB it is imperative that new drug targets be identified. The potential of Mycobacterium tuberculosis inosine monophosphate dehydrogenase (IMPDH) as a novel drug target was explored in the present study. IMPDH exclusively catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP) in the presence of the cofactor nicotinamide adenine dinucleotide (NAD(+)). Although the enzyme is a dehydrogenase, the enzyme does not catalyze the reverse reaction i.e. the conversion of XMP to IMP. Unlike other bacteria, M. tuberculosis harbors three IMPDH-like genes, designated as Mt-guaB1, Mt-guaB2 and Mt-guaB3 respectively. Of the three putative IMPDH's, we previously confirmed that Mt-GuaB2 was the only functional ortholog by characterizing the enzyme kinetically. Using an in silico approach based on designed scaffolds, a series of novel classes of inhibitors was identified. The inhibitors possess good activity against M. tuberculosis with MIC values in the range of 0.4 to 11.4 mu g mL(-1). Among the identified ligands, two inhibitors have nanomolar K(i)s against the Mt-GuaB2 enzyme.
C1 [Usha, Veeraraghavan; Gurcha, Sudagar S.; Besra, Gurdyal S.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.
   [Hobrath, Judith V.; Reynolds, Robert C.] So Res Inst, Drug Discovery Div, Birmingham, AL 35255 USA.
RP Usha, V (reprint author), Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.
EM g.besra@bham.ac.uk
OI Besra, Gurdyal/0000-0002-5605-0395
FU American Reinvestment and Recovery Act [1RC1AI086677-01]; National
   Institutes of Health (NIH); National Institute of Allergy and Infectious
   Diseases (NIAID); Tuberculosis Antimicrobial Acquisition and
   Coordinating Facility through research and development [NO1 AI-95385];
   Colorado State University; DHHS; NIH; NIAID-United States of America
   IDIQ [HHSN266200600011C]
FX GSB acknowledges support in the form of a Personal Research Chair from
   Mr. James Bardrick, Royal Society Wolfson Research Merit Award, as a
   former Lister Institute-Jenner Fellow. RCR acknowledges American
   Reinvestment and Recovery Act Grant 1RC1AI086677-01 (National Institutes
   of Health (NIH), National Institute of Allergy and Infectious Diseases
   (NIAID)) "Targeting MDR-TB''; the Tuberculosis Antimicrobial Acquisition
   and Coordinating Facility through research and development contracts NO1
   AI-95385 by Dr. Anne Lenaerts at Colorado State University (Program
   Officer: Dr. Robert Goldman); DHHS, NIH, NIAID-United States of America
   IDIQ contract number HHSN266200600011C by Dr. Anne Lenaerts at Colorado
   State University (Program Officer: Dr. Tina Parker). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ananthan S, 2009, TUBERCULOSIS, V89, P334, DOI 10.1016/j.tube.2009.05.008
   Arai M, 2008, BIOORGAN MED CHEM, V16, P6732, DOI 10.1016/j.bmc.2008.05.061
   BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333
   CARR SF, 1993, J BIOL CHEM, V268, P27286
   Chaturvedi V, 2007, J GEN APPL MICROBIOL, V53, P333, DOI 10.2323/jgam.53.333
   Chen LQ, 2010, J MED CHEM, V53, P4768, DOI 10.1021/jm100424m
   Chen P, 2003, BIOORG MED CHEM LETT, V13, P1345, DOI 10.1016/S0960-894X(03)00107-0
   Chiang CY, 2010, RESPIROLOGY, V15, P413, DOI 10.1111/j.1440-1843.2010.01738.x
   Colby TD, 1999, P NATL ACAD SCI USA, V96, P3531, DOI 10.1073/pnas.96.7.3531
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159                                                                   
   COONEY DA, 1982, BIOCHEM PHARMACOL, V31, P2133, DOI 10.1016/0006-2952(82)90436-1                                                    
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   Dhar TGM, 2002, J MED CHEM, V45, P2127, DOI 10.1021/jm0105777
   Digits JA, 1999, BIOCHEMISTRY-US, V38, P15388, DOI 10.1021/bi991558q                                                               
   Digits JA, 1999, BIOCHEMISTRY-US, V38, P2295, DOI 10.1021/bi982305k
   Dobie F, 2007, MOL BIOCHEM PARASIT, V152, P11, DOI 10.1016/j.molbiopara.2006.11.007
   Dye C, 2010, SCIENCE, V328, P856, DOI 10.1126/science.1185449
   Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200
   FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515                                                               
   Gan L, 2002, BIOCHEMISTRY-US, V41, P13309, DOI 10.1021/bi0203785
   GILBERT HJ, 1979, BIOCHEM J, V183, P481, DOI 10.1042/bj1830481                                                               
   Goldstein BM, 1999, CURR MED CHEM, V6, P519
   Harries AD, 2006, ANN TROP MED PARASIT, V100, P415, DOI 10.1179/136485906X91477
   HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001
   Hedstrom L, 2009, CHEM REV, V109, P2903, DOI 10.1021/cr900021w
   JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x
   Lenaerts AJM, 2003, ANTIMICROB AGENTS CH, V47, P783, DOI 10.1128/AAC.47.2.783-785.2003
   Lenaerts AJ, 2008, ANTIMICROB AGENTS CH, V52, P1513, DOI 10.1128/AAC.00897-07
   Li XZ, 2004, ANTIMICROB AGENTS CH, V48, P2415, DOI 10.1128/AAC.48.7.2415-2423.2004
   MacPherson IS, 2010, J AM CHEM SOC, V132, P1230, DOI 10.1021/ja909947a
   Maddry JA, 2009, TUBERCULOSIS, V89, P354, DOI 10.1016/j.tube.2009.07.006
   Martinson NA, 2010, P AM THORAC SOC, V8, P288
   Maurya SK, 2009, J MED CHEM, V52, P4623, DOI 10.1021/jm900410u
   McMillan FM, 2000, BIOCHEMISTRY-US, V39, P4533, DOI 10.1021/bi992645l
   OGara MJ, 1997, ANTIMICROB AGENTS CH, V41, P40
   Orme I, 2001, ANTIMICROB AGENTS CH, V45, P1943
   Park SJ, 2004, PROTEOMICS, V4, P3632, DOI 10.1002/pmic.200400921
   Pimkin M, 2009, J BIOL CHEM, V284, P7960, DOI 10.1074/jbc.M808541200
   Prosise GL, 2002, J BIOL CHEM, V277, P50654, DOI 10.1074/jbc.M208330200
   Reynolds RC, 2012, TUBERCULOSIS, V92, P72, DOI 10.1016/j.tube.2011.05.005
   Riera TV, 2008, BIOCHEMISTRY-US, V47, P8689, DOI 10.1021/bi800674a
   Rullas J, 2010, ANTIMICROB AGENTS CH, V54, P2262, DOI 10.1128/AAC.01423-09
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498
   Sharling L, 2010, PLOS NEGL TROP DIS
   Shu QN, 2008, MED RES REV, V28, P219, DOI 10.1002/med.20104
   Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1
   Umejiego NN, 2004, J BIOL CHEM, V279, P40320, DOI 10.1074/jbc.M407121200
   Usha V, 2010, MICROBIOLOGY, V715, P290
   Wang W, 1998, BIOCHEMISTRY-US, V37, P11949, DOI 10.1021/bi981132w                                                               
   Watterson SH, 2007, J MED CHEM, V50, P3730, DOI 10.1021/jm070299x
   Whitby FG, 1997, BIOCHEMISTRY-US, V36, P10666, DOI 10.1021/bi9708850                                                               
   Yew WW, 2011, AM J RESP CRIT CARE, V184, P180, DOI 10.1164/rccm.201102-0325UP
   Zhang RG, 1999, BIOCHEMISTRY-US, V38, P4691, DOI 10.1021/bi982858v                                                               
   Zhang XH, 2009, MICROB PATHOGENESIS, V47, P267, DOI 10.1016/j.micpath.2009.09.001
   Zhou X, 1997, J BIOL CHEM, V272, P21977, DOI 10.1074/jbc.272.35.21977
   Hedstrom L.K., 2007, Patent No. [WO 2007143557, 2007143557]
   Hedstrom L.K., 2010, Patent No. [WO 2010108187, 2010108187]
NR 58
TC 15
Z9 16
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2012
VL 7
IS 3
AR e33886
DI 10.1371/journal.pone.0033886
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 948SR
UT WOS:000304523400042
PM 22479467
OA gold
DA 2018-01-05
ER

PT J
AU Gelot, T
   Touron-Touceda, P
   Cregut, O
   Leonard, J
   Haacke, S
AF Gelot, Thomas
   Touron-Touceda, Patricia
   Cregut, Olivier
   Leonard, Jeremie
   Haacke, Stefan
TI Ultrafast Site-Specific Fluorescence Quenching of 2-Aminopurine in a DNA
   Hairpin Studied by Femtosecond Down-Conversion
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID CHARGE-TRANSFER DYNAMICS; NUCLEOCAPSID PROTEIN; COMPLEMENTARY SEQUENCES;
   TRANSIENT ABSORPTION; ELECTRON-TRANSFER; AQUEOUS-SOLUTION; STRAND
   TRANSFER; UP-CONVERSION; BINDING-SITE; RNA
AB The Delta P(-)PBS analog of the DNA primary binding sequence (PBS) of the HIV-1 genome labeled at different positions by 2-aminopurine (2-AP) is investigated by a novel femtosecond fluorescence down-conversion experiment with 0.3-ps time resolution. The high signal-to-noise ratio of the fluorescence kinetics makes it possible to reveal four distinct decay times ranging from 0.8 ps to 2-3 ns for all the three labeling positions. This suggests the existence of at least four different quenching conformations of 2-AP with its nearest neighbors, and underscores the structural heterogeneity of the loop region of Delta P(-)PBS. Sub-5-ps components are found and attributed to stacking interactions of 2-AP with the flanking guanine (G) side chains, consistent with the NMR structure of Delta P(-)PBS. The observation of a significant increase of their total amplitude when 2-AP is positioned close to the rigid 3'-half of the G-rich stem gives further support to this assignment. Only a minor portion of conformations involves slow nanosecond collisional quenching.
C1 [Gelot, Thomas; Touron-Touceda, Patricia; Cregut, Olivier; Leonard, Jeremie; Haacke, Stefan] Univ Strasbourg, CNRS, Inst Phys & Chim Mat Strasbourg, F-67034 Strasbourg, France.
RP Haacke, S (reprint author), Univ Strasbourg, CNRS, Inst Phys & Chim Mat Strasbourg, F-67034 Strasbourg, France.
EM haacke@unistra.fr
RI Haacke, Stefan/B-5554-2013; Leonard, Jeremie/A-9589-2012
OI Haacke, Stefan/0000-0002-6969-4667; 
FU Agence Nationale de la Recherche [ANR-2010-BLAN-1529-01]
FX We thank Pr. Yves Mely (University of Strasbourg) for insightful
   discussions and advice. G. Dekyndt and J.-P. Vola provided expert
   technical assistance. The FEMTOSTACK project is funded by the Agence
   Nationale de la Recherche contract ANR-2010-BLAN-1529-01.
CR Al-Hashimi HM, 2008, CURR OPIN STRUC BIOL, V18, P321, DOI 10.1016/j.sbi.2008.04.004
   Avilov SV, 2008, NUCLEIC ACIDS RES, V36, P885, DOI 10.1093/nar/gkm1109
   Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232
   Bombarda E, 1999, BIOPHYS J, V76, P1561, DOI 10.1016/S0006-3495(99)77315-7                                                   
   Bourbigot S, 2008, J MOL BIOL, V383, P1112, DOI 10.1016/j.jmb.2008.08.046
   Fiebig T, 2002, CHEMPHYSCHEM, V3, P781, DOI 10.1002/1439-7641(20020916)3:9<781::AID-CPHC781>3.0.CO;2-U                      
   FLEMING GR, 1978, P NATL ACAD SCI USA, V75, P4652, DOI 10.1073/pnas.75.10.4652
   Godet J, 2006, J MOL BIOL, V356, P1180, DOI 10.1016/j.jmb.2005.12.038
   Godet J, 2011, NUCLEIC ACIDS RES, V39, P6633, DOI 10.1093/nar/gkr274
   Haacke S, 1998, J OPT SOC AM B, V15, P1410, DOI 10.1364/JOSAB.15.001410
   Haustein E, 2004, CURR OPIN STRUC BIOL, V14, P531, DOI 10.1016/j.sbi.2004.09.004
   Jean JM, 2004, BIOCHEMISTRY-US, V43, P10277, DOI 10.1021/bi049701p
   Jean JM, 2001, P NATL ACAD SCI USA, V98, P37, DOI 10.1073/pnas.011442198
   Johnson NP, 2004, P NATL ACAD SCI USA, V101, P3426, DOI 10.1073/pnas.0400591101
   Larsen O.F.A., 2004, PHYS CHEM CHEM PHYS, V6, P154
   Larsen O.F.A., 2001, BIOPHYS J, V81, P1115
   Larsen OFA, 2003, CHEM PHYS LETT, V371, P157, DOI 10.1016/S0009-2614(03)00212-4
   Leonard J, 2010, PHYS CHEM CHEM PHYS, V12, P15744, DOI 10.1039/c0cp00615g
   Leonard J., 2011, J PHYS C SER, V277, P012017
   Liu JD, 2008, BIOCHEMISTRY-US, V47, P5962, DOI 10.1021/bi800210t
   Manoj P, 2008, CHEM PHYS, V352, P333, DOI 10.1016/j.chemphys.2008.07.005
   Qiu WH, 2008, CHEM PHYS, V350, P154, DOI 10.1016/j.chemphys.2008.01.061
   Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o
   Ramalanjaona N, 2007, J MOL BIOL, V374, P1041, DOI 10.1016/j.jmb.2007.10.001
   Rocquigny H., 2011, NUCLEIC ACIDS RES, V39, P6633
   Rogues B.P., 2008, J MOL BIOL, V383, P1112
   Schanz R, 2001, APPL PHYS LETT, V79, P566, DOI 10.1063/1.1387257
   Schuler B, 2008, CURR OPIN STRUC BIOL, V18, P16, DOI 10.1016/j.sbi.2007.12.003
   Sharma D, 2010, CHEM PHYS LETT, V489, P99, DOI 10.1016/j.cplett.2010.02.057
   Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b                                                               
   SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/ja00522a020
   Wan CZ, 2005, CHEM PHYS LETT, V412, P158, DOI 10.1016/j.cplett.2005.06.101
   Wan CZ, 2000, P NATL ACAD SCI USA, V97, P14052, DOI 10.1073/pnas.250483297
   Wang Q, 2007, PHOTOCHEM PHOTOBIOL, V83, P637, DOI 10.1111/j.1751-1097.2007.00115.x
   Xia TB, 2005, P NATL ACAD SCI USA, V102, P13013, DOI 10.1073/pnas.0506181102
   Xia TB, 2003, P NATL ACAD SCI USA, V100, P8119, DOI 10.1073/pnas.1433099100
   Xia TB, 2008, CURR OPIN CHEM BIOL, V12, P604, DOI 10.1016/j.cbpa.2008.08.033
   Zhao L, 2007, J AM CHEM SOC, V129, P4118, DOI 10.1021/ja068391q
NR 38
TC 11
Z9 11
U1 0
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD MAR 22
PY 2012
VL 116
IS 11
BP 2819
EP 2825
DI 10.1021/jp212187m
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 912AT
UT WOS:000301766500028
PM 22289047
DA 2018-01-05
ER

PT J
AU Kumar, S
   Kellish, P
   Robinson, WE
   Wang, DY
   Appella, DH
   Arya, DP
AF Kumar, Sunil
   Kellish, Patrick
   Robinson, W. Edward, Jr.
   Wang, Deyun
   Appella, Daniel H.
   Arya, Dev P.
TI Click Dimers To Target HIV TAR RNA Conformation
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEIC ACID INTERACTIONS; LONG TERMINAL
   REPEAT; DNA TRIPLE-HELIX; B-DNA; NEOMYCIN CONJUGATE; MAJOR GROOVE;
   RECOGNITION; BINDING; PROTEIN
AB A series of neomycin dimers have been synthesized using "click chemistry" with varying functionality and length in the linker region to target the human immunodeficiency virus type 1 (HIV-1) TAR RNA region of the HIV virus. The TAR (Trans-Activation Responsive) RNA region, a 59 bp stem-loop structure located at the 5'-end of all nascent viral transcripts, interacts with its target, a key regulatory protein, Tat, and necessitates the replication of HIV-1. Neomycin, an aminosugar, has been shown to exhibit multiple binding sites on TAR RNA. This observation prompted us to design and synthesize a library of triazole-linked neomycin dimers using click chemistry. The binding between neomycin dimers and TAR RNA was characterized using spectroscopic techniques, including FID (fluorescent intercalator displacement), a FRET (fluorescence resonance energy transfer) competitive assay, circular dichroism (CD), and UV thermal denaturation. UV thermal denaturation studies demonstrate that binding of neomycin dimers increases the melting temperature (T-m) of the HIV TAR RNA up to 10 degrees C. Ethidium bromide displacement (FID) and a FRET competition assay revealed nanomolar binding affinity between neomycin dimers and HIV TAR RNA, while in case of neomycin, only weak binding was detected. More importantly, most of the dimers exhibited lower IC50 values toward HIV TAR RNA, when compared to the fluorescent Tat peptide, and show increased selectivity over mutant TAR RNA. Cytopathic effects investigated using MT-2 cells indicate a number of the dimers with high affinity toward TAR show promising anti-HIV activity.
C1 [Kumar, Sunil; Kellish, Patrick; Arya, Dev P.] Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
   [Robinson, W. Edward, Jr.] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
   [Wang, Deyun; Appella, Daniel H.] NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Arya, DP (reprint author), Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
EM dparya@clemson.edu
RI perumal, murugiah/D-1565-2012
FU National Science Foundation [CHE/MCB-0134972]; National Institutes of
   Health [R15CA125724]
FX We thank the National Science Foundation (CHE/MCB-0134972) and the
   National Institutes of Health (R15CA125724) for financial support.
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Arya DP, 2011, ACCOUNTS CHEM RES, V44, P134, DOI 10.1021/ar100113q
   Arya DP, 2005, TOP CURR CHEM, V253, P149, DOI 10.1007/b100446
   Arya DP, 2004, BIOORG MED CHEM LETT, V14, P4643, DOI 10.1016/j.bmcl.2004.07.002
   Arya DP, 2003, J AM CHEM SOC, V125, P10148, DOI 10.1021/ja035117c
   Arya DP, 2003, J AM CHEM SOC, V125, P8070, DOI 10.1021/ja034241t
   Arya DP, 2003, J AM CHEM SOC, V125, P12398, DOI 10.1021/ja036742k
   Arya DP, 2003, J AM CHEM SOC, V125, P3733, DOI 10.1021/ja027765m
   Arya DP, 2001, J AM CHEM SOC, V123, P5385, DOI 10.1021/ja003052x
   Arya DP, 2001, J AM CHEM SOC, V123, P11093, DOI 10.1021/ja016481j
   Arya DP, 2000, BIOORG MED CHEM LETT, V10, P1897, DOI 10.1016/S0960-894X(00)00372-3                                                   
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   BERKHOUT B, 1989, J VIROL, V63, P5501
   Boger DL, 2001, J AM CHEM SOC, V123, P5878, DOI 10.1021/ja010041a
   Charles I, 2005, J CARBOHYD CHEM, V24, P145, DOI 10.1081/CAR-200059973
   Charles I, 2002, BIOORG MED CHEM LETT, V12, P1259, DOI 10.1016/S0960-894X(02)00157-9
   Charles I, 2007, BIOCONJUGATE CHEM, V18, P160, DOI 10.1021/bc060249r
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113                                             
   FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0                                                                
   Hamilton PL, 2012, NAT PROD REP, V29, P134, DOI 10.1039/c1np00054c
   HAUBER J, 1988, J VIROL, V62, P673
   Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Kolb HC, 2003, DRUG DISCOV TODAY, V8, P1128, DOI 10.1016/S1359-6446(03)02933-7
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kumar S, 2011, BIOORG MED CHEM LETT, V21, P4788, DOI 10.1016/j.bmcl.2011.06.058
   Kumar S, 2011, J AM CHEM SOC, V133, P7361, DOI 10.1021/ja108118v
   LEONARD R, 1988, P NATL ACAD SCI USA, V85, P3570, DOI 10.1073/pnas.85.10.3570
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Matsumoto C, 2000, BIOORG MED CHEM LETT, V10, P1857, DOI 10.1016/S0960-894X(00)00359-0
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3                                                   
   Michael K, 1999, BIOORGAN MED CHEM, V7, P1361, DOI 10.1016/S0968-0896(99)00071-1                                                   
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9                                                    
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Raghunathan D, 2006, NUCLEIC ACIDS RES, V34, P3599, DOI 10.1093/nar/gkl494
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Ranjan N, 2010, BIOCHEMISTRY-US, V49, P9891, DOI 10.1021/bi101517e
   RATMEYER LS, 1992, J MED CHEM, V35, P966, DOI 10.1021/jm00083a024
   RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X                                                       
   Riguet E, 2005, BIOORG MED CHEM LETT, V15, P4651, DOI 10.1016/j.bmcl.2005.07.082
   ROBINSON WE, 1989, J ACQ IMMUN DEF SYND, V2, P33
   ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4                  
   Sannes-Lowery KA, 1999, INT J MASS SPECTROM, V193, P115, DOI 10.1016/S1387-3806(99)00111-6
   Shaw NN, 2008, BIOORG MED CHEM LETT, V18, P4142, DOI 10.1016/j.bmcl.2008.05.090
   Shaw NN, 2008, BIOCHIMIE, V90, P1026, DOI 10.1016/j.biochi.2008.04.011
   SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009                                                             
   Suryawanshi H, 2010, J PHYS CHEM B, V114, P11155, DOI 10.1021/jp1000545
   TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723
   Thomas JR, 2008, CHEM REV, V108, P1171, DOI 10.1021/cr0681546
   Tor Y, 2006, BIOCHIMIE, V88, P1045, DOI 10.1016/j.biochi.2006.03.005
   Wang H, 1997, BIOORG MED CHEM LETT, V7, P1951, DOI 10.1016/S0960-894X(97)00339-9
   Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a
   Willis B, 2006, CURR ORG CHEM, V10, P663, DOI 10.2174/138527206776359739                                                      
   Willis B, 2006, BIOCHEMISTRY-US, V45, P10217, DOI 10.1021/bi0609265
   Willis B, 2006, ADV CARBOHYD CHEM BI, V60, P251, DOI 10.1016/S0065-2318(06)60006-1
   Willis B, 2010, BIOCHEMISTRY-US, V49, P452, DOI 10.1021/bi9016796
   Willis B, 2009, BIOORG MED CHEM LETT, V19, P4974, DOI 10.1016/j.bmcl.2009.07.079
   Xi H., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P327, DOI 10.2174/1568011054222328
   Xi HJ, 2011, BIOCHEMISTRY-US, V50, P9088, DOI 10.1021/bi201077h
   Xi HJ, 2010, BIOCHIMIE, V92, P514, DOI 10.1016/j.biochi.2010.02.004
   Xi HJ, 2009, FEBS LETT, V583, P2269, DOI 10.1016/j.febslet.2009.06.007
   Xue L, 2002, CHEM COMMUN, P70, DOI 10.1039/b108171c
   Xue LA, 2011, BIOCHEMISTRY-US, V50, P2838, DOI 10.1021/bi1017304
   Xue LA, 2010, BIOCHEMISTRY-US, V49, P5540, DOI 10.1021/bi100071j
NR 67
TC 37
Z9 37
U1 1
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 20
PY 2012
VL 51
IS 11
BP 2331
EP 2347
DI 10.1021/bi201657k
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 910KX
UT WOS:000301636700017
PM 22339203
OA green_accepted
DA 2018-01-05
ER

PT J
AU Fan, Q
   Zhao, J
   Li, H
   Zhu, L
   Li, GX
AF Fan, Qi
   Zhao, Jing
   Li, Hao
   Zhu, Li
   Li, Genxi
TI Exonuclease III-based and gold nanoparticle-assisted DNA detection with
   dual signal amplification
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Exonuclease III; Gold nanoparticles; HIV; DNA detection; Voltammetry;
   Chronocoulometry
ID ELECTRODES; COMBINATION; FABRICATION; MONOLAYERS; APOPTOSIS; APTAMER;
   PROBES; PCR
AB Herein we report a sensitive electrochemical biosensor for DNA detection by making use of exonuclease III and probe DNA functionalized gold nanoparticles. While probe DNA P1 modified on a gold electrode surface can self-hybridize into a stem-loop structure with an exonuclease III-resistant 3' overhang end, in the presence of target DNA, P1 may also hybridize with the target DNA to form a duplex region. Therefore, exonuclease III may selectively digest P1 from its 3'-hydroxyl termini until the duplex is fully consumed. Since a single target DNA can trigger exonuclease III digestion of numerous P1 strands, the first signal amplification is achieved. On the other hand, since the digested P1, exposing its complementary sequence to probe DNA P2, can further hybridize with P2 that has been previously modified on the surface of gold nanoparticles, many nanoparticles loaded with numerous DNA strands are immobilized onto the electrode surface. Consequently, large amount of electroactive molecules [Ru(NH3)(6)](3)(+) can bind with the DNA strands to produce an intense electrochemical response as the second signal amplification. Based on the studies with cyclic voltammetry (CV) and chronocoulometry (CC) techniques, the proposed biosensor can sensitively detect specific target DNA at a picomolar level with high specificity. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Fan, Qi; Zhao, Jing; Zhu, Li; Li, Genxi] Shanghai Univ, Sch Life Sci, Lab Biosensing Technol, Shanghai 200444, Peoples R China.
   [Li, Hao; Li, Genxi] Nanjing Univ, Dept Biochem, Nanjing 210093, Jiangsu, Peoples R China.
   [Li, Hao; Li, Genxi] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China.
RP Li, GX (reprint author), Shanghai Univ, Sch Life Sci, Lab Biosensing Technol, Shanghai 200444, Peoples R China.
EM genxili@nju.edu.cn
RI Li, Genxi/H-1952-2013
OI Li, Genxi/0000-0001-9663-9914
FU National Science Fund for Distinguished Young Scholars [20925520];
   Fundamental Research Funds for the Central Universities [1116020801];
   Shanghai Municipal Education Commission [J50108]
FX This work is supported by the National Science Fund for Distinguished
   Young Scholars (grant no. 20925520), the Fundamental Research Funds for
   the Central Universities (grant no. 1116020801), and the Leading
   Academic Discipline Project of Shanghai Municipal Education Commission
   (J50108).
CR Baur J, 2010, ANAL CHEM, V82, P1066, DOI 10.1021/ac9024329
   Cao Y, 2010, BIOSENS BIOELECTRON, V26, P87, DOI 10.1016/j.bios.2010.05.019
   Cui LA, 2011, BIOSENS BIOELECTRON, V26, P2796, DOI 10.1016/j.bios.2010.11.005
   Cui LA, 2010, ANALYST, V135, P2069, DOI 10.1039/c0an00215a
   Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475
   Halford WP, 1999, NAT BIOTECHNOL, V17, P835, DOI 10.1038/12783                                                                   
   Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986
   Hsieh K, 2010, LANGMUIR, V26, P10392, DOI 10.1021/la100227s
   Jin RC, 2003, J AM CHEM SOC, V125, P1643, DOI 10.1021/ja021096v
   Katz E, 2005, J AM CHEM SOC, V127, P9191, DOI 10.1021/ja0517771
   Lao RJ, 2005, ANAL CHEM, V77, P6475, DOI 10.1021/ac050911x
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Liu T, 2009, ANAL CHEM, V81, P2410, DOI 10.1021/ac801267s
   Miao P, 2011, BIOSENS BIOELECTRON, V27, P178, DOI 10.1016/j.bios.2011.06.047
   Miao P, 2011, CURR NANOSCI, V7, P354, DOI 10.2174/157341311795542345                                                      
   Miao P, 2009, ELECTROCHEM COMMUN, V11, P1904, DOI 10.1016/j.elecom.2009.08.013
   Miao P, 2009, BIOSENS BIOELECTRON, V24, P3347, DOI 10.1016/j.bios.2009.04.041
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Schweitzer B, 2001, CURR OPIN BIOTECH, V12, P21, DOI 10.1016/S0958-1669(00)00172-5                                                   
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Staudt LM, 2001, TRENDS IMMUNOL, V22, P35, DOI 10.1016/S1471-4906(00)01792-0
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Tan E, 2007, CLIN CHEM, V53, P2017, DOI 10.1373/clinchem.2007.091116
   Wang J, 2009, BIOSENS BIOELECTRON, V24, P1598, DOI 10.1016/j.bios.2008.08.030
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Xiao H, 2008, ANAL CHEM, V80, P5272, DOI 10.1021/ac8005268
   Xu W, 2009, ANGEW CHEM INT EDIT, V48, P6849, DOI 10.1002/anie.200901772
   Zhang J, 2006, J AM CHEM SOC, V128, P8575, DOI 10.1021/ja061521a
   Zhang M, 2011, CHEM COMMUN, V47, P3478, DOI 10.1039/c0cc05703g
   Zhao J, 2011, CHEM COMMUN, V47, P5262, DOI 10.1039/c1cc10186b
   Zuo XL, 2010, J AM CHEM SOC, V132, P1816, DOI 10.1021/ja909551b
NR 31
TC 54
Z9 54
U1 7
U2 124
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAR 15
PY 2012
VL 33
IS 1
BP 211
EP 215
DI 10.1016/j.bios.2012.01.003
PG 5
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 911EJ
UT WOS:000301699800033
PM 22305442
DA 2018-01-05
ER

PT J
AU Varadarajan, N
   Kwon, DS
   Law, KM
   Ogunniyi, AO
   Anahtar, MN
   Richter, JM
   Walker, BD
   Love, JC
AF Varadarajan, Navin
   Kwon, Douglas S.
   Law, Kenneth M.
   Ogunniyi, Adebola O.
   Anahtar, Melis N.
   Richter, James M.
   Walker, Bruce D.
   Love, J. Christopher
TI Rapid, efficient functional characterization and recovery of
   HIV-specific human CD8(+) T cells using microengraving
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE T-cell cloning; single-cell analysis; nanowells; microarrays; soft
   lithography
ID CYTOKINE FLOW-CYTOMETRY; VIRAL LOAD; ANTIRETROVIRAL THERAPY; VIRUS
   CONTROL; RESPONSES; ANTIGEN; INFECTION; ELISPOT; LYMPHOCYTES; MECHANISMS
AB The nature of certain clinical samples (tissue biopsies, fluids) or the subjects themselves (pediatric subjects, neonates) often constrain the number of cells available to evaluate the breadth of functional T-cell responses to infections or therapeutic interventions. The methods most commonly used to assess this functional diversity ex vivo and to recover specific cells to expand in vitro usually require more than 106 cells. Here we present a process to identify antigen-specific responses efficiently ex vivo from 10(4)-10(5) single cells from blood or mucosal tissues using dense arrays of subnanoliter wells. The approach combines on-chip imaging cytometry with a technique for capturing secreted proteins-called "microengraving"-to enumerate antigen-specific responses by single T cells in a manner comparable to conventional assays such as ELISpot and intracellular cytokine staining. Unlike those assays, however, the individual cells identified can be recovered readily by micromanipulation for further characterization in vitro. Applying this method to assess HIV-specific T-cell responses demonstrates that it is possible to establish clonal CD8(+) T-cell lines that represent the most abundant specificities present in circulation using 100- to 1,000-fold fewer cells than traditional approaches require and without extensive genotypic analysis a priori. This rapid (<24 h), efficient, and inexpensive process should improve the comparative study of human T-cell immunology across ages and anatomic compartments.
C1 [Varadarajan, Navin; Ogunniyi, Adebola O.; Love, J. Christopher] MIT, Dept Chem Engn, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Kwon, Douglas S.; Law, Kenneth M.; Anahtar, Melis N.; Walker, Bruce D.; Love, J. Christopher] MIT, Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA 02129 USA.
   [Kwon, Douglas S.; Law, Kenneth M.; Anahtar, Melis N.; Walker, Bruce D.; Love, J. Christopher] Harvard Univ, Charlestown, MA 02129 USA.
   [Kwon, Douglas S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Richter, James M.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Love, JC (reprint author), MIT, Dept Chem Engn, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
EM clove@mit.edu
RI Ghartouchent, malek/B-9088-2012
OI Varadarajan, Navin/0000-0001-7524-8228
FU Charles A. Dana Foundation; W.M. Keck Foundation; Ragon Institute of
   Massachusetts General Hospital; Massachusetts Institute of Technology;
   Harvard University; National Institute of Allergy and Infectious
   Diseases/National Institutes of Health [U54-AI057156]; National
   Institutes of Health [K08, NIGMS 5T32GM008334]; Burroughs Wellcome Fund;
   United Negro College-Merck
FX This research was supported by the Charles A. Dana Foundation, the W.M.
   Keck Foundation, and the Ragon Institute of Massachusetts General
   Hospital, Massachusetts Institute of Technology, and Harvard University.
   N.V. received support from National Institute of Allergy and Infectious
   Diseases/National Institutes of Health GrantU54-AI057156. D.S.K. is
   supported by a National Institutes of Health Mentored Clinical Scientist
   Development Award (K08) and the Burroughs Wellcome Fund. A.O.O. was
   supported in part by National Institutes of Health Biotechnology
   Training Fellowship NIGMS 5T32GM008334 and by a United Negro College
   Fund-Merck Graduate Science Research Dissertation Fellowship. J.C.L. is
   a Latham Family Career Development Professor.
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Altman JD, 2003, CURR PROTOC IMMUNOL, V53, P1731
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   Billam P, 2011, J BIOL CHEM, V286, P4829, DOI 10.1074/jbc.M110.191437
   BORROW P, 1994, J VIROL, V68, P6103
   Bradshaw EM, 2008, CLIN IMMUNOL, V129, P10, DOI 10.1016/j.clim.2008.06.009
   Chen H, 2009, J VIROL, V83, P3138, DOI 10.1128/JVI.02073-08
   Choi JH, 2010, BIOTECHNOL PROGR, V26, P888, DOI 10.1002/btpr.374
   Dalod M, 1999, J VIROL, V73, P7108
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Dyer WB, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-112
   Ellis JM, 2000, HUM IMMUNOL, V61, P334, DOI 10.1016/S0198-8859(99)00155-X
   Han C, 2010, LAB CHIP, V10, P2848, DOI 10.1039/c005296e
   Han Q, 2012, P NATL ACAD SCI USA, V109, P1605
   Han Q, 2010, LAB CHIP, V10, P1391, DOI 10.1039/b926849a
   Haney D, 2011, J IMMUNOL METHODS, V369, P33, DOI 10.1016/j.jim.2011.04.003
   Hoff A, 2010, CANCER IMMUNOL IMMUN, V59, P1379, DOI 10.1007/s00262-010-0867-4
   Karlsson AC, 2003, J IMMUNOL METHODS, V283, P141, DOI 10.1016/j.jim.2003.09.001
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KOUP RA, 1994, J VIROL, V68, P4650
   Maecker HT, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-17
   Martin-Hirsch P., 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001036, DOI 10.1002/14651858.CD001036]
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0
   Pahar B, 2003, J IMMUNOL METHODS, V282, P103, DOI 10.1016/j.jim.2003.08.003
   Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271
   Pira GL, 2007, J IMMUNOL METHODS, V326, P22, DOI 10.1016/j.jim.2007.06.012
   Robins HS, 2010, SCI TRANSL MED, V2
   Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121
   Saez-Cirion A, 2009, J IMMUNOL, V182, P7828, DOI 10.4049/jimmunol.0803928
   Schaubert KL, 2010, EUR J IMMUNOL, V40, P1950, DOI 10.1002/eji.200940079
   Shacklett BL, 2003, J IMMUNOL METHODS, V279, P17, DOI 10.1016/S0022-1759(03)00255-2
   Song Q, 2010, ANAL CHEM, V82, P473, DOI 10.1021/ac9024363
   Streeck H, 2009, NAT PROTOC, V4, P461, DOI 10.1038/nprot.2009.7
   Subira D, 2002, AM J CLIN PATHOL, V117, P952, DOI 10.1309/123P-CE6V-WYAK-BB1F                                                     
   Sun Y, 2003, J IMMUNOL METHODS, V272, P23, DOI 10.1016/S0022-1759(02)00328-9
   Toebes M, 2009, CURR PROTOC IMMUNOL, V87
   Varadarajan N, 2011, J CLIN INVEST, V121, P4322, DOI 10.1172/JCI58653
   Yang OO, 1997, J VIROL, V71, P3120
   Yue C, 2010, J PROTEOME RES, V9, P5629, DOI 10.1021/pr100447b
   Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006
NR 42
TC 54
Z9 55
U1 2
U2 33
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 6
PY 2012
VL 109
IS 10
BP 3885
EP 3890
DI 10.1073/pnas.1111205109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 903LJ
UT WOS:000301117700058
PM 22355106
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, J
   Li, AS
   Kou, XJ
   Xiao, L
   Li, P
   He, NY
   Li, K
AF Zhang, Jia
   Li, Alice Saint Sinoasia
   Kou, Xiaojin
   Xiao, Li
   Li, Ping
   He, Nongyue
   Li, Kai
TI Why CCR5 is Chosen as the Target for Stem Cell Gene Therapy for HIV
   Infection?
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE HIV; AIDS; Stem Cell; Gene Therapy; CCR5
ID CARBON NANOTUBES; DRUG-DELIVERY; IN-VITRO; NANOPARTICLES; RESISTANCE;
   INDIVIDUALS; CORECEPTOR; AGENTS; VIVO
AB Since the first case reported in 1981, more than 60 million individuals have succumbed to HIV worldwide. Although great efforts have been put forth in developing therapeutic drugs and effective vaccines for the treatment and prevention of HIV infection, these efforts are not correlated to the reported case of cured HIV infection. The first case of cured HIV infection, from allogenic stem cell transplantation, may shed light on future prevention and therapy of HIV infection. The choice of gene target, however, must first be evaluated regarding stem cell based gene therapy for HIV infection. Out of the tens of genes that had shown anti-HIV infection potentials, CCR5 was described to be effective in stem cell based gene therapy in 2005. Here, we appreciate the clinical observations that directly led to the choice of CCR5, rather than other genes for stem cell gene therapy.
C1 [Li, Ping] Nanjing Med Univ, Affiliated Hosp, Nanjing Matern & Child Hlth Hosp, Nanjing 210004, Jiangsu, Peoples R China.
   [Zhang, Jia; Li, Alice Saint Sinoasia; Xiao, Li] Soochow Univ, Affiliated Hosp 2, Mol Med Ctr, Suzhou 215004, Peoples R China.
   [Kou, Xiaojin; Li, Kai] Soochow Univ, Coll Pharmaceut Sci, Mol Med Lab, Suzhou 215123, Peoples R China.
   [He, Nongyue] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
RP Li, P (reprint author), Nanjing Med Univ, Affiliated Hosp, Nanjing Matern & Child Hlth Hosp, Nanjing 210004, Jiangsu, Peoples R China.
FU National Natural Science Foundation of China [30970877, 60927001];
   Chinese National 863 major grant [2008AA02Z436]; National Key Program
   for Developing Basic Research of China [2010CB933903]
FX This study is partially supported by National Natural Science Foundation
   of China (No. 30970877, 60927001), Chinese National 863 major grant
   (2008AA02Z436), and the National Key Program for Developing Basic
   Research of China (2010CB933903).
CR Alters K., 2011, BLOOD, V117, P279
   Anderson JS, 2009, JAIDS-J ACQ IMM DEF, V52, P152, DOI 10.1097/QAI.0b013e3181b010a0
   Barassi C, 2004, BLOOD, V104, P2205, DOI 10.1182/blood-2004-06-2134                                                      
   Brown DM, 2010, J BIOMED NANOTECHNOL, V6, P224, DOI 10.1166/jbn.2010.1117
   Chen CL, 2009, AFR J BIOTECHNOL, V8, P7379
   Chen L. L., 2005, J U S CHINA MED EDIT, V33, P166
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Floto RA, 2006, SCIENCE, V314, P454, DOI 10.1126/science.1133515
   Fowke KR, 2000, IMMUNOL CELL BIOL, V78, P586, DOI 10.1046/j.1440-1711.2000.00944.x
   Goyal R, 2011, J BIOMED NANOTECHNOL, V7, P38, DOI 10.1166/jbn.2011.1190
   Guo Q, 2010, J NANOSCI NANOTECHNO, V10, P6618, DOI 10.1166/jnn.2010.2550
   Hassan AOK, 2010, J BIOMED NANOTECHNOL, V6, P621, DOI 10.1166/jbn.2010.1141
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Ilbasmis-Tamer S, 2010, J BIOMED NANOTECHNOL, V6, P20, DOI 10.1166/jbn.2010.1099
   Liu DH, 2010, J BIOMED NANOTECHNOL, V6, P675, DOI 10.1166/jbn.2010.1160
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Liu TT, 2010, J BIOMED NANOTECHNOL, V6, P351, DOI 10.1166/jbn.2010.1129
   Malathi S, 2011, J BIOMED NANOTECHNOL, V7, P150, DOI 10.1166/jbn.2011.1244
   Nagarwal RC, 2010, J BIOMED NANOTECHNOL, V6, P648, DOI 10.1166/jbn.2010.1168
   Nimesh S, 2011, J BIOMED NANOTECHNOL, V7, P504, DOI 10.1166/jbn.2011.1313
   Oh DY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002747
   Paliwal R, 2011, J BIOMED NANOTECHNOL, V7, P130, DOI 10.1166/jbn.2011.1235
   Ruckmani K, 2010, J BIOMED NANOTECHNOL, V6, P43, DOI 10.1166/jbn.2010.1101
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Soman P, 2011, J BIOMED NANOTECHNOL, V7, P334, DOI 10.1166/jbn.2011.1295
   Sponarova D, 2011, J BIOMED NANOTECHNOL, V7, P384, DOI 10.1166/jbn.2011.1289
   Zhang J., 2011, BLOOD, V1, pe26
   Zhang J, 2007, MOL BIOTECHNOL, V37, P225, DOI 10.1007/s12033-007-9000-0                                                       
NR 31
TC 16
Z9 16
U1 0
U2 8
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD MAR
PY 2012
VL 12
IS 3
BP 2045
EP 2048
DI 10.1166/jnn.2012.5179
PG 4
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 955RX
UT WOS:000305039700045
PM 22755018
DA 2018-01-05
ER

PT J
AU Acevedo, O
   Ambrose, Z
   Flaherty, PT
   Aamer, H
   Jain, P
   Sambasivarao, SV
AF Acevedo, Orlando
   Ambrose, Zandrea
   Flaherty, Patrick T.
   Aamer, Hadega
   Jain, Prashi
   Sambasivarao, Somisetti V.
TI Identification of HIV Inhibitors Guided by Free Energy Perturbation
   Calculations
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Free energy perturbation; computer-aided drug design; cyclophilin; HIV;
   reverse transcriptase; protease; inhibitor
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING FREE-ENERGIES; HUMAN
   CYCLOPHILIN-A; REVERSE-TRANSCRIPTASE INHIBITORS; ACTIVE ANTIRETROVIRAL
   THERAPY; PROTEIN EXPRESSION PROFILES; PEPTIDYL-PROLYL ISOMERASE;
   STRUCTURE-BASED DESIGN; DRUG-RESISTANT HIV-1; CRYSTAL-STRUCTURE
AB Free energy perturbation (FEP) theory coupled to molecular dynamics (MD) or Monte Carlo (MC) statistical mechanics offers a theoretically precise method for determining the free energy differences of related biological inhibitors. Traditionally requiring extensive computational resources and expertise, it is only recently that its impact is being felt in drug discovery. A review of computer-aided anti-HIV efforts employing FEP calculations is provided here that describes early and recent successes in the design of human immunodeficiency virus type 1 (HIV-1) protease and non-nucleoside reverse transcriptase inhibitors. In addition, our ongoing work developing and optimizing leads for small molecule inhibitors of cyclophilin A (CypA) is highlighted as an update on the current capabilities of the field. CypA has been shown to aid HIV-1 replication by catalyzing the cis/trans isomerization of a conserved Gly-Pro motif in the N-terminal domain of HIV-1 capsid (CA) protein. In the absence of a functional CypA, e. g., by the addition of an inhibitor such as cyclosporine A (CsA), HIV-1 has reduced infectivity. Our simulations of acylurea-based and 1-indanylketone-based CypA inhibitors have determined that their nanomolar and micromolar binding affinities, respectively, are tied to their ability to stabilize Arg55 and Asn102. A structurally novel 1-(2,6-dichlorobenzamido) indole core was proposed to maximize these interactions. FEP-guided optimization, experimental synthesis, and biological testing of lead compounds for toxicity and inhibition of wild-type HIV-1 and CA mutants have demonstrated a dose-dependent inhibition of HIV-1 infection in two cell lines. While the inhibition is modest compared to CsA, the results are encouraging.
C1 [Acevedo, Orlando; Sambasivarao, Somisetti V.] Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA.
   [Ambrose, Zandrea; Aamer, Hadega] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA.
   [Flaherty, Patrick T.; Jain, Prashi] Duquesne Univ, Sch Pharm, Dept Med Chem, Pittsburgh, PA 15282 USA.
RP Acevedo, O (reprint author), Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA.
EM orlando.acevedo@auburn.edu
OI Flaherty, Patrick/0000-0001-7925-3227
FU National Center for Research Resources (NCRR), a component of the
   National Institutes of Health (NIH) [1 UL1 RR024153]; NIH Roadmap for
   Medical Research; Auburn University; Alabama Supercomputer Center
FX Gratitude is expressed to Auburn University and the Alabama
   Supercomputer Center for support of this research (O. A.). This project
   was supported by Grant 1 UL1 RR024153 (Z. A.) from the National Center
   for Research Resources (NCRR), a component of the National Institutes of
   Health (NIH) and NIH Roadmap for Medical Research, and its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official view of NCRR or NIH. Information on NCRR is
   available at http://www.ncrr.nih.gov/.
CR Acevedo O, 2009, J PHYS CHEM B, V113, P15372, DOI 10.1021/jp9069114
   Aiken C, 2006, CURR OPIN HIV AIDS, V1, P194, DOI 10.1097/01.COH.0000221591.11294.c1
   Aqvist J, 2002, ACCOUNTS CHEM RES, V35, P358, DOI 10.1021/ar010014p
   Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517                                                      
   Aumller T, 2010, BIOCHEMISTRY-US, V49, P1042
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Barik S, 2006, CELL MOL LIFE SCI, V63, P2889, DOI 10.1007/s00018-006-6215-3
   Barreiro G, 2007, J MED CHEM, V50, P5324, DOI 10.1021/jm070683u
   Barreiro G, 2007, J CHEM INF MODEL, V47, P2416, DOI 10.1021/ci700271z
   Bartz SR, 1997, METHODS, V12, P337, DOI 10.1006/meth.1997.0487
   BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184
   BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243
   Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975                                                           
   BILLICH A, 1995, J VIROL, V69, P2451
   Bosco DA, 2002, P NATL ACAD SCI USA, V99, P5247, DOI 10.1073/pnas.082100499
   Bosco DA, 2010, J MOL BIOL, V403, P723, DOI 10.1016/j.jmb.2010.08.001
   Boyce SE, 2009, J MOL BIOL, V394, P747, DOI 10.1016/j.jmb.2009.09.049
   Braaten D, 1997, J VIROL, V71, P2107
   Carter CA, 2008, ANNU REV MICROBIOL, V62, P425, DOI 10.1146/annurev.micro.62.081307.162758
   Cecilia D, 1998, J VIROL, V72, P6988
   Chatterji U, 2005, J BIOL CHEM, V280, P40293, DOI 10.1074/jbc.M506314200
   CHEN XN, 1995, J MED CHEM, V38, P42, DOI 10.1021/jm00001a009                                                             
   Chipot C, 2002, MOL SIMULAT, V28, P1, DOI 10.1080/08927020290004340
   Chipot C., 2007, FREE ENERGY CALCULAT, V86
   Chodera JD, 2011, CURR OPIN STRUC BIOL, V21, P150, DOI 10.1016/j.sbi.2011.01.011
   Christ CD, 2010, J COMPUT CHEM, V31, P1569, DOI 10.1002/jcc.21450
   Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755                                                                   
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   CLERCQ ED, 2005, J MED CHEM, V48, P1297
   COFFIN JM, 1997, RETROVIRUSES
   Curreli F, 2011, BIOORGAN MED CHEM, V19, P77, DOI 10.1016/j.bmc.2010.11.045
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Daum S, 2006, ANGEW CHEM INT EDIT, V45, P7454, DOI 10.1002/anie.200601569
   Daum S, 2009, BIOCHEMISTRY-US, V48, P6268, DOI 10.1021/bi9007287
   Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439
   Deng YQ, 2006, J CHEM THEORY COMPUT, V2, P1255, DOI 10.1021/ct060037v
   Dismuke DJ, 2006, J VIROL, V80, P3712, DOI 10.1128/JVI.80.8.3712-3720.2006
   Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899
   DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752
   DRIE JHV, 2007, J COMPUTER AIDED MOL, V21, P591
   Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375
   Dugave C, 2006, CIS T ISOMERIZATION
   Durrant JD, 2010, CURR OPIN PHARMACOL, V10, P770, DOI 10.1016/j.coph.2010.09.001
   Edlich F, 2006, HDB EXP PHARM, V172, P359
   Erion MD, 2007, J AM CHEM SOC, V129, P15480, DOI 10.1021/ja074869u
   Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753
   FERGUSON DM, 1991, J MED CHEM, V34, P2654, DOI 10.1021/jm00112a048                                                             
   Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622
   Fischer G, 2003, Rev Physiol Biochem Pharmacol, V148, P105, DOI 10.1007/s10254-003-0011-3
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   Flisiak R, 2008, HEPATOLOGY, V47, P817, DOI 10.1002/hep.22131
   Forshey BM, 2003, J VIROL, V77, P4409, DOI 10.1128/JVI.77.7.4409-4414.2003
   Forshey BM, 2002, J VIROL, V76, P5667, DOI 10.1128/JVI.76.11.5667-5677.2002
   FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0
   Fraser JS, 2009, NATURE, V462, P669, DOI 10.1038/nature08615
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V2006, P21
   Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1                                                   
   Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002                                                
   Gilson MK, 2007, ANNU REV BIOPH BIOM, V36, P21, DOI 10.1146/annurev.biophys.36.040306.132550
   Giorgio V, 2010, BBA-BIOENERGETICS, V1797, P1113, DOI 10.1016/j.bbabio.2009.12.006
   Golbik R, 2005, BIOCHEMISTRY-US, V44, P16026, DOI 10.1021/bi051442w
   Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299
   Guimaraes CRW, 2008, J CHEM INF MODEL, V48, P958, DOI 10.1021/ci800004w
   Hamelberg D, 2009, J AM CHEM SOC, V131, P147, DOI 10.1021/ja806146g
   HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408
   Hansson T, 1995, PROTEIN ENG, V8, P1137, DOI 10.1093/protein/8.11.1137
   Harrigan PR, 1999, AIDS, V13, P1863, DOI 10.1097/00002030-199910010-00008
   Hatziioannou T, 2005, J VIROL, V79, P176, DOI 10.1128/JVI.79.1.176-183.2005
   Hazuda D, 2009, ANNU REV PHARMACOL, V49, P377, DOI 10.1146/annurev.pharmtox.011008.145553
   Hecht D, 2010, DRUG DEVELOP RES, V72, P53
   Hopkins S, 2010, ANTIMICROB AGENTS CH, V54, P660, DOI 10.1128/AAC.00660-09
   Howard BA, 2004, LUNG CANCER-J IASLC, V46, P313, DOI 10.1016/j.lungcan.2004.05.013
   Hulten J, 1997, J MED CHEM, V40, P885, DOI 10.1021/jm960728j                                                               
   Ikeda Y, 2004, J VIROL, V78, P11816, DOI 10.1128/JVI.78.21.11816-11822.2004
   Ithara T, 1983, J CHEM SOC P1, V1, P1361
   Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6                          
   JARRY A, 1990, HISTOPATHOLOGY, V16, P133
   Jarvis LM, 2010, C EN, V88, P12
   Jorgensen WL, 2008, J CHEM THEORY COMPUT, V4, P869, DOI 10.1021/ct800011m
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297
   JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004                                                             
   JORGENSEN WL, 1985, J CHEM PHYS, V83, P3050, DOI 10.1063/1.449208                                                                
   Jorgensen WL, 2006, BIOORG MED CHEM LETT, V16, P663, DOI 10.1016/j.bmcl.2005.10.038
   Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361                                                         
   Jorgensen WL, 2005, P NATL ACAD SCI USA, V102, P6665, DOI 10.1073/pnas.0408037102
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Jorgensen W. L., 2006, QIKPROP
   KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0
   Kato Mitsunori, 2008, P268
   KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483
   KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Kim JT, 2006, J AM CHEM SOC, V128, P15372, DOI 10.1021/ja066472g
   Kirchmair Johannes, 2011, Infectious Disorders - Drug Targets, V11, P64
   Klebe G, 2006, DRUG DISCOV TODAY, V11, P580, DOI 10.1016/j.drudis.2006.05.012
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004                                                             
   KURE K, 1990, AM J PATHOL, V136, P1085
   Lammers M, 2010, NAT CHEM BIOL, V6, P331, DOI 10.1038/nchembio.342
   Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32
   Lee K, 2010, CELL HOST MICROBE, V7, P221, DOI 10.1016/j.chom.2010.02.007
   Leung CS, 2010, BIOORG MED CHEM LETT, V20, P2485, DOI 10.1016/j.bmcl.2010.03.006
   Lewis RA, 2010, CHEM MODEL APPL THEO, V7, P213, DOI 10.1039/9781849730884-000213
   Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100
   Li J, 2006, BIOORGAN MED CHEM, V14, P2209, DOI 10.1016/j.bmc.2005.11.006
   Li J, 2006, BIOORGAN MED CHEM, V14, P5527, DOI 10.1016/j.bmc.2006.04.026
   Li Jiebo, 2007, Infectious Disorders - Drug Targets, V7, P238, DOI 10.2174/187152607782110013
   LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6                                                    
   Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5
   Massova I, 2000, PERSPECT DRUG DISCOV, V18, P113, DOI 10.1023/A:1008763014207                                                         
   MCCARRICK MA, 1994, METHOD ENZYMOL, V241, P370
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Michel J, 2010, MOL INFORM, V29, P570, DOI 10.1002/minf.201000051
   Michel J, 2010, J COMPUT AID MOL DES, V24, P639, DOI 10.1007/s10822-010-9363-3
   MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183
   Miller CJ, 2005, J VIROL, V79, P9127
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   Milush JA, 2004, AIDS, V18, P2371
   Mobley DL, 2009, STRUCTURE, V17, P489, DOI 10.1016/j.str.2009.02.010
   Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060                                                                
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nakagawa M, 2005, GASTROENTEROLOGY, V129, P1031, DOI 10.1053/j.gastro.2005.06.031
   Navia MA, 1992, CURR OPIN STRUC BIOL, V2, P202
   NERI P, 1991, FEBS LETT, V290, P195, DOI 10.1016/0014-5793(91)81258-A
   Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008
   Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295
   Nichols SE, 2009, J CHEM INF MODEL, V49, P1272, DOI 10.1021/ci900068k
   Noy E, 2010, DRUG DEVELOP RES, V72, P36
   Ode H, 2006, J AM CHEM SOC, V128, P7887, DOI 10.1021/ja060682b
   Ono A, 2004, J VIROL, V78, P1552, DOI 10.1128/JVI.78.3.1552-1563.2004
   Palella Jr. FJ, 1998, NEW ENGL J MED, V338, P589
   PEARLMAN DA, 1994, J PHYS CHEM-US, V98, P1487, DOI 10.1021/j100056a020                                                             
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Pitera JW, 2009, CURR OPIN DRUG DISC, V12, P388
   Pohorille A, 2010, J PHYS CHEM B, V114, P10235, DOI 10.1021/jp102971x
   POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7
   Prada N, 2010, EXPERT OPIN INV DRUG, V19, P1087, DOI 10.1517/13543784.2010.501078
   PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903
   Ptak RG, 2008, ANTIMICROB AGENTS CH, V52, P1302, DOI 10.1128/AAC.01324-07
   Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198
   Pushkarsky T, 2007, BIOCHEM BIOPH RES CO, V363, P495, DOI 10.1016/j.bbrc.2007.08.192
   RAO BG, 1992, J AM CHEM SOC, V114, P4447, DOI 10.1021/ja00038a001                                                             
   RAO BG, 1994, J COMPUT CHEM, V15, P1241, DOI 10.1002/jcc.540151106                                                           
   Rao BG, 1996, J COMPUT AID MOL DES, V10, P23, DOI 10.1007/BF00124462
   REDDY MR, 1994, J MED CHEM, V37, P1145, DOI 10.1021/jm00034a012
   Reddy MR, 2001, J AM CHEM SOC, V123, P6246, DOI 10.1021/ja0103288
   REDDY MR, 1991, P NATL ACAD SCI USA, V88, P10287, DOI 10.1073/pnas.88.22.10287
   Reddy MR, 2000, REV COMP CH, V16, P217, DOI 10.1002/9780470125939.ch4
   REYNOLDS CA, 1992, MOL PHYS, V76, P251, DOI 10.1080/00268979200101321                                                       
   RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7
   Rizzo RC, 2000, J AM CHEM SOC, V122, P12898, DOI 10.1021/ja003113r
   Rodinger T, 2005, CURR OPIN STRUC BIOL, V15, P164, DOI 10.1016/j.sbi.2005.03.001
   ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763                                                           
   Ruiz-Caro J, 2006, BIOORG MED CHEM LETT, V16, P668, DOI 10.1016/j.bmcl.2005.10.037
   Sambasivarao SV, 2011, J CHEM INF MODEL, V51, P475, DOI 10.1021/ci1004114
   Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771
   Saphire ACS, 2000, IMMUNOL RES, V21, P211, DOI 10.1385/IR:21:2-3:211                                                           
   Schneider G, 2010, NAT REV DRUG DISCOV, V9, P273, DOI 10.1038/nrd3139
   SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007
   SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904                                                         
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Sham YY, 2000, PROTEINS, V39, P393, DOI 10.1002/(SICI)1097-0134(20000601)39:4<393::AID-PROT120>3.3.CO;2-8
   Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262                                                   
   Shet A, 2006, JAIDS-J ACQ IMM DEF, V41, P439, DOI 10.1097/01.qai.0000219290.49152.6a
   Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m
   Smith PD, 2003, J LEUKOCYTE BIOL, V74, P642, DOI 10.1189/jlb.0503219
   Sokolskaja E, 2006, J VIROL, V80, P2855, DOI 10.1128/JVI.80.6.2855-2862.2006
   Sokolskaja E, 2004, J VIROL, V78, P12800, DOI 10.1128/JVI.78.23.12800-12808.2004
   Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215
   Steinbrecher Thomas, 2008, Bioorg Med Chem, V16, P2385, DOI 10.1016/j.bmc.2007.11.070
   Steinbrecher T, 2010, CURR MED CHEM, V17, P767, DOI 10.2174/092986710790514453                                                      
   STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   Tan JJ, 2010, DRUG DISCOV TODAY, V15, P186, DOI 10.1016/j.drudis.2010.01.004
   Tang HL, 2010, VIRUSES-BASEL, V2, P1621, DOI 10.3390/v2081621
   Thakur VV, 2006, BIOORG MED CHEM LETT, V16, P5664, DOI 10.1016/j.bmcl.2006.08.037
   THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0
   Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910
   Towers GJ, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-40
   TROPSHA A, 1992, PROTEIN ENG, V5, P29, DOI 10.1093/protein/5.1.29
   Udier-Blagovic M, 2004, J MED CHEM, V47, P2389, DOI 10.1021/jm0303507
   Udier-Blagovic M, 2003, J AM CHEM SOC, V125, P6016, DOI 10.1021/ja034308c
   UNAIDS, 2010, REP GLOB AIDS EP
   Vacek G, 2008, CURR COMPUT-AID DRUG, V4, P2, DOI 10.2174/157340908783769247                                                      
   Vadivelan S, 2011, EUR J MED CHEM, V46, P851, DOI 10.1016/j.ejmech.2010.12.022
   Vajdos FE, 1997, PROTEIN SCI, V6, P2297
   van Gunsteren WF, 2002, HELV CHIM ACTA, V85, P3113, DOI 10.1002/1522-2675(200210)85:10<3113::AID-HLCA3113>3.0.CO;2-0                    
   VARNEY MD, 1994, J MED CHEM, V37, P2274, DOI 10.1021/jm00041a005
   Verani A, 2005, MOL IMMUNOL, V42, P195, DOI 10.1016/j.molimm.2004.06.020
   Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977
   WAINBERG MA, 1988, BLOOD, V72, P1904
   Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160                                                        
   Wang DP, 2001, BIOORG MED CHEM LETT, V11, P2799, DOI 10.1016/S0960-894X(01)00510-8
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang L, 2001, J COMPUT AID MOL DES, V15, P145, DOI 10.1023/A:1008156222963
   Wang W, 2000, J MOL BIOL, V303, P567, DOI 10.1006/jmbi.2000.4057
   Wang XDJ, 2006, BIOPOLYMERS, V84, P125, DOI [10.1002/bip.20240, 10.1102/bip.20240]
   Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449
   Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014
   Watashi K, 2005, HEPATOLOGY, V42, P1455
   Wittayanarakul K, 2008, J COMPUT CHEM, V29, P673, DOI 10.1002/jcc.20821
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   WONG CF, 1986, J AM CHEM SOC, V108, P3830, DOI 10.1021/ja00273a048
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Woods CJ, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3519057
   Yang F, 2008, J VIROL, V82, P5269, DOI 10.1128/JVI.02614-07
   Yang RF, 2007, J VIROL, V81, P3749, DOI 10.1128/JVI.02634-06
   Yao QZ, 2005, WORLD J SURG, V29, P276, DOI 10.1007/s00268-004-7812-7
   Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051
   Zeevaart JG, 2008, J AM CHEM SOC, V130, P9492, DOI 10.1021/ja8019214
   Zheng JM, 2008, CANCER RES, V68, P7769, DOI 10.1158/0008-5472.CAN-08-0639
   ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409                                                               
NR 216
TC 10
Z9 10
U1 1
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAR
PY 2012
VL 18
IS 9
BP 1199
EP 1216
PG 18
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 950US
UT WOS:000304676300004
PM 22316150
DA 2018-01-05
ER

PT J
AU Yosefi, F
   Randar, M
   Alavi, SM
   Samany, A
AF Yosefi, Farid
   Randar, Mahmoud
   Alavi, Saied Mohammad
   Samany, Amin
TI A study on Prevalence of Gastrointestinal Parasitic Infections in HIV
   (+) Patients Referred to Ahvaz Razi Hospital in 2008-2009
SO JUNDISHAPUR JOURNAL OF MICROBIOLOGY
LA English
DT Article
DE Intestinal Diseases; Parasitology; HIV Patients; Iran
ID POSITIVE INDIVIDUALS; INTESTINAL PARASITES; FREQUENCY; ETHIOPIA; CITY;
   IRAN
AB Background: Accute Immune Deficiency Syndrom (AIDS) is a serious and lethal disease in many parts of the world, rendering a patient sensitive to all opportunistic pathogens that can cause death as the disease progresses. Many patients suffer from intestinal opportunistic infections by parasites.
   Objectives: The aim of present study was to examine parasitic intestinal infections in AIDS patients in Razi Hospital, Ahvaz.
   Patients and Methods: We collected 100 stool samples from 60 HIV (+) patients who were referred to Razi Hospital, Ahvaz. The samples were examined by direct and MIF (merthiowlate-iodine-formaldehyde) method. All samples were stained with Ziehl-Neelsen (acid fast staining) and trichrome. General data, such as clinical signs, duration of disease, route of infection, and habitat of patient, were obtained by questionnaire.
   Results: Thirty percent of HIV (+) patients were infected with intestinal protozoan parasites. There was no significant difference in the prevalence of parasite infections between sex or age. The prevalence of parasitic infections was as follows: Blastocystis hominis,16.7%; Cryptosporidium parvum, 8.3%; Endolimax nano, 5%; Entamoeba coli,5%; Giardia intestinalis,3.3%; E. histolytica cyst, 1. 7%, and Dientamoeba fragilis,l. 7%.
   Conclusions: This study shows that the prevalence of parasitic infections is not high in HIV (+) patient in Ahvaz compared with other studies, but it is recommended that fecal examination be performed every 3 months to detect serious parasitic infections and that parasitic infections should be treated after laboratory diagnosis and in the presence of the gastrointestinal symptoms. Copyright 2012 Kowsar Corp. All rights reserved.
C1 [Randar, Mahmoud] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Parasitol, Ahwaz, Iran.
   [Yosefi, Farid; Alavi, Saied Mohammad] Ahvaz Jundishapur Univ Med Sci, Dept Infect Dis, Ahvaz Razi Hosp, Ahwaz, Iran.
   [Randar, Mahmoud] Ahvaz Jundishapur Univ Med Sci, Sch Med, Mycoparasitol Dept, Ahwaz, Iran.
   [Randar, Mahmoud] Ahvaz Jundishapur Univ Med Sci, Cellular & Mol Res Ctr, Ahwaz, Iran.
   [Alavi, Saied Mohammad] Ahvaz Jundishapur Univ Med Sci, Infect & Trop Dis Res Ctr, Ahwaz, Iran.
RP Randar, M (reprint author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Parasitol, Ahwaz, Iran.
EM mrah-dar2002@yahoo.com
RI Rahdar, Mahmoud/H-9261-2016
OI Rahdar, Mahmoud/0000-0001-6667-7020; alavi, seyed
   mohammad/0000-0003-4328-4747
FU Ahvaz Jundishapur university of Medical Sciences [87105]
FX This study was supported by the approved search project No. 87105
   Vice-chancellor of Ahvaz Jundishapur university of Medical Sciences.
CR Akhlaghi L, 2009, IRAN J PARASITOL, V4, P44
   Alaei K, 2004, INCIDENCE INTESTINAL
   Berenji F, 2010, JUNDISHAPUR J MICROB, V3, P61
   Daryani A, 2009, Pak J Biol Sci, V12, P1277, DOI 10.3923/pjbs.2009.1277.1281
   국상미, 2005, The Korean Journal of Parasitology, V43, P1
   Hailemariam G, 2004, JPN J INFECT DIS, V57, P41
   Kasper DL, 2004, HARRISONS PRINCIPLES
   Lindo JF, 1998, AM J TROP MED HYG, V58, P431, DOI 10.4269/ajtmh.1998.58.431                                                       
   Moges F, 2006, JPN J INFECT DIS, V59, P400
   Mohandas K, 2002, JPN J INFECT DIS, V55, P83
   Moran P, 2005, EXP PARASITOL, V110, P331, DOI 10.1016/j.exppara.2005.03.023
   Salehi L, 2009, JQUMS, V13, P73
   Zali MR, 2004, JPN J INFECT DIS, V57, P268
NR 13
TC 2
Z9 2
U1 1
U2 4
PU AHVAZ JUNDISHAPUR UNIV MED SCI
PI AHVAZ
PA PO BOX 6357-33118, AHVAZ, 00000, IRAN
SN 2008-3645
EI 2008-4161
J9 JUNDISHAPUR J MICROB
JI Jundishapur J. Microbiol.
PD SPR
PY 2012
VL 5
IS 2
BP 424
EP 426
DI 10.5812/jjm.3537
PG 3
WC Microbiology
SC Microbiology
GA 954WG
UT WOS:000304978100011
DA 2018-01-05
ER

PT J
AU Agrahari, V
   Youan, BBC
AF Agrahari, Vivek
   Youan, Bi-Botti C.
TI Sensitive and Rapid HPLC Quantification of Tenofovir from Hyaluronic
   Acid-Based Nanomedicine
SO AAPS PHARMSCITECH
LA English
DT Article
DE high-performance liquid chromatography; hyaluronic acid; molar
   absorptivity; nanomedicine; tenofovir
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN PLASMA; SPECTROMETRY METHOD;
   MASS-SPECTROMETRY; HIV PREVENTION; HUMAN SERUM; DELIVERY; EMTRICITABINE;
   FORMULATIONS; MICROBICIDES
AB The purpose of this study was to develop and validate a rapid, sensitive, and specific reversed-phase high-performance liquid chromatography method for the quantitative determination of native tenofovir (TNF) for various applications. Different analytical performance parameters such as linearity, precision, accuracy, limit of quantification (LOQ), limit of detection (LOD), and robustness were determined according to International Conference on Harmonization (ICH) guidelines. A Bridge (TM) C18 column (150 x 4.6 mm, 5 mu m) was used as stationary phase. The retention time of TNF was 1.54 +/- 0.03 min (n = 6). The assay was linear over the concentration range of 0.1-10 mu g/mL. The proposed method was sensitive with LOD and LOQ values equal to 50 and 100 ng/mL, respectively. The method was accurate with percent mean recovery from 95.41% to 102.90% and precise as percent RSD (relative standard deviation) values for intra-day, and inter-day precision were less than 2%. This method was utilized for the estimation of molar absorptivity of TNF at 259 nm (epsilon (259) = 12,518 L/mol/cm), calculated from linear regression analysis. The method was applied for determination of percentage of encapsulation efficiency ( 22.93 +/- 0.04%), drug loading (12.25 +/- 1.03%), in vitro drug release profile in the presence of enzyme (43% release in the first 3 h) and purification analysis of hyaluronic acid-based nanomedicine.
C1 [Agrahari, Vivek; Youan, Bi-Botti C.] Univ Missouri, Sch Pharm, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, Kansas City, MO 64108 USA.
RP Youan, BBC (reprint author), Univ Missouri, Sch Pharm, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, 2464 Charlotte, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
FU National Institute of Allergy And Infectious Diseases [R01AI087304]
FX The project described was supported by Grant Number R01AI087304 from the
   National Institute of Allergy And Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy And
   Infectious Diseases or the National Institutes of Health. We gratefully
   acknowledge Mr. Jack Liu (Zhenjiang Dong Yuan Biotech Co., Ltd.,
   Jiangsu, China) for providing samples of hyaluronic acid.
CR Al-Ghananeem AM, 2009, AAPS PHARMSCITECH, V10, P410, DOI 10.1208/s12249-009-9222-5
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   Bennetto-Hood C, 2007, RAPID COMMUN MASS SP, V21, P2087, DOI 10.1002/rcm.3056
   Carole E. S., 2011, CARBOHYD POLYM, V85, P469
   Checa A, 2009, ANAL CHIM ACTA, V647, P1, DOI 10.1016/j.aca.2009.05.028
   Choi KY, 2010, BIOMATERIALS, V31, P106, DOI 10.1016/j.biomaterials.2009.09.030
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   Delahunty T, 2009, J CHROMATOGR B, V877, P1907, DOI 10.1016/j.jchromb.2009.05.029
   Hackley V, 2001, NIST SP, V960- 3, P72
   Hu Z, 2009, United States patent, Patent No. [7,601,704 B2, 7601704]
   Huidobro AL, 2005, J PHARMACEUT BIOMED, V37, P687, DOI 10.1016/j.jpba.2004.11.039
   [Anonymous], 2005, ICH GUID Q2 R1 VAL A
   Jullien V, 2003, J CHROMATOGR B, V785, P377, DOI 10.1016/S1570-0232(02)00933-9                                                   
   Kandagal PB, 2008, ANAL LETT, V41, P561, DOI 10.1080/00032710801910742
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Khan A, 2010, J CHROMATOGR B, V878, P2339, DOI 10.1016/j.jchromb.2010.07.009
   Liebhafsky H.A., 1953, J CHEM EDUC, V30, P450
   Mayer KH, 2006, AIDS, V20, P543, DOI 10.1097/01.aids.0000210608.70762.c3
   Ndesendo VMK, 2008, AAPS PHARMSCITECH, V9, P505, DOI 10.1208/s12249-008-9073-5
   Nirogi RVS, 2005, ANAL CHIM ACTA, V553, P1, DOI 10.1016/j.aca.2005.08.007
   ONEIL MJ, 2001, MERCK INDEX
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Patel S, 2009, INT J PHARM CLIN RES, V1, P28
   Pelillo M, 2004, J CHROMATOGR A, V1023, P225, DOI 10.1016/S0021-9673(03)01206-8
   Raju NA., 2009, J PHARM RES, V2, P1103
   Rezk NL, 2005, J CHROMATOGR B, V822, P201, DOI 10.1016/j.jchromb.2005.06.019
   Rohan LC, 2010, PLOS ONE, V5, P1
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Romero-Perez A, 2010, VET RES COMMUN, V34, P71, DOI 10.1007/s11259-009-9335-z
   Rosen RK, 2008, J WOMENS HEALTH, V17, P383, DOI 10.1089/jwh.2006.0325
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Sentenac S, 2003, J CHROMATOGR B, V793, P317, DOI 10.1016/S1570-0232(03)00333-7
   Sun DQ, 2006, J PHARMACEUT BIOMED, V42, P372, DOI 10.1016/j.jpba.2006.04.019
   SWYER GIM, 1947, BIOCHEM J, V41, P409, DOI 10.1042/bj0410409                                                               
   Takahashi M, 2007, BIOL PHARM BULL, V30, P1784, DOI 10.1248/bpb.30.1784
   Xu MJ, 2008, J CHROMATOGR B, V864, P123, DOI 10.1016/j.jchromb.2008.01.053
   Yadav M, 2009, J CHROMATOGR SCI, V47, P140, DOI 10.1093/chromsci/47.2.140                                                       
   Zidan AS, 2010, AAPS J, V12, P202, DOI 10.1208/s12248-010-9177-1
NR 40
TC 8
Z9 8
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD MAR
PY 2012
VL 13
IS 1
BP 202
EP 210
DI 10.1208/s12249-011-9735-6
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 949CD
UT WOS:000304552300024
PM 22215290
OA green_published
DA 2018-01-05
ER

PT J
AU Singer, A
   Rapireddy, S
   Ly, DH
   Meller, A
AF Singer, Alon
   Rapireddy, Srinivas
   Ly, Danith H.
   Meller, Amit
TI Electronic Barcoding of a Viral Gene at the Single-Molecule Level
SO NANO LETTERS
LA English
DT Article
DE Nanopore; gamma PNA; sequence detection; molecular diagnostics;
   single-molecule; genotyping
ID PEPTIDE NUCLEIC-ACIDS; SEQUENCE B-DNA; NANOPORE SENSORS; STRAND
   INVASION; GAMMA-PNAS; DUPLEX DNA; MICRORNAS; BIOLOGY
AB A new single-molecule approach for rapid and purely electronic discrimination among similar genes is presented. Combining solid-state nanopores and gamma-modified synthetic peptide nucleic acid probes, we accurately barcode genes by counting the number of probes attached to each gene and measuring their relative spacing. We illustrate our method by sensing individual genes from two highly similar human immunodeficiency virus subtypes, demonstrating feasibility of a novel, single-molecule diagnostic platform for rapid pathogen classification.
C1 [Singer, Alon; Meller, Amit] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
   [Rapireddy, Srinivas; Ly, Danith H.] Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA.
RP Meller, A (reprint author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
EM ameller@bu.edu
OI Meller, Amit/0000-0001-7082-0985
FU Harvard's Center for Nanoscale Systems (CNS); National Institutes of
   Health [R01 HG-005871]; National Science Foundation [PHY-0646637,
   CHE-1012467]; DSF Charitable Foundation
FX The authors acknowledge support from Harvard's Center for Nanoscale
   Systems (CNS) and financial support from National Institutes of Health
   award R01 HG-005871 (A.M.) and National Science Foundation awards
   PHY-0646637 (A.M.) and CHE-1012467 (D.H.L.) as well as the DSF
   Charitable Foundation (D.H.L.). The authors thank A. Squires for editing
   the manuscript.
CR Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038
   Branton D, 2008, NAT BIOTECHNOL, V26, P1146, DOI 10.1038/nbt.1495
   Chenna V, 2008, CHEMBIOCHEM, V9, P2388, DOI 10.1002/cbic.200800441
   Deamer DW, 2002, ACCOUNTS CHEM RES, V35, P817, DOI 10.1021/ar000138m
   Domiati-Saad R, 2006, CLIN CHIM ACTA, V363, P197, DOI 10.1016/j.cccn.2005.05.049
   Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764
   Hansen GI, 2001, J MOL BIOL, V307, P67, DOI 10.1006/jmbi.2001.4487
   He GF, 2009, J AM CHEM SOC, V131, P12088, DOI 10.1021/ja900228j
   Kaittanis C, 2010, ADV DRUG DELIVER REV, V62, P408, DOI 10.1016/j.addr.2009.11.013
   Kim MJ, 2006, ADV MATER, V18, P3149, DOI 10.1002/adma.200601191
   Liu Yu-Tsueng, 2008, Infectious Disorders - Drug Targets, V8, P183
   Nielsen PE, 2010, CHEM BIODIVERS, V7, P786, DOI 10.1002/cbdv.201000005
   Rapireddy S, 2007, J AM CHEM SOC, V129, P15596, DOI 10.1021/ja074886j
   Rodenburg CM, 2001, AIDS RES HUM RETROV, V17, P161, DOI 10.1089/08892220150217247
   Sahu B, 2011, J ORG CHEM, V76, P5614, DOI 10.1021/jo200482d
   Singer A, 2010, NANO LETT, V10, P738, DOI 10.1021/nl100058y
   Venkatesan BM, 2011, NAT NANOTECHNOL, V6, P615, DOI [10.1038/nnano.2011.129, 10.1038/NNANO.2011.129]
   Wang Y, 2011, NAT NANOTECHNOL, V6, P668, DOI [10.1038/NNANO.2011.147, 10.1038/nnano.2011.147]
   Wanunu M., 2008, LAB MANUAL SINGLE MO
   Wanunu M, 2008, BIOPHYS J, V95, P4716, DOI 10.1529/biophysj.108.140475
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P807, DOI [10.1038/nnano.2010.202, 10.1038/NNANO.2010.202]
   Wanunu M, 2010, NAT NANOTECHNOL, V5, P160, DOI [10.1038/nnano.2009.379, 10.1038/NNANO.2009.379]
   Zhang N, 2010, J INFECT DIS, V201, pS42, DOI 10.1086/650389
NR 23
TC 41
Z9 41
U1 2
U2 34
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD MAR
PY 2012
VL 12
IS 3
BP 1722
EP 1728
DI 10.1021/nl300372a
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 907GW
UT WOS:000301406800105
PM 22352964
OA green_accepted
DA 2018-01-05
ER

PT J
AU Johnson, TJ
   Srinivasan, P
   Albright, TH
   Watson-Buckheit, K
   Rabe, L
   Martin, A
   Pau, CP
   Hendry, RM
   Otten, R
   McNicholl, J
   Buckheit, R
   Smith, J
   Kiser, PF
AF Johnson, Todd J.
   Srinivasan, Priya
   Albright, Theodore H.
   Watson-Buckheit, Karen
   Rabe, Lorna
   Martin, Amy
   Pau, Chou-Pong
   Hendry, R. Michael
   Otten, Ron
   McNicholl, Janet
   Buckheit, Robert, Jr.
   Smith, James
   Kiser, Patrick F.
TI Safe and Sustained Vaginal Delivery of Pyrimidinedione HIV-1 Inhibitors
   from Polyurethane Intravaginal Rings
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; DRUG-RELEASE; MICROBICIDES;
   DAPIVIRINE; OPTIMIZATION; MICROFLORA; DEVICES; TYPE-1; MATRIX; MEDIA
AB The potent antiretroviral pyrimidinediones IQP-0528 (PYD1) and IQP-0532 (PYD2) were formulated in polyurethane intravaginal rings (IVRs) as prophylactic drug delivery systems to prevent the sexual transmission of HIV-1. To aid in the selection of a pyrimidinedione candidate and the optimal loading of the drug in the IVR delivery system, four pyrimidinedione IVR formulations (PYD1 at 0.5 wt% [PYD1(0.5wt%)], PYD1(1wt%), PYD2(4wt%), and PYD2(14wt%)) were evaluated in pigtail macaques over 28 days for safety and pyrimidinedione vaginal biodistribution. Kinetic analysis of vaginal proinflammatory cytokines, native microflora, and drug levels suggested that all formulations were safe, but only the high-loaded PYD214wt% IVR demonstrated consistently high pyrimidinedione vaginal fluid and tissue levels over the 28-day study. This formulation delivered drug in excess of 10 mu g/ml to vaginal fluid and 1 mu g/g to vaginal tissue, a level over 1,000 times the in vitro 50% effective concentration. The in vitro release of PYD1 and PYD2 under nonsink conditions correlated well with in vivo release, both in amount and in kinetic profile, and therefore may serve as a more biologically relevant means of evaluating release in vitro than typically employed sink conditions. Lastly, the pyrimidinediones in the IVR formulation were chemically stable after 90 days of storage at elevated temperature, and the potent nanomolar-level antiviral activity of both molecules was retained after in vitro release. Altogether, these results point to the successful IVR formulation and vaginal biodistribution of the pyrimidinediones and demonstrate the usefulness of the pigtail macaque model in evaluating and screening antiretroviral IVR formulations prior to preclinical and clinical evaluation.
C1 [Johnson, Todd J.; Albright, Theodore H.; Kiser, Patrick F.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
   [Srinivasan, Priya; Martin, Amy; Pau, Chou-Pong; Hendry, R. Michael; Otten, Ron; McNicholl, Janet; Smith, James] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV,CCID, Atlanta, GA USA.
   [Watson-Buckheit, Karen; Buckheit, Robert, Jr.] ImQuest BioSci Inc, Frederick, MD USA.
   [Rabe, Lorna] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Biol, Magee Womens Res Inst, Pittsburgh, PA USA.
RP Kiser, PF (reprint author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
EM patrick.kiser@utah.edu
RI Kiser, Patrick/C-2843-2014
OI Kiser, Patrick/0000-0002-3868-7122
FU National Institutes of Health [U19AI076980, U19AI077289]; National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, U.S. Department of Health and Human Services [Y1-AI-0681-01]
FX Work conducted at the University of Utah was financially supported by
   National Institutes of Health grants U19AI076980 and U19AI077289. This
   project has been funded in part with federal funds from the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, U.S. Department of Health and Human Services, under interagency
   agreement no. Y1-AI-0681-01.
CR Buckheit Robert W. Jr., 2007, Antiviral Chemistry & Chemotherapy, V18, P259
   Buckheit RW, 2008, ANTIMICROB AGENTS CH, V52, P225, DOI 10.1128/AAC.00972-07
   BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2
   Chien YW, 2002, CLIN PHARMACOKINET, V41, P1267, DOI 10.2165/00003088-200241150-00003                                                
   CHIEN YW, 1974, J PHARM SCI, V63, P515, DOI 10.1002/jps.2600630405                                                          
   Clarke JG, 2002, SEX TRANSM DIS, V29, P288, DOI 10.1097/00007435-200205000-00007
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cu Y, 2009, ADV DRUG DELIVER REV, V61, P101, DOI 10.1016/j.addr.2008.09.006
   Geonnotti AR, 2010, J PHARM SCI-US, V99, P3514, DOI 10.1002/jps.22120
   Gonzalez RCB, 2004, INT J PHARM, V279, P27, DOI 10.1016/j.ijpharm.2004.04.010
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Gunawardana M, 2011, J MED MICROBIOL, V60, P828, DOI 10.1099/jmm.0.028225-0
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Hardy E, 2007, CONTRACEPTION, V76, P126, DOI 10.1016/j.contraception.2007.04.013
   Heise LL, 2011, CONTRACEPTION, V83, P10, DOI 10.1016/j.contraception.2010.06.009
   Helbling IM, 2011, J CONTROL RELEASE, V149, P258, DOI 10.1016/j.jconrel.2010.10.018
   Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1
   Huynh-ba K., 2009, HDB STABILITY TESTIN
   Iyer SS, 2006, BIOPHARM DRUG DISPOS, V27, P157, DOI 10.1002/bdd.493
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Kuklenyik Z, 2009, J CHROMATOGR SCI, V47, P365, DOI 10.1093/chromsci/47.5.365                                                       
   Mahalingam A, 2011, ANTIMICROB AGENTS CH, V55, P1650, DOI 10.1128/AAC.01368-10
   Malcolm K, 2003, J CONTROL RELEASE, V90, P217, DOI 10.1016/S0168-3659(03)00178-0
   Malcolm K, 2010, MICR 2010 PITTSB PA
   Miller L, 2005, CONTRACEPTION, V71, P65, DOI 10.1016/j.contraception.2004.07.015
   Mitchell C, 2011, J CLIN MICROBIOL, V49, P735, DOI 10.1128/JCM.00991-10
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1
   Nel A, 2009, JAIDS-J ACQ IMM DEF, V51, P416, DOI 10.1097/QAI.0b013e3181acb536
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Patton DL, 1996, SEX TRANSM DIS, V23, P489, DOI 10.1097/00007435-199611000-00009                                                
   Patton DL, 2008, SEX TRANSM DIS, V35, P889, DOI 10.1097/OLQ.0b013e31817dfdb8
   Promadej-Lanier N, 2009, J MED PRIMATOL, V38, P263, DOI 10.1111/j.1600-0684.2009.00354.x
   Rabe LK, 2003, J CLIN MICROBIOL, V41, P3260, DOI 10.1128/JCM.41.7.3260-3264.2003
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Saltzman W. M., 2001, DRUG DELIVERY ENG PR
   Sivin I, 1997, CONTRACEPTION, V55, P225, DOI 10.1016/S0010-7824(97)00008-5                                                   
   Srivastava P, 2004, BIOORGAN MED CHEM, V12, P6437, DOI 10.1016/j.bmc.2004.09.032
   Tang LJ, 2001, PHARM DEV TECHNOL, V6, P531, DOI 10.1081/PDT-120000291
   Thomas C, 2009, NAT MED, V15, P855, DOI 10.1038/nm0809-855
   UNAIDS, 2010, REP GLOB AIDS EP
   Van Rompay KKA, 2010, ANTIVIR RES, V85, P159, DOI 10.1016/j.antiviral.2009.07.008
   Veazey RS, 2008, CURR OPIN HIV AIDS, V3, P567, DOI 10.1097/COH.0b013e32830891bb
   Woolfson AD, 2006, AM J DRUG DELIV, V4, P7
NR 47
TC 34
Z9 34
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2012
VL 56
IS 3
BP 1291
EP 1299
DI 10.1128/AAC.05721-11
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 897DN
UT WOS:000300623300019
PM 22155820
OA gold
DA 2018-01-05
ER

PT J
AU Rahmat, D
   Khan, MI
   Shahnaz, G
   Sakloetsakun, D
   Perera, G
   Bernkop-Schnurch, A
AF Rahmat, Deni
   Khan, Mohammad I.
   Shahnaz, Gul
   Sakloetsakun, Duangkamon
   Perera, Glen
   Bernkop-Schnuerch, Andreas
TI Synergistic effects of conjugating cell penetrating peptides and
   thiomers on non-viral transfection efficiency
SO BIOMATERIALS
LA English
DT Article
DE Nanoparticles; Thioglycolic acid; Tat peptide; Transfection; Gene
   delivery
ID CHITOSAN-DNA NANOPARTICLES; IN-VITRO EVALUATION; GENE DELIVERY; PROTEIN
   TRANSDUCTION; HEPARAN-SULFATE; HIV-1 TAT; MEMBRANE; DRUG
AB Nanoparticles generated by complex coacervation of plasmid DNA (pDNA) and modified chitosans namely chitosan thioglycolic acid (TGA) conjugate and chitosan HIV-1 Tat peptide conjugate were evaluated as gene delivery systems. In order to optimize transfection efficiency, chitosan HIV-1 Tat peptide conjugate was combined with chitosan TGA before its complexation with pDNA. Particle size and zeta potential measurements were performed to characterize the generated nanoparticles. The nanoparticles transfection efficiencies were assessed by exploitation of the green fluorescent protein (GFP) reporter gene. HEK293 cells were incubated for 24 h with the nanoparticles and the GFP positive cells were observed by fluorescence microscopy. The nanoparticles in the size range of 200-300 nm could transfect HEK293 cells as a model cell line with different transfection efficiencies. Unlike chitosan TGA, chitosan HIV-1 Tat peptide led to increased zeta potential of nanoparticles as compared to unmodified chitosan. The transfection efficiency of the nanoparticles generated by combination of chitosan HIV-1 Tat peptide with chitosan TGA was comparatively higher than that of the nanoparticles generated by either chitosan TGA or the combination of chitosan HIV-1 Tat peptide with unmodified chitosan. After 72 h of incubation, the combination of chitosan HIV-1 Tat peptide with chitosan TGA was found to be 7.12- and 67.37 times more efficient than unmodified chitosan and pDNA alone, respectively and showed a synergistic effect in transfection of pDNA into the cells. Moreover, none of the nanoparticles showed any severe cytotoxicity. Accordingly, this strategy might result in a potent carrier for gene delivery. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Rahmat, Deni; Shahnaz, Gul; Perera, Glen; Bernkop-Schnuerch, Andreas] Leopold Franzens Univ Innsbruck, Inst Pharm, Dept Pharmaceut Technol, A-6020 Innsbruck, Austria.
   [Khan, Mohammad I.] Med Univ Innsbruck, Dept Internal Med 1, A-6020 Innsbruck, Austria.
   [Sakloetsakun, Duangkamon] Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen 40002, Thailand.
RP Bernkop-Schnurch, A (reprint author), Leopold Franzens Univ Innsbruck, Inst Pharm, Dept Pharmaceut Technol, Innrain 52,Josef Moller Haus, A-6020 Innsbruck, Austria.
EM andreas.bernkop@uibk.ac.at
RI Ghartouchent, malek/B-9088-2012
CR Bernkop-Schnurch A, 2000, J CONTROL RELEASE, V66, P39, DOI 10.1016/S0168-3659(99)00256-4
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142-9612(02)00507-0                                                   
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Hoekstra D, 2007, BIOCHEM SOC T, V35, P68, DOI 10.1042/BST0350068                                                              
   Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767                                                              
   Kafedjiiski K, 2005, PHARM RES, V22, P1480, DOI 10.1007/s11095-005-6248-6
   Lee D, 2007, PHARM RES, V24, P157, DOI 10.1007/s11095-006-9136-9
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   Mansouri S, 2004, EUR J PHARM BIOPHARM, V57, P1, DOI 10.1016/s0939-641(03)00155-3
   Martien R, 2008, NANOTECHNOLOGY, V19, P1
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Patel N, 1997, LANGMUIR, V13, P6485, DOI 10.1021/la970933h                                                               
   Schmitz T, 2007, BIOMATERIALS, V28, P524, DOI 10.1016/j.biomaterials.2006.08.017
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4
   Tamura M, 2004, J VIROL, V78, P3817, DOI 10.1128/JVI.78.8.3817-3826.2004
   WHITELEY NM, 1974, J MOL BIOL, V87, P541, DOI 10.1016/0022-2836(74)90103-X
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 21
TC 20
Z9 23
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2012
VL 33
IS 7
BP 2321
EP 2326
DI 10.1016/j.biomaterials.2011.11.046
PG 6
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 895CN
UT WOS:000300473900039
PM 22169137
DA 2018-01-05
ER

PT J
AU Scholten, DJ
   Canals, M
   Maussang, D
   Roumen, L
   Smit, MJ
   Wijtmans, M
   de Graaf, C
   Vischer, HF
   Leurs, R
AF Scholten, D. J.
   Canals, M.
   Maussang, D.
   Roumen, L.
   Smit, M. J.
   Wijtmans, M.
   de Graaf, C.
   Vischer, H. F.
   Leurs, R.
TI Pharmacological modulation of chemokine receptor function
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE allosterism; G protein-coupled receptors; chemokine receptors;
   functional selectivity; dimerization; crystal structures; nanobody;
   ligand interactions; binding sites
ID PROTEIN-COUPLED RECEPTOR; IMMUNODEFICIENCY-VIRUS TYPE-1; CCR5
   MONOCLONAL-ANTIBODY; 2ND EXTRACELLULAR LOOP; BICYCLAM NONPEPTIDE
   ANTAGONISTS; HIV-INFECTED ADULTS; SMALL-MOLECULE; BINDING-SITE; IN-VIVO;
   CXCR4 RECEPTOR
AB G protein-coupled chemokine receptors and their peptidergic ligands are interesting therapeutic targets due to their involvement in various immune-related diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease, HIV-1 infection and cancer. To tackle these diseases, a lot of effort has been focused on discovery and development of small-molecule chemokine receptor antagonists. This has been rewarded by the market approval of two novel chemokine receptor inhibitors, AMD3100 (CXCR4) and Maraviroc (CCR5) for stem cell mobilization and treatment of HIV-1 infection respectively. The recent GPCR crystal structures together with mutagenesis and pharmacological studies have aided in understanding how small-molecule ligands interact with chemokine receptors. Many of these ligands display behaviour deviating from simple competition and do not interact with the chemokine binding site, providing evidence for an allosteric mode of action. This review aims to give an overview of the evidence supporting modulation of this intriguing receptor family by a range of ligands, including small molecules, peptides and antibodies. Moreover, the computer-assisted modelling of chemokine receptorligand interactions is discussed in view of GPCR crystal structures. Finally, the implications of concepts such as functional selectivity and chemokine receptor dimerization are considered.
C1 [Scholten, D. J.; Canals, M.; Maussang, D.; Roumen, L.; Smit, M. J.; Wijtmans, M.; de Graaf, C.; Vischer, H. F.; Leurs, R.] Vrije Univ Amsterdam, Div Med Chem, Fac Sci, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands.
RP Leurs, R (reprint author), Vrije Univ Amsterdam, Div Med Chem, Fac Sci, Leiden Amsterdam Ctr Drug Res, De Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.
EM r.leurs@vu.nl
RI Ghartouchent, malek/B-9088-2012
OI Canals, Meritxell/0000-0002-7942-5006; Scholten,
   Danny/0000-0001-6822-9950; de Graaf, Chris/0000-0002-1226-2150
FU Top Institute Pharma [D1-105, T1-103-1]
FX This review was (in part) written within the framework of Top Institute
   Pharma, project number D1-105 (GPCR forum) and T1-103-1 (Chemokine
   Receptors).
CR Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225                                                           
   Alexander SPH, 2011, BRIT J PHARMACOL, V164, pS1, DOI 10.1111/j.1476-5381.2011.01649_1.x
   Allegretti M, 2005, J MED CHEM, V48, P4312, DOI 10.1021/jm049082i
   Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529
   Andrews G, 2008, MOL PHARMACOL, V73, P855, DOI 10.1124/mol.107.039321
   Arcemisbehere L, 2010, J BIOL CHEM, V285, P6337, DOI 10.1074/jbc.M109.083477
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Ballesteros J. A., 1995, METH NEUROSCI, V25, P366, DOI DOI 10.1016/S1043-9471(05)80049-7
   Bayry J, 2008, P NATL ACAD SCI USA, V105, P10221, DOI 10.1073/pnas.0803453105
   Becker OM, 2004, P NATL ACAD SCI USA, V101, P11304, DOI 10.1073/pnas.0401862101
   Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603
   Berchiche YA, 2011, MOL PHARMACOL, V79, P488, DOI 10.1124/mol.110.068486
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Berkhout TA, 2003, J MED CHEM, V46, P4070, DOI 10.1021/jm030862l
   Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101
   Blanpain C, 2003, J BIOL CHEM, V278, P5179, DOI 10.1074/jbc.M205684200
   Bongers G, 2010, J CLIN INVEST, V120, P3969, DOI 10.1172/JCI42563
   Bradley ME, 2009, BRIT J PHARMACOL, V158, P328, DOI 10.1111/j.1476-5381.2009.00182.x
   Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200                                                          
   Buntinx M, 2008, J PHARMACOL EXP THER, V327, P1, DOI 10.1124/jpet.108.140723
   Casarosa P, 2005, J BIOL CHEM, V280, P3275, DOI 10.1074/jbc.M407536200
   Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200
   Chakera A, 2008, MOL PHARMACOL, V73, P1362, DOI 10.1124/mol.107.040915
   Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577
   Cherezov V, 2010, METHODS MOL BIOL, V654, P141, DOI 10.1007/978-1-60761-762-4_8
   Cherney RJ, 2008, BIOORG MED CHEM LETT, V18, P5063, DOI 10.1016/j.bmcl.2008.07.123
   Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410
   Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323                                                             
   Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200
   Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06
   Contento RL, 2008, P NATL ACAD SCI USA, V105, P10101, DOI 10.1073/pnas.0804286105
   Cox MA, 2001, MOL PHARMACOL, V59, P707
   Davies MN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008084
   De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134
   De Clercq E, 2010, PHARMACOL THERAPEUT, V128, P509, DOI 10.1016/j.pharmthera.2010.08.009
   de Graaf C, 2008, PROTEINS, V71, P599, DOI 10.1002/prot.21724
   de Graaf C, 2009, CURR PHARM DESIGN, V15, P4026, DOI 10.2174/138161209789824786                                                      
   de Kruijf P, 2009, J PHARMACOL EXP THER, V329, P783, DOI 10.1124/jpet.108.148387
   de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Deupi X, 2004, BIOPHYS J, V86, P105, DOI 10.1016/S0006-3495(04)74088-6
   Dorsch S, 2009, NAT METHODS, V6, P225, DOI [10.1038/NMETH.1304, 10.1038/nmeth.1304]
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   El-Asmar L, 2005, MOL PHARMACOL, V67, P460, DOI 10.1124/mol.104.003624
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838                                       
   Fonseca JM, 2009, MOL PHARMACOL, V75, P1296, DOI 10.1124/mol.108.053876
   Galandrin S, 2007, TRENDS PHARMACOL SCI, V28, P423, DOI 10.1016/i.tips.2007.06.005
   Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200                                                          
   Ghassabeh GH, 2010, BIOTECH PHARM ASPECT, P29
   Gilbert J, 2011, AM J CARDIOL, V107, P906, DOI 10.1016/j.amjcard.2010.11.005
   GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631                                                           
   Gonsiorek W, 2007, J PHARMACOL EXP THER, V322, P477, DOI 10.1124/jpet.106.118927
   Gorry PR, 2002, LANCET, V359, P1832, DOI 10.1016/S0140-6736(02)08681-6
   Govaerts C, 2003, J BIOL CHEM, V278, P1892, DOI 10.1074/jbc.M205685200
   Govaerts C, 2001, J BIOL CHEM, V276, P13217, DOI 10.1074/jbc.M011670200
   Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0
   Hall SE, 2009, MOL PHARMACOL, V75, P1325, DOI 10.1124/mol.108.053470
   Handel TM, 2010, TRENDS PARASITOL, V26, P329, DOI 10.1016/j.pt.2010.03.010
   Haskell CA, 2006, MOL PHARMACOL, V69, P309, DOI 10.1124/mol.105.014779
   Hatse S, 2003, FEBS LETT, V546, P300, DOI 10.1016/S0014-5793(03)00609-4
   Hatse S, 2007, J VIROL, V81, P3632, DOI 10.1128/JVI.01941-06
   Haworth B, 2007, BIOCHEM PHARMACOL, V74, P891, DOI 10.1016/j.bcp.2007.06.032
   Hern JA, 2010, P NATL ACAD SCI USA, V107, P2693, DOI 10.1073/pnas.0907915107
   Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027
   Hutchings CJ, 2010, MABS-AUSTIN, V2, P594, DOI 10.4161/mabs.2.6.13420
   Ishii T, 2010, CLIN CANCER RES, V16, P1520, DOI 10.1158/1078-0432.CCR-09-2697
   Isik N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003424
   Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200
   Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772
   Jacobson JM, 2008, J INFECT DIS, V198, P1345, DOI 10.1086/592169
   Jacobson JM, 2010, ANTIMICROB AGENTS CH, V54, P4137, DOI 10.1128/AAC.00086-10
   Jacobson JM, 2010, J INFECT DIS, V201, P1481, DOI 10.1086/652190
   Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107
   Jekle A, 2003, J VIROL, V77, P5846, DOI 10.1128/JVI.77.10.5846-5854.2003
   Jensen PC, 2008, J BIOL CHEM, V283, P23121, DOI 10.1074/jbc.M803458200
   Jensen PC, 2007, MOL PHARMACOL, V72, P327, DOI 10.1124/mol.106.035543
   Jin HJ, 2007, J BIOL CHEM, V282, P27976, DOI 10.1074/jbc.M702654200
   Jones SW, 2006, OSTEOARTHR CARTILAGE, V14, P597, DOI 10.1016/j.joca.2006.01.007
   Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389
   Kehrl JH, 2009, CURR TOP MICROBIOL, V334, P107, DOI 10.1007/978-3-540-93864-4_5
   Kellenberger E, 2007, J MED CHEM, V50, P1294, DOI 10.1021/jm061389p
   Kenakin T, 2011, J PHARMACOL EXP THER, V336, P296, DOI 10.1124/jpet.110.173948
   Kenakin T, 2010, J RECEPT SIG TRANSD, V30, P313, DOI 10.3109/10799893.2010.503964
   Kenakin T, 2010, PHARMACOL REV, V62, P265, DOI 10.1124/pr.108.000992
   Kim JH, 2011, J MOL MODEL, V17, P2707, DOI 10.1007/s00894-010-0943-x
   Klibanov OM, 2009, CURR OPIN INVEST DR, V10, P845
   Kofuku Y, 2009, J BIOL CHEM, V284, P35240, DOI 10.1074/jbc.M109.024851
   Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Kraneveld AD, 2011, METH PRIN MED CHEM, V46, P107
   Kufareva I, 2011, STRUCTURE IN PRESS
   Kuroumalis A, 2005, J IMMUNOL, V175, P5403, DOI 10.4049/jimmunol.175.8.5403                                                     
   Kuszak AJ, 2009, J BIOL CHEM, V284, P26732, DOI 10.1074/jbc.M109.026922
   Lalezari J, 2008, J INFECT DIS, V197, P721, DOI 10.1086/527327
   Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200
   Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196
   Leach K, 2007, BIOCHEM PHARMACOL, V74, P881, DOI 10.1016/j.bcp.2007.06.019
   Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618
   Liu YQ, 2008, MOLECULES, V13, P2426, DOI 10.3390/molecules13102426
   Lohse MJ, 2010, CURR OPIN PHARMACOL, V10, P53, DOI 10.1016/j.coph.2009.10.007
   Luker KE, 2009, FASEB J, V23, P823, DOI 10.1096/fj.08-116749
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Maeda DY, 2010, J PHARMACOL EXP THER, V332, P145, DOI 10.1124/jpet.109.159020
   Maeda K, 2006, J BIOL CHEM, V281, P12688, DOI 10.1074/jbc.M.512688200
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   Maeda K, 2008, J MOL BIOL, V381, P956, DOI 10.1016/j.jmb.2008.06.041
   Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3                                                   
   Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964
   Maussang D, 2009, CANCER RES, V69, P2861, DOI 10.1158/0008-5472.CAN-08-2487
   May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159
   Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497
   Milligan G, 2010, CURR OPIN PHARMACOL, V10, P23, DOI 10.1016/j.coph.2009.09.010
   Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x
   Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200
   Molon B, 2005, NAT IMMUNOL, V6, P465, DOI 10.1038/ni1191
   Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084                                                        
   Moriconi A, 2007, J MED CHEM, V50, P3984, DOI 10.1021/jm061469t
   Muniz-Medina VM, 2009, MOL PHARMACOL, V75, P490, DOI 10.1124/mol.108.052555
   Murphy PM, 2011, CHEMOKINE RECEPTORS
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Nelson AL, 2010, NAT REV DRUG DISCOV, V9, P767, DOI 10.1038/nrd3229
   Nicholls DJ, 2008, MOL PHARMACOL, V74, P1193, DOI 10.1124/mol.107.044610
   Nijmeijer S, 2010, J BIOL CHEM, V285, P29632, DOI 10.1074/jbc.M110.115618
   Niwa R, 2004, CANCER RES, V64, P2127, DOI 10.1158/0008-5472.CAN-03-2068                                                   
   Nygaard R, 2010, J BIOL CHEM, V285, P19625, DOI 10.1074/jbc.M110.106021
   O'Hayre M, 2008, BIOCHEM J, V409, P635, DOI 10.1042/BJ20071493
   Olson WC, 1999, J VIROL, V73, P4145
   Olson WC, 2009, CURR OPIN HIV AIDS, V4, P104, DOI 10.1097/COH.0b013e3283224015
   Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875
   Ott TR, 2004, J BIOL CHEM, V279, P42383, DOI 10.1074/jbc.M401097200
   Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739                                                    
   Parenty G, 2008, BIOCHEM J, V412, P245, DOI 10.1042/BJ20071689
   Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972
   Pello OM, 2008, EUR J IMMUNOL, V38, P537, DOI 10.1002/eji.200737630
   Percherancier Y, 2005, J BIOL CHEM, V280, P9895, DOI 10.1074/jbc.M411151200
   Perez-Nueno VI, 2009, J CHEM INF MODEL, V49, P810, DOI 10.1021/ci800468q
   Pin JP, 2007, PHARMACOL REV, V59, P5, DOI 10.1124/pr.59.1.5
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Proudfoot AEI, 2008, ARTHRITIS RHEUM, V58, P1889, DOI 10.1002/art.23590
   Proudfoot AEI, 2010, EXPERT OPIN INV DRUG, V19, P345, DOI 10.1517/13543780903535867
   Rajagopal S, 2010, P NATL ACAD SCI USA, V107, P628, DOI 10.1073/pnas.0912852107
   Rajagopalan L, 2004, J BIOL CHEM, V279, P30000, DOI 10.1074/jbc.M313883200
   Reis RI, 2007, REGUL PEPTIDES, V140, P32, DOI 10.1016/j.regpep.2006.11.028
   Richter R, 2009, J IMMUNOL, V183, P1229, DOI 10.4049/jimmunol.0802145
   Ridker PM, 2007, J AM COLL CARDIOL, V49, P2129, DOI 10.1016/j.jacc.2007.02.052
   Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628
   Rodriguez-Frade JM, 2004, EMBO J, V23, P66, DOI 10.1038/sj.emboj.7600020
   Rosenkilde MM, 2007, J BIOL CHEM, V282, P27354, DOI 10.1074/jbc.M704739200
   Rosenkilde MM, 2007, MOL PHARMACOL, V71, P930, DOI 10.1124/mol.106.030031
   Rosenkilde MM, 2010, TRENDS PHARMACOL SCI, V31, P567, DOI 10.1016/j.tips.2010.08.006
   Rosenkilde MM, 2004, J BIOL CHEM, V279, P3033, DOI 10.1074/jbc.M309546200
   Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199
   Sachpatzidis A, 2003, J BIOL CHEM, V278, P896, DOI 10.1074/jbc.M204667200
   Saita Y, 2006, J IMMUNOL, V177, P3116, DOI 10.4049/jimmunol.177.5.3116                                                     
   Salchow K, 2010, BRIT J PHARMACOL, V159, P1429, DOI 10.1111/j.1476-5381.2009.00623.x
   Satoh M, 2006, EXPERT OPIN BIOL TH, V6, P1161, DOI 10.1517/14712598.6.11.1161
   Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957
   Schulte A, 2007, BIOCHEM BIOPH RES CO, V358, P233, DOI 10.1016/j.bbrc.2007.04.100
   Seibert C, 2006, VIROLOGY, V349, P41, DOI 10.1016/j.virol.2006.01.018
   Shamovsky I, 2009, J MED CHEM, V52, P7706, DOI 10.1021/jm900713y
   Slinger E, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001180
   Smolarek D, 2010, TRANSFUS CLIN BIOL, V17, P184, DOI 10.1016/j.tracli.2010.05.003
   Sohy D, 2007, J BIOL CHEM, V282, P30062, DOI 10.1074/jbc.M705302200
   Sohy D, 2009, J BIOL CHEM, V284, P31270, DOI 10.1074/jbc.M109.054809
   Springael JY, 2006, MOL PHARMACOL, V69, P1652, DOI 10.1124/mol.105.019414
   Staudinger R, 2001, BIOCHEM BIOPH RES CO, V286, P41, DOI 10.1006/bbrc.2001.5345
   Stroke IL, 2006, BIOCHEM BIOPH RES CO, V349, P221, DOI 10.1016/j.bbrc.2006.08.019
   Stupple PA, 2011, J MED CHEM, V54, P67, DOI 10.1021/jm100978n
   Surgand JS, 2006, PROTEINS, V62, P509, DOI 10.1002/prot.20768
   Tanaka T, 2010, J AM CHEM SOC, V132, P15899, DOI 10.1021/ja107447w
   Tchernychev B, 2010, P NATL ACAD SCI USA, V107, P22255, DOI 10.1073/pnas.1009633108
   Thoma G, 2008, J MED CHEM, V51, P7915, DOI 10.1021/jm801065q
   Tian Y, 2004, EUR J IMMUNOL, V34, P785, DOI 10.1002/eji.200324166
   Toth PT, 2004, J PHARMACOL EXP THER, V310, P8, DOI 10.1124/jpet.103.064956
   Tsibris AMN, 2007, ANNU REV MED, V58, P445, DOI 10.1146/annurev.med.58.080105.102908
   Tsukamoto H, 2010, J MOL BIOL, V399, P501, DOI 10.1016/j.jmb.2010.04.029
   Vaidehi N, 2006, J BIOL CHEM, V281, P27613, DOI 10.1074/jbc.M601389200
   Veldkamp CT, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160755
   Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200
   Vergunst CE, 2008, ARTHRITIS RHEUM, V58, P1931, DOI 10.1002/art.23591
   Verzijl D, 2008, J PHARMACOL EXP THER, V325, P544, DOI 10.1124/jpet.107.134783
   Vila-Coro AJ, 1999, FASEB J, V13, P1699
   Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797
   Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841
   Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102
   Walsh G, 2010, NAT BIOTECHNOL, V28, P917, DOI 10.1038/nbt0910-917
   Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101
   Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565
   Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0                                                                
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wilson S, 2005, J BIOL CHEM, V280, P28663, DOI 10.1074/jbc.M413475200
   Wise EL, 2007, J BIOL CHEM, V282, P27935, DOI 10.1074/jbc.M703255200
   Wong RSY, 2008, MOL PHARMACOL, V74, P1485, DOI 10.1124/mol.108.049775
   Wood A, 2005, PROGR MED CHEM, V43, P239, DOI 10.1016/S0079-6468(05)43007-6
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202                                                        
   Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235
   Zhang YN, 2010, J MED CHEM, V53, P7048, DOI 10.1021/jm1006676
   Zhao J, 1999, J EXP MED, V190, P101, DOI 10.1084/jem.190.1.101
   Zidar DA, 2009, P NATL ACAD SCI USA, V106, P9649, DOI 10.1073/pnas.0904361106
NR 206
TC 96
Z9 97
U1 0
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAR
PY 2012
VL 165
IS 6
SI SI
BP 1617
EP 1643
DI 10.1111/j.1476-5381.2011.01551.x
PG 27
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 897WC
UT WOS:000300689800003
PM 21699506
OA gold
DA 2018-01-05
ER

PT J
AU Caygill, RL
   Hodges, CS
   Holmes, JL
   Higson, SPJ
   Blair, GE
   Millner, PA
AF Caygill, Rebecca L.
   Hodges, Christopher S.
   Holmes, Joanne L.
   Higson, Seamus P. J.
   Blair, G. Eric
   Millner, Paul A.
TI Novel impedimetric immunosensor for the detection and quantitation of
   Adenovirus using reduced antibody fragments immobilized onto a
   conducting copolymer surface
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Electrochemical impedance spectroscopy (EIS); Adenovirus; Immunosensor;
   Detection; Biosensor
ID IMPEDANCE SPECTROSCOPY; VIRUS; DNA; GOLD; HYBRIDIZATION
AB The number of Adenovirus (Ad) infections detected in immunocompromised people has increased due to the number of patients receiving transplants, as well as the HIV pandemic. Ads cause life-threatening diseases specific to the infected organs of immunocompromised hosts, with discontinuation of immunosuppressive agents necessary to prevent morbidity. The methodology in this paper has been employed to develop a novel impedimetric based assay platform to detect and quantify human Ads, which is comparable in performance to current methods, such as ELISA and PCR, but is also less expensive and faster.
   Novel immunosensors have been fabricated using polyclonal antibodies raised against a human Ad (Ad5) capsid protein, which were selectively cleaved into antibody fragments by 2-mercaptoethylamine. The fragments were immobilized onto a functionalized conducting copolymer matrix comprising polyaniline and 2-aminobenzylamine. Fully fabricated sensors were incubated with two immunologically distinct serotypes of Ad, Ad5 and Ad3, with between 10 and 10(12) virus particles/mL prior to sensor interrogation. Electrochemical impedance spectroscopy was used to measure the charge transfer resistance of the sensors over a range of frequencies from 25 kHz to 0.1 Hz. Our data demonstrate that the immunosensors specifically detect, and differentiate between, closely related human Ad serotypes with a limit of detection of 10(3) virus particles/mL. In addition, atomic force microscopy was applied to study the sensor surface nanostructure. Future work looks to test virus containing clinical samples but this could be a viable and valuable alternative for point-of-care virus detection and quantification. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Caygill, Rebecca L.; Millner, Paul A.] Univ Leeds, Biosensors & Biocatalysis Lab, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.
   [Hodges, Christopher S.] Univ Leeds, Sch Proc Environm & Mat Engn, Leeds LD2 9JT, W Yorkshire, England.
   [Holmes, Joanne L.; Higson, Seamus P. J.] Cranfield Univ, Cranfield MK43 0AL, Beds, England.
   [Blair, G. Eric] Univ Leeds, Inst Mol & Cellular Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.
RP Millner, PA (reprint author), Univ Leeds, Biosensors & Biocatalysis Lab, Inst Membrane & Syst Biol, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England.
EM p.a.millner@leeds.ac.uk
FU BBSRC; Elisha Systems Ltd; Yorkshire Cancer Research
FX We gratefully acknowledge financial assistance from the BBSRC and Elisha
   Systems Ltd's sponsoring of a CASE award. Research in G. Eric Blair's
   laboratory is supported by Yorkshire Cancer Research. Our thanks also
   extend to Stuart D. Collyer for technical assistance in the operation of
   the Biodot, Tim D. Gibson for technical discussion and Laura White for
   editorial support.
CR ALLARD A, 1994, J MED VIROL, V44, P250, DOI 10.1002/jmv.1890440307
   Bandies J.E.B., 1947, DISCUSS FARADAY SOC, V1, P11
   BELL JA, 1955, JAMA-J AM MED ASSOC, V157, P1083, DOI 10.1001/jama.1955.02950300011003                                                
   Billah MM, 2010, BIOELECTROCHEMISTRY, V80, P49, DOI 10.1016/j.bioelechem.2010.08.005
   Billah M, 2008, MICROCHIM ACTA, V160, P447, DOI 10.1007/s00604-007-0793-0
   Clark L. C., 1962, ANN NY ACAD SCI, V105, P20
   Ding CF, 2008, BIOELECTROCHEMISTRY, V72, P28, DOI 10.1016/j.bioelechem.2007.11.001
   FADEN H, 1985, AM J PEDIAT HEMATOL, V7, P15
   Fang XQ, 2010, BIOSENS BIOELECTRON, V25, P1137, DOI 10.1016/j.bios.2009.09.037
   Hall K, 2009, VIROLOGY, V392, P222, DOI 10.1016/j.virol.2009.07.010
   HARLOW E, 1988, ANTIBODIES LAB MANUA, P617
   Hays HCW, 2006, SENSOR ACTUAT B-CHEM, V114, P1064, DOI 10.1016/j.snb.2005.08.039
   Hermanson G.T., 2008, BIOCONJUGATE TECHNIQ, P792
   Hianik T, 2001, BIOELECTROCHEMISTRY, V53, P199, DOI 10.1016/S0302-4598(00)00130-6                                                   
   HILLEMAN MR, 1954, P SOC EXP BIOL MED, V85, P183
   Hnaien M, 2008, BIOCHEM ENG J, V39, P443, DOI 10.1016/j.bej.2007.09.018
   Horcas I, 2007, REV SCI INSTRUMENTS, V78, DOI 10.1063/1.2432410
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Liu YT, 2011, ELECTROCHIM ACTA, V56, P4595, DOI 10.1016/j.electacta.2011.02.088
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9                                                    
   Murakami P, 1999, ANAL BIOCHEM, V274, P283, DOI 10.1006/abio.1999.4282
   Pan Y, 2010, BIOSENS BIOELECTRON, V26, P649, DOI 10.1016/j.bios.2010.07.002
   Raffa DL, 2006, J ELECTROANAL CHEM, V587, P60, DOI 10.1016/j.jelechem.2005.10.017
   Raffa DL, 2001, J ELECTROANAL CHEM, V504, P120, DOI 10.1016/S0022-0728(01)00352-7                                                   
   Romanova N, 2009, J VIROL METHODS, V159, P58, DOI 10.1016/j.jviromet.2009.02.026
   Rosales-Rivera LC, 2011, BIOSENS BIOELECTRON, V26, P4471, DOI 10.1016/j.bios.2011.05.004
   ROWE WP, 1953, P SOC EXP BIOL MED, V84, P570
   Smith AM, 2008, ADV DRUG DELIVER REV, V60, P1226, DOI 10.1016/j.addr.2008.03.015
   Wang HJ, 2011, J VIROL, V85, P6390, DOI 10.1128/JVI.00514-11
   Wold W., 2006, FIELDS VIROLOGY, P2395
   Yang LJ, 2004, ANAL CHEM, V76, P1107, DOI 10.1021/ac0352575
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang FF, 2004, J ELECTROANAL CHEM, V571, P133, DOI 10.1016/j.jelechem.2004.04.019
NR 33
TC 16
Z9 16
U1 4
U2 32
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD FEB 15
PY 2012
VL 32
IS 1
BP 104
EP 110
DI 10.1016/j.bios.2011.11.041
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 902AN
UT WOS:000301011100015
PM 22196880
DA 2018-01-05
ER

PT J
AU Ben Haij, N
   Mzoughi, O
   Planes, R
   Bahraoui, E
AF Ben Haij, Nawal
   Mzoughi, Olfa
   Planes, Remi
   Bahraoui, Elmostafa
TI Cationic nanoglycolipidic particles as vector and adjuvant for the study
   of the immunogenicity of SIV Nef protein
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nanoparticles; HIV-1; Nef; Antibodies; Adjuvant; Immunogenicity
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PATTERN-RECOGNITION RECEPTORS;
   CELL-SURFACE CD4; HIV-1 NEF; T-CELLS; IMMUNE-RESPONSES; INNATE IMMUNITY;
   DOWN-REGULATION; DOUBLE-BLIND; IN-VITRO
AB The objective of this study was to test the immunogenicity of Sly Nef protein formulated in cationic nanoglycolipidic particles of 100 nm of diameter. In parallel, the adjuvant effect of these nanoglycolipidic particles was compared in similar experiments using GST-Nef in association with the commonly strongest used complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant in association with MDP or MOP alone. Our results showed that these particles do not alter the integrity of our immunogen GST-Nef, which remains stable for more than three months at 4 degrees C. We demonstrated that in the presence of nanoglycolipidic particles antibodies against Nef were produced since the first injection and remained stable after the third injection with high titers for long lasting periods as observed with CFA and IFA/MDP adjuvant. The analysis of immunoglobulin isotype profiles of antibodies generated by the different protocols of immunization showed the preponderance of IgG1 isotypes suggesting the predominance of Th2-type immune response. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ben Haij, Nawal; Mzoughi, Olfa; Planes, Remi; Bahraoui, Elmostafa] Univ Paul Sabatier 1043, Unite Mixte INSERM, CNRS, Ctr Physiopathol Toulouse Purpan,CHU Purpan, Toulouse, France.
RP Bahraoui, E (reprint author), Lab Immunovirol, 118 Route Narbonne,4R3 B2, F-31062 Toulouse, France.
EM bahraoui@cict.fr
FU Agence Nationale de Recherche sur le SIDA (ANRS); SIDACTION; Ministere
   de la recherche et des Technologies; MRT
FX This work was supported by the Agence Nationale de Recherche sur le SIDA
   (ANRS), SIDACTION, and Ministere de la recherche et des Technologies.
   Ben Haij Nawal is recipient of a fellowship from MRT. We thank SA
   Biovector, and Dr D Betbeder for the preparation of the nanoparticles.
CR Baba TW, 1999, NAT MED, V5, P194
   BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X
   BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561
   Berton M, 1997, BBA-MOL CELL RES, V1355, P7, DOI 10.1016/S0167-4889(96)00111-5
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Buonaguro L, 2010, CURR HIV RES, V8, P299, DOI 10.2174/157016210791208659                                                      
   Castignolles N, 1996, VACCINE, V14, P1353, DOI 10.1016/S0264-410X(96)00043-6
   Cazeaux N, 2002, VACCINE, V20, P3322, DOI 10.1016/S0264-410X(02)00310-9
   CHAKRABARTI L, 1995, VIROLOGY, V213, P535, DOI 10.1006/viro.1995.0026
   Chang J, 2009, INT J PHARMACEUT, V379, P285, DOI 10.1016/j.ijpharm.2009.04.035
   CHOWERS MY, 1994, J VIROL, V68, P2906
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Collette Y, 1996, EUR J IMMUNOL, V26, P1788, DOI 10.1002/eji.1830260819
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917                                                         
   De Miguel I, 2000, PHARMACEUT RES, V17, P817, DOI 10.1023/A:1007504124603                                                         
   DE SK, 1994, J BIOL CHEM, V269, P6656
   DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988
   Debin A, 2002, VACCINE, V20, P2752, DOI 10.1016/S0264-410X(02)00191-3
   Dombu CY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/35/355102
   Fackler OT, 2007, NAT REV IMMUNOL, V7, P310, DOI 10.1038/nri2041
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9
   GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0
   Greene JM, 2010, J VIROL, V84, P3362, DOI 10.1128/JVI.02028-09
   GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0
   Heurtault B, 2010, EXPERT OPIN DRUG DEL, V7, P829, DOI 10.1517/17425247.2010.488687
   Jere A, 2010, MICROBES INFECT, V12, P65, DOI 10.1016/j.micinf.2009.09.009
   KAMINCHIK J, 1994, AIDS RES HUM RETROV, V10, P1003, DOI 10.1089/aid.1994.10.1003
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Major M, 1997, BBA-BIOMEMBRANES, V1327, P32, DOI 10.1016/S0005-2736(97)00041-2                                                   
   Mariani R, 1996, J VIROL, V70, P7752
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011
   MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101
   Moureau C, 2002, MOL IMMUNOL, V38, P607, DOI 10.1016/S0161-5890(01)00096-7
   Noviello CM, 2008, J VIROL, V82, P1249, DOI 10.1128/JVI.00660-07
   OTAKE K, 1994, J IMMUNOL, V153, P5826
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Prieur E, 1996, VACCINE, V14, P511, DOI 10.1016/0264-410X(95)00233-Q
   Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rudolph JM, 2009, J VIROL, V83, P11528, DOI 10.1128/JVI.01423-09
   Sinclair E, 1997, J VIROL, V71, P3641
   Stolp B, 2009, CELL HOST MICROBE, V6, P174, DOI 10.1016/j.chom.2009.06.004
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tatsis N, 2009, J IMMUNOL, V182, P6587, DOI 10.4049/jimmunol.0900317
   Tiollais P, 2010, PATHOL BIOL, V58, P243, DOI 10.1016/j.patbio.2010.04.002
   van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778                                                     
   von Hoegen P, 2001, ADV DRUG DELIVER REV, V51, P113, DOI 10.1016/S0169-409X(01)00175-2
NR 52
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD FEB 14
PY 2012
VL 423
IS 1
SI SI
BP 116
EP 123
DI 10.1016/j.ijpharm.2011.06.049
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 896CB
UT WOS:000300541900016
PM 21762763
DA 2018-01-05
ER

PT J
AU Wadhwa, S
   Jain, A
   Woodward, JG
   Mumper, RJ
AF Wadhwa, Saurabh
   Jain, Anekant
   Woodward, Jerold G.
   Mumper, Russell J.
TI Lipid nanocapsule as vaccine carriers for his-tagged proteins:
   Evaluation of antigen-specific immune responses to HIV I His-Gag p41 and
   systemic inflammatory responses
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Green fluorescent protein; Antigen; Dendritic cells; Adjuvant; Cytokine;
   Antibody
ID BIODEGRADABLE NANOPARTICLES; CROSS-PRESENTATION; HUMORAL RESPONSE;
   DENDRITIC CELLS; DELIVERY; MICROSPHERES; PEPTIDES; NTA; ENCAPSULATION;
   ALUMINUM
AB The purpose of this study was to design novel nanocapsules (NCs) with surface-chelated nickel (Ni-NCs) as a vaccine delivery system for histidine (His)-tagged protein antigens. Ni-NCs were characterized for binding His-tagged model proteins through high-affinity non-covalent interactions. The mean diameter and zeta potential of the optimized Ni-NCs were 214.9 nm and -14.8 mV, respectively. The optimal binding ratio of His-tagged Green Fluorescent Protein (His-GFP) and His-tagged HIV-1 Gag p41 (His-Gag p41) to the Ni-NCs was 1:221 and 1:480 w/w, respectively. Treatment of DC2.4 cells with Ni-NCs did not result in significant loss in the cell viability up to 24 h (<5%). We further evaluated the antibody response of the Ni-NCs using His-Gag p41 as a model antigen. Formulations were administered subcutaneously to BALB/c mice at day 0 (prime) and 14 (boost) followed by serum collection on day 28. Serum His-Gag p41-specific antibody levels were found to be significantly higher at 1 and 0.5 mu g doses of Gag p41-His-Ni-NCs (His-Gag p41 equivalent) compared with His-Gag p41 (1 mu g) adjuvanted with aluminum hydroxide (AH). The serum IgG2a levels induced by Gag p41-His-Ni-NCs (1 mu g) were significantly higher than AH adjuvanted His-Gag p41. The Ni-NCs alone did not result in the elevation of systemic IL-12/p40 and CCL5/RANTES inflammatory cytokine levels upon subcutaneous administration in BALB/c mice. In conclusion, the proposed Ni-NCs can bind His-tagged proteins and have the potential to be used as antigen delivery system capable of generating strong antigen-specific antibodies at doses much lower than with aluminum-based adjuvant and causing no significant elevation of systemic pro-inflammatory IL-12/p40 and CCL5/RANTES cytokines. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Mumper, Russell J.] Univ N Carolina, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Woodward, Jerold G.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40506 USA.
   [Mumper, Russell J.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Mumper, RJ (reprint author), Univ N Carolina, Ctr Nanotechnol Drug Delivery, Div Mol Pharmaceut, UNC Eshelman Sch Pharm, CB 7355,100G Beard Hall, Chapel Hill, NC 27599 USA.
EM mumper@email.unc.edu
OI Wadhwa, Saurabh/0000-0002-0154-681X
FU National Institute of Allergy and Infectious Diseases [R01AI058842];
   Amgen Graduate Fellowship
FX The project described was supported by Award Number R01AI058842 to RJM
   and JW from the National Institute of Allergy and Infectious Diseases.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Allergy and Infectious Diseases or the National Institutes of Health.
   The authors would like to thank Dr. Robert Seder (Vaccine Research
   Center, NIH-NIAID) for kindly providing His-Gag p41 and Dr. Kenneth L.
   Rock (Department of Pathology, University of Massachusetts Medical
   School) for providing DC2.4 dendritic cells. The authors would also like
   to thank Dr. Sohrab Habibi of the Mass Spectrometry Facility, Michael
   Chua of the Michael Hooker Microscopy Facility, Todd Gambling of
   Environmental Protection Agency at the University of North Carolina at
   Chapel Hill for assistance with ICP-MS, confocal microscopy and TEM
   analyses, respectively. SW would like to acknowledge financial
   assistance provided by the Amgen Graduate Fellowship.
CR Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   ALVING CR, 1995, ANN NY ACAD SCI, V754, P143, DOI 10.1111/j.1749-6632.1995.tb44447.x
   Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2                                                   
   Baylor NW, 2002, VACCINE, V20, pS18, DOI 10.1016/S0264-410X(02)00166-4                                                   
   Buzard Gregory S., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P179
   Chen JA, 2011, INT J NANOMED, V6, P77, DOI 10.2147/IJN.S15457
   Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1                                                   
   COOPER HM, 1987, J BIOL CHEM, V262, P11591
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Dong XW, 2009, CANCER RES, V69, P3918, DOI 10.1158/0008-5472.CAN-08-2747
   Dong XW, 2009, EUR J PHARM BIOPHARM, V72, P9, DOI 10.1016/j.ejpb.2008.11.012
   Duncan G, 2005, J CONTROL RELEASE, V110, P34, DOI 10.1016/j.jconrel.2005.09.007
   Fuchs SM, 2007, ACS CHEM BIOL, V2, P167, DOI 10.1021/cb600429k
   HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4
   Huang ZH, 2006, BIOCONJUGATE CHEM, V17, P1592, DOI 10.1021/bc0602228
   Huang ZH, 2009, BIOCONJUGATE CHEM, V20, P1667, DOI 10.1021/bc900309n
   Kim JS, 2007, BIOCONJUGATE CHEM, V18, P333, DOI 10.1021/bc060195I
   Klippstein R, 2010, NANOMED-NANOTECHNOL, V6, P523, DOI 10.1016/j.nano.2010.01.001
   Knecht S, 2009, J MOL RECOGNIT, V22, P270, DOI 10.1002/jmr.941
   Lauer SA, 2002, CYTOMETRY, V48, P136, DOI 10.1002/cyto.10124
   Maassen CBM, 2003, VACCINE, V21, P2751, DOI 10.1016/S0264-410X(03)00220-2
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164
   OTT G, 1995, VACCINE, V13, P1557, DOI 10.1016/0264-410X(95)00089-J                                                    
   Oyewumi MO, 2003, BIOCONJUGATE CHEM, V14, P404, DOI 10.1021/bc0340013
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Patel JD, 2007, J BIOMED NANOTECHNOL, V3, P97, DOI 10.1166/jbn.2007.007
   Patel JD, 2007, PHARM RES, V24, P343, DOI 10.1007/s11095-006-9154-7
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Platt V, 2010, BIOCONJUGATE CHEM, V21, P892, DOI 10.1021/bc900448f
   PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0                                                                
   RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X                                                   
   Romagnani S., 2000, ANN ALLERG ASTHMA IM, V85, P21
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P18
   SHAHUM E, 1988, IMMUNOLOGY, V65, P315
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Sloat BR, 2010, J CONTROL RELEASE, V141, P93, DOI 10.1016/j.jconrel.2009.08.023
   SMIALOWICZ RJ, 1984, ENVIRON RES, V33, P413, DOI 10.1016/0013-9351(84)90039-2
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10
   Yan WL, 2009, HIV AIDS-RES PALLIAT, V1, P1
NR 42
TC 6
Z9 7
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD FEB
PY 2012
VL 80
IS 2
BP 315
EP 322
DI 10.1016/j.ejpb.2011.10.016
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 907GU
UT WOS:000301406600010
PM 22068049
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tang, J
   Yin, R
   Tian, Y
   Huang, ZM
   Shi, JL
   Fu, XL
   Wang, L
   Wu, YZ
   Hao, F
   Ni, B
AF Tang, Jun
   Yin, Rui
   Tian, Yi
   Huang, Zeming
   Shi, Jinglei
   Fu, Xiaolan
   Wang, Li
   Wu, Yuzhang
   Hao, Fei
   Ni, Bing
TI A novel self-assembled nanoparticle vaccine with HIV-1 Tat(49-57)/HPV16
   E7(49-57) fusion peptide and GM-CSF DNA elicits potent and prolonged
   CD8(+) T cell-dependent anti-tumor immunity in mice
SO VACCINE
LA English
DT Article
DE HPV; E7(49-57); Nanoparticle; HIV Tat(49-57); GM-CSF
ID ANTIGEN GENE; TAT PEPTIDE; TUMOR; CANCER; ADJUVANT; PROTEIN;
   ENHANCEMENT; RESPONSES; DELIVERY; IMMUNOTHERAPY
AB Peptide-based vaccines derived from the E7 protein of human papillomavirus (HPV) type 16 were developed to induce effective T cell responses against established cervical cancer, but have met with limited clinical success. It is necessary to develop novel peptide-based strategies to substantially improve the immune response against HPV16-related cancer. In this study, we aimed to design a novel peptide-based self-assembled nanoparticle HPV16 vaccine by combining the cell-penetrating peptide HIV-1 Tat(49-57) that was fused with the HPV16 E7(49-57) cytotoxic T lymphocyte (CTL) epitope and the granulocyte-macrophage colony stimulating factor (GM-CSF) gene, and to investigate how it improves the immune response and the therapeutic outcome ex vivo and in vivo. Nanoparticles were prepared and identified by transmission electron microscopy (TEM), gel retardation and DNase I protection assays. This type of vaccine formulation formed the 20-80 nm nanoparticles, and greatly improved epitope-specific immunity both ex vivo and in vivo. Importantly, this vaccine type was associated with decreased tumor growth and enhanced long-term survival in the prophylactic and therapeutic mouse models. The underlying mechanisms were determined to involve priming of enhanced frequency of CD8(+). memory T subtype cells. These results suggest that the nanoparticle Tat-E7/pGM-CSE represents a promising novel approach to enhance the potency of peptide-based cervical cancer vaccines, and this vaccine design strategy may act as a useful reference for research of virus-associated diseases and specific tumor immunotherapies. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Tang, Jun; Yin, Rui; Hao, Fei] Third Mil Med Univ, Dept Dermatol, Southwestern Hosp, Chongqing 400038, Peoples R China.
   [Tian, Yi; Huang, Zeming; Shi, Jinglei; Fu, Xiaolan; Wang, Li; Wu, Yuzhang; Ni, Bing] Third Mil Med Univ, Inst Immunol PIA, Chongqing 400038, Peoples R China.
   [Tian, Yi; Huang, Zeming; Shi, Jinglei; Fu, Xiaolan; Wang, Li; Wu, Yuzhang; Ni, Bing] Third Mil Med Univ, Dept Immunol, Chongqing 400038, Peoples R China.
   [Tang, Jun] PLA, Dept Dermatol, Hosp 105, Hefei 230001, Peoples R China.
RP Hao, F (reprint author), Third Mil Med Univ, Dept Dermatol, Southwestern Hosp, Chongqing 400038, Peoples R China.
EM haofei62@medmail.com.cn; nibingxi@yahoo.com
OI Ni, Bing/0000-0002-4297-5346
FU National Natural Science Foundation of China [30500609, 30571835];
   National Major Project for New Drug Creation of China [2009ZX09503-005]
FX This work was supported by grants from the National Natural Science
   Foundation of China (nos. 30500609 and 30571835) and the National Major
   Project for New Drug Creation of China (2009ZX09503-005). We would like
   to thank Dr. Jennifer C. van Velkinburgh, who works for the van
   Velkinburgh Initiative for Collaborative BioMedical Research, for
   substantial writing assistance with this manuscript.
CR Awasthi S, 2003, BIOTECHNIQUES, V35, P600
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Chen CH, 2000, CANCER RES, V60, P1035
   Dalpke A, 2002, BIOL CHEM, V383, P1491, DOI 10.1515/BC.2002.171
   Disis ML, 1996, BLOOD, V88, P202
   Eiben GL, 2002, CANCER RES, V62, P5792
   Esposito C, 2006, COLLOID SURFACE B, V53, P187, DOI 10.1016/j.colsurfb.2006.09.011
   FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935
   FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929
   Giannouli C, 2003, ANTICANCER RES, V23, P3523
   Gritzapis AD, 2010, CANCER RES, V70, P2686, DOI 10.1158/0008-5472.CAN-09-2517
   Harbottle RP, 1998, HUM GENE THER, V9, P1037, DOI 10.1089/hum.1998.9.7-1037
   Hauser H, 2004, GENE THER, V11, P924, DOI 10.1038/sj.gt.3302160
   Hsieh CJ, 2004, VACCINE, V22, P3993, DOI 10.1016/j.vaccine.2004.03.057
   Karkada M, 2010, J IMMUNOTHER, V33, P250, DOI 10.1097/CJI.0b013e3181c1f1e9
   Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6
   Kim D, 2008, J IMMUNOL, V180, P7019, DOI 10.4049/jimmunol.180.10.7019                                                    
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kline JN, 2008, DRUG NEWS PERSPECT, V21, P434, DOI 10.1358/dnp.2008.21.8.1272133
   Ko SY, 2005, J IMMUNOL, V175, P3309, DOI 10.4049/jimmunol.175.5.3309                                                     
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Leifert JA, 2003, GENE THER, V10, P2067, DOI 10.1038/sj.gt.3302115
   Lin K, 2010, IMMUNOL RES, V47, P86, DOI 10.1007/s12026-009-8141-6
   Lin K, 2010, J FORMOS MED ASSOC, V109, P4, DOI 10.1016/S0929-6646(10)60017-4
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Parmiani G, 2007, ANN ONCOL, V18, P226, DOI 10.1093/annonc/mdl158
   Perez SA, 2011, CLIN CANCER RES, V16, P3495
   Roden RBS, 2004, HUM PATHOL, V35, P971, DOI 10.1016/j.humpath.2004.04.007
   SADOVNIKOVA E, 1994, INT IMMUNOL, V6, P289, DOI 10.1093/intimm/6.2.289
   Stanley Margaret, 2008, Nurs Times, V104, P38
   Torrens I, 2005, VACCINE, V23, P5768, DOI 10.1016/j.vaccine.2005.07.049
   Toubaji A, 2007, VACCINE, V25, P5882, DOI 10.1016/j.vaccine.2007.05.040
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wu YZ, 2002, J VIROL, V76, P10264, DOI 10.1128/JVI.76.20.10264-10269.2002
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
   Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350                                                      
NR 37
TC 16
Z9 21
U1 1
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB 1
PY 2012
VL 30
IS 6
BP 1071
EP 1082
DI 10.1016/j.vaccine.2011.12.029
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 901JO
UT WOS:000300963400014
PM 22178528
DA 2018-01-05
ER

PT J
AU Gorlani, A
   Brouwers, J
   McConville, C
   van der Bijl, P
   Malcolm, K
   Augustijns, P
   Quigley, AF
   Weiss, R
   De Haard, H
   Verrips, T
AF Gorlani, Andrea
   Brouwers, Joachim
   McConville, Christopher
   van der Bijl, Pieter
   Malcolm, Karl
   Augustijns, Patrick
   Quigley, Anna Forsman
   Weiss, Robin
   De Haard, Hans
   Verrips, Theo
TI Llama Antibody Fragments Have Good Potential for Application as HIV Type
   1 Topical Microbicides
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LARGE-SCALE PRODUCTION; SINGLE-CHAIN
   ANTIBODY; SACCHAROMYCES-CEREVISIAE; SEXUAL TRANSMISSION; INFECTION;
   FORMULATION; PREVENTION; STRATEGIES; NANOBODIES
AB There is an urgent global need for preventive strategies against HIV-1 infections. Llama heavy-chain antibody fragments (VHH) are a class of molecules recently described as potent cross-clade HIV-1 entry inhibitors. We studied the potential of a VHH-based microbicide in an application-oriented fashion. We show that VHH can be inexpensively produced in high amounts in the GRAS organism Saccharomyces cerevisiae, resulting in a very pure and endotoxin free product. VHH are very stable under conditions they might encounter during transport, storage, or use by women. We developed active formulations of VHH in aqueous gel and compressed and lyophilized tablets for controlled release from an intravaginal device. The release profile of the VHH from, e. g., a vaginal ring suggests sufficient bioavailability and protective concentration of the molecule at the mucosal site at the moment of the infection. The ex vivo penetration kinetics through human tissues show that the VHH diffuse into the mucosal layer and open the possibility to create a second defense layer either by blocking the HIV receptor binding sites or by blocking the receptors of immune cells in the mucosa. In conclusion, our data show that VHH have a high potential for HIV-1 microbicide application because of their low production costs, their high stability, and their favorable release and tissue penetration properties.
C1 [Gorlani, Andrea; De Haard, Hans; Verrips, Theo] Univ Utrecht, Dept Biol, Fac Sci, Utrecht, Netherlands.
   [Brouwers, Joachim; Augustijns, Patrick] Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, Louvain, Belgium.
   [McConville, Christopher; Malcolm, Karl] Queens Univ Belfast, Sch Pharm, Belfast BT7 1NN, Antrim, North Ireland.
   [van der Bijl, Pieter] Univ Stellenbosch, Dept Pharmacol, ZA-7600 Stellenbosch, South Africa.
   [Quigley, Anna Forsman; Weiss, Robin] UCL, Div Infect & Immun, MRC UCL Ctr Med Mol Virol, London, England.
RP Verrips, T (reprint author), Room W504,Kruitgebouw Padualaan 8, NL-3584 CH Utrecht, Netherlands.
EM c.t.verrips@uu.nl
RI Brouwers, Joachim/B-3602-2012; gorlani, andrea/C-5678-2014
OI Brouwers, Joachim/0000-0003-1478-6174; 
FU EU
FX This study was supported by EU grants Europrise and EMPRO. The authors
   thank Dr. Lucy Rutten for critical reading of the manuscript.
CR Abdool KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
   Balzarini J, 1996, BIOCHEM BIOPH RES CO, V219, P337, DOI 10.1006/bbrc.1996.0234
   Basson E, 2007, EUR J INFLAMM, V5, P15, DOI 10.1177/1721727X0700500103                                                      
   Borkow G, 1997, J VIROL, V71, P3023
   Coppieters K, 2006, ARTHRITIS RHEUM-US, V54, P1856, DOI 10.1002/art.21827
   Cutler B, 2008, LANCET INFECT DIS, V8, P685, DOI 10.1016/S1473-3099(08)70254-8
   El Khattabi M, 2006, CLIN VACCINE IMMUNOL, V13, P1079, DOI 10.1128/CVI.00107-06
   Fiscella K, 2004, AM J OBSTET GYNECOL, V191, P747, DOI 10.1016/j.ajog.2004.03.032
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   Frenken LGJ, 1998, RES IMMUNOL, V149, P589, DOI 10.1016/S0923-2494(98)80011-4                                                   
   Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X                                                   
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X
   Hermeling S, 2004, PHARM RES, V21, P897, DOI 10.1023/B:PHAM.0000029275.41323.a6                                              
   Hinz A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010482
   Huang BB, 2008, BIOTECHNOL LETT, V30, P1121, DOI 10.1007/s10529-008-9663-z
   Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107
   Klasse PJ, 2006, PLOS MED, V3, P1501, DOI 10.1371/journal.pmed.0030351
   Koh WWL, 2010, J BIOL CHEM, V285, P19116, DOI 10.1074/jbc.M110.116699
   Larkin M, 1999, LANCET, V354, P399, DOI 10.1016/S0140-6736(05)75818-9
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parren PW, 1995, AIDS, V9, P6
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Romano J, 2008, CURR OPIN HIV AIDS, V3, P558, DOI 10.1097/COH.0b013e328305b96e
   Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4
   Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Skoler-Karpoff S, 2009, LANCET, V372, P1977
   Strokappe NM, LLAMA ANTIBODY UNPUB
   Thomassen YE, 2002, ENZYME MICROB TECH, V30, P273, DOI 10.1016/S0141-0229(01)00497-5
   van de Laar T, 2007, BIOTECHNOL BIOENG, V96, P483, DOI 10.1002/bit.21150
   Van der Bijl P, 2008, EUR J INFLAMM, V6, P17, DOI 10.1177/1721727X0800600103                                                      
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Walker PR, 2003, NATURE, V422, P679, DOI 10.1038/422679a
   [Anonymous], 2008, 2008 REPORT GLOBAL A
NR 39
TC 18
Z9 18
U1 1
U2 8
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD FEB
PY 2012
VL 28
IS 2
BP 198
EP 205
DI 10.1089/aid.2011.0133
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 895VS
UT WOS:000300525400010
PM 21864083
DA 2018-01-05
ER

PT J
AU Grundemann, C
   Koehbach, J
   Huber, R
   Gruber, CW
AF Gruendemann, Carsten
   Koehbach, Johannes
   Huber, Roman
   Gruber, Christian W.
TI Do Plant Cyclotides Have Potential As Immunosuppressant Peptides?
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID CYCLIC-CYSTINE-KNOT; ANTI-HIV ACTIVITY; KALATA B1; OLDENLANDIA-AFFINIS;
   CIRCULAR MINIPROTEINS; FLOWERING PLANTS; DRUG DESIGN; PROTEINS;
   BIOSYNTHESIS; DISCOVERY
AB Cyclotides are an abundant and diverse group of ribosomally synthesized plant peptides containing a cyclic cystine-knotted structure that confers them with remarkable stability. They are explored for their distribution in plants, although little is known about the individual peptide content of a single species. Therefore, we chemically analyzed the crude extract of the coffee-family plant Oldenlandia affinis using a rapid peptidomics workflow utilizing nano-LC-MS, peptide reconstruct with database identification, and MS/MS automated sequence analysis to determine its cyclotide content. Biologically, cyclotides are mainly explored for applications in agriculture and drug design; here we report their growth-inhibiting effects on primary cells of the human immune system using biological and immunological end points in cell-based test systems. LC-MS quantification of the active O. affinis plant extract triggered the characterization of the antiproliferative activity of kalata B1, one of the most abundant cyclotides in this extract, on primary activated human lymphocytes. The effect has a defined concentration range and was not due to cytotoxicity, thus opening a new avenue to utilize native and synthetically optimized plant cyclotides for applications in immune-related disorders and as immunosuppressant peptides.
C1 [Koehbach, Johannes; Gruber, Christian W.] Med Univ Vienna, Ctr Physiol & Pharmacol, A-1090 Vienna, Austria.
   [Gruendemann, Carsten; Huber, Roman] Univ Med Ctr Freiburg, Dept Environm Hlth Sci, Ctr Complementary Med, D-79111 Freiburg, Germany.
RP Gruber, CW (reprint author), Med Univ Vienna, Ctr Physiol & Pharmacol, Schwarzspanierstr 17, A-1090 Vienna, Austria.
EM christian.w.gruber@meduniwien.ac.at
RI Koehbach, Johannes/P-3639-2014; Gruber, Christian/C-4406-2011
OI Koehbach, Johannes/0000-0002-7050-2693; Gruber,
   Christian/0000-0001-6060-7048
FU Austrian Science Fund (FWF) [P22889-B11]; Software AG foundation; DAMUS
   eV
FX Thanks to the individuals at the Department of Pharmacognosy, University
   of Vienna, Austria, who helped during the growth and harvest of O.
   affinis plants and to D.J. Craik, Institute for Molecular Bioscience,
   Australia, for the gift of seeds. MS data of this research have been
   obtained by access to the MS core facility of the Center for Physiology
   and Pharmacology, Medical University of Vienna. Work on bioactive
   peptides in the laboratory of C.W.G. is funded by the Austrian Science
   Fund (FWF, P22889-B11). C.G. and R.H. receive financial support from
   Software AG foundation and DAMUS eV.
CR Barbeta BL, 2008, P NATL ACAD SCI USA, V105, P1221, DOI 10.1073/pnas.0710338104
   Barry DG, 2003, BIOCHEMISTRY-US, V42, P6688, DOI 10.1021/bi027323n
   Chen B, 2005, J BIOL CHEM, V280, P22395, DOI 10.1074/jbc.M501737200
   Clark RJ, 2010, ANGEW CHEM INT EDIT, V49, P6545, DOI 10.1002/anie.201000620
   Clark RJ, 2010, BIOPOLYMERS, V94, P414, DOI 10.1002/bip.21372
   Clark RJ, 2006, BIOCHEM J, V394, P85, DOI 10.1042/BJ20051691
   Colgrave ML, 2008, BIOCHEMISTRY-US, V47, P5581, DOI 10.1021/bi800223y
   Colgrave ML, 2010, BIOPOLYMERS, V94, P592, DOI 10.1002/bip.21400
   Colgrave ML, 2009, ACTA TROP, V109, P163, DOI 10.1016/j.actatropica.2008.11.003
   Colgrave ML, 2005, J CHROMATOGR A, V1091, P187, DOI 10.1016/j.chroma.2005.07.094
   Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q
   Craik DJ, 2007, CURR OPIN DRUG DISC, V10, P176
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Craik DJ, 2006, BIOPOLYMERS, V84, P250, DOI 10.1002/hip.20451
   Craik DJ, 2006, SCIENCE, V311, P1563, DOI 10.1126/science.1125248
   Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5
   Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4                                                   
   Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007
   de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9
   Gillon AD, 2008, PLANT J, V53, P505, DOI 10.1111/j.1365-313X.2007.03357.x
   Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719
   GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400
   Gran L., 1970, MEDD NOR FARM SELSK, V12, P173
   Gran L, 2008, CHEM BIODIVERS, V5, P2014, DOI 10.1002/cbdv.200890184
   Gruber CW, 2008, PLANT CELL, V20, P2471, DOI 10.1105/tpc.108.062331
   Gruber CW, 2007, J BIOL CHEM, V282, P20435, DOI 10.1074/jbc.M700018200
   Gruber CW, 2007, TOXICON, V49, P561, DOI 10.1016/j.toxicon.2006.11.018
   Gruber CW, 2011, PLANTA MED, V77, P207, DOI 10.1055/s-0030-1250317
   Gruber CW, 2010, CURR PHARM DESIGN, V16, P3071
   Gruber CW, 2010, BIOPOLYMERS, V94, P565, DOI 10.1002/bip.21414
   Grundemann C, 2011, J ETHNOPHARMACOL, V136, P444, DOI 10.1016/j.jep.2011.05.018
   Henriques ST, 2011, J BIOL CHEM, V286, P24231, DOI 10.1074/jbc.M111.253393
   Huang YH, 2010, J BIOL CHEM, V285, P10797, DOI 10.1074/jbc.M109.089854
   Ireland DC, 2008, BIOPOLYMERS, V90, P51, DOI 10.1002/bip.20886
   Ireland DC, 2006, BIOCHEM J, V400, P1, DOI 10.1042/BJ20060627
   Ireland DC, 2010, J NAT PROD, V73, P1610, DOI 10.1021/np1000413
   Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898
   Kimura RH, 2006, ANGEW CHEM INT EDIT, V45, P973, DOI 10.1002/anie.200503882
   Kolmar H, 2009, CURR OPIN PHARMACOL, V9, P608, DOI 10.1016/j.coph.2009.05.004
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891
   MARTINEZBUENO M, 1994, J BACTERIOL, V176, P6334, DOI 10.1128/jb.176.20.6334-6339.1994                                                
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2
   Mylne JS, 2011, NAT CHEM BIOL, V7, P257, DOI 10.1038/nchembio.542
   Nguyen Giang Kien Truc, 2011, J Biol Chem, V286, P24275, DOI 10.1074/jbc.M111.229922
   Plan MRR, 2007, CHEMBIOCHEM, V8, P1001, DOI 10.1002/cbic.200700097
   Poth AG, 2011, P NATL ACAD SCI USA, V108, P10127, DOI 10.1073/pnas.1103660108
   Poth AG, 2011, ACS CHEM BIOL, V6, P345, DOI 10.1021/cb100388j
   Pratt JP, 2005, IN VITRO CELL DEV-AN, V41, P349, DOI 10.1290/0505034.1
   Rosengren KJ, 2003, J AM CHEM SOC, V125, P12464, DOI 10.1021/JA0367703
   Saska I, 2007, J BIOL CHEM, V282, P29721, DOI 10.1074/jbc.M705185200
   SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904                                                         
   Seydel P, 2007, APPL MICROBIOL BIOT, V77, P275, DOI 10.1007/s00253-007-1159-6
   Simonsen SM, 2005, PLANT CELL, V17, P3176, DOI 10.1105/tpc.105.034678
   Svangard E, 2004, J NAT PROD, V67, P144, DOI 10.1021/np030101l
   Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498
   Trabi M, 2004, J NAT PROD, V67, P806, DOI 10.1021/np034068e
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Wang CKL, 2008, NUCLEIC ACIDS RES, V36, pD206, DOI 10.1093/nar/gkm953
   Wang CKL, 2008, J NAT PROD, V71, P47, DOI 10.1021/np070393g
   Werle M, 2007, INT J PHARMACEUT, V332, P72, DOI 10.1016/j.ijpharm.2006.09.028
NR 61
TC 37
Z9 37
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
J9 J NAT PROD
JI J. Nat. Prod.
PD FEB
PY 2012
VL 75
IS 2
BP 167
EP 174
DI 10.1021/np200722w
PG 8
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA 896WG
UT WOS:000300601500009
PM 22272797
OA green_accepted
DA 2018-01-05
ER

PT J
AU Tian, XH
   Wei, F
   Wang, TX
   Wang, D
   Wang, J
   Lin, XN
   Wang, P
   Ren, L
AF Tian, Xin-hua
   Wei, Feng
   Wang, Tian-xiao
   Wang, Dong
   Wang, Jun
   Lin, Xiao-ning
   Wang, Peng
   Ren, Lei
TI Blood-brain barrier transport of Tat peptide and polyethylene glycol
   decorated gelatin-siloxane nanoparticle
SO MATERIALS LETTERS
LA English
DT Article
DE Biomaterials; Nanoparticles; Blood-brain barrier; Targeted delivery; In
   vivo assay
ID DRUG CARRIER; DELIVERY; CANCER; CNS
AB Contemporary treatment of brain diseases has been hampered by limited drug delivery across the blood-brain barrier (BBB). Herein, gelatin-siloxane nanoparticles (GSNPs) with controlled size and surface charge were synthesized through a two-step sol-gel process. In order to increase the efficiency of brain targeting, HIV-derived Tat peptide and PEG were further grafted onto GS NPs (Tat-PEG-GS NPs). In vivo imaging and TEM results indicated Tat-PEG-GS NPs could not only escape the capture by reticulo-endothelial system but also cross BBB and reach central nervous system of mice. Hence, Tat-PEG-GS NPs might represent a new type of non-viral vector for the delivery of drug or therapeutic DNA to brain by crossing BBB. (c) 2011 Elsevier B.V. All rights reserved.
C1 [Wang, Tian-xiao; Wang, Dong; Wang, Jun; Ren, Lei] Xiamen Univ, Dept Biomat, Coll Mat, Xiamen 361005, Peoples R China.
   [Tian, Xin-hua; Wei, Feng; Lin, Xiao-ning; Wang, Peng] Xiamen Univ, Dept Neurosurg, Affiliated Zhongshan Hosp, Xiamen 361004, Peoples R China.
   [Ren, Lei] Xiamen Univ, State Key Lab Phys Chem Solid Surfaces, Xiamen 361005, Peoples R China.
RP Ren, L (reprint author), Xiamen Univ, Dept Biomat, Coll Mat, Xiamen 361005, Peoples R China.
EM renlei@xmu.edu.cn
RI SKL, PCOSS/D-4395-2013; ren, lei/G-3459-2010; Wang, Dong/B-2285-2010
OI ren, lei/0000-0003-2131-1601; Wang, Dong/0000-0002-8209-210X
FU National Natural Science Foundation of China [30970733, 81171448,
   81172394]; National Basic Research Program of China [2010CB732402]
FX This work was financially supported by the National Natural Science
   Foundation of China (30970733, 81171448, 81172394), and the National
   Basic Research Program of China (2010CB732402).
CR Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028
   Herve F, 2008, AAPS J, V10, P455, DOI 10.1208/s12248-008-9055-2
   Huang RQ, 2010, BRAIN RES BULL, V81, P600, DOI 10.1016/j.brainresbull.2009.12.008
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Lu W, 2005, J CONTROL RELEASE, V107, P428, DOI 10.1016/j.jconrel.2005.03.027
   Pardridge WM, 2001, DRUG DISCOV TODAY, V6, P1, DOI 10.1016/S1359-6446(00)01583-X                                                   
   Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Wang ZY, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/44/445103
   Wei B, 2009, BIOMED PHARMACOTHER, V63, P313, DOI 10.1016/j.biopha.2008.07.086
   Yin P, 2010, MAT SCI ENG C-MATER, V30, P1260, DOI 10.1016/j.msec.2010.07.006
   Yuan W, 2010, MICROVASC RES, V80, P148, DOI 10.1016/j.mvr.2010.03.011
NR 15
TC 18
Z9 19
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-577X
J9 MATER LETT
JI Mater. Lett.
PD FEB 1
PY 2012
VL 68
BP 94
EP 96
DI 10.1016/j.matlet.2011.10.042
PG 3
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 895FC
UT WOS:000300480600027
DA 2018-01-05
ER

PT J
AU Avilov, SV
   Boudier, C
   Gottikh, M
   Darlix, JL
   Mely, Y
AF Avilov, Sergiy V.
   Boudier, Christian
   Gottikh, Marina
   Darlix, Jean-Luc
   Mely, Yves
TI Characterization of the Inhibition Mechanism of HIV-1 Nucleocapsid
   Protein Chaperone Activities by Methylated Oligoribonucleotides
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PLUS-STRAND TRANSFER; STRONG-STOP DNA;
   REVERSE TRANSCRIPTION; SECONDARY STRUCTURE; VIRAL-DNA; CTAR DNA;
   COMPLEMENTARY SEQUENCES; DESTABILIZING ACTIVITY; SHORT OLIGONUCLEOTIDES
AB Since currently available therapies against HIV/AIDS still show important drawbacks, the development of novel anti-HIV treatments is a key issue. We recently characterized methylated oligoribonucleotides (mONs) that extensively inhibit HIV-1 replication in primary T cells at nanomolar concentrations. The mONs were shown to target both HIV-1 reverse transcriptase (RT) and the nucleocapsid protein (NC), which is an essential partner of RT during viral DNA synthesis. To further understand the mechanism of such mONs, we studied by isothermal titration calorimetry and fluorescence-based techniques their NC binding properties and ability to inhibit the nucleic acid chaperone properties of NC. Notably, we investigated the ability of mONs to inhibit the NC-induced destabilization of the HIV-1 cTAR (complementary DNA sequence to TAR [transactivation response element]) stem-loop and the NC-promoted cTAR annealing to its complementary sequence, required at the early stage of HIV-1 viral DNA synthesis. Moreover, we compared the activity of the mONs to that of a number of modified and nonmodified oligonucleotides. Results show that the mONs inhibit NC by a competitive mechanism whereby the mONs tightly bind the NC peptide, mainly through nonelectrostatic interactions with the hydrophobic platform at the top of the NC zinc fingers. Taken together, these results favor the notion that the mONs impair the process of the RT-directed viral DNA synthesis by sequestering NC molecules, thus preventing the chaperoning of viral DNA synthesis by NC. These findings contribute to the understanding of the molecular basis for NC inhibition by mONs, which could be used for the rational design of antiretroviral compounds targeting HIV-1 NC protein.
C1 [Avilov, Sergiy V.; Boudier, Christian; Darlix, Jean-Luc; Mely, Yves] Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France.
   [Gottikh, Marina] Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia.
RP Mely, Y (reprint author), Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France.
EM yves.mely@unistra.fr
RI Avilov, Sergiy/A-2904-2012; Gottikh, Marina/D-7575-2012
FU European TRIOH Consortium; Agence Nationale de Recherches sur le SIDA
   (ANRS); Russian Foundation for Basic Research
FX The study was supported by the European TRIOH Consortium, the Agence
   Nationale de Recherches sur le SIDA (ANRS), and the Russian Foundation
   for Basic Research. S.V.A. was a fellow from the Fondation pour la
   Recherche Medicate, France (ACE20051206242).
CR Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Avilov SV, 2008, NUCLEIC ACIDS RES, V36, P885, DOI 10.1093/nar/gkm1109
   Avilov SV, 2009, BIOCHEMISTRY-US, V48, P2422, DOI 10.1021/bi8022366
   Beltz H, 2005, J MOL BIOL, V348, P1113, DOI 10.1016/j.jmb.2005.02.042
   Beltz H, 2004, J MOL BIOL, V338, P711, DOI 10.1016/j.jmb.2004.03.019
   Beltz H, 2003, J MOL BIOL, V328, P95, DOI 10.1016/S0022-2836(03)00244-4
   Bernacchi S, 2003, BIOPHYS J, V84, P643, DOI 10.1016/S0006-3495(03)74884-X                                                   
   Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2001.5429
   Bombarda E, 1999, BIOPHYS J, V76, P1561, DOI 10.1016/S0006-3495(99)77315-7                                                   
   Bourbigot S, 2008, J MOL BIOL, V383, P1112, DOI 10.1016/j.jmb.2008.08.046
   Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003
   CLEVER J, 1995, J VIROL, V69, P2101
   Darlix JL, 2011, J MOL BIOL, V410, P565, DOI 10.1016/j.jmb.2011.03.037
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   de Rocquigny H, 2008, MINI-REV MED CHEM, V8, P24
   DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0
   DORFMAN T, 1993, J VIROL, V67, P6159
   Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000                                                
   Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283                                                        
   Egele C, 2004, J MOL BIOL, V342, P453, DOI 10.1016/j.jmb.2004.07.059
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Fisher RJ, 1998, J VIROL, V72, P1902
   Godet J, 2006, J MOL BIOL, V356, P1180, DOI 10.1016/j.jmb.2005.12.038
   Godet J, 2011, NUCLEIC ACIDS RES, V39, P6633, DOI 10.1093/nar/gkr274
   Godet J, 2010, RNA BIOL, V7, P687, DOI 10.4161/rna.7.6.13616
   Goldschmidt Valerie, 2010, HIV Therapy, V4, P179, DOI 10.2217/HIV.10.3
   Golinelli MP, 2003, BIOCHEMISTRY-US, V42, P8153, DOI 10.1021/bi027039
   Grigorov B, 2011, NUCLEIC ACIDS RES, V39, P5586, DOI 10.1093/nar/gkr117
   Grohmann D, 2008, BIOCHEMISTRY-US, V47, P12230, DOI 10.1021/bi801386r
   Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000                                                
   Guo JH, 1997, J VIROL, V71, P5178
   Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200
   Korolev S, 2011, NUCLEOS NUCLEOT NUCL, V30, P651, DOI 10.1080/15257770.2011.592890
   Lakowitz J. R., 1999, PRINCIPLES FLUORESCE
   LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978
   Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6
   Mihailescu MR, 2004, P NATL ACAD SCI USA, V101, P1189, DOI 10.1073/pnas.0307966100
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X                                                   
   SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294
   Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3<301::AID-BIP5>3.3.CO;2-#
   Tisne C, 2004, J BIOL CHEM, V279, P3588, DOI 10.1074/jbc.M310368200
   Vo MN, 2009, J MOL BIOL, V386, P789, DOI 10.1016/j.jmb.2008.12.070
   Vuilleumier C, 1997, ANAL BIOCHEM, V244, P183, DOI 10.1006/abio.1996.9870
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
   Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 46
TC 6
Z9 6
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2012
VL 56
IS 2
BP 1010
EP 1018
DI 10.1128/AAC.05614-11
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 883TX
UT WOS:000299658900056
PM 22083480
OA gold
DA 2018-01-05
ER

PT J
AU Rathinakumar, R
   Dutta, M
   Zhu, P
   Johnson, WE
   Roux, KH
AF Rathinakumar, Ramesh
   Dutta, Moumita
   Zhu, Ping
   Johnson, Welkin E.
   Roux, Kenneth H.
TI Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to
   CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and
   Simian Immunodeficiency Virus Virions
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID BROADLY NEUTRALIZING ANTIBODIES; EXTERNAL REGION; HIV-1 GP41;
   NONNEUTRALIZING ANTIBODIES; EPITOPE RECOGNITION; CAPTURE ASSAY;
   ANTI-GP41 2F5; IN-VIVO; 4E10; ENVELOPE
AB The broadly neutralizing monoclonal antibodies (MAbs) 4E10, 2F5, and Z13e1 target membrane-proximal external region (MPER) epitopes of HIV-1 gp41 in a manner that remains controversial. The requirements for initial lipid bilayer binding and/or CD4 ligation have been proposed. To further investigate these issues, we probed for binding of these MAbs to human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) virions with protein A-conjugated gold (PAG) nanoparticles using negative-stain electron microscopy. We found moderate levels of PAG associated with unliganded HIV-1 and SIV virions incubated with the three MAbs. Significantly higher levels of PAG were associated with CD4-liganded HIV-1 (epitope-positive) but not SIV (epitope-negative) virions. A chimeric SIV virion displaying the HIV-1 4E10 epitope also showed significantly higher PAG association after CD4 ligation and incubation with 4E10. MAbs accumulated rapidly on CD4-liganded virions and slowly on unliganded virions, although both reached similar levels in time. Anti-MPER epitope-specific binding was stable to washout. Virions incubated with an irrelevant MAb or CD4-only (no MAb) showed negligible PAG association, as did a vesicle-rich fraction devoid of virions. Preincubation with Fab 4E10 inhibited both specific and nonspecific 4E10 IgG binding. Our data provide evidence for moderate association of anti-MPER MAbs to viral surfaces but not lipid vesicles, even in the absence of cognate epitopes. Significantly greater MAb interaction occurs in epitope-positive virions following long incubation or CD4 ligation. These findings are consistent with a two-stage binding model where these anti-MPER MAbs bind first to the viral lipid bilayer and then to the MPER epitopes following spontaneous or induced exposure.
C1 [Rathinakumar, Ramesh; Dutta, Moumita; Zhu, Ping; Roux, Kenneth H.] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA.
   [Rathinakumar, Ramesh; Dutta, Moumita; Zhu, Ping; Roux, Kenneth H.] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.
   [Johnson, Welkin E.] Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA.
RP Roux, KH (reprint author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.
EM roux@bio.fsu.edu
FU National Institutes of Health [AI055461, AI057039]
FX This study was supported by grants from the National Institutes of
   Health (AI055461 [K.H.R.] and AI057039 [W.E.J.]).
CR Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Alfsen A, 2002, J BIOL CHEM, V277, P25649, DOI 10.1074/jbc.M200554200
   Alving CR, 2008, AIDS, V22, P649, DOI 10.1097/QAD.0b013e3282f51922
   Apellaniz B, 2009, BIOCHEMISTRY-US, V48, P5320, DOI 10.1021/bi900504t
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08
   Binley JM, 2003, J VIROL, V77, P5678, DOI 10.1128/JVI.77.10.5678-5684.2003
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Brown BK, 2007, J VIROL, V81, P2087, DOI 10.1128/JVI.02011-06
   Bryson S, 2009, J VIROL, V83, P11862, DOI 10.1128/JVI.01604-09
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Chakrabarti BK, 2011, AIDS RES HUM RETROV, V27, P878
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   Crooks ET, 2011, J VIROL, V85, P5825, DOI 10.1128/JVI.00154-11
   Crooks Emma T., 2005, Human Antibodies, V14, P101
   de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004
   Dennison SM, 2009, J VIROL, V83, P10211, DOI 10.1128/JVI.00571-09
   Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002
   Franquelim HG, 2011, AIDS, V25, P419, DOI 10.1097/QAD.0b013e328342ff11
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Gorny MK, 2005, J VIROL, V79, P5232, DOI 10.1128/JVI.79.8.5232-5237.2005
   Gray ES, 2007, J VIROL, V81, P6187, DOI 10.1128/JVI.00239-07
   Gray ES, 2009, J VIROL, V83, P11265, DOI 10.1128/JVI.01359-09
   Gray ES, 2009, J VIROL, V83, P8925, DOI 10.1128/JVI.00758-09
   Gray ES, 2006, PLOS MED, V3, P1023, DOI 10.1371/journal.pmed.0030255
   Grundner C, 2002, J VIROL, V76, P3511, DOI 10.1128/JVI.76.7.3511-3521.2002
   Gustchina E, 2008, J VIROL, V82, P10032, DOI 10.1128/JVI.01050-08
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Hessell AJ, 2010, J VIROL, V84, P1302, DOI 10.1128/JVI.01272-09
   Honnen WJ, 2007, J VIROL, V81, P1424, DOI 10.1128/JVI.02054-06
   Huarte N, 2008, J VIROL, V82, P8986, DOI 10.1128/JVI.00846-08
   Ingale S, 2010, J PEPT SCI, V16, P716, DOI 10.1002/psc.1325
   Julien JP, 2010, J VIROL, V84, P4136, DOI 10.1128/JVI.02357-09
   Julien JP, 2008, J MOL BIOL, V384, P377, DOI 10.1016/j.jmb.2008.09.024
   Kang Y, 2009, VACCINE, V27, P5120, DOI 10.1016/j.vaccine.2009.06.037
   Klein JS, 2009, P NATL ACAD SCI USA, V106, P7385, DOI 10.1073/pnas.0811427106
   Leaman DP, 2010, J VIROL, V84, P3382, DOI 10.1128/JVI.02363-09
   Lenz O, 2005, J BIOL CHEM, V280, P4095, DOI 10.1074/jbc.M411088200
   Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   Manrique A, 2007, J VIROL, V81, P8793, DOI 10.1128/JVI.00598-07
   Matyas GR, 2009, AIDS, V23, P2069, DOI 10.1097/QAD.0b013e32832faea5
   Matyas GR, 2009, BBA-BIOMEMBRANES, V1788, P660, DOI 10.1016/j.bbamem.2008.11.015
   Mehandru S, 2004, J VIROL, V78, P14039, DOI 10.1128/JVI.78.24.10039-14042.2004
   Montero M, 2008, MICROBIOL MOL BIOL R, V72, P54, DOI 10.1128/MMBR.00020-07
   MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   MUSTER T, 1993, J VIROL, V67, P6642
   Nelson JD, 2008, VIROLOGY, V377, P170, DOI 10.1016/j.virol.2008.04.005
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   Nyambi PN, 2000, J VIROL, V74, P10670, DOI 10.1128/JVI.74.22.10670-10680.2000
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Peachman KK, 2010, VIRAL IMMUNOL, V23, P627, DOI 10.1089/vim.2010.0061
   Peachman KK, 2010, VIROLOGY, V408, P213, DOI 10.1016/j.virol.2010.09.029
   Pejchal R, 2009, J VIROL, V83, P8451, DOI 10.1128/JVI.00685-09
   Poignard P, 1996, J EXP MED, V183, P473, DOI 10.1084/jem.183.2.473
   Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003
   Roux KH, 2007, CURR OPIN STRUC BIOL, V17, P244, DOI 10.1016/j.sbi.2007.03.008
   Ruprecht CR, 2011, J EXP MED, V208, P439, DOI 10.1084/jem.20101907
   Sanchez-Martinez S, 2006, FEBS LETT, V580, P2395, DOI 10.1016/j.febslet.2006.03.067
   Sanchez-Martinez S, 2006, AIDS RES HUM RETROV, V22, P998, DOI 10.1089/aid.2006.22.998
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08
   Scherer EM, 2007, AIDS, V21, P2131, DOI 10.1097/QAD.0b013e3282a4a632                                                    
   Scherer EM, 2010, P NATL ACAD SCI USA, V107, P1529, DOI 10.1073/pnas.0909680107
   Shen XY, 2010, P NATL ACAD SCI USA, V107, P5972, DOI 10.1073/pnas.0912381107
   Shen XY, 2009, J VIROL, V83, P3617, DOI 10.1128/JVI.02631-08
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08
   Vcelar B, 2007, AIDS, V21, P2161, DOI 10.1097/QAD.0b013e328285da15                                                    
   Veiga AS, 2009, CHEMBIOCHEM, V10, P1032, DOI 10.1002/cbic.200800609
   Veiga AS, 2006, ANTIVIR RES, V71, P69, DOI 10.1016/j.antiviral.2006.02.002
   Vincent N, 2002, BBA-BIOMEMBRANES, V1567, P157, DOI 10.1016/S0005-2736(02)00611-9
   Vishwanathan SA, 2008, J VIROL, V82, P5118, DOI 10.1128/JVI.00305-08
   Yuste E, 2006, J VIROL, V80, P3030, DOI 10.1128/JVI.80.3030-3041.2006
   Zhang G, 2005, IMMUNOBIOLOGY, V210, P639, DOI 10.1016/j.imbio.2005.05.025
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.26334931100
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zwick MB, 2004, J VIROL, V78, P3155, DOI 10.1128/JVI.78.6.3155-3161.2004
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 86
TC 10
Z9 10
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2012
VL 86
IS 3
BP 1820
EP 1831
DI 10.1128/JVI.05489-11
PG 12
WC Virology
SC Virology
GA 879CT
UT WOS:000299308000048
PM 22090143
OA gold
DA 2018-01-05
ER

PT J
AU Liu, L
   Gronenborn, AM
   Bahar, I
AF Liu, Lin
   Gronenborn, Angela M.
   Bahar, Ivet
TI Longer simulations sample larger subspaces of conformations while
   maintaining robust mechanisms of motion
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE structure-encoded dynamics; molecular dynamics simulations; power law;
   global motions; equilibrium fluctuations of cyanovirin-N
ID MOLECULAR-DYNAMICS SIMULATIONS; ELASTIC NETWORK MODELS; X-RAY
   CRYSTALLOGRAPHY; ANTI-HIV ACTIVITY; CYANOVIRIN-N; PROTEIN DYNAMICS;
   RESIDUAL DIPOLAR; EQUILIBRIUM DYNAMICS; NMR-SPECTROSCOPY;
   SINGLE-PARAMETER
AB Recent studies suggest that protein motions observed in molecular simulations are related to biochemical activities, although the computed time scales do not necessarily match those of the experimentally observed processes. The molecular origin of this conflicting observation is explored here for a test protein, cyanovirin-N (CV-N), through a series of molecular dynamics simulations that span a time range of three orders of magnitude up to 0.4 mu s. Strikingly, increasing the simulation time leads to an approximately uniform amplification of the motional sizes, while maintaining the same conformational mechanics. Residue fluctuations exhibit amplitudes of 12 angstrom in the nanosecond simulations, whereas their average sizes increase by a factor of 45 in the microsecond regime. The mean-square displacements averaged over all residues (y) exhibit a power law dependence of the form y proportional to x0.26 on the simulation time (x). Essential dynamics analysis of the trajectories, on the other hand, demonstrates that CV-N has robust preferences to undergo specific types of motions that already can be detected at short simulation times, provided that multiple runs are performed and carefully analyzed. Proteins 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Liu, Lin; Bahar, Ivet] Univ Pittsburgh, Dept Computat & Syst Biol, Sch Med, Pittsburgh, PA 15213 USA.
   [Liu, Lin; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15213 USA.
RP Bahar, I (reprint author), Univ Pittsburgh, Dept Computat & Syst Biol, Sch Med, Suite 3064,Biomed Sci Tower 3,3501 5th Ave, Pittsburgh, PA 15213 USA.
EM bahar@pitt.edu
OI Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health [5R01LM007994, GM080642]
FX Grant sponsor: National Institutes of Health; Grant numbers:
   5R01LM007994, GM080642.
CR Abseher R, 1998, PROTEINS, V31, P370
   Akke M, 1996, J AM CHEM SOC, V118, P911, DOI 10.1021/ja953503r                                                               
   Amadei A, 1999, PROTEINS, V36, P419, DOI 10.1002/(SICI)1097-0134(19990901)36:4<419::AID-PROT5>3.0.CO;2-U
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X                                                   
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   Bahar I, 2010, ANNU REV BIOPHYS, V39, P23, DOI 10.1146/annurev.biophys.093008.131258
   Bakan A, 2009, P NATL ACAD SCI USA, V106, P14349, DOI 10.1073/pnas.0904214106
   Balsera MA, 1996, J PHYS CHEM-US, V100, P2567, DOI 10.1021/jp9536920                                                               
   Barrientos LG, 2006, PROTEIN ENG DES SEL, V19, P525, DOI 10.1093/protein/gzl040
   Barrientos LG, 2004, STRUCTURE, V12, P1799, DOI 10.1016/j.str.2004.07.019
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bouvignies G, 2005, P NATL ACAD SCI USA, V102, P13885, DOI 10.1073/pnas.0505129102
   Briggman KB, 2003, J AM CHEM SOC, V125, P10164, DOI 10.1021/ja035904+
   Bui JM, 2009, BIOPHYS J, V97, P2513, DOI 10.1016/j.bpj.2009.07.061
   Cavanagh J, 2001, NAT STRUCT BIOL, V8, P912, DOI 10.1038/nsb1101-912                                                             
   Caves LSD, 1998, PROTEIN SCI, V7, P649, DOI 10.1002/pro.5560070314                                                          
   CLARAGE JB, 1995, P NATL ACAD SCI USA, V92, P3288, DOI 10.1073/pnas.92.8.3288
   Cote Y, 2010, P NATL ACAD SCI USA, V107, P19844, DOI 10.1073/pnas.1013674107
   Cui Q., 2006, NORMAL MODE ANAL THE
   deSouza ON, 1997, BIOPHYS J, V72, P2395, DOI 10.1016/S0006-3495(97)78884-2                                                   
   Eyal E, 2007, BIOINFORMATICS, V23, pI175, DOI 10.1093/bioinformatics/btm186
   Falke JJ, 2002, SCIENCE, V295, P1480, DOI 10.1126/science.1069823                                                         
   Fersht AR, 2002, P NATL ACAD SCI USA, V99, P14122, DOI 10.1073/pnas.182542699                                                          
   Haliloglu T, 1997, PHYS REV LETT, V79, P3090, DOI 10.1103/PhysRevLett.79.3090
   Hall JB, 2006, J AM CHEM SOC, V128, P7855, DOI 10.1021/ja060406x
   Henzler-Wildman K, 2007, NATURE, V450, P964, DOI 10.1038/nature06522
   Henzler-Wildman KA, 2007, NATURE, V450, P838, DOI 10.1038/nature06410
   Hinsen K, 1998, PROTEINS, V33, P417, DOI 10.1002/(SICI)1097-0134(19981115)33:3<417::AID-PROT10>3.0.CO;2-8
   Huang XH, 2009, P NATL ACAD SCI USA, V106, P19765, DOI 10.1073/pnas.0909088106
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Kitao A, 1999, CURR OPIN STRUC BIOL, V9, P164, DOI 10.1016/S0959-440X(99)80023-2                                                   
   Kolano C, 2006, NATURE, V444, P469, DOI 10.1038/nature05352
   Lakomek NA, 2008, J BIOMOL NMR, V41, P139, DOI 10.1007/s10858-008-9244-4
   Lange OF, 2008, SCIENCE, V320, P1471, DOI 10.1126/science.1157092
   Li DW, 2010, J PHYS CHEM B, V114, P16036, DOI [10.1021/jp109908u, 10.1021/jp.109908u]
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   Liu L, 2009, PROTEINS, V77, P927, DOI 10.1002/prot.22518
   Luo GB, 2006, J PHYS CHEM B, V110, P9363, DOI 10.1021/jp057497p
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   Markwick PRL, 2009, J AM CHEM SOC, V131, P16968, DOI 10.1021/ja907476w
   Matei E, 2008, STRUCTURE, V16, P1183, DOI 10.1016/j.str.2008.05.011
   Matei E, 2010, J BIOL CHEM, V285, P13057, DOI 10.1074/jbc.M109.094938
   May A, 2008, J MED CHEM, V51, P3499, DOI 10.1021/jm800071v
   Michalet X, 2006, CHEM REV, V106, P1785, DOI 10.1021/cr0404343
   Morcos F, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001015
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Romo TD, 2011, PROTEINS, V79, P23, DOI 10.1002/prot.22855
   Roy J, 2010, BIOPHYS J, V99, P218, DOI 10.1016/j.bpj.2010.03.055
   Sandstrom C, 2008, BIOCHEMISTRY-US, V47, P3625, DOI 10.1021/bi702200m
   Schotte F, 2004, J STRUCT BIOL, V147, P235, DOI 10.1016/j.jsb.2004.06.009
   Senet P, 2008, P NATL ACAD SCI USA, V105, P19708, DOI 10.1073/pnas.0810679105
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Smith LJ, 2002, PROTEINS, V48, P487, DOI 10.1002/prot.10144
   Smock RG, 2009, SCIENCE, V324, P198, DOI 10.1126/science.1169377
   Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726
   Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905                                                     
   Trbovic N, 2008, PROTEINS, V71, P684, DOI 10.1002/prot.21750
   Wong IY, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.178101
   Yang LW, 2007, STRUCTURE, V15, P741, DOI 10.1016/j.str.2007.04.014
NR 61
TC 6
Z9 6
U1 0
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD FEB
PY 2012
VL 80
IS 2
BP 616
EP 625
DI 10.1002/prot.23225
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 874KJ
UT WOS:000298955600024
PM 22105881
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bhatt, RK
   Sharma, S
   Nath, M
AF Bhatt, Ranjan K.
   Sharma, Satyasheel
   Nath, Mahendra
TI La(OTf)(3)-catalyzed one-pot synthesis of meso-substituted porphyrinic
   thiazolidinones
SO MONATSHEFTE FUR CHEMIE
LA English
DT Article
DE Porphyrins; Photosensitizer; Photodynamic therapy; Regioselective
   nitration
ID SILYL ENOL ETHERS; ANTI-HIV AGENTS; PHOTODYNAMIC THERAPY; BERGMAN
   CYCLIZATION; ORGANIC-SYNTHESIS; ALDOL REACTION; DERIVATIVES; DESIGN;
   CHEMISTRY; ACID
AB An improved synthetic procedure is developed for the regioselective nitration of a phenyl group of meso-tetraphenylporphyrin by using NaNO2 in a mixture of trichloroacetic acid and AcOH. The meso-(4-nitrophenyl)porphyrins are successfully reduced to corresponding meso-(4-aminophenyl)porphyrins by SnCl2 under acidic conditions. In addition, an efficient one-pot methodology for synthesizing a series of novel meso-substituted porphyrinic thiazolidinone conjugates is developed by reacting meso-(4-aminophenyl)porphyrins with various aromatic aldehydes and mercaptoacetic acid in refluxing toluene using La(OTf)(3) as a catalyst. The products obtained are characterized on the basis of their spectral data. Preliminary photophysical properties of the newly synthesized compounds are reported.
C1 [Bhatt, Ranjan K.; Sharma, Satyasheel; Nath, Mahendra] Univ Delhi, Dept Chem, Delhi 110007, India.
RP Nath, M (reprint author), Univ Delhi, Dept Chem, Delhi 110007, India.
EM mnath@chemistry.du.ac.in
RI sharma, satyasheel/J-6546-2012
OI sharma, satyasheel/0000-0002-4983-1572
FU University of Delhi, India; Council of Scientific and Industrial
   Research, New Delhi, India
FX We thank the University of Delhi, India, for providing financial
   support. Satyasheel is grateful to Council of Scientific and Industrial
   Research, New Delhi, India, for the Junior Research Fellowship.
CR Aihara H, 2001, ANGEW CHEM INT EDIT, V40, P3439, DOI 10.1002/1521-3773(20010917)40:18<3439::AID-ANIE3439>3.0.CO;2-Z                  
   Barreca ML, 2002, J MED CHEM, V45, P5410, DOI 10.1021/jm020977+
   BETTELHEIM A, 1987, INORG CHEM, V26, P1009, DOI 10.1021/ic00254a011                                                             
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Cunico W, 2008, MINI-REV ORG CHEM, V5, P336, DOI 10.2174/157019308786242232                                                      
   Drain CM, 2009, CHEM REV, V109, P1630, DOI 10.1021/cr8002483
   Fox S, 2006, TETRAHEDRON, V62, P10039, DOI 10.1016/j.tet.2006.08.021
   Guo CC, 2004, BIOORGAN MED CHEM, V12, P2469, DOI 10.1016/j.bmc.2004.01.045
   Haeubl M, 2010, EUR J MED CHEM, V45, P760, DOI 10.1016/j.ejmech.2009.11.025
   Harriman A, 1996, CHEM SOC REV, V25, P41, DOI 10.1039/cs9962500041
   Hoffmann M, 2008, ANGEW CHEM INT EDIT, V47, P4993, DOI 10.1002/anie.200801188
   Hombrecher HK, 1996, BIOORG MED CHEM LETT, V6, P1199, DOI 10.1016/0960-894X(96)00201-6
   KELAREV VI, 2003, CHEM HETEROCYCL COMP, V39, P213
   KOBAYASHI S, 1994, SYNLETT, P689
   Kobayashi S, 2002, CHEM REV, V102, P2227, DOI 10.1021/cr010289i
   KOBAYASHI S, 1991, J AM CHEM SOC, V113, P4247, DOI 10.1021/ja00011a030                                                             
   KOBAYASHI S, 1995, SYNTHESIS-STUTTGART, P1195
   KOBAYASHI S, 1994, J ORG CHEM, V59, P3590, DOI 10.1021/jo00092a017                                                             
   Kobayashi S, 1988, CHEM LETT, P91
   KRUPER WJ, 1989, J ORG CHEM, V54, P2753, DOI 10.1021/jo00272a057
   Li Y, 2006, J ORG CHEM, V71, P8279, DOI 10.1021/jo061161+
   Luguya R, 2004, TETRAHEDRON, V60, P2757, DOI 10.1016/j.tet.2004.01.080
   MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328                                                                 
   MENG GZG, 1994, CAN J CHEM, V72, P1894, DOI 10.1139/v94-241                                                                 
   Nagarajan AS, 2009, INDIAN J CHEM B, V48, P1577
   Nakano A, 1998, ANGEW CHEM INT EDIT, V37, P3023, DOI 10.1002/(SICI)1521-3773(19981116)37:21<3023::AID-ANIE3023>3.0.CO;2-A
   Nath M, 2005, J AM CHEM SOC, V127, P478, DOI 10.1021/ja045979t
   Nath M, 2003, J AM CHEM SOC, V125, P11484, DOI 10.1021/ja0302782
   Nath M, 2003, CHEM COMMUN, P858, DOI 10.1039/b212923j
   Purrello R, 1999, COORDIN CHEM REV, V190, P683, DOI 10.1016/S0010-8545(99)00106-X                                                   
   Rawal RK, 2008, EUR J MED CHEM, V43, P2800, DOI 10.1016/j.ejmech.2007.12.015
   Shundo A, 2009, CHEM-EUR J, V15, P2486, DOI 10.1002/chem.200802469
   SINGH SP, 1981, CHEM REV, V81, P175, DOI 10.1021/cr00042a003                                                             
   Sol V, 1999, J ORG CHEM, V64, P4431, DOI 10.1021/jo982499+                                                               
   Weimin Shi, 2008, Bioorg Med Chem, V16, P5665, DOI 10.1016/j.bmc.2008.03.063
   Zakavi S, 2009, CATAL COMMUN, V10, P388, DOI 10.1016/j.catcom.2008.10.001
   Zheng JY, 1997, TETRAHEDRON, V53, P9115, DOI 10.1016/S0040-4020(97)00611-X
   Zhou HY, 2008, J MED CHEM, V51, P1242, DOI 10.1021/jm7012024
NR 38
TC 7
Z9 7
U1 0
U2 8
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-9247
J9 MONATSH CHEM
JI Mon. Chem.
PD FEB
PY 2012
VL 143
IS 2
BP 309
EP 316
DI 10.1007/s00706-011-0625-0
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 877KQ
UT WOS:000299179700020
DA 2018-01-05
ER

PT J
AU Hu, YW
   Wang, KK
   Zhang, QX
   Li, FH
   Wu, TS
   Niu, L
AF Hu, Yuwei
   Wang, Kaikai
   Zhang, Qixian
   Li, Fenghua
   Wu, Tongshun
   Niu, Li
TI Decorated graphene sheets for label-free DNA impedance biosensing
SO BIOMATERIALS
LA English
DT Article
DE Graphene; Perylene; DNA; Non-covalent; Impedance; Biosensing
ID CARBON-PASTE ELECTRODES; METHYLENE-BLUE; ELECTROCHEMICAL DETECTION;
   PERYLENE BISIMIDES; GRAPHITE OXIDE; HYBRIDIZATION; NANOSHEETS;
   NANOTUBES; PLATFORM; SENSITIVITY
AB An efficient DNA impedance biosensing platform is constructed, in which positively charged N,N-bis-(1-aminopropyl-3-propylimidazol salt)-3,4,9,10-perylene tetracarboxylic acid diimide (PDI) is anchored to graphene sheets. The pi-pi stacking and electronic interactions are elucidated by the distinct absorption features in UV-vis spectra and by quenching perylene fluorescence in contact with graphene. The rational design and tailoring of graphene surface invest it with desired properties (dispersive, structural, photoelectrical and conductive, etc.) and boost its application. Electrostatic interaction between PDI's positively charged imidazole rings and negatively charged phosphate backbones of single-stranded DNA (ssDNA) facilitates ssDNA immobilization. This manner is different from these mainly based on the attraction between the rings in DNA bases and the hexagonal cells of graphene, which is disturbed after hybridization and causes the leaving of formed double-stranded DNA from graphene surface. The electrostatic ssDNA grafting occupies phosphate backbones and particularly leaves the bases available for efficient hybridization. DNA immobilization and hybridization lead to PDI/graphene interfacial property changes, which are monitored by electrochemical impedance spectroscopy and adopted as the analytical signal. The conserved sequence of the pol gene of human immunodeficiency virus 1 is satisfactorily detected via this PDI/graphene platform and shows high reproducibility, selectivity. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Hu, Yuwei; Wang, Kaikai; Zhang, Qixian; Li, Fenghua; Wu, Tongshun; Niu, Li] Chinese Acad Sci, Changchun Inst Appl Chem, Engn Lab Modern Analyt Tech, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
   [Hu, Yuwei; Niu, Li] Jilin Univ, Coll Chem, Changchun 130012, Peoples R China.
RP Niu, L (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, Engn Lab Modern Analyt Tech, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
EM lniu@ciac.jl.cn
FU NSFC [21105096, 21175130]; Chinese Academy of Sciences [KGCX2-YW-231,
   YZ200906, YZ2010018]
FX The authors are most grateful to the NSFC (No. 21105096 and 21175130)
   and Chinese Academy of Sciences (No. KGCX2-YW-231, YZ200906 and
   YZ2010018) for their financial support.
CR Backes C, 2011, ADV MATER, V23, P2588, DOI 10.1002/adma.201100300
   Backes C, 2010, ADV MATER, V22, P788, DOI 10.1002/adma.200902525
   Backes C, 2009, J AM CHEM SOC, V131, P2172, DOI 10.1021/ja805660b
   Balakrishnan K, 2005, J AM CHEM SOC, V127, P10496, DOI 10.1021/ja052940v
   Balapanuru J, 2010, ANGEW CHEM INT EDIT, V49, P6549, DOI 10.1002/anie.201001004
   Batchelor-McAuley C, 2009, BIOSENS BIOELECTRON, V24, P3183, DOI 10.1016/j.bios.2009.01.045
   Bonanni A, 2011, ACS NANO, V5, P2356, DOI 10.1021/nn200091p
   Che YK, 2007, J AM CHEM SOC, V129, P7234, DOI 10.1021/ja071903w
   Chen CP, 2009, ANAL CHEM, V81, P36, DOI 10.1021/ac800986q
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Dubuisson E, 2011, ANAL CHEM, V83, P2452, DOI 10.1021/ac102431d
   Eda G, 2010, ADV MATER, V22, P505, DOI 10.1002/adma.200901996
   Ehli C, 2009, NAT CHEM, V1, P243, DOI [10.1038/NCHEM.214, 10.1038/nchem.214]
   Englert JM, 2009, ADV MATER, V21, P4265, DOI 10.1002/adma.200901578
   Erdem A, 2000, ANAL CHIM ACTA, V422, P139, DOI 10.1016/S0003-2670(00)01058-8                                                   
   Feng LY, 2011, BIOMATERIALS, V32, P2930, DOI 10.1016/j.biomaterials.2011.01.002
   Fujii S, 2010, J AM CHEM SOC, V132, P10034, DOI 10.1021/ja101265r
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Hu YW, 2010, CHEM-EUR J, V16, P1992, DOI 10.1002/chem.200901870
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Hu YW, 2011, BIOSENS BIOELECTRON, V26, P4355, DOI 10.1016/j.bios.2011.04.037
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017                                                             
   Jang H, 2010, ANGEW CHEM INT EDIT, V49, P5703, DOI 10.1002/anie.201001332
   Kara P, 2002, ELECTROANAL, V14, P1685, DOI 10.1002/elan.200290011
   Kerman K, 2002, ANAL CHIM ACTA, V462, P39, DOI 10.1016/S0003-2670(02)00308-2
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Kozhemyakina NV, 2010, ADV MATER, V22, P5483, DOI 10.1002/adma.201003206
   Li ADQ, 2003, CHEM-EUR J, V9, P4594, DOI 10.1002/chem.200305025
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li FH, 2010, LANGMUIR, V26, P12314, DOI 10.1021/la101534n
   Liu JY, 2005, ANAL CHEM, V77, P2756, DOI 10.1021/ac048088c
   Liu ZB, 2009, J PHYS CHEM B, V113, P9681, DOI 10.1021/jp9004357
   Loh KP, 2010, NAT CHEM, V2, P1015, DOI 10.1038/NCHEM.907
   Lu CH, 2010, CHEM-EUR J, V16, P4889, DOI 10.1002/chem.200903071
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   Meyer JC, 2007, NATURE, V446, P60, DOI 10.1038/nature05545
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Paenke O, 2008, ADV BIOCHEM ENG BIOT, V109, P195, DOI 10.1007/10_2007_081
   Pumera M, 2010, CHEM SOC REV, V39, P4146, DOI 10.1039/c002690p
   Song B, 2010, CHEMPHYSCHEM, V11, P585, DOI 10.1002/cphc.200900743
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Su Q, 2009, ADV MATER, V21, P3191, DOI 10.1002/adma.200803808
   Tang LAL, 2010, J AM CHEM SOC, V132, P10976, DOI 10.1021/ja104017y
   Wang S, 2008, ADV MATER, V20, P3440, DOI 10.1002/adma.200800279
   Wang S, 2010, ACS NANO, V4, P6180, DOI 10.1021/nn101800n
   Wang Y, 2010, J AM CHEM SOC, V132, P9274, DOI 10.1021/ja103169v
   White B, 2007, J PHYS CHEM C, V111, P13684, DOI 10.1021/jp070853e
   Yang HF, 2009, CHEM COMMUN, P3880, DOI 10.1039/b905085j
   Yang WR, 2002, ELECTROANAL, V14, P1299, DOI 10.1002/1521-4109(200210)14:18<1299::AID-ELAN1299>3.0.CO;2-Y
NR 49
TC 83
Z9 83
U1 2
U2 143
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2012
VL 33
IS 4
BP 1097
EP 1106
DI 10.1016/j.biomaterials.2011.10.045
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 864XI
UT WOS:000298273400011
PM 22061487
DA 2018-01-05
ER

PT J
AU Morgan, MJ
   Mukwembi, S
   Swart, HC
AF Morgan, M. J.
   Mukwembi, S.
   Swart, H. C.
TI A lower bound on the eccentric connectivity index of a graph
SO DISCRETE APPLIED MATHEMATICS
LA English
DT Article
DE Eccentricity; Eccentric connectivity index; Diameter
ID ANTI-HIV ACTIVITY; TOPOLOGICAL MODELS; PREDICTION; NANOTUBES
AB In pharmaceutical drug design, an important tool is the prediction of physicochemical, pharmacological and toxicological properties of compounds directly from their structure. In this regard, the Wiener index, first defined in 1947, has been widely researched, both for its chemical applications and mathematical properties. Many other indices have since been considered, and in 1997, Sharma, Goswami and Madan introduced the eccentric connectivity index, which has been identified to give a high degree of predictability. If G is a connected graph with vertex set V, then the eccentric connectivity index of G, xi(C) (G), is defined as Sigma(upsilon is an element of V) deg(upsilon)ec(upsilon), where deg(upsilon) is the degree of vertex upsilon and ec(upsilon) is its eccentricity. Several authors have determined extremal graphs, for various classes of graphs, for this index. We show that a known tight lower bound on the eccentric connectivity index for a tree T, in terms of order and diameter, is also valid for a general graph G, of given order and diameter. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Morgan, M. J.; Mukwembi, S.; Swart, H. C.] Univ KwaZulu Natal, Durban, South Africa.
RP Mukwembi, S (reprint author), Univ KwaZulu Natal, Durban, South Africa.
EM mukwembi@ukzn.ac.za
FU University of KwaZulu-Natal; National Research Foundation
FX The financial support by the University of KwaZulu-Natal is gratefully
   acknowledged. This material is based upon work financially supported by
   the National Research Foundation.
CR Ashrafi AR, 2011, MATCH-COMMUN MATH CO, V65, P221
   Ashrafi AR, 2011, J COMPUT APPL MATH, V235, P4561, DOI 10.1016/j.cam.2010.03.001
   Bajaj S, 2005, BIOORGAN MED CHEM, V13, P3263, DOI 10.1016/j.bmc.2005.02.033
   Basak SC, 2000, J CHEM INF COMP SCI, V40, P891, DOI 10.1021/ci990114y
   BASAK SC, 1995, TOXICOL LETT, V79, P239, DOI 10.1016/0378-4274(95)03375-U
   Doglic T., 2010, IRAN J MATH CHEM, V1, P45
   Dureja H, 2006, INT J PHARMACEUT, V323, P27, DOI 10.1016/j.ijpharm.2006.05.042
   Dureja H, 2008, J MOL GRAPH MODEL, V26, P1020, DOI 10.1016/j.jmgm.2007.08.008
   Grover Manish, 2000, Pharmaceutical Science and Technology Today, V3, P28, DOI 10.1016/S1461-5347(99)00214-X
   Lather V, 2005, BIOORGAN MED CHEM, V13, P1599, DOI 10.1016/j.bmc.2004.12.014
   Lather V, 2005, J MOL GRAPH MODEL, V23, P339, DOI 10.1016/j.jmgm.2004.11.005
   Lather V, 2004, J MOL STRUC-THEOCHEM, V678, P1, DOI 10.1016/j.theochem.2004.01.050
   Li X., 2006, MATH CHEM MONOGRAPHS, V1
   Morgan MJ, 2011, DISCRETE MATH, V311, P1229, DOI 10.1016/j.disc.2009.12.013
   Saheli M, 2010, MACED J CHEM CHEM EN, V29, P71
   Sharma V, 1997, J CHEM INF COMP SCI, V37, P273, DOI 10.1021/ci960049h                                                               
   Yu GH, 2011, J MATH ANAL APPL, V375, P99, DOI 10.1016/j.jmaa.2010.08.054
   Zhou B, 2010, MATCH-COMMUN MATH CO, V63, P181
NR 18
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-218X
J9 DISCRETE APPL MATH
JI Discret Appl. Math.
PD FEB
PY 2012
VL 160
IS 3
BP 248
EP 258
DI 10.1016/j.dam.2011.09.010
PG 11
WC Mathematics, Applied
SC Mathematics
GA 876YY
UT WOS:000299144900008
OA gold
DA 2018-01-05
ER

PT J
AU Dostal, J
   Brynda, J
   Hruskova-Heidingsfeldova, O
   Pachl, P
   Pichova, I
   Rezacova, P
AF Dostal, Jiri
   Brynda, Jiri
   Hruskova-Heidingsfeldova, Olga
   Pachl, Petr
   Pichova, Iva
   Rezacova, Pavlina
TI The crystal structure of protease Sapp1p from Candida parapsilosis in
   complex with the HIV protease inhibitor ritonavir
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Article
DE Secreted aspartic protease; virulence factor; X-ray structure;
   candidiasis
ID IMMUNODEFICIENCY-VIRUS PROTEASE; SECRETED ASPARTYL PROTEINASES;
   IN-VITRO; ALBICANS; MODEL; REFINEMENT; ADHERENCE; THERAPY; STRAINS;
   CELLS
AB Secreted aspartic proteases (Saps) are extracellular proteolytic enzymes that enhance the virulence of Candida pathogens. These enzymes therefore represent possible targets for therapeutic drug design. Saps are inhibited by nanomolar concentrations of the classical inhibitor of aspartic proteases pepstatin A and also by the inhibitors of the HIV protease, but with the K-i of micromolar values or higher. To contribute to the discussion regarding whether HIV protease inhibitors can act against opportunistic mycoses by the inhibition of Saps, we determined the structure of Sapp1p from Candida parapsilosis in complex with ritonavir (RTV), a clinically used inhibitor of the HIV protease. The crystal structure refined at resolution 2.4 angstrom proved binding of RTV into the active site of Sapp1p and provided the structural information necessary to evaluate the stability and specificity of the protein-inhibitor interaction.
C1 [Dostal, Jiri; Brynda, Jiri; Hruskova-Heidingsfeldova, Olga; Pachl, Petr; Pichova, Iva; Rezacova, Pavlina] Acad Sci Czech Republic, Inst Organ Chem & Biochem, Inst Mol Genet AS CR, Vvi, Prague 16610 6, Czech Republic.
   [Dostal, Jiri; Hruskova-Heidingsfeldova, Olga; Pichova, Iva] IOCB, Prague, Czech Republic.
   [Dostal, Jiri; Hruskova-Heidingsfeldova, Olga; Pichova, Iva] Gilead Res Ctr, Prague, Czech Republic.
   [Brynda, Jiri; Pachl, Petr; Rezacova, Pavlina] Acad Sci Czech Republic, Inst Mol Genet, Prague 16610 6, Czech Republic.
RP Rezacova, P (reprint author), Acad Sci Czech Republic, Inst Organ Chem & Biochem, Inst Mol Genet AS CR, Vvi, Flemingovo Namesti 2, Prague 16610 6, Czech Republic.
EM rezacova@uochb.cas.cz
RI Dostal, Jiri/E-9584-2012; HruskovaHeidingsfeld, Olga/B-2429-2009; Pachl,
   Petr/H-1344-2014; Pichova, Iva/G-7917-2014; Maloy Rezacova,
   Pavlina/G-3600-2014; Brynda, Jiri/G-2760-2014
OI HruskovaHeidingsfeld, Olga/0000-0001-9881-8473; 
FU Academy of Sciences of the Czech Republic [AV0Z40550506, AV0Z50520514];
   Ministry of Education of the Czech Republic [LC 531]; Czech Science
   Foundation [310/09/1945, 203/09/0820]
FX This work was supported by research projects AV0Z40550506, and
   AV0Z50520514 awarded by the Academy of Sciences of the Czech Republic.
   Additional support was awarded also by Ministry of Education of the
   Czech Republic (grant LC 531), and by the Czech Science Foundation
   (grants 310/09/1945 and 203/09/0820). Diffraction data were collected on
   beamline MX14.2 at BESSY, Berlin, Germany. The authors wish to thank
   Devon Maloy for critical proofreading of the manuscript.
CR Back-Brito GN, 2009, MYCOPATHOLOGIA, V167, P81, DOI 10.1007/s11046-008-9153-9
   Baradkar VP, 2010, INDIAN J PATHOL MICR, V53, P93, DOI 10.4103/0377-4929.59192
   Bektic J, 2001, FEMS IMMUNOL MED MIC, V31, P65, DOI 10.1016/S0928-8244(01)00242-5
   Betts MJ, 1999, PROTEIN ENG, V12, P271, DOI 10.1093/protein/12.4.271                                                        
   Borg-von Zepelin M, 1999, J INVEST DERMATOL, V113, P747, DOI 10.1046/j.1523-1747.1999.00747.x
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Cassone A, 1999, J INFECT DIS, V180, P448, DOI 10.1086/314871                                                                  
   DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303                                                     
   Lano De, 2002, PYMOL MOL GRAPHICS S
   Dostal J, 2003, J CLIN MICROBIOL, V41, P712, DOI 10.1128/JCM.41.712-716.2003
   Dostal J, 2009, J STRUCT BIOL, V167, P145, DOI 10.1016/j.jsb.2009.04.004
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Falkensammer B, 2007, MYCOSES, V50, P172, DOI [10.1111/j.1439-0507.2006.01353.x, 10.1111/j.0933-7407.2006.01353.x]
   Fallon K, 1997, INFECT IMMUN, V65, P551
   Hruskova-Heidingsfeldova O, 2008, FRONT BIOSCI, V13, P7227, DOI 10.2741/3224
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   Klabe RM, 1998, BIOCHEMISTRY-US, V37, P8735, DOI 10.1021/bi972555l
   LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648
   Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Munro CA, 2002, TRENDS MICROBIOL, V10, P173, DOI 10.1016/S0966-842X(02)02330-2
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003
   Piacenti FJ, 2006, PHARMACOTHERAPY, V26, P1111, DOI 10.1592/phco.26.8.1111
   Pichova I, 2001, EUR J BIOCHEM, V268, P2669, DOI 10.1046/j.1432-1327.2001.02152.x
   Rinnova M, 2000, ARCH BIOCHEM BIOPHYS, V382, P22, DOI 10.1006/abbi.2000.2017
   Schaller M, 2003, INFECT IMMUN, V71, P3227, DOI 10.1128/IAI.71.6.3227-3234.2003
   Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780                                                       
   Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 31
TC 3
Z9 4
U1 0
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1475-6366
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD FEB
PY 2012
VL 27
IS 1
BP 160
EP 165
DI 10.3109/14756366.2011.627508
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 871OZ
UT WOS:000298748800024
PM 22146051
OA gold
DA 2018-01-05
ER

PT J
AU Connell, BJ
   Baleux, F
   Coic, YM
   Clayette, P
   Bonnaffe, D
   Lortat-Jacob, H
AF Connell, Bridgette Janine
   Baleux, Francoise
   Coic, Yves-Marie
   Clayette, Pascal
   Bonnaffe, David
   Lortat-Jacob, Hugues
TI A Synthetic Heparan Sulfate-Mimetic Peptide Conjugated to a Mini CD4
   Displays Very High Anti-HIV-1 Activity Independently of Coreceptor Usage
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID HIV-1 ENVELOPE GLYCOPROTEIN; VIRUS TYPE-1 GP120; BINDING-SITE;
   CD4-INDUCED EPITOPES; CCR5; RECEPTOR; CHEMOKINE; ENTRY; INFECTION; CXCR4
AB The HIV-1 envelope gp120, which features both the virus receptor (CD4) and coreceptor (CCR5/CXCR4) binding sites, offers multiple sites for therapeutic intervention. However, the latter becomes exposed, thus vulnerable to inhibition, only transiently when the virus has already bound cellular CD4. To pierce this defense mechanism, we engineered a series of heparan sulfate mimicking tridecapeptides and showed that one of them target the gp120 coreceptor binding site with mu M affinity. Covalently linked to a CD4-mimetic that binds to gp120 and renders the coreceptor binding domain available to be targeted, the conjugated tridecapeptide now displays nano-molar affinity for its target. Using solubilized coreceptors captured on top of sensorchip we show that it inhibits gp120 binding to both CCR5 and CXCR4 and in peripheral blood mononuclear cells broadly inhibits HIV-1 replication with an IC50 of 1 nM.
C1 [Connell, Bridgette Janine; Lortat-Jacob, Hugues] Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,UMR 5075, F-38000 Grenoble, France.
   [Baleux, Francoise; Coic, Yves-Marie] Inst Pasteur, Unite Chim Biomol, URA CNRS 2128, F-75015 Paris, France.
   [Clayette, Pascal] CEA, Lab Neurovirol, F-92265 Fontenay Aux Roses, France.
   [Bonnaffe, David] Univ Paris 11, ICMMO UMR CNRS UPS 8182, Equipe Glycochim Mol & Macromol, Lab Chim Organ Multifonct, F-91405 Orsay, France.
RP Lortat-Jacob, H (reprint author), Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,UMR 5075, F-38000 Grenoble, France.
EM hugues.lortat-jacob@ibs.fr
OI Baleux, Francoise/0000-0003-4926-1060
FU Sidaction and "la Fondation Pierre Berge"
FX We thank Rahima Yousfi (BERTIN Pharma) for technical assistance. This
   work was supported by the Agence Nationale de la Recherche sur le SIDA
   (ANRS) and B.J.C. was supported by a grant from Sidaction and "la
   Fondation Pierre Berge." Soluble CD4, mAb 17b, and Cf2Th coreceptor
   expressing cells were obtained through the NIH AIDS Research and
   Reference Reagent Program from Drs. S. Iyer, J. Robinson and J.
   Sodroski, respectively. The following HIV-1 strains were obtained
   through the NIH AIDS Research and Reference Reagent Program from the
   UNAIDS Network for HIV Isolation and Characterization (92UG029 and
   98IN017), Dr. N. Halsey (92HT599), Drs. D. Ellenberger, P. Sullivan and
   R.B. Lal (96USHIPS4), Dr. J. Lavy (SF162), and the multi-center AIDS
   Cohort Study (92US723). Dr. F. Arenzana-Seisdedos is thanked for the
   kind gifts of maraviroc and AMD3100.
CR Acharya P, 2011, ACS CHEM BIOL, V6, P1069, DOI 10.1021/cb200068b
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Babcock GJ, 2001, J BIOL CHEM, V276, P38433, DOI 10.1074/jbc.M106229200                                                          
   Baleux F, 2009, NAT CHEM BIOL, V5, P743, DOI 10.1038/nchembio.207
   Baribaud F, 2001, J VIROL, V75, P8957, DOI 10.1128/JVI.75.19.8957-8967.2001                                                
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Biorn AC, 2004, BIOCHEMISTRY-US, V43, P1928, DOI 10.1021/bi035088i
   Brower ET, 2009, BIOCHEMISTRY-US, V48, P779, DOI 10.1021/bi8021476
   Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7
   Cohen C, 2008, VIROLOGY, V381, P46, DOI 10.1016/j.virol.2008.08.025
   Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762                                                         
   Crublet E, 2008, J BIOL CHEM, V283, P15193, DOI 10.1074/jbc.M800066200
   De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424
   Dervillez X, 2010, J VIROL, V84, P10131, DOI 10.1128/JVI.00165-10
   Dilhas A, 2008, J COMB CHEM, V10, P166, DOI 10.1021/cc8000019
   Doranz BJ, 1999, J VIROL, V73, P10346
   Dorfman T, 2006, J BIOL CHEM, V281, P28529, DOI 10.1074/jbc.M602732200
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Dragic T, 2001, J GEN VIROL, V82, P1807, DOI 10.1099/0022-1317-82-8-1807                                                     
   Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI13530
   Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200
   Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Flexner C, 2007, NAT REV DRUG DISCOV, V6, P959, DOI 10.1038/nrd2336
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   Imberty A, 2007, CARBOHYD RES, V342, P430, DOI 10.1016/j.carres.2006.12.019
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Kwong JA, 2011, J VIROL, V85, P7563, DOI 10.1128/JVI.00630-11
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617
   Maeda K, 2004, CURR OPIN PHARMACOL, V4, P447, DOI 10.1016/j.coph.2004.07.004
   Maynard HD, 2005, ACTA BIOMATER, V1, P451, DOI 10.1016/j.actbio.2005.04.004
   MCCORTTRANCHEPAIN I, 1992, INT J PEPT PROT RES, V39, P48
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745                                                        
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Nachman RJ, 2005, PEPTIDES, V26, P115, DOI 10.1016/j.peptides.2004.07.018
   Navratilova I, 2005, ANAL BIOCHEM, V339, P271, DOI 10.1016/j.ab.2004.12.017
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Seitz M, 2010, CHEM COMMUN, V46, P7754, DOI 10.1039/c0cc02913k
   Shafer RW, 2008, AIDS REV, V10, P67
   THALI M, 1993, J VIROL, V67, P3978
   Tilton JC, 2010, ANTIVIR RES, V85, P91, DOI 10.1016/j.antiviral.2009.07.022
   Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200
   Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0
   Xiang SH, 2002, AIDS RES HUM RETROV, V18, P1207, DOI 10.1089/08892220260387959                                                       
NR 47
TC 18
Z9 20
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD JAN 27
PY 2012
VL 19
IS 1
SI SI
BP 131
EP 139
DI 10.1016/j.chembiol.2011.12.009
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 889LF
UT WOS:000300074500013
PM 22284360
OA gold
DA 2018-01-05
ER

PT J
AU Lu, CH
   Zhang, Y
   Tang, SF
   Fang, ZB
   Yang, HH
   Chen, X
   Chen, GN
AF Lu, Chun-Hua
   Zhang, Yan
   Tang, Shui-Fen
   Fang, Zhi-Bin
   Yang, Huang-Hao
   Chen, Xi
   Chen, Guo-Nan
TI Sensing HIV related protein using epitope imprinted hydrophilic polymer
   coated quartz crystal microbalance
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Dopamine; Epitope imprinting; HIV-1; Molecularly imprinted polymers;
   Quartz crystal microbalance
ID SILICA NANOPARTICLES; AU NANOPARTICLES; COILED-COIL; TYPE-1 GP41;
   RECOGNITION; SURFACE; ANTIBODY; PEPTIDE; MECHANISM; MEMBRANES
AB We have developed a biomimetic sensor for the detection of human immunodeficiency virus type 1 (HIV-1) related protein (glycoprotein 41, gp41) based on epitope imprinting technique. gp41 is the transmembrane protein of HIV-1 and plays an important role in membrane fusion between viruses and infected cells. It is an important index for determining the extent of HIV-1 disease progression and the efficacy of therapeutic intervention. In this work, dopamine was used as the functional monomer and polymerized on the surface of quartz crystal microbalance (QCM) chip in the presence of template, a synthetic peptide with 35 amino acid residues, analogous to residues 579-613 of the gp41. This process resulted in grafting a hydrophilic molecularly imprinted polymer (MIP) film on the QCM chip. QCM measurement showed that the resulting MIP film not only had a great affinity towards the template peptide, but also could bind the corresponding gp41 protein specifically. The dissociation constant (K-d) of MIP for the template peptide was calculated to be 3.17 nM through Scatchard analysis, which was similar to those of monoclonal antibodies. Direct detection of the gp41 was achieved quantitatively using the resulting MIP-based biomimetic sensor. The detection limit of gp41 was 2 ng/mL, which was comparable to the reported ELISA method. In addition, the practical analytical performance of the sensor was examined by evaluating the detection of gp41 in human urine samples with satisfactory results. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Lu, Chun-Hua; Zhang, Yan; Tang, Shui-Fen; Fang, Zhi-Bin; Yang, Huang-Hao; Chen, Guo-Nan] Fuzhou Univ, Key Lab Anal & Detect Technol Food Safety, Fujian Prov Key Lab Anal & Detect Technol Food Sa, MOE,Coll Chem & Chem Engn, Fuzhou 350002, Peoples R China.
   [Chen, Xi] Xiamen Univ, State Key Lab Marine Environm Sci, Xiamen 361005, Peoples R China.
RP Yang, HH (reprint author), Fuzhou Univ, Key Lab Anal & Detect Technol Food Safety, Fujian Prov Key Lab Anal & Detect Technol Food Sa, MOE,Coll Chem & Chem Engn, Fuzhou 350002, Peoples R China.
EM hhyang@fio.org.cn; xichen@xmu.edu.cn
RI Lu, CH/G-4684-2010; Chen, X/G-4087-2010
FU National Basic Research Program of China [2010CB732403]; National
   Natural Science Foundation of China [20975023]; program for new century
   excellent talents in university of China [09-0014]; National Science
   Foundation of Fujian Province [2010J06003]
FX This work was supported by the National Basic Research Program of China
   (No. 2010CB732403), the grants from the National Natural Science
   Foundation of China (No. 20975023), the program for new century
   excellent talents in university of China (09-0014) and the National
   Science Foundation of Fujian Province (2010J06003).
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alexander C, 2006, J MOL RECOGNIT, V19, P106, DOI 10.1002/jmr.760
   Bossi A, 2007, BIOSENS BIOELECTRON, V22, P1131, DOI 10.1016/j.bios.2006.06.023
   Bossi A, 2001, ANAL CHEM, V73, P5281, DOI 10.1021/ac0006526
   Bui BTS, 2010, ANAL CHEM, V82, P4420, DOI 10.1021/ac100128c
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Burzio LA, 2000, BIOCHEMISTRY-US, V39, P11147, DOI 10.1021/bi0002434
   Buzon V, 2006, BIOCHEMISTRY-US, V45, P15768, DOI 10.1021/bi060622i
   Cai D, 2010, NAT NANOTECHNOL, V5, P597, DOI [10.1038/nnano.2010.114, 10.1038/NNANO.2010.114]
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Contreras LM, 2001, BIOCHEMISTRY-US, V40, P3196, DOI 10.1021/bi002613u
   Cutivet A, 2009, J AM CHEM SOC, V131, P14699, DOI 10.1021/ja901600e
   Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n
   Gao DM, 2007, J AM CHEM SOC, V129, P7859, DOI 10.1021/ja070975k
   Ge Y, 2008, TRENDS BIOTECHNOL, V26, P218, DOI 10.1016/j.tibtech.2008.01.001
   Ge Y, 2009, CHEM-EUR J, V15, P8100, DOI 10.1002/chem.200802401
   Haupt K, 2003, ANAL CHEM, V75, p376A, DOI 10.1021/ac031385h
   He HY, 2010, BIOSENS BIOELECTRON, V26, P760, DOI 10.1016/j.bios.2010.06.043
   Hinz A, 2009, VIROLOGY, V390, P221, DOI 10.1016/j.virol.2009.05.015
   Hoshino Y, 2008, J AM CHEM SOC, V130, P15242, DOI 10.1021/ja8062875
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Li JP, 2011, BIOSENS BIOELECTRON, V26, P2097, DOI 10.1016/j.bios.2010.09.013
   Li Y, 2006, ANAL CHEM, V78, P317, DOI 10.1021/ac050802i
   Nematollahzadeh A, 2011, ANGEW CHEM INT EDIT, V50, P495, DOI 10.1002/anie.201004774
   Nishino H, 2006, ANGEW CHEM INT EDIT, V45, P2392, DOI 10.1002/anie.200503760
   Ouyang RZ, 2008, CHEM COMMUN, P5761, DOI 10.1039/b810248a
   Ouyang RZ, 2007, ADV FUNCT MATER, V17, P3223, DOI 10.1002/adfm.200700143
   Ouyang R.Z., 2010, NANOTECHNOLOGY, V21
   Pernites R, 2011, BIOSENS BIOELECTRON, V26, P2766, DOI 10.1016/j.bios.2010.10.027
   Polyakov M. V., 1931, ZH FIZ KHIM, V2, P799
   Rachkov A, 2000, J CHROMATOGR A, V889, P111, DOI 10.1016/S0021-9673(00)00568-9                                                   
   Riskin M, 2008, J AM CHEM SOC, V130, P9726, DOI 10.1021/ja711278c
   Riskin M, 2009, J AM CHEM SOC, V131, P7368, DOI 10.1021/ja9001212
   Shi HQ, 1999, NATURE, V398, P593
   Stringer RC, 2010, ANAL CHEM, V82, P4015, DOI 10.1021/ac902838c
   Tai DF, 2010, ANAL CHEM, V82, P2290, DOI 10.1021/ac9024158
   Tai DF, 2005, ANAL CHEM, V77, P5140, DOI 10.1021/ac0504060
   Tan J, 2009, ANAL CHEM, V81, P5273, DOI 10.1021/ac900484x
   Tatemichi M, 2007, J AM CHEM SOC, V129, P10906, DOI 10.1021/ja071890m                                                               
   van der Leeden MC, 2005, LANGMUIR, V21, P11373, DOI 10.1021/la0515468
   VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0
   Wang HJ, 2006, J AM CHEM SOC, V128, P15954, DOI 10.1021/ja065116v
   WULFF G, 1972, ANGEW CHEM INT EDIT, V11, P341
   WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121                                                          
   Ye L, 2008, CHEM MATER, V20, P859, DOI 10.1021/cm703190w
   Zeng ZY, 2010, ACS NANO, V4, P199, DOI [10.1021/nn901256s, 10.1021/nn9011256s]
   Zhang W, 2011, BIOSENS BIOELECTRON, V26, P2553, DOI 10.1016/j.bios.2010.11.004
   Zhou WH, 2010, J MATER CHEM, V20, P880, DOI 10.1039/b916619j
NR 48
TC 73
Z9 75
U1 14
U2 213
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 15
PY 2012
VL 31
IS 1
BP 439
EP 444
DI 10.1016/j.bios.2011.11.008
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 895AK
UT WOS:000300468400068
PM 22143073
DA 2018-01-05
ER

PT J
AU Mitra, A
   Ignatovich, F
   Novotny, L
AF Mitra, Anirban
   Ignatovich, Filipp
   Novotny, Lukas
TI Real-time optical detection of single human and bacterial viruses based
   on dark-field interferometry
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Heterodyne interferometry; Dark-field microscopy; Viruses; Nanofluidics;
   Phage; Nanoparticles; Biosensing; Biodetection; Label-free flow
   cytometry
ID WHISPERING-GALLERY-MODE; NANOPARTICLE DETECTION; HIV-1; FLOW; CELL; RNA;
   PARTICLES; ASSAYS; BLOOD; WATER
AB The rapid and sensitive detection and characterization of human viruses and bacteriophage is extremely important in a variety of fields, such as medical diagnostics, immunology and vaccine research, and environmental contamination and quality control. We introduce an optical detection scheme for real-time and label-free detection of human viruses and bacteriophage as small as similar to 24 nm in radius. Combining the advantages of heterodyne interferometry and dark-field microscopy, this label-free method enables us to detect and characterize various biological nanoparticles with unsurpassed sensitivity and selectivity. We demonstrate the high sensitivity and precision of the method by analyzing a mixture containing HIV virus and bacteriophage. The method also resolves the distribution of small nano-impurities (similar to 20-30 nm) in clinically relevant virus samples. (C) 2011 Elsevier RV. All rights reserved.
C1 [Ignatovich, Filipp; Novotny, Lukas] Univ Rochester, Inst Opt, Rochester, NY 14627 USA.
   [Mitra, Anirban; Novotny, Lukas] Univ Rochester, Dept Phys & Astron, Rochester, NY 14627 USA.
RP Novotny, L (reprint author), Univ Rochester, Inst Opt, Rochester, NY 14627 USA.
FU NIH [1R21AI085543-01A1]
FX We thank Prof. Carrie Dykes for providing us the HIV virus samples,
   Prof. Steve Dewhurst and Dr. Jonelle Mattiacio for providing us the
   bacteriophage lambda sample, and Zack Lapin for help with SEM imaging.
   We also thank Steve Person and Dr. John Lesoine for help in fabricating
   the nanofluidic channels. This work is supported by NIH (grant
   1R21AI085543-01A1).
CR Anderson B, 2006, MICROORGANISMS BIOTE
   Batchelder J.S., 1991, U.S. Patent, Patent No. [5,061,070, 5061070]
   Berne B.J., 2000, DYNAMIC LIGHT SCATTE
   Bohren CF, 1983, ABSORPTION SCATTERIN
   Braslavsky I, 2001, APPL OPTICS, V40, P5650, DOI 10.1364/AO.40.005650
   Brussaard CPD, 2000, J VIROL METHODS, V85, P175, DOI 10.1016/S0166-0934(99)00167-6
   Choi MR, 2007, NANO LETT, V7, P3759, DOI 10.1021/nl072209h
   Chuan YP, 2008, BIOTECHNOL BIOENG, V99, P1425, DOI 10.1002/bit.21710
   Cromeans TL, 2008, J VIROL METHODS, V151, P140, DOI 10.1016/j.jviromet.2008.03.007
   Daaboul GG, 2010, NANO LETT, V10, P4727, DOI 10.1021/nl103210p
   Deutsch B, 2010, APPL OPTICS, V49, P4921, DOI 10.1364/AO.49.004921
   DIMITROV DS, 1993, J VIROL, V67, P2182
   DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167
   Engelmann I, 2008, J MED VIROL, V80, P467, DOI 10.1002/jmv.21095
   Ferris M.M., 2002, ANAL CHEM, V74, P198
   Fraikin JL, 2011, NAT NANOTECHNOL, V6, P308, DOI [10.1038/nnano.2011.24, 10.1038/NNANO.2011.24]
   GIVAN AL, 2001, FLOW CYTOMETRY 1 PRI
   Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545                                                         
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Hubner W, 2009, SCIENCE, V323, P1743, DOI 10.1126/science.1167525
   Ignatovich FV, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.013901
   Ignatovich FV, 2003, REV SCI INSTRUM, V74, P5231, DOI 10.1063/1.1628823
   Krug RM, 2003, ANTIVIR RES, V57, P147, DOI 10.1016/S0166-3542(02)00207-3
   Lindfors K, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.037401
   Mie G., 1908, ANN PHYS, V330, P376
   Mitra A, 2010, ACS NANO, V4, P1305, DOI 10.1021/nn901889v
   Morawska L, 2010, AIR QUAL CLIMATE CHA, V44, P18
   Oberdorster G., 2000, INT ARCH OCC ENV HEA, V74, P1
   OSTER G, 1950, J GEN PHYSIOL, V33, P445, DOI 10.1085/jgp.33.5.445
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Person S, 2011, NANO LETT, V11, P257, DOI 10.1021/nl103656y
   Plakhotnik T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.183602
   Porter J, 1997, FEMS MICROBIOL ECOL, V24, P93, DOI 10.1016/S0168-6496(97)00038-X                                                   
   Ramanathan V, 2008, NAT GEOSCI, V1, P221, DOI 10.1038/ngeo156
   Salter RS, 2010, APPL ENVIRON MICROB, V76, P7803, DOI 10.1128/AEM.01235-10
   Santiago-Rodriguez TM, 2010, WATER RES, V44, P4716, DOI 10.1016/j.watres.2010.07.078
   Somers CM, 2004, SCIENCE, V304, P1008, DOI 10.1126/science.1095815                                                         
   Stern E, 2007, NANO LETT, V7, P3405, DOI 10.1021/nl071792z
   STOFFEL CL, 2005, AM BIOTECHNOL LAB, V37, P24
   Takasaki T, 1997, ARCH VIROL, V142, P375, DOI 10.1007/s007050050083
   Tehe A, 2006, J CLIN VIROL, V37, P199, DOI 10.1016/j.jcv.2006.08.005
   Tsai WP, 1996, VIROLOGY, V226, P205, DOI 10.1006/viro.1996.0648
   Vollmer F, 2008, P NATL ACAD SCI USA, V105, P20701, DOI 10.1073/pnas.0808988106
   Vollmer F, 2008, NAT METHODS, V5, P591, DOI 10.1038/nmeth.1221
   Wali F, 2009, MICROELECTRON ENG, V86, P140, DOI 10.1016/j.mee.2008.09.046
   Yanik AA, 2010, NANO LETT, V10, P4962, DOI 10.1021/nl103025u
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Zhu J., 2009, NAT PHOTONICS, V4, P46
   Batchelder J. S., 1991, U.S. Patent, Patent No. [5 037 202, 5037202, 5,037,202]
NR 49
TC 19
Z9 19
U1 5
U2 46
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 15
PY 2012
VL 31
IS 1
BP 499
EP 504
DI 10.1016/j.bios.2011.11.025
PG 6
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 895AK
UT WOS:000300468400078
PM 22169818
OA green_accepted
DA 2018-01-05
ER

PT J
AU Witwer, KW
   Watson, AK
   Blankson, JN
   Clements, JE
AF Witwer, Kenneth W.
   Watson, Andria K.
   Blankson, Joel N.
   Clements, Janice E.
TI Relationships of PBMC microRNA expression, plasma viral load, and CD4+
   T-cell count in HIV-1-infected elite suppressors and viremic patients
SO RETROVIROLOGY
LA English
DT Article
DE human immunodeficiency virus; elite suppressor; microRNA; biomarker;
   NanoString; TaqMan low-density array; viral load; peripheral blood
   mononuclear cell; CD4+T-cell
ID REAL-TIME PCR; SEROPOSITIVE INDIVIDUALS; HIV-1 REPLICATION; MICROARRAY
   DATA; INFECTION; THERAPY; TECHNOLOGIES; MACROPHAGES; CONTROLLERS;
   SIGNATURE
AB Background: HIV-1-infected elite controllers or suppressors (ES) maintain undetectable viral loads (< 50 copies/mL) without antiretroviral therapy. The mechanisms of suppression are incompletely understood. Modulation of HIV-1 replication by miRNAs has been reported, but the role of small RNAs in ES is unknown. Using samples from a well-characterized ES cohort, untreated viremic patients, and uninfected controls, we explored the PBMC miRNA profile and probed the relationships of miRNA expression, CD4+ T-cell counts, and viral load.
   Results: miRNA profiles, obtained using multiple acquisition, data processing, and analysis methods, distinguished ES and uninfected controls from viremic HIV-1-infected patients. For several miRNAs, however, ES and viremic patients shared similar expression patterns. Differentially expressed miRNAs included those with reported roles in HIV-1 latency (miR-29 family members, miRs-125b and -150). Others, such as miR-31 and miR-31*, had no previously reported connection with HIV-1 infection but were found here to differ significantly with uncontrolled HIV-1 replication. Correlations of miRNA expression with CD4+ T-cell count and viral load were found, and we observed that ES with low CD4+ T-cell counts had miRNA profiles more closely related to viremic patients than controls. However, expression patterns indicate that miRNA variability cannot be explained solely by CD4+ T-cell variation.
   Conclusions: The intimate involvement of miRNAs in disease processes is underscored by connections of miRNA expression with the HIV disease clinical parameters of CD4 count and plasma viral load. However, miRNA profile changes are not explained completely by these variables. Significant declines of miRs-125b and -150, among others, in both ES and viremic patients indicate the persistence of host miRNA responses or ongoing effects of infection despite viral suppression by ES. We found no negative correlations with viral load in viremic patients, not even those that have been reported to silence HIV-1 in vitro, suggesting that the effects of these miRNAs are exerted in a focused, cell-type-specific manner. Finally, the observation that some ES with low CD4 counts were consistently related to viremic patients suggests that miRNAs may serve as biomarkers for risk of disease progression even in the presence of viral suppression.
C1 [Witwer, Kenneth W.; Watson, Andria K.; Clements, Janice E.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD 21025 USA.
   [Blankson, Joel N.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21025 USA.
   [Clements, Janice E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21025 USA.
   [Clements, Janice E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21025 USA.
RP Witwer, KW (reprint author), Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, 733 N Broadway, Baltimore, MD 21025 USA.
EM kwitwer1@jhmi.edu
RI Witwer, Kenneth/G-1626-2013
OI Witwer, Kenneth/0000-0003-1664-4233
FU  [R01 AI080328];  [MH070306];  [AI076113]
FX We thank the donors who made this study possible. We would also like to
   thank the staff of the Johns Hopkins DNA Analysis Facility, the Johns
   Hopkins MicroArray Core Facility, and all members of the Molecular and
   Comparative Pathobiology Retrovirus Laboratory for helpful discussions.
   This work was funded by R01 AI080328 (JNB) and MH070306 and AI076113
   (JEC).
CR Andrade A, 2008, CLIN INFECT DIS, V46, pE78, DOI 10.1086/529387
   Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674
   Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Bennasser Yamina, 2004, Retrovirology, V1, P43, DOI 10.1186/1742-4690-1-43
   Blankson J, 2011, CURR OPIN HIV AIDS, V6, P147, DOI 10.1097/COH.0b013e3283457868
   Camarillo C, 2011, METHODS MOL BIOL, V698, P419, DOI 10.1007/978-1-60761-999-4_30
   Chable-Bessia C, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-26
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Dudaronek JM, 2007, J IMMUNOL, V179, P7262, DOI 10.4049/jimmunol.179.11.7262                                                    
   Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578
   Edwards JK, 2010, J CARDIOVASC TRANSL, V3, P271, DOI 10.1007/s12265-010-9179-5
   Gaarz A, 2010, J MOL DIAGN, V12, P335, DOI 10.2353/jmoldx.2010.090116
   Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385
   Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110
   Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
   Hammond SM, 2006, TRENDS MOL MED, V12, P99, DOI 10.1016/j.molmed.2006.01.004
   Hersperger AR, 2011, CURR OPIN HIV AIDS, V6, P169, DOI 10.1097/COH.0b013e3283454c39
   Honda Y, 1998, J EXP MED, V188, P1255, DOI 10.1084/jem.188.7.1255                                                          
   Houzet L, 2011, BBA-GENE REGUL MECH, V1809, P686, DOI 10.1016/j.bbagrm.2011.05.009
   Houzet L, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-118
   Huang J, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705116200
   Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Narayanan A, 2011, EXPERT OPIN BIOL TH, V11, P17, DOI 10.1517/14712598.2011.540564
   Nathans R, 2009, MOL CELL, V34, P696, DOI 10.1016/j.molcel.2009.06.003
   Noorbakhsh F, 2010, FASEB J, V24, P1799, DOI 10.1096/fj.09-147819
   Norman KL, 2010, J VIROL, V84, P666, DOI 10.1128/JVI.01156-09
   O'Connell KA, 2009, TRENDS PHARMACOL SCI, V30, P631, DOI 10.1016/j.tips.2009.09.005
   Okulicz JF, 2010, CLIN INFECT DIS, V50, P1187, DOI 10.1086/651421
   Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029
   Pradervand S, 2009, RNA, V15, P493, DOI 10.1261/rna.1295509
   Rabi SA, 2011, J VIROL, V85, P979, DOI 10.1128/JVI.01721-10
   Rao YL, 2008, STAT APPL GENET MOL, V7
   Rossi RL, 2011, NAT IMMUNOL, V12, P796, DOI 10.1038/ni.2057
   Rouas R, 2009, EUR J IMMUNOL, V39, P1608, DOI 10.1002/eji.200838509
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
   Simon R, 2007, CANCER INFORM, V3, P11
   Smyth GK, 2005, STAT BIOL HEALTH, P397
   Spivak AM, 2011, J VIROL, V85, P10399, DOI 10.1128/JVI.05409-11
   Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263
   Swaminathan S., 2009, BLOOD, V113, P5030
   Swaminathan S, 2009, BLOOD, V113, P5029, DOI 10.1182/blood-2009-01-196741
   Tatro ET, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010337
   Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319
   Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000
   Witwer KW, 2011, AIDS, V25, P2057, DOI 10.1097/QAD.0b013e32834b95bf
   Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764
   Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56
   Yeung ML, 2009, NUCLEIC ACIDS RES, V37, P6575, DOI 10.1093/nar/gkp707
   Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81
NR 56
TC 74
Z9 78
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JAN 12
PY 2012
VL 9
AR 5
DI 10.1186/1742-4690-9-5
PG 15
WC Virology
SC Virology
GA 911LO
UT WOS:000301718500001
PM 22240256
OA gold
DA 2018-01-05
ER

PT J
AU Daubner, GM
   Clery, A
   Jayne, S
   Stevenin, J
   Allain, FHT
AF Daubner, Gerrit M.
   Clery, Antoine
   Jayne, Sandrine
   Stevenin, James
   Allain, Frederic H-T
TI A syn-anti conformational difference allows SRSF2 to recognize guanines
   and cytosines equally well
SO EMBO JOURNAL
LA English
DT Article
DE alternative splicing; HIV tat exon; NMR; protein-RNA complex; SR protein
ID PRE-MESSENGER-RNA; NMR STRUCTURE DETERMINATION; EXONIC SPLICING
   ENHANCERS; SR PROTEINS; STRUCTURAL BASIS; MOLECULAR-BASIS; PREMESSENGER
   RNA; HNRNP PROTEINS; SC35; SRP20
AB SRSF2 (SC35) is a key player in the regulation of alternative splicing events and binds degenerated RNA sequences with similar affinity in nanomolar range. We have determined the solution structure of the SRSF2 RRM bound to the 5'-U (CC) under bar AGU-3' and 5'-U (GG) under bar AGU-3' RNA, both identified as SRSF2 binding sites in the HIV-1 tat exon 2. RNA recognition is achieved through a novel sandwich-like structure with both termini forming a positively charged cavity to accommodate the four central nucleotides. To bind both RNA sequences equally well, SRSF2 forms a nearly identical network of intermolecular interactions by simply flipping the bases of the two consecutive (C) under bar or (G) under bar nucleotides into either anti or syn conformation. We validate this unusual mode of RNA recognition functionally by in-vitro and in-vivo splicing assays and propose a 5'-SSNG-3' (S = C/G) high-affinity binding consensus sequence for SRSF2. In conclusion, in addition to describe for the first time the RNA recognition mode of SRSF2, we provide the precise consensus sequence to identify new putative binding sites for this splicing factor. The EMBO Journal (2012) 31, 162-174. doi: 10.1038/emboj.2011.367; Published online 14 October 2011
C1 [Daubner, Gerrit M.; Clery, Antoine; Jayne, Sandrine; Allain, Frederic H-T] ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.
   [Stevenin, James] Univ Strasbourg, IGBMC, Dept Funct Genom, Strasbourg, France.
RP Allain, FHT (reprint author), ETH, Inst Mol Biol & Biophys, HPK G18, CH-8093 Zurich, Switzerland.
EM allain@mol.biol.ethz.ch
FU Swiss National Foundation; National Center for Competence in Research
   Structural Biology; EURASNET; European Molecular Biology Organization
FX We would like to thank M Blatter for his help with structure
   calculations; F Damberger and M Schubert for their invaluable knowledge
   of NMR spectroscopy; J Boudet for his advice and S Gerhardy for his
   assistance in the ITC measurements. Research of FH-TA is supported by
   the Swiss National Foundation, National Center for Competence in
   Research Structural Biology and EURASNET. AC was supported by the
   European Molecular Biology Organization for a postdoctoral fellowship.
CR Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0
   Arrisi-Mercado P, 2004, J BIOL CHEM, V279, P39331, DOI 10.1074/jbc.M405566200
   Auweter SD, 2006, NUCLEIC ACIDS RES, V34, P4943, DOI 10.1093/nar/gkl620
   Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194
   Barash Y, 2010, NATURE, V465, P53, DOI 10.1038/nature09000
   Been MD, 1995, RNA, V1, P1061
   Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720
   Bourgeois CF, 2004, PROG NUCLEIC ACID RE, V78, P37, DOI 10.1016/S0079-6603(04)78002-2
   Burkard ME, 2000, BIOCHEMISTRY-US, V39, P11748, DOI 10.1021/bi000720i
   Caputi M, 2002, EMBO J, V21, P845, DOI 10.1093/emboj/21.4.845                                                          
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967
   Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002
   Chowdhury S, 2006, EMBO J, V25, P2487, DOI 10.1038/sj.emboj.7601128
   Clery A, 2011, NAT STRUCT MOL BIOL, V18, P443, DOI 10.1038/nsmb.2001
   Colwill K, 1996, EMBO J, V15, P265
   Crovato TE, 2005, FEBS LETT, V579, P4138, DOI 10.1016/j.febslet.2005.06.044
   Das R, 2007, MOL CELL, V26, P867, DOI 10.1016/j.molcel.2007.05.036
   de la Mata M, 2006, NAT STRUCT MOL BIOL, V13, P973, DOI 10.1038/nsmb1155
   Disset A, 2006, HUM MOL GENET, V15, P999, DOI 10.1093/hmg/ddl015
   Dominguez C, 2011, PROG NUCL MAG RES SP, V58, P1, DOI 10.1016/j.pnmrs.2010.10.001
   Dreumont N, 2010, NUCLEIC ACIDS RES, V38, P1353, DOI 10.1093/nar/gkp1086
   DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445
   Gabut M, 2005, MOL CELL BIOL, V25, P3286, DOI 10.1128/MCB.25.8.3286-3294.2005
   Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189
   Hallay H, 2006, J BIOL CHEM, V281, P37159, DOI 10.1074/jbc.M603864200
   Handa N, 1999, NATURE, V398, P579
   Hargous Y, 2006, EMBO J, V25, P5126, DOI 10.1038/sj.emboj.7601385
   Hautbergue GM, 2008, J MAGN RESON, V191, P335, DOI 10.1016/j.jmr.2007.12.017
   Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3
   Herrmann T, 2002, J BIOMOL NMR, V24, P171, DOI 10.1023/A:1021614115432                                                         
   Hertel KJ, 2005, TRENDS BIOCHEM SCI, V30, P115, DOI 10.1016/j.tibs.2005.01.002
   Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7                                                   
   KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3
   Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461
   Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000
   Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501
   Oesterreich FC, 2011, TRENDS CELL BIOL, V21, P328, DOI 10.1016/j.tcb.2011.03.002
   Okunola HL, 2009, MOL CELL BIOL, V29, P5620, DOI 10.1128/MCB.01678-08
   Peterson RD, 2004, J BIOMOL NMR, V28, P59, DOI 10.1023/B:JNMR.0000012861.95939.05
   Qian W, 2011, NUCLEIC ACIDS RES, V39, P6161, DOI 10.1093/nar/gkr195
   Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0                                                                
   Saliou JM, 2009, FRONT BIOSCI-LANDMRK, V14, P2714, DOI 10.2741/4008
   Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404
   Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9                                                   
   Schaal TD, 1999, MOL CELL BIOL, V19, P1705
   Schaal TD, 1999, MOL CELL BIOL, V19, P261
   Shen HH, 2004, MOL CELL, V13, P367, DOI 10.1016/S1097-2765(04)00025-5
   Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171
   Solis AS, 2008, J BIOL CHEM, V283, P23619, DOI 10.1074/jbc.M710175200
   Solis AS, 2008, FRONT BIOSCI-LANDMRK, V13, P1926, DOI 10.2741/2812
   TACKE R, 1995, EMBO J, V14, P3540
   Tiwari Abhishek, 2007, In Silico Biology, V7, P651
   Tsuda K, 2011, NUCLEIC ACIDS RES, V39, P1538, DOI 10.1093/nar/gkq854
   Venables JP, 2008, MOL CELL BIOL, V28, P6033, DOI 10.1128/MCB.00726-08
   Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009
   Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164
   Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131
   Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308
   Wentz MP, 1997, J VIROL, V71, P8542
   WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I
   Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200
   Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9                                                   
NR 69
TC 49
Z9 51
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD JAN 4
PY 2012
VL 31
IS 1
BP 162
EP 174
DI 10.1038/emboj.2011.367
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 885YM
UT WOS:000299817400014
PM 22002536
OA green_published
DA 2018-01-05
ER

PT J
AU Xia, X
   Zhou, C
   Ballell, L
   Garcia-Bennett, AE
AF Xia, Xin
   Zhou, Chunfang
   Ballell, Lluis
   Garcia-Bennett, Alfonso E.
TI In vivo Enhancement in Bioavailability of Atazanavir in the Presence of
   Proton-Pump Inhibitors using Mesoporous Materials
SO CHEMMEDCHEM
LA English
DT Article
DE drug delivery; human immunodeficiency virus (HIV); mesoporous silica;
   proton-pump inhibitors; solubility
ID WATER-SOLUBLE DRUGS; DELIVERY; SILICA; SOLUBILITY; RELEASE; PHASE;
   SUPERSATURATION; MICROPARTICLES; STABILIZATION; NANOPARTICLES
C1 [Xia, Xin; Zhou, Chunfang] Nanol AB, S-11428 Stockholm, Sweden.
   [Garcia-Bennett, Alfonso E.] Uppsala Univ, Angstrom Lab, S-75121 Uppsala, Sweden.
   [Xia, Xin] Stockholm Univ, Dept Mat & Environm Chem, Arrhenius Lab, S-10691 Stockholm, Sweden.
   [Ballell, Lluis] GlaxoSmithKline Inc, Dis Developing World, Madrid 28769, Spain.
RP Xia, X (reprint author), Nanol AB, S-11428 Stockholm, Sweden.
EM alfonso.garcia@angstrom.uu.se
RI Garcia-Bennett, Alfonso/E-1716-2013
OI Garcia-Bennett, Alfonso/0000-0002-9097-0179
FU Swedish Research Council (Vetenskapradet); European Commission [261378,
   215884]
FX AEGB is supported by the Swedish Research Council (Vetenskapradet). The
   authors are grateful for support from the Seventh Framework Programme of
   the European Commission: EC-FP-7-ORCHID (grant no. 261378) and
   EC-FP-7-DENDREAMERS (grant no. 215884). The authors express their
   gratitude to Dr. Albert Mihranyan (Uppsala University, Sweden) for many
   helpful comments during the writing of this manuscript, and to Mr.
   Richard Lihammar (Stockholm University, Sweden) for performing NMR
   analysis.
CR Alcoutlabi M, 2005, J PHYS-CONDENS MAT, V17, pR461, DOI 10.1088/0953-8984/17/15/R01
   Atluri R, 2009, J AM CHEM SOC, V131, P3189, DOI 10.1021/ja8096477
   *BRIST MYERS SQUIB, 2004, PRESCR INF AT SULF
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Garcia-Bennett AE, 2004, CHEM MATER, V16, P3597, DOI 10.1021/cm049398e
   HITE M, 2003, ORAL DELIVERY POOR 1
   Hodgkins RP, 2005, MICROPOR MESOPOR MAT, V79, P241, DOI 10.1016/j.micromeso.2004.10.036
   Hou H, 2006, J PHARM SCI-US, V95, P896, DOI 10.1002/jps.20600
   Jackson CL, 1996, CHEM MATER, V8, P2128, DOI 10.1021/cm9601188                                                               
   Kaukonen AM, 2007, EUR J PHARM BIOPHARM, V66, P348, DOI 10.1016/j.ejpb.2006.11.021
   Leuner C, 2000, EUR J PHARM BIOPHARM, V50, P47, DOI 10.1016/S0939-6411(00)00076-X
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   LIPPENS BC, 1965, J CATAL, V4, P319, DOI 10.1016/0021-9517(65)90307-6                                                    
   Lu J, 2010, SMALL, V6, P1794, DOI 10.1002/smll.201000538
   Matteucci ME, 2007, MOL PHARM, V4, P782, DOI 10.1021/mp0700211
   Mellaerts R, 2008, INT J PHARMACEUT, V357, P169, DOI 10.1016/j.ijpharm.2008.01.049
   Mellaerts R, 2007, CHEM COMMUN, P1375, DOI 10.1039/b616746b
   Mohammed AR, 2004, INT J PHARM, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010
   Morgan MT, 2006, CANCER RES, V66, P11913, DOI 10.1158/0008-5472.CAN-06-2066
   Overhoff KA, 2008, PHARM RES-DORDR, V25, P167, DOI 10.1007/s11095-007-9417-y
   PRASAD R, 1994, PHIL MAG LETT, V70, P357, DOI 10.1080/09500839408240501
   Rengarajan GT, 2008, J MATER CHEM, V18, P2537, DOI 10.1039/b804266g
   Salonen J, 2005, J CONTROL RELEASE, V108, P362, DOI 10.1016/j.jconrel.2005.08.017
   Serajuddin ATM, 1999, J PHARM SCI, V88, P1058, DOI 10.1021/js980403l
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23
   Augustijns P, 2007, SOLVENT SYSTEMS THEI, P257
   Stromme M., 2009, NANOMED-NANOTECHNOL, V1, P140
   Swali V, 1997, J ORG CHEM, V62, P4902, DOI 10.1021/jo9708654                                                               
   Takehara Y, 1996, AM J PHYSIOL-GASTR L, V271, pG799
   TARAZONA P, 1987, MOL PHYS, V60, P573, DOI 10.1080/00268978700100381
   TARAZONA P, 1985, PHYS REV A, V31, P2672, DOI 10.1103/PhysRevA.31.2672
   Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Reg M. Vallet-, 2007, ANGEW CHEM, V119, P7692
   Van Speybroeck M, 2010, EUR J PHARM SCI, V41, P623, DOI 10.1016/j.ejps.2010.09.002
   Appel LE, 2006, From PCT Int. Appl, Patent No. [WO 2006024944 A2 20060309, 2006024944, WO 2006/024944 A2]
   KIM S, 2011, Patent No. 20110124689
   STRUCTURE PROPERTIES
NR 38
TC 19
Z9 19
U1 0
U2 20
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1860-7179
J9 CHEMMEDCHEM
JI ChemMedChem
PD JAN 2
PY 2012
VL 7
IS 1
BP 43
EP 48
DI 10.1002/cmdc.201100500
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 868TR
UT WOS:000298549100004
PM 22144293
DA 2018-01-05
ER

PT J
AU Basu, S
   Mukherjee, B
   Chowdhury, SR
   Paul, P
   Choudhury, R
   Kumar, A
   Mondal, L
   Hossain, CM
   Maji, R
AF Basu, Sumit
   Mukherjee, Biswajit
   Chowdhury, Samrat Roy
   Paul, Paramita
   Choudhury, Rupak
   Kumar, Ajeet
   Mondal, Laboni
   Hossain, Chowdhury Mobaswar
   Maji, Ruma
TI Colloidal gold-loaded, biodegradable, polymer-based stavudine
   nanoparticle uptake by macrophages: an in vitro study
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE stavudine; poly(d,l-lactic-co-glycolic acid); nanoparticles; colloidal
   gold; uptake by macrophages
ID POLY(VINYL ALCOHOL) HYDROGEL; DRUG-DELIVERY SYSTEMS; SUSTAINED-RELEASE;
   CELLULAR UPTAKE; MICROSPHERES; PROTEIN; HIV; MODEL; SIZE; AIDS
AB Objective: We describe the development, evaluation, and comparison of colloidal gold-loaded, poly(d,l-lactic-co-glycolic acid)-based nanoparticles containing anti-acquired immunodeficiency syndrome drug stavudine and uptake of these nanoparticles by macrophages in vitro.
   Methods: We used the following methods in this study: drug-excipient interaction by Fourier transform infrared spectroscopy, morphology of nanoparticles by field-emission scanning electron microscopy, particle size by a particle size analyzer, and zeta potential and polydispersity index by a zetasizer. Drug loading and in vitro release were evaluated for formulations. The best formulation was incorporated with fluorescein isothiocyanate. Macrophage uptake of fluorescein isothiocyanate nanoparticles was studied in vitro.
   Results: Variations in process parameters, such as speed of homogenization and amount of excipients, affected drug loading and the polydispersity index. We found that the drug was released for a prolonged period (over 63 days) from the nanoparticles, and observed cellular uptake of stavudine nanoparticles by macrophages.
   Conclusion: Experimental nanoparticles represent an interesting carrier system for the transport of stavudine to macrophages, providing reduced required drug dose and improved drug delivery to macrophages over an extended period. The presence of colloidal gold in the particles decreased the drug content and resulted in comparatively faster drug release.
C1 [Basu, Sumit; Mukherjee, Biswajit; Chowdhury, Samrat Roy; Paul, Paramita; Kumar, Ajeet; Mondal, Laboni; Hossain, Chowdhury Mobaswar; Maji, Ruma] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.
   [Basu, Sumit] Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77030 USA.
   [Choudhury, Rupak] Ballygunge Sci Coll, Dept Biochem, Kolkata, India.
RP Mukherjee, B (reprint author), Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.
EM biswajit55@yahoo.com
OI Mukherjee, Prof. Biswajit/0000-0002-7854-9680
FU Department of Biotechnology, Government of India
   [BCIL/NER-BPMC/2012/650]; Indian Council of Medical Research
   [45/20/2011/NAN/BMS]
FX We are indebted to the Department of Biotechnology, Government of India
   (Grant no BCIL/NER-BPMC/2012/650) and the Indian Council of Medical
   Research (Grant no 45/20/2011/NAN/BMS) for partially funding the
   research work.
CR Arnaiz B, 2012, BIOCONJUGATE CHEM, V23, P814, DOI 10.1021/bc200663r
   Bilensoy E, 2008, INT J PHARM, V347, P163, DOI 10.1016/j.ijpharm.2007.06.051
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   Falcon-Perez JM, 2005, J CELL SCI, V118, P5243, DOI 10.1242/jcs.02633
   Freese C, 2012, BIOMACROMOLECULES, V13, P1533, DOI 10.1021/bm300248u
   Fu XD, 2005, ARCH PHARM RES, V28, P1092, DOI 10.1007/BF02977407
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   Lopez-Gasco P, 2011, J MICROENCAPSUL, V28, P417, DOI 10.3109/02652048.2011.576785
   Mandal TK, 2002, PHARMACEUT RES, V19, P1713, DOI 10.1023/A:1020765615379                                                         
   Mocanu A, 2009, COLLOID SURFACE A, V338, P93, DOI 10.1016/j.colsurfa.2008.12.041
   Mukherjee B, 2007, INT J NANOMED, V2, P213
   Ojeda R, 2007, CARBOHYD RES, V342, P448, DOI 10.1016/j.carres.2006.11.018
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   Patil S, 2007, BIOMATERIALS, V28, P4600, DOI 10.1016/j.biomaterials.2007.07.029
   Patra HK, 2007, NANOMED-NANOTECHNOL, V3, P111, DOI 10.1016/j.nano.2007.03.005
   Pattnaik G, 2012, J MICROENCAPSUL, V29, P666, DOI 10.3109/02652048.2012.680509
   Sehra S, 2005, J MICROENCAPSUL, V22, P521, DOI 10.1080/02652040500162170
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shan MM, 2007, PLOS PATHOG, V3, P1637, DOI 10.1371/journal.ppat.0030169
   Silverstein RM, 1998, SPECTROMETRIC IDENTI, P71
   Song CX, 1998, J CONTROL RELEASE, V54, P201, DOI 10.1016/S0168-3659(98)00016-9
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Wang N, 1999, PHARMACEUT RES, V16, P1430, DOI 10.1023/A:1018911411381
   Wang X, 2009, CANCER RES TREAT, V41, P1, DOI 10.4143/crt.2009.41.1.1
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
NR 28
TC 18
Z9 18
U1 0
U2 33
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 6049
EP 6061
DI 10.2147/IJN.S38013
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 053AE
UT WOS:000312241000001
PM 23271908
OA gold
DA 2018-01-05
ER

PT J
AU Babiuch, K
   Gottschaldt, M
   Werz, O
   Schubert, US
AF Babiuch, Krzysztof
   Gottschaldt, Michael
   Werz, Oliver
   Schubert, Ulrich S.
TI Particulate transepithelial drug carriers: barriers and functional
   polymers
SO RSC ADVANCES
LA English
DT Review
ID POLYACRYL STARCH MICROPARTICLES; ANTIGEN-PRESENTING CELLS; MUCOSAL
   IMMUNE-RESPONSES; POLY(GAMMA-GLUTAMIC ACID) NANOPARTICLES;
   POLY(PROPYLENE SULFIDE) NANOPARTICLES; FOLLICLE-ASSOCIATED EPITHELIUM;
   HUMAN-IMMUNODEFICIENCY-VIRUS; VACCINE DELIVERY-SYSTEMS; PIG ALVEOLAR
   MACROPHAGES; TIGHT JUNCTION PROTEINS
AB This review may serve as a compilation of helpful guidelines for design, synthesis, formulation, and in vitro, ex vivo as well as in vivo evaluation of particulate drug delivery systems that cross epithelial barriers. It provides both chemist and biologist with a comprehensive overview of complex anatomorphological features encountered by intranasally, pulmonary and orally administered particles. In addition, the materials (structures, modifications, formulations, and activity) used in transepithelial delivery are discussed. It covers the biological as well as physicochemical aspects crucial for the successful development of particulate drug carriers and methods for their application.
C1 [Babiuch, Krzysztof; Gottschaldt, Michael; Schubert, Ulrich S.] Univ Jena, Lab Organ & Macromol Chem IOMC, D-07743 Jena, Germany.
   [Babiuch, Krzysztof; Gottschaldt, Michael; Werz, Oliver; Schubert, Ulrich S.] Univ Jena, Jena Ctr Soft Matter, D-07743 Jena, Germany.
   [Werz, Oliver] Univ Jena, Inst Pharm, Chair Pharmaceut Med Chem, D-07743 Jena, Germany.
   [Schubert, Ulrich S.] Dutch Polymer Inst, NL-5612 AB Eindhoven, Netherlands.
RP Babiuch, K (reprint author), Univ Jena, Lab Organ & Macromol Chem IOMC, Humboldtstr 10, D-07743 Jena, Germany.
EM Ulrich.Schubert@uni-jena.de
RI Schubert, Ulrich/B-5777-2009
OI Schubert, Ulrich/0000-0003-4978-4670
FU Thuringian Ministry for Education, Science, and Culture (NanoConSens)
   [B514-09051]; Carl-Zeiss-Foundation
FX The authors are grateful to the Thuringian Ministry for Education,
   Science, and Culture (grant #B514-09051, NanoConSens) and to
   Carl-Zeiss-Foundation for financial support, They would also like to
   thank Dr Stephanie Schubert for helpful comments.
CR Abdulla JMA, 2010, AAPS PHARMSCITECH, V11, P663, DOI 10.1208/s12249-010-9428-6
   Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7
   Alconcel S. N. S., 2011, POLYM CHEM
   Ali MS, 2007, LARYNGOSCOPE, V117, P932, DOI 10.1097/MLG.0b013e3180383651
   Alipour S, 2010, COLLOID SURFACE B, V81, P521, DOI 10.1016/j.colsurfb.2010.07.050
   Allen BL, 2011, ACS NANO, V5, P5263, DOI 10.1021/nn201477y
   Ally J, 2006, J AEROSOL MED, V19, P491, DOI 10.1089/jam.2006.19.491                                                         
   Alpar HO, 2005, ADV DRUG DELIVER REV, V57, P411, DOI 10.1016/j.addr.2004.09.004
   Amidi M, 2010, ADV DRUG DELIVER REV, V62, P59, DOI 10.1016/j.addr.2009.11.009
   Amsden B, 1999, MACROMOLECULES, V32, P874, DOI 10.1021/ma980922a                                                               
   Arbos P, 2002, J CONTROL RELEASE, V83, P321, DOI 10.1016/S0168-3659(02)00015-9
   ARTURSSON P, 1984, J PHARM SCI, V73, P1507, DOI 10.1002/jps.2600731103
   Azevedo AF, 2006, EUR J PHARM BIOPHARM, V64, P131, DOI 10.1016/j.ejpb.2006.04.007
   Azizi A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001147
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bansil R, 2006, CURR OPIN COLLOID IN, V11, P164, DOI 10.1016/j.cocis.2005.11.001
   Becer CR, 2010, J AM CHEM SOC, V132, P15130, DOI 10.1021/ja1056714
   Becer CR, 2009, ANGEW CHEM INT EDIT, V48, P4900, DOI 10.1002/anie.200900755
   Becer CR, 2009, MACROMOLECULES, V42, P2387, DOI 10.1021/ma9000176
   Beck-Broichsitter M, 2009, INT J PHARM, V367, P169, DOI 10.1016/j.ijpharm.2008.09.017
   Beck-Broichsitter M., 2011, J NANOMATER
   Behrens I, 2001, PHARMACEUT RES, V18, P1138, DOI 10.1023/A:1010974909998
   Benoit MA, 1999, INT J PHARM, V184, P73, DOI 10.1016/S0378-5173(99)00109-X
   Bernkop-Schnurch A, 2000, INT J PHARM, V194, P239, DOI 10.1016/S0378-5173(99)00387-7
   Bernkop-Schnurch A, 2001, J PHARM SCI, V90, P1907, DOI 10.1002/jps.1140
   Berthold A, 1996, J CONTROL RELEASE, V39, P17, DOI 10.1016/0168-3659(95)00129-8                                                    
   Bharatwaj B, 2010, BIOMATERIALS, V31, P7376, DOI 10.1016/j.biomaterials.2010.06.005
   BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0
   Biggs DL, 2003, J CONTROL RELEASE, V92, P147, DOI 10.1016/S0168-3659(03)00325-0
   Bland D, 2006, MUCOSAL IMMUNOLOGY V, P23
   Boddohi S, 2010, ADV MATER, V22, P2998, DOI 10.1002/adma.200903790
   Borges O, 2005, INT J PHARM, V299, P155, DOI 10.1016/j.ijpharm.2005.04.037
   Borges O, 2007, EUR J PHARM SCI, V32, P278, DOI 10.1016/j.ejps.2007.08.005
   Borges O, 2010, PHARM RES-DORD, V27, P211, DOI 10.1007/s11095-009-0011-3
   Bramwell VW, 2006, J PHARM PHARMACOL, V58, P717, DOI 10.1211/jpp.56.6.0002
   Brandhonneur N, 2009, EUR J PHARM SCI, V36, P474, DOI 10.1016/j.ejps.2008.11.013
   Brandon-Peppas L., 2000, HDB PHARM CONTROLLED
   Brandtzaeg P, 2008, MUCOSAL IMMUNOL, V1, P31, DOI 10.1038/mi.2007.9
   Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369
   Brazeau GA, 1998, J PHARM SCI, V87, P667, DOI 10.1021/js970315l                                                               
   BROEKAERT WF, 1984, BIOCHEM J, V221, P163, DOI 10.1042/bj2210163                                                               
   Buescher JM, 2007, CRIT REV BIOTECHNOL, V27, P1, DOI 10.1080/07388550601166458
   BUSUTTIL A, 1977, J ANAT, V124, P445
   Calvo P, 1997, BIOMATERIALS, V18, P1305, DOI 10.1016/S0142-9612(97)00061-6
   Calvo P, 1997, PHARMACEUT RES, V14, P1431, DOI 10.1023/A:1012128907225
   CANNON GJ, 1992, J CELL SCI, V101, P907
   Caputo A, 2009, VACCINE, V27, P3605, DOI 10.1016/j.vaccine.2009.03.047
   Caputo Antonella, 2008, Current Drug Delivery, V5, P230, DOI 10.2174/156720108785914961
   Caramella C, 2010, J DRUG DELIV SCI TEC, V20, P5, DOI 10.1016/S1773-2247(10)50001-7                                                   
   Carr KE, 1996, PHARMACEUT RES, V13, P1205, DOI 10.1023/A:1016064320334
   Celli JP, 2007, BIOMACROMOLECULES, V8, P1580, DOI 10.1021/bm0609691
   Cesta MF, 2006, TOXICOL PATHOL, V34, P599, DOI 10.1080/01926230600865531
   Chadwick S, 2010, ADV DRUG DELIVER REV, V62, P394, DOI 10.1016/j.addr.2009.11.012
   Challacombe SJ, 1997, VACCINE, V15, P169, DOI 10.1016/S0264-410X(96)00159-4
   CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164
   Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103
   Chan LW, 2002, INT J PHARM, V242, P259, DOI 10.1016/S0378-5173(02)00170-9
   Chan LW, 2002, BIOMATERIALS, V23, P1319, DOI 10.1016/S0142-9612(01)00250-2                                                   
   CHARLEY B, 1985, COMP IMMUNOL MICROB, V8, P99, DOI 10.1016/0147-9571(85)90037-2
   Chen K, 2010, IMMUNITY, V33, P479, DOI 10.1016/j.immuni.2010.09.013
   Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017
   Cho NH, 1998, J CONTROL RELEASE, V53, P215, DOI 10.1016/S0168-3659(97)00255-1                                                   
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Chourasia MK, 2004, DRUG DELIV, V11, P129, DOI 10.1080/10717540490280778
   Clark MA, 1998, INFECT IMMUN, V66, P1237
   Clausen AE, 2000, J PHARM SCI, V89, P1253, DOI 10.1002/1520-6017(200010)89:10<1253::AID-JPS3>3.0.CO;2-8                        
   Cleary J, 2004, LANGMUIR, V20, P9755, DOI 10.1021/la048993s
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cone RA, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P49, DOI 10.1016/B978-012491543-5/50008-5
   Cooper D, 2010, METHOD ENZYMOL, V480, P199, DOI 10.1016/S0076-6879(10)80011-4
   COPEMAN M, 1994, J GASTROEN HEPATOL, V9, pS55, DOI 10.1111/j.1440-1746.1994.tb01303.x
   CORNES JS, 1965, GUT, V6, P225, DOI 10.1136/gut.6.3.225
   Coucke D, 2009, VACCINE, V27, P1279, DOI 10.1016/j.vaccine.2008.12.013
   Crater JS, 2010, MACROMOL BIOSCI, V10, P1473, DOI 10.1002/mabi.201000137
   Creuwels LAJM, 1997, LUNG, V175, P1, DOI 10.1007/PL00007554                                                              
   Csaba N, 2009, ADV DRUG DELIVER REV, V61, P140, DOI 10.1016/j.addr.2008.09.005
   Cu Y, 2009, NAT MATER, V8, P11, DOI 10.1038/nmat2347
   Dailey LA, 2006, TOXICOL APPL PHARM, V215, P100, DOI 10.1016/j.tapp2.006.01.016
   Dailey LA, 2005, J CONTROL RELEASE, V101, P137, DOI 10.1016/j.jconrel.2004.09.03
   Damge C, 2010, J PHARM SCI-US, V99, P879, DOI 10.1002/jps.21874
   Davidovich-Pinhas M, 2010, EXPERT OPIN DRUG DEL, V7, P259, DOI 10.1517/17425240903473134
   Dawson M, 2003, J BIOL CHEM, V278, P50393, DOI 10.1074/jbc.M309026200
   De Koker S, 2011, CHEM SOC REV, V40, P320, DOI 10.1039/b914943k
   Dea-Ayuela MA, 2006, J DRUG TARGET, V14, P567, DOI 10.1080/10611860600849464
   DEGLING L, 1995, VACCINE, V13, P629, DOI 10.1016/0264-410X(94)00031-H                                                    
   Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7
   Delaney JT, 2010, SOFT MATTER, V6, P866, DOI 10.1039/b922888h
   Delgado A, 1999, VACCINE, V17, P2927, DOI 10.1016/S0264-410X(99)00140-1                                                   
   Deli MA, 2009, BBA-BIOMEMBRANES, V1788, P892, DOI 10.1016/j.bbamem.2008.09.016
   Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034
   Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400                                           
   Di Colo G, 2008, J PHARM SCI-US, V97, P1652, DOI 10.1002/jps.21043
   Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968                                                                 
   Dinarvand R, 2011, INT J NANOMED, V6, P877, DOI 10.2147/IJN.S18905
   Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7                                                   
   Donovan MD, 1998, ADV DRUG DELIVER REV, V29, P147, DOI 10.1016/S0169-409X(97)00066-5                                                   
   DORTA MJ, 1993, INT J PHARM, V100, P9, DOI 10.1016/0378-5173(93)90069-R
   Dubsky P, 2005, J CLIN IMMUNOL, V25, P551, DOI 10.1007/s10875-005-8216-7
   Duceppe N, 2010, EXPERT OPIN DRUG DEL, V7, P1191, DOI 10.1517/17425247.2010.514604
   Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   Elfstrand L, 2009, J PHARM SCI-US, V98, P3802, DOI 10.1002/jps.21693
   Emami J, 2009, J MICROENCAPSUL, V26, P1, DOI 10.1080/02652040802083900
   Esmaeili F, 2010, J DRUG DELIV SCI TEC, V20, P53, DOI 10.1016/S1773-2247(10)50006-6                                                   
   Espuelas S, 2008, BIOCONJUGATE CHEM, V19, P2385, DOI 10.1021/bc8002524
   EVANS MJ, 1988, AM REV RESPIR DIS, V138, P481, DOI 10.1164/ajrccm/138.2.481                                                        
   Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929
   Faraasen S, 2003, PHARMACEUT RES, V20, P237, DOI 10.1023/A:1022366921298
   Feng XH, 2010, ACS SYM SER, V1061, P3
   Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446                                                         
   Ferro VA, 2009, METHODS, V49, P299, DOI 10.1016/j.ymeth.2009.10.002
   Fiegel J, 2003, PHARMACEUT RES, V20, P788, DOI 10.1023/A:1023441804464
   Fievez V, 2009, EUR J PHARM BIOPHARM, V73, P16, DOI 10.1016/j.ejpb.2009.04.009
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Flanagan MP, 1999, VACCINE, V17, P72, DOI 10.1016/S0264-410X(98)00118-2                                                   
   Florindo H F, 2010, Int J Pharm, V390, P25, DOI 10.1016/j.ijpharm.2009.10.009
   Florindo HF, 2009, VACCINE, V27, P1230, DOI 10.1016/j.vaccine.2008.12.004
   Florindo HF, 2009, BIOMATERIALS, V30, P879, DOI 10.1016/j.biomaterials.2008.10.035
   FORSTNER G, 1995, ANNU REV PHYSIOL, V57, P585, DOI 10.1146/annurev.ph.57.030195.003101                                             
   Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045
   Gabor F, 2004, ADV DRUG DELIVER REV, V56, P459, DOI 10.1016/j.addr.2003.10.015
   Garg Neeraj K, 2010, Recent Pat Drug Deliv Formul, V4, P114
   Garinot M, 2007, J CONTROL RELEASE, V120, P195, DOI 10.1016/j.jconrel.2007.04.021
   Gebert A, 2000, Z GASTROENTEROL, V38, P855, DOI 10.1055/s-2000-10001
   GEBERT A, 1993, GASTROENTEROLOGY, V105, P1350, DOI 10.1016/0016-5085(93)90139-4                                                    
   Gebert A, 1999, SEMIN IMMUNOL, V11, P165, DOI 10.1006/smim.1999.0172                                                          
   GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135                                             
   George M, 2006, J CONTROL RELEASE, V114, P1, DOI 10.1016/j.jconrel.2006.04.017
   Giannasca PJ, 1999, INFECT IMMUN, V67, P946
   Goldsby RA, 2003, IMMUNOLOGY
   Gombotz WR, 1998, ADV DRUG DELIVER REV, V31, P267, DOI 10.1016/S0169-409X(97)00124-5
   Gonzalez-Mariscal L, 2005, ADV DRUG DELIVER REV, V57, P811, DOI 10.1016/j.addr.2005.01.004
   Goya AK, 2008, EXPERT OPIN THER PAT, V18, P1271, DOI 10.1517/13543770802514618
   Grabovac V, 2007, DRUG DEV IND PHARM, V33, P767, DOI 10.1080/03639040601050163
   Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
   Gullberg E, 2006, J PHARMACOL EXP THER, V319, P632, DOI 10.1124/jpet.106.107847
   Gupta A, 2009, J SCI IND RES INDIA, V68, P465
   Guttman JA, 2009, BBA-BIOMEMBRANES, V1788, P832, DOI 10.1016/j.bbamem.2008.10.028
   Halama A.R., 1990, P A RHINOLOGY, V28, P25
   Han IK, 2006, METHODS, V38, P106, DOI 10.1016/j.ymeth.2005.10.003
   Harandi AM, 2010, VACCINE, V28, P2363, DOI 10.1016/j.vaccine.2009.12.084
   Harush-Frenkel O, 2010, TOXICOL APPL PHARM, V246, P83, DOI 10.1016/j.taap.2010.04.011
   Hathaway LJ, 2000, CELL MOL LIFE SCI, V57, P323, DOI 10.1007/PL00000693
   He LZ, 2007, J IMMUNOL, V178, P6259, DOI 10.4049/jimmunol.178.10.6259                                                    
   Heegaard PMH, 2011, ARCH VIROL, V156, P183, DOI 10.1007/s00705-010-0863-1
   Hehar SS, 1999, CLIN OTOLARYNGOL, V24, P24, DOI 10.1046/j.1365-2273.1999.00190.x                                                
   Henning A, 2010, J AEROSOL MED PULM D, V23, P233, DOI 10.1089/jamp.2009.0806
   Heritage PL, 1996, IMMUNOLOGY, V88, P162, DOI 10.1046/j.1365-2567.1996.d01-639.x
   Heurtault B, 2010, EXPERT OPIN DRUG DEL, V7, P829, DOI 10.1517/17425247.2010.488687
   Hillery AM, 1996, INT J PHARM, V132, P123, DOI 10.1016/0378-5173(95)04353-5
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Hirosue S, 2010, VACCINE, V28, P7897, DOI 10.1016/j.vaccine.2010.09.077
   Hirota K, 2007, J CONTROL RELEASE, V119, P69, DOI 10.1016/j.jconrel.2007.01.013
   HOLT PG, 1990, INT ARCH ALLER A IMM, V91, P155, DOI 10.1159/000235107                                                               
   Ikada Y, 2000, MACROMOL RAPID COMM, V21, P117, DOI 10.1002/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.0.CO;2-X
   Irache JM, 2008, EXPERT OPIN DRUG DEL, V5, P703, DOI 10.1517/17425247.5.6.703 
   Ito F, 2004, COLLOID SURFACE B, V39, P17, DOI 10.1016/j.colsurfb.2004.08.016
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Jahnsen FL, 2004, AM J RESP CELL MOL, V30, P31, DOI 10.1165/rcmb.2002-0230OC
   Jeffery PK, 1998, AM J RESP CRIT CARE, V157, pS174, DOI 10.1164/ajrccm.157.5.rsaa-1                                                     
   Jepson MA, 2004, ADV DRUG DELIVER REV, V56, P511, DOI 10.1016/j.addr.2003.10.018
   Jones BG, 2002, INT J PHARM, V236, P65, DOI 10.1016/S0378-5173(02)00016-9
   Jung T, 2000, EUR J PHARM BIOPHARM, V50, P147, DOI 10.1016/S0939-6411(00)00084-9
   Kawashima Y, 2000, PHARM DEV TECHNOL, V5, P77, DOI 10.1081/PDT-100100522                                                           
   Kawashima Y, 1999, J CONTROL RELEASE, V62, P279, DOI 10.1016/S0168-3659(99)00048-6
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KIM CK, 1992, INT J PHARM, V79, P11, DOI 10.1016/0378-5173(92)90088-J
   Kim MS, 2005, MACROMOL RAPID COMM, V26, P643, DOI 10.1002/marc.200400650
   Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537
   Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217
   Koleske JV., 1978, POLYM BLENDS, V2, P369
   Kondoh M, 2008, DRUG DISCOV TODAY, V13, P180, DOI 10.1016/j.drudis.2007.11.005
   Kondoh M, 2006, BIOL PHARM BULL, V29, P1783, DOI 10.1248/bpb.29.1783
   Kopecek J, 2010, ADV DRUG DELIVER REV, V62, P122, DOI 10.1016/j.addr.2009.10.004
   Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110
   Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018
   Kumar MNVR, 2004, J NANOSCI NANOTECHNO, V4, P990, DOI 10.1166/jnn.2004.130
   KUMAR V, 1993, DRUG DEV IND PHARM, V19, P1, DOI 10.3109/03639049309038760                                                       
   Kunisawa J, 2005, CURR MOL MED, V5, P557, DOI 10.2174/1566524054863924
   KuoLee R, 2008, EXPERT OPIN DRUG DEL, V5, P693, DOI [10.1517/17425240802150668, 10.1517/17425247.5.6.693 ]
   Labet M, 2009, CHEM SOC REV, V38, P3484, DOI 10.1039/b820162p
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P86, DOI 10.1016/j.addr.2008.09.012
   Lane KB, 1998, J LEUKOCYTE BIOL, V64, P345
   Lassalle V, 2010, J CHEM TECHNOL BIOT, V85, P1588, DOI 10.1002/jctb.2470
   Lavelle EC, 2005, CELL MOL LIFE SCI, V62, P2750, DOI 10.1007/s00018-005-5290-1
   Lavelle Ed C, 2006, Expert Opin Drug Deliv, V3, P747, DOI 10.1517/17425247.3.6.747
   Le Droumaguet B, 2010, POLYM CHEM-UK, V1, P563, DOI 10.1039/b9py00363k
   Lee JW, 2000, J PHARM SCI, V89, P850, DOI 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G
   Leitner VM, 2004, J CONTROL RELEASE, V100, P87, DOI 10.1016/j.jconrel.2004.08.001
   Lemarchand C, 2004, EUR J PHARM BIOPHARM, V58, P327, DOI 10.1016/j.ejpb.2004.02.016
   Lemoine D, 1998, INT J PHARMACEUT, V176, P9, DOI 10.1016/S0378-5173(98)00303-2                                                   
   Leon-Rodriguez L, 2010, INT J PHARMACEUT, V402, P165, DOI 10.1016/j.ijpharm.2010.10.006
   Lindhorst TK, 2000, ESSENTIALS CARBOHYDR
   Ling J, 2008, J BIOL CHEM, V283, P30585, DOI 10.1074/jbc.M803548200
   Lu MG, 2010, ACS NANO, V4, P6303, DOI 10.1021/nn1018818
   MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442
   MACKAY M, 1991, ADV DRUG DELIVER REV, V7, P313, DOI 10.1016/0169-409X(91)90012-2
   Magnusson JP, 2011, POLYM CHEM-UK, V2, P48, DOI 10.1039/c0py00210k
   Maher S, 2008, CRIT REV THER DRUG, V25, P117, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i2.10                                    
   Makhlof A, 2011, J CONTROL RELEASE, V149, P81, DOI 10.1016/j.jconrel.2010.02.001
   Makino K, 2003, COLLOID SURFACE B, V27, P33, DOI 10.1016/S0927-7765(02)00042-5                                                   
   Man AL, 2004, IMMUNOLOGY, V113, P15, DOI 10.1111/j.1365-2567.2004.01964.x
   Manca ML, 2008, COLLOID SURFACE B, V62, P220, DOI 10.1016/j.colsurfb.2007.10.005
   Manocha B, 2008, CRIT REV BIOTECHNOL, V28, P83, DOI [10.1080/07388550802107483, 10.1080/07388550802107483 ]
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Mantis NJ, 2000, AM J PHYSIOL-GASTR L, V278, pG915
   Maric I, 1996, J IMMUNOL, V156, P1408
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   MASON RJ, 1980, J BIOL CHEM, V255, P5101
   Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687                                                                 
   Matsuo K, 1997, GUT, V40, P782, DOI 10.1136/gut.40.6.782                                                            
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   McGhee JR, 2011, NAT BIOTECHNOL, V29, P136, DOI 10.1038/nbt.1766
   Mestecky J., 2003, MUCOSAL IMMUNE SYSTE
   Mishra N, 2010, EXPERT OPIN THER PAT, V20, P661, DOI 10.1517/13543771003730425
   Mittal G, 2007, J CONTROL RELEASE, V119, P77, DOI 10.1016/j.jconrel.2007.01.016
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Mofidi N, 2000, PROCESS BIOCHEM, V35, P885, DOI 10.1016/S0032-9592(99)00149-1
   Mohamed F, 2008, J PHARM SCI-US, V97, P71, DOI 10.1002/jps.21082
   Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012
   Mundargi RC, 2008, J CONTROL RELEASE, V125, P193, DOI 10.1016/j.jconrel.2007.09.013
   Mygind N, 1998, ADV DRUG DELIVER REV, V29, P3, DOI 10.1016/S0169-409X(97)00058-6                                                   
   Nagler-Anderson C, 2001, NAT REV IMMUNOL, V1, P59, DOI 10.1038/35095573                                                                
   Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004
   Neutra M. R., 1999, DEFENSE MUSCOSAL SUR, V236, P17
   Newman KD, 2002, J BIOMED MATER RES, V60, P480, DOI 10.1002/jbm.10019
   Nguyen J, 2009, J CONTROL RELEASE, V140, P47, DOI 10.1016/j.jconrel.2009.07.017
   Nguyen J, 2008, J CONTROL RELEASE, V132, P243, DOI 10.1016/j.jconrel.2008.06.010
   Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   Norris DA, 1997, J APPL POLYM SCI, V63, P1481, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1481::AID-APP10>3.0.CO;2-5               
   O'Hagan DT, 2007, CLIN PHARMACOL THER, V82, P740, DOI 10.1038/sj.clpt.6100402
   O'Hara P, 2000, PHARMACEUT RES, V17, P955, DOI 10.1023/A:1007527204887                                                         
   OFFIT PA, 1994, VIROLOGY, V203, P134, DOI 10.1006/viro.1994.1463
   Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001
   Oh JK, 2011, SOFT MATTER, V7, P5096, DOI 10.1039/c0sm01539c
   Ohashi K, 2009, J CONTROL RELEASE, V135, P19, DOI 10.1016/j.jconrel.2008.11.027
   Ohland CL, 2010, AM J PHYSIOL-GASTR L, V298, pG807, DOI 10.1152/ajpgi.00243.2009
   Owen L., 1974, GASTROENTEROLOGY, V66, P189
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pabst R, 2010, AM J RESP CELL MOL, V43, P137, DOI 10.1165/rcmb.2010-0152RT
   Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007
   PAPPO J, 1988, GASTROENTEROLOGY, V95, P1173, DOI 10.1016/0016-5085(88)90347-2                                                    
   Paris L, 2008, BBA-BIOMEMBRANES, V1778, P646, DOI 10.1016/j.bbamem.2007.08.004
   Patel AR, 2008, J MICROENCAPSUL, V25, P531, DOI 10.1080/02652040802075526
   Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006
   PENNEY DP, 1988, INT REV CYTOL, V111, P231, DOI 10.1016/S0074-7696(08)61736-2
   Perez-Vilar J, 2007, HISTOL HISTOPATHOL, V22, P455, DOI 10.14670/HH-22.455
   Periwal SB, 1997, J VIROL, V71, P2844
   PERRIN DA, 1997, HDB BIODEGRADABLE PO
   Poo H, 2010, CHEM BIODIVERS, V7, P1555, DOI 10.1002/cbdv.200900283
   Porfire AS, 2010, INT J PHARMACEUT, V390, P37, DOI 10.1016/j.ijpharm.2009.08.017
   Porgador A, 1998, INFECT IMMUN, V66, P5876
   Pourcelle V, 2009, BIOMACROMOLECULES, V10, P966, DOI 10.1021/bm900027r
   Powell DW, 1987, PHYSL MEMBRANE DISOR, P559
   POYNER EA, 1995, J CONTROL RELEASE, V35, P41, DOI 10.1016/0168-3659(95)00017-3
   Pulendran B, 2004, IMMUNOL REV, V199, P227, DOI 10.1111/j.0105-2896.2004.00144.x                                                
   PULLAN RD, 1994, GUT, V35, P353, DOI 10.1136/gut.35.3.353
   Rajapaksa TE, 2010, J BIOL CHEM, V285, P23739, DOI 10.1074/jbc.M110.126359
   Rajapaksa Thejani E., 2010, Current Immunology Reviews, V6, P29
   Raman R, 2005, NAT METHODS, V2, P817, DOI 10.1038/NMETH807
   Rastogi R, 2007, INT J PHARM, V334, P71, DOI 10.1016/j.ijpharm.2006.10.024
   Ratzinger G, 2010, CRIT REV THER DRUG, V27, P1
   Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Rehor A, 2005, LANGMUIR, V21, P411, DOI 10.1021/la0478043
   Rehor A, 2002, MACROMOLECULES, V35, P8688, DOI 10.1021/ma0211378
   Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373
   Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001
   Roda G, 2010, WORLD J GASTROENTERO, V16, P4264, DOI 10.3748/wjg.v16.i34.4264
   Rosen H, 2005, NAT REV DRUG DISCOV, V4, P381, DOI 10.1038/nrd1721
   Russell-Jones GJ, 1999, INT J PHARM, V190, P165, DOI 10.1016/S0378-5173(99)00254-9
   SADAHIRO S, 1992, SURG RADIOL ANAT, V14, P251, DOI 10.1007/BF01794949                                                              
   Sakagami M, 2001, J CONTROL RELEASE, V77, P117, DOI 10.1016/S0168-3659(01)00475-8
   Sakagami M, 2002, J CONTROL RELEASE, V80, P207, DOI 10.1016/S0168-3659(02)00034-2                                                   
   Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091
   Salman HH, 2008, PHARM RES-DORD, V25, P2859, DOI 10.1007/s11095-008-9657-5
   Salman HH, 2007, VACCINE, V25, P8123, DOI 10.1016/j.vaccine.2007.09.044
   Sarmento B, 2007, PHARM RES, V24, P2198, DOI 10.1007/s11095-007-9367-4
   Sasisekharan R, 2006, ANNU REV BIOMED ENG, V8, P181, DOI 10.1146/annurev.bioeng.8.061505.095745
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Scalf LA, 2000, J AM ACAD DERMATOL, V42, P355, DOI 10.1016/S0190-9622(00)90111-7                                                   
   Schipper NGM, 1997, PHARMACEUT RES, V14, P923, DOI 10.1023/A:1012160102740
   SCHMOLKA IR, 1977, J AM OIL CHEM SOC, V54, P110, DOI 10.1007/BF02894385                                                              
   Schreiber S, 1997, AM J PHYSIOL-GASTR L, V272, pG63
   Schuhl JF, 1995, J INVEST ALLERG CLIN, V5, P333
   Seeberger PH, 2007, NATURE, V446, P1046, DOI 10.1038/nature05819
   Seo JY, 2002, INFECT IMMUN, V70, P1143, DOI 10.1128/IAI.70.3.1143-1149.2002
   Seong SY, 1999, INFECT IMMUN, V67, P3587
   Sharma R, 1996, HISTOCHEM CELL BIOL, V105, P459, DOI 10.1007/BF01457659
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   SHERMAN P, 1987, AM J PATHOL, V126, P527
   SHIBUYA N, 1987, J BIOL CHEM, V262, P1596
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996
   Sinha VR, 2004, INT J PHARM, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Sivadas N, 2008, INT J PHARM, V358, P159, DOI 10.1016/j.ijpharm.2008.03.024
   SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726                                                        
   Smith AM, 2001, BIOMACROMOLECULES, V2, P335, DOI 10.1021/bm000133c
   Smith DJ, 2008, RESP PHYSIOL NEUROBI, V163, P178, DOI 10.1016/j.resp.2008.03.006
   Song XR, 2010, CURR DRUG METAB, V11, P859, DOI 10.2174/138920010794479682
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   SOUMA T, 1987, ARCH HISTOL CYTOL, V50, P419, DOI 10.1679/aohc.50.419
   Sparnacci K, 2005, J BIOMAT SCI-POLYM E, V16, P1557, DOI 10.1163/156856205774576673
   Springer C, 2005, PEDIATR RES, V58, P537, DOI 10.1203/01.pdr.0000176910.62067.a0
   Stafford JL, 2002, CRIT REV MICROBIOL, V28, P187, DOI 10.1080/1040-840291046731
   Stano A, 2011, VACCINE, V29, P804, DOI 10.1016/j.vaccine.2010.11.010
   Stark WJ, 2011, ANGEW CHEM INT EDIT, V50, P1242, DOI 10.1002/anie.200906684
   Stertman L, 2004, VACCINE, V22, P2863, DOI 10.1016/j.vaccine.2003.12.019
   Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23
   Strindelius L, 2002, INFECT IMMUN, V70, P1434, DOI 10.1128/IAI.70.3.1434-1442.2002
   Suarez S, 2001, J ANTIMICROB CHEMOTH, V48, P431, DOI 10.1093/jac/48.3.431
   Sung MH, 2005, CHEM REC, V5, P352, DOI 10.1002/tcr.20061
   Svensson O, 2010, CURR OPIN COLLOID IN, V15, P395, DOI 10.1016/j.cocis.2010.05.015
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Takeuchi H., 1997, DRUG DELIV SYST, V12, P347
   Tamayo I, 2010, CLIN VACCINE IMMUNOL, V17, P1356, DOI 10.1128/CVI.00164-10
   Tang CK, 2008, EXPERT REV VACCINES, V7, P1005, DOI 10.1586/14760584.7.7.1005
   Tel J, 2010, J IMMUNOL, V184, P4276, DOI 10.4049/jimmunol.0903286
   Thomas SN, 2011, BIOMATERIALS, V32, P2194, DOI 10.1016/j.biomaterials.2010.11.037
   Thomasin C, 1998, J PHARM SCI, V87, P259, DOI 10.1021/js970047r
   Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702
   Thornton DJ, 1996, BIOCHEM J, V316, P967, DOI 10.1042/bj3160967                                                               
   Tobio M, 1998, PHARMACEUT RES, V15, P270, DOI 10.1023/A:1011922819926
   Tobio M, 2000, COLLOID SURFACE B, V18, P315, DOI 10.1016/S0927-7765(99)00157-5
   Torche AM, 1999, J CONTROL RELEASE, V58, P289, DOI 10.1016/S0168-3659(98)00166-7
   Torche AM, 2000, J DRUG TARGET, V7, P343
   Torrelles JB, 2008, CURR DRUG TARGETS, V9, P102
   TREPEL F, 1974, KLIN WOCHENSCHR, V52, P511, DOI 10.1007/BF01468720                                                              
   Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   van der Merwe SM, 2004, EUR J PHARM BIOPHARM, V58, P225, DOI 10.1016/j.ejpb.2004.03.023
   van der Vlies AJ, 2010, BIOCONJUGATE CHEM, V21, P653, DOI 10.1021/bc9004443
   van der Waaij LA, 2005, INFLAMM BOWEL DIS, V11, P865, DOI 10.1097/01.mib.0000179212.80778.d3
   VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613
   Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2                                                   
   Voltan R, 2007, PHARM RES-DORDR, V24, P1870, DOI 10.1007/s11095-007-9310-8
   von Ossowski I, 2010, APPL ENVIRON MICROB, V76, P2049, DOI 10.1128/AEM.01958-09
   Vonarbourg A, 2006, BIOMATERIALS, V27, P4356, DOI 10.1016/j.biomaterials.2006.03.039
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   WARD PD, 2000, PHARM SCI TECHNOL TO, V3, P346, DOI DOI 10.1016/S1461-5347(00)00302-3
   Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x                                              
   Weiss B, 2007, BIOCONJUGATE CHEM, V18, P1087, DOI 10.1021/bc060342f
   Weissenboeck A, 2004, PHARM RES, V21, P1917, DOI 10.1023/B:PHAM.0000045247.09724.26
   Wendorf J, 2006, J PHARM SCI-US, V95, P2738, DOI 10.1002/jps.20728
   Werle M, 2008, J PHARM PHARMACOL, V60, P273, DOI 10.1211/jpp.60.3.0001
   Widdicombeed J., 1997, AIRWAY SURFACE LIQUI
   Wikingsson LD, 2002, VACCINE, V20, P3355, DOI 10.1016/S0264-410X(02)00288-8
   Wilschut J, 2009, IMMUNOL LETT, V122, P118, DOI 10.1016/j.imlet.2008.11.006
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
   Wittmar M, 2006, MACROMOLECULES, V39, P1417, DOI 10.1021/ma051837n
   WOLF DP, 1977, FERTIL STERIL, V28, P41
   Xiang SD, 2006, METHODS, V40, P1, DOI 10.1016/j.ymeth.2006.05.016
   Yamamoto H, 2005, J CONTROL RELEASE, V102, P373, DOI 10.1016/j.jconrel.2004.10.010
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Ye LL, 2011, NAT BIOTECHNOL, V29, P158, DOI 10.1038/nbt.1742
   Yoshida A, 2006, MICROBES INFECT, V8, P2484, DOI 10.1016/j.micinf.2006.06.004
NR 373
TC 6
Z9 6
U1 0
U2 42
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2012
VL 2
IS 28
BP 10427
EP 10465
DI 10.1039/c2ra20726e
PG 39
WC Chemistry, Multidisciplinary
SC Chemistry
GA 051PS
UT WOS:000312140100001
DA 2018-01-05
ER

PT J
AU Pattnaik, G
   Sinha, B
   Mukherjee, B
   Ghosh, S
   Basak, S
   Mondal, S
   Bera, T
AF Pattnaik, Gurudutta
   Sinha, Biswadip
   Mukherjee, Biswajit
   Ghosh, Saikat
   Basak, Sandip
   Mondal, Subhasish
   Bera, Tanmoy
TI Submicron-size biodegradable polymer-based didanosine particles for
   treating HIV at early stage: an in vitro study
SO JOURNAL OF MICROENCAPSULATION
LA English
DT Article
DE poly(d,l-lactic-co-glycolic acid); nanoparticles; HIV; sustained
   release; macrophages
ID DIMETHYL-SULFOXIDE; DRUG-DELIVERY; PLGA NANOPARTICLES; PROTEIN CARRIERS;
   NANOTECHNOLOGY; RELEASE; MACROPHAGES; MECHANISMS; NETWORKS; MATRICES
AB Human immunodeficiency viruses (HIV) hide themselves in macrophages at the early stage of infection. Delivering drug in a sustained manner from polymeric nanoparticles in those cells could control the disease effectively. The study was intended to develop poly(d,l-lactic-co-glycolic acid)-based nanoparticles containing didanosine and to observe their uptake by macrophages in vitro. Various physicochemical evaluations related to nanoparticles, such as drug-excipient interaction, surface morphology, particle size, zeta potential, polydispersity index, drug loading, in vitro drug release and nanoparticle-uptake by macrophages in vitro were determined. Homogenising speeds and drug-polymer ratio varied drug loading and polydispersity index of nanoparticles, providing sustained drug release. Dimethyl sulphoxide/polyethylene glycol improved drug loading predominantly. Nanoparticle-uptake by macrophages was concentration dependent. Experimental nanoparticles successfully transported didanosine to macrophages in vitro, suggesting reduction of dose, thus minimising toxicity and side effects. Developed nanoparticle may control HIV infection effectively at an early stage.
C1 [Pattnaik, Gurudutta; Sinha, Biswadip; Mukherjee, Biswajit; Ghosh, Saikat; Basak, Sandip; Mondal, Subhasish; Bera, Tanmoy] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.
RP Mukherjee, B (reprint author), Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.
EM biswajit55@yahoo.com
OI Mukherjee, Prof. Biswajit/0000-0002-7854-9680
FU All Indian Council of Technical Education (Government of India) under
   Quality Improvement Programme [JSSCP/QIP/OT/153/2006-2007]
FX This study was funded by All Indian Council of Technical Education
   (Government of India) under Quality Improvement Programme (grant no.
   JSSCP/QIP/OT/153/2006-2007).
CR Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   Barreiro P, 2006, J ANTIMICROB CHEMOTH, V57, P806, DOI 10.1093/jac/dkl045
   Bennewitz MF, 2009, NEUROTHERAPEUTICS, V6, P323, DOI 10.1016/j.nurt.2009.01.018
   Brobyn RD, 2012, HUMAN TOXICOLOGY DIM
   Cunha-Filho MSS, 2007, J PHARMACEUT BIOMED, V45, P590, DOI 10.1016/j.jpba.2007.08.016
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   Gupta RB, 2006, NANOPARTICLE TECHNOL, V159, P85
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hixson AW, 1931, IND ENG CHEM, V23, P923, DOI 10.1021/ie50260a018
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kashino G, 2010, J RADIAT RES, V51, P733, DOI 10.1269/jrr.09106
   Kasongo KW, 2011, DRUG DEV IND PHARM, V37, P396, DOI 10.3109/03639045.2010.516264
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kim D, 2005, COLLOID SURFACE B, V40, P83, DOI 10.1016/j.colsurfb.2004.05.007
   Kim HW, 2005, INT J BIOL MACROMOL, V37, P221, DOI 10.1016/j.ijbiomac.2005.11.002
   KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   Li YP, 2001, J CONTROL RELEASE, V71, P203, DOI 10.1016/S0168-3659(01)00218-8
   Marques Rute, 2009, Journal of Biology (London), V8, P93, DOI 10.1186/jbiol194
   Mazzola L, 2003, NAT BIOTECHNOL, V21, P1137, DOI 10.1038/nbt1003-1137
   Mehrgan Hadi, 2005, IRAN J PHARM RES, V3, P137
   Mukherjee B, 2005, EUR J PHARM BIOPHARM, V59, P475, DOI 10.1016/j.ejpb.2004.09.009
   Mukherjee Biswajit, 2010, International Journal of Biomedical Nanoscience and Nanotechnology, V1, P230, DOI 10.1504/IJBNN.2010.034653
   Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545                                                 
   Parkin J, 1997, UROLOGY, V49, P105, DOI 10.1016/S0090-4295(97)00181-7
   Paull R, 2003, NAT BIOTECHNOL, V21, P1144, DOI 10.1038/nbt1003-1144
   Roy P, 2010, INT J NANOMED, V5, P1113, DOI 10.2147/IJN.S14787
   RUBIN LF, 1975, ANN NY ACAD SCI, V243, P98, DOI 10.1111/j.1749-6632.1975.tb25348.x
   Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9
   Schmid-Hempel P, 2008, PHILOS T R SOC LON B, V364, P85
   Siepmann J, 1999, PHARMACEUT RES, V16, P1748, DOI 10.1023/A:1018914301328
   Skumiel A, 2009, Journal of Physics: Conference Series, V149, DOI 10.1088/1742-6596/149/1/012111
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Tobio M, 1998, PHARMACEUT RES, V15, P270, DOI 10.1023/A:1011922819926
   Tyagi P, 2006, MOL PHARMACEUT, V3, P369, DOI 10.1021/mp060001j
   Wang X, 2009, CANCER RES TREAT, V41, P1, DOI 10.4143/crt.2009.41.1.1
   Young J, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-36
   Yue Peng-Fei, 2008, PDA J Pharm Sci Technol, V62, P32
NR 39
TC 9
Z9 9
U1 0
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0265-2048
EI 1464-5246
J9 J MICROENCAPSUL
JI J. Microencapsul.
PY 2012
VL 29
IS 7
BP 666
EP 676
DI 10.3109/02652048.2012.680509
PG 11
WC Chemistry, Applied; Engineering, Chemical; Pharmacology & Pharmacy
SC Chemistry; Engineering; Pharmacology & Pharmacy
GA 032VT
UT WOS:000310747900006
PM 22545676
DA 2018-01-05
ER

PT B
AU Soares, SS
   Pedro, L
   Ferreira, GNM
AF Soares, S. S.
   Pedro, L.
   Ferreira, G. N. M.
GP IEEE
TI Molecular determinants of Virus-Like Nanoparticle assembly in vitro and
   in animal cell culture
SO 2012 IEEE 2ND PORTUGUESE MEETING IN BIOENGINEERING (ENBENG)
LA English
DT Proceedings Paper
CT 2nd IEEE Portuguese Meeting in Bioengineering (ENBENG)
CY FEB 23-25, 2012
CL Coimbra, PORTUGAL
DE Virus-like particles; molecular therapy; tropism manipulation;
   purification; in vitro assembly
ID SIMIAN IMMUNODEFICIENCY VIRUS; MATRIX PROTEIN; GAG PROTEINS; PARTICLES;
   TYPE-1; VPR; P6(GAG); HIV-1; RELEASE; SUFFICIENT
AB Protein nanoparticles, such as virus-like particles (VLPs), consist only of the virus shell without any viral genetic information packaged inside. Similarly to viruses, the structural proteins that comprise a VLP can spontaneously self-assemble to form the particle or can assemble through several intermediate steps. This work addresses the characterization, manipulation and purification of a chimeric simian-human immunodeficiency VLP constructed by fusion of SIV matrix protein (p17) and HIV-1 p6 accessory protein. This fusion protein assembles as spherical nanoparticles of about 80 nm in diameter that are released to the culture media when expressed in HEK 293T cells. A simple two-step purification process was used to purify these nanoparticles. Also, different approaches - multiple-transfections or chemical coupling - were performed to target manipulation. Finally, a new approach for the production of these virus-like particles is described where the structural protein subunits are used and their assembly is promoted in vitro.
C1 [Soares, S. S.; Pedro, L.; Ferreira, G. N. M.] Univ Algarve, Ctr Mol & Struct Biomed, Inst Biotechnol & Biomed, CBME IBB,LA, Faro, Portugal.
RP Soares, SS (reprint author), Univ Algarve, Ctr Mol & Struct Biomed, Inst Biotechnol & Biomed, CBME IBB,LA, Faro, Portugal.
EM sssoares@ualg.pt; lpedro@ualg.pt; gferrei@ualg.pt
RI Ferreira, Guilherme/J-3310-2013
OI Ferreira, Guilherme/0000-0002-0210-0211
CR Accola MA, 1999, J VIROL, V73, P9992
   Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Cevc G., 1993, PHOSPHOLIPID HDB
   Costa MJL, 2007, BIOTECHNOL APPL BIOC, V48, P35, DOI 10.1042/BA20060208
   EMI N, 1991, J VIROL, V65, P1202
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Giddings AM, 1998, VIROLOGY, V248, P108, DOI 10.1006/viro.1998.9284
   Gonzalez SA, 1996, J VIROL, V70, P6384
   GONZALEZ SA, 1993, VIROLOGY, V194, P548, DOI 10.1006/viro.1993.1293
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   HAFFAR OK, 1990, J VIROL, V64, P3100
   Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017
   Kondo E, 1996, J VIROL, V70, P159
   KONDO E, 1995, J VIROL, V69, P2759
   Langel U., 2007, HDB CELL PENETRATING
   LU YL, 1995, J VIROL, V69, P6873
   Nitkiewicz J, 2004, J NEUROVIROL, V10, P400, DOI 10.1080/13550280490890097
   PARENT LJ, 1995, J VIROL, V69, P5455
   Pedro L, 2008, CHEM ENG TECHNOL, V31, P815, DOI 10.1002/ceat.200800176
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Wang JJ, 1999, AIDS, V13, P281, DOI 10.1097/00002030-199902040-00018
   YAMSHCHIKOV GV, 1995, VIROLOGY, V214, P50, DOI 10.1006/viro.1995.9955                                                          
NR 23
TC 0
Z9 0
U1 0
U2 5
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 978-1-4673-4524-8
PY 2012
PG 6
WC Engineering, Biomedical; Engineering, Electrical & Electronic
SC Engineering
GA BCK22
UT WOS:000310431000017
DA 2018-01-05
ER

PT J
AU Li, CL
   Huang, CC
   Chen, WH
   Chiang, CK
   Chang, HT
AF Li, Chi-Lin
   Huang, Chih-Ching
   Chen, Wei-Hsi
   Chiang, Cheng-Kang
   Chang, Huan-Tsung
TI Peroxidase mimicking DNA-gold nanoparticles for fluorescence detection
   of the lead ions in blood
SO ANALYST
LA English
DT Article
ID FREE COLORIMETRIC DETECTION; HYDROGEN-PEROXIDE; DEOXYRIBONUCLEIC-ACID;
   OXIDE NANOPARTICLES; CATALYTIC-ACTIVITY; GLUCOSE DETECTION; WHOLE-BLOOD;
   ANTI-HIV; MERCURY(II); DNAZYME
AB Oligonucleotide (T30695) modified gold nanoparticles (T30695-Au NPs) have been prepared and employed for quantification of lead ions (Pb2+) in blood. The detection of Pb2+ ions is through the formation of Au-Pb alloys and oligonucleotide-Pb2+ complexes that catalyze the H2O2-mediated oxidation of non-fluorescent Amplex UltraRed (AUR) to form a highly fluorescent oxidized AUR product. Surface-assisted laser desorption/ionization time-of-flight mass spectrometry (SALDI-TOF MS) and inductively coupled plasma mass spectrometry (ICP-MS) revealed the formation of Au-Pb alloys on the surfaces of the 40T30695-Au NPs (i.e., the system featuring 40 molecules of T30695 per Au NP) in the presence of Pb2+ ions, leading to increased catalytic activity for the H2O2-mediated oxidation of AUR. The fluorescence intensity (excitation/emission maxima: ca. 540/584 nm) of the oxidized AUR product is proportional to the concentration of Pb2+ ions over the range 0.1-100 nM, with a linear correlation (R-2 = 0.99). The 40T30695-Au NP/AUR probe is highly selective toward Pb2+ ions (by at least 200-fold over other tested metal ions). The 40T30695-Au NPs/AUR probe provided limits of detection (LOD, at a signal-to-noise ratio 3) for Pb2+ ions of 0.05 and 0.1 nM, in Tris-acetate solution (5 mM, pH 8.0) without and with salt (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1 mM CaCl2), respectively. Without conducting tedious sample pretreatment, the approach allows detection of Pb2+ ions in blood samples, showing the potential of the 40T30695-Au NPs/AUR assay for on-site and real-time detection of Pb2+ ions in biological samples.
C1 [Li, Chi-Lin; Chiang, Cheng-Kang; Chang, Huan-Tsung] Natl Taiwan Univ, Dept Chem, Taipei 10617, Taiwan.
   [Huang, Chih-Ching] Natl Taiwan Ocean Univ, Inst Biosci & Biotechnol, Keelung 20224, Taiwan.
   [Chen, Wei-Hsi] Inst Nucl Energy Res, Chem Anal Div, Tao Yuan 325, Taiwan.
RP Chang, HT (reprint author), Natl Taiwan Univ, Dept Chem, 1 Sect 4,Roosevelt Rd, Taipei 10617, Taiwan.
EM changht@ntu.edu.tw
RI Chang, Huan-Tsung/C-1183-2011
OI Huang, Chih-Ching/0000-0002-0363-1129; Chang,
   Huan-Tsung/0000-0002-5393-1410
FU National Science Council of Taiwan [NSC 98-2113M-002-011-MY3]; National
   Taiwan Health Research Institutes Taiwan [NHRI-EX100-10047NI]; Institute
   of Nuclear Energy Research [1002001INER082]
FX This study was supported by the National Science Council of Taiwan
   (contract NSC 98-2113M-002-011-MY3), the National Taiwan Health Research
   Institutes Taiwan (contract NHRI-EX100-10047NI), and the Institute of
   Nuclear Energy Research (contract 1002001INER082).
CR Asati A, 2009, ANGEW CHEM INT EDIT, V48, P2308, DOI 10.1002/anie.200805279
   Bellinger DC, 2004, PEDIATRICS, V113, P1016
   Bracey CL, 2009, CHEM SOC REV, V38, P2231, DOI 10.1039/b817729p
   Brainina K, 1996, ANAL CHIM ACTA, V330, P175, DOI 10.1016/0003-2670(96)00181-X                                                    
   Burke LD, 2002, GOLD BULL, V35, P3, DOI 10.1007/BF03214831                                                              
   Chen CK, 2010, BIOSENS BIOELECTRON, V25, P1922, DOI 10.1016/j.bios.2010.01.005
   Chen SJ, 2008, BIOSENS BIOELECTRON, V23, P1749, DOI 10.1016/j.bios.2008.02.008
   Chen YY, 2009, ANAL CHEM, V81, P9433, DOI 10.1021/ac9018268
   Chillrud SN, 2005, APPL GEOCHEM, V20, P807, DOI 10.1016/j.apgeochem.2004.11.002
   Dai ZH, 2009, CHEM-EUR J, V15, P4321, DOI 10.1002/chem.200802158
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Ding N, 2010, ANAL CHEM, V82, P5897, DOI 10.1021/ac100597s
   Elbaz J, 2008, CHEM COMMUN, P1569, DOI 10.1039/b716774a
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Gao SY, 2011, ANAL BIOANAL CHEM, V399, P91, DOI 10.1007/s00216-010-4276-5
   Garcia MA, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/28/283001
   Ghosh SK, 2007, CHEM REV, V107, P4797, DOI 10.1021/cr0680282
   GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008                                                             
   Hazarika Pompi, 2004, V283, P295
   He WW, 2011, BIOMATERIALS, V32, P1139, DOI 10.1016/j.biomaterials.2010.09.040
   He WW, 2010, CHEM MATER, V22, P2988, DOI 10.1021/cm100393v
   Huang CC, 2007, ANGEW CHEM INT EDIT, V46, P6824, DOI 10.1002/anie.200700803
   Huang CC, 2009, J MATER CHEM, V19, P755, DOI 10.1039/b808594c
   Huang CC, 2006, ANAL CHEM, V78, P8332, DOI 10.1021/ac061487i
   Huang KW, 2010, BIOSENS BIOELECTRON, V25, P984, DOI 10.1016/j.bios.2009.09.006
   Hung YL, 2010, TALANTA, V82, P516, DOI 10.1016/j.talanta.2010.05.004
   Jian JW, 2011, CHEM-EUR J, V17, P2374, DOI 10.1002/chem.201002825
   Jing N, 2000, J BIOL CHEM, V275, P3421, DOI 10.1074/jbc.275.5.3421
   Jing N, 2003, DNA CELL BIOL, V22, P685, DOI 10.1089/104454903770946665
   Jv Y, 2010, CHEM COMMUN, V46, P8017, DOI 10.1039/c0cc02698k
   Lanphear BP, 2002, J PEDIATR-US, V140, P40, DOI 10.1067/mpd.2002.120513
   Lee HY, 2009, ANGEW CHEM INT EDIT, V48, P1239, DOI 10.1002/anie.200804714
   Li CL, 2011, ANAL CHEM, V83, P225, DOI 10.1021/ac1028787
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li T, 2010, J AM CHEM SOC, V132, P13156, DOI 10.1021/ja105849m
   Lien CW, 2012, CHEM COMMUN, V48, P7952, DOI 10.1039/c2cc32833j
   Lin YW, 2011, ANALYST, V136, P863, DOI 10.1039/c0an00652a
   Liu CW, 2008, CHEM COMMUN, P2242, DOI 10.1039/b719856f
   Liu CW, 2008, LANGMUIR, V24, P8346, DOI 10.1021/la800589m
   Liu J, 2005, J AM CHEM SOC, V127, P12677, DOI 10.1021/ja053567u
   Liu JW, 2003, J AM CHEM SOC, V125, P6642, DOI 10.1021/ja034775u
   Liu M, 2012, CHEM COMMUN, V48, P7055, DOI 10.1039/c2cc32406g
   Liu M, 2012, ACS NANO, V6, P3142, DOI 10.1021/nn3010922
   Long YJ, 2011, CHEM COMMUN, V47, P11939, DOI 10.1039/c1cc14294a
   Lu Y, 2009, WIRES NANOMED NANOBI, V1, P35, DOI 10.1002/wnan.021
   Mazumdar D, 2010, CHEM COMMUN, V46, P1416, DOI 10.1039/b917772h
   Mucic RC, 1998, J AM CHEM SOC, V120, P12674, DOI 10.1021/ja982721s                                                               
   Nagraj N, 2009, CHEM COMMUN, P4103, DOI 10.1039/b903059j
   Needleman H, 2004, ANNU REV MED, V55, P209, DOI 10.1146/annurev.med.55.091902.103653
   Do NQ, 2011, NUCLEIC ACIDS RES, V39, P9448, DOI 10.1093/nar/gkr539
   Palmer CD, 2006, SPECTROCHIM ACTA B, V61, P980, DOI 10.1016/j.sab.2006.09.001
   PAPARAZZO E, 1995, SURF INTERFACE ANAL, V23, P69, DOI 10.1002/sia.740230205                                                           
   Pirmohamed T, 2010, CHEM COMMUN, V46, P2736, DOI 10.1039/b922024k
   Schmidbaur H, 2000, GOLD BULL, V33, P3, DOI 10.1007/BF03215477                                                              
   SEQUARIS JM, 1990, ELECTROANAL, V2, P35, DOI 10.1002/elan.1140020108
   Shen L, 2008, ANAL CHEM, V80, P6323, DOI 10.1021/ac800601y
   Snyrychova I, 2009, PHYSIOL PLANTARUM, V135, P1, DOI 10.1111/j.1399-3054.2008.01176.x
   Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783
   Song YJ, 2010, CHEM-EUR J, V16, P3617, DOI 10.1002/chem.200902643
   Tanaka A, 2003, SOLID STATE COMMUN, V126, P191, DOI 10.1016/S0038-1098(03)00105-4
   Towne V, 2004, ANAL BIOCHEM, V334, P290, DOI 10.1016/j.ab.2004.07.037
   Wang CI, 2012, ANAL CHIM ACTA, V745, P124, DOI 10.1016/j.aca.2012.07.041
   Wang H, 2009, J AM CHEM SOC, V131, P8221, DOI 10.1021/ja901132y
   Wang S, 2012, CHEMPHYSCHEM, V13, P1199, DOI 10.1002/cphc.201100906
   Wang XX, 2011, BIOSENS BIOELECTRON, V26, P3614, DOI 10.1016/j.bios.2011.02.014
   Wang ZD, 2008, ADV MATER, V20, P3263, DOI 10.1002/adma.200703181
   Wei H, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/9/095501
   Wen XD, 2009, J AM CHEM SOC, V131, P2199, DOI 10.1021/ja806884a
   Xiang Y, 2009, J AM CHEM SOC, V131, P15352, DOI 10.1021/ja905854a
   Yantasee W, 2007, ENVIRON HEALTH PERSP, V115, P1683, DOI 10.1289/ehp.10190
   Yoosaf K, 2007, J PHYS CHEM C, V111, P12839, DOI 10.1021/jp073923q
   Yu FQ, 2009, BIOMATERIALS, V30, P4716, DOI 10.1016/j.biomaterials.2009.05.005
   Zhang K, 2011, LANGMUIR, V27, P2796, DOI 10.1021/la104566e
   Zhao W, 2007, LANGMUIR, V23, P8597, DOI 10.1021/la7003276
   Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391
NR 75
TC 22
Z9 26
U1 3
U2 129
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
J9 ANALYST
JI Analyst
PY 2012
VL 137
IS 22
BP 5222
EP 5228
DI 10.1039/c2an35599j
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 020UF
UT WOS:000309839400009
PM 23032966
DA 2018-01-05
ER

PT S
AU Di Gianvincenzo, P
   Chiodo, F
   Marradi, M
   Penades, S
AF Di Gianvincenzo, Paolo
   Chiodo, Fabrizio
   Marradi, Marco
   Penades, Soledad
BE Duzgunes, N
TI GOLD MANNO-GLYCONANOPARTICLES FOR INTERVENING IN HIV GP120
   CARBOHYDRATE-MEDIATED PROCESSES
SO NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS,
   ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODY 2G12; FUSION
   INHIBITOR T-20; NMR-SPECTROSCOPY; GLYCOPROTEIN GP120; LIGAND-BINDING;
   AIDS PATIENTS; HTLV-III; DC-SIGN; TYPE-1
AB After nearly three decades since the discovery of human immunodeficiency virus (HIV) (1983), no effective vaccine or microbicide is available, and the virus continues to infect millions of people worldwide each year. HIV antiretroviral drugs reduce the death rate and improve the quality of life in infected patients, but they are not able to completely remove HIV from the body. The glycoprotein gp120, part of the envelope glycoprotein (Env) of HIV, is responsible for virus entry and infection of host cells. High-mannose type glycans that decorate gp120 are involved in different carbohydrate-mediated HIV binding. We have demonstrated that oligomannoside-coated gold nanoparticles (manno-GNPs) are able to interfere with HIV high-mannose glycan-mediated processes. In this chapter, we describe the methods for the preparation and characterization of manno-GNPs and the experiments performed by means of SPR and STD-NMR techniques to evaluate the ability of manno-GNPs to inhibit 2G12 antibody binding to gp120. The antibody 2G12-mediated HIV neutralization and the lectin DC-SIGN-mediated HIV trans-infection in cellular systems are also described.
C1 [Di Gianvincenzo, Paolo; Chiodo, Fabrizio; Marradi, Marco; Penades, Soledad] CIC BiomaGUNE, Lab GlycoNanotechnol, Biofunct Nanomat Unit, San Sebastian, Spain.
   [Marradi, Marco; Penades, Soledad] Biomat & Nanomed CIBER BBN, Biomed Res Networking Ctr Bioengn, San Sebastian, Spain.
RP Di Gianvincenzo, P (reprint author), CIC BiomaGUNE, Lab GlycoNanotechnol, Biofunct Nanomat Unit, San Sebastian, Spain.
RI Marradi, Marco/H-7247-2012; Chiodo, Fabrizio/R-1121-2017; biomaGUNE,
   CIC/J-9136-2014
OI Chiodo, Fabrizio/0000-0003-3619-9982; biomaGUNE, CIC/0000-0001-7690-0660
CR ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290                                                         
   Angulo J, 2010, CHEM-EUR J, V16, P7803, DOI 10.1002/chem.200903528
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291
   Barrientos AG, 2009, CARBOHYD RES, V344, P1474, DOI 10.1016/j.carres.2009.04.029
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e
   Berger S., 2004, 200 MORE NMR EXPT, P298
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Bravman T, 2006, ANAL BIOCHEM, V358, P281, DOI 10.1016/j.ab.2006.08.005
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   de la Fuente JM, 2001, ANGEW CHEM INT EDIT, V40, P2258
   De la Fuente JM, 2006, BBA-GEN SUBJECTS, V1760, P636, DOI 10.1016/j.bbagen.2005.12.001
   De Souza AC, 2006, METHOD ENZYMOL, V417, P221, DOI 10.1016/S0076-6879(06)17016-0
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g                                                               
   Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179
   Enriquez-Navas P. M., 2011, CHEM-EUR J, V17, P1369
   Fang GW, 1999, NAT MED, V5, P239
   FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17
   FENOUILLET E, 1994, TRENDS BIOCHEM SCI, V19, P65, DOI 10.1016/0968-0004(94)90034-5                                                    
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Garcia I, 2010, NANOMEDICINE-UK, V5, P777, DOI [10.2217/nnm.10.48, 10.2217/NNM.10.48]
   Garcia-Perez J, 2007, J MED VIROL, V79, P127, DOI 10.1002/jmv.20770
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Jimenez-Barbero J., 2003, NMR SPECTROSCOPY GLY
   Kabanova A, 2010, GLYCOCONJUGATE J, V27, P501, DOI 10.1007/s10719-010-9295-0
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d
   Marradi M., 2010, ADV CARBOHYD CHEM BI, V64, P212
   Marradi M, 2011, J MOL BIOL, V410, P798, DOI 10.1016/j.jmb.2011.03.042
   Martinez-Avila O., 2009, CHEMBIOCHEM, V10, P1806
   Martinez-Avila O., 2009, CHEM-EUR J, V15, P8974
   Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q
   Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233                                                          
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Platt EJ, 1998, J VIROL, V72, P2855
   Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3
   Rich RL, 2003, TRENDS MICROBIOL, V11, P124, DOI 10.1016/S0966-842X(03)00025-8
   SALMINEN MO, 1995, VIROLOGY, V213, P80, DOI 10.1006/viro.1995.1548
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Trkola A, 1996, J VIROL, V70, P1100
   van Kasteren SI, 2009, P NATL ACAD SCI USA, V106, P18, DOI 10.1073/pnas.0806787106
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
NR 53
TC 14
Z9 14
U1 2
U2 19
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-391858-1
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2012
VL 509
BP 21
EP 40
DI 10.1016/B978-0-12-391858-1.00002-2
PG 20
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BBU36
UT WOS:000308198000002
PM 22568899
DA 2018-01-05
ER

PT S
AU Mahajan, SD
   Law, WC
   Aalinkeel, R
   Reynolds, J
   Nair, BB
   Yong, KT
   Roy, I
   Prasad, PN
   Schwartz, SA
AF Mahajan, Supriya D.
   Law, Wing-Cheung
   Aalinkeel, Ravikumar
   Reynolds, Jessica
   Nair, Bindukumar B.
   Yong, Ken-Tye
   Roy, Indrajit
   Prasad, Paras N.
   Schwartz, Stanley A.
BE Duzgunes, N
TI NANOPARTICLE-MEDIATED TARGETED DELIVERY OF ANTIRETROVIRALS TO THE BRAIN
SO NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS,
   ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID PROTEASE INHIBITORS AMPRENAVIR; LIQUID-CHROMATOGRAPHIC ASSAY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; QUANTUM DOTS; HIV-1 ENCEPHALITIS;
   DRUG-DELIVERY; HUMAN PLASMA; RT-PCR; BARRIER; SAQUINAVIR
AB Nanotechnology offers a new platform for therapeutic delivery of antiretrovirals to the central nervous system (CNS) where human immunodeficiency virus (HIV-1) is sequestered in patients with HIV-1-associated neurological disorders (HAND). HAND is a spectrum of neurocognitive disorders that continue to persist in HIV-1-infected patients in spite of successful highly active antiretroviral therapy (HAART). Nanoformulated antiretroviral drugs offer multifunctionality, that is, the ability to package multiple diagnostic and therapeutic agents within the same nanocomposite, along with the added provisions of site-directed delivery, delivery across the blood brain barrier (BBB), and controlled release of therapeutics. We have stably incorporated the antiretroviral drug, Amprenavir, within a transferrin (Tf)-conjugated quantum dot (QD), and evaluated the transversing ability of this Tf-QD-Amprenavir nanoplex across an in vitro BBB model and analyzed its antiviral efficacy in HIV-1-infected monocytes. We describe methods for synthesis of the Tf-QD-Amprenavir nanoplex and approaches to evaluate both its BBB transversing capability and antiviral efficacy.
C1 [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Reynolds, Jessica; Nair, Bindukumar B.; Schwartz, Stanley A.] SUNY Buffalo, Innovat Ctr, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY 14260 USA.
   [Law, Wing-Cheung; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore.
   [Roy, Indrajit] Univ Delhi, Dept Chem, Delhi 110007, India.
RP Mahajan, SD (reprint author), SUNY Buffalo, Innovat Ctr, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY 14260 USA.
OI Law, Wing Cheung/0000-0003-3855-6170
FU NIDA NIH HHS [1R21DA030108-01, K01DA024577]; NLM NIH HHS
   [R01LM009726-01]
CR Aquaro S, 2004, ANTIVIR RES, V61, P133, DOI 10.1016/j.antiviral.2003.09.002
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   BRADBURY MWB, 1993, EXP PHYSIOL, V78, P453, DOI 10.1113/expphysiol.1993.sp003698                                                
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Conway B, 2000, EXPERT OPIN INV DRUG, V9, P371, DOI 10.1517/13543784.9.2.371
   Dailly E, 2001, J CHROMATOGR B, V758, P129, DOI 10.1016/S0378-4347(01)00117-7
   De Luca A, 2002, NEUROLOGY, V59, P342, DOI 10.1212/WNL.59.3.342                                                            
   Dickinson L, 2005, J CHROMATOGR B, V829, P82, DOI 10.1016/j.jchromb.2005.09.032
   Ding H, 2011, NANOSCALE, V3, P1813, DOI 10.1039/c1nr00001b
   Enting RH, 1998, AIDS, V12, P1941, DOI 10.1097/00002030-199815000-00005
   Erogbogbo F, 2011, ACS NANO, V5, P413, DOI 10.1021/nn1018945
   Erogbogbo F, 2010, ACS NANO, V4, P5131, DOI 10.1021/nn101016f
   Gaillard Pieter J, 2005, Expert Opin Drug Deliv, V2, P299, DOI 10.1517/17425247.2.2.299
   Hallmann R, 2000, ENDOTHELIUM-J ENDOTH, V7, P135, DOI 10.3109/10623320009072208                                                       
   Hu R, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/14/145105
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   Law WC, 2009, SMALL, V5, P1302, DOI 10.1002/smll.200801555
   Letendre Scott L, 2009, Top HIV Med, V17, P46
   Li JJ, 2003, J AM CHEM SOC, V125, P12567, DOI 10.1021/ja0363563
   Liu LW, 2011, ANALYST, V136, P1881, DOI 10.1039/c0an01017k
   Mahajan SD, 2008, J CLIN IMMUNOL, V28, P528, DOI 10.1007/s10875-008-9208-1
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Manna L, 2002, J AM CHEM SOC, V124, P7136, DOI 10.1021/ja025946i
   Meyer TPH, 2005, J IMMUNOL METHODS, V307, P150, DOI 10.1016/j.jim.2005.10.004
   Michalet X, 2006, CHEM REV, V106, P1785, DOI 10.1021/cr0404343
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Patel MM, 2009, CNS DRUGS, V23, P35, DOI 10.2165/0023210-200923010-00003
   Pathak S, 2006, J NEUROSCI, V26, P1893, DOI 10.1523/JNEUROSCI.3847-05.2006
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Prasad P. N., 2004, NANOPHOTONICS
   Prasad P. N., 2003, INTRO BIOPHOTONICS
   Qian J, 2007, J PHYS CHEM B, V111, P6969, DOI 10.1021/jp070620n
   Samia ACS, 2003, J AM CHEM SOC, V125, P15736, DOI 10.1021/ja0386905
   Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6
   Schroeder U, 1998, J PHARM SCI, V87, P1305, DOI 10.1021/js980084y
   Shapshak P, 2011, AIDS, V25, P123, DOI 10.1097/QAD.0b013e328340fd42
   Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033
   Singer EJ, 2010, NEUROL CLIN, V28, P253, DOI 10.1016/j.ncl.2009.09.018
   Sparidans RW, 2000, J CHROMATOGR B, V742, P185, DOI 10.1016/S0378-4347(00)00163-8                                                   
   Tu CQ, 2011, ACS MED CHEM LETT, V2, P285, DOI 10.1021/ml1002844
   Wang YY, 2009, IMMUNOTHERAPY, V1, P983, DOI [10.2217/imt.09.75, 10.2217/IMT.09.75]
   Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m
   Yong KT, 2010, CHEM COMMUN, V46, P7136, DOI 10.1039/c0cc00667j
   Yong KT, 2009, SMALL, V5, P1997, DOI 10.1002/smll.200900547
   Yong KT, 2009, ACS NANO, V3, P502, DOI 10.1021/nn8008933
NR 48
TC 14
Z9 15
U1 1
U2 18
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-391858-1
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2012
VL 509
BP 41
EP 60
DI 10.1016/B978-0-12-391858-1.00003-4
PG 20
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BBU36
UT WOS:000308198000003
PM 22568900
DA 2018-01-05
ER

PT S
AU Trabulo, S
   Cardoso, AL
   Cardoso, AMS
   Duzgunes, N
   Jurado, AS
   de Lima, MCP
AF Trabulo, Sara
   Cardoso, Ana L.
   Cardoso, Ana M. S.
   Duezguenes, Nejat
   Jurado, Amalia S.
   Pedroso de Lima, Maria C.
BE Duzgunes, N
TI CELL-PENETRATING PEPTIDE-BASED SYSTEMS FOR NUCLEIC ACID DELIVERY: A
   BIOLOGICAL AND BIOPHYSICAL APPROACH
SO NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS,
   ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID HUMAN IMMUNODEFICIENCY VIRUS; ANTISENSE OLIGONUCLEOTIDES; INTRACELLULAR
   DELIVERY; MEMBRANE INTERACTION; LIPID-COMPOSITION; MAMMALIAN-CELLS;
   SIRNA DELIVERY; GENE DELIVERY; TAT PEPTIDE; NANO DEVICE
AB The increasing knowledge on the genetic basis of disease provides a platform for the development of promising gene-targeted therapies that can be applied to numerous pathological conditions, including cancer. Such genetic-based approaches involve the use of nucleic acids as therapeutic agents, either for the insertion or for the repair and regulation of specific genes. However, despite the huge pharmacological potential of these molecules, their application remains highly dependent on the development of delivery systems capable of mediating efficient cellular uptake. The discovery of a class of small peptides, the so-called cell-penetrating peptides (CPPs), which are able to very efficiently cross cell membranes through a mechanism that is independent of membrane receptors or transporters and avoids lysosomal enzymatic degradation, has been enthusiastically considered of key interest to improve noninvasive cellular delivery of therapeutic molecules. A large number of CPPs have been applied successfully to mediate the intracellular delivery of nucleic acids, including the S4(13)PV peptide for which interactions with membranes and resulting biological effects are illustrated in this chapter. Here, we provide a description of the experimental procedures for the preparation of CPP-based nucleic acid complexes and assessment of their formation, the selection of those protocols leading to the most efficient complexes, the biophysical characterization of CPP membrane interactions, and the evaluation of the biological and cytotoxic activity of the complexes.
C1 [Trabulo, Sara; Cardoso, Ana L.; Cardoso, Ana M. S.; Jurado, Amalia S.; Pedroso de Lima, Maria C.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
   [Duezguenes, Nejat] Univ Pacific, Dept Biomed Sci, Arthur A Dugoni Sch Dent, San Francisco, CA USA.
   [Jurado, Amalia S.; Pedroso de Lima, Maria C.] Univ Coimbra, Dept Life Sci, Coimbra, Portugal.
RP Trabulo, S (reprint author), Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
RI Cardoso, Ana/D-6563-2014; Cardoso, Ana Luisa/M-4161-2013
OI Cardoso, Ana/0000-0002-1629-4782; Cardoso, Ana
   Luisa/0000-0001-5145-4561; S. Jurado, Amalia/0000-0001-7095-5337;
   Pedroso de Lima, Maria/0000-0003-1844-5027
CR Alves ID, 2008, BBA-GEN SUBJECTS, V1780, P948, DOI 10.1016/j.bbagen.2008.04.004
   ANDRICH MP, 1976, BIOCHEMISTRY-US, V15, P1257, DOI 10.1021/bi00651a013
   BARTLETT GR, 1959, J BIOL CHEM, V234, P469
   Cardoso A, 2009, METHOD ENZYMOL, V465, P267, DOI 10.1016/S0076-6879(09)65014-X
   Cardoso AMS, 2011, BBA-BIOMEMBRANES, V1808, P341, DOI 10.1016/j.bbamem.2010.09.026
   CHEN LA, 1977, J BIOL CHEM, V252, P2163
   Cherry R. J., 2005, STRUCTURE BIOL MEMBR, P389
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Duzgunes N, 2003, METHOD ENZYMOL, V367, P23
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gennis R. B., 1989, BIOMEMBRANES MOL STR
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guillen J, 2008, BIOCHEMISTRY-US, V47, P8214, DOI 10.1021/bi800814q
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hohne G. W. H., 1996, DIFFERENTIAL SCANNIN
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   JURADO AS, 1991, BIOCHEM BIOPH RES CO, V176, P356, DOI 10.1016/0006-291X(91)90932-W
   JURADO AS, 1991, ARCH BIOCHEM BIOPHYS, V289, P167, DOI 10.1016/0003-9861(91)90457-T
   Kang SH, 1998, BIOCHEMISTRY-US, V37, P6235, DOI 10.1021/bi980300h
   Khalil IA, 2007, GENE THER, V14, P682, DOI 10.1038/sj.gt.3302910
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024
   Kogure K, 2007, J CONTROL RELEASE, V122, P246, DOI 10.1016/j.jconrel.2007.06.018
   Kole R, 2004, ACTA BIOCHIM POL, V51, P373
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Mano M, 2006, BBA-BIOMEMBRANES, V1758, P336, DOI 10.1016/j.bbamem.2006.01.014
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200
   Morein S, 2000, BIOPHYS J, V78, P2475, DOI 10.1016/S0006-3495(00)76792-0                                                   
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Pooga M, 1998, FASEB J, V12, P67
   PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002
   Rosa SMLJ, 2000, BBA-MOL CELL BIOL L, V1487, P286, DOI 10.1016/S1388-1981(00)00122-0                                                   
   Ruthaven N. A., 2005, STRUCTURE BIOL MEMBR, P53
   Sazani P, 2003, Prog Mol Subcell Biol, V31, P217
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHINITZKY M, 1974, J BIOL CHEM, V249, P2652
   Tazi J, 2009, BBA-MOL BASIS DIS, V1792, P14, DOI 10.1016/j.bbadis.2008.09.017
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Trabulo S, 2011, MOL PHARMACEUT, V8, P1120, DOI 10.1021/mp100426e
   Trabulo S, 2008, J GENE MED, V10, P1210, DOI 10.1002/jgm.1247
   Trabulo S, 2010, J CONTROL RELEASE, V145, P149, DOI 10.1016/j.jconrel.2010.03.021
   TROTTER PJ, 1989, BIOCHIM BIOPHYS ACTA, V982, P131, DOI 10.1016/0005-2736(89)90183-1
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Zoonens M, 2008, BIOPHYS J, V95, P225, DOI 10.1529/biophysj.107.124156
NR 51
TC 5
Z9 5
U1 1
U2 22
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-391858-1
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2012
VL 509
BP 277
EP 300
DI 10.1016/B978-0-12-391858-1.00014-9
PG 24
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BBU36
UT WOS:000308198000014
PM 22568911
DA 2018-01-05
ER

PT J
AU Xu, J
   Jiang, BY
   Xie, JQ
   Xiang, Y
   Yuan, R
   Chai, YQ
AF Xu, Jin
   Jiang, Bingying
   Xie, Jiaqing
   Xiang, Yun
   Yuan, Ruo
   Chai, Yaqin
TI Sensitive point-of-care monitoring of HIV related DNA sequences with a
   personal glucometer
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID UNPURIFIED PCR AMPLICONS; ELECTROCHEMICAL BIOSENSOR; GLUCOSE METERS;
   HYBRIDIZATION INDICATOR; ELECTRONIC TRANSDUCTION; GRAPHITE-ELECTRODES;
   METHYLENE-BLUE; QUANTUM-DOT; AMPLIFICATION; SENSORS
AB The hybridizations between the HIV target DNA and the capture probes as well as the signal probes conjugated to the multi-invertase/nanoparticle composites lead to the conversion of sucrose to glucose, which is monitored by the personal glucometer and provides quantitative digital readings for point-of-care diagnosis of HIV DNA fragments.
C1 [Jiang, Bingying; Xie, Jiaqing] Chongqing Univ Technol, Sch Chem & Chem Engn, Chongqing 400054, Peoples R China.
   [Xu, Jin; Xiang, Yun; Yuan, Ruo; Chai, Yaqin] Southwest Univ, Sch Chem & Chem Engn, Minist Educ, Key Lab Luminescence & Real Time Anal, Chongqing 400715, Peoples R China.
RP Jiang, BY (reprint author), Chongqing Univ Technol, Sch Chem & Chem Engn, Chongqing 400054, Peoples R China.
EM jiangby@cqut.edu.cn; yunatswu@swu.edu.cn
FU National Natural Science Foundation of China [21275004, 20905062,
   21075100, 21173274]; Scientific Research Foundation for the Returned
   Overseas Chinese Scholars, Fundamental Research Funds for the Central
   Universities [XDJK2012A004]; Southwest University [SWUB2008078]
FX This work is supported by the National Natural Science Foundation of
   China (Nos. 21275004, 20905062, 21075100, and 21173274), the Scientific
   Research Foundation for the Returned Overseas Chinese Scholars,
   Fundamental Research Funds for the Central Universities (XDJK2012A004)
   and research funds from Southwest University (SWUB2008078).
CR Ahmed MU, 2007, ANALYST, V132, P431, DOI 10.1039/b615242b
   Azek F, 2000, ANAL BIOCHEM, V284, P107, DOI 10.1006/abio.2000.4692
   Bakker E, 2006, ANAL CHEM, V78, P3965, DOI 10.1021/ac060637m
   Blank M, 2005, CURR OPIN CHEM BIOL, V9, P336, DOI 10.1016/j.cbpa.2005.06.011
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chu LQ, 2007, ANGEW CHEM INT EDIT, V46, P4944, DOI 10.1002/anie.200605247
   CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x
   Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475
   Dominguez E, 2004, ANAL CHEM, V76, P3132, DOI 10.1021/ac0499672
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Du BA, 2006, ANGEW CHEM INT EDIT, V45, P8022, DOI 10.1002/anie.200603331
   Erdem A, 2007, TALANTA, V74, P318, DOI 10.1016/j.talanta.2007.10.012
   Famulok M, 2005, CURR OPIN MOL THER, V7, P137
   Famulok M, 2005, CHEMBIOCHEM, V6, P19, DOI 10.1002/cbic.200400299
   Famulok M, 2002, TRENDS BIOTECHNOL, V20, P462, DOI 10.1016/S0167-7799(02)02063-2
   Fan CH, 2005, TRENDS BIOTECHNOL, V23, P186, DOI 10.1016/j.tibtech.2005.02.005
   Fixe F, 2004, BIOSENS BIOELECTRON, V19, P1591, DOI 10.1016/j.bios.2003.12.012
   Gaylord BS, 2002, P NATL ACAD SCI USA, V99, P10954, DOI 10.1073/pnas.162375999
   Guo YS, 2011, CHEM COMMUN, V47, P1595, DOI 10.1039/c0cc03921g
   Hanrahan G, 2004, J ENVIRON MONITOR, V6, P657, DOI 10.1039/b403975k
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Jin Y, 2007, BIOSENS BIOELECTRON, V22, P1126, DOI 10.1016/j.bios.2006.04.011
   Jung YJ, 2007, J AM CHEM SOC, V129, P9349, DOI 10.1021/ja0676105
   Karadeniz H, 2007, ELECTROCHEM COMMUN, V9, P2167, DOI 10.1016/j.elecom.2007.05.016
   Kelley SO, 1999, NUCLEIC ACIDS RES, V27, P4830, DOI 10.1093/nar/27.24.4830
   Kerman K, 2002, ANAL CHIM ACTA, V462, P39, DOI 10.1016/S0003-2670(02)00308-2
   Lai RY, 2006, P NATL ACAD SCI USA, V103, P4017, DOI 10.1073/pnas.0511325103
   Li HK, 2005, ANGEW CHEM INT EDIT, V44, P5100, DOI 10.1002/anie.200500403
   Makrigiorgos GM, 2002, NAT BIOTECHNOL, V20, P936, DOI 10.1038/nbt724
   Miao WJ, 2003, ANAL CHEM, V75, P5825, DOI 10.1021/ac034596v
   Montagnana M, 2009, CLIN CHIM ACTA, V402, P7, DOI 10.1016/j.cca.2009.01.002
   Nie LB, 2007, J NANOSCI NANOTECHNO, V7, P560, DOI 10.1166/jnn.2007.126
   Nielsen M, 2004, APPL ENVIRON MICROB, V70, P6551, DOI 10.1128/AEM.70.11.6551-6558.2004
   Niemeyer CM, 1999, ANGEW CHEM INT EDIT, V38, P2865, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2865::AID-ANIE2865>3.0.CO;2-F            
   Oliveira-Brett AM, 2002, ANAL BIOANAL CHEM, V373, P717, DOI 10.1007/s00216-002-1259-1
   Ozsoz M, 2003, ANAL CHEM, V75, P2181, DOI 10.1021/ac026212r
   Patolsky F, 2001, J AM CHEM SOC, V123, P5194, DOI 10.1021/ja0036256
   Patolsky F, 2001, NAT BIOTECHNOL, V19, P253, DOI 10.1038/85704                                                                   
   Peterson AW, 2002, J AM CHEM SOC, V124, P14601, DOI 10.1021/ja0279996
   Pumera M, 2005, LANGMUIR, V21, P9625, DOI 10.1021/la051917k
   Qian XQ, 2010, CHEM-EUR J, V16, P14261, DOI 10.1002/chem.201002585
   Teles FRR, 2007, SENSORS-BASEL, V7, P2510, DOI 10.3390/s7112510
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Schweitzer B, 2001, CURR OPIN BIOTECH, V12, P21, DOI 10.1016/S0958-1669(00)00172-5                                                   
   Shi WB, 2011, CHEM COMMUN, V47, P10785, DOI 10.1039/c1cc14300j
   Staudt LM, 2001, TRENDS IMMUNOL, V22, P35, DOI 10.1016/S1471-4906(00)01792-0
   Su J, 2012, CHEM COMMUN, V48, P6909, DOI 10.1039/c2cc32729e
   Wang J, 2005, SMALL, V1, P1036, DOI 10.1002/smll.200500214
   Xia F, 2010, J AM CHEM SOC, V132, P14346, DOI 10.1021/ja104998m
   Xiang Y, 2012, ANAL CHEM, V84, P4174, DOI 10.1021/ac300517n
   Xiang Y, 2012, ANAL CHEM, V84, P1975, DOI 10.1021/ac203014s
   Xiang Y, 2011, NAT CHEM, V3, P697, DOI [10.1038/NCHEM.1092, 10.1038/nchem.1092]
   Xiang Y, 2011, ANAL CHEM, V83, P4302, DOI 10.1021/ac200564r
   Zhang J, 2006, J AM CHEM SOC, V128, P8575, DOI 10.1021/ja061521a
   Zhang YL, 2009, ANAL CHEM, V81, P1982, DOI 10.1021/ac802512d
NR 55
TC 25
Z9 25
U1 2
U2 75
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2012
VL 48
IS 87
BP 10733
EP 10735
DI 10.1039/c2cc35941c
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 016UD
UT WOS:000309544100009
PM 23011391
DA 2018-01-05
ER

PT J
AU Mahajan, SD
   Aalinkeel, R
   Law, WC
   Reynolds, JL
   Nair, BB
   Sykes, DE
   Yong, KT
   Roy, I
   Prasad, PN
   Schwartz, SA
AF Mahajan, Supriya D.
   Aalinkeel, Ravikumar
   Law, Wing-Cheung
   Reynolds, Jessica L.
   Nair, Bindukumar B.
   Sykes, Donald E.
   Yong, Ken-Tye
   Roy, Indrajit
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Anti-HIV-1 nanotherapeutics: promises and challenges for the future
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE nanotherapeutics; HAART; HIV; nano; nanomedicine; drug delivery
ID BLOOD-BRAIN-BARRIER; FLUORESCENT BIOLOGICAL LABELS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 PROTEASE INHIBITORS; DRUG-DELIVERY;
   IN-VIVO; ANTIRETROVIRAL DRUG; POLYMERIC NANOPARTICLES; INTRACELLULAR
   DELIVERY; QUANTUM DOTS
AB The advent of highly active antiretroviral therapy (HAART) has significantly improved the prognosis for human immunodeficiency virus (HIV)-infected patients, however the adverse side effects associated with prolonged HAART therapy use continue. Although systemic viral load can be undetectable, the virus remains sequestered in anatomically privileged sites within the body. Nanotechnology-based delivery systems are being developed to target the virus within different tissue compartments and are being evaluated for their safety and efficacy. The current review outlines the various nanomaterials that are becoming increasingly used in biomedical applications by virtue of their robustness, safety, multimodality, and multifunctionality. Nanotechnology can revolutionize the field of HIV medicine by not only improving diagnosis, but also by improving delivery of antiretrovirals to targeted regions in the body and by significantly enhancing the efficacy of the currently available antiretroviral medications.
C1 [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Reynolds, Jessica L.; Nair, Bindukumar B.; Sykes, Donald E.; Schwartz, Stanley A.] SUNY Buffalo, Dept Med, Div Rheumatol Allergy & Immunol, Buffalo, NY 14203 USA.
   [Law, Wing-Cheung; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14203 USA.
   [Roy, Indrajit] Univ Delhi, Dept Chem, Delhi 110007, India.
   [Yong, Ken-Tye] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore.
RP Mahajan, SD (reprint author), SUNY Buffalo, Dept Med, Div Rheumatol Allergy & Immunol, 444 Innovat Ctr,Buffalo Niagara Med Campus,640 El, Buffalo, NY 14203 USA.
EM smahajan@buffalo.edu
OI Law, Wing Cheung/0000-0003-3855-6170
FU NIDA NIH HHS [K01 DA024577]
CR Aigner A, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/71659
   Alam MI, 2010, EUR J PHARM SCI, V40, P385, DOI 10.1016/j.ejps.2010.05.003
   Armstead AL, 2011, INT J NANOMED, V6, P3281, DOI 10.2147/IJN.S27285
   AZoNano, NAN DENDR PROP FUT A
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Balkundi S, 2010, J VIS EXP, V46
   Bawa R, 2010, EUR J NANOMED, V3, P34, DOI 10.3884/0003.1.9
   Bekkara-Aounallah F, 2008, ADV FUNCT MATER, V18, P3715, DOI 10.1002/adfm.200800705
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   Boisselier E, 2009, CHEM SOC REV, V38, P1759, DOI 10.1039/b806051g
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Borgmann K, 2011, AIDS RES HUM RETROV, V27, P853, DOI [10.1089/aid.2010.0295, 10.1089/AID.2010.0295]
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Buxton DB, 2009, NANOMEDICINE-UK, V4, P331, DOI [10.2217/nnm.09.8, 10.2217/NNM.09.8]
   Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chawla P, 2010, MINI-REV MED CHEM, V10, P662, DOI 10.2174/138955710791572497                                                      
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Chrai S.S., 2002, PHARM TECH, V26, P28
   Couvreur P, 2006, NANO LETT, V6, P2544, DOI 10.1021/nl061942q
   Croy SR, 2006, CURR PHARM DESIGN, V12, P4669, DOI 10.2174/138161206779026245
   das Neves J, 2012, PHARM RES-DORDR, V29, P1468, DOI 10.1007/s11095-011-0622-3
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Dash PK, 2012, AIDS
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   de Martimprey H, 2009, EUR J PHARM BIOPHARM, V71, P490, DOI 10.1016/j.ejpb.2008.09.024
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Ding H, 2007, J PHYS CHEM C, V111, P12552, DOI 10.1021/jp0733419
   Dorfs D, 2011, COMPREHENSIVE NANOSCIENCE AND TECHNOLOGY, VOL 1: NANOMATERIALS, P219
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Elsabahy M, 2012, CHEM SOC REV, V41, P2545, DOI 10.1039/c2cs15327k
   Fu AH, 2007, NANO LETT, V7, P179, DOI 10.1021/nl0626434
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Guo PX, 2005, J NANOSCI NANOTECHNO, V5, P1964, DOI 10.1166/jnn.2005.446
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hauck TS, 2010, ADV DRUG DELIVER REV, V62, P438, DOI 10.1016/j.addr.2009.11.015
   Higuchi Y, 2010, BIODRUGS, V24, P195, DOI 10.2165/11534450-000000000-00000
   Hu R, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/14/145105
   Kadiu I, 2011, NANOMEDICINE-UK, V6, P975, DOI [10.2217/nnm.11.27, 10.2217/NNM.11.27]
   Kalkanidis M, 2006, METHODS, V40, P20, DOI 10.1016/j.ymeth.2006.05.018
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kim JM, 2011, IMMUNOTHERAPY-UK, V3, P247, DOI 10.2217/IMT.10.91
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kim SS, 2011, METHODS MOL BIOL, V721, P339, DOI 10.1007/978-1-61779-037-9_21
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kuo YC, 2012, COLLOID SURFACE B, V90, P75, DOI 10.1016/j.colsurfb.2011.09.048
   Kuo YC, 2011, COLLOID SURFACE B, V88, P682, DOI 10.1016/j.colsurfb.2011.07.060
   Kuo YC, 2011, COLLOID SURFACE B, V88, P158, DOI 10.1016/j.colsurfb.2011.06.026
   Kwon GS, 2006, DRUG DEVELOP RES, V67, P15, DOI 10.1002/ddr.20063
   Lammers T, 2011, ACCOUNTS CHEM RES, V44, P1029, DOI 10.1021/ar200019c
   Lara HH, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-30
   Law WC, 2012, THERANOSTICS, V2, P695, DOI 10.7150/thno.3459
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee DE, 2012, CHEM SOC REV, V41, P2656, DOI 10.1039/c2cs15261d
   Lee JE, 2010, J AM CHEM SOC, V132, P552, DOI 10.1021/ja905793q
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Letvin NL, 2005, ANNU REV MED, V56, P213, DOI 10.1146/annurev/med.54.101601.152349
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Liu LW, 2011, ANALYST, V136, P1881, DOI 10.1039/c0an01017k
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mahajan SD, 2012, METHOD ENZYMOL, V509, P43
   Mahajan SD, 2009, GLOBAL ANTIVIRAL J, V5, P45
   Mahajan S.D., 2011, PATHOLOG RES INT, V2011
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mason TG, 2006, J PHYS-CONDENS MAT, V18, pR635, DOI 10.1088/0953-8984/18/41/R01
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Parboosing R, 2012, VIRUSES-BASEL, V4, P488, DOI 10.3390/v4040488
   Pardridge WM, 2003, METHOD ENZYMOL, V373, P507
   Pedziwiatr-Werbicka E, 2011, COLLOID SURFACE B, V83, P360, DOI 10.1016/j.colsurfb.2010.12.008
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Prasad P. N., 2004, NANOPHOTONICS
   Prasad P. N., 2003, INTRO BIOPHOTONICS
   Ramana LN, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-57
   Ravina M, 2010, MINI-REV MED CHEM, V10, P73, DOI 10.2174/138955710791112569                                                      
   Saiyed ZM, 2010, INT J NANOMED, V5, P157
   Seale-Goldsmith MM, 2009, WIRES NANOMED NANOBI, V1, P553, DOI 10.1002/wnan.49
   Shaik N, 2008, J PHARM SCI-US, V97, P5421, DOI 10.1002/jps.21372
   Shegokar R, 2011, INT J PHARMACEUT, V421, P341, DOI 10.1016/j.ijpharm.2011.09.041
   Shi NY, 2001, PHARMACEUT RES, V18, P1091, DOI 10.1023/A:1010910523202                                                         
   Shi NY, 2001, P NATL ACAD SCI USA, V98, P12754, DOI 10.1073/pnas.221450098
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Torchilin VP, 2006, NANOPARTICULATES DRU, pxxix
   Toub N, 2006, BIOMED PHARMACOTHER, V60, P607, DOI 10.1016/j.biopha.2006.07.093
   Vinogradov Serguei, 2004, Expert Opin Drug Deliv, V1, P181, DOI 10.1517/17425247.1.1.181
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wan L, 2008, BIOCONJUGATE CHEM, V19, P28, DOI 10.1021/bc070066k
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Xu L, 2012, NANO LETT
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m
   Zhang JX, 2009, RECENT PAT NANOTECH, V3, P225, DOI 10.2174/187221009789177803
   Zhou JH, 2011, MOL THER, V19, P2228, DOI 10.1038/mt.2011.207
   Zhou JH, 2011, METHODS, V54, P284, DOI 10.1016/j.ymeth.2010.12.039
NR 106
TC 47
Z9 48
U1 1
U2 35
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 5301
EP 5314
DI 10.2147/IJN.S25871
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 015KT
UT WOS:000309445500001
PM 23055735
OA gold
DA 2018-01-05
ER

PT J
AU Fayaz, AM
   Ao, ZJ
   Girilal, M
   Chen, LY
   Xiao, XZ
   Kalaichelvan, PT
   Yao, XJ
AF Fayaz, A. Mohammed
   Ao, Zhujun
   Girilal, Morkattu
   Chen, Liyu
   Xiao, Xianzhong
   Kalaichelvan, P. T.
   Yao, Xiaojian
TI Inactivation of microbial infectiousness by silver nanoparticles-coated
   condom: a new approach to inhibit HIV- and HSV-transmitted infection
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE silver nanoparticles; condom; HIV-1; HSV-1/2; antimicrobial
ID GRAM-NEGATIVE BACTERIA; VIRUS; NANOTECHNOLOGY; TRANSMISSION;
   REPLICATION; PREVENTION; CELLS; MODEL
AB Recent research suggests that today's condoms are only 85% effective in preventing human immunodeficiency virus (HIV) and other sexually transmitted diseases. In response, there has been a push to develop more effective ways of decreasing the spread of the disease. The new nanotechnology-based condom holds the promise of being more potent than the first-generation products. The preliminary goal of this study was to develop a silver nanoparticles (Ag-NPs)coated polyurethane condom (PUC) and to investigate its antimicrobial potential including the inactivation of HIV and herpes simplex virus (HSV) infectiousness. The Ag-NPs-coated PUC was characterized by using ultraviolet-visible spectrophotometry, Fourier transform-infrared spectroscopy, high-resolution scanning electron microscopy, and energy-dispersive analysis of X-ray spectroscopy. Nanoparticles were stable on the PUC and not washed away by water. Morphology of the PUC was retained after coating. The NP binding is due to its interaction with the nitrogen atom of the PUC. No significant toxic effects was observed when human HeLa cells, 293T and C8166 T cells were contacted to Ag-NPs-coated PUC for three hours. Interestingly, our results demonstrated that the contact of the Ag-NPs-coated PUC with HIV-1 and HSV-1/2 was able to efficiently inactivate their infectiousness. In an attempt to elucidate the antiviral action of the Ag-NPs, we have demonstrated that the anti-HIV activity was primarily mediated by the Ag-NPs, which are associated with the PUC. In addition, the data showed that both macrophage (M)-tropic and T lymphocyte (T)-tropic strains of HIV-1 were highly sensitive to the Ag-NPs-coated PUC. Furthermore, we also showed that the Ag-NPs-coated PUC was able to inhibit the growth of bacteria and fungi. These results demonstrated that the Ag-NPs-coated PUC is able to directly inactivate the microbe's infectious ability and provides another defense line against these sexually transmitted microbial infections.
C1 [Fayaz, A. Mohammed; Ao, Zhujun; Yao, Xiaojian] Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB, Canada.
   [Girilal, Morkattu; Kalaichelvan, P. T.] Univ Madras, CAS Bot, Madras, Tamil Nadu, India.
   [Ao, Zhujun; Chen, Liyu; Yao, Xiaojian] Cent S Univ, Dept Microbiol, Changsha, Hunan, Peoples R China.
   [Chen, Liyu; Xiao, Xianzhong] Cent S Univ, Sch Basic Med Sci, Changsha, Hunan, Peoples R China.
RP Yao, XJ (reprint author), Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB, Canada.
EM yao2@cc.umanitoba.ca
FU CIHR International Infectious Disease and Global Health Training
   Program; CIHR HIV prevention operating grant [HPR85525]; Canadian
   Foundation for AIDS Research (CANFAR) [023-013]; Leaders Opportunity
   Fund Award from the Canadian Foundation of Innovation (CFI)
FX We would like to thank Drs Alberto Severini and Gary Kobinger for
   providing HSV-1/-2 virus strains and Vero-E6 cells. We also thank Dr M
   Emerman for the HeLa-CD4-CCR5-beta-Gal cells that were obtained through
   the AIDS Research Reference Reagent Program, Division of AIDS, NIAID,
   NIH. We also greatly appreciate the editorial review of Ms Courtney
   Bell. Z-J Ao is the recipient of a postdoctoral fellowship from the CIHR
   International Infectious Disease and Global Health Training Program (IID
   and GHTP). This work was financially supported by grants from a CIHR HIV
   prevention operating grant (HPR85525), the Canadian Foundation for AIDS
   Research (CANFAR grant# 023-013), and the Leaders Opportunity Fund Award
   from the Canadian Foundation of Innovation (CFI) to X-J Yao.
CR Ao Z, 2008, PLOS ONE, V3, P1995
   Ao ZJ, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-62
   Baker C, 2005, J NANOSCI NANOTECHNO, V5, P244, DOI 10.1166/jnn.2005.034
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Barnabas RV, 2006, PLOS MED, V3, pe138
   Bhol KC, 2005, BRIT J DERMATOL, V152, P1235, DOI 10.1111/j.1365-2133.2005.06575.x
   Burleson FG, 1992, VIROLOGY LAB MANUAL, P74
   Cassady KA, 1997, J ANTIMICROB CHEMOTH, V39, P119, DOI 10.1093/jac/39.2.119
   Centers for Disease Control and Prevention, COND STDS FACT SHEET
   Elechiguerra J., 2005, J NANOBIOTECHNOL, V3, P3
   Fayaz AM, 2010, NANOMED-NANOTECHNOL, V6, P103, DOI 10.1016/j.nano.2009.04.006
   Guggenbichler JP, 1999, INFECTION, V27, pS16, DOI 10.1007/BF02561612
   Handley MA, 2002, EPIDEMIOLOGY, V13, P431, DOI 10.1097/00001648-200207000-00011                                                
   Jain KK, 2003, EXPERT REV MOL DIAGN, V3, P153, DOI 10.1586/14737159.3.2.153                                                        
   Jain P, 2005, BIOTECHNOL BIOENG, V90, P59, DOI 10.1002/bit.20368
   Kim KJ, 2009, BIOMETALS, V22, P235, DOI 10.1007/s10534-008-9159-2
   KIMPTON J, 1992, J VIROL, V66, P2232
   Kippley J, 1996, ART NATURAL FAMILY P
   Lara H.H., 2010, J BIOTECHNOL, P8, DOI DOI 10.1186/1477-3155-8-1
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lu L, 2008, ANTIVIR THER, V13, P253
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Pauwels R, 1996, J ACQ IMMUN DEF SYND, V11, P211, DOI 10.1097/00042560-199603010-00001                                                
   Porcel E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085103
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Sibbald R Gary, 2007, Adv Skin Wound Care, V20, P549, DOI 10.1097/01.ASW.0000294757.05049.85
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Spira S, 2003, J ANTIMICROB CHEMOTH, V51, P229, DOI 10.1093/jac/dkg079
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077                                                      
   UNAIDS, 2012, MOR 80 COUNTR INCR T
   Wang J, 2010, COLLOID SURFACE B, V75, P520, DOI 10.1016/j.colsurfb.2009.09.029
   Weiss HA, 2001, AIDS, V15, pS97, DOI 10.1097/00002030-200108004-00011                                                
   World Health Organization, NON 9 IN PREV HIV IN
   Zahariadis G, 2010, SEX TRANSM DIS, V37, P696, DOI 10.1097/OLQ.0b013e3181e2cdab
NR 35
TC 33
Z9 33
U1 1
U2 32
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 5007
EP 5018
DI 10.2147/IJN.S34973
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 012VM
UT WOS:000309264700001
OA gold
DA 2018-01-05
ER

PT J
AU Wang, SQ
   Sarenac, D
   Chen, MH
   Huang, SH
   Giguel, FF
   Kuritzkes, DR
   Demirci, U
AF Wang, ShuQi
   Sarenac, Dusan
   Chen, Michael H.
   Huang, Shih-Han
   Giguel, Francoise F.
   Kuritzkes, Daniel R.
   Demirci, Utkan
TI Simple filter microchip for rapid separation of plasma and viruses from
   whole blood
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE microchip; filtration; virus isolation; plasma separation; point-of-care
ID MICROFLUIDIC DEVICE; HIV; DIAGNOSTICS; IMMUNOASSAY; SETTINGS; SAMPLES;
   SWINE; ELISA; SERUM; CELL
AB Sample preparation is a significant challenge for detection and sensing technologies, since the presence of blood cells can interfere with the accuracy and reliability of virus detection at the nanoscale for point-of-care testing. To the best of our knowledge, there is not an existing on-chip virus isolation technology that does not use complex fluidic pumps. Here, we presented a lab-on-a-chip filter device to isolate plasma and viruses from unprocessed whole blood based on size exclusion without using a micropump. We demonstrated that viruses (eg, HIV) can be separated on a filter-based chip (2-mu m pore size) from HIV-spiked whole blood at high recovery efficiencies of 89.9% +/- 5.0%, 80.5% +/- 4.3%, and 78.2% +/- 3.8%, for viral loads of 1000, 10,000 and 100,000 copies/mL, respectively. Meanwhile, 81.7% +/- 6.7% of red blood cells and 89.5% +/- 2.4% of white blood cells were retained on 2 mu m pore-sized filter microchips. We also tested these filter microchips with seven HIV-infected patient samples and observed recovery efficiencies ranging from 73.1% +/- 8.3% to 82.5% +/- 4.1%. These results are first steps towards developing disposable point-of-care diagnostics and monitoring devices for resource-constrained settings, as well as hospital and primary care settings.
C1 [Wang, ShuQi; Sarenac, Dusan; Chen, Michael H.; Huang, Shih-Han; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Bioacoust MEMS Med Lab, Dept Med,Div Biomed Engn,Med Sch, Boston, MA 02115 USA.
   [Giguel, Francoise F.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.
   [Kuritzkes, Daniel R.] Brigham & Womens Hosp, Sect Retroviral Therapeut, Boston, MA 02115 USA.
   [Demirci, Utkan] Harvard MIT Hlth Sci & Technol, Bioacoust MEMS Med BAMM Labs, Cambridge, MA 02139 USA.
RP Demirci, U (reprint author), Harvard MIT Hlth Sci & Technol, Bioacoust MEMS Med BAMM Labs, 65 Landsdowne St, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu
FU United States Army Medical Research and Materiel Command (USAM-RMC);
   Telemedicine and Advanced Technology Research Center (TATRC), at Fort
   Detrick, MD;  [NIH R01 A1081534];  [NIH R01A1093282];  [R21 AI087107]; 
   [NIH U54EB015408];  [R21 HL095960]
FX We would like to acknowledge NIH R01 A1081534, NIH R01A1093282, R21
   AI087107, NIH U54EB015408, and R21 HL095960. Also, this work was made
   possible by a research grant that was awarded and administered by the
   United States Army Medical Research and Materiel Command (USAM-RMC) and
   the Telemedicine and Advanced Technology Research Center (TATRC), at
   Fort Detrick, MD.
CR Al-Soud Waleed Abu, 2001, Journal of Clinical Microbiology, V39, P485, DOI 10.1128/JCM.39.2.485-493.2001
   Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Bhattacharyya A, 2006, ANAL CHEM, V78, P788, DOI 10.1021/ac051449j
   Bhattacharyya A, 2008, SENSOR ACTUAT B-CHEM, V129, P693, DOI 10.1016/j.snb.2007.09.057
   Candotti D, 2004, J VIROL METHODS, V118, P39, DOI [10.1016/S0166-0934(04)00019-9, 10.1016/j.jviromet.2004.01.017]
   Chakravarti A, 2003, DIAGN MICR INFEC DIS, V47, P563, DOI 10.1016/S0732-8893(03)00166-4
   Cohen J, 2010, SCIENCE, V327, P1563, DOI 10.1126/science.327.5973.1563
   Daaboul GG, 2011, BIOSENS BIOELECTRON, V26, P2221, DOI 10.1016/j.bios.2010.09.038
   Dimov IK, 2011, LAB CHIP, V11, P845, DOI 10.1039/c01c00403k
   GENTILE M, 1994, J VIROL METHODS, V48, P43, DOI 10.1016/0166-0934(94)90087-6
   Gurkan UA, 2011, LAB CHIP, V11, P3979, DOI 10.1039/c1lc20487d
   Gurkan UA, 2011, BIOTECHNOL J, V6, P138, DOI 10.1002/biot.201000427
   Hosokawa K, 2007, ANAL CHEM, V79, P6000, DOI 10.1021/ac070659o
   Kim SM, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2998695
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   LaBarre P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019738
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Li TJ, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/10/105024
   Liu CC, 2009, LAB CHIP, V9, P768, DOI 10.1039/b814322f
   Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Park YK, 2010, P NATL ACAD SCI USA, V107, P1289, DOI 10.1073/pnas.0910785107
   Qin LD, 2009, LAB CHIP, V9, P2016, DOI 10.1039/b821247c
   Raivio T, 2008, J PEDIATR GASTR NUTR, V47, P562, DOI 10.1097/MPG.0b013e3181615cde
   Santiago-Cordoba MA, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3599706
   Stevens WS, 2010, J INFECT DIS, V201, pS16, DOI 10.1086/650392
   Tanriverdi S, 2010, J INFECT DIS, V201, pS52, DOI 10.1086/650387
   Thorslund S, 2006, BIOMED MICRODEVICES, V8, P73, DOI 10.1007/s10544-006-6385-7
   Trevino J, 2009, CLIN CHIM ACTA, V403, P56, DOI 10.1016/j.cca.2009.01.015
   UNAIDS, 2010, UNAIDS REP GLOB AIDS
   Usdin M, 2010, J INFECT DIS, V201, pS73, DOI 10.1086/650384
   Vijaykrishna D, 2010, SCIENCE, V328, P1529, DOI 10.1126/science.1189132
   Walker GM, 2002, LAB CHIP, V2, P131, DOI 10.1039/b204381e
   Wang SQ, 2012, INT J NANOMED, V7, P2591, DOI 10.2147/IJN.S29629
   Wang SQ, 2012, LAB CHIP, V12, P1508, DOI 10.1039/c2lc20706k
   Wang SQ, 2011, LAB CHIP, V11, P3411, DOI 10.1039/c1lc20479c
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Wong AP, 2008, LAB CHIP, V8, P2032, DOI 10.1039/b809830c
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yang S, 2006, LAB CHIP, V6, P871, DOI 10.1039/b516401j
   Young B, 2006, WHEATHERS FUNCTIONAL
   Zhang JL, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/12/125025
NR 42
TC 28
Z9 28
U1 0
U2 63
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 5019
EP 5028
DI 10.2147/IJN.S32579
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 006BJ
UT WOS:000308793900001
PM 23055720
OA gold
DA 2018-01-05
ER

PT J
AU Bunz, H
   Plankenhorn, S
   Klein, R
AF Bunz, Hanno
   Plankenhorn, Sandra
   Klein, Reinhild
TI Effect of buckminsterfullerenes on cells of the innate and adaptive
   immune system: an in vitro study with human peripheral blood mononuclear
   cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE buckminsterfullerenes; polyhydroxy-C60; N-ethyl-polyamino-C60; natural
   killer cells; dendritic cells; T cells; cytokines
ID FULLERENE NANOMATERIALS INHIBIT; MOLECULAR-DYNAMICS SIMULATIONS;
   LYMPHOCYTE-TRANSFORMATION TEST; WATER-SOLUBLE FULLERENE;
   HYPERSENSITIVITY REACTIONS; IMMUNOCOMPETENT CELLS; CARBON NANOTUBES;
   TECHNICAL REPORT; HIV-1 PROTEASE; DERIVATIVES
AB C60 nanoparticles, the so-called buckminsterfullerenes, have attracted great attention for medical applications as carriers, enzyme inhibitors or radical scavengers. However, publications evaluating their immunological mechanisms are still rather limited. Therefore, we aimed to analyze systematically the in vitro influence of polyhydroxy-C60 (poly-C60) and N-ethyl-polyamino-C60 (nepo-C60) on peripheral blood mononuclear cells (PBMC) from healthy individuals, angling their effect on proliferation, expression of surface markers, and cytokine production. We isolated PBMC from 20 healthy subjects and incubated them in a first step only with poly-C60 or nepo-C60, and in a second step together with recall antigens (purified protein derivative, tetanus toxoid, bacillus Calmette-Guerin). Proliferation was determined by H-3-thymidine incorporation, activation of PBMC-subpopulations by flow cytometry by measurement of the activation marker CD69, and secretion of T helper cell type 1 (TH1)- (interferon-gamma [IFN-gamma], tumor necrosis factor beta [TNF-beta]), TH2- (interleukin-5 [IL-5], -13, -10) and macrophage/monocyte-related cytokines (IL-1, IL-6, TNF-alpha) into the supernatants by enzyme-linked immunosorbent assay. Both fullerenes did not influence T cell reactivity, with no enhanced expression of CD69 and production of T cell cytokines observed, the CD4/CD8 ratio remaining unaffected. In contrast, they significantly enhanced the release of IL-6 and CD69-expression by CD56 positive natural killer cells. PBMC, which had been cultured together with the three recall antigens were not affected by both fullerenes at all. These data indicate that fullerenes do not interact with T cell reactivity but may activate cells of the innate immune system. Furthermore, they seem to act only on 'naive' cells, which have not been prestimulated with recall antigens, there are however, large inter individual differences.
C1 [Bunz, Hanno; Plankenhorn, Sandra; Klein, Reinhild] Univ Tubingen, Dept Internal Med 2, D-72076 Tubingen, Germany.
RP Klein, R (reprint author), Univ Tubingen, Dept Internal Med 2, Otfried Muller Str 10, D-72076 Tubingen, Germany.
EM reinhild.klein@med.uni-tuebingen.de
FU Deutsche Forschungsgemeinschaft [Graduiertenkolleg 794]
FX HB had a scholarship of the Graduiertenkolleg 794 by the Deutsche
   Forschungsgemeinschaft.
CR Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002
   Andersen AJ, 2009, J BIOMED NANOTECHNOL, V5, P364, DOI 10.1166/jbn.2009.1045
   Bakry R, 2007, INT J NANOMED, V2, P639
   Barth H, 2003, CLIN EXP IMMUNOL, V134, P78, DOI 10.1046/j.1365-2249.2003.02265.x
   Barth H, 2003, HEPATO-GASTROENTEROL, V50, P201
   Barth H, 2002, J NEUROIMMUNOL, V133, P175, DOI 10.1016/S0165-5728(02)00355-7                                                   
   Bianco A, 2005, J AM CHEM SOC, V127, P58, DOI 10.1021/ja044293y
   Bosi S, 2000, BIOORG MED CHEM LETT, V10, P1043, DOI 10.1016/S0960-894X(00)00159-1
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   BRATTIG NW, 1988, EUR J CLIN PHARMACOL, V35, P39, DOI 10.1007/BF00555505                                                              
   Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438
   Calvaresi M, 2010, ACS NANO, V4, P2283, DOI 10.1021/nn901809b
   Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763
   Dellinger A, 2010, NANOMED-NANOTECHNOL, V6, P575, DOI 10.1016/j.nano.2010.01.008
   Dellinger A, 2009, EXP DERMATOL, V18, P1079, DOI 10.1111/j.1600-0625.2009.00904.x
   Dumortier H, 2006, NANO LETT, V6, P1522, DOI 10.1021/nl061160x
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Frick JS, 2006, EUR J IMMUNOL, V36, P1537, DOI 10.1002/eji.200635840
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Fusakio ME, 2011, J IMMUNOL, V187, P5805, DOI 10.4049/jimmunol.1100338
   Hedge S, 2004, FASEB J, V18, P1439
   Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216
   Ibrahim M, 2010, SPECTROCHIM ACTA A, V75, P702, DOI 10.1016/j.saa.2009.11.042
   Montanez MI, 2010, CURR OPIN ALLERGY CL, V10, P297, DOI 10.1097/ACI.0b013e32833b1f17
   Isakovic A, 2006, TOXICOL SCI, V91, P173, DOI 10.1093/toxsci/kfj127
   Klein R, 2004, PURE APPL CHEM, V76, P1269, DOI 10.1351/pac200476061269                                                         
   Klein R, 2008, CLIN IMMUNOL, V126, P322, DOI 10.1016/j.clim.2007.09.007
   Klein R, 2006, PURE APPL CHEM, V78, P2155, DOI 10.1351/pac200678112155
   Klein R, 2009, EUR J CLIN PHARMACOL, V65, P1195, DOI 10.1007/s00228-009-0705-9
   Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P168
   KROTO HW, 1991, CHEM REV, V91, P1213, DOI 10.1021/cr00006a005                                                             
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Lee J, 2010, ACS NANO, V4, P3580, DOI 10.1021/nn100866w
   Lee VS, 2007, J MOL GRAPH MODEL, V26, P558, DOI 10.1016/j.jmgm.2007.03.013
   Liu Y, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/41/415102
   Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001
   Mashino T, 2005, BIOORG MED CHEM LETT, V15, P1107, DOI 10.1016/j.bmcl.2004.12.030
   Mikawa M, 2001, BIOCONJUGATE CHEM, V12, P510, DOI 10.1021/bc000136m
   Mori T, 2006, TOXICOLOGY, V225, P48, DOI 10.1016/j.tox.2006.05.001
   Nielsen GD, 2008, BASIC CLIN PHARMACOL, V103, P197, DOI 10.1111/j.1742-7843.2008.00266.x
   Porter AE, 2007, ENVIRON SCI TECHNOL, V41, P3012, DOI 10.1021/es062541f
   Qing X, 2012, EUR J IMMUNOL
   Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665                                                      
   Sayes CM, 2005, BIOMATERIALS, V26, P7587, DOI 10.1016/j.biomaterials.2005.05.027
   Thaher F, 2011, INT IMMUNOPHARMACOL, V11, P1724, DOI 10.1016/j.intimp.2011.06.005
   Wehner R, 2011, J INNATE IMMUN, V3, P258, DOI 10.1159/000323923
   Yamawaki H, 2006, AM J PHYSIOL-CELL PH, V290, pC1495, DOI 10.1152/ajpcell.00481.2005
   Yang D, 2010, ACS NANO, V4, P1178, DOI 10.1021/nn901478z
   Yudoh K, 2009, INT J NANOMED, V4, P217
   Zhu JD, 2008, SMALL, V4, P1168, DOI 10.1002/smll.200701219
NR 50
TC 9
Z9 10
U1 1
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 4571
EP 4580
DI 10.2147/IJN.S33773
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 990RY
UT WOS:000307650200001
PM 22942641
OA gold
DA 2018-01-05
ER

PT J
AU Unzueta, U
   Cespedes, MV
   Ferrer-Miralles, N
   Casanova, I
   Cedano, J
   Corchero, JL
   Domingo-Espin, J
   Villaverde, A
   Mangues, R
   Vazquez, E
AF Unzueta, Ugutz
   Virtudes Cespedes, Maria
   Ferrer-Miralles, Neus
   Casanova, Isolda
   Cedano, Juan
   Luis Corchero, Jose
   Domingo-Espin, Joan
   Villaverde, Antonio
   Mangues, Ramon
   Vazquez, Esther
TI Intracellular CXCR4(+) cell targeting with T22-empowered protein-only
   nanoparticles
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE peptide tag; CXCR4; intracellular targeting; self-assembling;
   nanoparticles; colorectal cancer
ID SELF-ASSEMBLING PEPTIDES; COLORECTAL-CANCER; ESCHERICHIA-COLI; HOMING
   PEPTIDES; HIV ENTRY; NANOMEDICINE; DELIVERY; THERAPY; DESIGN; METASTASIS
AB Background: Cell-targeting peptides or proteins are appealing tools in nanomedicine and innovative medicines because they increase the local drug concentration and reduce potential side effects. CXC chemokine receptor 4 (CXCR4) is a cell surface marker associated with several severe human pathologies, including colorectal cancer, for which intracellular targeting agents are currently missing.
   Results: Four different peptides that bind CXCR4 were tested for their ability to internalize a green fluorescent protein-based reporter nanoparticle into CXCR4(+) cells. Among them, only the 18 mer peptide T22, an engineered segment derivative of polyphemusin II from the horseshoe crab, efficiently penetrated target cells via a rapid, receptor-specific endosomal route. This resulted in accumulation of the reporter nanoparticle in a fully fluorescent and stable form in the perinuclear region of the target cells, without toxicity either in cell culture or in an in vivo model of metastatic colorectal cancer.
   Conclusion: Given the urgent demand for targeting agents in the research, diagnosis, and treatment of CXCR4-linked diseases, including colorectal cancer and human immunodeficiency virus infection, T22 appears to be a promising tag for the intracellular delivery of protein drugs, nanoparticles, and imaging agents.
C1 [Unzueta, Ugutz; Ferrer-Miralles, Neus; Luis Corchero, Jose; Domingo-Espin, Joan; Villaverde, Antonio; Vazquez, Esther] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
   [Unzueta, Ugutz; Ferrer-Miralles, Neus; Luis Corchero, Jose; Domingo-Espin, Joan; Villaverde, Antonio; Vazquez, Esther] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
   [Unzueta, Ugutz; Virtudes Cespedes, Maria; Ferrer-Miralles, Neus; Casanova, Isolda; Luis Corchero, Jose; Domingo-Espin, Joan; Villaverde, Antonio; Mangues, Ramon; Vazquez, Esther] CIBER Bioingn Biomat & Nanomed, Barcelona, Spain.
   [Virtudes Cespedes, Maria; Casanova, Isolda; Mangues, Ramon] Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau, Oncogenesis & Antitumor Drug Grp, Barcelona, Spain.
   [Cedano, Juan] Univ Republ, Immunol Lab, Salto, Uruguay.
RP Villaverde, A (reprint author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
EM antoni.villaverde@uab.cat
RI Corchero, Jose/G-8413-2016; Ferrer-Miralles, Neus/G-7934-2016; CASANOVA
   RIGAT, ISOLDA/I-5393-2014; Unzueta, Ugutz/C-2521-2017
OI Corchero, Jose/0000-0002-6109-144X; Ferrer-Miralles,
   Neus/0000-0003-2981-3913; CASANOVA RIGAT, ISOLDA/0000-0002-1196-4724;
   Unzueta, Ugutz/0000-0001-5119-2266; Vazquez, Esther/0000-0003-1052-0424;
   Villaverde, Antonio/0000-0002-2615-4521; Mangues,
   Ramon/0000-0003-2661-9525
FU FIS [PS0900165, PS0900965]; MICINN [ACI2009-0919]; AGAUR [2009SGR-108];
   CIBER de Bioingenieria, Biomateriales y Nanomedicina; VI National RDi
   Plan; Iniciativa Ingenio; Consolider Program; CIBER; Instituto de Salud
   Carlos III; ISCIII; Institucio Catalana de Recerca i Estudis Avancats
   Academia
FX We appreciate the technical support of Fran Cortes from the Cell Culture
   Unit of the Servei de Cultius Cellulars, Produccio d'Anticossos i
   Citometria, of the Servei de Microscopia, and of the Protein Production
   Platform (CIBER-BBN). We also acknowledge the financial support received
   for the design and production of artificial viruses for gene therapy to
   EV, RM, and AV from FIS (PS0900165, PS0900965), MICINN (ACI2009-0919),
   AGAUR (2009SGR-108), and CIBER de Bioingenieria, Biomateriales y
   Nanomedicina, an initiative funded by the VI National R&D&D&i Plan
   2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions
   and financed by the Instituto de Salud Carlos III with assistance from
   the European Regional Development Fund. UU and JDE have received
   predoctoral fellowships from ISCIII and MICINN, respectively, and AV has
   received an Institucio Catalana de Recerca i Estudis Avancats Academia
   award.
CR Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Baig MS, 2010, INT J BIOL MACROMOL, V46, P47, DOI 10.1016/j.ijbiomac.2009.10.014
   Barbera VM, 2000, BBA-MOL BASIS DIS, V1502, P283, DOI 10.1016/S0925-4439(00)00054-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Domingo-Espin J, 2011, NANOMEDICINE-UK, V6, P1047, DOI [10.2217/nnm.11.28, 10.2217/NNM.11.28]
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Egorova A, 2009, J GENE MED, V11, P772, DOI 10.1002/jgm.1366
   Ellis LM, 2009, CLIN CANCER RES, V15, P7471, DOI 10.1158/1078-0432.CCR-09-1070
   Enback J, 2007, BIOCHEM SOC T, V35, P780, DOI 10.1042/BST0350780                                                              
   Ferrer-Miralles N, 2008, TRENDS BIOTECHNOL, V26, P267, DOI 10.1016/j.tibtech.2008.02.003
   Ferrer-Miralles N, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-101
   Fujii N, 2003, EXPERT OPIN INV DRUG, V12, P185, DOI 10.1517/eoid.12.2.185.21405
   Huang HZ, 2010, BIOMACROMOLECULES, V11, P3390, DOI 10.1021/bm100894j
   Jain M, 2007, CLIN CANCER RES, V13, P1374, DOI 10.1158/1078-0432.CCR-06-2436
   Kim J, 2006, ANN SURG, V244, P113, DOI 10.1097/01.sla.0000217690.65909.9c
   Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Kyle S, 2010, BIOMATERIALS, V31, P9395, DOI 10.1016/j.biomaterials.2010.08.051
   Laakkonen P, 2010, INTEGR BIOL-UK, V2, P326, DOI 10.1039/c0ib00013b
   Liang XY, 2008, CHEM BIOL DRUG DES, V72, P97, DOI 10.1111/j.1747-0285.2008.00681.x
   Liang ZX, 2005, CANCER RES, V65, P967
   Martinez-Alonso M, 2008, BIOTECHNOL BIOENG, V101, P1353, DOI 10.1002/bit.21996
   Milletti F, 2012, DRUG DISCOV TODAY
   Mocellin S, 2005, TRENDS MOL MED, V11, P327, DOI 10.1016/j.molmed.2005.05.002
   Murakami T, 1999, J VIROL, V73, P7489
   Pautler M, 2010, INT J NANOMED, V5, P803, DOI 10.2147/IJN.S13816
   Peled A, 2012, EXPERT OPIN INV DRUG, V21, P341, DOI 10.1517/13543784.2012.656197
   Riehemann K, 2009, ANGEW CHEM INT EDIT, V48, P872, DOI 10.1002/anie.200802585
   Rusconi S, 2007, CURR TOP MED CHEM, V7, P1273
   Sadatmousavi P, 2011, CURR PHARM BIOTECHNO, V12, P1089, DOI 10.2174/138920111796117409                                                      
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Seras-Franzoso J, 2012, NANOMEDICINE-UK, V7, P79, DOI [10.2217/NNM.11.83, 10.2217/nnm.11.83]
   SKIPPER HE, 1970, CANCER CHEMOTH REP 1, V54, P431
   Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Thurber GM, 2008, TRENDS PHARMACOL SCI, V29, P57, DOI 10.1016/j.tips.2007.11.004
   Toledo-Rubio V, 2010, J BIOMOL SCREEN, V15, P453, DOI 10.1177/1087057110363911
   Vazquez E, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-60
   Vazquez E, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475-2859-9-101
   Vazquez E, 2010, BIOMATERIALS, V31, P9333, DOI 10.1016/j.biomaterials.2010.08.065
   Vazquez E, 2010, NANOMEDICINE-UK, V5, P259, DOI 10.2217/NNM.09.98
   Villaverde A, 2010, MICROB CELL FACT, V9, DOI 10.1186/1475-2859-9-53
   Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773
   Wilen CB, 2012, ADV EXP MED BIOL, V726, P223, DOI 10.1007/978-1-4614-0980-9_10
   Wu W, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-9
   Zhao Y, 2010, J CONTROL RELEASE, V147, P392, DOI 10.1016/j.jconrel.2010.08.002
   Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v
NR 48
TC 27
Z9 27
U1 1
U2 24
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 4533
EP 4544
DI 10.2147/IJN.S34450
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 988OA
UT WOS:000307499200001
PM 22923991
OA gold
DA 2018-01-05
ER

PT S
AU Bessrour, R
   Belmiloud, Y
   Hosni, Z
   Tangour, B
AF Bessrour, R.
   Belmiloud, Y.
   Hosni, Z.
   Tangour, B.
BE Clementi, E
   Andre, JM
   McCammon, JA
TI Controlling Drug efficiency by encapsulation into carbon nanotubes: a
   theoretical study of the antitumor Cisplatin and the anti-HIV TIBO
   molecules
SO THEORY AND APPLICATIONS IN COMPUTATIONAL CHEMISTRY: THE FIRST DECADE OF
   THE SECOND MILLENNIUM
SE AIP Conference Proceedings
LA English
DT Proceedings Paper
CT International Congress on Theory and Applications in Computational
   Chemistry - The First Decade of the Second Millennium (TACC)
CY SEP 02-07, 2012
CL Univ Pavia, Pavia, ITALY
SP Fujitsu & RIKEN AISC, Comitato TACC
HO Univ Pavia
DE Carbon nanotube; Anti-HIV; Inhibitor Non-Nucleosidic of Inverse
   Transcriptase; TIBO; butterfly conformation; virus mutation; Cisplatin;
   drug nanovector; nanocarrier; antitumor; confinement energy
ID REVERSE-TRANSCRIPTASE INHIBITORS; ADVANCED BREAST-CANCER; CELL
   LUNG-CANCER; NONNUCLEOSIDE INHIBITORS; PHASE-II; CRYSTAL-STRUCTURES;
   FUNCTIONAL-GROUPS; PAMAM DENDRIMERS; BRAIN METASTASES; ORBITAL METHODS
AB From the beginning of last century, Paul Ehrlich, a specialist in the immune system and the Nobel Prize (1908) had raised the possibility of "magic bullets" can directly address, in an organism, drugs in a particular area of the body, sparing all other parts of side effects. Carbon nanotubes (CNTs) have particular property to cross cell membranes easily. In an effort to optimize the use of CNT as drug nanocarriers, we divided our study into two parts. In the first, our concern was to find the minimum diameter of a single wall CNT can encapsulate an anticancer drug that iscisplatin without altering its geometry in order conserve its therapeutic power. Behavior of one and two Cisplatin(Cp) molecules confined in capped and opened single-walled carbon nanotubes (CNTs) is studied by means of ab-initio calculations. Single molecule binding energies clearly exhibit encapsulation dependence on tube diameters that range from 6.26 angstrom to 12.04 angstrom. A weak stabilization energy of the Cp@(11,0) equal to -70 kcal.mol(-1) has been obtained corresponding to a CNT's diameter of 8.5 angstrom. We noticed that Cisplatin molecule changes shape when encapsulated into CNTs' whose diameters are less than 7.6 angstrom. In the presence of a second Cisplatin molecule in the (10,0) CNT, preferred position stays parallel to CNT's axis leading to a linear density of roughly 1588 molecules/mu m of CNT's length corresponding to a linear density of 7.9 10(-19) g / mu m. The Pt-195 chemical shift tensors are calculated using GIAO method. NMR calculations reveal that Platinum chemical shift is sensitive to CNT's diameter and is linearly correlated to confinement energy. Pt-195 chemical shift measurement may be a direct method to access to the diameter of the encapsulating CNT's and to control the amount of drug molecule transported by this CNT. In the second part, the opposite has been sought is to say how the use of nanotubes with different diameters can control the change in a geometry of an anti-HIV drug that is TIBO molecule to bypass the mutation of the virus which wiped out its therapeutic effect. This work deals with the butterfly conformation control of the anti-HIV TIBO molecule confined into carbon nanotubes (CNT). This theoretical study concerns the variation of some pertinent conformation descriptors such as butterfly angle, wingspan, volume, dipole moment, solvation energy and confinement energy versus carbon nanotube diameters. Obtained results show that it is possible to describe the configurations of actual drugs as 8-Cl or 9-Cl TIBO as the parent molecule TIBO encapsulated in an adequate CNT. Our approach indicates that drug confinement inside CNTs may be a promising way to use a same drug in order to fellow HIV virus mutations.
C1 [Bessrour, R.; Hosni, Z.; Tangour, B.] Univ Tunis El Manar, Res Unity Theoret Chem & React, Tunis, Tunisia.
   [Belmiloud, Y.] Univ Sci & Technol Houari Boumed, Lab Theoret Phys Chemi & Computat Chem, Algiers, Algeria.
RP Bessrour, R (reprint author), Univ Tunis El Manar, Res Unity Theoret Chem & React, Tunis, Tunisia.
CR Agarwal A, 2009, BIOMATERIALS, V30, P3588, DOI 10.1016/j.biomaterials.2009.03.016
   Agrawal P, 2007, BIOMATERIALS, V28, P3349, DOI 10.1016/j.biomaterials.2007.04.004
   Ajima K, 2006, J PHYS CHEM B, V110, P5773, DOI 10.1021/jp056813x
   Ajima K, 2005, MOL PHARMACEUT, V2, P475, DOI 10.1021/mp0500566
   Allinger N. J., 1977, AM CHEM SOC, V99, P8127
   Arnold E., 1996, DRUG DES DISCOVERY, V29, P13
   Barreca ML, 1999, BIOORGAN MED CHEM, V7, P2283, DOI 10.1016/S0968-0896(99)00181-9
   Belmiloud Y., 2008, BIOSCIENCES BIOTECHN, V5, P507
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   CARLONI P, 1995, CHEM PHYS LETT, V234, P50, DOI 10.1016/0009-2614(94)01488-H
   Carloni P, 2000, J PHYS CHEM B, V104, P823, DOI 10.1021/jp992590x                                                               
   Chauhan AS, 2003, J CONTROL RELEASE, V90, P335, DOI 10.1016/S0168-3659(03)00200-1
   COLLINS JB, 1976, J CHEM PHYS, V64, P5142, DOI 10.1063/1.432189
   Costa S, 2007, PHYS STATUS SOLIDI B, V244, P4315, DOI 10.1002/pssb.200776155
   Dans PD, 2008, J CHEM THEORY COMPUT, V4, P740, DOI 10.1021/ct7002385
   Dans PD, 2009, J CHEM INF MODEL, V49, P1407, DOI 10.1021/ci800421w
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   de Berredo RC, 2011, COMPUT THEOR CHEM, V965, P236, DOI 10.1016/j.comptc.2011.02.007
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   DITCHFIELD R, 1974, MOL PHYS, V27, P789, DOI 10.1080/00268977400100711                                                       
   Dziadziuszko R, 2003, EUR J CANCER, V39, P1271, DOI 10.1016/S0959-8049(03)00234-X
   Eriksson MAL, 1999, J MED CHEM, V42, P868, DOI 10.1021/jm980277y                                                               
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Figgen D, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3119665
   FREEMAN W, 1976, J MAGN RESON, V22, P473, DOI 10.1016/0022-2364(76)90010-X                                                    
   Fumoleau P, 2004, EUR J CANCER, V40, P536, DOI 10.1016/j.ejca.2003.11.007
   Gabano E, 2006, COORDIN CHEM REV, V250, P2158, DOI 10.1016/j.ccr.2006.02.011
   Garg R, 1999, CHEM REV, V99, P3525, DOI 10.1021/cr9703358                                                               
   Giorgio CG, 2005, LUNG CANCER-J IASLC, V50, P247, DOI 10.1016/j.lungcan.2005.05.026
   GUNDERSEN S, 1994, EUR J CANCER, V30A, P1775, DOI 10.1016/0959-8049(94)00213-O
   Gupta U, 2007, J PHARM PHARM SCI, V10, P358
   Gupta U, 2006, NANOMED-NANOTECHNOL, V2, P66, DOI 10.1016/j.nano.2006.04.002
   Haase D, 2011, CARBON NANOSTRUCT, P247, DOI 10.1007/978-3-642-14802-6_13
   Hampel S, 2008, NANOMEDICINE-UK, V3, P175, DOI 10.2217/17435889.3.2.175
   HEHRE WJ, 1969, J CHEM PHYS, V51, P2657, DOI 10.1063/1.1672392                                                               
   Hemmateenejad B, 2007, J IRAN CHEM SOC, V4, P481, DOI 10.1007/BF03247236                                                              
   Hemmateenejad B, 2005, J MOL STRUC-THEOCHEM, V732, P39, DOI 10.1016/j.theochem.2005.07.015
   Hilder T.A, 2007, CURRENT APPL PHYS, V18
   Hilder TA, 2008, CURR APPL PHYS, V8, P258, DOI 10.1016/j.cap.2007.10.011
   [Anonymous], HYPERCHEM7 5 WIND
   Jingshan R., 1995, STRUCTURE, V3, P915
   Kandaswamy J, 2008, ANAL BIOCHEM, V381, P18, DOI 10.1016/j.ab.2008.06.017
   Klingeler R, 2008, INT J HYPERTHER, V24, P496, DOI 10.1080/02656730802154786
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Kunze D, 2008, EUR UROL SUPPL, V7, P277, DOI 10.1016/S1569-9056(08)60820-9
   Larder B.A., 1993, INHIBITORS HIV REVER, P205
   Liu Z, 2008, CANCER RES, V68, P6652, DOI 10.1158/0008-5472.CAN-08-1468
   London F., 1937, J PHYS RADIUM, V8, P3974
   MILBURN GHW, 1966, J CHEM SOC A, P1609, DOI 10.1039/j19660001609                                                            
   Perez P, 2003, TETRAHEDRON, V59, P3117, DOI 10.1016/S0040-4020(03)00374-0
   Ravdin PM, 1997, EUR J CANCER, V33, pS7, DOI 10.1016/S0959-8049(97)90002-2
   Robertazzi A, 2004, J COMPUT CHEM, V25, P1060, DOI 10.1002/jcc.20038
   ROCHON FD, 1991, MAGN RESON CHEM, V29, P120, DOI 10.1002/mrc.1260290205                                                          
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   SCHAFER W, 1993, J MED CHEM, V36, P726, DOI 10.1021/jm00058a009
   Sebastiani D, 2008, ACS NANO, V2, P661, DOI 10.1021/nn700147w
   Singh P, 2008, BIOCONJUGATE CHEM, V19, P2239, DOI 10.1021/bc800125u
   Smith MBK, 2000, PROTEIN ENG, V13, P413, DOI 10.1093/protein/13.6.413
   Smith RH, 1998, J MED CHEM, V41, P5272, DOI 10.1021/jm9804174                                                               
   Taylor A, 2009, J NANOSCI NANOTECHNO, V9, P5709, DOI 10.1166/jnn.2009.1224
   Tekade RK, 2009, CHEM REV, V109, P49, DOI 10.1021/cr068212n
   TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0                                                                
   Turston DE, 2006, CHEM PHARM ANTICANCE, P37
   Wang LX, 2010, J MOL STRUC-THEOCHEM, V940, P76, DOI 10.1016/j.theochem.2009.10.013
   WHITE CT, 1993, PHYS REV B, V47, P5485, DOI 10.1103/PhysRevB.47.5485
   WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005
   Yanai T, 2004, CHEM PHYS LETT, V393, P51, DOI 10.1016/j.cplett.2004.06.011
NR 68
TC 6
Z9 6
U1 1
U2 17
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 978-0-7354-1057-2
J9 AIP CONF PROC
PY 2012
VL 1456
BP 229
EP 239
DI 10.1063/1.4730664
PG 11
WC Chemistry, Multidisciplinary; Physics, Applied
SC Chemistry; Physics
GA BBH81
UT WOS:000306907400024
DA 2018-01-05
ER

PT J
AU Xu, D
   Hu, ZH
   Su, J
   Wu, F
   Yuan, WE
AF Xu, Dan
   Hu, Zhenhua
   Su, Jing
   Wu, Fei
   Yuan, Weien
TI Micro and Nanotechnology for Intracellular Delivery Therapy Protein
SO NANO-MICRO LETTERS
LA English
DT Review
DE Intracellular delivery; Protein; Nanoparticle
ID HUMAN IMMUNODEFICIENCY VIRUS; CONTROLLED-RELEASE; SUSTAINED-RELEASE;
   IN-VIVO; TRANSDUCTION DOMAINS; DRUG-DELIVERY; LIPOSOMES; MICROPARTICLES;
   POLYMERS; CELLS
AB Proteins therapy is of great importance in the treatment of protein deficiency disease. Most human diseases are related to the malfunctioning of one or more proteins. The most effective and direct approach is protein therapy, which delivers the proteins into the target cell to replace the dysfunction protein and maintain the balance of organism. However, clinical application is frequently hampered by various biological harriers to their successful delivery. This review aims to discuss the recent advances about microparticles and nanoparticles fabricated using micro and nanotechnology for intracellular delivery therapy protein and give some suggestions about the promising delivery system.
C1 [Xu, Dan; Hu, Zhenhua; Su, Jing; Wu, Fei; Yuan, Weien] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China.
RP Wu, F (reprint author), Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.
EM gracefei@126.com; yuanweien@126.com
FU program of Major scientific and technological specialized project for
   "significant new formulation of new drugs" [2009ZX09310-007,
   2009ZX09301-007]; National Science Foundation of China Committee
   [30873180]; Ph.D. Programs Foundation of Ministry of Education of China
   [20090073120085]; Shanghai Science and Technology Committee
   [0952nm03700]
FX This work was partially supported by the program of Major scientific and
   technological specialized project for "significant new formulation of
   new drugs" (No. 2009ZX09310-007 and No. 2009ZX09301-007), National
   Science Foundation of China Committee (No. 30873180), Ph.D. Programs
   Foundation of Ministry of Education of China (No. 20090073120085), and
   the Shanghai Science and Technology Committee (No. 0952nm03700 and No.
   0952nm03700). The authors thank the Analytical Center of Shanghai
   Jiao-Tong University for Technical Support.
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Botterhuis NE, 2006, CHEM-EUR J, V12, P1448, DOI 10.1002/chem.200500588
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Bratt-Leal AM, 2011, BIOMATERIALS, V32, P48, DOI 10.1016/j.biomaterials.2010.08.113
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Dass CR, 1997, J PHARM PHARMACOL, V49, P972, DOI 10.1111/j.2042-7158.1997.tb06025.x                                              
   Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276
   Formiga FR, 2010, J CONTROL RELEASE, V147, P30, DOI 10.1016/j.jconrel.2010.07.097
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Geng Y, 2008, J CONTROL RELEASE, V130, P259, DOI 10.1016/j.jconrel.2008.06.011
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guelen B., 2004, ONCOGENE, V23, P1153, DOI DOI 10.1038/SJ.ONC.1207224
   Di Guglielmo G. M., 2003, NAT CELL BIOL, V5, P410, DOI DOI 10.1038/NCB975
   Ho A, 2001, CANCER RES, V61, P474
   Jiang WL, 2001, PHARMACEUT RES, V18, P878, DOI 10.1023/A:1011009117586                                                         
   Jostel A, 2005, CLIN ENDOCRINOL, V62, P623, DOI 10.1111/j.1365-2265.2005.02271.x
   Kusonwiriyawong C, 2003, EUR J PHARM BIOPHARM, V56, P237, DOI 10.1016/S0939-6411(03)00093-6
   Lai CY, 2003, J AM CHEM SOC, V125, P4451, DOI 10.1021/ja028650l
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Liechty WB, 2009, ADV MATER, V21, P3910, DOI 10.1002/adma.200901733
   Marc S., 2007, J CONTROL RELEASE, V119, P301, DOI DOI 10.1016/J.JCONREL.2007.03.003
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Porter AE, 2007, NAT NANOTECHNOL, V2, P713, DOI 10.1038/nnano.2007.347
   SESSA G, 1968, J LIPID RES, V9, P310
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Sun J, 2009, INT J CANCER, V124, P2973, DOI 10.1002/ijc.24279
   Tan ML, 2010, PEPTIDES, V31, P184, DOI 10.1016/j.peptides.2009.10.002
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Vinogradov SV, 2002, ADV DRUG DELIVER REV, V54, P135, DOI 10.1016/S0169-409X(01)00245-9                                                   
   Wan RQ, 1998, NEUROREPORT, V9, P677, DOI 10.1097/00001756-199803090-00021                                                
   Wang Wei, 1999, International Journal of Pharmaceutics (Amsterdam), V185, P129, DOI 10.1016/S0378-5173(99)00152-0
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
   Yessine MA, 2003, BBA-BIOMEMBRANES, V1613, P28, DOI 10.1016/S0005-2736(03)00137-8
   Yuan WE, 2009, POLYM ADVAN TECHNOL, V20, P834, DOI 10.1002/pat.1338
   Yuan WE, 2009, INT J PHARM, V366, P154, DOI 10.1016/j.ijpharm.2008.09.007
   Zamecnik J, 2004, NEUROPATH APPL NEURO, V30, P338, DOI 10.1046/j.1365-2990.2003.0541.x
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
NR 38
TC 10
Z9 10
U1 4
U2 33
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2311-6706
EI 2150-5551
J9 NANO-MICRO LETT
JI Nano-Micro Lett.
PY 2012
VL 4
IS 2
BP 118
EP 123
DI 10.3786/nml.v4i2.p118-123
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 982PS
UT WOS:000307058500009
DA 2018-01-05
ER

PT J
AU Zhou, WB
   Liu, XS
   Ji, J
AF Zhou, Wenbo
   Liu, Xiangsheng
   Ji, Jian
TI Fast and selective cancer cell uptake of therapeutic gold nanorods by
   surface modifications with phosphorylcholine and Tat
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID SYNTHETIC MULTIVALENT LIGANDS; NANOPARTICLES; DELIVERY; GROWTH; PROBES
AB Dual functionalization of gold nanorods (GNRs) with two kinds of surface ligands has been achieved. Phosphorylcholine (PC) could impart the GNRs with both biostability in the physiological environment and targetability towards cancer cells uniquely. On the other hand, the protein transduction domain of human immunodeficiency virus type 1 Tat peptide could induce the GNRs to be quickly internalized through cell membranes. The inductively coupled plasma mass spectroscopy (ICP-MS), TEM and UV-Vis assays all demonstrated that such dual-ligand GNRs exhibited both fast and selective cancer cell uptake advantages, which were utilized for more efficient cancer cell ablation under near-infrared (NIR) irradiation. This mode of the multivalent scaffold offers an optimized choice for future cell-based therapies.
C1 [Zhou, Wenbo; Liu, Xiangsheng; Ji, Jian] Zhejiang Univ, MOE Key Lab Macromol Synth & Functionalizat, Dept Polymer Sci & Engn, Hangzhou 310027, Peoples R China.
RP Ji, J (reprint author), Zhejiang Univ, MOE Key Lab Macromol Synth & Functionalizat, Dept Polymer Sci & Engn, Hangzhou 310027, Peoples R China.
EM jijian@zju.edu.cn
RI Zhou, Wenbo /A-7000-2013
OI Zhou, Wenbo /0000-0002-2431-8131; Ji, Jian/0000-0001-9870-4038
FU NSFC [50830106, 21174126]; National Science Fund for Distinguished Young
   Scholars [51025312]; National Basic Research Program of China
   [2011CB606203]; Ph. D. Programs Foundation of Ministry of Education of
   China [20110101110037]; State Key Laboratory of Supramolecular Structure
   and Materials (SKLSSM) [201204]
FX Financial supports from the NSFC-50830106, 21174126, National Science
   Fund for Distinguished Young Scholars (51025312), the National Basic
   Research Program of China (2011CB606203), Ph. D. Programs Foundation of
   Ministry of Education of China (20110101110037) and Open Project of
   State Key Laboratory of Supramolecular Structure and Materials (SKLSSM
   201204) are gratefully acknowledged.
CR Chen SF, 2005, J AM CHEM SOC, V127, P14473, DOI 10.1021/ja054169u
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293
   Ferrari M, 2008, NAT NANOTECHNOL, V3, P131, DOI 10.1038/nnano.2008.46
   Froment G. F., 2010, CHEM REACTOR ANAL DE
   Gestwicki JE, 2000, CHEM BIOL, V7, P583, DOI 10.1016/S1074-5521(00)00002-8                                                   
   Hower JC, 2009, J PHYS CHEM B, V113, P197, DOI 10.1021/jp8065713
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Iwasaki Y, 2005, ANAL BIOANAL CHEM, V381, P534, DOI 10.1007/s00216-004-2805-9
   Jin Q, 2008, CHEM COMMUN, P3058, DOI 10.1039/b801959b
   Joshi A, 2008, CHEM-EUR J, V14, P7738, DOI 10.1002/chem.200800278
   Kiessling LL, 2006, ANGEW CHEM INT EDIT, V45, P2348, DOI 10.1002/anie.200502794
   Lee BW, 2010, ANGEW CHEM INT EDIT, V49, P1971, DOI 10.1002/anie.200906482
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murphy CJ, 2005, J PHYS CHEM B, V109, P13857, DOI 10.1021/jp0516846
   Murphy CJ, 2002, ADV MATER, V14, P80, DOI 10.1002/1521-4095(20020104)14:1<80::AID-ADMA80>3.0.CO;2-#                       
   Nelson D. L., 2010, LEHNINGER PRINCIPLES
   Nicolaides NC, 2010, EXPERT OPIN DRUG DIS, V5, P1123, DOI 10.1517/17460441.2010.521496
   Nikoobakht B, 2003, CHEM MATER, V15, P1957, DOI 10.1021/cm0207321
   Owen RM, 2007, CHEMBIOCHEM, V8, P68, DOI 10.1002/cbic.200600339
   Oyelere AK, 2007, BIOCONJUGATE CHEM, V18, P1490, DOI 10.1021/bc070132i
   Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z
   Tassa C, 2010, BIOCONJUGATE CHEM, V21, P14, DOI 10.1021/bc900438a
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Wang LM, 2011, NANO LETT, V11, P772, DOI 10.1021/nl103992v
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Yu CX, 2007, NANO LETT, V7, P2300, DOI 10.1021/nl070894m
   ZHOU W, UNPUB
   Zhou WB, 2010, CHEM COMMUN, V46, P1479, DOI 10.1039/b915125g
NR 32
TC 14
Z9 14
U1 0
U2 40
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2012
VL 22
IS 28
BP 13969
EP 13976
DI 10.1039/c2jm16713a
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 965VU
UT WOS:000305796300019
DA 2018-01-05
ER

PT J
AU Liu, Y
   Huang, CZ
AF Liu, Yue
   Huang, Cheng Zhi
TI One-step conjugation chemistry of DNA with highly scattered silver
   nanoparticles for sandwich detection of DNA
SO ANALYST
LA English
DT Article
ID GOLD NANOPARTICLES; AQUEOUS DISPERSIONS; RAMAN-SCATTERING;
   HYBRIDIZATION; OLIGONUCLEOTIDES; AGGREGATION; STABILITY; FILMS; ASSAY
AB DNA-silver nanoparticle (AgNP) conjugates were facilely prepared through a one-step method, and then used for the quantitative detection of HIV DNA with a sandwich strategy based on their strong plasmon resonance scattering signals.
C1 [Liu, Yue; Huang, Cheng Zhi] Southwest Univ, Sch Chem & Chem Engn, Key Lab Luminescence & Real Time Anal, Educ Minist, Chongqing 400715, Peoples R China.
   [Huang, Cheng Zhi] Southwest Univ, Coll Pharmaceut Sci, Chongqing 400716, Peoples R China.
RP Huang, CZ (reprint author), Southwest Univ, Sch Chem & Chem Engn, Key Lab Luminescence & Real Time Anal, Educ Minist, Chongqing 400715, Peoples R China.
EM chengzhi@swu.edu.cn
FU National Natural Science Foundation of China (NSFC) [2011CB933500,
   21035005]; Postgraduate Science and Technology Innovation Program of
   Southwest China University [ky2011006]
FX This work was financially supported by the National Natural Science
   Foundation of China (NSFC, no. 2011CB933500 and 21035005) and the
   Postgraduate Science and Technology Innovation Program of Southwest
   China University (grant ky2011006).
CR Cao YW, 2001, J AM CHEM SOC, V123, P7961, DOI 10.1021/ja011342n
   Chen LQ, 2010, J PHYS CHEM B, V114, P3655, DOI 10.1021/jp9104618
   Chimentao RJ, 2004, CHEM COMMUN, P846, DOI 10.1039/b400762j
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Dhar S, 2009, J AM CHEM SOC, V131, P14652, DOI 10.1021/ja9071282
   Dougan JA, 2007, NUCLEIC ACIDS RES, V35, P3668, DOI 10.1093/nar/gkm237
   Du BA, 2006, ANGEW CHEM INT EDIT, V45, P8022, DOI 10.1002/anie.200603331
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Graham D, 2008, NAT NANOTECHNOL, V3, P548, DOI 10.1038/nnano.2008.189
   Graham D, 2006, CHEM COMMUN, P4363, DOI 10.1039/b607904k
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Huschka R, 2010, NANO LETT, V10, P4117, DOI 10.1021/nl102293b
   Lee JS, 2007, NANO LETT, V7, P2112, DOI 10.1021/nl071108g
   Li H, 2010, ANAL CHEM, V82, P5477, DOI 10.1021/ac101193e
   Lin JH, 2010, ANAL CHEM, V82, P8775, DOI 10.1021/ac102020n
   Liu J, 2006, NAT PROTOC, V1, P246, DOI 10.1038/nprot.2006.38
   Liu ZD, 2009, ENVIRON SCI TECHNOL, V43, P5022, DOI 10.1021/es9001983
   Oh JH, 2011, ANAL CHEM, V83, P7364, DOI 10.1021/ac201291y
   Qi WJ, 2010, CHEM COMMUN, V46, P4893, DOI 10.1039/c0cc00886a
   Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559
   Schultz S, 2000, P NATL ACAD SCI USA, V97, P996, DOI 10.1073/pnas.97.3.996                                                           
   Sharma J, 2008, CHEM COMMUN, P2140, DOI 10.1039/b800109j
   Thompson DG, 2008, ANAL CHEM, V80, P2805, DOI 10.1021/ac702403w
   Tokareva I, 2004, J AM CHEM SOC, V126, P15784, DOI 10.1021/ja046779k
   Vidal BC, 2005, NEW J CHEM, V29, P812, DOI 10.1039/b417683a
   Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759
   Yin YD, 2002, J MATER CHEM, V12, P522, DOI 10.1039/b107469e
   Zhang L, 2010, CHEM COMMUN, V46, P4303, DOI 10.1039/c0cc00231c
   Zu YB, 2009, ANAL CHEM, V81, P8523, DOI 10.1021/ac901459v
   Zu Y., 2010, WO Pat., Patent No. 2010110749
NR 30
TC 16
Z9 17
U1 5
U2 37
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
J9 ANALYST
JI Analyst
PY 2012
VL 137
IS 15
BP 3434
EP 3436
DI 10.1039/c2an35167f
PG 3
WC Chemistry, Analytical
SC Chemistry
GA 967CC
UT WOS:000305882700005
PM 22669124
DA 2018-01-05
ER

PT J
AU Meng, Y
   Liu, SF
   Li, J
   Meng, YF
   Zhao, XJ
AF Meng, Yao
   Liu, Shuangfeng
   Li, Juan
   Meng, Yanfa
   Zhao, Xiaojun
TI Preparation of an antitumor and antivirus agent: chemical modification
   of alpha-MMC and MAP30 from Momordica Charantia L. with covalent
   conjugation of polyethyelene glycol
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE ribosome-inactivating proteins; alpha-momorcharin; momordica anti-HIV
   protein; antitumor; antivirus; (mPEG)(2)-Lys-NHS (20 kDa);
   immunogenicity
ID RIBOSOME-INACTIVATING PROTEINS; ANTI-HIV; INFECTED-CELLS; PEGYLATION;
   REPLICATION; INHIBITOR; GAP31
AB Background: Alpha-momorcharin (alpha-MMC) and momordica anti-HIV protein (MAP30) derived from Momordica charantia L. have been confirmed to possess antitumor and antivirus activities due to their RNA-N-glycosidase activity. However, strong immunogenicity and short plasma half-life limit their clinical application. To solve this problem, the two proteins were modified with (mPEG)(2)-Lys-NHS (20 kDa).
   Methodology/principal findings: In this article, a novel purification strategy for the two main type I ribosome-inactivating proteins (RIPs), alpha-MMC and MAP30, was successfully developed for laboratory-scale preparation. Using this dramatic method, 200 mg of alpha-MMC and about 120 mg of MAP30 was obtained in only one purification process from 200 g of Momordica charantia seeds. The homogeneity and some other properties of the two proteins were assessed by gradient SDS-PAGE, electrospray ionization quadruple mass spectrometry, and N-terminal sequence analysis as well as Western blot. Two polyethylene glycol (PEG)ylated proteins were synthesized and purified. Homogeneous mono-, di-, or tri-PEGylated proteins were characterized by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The analysis of antitumor and antivirus activities indicated that the serial PEGylated RIPs preserved moderate activities on JAR choriocarcinoma cells and herpes simplex virus-1. Furthermore, both PEGylated proteins showed about 60%-70% antitumor and antivirus activities, and at the same time decreased 50%-70% immunogenicity when compared with their unmodified counterparts.
   Conclusion/significance: alpha-MMC and MAP30 obtained from this novel purification strategy can meet the requirement of a large amount of samples for research. Their chemical modification can solve the problem of strong immunogenicity and meanwhile preserve moderate activities. All these findings suggest the potential application of PEGylated alpha-MMC and PEGylated MAP30 as antitumor and antivirus agents. According to these results, PEGylated RIPs can be constructed with nanomaterials to be a targeting drug that can further decrease immunogenicity and side effects. Through nanotechnology we can make them low-release drugs, which can further prolong their half-life period in the human body.
C1 [Meng, Yao; Zhao, Xiaojun] Sichuan Univ, W China Hosp Lab Nanomed, Chengdu 610041, Peoples R China.
   [Meng, Yao; Liu, Shuangfeng] Chengdu Med Coll, Sch Med Lab Sci, Chengdu, Peoples R China.
   [Meng, Yao; Zhao, Xiaojun] Sichuan Univ, Inst Nanobiomed Technol & Membrane Biol, Chengdu 610041, Peoples R China.
   [Li, Juan; Meng, Yanfa] Sichuan Univ, Coll Life Sci, Key Lab Bioresources & Ecoenvironm,Minist Educ, Anim Dis Prevent & Food Safety Key Lab Sichuan Pr, Chengdu 610064, Peoples R China.
   [Zhao, Xiaojun] Harvard Univ, MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA.
RP Zhao, XJ (reprint author), Sichuan Univ, W China Hosp Lab Nanomed, Ke Yuan 4th St, Chengdu 610041, Peoples R China.
EM yfmeng0902@scu.edu.cn; xiaojunz@mit.edu
FU National Science Foundation of China [30770232]
FX This work was supported by the National Science Foundation of China
   (Grant No 30770232).
CR Bourinbaiar AS, 1996, BIOCHEM BIOPH RES CO, V219, P923, DOI 10.1006/bbrc.1996.0334
   FOATOMASI L, 1982, ARCH VIROL, V71, P323, DOI 10.1007/BF01315062
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2
   Huang PL, 1999, BIOCHEM BIOPH RES CO, V262, P615, DOI 10.1006/bbrc.1999.1213                                                          
   Kozlowski A, 2001, J CONTROL RELEASE, V72, P217, DOI 10.1016/S0168-3659(01)00277-2
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678
   LEEHUANG S, 1995, GENE, V161, P151, DOI 10.1016/0378-1119(95)00186-A
   LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O
   Li ME, 2009, ACTA BIOCH BIOPH SIN, V41, P792, DOI 10.1093/abbs/gmp068
   Lord J M, 1991, Semin Cell Biol, V2, P15
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NG TB, 1993, BIOCHEM MOL BIOL INT, V31, P447
   Read BE, 1956, PEN TSAO KANG MU
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
NR 21
TC 14
Z9 15
U1 1
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 3133
EP 3142
DI 10.2147/IJN.S30631
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 965JH
UT WOS:000305763400001
PM 22802682
OA gold
DA 2018-01-05
ER

PT S
AU McNeela, EA
   Lavelle, EC
AF McNeela, E. A.
   Lavelle, E. C.
BE Kozlowski, PA
TI Recent Advances in Microparticle and Nanoparticle Delivery Vehicles for
   Mucosal Vaccination
SO MUCOSAL VACCINES: MODERN CONCEPTS, STRATEGIES, AND CHALLENGES
SE Current Topics in Microbiology and Immunology
LA English
DT Review; Book Chapter
ID SYSTEMIC IMMUNE-RESPONSES; INTESTINAL M-CELLS; INACTIVATED
   HIV-1-CAPTURING NANOSPHERES; BORDETELLA-PERTUSSIS INFECTION;
   NASOPHARYNGEAL LYMPHOID-TISSUE; CYTOTOXIC T-LYMPHOCYTES; TARGETED
   DRUG-DELIVERY; PEG-PLA NANOPARTICLES; SIMPLEX-VIRUS TYPE-2; TOLL-LIKE
   RECEPTORS
AB The great potential of mucosal vaccination is widely accepted but progress in the clinical development of subunit mucosal vaccines has been disappointing. Of the available approaches, the use of polymer-based microparticles is attractive because these delivery vehicles can be specifically tailored for vaccines and they offer the potential for integration of adjuvant. Here we address recent developments in the use of particulates as mucosal vaccines and the potential of novel targeting strategies, formulation approaches and adjuvant combinations to enhance the efficacy of particle-based mucosal vaccines. This review discusses the current status of mucosal vaccines based on particles and highlights several of the strategies that are currently under investigation for improving their immunogenicity. These include enhancing the stability of formulations in the luminal environment, increasing uptake by specifically targeting particles to mucosal inductive sites, and augmenting immunogenicity through co-formulation with immunostimulatory agents.
C1 [McNeela, E. A.; Lavelle, E. C.] Trinity Coll Dublin, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin 2, Ireland.
RP McNeela, EA (reprint author), Trinity Coll Dublin, Adjuvant Res Grp, Sch Biochem & Immunol, Dublin 2, Ireland.
EM mcneele@tcd.ie
OI Lavelle, Ed/0000-0002-3167-1080
CR AGUADO MT, 1992, IMMUNOBIOLOGY, V184, P113, DOI 10.1016/S0171-2985(11)80470-5                                                   
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AllaouiAttarki K, 1997, INFECT IMMUN, V65, P853
   Almeida AJ, 1996, J DRUG TARGET, V3, P455, DOI 10.3109/10611869609015965                                                       
   Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
   Beier R, 1998, AM J PHYSIOL-GASTR L, V275, pG130
   Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Boland G, 2004, VACCINE, V23, P316, DOI 10.1016/j.vaccine.2004.06.006
   Bowman K, 2006, INT J NANOMED, V1, P117, DOI 10.2147/nano.2006.1.2.117
   Brandtzaeg Per, 2008, P33, DOI 10.1007/978-1-4020-8412-6_3
   Brayden DJ, 2001, EUR J PHARM SCI, V14, P183, DOI 10.1016/S0928-0987(01)00175-0                                                   
   Brooking J, 2001, J DRUG TARGET, V9, P267, DOI 10.3109/10611860108997935                                                       
   CAHILL ES, 1995, VACCINE, V13, P455, DOI 10.1016/0264-410X(94)00008-B                                                    
   Carcaboso AM, 2004, VACCINE, V22, P1423, DOI 10.1016/j.vaccine.2003.10.020
   Carcaboso AM, 2003, INT J PHARM, V260, P273, DOI 10.1016/S0378-5173(03)00266-7
   Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966                                                      
   Carpenter ZK, 2005, J CONTROL RELEASE, V104, P67, DOI 10.1016/j.jconrel.2005.01.014
   Chabot S, 2006, J IMMUNOL, V176, P4275, DOI 10.4049/jimmunol.176.7.4275                                                     
   CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164
   Chen F, 2008, INT J PHARM, V349, P226, DOI 10.1016/j.ijpharm.2007.07.035
   Chourasia MK, 2003, J PHARM PHARM SCI, V6, P33
   Clark MA, 2001, VACCINE, V20, P208
   Cleland JL, 1999, TRENDS BIOTECHNOL, V17, P25, DOI 10.1016/S0167-7799(98)01272-4
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   Coombes AGA, 1999, VACCINE, V17, P2410, DOI 10.1016/S0264-410X(99)00025-0
   Cranage Martin P, 2009, Expert Rev Anti Infect Ther, V7, P21, DOI 10.1586/14787210.7.1.21
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Czerkinsky C, 2011, CURR TOP MI IN PRESS
   Dailey LA, 2005, J CONTROL RELEASE, V101, P137, DOI 10.1016/j.jconrel.2004.09.03
   Damge C, 1996, J ANAT, V189, P491
   Dea-Ayuela MA, 2006, J DRUG TARGET, V14, P567, DOI 10.1080/10611860600849464
   Delgado A, 1999, VACCINE, V17, P2927, DOI 10.1016/S0264-410X(99)00140-1                                                   
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dong Z, 2005, AM J RHINOL, V19, P236
   Douce G, 1999, INFECT IMMUN, V67, P4400
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   ELDRIDGE JH, 1989, ADV EXP MED BIOL, V251, P191
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   Fattal E, 2002, INT J PHARM, V242, P15, DOI 10.1016/S0378-5173(02)00181-3
   FLORENCE AT, 1995, J DRUG TARGET, V3, P65, DOI 10.3109/10611869509015936                                                       
   Florindo HF, 2009, VACCINE, V27, P1230, DOI 10.1016/j.vaccine.2008.12.004
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Foster N, 2005, ADV DRUG DELIVER REV, V57, P431, DOI 10.1016/j.addr.2004.09.009
   Foster N, 1998, VACCINE, V16, P536, DOI 10.1016/S0264-410X(97)00222-3
   Fujimura Y, 2000, VIRCHOWS ARCH, V436, P560, DOI 10.1007/s004289900177                                                           
   Fujimura Y, 2006, MED MOL MORPHOL, V39, P181, DOI 10.1007/s00795-006-0335-6
   Gallichan WS, 2001, J IMMUNOL, V166, P3451, DOI 10.4049/jimmunol.166.5.3451                                                     
   Garinot M, 2007, J CONTROL RELEASE, V120, P195, DOI 10.1016/j.jconrel.2007.04.021
   GIANNASCA PJ, 1994, AM J PHYSIOL-GASTR L, V267, pG1108
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Gupta PN, 2007, J DRUG TARGET, V15, P701, DOI 10.1080/10611860701637982
   Gupta RK, 1998, ADV DRUG DELIV REV, V32, P225
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   Haltner E, 1997, EUR J PHARM BIOPHARM, V44, P3, DOI 10.1016/S0939-6411(97)00096-9
   Hamashin C, 2003, BIOORGAN MED CHEM, V11, P4991, DOI 10.1016/j.bmc.2003.09.002
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000                                                   
   Heritage PL, 1998, IMMUNOLOGY, V93, P249
   Herrmann JE, 1999, VIROLOGY, V259, P148, DOI 10.1006/viro.1999.9751
   Hussain N, 1998, PHARMACEUT RES, V15, P153, DOI 10.1023/A:1011981610840                                                         
   ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450
   Iqbal M, 2003, VACCINE, V21, P1478, DOI 10.1016/S0264-410X(02)00662-X
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x                                              
   JANI PU, 1992, INT J PHARM, V84, P245, DOI 10.1016/0378-5173(92)90162-U                                                    
   JEPSON MA, 1993, CELL TISSUE RES, V271, P399, DOI 10.1007/BF02913722                                                              
   Jepson MA, 1993, J DRUG TARGET, V1, P245, DOI 10.3109/10611869308996082
   Jones DH, 1996, INFECT IMMUN, V64, P489
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Kang ML, 2009, BIOTECHNOL ADV, V27, P857, DOI 10.1016/j.biotechadv.2009.06.007
   Katz DE, 2003, VACCINE, V21, P341, DOI 10.1016/S0264-410X(02)00613-8                                                   
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Kende M, 2002, VACCINE, V20, P1681, DOI 10.1016/S0264-410X(01)00484-4                                                   
   Kerr JR, 1999, J CLIN PATHOL-MOL PA, V52, P220
   Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lambert JS, 2001, VACCINE, V19, P3033, DOI 10.1016/S0264-410X(01)00051-2
   Lambkin I, 2003, PHARMACEUT RES, V20, P1258, DOI 10.1023/A:1025061317400
   Lavelle EC, 2005, CELL MOL LIFE SCI, V62, P2750, DOI 10.1007/s00018-005-5290-1
   Lavelle EC, 2001, CRIT REV THER DRUG, V18, P341
   Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17                                                       
   Lin SY, 2000, J MICROENCAPSUL, V17, P577
   Lunsford L, 2000, J DRUG TARGET, V8, P39, DOI 10.3109/10611860009009208                                                       
   Luzardo-Alvarez A, 2005, J CONTROL RELEASE, V109, P62, DOI 10.1016/j.jconrel.2005.09.015
   Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865
   McClean S, 1998, EUR J PHARM SCI, V6, P153, DOI 10.1016/S0928-0987(97)10007-0
   McCluskie MJ, 2000, VACCINE, V19, P950, DOI 10.1016/S0264-410X(00)00215-2                                                   
   Mestecky J, 2009, IMMUNOL LETT, V124, P57, DOI 10.1016/j.imlet.2009.03.013
   Minne A, 2007, IMMUNOLOGY, V122, P316, DOI 10.1111/j.1365-2567.2007.02641.x
   Minor P, 2009, VACCINE, V27, P2649, DOI 10.1016/j.vaccine.2009.02.071
   Misumi S, 2009, J IMMUNOL, V182, P6061, DOI 10.4049/jimmunol.0802928
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   MOLDOVEANU Z, 1993, J INFECT DIS, V167, P84, DOI 10.1093/infdis/167.1.84                                                         
   Monie Archana, 2008, Biologics, V2, P97
   Monteleone I, 2008, EUR J IMMUNOL, V38, P1533, DOI 10.1002/eji.200737909
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   Morcol T, 2004, INT J PHARM, V277, P91, DOI 10.1016/j.ijpharm.2003.07.016
   Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC
   NAISBETT B, 1994, INT J PHARMACEUT, V107, P223, DOI 10.1016/0378-5173(94)90438-3
   Neutra M R, 1992, Trends Cell Biol, V2, P134, DOI 10.1016/0962-8924(92)90099-9
   Newman KD, 2002, J BIOMED MATER RES, V60, P480, DOI 10.1002/jbm.10019
   Nochi T, 2007, P NATL ACAD SCI USA, V104, P10986, DOI 10.1073/pnas.0703766104
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   O'Hagan DT, 2009, DRUG DISCOV TODAY, V14, P541, DOI 10.1016/j.drudis.2009.02.009
   O'Hagan DT, 1998, J PHARM PHARMACOL, V50, P1, DOI 10.1111/j.2042-7158.1998.tb03298.x                                              
   OHagan DT, 1996, J ANAT, V189, P477
   PAPPO J, 1991, IMMUNOLOGY, V73, P277
   PARK TG, 1995, J CONTROL RELEASE, V33, P211, DOI 10.1016/0168-3659(94)00084-8
   Pun PB, 2009, INT IMMUNOPHARMACOL, V9, P468, DOI 10.1016/j.intimp.2009.01.012
   Reece JC, 2001, IMMUNOL CELL BIOL, V79, P255, DOI 10.1046/j.1440-1711.2001.01011.x                                                
   Roth-Walter F, 2005, IMMUNOL LETT, V100, P182, DOI 10.1016/j.imlet.2005.03.020
   Roy K, 1999, NAT MED, V5, P387
   Russell-Jones GJ, 2001, ADV DRUG DELIVER REV, V46, P59, DOI 10.1016/S0169-409X(00)00127-7                                                   
   Rydell N, 2006, VACCINE, V24, P5928, DOI 10.1016/j.vaccine.2006.03.001
   Saint-Lu N, 2009, ALLERGY, V64, P1003, DOI 10.1111/j.1398-9995.2009.01945.x
   Salerno-Goncalves R, 2002, J IMMUNOL, V169, P2196, DOI 10.4049/jimmunol.169.4.2196                                                     
   Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091
   Salman HH, 2007, VACCINE, V25, P8123, DOI 10.1016/j.vaccine.2007.09.044
   SASS W, 1990, AM J GASTROENTEROL, V85, P255
   Seong SY, 1999, INFECT IMMUN, V67, P3587
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Shimosato T, 2005, IMMUNOL LETT, V98, P83, DOI 10.1016/j.imlet.2004.10.026
   Shreedhar VK, 2003, INFECT IMMUN, V71, P504, DOI 10.1128/IAI.71.1.504-509.2003
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Singla AK, 2001, J PHARM PHARMACOL, V53, P1047, DOI 10.1211/0022357011776441                                                        
   SPIT BJ, 1989, CELL TISSUE RES, V255, P193
   Tabata Y, 1996, VACCINE, V14, P1677, DOI 10.1016/S0264-410X(96)00149-1
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   TACKET CO, 1994, VACCINE, V12, P1270, DOI 10.1016/S0264-410X(94)80038-2
   Tafaghodi M, 2006, INT J PHARM, V319, P37, DOI 10.1016/j.ijpharm.2006.03.047
   Takahata H, 1998, J CONTROL RELEASE, V50, P237, DOI 10.1016/S0168-3659(97)00145-4
   Tango M, 2000, ARCH HISTOL CYTOL, V63, P81, DOI 10.1679/aohc.63.81
   Tharanathan RN, 2003, CRIT REV FOOD SCI, V43, P61, DOI 10.1080/10408690390826455
   Thiele L, 2003, PHARMACEUT RES, V20, P221, DOI 10.1023/A:1022271020390
   Thompson AH, 1999, VACCINE, V17, P1404
   Tobio M, 1998, PHARMACEUT RES, V15, P270, DOI 10.1023/A:1011922819926
   Tobio M, 2000, COLLOID SURFACE B, V18, P315, DOI 10.1016/S0927-7765(99)00157-5
   Ugozzoli M, 1998, IMMUNOLOGY, V93, P563
   Vajdy M, 2001, ADV DRUG DELIVER REV, V51, P127, DOI 10.1016/S0169-409X(01)00167-3                                                   
   van Broekhoven CL, 2004, CANCER RES, V64, P4357, DOI 10.1158/0008-5472.CAN-04-0138
   van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005
   Vila A, 2002, J CONTROL RELEASE, V78, P15, DOI 10.1016/S0168-3659(01)00486-2                                                   
   Vila A, 2004, J AEROSOL MED, V17, P174, DOI 10.1089/0894268041457183
   Vila A, 2004, J CONTROL RELEASE, V98, P231, DOI 10.1016/j.jconrel.2004.04.026
   Vila A, 2002, POLYM ADVAN TECHNOL, V13, P851, DOI 10.1002/pat.280
   Vyas SP, 2007, EXPERT REV VACCINES, V6, P401, DOI 10.1586/14760584.6.3.401
   Wagner S, 2003, J IMMUNOL, V170, P1462, DOI 10.4049/jimmunol.170.3.1462                                                     
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   WATTS PJ, 1990, CRIT REV THER DRUG, V7, P235
   WhittumHudson JA, 1996, NAT MED, V2, P1116, DOI 10.1038/nm1096-1116
   WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C
   Yeh MK, 2002, J CONTROL RELEASE, V82, P237, DOI 10.1016/S0168-3659(02)00140-2                                                   
   Yue Y, 2009, VIROLOGY, V386, P438, DOI 10.1016/j.virol.2009.01.029
   Yuki Y, 2009, VACCINE, V27, P5982, DOI 10.1016/j.vaccine.2009.07.071
NR 161
TC 18
Z9 19
U1 0
U2 36
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0070-217X
BN 978-3-642-23692-1
J9 CURR TOP MICROBIOL
JI Curr.Top.Microbiol.Immunol.
PY 2012
VL 354
BP 75
EP 99
DI 10.1007/82_2011_140
D2 10.1007/978-3-642-23693-8
PG 25
WC Immunology; Microbiology
SC Immunology; Microbiology
GA BAD87
UT WOS:000303895300005
PM 21904984
DA 2018-01-05
ER

PT J
AU Kanmogne, GD
   Singh, S
   Roy, U
   Liu, XM
   McMillan, J
   Gorantla, S
   Balkundi, S
   Smith, N
   Alnouti, Y
   Gautam, N
   Zhou, Y
   Poluektova, L
   Kabanov, A
   Bronich, T
   Gendelman, HE
AF Kanmogne, Georgette D.
   Singh, Sangya
   Roy, Upal
   Liu, Xinming
   McMillan, JoEllyn
   Gorantla, Santhi
   Balkundi, Shantanu
   Smith, Nathan
   Alnouti, Yazen
   Gautam, Nagsen
   Zhou, You
   Poluektova, Larisa
   Kabanov, Alexander
   Bronich, Tatiana
   Gendelman, Howard E.
TI Mononuclear phagocyte intercellular crosstalk facilitates transmission
   of cell-targeted nanoformulated antiretroviral drugs to human brain
   endothelial cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE nanoART; folate; monocyte-endothelial cell interactions; blood-brain
   barrier; antiretroviral therapy; nanomedicine
ID HUMAN IMMUNODEFICIENCY VIRUS; CENTRAL-NERVOUS-SYSTEM; NEUROCOGNITIVE
   DISORDERS; LEUKOCYTE TRANSMIGRATION; FOLATE RECEPTOR; DELIVERY;
   NANOPARTICLES; HIV; THERAPY; BARRIER
AB Despite the successes of antiretroviral therapy (ART), HIV-associated neurocognitive disorders remain prevalent in infected people. This is due, in part, to incomplete ART penetration across the blood-brain barrier (BBB) and lymph nodes and to the establishment of viral sanctuaries within the central nervous system. In efforts to improve ART delivery, our laboratories developed a macrophage-carriage system for nanoformulated crystalline ART (nanoART) (atazanavir, ritonavir, indinavir, and efavirenz). We demonstrate that nanoART transfer from mononuclear phagocytes (MP) to human brain microvascular endothelial cells (HBMEC) can be realized through cell-to-cell contacts, which can facilitate drug passage across the BBB. Coculturing of donor MP containing nanoART with recipient HBMEC facilitates intercellular particle transfer. NanoART uptake was observed in up to 52% of HBMEC with limited cytotoxicity. Folate coating of nanoART increased MP to HBMEC particle transfer by up to 77%. To translate the cell assays into relevant animal models of disease, ritonavir and atazanavir nanoformulations were injected into HIV-1-infected NOD/scid-gamma(null)(c) null mice reconstituted with human peripheral blood lymphocytes. Atazanavir and ritonavir levels in brains of mice treated with folate-coated nanoART were three-to four-fold higher than in mice treated with noncoated particles. This was associated with decreased viral load in the spleen and brain, and diminished brain CD11b-associated glial activation. We postulate that monocyte-macrophage transfer of nanoART to brain endothelial cells could facilitate drug entry into the brain.
C1 [Kanmogne, Georgette D.; Singh, Sangya; Roy, Upal; Liu, Xinming; McMillan, JoEllyn; Gorantla, Santhi; Balkundi, Shantanu; Smith, Nathan; Poluektova, Larisa; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Alnouti, Yazen; Gautam, Nagsen; Kabanov, Alexander; Bronich, Tatiana] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Zhou, You] Univ Nebraska, Ctr Biotechnol, Lincoln, NE USA.
RP Kanmogne, GD (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM gkanmogne@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Roy, Upal/0000-0002-0325-567X; Poluektova, Larisa/0000-0001-7339-8732
FU National Institutes of Health [RO1MH081780, 1P01DA028555-01, P01
   NS043985, P30 MH062261, P20 RR15635, 2R37 NS36126, P01 NS31492, P01
   MH64570, 2R01 NS034239]
FX We thank Ms Robin Taylor for graphical support, Hong Li and Rafael
   Bressani for technical assistance, the University of Nebraska Medical
   Center Cell Analysis and FACS core facility for assistance with the FACS
   analysis, and the University of Nebraska-Lincoln microscopy core
   facility for assistance in confocal analyses. This work was supported by
   National Institutes of Health grants RO1MH081780 (to GDK);
   1P01DA028555-01, P01 NS043985, P30 MH062261, and P20 RR15635 (to HEG and
   GDK); and 2R37 NS36126, P01 NS31492, P01 MH64570, and 2R01 NS034239 (to
   HEG).
CR Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Balkundi S, 2011, INT J NANOMED, V6, P3393, DOI 10.2147/IJN.S27830
   Beduneau A, 2008, J CONTROL RELEASE, V126, P44, DOI 10.1016/j.jconrel.2007.11.001
   Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Bressani RF, 2011, NANOTOXICOLOGY, V5, P592, DOI 10.3109/17435390.2010.541292
   Buckner CM, 2006, J NEUROIMMUNE PHARM, V1, P160, DOI 10.1007/s11481-006-9017-3
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207
   Cosenza-Nashat MA, 2006, BRAIN PATHOL, V16, P256, DOI 10.1111/j.1750-3639.2006.00027.x                                                
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Ellis RJ, 2011, AIDS, V25, P1747, DOI 10.1097/QAD.0b013e32834a40cd
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Grant I., 2005, NEUROLOGY AIDS, P357
   Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727
   Huang JG, 2011, J CHROMATOGR B, V879, P2332, DOI 10.1016/j.jchromb.2011.06.032
   Kanmogne Georgette D, 2007, J Cereb Blood Flow Metab, V27, P123, DOI 10.1038/sj.jcbfm.9600330
   Kaur A, 2008, ACTA PHARMACEUT, V58, P61, DOI 10.2478/v10007-007-0045-1
   Kularatne SA, 2010, METHODS MOL BIOL, V624, P249, DOI 10.1007/978-1-60761-609-2_17
   Lu J, 2012, NANOMED-NANOTECHNOL, V8, P212, DOI 10.1016/j.nano.2011.06.002
   Lu YJ, 2002, CANCER IMMUNOL IMMUN, V51, P153, DOI 10.1007/s00262-002-0266-6
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Marraa CM, 2009, AIDS, V23, P1359, DOI 10.1097/QAD.0b013e32832c4152
   McArthur JC, 2010, ANN NEUROL, V67, P699, DOI 10.1002/ana.22053
   McMillan J, 2011, PROG MOL BIOL TRANSL, V104, P563, DOI 10.1016/B978-0-12-416020-0.00014-0
   Nath A, 2006, CURR OPIN NEUROL, V19, P358, DOI 10.1097/01.wco.0000236614.51592.ca                                              
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Patrick TA, 1997, J NEURO-ONCOL, V32, P111, DOI 10.1023/A:1005713115147                                                         
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Price RW, 2008, J INFECT DIS, V197, pS294, DOI 10.1086/533419
   Reddy JA, 2000, J CONTROL RELEASE, V64, P27, DOI 10.1016/S0168-3659(99)00135-2                                                   
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Stoddart CA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000655
   Wang X, 2009, ACS NANO, V3, P3165, DOI 10.1021/nn900649v
   Wu DF, 1999, PHARMACEUT RES, V16, P415, DOI 10.1023/A:1018829920158
   Yadav A, 2009, J NEUROIMMUNE PHARM, V4, P430, DOI 10.1007/s11481-009-9174-2
   Yang B, 2009, MICROVASC RES, V77, P212, DOI 10.1016/j.mvr.2008.11.003
   Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207
NR 45
TC 26
Z9 26
U1 0
U2 15
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2012
VL 7
BP 2373
EP 2388
DI 10.2147/IJN.S29454
PG 16
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 937NM
UT WOS:000303665200001
PM 22661891
OA gold
DA 2018-01-05
ER

PT J
AU Qin, ZP
   Chan, WCW
   Boulware, DR
   Akkin, T
   Butler, EK
   Bischof, JC
AF Qin, Zhenpeng
   Chan, Warren C. W.
   Boulware, David R.
   Akkin, Taner
   Butler, Elissa K.
   Bischof, John C.
TI Significantly Improved Analytical Sensitivity of Lateral Flow
   Immunoassays by Using Thermal Contrast
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE biosensors; diagnostics; immunoassays; nanoparticles; thermal contrast
ID RECONSTITUTION INFLAMMATORY SYNDROME; CRYPTOCOCCAL MENINGITIS; METAL
   NANOPARTICLES; GOLD NANOPARTICLES; OPTICAL-PROPERTIES; HIV; THERAPY;
   SERUM; MICROFLUIDICS; BIOMEDICINE
C1 [Qin, Zhenpeng; Bischof, John C.] Univ Minnesota, Dept Mech Engn, Minneapolis, MN 55455 USA.
   [Akkin, Taner; Bischof, John C.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
   [Bischof, John C.] Univ Minnesota, Dept Urol, Minneapolis, MN 55455 USA.
   [Boulware, David R.; Butler, Elissa K.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA.
   [Chan, Warren C. W.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [Chan, Warren C. W.] Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada.
RP Bischof, JC (reprint author), Univ Minnesota, Dept Mech Engn, 111 Church St SE, Minneapolis, MN 55455 USA.
EM bischof@umn.edu
RI Qin, Zhenpeng/N-6036-2015; Boulware, David/I-4533-2013
OI Qin, Zhenpeng/0000-0003-3406-3045; Boulware, David/0000-0002-4715-0060
FU University of Minnesota; NSF/CBET [1066343]; National Institute of
   Health, NIAID [K23AI073192, U01AI089244]
FX This work is supported partially by McKnight Professorship and Minnesota
   Futures Grant from the University of Minnesota, and NSF/CBET Grant no.
   1066343(JCB). D. R. B. is supported by the National Institute of Health,
   NIAID K23AI073192, and E. B. is supported by NIH NIAID U01AI089244. The
   authors thank Greg Huan and Vincent Blonigen for the help with the
   thermal contrast experiment, Neha Shah for the training of GNP
   synthesis, Robert Hafner and Pingyan Lei for the help with TEM imaging.
CR Bakhtiari ABS, 2009, ANGEW CHEM, V121, P4230
   Bakhtiari ABS, 2009, ANGEW CHEM INT EDIT, V48, P4166, DOI 10.1002/anie.200805303
   Bicanic T, 2009, JAIDS-J ACQ IMM DEF, V51, P130, DOI 10.1097/QAI.0b013e3181a56f2e
   Boulware DR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000384
   Boulware DR, 2010, J INFECT DIS, V202, P962, DOI 10.1086/655785
   Braun GB, 2009, ACS NANO, V3, P2007, DOI 10.1021/nn900469q
   Chen JY, 2007, NANO LETT, V7, P1318, DOI 10.1021/nl070345g
   Chin CD, 2011, NAT MED, V17, P1015, DOI 10.1038/nm.2408
   Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523
   Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h
   Galanzha EI, 2009, NAT NANOTECHNOL, V4, P855, DOI [10.1038/NNANO.2009.333, 10.1038/nnano.2009.333]
   Govorov AO, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70017-8                                                   
   Hauck TS, 2008, ADV MATER, V20, P3832, DOI 10.1002/adma.200800921
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Jain PK, 2006, J PHYS CHEM B, V110, P7238, DOI 10.1021/jp057170o
   Jarvis JN, 2011, CLIN INFECT DIS, V53, P1019, DOI 10.1093/cid/cir613
   Jarvis JN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-67
   Jarvis JN, 2009, CLIN INFECT DIS, V48, P856, DOI 10.1086/597262
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   Leduc C, 2011, ACS NANO, V5, P2587, DOI 10.1021/nn1023285
   Liu J., 2006, ANGEW CHEM, V118, P8123, DOI DOI 10.1002/ANGE.200603106
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P7955, DOI 10.1002/anie.200603106
   Lu W, 2010, CANCER RES, V70, P3177, DOI 10.1158/0008-5472.CAN-09-3379
   Maier S.A., 2007, PLASMONICS FUNDAMENT
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Meya DB, 2010, CLIN INFECT DIS, V51, P448, DOI 10.1086/655143
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Park BJ, 2009, AIDS, V23, P525, DOI 10.1097/QAD.0b013e328322ffac
   Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2
   Qin ZP, 2012, CHEM SOC REV, V41, P1191, DOI 10.1039/c1cs15184c
   Shen S, 2010, NAT NANOTECHNOL, V5, P251, DOI 10.1038/nnano.2010.27
   Siegel AC, 2009, LAB CHIP, V9, P2775, DOI 10.1039/b905832j
   von Maltzahn G, 2009, CANCER RES, V69, P3892, DOI 10.1158/0008-5472.CAN-08-4242
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 35
TC 36
Z9 36
U1 4
U2 49
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1433-7851
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2012
VL 51
IS 18
BP 4358
EP 4361
DI 10.1002/anie.201200997
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 930RZ
UT WOS:000303158300020
PM 22447488
OA green_accepted
DA 2018-01-05
ER

PT J
AU Symens, N
   Soenen, SJ
   Rejman, J
   Braeckmans, K
   De Smedt, SC
   Remaut, K
AF Symens, Nathalie
   Soenen, Stefaan J.
   Rejman, Joanna
   Braeckmans, Kevin
   De Smedt, Stefaan C.
   Remaut, Katrien
TI Intracellular partitioning of cell organelles and extraneous
   nanoparticles during mitosis
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Nonviral gene therapy or delivery particles; Quantum dots; Gold
   particles; Retroviruses; Latent viruses; Dextran; Plasmid DNA; Cell
   division; Cell cycle; Nucleus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEDIATED GENE-TRANSFER; MURINE
   LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; PAPILLOMAVIRUS E2 PROTEIN;
   LASER-SCANNING MICROSCOPY; SINGLE-PARTICLE TRACKING; CYCLIN-DEPENDENT
   KINASES; HOST MITOTIC CHROMOSOMES; NUCLEAR-PORE COMPLEX
AB The nucleocytoplasmic partitioning of nanoparticles as a result of cell division is highly relevant to the field of nonviral gene delivery. We reviewed the literature on the intracellular distribution of cell organelles (the endosomal vesicles, Golgi apparatus, endoplasmic reticulum and nucleus), foreign macromolecules (dextrans and plasmid DNA) and inorganic nanoparticles (gold, quantum dot and iron oxide) during mitosis. For nonviral gene delivery particles (lipid- or polymer-based), indirect proof of nuclear entry during mitosis is provided. We also describe how retroviruses and latent DNA viruses take advantage of mitosis to transfer their viral genome and segregate their episomes into the host daughter nuclei. Based on this knowledge, we propose strategies to improve nonviral gene delivery in dividing cells with the ultimate goal of designing nonviral gene delivery systems that are as efficient as their viral counterparts but non-immunogenic, non-oncogenic and easy and inexpensive to prepare. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Symens, Nathalie; Soenen, Stefaan J.; Rejman, Joanna; Braeckmans, Kevin; De Smedt, Stefaan C.; Remaut, Katrien] Univ Ghent, Lab Gen Biochem & Phys Pharm, Ghent Res Grp Nanomed, Fac Pharmaceut Sci, B-9000 Ghent, Belgium.
RP De Smedt, SC (reprint author), Univ Ghent, Lab Gen Biochem & Phys Pharm, Ghent Res Grp Nanomed, Fac Pharmaceut Sci, Harelbekestr 72, B-9000 Ghent, Belgium.
EM symensnathalie@hotmail.com; Stefaan.Soenen@Ugent.be;
   j_rejman@hotmail.com; Kevin.Braeckmans@Ugent.be;
   Stefaan.Desmedt@Ugent.be; Katrien.Remaut@Ugent.be
RI Remaut, Katrien/H-9535-2014; Soenen, Stefaan/D-7370-2014; Soenen,
   Stefaan/I-3188-2012
OI Remaut, Katrien/0000-0002-2244-1339; Soenen,
   Stefaan/0000-0003-2390-3133; De Smedt, Stefaan/0000-0002-8653-2598
FU The Agency for Innovation through Science and Technology in Flanders
   (IWT); Research Foundation Flanders (FWO)
FX The Agency for Innovation through Science and Technology in Flanders
   (IWT) and Research Foundation Flanders (FWO) are acknowledged with
   gratitude for their financial support.
CR Akinc A, 2005, J GENE MED, V7, P657, DOI 10.1002/jgm.696                                                                 
   Anderson JL, 2005, GENE THER, V12, P1667, DOI 10.1038/sj.gt.3302591
   Antonin W, 2008, FEBS LETT, V582, P2004, DOI 10.1016/j.febslet.2008.02.067
   BADER JP, 1967, J CELL PHYSIOL, V70, P301, DOI 10.1002/jcp.1040700310
   Barbera AJ, 2006, SCIENCE, V311, P856, DOI 10.1126/science.1120541
   Bastien N, 2000, VIROLOGY, V270, P124, DOI 10.1006/viro.2000.0265
   Bausinger R, 2006, ANGEW CHEM INT EDIT, V45, P1568, DOI 10.1002/anie.200503021
   BENAVENTE R, 1989, EUR J CELL BIOL, V50, P209
   Bergeland T, 2001, CURR BIOL, V11, P644, DOI 10.1016/S0960-9822(01)00177-4
   Bieber T, 2002, J CONTROL RELEASE, V82, P441, DOI 10.1016/S0168-3659(02)00129-3
   BIENIASZ PD, 1995, J VIROL, V69, P7295
   BIRKY CW, 1983, INT REV CYTOL, P49
   Bollen M, 2009, TRENDS CELL BIOL, V19, P531, DOI 10.1016/j.tcb.2009.06.005
   Braeckmans K, 2010, NANO LETT, V10, P4435, DOI 10.1021/nl103264u
   Breuzard G, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn287
   Brunner S, 2002, MOL THER, V5, P80, DOI 10.1006/mthe.2001.0509
   Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102
   BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4
   CAPECCHI MR, 1980, CELL, V22, P479, DOI 10.1016/0092-8674(80)90358-X
   CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295
   Conese M, 2004, GENE THER, V11, P1735, DOI 10.1038/sj.gt.3302362
   Coutinho Henrique Douglas M, 2009, Immun Ageing, V6, P4, DOI 10.1186/1742-4933-6-4
   de G.A., 2005, TRENDS BIOCHEM SCI, V30, P559
   Dean DA, 2005, GENE THER, V12, P881, DOI 10.1038/sj.gt.3302534
   Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   DOWTY ME, 1995, P NATL ACAD SCI USA, V92, P4572, DOI 10.1073/pnas.92.10.4572
   Dreaden EC, 2011, CHEM SOC REV, V40, P3391, DOI 10.1039/c0cs00180e
   Dunster K, 2002, EUR J CELL BIOL, V81, P117, DOI 10.1078/0171-9335-00232
   Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X
   Errington RJ, 2010, CELL CYCLE, V9, P121, DOI 10.4161/cc.9.1.10246                                                            
   Escriou V, 2001, J GENE MED, V3, P179, DOI 10.1002/jgm.174
   Escriou V, 1998, CELL BIOL TOXICOL, V14, P95, DOI 10.1023/A:1007425803756
   Fackelmayer FO, 2004, CURR PHARM DESIGN, V10, P2851, DOI 10.2174/1381612043383557
   Fahrbach KM, 2008, VIROLOGY, V370, P255, DOI 10.1016/j.virol.2007.09.008
   FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s
   Fasbender A, 1997, GENE THER, V4, P1173, DOI 10.1038/sj.gt.3300524
   FELDHERR CM, 1966, J CELL BIOL, V31, P199, DOI 10.1083/jcb.31.1.199
   FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1                                                             
   FRITSCH E, 1977, J VIROL, V21, P119
   gado-Canedo A., 2006, CYTOTECHNOLOGY, V51, P141
   Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669                                                
   Gasiorowski JZ, 2005, MOL THER, V12, P460, DOI 10.1016/j.ymthe.2005.05.001
   GAUTIER T, 1992, J CELL SCI, V102, P729
   Gilmartin GM, 1996, J VIROL, V70, P1775
   Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177
   Greber UF, 2003, TRAFFIC, V4, P136, DOI 10.1034/j.1600-0854.2003.00114.x                                                
   Grundhoff A, 2003, J VIROL, V77, P2779, DOI 10.1128/JVI.77.4.2779-2783.2003
   Guttinger S, 2009, NAT REV MOL CELL BIO, V10, P178, DOI 10.1038/nrm2641
   HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2
   HARRIS P, 1961, J BIOPHYS BIOCHEM CY, V11, P419, DOI 10.1083/jcb.11.2.419
   He Jie, 2005, Sheng Wu Gong Cheng Xue Bao, V21, P507
   HENDERSON LE, 1979, SCIENCE, V203, P1346, DOI 10.1126/science.218289
   HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308
   Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152
   Higa MM, 2006, METHODS, V39, P284, DOI 10.1016/j.ymeth.2006.06.004
   HILL CS, 1991, EMBO J, V10, P1939
   HSU TW, 1982, J VIROL, V44, P493
   HUMPHRIES EH, 1972, J VIROL, V10, P82
   Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698
   Inoue R, 2004, GENE THER, V11, P1195, DOI 10.1038/sj.gt.3302284
   Itaka K, 2004, J GENE MED, V6, P76, DOI 10.1002/jbm.470
   Jiang CW, 1998, HUM GENE THER, V9, P1531, DOI 10.1089/hum.1998.9.11-1531
   Katayama Y, 2002, BIOMACROMOLECULES, V3, P905, DOI 10.1021/bm025532h
   Katayama Y, 2001, MACROMOLECULES, V34, P8569, DOI 10.1021/ma010966a
   Katz RA, 2003, J VIROL, V77, P13412, DOI 10.1128/JVI.77.24.13412-13417.2003
   Khmelinskii A, 2011, CURR BIOL, V21, pR17, DOI 10.1016/j.cub.2010.11.034
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kishida T, 2008, J BIOTECHNOL, V133, P201, DOI 10.1016/j.jbiotec.2007.08.035
   KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446
   LabatMoleur F, 1996, GENE THER, V3, P1010
   Lam AP, 2010, GENE THER, V17, P439, DOI 10.1038/gt.2010.31
   Le Bihan O, 2011, NUCLEIC ACIDS RES, V39, P1595, DOI 10.1093/nar/gkq921
   Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867
   Lenart P, 2006, METHODS, V38, P17, DOI 10.1016/j.ymeth.2005.07.010
   Lewinski MK, 2005, ADV GENET, V55, P147, DOI 10.1016/S0065-2660(05)55005-3
   LEWIS P, 1992, EMBO J, V11, P3053
   LEWIS PF, 1994, J VIROL, V68, P510
   Li JJ, 2010, BIOMATERIALS, V31, P5996, DOI 10.1016/j.biomaterials.2010.04.014
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   Liu KK, 2009, BIOMATERIALS, V30, P4249, DOI 10.1016/j.biomaterials.2009.04.056
   Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004
   Lu F, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-262
   Lu L, 2011, J CELL BIOL, V194, P425, DOI 10.1083/jcb.201012063
   LUBYPHELPS K, 1989, METHOD CELL BIOL, V29, P59
   LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463
   LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865                                                           
   LUCOCQ JM, 1987, EMBO J, V6, P3239
   Ludtke JJ, 2002, MOL THER, V5, P579, DOI 10.1006/mthe.2002.0581
   Ludtke JJ, 1999, J CELL SCI, V112, P2033
   Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625
   MAISON C, 1993, J CELL BIOL, V123, P1491, DOI 10.1083/jcb.123.6.1491
   Malumbres M, 2011, PHYSIOL REV, V91, P973, DOI 10.1152/physrev.00025.2010
   Mannioui A, 2004, VIROLOGY, V329, P77, DOI 10.1016/j.virol.2004.08.022
   Mannisto M, 2005, J GENE MED, V7, P466, DOI 10.1002/jgm.693
   Maraldi NM, 2011, J CELL BIOCHEM, V112, P979, DOI 10.1002/jcb.22992
   Marenzi S, 1999, MOL BIOL REP, V26, P261, DOI 10.1023/A:1007009022336
   Margalit A, 2005, J CELL BIOCHEM, V95, P454, DOI 10.1002/jcb.20433
   Mastrobattista E, 2006, NAT REV DRUG DISCOV, V5, P115, DOI 10.1038/nrd1960
   MAUL GG, 1972, J CELL BIOL, V55, P433, DOI 10.1083/jcb.55.2.433
   McBride AA, 2006, CELL CYCLE, V5, P1499, DOI 10.4161/cc.5.14.3094
   McPhillips MG, 2006, J VIROL, V80, P9530, DOI 10.1128/JVI.01105-06
   Meehan AM, 2010, BBA-GENE REGUL MECH, V1799, P182, DOI 10.1016/j.bbagrm.2009.10.001
   Mesika A, 2005, HUM GENE THER, V16, P200, DOI 10.1089/hum.2005.16.200
   MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239                                                           
   Miller MD, 1997, J VIROL, V71, P5382
   Mistry AR, 1997, BIOTECHNIQUES, V22, P718
   Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234
   Mortimer I, 1999, GENE THER, V6, P403, DOI 10.1038/sj.gt.3300837
   Mullers E, 2011, J VIROL, V85, P9276, DOI 10.1128/JVI.00663-11
   Nayyar VK, 2009, J CELL SCI, V122, P4341, DOI 10.1242/jcs.060913
   NEWMEYER DD, 1986, EMBO J, V5, P501
   NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7
   NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535
   Oishi J, 2006, J CONTROL RELEASE, V110, P431, DOI 10.1016/j.jconrel.2005.10.007
   Oishi J, 2006, BIOORG MED CHEM LETT, V16, P5740, DOI 10.1016/j.bmcl.2006.08.096
   Perroncito A., 1910, Archives Italiennes de Biologie Pisa, V54
   Piirsoo M, 1996, EMBO J, V15, P1
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Prizan-Ravid A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001183
   Rabouille C, 2003, MOL MEMBR BIOL, V20, P117, DOI 10.1080/0968768031000084163
   Rajapakse I, 2011, J CELL BIOL, V192, P711, DOI 10.1083/jcb.201010129
   Rassa JC, 2003, MICROBES INFECT, V5, P961, DOI 10.1016/S1286-4579(03)00193-X
   Rejman J, 2010, J CONTROL RELEASE, V147, P385, DOI 10.1016/j.jconrel.2010.07.124
   Remaut K, 2007, MAT SCI ENG R, V58, P117, DOI 10.1016/j.mser.2007.06.001
   Remaut K, 2006, J CONTROL RELEASE, V115, P335, DOI 10.1016/j.jconrel.2006.08.009
   Ribbeck K, 2007, CURR BIOL, V17, P230, DOI 10.1016/j.cub.2006.11.050
   ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429
   ROE TY, 1993, EMBO J, V12, P2099
   Rosenberg N, 2001, P NATL ACAD SCI USA, V98, P4285, DOI 10.1073/pnas.091097698
   Roussel L, 2008, EMBO REP, V9, P1006, DOI 10.1038/embor.2008.145
   Sasaki A, 2010, J CONTROL RELEASE, V143, P104, DOI 10.1016/j.jconrel.2009.12.013
   Sauer AM, 2009, J CONTROL RELEASE, V137, P136, DOI 10.1016/j.jconrel.2009.04.003
   Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180                                                              
   Sears J, 2004, J VIROL, V78, P11487, DOI 10.1128/JVI.78.21.11487-11505.2004
   Sears J, 2003, J VIROL, V77, P11767, DOI 10.1128/JVI.77.21.11767-11780.2003
   Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80
   Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019
   Sekhar V, 2010, J VIROL, V84, P543, DOI 10.1128/JVI.01908-09
   Seleverstov O, 2006, NANO LETT, V6, P2826, DOI 10.1021/nl0619711
   Shen Y, 2009, INT J PHARMACEUT, V375, P140, DOI 10.1016/j.ijpharm.2009.03.040
   Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8
   Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955
   Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211
   Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013
   Shimizu K, 1997, BIOL PHARM BULL, V20, P881
   Shimizu N, 2005, NUCLEIC ACIDS RES, V33, P6296, DOI 10.1093/nar/gki946
   Shimozono S, 2009, BIOPHYS J, V97, P1288, DOI 10.1016/j.bpj.2009.06.024
   Silla T, 2010, J VIROL, V84, P11175, DOI 10.1128/JVI.01366-10
   Sloots A, 2005, FEBS J, V272, P4221, DOI 10.1111/j.1742-4658.2005.04834.x
   SMYTHE C, 1991, METHOD CELL BIOL, V35, P449
   Soenen SJH, 2009, NANOMEDICINE-UK, V4, P177, DOI 10.2217/17435889.4.2.177
   Soenen SJH, 2009, BIOMATERIALS, V30, P3691, DOI 10.1016/j.biomaterials.2009.03.040
   SPRINGETT GM, 1989, J VIROL, V63, P3865
   Srinivasan C, 2006, MOL THER, V14, P192, DOI 10.1016/j.ymthe.2006.03.010
   STEVENS BJ, 1965, J CELL BIOL, V24, P349, DOI 10.1083/jcb.24.3.349
   STEVENSON M, 1990, EMBO J, V9, P1551
   Subramanian A, 1999, NAT BIOTECHNOL, V17, P873
   Summers H, 2010, NANO TODAY, V5, P83, DOI 10.1016/j.nantod.2010.01.003
   Summers HD, 2011, NAT NANOTECHNOL, V6, P170, DOI [10.1038/nnano.2010.277, 10.1038/NNANO.2010.277]
   SWANSON JA, 1987, SCIENCE, V238, P548, DOI 10.1126/science.2443981                                                         
   Symens N., EFFICIENT TRAN UNPUB
   Symens N, 2011, MOL PHARMACEUT, V8, P1757, DOI 10.1021/mp200120v
   Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200
   TEMIN HM, 1967, J CELL PHYSIOL, V69, P53, DOI 10.1002/jcp.1040690108                                                          
   Tobaly-Tapiero J, 2008, TRAFFIC, V9, P1717, DOI 10.1111/j.1600-0854.2008.00792.x
   Trobridge G, 2004, J VIROL, V78, P2327, DOI 10.1128/JVI.78.5.2327-2335.2004
   Tseng WC, 1999, BBA-GENE STRUCT EXPR, V1445, P53, DOI 10.1016/S0167-4781(99)00039-1                                                   
   Tseng WC, 1996, BIOTECHNOL BIOENG, V50, P548, DOI 10.1002/(SICI)1097-0290(19960605)50:5<548::AID-BIT9>3.3.CO;2-K
   Ulbert S, 2006, J CELL BIOL, V173, P469, DOI 10.1083/jcb.200512078
   Van Craenenbroeck K, 2000, EUR J BIOCHEM, V267, P5665, DOI 10.1046/j.1432-1327.2000.01645.x                                                
   Van de Vosse David W, 2011, Wiley Interdiscip Rev Syst Biol Med, V3, P147, DOI 10.1002/wsbm.101
   van der Aa MAEM, 2006, PHARM RES, V23, P447, DOI 10.1007/s11095-005-9445-4
   Van Hooser AA, 2005, CHROMOSOMA, V114, P377, DOI 10.1007/s00412-005-0021-9
   Vandenbroucke RE, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm440
   VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2
   Wagner E.K., 2004, BASIC VIROLOGY
   Wagstaff KM, 2007, BIOCHEM J, V406, P185, DOI 10.1042/BJ20070505                                                              
   Walczak P, 2007, MAGN RESON MED, V58, P261, DOI 10.1002/mrm.21280
   Webster M, 2009, J CELL SCI, V122, P1477, DOI 10.1242/jcs.037333
   WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477                                                          
   WEISS RA, 1971, VIROLOGY, V46, P209, DOI 10.1016/0042-6822(71)90024-9
   Whittaker GR, 2003, ADV DRUG DELIVER REV, V55, P733, DOI 10.1016/S0169-409X(03)00051-6
   Wiese C, 1997, J CELL SCI, V110, P1489
   Wilke M, 1996, GENE THER, V3, P1133
   WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57
   Xiao BY, 2010, J VIROL, V84, P9718, DOI 10.1128/JVI.00713-10
   Yamashita M, 2004, J VIROL, V78, P5670, DOI 10.1128/JVI.78.11.5670-5678.2004
   You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7                                                   
   You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06
   Yuan XD, 2011, EXPERT OPIN DRUG DEL, V8, P521, DOI 10.1517/17425247.2011.559223
   Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2
   ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997                                                        
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   Zhang BQ, 2011, ACS NANO, V5, P129, DOI 10.1021/nn1018939
   Zhao N, 2011, INT J PHARMACEUT, V411, P197, DOI 10.1016/j.ijpharm.2011.03.038
NR 196
TC 24
Z9 24
U1 2
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD JAN
PY 2012
VL 64
IS 1
BP 78
EP 94
DI 10.1016/j.addr.2011.11.012
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 926PM
UT WOS:000302843300009
PM 22210278
DA 2018-01-05
ER

PT S
AU Gemmill, KB
   Delehanty, JB
   Stewart, MH
   Susumu, K
   Blanco-Canosa, JB
   Dawson, PE
   Huston, A
   Medintz, I
AF Gemmill, Kelly Boeneman
   Delehanty, James B.
   Stewart, Michael H.
   Susumu, Kimihiro
   Blanco-Canosa, Juan B.
   Dawson, Philip E.
   Huston, Alan
   Medintz, Igor
BE Parak, WJ
   Yamamoto, K
   Osinski, M
TI Further progress in cytosolic cellular delivery of quantum dots
SO COLLOIDAL NANOCRYSTALS FOR BIOMEDICAL APPLICATIONS VII
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Colloidal Nanocrystals for Biomedical Applications VII
CY JAN 21-22, 2012
CL San Francisco, CA
SP SPIE
DE Quantum Dots; Cells; Imaging; Endosomes; Bioconjugation
ID INTRACELLULAR DELIVERY; PROTEIN; SEMICONDUCTOR; BIOCONJUGATION;
   PALMITOYL; PEPTIDES; DEATH; CELLS
AB Currently there is considerable interest in using bioconjugated nanoparticles for in vivo imaging, biosensing and theranostics. Luminescent CdSe/ZnS core shell semiconductor quantum dots (QDs) have unique optical properties and bioconjugation capabilities that make them ideal prototypes for these purposes. We have previously described the metal-affinity association between the imidazole groups of terminal hexahistidine residues of peptides and proteins and the ZnS shell of quantum dots as a useful bioconjugation technique([1]). We have also demonstrated that QDs labeled with an oligohistidine-tagged cell penetrating peptide (CPP) derived from the HIV TAT-protein could undergo specific endocytosis-mediated cellular uptake in both HEK293T/17 and COS-1 cells([2]). However, the QDs were predominantly sequestered in the endosomes. This remains a significant hindrance to future potential cellular imaging applications which require the QDs to access other subcellular organelles. Here we describe the testing of several cytosolic QD delivery modalities including microinjection, the commercial cytosolic delivery agent PULSin, and the cytosolic delivery peptide Palm-1. Palm-1, a palmitylated peptide that is capable of both cellular uptake and rapid endosomal escape in multiple cell lines without concomitant toxicity([3]), is shown to be the superior method for cytosolic delivery of QDs. Potential intracellular applications for this peptide are discussed.
C1 [Gemmill, Kelly Boeneman; Delehanty, James B.; Medintz, Igor] USN, Ctr Bio Mol Sci & Engn Code 6900, Res Lab, Washington, DC 20375 USA.
   [Stewart, Michael H.; Susumu, Kimihiro; Huston, Alan] US Navy, Res Lab, Div Opt Sci, Washington, DC 20375 USA.
   [Blanco-Canosa, Juan B.; Dawson, Philip E.] Scripps Res Inst, Dept Cell Biol & Chem, La Jolla, CA 94118 USA.
RP Gemmill, KB (reprint author), USN, Ctr Bio Mol Sci & Engn Code 6900, Res Lab, Washington, DC 20375 USA.
RI Parak, Wolfgang J./M-3998-2014; Gemmill, Kelly/G-2167-2012
OI Parak, Wolfgang J./0000-0003-1672-6650; 
FU DTRA; DARPA; NRL Nanosciences Institute; ONR
FX The authors would like to acknowledge DTRA, DARPA, NRL Nanosciences
   Institute and ONR for their support.
CR Algar WR, 2011, ANAL CHEM, V83, P8826, DOI 10.1021/ac201331r
   Boeneman K, 2010, J AM CHEM SOC, V132, P5975, DOI 10.1021/ja100201w
   Cho SG, 2000, J NEUROSCI RES, V62, P234, DOI 10.1002/1097-4547(20001015)62:2<234::AID-JNR8>3.0.CO;2-8                        
   Dawson G, 2002, CANCER LETT, V187, P163, DOI 10.1016/S0304-3835(02)00403-2
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Delehanty JB, 2010, INTEGR BIOL-UK, V2, P265, DOI 10.1039/c0ib00002g
   Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   Li ZH, 2011, J NANOSCI NANOTECHNO, V11, P7521, DOI 10.1166/jnn.2011.5122
   Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012
   Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y
   MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0
   Medintz IL, 2008, BIOCONJUGATE CHEM, V19, P1785, DOI 10.1021/bc800089r
   Mei BC, 2008, J MATER CHEM, V18, P4949, DOI 10.1039/b810488c
   Sapsford KE, 2007, J PHYS CHEM C, V111, P11528, DOI 10.1021/jp073550t
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   Sperling RA, 2010, PHILOS T R SOC A, V368, P1333, DOI 10.1098/rsta.2009.0273
NR 17
TC 0
Z9 0
U1 0
U2 13
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-8875-6
J9 PROC SPIE
PY 2012
VL 8232
AR UNSP 82320B
DI 10.1117/12.906801
PG 7
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Optics
SC Engineering; Science & Technology - Other Topics; Optics
GA BZR41
UT WOS:000302562300006
DA 2018-01-05
ER

PT J
AU Mahajan, SD
   Aalinkeel, R
   Reynolds, JL
   Nair, B
   Sykes, DE
   Bonoiu, A
   Roy, I
   Yong, KT
   Law, WC
   Bergey, EJ
   Prasad, PN
   Schwartz, SA
AF Mahajan, Supriya D.
   Aalinkeel, Ravikumar
   Reynolds, Jessica L.
   Nair, Bindukumar
   Sykes, Donald E.
   Bonoiu, Adela
   Roy, Indrajit
   Yong, Ken-Tye
   Law, Wing-Cheung
   Bergey, Earl J.
   Prasad, Paras N.
   Schwartz, Stanley A.
TI Suppression of MMP-9 Expression in Brain Microvascular Endothelial Cells
   (BMVEC) Using a Gold Nanorod (GNR)-siRNA Nanoplex
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article
DE MMP-9; Gold Nano Rods; siRNA; Tight junctions; Gene silencing; BMVEC
ID MATRIX METALLOPROTEINASES; HIV-1 ENCEPHALITIS; SURFACE-CHEMISTRY;
   NERVOUS-SYSTEM; BARRIER; MIGRATION; DELIVERY; SIRNA; CNS;
   MATRIX-METALLOPROTEINASE-9
AB Inhibition of Matrix metalloproteinase-9 (MMP-9) activity using delivery of short interfering RNA (siRNA) molecules to brain microvascular endothelial cells (BMVECs) that constitute the BBB may have a significant impact on reducing the BBB permeability. Gold nano rods (GNRs) can electrostatically bind with MMP-9 siRNA to form a nanoplex and the uptake of this nanoplex by BMVEC cells can result in suppression of MMP-9 expression. The current study explores if this GNR-MMP-9 siRNA nanoplex gene silencing modulates the expression of tight junction (TJ) proteins in the BMVEC. The endothelial TJ's of the BBB play a critical role in controlling cellular traffic into the central nervous system. We hypothesize that silencing of the MMP-9 gene expression in BMVEC will increase the expression of TJ proteins thereby decrease endothelial permeability. Our results showed a significant increase in the gene and protein expression of TJ proteins: ZO-1, Occludin and Claudin-5 in BMVEC cells that were transfected with the GNRs-siRNA-MMP-9 nanoplex suggesting that BBB disruption, which results from loss of TJ function due to MMP-9 activation during neuroinflammation can be prevented by silencing MMP-9 expression.
C1 [Mahajan, Supriya D.; Aalinkeel, Ravikumar; Reynolds, Jessica L.; Nair, Bindukumar; Sykes, Donald E.; Schwartz, Stanley A.] SUNY Buffalo, Dept Med, Innovat Ctr, Div Allergy Immunol & Rheumatol, Buffalo, NY 14260 USA.
   [Bonoiu, Adela; Roy, Indrajit; Yong, Ken-Tye; Law, Wing-Cheung; Bergey, Earl J.; Prasad, Paras N.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
RP Mahajan, SD (reprint author), Dept Med, Div Allergy Immunol & Rheumatol, 444 Innovat Ctr,Buffalo Niagara Med Campus,640 El, Buffalo, NY 14203 USA.
EM smahajan@buffalo.edu
OI Law, Wing Cheung/0000-0003-3855-6170
FU National Institute of Health [RO1CA119397, NIAID-RO1LM009726-01, NIDA
   K01 DA024577, NIDA-1R21DA030108-01]; John R. Oishei Foundation; Kaleida
   Health Foundation
FX This study was supported by grants from the National Institute of Health
   [RO1CA119397 (PNP); NIAID-RO1LM009726-01 (SAS); NIDA K01 DA024577 (JR);
   NIDA-1R21DA030108-01 (SM)], the John R. Oishei and the Kaleida Health
   Foundations.
CR Abbott N Joan, 2004, Drug Discov Today Technol, V1, P407, DOI 10.1016/j.ddtec.2004.11.014
   Abbott NJ, 2005, CELL MOL NEUROBIOL, V25, P5, DOI 10.1007/s10571-004-1374-y
   Alvarez JI, 2006, J NEUROIMMUNOL, V173, P45, DOI 10.1016/j.jneuroim.2005.11.020
   Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050
   Bernacki J, 2008, PHARMACOL REP, V60, P600
   Bonoiu A, 2009, BRAIN RES, V1282, P142, DOI 10.1016/j.brainres.2009.05.047
   Bonoiu AC, 2009, P NATL ACAD SCI USA, V106, P5546, DOI 10.1073/pnas.0901715106
   Boven LA, 2000, NEUROPATH APPL NEURO, V26, P356, DOI 10.1046/j.1365-2990.2000.00255.x
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Cardona AE, 2008, J LEUKOCYTE BIOL, V84, P587, DOI 10.1189/jlb.1107763
   Daneman R., 2005, PLOS ONE, V5
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
   Hauck TS, 2008, SMALL, V4, P153, DOI 10.1002/smll.200700217
   Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006
   Li J, 2010, J CONTROL RELEASE, V142, P416, DOI 10.1016/j.jconrel.2009.11.008
   Li SD, 2009, BBA-BIOMEMBRANES, V1788, P2259, DOI 10.1016/j.bbamem.2009.06.022
   Patel MM, 2009, CNS DRUGS, V23, P35, DOI 10.2165/0023210-200923010-00003
   Paul R, 1998, ANN NEUROL, V44, P592, DOI 10.1002/ana.410440404
   Persidsky Y, 1997, J LEUKOCYTE BIOL, V62, P100
   Persidsky Y, 1997, J IMMUNOL, V158, P3499
   Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3
   Prasad P. N., 2004, NANOPHOTONICS
   Prasad P. N., 2003, INTRO BIOPHOTONICS
   Qiu Y, 2010, BIOMATERIALS, V31, P7606, DOI 10.1016/j.biomaterials.2010.06.051
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af
   Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108
   Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X
   Schrot S., 2010, BRAIN RES, V1367, P62
   Wang XY, 2000, J NEUROSCI, V20, P7037
   WOESSNER JF, 1991, FASEB J, V5, P2145
   Wu DT, 2000, J NEUROVIROL, V6, pS82
   Yong KT, 2007, NANO LETT, V7, P761, DOI 10.1021/nl063031m
   Yong KT, 2009, SMALL, V5, P1997, DOI 10.1002/smll.200900547
   Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571
NR 36
TC 16
Z9 16
U1 0
U2 14
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0882-0139
J9 IMMUNOL INVEST
JI Immunol. Invest.
PY 2012
VL 41
IS 4
BP 337
EP 355
DI 10.3109/08820139.2011.604863
PG 19
WC Immunology
SC Immunology
GA 916AV
UT WOS:000302069800001
PM 21864113
DA 2018-01-05
ER

PT J
AU Shen, WZ
   Li, MZ
   Wang, BL
   Liu, J
   Li, ZY
   Jiang, L
   Song, YL
AF Shen, Weizhi
   Li, Mingzhu
   Wang, Benli
   Liu, Jian
   Li, Zhiyuan
   Jiang, Lei
   Song, Yanlin
TI Hierarchical optical antenna: Gold nanoparticle-modified photonic
   crystal for highly-sensitive label-free DNA detection
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID SURFACE-PLASMON RESONANCE; MOLECULAR BEACON BIOSENSORS; COLORIMETRIC
   DETECTION; ENHANCED FLUORESCENCE; SPONTANEOUS EMISSION; SLOW PHOTONS;
   SPECTROSCOPY; OPAL; OLIGONUCLEOTIDES; NANOWIRES
AB Metallic nanoparticles combined with 3D photonic crystals (PC) are anticipated to achieve high light-use efficiency, which stimulates their promising applications as optical antenna. Here, we propose a hierarchical optical antenna from an inverse opal photonic crystal modified with gold nanoparticles (GNPs) and exploit it for highly-sensitive bio-sensing. Metallic nanostructures can induce efficient light-harvesting and boost the light-matter interaction through localized surface plasmon resonance (LSPR). Photonic crystals are also efficient optical antennas with the ability to manipulate incident light. The 3D photonic crystal can localize the excitation energy and induce intense LSPR of GNPs for fluorescent enhancement when the PC band edge agrees with the LSPR absorption wavelength of the GNPs and the excitation wavelength of the light source. The feasibility of our approach is demonstrated by label-free DNA detection of SARS and HIV, and the GNP-modified inverse opal gives rise to one magnitude enhancement of the signal intensity and the detection sensitivity. This hierarchical antenna is an interesting prospect for highly effective light harvesting through the optimized combination of the superior properties of photonic crystals and plasmonic materials.
C1 [Shen, Weizhi; Li, Mingzhu; Liu, Jian; Jiang, Lei; Song, Yanlin] Chinese Acad Sci, Inst Chem, New Mat Lab, Key Lab Organ Solids,BNLMS, Beijing 100190, Peoples R China.
   [Wang, Benli; Li, Zhiyuan] Chinese Acad Sci, Inst Phys, Lab Opt Phys, Beijing 100190, Peoples R China.
RP Li, MZ (reprint author), Chinese Acad Sci, Inst Chem, New Mat Lab, Key Lab Organ Solids,BNLMS, Beijing 100190, Peoples R China.
EM mingzhu@iccas.ac.cn; ylsong@iccas.ac.cn
RI Jiang, Lei/B-1066-2011; li, mingzhu/F-5586-2011; Liu, Jian/A-7195-2009;
   Li, Zhi-Yuan/H-6923-2017; Song, Yanlin/D-1230-2015
OI Liu, Jian/0000-0002-5614-2919; Li, Zhi-Yuan/0000-0003-4692-5028; 
FU National Nature Science Foundation [21003132, 21073203, 21004068,
   91127038, 51103004, 51173190]; 973 Program [2007CB936403, 2009CB930404,
   2011CB932303, 2011CB808400]
FX This work is supported by the National Nature Science Foundation (Grant
   Nos. 21003132, 21073203, 21004068, 91127038, 51103004 and 51173190), and
   the 973 Program (2007CB936403, 2009CB930404, 2011CB932303 and
   2011CB808400).
CR Anger P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.113002
   Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162
   Barry RA, 2006, LANGMUIR, V22, P1369, DOI 10.1021/la0519094
   Bechger L, 2005, J PHYS CHEM B, V109, P9980, DOI 10.1021/jp047489t
   Brown MD, 2011, NANO LETT, V11, P438, DOI 10.1021/nl1031106
   Cao SH, 2011, J AM CHEM SOC, V133, P1787, DOI 10.1021/ja107964s
   Cederquist KB, 2008, LANGMUIR, V24, P9162, DOI 10.1021/la703854x
   Chen JIL, 2008, J MATER CHEM, V18, P369, DOI 10.1039/b708474a
   Chen JIL, 2006, ADV MATER, V18, P1915, DOI 10.1002/adma.200600588
   Clark AW, 2010, ADV MATER, V22, P4025, DOI 10.1002/adma.201000131
   Coyle S, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.176801
   Du H, 2005, J AM CHEM SOC, V127, P7932, DOI 10.1021/ja042482a
   Du H, 2003, J AM CHEM SOC, V125, P4012, DOI 10.1021/ja0290781
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762                                                                   
   Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Galisteo-Lopez JF, 2011, ADV MATER, V23, P30, DOI 10.1002/adma.201000356
   Ganesh N, 2007, NAT NANOTECHNOL, V2, P515, DOI 10.1038/nnano.2007.216
   Gao SY, 2010, ADV FUNCT MATER, V20, P78, DOI 10.1002/adfm.200901232
   Hiep HM, 2009, ACS NANO, V3, P446, DOI 10.1021/nn800831a
   Huang XH, 2009, ADV MATER, V21, P4880, DOI 10.1002/adma.200802789
   Hutter E, 2004, ADV MATER, V16, P1685, DOI 10.1002/adma.200400271
   Ishizaki K, 2009, NATURE, V460, P367, DOI 10.1038/nature08190
   Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804
   JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486                                                     
   Lakowicz, 2002, ANAL BIOCHEM, V301, P261
   Lakowicz JR, 2005, ANAL BIOCHEM, V337, P171, DOI 10.1016/j.ab.2004.11.026
   Larsson EM, 2009, SCIENCE, V326, P1091, DOI 10.1126/science.1176593
   Lee JS, 2007, ANGEW CHEM INT EDIT, V46, P4093, DOI 10.1002/anie.200700269
   Li ZY, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.063904
   Lidorikis E, 2007, J APPL PHYS, V101, DOI 10.1063/1.2709863
   Liu J, 2010, ENERG ENVIRON SCI, V3, P1503, DOI 10.1039/c0ee00116c
   Lu ZD, 2009, J MATER CHEM, V19, P4597, DOI 10.1039/b903637g
   Maier S.A., 2007, PLASMONICS FUNDAMENT
   Mao X, 2009, CHEM COMMUN, P3065, DOI 10.1039/b822582f
   Nikolaev IS, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.115302
   Noginov MA, 2009, NATURE, V460, P1110, DOI 10.1038/nature08318
   O'Brien PG, 2007, ADV MATER, V19, P4177, DOI 10.1002/adma.200700564
   Oehlenschlager F, 1996, P NATL ACAD SCI USA, V93, P12811, DOI 10.1073/pnas.93.23.12811
   Peng HI, 2009, ACS NANO, V3, P2265, DOI 10.1021/nn900112e
   Rechberger W, 2003, OPT COMMUN, V220, P137, DOI 10.1016/S0030-4018(03)01357-9
   Romanov SG, 2011, ADV MATER, V23, P2515, DOI 10.1002/adma.201100460
   Schroden RC, 2001, CHEM MATER, V13, P2945, DOI 10.1021/cm010230s
   Shen WZ, 2011, BIOSENS BIOELECTRON, V26, P2165, DOI 10.1016/j.bios.2010.09.026
   Stoermer RL, 2006, J AM CHEM SOC, V128, P16892, DOI 10.1021/ja0658261
   Stoermer RL, 2006, J AM CHEM SOC, V128, P13243, DOI 10.1021/ja0637200
   Stranik O, 2005, SENSOR ACTUAT B-CHEM, V107, P148, DOI 10.1016/j.snb.2004.08.032
   Su KH, 2003, NANO LETT, V3, P1087, DOI 10.1021/nl034197f
   Tessier PM, 2000, J AM CHEM SOC, V122, P9554, DOI 10.1021/ja0022831
   Ueno K, 2008, ADV MATER, V20, P26, DOI 10.1002/adma.200602680
   Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607
   YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059                                                     
   Yang ZJ, 2008, ADV FUNCT MATER, V18, P3991, DOI 10.1002/adfm.200801022
   Yao JM, 2010, ADV MATER, V22, P1102, DOI 10.1002/adma.200904097
   Zhang YQ, 2007, J MATER CHEM, V17, P90, DOI 10.1039/b612905f
   Zhao YJ, 2010, ADV FUNCT MATER, V20, P2970, DOI 10.1002/adfm.201000098
   Zhou YM, 2005, J CLIN VIROL, V33, P123, DOI 10.1016/j.jcv.2004.10.019
NR 57
TC 25
Z9 25
U1 1
U2 92
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959-9428
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2012
VL 22
IS 16
BP 8127
EP 8133
DI 10.1039/c2jm16655k
PG 7
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 915LC
UT WOS:000302026100068
DA 2018-01-05
ER

PT J
AU Vavrova, J
   Rezacova, M
   Pejchal, J
AF Vavrova, Jirina
   Rezacova, Martina
   Pejchal, Jaroslav
TI Fullerene nanoparticles and their anti-oxidative effects: a comparison
   to other radioprotective agents
SO JOURNAL OF APPLIED BIOMEDICINE
LA English
DT Review
DE ionizing radiation; fullerenes; antioxidant; radioprotection;
   nanoparticles
ID SUPEROXIDE-DISMUTASE; BIOLOGICAL APPLICATIONS; PHOTODYNAMIC THERAPY;
   HIV-1 PROTEASE; RADIATION; AMIFOSTINE; RATS; C-60(OH)(24); IRRADIATION;
   PROTECTION
AB Radiation therapy occupies an important position in the treatment of malignant diseases in spite of the existence of radiation side effects on normal tissues. Thus, substances are being developed which are designed to reduce both the acute and long term radiation effects on healthy tissues. Currently a sulphur-containing compound amifostine (WR2721, ethyol) is used in clinical practice as a radioprotectant. However, it itself has considerable side effects including hypotension (found in 62% of patients), hypocalcaemia, diarrhoea, nausea, and vomiting. Carbon nanospheres, known as fullerenes, and their water soluble derivatives (e.g. C-60(OH)(24), dendrofullerene DF-1) exert anti-oxidative properties and reduce damage to the DNA in irradiated cells. Water soluble fullerenes are low-toxic substances and thus, are attractive in terms of their use as radioprotectants.
C1 [Vavrova, Jirina; Pejchal, Jaroslav] Univ Def, Fac Mil Hlth Sci, Dept Radiobiol, Hradec Kralove 50001, Czech Republic.
   [Rezacova, Martina] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biochem, Prague, Czech Republic.
RP Vavrova, J (reprint author), Univ Def, Fac Mil Hlth Sci, Dept Radiobiol, Trebesska 1575, Hradec Kralove 50001, Czech Republic.
EM vavrova@pmfhk.cz
RI Rezacova, Martina/A-2046-2009
OI Rezacova, Martina/0000-0001-5370-2290
FU Ministry of Defence of Czech Republic [MO0FVZ0000501, OVUOFVZ200806]
FX The authors would like to thank the Ministry of Defence of Czech
   Republic (project MO0FVZ0000501 and project OVUOFVZ200806) for financial
   support.
CR Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003
   Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002
   BACQ ZM, 1954, ACTA RADIOL, V41, P47, DOI 10.3109/00016925409175832                                                       
   Bakry R, 2007, INT J NANOMED, V2, P639
   Belikova NA, 2009, FEBS LETT, V583, P3437, DOI 10.1016/j.febslet.2009.10.013
   Blumenthal RD, 2000, INT J CANCER, V86, P276, DOI 10.1002/(SICI)1097-0215(20000415)86:2<276::AID-IJC19>3.3.CO;2-X
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Brown AP, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-34
   Cai XQ, 2010, TOXICOL APPL PHARM, V243, P27, DOI 10.1016/j.taap.2009.11.009
   Cheng YA, 2010, J MOL GRAPH MODEL, V29, P171, DOI 10.1016/j.jmgm.2010.05.009
   Citrin D, 2010, ONCOLOGIST, V15, P360, DOI 10.1634/theoncologist.2009-S104
   Dostal M, 1967, THESIS PURKYNE MILIT
   Dugan LL, 2001, PARKINSONISM RELAT D, V7, P243, DOI 10.1016/S1353-8020(00)00064-X                                                   
   Dugan LL, 1996, NEUROBIOL DIS, V3, P129, DOI 10.1006/nbdi.1996.0013
   Epperly MW, 2008, RADIAT RES, V170, P437, DOI 10.1667/RR1286.1
   Epperly MW, 2002, RADIAT RES, V157, P568, DOI 10.1667/0033-7587(2002)157[0568:MSDSIR]2.0.CO;2
   FRANCE HG, 1986, GASTROENTEROLOGY, V91, P644, DOI 10.1016/0016-5085(86)90634-7                                                    
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Hwang WYK, 2004, BONE MARROW TRANSPL, V34, P51, DOI 10.1038/sj.bmt.1704521
   Injac R, 2008, PHARMACOL REP, V60, P742
   Jensen AW, 1996, BIOORGAN MED CHEM, V4, P767, DOI 10.1016/0968-0896(96)00081-8
   Johnston HJ, 2010, TOXICOL SCI, V114, P162, DOI 10.1093/toxsci/kfp265
   Konopacka M, 1998, MUTAT RES-GEN TOX EN, V417, P85, DOI 10.1016/S1383-5718(98)00095-3
   Kouvaris JR, 2007, ONCOLOGIST, V12, P738, DOI 10.1634/theoncologist.12-6-738
   KUNA P, 1983, NEOPLASMA, V30, P349
   KUNA P, 1985, CHEM RADIOPROTECTION
   Kuna P., 2004, J APPL BIOMED, V2, P43
   Li W, 2011, BIOMATERIALS, V32, P4030, DOI 10.1016/j.biomaterials.2011.02.008
   Liu J, 2007, J CONTROL RELEASE, V117, P104, DOI 10.1016/j.jconrel.2006.10.008
   MALICK MA, 1978, EXPERIENTIA, V34, P1216, DOI 10.1007/BF01922966
   Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005
   Mroz P, 2007, PHOTOCH PHOTOBIO SCI, V6, P1139, DOI 10.1039/b711141j
   PETKAU A, 1978, PHOTOCHEM PHOTOBIOL, V28, P765, DOI 10.1111/j.1751-1097.1978.tb07015.x
   PIPER JR, 1969, J MED CHEM, V12, P236, DOI 10.1021/jm00302a010
   Prasad KN, 2002, CANCER TREAT REV, V28, P79, DOI 10.1054/ctrv.2002.0260
   SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P1707, DOI 10.1128/AAC.37.8.1707                                                           
   Tabata Y, 1997, JPN J CANCER RES, V88, P1108, DOI 10.1111/j.1349-7006.1997.tb00336.x                                              
   Theriot CA, 2010, RADIAT ENVIRON BIOPH, V49, P437, DOI 10.1007/s00411-010-0310-4
   Trajkovic S, 2007, COLLOID SURFACE B, V58, P39, DOI 10.1016/j.colsurfb.2007.01.005
   VACEK A, 1971, INT J RADIAT BIOL RE, V19, P323, DOI 10.1080/09553007114550441                                                       
   YIN JJ, 2008, BIOMATERIALS, V30, P611
   Yudoh K, 2009, INT J NANOMED, V4, P217
   YUHAS JM, 1980, BRIT J CANCER, V41, P832, DOI 10.1038/bjc.1980.150
   ZHEREBCHENKO P. G., 1963, RADIOBIOLOGIYA, V3, P595
NR 44
TC 10
Z9 10
U1 1
U2 38
PU UNIV SOUTH BOHEMIA
PI CESKA BUDEJOVICE
PA FAC HEALTH & SOCIAL STUD, JIROVCOVA, CESKA BUDEJOVICE, 370 04, CZECH
   REPUBLIC
SN 1214-021X
J9 J APPL BIOMED
JI J. Appl. Biomed.
PY 2012
VL 10
IS 1
BP 1
EP 8
DI 10.2478/v10136-012-0002-2
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 894CC
UT WOS:000300403600001
DA 2018-01-05
ER

PT J
AU Agashe, H
   Hu, ML
   Rohan, L
AF Agashe, Hrushikesh
   Hu, Minlu
   Rohan, Lisa
TI Formulation and Delivery of Microbicides
SO CURRENT HIV RESEARCH
LA English
DT Article
DE Drug Delivery; formulation; HIV Microbicide; pre-exposure prophylaxis
ID DRUG-DELIVERY; HIV-INFECTION; PREEXPOSURE PROPHYLAXIS; VAGINAL DELIVERY;
   LOW-INCOME; TRANSMISSION; PREVENTION; WOMEN; RISK; NANOPARTICLES
AB The development of pre-exposure prophylactics or microbicide products for the reduction or elimination of the sexual transmission of HIV has numerous challenges or barriers to success. Historically traditional dosage forms such as gels have been developed in the field but more recently controlled release dosage forms such as vaginal rings and novel dosage forms such as polymeric thin films have been studied. Studies have begun to incorporate scientific strategies into the formulation design of microbicide products in order to develop safer and more effective products. In addition advanced drug delivery strategies to overcome barriers to delivery and specific drug targeting methods are being employed. In the present review, a comprehensive discussion of formulation efforts and novel delivery strategies in the field of microbicide product development is presented.
C1 [Agashe, Hrushikesh; Hu, Minlu; Rohan, Lisa] Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
   [Agashe, Hrushikesh; Hu, Minlu; Rohan, Lisa] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
   [Rohan, Lisa] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
RP Rohan, L (reprint author), Magee Womens Res Inst, 204 Craft Ave,B509, Pittsburgh, PA 15213 USA.
EM rohanlc@upmc.edu
CR Adriaens E, 2008, SEX TRANSM DIS, V35, P512, DOI 10.1097/OLQ.0b013e3181644669
   Akil A, 2011, DRUG DELIV TRANSL RE, V1, P209, DOI 10.1007/s13346-011-0022-6
   Allen LV, 2002, ART SCI TECHNOLOGY P, P161
   Alukda D, 2011, J PHARM SCI, V8, P3345
   Baloglu E, 2006, PHARM DEV TECHNOL, V11, P477, DOI 10.1080/10837450600939784
   Baral S, 2007, PLOS MED, V4, P1901, DOI 10.1371/journal.pmed.0040339
   Baral S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004997
   Barnhart K, 2009, CONTRACEPTION, V79, P297, DOI 10.1016/j.contraception.2008.11.001
   Buchbinder SP, 2011, AIDS BEHAV, V15, pS72, DOI 10.1007/s10461-011-9894-1
   Carballo-Dieguez A, 2000, AM J PUBLIC HEALTH, V90, P1117, DOI 10.2105/AJPH.90.7.1117
   Doncel GF, 2010, ANTIVIR RES, V88, pS10, DOI 10.1016/j.antiviral.2010.09.018
   El-Gindy G. A., 2003, B PHARM SCI 1, V26, P29
   Fabio S, 2003, AIDS, V17, P1597
   Fabio SD, 2001, AIDS, V15, P2231
   Fetherston SM, THERAPEUTIC DELIVERY, V1, P785
   Forbes CJ, 2011, J CONT REL IN PRESS
   Fuchs EJ, 2007, J INFECT DIS, V195, P703, DOI 10.1086/511279
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   GARG S, 2001, PHARM TECHNOL, V25, P14
   Garg S, 2010, ANTIVIR RES, V88, P19
   Garg S, 2007, DRUG DEV IND PHARM, V33, P1340, DOI 10.1080/03639040701385782
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Gunawardana M, 2011, J MED MICROBIOL, V60, P828, DOI 10.1099/jmm.0.028225-0
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Hendrix C, 2011, C RETR OPP INF BOST
   Hendrix C, 2008, CLIN PHARMACOL THER, V83, P97, DOI 10.1038/sj.clpt.6100236
   Jim A, 2011, DRUG DELIV TRANSL RE, V1, P194
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Kalichman SC, 2009, SEX TRANSM INFECT, V85, P411, DOI 10.1136/sti.2008.035287
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Karim SSA, 2011, LANCET, V378, P279, DOI 10.1016/S0140-6736(11)60878-7
   Kinsley LA, 1987, LANCET, V329, P345
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431
   Misegades L, 2001, AIDS, V15, P534, DOI 10.1097/00002030-200103090-00017                                                
   Moench TR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-331
   Mollendorf CE, 2010, CONTRACEPTION, V81, P232
   Morrow RJ, 2011, EUR J PHARM BIOPHARM, V77, P3, DOI 10.1016/j.ejpb.2010.10.010
   Neff CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020209
   Nel AM, 2011, J WOMENS HEALTH, V20, P1207, DOI 10.1089/jwh.2010.2476
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Neves J, 2011, WILEY INTERDISCIPLIN, V3, P389
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Romano J, 2009, AIDS RES HUM RETROV, V25, P483, DOI 10.1089/aid.2008.0184
   Sassi AB, 2011, ANTIMICROB AGENTS CH, V55, P2282, DOI 10.1128/AAC.01190-10
   Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5
   Sudol KM, 2004, SEX TRANSM DIS, V31, P346, DOI 10.1097/00007435-200406000-00005
   Taha TE, 1998, AIDS, V12, P1699, DOI 10.1097/00002030-199813000-00019                                                
   UNAIDS, 2010, UNAIDS REP GLOB AIDS
   Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306
   Wang L, 2011, AIDS RES THER, V8, DOI 10.1186/1742-6405-8-12
   Whaley KJ, 2010, ANTIVIR RES, pS55
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Woolfson AD, 2010, INT J PHARMACEUT, V388, P136, DOI 10.1016/j.ijpharm.2009.12.042
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
   Yoo JW, 2006, INT J PHARM, V309, P139, DOI 10.1016/j.ijpharm.2005.11.020
   Zhanga T, 2011, EUR J PHA UNPUB 0620, P20
NR 61
TC 15
Z9 15
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-162X
J9 CURR HIV RES
JI Curr. HIV Res.
PD JAN
PY 2012
VL 10
IS 1
BP 88
EP 96
DI 10.2174/157016212799304599                                              
          
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 894EE
UT WOS:000300409000012
PM 22264050
DA 2018-01-05
ER

PT J
AU Cheng, K
   El-Boubbou, K
   Landry, CC
AF Cheng, Kai
   El-Boubbou, Kheireddine
   Landry, Christopher C.
TI Binding of HIV-1 gp120 Glycoprotein to Silica Nanoparticles Modified
   with CD4 Glycoprotein and CD4 Peptide Fragments
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE biomedical applications; protein binding; silica; surface modification;
   porous materials
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MAGNETIC GLYCO-NANOPARTICLES; DOPED
   MESOPOROUS SILICA; CAPSID P24 ANTIGEN; HUMAN SOLUBLE CD4; N-LINKED
   GLYCANS; ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES;
   MASS-SPECTROMETRY; CROSS-LINKING
AB An important step in human immunodeficiency virus infection involves the interaction between the viral envelope glycoprotein gp120 and the human host cell surface receptor CD4. Herein, we describe a CD4-functionalized mesoporous silica-based system to selectively capture HIV-gp120 with high binding efficiency. Using a protection-deprotection strategy developed recently by our group, the external surface of the mesoporous particles was selectively functionalized with soluble CD4 ("sCD4'') or an 18-peptide fragment mimicking the gp120 binding region. Confocal microscopy confirmed the CD4 locations and showed that the internal pores can be made accessible after external modification in a controlled manner. An evaluation of the ability of an 18-peptide CD4 fragment versus amide-immobilized sCD4 and sCD4 immobilized through its glycosidic group indicated that while all peptides were selective, the latter method was clearly best, with nearly complete removal of whole gp120 from solution. This study shows, for the first time, that sCD4 bound to mesoporous silica particles actively recognizes and retains high binding affinity for HIV-gp120. It is anticipated that, by proper modification of the accessible internal pores, our methodology can be adopted to develop porous platforms for HIV diagnosis, imaging, drug delivery, and vaccine development.
C1 [Cheng, Kai; El-Boubbou, Kheireddine; Landry, Christopher C.] Univ Vermont, Dept Chem, Burlington, VT 05405 USA.
RP Landry, CC (reprint author), Univ Vermont, Dept Chem, 82 Univ Pl, Burlington, VT 05405 USA.
EM christopher.landry@uvm.edu
CR ASHFORD DA, 1993, J BIOL CHEM, V268, P3260
   BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0                                                                
   Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820
   Bhattacharyya S, 2010, J BIOL CHEM, V285, P27100, DOI 10.1074/jbc.M110.152272
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   CHAMOW SM, 1992, J BIOL CHEM, V267, P15916
   Chen L, 2009, SCIENCE, V326, P1123, DOI 10.1126/science.1175868
   Cheng K, 2007, THESIS U VERMONT BUR
   Cheng K, 2007, J AM CHEM SOC, V129, P9674, DOI 10.1021/ja070598b
   Cheng K, 2010, ACS APPL MATER INTER, V2, P2489, DOI 10.1021/am100530t
   CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173
   Diskin R, 2010, NAT STRUCT MOL BIOL, V17, P608, DOI 10.1038/nsmb.1796
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   El-Boubbou K, 2007, J AM CHEM SOC, V129, P13392, DOI 10.1021/ja076086e
   El-Boubbou K, 2010, J AM CHEM SOC, V132, P4490, DOI 10.1021/ja100455c
   FENOUILLET E, 1989, J EXP MED, V169, P807, DOI 10.1084/jem.169.3.807
   Fenouillet E., 1989, J EXP MED, V169, P802
   Gallis KW, 1999, ADV MATER, V11, P1452, DOI 10.1002/(SICI)1521-4095(199912)11:17<1452::AID-ADMA1452>3.3.CO;2-I
   GALLIS KW, 2000, STUD SURF SCI CATAL, V129, P747
   Gizachew D, 1998, BIOCHEMISTRY-US, V37, P10616, DOI 10.1021/bi980652o
   HARIS PI, 1990, BIOCHEMISTRY-US, V29, P1377, DOI 10.1021/bi00458a005
   HARRIS RJ, 1990, EUR J BIOCHEM, V188, P291, DOI 10.1111/j.1432-1033.1990.tb15402.x
   Hedestam GBK, 2008, NAT REV MICROBIOL, V6, P143, DOI 10.1038/nrmicro1819
   Henkel B, 1998, J PEPT SCI, V4, P461, DOI 10.1002/(SICI)1099-1387(199812)4:8<461::AID-PSC165>3.0.CO;2-C
   Hillegass JM, 2011, INT J CANCER, V129, P233, DOI 10.1002/ijc.25666
   Houseman BT, 2003, LANGMUIR, V19, P1522, DOI 10.1021/la0262304
   Huang BX, 2004, J AM SOC MASS SPECTR, V15, P1237, DOI 10.1016/j.jasms.2004.05.004
   Huh S, 2003, CHEM MATER, V15, P4247, DOI 10.1021/cm0210041
   JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Koch M, 2003, VIROLOGY, V313, P387, DOI 10.1016/S0042-6822(03)00294-0
   Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lagenaur L.A., 2010, RETROVIROLOGY, V7, P1
   Liong M, 2009, ADV MATER, V21, P1684, DOI 10.1002/adma.200802646
   Liu SS, 2010, ANGEW CHEM INT EDIT, V49, P7557, DOI 10.1002/anie.201003602
   Liu YH, 2004, LANGMUIR, V20, P3231, DOI 10.1021/la0358421
   Livingston SR, 2008, J AM CHEM SOC, V130, P13214, DOI 10.1021/ja8056166
   Lu CW, 2007, NANO LETT, V7, P149, DOI 10.1021/nl0624263
   Mal NK, 2003, NATURE, V421, P350, DOI 10.1038/nature01362
   MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042                                                             
   MORIKAWA Y, 1990, AIDS RES HUM RETROV, V6, P765, DOI 10.1089/aid.1990.6.765
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Nassivera T, 2002, J CHROMATOGR A, V973, P97, DOI 10.1016/S0021-9673(02)01200-1                                                   
   Papandreou MJ, 1996, FEBS LETT, V379, P171, DOI 10.1016/0014-5793(95)01505-1
   Qian K, 2010, CHEM-EUR J, V16, P822, DOI 10.1002/chem.200902535
   Quinones-Kochs MI, 2002, J VIROL, V76, P4199, DOI 10.1128/JVI.76.9.4199-4211.2002
   RODWELL JD, 1986, P NATL ACAD SCI USA, V83, P2632, DOI 10.1073/pnas.83.8.2632
   Rosenholm J, 2010, J MATER CHEM, V20, P2707, DOI 10.1039/b920076b
   Rosenholm JM, 2010, NANOSCALE, V2, P1870, DOI 10.1039/c0nr00156b
   Rosenholm JM, 2009, NANO LETT, V9, P3308, DOI 10.1021/nl901589y
   RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0                                                                
   Sorensen AC, 2004, CHEM MATER, V16, P2157, DOI 10.1021/cm030239p
   Steinbacher JL, 2010, SMALL, V6, P2678, DOI 10.1002/smll.201001447
   Tang SX, 2007, JAIDS-J ACQ IMM DEF, V46, P231, DOI 10.1097/QAI.0b013e31814a554b
   Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386
   Vallet-Regi MA, 2006, J MATER CHEM, V16, P26, DOI 10.1039/b509744d
   Vinu A, 2005, J NANOSCI NANOTECHNO, V5, P347, DOI 10.1166/jnn.2005.089
   Vivero-Escoto JL, 2010, SMALL, V6, P1952, DOI 10.1002/smll.200901789
   Wan JJ, 2010, LANGMUIR, V26, P7444, DOI 10.1021/la9041698
   Wang JH, 2004, J CELL BIOCHEM, V93, P753, DOI 10.1002/jcb.20161
   Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496
   Xu YW, 2009, ANAL CHEM, V81, P503, DOI 10.1021/ac801912t
   Xuan H, 2005, ANAL BIOCHEM, V346, P300, DOI 10.1016/j.ab.2005.08.025
   Yang HH, 2004, ANAL CHEM, V76, P1316, DOI 10.1021/ac034920m
   Zhan QQ, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/5/055704
   Zhang LJ, 2010, SCI CHINA CHEM, V53, P695, DOI 10.1007/s11426-010-0112-1
   Zhang LJ, 2009, CHEM-EUR J, V15, P10158, DOI 10.1002/chem.200901347
   Gallis KW, 2002, US Patent, Patent No. [6334988, 6,334,988]
NR 71
TC 9
Z9 9
U1 2
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN
PY 2012
VL 4
IS 1
BP 235
EP 243
DI 10.1021/am2013008
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA 880LV
UT WOS:000299409500039
PM 22117536
DA 2018-01-05
ER

PT J
AU Yan, J
   Korolev, N
   Eom, KD
   Tam, JP
   Nordenskiold, L
AF Yan, Jiang
   Korolev, Nikolay
   Eom, Khee Dong
   Tam, James P.
   Nordenskioeld, Lars
TI Biophysical Properties and Supramolecular Structure of Self-Assembled
   Liposome/epsilon-Peptide/DNA Nanoparticles: Correlation with Gene
   Delivery
SO BIOMACROMOLECULES
LA English
DT Article
ID LIPID-DNA COMPLEXES; HIV-1 TAT PROTEIN; IN-VITRO; TRANSFECTION
   EFFICIENCY; NONVIRAL VECTORS; PHASE; LIPOPLEXES; STABILITY; LIPOSOMES;
   COPOLYMER
AB Using solid-phase synthesis, lysine can be oligomerized by a reaction of the peptide carboxylate with the epsilon-amino group to produce nontoxic, biodegradable cationic peptides, epsilon-oligo(L-lysines). Here alpha-substituted derivatives of such epsilon-oligo(L-lysines) containing arginine and histidine in the side chain were tested as vectors for in vitro gene delivery. Combination Of epsilon-oligolysines with the cationic lipid DOTAP and plasmid DNA resulted in transfection efficiency exceeding that of DOTAP alone, without significant increase in cytotoxicity. Synchrotron small-angle X-ray scattering studies revealed self-assembly of the DOTAP, epsilon-oligolysines, and DNA to ordered lamellar complexes. High transfection efficiency of the nanoparticles correlates with increase in zeta potential above +20 mV and requires particle size to be below 500 nm. The synergistic effect of branched epsilon-oligolysines and DOTAP in gene delivery can be explained by the increase in surface charge and by the supramolecular structure of the DOTAP/epsilon-oligolysine/DNA nanoparticles.
C1 [Yan, Jiang; Korolev, Nikolay; Eom, Khee Dong; Tam, James P.; Nordenskioeld, Lars] Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore.
RP Nordenskiold, L (reprint author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
EM LarsNor@ntu.edu.sg
RI Korolev, Nikolay/H-2335-2011
OI Tam, James P/0000-0003-4433-198X
FU Singapore Agency for Science Technology and Research (A*STAR) BMRC
   (Biomedical Research Council); Singapore Ministry of Education (MOE);
   ARC
FX This work was financially supported by the Singapore Agency for Science
   Technology and Research (A*STAR) BMRC (Biomedical Research Council)
   grant and by Singapore Ministry of Education (MOE) Tier 2 and ARC-Tier 1
   grants. The National Synchrotron Radiation Research Center (NSRRC) at
   Hsinchu, Taiwan is acknowledged for generous allocation of beamtime that
   enabled the Synchrotron X-Ray scattering measurements. We are indebted
   to the Small/Wide Angle X-ray Scattering beamline staff for technical
   assistance.
CR Bello-Roufai M, 2007, NUCLEIC ACIDS RES, V35, P728, DOI 10.1093/nar/gkl860
   Chen QR, 2000, GENE THER, V7, P1698, DOI 10.1038/sj.gt.3301294                                                           
   Chen QR, 2002, NUCLEIC ACIDS RES, V30, P1338, DOI 10.1093/nar/30.6.1338
   Chen QR, 2001, NUCLEIC ACIDS RES, V29, P1334, DOI 10.1093/nar/29.6.1334
   Duguid JG, 1998, BIOPHYS J, V74, P2802, DOI 10.1016/S0006-3495(98)77987-1                                                   
   Ewert K, 2004, CURR MED CHEM, V11, P133, DOI 10.2174/0929867043456160                                                        
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a
   Gao X, 2007, AAPS J, V9, pE92, DOI 10.1208/aapsj0901009
   Hofland HEJ, 1996, P NATL ACAD SCI USA, V93, P7305, DOI 10.1073/pnas.93.14.7305
   Huang D, 2008, BIOMACROMOLECULES, V9, P321, DOI 10.1021/bm700882g
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Jeng US, 2010, J APPL CRYSTALLOGR, V43, P110, DOI 10.1107/S0021889809043271
   Koltover I, 1999, BIOPHYS J, V77, P915, DOI 10.1016/S0006-3495(99)76942-0                                                   
   Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78                                                     
   Korolev N, 2004, J BIOMOL STRUCT DYN, V22, P215, DOI 10.1080/07391102.2004.10506997                                                  
   Korolev N, 2003, BIOPHYS CHEM, V104, P55, DOI 10.1016/S0301-4622(02)00338-1
   Korolev N, 2009, NUCLEIC ACIDS RES, V37, P7137, DOI 10.1093/nar/gkp683
   Koynova R, 2006, P NATL ACAD SCI USA, V103, P14373, DOI 10.1073/pnas.0603085103
   Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g                                                               
   Le Bihan O, 2011, NUCLEIC ACIDS RES, V39, P1595, DOI 10.1093/nar/gkq921
   Li D, 2010, BIOMACROMOLECULES, V11, P2221, DOI 10.1021/bm100141y
   Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1                                                   
   Marchini C, 2009, LANGMUIR, V25, P3013, DOI 10.1021/la8033726
   Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003                                                            
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Radler JO, 1998, LANGMUIR, V14, P4272, DOI 10.1021/la980360o
   Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810
   Rao NM, 2006, BIOSCIENCE REP, V26, P301, DOI 10.1007/s10540-006-9026-8
   Read ML, 2005, ADV GENET, V53, P19, DOI 10.1016/S0065-2660(05)53002-5
   Ross PC, 1999, GENE THER, V6, P651, DOI 10.1038/sj.gt.3300863
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X                                                   
   Segura T, 2001, ANNU REV MATER RES, V31, P25, DOI 10.1146/annurev.matsci.31.1.25                                                  
   Son KK, 2000, BBA-BIOMEMBRANES, V1468, P11, DOI 10.1016/S0005-2736(00)00312-6
   Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484                                                           
   Tam JP, 2002, EUR J BIOCHEM, V269, P923, DOI 10.1046/j.0014-2956.2001.02728.x                                                
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Yu W, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh049
NR 39
TC 14
Z9 14
U1 1
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD JAN
PY 2012
VL 13
IS 1
BP 124
EP 131
DI 10.1021/bm201359r
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 873QE
UT WOS:000298897300014
PM 22066663
DA 2018-01-05
ER

PT J
AU Lehtovaara, BC
   Verma, MS
   Gu, FX
AF Lehtovaara, Benjamin C.
   Verma, Mohit S.
   Gu, Frank X.
TI Synthesis of curdlan-graft-poly(ethylene glycol) and formulation of
   doxorubicin-loaded core-shell nanoparticles
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
DE curdlan; 1,3-beta-glucan; helix; doxorubicin; nanoparticle; core-shell;
   curdlan-g-PEG copolymer; controlled release
ID ANTI-HIV ACTIVITY; BETA-GLUCAN; ANTISENSE-OLIGONUCLEOTIDES;
   POLY(ETHYLENE GLYCOL); SURFACE MODIFICATION; BLOCK-COPOLYMERS; CURDLAN
   SULFATE; DRUG-DELIVERY; IN-VITRO; RELEASE
AB A new core-shell nanoparticle containing the chemotherapeutic drug doxorubicin was formulated via amphiphilic graft copolymer self-assembly using curdlan-graft-poly(ethylene glycol) (curdlan-g-PEG). The graft copolymer was synthesized through the dicyclohexylcarbodiimide ester linkage of carboxylated PEG to the hydroxyl groups of the curdlan backbone. The nanoparticles were 109.9 nm in size and encapsulated doxorubicin in high yield (4%-5% wt/wt). The nanoparticles also controlled the release of doxorubicin over 24 h with a release profile that followed a Fickian diffusion model. The biocompatibility of curdlan-g-PEG was confirmed by hemolysis assay. This is the first nanoparticle formulated using the hydrophobicity of curdlan for concealing the immunomodulatory potential of curdlan within the core.
C1 [Gu, Frank X.] Univ Waterloo, Waterloo Inst Nanotechnol, Waterloo, ON N2L 3G1, Canada.
   [Lehtovaara, Benjamin C.; Verma, Mohit S.; Gu, Frank X.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
RP Gu, FX (reprint author), Univ Waterloo, Waterloo Inst Nanotechnol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM frank.gu@uwaterloo.ca
RI Gu, Frank/G-8381-2011
OI Gu, Frank/0000-0001-8749-9075
FU Natural Sciences and Engineering Research Council of Canada
FX This work was financially supported by Natural Sciences and Engineering
   Research Council of Canada.
CR Borjihan G, 2003, POLYM ADVAN TECHNOL, V14, P326, DOI 10.1002/pat.315
   Choi YH, 1998, J CONTROL RELEASE, V54, P39, DOI 10.1016/S0168-3659(97)00174-0
   DRITZ SS, 1995, J ANIM SCI, V73, P3341
   Eicher SD, 2006, J ANIM SCI, V84, P2352, DOI 10.2527/jas.2005-770
   Evans SG, 1998, T ROY SOC TROP MED H, V92, P87, DOI 10.1016/S0035-9203(98)90969-5
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferreira DS, 2009, J BRAZIL CHEM SOC, V20, P1908, DOI 10.1590/S0103-50532009001000020
   Funami T, 1999, J FOOD SCI, V64, P883, DOI 10.1111/j.1365-2621.1999.tb15933.x
   JAGODZINSKI PP, 1994, VIROLOGY, V202, P735, DOI 10.1006/viro.1994.1395
   Jo S, 2000, BIOMATERIALS, V21, P605, DOI 10.1016/S0142-9612(99)00224-0
   Kang GD, 2006, INT J PHARM, V319, P29, DOI 10.1016/j.ijpharm.2006.03.032
   Karinaga R, 2006, BIOMATERIALS, V27, P1626, DOI 10.1016/j.biomaterials.2005.08.023
   Karinaga R, 2005, BIOMATERIALS, V26, P4866, DOI 10.1016/j.biomaterials.2004.11.031
   Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200
   Khandwekar AP, 2009, J MATER SCI-MATER M, V20, P1115, DOI 10.1007/s10856-008-3655-3
   Kohler N, 2006, SMALL, V2, P785, DOI 10.1002/smll.200600009
   Lehtovaara BC, 2011, J AGR FOOD CHEM, V59, P6813, DOI 10.1021/jf200964u
   Leung TCY, 2010, MATER CHEM PHYS, V121, P402, DOI 10.1016/j.matchemphys.2010.02.026
   Li L, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265601
   Luu YK, 2003, J CONTROL RELEASE, V89, P341, DOI 10.1016/S0168-3659(03)00097-X
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Mocanu G, 2008, J BIOACT COMPAT POL, V23, P82, DOI 10.1177/0883911507085071
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   NAKAO Y, 1991, J FOOD SCI, V56, P769, DOI 10.1111/j.1365-2621.1991.tb05378.x
   Ohno N, 2001, BIOL PHARM BULL, V24, P820, DOI 10.1248/bpb.24.820
   OHYA Y, 1995, J BIOACT COMPAT POL, V10, P51, DOI 10.1177/088391159501000106                                                      
   OSAWA Z, 1993, CARBOHYD POLYM, V21, P283, DOI 10.1016/0144-8617(93)90060-H                                                    
   Pechar M, 2005, J BIOACT COMPAT POL, V20, P319, DOI 10.1177/0883911505055161
   PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279
   Rice PJ, 2005, J PHARMACOL EXP THER, V314, P1079, DOI 10.1124/jpet.105.085415
   Riess G, 2003, PROG POLYM SCI, V28, P1107, DOI 10.1016/S0079-6700(03)00015-7
   Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2
   Saito H, 2007, J BIOACT COMPAT POL, V22, P589, DOI 10.1177/0883911507084653
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169-409X(01)00112-0                                                   
   Sonck E, 2010, VET IMMUNOL IMMUNOP, V135, P199, DOI 10.1016/j.vetimm.2009.11.014
   Subedi RK, 2009, EUR J PHARM SCI, V37, P508, DOI 10.1016/j.ejps.2009.04.008
   Ungurenasu C, 2007, J POLYM SCI POL CHEM, V45, P3124, DOI 10.1002/pola.22010
   Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777                                                               
   Wei D, 2002, WOUND REPAIR REGEN, V10, P161, DOI 10.1046/j.1524-475X.2002.10804.x                                                
   Xiong XY, 2005, J CONTROL RELEASE, V103, P73, DOI 10.1016/j.conrel.2004.11.018
   Yoo HS, 2001, J CONTROL RELEASE, V70, P63, DOI 10.1016/S0168-3659(00)00340-0
   Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561
   Zhang HB, 2002, INT J BIOL MACROMOL, V30, P7, DOI 10.1016/S0141-8130(01)00187-8                                                   
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 44
TC 9
Z9 9
U1 3
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883-9115
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD JAN
PY 2012
VL 27
IS 1
BP 3
EP 17
DI 10.1177/0883911511432511
PG 15
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA 878QJ
UT WOS:000299271300001
DA 2018-01-05
ER

PT J
AU Huang, CB
   Soenen, SJ
   van Gulck, E
   Vanham, G
   Rejman, J
   Van Calenbergh, S
   Vervaet, C
   Coenye, T
   Verstraelen, H
   Temmerman, M
   Demeester, J
   De Smedt, SC
AF Huang, Chaobo
   Soenen, Stefaan J.
   van Gulck, Ellen
   Vanham, Guido
   Rejman, Joanna
   Van Calenbergh, Serge
   Vervaet, Chris
   Coenye, Tom
   Verstraelen, Hans
   Temmerman, Marleen
   Demeester, Jo
   De Smedt, Stefaan C.
TI Electrospun cellulose acetate phthalate fibers for semen induced
   anti-HIV vaginal drug delivery
SO BIOMATERIALS
LA English
DT Article
DE Drug delivery; Electrospinning; Stimulus-responsive polymer; Cellulose
   acetate phthalate; HIV; Drug release
ID REVERSE-TRANSCRIPTASE INHIBITORS; MICROBICIDES; NANOPARTICLES;
   FORMULATION; PREVENTION; INFECTION; SIMULANT; POLYMERS; SYSTEMS; GP120
AB Despite many advances in modern medicine, human immunodeficiency virus (HIV) still affects the health of millions of people world-wide and much effort is put in developing methods to either prevent infection or to eradicate the virus after infection has occurred. Here, we describe the potential use of electrospun cellulose acetate phthalate (CAP) fibers as a tool to prevent HIV transmission. During the electrospinning process, anti-viral drugs can easily be incorporated in CAP fibers. Interestingly, as a result of the pH-dependent solubility of CAP, the fibers are stable in vaginal fluid (the healthy vaginal flora has a pH of below 4.5), whereas the addition of small amounts of human semen (pH between 7.4 and 8.4) immediately dissolves the fibers which results in the release of the encapsulated drugs. The pH-dependent release properties have been carefully studied and we show that the released anti-viral drugs, together with the CAP which has been reported to have intrinsic antimicrobial activity, efficiently neutralize HIV in vitro. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Huang, Chaobo; Soenen, Stefaan J.; Rejman, Joanna; Demeester, Jo; De Smedt, Stefaan C.] Univ Ghent, Lab Gen Biochem & Phys Pharm, Fac Pharmaceut Sci, B-9000 Ghent, Belgium.
   [van Gulck, Ellen; Vanham, Guido] Inst Trop Med, Virol Unit, Dept Microbiol, B-2000 Antwerp, Belgium.
   [Vanham, Guido] Univ Antwerp, Fac Pharmacol, B-2020 Antwerp, Belgium.
   [Van Calenbergh, Serge] Univ Ghent, Med Chem Lab, Fac Pharmaceut Sci, B-9000 Ghent, Belgium.
   [Vervaet, Chris] Univ Ghent, Lab Pharmaceut Technol, Fac Pharmaceut Sci, B-9000 Ghent, Belgium.
   [Coenye, Tom] Univ Ghent, Lab Pharmaceut Microbiol, Fac Pharmaceut Sci, B-9000 Ghent, Belgium.
   [Verstraelen, Hans; Temmerman, Marleen] Ghent Univ Hosp, Dept Obstet & Gynaecol, Ghent, Belgium.
RP De Smedt, SC (reprint author), Univ Ghent, Lab Gen Biochem & Phys Pharm, Fac Pharmaceut Sci, Harelbekestr 72, B-9000 Ghent, Belgium.
EM Stefaan.DeSmedt@UGent.be
RI Verstraelen, Hans/A-5602-2008; Coenye, Tom/A-6291-2014; Van Calenbergh,
   Serge/A-3167-2008; HUANG, Chaobo/E-7686-2011; Soenen,
   Stefaan/D-7370-2014; Soenen, Stefaan/I-3188-2012
OI Coenye, Tom/0000-0002-6407-0601; Van Calenbergh,
   Serge/0000-0002-4201-1264; Soenen, Stefaan/0000-0003-2390-3133; De
   Smedt, Stefaan/0000-0002-8653-2598; Verstraelen,
   Hans/0000-0002-4070-1587
FU Gent University
FX We thank Nele Matthijs for excellent technical assistance. SJS is a
   post-doctoral fellow from the FWO-Vlaanderen. We thank Gent University
   for its financial support (BOF).
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   Bowman MC, 2008, J AM CHEM SOC, V130, P6896, DOI 10.1021/ja710321g
   Brenner BG, 2011, J MED VIROL, V83, P751, DOI 10.1002/jmv.22047
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Di Fabio S, 2003, AIDS, V17, P1597, DOI 10.1097/01.aids.0000072663.21517.63
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   HASSELMANN C, 2003, CLIN MICROBIOL INFEC, P9
   Huang C, 2011, CHEM SOC REV, V40, P2417, DOI 10.1039/c0cs00181c
   Huang CB, 2010, ADV MATER, V22, P2657, DOI 10.1002/adma.201000130
   Hummelen R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012078
   JAMISON DT, 2006, HIV AIDS DIS MORTALI
   Jay JI, 2010, MOL PHARMACEUT, V7, P116, DOI 10.1021/mp900159n
   Liu SW, 2005, ANTIMICROB AGENTS CH, V49, P1830, DOI 10.1128/AAC.49.5.1830-1836.2005
   Malcolm RK, 2010, ANTIVIR RES, V88, pS30, DOI 10.1016/j.antiviral.2010.09.003
   McCutchan FE, 2006, J MED VIROL, V78, pS7, DOI 10.1002/jmv.20599
   Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
   Neurath AR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-27
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6                                                           
   Nyirjesy P, 2001, AM FAM PHYSICIAN, V63, P697
   Olaru N, 2010, IND ENG CHEM RES, V49, P1953, DOI 10.1021/ie901427f
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Pham PA, 2006, EXPERT OPIN DRUG MET, V2, P459, DOI 10.1517/17425255.2.3.459
   Poveda E, 2007, J ANTIMICROB CHEMOTH, V60, P1409, DOI 10.1093/jac/dkm372
   Rando RF, 2006, ANTIMICROB AGENTS CH, V50, P3081, DOI 10.1128/AAC.01609-05
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   Stone A, 2006, LANCET, V368, P431, DOI 10.1016/S0140-6736(06)69131-9                                                   
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Van Herrewege Y, 2004, ANTIMICROB AGENTS CH, V48, P3684, DOI 10.1128/AAC.48.10.3684-3689.2004
   Vasquez A, 2002, J CLIN MICROBIOL, V40, P2746, DOI 10.1128/JCM.40.8.2746-2746.2002
   Yu DG, 2010, J APPL POLYM SCI, V117, P1509, DOI 10.1002/app.32019
   2007, AIDS ALERT S1, V22
NR 34
TC 70
Z9 70
U1 2
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JAN
PY 2012
VL 33
IS 3
BP 962
EP 969
DI 10.1016/j.biomaterials.2011.10.004
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 864BQ
UT WOS:000298212400025
PM 22018388
DA 2018-01-05
ER

PT J
AU Gras, R
   Garcia, MI
   Gomez, R
   de la Mata, FJ
   Munoz-Fernandez, MA
   Lopez-Fernandez, LA
AF Gras, Rafael
   Garcia, Maria I.
   Gomez, Rafael
   Javier de la Mata, F.
   Angeles Munoz-Fernandez, M.
   Lopez-Fernandez, Luis A.
TI Carbosilane Dendrimer 2G-NN16 Represses Tc17 Differentiation in Primary
   T CD8+ Lymphocytes
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Tc17 cells; dendrimers; nanoparticles; gene expression; immune response
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   GENE-EXPRESSION PROFILES; BLOOD MONONUCLEAR-CELLS; VIRAL-INFECTION;
   DELIVERY; THERAPY; TH17; OLIGONUCLEOTIDES; FREQUENCY
AB We studied changes in gene expression induced by the carbosilane dendrimer 2G-NN16 to evaluate their potential as a vehicle for gene therapy and as medication. Global gene expression profiles on CD8+ T lymphocytes reveal that ribosomal proteins are induced in the presence of 2G-NN16. IL17A and IL17F, the principal interleukins secreted by Tc17 cells, a subset of CD8+ T lymphocytes, were down-regulated when cultured in the presence of this dendrimer. Microarray results were confirmed by real time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). 2G-NN16 also showed a high potential for in vitro inhibition of Tc17 differentiation of CD8+ T lymphocytes in the presence of the Tc17 differentiation molecules IL6 and TGF-B1. These findings suggest that 2G-NN16 could facilitate drug delivery and may be used to treat inflammatory processes driven by Tc17 cells.
C1 [Angeles Munoz-Fernandez, M.] Hosp Gen Univ Gregorio Maranon, Immunobiol Lab, Madrid 28007, Spain.
RP Munoz-Fernandez, MA (reprint author), Hosp Gen Univ Gregorio Maranon, Immunobiol Lab, Doctor Esquerdo 46, Madrid 28007, Spain.
EM mmunoz.hgugm@salud.madrid.org; llopezf.hgugm@salud.madrid.org
RI Gomez Ramirez, Rafael/K-1216-2014; Lopez-Fernandez, Luis/B-7330-2011; De
   la Mata, F. Javier/K-1649-2014
OI Gomez Ramirez, Rafael/0000-0001-6448-2414; Lopez-Fernandez,
   Luis/0000-0003-3964-5837; De la Mata, F. Javier/0000-0003-0418-3935;
   Munoz-Fernandez/0000-0002-0813-4500
FU Fondo de Investigacion Sanitaria [FIS PI09/02438, INTRASALUD
   RD09/0076/00103, FIS07/0110, PI08/222]; Programa Miguel Servet [FIS
   CP06/0267]; Red Tematica de Investigacion Cooperativa Sanitaria ISCIII
   [RED RIS RD06/0006/0035]; FIPSE [240800/09]; ERA-NET [NAN2007-31198- E];
   EuroNanoMed DENANORNA [TD0802-05876]; MNT-ERA NET [NAN2007-31135-E];
   COST Action [TD0802]; U.A.
FX We thank the "Centro de Transfusiones de la Comunidad de Madrid" for
   their generous gifts of buffy coats and Laura Diaz for flow cytometry
   technical help. This work was supported by the following grants: "Fondo
   de Investigacion Sanitaria" (FIS PI09/02438) and "Programa Miguel
   Servet" (FIS CP06/0267) to L.A.L.-F.; Red Tematica de Investigacion
   Cooperativa Sanitaria ISCIII (RED RIS RD06/0006/0035), and FIPSE
   240800/09, Fondo de Investigacion Sanitaria (INTRASALUD RD09/0076/00103,
   FIS07/0110), ERA-NET NAN2007-31198- E, EuroNanoMed DENANORNA (COST-STSM;
   TD0802-05876) to M.A.M.-F.; and MNT-ERA NET 2007 (NAN2007-31135-E),
   Fondo de Investigacion Sanitaria (PI08/222), COST Action (TD0802), and
   CIBER-BBN to authors from U.A.
CR Bermejo JF, 2007, CHEM-EUR J, V13, P483, DOI 10.1002/chem.200600594
   Blaak H, 2005, J VIROL, V79, P1686, DOI 10.1128/JVI.79.3.1686-1700.2005
   Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006
   Cox MA, 2011, TRENDS IMMUNOL, V32, P180, DOI 10.1016/j.it.2011.01.004
   Huang da W., 2009, NAT PROTOC, V4, P44, DOI DOI 10.1038/NPR0T.2008.211
   Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182
   Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092                                                   
   Gao X, 2007, AAPS J, V9, pE92, DOI 10.1208/aapsj0901009
   Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27
   Gonzalo T, 2010, CHEMMEDCHEM, V5, P921, DOI 10.1002/cmdc.201000029
   Gras R, 2009, PHARM RES-DORD, V26, P577, DOI 10.1007/s11095-008-9776-z
   Henriques A, 2010, CELL IMMUNOL, V264, P97, DOI 10.1016/j.cellimm.2010.05.004
   Jacobo P, 2011, REPRODUCTION, V141, P249, DOI 10.1530/REP-10-0362
   Jain NK, 2007, EXPERT OPIN DRUG DEL, V4, P495, DOI 10.1517/17425247.4.5.495
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Kondo T, 2009, J IMMUNOL, V182, P1794, DOI 10.4049/jimmunol.0801347
   Kuo JHS, 2010, MOL PHARMACEUT, V7, P805, DOI 10.1021/mp900303s
   Lai PS, 2007, J CONTROL RELEASE, V122, P39, DOI 10.1016/j.jconrel.2007.06.012
   Jimenez JL, 2010, BIODRUGS, V24, P331, DOI 10.2165/11538400-000000000-00000
   Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900
   Murray SM, 2010, J VIROL, V84, P12082, DOI 10.1128/JVI.01466-10
   Nakhlband A, 2010, J BIOMED NANOTECHNOL, V6, P360, DOI 10.1166/jbn.2010.1131
   Nigam P, 2011, J IMMUNOL, V186, P745, DOI 10.4049/jimmunol.1002807
   Omidi Y, 2009, INT J TOXICOL, V28, P113, DOI 10.1177/1091581809335177
   Oppeltz RF, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-38
   Perez-Martinez FC, 2011, PHARM RES-DORDR, V28, P1843, DOI 10.1007/s11095-010-0364-7
   Posadas I, 2009, PHARM RES-DORD, V26, P1181, DOI 10.1007/s11095-009-9839-9
   Puwipirom H, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3194
   Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0                                                   
   Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108
   Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1254704
   Sheng KC, 2008, EUR J IMMUNOL, V38, P424, DOI 10.1002/eji.200737578
   Vahey MT, 2002, AIDS RES HUM RETROV, V18, P179, DOI 10.1089/08892220252781239                                                       
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Wu W, 2010, J GASTROEN HEPATOL, V25, P750, DOI 10.1111/j.1440-1746.2009.06154.x
   Yen HR, 2009, J IMMUNOL, V183, P7161, DOI 10.4049/jimmunol.0900368
   Zhao XY, 2011, EUR J IMMUNOL, V41, P514, DOI 10.1002/eji.201040793
NR 37
TC 5
Z9 5
U1 2
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JAN
PY 2012
VL 9
IS 1
BP 102
EP 110
DI 10.1021/mp200305u
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 871BI
UT WOS:000298712200010
PM 22023154
DA 2018-01-05
ER

PT S
AU Esseghaier, C
   Ng, A
   Zourob, M
AF Esseghaier, Chiheb
   Ng, Andy
   Zourob, Mohammed
BE Kieffer, JC
TI A novel assay for rapid HIV-1 protease detection using optical sensors
   and magnetic carriers
SO PHOTONICS NORTH 2012
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Photonics North
CY JUN 06-08, 2012
CL Montreal, CANADA
SP Univ Laval, Ctr Optique, Photonique & Laser, Canadian Photon Consortium, Inst Natl Optique, Quebec Photon Network, Canadian Inst Photon Innovat, CMC Microsystems, Ecole Technologie Superieure, INRS
DE HIV-1 protease; biosensor; specificity; magnetic nanoparticles;
   impedance spectroscopy
AB In this work, a very simple electrochemical HIV-1 protease biosensor useful for the development of an inexpensive lab-on-a- chip (LOC) device was constructed. The detection mechanism was designed to minimize the complexity either in the recognition receptor immobilization step or during the detection itself. The magnetic self-assembled monolayer of HIV-1 protease substrate peptide was able to detect as low as 10 pg/ml of the protease within 25 minutes with high specificity.
C1 [Esseghaier, Chiheb; Ng, Andy; Zourob, Mohammed] INRS EMT, Varennes, PQ J3X 1S2, Canada.
RP Esseghaier, C (reprint author), INRS EMT, Varennes, PQ J3X 1S2, Canada.
EM zourob@emt.inrs.ca
RI Ng, Andy/I-3060-2016
OI Ng, Andy/0000-0003-3257-0801
CR Bianchi N, 1997, CLIN DIAGN VIROL, V8, P199, DOI 10.1016/S0928-0197(97)00025-1
   Brik A., 2003, ORG BIOMOL CHEM, V114, P5
   Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097                                                          
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   MONTAGNIER L, 1987, ANN INST PASTEUR VIR, V138, P3, DOI 10.1016/S0769-2617(87)80068-0                                                   
   Tran L.D., 2011, MAT SCI ENG C, V31, P477
   UNAIDS WHO, 2009, WHO LIB CAT IN PUBL
   Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051
NR 10
TC 0
Z9 0
U1 1
U2 9
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-9090-2
J9 PROC SPIE
PY 2012
VL 8412
AR 841209
DI 10.1117/12.2001479
PG 6
WC Optics
SC Optics
GA BA0KN
UT WOS:000331660100008
DA 2018-01-05
ER

PT B
AU Pedro, L
   Soares, SS
   Ferreira, GNM
AF Pedro, Luisa
   Soares, Sandra S.
   Ferreira, Guilherme N. M.
BE Jenkins, N
   Barron, N
   Alves, PM
TI Thermal and Detergent Tolerance for a Chimeric Bionanoparticle
SO PROCEEDINGS OF THE 21ST ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR
   ANIMAL CELL TECHNOLOGY (ESACT), 2009
SE ESACT Proceedings
LA English
DT Proceedings Paper
CT 21st Annual Meeting of the European-Society-for-Animal-Cell-Technology
   (ESACT)
CY JUN 07-10, 2009
CL Dublin, IRELAND
SP European Soc Animal Cell Technol
ID DELIVERY
AB Protein nanoparticles, such as virus-like particles (VLPs), are becoming the most attractive candidate for prophylactic vaccination, genetic and molecular therapies, since they can be engineered in order to encapsulate therapeutics, to target specific cells or tissues, and/or to stimulate humoral or cytotoxic responses (Kang et al. 1999; Schaffer and Lauffenburger 2000; Yamada et al. 2003). Nevertheless their successful application depends on a larger number of factors, in which their stability plays one of the most important roles. Moreover these bionanoparticles have to guaranty delivery of the therapeutical agent to the target cell overcoming different biological barriers in vivo (Kang et al. 1999). In this communication we studied the thermal stability and detergent tolerance of the viral bionanoparticles produced in our laboratory, based on a minimal construction by fusion of the SIV (Simian Immunodeficiency Virus) p17 matrix protein with the HIV-1 (Human Immunodeficiency Virus Type 1) p6 protein (Costa et al. 2007). The lipid membrane surrounding these VLPs confers them stability against proteolysis and may contribute for the thermal stability of the bionanoparticles. Stability studies have shown that bionanoparticles are stable at 37 C for 96 h. Also the matrix core has shown to be highly stable even at detergent concentrations as high as 20% (v/v) of Triton X-100.
C1 [Pedro, Luisa] Univ Algarve, Ctr Mol & Struct Biomed, IBB, Faro, Portugal.
RP Pedro, L (reprint author), Univ Algarve, Ctr Mol & Struct Biomed, IBB, Faro, Portugal.
EM lpedro@ualg.pt
FU Portuguese Foundation for Science and Technology (FCT)
   [PTDC/BIO/69682/2006];  [SFRII/BD/36674/2007];  [SFRH/BPD/30290/2006]
FX The authors thank to Portuguese Foundation for Science and Technology
   (FCT) the financial support through the research project
   PTDC/BIO/69682/2006 and the grants SFRII/BD/36674/2007 and
   SFRH/BPD/30290/2006.
CR Costa MJL, 2007, BIOTECHNOL APPL BIOC, V48, P35, DOI 10.1042/BA20060208
   Kang CY, 1999, BIOL CHEM, V380, P353, DOI 10.1515/BC.1999.047                                                             
   Schaffer DV, 2000, CURR OPIN MOL THER, V2, P155
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
BN 978-94-007-0883-9
J9 ESACT PROCEED
PY 2012
VL 5
BP 695
EP 698
DI 10.1007/978-94-007-0884-6_110
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA BH1NK
UT WOS:000398249100110
DA 2018-01-05
ER

PT J
AU McGuigan, C
   Madela, K
   Aljarah, M
   Bourdin, C
   Arrica, M
   Barrett, E
   Jones, S
   Kolykhalov, A
   Bleiman, B
   Bryant, KD
   Ganguly, B
   Gorovits, E
   Henson, G
   Hunley, D
   Hutchins, J
   Muhammad, J
   Obikhod, A
   Patti, J
   Walters, CR
   Wang, J
   Vernachio, J
   Ramamurty, CVS
   Battina, SK
   Chamberlain, S
AF McGuigan, Christopher
   Madela, Karolina
   Aljarah, Mohamed
   Bourdin, Claire
   Arrica, Maria
   Barrett, Emma
   Jones, Sarah
   Kolykhalov, Alexander
   Bleiman, Blair
   Bryant, K. Dawn
   Ganguly, Babita
   Gorovits, Elena
   Henson, Geoffrey
   Hunley, Damound
   Hutchins, Jeff
   Muhammad, Jerry
   Obikhod, Aleksandr
   Patti, Joseph
   Walters, C. Robin
   Wang, Jin
   Vernachio, John
   Ramamurty, Changalvala V. S.
   Battina, Srinivas K.
   Chamberlain, Stanley
TI Phosphorodiamidates as a Promising New Phosphate Prodrug Motif for
   Antiviral Drug Discovery: Application to Anti-HCV Agents
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; PHOSPHORAMIDATE
   DERIVATIVES; AMINO-ACID; NUCLEOSIDE ANALOGS; INHIBITORS; HIV; STAVUDINE;
   POTENT; D4T
AB We herein report phosphorodiamidates as a significant new phosphate prodrug motif. Sixty-seven phosphorodiamidates are reported of two 6-O-alkyl 2'-C-methyl guanosines, with significant variation in the diamidate structure. Both symmetrical and asymmetric phosphorodiamidates are reported, derived from various esterified amino acids, both D and L., and also from various simple amines. All of the compounds were evaluated versus hepatitis C virus in replicon assay, and nanomolar activity levels were observed. Many compounds were noncytotoxic at 100 mu M, leading to high antiviral selectivities. The agents are stable in acidic, neutral, and moderately basic media and in selected biological media but show efficient processing by carboxypeptidases and efficiently yield the free nucleoside monophosphate in cells. On the basis of in vitro data, eight leads were selected for additional in vivo evaluation, with the intent of selecting one candidate for progression toward clinical studies. This phosphorodiamidate prodrug method may have broad application outside of HCV and antivirals as it offers many of the advantages of phosphoramidate ProTides but without the chirality issues present in most cases.
C1 [McGuigan, Christopher; Madela, Karolina; Aljarah, Mohamed; Bourdin, Claire; Arrica, Maria; Barrett, Emma; Jones, Sarah] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales.
   [Kolykhalov, Alexander; Bleiman, Blair; Bryant, K. Dawn; Ganguly, Babita; Gorovits, Elena; Henson, Geoffrey; Hunley, Damound; Hutchins, Jeff; Muhammad, Jerry; Obikhod, Aleksandr; Patti, Joseph; Walters, C. Robin; Wang, Jin; Vernachio, John; Chamberlain, Stanley] Inhibitex Inc, Alpharetta, GA 30004 USA.
   [Ramamurty, Changalvala V. S.; Battina, Srinivas K.] CiVentiChem, Cary, NC 27513 USA.
RP McGuigan, C (reprint author), Cardiff Univ, Welsh Sch Pharm, King Edward VII Ave, Cardiff CF10 3NB, S Glam, Wales.
EM mcguigan@cardiff.ac.uk
RI McGuigan, Chris/P-1580-2014
OI McGuigan, Chris/0000-0001-8409-710X
CR Balzarini J, 1996, MOL PHARMACOL, V50, P1207
   Barry A., 2011, 46 EUR ASS STUD LIV
   Brown NA, 2009, EXPERT OPIN INV DRUG, V18, P709, DOI [10.1517/13543780902854194, 10.1517/13543780902854194 ]
   Chou TF, 2007, MOL PHARM, V4, P208, DOI 10.1021/mp060070y
   Congiatu C, 2006, J MED CHEM, V49, P452, DOI 10.1021/jm0509896
   Derudas M, 2009, J MED CHEM, V52, P5520, DOI 10.1021/jm9007856
   Drontle DP, 2004, MINI-REV MED CHEM, V4, P409
   ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007
   Erion MD, 2005, P NATL ACAD SCI USA, V102, P7970, DOI 10.1073/pnas.0502983102
   Erion MD, 2004, J AM CHEM SOC, V126, P5154, DOI 10.1021/ja031818y
   Erion M.D., 2011, J HEPATOL, V54, P187
   Furman P.A., 2009, HEPATOLOGY S, V48
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112
   JONES B C N M, 1991, Antiviral Chemistry and Chemotherapy, V2, P35
   McGuigan C, 1998, ANTIVIR CHEM CHEMOTH, V9, P473, DOI 10.1177/095632029800900603                                                      
   McGuigan C, 1996, ANTIVIR CHEM CHEMOTH, V7, P184, DOI 10.1177/095632029600700402                                                      
   McGuigan C, 1997, ANTIVIR RES, V35, P195, DOI 10.1016/S0166-3542(97)00029-6
   McGuigan C, 1998, ANTIVIR CHEM CHEMOTH, V9, P109, DOI 10.1177/095632029800900202                                                      
   McGuigan C, 2011, BIOORG MED CHEM LETT, V21, P6007, DOI 10.1016/j.bmcl.2011.06.013
   McGuigan C, 2010, BIOORG MED CHEM LETT, V20, P4850, DOI 10.1016/j.bmcl.2010.06.094
   McGuigan C, 2010, J MED CHEM, V53, P4949, DOI 10.1021/jm1003792
   McKenna CE, 2005, J ORGANOMET CHEM, V690, P2673, DOI 10.1016/j.jorganchem.2005.03.004
   Mehellou Y, 2009, CHEMMEDCHEM, V4, P1779, DOI 10.1002/cmdc.200900289
   Meier C, 1996, ANGEW CHEM INT EDIT, V35, P70, DOI 10.1002/anie.199600701                                                          
   Nillroth U, 1995, Drug Des Discov, V13, P43
   NILLROTH U, 1995, ANTIVIR CHEM CHEMOTH, V6, P50, DOI 10.1177/095632029500600107                                                      
   Pengram M., 2002, EJC SUPPL, V38, P99
   PERIGAUD C, 1994, BIOCHEM PHARMACOL, V48, P11, DOI 10.1016/0006-2952(94)90217-8
   ROMANOWSKA K, 1993, POL J CHEM, V67, P755
   SERAFINOWSKA HT, 1995, J MED CHEM, V38, P1372, DOI 10.1021/jm00008a015
   Soriano V, 2008, EXPERT OPIN EMERG DR, V13, P1, DOI [10.1517/14728214.13.1.1, 10.1517/14728214.13.1.1 ]
   Vernachio JH, 2011, ANTIMICROB AGENTS CH, V55, P1843, DOI 10.1128/AAC.01335-10
   Zhou XJ., 2011, ANTIMICROB AGENTS CH, V1, P76
NR 34
TC 18
Z9 19
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 22
PY 2011
VL 54
IS 24
BP 8632
EP 8645
DI 10.1021/jm2011673
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 860KD
UT WOS:000297946300035
PM 22039920
DA 2018-01-05
ER

PT J
AU Riedel, T
   Ghasparian, A
   Moehle, K
   Rusert, P
   Trkola, A
   Robinson, JA
AF Riedel, Tina
   Ghasparian, Arin
   Moehle, Kerstin
   Rusert, Peter
   Trkola, Alexandra
   Robinson, John A.
TI Synthetic Virus-Like Particles and Conformationally Constrained
   Peptidomimetics in Vaccine Design
SO CHEMBIOCHEM
LA English
DT Article
DE antibodies; HIV; lipopeptides; peptides; V3 loop; vaccines; virus-like
   particles
ID GP120 V3 LOOP; TYPE-1 ENVELOPE GLYCOPROTEINS; TOLL-LIKE RECEPTORS; HIV-1
   GP120; NEUTRALIZING ANTIBODY; CRYSTAL-STRUCTURE; T-CELL; ALTERNATIVE
   CONFORMATIONS; BROAD NEUTRALIZATION; ANTIGEN PRESENTATION
AB Conformationally constrained peptidomimetics could be of great value in the design of vaccines targeting protective epitopes on viral and bacterial pathogens. But the poor immunogenicity of small synthetic molecules represents a serious obstacle for their use in vaccine development. Here, we show how a constrained epitope mimetic can be rendered highly immunogenic through multivalent display on the surface of synthetic virus-like nanoparticles. The target epitope is the V3 loop from the gp120 glycoprotein of HIV-1 bound to the neutralizing antibody F425-B4e8. The antibody-bound V3 loop adopts a beta-hairpin conformation, which is effectively stabilized by transplantation onto a D-Pro-L-Pro template. The resulting mimetic after coupling to synthetic virus-like particles elicited antibodies in rabbits that recognized recombinant gp120. The elicited antibodies also blocked infection by the neutralization sensitive tier-1 strain MN of HIV-1, as well as engineered viruses with the V1V2 loop deleted; this result is consistent with screening of V3 by the V1V2 loop in intact trimeric viral gp120 spikes. The results provide new insights into HIV-1 vaccine design based on the V3 loop, and illustrate how knowledge from structural biology can be exploited for the design of constrained epitope mimetics, which can be delivered to the immune system by using a highly immunogenic synthetic nanoparticle delivery system.
C1 [Riedel, Tina; Ghasparian, Arin; Moehle, Kerstin; Robinson, John A.] Univ Zurich, Dept Chem, CH-8057 Zurich, Switzerland.
   [Rusert, Peter; Trkola, Alexandra] Univ Zurich, Inst Med Virol, CH-8057 Zurich, Switzerland.
RP Robinson, JA (reprint author), Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.
EM robinson@oci.uzh.ch
OI Trkola, Alexandra/0000-0003-1013-876X
FU Swiss National Science Foundation
FX The authors thank the Swiss National Science Foundation for financial
   support. The following reagent was obtained through the AIDS Research
   and Reference Reagent Program, Division of AIDS, NIAID, NIH: antibody
   F425-B4e8 from Dr. Marshall Posner and Dr. Lisa Cavacini.
CR BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486
   Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454
   Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887
   Bell CH, 2008, J MOL BIOL, V375, P969, DOI 10.1016/j.jmb.2007.11.013
   Boato F, 2007, ANGEW CHEM, V119, P9173
   Bontjer I, 2009, J VIROL, V83, P368, DOI 10.1128/JVI.01404-08
   Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004
   Cabezas E, 1999, J AM CHEM SOC, V121, P3862, DOI 10.1021/ja983212t                                                               
   Cabezas E, 2000, BIOCHEMISTRY-US, V39, P14377, DOI 10.1021/bi0003691
   Cao J, 1997, J VIROL, V71, P9808
   CATASTI P, 1995, J BIOL CHEM, V270, P2224, DOI 10.1074/jbc.270.5.2224                                                          
   CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009                                                             
   Chua BY, 2011, J IMMUNOL, V187, P1692, DOI 10.4049/jimmunol.1100486
   Cierpicki T, 2001, J BIOMOL NMR, V21, P249, DOI 10.1023/A:1012911329730
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   CONLEY AJ, 1994, VACCINE, V12, P445, DOI 10.1016/0264-410X(94)90123-6
   De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006
   Dhillon AK, 2008, ACTA CRYSTALLOGR D, V64, P792, DOI 10.1107/S0907444908013978
   Fesinmeyer RM, 2005, J BIOMOL NMR, V33, P213, DOI 10.1007/s10858-005-3731-7
   Fooksman DR, 2010, ANNU REV IMMUNOL, V28, P79, DOI 10.1146/annurev-immunol-030409-101308
   Germain RN, 2010, IMMUNITY, V33, P441, DOI 10.1016/j.immuni.2010.09.014
   Ghasparian A, 2011, CHEMBIOCHEM, V12, P100, DOI 10.1002/cbic.201000536
   Ghiara JB, 1997, J MOL BIOL, V266, P31, DOI 10.1006/jmbi.1996.0768
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   Gonzalez SF, 2011, ANNU REV IMMUNOL, V29, P215, DOI 10.1146/annurev-immunol-031210-101255
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   Hans Dhiraj, 2006, Med Chem, V2, P627
   Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373
   Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101
   Jiang LJ, 2000, HELV CHIM ACTA, V83, P3097, DOI 10.1002/1522-2675(20001220)83:12<3097::AID-HLCA3097>3.0.CO;2-1                  
   Jiang XQ, 2010, NAT STRUCT MOL BIOL, V17, P955, DOI 10.1038/nsmb.1861
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Long RD, 1997, J AM CHEM SOC, V119, P12394, DOI 10.1021/ja972758x                                                               
   Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004
   Mester B, 2009, BIOCHEMISTRY-US, V48, P7867, DOI 10.1021/bi900146g
   Mor A, 2009, BIOCHEMISTRY-US, V48, P3288, DOI 10.1021/bi802308n
   Moseri A, 2010, VIROLOGY, V401, P293, DOI 10.1016/j.virol.2010.03.007
   Nuccitelli A, 2011, P NATL ACAD SCI USA, V108, P10278, DOI 10.1073/pnas.1106590108
   Pantophlet R, 2007, VIROLOGY, V364, P441, DOI 10.1016/j.virol.2007.03.007
   Perriman AW, 2010, SMALL, V6, P1191, DOI 10.1002/smll.200901186
   Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Rappuoli R, 2011, LANCET, V378, P360, DOI 10.1016/S0140-6736(11)60440-6
   RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57
   RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325                                                         
   Robinson JA, 2008, ACCOUNTS CHEM RES, V41, P1278, DOI 10.1021/ar700259k
   Rosen O, 2005, BIOCHEMISTRY-US, V44, P7250, DOI 10.1021/bi047387t
   Rosen O, 2006, P NATL ACAD SCI USA, V103, P13950, DOI 10.1073/pnas.0606312103
   Rusert P, 2011, J EXP MED, V208, P1419, DOI 10.1084/jem.20110196
   Rusert P, 2009, AIDS, V23, P1319, DOI 10.1097/QAD.0b013e32832d92c2
   Saunders CJ, 2005, J VIROL, V79, P9069, DOI 10.1128/JVI.79.14.9069-9080.2005
   Segura E, 2009, CURR OPIN IMMUNOL, V21, P105, DOI 10.1016/j.coi.2009.03.011
   Sette A, 2010, IMMUNITY, V33, P530, DOI 10.1016/j.immuni.2010.09.017
   Shu I, 2011, J AM CHEM SOC, V133, P1196, DOI 10.1021/ja1088953
   Skwarczynski M, 2011, CURR DRUG DELIV, V8, P282, DOI 10.2174/156720111795256192                                                      
   Stamatatos L, 1998, J VIROL, V72, P7840
   Stamatatos L, 1998, AIDS RES HUM RETROV, V14, P1129, DOI 10.1089/aid.1998.14.1129
   Stanfield RL, 2006, J VIROL, V80, P6093, DOI 10.1128/JVI.00205-06
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   Stanfield RL, 2003, VIROLOGY, V315, P159, DOI 10.1016/S0042-6822(03)00525-7
   Stanfield RL, 1999, STRUCT FOLD DES, V7, P131, DOI 10.1016/S0969-2126(99)80020-3
   SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P
   TOLMAN RL, 1993, INT J PEPT PROT RES, V41, P455
   Tugarinov V, 1999, NAT STRUCT BIOL, V6, P331
   Tugarinov V, 2000, STRUCT FOLD DES, V8, P385, DOI 10.1016/S0969-2126(00)00119-2
   Vranken WF, 2001, EUR J BIOCHEM, V268, P2620, DOI 10.1046/j.1432-1327.2001.02146.x
   Wishart DS, 2011, PROG NUCL MAG RES SP, V58, P62, DOI 10.1016/j.pnmrs.2010.07.004
   WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010
   Wittelsberger A., 2000, ANGEW CHEM, V112, P1153
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu SR, 2010, P NATL ACAD SCI USA, V107, P18844, DOI 10.1073/pnas.1007227107
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   WYATT R, 1993, J VIROL, V67, P4557
   WYATT R, 1995, J VIROL, V69, P5723
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905                                                     
   [Anonymous], 2000, ANGEW CHEM INT ED, V39, P1111
   [Anonymous], 2007, ANGEW CHEM INT ED, V46, P9015
NR 83
TC 21
Z9 24
U1 1
U2 22
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1439-4227
J9 CHEMBIOCHEM
JI ChemBioChem
PD DEC 16
PY 2011
VL 12
IS 18
BP 2829
EP 2836
DI 10.1002/cbic.201100586
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 860MB
UT WOS:000297951300020
PM 22076829
DA 2018-01-05
ER

PT J
AU Gurevich, EL
   Temchura, VV
   Uberla, K
   Zybin, A
AF Gurevich, E. L.
   Temchura, V. V.
   Ueberla, K.
   Zybin, A.
TI Analytical features of particle counting sensor based on plasmon
   assisted microscopy of nano objects
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Surface plasmon resonance; Virus like particles
ID RESONANCE IMAGING MEASUREMENTS; IMMUNODEFICIENCY-VIRUS TYPE-1;
   SURFACE-PLASMONS; SINGLE VIRUSES; NEAR-FIELD; REAL-TIME; EXCITATION;
   NANOPARTICLES; INTERFERENCE; PROTEIN
AB We present a new analytical method for concentration measurements of nano objects of different nature such as polystyrene nanoparticles or viruses. The method is based on counting single particles of interest bound to a functionalized sensor surface. The counting rate was used for concentration measurements. For polystyrene particles, the counting rate was found to be in good agreement with the theoretically predicted one. Binding of human immunodeficiency virus (HIV) virus-like particles (VLPs) to the sensor surface functionalized with antibodies was observed. The concentration of HIV-VLP was estimated by means of well-characterized solutions of artificial nanoparticles as a reference material. The results are in a good agreement with standard enzyme-linked immunosorbent assay (ELISA) analysis. Factors are discussed which determine the detection power of the method. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Gurevich, E. L.; Zybin, A.] Leibniz Inst Analyt Wissensch ISAS eV, D-44139 Dortmund, Germany.
   [Temchura, V. V.; Ueberla, K.] Univ Bochum, Dept Mol & Med Virol, D-44801 Bochum, Germany.
RP Gurevich, EL (reprint author), Leibniz Inst Analyt Wissensch ISAS eV, Bunsen Kirchhoff Str 11, D-44139 Dortmund, Germany.
EM gurevich@isas.de; zybin@isas.de
RI Gurevich, Evgeny/C-6222-2008
OI Gurevich, Evgeny/0000-0001-9451-8983
FU Ministry of Innovation, Science, Research, and Technology of the state
   of North Rhine-Westphalia; Ministry of Education and Research of the
   Federal Republic of Germany; European Commission [LSHP-CT-2006-037611];
   DFG [SFB 876]
FX Financial support by the Ministry of Innovation, Science, Research, and
   Technology of the state of North Rhine-Westphalia and the Ministry of
   Education and Research of the Federal Republic of Germany is gratefully
   acknowledged. We are also grateful to the EU-project RaSP and
   collaborative research project EUROPRISE (LSHP-CT-2006-037611) granted
   by the European Commission and to the DFG-granted project SFB 876 for
   financial support.
CR Berger CEH, 1999, OPT COMMUN, V167, P183, DOI 10.1016/S0030-4018(99)00309-0
   BERGER CEH, 1994, REV SCI INSTRUM, V65, P2829, DOI 10.1063/1.1144623                                                               
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Brockman JM, 2000, ANNU REV PHYS CHEM, V51, P41, DOI 10.1146/annurev.physchem.51.1.41                                                
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018
   Hecht B, 1996, PHYS REV LETT, V77, P1889, DOI 10.1103/PhysRevLett.77.1889
   Homola J, 2008, CHEM REV, V108, P462, DOI 10.1021/cr068107d
   Jung LS, 1998, LANGMUIR, V14, P5636, DOI 10.1021/la971228b                                                               
   Konopsky VN, 2001, ULTRAMICROSCOPY, V88, P127, DOI 10.1016/S0304-3991(00)00131-5                                                   
   KRETSCHM.E, 1971, Z PHYS, V241, P313, DOI 10.1007/BF01395428
   Max-Planck Institute for Polymer Research, WINSPALL
   Nelson BP, 2001, ANAL CHEM, V73, P1, DOI 10.1021/ac0010431
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Piliarik M, 2008, SENSOR ACTUAT B-CHEM, V134, P353, DOI 10.1016/j.snb.2008.06.011
   Ramachandran A, 2008, BIOSENS BIOELECTRON, V23, P939, DOI 10.1016/j.bios.2007.09.007
   ROTHENHAUSLER B, 1988, NATURE, V332, P615, DOI 10.1038/332615a0
   Ruenraroengsak P, 2005, INT J PHARM, V298, P361, DOI 10.1016/j.ijpharm.2005.01.004
   Shumaker-Parry JS, 2004, ANAL CHEM, V76, P907, DOI 10.1021/ac034962a
   SJOLANDER S, 1991, ANAL CHEM, V63, P2338
   Smith EA, 2003, APPL SPECTROSC, V57, p320A, DOI 10.1366/000370203322554446
   Trkola A, 1996, J VIROL, V70, P1100
   Valle PJ, 1997, OPT COMMUN, V137, P334, DOI 10.1016/S0030-4018(96)00786-9
   Vollmer F, 2008, P NATL ACAD SCI USA, V105, P20701, DOI 10.1073/pnas.0808988106
   Wagner R, 2000, HUM GENE THER, V11, P2403, DOI 10.1089/104303400750038507
   Wanekaya AK, 2006, ELECTROANAL, V18, P533, DOI 10.1002/elan.200503449
   Wang SP, 2010, P NATL ACAD SCI USA, V107, P16028, DOI 10.1073/pnas.1005264107
   Weichert F, 2010, SENSOR ACTUAT B-CHEM, V151, P281, DOI 10.1016/j.snb.2010.08.005
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Young KR, 2006, METHODS, V40, P98, DOI 10.1016/j.ymeth.2006.05.024
   Zybin A, 2007, ANAL CHEM, V79, P4233, DOI 10.1021/ac070074u
   Zybin A, 2010, PLASMONICS, V5, P31, DOI 10.1007/s11468-009-9111-5
NR 32
TC 14
Z9 14
U1 0
U2 16
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD DEC 15
PY 2011
VL 160
IS 1
BP 1210
EP 1215
DI 10.1016/j.snb.2011.09.050
PG 6
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 871WJ
UT WOS:000298768100166
DA 2018-01-05
ER

PT J
AU Shegokar, R
   Singh, KK
AF Shegokar, Ranjita
   Singh, Kamalinder K.
TI Surface modified nevirapine nanosuspensions for viral reservoir
   targeting: In vitro and in vivo evaluation
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Nevirapine; HIV/AIDS; Nanosuspensions; High pressure homogenization;
   Pharmacokinetics; Targeting
ID ANTI-HIV DRUGS; PLASMA-PROTEIN ADSORPTION; POLYMERIC NANOPARTICLES;
   COATED LIPOSOMES; DELIVERY; PHARMACOKINETICS; BIODISTRIBUTION;
   MACROPHAGES; MECHANISMS; PARTICLES
AB Most of the time HIV virus escape immunological burden exerted by antiretroviral drugs and develops resistance against therapy. For complete eradication of virus from body one has to use long term chemotherapies, which results in drug toxicity, drug resistance and eventually poor patient compliance. Nevirapine (NNRTI, non nucleoside reverse transcriptase inhibitor) nanosuspensions were developed and surface modified with serum albumin, polysaccharide and polyethylene glycol to enhance its targeting potential. The biodistribution studies revealed improved antiretroviral drug accumulation in various organs of rat for nanosuspensions as compared to the plain drug solution when administered intravenously. Nanosuspension after surface modification showed further enhancement in accumulation. Higher MRT values of surface coated nanosuspension in brain, liver and spleen as compared to pure drug solution ensured enhanced bioavailability and prolonged residence of the drug at the target site. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Shegokar, Ranjita; Singh, Kamalinder K.] SNDT Womens Univ, CU Shah Coll Pharm, Bombay 400049, Maharashtra, India.
   [Shegokar, Ranjita] Free Univ Berlin, Inst Pharm, Dept Pharmaceut Biopharmaceut & NutriCosmet, D-12169 Berlin, Germany.
RP Singh, KK (reprint author), SNDT Womens Univ, CU Shah Coll Pharm, Bombay 400049, Maharashtra, India.
EM kksingh35@hotmail.com
FU All India Council of Technical Education (AICTE)
FX Authors would like to thank scientific staff at Bombay Veterinary
   College, Mumbai, India, PERD Research Centre, Ahmedabad, India, Panacea
   Biotec Ltd., Mumbai, India, Freie Universitat Berlin, Institute of
   Pharmacy, Department Pharmaceutics, Biopharmaceutics & NutriCosmetics,
   Berlin, Germany for their assistance during carrying out this work. We
   also thank All India Council of Technical Education (AICTE) for
   financial support.
CR Amiji Mansoor M, 2006, Discov Med, V6, P157
   Anderson KE, 1999, J CONTROL RELEASE, V60, P189, DOI 10.1016/S0168-3659(99)00072-3
   Arulsudar N, 2003, J DRUG TARGET, V11, P187, DOI 10.1080/10611860310001615415
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Barratt G. M., 2000, PHARM SCI TECHNOL TO, V3, P163
   Blunk T, 1996, EUR J PHARM BIOPHARM, V42, P262
   BLUNK T, 1993, ELECTROPHORESIS, V14, P1382, DOI 10.1002/elps.11501401214
   BLUNK T, 1994, THESIS FREIE U BERLI
   Buckton G, 1995, INTERFACIAL PHENOMEN, P154
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   Davis S. S., 1986, TARGETING DRUGS SYNT, P123
   Deng R, 2007, BLOOD, V109, P2470, DOI 10.1182/blood-2006-04-018093
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   *EXPASY, PROT SERV
   Fang RHT, 2008, AIDS, V22, P171, DOI 10.1097/QAD.0b013e3282f2589b                                                    
   Ferri C, 2006, RHEUMATOLOGY, V45, P72, DOI 10.1093/rheumatology/kei101
   GIMENEZ F, 2004, J ACQ IMMUN DEF SYND, V35, P102
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Immordino ML, 2006, INT J NANOMED, V1, P297
   KANG EC, 1994, INT J BIOL MACROMOL, V16, P348, DOI 10.1016/0141-8130(94)90068-X
   Kayser O, 2003, EXPERT OPIN INV DRUG, V12, P197, DOI 10.1517/eoid.12.2.197.21413
   KLIBANOV AL, 1991, AM J PHYSIOL, V261, P60
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lipton SA, 1998, ANNU REV PHARMACOL, V38, P159, DOI 10.1146/annurev.pharmtox.38.1.159
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   Na K, 2003, EUR J PHARM SCI, V18, P165, DOI 10.1016/S0928-0987(02)00257-9
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   PANTALEO G, 1993, NAT BIOTECHNOL, P362
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Santander-Ortega MJ, 2006, J COLLOID INTERF SCI, V302, P522, DOI 10.1016/j.jcis.2006.07.031
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shegokar R, 2011, PHARMAZIE, V66, P408, DOI 10.1691/ph.2011.0317
   Shegokar R, 2011, NANOMED-NANOTECHNOL, V7, P333, DOI 10.1016/j.nano.2010.10.012
   Streck EL, 2008, METAB BRAIN DIS, V23, P485, DOI 10.1007/s11011-008-9109-2
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wattendorf U, 2008, BIOMACROMOLECULES, V9, P100, DOI 10.1021/bm700857s
   YAZDANIAN M, 1998, IN C AIDS
   Yoncheva Krassimira, 2005, Expert Opin Drug Deliv, V2, P205, DOI 10.1517/17425247.2.2.205
NR 43
TC 29
Z9 32
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD DEC 15
PY 2011
VL 421
IS 2
BP 341
EP 352
DI 10.1016/j.ijpharm.2011.09.041
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 868MM
UT WOS:000298527400018
PM 21986114
DA 2018-01-05
ER

PT J
AU Hebishima, T
   Tada, S
   Takeshima, S
   Akaike, T
   Ito, Y
   Aida, Y
AF Hebishima, Takehisa
   Tada, Seiichi
   Takeshima, Shin-nosuke
   Akaike, Toshihiro
   Ito, Yoshihiro
   Aida, Yoko
TI Induction of antigen-specific immunity by pH-sensitive carbonate apatite
   as a potent vaccine carrier
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Carbonate apatite; Vaccine carrier; Dendritic cells; Antibody; Cellular
   immunity
ID HIV-1 GAG PROTEIN; DENDRITIC CELLS; INTERFERON-GAMMA; NANO-CRYSTALS;
   RESPONSES; ADJUVANT; GENERATION; DELIVERY; TUMOR; TH1
AB The ability of carbonate apatite (CO(3)Ap) to enhance antigen-specific immunity was examined in vitro and in vivo to investigate its utility as a vaccine carrier. Murine bone marrow-derived dendritic cells took up ovalbumin (OVA) containing CO(3)Ap more effectively than free OVA. Interestingly, mice immunized with OVA-containing CO(3)Ap produced OVA-specific antibodies more effectively than mice immunized with free OVA. Furthermore, immunization of C57BL/6 mice with OVA-containing CO(3)Ap induced the proliferation and antigen-specific production of IFN-gamma by splenocytes more strongly than immunization with free OVA. Moreover, no significant differences were detected in the induction of delayed-type hypersensitivity responses, an immune reaction involving an antigen-specific, cell-mediated immune response between OVA-containing CO(3)Ap and OVA-containing alumina salt (Alum), suggesting that CO(3)Ap induced cell-mediated immune response to the same degree as Alum, which is commonly used for clinical applications. This study is the first to demonstrate the induction of antigen-specific immune responses in vivo by CO(3)Ap. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Hebishima, Takehisa; Takeshima, Shin-nosuke; Aida, Yoko] RIKEN, Adv Sci Inst, Viral Infect Dis Unit, Wako, Saitama 3510198, Japan.
   [Tada, Seiichi; Ito, Yoshihiro] RIKEN, Adv Sci Inst, Nano Med Engn Lab, Wako, Saitama 3510198, Japan.
   [Akaike, Toshihiro] Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan.
RP Aida, Y (reprint author), RIKEN, Adv Sci Inst, Viral Infect Dis Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.
EM aida@riken.jp
RI Ito, Yoshihiro/F-4370-2012; Takeshima, Shinnosuke/E-1246-2011
OI Takeshima, Shinnosuke/0000-0001-9648-0480
FU Promotion of Basic and Applied Research for Innovations in Bio-oriented
   Industry
FX We are grateful to the Support Unit of the animal facilities of RIKEN
   BSI Research Resources Center for help with the keeping of animals. This
   work was supported by a Grant-in-Aid for Scientific Research (A and B)
   and by a grant from the Program for the Promotion of Basic and Applied
   Research for Innovations in Bio-oriented Industry.
CR ADOLF GR, 1985, ONCOLOGY, V42, P33
   Becker PD, 2006, VACCINE, V24, P5269, DOI 10.1016/j.vaccine.2005.11.008
   Bennewitz NL, 2005, BIOMATERIALS, V26, P2991, DOI 10.1016/j.biomaterials.2004.08.023
   Bhagawati-Prasad Vijay Ns, 2010, J Immune Based Ther Vaccines, V8, P1, DOI 10.1186/1476-8518-8-1
   Brasel K, 2000, BLOOD, V96, P3029
   Brewer JM, 1998, IMMUNOLOGY, V93, P41
   Chowdhury EH, 2007, INT J NANOMED, V2, P101, DOI 10.2147/nano.2007.2.1.101
   Chowdhury EH, 2006, GENE, V376, P87, DOI 10.1016/j.gene.2006.02.028
   Chowdlhury EH, 2005, BIOTECHNOL BIOENG, V90, P414, DOI 10.1002/bit.20398                                                               
   HIGASHI S, 1986, BIOMATERIALS, V7, P183, DOI 10.1016/0142-9612(86)90099-2                                                    
   Hossain S, 2010, J CONTROL RELEASE, V147, P101, DOI 10.1016/j.jconrel.2010.06.024
   Hutchings CL, 2005, J IMMUNOL, V175, P599, DOI 10.4049/jimmunol.175.1.599                                                      
   Khan IA, 1999, INFECT IMMUN, V67, P1887
   Matzelle MM, 2004, BIOMATERIALS, V25, P295, DOI 10.1016/S0142-9612(03)00531-3
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423
   Tada S, 2010, BIOMATERIALS, V31, P1453, DOI 10.1016/j.biomaterials.2009.10.016
   Tritel M, 2003, J IMMUNOL, V171, P2538, DOI 10.4049/jimmunol.171.5.2538                                                     
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Wan T, 2004, BLOOD, V103, P1747, DOI 10.1182/blood-2003-08-2828
   Wille-Reece U, 2005, J IMMUNOL, V174, P7676, DOI 10.4049/jimmunol.174.12.7676                                                    
   Zohra FT, 2009, BIOMATERIALS, V30, P4006, DOI 10.1016/j.biomaterials.2009.02.050
NR 22
TC 1
Z9 2
U1 0
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 2
PY 2011
VL 415
IS 4
BP 597
EP 601
DI 10.1016/j.bbrc.2011.10.114
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 861OT
UT WOS:000298029800012
PM 22074821
DA 2018-01-05
ER

PT J
AU Wang, QL
   Xiao, L
   Zhang, J
   He, NY
   Lu, XG
   Li, P
   Li, K
AF Wang, Qinglin
   Xiao, Li
   Zhang, Jia
   He, Nongyue
   Lu, Xueguan
   Li, Ping
   Li, Kai
TI A New Assay for CCR5del32 Mutation: Genotyping Through the Number of
   Fragments Amplified
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE CCR5del32; Number of Fragments; Deletion; HIV-1
ID DUAL-COLOR HYBRIDIZATION; SINGLE-BASE EXTENSION; MAGNETIC NANOPARTICLES;
   DISEASE PROGRESSION; POLYMORPHISMS; ARRAY; MICROARRAY
AB CCR5 is a coreceptor for the entry of HIV into CD4+ cells and some of its natural mutants possess potential protection against HIV-1 infection. Individuals with the CCR5-Delta 32 genotype have a lower possibility of being infected with HIV and take longer to progress to AIDS if infected. The present study demonstrated a new primer extension assay for genetic analysis of the CCR5del32 mutation: each genotype is determined by a specific number of fragments amplified. Quick and efficient screening and testing of this specific genotype is clinically useful in epidemiological study, risk analysis, and determining donors for allogenic stem cell transplantation.
C1 [Li, Ping] Hosp Infect Dis Jiang Su Prov, Nanjing 210003, Peoples R China.
   [Wang, Qinglin; Xiao, Li; Zhang, Jia; Li, Kai] Soochow Univ, Coll Pharmaceut Sci, Mol Med Lab, Suzhou 215123, Peoples R China.
   [Xiao, Li; Lu, Xueguan] Soochow Univ, Mol Med Lab, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
   [He, Nongyue] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Peoples R China.
RP Li, P (reprint author), Hosp Infect Dis Jiang Su Prov, Nanjing 210003, Peoples R China.
FU National Natural Science Foundation of China [30970877]; Chinese
   National 863 major grant [2008AA02Z436]
FX This study is partially supported by National Natural Science Foundation
   of China (No. 30970877) and Chinese National 863 major grant
   (2008AA02Z436).
CR Alters K., 2011, BLOOD, V117, P279
   Barassi C, 2004, BLOOD, V104, P2205, DOI 10.1182/blood-2004-06-2134                                                      
   Chen L. L., 2005, J U S CHINA MED EDIT, V33, P166
   Cheng L, 2009, J BIOMED NANOTECHNOL, V5, P542, DOI 10.1166/jbn.2009.1058
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   Ioannidis JPA, 2001, ANN INTERN MED, V135, P782, DOI 10.7326/0003-4819-135-9-200111060-00008
   Landovitz R. J., 2009, NEW ENGL J MED, V18, P1768
   Li K., 2011, BLOOD E LETT, V01, P26
   Li S, 2010, ANAL BIOCHEM, V405, P141, DOI 10.1016/j.ab.2010.05.016
   Liu HN, 2010, BIOSENS BIOELECTRON, V26, P1442, DOI 10.1016/j.bios.2010.07.078
   Liu HN, 2010, J NANOSCI NANOTECHNO, V10, P5311, DOI 10.1166/jnn.2010.2386
   Liu HN, 2009, ANAL BIOCHEM, V386, P126, DOI 10.1016/j.ab.2008.11.035
   Tian L, 2009, J BIOMED NANOTECHNOL, V5, P511, DOI 10.1166/jbn.2009.1066
   Zhang Jia, 2006, Current Pharmacogenomics, V4, P121, DOI 10.2174/157016006776286800
   Zhang J, 2007, MOL BIOTECHNOL, V37, P225, DOI 10.1007/s12033-007-9000-0                                                       
   Zhang J, 2010, APPL BIOCHEM BIOTECH, V162, P321, DOI 10.1007/s12010-009-8793-7
   Zhang L, 2003, MOL BIOTECHNOL, V25, P107
   Zhao H, 2011, J BIOMED NANOTECHNOL, V7, P292, DOI 10.1166/jbn.2011.1287
NR 19
TC 11
Z9 11
U1 0
U2 4
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD DEC
PY 2011
VL 7
IS 6
BP 754
EP 758
DI 10.1166/jbn.2011.1345
PG 5
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA 902ZJ
UT WOS:000301082400003
PM 22416573
DA 2018-01-05
ER

PT J
AU Lehmann, M
   Rocha, S
   Mangeat, B
   Blanchet, F
   Uji-i, H
   Hofkens, J
   Piguet, V
AF Lehmann, Martin
   Rocha, Susana
   Mangeat, Bastien
   Blanchet, Fabien
   Uji-i, Hiroshi
   Hofkens, Johan
   Piguet, Vincent
TI Quantitative Multicolor Super-Resolution Microscopy Reveals Tetherin
   HIV-1 Interaction
SO PLOS PATHOGENS
LA English
DT Article
ID PHOTOACTIVATION-LOCALIZATION MICROSCOPY; LIPID RAFTS;
   FLUORESCENT-PROBES; PLASMA-MEMBRANE; CELL-MEMBRANES; LIVE CELLS;
   PROTEIN; RELEASE; VPU; VIRIONS
AB Virus assembly and interaction with host-cell proteins occur at length scales below the diffraction limit of visible light. Novel super-resolution microscopy techniques achieve nanometer resolution of fluorescently labeled molecules. The cellular restriction factor tetherin (also known as CD317, BST-2 or HM1.24) inhibits the release of human immunodeficiency virus 1 (HIV-1) through direct incorporation into viral membranes and is counteracted by the HIV-1 protein Vpu. For super-resolution analysis of HIV-1 and tetherin interactions, we established fluorescence labeling of HIV-1 proteins and tetherin that preserved HIV-1 particle formation and Vpu-dependent restriction, respectively. Multicolor super-resolution microscopy revealed important structural features of individual HIV-1 virions, virus assembly sites and their interaction with tetherin at the plasma membrane. Tetherin localization to micro-domains was dependent on both tetherin membrane anchors. Tetherin clusters containing on average 4 to 7 tetherin dimers were visualized at HIV-1 assembly sites. Combined biochemical and super-resolution analysis revealed that extended tetherin dimers incorporate both N-termini into assembling virus particles and restrict HIV-1 release. Neither tetherin domains nor HIV-1 assembly sites showed enrichment of the raft marker GM1. Together, our super-resolution microscopy analysis of HIV-1 interactions with tetherin provides new insights into the mechanism of tetherin-mediated HIV-1 restriction and paves the way for future studies of virus-host interactions.
C1 [Lehmann, Martin; Mangeat, Bastien; Piguet, Vincent] Univ Hosp Geneva, Dept Microbiol & Mol Med, Geneva, Switzerland.
   [Lehmann, Martin; Mangeat, Bastien; Piguet, Vincent] Univ Hosp Geneva, Dept Dermatol, Geneva, Switzerland.
   [Lehmann, Martin; Mangeat, Bastien; Piguet, Vincent] Univ Hosp Geneva, Dept Venereol, Geneva, Switzerland.
   [Lehmann, Martin; Mangeat, Bastien; Piguet, Vincent] Med Sch Geneva, Geneva, Switzerland.
   [Rocha, Susana; Uji-i, Hiroshi; Hofkens, Johan] Katholieke Univ Leuven, Dept Chem, Lab Photochem & Spect, B-3001 Heverlee, Belgium.
   [Mangeat, Bastien; Blanchet, Fabien; Piguet, Vincent] Cardiff Univ, Sch Med, Dept Dermatol & Wound Healing, Cardiff, S Glam, Wales.
   [Mangeat, Bastien; Blanchet, Fabien; Piguet, Vincent] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales.
RP Lehmann, M (reprint author), Univ Hosp Geneva, Dept Microbiol & Mol Med, Geneva, Switzerland.
EM piguetv@cardiff.ac.uk
RI Rocha, Susana/O-7622-2016
OI Rocha, Susana/0000-0003-1258-9396; Hofkens, Johan/0000-0002-9101-0567
FU Human Science Frontier Program; Swiss National Science Foundation;
   Portuguese Foundation for Science and Technology (FCT)
   [SFRH/BD/27265/2006]; Flemish government; K.U. Leuven [GOA 2006/2,
   CREA2007]; Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO)
   [G.0402.09]; Herculesstichting
FX VP was supported by the Human Science Frontier Program and Swiss
   National Science Foundation. SR was supported by Portuguese Foundation
   for Science and Technology (FCT) PhD grant SFRH/BD/27265/2006. JH was
   supported by the long-term structural funding program "Methusalem" by
   the Flemish government, the K.U. Leuven research fund (GOA 2006/2,
   CREA2007), Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO grant
   G.0402.09) and the Herculesstichting. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506
   Andrew AJ, 2011, J BIOL CHEM, V286, P39967, DOI 10.1074/jbc.M111.287011
   Annibale P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022678
   Annibale P, 2011, NAT METHODS, V8, P527, DOI 10.1038/nmeth.1627
   Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598
   Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344
   Bieniasz PD, 2009, CELL HOST MICROBE, V5, P550, DOI 10.1016/j.chom.2009.05.015
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Carlson LA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001173
   Chudakov DM, 2007, NAT PROTOC, V2, P2024, DOI 10.1038/nprot.2007.291
   Churchman LS, 2005, P NATL ACAD SCI USA, V102, P1419, DOI 10.1073/pnas.0409487102
   Fitzpatrick K, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000701
   Flors C, 2007, J AM CHEM SOC, V129, P13970, DOI 10.1021/ja074704l
   Goffinet C, 2009, CELL HOST MICROBE, V5, P285, DOI 10.1016/j.chom.2009.01.009
   Greenfield D, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000137
   Gupta RK, 2009, P NATL ACAD SCI USA, V106, P20889, DOI 10.1073/pnas.0907075106
   Habermann A, 2010, J VIROL, V84, P4646, DOI 10.1128/JVI.02421-09
   Habuchi S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003944
   Hammonds J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000749
   Heilemann M, 2008, ANGEW CHEM INT EDIT, V47, P6172, DOI 10.1002/anie.200802376
   Heilemann M, 2009, ANGEW CHEM INT EDIT, V48, P6903, DOI 10.1002/anie.200902073
   Hess ST, 2007, P NATL ACAD SCI USA, V104, P17370, DOI 10.1073/pnas.0708066104
   Hess ST, 2006, BIOPHYS J, V91, P4258, DOI 10.1529/biophysj.106.091116
   Hinz A, 2010, CELL HOST MICROBE, V7, P314, DOI 10.1016/j.chom.2010.03.005
   Hogue IB, 2011, J VIROL, V85, P9749, DOI 10.1128/JVI.00743-11
   Huang B, 2010, CELL, V143, P1047, DOI 10.1016/j.cell.2010.12.002
   Ivanchenko S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000652
   Jia B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000429
   Jones SA, 2011, NAT METHODS, V8, P499, DOI [10.1038/nmeth.1605, 10.1038/NMETH.1605]
   Jouvenet N, 2008, NATURE, V454, P236, DOI 10.1038/nature06998
   Jouvenet N, 2009, J VIROL, V83, P1837, DOI 10.1128/JVI.02211-08
   Krementsov DN, 2010, TRAFFIC, V11, P1401, DOI 10.1111/j.1600-0854.2010.01111.x
   Kupzig S, 2003, TRAFFIC, V4, P694, DOI 10.1034/j.1600-0854.2003.00129.x                                                
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   Le Tortorec A, 2009, J VIROL, V83, P11966, DOI 10.1128/JVI.01515-09
   Leung K, 2008, CELL HOST MICROBE, V3, P285, DOI 10.1016/j.chom.2008.04.004
   Lillemeier BF, 2009, NAT IMMUNOL, V11, P90
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Mangeat B, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000574
   Manley S, 2008, NAT METHODS, V5, P155, DOI 10.1038/NMETH.1176
   Mansouri M, 2009, J VIROL, V83, P9672, DOI 10.1128/JVI.00597-09
   Masuyama N, 2009, J BIOL CHEM, V284, P15927, DOI 10.1074/jbc.M109.005124
   McNatt MW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000300
   Mitchell RS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000450
   Miyagi E, 2011, J VIROL, V85, P11981, DOI 10.1128/JVI.05176-11
   Miyagi E, 2009, P NATL ACAD SCI USA, V106, P2868, DOI 10.1073/pnas.0813223106
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Neil SJD, 2006, PLOS PATHOG, V2, P354, DOI 10.1371/journal.ppat.0020039
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Pais-Correia A. M., 2009, NAT MED, V16, P83
   Perez-Caballero D, 2009, CELL, V139, P499, DOI 10.1016/j.cell.2009.08.039
   Rollason R, 2009, J CELL BIOL, V184, P721, DOI 10.1083/jcb.200804154
   Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929
   Sakuma T, 2009, J VIROL, V83, P2382, DOI 10.1128/JVI.01607-08
   Sauter D, 2009, CELL HOST MICROBE, V6, P409, DOI 10.1016/j.chom.2009.10.004
   Schneider R, 1997, J VIROL, V71, P4892
   Shroff H, 2007, P NATL ACAD SCI USA, V104, P20308, DOI 10.1073/pnas.0710517105
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Subach FV, 2009, P NATL ACAD SCI USA, V106, P21097, DOI 10.1073/pnas.0909204106
   Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001
   van Zanten TS, 2010, P NATL ACAD SCI USA, V107, P15437, DOI 10.1073/pnas.1003876107
   Wendy L, 2008, COMPUTATIONAL STAT H
   Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 66
TC 74
Z9 75
U1 2
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2011
VL 7
IS 12
AR e1002456
DI 10.1371/journal.ppat.1002456
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 876LH
UT WOS:000299108500063
PM 22194693
OA gold
DA 2018-01-05
ER

PT J
AU Vanlandschoot, P
   Stortelers, C
   Beirnaert, E
   Ibanez, LI
   Schepens, B
   Depla, E
   Saelens, X
AF Vanlandschoot, Peter
   Stortelers, Catelijne
   Beirnaert, Els
   Ibanez, Lorena Itati
   Schepens, Bert
   Depla, Erik
   Saelens, Xavier
TI Nanobodies (R): New ammunition to battle viruses
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE Nanobody; Camelidae; Heavy chain-only antibody; VHH; Antiviral
ID SINGLE-DOMAIN ANTIBODY; RESPIRATORY-SYNCYTIAL-VIRUS;
   HUMAN-IMMUNODEFICIENCY-VIRUS; HEAVY-CHAIN ANTIBODIES; HEPATITIS-B-VIRUS;
   PORCINE ENDOGENOUS RETROVIRUSES; HUMAN MONOCLONAL-ANTIBODY;
   ROTAVIRUS-INDUCED DIARRHEA; RECEPTOR-BINDING PROTEIN; NUCLEAR EXPORT
   SIGNAL
AB In 1989, anew type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH) was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies (R). Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage) will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity. (C) 2011 Published by Elsevier B.V.
C1 [Vanlandschoot, Peter; Stortelers, Catelijne; Beirnaert, Els; Depla, Erik] Ablynx NV, B-9052 Ghent, Belgium.
   [Ibanez, Lorena Itati; Schepens, Bert; Saelens, Xavier] VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium.
   [Ibanez, Lorena Itati; Schepens, Bert; Saelens, Xavier] Univ Ghent, Dept Biomed Mol Biol, B-9052 Ghent, Belgium.
RP Vanlandschoot, P (reprint author), Ablynx NV, Technol Pk 21, B-9052 Ghent, Belgium.
EM Peter.Vanlandschoot@Ablynx.com
RI Saelens, Xavier/N-5728-2015
FU Institute for the Promotion of Innovation by Science and technology in
   Flanders Ghent from the Flemish government [IWT70050]
FX The authors would like to thank all the colleagues at Ablynx and our
   academic collaborators who have contributed to the antiviral Nanobody
   work mentioned in this paper. Part of the work performed by Ablynx and
   our collaborators was supported by the Institute for the Promotion of
   Innovation by Science and technology in Flanders Ghent (IWT70050) from
   the Flemish government.
CR BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P9339, DOI 10.1073/pnas.89.19.9339                                                         
   Beekwilder J, 2008, EUR J PLANT PATHOL, V121, P477, DOI 10.1007/s10658-007-9265-y
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Bouchet J, 2011, BLOOD, V117, P3559, DOI 10.1182/blood-2010-07-296749
   Bruss V, 2007, WORLD J GASTROENTERO, V13, P65, DOI 10.3748/wjg.v13.i1.65                                                           
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   Calder LJ, 2000, VIROLOGY, V271, P122, DOI 10.1006/viro.2000.0279                                                          
   Conrath K, 2009, PROTEIN SCI, V18, P619, DOI 10.1002/pro.69
   Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001
   Conrath KE, 2001, J BIOL CHEM, V276, P7346
   Coppieters K, 2006, ARTHRITIS RHEUM-US, V54, P1856, DOI 10.1002/art.21827
   Corthesy B, 2006, J VIROL, V80, P10692, DOI 10.1128/JVI.00927-06
   Martin MC, 2011, APPL ENVIRON MICROB, V77, P2174, DOI 10.1128/AEM.02690-10
   Czauderna F, 2000, J VIROL, V74, P4028, DOI 10.1128/JVI.74.9.4028-4038.2000
   Daelemans D, 2005, MOL CELL BIOL, V25, P728, DOI 10.1128/MCB.25.2.728-739.2005
   Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251
   Daley LP, 2010, CLIN VACCINE IMMUNOL, V17, P239, DOI 10.1128/CVI.00421-09
   Daley-Bauer LP, 2010, CLIN VACCINE IMMUNOL, V17, P2007, DOI 10.1128/CVI.00287-10
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103
   De Haard HJW, 2005, J BACTERIOL, V187, P4531, DOI 10.1128/JB.187.13.4531-4541.2005
   Dekker S, 2003, J VIROL, V77, P12132, DOI 10.1128/JVI.77.22.12132-12139.2003
   Deng YM, 2000, TRANSPLANTATION, V70, P1010, DOI 10.1097/00007890-200010150-00004
   Denner J, 2011, XENOTRANSPLANTATION, V18, P151, DOI 10.1111/j.1399-3089.2011.00636.x
   Deschacht N, 2010, J IMMUNOL, V184, P5696, DOI 10.4049/jimmunol.0903722
   Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803
   Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200
   Dolk E, 2005, APPL ENVIRON MICROB, V71, P442, DOI 10.1128/AEM.71.1.442-450.2005
   Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602
   Ewert S, 2002, BIOCHEMISTRY-US, V41, P3628, DOI 10.1021/bi011239a
   FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389                                                        
   Feld J, 2003, HEPATOLOGY, V38, P545, DOI 10.1053/jhep.2003.50389
   FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0
   Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2
   Forsman A, 2008, J VIROL, V82, P12069, DOI 10.1128/JVI.01379-08
   Foster JL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-84
   Fukuda M, 1997, NATURE, V390, P308
   Garaicoechea L, 2008, J VIROL, V82, P9753, DOI 10.1128/JVI.00436-08
   Goldman ER, 2006, ANAL CHEM, V78, P8245, DOI 10.1021/ac0610053
   Goudsmit J, 2006, J INFECT DIS, V193, P796, DOI 10.1086/500470
   GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0                                                                
   Groot AJ, 2006, LAB INVEST, V86, P345, DOI 10.1038/labinvest.3700395
   GROOTHUIS JR, 1993, NEW ENGL J MED, V329, P1524, DOI 10.1056/NEJM199311183292102                                                     
   Gualtero DF, 2007, ARCH VIROL, V152, P2183, DOI 10.1007/s00705-007-1055-5
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507                                                     
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1
   Harmsen MM, 2008, VET MICROBIOL, V132, P56, DOI 10.1016/j.vetmic.2008.04.030
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Harmsen MM, 2007, VET MICROBIOL, V120, P193, DOI 10.1016/j.vetmic.2006.10.029
   Harmsen MM, 2006, APPL MICROBIOL BIOT, V72, P544, DOI 10.1007/s00253-005-0300-7
   Harmsen MM, 2009, APPL MICROBIOL BIOT, V84, P1087, DOI 10.1007/s00253-009-2029-1
   Harmsen MM, 2009, VACCINE, V27, P1904, DOI 10.1016/j.vaccine.2009.01.110
   Harmsen MM, 2005, VACCINE, V23, P4926, DOI 10.1016/j.vaccine.2005.05.017
   Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X
   HEMMING VG, 1985, J INFECT DIS, V152, P1083, DOI 10.1093/infdis/152.5.1083                                                       
   HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004
   Hilleman MR, 2003, VACCINE, V21, P4626, DOI 10.1016/S0264-410X(03)00529-2
   Hinz A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010482
   Hmila I, 2010, FASEB J, V24, P3479, DOI 10.1096/fj.09-148213
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Hultberg A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017665
   Hultberg A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-58
   Ibanez LI, 2011, J INFECT DIS, V203, P1063, DOI 10.1093/infdis/jiq168
   Jahnichen S, 2010, P NATL ACAD SCI USA, V107, P20565, DOI 10.1073/pnas.1012865107
   Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115                                                                  
   Kann M, 2007, WORLD J GASTROENTERO, V13, P39, DOI 10.3748/wjg.v13.i1.39                                                           
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Klooster R, 2009, J IMMUNOL METHODS, V342, P1, DOI 10.1016/j.jim.2008.10.009
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Koh WWL, 2010, J BIOL CHEM, V285, P19116, DOI 10.1074/jbc.M110.116699
   Kolkman JA, 2010, DRUG DISCOV TODAY TE, V7, pe139, DOI [10.1016/j.ddtec.2010.03.002, DOI 10.1016/J.DDTEC.2010.03.002]
   Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228
   Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Lavanchy D, 2008, BEST PRACT RES CL GA, V22, P991, DOI 10.1016/j.bpg.2008.11.002
   Ledeboer AM, 2002, J DAIRY SCI, V85, P1376, DOI 10.3168/jds.S0022-0302(02)74204-5                                               
   LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489
   Mai KT, 2006, HISTOPATHOLOGY, V49, P515, DOI 10.1111/j.1365-2559.2006.02539.x
   MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0
   Moineau S, 1999, ANTON LEEUW INT J G, V76, P377, DOI 10.1023/A:1002045701064
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599
   Muller T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000542
   Muhamuda K, 2007, HUM VACCINES, V3, P192, DOI 10.4161/hv.3.5.4386                                                             
   MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129
   Muyldermans S, 2009, VET IMMUNOL IMMUNOP, V128, P178, DOI 10.1016/j.vetimm.2008.10.299
   Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X
   Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6
   Nguyen VK, 1999, MOL IMMUNOL, V36, P515
   Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921                                                          
   Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8
   Pant N, 2006, J INFECT DIS, V194, P1580, DOI 10.1086/508747
   Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282
   Patience C, 2001, J VIROL, V75, P2771, DOI 10.1128/JVI.75.6.2771-2775.2001
   Perez JMJ, 2001, BIOCHEMISTRY-US, V40, P74, DOI 10.1021/bi0009082
   Peterson AT, 2004, EMERG INFECT DIS, V10, P40, DOI 10.3201/eid1001.030125                                                          
   Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942
   Platt JL, 2002, NAT BIOTECHNOL, V20, P231, DOI 10.1038/nbt0302-231
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   PRINCE GA, 1985, VIRUS RES, V3, P193, DOI 10.1016/0168-1702(85)90045-0                                                    
   Rabe B, 2003, P NATL ACAD SCI USA, V100, P9849, DOI 10.1073/pnas.1730940100
   ROBEN P, 1994, J VIROL, V68, P4821
   Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4
   Russell CA, 2008, SCIENCE, V320, P340, DOI 10.1126/science.1154137
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Sarker SA, 2001, J PEDIATR GASTR NUTR, V32, P19, DOI 10.1097/00005176-200101000-00009
   Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X
   Serruys B, 2010, J GEN VIROL, V91, P643, DOI 10.1099/vir.0.016063-0
   Serruys B, 2009, HEPATOLOGY, V49, P39, DOI 10.1002/hep.22609
   Sherwood LJ, 2007, J INFECT DIS, V196, pS213, DOI 10.1086/520586
   Simoes EAF, 1996, J PEDIATR-US, V129, P214, DOI 10.1016/S0022-3476(96)70245-7
   Specke V, 2001, VIROLOGY, V285, P177, DOI 10.1006/viro.2001.0934
   Spinelli S, 2006, NAT STRUCT MOL BIOL, V13, P85, DOI 10.1038/nsmb1029
   Stewart CS, 2007, TOXICON, V49, P699, DOI 10.1016/j.toxicon.2006.11.023
   Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200
   Stijlemans B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002072
   Stone E, 2007, MOL IMMUNOL, V44, P2487, DOI 10.1016/j.molimm.2006.10.020
   Stone E, 2007, J IMMUNOL METHODS, V318, P88, DOI 10.1016/j.jim.2006.10.006
   Takeuchi Y, 1998, J VIROL, V72, P9986
   TAYLOR G, 1984, IMMUNOLOGY, V52, P137
   Thys B, 2011, J VIROL METHODS, V173, P300, DOI 10.1016/j.jviromet.2011.02.023
   Thys B, 2010, ANTIVIR RES, V87, P257, DOI 10.1016/j.antiviral.2010.05.012
   Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384
   Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E
   Tremblay DM, 2006, J BACTERIOL, V188, P2400, DOI 10.1128/JB.188.7.2400-2410.2006
   Trkola A, 1996, J VIROL, V70, P1100
   Van Bockstaele F, 2009, CURR OPIN INVEST DR, V10, P1212
   Van den Abbeele A, 2010, CELL MOL LIFE SCI, V67, P1519, DOI 10.1007/s00018-010-0266-1
   van der Laan LJW, 2000, NATURE, V407, P90
   van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8
   van der Vaart JM, 2006, VACCINE, V24, P4130, DOI 10.1016/j.vaccine.2006.02.045
   Vercruysse T, 2011, RNA BIOL, V8, P316, DOI 10.4161/rna.8.2.13782
   Vercruysse T, 2010, J BIOL CHEM, V285, P21768, DOI 10.1074/jbc.M110.112490
   Verheesen P, 2006, BBA-PROTEINS PROTEOM, V1764, P1307, DOI 10.1016/j.bbapap.2006.05.011
   Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200
   Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6
   WALSH EE, 1984, INFECT IMMUN, V43, P756
   Ward R, 2009, PEDIATR INFECT DIS J, V28, pS57, DOI 10.1097/INF.0b013e3181967c16
   Wassilak S, 2010, EXPERT REV VACCINES, V9, P447, DOI 10.1586/ERV.10.45
   Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7
   Woolven BP, 1999, IMMUNOGENETICS, V50, P98, DOI 10.1007/s002510050694
   Wu H, 2008, CURR TOP MICROBIOL, V317, P103
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Xu Ruian, 2003, Current Gene Therapy, V3, P341, DOI 10.2174/1566523034578294
   Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599
   Zhang JB, 2004, J MOL BIOL, V335, P49, DOI 10.1016/j.jmb.2003.09.034
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zoulim F, 2011, LIVER INT, V31, P111, DOI 10.1111/j.1478-3231.2010.02399.x
NR 155
TC 53
Z9 58
U1 3
U2 69
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD DEC
PY 2011
VL 92
IS 3
BP 389
EP 407
DI 10.1016/j.antiviral.2011.09.002
PG 19
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 862XJ
UT WOS:000298127100001
PM 21939690
DA 2018-01-05
ER

PT J
AU Dejardin, T
   de la Fuente, J
   del Pino, P
   Furlani, EP
   Mullin, M
   Smith, CA
   Berry, CC
AF Dejardin, Theophile
   de la Fuente, Jesus
   del Pino, Pablo
   Furlani, Edward P.
   Mullin, Margaret
   Smith, C-A
   Berry, Catherine C.
TI Influence of both a static magnetic field and penetratin on magnetic
   nanoparticle delivery into fibroblasts
SO NANOMEDICINE
LA English
DT Article
DE cell uptake; endocytosis; magnetic; magnetic field; nanoparticle;
   penetratin
ID HUMAN IMMUNODEFICIENCY VIRUS; ARGININE-RICH PEPTIDES; CELLULAR UPTAKE;
   ANTENNAPEDIA HOMEODOMAIN; MEMBRANE TRANSLOCATION; GENE DELIVERY; LIVING
   CELLS; 3RD HELIX; PROTEIN; MAGNETOFECTION
AB Aim: With regards to nanoparticles, all biomedical applications require cellular uptake, which to date remains a hurdle to further progress. This study aims to compare both the attractive force of a static magnetic field and the cell penetrating capability of penetratin; two techniques currently employed to enhance cell uptake. Materials & Methods: Fluorescent magnetic nanoparticles were functionalized with penetratin and cells were challenged with or without the particles in the presence/absence of a static magnetic field (350 mT). Following ana-lysis of the magnetic field applied, cellular uptake and behavior was assessed in terms of fluorescence microscopy, clathrin and caveolin levels, scanning electron microscopy and transmission electron microscopy. Results: Modeling of the field applied demonstrated varying field patterns across the cell culture area, reflected by higher particle uptake at higher field strengths. Both penetratin and the magnetic field increased cell uptake with penetratin proving more efficient. Interestingly, the magnetic field stimulated clathrin-mediated endocytosis and subsequent particle uptake.
C1 [Dejardin, Theophile; Mullin, Margaret; Smith, C-A; Berry, Catherine C.] Univ Glasgow, Ctr Cell Engn, Glasgow G12 8QQ, Lanark, Scotland.
   [de la Fuente, Jesus; del Pino, Pablo] Univ Saragossa, Lab Glyconanotechnol, Zaragoza, Spain.
   [Furlani, Edward P.] SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA.
RP Berry, CC (reprint author), Univ Glasgow, Ctr Cell Engn, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.
EM catherine.berry@glasgow.ac.uk
RI del Pino, Pablo/I-3536-2012; Xu, Qingguo/C-1962-2014
OI del Pino, Pablo/0000-0003-1318-6839; Xu, Qingguo/0000-0003-3191-0771; de
   la Fuente, Jesus M/0000-0003-1081-8482
CR Amand HL, 2008, BIOCHEM BIOPH RES CO, V371, P621, DOI 10.1016/j.bbrc.2008.04.039
   Au KW, 2009, BIOCHEM BIOPH RES CO, V379, P898, DOI 10.1016/j.bbrc.2008.12.160
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Berry CC, 2005, J MATER CHEM, V15, P543, DOI 10.1039/b409715g
   Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022-3727/36/13/203
   Berry CC, 2009, J PHYS D, V42
   Borm Paul J A, 2006, Part Fibre Toxicol, V3, P11, DOI 10.1186/1743-8977-3-11
   Buerli T, 2007, NAT PROTOC, V2, P3090, DOI 10.1038/nprot.2007.445
   Chawla P, 2010, MINI-REV MED CHEM, V10, P662, DOI 10.2174/138955710791572497                                                      
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Frasca G, 2009, LANGMUIR, V25, P2348, DOI 10.1021/la8030792
   Furlani EP, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.061914
   Furlani EP, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.061919
   Furlani EP, 2006, J APPL PHYS, V99, DOI 10.1063/1.2164531
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GOULD P, 2004, MATER TODAY, V36, P43
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Haim H, 2005, J VIROL, V79, P622, DOI 10.1128/JVI.79.1.622-625.2005
   Howl J, 2007, BIOCHEM SOC T, V35, P767, DOI 10.1042/BST0350767                                                              
   Hruby M, 2005, J CONTROL RELEASE, V103, P137, DOI 10.1016/j.jconrel.2004.11.017
   Hyun C, 2008, STEM CELLS DEV, V17, P133, DOI 10.1089/scd.2007.0064
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kamau SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl035
   KELF TA, 2010, NANOTECHNOLOGY, V21
   Letoha T, 2010, BBA-BIOMEMBRANES, V1798, P2258, DOI 10.1016/j.bbamem.2010.01.022
   Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6                                                   
   Loubery S, 2008, TRAFFIC, V9, P492, DOI 10.1111/j.1600-0854.2008.00704.x
   Lubbe AS, 2001, J SURG RES, V95, P200, DOI 10.1006/jsre.2000.6030
   LUDIN P, 2008, BIOCONJUG CHEM, V19, P2535
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Moisescu MG, 2009, BIOELECTROMAGNETICS, V30, P222, DOI 10.1002/bem.20463
   Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000
   MYJHAYLYK O, 2008, CURR OPIN MOL THER, V10, P493
   MYJHAYLYK O, 2009, METHOD MOL BIOL, V487, P111
   Nan XL, 2005, J PHYS CHEM B, V109, P24220, DOI 10.1021/jp056360w
   OHGUSHI M, 1978, J MAGN RESON, V29, P599, DOI 10.1016/0022-2364(78)90018-5                                                    
   Persson D, 2004, BBA-BIOMEMBRANES, V1665, P142, DOI 10.1016/j.bbamem.2004.07.008
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   Sauer AM, 2009, J CONTROL RELEASE, V137, P136, DOI 10.1016/j.jconrel.2009.04.003
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   Sitharaman B, 2007, J BIOMED NANOTECHNOL, V3, P342, DOI 10.1166/jbn2007.043
   Smith CA, 2010, BIOMATERIALS, V15, P4392
   Soenen SJH, 2011, BIOMATERIALS, V32, P195, DOI 10.1016/j.biomaterials.2010.08.075
   Soenen SJH, 2009, CONTRAST MEDIA MOL I, V4, P207, DOI 10.1002/cmmi.282
   Sumer B, 2008, NANOMEDICINE-UK, V3, P137, DOI 10.2217/17435889.3.2.137
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009
   ZHOU L, 2011, BIOMACROMOLECULES, V2, P1460
NR 57
TC 13
Z9 14
U1 3
U2 29
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD DEC
PY 2011
VL 6
IS 10
BP 1719
EP 1731
DI 10.2217/NNM.11.65
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 867XW
UT WOS:000298489100011
PM 21809899
DA 2018-01-05
ER

PT J
AU Zhou, JH
   Neff, CP
   Liu, XX
   Zhang, J
   Li, HT
   Smith, DD
   Swiderski, P
   Aboellail, T
   Huang, YY
   Du, Q
   Liang, ZC
   Peng, L
   Akkina, R
   Rossi, JJ
AF Zhou, Jiehua
   Neff, C. Preston
   Liu, Xiaoxuan
   Zhang, Jane
   Li, Haitang
   Smith, David D.
   Swiderski, Piotr
   Aboellail, Tawfik
   Huang, Yuanyu
   Du, Quan
   Liang, Zicai
   Peng, Ling
   Akkina, Ramesh
   Rossi, John J.
TI Systemic Administration of Combinatorial dsiRNAs via Nanoparticles
   Efficiently Suppresses HIV-1 Infection in Humanized Mice
SO MOLECULAR THERAPY
LA English
DT Article
ID DOUBLE-STRANDED-RNA; SIRNA DELIVERY; PAMAM DENDRIMERS; PRIMARY-CELLS;
   INTERFERENCE; PROGRESS; COMPLEXES; CLEAVAGE; DISEASE; POTENT
AB We evaluated the in vivo efficacy of structurally flexible, cationic PAMAM dendrimers as a small interfering RNA (siRNA) delivery system in a Rag2(-)/(-)gamma c(-)/(-) (RAG-hu) humanized mouse model for HIV-1 infection. HIV-infected humanized Rag2(-)/(-)gamma c(-)/(-) mice (RAG-hu) were injected intravenously (i.v.) with dendrimer-siRNA nanoparticles consisting of a cocktail of dicer substrate siRNAs (dsiRNAs) targeting both viral and cellular transcripts. We report in this study that the dendrimer-dsiRNA treatment suppressed HIV-1 infection by several orders of magnitude and protected against viral induced CD4(+) T-cell depletion. We also demonstrated that follow-up injections of the dendrimer-cocktailed dsiRNAs following viral rebound resulted in complete inhibition of HIV-1 titers. Biodistribution studies demonstrate that the dendrimer-dsiRNAs preferentially accumulate in peripheral blood mononuclear cells (PBMCs) and liver and do not exhibit any discernable toxicity. These data demonstrate for the first time efficacious combinatorial delivery of anti-host and -viral siRNAs for HIV-1 treatment in vivo. The dendrimer delivery approach therefore represents a promising method for systemic delivery of combinations of siRNAs for treatment of HIV-1 infection. Received 26 July 2011; accepted 30 August 2011; published online 27 September 2011. doi:10.1038/mt.2011.207
C1 [Zhou, Jiehua; Zhang, Jane; Li, Haitang; Rossi, John J.] Beckman Res Inst City Hope, Dept Mol & Cellular Biol, Duarte, CA 91010 USA.
   [Neff, C. Preston; Aboellail, Tawfik; Akkina, Ramesh] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
   [Liu, Xiaoxuan] Wuhan Univ, Coll Chem & Mol Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Liu, Xiaoxuan; Peng, Ling] CNRS, Ctr Interdisciplinaire Nanosci Marseille, UPR 3118, Marseille 09, France.
   [Smith, David D.] Beckman Res Inst City Hope, Div Biostat, Duarte, CA 91010 USA.
   [Swiderski, Piotr] Beckman Res Inst City Hope, Dept Mol Med, Shared Resource DNA RNA Peptide, Duarte, CA 91010 USA.
   [Huang, Yuanyu; Du, Quan; Liang, Zicai] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China.
RP Rossi, JJ (reprint author), Beckman Res Inst City Hope, Dept Mol & Cellular Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.
EM Ramesh.akkina@colostate.edu; jrossi@coh.org
RI Peng, Ling/D-1911-2013; Liang, Zicai/A-2646-2013; Huang,
   Yuanyu/H-8466-2014
OI Peng, Ling/0000-0002-0878-3199; Huang, Yuanyu/0000-0003-3935-7245;
   Smith, David/0000-0001-9644-2353
FU NIH [RO1, AI057066, AI073255, AI29329, HL07470]; EU; CNRS CNRS-USA;
   Colorado Center for AIDS Research [P30 AI054907]
FX We thank NIH AIDS Research and Reference Reagents Program for
   HIV-1-related reagents used in this work. This work was supported by NIH
   RO1 grants AI057066 and AI073255 to R. A., AI29329 and HL07470 to
   J.J.R., EU FP7 EuroNanoMed program "DENANORNA" to LP, and CNRS project
   CNRS-USA to LP. This work has also been facilitated by the
   infrastructure and resources provided by the Colorado Center for AIDS
   Research Grant P30 AI054907. The authors declared no confilict of
   interest.
CR Anderson J, 2003, OLIGONUCLEOTIDES, V13, P303, DOI 10.1089/154545703322616989
   Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001
   Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020
   Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76
   Berkhout B, 2009, EXPERT OPIN BIOL TH, V9, P161, DOI [10.1517/14712590802653619, 10.1517/14712590802653619 ]
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Christ F, 2008, CURR BIOL, V18, P1192, DOI 10.1016/j.cub.2008.07.079
   Das AT, 2004, J VIROL, V78, P2601, DOI 10.1128/JVI.78.5.2601-2605.2004
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Denton Paul W, 2009, Curr HIV/AIDS Rep, V6, P13, DOI 10.1007/s11904-009-0003-2
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Kim SS, 2010, MOL THER, V18, P370, DOI 10.1038/mt.2009.271
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Lee NS, 2004, VIRUS RES, V102, P53, DOI 10.1016/j.virusres.2004.01.015
   Legrand N, 2009, CELL HOST MICROBE, V6, P5, DOI 10.1016/j.chom.2009.06.006
   Liu XX, 2009, CHEMMEDCHEM, V4, P1302, DOI 10.1002/cmdc.200900076
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Martinez Miguel Angel, 2009, V487, P343, DOI [10.1007/978-1-60327-547-7_17, 10.1007/978-1-60327-547_17]
   Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044
   Mehandru S, 2008, CURR OPIN HIV AIDS, V3, P22, DOI 10.1097/COH.0b013e3282f331b0
   Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007                                                    
   Neff CP, 2011, SCI TRANSL MED, V3
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Paiardini M, 2008, AIDS REV, V10, P36
   Perez AP, 2009, INT J PHARMACEUT, V380, P189, DOI 10.1016/j.ijpharm.2009.06.035
   Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180
   ROSSI JJ, 2006, BIOTECHNIQUES S, P25
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Scherer L, 2007, GENE THER, V14, P1057, DOI 10.1038/sj.gt.3302977
   Schlee M, 2006, MOL THER, V14, P463, DOI 10.1016/j.ymthe.2006.06.001
   Shen XC, 2007, ORG BIOMOL CHEM, V5, P3674, DOI 10.1039/b711242d
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Van Duyne R, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-76
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wu JY, 2005, CHEM COMMUN, P313, DOI 10.1039/b414241a
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2006, CHEM COMMUN, P2362, DOI 10.1039/b601381c
   Zhou JH, 2009, NUCLEIC ACIDS RES, V37, P3094, DOI 10.1093/nar/gkp185
NR 45
TC 85
Z9 85
U1 3
U2 23
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD DEC
PY 2011
VL 19
IS 12
BP 2228
EP 2238
DI 10.1038/mt.2011.207
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 861SK
UT WOS:000298039300017
PM 21952167
OA gold
DA 2018-01-05
ER

PT J
AU Xiang, DX
   Chen, Q
   Pang, L
   Zheng, CL
AF Xiang, Dong-xi
   Chen, Qian
   Pang, Lin
   Zheng, Cong-long
TI Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in
   vitro
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Silver nanoparticles; H1N1 influenza A virus; Antiviral activity
ID ESCHERICHIA-COLI; INDUCED APOPTOSIS; CELLS; REPLICATION; ACTIVATION;
   PROTEINS; CULTURE
AB Silver nanoparticles have demonstrated efficient inhibitory activities against human immunodeficiency virus (HIV)and hepatitis B virus (HBV). However, the effects of silver nanoparticles against H1N1 influenza A virus remain unexplored. In this study, the interaction of silver nanoparticles with H1N1 influenza A virus was investigated. Silver nanoparticles with mean particle diameters of 10 nm were prepared for the hemagglutination inhibition test, the embryo inoculation assay, and the Mosmann-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, where these tests were used to determine the inhibitory activity of silver nanoparticles on H1N1 influenza A virus. MOCK cells were used as the infection model. Electron microscopy analysis and flow cytometry assay were used to determine whether silver nanoparticles could reduce H1N1 influenza A virus-induced apoptosis in MOCK cells. This study demonstrates that silver nanoparticles have anti-H1N1 influenza A virus activities. The inhibitory effects of silver nanoparticles on influenza A virus may be a novel clinical strategy for the prevention of influenza virus infection during the early dissemination stage of the virus. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Xiang, Dong-xi; Zheng, Cong-long] Dalian Univ, Dept Microbiol, Coll Med, Dalian 116622, Liaoning, Peoples R China.
   [Chen, Qian] Dalian Univ, Affiliated Xinhua Hosp, Dept Plast Surg, Dalian 116021, Liaoning, Peoples R China.
   [Pang, Lin] Univ Queensland, Sch Chem & Mol Biol, St Lucia, Qld 4072, Australia.
RP Zheng, CL (reprint author), Dalian Univ, Dept Microbiol, Coll Med, 10 Xue Fu St, Dalian 116622, Liaoning, Peoples R China.
EM zcl9812@yahoo.com.cn
FU National Natural Science Foundation of China [30870681]
FX This study was supported by National Natural Science Foundation of China
   (No. 30870681). We thank Dr. Xu-lin Chen, who worked in Wuhan Institute
   of Virology, Chinese Academy of Sciences, for offering the H1N1
   influenza A virus for our study.
CR Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Bardiya N, 2005, APPL MICROBIOL BIOT, V67, P299, DOI 10.1007/s00253-004-1874-1
   Bonnemann H, 2001, EUR J INORG CHEM, P2455
   Chen HY, 2005, LIFE SCI, V77, P768, DOI 10.1016/j.lfs.2004.12.032
   Chu C, 2009, P NATL ACAD SCI USA, V106, P14802, DOI 10.1073/pnas.0905912106
   Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407                                                    
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   Elechiguerra Jose Luis, 2005, J Nanobiotechnology, V3, P6
   Guggenbichler JP, 1999, INFECTION, V27, pS16, DOI 10.1007/BF02561612
   Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605
   Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100
   Kurokawa M, 1999, INT J MOL MED, V3, P527
   Li XZ, 1997, J BACTERIOL, V179, P6127, DOI 10.1128/jb.179.19.6127-6132.1997                                                
   Li Y, 2006, J HOSP INFECT, V62, P58, DOI 10.1016/i.jhin.2005.04.015
   Lu L, 2008, ANTIVIR THER, V13, P253
   Morris SJ, 1999, J GEN VIROL, V80, P137, DOI 10.1099/0022-1317-80-1-137                                                      
   Morris SJ, 2005, VIROLOGY, V335, P198, DOI 10.1016/j.virol.2005.02.019
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Percival Steven L, 2007, Int Wound J, V4, P186, DOI 10.1111/j.1742-481X.2007.00296.x
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Samuel U, 2004, INT J ANTIMICROB AG, V23, pS75, DOI 10.1016/j.ijantimicag.2003.12.004
   Shahverdi AR, 2007, NANOMED-NANOTECHNOL, V3, P168, DOI 10.1016/j.nano.2007.02.001
   Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Stasakova J, 2005, J GEN VIROL, V86, P185, DOI 10.1099/vir.0.80422-0
   Stray SJ, 2001, VIRUS RES, V77, P3, DOI 10.1016/S0168-1702(01)00260-X                                                   
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Suwannakarn K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009717
   TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Wang T.T., 2010, J PLOS PATHOG
   Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350                                                         
   Xiang B, 2008, BIOCHEM BIOPH RES CO, V377, P210, DOI 10.1016/j.bbrc.2008.09.120
   Yang PH, 2007, ANAL CHIM ACTA, V585, P331, DOI 10.1016/j.aca.2007.01.011
   Zhang CF, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-51
NR 36
TC 52
Z9 55
U1 4
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD DEC
PY 2011
VL 178
IS 1-2
BP 137
EP 142
DI 10.1016/j.jviromet.2011.09.003
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 853UQ
UT WOS:000297451600020
PM 21945220
DA 2018-01-05
ER

PT J
AU Zonin, E
   Moscatiello, R
   Miuzzo, M
   Cavallarin, N
   Di Paolo, ML
   Sandona, D
   Marin, O
   Brini, M
   Negro, A
   Navazio, L
AF Zonin, Elisabetta
   Moscatiello, Roberto
   Miuzzo, Manuela
   Cavallarin, Nadia
   Di Paolo, Maria Luisa
   Sandona, Dorianna
   Marin, Oriano
   Brini, Marisa
   Negro, Alessandro
   Navazio, Lorella
TI TAT-Mediated Aequorin Transduction: An Alternative Approach for
   Effective Calcium Measurements in Plant Cells
SO PLANT AND CELL PHYSIOLOGY
LA English
DT Article
DE Aequorin; Calcium; Cell-penetrating peptides; Plant cell cultures;
   Protein transduction; TAT
ID INTRACELLULAR DELIVERY PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS;
   PENETRATING PEPTIDES; LIVING CELLS; CELLULAR INTERNALIZATION;
   PARKINSONS-DISEASE; SOYBEAN CELLS; PROTEIN; SUSPENSION; MECHANISM
AB Cell-penetrating peptides are short cationic peptides with the property of translocating across the plasma membrane and transferring macromolecules otherwise unable to permeate cell membranes. We investigated the potential ability of the protein transduction domain derived from amino acids 47-57 of the human immunodeficiency virus type 1 (HIV-1) TAT (transactivator of transcription) protein to be used as a nanocarrier for the delivery of aequorin, a Ca2+-sensitive photoprotein widely used as a reliable Ca2+ reporter in cell populations. The TAT peptide, either covalently linked to apoaequorin or ionically bound to plasmids encoding differentially targeted aequorin, was supplied to plant suspension-cultured cells. The TAT-aequorin fusion protein was found to be rapidly and effectively translocated into plant cells. The chimeric molecule was internalized in fully active biological form and at levels suitable to monitor intracellular Ca2+ concentrations. Plant cells incubated for just 5 min with TAT-aequorin responded to different environmental stimuli with the expected Ca2+ signatures. On the other hand, TAT-mediated plasmid internalization did not provide the necessary level of transformation efficiency to allow calibration of luminescence signals into Ca2+ concentration values. These results indicate that TAT-mediated aequorin transduction is a promising alternative to traditional plant transformation methods to monitor intracellular Ca2+ dynamics rapidly and effectively in plant cells.
C1 [Zonin, Elisabetta; Moscatiello, Roberto; Navazio, Lorella] Univ Padua, Dipartimento Biol, I-35131 Padua, Italy.
   [Miuzzo, Manuela; Sandona, Dorianna] Univ Padua, Dipartimento Sci Biomed Sperimentali, I-35131 Padua, Italy.
   [Cavallarin, Nadia] Univ Padua, Ctr Ric Interdipartimentale Biotecnol Innovat, I-35131 Padua, Italy.
   [Di Paolo, Maria Luisa; Marin, Oriano; Brini, Marisa; Negro, Alessandro] Univ Padua, Dipartimento Chim Biol, I-35131 Padua, Italy.
RP Navazio, L (reprint author), Univ Padua, Dipartimento Biol, Via U Bassi 58-B, I-35131 Padua, Italy.
EM lorella.navazio@unipd.it
OI Brini, Marisa/0000-0001-5141-0243
FU Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale
   [2008WKPAWW]; Ricerca Scientifica quota EX-60% [60A06-2248/11]
FX This work was supported by Programmi di Ricerca Scientifica di Rilevante
   Interesse Nazionale [2008WKPAWW to L.N.]; Ricerca Scientifica quota
   EX-60% [60A06-2248/11 to L.N.].
CR BAKER CJ, 1994, PLANT CELL TISS ORG, V39, P7
   Batelli S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001884
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896                                                         
   Brini M, 2008, METHODS, V46, P160, DOI 10.1016/j.ymeth.2008.09.011
   Cardarelli F, 2008, TRAFFIC, V9, P528, DOI 10.1111/j.1600-0854.2007.00696.x
   Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046
   Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x
   Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076
   Cheon SH, 2009, J MICROBIOL BIOTECHN, V19, P781, DOI 10.4014/jmb.0901.057
   Choi HS, 2006, BBA-GEN SUBJECTS, V1760, P1604, DOI 10.1016/j.bbagen.2006.09.011
   Chugh A, 2008, FEBS J, V275, P2403, DOI 10.1111/j.1742-4658.2008.06384.x
   Chugh A, 2008, J PEPT SCI, V14, P477, DOI 10.1002/psc.937
   Chugh A, 2010, IUBMB LIFE, V62, P183, DOI 10.1002/iub.297
   Chugh A, 2009, PLANT CELL REP, V28, P801, DOI 10.1007/s00299-009-0692-4
   Costa A, 2010, PLANT J, V62, P760, DOI 10.1111/j.1365-313X.2010.04190.x
   Dodd AN, 2010, ANNU REV PLANT BIOL, V61, P593, DOI 10.1146/annurev-arplant-070109-104628
   Eggenberger K, 2009, CHEMBIOCHEM, V10, P2504, DOI 10.1002/cbic.200900331
   El-Andaloussi S, 2005, CURR PHARM DESIGN, V11, P3597, DOI 10.2174/138161205774580796
   Eudes F, 2008, PLANT SIGNAL BEHAV, V3, P549, DOI 10.1002/psc.937
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x                                              
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160
   HORN ME, 1983, PLANT PHYSIOL, V72, P426, DOI 10.1104/pp.72.2.426
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   LIU H, 2006, BIOTECHNOL ADV, V24, P1
   Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004
   Mazars C, 2009, NEW PHYTOL, V181, P261, DOI 10.1111/j.1469-8137.2008.02680.x
   McAinsh MR, 2009, NEW PHYTOL, V181, P275, DOI 10.1111/j.1469-8137.2008.02682.x
   Mithofer A, 1999, PLANTA, V207, P566, DOI 10.1007/s004250050519
   Mizuno T, 2009, J PEPT SCI, V15, P259, DOI 10.1002/psc.1079
   Navazio L, 2007, PLANT PHYSIOL, V144, P673, DOI 10.1104/pp.106.086959
   Plieth C, 1999, PLANT J, V18, P491, DOI 10.1046/j.1365-313X.1999.00471.x
   Qi XP, 2011, MOL PLANT MICROBE IN, V24, P25, DOI 10.1094/MPMI-07-10-0147
   Recchia A, 2008, NEUROBIOL DIS, V30, P8, DOI 10.1016/j.nbd.2007.11.002
   Rosenbluh J, 2004, BBA-BIOMEMBRANES, V1664, P230, DOI 10.1016/j.bbamem.2004.06.003
   Sawant R, 2011, METHODS MOL BIOL, V683, P431, DOI 10.1007/978-1-60761-919-2_31
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Unnamalai N, 2004, FEBS LETT, V566, P307, DOI 10.1016/j.febslet.2004.04.018
   van der Luit AH, 1999, PLANT PHYSIOL, V121, P705, DOI 10.1104/pp.121.3.705
   Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205
   YING L, 2009, SCI AGR SIN, V42, P1918
NR 47
TC 7
Z9 7
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0032-0781
J9 PLANT CELL PHYSIOL
JI Plant Cell Physiol.
PD DEC
PY 2011
VL 52
IS 12
BP 2225
EP 2235
DI 10.1093/pcp/pcr145
PG 11
WC Plant Sciences; Cell Biology
SC Plant Sciences; Cell Biology
GA 859IQ
UT WOS:000297870500017
PM 22025557
OA gold
DA 2018-01-05
ER

PT J
AU Alving, CR
   Rao, M
   Peachman, KK
   Asher, L
   Rao, VB
AF Alving, Carl R.
   Rao, Mangala
   Peachman, Kristina K.
   Asher, Ludmila
   Rao, Venigalla B.
TI Liposomes containing glucosyl ceramide specifically bind T4
   bacteriophage: a self-assembling nanocarrier formulation
SO JOURNAL OF LIPOSOME RESEARCH
LA English
DT Article
DE Adjuvant; nanotechnology; vaccines
ID IMMUNODEFICIENCY-VIRUS TYPE-1; VACCINE ADJUVANTS; LIPID-A;
   BACTERIOPHAGE-T4; LIPOPOLYSACCHARIDE; PROTEIN; STRATEGY; ANTIGENS;
   DISPLAY; REGION
AB A unique formulation is described comprising liposomes containing glucosyl ceramide (GluCer) in the lipid bilayer to which bacteriophage T4 was attached. Binding of the phage T4 did not occur to glycolipids, such as galactosyl ceramide, containing an aldose in which the C-2 or C-4 conformations were not identical to glucose. These results strongly support previous proposals that glucose is a major receptor moiety for T4 binding to Escherichia coli. By using the binding of T4 to liposomal GluCer, we further describe a formulation that can be used as a self-assembling combined antigen and adjuvant carrier. A peptide antigen derived from C-trimer (Ct) of HIV-1 gp41 was fused to the highly antigenic outer capsid protein (Hoc), a nonessential protein of T4 that spontaneously binds to the T4 capsid. This resulted in display of the Ct-Hoc construct on the T4 capsid, and specific binding of a human monoclonal antibody that recognizes a peptide sequence of Ct was demonstrated. Liposomes containing monophosphoryl lipid A (MPLA) have been demonstrated to have potent adjuvant activities for experimental vaccines both in humans and animals, and because of this, mice were immunized with the Ct-Hoc-T4 construct that was bound to liposomes containing both GluCer and MPLA, resulting in the induction of high titers of Ct-specific antibodies. We conclude that liposomes containing both GluCer and MPLA can spontaneously bind to a construct of T4 that displays antigens that spontaneously binds to the capsid of T4 bacteriophage. This formulation could be utilized as an easily manufactured self-assembling antigen and adjuvant carrier.
C1 [Alving, Carl R.; Rao, Mangala; Peachman, Kristina K.; Asher, Ludmila] Walter Reed Army Inst Res, Div Retrovirol, US Mil HIV Res Program, Dept Adjuvant & Antigen Res, Rockville, MD 20850 USA.
   [Peachman, Kristina K.; Asher, Ludmila; Rao, Venigalla B.] Henry M Jackson Fdn Adv Mil Med, US Mil HIV Res Program, Rockville, MD USA.
   Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.
RP Alving, CR (reprint author), Walter Reed Army Inst Res, Div Retrovirol, US Mil HIV Res Program, Dept Adjuvant & Antigen Res, 1600 E Gude Dr, Rockville, MD 20850 USA.
EM calving@hivresearch.org
OI Rao, Venigalla/0000-0002-0777-6587
FU Henry M. Jackson Foundation for the Advancement of Military Medicine
   [DAMD17-93-V-3004]; U.S. Army Medical Research and Material Command
FX This work was supported through Cooperative Agreement no.
   DAMD17-93-V-3004 between the Henry M. Jackson Foundation for the
   Advancement of Military Medicine and the U.S. Army Medical Research and
   Material Command, working together with the Division of AIDS, National
   Institute for Allergy and Infectious Diseases, National Institutes of
   Health (Bethesda, Maryland, USA).
CR Alving CR, 2008, VACCINE, V26, P3036, DOI 10.1016/j.vaccine.2007.12.002
   Alving CR, 2002, VACCINE, V20, pS56, DOI 10.1016/S0264-410X(02)00174-3                                                   
   ALVING CR, 1993, IMMUNOBIOLOGY, V187, P430, DOI 10.1016/S0171-2985(11)80355-4                                                   
   Beck Z, 2007, BIOCHEM BIOPH RES CO, V354, P747, DOI 10.1016/j.bbrc.2007.01.033
   DAWES J, 1975, NATURE, V256, P127, DOI 10.1038/256127a0
   FRIES LF, 1992, P NATL ACAD SCI USA, V89, P358, DOI 10.1073/pnas.89.1.358
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6-5-723
   Garcon N, 2009, SCI AM, V301, P72, DOI 10.1038/scientificamerican1009-72                                               
   Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
   Harandi AM, 2009, EXPERT REV VACCINES, V8, P293, DOI 10.1586/14760584.8.3.293
   HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4
   Leiman PG, 2003, J MOL BIOL, V328, P821, DOI 10.1016/S0022-2836(03)00366-8
   MUSTER T, 1993, J VIROL, V67, P6642
   PREHM P, 1976, J MOL BIOL, V101, P277, DOI 10.1016/0022-2836(76)90377-6
   Rao M, 2004, IMMUNOL CELL BIOL, V82, P523, DOI 10.1111/j.1440-1711.2004.01283.x
   Rao M, 2011, VACCINE, V29, P873, DOI 10.1016/j.vaccine.2010.11.049
   Rao VB, 2001, J MOL BIOL, V314, P401, DOI 10.1006/jmbi.2001.5169
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Sathaliyawala T, 2006, J VIROL, V80, P7688, DOI 10.1128/JVI.00235-06
   Shivachandra SB, 2007, VACCINE, V25, P1225, DOI 10.1016/j.vaccine.2006.10.010
   Shivachandra SB, 2006, VIROLOGY, V345, P190, DOI 10.1016/j.virol.2005.10.037
   Wassef N M, 1994, Immunomethods, V4, P217, DOI 10.1006/immu.1994.1023
   YU F, 1982, J BACTERIOL, V151, P718
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 24
TC 0
Z9 0
U1 1
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0898-2104
J9 J LIPOSOME RES
JI J. Liposome Res.
PD DEC
PY 2011
VL 21
IS 4
BP 279
EP 285
DI 10.3109/08982104.2011.559646
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 848OF
UT WOS:000297060200003
PM 21401373
DA 2018-01-05
ER

PT J
AU Lu, WB
   Qin, XY
   Luo, YL
   Chang, GH
   Sun, XP
AF Lu, Wenbo
   Qin, Xiaoyun
   Luo, Yonglan
   Chang, Guohui
   Sun, Xuping
TI CdS quantum dots as a fluorescent sensing platform for nucleic acid
   detection
SO MICROCHIMICA ACTA
LA English
DT Article
DE CdS quantum dots; DNA detection; Fluorescence
ID DNA ANALYSIS; NANOPARTICLES; PROBES; OLIGONUCLEOTIDES; BIOMOLECULES;
   NANOCRYSTALS
AB We demonstrate that CdS quantum dots (QDs) can be applied to fluorescence-enhanced detection of nucleic acids in a two-step protocol. In step one, a fluorescently labeled single-stranded DNA probe is adsorbed on the QDs to quench its luminescence. In step two, the hybridization of the probe with its target ssDNA produces a double-stranded DNA which detaches from the QD. This, in turn, leads to the recovery of the fluorescence of the label. The lower detection limit of the assay is as low as 1 nM. The scheme (that was applied to detect a target DNA related to the HIV) is simple and can differentiate between perfectly complementary targets and mismatches.
C1 [Lu, Wenbo; Qin, Xiaoyun; Luo, Yonglan; Chang, Guohui; Sun, Xuping] China W Normal Univ, Sch Chem & Chem Engn, Chem Synth & Pollut Control Key Lab Sichuan Prov, Nanchong 637002, Sichuan, Peoples R China.
RP Sun, XP (reprint author), China W Normal Univ, Sch Chem & Chem Engn, Chem Synth & Pollut Control Key Lab Sichuan Prov, Nanchong 637002, Sichuan, Peoples R China.
EM sun.xuping@hotmail.com
RI Lu, Wenbo/H-4653-2011
OI Lu, Wenbo/0000-0001-8158-7947
CR Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933                                                    
   ATAY Z, 2009, J NANOPART RES, V12, P2241
   Balu AM, 2010, MATER CHEM PHYS, V124, P52, DOI 10.1016/j.matchemphys.2010.07.046
   Brayner R, 2008, NANO TODAY, V3, P48, DOI 10.1016/S1748-0132(08)70015-X                                                   
   Coe S, 2002, NATURE, V420, P800, DOI 10.1038/nature01217
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762                                                                   
   Gresham D, 2006, SCIENCE, V311, P1932, DOI 10.1126/science.1123726
   He SJ, 2010, ADV FUNCT MATER, V20, P453, DOI 10.1002/adfm.200901639
   Jin J, 2003, CHINESE J CHEM, V21, P208
   Kim T, 2009, J PHYS CHEM B, V113, P14487, DOI 10.1021/jp906096a
   Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u
   Li HL, 2011, SMALL, V7, P1562, DOI 10.1002/smll.201100068
   Li HL, 2011, MACROMOL RAPID COMM, V32, P899, DOI 10.1002/marc.201100108
   Li HL, 2011, ANAL METHODS-UK, V3, P1051, DOI 10.1039/c0ay00746c
   Li HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018958
   Li HL, 2011, J MATER CHEM, V21, P824, DOI 10.1039/c0jm02695f
   Li HL, 2011, J MATER CHEM, V21, P4663, DOI 10.1039/c0jm04107f
   Li HL, 2011, CHEM COMMUN, V47, P2625, DOI 10.1039/c0cc05394e
   Li HL, 2011, CHEM COMMUN, V47, P961, DOI 10.1039/c0cc04326e
   Li HX, 2004, ANAL CHEM, V76, P5414, DOI 10.1021/ac049173n
   Liu S., 2010, NANOSCALE, V3, P967
   Liu S, 2011, J MATER CHEM, V21, P339, DOI 10.1039/c0jm03337e
   Liu YL, 2011, BIOMATERIALS, V32, P1185, DOI 10.1016/j.biomaterials.2010.10.022
   Lu CH, 2009, ANGEW CHEM INT EDIT, V48, P4785, DOI 10.1002/anie.200901479
   LUO Y, 2011, NANOTECHNOLOGY, V22, P95506
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Nair PS, 2001, J MATER CHEM, V11, P1555
   Ray PC, 2007, PLASMONICS, V2, P173, DOI 10.1007/s11468-007-9036-9
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Song SP, 2009, ANGEW CHEM INT EDIT, V48, P8670, DOI 10.1002/anie.200901887
   Tian JQ, 2011, ANALYST, V136, P2221, DOI 10.1039/c0an00944j
   Tian JQ, 2011, LANGMUIR, V27, P874, DOI 10.1021/la103799e
   WANG L, 2010, NUCLEIC ACIDS RES, V39, pE37
   Wei MY, 2011, MICROCHIM ACTA, V172, P247, DOI 10.1007/s00604-010-0519-6
   Yang RH, 2008, ANAL CHEM, V80, P7408, DOI 10.1021/ac801118p
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
   Zhang YW, 2011, LANGMUIR, V27, P2170, DOI 10.1021/la105092f
NR 37
TC 23
Z9 25
U1 2
U2 36
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-3672
J9 MICROCHIM ACTA
JI Microchim. Acta
PD DEC
PY 2011
VL 175
IS 3-4
BP 355
EP 359
DI 10.1007/s00604-011-0657-5
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 846SZ
UT WOS:000296924800019
DA 2018-01-05
ER

PT J
AU Kadiu, I
   Gendelman, HE
AF Kadiu, Irena
   Gendelman, Howard E.
TI Human Immunodeficiency Virus type 1 Endocytic Trafficking Through
   Macrophage Bridging Conduits Facilitates Spread of Infection
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE HIV-1; Macrophage; Bridging conduits; Tunneling nanotubes; Recycling
   endosomes; Multivesicular bodies; Viral trafficking; Endocytic sorting;
   Lysosomes; Early endosomes; Motor proteins; Tubulin; Intercellular viral
   spread
ID MEMBRANE NANOTUBES; PLASMA-MEMBRANE; TUNNELING NANOTUBES; HIV-1
   ASSEMBLES; LATE ENDOSOMES; IN-VIVO; CELLS; PROTEINS; PATHWAY;
   COMPARTMENTS
AB Bridging conduits (BC) sustain communication and homeostasis between distant tethered cells. These are also exploited commonly for direct cell-to-cell transfer of microbial agents. Conduits efficiently spread infection, effectively, at speeds faster than fluid phase exchange while shielding the microbe against otherwise effective humoral immunity. Our laboratory has sought to uncover the mechanism(s) for these events for human immunodeficiency virus type one (HIV-1) infection. Indeed, in our prior works HIV-1 Env and Gag antigen and fluorescent virus tracking were shown sequestered into endoplasmic reticulum-Golgi organelles but the outcomes for spreading viral infection remained poorly defined. Herein, we show that HIV-1 specifically traffics through endocytic compartments contained within BC and directing such macrophage-to-macrophage viral transfers. Following clathrin-dependent viral entry, HIV-1 constituents bypass degradation by differential sorting from early to Rab11(+) recycling endosomes and multivesicular bodies. Virus-containing endocytic viral cargoes propelled by myosin II through BC spread to neighboring uninfected cells. Disruption of endosomal motility with cytochalasin D, nocodasole and blebbistatin diminish intercellular viral spread. These data lead us to propose that HIV-1 hijacks macrophage endocytic and cytoskeletal machineries for high-speed cell-to-cell spread.
C1 [Kadiu, Irena; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU National Institutes of Health [P20 DA026146, 5P01 DA028555-02, R01
   NS36126, P01 NS31492, 2R01 NS034239, P20 RR15635, P01 MH64570, P01
   NS43985]
FX We thank Drs. R. L. Mosley, H. S. Fox and R. Taylor for the critical
   reading of the manuscript. We would like to acknowledge Dr. F. Kieken,
   F. Robert for bioinformatics support; T. Bargar, J. Taylor for their
   assistance with electron and confocal microscopy, B. Wassom for graphic
   design of the elements in Figure S8. This work was supported in part by
   National Institutes of Health grants P20 DA026146, 5P01 DA028555-02, R01
   NS36126, P01 NS31492, 2R01 NS034239, P20 RR15635, P01 MH64570, and P01
   NS43985 (to H.E.G). The authors declare no competing financial
   interests.
CR Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4
   Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6
   Beckner ME, 2005, LAB INVEST, V85, P316, DOI 10.1038/labinvest.3700239
   Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732                                                                  
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
   Bright NA, 1997, J CELL SCI, V110, P2027
   Brown K, 2008, FASEB J, V22, P3776, DOI 10.1096/fj.08-107441
   BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W                                                    
   CALLAHAN KM, 1993, J IMMUNOL, V151, P2928
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Christoforidis S, 1999, NATURE, V397, P621
   Ciborowski P, 2006, CURR HIV RES, V4, P279, DOI 10.2174/157016206777709474
   de Gassart A, 2004, TRAFFIC, V5, P896, DOI 10.1111/j.1600-0854.2004.00223.x
   Denek M, 2007, J CELL BIOL, V177, P329, DOI 10.1083/jcb.200609050
   DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P                  
   Dixit R, 2008, NEUROSCI LETT, V440, P113, DOI 10.1016/j.neulet.2008.05.031
   EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337
   Eugenin EA, 2009, CELL IMMUNOL, V254, P142, DOI 10.1016/j.cellimm.2008.08.005
   Eugenin Eliseo A, 2009, Commun Integr Biol, V2, P243
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2                                                   
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gill DJ, 2007, EMBO J, V26, P600, DOI 10.1038/sj.emboj.7601501
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360
   Jouve M, 2007, CELL HOST MICROBE, V2, P85, DOI 10.1016/j.chom.2007.06.011
   Kadin I, 2007, J IMMUNOL, V178, P6404, DOI 10.4049/jimmunol.178.10.6404                                                    
   Kadiu I, 2011, J PROTEOME RES, V10, P3225, DOI 10.1021/pr200262q
   Kadiu I, 2009, CELL IMMUNOL, V258, P44, DOI 10.1016/j.cellimm.2009.03.012
   Lundquist EA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000142
   Luzio JP, 2005, BIOCHEM SOC SYMP, V72, P77, DOI 10.1042/bss0720077                                                              
   Martin N, 2009, CURR OPIN HIV AIDS, V4, P143, DOI 10.1097/COH.0b013e328322f94a
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   ORENSTEIN JM, 1988, J VIROL, V62, P2578
   Ott DE, 2000, VIROLOGY, V266, P42, DOI 10.1006/viro.1999.0075
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   Platt EJ, 1998, J VIROL, V72, P2855
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sharova N, 2005, EMBO J, V24, P2481, DOI 10.1038/sj.emboj.7600707
   Sherer NM, 2008, TRENDS CELL BIOL, V18, P414, DOI 10.1016/j.tcb.2008.07.003
   Sherer NM, 2007, NAT CELL BIOL, V9, P310, DOI 10.1038/ncb1544
   Simons M, 2009, CURR OPIN CELL BIOL
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Trischler M, 1999, J CELL SCI, V112, P4773
   Uchil PD, 2009, CELL, V137, P402, DOI 10.1016/j.cell.2009.04.033
   Vonna L, 2007, EUR BIOPHYS J BIOPHY, V36, P145, DOI 10.1007/s00249-006-0118-y
   Wang JJ, 2001, APPL IMMUNOHISTO M M, V9, P371, DOI 10.1097/00022744-200112000-00014                                                
   Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055                                                                
NR 57
TC 31
Z9 31
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD DEC
PY 2011
VL 6
IS 4
SI SI
BP 658
EP 675
DI 10.1007/s11481-011-9298-z
PG 18
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 843DC
UT WOS:000296651500022
PM 21789505
OA gold
DA 2018-01-05
ER

PT J
AU Choi, S
   Lee, J
   Kumar, P
   Lee, KY
   Lee, SK
AF Choi, Sunmi
   Lee, Jangwook
   Kumar, Priti
   Lee, Kuen Yong
   Lee, Sang-Kyung
TI Single chain variable fragment CD7 antibody conjugated PLGA/HDAC
   inhibitor immuno-nanoparticles: Developing human T cell-specific
   nano-technology for delivery of therapeutic drugs targeting latent HIV
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Meeting Abstract
CT 1st Symposium on Innovative Polymers for Controlled Delivery
CY SEP 14-17, 2010
CL Suzhou, PEOPLES R CHINA
DE Latency virus; HIV; HDAC inhibitor; PLGA; scFvCD7; Immuno-nanoparticle
ID HISTONE DEACETYLASE INHIBITORS
C1 [Choi, Sunmi; Lee, Jangwook; Lee, Kuen Yong; Lee, Sang-Kyung] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.
   [Choi, Sunmi; Lee, Jangwook; Lee, Kuen Yong; Lee, Sang-Kyung] Hanyang Univ, Inst Bioengn & Biophamaceut Res, Seoul 133791, South Korea.
   [Choi, Sunmi; Lee, Jangwook; Lee, Kuen Yong; Lee, Sang-Kyung] Hanyang Univ, Inst Aging Soc, Seoul 133791, South Korea.
   [Lee, Sang-Kyung] Yale Univ, Dept Internal Med, New Haven, CT 06520 USA.
EM choi_sunmi@naver.com
CR Archin NM, 2009, AIDS, V23, P1799, DOI 10.1097/QAD.0b013e32832ec1dc
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Savarino A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-52
   Strayer DS, 2005, MOL THER, V11, P823, DOI 10.1016/j.ymthe.2005.01.020
   Williams SA, 2007, CYTOKINE, V39, P63, DOI 10.1016/j.cyto.2007.05.017
NR 5
TC 5
Z9 5
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 30
PY 2011
VL 152
SU 1
BP E9
EP E10
DI 10.1016/j.jconrel.2011.08.089
PG 3
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 876RO
UT WOS:000299125600007
PM 22195949
DA 2018-01-05
ER

PT J
AU Qin, Y
   Chen, HL
   Zhang, QY
   Wang, XX
   Yuan, WM
   Kuai, R
   Tang, J
   Zhang, L
   Zhang, ZR
   Zhang, Q
   Liu, J
   He, Q
AF Qin, Yao
   Chen, Huali
   Zhang, Qianyu
   Wang, Xiaoxiao
   Yuan, Wenmin
   Kuai, Rui
   Tang, Jie
   Zhang, Li
   Zhang, Zhirong
   Zhang, Qiang
   Liu, Ji
   He, Qin
TI Liposome formulated with TAT-modified cholesterol for improving brain
   delivery and therapeutic efficacy on brain glioma in animals
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE TAT; Cholesterol; Doxorubicin; Brain delivery; Blood-brain barrier
ID DRUG-DELIVERY; HIV-1 TAT; PROTEIN TRANSDUCTION; PLASMA-MEMBRANE;
   BREAST-CANCER; TUMOR-MODEL; DOXORUBICIN; BARRIER; NANOPARTICLES;
   EFFICIENT
AB The treatment of central nervous system diseases such as brain glioma is a major challenge due to the presence of the blood-brain barrier (BBB). A cell-penetrating peptide TAT (AYGRKKRRQRRR), which appears to enter cells with alacrity, was employed to enhance the delivery efficiency of normal drug formulation to the brain. Targeting liposomal formulations often apply modified phospholipids as anchors. However, cholesterol, another liposomal component more stable and cheaper, has not been fully investigated as an alternative anchor. In our study, TAT was covalently conjugated with cholesterol for preparing doxorubicin-loaded liposome for brain glioma therapy. Cellular uptake by brain capillary endothelial cells (BCECs) and C6 glioma cells was explored. The anti-proliferative activity against C6s confirmed strong inhibitory effect of the liposomes modified with doxorubicin-loaded TAT. The bio-distribution findings in brains and hearts were evident of higher efficiency of brain delivery and lower cardiotoxic risk. The results on survival of the brain glioma-bearing animals indicate that survival time of the glioma-bearing rats treated with TAT-modified liposome was much longer than in the other groups. In conclusion, the potency of the TAT-modified liposome to enter the BBB appears to be related with the TAT on the liposome's surface. The TAT-modified liposome may improve the therapeutic efficacy on brain glioma in vitro and in vivo. (c) 2011 Elsevier B.V. All rights reserved.
C1 [He, Qin] Sichuan Univ, W China Sch Pharmaceut, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu Municipality 610041, Sichuan Provinc, Peoples R China.
   [Liu, Ji] Sichuan Univ, W China Sch Preclin & Forens Med, Chengdu Municipality 610041, Sichuan Provinc, Peoples R China.
   [Qin, Yao] Taiji Grp, Chongqing Municipality 401147, Peoples R China.
   [Zhang, Qiang] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
RP He, Q (reprint author), Sichuan Univ, W China Sch Pharmaceut, Key Lab Drug Targeting & Drug Delivery Syst, 17 Sect 3,So Renmin Nan Rd, Chengdu Municipality 610041, Sichuan Provinc, Peoples R China.
EM liuji6103@163.com; qinhe@scu.edu.cn
OI Zhang, Qianyu/0000-0002-0758-2432; Kuai, Rui/0000-0003-2324-1272
FU National Natural Science Foundation of China [30873166, 81072599,
   81130060]; National Basic Research Program of China [2009CB903300]
FX We are thankful for the financial support of the National Natural
   Science Foundation of China (30873166, 81072599), the State Key Program
   of National Natural Science Foundation of China (81130060) and the
   National Basic Research Program of China (2009CB903300).
CR Adam JF, 2006, INT J RADIAT ONCOL, V64, P603, DOI 10.1016/j.ijrobp.2005.09.004
   Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Begley DJ, 2004, PHARMACOL THERAPEUT, V104, P29, DOI 10.1016/j.pharmthera.2004.08.001
   Brigger I, 2004, J CONTROL RELEASE, V100, P29, DOI 10.1016/j.jconrel.2004.07.019
   Charrois GJR, 2004, BBA-BIOMEMBRANES, V1663, P167, DOI 10.1016/j.bbamem.2004.03.006
   Derossi D., 1818, J BIOL CHEM, V271, P8
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Gu YT, 2007, BRAIN RES, V1162, P1, DOI 10.1016/j.brainres.2007.05.053
   Han HD, 2006, INT J PHARM, V313, P181, DOI 10.1016/j.ijpharm.2006.02.007
   HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9
   Huynh GH, 2006, J CONTROL RELEASE, V110, P236, DOI 10.1016/j.jconrel.2005.09.053
   Jung SH, 2010, COLLOID SURFACE B, V76, P434, DOI 10.1016/j.colsurfb.2009.12.002
   Kumagai A.K., 1521, J BIOL CHEM, V262, P4
   LASIC DD, 1995, BBA-BIOMEMBRANES, V1239, P145, DOI 10.1016/0005-2736(95)00159-Z
   LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H                                                    
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   Maeda N, 2004, J CONTROL RELEASE, V100, P41, DOI 10.1016/j.jconrel.2004.07.033
   MAYER LD, 1989, CANCER RES, V49, P5922
   Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x
   Pardridge WM, 2005, INT CONGR SER, V1277, P49, DOI 10.1016/j.ics.2005.02.011
   PARDRIDGE WM, 1989, J PHARMACOL EXP THER, V251, P821
   Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j,jconrel.2006.10.015
   Qin Y, 2011, INT J PHARMACEUT, V419, P85, DOI 10.1016/j.ijpharm.2011.07.021
   Roney C, 2005, J CONTROL RELEASE, V108, P193, DOI 10.1016/j.jconrel.2005.07.024
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X
   TAKASATO Y, 1984, AM J PHYSIOL, V247, pH484
   Tamai I, 1996, ADV DRUG DELIVER REV, V19, P401, DOI 10.1016/0169-409X(96)00011-7
   TERASAKI T, 1989, J PHARMACOL EXP THER, V251, P351
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Tromberg BJ, 2008, MED PHYS, V35, P2443, DOI 10.1118/1.2919078
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xiong XB, 2005, J CONTROL RELEASE, V107, P262, DOI 10.1016/j.jconrel.2005.03.030
   Xu RX, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1837
   Yang Y, 2009, J CONTROL RELEASE, V135, P175, DOI 10.1016/j.jconrel.2009.01.007
   Zhao XB, 2007, J PHARM SCI-US, V96, P2424, DOI 10.1002/jps.20885
NR 42
TC 70
Z9 82
U1 6
U2 64
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD NOV 28
PY 2011
VL 420
IS 2
BP 304
EP 312
DI 10.1016/j.ijpharm.2011.09.008
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 934DP
UT WOS:000303423800015
PM 21945185
DA 2018-01-05
ER

PT J
AU Smith, RA
   Raugi, DN
   Kiviat, NB
   Hawes, SE
   Mullins, JI
   Sow, PS
   Gottlieb, GS
AF Smith, Robert A.
   Raugi, Dana N.
   Kiviat, Nancy B.
   Hawes, Stephen E.
   Mullins, James I.
   Sow, Papa S.
   Gottlieb, Geoffrey S.
CA Univ Washington
TI Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations
   Q148R and N155H confer raltegravir resistance
SO AIDS
LA English
DT Article
DE HIV-1; HIV-2; integrase; N155H; Q148R; raltegravir; resistance; Y143C
ID RANDOMIZED CONTROLLED-TRIAL; IMMUNOLOGICAL RESPONSE; INHIBITOR
   RESISTANCE; PROTEASE INHIBITORS; DRUG-RESISTANCE; TREATMENT-NAIVE;
   VIRUS; INFECTION; EFFICACY; THERAPY
AB Objectives: Raltegravir is the first integrase strand transfer inhibitor approved for treating HIV-1 infection. Although emerging data suggest that raltegravir may also be useful for HIV-2 treatment, studies addressing the in-vitro susceptibility of HIV-2 to raltegravir are scarce, and the genetic pathways leading to raltegravir resistance in HIV-2 have not been adequately characterized. Our objectives were to directly compare the susceptibilities of HIV-1 and HIV-2 to raltegravir and to examine the role of mutations in HIV-2 integrase in emergent raltegravir resistance.
   Materials and methods: Single-cycle and spreading infection assays were used to quantify the sensitivities of wild-type HIV-1 and HIV-2 strains to raltegravir. HIV-2 integrase mutants were constructed by site-directed mutagenesis, and the replication capacities and raltegravir susceptibilities of the resultant variants were analyzed in single-cycle assays.
   Results: Raltegravir showed comparable activity againstwild-type HIV-1 andHIV-2 in both single-cycle and spreading infections, with EC50 values in the low nanomolar range. Amino acid changes Q148R and N155H individually conferred resistance to raltegravir (14-fold and seven-fold, respectively), whereas the Y143C replacement had no statistically significant effect on raltegravir sensitivity. The combination of Q148R with N155H resulted in high-level raltegravir resistance (> 1000-fold). In addition, all HIV-2 integrase variants tested showed impairments in replication capacity.
   Conclusion: Our data support clinical studies of raltegravir for treating HIV-2 infection and show that the Q148R and N155H changes alone are sufficient for raltegravir resistance in HIV-2. Further efforts are needed to improve access to HIV-2-active antiretrovirals, including raltegravir, in resource-limited areas where HIV-2 is endemic. (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins
C1 [Smith, Robert A.; Kiviat, Nancy B.] Univ Washington, Dept Pathol, Seattle, WA 98109 USA.
   [Raugi, Dana N.; Mullins, James I.; Gottlieb, Geoffrey S.] Univ Washington, Dept Med, Seattle, WA 98109 USA.
   [Hawes, Stephen E.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98109 USA.
   [Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98109 USA.
   [Sow, Papa S.] Univ Cheikh Anta Diop Dakar, Ctr Hosp Univ Fann, Clin Malad Infect Ibrahima DIOP Mar, Dakar, Senegal.
RP Smith, RA (reprint author), Univ Washington, Dept Pathol, 960 Republican St,Box 358070, Seattle, WA 98109 USA.
EM smithra@u.washington.edu
OI Gottlieb, Geoffrey/0000-0002-5749-481X
FU National Institutes of Health/National Institute of Allergy and
   Infectious Diseases [2R01-AI060466]; University of Washington Center for
   AIDS Research [P30 AI27757]; University of Washington
FX These studies were supported by grants to GSG from the National
   Institutes of Health/National Institute of Allergy and Infectious
   Diseases (2R01-AI060466), the University of Washington Center for AIDS
   Research, and the University of Washington Royalty Research Fund.
   Additional support was provided through a New Investigator Award to
   R.A.S. from the University of Washington Center for AIDS Research (P30
   AI27757).
CR Armstrong-James D, 2010, ANTIVIR RES, V86, P224, DOI 10.1016/j.antiviral.2010.02.324
   Bar-Magen T, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-103
   Blanco JL, 2011, J INFECT DIS, V203, P1204, DOI 10.1093/infdis/jir025
   Briz V, 2009, AIDS RES HUM RETROV, V25, P225, DOI 10.1089/aid.2008.0222
   Charpentier C, 2011, ANTIMICROB AGENTS CH, V55, P1293, DOI 10.1128/AAC.00942-10
   Chiara M, 2010, INDIAN J MED RES, V132, P683
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   Damond F, 2008, AIDS, V22, P665, DOI 10.1097/QAD.0b013e3282f51203
   de Silva TI, 2008, TRENDS MICROBIOL, V16, P588, DOI 10.1016/j.tim.2008.09.003
   Delelis O, 2010, ANTIMICROB AGENTS CH, V54, P491, DOI 10.1128/AAC.01075-09
   Eron JJ, 2010, LANCET, V375, P396, DOI 10.1016/S0140-6736(09)62041-9
   Fransen S, 2009, J VIROL, V83, P11440, DOI 10.1128/JVI.01168-09
   Garrett N, 2008, AIDS, V22, P1091, DOI 10.1097/QAD.0b013e3282f9b165
   Goethals O, 2008, J VIROL, V82, P10366, DOI 10.1128/JVI.00470-08
   Goethals O, 2010, VIROLOGY, V402, P338, DOI 10.1016/j.virol.2010.03.034
   Gottlieb GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022204
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Kobayashi M, 2011, ANTIMICROB AGENTS CH, V55, P813, DOI 10.1128/AAC.01209-10
   Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1
   Low A, 2009, ANTIMICROB AGENTS CH, V53, P4275, DOI 10.1128/AAC.00397-09
   Martinez E, 2010, AIDS, V24, P1697, DOI 10.1097/QAD.0b013e32833a608a
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   Menendez-Arias L, 2008, TRENDS PHARMACOL SCI, V29, P42, DOI 10.1016/j.tips.2007.10.013
   Ni XJ, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-68
   Quercia R, 2009, J VIROL, V83, P10245, DOI 10.1128/JVI.00894-09
   Roquebert B, 2008, J ANTIMICROB CHEMOTH, V62, P914, DOI 10.1093/jac/dkn335
   Roquebert B, 2008, AIDS, V22, P2045, DOI 10.1097/QAD.0b013e32830f4c7d
   Salgado M, 2009, J CLIN VIROL, V46, P173, DOI 10.1016/j.jcv.2009.06.020
   Smith RA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-70
   Smith RA, 2009, J INFECT DIS, V199, P1323, DOI 10.1086/597802
   Summa V, 2008, J MED CHEM, V51, P5843, DOI 10.1021/jm800245z
   Van Baelen K, 2009, J VIROL METHODS, V161, P231, DOI 10.1016/j.jviromet.2009.06.015
   van der Loeff MFS, 1999, AIDS, V13, pS69
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Xu L, 2008, AIDS RES HUM RETROV, V24, P1003, DOI 10.1089/aid.2007.0303
   Xu L, 2009, AIDS RES HUM RETROV, V25, P843, DOI 10.1089/aid.2009.0039
NR 37
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD NOV 28
PY 2011
VL 25
IS 18
BP 2235
EP 2241
DI 10.1097/QAD.0b013e32834d8e52
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 844XC
UT WOS:000296784300005
PM 21971360
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hou, GJ
   Byeon, IJL
   Ahn, J
   Gronenborn, AM
   Polenova, T
AF Hou, Guangjin
   Byeon, In-Ja L.
   Ahn, Jinwoo
   Gronenborn, Angela M.
   Polenova, Tatyana
TI H-1-C-13/H-1-N-15 Heteronuclear Dipolar Recoupling by R-Symmetry
   Sequences Under Fast Magic Angle Spinning for Dynamics Analysis of
   Biological and Organic Solids
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID STATE NMR-SPECTROSCOPY; NUCLEAR-MAGNETIC-RESONANCE; CHEMICAL-SHIFT;
   DISTANCE MEASUREMENTS; CROSS-POLARIZATION; ROTATING SOLIDS; PULSE
   SEQUENCES; SENSITIVITY ENHANCEMENT; MICROCRYSTALLINE UBIQUITIN; PF1
   BACTERIOPHAGE
AB Fast magic angle spinning (MAS) NMR spectroscopy is becoming increasingly important in structural and dynamics studies of biological systems and inorganic materials. Superior spectral resolution due to the efficient averaging of the dipolar couplings can be attained at MAS frequencies of 40 kHz and higher with appropriate decoupling techniques, while proton detection gives rise to significant sensitivity gains, therefore making fast MAS conditions advantageous across the board compared with the conventional slow- and moderate-MAS approaches. At the same time, many of the dipolar recoupling approaches that currently constitute the basis for structural and dynamics studies of solid materials and that are designed for MAS frequencies of 20 kHz and below, fail above 30 kHz. In this report, we present an approach for H-1-C-13/H-1-N-15 heteronuclear dipolar recoupling under fast MAS conditions using R-type symmetry sequences, which is suitable even for fully protonated systems. A series of rotor-synchronized R-type symmetry pulse schemes are explored for the determination of structure and dynamics in biological and organic systems. The investigations of the performance of the various RNnv-symmetry sequences at the MAS frequency of 40 kHz experimentally and by numerical simulations on [U-C-13,N-15]-alanine and [U-C-13,N-15]-N-acetyl-valine, revealed excellent performance for sequences with high symmetry number ratio (N/2n > 2.5). Further applications of this approach are presented for two proteins, sparsely C-13/uniformly(15)N-enriched CAP-Gly domain of dynactin and U-C-13,N-15-Tyr enriched C-terminal domain of HIV-1 CA protein. Two-dimensional (2D) and 3D R16(3)(2)-based DIPSHIFT experiments carried out at the MAS frequency of 40 kHz, yielded site-specific H-1-C-13/H-1-N-15 heteronuclear dipolar coupling constants for CAP-Gly and CTD CA, reporting on the dynamic behavior of these proteins on time scales of nano- to microseconds. The R-symmetry-based dipolar recoupling under fast MAS is expected to find numerous applications in studies of protein assemblies and organic solids by MAS NMR spectroscopy.
C1 [Hou, Guangjin; Polenova, Tatyana] Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.
   [Hou, Guangjin; Byeon, In-Ja L.; Ahn, Jinwoo; Gronenborn, Angela M.; Polenova, Tatyana] Univ Pittsburgh, Pittsburgh Ctr HIV Prot Interact, Sch Med, Pittsburgh, PA 15261 USA.
   [Byeon, In-Ja L.; Ahn, Jinwoo; Gronenborn, Angela M.] Univ Pittsburgh, Dept Biol Struct, Sch Med, Pittsburgh, PA 15261 USA.
RP Polenova, T (reprint author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.
EM tpolenov@udel.edu
OI Gronenborn, Angela M/0000-0001-9072-3525
FU National Institutes of Health (NIH) [P50GM082251]; NIGMS
   [R01GM085306-01A1]; NCRR [P20RR015588]
FX This work was supported by the National Institutes of Health (NIH Grants
   P50GM082251 and R01GM085306-01A1 from NIGMS, and P20RR015588 from NCRR)
   and is a contribution from the Pittsburgh Center for HIV Protein
   Interactions. We thank Ago Samoson for the 1.8 mm triple-resonance MAS
   probe, Malcolm Levitt for the Mathematica package of symmetry sequences,
   Si Yan for preparing the CAP-Gly protein sample, and Yun Han for
   preparing the HIV-1 CTD CA capsid protein sample.
CR ANDREW ER, 1959, NATURE, V183, P1802, DOI 10.1038/1831802a0                                                               
   Andronesi O.C., 2004, J BIOMOL NMR, V30, P253
   Bak M, 2000, J MAGN RESON, V147, P296, DOI 10.1006/jmre.2000.2179
   Baldus M, 1998, MOL PHYS, V95, P1197, DOI 10.1080/002689798166215
   Bayro MJ, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2834736
   Bennett AE, 1998, J AM CHEM SOC, V120, P4897, DOI 10.1021/ja980191u                                                               
   BENNETT AE, 1992, J CHEM PHYS, V96, P8624, DOI 10.1063/1.462267
   Berthet-Colominas C, 1999, EMBO J, V18, P1124, DOI 10.1093/emboj/18.5.1124
   Bjerring M, 2003, CHEM PHYS LETT, V370, P496, DOI 10.1016/S0009-2614(03)00103-9
   Brinkmann A, 2001, J CHEM PHYS, V115, P357, DOI 10.1063/1.1377031
   Brinkmann A, 2006, J AM CHEM SOC, V128, P14758, DOI 10.1021/ja065415k
   Brinkmann A, 2006, J PHYS CHEM B, V110, P16089, DOI 10.1021/jp062809p
   Carravetta M, 2000, CHEM PHYS LETT, V321, P205, DOI 10.1016/S0009-2614(00)00340-7
   Chan JCC, 2003, J CHEM PHYS, V118, P8378, DOI 10.1063/1.1565109
   Chou FC, 2009, J MAGN RESON, V197, P96, DOI 10.1016/j.jmr.2008.11.013
   De Paepe G, 2006, J AM CHEM SOC, V128, P1776, DOI 10.1021/ja0550430
   Deazevedo E.R., 2008, J CHEM PHYS, V128
   DESTRO R, 1988, J PHYS CHEM-US, V92, P966, DOI 10.1021/j100315a022                                                             
   Duma L, 2008, CHEMPHYSCHEM, V9, P1104, DOI 10.1002/cphc.200800053
   Dvinskikh SV, 2004, J MAGN RESON, V168, P194, DOI 10.1016/j.jmr.2004.03.001
   Eden M, 2003, CHEM PHYS LETT, V378, P55, DOI 10.1016/S0009-2614(03)01241-7
   Eden M, 1999, J CHEM PHYS, V111, P1511, DOI 10.1063/1.479410
   Eden M, 2009, J MAGN RESON, V200, P267, DOI 10.1016/j.jmr.2009.07.007
   Ernst M, 1996, J CHEM PHYS, V105, P3387, DOI 10.1063/1.472224                                                                
   Franks WT, 2005, J AM CHEM SOC, V127, P12291, DOI 10.1021/ja044497e
   Fu RQ, 1997, CHEM PHYS LETT, V272, P361, DOI 10.1016/S0009-2614(97)00537-X
   GULLION T, 1992, CHEM PHYS LETT, V194, P423, DOI 10.1016/0009-2614(92)86076-T
   GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1                                                    
   Han Y, 2010, J AM CHEM SOC, V132, P1976, DOI 10.1021/ja908687k
   HESTER RK, 1976, PHYS REV LETT, V36, P1081, DOI 10.1103/PhysRevLett.36.1081                                                     
   Hong M, 1997, J PHYS CHEM B, V101, P5869, DOI 10.1021/jp970887u                                                               
   Hou GJ, 2011, J AM CHEM SOC, V133, P3943, DOI 10.1021/ja108650x
   Hou G, 2010, PHYS CHEM CHEM PHYS, V12, P14873, DOI 10.1039/c0cp00795a
   Hu KN, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3176874
   Huster D, 2002, MAGNET RESON MED, V48, P624, DOI 10.1002/mrm.10272
   Igumenova TI, 2004, J AM CHEM SOC, V126, P5323, DOI 10.1021/ja030546w
   Ishii Y, 2000, J MAGN RESON, V142, P199, DOI 10.1006/jmre.1999.1976
   Ishii Y, 2001, J CHEM PHYS, V114, P8473, DOI 10.1063/1.1359445
   Ishii Y, 2001, J AM CHEM SOC, V123, P2921, DOI 10.1021/ja015505j
   Ishii Y., 2007, MAGN RESON CHEM, V45, pS221
   Jung J, 2010, BIOMOL NMR ASSIGN, V4, P21, DOI 10.1007/s12104-009-9198-9
   Lange A, 2009, CHEM PHYS LETT, V468, P100, DOI 10.1016/j.cplett.2008.11.089
   LEHMANN MS, 1972, J AM CHEM SOC, V94, P2657, DOI 10.1021/ja00763a016
   Levitt M.H., 2002, ENCY NMR, P165
   Lewandowski JR, 2007, J AM CHEM SOC, V129, P728, DOI 10.1021/ja0650394
   Lewandowski JR, 2009, J PHYS CHEM B, V113, P9062, DOI 10.1021/jp810280t
   Lewandowski JR, 2009, J AM CHEM SOC, V131, P5769, DOI 10.1021/ja806578y
   Lorieau JL, 2008, P NATL ACAD SCI USA, V105, P10366, DOI 10.1073/pnas.0800405105
   LOWE IJ, 1959, PHYS REV LETT, V2, P285, DOI 10.1103/PhysRevLett.2.285                                                       
   Madhu PK, 2001, CHEM PHYS LETT, V346, P142, DOI 10.1016/S0009-2614(01)00876-4
   Marulanda D, 2004, J AM CHEM SOC, V126, P16608, DOI 10.1021/ja0464589
   McDermott AE, 2004, CURR OPIN STRUC BIOL, V14, P554, DOI 10.1016/j.sbi.2004.09.007
   McDermott A, 2007, CURR OPIN STRUC BIOL, V17, P617, DOI 10.1016/j.sbi.2007.10.001
   METZ G, 1994, J MAGN RESON SER A, V110, P219, DOI 10.1006/jmra.1994.1208
   MUNOWITZ MG, 1981, J AM CHEM SOC, V103, P2529, DOI 10.1021/ja00400a007                                                             
   Neue G, 1997, SOLID STATE NUCL MAG, V7, P333, DOI 10.1016/S0926-2040(96)01291-X                                                   
   Nielsen AB, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3157737
   Reif B, 2003, J MAGN RESON, V160, P78, DOI 10.1016/S1090-7807(02)00035-6                                                   
   Reif B, 2001, J MAGN RESON, V151, P320, DOI 10.1006/jmre.2001.2354
   Samoson A, 2005, TOP CURR CHEM, V246, P15, DOI [10.1007/b98647, 10.1007/b98467]
   Samoson A, 2001, SOLID STATE NUCL MAG, V20, P130, DOI 10.1006/snmr.2001.0037
   Schanda P, 2011, J MAGN RESON, V210, P246, DOI 10.1016/j.jmr.2011.03.015
   Schanda P, 2010, J AM CHEM SOC, V132, P15957, DOI 10.1021/ja100726a
   SCHMIDT-ROHR K, 1992, MACROMOLECULES, V25, P3273, DOI 10.1021/ma00038a037                                                             
   Schnell I, 2004, PROG NUCL MAG RES SP, V45, P145, DOI 10.1016/j.pnmrs.2004.06.003
   Scholz I, 2008, CHEM PHYS LETT, V460, P278, DOI 10.1016/j.cplett.2008.05.058
   Sun SJ, 2009, J AM CHEM SOC, V131, P10113, DOI 10.1021/ja902003u
   TEKELY P, 1986, J PHYS CHEM-US, V90, P5608, DOI 10.1021/j100280a026                                                             
   Ternois F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967
   Thiriot DS, 2004, J MOL BIOL, V341, P869, DOI 10.1016/j.jmb.2004.06.038
   TYCKO R, 1990, CHEM PHYS LETT, V173, P461, DOI 10.1016/0009-2614(90)87235-J                                                    
   Tycko R, 2003, PROG NUCL MAG RES SP, V42, P53, DOI 10.1016/S0079-6565(03)00003-7
   Tycko R, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2437194
   van Rossum BJ, 2000, J AM CHEM SOC, V122, P3465
   Verel R, 2001, J MAGN RESON, V150, P81, DOI 10.1006/jmre.2001.2310
   Wei YF, 2002, J MAGN RESON, V158, P23, DOI 10.1016/S1090-7807(02)00056-3                                                   
   Weingarth M, 2009, CHEM PHYS LETT, V469, P342, DOI 10.1016/j.cplett.2008.12.084
   Yang J, 2009, J AM CHEM SOC, V131, P13690, DOI 10.1021/ja9037802
   Zhao X, 2001, J AM CHEM SOC, V123, P11097, DOI 10.1021/ja016328p
   Zhao X, 2001, CHEM PHYS LETT, V342, P353, DOI 10.1016/S0009-2614(01)00593-0                                                   
   Zhou DH, 2008, ANGEW CHEM INT EDIT, V47, P7328, DOI 10.1002/anie.200802108
   Zhou DH, 2009, ANGEW CHEM INT EDIT, V48, P1253, DOI 10.1002/anie.200801029
   ZUMBULYADIS N, 1986, PHYS REV B, V33, P6495, DOI 10.1103/PhysRevB.33.6495
NR 83
TC 44
Z9 44
U1 6
U2 65
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 23
PY 2011
VL 133
IS 46
BP 18646
EP 18655
DI 10.1021/ja203771a
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 853AP
UT WOS:000297398900035
PM 21995349
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhang, XP
   Ma, XM
   Dou, F
   Zhao, PX
   Liu, HM
AF Zhang, Xinping
   Ma, Xuemei
   Dou, Fei
   Zhao, Pengxiang
   Liu, Hongmei
TI A Biosensor Based on Metallic Photonic Crystals for the Detection of
   Specific Bioreactions
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID PLASMON RESONANCE; NANOHOLE ARRAYS; REAL-TIME; NANOIMPRINT LITHOGRAPHY;
   GOLD NANOPARTICLES; WAVE-GUIDE; LARGE-AREA; METAMATERIALS; TRANSMISSION;
   SENSITIVITY
AB An optical biosensor based on waveguided metallic photonic crystals (MPCs) is reported for the sensitive testing of biomolecular interactions, which provides practical approaches for the label-free detection of specific bioreactions. The enhancement of the sensitivity or the amplification of the sensor signal by the coupling between the waveguide resonance mode and particle-plasmon resonance (PPR) breaks through the bottle-neck of the intrinsic response sensitivity defined by the spectral shift of the PPR. The success of this sensor is demonstrated by sensing the specific reaction between the HIV-1 capsid protein (p24) antigen and the monoclonal anti-p24 antibody, where the dynamics of the bioreactions can be recorded with a potentially high time resolution. This new sensor stands out due to its compact design and its new physics, compared with conventional devices, its simple operation, the simple fabrication of the MPC chip and the low cost of the whole system.
C1 [Zhang, Xinping; Dou, Fei; Liu, Hongmei] Beijing Univ Technol, Coll Appl Sci, Beijing 100124, Peoples R China.
   [Ma, Xuemei; Zhao, Pengxiang] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China.
RP Zhang, XP (reprint author), Beijing Univ Technol, Coll Appl Sci, Beijing 100124, Peoples R China.
EM zhangxinping@bjut.edu.cn
FU High-Tech Research and Development Program of China [2007AA03Z306];
   National Science Foundation of China [11074018]; Beijing Educational
   Commission [KZ200810005004]; Program for New Century Excellent Talents
   in University (NCET); Research Fund for the Doctoral Program of Higher
   Education of China (RFDP) [20091103110012]
FX This work was supported by the High-Tech Research and Development
   Program of China (2007AA03Z306), the National Science Foundation of
   China (11074018), the Beijing Educational Commission (KZ200810005004),
   the Program for New Century Excellent Talents in University (NCET) and
   the Research Fund for the Doctoral Program of Higher Education of China
   (RFDP, 20091103110012).
CR Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162
   Brolo AG, 2004, LANGMUIR, V20, P4813, DOI 10.1021/la0493621
   Chien FC, 2007, BIOSENS BIOELECTRON, V22, P2737, DOI 10.1016/j.bios.2006.11.021
   Christ A, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.125113
   Christ A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.183901
   De Leebeeck A, 2007, ANAL CHEM, V79, P4094, DOI 10.1021/ac070001a
   Gordon R, 2008, ACCOUNTS CHEM RES, V41, P1049, DOI 10.1021/ar800074d
   Guo HC, 2005, APPL PHYS B-LASERS O, V81, P271, DOI 10.1007/s00340-005-1817-2
   Ji J, 2008, ANAL CHEM, V80, P2491, DOI 10.1021/ac7023206
   Johansen K, 2000, REV SCI INSTRUM, V71, P3530, DOI 10.1063/1.1287631
   Kabashin AV, 2009, NAT MATER, V8, P867, DOI [10.1038/nmat2546, 10.1038/NMAT2546]
   Linden S, 2001, APPL PHYS B-LASERS O, V73, P311, DOI 10.1007/s003400100653
   Liu N, 2010, NANO LETT, V10, P1103, DOI 10.1021/nl902621d
   Lucas BD, 2008, ADV MATER, V20, P1129, DOI 10.1002/adma.200700225
   Luk'yanchuk B, 2010, NAT MATER, V9, P707, DOI [10.1038/NMAT2810, 10.1038/nmat2810]
   Malyarchuk V, 2005, OPT EXPRESS, V13, P5669, DOI 10.1364/OPEX.13.005669                                                          
   McFarland AD, 2003, NANO LETT, V3, P1057, DOI 10.1021/nl034372s
   McPhillips J, 2010, ACS NANO, V4, P2210, DOI 10.1021/nn9015828
   Nau D, 2010, OPT LETT, V35, P3150, DOI 10.1364/OL.35.003150
   Oulton RF, 2008, NAT PHOTONICS, V2, P496, DOI 10.1038/nphoton.2008.131
   Pang ZG, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/14/145303
   Park DK, 2010, LANGMUIR, V26, P6119, DOI 10.1021/la100598v
   Schnell M, 2009, NAT PHOTONICS, V3, P287, DOI 10.1038/NPHOTON.2009.46
   Stark PRH, 2005, METHODS, V37, P37, DOI 10.1016/j.ymeth.2005.05.006
   Stewart ME, 2006, P NATL ACAD SCI USA, V103, P17143, DOI 10.1073/pnas.0606216103
   Tetz KA, 2006, OPT LETT, V31, P1528, DOI 10.1364/OL.31.001528
   Yang JC, 2008, NANO LETT, V8, P2718, DOI 10.1021/nl801043t
   Yu NF, 2008, NAT PHOTONICS, V2, P564, DOI 10.1038/nphoton.2008.152
   Zentgraf T, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.195415
   Zhang XP, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2717567
   Zhang XP, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/42/425303
   Zhang XP, 2006, NANO LETT, V6, P651, DOI 10.1021/nl052361o
NR 32
TC 39
Z9 43
U1 2
U2 120
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1616-301X
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD NOV 22
PY 2011
VL 21
IS 22
BP 4219
EP 4227
DI 10.1002/adfm.201101366
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 849AV
UT WOS:000297097900003
DA 2018-01-05
ER

PT J
AU Emani, PS
   Olsen, GL
   Varani, G
   Drobny, GP
AF Emani, Prashant S.
   Olsen, Gregory L.
   Varani, Gabriele
   Drobny, Gary P.
TI Theory of Nonrigid Rotational Motion Applied to NMR Relaxation in RNA
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID TAR RNA; SOLID-STATE; MOLECULAR-DYNAMICS; C-13 RELAXATION;
   BROWNIAN-MOTION; RECOGNITION; DNA; SPECTROSCOPY; DIFFUSION; COUPLINGS
AB Solution NMR spectroscopy can elucidate many features of the structure and dynamics of macromolecules, yet relaxation measurements, the most common source of experimental information on dynamics, can sample only certain ranges of dynamic rates. A complete characterization of motion of a macromolecule thus requires the introduction of complementary experimental approaches. Solid-state NMR spectroscopy successfully probes the time scale of nanoseconds to microseconds, a dynamic window where solution NMR results have been deficient, and probes conditions where the averaging effects of rotational diffusion of the molecule are absent. Combining the results of the two distinct techniques within a single framework provides greater insight into dynamics, but this task requires the common interpretation of results recorded under very different experimental conditions. Herein, we provide a unified description of dynamics that is robust to the presence of large-scale conformational exchange, where the diffusion tensor of the molecule varies on a time scale comparable to rotational diffusion in solution. We apply this methodology to the HIV-1 TAR RNA molecule, where conformational rearrangements are both substantial and functionally important. The formalism described herein is of greater generality than earlier combined solid-state/solution NMR interpretations, if detailed molecular structures are available, and can offer a more complete description of RNA dynamics than either solution or solid-state NMR spectroscopy alone.
C1 [Emani, Prashant S.; Drobny, Gary P.] Univ Washington, Dept Phys, Seattle, WA 98195 USA.
   [Olsen, Gregory L.; Varani, Gabriele; Drobny, Gary P.] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Varani, Gabriele] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
RP Drobny, GP (reprint author), Univ Washington, Dept Phys, Box 351700, Seattle, WA 98195 USA.
EM drobny@chem.washington.edu
RI Olsen, Greg/B-7525-2008
OI Olsen, Greg/0000-0001-6039-8434
FU NSF [MCB-0642253]; NIH [RO1-EB03152]
FX This work was supported by grants from the NSF (MCB-0642253) and NIH
   (RO1-EB03152) to G.P.D. and G.V. We are grateful to Michael Bardaro for
   providing the TAR relaxation data and error analysis and to Jason Ash
   and Dorothy Echodu for helpful discussions and suggestions.
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Al-Hashimi HM, 2007, BIOPOLYMERS, V86, P345, DOI 10.1002/bip.20754
   Bardaro MF, 2009, NUCLEIC ACIDS RES, V37, P1529, DOI 10.1093/nar/gkn1074
   Blackledge M, 2005, PROG NUCL MAG RES SP, V46, P23, DOI 10.1016/j.pnmrs.2004.11.002
   Bothe JR, 2011, J AM CHEM SOC, V133, P2016, DOI 10.1021/ja1073068
   Brodsky AS, 1997, J MOL BIOL, V267, P624, DOI 10.1006/jmbi.1996.0879
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   Dethoff EA, 2008, BIOPHYS J, V95, P3906, DOI 10.1529/biophysj.108.140285
   Emani PS, 2010, J PHYS CHEM B, V114, P15991, DOI 10.1021/jp107193z
   Falb M, 2010, NUCLEIC ACIDS RES, V38, P6274, DOI 10.1093/nar/gkq380
   FAVRO LD, 1960, PHYS REV, V119, P53, DOI 10.1103/PhysRev.119.53                                                          
   FREED JH, 1964, J CHEM PHYS, V41, P2077, DOI 10.1063/1.1726208
   Greenleaf WJ, 2008, SCIENCE, V319, P630, DOI 10.1126/science.1151298
   Hennig M, 2000, NUCLEIC ACIDS RES, V28, P1585, DOI 10.1093/nar/28.7.1585
   HUNTRESS WT, 1968, J CHEM PHYS, V48, P3524, DOI 10.1063/1.1669645                                                               
   Jackson J. D., 1998, CLASSICAL ELECTRODYN
   KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5
   Koplin J, 2005, STRUCTURE, V13, P1255, DOI 10.1016/j.str.2005.05.015
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041
   Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680
   MILLERO FJ, 1971, J CHEM ENG DATA, V16, P85, DOI 10.1021/je60048a006                                                             
   Olsen GL, 2008, J AM CHEM SOC, V130, P2896, DOI 10.1021/ja0778803
   Olsen GL, 2010, J AM CHEM SOC, V132, P303, DOI 10.1021/ja907515s
   Olsen GL, 2009, J BIOMOL NMR, V45, P133, DOI 10.1007/s10858-009-9355-6
   Pederson K, 2008, J AM CHEM SOC, V130, P9072, DOI 10.1021/ja801243d
   Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Razga F, 2006, STRUCTURE, V14, P825, DOI 10.1016/j.str.2006.02.012
   Rose M. E., 1957, ELEMENTARY THEORY AN
   Shajani Z, 2008, BIOCHEMISTRY-US, V47, P7617, DOI 10.1021/bi7020469
   Shajani Z, 2007, BIOPOLYMERS, V86, P348, DOI 10.1002/bip.20650
   Shajani Z, 2006, TRENDS BIOCHEM SCI, V31, P421, DOI 10.1016/j.tibs.2006.06.002
   Stelzer AC, 2009, METHODS, V49, P167, DOI 10.1016/j.ymeth.2009.08.006
   Stoddard CD, 2010, STRUCTURE, V18, P787, DOI 10.1016/j.str.2010.04.006
   Tinkham M, 1964, GROUP THEORY QUANTUM
   Tugarinov V, 2001, J AM CHEM SOC, V123, P3055, DOI 10.1021/ja003803v
   WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390                                                               
   Wong V, 2009, P NATL ACAD SCI USA, V106, P11016, DOI 10.1073/pnas.0809994106
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2008, NAT METHODS, V5, P243, DOI 10.1038/NMETH.1180
   Zhang Q, 2007, NATURE, V450, P1263, DOI 10.1038/nature06389
   Zhang Q, 2009, RNA, V15, P1941, DOI 10.1261/rna.1806909
NR 46
TC 10
Z9 10
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD NOV 10
PY 2011
VL 115
IS 44
BP 12055
EP 12069
DI 10.1021/jp204499x
PG 15
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 839TY
UT WOS:000296393500001
PM 21870804
OA green_accepted
DA 2018-01-05
ER

PT J
AU Gonzalez, G
   DaFonseca, S
   Errazuriz, E
   Coric, P
   Souquet, F
   Turcaud, S
   Boulanger, P
   Bouaziz, S
   Hong, SS
AF Gonzalez, Gaelle
   DaFonseca, Sandrina
   Errazuriz, Elisabeth
   Coric, Pascale
   Souquet, Florence
   Turcaud, Serge
   Boulanger, Pierre
   Bouaziz, Serge
   Hong, Saw See
TI Characterization of a Novel Type of HIV-1 Particle Assembly Inhibitor
   Using a Quantitative Luciferase-Vpr Packaging-Based Assay
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BACULOVIRUS-INFECTED CELLS; BETULINIC
   ACID-DERIVATIVES; ALPHA-HELICAL STRUCTURE; GAG PRECURSOR; IN-VITRO;
   ADENOVIRUS DODECAHEDRON; VIRION INCORPORATION; FUSION PROTEINS;
   REGULATORY PROTEIN
AB The HIV-1 auxiliary protein Vpr and Vpr-fusion proteins can be copackaged with Gag precursor (Pr55Gag) into virions or membrane-enveloped virus-like particles (VLP). Taking advantage of this property, we developed a simple and sensitive method to evaluate potential inhibitors of HIV-1 assembly in a living cell system. Two proteins were coexpressed in recombinant baculovirus-infected Sf9 cells, Pr55Gag, which formed the VLP backbone, and luciferase fused to the N-terminus of Vpr (LucVpr). VLP-encapsidated LucVpr retained the enzymatic activity of free luciferase. The levels of luciferase activity present in the pelletable fraction recovered from the culture medium correlated with the amounts of extracellular VLP released by Sf9 cells assayed by conventional immunological methods. Our luciferase-based assay was then applied to the characterization of betulinic acid (BA) derivatives that differed from the leader compound PA-457 (or DSB) by their substituant on carbon-28. The beta-alanine-conjugated and lysine-conjugated DSB could not be evaluated for their antiviral potentials due to their high cytotoxicity, whereas two other compounds with a lesser cytotoxicity, glycine-conjugated and epsilon-NH-Boc-lysine-conjugated DSB, exerted a dose-dependent negative effect on VLP assembly and budding. A fifth compound with a low cytotoxicity, EP-39 (ethylene diamine-conjugated DSB), showed a novel type of antiviral effect. EP-39 provoked an aberrant assembly of VLP, resulting in nonenveloped, morula-like particles of 100-nm in diameter. Each morula was composed of nanoparticle subunits of 20-nm in diameter, which possibly mimicked transient intermediates of the HIV-1 Gag assembly process. Chemical cross-linking in situ suggested that EP-39 favored the formation or/and persistence of Pr55Gag trimers over other oligomeric species. EP-39 showed a novel type of negative effect on HIV-1 assembly, targeting the Pr55Gag oligomerisation. The biological effect of EP-39 underlined the critical role of the nature of the side chain at position 28 of BA derivatives in their anti-HIV-1 activity.
C1 [Gonzalez, Gaelle; Errazuriz, Elisabeth] Univ Lyon 1, Fac Med, Ctr Commun Imagerie Laennec, F-69365 Lyon, France.
   [Gonzalez, Gaelle; DaFonseca, Sandrina; Boulanger, Pierre; Hong, Saw See] INRA, UMR 754, Lyon, France.
   [Coric, Pascale; Bouaziz, Serge] Univ Paris 05, UFR Sci Pharmaceut & Biol, CNRS, Lab Cristallog & RMN Biol,UMR 8015, Paris, France.
   [Souquet, Florence; Turcaud, Serge] Univ Paris 05, UFR Sci Pharmaceut & Biol, CNRS, Lab Synth & Struct Mol Interet Pharmacol,UMR 8638, Paris, France.
RP Gonzalez, G (reprint author), Univ Lyon 1, Fac Med, Ctr Commun Imagerie Laennec, F-69365 Lyon, France.
EM serge.bouaziz@parisdescartes.fr; sawsee.hong@univ-lyon1.fr
RI Hong, Saw See/M-9818-2017; bouaziz, serge/C-1401-2014
OI Hong, Saw See/0000-0001-8871-0901; 
FU French AIDS foundation (SIDACTION) [A/19-3-01541]; Agence Nationale de
   Recherche sur le SIDA (ANRS) [DendrAde]; French Foundation for Cystic
   Fibrosis
FX This work has been supported by the French AIDS foundation
   (SIDACTION-contract A/19-3-01541) and the Agence Nationale de Recherche
   sur le SIDA (ANRS, Grant DendrAde 2007-2008). SDF was the recipient of
   an ANRS fellowship, and GG was the recipient of a fellowship from the
   French Foundation for Cystic Fibrosis (Vaincre la Mucoviscidose). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Accola MA, 1999, J VIROL, V73, P9992
   Accola MA, 1998, J VIROL, V72, P2072
   Adamson CS, 2007, ADV PHARMACOL, V55, P347, DOI 10.1016/S1054-3589(07)55010-6
   Adamson CS, 2006, J VIROL, V80, P10957, DOI 10.1128/JVI.01369-06
   Adamson CS, 2010, ANTIVIR RES, V85, P119, DOI 10.1016/j.antiviral.2009.09.009
   Adamson CS, 2009, J VIROL, V83, P4884, DOI 10.1128/JVI.02659-08
   Adamson CS, 2004, REV MED VIROL, V14, P107, DOI 10.1002/rmv.418
   Aguiar RS, 2008, J BIOL CHEM, V283, P2518, DOI 10.1074/jbc.M706436200
   Aiken C, 2005, TRENDS MOL MED, V11, P31, DOI 10.1016/j.molmed.2004.11.001
   Alfadhli A, 2005, J VIROL, V79, P14498, DOI 10.1128/JVI.79.23.14498-14506.2005
   Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083
   Briggs JAG, 2006, J MOL BIOL, V355, P157, DOI 10.1016/j.jmb.2005.10.025
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   CARRIERE C, 1995, J VIROL, V69, P2366
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   CHAZAL N, 1994, J VIROL, V68, P111
   CHAZAL N, 1995, J VIROL, V69, P365
   Cimarelli A, 2002, CELL MOL LIFE SCI, V59, P1166, DOI 10.1007/s00018-002-8495-6
   COHEN EA, 1990, J VIROL, V64, P3097
   DaFonseca S, 2007, ANTIVIR THER, V12, P1185
   DaFonseca S, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-162
   de Marco A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001215
   Dorr CR, 2011, BIOORG MED CHEM LETT, V21, P542, DOI 10.1016/j.bmcl.2010.10.078
   Fender P, 1997, NAT BIOTECHNOL, V15, P52, DOI 10.1038/nbt0197-52                                                              
   Fender P, 2003, J VIROL, V77, P4960, DOI 10.1128/JVI.77.8.4960-4964.2003
   Fender P, 2008, VIROLOGY, V371, P155, DOI 10.1016/j.virol.2007.09.026
   Fritz JV, 2010, J VIROL, V84, P1585, DOI 10.1128/JVI.01691-09
   Gay B, 1998, VIROLOGY, V247, P160, DOI 10.1006/viro.1998.9237
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Greene WC, 2008, ANTIVIR RES, V80, P251, DOI 10.1016/j.antiviral.2008.08.003
   HONG SS, 1993, J VIROL, V67, P2787
   Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294
   Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069                                                     
   JACOBS E, 1989, GENE, V79, P71, DOI 10.1016/0378-1119(89)90093-0
   Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001
   Jeong HJ, 1999, BIOORG MED CHEM LETT, V9, P1201, DOI 10.1016/S0960-894X(99)00165-1
   Kanamoto T, 2001, ANTIMICROB AGENTS CH, V45, P1225, DOI 10.1128/AAC.45.4.1225-1230.2001
   Kashiwada Y, 1996, J MED CHEM, V39, P1016, DOI 10.1021/jm950922q
   Keller PW, 2011, J VIROL, V85, P1420, DOI 10.1128/JVI.01926-10
   KLIKOVA M, 1995, J VIROL, V69, P1093
   KNOLLER S, 1991, J BIOL CHEM, V266, P2795
   Kobinger GP, 1998, J VIROL, V72, P5441
   Labrosse B, 1997, J VIROL, V71, P8230
   Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102
   LAVALLEE C, 1994, J VIROL, V68, P1926
   Le Rouzic E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-11
   Li F, 2003, P NATL ACAD SCI USA, V100, P13555, DOI 10.1073/pnas.2234683100
   Li F, 2006, VIROLOGY, V356, P217, DOI 10.1016/j.virol.2006.07.023
   LU YL, 1993, J VIROL, V67, P6542
   LU YL, 1995, J VIROL, V69, P6873
   MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794
   MAYAUX JF, 1994, P NATL ACAD SCI USA, V91, P3564, DOI 10.1073/pnas.91.9.3564
   Morellet N, 2005, PROTEIN SCI, V14, P375, DOI 10.1110/ps.041087605
   Morellet N, 2003, J MOL BIOL, V327, P215, DOI 10.1016/S0022-2836(03)00060-3                                                   
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Muller B, 2000, J VIROL, V74, P9727, DOI 10.1128/JVI.74.20.9727-9731.2000
   Muriaux D, 2004, CURR PHARM DESIGN, V10, P3725, DOI 10.2174/1381612043382701
   Muriaux D, 2001, P NATL ACAD SCI USA, V98, P5246, DOI 10.1073/pnas.091000398
   PAXTON W, 1993, J VIROL, V67, P7229
   Perrin-Tricaud C, 1999, VIROLOGY, V255, P20, DOI 10.1006/viro.1998.9573                                                          
   Peytavi R, 1999, J BIOL CHEM, V274, P1635, DOI 10.1074/jbc.274.3.1635
   ROYER M, 1992, J VIROL, V66, P3230
   ROYER M, 1991, VIROLOGY, V184, P417, DOI 10.1016/0042-6822(91)90861-5
   Royer M, 1997, J GEN VIROL, V78, P131, DOI 10.1099/0022-1317-78-1-131                                                      
   Sakalian M, 2006, J VIROL, V80, P5716, DOI 10.1128/JVI.02743-05
   Sakuragi S, 2006, MICROBES INFECT, V8, P1875, DOI 10.1016/j.micinf.2006.02.027
   Selig L, 1999, J VIROL, V73, P592
   Shvadchak V, 2009, BIOCHIMIE, V91, P916, DOI 10.1016/j.biochi.2009.04.014
   Singh SP, 2000, J VIROL, V74, P10650, DOI 10.1128/JVI.74.22.10650-10657.2000
   Soler F, 1996, J MED CHEM, V39, P1069, DOI 10.1021/jm950669u
   Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964
   Swanson CM, 2004, EMBO J, V23, P2632, DOI 10.1038/sj.emboj.7600270
   Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10
   Tang C, 2003, J MOL BIOL, V327, P1013, DOI 10.1016/S0022-2836(03)00289-4
   Ternois F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967
   TURCAUD S, 2011, J MED CHEM UNPUB
   Votteler J, 2007, J VIROL, V81, P9572, DOI 10.1128/JVI.02803-06
   Wainberg MA, 2009, ANTIVIR RES, V81, P1, DOI 10.1016/j.antiviral.2008.09.003
   WANG CT, 1994, VIROLOGY, V200, P524, DOI 10.1006/viro.1994.1215
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   WU XY, 1995, J VIROL, V69, P3389
   Yao Xiao-Jian, 2004, Retrovirology, V1, P21, DOI 10.1186/1742-4690-1-21
   Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988                                                           
   YAO XJ, 1995, J VIROL, V69, P7032
   Yuan XO, 2004, VIROLOGY, V324, P525, DOI 10.1016/j.virol.2004.04.009
   Zhou J, 2004, J VIROL, V78, P922, DOI 10.1128/JVI.78.2.922-929.2004
   Zhou Jing, 2004, Retrovirology, V1, P15, DOI 10.1186/1742-4690-1-15
   ZHOU X, 1994, J VIROL, V68, P2556
NR 88
TC 5
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 3
PY 2011
VL 6
IS 11
AR e27234
DI 10.1371/journal.pone.0027234
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 850LV
UT WOS:000297197000035
PM 22073298
OA gold
DA 2018-01-05
ER

PT J
AU Sullad, AG
   Manjeshwar, LS
   Aminabhavi, TM
AF Sullad, Anita G.
   Manjeshwar, Lata S.
   Aminabhavi, Tejraj M.
TI Novel Semi-interpenetrating Microspheres of Dextran-grafted-Acrylamide
   and Poly(Vinyl Alcohol) for Controlled Release of Abacavir Sulfate
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article
ID DRUG-DELIVERY-SYSTEMS; GUAR GUM MATRICES; HYDROGEL MICROSPHERES; BLEND
   MICROSPHERES; CHITOSAN; THEOPHYLLINE; NANOPARTICLES; TRANSPORT
AB A novel drug delivery system using semi-interpenetrating (semi-IPN) microspheres of dextran-grafted-acrylamide (Dex-g-AArn) and poly(vinyl alcohol) (PVA) was prepared in the size range of 80-100 mu m by emulsion cross-linking for investigating controlled release (CR) of an anti-HIV agent, abacavir sulfate. The graft copolymer was confirmed by Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). The microspheres were characterized for morphology, swelling, and in vitro release of abacavir sulfate in pH 1.2 and 7.4 buffer media to display the effect of drug release in acidic and alkaline conditions. The kinetics of in vitro release was analyzed using the empirical equations to understand the nature of release mechanism.
C1 [Sullad, Anita G.; Manjeshwar, Lata S.] Karnatak Univ, Dept Chem, Dharwad 580003, Karnataka, India.
   [Aminabhavi, Tejraj M.] SETs Coll Pharm, Dharwad 580002, Karnataka, India.
RP Manjeshwar, LS (reprint author), Karnatak Univ, Dept Chem, Dharwad 580003, Karnataka, India.
EM latamanjeshwar@yahoo.com
FU University Grants Commission (UGC), New Delhi, India
   [KU/SCH/UGC/RFSMS/2008-09]; CSIR, New Delhi [21(0760)/09/EMR-II]
FX A.G.S. is thankful to University Grants Commission (UGC), New Delhi,
   India (KU/SCH/UGC/RFSMS/2008-09) for a fellowship. T.M.A. thanks CSIR
   [21(0760)/09/EMR-II], New Delhi for the award of Emeritus Scientist.
CR Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Agnihotri SA, 2006, EUR J PHARM BIOPHARM, V63, P249, DOI 10.1016/j.ejpb.12.008
   Cascone MG, 2002, J MATER SCI-MATER M, V13, P265, DOI 10.1023/A:1014006800514                                                         
   Cascone MG, 1999, J MATER SCI-MATER M, V10, P301, DOI 10.1023/A:1008961614439                                                         
   Fares MM, 2010, J THERM ANAL CALORIM, V99, P659, DOI 10.1007/s10973-009-0213-2
   Gao BJ, 2004, COLLOID POLYM SCI, V282, P1008, DOI 10.1007/s00396-003-1025-8
   Jeong YI, 2006, ARCH PHARM RES, V29, P712, DOI 10.1007/BF02968257
   Kosmidis K, 2003, INT J PHARM, V254, P183, DOI 10.1016/S0378-5173(03)00030-9
   Kulkarni AR, 1999, J APPL POLYM SCI, V73, P2437, DOI 10.1002/(SICI)1097-4628(19990919)73:12<2437::AID-APP12>3.0.CO;2-7               
   Kumashiro Y, 2001, BIOMACROMOLECULES, V2, P874, DOI 10.1021/bm015527y
   Lee PW, 2010, BIOMATERIALS, V31, P2425, DOI 10.1016/j.biomaterials.2009.11.100
   Maswadeh Hamzah M, 2006, Acta Pol Pharm, V63, P63
   Mundargi RC, 2007, DRUG DEV IND PHARM, V33, P79, DOI 10.1080/03639040600975030
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   Rokhade AP, 2007, J MICROENCAPSUL, V24, P274, DOI 10.1080/02652040701281365
   Rokhade AP, 2007, CARBOHYD POLYM, V67, P605, DOI 10.1016/j.carbpol.2006.07.001
   Soppimath KS, 2001, J CONTROL RELEASE, V75, P331, DOI 10.1016/S0168-3659(01)00404-7
   Soppirnath KS, 2002, EUR J PHARM BIOPHARM, V53, P87, DOI 10.1016/S0939-6411(01)00205-3
   Sullad AG, 2010, IND ENG CHEM RES, V49, P7323, DOI 10.1021/ie100389v
   Sullad AG, 2010, J APPL POLYM SCI, V117, P1361, DOI 10.1002/app.31866
   Sullad AG, 2010, J APPL POLYM SCI, V116, P1226, DOI 10.1002/app.29625
   Sutar PB, 2008, J MATER SCI-MATER M, V19, P2247, DOI 10.1007/s10856-007-3162-y
   Zhao L, 2006, CARBOHYD POLYM, V64, P473, DOI 10.1016/j.carbpol.2005.12.014
NR 23
TC 5
Z9 6
U1 2
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD NOV 2
PY 2011
VL 50
IS 21
BP 11778
EP 11784
DI 10.1021/ie2006438
PG 7
WC Engineering, Chemical
SC Engineering
GA 836RH
UT WOS:000296128300002
DA 2018-01-05
ER

PT J
AU Sharma, P
   Garg, S
AF Sharma, Puneet
   Garg, Sanjay
TI Pure drug and polymer based nanotechnologies for the improved
   solubility, stability, bioavailability and targeting of anti-HIV drugs
   (vol 62, pg 491, 2010)
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Correction
C1 [Sharma, Puneet; Garg, Sanjay] Univ Auckland, Sch Pharm, Auckland 1, New Zealand.
RP Garg, S (reprint author), Univ Auckland, Sch Pharm, Auckland 1, New Zealand.
EM s.garg@auckland.ac.nz
CR Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
NR 1
TC 1
Z9 1
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD NOV
PY 2011
VL 63
IS 14-15
BP 1372
EP 1372
DI 10.1016/j.addr.2011.06.007
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 873GW
UT WOS:000298870100013
DA 2018-01-05
ER

PT J
AU Todorova, R
AF Todorova, Roumiana
TI Comparative analysis of the methods of drug and protein delivery for the
   treatment of cancer, genetic diseases and diagnostics
SO DRUG DELIVERY
LA English
DT Review
DE Electroporation; nanoparticles; cell-penetrating peptides; treatment of
   cancer; gene therapy; vitamin-mediated targeting; ultrasonic drug
   delivery
ID CELL-PENETRATING PEPTIDES; PERMEABLE MINIATURE PROTEINS; HUMAN
   IMMUNODEFICIENCY VIRUS; III SECRETION MACHINES; MAMMALIAN-CELLS;
   INTRACELLULAR DELIVERY; CHITOSAN NANOPARTICLES; ADHERENT CELLS;
   NUCLEIC-ACIDS; IN-VITRO
AB The methods of protein and drug delivery for the treatment of cancer, genetic diseases and diagnostics were summarized. The potential of protein transduction is discussed and the recent developments in the field are reviewed. An overview is provided of the non-viral delivery methods such as liposomes, polymer-based delivery, cell-penetrating peptides, bacterial secretion, cells, virosomes, physical methods including electroporation, microinjection, osmotic lysis, nanoparticles, sonoporation to locally inject therapeutic molecules. The characteristic properties of non-viral vectors and their use for the delivery of therapeutic molecules for the diagnosis and treatment of disorders and to target tumors are also discussed. The potential of the transduced peptides and proteins was used as new therapeutic compounds against infectious diseases, to complement deficiencies in specific genes, to specifically kill tumour cells, for gene therapy. The protein delivery vectors can enhance the transfection at low concentrations and help to develop future gene delivery systems with reduced toxicity. Vitamin B12, folic acid, biotin, and riboflavin are essential in the treatment of cancer. Ultrasound has a potential in the delivery of therapeutic agents. The new developing technologies of drug delivery and targeting offer the possibility to improve the therapeutic possibilities of the existing drugs and to develop novel therapeutics.
C1 Bulgarian Acad Sci, Inst Biophys & Biomed Engn, BU-1113 Sofia, Bulgaria.
RP Todorova, R (reprint author), Bulgarian Acad Sci, Inst Biophys & Biomed Engn, BU-1113 Sofia, Bulgaria.
EM todorova@bio21.bas.bg
RI Todorova, Roumiana/M-2449-2017
CR Alonso-Sande M, 2006, MACROMOLECULES, V39, P4152, DOI 10.1021/ma060230j
   Babizhayev Mark A, 2010, Recent Pat Drug Deliv Formul, V4, P198
   Bright GR, 1996, CYTOMETRY, V24, P226, DOI 10.1002/(SICI)1097-0320(19960701)24:3<226::AID-CYTO5>3.3.CO;2-Y
   Buse J, 2010, NANOMEDICINE-UK, V5, P1237, DOI [10.2217/nnm.10.107, 10.2217/NNM.10.107]
   Xu G, 2006, EUR J PHARM SCI, V27, P4311
   Caron NJ, 2001, MOL THER, V3, P3310
   Cassinelli G, 2006, MOL CANCER THER, V5, P2388, DOI 10.1158/1535-7163.MCT-06-0245
   Chandna P, 2007, MOL PHARM, V4, P668, DOI 10.1021/mp070053o
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   Clark DD, 2002, J PROTEOME RES, V1, P207, DOI 10.1021/pr0255093
   Coulberson AL, 2003, J CONTROL RELEASE, V86, P361, DOI 10.1016/S0168-3659(02)00417-0
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   Cronican JJ, 2010, ACS CHEM BIOL, V5, P747, DOI 10.1021/cb1001153
   Cuna M, 2006, J NANOSCI NANOTECHNO, V6, P2887, DOI 10.1166/jnn.2006.435
   Dalkara D, 2006, J CONTROL RELEASE, V116, P353, DOI 10.1016/j.jconrel.2006.10.005
   Daniels DS, 2007, J AM CHEM SOC, V129, P14578, DOI 10.1021/ja0772445
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   Delom F, 2007, BIOCHEM BIOPH RES CO, V352, P587, DOI 10.1016/j.bbrc.2006.11.046
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2005, CURR PHARM DESIGN, V11, P3629, DOI 10.2174/138161205774580741                                                      
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dudek AZ, 2010, TRANSL RES, V156, P136, DOI 10.1016/j.trsl.2010.07.003
   Dudek NL, 2010, CURR PHARM DESIGN, V16, P3149
   Eksioglu-Demiralp E, 2003, J IMMUNOL METHODS, V275, P41, DOI 10.1016/S0022-1759(02)00554-9
   El Andaloussi S, 2007, NAT PROTOC, V2, P2043, DOI 10.1038/nprot.2007.302
   El-Andaloussi S, 2007, MOL THER, V15, P1820, DOI 10.1038/sj.mt.6300255
   El-Andaloussi S, 2006, J GENE MED, V8, P1262, DOI 10.1002/jgm.950
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2007, PROTEIN ENG DES SEL, V20, P505, DOI 10.1093/protein/gzm051
   Fuchs SM, 2007, ACS CHEM BIOL, V2, P167, DOI 10.1021/cb600429k
   Futami J, 2005, J BIOSCI BIOENG, V99, P95, DOI 10.1263/jbb.99.095
   GABEL CA, 1986, J CELL BIOL, V103, P1817, DOI 10.1083/jcb.103.5.1817
   Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322
   Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272
   GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta Y, 2011, CURR NANOSCI, V7, P427, DOI 10.2174/157341311795542534                                                      
   Hasadsri L, 2009, J BIOL CHEM, V284, P6972, DOI 10.1074/jbc.M805956200
   Heitz F, 2009, BRIT J PHARMACOL, V157, P2195
   Howard WA, 1997, BIOCONJUGATE CHEM, V8, P498, DOI 10.1021/bc970077l                                                               
   Hussey SL, 2002, J AM CHEM SOC, V124, P6265, DOI 10.1021/ja0258733
   Jain KK, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-83
   Jarvert P, 2007, BIOCHEM SOC T, V35, P770
   Johnson RM, 2011, METHODS MOL BIOL, V683, P535, DOI 10.1007/978-1-60761-919-2_38
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Kaneda Y, 2010, EXPERT OPIN DRUG DEL, V7, P1079, DOI 10.1517/17425247.2010.510511
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Koren E, 2011, DRUG DELIV, V18, P377, DOI 10.3109/10717544.2011.567310
   Langel U., 2007, HDB CELL PENETRATING
   Lawrence MS, 2007, J AM CHEM SOC, V129, P10110, DOI 10.1021/ja071641y
   Leamon CP, 2005, BIOCONJUGATE CHEM, V16, P803, DOI 10.1021/bc049709b
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320                                                          
   Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305                                                         
   Low PS, 2008, ACCOUNTS CHEM RES, V41, P120, DOI 10.1021/ar7000815
   LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6
   MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734                                                        
   Mashiba H, 2001, CANCER BIOTHER RADIO, V16, P495, DOI 10.1089/10849780152752092
   May CM, 2001, NAT BIOTECHNOL, V19, P1173
   McNaughton BR, 2009, P NATL ACAD SCI USA, V106, P156111
   Nagaraj NS, 2010, EXPERT REV PROTEOMIC, V7, P613, DOI 10.1586/EPR.10.70
   NAKANISHI O, 1993, J BIOL CHEM, V268, P10754
   OKADA CY, 1982, CELL, V29, P33, DOI 10.1016/0092-8674(82)90087-3
   Patsch C, 2010, METHODS, V53, P386
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Pitt William G, 2004, Expert Opin Drug Deliv, V1, P37, DOI 10.1517/17425247.1.1.37
   Potts R O, 1997, Pharm Biotechnol, V10, P213
   Price VH, 2003, J INVEST DERM SYMP P, V8, P207, DOI 10.1046/j.1087-0024.2003.00811.x
   RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104
   RAPTIS LH, 1995, MOL BIOTECHNOL, V4, P129, DOI 10.1007/BF02921607
   Reddy JA, 2006, CANCER CHEMOTH PHARM, V58, P229, DOI 10.1007/s00280-005-0151-z
   Rizk SS, 2009, P NATL ACAD SCI USA, V106, P11011, DOI 10.1073/pnas.0904907106
   Rosenholm JM, 2010, NANOSCALE, V2, P1870, DOI 10.1039/c0nr00156b
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295
   Russell-Jones G, 2004, J INORG BIOCHEM, V98, P1625, DOI 10.1016/j.jinorgbio.2004.07.009
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sebbage V., 2009, BIOSCI HORIZONS, V2, P64
   Smith BA, 2008, J AM CHEM SOC, V130, P2948, DOI 10.1021/ja800074v
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Todorova R, 2009, APPL BIOCHEM MICROB, V45, P493
   Vivero-Escoto JL, 2010, SMALL, V6, P1952, DOI 10.1002/smll.200901789
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P297
   Waibel R, 2008, CANCER RES, V68, P2904, DOI 10.1158/0008-5472.CAN-07-6771
   Wang S, 1998, J CONTROL RELEASE, V53, P39, DOI 10.1016/S0168-3659(97)00236-8                                                   
   Watanabe S, 2008, BIOCHEM BIOPH RES CO, V369, P695, DOI 10.1016/j.bbrc.2008.02.089
   Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200
   Zheng XY, 2003, CANCER RES, V63, P6909
   Ye F, 2005, United States Patent, Patent No. 7829290
   Kaczmarczyk SJ, 2008, Patent, HHS, Reference, Patent No. [E-010-2008/0PCT, E01020080]
NR 99
TC 7
Z9 7
U1 4
U2 39
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-7544
J9 DRUG DELIV
JI Drug Deliv.
PD NOV
PY 2011
VL 18
IS 8
BP 586
EP 598
DI 10.3109/10717544.2011.600783
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 852ES
UT WOS:000297335700006
PM 21864112
OA gold
DA 2018-01-05
ER

PT J
AU Li, M
   Gustchina, A
   Matuz, K
   Tozser, J
   Namwong, S
   Goldfarb, NE
   Dunn, BM
   Wlodawer, A
AF Li, Mi
   Gustchina, Alla
   Matuz, Krisztina
   Toezser, Jozsef
   Namwong, Sirilak
   Goldfarb, Nathan E.
   Dunn, Ben M.
   Wlodawer, Alexander
TI Structural and biochemical characterization of the inhibitor complexes
   of xenotropic murine leukemia virus-related virus protease
SO FEBS JOURNAL
LA English
DT Article
DE aspartic protease; enzyme inhibition; inhibitor binding; retrovirus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC-FATIGUE-SYNDROME;
   CRYSTAL-STRUCTURE; HIV-1 PROTEASE; TYPE-1 PROTEASE; RETROVIRUS XMRV; FIV
   PROTEASE; PEPSTATIN-A; PROTEINASE; AMPRENAVIR
AB Interactions between the protease (PR) encoded by the xenotropic murine leukemia virus-related virus and a number of potential inhibitors have been investigated by biochemical and structural techniques. It was observed that several inhibitors used clinically against HIV PR exhibit nanomolar or even subnanomolar values of Ki, depending on the exact experimental conditions. Both TL-3, a universal inhibitor of retroviral PRs, and some inhibitors originally shown to inhibit plasmepsins were also quite potent, whereas inhibition by pepstatin A was considerably weaker. Crystal structures of the complexes of xenotropic murine leukemia virus-related virus PR with TL-3, amprenavir and pepstatin A were solved at high resolution and compared with the structures of complexes of these inhibitors with other retropepsins. Whereas TL-3 and amprenavir bound in a predictable manner, spanning the substrate-binding site of the enzyme, two molecules of pepstatin A bound simultaneously in an unprecedented manner, leaving the catalytic water molecule in place.
C1 [Li, Mi; Gustchina, Alla; Wlodawer, Alexander] NCI, MCL, Prot Struct Sect, Frederick, MD 21702 USA.
   [Li, Mi] SAIC Frederick, Basic Res Program, Frederick, MD USA.
   [Matuz, Krisztina; Toezser, Jozsef] Univ Debrecen, Dept Biochem & Mol Biol, Fac Med, Debrecen, Hungary.
   [Namwong, Sirilak] Suan Sunandha Rajabhat Univ, Fac Sci & Technol, Dept Biotechnol, Bangkok, Thailand.
   [Goldfarb, Nathan E.; Dunn, Ben M.] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
RP Wlodawer, A (reprint author), NCI, MCL, Prot Struct Sect, Bldg 536,Rm 5, Frederick, MD 21702 USA.
EM wlodawer@nih.gov
RI Tozser, Jozsef/A-7840-2008
OI Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729
FU US Department of Energy, Office of Science, Office of Basic Energy
   Sciences [W-31-109-Eng-38]; TAMOP [4.2.1./B-09/1/KONV-2010-0007];
   Hungarian Science and Research Fund [OTKA K68288]; NIH, National Cancer
   Institute, Center for Cancer Research; National Cancer Institute,
   National Institutes of Health [HHSN261200800001E]; NIAID [R37 AI28571];
   Ruth L. Kirschstein National Research Service Award [5T32 CA009126-33]
FX The help of B. Farkas with kinetic and inhibition measurements is
   greatly appreciated. We acknowledge the use of beamline 22-ID of the
   Southeast Regional Collaborative Access Team, located at the Advanced
   Photon Source, Argonne National Laboratory. Use of the Advanced Photon
   Source was supported by the US Department of Energy, Office of Science,
   Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. The
   work of K. Matuz and J. Tozser was supported by the TAMOP
   4.2.1./B-09/1/KONV-2010-0007 project and by the Hungarian Science and
   Research Fund (OTKA K68288). This work was also supported in part by the
   Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer Research, and with Federal funds from the National
   Cancer Institute, National Institutes of Health, under Contract
   HHSN261200800001E, and by grant R37 AI28571 from NIAID to B. M. Dunn. N.
   E. Goldfarb was supported by a Ruth L. Kirschstein National Research
   Service Award 5T32 CA009126-33 Training Grant in Cancer Biology. The
   content of this publication does not necessarily reflect the views or
   policies of the Department of Health and Human Services, and nor does
   the mention of trade names, commercial products or organizations imply
   endorsement by the US Government.
CR BAILEY D, 1993, BIOCHEM J, V289, P363, DOI 10.1042/bj2890363                                                               
   Bhaumik P, 2012, BBA-PROTEINS PROTEOM, V1824, P207, DOI 10.1016/j.bbapap.2011.04.008
   Bhaumik P, 2011, J STRUCT BIOL, V175, P73, DOI 10.1016/j.jsb.2011.04.009
   BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052                                                             
   BRODER S, 1984, NEW ENGL J MED, V311, P1292, DOI 10.1056/NEJM198411153112006
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729                                                       
   Cohen J, 2011, SCIENCE, V331, P1253, DOI 10.1126/science.331.6022.1253
   Coman RM, 2008, BIOCHEMISTRY-US, V47, P731, DOI 10.1021/bi7018332
   Lano De, 2002, PYMOL MOL GRAPHICS S
   DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197                                                               
   Dunn B M, 1994, Methods Mol Biol, V36, P225
   Feher A, 2006, J GEN VIROL, V87, P1321, DOI 10.1099/vir.0.81382-0
   FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209
   Fung HB, 2000, CLIN THER, V22, P549, DOI 10.1016/S0149-2918(00)80044-2
   Gillette WK, 2010, PROTEIN EXPRES PURIF, V76, P238
   Groom HCT, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-10
   Heaslet H, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-1
   Hohn O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015632
   Hue S, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-111
   JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137
   Janka L, 2008, PROTEIN PEPTIDE LETT, V15, P868, DOI 10.2174/092986608785849218
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Knox K, 2011, SCIENCE, V333, P94, DOI 10.1126/science.1204963
   Li M, 2000, PROTEINS, V38, P29, DOI 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N
   Li M, 2005, P NATL ACAD SCI USA, V102, P18322
   Li M, 2011, NAT STRUCT MOL BIOL, V18, P227, DOI 10.1038/nsmb.1964
   Lombardi VC, 2009, SCIENCE, V326, P585, DOI 10.1126/science.1179052
   MAIBAUM J, 1988, J MED CHEM, V31, P625, DOI 10.1021/jm00398a022
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mikovits JA, 2010, VIRULENCE, V1, P386, DOI 10.4161/viru.1.5.12486
   MONTAGNIER L, 1985, ANN INTERN MED, V103, P689, DOI 10.7326/0003-4819-103-5-689
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Noble S, 2000, DRUGS, V60, P1383, DOI 10.2165/00003495-200060060-00012
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Paprotka T, 2011, SCIENCE, V333, P97, DOI 10.1126/science.1205292
   Perryman AL, 2006, BIOPOLYMERS, V82, P272, DOI 10.1002/bip.20497
   Perryman AL, 2010, CHEM BIOL DRUG DES, V75, P257, DOI 10.1111/j.1747-0285.2009.00943.x
   Prade L, 2005, J BIOL CHEM, V280, P23837, DOI 10.1074/jbc.M501519200
   RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   Schlaberg R, 2009, P NATL ACAD SCI USA, V106, P16351, DOI 10.1073/pnas.0906922106
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   Shen CH, 2010, FEBS J, V277, P3699, DOI 10.1111/j.1742-4658.2010.07771.x
   Sirkis R, 2006, J MOL BIOL, V364, P376, DOI 10.1016/j.jmb.2006.08.056
   SLEE DH, 1995, J AM CHEM SOC, V117, P11867, DOI 10.1021/ja00153a008                                                             
   Smith RA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-112
   Smith RA, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-70
   TOZSER J, 1991, FEBS LETT, V279, P356, DOI 10.1016/0014-5793(91)80186-7
   UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259                                                      
   WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
NR 52
TC 5
Z9 5
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-464X
J9 FEBS J
JI FEBS J.
PD NOV
PY 2011
VL 278
IS 22
BP 4413
EP 4424
DI 10.1111/j.1742-4658.2011.08364.x
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 849WI
UT WOS:000297155600024
PM 21951660
OA gold
DA 2018-01-05
ER

PT J
AU Magee, WC
   Valiaeva, N
   Beadle, JR
   Richman, DD
   Hostetler, KY
   Evans, DH
AF Magee, Wendy C.
   Valiaeva, Nadejda
   Beadle, James R.
   Richman, Douglas D.
   Hostetler, Karl Y.
   Evans, David H.
TI Inhibition of HIV-1 by Octadecyloxyethyl Esters of
   (S)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl] Nucleosides and Evaluation of
   Their Mechanism of Action
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIVIRAL ACTIVITY; VACCINIA VIRUS;
   IN-VITRO; REVERSE-TRANSCRIPTASE; DNA-POLYMERASE; ANTIRETROVIRAL THERAPY;
   CIDOFOVIR; CYTOMEGALOVIRUS; PHOSPHONATES
AB (S)-1-[3-hydroxy-2-(phosphonomethoxy) propyl] cytosine (HPMPC [cidofovir]) and (S)-9-[3-hydroxy-2(phosphonomethoxy) propyl] adenine (HPMPA) are potent inhibitors of a variety of DNA viruses. These drugs possess a 3'-hydroxyl equivalent which could support chain extension from an incorporated drug molecule. HPMPC and HPMPA were initially reported to lack activity against human immunodeficiency virus type 1 (HIV-1); more recent results have shown that the octadecyloxyethyl (ODE) and hexadecyloxypropyl (HDP) esters of HPMPA are potent inhibitors of the virus. We have synthesized the ODE esters of a series of (S)-[3-hydroxy-2-(phosphonomethoxy) propyl] (HPMP) nucleosides, including HPMPC, HPMP-guanine (HPMPG), HPMP-thymine (HPMPT), and HPMP-diaminopurine (HPMPDAP), as well as the ODE ester of the obligate chain terminator (S)-9-[3-methoxy-2-(phosphonomethoxy)-propyl] adenine (MPMPA). All compounds except ODE-HPMPT were inhibitors of HIV-1 replication at low nanomolar concentrations. These compounds were also inhibitors of the replication of HIV-1 variants that are resistant to various nucleoside reverse transcriptase (RT) inhibitors at concentrations several times lower than would be expected to be achieved in vivo. To investigate the mechanism of the antiviral activity, the active metabolites of HPMPC and HPMPA were studied for their effects on reactions catalyzed by HIV-1 RT. Incorporation of HPMPC and HPMPA into a DNA primer strand resulted in multiple inhibitory effects exerted on the enzyme and showed that neither compound acts as an absolute chain terminator. Further, inhibition of HIV-1 RT also occurred when these drugs were located in the template strand. These results indicate that HPMPC and HPMPA inhibit HIV-1 by a complex mechanism and suggest that this class of drugs has a broader spectrum of activity than previously shown.
C1 [Magee, Wendy C.; Evans, David H.] Univ Alberta, Dept Med Microbiol & Immunol, Li Ka Shing Inst Virol, Katz Grp Ctr, Edmonton, AB T6G 2E1, Canada.
   [Valiaeva, Nadejda; Beadle, James R.; Richman, Douglas D.; Hostetler, Karl Y.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Valiaeva, Nadejda; Beadle, James R.; Richman, Douglas D.; Hostetler, Karl Y.] Vet Med Res Fdn, San Diego, CA 92161 USA.
RP Evans, DH (reprint author), Univ Alberta, Dept Med Microbiol & Immunol, Li Ka Shing Inst Virol, Katz Grp Ctr, 6020 K, Edmonton, AB T6G 2E1, Canada.
EM devans@ualberta.ca
RI Evans, David/M-1912-2016
OI Evans, David/0000-0001-5871-299X
FU Canadian Institutes of Health Research [MOP-10923]; NIH [AI071803,
   AI074057]; UCSD (University of California, San Diego) Center for AIDS
   Research [AI36214, AI074621]
FX This study was supported in part by operating grant MOP-10923 from the
   Canadian Institutes of Health Research (D.H.E.), by NIH grants AI071803
   and AI074057 (K.Y.H.), and by UCSD (University of California, San Diego)
   Center for AIDS Research grants AI36214 and AI074621 (D.D.R.).
CR Aldern KA, 2003, MOL PHARMACOL, V63, P678, DOI 10.1124/mol.63.3.678                                                            
   Andrei G, 2006, J VIROL, V80, P9391, DOI 10.1128/JVI.00605-06
   Baker R, 2003, ANTIVIR RES, V57, P13, DOI 10.1016/S0166-3542(02)00196-1
   BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332                                                            
   Beadle JR, 2006, J MED CHEM, V49, P2010, DOI 10.1021/jm050473m
   Beadle JR, 2002, ANTIMICROB AGENTS CH, V46, P2381, DOI 10.1128/AAC.46.8.2381-2386.2002
   Cherrington JM, 1996, ANTIMICROB AGENTS CH, V40, P1270
   De Clercq E, 2005, NAT REV DRUG DISCOV, V4, P928, DOI 10.1038/nrd1877
   Deayton JR, 2004, LANCET, V363, P2116, DOI 10.1016/S0140-6736(04)16500-8
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   DECLERCQ E, 1986, NATURE, V323, P464
   Domaoal RA, 2008, J BIOL CHEM, V283, P5452, DOI 10.1074/jbc.M707834200
   Frangeul A, 2008, ANTIVIR THER, V13, P115
   Gilbert DN, 2010, SANFORD GUIDE ANTIMI
   Hammond JL, 2001, ANTIMICROB AGENTS CH, V45, P1621, DOI 10.1128/AAC.45.6.1621-1628.2001
   Hostetler KY, 2006, ANTIMICROB AGENTS CH, V50, P2857, DOI 10.1128/AAC.01223-05
   Hostetler KY, 2009, ANTIVIR RES, V82, pA84, DOI 10.1016/j.antiviral.2009.01.005
   Jabs DA, 2005, OPHTHALMOLOGY, V112, P771, DOI 10.1016/j.ophtha.2004.10.049
   JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095                                                           
   Julien O, 2011, J AM CHEM SOC, V133, P2264, DOI 10.1021/ja109823e
   Kornbluth RS, 2006, ANTIMICROB AGENTS CH, V50, P4038, DOI 10.1128/AAC.00380-06
   Lanier R, 2010, VIRUSES-BASEL, V2, P2740, DOI 10.3390/v2122740
   Magee WC, 2005, ANTIMICROB AGENTS CH, V49, P3153, DOI 10.1128/AAC.49.8.3153-3162.2005                                                 
   Magee WC, 2008, ANTIMICROB AGENTS CH, V52, P586, DOI 10.1128/AAC.01172-07
   Naeger DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008886
   Painter GR, 2007, ANTIMICROB AGENTS CH, V51, P3505, DOI 10.1128/AAC.00460-07
   PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025                                                           
   Sambrook J, 2001, MOL CLONING LAB MANU
   Srinivas RV, 1997, ANTIVIR RES, V35, P23, DOI 10.1016/S0166-3542(97)01035-8
   Tchesnokov EP, 2008, J BIOL CHEM, V283, P34218, DOI 10.1074/jbc.M806797200
   VALIAEVA N, BIOORG MED CHEM, V19, P4616
   Valiaeva N, 2009, ANTIVIR RES, V84, P254, DOI 10.1016/j.antiviral.2009.09.012
   WONG JL, 1970, J ORG CHEM, V35, P3786, DOI 10.1021/jo00836a045                                                             
   Xiong XF, 1997, ANTIMICROB AGENTS CH, V41, P594
NR 34
TC 7
Z9 7
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2011
VL 55
IS 11
BP 5063
EP 5072
DI 10.1128/AAC.05161-11
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 839NX
UT WOS:000296375600016
PM 21896914
OA gold
DA 2018-01-05
ER

PT J
AU Zhang, T
   Sturgis, TF
   Youan, BBC
AF Zhang, Tao
   Sturgis, Timothy F.
   Youan, Bi-Botti C.
TI pH-responsive nanoparticles releasing tenofovir intended for the
   prevention of HIV transmission
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE pH-responsive; Nanoparticles; Tenofovir; Tenofovir disoproxil fumarate;
   Topical delivery; HIV/AIDS microbicide
ID LOADED POLYMERIC NANOPARTICLES; IN-VIVO EVALUATION; BIODEGRADABLE
   NANOPARTICLES; DEPENDENT INTERNALIZATION; VAGINAL MICROBICIDE; CELL
   LINE; DELIVERY; PLGA; FORMULATION; VITRO
AB This study is designed to test the hypothesis-that tenofovir (TNF) or tenofovir disoproxil fumarate (TDF) loaded nanoparticles (NPs) prepared with a blend of poly(lactic-co-glycolic acid) (PLGA) and methacrylic acid copolymer (Eudragit (R) S-100, or S-100) are noncytotoxic and exhibit significant pH-responsive release of anti-HIV microbicides in the presence of human semen fluid simulant (SFS). After NPs preparation by emulsification diffusion, their size, encapsulation efficiency (EE%), drug release profile, morphology, and cytotoxicity are characterized by dynamic light scattering, spectrophotometry, transmission electron microscopy, and cellular viability assay/transepithelial electrical resistance measurement, respectively. Cellular uptake was elucidated by fluorescence spectroscopy and confocal microscopy. The NPs have an average size of 250 nm, maximal EE% of 16.1% and 37.2% for TNF and TDF, respectively. There is a 4-fold increase in the drug release rate from the 75% S-100 blend in the presence of SFS over 72 h. At a concentration up to 10 mg/ml, the PLGA/S-100 NPs are noncytotoxic for 48 h to vaginal endocervical/epithelial cells and Lactobacillus crispatus. The particle uptake (similar to 50% in 24 h) by these vaginal cell lines mostly occurred through caveolin-mediated pathway. These data suggest the promise of using PLGA/S-100 NPs as an alternative controlled drug delivery system in intravaginal delivery of an anti-HIV/AIDS microbicide. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Zhang, Tao; Youan, Bi-Botti C.] Univ Missouri, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, Kansas City, MO 64108 USA.
   [Sturgis, Timothy F.] Univ Missouri, Dept Environm Hlth & Safety, Kansas City, MO 64108 USA.
RP Youan, BBC (reprint author), Univ Missouri, Lab Future Nanomed & Theoret Chronopharmaceut, Div Pharmaceut Sci, 2464 Charlotte, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
RI Zhang, Tao/G-1312-2014
FU National Institute of Allergy And Infectious Diseases [R21AI083092]
FX The work presented was supported by Award Number R21AI083092 from the
   National Institute of Allergy And Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institute of Allergy And
   Infectious Diseases or the National Institutes of Health. The authors
   would also like to thank the support from Dr. Jeffery Price (Associate
   Professor, School of Biological Sciences of University of
   Missouri-Kansas City for Confocal microscopic study, Dr. Elisabet
   Nalvarte (Research Associate Professor, Department of Oral Biology,
   University of Missouri-Kansas City, MO) for fluorescent spectrophotomer,
   and Louis Ross, Cheryl Jensen, and Randy Tindall (Electron Microscopy
   Center, University of Missouri-Columbia, MO) for the electron
   microscopy.
CR Asasutjarit R, 2007, PHARM RES, V24, P1098, DOI 10.1007/s11095-007-9234-3
   Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298
   Badawy SIF, 2007, J PHARM SCI-US, V96, P948, DOI 10.1002/jps.20932
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Basarkar A, 2009, PHARM RES-DORD, V26, P72, DOI 10.1007/s11095-008-9710-4
   Carballo-Dieguez A, 2007, AIDS CARE, V19, P1026, DOI 10.1080/09540120701294237
   Cetin M, 2010, AAPS PHARMSCITECH, V11, P1250, DOI 10.1208/s12249-010-9489-6
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dillen K, 2008, INT J PHARMACEUT, V349, P234, DOI 10.1016/j.ijpharm.2007.07.041
   Douglas KL, 2008, EUR J PHARM BIOPHARM, V68, P676, DOI 10.1016/j.ejpb.2007.09.002
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Dubey V, 2010, NANOMED-NANOTECHNOL, V6, P590, DOI 10.1016/j.nano.2010.01.002
   Fichorova RN, 1999, BIOL REPROD, V60, P508, DOI 10.1095/biolreprod60.2.508                                                      
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Garg S, 2005, PHARM RES, V22, P584, DOI 10.1007/s11095-005-2494-x
   GARG S, 2001, PHARM TECHNOL DRUG D, V11, P14
   Glowka E, 2010, J MICROENCAPSUL, V27, P25, DOI 10.3109/02652040902751125
   Goddeeris C, 2008, EUR J PHARM BIOPHARM, V70, P861, DOI 10.1016/j.ejpb.2008.07.006
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Houchin ML, 2007, J CONTROL RELEASE, V117, P413, DOI 10.1016/j.jconrel.2006.11.023
   Ibrahim HK, 2010, MOL PHARMACEUT, V7, P576, DOI 10.1021/mp900279c
   Jain D, 2005, AAPS PHARMSCITECH, V6
   Jiao YY, 2002, CIRCULATION, V105, P230, DOI 10.1161/hc0202.101988                                                           
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   JORGENSON JH, 1999, MANUAL CLIN MICROBIO
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kathleen D, 2006, INT J PHARM, V314, P72, DOI 10.1016/j.ijpharm.2006.01.041
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289                                                           
   Klose D, 2008, INT J PHARMACEUT, V354, P95, DOI 10.1016/j.ijpharm.2007.10.030
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   Li L, 2005, J CONTROL RELEASE, V101, P163, DOI 10.1016/j.jconrel.2004.07.029
   Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mauck CK, 2004, CONTRACEPTION, V70, P233, DOI 10.1016/j.contraception.2004.04.010
   Morrow RJ, 2011, EUR J PHARM BIOPHARM, V77, P3, DOI 10.1016/j.ejpb.2010.10.010
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168-3659(02)00320-6
   Murakami H, 1999, INT J PHARM, V187, P143, DOI 10.1016/S0378-5173(99)00187-8
   Nguyen DA, 2005, AICHE J, V51, P415, DOI 10.1002/aic.10329                                                               
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Pool R, 2000, Cult Health Sex, V2, P197, DOI 10.1080/136910500300804
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Tsukatani T, 2008, J MICROBIOL METH, V75, P109, DOI 10.1016/j.mimet.2008.05.016
   *UFAD ADM, 2008, FDA VIR PRESCR INF
   *UNAIDS WHO, 2009, REP GLOB AIDS EP, P362
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Wilks M, 2004, J CLIN MICROBIOL, V42, P713, DOI 10.1128/JCM.42.2.713-717.2004
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Woolfson AD, 2010, INT J PHARMACEUT, V388, P136, DOI 10.1016/j.ijpharm.2009.12.042
   Xie JW, 2005, PHARM RES, V22, P2079, DOI 10.1007/s11095-005-7782-y
   Zolnik BS, 2007, J CONTROL RELEASE, V122, P338, DOI 10.1016/j.jconrel.2007.05.034
NR 59
TC 48
Z9 49
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD NOV
PY 2011
VL 79
IS 3
BP 526
EP 536
DI 10.1016/j.ejpb.2011.06.007
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 846UX
UT WOS:000296929800007
PM 21736940
OA green_accepted
DA 2018-01-05
ER

PT J
AU Mukundan, VT
   Do, NQ
   Phan, AT
AF Mukundan, Vineeth Thachappilly
   Ngoc Quang Do
   Anh Tuan Phan
TI HIV-1 integrase inhibitor T30177 forms a stacked dimeric G-quadruplex
   structure containing bulges
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; C-MYC PROMOTER; ANTI-HIV-1 ACTIVITY;
   POTENT INHIBITOR; QUARTET STRUCTURES; DNA QUADRUPLEX; HUMAN TELOMERE;
   NUCLEIC-ACIDS; LOOP-LENGTH; IN-VITRO
AB T30177 is a G-rich oligonucleotide with the sequence (GTGGTGGGTGGGTGGGT) which inhibits the HIV-1 integrase activity at nanomolar concentrations. Here we show that this DNA sequence forms in K(+) solution a dimeric G-quadruplex structure comprising a total of six G-tetrad layers through the stacking of two propeller-type parallel-stranded G-quadruplex subunits at their 5'-end. All twelve guanines in the sequence participate in the G-tetrad formation, despite the interruption in the first G-tract by a thymine, which forms a bulge between two adjacent G-tetrads. In this work, we also propose a simple analytical approach to stoichiometry determination using concentration-dependent melting curves.
C1 [Mukundan, Vineeth Thachappilly; Ngoc Quang Do; Anh Tuan Phan] Nanyang Technol Univ, Sch Phys & Math Sci, Singapore, Singapore.
   [Ngoc Quang Do] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore.
RP Phan, AT (reprint author), Nanyang Technol Univ, Sch Phys & Math Sci, Singapore, Singapore.
EM phantuan@ntu.edu.sg
RI Phan, Anh Tuan/A-3673-2010
OI Phan, Anh Tuan/0000-0002-4970-3861
FU Singapore Ministry of Education [ARC30/07, RG62/07]; Singapore
   Biomedical Research Council [07/1/22/19/542]; Oxford University Press
FX Singapore Ministry of Education grants (ARC30/07 and RG62/07); Singapore
   Biomedical Research Council (grant 07/1/22/19/542 to A. T. P.). Funding
   for open access charge: Waived by Oxford University Press.
CR BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Bugaut A, 2008, BIOCHEMISTRY-US, V47, P689, DOI 10.1021/bi701873c
   Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655
   CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909
   Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200
   Davis JT, 2004, ANGEW CHEM INT EDIT, V43, P668, DOI 10.1002/anie.200300589                                                          
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   DO NQ, 2011, NUCLEIC ACIDS RES, DOI DOI 10.1093/NAR/GKR539
   GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013                                                         
   Guedin A, 2008, BIOCHIMIE, V90, P686, DOI 10.1016/j.biochi.2008.01.009
   Guedin A, 2010, NUCLEIC ACIDS RES, V38, P7858, DOI 10.1093/nar/gkq639
   Hazel P, 2004, J AM CHEM SOC, V126, P16405, DOI 10.1021/ja045154j
   Huang XN, 1997, NUCLEIC ACIDS RES, V25, P4758, DOI 10.1093/nar/25.23.4758                                                          
   JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404
   Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967                                                  
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jing NJ, 2004, CANCER RES, V64, P6603, DOI 10.1158/0008-5472.CAN-03-4041
   Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y
   Koizumi M, 1997, BIOORGAN MED CHEM, V5, P2235, DOI 10.1016/S0968-0896(97)00161-2                                                   
   Li HH, 2008, J AM SOC MASS SPECTR, V19, P550, DOI 10.1016/j.jasms.2008.01.012
   Li MH, 2010, J MOL MODEL, V16, P645, DOI 10.1007/s00894-009-0592-0
   Lim KW, 2010, J AM CHEM SOC, V132, P12331, DOI 10.1021/ja101252n
   Lim KW, 2009, NUCLEIC ACIDS RES, V37, P6239, DOI 10.1093/nar/gkp630
   Maizels N, 2006, NAT STRUCT MOL BIOL, V13, P1055, DOI 10.1038/nsmb1168
   Marchand C, 2009, CURR TOP MED CHEM, V9, P1016, DOI 10.2174/156802609789630910                                                      
   MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   Mergny JL, 1998, FEBS LETT, V435, P74, DOI 10.1016/S0014-5793(98)01043-6
   Michalowski D, 2008, NUCLEIC ACIDS RES, V36, P7124, DOI 10.1093/nar/gkn891
   Neidle S, 2009, CURR OPIN STRUC BIOL, V19, P239, DOI 10.1016/j.sbi.2009.04.001
   OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426                                                          
   Oliviero G, 2010, CHEM COMMUN, V46, P8971, DOI 10.1039/c0cc02866e
   Pan BC, 2003, STRUCTURE, V11, P1423, DOI 10.1016/j.str.2003.09.017
   Patel DJ, 2007, NUCLEIC ACIDS RES, V35, P7429, DOI 10.1093/nar/gkm711
   Pedersen EB, 2011, NUCLEIC ACIDS RES, V39, P2470, DOI 10.1093/nar/gkq1133
   Phan AT, 2006, CURR OPIN STRUC BIOL, V16, P288, DOI 10.1016/j.sbi.2006.05.011
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k
   Phan AT, 2002, J AM CHEM SOC, V124, P1160, DOI 10.1021/ja011977m
   Phan AT, 2000, J BIOMOL NMR, V16, P175, DOI 10.1023/A:1008355231085
   Phan AT, 2001, METHOD ENZYMOL, V338, P341
   Qi HY, 2006, CANCER RES, V66, P11808, DOI 10.1158/0008-5472.CAN-06-1225
   Rachwal PA, 2007, NUCLEIC ACIDS RES, V35, P4214, DOI 10.1093/nar/gkm316
   RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754                                                          
   Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b
   Smargiasso N, 2008, J AM CHEM SOC, V130, P10208, DOI 10.1021/ja801535e
   SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040                                                             
   Urata H, 2004, BIOCHEM BIOPH RES CO, V313, P55, DOI 10.1016/j.bbrc.2003.11.094
   WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356
NR 50
TC 46
Z9 46
U1 0
U2 34
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV
PY 2011
VL 39
IS 20
BP 8984
EP 8991
DI 10.1093/nar/gkr540
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 839CW
UT WOS:000296343400035
PM 21771859
OA gold
DA 2018-01-05
ER

PT J
AU Kolski-Andreaco, A
AF Kolski-Andreaco, Aaron
TI November 2011: This Month in JoVE
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE This Month in JoVE; Issue 57
AB The November issue of the Journal of Visualized Experiments begins with a series of behavioral experiments for measuring prehension ability in primates. Investigators from the University of Fribourg demonstrate four grasping and reaching tasks, which all follow common steps for comfortably restraining the animal and correctly positioning its head. The Brinkman Board test is used to assess reaching for static objects, while the Rotating Brinkman Board presents a condition where animals need to anticipate object position. The Brinkman Box test allows dexterity to be investigated under conditions where the monkey has fewer degrees of freedom to perform grasping task and cannot use vision to guide movement. While the brinkman board and box tests solely rely on analysis of video obtained during experiments, in order to generate data, the drawer reaching task apparatus has detectors that monitor grip and load forces as well as drawer position, making this test appropriate for measuring strength as well as prehension ability. In combination, these four tests provide a powerful approach to assess motor control in the distal forelimb, and the Fribourg group presents data from both lesion studies and experiments aimed to test potential therapies for spinal cord injury.
   In Clinical and Translational Medicine, collaborators from the Division of Surgical Research at the University Hospital Zurich and the Institute of Laboratory Animal Science at the University of Zurich, work together to implant a radiotelemetry device in mice, which can be used to take physiological measurements in freely moving animals. The devices consist of two leads, which are capable of measuring biopotential activity (ECG, EEG, or EMG) as well as temperature, and a lightweight radio transmitter (1-200 Hz in bandwidth) that can be implanted in the abdominal cavity. The stress of animal handling as well as anesthesia are known confounding elements, which impact physiological measurements, so radiotelemetry devices are a convenient way to acquire physiological data from animals in an unperturbed, natural state, as well as take measurements of multiple animals, simultaneously.
   JoVE also adds to its host of electroporation protocols with a method for introducing macromoledules into the craniofacial mesenchyme of developing Xenopus laevis tadpoles, from the Liu Lab at King's College London. Xenopus tadpoles are transferred to an electroporation chamber, where they can be injected with nucleic acid, and then subjected to electroporation, which will deliver expression vectors or morpholinos into the developing craniofacial tissue. Gene delivery into differentiated cartilage is inherently problematic, and the Liu lab shows that, through elecroporation, morpholinos can be introduced into procartilaginous and cartilaginous tissues of the Xenopus tadpole throughout a range of developmental stages.
   In Bioengineering, the Zuckerman group from the Lawrence Berkeley National Laboratory illustrates their method for synthesizing peptoids, a class of biologically-active organic molecules that resemble peptides, but have their side chains attached to the nitrogen of the peptide bond, rather than the alpha carbon, which makes them resistant to proteolysis. The Zuckerman group demonstrates submonomer synthesis, where peptide monomers are added sequentially in bromoacetylation and bromide displacement reactions, allowing peptoid chain length and composition to be precisely controlled. Furthermore, the fact that synthesis is done on amide resin, and is hence, solid phase synthesis, greatly simplifies purification of the synthesized peptoids. These authors also show how the newly-synthesized peptoids can be induced to selfassemble into highly-ordered structures, termed nanosheets, which can be visualized by fluorescence and scanning electron microscopy. These nanosheets could serve as a potential platform for protein and membrane mimetics.
   Later in the month, JoVE features an assay for measuring phagocytic activity in cells exposed to clinical antibody samples for our Immunology and Infection section. Collaborators from Massachusetts General Hospital and Dartmouth College show that THP-1 cells will engulf antibodybound antigen coated beads in timelapse video microscopy and present a plate-based flow cytometry method for quantifying the extent of phagocytosis. Our authors use this method to determine the ability of different antibody samples to induce phagocytosis, such as those from HIV patients both treated and untreated with anti-retroviral therapies.
   This summary of JoVE's content in November provides a brief overview of JoVE's highlights for the month. Other noteworthy articles include methods for live imaging of cytoskeletal dynamics in endothelial cells, measuring calcium flux in cardiomyocytes, and slice electrophysiology of adult born neurons in the olfactory bulb.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD NOV
PY 2011
IS 57
AR UNSP e4025
DI 10.3791/4025
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36OZ
UT WOS:000209222200051
OA gold
DA 2018-01-05
ER

PT J
AU Qin, Y
   Chen, HL
   Yuan, WM
   Kuai, R
   Zhang, QY
   Xie, FL
   Zhang, L
   Zhang, ZR
   Liu, J
   He, Q
AF Qin, Yao
   Chen, Huali
   Yuan, Wenmin
   Kuai, Rui
   Zhang, Qianyu
   Xie, Fulan
   Zhang, Li
   Zhang, Zhirong
   Liu, Ji
   He, Qin
TI Liposome formulated with TAT-modified cholesterol for enhancing the
   brain delivery
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE TAT; Cholesterol; Liposome; Brain delivery; Blood-brain barrier
ID STERICALLY STABILIZED LIPOSOMES; HIV-1 TAT; IN-VITRO; PROTEIN
   TRANSDUCTION; DRUG-DELIVERY; BARRIER; NANOPARTICLES; INTERNALIZATION;
   PERMEABILITY; TRANSCYTOSIS
AB Delivery of drugs to the brain is a major challenge due to the presence of the blood-brain barrier (BBB). The cell penetrating peptide TAT, which appears to enter cells with alacrity, can pass through the BBB efficiently. With this in mind, a novel TAT-modified liposome (TAT-LIP) was developed for overcoming the ineffective delivery of normal drug formulation to the brain. Targeting liposomal formulations are always composed of modified phospholipids as an anchor. However, cholesterol, another liposomal component, which was more stable and cheaper, has not been fully investigated as an alternative anchor. In this study, TAT was covalently conjugated with the cholesterol to prepare the liposome. The cellular uptake by brain capillary endothelial cells (BCECs) of rats and the mechanism of TAT-LIP pathway of endocytosis was explored. The blood brain barrier model in vitro was established to evaluate the transendothelial ability crossing the BBB and its transport mechanism. The biodistribution of each formulation was further identified. The results showed that the positive charge of the TAT-LIP played an important role in enhancing its brain delivery. The absorptive endocytosis might be one of the mechanisms of TAT-LIP crossing the BBB. In conclusion, the experimental data in vitro and in vivo indicated that the TAT-LIP was a promising brain drug delivery system due to its high delivery efficiency across the BBB. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Liu, Ji] Sichuan Univ, W China Sch Preclin & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
   [Qin, Yao; Chen, Huali; Yuan, Wenmin; Kuai, Rui; Zhang, Qianyu; Xie, Fulan; Zhang, Li; Zhang, Zhirong; He, Qin] Sichuan Univ, Key Lab Drug Targeting & Drug Delivery Syst, W China Sch Pharm, Chengdu 610041, Sichuan, Peoples R China.
   [Qin, Yao] Taiji Grp, Chongqing 401147, Peoples R China.
RP Liu, J (reprint author), Sichuan Univ, W China Sch Preclin & Forens Med, 17,Block 3,So Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.
EM liuji6103@163.com; qinhe@scu.edu.cn
OI Kuai, Rui/0000-0003-2324-1272
FU National Basic Research Program, China [2007CB935801]; National Natural
   and Science Foundation of China [30873166]; National S & T Major Project
   of China [2009ZX09310-002]
FX This research was supported by the National Basic Research Program
   (2007CB935801) of China, National Natural and Science Foundation of
   China (No. 30873166), and the National S & T Major Project of China (No.
   2009ZX09310-002).
CR Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003
   Cecchelli R, 2007, NAT REV DRUG DISCOV, V6, P650, DOI 10.1038/nrd2368
   Chen HL, 2010, EUR J PHARM SCI, V40, P94, DOI 10.1016/j.ejps.2010.03.007
   Chen Q, 2009, J DRUG TARGET, V17, P318, DOI 10.1080/10611860902795399
   Chen Y., 2004, Current Drug Delivery, V1, P361, DOI 10.2174/1567201043334542
   Chertok B, 2009, BIOMATERIALS, V30, P6780, DOI 10.1016/j.biomaterials.2009.08.040
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Du J, 2009, MOL PHARMACEUT, V6, P905, DOI 10.1021/mp800218q
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Han HD, 2006, INT J PHARM, V313, P181, DOI 10.1016/j.ijpharm.2006.02.007
   Hu KL, 2009, J CONTROL RELEASE, V134, P55, DOI 10.1016/j.jconrel.2008.10.016
   Kaur IP, 2008, J CONTROL RELEASE, V127, P97, DOI 10.1016/j.jconrel.2007.12.018
   Kheirolomoom A, 2007, BIOMATERIALS, V28, P4311, DOI 10.1016/j.biomaterials.2007.06.008
   Lasic DD, 1996, NATURE, V380, P561, DOI 10.1038/380561a0                                                                
   Li LH, 2008, BIOMATERIALS, V29, P1509, DOI 10.1016/j.biomaterials.2007.11.014
   Li SD, 2010, J CONTROL RELEASE, V145, P178, DOI 10.1016/j.jconrel.2010.03.016
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   Lu W, 2005, INT J PHARM, V295, P247, DOI 10.1016/j.ijpharm.2005.01.043
   Miller CR, 1998, BIOCHEMISTRY-US, V37, P12875, DOI 10.1021/bi980096y                                                               
   Newton Herbert B, 2006, Expert Rev Neurother, V6, P1495, DOI 10.1586/14737175.6.10.1495
   Ntziachristos V, 2003, EUR RADIOL, V13, P195, DOI 10.1007/s00330-002-1524-x
   Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905
   Pardridge WM, 2005, INT CONGR SER, V1277, P49, DOI 10.1016/j.ics.2005.02.011
   Pardridge WM, 2002, DRUG DISCOV TODAY, V7, P5, DOI 10.1016/S1359-6446(01)02082-7                                                   
   PARDRIDGE WM, 1994, TRENDS BIOTECHNOL, V12, P239, DOI 10.1016/0167-7799(94)90123-6
   PARR MJ, 1994, BBA-BIOMEMBRANES, V1195, P21, DOI 10.1016/0005-2736(94)90004-3
   Pham W, 2005, NEUROIMAGE, V28, P287, DOI 10.1016/j.neuroimage.2005.06.007
   Qin Y, 2010, J DRUG TARGET, V18, P536, DOI 10.3109/10611861003587235
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217                                                          
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SIFLINGERBIRNBOIM A, 1987, J CELL PHYSIOL, V132, P111, DOI 10.1002/jcp.1041320115
   Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9
   Temsamani Jamal, 2003, Prog Drug Res, V61, P221
   Tromberg BJ, 2008, MED PHYS, V35, P2443, DOI 10.1118/1.2919078
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Xu RX, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1837
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhao XB, 2007, J PHARM SCI-US, V96, P2424, DOI 10.1002/jps.20885
NR 43
TC 51
Z9 63
U1 2
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 31
PY 2011
VL 419
IS 1-2
BP 85
EP 95
DI 10.1016/j.ijpharm.2011.07.021
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 838QJ
UT WOS:000296307000011
PM 21807083
DA 2018-01-05
ER

PT J
AU McNeer, NA
   Schleifman, EB
   Glazer, PM
   Saltzman, WM
AF McNeer, Nicole Ali
   Schleifman, Erica B.
   Glazer, Peter M.
   Saltzman, W. Mark
TI Polymer delivery systems for site-specific genome editing
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 15th International Symposium on Recent Advances in Drug Delivery Systems
CY FEB 13-16, 2011
CL Salt Lake City, UT
SP Samyang Co, Abbott Vasc, Watson Pharmaceut, CibaVis, NOF, Boryung Pharmaceut, Green Cross, Kanarb, Univ Utah Coll Pharm, Teikoku Seiyaku, Shiseido
DE Gene therapy; Triplex forming oligonucleotides; Peptide nucleic acids;
   Nanoparticles; Hematopoietic stem cells; Poly(lactic-co-glycolic acid)
ID HEMATOPOIETIC STEM-CELLS; PEPTIDE NUCLEIC-ACIDS; PLGA NANOPARTICLES;
   HELA-CELLS; PNA; GENE; DNA; RECOMBINATION; MICE
AB Triplex-forming peptide nucleic acids (PNAs) can be used to coordinate the recombination of short 50-60 bp "donor DNA" fragments into genomic DNA, resulting in site-specific correction of genetic mutations or the introduction of advantageous genetic modifications. Site-specific gene editing in hematopoietic stem and progenitor cells (HSPCs) could result in the treatment or cure of inherited disorders of the blood such as beta-thalassemia or sickle cell anemia. Gene editing in HSPCs and differentiated T cells could also help combat HIV infection by modifying the HIV co-receptor CCR5, which is necessary for R5-tropic HIV entry. However, translation of genome modification technologies to clinical practice is limited by challenges in intracellular delivery, especially in difficult-to-transfect hematolymphoid cells. Here, we review the use of engineered biodegradable polymer nanoparticles for site-specific genome editing in human hematopoietic cells, which represent a promising approach for ex vivo and in vivo gene therapy. (C) 2011 Elsevier B.V. All rights reserved.
C1 [McNeer, Nicole Ali; Saltzman, W. Mark] Yale Univ, Dept Biomed Engn, New Haven, CT 06511 USA.
   [Schleifman, Erica B.; Glazer, Peter M.] Yale Univ, Dept Genet, New Haven, CT 06511 USA.
   [Schleifman, Erica B.; Glazer, Peter M.] Yale Univ, Dept Therapeut Radiol, New Haven, CT 06511 USA.
RP Saltzman, WM (reprint author), Yale Univ, Dept Biomed Engn, MEC 414,55 Prospect St, New Haven, CT 06511 USA.
EM mark.saltzman@yale.edu
FU NIBIB NIH HHS [R01 EB000487-20, R01 EB000487-17, R01 EB000487-19, R01
   EB000487-14, R01 EB000487-18A2, EB000487, R56 EB000487, R01 EB000487-13,
   R01 EB000487, R01 EB000487-16, R01 EB000487-15]; NHLBI NIH HHS [R01
   HL085416-03W1, R01 HL082655, R01 HL085416, R01 HL085416-04, R01
   HL085416-01, HL082655, F30 HL110372, HL085416, R01 HL085416-05, R01
   HL085416-03, R01 HL085416-02]; NIGMS NIH HHS [T32 GM007205, T32GM07205]
CR AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595
   Blum JS, 2008, J CONTROL RELEASE, V129, P66, DOI 10.1016/j.jconrel.2008.04.002
   Cartiera MS, 2009, BIOMATERIALS, V30, P2790, DOI 10.1016/j.biomaterials.2009.01.057
   Chin JY, 2008, P NATL ACAD SCI USA, V105, P13514, DOI 10.1073/pnas.0711793105
   Fahmy TM, 2005, BIOMATERIALS, V26, P5727, DOI 10.1016/j.biomaterials.2005.02.025
   Fang H, 2009, MOL PHARMACEUT, V6, P615, DOI 10.1021/mp800199w
   Harris TJ, 2010, BIOMATERIALS, V31, P998, DOI 10.1016/j.biomaterials.2009.10.012
   Holt N, 2010, NAT BIOTECHNOL, V28, P839, DOI 10.1038/nbt.1663
   Ivanova GD, 2008, NUCLEIC ACIDS RES, V36, P6418, DOI 10.1093/nar/gkn671
   Koppelhus U, 2003, ADV DRUG DELIVER REV, V55, P267, DOI 10.1016/S0169-409X(02)00182-5                                                   
   Koppelhus U, 2008, BIOCONJUGATE CHEM, V19, P1526, DOI 10.1021/bc800068h
   Luo D, 1999, PHARMACEUT RES, V16, P1300, DOI 10.1023/A:1014870102295
   Markman M, 2003, LANCET ONCOL, V4, P277, DOI 10.1016/S1470-2045(03)01074-X
   Maurisse R, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-9
   McNeer NA, 2011, MOL THER, V19, P172, DOI 10.1038/mt.2010.200
   Papapetrou EP, 2005, GENE THER, V12, pS118, DOI 10.1038/sj.gt.3302626
   Park J, 2011, MOL PHARMACEUT, V8, P143, DOI 10.1021/mp100203a
   Persons DA, 2010, ANN NY ACAD SCI, V1202, P69, DOI 10.1111/j.1749-6632.2010.05581.x
   Qaddoumi MG, 2004, PHARM RES, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76                                              
   Rogers FA, 2002, P NATL ACAD SCI USA, V99, P16695, DOI 10.1073/pnas.262556899
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Schleifman E.B., 2010, AM SOC GEN THER 13 A
   Schleifman Erica B., 2008, V435, P175, DOI 10.1007/978-1-59745-232-8_13
   Shen G., 2009, BIOCONJUG CHEM
   Shiraishi T, 2008, NUCLEIC ACIDS RES, V36, P4424, DOI 10.1093/nar/gkn401
   Shiraishi T, 2006, NAT PROTOC, V1, P633, DOI 10.1038/nprot.2006.92
   Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334
   Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530
   Win KY, 2005, BIOMATERIALS, V26, P2713, DOI 10.1016/j.biomaterials.2004.07.050
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
NR 30
TC 7
Z9 8
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 30
PY 2011
VL 155
IS 2
BP 312
EP 316
DI 10.1016/j.jconrel.2011.05.011
PG 5
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 849CD
UT WOS:000297102200025
PM 21620910
OA green_accepted
DA 2018-01-05
ER

PT J
AU Uto, T
   Akagi, T
   Toyama, M
   Nishi, Y
   Shima, F
   Akashi, M
   Baba, M
AF Uto, Tomofumi
   Akagi, Takami
   Toyama, Masaaki
   Nishi, Yosuke
   Shima, Fumiaki
   Akashi, Mitsuru
   Baba, Masanori
TI Comparative activity of biodegradable nanoparticles with aluminum
   adjuvants: Antigen uptake by dendritic cells and induction of immune
   response in mice
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE Nanoparticle; Adjuvant; Dendritic cell; Adaptive immunity; Vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TOLL-LIKE RECEPTORS; VACCINE ADJUVANTS;
   INNATE; LIPOPOLYSACCHARIDE; FUTURE; GP120
AB Biodegradable poly(gamma-glutamic acid) (gamma-PGA) nanoparticles (NPs) are considered to be an excellent antigen carrier. Antigen-carrying gamma-PGA NPs were examined for their uptake by murine dendritic cells (DCs) and subsequent induction of antigen-specific immune responses in mice and compared with aluminum (AL) adjuvants. Ovalbumin (OVA)-carrying NPs (FIwC-OVA-NPs) were taken up much more efficiently by DCs than OVA alone or its AL-associated form. Both OVA-NPs and OVA+AL were detected in an intracellular lysosome compartment of DCs. Furthermore, the uptake of gamma-PGA NPs was inhibited in the presence of pinocytosis and phagocytosis inhibitors. Significantly higher induction of antigen-specific CD8(+) T cells was observed in mice immunized with OVA-carrying gamma-PGA NPs than in those immunized with OVA alone, OVA+AL OVA+3-O-desacyl-4'-monophosphoryl lipid A (MPL), and OVA + AL + MPL Thus, gamma-PGA NPs may have great potential as an effective vaccine carrier and adjuvant for clinical use. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Uto, Tomofumi; Toyama, Masaaki; Nishi, Yosuke; Baba, Masanori] Kagoshima Univ, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, Grad Sch Med & Dent Sci, Kagoshima 8900544, Japan.
   [Akagi, Takami; Shima, Fumiaki; Akashi, Mitsuru] Osaka Univ, Dept Mol Chem, Grad Sch Engn, Suita, Osaka 5650871, Japan.
   [Uto, Tomofumi; Akagi, Takami; Toyama, Masaaki; Nishi, Yosuke; Shima, Fumiaki; Akashi, Mitsuru; Baba, Masanori] Japan Sci & Technol Agcy JST, Tokyo 1500002, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, Grad Sch Med & Dent Sci, Kagoshima 8900544, Japan.
EM m-baba@m2.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
FU Japan Science and Technology Agency
FX This work was supported by Core Research for Evolutional Science and
   Technology from the Japan Science and Technology Agency.
CR Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Eidsmo L, 2009, J IMMUNOL, V182, P3165, DOI 10.4049/jimmunol.0802950
   Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6-5-723
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618                                                      
   Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926                                                         
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Koyama S, 2009, EXPERT REV VACCINES, V8, P1099, DOI [10.1586/erv.09.57, 10.1586/ERV.09.57]
   Okamoto S, 2009, VACCINE, V27, P5896, DOI 10.1016/j.vaccine.2009.07.037
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   QURESHI N, 1982, J BIOL CHEM, V257, P1808
   Sato Katsuaki, 2007, Allergol Int, V56, P183, DOI 10.2332/allergolint.R-06-139
   Uto T, 2009, BIOCHEM BIOPH RES CO, V379, P600, DOI 10.1016/j.bbrc.2008.12.122
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Uto T, 2009, IMMUNOL LETT, V125, P46, DOI 10.1016/j.imlet.2009.05.008
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Yamaguchi S, 2010, CANCER IMMUNOL IMMUN, V59, P759, DOI 10.1007/s00262-009-0796-2
NR 23
TC 24
Z9 24
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD OCT 30
PY 2011
VL 140
IS 1-2
BP 36
EP 43
DI 10.1016/j.imlet.2011.06.002
PG 8
WC Immunology
SC Immunology
GA 826IC
UT WOS:000295346800006
PM 21693134
DA 2018-01-05
ER

PT J
AU Roh, C
   Jo, SK
AF Roh, Changhyun
   Jo, Sung-Kee
TI (-)-Epigallocatechin gallate inhibits hepatitis C virus (HCV) viral
   protein NS5B
SO TALANTA
LA English
DT Article
DE Viral protein; Inhibitor; Screening; Quantum dots; RNA oligonucleotide
ID DEPENDENT RNA-POLYMERASE; GREEN TEA CATECHINS; QUANTUM-DOTS; MECHANISTIC
   INSIGHTS; THERAPEUTIC TARGETS; GENE-EXPRESSION; PROSTATE-CANCER; HIV-1;
   FLAVONOIDS; PRINCIPLE
AB In this study, we elucidated a small molecule inhibitor on viral protein NS58 identified through a high-throughput screening strategy using optical nanoparticle-based RNA oligonucleotide. We have previously shown that quantum dots (QDs)-RNA oligonucleotide can specifically recognize the HCV viral proteins. We have also demonstrated that conjugated QDs-RNA oligonucleotide can specifically and sensitively interact with designed biochips [1,2]. Among the flavonoids examined, (-)-epigallocatechin gallate (EGCG) demonstrated a remarkable inhibition activity on HCV viral protein, NS5B. (-)-Epigallocatechin gallate, at 0.005 mu g mL(-1) or more, concentration-dependently attenuated the binding affinity on a designed biochip as evidenced by QDs-RNA oligonucleotide. At a concentration of 0.1 mu g mL(-1), (-)epigallocatechin gallate showed a 50% inhibition activity on QDs-RNA oligonucleotide biochip assay. We screened a small molecule inhibitor on the viral protein, NS5B, identified through a high-throughput screening strategy using on-chip optical nanoparticle-based RNA oligonucleotide on chip. In this designed strategy, the convenient and efficient screening and development of an on-chip viral protein inhibitor using a QDs-RNA oligonucleotide assay is achievable with high sensitivity and simplicity. In addition, this platform is expected to be applicable toward the inhibitor screening of other types of diseases. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Roh, Changhyun; Jo, Sung-Kee] KAERI, Radiat Res Div Biotechnol, ARTI, Jeongeup 580185, Jeonbuk, South Korea.
RP Roh, C (reprint author), KAERI, Radiat Res Div Biotechnol, ARTI, 1266 Sinjeong Dong, Jeongeup 580185, Jeonbuk, South Korea.
EM chroh@kaeri.re.kr
OI Roh, Changhyun/0000-0002-0542-4828
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2011-0010634]; SNU-KAERI Degree & Research
   center for radiation convergence sciences from the Korea Research
   Council of Foundation (KRCF) Science and Technology, Republic of Korea
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (grant no. 2011-0010634). This work
   was partially supported by SNU-KAERI Degree & Research center for
   radiation convergence sciences from the Korea Research Council of
   Foundation (KRCF) Science and Technology, Republic of Korea.
CR Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8
   Aktas O, 2007, J NEUROIMMUNOL, V184, P17, DOI 10.1016/j.jneuroim.2006.11.026
   Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Castello G, 2010, CLIN IMMUNOL, V134, P237, DOI 10.1016/j.clim.2009.10.007
   Ciesek S, 2009, HEPATOLOGY, V50, P1638, DOI 10.1002/hep.23281
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   Das A., 2009, CANCER, V116, P164
   De Sousa RRR, 2007, J ENZYM INHIB MED CH, V22, P439, DOI 10.1080/14756360601162063
   DEFRANCESCO R, 2003, ANTIVIR RES, V58, P11
   Dixon RA, 2002, PHYTOCHEMISTRY, V60, P205, DOI 10.1016/S0031-9422(02)00116-4
   Ferrari E, 1999, J VIROL, V73, P1649
   Galeotti F, 2008, PHYTOCHEM LETT, V1, P44, DOI 10.1016/j.phytol.2007.10.001
   Hamza A, 2006, J PHYS CHEM B, V110, P2910, DOI 10.1021/jp0550762
   Heinonen Satu-Maarit, 2002, Phytochemistry Reviews, V1, P175, DOI 10.1023/A:1022555216303
   Hsieh TC, 2009, ANTICANCER RES, V29, P4025
   Katiyar S, 2007, J NUTR BIOCHEM, V18, P287, DOI 10.1016/j.jnutbio.2006.08.004
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Maheshwari Anurag, 2010, Clin Liver Dis, V14, P169, DOI 10.1016/j.cld.2009.11.007
   Middleton J. E., 1992, BIOCHEM PHARMACOL, V43, P1167
   Pawlotsky JM, 2006, CURR TOP MICROBIOL, V299, P261
   Philips BJ, 2009, BIOMED RES-TOKYO, V30, P207, DOI 10.2220/biomedres.30.207                                                        
   Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   Qiao YY, 2009, ARCH PHARM RES, V32, P1309, DOI 10.1007/s12272-009-1917-3
   Reed KE, 2000, CURR TOP MICROBIOL, V242, P55
   Rivas-Estilla AM, 2003, REV INVEST CLIN, V55, P51
   Roh C, 2010, J CHEM TECHNOL BIOT, V85, P1130, DOI 10.1002/jctb.2409
   Roh C, 2010, INT J NANOMED, V5, P323
   Ryu K, 2009, BIOORGAN MED CHEM, V17, P2975, DOI 10.1016/j.bmc.2009.03.024
   Shi ST, 2001, CELL MOL LIFE SCI, V58, P1276, DOI 10.1007/PL00000939                                                              
   Smith AM, 2009, NAT BIOTECHNOL, V27, P732, DOI 10.1038/nbt0809-732
   Spencer JPE, 2008, BRIT J NUTR, V99, pES60, DOI 10.1017/S0007114508965776
   TONIUTTO P, 2011, DRUGS, V11, P738
   Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016
   Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914                                                                
   Yu WW, 2006, BIOCHEM BIOPH RES CO, V348, P781, DOI 10.1016/j.bbrc.2006.07.160
NR 37
TC 13
Z9 13
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD OCT 15
PY 2011
VL 85
IS 5
BP 2639
EP 2642
DI 10.1016/j.talanta.2011.08.035
PG 4
WC Chemistry, Analytical
SC Chemistry
GA 836MK
UT WOS:000296115600056
PM 21962695
DA 2018-01-05
ER

PT J
AU Chen, L
   Liu, XL
   Su, B
   Li, J
   Jiang, L
   Han, D
   Wang, ST
AF Chen, Li
   Liu, Xueli
   Su, Bin
   Li, Jing
   Jiang, Lei
   Han, Dong
   Wang, Shutao
TI Aptamer-Mediated Efficient Capture and Release of T Lymphocytes on
   Nanostructured Surfaces
SO ADVANCED MATERIALS
LA English
DT Article
ID SILICON NANOWIRE ARRAYS; IMMUNODEFICIENCY-VIRUS-INFECTION; CIRCULATING
   TUMOR-CELLS; CANCER-CELLS; ANTIBODY MICROARRAY; HIV-INFECTION;
   NANOSCALE; DEPLETION; ADHESION; BLOOD
AB A nanostructured platform that combines silicon nanowire arrays and DNA aptamers realizes significant capture and efficient release of T lymphocytes. An approximately two orders of magnitude enhancement in capture efficiency compared to planar surfaces is observed with good release performance. This method of capture and release provides an artful strategy to fulfill the demands of cell isolation and diagnosis.
C1 [Li, Jing; Han, Dong] Natl Ctr NanoSci & Technol, Beijing 100190, Peoples R China.
   [Chen, Li; Liu, Xueli; Su, Bin; Jiang, Lei; Wang, Shutao] Chinese Acad Sci, Inst Chem, BNLMS, Beijing, Peoples R China.
   [Chen, Li; Liu, Xueli; Li, Jing] Chinese Acad Sci, Grad Sch, Beijing 100864, Peoples R China.
RP Han, D (reprint author), Natl Ctr NanoSci & Technol, Beijing 100190, Peoples R China.
EM dhan@nanoctr.cn; stwang@iccas.ac.cn
RI Su, Bin/D-5635-2015; Shutao, Wang/E-5448-2011
OI Su, Bin/0000-0002-7122-6694; Shutao, Wang/0000-0002-2559-5181
FU National Research Fund for Fundamental Key Projects [2010CB934700,
   2009CB930404, 2007CB936403]; National Natural Science Foundation
   [20920102036, 20974113]; David Geffen School of Medicine at UCLA
FX The authors acknowledge financial support from the National Research
   Fund for Fundamental Key Projects (2010CB934700, 2009CB930404,
   2007CB936403), and the National Natural Science Foundation (20920102036,
   20974113). The authors also thank Prof. Fulong Liao, Prof. Dongsheng
   Liu, Jiayi Xie, Quanmei Sun, Dr. Bo Yuan, Dr. Ke Zhang, Dr. Ligeng Xu,
   Dr. Ling Lin, Dr. Zhongxin Xue, and Lin Jin for technical support and
   helpful discussions. Gwen Owens from the David Geffen School of Medicine
   at UCLA is greatly appreciated for support and helpful suggestions.
CR Adams AA, 2008, J AM CHEM SOC, V130, P8633, DOI 10.1021/ja8015022
   Angres B, 2005, EXPERT REV MOL DIAGN, V5, P769, DOI 10.1586/14737159.5-5.769
   Barsov EV, 2006, IMMUNOL LETT, V105, P26, DOI 10.1016/j.imlet.2005.11.029
   Belov L, 2001, CANCER RES, V61, P4483
   Bettinger CJ, 2009, ANGEW CHEM INT EDIT, V48, P5406, DOI 10.1002/anie.200805179
   Cash KJ, 2009, J AM CHEM SOC, V131, P6955, DOI 10.1021/ja9011595
   Chen DS, 2005, PLOS MED, V2, P1018, DOI 10.1371/journal.pmed.0020265
   Chen L, 2011, COLLOID SURFACE B, V85, P2, DOI 10.1016/j.colsurfb.2010.10.034
   Chen L, 2009, J AM CHEM SOC, V131, P10467, DOI 10.1021/ja9019935
   Falsey JR, 2001, BIOCONJUGATE CHEM, V12, P346, DOI 10.1021/bc000141q
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Fang XH, 2010, ACCOUNTS CHEM RES, V43, P48, DOI 10.1021/ar900101s
   Fischer KE, 2009, NANO LETT, V9, P716, DOI 10.1021/nl803219f
   Gao ZQ, 2007, ANAL CHEM, V79, P3291, DOI 10.1021/ac061808q
   Guarner J, 1997, CYTOMETRY, V30, P178, DOI 10.1002/(SICI)1097-0320(19970815)30:4<178::AID-CYTO3>3.0.CO;2-G
   Gupta HS, 2006, P NATL ACAD SCI USA, V103, P17741, DOI 10.1073/pnas.0604237103
   Herr JK, 2006, ANAL CHEM, V78, P2918, DOI 10.1021/ac052015r
   Hochbaum AI, 2008, NATURE, V451, P163, DOI 10.1038/nature06381
   Hochbaum AI, 2010, CHEM REV, V110, P527, DOI 10.1021/cr900075v
   Hoff A, 2002, CHEMBIOCHEM, V3, P1183, DOI 10.1002/1439-7633(20021202)3:12<1183::AID-CBIC1183>3.0.CO;2-Q                   
   Hoff A, 2004, MOL DIVERS, V8, P311, DOI 10.1023/B:MODI.0000036241.85469.85
   Hou S, 2008, ANGEW CHEM INT EDIT, V47, P1072, DOI 10.1002/anie.200704264
   Kim H, 2006, ADV FUNCT MATER, V16, P1313, DOI 10.1002/adfm.200500888
   Kim ST, 2010, NANO LETT, V10, P2877, DOI 10.1021/nl100942p
   Kim W, 2007, J AM CHEM SOC, V129, P7228, DOI 10.1021/ja071456k
   Ko IK, 2005, BIOMATERIALS, V26, P687, DOI 10.1016/j.biomaterials.2004.03.014
   Kwong GA, 2009, J AM CHEM SOC, V131, P9695, DOI 10.1021/ja9006707
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Peng KQ, 2005, ANGEW CHEM INT EDIT, V44, P2737, DOI 10.1002/anie.200462995
   Phillips JA, 2009, ANAL CHEM, V81, P1033, DOI 10.1021/ac802092j
   Yi C., 2008, ACS APPL MATER INTER, V1, P30, DOI [10.1021/am800027d, DOI 10.1021/AM800027D)]
   Qi SJ, 2009, ACS APPL MATER INTER, V1, P30, DOI 10.1021/am800027d
   Ranella A, 2010, ACTA BIOMATER, V6, P2711, DOI 10.1016/j.actbio.2010.01.016
   Shalek AK, 2010, P NATL ACAD SCI USA, V107, P1870, DOI 10.1073/pnas.0909350107
   Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103
   Shao MW, 2005, ADV FUNCT MATER, V15, P1478, DOI 10.1002/adfm.200500080
   Sherman GG, 1999, J IMMUNOL METHODS, V222, P209, DOI 10.1016/S0022-1759(98)00172-0                                                   
   SILICIANO RF, 1988, CELL, V54, P561, DOI 10.1016/0092-8674(88)90078-5
   Smit-McBride Z, 1998, J VIROL, V72, P6646
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   Sun TL, 2007, J AM CHEM SOC, V129, P1496, DOI 10.1021/ja0686155
   Veazey RS, 2001, TRENDS IMMUNOL, V22, P626, DOI 10.1016/S1471-4906(01)02039-7
   Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427                                                    
   Wang ST, 2011, ANGEW CHEM INT EDIT, V50, P3084, DOI 10.1002/anie.201005853
   Wang ST, 2009, ANGEW CHEM INT EDIT, V48, P8970, DOI 10.1002/anie.200901668
   Wang ZK, 2010, ANAL CHEM, V82, P36, DOI 10.1021/ac902144w
   Xu Y, 2009, ANAL CHEM, V81, P7436, DOI 10.1021/ac9012072
   Zieglschmid V, 2005, CRIT REV CL LAB SCI, V42, P155, DOI 10.1080/10408360590913696
NR 48
TC 109
Z9 112
U1 12
U2 217
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD OCT 11
PY 2011
VL 23
IS 38
BP 4376
EP +
DI 10.1002/adma.201102435
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 847XH
UT WOS:000297007000004
PM 21882263
DA 2018-01-05
ER

PT J
AU Pallaoro, A
   Braun, GB
   Moskovits, M
AF Pallaoro, Alessia
   Braun, Gary B.
   Moskovits, Martin
TI Quantitative ratiometric discrimination between noncancerous and
   cancerous prostate cells based on neuropilin-1 overexpression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE surface-enhanced Raman spectroscopy biomarker; cancer cell
   identification; multiplexing; silver nanoparticles
ID HUMAN IMMUNODEFICIENCY VIRUS; CIRCULATING TUMOR-CELLS; SURFACE-ENHANCED
   RAMAN; PROTEIN; FLUORESCENCE; SPECTROSCOPY; SCATTERING; ELECTRODE;
   PEPTIDES; DELIVERY
AB A multiplexed, ratiometric method is described that can confidently distinguish between cancerous and noncancerous epithelial prostate cells in vitro. The technique is based on bright surface-enhanced resonance Raman scattering (SERRS) biotags (SBTs) infused with unique Raman reporter molecules, and carrying cell-specific peptides. Two sets of SBTs were used. One targets the neuropilin-1 (NRP-1) receptors of cancer cells through the RPARPAR peptide. The other functions as a positive control (PC) and binds to both noncancerous and cancer cells through the HIV-derived TAT peptide. Point-by-point 2D Raman maps of the spatial distribution of the two tags were constructed with subcellular resolution from cells simultaneously incubated with the two sets of SBTs. Averaging the SERRS signal over a given cell yielded an NRP/PC ratio from which a robust quantitative measure of the overexpression of the NRP-1 by the cancer cell line was extracted. The use of a local, on-cell reference produces quantitative, statistically robust measures of overexpression independent of such sources of uncertainty as variations in the location of the focal plane, the local cell concentration, and turbidity.
C1 [Pallaoro, Alessia; Braun, Gary B.; Moskovits, Martin] Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.
RP Moskovits, M (reprint author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.
EM moskovits@chem.ucsb.edu
RI Braun, Gary/A-4913-2009; Pallaoro, Alessia/C-4206-2011
OI Braun, Gary/0000-0002-6301-0228; 
FU Institute for Collaborative Biotechnologies from US Army Research Office
   [DAAD19-03-D-0004]; National Science Foundation [DMR-0080034,
   DMR-0216466]; Santa Barbara Cancer Center
FX We are grateful to Professor Erkki Ruoslahti for providing us with
   advice and samples of the FAM-C-X-GRPARPAR-OH peptide. We thank
   Professor Norbert Reich at University of California, Santa Barbara, and
   Dr. Tambet Teesalu in the Ruoslahti lab for many helpful discussions.
   This work was supported by the Institute for Collaborative
   Biotechnologies through Grant DAAD19-03-D-0004 from the US Army Research
   Office and made extensive use of the Materials Research Laboratory
   Central Facilities at University of California, Santa Barbara, supported
   by the National Science Foundation under Awards DMR-0080034 and
   DMR-0216466 for the high-resolution transmission electron
   microscopy/scanning transmission electron microscopy. G. B. B. was also
   supported in part by a fellowship from the Santa Barbara Cancer Center.
CR Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215
   Braun GB, 2009, J PHYS CHEM C, V113, P13622, DOI 10.1021/jp903399p
   Braun GB, 2009, ACS NANO, V3, P2007, DOI 10.1021/nn900469q
   Chen B, 2008, LANGMUIR, V24, P11866, DOI 10.1021/la802048s
   Crow P, 2005, BRIT J CANCER, V92, P2166, DOI 10.1038/sj.bjc.6602638
   Eschwege P, 2009, BRIT J CANCER, V100, P608, DOI 10.1038/sj.bjc.6604912
   Feng SY, 2010, BIOSENS BIOELECTRON, V25, P2414, DOI 10.1016/j.bios.2010.03.033
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guarrotxena N., 2010, LANGMUIR, V27, P347
   Harris A. T., 2009, HEAD NECK ONCOL, V1, P1, DOI DOI 10.1186/1758-3284-1-38
   HARVEY TJ, 2008, J BIOMED OPT, V13
   HUTCHINSON K, 1984, J CHEM SOC FARAD T 1, V80, P2053, DOI 10.1039/f19848002053
   Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Lutz B, 2008, J HISTOCHEM CYTOCHEM, V56, P371, DOI 10.1369/jhc.7A7313.2007
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   NAUJOK RR, 1993, LANGMUIR, V9, P1771, DOI 10.1021/la00031a026                                                             
   Pallaoro A, 2010, SMALL, V6, P618, DOI 10.1002/smll.200901893
   Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375
   Roupret M, 2007, CLIN CANCER RES, V13, P1720, DOI 10.1158/1078-0432.CCR-06-2467
   Sabatte G, 2008, ANAL CHEM, V80, P2351, DOI 10.1021/ac071343j
   Scher HI, 2009, LANCET ONCOL, V10, P233, DOI 10.1016/S1470-2045(08)70340-1
   Sun L, 2007, NANO LETT, V7, P351, DOI 10.1021/nl062453t
   Taleb A, 2006, J PHYS CHEM B, V110, P19625, DOI 10.1021/jp061981q
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Vajna B, 2010, J PHARMACEUT BIOMED, V51, P30, DOI 10.1016/j.jpba.2009.07.030
   Yuen JM, 2010, ANAL CHEM, V82, P8382, DOI 10.1021/ac101951j
   Zhang L, 2005, ANAL CHIM ACTA, V545, P262, DOI 10.1016/j.aca.2005.04.080
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
   WEBBER MME, 2001, Patent No. 5824488
NR 31
TC 49
Z9 50
U1 1
U2 34
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 4
PY 2011
VL 108
IS 40
BP 16559
EP 16564
DI 10.1073/pnas.1109490108
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 828WX
UT WOS:000295536000022
PM 21930955
OA gold
DA 2018-01-05
ER

PT J
AU He, NY
   Zeng, X
   Wang, WD
   Deng, KL
   Pan, YZ
   Xiao, L
   Zhang, J
   Li, K
AF He, Nongyue
   Zeng, Xin
   Wang, Weida
   Deng, Kunlong
   Pan, Yunzhi
   Xiao, Li
   Zhang, Jia
   Li, Kai
TI Challenges and Future Expectations of Reversed Gene Therapy
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Reversed Gene Therapy; Loss of Function; CCR5; Hematopoietic Stem Cells;
   HIV
ID ZINC-FINGER NUCLEASES; DELIVERY-SYSTEMS; BRANCHED POLYETHYLENIMINE;
   TRIAMCINOLONE ACETONIDE; TRANSFECTION EFFICIENCY; HIV-INFECTION;
   IN-VITRO; NANOPARTICLES; DNA; VECTORS
AB Gene therapy is a genetic intervention used for the prevention or treatment of diseases by targeting selected genes with specific nucleotides. The most common form of gene therapy involves the establishment of a function by transfer of functional genes or correction of mutated genes. In other situations, suppression or abolishment of a function is required in order to balance a complicated regulatory system or to deplete cellular molecules crucial for pathogen infection. The latter in fact employs an opposite strategy compared to those used in classical gene therapy, and can be defined as reversed gene therapy. This paper takes CCR5-based stem cell gene therapy as an example to discuss the challenges and future expectations of reversed gene therapy.
C1 [Wang, Weida; Deng, Kunlong; Pan, Yunzhi; Xiao, Li; Zhang, Jia; Li, Kai] Soochow Univ, Mol Med Lab, Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
   [He, Nongyue; Zeng, Xin] Southeast Univ, State Key Lab Bioelect, Sch Biol Sci & Med Engn, Nanjing 210096, Jiangsu, Peoples R China.
   [Wang, Weida] Suzhou Inst Chinese Mat Med, Suzhou 215123, Peoples R China.
RP Li, K (reprint author), Soochow Univ, Mol Med Lab, Coll Pharmaceut Sci, Suzhou 215123, Peoples R China.
FU National Natural Science Foundation of China [30970877, 60927001];
   Chinese National 863 major [2008AA02Z436]; National Key Program for
   Developing Basic Research of China [2010CB933903]; Jiangsu Higher
   Education Institutions
FX This study is partially supported by National Natural Science Foundation
   of China (No. 30970877, 60927001), Chinese National 863 major grant
   (2008AA02Z436), the National Key Program for Developing Basic Research
   of China (2010CB933903), and the Priority Academic Program Development
   of Jiangsu Higher Education Institutions.
CR Alemdaroglu FE, 2007, ORG BIOMOL CHEM, V5, P1311, DOI 10.1039/b617941j
   Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Cebrian V, 2011, ACTA BIOMATER, V7, P3645, DOI 10.1016/j.actbio.2011.06.018
   Chen LM, 2010, GASTROENTEROLOGY, V138, P1123, DOI 10.1053/j.gastro.2009.10.046
   Chen L. L., 2005, J U S CHINA MED EDIT, V33, P166
   Dai JA, 2011, BIOMATERIALS, V32, P1694, DOI 10.1016/j.biomaterials.2010.10.044
   De Smedt SC, 2000, PHARMACEUT RES, V17, P113, DOI 10.1023/A:1007548826495                                                         
   Deng JZ, 2011, ACTA BIOMATER, V7, P2200, DOI 10.1016/j.actbio.2011.02.003
   Feng ZQ, 2009, BIOMATERIALS, V30, P2753, DOI 10.1016/j.biomaterials.2009.01.053
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Gao X, 2011, J BIOMED NANOTECHNOL, V7, P285, DOI 10.1166/jbn.2011.1280
   Gauglitz GG, 2011, MOL PHARMACEUT, V8, P1471, DOI 10.1021/mp2001457
   Goyal R, 2011, J BIOMED NANOTECHNOL, V7, P52, DOI 10.1166/jbn.2011.1197
   Heike Yuji, 2009, Nihon Rinsho, V67, P1958
   Herber-Jonat S, 2011, INFLAMM RES, V60, P245, DOI 10.1007/s00011-010-0260-y
   Kitchen SG, 2011, CURR OPIN HIV AIDS, V6, P68, DOI 10.1097/COH.0b013e3283412370
   KOLOSTOVA K, 2011, AM J OTOLARYNGOL
   Landovitz RJ, 2009, NEW ENGL J MED, V361, P1768, DOI 10.1056/NEJMcp0904189
   Li T, 2011, NUCLEIC ACIDS RES, V39, P359, DOI 10.1093/nar/gkq704
   Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353
   Ma K, 2010, J GENE MED, V12, P669, DOI 10.1002/jgm.1485
   Ma K, 2009, BIOMATERIALS, V30, P6109, DOI 10.1016/j.biomaterials.2009.07.036
   Ma K, 2009, BIOMATERIALS, V30, P3780, DOI 10.1016/j.biomaterials.2009.03.042
   Mok HJ, 2008, EUR J PHARM BIOPHARM, V68, P105, DOI 10.1016/j.ejpb.2007.04.022
   Namgung R, 2010, BIOMATERIALS, V31, P4204, DOI 10.1016/j.biomaterials.2010.01.123
   Nimesh S, 2011, J BIOMED NANOTECHNOL, V7, P504, DOI 10.1166/jbn.2011.1313
   Oliveira H, 2010, J BIOMED MATER RES A, V95A, P801, DOI 10.1002/jbm.a.32874
   Perez EE, 2008, NAT BIOTECHNOL, V26, P808, DOI 10.1038/nbt1410
   Poinern GEJ, 2010, J BIOMED NANOTECHNOL, V6, P497, DOI 10.1166/jbn.2010.1148
   Qi XD, 2011, ANTI-CANCER DRUG, V22, P556, DOI 10.1097/CAD.0b013e328345b4e7
   Rejinold NS, 2011, J BIOMED NANOTECHNOL, V7, P521, DOI 10.1166/jbn.2011.1320
   ROGERS ML, 2011, J CONTROL RELEASE
   Singh R, 2011, J BIOMED NANOTECHNOL, V7, P489, DOI 10.1166/jbn.2011.1324
   Tan L, 2010, CANCER BIOL THER, V9, P350, DOI 10.4161/cbt.9.5.10879                                                           
   Verma AK, 2011, J BIOMED NANOTECHNOL, V7, P63, DOI 10.1166/jbn.2011.1202
   Vural I, 2011, J BIOMED NANOTECHNOL, V7, P426, DOI 10.1166/jbn.2011.1294
   Wang T, 2007, J NANOSCI NANOTECHNO, V7, P4571, DOI 10.1166/jnn.2007.882
   Wang T, 2010, NANOSCALE, V2, P230, DOI 10.1039/b9nr00125e
   Wang T, 2011, J PHYS CHEM C, V115, P7613, DOI 10.1021/jp200546h
   Wang YH, 2011, BIOMACROMOLECULES, V12, P1032, DOI 10.1021/bm101364f
   Wang YH, 2011, NANOMED-NANOTECHNOL, V7, P193, DOI 10.1016/j.nano.2010.08.003
   Warnock JN, 2011, METHODS MOL BIOL, V737, P1, DOI 10.1007/978-1-61779-095-9_1
   Wijagkanalan W, 2011, J CONTROL RELEASE, V149, P42, DOI 10.1016/j.jconrel.2009.12.016
   Williams PD, 2011, CARDIOVASC RES, V91, P565, DOI 10.1093/cvr/cvr197
   Zhang Meizhen, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P178, DOI 10.3969/j.issn.1672-7347.2011.02.016
NR 45
TC 11
Z9 11
U1 0
U2 12
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2011
VL 11
IS 10
BP 8634
EP 8638
DI 10.1166/jnn.2011.5723
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 866ES
UT WOS:000298363900030
PM 22400236
DA 2018-01-05
ER

PT J
AU Moura, M
   Josse, S
   Albert, NVN
   Fournier, C
   Duverlie, G
   Castelain, S
   Soriano, E
   Marco-Contelles, J
   Balzarini, J
   Postel, D
AF Moura, Marina
   Josse, Solen
   Albert Nguyen Van Nhien
   Fournier, Carole
   Duverlie, Gilles
   Castelain, Sandrine
   Soriano, Elena
   Marco-Contelles, Jose
   Balzarini, Jan
   Postel, Denis
TI Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds
   against HIV-1 and HCV
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE TSAO-T; N-3 acylated nucleoside; HIV-1; HCV; RT inhibitor
ID HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT
   RNA-POLYMERASE; REVERSE-TRANSCRIPTASE; ANTI-HIV-1 ACTIVITY; NUCLEOSIDE
   ANALOGS; ANTIVIRAL ACTIVITY; INHIBITORS; REPLICATION; DERIVATIVES
AB Preparation of a small library of derivatives of the potent HIV-1 Reverse Transcriptase inhibitor TSAO-T bearing mono or di-carbonyl substituents (designed after docking analysis) at position N-3 is reported. A one-pot synthetic methodology has been developed that involves: (i) mono-reaction of TSAO-T with glutaryl dichloride under phase transfer conditions and (ii) in situ acyclic substitution of the remaining chloro atom by oxygen or nitrogen nucleophiles. The method is compatible with the polyfunctionality of the TSAO-T molecule, proceeds with high conversion yields and allows introducing molecular diversity. The anti-HIV-1 and -HCV activity was studied in cell culture. The new N-3 acylated TSAO-T derivatives are active against HIV-1 (nanomolar range). Anti-HCV activity was observed in the micromolar range, that is at compound concentrations that were found cytostatic against human T-lymphocytes. (C) 2011 Elsevier Masson SAS. All rights reserved.
C1 [Moura, Marina; Josse, Solen; Albert Nguyen Van Nhien; Postel, Denis] Univ Picardie Jules Verne, Lab Glucides, UMR 6219, F-80039 Amiens, France.
   [Fournier, Carole; Duverlie, Gilles; Castelain, Sandrine] Ctr Hosp Univ Amiens, Virol Lab, F-80054 Amiens, France.
   [Fournier, Carole; Duverlie, Gilles; Castelain, Sandrine] Univ Picardie Jules Verne, EA4294, F-80036 Amiens, France.
   [Soriano, Elena; Marco-Contelles, Jose] CSIC, Lab Rad Libres & Quim Computac IQOG, E-28006 Madrid, Spain.
   [Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Postel, D (reprint author), Univ Picardie Jules Verne, Lab Glucides, UMR 6219, 33 Rue St Leu, F-80039 Amiens, France.
EM denis.postel@u-picardie.fr
OI Castelain, Sandrine/0000-0002-2670-3148
FU Conseil Regional de Picardie; K.U.Leuven (GOA) [10/014]
FX We thank the Conseil Regional de Picardie for financial support and
   D.Lesur for his helpful analysis work. Mrs. Leen Ingels provided
   excellent technical assistance for the HIV assays. The HIV research of
   JB was supported by the K.U.Leuven (GOA no. 10/014).
CR Anderson KB, 2004, CLIN INFECT DIS, V39, P1507, DOI 10.1086/425360                                                                  
   BALZARINI J, 1993, J VIROL, V67, P5353
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   Bassit Leda, 2008, Antiviral Chemistry & Chemotherapy, V19, P25
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   Bonache MC, 2008, NUCLEOS NUCLEOT NUCL, V27, P351, DOI 10.1080/15257770801943990
   Bonache MC, 2005, J MED CHEM, V48, P6653, DOI 10.1021/jm050437n
   Bonache MC, 2003, NUCLEOS NUCLEOT NUCL, V22, P947, DOI 10.1081/NCN-120022692
   Camarasa MJ, 2004, CURR TOP MED CHEM, V4, P945, DOI 10.2174/1568026043388600                                                        
   CAMARASA MJ, 1992, J MED CHEM, V35, P2721, DOI 10.1021/jm00093a002
   Camarasa MJ, 2000, J CARBOHYD CHEM, V19, P451, DOI 10.1080/07328300008544093                                                       
   Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200
   Chamorro C, 2000, ANTIVIR CHEM CHEMOTH, V11, P61, DOI 10.1177/095632020001100106                                                      
   Clark JL, 2005, J MED CHEM, V48, P5504, DOI 10.1021/jm0502788
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Das K, 2011, J MED CHEM, V54, P2727, DOI 10.1021/jm101536x
   De Francesco R, 2007, ADV DRUG DELIVER REV, V59, P1242, DOI 10.1016/j.addr.2007.04.016
   Delgrange D, 2007, J GEN VIROL, V88, P2495, DOI 10.1099/vir.0.82872-0
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Eldrup AB, 2004, J MED CHEM, V47, P2283, DOI 10.1021/jm030424e
   Frisch M. J., 2001, GAUSSIAN98 REVISION
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Morris G.M., 2000, AUTODOCK AUTOMATED D
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Perez-Perez M.J., 1992, TETRAHEDRON LETT, V33, P3029
   PEREZPEREZ MJ, 1992, J MED CHEM, V35, P2988, DOI 10.1021/jm00094a009
   Polienko JF, 2008, J ORG CHEM, V73, P502, DOI 10.1021/jo701803a
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SEKINE M, 1989, J ORG CHEM, V54, P2321, DOI 10.1021/jo00271a015
   Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042                                                                  
   Sommadossi J.-P., 2001, METHODS COMPOSITIONS
   Stuyver LJ, 2003, ANTIMICROB AGENTS CH, V47, P244, DOI 10.1128/AAC.47.1.244-254.2003
   Szabo E, 2003, PATHOL ONCOL RES, V9, P215, DOI 10.1007/BF02893380                                                              
   Tomassi C, 2008, BIOORGAN MED CHEM, V16, P4733, DOI 10.1016/j.bmc.2008.02.026
   Tomassi C, 2008, BIOORG MED CHEM LETT, V18, P2277, DOI 10.1016/j.bmcl.2008.03.010
   Tsou LK, 2010, BIOORG MED CHEM LETT, V20, P2137, DOI 10.1016/j.bmcl.2010.02.043
   Van Nhien AN, 2005, J MED CHEM, V48, P4276, DOI 10.1021/jm050091g
   Vrolijk JM, 2003, J VIROL METHODS, V110, P201, DOI 10.1016/S0166-0934(03)00134-4
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Wei Y, 2009, BIOORGAN MED CHEM, V17, P3003, DOI 10.1016/j.bmc.2009.03.019
NR 40
TC 5
Z9 6
U1 0
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD OCT
PY 2011
VL 46
IS 10
BP 5046
EP 5056
DI 10.1016/j.ejmech.2011.08.017
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 835MX
UT WOS:000296041600028
PM 21880398
DA 2018-01-05
ER

PT J
AU Tzoupis, H
   Leonis, G
   Durdagi, S
   Mouchlis, V
   Mavromoustakos, T
   Papadopoulos, MG
AF Tzoupis, Haralambos
   Leonis, Georgios
   Durdagi, Serdar
   Mouchlis, Varnavas
   Mavromoustakos, Thomas
   Papadopoulos, Manthos G.
TI Binding of novel fullerene inhibitors to HIV-1 protease: insight through
   molecular dynamics and molecular mechanics Poisson-Boltzmann surface
   area calculations
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE HIV-1 PR; QSAR; Molecular dynamics; MM-PBSA; Fullerenes
ID FREE-ENERGY CALCULATIONS; VIRUS TYPE-1 PROTEASE; DRUG-RESISTANCE;
   EFFICIENT GENERATION; SUBSTRATE-BINDING; CARBON NANOTUBES; AM1-BCC
   MODEL; PR INHIBITORS; FORCE-FIELDS; WILD-TYPE
AB The objectives of this study include the design of a series of novel fullerene-based inhibitors for HIV-1 protease (HIV-1 PR), by employing two strategies that can also be applied to the design of inhibitors for any other target. Additionally, the interactions which contribute to the observed exceptionally high binding free energies were analyzed. In particular, we investigated: (1) hydrogen bonding (H-bond) interactions between specific fullerene derivatives and the protease, (2) the regions of HIV-1 PR that play a significant role in binding, (3) protease changes upon binding and (4) various contributions to the binding free energy, in order to identify the most significant of them. This study has been performed by employing a docking technique, two 3D-QSAR models, molecular dynamics (MD) simulations and the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) method. Our computed binding free energies are in satisfactory agreement with the experimental results. The suitability of specific fullerene derivatives as drug candidates was further enhanced, after ADMET (absorption, distribution, metabolism, excretion and toxicity) properties have been estimated to be promising. The outcomes of this study revealed important protein-ligand interaction patterns that may lead towards the development of novel, potent HIV-1 PR inhibitors.
C1 [Tzoupis, Haralambos; Leonis, Georgios; Mavromoustakos, Thomas; Papadopoulos, Manthos G.] Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, Athens 11635, Greece.
   [Tzoupis, Haralambos; Mouchlis, Varnavas; Mavromoustakos, Thomas] Univ Athens, Dept Chem, Athens 15771, Greece.
   [Durdagi, Serdar] Univ Calgary, Dept Biol Sci, Inst Biocomplex & Informat, Calgary, AB T2N 1N4, Canada.
RP Leonis, G (reprint author), Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, 48 Vas Constantinou Ave, Athens 11635, Greece.
EM gleonis@eie.gr; mpapad@eie.gr
RI Durdagi, Serdar/B-6862-2009
OI MAVROMOUSTAKOS, THOMAS/0000-0001-5309-992X; Durdagi,
   Serdar/0000-0002-0426-0905
FU CINECA under ISCRA initiative; European Commission [245866]; European
   Union; Greek national funds through the Operational Program "Education
   and Lifelong Learning" of the National Strategic Reference Framework
   (NSRF)-Research Funding Program: Heracleitus II
FX We acknowledge the CINECA award under the ISCRA initiative, for the
   availability of high performance computing resources and support. This
   work was supported by funding provided by the European Commission for
   the FP7-REGPOT-2009-1 Project 'ARCADE' (Grant Agreement No. 245866).
   Also, the research has been co-financed by the European Union (European
   Social Fund-ESF) and Greek national funds through the Operational
   Program "Education and Lifelong Learning" of the National Strategic
   Reference Framework (NSRF)-Research Funding Program: Heracleitus II.
   Investing in knowledge society through the European Social Fund.
CR Ajay, 1999, J MED CHEM, V42, P4942, DOI 10.1021/jm990017w                                                               
   Anson BD, 2005, LANCET, V365, P682
   Thompson Mark A., ARGUSLAB 4 0 1 MA TH
   BINGEL C, 1993, CHEM BER-RECL, V126, P1957, DOI 10.1002/cber.19931260829                                                        
   Bjelakovic MS, 2007, CARBON, V45, P2260, DOI 10.1016/j.carbon.2007.06.027
   Cai YF, 2010, J CHEM THEORY COMPUT, V6, P1358, DOI 10.1021/ct9004678                                                               
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Case D. A., 2006, AMBER 9
   Charlier L, 2007, PHYS CHEM CHEM PHYS, V9, P576
   CHEN ZG, 1994, J BIOL CHEM, V269, P26344
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Freitas RP, 2008, TETRAHEDRON, V64, P11409, DOI 10.1016/j.tet.2008.09.047
   Durdagi S, 2010, CURR MED CHEM, V17, P3514, DOI 10.2174/092986710792927886                                                      
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Durdagi S, 2008, BIOORG MED CHEM LETT, V18, P6283, DOI 10.1016/j.bmcl.2008.09.107
   Durdagi S, 2009, J CHEM INF MODEL, V49, P1139, DOI 10.1021/ci900047s
   Freedberg DI, 2002, PROTEIN SCI, V11, P221, DOI 10.1110/ps.33202
   Friedman H.S., 1998, J MED CHEM, V41, P2424
   Friedman H.S., 1993, J AM CHEM SOC, V115, P6506
   GANAPATHI PS, 1995, J ORG CHEM, V60, P2954, DOI 10.1021/jo00115a002                                                             
   Giordani S, 2009, CARBON, V47, P578, DOI 10.1016/j.carbon.2008.10.036
   Gouda H, 2003, BIOPOLYMERS, V68, P16, DOI 10.1002/bip.10270
   Hamacher K, 2008, GENE, V422, P30, DOI 10.1016/j.gene.2008.06.007
   HANSCH C, 1973, J MED CHEM, V16, P1217, DOI 10.1021/jm00269a004
   Hornak V, 2006, J AM CHEM SOC, V128, P2812, DOI 10.1021/ja058211x
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hou T, 2008, PROTEINS, V71, P1163, DOI 10.1002/prot.21808
   Hou TJ, 2007, J MED CHEM, V50, P1177, DOI 10.1021/jm0609162
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Huang ST, 2008, BIOORGAN MED CHEM, V16, P8619, DOI 10.1016/j.bmc.2008.08.004
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024
   Ioakimidis L, 2008, QSAR COMB SCI, V4, P445
   Ioannou E, 2007, TETRAHEDRON, V63, P7070, DOI 10.1016/j.tet.2007.05.011
   Irvine JD, 1999, J PHARM SCI, V88, P28, DOI 10.1021/js9803205
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Jafvert CT, 2008, ENVIRON SCI TECHNOL, V42, P5945, DOI 10.1021/es702809a
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P
   Jewell NA, 2003, J ANTIMICROB CHEMOTH, V52, P547, DOI 10.1093/jac/dkg387
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kaldor SW, 1997, J MED CHEM, V40, P3797
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Leach A.R., 2001, MOL MODELLING PRINCI
   Lee VS, 2007, J MOL GRAPH MODEL, V26, P558, DOI 10.1016/j.jmgm.2007.03.013
   Lefebvre E, 2008, AIDS REV, V10, P131
   Loboda O, 2009, J PHYS CHEM A, V113, P1159, DOI 10.1021/jp808234x
   Luo SH, 2011, INT J PHARMACEUT, V414, P77, DOI 10.1016/j.ijpharm.2011.05.001
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   Mongan J, 2004, J COMPUT CHEM, V25, P2038, DOI 10.1002/jcc.20139
   Muzammil S, 2007, J VIROL, V81, P5144, DOI 10.1128/JVI.02706-06
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Ohtaka H, 2002, PROTEIN SCI, V11, P1908, DOI 10.1110/ps.0206402
   Piana S, 2001, J AM CHEM SOC, V123, P8730, DOI 10.1021/ja003145e
   Pietrucci F, 2009, J AM CHEM SOC, V131, P11811, DOI 10.1021/ja903045y
   Promsri S, 2005, J MOL STRUC-THEOCHEM, V715, P47, DOI 10.1016/j.theochem.2004.10.052
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Reyes CM, 2000, J MOL BIOL, V297, P1145, DOI 10.1006/jmbi.2000.3629                                                          
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   [Anonymous], 2009, QIKPROP VERS 3 3
   SENGUPTA D, 2007, J BIOSCIENCE, V32, P1316
   SHANNO DF, 1970, MATH COMPUT, V24, P647, DOI 10.2307/2004840
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Stoica I, 2008, J AM CHEM SOC, V130, P2639, DOI 10.1021/ja0779250
   Tasis D, 2003, CR CHIM, V6, P597, DOI 10.1016/S1631-0748(03)00095-X
   Thompson BC, 2008, ANGEW CHEM INT EDIT, V47, P58, DOI 10.1002/anie.200702506
   TONIOLO C, 1994, J MED CHEM, V37, P4558, DOI 10.1021/jm00052a015
   [Anonymous], SYBYL 8 0
   Troshina OA, 2007, ORG BIOMOL CHEM, V5, P2783, DOI 10.1039/b705331b
   Trylska J, 2007, BIOPHYS J, V92, P4179, DOI 10.1529/biophysj.106.100560
   Tsumoto H, 2008, BIOORG MED CHEM LETT, V18, P657, DOI 10.1016/j.bmcl.2007.11.065
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang W, 2001, J AM CHEM SOC, V123, P3986, DOI 10.1021/ja003164o
   Wang W, 2001, ANNU REV BIOPH BIOM, V30, P211, DOI 10.1146/annurev.biophys.30.1.211                                                
   Waterbeemd H., 2003, NAT REV DRUG DISCOV, V2, P192, DOI DOI 10.1038/NRD1032
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   Yazdanian M, 1998, PHARMACEUT RES, V15, P1490, DOI 10.1023/A:1011930411574
   Zalesny R, 2010, PHYS CHEM CHEM PHYS, V12, P373, DOI 10.1039/b917825b
   Zhang HW, 2010, BIOORG MED CHEM LETT, V20, P60, DOI 10.1016/j.bmcl.2009.11.031
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   Zoete V, 2002, J MOL BIOL, V315, P21, DOI 10.1006/jmbi.2001.5173
NR 81
TC 29
Z9 29
U1 1
U2 41
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD OCT
PY 2011
VL 25
IS 10
BP 959
EP 976
DI 10.1007/s10822-011-9475-4
PG 18
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 849NO
UT WOS:000297132500005
PM 21969102
DA 2018-01-05
ER

PT J
AU Galdiero, S
   Falanga, A
   Vitiello, M
   Cantisani, M
   Marra, V
   Galdiero, M
AF Galdiero, Stefania
   Falanga, Annarita
   Vitiello, Mariateresa
   Cantisani, Marco
   Marra, Veronica
   Galdiero, Massimiliano
TI Silver Nanoparticles as Potential Antiviral Agents
SO MOLECULES
LA English
DT Review
DE silver nanoparticles; virus infection; antiviral therapy
ID HERPES-SIMPLEX-VIRUS; TYPE-1 GLYCOPROTEIN-H; GRAM-NEGATIVE BACTERIA;
   CELL-ASSOCIATED HIV-1; IN-VITRO TOXICITY; ESCHERICHIA-COLI; GOLD
   NANOPARTICLES; ANTIBACTERIAL ACTIVITY; METAL NANOPARTICLES;
   MEMBRANE-FUSION
AB Virus infections pose significant global health challenges, especially in view of the fact that the emergence of resistant viral strains and the adverse side effects associated with prolonged use continue to slow down the application of effective antiviral therapies. This makes imperative the need for the development of safe and potent alternatives to conventional antiviral drugs. In the present scenario, nanoscale materials have emerged as novel antiviral agents for the possibilities offered by their unique chemical and physical properties. Silver nanoparticles have mainly been studied for their antimicrobial potential against bacteria, but have also proven to be active against several types of viruses including human imunodeficiency virus, hepatitis B virus, herpes simplex virus, respiratory syncytial virus, and monkey pox virus. The use of metal nanoparticles provides an interesting opportunity for novel antiviral therapies. Since metals may attack a broad range of targets in the virus there is a lower possibility to develop resistance as compared to conventional antivirals. The present review focuses on the development of methods for the production of silver nanoparticles and on their use as antiviral therapeutics against pathogenic viruses.
C1 [Vitiello, Mariateresa; Marra, Veronica; Galdiero, Massimiliano] Univ Naples 2, Dept Expt Med, I-80138 Naples, Italy.
   [Galdiero, Stefania; Falanga, Annarita; Cantisani, Marco] Dept Biol Sci, Div Biostruct, I-80134 Naples, Italy.
   [Galdiero, Stefania; Galdiero, Massimiliano] CIRPeB, Dept Biol Sci, I-80134 Naples, Italy.
   [Galdiero, Stefania] CNR, IBB CNR, I-80134 Naples, Italy.
RP Galdiero, M (reprint author), Univ Naples 2, Dept Expt Med, Via Crecchio 7, I-80138 Naples, Italy.
EM sgaldier@unina.it; annarita.falanga@unina.it;
   mteresa.vitiello@unina2.it; marco.cantisani@unina.it;
   veronica_marra@hotmail.it; massimilianogaldiero@unina2.it
OI galdiero, stefania/0000-0002-7849-7024; FALANGA,
   Annarita/0000-0001-6538-8585; Falanga, Anna/0000-0001-6906-9020
CR Abbaszadegan M, 2003, J AM WATER WORKS ASS, V95, P107
   Ahmad Z., 2005, INT J ANTIMICROB AG, V26, P298, DOI DOI 10.1016/J.IJANTIMICAG.2005.07.012
   Aillon KL, 2009, ADV DRUG DELIVER REV, V61, P457, DOI 10.1016/j.addr.2009.03.010
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Ayyappan S, 1997, J MATER RES, V12, P398, DOI 10.1557/JMR.1997.0057                                                           
   Banoee M, 2010, J BIOMED MATER RES B, V93B, P557, DOI 10.1002/jbm.b.31615
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Baram-Pinto D, 2009, BIOCONJUGATE CHEM, V20, P1497, DOI 10.1021/bc900215b
   Belhacova L, 1999, J CHEM TECHNOL BIOT, V74, P149, DOI 10.1002/(SICI)1097-4660(199902)74:2<149::AID-JCTB2>3.0.CO;2-Q
   Benabbou AK, 2007, APPL CATAL B-ENVIRON, V76, P257, DOI 10.1016/j.apcatb.2007.05.026
   Bonet F, 1999, INT J INORG MATER, V1, P47, DOI 10.1016/S1463-0176(99)00007-1                                                   
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Buchimier M.J., 2007, VIROLOGY, P1791
   Chaloupka K, 2010, TRENDS BIOTECHNOL, V28, P580, DOI 10.1016/j.tibtech.2010.07.006
   Chen X, 2008, TOXICOL LETT, V176, P1, DOI 10.1016/j.toxlet.2007.10.004
   Cho M, 2005, APPL ENVIRON MICROB, V71, P270, DOI 10.1128/AEM.71.1.270-275.2005
   Collins KB, 2000, NAT MED, V6, P475
   Collins P.L., 2007, VIROLOGY, P1601
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790                                                            
   Cao C, 2011, SMALL, V7, P1701, DOI 10.1002/smll.201100294
   Daaboul GG, 2010, NANO LETT, V10, P4727, DOI 10.1021/nl103210p
   Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817
   DOMS RW, 2000, J CELL BIOL, V151, P9
   Elechiguerra J.L., 2005, J NANOBIOTECHNOL, V29, P3, DOI DOI 10.1186/1477-3155-3-6
   Esteban D., 2010, VET RES, V41, P38
   Falanga A., 2011, NANOMEDICINE, DOI [10.1016/j.n.nano.2011.04.009, DOI 10.1016/J.N.NANO.2011.04.009]
   Fayaz AM, 2010, NANOMED-NANOTECHNOL, V6, P103, DOI 10.1016/j.nano.2009.04.006
   Gajbhiye M, 2009, NANOMED-NANOTECHNOL, V5, P382, DOI 10.1016/j.nano.2009.06.005
   Galdiero S, 2005, J BIOL CHEM, V280, P28632, DOI 10.1074/jbc.M505196200
   Galdiero S, 2006, J GEN VIROL, V87, P1085, DOI 10.1099/vir.0.81794-0
   Galdiero S, 2008, J BIOL CHEM, V283, P29993, DOI 10.1074/jbc.M803092200
   Galdiero S, 2007, CHEMBIOCHEM, V8, P885, DOI 10.1002/cbic.200700044
   Galdiero S, 2010, J BIOL CHEM, V285, P17123, DOI 10.1074/jbc.M110.114819
   Goff P., 2007, VIROLOGY, P2000
   Hallaj-Nezhadi S, 2010, PHARMAZIE, V65, P855, DOI 10.1691/ph.2010.0168
   Hamza IA, 2009, J GEN VIROL, V90, P2634, DOI 10.1099/vir.0.013557-0
   Hannah BP, 2007, J VIROL, V81, P4858, DOI 10.1128/JVI.02755-06
   Heldwein EE, 2008, CELL MOL LIFE SCI, V65, P1653, DOI 10.1007/s00018-008-7570-z
   Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548
   HELENIUS A, 2007, FIELDS VIROLOGY, P99
   HENDERSON DA, 1987, B WORLD HEALTH ORGAN, V65, P535
   HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004                                                             
   Howard C.R., 1985, J GEN VIROL, V66, P2344
   Hoyme U B, 1993, Infect Dis Obstet Gynecol, V1, P32, DOI 10.1155/S1064744993000080
   HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4
   Hussain SM, 2005, TOXICOL IN VITRO, V19, P975, DOI 10.1016/j.tiv.2005.06.034
   IAPALUCCI S, 1991, VIROLOGY, V182, P269, DOI 10.1016/0042-6822(91)90670-7
   Johnson DC, 2011, NAT REV MICROBIOL, V9, P382, DOI 10.1038/nrmicro2559
   Kalimuthu K, 2008, COLLOID SURFACE B, V65, P150, DOI 10.1016/j.colsurfb.2008.02.018
   Kalishwaralal K, 2010, COLLOID SURFACE B, V77, P257, DOI 10.1016/j.colsurfb.2010.02.007
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Kennedy LC, 2011, SMALL, V7, P169, DOI 10.1002/smll.201000134
   Kikuchi Y, 1997, J PHOTOCH PHOTOBIO A, V106, P51, DOI 10.1016/S1010-6030(97)00038-5                                                   
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kim Juyoung, 2009, J Biol Eng, V3, P20, DOI 10.1186/1754-1611-3-20
   Kim KJ, 2008, J MICROBIOL BIOTECHN, V18, P1482
   Kim KJ, 2009, BIOMETALS, V22, P235, DOI 10.1007/s10534-008-9159-2
   Kim YS, 2008, INHAL TOXICOL, V20, P575, DOI 10.1080/08958370701874663 
   Koizumi Y, 2002, BIOCHEM ENG J, V12, P107, DOI 10.1016/S1369-703X(02)00046-3                                                   
   Lanone S, 2006, CURR MOL MED, V6, P651, DOI 10.2174/156652406778195026                                                      
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Li Y, 2006, J HOSP INFECT, V62, P58, DOI 10.1016/i.jhin.2005.04.015
   Liga MV, 2011, WATER RES, V45, P535, DOI 10.1016/j.watres.2010.09.012
   LONGENBERGER L, 1995, J PHYS CHEM-US, V99, P475, DOI 10.1021/j100002a001                                                             
   Lu L, 2008, ANTIVIR THER, V13, P253
   Marambio-Jones C, 2010, J NANOPART RES, V12, P1531, DOI 10.1007/s11051-010-9900-y
   Melby Tom, 2009, V189, P177
   Miranda OR, 2010, CURR OPIN CHEM BIOL, V14, P728, DOI 10.1016/j.cbpa.2010.07.021
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Nanda A, 2009, NANOMED-NANOTECHNOL, V5, P452, DOI 10.1016/j.nano.2009.01.012
   Narayanan KB, 2010, ADV COLLOID INTERFAC, V156, P1, DOI 10.1016/j.cis.2010.02.001
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Palese P., 2007, VIROLOGY, P1647
   Panacek A, 2006, J PHYS CHEM B, V110, P16248, DOI 10.1021/jp063826h
   Panigrahi S, 2004, J NANOPART RES, V6, P411, DOI 10.1007/s11051-004-6575-2
   Panyala NR, 2008, J APPL BIOMED, V6, P117
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Parker S, 2007, FUTURE MICROBIOL, V2, P17, DOI 10.2217/17460913.2.1.17
   Pellet P.E., 2007, VIROLOGY, P2479
   Pissuwan D, 2009, SMALL, V5, P1030, DOI 10.1002/smll.200801018
   Portney NG, 2006, ANAL BIOANAL CHEM, V384, P620, DOI 10.1007/s00216-005-0247-7
   Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42
   Rahman I, 2000, BIOCHEM PHARMACOL, V60, P1041, DOI 10.1016/S0006-2952(00)00392-0
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Raveendran P, 2003, J AM CHEM SOC, V125, P13940, DOI 10.1021/ja029267j
   Rogers JV, 2008, NANOSCALE RES LETT, V3, P129, DOI 10.1007/s11671-008-9128-2
   Roizman B., 2007, VIROLOGY, P2502
   Roux KH, 2007, CURR OPIN STRUC BIOL, V17, P244, DOI 10.1016/j.sbi.2007.03.008
   Saravanana M, 2010, COLLOID SURFACE B, V77, P214, DOI 10.1016/j.colsurfb.2010.01.026
   Schabes-Retchkiman PS, 2006, OPT MATER, V29, P95, DOI 10.1016/j.optmat.2006.03.014
   Schrand AM, 2010, WIRES NANOMED NANOBI, V2, P544, DOI 10.1002/wnan.103
   Scott RWJ, 2003, CHEM MATER, V15, P3873, DOI 10.1021/cm034485c
   Seeger C., 2007, VIROLOGY, P2977
   Shahverdi AR, 2007, NANOMED-NANOTECHNOL, V3, P168, DOI 10.1016/j.nano.2007.02.001
   Shirtcliffe N, 1999, J COLLOID INTERF SCI, V211, P122, DOI 10.1006/jcis.1998.5980                                                          
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI200113799
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Stampfer SD, 2010, J VIROL, V84, P12924, DOI 10.1128/JVI.01750-10
   Stebounova LV, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-5
   Sukasema C, 2008, INT J ANTIMICROB AG, V31, P277, DOI 10.1016/j.ijantimicag.2007.10.029
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tang B, 2011, J COLLOID INTERF SCI, V356, P513, DOI 10.1016/j.jcis.2011.01.054
   Turner A, 1998, J VIROL, V72, P873
   Vitiello M, 2009, PROTEIN PEPTIDE LETT, V16, P786, DOI 10.2174/092986609788681742                                                      
   WEI C, 1994, ENVIRON SCI TECHNOL, V28, P934, DOI 10.1021/es00054a027
   Wei DW, 2009, CARBOHYD RES, V344, P2375, DOI 10.1016/j.carres.2009.09.001
   Wong M, 2009, WATER RES, V43, P1137, DOI 10.1016/j.watres.2008.11.051
   Yoon KY, 2007, SCI TOTAL ENVIRON, V373, P572, DOI 10.1016/j.scitotenv.2006.11.007
   Zhang YW, 2008, J COLLOID INTERF SCI, V325, P371, DOI 10.1016/j.jcis.2008.05.063
   Zhao YY, 2010, J AM CHEM SOC, V132, P12349, DOI 10.1021/ja1028843
   Zussman A, 2003, AIDS, V17, P653, DOI 10.1097/01.aids.0000050826.06065.5f
NR 117
TC 132
Z9 137
U1 7
U2 84
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2011
VL 16
IS 10
BP 8894
EP 8918
DI 10.3390/molecules16108894
PG 25
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 847KY
UT WOS:000296973000051
PM 22024958
OA gold
DA 2018-01-05
ER

PT J
AU Lori, F
AF Lori, Franco
TI DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the
   treatment of HIV/AIDS
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE AIDS; dendritic cells; DermaPrep; DermaVir; HIV; Langerhans cells;
   therapeutic vaccine; transdermal vaccine delivery; vaccine; virus-like
   particles
ID PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNODEFICIENCY-VIRUS TYPE-1; CELLULAR
   IMMUNE-RESPONSES; HIV-INFECTED PATIENTS; LOW-LEVEL VIREMIA; DENDRITIC
   CELLS; ANTIRETROVIRAL THERAPY; MEDIATED-IMMUNITY; LIFE-SPAN; IN-VIVO
AB The HIV global pandemic continues to rage with over 33 million people living with the disease. Although multidrug therapy has improved the prognosis for those infected by the virus, it has not eradicated the infection. Immunological therapies, including therapeutic vaccines, are needed to supplement drug therapy in the search for a 'functional cure' for HIV. DermaVir (Genetic Immunity Kft, Budapest, Hungary and McLean, Virginia, USA), an experimental HIV/AIDS therapeutic vaccine, combines three key elements of rational therapeutic vaccine design: a single plasmid DNA (pDNA) immunogen expressing 15 HIV antigens, a synthetic pDNA nanomedicine formulation and a dendritic cell-targeting topical-vaccine administration. DermaVir's novel mechanism of action, natural transport by epidermal Langerhans cells to the lymph nodes to express the pDNA-encoded HIV antigens and induce precursor/memory T cells with high proliferation capacity, has been consistently demonstrated in mouse, rabbit, primate and human subjects. Safety, immunogenicity and preliminary efficacy of DermaVir have been clinically demonstrated in HIV-infected human subjects. The DermaVir technology platform for dendritic cell-based therapeutic vaccination might offer a new treatment paradigm for cancer and infectious diseases.
C1 ViroStat Srl, I-07100 Sassari, Italy.
RP Lori, F (reprint author), ViroStat Srl, Viale Umberto 1, I-07100 Sassari, Italy.
EM rightpv@tin.it
FU Research Institute for Genetic and Human Therapy (RIGHT); European
   Union; Hungarian National Office for Research and Technology (NKTH)
   [HIKC05, DVCLIN01]; DAIDS; NIAID; NIH
FX This work was supported by the Research Institute for Genetic and Human
   Therapy (RIGHT), the European Union FP6 Marie Curie Excellence Chair
   Programme and the Hungarian National Office for Research and Technology
   (NKTH; HIKC05 and DVCLIN01). The author is grateful to DAIDS, NIAID and
   the NIH for several preclinical and clinical studies. The author has
   stock ownership in Genetic Immunity LLC. The author has no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Abbott A, 2010, NATURE, V466, P539, DOI 10.1038/466539a
   Abdulhaqq SA, 2008, IMMUNOL RES, V42, P219, DOI 10.1007/s12026-008-8076-3
   Ada G, 2005, MOL BIOTECHNOL, V29, P255, DOI 10.1385/MB:29:3:255                                                             
   Anderson RJ, 2007, VACCINE, V25, pB24, DOI 10.1016/j.vaccine.2007.05.030
   Babiuk LA, 2003, VACCINE, V21, P649, DOI 10.1016/S0264-410X(02)00574-1
   Bauer J, 2001, J INVEST DERMATOL, V116, P313, DOI 10.1046/j.1523-1747.2001.01247.x                                                
   Bellier B, 2009, VACCINE, V27, P5772, DOI 10.1016/j.vaccine.2009.07.059
   Blazevic V, 2006, AIDS RES HUM RETROV, V22, P667, DOI 10.1089/aid.2006.22.667
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Calarota SA, 2008, J IMMUNOL, V180, P5907, DOI 10.4049/jimmunol.180.9.5907                                                     
   Calarota SA, 2007, VACCINE, V25, P3070, DOI 10.1016/j.vaccine.2007.01.024
   Choosakoonkriang S, 2003, J PHARM SCI, V92, P1710, DOI 10.1002/jps.10437
   Coffin J, 2010, HIV DART 2010 FRONT
   Cristillo AD, 2007, VIROLOGY, V366, P197, DOI 10.1016/j.virol.2007.04.012
   Davis BS, 2001, J VIROL, V75, P4040, DOI 10.1128/JVI.75.9.4040-4047.2001
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005
   Ellenberger D, 2005, VIROLOGY, V340, P21, DOI 10.1016/j.virol.2005.06.014
   Fioretti D, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/174378
   Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461
   Gandhi RT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000321
   Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
   Garver KA, 2005, DIS AQUAT ORGAN, V64, P13, DOI 10.3354/dao064013
   GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401
   Hatano H, 2011, J INFECT DIS, V203, P960, DOI 10.1093/infdis/jiq138
   Hatano H, 2010, AIDS, V24, P2528, DOI 10.1097/QAD.0b013e32833dba03
   Jones T, 2010, CURR OPIN INVEST DR, V11, P964
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675                                                     
   Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252
   Korber B, 2008, HIV MOL IMMUNOLOGY
   Ladell K, 2008, J IMMUNOL, V180, P7907, DOI 10.4049/jimmunol.180.12.7907                                                    
   Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lisziewicz J, 2008, CROI 2008 BOST US 3
   Lisziewicz J, 2008, 15 C RETR OPP INF BO
   Liu LZ, 2010, NAT MED, V16, P224, DOI 10.1038/nm.2078
   Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003
   Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591                                                   
   Losina E, 2009, CLIN INFECT DIS, V49, P1570, DOI 10.1086/644772
   Malm M, 2007, VACCINE, V25, P3293, DOI 10.1016/j.vaccine.2007.01.003
   MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Montefiori DC, 2001, J VIROL, V75, P5879, DOI 10.1128/JVI.75.13.5879-5890.2001                                                
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Ohana P., 2004, GENE THER MOL BIOL, V8, P181
   Paavonen J, 2009, Lancet, V374, P301, DOI 10.1016/S0140-6736(09)61248-4
   Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105
   Peachman KK, 2003, METHODS, V31, P232, DOI 10.1016/S1046-2023(03)00137-3
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Piccinini G, 2002, J VIROL, V76, P2274, DOI 10.1128/JVI.76.5.2274-2278.2002
   Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075
   Powles T, 2009, J CLIN ONCOL, V27, P884, DOI 10.1200/JCO.2008.19.6626
   Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3                                                   
   Reddy ST, 2006, TRENDS IMMUNOL, V27, P573, DOI 10.1016/j.it.2006.10.005
   Rodriguez B, 2010, 18 INT AIDS C VIENN
   Routy JP, 2010, IMMUNOTHERAPY-UK, V2, P467, DOI 10.2217/IMT.10.28
   Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507
   Schnuriger A, 2009, AIDS, V23, P2079, DOI 10.1097/QAD.0b013e328330ed24
   Somogyi E, 2011, VACCINE, V29, P744, DOI 10.1016/j.vaccine.2010.11.019
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415
   Stevenson FK, 2010, CURR OPIN IMMUNOL, V22, P264, DOI 10.1016/j.coi.2010.01.019
   TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0
   Thacker EL, 2006, J ANIM SCI, V84, P733
   Toke ER, 2010, INT J PHARMACEUT, V392, P261, DOI 10.1016/j.ijpharm.2010.03.048
   Uglietti A, 2011, EXPERT OPIN INV DRUG, V20, P559, DOI 10.1517/13543784.2011.565047
   *UNAIDS, 2007 AIDS EP UPD
   vanLunzen J., 2010, 18 INT AIDS C VIENN
   Vidal C, 1998, J ACQ IMMUN DEF SYND, V19, P55, DOI 10.1097/00042560-199809010-00009                                                
   Villa LL, 2007, NEW ENGL J MED, V356, P1915
   von Harpe A, 2000, J CONTROL RELEASE, V69, P309, DOI 10.1016/S0168-3659(00)00317-5
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Yang OO, 2002, J VIROL, V76, P1626, DOI 10.1128/JVI.76.4.1626-1631.2002
   Zinkernagel RM, 2000, SEMIN IMMUNOL, V12, P163, DOI 10.1006/smim.2000.0253                                                          
   Zinkernagel RM, 2000, SEMIN IMMUNOL, V12, P257
   [Anonymous], ANTIRETROVIRAL SPARI
   [Anonymous], SAFETY TOLERABILITY
   [Anonymous], DERMAVIR PATCH LC002
   [Anonymous], GLOBAL ALERT RESPONS
   2008 REPORT GLOBAL A
   [Anonymous], HIV MED MUCH DO THEY
NR 86
TC 12
Z9 13
U1 0
U2 8
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD OCT
PY 2011
VL 10
IS 10
BP 1371
EP 1384
DI 10.1586/ERV.11.118
PG 14
WC Immunology
SC Immunology
GA 840GL
UT WOS:000296427100009
PM 21988301
DA 2018-01-05
ER

PT J
AU Yang, ML
   Chen, YH
   Wang, SW
   Huang, YJ
   Leu, CH
   Yeh, NC
   Chu, CY
   Lin, CC
   Shieh, GS
   Chen, YL
   Wang, JR
   Wang, CH
   Wu, CL
   Shiau, AL
AF Yang, Mei-Lin
   Chen, Yu-Hung
   Wang, Shainn-Wei
   Huang, Yen-Jang
   Leu, Chia-Hsing
   Yeh, Nai-Chi
   Chu, Chun-Yen
   Lin, Chia-Cheng
   Shieh, Gia-Shing
   Chen, Yuh-Ling
   Wang, Jen-Ren
   Wang, Ching-Ho
   Wu, Chao-Liang
   Shiau, Ai-Li
TI Galectin-1 Binds to Influenza Virus and Ameliorates Influenza Virus
   Pathogenesis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID SURFACTANT PROTEIN-D; PROMOTES HIV-1 INFECTIVITY; A VIRUS;
   MONOCLONAL-ANTIBODY; GLYCAN INTERACTIONS; NEURAMINIDASE GENE; ANTIVIRAL
   ACTIVITY; RECEPTOR-BINDING; IN-VITRO; HEMAGGLUTININ
AB Innate immune response is important for viral clearance during influenza virus infection. Galectin-1, which belongs to S-type lectins, contains a conserved carbohydrate recognition domain that recognizes galactose-containing oligosaccharides. Since the envelope proteins of influenza virus are highly glycosylated, we studied the role of galectin-1 in influenza virus infection in vitro and in mice. We found that galectin-1 was upregulated in the lungs of mice during influenza virus infection. There was a positive correlation between galectin-1 levels and viral loads during the acute phase of viral infection. Cells treated with recombinant human galectin-1 generated lower viral yields after influenza virus infection. Galectin-1 could directly bind to the envelope glycoproteins of influenza A/WSN/33 virus and inhibit its hemagglutination activity and infectivity. It also bound to different subtypes of influenza A virus with micromolar dissociation constant (K(d)) values and protected cells against influenza virus-induced cell death. We used nanoparticle, surface plasmon resonance analysis and transmission electron microscopy to further demonstrate the direct binding of galectin-1 to influenza virus. More importantly, we show for the first time that intranasal treatment of galectin-1 could enhance survival of mice against lethal challenge with influenza virus by reducing viral load, inflammation, and apoptosis in the lung. Furthermore, galectin-1 knockout mice were more susceptible to influenza virus infection than wild-type mice. Collectively, our results indicate that galectin-1 has anti-influenza virus activity by binding to viral surface and inhibiting its infectivity. Thus, galectin-1 may be further explored as a novel therapeutic agent for influenza.
C1 [Yeh, Nai-Chi; Shiau, Ai-Li] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan.
   [Yang, Mei-Lin; Huang, Yen-Jang; Leu, Chia-Hsing; Wu, Chao-Liang; Shiau, Ai-Li] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan.
   [Chen, Yu-Hung; Wu, Chao-Liang] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan.
   [Wang, Shainn-Wei] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan 70101, Taiwan.
   [Chen, Yuh-Ling] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan.
   [Wang, Jen-Ren] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan 70101, Taiwan.
   [Chu, Chun-Yen] Natl Pingtung Univ Sci & Technol, Grad Inst Anim Vaccine Technol, Pingtung, Taiwan.
   [Lin, Chia-Cheng] Tainan Hosp, Dept Hlth, Dept Pathol, Executive Yuan, Taiwan.
   [Shieh, Gia-Shing] Tainan Hosp, Dept Hlth, Dept Urol, Executive Yuan, Taiwan.
   [Wang, Ching-Ho] Natl Taiwan Univ, Sch Vet Med, Taipei 10764, Taiwan.
RP Shiau, AL (reprint author), Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, 1 Univ Rd, Tainan 70101, Taiwan.
EM wumolbio@mail.ncku.edu.tw; alshiau@mail.ncku.edu.tw
RI shiau, A-Li /C-2885-2012; Wang, Shainn-Wei/B-9644-2009; Chen,
   Yu-Hung/F-4167-2010; Wu, Chao-Liang/K-5272-2013; Wang,
   Jen-Ren/F-5254-2011
OI shiau, A-Li /0000-0003-2449-8547; Wu, Chao-Liang/0000-0001-7821-9406;
   Wang, Jen-Ren/0000-0002-4127-4046
FU National Institutes of Health; National Institute of General Medical
   Sciences [GM62116]; National Science Council, Taiwan [NSC
   99-2120-M-006-007, NSC 99-2321-B-006-009]; Center for Frontier Materials
   and Micro/Nano Science and Technology, National Cheng Kung University,
   Taiwan
FX We acknowledge the National Institutes of Health-sponsored MMRRC
   National System as the source of galectin-1 knockout mice for use in
   this study. The mice were produced and deposited with the MMRRC by the
   Consortium for Functional Glycomics supported by the National Institute
   of General Medical Sciences (GM62116). This study was supported by
   grants from the National Science Council, Taiwan (NSC 99-2120-M-006-007
   and NSC 99-2321-B-006-009) and the Center for Frontier Materials and
   Micro/Nano Science and Technology, National Cheng Kung University,
   Taiwan.
CR BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X
   Buchweitz JP, 2007, J PHARMACOL EXP THER, V323, P675, DOI 10.1124/jpet.107.124719
   Chen YC, 2008, AVIAN DIS, V52, P124, DOI 10.1637/8076-071807-Reg
   Dhirapong A, 2009, AUTOIMMUN REV, V8, P360, DOI 10.1016/j.autrev.2008.11.009
   FIELDS S, 1981, NATURE, V290, P213, DOI 10.1038/290213a0
   Fowler M, 2006, CELL MICROBIOL, V8, P44, DOI 10.1111/j.1462-5822.2005.00599.x
   Garner OB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000993
   Gauthier S, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-105
   Govorkova EA, 2004, ANTIMICROB AGENTS CH, V48, P4855, DOI 10.1128/AAC.48.12.4855-4863.2004
   GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008                                                             
   Hartshorn KL, 2006, J IMMUNOL, V176, P6962, DOI 10.4049/jimmunol.176.11.6962                                                    
   Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449
   Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156
   Hawgood S, 2004, J VIROL, V78, P8565, DOI 10.1128/JVI.78.16.8565-8572.2004
   HITI AL, 1982, J VIROL, V41, P730
   Horvath A, 2001, ANTIVIR RES, V52, P43, DOI 10.1016/S0166-3542(01)00158-9
   Hsieh SH, 2008, ONCOGENE, V27, P3746, DOI 10.1038/sj.onc.1211029
   Jia W, 2008, J IMMUNOL, V180, P6255, DOI 10.4049/jimmunol.180.9.6255                                                     
   KEIL W, 1985, EMBO J, V4, P2711
   Krishnamoorthy L, 2009, NAT CHEM BIOL, V5, P244, DOI 10.1038/nchembio.151
   Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430                                                         
   LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868                                                    
   Levroney EL, 2005, J IMMUNOL, V175, P413, DOI 10.4049/jimmunol.175.1.413                                                      
   Matrosovich M, 2003, REV MED VIROL, V13, P85, DOI 10.1002/rmv.375
   Matsuoka Y, 2009, J VIROL, V83, P4704, DOI 10.1128/JVI.01987-08
   Mercier S, 2008, VIROLOGY, V371, P121, DOI 10.1016/j.virol.2007.09.034
   Mitnaul LJ, 2000, J VIROL, V74, P6015, DOI 10.1128/JVI.74.13.6015-6020.2000
   Nieminen J, 2008, J IMMUNOL, V180, P2466, DOI 10.4049/jimmunol.180.4.2466                                                     
   Nunoi H, 2005, PEDIATR INT, V47, P175, DOI 10.1111/j.1442-200x.2005.02042.x
   Ouellet M, 2005, J IMMUNOL, V174, P4120, DOI 10.4049/jimmunol.174.7.4120                                                     
   POIRIER F, 1993, DEVELOPMENT, V119, P1229
   Rabinovich GA, 2007, SCAND J IMMUNOL, V66, P143, DOI 10.1111/j.1365-3083.2007.01986.x
   Rabinovich GA, 2007, CURR OPIN STRUC BIOL, V17, P513, DOI 10.1016/j.sbi.2007.09.002
   Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536
   Reading PC, 2008, J IMMUNOL, V180, P3391, DOI 10.4049/jimmunol.180.5.3391                                                     
   Reading PC, 1997, J VIROL, V71, P8204
   SCHULMAN JL, 1977, J VIROL, V24, P170
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   SKEHEL JJ, 1984, P NATL ACAD SCI-BIOL, V81, P1779, DOI 10.1073/pnas.81.6.1779
   Stowell SR, 2008, J IMMUNOL, V180, P3091, DOI 10.4049/jimmunol.180.5.3091                                                     
   SUGIURA A, 1980, VIROLOGY, V101, P440, DOI 10.1016/0042-6822(80)90457-2
   Thanh NTK, 2002, ANAL CHEM, V74, P1624, DOI 10.1021/ac011127p
   Tsai CY, 2007, ARTHRITIS RHEUM, V56, P544, DOI 10.1002/art.22401
   van Kooyk Y, 2008, NAT IMMUNOL, V9, P593, DOI 10.1038/ni.f.203
   Vasta GR, 2009, NAT REV MICROBIOL, V7, P424, DOI 10.1038/nrmicro2146
   Vigerust DJ, 2007, J VIROL, V81, P8593, DOI 10.1128/JVI.00690-07
   Vray B, 2004, GLYCOBIOLOGY, V14, P647, DOI 10.1093/glycob/cwh068
   Wagner R, 2000, J VIROL, V74, P6316, DOI 10.1128/JVI.74.14.6316-6323.2000
   Wang CW, 2003, AVIAN DIS, V47, P1416, DOI 10.1637/6093                                                                    
   Welliver TP, 2007, J INFECT DIS, V195, P1126, DOI 10.1086/512615
   White M, 2008, J IMMUNOL, V181, P7936, DOI 10.4049/jimmunol.181.11.7936                                                    
   White MR, 2008, EXPERT REV CLIN IMMU, V4, P497, DOI 10.1586/1744666X.4.4.497
   White MR, 2001, BIOCHEM BIOPH RES CO, V286, P206, DOI 10.1006/bbrc.2001.5373
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   Yingsakmongkon S, 2008, BIOL PHARM BULL, V31, P511, DOI 10.1248/bpb.31.511
   Zhou Qun, 1993, Archives of Biochemistry and Biophysics, V300, P6
NR 56
TC 40
Z9 40
U1 1
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2011
VL 85
IS 19
BP 10010
EP 10020
DI 10.1128/JVI.00301-11
PG 11
WC Virology
SC Virology
GA 837ZH
UT WOS:000296253900033
PM 21795357
OA gold
DA 2018-01-05
ER

PT J
AU Pavot, V
   Rochereau, N
   Genin, C
   Perouzel, E
   Tiraby, G
   Delaire, T
   Paul, S
   Verrier, B
AF Pavot, V.
   Rochereau, N.
   Genin, C.
   Perouzel, E.
   Tiraby, G.
   Delaire, T.
   Paul, S.
   Verrier, B.
TI Co-Administration of NOD1 and NOD2 Ligands with HIV-1 p24 Increase
   Mucosal Immune Potency of Biodegradable Nanocarriers
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT Conference on AIDS Vaccine
CY SEP 12-15, 2011
CL Bangkok, THAILAND
C1 [Pavot, V.; Verrier, B.] IBCP CNRS, Lyon, France.
   [Rochereau, N.; Genin, C.; Paul, S.] GIMAP, Saint Etienne, France.
   [Perouzel, E.; Tiraby, G.] Invivogen, Toulouse, France.
   [Delaire, T.] LMPB, Lyon, France.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2011
VL 27
IS 10
BP A36
EP A37
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 832GD
UT WOS:000295790500085
DA 2018-01-05
ER

PT J
AU Autino, B
   Odolini, S
   Nitiema, H
   Kiema, D
   Melzani, A
   Pietra, V
   Simpore, J
   Castelli, F
AF Autino, B.
   Odolini, S.
   Nitiema, H.
   Kiema, D.
   Melzani, A.
   Pietra, V.
   Simpore, J.
   Castelli, F.
TI International migrations and HIV care in the rural district of Nanoro,
   Burkina Faso
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Autino, B.; Odolini, S.; Melzani, A.; Castelli, F.] Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy.
   [Autino, B.; Odolini, S.; Melzani, A.; Pietra, V.; Castelli, F.] Med Mundi Italia, Brescia, Italy.
   [Simpore, J.] Ctr Rech Biomol Pietro Annigoni CERBA, Ouagadougou, Burkina Faso.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2011
VL 16
SU 1
SI SI
BP 367
EP 367
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 828RC
UT WOS:000295519101240
DA 2018-01-05
ER

PT J
AU Chiappetta, DA
   Facorro, G
   de Celis, ER
   Sosnik, A
AF Chiappetta, Diego A.
   Facorro, Graciela
   de Celis, Emilio Rubin
   Sosnik, Alejandro
TI Synergistic encapsulation of the anti-HIV agent efavirenz within mixed
   poloxamine/poloxamer polymeric micelles
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Poloxamer/poloxamine mixed polymeric micelles; Micellar fluidity and
   polarity; Electronic spin resonance (ESR); Pediatric HIV/AIDS
   pharmacotherapy; Synergistic efavirenz encapsulation
ID OXIDE BLOCK-COPOLYMERS; DRUG-DELIVERY; PEDIATRIC HIV; MICELLIZATION;
   BEHAVIOR; PHARMACOTHERAPY; FORMULATIONS
AB This study investigated the synergistic performance of mixed polymeric micelles made of linear and branched poly(ethylene oxide)-poly (propylene oxide) for the more effective encapsulation of the anti-HIV drug efavirenz. The co-micellization process of 10% binary systems combining different weight ratios of a highly hydrophilic poloxamer (Pluronic F127) and a more hydrophobic poloxamine counterpart (Tetronic T304 and T904) was investigated by means of dynamic light scattering, cloud point and electronic spin resonance experiments. Then, the synergistic solubilization capacity of the micelles was shown. Findings revealed a sharp solubility increase from 4 mu g/ml up to more than 33 mg/ml, representing a 8430-fold increase. Moreover, the drug-loaded mixed micelles displayed increased physical stability over time in comparison with pure poloxamine ones. Overall findings confirmed the enormous versatility of the poloxamer/poloxamine systems as Trojan nanocarriers for drug encapsulation and release by the oral route and they entail a relevant enhancement of the previous art towards a more compliant pediatric HIV pharmacotherapy.
   From the Clinical Editor: In this study, the authors demonstrate the versatility of poloxamer/poloxamine systems as Trojan nanocarriers for anti-HIV drug encapsulation and release by the oral route. A highly relevant stability and solubility enhancement is shown, which may ultimately lead to more compliant anti-HIV pharmacotherapy. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Grp Biomat & Nanotechnol Improved Med BIONIMED, Dept Pharmaceut Technol, Fac Pharm & Biochem, RA-1053 Buenos Aires, DF, Argentina.
   [Chiappetta, Diego A.; Sosnik, Alejandro] Univ Buenos Aires, Natl Sci Res Council CONICET, RA-1053 Buenos Aires, DF, Argentina.
   [Facorro, Graciela; de Celis, Emilio Rubin] Univ Buenos Aires, Dept Phys, Fac Pharm & Biochem, RA-1053 Buenos Aires, DF, Argentina.
RP Sosnik, A (reprint author), Univ Buenos Aires, Grp Biomat & Nanotechnol Improved Med BIONIMED, Dept Pharmaceut Technol, Fac Pharm & Biochem, RA-1053 Buenos Aires, DF, Argentina.
EM alesosnik@gmail.com
FU University of Buenos Aires [UBACyT 20020090200016]; CONICET [PIP
   11220090100220]
FX The work was supported by the University of Buenos Aires (Grant UBACyT
   20020090200016) and CONICET (Grant PIP 11220090100220).
CR Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2                                                   
   Alvarez-Lorenzo C, 2010, NANOMEDICINE-UK, V5, P1371, DOI [10.2217/nnm.10.53, 10.2217/NNM.10.53]
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   *AVERT ORG, 2010, AIDS ORPH
   Bahal SM, 2003, PHARM DEV TECHNOL, V8, P111, DOI 10.1081/PDT-120017518
   Bakshi M.S., 2006, COLLOID POLYM SCI, V284, P1363
   Barrueco N, 2005, Farm Hosp, V29, P367
   Brown E., 2007, ANTIRETROVIRAL THERA, P419
   Chiappetta DA, 2010, CURR HIV RES, V8, P23
   Chiappetta DA, 2008, EUR J PHARM BIOPHARM, V69, P535, DOI 10.1016/j.ejpb.2007.11.021
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022
   Chiappetta DA, 2011, BIOMATERIALS, V32, P2379, DOI 10.1016/j.biomaterials.2010.11.082
   Chiappetta DA, 2010, EUR J PHARM BIOPHARM, V76, P24, DOI 10.1016/j.ejpb.2010.05.007
   Chiappetta DA, 2010, NANOMEDICINE-UK, V5, P11, DOI 10.2217/NNM.09.90
   Chiappetta DA, 2009, AAPS PHARMSCITECH, V10, P1, DOI 10.1208/s12249-008-9168-z
   CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327                                                            
   da Silva RC, 1998, J COLLOID INTERF SCI, V202, P385, DOI 10.1006/jcis.1998.5456                                                          
   Fabbiani M, 2009, J ANTIMICROB CHEMOTH, V64, P109, DOI 10.1093/jac/dkp132
   Friedland G, 2006, J ANTIMICROB CHEMOTH, V58, P1299, DOI 10.1093/jac/dkl399
   Giaquinto C, 2008, CLIN DRUG INVEST, V28, P375, DOI 10.2165/00044011-200828060-00005                                                
   Gonzalez-Lopez J, 2008, LANGMUIR, V24, P10688, DOI 10.1021/la8016563
   Kempe S, 2010, EUR J PHARM BIOPHARM, V74, P55, DOI 10.1016/j.ejpb.2009.08.007
   Li L, 2008, J COLLOID INTERF SCI, V317, P326, DOI 10.1016/j.jcis.2007.09.053
   Lurie DJ, 2005, ADV DRUG DELIVER REV, V57, P1171, DOI 10.1016/j.addr.2005.01.023
   Mathot F, 2007, J CONTROL RELEASE, V124, P134, DOI 10.1016/j.jconrel.2007.09.001
   MATIC S, 2006, WHO PUBLICATIONS
   Nandni D, 2009, J COLLOID INTERF SCI, V338, P420, DOI 10.1016/j.jcis.2009.06.038
   Oh KT, 2004, J CONTROL RELEASE, V94, P411, DOI 10.1016/j.jcornel.2003.10.018
   Pandit N, 2000, J COLLOID INTERF SCI, V222, P213, DOI 10.1006/jcis.1999.6628                                                          
   Peroni R. N., 2010, 1 WORLD C NAN DRUG D
   Riess G, 2003, PROG POLYM SCI, V28, P1107, DOI 10.1016/S0079-6700(03)00015-7
   Sellers RS, 2005, DRUG CHEM TOXICOL, V28, P423, DOI 10.1080/01480540500262839
   Sharma PK, 2008, COLLOID SURFACE B, V61, P53, DOI 10.1016/j.colsurfb.2007.07.002
   Sosnik Alejandro, 2008, Recent Patents on Biomedical Engineering, V1, P43, DOI 10.2174/1874764710801010043
   SOSNIK A, 2008, J CONTROL RELEASE, V138, P2
   Sosnik A, 2010, NANOMEDICINE-UK, V5, P833, DOI 10.2217/NNM.10.64
   Sosnik A, 2010, ADV DRUG DELIVER REV, V62, P375, DOI 10.1016/j.addr.2009.11.010
   United States President's Emergency Plan for AIDS Relief, US PRESIDENTS EMERGE
   van den Bergh BAI, 2001, INT J PHARM, V217, P13, DOI 10.1016/S0378-5173(01)00576-2
   van Luin M, 2009, JAIDS-J ACQ IMM DEF, V52, P240, DOI 10.1097/QAI.0b013e3181b061e6
   Wei Z, 2009, INT J PHARMACEUT, V376, P176, DOI 10.1016/j.ijpharm.2009.04.030
   *WHO, MAK MED CHILD SIZ
   [Anonymous], 2007, AIDS EP UPD
   Wintergerst U, 2008, J ANTIMICROB CHEMOTH, V61, P1336, DOI 10.1093/jac/dkn112
   XU RL, 1991, MACROMOLECULES, V24, P87, DOI 10.1021/ma00001a014                                                             
   [Anonymous], 2001, PAN AM J PUBLIC HLTH, V10, P426
NR 46
TC 42
Z9 42
U1 2
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD OCT
PY 2011
VL 7
IS 5
BP 624
EP 637
DI 10.1016/j.nano.2011.01.017
PG 14
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 832TZ
UT WOS:000295832400013
PM 21371572
DA 2018-01-05
ER

PT J
AU Pruzina, S
   Williams, GT
   Kaneva, G
   Davies, SL
   Martin-Lopez, A
   Bruggemann, M
   Vieira, SM
   Jeffs, SA
   Sattentau, QJ
   Neuberger, MS
AF Pruzina, Sara
   Williams, Gareth T.
   Kaneva, Galina
   Davies, Sarah L.
   Martin-Lopez, Alicia
   Brueggemann, Marianne
   Vieira, Sueli M.
   Jeffs, Simon A.
   Sattentau, Quentin J.
   Neuberger, Michael S.
TI Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based
   human immunoglobulin transloci
SO PROTEIN ENGINEERING DESIGN & SELECTION
LA English
DT Article
DE affinity maturation; antibody engineering; humanised mice; somatic
   mutation; transgenic mice
ID FOLLICULAR DENDRITIC CELLS; FULLY HUMAN-ANTIBODIES; TRANSGENIC MICE;
   B-CELLS; REGION; EXPRESSION; GENERATION; DIVERSITY; GP120; HEAVY
AB Mice carrying human immunoglobulin transloci were immunised with HIV-1 gp140 antigen to gain insight into the range and nature of human monoclonal antibodies (mAbs) that can be elicited from such humanised mice. Using five-feature mice that harbour YAC-based germline-configuration human IgM, Ig and Ig transloci in a mouse background disrupted for endogenous mouse IgH and Ig expression, gp140-specific human IgM mAbs were readily elicited following serial immunisation. These mAbs were converted to human IgG1 format and were found to bind diverse epitopes within gp140, exhibiting high functional affinity for the antigentypically in the nanomolar or sub-nanomolar range. The number of specific, stable hybridomas per mouse was, however, low (typically around five) with the hybridomas within individual mice often being clonally related. Nevertheless, different mice used B cell clones expressing varied V(D)J combinations, with affinity maturation through somatic hypermutation making a critical contribution. Thus, a wide range of distinct high-affinity mAbs can be obtained by immunising multiple animals. The results confirm the utility of the translocus-mouse approach and give insight into strategies for possible future improvement.
C1 [Pruzina, Sara; Williams, Gareth T.; Kaneva, Galina; Davies, Sarah L.; Martin-Lopez, Alicia; Neuberger, Michael S.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England.
   [Martin-Lopez, Alicia] Univ Almeria, Dept Chem Engn, Almeria, Spain.
   [Brueggemann, Marianne] Recombinant Antibody Technol Ltd, Cambridge CB22 3AT, England.
   [Vieira, Sueli M.; Jeffs, Simon A.] Univ London Imperial Coll Sci Technol & Med, Jefferiss Trust Res Labs, Fac Med, London, England.
   [Sattentau, Quentin J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
RP Neuberger, MS (reprint author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.
EM msn@mrc-lmb.cam.ac.uk
FU Bill and Melinda Gates Foundation
FX We thank Wai Ching Hon for advice and guidance on surface plasmon
   resonance, the LMB Biomedical staff for help with animal handling,
   Amelia Fuertes for sharing protocols and Hedde Wardemann for generous
   provision of IgG expression vectors. The research was conducted as part
   of the Collaboration for AIDS Vaccine Discovery funded by the Bill and
   Melinda Gates Foundation: we are most grateful to Robin Weiss for his
   leadership of the collaborative programme under which this work was
   carried out.
CR BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837
   Corti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008805
   Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752
   Davis CG, 1999, CANCER METAST REV, V18, P421, DOI 10.1023/A:1006321231510
   Haberman AM, 2003, NAT REV IMMUNOL, V3, P757, DOI 10.1038/nri1178
   Hannum LG, 2000, J EXP MED, V192, P931, DOI 10.1084/jem.192.7.931                                                           
   Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126
   Jeffs SA, 2004, VACCINE, V22, P1032, DOI 10.1016/j.vaccine.2003.08.042
   Krashias G, 2010, VACCINE, V28, P2482, DOI 10.1016/j.vaccine.2010.01.046
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lonberg N, 2005, NAT BIOTECHNOL, V23, P1117, DOI 10.1038/nbt1135
   Lonberg N, 2008, CURR OPIN IMMUNOL, V20, P450, DOI 10.1016/j.coi.2008.06.004
   Magadan S, 2002, BIOTECHNIQUES, V33, P680
   Nelson AL, 2010, NAT REV DRUG DISCOV, V9, P767, DOI 10.1038/nrd3229
   Nicholson IC, 1999, J IMMUNOL, V163, P6898
   Pantophlet R, 2006, ANNU REV IMMUNOL, V24, P739, DOI 10.1146/annurev.immunol.24.021605.090557
   Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073                                                            
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Vincent-Fabert C, 2010, BLOOD, V116, P1895, DOI 10.1182/blood-2010-01-264689
   Wagner SD, 1996, GENOMICS, V35, P405, DOI 10.1006/geno.1996.0379
   Wang M, 2009, NAT STRUCT MOL BIOL, V16, P769, DOI 10.1038/nsmb.1623
   Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6
NR 27
TC 9
Z9 12
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-0126
J9 PROTEIN ENG DES SEL
JI Protein Eng. Des. Sel.
PD OCT
PY 2011
VL 24
IS 10
BP 791
EP 799
DI 10.1093/protein/gzr038
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 819HO
UT WOS:000294816200003
PM 21810921
OA gold
DA 2018-01-05
ER

PT J
AU Cambre, JN
   Sumerlin, BS
AF Cambre, Jennifer N.
   Sumerlin, Brent S.
TI Biomedical applications of boronic acid polymers
SO POLYMER
LA English
DT Article
DE Boronic acid; Glucose sensors; Insulin delivery; HIV inhibition; Lipase
   inhibition
ID LIVING RADICAL POLYMERIZATION; GLUCOSE-RESPONSIVE MICROGELS;
   NEUTRON-CAPTURE THERAPY; POLYANILINE/CARBON NANOTUBE COMPOSITE;
   ORGANOBORON QUINOLATE POLYMERS; INDUCED CONFORMATIONAL-CHANGES;
   FRAGMENTATION CHAIN TRANSFER; INSULIN DELIVERY-SYSTEM; CROSS-LINKED
   HYDROGEL; PHENYLBORONIC ACID
AB Boron-containing organic compounds have found widespread use in synthetic organic chemistry. More recently, boronic acid-containing polymers have proven valuable in a variety of biomedical applications, including the treatment of HIV, obesity, diabetes, and cancer. However, as compared to many other classes of functional polymers, boronic acid-containing (co)polymers remain underutilized, despite their unique reactivity, solubility, and responsive nature. This Feature Article highlights research in this area, with particular focus on recent developments in synthesis, processing, and materials development that have enabled the preparation of new biomaterials. In addition to providing an overview to the current state of the art, we emphasize the versatility of boronic acid polymers and suggest routes for their further employment in other potential biomedical applications. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Cambre, Jennifer N.; Sumerlin, Brent S.] So Methodist Univ, Dept Chem, Dallas, TX 75275 USA.
RP Sumerlin, BS (reprint author), So Methodist Univ, Dept Chem, 3215 Daniel Ave, Dallas, TX 75275 USA.
EM bsumerlin@smu.edu
RI Sumerlin, Brent/C-8924-2015
OI Sumerlin, Brent/0000-0001-5749-5444
FU National Science Foundation [DMR-0846792]
FX A portion of this material is based upon work supported by the National
   Science Foundation under Grant No. DMR-0846792.
CR ABOUAKIL N, 1989, BIOCHIM BIOPHYS ACTA, V1004, P215, DOI 10.1016/0005-2760(89)90270-1
   Alexeev VL, 2004, CLIN CHEM, V50, P2353, DOI 10.1373/clinchem.2004.039701
   Alexeev VL, 2003, ANAL CHEM, V75, P2316, DOI 10.1021/ac030021m
   Ali SR, 2007, J PHYS CHEM B, V111, P12275, DOI 10.1021/jp073705x
   Ali SR, 2007, ANAL CHEM, V79, P2583, DOI 10.1021/ac062068o
   Ali SR, 2008, SENSORS-BASEL, V8, P8423, DOI 10.3390/s8128423
   Appleton B, 2000, SENSOR ACTUAT B-CHEM, V65, P302, DOI 10.1016/S0925-4005(99)00299-3
   Arimori S, 2001, CHEM COMMUN, P1836, DOI 10.1039/b105994g                                                                
   Arnold FH, 2000, J MEMBRANE SCI, V167, P227, DOI 10.1016/S0376-7388(99)00283-5                                                   
   Asher SA, 2003, J AM CHEM SOC, V125, P3322, DOI 10.1021/ja021037h
   Azab AK, 2005, J CONTROL RELEASE, V106, P14, DOI 10.1016/j.jconrel.2005.03.015
   Baldock C, 2010, PHYS MED BIOL, V55, pR1, DOI 10.1088/0031-9155/55/5/R01
   Ballerstadt R, 2000, ANAL CHEM, V72, P4185, DOI 10.1021/ac000215r
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1                                                   
   Ben-Moshe M, 2006, ANAL CHEM, V78, P5149, DOI 10.1021/ac060643i
   Bench BJ, 2004, J COLLOID INTERF SCI, V270, P315, DOI 10.1016/j.jcis.2003.11.005
   Berube M, 2008, J ORG CHEM, V73, P6471, DOI 10.1021/jo800788s
   Braunecker WA, 2007, PROG POLYM SCI, V32, P93, DOI 10.1016/j.progpolymsci.2006.11.002
   Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781                                                   
   Cai QY, 2004, ANAL CHEM, V76, P4038, DOI 10.1021/ac0498516
   Cambre JN, 2007, J AM CHEM SOC, V129, P10348, DOI 10.1021/ja074239s
   Cappuccio FE, 2004, J FLUORESC, V14, P521, DOI 10.1023/B:JOFL.0000039340.94188.2a
   Cheng F, 2011, POLYM CHEM, DOI [10.1039/C1031PY00123J, DOI 10.1039/C1031PY00123J]
   Cheng F, 2010, CHEM COMMUN, V46, P3717, DOI 10.1039/b920667a
   Cheng SY, 2004, BIOTECHNOL BIOENG, V87, P863, DOI 10.1002/bit.20195
   Cheung W, 2009, J MATER CHEM, V19, P6465, DOI 10.1039/b823065j
   Chiefari J, 1998, MACROMOLECULES, V31, P5559, DOI 10.1021/ma9804951                                                               
   CHOI YK, 1992, INT J PHARM, V80, P9
   Chu LY, 2004, J CONTROL RELEASE, V97, P43, DOI 10.1016/j.jconrel.2004.02.026
   Cui CZ, 2010, J POLYM SCI POL CHEM, V48, P2438, DOI 10.1002/pola.24014
   Cui CZ, 2009, J POLYM SCI POL CHEM, V47, P6612, DOI 10.1002/pola.23703
   De Geest BG, 2006, LANGMUIR, V22, P5070, DOI 10.1021/la053368o
   De P, 2008, BIOMACROMOLECULES, V9, P1064, DOI 10.1021/bm701255v
   De P, 2009, MACROMOLECULES, V42, P5614, DOI 10.1021/ma900835y
   Egawa Y, 2009, MAT SCI ENG C-BIO S, V29, P115, DOI 10.1016/j.msec.2008.05.014
   Fabre B, 2003, CHEM COMMUN, P2982, DOI 10.1039/b311198a
   Fang H, 2004, J FLUORESC, V14, P481, DOI 10.1023/B:JOFL.0000039336.51399.3b
   Frankland E, 1860, LIEBIGS ANN CHEM, V115, P319
   Gamsey S, 2006, LANGMUIR, V22, P9067, DOI 10.1021/la0617053
   Gao SH, 2001, BIOORG CHEM, V29, P308, DOI 10.1006/bioo.2001.1219
   GARNER CW, 1980, J BIOL CHEM, V255, P5064
   Goy A, 2004, CLIN LYMPHOMA, V4, P230, DOI 10.3816/CLM.2004.n.003
   Granot E, 2008, ADV FUNCT MATER, V18, P478, DOI 10.1002/adfm.200700498
   Guiseppi-Elie A, 2002, ADV MATER, V14, P743, DOI 10.1002/1521-4095(20020517)14:10<743::AID-ADMA743>3.0.CO;2-H                    
   Hall DG, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P1, DOI 10.1002/3527606548.ch1
   Hassan CM, 1997, MACROMOLECULES, V30, P6166, DOI 10.1021/ma970117g                                                               
   Hisamitsu I, 1997, PHARMACEUT RES, V14, P289, DOI 10.1023/A:1012033718302                                                         
   Hoare T, 2008, BIOMACROMOLECULES, V9, P733, DOI 10.1021/bm701203r
   Hoare T, 2007, MACROMOLECULES, V40, P670, DOI 10.1021/ma062254w
   Hosmane NS, 2009, J ORGANOMET CHEM, V694, P1690, DOI 10.1016/j.jorganchem.2008.11.059
   Huang HY, 2008, PHARM RES-DORDR, V25, P1150, DOI 10.1007/s11095-007-9507-x
   Hubbard SA, 1998, BIOL TRACE ELEM RES, V66, P343, DOI 10.1007/BF02783147
   Huh P, 2007, BIOMACROMOLECULES, V8, P3602, DOI 10.1021/bm070421+
   Huval CC, 2004, POLYM BORONIC ACID D
   ITO Y, 1989, J CONTROL RELEASE, V10, P195, DOI 10.1016/0168-3659(89)90063-1
   Ivanov AE, 2008, J BIOMED MATER RES A, P213
   Ivanov AE, 2006, CHEM-EUR J, V12, P7204, DOI 10.1002/chem.200600342
   Ivanov AE, 2010, COLLOID SURFACE B, V75, P510, DOI 10.1016/j.colsurfb.2009.09.028
   Jakle F, 2010, CHEM REV, V110, P3985, DOI 10.1021/cr100026f
   Jakle F, 2006, COORDIN CHEM REV, V250, P1107, DOI 10.1016/j.ccr.2006.01.007
   Jakle F, 2005, J INORG ORGANOMET P, V15, P293, DOI 10.1007/s10904-005-7870-9
   James TD, 2002, TOP CURR CHEM, V218, P159
   James TD, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P441, DOI 10.1002/3527606548.ch12
   Jang WD, 2009, PROG POLYM SCI, V34, P1, DOI 10.1016/j.progpolymsci.2008.08.003
   Jay JI, 2010, MOL PHARMACEUT, V7, P116, DOI 10.1021/mp900159n
   Jay JI, 2009, ADV FUNCT MATER, V19, P2969, DOI 10.1002/adfm.200900757
   Jin QA, 2010, POLYMER, V51, P3068, DOI 10.1016/j.polymer.2010.04.061
   Jin XJ, 2009, BIOMACROMOLECULES, V10, P1337, DOI 10.1021/bm8010006
   [Anonymous], 2010, UNAIDS REP GLOB HIV
   JUSTICE JB, 1993, J NEUROSCI METH, V48, P263, DOI 10.1016/0165-0270(93)90097-B
   Kabilan S, 2005, BIOSENS BIOELECTRON, V20, P1602, DOI 10.1016/j.bios.2004.07.005
   Kabilan S, 2004, J MOL RECOGNIT, V17, P162, DOI 10.1002/jmr.663
   Kahraman G, 2004, POLYMER, V45, P5813, DOI 10.1016/j.polymer.2004.06.028
   Kanekiyo Y, 2005, MACROMOL RAPID COMM, V26, P1542, DOI 10.1002/marc.200500423
   Kang SI, 2003, J CONTROL RELEASE, V86, P115, DOI 10.1016/S0168-3659(02)00409-1
   KATAOKA K, 1994, MACROMOLECULES, V27, P1061, DOI 10.1021/ma00082a028                                                             
   Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d                                                               
   KATO M, 1995, MACROMOLECULES, V28, P1721, DOI 10.1021/ma00109a056                                                             
   KETTNER CA, 1984, J BIOL CHEM, V259, P5106
   Kikuchi A, 1996, ANAL CHEM, V68, P823, DOI 10.1021/ac950748d
   KIM CK, 1994, INT J PHARM, V101, P191
   Kim KT, 2009, J AM CHEM SOC, V131, P13908, DOI 10.1021/ja905652w
   Kim KT, 2009, ADV MATER, V21, P2787, DOI 10.1002/adma.200900300
   KIMURA T, 1995, TETRAHEDRON LETT, V36, P559, DOI 10.1016/0040-4039(94)02252-7
   KIMURA T, 1995, J CHEM SOC PERK T 2, P1889, DOI 10.1039/p29950001889                                                            
   KOEHLER KA, 1971, BIOCHEMISTRY-US, V10, P2477
   KORCEK S, 1972, J CHEM SOC PERK T 2, P242, DOI 10.1039/p29720000242                                                            
   Korich AL, 2010, DALTON T, V39, P1423, DOI 10.1039/b917043j
   Krasia T, 2003, CHEM COMMUN, P538, DOI 10.1039/b212634f                                                                
   Lapeyre V, 2008, J COLLOID INTERF SCI, V327, P316, DOI 10.1016/j.jcis.2008.08.039
   Lapeyre V, 2006, BIOMACROMOLECULES, V7, P3356, DOI 10.1021/bm060588n
   LAUER M, 1983, J ORGANOMET CHEM, V256, P1, DOI 10.1016/S0022-328X(00)99290-8                                                   
   Lee JH, 2005, J AM SOC MASS SPECTR, V16, P1456, DOI 10.1016/j.jasms.2005.04.005
   Liu F, 1997, BIOCONJUGATE CHEM, V8, P664, DOI 10.1021/bc970128e
   LIU XC, 1995, J ORGANOMET CHEM, V493, P91, DOI 10.1016/0022-328X(94)05337-B                                                    
   LORAND JP, 1959, J ORG CHEM, V24, P769, DOI 10.1021/jo01088a011                                                             
   Ma YF, 2006, J PHYS CHEM B, V110, P16359, DOI 10.1021/jp0614897
   Mathiyarasu J, 2005, J APPL ELECTROCHEM, V35, P513, DOI 10.1007/s10800-005-0914-6
   Matsumoto A, 2004, BIOMACROMOLECULES, V5, P1038, DOI 10.1021/bm0345413
   Matsumoto A, 2004, MACROMOLECULES, V37, P1502, DOI 10.1021/ma035382i
   Matsumoto A, 2003, BIOMACROMOLECULES, V4, P1410, DOI 10.1021/bm034139o
   Matsumoto A, 2010, CHEM COMMUN, V46, P2203, DOI 10.1039/b920319b
   MATTHEWS DA, 1975, J BIOL CHEM, V250, P7120
   Matyjaszewski K., 2002, HDB RADICAL POLYM
   Meacham SL, 1998, BIOL TRACE ELEM RES, V66, P65, DOI 10.1007/BF02783127
   Miyata T, 2004, J BIOMAT SCI-POLYM E, V15, P1085, DOI 10.1163/1568562041753061
   Miyata T, 2002, ADV DRUG DELIVER REV, V54, P79, DOI 10.1016/S0169-409X(01)00241-1
   MIYAZAKI H, 1993, BIOCHEM BIOPH RES CO, V195, P829, DOI 10.1006/bbrc.1993.2120
   Moad G, 2005, AUST J CHEM, V58, P379, DOI 10.1071/CH05072
   Murabayashi S, 2002, THER APHER, V6, P425, DOI 10.1046/j.1526-0968.2002.00465.x                                                
   Muscatello MMW, 2009, ANAL CHEM, V81, P4978, DOI 10.1021/ac900006x
   NAGASAKI T, 1994, CHEM LETT, P1495, DOI 10.1246/cl.1994.1495
   Niu WJ, 2005, CHEM COMMUN, P4342, DOI 10.1039/b504634c
   Okada H, 2001, DRUG DELIVERY TARGET, P301
   Okasaka Y, 2010, COLLOID SURFACE B, V79, P434, DOI 10.1016/j.colsurfb.2010.05.015
   ONEILL RD, 1994, ANALYST, V119, P767, DOI 10.1039/an9941900767
   Otsuka H, 2006, EUR CELLS MATER, V12, P36, DOI 10.22203/eCM.v012a04                                                            
   Ozdemir A, 2000, J APPL POLYM SCI, V78, P268, DOI 10.1002/1097-4628(20001010)78:2<268::AID-APP50>3.0.CO;2-D
   Perrier S, 2005, J POLYM SCI POL CHEM, V43, P5347, DOI 10.1002/pola.20986
   Petasis NA, 2007, AUST J CHEM, V60, P795, DOI 10.1071/CH07360
   PHILIPP M, 1971, P NATL ACAD SCI USA, V68, P478, DOI 10.1073/pnas.68.2.478
   Pringsheim E, 1999, ADV MATER, V11, P865, DOI 10.1002/(SICI)1521-4095(199907)11:10<865::AID-ADMA865>3.0.CO;2-B
   Qin Y, 2004, J AM CHEM SOC, V126, P7015, DOI 10.1021/ja0391331
   Qin Y, 2004, MACROMOLECULES, V37, P7123, DOI 10.1021/ma035880r
   Qin Y, 2005, MACROMOLECULES, V38, P8987, DOI 10.1021/ma051615p
   Qin Y, 2002, J AM CHEM SOC, V124, P12672, DOI 10.1021/ja020773i
   Qin Y, 2003, MACROMOL SYMP, V196, P337, DOI 10.1002/masy.200390172                                                          
   Qin Y, 2006, MACROMOLECULES, V39, P9041, DOI 10.1021/ma061805f
   Qin Y, 2007, J INORG ORGANOMET P, V17, P149, DOI 10.1007/s10904-006-9084-1
   Richold M, 1998, BIOL TRACE ELEM RES, V66, P121, DOI 10.1007/BF02783132
   RICKA J, 1984, MACROMOLECULES, V17, P2916, DOI 10.1021/ma00142a081                                                             
   Roberts MC, 2008, MACROMOLECULES, V41, P8832, DOI 10.1021/ma8012674
   Roberts MC, 2007, ADV MATER, V19, P2503, DOI 10.1002/adma.200602649
   Roy D, 2008, CHEM COMMUN, P2477, DOI 10.1039/b802293c
   Roy D, 2010, PROG POLYM SCI, V35, P278, DOI 10.1016/j.progpolymsci.2009.10.008
   Roy D, 2009, CHEM COMMUN, P2106, DOI 10.1039/b900374f
   Russell RJ, 1999, ANAL CHEM, V71, P3126, DOI 10.1021/ac990060r
   Rzayev ZMO, 2007, COLLECT CZECH CHEM C, V72, P1591, DOI 10.1135/cccc20071591
   Saito A, 2010, BIOMED MATER, V5, DOI 10.1088/1748-6041/5/5/054101
   Samoei GK, 2006, ANGEW CHEM INT EDIT, V45, P5319, DOI 10.1002/anie.200601398
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R                                                    
   Schneider HJ, 2007, SENSORS-BASEL, V7, P1578, DOI 10.3390/s7081578
   Senel S, 2003, COLLOID SURFACE A, V219, P17, DOI 10.1016/S0927-7757(03)00007-4
   SEYMOUR LW, 1987, J BIOMED MATER RES, V21, P1341, DOI 10.1002/jbm.820211106
   SHIINO D, 1994, BIOMATERIALS, V15, P121, DOI 10.1016/0142-9612(94)90261-5                                                    
   Shiino D, 1995, J CONTROL RELEASE, V37, P269, DOI 10.1016/0168-3659(95)00084-4
   SHIINO D, 1994, J INTEL MAT SYST STR, V5, P311, DOI 10.1177/1045389X9400500303                                                      
   Shiino D, 1996, J BIOMAT SCI-POLYM E, V7, P697
   Shoji E, 2002, J AM CHEM SOC, V124, P12486, DOI 10.1021/ja0267371
   Shoji E, 2001, J AM CHEM SOC, V123, P3383, DOI 10.1021/ja005906j
   Soloway AH, 1998, CHEM REV, V98, P1515, DOI 10.1021/cr941195u                                                               
   SPIELVOGEL BF, 1994, PHOSPHORUS SULFUR, V87, P267, DOI 10.1080/10426509408037459                                                       
   Springsteen G, 2002, TETRAHEDRON, V58, P5291, DOI 10.1016/S0040-4020(02)00489-1                                                   
   Stenzel MH, 2008, CHEM COMMUN, P3486, DOI 10.1039/b805464a
   Stolowitz ML, 2001, BIOCONJUGATE CHEM, V12, P229, DOI 10.1021/bc0000942
   Suri JT, 2003, ANGEW CHEM INT EDIT, V42, P5857, DOI 10.1002/anie.200352405
   Svendsen A, 2000, BBA-PROTEIN STRUCT M, V1543, P223, DOI 10.1016/S0167-4838(00)00239-9                                                   
   Tanna S, 2006, BIOMATERIALS, V27, P4498, DOI 10.1016/j.biomaterials.2006.04.007
   Tanna S, 2006, BIOMATERIALS, V27, P1586, DOI 10.1016/j.biomaterials.2005.08.011
   TeviBenissan C, 1997, CLIN DIAGN LAB IMMUN, V4, P367
   Tierney S, 2009, BIOSENS BIOELECTRON, V24, P2034, DOI 10.1016/j.bios.2008.10.014
   Traitel T, 2000, BIOMATERIALS, V21, P1679, DOI 10.1016/S0142-9612(00)00050-8
   Trippier PC, 2010, MEDCHEMCOMM, V1, P183, DOI 10.1039/c0md00119h
   Uguzdogan E, 2003, POLYM INT, V52, P649, DOI 10.1002/pi.1169
   Uguzdogan E, 2002, MACROMOL BIOSCI, V2, P214, DOI 10.1002/1616-5195(200206)2:5<214::AID-MABI214>3.0.CO;2-D
   VAINIO P, 1982, BIOCHIM BIOPHYS ACTA, V711, P386, DOI 10.1016/0005-2760(82)90051-0
   Valliant JF, 2001, J INORG BIOCHEM, V85, P43, DOI 10.1016/S0162-0134(00)00222-1                                                   
   Venton BJ, 2003, ANAL CHEM, V75, p414A, DOI 10.1021/ac031421c                                                               
   Vogt AP, 2006, MACROMOLECULES, V39, P5286, DOI 10.1021/ma0610461
   Wang BL, 2009, LANGMUIR, V25, P12522, DOI 10.1021/la901776a
   WANG JS, 1995, J AM CHEM SOC, V117, P5614, DOI 10.1021/ja00125a035                                                             
   Wang W, 2002, CURR ORG CHEM, V6, P1285, DOI 10.2174/1385272023373446                                                        
   Washburn RM, 1959, ADV CHEM SER, V23, P102
   WEIR RJ, 1972, TOXICOL APPL PHARM, V23, P351, DOI 10.1016/0041-008X(72)90037-3
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Wiley JP, 2001, BIOCONJUGATE CHEM, V12, P240, DOI 10.1021/bc0000861
   Winblade ND, 2000, BIOMACROMOLECULES, V1, P523, DOI 10.1021/bm000040v
   Wiskur SL, 2001, ORG LETT, V3, P1311, DOI 10.1021/ol0156805
   WULFF G, 1982, PURE APPL CHEM, V54, P2093, DOI 10.1351/pac198254112093                                                         
   Xue CH, 2008, CHEM-EUR J, V14, P1648, DOI 10.1002/chem.200701376
   Yan J, 2004, TETRAHEDRON, V60, P11205, DOI 10.1016/j.tet.2004.08.051
   Yang WQ, 2005, BORONIC ACIDS: PREPARATION AND APPLICATIONS IN ORGANIC SYNTHESIS AND MEDICINE, P481, DOI 10.1002/3527606548.ch13
   Yang WQ, 2003, MED RES REV, V23, P346, DOI 10.1002/med.10043
   Yu C, 2009, CHEM COMMUN, P1347, DOI 10.1039/b820397k
   Zenkl G, 2008, MACROMOL BIOSCI, V8, P146, DOI 10.1002/mabi.200700174
   Zhang LZ, 2011, MACROMOL RAPID COMM, V32, P534, DOI 10.1002/marc.201000757
   Zhang SB, 2008, POLYM ADVAN TECHNOL, V19, P937, DOI 10.1002/pat.1079
   Zhang YJ, 2007, BIOMACROMOLECULES, V8, P3842, DOI 10.1021/bm700802p
   Zhang YJ, 2006, BIOMACROMOLECULES, V7, P3196, DOI 10.1021/bm060557s
   Holmes-Farley SR, 2003, PCT/US, Patent No. [02/20947, 0220947]
NR 191
TC 166
Z9 167
U1 7
U2 191
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
EI 1873-2291
J9 POLYMER
JI Polymer
PD SEP 29
PY 2011
VL 52
IS 21
BP 4631
EP 4643
DI 10.1016/j.polymer.2011.07.057
PG 13
WC Polymer Science
SC Polymer Science
GA 827JN
UT WOS:000295424900001
OA gold
DA 2018-01-05
ER

PT J
AU Shegokar, R
   Singh, KK
   Muller, RH
AF Shegokar, R.
   Singh, K. K.
   Mueller, R. H.
TI Production & stability of stavudine solid lipid nanoparticles-From lab
   to industrial scale
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE HIV/AIDS; Solid lipid nanoparticles; Large-scale production; High
   pressure homogenization; Stability
ID DRUG-DELIVERY SYSTEMS; IN-VITRO; POLYMERIC NANOPARTICLES; INTRACELLULAR
   DELIVERY; SLN; FORMULATION; EMULSIONS; NLC
AB The production of stavudine-loaded solid lipid nanoparticles (SLN) for intravenous injection was scaled up from lab scale (40g) to medium scale (10 kg) and large scale (20/60 kg). The SLN were produced by high pressure homogenization of stavudine lipid melt dispersed in hot surfactant solution (pre-emulsion) applying 800 bar pressure. Employed were piston-gap homogenizers with increasing capacity (APV Gaulin products LAB 40, LAB 60 and Gaulin 5.5; and Avestin C50), using them in the continuous (circulation) and discontinuous mode. Size analysis was performed by photon correlation spectroscopy (PCS), laser diffractometry and light microscopy. At lab scale a PCS size of 53 nm was obtained. At the same pressure, all homogenizers on larger scale yielded a size in the range of the lab scale product (35-70 nm). Differences were found in the size as a function of circulation time (size increase or size reduction with time) and the number of cycles required (1 or 5) for the optimal product. The stavudine SLN formulation (2% lipid content, high surfactant to lipid ratio) showed a different behavior to conventional higher concentrated SLN suspensions or nanoemulsions (10% or 20% lipid/oil, low surfactant to lipid ratio). In general, smallest sizes were obtained in the discontinuous mode after just one homogenization cycle. The continuous production mode was only efficient with a 10 kg batch size using the LAB 60. In addition, the long-term stability over 1 year was monitored at refrigeration, room temperature and at 40 degrees C to assess a potential effect of the homogenizer type on stability. All batches at room temperature and below were stable, only a negligible increase in size was observed. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Shegokar, R.; Mueller, R. H.] Free Univ Berlin, Inst Pharm, Dept Pharmaceut Biopharmaceut & NutriCosmet, D-12169 Berlin, Germany.
   [Shegokar, R.; Singh, K. K.] SNDT Womens Univ, CU Shah Coll Pharm, Bombay 400049, Maharashtra, India.
RP Muller, RH (reprint author), Free Univ Berlin, Inst Pharm, Dept Pharmaceut Biopharmaceut & NutriCosmet, Kelchstr 31, D-12169 Berlin, Germany.
EM nanoteam@gmx.com
CR Abdelbary G, 2009, AAPS PHARMSCITECH, V10, P211, DOI 10.1208/s12249-009-9197-2
   Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Asasutjarit R, 2007, PHARM RES, V24, P1098, DOI 10.1007/s11095-007-9234-3
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Basaran E, 2010, J MICROENCAPSUL, V27, P37, DOI 10.3109/02652040902846883
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Berry CC, 2008, NANOMEDICINE-UK, V3, P357, DOI 10.2217/17435889.3.3.357
   Bhalekar MR, 2009, AAPS PHARMSCITECH, V10, P289, DOI 10.1208/s12249-009-9199-0
   BONDI ML, 2009, NANOMEDICINE-UK, V5, P25
   BULLOCK L, 1992, JPEN-PARENTER ENTER, V16, P64, DOI 10.1177/014860719201600164                                                      
   Chattopadhyay N, 2008, PHARM RES-DORDR, V25, P2262, DOI 10.1007/s11095-008-9615-2
   Deshpande GC, 2009, J PEDIATR GASTR NUTR, V49, P619, DOI 10.1097/MPG.0b013e31819ca1b8
   Dingler A., 1998, THESIS FREIE U BERLI
   Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5
   Govender T, 2008, DRUG DELIV, V15, P493, DOI 10.1080/10717540802321776 
   Hou DZ, 2003, BIOMATERIALS, V24, P1781, DOI 10.1016/S0142-9612(02)00578-1
   JARCHAU M, 1997, HOCHDRUCKHOMOGENISIE, P20
   Krohn K, 2006, CURR OPIN CLIN NUTR, V9, P319, DOI 10.1097/01.mco.0000222118.76536.ad
   Manjunath K, 2005, METHOD FIND EXP CLIN, V27, P127, DOI 10.1358/mf.2005.27.2.876286
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   MULLER RH, 1995, EUR J PHARM BIOPHARM, V41, P62
   Muller RH, 2000, HDB PHARM CONTROLLED, P359
   RADOMSKA R, 1999, PHARMAZIE, V54, P903
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   SCHNEPPE T, 1998, THESIS FREIE U BERLI
   SCHWARZ C, 1995, THESIS FREIE U BERLI
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   SHEGOKAR R, 2009, 69 INT C FIP TURK
   SHEGOKAR R, 2008, 8 INT S CRS IND LOC
   SHEGOKAR R, 2010, THESIS SNDT WOMENS U
   SHEGOKAR R, 2009, 9 INT S CONTR REL SO, pP60
   Souto EB, 2005, INT J PHARMACEUT, V295, P261, DOI 10.1016/j.ijpharm.2005.02.005
   Westesen K, 1997, J CONTROL RELEASE, V48, P223, DOI 10.1016/S0168-3659(97)00046-1
   Weyhers H, 2006, PHARMAZIE, V61, P539
   Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002
   MULLER RH, 2000, Patent No. 0004565
NR 37
TC 50
Z9 51
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP 20
PY 2011
VL 416
IS 2
SI SI
BP 461
EP 470
DI 10.1016/j.ijpharm.2010.08.014
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 828LC
UT WOS:000295501500010
PM 20727389
DA 2018-01-05
ER

PT J
AU Lara, HH
   Ixtepan-Turrent, L
   Trevino, ENG
   Singh, DK
AF Lara, Humberto H.
   Ixtepan-Turrent, Liliana
   Garza Trevino, Elsa N.
   Singh, Dinesh K.
TI Use of silver nanoparticles increased inhibition of cell-associated
   HIV-1 infection by neutralizing antibodies developed against HIV-1
   envelope proteins
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Silver Nanoparticles; Neutralizing Antibodies; HIV; gp120; gp41
ID VIRUS ENVELOPE; BIOPHARMACEUTICALS; GLYCOPROTEIN; MORTALITY; THERAPY;
   MODE
AB Background: HIV/AIDS pandemic is a worldwide public health issue. There is a need for new approaches to develop new antiviral compounds or other therapeutic strategies to limit viral transmission. The envelope glycoproteins gp120 and gp41 of HIV are the main targets for both silver nanoparticles (AgNPs) and neutralizing antibodies. There is an urgency to optimize the efficiency of the neutralizing antibodies (NABs). In this study, we demonstrated that there is an additive effect between the four NABs and AgNPs when combined against cell-associated HIV-1 infection in vitro
   Results: Four NABs (Monoclonal antibody to HIV-1 gp41 126-7, HIV-1 gp120 Antiserum PB1 Sub 2, HIV-1 gp120 Antiserum PB1, HIV-1 gp120 Monoclonal Antibody F425 B4e8) with or without AgNPs of 30-50 nm in size were tested against cell free and cell-associated HIV(IIIB) virus. All NABs inhibited HIV-1 cell free infection at a dose response manner, but with AgNPs an antiviral additive effect was not achieved Although there was no inhibition of infection with cell-associated virus by the NABs itself, AgNPs alone were able to inhibit cell associated virus infection and more importantly, when mixed together with NABs they inhibited the HIV-1 cell associated infection in an additive manner.
   Discussion: The most attractive strategies to deal with the HIV problem are the development of a prophylactic vaccine and the development of effective topical vaginal microbicide. For two decades a potent vaccine that inhibits transmission of infection of HIV has been searched. There are vaccines that elicit NABs but none of them has the efficacy to stop transmission of HIV-1 infection. We propose that with the addition of AgNPs, NABs will have an additive effect and become more potent to inhibit cell-associated HIV-1 transmission/infection.
   Conclusions: The addition of AgNPs to NABs has significantly increased the neutralizing potency of NABs in prevention of cell-associated HIV-1 transmission/infection. Further exploration is required to standardize potentiation of NABs by AgNPs. It is also required to evaluate in vivo toxicity of AgNPs before AgNPs could be incorporated in any antiviral vaginal creams.
C1 [Lara, Humberto H.; Singh, Dinesh K.] Winston Salem State Univ, Dept Life Sci, Winston Salem, NC 27110 USA.
   [Ixtepan-Turrent, Liliana; Garza Trevino, Elsa N.] Fac Med Univ Autonoma Nuevo Leon, Dept Bioquimicay Med Mol, Lab Terapia Celular, Nuevo Leon, Mexico.
RP Singh, DK (reprint author), Winston Salem State Univ, Dept Life Sci, Winston Salem, NC 27110 USA.
EM singhd@wssu.edu
OI Lara, Humberto H/0000-0003-4854-9839; Ixtepan Turrent,
   Liliana/0000-0002-5352-5383
FU National Center on Minority Health and Health Disparities [P20MD002303];
   National Institute of General Medical Sciences of NIH [SC3GM084802];
   Winston-Salem State University's Center of Excellence for the
   Elimination of Health Disparities.
FX The project described was supported by Award Number P20MD002303 from the
   National Center on Minority Health and Health Disparities, and
   SC3GM084802 from National Institute of General Medical Sciences of NIH
   to DKS. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Center on
   Minority Health and Health Disparities or NIGMS or the National
   Institutes of Health. This research is a project supported by
   Winston-Salem State University's Center of Excellence for the
   Elimination of Health Disparities.
CR Bansi L, 2011, AIDS, V25, P603, DOI 10.1097/QAD.0b013e32834403a0
   Bell CH, 2008, J MOL BIOL, V375, P969, DOI 10.1016/j.jmb.2007.11.013
   Blais Marie-Eve, 2009, F1000 Biol Rep, V1, P50, DOI 10.3410/B1-50
   Das N J, 2010, ADV DRUG DELIV REV, V62, P458
   DIANE V, 2011, RETROVIROLOGY, V8, P34
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406
   Hessell A.J., 2009, PLOS PATHOG, V5, DOI DOI 10.1371/JOURNAL.PPAT.1000433
   KLASSE P, 2011, AIDS RES HUM RETROVI
   Lansdown ABG, 2010, ADV PHARMACOL SCI, DOI 10.1155/2010/910686
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lara HH, 2010, WORLD J MICROB BIOT, V26, P615, DOI 10.1007/s11274-009-0211-3
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   MATSUSHITA S, 1988, J VIROL, V62, P2107
   Muangman P, 2010, INT WOUND J, V7, P271, DOI 10.1111/j.1742-481X.2010.00690.x
   NUNEZ NVA, 2009, NANOBIOTECHNOLOGY, V5, P1
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Perno CF, 2011, ANN I SUPER SANITA, V47, P41, DOI 10.4415/ANN_11_01_09
   PUTNEY SD, 1986, SCIENCE, V234, P1392, DOI 10.1126/science.2431482                                                         
   RUSCHE JR, 1987, P NATL ACAD SCI USA, V84, P6924, DOI 10.1073/pnas.84.19.6924                                                         
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   Villalonga-Barber C, 2008, CURR TOP MED CHEM, V8, P1294, DOI 10.2174/156802608785849012
   Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Yuan W, 2009, AIDS RES HUM RETROV, V25, P319, DOI 10.1089/aid.2008.0213
   Zuppa AA, 2011, J MATERN-FETAL NEO M, V24, P769, DOI 10.3109/14767058.2010.531326
NR 28
TC 28
Z9 28
U1 1
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD SEP 18
PY 2011
VL 9
AR 38
DI 10.1186/1477-3155-9-38
PG 9
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 828NT
UT WOS:000295509400001
PM 21923937
OA gold
DA 2018-01-05
ER

PT J
AU Meng, JN
   Sturgis, TF
   Youan, BBC
AF Meng, Jianing
   Sturgis, Timothy F.
   Youan, Bi-Botti C.
TI Engineering tenofovir loaded chitosan nanoparticles to maximize
   microbicide mucoadhesion
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Chitosan nanoparticles; HIV prevention; Mucoadhesion; Tenofovir; Vaginal
   drug delivery
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; DRUG-DELIVERY; ORAL ABSORPTION;
   CROSS-LINKING; CELL-LINE; EX-VIVO; POLYMERS; MUCOSA; NANOCOMPLEXES
AB The objective of this study was to engineer a model anti-HIV microbicide (tenofovir) loaded chitosan based nanoparticles (NPs). Box-Behnken design allowed to assess the influence of formulation variables on the size of NPs and drug encapsulation efficiency (EE%) that were analyzed by dynamic light scattering and UV spectroscopy, respectively. The effect of the NPs on vaginal epithelial cells and Lactobacillus crispatus viability and their mucoadhesion to porcine vaginal tissue were assessed by cytotoxicity assays and fluorimetry, respectively. In the optimal aqueous conditions, the EE% and NPs size were 5.83% and 207.97 nm, respectively. With 50% (v/v) ethanol/water as alternative solvent, these two responses increased to 20% and 602 nm, respectively. Unlike small size (182 nm) exhibiting burst release, drug release from medium (281 nm) and large (602 nm)-sized NPs fitted the Higuchi (r(2) = 0.991) and first-order release (r(2) = 0.999) models, respectively. These NPs were not cytotoxic to both the vaginal epithelial cell line and L crispatus for 48 h. When the diameter of the NPs decreased from 900 to 188 nm, the mucoadhesion increased from 6% to 12%. However, the combinatorial effect of EE% and percent mucoadhesion for larger size NPs was the highest. Overall, large-size, microbicide loaded chitosan NPs appeared to be promising nanomedicines for the prevention of HIV transmission. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Meng, Jianing; Youan, Bi-Botti C.] Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmacect, Kansas City, MO 64108 USA.
   [Sturgis, Timothy F.] Univ Missouri, Dept Environm Hlth & Safety, Kansas City, MO 64110 USA.
RP Youan, BBC (reprint author), Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmacect, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
RI Meng, Jianing/I-1483-2017
OI Meng, Jianing/0000-0001-6913-0880
FU National Institute of Allergy and Infectious Diseases [R21A1083092]
FX The work presented was supported by Award Number R21A1083092 from the
   National Institute of Allergy and Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official view of the National Institute of Allergy and
   Infectious Diseases or the National Institute of Health. The authors are
   grateful to Dr. Vladimir M. Dusevich (School of Dentistry, University of
   Missouri-Kansas City, MO) for the transmission electron microscope. The
   authors also would like to thank Mrs. Claire Forster (Fairview Farm Meat
   Co., Topeka, KS,) for kindly providing the fresh porcine vaginal tissue.
CR Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   Alukda D, 2011, J PHARM SCI-US, V100, P3345, DOI 10.1002/jps.22529
   ANDERSON PL, 2010, J ANTIMICROB CHEMOTH, V66, P240
   Aranaz I., 2009, CURR CHEM BIOL, V3, P203, DOI DOI 10.2174/187231309788166415
   ARYA G, 2011, NANOMEDICINE
   Baloglu E, 2009, J PHARM PHARM SCI, V12, P312, DOI 10.18433/J3HP41                                                                 
   Balzarini J, 2002, ANTIMICROB AGENTS CH, V46, P2185, DOI 10.1128/AAC.46.7.2185-2193.2002
   Bao HQ, 2008, J COLLOID INTERF SCI, V328, P270, DOI 10.1016/j.jcis.2008.09.003
   Bei D, 2009, AAPS PHARMSCITECH, V10, P1040, DOI 10.1208/s12249-009-9296-0
   Bei D, 2009, AAPS PHARMSCITECH, V10, P1032, DOI 10.1208/s12249-009-9293-3
   Bhatt DC, 2008, YAKUGAKU ZASSHI, V128, P1325, DOI 10.1248/yakushi.128.1325
   BRAVOOSUNA L, 2007, BIOMATERIALS, V28, P2233
   Calvo P, 1997, PHARMACEUT RES, V14, P1431, DOI 10.1023/A:1012128907225
   Cordova M, 2008, MACROMOLECULES, V41, P4398, DOI 10.1021/ma800211d
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1                                                   
   das Neves J, 2011, WIRES NANOMED NANOBI, V3, P389, DOI 10.1002/wnan.144
   De Campos AM, 2003, EUR J PHARM SCI, V20, P73, DOI 10.1016/S0928-0987(03)00178-7
   Denkbas EB, 2000, J MEMBRANE SCI, V172, P33, DOI 10.1016/S0376-7388(00)00314-8                                                   
   DUAN J, 2010, INT J PHARM
   Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026
   Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446                                                         
   Ghaderi R, 1997, PHARMACEUT RES, V14, P1556, DOI 10.1023/A:1012122200381
   Grabovac V, 2005, ADV DRUG DELIVER REV, V57, P1713, DOI 10.1016/j.addr.2005.07.006
   Grayson ACR, 2006, PHARM RES, V23, P1868, DOI 10.1007/s11095-006-9009-2
   Grim SA, 2003, ANN PHARMACOTHER, V37, P849, DOI 10.1345/aph.1C388
   HACKLEY VA, 2001, NIST RECOMMENDED PRA, V960, P76
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hu M, 2010, J AGR FOOD CHEM, V58, P1283, DOI 10.1021/jf903270y
   Ikinci G, 2002, INT J PHARM, V235, P121, DOI 10.1016/S0378-5173(01)00974-7
   Jackson SJ, 2001, EUR J PHARM BIOPHARM, V52, P121, DOI 10.1016/S0939-6411(01)00156-4
   Johnson TJ, 2010, EUR J PHARM SCI, V39, P203, DOI 10.1016/j.ejps.2009.11.007
   Jung T, 2000, EUR J PHARM BIOPHARM, V50, P147, DOI 10.1016/S0939-6411(00)00084-9
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289                                                           
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Leane MM, 2004, INT J PHARM, V271, P241, DOI 10.1016/j.ijpharm.2003.11.023
   LIDE DR, 1999, CRC HDB CHEM PHYS, P6
   Ma LH, 2010, COLLOID SURFACE B, V75, P448, DOI 10.1016/j.colsurfb.2009.09.018
   Ma ZS, 2003, PHARM RES, V20, P1812, DOI 10.1023/B:PHAM.0000003379.76417.3e                                              
   Miller JC, 1993, STAT ANAL CHEM
   Mohammadpourdounighi N, 2010, NANOMED-NANOTECHNOL, V6, P137, DOI 10.1016/j.nano.2009.06.002
   Nasti A, 2009, PHARM RES-DORD, V26, P1918, DOI 10.1007/s11095-009-9908-0
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Parveen S, 2010, ACTA BIOMATER, V6, P3120, DOI 10.1016/j.actbio.2010.02.010
   Plapied L, 2010, INT J PHARMACEUT, V398, P210, DOI 10.1016/j.ijpharm.2010.07.041
   Quayle AJ, 2002, J REPROD IMMUNOL, V57, P61, DOI 10.1016/S0165-0378(02)00019-0                                                   
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Sano M, 1999, CHEM PHARM BULL, V47, P1044
   Sayin B, 2009, EUR J PHARM SCI, V38, P362, DOI 10.1016/j.ejps.2009.08.010
   Songsurang K, 2011, ARCH PHARM RES, V34, P583, DOI 10.1007/s12272-011-0408-5
   Squier CA, 2008, J PHARM SCI-US, V97, P9, DOI 10.1002/jps.21077
   Sun W, 2010, INT J PHARMACEUT, V386, P275, DOI 10.1016/j.ijpharm.2009.11.025
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023
   Thongborisute J, 2006, J LIPOSOME RES, V16, P127, DOI 10.1080/08982100600680816
   Tiyaboonchai W, 2007, INT J PHARMACEUT, V329, P142, DOI 10.1016/j.ijpharm.2006.08.013
   Tobyn MJ, 1997, EUR J PHARM BIOPHARM, V43, P65, DOI 10.1016/S0939-6411(96)00009-4
   Van Gelder J, 1999, INT J PHARMACEUT, V186, P127, DOI 10.1016/S0378-5173(99)00150-7
   Vander Heyden Y, 2001, J PHARMACEUT BIOMED, V24, P723, DOI 10.1016/S0731-7085(00)00529-X                                                   
   VLLASALIU D, 2010, INT J PHARM
   Wiegand C, 2010, SKIN PHARMACOL PHYS, V23, P164, DOI 10.1159/000276996
   Wilks M, 2004, J CLIN MICROBIOL, V42, P713, DOI 10.1128/JCM.42.2.713-717.2004
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Wu Y, 2005, INT J PHARM, V295, P235, DOI 10.1016/j.ijpharm.2005.01.042
   Wu Y, 2009, BIORESOURCE TECHNOL, V100, P3459, DOI 10.1016/j.biortech.2009.02.018
   Yu CY, 2009, LANGMUIR, V25, P11720, DOI 10.1021/la901389v
   Zhang SL, 2010, INT J PHARMACEUT, V397, P211, DOI 10.1016/j.ijpharm.2010.07.007
NR 68
TC 76
Z9 76
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD SEP 18
PY 2011
VL 44
IS 1-2
BP 57
EP 67
DI 10.1016/j.ejps.2011.06.007
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 823GB
UT WOS:000295109400008
PM 21704704
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zidan, AS
   Rahman, Z
   Khan, MA
AF Zidan, Ahmed S.
   Rahman, Ziyaur
   Khan, Mansoor A.
TI Product and process understanding of a novel pediatric anti-HIV
   tenofovir niosomes with a high-pressure homogenizer
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Tenofovir; Niosomes; Microfluidization; Factorial design;
   Characterization
ID VESICLES NIOSOMES; DRUG-DELIVERY; IN-VITRO; LIPOSOMES; NANOPARTICLES;
   FORMULATION; ABSORPTION; DESIGN; SKIN
AB A variety of factors were systemically evaluated in order to establish the characteristics of the niosomes obtained with a high-pressure homogenizer. The vesicular sizing parameters, electrical properties, drug entrapment data and drug release characteristics were investigated using two groups of factors. The first group presented the physical process variables such as pressure of the homogenizer and the times that the samples were processed (cycles). The second group encompassed the compositional variables such as the drug loading, surfactant chain length, cholesterol level and the level of the charge imparting agent. The obtained data showed that the drug distributed within both the aqueous and lipid phases of the formed niosomes. Saturation-like behaviors for both the effect of homogenization cycles on the produced size and the effect of the pressure on the size homogeneity were recorded. In contrast to the drug entrapment and conductivity of the niosomal suspension, the vesicular size parameters as well as the zeta potential were inversely proportional with the homogenization parameters. Drug release was significantly affected by the compositional factors rather than the physical ones. The current study demonstrated the usefulness of the microfluidization for the production and further scale-up of anti-HIV niosomes with very small mean vesicular sizes. Published by Elsevier B.V.
C1 [Khan, Mansoor A.] US FDA, Div Prod Qual Res, CDER, OPS,OTR, Silver Spring, MD 20993 USA.
   [Zidan, Ahmed S.] Zagazig Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Zagazig, Egypt.
RP Khan, MA (reprint author), US FDA, Div Prod Qual Res, CDER, OPS,OTR, LS Bldg 64,Room 1070,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM Mansoor.Khan@fda.hhs.gov
RI Zidan, Ahmed/I-1147-2012
OI Rahman, Ziyaur/0000-0002-0402-825X
FU Oak Ridge Institute for Science and Education (ORISE); National
   Institute of Health (IAA) [Y1-HD-0052-01]
FX The authors would like to acknowledge the Oak Ridge Institute for
   Science and Education (ORISE) for its support with a research
   postdoctoral fellowship. This work was supported in part by a funding
   from the National Institute of Health (IAA, Y1-HD-0052-01).
CR Abd-Elbary A, 2008, INT J PHARMACEUT, V357, P189, DOI 10.1016/j.ijpharm.2008.01.056
   ATTIA IA, 2007, AAPS PHARMSCITECH, V8, pE1
   BALAKRISHNAN P, 2009, INT J PHARMACEUT, V337, P1
   Barnadas-Rodriguez R, 2001, INT J PHARM, V213, P175, DOI 10.1016/S0378-5173(00)00661-X                                                   
   Box G. E. P., 1987, EMPIRICAL MODEL BUIL, P688
   BRANDL M, 1990, DRUG DEV IND PHARM, V16, P2167, DOI 10.3109/03639049009023648
   Chauhan K, 2007, BIORESOURCE TECHNOL, V98, P98, DOI 10.1016/j.biortech.2005.11.017
   Cirovic DA, 1998, TALANTA, V45, P989, DOI 10.1016/S0039-9140(97)00205-1                                                   
   DELEERS M, 1982, PHARMACOL RES COMMUN, V14, P333, DOI 10.1016/S0031-6989(82)80103-3
   Fang JY, 2001, INT J PHARM, V215, P91, DOI 10.1016/S0378-5173(00)00669-4
   FARDIS M, 2007, PHARM ASPECTS, V5, P1347
   Furlanetto S, 2006, EUR J PHARM BIOPHARM, V62, P77, DOI 10.1016/j.ejpb.2005.07.001
   Gilead Sciences Inc, 2001, VIR TEN PROD MON
   Guinedi AS, 2005, INT J PHARM, V306, P71, DOI 10.1016/j.ijpharm.2005.09.023
   HARRIGAN PR, 1993, BIOCHIM BIOPHYS ACTA, V1149, P329, DOI 10.1016/0005-2736(93)90218-O
   Hong MH, 2009, J CONTROL RELEASE, V133, P96, DOI 10.1016/j.jconrel.2008.09.005
   Israelachvili J. N., 1985, INTERMOLECULAR SURFA
   Jullien V, 2003, J CHROMATOGR B, V785, P377, DOI 10.1016/S1570-0232(02)00933-9                                                   
   Kang HS, 2002, J COLLOID INTERF SCI, V255, P352, DOI 10.1006/jcis.2002.8675
   KATSUHIDE Y, 2002, P JSCE, V698, P93
   Kikuchi H, 1999, J CONTROL RELEASE, V62, P269, DOI 10.1016/S0168-3659(99)00047-4                                                   
   Lamprecht A, 1999, INT J PHARM, V184, P97, DOI 10.1016/S0378-5173(99)00107-6                                                   
   Manosroi A, 2010, INT J PHARMACEUT, V392, P304, DOI 10.1016/j.ijpharm.2010.03.064
   Mohammed AR, 2004, INT J PHARM, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010
   Pardakhty A, 2007, INT J PHARMACEUT, V328, P130, DOI 10.1016/j.ijpharm.2006.08.002
   PLACKETT RL, 1946, BIOMETRIKA, V33, P305, DOI 10.2307/2332195
   POUTON CW, 1985, J CLIN HOSP PHARM, V10, P45
   RENTEL CO, 1996, P LIP ADV PROGR DRUG, P42
   SADAR MJ, 1998, HACH TECHNICAL INFOR
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P1484
   Thompson AK, 2006, J DAIRY SCI, V89, P410, DOI 10.3168/jds.S0022-0302(06)72105-1                                               
   UCHEGBU IF, 1995, ADV COLLOID INTERFAC, V58, P1, DOI 10.1016/0001-8686(95)00242-I                                                    
   Uchegbu IF, 1998, INT J PHARM, V172, P33, DOI 10.1016/S0378-5173(98)00169-0                                                   
   Van Gelder J, 2000, DRUG METAB DISPOS, V28, P1394
   Vora B, 1998, J CONTROL RELEASE, V54, P149, DOI 10.1016/S0168-3659(97)00100-4                                                   
   WEBB MS, 1995, BBA-BIOMEMBRANES, V1238, P147, DOI 10.1016/0005-2736(95)00121-I
   YOSHIOKA T, 1994, INT J PHARM, V105, P1, DOI 10.1016/0378-5173(94)90228-3                                                    
   ZIDAN AS, 2010, AAPS J, V2, P202
   ZSCHORNIG, 1992, CHEM PHYS LIPIDS, V63, P15
NR 40
TC 16
Z9 16
U1 2
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD SEP 18
PY 2011
VL 44
IS 1-2
BP 93
EP 102
DI 10.1016/j.ejps.2011.06.012
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 823GB
UT WOS:000295109400012
PM 21726640
DA 2018-01-05
ER

PT J
AU Ilic, A
   Yu, GH
   Feng, LH
AF Ilic, Aleksandar
   Yu, Guihai
   Feng, Lihua
TI On the eccentric distance sum of graphs
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article
DE Vertex eccentricity; Eccentric distance sum; Eccentric connectivity
   index; Trees; Graph product; Extremal graphs
ID ANTI-HIV ACTIVITY; CONNECTIVITY INDEX; WIENER INDEX; TOPOLOGICAL
   DESCRIPTOR; TREES; DERIVATIVES; OPERATIONS; ZAGREB
AB The eccentric distance sum is a novel topological index that offers a vast potential for structure activity/property relationships. For a graph C, it is defined as xi(d)(G) = Sigma(v is an element of V) epsilon(v)D(v), where epsilon(v) is the eccentricity of the vertex v and D(v) = Sigma(u is an element of V(G)) d(u, v) is the sum of all distances from the vertex v. Motivated by [G. Yu, L Feng, A. Ilic, On the eccentric distance sum of trees and unicyclic graphs, J. Math. Anal. Appl. 375 (2011) 934-944], in this paper we characterize the extremal trees and graphs with maximal eccentric distance sum. Various lower and upper bounds for the eccentric distance sum in terms of other graph invariants including the Wiener index, the degree distance, eccentric connectivity index, independence number, connectivity, matching number, chromatic number and clique number are established. In addition, we present explicit formulae for the values of eccentric distance sum for the Cartesian product, applied to some graphs of chemical interest (like nanotubes and nanotori). (C) 2011 Elsevier Inc. All rights reserved.
C1 [Ilic, Aleksandar] Univ Nis, Fac Sci & Math, Nish 18000, Serbia.
   [Yu, Guihai; Feng, Lihua] Shandong Inst Business & Technol, Sch Math, Yantai 264005, Shandong, Peoples R China.
   [Feng, Lihua] Cent S Univ, Dept Math, Changsha 410075, Hunan, Peoples R China.
RP Ilic, A (reprint author), Univ Nis, Fac Sci & Math, Visegradska 33, Nish 18000, Serbia.
EM aleksandari@gmail.com; yuguihai@126.com; fenglh@163.com
RI Feng, Lihua/E-3839-2016
OI Feng, Lihua/0000-0003-4144-1649
FU Serbian Ministry of Science [174010, 174033]; Postdoctoral Science
   Foundation of Central South University; China Postdoctoral Science
   Foundation; NNSFC [70901048, 10871205]; Natural Science Foundation of
   Shandong [BS2010SF017, Y2008A04]; BMNSF [4112052]
FX Supported by Research projects 174010 and 174033 of the Serbian Ministry
   of Science, Postdoctoral Science Foundation of Central South University,
   China Postdoctoral Science Foundation, NNSFC (Nos. 70901048, 10871205),
   Natural Science Foundation of Shandong (Nos. BS2010SF017, Y2008A04) and
   BMNSF (4112052).
CR Ashrafi AR, 2011, MATCH-COMMUN MATH CO, V65, P221
   Ashrafi AR, 2011, J COMPUT APPL MATH, V235, P4561, DOI 10.1016/j.cam.2010.03.001
   Bajaj S, 2006, QSAR COMB SCI, V25, P813, DOI 10.1002/qsar.200430918
   Bollobas B, 1999, J COMB THEORY B, V75, P160, DOI 10.1006/jctb.1998.1873                                                          
   BUCKLEY F, 1989, ANN NY ACAD SCI, V576, P71, DOI 10.1111/j.1749-6632.1989.tb16384.x                                              
   Dankelmann P, 2004, UTILITAS MATHEMATICA, V65, P41
   DOBRYNIN AA, 1994, J CHEM INF COMP SCI, V34, P1082, DOI 10.1021/ci00021a008
   Dobrynin AA, 2002, ACTA APPL MATH, V72, P247, DOI 10.1023/A:1016290123303                                                         
   Dobrynin AA, 2001, ACTA APPL MATH, V66, P211, DOI 10.1023/A:1010767517079                                                         
   DOSLIC T, 2010, IRAN J MATH IN PRESS, V1
   DOSLIC T, 2009, ECCENTRIC CONN UNPUB
   Dureja H, 2008, J MOL GRAPH MODEL, V26, P1020, DOI 10.1016/j.jmgm.2007.08.008
   ENTRINGER RC, 1976, CZECH MATH J, V26, P283
   Feng LH, 2010, APPL MATH LETT, V23, P943, DOI 10.1016/j.aml.2010.04.017
   Gupta S, 2002, J MATH ANAL APPL, V275, P386, DOI 10.1016/S0022-247X(02)00373-6
   Gupta S, 2002, J MATH ANAL APPL, V266, P259, DOI 10.1006/jmaa.2000.7243
   GUTMAN I, 1994, J CHEM INF COMP SCI, V34, P1087, DOI 10.1021/ci00021a009
   HARARY F, 1962, P NATL ACAD SCI USA, V48, P1142, DOI 10.1073/pnas.48.7.1142                                                          
   Hossein-Zadeh S, 2009, FILOMAT, V23, P103, DOI 10.2298/FIL0903103H
   Hua HB, 2009, MATCH-COMMUN MATH CO, V61, P643
   Ilic A., 2010, MATH CHEM MONOGR, V9
   Ilic A, 2011, MATCH-COMMUN MATH CO, V65, P731
   Ilic A, 2010, MATCH-COMMUN MATH CO, V63, P411
   Imrich W., 2000, PRODUCT GRAPHS STRUC
   Khalifeh MH, 2009, DISCRETE APPL MATH, V157, P804, DOI 10.1016/j.dam.2008.06.015
   Kumar V, 2004, J MOL MODEL, V10, P399, DOI 10.1007/s00894-004-0215-8
   Liu HQ, 2008, MATCH-COMMUN MATH CO, V60, P85
   Morgan MJ, 2011, DISCRETE MATH, V311, P1229, DOI 10.1016/j.disc.2009.12.013
   NIKIFOROV V, 2009, ELECT J COMBIN, V15
   Sardana S, 2003, J MOL STRUC-THEOCHEM, V624, P53, DOI 10.1016/S0166-1280(02)00737-6
   Sardana S, 2002, J MOL MODEL, V8, P258, DOI 10.1007/s00894-002-0093-X
   Sharma V, 1997, J CHEM INF COMP SCI, V37, P273, DOI 10.1021/ci960049h                                                               
   Turan P., 1941, MAT FIZ LAPOK, V48, P436
   Yousefi-Azari H, 2008, APPL MATH LETT, V21, P624, DOI 10.1016/j.aml.2007.07.015
   Yu G., 2011, J MATH ANAL APPL, V375, P934
   Zhou B, 2010, MATCH-COMMUN MATH CO, V63, P181
NR 36
TC 38
Z9 38
U1 2
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD SEP 15
PY 2011
VL 381
IS 2
BP 590
EP 600
DI 10.1016/j.jmaa.2011.02.086
PG 11
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 768XL
UT WOS:000290972700013
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, C
   Cheng, XH
AF Zhao, Chao
   Cheng, Xuanhong
TI Microfluidic separation of viruses from blood cells based on intrinsic
   transport processes
SO BIOMICROFLUIDICS
LA English
DT Article
DE biodiffusion; bioMEMS; blood; cellular biophysics; microfluidics;
   microorganisms; nanoparticles; separation
ID WHOLE HUMAN BLOOD; PLASMA; DEVICE; CHIP; MICROCHANNELS; PURIFICATION;
   EXTRACTION; PARTICLES; SYSTEM; HIV
AB Clinical analysis of acute viral infection in blood requires the separation of viral particles from blood cells, since the cytoplasmic enzyme inhibits the subsequent viral detection. To facilitate this procedure in settings without access to a centrifuge, we present a microfluidic device to continuously purify bionanoparticles from cells based on their different intrinsic movements on the microscale. In this device, a biological sample is layered on top of a physiological buffer, and both fluids are transported horizontally at the same flow rate in a straight channel under laminar flow. While the micron sized particles such as cells sediment to the bottom layer with a predictable terminal velocity, the nanoparticles move vertically by diffusion. As their vertical travel distances have a different dependence on time, the micro- and nanoparticles can preferentially reside in the bottom and top layers respectively after certain residence time, yielding purified viruses. We first performed numerical analysis to predicate the particle separation and then tested the theory using suspensions of synthetic particles and biological samples. The experimental results using dilute synthetic particles closely matched the numerical analysis of a two layer flow system containing different sized particles. Similar purification was achieved using diluted blood spiked with human immunodeficiency virus. However, viral purification in whole blood is compromised due to extensive bioparticle collisions. With the parallelization and automation potential offered by microfluidics, this device has the potential to function as an upstream sample preparation module to continuously provide cell depleted bio-nanoparticles for downstream analysis. (C) 2011 American Institute of Physics. [doi:10.1063/1.3609262]
C1 [Cheng, Xuanhong] Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
   Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
RP Cheng, XH (reprint author), Lehigh Univ, Dept Mat Sci & Engn, Bethlehem, PA 18015 USA.
EM xuc207@lehigh.edu
FU National Institute of Health [NIAID-1R21AI081638]
FX We are grateful for the helpful discussions with Professor James
   Gilchrist. The HIV viral stock was kindly prepared by Yi Hu. Funding for
   the research was provided by National Institute of Health under Grant
   No. NIAID-1R21AI081638.
CR Arifin DR, 2007, BIOMICROFLUIDICS, V1, DOI 10.1063/1.2409629
   Blumel J, 2005, TRANSFUS MED HEMOTH, V32, P196, DOI 10.1159/000087620
   Cabrales P, 2005, AM J PHYSIOL-HEART C, V289, pH2392, DOI 10.1152/ajpheart.00225.2005
   Chen GD, 2010, ANAL CHEM, V82, P723, DOI 10.1021/ac9024522
   Chen HH, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2917794
   Chen X, 2009, ELECTROPHORESIS, V30, P3168, DOI 10.1002/elps.200900068
   CHIEN S, 1970, SCIENCE, V168, P977, DOI 10.1126/science.168.3934.977                                                    
   Cho YK, 2007, LAB CHIP, V7, P565, DOI 10.1039/b616115d
   Crowley TA, 2005, LAB CHIP, V5, P922, DOI 10.1039/b502930a
   Davis JA, 2006, P NATL ACAD SCI USA, V103, P14779, DOI 10.1073/pnas.0605967103
   Di Carlo D, 2007, P NATL ACAD SCI USA, V104, P18892, DOI 10.1073/pnas.0704958104
   Hsu CH, 2008, LAB CHIP, V8, P2128, DOI 10.1039/b813434k
   Rodriguez-Villarreal AI, 2010, LAB CHIP, V10, P211, DOI 10.1039/b904531g
   Jaggi RD, 2007, MICROFLUID NANOFLUID, V3, P47, DOI 10.1007/s10404-006-0104-9
   Kersaudy-Kerhoas M, 2010, LAB CHIP, V10, P1587, DOI 10.1039/b926834k
   Lee BS, 2009, LAB CHIP, V9, P1548, DOI 10.1039/b820321k
   Lien KY, 2007, LAB CHIP, V7, P868, DOI 10.1039/b700516d
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   NAKASHIMA Y, 2009, SENSOR ACTUAT B-CHEM, V145, P561
   Qu BY, 2008, ANAL BIOANAL CHEM, V392, P1317, DOI 10.1007/s00216-008-2382-4
   Russom A, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/7/075025
   Sollier E, 2009, SENSOR ACTUAT B-CHEM, V141, P617, DOI 10.1016/j.snb.2009.05.023
   Tachi T, 2009, ANAL CHEM, V81, P3194, DOI 10.1021/ac802434z
   Thorslund S, 2006, BIOMED MICRODEVICES, V8, P73, DOI 10.1007/s10544-006-6385-7
   Truskey GA, 2009, TRANSPORT PHENOMENA
   VanDelinder V, 2006, ANAL CHEM, V78, P3765, DOI 10.1021/ac060042r
   Wong AP, 2008, LAB CHIP, V8, P2032, DOI 10.1039/b809830c
   Yang S, 2006, LAB CHIP, V6, P871, DOI 10.1039/b516401j
   Zhang JL, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/12/125025
   ZHANG XG, 1991, J FLUID MECH, V230, P479, DOI 10.1017/S0022112091000861                                                       
NR 30
TC 10
Z9 10
U1 5
U2 59
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 1932-1058
J9 BIOMICROFLUIDICS
JI Biomicrofluidics
PD SEP
PY 2011
VL 5
IS 3
AR 032004
DI 10.1063/1.3609262
PG 10
WC Biochemical Research Methods; Biophysics; Nanoscience & Nanotechnology;
   Physics, Fluids & Plasmas
SC Biochemistry & Molecular Biology; Biophysics; Science & Technology -
   Other Topics; Physics
GA 829XE
UT WOS:000295618500006
PM 22007267
OA green_published
DA 2018-01-05
ER

PT J
AU Ni, X
   Castanares, M
   Mukherjee, A
   Lupold, SE
AF Ni, X.
   Castanares, M.
   Mukherjee, A.
   Lupold, S. E.
TI Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Aptamers; clinical trial; imaging; nanoparticle; oligonucleotides;
   SELEX; siRNA; target therapy
ID HUMAN PROSTATE-CANCER; VON-WILLEBRAND-FACTOR; ENDOTHELIAL GROWTH-FACTOR;
   NF-KAPPA-B; IN-VIVO; SIRNA CHIMERAS; OCULAR NEOVASCULARIZATION;
   VASCULAR-PERMEABILITY; MEMBRANE ANTIGEN; RNA MOLECULES
AB Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like cancer, HIV, and macular degeneration. In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin. The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials. With advances in targeted-therapy, imaging, and nanotechnology, aptamers are readily considered as potential targeting ligands because of their chemical synthesis and ease of modification for conjugation. Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV. In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics. In this review, we will discuss the current state of aptamers in clinical trials as well as some promising aptamers in pre-clinical development.
C1 [Lupold, S. E.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
   [Ni, X.; Castanares, M.; Mukherjee, A.; Lupold, S. E.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA.
   [Lupold, S. E.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21287 USA.
RP Lupold, SE (reprint author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 600 N Wolfe St,Pk 209, Baltimore, MD 21287 USA.
EM slupold@jhmi.edu
FU NIH/NCI [5P50CA058236]; NIGMS [F31GM79838, 5R01CA143299-02]; Patrick C
   Walsh Prostate Cancer Research Fund; Prostate Cancer Foundation; Safeway
FX We would like to thank the following funding sources: NIH/NCI
   5P50CA058236 (XN, SEL), NIGMS F31GM79838 MC); 5R01CA143299- 02 (SEL),
   the Patrick C Walsh Prostate Cancer Research Fund, the Prostate Cancer
   Foundation, and Safeway (AM, SEL).
CR Bander NH, 2006, NAT CLIN PRACT UROL, V3, P216, DOI 10.1038/ncpuro0452
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369                                                        
   Berezovski MV, 2008, J AM CHEM SOC, V130, P9137, DOI 10.1021/ja801951p
   Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X
   Borbas KE, 2007, BIOCONJUGATE CHEM, V18, P1205, DOI 10.1021/bc0700741
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x                                                
   Burmeister PE, 2006, OLIGONUCLEOTIDES, V16, P337, DOI 10.1089/oli.2006.16.337
   CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652
   Chan MY, 2008, CIRCULATION, V117, P2865, DOI 10.1161/CIRCULATIONAHA.107.745687
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9                                                   
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   CHI ZQ, 2011, NANOSCALE, V3, P2454
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Cosmi B, 2009, CURR OPIN MOL THER, V11, P322
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Dey AK, 2005, RNA, V11, P873, DOI 10.1261/rna.7205405
   Dhar S, 2011, P NATL ACAD SCI USA, V108, P1850, DOI 10.1073/pnas.1011379108
   Di Cresce C, 2010, CURR CANCER DRUG TAR, V10, P555, DOI 10.2174/156800910791859452                                                      
   Diener JL, 2009, J THROMB HAEMOST, V7, P1155, DOI 10.1111/j.1538-7836.2009.03459.x
   Eaton BE, 1997, BIOORGAN MED CHEM, V5, P1087, DOI 10.1016/S0968-0896(97)00044-8                                                   
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443                                             
   Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550                                                   
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811                                                         
   Gilbert JC, 2007, CIRCULATION, V116, P2678, DOI 10.1161/CIRCULATIONAHA.107.724864
   GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620
   Girvan AC, 2006, MOL CANCER THER, V5, P1790, DOI 10.1158/1535-7163.MCT-05-0361
   Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+
   GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2                                                    
   Healy JM, 2004, PHARM RES, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Hicke BJ, 2000, J CLIN INVEST, V106, P923, DOI 10.1172/JCI11324
   Hicke BJ, 2006, J NUCL MED, V47, P668
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Hwang DW, 2010, J NUCL MED, V51, P98, DOI 10.2967/jnumed.109.069880
   Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Keefe AD, 2010, NAT REV DRUG DISCOV, V9, P537, DOI 10.1038/nrd3141
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W
   Kulkarni O, 2007, J AM SOC NEPHROL, V18, P2350, DOI 10.1681/ASN.2006121348
   Lebruska LL, 1999, BIOCHEMISTRY-US, V38, P3168, DOI 10.1021/bi982515x                                                               
   Lin Y, 1996, NUCLEIC ACIDS RES, V24, P3407, DOI 10.1093/nar/24.17.3407
   LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229
   Lupold SE, 2002, CANCER RES, V62, P4029
   MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mann AP, 2010, PLOS ONE, V5
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Neff C.P., 2011, SCI TRANSL MED, V3, p66ra6
   Ni XH, 2011, J CLIN INVEST, V121, P2383, DOI 10.1172/JCI45109
   Ninichuk V, 2008, AM J PATHOL, V172, P628, DOI 10.2353/ajpath.2008.070601
   Nolte A, 1996, NAT BIOTECHNOL, V14, P1116, DOI 10.1038/nbt0996-1116
   Pieve Chiara Da, 2009, Nucl Med Biol, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004
   Povsic TJ, 2011, AM HEART J, V161, P261, DOI 10.1016/j.ahj.2010.10.022
   Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje
   Reis CA, 1998, INT J CANCER, V79, P402, DOI 10.1002/(SICI)1097-0215(19980821)79:4<402::AID-IJC16>3.0.CO;2-6
   Ritchie C, 2007, COMBINATION APTAMER
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   Savla R., 2011, J CONTROL RELEASE
   Sayyed SG, 2009, DIABETOLOGIA, V52, P2445, DOI 10.1007/s00125-009-1493-6
   Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862
   Shi H, 2011, P NATL ACAD SCI USA, V108, P3900, DOI 10.1073/pnas.1016197108
   Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723
   SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Troyer JK, 1997, PROSTATE, V30, P232, DOI 10.1002/(SICI)1097-0045(19970301)30:4<232::AID-PROS2>3.0.CO;2-N
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Waters EK, 2009, J THROMB HAEMOST S2
   Watorek W, 1988, Adv Exp Med Biol, V240, P23
   Watson SR, 2000, ANTISENSE NUCLEIC A, V10, P63, DOI 10.1089/oli.1.2000.10.63
   Wheeler LA, 2011, J CLIN INVEST, V121, P2401, DOI 10.1172/JCI45876
   Wright G L Jr, 1995, Urol Oncol, V1, P18, DOI 10.1016/1078-1439(95)00002-Y
   YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873
   Yigit MV, 2008, BIOCONJUGATE CHEM, V19, P412, DOI 10.1021/bc7003928
   ZAGZAG D, 1995, CANCER RES, V55, P907
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
NR 85
TC 117
Z9 125
U1 4
U2 90
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD SEP
PY 2011
VL 18
IS 27
BP 4206
EP 4214
DI 10.2174/092986711797189600                                              
          
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 827SE
UT WOS:000295447500012
PM 21838685
OA green_accepted
DA 2018-01-05
ER

PT J
AU Makatini, MM
   Petzold, K
   Sriharsha, SN
   Ndlovu, N
   Soliman, MES
   Honarparvar, B
   Parboosing, R
   Naidoo, A
   Arvidsson, PI
   Sayed, Y
   Govender, P
   Maguire, GEM
   Kruger, HG
   Govender, T
AF Makatini, Maya M.
   Petzold, Katja
   Sriharsha, Shimoga N.
   Ndlovu, N.
   Soliman, Mahmoud E. S.
   Honarparvar, Bahareh
   Parboosing, Raveen
   Naidoo, Anneta
   Arvidsson, Per I.
   Sayed, Yasien
   Govender, Patrick
   Maguire, Glenn E. M.
   Kruger, Hendrik G.
   Govender, Thavendran
TI Synthesis and structural studies of pentacycloundecane-based HIV-1 PR
   inhibitors: A hybrid 2D NMR and docking/QM/MM/MD approach
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Pentacycloundecane (PCU) peptides; HIV protease inhibitor; EASY-ROESY;
   Docking; QM/MM/MD; Molecular dynamics simulation
ID BIOLOGICALLY-ACTIVE POLYCYCLOALKANES; POLYCYCLIC CAGE COMPOUNDS;
   PROTEASE INHIBITORS; DRUG DISCOVERY; FREE-ENERGY; MOLECULAR-DYNAMICS;
   MEDICINAL AGENTS; TRANSITION-STATE; ADAMANTYL GROUP; FORCE-FIELD
AB Pentacycloundecane (PCU) lactam-peptide based HIV protease inhibitors were synthesized and nanomolar activity against the resistance-prone wild type C-South African HIV protease is reported. NMR investigations indicated that the activity is related to the chirality of the PCU moiety and its ability to induce conformations of the coupled peptide side chain. EASY-ROESY NMR experiments gave information about the 3D structure of the cage peptides and 3D solution structure could be linked to the experimental IC(50) activity profile of the considered inhibitors. QM/MM/MD simulations of the inhibitors in solution confirmed the NMR observed conformations. Docking experiments and QM/MM/MD simulations of the inhibitor-HIV PR complexes were also performed. These computational results complimented the experimental inhibition activities and enabled us to report a unique binding mode for PCU-based inhibitors at the active site of HIV-protease enzyme. A conserved hydrogen bonding pattern between the norstatine type functional group of the PCU hydroxylactam and active site residues, ASP25/ASP25', was observed in all active compounds. The biological significance and possible mode of inhibition by PCU-based HIV PR inhibitors discussed herein provide us with a deeper understanding of the mode of action of these novel inhibitors. The PCU-peptides are between 6000 and 8500 time less toxic to human MT-4 cells than Lopinavir. This potentially creates new application avenues for these putative inhibitors to be investigated against a vast number of other disease-related proteases. (C) 2011 Elsevier Masson SAS. All rights reserved.
C1 [Petzold, Katja; Sriharsha, Shimoga N.; Ndlovu, N.; Honarparvar, Bahareh; Maguire, Glenn E. M.; Kruger, Hendrik G.] Univ KwaZulu Natal, Sch Chem, ZA-4001 Durban, South Africa.
   [Makatini, Maya M.; Parboosing, Raveen; Arvidsson, Per I.; Govender, Thavendran] Univ KwaZulu Natal, Sch Pharm & Pharmacol, ZA-4001 Durban, South Africa.
   [Soliman, Mahmoud E. S.] Zagazig Univ, Fac Pharm, Dept Organ Pharmaceut Chem, Zagazig 44519, Egypt.
   [Parboosing, Raveen; Naidoo, Anneta] Univ KwaZulu Natal, Dept Virol, Natl Hlth Lab Serv, ZA-4001 Durban, South Africa.
   [Arvidsson, Per I.] Uppsala Univ, Dept Med Chem, Uppsala Biomed Ctr, SE-75123 Uppsala, Sweden.
   [Arvidsson, Per I.] AstraZeneca R&D Sodertalje, Discovery CNS & Pain Control, S-15185 Sodertalje, Sweden.
   [Sayed, Yasien] Univ Witwatersrand, Prot Struct Funct Res Unit, Sch Mol & Cell Biol, ZA-2050 Johannesburg, South Africa.
   [Govender, Patrick] Univ KwaZulu Natal, Sch Biochem Genet & Microbiol, ZA-4001 Durban, South Africa.
RP Kruger, HG (reprint author), Univ KwaZulu Natal, Sch Chem, Vars Dr, ZA-4001 Durban, South Africa.
EM mess20@bath.ac.uk; kruger@ukzn.ac.za; govenderthav@ukzn.ac.za
RI Kruger, Gert/B-1687-2009; Govender, Thavendran/H-6838-2013; Maguire,
   Glenn/C-5591-2013; Petzold, Katja/E-9816-2011; Petzold,
   Katja/M-7298-2015; Arvidsson, Per/N-4864-2013
OI Kruger, Gert/0000-0003-0606-2053; Govender,
   Thavendran/0000-0003-2511-2503; Maguire, Glenn/0000-0002-9135-5370;
   Petzold, Katja/0000-0001-9470-0347; Petzold, Katja/0000-0001-9470-0347;
   Arvidsson, Per/0000-0002-9453-6812; Parboosing,
   Raveen/0000-0002-5476-1011; Soliman, Mahmoud/0000-0002-8711-7783;
   Govender, Patrick/0000-0002-9131-590X
FU NRF (SA) TG [GUN: 66319]; KP [GUN: 69728]; CHPC (SA); HGK; PIA
   (SA-Sweden bilateral grant); Aspen Pharmacare
FX This research was supported by NRF (SA) TG (GUN: 66319), KP (GUN:
   69728), CHPC (SA), HGK and PIA (SA-Sweden bilateral grant) and Aspen
   Pharmacare. The authors thank Prof. Jurgen Schleucher and Mr. Dilip
   Jagjivan for their assistance with the NMR experiments.
CR AIGAMI K, 1976, J MED CHEM, V19, P536, DOI 10.1021/jm00226a018
   Avogadro, OP SOURC MOL BUILD V
   Bisetty K, 2006, J PEPT SCI, V12, P92, DOI 10.1002/psc.692
   Bisetty K, 2004, J PEPT SCI, V10, P274, DOI 10.1002/psc.526
   Bosi S, 2003, BIOORG MED CHEM LETT, V13, P4437, DOI 10.1016/j.bmcl.2003.09.016
   Boyle GA, 2008, STRUCT CHEM, V19, P429, DOI 10.1007/s11224-008-9298-7
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   BROOKES KB, 1992, S AFR J CHEM-S-AFR T, V45, P8
   CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045                                                             
   Clayden J, 2009, ANGEW CHEM INT EDIT, V48, P6398, DOI 10.1002/anie.200901719
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t
   Field MJ, 2000, J COMPUT CHEM, V21, P1088, DOI 10.1002/1096-987X(200009)21:12<1088::AID-JCC5>3.0.CO;2-8
   Frimurer TM, 2003, BIOPHYS J, V84, P2273, DOI 10.1016/S0006-3495(03)75033-4
   Geldenhuys WJ, 2005, MED RES REV, V25, P21, DOI 10.1002/med.20013                                                               
   GERZON K, 1967, J MED CHEM, V10, P189, DOI 10.1021/jm00314a014
   Gokul V, 2004, J MOL STRUC-THEOCHEM, V672, P119, DOI 10.1016/j.theochem.2003.11.011
   Grobler E, 2006, BIOORGAN MED CHEM, V14, P1176, DOI 10.1016/j.bmc.2005.09.042
   Hodge CN, 1998, J AM CHEM SOC, V120, P4570, DOI 10.1021/ja972357h                                                               
   Hou TJ, 2007, J MED CHEM, V50, P1177, DOI 10.1021/jm0609162
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   INAMOTO Y, 1977, J MED CHEM, V20, P1371, DOI 10.1021/jm00221a003
   James B, 2007, TETRAHEDRON LETT, V48, P6204, DOI 10.1016/j.tetlet.2007.06.125
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   Klabe RM, 1998, BIOCHEMISTRY-US, V37, P8735, DOI 10.1021/bi972555l
   Kruger HG, 2004, J ORG CHEM, V69, P4863, DOI 10.1021/jo0357723
   Lebon F, 2000, CURR MED CHEM, V7, P455, DOI 10.2174/0929867003375146                                                        
   Lee J, 2010, ANTIVIR RES, V85, P425, DOI 10.1016/j.antiviral.2009.11.002
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   Locuson CW, 2007, J MED CHEM, V50, P1158, DOI 10.1021/jm060706p
   MAKATINI MM, 2011, BIOORGANIC MED CHEM
   Malan SF, 1998, PHARMAZIE, V53, P859
   Martins FJC, 2004, MAGN RESON CHEM, V42, P402, DOI 10.1002/mrc.1355
   Martins FJC, 2001, TETRAHEDRON, V57, P1601, DOI 10.1016/S0040-4020(00)01140-6
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Mosebi S, 2008, J VIROL, V82, P11476, DOI 10.1128/JVI.00726-08
   Neumeyer J.L., 1989, PRINCIPLES MED CHEM
   Ohno Y, 1996, BIOORGAN MED CHEM, V4, P1565, DOI 10.1016/0968-0896(96)00149-6
   Oliver DW, 2008, MED CHEM RES, V17, P137, DOI 10.1007/s00044-007-9044-5
   OLIVER DW, 1991, ARZNEIMITTEL-FORSCH, V41-1, P549
   OLIVER DW, 1991, J MED CHEM, V34, P851, DOI 10.1021/jm00106a053
   Onajole OK, 2010, EUR J MED CHEM, V45, P2075, DOI 10.1016/j.ejmech.2010.01.046
   RAPALA RT, 1965, J MED CHEM, V8, P580, DOI 10.1021/jm00329a007
   ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168
   SCUDIERO DA, 1988, CANCER RES, V48, P4827
   Shen CH, 2010, FEBS J, V277, P3699, DOI 10.1111/j.1742-4658.2010.07771.x
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   SMITH BI, 1996, NATURE STRUCTURAL BI, V3, P946
   Soares TA, 2000, J MOL RECOGNIT, V13, P146, DOI 10.1002/1099-1352(200005/06)13:3<146::AID-JMR497>3.0.CO;2-4
   Thiele CM, 2009, CHEM-EUR J, V15, P585, DOI 10.1002/chem.200802027
   Tie YF, 2005, FEBS J, V272, P5265, DOI 10.1111/j.1742-4658.2005.04923.x
   TSUZUKI N, 1994, J PHARM SCI, V83, P481, DOI 10.1002/jps.2600830407
   Tyndall JDA, 2000, J MED CHEM, V43, P3495, DOI 10.1021/jm000013n                                                               
   Velaquez-Campoy Adrian, 2003, AIDS Reviews, V5, P165
   VOLDENG AN, 1968, J PHARM SCI, V57, P1053, DOI 10.1002/jps.2600570638
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wu XY, 2008, J MED CHEM, V51, P1053, DOI 10.1021/jm070680h
NR 65
TC 23
Z9 24
U1 2
U2 28
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP
PY 2011
VL 46
IS 9
BP 3976
EP 3985
DI 10.1016/j.ejmech.2011.05.071
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 824YF
UT WOS:000295237400046
PM 21741133
DA 2018-01-05
ER

PT J
AU Phan, TG
   Kapusinszky, B
   Wang, CL
   Rose, RK
   Lipton, HL
   Delwart, EL
AF Phan, Tung G.
   Kapusinszky, Beatrix
   Wang, Chunlin
   Rose, Robert K.
   Lipton, Howard L.
   Delwart, Eric L.
TI The Fecal Viral Flora of Wild Rodents
SO PLOS PATHOGENS
LA English
DT Article
ID TICK-BORNE ENCEPHALITIS; HANTAVIRUS PULMONARY SYNDROME;
   SIN-NOMBRE-VIRUS; PORCINE-CIRCOVIRUS TYPE-1; HIV-INFECTED PATIENTS;
   PICORNA-LIKE VIRUSES; MOLECULAR CHARACTERIZATION; METAGENOMIC ANALYSIS;
   PUBLIC-HEALTH; PUUMALA VIRUS
AB The frequent interactions of rodents with humans make them a common source of zoonotic infections. To obtain an initial unbiased measure of the viral diversity in the enteric tract of wild rodents we sequenced partially purified, randomly amplified viral RNA and DNA in the feces of 105 wild rodents (mouse, vole, and rat) collected in California and Virginia. We identified in decreasing frequency sequences related to the mammalian viruses families Circoviridae, Picobirnaviridae, Picornaviridae, Astroviridae, Parvoviridae, Papillomaviridae, Adenoviridae, and Coronaviridae. Seventeen small circular DNA genomes containing one or two replicase genes distantly related to the Circoviridae representing several potentially new viral families were characterized. In the Picornaviridae family two new candidate genera as well as a close genetic relative of the human pathogen Aichi virus were characterized. Fragments of the first mouse sapelovirus and picobirnaviruses were identified and the first murine astrovirus genome was characterized. A mouse papillomavirus genome and fragments of a novel adenovirus and adenovirus-associated virus were also sequenced. The next largest fraction of the rodent fecal virome was related to insect viruses of the Densoviridae, Iridoviridae, Polydnaviridae, Dicistroviriade, Bromoviridae, and Virgaviridae families followed by plant virus-related sequences in the Nanoviridae, Geminiviridae, Phycodnaviridae, Secoviridae, Partitiviridae, Tymoviridae, Alphaflexiviridae, and Tombusviridae families reflecting the largely insect and plant rodent diet. Phylogenetic analyses of full and partial viral genomes therefore revealed many previously unreported viral species, genera, and families. The close genetic similarities noted between some rodent and human viruses might reflect past zoonoses. This study increases our understanding of the viral diversity in wild rodents and highlights the large number of still uncharacterized viruses in mammals.
C1 [Phan, Tung G.; Kapusinszky, Beatrix; Delwart, Eric L.] Blood Syst Res Inst, San Francisco, CA USA.
   [Phan, Tung G.; Kapusinszky, Beatrix; Delwart, Eric L.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Kapusinszky, Beatrix] Natl Ctr Epidemiol, Dept Viral Diagnost, Budapest, Hungary.
   [Wang, Chunlin] Stanford Univ, Med Ctr, Div Infect Dis, Stanford, CA 94305 USA.
   [Rose, Robert K.] Old Dominion Univ, Dept Biol Sci, Norfolk, VA 23529 USA.
   [Lipton, Howard L.] Univ Illinois, Dept Neurol & Microbiol Immunol, Chicago, IL USA.
RP Phan, TG (reprint author), Blood Syst Res Inst, San Francisco, CA USA.
EM delwarte@medicine.ucsf.edu
OI Delwart, Eric/0000-0002-6296-4484
FU NHLBI [R01HL083254]; Blood Systems Research Institute; NSF [CNS-0619926]
FX We acknowledge NHLBI grant R01HL083254 and Blood Systems Research
   Institute for support to E.L.D and NSF award CNS-0619926 to Bio-X2
   cluster at Stanford University for computer resources. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Arden KE, 2010, REV MED VIROL, V20, P156, DOI 10.1002/rmv.644
   Bakhvalova VN, 2006, VECTOR-BORNE ZOONOT, V6, P32, DOI 10.1089/vbz.2006.6.32
   Banyai K, 2010, VET MICROBIOL, V142, P416, DOI 10.1016/j.vetmic.2009.10.014
   Bengis RH, 2004, REV SCI TECH OIE, V23, P497
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Bhattacharya R, 2006, INFECT GENET EVOL, V6, P453, DOI 10.1016/j.meegid.2006.02.005
   Blinkova O, 2009, J CLIN MICROBIOL, V47, P3507, DOI 10.1128/JCM.01062-09
   Blinkova O, 2010, J GEN VIROL, V91, P74, DOI 10.1099/vir.0.015446-0
   Blinkova O, 2009, J VIROL, V83, P4631, DOI 10.1128/JVI.02085-08
   Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003
   Breitbart M, 2002, P NATL ACAD SCI USA, V99, P14250, DOI 10.1073/pnas.202488399
   Briese T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000455
   Brown KE, 2010, REV MED VIROL, V20, P231, DOI 10.1002/rmv.648
   Buzinaro MG, 2003, VET J, V166, P185, DOI 10.1016/S1090-0233(03)00031-5
   Cann AJ, 2005, VIRUS GENES, V30, P151, DOI 10.1007/s11262-004-5624-3
   Chandra R, 1997, ACTA VIROL, V41, P59
   Charrel RN, 2010, VET MICROBIOL, V140, P213, DOI 10.1016/j.vetmic.2009.08.027
   Chiu CY, 2008, P NATL ACAD SCI USA, V105, P14124, DOI 10.1073/pnas.0805968105
   Chomel BB, 2007, EMERG INFECT DIS, V13, P6, DOI 10.3201/eid1301.060480                                                          
   Chu DKW, 2008, J VIROL, V82, P9107, DOI 10.1128/JVI.00857-08
   Chu DKW, 2010, J GEN VIROL, V91, P2457, DOI 10.1099/vir.0.022764-0
   Culley AI, 2006, SCIENCE, V312, P1795, DOI 10.1126/science.1127404
   Culley AI, 2003, NATURE, V424, P1054, DOI 10.1038/nature01886
   Cutler SJ, 2010, EMERG INFECT DIS, V16, P1, DOI 10.3201/eid1601.081467
   Davis S, 2005, VECTOR-BORNE ZOONOT, V5, P305, DOI 10.1089/vbz.2005.5.305
   Day JM, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-313
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Delwart EL, 2007, REV MED VIROL, V17, P115, DOI 10.1002/rmv.532
   Donaldson EF, 2010, J VIROL, V84, P13004, DOI 10.1128/JVI.01255-10
   Fregolente MCD, 2009, ARCH VIROL, V154, P1953, DOI 10.1007/s00705-009-0537-z
   Fregolente MCD, 2009, VIRUS RES, V143, P134, DOI 10.1016/j.virusres.2009.03.006
   Dvorak CMT, 2001, VIROLOGY, V290, P261, DOI 10.1006/viro.2001.1193
   Enria DA, 2000, INFECT DIS CLIN N AM, V14, P167, DOI 10.1016/S0891-5520(05)70223-3
   Faurez F, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-60
   Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011
   Finkbeiner SR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-161
   Finkbeiner SR, 2009, J VIROL, V83, P10836, DOI 10.1128/JVI.00998-09
   FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670                                                       
   Ganesh B, 2010, INFECT GENET EVOL, V10, P511, DOI 10.1016/j.meegid.2010.02.008
   Gibbs MJ, 2006, MOL BIOL EVOL, V23, P1097, DOI 10.1093/molbev/msj122
   Giordano MO, 2011, J INFECTION, V62, P45, DOI 10.1016/j.jinf.2010.09.031
   Giordano MO, 1998, J ACQ IMMUN DEF SYND, V18, P380, DOI 10.1097/00042560-199808010-00010                                                
   Giordano MO, 1999, AIDS RES HUM RETROV, V15, P1427, DOI 10.1089/088922299309937
   Goldsmith CS, 1995, ARCH VIROL, V140, P2107, DOI 10.1007/BF01323234
   Greninger AL, 2010, CLIN VACCINE IMMUNOL, V17, P1584, DOI 10.1128/CVI.00152-10
   Greninger AL, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-82
   Habayeb MS, 2006, J GEN VIROL, V87, P3045, DOI 10.1099/vir.0.81997-0
   Hartley CJ, 2005, J VIROL, V79, P13385, DOI 10.1128/JVI.79.21.13385-13398.2005
   Henckaerts E, 2010, FUTURE VIROL, V5, P555, DOI 10.2217/FVL.10.48
   HJELLE B, 1995, CRIT REV CL LAB SCI, V32, P469, DOI 10.3109/10408369509082592                                                       
   Hjertqvist M, 2010, EMERG INFECT DIS, V16, P1584, DOI 10.3201/eid1610.100242
   Holtz LR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-86
   Honkavuori KS, 2011, EMERG INFECT DIS, V17, P480, DOI 10.3201/eid1703.101410
   Huchon D, 2002, MOL BIOL EVOL, V19, P1053, DOI 10.1093/oxfordjournals.molbev.a004164                                           
   Ishida S, 2008, JPN J INFECT DIS, V61, P504
   Jeong AY, 2011, CLIN MICROBIOL INFEC, V17, P404, DOI 10.1111/j.1469-0691.2010.03263.x
   Jones MS, 2007, J CLIN MICROBIOL, V45, P2144, DOI 10.1128/JCM.00174-07
   Kaikkonen S, 2010, EPIDEMIOL INFECT, V138, P1166, DOI 10.1017/S0950268809991300
   Kapoor A, 2009, J GEN VIROL, V90, P2965, DOI 10.1099/vir.0.014449-0
   Katayama K, 2002, VIROLOGY, V299, P225, DOI 10.1006/viro.2002.1568
   Kennedy J, 2008, MICROB CELL FACT, V7, DOI 10.1186/1475-2859-7-27
   KHAN AS, 1995, J MED VIROL, V46, P281, DOI 10.1002/jmv.1890460320
   Khan AS, 1996, J INFECT DIS, V173, P1297, DOI 10.1093/infdis/173.6.1297                                                       
   Khan SH, 2008, ANTIVIR RES, V78, P103, DOI 10.1016/j.antiviral.2007.11.003
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581                                                              
   Klein SL, 2007, CURR TOP MICROBIOL, V315, P217
   Klempa B, 2009, CLIN MICROBIOL INFEC, V15, P518, DOI 10.1111/j.1469-0691.2009.02848.x
   Klempa B, 2009, J VIROL, V83, P5749, DOI 10.1128/JVI.02281-08
   Korva M, 2009, VIRUS RES, V144, P318, DOI 10.1016/j.virusres.2009.04.021
   Kunz Anjali N, 2010, Curr Infect Dis Rep, V12, P81, DOI 10.1007/s11908-010-0084-5
   Le Guyader FS, 2008, J CLIN MICROBIOL, V46, P4011, DOI 10.1128/JCM.01044-08
   LEDUC JW, 1987, LAB ANIM SCI, V37, P413
   Li L, 2011, J GEN VIROL
   Li LL, 2011, J GEN VIROL, V92, P768, DOI 10.1099/vir.0.028704-0
   Li LL, 2010, J VIROL, V84, P6955, DOI 10.1128/JVI.00501-10
   Li LL, 2010, J VIROL, V84, P1674, DOI 10.1128/JVI.02109-09
   Li LL, 2009, J VIROL, V83, P12002, DOI 10.1128/JVI.01241-09
   Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4
   Lipkin WI, 2009, ANN NY ACAD SCI, V1171, pE6, DOI 10.1111/j.1749-6632.2009.05056.x
   Lonner BN, 2008, VECTOR-BORNE ZOONOT, V8, P433, DOI 10.1089/vbz.2007.0232
   Vilarino ML, 2009, INT MICROBIOL, V12, P145, DOI 10.2436/20.1501.01.92
   MACKENZIE RB, 1972, B WORLD HEALTH ORGAN, V47, P161
   Makary P, 2010, EPIDEMIOL INFECT, V138, P1484, DOI 10.1017/S0950268810000087
   Mansfield KL, 2009, J GEN VIROL, V90, P1781, DOI 10.1099/vir.0.011437-0
   Martella V, 2008, EMERG INFECT DIS, V14, P1306, DOI 10.3201/eid1408.080062
   Masachessi G, 2007, ARCH VIROL, V152, P989, DOI 10.1007/s00705-006-0900-2
   Meerburg BG, 2009, CRIT REV MICROBIOL, V35, P221, DOI 10.1080/10408410902989837
   Mills JN, 1998, EMERG INFECT DIS, V4, P529, DOI 10.3201/eid0404.980403                                                          
   Monroe MC, 1999, EMERG INFECT DIS, V5, P75, DOI 10.3201/eid0501.990109                                                          
   Ng TFF, 2009, J VIROL, V83, P2500, DOI 10.1128/JVI.01946-08
   NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615
   Olivier V, 2008, VIRUS RES, V132, P59, DOI 10.1016/j.virusres.2007.10.014
   Olson EJ, 2004, J VET DIAGN INVEST, V16, P461, DOI 10.1177/104063870401600518                                                      
   Oncul O, 2011, EMERG INFECT DIS, V17, P303, DOI 10.3201/eid1702.100663
   Palacios G, 2007, EMERG INFECT DIS, V13, P73, DOI 10.3201/eid1301.060837                                                          
   Papa A, 2011, EMERG INFECT DIS, V17, P308, DOI 10.3201/eid1702.101275
   Paul S, 2006, J GEN VIROL, V87, P1237, DOI 10.1099/vir.0.81642-0
   PEREIRA HG, 1988, J GEN VIROL, V69, P2749, DOI 10.1099/0022-1317-69-11-2749
   Pettersson L, 2008, EMERG INFECT DIS, V14, P808, DOI 10.3201/eid1405.071124
   Pham NTK, 2007, J CLIN MICROBIOL, V45, P2287, DOI 10.1128/JCM.00525-07
   PLYUSNIN A, 1994, J VIROL, V68, P7833
   Quan PL, 2010, EMERG INFECT DIS, V16, P918, DOI 10.3201/eid1606.091536
   Reuter G, 2011, REV MED VIROL, V21, P32, DOI 10.1002/rmv.677
   Reuter G, 2011, ARCH VIROL, V156, P125, DOI 10.1007/s00705-010-0827-5
   Rivera R, 2010, J GEN VIROL, V91, P166, DOI 10.1099/vir.0.015222-0
   Rivers MN, 2009, SOUTH MED J, V102, P36, DOI 10.1097/SMJ.0b013e318187d06f
   Rosario K, 2011, J GEN VIROL, V92, P1302, DOI 10.1099/vir.0.030338-0
   Rosario K, 2009, ENVIRON MICROBIOL, V11, P2806, DOI 10.1111/j.1462-2920.2009.01964.x
   Rosario K, 2009, J GEN VIROL, V90, P2418, DOI 10.1099/vir.0.012955-0
   ROWE JE, 1995, VIROLOGY, V213, P122, DOI 10.1006/viro.1995.1552
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Schultze D, 2002, EUR J CLIN MICROBIOL, V21, P304, DOI 10.1007/s10096-002-0705-5
   SCHWARZ TF, 1995, J VIROL METHODS, V51, P349, DOI 10.1016/0166-0934(94)00142-4
   Sdiri-Loulizi K, 2009, J CLIN MICROBIOL, V47, P2275, DOI 10.1128/JCM.00913-09
   Shan TL, 2010, EMERG INFECT DIS, V16, P1303, DOI 10.3201/eid1608.100087
   Simon C, 2011, APPL ENVIRON MICROB, V77, P1153, DOI 10.1128/AEM.02345-10
   Smith JG, 2010, CURR TOP MICROBIOL, V343, P195, DOI 10.1007/82_2010_16
   Song Jin-Won, 2002, International Journal of Infectious Diseases, V6, P31, DOI 10.1016/S1201-9712(02)90133-5
   Song JW, 2004, VIRUS GENES, V29, P239, DOI 10.1023/B:VIRU.0000036384.50102.cf
   SRIVASTAVA A, 1983, J VIROL, V45, P555
   Steinfeldt T, 2001, VIROLOGY, V291, P152, DOI 10.1006/viro.2001.1203
   Steinfeldt T, 2007, J VIROL, V81, P5696, DOI 10.1128/JVI.02420-06
   Svraka S, 2010, J GEN VIROL, V91, P2846, DOI 10.1099/vir.0.024612-0
   Tang P, 2010, FUTURE MICROBIOL, V5, P177, DOI [10.2217/fmb.09.120, 10.2217/FMB.09.120]
   Tersago K, 2008, VECTOR-BORNE ZOONOT, V8, P235, DOI 10.1089/vbz.2007.0160
   Tong SX, 2010, AM J TROP MED HYG, V82, P967, DOI 10.4269/ajtmh.2010.09-0668
   Tonteri E, 2011, EMERG INFECT DIS, V17, P72, DOI 10.3201/eid1701.100051
   TORRESPEREZ F, EMERG INFECT DIS, V16, P308
   Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212
   TURELL MJ, 1995, AM J TROP MED HYG, V52, P180
   van Leeuwen M, 2010, J CLIN MICROBIOL, V48, P1787, DOI 10.1128/JCM.02452-09
   Vapalahti O, 2003, LANCET INFECT DIS, V3, P653, DOI 10.1016/S1473-3099(03)00774-6
   Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08
   Walter JE, 2003, CURR OPIN INFECT DIS, V16, P247, DOI 10.1097/01.qco.0000073775.11390.60
   Wang D, 2002, P NATL ACAD SCI USA, V99, P15687, DOI 10.1073/pnas.242579699
   White DJ, 1996, ARCH INTERN MED, V156, P722, DOI 10.1001/archinte.156.7.722
   Woo PCY, 2010, J GEN VIROL, V91, P2433, DOI 10.1099/vir.0.021717-0
   Yamashita T, 1998, J VIROL, V72, P8408
   YAMASHITA T, 1993, J CLIN MICROBIOL, V31, P2938
   YAMASHITA T, 1991, J INFECT DIS, V164, P954, DOI 10.1093/infdis/164.5.954                                                        
   Yamashita Y, 2010, J MED VIROL, V82, P720, DOI 10.1002/jmv.21646
   Yoon HS, SCIENCE, V332, P714
   Yu X, 2010, P NATL ACAD SCI USA, V107, P8387, DOI 10.1073/pnas.0913535107
   Zeier M, 2005, VIRUS GENES, V30, P157, DOI 10.1007/s11262-004-5625-2
   Zhang YZ, 2009, EMERG INFECT DIS, V15, P885, DOI 10.3201/eid1506.081126
   ZHANG YZ, EMERG INFECT DIS, V16, P1195
   Zhu HC, 2009, J GEN VIROL, V90, P883, DOI 10.1099/vir.0.007732-0
   Zou Y, 2008, J MED VIROL, V80, P680, DOI 10.1002/jmv.21119
   Zuo SQ, 2008, AM J TROP MED HYG, V78, P833
NR 149
TC 167
Z9 173
U1 8
U2 59
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2011
VL 7
IS 9
AR e1002218
DI 10.1371/journal.ppat.1002218
PG 16
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 827DY
UT WOS:000295409000022
PM 21909269
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Kesharwani, P
   Gajbhiye, V
   Tekade, RK
   Jain, NK
AF Kesharwani, Prashant
   Gajbhiye, Virendra
   Tekade, Rakesh K.
   Jain, Narendra K.
TI Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Dendrimer; cell line; cancer; corticosteroid hormones; anti-HIV;
   photodynamic therapy; transfection
ID EPSTEIN-BARR-VIRUS; NEUTRON-CAPTURE THERAPY; ENCAPSULATED ANTITUBERCULAR
   DRUGS; POLY PROPYLENEIMINE DENDRIMER; PHOTODYNAMIC THERAPY; IN-VITRO;
   5-AMINOLEVULINIC ACID; GENE-EXPRESSION; POLYAMIDOAMINE DENDRIMER; PAMAM
   DENDRIMERS
AB Dendrimers, by virtue of their therapeutic value, have recently generated enormous interest among biomedical scientists. Advancement of dendrimeric nano-architecture with well defined size, shape and controlled exterior functionality embraces promise in biomedical and pharmaceutical applications such as drug delivery, solubilization, DNA transfection and diagnosis. Highly branched, monodisperse, stable molecular level and low polydispersity with micelle-like behavior possessing nano-scale container property distinguish these structures as inimitable and optimum carrier for those applications. Dendrimers has been evaluated for delivery of different types of bioactives inside the cells. Different types of techniques are being used for exploring dendrimer safety and efficacy via cell cytotoxicity assays, cell uptake studies by fluorescent microscopy, cell line studies, flow cytometry, gamma scintigraphy and confocal microscopy; are being used over a decade. Among these, cell line studies are widely used for ex vivo characterization of dendrimers and other nanocarriers. Cell lines are homogeneous population of cells, stable after mitosis, and have an unlimited capacity for division. This review focuses on the use of different cell line studies including anticancer drugs, anti-HIV drugs, anti-inflammatory drugs, anti-tubercular-drugs, photodynamic therapy, hormonal therapy employing dendritic nanocarrier.
C1 [Kesharwani, Prashant; Gajbhiye, Virendra; Tekade, Rakesh K.; Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Lab, Sagar 470003, MP, India.
EM jnarendr@yahoo.co.in
FU All India Council of Technical Education (AICTE), New Delhi, India
FX One of the authors Mr. Prashant Kesharwani is thankful to All India
   Council of Technical Education (AICTE), New Delhi, India for providing
   financial assistance in the form of junior research fellowship (JRF)
   during this work.
CR Ackermann B, 2002, PEDIATR HEMAT ONCOL, V19, P509, DOI 10.1080/08880010290097332
   Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x                                                
   Agarwal A, 2009, BIOMATERIALS, V30, P1
   Agashe HB, 2006, J PHARM PHARMACOL, V58, P1491, DOI 10.1211/jpp.58.11.0010
   ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5
   Alarcon GS, 2000, IMMUNOPHARMACOLOGY, V47, P259, DOI 10.1016/S0162-3109(00)00184-3                                                   
   Arima H, 2001, BIOCONJUGATE CHEM, V12, P476, DOI 10.1021/bc000111n
   Aristarchos P, 2005, INT J PHARMACEUT, V302, P29
   BALLET F, 1987, CANCER CHEMOTH PHARM, V19, P240
   Barnard D. L., 1997, Antiviral Research, V34, pA88
   Barth RF, 2005, CLIN CANCER RES, V11, P3987, DOI 10.1158/1078-0432.CCR-05-0035                                                   
   Barth RF, 2004, APPL RADIAT ISOTOPES, V61, P899, DOI 10.1016/j.apradiso.2004.05.004
   Battah SH, 2001, BIOCONJUGATE CHEM, V12, P980, DOI 10.1021/bc010027n                                                               
   Battah S, 2007, MOL CANCER THER, V6, P876, DOI 10.1158/1535-7163.MCT-06-0359
   Beezer AE, 2003, TETRAHEDRON, V59, P3873, DOI 10.1016/S0040-4020(03)00437-X
   Bharathi D, 2007, J BIOMED NANOTECHNOL, V3, P384
   Blum HF, 1941, J AM PHARM ASSOC, V8, P228
   BODLEY A, 1989, CANCER RES, V49, P5969
   Calabresi P, 1996, PHARMACOL BASIS THER, P1226
   Choi JS, 2006, INT J PHARM, V320, P171, DOI 10.1016/j.ijpharm.2006.05.002
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Cook JA, 1989, ANAL BIOCHEM, V15, P1
   D'Emanuele A, 2004, J CONTROL RELEASE, V95, P447, DOI 10.1016/j.jconrel.2003.12.006
   Davies NM, 1997, CLIN PHARMACOKINET, V32, P268, DOI 10.2165/00003088-199732040-00002
   Dhanikula RS, 2008, MOL PHARM, V5, P105, DOI 10.1021/mp700086j
   Di Venosa GM, 2006, INT J BIOCHEM CELL B, V38, P82, DOI 10.1016/j.biocel.2005.08.001
   DODION P, 1987, CANCER RES, V47, P1036
   Dutta T, 2006, J EXP NANOSCI, V1, P235, DOI 10.1080/17458080600647146
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X
   Eisenhauer EA, 1998, DRUGS, V55, P5, DOI 10.2165/00003495-199855010-00002
   Fan WM, 1999, BIOCHEM PHARMACOL, V57, P1215
   FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834
   GAHN TA, 1995, J VIROL, V69, P2633
   Gajbhiye V, 2007, CURR PHARM DESIGN, V13, P415, DOI 10.2174/138161207780162999
   Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002
   Genestier L, 2000, IMMUNOPHARMACOLOGY, V47, P247, DOI 10.1016/S0162-3109(00)00189-2
   Gopin A, 2006, BIOCONJUGATE CHEM, V17, P1432, DOI 10.1021/bc060180n
   Gurdag S, 2006, BIOCONJUGATE CHEM, V17, P275, DOI 10.1021/bc0501855
   Harada Y, 2000, CANCER GENE THER, V7, P27, DOI 10.1038/sj.cgt.7700079
   Harrington WR, 2006, MOL ENDOCRINOL, V20, P491, DOI 10.1210/me.2005-0186
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   James G, 1999, US SEER PROGRAM, P1975
   Jang WD, 2006, J CONTROL RELEASE, V113, P73, DOI 10.1016/j.jconrel.2006.03.009
   JANKELEVICH S, 1992, EMBO J, V11, P1165
   Jevprasesphant R, 2003, PHARMACEUT RES, V20, P1543, DOI 10.1023/A:1026166729873                                                         
   Jevprasesphant R, 2004, J CONTROLL REL, V20, P1543
   Jonathan M, 2002, J CONTROL RELEASE, V79, P255
   Jordan MA, 1999, METHOD CELL BIOL, V61, P267
   Kannan S, 2004, J BIOMAT SCI-POLYM E, V15, P311, DOI 10.1163/156856204322977201
   Khandare J, 2005, BIOCONJUGATE CHEM, V16, P330, DOI 10.1021/bc0498018
   Khandare JJ, 2006, BIOCONJUGATE CHEM, V17, P1464, DOI 10.1021/bc060240p
   KIRCHMAIER AL, 1995, J VIROL, V69, P1280
   Kitchens KM, 2006, PHARM RES, V23, P2818, DOI 10.1007/s11095-006-9122-2
   Kohn KW, 2000, ANN NY ACAD SCI, V922, P11
   Kojima C, 2007, BIOCONJUGATE CHEM, V18, P663, DOI 10.1021/bc060244u
   Kolhatkar RB, 2008, PHARM RES, P9572
   Kolhe P, 2006, BIOMATERIALS, V27, P660, DOI 10.1016/j.biomaterials.2005.06.007
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6                                                   
   Lee CC, 2006, P NATL ACAD SCI USA, V103, P16649, DOI 10.1073/pnas.0607705103
   Liu LF, 2000, ANN NY ACAD SCI, V922, P1
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Majoros IJ, 2006, BIOMACROMOLECULES, V7, P572, DOI 10.1021/bm0506142
   Malik N, 1999, ANTI-CANCER DRUG, V10, P767, DOI 10.1097/00001813-199909000-00010
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   MIDDLETON T, 1994, J VIROL, V68, P4067
   Morgan MT, 2006, CANCER RES, V66, P11913, DOI 10.1158/0008-5472.CAN-06-2066
   Morgan MT, 2003, J AM CHEM SOC, V125, P15485, DOI 10.1021/ja0347383
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Myc A, 2007, BIOMACROMOLECULES, V8, P2986, DOI 10.1021/bm700727g
   Najlah M, 2007, INT J PHARM, V336, P183, DOI 10.1016/j.ijpharm.2006.11.047
   Nakagishi Y, 2005, AM ASS CANC RES ANAH, P16
   Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836
   Omayra L, 2002, BIOCONJUGATE CHEM, V13, P453, DOI DOI 10.1021/BC010103M
   Omidi Y, 2005, J DRUG TARGET, V13, P431, DOI 10.1080/10611860500418881
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001
   Patri AK, 2005, ADV DRUG DELIVER REV, V57, P2203, DOI 10.1016/j.addr.2005.09.014
   Perumal OP, 2008, BIOMATERIALS, V29, P3469
   Quintana A, 2002, PHARMACEUT RES, V19, P1310, DOI 10.1023/A:1020398624602
   RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X
   ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U
   ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1
   Schacht V, 2006, PHOTOCH PHOTOBIO SCI, V5, P452, DOI 10.1039/b514128a
   Schatzlein AG, 2005, J CONTROL RELEASE, V101, P247, DOI 10.1016/j.jconrel.2004.08.024
   Seib FP, 2007, J CONTROL RELEASE, V117, P291, DOI 10.1016/j.jconrel.2006.10.020
   Shamis M, 2004, J AM CHEM SOC, V126, P1726, DOI 10.1021/ja039052p
   Sharma A, 2004, INT J ANTIMICROB AG, V24, P599, DOI 10.1016/j.ijantimicag.2004.07.010
   Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b
   Shukla R, 2008, NANOTECHNOLOGY, V19, P143
   Shukla S, 2003, BIOCONJUGATE CHEM, V14, P158, DOI 10.1021/bc025586o
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Solassol J, 2004, J GEN VIROL, V85, P1791, DOI 10.1099/vir.0.19726-0
   SPENCER CM, 1994, DRUGS, V48, P794, DOI 10.2165/00003495-199448050-00009                                                
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Tabata HM, 2000, GENE THER, V7, P53
   Tekade RK, 2009, CHEM REV, V109, P49, DOI 10.1021/cr068212n
   Tekade RK, 2008, J DRUG TARGET, V16, P758, DOI [10.1080/10611860802473154, 10.1080/10611860802473154 ]
   Tekade RK, 2008, J MICROENCAPSUL, V15, P1
   TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Thomas TP, 2005, J MED CHEM, V48, P3729, DOI 10.1021/jm040187v
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   TUREK JJ, 1993, J CELL SCI, V106, P423
   Tziveleka LA, 2007, J CONTROL RELEASE, V117, P137, DOI 10.1016/j.jconrel.2006.10.019
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232
   Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016
   Wagner E, 1998, ADV DRUG DELIV REV, V30, P97
   Wall ME, 1996, ANN NY ACAD SCI, V803, P1, DOI 10.1111/j.1749-6632.1996.tb26371.x
   Wu G, 2006, MOL CANCER THER, V5, P52, DOI 10.1158/1535-7163.MCT-05-0325
   Wu G, 2006, ANTICANCER AGENTS ME, V6, P1
   Yang W, 2008, EUR J MED CHEM, V44, P862
   Yellepeddi VK, 2009, ANTICANCER RES, V29, P2933
   ZHOU XH, 1991, BIOCHIM BIOPHYS ACTA, V1065, P8, DOI 10.1016/0005-2736(91)90003-Q
NR 117
TC 21
Z9 21
U1 3
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD SEP
PY 2011
VL 12
IS 10
BP 1478
EP 1497
DI 10.2174/138945011796818135                                              
          
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 827DK
UT WOS:000295407100016
PM 21443471
DA 2018-01-05
ER

PT J
AU Bondioli, L
   Ludovisi, A
   Tosi, G
   Ruozi, B
   Forni, F
   Pozio, E
   Vandelli, MA
   Gomez-Morales, MA
AF Bondioli, L.
   Ludovisi, A.
   Tosi, G.
   Ruozi, B.
   Forni, F.
   Pozio, E.
   Vandelli, M. A.
   Gomez-Morales, M. A.
TI The loading of labelled antibody-engineered nanoparticles with Indinavir
   increases its in vitro efficacy against Cryptosporidium parvum
SO PARASITOLOGY
LA English
DT Article
DE Cryptosporidium parvum; flow cytometry; Indinavir; nanoparticles;
   protease inhibitors
ID POLY(LACTIC ACID) NANOPARTICLES; ANTIRETROVIRAL THERAPY; DRUG-DELIVERY;
   PROTEASE INHIBITORS; HIV; INFECTION; RELEASE; MICROSPHERES; EXCYSTATION;
   FORMULATION
AB There is much evidence to indicate the ability of Indinavir (IND) to reduce Cryptosporidium parvum infection in both in vitro and in vivo models. However, there are limitations to the administration of IND as such, due to its renal toxicity and the high rate of metabolism and degradation. We aimed to encapsulate IND in biodegradable poly (D, L-lactide-co-glycolide) nanoparticles (Np) and to engineer their surface by conjugation with an anti-Cryptosporidium IgG polyclonal antibody (Ab). Tetramethylrhodamine-labelled Np were loaded with IND and modified by conjugation with an Ab. The IND-loaded modified Np (Ab-TMR-IND-Np) did not show any change, as demonstrated by chemical analysis studies. Simultaneous addition of 50 mu M Ab-TMR-IND-Np and excysted oocysts to the cell culture resulted in complete inhibition of the infection. In C. parvum-infected cells, the extent to which the infection decreased depended on the duration of treatment with the Ab-TMR-IND-Np. The antibody-engineered Np loaded with IND were able to target C. parvum in infected cells and therefore might represent a novel therapeutic strategy against Cryptosporidium sp. infection. Moreover, the use of Np as an IND delivery device, allows the development of a more appropriate dose formulation thereby reducing the IND side effects.
C1 [Ludovisi, A.; Pozio, E.; Gomez-Morales, M. A.] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy.
   [Bondioli, L.; Tosi, G.; Ruozi, B.; Forni, F.; Vandelli, M. A.] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, I-41100 Modena, Italy.
RP Gomez-Morales, MA (reprint author), Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM mariaangeles.gomezmorales@iss.it
RI Tosi, Giovanni/D-4547-2011; Forni, Flavio/D-5492-2015; GOMEZ MORALES,
   MARIA DE LOS ANGELES/O-2283-2015; Ruozi, Barbara/D-5500-2015; Vandelli,
   Maria Angela/D-5497-2015
OI Tosi, Giovanni/0000-0001-8318-667X; Forni, Flavio/0000-0001-5974-6286;
   GOMEZ MORALES, MARIA DE LOS ANGELES/0000-0001-9116-4948; Ruozi,
   Barbara/0000-0002-2400-9910; Vandelli, Maria Angela/0000-0003-1462-8133
FU Istituto Superiore di Sanita
FX This work was supported by the Istituto Superiore di Sanita.
CR AMADI B, 2009, BMC INFECT DIS, V2, P195
   Askin D, 1998, Curr Opin Drug Discov Devel, V1, P338
   Battegay M, 2008, J ANTIMICROB CHEMOTH, V62, P41, DOI 10.1093/jac/dkn169
   Batycky RP, 1997, J PHARM SCI, V86, P1464, DOI 10.1021/js9604117
   Bobin S, 1998, PATHOL BIOL, V46, P418
   Caccio S, 2002, EMERG INFECT DIS, V8, P85, DOI 10.3201/eid0801.010269                                                          
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441
   COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384                                                         
   Costantino L, 2006, BIOMATERIALS, V27, P4635, DOI 10.1016/j.biomaterials.2006.04.026
   Pereira de Oliveira M., 2005, PHARM RES, V22, P1898, DOI DOI 10.1007/S11095-005-7147-6
   Dimitrov DS, 2008, J COMPUT THEOR NANOS, V5, P751
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Ethelberg S, 2009, EPIDEMIOL INFECT, V137, P348, DOI 10.1017/S0950268808001817
   FESSI H, 1989, INT J PHARM, V55, pR1, DOI 10.1016/0378-5173(89)90281-0
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gargala G, 2008, PARASITE, V15, P275, DOI 10.1051/parasite/2008153275                                                     
   Gref R, 2003, BIOMATERIALS, V24, P4529, DOI 10.1016/S0142-9612(03)00348-X
   Gut J, 1999, J EUKARYOT MICROBIOL, V46, p56S
   Harush-Frenkel O, 2008, CRIT REV THER DRUG, V25, P485, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i6.10                                    
   Hommer V, 2003, J ANTIMICROB CHEMOTH, V52, P359, DOI 10.1093/jac/dkg357
   Huang X, 2002, INT J PHARM, V248, P183, DOI 10.1016/S0378-5173(02)00433-7                                                   
   Hunter PR, 2004, CLIN INFECT DIS, V39, P504, DOI 10.1086/422649
   HUWLYER J, 1996, P NATL ACAD SCI USA, V93, P14164
   Ives NJ, 2001, J INFECTION, V42, P134, DOI 10.1053/jinf.2001.0810
   Jancic B, 2005, CHROMATOGRAPHIA, V62, P233, DOI 10.1365/s10337-005-0617-5                                                       
   Jao J, 2010, ADV CHRONIC KIDNEY D, V17, P72, DOI 10.1053/j.ackd.2009.07.009
   Mele R, 2003, INT J PARASITOL, V33, P757, DOI 10.1016/S0020-7519(03)00093-6
   Miao YM, 2000, J ACQ IMMUN DEF SYND, V25, P124, DOI 10.1097/00126334-200010010-00006
   Mor SM, 2008, CLIN INFECT DIS, V47, P915, DOI 10.1086/591539
   Motta I, 2002, MICROBES INFECT, V4, P821, DOI 10.1016/S1286-4579(02)01602-7
   Nobs L, 2003, INT J PHARM, V250, P327, DOI 10.1016/S0378-5173(02)00542-2
   Nobs L, 2004, EUR J PHARM BIOPHARM, V58, P483, DOI 10.1016/j.ejpb.2004.04.006
   Plutzer J, 2009, VET PARASITOL, V165, P187, DOI 10.1016/j.vetpar.2009.07.003
   Pozio E, 2005, TRENDS PARASITOL, V21, P58, DOI 10.1016/j.pt.2004.11.003
   Rafati H, 1997, J CONTROL RELEASE, V43, P89, DOI 10.1016/S0168-3659(96)01475-7                                                   
   RANUCCI L, 1993, INFECT IMMUN, V61, P2347
   ROSSI P, 1990, J CLIN MICROBIOL, V28, P356
   ROSSIGNOL JF, 2010, EXPT PARASITOLOTOGY, V184, P103
   SAH HK, 1994, J CONTROL RELEASE, V30, P201, DOI 10.1016/0168-3659(94)90026-4                                                    
   Sanvicens N, 2008, TRENDS BIOTECHNOL, V26, P425, DOI 10.1016/j.tibtech.2008.04.005
   Slifko TR, 1999, APPL ENVIRON MICROB, V65, P3936
   Torchilin VP, 2006, ADV DRUG DELIVER REV, V58, P1532, DOI 10.1016/j.addr.2006.09.009
   Tosi G, 2008, EXPERT OPIN DRUG DEL, V5, P155, DOI 10.1517/17425247.5.2.155
   UCHIDA K, 1996, J MICROENCAPSUL, V13, P509
   UPTON SJ, 1995, J CLIN MICROBIOL, V33, P371
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
   Wang AZ, 2008, EXPERT OPIN BIOL TH, V8, P1063, DOI [10.1517/14712590802181330, 10.1517/14712598.8.8.1063 ]
   Xu ZT, 1997, BIOORGAN MED CHEM, V5, P1137, DOI 10.1016/S0968-0896(97)00050-3
   Zardi EM, 2005, CHEMOTHERAPY, V51, P193, DOI 10.1159/000086920
NR 49
TC 5
Z9 6
U1 1
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0031-1820
J9 PARASITOLOGY
JI Parasitology
PD SEP
PY 2011
VL 138
IS 11
BP 1384
EP 1391
DI 10.1017/S0031182011001119
PG 8
WC Parasitology
SC Parasitology
GA 826BD
UT WOS:000295325500007
PM 21819637
DA 2018-01-05
ER

PT J
AU Vieweger, M
   Goicochea, N
   Koh, ES
   Dragnea, B
AF Vieweger, Mario
   Goicochea, Nancy
   Koh, Eun Sohl
   Dragnea, Bogdan
TI Photothermal Imaging and Measurement of Protein Shell Stoichiometry of
   Single HIV-1 Gag Virus-like Nanoparticles
SO ACS NANO
LA English
DT Article
DE photothermal heterodyne imaging (PHI); virus-like nanoparticles (VLPs);
   HIV-1 Gag; protein shell stoichiometry
ID BROME-MOSAIC-VIRUS; IN-VITRO; THERMAL-CONDUCTIVITY; GOLD NANOPARTICLES;
   HEAT-CAPACITY; MELTING PROCESS; VIRAL CAPSIDS; MICROSCOPY; TRACKING;
   ENTRY
AB Virus life stages often constitute a complex chain of events, difficult to track in vivo and in real-time. Challenges are associated with spatial and time limitations of current probes: most viruses are smaller than the diffraction limit of optical microscopes while the entire time scale of virus dynamics spans over 8 orders of magnitude. Thus, virus processes such as entry, disassembly, and egress have generally remained poorly understood. Here we discuss photothermal heterodyne imaging (PHI) as a possible alternative to fluorescence microscopy in the study of single virus-like nanoparticle (VNP) dynamics, with relevance in particular to virus uncoating. Being based on optical absorption rather than emission, PHI could potentially surpass some of the current limitations associated with fluorescent labels. As proof-of-principle, single VNPs self-assembled from 60 nm DNA-functionalized gold nanoparticles (DNA-Au NPs) encapsulated in a Gag protein shell of the human immunodeficiency virus (HIV-1) were imaged, and their photothermal response was compared with DNA-Au NPs. For the first time, the protein stoichiometry of a single virus-like particle was estimated by a method other than electron microscopy.
C1 [Vieweger, Mario; Goicochea, Nancy; Koh, Eun Sohl; Dragnea, Bogdan] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
RP Dragnea, B (reprint author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
EM dragnea@indiana.edu
FU Indiana University; National Institutes of Health [GM081029]; Indiana
   METACyt Initiative of Indiana University; Lilly Endowment, Inc.
FX We are grateful to Siddharta Datta and Alan Rein for supplying the HIV-1
   Gag proteins. M.C.V. is grateful for a College of Arts and Sciences
   Dissertation Year Research Fellowship from Indiana University. We
   acknowledge support from the National Institutes of Health (Grant
   GM081029). This research was also supported by the Indiana METACyt
   Initiative of Indiana University, funded in part through a major grant
   from the Lilly Endowment, Inc.
CR BANCROFT JB, 1967, VIROLOGY, V31, P354, DOI 10.1016/0042-6822(67)90180-8
   Berciaud S, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.045424
   Berciaud S, 2005, NANO LETT, V5, P2160, DOI 10.1021/nl051805d
   Boyer D, 2002, SCIENCE, V297, P1160, DOI 10.1126/science.1073765
   Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615
   Brandenburg B, 2007, PLOS BIOL, V5, P1543, DOI 10.1371/journal.pbio.0050183
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Burckhardt CJ, 2008, NAT CELL BIOL, V10, P9, DOI 10.1038/ncb0108-9
   Campbell S, 1999, J VIROL, V73, P2270
   Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698
   Carey CR, 2010, J PHYS CHEM C, V114, P16029, DOI 10.1021/jp101891a
   Chen C, 2006, NANO LETT, V6, P611, DOI 10.1021/nl0600878
   Cognet L, 2003, P NATL ACAD SCI USA, V100, P11350, DOI 10.1073/pnas.1534635100
   Cognet L, 2008, ANAL CHEM, V80, P2288, DOI 10.1021/ac086020h                                                               
   Daniel MC, 2010, ACS NANO, V4, P3853, DOI 10.1021/nn1005073
   Datta Siddhartha A. K., 2009, V485, P197, DOI 10.1007/978-1-59745-170-3_14
   Dixit SK, 2006, NANO LETT, V6, P1993, DOI 10.1021/nl061165u
   Dorsey N. E., 1940, PROPERTIES ORDINARY
   Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211
   Dragnea B, 2003, J AM CHEM SOC, V125, P6374, DOI 10.1021/ja0343609
   Durchschlag H, 2008, PROG COLL POL SCI S, V134, P19, DOI 10.1007/2882_2008_081
   Fisher K, 2006, CURR OPIN MOL THER, V8, P301
   Gaiduk A, 2010, CHEM SCI, V1, P343, DOI 10.1039/c0sc00210k
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Gao XL, 2008, BIOCHEM BIOPH RES CO, V377, P35, DOI 10.1016/j.bbrc.2008.09.077
   GEDDES CD, 2006, REV FLUORESCENCE 200, V3
   Giblin J, 2010, ACS NANO, V4, P358, DOI 10.1021/nn901172s
   Gladnikoff M, 2008, BIOPHYS J, V94, P320, DOI 10.1529/biophysj.107.114579
   GOICOCHEA NL, 2011, J MOL BIOL IN PRESS
   GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Hamilton G, 2006, NATURE, V441, P683, DOI 10.1038/441683a
   Harms GS, 2001, BIOPHYS J, V80, P2396, DOI 10.1016/S0006-3495(01)76209-1                                                   
   HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404                                                            
   Hema M, 2010, MOL PLANT MICROBE IN, V23, P1433, DOI 10.1094/MPMI-05-10-0118
   Huang XL, 2007, NANO LETT, V7, P2407, DOI 10.1021/nl071083l
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Kang S, 2010, BIOMACROMOLECULES, V11, P2804, DOI 10.1021/bm100877q
   Khayet M, 2005, INT J THERMOPHYS, V26, P637, DOI 10.1007/s10765-005-5568-4
   Kukura P, 2009, NAT METHODS, V6, P923, DOI 10.1038/nmeth.1395
   Leduc C, 2011, ACS NANO, V5, P2587, DOI 10.1021/nn1023285
   Lehmann MJ, 2005, J CELL BIOL, V170, P317, DOI 10.1083/jcb.200503059
   Lervik A, 2010, PHYS CHEM CHEM PHYS, V12, P1610, DOI 10.1039/b918607g
   Lockney DM, 2011, BIOCONJUGATE CHEM, V22, P67, DOI 10.1021/bc100361z
   Loo L, 2007, J AM CHEM SOC, V129, P11111, DOI 10.1021/ja071896b
   Manchester Marianne, 2009, Curr Top Microbiol Immunol, V327, pv
   Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007
   Michalet X, 2007, J MOD OPTIC, V54, P239, DOI 10.1080/09500340600769067
   Montiel D, 2010, LASER PHOTONICS REV, V4, P374, DOI 10.1002/lpor.200910012
   Moyano DF, 2011, LANGMUIR, V27, P10376, DOI 10.1021/la2004535
   Mrevlishvili GM, 1998, THERMOCHIM ACTA, V308, P49, DOI 10.1016/S0040-6031(97)00329-8                                                   
   Nan XL, 2008, CHEMPHYSCHEM, V9, P707, DOI 10.1002/cphc.200700839
   Patterson G, 2010, ANNU REV PHYS CHEM, V61, P345, DOI 10.1146/annurev.physchem.012809.103444
   Pustovalov VK, 2008, LASER PHYS LETT, V5, P775, DOI 10.1002/lapl.200810072
   Qian W, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3477179
   Rana S, 2010, CURR OPIN CHEM BIOL, V14, P828, DOI 10.1016/j.cbpa.2010.10.001
   Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c                                                               
   Rust MJ, 2004, NAT STRUCT MOL BIOL, V11, P567, DOI 10.1038/nsmb769
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819
   Smart AC, 1999, HYDROBIOLOGIA, V395, P379, DOI 10.1023/A:1017055214845                                                         
   Sochava I V, 1982, Mol Biol (Mosk), V16, P386
   SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6
   Sun J, 2007, P NATL ACAD SCI USA, V104, P1354, DOI 10.1073/pnas.0610542104
   Suttle CA, 2005, NATURE, V437, P356, DOI 10.1038/nature04160
   TULISZKA M, 1993, THERMOCHIM ACTA, V219, P355, DOI 10.1016/0040-6031(93)80512-9                                                    
   TULISZKA M, 1992, THERMOCHIM ACTA, V194, P67, DOI 10.1016/0040-6031(92)80005-H                                                    
   van Dijk MA, 2006, PHYS CHEM CHEM PHYS, V8, P3486, DOI 10.1039/b606090k
   Van Dijk MA, 2005, ACCOUNTS CHEM RES, V38, P594, DOI 10.1021/ar0401303
   van Vlijmen HWT, 2005, J MOL BIOL, V350, P528, DOI 10.1016/j.jmb.2005.03.028
   WEN J, 1996, PHYSICAL PROPERTIES, P101
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   YANG PH, 1979, BIOCHEMISTRY-US, V18, P2654, DOI 10.1021/bi00579a035                                                             
   ZULAUF M, 1977, J MOL BIOL, V114, P259, DOI 10.1016/0022-2836(77)90209-1
NR 75
TC 12
Z9 12
U1 0
U2 43
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD SEP
PY 2011
VL 5
IS 9
BP 7324
EP 7333
DI 10.1021/nn202184x
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 824FI
UT WOS:000295187400064
PM 21854038
OA green_accepted
DA 2018-01-05
ER

PT J
AU Aoki, T
   Miyauchi, K
   Urano, E
   Ichikawa, R
   Komano, J
AF Aoki, T.
   Miyauchi, K.
   Urano, E.
   Ichikawa, R.
   Komano, J.
TI Protein transduction by pseudotyped lentivirus-like nanoparticles
SO GENE THERAPY
LA English
DT Article
DE LENA; BlaM; Gag; protein transduction; lentiviral vector
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GAG; HIV-1; VECTORS; FUSION; EXPRESSION;
   DELIVERY; SEQUENCE; DOMAIN
AB A simple, efficient and reproducible method to transduce proteins into mammalian cells has not been established. Here we describe a novel protein transduction method based on a lentiviral vector. We have developed a method to package several thousand foreign protein molecules into a lentivirus-like nanoparticle (LENA) and deliver them into mammalian cells. In this proof-of-concept study, we used beta-lactamase (BlaM) as a reporter molecule. The amino-terminus of BlaM was fused to the myristoylation signal of lyn, which was placed upstream of the amino-terminus of Gag (BlaM-gag-pol). By co-transfection of plasmids encoding BlaM-gag-pol and vesicular stomatitis virus-G (VSV-G) into 293T cells, LENA were produced containing BlaM enzyme molecules as many as Gag per capsid, which has been reported to be similar to 5000 molecules, but lacking the viral genome. Infection of 293T and MT-4 cells by VSV-G-pseudotyped BlaM-containing LENA led to successful transduction of BlaM molecules into the cell cytoplasm, as detected by cleavage of the fluorescent BlaM substrate CCF2-AM. LENA-mediated transient protein transduction does not damage cellular DNA, and the preparation of highly purified protein is not necessary. This technology is potentially useful in various basic and clinical applications. Gene Therapy (2011) 18, 936-941; doi:10.1038/gt.2011.38; published online 31 March 2011
C1 [Aoki, T.; Miyauchi, K.; Urano, E.; Ichikawa, R.; Komano, J.] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan.
RP Komano, J (reprint author), Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.
EM ajkomano@nih.go.jp
FU Japan Health Science Foundation; Japanese Ministry of Health, Labor, and
   Welfare [H18-AIDS-W-003]; Japanese Ministry of Education, Culture,
   Sports, Science and Technology [18689014, 18659136]
FX This work was supported by the Japan Health Science Foundation, the
   Japanese Ministry of Health, Labor, and Welfare (H18-AIDS-W-003 to JK)
   and the Japanese Ministry of Education, Culture, Sports, Science and
   Technology (18689014 and 18659136 to JK).
CR AOKI T, 2010, GENE THER, V55, P1124
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Campbell RE, 2004, TRENDS BIOTECHNOL, V22, P208, DOI 10.1016/j.tibtech.2004.03.012
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Cockrell AS, 2007, MOL BIOTECHNOL, V36, P184, DOI 10.1007/s12033-007-0010-8
   Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383
   Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07
   JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0
   Klein KC, 2007, AIDS REV, V9, P150
   Komano J, 2004, MOL BIOL CELL, V15, P5197, DOI 10.1091/mbc.E04-04-0279
   Lundberg C, 2008, CURR GENE THER, V8, P461, DOI 10.2174/156652308786847996                                                      
   MacGregor R R, 2001, Hum Gene Ther, V12, P2028
   MCCART JA, 2008, GENE CELL THERAPY TH, P245
   Miyauchi K, 2005, J VIROL, V79, P4720, DOI 10.1128/JVI.79.8.4720-4729.2005
   Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Urano E, 2008, J GEN VIROL, V89, P3144, DOI 10.1099/vir.0.2008/004820-0
   Voelkel C, 2010, P NATL ACAD SCI USA, V107, P7805, DOI 10.1073/pnas.0914517107
   Wagner R, 2000, HUM GENE THER, V11, P2403, DOI 10.1089/104303400750038507
   Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004
   Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229
   Zhang Y, 2008, CURR OPIN BIOTECH, V19, P506, DOI 10.1016/j.copbio.2008.07.005
NR 22
TC 10
Z9 10
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD SEP
PY 2011
VL 18
IS 9
BP 936
EP 941
DI 10.1038/gt.2011.38
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 817PC
UT WOS:000294685300011
PM 21451580
OA gold
DA 2018-01-05
ER

PT J
AU Wang, MS
   Black, JC
   Knowles, MK
   Reed, SM
AF Wang, Min S.
   Black, Joshua C.
   Knowles, Michelle K.
   Reed, Scott M.
TI C-reactive protein (CRP) aptamer binds to monomeric but not pentameric
   form of CRP
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE C-reactive protein; Isoform; Aptamer; Cardiovascular disease; TIRF
   microscopy; Fluorescence anisotropy
ID HIV-1 TAT PROTEIN; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION;
   HUMAN-NEUTROPHILS; APOPTOTIC CELLS; COMPLEMENT; LIGANDS;
   PHOSPHATIDYLCHOLINE; BACTERIOPHAGE-T4; REARRANGEMENT
AB Native C-reactive protein (CRP) is composed of five identical subunits arranged in a pentameric structure (pCRP). Binding of pCRP to damaged cell membranes produces a second isoform, modified CRP, which has similar antigenicity to isolated monomeric subunits of CRP (mCRP). Emerging evidence indicates that modified CRP plays a role in inflammation and atherosclerosis, however, there are very few techniques that can distinguish the different isoforms of CRP. Here we show that an RNA aptamer binds specifically to mCRP and not to pCRP. Using this aptamer, we describe a simple, fast, and sensitive assay to detect nanomolar concentrations of mCRP using fluorescence anisotropy. In addition, we show that this aptamer can be used to detect mCRP in polyacrylamide gels and bound to a surface using total internal reflection fluorescence microscopy. The biological activity of the mCRP we prepared by heating pCRP with 0.1% sodium dodecyl sulfate was confirmed by observing binding to the complement protein, C1q. This probe provides an important tool for CRP research and has the potential to improve clinical diagnostics that predict risk for cardiovascular disease.
C1 [Wang, Min S.; Reed, Scott M.] Univ Colorado, Dept Chem, Denver, CO 80217 USA.
   [Black, Joshua C.; Knowles, Michelle K.] Univ Denver, Dept Chem & Biochem, Denver, CO 80208 USA.
RP Reed, SM (reprint author), Univ Colorado, Dept Chem, Denver, CO 80217 USA.
EM scott.reed@ucdenver.edu
RI Wang, Min/C-6495-2009
OI Wang, Min/0000-0002-8978-4918
FU NIH [1R15GM088960-01]; NSF [CBET-1033161, CBET-1033215]
FX Support from NIH 1R15GM088960-01 (SMR), NSF CBET-1033161 (SMR), and NSF
   CBET-1033215 (MKK) is acknowledged. We thank the UCD Biology department
   for use of the Odyssey imager.
CR Agrawal A, 2001, J IMMUNOL, V166, P3998, DOI 10.4049/jimmunol.166.6.3998                                                     
   Bini A, 2008, ANAL BIOANAL CHEM, V390, P1077, DOI 10.1007/s00216-007-1736-7
   Biro A, 2007, IMMUNOLOGY, V121, P40, DOI 10.1111/j.1365-2567.2007.02535.x
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   DAuria S, 1997, BIOCHEM J, V323, P833, DOI 10.1042/bj3230833                                                               
   Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002
   Eisenhardt SU, 2009, CELL CYCLE, V8, P3885, DOI 10.4161/cc.8.23.10068
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353                                                          
   Hu WP, 2006, BIOSENS BIOELECTRON, V21, P1631, DOI 10.1016/j.bios.2005.11.001
   Huang CJ, 2010, BIOSENS BIOELECTRON, V25, P1761, DOI 10.1016/j.bios.2009.12.029
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200
   Kim S. D., 2004, PREL P 10 INT M DNA, P334
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Li W, 2007, ANALYST, V132, P107, DOI 10.1039/b614138b
   Mackiewicz MR, 2010, J PHYS CHEM B, V114, P5556, DOI 10.1021/jp911617q
   McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   POTEMPA LA, 1988, INFLAMMATION, V12, P391, DOI 10.1007/BF00915774                                                              
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   POTEMPA LA, 1987, MOL IMMUNOL, V24, P531, DOI 10.1016/0161-5890(87)90028-9
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Schwedler SB, 2003, NEPHROL DIAL TRANSPL, V18, P2300, DOI 10.1093/ndt/gfg407
   Singh SK, 2009, CLIN CHIM ACTA, V406, P151, DOI 10.1016/j.cca.2009.06.018
   Stoltenburg R, 2005, ANAL BIOANAL CHEM, V383, P83, DOI 10.1007/s00216-005-3388-9
   Taylor KE, 2007, IMMUNOLOGY, V120, P404, DOI 10.1111/j.1365-2567.2006.02516.x
   Thompson D, 1999, STRUCT FOLD DES, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vaith P, 2000, ARTERIOSCL THROM VAS, V20, P1173, DOI 10.1161/01.ATV.20.4.1173                                                        
   van der Zee PM, 2010, CLIN IMMUNOL, V135, P490, DOI 10.1016/j.clim.2010.01.002
   VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820
   Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6
   Wagner M, 2010, INT J MOL SCI, V11, P956, DOI 10.3390/ijms11030956
   Xiao Y, 2005, J AM CHEM SOC, V127, P17990, DOI 10.1021/ja056555h
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   YING SC, 1989, J IMMUNOL, V143, P221
   Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355                                                     
NR 47
TC 18
Z9 21
U1 1
U2 25
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD SEP
PY 2011
VL 401
IS 4
BP 1309
EP 1318
DI 10.1007/s00216-011-5174-1
PG 10
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 804CW
UT WOS:000293632700025
PM 21725632
OA green_accepted
DA 2018-01-05
ER

PT J
AU Jassal, MS
   Aldrovandi, GM
AF Jassal, Mandeep S.
   Aldrovandi, Grace M.
TI 2050: Ending the odyssey of the great white plague Part of a series on
   Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio
   Clementi, and Massimo Molteni
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Tuberculosis; Antituberculous; Chemotherapy; Drug trials; Drug delivery;
   Pediatric
ID BLOOD BACTERICIDAL ACTIVITY; PULMONARY TUBERCULOSIS; CHALLENGES;
   BIOMARKERS; RIFAMPICIN; DRUGS
AB The United Nation's Millennium Development Goal of tuberculosis (TB) elimination by 2050 may be a realizable goal by concerting efforts of the numerous stakeholders involved in the development of novel antituberculous therapeutics. Improving pre-clinical models by the research community is one aspect of the drug development pipeline that will continue to require refinement. Better in vitro and animal models are needed to expand the chemical scaffolds of anti-TB agents. These constructs must be designed and utilized in a manner that is also pertinent to the pediatric population by addressing varying age-based drug metabolism rates. Novel technologies that utilize nanomedicine and genomic research may as well have a significant impact on future therapeutics; however, their development must acknowledge the key populations whose underlying disease pathology continues to drive the pandemic - both adults and children with latent TB, HIV/AIDS and diabetes. Challenging the long-standing orthodoxy of applying equivalent TB treatments for standard first line regimens among the adult and pediatric populations must also continue to be a major focus in future drug development strategies. Studies that include pediatric populations will require a greater variety of medication formulations, biomarkers that do not rely on sputum production and diagnostic technologies that are efficacious in paucibacillary disease. Significant programmatic barriers currently exist in key aspects of the described drug development pipeline, but strategic approaches can overcome these roadblocks - including the complex regulatory requirements involving the inclusion of children in drug trials. All such endeavors will require not only more focused research initiatives, but greater institutional support from the pharmaceutical industry, non-governmental organizations and national health sectors. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Jassal, Mandeep S.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Pediat Pulmonol, Los Angeles, CA 90027 USA.
   [Aldrovandi, Grace M.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Pediat Infect Dis, Los Angeles, CA 90027 USA.
RP Jassal, MS (reprint author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Pediat Pulmonol, Los Angeles, CA 90027 USA.
CR Dooley KE, 2009, LANCET INFECT DIS, V9, P737, DOI 10.1016/S1473-3099(09)70282-8
   du Toit LC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-118
   *GLOB ALL TB DRUG, CRIT PATH TB REG IN
   Koul A, 2011, NATURE, V469, P483, DOI 10.1038/nature09657
   L'homme RFA, 2009, AIDS, V23, P863, DOI 10.1097/QAD.0b013e328329148e
   Leibert E, 2010, EXPERT REV ANTI-INFE, V8, P801, DOI [10.1586/eri.10.60, 10.1586/ERI.10.60]
   Lenaerts AJ, 2008, TRENDS MICROBIOL, V16, P48, DOI 10.1016/j.tim.2007.12.002
   Ma ZK, 2010, LANCET, V375, P2100, DOI 10.1016/S0140-6736(10)60359-9
   Niemi M, 2003, CLIN PHARMACOKINET, V42, P819, DOI 10.2165/00003088-200342090-00003                                                
   O'Toole R, 2010, ADV APPL MICROBIOL, V71, P75, DOI 10.1016/S0065-2164(10)71003-0
   Phillips M, 2007, TUBERCULOSIS, V87, P44, DOI 10.1016/j.tube.2006.03.004
   Swaminathan S, 2010, CLIN INFECT DIS, V50, pS184, DOI 10.1086/651490
   Wallis RS, 2010, J INFECT DIS, V202, P745, DOI 10.1086/655471
   Wallis RS, 2010, LANCET, V375, P1920, DOI 10.1016/S0140-6736(10)60359-5
   Wallis RS, 2003, J INFECT DIS, V187, P270, DOI 10.1086/346053
NR 15
TC 3
Z9 3
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2011
VL 64
IS 3
BP 176
EP 179
DI 10.1016/j.phrs.2011.03.019
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 797JK
UT WOS:000293120100002
PM 21540112
DA 2018-01-05
ER

PT J
AU Prabhakar, K
   Afzal, SM
   Kumar, PU
   Rajanna, A
   Kishan, V
AF Prabhakar, Kandadi
   Afzal, Syed Muzammil
   Kumar, Putcha Uday
   Rajanna, Ajumeera
   Kishan, Veerabrahma
TI Brain delivery of transferrin coupled indinavir submicron lipid
   emulsions-Pharmacokinetics and tissue distribution
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Targeted brain delivery; Indinavir lipid nanoemulsions; Holo
   transferrin; Pharmacokinetics; Tissue distribution
ID HIV-1 PROTEASE INHIBITORS; P-GLYCOPROTEIN; DRUG-DELIVERY; BARRIER;
   RECEPTOR; TRANSPORT; METABOLISM; BINDING; SYSTEMS; CELLS
AB Indinavir, an antiretroviral protease inhibitor used in treatment of HIV infection has limited penetration into brain due to efflux of P-glycoprotein. The aim of this work was to develop transferrin coupled submicron lipid emulsions (SLEs) containing indinavir for delivery to brain. Stearylamine containing SLEs were prepared, characterized, tested for stability and optimized formulation (SLE-4) was developed. Transferrin was coupled to get SLE-6 by water soluble EDC method and purified by gel filtration. The coupled transferrin was quantified by modified Bradford dye assay method. The fluorescent dye (DiD oil) incorporated SLEs were used to check the brain specific delivery of SLEs. The in vivo pharmacokinetic and tissue distribution were conducted in mice. During pharmacokinetic studies, there was no significant difference in the serum levels of indinavir from SLE-1, SLE-4 and SLE-6 formulations at all time points. In tissue distribution studies the therapeutic availability (TA) of indinavir in brain from SLE-6 was 4.69, 3.1 and 1.7 times higher than drug solution, SLE-1 and SLE-4 respectively whereas, the TA of indinavir from SLE-4 was 2.76 and 1.82 times the drug solution and SLE-1. The brain to serum ratios with SLE-6 were above one indicates the brain specific delivery. The brain delivery of indinavir was improved with transferrin ligand attachment to SLEs by receptor mediated transcytosis. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Prabhakar, Kandadi; Afzal, Syed Muzammil; Kishan, Veerabrahma] Kakatiya Univ, Univ Coll Pharmaceut Sci, Dept Pharmaceut, Nanotechnol Lab, Warangal 506009, Andhra Pradesh, India.
   [Kumar, Putcha Uday; Rajanna, Ajumeera] Natl Inst Nutr, Hyderabad 500007, Andhra Pradesh, India.
RP Kishan, V (reprint author), Kakatiya Univ, Univ Coll Pharmaceut Sci, Dept Pharmaceut, Nanotechnol Lab, Warangal 506009, Andhra Pradesh, India.
EM vbkishan@yahoo.com
FU AICTE [8023/BOR/RID/RPS-155/2008-2009]
FX The authors are thankful to Mr. Srinivas, pathology division, NIN,
   Hyderabad for his help in Cryomicrotome and fluorescent microscopic
   studies. The authors would like to thank AICTE for financial support by
   RPS project F. No. 8023/BOR/RID/RPS-155/2008-2009.
CR ALLEN N, 2002, BIOSCIENCE REP, V22, P225
   Antinori A, 2003, SCAND J INFECT DIS, V35, P41, DOI 10.1080/03008870310009650
   Bachmeier CJ, 2005, PHARM RES, V22, P1259, DOI 10.1007/s11095-005-5271-y
   Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8
   Choo EF, 2000, DRUG METAB DISPOS, V28, P655
   Georgiou CD, 2008, ANAL BIOANAL CHEM, V391, P391, DOI 10.1007/s00216-008-1996-x
   GROVES MJ, 1993, J PHARM PHARMACOL, V45, P592, DOI 10.1111/j.2042-7158.1993.tb05658.x                                              
   Hamidi M, 2006, LIFE SCI, V79, P991, DOI 10.1016/j.lfs.2006.05.010
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Jolliet-Riant P, 1999, FUND CLIN PHARMACOL, V13, P16, DOI 10.1111/j.1472-8206.1999.tb00316.x                                              
   Kandanearatchi A, 2003, BRAIN PATHOL, V13, P104
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
   Lundberg BB, 1999, J PHARM PHARMACOL, V51, P1099, DOI 10.1211/0022357991776787
   Lundberg BB, 2004, J CONTROL RELEASE, V94, P155, DOI 10.1016/j.jconrel.2003.09.016
   Lundberg BB, 2003, J CONTROL RELEASE, V86, P93, DOI 10.1016/S0168-3659(02)00323-1
   Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674                                                         
   PARDRIDGE WM, 1994, TRENDS BIOTECHNOL, V12, P239, DOI 10.1016/0167-7799(94)90123-6
   Pialoux G, 1997, AIDS, V11, P1302, DOI 10.1097/00002030-199710001-00009                                                
   Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9                                                   
   Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7
   Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4
   Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086
   VARSHIKA E, 2009, J PHARM SCI TECHNOL, V63, P1368
   Vyas TK, 2008, INT J PHARM, V347, P93, DOI 10.1016/j.ijpharm.2007.06.016
   YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505                                                               
   ZHONG MQ, 2002, PHARMACOL REV, V54, P561
NR 28
TC 17
Z9 17
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD SEP 1
PY 2011
VL 86
IS 2
BP 305
EP 313
DI 10.1016/j.colsurfb.2011.04.013
PG 9
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 785KB
UT WOS:000292226800008
PM 21565469
DA 2018-01-05
ER

PT J
AU Liard, C
   Munier, S
   Arias, M
   Joulin-Giet, A
   Bonduelle, O
   Duffy, D
   Shattock, RJ
   Verrier, B
   Combadiere, B
AF Liard, Christelle
   Munier, Severine
   Arias, Mauricio
   Joulin-Giet, Alix
   Bonduelle, Olivia
   Duffy, Darragh
   Shattock, Robin J.
   Verrier, Bernard
   Combadiere, Behazine
TI Targeting of HIV-p24 particle-based vaccine into differential skin
   layers induces distinct arms of the immune responses
SO VACCINE
LA English
DT Article
DE Skin; Nanoparticles; Cellular responses; Mucosal responses; Vaccination
ID DERMAL DENDRITIC CELLS; LANGERHANS CELLS; PLA NANOPARTICLES;
   TRANSCUTANEOUS IMMUNIZATION; INTRADERMAL VACCINATION;
   ANTIBODY-RESPONSES; INFLUENZA VACCINE; MUCOSAL IMMUNITY; IN-VIVO;
   CHILDREN
AB Skin routes of immunization such as subcutaneous (SC), intradermal (ID) and transcutaneous (TC) administration are utilized for vaccination against various pathogens, without understanding their potential impact on the outcome of immune responses. We demonstrated that SC immunization induced HIV-1 p24 specific IgG in absence of antigen-specific CD8 T cells, whereas the ID route induced both cellular and humoral responses. Interestingly, TC application through empty hair follicular ducts, targeting epidermal Langerhans Cells (LCs), induced major CD8 effector cells, in the absence of IgG. However, high levels of mucosal IgA, were localized in the stratified epithelium of the vagina after TC prime. We propose that re-directing the immune responses by targeting differential skin immunization routes, offers enormous potential for innovative vaccination strategies, especially against HIV. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Liard, Christelle; Joulin-Giet, Alix; Bonduelle, Olivia; Duffy, Darragh; Combadiere, Behazine] INSERM, Lab Immun & Infect, UMR S 945, F-75013 Paris 13, France.
   [Liard, Christelle; Joulin-Giet, Alix; Bonduelle, Olivia; Duffy, Darragh; Combadiere, Behazine] Univ Paris 06, Lab Immun & Infect, F-75013 Paris 13, France.
   [Munier, Severine; Verrier, Bernard] UMR 5086 CNRS UCBL, Inst Biol & Chim Prot, F-69367 Lyon 07, France.
   [Arias, Mauricio; Shattock, Robin J.] St Georges Univ London, Ctr Infect, Div Cellular & Mol Med, London, England.
RP Combadiere, B (reprint author), INSERM, Lab Immun & Infect, UMR S 945, 91 Blvd Hop,83-91 Blvd Hop, F-75013 Paris 13, France.
EM behazine.combadiere@upmc.fr
RI Combadiere, Behazine/G-3881-2013
FU EU; Fondation pour la Recherche Medicale (FRM); Agence National de la
   Recherche contre le SIDA (ANRS)
FX This work was supported by EU-FP6 health program, MuNanoVac "Mucosal HIV
   vaccines" and EU-FP7 health program, CUT'HIVAC "Cutaneous HIV
   vaccination". C. Liard was supported by a grant from Fondation pour la
   Recherche Medicale (FRM). B. Combadiere is a recipient of
   INSERM-Interface AP/HP program. Darragh Duffy was a recipient of Agence
   National de la Recherche contre le SIDA (ANRS) grant.
CR Abadie V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008159
   Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Belshe RB, 2004, NEW ENGL J MED, V351, P2286, DOI 10.1056/NEJMoa043555
   Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368
   Belyakov IM, 2008, VIROLOGY, V381, P106, DOI 10.1016/j.virol.2008.08.019
   Belyakov IM, 2006, BLOOD, V107, P3258, DOI 10.1182/blood-2005-11-4374
   Belyakov IM, 2004, IMMUNITY, V20, P247, DOI 10.1016/S1074-7613(04)00053-6                                                   
   Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x
   Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481
   Combadiere B, 2008, COMP IMMUNOL MICROB, V31, P293, DOI 10.1016/j.cimid.2007.07.015
   Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818
   Cranage MP, 2010, MUCOSAL IMMUNOL, V3, P57, DOI 10.1038/mi.2009.110
   Cranage Martin P, 2009, Expert Rev Anti Infect Ther, V7, P21, DOI 10.1586/14787210.7.1.21
   Egemen A, 1998, VACCINE, V16, P1511, DOI 10.1016/S0264-410X(98)80006-6
   ERARD F, 1994, RES IMMUNOL, V145, P643, DOI 10.1016/S0923-2494(05)80047-1                                                   
   Estcourt MJ, 2005, EUR J IMMUNOL, V35, P2532, DOI 10.1002/eji.200535184
   Eyles JE, 2004, VACCINE, V22, P4365, DOI 10.1016/j.vaccine.2004.02.049
   Fay JW, 2006, CANCER IMMUNOL IMMUN, V55, P1209, DOI 10.1007/s00262-005-0106-6
   FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303
   Poulin LF, 2010, J EXP MED, V207, P1261, DOI 10.1084/jem.20092618
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014                                                                   
   Glenn GM, 2007, INFECT IMMUN, V75, P2163, DOI 10.1128/IAI.01740-06
   Guillon C, 2007, VACCINE, V25, P7491, DOI 10.1016/j.vaccine.2007.08.060
   Guy B, 1998, CLIN DIAGN LAB IMMUN, V5, P732
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Haynes BF, 2008, J ALLERGY CLIN IMMUN, V122, P3, DOI 10.1016/j.jaci.2008.03.036
   Hilleman MR, 2000, J HUMAN VIROL, V3, P63
   Jespers V, 2010, EXPERT REV VACCINES, V9, P381, DOI 10.1586/ERV.10.21
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kaufman DR, 2008, J IMMUNOL, V181, P4188, DOI 10.4049/jimmunol.181.6.4188                                                     
   Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004
   Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013
   Knorr F, 2009, EUR J PHARM BIOPHARM, V71, P173, DOI 10.1016/j.ejpb.2008.11.001
   Kunzi V, 2009, VACCINE, V27, P1261, DOI 10.1016/j.vaccine.2008.12.008
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   Laurent PE, 2007, VACCINE, V25, P8833, DOI 10.1016/j.vaceine.2007.10.020
   Levine MM, 2004, NAT IMMUNOL, V5, P460, DOI 10.1038/ni0504-465
   Mahe B, 2009, J INVEST DERMATOL, V129, P1156, DOI 10.1038/jid.2008.356
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455
   Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728
   Montefiori DC, 2007, CURR OPIN HIV AIDS, V2, P169, DOI 10.1097/COH.0b013e3280ef691e
   Mottram PL, 2007, MOL PHARMACEUT, V4, P73, DOI 10.1021/mp060096p
   Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511
   Nandedkar TD, 2009, J BIOSCIENCES, V34, P995, DOI 10.1007/s12038-009-0114-3
   Nasir A, 2009, J INVEST DERMATOL, V129, P1055, DOI 10.1038/jid.2009.63
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Ochoa MT, 2008, J INVEST DERMATOL, V128, P2225, DOI 10.1038/jid.2008.56
   Paus E, 1999, TUMOR BIOL, V20, P52, DOI 10.1159/000056531                                                               
   Paus R, 1999, J INVEST DERM SYMP P, V4, P226, DOI 10.1038/sj.jidsp.5640217                                                        
   Primard C, 2010, BIOMATERIALS, V31, P6060, DOI 10.1016/j.biomaterials.2010.04.021
   Pulendran B, 2006, CELL, V124, P849, DOI 10.1016/j.cell.2006.02.019
   Rappuoli R, 2007, NAT BIOTECHNOL, V25, P1361, DOI 10.1038/nbt1207-1361
   Ratzinger G, 2004, J IMMUNOL, V173, P2780, DOI 10.4049/jimmunol.173.4.2780                                                     
   Romani N, 2010, IMMUNOL CELL BIOL, V88, P424, DOI 10.1038/icb.2010.39
   Sabchareon A, 1998, PEDIATR INFECT DIS J, V17, P1001, DOI 10.1097/00006454-199811000-00007
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729
   Skountzou I, 2006, VACCINE, V24, P6110, DOI 10.1016/j.vaccine.2006.05.014
   Stoitzner P, 2008, J IMMUNOL, V180, P1991, DOI 10.4049/jimmunol.180.3.1991                                                     
   Sumida SM, 2004, J CLIN INVEST, V114, P1334, DOI 10.1172/JCI200422608
   Ueno H, 2010, IMMUNOL CELL BIOL, V88, P376, DOI 10.1038/icb.2010.28
   Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077
   Vien NC, 2008, T ROY SOC TROP MED H, V102, P294, DOI 10.1016/j.trstmh.2007.11.010
   Villadangos JA, 2010, J EXP MED, V207, P1131, DOI 10.1084/jem.20100985
   Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898
   Vogt A, 2008, J IMMUNOL, V180, P1482, DOI 10.4049/jimmunol.180.3.1482                                                     
   Vogt A, 2006, J INVEST DERMATOL, V126, P1316, DOI 10.1038/sj.jid.5700226
   Wosicka H, 2010, J DERMATOL SCI, V57, P83, DOI 10.1016/j.jdermsci.2009.12.005
   Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225
NR 73
TC 35
Z9 35
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 26
PY 2011
VL 29
IS 37
BP 6379
EP 6391
DI 10.1016/j.vaccine.2011.04.080
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 825AR
UT WOS:000295243800031
PM 21554912
DA 2018-01-05
ER

PT J
AU Fujita, Y
   Taguchi, H
AF Fujita, Yoshio
   Taguchi, Hiroaki
TI Current status of multiple antigen-presenting peptide vaccine systems:
   Application of organic and inorganic nanoparticles
SO CHEMISTRY CENTRAL JOURNAL
LA English
DT Review
ID A STREPTOCOCCAL VACCINE; CELL-PENETRATING PEPTIDES; HEPATITIS-C VIRUS;
   FUNCTIONALIZED GOLD NANOPARTICLES; NATIVE CHEMICAL LIGATION; TOLL-LIKE
   RECEPTOR-2; HIV-1 GP41 PEPTIDES; DENDRITIC CELLS; SYNTHETIC PEPTIDES;
   T-HELPER
AB Many studies are currently investigating the development of safe and effective vaccines to prevent various infectious diseases. Multiple antigen-presenting peptide vaccine systems have been developed to avoid the adverse effects associated with conventional vaccines (i.e., live-attenuated, killed or inactivated pathogens), carrier proteins and cytotoxic adjuvants. Recently, two main approaches have been used to develop multiple antigen-presenting peptide vaccine systems: (1) the addition of functional components, e.g., T-cell epitopes, cell-penetrating peptides, and lipophilic moieties; and (2) synthetic approaches using size-defined nanomaterials, e.g., self-assembling peptides, non-peptidic dendrimers, and gold nanoparticles, as antigen-displaying platforms. This review summarizes the recent experimental studies directed to the development of multiple antigen-presenting peptide vaccine systems.
C1 [Fujita, Yoshio; Taguchi, Hiroaki] Suzuka Univ Med Sci, Fac Pharmaceut Sci, Suzuka, Mie 5138670, Japan.
RP Fujita, Y (reprint author), Suzuka Univ Med Sci, Fac Pharmaceut Sci, 3500-3 Minami Tamagaki, Suzuka, Mie 5138670, Japan.
EM yfujita@suzuka-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology in Japan
   [23790144]
FX This work was supported by Grants-in-Aid for Young Scientists (B) from
   the Ministry of Education, Culture, Sports, Science and Technology in
   Japan to YF (23790144).
CR Abdel-Aal ABM, 2008, J MED CHEM, V51, P167, DOI 10.1021/jm701091d
   Abdel-Aal ABM, 2010, J MED CHEM, V53, P8041, DOI 10.1021/jm1007787
   Arvizo R, 2010, EXPERT OPIN DRUG DEL, V7, P753, DOI 10.1517/17425241003777010
   Avery O T, 1931, J Exp Med, V54, P437, DOI 10.1084/jem.54.3.437
   BenMohamed L, 1997, EUR J IMMUNOL, V27, P1242, DOI 10.1002/eji.1830270528
   BHATTACHARJEE RN, 2005, CURR IMMUNOL REV, V1, P81, DOI DOI 10.2174/1573395052952897
   Boykins RA, 2000, PEPTIDES, V21, P9, DOI 10.1016/S0196-9781(99)00172-2
   Brandt ER, 2000, NAT MED, V6, P455
   Brooks NA, 2010, BBA-BIOMEMBRANES, V1798, P2286, DOI 10.1016/j.bbamem.2010.05.007
   Brooks NA, 2010, BBA-REV CANCER, V1805, P25, DOI 10.1016/j.bbcan.2009.09.004
   Brown SD, 2010, J AM CHEM SOC, V132, P4678, DOI 10.1021/ja908117a
   Burkhard P, 2000, PROTEIN SCI, V9, P2294, DOI 10.1110/ps.9.12.2294                                                            
   Cairo CW, 2002, J AM CHEM SOC, V124, P1615, DOI 10.1021/ja016727k
   Carballido E, 2011, CURR ONCOL REP, V13, P112, DOI 10.1007/s11912-011-0152-5
   Chen YS, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/19/195101
   Chen YS, 2009, NANOSCALE RES LETT, V4, P858, DOI 10.1007/s11671-009-9334-6
   Chua BY, 2003, IMMUNOL CELL BIOL, V81, P67, DOI 10.1046/j.1440-1711.2003.01133.x
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Cruz LJ, 2011, MOL PHARMACEUT, V8, P104, DOI 10.1021/mp100178k
   Dale JB, 2008, ADV EXP MED BIOL, V609, P53, DOI 10.1007/978-0-387-73960-1_5
   DEFOORT JP, 1992, INT J PEPT PROT RES, V40, P214
   DEFOORT JP, 1992, P NATL ACAD SCI USA, V89, P3879, DOI 10.1073/pnas.89.9.3879                                                          
   DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0
   DIJOHN D, 1989, LANCET, V2, P1415
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eck W, 2008, ACS NANO, V2, P2263, DOI 10.1021/nn800429d
   Edenhofer F, 2008, CURR PHARM DESIGN, V14, P3628, DOI 10.2174/138161208786898833                                                      
   ETLINGER HM, 1991, VACCINE, V9, P512, DOI 10.1016/0264-410X(91)90038-8
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Fujita Y, 2008, BIOPOLYMERS, V90, P624, DOI 10.1002/bip.21002
   Fujita Y, 2008, BIOORGAN MED CHEM, V16, P8907, DOI 10.1016/j.bmc.2008.08.064
   Garcia LS, 2010, CLIN LAB MED, V30, P93, DOI 10.1016/j.cll.2009.10.001
   Genton B, 2008, EXPERT REV VACCINES, V7, P597, DOI 10.1586/14760584.7.5.597
   Ghosh S, 1999, INT IMMUNOL, V11, P1103, DOI 10.1093/intimm/11.7.1103                                                        
   Gibson JD, 2007, J AM CHEM SOC, V129, P11653, DOI 10.1021/ja075181k
   Hartgerink JD, 1996, J AM CHEM SOC, V118, P43, DOI 10.1021/ja953070s                                                               
   Heegaard PM, 2010, ARCH VIROL, V156, P183
   HERZENBERG LA, 1980, NATURE, V285, P664, DOI 10.1038/285664a0
   HOPP TP, 1984, MOL IMMUNOL, V21, P13, DOI 10.1016/0161-5890(84)90084-1
   Horvath A, 2004, J MED CHEM, V47, P4100, DOI 10.1021/jm040041w
   Horvath A, 2002, J MED CHEM, V45, P1387, DOI 10.1021/jm0110441
   HUANG WL, 1994, MOL IMMUNOL, V31, P1191, DOI 10.1016/0161-5890(94)90033-7                                                    
   Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101
   Jackson DC, 1997, VACCINE, V15, P1697, DOI 10.1016/S0264-410X(97)00085-6
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Jung JP, 2008, BIOMATERIALS, V29, P2143, DOI 10.1016/j.biomaterials.2008.01.008
   Jung JP, 2009, BIOMATERIALS, V30, P2400, DOI 10.1016/j.biomaterials.2009.01.033
   Kaba SA, 2009, J IMMUNOL, V183, P7268, DOI 10.4049/jimmunol.0901957
   Kale AA, 2007, J LIPOSOME RES, V17, P197, DOI 10.1080/08982100701525035
   Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kim JH, 2010, CURR OPIN HIV AIDS, V5, P428, DOI 10.1097/COH.0b013e32833d17ac
   KUMAR A, 1992, J IMMUNOL, V148, P1499
   Landsteiner K., 1962, SPECIFICITY SEROLOGI
   Langhans B, 2001, IMMUNOLOGY, V102, P460, DOI 10.1046/j.1365-2567.2001.01209.x
   Lau YF, 2006, INT IMMUNOL, V18, P1801, DOI 10.1093/intimm/dxl114
   Livingston BD, 1997, J IMMUNOL, V159, P1383
   Loing E, 2000, J IMMUNOL, V164, P900, DOI 10.4049/jimmunol.164.2.900                                                      
   Loo C, 2004, TECHNOL CANCER RES T, V3, P33, DOI 10.1177/153303460400300104                                                      
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761                                                    
   Male KB, 2008, ANAL CHEM, V80, P5487, DOI 10.1021/ac8004555
   Malugin A., 2010, J APPL TOXICOL, V30, P212
   Martin MN, 2010, LANGMUIR, V26, P7410, DOI 10.1021/la100591h
   Mathieu MN, 2000, J PEPT SCI, V6, P235, DOI 10.1002/(SICI)1099-1387(200005)6:5<235::AID-PSC247>3.0.CO;2-J
   McKenzie F, 2008, CHEM COMMUN, P2367, DOI 10.1039/b802163e
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moyle PM, 2007, TETRAHEDRON LETT, V48, P4965, DOI 10.1016/j.tetlet.2007.05.129
   Moyle PM, 2006, J MED CHEM, V49, P6364, DOI 10.1021/jm060475m
   Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951
   NARDELLI B, 1994, VACCINE, V12, P1335, DOI 10.1016/S0264-410X(94)80062-5
   Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871
   Ni JH, 2004, BIOORGAN MED CHEM, V12, P3141, DOI 10.1016/j.bmc.2004.04.008
   OBrienSimpson NM, 1997, J AM CHEM SOC, V119, P1183, DOI 10.1021/ja962707k                                                               
   Oka Y, 2009, ANTI-CANCER AGENT ME, V9, P787, DOI 10.2174/187152009789056958                                                      
   Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895
   Perrault SD, 2009, J AM CHEM SOC, V131, P17042, DOI 10.1021/ja907069u
   Pialoux G, 2001, AIDS, V15, P1239, DOI 10.1097/00002030-200107060-00005
   Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x
   Pissuwan D, 2006, TRENDS BIOTECHNOL, V24, P62, DOI 10.1016/j.tibtech.2005.12.004
   Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377
   Rajagopal K, 2004, CURR OPIN STRUC BIOL, V14, P480, DOI 10.1016/j.sbi.2004.06.006
   Reches M, 2006, CURR NANOSCI, V2, P105, DOI 10.2174/157341306776875802                                                      
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   ROUAIX F, 1994, VACCINE, V12, P1209, DOI 10.1016/0264-410X(94)90245-3
   Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107
   Sadler K, 2002, J PEPT RES, V60, P150, DOI 10.1034/j.1399-3011.2002.21009.x
   Salmon-Ceron D, 2010, AIDS, V24, P2211, DOI 10.1097/QAD.0b013e32833ce566
   SCHUTZE MP, 1985, J IMMUNOL, V135, P2319
   Pappalardo JS, 2009, J CONTROL RELEASE, V134, P41, DOI 10.1016/j.jconrel.2008.11.006
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Skwarczynski M, 2010, ANGEW CHEM INT EDIT, V49, P5742, DOI 10.1002/anie.201002221
   Sperling RA, 2008, CHEM SOC REV, V37, P1896, DOI 10.1039/b712170a
   Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe
   Stokes RJ, 2009, ANALYST, V134, P170, DOI 10.1039/b815117b
   Stoll-Keller F, 2009, EXPERT REV VACCINES, V8, P333, DOI 10.1586/14760584.8.3.333
   Sundaram R, 2002, BIOPOLYMERS, V66, P200, DOI 10.1002/bip.10258
   Tacken PJ, 2008, J IMMUNOL, V180, P7687, DOI 10.4049/jimmunol.180.11.7687                                                    
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   TOMII A, 1991, JPN J MED SCI BIOL, V44, P75, DOI 10.7883/yoken1952.44.75                                                         
   Turkevich J., 1985, GOLD BULL, V18, P86, DOI DOI 10.1007/BF03214690
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Vaccari M, 2010, EXPERT REV VACCINES, V9, P997, DOI [10.1586/erv.10.104, 10.1586/ERV.10.104]
   Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202
   Voronin Y, 2010, CURR OPIN HIV AIDS, V5, P414, DOI 10.1097/COH.0b013e32833cfe32
   Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871
   Wang LX, 2003, BIOORGAN MED CHEM, V11, P159, DOI 10.1016/S0968-0896(02)00339-5
   Yu CI, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/548280
   Zaman M, 2010, VACCINE, V28, P2243, DOI 10.1016/j.vaccine.2009.12.046
   Zeng WG, 1996, J PEPT SCI, V2, P66
   Zeng WG, 2000, VACCINE, V18, P1031, DOI 10.1016/S0264-410X(99)00346-1                                                   
   Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905                                                     
   Zeng WG, 2001, VACCINE, V19, P3843, DOI 10.1016/S0264-410X(01)00152-9
   Zhang LS, 1996, ANAL BIOCHEM, V233, P87, DOI 10.1006/abio.1996.0011
   Zhou XF, 2008, BIOMATERIALS, V29, P111, DOI 10.1016/j.biomaterials.2007.09.007
   Zhu XM, 2004, EUR J IMMUNOL, V34, P3102, DOI 10.1002/eji.200425166
NR 118
TC 21
Z9 21
U1 2
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-153X
J9 CHEM CENT J
JI Chem. Cent. J.
PD AUG 23
PY 2011
VL 5
AR 48
DI 10.1186/1752-153X-5-48
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA 827XR
UT WOS:000295464100001
PM 21861904
OA gold
DA 2018-01-05
ER

PT J
AU Gandapu, U
   Chaitanya, RK
   Kishore, G
   Reddy, RC
   Kondapi, AK
AF Gandapu, Upendhar
   Chaitanya, R. K.
   Kishore, Golla
   Reddy, Raju C.
   Kondapi, Anand K.
TI Curcumin-Loaded Apotransferrin Nanoparticles Provide Efficient Cellular
   Uptake and Effectively Inhibit HIV-1 Replication In Vitro
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TARGETED DRUG-DELIVERY; LONG TERMINAL
   REPEAT; ENCAPSULATED CURCUMIN; RECEIVING ZIDOVUDINE; DIFERULOYL METHANE;
   GENE-EXPRESSION; RATS; INTEGRASE; CELLS
AB Background: Curcumin (diferuloylmethane) shows significant activity across a wide spectrum of conditions, but its usefulness is rather limited because of its low bioavailability. Use of nanoparticle formulations to enhance curcumin bioavailability is an emerging area of research.
   Methodology/Principal Findings: In the present study, curcumin-loaded apotransferrin nanoparticles (nano-curcumin) prepared by sol-oil chemistry and were characterized by electron and atomic force microscopy. Confocal studies and fluorimetric analysis revealed that these particles enter T cells through transferrin-mediated endocytosis. Nano-curcumin releases significant quantities of drug gradually over a fairly long period, similar to 50% of curcumin still remaining at 6 h of time. In contrast, intracellular soluble curcumin (sol-curcumin) reaches a maximum at 2 h followed by its complete elimination by 4 h. While sol-curcumin (GI(50) = 15.6 mu M) is twice more toxic than nano-curcumin (GI(50) = 32.5 mu M), nano-curcumin (IC(50) < 1.75 mu M) shows a higher anti-HIV activity compared to sol-curcumin (IC(50) = 5.1 mu M). Studies in vitro showed that nano-curcumin prominently inhibited the HIV-1 induced expression of Topo II alpha, IL-1 beta and COX-2, an effect not seen with sol-curcumin. Nano-curcumin did not affect the expression of Topoisomerase II beta and TNF alpha. This point out that nano-curcumin affects the HIV-1 induced inflammatory responses through pathways downstream or independent of TNF alpha. Furthermore, nano-curcumin completely blocks the synthesis of viral cDNA in the gag region suggesting that the nano-curcumin mediated inhibition of HIV-1 replication is targeted to viral cDNA synthesis.
   Conclusion: Curcumin-loaded apotransferrin nanoparticles are highly efficacious inhibitors of HIV-1 replication in vitro and promise a high potential for clinical usefulness.
C1 [Gandapu, Upendhar; Chaitanya, R. K.; Kondapi, Anand K.] Univ Hyderabad, Dept Biotechnol, Hyderabad 500134, Andhra Pradesh, India.
   [Kishore, Golla; Kondapi, Anand K.] Univ Hyderabad, Dept Biochem, Sch Life Sci, Hyderabad 500134, Andhra Pradesh, India.
   [Kishore, Golla; Kondapi, Anand K.] Univ Hyderabad, Ctr Nanotechnol, Hyderabad 500134, Andhra Pradesh, India.
   [Reddy, Raju C.] Emory Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA.
RP Gandapu, U (reprint author), Univ Hyderabad, Dept Biotechnol, Hyderabad 500134, Andhra Pradesh, India.
EM akksl@uohyd.ernet.in
FU National Institutes of Health [AI079539]; Indian Council of Medical
   Research [Indo-US/67/2007-ECD-II]
FX This work was supported by National Institutes of Health grant AI079539
   and Indian Council of Medical Research grant Indo-US/67/2007-ECD-II. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anand P, 2007, MOL PHARM, V4, P807, DOI 10.1021/mp700113r
   Babu PS, 1997, MOL CELL BIOCHEM, V166, P169, DOI 10.1023/A:1006819605211
   Barthelemy S, 1998, RES VIROLOGY, V149, P43, DOI 10.1016/S0923-2516(97)86899-9                                                   
   Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Bouille P, 1999, J MOL BIOL, V285, P945, DOI 10.1006/jmbi.1998.2360                                                          
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   DEODHAR SD, 1980, INDIAN J MED RES, V71, P632
   Deveaud C, 2005, BIOCHEM PHARMACOL, V70, P90, DOI 10.1016/j.bcp.2005.04.015
   Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623
   KISO Y, 1983, PLANTA MED, V49, P185, DOI 10.1055/s-2007-969845
   Kondapi AK, 2006, ARCH BIOCHEM BIOPHYS, V450, P123, DOI 10.1016/j.abb.2006.04.003
   Krishna ADS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007240
   KUMAR DR, 2010, NANOMED-NANOTECHNOL, V6, P153
   KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4
   LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839
   Li L, 2005, CANCER, V104, P1322, DOI 10.1002/cncr.21300
   Mahady GB, 2002, ANTICANCER RES, V22, P4179
   Mandraju RK, 2007, ARCH BIOCHEM BIOPHYS, V461, P40, DOI 10.1016/j.abb.2007.01.026
   Martin-Cordero C, 2003, J ENZYM INHIB MED CH, V18, P505, DOI 10.1080/14756360310001613085
   MAZUMDER A, 1995, BIOCHEM PHARMACOL, V49, P1165, DOI 10.1016/0006-2952(95)98514-A
   MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607
   Moh R, 2005, ANTIVIR THER, V10, P615
   Nirmala C, 1996, MOL CELL BIOCHEM, V159, P85, DOI 10.1007/BF00420910
   OLANO JP, 1995, CLIN INFECT DIS, V21, P973, DOI 10.1093/clinids/21.4.973                                                        
   Padhye S, 2010, MINI-REV MED CHEM, V10, P372, DOI 10.2174/138955710791330891                                                      
   PRUSS D, 1994, J BIOL CHEM, V269, P25031
   PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913
   Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561                                                             
   Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4                                                    
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   SINNWELL TM, 1995, J CLIN INVEST, V96, P126, DOI 10.1172/JCI118012                                                               
   SMITH SD, 1984, CANCER RES, V44, P5657
   SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x                                              
   SRIVASTAVA R, 1985, THROMB RES, V40, P413, DOI 10.1016/0049-3848(85)90276-2
   Sui Z, 1993, Bioorg Med Chem, V1, P415, DOI 10.1016/S0968-0896(00)82152-5
   Sun AM, 2006, J MED CHEM, V49, P3153, DOI 10.1021/jm051141k
   Taher MM, 2003, MOL CELL BIOCHEM, V254, P289, DOI 10.1023/A:1027393719610
   Thorstensen K, 1993, Scand J Clin Lab Invest Suppl, V215, P113
   Venkatesan N, 2000, BRIT J PHARMACOL, V129, P231, DOI 10.1038/sj.bjp.0703067
NR 41
TC 30
Z9 31
U1 0
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2011
VL 6
IS 8
AR e23388
DI 10.1371/journal.pone.0023388
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 811XK
UT WOS:000294251800010
PM 21887247
OA gold
DA 2018-01-05
ER

PT J
AU Kumar, S
   Arya, DP
AF Kumar, Sunil
   Arya, Dev P.
TI Recognition of HIV TAR RNA by triazole linked neomycin dimers
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE RNA; DNA
ID AMINOGLYCOSIDE ANTIBIOTICS; IMMUNODEFICIENCY-VIRUS; TRIPLE RECOGNITION;
   SMALL MOLECULES; B-DNA; BINDING; INHIBITION; PROTEIN; CONJUGATE; DUPLEX
AB A series of neomycin dimers have been synthesized using 'click chemistry' with varying linker functionality and length to target the TAR RNA region of HIV virus. TAR (trans activation response) RNA region, a 59 base pair stem loop structure located at 5'-end of all nascent HIV-1 transcripts interacts with a key regulatory protein, Tat, and necessitates the replication of HIV-1 virus. Neomycin, an aminosugar, has been shown to exhibit more than one binding site with HIV TAR RNA. Multiple TAR binding sites of neomycin prompted us to design and synthesize a small library of neomycin dimers using click chemistry. The binding between neomycin dimers and HIV TAR RNA was characterized using spectroscopic techniques including FID (Fluorescent Intercalator Displacement) titration and UV-thermal denaturation. UV thermal denaturation studies demonstrate that neomycin dimer binding increase the melting temperature (T(m)) of the HIV TAR RNA up to 10 degrees C. Ethidium bromide displacement titrations revealed nanomolar IC(50) between neomycin dimers and HIV TAR RNA, whereas with neomycin, a much higher IC(50) in the micromolar range is observed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Kumar, Sunil; Arya, Dev P.] Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
RP Arya, DP (reprint author), Clemson Univ, Dept Chem, Med Chem Lab, Clemson, SC 29634 USA.
EM dparya@clemson.edu
FU National Institute of Health [R15CA125724]
FX This work was supported by National Institute of Health Grant
   (R15CA125724 to D.P.A.)
CR Arya DP, 2005, TOP CURR CHEM, V253, P149, DOI 10.1007/b100446
   Arya DP, 2004, BIOORG MED CHEM LETT, V14, P4643, DOI 10.1016/j.bmcl.2004.07.002
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   Bernacchi S, 2007, NUCLEIC ACIDS RES, V35, P7128, DOI 10.1093/nar/gkm856
   Boger DL, 2001, J AM CHEM SOC, V123, P5878, DOI 10.1021/ja010041a
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   Earnshaw DJ, 1998, NUCLEIC ACIDS RES, V26, P5551, DOI 10.1093/nar/26.24.5551
   FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0                                                                
   Frankel A D, 1992, Curr Opin Genet Dev, V2, P293, DOI 10.1016/S0959-437X(05)80287-4
   Hermann T, 1998, BIOPOLYMERS, V48, P155, DOI 10.1002/(SICI)1097-0282(1998)48:2<155::AID-BIP5>3.0.CO;2-I                      
   Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Kumar S, 2011, J AM CHEM SOC, V133, P7361, DOI 10.1021/ja108118v
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041
   LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734
   Luedtke NW, 2002, CHEMBIOCHEM, V3, P766, DOI 10.1002/1439-7633(20020802)3:8<766::AID-CBIC766>3.0.CO;2-X
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3                                                   
   MEI HY, 1995, BIOORG MED CHEM LETT, V5, P2755, DOI 10.1016/0960-894X(95)00467-8
   Michael K, 1999, BIOORGAN MED CHEM, V7, P1361, DOI 10.1016/S0968-0896(99)00071-1                                                   
   Mikkelsen NE, 1999, P NATL ACAD SCI USA, V96, P6155, DOI 10.1073/pnas.96.11.6155
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Ranjan N, 2010, BIOCHEMISTRY-US, V49, P9891, DOI 10.1021/bi101517e
   RATMEYER LS, 1992, J MED CHEM, V35, P966, DOI 10.1021/jm00083a024
   Sannes-Lowery KA, 1999, INT J MASS SPECTROM, V193, P115, DOI 10.1016/S1387-3806(99)00111-6
   Shaw NN, 2008, BIOORG MED CHEM LETT, V18, P4142, DOI 10.1016/j.bmcl.2008.05.090
   Shaw NN, 2008, BIOCHIMIE, V90, P1026, DOI 10.1016/j.biochi.2008.04.011
   TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723
   Thomas JR, 2008, CHEM REV, V108, P1171, DOI 10.1021/cr0681546
   Tok JBH, 1999, BIOCHEMISTRY-US, V38, P199, DOI 10.1021/bi9819428
   Tok JBH, 2001, BIOORG MED CHEM LETT, V11, P2987, DOI 10.1016/S0960-894X(01)00602-3
   VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O
   Wang H, 1997, BIOORG MED CHEM LETT, V7, P1951, DOI 10.1016/S0960-894X(97)00339-9
   Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a
   Willis B, 2006, CURR ORG CHEM, V10, P663, DOI 10.2174/138527206776359739                                                      
   Willis B, 2006, ADV CARBOHYD CHEM BI, V60, P251, DOI 10.1016/S0065-2318(06)60006-1
   Willis B, 2010, BIOCHEMISTRY-US, V49, P452, DOI 10.1021/bi9016796
   Willis B, 2009, BIOORG MED CHEM LETT, V19, P4974, DOI 10.1016/j.bmcl.2009.07.079
   Xi HJ, 2009, FEBS LETT, V583, P2269, DOI 10.1016/j.febslet.2009.06.007
   Xue L, 2002, CHEM COMMUN, P70, DOI 10.1039/b108171c
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
NR 44
TC 24
Z9 24
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 15
PY 2011
VL 21
IS 16
BP 4788
EP 4792
DI 10.1016/j.bmcl.2011.06.058
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 797ZB
UT WOS:000293168000026
PM 21757341
OA green_accepted
DA 2018-01-05
ER

PT J
AU O'Driscoll, C
AF O'Driscoll, Cath
TI Nanotechnology Vaccine functional 'cure' for HIV
SO CHEMISTRY & INDUSTRY
LA English
DT News Item
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SOC CHEMICAL INDUSTRY
PI LONDON
PA 14 BELGRAVE SQUARE, LONDON SW1X 8PS, ENGLAND
SN 0009-3068
J9 CHEM IND-LONDON
JI Chem. Ind.
PD AUG 8
PY 2011
IS 15
BP 9
EP 9
PG 1
WC Chemistry, Applied
SC Chemistry
GA 810AI
UT WOS:000294097400010
DA 2018-01-05
ER

PT J
AU Lara, HH
   Garza-Trevino, EN
   Ixtepan-Turrent, L
   Singh, DK
AF Lara, Humberto H.
   Garza-Trevino, Elsa N.
   Ixtepan-Turrent, Liliana
   Singh, Dinesh K.
TI Silver nanoparticles are broad-spectrum bactericidal and virucidal
   compounds
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Review
DE Silver Nanoparticles; Virucides; Bactericides; HIV/AIDS; Antibacterial
   agents
ID ESCHERICHIA-COLI; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY;
   PROTEOMIC ANALYSIS; CELLS; NITRATE; MECHANISM; VIRUS; BIOCOMPATIBILITY;
   SULFADIAZINE
AB The advance in nanotechnology has enabled us to utilize particles in the size of the nanoscale. This has created new therapeutic horizons, and in the case of silver, the currently available data only reveals the surface of the potential benefits and the wide range of applications. Interactions between viral biomolecules and silver nanoparticles suggest that the use of nanosystems may contribute importantly for the enhancement of current prevention of infection and antiviral therapies. Recently, it has been suggested that silver nanoparticles (AgNPs) bind with external membrane of lipid enveloped virus to prevent the infection. Nevertheless, the interaction of AgNPs with viruses is a largely unexplored field. AgNPs has been studied particularly on HIV where it was demonstrated the mechanism of antiviral action of the nanoparticles as well as the inhibition the transmission of HIV-1 infection in human cervix organ culture. This review discusses recent advances in the understanding of the biocidal mechanisms of action of silver Nanoparticles.
C1 [Lara, Humberto H.; Singh, Dinesh K.] Winston Salem State Univ, Dept Life Sci, Winston Salem, NC 27110 USA.
   [Garza-Trevino, Elsa N.; Ixtepan-Turrent, Liliana] Univ Autonoma Nuevo Leon, Fac Med, Dept Bioquim & Med Mol, Lab Terapia Celular, Nuevo Leon, Mexico.
RP Singh, DK (reprint author), Winston Salem State Univ, Dept Life Sci, Winston Salem, NC 27110 USA.
EM singhd@wssu.edu
OI Lara, Humberto H/0000-0003-4854-9839; Ixtepan Turrent,
   Liliana/0000-0002-5352-5383
FU National Center on Minority Health and Health Disparities [P20MD002303];
   National Institute of General Medical Sciences of NIH [SC3GM084802];
   Winston-Salem State University's Center of Excellence for the
   Elimination of Health Disparities; NIH
FX DKS: is an associate professor of microbiology at the Winston Salem
   State University. DKS' lab is working on development of a DNA vaccine
   for HIV/AIDS. His other research interest involves prevention of HIV-1
   transmission at the cervical/vaginal mucosal surfaces. His current
   research is funded by two NIH grants.; The work described was supported
   by Award Number P20MD002303 from the National Center on Minority Health
   and Health Disparities, and SC3GM084802 from National Institute of
   General Medical Sciences of NIH to DKS. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Center on Minority Health and Health
   Disparities or NIGMS or the National Institutes of Health. This research
   is a project supported by Winston-Salem State University's Center of
   Excellence for the Elimination of Health Disparities.
CR Alidaee MR, 2005, BRIT J DERMATOL, V153, P521, DOI 10.1111/j.1365-2133.2005.06490.x
   Amro NA, 2000, LANGMUIR, V16, P2789, DOI 10.1021/la991013x                                                               
   AshaRani PV, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-65
   Aymonier C, 2002, CHEM COMMUN, P3018, DOI 10.1039/b208575e
   Baker C, 2005, J NANOSCI NANOTECHNO, V5, P244, DOI 10.1166/jnn.2005.034
   Borkow G, 2004, FASEB J, V18, P1728, DOI 10.1096/fj.04-2029fje
   Catauro M, 2004, J MATER SCI-MATER M, V15, P831, DOI 10.1023/B:JMSM.0000032825.51052.00                                              
   Chung YC, 2008, BIOMATERIALS, V29, P1807, DOI 10.1016/j.biomaterials.2007.12.032
   Crabtree JH, 2003, PERITON DIALYSIS INT, V23, P368
   Cremel M, 2005, J LEUKOCYTE BIOL, V78, P158, DOI 10.1189/jlb.0305147
   Danilczuk M, 2006, SPECTROCHIM ACTA A, V63, P189, DOI 10.1016/j.saa.2005.05.002
   Dibrov P, 2002, ANTIMICROB AGENTS CH, V46, P2668, DOI 10.1128/AAC.46.8.2668-2670.2002
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Fahey JV, 2008, MUCOSAL IMMUNOL, V1, P317, DOI 10.1038/mi.2008.20
   Fukuoka A, 2001, J AM CHEM SOC, V123, P3373, DOI 10.1021/ja004067y
   FURR JR, 1994, J HOSP INFECT, V27, P201, DOI 10.1016/0195-6701(94)90128-7
   Gajbhiye M, 2009, NANOMED-NANOTECHNOL, V5, P382, DOI 10.1016/j.nano.2009.06.005
   George N, 1997, BURNS, V23, P493, DOI 10.1016/S0305-4179(97)00047-8
   Gougeon ML, 1996, J IMMUNOL, V156, P3509
   Greulich C, 2009, LANGENBECK ARCH SURG, V394, P495, DOI 10.1007/s00423-009-0472-1
   HOFFMANN S, 1984, SCAND J PLAST RECONS, V18, P119, DOI 10.3109/02844318409057413                                                       
   Hoyme U B, 1993, Infect Dis Obstet Gynecol, V1, P32, DOI 10.1155/S1064744993000080
   Hsin YH, 2008, TOXICOL LETT, V179, P130, DOI 10.1016/j.toxlet.2008.04.015
   Illingworth B, 2000, J HEART VALVE DIS, V9, P135
   Jain P, 2005, BIOTECHNOL BIOENG, V90, P59, DOI 10.1002/bit.20368
   Kawata K, 2009, ENVIRON SCI TECHNOL, V43, P6046, DOI 10.1021/es900754q
   Khare MD, 2007, J INFECTION, V54, P146, DOI 10.1016/j.jinf.2006.03.002
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kokura S, 2010, NANOMED-NANOTECHNOL, V6, P570, DOI 10.1016/j.nano.2009.12.002
   Kondow T, 2000, ANNU REV PHYS CHEM, V51, P731, DOI 10.1146/annurev.physchem.51.1.731                                               
   Lansdown ABG, 2010, ADV PHARMACOL SCI, DOI 10.1155/2010/910686
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P1, DOI 10.1186/1477-3155-8-1
   Lara HH, 2010, WORLD J MICROB BIOT, V26, P615, DOI 10.1007/s11274-009-0211-3
   Li WR, 2010, APPL MICROBIOL BIOT, V85, P1115, DOI 10.1007/s00253-009-2159-5
   Liau SY, 1997, LETT APPL MICROBIOL, V25, P279, DOI 10.1046/j.1472-765X.1997.00219.x                                                
   Lok CN, 2006, J PROTEOME RES, V5, P916, DOI 10.1021/pr0504079
   Lu L, 2008, ANTIVIR THER, V13, P253
   McGowan I, 2006, BIOLOGICALS, V34, P241, DOI 10.1016/j.biologicals.2006.08.002
   Mehrbod P, 2009, DARU, V17, P88
   Miura N, 2009, BIOCHEM BIOPH RES CO, V390, P733, DOI 10.1016/j.bbrc.2009.10.039
   Mohanrai V J, 2006, J PHARM RES, V5, P561
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park EJ, 2010, TOXICOL IN VITRO, V24, P872, DOI 10.1016/j.tiv.2009.12.001
   Poon VKM, 2004, BURNS, V30, P140, DOI 10.1016/j.burns.2003.09.030
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Ruparelia JP, 2008, ACTA BIOMATER, V4, P707, DOI 10.1016/j.actbio.2007.11.006
   Salata O.V., 2004, J NANOBIOTECHNOL, V2, P3, DOI DOI 10.1186/1477-3155-2-3
   Shahverdi AR, 2007, NANOMED-NANOTECHNOL, V3, P168, DOI 10.1016/j.nano.2007.02.001
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sun RWY, 2005, CHEM COMMUN, P5059, DOI 10.1039/b510984a
   Tanweer F, 2008, CLIN OTOLARYNGOL, V33, P503, DOI 10.1111/j.1749-4486.2008.01803.x
   Tian J, 2007, CHEMMEDCHEM, V2, P129, DOI 10.1002/cmdc.200600171
   Wira CR, 2004, IMMUNOLOGY, V111, P13, DOI 10.1046/j.1365-2567.2003.01796.x
   Wright JB, 2002, WOUND REPAIR REGEN, V10, P141, DOI 10.1046/j.1524-475X.2002.10308.x                                                
   Yamanaka M, 2005, APPL ENVIRON MICROB, V71, P7589, DOI 10.1128/AEM.71.11.7589-7593.2005
   Yen HJ, 2009, SMALL, V5, P1553, DOI 10.1002/smll.200900126
   Zhang GZ, 2001, ACCOUNTS CHEM RES, V34, P249, DOI 10.1021/ar000011x
NR 61
TC 168
Z9 174
U1 17
U2 129
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD AUG 3
PY 2011
VL 9
AR 30
DI 10.1186/1477-3155-9-30
PG 8
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 815BG
UT WOS:000294500500001
PM 21812950
OA gold
DA 2018-01-05
ER

PT J
AU Kadiu, I
   Nowacek, A
   McMillan, J
   Gendelman, HE
AF Kadiu, Irena
   Nowacek, Ari
   McMillan, JoEllyn
   Gendelman, Howard E.
TI Macrophage endocytic trafficking of antiretroviral nanoparticles
SO NANOMEDICINE
LA English
DT Article
DE antiretroviral therapy; drug delivery; endocytic trafficking; HIV;
   homogenization; monocyte-derived macrophages; nanoformulated
   antiretroviral drugs; Rab11; recycling endosomes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-GOLGI NETWORK; PERICENTRIOLAR
   RECYCLING ENDOSOME; ANTI-HIV DRUGS; RAB PROTEINS; MURINE MODEL;
   DELIVERY; MEMBRANE; THERAPY; CELLS
AB Aim: Nanoformulated antiretroviral therapy can improve drug compliance for people infected with HIV. Additional benefits would include specific drug deliveries to viral reservoirs and reduction in systemic toxicities. Methods: In this article, we describe mechanisms of crystalline antiretroviral nanoparticle (NP) uptake, intracellular trafficking and release in human monocyte-derived macrophages. Results: Following clathrin-dependent endocytosis NPs bypassed lysosomal degradation by sorting from early endosomes to recycling endosome pathways. Disruption of this pathway by siRNAs or brefeldin-A impaired particle release. Proteomic and biological analysis demonstrated that particle recycling was primarily Rab11 regulated. Particles were released intact and retained complete antiretroviral efficacy. Conclusion: These results suggest possible pathways of subcellular transport of antiretroviral nanoformulations that preserve both particle integrity and antiretroviral activities demonstrating the potential utility of this approach for targeted drug delivery.
C1 [Kadiu, Irena; Nowacek, Ari; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
FU NIH [PO1 DA028555, P20 RR15635, 1 P01 NS043985-01, 2R37 NS36126, 5 P01
   DA026146, 5 P01 MH64570-03]
FX This work was supported by NIH grants PO1 DA028555, P20 RR15635, 1 P01
   NS043985-01, 2R37 NS36126, 5 P01 DA026146 and 5 P01 MH64570-03. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Altice FL, 2010, LANCET, V376, P367, DOI 10.1016/S0140-6736(10)60829-X
   Anuurad E, 2009, METAB SYNDR RELAT D, V7, P401, DOI 10.1089/met.2008.0096
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Barbaro G, 2007, CURR PHARM DESIGN, V13, P2208, DOI 10.2174/138161207781039661
   Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030
   Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008
   Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6
   Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343
   Beyrer C, 2010, LANCET, V376, P551, DOI 10.1016/S0140-6736(10)60928-2
   Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732                                                                  
   Blyth CC, 2010, COCHRANE DB SYST REV, V2
   Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985
   BRESSANI R, 2010, NANOTOXICOLOGY
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Brynskikh AM, 2010, NANOMEDICINE-UK, V5, P379, DOI 10.2217/NNM.10.7
   Cayouette S, 2010, BBA-MOL CELL RES, V1803, P805, DOI 10.1016/j.bbamcr.2010.03.010
   Chen W, 2001, METHOD ENZYMOL, V329, P165
   Chu P, 2009, CURR MED RES OPIN, V25, P3011, DOI 10.1185/03007990903379077
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680
   De Cock KM, 2008, LANCET, V371, P2068, DOI 10.1016/S0140-6736(08)60732-1
   Destache CJ, 2010, J ANTIMICROB CHEMOTH, V65, P2183, DOI 10.1093/jac/dkq318
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Hattula K, 2006, J CELL SCI, V119, P4866, DOI 10.1242/jcs.03275
   Hoekstra D, 2004, J CELL SCI, V117, P2183, DOI 10.1242/jcs.01217
   Hsu VW, 2010, CURR OPIN CELL BIOL, V22, P528, DOI 10.1016/j.ceb.2010.05.008
   Jing J, 2009, HISTOL HISTOPATHOL, V24, P1171, DOI 10.14670/HH-24.1171
   Jones MC, 2006, CURR OPIN CELL BIOL, V18, P549, DOI 10.1016/j.ceb.2006.08.003
   Jordens I, 2005, TRAFFIC, V6, P1070, DOI 10.1111/j.1600-0854.2005.00336.x
   Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99
   Junutula JR, 2004, MOL BIOL CELL, V15, P2218, DOI 10.1091/mbc.E03-10-0777
   KALTER DC, 1991, J IMMUNOL, V146, P3396
   Kraft-Terry SD, 2010, NEUROBIOL DIS, V37, P542, DOI 10.1016/j.nbd.2009.12.015
   Kramer Andrea Sebben, 2009, Arq Bras Cardiol, V93, P561, DOI 10.1590/S0066-782X2009001100019
   Kumari S, 2010, CELL RES, V20, P256, DOI 10.1038/cr.2010.19
   Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200
   Liu YT, 2008, J NEUROIMMUNOL, V200, P41, DOI 10.1016/j.jneuroim.2008.06.009
   LOMBARDI D, 1993, EMBO J, V12, P677
   Luzio JP, 2009, BIOCHEM SOC T, V37, P1019, DOI 10.1042/BST0371019
   Marre S, 2010, CHEM SOC REV, V39, P1183, DOI 10.1039/b821324k
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   Meltzer M S, 1992, Curr Top Microbiol Immunol, V181, P239
   MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125
   MELTZER MS, 1990, AIDS RES HUM RETROV, V6, P967
   Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Murray JL, 2005, J VIROL, V79, P11742, DOI 10.1128/JVI.79.18.11742-11751.2005
   Nowacek AS, 2011, J CONTROL RELEASE, V150, P204, DOI 10.1016/j.jconrel.2010.11.019
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   NOWACEK AS, 2010, J NEUROIMMUNE PHARM
   Pagano L, 2010, BLOOD REV, V24, P51, DOI 10.1016/j.blre.2009.11.003
   Parent A, 2009, BIOCHEM J, V418, P163, DOI 10.1042/BJ20080867
   Pasqualato S, 2004, J BIOL CHEM, V279, P11480, DOI 10.1074/jbc.M310558200
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Schonteich E, 2008, J CELL SCI, V121, P3824, DOI 10.1242/jcs.032441
   Seaman MNJ, 2008, CELL MOL LIFE SCI, V65, P2842, DOI 10.1007/s00018-008-8354-1
   Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123
   Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901
   Taiwo B, 2010, J ANTIMICROB CHEMOTH, V65, P1100, DOI 10.1093/jac/dkq096
   Takatsuka T, 2009, CHEM PHARM BULL, V57, P1061, DOI 10.1248/cpb.57.1061                                                             
   Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913
   *UNIPROT, UNIPROT ACC NUMB
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   VANDERSLUIJS P, 1992, EMBO J, V11, P4379
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   Varthakavi V, 2006, TRAFFIC, V7, P298, DOI 10.1111/j.1600-0854.2005.00380.x
   Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921
   Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X
   Yamamoto H, 2010, MOL BIOL CELL, V21, P2746, DOI 10.1091/mbc.E10-01-0074
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055                                                                
   JACOP PLUGINS
   ENTREZ PUBMED
   SUBCELLULAR LOCALIZA
NR 79
TC 29
Z9 29
U1 2
U2 16
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD AUG
PY 2011
VL 6
IS 6
BP 975
EP 994
DI 10.2217/NNM.11.27
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 830ZE
UT WOS:000295697600012
PM 21417829
OA green_accepted
DA 2018-01-05
ER

PT J
AU Petri, L
   Ferreira, M
   Moraes, ML
AF Petri, Lais
   Ferreira, Marystela
   Moraes, Marli L.
TI Toward Preserving the Structure of the Antigenic Peptide p17-1 from the
   HIV-1 p17 Protein in Nanostructured Films
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE HIV-1 Peptide; Layer-by-Layer Film; Liposome; Immunosensor
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IMPEDIMETRIC IMMUNOSENSOR; SECONDARY
   STRUCTURE; SYNTHETIC PEPTIDES; MEMBRANE-FUSION; ANTIBODIES;
   IMMOBILIZATION; MONOLAYER
AB Antigenic peptides may be immobilized in nanostructured films in order to build highly specific immunosensors and other devices that require molecular recognition, with no need to use complex molecules. A major challenge for such endeavors, however, is to preserve the secondary structure of the peptides after immobilization. In this study, we show that the peptide p17-1 (LSGGELDR-WEKIRLRPGG), derived from the HIV-1 p17 protein, may be immobilized in Layer-by-Layer (LbL) films made with polyelectrolytes. Its structure was preserved only if incorporated into phospholipid liposomes, according to fluorescence and circular dichroism (CD) spectroscopy. The lack of secondary structure for the peptide in the LbL film may be associated with the film-forming procedure in which p17-1 was adsorbed from an aqueous solution, where it does not form alpha helices. The importance of structure preservation was clear in the attempts to produce electrochemical immunosensors with the p17-1 peptide without being protected in liposomes in an LbL film. There was no detectable influence of the presence of anti-p17 antibodies, though some molecular interaction could be inferred from the voltammograms. In contrast, for p17-1 incorporated in liposomes electrochemical immunosensors could be obtained with the voltamogramms showing strong molecular recognition with the antibodies. These results indicated that phospholipids serve as a suitable matrix for immobilization of peptides, and confirmed the importance of structure preservation in electrochemical immunosensors.
C1 [Petri, Lais; Ferreira, Marystela; Moraes, Marli L.] Univ Fed Sao Carlos, BR-18052780 Sorocaba, SP, Brazil.
RP Moraes, ML (reprint author), Univ Fed Sao Carlos, Campus Sorocaba, BR-18052780 Sorocaba, SP, Brazil.
RI Moraes, Marli/D-9263-2012; Petri, Lais/D-6404-2015; Ferreira,
   Marystela/B-8941-2013
OI Moraes, Marli/0000-0003-0213-3686; Petri, Lais/0000-0001-9727-1939;
   Ferreira, Marystela/0000-0002-9459-8167
FU FAPESP; CNPq; Capes; nBioNet (Brazil)
FX This work was supported by FAPESP, CNPq, Capes and nBioNet (Brazil).
CR ARNON R, 1991, MOL IMMUNOL, V28, P209, DOI 10.1016/0161-5890(91)90063-P                                                    
   Ben-Efraim I, 1999, J MOL BIOL, V285, P609, DOI 10.1006/jmbi.1998.2370                                                          
   Campana PT, 2005, BIOPHYS CHEM, V113, P175, DOI 10.1016/j.bpc.2004.08.006
   Cohen MH, 2003, AIDS, V17, P2121, DOI 10.1097/01.aids.0000088181.01779.d2
   Epand RM, 2000, BIOPOLYMERS, V55, P358, DOI 10.1002/1097-0282(2000)55:5<358::AID-BIP1009>3.0.CO;2-8
   Ghindilis AL, 1998, BIOSENS BIOELECTRON, V13, P113, DOI 10.1016/S0956-5663(97)00031-6
   Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097
   Gomara MJ, 2007, CURR MED CHEM, V14, P531, DOI 10.2174/092986707780059698                                                      
   Granade TC, 1998, CLIN DIAGN LAB IMMUN, V5, P171
   HANCOCK REW, 2001, LANCET INFECT DIS, V1, P8
   Holzinger M, 2009, J NANOSCI NANOTECHNO, V9, P6042, DOI 10.1166/jnn.2009.1549
   Ishiguro R, 1996, BIOCHEMISTRY-US, V35, P4976, DOI 10.1021/bi952547+                                                               
   Jackson JB, 1997, J CLIN MICROBIOL, V35, P1118
   JONES JH, 1994, CHEM SYNTHESIS PEPTI, P240
   JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P16
   Jung YW, 2009, ANAL CHEM, V81, P936, DOI 10.1021/ac8014565
   KNICHEL M, 1995, SENSOR ACTUAT B-CHEM, V28, P85, DOI 10.1016/0925-4005(94)01543-Q                                                    
   Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, P954
   Moraes ML, 2008, MAT SCI ENG C-BIO S, V28, P467, DOI 10.1016/j.msec.2007.04.017
   Moraes ML, 2010, J COLLOID INTERF SCI, V350, P268, DOI 10.1016/j.jcis.2010.06.043
   Moraes ML, 2009, MAT SCI ENG C-BIO S, V29, P442, DOI 10.1016/j.msec.2008.08.040
   Moraes ML, 2005, COLLOID SURFACE B, V41, P15, DOI 10.1016/j.colsurfb.2004.10.026
   Nakanishi K., 1994, CIRCULAR DICHROISM P
   Nygren P, 2010, LANGMUIR, V26, P6437, DOI 10.1021/la100027n
   Oku N, 2002, ONCOGENE, V21, P2662, DOI 10.1038/sj/onc/1205347
   Rickert J, 1996, BIOSENS BIOELECTRON, V11, P757, DOI 10.1016/0956-5663(96)85927-6
   Samuel O, 2001, BIOCHEMISTRY-US, V40, P1340, DOI 10.1021/bi001533n
   Sapsford KE, 2010, BIOCONJUGATE CHEM, V21, P393, DOI 10.1021/bc9003712
   Schonhoff M, 2003, J PHYS-CONDENS MAT, V15, pR1781, DOI 10.1088/0953-8984/15/49/R01
   SOTORAMIREZ LE, 1992, J CLIN MICROBIOL, V30, P2780
   Tai DF, 2010, ANAL CHEM, V82, P2290, DOI 10.1021/ac9024158
   Talhari DT, 2009, BBA-BIOMEMBRANES, V1788, P2320, DOI 10.1016/j.bbamem.2009.07.023
   Tonarelli G, 2000, LETT PEPT SCI, V7, P217, DOI 10.1007/BF02447860
   UNAIDS, UNAIDS REP GLOB AIDS
   Wright PF, 2002, AIDS RES HUM RETROV, V18, P1291, DOI 10.1089/088922202320886334
NR 35
TC 6
Z9 6
U1 0
U2 6
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD AUG
PY 2011
VL 11
IS 8
BP 6705
EP 6709
DI 10.1166/jnn.2011.4216
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 825QH
UT WOS:000295296400009
PM 22103071
DA 2018-01-05
ER

PT J
AU Lefrancois, M
   Lefebvre, MR
   Saint-Onge, G
   Boulais, PE
   Lamothe, S
   Leduc, R
   Lavigne, P
   Heveker, N
   Escher, E
AF Lefrancois, Marilou
   Lefebvre, Marie-Reine
   Saint-Onge, Genevieve
   Boulais, Philip E.
   Lamothe, Simon
   Leduc, Richard
   Lavigne, Pierre
   Heveker, Nikolaus
   Escher, Emanuel
TI Agonists for the Chemokine Receptor CXCR4
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CXCR4; agonist; CXCL12; T140; chemotaxis
ID HIV PEPTIDE T140; CARCINOMA CELLS; SMALL-MOLECULE; BREAST-CANCER;
   ANTAGONISTS; CORECEPTOR; INHIBITOR; BINDING; POTENT; DISSOCIATION
AB The development of agonists for the chemokine receptor CXCR4 could provide promising therapeutic candidates. On the basis of previously forwarded two site model of chemoldne-receptor interactions, we hypothesized that linking the agonistic N-terminus of SDF-1 to the T140 backbone would yield new high-affinity agonists of CXCR4. We developed chimeras with the agonistic SDF-1 N-terminus grafted to a T140 side chain and tested their binding affinity and chemotactic agonist activity. While chimeras with the peptide grafted onto position 12 of T140 remained high-affinity antagonists, those bearing the peptide on position 14 were in part agonists. One chimera was a full CXCR4 agonist with 25 nM affinity, and several chimeras showed low nanomolar affinities with partial agonist activity. Our results confirmed that we have developed high-affinity agonists of CXCR4.
C1 [Lefrancois, Marilou; Lefebvre, Marie-Reine; Boulais, Philip E.; Leduc, Richard; Lavigne, Pierre; Escher, Emanuel] Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.
   [Saint-Onge, Genevieve; Lamothe, Simon; Heveker, Nikolaus] Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada.
   [Lamothe, Simon; Heveker, Nikolaus] Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.
RP Escher, E (reprint author), Univ Sherbrooke, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada.
EM Emanuel.Escher@USherbrooke.ca
RI Heveker, Nikolaus/G-5306-2012
FU Canadian Institutes of Health research (CIHR)
FX This work was funded by the Canadian Institutes of Health research
   (CIHR). P.E.B. and S.L. are holders of a CIHR studentship.
CR Boulais PE, 2009, BIOCHEM PHARMACOL, V78, P1382, DOI 10.1016/j.bcp.2009.07.007
   Burger JA, 2009, LEUKEMIA, V23, P43, DOI 10.1038/leu.2008.299
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   De Clercq E, 2010, PHARMACOL THERAPEUT, V128, P509, DOI 10.1016/j.pharmthera.2010.08.009
   DeMarco SJ, 2006, BIOORGAN MED CHEM, V14, P8396, DOI 10.1016/j.bmc.2006.09.003
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0
   Hendrix CW, 2004, JAIDS-J ACQ IMM DEF, V37, P1253, DOI 10.1097/01.qai.0000137371.80695.ef
   Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1
   Ichiyama K, 2003, P NATL ACAD SCI USA, V100, P4185, DOI 10.1073/pnas.0630420100
   Li K, 2006, STEM CELLS, V24, P55, DOI 10.1634/stemcells.2005-0082
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Pelus LM, 2005, EXP HEMATOL, V33, P295, DOI 10.1016/j.exphem.2004.11.008
   Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9
   Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7
   Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Tchernychev B, 2010, P NATL ACAD SCI USA, V107, P22255, DOI 10.1073/pnas.1009633108
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751
   Wendt MK, 2008, GASTROENTEROLOGY, V135, P508, DOI 10.1053/j.gastro.2008.05.033
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Yang OO, 1999, J VIROL, V73, P4582
   Zhou NM, 2003, VIROLOGY, V312, P196, DOI 10.1016/S0042-6822(03)00185-5
NR 25
TC 20
Z9 20
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD AUG
PY 2011
VL 2
IS 8
BP 597
EP 602
DI 10.1021/ml200084n
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 809SB
UT WOS:000294075900008
OA gold
DA 2018-01-05
ER

PT J
AU Choi, YS
   Lee, JY
   Suh, JS
   Lee, SJ
   Yang, VC
   Chung, CP
   Park, YJ
AF Choi, Young Suk
   Lee, Jue Yeon
   Suh, Jin Sook
   Lee, Seung Jin
   Yang, Victor C.
   Chung, Chong Pyoung
   Park, Yoon Jeong
TI Cell Penetrating Peptides for Tumor Targeting
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Review
DE Antitumor drug delivery; cell penetrating peptides (cpp); molecular
   cargo; intracellular drug delivery
ID MOLECULAR-WEIGHT PROTAMINE; HUMAN-IMMUNODEFICIENCY-VIRUS; ARGININE-RICH
   PEPTIDES; MEMBRANE-PERMEABLE PEPTIDES; HIV-1 TAT PROTEIN; EFFICIENT
   INTRACELLULAR DELIVERY; ANTENNAPEDIA HOMEOBOX PEPTIDE; METAL-LINKED
   DIMER; IN-VIVO; MAMMALIAN-CELLS
AB Anticancer drug delivery has been hindered due to cell membrane permeability and the lack of a selective marker for tumor cells. Cell permeability is related to the bioavailability of drugs and has therefore been considered to be an essential step for achieving therapeutic efficacy. While different types of transporters currently exist, cell penetrating peptides (CPPs) have become one of the most popular and effective tools for intracellular drug delivery. Most of the original CPPs are short peptides with basic residues. The mechanism of CPP cell entry remains to be established; however, the CPPs can deliver any type of molecular cargo including solid nanoparticles. Herein, this paper will discuss the classification of CPPs, the mechanism of cell entry, the application of CPPs in tumor therapy, and recent advances in targeted cell penetration that involve CPPs.
C1 [Choi, Young Suk; Suh, Jin Sook; Park, Yoon Jeong] Seoul Natl Univ, Dent Res Inst, Dept Dent Regenerat Biotechnol, Seoul 110749, South Korea.
   [Choi, Young Suk; Suh, Jin Sook; Park, Yoon Jeong] Seoul Natl Univ, Sch Dent, Seoul 110749, South Korea.
   [Yang, Victor C.] Univ Michigan, Dept Pharmaceut Sci, Coll Pharm, Ann Arbor, MI 48109 USA.
   [Chung, Chong Pyoung] Seoul Natl Univ, Dept Periodontol, Coll Dent, Seoul 110749, South Korea.
   [Chung, Chong Pyoung] Seoul Natl Univ, Intellectual Biointerface Engn Ctr, Seoul 110749, South Korea.
   [Lee, Seung Jin] Ewha Womans Univ, Coll Pharm, Dept Ind Pharm, Seoul, South Korea.
   [Lee, Jue Yeon] NIBEC, Res Inst, Jincheon, South Korea.
RP Park, YJ (reprint author), Seoul Natl Univ, Dent Res Inst, Dept Dent Regenerat Biotechnol, 28-2 Yongon Dong, Seoul 110749, South Korea.
EM parkyj@snu.ac.kr
FU Ministry of Health, Welfare and Family Affairs, Korea [A080927]
FX This study was supported by the Ministry of Health, Welfare and Family
   Affairs (#A080927), Korea.
CR Aints A, 2001, GENE THER, V8, P1051, DOI 10.1038/sj.gt.3301493
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518
   Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
   Begam M, 2006, PHYTOCHEMISTRY, V67, P2441, DOI 10.1016/j.phytochem.2006.08.015
   Berger AJ, 2004, CANCER RES, V64, P8767, DOI 10.1158/0008-5472.CAN-04-1384
   Bosslet K, 1998, CANCER RES, V58, P1195
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Byun Y, 1999, THROMB RES, V94, P53, DOI 10.1016/S0049-3848(98)00201-1                                                   
   Chai JJ, 2000, NATURE, V406, P855
   Chang LC, 2001, AAPS PHARMSCI, V3, part. no.
   Chang LC, 2001, AAPS PHARMSCI, V3, part. no.
   Chari RVJ, 1998, ADV DRUG DELIVER REV, V31, P89, DOI 10.1016/S0169-409X(97)00095-1
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   Choi SW, 2010, BIOTECHNOL PROGR, V26, P57, DOI 10.1002/btpr.310
   Choi YS, 2010, BIOMATERIALS, V31, P1429, DOI 10.1016/j.biomaterials.2009.11.001
   CHOI YS, 2009, BIOMATERIALS
   Crombez L, 2007, BIOCHEM SOC T, V35, P44, DOI 10.1042/BST0350044                                                              
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9                                                    
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Deshayes S, 2008, ADV DRUG DELIVER REV, V60, P537, DOI 10.1016/j.addr.2007.09.005
   Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901                                                                   
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Dupont E, 2007, J BIOL CHEM, V282, P8994, DOI 10.1074/jbc.M609246200
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850
   Elmquist A, 2006, BBA-BIOMEMBRANES, V1758, P721, DOI 10.1016/j.bbamem.2006.05.013
   Endoh T, 2009, ADV DRUG DELIVER REV, V61, P704, DOI 10.1016/j.addr.2009.04.005
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001
   FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944
   FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735
   Futaki S, 2003, J MOL RECOGNIT, V16, P260, DOI 10.1002/jmr.635
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487
   GOLDMACHER VS, 1986, J CELL BIOL, V102, P1312, DOI 10.1083/jcb.102.4.1312
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greenwald RB, 2000, CRIT REV THER DRUG, V17, P101
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Harada H, 2002, CANCER RES, V62, P2013
   Harada Hiroshi, 2006, Breast Cancer, V13, P16, DOI 10.2325/jbcs.13.16
   Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341                                                    
   Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298
   JAIN RK, 1991, INT J RADIAT BIOL, V60, P85, DOI 10.1080/09553009114551621
   JAIN RK, 1988, CANCER RES, V48, P7022
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929                                                             
   Johansson HJ, 2008, MOL THER, V16, P115, DOI 10.1038/sj.mt.6300346
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kerkis A, 2006, IUBMB LIFE, V58, P7, DOI 10.1080/15216540500494508
   Kopecek J, 2000, EUR J PHARM BIOPHARM, V50, P61, DOI 10.1016/S0939-6411(00)00075-8                                                   
   Krawetz JE, 2000, EUR J BIOCHEM, V267, P1966, DOI 10.1046/j.1432-1327.2000.01200.x
   Kwon YM, 2008, EXPERT OPIN DRUG DEL, V5, P1255, DOI 10.1517/17425240802498059 
   Kwon YM, 2008, J CONTROL RELEASE, V130, P252, DOI 10.1016/j.jconrel.2008.06.017
   Lee LM, 2001, AAPS PHARMSCI, V3, part. no.
   Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2003, BIOCHEMISTRY-MOSCOW+, V68, P116, DOI 10.1023/A:1022109905487
   Liang JF, 2002, J CONTROL RELEASE, V78, P67, DOI 10.1016/S0168-3659(01)00484-9
   Liang JF, 2001, J CONTROL RELEASE, V72, P145, DOI 10.1016/S0168-3659(01)00270-X
   Liu YJ, 2009, MOL THER, V17, P1509, DOI 10.1038/mt.2009.43
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051                                                              
   Marcucci F, 2004, DRUG DISCOV TODAY, V9, P219, DOI 10.1016/S1359-6446(03)02988-X                                                   
   Martinez-Ruiz G, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-48
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Mizukawa K, 2006, J NEURO-ONCOL, V77, P247, DOI 10.1007/s11060-005-9045-5
   Moon C, 2008, J BIOMED MATER RES A, V84A, P238, DOI 10.1002/jbm.a.31452
   Mori S, 2004, CANCER, V100, P1673, DOI 10.1002/cncr.20164
   Morishita M, 2007, J CONTROL RELEASE, V118, P177, DOI 10.1016/j.jconrel.2006.12.022
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Mueller J, 2008, BIOCONJUGATE CHEM, V19, P2363, DOI 10.1021/bc800194e
   Nachmias B, 2004, SEMIN CANCER BIOL, V14, P231, DOI 10.1016/j.semcancer.2004.04.002
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Nori A, 2005, ADV DRUG DELIVER REV, V57, P609, DOI 10.1016/j.addr.2004.10.006
   Olson ES, 2009, INTEGR BIOL, V1, P382, DOI 10.1039/b904890a
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pujals S, 2006, BBA-BIOMEMBRANES, V1758, P264, DOI 10.1016/j.bbamem.2006.01.006
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   Rosenbluh J, 2005, J MOL BIOL, V345, P387, DOI 10.1016/j.jmb.2004.10.046
   Rosenbluh J, 2004, BBA-BIOMEMBRANES, V1664, P230, DOI 10.1016/j.bbamem.2004.06.003
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914
   RUBEN S, 1989, J VIROL, V63, P1
   Russell-Jones G J, 1999, Pharm Biotechnol, V12, P493
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632
   Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2
   SIOMI H, 1990, J VIROL, V64, P1803
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder EL, 2005, CANCER RES, V65, P10646, DOI 10.1158/0008-5472.CAN-05-0118
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Syrigos KN, 1999, ANTICANCER RES, V19, P605
   Takenobu T, 2002, MOL CANCER THER, V1, P1043
   Talvensaari-Mattila A, 2003, BRIT J CANCER, V89, P1270, DOI 10.1038/sj.bjc.6601238
   Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747
   Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tsui B, 2001, THROMB RES, V101, P417, DOI 10.1016/S0049-3848(00)00427-8
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Vandenbroucke RE, 2007, BBA-BIOMEMBRANES, V1768, P571, DOI 10.1016/j.bbamem.2006.11.006
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Vives E, 2008, BBA-REV CANCER, V1786, P126, DOI 10.1016/j.bbcan.2008.03.001
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Watkins CL, 2009, BIOCHEM J, V420, P179, DOI 10.1042/BJ20090042
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wu G, 2000, NATURE, V408, P1008
   Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242                                                                   
   Yang LL, 2003, CANCER RES, V63, P831
   Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
NR 145
TC 15
Z9 16
U1 2
U2 29
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD AUG
PY 2011
VL 12
IS 8
BP 1166
EP 1182
PG 17
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 807AI
UT WOS:000293860100009
PM 21470141
DA 2018-01-05
ER

PT J
AU Huang, JG
   Gautam, N
   Bathena, SPR
   Roy, U
   McMillan, J
   Gendelman, HE
   Alnouti, Y
AF Huang, Jiangeng
   Gautam, Nagsen
   Bathena, Sai Praneeth R.
   Roy, Upal
   McMillan, JoEllyn
   Gendelman, Howard E.
   Alnouti, Yazen
TI UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir,
   atazanavir, and efavirenz in mouse serum and tissues
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article
DE Antiretroviral drugs; UPLC-MS/MS; Pharmacokinetics; Tissue distribution
ID TANDEM MASS-SPECTROMETRY; HIV-PROTEASE INHIBITORS; PERFORMANCE
   LIQUID-CHROMATOGRAPHY; REVERSE-TRANSCRIPTASE INHIBITORS; BLOOD
   MONONUCLEAR-CELLS; HUMAN PLASMA; QUANTITATIVE-DETERMINATION;
   ANTIRETROVIRAL AGENTS; DRUGS INDINAVIR; LOPINAVIR
AB Animal pharmacokinetic and tissue distribution assays of antiretroviral therapeutic drugs require accurate drug quantification in biological fluids and tissues. Here we report a simple, rapid, and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for quantification of commonly used antiretroviral drugs ritonavir (RTV), indinavir (IDV), atazanavir (ATV), and efavirenz (EFV) in mouse serum and tissues (liver, kidney, lung, and spleen). These antiretroviral drugs are currently the cornerstones of common therapeutic regimens for human immunodeficiency virus (HIV) infection. Chromatographic separation was achieved using a gradient mobile phase (5% acetonitrile in methanol and 7.5 mM ammonium acetate (pH 4.0)) on an ACQUITY UPLC (R) BEH Shield RP 18 column. All compounds eluted within a 7 min run time. Lopinavir was used as an internal standard. Detection was achieved by dual positive and negative ionization modes on a quadrupole linear ion trap hybrid mass spectrometer with an electrospray ionization (ESI) source. The dynamic range was 0.2-1000 ng/mL for RN, IDV, and ATV, and 0.5-1000 for EFV. The method was validated and showed high and consistent intra-day and inter-day accuracy and precision for all analytes. This method is used to support the preclinical development studies of targeted- and sustained-release combination ART (nanoART). The current data demonstrate a 1.5-4 fold increase in serum and tissue AUC of nanoformulated ATV, RTV, and EFV administered to mice when compared to native drug. In addition, the tested formulation enhanced exposure of the same anti-HIV drugs in mouse tissues. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Huang, Jiangeng; Gautam, Nagsen; Bathena, Sai Praneeth R.; Alnouti, Yazen] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm 3039, Omaha, NE 68198 USA.
   [Roy, Upal; McMillan, JoEllyn; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
RP Alnouti, Y (reprint author), Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm 3039, Omaha, NE 68198 USA.
EM yalnouti@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Roy, Upal/0000-0002-0325-567X
FU NIH [PO1 DA028555-01]
FX This work was supported in part by NIH grant PO1 DA028555-01.
CR Chi JD, 2002, J PHARMACEUT BIOMED, V30, P675, DOI 10.1016/S0731-7085(02)00357-6
   Colombo S, 2005, J CHROMATOGR B, V819, P259, DOI 10.1016/j.jchromb.2005.02.010
   Cressey TR, 2007, EXPERT OPIN DRUG MET, V3, P347, DOI 10.1517/17425255.3.3.347
   de Saint-Martin L, 2010, AIDS, V24, P2797, DOI 10.1097/QAD.0b013e328340a21f
   Dickinson L, 2005, J CHROMATOGR B, V829, P82, DOI 10.1016/j.jchromb.2005.09.032
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Droste JAH, 2003, THER DRUG MONIT, V25, P393, DOI 10.1097/00007691-200306000-00023
   Egge-Jacobsen W, 2004, THER DRUG MONIT, V26, P546, DOI 10.1097/00007691-200410000-00014                                                
   Ehrhardt M, 2007, J CHROMATOGR B, V850, P249, DOI 10.1016/j.jchromb.2006.11.037
   Elens L, 2009, J CHROMATOGR B, V877, P1805, DOI 10.1016/j.jchromb.2009.04.046
   Elens L, 2009, CLIN CHEM, V55, P170, DOI 10.1373/clinchem.2008.108647
   Else L, 2010, J CHROMATOGR B, V878, P1455, DOI 10.1016/j.jchromb.2010.03.036
   Fan B, 2002, BIOMED CHROMATOGR, V16, P383, DOI 10.1002/bmc.169
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Huang Y, 2008, RAPID COMMUN MASS SP, V22, P3401, DOI 10.1002/rcm.3750
   Justesen US, 2003, J CHROMATOGR B, V783, P491, DOI 10.1016/S1570-0232(02)00728-6
   Koal T, 2005, RAPID COMMUN MASS SP, V19, P2995, DOI 10.1002/rcm.2158
   Lindl KA, 2010, J NEUROIMMUNE PHARM, V5, P294, DOI 10.1007/s11481-010-9205-z
   Little JL, 2006, J CHROMATOGR B, V833, P219, DOI 10.1016/j.jchromb.2006.02.011
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   NOWACEK AS, 2011, J CONTROL RELEASE
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16                                              
   Peoples MC, 2008, BIOMED CHROMATOGR, V22, P1272, DOI 10.1002/bmc.1057
   Quaranta S, 2009, THER DRUG MONIT, V31, P695, DOI 10.1097/FTD.0b013e3181c05adf
   Rentsch KM, 2003, J CHROMATOGR B, V788, P339, DOI 10.1016/S1570-0232(03)00039-4
   Rezk NL, 2009, TALANTA, V79, P1372, DOI 10.1016/j.talanta.2009.06.005
   Spaulding A, 2010, COCHRANE DB SYST REV, V10
   ter Heine R, 2008, J CHROMATOGR B, V867, P205, DOI 10.1016/j.jchromb.2008.04.003
   ter Heine R, 2009, J CHROMATOGR B, V877, P575, DOI 10.1016/j.jchromb.2009.01.011
   ter Heine R, 2007, RAPID COMMUN MASS SP, V21, P2505, DOI 10.1002/rcm.3119
   ter Heine R, 2010, CLIN CHEM LAB MED, V48, P1153, DOI 10.1515/CCLM.2010.225
   Torti C, 2005, J ANTIMICROB CHEMOTH, V56, P190, DOI 10.1093/jac/dki172
   Turner ML, 2003, J CHROMATOGR B, V784, P331, DOI 10.1016/S1570-0232(02)00822-X
   Usami Y, 2003, CHEM PHARM BULL, V51, P715
   Volosov A, 2002, CLIN BIOCHEM, V35, P99, DOI 10.1016/S0009-9120(02)00286-2
NR 39
TC 16
Z9 17
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD AUG 1
PY 2011
VL 879
IS 23
BP 2332
EP 2338
DI 10.1016/j.jchromb.2011.06.032
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 805JN
UT WOS:000293722800024
PM 21752731
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chin, CD
   Laksanasopin, T
   Cheung, YK
   Steinmiller, D
   Linder, V
   Parsa, H
   Wang, J
   Moore, H
   Rouse, R
   Umviligihozo, G
   Karita, E
   Mwambarangwe, L
   Braunstein, SL
   van de Wijgert, J
   Sahabo, R
   Justman, JE
   El-Sadr, W
   Sia, SK
AF Chin, Curtis D.
   Laksanasopin, Tassaneewan
   Cheung, Yuk Kee
   Steinmiller, David
   Linder, Vincent
   Parsa, Hesam
   Wang, Jennifer
   Moore, Hannah
   Rouse, Robert
   Umviligihozo, Gisele
   Karita, Etienne
   Mwambarangwe, Lambert
   Braunstein, Sarah L.
   van de Wijgert, Janneke
   Sahabo, Ruben
   Justman, Jessica E.
   El-Sadr, Wafaa
   Sia, Samuel K.
TI Microfluidics-based diagnostics of infectious diseases in the developing
   world
SO NATURE MEDICINE
LA English
DT Article
ID RESOURCE-POOR SETTINGS; GLOBAL HEALTH; DEVICES; HIV; OPPORTUNITIES;
   IMMUNOASSAYS; COUNTRIES; FUTURE; VIRUS; TIME
AB One of the great challenges in science and engineering today is to develop technologies to improve the health of people in the poorest regions of the world. Here we integrated new procedures for manufacturing, fluid handling and signal detection in microfluidics into a single, easy-to-use point-of-care (POC) assay that faithfully replicates all steps of ELISA, at a lower total material cost. We performed this 'mChip' assay in Rwanda on hundreds of locally collected human samples. The chip had excellent performance in the diagnosis of HIV using only 1 mu l of unprocessed whole blood and an ability to simultaneously diagnose HIV and syphilis with sensitivities and specificities that rival those of reference benchtop assays. Unlike most current rapid tests, the mChip test does not require user interpretation of the signal. Overall, we demonstrate an integrated strategy for miniaturizing complex laboratory assays using microfluidics and nanoparticles to enable POC diagnostics and early detection of infectious diseases in remote settings.
C1 [Chin, Curtis D.; Laksanasopin, Tassaneewan; Cheung, Yuk Kee; Parsa, Hesam; Wang, Jennifer; Moore, Hannah; Rouse, Robert; Sia, Samuel K.] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
   [Steinmiller, David; Linder, Vincent] Claros Diagnost, Woburn, MA USA.
   [Umviligihozo, Gisele; Karita, Etienne] Projet San Francisco, Rwanda Zambia HIV Res Grp, Kigali, Rwanda.
   [Mwambarangwe, Lambert; van de Wijgert, Janneke] Projet Ubuzima, Kigali, Rwanda.
   [Braunstein, Sarah L.; Sahabo, Ruben; Justman, Jessica E.; El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Programs, New York, NY USA.
   [van de Wijgert, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Ctr Poverty Related Communicable Dis, NL-1105 AZ Amsterdam, Netherlands.
   [van de Wijgert, Janneke] Ctr Infect & Immun, Amsterdam, Netherlands.
RP Sia, SK (reprint author), Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
EM ss2735@columbia.edu
OI Poh, Yukkee/0000-0001-6925-8614
FU Wallace H. Coulter Foundation; US National Institutes of Health
   [1R41AI076187]; Royal Thai Government; Croucher Foundation Scholarship;
   Frank H. Buck Scholarship
FX We thank the Wallace H. Coulter Foundation, the US National Institutes
   of Health (1R41AI076187), a Royal Thai Government Scholarship (to T.
   L.), a Croucher Foundation Scholarship (to Y.K.C.) and a Frank H. Buck
   Scholarship (to C. D. C.) for financial support. We thank A. Leek, J.
   Taylor, N. Karaseva and E. Tan for helping in assay development and data
   on reagent stability and for assisting in design of the reader. We thank
   J. Kymissis, M. Steele, R. Peck, G. Whitesides and R. Peeling for
   helpful discussions. We thank S. Koblavi-Deme, A. Nyaruhirira, J.
   Kamwesiga, V. Mugisha, N. Micheu, M. Munyangabo, D. Nash, J.
   Mushingantahe, C. Mutezemariya, A. Binagwaho and N. Veldhuijzen for
   assistance with the procurement of laboratory supplies and approval of
   study protocols in Rwanda and for facilitating access to clinical
   specimens. We thank D. Rouse, R. Satcher, E. Bailey and M. Wirth for
   assessments of clinical need and social impact.
CR Aledort Julia E, 2006, Nature, V444 Suppl 1, P59, DOI 10.1038/nature05447
   Banoo S, 2006, NAT REV MICROBIOL, pS20, DOI 10.1038/nrmicro1570
   Becker H, 2002, TALANTA, V56, P267, DOI 10.1016/S0039-9140(01)00594-X                                                   
   Beelaert G, 2002, J VIROL METHODS, V105, P197, DOI 10.1016/S0166-0934(02)00102-7
   Hay Burgess D. C., 2006, NATURE S1, V444, P1, DOI DOI 10.1038/NATURE05440
   Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Daar AS, 2002, NAT GENET, V32, P229, DOI 10.1038/ng1038-229
   De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175
   GATARAYIHA JP, 2006, RWANDA DEMOGRAPHIC H
   Gray RH, 2007, BRIT MED J, V335, P188, DOI 10.1136/bmj.39210.582801.BE
   Herring A, 2006, NAT REV MICROBIOL, pS33, DOI 10.1038/nrmicro1563
   Jani IV, 2002, LANCET INFECT DIS, V2, P243, DOI 10.1016/S1473-3099(02)00242-6
   Klarkowski DB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004351
   LAKSANASOPIN T, 2009, P SOC PHOTO-OPT INS, V7318, P1057
   Laxminarayan R, 2006, LANCET, V367, P1193, DOI 10.1016/S0140-6736(06)68440-7
   Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Martinez AW, 2008, ANAL CHEM, V80, P3699, DOI 10.1021/ac800112r
   Miranda AE, 2001, SEX TRANSM DIS, V28, P710, DOI 10.1097/00007435-200112000-00008
   Mylonakis E, 2000, AM J MED, V109, P568, DOI 10.1016/S0002-9343(00)00583-0
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Oh KW, 2006, J MICROMECH MICROENG, V16, pR13, DOI 10.1088/0960-1317/16/5/R01
   Parsa H, 2008, LAB CHIP, V8, P2062, DOI 10.1039/b813350f
   Patakfalvi R, 2007, J NANOPART RES, V9, P353, DOI 10.1007/s11051-006-9139-9
   Pavie J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011581
   Peeling RW, 2006, NAT REV MICROBIOL, V4, P909, DOI 10.1038/nrmicro1555
   Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996
   West J, 2008, ANAL CHEM, V80, P4403, DOI 10.1021/ac800680j
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Wootton RCR, 2010, NATURE, V464, P839, DOI 10.1038/464839a
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 34
TC 328
Z9 333
U1 27
U2 280
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2011
VL 17
IS 8
BP 1015
EP U138
DI 10.1038/nm.2408
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 802JW
UT WOS:000293507400037
PM 21804541
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Hockova, D
   Holy, A
   Andrei, G
   Snoeck, R
   Balzarini, J
AF Hockova, Dana
   Holy, Antonin
   Andrei, Graciela
   Snoeck, Robert
   Balzarini, Jan
TI Acyclic nucleoside phosphonates with a branched
   2-(2-phosphonoethoxy)ethyl chain: Efficient synthesis and antiviral
   activity
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Acyclic nucleoside phosphonates; Drug design; Antiviral activity;
   Purines; Pyrimidines
ID HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; IMMUNODEFICIENCY-VIRUS;
   NUCLEOTIDE ANALOGS; ADEFOVIR DIPIVOXIL; PERSPECTIVES; INHIBITION;
   STRAINS; TARGET; DRUGS; PMPA
AB Series of novel acyclic nucleoside phosphonates (ANPs) with various nucleobases and 2-(2-phosphonoethoxy) ethyl (PEE) chain bearing various substituents in beta-position to the phosphonate moiety were prepared. The influence of structural alternations on antiviral activity was studied. Several derivatives exhibit antiviral activity against HIV and vaccinia virus (middle micromolar range), HSV-1 and HSV-2 (lower micromolar range) and VZV and CMV (nanomolar range), although the parent unbranched PEE-ANPs are inactive. Adenine as a nucleobase and the methyl group attached to the PEE chain proved to be a prerequisite to afford pronounced antiviral activity. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Hockova, Dana; Holy, Antonin] Acad Sci Czech Republic, Inst Organ Chem & Biochem, CZ-16610 Prague 6, Czech Republic.
   [Andrei, Graciela; Snoeck, Robert; Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Leuven, Belgium.
RP Hockova, D (reprint author), Acad Sci Czech Republic, Inst Organ Chem & Biochem, CZ-16610 Prague 6, Czech Republic.
EM lasice@uochb.cas.cz
RI Hockova, Dana/B-1408-2012; Snoeck, Robert/V-3867-2017; Andrei,
   Graciela/V-7721-2017
OI Snoeck, Robert/0000-0002-7586-5434; Andrei, Graciela/0000-0003-2609-4896
FU Institute of Organic Chemistry and Biochemistry [AVOZ40550506]; Agency
   of the Czech Republic [P207/11/0108]; Centre for New Antivirals and
   Antineoplastics (Ministry of Education, Youth and Sports of the Czech
   Republic) [1M0508]; Gilead Sciences, Inc. (Foster City, CA, USA);
   "Geconcerteerde Onderzoeksacties" (GOA) of the KU Leuven [10/014]
FX This work is a part of the research project AVOZ40550506 of the
   Institute of Organic Chemistry and Biochemistry and was supported by the
   Grant Agency of the Czech Republic (Grant No. P207/11/0108) and Centre
   for New Antivirals and Antineoplastics (1M0508, Ministry of Education,
   Youth and Sports of the Czech Republic). This study was also supported
   by Gilead Sciences, Inc. (Foster City, CA, USA) and the "Geconcerteerde
   Onderzoeksacties" (GOA), Krediet nr. 10/014" of the KU Leuven. We also
   thank Anita Camps, Steven Carmans, Frieda De Meyer, Leentje Persoons,
   Leen Ingels, Wim Van Dam, Lies Van den Heurck and Lizette van Berckelaer
   for excellent technical assistance with the antiviral/cytostatic assays.
CR BABA M, 1987, EUR J CLIN MICROBIOL, V6, P158, DOI 10.1007/BF02018198
   Bordigoni Pierre, 2001, Clinical Infectious Diseases, V32, P1290, DOI 10.1086/319984
   De Clercq E, 2005, NAT REV DRUG DISCOV, V4, P928, DOI 10.1038/nrd1877
   De Clercq E, 2007, ANTIVIR RES, V75, P1, DOI 10.1016/j.antiviral.2006.10.006
   De Clercq E, 2009, MED RES REV, V29, P611, DOI 10.1002/med.20153
   DECLERCQ E, 1981, MOL PHARMACOL, V19, P321
   Dolakova P, 2009, EUR J ORG CHEM, P1082, DOI 10.1002/ejoc.200800911
   Gilson RJC, 1999, J VIRAL HEPATITIS, V6, P387, DOI 10.1046/j.1365-2893.1999.00182.x
   Hockova D, 2010, EUR J ORG CHEM, P2885, DOI 10.1002/ejoc.201000061
   Hockova D, 2009, BIOORGAN MED CHEM, V17, P6218, DOI 10.1016/j.bmc.2009.07.044
   HOLY A, 1990, COLLECT CZECH CHEM C, V55, P809, DOI 10.1135/cccc19900809                                                            
   Keough DT, 2010, MOL BIOCHEM PARASIT, V173, P165, DOI 10.1016/j.molbiopara.2010.05.018
   Keough DT, 2009, J MED CHEM, V52, P4391, DOI 10.1021/jm900267n
   Lee WA, 2006, ANTIVIR RES, V71, P254, DOI 10.1016/j.antiviral.2006.05.020
   MAUDGAL PC, 1987, INVEST OPHTH VIS SCI, V28, P243
   Montagu A, 2011, TETRAHEDRON, V67, P5319, DOI 10.1016/j.tet.2011.05.017
   MUL YM, 1989, NUCLEIC ACIDS RES, V17, P8917, DOI 10.1093/nar/17.22.8917                                                          
   Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1
   Perrillo R, 2000, HEPATOLOGY, V32, P129, DOI 10.1053/jhep.2000.8626                                                          
   Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P1484
   STARRETT JE, 1992, ANTIVIR RES, V19, P267, DOI 10.1016/0166-3542(92)90084-I
   Topalis D, 2011, J MED CHEM, V54, P222, DOI 10.1021/jm1011462
   Van Rompay KKA, 2000, J VIROL, V74, P1767, DOI 10.1128/JVI.74.4.1767-1774.2000                                                 
NR 23
TC 5
Z9 5
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG
PY 2011
VL 19
IS 15
BP 4445
EP 4453
DI 10.1016/j.bmc.2011.06.045
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 794PQ
UT WOS:000292913400004
PM 21745746
DA 2018-01-05
ER

PT J
AU Valiaeva, N
   Wyles, DL
   Schooley, RT
   Hwu, JB
   Beadle, JR
   Prichard, MN
   Hostetler, KY
AF Valiaeva, Nadejda
   Wyles, David L.
   Schooley, Robert T.
   Hwu, Julia B.
   Beadle, James R.
   Prichard, Mark N.
   Hostetler, Karl Y.
TI Synthesis and antiviral evaluation of
   9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl
   esters: Inhibitors of hepatitis C virus and HIV-1 replication
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Antiviral prodrugs; Hepatitis C virus; Human immunodeficiency virus-1;
   Alkoxyalkyl prodrugs; Nucleoside phosphonate prodrugs
ID IN-VITRO; NUCLEOSIDE PHOSPHONATES; RNA-SYNTHESIS; POTENT; RESISTANCE;
   CIDOFOVIR; TELAPREVIR; POLYMERASE; INFECTION; ADENINE
AB We reported previously that octadecyloxyethyl 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]adenine (ODE-(S)-HPMPA) was active against genotype 1b and 2a hepatitis C virus (HCV) replicons. This is surprising because acyclic nucleoside phosphonates have been regarded as having antiviral activity only against double stranded DNA viruses, HIV and HBV. We synthesized octadecyloxyethyl 9-(S)[ 3-methoxy-2-(phosphonomethoxy) propyl]-adenine and found it to be active in genotype 1b and 2a HCV replicons with EC(50) values of 1-2 mu M and a CC(50) of >150 mu M. Analogs with substitutions at the 3'-hydroxyl larger than methyl or ethyl, or with other purine bases were less active but most compounds had significant antiviral activity against HIV-1 in vitro. The most active anti-HIV compound was octadecyloxyethyl 9-(R)-[3-methoxy-2-(phosphonomethoxy) propyl] guanine with an EC(50) <0.01 nanomolar and a selectivity index of >4.4 million. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Valiaeva, Nadejda; Wyles, David L.; Schooley, Robert T.; Beadle, James R.; Hostetler, Karl Y.] Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
   [Valiaeva, Nadejda; Hwu, Julia B.; Beadle, James R.; Hostetler, Karl Y.] Vet Med Res Fdn, La Jolla, CA USA.
   [Prichard, Mark N.] Univ Alabama, Sch Med, Dept Pediat, Birmingham, AL USA.
RP Hostetler, KY (reprint author), Univ Calif San Diego, Div Infect Dis, San Diego, CA 92103 USA.
EM khostetler@ucsd.edu
FU NIH [AI-076558, AI-074057, AI-071803, AI-069989, N01-AI-30049]
FX This work was supported in part by NIH Grants AI-076558 (R. T. S.),
   AI-074057, AI-071803, AI-069989 (K.Y.H.) and contract N01-AI-30049
   (M.N.P.). The authors wish to thank Krysten Jones, Kathy A. Aldern,
   Julissa Trahan, Kathy A. Keith and Caroll B. Hartline for technical
   assistance.
CR Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004
   Beadle JR, 2006, J MED CHEM, V49, P2010, DOI 10.1021/jm050473m
   BRODFUEHRER PR, 1994, TETRAHEDRON LETT, V35, P3243, DOI 10.1016/S0040-4039(00)76875-4
   Buller RM, 2004, VIROLOGY, V318, P474, DOI 10.1016/j.virol.2003.11.015
   Falck-Ytter Y, 2002, ANN INTERN MED, V136, P288, DOI 10.7326/0003-4819-136-4-200202190-00008
   Hostetler KY, 2006, ANTIMICROB AGENTS CH, V50, P2857, DOI 10.1128/AAC.01223-05
   Hostetler KY, 2009, ANTIVIR RES, V82, pA84, DOI 10.1016/j.antiviral.2009.01.005
   Howe AYM, 2008, ANTIMICROB AGENTS CH, V52, P3327, DOI 10.1128/AAC.00238-08
   Huggins JW, 2002, ANTIVIR RES, V53, pA66
   Kern ER, 2002, ANTIMICROB AGENTS CH, V46, P991, DOI 10.1128/AAC.46.4.991-995.2002
   Klumpp K, 2006, J BIOL CHEM, V281, P3793, DOI 10.1074/jbc.M510195200
   Lam AM, 2011, ANTIMICROB AGENTS CH, V55, P2566, DOI 10.1128/AAC.00032-11
   Magee WC, 2008, ANTIMICROB AGENTS CH, V52, P586, DOI 10.1128/AAC.01172-07
   McCown MF, 2008, ANTIMICROB AGENTS CH, V52, P1604, DOI 10.1128/AAC.01317-07
   McCown MF, 2009, ANTIMICROB AGENTS CH, V53, P2129, DOI 10.1128/AAC.01598-08
   Morrey JD, 2009, ANTIMICROB AGENTS CH, V53, P2865, DOI 10.1128/AAC.00114-09
   Painter GR, 2007, ANTIMICROB AGENTS CH, V51, P3505, DOI 10.1128/AAC.00460-07
   Prichard MN, 2008, ANTIMICROB AGENTS CH, V52, P4326, DOI 10.1128/AAC.00918-08
   Romine JL, 2011, ACS MED CHEM LETT, V2, P224, DOI 10.1021/ml1002647
   Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037
   Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055
   TI GS, 1982, J AM CHEM SOC, V104, P1316, DOI 10.1021/ja00369a029                                                             
   Valiaeva N, 2006, ANTIVIR RES, V72, P10, DOI 10.1016/j.antiviral.2006.03.007
   Wyles DL, 2007, J VIROL, V81, P3005, DOI 10.1128/JVI.02083-06
   Wyles DL, 2009, ANTIMICROB AGENTS CH, V53, P2660, DOI 10.1128/AAC.01546-08
NR 25
TC 9
Z9 9
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG
PY 2011
VL 19
IS 15
BP 4616
EP 4625
DI 10.1016/j.bmc.2011.06.009
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 794PQ
UT WOS:000292913400022
PM 21719300
OA green_accepted
DA 2018-01-05
ER

PT J
AU Borgmann, K
   Rao, KS
   Labhasetwar, V
   Ghorpade, A
AF Borgmann, Kathleen
   Rao, Kavitha S.
   Labhasetwar, Vinod
   Ghorpade, Anuja
TI Efficacy of Tat-Conjugated Ritonavir-Loaded Nanoparticles in Reducing
   HIV-1 Replication in Monocyte-Derived Macrophages and Cytocompatibility
   with Macrophages and Human Neurons
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE
   INHIBITORS; PLGA NANOPARTICLES; INFECTED PATIENTS; DRUG-DELIVERY;
   PHARMACOKINETICS; DEMENTIA; BRAIN; LOPINAVIR/RITONAVIR
AB Human immunodeficiency virus (HIV)-1 targets mononuclear phagocytes (MP), which disseminate infection to organs such as brain, spleen and lymph. Thus MP, which include microglia, tissue macrophages and infiltrating monocyte-derived macrophages (MDM), are important target of anti-HIV-1 drug therapy. Most of the currently used antiretroviral drugs are effective in reducing viral loadin the periphery but cannot effectively eradicate infection from tissue reservoirs such as brain MP. HIV-1 infection of the central nervous system can lead to a wide variety of HIV-1-associated neurocognitive disorders. In this study, we demonstrate that ritonavir-loaded nanoparticles (RNPs) are effective in inhibiting HIV-1 infection of MDM. Reduced infection is observed in multiple read-out systems including reduction of cytopathic effects, HIV-1 p24 protein secretion and production of progeny virions. Furthermore, the RNPs retained antiretroviral efficacy after being removed from MDM cultures. As HIV-1-infected cells in the brain are likely to survive for a long period of time, both acute and chronic infection paradigms were evaluated. Tat-peptide-conjugated RNPs (Tat-RNP) were effective in both short-term and long-term HIV-1-infected MDM. Importantly, we confirm that delivery of RNPs, both with and without Tat-peptide conjugation, is toxic neither to MDM nor to neural cells, which may be bystander targets of the nanoformulations. In conclusion, Tat-NPs could be a safe and effective way of delivering anti-HIV-1 drugs for controlling viral replication occurring within brain MP.
C1 [Borgmann, Kathleen; Ghorpade, Anuja] Univ N Texas Hlth Sci Ctr, Dept Cell Biol & Anat, Ft Worth, TX 76107 USA.
   [Rao, Kavitha S.; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44106 USA.
RP Ghorpade, A (reprint author), Univ N Texas Hlth Sci Ctr, Dept Cell Biol & Anat, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM anuja.ghorpade@unthsc.edu
OI Borgmann, Kathleen/0000-0003-0897-390X
FU NIH [1R01 NS048837-06, 1R21 MH67525]
FX This study was supported by NIH Grants 1R01 NS048837-06 (to A.G.) and
   1R21 MH67525 (to V.L.).
CR Ances BM, 2007, SEMIN NEUROL, V27, P86, DOI 10.1055/s-2006-956759
   Aquaro S, 2002, J MED VIROL, V68, P479, DOI 10.1002/jmv.10245
   Aquaro Stefano, 2008, Recent Pat CNS Drug Discov, V3, P23
   Asare E, 1996, AM J PATHOL, V148, P31
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bevilacqua Maurizio, 2009, J Cardiometab Syndr, V4, P40, DOI 10.1111/j.1559-4572.2008.00027.x
   Boykins RA, 1999, J IMMUNOL, V163, P15
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Bruce RD, 2010, JAIDS-J ACQ IMM DEF, V54, P511, DOI 10.1097/QAI.0b013e3181d3cad3
   Cressey TR, 2010, AIDS, V24, P2193, DOI 10.1097/QAD.0b013e32833ce57d
   Crowe SM, 1995, AUST NZ J MED, V25, P777, DOI 10.1111/j.1445-5994.1995.tb02881.x                                              
   CURRAN A, 2010, J ANTIMICROB CHEMOTH, V24, P1083
   Cuzin L, 2008, AIDS REV, V10, P205
   DeJesus E, 2010, ANTIVIR THER, V15, P711, DOI 10.3851/IMP1562
   Deshpande M, 2005, NEUROTOX RES, V7, P183, DOI 10.1007/BF03036448                                                              
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Everall IP, 1999, BRAIN PATHOL, V9, P209
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   German P, 2010, JAIDS-J ACQ IMM DEF, V55, P323, DOI 10.1097/QAI.0b013e3181eb376b
   Ghorpade A, 1998, J VIROL, V72, P3340
   GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510                                                           
   Grant I, 2005, NEUROLOGY AIDS
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Haughey NJ, 2001, J NEUROCHEM, V78, P457, DOI 10.1046/j.1471-4159.2001.00396.x
   Jain R, 2005, INT J PHARM, V303, P8, DOI 10.1016/j.ijpharm.2005.06.017
   JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163
   King JE, 2006, MICROBES INFECT, V8, P1347, DOI 10.1016/j.micinf.2005.11.014
   KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903
   Kutza J, 2002, AIDS RES HUM RETROV, V18, P619, DOI 10.1089/088922202760019310
   Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x                                                               
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Nieminen TH, 2010, EUR J CLIN PHARMACOL, V66, P977, DOI 10.1007/s00228-010-0879-1
   Noursadeghi M, 2006, JAIDS-J ACQ IMM DEF, V41, P532, DOI 10.1097/01.qai.0000209912.17695.e5                                              
   Nowacek AS, 2010, J NEUROIMMUNE PHARM, V5, P592, DOI 10.1007/s11481-010-9198-7
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Ofotokun I, 2008, PHARMACOTHERAPY, V28, P74, DOI 10.1592/phco.28.1.74
   Penzak SR, 2010, PHARMACOTHERAPY, V30, P797, DOI 10.1592/phco.30.8.797
   Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1
   Richmond SR, 2010, BBA-MOL CELL BIOL L, V1801, P559, DOI 10.1016/j.bbalip.2010.01.007
   SABATIER JM, 1991, J VIROL, V65, P961
   Sacktor N, 2002, J NEUROVIROL, V8, P115, DOI 10.1080/13550280290101094
   Sawant R, 2010, MOL BIOSYST, V6, P628, DOI 10.1039/b916297f
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   Sekar V, 2010, ANTIMICROB AGENTS CH, V54, P4440, DOI 10.1128/AAC.01749-09
   Sharma P, 2010, ADV DRUG DELIVER REV, V62, P491, DOI 10.1016/j.addr.2009.11.019
   ter Heine R, 2010, BRIT J CLIN PHARMACO, V69, P475, DOI 10.1111/j.1365-2125.2010.03634.x
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Torchilin VP, 2008, ADV DRUG DELIVER REV, V60, P548, DOI 10.1016/j.addr.2007.10.008
   Tuladhar SM, 2006, ANN THORAC SURG, V82, P1519, DOI 10.1016/j.athoracsur.2006.02.059
   van Kampen JJA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011409
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
NR 58
TC 17
Z9 18
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD AUG
PY 2011
VL 27
IS 8
BP 853
EP 862
DI 10.1089/aid.2010.0295
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 803IV
UT WOS:000293575900007
PM 21175357
OA green_published
DA 2018-01-05
ER

PT J
AU Fu, CY
   Johnson, JE
AF Fu, Chi-yu
   Johnson, Johnson E.
TI Viral life cycles captured in three-dimensions with electron microscopy
   tomography
SO CURRENT OPINION IN VIROLOGY
LA English
DT Article
ID TURRETED ICOSAHEDRAL VIRUS; HERPES-SIMPLEX-VIRUS; CRYOELECTRON
   TOMOGRAPHY; VACCINIA VIRUS; STRUCTURAL-CHANGES; ARCHAEAL VIRUS; CAPSID
   PROTEIN; HIV-1 CORE; CELLS; REVEALS
AB Viruses hijack host-cell functions and optimize them for viral replication causing a severe threat to human health. However, viruses are also tools to understand cell biology and they may be effective reagents in nanomedicine. Studies from the molecular to cellular levels are aimed at understanding the details of viral life cycles and the underlying virus-host interactions. Recent developments in electron microscopy tomography allow viral and cellular events to be observed in fine structural detail in three-dimensions. By combining high-resolution structures of individual proteins and macrocomplexes obtained by crystallography and electron cryomicroscopy and image reconstruction with reconstructions performed on subtomographic volumes, electron tomography has advanced the structural and mechanistic understanding of virus infections both in vitro and in host cells.
C1 [Fu, Chi-yu; Johnson, Johnson E.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Johnson, JE (reprint author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM jackj@scripps.edu
FU National Institutes of Health [GM54076]
FX This work was supported by grants from the National Institutes of Health
   GM54076. We thank Mohammad W. Bahar, David Stuart, and Jonathan Grimes
   for providing the coordinates for the vaccinia virus D9 protein (used in
   Figure 4) prior to publication.
CR Al-Amoudi A, 2004, J STRUCT BIOL, V148, P131, DOI 10.1016/j.jsb.2004.03.010
   Bahar MW, STRUCTURE IN PRESS
   Battisti AJ, 2011, J VIROL, V85, P835, DOI 10.1128/JVI.01847-10
   Bostina M, 2011, J VIROL, V85, P776, DOI 10.1128/JVI.00531-10
   Bravo A, 2005, FEMS MICROBIOL REV, V29, P25, DOI 10.1016/j.femsre.2004.06.003
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010
   Brumfield SK, 2009, J VIROL, V83, P5964, DOI 10.1128/JVI.02668-08
   Butan C, 2010, J VIROL, V84, P6377, DOI 10.1128/JVI.00207-10
   Cardone G, 2007, VIROLOGY, V361, P426, DOI 10.1016/j.virol.2006.10.047
   Carlson LA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001173
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Chang JT, 2007, J VIROL, V81, P2065, DOI 10.1128/JVI.02053-06
   Chang JT, 2010, J MOL BIOL, V402, P731, DOI 10.1016/j.jmb.2010.07.058
   Chen J, 2011, J VIROL, V85, P6077, DOI 10.1128/JVI.00103-11
   Chlanda P, 2009, CELL HOST MICROBE, V6, P81, DOI 10.1016/j.chom.2009.05.021
   Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790
   Cyrklaff M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000420
   Dai W, 2010, P NATL ACAD SCI USA, V107, P4347, DOI 10.1073/pnas.0915008107
   de Marco A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001215
   de Marco A, 2010, J VIROL, V84, P11729, DOI 10.1128/JVI.01423-10
   Deng BB, 2008, J STRUCT BIOL, V161, P419, DOI 10.1016/j.jsb.2007.10.016
   Diestra E, 2009, J STRUCT BIOL, V165, P157, DOI 10.1016/j.jsb.2008.11.009
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   Fontana J, 2010, VIROLOGY, V405, P579, DOI 10.1016/j.virol.2010.06.043
   Fu CY, 2010, STRUCTURE, V18, P1579, DOI 10.1016/j.str.2010.10.005
   Fukuda Y, 2009, J STRUCT BIOL, V168, P476, DOI 10.1016/j.jsb.2009.08.011
   Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793
   Gangodkar S, 2010, J ELECTRON MICROSC, V59, P503, DOI 10.1093/jmicro/dfq063
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Grunewald K, 2006, CURR OPIN MICROBIOL, V9, P437, DOI 10.1016/j.mib.2006.06.016
   Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284
   Harris A, 2006, P NATL ACAD SCI USA, V103, P19123, DOI 10.1073/pnas.0607614103
   Huiskonen JT, 2010, J VIROL, V84, P4889, DOI 10.1128/JVI.00057-10
   Hyun JK, 2007, J VIROL, V81, P11075, DOI 10.1128/JVI.00594-07
   Iwasaki K, 2010, CURR OPIN STRUC BIOL, V20, P632, DOI 10.1016/j.sbi.2010.08.007
   Chichon FJ, 2009, BIOL CELL, V101, P401, DOI 10.1042/BC20080176
   Jensen GJ, 2007, CURR OPIN STRUC BIOL, V17, P260, DOI 10.1016/j.sbi.2007.03.002
   Keller PW, 2011, J VIROL, V85, P1420, DOI 10.1128/JVI.01926-10
   Khayat R, 2005, P NATL ACAD SCI USA, V102, P18944, DOI 10.1073/pnas.0506383102
   Khayat R, 2010, J VIROL, V84, P9575, DOI 10.1128/JVI.00708-10
   Lanman J, 2008, J STRUCT BIOL, V161, P439, DOI 10.1016/j.jsb.2007.09.009
   Lee KK, 2010, EMBO J, V29, P1299, DOI 10.1038/emboj.2010.13
   Leo-Macias A, 2011, VIROLOGY, V414, P103, DOI 10.1016/j.virol.2011.03.020
   Li S, 2000, NATURE, V407, P409
   Liu XA, 2010, NAT STRUCT MOL BIOL, V17, P830, DOI 10.1038/nsmb.1823
   Lucic V, 2005, ANNU REV BIOCHEM, V74, P833, DOI 10.1146/annurev.biochem.73.011303.074112
   Maurer UE, 2008, P NATL ACAD SCI USA, V105, P10559, DOI 10.1073/pnas.0801674105
   Mercogliano CP, 2007, J STRUCT BIOL, V160, P70, DOI 10.1016/j.jsb.2007.06.010
   Milazzo AC, 2010, ULTRAMICROSCOPY, V110, P741, DOI 10.1016/j.ultramic.2010.03.007
   Murata K, 2010, STRUCTURE, V18, P903, DOI 10.1016/j.str.2010.06.006
   Nemecek D, 2010, J STRUCT BIOL, V171, P389, DOI 10.1016/j.jsb.2010.06.005
   Netherton C, 2007, ADV VIRUS RES, V70, P101, DOI 10.1016/S0065-3527(07)70004-0
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Noda T, 2006, NATURE, V439, P490, DOI 10.1038/nature04378
   Ortmann AC, 2008, J VIROL, V82, P4874, DOI 10.1128/JVI.02583-07
   Ortmann AC, 2006, NAT REV MICROBIOL, V4, P520, DOI 10.1038/nrmicro1444
   Peng L, 2010, STRUCTURE, V18, P47, DOI 10.1016/j.str.2009.10.017
   Plitzko JM, 2009, CURR OPIN BIOTECH, V20, P83, DOI 10.1016/j.copbio.2009.03.008
   Quax TEF, 2011, P NATL ACAD SCI USA, V108, P3354, DOI 10.1073/pnas.1018052108
   Snyder JC, 2011, J VIROL, V85, P6287, DOI 10.1128/JVI.00379-11
   Soonsawad P, 2010, J VIROL, V84, P11145, DOI 10.1128/JVI.00036-10
   Sosinsky GE, 2008, J STRUCT BIOL, V161, P359, DOI 10.1016/j.jsb.2007.09.002
   Sosinsky GE, 2007, METHOD CELL BIOL, V79, P575, DOI 10.1016/S0091-679X(06)79023-9
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   Subramaniam S, 2007, CURR OPIN STRUC BIOL, V17, P596, DOI 10.1016/j.sbi.2007.09.009
   Wang Q, 2011, STRUCTURE, V19, P147, DOI 10.1016/j.str.2010.12.002
   Welsch S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000875
   White TA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001249
NR 69
TC 9
Z9 9
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1879-6257
J9 CURR OPIN VIROL
JI Curr. Opin. Virol.
PD AUG
PY 2011
VL 1
IS 2
BP 125
EP 133
DI 10.1016/j.coviro.2011.06.008
PG 9
WC Virology
SC Virology
GA 051FQ
UT WOS:000312112000007
PM 21887207
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zennami, K
   Yoshikawa, K
   Kondo, E
   Nakamura, K
   Yamada, Y
   De Velasco, MA
   Tanaka, M
   Uemura, H
   Shimazui, T
   Akaza, H
   Saga, S
   Ueda, R
   Honda, N
AF Zennami, Kenji
   Yoshikawa, Kazuhiro
   Kondo, Eisaku
   Nakamura, Kogenta
   Yamada, Yoshiaki
   De Velasco, Marco A.
   Tanaka, Motoyoshi
   Uemura, Hirotsugu
   Shimazui, Toru
   Akaza, Hideyuki
   Saga, Shinsuke
   Ueda, Ryuzo
   Honda, Nobuaki
TI A new molecular targeted therapeutic approach for renal cell carcinoma
   with a p16 functional peptide using a novel transporter system
SO ONCOLOGY REPORTS
LA English
DT Article
DE PTD; p16; renal cell carcinoma
ID HUMAN IMMUNODEFICIENCY VIRUS; PHASE-II TRIAL; INTERFERON-ALPHA; 1ST-LINE
   TREATMENT; MAMMALIAN-CELLS; TRANSDUCTION; SORAFENIB; DELIVERY; PROTEIN;
   CANCER
AB Molecular targeting agents have become formidable anticancer weapons showing much promise against refractory tumors and functional peptides and are among the more desirable of these nanobio-tools. Intracellular delivery of multiple functional peptides forms the basis for a potent, non-invasive mode of delivery, providing distinctive therapeutic advantages. We examine the growth suppression efficiency of human renal cell carcinoma (RCC) by single-peptide targeting. We simultaneously introduced p16(INK4a) tumor suppressor peptides by Wr-T-mediated peptide delivery. Wr-T-mediated transport of p16(INK4a) functional peptide into 10 RCC lines, lacking expression of the p16(INK4a) molecule, reversed the specific loss of p16 function, thereby drastically inhibiting tumor growth in all but 3 lines by >95% within the first 96 h. In vivo analysis using SK-RC-7 RCC xenografts in nude mice demonstrated tumor growth inhibition by the p16(INK4a) peptide alone, however, inoculation of Wr-T and the p16(INK4a) a functional peptide mixture, via the heart resulted in complete tumor regression. Thus, restoration of tumor suppressor function with Wr-T peptide delivery represents a powerful approach, with mechanistic implications for the development of efficacious molecular targeting therapeutics against intractable RCC.
C1 [Yoshikawa, Kazuhiro] Aichi Med Univ, Div Clin Res Promot, Dept Urol, Sch Med, Aichi 4801195, Japan.
   Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Aichi 4648681, Japan.
   [De Velasco, Marco A.; Tanaka, Motoyoshi; Uemura, Hirotsugu] Kingston Univ, Dept Urol, Sch Med, Osaka 5898511, Japan.
   [Kondo, Eisaku; Shimazui, Toru] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Urol, Tsukuba, Ibaraki 3058575, Japan.
   [Akaza, Hideyuki] Univ Tokyo, Dept Strateg Invest Comprehens Canc Network, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan.
   [Saga, Shinsuke] Nagoya City Univ, Grad Sch Med Sci, Aichi 4678601, Japan.
   [Akaza, Hideyuki] Aichi Med Univ, Dept Pathol, Sch Med, Aichi 4678601, Japan.
RP Yoshikawa, K (reprint author), Aichi Med Univ, Div Clin Res Promot, Dept Urol, Sch Med, Aichi 4801195, Japan.
EM yoshikaw@aichi-med-u.ac.jp
CR Akaza Hideyuki, 2006, Int J Clin Oncol, V11, P434, DOI 10.1007/s10147-006-0596-z
   Arvanitis DA, 2008, ONCOL REP, V20, P751, DOI 10.3892/or_00000070
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1
   Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342
   Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580                                                          
   FISHER PM, 2001, BIOCONJUG CHEM, V12, P825
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688                                                       
   Gollob JA, 2007, J CLIN ONCOL, V25, P3288, DOI 10.1200/JCO.2007.10.8613
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Ikuerowo SO, 2007, EUR UROL, V51, P732, DOI 10.1016/j.eururo.2006.08.010
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Kawada Y, 2001, JPN J CANCER RES, V92, P1293, DOI 10.1111/j.1349-7006.2001.tb02152.x                                              
   Klapper JA, 2008, CANCER, V113, P293, DOI 10.1002/cncr.23552
   Kondo E, 2004, MOL CANCER THER, V3, P1623
   Kondo E, 2008, MOL CANCER THER, V7, P1461, DOI 10.1158/1535-7163.MCT-07-2010
   Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Motzer RJ, 2007, J CLIN ONCOL, V25, P3958, DOI 10.1200/JCO.2006.10.5916
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044                                                            
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Ritchie A, 1999, LANCET, V353, P14
   Ryan CW, 2007, J CLIN ONCOL, V25, P3296, DOI 10.1200/JCO.2007.11.1047
   SCHARML P, 2001, AM J PATHOL, V158, P593
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WIRTH MP, 1993, UROL CLIN N AM, V20, P283
NR 31
TC 3
Z9 4
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2011
VL 26
IS 2
BP 327
EP 333
DI 10.3892/or.2011.1290
PG 7
WC Oncology
SC Oncology
GA 790IK
UT WOS:000292581500005
PM 21567093
OA gold
DA 2018-01-05
ER

PT J
AU Uto, T
   Akagi, T
   Yoshinaga, K
   Toyama, M
   Akashi, M
   Baba, M
AF Uto, Tomofumi
   Akagi, Takami
   Yoshinaga, Keisuke
   Toyama, Masaaki
   Akashi, Mitsuru
   Baba, Masanori
TI The induction of innate and adaptive immunity by biodegradable
   poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling
   pathway
SO BIOMATERIALS
LA English
DT Article
DE Nanoparticle; Adjuvant; Antigen carrier; Toll-like receptor
ID TOLL-LIKE RECEPTORS; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES;
   DENDRITIC CELLS; VACCINE ADJUVANTS; ACTIVATION; RECOGNITION; PROTEIN;
   DELIVERY; GP120
AB The induction of adaptive immunity through the activation of innate immunity is indispensable for vaccine development. Although strategies for particulate antigen delivery are widely investigated, their immunological mechanisms are unclear. We describe in this study that biodegradable nanoparticles (NPs) elaborated with poly(gamma-glutamic acid) (gamma-PGA) are able to induce potent innate and adaptive immune responses through Toll-like receptor 4 (TLR4) and MyD88 signaling pathways. The production of inflammatory cytokines from macrophages and the maturation of dendritic cells were impaired in MyD88-knockout and TLR4-deficient mice compared with their wild-types, when the cells were stimulated with gamma-PGA NPs. The immunization of these mice with antigen-carrying gamma-PGA NPs also resulted in diminished induction of antigen-specific cellular immune responses. These results suggest that gamma-PGA NPs have not only an antigen-carrying capacity but also a potent adjuvant function of eliciting adaptive immune responses to the carrying antigen through recognition of the first-line host-sensor system. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Uto, Tomofumi; Toyama, Masaaki; Baba, Masanori] Kagoshima Univ, Grad Sch Med & Dent Sci, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, Kagoshima 8908544, Japan.
   [Akagi, Takami; Akashi, Mitsuru] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   [Yoshinaga, Keisuke] Kumamoto Natl Coll Technol, Dept Biol & Chem Syst Engn, Yatsushiro 8668501, Japan.
   [Uto, Tomofumi; Akagi, Takami; Yoshinaga, Keisuke; Akashi, Mitsuru; Baba, Masanori] Japan Sci & Technol Agcy JST, Core Res Evolut Sci & Technol CREST, Tokyo 1500002, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.
EM m-baba@vanilla.ocn.ne.jp
RI Baba, Masanori/G-3867-2011
FU Japan Science and Technology Agency (JST)
FX We sincerely thank Drs. K.J. Ishii and S. Hashiguchi for their
   discussions and experimental advices. This work was supported by CREST
   from the Japan Science and Technology Agency (JST).
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2007, BIOMATERIALS, V28, P3427, DOI 10.1016/j.biomaterials.2007.04.023
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059                                                     
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071                                                         
   De Gregorio E, 2009, CURR OPIN IMMUNOL, V21, P339, DOI 10.1016/j.coi.2009.05.003
   Himeno A, 2010, VACCINE, V28, P5377, DOI 10.1016/j.vaccine.2010.04.110
   Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017
   Look M, 2010, ADV DRUG DELIVER REV, V62, P378, DOI 10.1016/j.addr.2009.11.011
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   O'Brien GC, 2005, J IMMUNOL, V174, P1020, DOI 10.4049/jimmunol.174.2.1020                                                     
   Okamoto S, 2009, VACCINE, V27, P5896, DOI 10.1016/j.vaccine.2009.07.037
   Palliser D, 2004, J IMMUNOL, V172, P2885, DOI 10.4049/jimmunol.172.5.2885                                                     
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210
   Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   Sato Katsuaki, 2007, Allergol Int, V56, P183, DOI 10.2332/allergolint.R-06-139
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Vazquez-Torres A, 2004, J IMMUNOL, V172, P6202, DOI 10.4049/jimmunol.172.10.6202                                                    
   Wang X, 2007, J VIROL, V81, P10009, DOI 10.1128/JVI.00489-07
   Yamaguchi S, 2010, CANCER IMMUNOL IMMUN, V59, P759, DOI 10.1007/s00262-009-0796-2
   Yang YW, 2008, BIOMATERIALS, V29, P2516, DOI 10.1016/j.biomaterials.2008.02.015
   Zhu JG, 2009, J CLIN INVEST, V119, P2388, DOI 10.1172/JCI37607
   Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105
NR 30
TC 60
Z9 62
U1 2
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2011
VL 32
IS 22
BP 5206
EP 5212
DI 10.1016/j.biomaterials.2011.03.052
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 780ZP
UT WOS:000291900700023
PM 21492934
DA 2018-01-05
ER

PT J
AU Huang, SS
   Shao, JQ
   Gao, LF
   Qi, YZ
   Ye, L
AF Huang, Shanshan
   Shao, Jianqun
   Gao, Lifang
   Qi, Yingzhe
   Ye, Ling
TI Adsorption of Cathepsin B-sensitive peptide conjugated DOX on
   nanodiamonds
SO APPLIED SURFACE SCIENCE
LA English
DT Article
DE Adsorption kinetics; Adsorption thermodynamics; DOX; Nanodiamonds; TAT
ID DIAMOND NANOPARTICLES; OXIDATIVE STRESS; AQUEOUS-SOLUTION; MODEL;
   DELIVERY; SORPTION; LINKERS
AB Drug delivery mediated by nanodiamonds (NDs) has shown great promise in controlled drug release field. In present study, dipeptide (Phe-Lys) conjugated antitumor drug doxorubicin hydrochloride (DOX) with self-immolative p-aminobenzylcarbonyl (PABC) spacer was non-covalently bound to carboxylated NDs via the electrostatic interactions. HIV-1 trans-activating transcriptor peptide (TAT) was additionally integrated to this ND-based delivery system in order to enhance the transmembrane efficiency. Fourier transforms infrared spectroscopy (FTIR), transmission electron microscopy (TEM) and zeta potentials were applied to characterize the DOX and TAT loaded ND delivery platform. The adsorption equilibrium, kinetics and thermodynamics for the adsorption of peptide conjugated DOX onto NDs were investigated. It was found that the adsorption fitted well with the Freundlich model and conformed to pseudo-second order kinetics. It also showed that the adsorption was a spontaneous and exothermic process. Therefore, our work offered a facile way to formulate a ND-based drug delivery platform with multifunctionality in a layer by layer adsorption fashion. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Huang, Shanshan; Shao, Jianqun; Qi, Yingzhe; Ye, Ling] Capital Med Univ, Sch Chem Biol & Pharmaceut Sci, Beijing 100069, Peoples R China.
   [Gao, Lifang] Capital Med Univ, Ctr Food & Drug Safety Evaluat, Beijing 100069, Peoples R China.
RP Ye, L (reprint author), Capital Med Univ, Sch Chem Biol & Pharmaceut Sci, Beijing 100069, Peoples R China.
EM lingye@ccmu.edu.cn
FU Beijing Municipal Education Committee [KM200810025025, KM20110025007];
   Funding Project for Academic Human Resources Development in Institutions
   of Higher Learning under the Jurisdiction of Beijing Municipality
   [PHR201007114]
FX This work was supported by Beijing Municipal Education Committee (No.
   KM200810025025 and KM20110025007) and Funding Project for Academic Human
   Resources Development in Institutions of Higher Learning under the
   Jurisdiction of Beijing Municipality (No. PHR201007114). We also would
   like to acknowledge the use of resources at Beijing Area Major
   Laboratory of Peptide and Small Molecular Drugs.
CR Abu Ajaj K, 2009, BIOCONJUGATE CHEM, V20, P390, DOI 10.1021/bc800429q
   Akkaya G, 2005, PROCESS BIOCHEM, V40, P3559, DOI 10.1016/j.procbio.2005.03.048
   Alley E., 2000, WATER QUALITY CONTRO
   Chen M, 2009, ACS NANO, V3, P2016, DOI 10.1021/nn900480m
   Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j
   Faklaris O, 2008, SMALL, V4, P2236, DOI 10.1002/smll.200800655
   Freundlich H., 1906, PHYS CHEM SOC, V40, P1361
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5                                                   
   Ho YS, 1998, PROCESS SAF ENVIRON, V76, P183, DOI 10.1205/095758298529326                                                         
   Horsfall M, 2004, B KOR CHEM SOC, V25, P969
   Huang H, 2007, NANO LETT, V7, P3305, DOI 10.1021/nl071521o
   Huang LCL, 2004, LANGMUIR, V20, P5879, DOI 10.1021/la0495736
   KARPOVICH DS, 1994, LANGMUIR, V10, P3315, DOI 10.1021/la00021a066                                                             
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   LIU KK, 2008, NANOTECHNOLOGY, V19, P10
   Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966
   Areco MM, 2010, COLLOID SURFACE B, V81, P620, DOI 10.1016/j.colsurfb.2010.08.014
   Nguyen TTB, 2007, DIAM RELAT MATER, V16, P872, DOI 10.1016/j.diamond.2007.01.030
   Oberdorster E, 2004, ENVIRON HEALTH PERSP, V112, P1058, DOI 10.1289/ehp.7021
   Peetla C, 2009, MOL PHARMACEUT, V6, P1311, DOI 10.1021/mp900011h
   Salehi R, 2010, COLLOID SURFACE B, V80, P86, DOI 10.1016/j.colsurfb.2010.05.039
   Schrand AM, 2007, J PHYS CHEM B, V111, P2, DOI 10.1021/jp066387v
   Shimkunas RA, 2009, BIOMATERIALS, V30, P5720, DOI 10.1016/j.biomaterials.2009.07.004
   Sun DH, 2010, J HAZARD MATER, V181, P335, DOI 10.1016/j.jhazmat.2010.05.015
   1994, CANC CHEM HDB
NR 25
TC 8
Z9 8
U1 1
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD AUG 1
PY 2011
VL 257
IS 20
BP 8617
EP 8622
DI 10.1016/j.apsusc.2011.05.033
PG 6
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 778SF
UT WOS:000291725100054
DA 2018-01-05
ER

PT J
AU Alukda, D
   Sturgis, T
   Youan, BBC
AF Alukda, Dima
   Sturgis, Timothy
   Youan, Bi-Botti C.
TI Formulation of Tenofovir-Loaded Functionalized Solid Lipid Nanoparticles
   Intended for HIV Prevention
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE coating; colloids; formulation; functionalization; HIV prevention;
   lipids; nanoparticles; tenofovir; topical drug delivery
ID BOVINE SERUM-ALBUMIN; DRUG-DELIVERY; LIGHT-SCATTERING; MICROBICIDE;
   TRANSPORT; HEPARIN; SYSTEMS; POLY(L-LYSINE); TRANSMISSION; CONJUGATE
AB The objective of this study is to engineer polylysine-heparin functionalized solid lipid nanoparticles (fSLNs) for the use of a vaginal microbicide delivery template for HIV prevention. The fSLNs are prepared using a modified phase-inversion technique followed by a layer-by-layer deposition method. The Box-Behnken experimental design is used to analyze the influence of three factors (X(1) = bovine serum albumin concentration, X(2) = pH of the aqueous phase, and X(3) = lipid amount) on the particle mean diameter (PMD) measured by dynamic light scattering (DLS). Tenofovir is used as a model anti-HIV microbicide. The SLNs are also characterized for morphology, zeta potential (zeta), percent drug encapsulation efficiency (EE%), and cytotoxicity on a human vaginal epithelial cell line by electron microscopy, DLS, ultraviolet, and fluorescence spectroscopy, respectively. The statistical model predicts particle size (Y) with 90% confidence and the Y values are significantly affected by X(1) and X(2). The produced fSLNs appear noncytotoxic and exhibit a platelet-like shape with respective PMD, EE%, and zeta value of 153 nm, 8.3%, and - 51mV. These fSLNs intended to be administered topically have the potential to enhance cellular uptake of hydrophobic microbicides and outdistance the virus during the HIV/AIDS infection process, possibly leading to more effective prevention of the disease transmission. (C) 2011 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100: 3345-3356, 2011
C1 [Alukda, Dima; Youan, Bi-Botti C.] Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, Kansas City, MO 64108 USA.
   [Sturgis, Timothy] Univ Missouri, Dept Environm Hlth & Safety, Kansas City, MO 64110 USA.
RP Youan, BBC (reprint author), Univ Missouri, Div Pharmaceut Sci, Lab Future Nanomed & Theoret Chronopharmaceut, Kansas City, MO 64108 USA.
EM youanb@umkc.edu
FU National Institute of Allergy and Infectious Diseases [R21A1083092]
FX The work presented was supported by Award Number R21A1083092 from the
   National Institute of Allergy and Infectious Diseases. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official view of the National Institute of Allergy and
   Infectious Diseases or the National Institutes of Health. We are also
   grateful to Dr. Edward Gogol (School of Biological Sciences, University
   of Missouri, Kansas City, Missouri) for his valuable collaboration and
   help in TEM imaging.
CR Almeida AJ, 2007, ADV DRUG DELIVER REV, V59, P478, DOI 10.1016/j.addr.2007.04.007
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011
   Bunjes H, 2007, LANGMUIR, V23, P4005, DOI 10.1021/la062904p
   CATALAN J, 1995, LIEBIGS ANN, P793
   Chen HB, 2006, J CONTROL RELEASE, V110, P296, DOI 10.1016/jjconrel.2005.09.052
   Cranage M, 2008, PLOS MED, V5, P1238, DOI 10.1371/journal.pmed.0050157
   Curvale R, 2008, INT J BIOL MACROMOL, V42, P133, DOI 10.1016/j.ijbiomac.2007.10.007
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   Estey T, 2006, J PHARM SCI-US, V95, P1626, DOI 10.1002/jps.20625
   Garg Anita B, 2009, Antivir Chem Chemother, V19, P143
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   HARRINGTON WF, 1956, BIOCHEM J, V62, P569, DOI 10.1042/bj0620569                                                               
   Higai K, 2009, BIOCHEM BIOPH RES CO, V386, P709, DOI 10.1016/j.bbrc.2009.06.101
   Jayagopal A, 2008, IEEE T NANOBIOSCI, V7, P28, DOI 10.1109/TNB.2008.2000147
   Katzel U, 2008, PART PART SYST CHAR, V25, P19, DOI 10.1002/ppsc.200700005
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   KOLCHENS S, 1993, CHEM PHYS LIPIDS, V65, P1, DOI 10.1016/0009-3084(93)90076-F
   KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153                                                               
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lee WA, 2005, ANTIMICROB AGENTS CH, V49, P1898, DOI 10.1128/AAC.49.5.1898-1906.2005
   MAGENHEIM B, 1996, MICROENCAPSULATION, P93
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867
   MONTGOMERY DC, 1995, RESPONSE SURFACE MET, P405
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Olbrich C, 2002, J DRUG TARGET, V10, P387, DOI 10.1080/1061186021000001832
   Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   PATEL BS, INT J PHARM CLIN RES, V1, P28
   Peng ZG, 2004, J COLLOID INTERF SCI, V271, P277, DOI 10.1016/j.jcis.2003.12.022
   PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0
   RABOUDI N, 1992, J BIOL CHEM, V267, P11930
   RICHARDS LJ, 1993, J CHEM EDUC, V70, P685
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   Rohan LC, 2009, AAPS J, V11, P78, DOI 10.1208/s12248-009-9082-7
   RYSER HJP, 1978, P NATL ACAD SCI USA, V75, P3867, DOI 10.1073/pnas.75.8.3867                                                          
   RYSER HJP, 1982, J CELL PHYSIOL, V113, P167, DOI 10.1002/jcp.1041130126                                                          
   Sassi AB, 2008, J PHARM SCI-US, V97, P3123, DOI 10.1002/jps.21192
   Sato K, 2001, CHEM ENG SCI, V56, P2255, DOI 10.1016/S0009-2509(00)00458-9                                                   
   Schubert MA, 2003, EUR J PHARM BIOPHARM, V55, P125, DOI 10.1016/S0939-6411(02)00130-3
   SHEN WC, 1981, P NATL ACAD SCI-BIOL, V78, P7589, DOI 10.1073/pnas.78.12.7589
   SJOSTROM B, 1995, PHARMACEUT RES, V12, P39, DOI 10.1023/A:1016278302046
   SUZANNE M, 2007, CRYOPRESERVATION FRE, P237
   Takatori M, 2006, ANESTH ANALG, V102, P462, DOI 10.1213/01.ane.0000194334.69103.50
   UNAIDS, 2008, 2008 REP GLOB AIDS E
   Van Gelder J, 1999, INT J PHARMACEUT, V186, P127, DOI 10.1016/S0378-5173(99)00150-7
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   Wasan KM, 2009, J PHARM SCI-US, V98, P379, DOI 10.1002/jps.21435
   WETZEL R, 1980, EUR J BIOCHEM, V104, P469, DOI 10.1111/j.1432-1033.1980.tb04449.x
   WILLIAMS CM, 2003, 44 INT C BIOSC LIP O
   Wong HL, 2004, J PHARM SCI-US, V93, P1993, DOI 10.1002/jps.20100
   ZHANG T, 2010, J PHARM SCI, V100
   Zilka A, 2005, BIOCHEMISTRY-US, V44, P14477, DOI 10.1021/bi051241s
NR 58
TC 43
Z9 43
U1 0
U2 15
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3549
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD AUG
PY 2011
VL 100
IS 8
BP 3345
EP 3356
DI 10.1002/jps.22529
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 777JO
UT WOS:000291612000030
PM 21437910
OA green_accepted
DA 2018-01-05
ER

PT J
AU Marradi, M
   Di Gianvincenzo, P
   Enriquez-Navas, PM
   Martinez-Avila, OM
   Chiodo, F
   Yuste, E
   Angulo, J
   Penades, S
AF Marradi, Marco
   Di Gianvincenzo, Paolo
   Enriquez-Navas, Pedro M.
   Martinez-Avila, Olga M.
   Chiodo, Fabrizio
   Yuste, Eloisa
   Angulo, Jesus
   Penades, Soledad
TI Gold Nanoparticles Coated with Oligomannosides of HIV-1 Glycoprotein
   gp120 Mimic the Carbohydrate Epitope of Antibody 2G12
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE multivalent gold glyconanoparticles; high-mannose-type oligosaccharides;
   surface plasmon resonance; NMR spectroscopy; 2G12/gp120 inhibition
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSFER DIFFERENCE NMR; FUSION INHIBITOR
   T-20; DC-SIGN; ENVELOPE GLYCOPROTEIN; TRANS-INFECTION; LIGAND-BINDING;
   T-CELLS; VACCINE; GLYCONANOPARTICLES
AB After three decades of research, an effective vaccine against the pandemic AIDS caused by human immunodeficiency virus (HIV) is not still available, and a deeper understanding of HIV immunology, as well as new chemical tools that may contribute to improve the currently available arsenal against the virus, is highly wanted. Among the few broadly neutralizing human immunodeficiency virus type 1 (HIV-1) monoclonal antibodies, 2G12 is the only carbohydrate-directed one. 2G12 recognizes a cluster of high-mannose glycans on the viral envelope glycoprotein gp120. This type of glycan has thus been envisaged as a target to develop an HIV vaccine that is capable of eliciting 2G12-like antibodies. Herein we show that gold nanoparticles coated with self-assembled monolayers of synthetic oligomannosides [manno-gold glyconanoparticles (GNPs)], which are present in gp120, are able to bind 2G12 with high affinity and to interfere with 2G12/gp120 binding, as determined by surface plasmon resonance and saturation transfer difference NMR spectroscopy. Cellular neutralization assays demonstrated that GNPs coated with a linear tetramannoside could block the 2G12-mediated neutralization of a replication-competent virus under conditions that resemble the ones in which normal serum prevents infection of the target cell. Dispersibility in water and physiological media, absence of cytotoxicity, and the possibility of inserting more than one component into the same nanoparticle make manno-GNPs versatile, polyvalent, and multifunctional systems that may aid efforts to develop new multifaceted strategies against HIV. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Marradi, Marco; Di Gianvincenzo, Paolo; Enriquez-Navas, Pedro M.; Martinez-Avila, Olga M.; Chiodo, Fabrizio; Penades, Soledad] CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, E-20009 San Sebastian, Spain.
   [Marradi, Marco; Penades, Soledad] Biomed Res Networking Ctr Bioengn Biomat & Nanome, E-20009 San Sebastian, Spain.
   [Yuste, Eloisa] Univ Barcelona, Hosp Clin, IDIBAPS, Retrovirol & Viral Immunopathol Lab, Barcelona, Spain.
   [Yuste, Eloisa] Univ Barcelona, Fac Med, Hosp Clin, HIVACAT, Barcelona 7, Spain.
   [Angulo, Jesus] Inst Invest Quim CSIC US, Dept Bioorgan Chem, E-41092 Seville, Spain.
RP Marradi, M (reprint author), CIC BiomaGUNE, Biofunct Nanomat Unit, Lab GlycoNanotechnol, Paseo Miramon 182, E-20009 San Sebastian, Spain.
EM mmarradi.ciber-bbn@cicbiomagune.es; spenades@cicbiomagune.es
RI biomaGUNE, CIC/J-9136-2014; Chiodo, Fabrizio/R-1121-2017; Angulo,
   Jesus/H-1253-2011; Marradi, Marco/H-7247-2012
OI biomaGUNE, CIC/0000-0001-7690-0660; Chiodo,
   Fabrizio/0000-0003-3619-9982; Angulo, Jesus/0000-0001-7250-5639; 
FU Spanish Ministry of Science and Innovation MICINN [CTQ2008-04638/BQU];
   European Union [Health-F3-2009-242135]; Department of Industry of the
   Basque Country [ETOR-TEK2009]; Ministerio de Ciencia e Innovacion; FIPSE
   [36780/08]; EC
FX This work was supported by the Spanish Ministry of Science and
   Innovation MICINN (grant CTQ2008-04638/BQU), the European Union (CHAARM
   grant Health-F3-2009-242135), and the Department of Industry of the
   Basque Country (grant ETOR-TEK2009). TZM-bl was obtained from Dr. John
   C. Kappes, Dr. Xiaoyun Wu, and Tranzyme, Inc., through the National
   Institutes of Health AIDS Research and Reference Reagent Program,
   Division of AIDS, National Institute of Allergy and Infectious Diseases,
   National Institutes of Health. HIV-1 gp120 mAb 2G12 was kindly supplied
   by Dr. D. Katinger (Polymun Scientific, Vienna, Austria). Recombinant
   gp120 from the HIV-1 CN54 clone (repository reference ARP683) was
   obtained from the Program EVA Center for AIDS Reagents, National
   Institute for Biological Standards and Control, UK (supported by the EC
   FP6/7 Europrise Network of Excellence, the AVIP and NGIN consortia, and
   the Bill and Melinda Gates GHRC-CAVD Project), and was donated by Prof.
   Ian Jones (Reading University, UK). Prof. Ian Jones is also acknowledged
   for the information on HIV-1 gp120 used in this work. J.A. acknowledges
   financial support from the Ministerio de Ciencia e Innovacion through
   the Ramon y Cajal program. E.Y. acknowledges financial support from
   FIPSE 36780/08.
CR Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010
   Agrawal-Gamse C, 2011, J VIROL, V85, P470, DOI 10.1128/JVI.01349-10
   Angulo J, 2010, CHEM-EUR J, V16, P7803, DOI 10.1002/chem.200903528
   Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08
   Astronomo RD, 2010, CHEM BIOL, V17, P357, DOI 10.1016/j.chembiol.2010.03.012
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Barouch DH, 2008, NATURE, V455, P613, DOI 10.1038/nature07352
   Barrientos AG, 2003, CHEM-EUR J, V9, P1909, DOI 10.1002/chem.200204544
   Benie AJ, 2003, J AM CHEM SOC, V125, P14, DOI 10.1021/ja027691e
   Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101
   Bryan MC, 2004, J AM CHEM SOC, V126, P8640, DOI 10.1021/ja048433f
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011
   de la Fuente J.M., 2001, ANGEW CHEM INT EDIT, V40, P2257, DOI DOI 10.1002/1521-3773(20010618)40:12
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Doores KJ, 2010, P NATL ACAD SCI USA, V107, P13800, DOI 10.1073/pnas.1006498107
   Dudkin VY, 2004, J AM CHEM SOC, V126, P9560, DOI 10.1021/ja047720g                                                               
   Dunlop DC, 2010, GLYCOBIOLOGY, V20, P812, DOI 10.1093/glycob/cwq020
   Enriquez-Navas P. M., 2011, CHEM-EUR J, V17, P1369
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505
   Garcia-Perez J, 2007, J MED VIROL, V79, P127, DOI 10.1002/jmv.20770
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   He L, 2000, J AM CHEM SOC, V122, P9071, DOI 10.1021/ja001215b
   Joyce JG, 2008, P NATL ACAD SCI USA, V105, P15684, DOI 10.1073/pnas.0807837105
   Kabanova A, 2010, GLYCOCONJUGATE J, V27, P501, DOI 10.1007/s10719-010-9295-0
   Kong L, 2010, J MOL BIOL, V403, P131, DOI 10.1016/j.jmb.2010.08.033
   Krauss IJ, 2007, J AM CHEM SOC, V129, P11042, DOI 10.1021/ja074804r
   Lee HK, 2004, ANGEW CHEM INT EDIT, V43, P1000, DOI 10.1002/anie.200353105
   Li HG, 2004, ORG BIOMOL CHEM, V2, P483, DOI 10.1039/b314565d
   Liang PH, 2007, J AM CHEM SOC, V129, P11177, DOI 10.1021/ja072931h
   Luallen RJ, 2008, J VIROL, V82, P6447, DOI 10.1128/JVI.00412-08
   Marradi M, 2010, ADV CARBOHYD CHEM BI, V64, P211, DOI 10.1016/S0065-2318(10)64005-X
   Martinez-Avila O, 2009, CHEM-EUR J, V15, P9874, DOI 10.1002/chem.200900923
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q
   Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Ni JH, 2006, BIOCONJUGATE CHEM, V17, P493, DOI 10.1021/bc0502816
   Pashov A, 2007, CURR PHARM DESIGN, V13, P185, DOI 10.2174/138161207779313678
   Platt EJ, 1998, J VIROL, V72, P2855
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Rojo J, 2004, CHEMBIOCHEM, V5, P291, DOI 10.1002/cbic.200300726
   Sattin S, 2010, ACS CHEM BIOL, V5, P301, DOI 10.1021/cb900216e
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Trkola A, 1996, J VIROL, V70, P1100
   Wang JS, 2007, ORG BIOMOL CHEM, V5, P1529, DOI 10.1039/b702961f
   Wang LX, 2006, ACS SYM SER, V932, P133
   Wang LX, 2004, CHEM BIOL, V11, P127, DOI 10.1016/j.chembiol.2003.12.020
   Wang SK, 2008, P NATL ACAD SCI USA, V105, P3690, DOI 10.1073/pnas.0712326105
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
NR 56
TC 41
Z9 41
U1 6
U2 35
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUL 29
PY 2011
VL 410
IS 5
SI SI
BP 798
EP 810
DI 10.1016/j.jmb.2011.03.042
PN 2
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 804SK
UT WOS:000293674100003
PM 21440555
DA 2018-01-05
ER

PT J
AU Britan-Rosich, E
   Nowarski, R
   Kotler, M
AF Britan-Rosich, Elena
   Nowarski, Roni
   Kotler, Moshe
TI Multifaceted Counter-APOBEC3G Mechanisms Employed by HIV-1 Vif
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE deaminase; peptides; enzyme kinetics; virion; innate immunity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; APOBEC3G CYTIDINE DEAMINASE; VIRION
   INFECTIVITY FACTOR; RNA-EDITING ENZYME; C-TERMINAL DOMAIN; TYPE-1 VIF;
   INTRACELLULAR EXPRESSION; ENDOGENOUS RETROVIRUSES; ANTIVIRAL ACTIVITY;
   VIRAL INFECTIVITY
AB In the absence of human immunodeficiency virus type 1 (HIV-1) Vif protein, the host antiviral deaminase apolipoprotein B mRNA-editing enzymecatalytic polypeptide-like 3G (A3G) restricts the production of infectious HIV-1 by deamination of dC residues in the negative single-stranded DNA produced by reverse transcription. The Vif protein averts the lethal threat of deamination by precluding the packaging of A3G into assembling virions by mediating proteasomal degradation of A3G. In spite of this robust Vif activity, residual A3G molecules that escape degradation and incorporate into newly assembled virions are potentially deleterious to the virus. We hypothesized that virion-associated Vif inhibits A3G enzymatic activity and therefore prevents lethal mutagenesis of the newly synthesized viral DNA. Here, we show that (i) Vif-proficient HIV-1 particles released from H9 cells contain A3G with lower specific activity compared with Delta vif-virus-associated A3G, (ii) encapsidated HIV-1 Vif inhibits the deamination activity of recombinant A3G, and (iii) purified HIV-1 Vif protein and the Vif-derived peptide Vif25-39 inhibit A3G activity in vitro at nanomolar concentrations in an uncompetitive manner. Our results manifest the potentiality of Vif to control the deamination threat in virions or in the pre-integration complexes following entry to target cells. Hence, virion-associated Vif could serve as a last line of defense, protecting the virus against A3G antiviral activity. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Britan-Rosich, Elena; Nowarski, Roni; Kotler, Moshe] Hebrew Univ Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel.
   [Britan-Rosich, Elena; Nowarski, Roni; Kotler, Moshe] Hebrew Univ Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.
RP Kotler, M (reprint author), Hebrew Univ Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel.
EM mkotler@cc.huji.ac.il
FU NIH [P01 GM091743]; US Israel Binational Science Foundation; Israel
   Ministry of Health
FX This work was carried out in the Peter A. Krueger Laboratory with the
   generous support of Nancy and Lawrence Glick and Pat and Marvin Weiss.
   We thank Dr. D. Gabuzda for providing the Vif-expressing vector and
   polyclonal Vif serum and Dr. K. Strebel for providing pcDNA-APO3G and
   pcDNA-APO3G D128K plasmids. The following reagents were obtained through
   the AIDS Research and Reference Reagent Program, Division of AIDS, MAID,
   NIH: HIV-1 Vif peptides from Division of Acquired Immunodeficiency
   Syndrome, NIAID, and anti-A3G polyclonal antibodies from Dr. Jaisri
   Lingappa. This work was supported in part by NIH Grant P01 GM091743, US
   Israel Binational Science Foundation, and the Israel Ministry of Health.
   We thank Drs. Reuben S. Harris, Asaf Friedler and Akram Alian for
   constructive and helpful discussion and Mrs. S. Amir for editing the
   manuscript.
CR Ao ZJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001995
   Auclair JR, 2007, PROTEINS, V69, P270, DOI 10.1002/prot.21471
   Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046
   Bernacchi S, 2007, J BIOL CHEM, V282, P26361, DOI 10.1074/jbc.M703122200
   Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101
   BORMAN AM, 1995, VIROLOGY, V208, P601, DOI 10.1006/viro.1995.1191
   Browne EP, 2009, VIROLOGY, V387, P313, DOI 10.1016/j.virol.2009.02.026
   Camaur D, 1996, J VIROL, V70, P6106
   Carr JM, 2006, VIROLOGY, V351, P80, DOI 10.1016/j.virol.2006.03.027
   CHESEBRO B, 1992, J VIROL, V66, P6547
   Chiu YL, 2006, P NATL ACAD SCI USA, V103, P15588, DOI 10.1073/pnas.0604524103
   Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026
   Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034
   Dettenhofer M, 1999, J VIROL, V73, P1460
   Esnault C, 2006, NUCLEIC ACIDS RES, V34, P1522, DOI 10.1093/nar/gkl054
   Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238
   Etard C, 2010, J CELL BIOL, V189, P527, DOI 10.1083/jcb.200912125
   Gifford RJ, 2008, AIDS, V22, P717, DOI 10.1097/QAD.0b013e3282f5e07a
   GONCALVES J, 1994, J VIROL, V68, P704
   Green LA, 2009, J BIOL CHEM, V284, P13363, DOI 10.1074/jbc.M806631200
   Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200
   Hakata Y, 2006, J BIOL CHEM, V281, P36624, DOI 10.1074/jbc.M604980200
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   Hultquist JF, 2009, FUTURE VIROL, V4, P605, DOI 10.2217/FVL.09.59
   Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05
   Iwatani Y, 2009, P NATL ACAD SCI USA, V106, P19539, DOI 10.1073/pnas.0906652106
   Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001
   Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718
   Jonsson SR, 2006, NUCLEIC ACIDS RES, V34, P5683, DOI 10.1093/nar/gkl721
   Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003
   Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003
   Kao S, 2007, VIROLOGY, V369, P329, DOI 10.1016/j.virol.2007.08.005
   Kao Sandra, 2004, Retrovirology, V1, P27, DOI 10.1186/1742-4690-1-27
   Khamsri B, 2006, INT J MOL MED, V18, P679
   Kim EY, 2010, J VIROL, V84, P10402, DOI 10.1128/JVI.01223-10
   KIMPTON J, 1992, J VIROL, V66, P2232
   Langlois MA, 2005, NUCLEIC ACIDS RES, V33, P1913, DOI 10.1093/nar/gki343
   Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338
   Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925                                                          
   LIU HM, 1995, J VIROL, V69, P7630
   Luo K, 2005, P NATL ACAD SCI USA, V102, P11444, DOI 10.1073/pnas.0502440102
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200
   Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4                                                   
   Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946
   Mehle A, 2006, J BIOL CHEM, V281, P17259, DOI 10.1074/jbc.M602413200
   Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200
   Mulder LCF, 2008, P NATL ACAD SCI USA, V105, P5501, DOI 10.1073/pnas.0710190105
   Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470                                                        
   Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
   Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011
   Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068
   Nowarski R, 2008, NAT STRUCT MOL BIOL, V15, P1059, DOI 10.1038/nsmb.1495
   OBERSTE MS, 1992, VIRUS GENES, V6, P95, DOI 10.1007/BF01703760
   Pillai SK, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-26
   Rangel HR, 2009, J INFECT DEV COUNTR, V3, P531
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   Reingewertz TH, 2010, PROTEIN PEPTIDE LETT, V17, P988
   Reingewertz TH, 2009, PROTEIN ENG DES SEL, V22, P281, DOI 10.1093/protein/gzp004
   REIZER J, 1994, PROTEIN SCI, V3, P853
   Sadler HA, 2010, J VIROL, V84, P7396, DOI 10.1128/JVI.00056-10
   Santa-Marta M, 2005, J BIOL CHEM, V280, P8765, DOI 10.1074/jbc.M409309200
   Santa-Marta M, 2007, MOL IMMUNOL, V44, P583, DOI 10.1016/j.molimm.2006.02.005
   Sato K, 2010, J VIROL, V84, P9546, DOI 10.1128/JVI.00823-10
   Sato Y, 2010, J BIOL CHEM, V285, P7111, DOI 10.1074/jbc.M109.052977
   Schrofelbauer Barbel, 2004, Proceedings of the National Academy of Sciences of the United States of America, V101, P3927, DOI 10.1073/pnas.0307132101
   Schumacher AJ, 2005, P NATL ACAD SCI USA, V102, P9854, DOI 10.1073/pnas.0501694102
   Simon JHM, 1999, J VIROL, V73, P2675
   Simon JHM, 1998, VIROLOGY, V248, P182, DOI 10.1006/viro.1998.9296
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554
   Tian CJ, 2006, J VIROL, V80, P3112, DOI 10.1128/JVI.80.6.3112-3115.2006
   VARTANIAN JP, 1991, J VIROL, V65, P1779
   Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4
   Xiao ZX, 2006, VIROLOGY, V349, P290, DOI 10.1016/j.virol.2006.02.002
   Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101
   Yamashita T, 2010, MICROBES INFECT, V12, P166, DOI 10.1016/j.micinf.2009.11.007
   Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121                                                        
   Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
NR 80
TC 17
Z9 17
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUL 29
PY 2011
VL 410
IS 5
SI SI
BP 1065
EP 1076
DI 10.1016/j.jmb.2011.03.058
PN 2
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 804SK
UT WOS:000293674100022
PM 21763507
OA green_accepted
DA 2018-01-05
ER

PT J
AU Skanji, R
   Andrieux, K
   Lalanne, M
   Caron, J
   Bourgaux, C
   Degrouard, J
   Brisset, F
   Gueutin, C
   Chacun, H
   Dereuddre-Bosquet, N
   Paci, A
   Vassal, G
   Bauduin, L
   Garcia-Argote, S
   Rousseau, B
   Clayette, P
   Desmaele, D
   Couvreur, P
AF Skanji, Rym
   Andrieux, Karine
   Lalanne, Muriel
   Caron, Joachim
   Bourgaux, Claudie
   Degrouard, Jeril
   Brisset, Francois
   Gueutin, Claire
   Chacun, Helene
   Dereuddre-Bosquet, Nathalie
   Paci, Angelo
   Vassal, Gilles
   Bauduin, Laurent
   Garcia-Argote, Sebastien
   Rousseau, Bernard
   Clayette, Pascal
   Desmaele, Didier
   Couvreur, Patrick
TI A new nanomedicine based on didanosine glycerolipidic prodrug enhances
   the long term accumulation of drug in a HIV sanctuary
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Antiviral activity; Didanosine; In vivo experiments; Liposomes; Prodrug
ID X-RAY-DIFFRACTION; LYMPHATIC DELIVERY; SIZE DISTRIBUTION; LIPOSOMES;
   DIPALMITOYLPHOSPHATIDYLCHOLINE; 2',3'-DIDEOXYINOSINE; CALORIMETRY;
   VESICLES; AIDS
AB New nanomedicines could improve drug accumulation in HIV sanctuaries and ameliorate their antiretroviral efficiency. In this view, we propose herein a combined strategy based on a biomimetic prodrug of ddI and its formulation in well-characterized lipid nanoobjects. The glycerolipidic prodrug of ddI (ProddINP) has been synthesized and its bulk structure was characterized. An appropriate formulation of this prodrug has been designed using a rational approach combining different physicochemical techniques. The high incorporation ratio of the prodrug into dipalmitoylphosphatidylcholine (DPPC) bilayers was determined by DSC. Then two liposome preparation methods were compared, with respect to size, incorporation yield and molecular/supramolecular organization of vesicles. The best liposomal formulation of ProddINP has been checked to keep intact the anti-HIV activity of ddI. This formulation was finally compared to ddI after oral route in rat. The animal experiments evidenced the increase of ddI blood half life (3-fold) and its enhanced accumulation as prodrug form at 24 h in numerous organs and especially intestine after administration of ProddINP in comparison with free drug. Finally, the tested liposomal formulation of ProddINP seems to be a promising approach to eradicate HIV infection from intestinal sanctuaries where the virus can concentrate. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Skanji, Rym; Andrieux, Karine; Lalanne, Muriel; Bourgaux, Claudie; Gueutin, Claire; Chacun, Helene; Couvreur, Patrick] Univ Paris 11, CNRS, IFR 141, UMR 8612, F-92296 Chatenay Malabry, France.
   [Caron, Joachim; Desmaele, Didier] Univ Paris 11, CNRS, IFR 141, UMR 8076, F-92296 Chatenay Malabry, France.
   [Degrouard, Jeril] Univ Paris 11, CNRS, LPS, UMR 8502, F-91400 Orsay, France.
   [Brisset, Francois] Univ Paris 11, CNRS, ICMMO, UMR 8182, F-91400 Orsay, France.
   [Dereuddre-Bosquet, Nathalie; Clayette, Pascal] CEA, Lab Neurovirol, F-92265 Fontenay Aux Roses, France.
   [Paci, Angelo; Vassal, Gilles] Univ Paris 11, UPRES EA 3535, IFR 54, F-94805 Villejuif, France.
   [Bauduin, Laurent] CEA, Lab Bioanal, F-91191 Gif Sur Yvette, France.
   [Garcia-Argote, Sebastien; Rousseau, Bernard] CEA Saclay, Dept Radiolabeled Mol, F-91191 Gif Sur Yvette, France.
RP Andrieux, K (reprint author), Univ Paris 11, CNRS, IFR 141, UMR 8612, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.
EM karine.andrieux@u-psud.fr
RI Andrieux, Karine/P-3010-2017; COUVREUR, Patrick/G-4844-2011
OI Andrieux, Karine/0000-0002-2002-7556; COUVREUR,
   Patrick/0000-0001-7961-5443
FU Agence Nationale de la Recherche (ANR) [NT05-1_43236 SYLIANNU]; PRES
   Universud Paris (Institut du medicament); MENRT
FX The financial support of "Agence Nationale de la Recherche" (ANR, grant
   NT05-1_43236 SYLIANNU) and the PRES Universud Paris (Institut du
   medicament, appel d'offre 2008) are acknowledged. Authors thank MENRT
   for providing financial support to M. Lalanne, for technical support M.
   Besnard (CNRS, UMR 8612), V. Domergue (Animalerie centrale, Faculte de
   Pharmacie, Chatenay-Malabry), Emeline CHU-VAN et Celine DECLEIN (Bertin
   Pharma, CEA) and Nicolas Tsapis (CNRS, UMR 8612) for manuscript
   corrections.
CR Bangham AD, 1974, METHODS MEMBRANE BIO, V1, P1
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BRAMER SL, 1993, J PHARMACOL EXP THER, V265, P731
   Brubach JB, 2007, INT J PHARM, V336, P248, DOI 10.1016/j.ijpharm.2006.11.057
   CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251                                             
   Carion-Taravella B, 2002, LANGMUIR, V18, P325, DOI 10.1021/la001638r
   CROWE LM, 1985, ARCH BIOCHEM BIOPHYS, V242, P240, DOI 10.1016/0003-9861(85)90498-9
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   FERREIRA GC, 1990, J LIPID RES, V31, P889
   Forte L, 1998, J THERM ANAL CALORIM, V51, P773, DOI 10.1007/BF03341454                                                              
   Gomez-Graete C, 2007, INT J PHARM, V331, P153, DOI 10.1016/j.ijpharm.2006.11.028
   GRABIELLEMADELMONT C, 1983, J COLLOID INTERF SCI, V95, P471, DOI 10.1016/0021-9797(83)90207-2                                                    
   HARRIGAN PR, 1990, CHEM PHYS LIPIDS, V52, P139, DOI 10.1016/0009-3084(90)90157-M
   HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048
   KARBER G, 1931, ARCH EXP PATHOL PH, V162, P956
   Lalanne M, 2007, BIOORG MED CHEM LETT, V17, P2237, DOI 10.1016/j.bmcl.2007.01.062
   Lalanne M, 2009, INT J PHARMACEUT, V379, P235, DOI 10.1016/j.ijpharm.2009.05.030
   LESIEUR S, 1993, CHEM PHYS LIPIDS, V64, P57, DOI 10.1016/0009-3084(93)90058-B
   Manouilov KK, 1997, ANTIVIR RES, V34, P91, DOI 10.1016/S0166-3542(96)01023-6
   MAYHEW E, 1984, BIOCHIM BIOPHYS ACTA, V775, P169, DOI 10.1016/0005-2736(84)90167-6
   O'Driscoll CM, 2002, EUR J PHARM SCI, V15, P405, DOI 10.1016/S0928-0987(02)00051-9
   OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3
   RAY GF, 1990, DRUG METAB DISPOS, V18, P654
   SAUNDERS L, 1962, J PHARM PHARMACOL, V14, P567, DOI 10.1111/j.2042-7158.1962.tb11141.x                                              
   Shaaya O, 2003, PHARMACEUT RES, V20, P205, DOI 10.1023/A:1022214919481                                                         
   SJOSTROM B, 1992, INT J PHARM, V88, P53, DOI 10.1016/0378-5173(92)90303-J
   Small D. M, 1986, HDB LIPID RES, P475
   SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343
   Wang J, 2002, PHARMACEUT RES, V19, P609, DOI 10.1023/A:1015397811161
   Yatvin MB, 1999, ADV DRUG DELIVER REV, V39, P165, DOI 10.1016/S0169-409X(99)00025-3                                                   
NR 30
TC 7
Z9 7
U1 2
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 29
PY 2011
VL 414
IS 1-2
BP 285
EP 297
DI 10.1016/j.ijpharm.2011.05.005
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 793BN
UT WOS:000292795500036
PM 21596125
DA 2018-01-05
ER

PT J
AU Goicochea, NL
   Datta, SAK
   Ayaluru, M
   Kao, C
   Rein, A
   Dragnea, B
AF Goicochea, Nancy L.
   Datta, Siddhartha A. K.
   Ayaluru, Murali
   Kao, Cheng
   Rein, Alan
   Dragnea, Bogdan
TI Structure and Stoichiometry of Template-Directed Recombinant HIV-1 Gag
   Particles
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE HIV Gag; nanoparticle; templated virus assembly; liquid crystal;
   electron microscopy
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ASSEMBLY IN-VITRO; NUCLEOCAPSID PROTEIN;
   ELECTRON CRYOTOMOGRAPHY; 3-DIMENSIONAL STRUCTURE; GOLD NANOPARTICLES;
   MATRIX PROTEIN; CAPSIDS; DOMAIN; CORE
AB Size polydispersity of immature human immunodeficiency virus type 1 (HIV-1) particles represents a challenge for traditional methods of biological ultrastructural analysis. An in vitro model for immature HIV-1 particles constructed from recombinant Gag proteins lacking residues 16-99 and the p6 domain assembled around spherical nanoparticles functionalized with DNA. This template-directed assembly approach led to a significant reduction in size polydispersity and revealed previously unknown structural features of immature-like HIV-1 particles. Electron microscopy and image reconstruction of these particles suggest that the Gag shell formed from different protein regions that are connected by a "scar"-an extended defect connecting the edges of two continuous, regularly packed protein layers. Thus, instead of a holey protein array, the experimental model presented here appears to consist of a continuous array of similar to 5000 proteins enveloping the core, in which regular regions are separated by extended areas of disorder. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Datta, Siddhartha A. K.; Rein, Alan] NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
   [Goicochea, Nancy L.; Dragnea, Bogdan] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   [Ayaluru, Murali; Kao, Cheng] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.
RP Rein, A (reprint author), NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
EM reina@mail.nih.gov; dragnea@indiana.edu
RI Murali, Ayaluru/G-3401-2014
OI Murali, Ayaluru/0000-0001-6406-6840; Datta,
   Siddhartha/0000-0002-4098-7490
FU National Science Foundation [0832651, 0708590]; National Institutes of
   Health [GM081029]; NIH, National Cancer Institute, Center for Cancer
   Research
FX We gratefully acknowledge support from the National Science Foundation
   (grants 0832651 and 0708590) and the National Institutes of Health
   (grant GM081029). This work was also supported in part by the Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer Research.
CR Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Aniagyei SE, 2009, NANO LETT, V9, P393, DOI 10.1021/nl8032476
   Bausch AR, 2003, SCIENCE, V299, P1716, DOI 10.1126/science.1081160                                                         
   Belyi VA, 2006, P NATL ACAD SCI USA, V103, P17174, DOI 10.1073/pnas.0608311103
   Benjamin J, 2005, J MOL BIOL, V346, P577, DOI 10.1016/j.jmb.2004.11.064
   Briggs JAG, 2009, P NATL ACAD SCI USA, V106, P11090, DOI 10.1073/pnas.0903535106
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Bruinsma RF, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.248101
   Campbell S, 1999, J VIROL, V73, P2270
   Campbell S, 2001, P NATL ACAD SCI USA, V98, P10875, DOI 10.1073/pnas.191224698
   Carlson LA, 2008, CELL HOST MICROBE, V4, P592, DOI 10.1016/j.chom.2008.10.013
   Chang CB, 2008, ACS NANO, V2, P281, DOI 10.1021/nn700385z
   Datta SAK, 2007, J MOL BIOL, V365, P799, DOI 10.1016/j.jmb.2006.10.072
   Datta Siddhartha A. K., 2009, V485, P197, DOI 10.1007/978-1-59745-170-3_14
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   Dixit SK, 2006, NANO LETT, V6, P1993, DOI 10.1021/nl061165u
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   Fisher RJ, 1998, J VIROL, V72, P1902
   Frank J, 2006, 3 DIMENSIONAL ELECT
   Fuller SD, 1997, CURR BIOL, V7, P729, DOI 10.1016/S0960-9822(06)00331-9
   Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1                                                   
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Goicochea NL, 2007, NANO LETT, V7, P2281, DOI 10.1021/nl070860e
   Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694
   Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099
   Hu YF, 2008, BIOPHYS J, V94, P1428, DOI 10.1529/biophysj.107.117473
   Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582
   Johnson JE, 1998, NAT STRUCT BIOL, V5, P849, DOI 10.1038/2288
   Kuna JJ, 2009, NAT MATER, V8, P837, DOI [10.1038/nmat2534, 10.1038/NMAT2534]
   Lacerda SHD, 2010, ACS NANO, V4, P365, DOI 10.1021/nn9011187
   Levandovsky A, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.198102
   Loo L, 2007, J AM CHEM SOC, V129, P11111, DOI 10.1021/ja071896b
   Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174
   Luedtke WD, 1998, J PHYS CHEM B, V102, P6566, DOI 10.1021/jp981745i                                                               
   MASSIAH MA, 1994, J MOL BIOL, V244, P198, DOI 10.1006/jmbi.1994.1719
   Nelson DR, 2002, NANO LETT, V2, P1125, DOI 10.1021/n10202096
   Nguyen HD, 2007, NANO LETT, V7, P338, DOI 10.1021/nl062449h
   Perez-Caballero D, 2004, J VIROL, V78, P9560, DOI 10.1128/JVI.78.17.9560-9563.2004
   PORNILLOS, 2002, TRENDS CELL BIOL, V12, P569
   Pornillos O, 2009, CELL, V137, P1282, DOI 10.1016/j.cell.2009.04.0634
   Rulli SJ, 2007, J VIROL, V81, P6623, DOI 10.1128/JVI.02833-06
   Salzwedel K, 2007, AIDS REV, V9, P162
   SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1
   Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Sun J, 2007, P NATL ACAD SCI USA, V104, P1354, DOI 10.1073/pnas.0610542104
   Tang C, 2002, NAT STRUCT BIOL, V9, P537, DOI 10.1038/nsb806
   Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8                                                   
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   Wright ER, 2007, EMBO J, V26, P2218, DOI 10.1038/sj.emboj.7601664
   Zhang H, 2008, J MOL BIOL, V378, P565, DOI 10.1016/j.jmb.2008.02.066
NR 56
TC 13
Z9 13
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUL 22
PY 2011
VL 410
IS 4
SI SI
BP 667
EP 680
DI 10.1016/j.jmb.2011.04.012
PN 1
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 804SJ
UT WOS:000293674000014
PM 21762807
OA green_accepted
DA 2018-01-05
ER

PT J
AU Pallesen, J
AF Pallesen, Jesper
TI Structure of the HIV-1 5 ' Untranslated Region Dimer Alone and in
   Complex with Gold Nanocolloids: Support of a TAR-TAR-Containing 5 '
   Dimer Linkage Site (DLS) and a 3 ' DIS-DIS-Containing DLS
SO BIOCHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; GENOMIC-RNA DIMERIZATION; PRIMER
   ACTIVATION SIGNAL; ATOMIC-FORCE MICROSCOPY; KISSING-LOOP DOMAIN; REVERSE
   TRANSCRIPTION; IN-VITRO; NUCLEOCAPSID PROTEIN; VIRAL INFECTIVITY;
   RESPONSE ELEMENT
AB The formation of a genomic RNA dimer is critical for the HIV-1 replication cycle, and dimerization is known to initiate within the 5'UTR (5' untranslated region) of the viral RNA. However, the 5'UTR constitutes the 335 terminal nucleotides, and because of this considerable size, it has been difficult to study the global structure using conventional structural methods. Here, the atomic force microscope has been used to directly visualize the dimer formed from RNAs including HIV-1 nucleotides 1-744. Gold nanocolloids were deposited on the primer binding site regions in the dimer as an internal control. The dimer showed distinct ring morphology with up to two gold nanocolloids deposited within the ring and one or two strands extending from the ring. This morphology implies a dimer including a DIS-DIS (dimerization initiation site)-containing 3' dimer linkage site (DLS) and a TAR-TAR (trans-activation region)-containing 5'DLS. Furthermore, the dimer was formed under the influence of Mg(2+) and was imaged with an atomic force microscope under buffer conditions. The overall ring morphology containing a 5'DLS and a 3'DLS with one or two strands extending from it was conserved in these atomic force microscopy images. This indicates that the observed dimer morphology is physiologically significant. Moreover, evidence of multiple dimer interstrand contacts downstream of the major splice donor were observed, which indicates a component in the selection of full-length genomic RNA in dimer formation during virion packaging.
C1 Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.
RP Pallesen, J (reprint author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, 650 W 168th St,BB2-221, New York, NY 10032 USA.
EM jp2854@columbia.edu
FU Danish Research Councils; Danish National Research Foundation; Carlsberg
   Foundation
FX I am grateful of the financial support given to the Interdisciplinary
   Nanoscience Center and the Center for DNA Technology from the Danish
   Research Councils, the Danish National Research Foundation and the
   Carlsberg Foundation.
CR Abbink TEM, 2004, J VIROL, V78, P10706, DOI 10.1128/jvi.78.19.10706-10714.2004
   Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200
   Andersen ES, 2004, J BIOL CHEM, V279, P22243, DOI 10.1074/jbc.M314326200
   Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002
   Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200                                                          
   BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5
   Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1
   Berkhout B, 1996, J VIROL, V70, P6723
   Berkhout B, 2000, Adv Pharmacol, V48, P29
   Clever JL, 1997, J VIROL, V71, P3407
   Damgaard CK, 2004, J MOL BIOL, V336, P369, DOI 10.1016/j.jmb.2003.12.010
   DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y
   DIBHAJJ F, 1993, PROTEIN SCI, V2, P231
   Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301
   Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585
   Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881                                                       
   Jakobsen MR, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh064
   Jalalirad M, 2010, VIROLOGY, V407, P225, DOI 10.1016/j.virol.2010.08.013
   KHAN R, 1992, J BIOL CHEM, V267, P6689
   KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7
   LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P9366, DOI 10.1021/bi960395s                                                               
   Laughrea M, 2001, VIROLOGY, V281, P109, DOI 10.1006/viro.2000.0778
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f                                                               
   Laughrea M, 1997, J VIROL, V71, P3397
   LEAR AL, 1995, VIROLOGY, V212, P47, DOI 10.1006/viro.1995.1452
   Loweth CJ, 1999, ANGEW CHEM INT EDIT, V38, P1808, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1808::AID-ANIE1808>3.3.CO;2-3
   MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145
   MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349
   Miyazaki Y, 2010, J MOL BIOL, V404, P751, DOI 10.1016/j.jmb.2010.09.009
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686                                                        
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Ooms M, 2007, NUCLEIC ACIDS RES, V35, P1649, DOI 10.1093/nar/gkm046
   Ortiz-Conde BA, 1999, J VIROL, V73, P7165
   Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200
   Pallesen J, 2009, FEBS J, V276, P4223, DOI 10.1111/j.1742-4658.2009.07130.x
   PRATS AC, 1988, EMBO J, V7, P1777
   Sakuragi J, 1997, J VIROL, V71, P3250
   Sakuragi JI, 2007, J VIROL, V81, P7985, DOI 10.1128/JVI.00429-07
   Santos NC, 2004, BIOPHYS CHEM, V107, P133, DOI 10.1016/j.bpc.2003.09.001
   Shen N, 2000, J VIROL, V74, P5729, DOI 10.1128/JVI.74.12.5729-5735.2000
   Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Song R, 2008, BIOCHEMISTRY-US, V47, P3283, DOI 10.1021/bi7023173
   Tanigawa M, 1998, ANAL CHIM ACTA, V365, P19, DOI 10.1016/S0003-2670(97)00709-5                                                   
   TSUCHIHASHI Z, 1994, J VIROL, V68, P5863
   YOU JC, 1994, J BIOL CHEM, V269, P31491
NR 47
TC 3
Z9 4
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 19
PY 2011
VL 50
IS 28
BP 6170
EP 6177
DI 10.1021/bi200488h
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 790VF
UT WOS:000292617600002
PM 21663314
DA 2018-01-05
ER

PT J
AU Hu, YW
   Hua, SC
   Li, FH
   Jiang, YY
   Bai, XX
   Li, D
   Niu, L
AF Hu, Yuwei
   Hua, Shucheng
   Li, Fenghua
   Jiang, Yuanyuan
   Bai, Xiaoxue
   Li, Dan
   Niu, Li
TI Green-synthesized gold nanoparticles decorated graphene sheets for
   label-free electrochemical impedance DNA hybridization biosensing
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Gold nanoparticles; Graphene; Label-free; Impedance; DNA
ID IONIC LIQUID; PAT GENE; ELECTRODES; SENSOR; COMPOSITE; PROBE; OXIDE;
   ACID; FILM; SENSITIVITY
AB Sensitive electrochemical impedance assay of DNA hybridization by using a novel graphene sheets platform was achieved. The graphene sheets were firstly functionalized with 3,4,9,10-perylene tetracarboxylic acid (PICA). PICA molecules separated graphene sheets efficiently and introduced more negatively-charged -COOH sites, both of which were beneficial to the decoration of graphene with gold nanoparticles. Then amine-terminated ionic liquid (NH2-IL) was applied to the reduction of HAuCl4 to gold nanoparticles. The green-synthesized gold nanoparticles, with the mean diameter of 3 nm, dispersed uniformly on graphene sheets and its outer layer was positively charged imidazole termini. Due to the presence of large graphene sheets and NH2-IL protected gold nanoparticles, DNA probes could be immobilized via electrostatic interaction and adsorption effect. Electrochemical impedance value increased after DNA probes immobilization and hybridization, which was adopted as the signal for label-free DNA hybridization detection. Unlike previously anchoring DNA to gold nanoparticles, this label-free method was simple and noninvasive. The conserved sequence of the pot gene of human immunodeficiency virus 1 was satisfactorily detected via this strategy. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Hu, Yuwei; Hua, Shucheng; Bai, Xiaoxue; Li, Dan; Niu, Li] Jilin Univ, Coll Chem, Changchun 130021, Peoples R China.
   [Hu, Yuwei; Hua, Shucheng; Bai, Xiaoxue; Li, Dan; Niu, Li] Jilin Univ, Norman Bethune Coll Med, Changchun 130021, Peoples R China.
   [Hu, Yuwei; Li, Fenghua; Jiang, Yuanyuan; Niu, Li] Chinese Acad Sci, Changchun Inst Appl Chem, Engn Lab Modern Analyt Techn, State Key Lab Electroanalyt Chem, Changchun 130022, Peoples R China.
RP Hua, SC (reprint author), Jilin Univ, Coll Chem, Changchun 130021, Peoples R China.
EM huashucheng@jlu.edu.cn; lniu@ciac.jl.cn
OI niu, li/0000-0003-3652-2903
FU NSFC, China [20827004]; Department of Science and Technology of Jilin
   Province [20080518]; Chinese Academy of Science [KGCX2-YW-231, YZ200906,
   YZ2010018]
FX The authors are most grateful to the NSFC, China (20827004), the
   Department of Science and Technology of Jilin Province (No.20080518) and
   Chinese Academy of Science (KGCX2-YW-231, and YZ200906, YZ2010018) for
   their financial support.
CR Alfonta L, 2001, ANAL CHEM, V73, P91, DOI 10.1021/ac00819v
   Bai YH, 2010, ANALYST, V135, P1672, DOI 10.1039/b923847f
   Batchelor-McAuley C, 2009, BIOSENS BIOELECTRON, V24, P3183, DOI 10.1016/j.bios.2009.01.045
   Chen CP, 2009, ANAL CHEM, V81, P36, DOI 10.1021/ac800986q
   Dong XC, 2010, ADV MATER, V22, P1649, DOI 10.1002/adma.200903645
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Feng YY, 2008, ANAL CHIM ACTA, V616, P144, DOI 10.1016/j.aca.2008.04.022
   Fujii S, 2010, J AM CHEM SOC, V132, P10034, DOI 10.1021/ja101265r
   Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877
   Guo HL, 2009, ACS NANO, V3, P2653, DOI 10.1021/nn900227d
   Hu YW, 2010, CHEM-EUR J, V16, P1992, DOI 10.1002/chem.200901870
   Hu YW, 2011, CHEM COMMUN, V47, P1743, DOI 10.1039/c0cc04514d
   Huang X, 2010, SMALL, V6, P513, DOI 10.1002/smll.200902001
   Katz E, 2005, J AM CHEM SOC, V127, P9191, DOI 10.1021/ja0517771
   Keighley SD, 2008, BIOSENS BIOELECTRON, V23, P1291, DOI 10.1016/j.bios.2007.11.012
   Kovtyukhova NI, 1999, CHEM MATER, V11, P771, DOI 10.1021/cm981085u                                                               
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Li FH, 2010, LANGMUIR, V26, P12314, DOI 10.1021/la101534n
   Li FH, 2010, TALANTA, V81, P1063, DOI 10.1016/j.talanta.2010.01.061
   Li FH, 2009, J MATER CHEM, V19, P4022, DOI 10.1039/b902791b
   Liu JY, 2005, ANAL CHEM, V77, P2756, DOI 10.1021/ac048088c
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Lu CH, 2010, CHEM COMMUN, V46, P3116, DOI 10.1039/b926893f
   Lu W, 2008, BIOSENS BIOELECTRON, V23, P1534, DOI 10.1016/j.bios.2008.01.011
   Paenke O, 2008, ADV BIOCHEM ENG BIOT, V109, P195, DOI 10.1007/10_2007_081
   Peng H, 2007, J AM CHEM SOC, V129, P3048, DOI 10.1021/ja0685452
   Peng H, 2009, BIOMATERIALS, V30, P2132, DOI 10.1016/j.biomaterials.2008.12.065
   Peter C, 2001, FRESEN J ANAL CHEM, V371, P120, DOI 10.1007/s002160101006
   Shiigi H, 2005, J AM CHEM SOC, V127, P3280, DOI 10.1021/ja0445793
   Tang LAL, 2010, J AM CHEM SOC, V132, P10976, DOI 10.1021/ja104017y
   Thomas SW, 2007, CHEM REV, V107, P1339, DOI 10.1021/cr0501339
   Wang ZJ, 2008, GREEN CHEM, V10, P907, DOI 10.1039/b806453a
   Williams G, 2008, ACS NANO, V2, P1487, DOI 10.1021/nn800251f
   Williams G, 2009, LANGMUIR, V25, P13869, DOI 10.1021/la900905h
   Yang HF, 2010, LANGMUIR, V26, P6708, DOI 10.1021/la100365z
   Yang HF, 2009, J MATER CHEM, V19, P4632, DOI 10.1039/b901421g
   Yang HF, 2009, CHEM COMMUN, P3880, DOI 10.1039/b905085j
   Yang J, 2007, ANAL BIOCHEM, V365, P24, DOI 10.1016/j.ab.2006.12.039
   Yang T, 2008, TALANTA, V75, P987, DOI 10.1016/j.talanta.2007.12.049
   Yang WR, 2002, ELECTROANAL, V14, P1299, DOI 10.1002/1521-4109(200210)14:18<1299::AID-ELAN1299>3.0.CO;2-Y
   Yin Y, 2005, NATURE, V437, P664, DOI 10.1038/nature04165
   Zhang XZ, 2009, ANAL CHEM, V81, P6006, DOI 10.1021/ac802026j
   Zhou N, 2009, TALANTA, V77, P1021, DOI 10.1016/j.talanta.2008.07.058
   Zhu JM, 2007, J PHYS CHEM C, V111, P7629, DOI 10.1021/jp0711850
NR 44
TC 57
Z9 59
U1 5
U2 116
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JUL 15
PY 2011
VL 26
IS 11
BP 4355
EP 4361
DI 10.1016/j.bios.2011.04.037
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 797DG
UT WOS:000293104100016
PM 21592769
DA 2018-01-05
ER

PT J
AU Kheiri, F
   Sabzi, RE
   Jannatdoust, E
   Shojaeefar, E
   Sedghi, H
AF Kheiri, F.
   Sabzi, R. E.
   Jannatdoust, E.
   Shojaeefar, E.
   Sedghi, H.
TI A novel amperometric immunosensor based on acetone-extracted propolis
   for the detection of the HIV-1 p24 antigen
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Immunosensor; p24 antigen; Gold nanoparticles; Acetone-extracted
   propolis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GOLD NANOPARTICLES; MODIFIED ELECTRODE;
   ASSAYS; ANTIBACTERIAL; INFECTION; SURFACE
AB A novel amperometric immunosensor for the detection of the p24 antigen (p24Ag) from HIV-1 was constructed using gold nanoparticles (GNP), multi-walled carbon nanotubes (MWCNTs), and an acetone-extracted propolis film (AEP). First, amino-functionalized MWCNTs (MWCNTNH2) were prepared and dispersed in an HAuCl4 solution to synthesize GNPs in situ. Next, the GNP/CNT/AEP nanocomposite was prepared by mixing an AEP solution and the GNP/CNT powder. The nanocomposite was dripped onto a gold electrode (GE), and then p24 antibody (anti-p24 Ab) was immobilized on the resulting modified gold electrode to construct the immunosensor. The assembly process was characterized using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). The factors that were likely to influence the performance of the proposed immunosensor were studied in detail. Under optimal conditions, the proposed immunosensor exhibited good electrochemical sensitivity to the presence of p24 in a concentration range of 0.01 to 60.00 ng/mL, with a relatively low detection limit of 0.0064 ng/mL(S/N = 3). Moreover, the proposed immunosensor showed a rapid (<= 18 s) and highly sensitive amperometric response (0.018 and 1.940 mu A/ng mL(-1)) to p24 with acceptable stability and reproducibility. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Kheiri, F.; Sabzi, R. E.] Urmia Univ, Fac Sci, Dept Chem, Orumiyeh, Iran.
   [Kheiri, F.; Sabzi, R. E.; Shojaeefar, E.] Urmia Univ, Inst Biotechnol, Orumiyeh, Iran.
   [Jannatdoust, E.] Urmia Univ Technol, Fac Chem Engraining, Orumiyeh, Iran.
   [Sedghi, H.] Urmia Univ, Fac Sci, Dept Phys, Orumiyeh, Iran.
RP Sabzi, RE (reprint author), Urmia Univ, Fac Sci, Dept Chem, Orumiyeh, Iran.
EM rezasabzi@yahoo.com
FU Iran National Science Foundation (INSF) [89003551]
FX The authors herein express their great appreciation for the financial
   support received from Iran National Science Foundation (INSF) (Project
   No. 89003551).
CR Abbas K.A., 2005, CELLULAR MOL IMMUNOL, P464
   Bo Q., 2010, ANAL CHIM ACTA, V663, P147
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   Castilho PV, 2005, PEPTIDES, V26, P243, DOI 10.1016/j.peptides.2004.09.014
   Daniel A., 2005, LANGMUIR, V21, P6891
   Dianping Tang, 2010, Journal of Agricultural and Food Chemistry, V58, P10824
   Gan N, 2008, CHINESE J ANAL CHEM, V36, P1167, DOI 10.1016/S1872-2040(08)60064-X                                                   
   Gan N, 2010, MOLECULES, V15, P5053, DOI 10.3390/molecules15075053
   Girgin G, 2009, IMMUNOBIOLOGY, V214, P129, DOI 10.1016/j.imbio.2008.07.002
   Goldsby R.A., 2000, KUBY IMMUNOLOGY, P467
   Gurtler L, 1996, LANCET, V348, P176, DOI 10.1016/S0140-6736(96)01036-7
   Hermanson T., 2008, BIOCONJUGATE TECHNIQ, P379
   Huleihel M, 2009, J PHOTOCH PHOTOBIO B, V96, P17, DOI 10.1016/j.jphotobiol.2009.03.009
   Iweala OI, 2004, CONTRACEPTION, V70, P141, DOI 10.1016/j.contraception.2004.03.012
   Jiang XS, 2008, BIOSENS BIOELECTRON, V23, P1577, DOI 10.1016/j.bios.2008.01.035
   Kheiri F., 2011, J SOLID STATE ELECTR, DOI 1007/s.10008-010-1250-2
   Kim EY, 2008, NANOMEDICINE-UK, V3, P293, DOI 10.2217/17435889.3.3.293
   Kujumgiev A, 1999, J ETHNOPHARMACOL, V64, P235, DOI 10.1016/S0378-8741(98)00131-7
   Li N, 2010, ELECTROCHEM COMMUN, V12, P939, DOI 10.1016/j.elecom.2010.04.026
   Li WJ, 2010, BIOSENS BIOELECTRON, V25, P2548, DOI 10.1016/j.bios.2010.04.011
   Lin JH, 2009, ANAL BIOCHEM, V384, P130, DOI 10.1016/j.ab.2008.09.033
   Ly TD, 2001, EUR J CLIN MICROBIOL, V20, P104, DOI 10.1007/s10096-001-8057-0
   Ly TD, 2007, J VIROL METHODS, V143, P86, DOI 10.1016/j.jviromet.2007.02.013
   Mehmet S., 2010, SENSOR ACTUAT B-CHEM, V145, P444
   Ou CF, 2007, ANAL CHIM ACTA, V603, P205, DOI 10.1016/j.aca.2007.08.052
   Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
   Respess RA, 2001, AIDS, V15, pS49, DOI 10.1097/00002030-200104003-00007
   Rezaei B, 2011, BIOSENS BIOELECTRON, V26, P2130, DOI 10.1016/j.bios.2010.09.020
   ROSSMANN MG, 1988, P NATL ACAD SCI USA, V85, P4625, DOI 10.1073/pnas.85.13.4625
   Shimizu K, 2004, ARCH BIOCHEM BIOPHYS, V424, P181, DOI 10.1016/j.abb.2004.02.021
   Tang DP, 2004, ANAL BIOCHEM, V333, P345, DOI 10.1016/j.ab.2004.06.035
   Teeparuksapun K, 2010, ANAL CHEM, V82, P8406, DOI 10.1021/ac102144a
   Xuan L., 2010, ANAL CHEM, V82, P7351
   Ya-dong C., 2009, CHIN J SENS ACTUATOR, V2, P53
   Ying Z., 2006, SENSOR ACTUAT B-CHEM, V114, P631
   Zhuo Y, 2008, BIOMATERIALS, V29, P1501, DOI 10.1016/j.biomaterials.2007.12.007
NR 36
TC 27
Z9 28
U1 2
U2 37
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JUL 15
PY 2011
VL 26
IS 11
BP 4457
EP 4463
DI 10.1016/j.bios.2011.05.002
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 797DG
UT WOS:000293104100032
PM 21621403
DA 2018-01-05
ER

PT J
AU Labib, M
   Martic, S
   Shipman, PC
   Kraatz, HB
AF Labib, Mahmoud
   Martic, Sanela
   Shipman, Patrick C.
   Kraatz, Heinz-Bernhard
TI Electrochemical analysis of HIV-1 reverse transcriptase serum level:
   Exploiting protein binding to a functionalized nanostructured surface
SO TALANTA
LA English
DT Article
DE HIV-1 reverse transcriptase; Ferrocene; Square wave voltammetry;
   Bioorganometallics; Nanogold
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NANOTUBE MODIFIED ELECTRODE; EDGE-PLANE
   SITES; CARBON ELECTRODES; MASS-SPECTROMETRY; VIRAL LOAD; ASSAY;
   BIOSENSOR; SENSOR; FILMS
AB This manuscript describes an electrochemical approach to the detection of the reverse transcriptase of the human immunodeficiency virus type-1 (HIV-1 RT) in serum exploiting an organometallic peptide conjugate that is chemically linked to a nanostructured gold surface. The assay format is based on the formation of a thin film of a ferrocene-labeled lipoic acid (Fc-LA) onto a gold nanoparticles-functionalized screen-printed carbon electrode (GNPs-SPCE). Time-of-Flight secondary ion mass spectrometry (TOF-SIMS) and X-ray photoelectron spectroscopy were employed to confirm the binding of the Fc-LA to the electrode surface via formation of a gold-thiol bond. The RT biosensor was developed by covalent attachment of the peptide VEAIIRILQQLLFIH to the carboxylic acid group of Fc-LA. Square wave voltammetry offered a two-dimensional measurement of RT based on the anodic shift and reduction of current density of the Fc redox signal upon binding of RT to its specific peptide. This allowed a linear quantification of the target RT in the range of 1-500 pg mL(-1) equivalent to 0.9-427 fM, with a detection limit of 0.8 pg mL(-1) (0.7 fM) with a short response time. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Labib, Mahmoud; Martic, Sanela; Shipman, Patrick C.; Kraatz, Heinz-Bernhard] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada.
RP Kraatz, HB (reprint author), Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 5B7, Canada.
EM hkraatz@uwo.ca
RI Labib, Mahmoud/P-2267-2014; Kraatz, Heinz-Bernhard/D-2246-2014
OI Labib, Mahmoud/0000-0003-4565-2056; Kraatz,
   Heinz-Bernhard/0000-0002-7149-0110
FU University of Western Ontario; Natural Sciences and Engineering Research
   Council of Canada (NSERC); Western Innovation Fund (WIF)
FX M. Labib is grateful to the University of Western Ontario for funding.
   This work was supported by grants from the Natural Sciences and
   Engineering Research Council of Canada (NSERC) and the Western
   Innovation Fund (WIF). The author is also thankful to Western Surface
   Science Department and Nanofabrication facility for access to their
   instruments and for valuable assistance.
CR Angleraud B, 2001, DIAM RELAT MATER, V10, P1142, DOI 10.1016/S0925-9635(00)00384-8                                                   
   Appoh FE, 2007, J PHYS CHEM C, V111, P4235, DOI 10.1021/jp065363l
   Appoh FE, 2006, LANGMUIR, V22, P10515, DOI 10.1021/la061114c
   Banks CE, 2005, CHEM COMMUN, P829, DOI 10.1039/b413177k
   Bard A. J., 2001, ELECTROCHEMICAL METH
   Belu AM, 2003, BIOMATERIALS, V24, P3635, DOI 10.1016/S0142-9612(03)00159-5
   Brown P, 2000, NATURE, V405, P263, DOI 10.1038/35012760                                                                
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Chen JC, 2006, SENSOR ACTUAT B-CHEM, V115, P473, DOI 10.1016/j.snb.2005.10.015
   Creager SE, 1998, ANAL CHEM, V70, P4257, DOI 10.1021/ac980482l                                                               
   Cui G, 2001, ANALYST, V126, P1399, DOI 10.1039/b102934g
   Darmstadt H, 2003, CARBON, V41, P2662, DOI 10.1016/S0008-6223(03)00325-7
   Dekanski A, 2001, CARBON, V39, P1195, DOI 10.1016/S0008-6223(00)00228-1                                                   
   Dey SK, 2007, LANGMUIR, V23, P6475, DOI 10.1021/la070175n
   Escamilla-Gomez V, 2009, BIOSENS BIOELECTRON, V24, P2678, DOI 10.1016/j.bios.2009.01.043
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Feng B, 2009, J IMMUNOASS IMMUNOCH, V30, P457, DOI 10.1080/15321810903188318
   Garcia-Gonzalez R, 2008, ELECTROCHIM ACTA, V53, P3242, DOI 10.1016/j.electacta.2007.07.059
   Ghamouss F, 2007, ELECTROCHIM ACTA, V52, P5053, DOI 10.1016/j.electacta.2007.02.015
   Ghamouss F, 2009, ELECTROCHIM ACTA, V54, P3026, DOI 10.1016/j.electacta.2008.12.011
   Ghamouss F, 2010, ELECTROCHIM ACTA, V55, P6517, DOI 10.1016/j.electacta.2010.06.028
   Gleenberg IO, 2007, J MOL BIOL, V369, P1230, DOI 10.1016/j.jmb.2007.03.073
   Gronewold TMA, 2009, J PROTEOME RES, V8, P3568, DOI 10.1021/pr900265r
   Hanif M, 2010, INORG CHEM, V49, P7953, DOI 10.1021/ic1009785
   Ji XB, 2006, CHEMPHYSCHEM, V7, P1337, DOI 10.1002/cphc.200600098
   Jiang XQ, 2010, BIOSENS BIOELECTRON, V25, P1622, DOI 10.1016/j.bios.2009.11.024
   Kadara RO, 2008, ELECTROCHEM COMMUN, V10, P1517, DOI 10.1016/j.elecom.2008.08.002
   Kadara RO, 2009, SENSOR ACTUAT B-CHEM, V138, P556, DOI 10.1016/j.snb.2009.01.044
   KALIA V, 2005, J VIROL, V79, P2079
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   Kim YP, 2007, ANGEW CHEM INT EDIT, V46, P6816, DOI 10.1002/anie.200701418
   Krebs JF, 2008, BIOCONJUGATE CHEM, V19, P185, DOI 10.1021/bc700284y
   LABIB M, 2011, ELECTROCHIM IN PRESS, DOI DOI 10.1016/J.ELECTACTA.2011.03.063
   Labib M, 2009, ANAL CHIM ACTA, V634, P255, DOI 10.1016/j.aca.2008.12.035
   Labib M, 2011, ANALYST, V136, P708, DOI 10.1039/c0an00741b
   Labib M, 2010, ANAL BIOANAL CHEM, V397, P1217, DOI 10.1007/s00216-010-3641-8
   Labib M, 2010, ANAL CHIM ACTA, V659, P194, DOI 10.1016/j.aca.2009.11.028
   Labib M, 2009, BIOTECHNOL BIOENG, V104, P312, DOI 10.1002/bit.22395
   Labib M, 2009, ANAL BIOANAL CHEM, V393, P1539, DOI 10.1007/s00216-008-2559-x
   Lakshminarayanan PV, 2004, CARBON, V42, P2433, DOI 10.1016/j.carbon.2004.04.040
   LAVIRON E, 1982, ELECTROANAL CHEM, V12, P53
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   Lee KS, 2010, BIOMATERIALS, V31, P7827, DOI 10.1016/j.biomaterials.2010.06.052
   Liu DZ, 2002, J PHYS CHEM B, V106, P2933, DOI 10.1021/jp011876a
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mahmoud KA, 2007, CHEM-EUR J, V13, P5885, DOI 10.1002/chem.200601878
   Mahmoud KA, 2010, ANAL LETT, V43, P1680, DOI 10.1080/00032711003653924
   Manocha M, 2003, IMMUNOL LETT, V85, P275, DOI 10.1016/S0165-2478(02)00257-2                                                   
   Martic S, 2011, ANALYST, V136, P107, DOI 10.1039/c0an00438c
   Muller J, 2010, METHODS MOL BIOL, V630, P319, DOI 10.1007/978-1-60761-629-0_20
   Newton MD, 2007, PHYS CHEM CHEM PHYS, V9, P555, DOI 10.1039/b611448b
   OSTERYOUNG J, 1986, ELECTROANAL CHEM, V14, P209
   Qi H, 2003, J AM CHEM SOC, V125, P15250, DOI 10.1021/ja0371909
   Rao CNR, 2000, CHEM SOC REV, V29, P27, DOI 10.1039/a904518j                                                                
   Ricci F, 2007, CHEM COMMUN, P3768, DOI 10.1039/b708882e
   Ricci F, 2007, LANGMUIR, V23, P6827, DOI 10.1021/la700328r
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   ROWE GK, 1994, J PHYS CHEM-US, V98, P5500, DOI 10.1021/j100072a017                                                             
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Sek S, 2003, J ELECTROANAL CHEM, V550, P359, DOI 10.1016/S0022-0728(03)00025-1
   Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005
   Swanson P, 2005, J CLIN MICROBIOL, V43, P3860, DOI 10.1128/JCM.43.8.3860-3868.2005
   Tetard F, 2005, THIN SOLID FILMS, V482, P192, DOI 10.1016/j.tsf.2004.11.172
   Torti C, 2007, HIV CLIN TRIALS, V8, P112, DOI 10.1310/hct0803-112
   Wei H, 2007, ANAL CHIM ACTA, V588, P297, DOI 10.1016/j.aca.2007.02.006
   Zanello P., 2003, INORGANIC ELECTROCHE
   ZHANG H, 2008, J AM CHEM SOC, V134, P34
   Zhang HQ, 2006, ANGEW CHEM INT EDIT, V45, P1576, DOI 10.1002/anie.200503345
NR 69
TC 25
Z9 25
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD JUL 15
PY 2011
VL 85
IS 1
BP 770
EP 778
DI 10.1016/j.talanta.2011.04.070
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 793UH
UT WOS:000292848900110
PM 21645772
DA 2018-01-05
ER

PT J
AU Pylaev, TE
   Khanadeev, VA
   Khlebtsov, BN
   Dykman, LA
   Bogatyrev, VA
   Khlebtsov, NG
AF Pylaev, T. E.
   Khanadeev, V. A.
   Khlebtsov, B. N.
   Dykman, L. A.
   Bogatyrev, V. A.
   Khlebtsov, N. G.
TI Colorimetric and dynamic light scattering detection of DNA sequences by
   using positively charged gold nanospheres: a comparative study with gold
   nanorods
SO NANOTECHNOLOGY
LA English
DT Article
ID COLLOIDAL GOLD; NANOPARTICLES; SPECTROSCOPY; AGGREGATION; ABSORPTION;
   PROTEINS; SPECTRA; PROBE; SIZE
AB We introduce a new genosensing approach employing CTAB (cetyltrimethylammonium bromide)-coated positively charged colloidal gold nanoparticles (GNPs) to detect target DNA sequences by using absorption spectroscopy and dynamic light scattering. The approach is compared with a previously reported method employing unmodified CTAB-coated gold nanorods (GNRs). Both approaches are based on the observation that whereas the addition of probe and target ssDNA to CTAB-coated particles results in particle aggregation, no aggregation is observed after addition of probe and nontarget DNA sequences. Our goal was to compare the feasibility and sensitivity of both methods. A 21-mer ssDNA from the human immunodeficiency virus type 1 HIV-1 U5 long terminal repeat (LTR) sequence and a 23-mer ssDNA from the Bacillus anthracis cryptic protein and protective antigen precursor (pagA) genes were used as ssDNA models. In the case of GNRs, unexpectedly, the colorimetric test failed with perfect cigar-like particles but could be performed with dumbbell and dog-bone rods. By contrast, our approach with cationic CTAB-coated GNPs is easy to implement and possesses excellent feasibility with retention of comparable sensitivity-a 0.1 nM concentration of target cDNA can be detected with the naked eye and 10 pM by dynamic light scattering (DLS) measurements. The specificity of our method is illustrated by successful DLS detection of one-three base mismatches in cDNA sequences for both DNA models. These results suggest that the cationic GNPs and DLS can be used for genosensing under optimal DNA hybridization conditions without any chemical modifications of the particle surface with ssDNA molecules and signal amplification. Finally, we discuss a more than two-three-order difference in the reported estimations of the detection sensitivity of colorimetric methods (0.1 to 10-100 pM) to show that the existing aggregation models are inconsistent with the detection limits of about 0.1-1 pM DNA and that other explanations should be developed.
C1 [Pylaev, T. E.; Khanadeev, V. A.; Khlebtsov, B. N.; Dykman, L. A.; Bogatyrev, V. A.; Khlebtsov, N. G.] RAS, Inst Biochem & Physiol Plants & Microorganisms, Saratov 410049, Russia.
   [Bogatyrev, V. A.; Khlebtsov, N. G.] Saratov NG Chernyshevskii State Univ, Saratov 410012, Russia.
RP Khlebtsov, NG (reprint author), RAS, Inst Biochem & Physiol Plants & Microorganisms, 13 Prospekt Entuziastov, Saratov 410049, Russia.
EM khlebtsov@ibppm.sgu.ru
RI Khanadeev, Vitaly/N-5817-2016; Pylaev, Timofey/A-8401-2016; Khlebtsov,
   Nikolai/D-6199-2017
OI Khanadeev, Vitaly/0000-0003-3404-5402; Khlebtsov,
   Nikolai/0000-0002-2055-7784
FU Russian Foundation for Basic Research; Ministry of Education and Science
   of the Russian Federation [1057.2011.2, 2.1.1/2950, 14.740.11.260,
   02.740.11.0484]; Government of the RF
FX This research was supported by the Russian Foundation for Basic
   Research, by grants from the President and the Ministry of Education and
   Science of the Russian Federation (nos-1057.2011.2, 2.1.1/2950,
   14.740.11.260, and 02.740.11.0484), and by a grant from the Government
   of the RF designed to support scientific research projects implemented
   under the supervision of leading scientists at Russian institutions of
   higher education. We thank D N Tychinin (IBPPM RAS) for his help in
   preparation of the manuscript.
CR Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391
   Berne B.J., 2000, DYNAMIC LIGHT SCATTE
   Bogatyrev VA, 2004, OPT SPECTROSC+, V96, P128, DOI 10.1134/1.1643997
   CIESIOLKA T, 1988, ANAL BIOCHEM, V168, P280, DOI 10.1016/0003-2697(88)90319-3
   D'Agata R, 2010, BIOSENS BIOELECTRON, V25, P2095, DOI 10.1016/j.bios.2010.02.008
   Dai Q, 2008, J AM CHEM SOC, V130, P8138, DOI 10.1021/ja801947e
   Darbha GK, 2008, CHEM-EUR J, V14, P3896, DOI 10.1002/chem.200701850
   Doria G, 2007, IET NANOBIOTECHNOL, V1, P53, DOI 10.1049/iet-nbt:20070001
   Dujardin E, 2001, CHEM COMMUN, P1264, DOI 10.1039/b102319p                                                                
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Hu J, 2010, ANALYST, V135, P1084, DOI 10.1039/b920358c
   Jain PK, 2010, CHEM PHYS LETT, V487, P153, DOI 10.1016/j.cplett.2010.01.062
   Khlebtsov BN, 2011, COLLOID J+, V73, P118, DOI 10.1134/S1061933X11010078
   Khlebtsov B, 2006, NANOTECHNOLOGY, V17, P5167, DOI 10.1088/0957-4484/17/20/022
   Khlebtsov NG, 2004, J QUANT SPECTROSC RA, V89, P133, DOI 10.1016/j.jqsrt.2004.05.017
   Khlebtsov NG, 2000, COLLOID J+, V62, P765, DOI 10.1023/A:1026643111821                                                         
   Khlebtsov NG, 2008, ANAL CHEM, V80, P6620, DOI 10.1021/ac800834n
   Lee JH, 2010, ADV DRUG DELIVER REV, V62, P592, DOI 10.1016/j.addr.2010.03.003
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Ma ZF, 2010, ANAL CHIM ACTA, V673, P179, DOI 10.1016/j.aca.2010.05.036
   Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Oldenburg SJ, 2002, ANAL BIOCHEM, V309, P109, DOI 10.1016/S0003-2697(02)00410-4
   Pan BF, 2005, NANOTECHNOLOGY, V16, P1776, DOI 10.1088/0957-4484/16/9/061
   Ratto F, 2010, J NANOPART RES, V12, P2029, DOI 10.1007/s11051-009-9712-0
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Sato K, 2006, ANAL BIOCHEM, V350, P162, DOI 10.1016/j.ab.2005.12.009
   Sato K., 2005, NUCLEIC ACIDS RES, V33, pD174
   Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z
   Shawky SM, 2010, CLIN BIOCHEM, V43, P1163, DOI 10.1016/j.clinbiochem.2010.07.001
   Song JZ, 2010, CHEM COMMUN, V46, P5548, DOI 10.1039/c0cc00308e
   Storhoff JJ, 2000, J AM CHEM SOC, V122, P4640, DOI 10.1021/ja993825l                                                               
   Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i                                                               
   Wang LH, 2006, CHEM COMMUN, P3780, DOI 10.1039/b607448k
   WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8
   Witten KG, 2008, PHYS CHEM CHEM PHYS, V10, P1870, DOI 10.1039/b719762d
   Xia F, 2010, P NATL ACAD SCI USA, V107, P10837, DOI 10.1073/pnas.1005632107
NR 37
TC 17
Z9 18
U1 2
U2 41
PU IOP PUBLISHING LTD
PI BRISTOL
PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND
SN 0957-4484
J9 NANOTECHNOLOGY
JI Nanotechnology
PD JUL 15
PY 2011
VL 22
IS 28
AR 285501
DI 10.1088/0957-4484/22/28/285501
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA 775NX
UT WOS:000291468000020
PM 21625041
DA 2018-01-05
ER

PT J
AU Lehtovaara, BC
   Gu, FX
AF Lehtovaara, Benjamin C.
   Gu, Frank X.
TI Pharmacological, Structural, and Drug Delivery Properties and
   Applications of 1,3-beta-Glucans
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Review
DE 1,3-beta-glucans; Curdlan; schizophyllan; helix; freeze-thaw; antitumor;
   infection; nanostructure; nanoparticle; drug delivery; polynucleotide
ID LIQUID-CRYSTALLINE GEL; FAECALIS VAR MYXOGENES; ANTI-HIV ACTIVITY;
   POLYSACCHARIDE-POLYNUCLEOTIDE COMPLEXES; ATOMIC-FORCE MICROSCOPY; AIDS
   VIRUS-INFECTION; ONE-DIMENSIONAL HOST; BETA-GLUCAN; IN-VITRO; CURDLAN
   SULFATE
AB 1,3-beta-Glucans are a class of natural polysaccharides with unique pharmacological properties and the ability to form single- and triple-helical structures that can be formed into resilient gels with the application of heat and humidity. The pharmacological capabilities of 1,3-beta-glucans include the impartation of tumor inhibition, resistance to infectious disease, and improvements in wound healing. Curdlan is a linear 1,3-beta-glucan that has been used extensively to study the nature of these helical structures and gels, and Curdlan sulfates have found ongoing application in the inhibition of HIV infection. 1,3-beta-Glucan gels have been used in food science as stabilizers and encapsulating agents, in nanoscience as scaffolds to build nanofibers and nanowires, and in drug delivery to form nanoparticles and create helical micelles encapsulating polynucleotides. 1,3-beta-Glucans are beginning to have enormous significance due to their dual nature as structure:forming agents and pharmacological substances, and research is especially focused on the application of these polymers in animal nutrition and drug delivery.
C1 [Gu, Frank X.] Univ Waterloo, Waterloo Inst Nanotechnol, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
RP Gu, FX (reprint author), Univ Waterloo, Waterloo Inst Nanotechnol, Dept Chem Engn, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM frank.gu@uwaterloo.ca
RI Gu, Frank/G-8381-2011
OI Gu, Frank/0000-0001-8749-9075
CR Bae AH, 2007, NEW J CHEM, V31, P618, DOI 10.1039/b615757b
   BAGASRA O, 1988, J INFECT DIS, V158, P1084, DOI 10.1093/infdis/158.5.1084                                                       
   BLUHM TL, 1982, CARBOHYD RES, V100, P117, DOI 10.1016/S0008-6215(00)81030-7                                                   
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3
   Borjihan G, 2003, POLYM ADVAN TECHNOL, V14, P326, DOI 10.1002/pat.315
   BRADE V, 1973, J IMMUNOL, V111, P1389
   BROWDER W, 1988, SURGERY, V104, P224
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Cheung NKV, 2002, CANCER IMMUNOL IMMUN, V51, P557, DOI 10.1007/s00262-002-0321-3
   CHIHARA G, 1983, ADV EXP MED BIOL, V166, P189
   CHIHARA G, 1970, NATURE, V225, P943, DOI 10.1038/225943a0                                                                
   CHUAH CT, 1983, MACROMOLECULES, V16, P1375, DOI 10.1021/ma00242a020                                                             
   Czaja W, 2006, BIOMATERIALS, V27, P145, DOI 10.1016/j.biomaterials.2005.07.035
   CZOP JK, 1986, PATHOL IMMUNOPATH R, V5, P286, DOI 10.1159/000157022
   De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8
   Delatte SJ, 2001, J PEDIATR SURG, V36, P113, DOI 10.1053/jpsu.2001.20024
   DEMLEITNER S, 1992, CARBOHYD RES, V226, P247, DOI 10.1016/0008-6215(92)84072-Z
   DEMLEITNER S, 1992, CARBOHYD RES, V226, P239, DOI 10.1016/0008-6215(92)84071-Y
   DESLANDES Y, 1980, MACROMOLECULES, V13, P1466, DOI 10.1021/ma60078a020                                                             
   DILUZIO NR, 1978, INFECT IMMUN, V20, P804
   Dobashi T, 2005, LANGMUIR, V21, P2, DOI 10.1021/la047901w
   Dobashi T, 2004, LANGMUIR, V20, P6530, DOI 10.1021/la035822z
   DRITZ SS, 1995, J ANIM SCI, V73, P3341
   Dunstan DE, 2007, INT J BIOL MACROMOL, V40, P362, DOI 10.1016/j.ijbiomac.2006.09.016
   Eicher SD, 2006, J ANIM SCI, V84, P2352, DOI 10.2527/jas.2005-770
   Evans SG, 1998, T ROY SOC TROP MED H, V92, P87, DOI 10.1016/S0035-9203(98)90969-5
   Ferreira DS, 2009, J BRAZIL CHEM SOC, V20, P1908, DOI 10.1590/S0103-50532009001000020
   FUJIMOTO T, 1992, BIOTHERAPY, V5, P153, DOI 10.1007/BF02171701                                                              
   Funami T, 1998, J FOOD SCI, V63, P283
   Funami T, 1999, J FOOD SCI, V64, P883, DOI 10.1111/j.1365-2621.1999.tb15933.x
   Furusawa K, 2007, J PHYS CHEM B, V111, P14423, DOI 10.1021/jp076135+
   Gagnon MA, 2007, APPL SPECTROSC, V61, P374, DOI 10.1366/000370207780466136
   Gao Y, 1997, MACROMOLECULES, V30, P3224, DOI 10.1021/ma961711d                                                               
   Gao Y, 1999, MACROMOLECULES, V32, P8319, DOI 10.1021/ma990782k                                                               
   Gombotz WR, 1998, ADV DRUG DELIVER REV, V31, P267, DOI 10.1016/S0169-409X(97)00124-5
   HAMURO J, 1973, NATURE, V245, P40, DOI 10.1038/245040a0
   HAMURO J, 1971, NATURE, V233, P486, DOI 10.1038/233486a0
   HAMURO J, 1978, IMMUNOLOGY, V34, P695
   HARADA T, 1968, ARCH BIOCHEM BIOPHYS, V124, P292, DOI 10.1016/0003-9861(68)90330-5                                                    
   HARADA T, 1966, AGR BIOL CHEM TOKYO, V30, P196, DOI 10.1080/00021369.1966.10858574                                                  
   HARADA T, 1964, BIOCHIM BIOPHYS ACTA, V83, P374, DOI 10.1016/0926-6526(64)90023-0
   HARADA T, 1979, J ELECTRON MICROSC, V28, P147
   Haraguchi S, 2005, ORG LETT, V7, P5605, DOI 10.1021/ol052170s
   Hasegawa T, 2006, CHEM LETT, V35, P82, DOI 10.1246/cl.2006.82
   Hasegawa T, 2006, CARBOHYD RES, V341, P35, DOI 10.1016/j.carres.2005.10.009
   Hasegawa T, 2005, CHEM LETT, V34, P1118, DOI 10.1246/cl.2005.1118
   Hasegawa T, 2007, ORG BIOMOL CHEM, V5, P2404, DOI 10.1039/b703720a
   Hida TH, 2009, INFLAMM RES, V58, P9, DOI 10.1007/s00011-008-8141-3
   IINO K, 1985, CARBOHYD RES, V141, P111, DOI 10.1016/S0008-6215(00)90760-2
   Ikeda M, 2007, J AM CHEM SOC, V129, P3979, DOI 10.1021/ja0684343
   Ikeda S, 2005, J AGR FOOD CHEM, V53, P786, DOI 10.1021/jf048797r
   JAGODZINSKI PP, 1994, VIROLOGY, V202, P735, DOI 10.1006/viro.1994.1395
   Jagodzinski PP, 1996, VIROLOGY, V226, P217, DOI 10.1006/viro.1996.0649
   Jeon KJ, 1997, MACROMOLECULES, V30, P1997, DOI 10.1021/ma961392q                                                               
   Juul-Madsen HR, 2010, LIVEST SCI, V133, P249, DOI 10.1016/j.livsci.2010.06.078
   KANKE M, 1995, BIOL PHARM BULL, V18, P1104
   KANKE M, 1995, BIOL PHARM BULL, V18, P1154
   Karinaga R, 2006, BIOMATERIALS, V27, P1626, DOI 10.1016/j.biomaterials.2005.08.023
   Karinaga R, 2005, BIOMATERIALS, V26, P4866, DOI 10.1016/j.biomaterials.2004.11.031
   Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200
   Keenan J, 2010, ATHEROSCLEROSIS SUPP, V11, P123, DOI 10.1016/S1567-5688(10)70567-5                                                   
   Kerckhoffs DAJM, 2003, AM J CLIN NUTR, V78, P221
   Kim BD, 2005, EUR J PHARM SCI, V24, P199, DOI 10.1016/j.ejps.2004.10.008
   Kimura T, 2000, CHEM LETT, P1242, DOI 10.1246/cl.2000.1242
   KONNO A, 1991, FOOD HYDROCOLLOID, V5, P427, DOI 10.1016/S0268-005X(09)80101-X                                                   
   Kougias P, 2001, INFECT IMMUN, V69, P3933, DOI 10.1128/IAI.69.6.3933-3938.2001
   Koumoto K, 2001, CHEM LETT, P908, DOI 10.1246/cl.2001.908                                                             
   Lee MH, 2002, FOOD HYDROCOLLOID, V16, P345, DOI 10.1016/S0268-005X(01)00107-2
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378-5173(92)90353-4                                                    
   Leung TCY, 2010, MATER CHEM PHYS, V121, P402, DOI 10.1016/j.matchemphys.2010.02.026
   Li C, 2005, CHEM LETT, V34, P1532, DOI 10.1246/cl.2005.1532
   Li J, 2006, J ANIM SCI, V84, P2374, DOI 10.2527/jas.2004-541
   Li L, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265601
   Liu JJ, 2009, EXP MOL PATHOL, V86, P208, DOI 10.1016/j.yexmp.2009.01.006
   Ljungman AG, 1998, ENVIRON TOXICOL PHAR, V5, P273, DOI 10.1016/S1382-6689(98)00011-8
   MAEDA I, 1967, AGR BIOL CHEM TOKYO, V31, P1184, DOI 10.1080/00021369.1967.10858949                                                  
   MAEDA YY, 1974, NATURE, V252, P250, DOI 10.1038/252250a0
   MAEDA YY, 1971, NATURE, V229, P634, DOI 10.1038/229634a0
   Marchesan S, 2005, BIOORG MED CHEM LETT, V15, P3615, DOI 10.1016/j.bmcl.2005.05.069
   McIntire TM, 1998, J AM CHEM SOC, V120, P6909, DOI 10.1021/ja981203e                                                               
   Miyoshi K, 2005, BIOMACROMOLECULES, V6, P1540, DOI 10.1021/bm049218u
   Miyoshi K, 2004, CHEM BIODIVERS, V1, P916, DOI 10.1002/cbdv.200490073                                                          
   Moon CJ, 2005, PROCESS BIOCHEM, V40, P1279, DOI 10.1016/j.procbio.2004.05.009
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Naito T, 1998, MED MICROBIOL IMMUN, V187, P43, DOI 10.1007/s004300050072                                                           
   NAKAO Y, 1991, J FOOD SCI, V56, P769, DOI 10.1111/j.1365-2621.1991.tb05378.x
   Nobe M, 2005, BIOMACROMOLECULES, V6, P3373, DOI 10.1021/bm050420m
   Numata M, 2005, CHEM COMMUN, P4655, DOI 10.1039/b509285j
   Numata M, 2005, ORG BIOMOL CHEM, V3, P2255, DOI 10.1039/b500156k
   Numata M, 2004, CHEM LETT, V33, P232, DOI 10.1246/cl.2004.232                                                             
   Numata M, 2008, CHEM-EUR J, V14, P2398, DOI 10.1002/chem.200701205
   Ohno N, 2001, BIOL PHARM BULL, V24, P820, DOI 10.1248/bpb.24.820
   Ohno N, 1996, IMMUNOL LETT, V52, P1, DOI 10.1016/0165-2478(96)02538-2
   OHNO N, 1990, J PHARMACOBIO-DYNAM, V13, P525, DOI 10.1248/bpb1978.13.525                                                          
   OSAWA Z, 1993, CARBOHYD POLYM, V21, P283, DOI 10.1016/0144-8617(93)90060-H                                                    
   PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279
   Plahar MA, 2006, INT J FOOD SCI TECH, V41, P962, DOI 10.1111/j.1365-2621.2005.01153.x
   Portera CA, 1997, AM SURGEON, V63, P125
   Rice PJ, 2005, J PHARMACOL EXP THER, V314, P1079, DOI 10.1124/jpet.105.085415
   RIGGI SJ, 1961, AM J PHYSIOL, V200, P297
   Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0                                                   
   Ruiz-Herrera J, 2006, FEMS YEAST RES, V6, P14, DOI 10.1111/j.1567-1364.2005.00017.x
   SAITO H, 1977, BIOCHEMISTRY-US, V16, P908, DOI 10.1021/bi00624a015                                                             
   SASAKI T, 1979, EUR J CANCER, V15, P211, DOI 10.1016/0014-2964(79)90062-8                                                    
   SASAKI T, 1978, CANCER RES, V38, P379
   Sonck E, 2010, VET IMMUNOL IMMUNOP, V135, P199, DOI 10.1016/j.vetimm.2009.11.014
   Stuyven E, 2009, VET IMMUNOL IMMUNOP, V128, P60, DOI 10.1016/j.vetimm.2008.10.311
   Subedi RK, 2009, EUR J PHARM SCI, V37, P508, DOI 10.1016/j.ejps.2009.04.008
   SUNDARALINGAM M, 1968, BIOPOLYMERS, V6, P189, DOI 10.1002/bip.1968.360060204                                                      
   Sutherland IW, 2001, INT DAIRY J, V11, P663, DOI 10.1016/S0958-6946(01)00112-1
   Tada T, 1997, BIOPOLYMERS, V42, P479, DOI 10.1002/(SICI)1097-0282(19971005)42:4<479::AID-BIP10>3.0.CO;2-B
   Tada T, 2001, BIOPOLYMERS, V58, P129, DOI 10.1002/1097-0282(200102)58:2<129::AID-BIP20>3.0.CO;2-Z
   TAGUCHI T, 1983, ADV EXP MED BIOL, V166, P181
   TakedaHirokawa N, 1997, MICROBIOL IMMUNOL, V41, P741, DOI 10.1111/j.1348-0421.1997.tb01920.x                                              
   Ungurenasu C, 2007, J POLYM SCI POL CHEM, V45, P3124, DOI 10.1002/pola.22010
   van Bruggen R, 2009, MOL IMMUNOL, V47, P575, DOI 10.1016/j.molimm.2009.09.018
   Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777                                                               
   Wang WS, 1997, COMP IMMUNOL MICROB, V20, P261, DOI 10.1016/S0147-9571(96)00035-5
   Wasser SP, 2002, APPL MICROBIOL BIOT, V60, P258, DOI 10.1007/s00253-002-1076-7
   Wei D, 2002, WOUND REPAIR REGEN, V10, P161, DOI 10.1046/j.1524-475X.2002.10804.x                                                
   Williams PD, 2009, J FOOD PROCESS PRES, V33, P126, DOI 10.1111/j.1745-4549.2009.00364.x
   Wolever TMS, 2010, AM J CLIN NUTR, V92, P723, DOI 10.3945/ajcn.2010.29174
   Wong SS, 2010, INT J BIOL MACROMOL, V46, P385, DOI 10.1016/j.ijbiomac.2009.12.011
   Xu S, 2009, J BIOL CHEM, V284, P7038, DOI 10.1074/jbc.M806650200
   Yang P, 2008, ADV THER, V25, P787, DOI 10.1007/s12325-008-0079-x
   YANO T, 1991, J FISH DIS, V14, P577, DOI 10.1111/j.1365-2761.1991.tb00613.x
   YOSHIDA T, 1994, MACROMOLECULES, V27, P6272, DOI 10.1021/ma00100a007                                                             
   YOSHIDA T, 1990, MACROMOLECULES, V23, P3717, DOI 10.1021/ma00218a001                                                             
   Zhang HB, 2002, INT J BIOL MACROMOL, V30, P7, DOI 10.1016/S0141-8130(01)00187-8                                                   
   Zhang L, 2003, NANO LETT, V3, P1119, DOI 10.1021/nl034298d
   Zhang M, 2004, CARBOHYD RES, V339, P2297, DOI 10.1016/j.carres.2004.07.003
NR 133
TC 51
Z9 52
U1 7
U2 76
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUL 13
PY 2011
VL 59
IS 13
BP 6813
EP 6828
DI 10.1021/jf200964u
PG 16
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 788AL
UT WOS:000292417700001
PM 21609131
DA 2018-01-05
ER

PT J
AU Grigorov, B
   Bocquin, A
   Gabus, C
   Avilov, S
   Mely, Y
   Agopian, A
   Divita, G
   Gottikh, M
   Witvrouw, M
   Darlix, JL
AF Grigorov, Boyan
   Bocquin, Anne
   Gabus, Caroline
   Avilov, Sergey
   Mely, Yves
   Agopian, Audrey
   Divita, Gilles
   Gottikh, Marina
   Witvrouw, Myriam
   Darlix, Jean-Luc
TI Identification of a methylated oligoribonucleotide as a potent inhibitor
   of HIV-1 reverse transcription complex
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID TYPE-1 NUCLEOCAPSID PROTEIN; ACID-CHAPERONE ACTIVITY; PEPTIDE-BASED
   CARRIER; IMMUNODEFICIENCY-VIRUS; RESISTANCE MUTATIONS;
   MOLECULAR-MECHANISMS; DNA-SYNTHESIS; ZINC FINGERS; VIRAL-RNA; IN-VITRO
AB Upon HIV-1 infection of a target cell, the viral reverse transcriptase (RT) copies the genomic RNA to synthesize the viral DNA. The genomic RNA is within the incoming HIV-1 core where it is coated by molecules of nucleocapsid (NC) protein that chaperones the reverse transcription process. Indeed, the RT chaperoning properties of NC extend from the initiation of cDNA synthesis to completion of the viral DNA. New and effective drugs against HIV-1 continue to be required, which prompted us to search for compounds aimed at inhibiting NC protein. Here, we report that the NC chaperoning activity is extensively inhibited in vitro by small methylated oligoribonucleotides (mODN). These mODNs were delivered intracellularly using a cell-penetrating-peptide and found to impede HIV-1 replication in primary human cells at nanomolar concentrations. Extensive analysis showed that viral cDNA synthesis was severely impaired by mODNs. Partially resistant viruses with mutations in NC and RT emerged after months of passaging in cell culture. A HIV-1 molecular clone (NL4.3) bearing these mutations was found to replicate at high concentrations of mODN, albeit with a reduced fitness. Small, methylated ODNs such as mODN-11 appear to be a new type of highly potent inhibitor of HIV-1.
C1 [Grigorov, Boyan; Bocquin, Anne; Gabus, Caroline; Darlix, Jean-Luc] ENS Lyon, INSERM 758, F-69364 Lyon, France.
   [Avilov, Sergey; Mely, Yves] Univ Strasboug, CNRS, Lab Biophoton & Pharmacol, UMR 7213, Illkirch Graffenstaden, France.
   [Avilov, Sergey] Palladin Inst Biochem, Kiev, Ukraine.
   [Agopian, Audrey; Divita, Gilles] CNRS, CRBM, UMR5237, F-34293 Montpellier 5, France.
   [Gottikh, Marina] Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia.
   [Witvrouw, Myriam] Katholieke Univ Leuven, HIV Lab, B-3000 Louvain, Belgium.
   [Witvrouw, Myriam] KU Leuven Res & Dev, B-3000 Louvain, Belgium.
RP Grigorov, B (reprint author), ENS Lyon, INSERM 758, 46 Allee Italie, F-69364 Lyon, France.
EM boyan.grigorov@inserm.fr; jldarlix@cns-lyon.fr
RI Avilov, Sergiy/A-2904-2012; Gottikh, Marina/D-7575-2012
FU European TRIOH Consortium (Europe); Agence Nationale de Recherches sur
   le SIDA (ANRS France); Sidaction (France); FINOVI (Lyon, France);
   Russian Foundation for Basic Research [08-04-01252, 08-04-01293];
   Fondation pour la Recherche Medicale, France [ACE20051206242]; INSERM;
   ANRS; FINOVI
FX European TRIOH Consortium within the FP6 (Europe); Agence Nationale de
   Recherches sur le SIDA (ANRS France); Sidaction (France); FINOVI (Lyon,
   France); the Russian Foundation for Basic Research (projects 08-04-01252
   and 08-04-01293); Fondation pour la Recherche Medicale, France
   (ACE20051206242 to S. A.). Funding for open access charge: INSERM, ANRS,
   FINOVI.
CR Arfi V, 2009, J VIROL, V83, P7524, DOI 10.1128/JVI.00429-09
   Avilov SV, 2009, BIOCHEMISTRY-US, V48, P2422, DOI 10.1021/bi8022366
   Bacheler LT, 2000, ANTIMICROB AGENTS CH, V44, P2475, DOI 10.1128/AAC.44.9.2475-2484.2000                                                 
   Ben Ali M, 2007, J MOL BIOL, V372, P1082, DOI 10.1016/j.jmb.2007.07.026
   Berglund JA, 1997, NUCLEIC ACIDS RES, V25, P1042, DOI 10.1093/nar/25.5.1042
   Buckman JS, 2003, J VIROL, V77, P1469, DOI 10.1128/JVI.77.2.1469-1480.2003
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Crombez L, 2008, CURR PHARM DESIGN, V14, P3656, DOI 10.2174/138161208786898842
   D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210
   Darlix JL, 2007, ADV PHARMACOL, V55, P299, DOI 10.1016/S1054-3589(07)55009-X
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   de Rocquigny H, 2008, MINI-REV MED CHEM, V8, P24
   DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472                                                         
   Fisher RJ, 1998, J VIROL, V72, P1902
   Godet J, 2006, J MOL BIOL, V356, P1180, DOI 10.1016/j.jmb.2005.12.038
   Gotte M, 2010, BBA-PROTEINS PROTEOM, V1804, P1202, DOI 10.1016/j.bbapap.2009.07.020
   Goldschmidt Valerie, 2010, HIV Therapy, V4, P179, DOI 10.2217/HIV.10.3
   Goujon C, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-2
   Grigorov B, 2006, J MOL BIOL, V359, P848, DOI 10.1016/j.jmb.2006.04.017
   Grigorov B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-54
   Grigorov B, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-28
   Grohmann D, 2008, BIOCHEMISTRY-US, V47, P12230, DOI 10.1021/bi801386r
   Hombrouck A, 2008, ANTIMICROB AGENTS CH, V52, P2861, DOI 10.1128/AAC.00210-08
   Iordanskiy Sergey N., 2009, V485, P121, DOI 10.1007/978-1-59745-170-3_9
   Ivanyi-Nagy R, 2008, NUCLEIC ACIDS RES, V36, P712, DOI 10.1093/nar/gkm1051
   Jarrosson-Wuilleme L, 2006, J VIROL, V80, P1152, DOI 10.1128/JVI.80.3.1152-1159.2006
   Joly V, 2004, ANTIMICROB AGENTS CH, V48, P172, DOI 10.1128/AAC.48.1.172-175.2004
   Kuciak M, 2008, NUCLEIC ACIDS RES, V36, P3389, DOI 10.1093/nar/gkn177
   LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978
   Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781
   Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6
   Levin JG, 2010, RNA BIOL, V7, P754, DOI 10.4161/rna.7.6.14115
   Martinez-Picado J, 2008, VIRUS RES, V134, P104, DOI 10.1016/j.virusres.2007.12.021
   MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376
   Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116
   Morris MC, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm053
   Morris MC, 2004, GENE THER, V11, P757, DOI 10.1038/sj.gt.3302235
   Moscardini M, 2002, J MOL BIOL, V318, P149, DOI 10.1016/S0022-2836(02)00092-X
   Mougel M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-24
   Nijhuis M, 2007, PLOS MED, V4, P152, DOI 10.1371/journal.pmed.0040036
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Thomas JA, 2008, VIRUS RES, V134, P39, DOI 10.1016/j.virusres.2007.12.006
   Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522
   Vo MN, 2009, J MOL BIOL, V386, P789, DOI 10.1016/j.jmb.2008.12.070
   Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p                                                               
NR 48
TC 12
Z9 12
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL
PY 2011
VL 39
IS 13
BP 5586
EP 5596
DI 10.1093/nar/gkr117
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 795ZV
UT WOS:000293020000029
PM 21447560
OA gold
DA 2018-01-05
ER

PT J
AU Hashempour, H
   Ghassempour, A
   Daly, NL
   Spengler, B
   Rompp, A
AF Hashempour, Hossein
   Ghassempour, Alireza
   Daly, Norelle L.
   Spengler, Bernhard
   Roempp, Andreas
TI Analysis of Cyclotides in Viola ignobilis by Nano Liquid Chromatography
   Fourier Transform Mass Spectrometry
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Cyclic peptide; Cyclotide; nano-LC FTMS; Varv peptide A; Viola ignobilis
ID CYCLIC CYSTINE KNOT; OLDENLANDIA-AFFINIS; STRUCTURAL MOTIF; PLANT
   CYCLOTIDES; NATURAL-PRODUCTS; PEPTIDES; PROTEINS; MS; DATABASE; CYBASE
AB Cyclotides are macrocyclic knotted peptides originating from plants. They are extremely stable and have a range of bioactivities including anti-HIV and insecticidal activity. Given the stability of the cyclotide framework, there is interest in using these peptides as scaffolds in drug design. In the current study, we have shown that nano-LC Fourier transform mass spectrometry (FTMS) is an effective method of analyzing cyclotides in plants. In addition, we have used this technique to find cyclotides in a novel species, Viola ignobilis (Violaceae plant family), which was collected from the East Azerbaijan province of Iran. Varv peptide A, cycloviolacin B2, and cycloviolacin O8 were found in this species. This study provides a novel method for directly analyzing cyclotide sequences without enzymatic digestion and further information regarding the distribution of cyclotides in plant species.
C1 [Hashempour, Hossein; Ghassempour, Alireza] Shahid Beheshti Univ, Med Plants & Drugs Res Inst, Tehran, Iran.
   [Daly, Norelle L.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   [Spengler, Bernhard; Roempp, Andreas] Univ Giessen, Inst Inorgan & Analyt Chem, Giessen, Germany.
RP Ghassempour, A (reprint author), Shahid Beheshti Univ, Med Plants & Drugs Res Inst, Tehran, Iran.
EM aghassempour@scientist.com; andreas.roempp@anorg.chemie.uni-giessen.de
RI Roempp, Andreas/C-3922-2011; Spengler, Bernhard/A-9497-2012; Daly,
   Norelle/D-4302-2013
OI Hashempour, Hossein/0000-0001-8518-6411
FU Shahid Beheshti University Research Council
FX This work has been supported by a grant from the Shahid Beheshti
   University Research Council.
CR Avula B, 2009, PLANTA MED, V75, P381, DOI 10.1055/s-0028-1088384
   Broussalis AM, 2001, PHYTOCHEMISTRY, V58, P47, DOI 10.1016/S0031-9422(01)00173-X
   Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r                                                               
   Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Feng X, 2007, ANAL BIOANAL CHEM, V389, P1341, DOI 10.1007/s00216-007-1468-8
   GRAN L, 1973, LLOYDIA, V36, P207
   GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064
   Ishihama Y, 2005, J CHROMATOGR A, V1067, P73, DOI 10.1016/j.chroma.2004.10.107
   Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898
   Kelleher N. L., 2004, ANAL CHEM, V76, p197A
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   McDonald LA, 2003, ANAL CHEM, V75, P2730, DOI 10.1021/ac0264731
   Mulvenna JP, 2006, NUCLEIC ACIDS RES, V34, pD192, DOI 10.1093/nar/gkj005
   Qiao X, 2009, PLANTA MED, V75, P1613, DOI 10.1055/s-0029-1185866
   Saska I, 2008, J CHROMATOGR B, V872, P107, DOI 10.1016/j.jchromb.2008.07.023
   Saska I, 2007, J BIOL CHEM, V282, P29721, DOI 10.1074/jbc.M705185200
   Schopke T., 1993, SCI PHARM, V61, P145
   Shen YF, 2002, ANAL CHEM, V74, P4235, DOI 10.1021/ac0202280
   Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913
   Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1
   Wang CKL, 2008, NUCLEIC ACIDS RES, V36, pD206, DOI 10.1093/nar/gkm953
NR 22
TC 5
Z9 5
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8665
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PD JUL
PY 2011
VL 18
IS 7
BP 747
EP 752
DI 10.2174/092986611795446030                                              
          
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 792PV
UT WOS:000292760900014
PM 21413917
DA 2018-01-05
ER

PT J
AU Kadiu, I
   Gendelman, HE
AF Kadiu, Irena
   Gendelman, Howard E.
TI Macrophage Bridging Conduit Trafficking of HIV-1 Through the Endoplasmic
   Reticulum and Golgi Network
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE proteomics; macrophage; HIV-1; intercellular transfer; endocytic
   traffic; tunneling nanotubes; bridging conduits; Golgi; endoplasmic
   reticulum
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEMBRANE NANOTUBES; TUNNELING NANOTUBES;
   LIVING CELLS; T-CELLS; TYPE-1; TRANS; ENDOSOMES; GLYCOSYLATION;
   PATHOGENESIS
AB Bridging conduits (BC) are tubular protrusions that facilitate cytoplasm and membrane exchanges between tethered cells. We now report that the human immunodeficiency virus type I (HIV-1) exploits these conduits to accelerate its spread and to shield it from immune surveillance. Endosome transport through BC drives HIV-1 intercellular transfers. How this occurs was studied in human monocyte-derived macrophages using proteomic, biochemical, and imaging techniques. Endosome, endoplasmic reticulum (ER), Golgi markers, and HIV-1 proteins were identified by proteomic assays in isolated conduits. Both the ER and Golgi showed elongated and tubular morphologies that extended into the conduits of polarized macrophages. Env and Gag antigen and fluorescent HIV-1 tracking demonstrated that these viral constituents were sequestered into endocytic and ER-Golgi organelles. Sequestered infectious viral components targeted the Golgi and ER by retrograde transport from early and Rab9 late endosomes. Disruption of the ER-Golgi network impaired HIV-1 trafficking in the conduit endosomes. This study provides, for the first time, mechanisms for how BC Golgi and ER direct cell-cell viral transfer.
C1 [Kadiu, Irena; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM ikadiu@unmc.edu; hegendel@unmc.edu
FU National Institutes of Health [P20 DA026146, 5P01 DA028555-02, R01
   NS36126, P01 NS31492, 2R01 NS034239, P20 RR15635, P01 MH64570, P01
   NS43985]
FX We acknowledge K. Brown for her assistance with proteomics data
   analysis, T. Bargar and J. Taylor for their assistance with electron and
   confocal microscopy, and B. Wassom for graphic design of the synopsis
   graphic presentation. This work was supported in part by National
   Institutes of Health grants P20 DA026146, 5P01 DA028555-02, R01 NS36126,
   P01 NS31492, 2R01 NS034239, P20 RR15635, P01 MH64570, and P01 NS43985
   (to H.E.G). We declare no competing financial interests.
CR Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003
   Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779                                                     
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631                                                             
   Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797
   De Matteis MA, 2008, NAT REV MOL CELL BIO, V9, P273, DOI 10.1038/nrm2378
   Felts RL, 2010, P NATL ACAD SCI USA, V107, P13336, DOI 10.1073/pnas.1003040107
   GENDELMAN HE, 1989, AIDS, V3, P475, DOI 10.1097/00002030-198908000-00001
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gerdes HH, 2007, FEBS LETT, V581, P2194, DOI 10.1016/j.febslet.2007.03.071
   Gottwein E, 2005, J VIROL, V79, P9134, DOI 10.1128/JVI.79.14.9134-9144.2005
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841
   Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922                                                              
   Gurke S, 2008, HISTOCHEM CELL BIOL, V129, P539, DOI 10.1007/s00418-008-0412-0
   Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7
   Kadin I, 2007, J IMMUNOL, V178, P6404, DOI 10.4049/jimmunol.178.10.6404                                                    
   Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818                                                              
   Kadiu I, 2009, CELL IMMUNOL, V258, P44, DOI 10.1016/j.cellimm.2009.03.012
   Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1
   Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046
   Murray JL, 2005, J VIROL, V79, P11742, DOI 10.1128/JVI.79.18.11742-11751.2005
   NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0
   Onfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476                                                    
   Ono A, 2000, J VIROL, V74, P2855, DOI 10.1128/JVI.74.6.2855-2866.2000
   ORENSTEIN JM, 1988, J VIROL, V62, P2578
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   PINTER A, 1988, J VIROL, V62, P1016
   Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370                                                   
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133
   Sharova N, 2005, EMBO J, V24, P2481, DOI 10.1038/sj.emboj.7600707
   Sotelo-Silveira JR, 2006, TRAFFIC, V7, P508, DOI 10.1111/j.1600-0854.2006.00405.x
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Valente ST, 2009, MOL CELL, V36, P279, DOI 10.1016/j.molcel.2009.10.004
   Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5                                                   
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
   Zhou P, 1998, J IMMUNOL, V160, P1489
NR 39
TC 30
Z9 31
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD JUL
PY 2011
VL 10
IS 7
BP 3225
EP 3238
DI 10.1021/pr200262q
PG 14
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 788AI
UT WOS:000292417400031
PM 21563830
OA gold
DA 2018-01-05
ER

PT J
AU Iost, RM
   Madurro, JM
   Brito-Madurro, AG
   Nantes, IL
   Caseli, L
   Crespilho, FN
AF Iost, Rodrigo M.
   Madurro, Joao M.
   Brito-Madurro, Ana G.
   Nantes, Iseli L.
   Caseli, Luciano
   Crespilho, Frank N.
TI Strategies of Nano-Manipulation for Application in Electrochemical
   Biosensors
SO INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE
LA English
DT Review
DE Nanomaterials; nanostructured films; nano-manipulation; biological
   molecules; electrochemistry; biosensor
ID LAYER-BY-LAYER; LANGMUIR-BLODGETT-FILMS; GLASSY-CARBON ELECTRODE;
   ELECTROACTIVE NANOSTRUCTURED MEMBRANES; SELF-ASSEMBLED MONOLAYERS;
   FUNCTIONALIZED GOLD NANOPARTICLES; CATIONIC BIPOLAR AMPHIPHILES;
   HUMAN-IMMUNODEFICIENCY-VIRUS; QUARTZ-CRYSTAL MICROBALANCE; DNA
   HYBRIDIZATION DETECTION
AB Manipulation techniques of materials at nanoscale level have been pointed in the last decades as a promising tool to develop a new class of modified electrodes applicable in biosensors. Also, the high control of material properties is crucial to detect single events at molecular and atomic level. For instance, nanostructured thin films obtained by Langmuir-Blodgett (LB) and Layer-by-layer (LbL) techniques has been reported as an interesting approach to obtain more selective and sensitive modified electrodes and in addition to nanostructured materials are promising strategies for the fabrication of electrochemical biodevices. Thus, our main focus in this review paper is to show an overview on recent trends in the utilization of manipulation techniques applied to the development of electrochemical biosensors. Emphasis will be given in the utilization of different techniques utilized on the modification of electrodes to enhance electrochemical biosensing performance of enzyme-, protein- and DNA-based biosensors and nano-based electrochemical biosensors for diagnosis.
C1 [Madurro, Joao M.] Univ Fed Uberlandia, Inst Quim, BR-38400 Uberlandia, MG, Brazil.
   [Brito-Madurro, Ana G.] Univ Fed Uberlandia, Inst Genet & Bioquim, BR-38400 Uberlandia, MG, Brazil.
   [Caseli, Luciano] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Diadema, Brazil.
EM frank.crespilho@ufabc.edu.br
RI Caseli, Luciano/D-9533-2012; Iost, R/K-8675-2012; Crespilho,
   Frank/A-4813-2011; Nantes-Cardoso, Iseli/B-9517-2012
OI Iost, R/0000-0003-2099-5052; Nantes-Cardoso, Iseli/0000-0003-1434-3154;
   Brito-Madurro, Ana Graci/0000-0003-3698-9845; Crespilho, Frank
   Nelson/0000-0003-4830-652X
FU FAPESP [2009/15558-1]; CAPES; CNPq; INEO; NanoBioMed-Brasil Network
   (CAPES); FAPEMIG
FX We gratefully acknowledge the financial support from FAPESP (Frank N.
   Crespilho, Project Number 2009/15558-1), CAPES, CNPq, INEO, and
   NanoBioMed-Brasil Network (CAPES) and FAPEMIG.
CR Afonso AS, 2010, J APPL POLYM SCI, V118, P2921, DOI 10.1002/app.32595
   Agui L, 2006, SENSOR ACTUAT B-CHEM, V113, P272, DOI 10.1016/j.snb.2005.03.001
   Alarcon-Angeles G, 2010, BIOSENS BIOELECTRON, V26, P1768, DOI 10.1016/j.bios.2010.08.058
   Albertini VR, 2003, APPL PHYS LETT, V82, P3868, DOI 10.1063/1.1579868
   Alencar WS, 2007, J PHYS CHEM C, V111, P12817, DOI 10.1021/jp070695r
   Alencar WS, 2009, PHYS CHEM CHEM PHYS, V11, P5086, DOI 10.1039/b821915j
   Alexeyeva N, 2010, J ELECTROANAL CHEM, V648, P169, DOI 10.1016/j.jelechem.2010.07.014
   Martins MVA, 2010, ELECTROCHEM COMMUN, V12, P1509, DOI 10.1016/j.elecom.2010.08.020
   Altschuler GM, 2009, FEBS LETT, V583, P782, DOI 10.1016/j.febslet.2009.01.031
   Apetrei C., 2011, BIOSENS BIOELECTRON, V15, P2513
   Baeumner J., 2002, ANAL CHEM, V74, P1442
   BARBIER B, 1990, J ELECTROCHEM SOC, V137, P1757, DOI 10.1149/1.2086794                                                               
   Bardecker JA, 2008, J AM CHEM SOC, V130, P7226, DOI 10.1021/ja802407f
   Barreira SVP, 2004, J PHYS CHEM B, V108, P17973, DOI 10.1021/jp0466845
   Batchelor-McAuley C, 2009, BIOSENS BIOELECTRON, V24, P3183, DOI 10.1016/j.bios.2009.01.045
   Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928
   Beck JD, 2005, NANO LETT, V5, P777, DOI 10.1021/nl047861g
   Bernard C. H., 2008, J PHYS CHEM, V112, P4141
   Besteman K, 2003, NANO LETT, V3, P727, DOI 10.1021/nl034139u
   Bistolas N, 2005, BIOSENS BIOELECTRON, V20, P2408, DOI 10.1016/j.bios.2004.11.023
   Blodgett KB, 1935, J AM CHEM SOC, V57, P1007, DOI 10.1021/ja01309a011
   Blodgett KB, 1934, J AM CHEM SOC, V56, P495, DOI 10.1021/ja01317a513                                                             
   Bocchi M, 2009, BIOSENS BIOELECTRON, V24, P1177, DOI 10.1016/j.bios.2008.07.014
   Bonanni A, 2009, BIOSENS BIOELECTRON, V24, P2885, DOI 10.1016/j.bios.2009.02.023
   BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0
   Brito-Madurro AG, 2007, J MATER SCI, V42, P3238, DOI 10.1007/s10853-006-0235-0
   Byeon JY, 2010, LANGMUIR, V26, P15430, DOI 10.1021/la1021824
   Cabaj J, 2010, SENSOR ACTUAT B-CHEM, V143, P508, DOI 10.1016/j.snb.2009.09.047
   Cai H, 2003, ANAL BIOANAL CHEM, V375, P287, DOI 10.1007/s00216-002-1652-9
   Calvo C., 2004, BIOSENS BIOELECTRON, V19, P1219
   Cao SR, 2007, BIOPROC BIOSYST ENG, V30, P71, DOI 10.1007/s00449-006-0100-1
   Caruso F, 2000, COLLOID SURFACE A, V169, P287, DOI 10.1016/S0927-7757(00)00443-X                                                   
   Caruso F, 2000, LANGMUIR, V16, P1485, DOI 10.1021/la991161n                                                               
   Carvalho RC, 2010, ANAL BIOANAL CHEM, V398, P1675, DOI 10.1007/s00216-010-3966-3
   Caseli L., 2008, J COLLOID INTERF SCI, V8, P108
   Caseli L, 2008, J COLLOID INTERF SCI, V319, P100, DOI 10.1016/j.jcis.2007.12.007
   Caseli L, 2006, LANGMUIR, V22, P8501, DOI 10.1021/la061799g
   Caseli L, 2009, LANGMUIR, V25, P3057, DOI 10.1021/la8037445
   Cassier T., 1998, SUPRAMOL SCI, V5, P3
   Castillo J, 2004, SENSOR ACTUAT B-CHEM, V102, P179, DOI 10.1016/j.snb.2004.04.084
   Cella LN, 2010, ANAL CHEM, V82, P2042, DOI 10.1021/ac902791q
   Chen M, 2011, SENSOR ACTUAT B-CHEM, V152, P14, DOI 10.1016/j.snb.2010.09.063
   Chen Q, 2010, BIOSENS BIOELECTRON, V26, P575, DOI 10.1016/j.bios.2010.07.034
   Chen QP, 2009, BIOSENS BIOELECTRON, V24, P2991, DOI 10.1016/j.bios.2009.03.007
   Chen Y, 2003, J MATER CHEM, V13, P2405, DOI 10.1039/b307895g
   Claridge S. A., 2009, J AM CHEM SOC, V130, P9598
   Cooper CL, 2005, CURR OPIN COLLOID IN, V10, P52, DOI 10.1016/j.cocis.2005.05.007
   Corbierre MK, 2001, J AM CHEM SOC, V123, P10411, DOI 10.1021/ja0166287
   Cotton GJ, 1999, J AM CHEM SOC, V121, P1100, DOI 10.1021/ja983804b                                                               
   Crespilho FN, 2006, ELECTROCHEM COMMUN, V8, P348, DOI 10.1016/j.elecom.2005.12.003
   Crespilho FN, 2005, ENVIRON SCI TECHNOL, V39, P5385, DOI 10.1021/es050552n
   Crespilho F.N., 2006, J PHYS CHEM B, V110, P17748
   Crespilho F.N., 2009, J PHYS CHEM C, V1133, P6037
   Crespilho FN, 2008, TALANTA, V76, P922, DOI 10.1016/j.talanta.2008.04.054
   Crespilho FN, 2007, ELECTROANAL, V19, P805, DOI 10.1002/elan.200603775
   Crespilho FN, 2006, INT J ELECTROCHEM SC, V1, P194
   Crespilho FN, 2006, INT J ELECTROCHEM SC, V1, P151
   Crespilho FN, 2007, ELECTROCHIM ACTA, V52, P4649, DOI 10.1016/j.electacta.2007.01.048
   Crespilho FN, 2006, ELECTROCHEM COMMUN, V8, P1665, DOI 10.1016/j.elecom.2006.07.032
   Crespilho FN, 2006, J NANOSCI NANOTECHNO, V6, P2588, DOI 10.1166/jnn.2006.543
   Crespilho FN, 2009, ELECTROCHEM COMMUN, V11, P1744, DOI 10.1016/j.elecom.2009.07.006
   Crespilho FN, 2009, CHEM PHYS LETT, V469, P186, DOI 10.1016/j.cplett.2008.12.078
   Crespilho FN, 2009, BIOSENS BIOELECTRON, V24, P3073, DOI 10.1016/j.bios.2009.03.026
   Crooks RM, 2001, ACCOUNTS CHEM RES, V34, P181, DOI 10.1021/ar000110a
   CRUMBLISS AL, 1992, BIOTECHNOL BIOENG, V40, P483, DOI 10.1002/bit.260400406
   Curulli A, 2004, BIOSENS BIOELECTRON, V20, P1223, DOI 10.1016/j.bios.2004.06.026
   Dahlin AB, 2009, ANAL CHEM, V81, P6572, DOI 10.1021/ac901175k
   Dai H, 2010, BIOSENS BIOELECTRON, V25, P1414, DOI 10.1016/j.bios.2009.10.042
   Daneshgar P, 2009, J APPL ELECTROCHEM, V39, P1983, DOI 10.1007/s10800-009-9908-0
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   da Silva W.C., 2010, PHYS CHEM CHEM PHYS, V12, P15505
   Davis F, 2005, BIOSENS BIOELECTRON, V21, P1, DOI 10.1016/j.bios.2004.10.001
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232                                                   
   DECHER G, 1991, MAKROMOL CHEM-M SYMP, V46, P321, DOI 10.1002/masy.19910460145                                                        
   DECHER G, 1991, BER BUNSEN PHYS CHEM, V95, P1430, DOI 10.1002/bbpc.19910951122                                                        
   Decossas S, 2003, SURF SCI, V543, P57, DOI 10.1016/S0039-6028(03)00919-1
   Dekker C, 2007, NAT NANOTECHNOL, V2, P209, DOI 10.1038/nnano.2007.27
   Deng CY, 2010, BIOSENS BIOELECTRON, V26, P213, DOI 10.1016/j.bios.2010.06.013
   Deng SY, 2009, BIOSENS BIOELECTRON, V25, P373, DOI 10.1016/j.bios.2009.07.016
   Diez-Pascual A.M., 2007, COLLOID INTERF SCI, V2, P398
   Dios A.S., 2010, ANAL CHIM ACTA, V666, P1, DOI DOI 10.1016/J.ACA.2010.03.038
   Downard AJ, 1995, ANAL CHIM ACTA, V317, P303, DOI 10.1016/0003-2670(95)00397-5
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   Du BA, 2006, ANGEW CHEM INT EDIT, V45, P8022, DOI 10.1002/anie.200603331
   Du P, 2009, BIOSENS BIOELECTRON, V24, P3223, DOI 10.1016/j.bios.2009.04.012
   Du P, 2009, BIOELECTROCHEMISTRY, V75, P37, DOI 10.1016/j.bioelechem.2009.01.003
   Duffy MJ, 2003, EUR J CANCER, V39, P718, DOI 10.1016/S0959-8049(02)00811-0
   Evtugyn GA, 2011, CURR ANAL CHEM, V7, P8
   Farah AA, 2008, J COLLOID INTERF SCI, V319, P572, DOI 10.1016/j.jcis.2007.11.030
   Ferreira LF, 2008, POLYM INT, V57, P644, DOI 10.1002/pi.2392
   Ferreira M, 2004, BIOSENS BIOELECTRON, V19, P1611, DOI 10.1016/j.bios.2003.12.025
   Ferreyra N, 2004, ELECTROCHIM ACTA, V49, P477, DOI 10.1016/j.electacta.2003.09.004
   Fiorito PA, 2001, J BRAZIL CHEM SOC, V12, P729
   Franco DL, 2008, POLYM ENG SCI, V48, P2043, DOI 10.1002/pen.21044
   Freire RS, 2003, ANAL CHIM ACTA, V485, P263, DOI 10.1016/S0003-2670(03)00414-8
   Freire RS, 2002, ANALYST, V127, P258, DOI 10.1039/b110011d                                                                
   Fu Y, 2002, MACROMOL RAPID COMM, V23, P256, DOI 10.1002/1521-3927(20020301)23:4<256::AID-MARC256>3.0.CO;2-5                     
   Fu YC, 2009, ADV FUNCT MATER, V19, P1784, DOI 10.1002/adfm.200801576
   Gao QA, 2011, SENSOR ACTUAT B-CHEM, V153, P219, DOI 10.1016/j.snb.2010.10.034
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Ghindilis A, 2000, BIOCHEM SOC T, V28, P84, DOI 10.1042/bst0280084                                                              
   Giner I, 2009, J PHYS CHEM C, V113, P18827, DOI 10.1021/jp907235n
   Girard-Egrot AP, 2005, ADV COLLOID INTERFAC, V116, P205, DOI 10.1016/j.cis.2005.04.006
   Girard-Egrot AP, 1998, LANGMUIR, V14, P476, DOI 10.1021/la970116h                                                               
   Gish DA, 2007, ANAL CHEM, V79, P4228, DOI 10.1021/ac0622274
   Goldstein J., 1975, PRACTICAL SCANNING E
   Gooding JJ, 1999, TRAC-TREND ANAL CHEM, V18, P525, DOI 10.1016/S0165-9936(99)00133-8
   Goto TE, 2011, LANGMUIR, V27, P2667, DOI 10.1021/la104822r
   Goto TE, 2010, LANGMUIR, V26, P11135, DOI 10.1021/la101648x
   Goulart LR, 2010, CRIT REV IMMUNOL, V30, P201, DOI 10.1615/CritRevImmunol.v30.i2.70                                                
   Gufler PC, 2004, BBA-BIOMEMBRANES, V1661, P154, DOI 10.1016/j.bbamem.2003.12.009
   Guo SJ, 2009, TRAC-TREND ANAL CHEM, V28, P96, DOI 10.1016/j.trac.2008.10.014
   Gustavsson M, 2004, J ELECTROANAL CHEM, V568, P371, DOI 10.1016/j.jelechem.2004.01.031
   Han XA, 2010, MICROCHIM ACTA, V171, P233, DOI 10.1007/s00604-010-0424-z
   Harel E, 2005, NANO LETT, V5, P2624, DOI 10.1021/nl0342592
   Hashemnia S, 2011, INT J ELECTROCHEM SC, V6, P581
   He B, 2008, CURR OPIN CHEM BIOL, V12, P522, DOI 10.1016/j.cbpa.2008.08.027
   Hegnerova K, 2009, SENSOR ACTUAT B-CHEM, V139, P69, DOI 10.1016/j.snb.2008.09.006
   Hejazi MS, 2010, ANAL BIOCHEM, V399, P118, DOI 10.1016/j.ab.2009.11.019
   Heli H, 2009, ANAL BIOCHEM, V388, P81, DOI 10.1016/j.ab.2009.02.021
   Heller I, 2006, J AM CHEM SOC, V128, P7353, DOI 10.1021/ja061212k
   Higginbotham AL, 2010, ACS NANO, V4, P2059, DOI 10.1021/nn100118m
   Hoeben F.J.M., 2009, ACS NANO, V2, P2497
   Hong JM, 2009, SENSOR ACTUAT B-CHEM, V140, P222, DOI 10.1016/j.snb.2009.04.032
   Hooda V, 2009, SENSOR ACTUAT B-CHEM, V136, P235, DOI 10.1016/j.snb.2008.09.047
   Hoshi T, 2000, ANAL SCI, V16, P1009, DOI 10.2116/analsci.16.1009                                                         
   Hou Y, 2010, NANO LETT, V10, P2727, DOI 10.1021/nl101723g
   Houska M, 2004, J COLLOID INTERF SCI, V273, P140, DOI 10.1016/j.jcis.2003.12.056
   Hrapovic S, 2004, ANAL CHEM, V76, P1083, DOI 10.1021/ac035143t
   Hu J, 2002, NANO LETT, V2, P55, DOI 10.1021/nl0156336
   Hu P, 2008, ANAL CHEM, V80, P1819, DOI 10.1021/ac702187y
   Hu ZC, 2010, CARBON, V48, P3729, DOI 10.1016/j.carbon.2010.06.035
   Huang KJ, 2008, COLLOID SURFACE B, V64, P269, DOI 10.1016/j.colsurfb.2008.02.003
   Huang KJ, 2011, THIN SOLID FILMS, V519, P3925, DOI 10.1016/j.tsf.2011.01.342
   Humenik M, 2008, BIOCONJUGATE CHEM, V19, P2456, DOI 10.1021/bc800353z
   Iost Rodrigo Michelin, 2011, Front Biosci (Elite Ed), V3, P663, DOI 10.2741/e278
   Ishii Y, 2001, TRENDS BIOTECHNOL, V19, P211, DOI 10.1016/S0167-7799(01)01635-3
   Ivnitski D, 2006, ELECTROCHEM COMMUN, V8, P1204, DOI 10.1016/j.elecom.2006.05.024
   Jacobs CB, 2010, ANAL CHIM ACTA, V662, P105, DOI 10.1016/j.aca.2010.01.009
   Jamal M, 2009, BIOSENS BIOELECTRON, V24, P2926, DOI 10.1016/j.bios.2009.02.032
   Jeong RA, 2003, BIOSENS BIOELECTRON, V19, P313, DOI 10.1016/S0956-5663(03)00219-7
   Jia F, 2008, BIOSENS BIOELECTRON, V24, P945, DOI 10.1016/j.bios.2008.07.057
   Jia JB, 2002, ANAL CHEM, V74, P2217, DOI 10.1021/ac011116w
   Jiang W, 2011, BIOSENS BIOELECTRON, V26, P2786, DOI 10.1016/j.bios.2010.10.042
   Jiang YJ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075714
   Jiao LY, 2010, NAT NANOTECHNOL, V5, P321, DOI [10.1038/NNANO.2010.54, 10.1038/nnano.2010.54]
   Jie GF, 2007, ANAL CHEM, V79, P5574, DOI 10.1021/ac062357c
   Jin JH, 2010, BIOTECHNOL LETT, V32, P413, DOI 10.1007/s10529-009-0155-6
   Ju HX, 1999, ELECTROANAL, V11, P124, DOI 10.1002/(SICI)1521-4109(199902)11:2<124::AID-ELAN124>3.0.CO;2-B
   Justo Y, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/29/295606
   Kang D, 2009, ANAL CHEM, V81, P9109, DOI 10.1021/ac901811n
   Kang XH, 2008, TALANTA, V74, P879, DOI 10.1016/j.talanta.2007.07.019
   Kang XH, 2009, BIOSENS BIOELECTRON, V25, P901, DOI 10.1016/j.bios.2009.09.004
   Kharitonov AB, 2000, SENSOR ACTUAT B-CHEM, V70, P222, DOI 10.1016/S0925-4005(00)00573-6
   Kim YR, 2010, BIOSENS BIOELECTRON, V25, P2366, DOI 10.1016/j.bios.2010.02.031
   Kissinger PT, 2005, BIOSENS BIOELECTRON, V20, P2512, DOI 10.1016/j.bios.2004.10.004
   Kobayashi M, 2004, ELECTROCHEM COMMUN, V6, P337, DOI 10.1016/j.elecom.2004.01.012
   Korayem MH, 2009, INT J ADV MANUF TECH, V41, P714, DOI 10.1007/s00170-008-1519-0
   Kruusenberg I, 2010, ELECTROCHEM COMMUN, V12, P920, DOI 10.1016/j.elecom.2010.04.021
   Kumpumbu-Kalemba L, 2000, CHEM COMMUN, P1847, DOI 10.1039/a909744i                                                                
   Kundu S, 2008, INORG CHEM, V47, P6344, DOI 10.1021/ic8004135
   Labib M, 2010, ANAL CHIM ACTA, V659, P194, DOI 10.1016/j.aca.2009.11.028
   Lahav M, 2000, J AM CHEM SOC, V122, P11480, DOI 10.1021/ja002568d
   Lange U, 2008, ANAL CHIM ACTA, V614, P1, DOI 10.1016/j.aca.2008.02.068
   Langmuir I, 1917, J AM CHEM SOC, V39, P1848, DOI 10.1021/ja02254a006                                                             
   Leblanc RM, 2006, CURR OPIN CHEM BIOL, V10, P529, DOI 10.1016/j.cbpa.2006.09.010
   Lee D, 2011, LANGMUIR, V27, P3348, DOI 10.1021/la1047547
   Li B, 2007, J AM CHEM SOC, V129, P6668, DOI 10.1021/ja0687015
   Li F, 2011, BIOSENS BIOELECTRON, V26, P1947, DOI 10.1016/j.bios.2010.07.076
   Li F, 2011, BIOSENS BIOELECTRON, V26, P2619, DOI 10.1016/j.bios.2010.11.020
   Li FH, 2009, BIOSENS BIOELECTRON, V24, P1765, DOI 10.1016/j.bios.2008.09.005
   Li GY, 2004, IEEE-ASME T MECH, V9, P358, DOI 10.1109/TMECH.2004.828651
   Li J, 2003, ANAL BIOANAL CHEM, V376, P902, DOI 10.1007/s00216-003-1989-8
   Li J, 2007, BIOSENS BIOELECTRON, V22, P2898, DOI 10.1016/j.bios.2006.12.004
   Li LD, 2011, BIOSENS BIOELECTRON, V26, P2781, DOI 10.1016/j.bios.2010.10.041
   Li N, 2011, J ELECTROANAL CHEM, V651, P12, DOI 10.1016/j.jelechem.2010.11.012
   Liao CS, 2005, BIOSENS BIOELECTRON, V20, P1341, DOI 10.1016/j.bios.2004.05.006
   Lim SH, 2005, BIOSENS BIOELECTRON, V20, P2341, DOI 10.1016/j.bios.2004.08.005
   Lin JH, 2009, SENSOR ACTUAT B-CHEM, V137, P768, DOI 10.1016/j.snb.2009.01.033
   Liu GD, 2006, ELECTROCHEM COMMUN, V8, P251, DOI 10.1016/j.elecom.2005.11.015
   Liu LJ, 2007, BIOSENS BIOELECTRON, V22, P3210, DOI 10.1016/j.bios.2007.02.018
   Liu XJ, 2000, ANAL BIOCHEM, V283, P56, DOI 10.1006/abio.2000.4656
   Liu Y, 2010, LANGMUIR, V26, P6158, DOI 10.1021/la100886x
   Lojou E, 2003, J ELECTROANAL CHEM, V557, P37, DOI 10.1016/S0022-0728(03)00347-4
   Lojou E., 2004, J ELECTROANAL CHEM, V573, P159
   Lowry JP, 1998, J NEUROSCI METH, V79, P65, DOI 10.1016/S0165-0270(97)00171-4
   Lu HY, 2006, ELECTROANAL, V18, P379, DOI 10.1002/elan.200503420
   Lu TL, 2010, SENSOR ACTUAT B-CHEM, V148, P590, DOI 10.1016/j.snb.2010.05.037
   Lucarelli F, 2004, BIOSENS BIOELECTRON, V19, P515, DOI 10.1016/S0956-5663(03)00256-2
   Luo XL, 2004, ANAL BIOCHEM, V334, P284, DOI 10.1016/j.ab.2004.07.005
   LVOV Y, 1993, LANGMUIR, V9, P481, DOI 10.1021/la00026a020                                                             
   LVOV Y, 1996, THIN SOLID FILMS, V797, P284
   Lvov Y., 2002, COLLOID SURF A, V375, P198
   Manesh KM, 2008, BIOSENS BIOELECTRON, V23, P771, DOI 10.1016/j.bios.2007.08.016
   MAOZ R, 1988, J CHIM PHYS PCB, V85, P1059, DOI 10.1051/jcp/1988851059                                                          
   Mateo C, 2007, ENZYME MICROB TECH, V40, P1451, DOI 10.1016/j.enzmictec.2007.01.018
   Matharu Z, 2009, ELECTROANAL, V21, P1587, DOI 10.1002/elan.200904578
   Matsumoto Y, 2007, J ELECTROANAL CHEM, V610, P193, DOI 10.1016/j.jelechem.2007.07.010
   Matthews BD, 2004, APPL PHYS LETT, V85, P2968, DOI 10.1063/1.1802383
   Mazloum-Ardakani M, 2010, INT J ELECTROCHEM SC, V5, P147
   Mazzoldi A, 2008, MAT SCI ENG C-BIO S, V28, P1057, DOI 10.1016/j.msec.2007.04.032
   Mecheri B, 2004, IEEE SENS J, V4, P171, DOI 10.1109/JSEN.2004.823675
   Mello LD, 2003, SENSOR ACTUAT B-CHEM, V96, P636, DOI 10.1016/j.snb.2003.07.008
   MILLAN KM, 1993, ANAL CHEM, V65, P2317, DOI 10.1021/ac00065a025
   MILLAN KM, 1994, ANAL CHEM, V66, P2943, DOI 10.1021/ac00090a023                                                             
   Minasyan SH, 2006, BIOELECTROCHEMISTRY, V68, P48, DOI 10.1016/j.bioelechem.2005.03.006
   Minot ED, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2775090
   Montanha EA, 2010, COLLOID SURFACE B, V77, P161, DOI 10.1016/j.colsurfb.2010.01.017
   Moraes ML, 2009, MAT SCI ENG C-BIO S, V29, P442, DOI 10.1016/j.msec.2008.08.040
   Moreno M, 2010, TALANTA, V80, P2149, DOI 10.1016/j.talanta.2009.11.022
   Beissenhirtz Moritz K., 2004, ANGEW CHEM INT EDIT, V43, P4357
   Munge B, 2005, ANAL CHEM, V77, P4662, DOI 10.1021/ac050132g
   Murugadoss A, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/01/015603
   Nai SML, 2008, J ELECTRON MATER, V37, P515, DOI 10.1007/s11664-008-0379-6
   Nikitin PI, 2007, J MAGN MAGN MATER, V311, P445, DOI 10.1016/j.jmmm.2006.10.1180
   Nishida S, 2002, ULTRAMICROSCOPY, V91, P269, DOI 10.1016/S0304-3991(02)00108-0
   Niu SY, 2006, J ELECTROANAL CHEM, V597, P111, DOI 10.1016/j.jelechem.2006.09.005
   Niu SY, 2009, J INORG BIOCHEM, V103, P43, DOI 10.1016/j.jinorgbio.2008.09.001
   Njagi J, 2010, ANAL CHEM, V82, P989, DOI 10.1021/ac9022605
   OHNUKI Y, 1983, J ELECTROANAL CHEM, V158, P55, DOI 10.1016/S0022-0728(83)80338-6
   Oliveira RML, 2010, J MATER SCI, V45, P475, DOI 10.1007/s10853-009-3964-z
   Ozsoz M, 2003, ANAL CHEM, V75, P2181, DOI 10.1021/ac026212r
   Pal T, 1997, LANGMUIR, V13, P1481, DOI 10.1021/la960834o                                                               
   Pandey PC, 2001, SENSOR ACTUAT B-CHEM, V75, P48, DOI 10.1016/S0925-4005(00)00741-3
   Parker M.-C., 1996, PROTEIN SCI, P52329
   Paterno LG, 2001, QUIM NOVA, V24, P228, DOI 10.1590/S0100-40422001000200013                                                 
   Patil SJ, 2008, SENSOR ACTUAT B-CHEM, V129, P859, DOI 10.1016/j.snb.2007.09.080
   Pavinatto F.J., 2010, LANGMUIR, V25, P10051
   Peng H, 2009, BIOMATERIALS, V30, P2132, DOI 10.1016/j.biomaterials.2008.12.065
   Periasamy AP, 2011, BIOELECTROCHEMISTRY, V80, P114, DOI 10.1016/j.bioelechem.2010.06.009
   Pizzolato F, 2000, QUIM ANAL, V19, P32
   Prakash G., 2009, NEW J PHYS, V12
   Prasad BB, 2010, ANAL CHIM ACTA, V681, P16, DOI 10.1016/j.aca.2010.09.027
   Pumera M, 2007, SENSOR ACTUAT B-CHEM, V123, P1195, DOI 10.1016/j.snb.2006.11.016
   Pumera M, 2010, CHEM SOC REV, V39, P4146, DOI 10.1039/c002690p
   Pumera M, 2010, TRAC-TREND ANAL CHEM, V29, P954, DOI 10.1016/j.trac.2010.05.011
   Qu N, 2011, BIOSENS BIOELECTRON, V26, P2292, DOI 10.1016/j.bios.2010.09.054
   Quinn BM, 2005, J AM CHEM SOC, V127, P6146, DOI 10.1021/ja0508828                                                               
   Ram MK, 2001, BIOSENS BIOELECTRON, V16, P849, DOI 10.1016/S0956-5663(01)00208-1
   Ramanavicius A, 2005, BIOSENS BIOELECTRON, V20, P1962, DOI 10.1016/j.bios.2004.08.032
   Ramesha GK, 2009, J PHYS CHEM C, V113, P7985, DOI 10.1021/jp811377n
   Rao CNR, 2010, J PHYS CHEM LETT, V1, P572, DOI 10.1021/jz9004174
   Ren HX, 2009, TALANTA, V78, P1371, DOI 10.1016/j.talanta.2009.02.024
   Ren Xiangling, 2005, Biosens Bioelectron, V21, P433, DOI 10.1016/j.bios.2004.08.052
   Revenga-Parra M, 2007, BIOSENS BIOELECTRON, V22, P2675, DOI 10.1016/j.bios.2006.11.002
   Rivas GA, 2007, TALANTA, V74, P291, DOI 10.1016/j.talanta.2007.10.013
   Rocha AR, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/34/345202
   Rusling JF, 2009, BIOELECTROCHEMISTRY, V76, P189, DOI 10.1016/j.bioelechem.2009.03.011
   Rusling JF, 2003, J COLLOID INTERF SCI, V262, P1, DOI 10.1016/S0021-9797(03)00148-6
   Sadik OA, 2009, BIOSENS BIOELECTRON, V24, P2749, DOI 10.1016/j.bios.2008.10.003
   Sally A. E., 2005, ELECTROANAL, V7, P913
   Santos AS, 2003, J ELECTROANAL CHEM, V547, P135, DOI 10.1016/S0022-0728(03)00186-4
   Santos TCF, 2010, LANGMUIR, V26, P5869, DOI 10.1021/la9038107
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Sau TK, 2004, J AM CHEM SOC, V126, P8648, DOI 10.1021/ja047846d
   Scarano S, 2010, BIOSENS BIOELECTRON, V25, P957, DOI 10.1016/j.bios.2009.08.039
   Schmidt TF, 2008, BBA-BIOMEMBRANES, V1778, P2291, DOI 10.1016/j.bbamem.2008.05.012
   Schnorr JM, 2011, CHEM MATER, V23, P646, DOI 10.1021/cm102406h
   SCHUHMANN W, 1991, ADV MATER, V3, P388, DOI 10.1002/adma.19910030711                                                        
   Scott RWJ, 2005, J AM CHEM SOC, V127, P1380, DOI 10.1021/ja044446h
   Scott RWJ, 2005, J PHYS CHEM B, V109, P692, DOI 10.1021/jp0469665
   SCOUTEN WH, 1995, TRENDS BIOTECHNOL, V13, P178, DOI 10.1016/S0167-7799(00)88935-0                                                   
   Shan C., 2009, ANAL CHEM, V81, P2379
   Shan CS, 2010, BIOSENS BIOELECTRON, V25, P1504, DOI 10.1016/j.bios.2009.11.009
   Sharma M. K., 2008, J CLIN MICROBIOL, V65, P3759
   Sharma SK, 2004, BIOSENS BIOELECTRON, V20, P651, DOI 10.1016/j.bios.2004.03.020
   Shen HY, 2011, INT J ELECTROCHEM SC, V6, P532
   Shen L, 2010, ELECTROCHEM COMMUN, V12, P876, DOI 10.1016/j.elecom.2010.04.010
   Sheng QL, 2010, BIOSENS BIOELECTRON, V25, P2071, DOI 10.1016/j.bios.2010.02.002
   Shi GY, 2007, ELECTROCHEM COMMUN, V9, P1719, DOI 10.1016/j.elecom.2007.03.019
   Shie JW, 2008, TALANTA, V74, P1659, DOI 10.1016/j.talanta.2007.10.034
   Silva FB, 2008, INT J MOL SCI, V9, P1173, DOI 10.3390/ijms9071173
   Silva TAR, 2008, POLYM ENG SCI, V48, P1963, DOI 10.1002/pen.21026
   Silva TAR, 2009, MAT SCI ENG C-BIO S, V29, P539, DOI 10.1016/j.msec.2008.09.048
   Singh R, 2010, THIN SOLID FILMS, V519, P1135, DOI 10.1016/j.tsf.2010.08.057
   Singhal R, 2003, CURR APPL PHYS, V3, P275, DOI 10.1016/S1567-1739(02)00215-8
   Singhal R, 2002, BIOSENS BIOELECTRON, V17, P697, DOI 10.1016/S0956-5663(02)00020-9
   Siqueira JR, 2007, ELECTROCHEM COMMUN, V9, P2676, DOI 10.1016/j.elecom.2007.08.009
   Siqueira JR, 2006, J PHYS CHEM B, V110, P22690, DOI 10.1021/jp0649089
   Siqueira JR, 2009, BIOSENS BIOELECTRON, V25, P497, DOI 10.1016/j.bios.2009.07.007
   Sljukic B, 2006, NANO LETT, V6, P1556, DOI 10.1021/nl060366v
   Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191
   Song W., 2010, BIOSENS BIOELECTRON, V26, P3181
   Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783
   Squeira Jr. J.R., 2010, BIOSENS BIOELECTRON, V25, P1255
   Suga H., 2009, APPL PHYS EXPRESS, V2
   Sumaru K, 2007, BIOSENS BIOELECTRON, V22, P2356, DOI 10.1016/j.bios.2006.09.012
   Sun KJ, 2008, J APPL PHYS, V103, DOI 10.1063/1.2832616
   Sun Q, 2010, LANGMUIR, V26, P10259, DOI 10.1021/la100432t
   Tam PD, 2009, J IMMUNOL METHODS, V350, P118, DOI 10.1016/j.jim.2009.08.002
   TANG FQ, 1992, BIOSENS BIOELECTRON, V7, P503, DOI 10.1016/0956-5663(92)80007-X                                                    
   Tang LH, 2007, TALANTA, V73, P438, DOI 10.1016/j.talanta.2007.04.008
   Tang ZY, 2006, ADV MATER, V18, P3203, DOI 10.1002/adma.200600113                                                          
   Teles FRR, 2008, MAT SCI ENG C-BIO S, V28, P1530, DOI 10.1016/j.msec.2008.04.010
   Teles FRR, 2008, TALANTA, V77, P606, DOI 10.1016/j.talanta.2008.07.024
   Terui N, 2006, ANAL SCI, V22, P895, DOI 10.2116/analsci.22.895
   Tiemeyer S, 2010, LANGMUIR, V26, P14064, DOI 10.1021/la102616h
   Turgeon SL, 2007, CURR OPIN COLLOID IN, V12, P166, DOI 10.1016/j.cocis.2007.07.007
   Vago M., 2003, SENSOR ACTUAT B-CHEM, V96, P407
   Vamakaki V, 2007, SENSOR ACTUAT B-CHEM, V126, P193, DOI 10.1016/j.snb.2006.11.042
   Vashist SK, 2011, BIOTECHNOL ADV, V29, P169, DOI 10.1016/j.biotechadv.2010.10.002
   Vidal JC, 2004, TALANTA, V64, P655, DOI 10.1016/j.talanta.2004.03.038
   Vo-Dinh T, 2000, FRESEN J ANAL CHEM, V366, P540, DOI 10.1007/s002160051549
   VOLKOV A, 1980, J ELECTROANAL CHEM, V115, P279, DOI 10.1016/S0022-0728(80)80332-9
   Wan D, 2010, ACS APPL MATER INTER, V2, P3083, DOI 10.1021/am100591t
   Wang DH, 2009, ACS NANO, V3, P907, DOI 10.1021/nn900150y
   Wang F, 2009, ELECTROANAL, V21, P1692, DOI 10.1002/elan.200804595
   Wang HC, 2009, BIOSENS BIOELECTRON, V25, P142, DOI 10.1016/j.bios.2009.06.022
   WANG J, 1991, ELECTROANAL, V3, P255, DOI 10.1002/elan.1140030404
   Wang J, 2003, ANALYST, V128, P1382, DOI 10.1039/b309928h
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Wang J., 2003, J AM CHEM SOC, V125, P1470
   Wang JJ, 2005, J ELECTROANAL CHEM, V575, P139, DOI 10.1016/j.jelechem.2004.08.023
   Wang J, 2008, TRAC-TREND ANAL CHEM, V27, P619, DOI 10.1016/j.trac.2008.05.009
   Wang K, 2011, BIOSENS BIOELECTRON, V26, P2252, DOI 10.1016/j.bios.2010.09.043
   Wang RH, 2009, TALANTA, V79, P159, DOI 10.1016/j.talanta.2009.03.017
   Wang SM, 2010, ANAL BIOCHEM, V405, P230, DOI 10.1016/j.ab.2010.06.014
   Wang XY, 2010, ANAL LETT, V43, P1507, DOI 10.1080/00032710903502074
   Weber JE, 2011, MAT SCI ENG C-MATER, V31, P821, DOI 10.1016/j.msec.2010.12.009
   Wegerich F, 2009, ANAL CHEM, V81, P2976, DOI 10.1021/ac802571h
   WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206
   Wu H, 2009, TALANTA, V80, P403, DOI 10.1016/j.talanta.2009.06.054
   Wu Y., 2009, MICROCHIM ACTA, V159, P1
   Wu ZY, 2001, BIOSENS BIOELECTRON, V16, P47, DOI 10.1016/S0956-5663(00)00132-9
   Xiang CL, 2008, ELECTROCHEM COMMUN, V10, P38, DOI 10.1016/j.elecom.2007.10.030
   Xiao YH, 2007, BIOSENS BIOELECTRON, V22, P3161, DOI 10.1016/j.bios.2007.02.008
   Xu JS, 2008, INT J ELECTROCHEM SC, V3, P519
   Xu SJ, 2010, ANAL CHEM, V82, P9566, DOI 10.1021/ac102296g
   Yang HP, 2010, BIOSENS BIOELECTRON, V26, P295, DOI 10.1016/j.bios.2010.06.036
   Yang HC, 2011, COLLOID SURFACE B, V82, P463, DOI 10.1016/j.colsurfb.2010.10.003
   Yang LMC, 2008, ANAL CHEM, V80, P5695, DOI 10.1021/ac8008109
   Yang YJ, 2007, MAT SCI ENG B-SOLID, V139, P251, DOI 10.1016/j.mseb.2007.02.003
   Yao HB, 2010, J MATER CHEM, V20, P5190, DOI 10.1039/c0jm00094a
   Yeh CH, 2009, SENSOR ACTUAT B-CHEM, V139, P387, DOI 10.1016/j.snb.2009.03.029
   Yemini M, 2005, ANAL CHEM, V77, P5155, DOI 10.1021/ac050414g
   Yin F., 2006, COLLOID SURF A, V284, P124
   Yun YH, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70171-8                                                   
   YURONG L, 2010, J MECH BEHAV BIOMED, V3, P203
   ZAITSEV SY, 1993, COLLOID SURFACE A, V75, P211, DOI 10.1016/0927-7757(93)80432-E                                                    
   Zeng GH, 2010, LANGMUIR, V26, P15022, DOI 10.1021/la102806v
   Zhai JH, 1997, BIOTECHNOL ADV, V15, P43, DOI 10.1016/S0734-9750(97)00003-7
   Zhai R, 2010, CATAL COMMUN, V12, P259, DOI 10.1016/j.catcom.2010.09.030
   Zhang D, 2004, LANGMUIR, V20, P7303, DOI 10.1021/la049667f
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang H, 2006, J PHYS CHEM B, V110, P2171, DOI 10.1021/jp055301f
   Zhang M, 2009, MATER TODAY, V12, P12, DOI 10.1016/S1369-7021(09)70176-2
   Zhang M. N., 2005, BIOSENS BIOELECTRON, V20, P270
   Zhang SX, 2005, BIOELECTROCHEMISTRY, V67, P15, DOI 10.1016/j.bioelechem.2004.12.002
   Zhang YZ, 2009, ELECTROCHIM ACTA, V54, P2385, DOI 10.1016/j.electacta.2008.10.052
   Zhang ZJ, 2011, J ELECTROANAL CHEM, V650, P241, DOI 10.1016/j.jelechem.2010.10.016
   Zhao G, 2006, ELECTROCHEM COMMUN, V8, P148, DOI 10.1016/j.elecom.2005.11.001
   Zhao HT, 2006, ANAL BIOCHEM, V350, P138, DOI 10.1016/j.ab.2005.11.034
   Zhao W, 2006, ELECTROANAL, V18, P1737, DOI 10.1002/elan.200603630
   Zhang L., 2011, INT J ELECTROCHEM SC, V6, P819
   Zheng W, 2008, TALANTA, V74, P1414, DOI 10.1016/j.talanta.2007.09.017
   Zheng W, 2010, ELECTROCHEM COMMUN, V12, P869, DOI 10.1016/j.elecom.2010.04.006
   Zheng W., 2010, NANO LETT, V10, P4089
   Zhou LP, 2001, ANAL CHEM, V73, P4780, DOI 10.1021/ac0105639
   Zhu XB, 2009, ELECTROCHEM COMMUN, V11, P1543, DOI 10.1016/j.elecom.2009.05.055
   Zhuo Y, 2009, BIOMATERIALS, V30, P2284, DOI 10.1016/j.biomaterials.2009.01.002
   Zou YJ, 2008, BIOSENS BIOELECTRON, V23, P1010, DOI 10.1016/j.bios.2007.10.009
NR 361
TC 38
Z9 39
U1 8
U2 69
PU ESG
PI BELGRADE
PA BORIVOJA STEVANOVICA 25-7, BELGRADE, 11000, SERBIA
SN 1452-3981
J9 INT J ELECTROCHEM SC
JI Int. J. Electrochem. Sci.
PD JUL
PY 2011
VL 6
IS 7
BP 2965
EP 2997
PG 33
WC Electrochemistry
SC Electrochemistry
GA 786TS
UT WOS:000292331400050
DA 2018-01-05
ER

PT J
AU das Neves, J
   Amiji, M
   Sarmento, B
AF das Neves, Jose
   Amiji, Mansoor
   Sarmento, Bruno
TI Mucoadhesive nanosystems for vaginal microbicide development: friend or
   foe?
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID BIODEGRADABLE POLYMER NANOPARTICLES; DRUG-DELIVERY SYSTEMS; IN-VITRO
   EVALUATION; HUMAN MUCUS BARRIER; CERVICAL-MUCUS; TARGETED DELIVERY; HIV
   PREVENTION; NANOTECHNOLOGY; INFECTION; TRANSMISSION
AB Topical microbicides are apromising strategy in the prevention of vaginal and rectal HIV transmission as well as other sexually transmitted pathogens. The perspective of developing nanotechnology-based systems for topical microbicides seems to be useful because important features such as enhanced drug release, targeting, and epithelial penetration can be achieved. However, the interaction of nanoparticles with the mucus fluids that cover the cervicovaginal mucosal epithelium, which can work either as a docking point or as a barrier for diffusion, has been frequently neglected. In this review, we discuss the principles of nanosystems' adhesion to the mucosal tissue and how this relates to the development of optimized microbicide formulations. (C) 2011 John Wiley & Sons, Inc. WIREs Nanomed Nanobiotechnol 2011 3 389-399 DOI: 10.1002/wnan.144
C1 [das Neves, Jose; Sarmento, Bruno] Univ Porto, Dept Pharmaceut Technol, Fac Pharm, P-4100 Oporto, Portugal.
   [Amiji, Mansoor] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
   [Sarmento, Bruno] Inst Super Ciencias Saude Norte, Dept Pharmaceut Sci, Hlth Sci Res Ctr, CICS, Gandra, Portugal.
RP Sarmento, B (reprint author), Univ Porto, Dept Pharmaceut Technol, Fac Pharm, Rua Campo Alegre 823, P-4100 Oporto, Portugal.
EM bruno.sarmento@ff.up.pt
RI das Neves, Jose/J-8369-2013; Sarmento, Bruno/J-6265-2013; Amiji,
   Mansoor/A-4365-2014
OI das Neves, Jose/0000-0002-2317-2759; Sarmento,
   Bruno/0000-0001-5763-7553; Amiji, Mansoor/0000-0001-6170-881X
FU Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BD/43393/2008]
FX Jose das Neves gratefully acknowledges Fundacao para a Ciencia e a
   Tecnologia, Portugal for financial support (grant SFRH/BD/43393/2008).
CR Aka-Any-Grah A, 2010, EUR J PHARM BIOPHARM, V76, P296, DOI 10.1016/j.ejpb.2010.07.004
   BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223                                             
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   Berman JR, 2002, WORLD J UROL, V20, P111, DOI 10.1007/s00345-002-0281-4
   BERNKOPSCHNU RCHA, 2006, INT J PHARMACEUT, V317, P76
   Boukari H, 2009, BIOMACROMOLECULES, V10, P2482, DOI 10.1021/bm900344q
   Bravo-Osuna I, 2007, BIOMATERIALS, V28, P2233, DOI 10.1016/j.biomaterials.2007.01.005
   Caron M, 2010, VIROLOGY, V405, P225, DOI 10.1016/j.virol.2010.06.008
   Ceric F, 2005, J ELECTRON MICROSC, V54, P479, DOI 10.1093/jmicro/dfh106
   Chen EYT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015434
   Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706
   Cone RA, 2009, ADV DRUG DELIVER REV, V61, P75, DOI 10.1016/j.addr.2008.09.008
   Cone RA, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P49, DOI 10.1016/B978-012491543-5/50008-5
   Crater JS, 2010, MACROMOL BIOSCI, V10, P1473, DOI 10.1002/mabi.201000137
   Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254
   Cui FY, 2006, INT J PHARM, V316, P154, DOI 10.1016/j.ijpharm.2006.02.031
   das Neves J, 2008, EUR J PHARM BIOPHARM, V69, P622, DOI 10.1016/j.ejpb.2007.12.007
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   das Neves J., 2008, PHARM MANUFACTURING, P809
   du Toit LC, 2010, ADV DRUG DELIVER REV, V62, P532, DOI 10.1016/j.addr.2009.11.022
   DURRER C, 1994, PHARMACEUT RES, V11, P680, DOI 10.1023/A:1018920128007
   Gali Y, 2010, ANTIMICROB AGENTS CH, V54, P5105, DOI 10.1128/AAC.00456-10
   Garcia-Lerma JG, 2010, TRENDS PHARMACOL SCI, V31, P74, DOI 10.1016/j.tips.2009.10.009
   Garg S, 2001, CONTRACEPTION, V64, P67, DOI 10.1016/S0010-7824(01)00217-7
   Grabovac V, 2007, DRUG DEV IND PHARM, V33, P767, DOI 10.1080/03639040601050163
   Gunaseelan S, 2010, ADV DRUG DELIVER REV, V62, P518, DOI 10.1016/j.addr.2009.11.021
   Gupta KM, 2007, J PHARM SCI-US, V96, P670, DOI 10.1002/jps.20752
   Ham AS, 2009, PHARM RES-DORD, V26, P502, DOI 10.1007/s11095-008-9765-2
   Henning A, 2010, J AEROSOL MED PULM D, V23, P233, DOI 10.1089/jamp.2009.0806
   Huang YB, 2000, J CONTROL RELEASE, V65, P63, DOI 10.1016/S0168-3659(99)00233-3                                                   
   Jabr-Milane L, 2008, J CONTROL RELEASE, V130, P121, DOI 10.1016/j.jconrel.2008.04.016
   Jubeh TT, 2004, PHARM RES, V21, P447, DOI 10.1023/B:PHAM.0000019298.29561.cd
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Kashuba AD, 2010, 18 INT AIDS C VIENN
   Kim PS, 2010, WIRES NANOMED NANOBI, V2, P693, DOI 10.1002/wnan.118
   Kish-Catalone T, 2007, AIDS RES HUM RETROV, V23, P33, DOI 10.1089/aid.2006.0076
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Lai BE, 2008, J PHARM SCI, V97, P1028
   Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104
   Lai SK, 2010, P NATL ACAD SCI USA, V107, P598, DOI 10.1073/pnas.0911748107
   Lai SK, 2009, J VIROL, V83, P11196, DOI 10.1128/JVI.01899-08
   Lai SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004294
   Lara Humberto H., 2010, Journal of Nanobiotechnology, V8, P15, DOI 10.1186/1477-3155-8-15
   Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848
   Lee CH, 2002, CONTRACEPTION, V65, P435, DOI 10.1016/S0010-7824(02)00300-1
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Mallipeddi R, 2010, EXPERT OPIN DRUG DEL, V7, P37, DOI 10.1517/17425240903338055
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Martinez-Avila O, 2009, CHEMBIOCHEM, V10, P1806, DOI 10.1002/cbic.200900294
   McGill SL, 2010, MOL PHARMACEUT, V7, P2280, DOI 10.1021/mp100242r
   Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d
   Nuttall J, 2010, DRUGS, V70, P1231, DOI 10.2165/10898650-000000000-00000
   Owen DH, 2005, J ANDROL, V26, P459, DOI 10.2164/jandrol.04104
   Owen DH, 1999, CONTRACEPTION, V59, P91, DOI 10.1016/S0010-7824(99)00010-4                                                   
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1675, DOI 10.1016/j.addr.2004.03.001
   Ponchel G, 1997, EUR J PHARM BIOPHARM, V44, P25, DOI 10.1016/S0939-6411(97)00098-2
   Rupp R, 2007, INT J NANOMED, V2, P561
   Sarmento B, 2007, PHARM RES, V24, P2198, DOI 10.1007/s11095-007-9367-4
   Serra L, 2009, EUR J PHARM BIOPHARM, V71, P519, DOI 10.1016/j.ejpb.2008.09.022
   SHEEHAN JK, 1986, BIOCHEM J, V239, P147, DOI 10.1042/bj2390147                                                               
   Smart JD, 2005, ADV DRUG DELIVER REV, V57, P1556, DOI 10.1016/j.addr.2005.07.001
   Suh J, 2005, ADV DRUG DELIVER REV, V57, P63, DOI 10.1016/j.addr.2004.06.001
   Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106
   UNAIDS/ WHO, 2009, AIDS EP UPD 2009
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   van de Wijgert JHHM, 2007, AIDS, V21, P2369, DOI 10.1097/QAD.0b013e3282ef83fd                                                    
   Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526
   Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006
   Willits RK, 2001, BIOMATERIALS, V22, P445, DOI 10.1016/S0142-9612(00)00197-6
   WOLF DP, 1980, BIOCHIM BIOPHYS ACTA, V630, P545
   Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]
   Yang HT, 2008, AAPS J, V10, P606, DOI 10.1208/s12248-008-9070-3
   Yang M, 2011, ANGEW CHEM INT EDIT, V50, P2597, DOI 10.1002/anie.201006849
   Yoo JW, 2011, INT J PHARMACEUT, V403, P262, DOI 10.1016/j.ijpharm.2010.10.032
NR 75
TC 38
Z9 38
U1 3
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1939-5116
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD JUL-AUG
PY 2011
VL 3
IS 4
BP 389
EP 399
DI 10.1002/wnan.144
PG 11
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 777CX
UT WOS:000291593300005
PM 21506290
DA 2018-01-05
ER

PT J
AU Apellaniz, B
   Garcia-Saez, AJ
   Nir, S
   Nieva, JL
AF Apellaniz, Beatriz
   Garcia-Saez, Ana J.
   Nir, Shlomo
   Nieva, Jose L.
TI Destabilization exerted by peptides derived from the membrane-proximal
   external region of HIV-1 gp41 in lipid vesicles supporting fluid phase
   coexistence
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE MPER; HIV gp41; Membrane fusion; Lytic pore; Lipid rafts; Lo-Ld
   coexistence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENV-MEDIATED FUSION; PORE FORMATION;
   BIOLOGICAL-MEMBRANES; AMPHIPATHIC PEPTIDES; BILAYER VESICLES; VIRAL
   MEMBRANE; TYPE-1 GP41; CHOLESTEROL; RAFTS
AB The human immonodeficiency virus (HIV) envelope is enriched in cholesterol and sphingomyelin, two lipids that sustain the formation of laterally segregated liquid-ordered fluid domains in model systems. Several evidences indicate that the high lipid order existing at the envelope may play a role in HIV pathogenesis. A putative mechanism might involve the modulation of the membrane-perturbing function of the gp41 membrane-proximal external region (MPER). To test such hypothesis, we investigate here the effect of lipid phase coexistence on the membrane-restructuring properties of NpreTM and CpreTM, two peptides based on the amino- and carboxy-terminal MPER sequences, respectively. Fluid phase coexistence elicited the fusogenic activity of NpreTM at high membrane doses and stimulated "graded" leakage at low doses. By comparison, the effect on CpreTM was restricted to an enhancement of "all-or-none" leakage that was consistent with the promotion of its surface aggregation. Confocal microscopy of single vesicles revealed the preference of both peptides for liquid-disordered domains. Accordingly, we speculate that confinement into envelope fluid nanodomains might boost the distinct capacities of HIV MPER hydrophobic modules for inducing membrane defects during fusion. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Apellaniz, Beatriz; Nieva, Jose L.] Univ Basque Country, Unidad Biofis, CSIC, EHU, E-48080 Bilbao, Spain.
   [Apellaniz, Beatriz; Nieva, Jose L.] Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain.
   [Garcia-Saez, Ana J.] Max Planck Inst Met Res, D-69120 Heidelberg, Germany.
   [Garcia-Saez, Ana J.] German Canc Res Ctr, D-69120 Heidelberg, Germany.
   [Nir, Shlomo] Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Seagram Ctr Soil & Water Sci, IL-76100 Rehovot, Israel.
RP Nieva, JL (reprint author), Univ Basque Country, Unidad Biofis, CSIC, EHU, Aptdo 644, E-48080 Bilbao, Spain.
EM gbpniesj@lg.ehu.es
RI Apellaniz, Beatriz/E-9291-2012
FU Spanish MCINN, Basque Government; University of the Basque Country [GIU
   06/42, DIPE08/12]; Spanish MEC
FX We acknowledge the financial support of Spanish MCINN, Basque Government
   and the University of the Basque Country (BIO 2008-00772, GIU 06/42 and
   DIPE08/12 grants to J.L.N.). BA. was recipient of a pre-doctoral
   fellowship of the Spanish MEC.
CR Allende D, 2005, BIOPHYS J, V88, P1828, DOI 10.1529/biophysj.104.049817
   ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900
   ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181
   Apellaniz B, 2010, BIOPHYS J, V99, P3619, DOI 10.1016/j.bpj.2010.09.027
   Apellaniz B, 2009, BIOCHEMISTRY-US, V48, P5320, DOI 10.1021/bi900504t
   Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   Brugger B, 2006, P NATL ACAD SCI USA, V103, P2641, DOI 10.1073/pnas.0511136103
   Campelo F, 2008, BIOPHYS J, V95, P2325, DOI 10.1529/biophysj.108.133173
   Chernomordik LV, 2008, NAT STRUCT MOL BIOL, V15, P675, DOI 10.1038/nsmb.1455
   Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504
   Coskun U, 2010, FEBS LETT, V584, P1685, DOI 10.1016/j.febslet.2009.12.043
   de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5                                                   
   Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0                                                   
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005
   Epand RF, 2005, BIOCHEMISTRY-US, V44, P5525, DOI 10.1021/bi0500224
   Epand RF, 2006, BIOCHEMISTRY-US, V45, P6105, DOI 10.1021/bi060245+
   Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5
   Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002
   HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8                                                    
   Kozlov MM, 2010, TRENDS BIOCHEM SCI, V35, P699, DOI 10.1016/j.tibs.2010.06.003
   Ladokhin AS, 1997, METHOD ENZYMOL, V278, P474
   Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4                                                   
   Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Lorizate M, 2008, BBA-BIOMEMBRANES, V1778, P1624, DOI 10.1016/j.bbamem.2007.12.018
   Lorizate M, 2009, J BIOL CHEM, V284, P22238, DOI 10.1074/jbc.M109.029256
   Lorizate M, 2006, J BIOL CHEM, V281, P39598, DOI 10.1074/jbc.M605998200
   Magnus C, 2009, J VIROL, V83, P1523, DOI 10.1128/JVI.01764-08
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Nicol F, 1996, BIOPHYS J, V71, P3288, DOI 10.1016/S0006-3495(96)79521-8                                                   
   Nicol F, 2000, BIOPHYS J, V78, P818, DOI 10.1016/S0006-3495(00)76639-2                                                   
   Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7
   Pokorny A, 2005, BIOCHEMISTRY-US, V44, P9538, DOI 10.1021/bi0506371
   Rausch JM, 2007, BIOCHEMISTRY-US, V46, P12124, DOI 10.1021/bi700978h
   Rawicz W, 2008, BIOPHYS J, V94, P4725, DOI 10.1529/biophysj.107.121731
   Saez-Cirion A, 2002, J BIOL CHEM, V277, P21776, DOI 10.1074/jbc.M202255200
   Saez-Cirion A, 2003, BIOPHYS J, V85, P3769, DOI 10.1016/S0006-3495(03)74792-4                                                   
   Salzwedel K, 1999, J VIROL, V73, P2469
   Schon P, 2008, BIOPHYS J, V95, P691, DOI 10.1529/biophysj.108.129981
   Shang L, 2008, J VIROL, V82, P5417, DOI 10.1128/JVI.02666-07
   Shnaper S, 2004, J BIOL CHEM, V279, P18526, DOI 10.1074/jbc.M304950200
   Sougrat R, 2007, PLOS PATHOG, V3, P571, DOI 10.1371/journal.ppat.0030063
   STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023
   Suarez T, 2000, FEBS LETT, V477, P145, DOI 10.1016/S0014-5793(00)01785-3                                                   
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Vidal A, 2005, BIOPHYS J, V89, P1102, DOI 10.1529/biophysj.105.062380
   Vishwanathan SA, 2008, BIOCHEMISTRY-US, V47, P124, DOI 10.1021/bi7018892
   Vishwanathan SA, 2008, J VIROL, V82, P5118, DOI 10.1128/JVI.00305-08
   Waheed AA, 2009, VIRUS RES, V143, P162, DOI 10.1016/j.virusres.2009.04.007
   White SH, 1998, METHOD ENZYMOL, V295, P62
   WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902                                                          
   Zemel A, 2005, EUR BIOPHYS J BIOPHY, V34, P230, DOI 10.1007/s00249-004-0445-9
   Zemel A, 2008, J PHYS CHEM B, V112, P6988, DOI 10.1021/jp711107y
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 56
TC 5
Z9 5
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD JUL
PY 2011
VL 1808
IS 7
BP 1797
EP 1805
DI 10.1016/j.bbamem.2011.02.005
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 771PB
UT WOS:000291172100003
PM 21316335
OA gold
DA 2018-01-05
ER

PT J
AU Koren, E
   Apte, A
   Sawant, RR
   Grunwald, J
   Torchilin, VP
AF Koren, Erez
   Apte, Anjali
   Sawant, Rupa R.
   Grunwald, Jacob
   Torchilin, Vladimir P.
TI Cell-penetrating TAT peptide in drug delivery systems: Proteolytic
   stability requirements
SO DRUG DELIVERY
LA English
DT Article
DE Drug delivery; TAT peptide; polymeric micelles; PEG-PE; proteolytic
   cleavage; steric shielding
ID HUMAN IMMUNODEFICIENCY VIRUS; PHARMACEUTICAL NANOCARRIERS; METABOLIC
   CLEAVAGE; LOADED LIPOSOMES; IN-VITRO; PROTEIN; VIVO
AB The stability and activity of the HIV cell-penetrating TAT peptide (TATp) on the surface of TATp-modified micelles and liposomes in relation to its proteolytic cleavage was investigated. TATp moieties were attached to the surface of these nanocarriers using TATp modified with a conjugate of phosphatidyl ethanolamine with a ''short'' PEG (PEG-PE). Following pre-incubation with trypsin, elastase, or collagenase, the proteolytic stability of TATp on the surface of these modified carriers was studied by HPLC with fluorescence detection using fluorenylmethyl chloroformate (FMOC) labeling. All tested enzymes produced a dose-dependent cleavage of TATp as shown by the presence of TATp Arg-Arg fragments. Inhibition of TATp cleavage occurred when these TATp-micelles were modified by the addition of longer PEG-PE blocks, indicating an effective shielding of TATp from proteolysis by these blocks. TATp-modified carriers were also tested for their ability to accumulate in EL-4, HeLa, and B16-F10 cells. Trypsin treatment of TATp-modified liposomes and micelles resulted in decreased uptake and cell interaction, as measured by fluorescence microscopy and fluorescence-activated cell sorting techniques. Furthermore, a decrease in the cytotoxicity of TATp-modified liposomes loaded with doxorubicin (Doxil) was observed following trypsin treatment. In conclusion, steric shielding of TATp is essential to ensure its in vivo therapeutic function.</.
C1 [Koren, Erez] Northeastern Univ, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA.
RP Koren, E (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol & Nanomed, 213 Mugar Life Sci Bldg,360 Huntington Ave, Boston, MA 02115 USA.
EM e.koren@neu.edu
FU NIH [RO1 CA121838, RO1 CA128486]
FX This work was supported by the NIH grants RO1 CA121838 and RO1 CA128486
   to Vladimir P. Torchilin.
CR Abes R, 2007, BIOCHEM SOC T, V35, P775, DOI 10.1042/BST0350775                                                              
   Bae Y, 2009, ADV DRUG DELIVER REV, V61, P768, DOI 10.1016/j.addr.2009.04.016
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044                                                             
   Foerg C, 2008, AAPS J, V10, P349, DOI 10.1208/s12248-008-9029-4
   Foged C, 2008, EXPERT OPIN DRUG DEL, V5, P105, DOI 10.1517/17425247.5.1.105
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grunwald J, 2009, BIOCONJUGATE CHEM, V20, P1531, DOI 10.1021/bc900081e
   Gupta B, 2007, CANCER IMMUNOL IMMUN, V56, P1215, DOI 10.1007/s00262-006-0273-0
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Jarvert P, 2007, BIOCHEM SOC T, V35, P770
   Kale AA, 2010, METHODS MOL BIOL, V605, P213, DOI 10.1007/978-1-60327-360-2_15
   Kersemans V, 2008, CURR PHARM DESIGN, V14, P2415, DOI 10.2174/138161208785777432                                                      
   Sawant RR, 2009, INT J PHARMACEUT, V374, P114, DOI 10.1016/j.ijpharm.2009.02.022
   Torchilin VP, 2008, BIOPOLYMERS, V90, P604, DOI 10.1002/bip.20989
   Torchilin Vladimir P., 2008, V4, P1
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trehin R, 2004, BIOCHEM J, V382, P945, DOI 10.1042/BJ20040238                                                              
   Wang T, 2010, NANOMEDICINE-UK, V5, P563, DOI 10.2217/NNM.10.30
NR 20
TC 53
Z9 55
U1 0
U2 16
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1071-7544
J9 DRUG DELIV
JI Drug Deliv.
PD JUL
PY 2011
VL 18
IS 5
BP 377
EP 384
DI 10.3109/10717544.2011.567310
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 774NU
UT WOS:000291394100010
PM 21438724
OA gold
DA 2018-01-05
ER

PT J
AU Gao, BL
   Zhang, CM
   Yin, YZ
   Tang, LQ
   Liu, ZP
AF Gao, Bing-Lei
   Zhang, Cheng-Mei
   Yin, Yi-Zhen
   Tang, Long-Qian
   Liu, Zhao-Peng
TI Design and synthesis of potent HIV-1 protease inhibitors incorporating
   hydroxyprolinamides as novel P2 ligands
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 protease inhibitors; Hydroxyprolinamide; P2 ligand;
   Drug-resistant; Design; Synthesis
ID DRUG-RESISTANCE; DISCOVERY; PROGRESS; BINDING; TMC114
AB A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different hydroxyprolinamide P2 ligands were designed and synthesized. Variation of substitutions at the P2 significantly affected the enzyme inhibitory potency of the inhibitors. Compounds 2a and 2d showed excellent enzyme inhibitory activity with IC50 values in the nanomolar range. An active site binding model for inhibitors 2a and 2d was suggested based upon the computational-docking results of the ligand with HIV-1 protease. This model offers molecular insights regarding ligand-binding site interactions of the hydroxyprolinamide-derived novel P2-ligand. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Gao, Bing-Lei; Zhang, Cheng-Mei; Yin, Yi-Zhen; Tang, Long-Qian; Liu, Zhao-Peng] Shandong Univ, Sch Pharmaceut Sci, Jinan 250012, Shandong, Peoples R China.
RP Liu, ZP (reprint author), Shandong Univ, Sch Pharmaceut Sci, 44 Wenhua Xilu, Jinan 250012, Shandong, Peoples R China.
EM liuzhaop@sdu.edu.cn
FU National Natural Science Foundation of China (NSFC) [81072517]
FX This work was supported partially by the National Natural Science
   Foundation of China (NSFC, Grant No. 81072517).
CR Ali A, 2006, J MED CHEM, V49, P7342, DOI 10.1021/jm060666p
   Anderson Jeffrey, 2009, V189, P85
   Armbruster Christine, 2008, Anti-Infective Agents in Medicinal Chemistry, V7, P201, DOI 10.2174/187152108784911296
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y
   Ghosh AK, 2008, ACCOUNTS CHEM RES, V41, P78, DOI 10.1021/ar7001232
   Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181
   Hue S, 2009, J VIROL, V83, P2645, DOI 10.1128/JVI.01556-08
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007
   Lucas GM, 2005, J ANTIMICROB CHEMOTH, V55, P413, DOI 10.1093/jac/dki042
   Mastrolorenzo A, 2007, CURR MED CHEM, V14, P2734, DOI 10.2174/092986707782360141                                                      
   Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330                                                        
   Rodriguez-Barrios F, 2004, CURR TOP MED CHEM, V4, P991, DOI 10.2174/1568026043388529
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Tamaki M, 2001, J ORG CHEM, V66, P3593, DOI 10.1021/jo005625u
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
NR 20
TC 6
Z9 7
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 15
PY 2011
VL 21
IS 12
BP 3730
EP 3733
DI 10.1016/j.bmcl.2011.04.070
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 771GT
UT WOS:000291145900046
PM 21555220
DA 2018-01-05
ER

PT J
AU De Francesco, MA
   Baronio, M
   Poiesi, C
AF De Francesco, Maria A.
   Baronio, Manuela
   Poiesi, Claudio
TI HIV-1 p17 Matrix Protein Interacts with Heparan Sulfate Side Chain of
   CD44v3, Syndecan-2, and Syndecan-4 Proteoglycans Expressed on Human
   Activated CD4(+) T Cells Affecting Tumor Necrosis Factor alpha and
   Interleukin 2 Production
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HOMING RECEPTOR CD44;
   ANTIRETROVIRAL-THERAPY; GROWTH-FACTOR; LYMPH-NODES; BINDING; FORMS;
   REPLICATION; LYMPHOCYTES; INFECTION
AB HIV-1 p17 contains C-and N-terminal sequences with positively charged residues and a consensus cluster for heparin binding. We have previously demonstrated by affinity chromatography that HIV-1 p17 binds strongly to heparin-agarose at physiological pH and to human activated CD4(+) T cells. In this study we demonstrated that the viral protein binds to heparan sulfate side chains of syndecan-2, syndecan-4, and CD44v3 purified from HeLa cells and that these heparan sulfate proteoglycans (HSPGs) co-localize with HIV-1 p17 on activated human CD4(+) T cells by confocal fluorescence analysis. Moreover, we observed a stimulatory or inhibitory activity when CD4(+) T cells were activated with mitogens together with nanomolar or micromolar concentrations of the matrix protein.
C1 [Poiesi, Claudio] Spedali Civil Brescia, Inst Microbiol & Virol, Lab Microbiol & Virol, I-25123 Brescia, Italy.
   [De Francesco, Maria A.] Univ Brescia, Sch Med, Inst Microbiol, I-25123 Brescia, Italy.
   [Baronio, Manuela] Osped St Orsola, Dept Intens Care Unit, I-27 Brescia, Italy.
RP Poiesi, C (reprint author), Spedali Civil Brescia, Inst Microbiol & Virol, Lab Microbiol & Virol, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
EM claudio.poiesi@tiscali.it
FU Ministero dell'Universita e della Ricerca Scientifica e Tecnologica
FX This work was supported in part by the Ministero dell'Universita e della
   Ricerca Scientifica e Tecnologica.
CR Alfadhli A, 2007, J VIROL, V81, P1472, DOI 10.1128/JVI.02122-06
   Appay V, 2000, INT IMMUNOL, V12, P1173, DOI 10.1093/intimm/12.8.1173
   BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   Borland G, 1998, IMMUNOLOGY, V93, P139
   BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523
   Cannon PM, 1997, J VIROL, V71, P3474
   Carey DJ, 1997, BIOCHEM J, V327, P1
   Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002
   Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990
   Conte MR, 1998, VIROLOGY, V246, P191, DOI 10.1006/viro.1998.9206
   COSTES S, 2002, P MICROSC MICROANAL, V8
   De Francesco MA, 1998, AIDS, V12, P245, DOI 10.1097/00002030-199803000-00001                                                
   De Francesco MA, 2002, P NATL ACAD SCI USA, V99, P9972, DOI 10.1073/pnas.142274699
   DORFMAN T, 1994, J VIROL, V68, P1689
   Douek DC, 2001, J IMMUNOL, V167, P6663, DOI 10.4049/jimmunol.167.11.6663                                                    
   FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129
   Fiorentini S, 2008, P NATL ACAD SCI USA, V105, P3867, DOI 10.1073/pnas.0800370105
   FORSTERHORVA THC, 2001, EUR J IMMUNOL, V31, P600
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002
   Goldsmith EJ, 2007, CHEM REV, V107, P5065, DOI 10.1021/cr068221w
   HARDINGHAM TE, 1992, FASEB J, V6, P861
   Hill CP, 1996, P NATL ACAD SCI USA, V93, P3099, DOI 10.1073/pnas.93.7.3099
   JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673
   KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303
   Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731
   LASKIN JD, 1991, LEUKEMIA RES, V15, P515, DOI 10.1016/0145-2126(91)90063-Y                                                    
   Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097
   LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x                                              
   LU W, 1995, NAT MED, V1, P386, DOI 10.1038/nm0595-386b                                                             
   Poiesi C, 2008, VIRUS RES, V132, P25, DOI 10.1016/j.virusres.2007.10.006
   Popovic M, 2005, P NATL ACAD SCI USA, V102, P14807, DOI 10.1073/pnas.0506857102
   Proudfoot AEI, 2006, BIOCHEM SOC T, V34, P422, DOI 10.1042/BST0340422                                                              
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Roscic-Mrkic B, 2003, BLOOD, V102, P1169, DOI 10.1182/blood-2003-02-0488
   Schacker TW, 2006, CLIN VACCINE IMMUNOL, V13, P556, DOI 10.1128/CVI.13.5.556-560.2006
   SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160                                                        
   Seddon B, 2003, CURR OPIN IMMUNOL, V15, P321, DOI 10.1016/S0952-7915(03)00049-9
   Sieg SF, 2005, J INFECT DIS, V192, P62, DOI 10.1086/430620
   Surh CD, 2005, SEMIN IMMUNOL, V17, P183, DOI 10.1016/j.smim.2005.02.007
   TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0
   Teixe T, 2008, MOL IMMUNOL, V45, P2905, DOI 10.1016/j.molimm.2008.01.033
   Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002
   van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499                                                         
   Verli H, 2007, J MOL GRAPH MODEL, V26, P62, DOI 10.1016/j.jmgm.2006.09.009
   YU XF, 1992, J VIROL, V66, P4966
NR 47
TC 15
Z9 15
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 3
PY 2011
VL 286
IS 22
BP 19541
EP 19548
DI 10.1074/jbc.M110.191270
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 769OZ
UT WOS:000291027700037
PM 21482826
OA gold
DA 2018-01-05
ER

PT J
AU Shegokar, R
   Singh, KK
AF Shegokar, R.
   Singh, K. K.
TI Nevirapine nanosuspensions for HIV reservoir targeting
SO PHARMAZIE
LA English
DT Article
ID DRUG-DELIVERY; SUSPENSIONS
AB In this paper we discuss, production, characterization and in-vivo evaluation of nevirapine nanosuspensions. Laser diffraction showed that the average particles size was 457 nm. Following single-dose administration, the plasma gamma concentration profiles showed fast release. Macrophage uptake studies confirmed enhanced cellular uptake for nanonized nevirapine with no added cytotoxicity. Gamma scintigraphy showed that the nanosuspension prepared can be used to target spleen, thymus and lungs, which represent anatomical viral reservoirs. Thus nevirapine nanosuspensions with targeting potential have been prepared successfully.
C1 [Shegokar, R.; Singh, K. K.] SNDT Womens Univ, CU Shah Coll Pharm, Bombay 400049, Maharashtra, India.
   [Shegokar, R.] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & NutriCosmet, D-1000 Berlin, Germany.
RP Singh, KK (reprint author), SNDT Womens Univ, CU Shah Coll Pharm, Bombay 400049, Maharashtra, India.
EM kksingh35@rediffmail.com
FU All India Council of Technical Education (AICTE)
FX The authors thank the All India Council of Technical Education (AICTE)
   for financial support the and Bombay Veterinary college for providing
   facility for carrying out Gammascintigraphy studies.
CR Barratt G. M., 2000, PHARM SCI TECHNOL TO, V3, P163
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Gao L, 2008, INT J PHARM, V355, P321, DOI 10.1016/j.ijpharm.2007.12.016
   Jacobs C, 2002, PHARMACEUT RES, V19, P189, DOI 10.1023/A:1014276917363
   Junghanns JUAH, 2008, INT J NANOMED, V3, P295
   KAYES JB, 1977, J PHARM PHARMACOL, V29, P199, DOI 10.1111/j.2042-7158.1977.tb11288.x                                              
   Kayser O, 2000, INT J PHARM, V196, P253, DOI 10.1016/S0378-5173(99)00434-2
   Lipinski C. A., 2002, AM PHARM REV, V5, P82
   Mauludin R, 2009, EUR J PHARM SCI, V36, P502, DOI 10.1016/j.ejps.2008.12.002
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Mitra M, 1995, INT J PHARMACEUT, V122, P35
   Mosqueira VCF, 2001, BIOMATERIALS, V22, P2967, DOI 10.1016/S0142-9612(01)00043-6
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Muller RH, 2000, HDB PHARM CONTROLLED, P359
   Patravale VB, 2004, J PHARM PHARMACOL, V56, P827, DOI 10.1211/0022357023691
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Sharland M, 1998, LANCET, V352, P577, DOI 10.1016/S0140-6736(05)79289-8                                                   
   Shobha R., 1999, INT J PHARM SCI, V61, P69
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   VANTKLOOSTER R, 2008, C RETR OPP TUN INF F
   Wong J, 2008, ADV DRUG DELIVER REV, V60, P939, DOI 10.1016/j.addr.2007.11.008
   YAZDANIAN M, 1998, INT C AIDS
NR 22
TC 9
Z9 11
U1 0
U2 1
PU GOVI-VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD JUN
PY 2011
VL 66
IS 6
BP 408
EP 415
DI 10.1691/ph.2011.0317
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 792NE
UT WOS:000292753000004
PM 21699078
DA 2018-01-05
ER

PT J
AU Lin, YC
   Perryman, AL
   Olson, AJ
   Torbett, BE
   Elder, JH
   Stout, CD
AF Lin, Ying-Chuan
   Perryman, Alexander L.
   Olson, Arthur J.
   Torbett, Bruce E.
   Elder, John H.
   Stout, C. David
TI Structural basis for drug and substrate specificity exhibited by FIV
   encoding a chimeric FIV/HIV protease
SO ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
LA English
DT Article
DE chimeric FIV; HIV protease; feline immunodeficiency virus; darunavir;
   lopinavir
ID FELINE IMMUNODEFICIENCY VIRUS; HIV-1 PROTEASE; IN-VITRO;
   CRYSTAL-STRUCTURES; INHIBITOR; RESISTANCE; INTEGRATION; MECHANISMS;
   LOPINAVIR; PROGRAM
AB A chimeric feline immunodeficiency virus (FIV) protease (PR) has been engineered that supports infectivity but confers sensitivity to the human immunodeficiency virus (HIV) PR inhibitors darunavir (DRV) and lopinavir (LPV). The 6s-98S PR has five replacements mimicking homologous residues in HIV PR and a sixth which mutated from Pro to Ser during selection. Crystal structures of the 6s-98S FIV PR chimera with DRV and LPV bound have been determined at 1.7 and 1.8 A resolution, respectively. The structures reveal the role of a flexible 90s loop and residue 98 in supporting Gag processing and infectivity and the roles of residue 37 in the active site and residues 55, 57 and 59 in the flap in conferring the ability to specifically recognize HIV PR drugs. Specifically, Ile37Val preserves tertiary structure but prevents steric clashes with DRV and LPV. Asn55Met and Val59Ile induce a distinct kink in the flap and a new hydrogen bond to DRV. Ile98Pro -> Ser and Pro100Asn increase 90s loop flexibility, Gln99Val contributes hydrophobic contacts to DRV and LPV, and Pro100Asn forms compensatory hydrogen bonds. The chimeric PR exhibits a comparable number of hydrogen bonds, electrostatic interactions and hydrophobic contacts with DRV and LPV as in the corresponding HIV PR complexes, consistent with IC50 values in the nanomolar range.
C1 [Perryman, Alexander L.; Olson, Arthur J.; Stout, C. David] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   [Lin, Ying-Chuan; Elder, John H.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Torbett, Bruce E.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.
RP Stout, CD (reprint author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM dave@scripps.edu
FU NIH [P01 GM083658, R01 AI081585]; Department of Energy, Office of
   Biological and Environmental Research; National Institutes of Health,
   National Center for Research Resources; National Institute of General
   Medical Sciences
FX This research was supported by NIH grants P01 GM083658 (AJO, BET, JHE
   and CDS) and R01 AI081585 (JHE). Portions of this research were carried
   out at the Stanford Synchrotron Radiation Lightsource, a national user
   facility operated by Stanford University on behalf of the US Department
   of Energy, Office of Basic Energy Sciences. The SSRL Structural
   Molecular Biology Program is supported by the Department of Energy,
   Office of Biological and Environmental Research, the National Institutes
   of Health, National Center for Research Resources, Biomedical Technology
   Program and the National Institute of General Medical Sciences.
   Lopinavir was obtained through the NIH AIDS Research and Reference
   Reagent Program, Division of AIDS, NIAID, NIH. This research was carried
   out to support and extend the FightAIDS@Home project (a part of IBM's
   'World Community Grid').
CR Anderson Jeffrey, 2009, V189, P85
   Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
   Buhler B, 2001, J VIROL, V75, P9502, DOI 10.1128/JVI.75.19.9502-9508.2001
   Bulgheroni E, 2004, J ANTIMICROB CHEMOTH, V53, P464, DOI 10.1093/jac/dkh103
   Dandache S, 2008, J MED VIROL, V80, P2053, DOI 10.1002/jmv.21329
   Elder JH, 2008, VET IMMUNOL IMMUNOP, V123, P3, DOI 10.1016/j.vetimm.2008.01.007
   Elder JH, 2010, CURR HIV RES, V8, P73, DOI 10.2174/157016210790416389                                                      
   Heaslet H, 2006, J MOL BIOL, V356, P967, DOI 10.1016/j.jmb.2005.11.094
   Heaslet H, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-1
   Johnson Victoria A, 2010, Top HIV Med, V18, P156
   Johnson Victoria A, 2008, Top HIV Med, V16, P138
   Kervinen J, 1998, PROTEIN SCI, V7, P2314, DOI 10.1002/pro.5560071108                                                          
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Laco GS, 1997, BIOCHEMISTRY-US, V36, P10696, DOI 10.1021/bi9707436
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   Lee TY, 1999, J AM CHEM SOC, V121, P1145, DOI 10.1021/ja982893p                                                               
   Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X
   Li M, 2000, PROTEINS, V38, P29, DOI 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N
   Lin YC, 2006, J VIROL, V80, P7832, DOI 10.1128/JVI.00374-06
   Lin YC, 2010, J VIROL, V84, P6799, DOI 10.1128/JVI.00294-10
   McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Perryman AL, 2010, CHEM BIOL DRUG DES, V75, P257, DOI 10.1111/j.1747-0285.2009.00943.x
   Pokorna J, 2009, VIRUSES-BASEL, V1, P1209, DOI 10.3390/v1031209
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sherman W, 2008, CHEM BIOL DRUG DES, V71, P387, DOI 10.1111/j.1747-0285.2008.00659.x
   Soltis SM, 2008, ACTA CRYSTALLOGR D, V64, P1210, DOI 10.1107/S0907444908030564
   Stoll V, 2002, BIOORGAN MED CHEM, V10, P2803, DOI 10.1016/S0968-0896(02)00051-2
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480
NR 35
TC 6
Z9 6
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0907-4449
J9 ACTA CRYSTALLOGR D
JI Acta Crystallogr. Sect. D-Biol. Crystallogr.
PD JUN
PY 2011
VL 67
BP 540
EP 548
DI 10.1107/S0907444911011681
PN 6
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA 772DR
UT WOS:000291212900006
PM 21636894
OA gold
DA 2018-01-05
ER

PT J
AU Pylaev, TE
   Khanadeev, VA
   Khlebtsov, BN
   Dykman, LA
   Bogatyrev, VA
   Khlebtsov, NG
AF Pylaev, T. E.
   Khanadeev, V. A.
   Khlebtsov, B. N.
   Dykman, L. A.
   Bogatyrev, V. A.
   Khlebtsov, N. G.
TI Effects of shape and charge of colloidal gold nanoparticles in
   colorimetric determination of DNA sequences
SO COLLOID JOURNAL
LA English
DT Article
ID LIGHT-SCATTERING; OPTICAL-PROPERTIES; PARTICLE-SIZE; NANORODS;
   OLIGONUCLEOTIDES; HYBRIDIZATION; ASSEMBLIES
AB The principles of colorimetric detecting oligonucleotides with the help of gold nanospheres and nanorods are discussed. Marker sequences of fragments of HIV-1 genome and Bacillus anthracis are used as models. Experimental data are reported that demonstrate the influence of gold nanorod morphology on the reproducibility of colorimetric tests. A new method is proposed for detecting oligonucleotides based on the application of positively charged gold nanospheres in combination with absorption spectroscopy and dynamic light scattering. Charge reversal of negatively charged gold nanospheres is implemented through the bilayer adsorption of cetyltrimethylammonium bromide molecules. The sensitivity of the proposed method is comparable with the detection of DNA sequences via the colorimetric protocol using nanorods, but it is more simple and stable from the viewpoint of realization. It is shown that the colorimetric tests using gold nanorods and nanospheres do not provide reliable information on the presence of single- and three-base mismatches in target oligonucleotides.
C1 [Pylaev, T. E.; Khlebtsov, B. N.; Dykman, L. A.; Bogatyrev, V. A.; Khlebtsov, N. G.] Russian Acad Sci, Inst Biochem & Physiol Plants & Microorganisms, Saratov 410049, Russia.
   [Khanadeev, V. A.; Bogatyrev, V. A.; Khlebtsov, N. G.] NG Chernyshevskii Saratov State Univ, Saratov 410012, Russia.
RP Pylaev, TE (reprint author), Russian Acad Sci, Inst Biochem & Physiol Plants & Microorganisms, Pr Entuziastov 13, Saratov 410049, Russia.
RI Khanadeev, Vitaly/N-5817-2016; Pylaev, Timofey/A-8401-2016; Khlebtsov,
   Nikolai/D-6199-2017
OI Khanadeev, Vitaly/0000-0003-3404-5402; Khlebtsov,
   Nikolai/0000-0002-2055-7784
FU Russian Foundation for Basic Research [08-02-00399a, 09-02-00496-a];
   federal goal-oriented programs "Development of Science Potential of
   Higher School" [2.2.1.1/2950]; Scientific and Educational Personnel of
   Innovation Russia [02.740.11.0484]; U.M.N.I.K.;  [MK-684.2009.2]
FX This work was supported by the Russian Foundation for Basic Research
   (project nos. 08-02-00399a and 09-02-00496-a) and the federal
   goal-oriented programs "Development of Science Potential of Higher
   School" (project no. 2.2.1.1/2950) and "Scientific and Educational
   Personnel of Innovation Russia (project no. 02.740.11.0484). The studies
   performed by B.N. Khlebtsov were supported by the Russian President
   grant MK-684.2009.2, and the studies implemented by postgraduate student
   V.A. Khanadeev were supported by the state contract within the framework
   of the program "U.M.N.I.K."
CR [Алексеева А.В. Alekseeva A.V.], 2006, [Коллоидный журнал, Kolloidnyi zhurnal], V68, P725
   Bao P, 2002, ANAL CHEM, V74, P1792, DOI 10.1021/ac0111964
   Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391
   BOGATYREV VA, 2004, OPT SPEKTROSK, V96, P139
   BOGATYREV VA, 2002, KOLLOID ZH, V64, P745
   Dai Q, 2008, J AM CHEM SOC, V130, P8138, DOI 10.1021/ja801947e
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Derjaguin B. V., 1987, SURFACE FORCES
   Doria G, 2007, IET NANOBIOTECHNOL, V1, P53, DOI 10.1049/iet-nbt:20070001
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Jain PK, 2006, J PHYS CHEM B, V110, P18243, DOI 10.1021/jp063879z
   Khlebtsov BN, 2008, J PHYS CHEM C, V112, P12760, DOI 10.1021/jp802874x
   Khlebtsov NG, 2004, NATO SCI SER II MATH, V161, P265
   Khlebtsov NG, 2004, J QUANT SPECTROSC RA, V89, P133, DOI 10.1016/j.jqsrt.2004.05.017
   Khlebtsov N.G., 2000, KOLLOID ZH, V62, P844
   Lazarides AA, 2000, J PHYS CHEM B, V104, P460, DOI 10.1021/jp992179+
   Li HX, 2005, ANAL CHEM, V77, P6229, DOI 10.1021/ac050921y
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li HX, 2004, J AM CHEM SOC, V126, P10958, DOI 10.1021/ja048749n
   Markel VA, 1996, PHYS REV B, V53, P2425, DOI 10.1103/PhysRevB.53.2425
   Mirkin CA, 2000, INORG CHEM, V39, P2258, DOI 10.1021/ic991123r
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Oldenburg SJ, 2002, ANAL BIOCHEM, V309, P109, DOI 10.1016/S0003-2697(02)00410-4
   Parak WJ, 2003, NANOTECHNOLOGY, V14, pR15, DOI 10.1088/0957-4484/14/7/201
   Ratto F, 2010, J NANOPART RES, V12, P2029, DOI 10.1007/s11051-009-9712-0
   Reynolds RA, 2000, J AM CHEM SOC, V122, P3795, DOI 10.1021/ja000133k                                                               
   Sato K, 2006, ANAL BIOCHEM, V350, P162, DOI 10.1016/j.ab.2005.12.009
   Sato K., 2005, NUCLEIC ACIDS RES, V33, pD174
   Sau TK, 2004, LANGMUIR, V20, P6414, DOI 10.1021/la049463z
   Shulepov SY, 1996, J COLLOID INTERF SCI, V182, P388, DOI 10.1006/jcis.1996.0478                                                          
   Storhoff JJ, 2000, J AM CHEM SOC, V122, P4640, DOI 10.1021/ja993825l                                                               
   Takahashi H, 2005, CHEM COMMUN, P2247, DOI 10.1039/b500337g
   Xu XD, 2006, ADV FUNCT MATER, V16, P2170, DOI 10.1002/adfm.200500878
   Zhang J., 2008, SMALL, V8, P1196
NR 36
TC 2
Z9 2
U1 0
U2 21
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1061-933X
J9 COLLOID J+
JI Colloid J.
PD JUN
PY 2011
VL 73
IS 3
BP 368
EP 377
DI 10.1134/S1061933X11020104
PG 10
WC Chemistry, Physical
SC Chemistry
GA 772RX
UT WOS:000291253900010
DA 2018-01-05
ER

PT J
AU Shegokar, R
   Jansch, M
   Singh, KK
   Muller, RH
AF Shegokar, Ranjita
   Jansch, Mirko
   Singh, Kamalinder K.
   Mueller, Rainer H.
TI In vitro protein adsorption studies on nevirapine nanosuspensions for
   HIV/AIDS chemotherapy
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE HIV/AIDS; NS; Drug targeting; Biodistribution; 2-D PAGE
ID PEG-CHAIN-LENGTH; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS;
   SOLID-LIPID-NANOPARTICLES; BLOOD-BRAIN-BARRIER; DRUG-DELIVERY; MAGNETITE
   NANOPARTICLES; SURFACE-MODIFICATION; COLLOIDAL CARRIERS; PLASMA;
   PARTICLES
AB Nevirapine is a poorly water-soluble antiretroviral drug. Intravenous nevirapine nanosuspensions (NS) (457 +/- 10 nm) were prepared by high-pressure homogenization. NS were surface modified by stabilizer adsorption, e. g., serum albumin, polysaccharide and polyethylene glycol (PEG) 1000. The NS were characterized for mean particle size, particle size distribution and polydispersity index. The targeting potential of the nonmodified and three surface-modified NS to the mononuclear phagocytic system (MPS) cells that serve as potent viral reservoirs was assessed by in vitro protein adsorption studies using two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). The adsorption patterns were qualitatively identical, but showed quantitative differences. The relatively adsorbed high amounts of immunoglobulins indicate uptake by liver and spleen, observed quantitative differences (e.g., the amount of dysopsonin albumin and apolipoproteins) can modulate the organ distribution. Controlled in vitro optimization of the protein adsorption by surface modification of the nanocrystals can reduce the number of animals required for in vivo studies and accelerate development of targeted nanoparticles.
   From the Clinical Editor: In this study, intravenous nevirapine (a poorly water-soluble antiretroviral drug) nanosuspensions were prepared by high-pressure homogenization and characterized. (C) 2011 Published by Elsevier Inc.
C1 [Shegokar, Ranjita; Jansch, Mirko; Mueller, Rainer H.] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & NutriCosmet, Inst Pharm, D-1000 Berlin, Germany.
   [Shegokar, Ranjita; Singh, Kamalinder K.] SNDT Womens Univ, CU Shah Coll Pharm, Bombay, Maharashtra, India.
RP Muller, RH (reprint author), Free Univ Berlin, Dept Pharmaceut Biopharmaceut & NutriCosmet, Inst Pharm, D-1000 Berlin, Germany.
EM nanoteam@gmx.com
FU Deutsche Forschungsgemeinschaft (DFG); Deutscher Akademischer Austausch
   Dienst (DAAD)
FX The authors would like to thank Deutsche Forschungsgemeinschaft (DFG)
   and Deutscher Akademischer Austausch Dienst (DAAD) for financial
   support.
CR ANDERSON L, 1977, P NATL ACAD SCI USA, V74, P5421, DOI 10.1073/pnas.74.12.5421
   Babensee JE, 1998, BIOMATERIALS, V19, P839, DOI 10.1016/S0142-9612(97)00242-1
   Blunk T, 1996, EUR J PHARM BIOPHARM, V42, P262
   BLUNK T, 1993, ELECTROPHORESIS, V14, P1382, DOI 10.1002/elps.11501401214
   BLUNK T, 1994, THESIS CHRISTIANALBR
   Camner P, 2002, J APPL PHYSIOL, V92, P2608, DOI 10.1152/japplphysiol.01067.2001
   FENG L, 1994, J BIOMED MATER RES, V28, P735, DOI 10.1002/jbm.820280611
   Gessner A, 2006, PHARMAZIE, V61, P293
   Gessner A, 2000, ELECTROPHORESIS, V21, P2438, DOI 10.1002/1522-2683(20000701)21:12<2438::AID-ELPS2438>3.0.CO;2-F
   Goppert TM, 2005, EUR J PHARM BIOPHARM, V60, P361, DOI 10.1016/j.ejpb.2005.02.006
   Goppert TM, 2003, J DRUG TARGET, V11, P225, DOI 10.1080/10611860310001615956
   Gref R, 2000, COLLOID SURFACE B, V18, P301, DOI 10.1016/S0927-7765(99)00156-3                                                   
   Gupta AK, 2004, J MATER SCI-MATER M, V15, P493, DOI 10.1023/B:JMSM.0000021126.32934.20                                              
   Harnisch S, 1998, ELECTROPHORESIS, V19, P349, DOI 10.1002/elps.1150190233
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024-3205(87)90138-X
   Jorgensen L, 2009, J LIPOSOME RES, V19, P99, DOI 10.1080/08982100902805475
   JULIANO R L, 1988, Advanced Drug Delivery Reviews, V2, P31, DOI 10.1016/0169-409X(88)90004-X
   Kang SC, 2007, J NANOSCI NANOTECHNO, V7, P3706, DOI 10.1166/jnn.2007.022
   Kim HR, 2007, BIOMACROMOLECULES, V8, P793, DOI 10.1021/bm060711a
   KLOSE J, 1975, HUMANGENETIK, V26, P231
   Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Kreuter J, 1997, J CONTROL RELEASE, V49, P81, DOI 10.1016/S0168-3659(97)00061-8
   LEROUX JC, 1995, LIFE SCI, V57, P695, DOI 10.1016/0024-3205(95)00321-V                                                    
   LUCK M, 1998, 2 DIMENSIONAL ELECTR, P109
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P157, DOI 10.1016/0167-4889(93)90137-E
   Mosqueira VCF, 2001, PHARMACEUT RES, V18, P1411, DOI 10.1023/A:1012248721523                                                         
   MULLER RH, 1989, BIOADHESION POSSIBIL, P202
   MULLER RH, 2006, PRODUCTION BIOFUNCTI, V2
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Ogawara K, 2004, J CONTROL RELEASE, V100, P451, DOI 10.1016/j.jconrel.2004.07.028
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Price ME, 2001, BBA-BIOMEMBRANES, V1512, P191, DOI 10.1016/S0005-2736(01)00330-3                                                   
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Seehof K, 2000, INT J PHARM, V196, P231, DOI 10.1016/S0378-5173(99)00429-9
   Servoli E, 2008, MACROMOL BIOSCI, V8, P1126, DOI 10.1002/mabi.200800110
   SHEGOKAR R, 2010, THESIS SNDT WOMENS U
   Shehata T, 2008, INT J PHARM, V359, P272, DOI 10.1016/j.ijpharm.2008.04.004
   Thode K, 1997, PHARMACEUT RES, V14, P905, DOI 10.1023/A:1012104017761
   Yamazaki A, 1999, BBA-BIOMEMBRANES, V1421, P103, DOI 10.1016/S0005-2736(99)00117-0
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 42
TC 14
Z9 16
U1 1
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD JUN
PY 2011
VL 7
IS 3
BP 333
EP 340
DI 10.1016/j.nano.2010.10.012
PG 8
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 769QI
UT WOS:000291032800010
PM 21094278
DA 2018-01-05
ER

PT J
AU Scaffidi, JP
   Gregas, MK
   Lauly, B
   Zhang, Y
   Vo-Dinh, T
AF Scaffidi, Jonathan P.
   Gregas, Molly K.
   Lauly, Benoit
   Zhang, Yan
   Vo-Dinh, Tuan
TI Activity of Psoralen-Functionalized Nanoscintillators against Cancer
   Cells upon X-ray Excitation
SO ACS NANO
LA English
DT Article
DE PUVA; psoralen; nanoscintillator; yttrium oxide; Y2O3
ID GOLD NANOPARTICLES; SCINTILLATION PROPERTIES; PHOTODYNAMIC THERAPY;
   IN-VITRO; DRUG ACCUMULATION; CLONOGENIC-ASSAY; GROWTH-FACTORS;
   BREAST-CANCER; LEAD SULFATE; LIGHT YIELD
AB We report development of a nanoparticle-based, X-ray-activated anticancer "nanodrug" composed of yttrium oxide (Y2O3) nanoscintiliators, a fragment of the HIV-1 TAT peptide, and psoralen. In this formulation, X-ray radiation is absorbed by the Y2O3 nanoscintillators, which then emit UVA light. Absorption of UVA photons by nanoparticle-tethered psoralen has the potential to cross-link adenine and thymine residues in DNA. OVA-Induced cross-linking by free psoralen upon activation with OVA light has previously been shown to cause apoptosis in vitro and an immunogenic response in vivo. Studies using the PC-3 human prostate cancer cell line demonstrate that X-ray excitation of these psoralen-functionalized Y2O3 nanosdntillators yields concentration-dependent reductions in cell number when compared to control cultures containing psoralen-free Y2O3 nanoscintillators.
C1 [Scaffidi, Jonathan P.; Gregas, Molly K.; Lauly, Benoit; Zhang, Yan; Vo-Dinh, Tuan] Duke Univ, Fitzpatrick Inst Photon, Durham, NC 27708 USA.
   [Scaffidi, Jonathan P.; Gregas, Molly K.; Lauly, Benoit; Zhang, Yan; Vo-Dinh, Tuan] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Vo-Dinh, Tuan] Duke Univ, Dept Chem, Durham, NC 27708 USA.
RP Vo-Dinh, T (reprint author), Duke Univ, Fitzpatrick Inst Photon, Durham, NC 27708 USA.
EM tuan.vodinh@duke.edu
RI Zhang, Yan/F-9715-2011
FU Immunolight, LLC.
FX The authors gratefully acknowledge many productive discussions with Dr.
   Guy Griffin and financial support from Immunolight, LLC.
CR BARYSHEVSKY VG, 1991, NUCL INSTRUM METH B, V58, P291, DOI 10.1016/0168-583X(91)95605-D
   Bethea D, 1999, J DERMATOL SCI, V19, P78, DOI 10.1016/S0923-1811(98)00064-4                                                   
   Birowosuto MD, 2006, IEEE T NUCL SCI, V53, P3028, DOI 10.1109/TNS.2006.880969
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   CHAPLIN DJ, 1986, INT J RADIAT ONCOL, V12, P1279, DOI 10.1016/0360-3016(86)90153-7                                                    
   Chatterjee DK, 2008, ADV DRUG DELIVER REV, V60, P1627, DOI 10.1016/j.addr.2008.08.003
   Chattopadhyay N, 2010, MOL PHARMACEUT, V7, P2194, DOI 10.1021/mp100207t
   Chen W, 2006, J APPL PHYS, V99, DOI 10.1063/1.2168234
   Chen W, 2006, J NANOSCI NANOTECHNO, V6, P1159, DOI 10.1166/jnn.2006.327
   Chithrani DB, 2010, RADIAT RES, V173, P719, DOI 10.1667/RR1984.1
   Chiu SJ, 2003, RADIAT RES, V159, P391, DOI 10.1667/0033-7587(2003)159[0391:GOETRO]2.0.CO;2
   Cuenca AG, 2006, CANCER, V107, P459, DOI 10.1002/cncr.22035
   de Haas JTM, 2008, IEEE T NUCL SCI, V55, P1086, DOI 10.1109/TNS.2008.922819
   de Haas JTM, 2005, NUCL INSTRUM METH A, V537, P97, DOI 10.1016/j.nima.2004.07.243
   DENT MF, 1995, CYTOTECHNOLOGY, V17, P27, DOI 10.1007/BF00749218
   Dong Y, 2007, INT J PHARM, V342, P208, DOI 10.1016/j.ijpharm.2007.04.031
   Dorenbos P, 2005, PHYS STATUS SOLIDI A, V202, P195, DOI 10.1002/pssa.200460106
   Dorenbos P, 1995, RADIAT EFF DEFECT S, V135, P321, DOI 10.1080/10420159508229859                                                       
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Felice DL, 2009, J FUNCT FOODS, V1, P109, DOI 10.1016/j.jff.2008.09.014
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Gasparro F P, 1997, Recent Results Cancer Res, V143, P101
   GORODETSKY R, 1995, ISRAEL J MED SCI, V31, P95
   Gregas MK, 2010, APPL SPECTROSC, V64, P858, DOI 10.1366/000370210792081037
   Gulyaev AE, 1999, PHARMACEUT RES, V16, P1564, DOI 10.1023/A:1018983904537
   Hainfeld JF, 2010, PHYS MED BIOL, V55, P3045, DOI 10.1088/0031-9155/55/11/004
   Hainfeld JF, 2004, PHYS MED BIOL, V49, pN309, DOI 10.1088/0031-9155/49/18/N03
   HENDERSON BW, 1987, CANCER RES, V47, P3110
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Huang Z, 2003, PHOTOCHEM PHOTOBIOL, V78, P496, DOI 10.1562/0031-8655(2003)078<0496:HETTCK>2.0.CO;2                                 
   Juzenas P, 2008, ADV DRUG DELIVER REV, V60, P1600, DOI 10.1016/j.addr.2008.08.004
   Kim JK, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/42/425102
   Kim K, 2008, BIOTECHNOL LETT, V30, P1331, DOI 10.1007/s10529-008-9695-4
   Kong T, 2008, SMALL, V4, P1537, DOI 10.1002/smll.200700794
   LEMPICKI A, 1995, IEEE T NUCL SCI, V42, P280, DOI 10.1109/23.467836
   LEMPICKI A, 1993, IEEE T NUCL SCI, V40, P384, DOI 10.1109/23.256585
   Li JY, 2007, CHEMMEDCHEM, V2, P374, DOI [10.1002/cmdc.200600264, 10.1002/cdmc.200600264]
   Liu CJ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/29/295104
   LIU YF, 2008, J APPL PHYS, V103
   Liu YF, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2835701
   LOEF EVD, 2005, NUCL INSTRUM METH A, V537, P232
   LOEF EVD, 2001, IEEE T NUCL SCI, V48, P341
   Lovell JF, 2010, CHEM REV, V110, P2839, DOI 10.1021/cr900236h
   MALANE MS, 1991, ANN NY ACAD SCI, V636, P196, DOI 10.1111/j.1749-6632.1991.tb33451.x                                              
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Mares JA, 2004, RADIAT MEAS, V38, P353, DOI 10.1016/j.radmeas.2004.04.004
   Menge PR, 2007, NUCL INSTRUM METH A, V579, P6, DOI 10.1016/j.nima.2007.04.002
   Morgan NY, 2009, RADIAT RES, V171, P236, DOI 10.1667/RR1470.1
   MOSES WW, 1992, IEEE T NUCL SCI, V39, P1190, DOI 10.1109/23.173176
   MOSES WW, 1995, IEEE T NUCL SCI, V42, P275, DOI 10.1109/23.467837
   Moszynski M, 1997, NUCL INSTRUM METH A, V385, P123, DOI 10.1016/S0168-9002(96)00875-3
   Moszynski M, 1997, IEEE T NUCL SCI, V44, P1052, DOI 10.1109/23.603803
   Mueller H, 2004, J BIOMOL SCREEN, V9, P506, DOI 10.1177/1087057104265386
   Nystrom AM, 2008, CHEM COMMUN, P3579, DOI 10.1039/b805428b
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   OGORODNIKOV IN, 1996, INORGANIC SCINTILLAT, P216
   OLIVER MH, 1989, J CELL SCI, V92, P513
   PELLETIER B, 1988, J BIOCHEM BIOPH METH, V16, P63, DOI 10.1016/0165-022X(88)90104-2                                                    
   PLUMB JA, 1999, CYTOTOXIC DRUG RESIS, P25
   QUINTILIANI M, 1979, INT J RADIAT ONCOL, V5, P1069, DOI 10.1016/0360-3016(79)90621-7                                                    
   Rapoport N, 2007, J NATL CANCER I, V99, P1095, DOI 10.1093/jnci/dim043
   Reis PA, 2008, FOOD CHEM, V108, P1094, DOI 10.1016/j.foodchem.2007.11.060
   Roeske JC, 2007, TECHNOL CANCER RES T, V6, P395, DOI 10.1177/153303460700600504                                                      
   Roy UN, 2007, NUCL INSTRUM METH A, V579, P46, DOI 10.1016/j.nima.2007.04.126
   Salacka JS, 2010, IEEE T NUCL SCI, V57, P901, DOI 10.1109/TNS.2010.2043117
   Schubert D, 2006, BIOCHEM BIOPH RES CO, V342, P86, DOI 10.1016/j.bbrc.2006.01.129
   SCRAGG MA, 1991, ANAL BIOCHEM, V198, P80, DOI 10.1016/0003-2697(91)90509-R
   Shah KS, 2005, IEEE T NUCL SCI, V52, P3157, DOI 10.1109/TNS.2005.860155
   Song M, 2008, J BIOMED MATER RES A, V86A, P942, DOI 10.1002/jbm.a.31692
   SPIJKER JC, 1999, J LUMIN, V85, P1
   Takahashi J, 2007, NANOBIOTECHNOLOGY, V3, P116
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   van Loef EVD, 2002, NUCL INSTRUM METH A, V486, P254, DOI 10.1016/S0168-9002(02)00712-X                                                   
   VANTSPIJKER JC, 1995, RADIAT MEAS, V24, P379, DOI 10.1016/1350-4487(95)00019-B
   Vetrone F, 2004, NANOTECHNOLOGY, V15, P75, DOI 10.1088/0957-4484/15/1/015
   Visaria RK, 2006, MOL CANCER THER, V5, P1014, DOI 10.1158/1535-7163.MCT-05-0381
   Wang L, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/47/475103
   Wang SZ, 2004, J MATER CHEM, V14, P487, DOI 10.1039/b311429e
   WEISENTHAL LM, 1983, CANCER RES, V43, P258
   Wisniewski D, 1997, J LUMIN, V72-4, P789, DOI 10.1016/S0022-2313(97)80792-2
   Wojtowicz AJ, 2001, J PHYS-CONDENS MAT, V13, P9599, DOI 10.1088/0953-8984/13/42/318
   Yih TC, 2005, NANOMED-NANOTECHNOL, V1, P191, DOI 10.1016/j.nano.2005.04.001
   Yuan JL, 2007, J SOLID STATE CHEM, V180, P3381, DOI 10.1016/j.jssc.2007.09.021
   Zadneprovski BI, 2004, INORG MATER+, V40, P735, DOI 10.1023/B:INMA.0000034773.78589.51
   Zako T, 2008, J MATER SCI, V43, P5325, DOI 10.1007/s10853-008-2776-x
   Zhang HP, 2006, MAT SCI ENG B-SOLID, V130, P151, DOI 10.1016/j.mseb.2006.02.067
   ZHANG JG, 1994, IEEE T NUCL SCI, V41, P669, DOI 10.1109/23.322786
   Zhang RY, 2006, NANOTECHNOLOGY, V17, P3622, DOI 10.1088/0957-4484/17/14/043
   Zhang ZP, 2008, PHARM RES-DORDR, V25, P1925, DOI 10.1007/s11095-008-9611-6
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 92
TC 28
Z9 29
U1 4
U2 52
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2011
VL 5
IS 6
BP 4679
EP 4687
DI 10.1021/nn200511m
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 783AZ
UT WOS:000292055200050
PM 21553850
DA 2018-01-05
ER

PT J
AU Krpetic, Z
   Saleemi, S
   Prior, IA
   See, V
   Qureshi, R
   Brust, M
AF Krpetic, Zeljka
   Saleemi, Samia
   Prior, Ian A.
   See, Violaine
   Qureshi, Rumana
   Brust, Mathias
TI Negotiation of Intracellular Membrane Barriers by TAT-Modified Gold
   Nanoparticles
SO ACS NANO
LA English
DT Article
DE gold nanoparticles; cellular uptake; cell-penetrating peptides; TAT;
   intracellular trafficking; endosomal escape; transmission electron
   microscopy
ID PHOTOTHERMAL THERAPY; CELLULAR UPTAKE; QUANTUM DOTS; PEPTIDE; CELLS
AB This paper contributes to the debate on how nanosized objects negotiate membrane barriers inside biological cells. The uptake of peptide-modified gold nanoparticles by HeLa cells has been quantified using atomic emission spectroscopy. The TAT peptide from the HIV virus was singled out as a particularly effective promoter of cellular uptake. The evolution of the intracellular distribution of TAT-modified gold nanoparticles with time has been studied in detail by TEM and systematic image analysis. An unusual trend of particles disappearing from the cytosol and the nucleus and accumulating massively in vesicular bodies was observed. Subsequent release of the particles, both by membrane rupture and by direct transfer across the membrane boundary, was frequently found. Ultimately, near total clearing of particles from the cells occurred. This work provides support for the hypothesis that cell-penetrating peptides can enable small objects to, negotiate membrane barriers also in the absence of dedicated transport mechanisms.
C1 [Krpetic, Zeljka; Saleemi, Samia; Brust, Mathias] Univ Liverpool, Dept Chem, Ctr Nanoscale Sci, Liverpool L69 7ZD, Merseyside, England.
   [Prior, Ian A.] Univ Liverpool, Physiol Lab, Inst Translat Res, Liverpool L69 3BX, Merseyside, England.
   [See, Violaine] Univ Liverpool, Inst Integrat Biol, Ctr Cell Imaging, Liverpool L69 7ZB, Merseyside, England.
   [Saleemi, Samia; Qureshi, Rumana] Quaid I Azam Univ, Dept Chem, Electrochem Grp, Islamabad, Pakistan.
RP Brust, M (reprint author), Univ Liverpool, Dept Chem, Ctr Nanoscale Sci, Crown St, Liverpool L69 7ZD, Merseyside, England.
EM M.Brust@liverpool.ac.uk
RI Krpetic, Zeljka/K-6154-2012
OI Krpetic, Zeljka/0000-0003-1129-6831; Brust, Mathias/0000-0001-6301-7123;
   Prior, Ian/0000-0002-4055-5161
FU Higher Education Commission (HEC) of Pakistan
FX The authors wish to thank Alison Beckett for TEM assistance and George
   Miller for the AES measurements. Partial financial support from the
   Higher Education Commission (HEC) of Pakistan is greatly acknowledged
   (S.S. and R.Q.).
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Arnida, 2010, J APPL TOXICOL, V30, P212, DOI 10.1002/jat.1486
   AVNESH K, 2011, EXPERT OPIN DRUG DEL, V8, P141
   Bartczak D, 2011, NANO LETT, V11, P1358, DOI 10.1021/nl104528s
   Bartczak D, 2011, SMALL, V7, P388, DOI 10.1002/smll.201001816
   Brandenberger C, 2010, SMALL, V6, P1669, DOI 10.1002/smll.201000528
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani DB, 2010, MOL MEMBR BIOL, V27, P299, DOI 10.3109/09687688.2010.507787
   Choi WI, 2011, ACS NANO, V5, P1995, DOI 10.1021/nn103047r
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035
   FENS G, 1973, NATURE, V241, P20
   Hainfeld J. F., 2004, PHYS MED BIOL, V49, pN309
   HUANG XH, 2010, J BIOMED OPT, V15
   Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x
   Ikah DSK, 2006, TOXICOLOGY, V219, P238
   Kim C, 2010, NAT CHEM, V2, P962, DOI [10.1038/NCHEM.858, 10.1038/nchem.858]
   Koo OM, 2005, NANOMED-NANOTECHNOL, V1, P193, DOI 10.1016/j.nano.2005.06.004
   Krpetic Z, 2010, NANO LETT, V10, P4549, DOI 10.1021/nl103142t
   Krpetic Z, 2010, LANGMUIR, V26, P14799, DOI 10.1021/la102758f
   Krug HF, 2011, ANGEW CHEM INT EDIT, V50, P1260, DOI 10.1002/anie.201001037
   Levy R, 2004, J AM CHEM SOC, V126, P10076, DOI 10.1021/ja0487269
   LUCCARDINI C, 2007, J BIOMED BIOTECHNOL, P1
   Lundberg P, 2006, INT J PEPT RES THER, V12, P105, DOI 10.1007/s10989-005-9007-y
   Maynard AD, 2010, TOXICOL SCI, V120, pS109
   Nam J, 2009, J AM CHEM SOC, V131, P13639, DOI 10.1021/ja902062j
   Nativo P, 2008, ACS NANO, V2, P1639, DOI 10.1021/nn800330a
   Parak WJ, 2005, NANOTECHNOLOGY, V16, pR9, DOI 10.1088/0957-4484/16/2/R01
   Pujals S, 2009, CHEMBIOCHEM, V10, P1025, DOI 10.1002/cbic.200800843
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   See V, 2009, ACS NANO, V3, P2461, DOI 10.1021/nn9006994
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   Vega RA, 2010, SURGERY, V148, P858, DOI 10.1016/j.surg.2010.07.036
   Wang SH, 2010, J NANOBIOTECHNOL, V8, DOI 10.1186/1477-3155-8-33
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
NR 37
TC 85
Z9 85
U1 2
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2011
VL 5
IS 6
BP 5195
EP 5201
DI 10.1021/nn201369k
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 783AZ
UT WOS:000292055200111
PM 21609028
DA 2018-01-05
ER

PT J
AU Telwatte, S
   Moore, K
   Johnson, A
   Tyssen, D
   Sterjovski, J
   Aldunate, M
   Gorry, PR
   Ramsland, PA
   Lewis, GR
   Paull, JRA
   Sonza, S
   Tachedjian, G
AF Telwatte, Sushama
   Moore, Katie
   Johnson, Adam
   Tyssen, David
   Sterjovski, Jasminka
   Aldunate, Muriel
   Gorry, Paul R.
   Ramsland, Paul A.
   Lewis, Gareth R.
   Paull, Jeremy R. A.
   Sonza, Secondo
   Tachedjian, Gilda
TI Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Dendrimer; Microbicide; SPL7013; HIV; Virucidal activity
ID TOPICAL MICROBICIDES; EXPLANT CULTURE; CANDIDATE; INFECTION; GEL;
   PREVENTION; SAFETY; HERPES; TRANSMISSION; ACQUISITION
AB Topical microbicides for use by women to prevent the transmission of human immunodeficiency virus (HIV) and other sexually transmitted infections are urgently required. Dendrimers are highly branched nanoparticles being developed as microbicides. SPL7013 is a dendrimer with broad-spectrum activity against HIV type I (HIV-1) and -2 (HIV-2), herpes simplex viruses type-1 (HSV-1) and -2 (HSV-2) and human papillomavirus. SPL7013 [3% (w/w)] has been formulated in a mucoadhesive carbopol gel (VivaGel (R)) for use as a topical microbicide. Previous studies showed that SPL7013 has similar potency against CXCR4-(X4) and CCR5-using (R5) strains of HIV-1 and that it blocks viral entry. However, the ability of SPL7013 to directly inactivate HIV-1 is unknown. We examined whether SPL7013 demonstrates virucidal activity against X4 (NL4.3, MBC200, CMU02 clade EA and 92UG046 clade D), R5 (Ba-L, NB25 and 92RW016 clade A) and dual-tropic (R5X4; MACS1-spln) HIV-1 using a modified HLA-DR viral capture method and by polyethylene glycol precipitation. Evaluation of virion integrity was determined by ultracentrifugation through a sucrose cushion and detection of viral proteins by Western blot analysis. SPL7013 demonstrated potent virucidal activity against X4 and R5X4 strains, although virucidal activity was less potent for the 92UG046 X4 clade D isolate. Where potent virucidal activity was observed, the 50% virucidal concentrations were similar to the 50% effective concentrations previously reported in drug susceptibility assays, indicating that the main mode of action of SPL7013 is by direct viral inactivation for these strains. In contrast, SPL7013 lacked potent virucidal activity against R5 HIV-1 strains. Evaluation of the virucidal mechanism showed that SPL7013-treated NL4.3, 92UG046 and MACS1-spln virions were intact with no significant decrease in gp120 surface protein with respect to p24 capsid content compared to the corresponding untreated virus. These studies demonstrate that SPL7013 is virucidal against HIV-1 strains that utilize the CXCR4 coreceptor but not viruses tested in this study that solely use CCR5 by a mechanism that is distinct from virion disruption or loss of gp120. In addition, the mode of action by which SPL7013 prevents infection of cells with X4 and R5X4 strains is likely to differ from R5 strains of HIV-1. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Telwatte, Sushama; Moore, Katie; Johnson, Adam; Tyssen, David; Sterjovski, Jasminka; Aldunate, Muriel; Gorry, Paul R.; Ramsland, Paul A.; Sonza, Secondo; Tachedjian, Gilda] Burnet Inst, Ctr Virol, Melbourne, Vic 3004, Australia.
   [Telwatte, Sushama; Moore, Katie; Johnson, Adam; Tyssen, David; Sterjovski, Jasminka; Aldunate, Muriel; Gorry, Paul R.; Ramsland, Paul A.; Sonza, Secondo; Tachedjian, Gilda] Burnet Inst, Ctr Immunol, Melbourne, Vic 3004, Australia.
   [Gorry, Paul R.; Tachedjian, Gilda] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia.
   [Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia.
   [Ramsland, Paul A.] Univ Melbourne, Dept Surg Austin Hlth, Melbourne, Vic 3084, Australia.
   [Ramsland, Paul A.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
   [Lewis, Gareth R.; Paull, Jeremy R. A.] Starpharma Pty Ltd, Melbourne, Vic 3004, Australia.
   [Aldunate, Muriel; Sonza, Secondo; Tachedjian, Gilda] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia.
RP Tachedjian, G (reprint author), Mol Interact Grp, Ctr Virol, Burnet Inst, GPO Box 2284, Melbourne, Vic 3001, Australia.
EM sushama.t@burnet.edu.au; katie.moore@burne-t.edu.au;
   adamj@burnet.edu.au; davidt@burnet.edu.au; jasminka@burnet.edu.au;
   muriel@burnet.edu.au; gorry@burnet.edu.au; pramsland@burnet.edu.au;
   gareth.lewis@starpharma.com; jeremy.paull@starpharma.com;
   sonza@burnet.edu.au; gildat@burnet.edu.au
OI Sterjovski, Jasminka/0000-0002-2471-3000; Ramsland,
   Paul/0000-0002-2107-2738; Tachedjian, Gilda/0000-0002-7733-7037
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human Services [U19
   A1060598, HHSN266200500042C]; National Health and Medical Research
   Council (NHMRC) of Australia [543105]; Australian Centre for HIV and
   Hepatitis Virology Research (ACH2); ACH2 funding; NHMRC [365209]
FX We thank the NIH AIDS Research & Reference Reagent Program Division of
   AIDS, NIAID, NIH and The UNAIDS Network for HIV Isolation and
   Characterization for providing HIV-1 isolates 92UG046 and 92RW016 used
   in this study. TZM-bl cells were obtained through the NIH AIDS Research
   and Reference Reagent Program, contributed by Drs. John C. Kappes,
   Xiaoyun Wu and Tranzyme Inc. We thank Dana Gabuzda for providing the
   MACS1-spin isolate, Anthony L. Cunningham for providing HIV-1 patient
   isolate NB25, Dale McPhee for providing the human p24 antibody and HIV-1
   strain MBC200, and Andy Poumbourios for providing the gp120 antibody,
   567. We also thank Al Profy for providing PRO 2000. This study was
   supported by US Federal funds from the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, Department of Health
   and Human Services Grant No. U19 A1060598 and Contract No.
   HHSN266200500042C awarded to Starpharma Pty Ltd. G. Tachedjian was
   supported by the National Health and Medical Research Council (NHMRC) of
   Australia Senior Research Fellowship 543105 and funding from the
   Australian Centre for HIV and Hepatitis Virology Research (ACH2). J.
   Sterjovski was supported by ACH2 funding. PRG was supported by an NHMRC
   Level 2 Biomedical Career Development Award and Paul A. Ramsland was
   supported by an NHMRC R Douglas Wright Career Development Award 365209.
   The authors gratefully acknowledge the contribution to this work of the
   Victorian Operational Infrastructure Support Program received by the
   Burnet Institute. The funding agencies had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. All results and conclusions of this report are those of the
   authors and do not necessarily represent the views of NIH.
CR Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424                                                                  
   Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Brown JM, 2007, AIDS, V21, P1515, DOI 10.1097/QAD.0b013e3282004929
   Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Figueiredo A, 2006, PLOS PATHOG, V2, P1051, DOI 10.1371/journal.ppat.0020119
   Fletcher PS, 2008, CURR OPIN INVEST DR, V9, P189
   Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7                                             
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Gorry PR, 2001, J VIROL, V75, P10073, DOI 10.1128/JVI.75.21.10073-10089.2001
   Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-27
   Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6                                                           
   O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac
   Oelrichs RB, 2000, J BIOMED SCI, V7, P128, DOI 10.1159/000025438
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   Pinter A, 2007, CURR HIV RES, V5, P542, DOI 10.2174/157016207782418470
   Rupp R, 2007, INT J NANOMED, V2, P561
   Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234
   Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005
   Shutt DC, 1998, J CELL SCI, V111, P99
   Sonza S, 2009, ANTIMICROB AGENTS CH, V53, P3565, DOI 10.1128/AAC.00102-09
   Sterjovski J, 2010, VIROLOGY, V404, P269, DOI 10.1016/j.virol.2010.05.006
   Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309
   *UNAIDS, 2008, JOINT UN PROGR HIV A
NR 31
TC 52
Z9 52
U1 0
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD JUN
PY 2011
VL 90
IS 3
BP 195
EP 199
DI 10.1016/j.antiviral.2011.03.186
PG 5
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 781ED
UT WOS:000291912500013
PM 21459115
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhou, JH
   Li, HT
   Zhang, JE
   Piotr, S
   Rossi, J
AF Zhou, Jiehua
   Li, Haitang
   Zhang, Jane
   Piotr, Swiderski
   Rossi, John
TI Development of Cell-type specific anti-HIV gp120 aptamers for siRNA
   delivery
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Immunology; Issue 52; SELEX (Systematic Evolution of Ligands by
   EXponential enrichment); RNA aptamer; HIV-1 gp120; RNAi (RNA
   interference); siRNA (small interfering RNA); cell-type specific
   delivery
AB The global epidemic of infection by HIV has created an urgent need for new classes of antiretroviral agents. The potent ability of small interfering (si) RNAs to inhibit the expression of complementary RNA transcripts is being exploited as a new class of therapeutics for a variety of diseases including HIV. Many previous reports have shown that novel RNAi-based anti-HIV/AIDS therapeutic strategies have considerable promise; however, a key obstacle to the successful therapeutic application and clinical translation of siRNAs is efficient delivery. Particularly, considering the safety and efficacy of RNAi-based therapeutics, it is highly desirable to develop a targeted intracellular siRNA delivery approach to specific cell populations or tissues. The HIV-1 gp120 protein, a glycoprotein envelope on the surface of HIV-1, plays an important role in viral entry into CD4 cells. The interaction of gp120 and CD4 that triggers HIV-1 entry and initiates cell fusion has been validated as a clinically relevant anti-viral strategy for drug discovery.
   Herein, we firstly discuss the selection and identification of 2'-F modified anti-HIV gp120 RNA aptamers. Using a conventional nitrocellulose filter SELEX method, several new aptamers with nanomolar affinity were isolated from a 50 random nt RNA library. In order to successfully obtain bound species with higher affinity, the selection stringency is carefully controlled by adjusting the conditions. The selected aptamers can specifically bind and be rapidly internalized into cells expressing the HIV-1 envelope protein. Additionally, the aptamers alone can neutralize HIV-1 infectivity. Based upon the best aptamer A-1, we also create a novel dual inhibitory function anti-gp120 aptamer-siRNA chimera in which both the aptamer and the siRNA portions have potent anti-HIV activities. Further, we utilize the gp120 aptamer-siRNA chimeras for cell-type specific delivery of the siRNA into HIV-1 infected cells. This dual function chimera shows considerable potential for combining various nucleic acid therapeutic agents (aptamer and siRNA) in suppressing HIV-1 infection, making the aptamer-siRNA chimeras attractive therapeutic candidates for patients failing highly active antiretroviral therapy (HAART).
C1 [Zhou, Jiehua; Li, Haitang; Rossi, John] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA USA.
   [Zhang, Jane] City Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA USA.
   [Piotr, Swiderski] City Hope Natl Med Ctr, Beckman Res Inst, Shared Resource DNA RNA Peptide, Duarte, CA USA.
RP Rossi, J (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol & Cellular Biol, Duarte, CA USA.
EM Jrossi@coh.org
FU National Institutes of Health [AI29329, HL07470]
FX We thank Britta Hoehn, Guihua Sun, Harris Soifer and Lisa Scherer for
   helpful discussions. This work was supported by grants from the National
   Institutes of Health AI29329 and HL07470 awarded to J.J.R. The following
   reagents were obtained through the NIH AIDS Research and Reference
   Reagent Program, Division of AIDS, NIAID, NIH: The CHO-EE and CHO-gp160
   cell line; the pNL4-3 luc vector; HIV-1<INF>BaL</INF> gp120 from DAIDS,
   NIAID.
CR Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Famulok M, 2007, CHEM REV, V107, P3715, DOI 10.1021/cr0306743
   Fitzwater T, 1996, METHOD ENZYMOL, V267, P275
   Mayer G, 2009, ANGEW CHEM INT EDIT, V48, P2672, DOI 10.1002/anie.200804643
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   WEISS CD, 1993, J VIROL, V67, P7060
   Zhou J., 2009, NUCL ACIDS RES
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
   Zhou JH, 2009, CURR TOP MED CHEM, V9, P1144, DOI 10.2174/156802609789630893                                                      
NR 14
TC 0
Z9 0
U1 0
U2 6
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2011
IS 52
AR UNSP e2954
DI 10.3791/2954
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36MB
UT WOS:000209214900045
OA green_published
DA 2018-01-05
ER

PT J
AU Zhou, JH
   Shu, Y
   Guo, PX
   Smith, DD
   Rossi, JJ
AF Zhou, Jiehua
   Shu, Yi
   Guo, Peixuan
   Smith, David D.
   Rossi, John J.
TI Dual functional RNA nanoparticles containing phi29 motor pRNA and
   anti-gp120 aptamer for cell-type specific delivery and HIV-1 Inhibition
SO METHODS
LA English
DT Article
DE RNAi; Anti-gp120 aptamer; Nanobiotechnology; Bionanotechnology;
   Nanotechnology; AIDS treatment; Viral DNA packaging; Nanomotors
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INTERFERENCE-BASED THERAPEUTICS;
   NEUTRALIZES R5 STRAINS; DNA PACKAGING MOTOR; SIRNA DELIVERY;
   BACTERIOPHAGE-PHI-29 DNA; ENVELOPE GLYCOPROTEIN; SEQUENCE REQUIREMENT;
   POTENTIAL PARTS; CANCER-CELLS
AB The potent ability of small interfering RNA (siRNA) to inhibit the expression of complementary RNA transcripts is being exploited as a new class of therapeutics for diseases including HIV. However, efficient delivery of siRNAs remains a key obstacle to successful application. A targeted intracellular delivery approach for siRNAs to specific cell types is highly desirable. HIV-1 infection is initiated by the interactions between viral glycoprotein gp120 and cell surface receptor CD4, leading to fusion of the viral membrane with the target cell membrane. Once HIV infects a cell it produces gp120 which is displayed at the cell surface. We previously described a novel dual inhibitory anti-gp120 aptamer-siRNA chimera in which both the aptamer and the siRNA portions have potent anti-HIV activities. We also demonstrated that gp120 can be used for aptamer mediated delivery of anti-HIV siRNAs.
   Here we report the design, construction and evaluation of chimerical RNA nanoparticles containing a HIV gp120-binding aptamer escorted by the pRNA of bacteriophage phi29 DNA-packaging motor. We demonstrate that pRNA-aptamer chimeras specifically bind to and are internalized into cells expressing HIV gp120. Moreover, the pRNA-aptamer chimeras alone also provide HIV inhibitory function by blocking viral infectivity. The Ab' pRNA-siRNA chimera with 2'-F modified pyrimidines in the sense strand not only improved the RNA stability in serum, but also was functionally processed by Dicer, resulting in specific target gene silencing. Therefore, this dual functional pRNA-aptamer not only represents a potential HIV-1 inhibitor, but also provides a cell-type specific siRNA delivery vehicle, showing promise for systemic anti-HIV therapy. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Rossi, John J.] City Hope Natl Med Ctr, Grad Sch Biol Sci, Duarte, CA 91010 USA.
   [Zhou, Jiehua; Rossi, John J.] City Hope Natl Med Ctr, Div Mol & Cellular Biol, Duarte, CA 91010 USA.
   [Shu, Yi; Guo, Peixuan] Univ Cincinnati, SEEBME, Nanobiomed Ctr, Cincinnati, OH 45267 USA.
   [Smith, David D.] City Hope Natl Med Ctr, Beckman Res Inst, Div Biostat, Duarte, CA 91010 USA.
RP Rossi, JJ (reprint author), City Hope Natl Med Ctr, Grad Sch Biol Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM Jzhou@coh.org; shuyi@mail.uc.edu; guopn@ucmail.uc.edu; Dsmith02@coh.org;
   Jrossi@coh.org
RI Guo, Peixuan/I-7184-2015
OI Smith, David/0000-0001-9644-2353
FU National Institutes of Health; NIH Nanomedicine Development Center on
   Phi29 DNA-packaging Motor for Nanomedicine, through the NIH Roadmap for
   Medical Research [PN2 EY 018230]; NIH [AI29329, EB003730]
FX We thank Haitang Li and Jang Zhang for HIV-1 challenge assay. This work
   was supported by grants from the National Institutes of Health awarded
   to J.J.R and P.X.G. This work was supported by the NIH Nanomedicine
   Development Center on Phi29 DNA-packaging Motor for Nanomedicine,
   through the NIH Roadmap for Medical Research (PN2 EY 018230) as well as
   NIH Grants AI29329 to J.J.R. and EB003730 to P.G. The following reagents
   were obtained through the NIH AIDS Research and Reference Reagent
   Program, Division of AIDS, NIAID, NIH: The CHO-EE and CHO-gp160 cell
   line: HIV NL4-3 virus: HIV-1 Bal. gp120.
CR Blair WS, 2000, DRUG DISCOV TODAY, V5, P183, DOI 10.1016/S1359-6446(00)01484-7
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199
   Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350
   Cohen C, 2008, VIROLOGY, V381, P46, DOI 10.1016/j.virol.2008.08.025
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Dey AK, 2005, J VIROL, V79, P13806, DOI 10.1128/JVI.79.21.13806-13810.2005
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Garver K, 1997, RNA, V3, P1068
   Guo PX, 2010, NAT NANOTECHNOL, V5, P833, DOI [10.1038/nnano.2010.231, 10.1038/NNANO.2010.231]
   Guo PX, 2005, J NANOSCI NANOTECHNO, V5, P1964, DOI 10.1166/jnn.2005.446
   GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124                                                         
   Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0
   Guo S, 2006, GENE THER, V13, P814, DOI 10.1038/sj.gt.3302716
   Guo SC, 2005, HUM GENE THER, V16, P1097, DOI 10.1089/hum.2005.16.1097
   Hoeprich S, 2002, J BIOL CHEM, V277, P20794, DOI 10.1074/jbc.M112061200
   Khaled A, 2005, NANO LETT, V5, P1797, DOI 10.1021/nl051264s
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Li L, 2009, MOL BIOSYST, V5, P1361, DOI 10.1039/b903428e
   LIU J, 2010, ACS NANO
   Liu Z, 2007, ANGEW CHEM INT EDIT, V46, P2023, DOI 10.1002/anie.200604295
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   REID RJD, 1994, J BIOL CHEM, V269, P18656
   REID RJD, 1994, J BIOL CHEM, V269, P5157
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367
   Scherer L, 2007, GENE THER, V14, P1057, DOI 10.1038/sj.gt.3302977
   Shu D, 2003, J NANOSCI NANOTECHNO, V3, P295, DOI 10.1166/jnn.2003.160
   Shu D, 2004, NANO LETT, V4, P1717, DOI [10.1021/nl0494497, 10.1021/nl04994497]
   Subramanya S, 2010, EXPERT OPIN BIOL TH, V10, P201, DOI 10.1517/14712590903448158
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Weber N, 2008, J CONTROL RELEASE, V132, P55, DOI 10.1016/j.jconrel.2008.07.035
   WEISS CD, 1993, J VIROL, V67, P7060
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267                                                          
   Zhang CL, 1997, RNA, V3, P315
   Zhou J., 2009, NUCL ACIDS RES
   Zhou JH, 2008, MOL THER, V16, P1481, DOI 10.1038/mt.2008.92
NR 48
TC 47
Z9 51
U1 0
U2 24
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD JUN
PY 2011
VL 54
IS 2
BP 284
EP 294
DI 10.1016/j.ymeth.2010.12.039
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 782MG
UT WOS:000292013200010
PM 21256218
OA green_accepted
DA 2018-01-05
ER

PT J
AU Labib, M
   Shipman, PO
   Martic, S
   Kraatz, HB
AF Labib, Mahmoud
   Shipman, Patrick O.
   Martic, Sanela
   Kraatz, Heinz-Bernhard
TI A bioorganometallic approach for rapid electrochemical analysis of human
   immunodeficiency virus type-1 reverse transcriptase in serum
SO ELECTROCHIMICA ACTA
LA English
DT Article
DE Bioorganometallics; Ferrocene; HIV-1 reverse transcriptase; Human serum;
   Square wave voltammetry
ID ELECTRON-TRANSFER; GOLD NANOPARTICLES; MASS-SPECTROMETRY; HIV-1
   PROTEASE; VIRAL LOAD; PEPTIDE; ASSAY; BIOSENSOR; DNA; PROTEINS
AB Determination of low-abundance human immunodeficiency virus (HIV) enzymes is essential for early detection of the viral infection. Designed for the rapid detection of the virus in human serum, a rapid and ultrasensitive electrochemical assay for HIV-1 reverse transcriptase (HIV-1 RI) is presented in this article. The assay format is based on the formation of a self-assembled monolayer (SAM) of a synthesized ferrocene (Fc)-labeled lipoic acid onto a gold electrode. X-ray photoelectron spectroscopy (XPS) and Time-of-Flight secondary ion mass spectrometry (ToF-SIMS) were employed to confirm the binding of the Fc-labeled lipoic acid to the gold via the Au-S bond. A short RT-specific peptide, VEAIIRILQQLLFIH, was covalently attached to the Fc-labeled lipoic acid. Square wave voltammetry (SWV) offered a two-dimensional measurement of RI based on the anodic shift and reduction of current density of the Fc redox signal upon binding of RT to its specific peptide. This allowed a linear quantification of the target RI in the range of 100-500 pg mL(-1), equivalent to 85.5-427.4 fM. with a detection limit of 50 pg mL(-1) (42.7 fM). The developed biosensor is inexpensive, easy to prepare and operate, and allows a highly selective detection of RI in 20s. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Labib, Mahmoud; Shipman, Patrick O.; Martic, Sanela; Kraatz, Heinz-Bernhard] Univ Western Ontario, Dept Chem, London, ON N6A 5B7, Canada.
RP Kraatz, HB (reprint author), Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 5B7, Canada.
EM hkraatz@uwo.ca
RI Labib, Mahmoud/P-2267-2014; Kraatz, Heinz-Bernhard/D-2246-2014
OI Labib, Mahmoud/0000-0003-4565-2056; Kraatz,
   Heinz-Bernhard/0000-0002-7149-0110
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Western Innovation Fund (WIF)
FX M. Labib is grateful to the University of Western Ontario for funding.
   This work was supported by operating grants from the Natural Sciences
   and Engineering Research Council of Canada (NSERC) and the Western
   Innovation Fund (WIF). The author is also thankful to Western Surface
   Science Department and Nanofabrication facility for access to their
   instruments and for valuable assistance.
CR Ayela C, 2007, BIOSENS BIOELECTRON, V22, P3113, DOI 10.1016/j.bios.2007.01.020
   Bard A. J., 2001, ELECTROCHEMICAL METH
   Belu AM, 2003, BIOMATERIALS, V24, P3635, DOI 10.1016/S0142-9612(03)00159-5
   Brown P, 2000, NATURE, V405, P263, DOI 10.1038/35012760                                                                
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Creager SE, 1998, ANAL CHEM, V70, P4257, DOI 10.1021/ac980482l                                                               
   CREAGER SE, 1991, ANAL CHIM ACTA, V246, P233, DOI 10.1016/S0003-2670(00)80680-7                                                   
   Dey SK, 2007, LANGMUIR, V23, P6475, DOI 10.1021/la070175n
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Feng B, 2009, J IMMUNOASS IMMUNOCH, V30, P457, DOI 10.1080/15321810903188318
   Finklea HO, 1996, ELECTROANAL CHEM, V19, P109
   Gleenberg IO, 2007, J MOL BIOL, V369, P1230, DOI 10.1016/j.jmb.2007.03.073
   Gronewold TMA, 2009, J PROTEOME RES, V8, P3568, DOI 10.1021/pr900265r
   Hanif M, 2010, INORG CHEM, V49, P7953, DOI 10.1021/ic1009785
   Jiang XQ, 2010, BIOSENS BIOELECTRON, V25, P1622, DOI 10.1016/j.bios.2009.11.024
   KALIA V, 2005, J VIROL, V79, P2079
   Kerman K, 2007, CHEM COMMUN, P3829, DOI 10.1039/b707140j
   Kim YP, 2007, ANGEW CHEM INT EDIT, V46, P6816, DOI 10.1002/anie.200701418
   Krebs JF, 2008, BIOCONJUGATE CHEM, V19, P185, DOI 10.1021/bc700284y
   Labib M, 2009, ANAL CHIM ACTA, V634, P255, DOI 10.1016/j.aca.2008.12.035
   Labib M, 2011, ANALYST, V136, P708, DOI 10.1039/c0an00741b
   Labib M, 2010, ANAL BIOANAL CHEM, V397, P1217, DOI 10.1007/s00216-010-3641-8
   Labib M, 2010, ANAL CHIM ACTA, V659, P194, DOI 10.1016/j.aca.2009.11.028
   Labib M, 2009, BIOTECHNOL BIOENG, V104, P312, DOI 10.1002/bit.22395
   Labib M, 2009, ANAL BIOANAL CHEM, V393, P1539, DOI 10.1007/s00216-008-2559-x
   LAVIRON E, 1982, ELECTROANAL CHEM, V12, P53
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   Le Floch F, 2006, ANAL CHEM, V78, P4727, DOI 10.1021/ac0521955
   Li LD, 2010, SENSOR ACTUAT B-CHEM, V149, P110, DOI 10.1016/j.snb.2010.06.015
   Long YT, 2003, BIOPHYS J, V84, P3218, DOI 10.1016/S0006-3495(03)70046-0                                                   
   Mahmoud KA, 2008, ANAL CHEM, V80, P7056, DOI 10.1021/ac801174r
   Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774
   Mahmoud KA, 2007, CHEM-EUR J, V13, P5885, DOI 10.1002/chem.200601878
   Manocha M, 2003, IMMUNOL LETT, V85, P275, DOI 10.1016/S0165-2478(02)00257-2                                                   
   Martic S, 2011, ANALYST, V136, P107, DOI 10.1039/c0an00438c
   Muller J, 2010, METHODS MOL BIOL, V630, P319, DOI 10.1007/978-1-60761-629-0_20
   MURRAY RW, 1982, ELECTROANALYTICAL CH, V12, P191
   Newton MD, 2007, PHYS CHEM CHEM PHYS, V9, P555, DOI 10.1039/b611448b
   OSTERYOUNG J, 1986, ELECTROANAL CHEM, V14, P209
   Pai NP, 2007, EXPERT REV MOL DIAGN, V7, P325, DOI 10.1586/14737159.7.4.325
   Plumb K, 2003, BIOCONJUGATE CHEM, V14, P601, DOI 10.1021/bc0256446
   Ricci F, 2007, CHEM COMMUN, P3768, DOI 10.1039/b708882e
   Ricci F, 2007, LANGMUIR, V23, P6827, DOI 10.1021/la700328r
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   ROWE GK, 1994, J PHYS CHEM-US, V98, P5500, DOI 10.1021/j100072a017                                                             
   Sapsford KE, 2008, MATER TODAY, V11, P38, DOI 10.1016/S1369-7021(08)70018-X
   Sarafianos SG, 2009, J MOL BIOL, V385, P693, DOI 10.1016/j.jmb.2008.10.071
   Sek S, 2003, J ELECTROANAL CHEM, V550, P359, DOI 10.1016/S0022-0728(03)00025-1
   Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005
   Swanson P, 2005, J CLIN MICROBIOL, V43, P3860, DOI 10.1128/JCM.43.8.3860-3868.2005
   Torti C, 2007, HIV CLIN TRIALS, V8, P112, DOI 10.1310/hct0803-112
   Wilson MS, 2006, ANAL CHEM, V78, P2507, DOI 10.1021/ac0518452
   ZHANG H, 2008, J AM CHEM SOC, V134, P34
   Zhang HQ, 2006, ANGEW CHEM INT EDIT, V45, P1576, DOI 10.1002/anie.200503345
NR 54
TC 16
Z9 16
U1 1
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0013-4686
J9 ELECTROCHIM ACTA
JI Electrochim. Acta
PD MAY 30
PY 2011
VL 56
IS 14
BP 5122
EP 5128
DI 10.1016/j.electacta.2011.03.063
PG 7
WC Electrochemistry
SC Electrochemistry
GA 781CD
UT WOS:000291907300028
DA 2018-01-05
ER

PT J
AU Matejicek, P
   Brus, J
   Jigounov, A
   Plestil, J
   Uchman, M
   Prochazka, K
   Gradzielski, M
AF Matejicek, Pavel
   Brus, Jiri
   Jigounov, Alexander
   Plestil, Josef
   Uchman, Mariusz
   Prochazka, Karel
   Gradzielski, Michael
TI On the Structure of Polymeric Composite of Metallacarborane with
   Poly(ethylene oxide)
SO MACROMOLECULES
LA English
DT Article
ID SOLID-STATE NMR; COBALT DICARBOLLIDE; MOLECULAR-STRUCTURE; POLYETHYLENE
   OXIDE; CRYSTAL-STRUCTURE; LIGHT-SCATTERING; BUILDING-BLOCKS; HIV
   PROTEASE; ELECTROLYTES; NANOCOMPOSITES
AB We studied a structure of polymeric composite based on spontaneous precipitation of sodium [3-cobalt(III) bis(1,2-dicarbollide)], NaCoD, with poly(ethylene oxide), PEO, in salted aqueous solutions. Although the solid nanocomposite, which can be considered as a homogeneous matter, cannot form monocrystals due to the high flexibility of PEO chains, we can characterize the PEO/NaCoD structure by means of solid state NMR spectroscopy, from WAXS reflections and with help of already published structures of related systems. It indicates that the layered structure of solid NaCoD and the helical crystalline structure of PEO have disappeared after their mutual interaction. The NMR results clearly show that CoD(-) anions are regularly dispersed within the PEO matrix, which consists of two distinct types of polymeric chains: one part interacting with dicarbollide clusters and the second one acting as a ligand of sodium counterions that also form regular pattern within the composite.
C1 [Matejicek, Pavel; Uchman, Mariusz; Prochazka, Karel] Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12840 2, Czech Republic.
   [Brus, Jiri; Jigounov, Alexander; Plestil, Josef] Acad Sci Czech Republic, Inst Macromol Chem, VVI, Prague 16206 6, Czech Republic.
   [Gradzielski, Michael] Tech Univ Berlin, Stranski Lab Phys Chem & Theoret Chem, Inst Chem, D-10623 Berlin, Germany.
RP Matejicek, P (reprint author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Hlavova 2030, Prague 12840 2, Czech Republic.
EM matej@lynette.natur.cuni.cz
RI Prochazka, Karel/C-3012-2014; Zhigunov, Alexander/C-3924-2012; Uchman,
   Mariusz/B-2302-2009; Brus, Jiri/G-3459-2014; Plestil, Josef/H-6807-2014;
   Matejicek, Pavel/M-6582-2017
OI Prochazka, Karel/0000-0003-2144-5378; Matejicek,
   Pavel/0000-0001-5482-3465; Brus, Jiri/0000-0003-2692-612X
FU Grant Agency of the Academy of Sciences of the Czech Republic
   [IAAX00320901]; Ministry of Education of the Czech Republic
   [MSM0021620857]; Academy of Sciences of the Czech Republic
   [AV0Z40500505]; Ministry of Education, Youth and Sports [2B08021];
   German Academic Exchange Service DAAD [MEB100907]
FX P.M., M.U., and K.P. acknowledge the financial support of the Grant
   Agency of the Academy of Sciences of the Czech Republic IAAX00320901 and
   long term Research Plan of the Ministry of Education of the Czech
   Republic MSM0021620857. This research was supported by the Academy of
   Sciences of the Czech Republic AV0Z40500505, by the Ministry of
   Education, Youth and Sports (Grant No. 2B08021), and by the German
   Academic Exchange Service DAAD (Grant No. MEB100907). The authors thank
   Jindrich Hasek, Josef Baldrian, Antonin Sikora from IMC, Jana Havlickova
   from CU, and Ingo Hoffmann from TUB for their helpful advice and
   assistance.
CR Baril D, 1997, SOLID STATE IONICS, V94, P35, DOI 10.1016/S0167-2738(96)00614-5
   Bastek J, 2010, ELECTROCHIM ACTA, V55, P1289, DOI 10.1016/j.electacta.2009.04.040
   BERNSON A, 1995, POLYMER, V36, P4471, DOI 10.1016/0032-3861(95)96855-3                                                    
   Boring E, 1998, ORGANOMETALLICS, V17, P3865, DOI 10.1021/om980242w                                                               
   BORODINSKY L, 1982, INORG CHEM, V21, P1686, DOI 10.1021/ic00134a087                                                             
   Brus J, 2005, J PHYS CHEM A, V109, P5050, DOI 10.1021/jp0503821
   Brus J, 2004, MACROMOLECULES, V37, P1346, DOI 10.1021/ma035608h
   Brus J, 2008, MACROMOLECULES, V41, P372, DOI 10.1021/ma702140g                                                               
   Bubniak GA, 2002, LANGMUIR, V18, P5967, DOI 10.1021/la011748d
   Buhl M, 2005, CHEM-EUR J, V11, P4109, DOI 10.1002/chem.200401202
   Chamberlin RM, 1997, INORG CHEM, V36, P809, DOI 10.1021/ic960811x                                                               
   Chandrasekaran R, 2001, J SOLID STATE ELECTR, V5, P355, DOI 10.1007/s100080000156                                                           
   Chevrot G, 2006, J PHYS CHEM B, V110, P9488, DOI 10.1021/jp060930q
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   COCHRAN W, 1952, ACTA CRYSTALLOGR, V5, P581, DOI 10.1107/S0365110X52001635                                                       
   Croce F, 1999, J PHYS CHEM B, V103, P10632, DOI 10.1021/jp992307u                                                               
   Dash BP, 2010, ORGANOMETALLICS, V29, P5230, DOI 10.1021/om100365t
   Di Meo C, 2007, BIOMACROMOLECULES, V8, P552, DOI 10.1021/bm0607426
   Farras P, 2008, INORG CHEM, V47, P9497, DOI 10.1021/ic801139x
   Farras P, 2009, INORG CHEM, V48, P8210, DOI 10.1021/ic9006907
   Fino SA, 1997, INORG CHEM, V36, P4604, DOI 10.1021/ic961182u                                                               
   Grimes RN, 2004, J CHEM EDUC, V81, P658
   Grimes RN, 2000, MOL CRYST LIQ CRYST, V342, P7, DOI 10.1080/10587250008038238                                                       
   Hardie M. J., 2006, J CHEM CRYSTALLOGR, V37, P69
   HAWTHORNE MF, 1965, J AM CHEM SOC, V87, P1818, DOI 10.1021/ja01086a053                                                             
   HLATKY GG, 1992, ORGANOMETALLICS, V11, P1413, DOI 10.1021/om00039a058                                                             
   Hong M, 2002, J PHYS CHEM B, V106, P7355, DOI 10.1021/jp0156064
   Juarez-Perez EJ, 2010, LANGMUIR, V26, P12185, DOI 10.1021/la100724r
   Juarez-Perez EJ, 2010, MACROMOLECULES, V43, P150, DOI 10.1021/ma9019575
   KHATTAR R, 1990, INORG CHEM, V29, P2191, DOI 10.1021/ic00337a002                                                             
   Kimura H, 2003, CHEM MATER, V15, P355, DOI 10.1021/cm0212921
   Koster TKJ, 2008, SOLID STATE IONICS, V178, P1879, DOI 10.1016/j.ssi.2007.12.019
   Koster TKJ, 2010, SOLID STATE IONICS, V181, P489, DOI 10.1016/j.ssi.2010.02.005
   Kokado K, 2009, MACROMOLECULES, V42, P9238, DOI 10.1021/ma902094u
   Kozisek M, 2008, J MED CHEM, V51, P4839, DOI 10.1021/jm8002334
   Lad MD, 2003, LANGMUIR, V19, P5098, DOI 10.1021/la0269560
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lazzara G, 2009, J PHYS CHEM C, V113, P12213, DOI 10.1021/jp901909w
   LEMMON JP, 1995, ELECTROCHIM ACTA, V40, P2245, DOI 10.1016/0013-4686(95)00171-A                                                    
   Lesnikowski ZJ, 2007, COLLECT CZECH CHEM C, V72, P1646, DOI 10.1135/cccc20071646
   LIGHTFOOT P, 1993, SCIENCE, V262, P883, DOI 10.1126/science.262.5135.883                                                    
   Liu Y, 2009, POLYMER, V50, P2601, DOI 10.1016/j.polymer.2009.03.050
   MALIC N, 2001, CHEM COMMUN, V1, P16
   Masalles C, 2000, ADV MATER, V12, P1199, DOI 10.1002/1521-4095(200008)12:16<1199::AID-ADMA1199>3.0.CO;2-W
   Masalles C, 2002, ANAL BIOANAL CHEM, V372, P513, DOI 10.1007/s00216-001-1221-7
   Matejicek P, 2006, LANGMUIR, V22, P575, DOI 10.1021/la052201s
   Matejicek P, 2009, MACROMOLECULES, V42, P4829, DOI 10.1021/ma900484y
   Murata K, 2000, ELECTROCHIM ACTA, V45, P1501, DOI 10.1016/S0013-4686(99)00365-5                                                   
   Nunez R, 2010, INORG CHEM, V49, P9993, DOI 10.1021/ic101306w
   Packirisamy S, 1996, PROG POLYM SCI, V21, P707, DOI 10.1016/0079-6700(96)00002-0                                                    
   Palmer AG, 1996, J PHYS CHEM-US, V100, P13293, DOI 10.1021/jp9606117                                                               
   Peterson JJ, 2009, MACROMOLECULES, V42, P8594, DOI 10.1021/ma901703r
   Planas JG, 2005, J AM CHEM SOC, V127, P15976, DOI 10.1021/ja055210w
   PLESEK J, 1992, CHEM REV, V92, P269, DOI 10.1021/cr00010a005                                                             
   Quartarone E, 1998, SOLID STATE IONICS, V110, P1, DOI 10.1016/S0167-2738(98)00114-3
   Reinholdt MX, 2005, J PHYS CHEM B, V109, P16296, DOI 10.1021/jp052601o
   Rezacova P., 2011, BORON SCI NEW TECHNO
   Rezacova P, 2009, J MED CHEM, V52, P7132, DOI 10.1021/jm9011388
   Saujanya C, 1997, J APPL POLYM SCI, V65, P1127, DOI 10.1002/(SICI)1097-4628(19970808)65:6<1127::AID-APP8>3.0.CO;2-M                 
   Sawers LJM, 1998, SOLID STATE IONICS, V107, P13, DOI 10.1016/S0167-2738(97)00517-1
   Sivaev IB, 2009, EUR J INORG CHEM, P1433, DOI 10.1002/ejic.200900003
   Song JY, 1999, J POWER SOURCES, V77, P183, DOI 10.1016/S0378-7753(98)00193-1
   TADOKORO H, 1964, MAKROMOLEKUL CHEM, V73, P109
   Tiritiris I, 2007, APPL MAGN RESON, V32, P459, DOI 10.1007/s00723-007-0037-9
   Uchman M, 2010, J COLLOID INTERF SCI, V348, P129, DOI 10.1016/j.jcis.2010.04.037
   Uchman M, 2010, LANGMUIR, V26, P6268, DOI 10.1021/la904047k
   WU JH, 1993, CHEM MATER, V5, P835, DOI 10.1021/cm00030a019                                                             
   ZALKIN A, 1967, INORG CHEM, V6, P1911, DOI 10.1021/ic50056a033                                                             
   Zhu L, 2001, MACROMOLECULES, V34, P1244, DOI 10.1021/ma001882p
NR 69
TC 31
Z9 31
U1 1
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD MAY 24
PY 2011
VL 44
IS 10
BP 3847
EP 3855
DI 10.1021/ma200502t
PG 9
WC Polymer Science
SC Polymer Science
GA 762WE
UT WOS:000290511500022
DA 2018-01-05
ER

PT J
AU Xie, XJ
   Xu, W
   Li, TH
   Liu, XG
AF Xie, Xiaoji
   Xu, Wei
   Li, Tianhu
   Liu, Xiaogang
TI Colorimetric Detection of HIV-1 Ribonuclease H Activity by Gold
   Nanoparticles
SO SMALL
LA English
DT Article
ID ROLLING CIRCLE AMPLIFICATION; ENHANCED RAMAN-SCATTERING; RNASE-H; DNA
   DETECTION; INHIBITION; PROBES; ASSAY; ACID; ENZYME; HYBRIDIZATION
C1 [Xie, Xiaoji; Xu, Wei; Liu, Xiaogang] Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore.
   [Liu, Xiaogang] Inst Mat Res & Engn, Singapore 117602, Singapore.
   [Li, Tianhu] Nanyang Technol Univ, Div Chem & Biol Chem, Sch Phys & Math Sci, Singapore 637371, Singapore.
RP Liu, XG (reprint author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.
EM chmlx@nus.edu.sg
RI LIU, XIAOGANG/A-8038-2011; Li, Tianhu/G-3531-2010; Xie,
   Xiaoji/L-2567-2014
OI LIU, XIAOGANG/0000-0003-2517-5790; 
FU National University of Singapore [R-143-000-427]; Ministry of Education
   [R-143-000-453]; Singapore-MIT Alliance; Agency for Science, Technology,
   and Research [R-143-000-366]
FX This work is supported by the National University of Singapore
   (R-143-000-427), the Ministry of Education (R-143-000-453), the
   Singapore-MIT Alliance, and the Agency for Science, Technology, and
   Research (R-143-000-366). This Communication is part of the Special
   Issue on Nanotechnology with Soft Matter.
CR Ali MM, 2009, ANGEW CHEM INT EDIT, V48, P3512, DOI 10.1002/anie.200805966
   Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933                                                    
   Bi S, 2010, ANGEW CHEM INT EDIT, V49, P4438, DOI 10.1002/anie.201000840
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chen G, 2010, J AM CHEM SOC, V132, P3644, DOI 10.1021/ja9090885
   Chen W, 2008, ANAL CHEM, V80, P8485, DOI 10.1021/ac8012225
   Chompoosor A, 2010, SMALL, V6, P2246, DOI 10.1002/smll.201000463
   DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569
   Driskell JD, 2010, CHEM COMMUN, V46, P3298, DOI 10.1039/c002059a
   Hu D, 2010, CHEM-EUR J, V16, P2605, DOI 10.1002/chem.200902166
   Huang YF, 2009, J AM CHEM SOC, V131, P17328, DOI 10.1021/ja907125t
   Jang KJ, 2009, SMALL, V5, P2665, DOI 10.1002/smll.200901105
   Jiang TT, 2009, CHEM COMMUN, P1972, DOI 10.1039/b818853j
   KANAYA E, 1995, EUR J BIOCHEM, V231, P557, DOI 10.1111/j.1432-1033.1995.tb20732.x
   Kanjanawarut R, 2009, ANAL CHEM, V81, P6122, DOI 10.1021/ac900525k
   Kharlamova T, 2009, MED CHEM, V5, P398
   Kim C, 2010, NAT CHEM, V2, P962, DOI [10.1038/NCHEM.858, 10.1038/nchem.858]
   Kim JH, 2007, CHEM COMMUN, P4342, DOI 10.1039/b710306a
   Kim YP, 2010, CHEM COMMUN, V46, P76, DOI 10.1039/b915612g
   Lan T, 2010, CHEM COMMUN, V46, P3896, DOI 10.1039/b926910j
   Lee JH, 2008, J AM CHEM SOC, V130, P14217, DOI 10.1021/ja803607z
   Li D, 2010, ACCOUNTS CHEM RES, V43, P631, DOI 10.1021/ar900245u
   Li HX, 2004, P NATL ACAD SCI USA, V101, P14036, DOI 10.1073/pnas.0406115101
   Li TH, 1997, CHEM BIOL, V4, P209, DOI 10.1016/S1074-5521(97)90290-8
   Liu JW, 2009, CHEM REV, V109, P1948, DOI 10.1021/cr030183i
   Liu XG, 2006, SMALL, V2, P1046, DOI 10.1002/smll.200600219
   Liu XG, 2009, ANGEW CHEM INT EDIT, V48, P3018, DOI 10.1002/anie.200805972
   Mazumdar D, 2010, CHEM COMMUN, V46, P1416, DOI 10.1039/b917772h
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Parniak MA, 2003, ANAL BIOCHEM, V322, P33, DOI 10.1016/j.ab.2003.06.001
   Qu L.J., 2010, ANAL CHEM, V82, P6015
   Sato K, 2003, J AM CHEM SOC, V125, P8102, DOI 10.1021/ja034876s
   Schultz SJ, 2008, VIRUS RES, V134, P86, DOI 10.1016/j.virusres.2007.12.007
   Shaw-Reid CA, 2003, J BIOL CHEM, V278, P2777, DOI 10.1074/jbc.C200621200
   Sluis-Cremer N, 2002, MOL PHARMACOL, V62, P398, DOI 10.1124/mol.62.2.398
   Su XD, 2009, ACS NANO, V3, P2751, DOI 10.1021/nn9005768
   Tan YN, 2010, ACS NANO, V4, P5101, DOI 10.1021/nn100943d
   Tan YN, 2010, ANAL CHEM, V82, P2759, DOI 10.1021/ac9026498
   Thompson DG, 2008, ANAL CHEM, V80, P2805, DOI 10.1021/ac702403w
   TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   Wahba AS, 2010, NUCLEIC ACIDS RES, V38, P1048, DOI 10.1093/nar/gkp1022
   Wang F, 2008, J AM CHEM SOC, V130, P5642, DOI 10.1021/ja800868a
   Wang F, 2008, ANGEW CHEM INT EDIT, V47, P906, DOI 10.1002/anie.200704520
   Wang F, 2010, ANGEW CHEM INT EDIT, V49, P7456, DOI 10.1002/anie.201003959
   Wang F, 2010, SPECTROSC LETT, V43, P400, DOI 10.1080/00387010.2010.487018
   Wang F, 2010, ANALYST, V135, P1839, DOI 10.1039/c0an00144a
   Wang F, 2010, NATURE, V463, P1061, DOI 10.1038/nature08777
   Wang JA, 2010, CR CHIM, V13, P731, DOI 10.1016/j.crci.2010.03.021
   Wang Y, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1089
   Wang Y, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/20/205502
   Wang ZD, 2010, NANO LETT, V10, P1886, DOI 10.1021/nl100675p
   Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200
   Xiang Y, 2010, ANAL CHEM, V82, P4122, DOI 10.1021/ac100244h
   Xiao JC, 2010, J AM CHEM SOC, V132, P6926, DOI 10.1021/ja102154b
   Xu W, 2009, ANGEW CHEM INT EDIT, V48, P6849, DOI 10.1002/anie.200901772
   Xue XJ, 2008, J AM CHEM SOC, V130, P3244, DOI 10.1021/ja76716c
   Xue XJ, 2009, J AM CHEM SOC, V131, P11668, DOI 10.1021/ja904728v
   Yang MX, 2009, SMALL, V5, P198, DOI 10.1002/smll.200800777
   Yuan WY, 2009, LANGMUIR, V25, P7578, DOI 10.1021/la901443x
   Zhang HJ, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3505152
   Zhang HJ, 2010, NANOSCALE, V2, P2302, DOI 10.1039/c0nr00398k
   Zhang HJ, 2009, SMALL, V5, P2797, DOI 10.1002/smll.200900938
   Zhang J, 2008, SMALL, V4, P1196, DOI 10.1002/smll.200800057
   Zhang J, 2010, SMALL, V6, P201, DOI 10.1002/smll.200901012
   Zhao WA, 2008, ANGEW CHEM INT EDIT, V47, P6330, DOI 10.1002/anie.200705982
   Zhou X, 2010, J AM CHEM SOC, V132, P4161, DOI 10.1021/ja9081827
   Zhu D, 2010, CHEM COMMUN, V46, P5226, DOI 10.1039/c0cc00791a
   Zhu Z, 2010, ANGEW CHEM INT EDIT, V49, P1052, DOI 10.1002/anie.200905570
   ZOU X, 2010, J AM CHEM SOC, V132, P1816
NR 70
TC 39
Z9 39
U1 7
U2 60
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD MAY 23
PY 2011
VL 7
IS 10
BP 1393
EP 1396
DI 10.1002/smll.201002150
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 770LL
UT WOS:000291087900009
PM 21438149
DA 2018-01-05
ER

PT J
AU Ndeezi, G
   Tumwine, JK
   Ndugwa, CM
   Bolann, BJ
   Tylleskar, T
AF Ndeezi, Grace
   Tumwine, James K.
   Ndugwa, Christopher M.
   Bolann, Bjorn J.
   Tylleskar, Thorkild
TI Multiple micronutrient supplementation improves vitamin B-12 and folate
   concentrations of HIV infected children in Uganda: a randomized
   controlled trial
SO NUTRITION JOURNAL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; COBALAMIN DEFICIENCY; DISEASE PROGRESSION;
   METHYLMALONIC ACID; SERUM VITAMIN-B-12; SCHOOL-CHILDREN; HIGH
   PREVALENCE; PREGNANT-WOMEN; YOUNG-CHILDREN; INFANTS
AB Background: The effect of multiple micronutrient supplementation on vitamin B-12 and folate has hither to not been reported in African HIV infected children. This paper describes vitamin B-12 and folate status of Ugandan HIV infected children aged 1-5 years and reports the effect of multiple micronutrient supplementation on serum vitamin B-12 and folate concentrations.
   Methods: Of 847 children who participated in a multiple micronutrient supplementation trial, 214 were assessed for vitamin B-12 and folate concentrations pre and post supplementation. One hundred and four children were randomised to two times the recommended dietary allowance (RDA) of a 14 multiple micronutrient supplement (MMS) and 114 to a 'standard of care' supplement of 6 multivitamins (MV). Serum vitamin B-12 was measured by an electrochemiluminescence immunoassay and folate by a competitive protein-binding assay using Modular E (Roche) automatic analyzer. Vitamin B-12 concentrations were considered low if less than 221picomoles per litre (pmol/L) and folate if < 13.4 nanomoles per litre (nmol/L). The Wilcoxon Signed Ranks test was used to measure the difference between pre and post supplementation concentrations.
   Results: Vitamin B-12 was low in 60/214 (28%) and folate in 62/214 (29.0%) children. In the MMS group, the median concentration (IQR) of vitamin B12 at 6 months was 401.5 (264.3 - 518.8) pmol/L compared to the baseline of 285.5 (216.5 - 371.8) pmol/L, p < 0.001. The median (IQR) folate concentrations increased from 17.3 (13.5 - 26.6) nmol/L to 27.7 (21.1 - 33.4) nmol/L, p < 0.001. In the 'standard of care' MV supplemented group, the median concentration (IQR) of vitamin B12 at 6 months was 288.5 (198.8 - 391.0) pmol/L compared to the baseline of 280.0 (211.5 - 386.3) pmol/L while the median (IQR) folate concentrations at 6 months were 16.5 (11.7 - 22.1) nmol/L compared to 15.7 (11.9 - 22.1) nmol/L at baseline. There was a significant difference in the MMS group in both vitamin B-12 and folate concentrations but no difference in the MV group.
   Conclusions: Almost a third of the HIV infected Ugandan children aged 1-5 years had low serum concentrations of vitamin B-12 and folate. Multiple micronutrient supplementation compared to the 'standard of care' supplement of 6 multivitamins improved the vitamin B-12 and folate status of HIV infected children in Uganda.
C1 [Ndeezi, Grace; Tumwine, James K.; Ndugwa, Christopher M.] Makerere Univ, Coll Hlth Sci, Sch Med, Dept Paediat & Child Hlth, Kampala, Uganda.
   [Ndeezi, Grace; Tylleskar, Thorkild] Univ Bergen, Ctr Int Hlth, N-5020 Bergen, Norway.
   [Bolann, Bjorn J.] Haukeland Hosp, Lab Clin Biochem, N-5021 Bergen, Norway.
   [Bolann, Bjorn J.] Univ Bergen, Inst Med, N-5020 Bergen, Norway.
RP Ndeezi, G (reprint author), Makerere Univ, Coll Hlth Sci, Sch Med, Dept Paediat & Child Hlth, Kampala, Uganda.
EM gracendeezi@yahoo.com
RI Tylleskar, Thorkild/S-5529-2017
OI Tylleskar, Thorkild/0000-0003-4801-4324
FU The Norwegian Council for Higher Education for Development Research and
   Education (NUTU)
FX We thank the children and their mothers/caretakers without whose
   participation the study would have been impossible to carry out. We are
   very grateful to all the participating hospitals and HIV care
   institutions, the paediatricians and other study personnel for making
   this study a success. The study was carried out as part of the
   'Essential Child Health and Nutrition Project in Uganda', a
   collaboration between the Department of Paediatrics and Child Health,
   School of Medicine, Makerere University College of Health Sciences and
   the Centre for International Health, University of Bergen. The Norwegian
   Council for Higher Education's Programme for Development Research and
   Education (NUTU) funded the study.
CR ALLEN LH, 1995, AM J CLIN NUTR, V62, P1013
   Ash DM, 2003, AM J CLIN NUTR, V77, P891
   BAUM MK, 1995, AIDS, V9, P1051, DOI 10.1097/00002030-199509000-00010
   Baylin A, 2005, EUR J CLIN NUTR, V59, P960, DOI 10.1038/sj.ejcn.1602201
   Carmel Ralph, 2003, Hematology Am Soc Hematol Educ Program, P62
   Castro L, 2009, TROP DOCT, V39, P83, DOI 10.1258/td.2008.080069
   Chatterjee A, 2010, J TROP PEDIATRICS, V56, P27, DOI 10.1093/tropej/fmp045
   DOWLING S, 1993, EUR J CLIN NUTR, V47, P803
   Eley BS, 2002, ANN TROP PAEDIATR, V22, P19, DOI [10.1179/027249302125000111, 10.1180/027249302125000111]
   Garcia-Casal MN, 2005, EUR J CLIN NUTR, V59, P1064, DOI 10.1038/sj.ejcn.1602212
   HARRIMAN GR, 1989, ARCH INTERN MED, V149, P2039, DOI 10.1001/archinte.149.9.2039
   Hepburn MJ, 2004, INT J STD AIDS, V15, P127, DOI 10.1258/095646204322764334                                                      
   Kaiser JD, 2006, JAIDS-J ACQ IMM DEF, V42, P523, DOI 10.1097/01.qai.0000230529.25083.42
   Malik ZA, 2009, AIDS, V23, P403, DOI 10.1097/QAD.0b013e32831ef4f7
   Monsen AUB, 2003, CLIN CHEM, V49, P2067, DOI 10.1373/clinchem.2003.019869
   Monteiro JP, 2009, NUTR RES, V29, P716, DOI 10.1016/j.nutres.2009.10.001
   Ndeezi G, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-68
   OSEI AK, J NUTR, V140, P1146
   Pasricha SR, 2010, PEDIATRICS, V126, pE140, DOI 10.1542/peds.2009-3108
   Remacha AF, 1999, SEMIN HEMATOL, V36, P75
   Rogers LM, 2003, AM J CLIN NUTR, V77, P433
   RULE SAJ, 1994, AM J HEMATOL, V47, P167, DOI 10.1002/ajh.2830470304                                                          
   Siekmann JH, 2003, J NUTR, V133, p3972S
   Subar AF, 1998, PEDIATRICS, V102, P913, DOI 10.1542/peds.102.4.913
   TaneJa S, 2007, AM J CLIN NUTR, V86, P1302
   Tang AM, 1997, J NUTR, V127, P345
   Varma JL, 2007, AM J CLIN NUTR, V85, P1127
   Vilaseca MA, 2001, EUR J CLIN INVEST, V31, P992, DOI 10.1046/j.1365-2362.2001.00916.x
   Wamani H, 2005, J TROP PEDIATRICS, V51, P356, DOI 10.1093/tropej/fmi048
   Zengin E, 2009, ACTA PAEDIATR, V98, P98, DOI 10.1111/j.1651-2227.2008.01059.x
NR 30
TC 7
Z9 7
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD MAY 21
PY 2011
VL 10
AR 56
DI 10.1186/1475-2891-10-56
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 780OB
UT WOS:000291866400001
PM 21600005
OA gold
DA 2018-01-05
ER

PT J
AU Sassolas, A
   Blum, LJ
   Leca-Bouvier, BD
AF Sassolas, Audrey
   Blum, Loic J.
   Leca-Bouvier, Beatrice D.
TI Optical detection systems using immobilized aptamers
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Review
DE Optical detection; Aptamers; Aptasensors; Microarrays; Heterogeneous
   assays
ID SURFACE-PLASMON RESONANCE; SWITCHING SIGNALING APTAMERS; IN-VITRO
   SELECTION; ANTIBODY MICROARRAY TECHNOLOGY; SILICA NANOPARTICLE
   APTASENSOR; NUCLEIC-ACID LIGANDS; SINGLE-STRANDED-DNA; HIV-1 TAT
   PROTEIN; RNA APTAMERS; ELECTROGENERATED CHEMILUMINESCENCE
AB Advances in the development and the applications of optical biosensing systems based on immobilized aptamers are presented. These nucleic acid sequences have been used as new molecular recognition elements to develop heterogeneous assays, biosensors and microarrays. Among different detection modes that have been employed, optical ones which are described here are among the most used. Since their first report in 1996, numerous optical detection systems using aptamers and mainly based on fluorescence have been developed. Two main approaches have been used: label-based (using fluorophore, luminophore, enzyme, nanoparticles) or aptamer label-free detection systems (e.g. surface plasmon resonance, optical resonance). Most methods are based on a labeling approach. Some targets can be optically detected using not only colorimetry, chemiluminescence or the most developed fluorescence mode but also more recent non conventional optical methods such as surface plasmon-coupled directional emission (SPCDE). The first SPCDE-based aptasensor for thrombin detection has recently been reported in 2009. Aptasensors based on surface-enhanced Raman scattering spectroscopy (SERS) which presents advantages compared to fluorescence have also been described. Different label-free techniques have recently been shown to be suitable for developing performant aptasensors or aptamer-based microarrays, such as surface plasmon resonance (SPR), diffraction grating, evanescent-field-coupled (EFC) waveguide-mode, optical resonance or Brewster angle straddle interferometry (BASI). Important advances have been realized on optical aptamer-based detection systems that appear as highly efficient devices with enormous potential. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Sassolas, Audrey; Blum, Loic J.; Leca-Bouvier, Beatrice D.] Univ Lyon 1, ICBMS, Inst Chim & Biochim Mol & Supramol, Equipe GEMBAS,ICBMS,CNRS,ICBMS 5246, F-69622 Villeurbanne, France.
RP Leca-Bouvier, BD (reprint author), ICBMS UMR 5246, Bat CPE,43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.
EM leca@univ-lyon1.fr
CR Aberem MB, 2006, ADV MATER, V18, P2703, DOI 10.1002/adma.200601651
   Acharya G., 2007, ANGEW CHEM INT EDIT, V46, P1
   Allain LR, 2002, ANAL CHIM ACTA, V469, P149, DOI 10.1016/S0003-2670(01)01537-9                                                   
   Angenendt P, 2005, DRUG DISCOV TODAY, V10, P503, DOI 10.1016/S1359-6446(05)03392-1                                                   
   Babkina SS, 2006, J ANAL CHEM+, V61, P728, DOI 10.1134/S1061934806080028
   Bai JG, 2008, CHEM-ASIAN J, V3, P1935, DOI 10.1002/asia.200800104
   Balamurugan S, 2008, ANAL BIOANAL CHEM, V390, P1009, DOI 10.1007/s00216-007-1587-2
   Berensmeier S, 2006, APPL MICROBIOL BIOT, V73, P495, DOI 10.1007/s00253-006-0675-0
   Bini A, 2007, ANAL CHEM, V79, P3016, DOI 10.1021/ac070096g
   Blank M, 2005, CURR OPIN CHEM BIOL, V9, P336, DOI 10.1016/j.cbpa.2005.06.011
   Bock C, 2004, PROTEOMICS, V4, P609, DOI 10.1002/pmic.200300631
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brody EN, 1999, MOL DIAGN, V4, P381, DOI 10.1016/S1084-8592(99)80014-9                                                   
   Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chambers JP, 2008, CURR ISSUES MOL BIOL, V10, P1
   Chang CL, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2746409
   Chen JW, 2008, CHEM-EUR J, V14, P8374, DOI 10.1002/chem.200701307
   Cheng AKH, 2009, BIOELECTROCHEMISTRY, V77, P1, DOI 10.1016/j.bioelechem.2009.04.007
   Cho EJ, 2006, ANAL CHIM ACTA, V564, P82, DOI 10.1016/j.aca.2005.12.038
   Collett JR, 2005, METHODS, V37, P4, DOI 10.1016/j.ymeth.2005.05.009
   Collett JR, 2005, ANAL BIOCHEM, V338, P113, DOI 10.1016/j.ab.2004.11.027
   Davis KA, 1996, NUCLEIC ACIDS RES, V24, P702, DOI 10.1093/nar/24.4.702
   DEISINGH AK, 2006, RNA MED, P341
   DIGIUSTO DA, 2006, TOP CURR CHEM, V261, P131
   Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021
   Dunn B, 1998, ACTA MATER, V46, P737, DOI 10.1016/S1359-6454(97)00254-1                                                   
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Fabris L, 2008, ADV FUNCT MATER, V18, P2518, DOI 10.1002/adfm.200800301
   FAMULOK A, 1992, ANGEW CHEM INT EDIT, V31, P979
   FAMULOK A, 2007, CHEM REV, V107, P3715
   Fang LY, 2008, ANAL CHIM ACTA, V628, P80, DOI 10.1016/j.aca.2008.08.041
   Fischer N, 2007, CURR OPIN CHEM BIOL, V11, P316, DOI 10.1016/j.cbpa.2007.05.017
   Fujimaki M, 2008, OPT EXPRESS, V16, P6408, DOI 10.1364/OE.16.006408
   Fukuda K, 2000, EUR J BIOCHEM, V267, P3685, DOI 10.1046/j.1432-1327.2000.01400.x                                                
   Gao T, 2007, ANAL CHEM, V79, P7589, DOI 10.1021/ac071082d
   Geddes CD, 2004, J FLUORESC, V14, P119, DOI 10.1023/B:JOFL.0000014809.64610.a8
   Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029
   Gill I, 2000, TRENDS BIOTECHNOL, V18, P282, DOI 10.1016/S0167-7799(00)01457-8
   Gill R, 2006, SMALL, V2, P1037, DOI 10.1002/smll.200600133
   Glokler J, 2003, J CHROMATOGR B, V797, P229, DOI 10.1016/j.jchromb.2003.08.034
   Goh JB, 2005, SENSOR ACTUAT B-CHEM, V106, P243, DOI 10.1016/j.snb.2004.08.003
   Goh JB, 2003, ANAL BIOCHEM, V313, P262, DOI 10.1016/S0003-2697(02)00634-6
   Goh JB, 2002, ANAL BIOANAL CHEM, V374, P54, DOI 10.1007/s00216-002-1478-5
   Gooding JJ, 2006, ANAL CHIM ACTA, V559, P137, DOI 10.1016/j.aca.2005.12.020
   Gopinath SCB, 2008, ANAL CHEM, V80, P6602, DOI 10.1021/ac800767s
   Gopinath SCB, 2007, ANAL BIOANAL CHEM, V387, P171, DOI 10.1007/s00216-006-0826-2
   Green RJ, 2000, BIOMATERIALS, V21, P1823, DOI 10.1016/S0142-9612(00)00077-6
   Hamula CLA, 2006, TRAC-TREND ANAL CHEM, V25, P681, DOI 10.1016/j.trac.2006.05.007
   Hanumegowda NM, 2005, SENS LETT, V3, P315, DOI 10.1166/sl.2005.044
   Hianik T, 2009, ELECTROANAL, V21, P1223, DOI 10.1002/elan.200904566
   Hilton JP, 2011, SENSOR ACTUAT A-PHYS, V166, P241, DOI 10.1016/j.sna.2009.12.006
   Ho HA, 2005, J AM CHEM SOC, V127, P12673, DOI 10.1021/ja053417j
   Ho H. A., 2002, ANGEW CHEM, V114, P1618
   Ho HA, 2008, ACCOUNTS CHEM RES, V41, P168, DOI 10.1021/ar700115t
   Hock B, 1997, ANAL CHIM ACTA, V347, P177, DOI 10.1016/S0003-2670(97)00167-0
   Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9
   Homola J, 2006, SPRINGER SER CHEM SE, V4, P1, DOI 10.1007/b100321
   Huang HP, 2009, BIOSENS BIOELECTRON, V25, P927, DOI 10.1016/j.bios.2009.08.008
   Hwang J, 2000, BIOCHEM BIOPH RES CO, V279, P557, DOI 10.1006/bbrc.2000.4007
   Ikebukuro K, 2004, ANAL LETT, V37, P2901, DOI 10.1081/AL-200035778
   JAMES W, 2000, APTAMERS ENCY ANAL C
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jiang YX, 2003, ANAL CHEM, V75, P2112, DOI 10.1021/ac026182s
   Kandimalla VB, 2004, ANAL LETT, V37, P2215, DOI 10.1081/AL-200028005
   Karlsson R, 2004, J MOL RECOGNIT, V17, P151, DOI 10.1002/jmr.660
   Kim DK, 2008, ANAL BIOCHEM, V379, P1, DOI 10.1016/j.ab.2008.04.029
   Kim YH, 2009, SENSOR ACTUAT B-CHEM, V139, P471, DOI 10.1016/j.snb.2009.03.013
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Kleinjung F, 1998, ANAL CHEM, V70, P328, DOI 10.1021/ac9706483                                                               
   KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358
   Kneipp K, 1999, CHEM REV, V99, P2957, DOI 10.1021/cr980133r                                                               
   Kopylov A. M., 2000, Molekulyarnaya Biologiya (Moscow), V34, P1097
   Kusnezow W, 2002, BIOTECHNIQUES, P14
   Lakowicz JR, 2004, ANAL BIOCHEM, V324, P153, DOI 10.1016/j.ab.2003.09.039
   Lakowicz JR, 2005, ANAL BIOCHEM, V337, P171, DOI 10.1016/j.ab.2004.11.026
   Leca-Bouvier B, 2005, ANAL LETT, V38, P1491, DOI 10.1081/AL-200065780
   Lee JF, 2006, CURR OPIN CHEM BIOL, V10, P282, DOI 10.1016/j.cbpa.2006.03.015
   Lee JO, 2008, ANAL BIOANAL CHEM, V390, P1023, DOI 10.1007/s00216-007-1643-y
   Lee M, 2000, ANAL BIOCHEM, V282, P142, DOI 10.1006/abio.2000.4595                                                          
   Lee S, 2007, BIOCHEM BIOPH RES CO, V358, P47, DOI 10.1016/j.bbrc.2007.04.057
   Lee SJ, 2008, ANAL CHEM, V80, P2867, DOI 10.1021/ac800050a
   Li Y, 2007, ELECTROCHEM COMMUN, V9, P2571, DOI 10.1016/j.elecom.2007.07.038
   Li Y, 2007, ANAL CHEM, V79, P1082, DOI 10.1021/ac061849m
   Li Y, 2006, NUCLEIC ACIDS RES, V34, P6416, DOI 10.1093/nar/gkl738
   Li YY, 2007, CLIN CHEM, V53, P1061, DOI 10.1373/clinchem.2006.082271
   Li Y, 2008, DIABETES OBES METAB, V10, P10, DOI 10.1111/j.1463-1326.2007.00708.x
   Li ZP, 2005, ANAL CHIM ACTA, V551, P85, DOI 10.1016/j.aca.2005.07.014
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Liu JW, 2009, CHEM REV, V109, P1948, DOI 10.1021/cr030183i
   Liu XM, 2003, J MOL RECOGNIT, V16, P23, DOI 10.1002/jmr.604
   Mairal T, 2008, ANAL BIOANAL CHEM, V390, P989, DOI 10.1007/s00216-007-1346-4
   Marquette CA, 2006, BIOSENS BIOELECTRON, V21, P1424, DOI 10.1016/j.bios.2004.09.037
   Mascini M, 2007, ANAL LETT, V40, P1386, DOI 10.1080/00032710701327062
   Mascini M, 2007, ANAL LETT, V40, P403, DOI 10.1080/00032710601102391
   Matveeva EG, 2005, ANAL BIOCHEM, V344, P161, DOI 10.1016/j.ab.2005.07.005
   McCauley TG, 2003, ANAL BIOCHEM, V319, P244, DOI 10.1016/S0003-2697(03)00297-5
   MEIR A, 2007, HDB BIOSENSORS BIOCH
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   MIR M, 2007, IVD TECHNOLOGY   MAY, P39
   Mukhopadhyay R, 2005, ANAL CHEM, V77, p114A, DOI 10.1021/ac053344m                                                               
   Murphy M.B., 2003, NUCLEIC ACIDS RES, V31, P1
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nutiu R, 2005, ABSTR PAP AM CHEM S, V229, pU118
   Nutiu R, 2005, METHODS, V37, P16, DOI 10.1016/j.ymeth.2005.07.001
   Nutiu R, 2005, ANGEW CHEM INT EDIT, V44, P1061, DOI 10.1002/anie.200461848
   Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o
   Nutiu R, 2004, CHEM-EUR J, V10, P1868, DOI 10.1002/cheem.200305470
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   Osawa Y, 2009, ELECTROANAL, V21, P1303, DOI 10.1002/elan.200804559
   Palecek E, 2007, TALANTA, V74, P276, DOI 10.1016/j.talanta.2007.08.020
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Phillips KS, 2007, ANAL BIOANAL CHEM, V387, P1831, DOI 10.1007/s00216-006-1052-7
   Polonschii C, 2010, TALANTA, V80, P2157, DOI 10.1016/j.talanta.2009.11.023
   Porschewski P, 2006, J BIOMOL SCREEN, V11, P773, DOI 10.1177/1087057106292138
   Potyrailo RA, 1998, ANAL CHEM, V70, P3419, DOI 10.1021/ac9802325                                                               
   Proske D, 2005, APPL MICROBIOL BIOT, V69, P367, DOI 10.1007/s00253-005-0193-5
   Quan HY, 2005, J QUANT SPECTROSC RA, V93, P231, DOI 10.1016/j.jqsrt.2004.08.023
   Ravelet C, 2006, J CHROMATOGR A, V1117, P1, DOI 10.1016/j.chroma.2006.03.101
   Raymond FR, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-10
   Ricci F, 2007, ANAL CHIM ACTA, V605, P111, DOI 10.1016/j.aca.2007.10.046
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Rupcich N, 2005, ANAL CHEM, V77, P4300, DOI 10.1021/ac0506480
   Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467
   Sassolas A, 2011, ANALYST, V136, P257, DOI 10.1039/c0an00281j
   Sassolas A, 2009, ELECTROANAL, V21, P1237, DOI 10.1002/elan.200804554
   Savran CA, 2004, ANAL CHEM, V76, P3194, DOI 10.1021/ac049859f
   Schlensog MD, 2004, SENSOR ACTUAT B-CHEM, V101, P308, DOI 10.1016/j.snb.2004.03.015
   Shlyahovsky B, 2007, BIOSENS BIOELECTRON, V22, P2570, DOI 10.1016/j.bios.2006.10.009
   SILVERMAN SK, 2007, ARTIFICIAL FUNCTIONA
   Song SP, 2008, TRAC-TREND ANAL CHEM, V27, P108, DOI 10.1016/j.trac.2007.12.004
   Stadtherr K, 2005, ANAL CHEM, V77, P3437, DOI 10.1021/ac0483421
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6
   Templin MF, 2002, DRUG DISCOV TODAY, V7, P815, DOI 10.1016/S1359-6446(00)01910-2
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   Torres-Chavolla E, 2009, BIOSENS BIOELECTRON, V24, P3175, DOI 10.1016/j.bios.2008.11.010
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ueyama H, 2002, J AM CHEM SOC, V124, P14286, DOI 10.1021/ja026892f
   Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452                                                        
   Velasco-Garcia MN, 2009, GENE THER MOL BIOL, V13, P1
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   Vollmer F, 2003, BIOPHYS J, V85, P1974, DOI 10.1016/S0006-3495(03)74625-6
   Vollmer F, 2002, APPL PHYS LETT, V80, P4057, DOI 10.1063/1.1482797
   Wang JL, 2008, ANAL CHEM, V80, P7174, DOI 10.1021/ac801281c
   Wang L, 2005, NANO LETT, V5, P37, DOI 10.1021/nl048417g
   Wang XY, 2008, CHINESE J CHEM, V26, P315, DOI 10.1002/cjoc.200890061
   Wang XY, 2007, ANAL CHIM ACTA, V598, P242, DOI 10.1016/j.aca.2007.07.050
   Wang XY, 2010, ANAL CHIM ACTA, V658, P128, DOI 10.1016/j.aca.2009.11.007
   Wang Y, 2007, CHEM COMMUN, P5220, DOI 10.1039/b709492b
   Wang ZZ, 2007, ANAL BIOANAL CHEM, V389, P819, DOI 10.1007/s00216-007-1510-x
   White IM, 2005, OPT LETT, V30, P3189, DOI 10.1364/OL.30.003189
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Xie TT, 2009, CHEM COMMUN, P3190, DOI 10.1039/b823352g
   Xu H, 2009, ANAL CHEM, V81, P669, DOI 10.1021/ac8020592
   Xu Y, 2009, ELECTROANAL, V21, P1251, DOI 10.1002/elan.200804561
   Yamamoto R, 2000, GENES CELLS, V5, P371, DOI 10.1046/j.1365-2443.2000.00330.x                                                
   Yan XL, 2010, ANALYST, V135, P2400, DOI 10.1039/c0an00163e
   Yan XL, 2009, TALANTA, V79, P383, DOI 10.1016/j.talanta.2009.03.063
   Zhang ZF, 2005, ANAL CHEM, V77, P3324, DOI 10.1021/ac050036f
   Zhang ZX, 2010, SENSOR ACTUAT B-CHEM, V147, P428, DOI 10.1016/j.snb.2010.02.013
   Zhu HY, 2006, SENSORS-BASEL, V6, P785, DOI 10.3390/s6080785                                                                
   Zichi D, 2002, CLIN CHEM, V48, P1865
   ZUBRITSKY E, 2007, ANAL CHEM, V1, P7941
NR 168
TC 49
Z9 49
U1 3
U2 201
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAY 15
PY 2011
VL 26
IS 9
BP 3725
EP 3736
DI 10.1016/j.bios.2011.02.031
PG 12
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 771RK
UT WOS:000291178200001
PM 21419619
DA 2018-01-05
ER

PT J
AU Jin, YG
   Xin, R
   Tong, L
   Du, LN
   Li, M
AF Jin, Yiguang
   Xin, Rui
   Tong, Li
   Du, Lina
   Li, Miao
TI Combination Anti-HIV Therapy with the Self-Assemblies of an Asymmetric
   Bolaamphiphilic Zidovudine/Didanosine Prodrug
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE anti-HIV; bolaamphiphile; didanosine; prodrug; self-assembly; zidovudine
ID DRUG-DELIVERY SYSTEMS; HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEOTIDE
   BOLAAMPHIPHILES; VITRO/IN-VIVO; L-DOPA; DERIVATIVES; DIDANOSINE;
   ZIDOVUDINE; INHIBITORS; INTERFACE
AB Combination anti-HIV therapy is important for AIDS treatment. A bolaamphiphilic prodrug, zidovudine-phosphoryl-deoxycholyl didanosine (ZPDD), was synthesized, combining zidovudine (AZT) and didanosine (ddI) in one molecule. As one lipid derivative of nucleosides, ZPDD showed special solubility with free soluble in chloroform and tetrahydrofuran but was slightly soluble in cyclohexane. The amphiphilicity of ZPDD was shown according to the monolayers at the air water interface. ZPDD self-assembled to the spherical vesicles in water with 174 nm in size and -31.3 mV of zeta potential. The stability of assemblies depended on pH because the phosphoryl zidovudine group could release hydrogen ions. ZPDD was rapidly degraded to AZT in the plasma and tissues of mice. ZPDD self-assemblies had high anti-HIV activity in vitro with the half effective concentration (EC(50)) of 5 nM. ZPDD self-assemblies may be targeting macrophages since ZPDD was found in macrophage-rich tissues in vivo and rapidly released AZT in the targeted tissues after intravenous administration to mice. The bioavailability of ZPDD was 90.5% and 30.8% for the intraperitoneal and oral administrations compared with the venous route. The self-assemblies of bolaamphiphilic prodrugs could simultaneously deliver two types of drugs to targeted tissues and would become a promising nanomedicine.
C1 [Jin, Yiguang; Xin, Rui; Du, Lina; Li, Miao] Beijing Inst Radiat Med, Dept Pharmaceut Sci, Beijing 100850, Peoples R China.
   [Jin, Yiguang; Xin, Rui] Henan Univ, Pharmaceut Coll, Inst Pharm, Kaifeng 475004, Henan, Peoples R China.
   [Tong, Li] Beijing Normal Univ, Coll Life Sci, Beijing 100875, Peoples R China.
RP Jin, YG (reprint author), Beijing Inst Radiat Med, Dept Pharmaceut Sci, 27 Taiping Rd, Beijing 100850, Peoples R China.
EM jinyg@bmi.ac.cn
RI Jin, Yiguang/H-6742-2013; Jin, Yiguang/A-9306-2008
OI Jin, Yiguang/0000-0002-3528-1397
FU National Natural Science Foundation of China [30672542]; National Key
   Technologies R&D Program for New Drugs [2009ZX-09301-002]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30672542) and the National Key Technologies R&D Program for
   New Drugs (No. 2009ZX-09301-002). The authors also acknowledge Prof. Dr.
   Minghua Liu of CAS for useful discussion.
CR Ambrosi M, 2006, J AM CHEM SOC, V128, P7209, DOI 10.1021/ja057730x
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Barreiro P, 2004, AIDS REV, V6, P234
   Bussmann H, 2009, JAIDS-J ACQ IMM DEF, V51, P37, DOI 10.1097/QAI.0b013e31819ff102
   BUSSO M, 1988, AIDS RES HUM RETROV, V4, P449, DOI 10.1089/aid.1988.4.449
   CAPPELLACCI L, 2008, NUCLEOS NUCLEOT, P460
   Di Stefano A, 2004, J CONTROL RELEASE, V99, P293, DOI 10.1016/j.jconrel.2004.07.010
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Fabio K, 2003, BIOCONJUGATE CHEM, V14, P358, DOI 10.1021/bc025645y
   Falandry C, 2009, ANN ONCOL, V20, P615, DOI 10.1093/annonc/mdn693
   Fuhrhop Jurgen-Hinrich, 2004, Chem Rev, V104, P2901, DOI 10.1021/cr030602b
   GARZONABURBEH A, 1986, J MED CHEM, V29, P687, DOI 10.1021/jm00155a018                                                             
   Gavegnano Christina, 2009, Antiviral Chemistry & Chemotherapy, V20, P63, DOI 10.3851/IMP1374
   Guenther S, 2002, BIOORG MED CHEM LETT, V12, P2233, DOI 10.1016/S0960-894X(02)00353-0
   Gupta U, 2010, ADV DRUG DELIVER REV, V62, P478, DOI 10.1016/j.addr.2009.11.018
   Iwaura R, 2003, ANGEW CHEM INT EDIT, V42, P1009, DOI 10.1002/anie.200390257                                                          
   Iwaura R, 2002, CHEM MATER, V14, P3047, DOI 10.1021/cm020263n
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Jin YG, 2008, COLLOID SURFACE B, V64, P229, DOI 10.1016/j.colsurfb.2008.01.023
   Jin YG, 2008, INT J PHARM, V350, P330, DOI 10.1016/j.ijpharm.2007.08.037
   Jin YG, 2010, INT J PHARMACEUT, V386, P268, DOI 10.1016/j.ijpharm.2009.11.018
   Jin YG, 2009, INT J PHARMACEUT, V381, P40, DOI 10.1016/j.ijpharm.2009.07.024
   Jin YG, 2009, INT J PHARM, V368, P207, DOI 10.1016/j.ijpharm.2008.10.009
   KIM JM, 1992, LANGMUIR, V8, P631
   Li SY, 2009, J PHYS CHEM B, V113, P1143, DOI 10.1021/jp808079h
   Lutz JF, 2006, LANGMUIR, V22, P7411, DOI 10.1021/la061382a
   Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902                                                     
   Mamo T, 2010, NANOMEDICINE-UK, V5, P269, DOI [10.2217/nnm.10.1, 10.2217/NNM.10.1]
   Mavromoustakos T, 2001, J MED CHEM, V44, P1702, DOI 10.1021/jm001121c
   Meister A, 2007, LANGMUIR, V23, P6063, DOI 10.1021/la070029h
   MINAGAWA T, 1995, BIOCHEM PHARMACOL, V49, P1361, DOI 10.1016/0006-2952(95)00071-7
   Muzzalupo R, 2005, COLLOID SURFACE B, V46, P78, DOI 10.1016/j.colsurfb.2005.09.003
   Neves JD, 2010, ADV DRUG DELIV REV, V62, P458, DOI DOI 10.1016/J.ADDR.2009.11.017
   Nishioka Y, 2001, ADV DRUG DELIVER REV, V47, P55, DOI 10.1016/S0169-409X(00)00121-6
   Romeo S, 2008, CHEMMEDCHEM, V3, P418, DOI 10.1002/cmdc.200700166
   Rossi L., 2005, Current Medicinal Chemistry - Anti-Infective Agents, V4, P37, DOI 10.2174/1568012052931214
   Sanz G, 2009, NAT CLIN PRACT CARD, V6, P101, DOI 10.1038/ncpcardio1419
   Song XR, 2010, J PHARM SCI-US, V99, P4874, DOI 10.1002/jps.22200
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Tardi PG, 2007, BBA-BIOMEMBRANES, V1768, P678, DOI 10.1016/j.bbamem.2006.11.014
   Weissig V, 2001, ADV DRUG DELIVER REV, V49, P127, DOI 10.1016/S0169-409X(01)00131-4
   Zhan P, 2009, CURR PHARM DESIGN, V15, P1893, DOI 10.2174/138161209788453266                                                      
   Zhou XJ, 1997, J CLIN PHARMACOL, V37, P201, DOI 10.1002/j.1552-4604.1997.tb04782.x                                              
NR 43
TC 18
Z9 21
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY-JUN
PY 2011
VL 8
IS 3
BP 867
EP 876
DI 10.1021/mp100457d
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 772KW
UT WOS:000291233800024
PM 21553876
DA 2018-01-05
ER

PT J
AU Lalonde, MS
   Lobritz, MA
   Ratcliff, A
   Chamanian, M
   Athanassiou, Z
   Tyagi, M
   Wong, JL
   Robinson, JA
   Karn, J
   Varani, G
   Arts, EJ
AF Lalonde, Matthew S.
   Lobritz, Michael A.
   Ratcliff, Annette
   Chamanian, Mastooreh
   Athanassiou, Zafiria
   Tyagi, Mudit
   Wong, Julian
   Robinson, John A.
   Karn, Jonathan
   Varani, Gabriele
   Arts, Eric J.
TI Inhibition of Both HIV-1 Reverse Transcription and Gene Expression by a
   Cyclic Peptide that Binds the Tat-Transactivating Response Element (TAR)
   RNA
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-PENETRATING PEPTIDES; STRONG-STOP
   DNA; IN-VITRO; STRAND TRANSFER; P-TEFB; NUCLEOCAPSID PROTEIN;
   HIGH-AFFINITY; ANTIRETROVIRAL THERAPY; TERMINATOR SEQUENCES
AB The RNA response element TAR plays a critical role in HIV replication by providing a binding site for the recruitment of the viral transactivator protein Tat. Using a structure-guided approach, we have developed a series of conformationally-constrained cyclic peptides that act as structural mimics of the Tat RNA binding region and block Tat-TAR interactions at nanomolar concentrations in vitro. Here we show that these compounds block Tat-dependent transcription in cell-free systems and in cell-based reporter assays. The compounds are also cell permeable, have low toxicity, and inhibit replication of diverse HIV-1 strains, including both CXCR4-tropic and CCR5-tropic primary HIV-1 isolates of the divergent subtypes A, B, C, D and CRF01_AE. In human peripheral blood mononuclear cells, the cyclic peptidomimetic L50 exhibited an IC(50) similar to 250 nM. Surprisingly, inhibition of LTR-driven HIV-1 transcription could not account for the full antiviral activity. Timed drug-addition experiments revealed that L-50 has a bi-phasic inhibition curve with the first phase occurring after HIV-1 entry into the host cell and during the initiation of HIV-1 reverse transcription. The second phase coincides with inhibition of HIV-1 transcription. Reconstituted reverse transcription assays confirm that HIV-1 (2) strand strong stop DNA synthesis is blocked by L50-TAR RNA interactions in-vitro. These findings are consistent with genetic evidence that TAR plays critical roles both during reverse transcription and during HIV gene expression. Our results suggest that antiviral drugs targeting TAR RNA might be highly effective due to a dual inhibitory mechanism.
C1 [Lobritz, Michael A.; Ratcliff, Annette; Chamanian, Mastooreh; Tyagi, Mudit; Wong, Julian; Karn, Jonathan; Arts, Eric J.] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
   [Lalonde, Matthew S.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.
   [Athanassiou, Zafiria; Varani, Gabriele] Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   [Athanassiou, Zafiria; Varani, Gabriele] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Robinson, John A.] Univ Zurich, Dept Chem, Zurich, Switzerland.
   [Arts, Eric J.] Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA.
RP Arts, EJ (reprint author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
EM eja3@case.edu
RI Lalonde, Matthew/I-1134-2012
FU NIAID, NIH [AI70090]
FX This study was supported by R01 grant(AI70090) from NIAID, NIH. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADACHI A, 1986, J VIROL, V59, P284
   Apolloni Ann, 2007, Curr HIV Res, V5, P473
   Arien KK, 2007, NAT REV MICROBIOL, V5, P141, DOI 10.1038/nrmicro1594
   Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063
   ARTS EJ, 1994, J BIOL CHEM, V269, P14672
   Athanassiou Z, 2004, J AM CHEM SOC, V126, P6906, DOI 10.1021/ja0497680
   Athanassiou Z, 2007, BIOCHEMISTRY-US, V46, P741, DOI 10.1021/bi0619371
   BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041
   Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035                                                       
   Boudier C, 2010, J MOL BIOL, V400, P487, DOI 10.1016/j.jmb.2010.05.033
   Bourgeois CF, 2002, MOL CELL BIOL, V22, P1079, DOI 10.1128/MCB.22.4.1079-1093.2002
   Branch AD, 1998, TRENDS BIOCHEM SCI, V23, P45, DOI 10.1016/S0968-0004(97)01155-9                                                   
   CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128
   CUPELLI LA, 1995, J VIROL, V69, P2640
   Daelemans D, 2000, MOL PHARMACOL, V57, P116
   Das AT, 2007, J VIROL, V81, P7742, DOI 10.1128/JVI.00392-07
   Davidson A, 2009, P NATL ACAD SCI USA, V106, P11931, DOI 10.1073/pnas.0900629106
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   De Clercq E, 2010, ANTIVIR RES, V85, P19, DOI 10.1016/j.antiviral.2009.10.005
   Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395
   Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000                                                
   Dudley DM, 2009, BIOTECHNIQUES, V46, P458, DOI 10.2144/000113119
   Dudley DM, 2009, J VIROL, V83, P5067, DOI 10.1128/JVI.00055-09
   FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0
   Fujinaga K, 2004, MOL CELL BIOL, V24, P787, DOI 10.1128/MCB.24.2.787-795.2004
   GRAEBLE MA, 1993, P NATL ACAD SCI USA, V90, P6184, DOI 10.1073/pnas.90.13.6184
   Guo JH, 1997, J VIROL, V71, P5178
   Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224
   Harrich D, 1996, J VIROL, V70, P4017
   He MZ, 2005, BIOORG MED CHEM LETT, V15, P3978, DOI 10.1016/j.bmcl.2005.01.068
   Heilman-Miller SL, 2004, J BIOL CHEM, V279, P44154, DOI 10.1074/jbc.M401646200
   HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787
   HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331                                                         
   Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h
   Hwang S, 2003, J BIOL CHEM, V278, P39092, DOI 10.1074/jbc.M301749200
   Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Karn J, 2011, CURR OPIN HIV AIDS, V6, P4, DOI 10.1097/COH.0b013e328340ffbb
   Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260
   Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002
   Lassen KG, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000377
   Lee CW, 2005, BIOORG MED CHEM LETT, V15, P4243, DOI 10.1016/j.bmcl.2005.06.077
   Leeper TC, 2005, BIOCHEMISTRY-US, V44, P12362, DOI 10.1021/bi0510532
   Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001
   Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633
   MANN DA, 1991, EMBO J, V10, P1733
   Marozsan AJ, 2001, J VIROL, V75, P8624, DOI 10.1128/JVI.75.18.8624-8638.2001
   Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u                                                               
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Meredith LW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007769
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   OBrien WA, 1996, J VIROL, V70, P2825
   PAGE KA, 1990, J VIROL, V64, P5270
   Pan CF, 2007, J MED CHEM, V50, P2285, DOI 10.1021/jm070014g
   Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014
   Pugach P, 2007, VIROLOGY, V361, P212, DOI 10.1016/j.virol.2006.11.004
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   Renner S, 2005, CHEMBIOCHEM, V6, P1119, DOI 10.1002/cbic.200400376
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706
   Scott MS, 2010, NUCLEIC ACIDS RES, V38, P7388, DOI 10.1093/nar/gkq653
   SUMNERSMITH M, 1995, DRUG EXP CLIN RES, V21, P1
   Tahirov TH, 2010, NATURE, V465, P747, DOI 10.1038/nature09131
   Taiwo B, 2010, J ANTIMICROB CHEMOTH, V65, P1100, DOI 10.1093/jac/dkq096
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Tamilarasu N, 2001, BIOORG MED CHEM LETT, V11, P505, DOI 10.1016/S0960-894X(00)00709-5
   Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000                                                
   Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9
   Weber J, 2006, J VIROL METHODS, V136, P102, DOI 10.1016/j.jviromet.2006.04.004
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6
   Zeng YN, 2007, P NATL ACAD SCI USA, V104, P12651, DOI 10.1073/pnas.0700350104
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 78
TC 32
Z9 32
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2011
VL 7
IS 5
AR e1002038
DI 10.1371/journal.ppat.1002038
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 769LC
UT WOS:000291014000022
PM 21625572
OA gold
DA 2018-01-05
ER

PT J
AU Gruber, K
   Horlacher, T
   Castelli, R
   Mader, A
   Seeberger, PH
   Hermann, BA
AF Gruber, Kathrin
   Horlacher, Tim
   Castelli, Riccardo
   Mader, Andreas
   Seeberger, Peter H.
   Hermann, Bianca A.
TI Cantilever Array Sensors Detect Specific Carbohydrate-Protein
   Interactions with Picomolar Sensitivity
SO ACS NANO
LA English
DT Article
DE cantilever array sensors; glycomics; nanomechanics; biosensors;
   cyanovirin-N
ID ENVELOPE GLYCOPROTEIN GP120; SELF-ASSEMBLED MONOLAYERS; CYANOVIRIN-N;
   NANOMECHANICAL DETECTION; ESCHERICHIA-COLI; RAPID BIOSENSOR; BINDING;
   SURFACE; OLIGOSACCHARIDES; RECOGNITION
AB Advances in carbohydrate sequencing technologies have revealed the tremendous complexity of the glycome. This complexity reflects the structural and chemical diversity of carbohydrates and is greater than that of proteins and oligonucleotides. The next step in understanding the biological function of carbohydrates requires the identification and quantification of carbohydrate interactions with other biomolecules, in particular, with proteins. To this end, we have developed a cantilever array biosensor with a self-assembling carbohydrate-based sensing layer that selectively and sensitively detects carbohydrate protein binding interactions. Specifically, we examined binding of mannosides and the protein cyanovirin-N, which binds and blocks the human immunodeficiency virus (HIV). Cyanovirin-N binding to immobilized oligomannosides on the cantilever resulted In mechanical surface stress that Is transduced into a mechanical force and cantilever bending. The degree and duration of cantilever deflection correlates with the interaction's strength, and comparative binding experiments reveal molecular binding preferences. This study establishes that carbohydrate-based cantilever biosensors are a robust, label-free, and scalable means to analyze carbohydrate-protein interactions and to detect picomolar concentrations of carbohydrate-binding proteins.
C1 [Horlacher, Tim; Castelli, Riccardo; Seeberger, Peter H.] Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, D-14195 Berlin, Germany.
   [Gruber, Kathrin; Mader, Andreas] Univ Munich, Dept Phys, D-85748 Garching, Germany.
   [Gruber, Kathrin; Hermann, Bianca A.] Walther Meissner Inst Tieftemp Forsch, D-85748 Garching, Germany.
   [Gruber, Kathrin; Hermann, Bianca A.] CENS, D-85748 Garching, Germany.
   [Seeberger, Peter H.] Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany.
RP Seeberger, PH (reprint author), Max Planck Inst Colloids & Interfaces, Dept Biomol Syst, Amimallee 22, D-14195 Berlin, Germany.
EM peter.seeberger@mpikg.mpg.de; b.hermann@cens.de
FU ERA; NCCR-Nanoscale Science; Center for Nano Science (CeNS); excellence
   cluster Nanosystems Initiative Munich (NIM); elite network of Bavaria;
   Walther-Meissner-Institute; Bavarian Academy of Science and Humanities;
   ETH Zurich; Swiss National Fonds (SNF); Max-Planck-Society;  [NRP47]
FX We acknowledge the ERA-Chemistry program, NRP47, NCCR-Nanoscale Science,
   Center for Nano Science (CeNS), and the excellence cluster Nanosystems
   Initiative Munich (NIM), the elite network of Bavaria and the
   Walther-Meissner-Institute, Bavarian Academy of Science and Humanities,
   for financial support. We thank the ETH Zurich, the Swiss National Fonds
   (SNF), and the Max-Planck-Society for generous financial support. We
   thank B. O'Keefe for generously providing the CV-N samples. We are
   thankful for equipment cooperation with the groups of Prof. M.-C. Amann
   (Walter-Schottky-Institute), Prof. J. Kotthaus, Prof. J. Radler (both
   LMU Munich), and Concentris GmbH. Scientific discussions with and
   support by J. Miser, U. Hubler, M. Bammerlin, F. Trixler, M. Hennemeyer,
   R. Stark, T. Sobey, D. Heinrich, V. Schittler, S. Nieratschker, S.
   Jannuzzi, J. Buttner, C. Rohr, and A. Malecki are gratefully
   acknowledged. We thank C. Rohr for help with the artwork. Technical
   support of A. Habel, K. Helm-Knapp, J. Geismann, and H. Thies and
   co-workers is gratefully appreciated. We thank Dr. V. Mountain for
   critically editing the manuscript.
CR Backmann N, 2005, P NATL ACAD SCI USA, V102, P14587, DOI 10.1073/pnas.0504917102
   Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRAUN T, 2001, NAT BIOTECHNOL, V19, P856
   Danishefsky SJ, 2000, ANGEW CHEM INT EDIT, V39, P836, DOI 10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO;2-I               
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735
   Gfeller KY, 2005, BIOSENS BIOELECTRON, V21, P528, DOI 10.1016/j.bios.2004.11.018
   Gfeller KY, 2005, APPL ENVIRON MICROB, V71, P2626, DOI 10.1128/AEM.71.5.2626-2631.2005
   Godin M, 2004, LANGMUIR, V20, P7090, DOI 10.1021/la030257l
   Hansen KM, 2001, ANAL CHEM, V73, P1567, DOI 10.1021/ac0012748
   Huber F, 2006, BIOSENS BIOELECTRON, V21, P1599, DOI 10.1016/j.bios.2005.07.018
   Kansas GS, 1996, BLOOD, V88, P3259
   Lam Y, 2006, NANOMED-NANOTECHNOL, V2, P222, DOI 10.1016/j.nano.2006.10.002
   Liang PH, 2007, J AM CHEM SOC, V129, P11177, DOI 10.1021/ja072931h
   Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X
   McKendry R, 2002, P NATL ACAD SCI USA, V99, P9783, DOI 10.1073/pnas.152330199
   Moulin AM, 1999, LANGMUIR, V15, P8776, DOI 10.1021/la990416u                                                               
   Ndieyira JW, 2008, NAT NANOTECHNOL, V3, P691, DOI 10.1038/nnano.2008.275
   Park J, 2005, ANAL CHEM, V77, P6571, DOI 10.1021/ac0507800
   Park S, 2004, J AM CHEM SOC, V126, P4812, DOI 10.1021/ja0391661
   PAULSON JC, 2008, CHEM SOC REV, V37, P1414
   Pera I, 2007, LANGMUIR, V23, P1543, DOI 10.1021/la0624337
   Plante OJ, 2001, SCIENCE, V291, P1523, DOI 10.1126/science.1057324
   Ratner DM, 2004, CHEMBIOCHEM, V5, P1375, DOI 10.1002/cbic.200400106
   Ratner DM, 2002, EUR J ORG CHEM, P826
   Seeberger PH, 2005, NAT REV DRUG DISCOV, V4, P751, DOI 10.1038/nrd1823
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Tamborrini M, 2006, ANGEW CHEM INT EDIT, V45, P6581, DOI 10.1002/anie.200602048
   TZENG TRJ, 2010, J HEAT TRANSFER, V133
   Varki A., 2009, ESSENTIALS GLYCOBIOL
   WANG JL, 1971, P NATL ACAD SCI USA, V68, P1130, DOI 10.1073/pnas.68.6.1130
   Xu S, 1998, J CHEM PHYS, V108, P5002, DOI 10.1063/1.475908
   Yue M, 2008, NANO LETT, V8, P520, DOI 10.1021/nl072740c
   Zhang J, 2006, NAT NANOTECHNOL, V1, P214, DOI 10.1038/nnano.2006.134
   Zhang Y, 2006, ANAL CHEM, V78, P2001, DOI 10.1021/ac051919+
NR 39
TC 58
Z9 58
U1 2
U2 47
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD MAY
PY 2011
VL 5
IS 5
BP 3670
EP 3678
DI 10.1021/nn103626q
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 767AD
UT WOS:000290826800032
PM 21388220
DA 2018-01-05
ER

PT J
AU Loudos, G
   Kagadis, GC
   Psimadas, D
AF Loudos, George
   Kagadis, George C.
   Psimadas, Dimitris
TI Current status and future perspectives of in vivo small animal imaging
   using radiolabeled nanoparticles
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Drug release; Molecular imaging; Small animal imaging; SPECT; PET;
   Radiolabeled nanoparticles; Angiogenesis
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; POSITRON-EMISSION-TOMOGRAPHY;
   COMPUTERIZED ANALYSIS; TUMOR ANGIOGENESIS; BREAST-CANCER;
   CHORIOALLANTOIC MEMBRANE; LABELED NANOPARTICLES; BIOLOGICAL EVALUATION;
   IONIZING-RADIATION; DRUG DISCOVERY
AB Small animal molecular imaging is a rapidly expanding efficient tool to study biological processes non-invasively. The use of radiolabeled tracers provides non-destructive, imaging information, allowing time related phenomena to be repeatedly studied in a single animal. In the last decade there has been an enormous progress in related technologies and a number of dedicated imaging systems overcome the limitations that the size of small animal possesses. On the other hand, nanoparticles (NPs) gain increased interest, due to their unique properties, which make them perfect candidates for biological applications. Over the past 5 years the two fields seem to cross more and more often; radiolabeled NPs have been assessed in numerous pre-clinical studies that range from oncology, till HIV treatment. In this article the current status in the tools, applications and trends of radiolabeled NPs reviewed. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Kagadis, George C.] Univ Patras, Dept Med Phys, Sch Med, GR-26504 Rion, Greece.
   [Loudos, George; Psimadas, Dimitris] Technol Educ Inst Athens AG, Dept Med Instruments Technol, Egaleo 12210, Greece.
   [Psimadas, Dimitris] Natl Ctr Sci Res Demokritos, Inst Radioisotopes & Radiodiagnost Prod, Athens 15310, Greece.
RP Kagadis, GC (reprint author), Univ Patras, Dept Med Phys, Sch Med, POB 13273, GR-26504 Rion, Greece.
EM gloudos@teiath.gr; gkagad@gmail.com; dpsimad@chem.uoa.gr
OI Kagadis, George/0000-0002-6983-2863
CR Acton PD, 2002, EUR J NUCL MED MOL I, V29, P1507, DOI 10.1007/s00259-002-0903-5
   ALMUTAIRI A, 2009, EUR C CLIN NAN
   Arulsudar N, 2003, J DRUG TARGET, V11, P187, DOI 10.1080/10611860310001615415
   Balaban R S, 2001, ILAR J, V42, P248
   Ballot S, 2006, EUR J NUCL MED MOL I, V33, P602, DOI 10.1007/s00259-005-0007-0
   Banerjee T, 2005, INT J PHARM, V289, P189, DOI 10.1016/j.ijpharm.2004.09.022
   Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104
   Beckmann N, 2007, NMR BIOMED, V20, P154, DOI 10.1002/nbm.1153
   Been LB, 2004, EUR J NUCL MED MOL I, V31, P1659, DOI 10.1007/s00259-004-1687-6
   BIDAUT L, 1996, PHYS MEDICA, V12, P94
   Blankenberg FG, 2002, J MAGN RESON IMAGING, V16, P352, DOI 10.1002/jmri.10171
   Cao JQ, 2004, J MAGN MAGN MATER, V277, P165, DOI 10.1016/j.jmmm.2003.10.022
   CARTIER R, 2007, NANOTECHNOLOGY, V18
   Chakrabarti A, 2007, CANCER BIOL THER, V6, P948, DOI 10.4161/cbt.6.6.4191                                                            
   Chatziioannou AF, 2002, EUR J NUCL MED, V29, P98, DOI 10.1007/s00259-001-0683-3                                                       
   CHATZIIOANNOU AF, 2005, P AM THORAC SOC, V2, P10
   Chatziioannou Arion F, 2005, Proc Am Thorac Soc, V2, P533, DOI 10.1513/pats.200508-079DS
   Chen XY, 2004, EUR J NUCL MED MOL I, V31, P1081, DOI 10.1007/s00259-003-1452-2
   Chung YH, 2004, PHYS MED BIOL, V49, P2881, DOI 10.1088/0031-9155/49/13/008
   Coleman PJ, 2004, J MED CHEM, V47, P4829, DOI 10.1021/jm049874c
   Cormode DP, 2009, ARTERIOSCL THROM VAS, V29, P992, DOI 10.1161/ATVBAHA.108.165506
   De Vincentis G, 1998, BREAST CANCER RES TR, V48, P159, DOI 10.1023/A:1005938722849
   Devaraj NK, 2009, BIOCONJUGATE CHEM, V20, P397, DOI 10.1021/bc8004649
   Dobrucki LW, 2007, CURR OPIN BIOTECH, V18, P90, DOI 10.1016/j.copbio.2007.01.005
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Ercan MT, 2000, CURR PHARM DESIGN, V6, P1159, DOI 10.2174/1381612003399914
   Evans SM, 2000, J NUCL MED, V41, P327
   Fani M, 2007, RADIOCHIM ACTA, V95, P351, DOI 10.1524/ract.2007.95.5.351
   Fischer BM, 2006, RESPIRATION, V73, P267, DOI 10.1159/000092080
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Fu CM, 2004, IEEE T MAGN, V40, P3003, DOI 10.1109/TMAG.2004.834199
   Fujibayashi Y, 1997, J NUCL MED, V38, P1155
   Furenlid LR, 2004, IEEE T NUCL SCI, V51, P631, DOI 10.1109/TNS.2004.830975
   Gillies ER, 2005, MOL PHARMACEUT, V2, P129, DOI 10.1021/mp049886u
   Gorantla S, 2006, J LEUKOCYTE BIOL, V80, P1165, DOI 10.1189/jlb.0206110
   Gross S, 2006, CURR OPIN CHEM BIOL, V10, P334, DOI 10.1016/j.cbpa.2006.06.028
   Halder KK, 2008, J DRUG TARGET, V16, P311, DOI [10.1080/10611860801899300, 10.1080/10611860801899300 ]
   Hamoudeh M, 2008, ADV DRUG DELIVER REV, V60, P1329, DOI 10.1016/j.addr.2008.04.013
   Harry VN, 2010, LANCET ONCOL, V11, P92, DOI 10.1016/S1470-2045(09)70190-1
   Haubner R, 1999, J NUCL MED, V40, P1061
   Hofmann M, 2001, EUR J NUCL MED, V28, P1751, DOI 10.1007/s002590100639                                                           
   Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200                                                         
   Humm JL, 2003, EUR J NUCL MED MOL I, V30, P1574, DOI 10.1007/s00259-003-1266-2
   Kagadis GC, 2008, J DIGIT IMAGING, V21, P433, DOI 10.1007/s10278-007-9047-2
   Karnabatidis D, 2001, ACTA RADIOL, V42, P333, DOI 10.1080/028418501127346747
   Katsanos K, 2009, J VASC SURG, V49, P1000, DOI 10.1016/j.jvs.2008.11.004
   Kennel SJ, 2008, NUCL MED BIOL, V35, P501, DOI 10.1016/j.nucmedbio.2008.02.001
   Kim EM, 2007, J DRUG TARGET, V15, P595, DOI 10.1080/10611860701502830
   Kommareddy S, 2007, J PHARM SCI-US, V96, P397, DOI 10.1002/jps.20813
   Koo OM, 2005, NANOMED-NANOTECHNOL, V1, P193, DOI 10.1016/j.nano.2005.06.004
   Larobina M, 2006, CURR MED IMAGING REV, V2, P187, DOI 10.2174/157340506776930610                                                      
   Lewis JS, 2002, EUR J CANCER, V38, P2173, DOI 10.1016/S0959-8049(02)00394-5                                                   
   Li KCP, 2009, EUR J RADIOL, V70, P201, DOI 10.1016/j.ejrad.2009.01.046
   Li ZB, 2007, BIOCONJUGATE CHEM, V18, P1987, DOI 10.1021/bc700226v
   Loudos G, 2007, IEEE T NUCL SCI, V54, P454, DOI 10.1109/TNS.2007.896212
   Lyons SK, 2005, J PATHOL, V205, P194, DOI 10.1002/path.1697
   Ma KH, 2002, NUCL MED BIOL, V29, P561, DOI 10.1016/S0969-8051(02)00303-7                                                   
   Majewski S, 2001, IEEE T NUCL SCI, V48, P822, DOI 10.1109/23.940170
   Matsumoto T, 2004, BIOMATERIALS, V25, P3807, DOI 10.1016/j.biomaterials.2003.10.081
   McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713                                                              
   Meikle SR, 2005, PHYS MED BIOL, V50, pR45, DOI 10.1088/0031-9155/50/22/R01
   Mizushima Y, 2006, J CONTROL RELEASE, V110, P260, DOI 10.1016/j.jconrel.2005.09.051
   Moses WW, 2003, IEEE T NUCL SCI, V50, P1325, DOI 10.1109/TNS.2003.817319
   Muro S, 2006, J PHARMACOL EXP THER, V317, P1161, DOI 10.1124/jpet.105.098970
   Nahrendorf M, 2008, CIRCULATION, V117, P379, DOI 10.1161/CIRCULATIONAHA.107.741181
   Nakazawa A, 2004, CHEST, V126, P1372, DOI 10.1378/chest.126.4.1372                                                        
   Nikiforidis G, 1999, EUR J RADIOL, V29, P168, DOI 10.1016/S0720-048X(98)00025-4
   Nikiforidis GC, 2008, MED PHYS, V35, P3444, DOI 10.1118/1.2948321
   Ong HT, 2008, J NANOPART RES, V10, P141, DOI 10.1007/s11051-007-9239-1
   Onthank DC, 2004, BIOCONJUGATE CHEM, V15, P235, DOI 10.1021/bc034108q
   Pani R, 2004, NUCL INSTRUM METH B, V213, P197, DOI 10.1016/S0168-583X(03)01571-4
   PHELPS ME, 1991, NEUROCHEM RES, V16, P929, DOI 10.1007/BF00965836                                                              
   Reddy LH, 2004, J DRUG TARGET, V12, P443, DOI 10.1080/10611860400011406
   Rogers BE, 2004, CANCER BIOTHER RADIO, V19, P25, DOI 10.1089/108497804773391649
   Rossin R, 2008, J NUCL MED, V49, P103, DOI 10.2967/jnumed.107.045302
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Rutman AM, 2009, EUR J RADIOL, V70, P232, DOI 10.1016/j.ejrad.2009.01.050
   Sajja Hari Krishna, 2009, Curr Drug Discov Technol, V6, P43
   Schipper ML, 2007, J NUCL MED, V48, P1511, DOI 10.2967/jnumed.107.040071
   Schluep T, 2009, P NATL ACAD SCI USA, V106, P11394, DOI 10.1073/pnas.0905487106
   Schmieder AH, 2008, FASEB J, V22, P4179, DOI 10.1096/fj.08-112060
   Semmler-Behnke M, 2007, ENVIRON HEALTH PERSP, V115, P728, DOI 10.1289/ehp.9685
   Sharp TL, 2005, NUCL MED BIOL, V32, P875, DOI 10.1016/j.nucmedbio.2005.05.010
   Shokeen M, 2008, Q J NUCL MED MOL IM, V52, P267
   Siablis D, 2006, INT UROL NEPHROL, V38, P407, DOI 10.1007/s11255-005-3617-3
   Singh R, 2006, P NATL ACAD SCI USA, V103, P3357, DOI 10.1073/pnas.0509009103
   Snehalatha M, 2008, DRUG DELIV, V15, P277, DOI 10.1080/10717540802006500 
   Sofou S, 2008, INT J NANOMED, V3, P181
   Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3
   Unni PR, 2002, NUCL MED BIOL, V29, P199, DOI 10.1016/S0969-8051(01)00303-1
   Vaidyanathan G, 2006, NAT PROTOC, V1, P1655, DOI 10.1038/nprot.2006.264
   Vera DR, 2001, NUCL MED BIOL, V28, P493, DOI 10.1016/S0969-8051(01)00218-9
   Wahl DA, 2006, EUR CELLS MATER, V11, P43, DOI 10.22203/eCM.v011a06                                                            
   WANG R, 2007, COLLOID POLYM SCI, V283, P91
   Webb S, 1988, PHYS MED IMAGING
   Weber WA, 1999, STRAHLENTHER ONKOL, V175, P356, DOI 10.1007/s000660050022
   Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p
   Weissleder R, 2001, RADIOLOGY, V219, P316, DOI 10.1148/radiology.219.2.r01ma19316                                              
   Winter PM, 2008, JACC-CARDIOVASC IMAG, V1, P624, DOI 10.1016/j.jcmg.2008.06.003
   Wong FC, 2009, EUR J RADIOL, V70, P205, DOI 10.1016/j.ejrad.2009.01.049
   WONHO L, 2004, IEEE NUCL SCI S C, P861
   Xu JQ, 2007, MACROMOLECULES, V40, P2971, DOI 10.1021/ma070267j
   Yamamuro T, 1998, BIOMATERIALS, V19, P1479, DOI 10.1016/S0142-9612(98)00062-3
   Zaidi H, 2006, Z MED PHYS, V16, P6
   Zheng QH, 2002, NUCL MED BIOL, V29, P761, DOI 10.1016/S0969-8051(02)00338-4
   Zinn KR, 2000, J NUCL MED, V41, P887
NR 106
TC 20
Z9 20
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0720-048X
EI 1872-7727
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD MAY
PY 2011
VL 78
IS 2
BP 287
EP 295
DI 10.1016/j.ejrad.2010.06.025
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 766BT
UT WOS:000290755200020
PM 20637553
DA 2018-01-05
ER

PT J
AU Kesel, AJ
AF Kesel, Andreas J.
TI Broad-spectrum antiviral activity including human immunodeficiency and
   hepatitis C viruses mediated by a novel retinoid thiosemicarbazone
   derivative
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Thiosemicarbazone derivatives; Hepatitis C virus (HCV); HCV Huh7 ET
   replicon; Retinoid thiosemicarbazone; HCV replicon replication
   inhibitors; HIV-1 inhibitor
ID IN-VITRO ACTIVITY; VITAMIN-A; HEPATOCELLULAR-CARCINOMA; POLYMERASE
   INHIBITORS; INITIAL TREATMENT; INTERFERON-ALPHA; RNA REPLICATION; PLUS
   RIBAVIRIN; B VIRUS; COMBINATION
AB Aromatic aldehyde-derived thiosemicarbazones 4-6, the S-substituted modified thiosemicarbazones 7/8, and a vitamin A-derived (retinoid) thiosemicarbazone derivative 12 were investigated as inhibitors of human hepatitis C virus (HCV) subgenomic RNA replicon Huh7 ET (luc-ubi-neo/ET) replication. Compounds 4-6 and 12 were found to be potent suppressors of HCV RNA replicon replication. The trifluoromethoxy-substituted thiosemicarbazone 6 and the retinoid thiosemicarbazone derivative 12 were even superior in selectivity to the included reference agent recombinant human alpha-interferon-2b, showing potencies in the nanomolar range of concentration. In addition, compounds 5, 6, 8 and 12 were tested as inhibitors of cytopathic effect (CPE) induced by human varicella-zoster virus (VZV) and/or human cytomegalovirus (HCMV). Compounds 4-6, 8 and 12 were additionally examined as inhibitors of CPE induced by cowpox virus and vaccinia virus. Thiosemicarbazone 4 was inhibitory on cowpox and vaccinia virus replication comparable in potency and selectivity to the reference agent cidofovir. Retinoid thiosemicarbazone derivative 12 was active as micromolar inhibitor of VZV, HCMV, and, in addition, human immunodeficiency virus type 1 (HIV-1) replication. These results indicate that thiosemicarbazone derivatives are appropriate lead structures to be evaluated in targeted antiviral therapies for hepatitis C (STAT-C), and that the vitamin A-related thiosemicarbazone derivative 12 emerges as a broad-spectrum antiviral agent, co-suppressing the multiplication of important RNA and DNA viruses. (C) 2011 Elsevier Masson SAS. All rights reserved.
RP Kesel, AJ (reprint author), Chammunsterstr 47, D-81827 Munich, Germany.
EM andreas.kesel@munich.netsurf.de
FU NIAID [N01-AI-30047 (AACF)]
FX Thanks are due to the National Institute of Allergy and Infectious
   Diseases (NIAID) and the Antimicrobial Acquisition and Coordinating
   Facility (AACF) of the Southern Research Institute (SRI) (Birmingham,
   AL, USA) for performing the HCV screening. Gratefully acknowledged is
   the NIAID grant contract N01-AI-30047 (AACF). HCV data were generated by
   Dr. Zhuhui Huang and Dr. Michael G. Murray at SRI, Frederick, MD, USA.
   VZV, HCMV and Orthopoxvirus data were generated by Dr. Mark N. Prichard
   at University of Alabama, Birmingham, AL, USA. Special acknowledgment
   goes to Dr. Joseph A. Maddry at SRI for the generous management of AACF
   screenings. I am deeply indepted to Prof. Dr. R.F. Schinazi at the
   Center for AIDS Research, Emory University School of Medicine (Atlanta,
   GA, USA) for providing the HIV-1 data. Thankfully appreciated are the
   analytical services of Dr. Thomas M. Haider and Dipl.-Chem. Volker Krey
   (TopLab GmbH), Dr. Christoph Freudenberger and Eva-Maria May (Currenta
   GmbH) and Klaus Hecker (HEKAtech GmbH). Especially thankfully
   appreciated is the generous and patient involvement of Dr. Wolfram
   Taiber and Dr. Martin Elhardt (CEM Chemieschule Dr. Erwin Elhardt,
   Munchen).
CR Asselah T, 2009, LIVER INT, V29, P57, DOI 10.1111/j.1478-3231.2008.01928.x
   Baker D E, 2001, Rev Gastroenterol Disord, V1, P87
   Baker Danial E, 2003, Rev Gastroenterol Disord, V3, P93
   BAUER DJ, 1962, B WORLD HEALTH ORGAN, V26, P727
   BEASLEY RP, 1981, LANCET, V2, P1129
   CHANG SYP, 1993, NATURE, V363, P466, DOI 10.1038/363466a0                                                                
   CHATTOPADHYAY D, 1988, J CRYST SPECTROSC, V18, P701, DOI 10.1007/BF01164291                                                              
   Chen CS, 2009, J MED CHEM, V52, P2716, DOI 10.1021/jm8011905
   De Clercq E, 2001, CLIN MICROBIOL REV, V14, P382, DOI 10.1128/CMR.14.2.382-397.2001
   Eid AJ, 2010, DRUGS, V70, P965, DOI 10.2165/10898540-000000000-00000
   ENGLERT G, 1975, HELV CHIM ACTA, V58, P2367, DOI 10.1002/hlca.19750580817
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   Finkielsztein LM, 2008, EUR J MED CHEM, V43, P1767, DOI 10.1016/j.ejmech.2007.10.023
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Gao M, 2010, NATURE, V465, P96, DOI 10.1038/nature08960
   Garcia Cybele C., 2003, Antiviral Chemistry & Chemotherapy, V14, P99
   GREEN H. N., 1928, BRIT MED JOUR, V2, P691
   GREVER MR, 1992, SEMIN ONCOL, V19, P622
   Kandil S, 2009, BIOORG MED CHEM LETT, V19, P2935, DOI 10.1016/j.bmcl.2009.04.074
   Kern ER, 2009, ANTIMICROB AGENTS CH, V53, P572, DOI 10.1128/AAC.01257-08
   Kern ER, 2005, ANTIMICROB AGENTS CH, V49, P1039, DOI 10.1128/AAC.49.3.1039-1045.2005
   Kim HJ, 2009, J MED CHEM, V52, P206, DOI 10.1021/jm801418v
   Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001
   Kwong AD, 2008, CURR OPIN PHARMACOL, V8, P522, DOI 10.1016/j.coph.2008.09.007
   Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645                                                
   Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099
   Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017
   Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110
   Ma S, 2006, ANTIMICROB AGENTS CH, V50, P2976, DOI 10.1128/AAC.00310-06
   Manfroni G, 2009, J MED CHEM, V52, P3354, DOI 10.1021/jm801608u
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Marcellin P, 2009, LIVER INT, V29, P1, DOI 10.1111/j.1478-3231.2008.01947.x
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Meager A, 2001, J IMMUNOL METHODS, V257, P17, DOI 10.1016/S0022-1759(01)00460-4                                                   
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6
   PATTARONI C, 1981, HELV CHIM ACTA, V64, P1969, DOI 10.1002/hlca.19810640702                                                        
   PFAU CJ, 1982, HDB EXP PHARM, V61, P147
   PICKART L, 1980, NATURE, V288, P715, DOI 10.1038/288715a0
   Quenelle DC, 2007, ANTIMICROB AGENTS CH, V51, P4118, DOI 10.1128/AAC.00762-07
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Ross AC, 1996, FASEB J, V10, P979
   Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002
   *SCHER CORP, 2006, PROD INF INTR INT AL
   SCHINAZI RF, 1990, ANTIMICROB AGENTS CH, V34, P1061, DOI 10.1128/AAC.34.6.1061                                                           
   Semba RD, 1999, P NUTR SOC, V58, P719, DOI 10.1017/S0029665199000944
   Shimakami T, 2009, CURR OPIN PHARMACOL, V9, P537, DOI 10.1016/j.coph.2009.08.008
   SIROTENKO AA, 1952, MIKROCHIM ACTA WIEN, V40, P30
   SPIRA TJ, 1987, J CLIN MICROBIOL, V25, P97
   Stuyver LJ, 2002, ANTIMICROB AGENTS CH, V46, P3854, DOI 10.1128/AAC.46.12.3854-3860.2002
   Tong X, 2010, ANTIMICROB AGENTS CH, V54, P2365, DOI 10.1128/AAC.00135-10
   Yu Y, 2006, TALANTA, V69, P103, DOI 10.1016/j.talanta.2005.09.015
   ALTAMURA S, 2003, Patent No. 20030176503
NR 53
TC 17
Z9 20
U1 0
U2 5
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAY
PY 2011
VL 46
IS 5
BP 1656
EP 1664
DI 10.1016/j.ejmech.2011.02.014
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 751YW
UT WOS:000289655100022
PM 21376429
DA 2018-01-05
ER

PT J
AU Lee, JY
   Choi, YS
   Suh, JS
   Kwon, YM
   Yang, VC
   Lee, SJ
   Chung, CP
   Park, YJ
AF Lee, Jue-Yeon
   Choi, Young-Suk
   Suh, Jin-Sook
   Kwon, Young-Min
   Yang, Victor C.
   Lee, Seung-Jin
   Chung, Chong-Pyoung
   Park, Yoon-Jeong
TI Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient
   cancer therapy
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE Cell-penetrating peptide; TAT; chitosan conjugate; doxorubicin; tumor
ID DOXORUBICIN INDUCES APOPTOSIS; SELF-ASSEMBLED NANOPARTICLES;
   OVARIAN-CARCINOMA CELLS; ACID-MODIFIED CHITOSAN; WEIGHT PROTAMINE LMWP;
   IN-VIVO; DELIVERY-SYSTEM; GENE DELIVERY; PROTEIN TRANSDUCTION;
   ANTITUMOR-ACTIVITY
AB In this study, a cell-penetrating peptide, the transactivating transcriptional factor (TAT) domain from HIV, was linked to a chitosan/doxorubicin (chitosan/DOX) conjugate to form a chitosan/DOX/TAT hybrid. The synthesized chitosan/DOX/TAT conjugate showed a different intracellular distribution pattern from a conjugate without TAT. Unlike both free DOX and the conjugate without TAT, the chitosan/DOX/TAT conjugate was capable of efficient cell entry. The chitosan/DOX/TAT conjugate was found to be highly cytotoxic, with an IC50 value of approximately 480 nM, 2 times less than that of chitosan/DOX (980 nM). The chitosan/DOX/TAT provided decreases in tumor volume of 77.4 and 57.5% compared to free DOX and chitosan/DOX, respectively, in tumor-bearing mice. Therefore, this study suggests that TAT-mediated chitosan/DOX conjugate delivery is effective in slowing tumor growth.
C1 [Lee, Jue-Yeon; Choi, Young-Suk; Suh, Jin-Sook; Park, Yoon-Jeong] Seoul Natl Univ, Sch Dent, Dept Craniomaxillofacial Reconstruct Sci, Seoul, South Korea.
   [Lee, Jue-Yeon; Choi, Young-Suk; Suh, Jin-Sook; Chung, Chong-Pyoung; Park, Yoon-Jeong] Seoul Natl Univ, Coll Dent, Intellectual Biointerface Engn Ctr, Seoul, South Korea.
   [Kwon, Young-Min; Yang, Victor C.] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA.
   [Lee, Seung-Jin] Ewha Womans Univ, Coll Pharm, Dept Pharm, Seoul, South Korea.
   [Chung, Chong-Pyoung] Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul, South Korea.
RP Park, YJ (reprint author), Seoul Natl Univ, Sch Dent, Dept Craniomaxillofacial Reconstruct Sci, Seoul, South Korea.
EM parkyj@snu.ac.kr
FU Korea Healthcare technology RD project; Ministry for Health, Welfare &
   Family Affairs, Republic of Korea [A080927]
FX Grant sponsors: Korea Healthcare technology R&D project, Ministry for
   Health, Welfare & Family Affairs, Republic of Korea; Grant number:
   A080927
CR Aoki T, 2006, BIOSCI BIOTECH BIOCH, V70, P2349, DOI 10.1271/bbb.50398
   Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861
   BALLY MB, 1990, CANCER CHEMOTH PHARM, V27, P13, DOI 10.1007/BF00689270                                                              
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Chang LC, 2001, AAPS PHARMSCI, V3, part. no.
   Chari RVJ, 1998, ADV DRUG DELIVER REV, V31, P89, DOI 10.1016/S0169-409X(97)00095-1
   Cheng J, 2004, MOL PHARMACEUT, V1, P183, DOI 10.1021/mp049966y
   Dufes C, 2000, PHARMACEUT RES, V17, P1250, DOI 10.1023/A:1026422915326
   DUNCAN R, 1992, ANTI-CANCER DRUG, V3, P175, DOI 10.1097/00001813-199206000-00001
   Eliaz RE, 2004, CANCER RES, V64, P711, DOI 10.1158/0008-5472.CAN-03-0654                                                   
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Kang HM, 2005, PHARM RES, V22, P2099, DOI 10.1007/s11095-005-8330-5
   Kim YH, 2001, BIOCONJUGATE CHEM, V12, P932, DOI 10.1021/bc015510c
   Kopecek J, 2000, EUR J PHARM BIOPHARM, V50, P61, DOI 10.1016/S0939-6411(00)00075-8                                                   
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Lee JY, 2009, BIOTECHNOL APPL BIOC, V52, P69, DOI 10.1042/BA20070169
   Lee KY, 2000, COLLOID POLYM SCI, V278, P1216, DOI 10.1007/s003960000389                                                           
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOORG MED CHEM LETT, V15, P5071, DOI 10.1016/j.bmcl.2005.07.087
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Liang JF, 2002, J CONTROL RELEASE, V78, P67, DOI 10.1016/S0168-3659(01)00484-9
   Liu LH, 2008, BIOPOLYMERS, V90, P617, DOI 10.1002/bip.20998
   MAEDA H, 1992, BIOCONJUGATE CHEM, V3, P351, DOI 10.1021/bc00017a001
   Malugin A, 2006, MOL PHARMACEUT, V3, P351, DOI 10.1021/mp050065e
   Malugin A, 2004, MOL PHARMACEUT, V1, P174, DOI 10.1021/mp049967q
   McGrath MS, 2003, CANCER RES, V63, P72
   Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X                                                   
   Moon C, 2008, J BIOMED MATER RES A, V84A, P238, DOI 10.1002/jbm.a.31452
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Nori A, 2005, ADV DRUG DELIVER REV, V57, P609, DOI 10.1016/j.addr.2004.10.006
   Park JH, 2006, BIOMATERIALS, V27, P119, DOI 10.1016/j.biomaterials.2005.05.028
   Park YJ, 2006, BIOTECHNOL APPL BIOC, V43, P17, DOI 10.1042/BA20050075
   Park YJ, 2005, FASEB J, V19, P1555, DOI 10.1096/fj.04-2322fje
   Rosenblum MG, 1999, CLIN CANCER RES, V5, P865
   Roy K, 1999, NAT MED, V5, P387
   Ruel-Gariepy E, 2002, J CONTROL RELEASE, V82, P373, DOI 10.1016/S0168-3659(02)00146-3                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Syrigos KN, 1999, ANTICANCER RES, V19, P605
   Wagner E, 1998, ADV DRUG DELIV REV, V30, P97
   Westermeier R, 2005, ELECTROPHORESIS IN PRACTICE: A GUIDE TO METHODS AND APPLICATIONS OF DNA AND PROTEIN SEPARATIONS, P1
   Yoo HS, 2005, J CONTROL RELEASE, V103, P235, DOI 10.1016/j.jconrel.2004.11.033
NR 43
TC 29
Z9 30
U1 4
U2 34
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2011
VL 128
IS 10
BP 2470
EP 2480
DI 10.1002/ijc.25578
PG 11
WC Oncology
SC Oncology
GA 740SZ
UT WOS:000288816000023
PM 20669230
OA gold
DA 2018-01-05
ER

PT J
AU Kao, CC
   Ni, P
   Hema, M
   Huang, XL
   Dragnea, B
AF Kao, C. Cheng
   Ni, Peng
   Hema, Masarapu
   Huang, Xinlei
   Dragnea, Bogdan
TI The coat protein leads the way: an update on basic and applied studies
   with the Brome mosaic virus coat protein
SO MOLECULAR PLANT PATHOLOGY
LA English
DT Review
ID CHLOROTIC MOTTLE VIRUS; NUCLEAR-MAGNETIC-RESONANCE; HUMAN
   IMMUNODEFICIENCY VIRUS; PATHOGEN-DERIVED RESISTANCE; DEPENDENT
   RNA-POLYMERASE; LONG-DISTANCE MOVEMENT; BUSHY STUNT VIRUS; N-TERMINAL
   PART; CELL-TO-CELL; CAPSID PROTEIN
AB P>The Brome mosaic virus (BMV) coat protein (CP) accompanies the three BMV genomic RNAs and the subgenomic RNA into and out of cells in an infection cycle. In addition to serving as a protective shell for all of the BMV RNAs, CP plays regulatory roles during the infection process that are mediated through specific binding of RNA elements in the BMV genome. One regulatory RNA element is the B box present in the 5' untranslated region (UTR) of BMV RNA1 and RNA2 that play important roles in the formation of the BMV replication factory, as well as the regulation of translation. A second element is within the tRNA-like 3' UTR of all BMV RNAs that is required for efficient RNA replication. The BMV CP can also encapsidate ligand-coated metal nanoparticles to form virus-like particles (VLPs). This update summarizes the interaction between the BMV CP and RNAs that can regulate RNA synthesis, translation and RNA encapsidation, as well as the formation of VLPs.
C1 [Kao, C. Cheng; Ni, Peng; Hema, Masarapu] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA.
   [Huang, Xinlei; Dragnea, Bogdan] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
RP Kao, CC (reprint author), Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA.
EM ckao@indiana.edu
FU National Science Foundation [MCB0641362]; National Institutes of Health
   (NIH) [1R01AI090280, GM081929]
FX We thank Laura Kao for editing the manuscript and members of the IU and
   A&M Cereal Killers, former and present, for wonderful discussions. This
   work was supported by National Science Foundation grant MCB0641362 and
   National Institutes of Health (NIH) grant 1R01AI090280 to CCK, and NIH
   grant GM081929 for Bioimaging to BD and CCK. Hema Masarapu acknowledges
   the Department of Biotechnology, New Delhi, India for providing a
   long-term Overseas Associateship.
CR ADOLPH KW, 1976, PHILOS T ROY SOC B, V276, P113, DOI 10.1098/rstb.1976.0102
   Ahlquist P, 2006, NAT REV MICROBIOL, V4, P371, DOI 10.1038/nrmicro1389
   Ahlquist P, 1992, Curr Opin Genet Dev, V2, P71, DOI 10.1016/S0959-437X(05)80325-9
   AMES BN, 1960, J BIOL CHEM, V235, P769
   Annamalai P, 2005, VIROLOGY, V338, P96, DOI 10.1016/j.virol.2005.05.013
   Annamalai P, 2008, J VIROL, V82, P1484, DOI 10.1128/JVI.01540-07
   Annamalai P, 2007, J VIROL, V81, P173, DOI 10.1128/JVI.01500-06
   Annamalai P, 2006, J VIROL, V80, P10096, DOI 10.1128/JVI.01186-06
   Asurmendi S, 2004, P NATL ACAD SCI USA, V101, P1415, DOI 10.1073/pnas.0307778101
   BANCROFT JB, 1967, VIROLOGY, V32, P354, DOI 10.1016/0042-6822(67)90284-X
   BANCROFT JB, 1969, VIROLOGY, V39, P924, DOI 10.1016/0042-6822(69)90029-4
   Baulcombe DC, 1996, PLANT CELL, V8, P1833
   BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315                                             
   Belyi VA, 2006, P NATL ACAD SCI USA, V103, P17174, DOI 10.1073/pnas.0608311103
   Bol JF, 2005, ANNU REV PHYTOPATHOL, V43, P39, DOI 10.1146/annurev.phyto.43.101804.120505
   Calhoun SL, 2007, VIROLOGY, V364, P407, DOI 10.1016/j.virol.2007.03.034
   Chapman MR, 1999, J MOL BIOL, V286, P709, DOI 10.1006/jmbi.1998.2503
   Cheluvaraja S, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3316793
   Chen C, 2006, NANO LETT, V6, P611, DOI 10.1021/nl0600878
   Chen JB, 2001, J VIROL, V75, P3207, DOI 10.1128/JVI.75.7.3207-3219.2001
   Choi SK, 2004, J VIROL, V78, P13420, DOI 10.1128/JVI.78.24.13420-13429.2004
   Choi YG, 2003, J VIROL, V77, P9750, DOI 10.1128/JVI.77.18.9750-9757.2003
   Choi YG, 2002, P NATL ACAD SCI USA, V99, P655, DOI 10.1073/pnas.022618199
   COHEN SS, 1981, P NATL ACAD SCI-BIOL, V78, P5470, DOI 10.1073/pnas.78.9.5470
   CUILLEL M, 1981, VIROLOGY, V110, P63, DOI 10.1016/0042-6822(81)90008-8
   Damayanti TA, 2003, J VIROL, V77, P9979, DOI 10.1128/JVI.77.18.9979-9986.2003
   Daniel MC, 2010, ACS NANO, V4, P3853, DOI 10.1021/nn1005073
   Destito G, 2009, CURR TOP MICROBIOL, V327, P95
   Dixit SK, 2006, NANO LETT, V6, P1993, DOI 10.1021/nl061165u
   Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211
   Dragnea B, 2003, J AM CHEM SOC, V125, P6374, DOI 10.1021/ja0343609
   DREHER TW, 1988, J MOL BIOL, V201, P31, DOI 10.1016/0022-2836(88)90436-6
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gelvin SB, 2003, MICROBIOL MOL BIOL R, V67, P16, DOI 10.1128/MMBR.67.1.16-37.2003
   Gopinath K, 2005, J VIROL, V79, P14222, DOI 10.1128/JVI.79.22.14222-14234.2005
   Gopinath K, 2007, PLANT CELL, V19, P1179, DOI 10.1105/tpc.107.050088
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Guerra-Peraza O, 2005, J GEN VIROL, V86, P1815, DOI 10.1099/vir.0.80920-0
   Guogas LM, 2005, J VIROL, V79, P5752, DOI 10.1128/JVI.79.9.5752-5761.2005
   HACKLAND AF, 1994, ARCH VIROL, V139, P1, DOI 10.1007/BF01309451
   HALL TC, 1987, J CELL SCI, P287
   Hema M, 2010, MOL PLANT MICROBE IN, V23, P1433, DOI 10.1094/MPMI-05-10-0118
   HERZOG M, 1978, VIROLOGY, V86, P48, DOI 10.1016/0042-6822(78)90006-5
   HIEBERT E, 1968, VIROLOGY, V34, P492, DOI 10.1016/0042-6822(68)90069-X
   Hsu C, 2006, VIROLOGY, V349, P222, DOI 10.1016/j.virol.2006.02.038
   HU CC, 1995, J VIROL METHODS, V55, P367, DOI 10.1016/0166-0934(95)00085-1                                                    
   Huang XL, 2007, NANO LETT, V7, P2407, DOI 10.1021/nl071083l
   Hutchinson EC, 2010, J GEN VIROL, V91, P313, DOI 10.1099/vir.0.017608-0
   Ilkow CS, 2008, J VIROL, V82, P4284, DOI 10.1128/JVI.02732-07
   Ilkow CS, 2010, FUTURE MICROBIOL, V5, P571, DOI [10.2217/fmb.10.27, 10.2217/FMB.10.27]
   INCARDONA NL, 1964, BIOPHYS J, V4, P11, DOI 10.1016/S0006-3495(64)86766-7                                                   
   JACROT B, 1977, NATURE, V266, P417, DOI 10.1038/266417a0
   JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0                                                    
   JANDA M, 1993, CELL, V72, P961, DOI 10.1016/0092-8674(93)90584-D
   Kao CC, 2000, MOL PLANT PATHOL, V1, P91, DOI 10.1046/j.1364-3703.2000.00017.x
   KASSANIS B, 1969, J GEN VIROL, V4, P385, DOI 10.1099/0022-1317-4-3-385
   Khalil AS, 2007, P NATL ACAD SCI USA, V104, P4892, DOI 10.1073/pnas.0605727104
   Kim CH, 2000, NAT STRUCT BIOL, V7, P415, DOI 10.1038/75202
   Kim CH, 2001, J MOL BIOL, V307, P827, DOI 10.1006/jmbi.2001.4497
   Kim YC, 2005, J BIOL CHEM, V280, P38011, DOI 10.1074/jbc.M508145200
   Krishna NK, 2005, VIRAL IMMUNOL, V18, P17, DOI 10.1089/vim.2005.18.17
   Lee SK, 2001, VIROLOGY, V286, P317, DOI 10.1006/viro.2001.0979
   Lee YJ, 2009, SCIENCE, V324, P1051, DOI [10.1126/science.1171541, 10.1126/science.1169041]
   Liepold LO, 2005, PHYS BIOL, V2, pS166, DOI 10.1088/1478-3975/2/4/S11
   Lucas RW, 2002, J MOL BIOL, V317, P95, DOI 10.1006/jmbi.2001.5389
   Lucas RW, 2001, VIROLOGY, V286, P290, DOI 10.1006/viro.2000.0897
   Manchester M, 2006, ADV DRUG DELIVER REV, V58, P1505, DOI 10.1016/j.addr.2006.09.014
   Mansur HS, 2010, WIRES NANOMED NANOBI, V2, P113, DOI 10.1002/wnan.78
   Martin BD, 2006, J NANOSCI NANOTECHNO, V6, P2451, DOI 10.1166/jnn.2006.548
   Miller ED, 1998, METH MOL B, V81, P25
   Miller WA, 2006, ANNU REV PHYTOPATHOL, V44, P447, DOI 10.1146/annurev.phyto.44.070505.143353
   Nam YS, 2010, NAT NANOTECHNOL, V5, P340, DOI [10.1038/nnano.2010.57, 10.1038/NNANO.2010.57]
   Noueiry AO, 2003, ANNU REV PHYTOPATHOL, V41, P77, DOI 10.1146/annurev.phyto.41.052002.095717
   Okinaka Y, 2001, J VIROL, V75, P5385, DOI 10.1128/JVI.75.11.5385-5390.2001
   Olspert A, 2010, VIRUS GENES, V40, P423, DOI 10.1007/s11262-010-0456-9
   Patton JT, 2000, VIROLOGY, V277, P217, DOI 10.1006/viro.2000.0645
   PFEIFFER P, 1977, VIROLOGY, V81, P419, DOI 10.1016/0042-6822(77)90157-X
   Pinaud F, 2010, NAT METHODS, V7, P275, DOI [10.1038/NMETH.1444, 10.1038/nmeth.1444]
   Prins M, 2008, MOL PLANT PATHOL, V9, P73, DOI [10.1111/J.1364-3703.2007.00447.X, 10.1111/j.1364-3703.2007.00447.x]
   QI X, 2010, MOL PLANT M IN PRESS
   Qu F, 2003, J VIROL, V77, P511, DOI 10.1128/JVI.77.1.511-522.2003
   Rae CS, 2005, VIROLOGY, V343, P224, DOI 10.1016/j.virol.2005.08.017
   Rao ALN, 2006, ANNU REV PHYTOPATHOL, V44, P61, DOI 10.1146/annurev.phyto.44.070505.143334
   Rao ALN, 1996, VIROLOGY, V226, P294, DOI 10.1006/viro.1996.0657
   RAO ALN, 1995, VIROLOGY, V211, P42, DOI 10.1006/viro.1995.1377
   Reade R, 2010, VIROLOGY, V403, P181, DOI 10.1016/j.virol.2010.03.045
   Reddy DVR, 2009, ADV VIRUS RES, V75, P185, DOI 10.1016/S0065-3527(09)07506-X
   Reichert VL, 2007, VIROLOGY, V364, P214, DOI 10.1016/j.virol.2007.02.026
   SACHER R, 1989, J VIROL, V63, P4545
   Sapsford KE, 2006, BIOSENS BIOELECTRON, V21, P1668, DOI 10.1016/j.bios.2005.09.003
   Sharma P, 2009, VIRUS RES, V144, P145, DOI 10.1016/j.virusres.2009.04.019
   Shenton W, 1999, ADV MATER, V11, P253, DOI 10.1002/(SICI)1521-4095(199903)11:3<253::AID-ADMA253>3.3.CO;2-Z
   SHEPPARD SL, 1980, J VIROL, V34, P266
   Shimoike T, 1999, J VIROL, V73, P9718
   Sivakumaran K, 2000, MOL PLANT PATHOL, V1, P337, DOI 10.1046/j.1364-3703.2000.00037.x
   Sivakumaran K, 2004, J VIROL, V78, P6091, DOI 10.1128/JVI.78.12.6091-6101.2004
   Speir JA, 2006, J VIROL, V80, P3582, DOI 10.1128/JVI.80.7.3582-3591.2006
   Steinmetz NF, 2009, CURR TOP MICROBIOL, V327, P23
   Steinmetz NF, 2009, J AM CHEM SOC, V131, P17093, DOI 10.1021/ja902293w
   Suci PA, 2007, LANGMUIR, V23, P12280, DOI 10.1021/la7021424
   Sudarshana Mysore R, 2007, Methods Mol Biol, V354, P183
   Sullivan ML, 1999, J VIROL, V73, P2622
   Sun J, 2007, P NATL ACAD SCI USA, V104, P1354, DOI 10.1073/pnas.0610542104
   Takeda A, 2004, J GEN VIROL, V85, P1751, DOI 10.1099/vir.0.79976-0
   Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x                                                
   VANDERGRAAF M, 1991, J MOL BIOL, V220, P701, DOI 10.1016/0022-2836(91)90111-I
   VERDUIN BJM, 1969, VIROLOGY, V37, P501, DOI 10.1016/0042-6822(69)90240-2
   Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555
   VRIEND G, 1981, FEBS LETT, V134, P167, DOI 10.1016/0014-5793(81)80593-5                                                    
   VRIEND G, 1982, FEBS LETT, V145, P49, DOI 10.1016/0014-5793(82)81204-0                                                    
   VRIEND G, 1986, J MOL BIOL, V191, P453, DOI 10.1016/0022-2836(86)90140-3
   VRIEND G, 1982, FEBS LETT, V146, P319, DOI 10.1016/0014-5793(82)80943-5
   Wang Q, 2002, CHEM BIOL, V9, P813, DOI 10.1016/S1074-5521(02)00166-7
   WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134
   WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185, DOI 10.1016/S0079-6603(08)60842-9
   Yi GG, 2008, J VIROL, V82, P3045, DOI 10.1128/JVI.02390-07
   Yi GH, 2007, J VIROL, V81, P1601, DOI 10.1128/JVI.01991-06
   Yi GH, 2009, J MOL BIOL, V391, P314, DOI 10.1016/j.jmb.2009.05.065
   Yi G, 2009, RNA, V15, P615, DOI 10.1261/rna.1375509
   Young M, 2008, ANNU REV PHYTOPATHOL, V46, P361, DOI 10.1146/annurev.phyto.032508.131939
   YUSIBOV VM, 1995, VIROLOGY, V208, P405, DOI 10.1006/viro.1995.1168
   Zhu J, 2007, P NATL ACAD SCI USA, V104, P3129, DOI 10.1073/pnas.0611617104
NR 122
TC 19
Z9 19
U1 0
U2 21
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1464-6722
J9 MOL PLANT PATHOL
JI Mol. Plant Pathol.
PD MAY
PY 2011
VL 12
IS 4
BP 403
EP 412
DI 10.1111/j.1364-3703.2010.00678.x
PG 10
WC Plant Sciences
SC Plant Sciences
GA 745ET
UT WOS:000289149400009
PM 21453435
DA 2018-01-05
ER

PT J
AU Dubey, V
   Nahar, M
   Mishra, D
   Mishra, P
   Jain, NK
AF Dubey, Vaibhav
   Nahar, Manoj
   Mishra, Dinesh
   Mishra, Pradyumna
   Jain, N. K.
TI Surface structured liposomes for site specific delivery of an antiviral
   agent-indinavir
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Targeted drug delivery; liposomes; drug targeting; drug delivery
ID GALACTOSYLATED CATIONIC LIPOSOMES; POLY PROPYLENEIMINE DENDRIMER;
   MOLECULAR WEIGHT SOLUTES; ENHANCED CELLULAR UPTAKE; IN-VITRO; ALTERED
   PHARMACOKINETICS; MANNOSYLATED LIPOSOMES; TRANSDERMAL DELIVERY; PROTEASE
   INHIBITORS; TISSUE DISTRIBUTION
AB The present investigation was aimed at targeting indinavir, a protease inhibitor to cells of mononuclear phagocyte system (MPS) via mannosylated liposomes. beta-D-1-thiomannopyranoside residues were covalently coupled with dimyristoyl phosphatidylethanolamine (DMPE) to generate mannosylated-DMPE (Man-DMPE) conjugate which was further incorporated with disteroyl phosphatidyl choline and cholesterol to prepare mannosylated liposomes. The optimized mannosylated liposomes were nanometric in size (142 +/-+/- 2.8 nm) with optimum entrapment efficiency (88.7 +/-+/- 2.3%). Less than 20% cumulative drug release was observed from the prepared formulations in 24 h in phosphate buffer saline (pH 7.4). Cellular uptake studies performed on J774.A1 macrophage cell line via flow cytometric analysis depicted enhanced uptake of mannosylated liposomes as compared to plain liposomes. Annexin-V-fluorescein isothiocyanate/propidium iodide apoptosis assay delineated marginal cytotoxicity in macrophages from the developed formulation. Plasma and tissue distribution studies performed to assess the drug reach to macrophage rich regions depicted a significant level (P < 0.05) of indinavir in macrophage rich tissues like liver, spleen, and lungs from mannosylated liposomes as compared to plain liposomes and free drug. The conducted studies suggest the potential of indinavir loaded mannosylated liposomes for anti-human immunodeficiency virus therapy.
C1 [Dubey, Vaibhav; Nahar, Manoj; Mishra, Dinesh; Jain, N. K.] Dr Hari Singh Gour Vishwavidyalaya, Pharmaceut Res Lab, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
   [Mishra, Pradyumna] Bhopal Mem Hosp & Res Ctr, Bhopal, Madhya Pradesh, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Pharmaceut Res Lab, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
EM jnarendr@yahoo.co.in
OI Mishra, Pradyumna/0000-0002-0795-2819
FU Council of Scientific and Industrial Research (CSIR), New Delhi
FX One of the authors (Vaibhav Dubey) is grateful to Council of Scientific
   and Industrial Research (CSIR), New Delhi for providing financial
   assistance in the form of Senior Research Fellowship. The authors report
   no conflict of interest.
CR Aarnoutse RE, 2003, DRUGS, V63, P741, DOI 10.2165/00003495-200363080-00002
   Allen TM, 1998, MEDICAL APPLICATIONS OF LIPOSOMES, P297, DOI 10.1016/B978-044482917-7/50018-1
   AMIJI MM, 2006, EXPERT OPIN DRUG DEL, V3, P613
   Andrews L, 2000, INF DIS CLIN N AM, V14, P1
   Ashton PR, 1997, CHEM-EUR J, V3, P974, DOI 10.1002/chem.19970030620                                                        
   BARRATT G, 1986, BIOCHIM BIOPHYS ACTA, V862, P153, DOI 10.1016/0005-2736(86)90479-7
   Choi SU, 2008, J PHARM SCI-US, V97, P931, DOI 10.1002/jps.21020
   Dieleman JP, 1999, AIDS, V13, P473, DOI 10.1097/00002030-199903110-00005                                                
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dubey V, 2006, BIOMATERIALS, V27, P3491, DOI 10.1016/j.biomaterials.2006.01.060
   Dubey V, 2007, J CONTROL RELEASE, V123, P148, DOI 10.1016/j.jconrel.2007.08.005
   DUSSERRE N, 1995, AIDS, V9, P833, DOI 10.1097/00002030-199508000-00002
   Dutta T, 2007, BBA-GEN SUBJECTS, V1770, P681, DOI 10.1016/j.bbagen.2006.12.007
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   FIDLER IJ, 1985, J BIOL RESP MODIF, V4, P298
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   FURNISS BS, 1989, TXB ORGANIC CHEM PEA, P644
   GARCON N, 1988, IMMUNOLOGY, V64, P743
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   Garg M, 2006, J DRUG TARGET, V14, P1, DOI 10.1080/10611860500525370
   Garg M, 2008, EUR J PHARM SCI, V33, P271, DOI 10.1016/j.ejps.2007.12.006
   Garg M, 2007, EUR J PHARM BIOPHARM, V67, P76, DOI 10.1016/j.ejpb.2006.12.019
   Garg M, 2007, AAPS PHARMSCITECH, V8
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   HANSEN CB, 1995, BBA-BIOMEMBRANES, V1239, P133, DOI 10.1016/0005-2736(95)00138-S
   HERMAN EH, 1983, CANCER RES, V43, P5427
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Kawakami S, 2000, BBA-GEN SUBJECTS, V1524, P258, DOI 10.1016/S0304-4165(00)00163-X
   KIRPOTIN D, 1996, P AM ASSOC CANC RES, V37, P3186
   KLIBANOV AL, 1996, J LIPOSOME RES, V6, P195
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Lin JH, 1996, DRUG METAB DISPOS, V24, P1111
   LITZINGER DC, 1994, BBA-BIOMEMBRANES, V1190, P99, DOI 10.1016/0005-2736(94)90038-8
   LOPEZBERESTEIN G, 1987, J CLIN ONCOL, V5, P310, DOI 10.1200/JCO.1987.5.2.310                                                        
   LOPEZBERESTEIN G, 1984, CANCER RES, V44, P375
   MEHTA RT, 1987, ANTIMICROB AGENTS CH, V31, P1901, DOI 10.1128/AAC.31.12.1901                                                          
   Mishra D, 2008, EUR J PHARM SCI, V33, P424, DOI 10.1016/j.ejps.2008.01.015
   MULLER CD, 1989, BIOCHIM BIOPHYS ACTA, V986, P97, DOI 10.1016/0005-2736(89)90277-0
   Nahar M, 2010, J DRUG TARGET, V18, P93, DOI 10.3109/10611860903115290
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   PEREZSOLER R, 1989, CANCER TREAT REV, V16, P67, DOI 10.1016/0305-7372(89)90011-X                                                    
   POSTE G, 1982, CANCER RES, V42, P1412
   RAHMAN A, 1985, CANCER RES, V45, P796
   Reiter WJ, 1999, J UROLOGY, V161, P1082, DOI 10.1016/S0022-5347(01)61595-7                                                   
   ROBERT BV, 1972, BIOL STRUCTURE FUNCT, V2, P27
   Salahuddin S, 2007, J ANTIMICROB CHEMOTH, V59, P114, DOI 10.1093/jac/dkl436
   Sato A, 2007, BIOMATERIALS, V28, P1434, DOI 10.1016/j.biomaterials.2006.11.010
   SATO T, 1992, PROG LIPID RES, V31, P345, DOI 10.1016/0163-7827(92)90001-Y
   Schiffman SS, 1999, NUTRITION, V15, P767, DOI 10.1016/S0899-9007(99)00152-5
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   Shigeta K, 2007, J CONTROL RELEASE, V118, P262, DOI 10.1016/j.jconrel.2006.12.019
   Singh P, 2008, J PHARMACEUT BIOMED, V47, P248, DOI 10.1016/j.jpba.2008.01.001
   SORENSEN EN, 1977, ANAL BIOCHEM, V82, P376, DOI 10.1016/0003-2697(77)90175-0
   TOTEVA MM, 2007, J PHARM SCI, V97, P3810
   TREAT J, 1989, P353
   Vlahakis SR, 2003, J INFECT DIS, V188, P1455, DOI 10.1086/379738
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Williams GC, 1999, ADV DRUG DELIVER REV, V39, P211, DOI 10.1016/S0169-409X(99)00027-7                                                   
   YAMASHITA C, 1991, JPN J CANCER RES, V82, P569, DOI 10.1111/j.1349-7006.1991.tb01888.x                                              
   ZALIPSKY S, 1995, BIOCONJUGATE CHEM, V6, P705, DOI 10.1021/bc00036a008                                                             
NR 62
TC 2
Z9 3
U1 1
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PD MAY
PY 2011
VL 19
IS 4
BP 258
EP 269
DI 10.3109/1061186X.2010.499460
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 738VO
UT WOS:000288670900003
PM 20604740
DA 2018-01-05
ER

PT J
AU Baoum, AA
   Berkland, C
AF Baoum, Abdulgader A.
   Berkland, Cory
TI Calcium Condensation of DNA Complexed with Cell-Penetrating Peptides
   Offers Efficient, Noncytotoxic Gene Delivery
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Letter
DE gene delivery; plasmid DNA; cell-penetrating peptides; A549 cells;
   stability; nanoparticles; stability; cytotoxicity
ID LOW-MOLECULAR-WEIGHT; CARBOHYDRATE-CONTAINING POLYCATIONS; HIV-1 TAT
   PROTEIN; NONVIRAL VECTOR; TRANSFECTION; POLYETHYLENIMINE; SYSTEMS;
   POLY(ETHYLENIMINE); POLYMERIZATION; BIOMATERIALS
AB Drug delivery strategies using cell-penetrating peptides (CPPs) have been widely explored to improve the intracellular delivery of a large number of cargo molecules. Electrostatic complexation of plasmid DNA using CPPs has been less explored due to the relatively large complexes formed and the low levels of gene expression achieved when using these low-molecular-weight polycations as DNA condensing agents. Here, condensing nascent CPP polyplexes using CaCl2 produced small and stable nanoparticles leading to gene expression levels higher than observed for control polyethylenimine gene vectors. This simple formulation approach showed negligible cytotoxicity in A549 lung epithelial cells and maintained particle size and transfection efficiency even in the presence of serum. (C) 2010Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:1637-1642, 2011
C1 [Baoum, Abdulgader A.; Berkland, Cory] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.
   [Berkland, Cory] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66045 USA.
RP Berkland, C (reprint author), Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.
EM berkland@ku.edu
FU NCRR NIH HHS [P20 RR016443]; NIAMS NIH HHS [R03 AR054035]; NIGMS NIH HHS
   [T32 GM08359-11, T32 GM008359]
CR Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c
   Alexis F, 2006, ADV MATER, V18, P2174, DOI 10.1002/adma.200502173
   Brissault B, 2003, BIOCONJUGATE CHEM, V14, P581, DOI 10.1021/bc0200529
   Davis ME, 2002, CURR OPIN BIOTECH, V13, P128, DOI 10.1016/S0958-1669(02)00294-X
   De Smedt SC, 2000, PHARMACEUT RES, V17, P113, DOI 10.1023/A:1007548826495                                                         
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   Dufourcq J, 1998, FEBS LETT, V421, P7, DOI 10.1016/S0014-5793(97)01522-6                                                   
   Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
   Gebhart CL, 2001, J CONTROL RELEASE, V73, P401, DOI 10.1016/S0168-3659(01)00357-1
   Godbey WT, 2001, J CONTROL RELEASE, V72, P115, DOI 10.1016/S0168-3659(01)00267-X
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x
   Hwang SJ, 2001, BIOCONJUGATE CHEM, V12, P280, DOI 10.1021/bc0001084
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Jeong JH, 2001, J CONTROL RELEASE, V73, P391, DOI 10.1016/S0168-3659(01)00310-8                                                   
   Jones SW, 2005, BRIT J PHARMACOL, V145, P1093, DOI 10.1038/sj.bjp.0706279
   Lo SL, 2008, BIOMATERIALS, V29, P2408, DOI 10.1016/j.biomaterials.2008.01.031
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Ma Haiching, 2001, Current Pharmaceutical Biotechnology, V2, P1, DOI 10.2174/1389201013378770
   Mahato RI, 1999, ADV GENET, V41, P95, DOI 10.1016/S0065-2660(08)60152-2
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   McKenzie DL, 2000, BIOCONJUGATE CHEM, V11, P901, DOI 10.1021/bc000056i
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Oupicky D, 2002, J AM CHEM SOC, V124, P8, DOI 10.1021/ja016440n
   Papapostolou D, 2007, P NATL ACAD SCI USA, V104, P10853, DOI 10.1073/pnas.0700801104
   Perry HA, 2008, J FLUORESC, V18, P155, DOI 10.1007/s10895-007-0254-5
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   Reineke TM, 2003, BIOCONJUGATE CHEM, V14, P247, DOI 10.1021/bc025592k
   Reineke TM, 2003, BIOCONJUGATE CHEM, V14, P255, DOI 10.1021/bc025593c
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Saleh AF, 2010, J CONTROL RELEASE, V143, P233, DOI 10.1016/j.jconrel.2009.12.025
   Saleh AFA, 2008, BIOPOLYMERS, V89, P62, DOI 10.1002/bip.20854
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Sloots A, 2005, FEBS J, V272, P4221, DOI 10.1111/j.1742-4658.2005.04834.x
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Trehin R, 2004, PHARM RES, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3
   Trubetskoy VS, 1998, NUCLEIC ACIDS RES, V26, P4178, DOI 10.1093/nar/26.18.4178
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Woolfson DN, 2006, CURR OPIN CHEM BIOL, V10, P559, DOI 10.1016/j.cbpa.2006.09.019
   Zelikin AN, 2002, BIOCONJUGATE CHEM, V13, P548, DOI 10.1021/bc015553t
   Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874
   Zhang XP, 2009, MOL PHARMACEUT, V6, P836, DOI 10.1021/mp800121f
NR 48
TC 18
Z9 18
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD MAY
PY 2011
VL 100
IS 5
BP 1637
EP 1642
DI 10.1002/jps.22407
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 736TL
UT WOS:000288516900004
PM 21374602
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bronshtein, T
   Toledano, N
   Danino, D
   Pollack, S
   Machluf, M
AF Bronshtein, Tomer
   Toledano, Naama
   Danino, Dganit
   Pollack, Shimon
   Machluf, Marcelle
TI Cell derived liposomes expressing CCR5 as a new targeted drug-delivery
   system for HIV infected cells
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Liposome; Cell-derived; HIV; AIDS; CCR5; EDTA
ID VIRUS TYPE-1 ENVELOPE; CD4(+) T-LYMPHOCYTES; CLINICAL-APPLICATIONS;
   ALAMAR BLUE; RECEPTORS; NANOMEDICINES; CAVITATION; ANTIBODIES; FUSION;
   MICE
AB Anti-retroviral-therapies against HIV/AIDS focus on inhibiting viral growth and may slow AIDS progression, but not cure the disease. Here we describe an approach to treat HIV as a cellular pathology by targeting cell derived liposomes against HIV-infected cells. Cell-derived-liposomes were prepared from the cytoplasmatic membranes of cells expressing CCR5, the human receptor for gp120, that is found on the surface of virions and HIV-infected cells. The specific targeting and cytotoxicity of the cell-derived liposomes towards gp120-expressing cells were studied. Cell-derived liposomes exhibited unilamellar morphology and were found to be of 100-200 nm in diameter. Moreover, CCR5 that was expressed on the surface of the cell-derived liposomes was biologically active and correctly oriented. Cell-derived liposomes incubated with HIV-infected model cells exhibited significant and specific targeting to those gp120-expressing cells. To demonstrate the system efficacy, EDTA was selected as liposomal encapsulate and was shown to cause high cytotoxic effect when introduced into the cell cytoplasm. Finally, cell-derived liposomes containing EDTA led to a 60% reduction in the viability of gp120-expressing cells compared to no effect on control cells that do not express gp120. These results demonstrate the specific targeting and cytotoxic effect of CCR5-conjugated cell-derived liposomes towards gp120-expressing HIV model cells, suggesting for a potential new therapeutic approach. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Bronshtein, Tomer; Toledano, Naama; Danino, Dganit; Machluf, Marcelle] Technion Israel Inst Technol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel.
   [Pollack, Shimon] Technion Israel Inst Technol, Rappaport Fac Med, Dept Immunol, IL-32000 Haifa, Israel.
   [Pollack, Shimon] Immunol Allergy & AIDS Inst, Haifa, Israel.
RP Machluf, M (reprint author), Technion Israel Inst Technol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel.
EM machlufm@tx.technion.ac.il
RI Danino, Dganit/D-6832-2016; Toledano Furman, Naama/N-1854-2016
OI Danino, Dganit/0000-0002-9782-4940; Toledano Furman,
   Naama/0000-0002-2687-7068
CR AHMAD A, 1993, VIROLOGY, V192, P447, DOI 10.1006/viro.1993.1060
   AHMAD I, 1993, CANCER RES, V53, P1484
   Altmeyer R, 1999, VIROLOGY, V259, P314, DOI 10.1006/viro.1999.9780
   Anzinger JJ, 2006, VIRUS RES, V122, P183, DOI 10.1016/j.virusres.2006.06.006
   Binley JM, 2002, J VIROL, V76, P2606, DOI 10.1128/JVI.76.6.2606-2616.2002
   BOONE CW, 1969, J CELL BIOL, V41, P378, DOI 10.1083/jcb.41.2.378
   BUCHENOSMOND, 2004, HUMAN IMMUNODEFICIEN
   Cevc G, 1996, CRIT REV THER DRUG, V13, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30                                  
   Danino D, 2004, J STRUCT BIOL, V147, P259, DOI 10.1016/j.jsb.2004.04.005
   De Clercq E, 2005, MINI-REV MED CHEM, V5, P805, DOI 10.2174/1389557054867075
   Devesa F, 2002, EUR J BIOCHEM, V269, P5163, DOI 10.1046/j.1432-1033.2002.03213.x
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   DOULAH MS, 1977, BIOTECHNOL BIOENG, V19, P649, DOI 10.1002/bit.260190504
   Fenske DB, 2008, TOXICOL PATHOL, V36, P21, DOI 10.1177/0192623307310960
   Fenske DB, 2008, EXPERT OPIN DRUG DEL, V5, P25, DOI 10.1517/17425247.5.1.25
   Flora SJS, 2008, INDIAN J MED RES, V128, P501
   Gonzalez RJ, 2001, TOXICOL IN VITRO, V15, P257, DOI 10.1016/S0887-2333(01)00014-5
   Hattori Y, 2000, J CONTROL RELEASE, V69, P369, DOI 10.1016/S0168-3659(00)00338-2
   HEINKELEIN M, 1995, J VIROL, V69, P6925
   Ho CW, 2006, PROCESS BIOCHEM, V41, P1829, DOI 10.1016/j.procbio.2006.03.043
   Hofheinz RD, 2005, ANTI-CANCER DRUG, V16, P691, DOI 10.1097/01.cad.0000167902.53039.5a
   HUGENSCHMIDT S, 1993, ARCH TOXICOL, V67, P76, DOI 10.1007/BF02072040
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4
   Lentz BR, 2007, EUR BIOPHYS J BIOPHY, V36, P315, DOI 10.1007/s00249-006-0097-z
   Mirzabekov T, 2000, NAT BIOTECHNOL, V18, P649, DOI 10.1038/76501                                                                   
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745                                                        
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Patil Siddhesh D, 2004, AAPS J, V6, pe29
   Piguet V, 2001, SEMIN IMMUNOL, V13, P51, DOI 10.1006/smim.2000.0295
   Rambaut A, 2004, NAT REV GENET, V5, P52, DOI 10.1038/nrg1246
   REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G                                                    
   Requena M, 2008, IMMUNOLOGY, V123, P508, DOI 10.1111/j.1365-2567.2007.02717.x
   Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004
   SCHACKER T, 1994, J INFECT DIS, V169, P37, DOI 10.1093/infdis/169.1.37                                                         
   SCHOMBURG D, 2009, BRENDA COMPREHENSIVE
   Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004
   Sundaram J, 2003, BIOPHYS J, V84, P3087, DOI 10.1016/S0006-3495(03)70034-4                                                   
   Tang H, 2002, PHARMACEUT RES, V19, P1160, DOI 10.1023/A:1019898109793
   U.S National Library of Medicine, 2009, CHEMIDPLUS ADV
   Westerman LE, 2000, J IMMUNOTHER, V23, P456, DOI 10.1097/00002371-200007000-00009
   WOLFRUM B, 2003, ULTR 2003 IEEE S, V831, P837
   Yallop CA, 2001, CYTOTECHNOLOGY, V35, P101, DOI 10.1023/A:1017550902771
   Yang ZY, 2004, J VIROL, V78, P4029, DOI 10.1128/JVI.78.8.4029-4036.2004
NR 44
TC 17
Z9 17
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD APR 30
PY 2011
VL 151
IS 2
BP 139
EP 148
DI 10.1016/j.jconrel.2011.02.023
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 780HR
UT WOS:000291845600006
PM 21362450
DA 2018-01-05
ER

PT J
AU Rotili, D
   Tarantino, D
   Artico, M
   Nawrozkij, MB
   Gonzalez-Ortega, E
   Clotet, B
   Samuele, A
   Este, JA
   Maga, G
   Mai, A
AF Rotili, Dante
   Tarantino, Domenico
   Artico, Marino
   Nawrozkij, Maxim B.
   Gonzalez-Ortega, Emmanuel
   Clotet, Bonaventura
   Samuele, Alberta
   Este, Jose A.
   Maga, Giovanni
   Mai, Antonello
TI Diarylpyrimidine-Dihydrobenzyloxopyrimidine Hybrids: New, Wide-Spectrum
   Anti-HIV-1 Agents Active at (Sub)-Nanomolar Level
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; STRUCTURE-BASED DESIGN; ANTI-HIV DRUG;
   ANTIRETROVIRAL THERAPY; ENTRY INHIBITORS; HIGHLY POTENT; WILD-TYPE;
   IN-VITRO; RESISTANCE; MUTANTS
AB Here, we describe a novel small series of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that combine peculiar structural features of diarylpyrimidines (DAPYs) and dihydro-alkoxy-benzyl-oxopyrimidines. (DABOs). These DAPY-DABO hybrids (1-4) showed a, characteristic SAR profile and a nanomolar anti-HIV-1 activity at both enzymatic and cellular level. In particular, the two compounds 4d and 2d, with a (sub)nano molar activity against wild-type and clinically relevant HIV-1 mutant strains, were selected, as lead compounds for next optimization studies.
C1 [Gonzalez-Ortega, Emmanuel; Clotet, Bonaventura; Este, Jose A.] Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab IrsiCaixa, Badalona 08916, Spain.
   [Rotili, Dante; Tarantino, Domenico; Artico, Marino; Mai, Antonello] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy.
   [Nawrozkij, Maxim B.] Volgograd State Tech Univ, Volgograd 400131, Russia.
   [Samuele, Alberta; Maga, Giovanni] CNR, Ist Genet Mol IGM, I-27100 Pavia, Italy.
RP Este, JA (reprint author), Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab IrsiCaixa, Badalona 08916, Spain.
EM iaeste@irsicaixa.es; maga@igm.cnr.it; antonello.mai@uniroma1.it
RI Nawrozkij, Maxim/N-6646-2015; Este, Jose/B-5509-2008; Rotili,
   Dante/J-9157-2016
OI Nawrozkij, Maxim/0000-0001-5432-1326; Este, Jose/0000-0002-1436-5823;
   Rotili, Dante/0000-0002-8428-8763; Mai, Antonello/0000-0001-9176-2382
FU Spanish Ministry of Science [BFU2009-06958, SAF2010-21617-C02-00];
   Italian National AIDS Program [40H26]
FX This work was partially supported by grants from the Spanish Ministry of
   Science (projects BFU2009-06958 and SAF2010-21617-C02-00) and by the
   Italian National AIDS Program ISS Grant 40H26.
CR Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   CAACIO R, 2007, CHEMMEDCHEM, V2, P445
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   de Bethune MP, 2010, ANTIVIR RES, V85, P75, DOI 10.1016/j.antiviral.2009.09.008
   Este JA, 2007, LANCET, V370, P81, DOI 10.1016/S0140-6736(07)61052-6
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Gonzalez-Ortega E, 2010, ANTIMICROB AGENTS CH, V54, P4487, DOI 10.1128/AAC.00359-10
   GUILLEMONTI, 2005, J MED CHEM, V48, P2072
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Johnson LB, 2009, CLIN INFECT DIS, V48, P1123, DOI 10.1086/597469
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Mai A, 2007, J MED CHEM, V50, P5412, DOI 10.1021/jm070811e
   McColl DJ, 2010, ANTIVIR RES, V85, P101, DOI 10.1016/j.antiviral.2009.11.004
   Moncunill G, 2008, AIDS, V22, P23, DOI 10.1097/QAD.0b013e3282f303e6                                                    
   Moncunill G, 2008, MOL PHARMACOL, V73, P1264, DOI 10.1124/mol.107.042911
   Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061
   Mugnaini C, 2007, J MED CHEM, V50, P6580, DOI 10.1021/jm0708230
   Nawrozkij MB, 2008, J MED CHEM, V51, P4641, DOI 10.1021/jm800340w
   Ragno R, 2004, J MED CHEM, V47, P928, DOI 10.1021/jm0309856
   Samuele A, 2008, CHEMMEDCHEM, V3, P1412, DOI 10.1002/cmdc.200800051
   Tavares FX, 2004, J MED CHEM, V47, P4716, DOI 10.1021/jm040063i
   Tilton JC, 2010, ANTIVIR RES, V85, P91, DOI 10.1016/j.antiviral.2009.07.022
   Wensing AMJ, 2010, ANTIVIR RES, V85, P59, DOI 10.1016/j.antiviral.2009.10.003
   *WHO UNAIDS, 2009, AIDS EP UPD
NR 30
TC 35
Z9 37
U1 1
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 28
PY 2011
VL 54
IS 8
BP 3091
EP 3096
DI 10.1021/jm101626c
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 752ND
UT WOS:000289697800043
PM 21438533
DA 2018-01-05
ER

PT J
AU Makatini, MM
   Petzold, K
   Sriharsha, SN
   Soliman, MES
   Honarparvar, B
   Arvidsson, PI
   Sayed, Y
   Govender, P
   Maguire, GEM
   Kruger, HG
   Govender, T
AF Makatini, Maya M.
   Petzold, Katja
   Sriharsha, Shimoga N.
   Soliman, Mahmoud E. S.
   Honarparvar, Bahareh
   Arvidsson, Per I.
   Sayed, Yasien
   Govender, Patrick
   Maguire, Glenn E. M.
   Kruger, Hendrik G.
   Govender, Thavendran
TI Pentacycloundecane-based inhibitors of wild-type C-South African
   HIV-protease
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Pentacycloundecane peptides; HIV-protease inhibitor; EASY-ROESY;
   Inhibitory concentration (IC50); Molecular docking
ID BIOLOGICALLY-ACTIVE POLYCYCLOALKANES; POLYCYCLIC CAGE COMPOUNDS;
   MEDICINAL AGENTS; ADAMANTYL GROUP; DRUG DISCOVERY; DERIVATIVES; ANALOGS;
   DESIGN
AB In this study, we present the first account of pentacycloundecane (PCU) peptide based HIV-protease inhibitors. The inhibitor exhibiting the highest activity made use of a natural HIV-protease substrate peptide sequence, that is, attached to the cage (PCU-EAIS). This compound showed nanomolar IC50 activity against the resistance-prone wild type C-South African HIV-protease (C-SA) catalytic site via a norstatine type functional group of the PCU hydroxy lactam. NMR was employed to determine a logical correlation between the inhibitory concentration (IC50) results and the 3D structure of the corresponding inhibitors in solution. NMR investigations indicated that the activity is related to the chirality of the PCU moiety and its ability to induce conformations of the coupled peptide side chain. The results from docking experiments coincided with the experimental observed activities. These findings open up useful applications for this family of cage peptide inhibitors, considering the vast number of alternative disease related proteases that exist. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Petzold, Katja; Sriharsha, Shimoga N.; Honarparvar, Bahareh; Maguire, Glenn E. M.; Kruger, Hendrik G.] Univ KwaZulu Natal, Sch Chem, ZA-4001 Durban, South Africa.
   [Makatini, Maya M.; Arvidsson, Per I.; Govender, Thavendran] Univ KwaZulu Natal, Sch Pharm & Pharmacol, ZA-4001 Durban, South Africa.
   [Soliman, Mahmoud E. S.] Zagazig Univ, Fac Pharm, Dept Organ Pharmaceut Chem, Zagazig 44519, Egypt.
   [Arvidsson, Per I.] Uppsala Univ, Uppsala Biomed Ctr, Dept Med Chem, SE-75123 Uppsala, Sweden.
   [Arvidsson, Per I.] AstraZeneca R&D Sodertalje, CNSP iMed, Innovat Med, S-15185 Sodertalje, Sweden.
   [Sayed, Yasien] Univ Witwatersrand, Sch Mol & Cell Biol, ZA-2050 Wits, South Africa.
   [Govender, Patrick] Univ KwaZulu Natal, Sch Biochem, ZA-4001 Durban, South Africa.
RP Kruger, HG (reprint author), Univ KwaZulu Natal, Sch Chem, ZA-4001 Durban, South Africa.
EM kruger@ukzn.ac.za; govenderthav@ukzn.ac.za
RI Petzold, Katja/E-9816-2011; Govender, Thavendran/H-6838-2013; Arvidsson,
   Per/N-4864-2013; Maguire, Glenn/C-5591-2013; Petzold, Katja/M-7298-2015;
   Govender, Patrick/I-6795-2012; Kruger, Gert/B-1687-2009
OI Petzold, Katja/0000-0001-9470-0347; Govender,
   Thavendran/0000-0003-2511-2503; Arvidsson, Per/0000-0002-9453-6812;
   Maguire, Glenn/0000-0002-9135-5370; Petzold, Katja/0000-0001-9470-0347;
   Govender, Patrick/0000-0002-9131-590X; Kruger, Gert/0000-0003-0606-2053;
   Soliman, Mahmoud/0000-0002-8711-7783
FU NRF (SA) [66319, 69728]
FX This research was supported by NRF (SA) T. G. (GUN: 66319), K. P. (GUN:
   69728), H. G. K. and P. I. A. (SA-Sweden bilateral grant) and Aspen
   Pharmacare. The authors thank Prof. Jurgen Schleucher and Mr. Dilip
   Jagjivan for their assistance with the NMR experiments.
CR Acosta EP, 2000, CLIN INFECT DIS, V30, pS151, DOI 10.1086/313852                                                                  
   AIGAMI K, 1976, J MED CHEM, V19, P536, DOI 10.1021/jm00226a018
   Bisetty K, 2006, J PEPT SCI, V12, P92, DOI 10.1002/psc.692
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   BROOKES KB, 1992, S AFR J CHEM-S-AFR T, V45, P8
   Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t
   Geldenhuys WJ, 2005, MED RES REV, V25, P21, DOI 10.1002/med.20013                                                               
   GERZON K, 1967, J MED CHEM, V10, P189, DOI 10.1021/jm00314a014
   Grobler E, 2006, BIOORGAN MED CHEM, V14, P1176, DOI 10.1016/j.bmc.2005.09.042
   INAMOTO Y, 1977, J MED CHEM, V20, P1371, DOI 10.1021/jm00221a003
   Ito FM, 2007, MOLECULES, V12, P271, DOI 10.3390/12020271                                                                
   James B, 2007, TETRAHEDRON LETT, V48, P6204, DOI 10.1016/j.tetlet.2007.06.125
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   Kruger HG, 2006, J MOL STRUC-THEOCHEM, V771, P165, DOI 10.1016/j.theochem.2006.03.037
   Kruger HG, 2004, J ORG CHEM, V69, P4863, DOI 10.1021/jo0357723
   Lee J, 2010, ANTIVIR RES, V85, P425, DOI 10.1016/j.antiviral.2009.11.002
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   Malan SF, 1998, PHARMAZIE, V53, P859
   MARCHAND AP, 1974, J ORG CHEM, V39, P1596, DOI 10.1021/jo00924a037                                                             
   Marchand A. P., 1989, ADV THEORETICALLY IN, V1, P357
   Foye W. O., 1989, PRINCIPLES MED CHEM, P223
   Oliver DW, 2008, MED CHEM RES, V17, P137, DOI 10.1007/s00044-007-9044-5
   OLIVER DW, 1991, ARZNEIMITTEL-FORSCH, V41-1, P549
   OLIVER DW, 1991, J MED CHEM, V34, P851, DOI 10.1021/jm00106a053
   Onajole OK, 2010, EUR J MED CHEM, V45, P2075, DOI 10.1016/j.ejmech.2010.01.046
   RAPALA RT, 1965, J MED CHEM, V8, P580, DOI 10.1021/jm00329a007
   Rodriguez-Barrios F, 2004, CURR TOP MED CHEM, V4, P991, DOI 10.2174/1568026043388529
   SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168
   Thiele CM, 2009, CHEM-EUR J, V15, P585, DOI 10.1002/chem.200802027
   TSUZUKI N, 1994, J PHARM SCI, V83, P481, DOI 10.1002/jps.2600830407
   Velaquez-Campoy Adrian, 2003, AIDS Reviews, V5, P165
   VOLDENG AN, 1968, J PHARM SCI, V57, P1053, DOI 10.1002/jps.2600570638
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Zhang XQ, 1999, J INFECT DIS, V180, P1833, DOI 10.1086/315123
NR 34
TC 31
Z9 31
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 15
PY 2011
VL 21
IS 8
BP 2274
EP 2277
DI 10.1016/j.bmcl.2011.02.105
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 744DP
UT WOS:000289074700020
PM 21429747
DA 2018-01-05
ER

PT J
AU Tang, J
   Maddali, K
   Dreis, CD
   Sham, YY
   Vince, R
   Pommier, Y
   Wang, ZQ
AF Tang, Jing
   Maddali, Kasthuraiah
   Dreis, Christine D.
   Sham, Yuk Y.
   Vince, Robert
   Pommier, Yves
   Wang, Zhengqiang
TI 6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV
   reverse transcriptase and integrase
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; 6-Benzoyl-3-hydroxypyrimidine-2,4-diones; Dual inhibitors; Reverse
   transcriptase; Integrase
ID NONNUCLEOSIDE INHIBITORS; ANTIRETROVIRAL THERAPY; PHARMACOPHORE MODEL;
   ANTI-HIV-1 ACTIVITY; DESIGN; PYRIMIDINEDIONES; STRATEGIES; ADHERENCE;
   ANALOGS; UPDATE
AB N-3-Hydroxylation of pyrimidine-2,4-diones was recently found to yield inhibitors of both HIV-1 reverse transcriptase (RT) and integrase (IN). An extended series of analogues featuring a benzoyl group at the C-6 position of the pyrimidine ring was synthesized. Through biochemical studies it was found that these new analogues are dually active against both RT and IN in low micromolar range. Antiviral assays confirmed that these new inhibitors are active against HIV-1 in cell culture at nanomolar to low micromolar range, further validating 3-hydroxypyrimidine-2,4-diones as a viable scaffold for antiviral development. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Tang, Jing; Dreis, Christine D.; Sham, Yuk Y.; Vince, Robert; Wang, Zhengqiang] Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN 55455 USA.
   [Maddali, Kasthuraiah; Pommier, Yves] NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.
RP Wang, ZQ (reprint author), Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, 516 Delaware St SE, Minneapolis, MN 55455 USA.
EM wangx472@umn.edu
RI Sham, Yuk/A-6472-2011
OI Sham, Yuk/0000-0003-2601-8930
FU Center for Drug Design at the University of Minnesota; Center for Cancer
   Research, National Cancer Institute, NIH; NIH-IATAP
FX This research was supported by the Center for Drug Design at the
   University of Minnesota, by the Center for Cancer Research, National
   Cancer Institute, NIH, and by an NIH-IATAP grant to Y. P. and K. M. We
   thank Roger Ptak at Southern Research Institute for antiviral assays and
   the Minnesota Supercomputing Institute for modeling resources.
CR Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Barreiro Pablo, 2002, AIDS Reviews, V4, P233
   Berkley S, 2010, NAT MED, V16, P981, DOI 10.1038/nm0910-981
   Buckheit Robert W. Jr., 2007, Antiviral Chemistry & Chemotherapy, V18, P259
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773                                                      
   Dayam R, 2005, J MED CHEM, V48, P111, DOI 10.1021/jm0496077
   De Luca L, 2008, BIOORG MED CHEM LETT, V18, P2891, DOI 10.1016/j.bmcl.2008.03.089
   Friesner R.A., 2004, J MED CHEM, V47, P1139
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Ji L, 2007, J MED CHEM, V50, P1778, DOI 10.1021/jm061167r
   Ji L, 2007, EUR J MED CHEM, V42, P198, DOI 10.1016/j.ejmech.2006.09.018
   Ji L, 2006, CHEM PHARM BULL, V54, P1248, DOI 10.1248/cpb.54.1248
   Katende-Kyenda NL, 2008, J CLIN PHARM THER, V33, P393, DOI 10.1111/j.1365-2710.2008.00930.x
   Loksha YM, 2009, ARCH PHARM, V342, P501, DOI 10.1002/ardp.200900058
   Mitchell ML, 2010, BIOORG MED CHEM LETT, V20, P1589, DOI 10.1016/j.bmcl.2010.01.085
   Mitchell ML, 2010, BIOORG MED CHEM LETT, V20, P1585, DOI 10.1016/j.bmcl.2010.01.086
   Mustata GL, 2004, BIOORG MED CHEM LETT, V14, P1447, DOI 10.1016/j.bmcl.2004.01.027
   Negredo E, 2006, J ANTIMICROB CHEMOTH, V58, P235, DOI 10.1093/jac/dkl191
   Piacenti FJ, 2006, PHARMACOTHERAPY, V26, P1111, DOI 10.1592/phco.26.8.1111
   Stone VE, 2001, CLIN INFECT DIS, V33, P865, DOI 10.1086/322698                                                                  
   Tang J, 2011, ACS MED CHEM LETT, V2, P63, DOI 10.1021/ml1002162
   Tang J, 2010, BIOORG MED CHEM LETT, V20, P3275, DOI 10.1016/j.bmcl.2010.04.048
   Titti F, 2007, EXPERT OPIN EMERG DR, V12, P23, DOI 10.1517/14728214.12.1.23
   Wang Z, 2008, BIOORGAN MED CHEM, V16, P3587, DOI 10.1016/j.bmc.2008.02.007
   Wang ZQ, 2008, BIOORG MED CHEM LETT, V18, P1293, DOI 10.1016/j.bmcl.2008.01.025
   Wang ZQ, 2007, J MED CHEM, V50, P3416, DOI 10.1021/jm070512p
   Wang ZQ, 2010, BIOORGAN MED CHEM, V18, P4202, DOI 10.1016/j.bmc.2010.05.004
   Yeni P, 2006, J HEPATOL, V44, pS100, DOI 10.1016/j.jhep.2005.11.021
NR 29
TC 19
Z9 22
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 15
PY 2011
VL 21
IS 8
BP 2400
EP 2402
DI 10.1016/j.bmcl.2011.02.069
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 744DP
UT WOS:000289074700047
PM 21392991
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kovochich, M
   Marsden, MD
   Zack, JA
AF Kovochich, Michael
   Marsden, Matthew D.
   Zack, Jerome A.
TI Activation of Latent HIV Using Drug-Loaded Nanoparticles
SO PLOS ONE
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNODEFICIENCY-VIRUS TYPE-1;
   NON-HODGKINS-LYMPHOMA; CELLS-IN-VITRO; BRYOSTATIN 1; PHASE-II; T-CELLS;
   HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; LIPOSOMES
AB Antiretroviral therapy is currently only capable of controlling HIV replication rather than completely eradicating virus from patients. This is due in part to the establishment of a latent virus reservoir in resting CD4(+) T cells, which persists even in the presence of HAART. It is thought that forced activation of latently infected cells could induce virus production, allowing targeting of the cell by the immune response. A variety of molecules are able to stimulate HIV from latency. However no tested purging strategy has proven capable of eliminating the infection completely or preventing viral rebound if therapy is stopped. Hence novel latency activation approaches are required. Nanoparticles can offer several advantages over more traditional drug delivery methods, including improved drug solubility, stability, and the ability to simultaneously target multiple different molecules to particular cell or tissue types. Here we describe the development of a novel lipid nanoparticle with the protein kinase C activator bryostatin-2 incorporated (LNP-Bry). These particles can target and activate primary human CD4(+) T-cells and stimulate latent virus production from human T-cell lines in vitro and from latently infected cells in a humanized mouse model ex vivo. This activation was synergistically enhanced by the HDAC inhibitor sodium butyrate. Furthermore, LNP-Bry can also be loaded with the protease inhibitor nelfinavir (LNP-Bry-Nel), producing a particle capable of both activating latent virus and inhibiting viral spread. Taken together these data demonstrate the ability of nanotechnological approaches to provide improved methods for activating latent HIV and provide key proof-of-principle experiments showing how novel delivery systems may enhance future HIV therapy.
C1 [Kovochich, Michael; Zack, Jerome A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Marsden, Matthew D.; Zack, Jerome A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
RP Kovochich, M (reprint author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
EM jzack@ucla.edu
FU NIH [AI070010]
FX This work was supported by NIH grant AI070010 and by the UCLA CFAR. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arlen PA, 2006, J VIROL, V80, P1599, DOI 10.1128/JVI.80.3.1599-1603.2006
   Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Brooks DG, 2002, J VIROL, V76, P1673, DOI 10.1128/JVI.76.4.1673-1681.2002
   Brooks DG, 2001, NAT MED, V7, P459, DOI 10.1038/86531
   Brooks DG, 2003, P NATL ACAD SCI USA, V100, P12955, DOI 10.1073/pnas.1133345100
   Brooks DG, 2003, IMMUNITY, V19, P413, DOI 10.1016/S1074-7613(03)00236-X                                                   
   CAGDAS FM, PHARM DEV TECHNOL
   Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002
   Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J
   FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729
   GABIZON A, 1994, CANCER RES, V54, P987
   GABIZON A, 1994, ACTA ONCOL, V33, P779, DOI 10.3109/02841869409083948                                                       
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005
   HANSEN CB, 1995, BBA-BIOMEMBRANES, V1239, P133, DOI 10.1016/0005-2736(95)00138-S
   JONES HW, 1971, OBSTET GYNECOL, V38, P945
   Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188
   Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI [10.1080/10611860802475688, 10.1080/10611860802475688 ]
   Korin YD, 2002, J VIROL, V76, P8118, DOI 10.1128/JVI.76.16.8118-8123.2002
   LAUGHLIN MA, 1993, VIROLOGY, V196, P496, DOI 10.1006/viro.1993.1505
   Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5
   Levchenko TS, 2002, INT J PHARM, V240, P95, DOI 10.1016/S0378-5173(02)00129-1
   Lindkvist Annica, 2009, AIDS Res Ther, V6, P15, DOI 10.1186/1742-6405-6-15
   MEHLA R, PLOS ONE, V5
   Mohammad RM, 1998, CLIN CANCER RES, V4, P445
   Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4
   Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5
   PEREZ M, CURR HIV RES
   PETROS RA, NAT REV DRUG DISCOV, V9, P615
   Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96
   Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012
   Propper DJ, 1998, BRIT J CANCER, V78, P1337, DOI 10.1038/bjc.1998.680
   QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674
   Reuse S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006093
   Scripture-Adams DD, 2002, J VIROL, V76, P13077, DOI 10.1128/JVI.76.24.13077-13082.2002
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Van Praag RME, 2001, J CLIN IMMUNOL, V21, P218, DOI 10.1023/A:1011091300321
   Varterasian ML, 2000, CLIN CANCER RES, V6, P825
   Varterasian ML, 2001, INVEST NEW DRUG, V19, P245, DOI 10.1023/A:1010676719178
   Varterasian ML, 1998, J CLIN ONCOL, V16, P56, DOI 10.1200/JCO.1998.16.1.56                                                        
   VLACH J, 1992, VIROLOGY, V187, P63, DOI 10.1016/0042-6822(92)90295-Z
   Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006/1211
   Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400
NR 49
TC 40
Z9 41
U1 3
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2011
VL 6
IS 4
AR e18270
DI 10.1371/journal.pone.0018270
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 745UD
UT WOS:000289191300015
PM 21483687
OA gold
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Nanoparticle shows promise for the delivery of vaccines for HIV, malaria
   and other infectious diseases
SO NANOMEDICINE
LA English
DT News Item
CR Moon JJ, 2011, NAT MATER, V10, P243, DOI [10.1038/nmat2960, 10.1038/NMAT2960]
NR 1
TC 0
Z9 0
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD APR
PY 2011
VL 6
IS 3
BP 416
EP 416
PG 1
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 764AW
UT WOS:000290601800004
DA 2018-01-05
ER

PT J
AU Shegokar, R
   Singh, KK
AF Shegokar, R.
   Singh, K. K.
TI Stavudine entrapped lipid nanoparticles for targeting lymphatic HIV
   reservoirs
SO PHARMAZIE
LA English
DT Article
ID DRUG-DELIVERY; CYANOACRYLATE NANOPARTICLES; BODY DISTRIBUTION;
   MACROPHAGES; BIODISTRIBUTION; LIPOSOMES; SYSTEMS
AB The main objective of present research study was to evaluate the potential of lipid nanoparticles for active delivery of an antiretroviral drug to lymphatic tissues. Stavudine entrapped drug loaded solid lipid nanoparticles (SLNs) were prepared and characterized for a variety of physicochemical parameters such as appearance, particle size, polydispersity index and zeta potential. The targeting potential of the prepared nanoparticles was investigated by carrying out ex vivo cellular uptake studies in macrophages which depicted several times enhanced uptake as compared to pure drug solution. Further, the lymphatic drug levels and organ distribution studies demonstrated efficiency of the developed nanoparticles for prolonged residence in spleenic tissues. Thus it was concluded that stavudine entrapped lipid carriers can be exploited for effective and targeted delivery to cellular and anatomical HIV reservoirs and may ultimately increase the therapeutic safety and reduce side effects.
C1 [Shegokar, R.; Singh, K. K.] SNDT Womens Univ, CU Shah Coll Pharm, Bombay, Maharashtra, India.
   [Shegokar, R.] Free Univ Berlin, Dept Pharmaceut, Inst Pharm Biopharmaceut & NutriCosmet, D-1000 Berlin, Germany.
RP Singh, KK (reprint author), SNDT Womens Univ, CU Shah Coll Pharm, Bombay, Maharashtra, India.
EM kksingh35@rediffmail.com
FU AICTE (All India Council of Technical Education)
FX The authors would like to thank AICTE (All India Council of Technical
   Education) for financial support. Bombay Veterinary college for
   providing facility for carrying out Gammascintigraphy studies and PERD
   Centre for cellular uptake studies.
CR Al-Haj N, 2009, INT J PHARMACOL, V5, P90, DOI 10.3923/ijp.2009.90.93
   Amiji Mansoor M, 2006, Discov Med, V6, P157
   Banerjee T, 2002, INT J PHARM, V243, P93, DOI 10.1016/S0378-5173(02)00267-3
   DAEMEN T, 1992, RES IMMUNOL, V143, P211, DOI 10.1016/S0923-2494(92)80168-K
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Escobar Y, 2003, P W PHARMACOL SOC, V46, P109
   Ghosh PK, 2006, AAPS PHARMSCITECH, V7
   Gordon R, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-S1-S13
   GUIMARAES NN, 2010, EXPERT OPIN DRUG SAF
   Hou DZ, 2003, BIOMATERIALS, V24, P1781, DOI 10.1016/S0142-9612(02)00578-1
   Huang M, 2005, ACTA PHARMACOL SIN, V26, P1512, DOI 10.1111/j.1745-7254.2005.00216.x
   Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004
   Jayagopal A, 2008, IEEE T NANOBIOSCI, V7, P28, DOI 10.1109/TNB.2008.2000147
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Lanao JM, 2007, J DRUG TARGET, V15, P21, DOI 10.1080/10611860600942178
   Lecaroz C, 2006, J ANTIMICROB CHEMOTH, V58, P549, DOI 10.1093/jac/dkl257
   Lee CM, 2005, CANCER BIOTHER RADIO, V20, P620, DOI 10.1089/cbr.2005.20.620
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Nassimi Matthias, 2009, Inhal Toxicol, V21 Suppl 1, P104, DOI 10.1080/08958370903005769
   Patil RR, 2008, J BIOMED NANOTECHNOL, V4, P359, DOI 10.1166/jbn.2008.320
   RICHARDSON VJ, 1977, BIOCHEM SOC TRANS, V5, P190
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   Vyas SP, 2006, J PHARM PHARMACOL, V58, P321, DOI 10.1211/jpp.58.3.0005
   Vyas Tushar K, 2006, Expert Opin Drug Deliv, V3, P613, DOI 10.1517/17425247.3.5.613
   zur Muhlen A, 1998, EUR J PHARM BIOPHARM, V45, P149, DOI 10.1016/S0939-6411(97)00150-1                                                   
NR 29
TC 10
Z9 11
U1 0
U2 7
PU GOVI-VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD APR
PY 2011
VL 66
IS 4
BP 264
EP 271
DI 10.1691/ph.2011.0149
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 758SK
UT WOS:000290186500005
PM 21612153
DA 2018-01-05
ER

PT J
AU Simpson, ML
   Cummings, PT
AF Simpson, Michael L.
   Cummings, Peter T.
TI Fluctuations and Correlations in Physical and Biological Nanosystems:
   The Tale Is in the Tails
SO ACS NANO
LA English
DT Article
ID STOCHASTIC GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN
   EXPRESSION; GLOBAL ANALYSIS; SINGLE-CELL; NOISE; MEMBRANES; HIV-1;
   YEAST; INDIVIDUALITY
AB The inherently small system sizes Involved imply that, in the absence of large applied fields designed to overwhelm them, fluctuations will play a major role in determining the response and functionality of nanoscale systems. Theoretical advances over the past two decades have provided fresh insight into fluctuations and their role at the nanoscale, even in the presence of arbitrarily large applied external fields. In contrast to traditional engineered systems, Nature's approach to nanotechnology is to embrace and to exploit fluctuations and noise to create adaptable, persistent, optimized functional architectures. We describe some of the mechanisms by which Nature exploits noise, with the goal of applying these lessons to engineered physical and chemical nanosystems. In particular, we emphasize the critical role of the tails of distributions of properties In both physical and biological nanosystems and their impact On system behavior.
C1 [Simpson, Michael L.; Cummings, Peter T.] Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Oak Ridge, TN 37831 USA.
   [Simpson, Michael L.] Univ Tennessee, Dept Mat Sci & Engn, Knoxville, TN 37996 USA.
   [Cummings, Peter T.] Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA.
RP Simpson, ML (reprint author), Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Oak Ridge, TN 37831 USA.
EM simpsonml1@ornl.gov; peter.cummings@vanderbilt.edu
RI Simpson, Michael/A-8410-2011; Cummings, Peter/B-8762-2013
OI Simpson, Michael/0000-0002-3933-3457; Cummings,
   Peter/0000-0002-9766-2216
FU Scientific User Facilities Division, Office of Basic Energy Sciences,
   Office of Science, Department of Energy
FX The authors acknowledge the support of this research, conducted in the
   Center for Nanophase Materials Sciences (CNMS) at Oak Ridge National
   Laboratory, by the Scientific User Facilities Division, Office of Basic
   Energy Sciences, Office of Science, Department of Energy. We also
   acknowledge our numerous conversations and collaborations with
   colleagues both within and outside the CNMS: Pat Collier, Chris Cox, Roy
   Dar, Mitch Doktycz, Denis Evans, Jason Fowlkes, Scott T. Retterer, Bobby
   Sumpter, Leor Weinberger, and Xioaguang Zhang.
CR Acar M, 2008, NAT GENET, V40, P471, DOI 10.1038/ng.110
   Avery SV, 2006, NAT REV MICROBIOL, V4, P577, DOI 10.1038/nrmicro1460
   Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807
   Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3                                                   
   Blake WJ, 2006, MOL CELL, V24, P853, DOI 10.1016/j.molcel.2006.11.003
   Colman-Lerner A, 2005, NATURE, V437, P699, DOI 10.1038/nature03998
   Dar RD, 2010, CHAOS, V20, DOI 10.1063/1.3486800
   Doktycz MJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100165
   Evans DJ, 2002, ADV PHYS, V51, P1529, DOI 10.1080/00018730210155133
   Fletcher BL, 2008, ACS NANO, V2, P247, DOI 10.1021/nn700212k
   Fletcher BL, 2004, NANO LETT, V4, P1809, DOI 10.1021/nl0493702
   Fowlkes JD, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/41/415301
   Fowlkes JD, 2005, NANOTECHNOLOGY, V16, P3101, DOI 10.1088/0957-4484/16/12/063
   Fraser HB, 2004, PLOS BIOL, V2, P834, DOI 10.1371/journal.pbio.0020137
   Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046
   Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546                                                    
   Korobkova E, 2004, NATURE, V428, P574, DOI 10.1038/nature02404
   Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090
   Lee YJ, 2009, SCIENCE, V324, P1051, DOI [10.1126/science.1171541, 10.1126/science.1169041]
   Lehner B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001185
   Mao CB, 2004, SCIENCE, V303, P213, DOI 10.1126/science.1092740
   Moore G. E., 1965, ELECTRONICS, V38, P114, DOI DOI 10.1109/JPROC.1998.658762
   Nam KT, 2008, P NATL ACAD SCI USA, V105, P17227, DOI 10.1073/pnas.0711620105
   Nam KT, 2006, SCIENCE, V312, P885, DOI 10.1126/science.1122716
   Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785
   Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665                                                
   Retterer ST, 2010, LAB CHIP, V10, P1174, DOI 10.1039/b921592a
   RIBES V, 2009, PERSPECT BIOL, P1
   Simpson ML, 2009, WIRES NANOMED NANOBI, V1, P214, DOI 10.1002/wnan.022
   Simpson ML, 2004, J THEOR BIOL, V229, P383, DOI 10.1016/j.jtbi.2004.04.017
   Simpson ML, 2003, P NATL ACAD SCI USA, V100, P4551, DOI 10.1073/pnas.0736140100
   Simpson ML, 2001, TRENDS BIOTECHNOL, V19, P317, DOI 10.1016/S0167-7799(01)01691-2                                                   
   Singh A, 2010, BIOPHYS J, V98, pL32, DOI 10.1016/j.bpj.2010.03.001
   Singh A, 2009, CURR OPIN MICROBIOL, V12, P460, DOI 10.1016/j.mib.2009.06.016
   SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0
   Stern S, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100147
   Thattai M, 2004, GENETICS, V167, P523, DOI 10.1534/genetics.167.1.523
   Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0
   Wang GM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.050601
   Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799
   Weinberger LS, 2008, NAT GENET, V40, P466, DOI 10.1038/ng.116
   Weinberger LS, 2007, PLOS BIOL, V5, P67, DOI 10.1371/journal.pbio.0050009
   Weinberger LS, 2005, CELL, V122, P169, DOI 10.1016/j.cell.2005.06.006
   Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191
NR 44
TC 6
Z9 6
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD APR
PY 2011
VL 5
IS 4
BP 2425
EP 2432
DI 10.1021/nn201011m
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 753CJ
UT WOS:000289742100003
PM 21456547
DA 2018-01-05
ER

PT J
AU Talha, SM
   Salminen, T
   Swaminathan, S
   Soukka, T
   Pettersson, K
   Khanna, N
AF Talha, Sheikh M.
   Salminen, Teppo
   Swaminathan, Sathyamangalam
   Soukka, Tero
   Pettersson, Kim
   Khanna, Navin
TI A highly sensitive and specific time resolved fluorometric bridge assay
   for antibodies to HIV-1 and -2
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HIV; Europium; Nanoparticles; Time resolved fluorometry; Immunoassay
ID IMMUNODEFICIENCY-VIRUS TYPE-2; HUMAN-SERA; ENVELOPE; ANTIGEN;
   PURIFICATION; BINDING; FLUOROIMMUNOASSAY; GLYCOPROTEIN; EXPRESSION;
   EPITOPES
AB This study addresses the continuing need to develop human immunodeficiency virus-1 (HIV-1) and HIV-2 immunoassays with increased sensitivity. Two chimeric antigens, r-HIV-1 env. incorporating immunoreactive regions of HIV-1 glycoprotein (gp) 120 and gp41, and r-HIV-2env, incorporating HIV-2 gp125 and gp36, and their corresponding in vivo biotinylated versions, r-Bio-HIV-1env and r-Bio-HIV-2env, were expressed in Escherichia coli and purified by single step affinity chromatography. These antigens were used to set up a bridge assay for the detection of anti-HIV antibodies. Anti-HIV-1 and HIV-2 antibodies in sera were captured using a mixture of the biotinylated antigens, immobilized on streptavidin-coated microtiter wells, and revealed using a mixture of the non-biotinylated antigens, labeled with either Eu(3+) chelate or with nanoparticles doped with the Eu(3+) chelate, followed by fluorescence measurement using time resolved fluorometry (TRF). The performance of this TRF immunoassay was compared to that of five commercial HIV ELISAs using well-characterized sera panels. The results show that the TRF immunoassay using either form of the label was in complete agreement with the commercial assays. The use of the Eu(3+) chelate label enhanced sensitivity significantly when used in the nanoparticle format as evidenced by the very high signal-to-cut-off ratios. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Talha, Sheikh M.; Swaminathan, Sathyamangalam; Khanna, Navin] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India.
   [Salminen, Teppo; Soukka, Tero; Pettersson, Kim] Univ Turku, Dept Biotechnol, Turku, Finland.
RP Khanna, N (reprint author), Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, India.
EM navin@icgeb.res.in
OI Talha, Sheikh Mohammad/0000-0003-1997-9530; Swaminathan,
   Sathyamangalam/0000-0002-4388-2248
FU Department of Biotechnology, Government of India; Academy of Finland,
   Finland [115524]; University Grants Commission, Government of India
FX This work has been carried out under a bilateral Indo-Finnish
   collaborative research programme. The authors are grateful to the
   Department of Biotechnology, Government of India, and the Academy of
   Finland (Grant #115524), Finland, for funding. SMT was the recipient of
   a research fellowship from the University Grants Commission, Government
   of India. The authors acknowledge Ms. Nisha Dhar for her help in protein
   characterization and Ms. Upasana Arora for her help in statistical
   analysis of the data.
CR ACETI A, 1987, J VIROL METHODS, V16, P303, DOI 10.1016/0166-0934(87)90015-2
   Allain JP, 2009, BIOLOGICALS, V37, P71, DOI 10.1016/j.biologicals.2009.01.002
   Batra G, 2010, PROTEIN EXPRES PURIF, V74, P99, DOI 10.1016/j.pep.2010.04.017
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Chugh D. A., 2006, PROTEIN EXPRES PURIF, V47, P319
   Constantine NT, 2005, INDIAN J MED RES, V121, P519
   DEWOLF F, 1991, J GEN VIROL, V72, P1261, DOI 10.1099/0022-1317-72-6-1261                                                     
   Freed EO, 2007, FIELDS VIROLOGY, P2107
   Harma H, 2001, CLIN CHEM, V47, P561
   HORAL P, 1991, J VIROL, V65, P2718
   HUANG ML, 1991, J VIROL, V65, P5073
   KURITZKES D.R., 2007, FIELDS VIROLOGY, P2187
   Lode P. V., 2003, ANAL CHEM, V75, P3193
   Marcelino JM, 2006, J CLIN MICROBIOL, V44, P607, DOI 10.1128/JCM.44.2.607-611.2006
   NORRBY E, 1991, AIDS RES HUM RETROV, V7, P279, DOI 10.1089/aid.1991.7.279
   Pettersson K., 2003, POINT CARE, V2, P225
   SIITARI H, 1990, J CLIN MICROBIOL, V28, P2022
   Sohn MJ, 1996, J BIOTECHNOL, V45, P211, DOI 10.1016/0168-1656(95)00169-7
   Soukka T, 2001, ANAL CHEM, V73, P2254, DOI 10.1021/ac001287i
   Talha SM, 2010, CLIN VACCINE IMMUNOL, V17, P335, DOI 10.1128/CVI.00283-09
   USHIJIMA H, 1991, J IMMUNOL METHODS, V144, P57, DOI 10.1016/0022-1759(91)90230-D
   *WHO, 2009, AIDS EPID UPD
   Yang KY, 2009, J BIOSCI BIOENG, V108, P5, DOI 10.1016/j.jbiosc.2009.02.009
NR 23
TC 10
Z9 10
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
J9 J VIROL METHODS
JI J. Virol. Methods
PD APR
PY 2011
VL 173
IS 1
BP 24
EP 30
DI 10.1016/j.jviromet.2011.01.001
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 753GF
UT WOS:000289759600005
PM 21232554
DA 2018-01-05
ER

PT J
AU Buch, I
   Tsai, CJ
   Wolfson, HJ
   Nussinov, R
AF Buch, Idit
   Tsai, Chung-Jung
   Wolfson, Haim J.
   Nussinov, Ruth
TI Symmetry-Based Self-assembled Nanotubes Constructed Using Native Protein
   Structures: The Key Role of Flexible Linkers
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Building blocks; molecular dynamics simulations; nanotube design;
   self-assembly; oligomerization domain; symmetry
ID MOLECULAR-DYNAMICS; PEPTIDE NANOTUBES; BUILDING-BLOCKS; POLYPROLINE-II;
   SIMULATION; DESIGN; NANOSTRUCTURES; NANOSCALE; NANOWIRES; VESICLES
AB We construct nanotubes using native protein structures and their native associations from structural databases. The construction is based on a shape-guided symmetric self-assembly concept. Our strategy involves fusing judiciously-selected oligomerization domains via peptide linkers. Linkers are inherently flexible, hence their choice is critical: they should position the domains in three-dimensional space in the desired orientation while retaining their own natural conformational tendencies; however, at the same time, retain the construct stability. Here we outline a design scheme which accounts for linker flexibility considerations, and present two examples. The first is HIV-1 capsid protein, which in vitro self-assembles into nanotubes and conical capsids, and its linker exists as a short flexible loop. The second involves novel nanotubes construction based on antimicrobial homodimer Magainin 2, employing linkers of distinct lengths and flexibility levels. Our strategy utilizes the abundance of unique shapes and sizes of proteins and their building blocks which can assemble into a vast number of combinations, and consequently, nanotubes of distinct morphologies and diameters. Computational design and assessment methodologies can help reduce the number of candidates for experimental validation. This is an invited paper for a special issue on protein dynamics, here focusing on flexibility in nanotube design based on protein building blocks.
C1 [Tsai, Chung-Jung; Nussinov, Ruth] NCI, SAIC Frederick Inc, Ctr Canc Res Nanobiol Program, Frederick, MD 21702 USA.
   [Buch, Idit; Nussinov, Ruth] Tel Aviv Univ, Sackler Fac Med, Sackler Inst Mol Med, Dept Human Genet, IL-69978 Tel Aviv, Israel.
   [Wolfson, Haim J.] Tel Aviv Univ, Sch Comp Sci, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), NCI, SAIC Frederick Inc, Ctr Canc Res Nanobiol Program, Bldg 469,Rm 151, Frederick, MD 21702 USA.
EM ruthnu@helix.nih.gov
FU National Cancer Institute, National Institutes of Health
   [HHSN261200800001E]; NIH, National Cancer Institute, Center for Cancer
   Research
FX We thank Dr. Bernard R Brooks for fruitful discussions and support. This
   project has been funded in whole or in part with Federal funds from the
   National Cancer Institute, National Institutes of Health, under contract
   number HHSN261200800001E. The content of this publication does not
   necessarily reflect the views or policies of the Department of Health
   and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government.
   This research was supported (in part) by the Intramural Research Program
   of the NIH, National Cancer Institute, Center for Cancer Research. This
   study utilized the high-performance computational capabilities of the
   LoBoS supercomputers as well as the Biowulf PC/Linux cluster at the
   National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov).
CR ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047
   Aksimentiev Aleksei, 2008, V474, P181, DOI 10.1007/978-1-59745-480-3_11
   Amblard M, 2006, MOL BIOTECHNOL, V33, P239, DOI 10.1385/MB:33:3:239                                                             
   Andre I, 2007, P NATL ACAD SCI USA, V104, P17656, DOI 10.1073/pnas.0702626104
   Ballano G, 2008, J PHYS CHEM B, V112, P13101, DOI 10.1021/jp8032116
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Buch I, 2009, NANO LETT, V9, P1096, DOI 10.1021/nl803521j
   Campos-Olivas R, 2000, J MOL BIOL, V296, P633, DOI 10.1006/jmbi.1999.3475
   Cardone G, 2009, NATURE, V457, P694, DOI 10.1038/nature07724
   Carlson JCT, 2006, J AM CHEM SOC, V128, P7630, DOI 10.1021/ja0606031e
   Cubellis MV, 2005, PROTEINS, V58, P880, DOI 10.1002/prot.20327                                                              
   Cui H, 2009, NANO LETT, V9, P945, DOI 10.1021/nl802813f
   Elgersma RC, 2006, CHEM-EUR J, V12, P3714, DOI 10.1002/chem.200501374
   Eswar N, 2007, CURR PROTOC PROTEIN, P291, DOI DOI 10.1002/0471140864.PS0209S50
   FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648                                                                
   Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018
   Garcia-Fandino R, 2009, J AM CHEM SOC, V131, P15678, DOI 10.1021/ja903400n
   Gardner MK, 2008, CURR OPIN CELL BIOL, V20, P64, DOI 10.1016/j.ceb.2007.12.003
   Gazit E, 2008, NAT NANOTECHNOL, V3, P8, DOI 10.1038/nnano.2007.435
   Gorbitz CH, 2007, CHEM-EUR J, V13, P1022, DOI 10.1002/chem.200601427
   Hara T, 2001, BIOPOLYMERS, V58, P437, DOI 10.1002/1097-0282(20010405)58:4<437::AID-BIP1019>3.0.CO;2-I
   Haspel N, 2007, BIOPHYS J, V93, P245, DOI 10.1529/biophysj.106.100644
   Haspel N, 2006, STRUCTURE, V14, P1137, DOI 10.1016/j.str.2006.05.016
   Hess H, 2005, NANO LETT, V5, P629, DOI 10.1021/nl0478427
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5
   Ji SC, 2006, LANGMUIR, V22, P553, DOI 10.1021/la0525067
   Jin ZM, 1999, J MOL BIOL, V286, P83, DOI 10.1006/jmbi.1998.2443
   Kent SBH, 2009, CHEM SOC REV, V38, P338, DOI 10.1039/b700141j
   Klein ML, 2008, SCIENCE, V321, P798, DOI 10.1126/science.1157834
   Li S, 2000, NATURE, V407, P409
   Lim YB, 2007, ANGEW CHEM INT EDIT, V46, P3475, DOI 10.1002/anie.200604576
   Minamino T, 2008, CURR OPIN STRUC BIOL, V18, P693, DOI 10.1016/j.sbi.2008.09.006
   Padilla JE, 2001, P NATL ACAD SCI USA, V98, P2217, DOI 10.1073/pnas.041614998
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Raman S, 2006, NANOMED-NANOTECHNOL, V2, P95, DOI 10.1016/j.nano.2006.04.007
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387                                                         
   Ruiz R, 2008, SCIENCE, V321, P936, DOI 10.1126/science.1157626
   Tsai CJ, 2006, PLOS COMPUT BIOL, V2, P311, DOI 10.1371/journal.pcbi.0020042
   Usui K, 2009, PROTEIN SCI, V18, P960, DOI 10.1002/pro.106
   Van Workum K, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.031502
   Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599
   Wakamatsu K, 2002, BIOPOLYMERS, V64, P314, DOI 10.1002/bip.10198
   Yan XH, 2008, CHEM-EUR J, V14, P5974, DOI 10.1002/chem.200800012
   Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299
   Yeates TO, 2007, BIOCHEM SOC T, V35, P508, DOI 10.1042/BST0350508                                                              
   Zhao Z, 2009, J COMPUT THEOR NANOS, V6, P1338, DOI 10.1166/jctn.2009.1183
   Zheng J, 2008, J PHYS CHEM B, V112, P6856, DOI 10.1021/jp711335b
NR 51
TC 0
Z9 0
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8665
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PD APR
PY 2011
VL 18
IS 4
BP 362
EP 372
DI 10.2174/092986611794653996
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 753MO
UT WOS:000289780100006
PM 21222638
DA 2018-01-05
ER

PT J
AU Poth, AG
   Colgrave, ML
   Philip, R
   Kerenga, B
   Daly, NL
   Anderson, MA
   Craik, DJ
AF Poth, Aaron G.
   Colgrave, Michelle L.
   Philip, Reynold
   Kerenga, Bomai
   Daly, Norelle L.
   Anderson, Marilyn A.
   Craik, David J.
TI Discovery of Cyclotides in the Fabaceae Plant Family Provides New
   Insights into the Cyclization, Evolution, and Distribution of Circular
   Proteins
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID BACKBONE-CYCLIZED PEPTIDES; CLITORIA-TERNATEA; OLDENLANDIA-AFFINIS;
   CYSTINE-KNOT; KALATA B1; ASPARAGINYL ENDOPEPTIDASE; VIOLA-ODORATA;
   ANTHELMINTIC ACTIVITY; CHASSALIA-PARVIFOLIA; MACROCYCLIC PEPTIDES
AB Cyclotides are plant proteins whose defining structural features are a head-to-tail cyclized backbone and three interlocking disulfide bonds, which in combination are known as a cyclic cystine knot. This unique structural motif confers cyclotides with exceptional resistance to proteolysis. Their endogenous function is thought to be as plant defense agents, associated with their insecticidal and larval growth-inhibitory properties. However, in addition, an array of pharmaceutically relevant biological activities has been ascribed to cyclotides, including anti-HIV, anthelmintic, uterotonic, and antimicrobial effects. So far, >150 cyclotides have been elucidated from members of the Rubiaceae, Violaceae, and Cucurbitaceae plant families, but their wider distribution among other plant families remains unclear. Clitoria ternatea (Butterfly pea) is a member of plant family Fabaceae and through its usage in traditional medicine to aid childbirth bears similarity to Oldenlandia affinis, from which many cyclotides have been isolated. Using a combination of nanospray and matrix assisted laser desorption ionization-time-of-flight (MALDI-TOF) analyses, we examined seed extracts of C. ternatea and discovered cyclotides in the Fabaceae, the third largest family of flowering plants. We characterized 12 novel cyclotides, thus expanding knowledge of cyclotide distribution and evolution within the plant kingdom. The discovery of cyclotides containing novel sequence motifs near the in planta cyclization site has provided new insights into cyclotide biosynthesis. In particular, MS analyses of the novel cyclotides from C. ternatea suggest that Asn to Asp variants at the cyclization site are more common than previously recognized Moreover, this study provides impetus for the examination of other economically and agriculturally significant species, within Fabaceae, now the largest plant family from which cyclotides have been described.
C1 [Poth, Aaron G.; Daly, Norelle L.; Craik, David J.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia.
   [Poth, Aaron G.; Colgrave, Michelle L.] CSIRO Livestock Ind, St Lucia, Qld, Australia.
   [Philip, Reynold; Kerenga, Bomai] Univ Papua New Guinea, Dept Chem, Port Moresby, Papua N Guinea.
   [Anderson, Marilyn A.] La Trobe Univ, Dept Biochem, Melbourne, Vic, Australia.
RP Craik, DJ (reprint author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia.
EM d.craik@uq.edu.au
RI Craik, David/B-1695-2010; Anderson, Marilyn/A-4259-2012; Poth,
   Aaron/D-2060-2017; Daly, Norelle/D-4302-2013; Colgrave,
   Michelle/A-5710-2012
OI Craik, David/0000-0003-0007-6796; Anderson, Marilyn/0000-0002-8257-5128;
   Poth, Aaron/0000-0002-1497-8347; Colgrave, Michelle/0000-0001-8463-805X
FU Australian Research Council [DP0984390]
FX This research was supported by a grant from the Australian Research
   Council (DP0984390). D.J.C. is a NHMRC Professorial Research Fellow.
   N.L.D. is a Queensland Smart State Fellow. We are grateful to A. Jones
   of the Molecular and Cellular Proteomics Mass Spectrometry Facility at
   the Institute for Molecular Bioscience (The University of Queensland)
   for providing technical support and access to the mass spectrometry
   facility. The authors thank A. Cooper for revisions to the manuscript.
CR ABE Y, 1993, J BIOL CHEM, V268, P3525
   Barbeta BL, 2008, P NATL ACAD SCI USA, V105, P1221, DOI 10.1073/pnas.0710338104
   Camarero JA, 2007, CHEMBIOCHEM, V8, P1363, DOI 10.1002/cbic.200700183
   CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0
   Chen B, 2006, J NAT PROD, V69, P23, DOI 10.1021/np050317i
   Colgrave ML, 2008, CHEMBIOCHEM, V9, P1939, DOI 10.1002/cbic.200800174
   Colgrave ML, 2008, BIOCHEMISTRY-US, V47, P5581, DOI 10.1021/bi800223y
   Colgrave ML, 2009, ACTA TROP, V109, P163, DOI 10.1016/j.actatropica.2008.11.003
   Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q
   Craik DJ, 2010, CELL MOL LIFE SCI, V67, P9, DOI 10.1007/s00018-009-0159-3
   Craik DJ, 2009, TRENDS PLANT SCI, V14, P328, DOI 10.1016/j.tplants.2009.03.003
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276
   Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200
   FANTZ PR, 1991, ECON BOT, V45, P511, DOI 10.1007/BF02930715
   Gao YJ, 2010, BIOORGAN MED CHEM, V18, P1331, DOI 10.1016/j.bmc.2009.12.026
   Gillon AD, 2008, PLANT J, V53, P505, DOI 10.1111/j.1365-313X.2007.03357.x
   Goel A. K., 2002, Indian Journal of Experimental Biology, V40, P812
   Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719
   GORMAN CF, 1969, SCIENCE, V163, P671, DOI 10.1126/science.163.3868.671                                                    
   Graham PH, 2003, PLANT PHYSIOL, V131, P872, DOI 10.1104/pp.017004
   GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400
   GRAN L, 1973, LLOYDIA, V36, P174
   Gran L., 1970, MEDD NORSK FARM SELS, V32, P173
   Gruber CW, 2008, PLANT CELL, V20, P2471, DOI 10.1105/tpc.108.062331
   Gruber CW, 2010, BIOPOLYMERS, V94, P565, DOI 10.1002/bip.21414
   Gunasekera S, 2008, J MED CHEM, V51, P7697, DOI 10.1021/jm800704e
   GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064
   Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r
   Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2
   Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r
   Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756                                                               
   Huang YH, 2010, J BIOL CHEM, V285, P10797, DOI 10.1074/jbc.M109.089854
   Huang YH, 2009, J BIOL CHEM, V284, P20699, DOI 10.1074/jbc.M109.003384
   Ireland DC, 2006, BIOCHEM J, V400, P1, DOI 10.1042/BJ20060627
   Ireland DC, 2006, J MOL BIOL, V357, P1522, DOI 10.1016/j.jmb.2006.01.051
   Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898
   Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h
   Kaas Q, 2010, BIOPOLYMERS, V94, P584, DOI 10.1002/bip.21424
   Kamilla L, 2009, MICROSC MICROANAL, V15, P366, DOI 10.1017/S1431927609090783
   Kelemu S, 2004, PLANT PHYSIOL BIOCH, V42, P867, DOI 10.1016/j.plaphy.2004.10.013
   Khadatkar SN, 2008, PHARMACOGN MAG, V4, P148
   Kolmar H, 2008, FEBS J, V275, P2684, DOI 10.1111/j.1742-4658.2008.06440.x
   Malabadi Ravindra B., 2005, Journal of Medicinal and Aromatic Plant Sciences, V27, P26
   Mathew N, 2009, PARASITOL RES, V104, P1017, DOI 10.1007/s00436-008-1284-x
   MIN W, 1994, NAT STRUCT BIOL, V1, P502, DOI 10.1038/nsb0894-502                                                             
   Morris JB, 1997, ECON BOT, V51, P251, DOI 10.1007/BF02862094
   Mukherjeea PK, 2008, J ETHNOPHARMACOL, V120, P291, DOI 10.1016/j.jep.2008.09.009
   Mulvenna JP, 2006, PLANT CELL, V18, P2134, DOI 10.1105/tpc.106.042812
   Mulvenna JP, 2005, J BIOL CHEM, V280, P32245, DOI 10.1074/jbc.M506060200
   Mylne JS, 2010, BIOPOLYMERS, V94, P635, DOI 10.1002/bip.21419
   OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W
   Plan MRR, 2008, J AGR FOOD CHEM, V56, P5237, DOI 10.1021/jf800302f
   Pranting M, 2010, J ANTIMICROB CHEMOTH, V65, P1964, DOI 10.1093/jac/dkq220
   Qin QP, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-111
   SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002
   Saska I, 2008, J CHROMATOGR B, V872, P107, DOI 10.1016/j.jchromb.2008.07.023
   Saska I, 2007, J BIOL CHEM, V282, P29721, DOI 10.1074/jbc.M705185200
   Schopke T., 1993, SCI PHARM, V61, P145
   Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913
   Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498
   Thongyoo P, 2007, CHEMBIOCHEM, V8, P1107, DOI 10.1002/cbic.200700187
   Thongyoo P, 2009, J MED CHEM, V52, P6197, DOI 10.1021/jm901233u
   VIETMEYER ND, 1986, SCIENCE, V232, P1379, DOI 10.1126/science.232.4756.1379
   WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002
   WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532
NR 67
TC 68
Z9 83
U1 2
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD APR
PY 2011
VL 6
IS 4
BP 345
EP 355
DI 10.1021/cb100388j
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 749HP
UT WOS:000289455400008
PM 21194241
DA 2018-01-05
ER

PT J
AU Ragnaill, MN
   Brown, M
   Ye, D
   Bramini, M
   Callanan, S
   Lynch, I
   Dawson, KA
AF Ragnaill, Michelle Nic
   Brown, Meredith
   Ye, Dong
   Bramini, Mattia
   Callanan, Sean
   Lynch, Iseult
   Dawson, Kenneth A.
TI Internal benchmarking of a human blood-brain barrier cell model for
   screening of nanoparticle uptake and transcytosis
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article; Proceedings Paper
CT 8th International Conference and Workshop on Biological Barriers - in
   Vitro Tools in Nanotoxicology and Nanomedicine
CY MAR 21-APR 01, 2010
CL Saarland Univ, Saarbrucken, GERMANY
SP GALENOS Network
HO Saarland Univ
DE Blood-brain barrier; Nanoparticles; Transcytosis; Bionanointeraction
ID DRUG TRANSPORT; CORONA; LINE
AB Transport of drugs across the blood-brain barrier, which protects the brain from harmful agents, is considered the holy grail of targeted delivery, due to the extreme effectiveness of this barrier at preventing passage of non-essential molecules through to the brain. This has caused severe limitations for therapeutics for many brain-associated diseases, such as HIV and neurodegenerative diseases. Nanomaterials, as a result of their small size (in the order of many protein-lipid clusters routinely transported by cells) and their large surface area (which acts as a scaffold for proteins thereby rendering nanoparticles as biological entities) offer great promise for neuro-therapeutics. However, in parallel with developing neuro-therapeutic applications based on nanotechnology, it is essential to ensure their safety and long-term consequences upon reaching the brain. One approach to determining safe application of nanomaterials in biology is to obtain a deep mechanistic understanding of the interactions between nanomaterials and living systems (bionanointeractions). To this end, we report here on the establishment and internal round robin validation of a human cell model of the blood-brain barrier for use as a tool for screening nanoparticles interactions, and assessing the critical nanoscale parameters that determine transcytosis. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ragnaill, Michelle Nic] Univ Coll Dublin, Ctr BioNano Interact, Sch Chem & Chem Biol, Dublin 4, Ireland.
   [Ragnaill, Michelle Nic; Brown, Meredith; Ye, Dong; Bramini, Mattia; Lynch, Iseult; Dawson, Kenneth A.] Univ Coll Dublin, UCD Conway Inst, Dublin 4, Ireland.
   [Brown, Meredith; Callanan, Sean] Univ Coll Dublin, Sch Agr Food Sci & Vet Med, Dublin 4, Ireland.
RP Ragnaill, MN (reprint author), Univ Coll Dublin, Ctr BioNano Interact, Sch Chem & Chem Biol, Dublin 4, Ireland.
EM michelle.nicraghnaill@ucd.ie
RI Bramini, Mattia/Q-6130-2016; Dawson, Kenneth A./L-2540-2016; Lynch,
   Iseult/I-3915-2014
OI Bramini, Mattia/0000-0002-0381-9391; Dawson, Kenneth
   A./0000-0002-0568-6588; Lynch, Iseult/0000-0003-4250-4584
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3
   Cedervall T, 2007, ANGEW CHEM INT EDIT, V46, P5754, DOI 10.1002/anie.200700465
   Chapagain ML, 2007, VIROLOGY, V364, P55, DOI 10.1016/j.virol.2007.02.018
   Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3
   Diabate S, 2008, ATLA-ALTERN LAB ANIM, V36, P285
   Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223
   Fletcher NF, 2006, VET IMMUNOL IMMUNOP, V109, P233, DOI 10.1016/j.vetimm.2005.08.025
   Hellstrand E, 2009, FEBS J, V276, P3372, DOI 10.1111/j.1742-4658.2009.07062.x
   Juillerat-Jeanneret L, 2008, DRUG DISCOV TODAY, V13, P1099, DOI 10.1016/j.drudis.2008.09.005
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   Lynch I, 2009, NAT NANOTECHNOL, V4, P546, DOI 10.1038/nnano.2009.248
   Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139
   Oberdorster G, 2009, J NANOSCI NANOTECHNO, V9, P4996, DOI 10.1166/jnn.2009.GR02
   Poller B, 2008, J NEUROCHEM, V107, P1358, DOI 10.1111/j.1471-4159.2008.05730.x
   Rothen-Rutishauser Barbara, 2007, Part Fibre Toxicol, V4, P9, DOI 10.1186/1743-8977-4-9
   SALVATI A, EXPT THEORE IN PRESS
   Walczyk D, 2010, J AM CHEM SOC, V132, P5761, DOI 10.1021/ja910675v
   Weksler BB, 2005, FASEB J, V19, P1872
   Zensi A, 2010, J DRUG TARGET, V18, P842, DOI 10.3109/1061186X.2010.513712
NR 20
TC 49
Z9 52
U1 1
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD APR
PY 2011
VL 77
IS 3
SI SI
BP 360
EP 367
DI 10.1016/j.ejpb.2010.12.024
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 748HD
UT WOS:000289380300005
PM 21236340
DA 2018-01-05
ER

PT J
AU Mahalingam, A
   Simmons, AP
   Ugaonkar, SR
   Watson, KM
   Dezzutti, CS
   Rohan, LC
   Buckheit, RW
   Kiser, PF
AF Mahalingam, Alamelu
   Simmons, Adam P.
   Ugaonkar, Shweta R.
   Watson, Karen M.
   Dezzutti, Charlene S.
   Rohan, Lisa C.
   Buckheit, Robert W., Jr.
   Kiser, Patrick F.
TI Vaginal Microbicide Gel for Delivery of IQP-0528, a Pyrimidinedione
   Analog with a Dual Mechanism of Action against HIV-1
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITOR;
   IN-VITRO; DRUG-DELIVERY; TOPICAL MICROBICIDES; MODEL; MUCOSA; VIVO;
   TRANSMISSION; PERMEABILITY
AB Pyrimidinediones, a novel class of compounds, have previously been shown to possess antiviral activity at nanomolar concentrations. One member of this class of compounds, IQP-0528, was selected as the lead molecule for formulation development owing to its stability at physiologically relevant conditions, wide therapeutic window, and antiviral activity in the nanomolar range. Here, we report the development of two vaginal gels-3.0% hydroxyethyl cellulose (HEC) formulation and a 0.65% Carbopol formulation-for the sustained delivery of IQP-0528. Stability studies under accelerated conditions confirmed the chemical stability of IQP-0528 and mechanical stability of the gel formulation for 3 months. In vitro release studies revealed that diffusion-controlled release of IQP-0528 occurred over 6 h, with an initial lag time of approximately 1 h. Based on the drug release profile, the 3.0% HEC gel was selected as the lead formulation for safety and activity evaluations. The in vitro and ex vivo safety evaluations showed no significant loss in cell viability or significant inflammatory response after treatment with a 3.0% HEC gel containing 0.25% IQP-0528. In an in vitro HIV- 1 entry inhibition assay, the lead formulation showed an 50% effective concentration of 0.14 mu g/ml for gel in culture media, which corresponds to similar to 0.001 mu M IQP-0528. The antiviral activity was further confirmed by using polarized cervical explants, in which the formulation showed complete protection against HIV infection. In summary, these results are encouraging and warrant further evaluation of IQP-0528 gel formulations in in vivo models, as well as the development of alternative formulations for the delivery of IQP-0528 as a microbicide.
C1 [Simmons, Adam P.; Ugaonkar, Shweta R.; Kiser, Patrick F.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
   [Mahalingam, Alamelu; Kiser, Patrick F.] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
   [Watson, Karen M.; Buckheit, Robert W., Jr.] ImQuest BioSci Inc, Frederick, MD 21704 USA.
   [Dezzutti, Charlene S.; Rohan, Lisa C.] Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.
RP Kiser, PF (reprint author), Univ Utah, Dept Bioengn, 20 S 2030 E Room 108, Salt Lake City, UT 84112 USA.
EM patrick.kiser@utah.edu
RI Kiser, Patrick/C-2843-2014
OI Kiser, Patrick/0000-0002-3868-7122
FU SBIR [2-R44-AI067047-02]; NIH [5U19AI077289-03]
FX This study was supported by SBIR grant 2-R44-AI067047-02 and NIH grant
   5U19AI077289-03.
CR Ayehunie S, 2006, TOXICOL IN VITRO, V20, P689, DOI 10.1016/j.tiv.2005.10.002
   Buckheit Robert W. Jr., 2007, Antiviral Chemistry & Chemotherapy, V18, P259
   Buckheit RW, 2008, ANTIMICROB AGENTS CH, V52, P225, DOI 10.1128/AAC.00972-07
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90
   Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06
   das Neves J, 2006, INT J PHARM, V318, P1, DOI 10.1016/j.ijpharm.2006.03.012
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Fichorova RN, 1999, BIOL REPROD, V60, P508, DOI 10.1095/biolreprod60.2.508                                                      
   Fichorova RN, 2004, BIOL REPROD, V71, P761, DOI 10.1095/biolreprod.104.029603
   Flynn GL, 1999, PHARMACEUT RES, V16, P1325, DOI 10.1023/A:1018997520950
   Garg AB, 2009, ANTIVIR CHEM CHEMOTH, V19, P143
   Gibaldi M, 2007, GIBALDIS DRUG DELIVE
   Grabovac V, 2005, ADV DRUG DELIVER REV, V57, P1713, DOI 10.1016/j.addr.2005.07.006
   Grant RM, 2008, SCIENCE, V321, P532, DOI 10.1126/science.1160355
   Gupta KM, 2008, J PHARM SCI-US, V97, P4228, DOI 10.1002/jps.21331
   Hadgraft J, 2005, INT J PHARM, V305, P2, DOI 10.1016/j.ijpharm.2005.07.014
   HIGUCHI WI, 1962, J PHARM SCI, V51, P802, DOI 10.1002/jps.2600510825
   Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748
   Klasse Per Johan, 2008, Annu Rev Med, V59, P455, DOI 10.1146/annurev.med.59.061206.112737
   Kulkarni U, 2010, J PHARM SCI-US, V99, P1265, DOI 10.1002/jps.21907
   Lewi Paul, 2004, Drugs R D, V5, P245, DOI 10.2165/00126839-200405050-00001
   Mahalingam A, 2010, PHARM RES-DORDR, V27, P2478, DOI 10.1007/s11095-010-0244-1
   Milligan GN, 2002, SEX TRANSM DIS, V29, P597, DOI 10.1097/00007435-200210000-00006
   Owen DH, 2000, CONTRACEPTION, V62, P321, DOI 10.1016/S0010-7824(00)00184-0                                                   
   Rohan LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009310
   SCHOOFS M, 2010, 18 INT AIDS C VIENN
   Singla AK, 2000, DRUG DEV IND PHARM, V26, P913, DOI 10.1081/DDC-100101318
   Smith Stephen M, 2004, Retrovirology, V1, P16, DOI 10.1186/1742-4690-1-16
   Squier CA, 2008, J PHARM SCI-US, V97, P9, DOI 10.1002/jps.21077
   STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460
   Terrazas-Aranda Katty, 2007, Antiviral Chemistry & Chemotherapy, V18, P141
   Tien D, 2005, AIDS RES HUM RETROV, V21, P845, DOI 10.1089/aid.2005.21.845
   Uchegbu I.F., 2006, POLYM DRUG DELIVERY
   Valenta C, 2005, ADV DRUG DELIVER REV, V57, P1692, DOI 10.1016/j.addr.2005.07.004
   van Eyk A D, 2006, SADJ, V61, P200
   van Eyk AD, 2005, INT J PHARM, V305, P105, DOI 10.1016/j.ijpharm.2005.09.002
   Vermani K., 2000, PSTT, V3, P359, DOI [10.1016/S1461-5347(00)00296-0, DOI 10.1016/S1461-5347(00)00296-0]
   Walters K. A., 2002, DERMATOLOGICAL TRANS
   Wilson DP, 2008, P NATL ACAD SCI USA, V105, P9835, DOI 10.1073/pnas.0711813105
   Woolfson AD, 2000, CRIT REV THER DRUG, V17, P509
   Youle Mike, 2003, J Int Assoc Physicians AIDS Care (Chic), V2, P102, DOI 10.1177/154510970300200302
NR 42
TC 41
Z9 41
U1 0
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 2011
VL 55
IS 4
BP 1650
EP 1660
DI 10.1128/AAC.01368-10
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 737US
UT WOS:000288594600041
PM 21245437
OA gold
DA 2018-01-05
ER

PT J
AU Agrati, C
   Marianecci, C
   Sennato, S
   Carafa, M
   Bordoni, V
   Cimini, E
   Tempestilli, M
   Pucillo, LP
   Turchi, F
   Martini, F
   Borioni, G
   Bordi, F
AF Agrati, Chiara
   Marianecci, Carlotta
   Sennato, Simona
   Carafa, Maria
   Bordoni, Veronica
   Cimini, Eleonora
   Tempestilli, Massimo
   Pucillo, Leopoldo P.
   Turchi, Federica
   Martini, Federico
   Borioni, Giorgio
   Bordi, Federico
TI Multicompartment vectors as novel drug delivery systems: selective
   activation of T gamma delta lymphocytes after zoledronic acid delivery
SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Nanovectors; Polyelectrolyte-niosome complexes; Zoledronic acid; T gamma
   delta lymphocytes; HIV therapy
ID SURFACTANT VESICLES NIOSOMES; CELLS; SIZE; INTERNALIZATION;
   NANOPARTICLES; COMPLEXATION; POLYIONS; DENSITY; BINDING
AB Multicompartment nanoscopic carriers can be easily assembled by inducing the aggregation of anionic "hybrid" niosomes by means of cationic biocompatible polyelectrolytes. The resulting vesicle clusters, whose size and overall net charge can be easily controlled by varying the polyelectrolyte-to-particle charge ratio, show an interesting potential for multidrug delivery. In this article we provide strong evidence for their effective use in vitro as multicompartment vectors selectively directed toward monocyte/macrophage cells, showing that the monocyte/macrophage-mediated activation of T gamma delta lymphocytes induced by zoledronic acid is enhanced by a factor 10(3) when the zoledronic acid is intracellularly delivered through these carriers. Furthermore, the multicompartment epsilon-polylysine niosome clusters, with their intrinsic selectivity toward macrophages, appear particularly suitable for implementing therapeutic strategies against chronically infected macrophages.
   From the Clinical Editor: epsilon-polylysine niosome clusters, with their intrinsic selectivity toward macrophages, offer the potential for multidrug delivery. The effectiveness of aminobisphosphonate zoledronate is demonstrated to enhance the recruitment of T gamma delta lymphocytes by macrophages by 2 orders of magnitude, suggesting a new therapeutic strategy for addressing pathologies featuring chronically infected macrophages. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Marianecci, Carlotta; Carafa, Maria] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy.
   [Agrati, Chiara; Bordoni, Veronica; Cimini, Eleonora; Tempestilli, Massimo; Pucillo, Leopoldo P.; Turchi, Federica; Martini, Federico] Natl Inst Infect Dis Lazzaro Spallanzani, Rome, Italy.
   [Sennato, Simona; Bordi, Federico] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy.
   [Sennato, Simona] Univ Roma La Sapienza, CNISM, I-00185 Rome, Italy.
   [Borioni, Giorgio] Synth Act Srl, Rome, Italy.
   [Bordi, Federico] Univ Roma La Sapienza, INFM CRS SOFT, I-00185 Rome, Italy.
RP Carafa, M (reprint author), Univ Roma La Sapienza, Dept Drug Chem & Technol, Piazzale A Moro 5, I-00185 Rome, Italy.
EM maria.carafa@uniroma1.it
RI carafa, maria/F-8172-2011; tempestilli, massimo/K-5952-2016; Bordi,
   Federico/H-1862-2011
OI tempestilli, massimo/0000-0003-3107-7441; Bordi,
   Federico/0000-0001-6373-5176; Carafa, Maria/0000-0002-3968-3385;
   SENNATO, Simona/0000-0003-4793-5359
FU MIUR (Italian Department for Education and Scientific Research); FILAS
FX This work was supported by MIUR (Italian Department for Education and
   Scientific Research) and by FILAS (research grant within the Project:
   "Poly-Electro-Somes (PESo): a new delivery system for controlled
   multidrug release").
CR Agrati C, 2009, J IMMUNOL, V182, P522, DOI 10.4049/jimmunol.182.1.522                                                      
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P1283, DOI 10.1210/jc.2006-2216
   Bordi F, 2005, CHEM PHYS LETT, V409, P134, DOI 10.1016/j.cplett.2005.04.107
   Bordi F, 2004, LANGMUIR, V20, P5214, DOI 10.1021/la036006u
   Bordi F, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/20/203102
   Carafa M, 1998, INT J PHARM, V160, P51, DOI 10.1016/S0378-5173(97)00294-9                                                   
   Champion JA, 2008, PHARM RES-DORDR, V25, P1815, DOI 10.1007/s11095-008-9562-y
   Deeks ED, 2008, DRUG AGING, V25, P963, DOI 10.2165/0002512-200825110-00007
   Di Marzio L, 2008, BBA-BIOMEMBRANES, V1778, P2749, DOI 10.1016/j.bbamem.2008.07.029
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z
   Hong MH, 2009, J CONTROL RELEASE, V133, P96, DOI 10.1016/j.jconrel.2008.09.005
   Huang YZ, 2008, J MATER SCI-MATER M, V19, P607, DOI 10.1007/s10856-007-3193-4
   Katakura H, 2004, J GENE MED, V6, P471, DOI 10.1002/jgm.519
   KATO H, 1989, J ASSOC OFF ANA CHEM, V72, P27
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Li Y, 2009, BIOMACROMOLECULES, V10, P2284, DOI 10.1021/bm900456x
   Liu HP, 2010, CHEM-EUR J, V16, P3791, DOI 10.1002/chem.200901546
   Menger FM, 2003, J AM CHEM SOC, V125, P2846, DOI 10.1021/ja021337z
   Mishra B, 2010, NANOMED-NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Pathak A, 2008, INT J NANOMED, V3, P31
   Poccia F., 2002, Current Molecular Medicine (Hilversum), V2, P769, DOI 10.2174/1566524023361880
   Poccia F, 2009, AIDS, V23, P555, DOI 10.1097/QAD.0b013e3283244619
   PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4
   Ragusa A, 2007, IEEE T NANOBIOSCI, V6, P319, DOI 10.1109/TNB.2007.908996
   Rao BM, 2005, J PHARMACEUT BIOMED, V39, P781, DOI 10.1016/j.jpba.2005.04.012
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Sennato S, 2008, J PHYS CHEM B, V112, P3720, DOI 10.1021/jp0775449
   Sosnik A, 2009, J CONTROL RELEASE, V138, P2, DOI 10.1016/j.jconrel.2009.05.007
   UCHEGBU IF, 1995, ADV COLLOID INTERFAC, V58, P1, DOI 10.1016/0001-8686(95)00242-I                                                    
   UCHEGBU IF, 2006, EXPERT OPIN DRUG DEL, V3, P639
   Waku T, 2007, MACROMOLECULES, V40, P6385, DOI 10.1021/ma0707638                                                               
   Wang XS, 2001, J CELL BIOCHEM, V81, P557, DOI 10.1002/1097-4644(20010601)81:3<557::AID-JCB1069>3.0.CO;2-T                     
NR 35
TC 13
Z9 13
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549-9634
J9 NANOMED-NANOTECHNOL
JI Nanomed.-Nanotechnol. Biol. Med.
PD APR
PY 2011
VL 7
IS 2
BP 153
EP 161
DI 10.1016/j.nano.2010.10.003
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA 738NK
UT WOS:000288646300005
PM 21034859
DA 2018-01-05
ER

PT J
AU Ashutosh, F
   Borgmann, K
   Tang, L
   Labhasetwar, V
   Ghorpade, A
AF Ashutosh, F.
   Borgmann, K.
   Tang, L.
   Labhasetwar, V.
   Ghorpade, A.
TI A Gene Therapeutic Approach For HIV-1 Associated Dementia (HAD) using
   Targeted Nanoparticles for TIMP-1 Delivery into CNS
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Meeting Abstract
C1 [Ashutosh, F.; Borgmann, K.; Tang, L.; Ghorpade, A.] Univ N Texas Hlth Sci Ctr, Dept Cell Biol & Anat, Ft Worth, TX 76107 USA.
   [Labhasetwar, V.] Cleveland Clin Lerner Coll Med, Dept Biomed Engn, Cleveland, OH 44195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD APR
PY 2011
VL 6
SU 1
BP S24
EP S24
PG 1
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 920KF
UT WOS:000302402500041
DA 2018-01-05
ER

PT J
AU Shcharbin, D
   Pedziwiatr, E
   Nowacka, O
   Kumar, M
   Zaborski, M
   Ortega, P
   de la Mata, FJ
   Gomez, R
   Munoz-Fernandez, MA
   Bryszewska, M
AF Shcharbin, Dzmitry
   Pedziwiatr, Elzbieta
   Nowacka, Olga
   Kumar, Mayank
   Zaborski, Marian
   Ortega, Paula
   de la Mata, F. Javier
   Gomez, Rafael
   Munoz-Fernandez, Ma Angeles
   Bryszewska, Maria
TI Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Carbosilane dendrimer; siGAG1; Complex; Circular dichroism;
   Fluorescence; Zeta-potential; Zeta-size
ID ETHIDIUM-BROMIDE; DNA; TRANSFECTION
AB A new mechanism of gene expression inhibition has been discovered as RNA interference, in which the ability of double-stranded RNA to stimulate specific degradation of an mRNA target with a complementary sequence to one of the double-stranded RNA strands. Water-soluble carbosilane dendrimers containing ammonium or amine groups at their periphery are biocompatible molecules that may be good candidates as non-viral carriers of small interfering RNA. In studying the formation of complex between anti-HIV siRNA siGAG1 and carbosilane dendrimers NN8 and NN16 by circular dichroism, fluorescence, and zeta-potential, the size of nanoparticles formed has been estimated by dynamic light scattering. At a charge ratio of 1:3-4 (siGAG1:dendrimer), the dendriplexes formed were in the size range of 250-350 nm. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Shcharbin, Dzmitry] NASB, Inst Biophys & Cell Engn, Minsk 220072, Byelarus.
   [Pedziwiatr, Elzbieta; Nowacka, Olga; Kumar, Mayank; Bryszewska, Maria] Univ Lodz, Dept Gen Biophys, PL-90131 Lodz, Poland.
   [Zaborski, Marian] Tech Univ Lodz, Inst Polymer & Dye Technol, PL-90924 Lodz, Poland.
   [Ortega, Paula; de la Mata, F. Javier; Gomez, Rafael] Univ Alcala de Henares, Dept Quim Inorgan, CIBER BBN, E-28871 Alcala De Henares, Spain.
   [Munoz-Fernandez, Ma Angeles] Univ Gregorio Maranon, Gen Hosp, Lab Inmunobiol Mol, CIBER BBN, Madrid, Spain.
RP Shcharbin, D (reprint author), NASB, Inst Biophys & Cell Engn, Akademicheskaja 27, Minsk 220072, Byelarus.
RI ortega lopez, paula/K-3910-2014; De la Mata, F. Javier/K-1649-2014;
   Shcharbin, Dzmitry/G-2046-2011; Gomez Ramirez, Rafael/K-1216-2014
OI ortega lopez, paula/0000-0003-0377-5429; De la Mata, F.
   Javier/0000-0003-0418-3935; Shcharbin, Dzmitry/0000-0002-1414-4465;
   Gomez Ramirez, Rafael/0000-0001-6448-2414;
   Munoz-Fernandez/0000-0002-0813-4500; Bryszewska,
   Maria/0000-0003-4676-3743; Pedziwiatr-Werbicka,
   Elzbieta/0000-0001-7943-2612
FU ERA-NET MNT
FX This work was supported by grant ERA-NET MNT 2007.
CR Chen W, 2000, LANGMUIR, V16, P15, DOI 10.1021/la981429v                                                               
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Lee CY, 2001, B KOR CHEM SOC, V22, P87
   Ortega P, 2006, EUR J INORG CHEM, P1388, DOI 10.1002/ejic.200500782
   Pope LH, 2000, J MICROSC-OXFORD, V199, P68, DOI 10.1046/j.1365-2818.2000.00703.x
   QUILLARDET P, 1988, TRENDS GENET, V4, P89, DOI 10.1016/0168-9525(88)90092-3
   Shcharbin DG, 2009, BIOCHEMISTRY-MOSCOW+, V74, P1070, DOI 10.1134/S0006297909100022
   Shcharbin D, 2007, BIOMACROMOLECULES, V8, P2059, DOI 10.1021/bm070333p
   TSAI C, 1977, J MOL BIOL, V114, P301, DOI 10.1016/0022-2836(77)90252-2
NR 9
TC 18
Z9 19
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD APR 1
PY 2011
VL 83
IS 2
BP 388
EP 391
DI 10.1016/j.colsurfb.2010.11.009
PG 4
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 720GF
UT WOS:000287268000027
PM 21145713
DA 2018-01-05
ER

PT J
AU Tang, Y
   Lin, CJ
   Tian, XC
AF Tang, Yong
   Lin, Chih-Jen
   Tian, X. Cindy
TI Functionality and Transduction Condition Evaluation of Recombinant Klf4
   for Improved Reprogramming of iPS Cells
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; KRUPPEL-LIKE FACTOR; HUMAN IMMUNODEFICIENCY
   VIRUS; TAT-FUSION PROTEINS; SMALL-MOLECULE COMPOUNDS; HUMAN
   SOMATIC-CELLS; DEFINED FACTORS; YAMANAKA FACTORS; MAMMALIAN-CELLS;
   INDUCTION
AB The induced pluripotent stem cell (iPSC) technology holds great potential in regenerative therapy. iPSCs could be induced by proteins (piPSC) linked with poly-arginine cell-penetrating peptides (CPPs) without the risk of genomic alteration, athough with extremely low efficiency and delayed reprogramming. We aimed to evaluate the reprogramming potency of purified mouse Klf4 proteins linked with the CPP of HIV transactivator of transcription (TAT) or Drosophila Penetratin protein at the N- or C-terminus. Eukaryotically expressed recombinant Klf4 targeted cell nucleus while the purified proteins localized in the cytoplasmic and peri-nuclear region. However, using a combined transduction of Klf4 protein and retroviruses expressing Oct4, Sox2, and c-Myc (OSM), we found both TAT-and penetratin-linked Klf4 proteins significantly induced mouse iPSC formation at the nanomolar level in 2 to 4 weeks. Klf4 protein with TAT at the N-terminus showed no reprogramming activity while the fusion protein, with Discosoma red fluorescent protein (DsRed) between TAT and Klf4, exhibited significant iPSC induction function. The iPSCs induced by Klf4 protein and retroviral OSM combinations were pluripotent. Using the protein/retroviral OSM reprogramming assay, we further evaluated Klf4 protein transduction conditions and showed that four continued transductions by purified Klf4 proteins are sufficient for effective iPSC induction. Our results demonstrated for the first time that TAT-and Penetratin-linked Klf4 proteins can effectively replace viral Klf4 in reprogramming fibroblasts, and provided a valuable strategy to evaluate recombinant proteins and transduction conditions for the improvement of piPSC induction efficiency.
C1 [Tang, Yong; Lin, Chih-Jen; Tian, X. Cindy] Univ Connecticut, Ctr Regenerat Biol, Dept Anim Sci, Storrs, CT 06269 USA.
RP Tian, XC (reprint author), Univ Connecticut, Ctr Regenerat Biol, Dept Anim Sci, 1390 Storrs Rd, Storrs, CT 06269 USA.
EM xiuchun.tian@uconn.edu
FU USDA [1265-31000-091-02S]
FX We greatly appreciate Dr. David Goldhamer, Dr. Carolyn Teschke, Dr.
   Lawrence Silbart, and Dr. Yinghong Ma for their critical input to this
   project. We thank Dr. Chul Kim and Dr. Tomokazu Amano for MEF cell
   preparation, and Dr. Toshio Kitamura in the University of Tokyo for
   PlatE cells. This project was supported by USDA Grant
   1265-31000-091-02S.
CR Bosnali M, 2008, BIOL CHEM, V389, P851, DOI 10.1515/BC.2008.106
   Brambrink T, 2008, CELL STEM CELL, V2, P151, DOI 10.1016/j.stem.2008.01.004
   Brembeck FH, 2000, J BIOL CHEM, V275, P28230
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Duinsbergen D, 2009, ANN NY ACAD SCI, V1176, P197, DOI 10.1111/j.1749-6632.2009.04563.x
   Edenhofer F, 2008, CURR PHARM DESIGN, V14, P3628, DOI 10.2174/138161208786898833                                                      
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Heng JC, 2009, CELL STEM CELL, V6, P167
   Huang JY, 2009, CELL RES, V19, P1127, DOI 10.1038/cr.2009.106
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747
   Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kwon HY, 2000, FEBS LETT, V485, P163, DOI 10.1016/S0014-5793(00)02215-8
   Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004.07.2681
   Liu XS, 2008, CELL RES, V18, P1177, DOI 10.1038/cr.2008.309
   Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206                                                           
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   PAN C, 2009, MOL BIOL REP, V37, P2117
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Patel S, 2006, P NATL ACAD SCI USA, V103, P18668, DOI 10.1073/pnas.0608658103
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504
   Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009                                                        
   Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001
   Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024                                                      
   Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Yang WC, 2009, BIOTECHNOL BIOENG, V104, P1047, DOI 10.1002/bit.22517
   Yu JY, 2007, SCIENCE, V318, P1917, DOI [10.1126/science.1151526, 10.1126/science.1172482]
   Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958
   Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005
NR 49
TC 13
Z9 13
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD APR
PY 2011
VL 13
IS 2
BP 99
EP 112
DI 10.1089/cell.2010.0072
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA 746WW
UT WOS:000289280400002
PM 21473687
DA 2018-01-05
ER

PT J
AU Sajti, CL
   Barchanski, A
   Wagener, P
   Klein, S
   Barcikowski, S
AF Sajti, Csaba Laszlo
   Barchanski, Annette
   Wagener, Philipp
   Klein, Sabine
   Barcikowski, Stephan
TI Delay Time and Concentration Effects During Bioconjugation of Nanosecond
   Laser-Generated Nanoparticles in a Liquid Flow
SO JOURNAL OF PHYSICAL CHEMISTRY C
LA English
DT Article
ID FUNCTIONALIZED GOLD NANOPARTICLES; CELL-PENETRATING PEPTIDES;
   AQUEOUS-SOLUTION; ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX; ABLATION;
   FEMTOSECOND; SIZE; SURFACE; DELIVERY
AB Fast ex situ functionalization of gold nanoparticles with fluorophore-labeled cell-penetrating peptides is investigated with a novel liquid flow cascade injection system. Successful conjugation is proved by various methods, such as UV-vis spectrometry and electron microscopy, whereas nanoparticle size-quenching is clearly observed. By variation of the peptide concentration introduced promptly after particle generation, gold nanoparticle bioconjugates with different degrees of cluster formation and/or aggregation and different peptide surface coverage values are obtained. The sizes of synthesized inorganic-organic gold nanoparticle bioconjugate show obvious correlation with time-delayed conjugation, giving evidence that laser-generated nanoparticles continue growing outside the cavitation bubble in the multisecond time scale until achieving their final size. Introducing 6.6 mu M bioactive ligands, the highest conjugation efficiency of 93% and zeta potential of 27.5 mV is reached at the shortest delay time (200 ms), resulting in 20 nm average sized bioconjugates. Finally, in a preliminary biological application, laser scanning confocal microscopy clearly revealed an amplified cellular uptake using HIV-1 transactivator peptide-conjugated gold nanoparticles compared with nonconjugated entities within embryonic fibroblasts after a short coincubation time of 1 h. The generation of high amounts of highly pure cell-penetrating nanomarkers by the nanosecond laser-assisted fast ex situ conjugation is thus a promising method to probe biological activities such as nanodrug internalization mechanisms.
C1 [Sajti, Csaba Laszlo; Barchanski, Annette; Wagener, Philipp; Barcikowski, Stephan] Laser Zentrum Hannover eV, D-30419 Hannover, Germany.
   [Klein, Sabine] Inst Farm Anim Genet, D-31535 Neustadt, Germany.
RP Barcikowski, S (reprint author), Laser Zentrum Hannover eV, Hollerithallee 8, D-30419 Hannover, Germany.
EM s.barcikowski@lzh.de
RI Barcikowski, Stephan/I-4754-2012; Wagener, Philipp/H-1582-2012
OI Barcikowski, Stephan/0000-0002-9739-7272; 
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
FX We gratefully acknowledge the help of Kerstin Rohn (Institut fur
   Pathologie Tierarztliche Hochschule Hannover) for the transmission
   electron microscopy measurements. This work was supported by funding
   from the Deutsche Forschungsgemeinschaft (DFG, German Research
   Foundation) for the Cluster of Excellence REBIRTH (From Regenerative
   Biology to Reconstructive Therapy).
CR Berry CC, 2007, IEEE T NANOBIOSCI, V6, P262, DOI 10.1109/TNB.2007.908973
   Besner S, 2009, J PHYS CHEM C, V113, P9526, DOI 10.1021/jp809275v
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Chichkov BN, 1996, APPL PHYS A-MATER, V63, P109, DOI 10.1007/BF01567637
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dom G, 2003, NUCLEIC ACIDS RES, V31, P556, DOI 10.1093/nar/gkg160
   Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Grandbois M, 1999, SCIENCE, V283, P1727, DOI 10.1126/science.283.5408.1727                                                   
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gronbeck H, 2000, J AM CHEM SOC, V122, P3839, DOI 10.1021/ja993622x
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jain PK, 2006, J PHYS CHEM B, V110, P18243, DOI 10.1021/jp063879z
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Kabashin AV, 2003, J PHYS CHEM B, V107, P4527, DOI 10.1021/jp034345q
   Lee SH, 2008, INT J PHARMACEUT, V364, P94, DOI 10.1016/j.ijpharm.2008.07.027
   Lewinski N, 2008, SMALL, V4, P26, DOI 10.1002/smll.200700595
   Link S, 2000, J PHYS CHEM B, V104, P6152, DOI 10.1021/jp000679t
   Link S, 1999, J PHYS CHEM B, V103, P8410, DOI 10.1021/jp9917648
   Ma LL, 2009, ACS NANO, V3, P2686, DOI 10.1021/nn900440e
   Mafune F, 2000, J PHYS CHEM B, V104, P9111, DOI 10.1021/jp001336y
   Mafune F, 2001, J PHYS CHEM B, V105, P5114, DOI 10.1021/jp0037091
   NUZZO RG, 1987, J AM CHEM SOC, V109, P2358, DOI 10.1021/ja00242a020                                                             
   Peng S, 2010, P NATL ACAD SCI USA, V107, P14530, DOI 10.1073/pnas.1007524107
   Petersen S., 2009, ADV FUNCT MATER, V19, P1
   Petersen S, 2009, J PHYS CHEM C, V113, P19830, DOI 10.1021/jp905962f
   Polte J, 2010, ACS NANO, V4, P1076, DOI 10.1021/nn901499c
   Sajti CL, 2010, APPL PHYS A-MATER, V101, P259, DOI 10.1007/s00339-010-5813-y
   Sajti CL, 2010, APPL PHYS A-MATER, V100, P203, DOI 10.1007/s00339-010-5572-9
   Sajti CL, 2010, J PHYS CHEM C, V114, P2421, DOI 10.1021/jp906960g
   SAJTI L, 2007, APPL PHYS A, V89, P315
   Salmaso S, 2009, J MATER CHEM, V19, P1608, DOI 10.1039/b816603j
   Schlenoff JB, 1995, J AM CHEM SOC, V117, P12528, DOI 10.1021/ja00155a016                                                             
   Sokolov K, 2003, TECHNOL CANCER RES T, V2, P491, DOI 10.1177/153303460300200602                                                      
   Stewart KM, 2008, ORG BIOMOL CHEM, V6, P2242, DOI 10.1039/b719950c
   Sylvestre JP, 2005, APPL PHYS A-MATER, V80, P753, DOI 10.1007/s00339-004-3081-4
   Sylvestre JP, 2004, J PHYS CHEM B, V108, P16864, DOI 10.1021/jp047134+
   Thurn KT, 2007, NANOSCALE RES LETT, V2, P430, DOI 10.1007/s11671-007-9081-5
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055                                                            
   Walter Johanna G., 2010, Journal of Nanobiotechnology, V8, P21, DOI 10.1186/1477-3155-8-21
   Yong KT, 2009, PLASMONICS, V4, P79, DOI 10.1007/s11468-009-9078-2
NR 44
TC 23
Z9 23
U1 3
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1932-7447
J9 J PHYS CHEM C
JI J. Phys. Chem. C
PD MAR 31
PY 2011
VL 115
IS 12
BP 5094
EP 5101
DI 10.1021/jp1093405
PG 8
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 738MV
UT WOS:000288644800015
DA 2018-01-05
ER

PT J
AU Imamura, J
   Suzuki, Y
   Gonda, K
   Roy, CN
   Gatanaga, H
   Ohuchi, N
   Higuchi, H
AF Imamura, Junji
   Suzuki, Yasuhiro
   Gonda, Kohsuke
   Roy, Chandra Nath
   Gatanaga, Hiroyuki
   Ohuchi, Noriaki
   Higuchi, Hideo
TI Single Particle Tracking Confirms That Multivalent Tat Protein
   Transduction Domain-induced Heparan Sulfate Proteoglycan Cross-linkage
   Activates Rac1 for Internalization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 TAT; QUANTUM DOTS; LIVING CELLS;
   VESICLE TRANSPORT; BINDING MECHANISM; MOLECULE TRACKING;
   PLASMA-MEMBRANE; FUSION PROTEINS; GROWTH-FACTOR
AB The mechanism by which HIV-1-Tat protein transduction domain (TatP) enters the cell remains unclear because of an insufficient understanding of the initial kinetics of peptide entry. Here, we report the successful visualization and tracking of TatP molecular kinetics on the cell surface with 7-nm spatial precision using quantum dots. Strong cell binding was only observed with a TatP valence of >= 8, whereas monovalent TatP binding was negligible. The requirement of the cell-surface heparan sulfate (HS) chains of HS proteoglycans (HSPGs) for TatP binding and intracellular transport was demonstrated by the enzymatic removal of HS and simultaneous observation of two individual particles. Multivalent TatP induces HSPG cross-linking, recruiting activated Rac1 to adjacent lipid rafts and thereby enhancing the recruitment of TatP/HSPG to actin-associated microdomains and its internalization by macropinocytosis. These findings clarify the initial binding mechanism of TatP to the cell surface and demonstrate the importance of TatP valence for strong surface binding and signal transduction. Our data also shed light on the ability of TatP to exploit the machinery of living cells, using HSPG signaling to activate Rac1 and alter TatP mobility and internalization. This work should guide the future design of TatP-based peptides as therapeutic nano-carriers with efficient transduction.
C1 [Imamura, Junji; Suzuki, Yasuhiro; Roy, Chandra Nath] Tohoku Univ, Grad Sch Med, Dept Emerging Infect Dis, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Gonda, Kohsuke; Ohuchi, Noriaki] Tohoku Univ, Grad Sch Med, Dept Nanomed Sci, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   [Gatanaga, Hiroyuki] Int Med Ctr Japan, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan.
   [Ohuchi, Noriaki] Tohoku Univ, Dept Surg Oncol, Grad Sch Med, Aoba Ku, Sendai, Miyagi 9808574, Japan.
   [Higuchi, Hideo] Univ Tokyo, Dept Phys, Grad Sch Sci, Hongo Bunkyou Ku, Tokyo 1138654, Japan.
RP Suzuki, Y (reprint author), Tohoku Univ, Grad Sch Med, Dept Emerging Infect Dis, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM suzukiy39@med.tohoku.ac.jp
RI Roy, Chandra Nath/E-8710-2010
OI Roy, Chandra Nath/0000-0001-6667-1550
FU Ministry of Health, Labor, and Welfare of Japan; Japanese Foundation for
   AIDS Prevention
FX This work was supported by a grant-in-aid for AIDS research from the
   Ministry of Health, Labor, and Welfare of Japan and by the Japanese
   Foundation for AIDS Prevention (to Y. S.).
CR Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   BARTHOLOMEW JS, 1985, BIOCHEM J, V227, P429, DOI 10.1042/bj2270429                                                               
   Chauhan A, 2007, J CONTROL RELEASE, V117, P148, DOI 10.1016/j.jconrel.2006.10.031
   Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f
   DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961
   del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571
   Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI13530
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050
   Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101
   Gonda K, 2010, J BIOL CHEM, V285, P2750, DOI 10.1074/jbc.M109.075374
   Grande-Garcia A, 2005, BIOCHEM SOC T, V33, P609, DOI 10.1042/BST0330609                                                              
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grimmer S, 2002, J CELL SCI, V115, P2953
   Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964
   Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891                                                              
   Hikage M, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/18/185103
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637
   Lidke DS, 2005, J CELL BIOL, V170, P619, DOI 10.1083/jcb.200503140                                                           
   Liu Y, 2000, NAT MED, V6, P1380
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Mishra A, 2008, ANGEW CHEM INT EDIT, V47, P2986, DOI 10.1002/anie.200704444
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nguyen VT, 2003, EMBO J, V22, P4968, DOI 10.1093/emboj/cdg498
   Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8
   Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041                                                         
   Suzuki KGN, 2007, J CELL BIOL, V177, P717, DOI 10.1083/jcb.200609174
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064                                                     
   Tada H, 2007, CANCER RES, V67, P1138, DOI 10.1158/0008-5472.CAN-06-1185
   Toschi E, 2006, MOL BIOL CELL, V17, P1985, DOI 10.1091/mbc.E05-08-0717
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Watanabe TM, 2007, BIOPHYS J, V92, P4109, DOI 10.1529/biophysj.106.094649
   Watanabe TM, 2007, BIOCHEM BIOPH RES CO, V359, P1, DOI 10.1016/j.bbrc.2007.04.168
   Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
NR 49
TC 24
Z9 24
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 25
PY 2011
VL 286
IS 12
BP 10581
EP 10592
DI 10.1074/jbc.M110.187450
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 737CU
UT WOS:000288547000073
PM 21199870
OA gold
DA 2018-01-05
ER

PT J
AU La Regina, G
   Coluccia, A
   Brancale, A
   Piscitelli, F
   Gatti, V
   Maga, G
   Samuele, A
   Pannecouque, C
   Schols, D
   Balzarini, J
   Novellino, E
   Silvestri, R
AF La Regina, Giuseppe
   Coluccia, Antonio
   Brancale, Andrea
   Piscitelli, Francesco
   Gatti, Valerio
   Maga, Giovanni
   Samuele, Alberta
   Pannecouque, Christophe
   Schols, Dominique
   Balzarini, Jan
   Novellino, Ettore
   Silvestri, Romano
TI Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase
   Inhibitors: New Cyclic Substituents at Indole-2-carboxamide
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID INDOLYL ARYL SULFONES; DEFICIENCY SYNDROME AIDS; AMBER FORCE-FIELD;
   RESISTANCE MUTATIONS; WILD-TYPE; DRUG-RESISTANCE; CRYSTAL-STRUCTURES;
   BINDING MODE; IN-VITRO; DERIVATIVES
AB New indolylarylsulfone derivatives bearing cyclic substituents at indole-2-carboxamide linked through a methylene/ethylene spacer were potent inhibitors of the WT HIV-1 replication in CEM and PBMC cells with inhibitory concentrations in the low nanomolar range. Against the mutant L100I and K103N RT HIV-1 strains in MT-4 cells, compounds 20, 24-26, 36, and 40 showed antiviral potency superior to that of NVP and EFV. Against these mutant strains, derivatives 20, 24-26, and 40 were equipotent to ETV. Molecular docking experiments on this novel series of IAS analogues have also suggested that the H-bond interaction between the nitrogen atom in the carboxamide chain of IAS and Glu138:B is important in the binding of these compounds. These results are in accordance with the experimental data obtained on the WT and on the mutant HIV-1 strains tested.
C1 [La Regina, Giuseppe; Coluccia, Antonio; Piscitelli, Francesco; Gatti, Valerio; Silvestri, Romano] Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy.
   [Brancale, Andrea] Cardiff Univ, Welsh Sch Pharm, Cardiff CF10 3NB, S Glam, Wales.
   [Maga, Giovanni; Samuele, Alberta] CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   [Novellino, Ettore] Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   [Pannecouque, Christophe; Schols, Dominique; Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Silvestri, R (reprint author), Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM romano.silvestri@uniroma1.it
RI Schols, Dominique/S-9057-2017; Brancale, Andrea/N-9445-2014; La Regina,
   Giuseppe/I-2161-2012
OI Schols, Dominique/0000-0003-3256-5850; Brancale,
   Andrea/0000-0002-9728-3419; La Regina, Giuseppe/0000-0003-3252-1161;
   /0000-0002-7940-8206; Novellino, Ettore/0000-0002-2181-2142; Silvestri,
   Romano/0000-0003-2489-0178
FU Istituto Pasteur; Fondazione Cenci Bolognetti [2009]; FILAS (Finanziaria
   Laziale di Sviluppo) [2010]
FX The authors are indebted to Istituto Pasteur, Fondazione Cenci
   Bolognetti (Grant 2009) and FILAS (Finanziaria Laziale di Sviluppo,
   Grant 2010) for financial support. The authors also thank I. Nikolova
   and A. Galabov, Bulgarian Academy of Sciences, Sofia, Bulgaria, for the
   biological evaluation against Coxsackie B4 virus.
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   [Anonymous], FLEXX VERS 2 2
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Ceccherini-Silberstein F, 2007, J VIROL, V81, P11507, DOI 10.1128/JVI.00303-07
   [Anonymous], COD SCOR SVL WAS OBT
   [Anonymous], MOL OP ENV MOE VERS
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   Cywin CL, 1998, J MED CHEM, V41, P2972, DOI 10.1021/jm9707030
   Das K, 2008, P NATL ACAD SCI USA, V105, P1466, DOI 10.1073/pnas.0711209105
   De Clercq E, 2010, J MED CHEM, V53, P1438, DOI 10.1021/jm900932g
   De Martino Gabriella, 2006, Antiviral Chemistry & Chemotherapy, V17, P59
   [Anonymous], PYMOL VERS 1 2R1
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823                                                         
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Haubrich R, 2008, NAT REV DRUG DISCOV, V7, P287, DOI 10.1038/nrd2563
   Hawkins T, 2010, ANTIVIR RES, V85, P201, DOI 10.1016/j.antiviral.2009.10.016
   Klunder JM, 1998, J MED CHEM, V41, P2960, DOI 10.1021/jm9707028
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Korb O, 2006, LECT NOTES COMPUT SC, V4150, P247
   La Regina G, 2007, J MED CHEM, V50, P5034, DOI 10.1021/jm070488f
   La G. Regina, 2010, ANTIVIR CHEM CHEMOTH, V20, P231
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Meagher KL, 2003, J COMPUT CHEM, V24, P1016, DOI 10.1002/jcc.10262
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Menendez-Arias L, 2010, ANTIVIR RES, V85, P210, DOI 10.1016/j.antiviral.2009.07.006
   Pannecouque C, 2008, NAT PROTOC, V3, P427, DOI 10.1038/nprot.2007.517
   Paredes R, 2010, ANTIVIR RES, V85, P245, DOI 10.1016/j.antiviral.2009.09.015
   Piscitelli F, 2009, J MED CHEM, V52, P1922, DOI 10.1021/jm801470b
   Polinsky A, 2008, PRACTICE OF MEDICINAL CHEMISTRY, 3RD EDITION, P244, DOI 10.1016/B978-0-12-374194-3.00012-3
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2006, J MED CHEM, V49, P3172, DOI 10.1021/jm0512490
   Ren J, 2004, J MOL BIOL, V336, P569, DOI 10.1016/j.jmb.2003.12.055
   Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   Ren JS, 2007, J MED CHEM, V50, P2301, DOI 10.1021/jm061117m
   Silvestri R, 2004, J MED CHEM, V47, P3892, DOI 10.1021/jm031147e
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   Silvestri R, 2003, J MED CHEM, V46, P917, DOI 10.1021/jm0256124
   Silvestri R, 2006, J MED CHEM, V49, P5840, DOI 10.1021/jm0602716
   Silvestri Romano, 2004, Farmaco (Lausanne), V59, P201, DOI 10.1016/j.farmac.2003.11.004
   Sweeneyl Z. K., 2008, CURR OPIN DRUG DISC, V11, P454
   Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y
   Van Nhien AN, 2005, J MED CHEM, V48, P4276, DOI 10.1021/jm050091g
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Vingerhoets J, 2005, J VIROL, V79, P12773, DOI 10.1128/JVI.79.20.12773-12782.2005
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   Zhao ZJ, 2008, BIOORG MED CHEM LETT, V18, P554, DOI 10.1016/j.bmcl.2007.11.085
   [Anonymous], AMBERTOOLS VERS 1 4
   Williams T. A., 1992, 2009 AIDS EPIDEMIC U, Patent No. EP 0 530 907 Al
   Williams T. A, 1992, Patent Application EP, Patent No. [0 530 907 A1, 0530907]
NR 54
TC 42
Z9 43
U1 2
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 24
PY 2011
VL 54
IS 6
BP 1587
EP 1598
DI 10.1021/jm101614j
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 735GF
UT WOS:000288400700005
PM 21366296
DA 2018-01-05
ER

PT J
AU Pimpha, N
   Chaleawlert-umpon, S
   Chruewkamlow, N
   Kasinrerk, W
AF Pimpha, Nuttaporn
   Chaleawlert-umpon, Saowaluk
   Chruewkamlow, Nuttapol
   Kasinrerk, Watchara
TI Preparation of anti-CD4 monoclonal antibody-conjugated magnetic
   poly(glycidyl methacrylate) particles and their application on CD4(+)
   lymphocyte separation
SO TALANTA
LA English
DT Article
DE Immunomagnetic particles; Poly(glycidyl methacrylate); Anti-CD4
   monoclonal antibody; CD4(+) lymphocyte separation
ID HIV-INFECTED INDIVIDUALS; CELL-SEPARATION; NANOPARTICLES; MICROSPHERES;
   POLYMERIZATION; ADSORPTION; EXPANSION; BEADS
AB Novel immunomagnetic particles have been prepared for separation of CD4(+) lymphocytes. The magnetic nanoparticles with a diameter of approximately 5-6 nm were first synthesized by co-precipitation from ferrous and ferric iron solutions and subsequently encapsulated with poly(glycidyl methacrylate) (PGMA) by precipitation polymerization. Monoclonal antibody specific to CD4 molecules expressed on CD4(+) lymphocytes was conjugated to the surface of magnetic PGMA particles through covalent bonding between epoxide functional groups on the particle surface and primary amine groups of the antibodies. The generated immunomagnetic particles have successfully separated CD4(+) lymphocytes from whole blood with over 95% purity. The results indicated that these particles can be employed for cell separation and provide a strong potential to be applied in various biomedical applications including diagnosis, and monitoring of human diseases. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Pimpha, Nuttaporn; Chaleawlert-umpon, Saowaluk] Natl Sci & Technol Dev Agcy, Natl Nanotechnol Ctr, Klongluang 12120, Pathumthani, Thailand.
   [Chruewkamlow, Nuttapol; Kasinrerk, Watchara] Chiang Mai Univ, Biomed Technol Res Ctr, Natl Ctr Genet Engn & Biotechnol, Natl Sci & Technol Dev Agcy,Fac Associated Med Sc, Chiang Mai 50200, Thailand.
   [Kasinrerk, Watchara] Chiang Mai Univ, Div Clin Immunol, Dept Med Technol, Fac Associated Med Sci, Chiang Mai 50200, Thailand.
RP Pimpha, N (reprint author), Natl Sci & Technol Dev Agcy, Natl Nanotechnol Ctr, 113 Thailand Sci Pk,Pahonyothin Rd,Klong 1, Klongluang 12120, Pathumthani, Thailand.
EM Nuttaporn@nanotec.or.th; Watchara@chiangmai.ac.th
RI Pimpha, Nuttaporn/D-3724-2012
FU National Nanotechnology Center, Thailand; National Sciences and
   Technology Development Agency (Thailand); National Science and
   Development Agency Nanotechnology Center, Thailand
FX This research was financially supported from the National Nanotechnology
   Center, National Science and Development Agency Nanotechnology Center,
   Thailand and the NSTDA Research Chair Grant, National Sciences and
   Technology Development Agency (Thailand). K.M. is a Ph.D student of the
   Biomedical Sciences program, Faculty of Associated Medical Sciences,
   Chiang Mai University.
CR Abbas AK, 2003, CELLULAR MOL IMMUNOL
   Ayyappan S, 2008, J PHYS CHEM C, V112, P18376, DOI 10.1021/jp8052899
   Bayramoglu G, 2007, J HAZARD MATER, V144, P449, DOI 10.1016/j.jhazmat.2006.10.058
   Bayramoglu G, 2007, COLLOID SURFACE A, V297, P55, DOI 10.1016/j.colsurfa.2006.10.023
   Carnaud C, 2010, PRION, V4, P66, DOI 10.4161/pri.4.2.12597                                                           
   Chairam S, 2008, J MAGN MAGN MATER, V320, P2039, DOI 10.1016/j.jmmm.2008.02.168
   Chaleawlert-umpon S, 2010, J BIOMAT SCI-POLYM E, V21, P1515, DOI 10.1163/092050609X12519805626031
   Chastellain M, 2004, J Colloid Interface Sci, V278, P353, DOI 10.1016/j.jcis.2004.06.025
   Chen M, 2008, J PHYS CHEM C, V112, P6710, DOI 10.1021/jp710775j
   Chung TH, 2008, REACT FUNCT POLYM, V68, P1441, DOI 10.1016/j.reactfunctpolym.2008.07.003
   Chung TH, 2009, J MAGN MAGN MATER, V321, P1635, DOI 10.1016/j.jmmm.2009.02.103
   DEGRUTTOLA V, 1994, INFECT AGENT DIS, V2, P304
   Dybul Mark, 2002, MMWR Recomm Rep, V51, P1
   Dykes JH, 2007, TRANSFUSION, V47, P2134, DOI 10.1111/j.1537-2995.2007.01438.x
   Gao D, 2010, TALANTA, V82, P528, DOI 10.1016/j.talanta.2010.05.019
   GRUPP SA, 2010, CURR TOP MICROBIOL I
   Hatch GP, 2001, J MAGN MAGN MATER, V225, P262, DOI 10.1016/S0304-8853(00)01250-6                                                   
   Horak D, 2007, J MAGN MAGN MATER, V311, P500, DOI 10.1016/j.jmmm.2006.08.006
   Jin JM, 2007, POLYMER, V48, P3107, DOI 10.1016/j.polymer.2007.03.068
   Kim ST, 2010, NANO LETT, V10, P2877, DOI 10.1021/nl100942p
   KLYUCHNIKOV E, 2010, BIOL BLOOD MARR 0714
   Kuhara M, 2004, ANAL CHEM, V76, P6207, DOI 10.1021/ac0493727
   Liu HL, 2008, BIOMATERIALS, V29, P4003, DOI 10.1016/j.biomaterials.2008.06.031
   LIU XQ, 2003, CHINA PART, V1, P76
   McCloskey KE, 2003, ANAL CHEM, V75, P6868, DOI 10.1021/ac034315j
   Mikhaylova M, 2004, LANGMUIR, V20, P2472, DOI 10.1021/la035648e
   Neurauter AA, 2007, ADV BIOCHEM ENG BIOT, V106, P41, DOI 10.1007/10_2007_072
   Nielsen SD, 1997, J IMMUNOL METHODS, V200, P107, DOI 10.1016/S0022-1759(96)00193-7
   Nouanthong P, 2006, CLIN VACCINE IMMUNOL, V13, P598, DOI 10.1128/CVI.13.5.5.598-601.2006
   Omer-Mizrahi M, 2009, J COLLOID INTERF SCI, V329, P228, DOI 10.1016/j.jcis.2008.09.047
   Pollert E, 2006, J MAGN MAGN MATER, V306, P241, DOI 10.1016/j.jmmm.2006.03.069
   Rittich B, 2006, COLLOID SURFACE B, V52, P143, DOI 10.1016/j.colsurfb.2006.04.012
   Srithanaviboonchai K, 2008, JAIDS-J ACQ IMM DEF, V47, P135, DOI 10.1097/QAI.0b013e3181624ab5                                                    
   Stanciu LA, 1996, J IMMUNOL METHODS, V189, P107, DOI 10.1016/0022-1759(95)00240-5
   Thiel A, 1998, IMMUNOTECHNOLOGY, V4, P89, DOI 10.1016/S1380-2933(98)00010-4
   Viali WR, 2010, J PHYS CHEM C, V114, P179, DOI 10.1021/jp908732b
   Xue B, 2002, J CHROMATOGR A, V947, P185, DOI 10.1016/S0021-9673(01)01602-8
NR 37
TC 19
Z9 19
U1 1
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD MAR 15
PY 2011
VL 84
IS 1
BP 89
EP 97
DI 10.1016/j.talanta.2010.12.032
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 734OC
UT WOS:000288342400015
PM 21315903
DA 2018-01-05
ER

PT J
AU Hartono, YD
   Lee, AN
   Lee-Huang, S
   Zhang, DW
AF Hartono, Yossa Dwi
   Lee, Angelina Noviani
   Lee-Huang, Sylvia
   Zhang, Dawei
TI Computational study of bindings of HL9, a nonapeptide fragment of human
   lysozyme, to HIV-1 fusion protein gp41
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 gp41; Human lysozyme; HL9
ID SOLVATED INTERACTION ENERGY; MOLECULAR-DYNAMICS; MEMBRANE-FUSION; CORE;
   GLYCOPROTEIN; SIMULATIONS; INHIBITION; MECHANICS; COMPLEX; ENTRY
AB HL9 is a nonapeptide fragment of human lysozyme which has been shown to have anti-HIV-1 activity in nanomolar concentration. This study aims to explain this inhibitory activity by using molecular dynamics (MD) simulation, focusing on the ectodomain of gp41, the envelope glycoprotein of HIV-1 crucial to membrane fusion. It was found that in HL9, two Trp residues separated by two others occupy the conserved hydrophobic pocket on gp41 and thus inhibit fusion in dominant-negative manner. Detailed HL9-gp41 binding interactions and free energies of binding were obtained through MD simulation and solvated interaction energies (SIE) calculation, giving a binding free energy of -8.25 kcal/mol which is in close agreement with the experimental value of -9.96 kcal/mol. Since C-helical region (C34) of gp41 also has two Trp residues separated by two others, this arrangement may be generalised and used to scan peptide library and to find those having similar manner of inhibition. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Hartono, Yossa Dwi; Lee, Angelina Noviani; Zhang, Dawei] Nanyang Technol Univ, Sch Phys & Math Sci, Div Chem & Biol Chem, Singapore 637371, Singapore.
   [Lee-Huang, Sylvia] NYU, Langone Med Ctr, Dept Biochem, New York, NY 10016 USA.
RP Zhang, DW (reprint author), Nanyang Technol Univ, Sch Phys & Math Sci, Div Chem & Biol Chem, Singapore 637371, Singapore.
EM zhangdw@ntu.edu.sg
RI Zhang, Dawei/C-5981-2008
OI Hartono, Yossa Dwi/0000-0002-7829-9247; Lee-Huang,
   Sylvia/0000-0003-3302-241X
FU Nanyang Technological University; Singapore AcRF [M52110095]
FX D.W.Z. is supported in part by Nanyang Technological University start-up
   Grant, and in part by Singapore AcRF Tier 1 Grant of M52110095.
CR Bao J, 2007, FEBS LETT, V581, P2737, DOI 10.1016/j.febslet.2007.05.029
   Case D. A., 2006, AMBER, V9
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985
   Cui QZ, 2008, J MOL BIOL, V379, P787, DOI 10.1016/j.jmb.2008.04.035
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Frey G, 2006, P NATL ACAD SCI USA, V103, P13938, DOI 10.1073/pnas.0601036103
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q
   Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678
   Lee-Huang S, 2005, BIOCHEMISTRY-US, V44, P4648, DOI 10.1021/bi0477081
   Lee-Huang S, 2007, BIOCHEM BIOPH RES CO, V354, P872, DOI 10.1016/j.bbrc.2007.01.071
   Liu SW, 2007, CURR PHARM DESIGN, V13, P143, DOI 10.2174/138161207779313722
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Luo R, 2002, J COMPUT CHEM, V23, P1244, DOI 10.1002/jcc.10120
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Naim M, 2007, J CHEM INF MODEL, V47, P122, DOI 10.1021/ci600406v
   ROSSI AD, 1992, AIDS, V6, P1117
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Tsui V, 2001, J PHYS CHEM B, V105, P11314, DOI 10.1021/jp011923z
NR 24
TC 10
Z9 10
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAR 15
PY 2011
VL 21
IS 6
BP 1607
EP 1611
DI 10.1016/j.bmcl.2011.01.121
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 730DM
UT WOS:000288012800007
PM 21334893
DA 2018-01-05
ER

PT J
AU Pierre, F
   O'Brien, SE
   Haddach, M
   Bourbon, P
   Schwaebe, MK
   Stefan, E
   Darjania, L
   Stansfield, R
   Ho, C
   Siddiqui-Jain, A
   Streiner, N
   Rice, WG
   Anderes, K
   Ryckman, DM
AF Pierre, Fabrice
   O'Brien, Sean E.
   Haddach, Mustapha
   Bourbon, Pauline
   Schwaebe, Michael K.
   Stefan, Eric
   Darjania, Levan
   Stansfield, Ryan
   Ho, Caroline
   Siddiqui-Jain, Adam
   Streiner, Nicole
   Rice, William G.
   Anderes, Kenna
   Ryckman, David M.
TI Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2:
   SAR and preliminary assessment of their analgesic and anti-viral
   properties
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE CK2; Kinase inhibitor; HIV; Inflammation Pain
ID HUMAN PROSTATE-CANCER; CHANNEL FUNCTION; FORMALIN TEST; IN-VITRO;
   TARGET; PHOSPHORYLATION; STIMULATION; INSIGHTS; THERAPY; CELLS
AB We describe the discovery of novel potent substituted pyrimido[4,5-c]quinoline ATP-competitive inhibitors of protein kinase CK2. A binding model of the inhibitors with the protein was elaborated on the basis of SAR and revealed various modes of interaction with the hinge region. Representative analog 14k (CK2 IC(50) = 9 nM) showed anti-viral activity at nanomolar concentrations against HIV-1. Orally available compound 7e (CK2 IC(50) = 3 nM) reduced pain in the phase II of a murine formalin model. These preliminary data confirm that properly optimized CK2 inhibitors may be used for anti-viral and pain therapy. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Pierre, Fabrice; O'Brien, Sean E.; Haddach, Mustapha; Bourbon, Pauline; Schwaebe, Michael K.; Stefan, Eric; Darjania, Levan; Stansfield, Ryan; Ho, Caroline; Siddiqui-Jain, Adam; Streiner, Nicole; Rice, William G.; Anderes, Kenna; Ryckman, David M.] Cylene Pharmaceut, San Diego, CA 92121 USA.
RP Pierre, F (reprint author), Cylene Pharmaceut, 5820 Nancy Ridge Dr,Suite 200, San Diego, CA 92121 USA.
EM fpierre@cylenepharma.com
CR Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001
   Battistutta R, 2009, CELL MOL LIFE SCI, V66, P1868, DOI 10.1007/s00018-009-9155-x
   Battistutta R, 2007, CHEMBIOCHEM, V8, P1804, DOI 10.1002/cbic.200700307
   Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8
   BURNETT G, 1954, J BIOL CHEM, V211, P969
   Caples MJ, 2006, VIROLOGY, V348, P156, DOI 10.1016/j.virol.2005.12.028
   COZZA G, 2009, MED RES REV, V30, P419
   Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110
   Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604
   Duncan J. S., 2007, BIOCHIM BIOPHYS ACTA, V1784, P33
   Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933
   Haneda E, 2000, BIOCHEM BIOPH RES CO, V275, P434, DOI 10.1006/bbrc.2000.3319
   Harada S, 1999, BIOL PHARM BULL, V22, P1122
   Hodgetts KJ, 2003, ORG LETT, V5, P2911, DOI 10.1021/ol0350285
   HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1
   Jones S, 2003, NEUROSCIENCE, V119, P629, DOI 10.1016/S0306-4522(03)00202-1
   Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411
   Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021
   Li XQ, 2005, PAIN, V115, P182, DOI 10.1016/j.pain.2005.02.025
   Lieberman DN, 1999, NAT NEUROSCI, V2, P125, DOI 10.1038/5680                                                                    
   Najda-Bernatowicz A, 2009, BIOORGAN MED CHEM, V17, P1573, DOI 10.1016/j.bmc.2008.12.071
   Niefind K, 2009, CELL MOL LIFE SCI, V66, P1800, DOI 10.1007/s00018-009-9149-8
   Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320
   Pierre F, 2011, J MED CHEM, V54, P635, DOI 10.1021/jm101251q
   Prudent R, 2010, CANCER RES, V70, P9865, DOI 10.1158/0008-5472.CAN-10-0917
   Prudent R, 2009, CHEM BIOL, V16, P112, DOI 10.1016/j.chembiol.2009.01.004
   Quadroni M, 1998, BIOCHEMISTRY-US, V37, P6523, DOI 10.1021/bi972930+
   Ruzzene M, 2010, BBA-PROTEINS PROTEOM, V1804, P499, DOI 10.1016/j.bbapap.2009.07.018
   Saddi GM, 2000, PAIN, V89, P53, DOI 10.1016/S0304-3959(00)00348-1                                                   
   Sandholt IS, 2009, ANTI-CANCER DRUG, V20, P238, DOI 10.1097/CAD.0b013e328326472e
   Sarno S, 2005, MOL CELL BIOCHEM, V274, P69, DOI 10.1007/s11010-005-3079-z
   Sarno S, 2003, BIOCHEM J, V374, P639, DOI 10.1042/BJ20030674
   Sarno S, 2008, MOL BIOSYST, V4, P889, DOI 10.1039/b805534c
   Siddiqui-Jain A, 2010, CANCER RES, V70, P10288, DOI 10.1158/0008-5472.CAN-10-1893
   Slaton JW, 2004, MOL CANCER RES, V2, P712
   Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96
   Zhu D, 2010, MOL CELL BIOCHEM, V333, P159, DOI 10.1007/s11010-009-0216-0
   Barreau M., 1978, US, Patent No. 4110450
NR 38
TC 8
Z9 8
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAR 15
PY 2011
VL 21
IS 6
BP 1687
EP 1691
DI 10.1016/j.bmcl.2011.01.091
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 730DM
UT WOS:000288012800025
PM 21316963
DA 2018-01-05
ER

PT J
AU Lam, DT
   Binh, HN
   Nguyen, VH
   Hoang, VT
   Huy, LN
   Phuc, XN
AF Lam Dai Tran
   Binh Hai Nguyen
   Nguyen Van Hieu
   Hoang Vinh Tran
   Huy Le Nguyen
   Phuc Xuan Nguyen
TI Electrochemical detection of short HIV sequences on chitosan/Fe3O4
   nanoparticle based screen printed electrodes
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Chitosan (CS); Fe3O4 nanoparticles; Electrochemical detection; Screen
   printed electrode (SPE); Human immunodeficiency virus (HIV)
ID DNA HYBRIDIZATION; METHYLENE-BLUE; BIOSENSORS; OLIGONUCLEOTIDES;
   IMMOBILIZATION; GENOSENSOR; POLYMER; DAMAGE; VIRUS; FILMS
AB In this study, a novel CS/Fe3O4 nanobiocomposite-based platform for electrochemical detection of HIV-1 was developed. The most attractive feature of this system is a suitable microenvironment (Fe3O4 nanoparticles) which could contribute to electron transfer and thus sensitivity enhancement when using methylene blue (MB) as an external mediator and Square Wave Voltammetry (SWV), Electrochemical Impedance Spectroscopy (EIS) techniques. The proposed screen printed electrode (SPE) had a low detection limit (as low as 50 pM), acceptable stability and good reproducibility, which would be valuable for clinical diagnosis. In addition, this sensing interface may be feasibly adapted for multiplexed detection of other species of bacterial pathogens. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Lam Dai Tran; Binh Hai Nguyen; Phuc Xuan Nguyen] Vietnamese Acad Sci & Technol, Inst Mat Sci, Hanoi, Vietnam.
   [Nguyen Van Hieu] Hanoi Univ Sci & Technol, Int Training Inst Mat Sci, Hanoi, Vietnam.
   [Hoang Vinh Tran; Huy Le Nguyen] Hanoi Univ Sci & Technol, Fac Chem Technol, Hanoi, Vietnam.
RP Lam, DT (reprint author), Vietnamese Acad Sci & Technol, Inst Mat Sci, 18 Hoang Quoc Viet Rd, Hanoi, Vietnam.
EM lamtd@ims.vast.ac.vn
RI Nguyen, Huy/E-3427-2013; Nguyen, Hieu/C-7172-2011
OI Nguyen, Huy/0000-0002-8067-2565; Nguyen, Hieu/0000-0002-9613-9108; Tran,
   Hoang Vinh/0000-0003-1777-5526
FU Korean-Vietnamese joint research grant [59/2615/2010/HD-NDT]; Vietnam
   National Foundation for Science and Technology Development (NAFOSTED
   [104.03.2010.60]
FX The authors are grateful for the financial support for this work by the
   Korean-Vietnamese joint research grant (2010-2011, code
   59/2615/2010/HD-NDT) and the Vietnam National Foundation for Science and
   Technology Development (NAFOSTED) basic research grant in Chemistry
   (2011-2013, code 104.03.2010.60).
CR Arias P, 2009, J ELECTROANAL CHEM, V634, P123, DOI 10.1016/j.jelechem.2009.07.022
   Bard A.J., 2001, ELECTROCHEMICAL METH
   FRANCESCHETTI DR, 1982, J ELECTROCHEM SOC, V129, P1754, DOI 10.1149/1.2124270
   Gooding JJ, 2004, BIOSENS BIOELECTRON, V20, P260, DOI 10.1016/j.bios.2004.01.010
   Huang JL, 2010, BIOSENS BIOELECTRON, V25, P1204, DOI 10.1016/j.bios.2009.10.036
   Kara P, 2002, ELECTROCHEM COMMUN, V4, P705, DOI 10.1016/S1388-2481(02)00428-9                                                   
   Kaushik A, 2009, SENSOR ACTUAT B-CHEM, V138, P572, DOI 10.1016/j.snb.2009.02.005
   Kelley SO, 1999, SCIENCE, V283, P375, DOI 10.1126/science.283.5400.375
   Kelley SO, 1999, ANGEW CHEM INT EDIT, V38, P941, DOI 10.1002/(SICI)1521-3773(19990401)38:7<941::AID-ANIE941>3.0.CO;2-7               
   Kobayashi M, 2004, ELECTROCHEM COMMUN, V6, P337, DOI 10.1016/j.elecom.2004.01.012
   Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1
   LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3
   LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942
   Lucarelli F, 2008, ANAL CHIM ACTA, V609, P139, DOI 10.1016/j.aca.2007.12.035
   Ma ZY, 2005, J POLYM SCI POL CHEM, V43, P3433, DOI 10.1002/pola.20803
   Marrazza G, 1999, ANAL CHIM ACTA, V387, P297, DOI 10.1016/S0003-2670(99)00051-3
   Meric B, 2002, TALANTA, V56, P837, DOI 10.1016/S0039-9140(01)00650-6
   O'Handley R. C., 2000, MODERN MAGNETIC MAT
   Palecek E, 1998, BIOSENS BIOELECTRON, V13, P621, DOI 10.1016/S0956-5663(98)00017-7
   Palecek E, 2001, ANAL CHEM, V73, p74A, DOI 10.1021/ac0123936                                                               
   Pham MC, 2003, ANAL CHEM, V75, P6748, DOI 10.1021/ac034770f
   Piro B, 2005, J ELECTROANAL CHEM, V577, P155, DOI 10.1016/j.jelechem.2004.12.002
   Pividori MI, 2000, BIOSENS BIOELECTRON, V15, P291, DOI 10.1016/S0956-5663(00)00071-3
   Tran HV, 2010, MAT SCI ENG C-MATER, V30, P304, DOI 10.1016/j.msec.2009.11.008
   Tran LD, 2003, SYNTHETIC MET, V139, P251, DOI 10.1016/S0379-6779(03)00131-0
   TRAN LD, 2003, THESIS U PARIS 7 PAR
   UNAIDS, 2009, AIDS EP UPD DEC 2009
   WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543
   Wang J, 2006, BIOSENS BIOELECTRON, V21, P1887, DOI 10.1016/j.bios.2005.10.027
   Wong ELS, 2005, SENSOR ACTUAT B-CHEM, V111, P515, DOI 10.1016/j.snb.2005.03.072
   Yang LQ, 2009, BIOSENS BIOELECTRON, V25, P889, DOI 10.1016/j.bios.2009.09.002
NR 31
TC 5
Z9 5
U1 2
U2 43
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD MAR 12
PY 2011
VL 31
IS 2
BP 477
EP 485
DI 10.1016/j.msec.2010.11.007
PG 9
WC Materials Science, Biomaterials
SC Materials Science
GA 713AR
UT WOS:000286707900058
DA 2018-01-05
ER

PT J
AU Nowacek, AS
   Balkundi, S
   McMillan, J
   Roy, U
   Martinez-Skinner, A
   Mosley, RL
   Kanmogne, G
   Kabanov, AV
   Bronich, T
   Gendelman, HE
AF Nowacek, Ari S.
   Balkundi, Shantanu
   McMillan, JoEllyn
   Roy, Upal
   Martinez-Skinner, Andrea
   Mosley, R. Lee
   Kanmogne, Georgette
   Kabanov, Alexander V.
   Bronich, Tatiana
   Gendelman, Howard E.
TI Analyses of nanoformulated antiretroviral drug charge, size, shape and
   content for uptake, drug release and antiviral activities in human
   monocyte-derived macrophages
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Antiretroviral; Nanoparticles; HIV; Crystalline; Macrophage; Monocyte;
   Nanomedicine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WATER-SOLUBLE DRUGS; ANTI-HIV DRUGS;
   PHYSICOCHEMICAL PROPERTIES; DELIVERY; THERAPY; NANOPARTICLES; CELLS;
   PHARMACOKINETICS; ADHERENCE
AB Long-term antiretroviral therapy (ART) for human immunodeficiency virus type one (HIV-1) infection shows limitations in pharmacokinetics and biodistribution while inducing metabolic and cytotoxic aberrations. In turn, ART commonly requires complex dosing schedules and leads to the emergence of viral resistance and treatment failures. We posit that the development of nanoformulated ART could preclude such limitations and affect improved clinical outcomes. To this end, we wet-milled 20 nanoparticle formulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz, collectively referred to as "nanoART," then assessed their performance using a range of physicochemical and biological tests. These tests were based on cell-nanoparticle interactions using monocyte-derived macrophages and their abilities to uptake and release nanoformulated drugs and affect viral replication. We demonstrate that physical characteristics such as particle size, surfactant coating, surface charge, and most importantly shape are predictors of cell uptake and antiretroviral efficacy. These studies bring this line of research a step closer to developing nanoART that can be used in the clinic to affect the course of HIV-1 infection. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Nowacek, Ari S.; Balkundi, Shantanu; McMillan, JoEllyn; Roy, Upal; Martinez-Skinner, Andrea; Mosley, R. Lee; Kanmogne, Georgette; Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Kabanov, Alexander V.; Bronich, Tatiana] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
   [Mosley, R. Lee; Kabanov, Alexander V.; Bronich, Tatiana; Gendelman, Howard E.] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE 68198 USA.
RP Gendelman, HE (reprint author), 985880 Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
EM anowacek@unmc.edu; sbalkundi@unmc.edu; jmmcmillan@unmc.edu;
   uroy@unmc.edu; amartinezskinner@unmc.edu; rlmosley@unmc.edu;
   gkanmogne@unmc.edu; akabanov@unmc.edu; tbronich@unmc.edu;
   hegendel@unmc.edu
RI ROY, UPAL/C-6126-2012
OI Roy, Upal/0000-0002-0325-567X
FU National Institutes of Health [1P01 DA028555, 2R01 NS034239, 2R37
   NS36126, P01 NS31492, P20RR 15635, P01MH64570, P01 NS43985]; Baxter
   Healthcare
FX The work was supported by the National Institutes of Health grants 1P01
   DA028555, 2R01 NS034239, 2R37 NS36126, P01 NS31492, P20RR 15635,
   P01MH64570, and P01 NS43985 (to H.E.G.) and from a research grant from
   Baxter Healthcare. The authors thank Ms. Robin Taylor for critical
   reading of the manuscript and outstanding graphic and literary support.
   The authors also would like to thank Dr. Han Chen and Dr. You Zhou of
   the University of Nebraska-Lincoln electron microscopy core facility for
   supplying the scanning and transmission electron microscopy images. The
   authors would also like to thank Megan Marquardt and LeAnn Tiede for
   assistance in acquiring the live-cell confocal microscopy videos.
CR Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006
   Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129
   Benaroch P, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-29
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Caldorera-Moore M, 2010, EXPERT OPIN DRUG DEL, V7, P479, DOI 10.1517/17425240903579971
   Chirenje ZM, 2010, EXPERT REV ANTI-INFE, V8, P1177, DOI 10.1586/ERI.10.79
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Danel C, 2009, J INFECT DIS, V199, P66, DOI 10.1086/595298
   das Neves J, 2010, ADV DRUG DELIVER REV, V62, P458, DOI 10.1016/j.addr.2009.11.017
   Destache CJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-198
   Doshi N, 2010, J R SOC INTERFACE, V7, pS403, DOI 10.1098/rsif.2010.0134.focus
   Dou HY, 2007, VIROLOGY, V358, P148, DOI 10.1016/j.virol.2006.08.012
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Ferrari M, 2008, NAT NANOTECHNOL, V3, P131, DOI 10.1038/nnano.2008.46
   Garvie PA, 2009, J ADOLESCENT HEALTH, V44, P124, DOI 10.1016/j.jadohealth.2008.05.006
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Hu JH, 2004, DRUG DEV IND PHARM, V30, P233, DOI 10.1081/DDC-120030422
   Huang XL, 2010, BIOMATERIALS, V31, P438, DOI 10.1016/j.biomaterials.2009.09.060
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   KALTER DC, 1991, J IMMUNOL, V146, P298
   Kuroda MJ, 2010, J LEUKOCYTE BIOL, V87, P569, DOI 10.1189/jlb.0909626
   Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32
   Mahajan SD, 2010, CURR HIV RES, V8, P396
   Mallipeddi R, 2010, INT J NANOMED, V5, P533
   Meade CS, 2009, AIDS PATIENT CARE ST, V23, P259, DOI 10.1089/apc.2008.0210
   Moreno S, 2010, J ANTIMICROB CHEMOTH, V65, P827, DOI 10.1093/jac/dkq061
   Nowacek A, 2010, J NEUROIMMUNE PHARM, V5, pS31
   Nowacek A, 2009, NANOMEDICINE-UK, V4, P557, DOI 10.2217/NMM.09.38
   Nowacek AS, 2009, NANOMEDICINE-UK, V4, P903, DOI [10.2217/nnm.09.71, 10.2217/NNM.09.71]
   Parikh UM, 2009, J VIROL, V83, P10358, DOI 10.1128/JVI.01073-09
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Rao KS, 2009, EXPERT OPIN DRUG DEL, V6, P771, DOI 10.1517/17425240903081705
   Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000                                                 
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Royal SW, 2009, AIDS CARE, V21, P448, DOI 10.1080/09540120802270250
   Shannon MV, 2007, HADDAD WINCHESTERS C
   Slowing I, 2006, J AM CHEM SOC, V128, P14792, DOI 10.1021/ja0645943
   Takatsuka T, 2009, CHEM PHARM BULL, V57, P1061, DOI 10.1248/cpb.57.1061                                                             
   Tanaka Y, 2009, CHEM PHARM BULL, V57, P1050, DOI 10.1248/cpb.57.1050                                                             
   Vallhov H, 2007, NANO LETT, V7, P3576, DOI 10.1021/nI0714785
   Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005
   van 't Klooster G, 2010, ANTIMICROB AGENTS CH, V54, P2042, DOI 10.1128/AAC.01529-09
   Varatharajan L, 2009, ANTIVIR RES, V82, pA99, DOI 10.1016/j.antiviral.2008.12.013
   von Hentig N, 2008, J ANTIMICROB CHEMOTH, V62, P579, DOI 10.1093/jac/dkn204
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wong HL, 2010, ADV DRUG DELIVER REV, V62, P503, DOI 10.1016/j.addr.2009.11.020
   Yang L, 2010, BIOORGAN MED CHEM, V18, P117, DOI 10.1016/j.bmc.2009.11.013
   Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082
NR 53
TC 58
Z9 59
U1 0
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 10
PY 2011
VL 150
IS 2
BP 204
EP 211
DI 10.1016/j.jconrel.2010.11.019
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 752OG
UT WOS:000289701200011
PM 21108978
OA green_accepted
DA 2018-01-05
ER

PT J
AU Wang, RB
   Xue, CH
   Gao, M
   Qi, HL
   Zhang, CX
AF Wang, Ruibing
   Xue, Chenghu
   Gao, Mei
   Qi, Honglan
   Zhang, Chengxiao
TI Ultratrace voltammetric method for the detection of DNA sequence related
   to human immunodeficiency virus type 1
SO MICROCHIMICA ACTA
LA English
DT Article
DE DNA hybridization; Human immunodeficiency virus; Microelectrode;
   Multiwall carbon-nanotubes; Silver nanoparticle
ID ELECTROCHEMICAL DETECTION; CARBON-NANOTUBES; SILVER NANOPARTICLES;
   HYBRIDIZATION; PROBE; AMPLIFICATION; BIOSENSOR; SURFACES; TRANSDUCTION;
   ELECTRODES
AB An ultra-trace voltammetric method was developed for the determination of single strand DNA (ss-DNA) related to the human immunodeficiency virus type 1 (HIV-1). It is based on the signal amplification of carbon nanotubes loaded with silver nanoparticles and placed on a gold microelectrode. The capture ss-DNA (a 21-mer) possessing a thiol group at the 3' end was self-assembled onto the surface of the gold microelectrode. It was then hybridized with target HIV-1 ss-DNA (a 42-mer) and further hybridized with the electrochemical probe (a 18-mer ss-DNA) tagged with multiwall carbon nanotubes and loaded with silver nanoparticles. The resulting formation of a DNA sandwich conjugate led to a strong electrochemical oxidation signal that was linearly proportional to the concentration of HIV-1 ss-DNA in the range from 1.0 to 100 pM. The detection limit was 0.5 pM (at an S/N of 3). This was equivalent to 0.05 fmol of HIV-1 ss-DNA in a volume of 20 mu L. The relative standard deviation was 4.0% at 1.0 pM (n=11). Non-complementary ss-DNA of HIV-1 ss-DNA was effectively discriminated. This work demonstrates that the employment of the microelectrode and a sandwich hybridization model is promising in terms of sensitive and selective electrochemical detection of DNA.
C1 [Wang, Ruibing; Xue, Chenghu] Yulin Univ, Sch Chem & Chem Engn, Yulin 719000, Peoples R China.
   [Xue, Chenghu; Gao, Mei; Qi, Honglan; Zhang, Chengxiao] Shaanxi Normal Univ, Sch Chem & Mat Sci, Key Lab Analyt Chem Life Sci Shaanxi Prov, Xian 710062, Peoples R China.
RP Wang, RB (reprint author), Yulin Univ, Sch Chem & Chem Engn, Yulin 719000, Peoples R China.
EM ylcwrb@163.com; honglanqi@snnu.edu.cn
FU National Science Foundations of China [20805028]; Yulin Science and
   Technology Bureau [Shfz200816]
FX Financial supports from the National Science Foundations of China (No.
   20805028) and Social Development Project of Yulin Science and Technology
   Bureau (No. Shfz200816) are gratefully acknowledged.
CR Bouchet A, 2007, BIOSENS BIOELECTRON, V23, P735, DOI 10.1016/j.bios.2007.06.018
   DAVIS GR, 1990, J INFECT DIS, V162, P13, DOI 10.1093/infdis/162.1.13                                                         
   de-Los-Santos-Alvarez P, 2002, ANAL CHEM, V74, P3342, DOI 10.1021/ac015749m
   Gao M, 2008, ELECTROANAL, V20, P123, DOI 10.1002/clan.200703998
   He PA, 2006, MICROCHIM ACTA, V152, P175, DOI 10.1007/s00604-005-0445-1
   He W, 2008, ANAL CHEM, V80, P8424, DOI 10.1021/ac801005d
   Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586                                                               
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Kabilov M, 2004, NUCLEOS NUCLEOT NUCL, V23, P1023, DOI 10.1081/NCN-200026060
   Kesselring D, 2008, J AM CHEM SOC, V130, P11290, DOI 10.1021/ja804661h
   Kim BC, 2009, ANAL CHEM, V81, P2388, DOI 10.1021/ac802267u
   Laczka O, 2009, ANAL CHIM ACTA, V641, P1, DOI 10.1016/j.aca.2009.03.008
   Li D, 2007, CHEM COMMUN, P3544, DOI 10.1039/b704731b
   Lin Z, 2008, ANAL CHEM, V80, P6830, DOI 10.1021/ac801389d
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700                                                          
   NICHOLLS PJ, 1989, J CLIN LAB ANAL, V3, P122, DOI 10.1002/jcla.1860030210                                                         
   Niu SY, 2006, J ELECTROANAL CHEM, V597, P111, DOI 10.1016/j.jelechem.2006.09.005
   Patolsky F, 2001, J AM CHEM SOC, V123, P5194, DOI 10.1021/ja0036256
   Peterson AW, 2001, NUCLEIC ACIDS RES, V29, P5163, DOI 10.1093/nar/29.24.5163                                                          
   Peterson AW, 2002, J AM CHEM SOC, V124, P14601, DOI 10.1021/ja0279996
   Qi H, 2007, TALANTA, V72, P1030, DOI 10.1016/j.talanta.2006.12.032
   Reisberg S, 2006, BIOELECTROCHEMISTRY, V69, P172, DOI 10.1016/j.bioelechem.2005.12.007
   Rijiravanich P, 2008, ANAL CHEM, V80, P3904, DOI 10.1021/ac701867m
   Shao YH, 1997, ANAL CHEM, V69, P1627, DOI 10.1021/ac960887a                                                               
   Wang J, 2004, J AM CHEM SOC, V126, P3010, DOI 10.1021/ja031723w
   Wang J, 2003, ELECTROCHEM COMMUN, V5, P1000, DOI 10.1016/j.elecom.2003.09.010
   Wang J, 2003, ANAL CHEM, V75, P3941, DOI 10.1021/ac0344079
   Wang J, 2003, LANGMUIR, V19, P989, DOI 10.1021/la026697e
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032
   Zhang J, 2008, ANAL CHEM, V80, P2888, DOI 10.1021/ac701995g
   Zhu NN, 2003, ANAL CHIM ACTA, V481, P181, DOI 10.1016/S0003-2670(03)00123-5
NR 32
TC 7
Z9 7
U1 0
U2 26
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-3672
J9 MICROCHIM ACTA
JI Microchim. Acta
PD MAR
PY 2011
VL 172
IS 3-4
BP 291
EP 297
DI 10.1007/s00604-010-0490-2
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 762ZN
UT WOS:000290521600006
DA 2018-01-05
ER

PT J
AU Marchand, V
   Santerre, M
   Aigueperse, C
   Fouillen, L
   Saliou, JM
   Van Dorsselaer, A
   Sanglier-Cianferani, S
   Branlant, C
   Motorin, Y
AF Marchand, Virginie
   Santerre, Maryline
   Aigueperse, Christelle
   Fouillen, Laetitia
   Saliou, Jean-Michel
   Van Dorsselaer, Alain
   Sanglier-Cianferani, Sarah
   Branlant, Christiane
   Motorin, Yuri
TI Identification of protein partners of the human immunodeficiency virus 1
   tat/rev exon 3 leads to the discovery of a new HIV-1 splicing regulator,
   protein hnRNP K
SO RNA BIOLOGY
LA English
DT Article
DE virus HIV-1; RNP affinity chromatography; mass spectrometry; splicing
   regulation; nucleolin; hnRNP K
ID RNA-BINDING SPECIFICITY; PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN-K;
   SR PROTEINS; POSTTRANSCRIPTIONAL REGULATION; COOPERATIVE BINDING;
   SECONDARY STRUCTURE; DOMAINS DETERMINE; ENHANCER COMPLEX; ALTERNATIVE
   EXON
AB HIV-1 pre-mRNA splicing depends upon 4 donor and 8 acceptor sites, which are used in combination to produce more than 40 different mRNAs. The acceptor site A7 plays an essential role for tat and rev mRNA production. The SLS2-A7 stem-loop structure containing site A7 was also proposed to modulate HIV-1 RNA export by the Rev protein. To further characterize nuclear factors involved in these processes, we purified RNP complexes formed by incubation of SLS2-A7 RNA transcripts in HeLa cell nuclear extracts by affinity chromatography and identified 33 associated proteins by nanoLC-MS/MS. By UV cross-linking, immunoselection and EMSA, we showed that, in addition to the well-known hnRNP A1 inhibitor of site A7, nucleolin, hnRNP H and hnRNP K interact directly with SLS2-A7 RNA. Nucleolin binds to a cluster of successive canonical NRE motifs in SLS2-A7 RNA, which is unique in HIV-1 RNA. Proteins hnRNP A1 and hnRNP K bind synergistically to SLS2-A7 RNA and both have a negative effect on site A7 activity. By the use of a plasmid expressing a truncated version of HIV-1 RNA, we showed a strong effect of the overexpression of hnRNP K in HeLa cells on HIV-1 alternative splicing. As a consequence, production of the Nef protein was strongly reduced. Interestingly also, many proteins identified in our proteomic analysis are known to modulate either the Rev activity or other mechanisms required for HIV-1 multiplication and several of them seem to be recruited by hnRNP K, suggesting that hnRNP K plays an important role for HIV-1 biology.
C1 [Marchand, Virginie; Santerre, Maryline; Aigueperse, Christelle; Branlant, Christiane; Motorin, Yuri] Nancy Univ, CNRS UHP, Lab ARN RNP Maturat Struct Fonct Enzymol Mol & St, Fac Sci & Technol,UMR7214, Strasbourg, France.
   [Fouillen, Laetitia; Saliou, Jean-Michel; Van Dorsselaer, Alain; Sanglier-Cianferani, Sarah] Univ Strasbourg, CNRS, Lab Spectrometrie Masse BioOrgan LSMBO, IPHC,UMR7178, Strasbourg, France.
RP Branlant, C (reprint author), Nancy Univ, CNRS UHP, Lab ARN RNP Maturat Struct Fonct Enzymol Mol & St, Fac Sci & Technol,UMR7214, Strasbourg, France.
EM Christiane.Branlant@maem.uhp-nancy.fr
RI MARCHAND, Virginie/A-6866-2012; MOTORIN, Yuri/E-2499-2011
FU Alsace Region; ALIX compagny; Centre National de la Recherche
   Scientifique (CNRS); the french "Ministere de la Recherche et de
   l'Enseignement Superieur"; Universite de Strasbourg (UdS); the french
   "Agence Nationale de la Recherche sur le SIDA" (ANRS) [05195-06194,
   08061-09069]; the french "Agence Nationale pour la Recherche" (ANR)
   [ANR-05-BLAN-0261-03]; European Community [LSHG-CT-2005-518238]; the
   "Pole de Recherche Scientifique et Technologique Bioingenierie" of
   Region Lorraine
FX R. Luhrmann is thanked for his generous gift of plasmids MS2-MBP and
   pAdML-M3 and for the training in his laboratory of V.M.D. Black is
   acknowledged for his generous gift of plasmid pET15b-hnRNP H. J.
   Stevenin is thanked for his generous gift of plasmids pXJ41 and
   pXJ41-ASF/SF2 and the ASF/SF2 antibodies. P. Bouvet is thanked for his
   generous gift of plasmid pET15b-p30. G. Dreyfuss is thanked for his
   generous gift of plasmid. pET11a-hnRNPA1 and hnRNP A1 specific
   antibodies. J. Valcarcel is acknowledged for his generous gift of
   U2AF<SUP>65</SUP> specific antibodies. A. M. Aubertin is thanked for
   giving us the MaTG0020 antibody directed against the Nef protein. S.
   Muller is thanked for her generous gift of nucleolin antibodies. We
   thank C.M. Stoltzfus from Iowa University for the generous gift of
   plasmid p Delta PSP. V.M. and M.S. were fellows of the french "Ministere
   de la Recherche et de l'Enseignement Superieur". V.M. was a
   post-doctoral fellow of the EURASNET European network. MS was a fellow
   of the Sidaction foundation for her last year of Ph.D., preparation.
   L.F. was supported by the Alsace Region and ALIX compagny. J.M.S. was a
   post-doctoral fellow of Sidaction foundation. This work was supported by
   the Centre National de la Recherche Scientifique (CNRS), the french
   "Ministere de la Recherche et de l'Enseignement Superieur", the
   Universite de Strasbourg (UdS), the Alsace Region, the french "Agence
   Nationale de la Recherche sur le SIDA" (ANRS) (Contracts numbers
   05195-06194 and 08061-09069), the french "Agence Nationale pour la
   Recherche" (ANR) (contract number ANR-05-BLAN-0261-03), the European
   Community (EURASNET Rex, Contract number LSHG-CT-2005-518238) and the
   "Pole de Recherche Scientifique et Technologique Bioingenierie" of
   Region Lorraine.
CR Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870
   Bacharach E, 2000, J VIROL, V74, P11027, DOI 10.1128/JVI.74.23.11027-11039.2000
   BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607                                                           
   Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048
   Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025
   Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347
   Bouvet P, 2001, J MOL BIOL, V309, P763, DOI 10.1006/jmbi.2001.4691
   Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060                                                        
   Caputi M, 2001, J BIOL CHEM, V276, P43850, DOI 10.1074/jbc.M102861200                                                          
   Chen CY, 2000, GENE DEV, V14, P1236
   Chen HC, 2002, J BIOL CHEM, V277, P40403, DOI 10.1074/jbc.M206981200
   Chou MY, 1999, MOL CELL BIOL, V19, P69
   COCHRANE AW, 1990, J VIROL, V64, P881
   Cullen BR, 2003, TRENDS BIOCHEM SCI, V28, P419, DOI 10.1016/S0968-0004(03)00142-7
   Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2
   Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075
   Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091
   De Vos RCH, 2007, NAT PROTOC, V2, P778, DOI 10.1038/nprot.2007.95
   Deckert J, 2006, MOL CELL BIOL, V26, P5528, DOI 10.1128/MCB.00582-06
   Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200
   Fang JH, 2004, VIROLOGY, V330, P471, DOI 10.1016/j.virol.2004.09.039
   Finger LD, 2004, BIOCHEMISTRY-US, V43, P6937, DOI 10.1021/bi049904d
   FISETTE JF, 2009, RNA, V16, P228
   Ginisty H, 2000, J BIOL CHEM, V275, P18845, DOI 10.1074/jbc.M002350200
   Ginisty H, 1999, J CELL SCI, V112, P761
   Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200                                                          
   Griffith BN, 2006, BBA-GENE STRUCT EXPR, V1759, P552, DOI 10.1016/j.bbaexp.2006.10.001
   HALLAY H, 2006, THESIS H POINCARE U
   Hallay H, 2006, J BIOL CHEM, V281, P37159, DOI 10.1074/jbc.M603864200
   Hamasaki K, 1998, BIOCHEMISTRY-US, V37, P656, DOI 10.1021/bi971095t
   Hartmuth Klaus, 2004, Methods Mol Biol, V257, P47, DOI 10.1385/1-59259-750-5:047
   Huang Y, 2009, FEBS LETT, V583, P638, DOI 10.1016/j.febslet.2009.01.028
   Jablonski JA, 2009, J VIROL, V83, P981, DOI 10.1128/JVI.01801-08
   Jacquenet S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-33
   Jacquenet S, 2001, J BIOL CHEM, V276, P40464, DOI 10.1074/jbc.M104070200
   Jacquenet S, 2001, NUCLEIC ACIDS RES, V29, P464, DOI 10.1093/nar/29.2.464                                                            
   Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088
   Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687                                                          
   LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549                                                         
   Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709
   Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276
   Marchand V, 2002, J MOL BIOL, V323, P629, DOI 10.1016/S0022-2836(02)00967-1
   Mayeda A, 1999, MOL CELL BIOL, V19, P1853
   McLaren M, 2009, VIROLOGY, V385, P93, DOI 10.1016/j.virol.2008.10.049
   Michienzi A, 2000, P NATL ACAD SCI USA, V97, P8955, DOI 10.1073/pnas.97.16.8955                                                         
   Miguet L, 2009, J PROTEOME RES, V8, P3346, DOI 10.1021/pr801102c
   Mikula M, 2006, PROTEOMICS, V6, P2395, DOI 10.1002/pmic.200500632
   Mongelard F, 2007, TRENDS CELL BIOL, V17, P80, DOI 10.1016/j.tcb.2006.11.010
   Nekhai S, 2006, FUTURE MICROBIOL, V1, P417, DOI 10.2217/17460913.1.4.417
   Nicol SM, 2010, METHODS MOL BIOL, V587, P265, DOI 10.1007/978-1-60327-355-8_19
   Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522
   Okunola HL, 2009, MOL CELL BIOL, V29, P5620, DOI 10.1128/MCB.01678-08
   PURCELL DFJ, 1993, J VIROL, V67, P6365
   Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479
   Revil T, 2009, J BIOL CHEM, V284, P21458, DOI 10.1074/jbc.M109.019711
   Ropers D, 2004, J BIOL CHEM, V279, P29963, DOI 10.1074/jbc.M404452200
   Saliou JM, 2009, FRONT BIOSCI-LANDMRK, V14, P2714, DOI 10.2741/4008
   Schaub MC, 2007, J BIOL CHEM, V282, P13617, DOI 10.1074/jbc.M700774200
   Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109
   Si ZH, 1998, MOL CELL BIOL, V18, P5404, DOI 10.1128/MCB.18.9.5404                                                           
   STAFFA A, 1995, MOL CELL BIOL, V15, P4597
   STOLTZFUS MC, 2009, ADV VIRUS RES, V74, P1
   Tange TO, 2001, J MOL BIOL, V312, P649, DOI 10.1006/jmbi.2001.4971                                                          
   Tange TO, 2001, EMBO J, V20, P5748
   Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136
   Ueno T, 2004, MICROBIOL IMMUNOL, V48, P111, DOI 10.1111/j.1348-0421.2004.tb03496.x                                              
   Watts JM, 2009, NATURE, V460, P711, DOI 10.1038/nature08237
   Wolf D, 2008, CELL HOST MICROBE, V4, P398, DOI 10.1016/j.chom.2008.08.013
   Woolaway K, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-28
   Yang Jian-Ping, 2002, Oncogene, V21, P7187, DOI 10.1038/sj.onc.1205759
   Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933
   Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9                                                   
NR 72
TC 20
Z9 20
U1 0
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1547-6286
J9 RNA BIOL
JI RNA Biol.
PD MAR-APR
PY 2011
VL 8
IS 2
SI SI
BP 325
EP 342
DI 10.4161/rna/8.2.13984
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 755MA
UT WOS:000289934300019
PM 21368586
DA 2018-01-05
ER

PT J
AU Smith, AB
   Charnley, AK
   Hirschmann, R
AF Smith, Amos B., III
   Charnley, Adam K.
   Hirschmann, Ralph
TI Pyrrolinone-Based Peptidomimetics. "Let the Enzyme or Receptor be the
   Judge"
SO ACCOUNTS OF CHEMICAL RESEARCH
LA English
DT Review
ID HIV-1 PROTEASE INHIBITORS; SCALEMIC 3,5,5-TRISUBSTITUTED
   PYRROLIN-4-ONES; PEPTIDE HYBRID LIGAND; RAY CRYSTAL-STRUCTURE; CLASS-II;
   2ND-GENERATION SYNTHESIS; BIOLOGICAL EVALUATION; STRUCTURAL-ANALYSIS;
   IMPROVED TRANSPORT; ANTIVIRAL ACTIVITY
AB Peptides and proteins, evolved by nature to perform vital biological functions, would constitute ideal candidates for therapeutic intervention were it not for their generally poor pharmacokinetic profiles. Nonpeptide peptidomimetics have thus been pursued because they might overcome these limitations while maintaining both the potency and selectivity of the parent peptide or protein. Since the late 1980s, we have sought to design, synthesize, and evaluate a novel, proteolytically stable nonpeptide peptidomimetic scaffold consisting of a repeating structural unit amenable to iterative construction; a primary concern is maintaining both the appropriate peptide-like side-chains and requisite hydrogen bonding. In this Account, we detail how efforts in the Smith-Hirschmann laboratories culminated in the identification of the 3,5-linked polypyrrolinone scaffold.
   We developed effective synthetic protocols, both in solution and on solid supports, for iterative construction of diverse polypyrrolinones that present functionalized peptide-like side-chains. As a result of the rigid nature of the pyrrolinone scaffold, control over the backbone conformation could be exerted by modulation of the stereogenicity of the constituent monomers and the network of intramolecular hydrogen bonding. The extended conformation of the homochiral 3,5-linked polypyrrolinone scaffold proved to be an excellent mimic for beta-strands and beta-sheets. Application to enzyme inhibitor design and synthesis led not only to modest inhibitors of the aspartic acid protease renin and the matrix metalloprotease class of enzymes, but importantly to bioavailable HIV-1 protease inhibitors with subnanomolar binding constants.
   The design and synthesis of a competent peptide-pyrrolinone hybrid ligand for the class II major histocompatibility complex (MHC) antigen protein HLA-DR1 further demonstrated the utility of the 3,5-polypyrrolinone motif as a mimic for the extended polyproline type II peptide backbone. Equally important, we sought to define, by synthesis, the additional conformational space accessible to the polypyrrolinone structural motif, with the ultimate goal of accessing pyrrolinone-based turn and helix mimetics. Toward this end, a mono-N-methylated bispyrrolinone was found to adopt an extended helical array in the solid state. Subsequent synthesis of D,L-alternating (heterochiral) tetrapyrrolinones both validated the expected turn conformations in solution and led to a functionally active mimetic of a peptidal beta-turn (similar to somatostatin). Finally, the design, synthesis, and structural evaluation of both acyclic and cyclic heterochiral (that is, D,L-alternating) hexapyrrolinones yielded nanotube-like assemblies in the solid state. Taken together, these results illustrate the remarkable potential of the 3,5-linked polypyrrolinone scaffold as beta-strand, beta-sheet, beta-turn, and potentially helical peptidomimetics.
C1 [Smith, Amos B., III; Charnley, Adam K.; Hirschmann, Ralph] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
RP Smith, AB (reprint author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
EM smithab@sas.upenn.edu
FU NIH [GM-41821]; Merck Research Laboratories; Hoffmann-La Roche
FX A.B.S. dedicates this Account to the memory of Ralph Hirschmann, friend,
   colleague, and mentor. We thank our many co-workers and collaborators
   who have contributed greatly to this research program, and whose names
   appear in the references cited. Financial support was provided by the
   NIH, through Grant GM-41821, and by the Merck Research Laboratories and
   Hoffmann-La Roche.
CR Bolin D. R., UNPUB
   Brewster UC, 2003, AM J MED SCI, V326, P15, DOI 10.1097/00000441-200307000-00003                                                
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   CHAMLEY A, 2005, THESIS U PENNSYLVANI
   Clark TD, 1998, J AM CHEM SOC, V120, P8949, DOI 10.1021/ja981485i                                                               
   DESANTIS P, 1974, MACROMOLECULES, V7, P52, DOI 10.1021/ma60037a011                                                             
   FAVOR DA, 1998, THESIS U PENNSYLVANI
   GREENHILL JV, 1977, CHEM SOC REV, V6, P277, DOI 10.1039/cs9770600277                                                            
   GUZMAN MC, 1994, THESIS U PENNSYLVANI
   HAMMER J, 1994, P NATL ACAD SCI USA, V91, P4456, DOI 10.1073/pnas.91.10.4456
   Hanessian S, 2008, J ORG CHEM, V73, P1181, DOI 10.1021/jo701621c
   HIROI K, 1972, CHEM PHARM BULL, V20, P246
   HIRSCHMANN R, 1992, J AM CHEM SOC, V114, P9217, DOI 10.1021/ja00049a081
   Hirschmann RF, 2009, ACCOUNTS CHEM RES, V42, P1511, DOI 10.1021/ar900020x
   HUISGEN R, 1957, CHEM BER-RECL, V90, P1432, DOI 10.1002/cber.19570900807                                                        
   Umeyama H., 1988, J MED CHEM, V31, P701
   Johnson W H, 1987, J Enzyme Inhib, V2, P1, DOI 10.3109/14756368709030352
   KANE IL, 1975, ACTA CRYSTALLOGR B, V31, P555
   KARADY S, 1984, TETRAHEDRON LETT, V25, P4337, DOI 10.1016/S0040-4039(01)81432-5                                                   
   Lee KH, 2000, J AM CHEM SOC, V122, P8370, DOI 10.1021/ja000994t
   LULY Jr, 1988, J MED CHEM, V31, P2264, DOI 10.1021/jm00120a005
   LYLE TA, 1991, J MED CHEM, V34, P1228, DOI 10.1021/jm00107a051                                                             
   Nicolaou K. C., 1990, DESIGN SYNTHESIS PEP, P881
   NUTT RF, 1983, INT J PEPT PROT RES, V21, P66
   PRECIGOUX G, 1987, J AM CHEM SOC, V109, P7463, DOI 10.1021/ja00258a034
   Rich D. H., 1990, COMPREHENSIVE MED CH, V2, P391
   SEEBACH D, 1981, HELV CHIM ACTA, V64, P2704, DOI 10.1002/hlca.19810640829                                                        
   SEEBACH D, 1985, HELV CHIM ACTA, V68, P1243, DOI 10.1002/hlca.19850680521
   Seebach D, 1996, ANGEW CHEM INT EDIT, V35, P2708, DOI 10.1002/anie.199627081                                                          
   Smith AB, 2000, J AM CHEM SOC, V122, P11037, DOI 10.1021/ja002964w
   Smith AB, 2006, BIOORG MED CHEM LETT, V16, P859, DOI 10.1016/j.bmcl.2005.11.011
   Smith AB, 2005, ORG LETT, V7, P399, DOI 10.1021/ol0476974
   Smith AB, 1997, J MED CHEM, V40, P2440, DOI 10.1021/jm970195u                                                               
   Smith AB, 2003, J MED CHEM, V46, P1831, DOI 10.1021/jm0204587
   Smith AB, 1996, BIOORGAN MED CHEM, V4, P1021, DOI 10.1016/0968-0896(96)00094-6
   Smith AB, 2000, ORG LETT, V2, P3809, DOI 10.1021/ol000254p
   Smith AB, 1999, J AM CHEM SOC, V121, P9286, DOI 10.1021/ja991251e                                                               
   SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093
   SMITH AB, 1993, TETRAHEDRON LETT, V34, P63, DOI 10.1016/S0040-4039(00)60058-8
   SMITH AB, 1994, J MED CHEM, V37, P215, DOI 10.1021/jm00028a001
   SMITH AB, 1995, J AM CHEM SOC, V117, P11113, DOI 10.1021/ja00150a011                                                             
   Smith AB, 1997, TETRAHEDRON LETT, V38, P3809, DOI 10.1016/S0040-4039(97)00752-1                                                   
   Smith AB, 2000, ORG LETT, V2, P2041, DOI 10.1021/ol005931u
   Smith AB, 2000, ORG LETT, V2, P2037, DOI 10.1021/ol0059293
   SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017
   Smith AB, 1999, BIOORGAN MED CHEM, V7, P9, DOI 10.1016/S0968-0896(98)00234-X                                                   
   Smith AB, 2010, ORG LETT, V12, P2990, DOI 10.1021/ol101007n
   Smith AB, 2010, ORG LETT, V12, P2994, DOI 10.1021/ol101008y
   STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0
   THOMPSON WJ, 1992, J MED CHEM, V35, P1685, DOI 10.1021/jm00088a003                                                             
   TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786
   TOMASIC L, 1987, HELV CHIM ACTA, V70, P1012, DOI 10.1002/hlca.19870700413
   Tyndall JDA, 2005, CHEM REV, V105, P973, DOI 10.1021/cr040669e
   VACCA JP, 1991, J MED CHEM, V34, P1225, DOI 10.1021/jm00107a050
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   VEBER DF, 1978, P NATL ACAD SCI USA, V75, P2636, DOI 10.1073/pnas.75.6.2636
   AMATO JS, 1985, Patent No. 4508921
   [Anonymous], 2008, ACC CHEM RES, V41
   2010, BIOCH BIOPHYS ACTA, V1803, P1
NR 59
TC 54
Z9 54
U1 3
U2 42
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0001-4842
J9 ACCOUNTS CHEM RES
JI Accounts Chem. Res.
PD MAR
PY 2011
VL 44
IS 3
BP 180
EP 193
DI 10.1021/ar1001186
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA 744XV
UT WOS:000289129400003
PM 21175156
OA green_accepted
DA 2018-01-05
ER

PT J
AU Kanwar, JR
   Mahidhara, G
   Kanwar, RK
AF Kanwar, Jagat R.
   Mahidhara, Ganesh
   Kanwar, Rupinder K.
TI Foundation review: Antiangiogenic therapy using nanotechnological-based
   delivery system
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; CELL-PENETRATING PEPTIDE; SMALL INTERFERING
   RNA; POLYELECTROLYTE COMPLEX MICELLES; HUMAN IMMUNODEFICIENCY VIRUS;
   NEGATIVE SURVIVIN PROTEIN; APTAMER-SIRNA CHIMERAS; PROSTATE-CANCER
   CELLS; SHORT HAIRPIN RNAS; MAMMALIAN-CELLS
AB Of the many approaches for the treatment of cancer, angiogenesis and the additional promotion of apoptosis in cancer stem cells by using combinatorial therapy is usually the most recommended. There has been increased interest in the use of antiapoptotic and antiangiogenic biomolecules, such as antiangiogenic microRNA, small interfering RNA, inhibitor of apoptosis protein-binding peptides and Von Hippel-Lindau tumor suppressors, as well as targeting ligands, such as aptamers. Therefore, it is tempting to suggest that such molecules could be used for anticancer therapy. As we review here, such exploitation can be achieved by using nanotechnology and RNA-carrying cationic cell-penetrating peptides, for better protection from the enzymatic digestion and enhanced cellular internalization of these biomolecules.
C1 [Kanwar, Jagat R.; Mahidhara, Ganesh; Kanwar, Rupinder K.] Deakin Univ, Inst Technol Res & Innovat, Ctr Biotechnol & Interdisciplinary Biosci BioDeak, Lab Immunol & Mol Biomed Res, Waurn Ponds, Vic 3217, Australia.
RP Kanwar, JR (reprint author), Deakin Univ, Inst Technol Res & Innovat, Ctr Biotechnol & Interdisciplinary Biosci BioDeak, Lab Immunol & Mol Biomed Res, Waurn Ponds, Vic 3217, Australia.
EM jagat.kanwar@deakin.edu.au
CR Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Albarran B, 2005, PROTEIN ENG DES SEL, V18, P147, DOI 10.1093/protein/gzi014
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Arthanari Y, 2010, J CONTROL RELEASE, V145, P272, DOI 10.1016/j.jconrel.2010.04.011
   AZNAVOORIAN S, 1993, CANCER, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L
   Baratchi S, 2010, CRIT REV BIOCHEM MOL, V45, P535, DOI 10.3109/10409238.2010.516740
   Baratchi S, 2009, CURR NANOSCI, V5, P15, DOI 10.2174/157341309787314665                                                      
   Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439
   Bawa Raj, 2009, Nanomedicine, V5, P5
   Benny O, 2008, NAT BIOTECHNOL, V26, P799, DOI 10.1038/nbt1415
   Bivalkar-Mehla S, 2011, VIRUS RES, V155, P1, DOI 10.1016/j.virusres.2010.10.003
   Blind M, 1999, P NATL ACAD SCI USA, V96, P3606, DOI 10.1073/pnas.96.7.3606
   Brunckhorst MK, 2010, CANCER RES, V70, P7283, DOI 10.1158/0008-5472.CAN-09-4125
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286                                                         
   Cevc G, 2004, ADV DRUG DELIVER REV, V56, P675, DOI 10.1016/j.addr.2003.10.028
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137                                                   
   Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133
   Cherian AK, 2000, DRUG DEV IND PHARM, V26, P459, DOI 10.1081/DDC-100101255
   Cheung CHA, 2006, EJC SUPPL, V4, P149, DOI 10.1016/S1359-6349(06)70493-1
   Cheung CHA, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-36
   Cheung CHA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-77
   Choi Y, 2005, CHEM BIOL, V12, P35, DOI 10.1016/j.chembiol.2004.10.016
   Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388
   Cleland J L, 1997, Pharm Biotechnol, V10, P1
   CONRADI RA, 1992, PHARMACEUT RES, V9, P435, DOI 10.1023/A:1015867608405
   Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215
   Das M, 2011, ACTA BIOMATER, V7, P355, DOI 10.1016/j.actbio.2010.08.010
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Del Gaizo V, 2003, MOL THER, V7, P720, DOI 10.1016/S1525-0016(03)00130-8
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s
   Devalapally H, 2008, CLIN CANCER RES, V14, P3193, DOI 10.1158/1078-0432.CCR-07-4973
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   ENDOH T, 2007, NUCL ACIDS S SER OXF, V51, P127
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006-291X(02)00445-X
   Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27                                                               
   Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6
   FOLKMAN J, 1990, BIOMATERIALS, V11, P615, DOI 10.1016/0142-9612(90)90017-K                                                    
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   GRIFFIN LC, 1993, BLOOD, V81, P3271
   Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540
   HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283                                                          
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Harada H, 2002, CANCER RES, V62, P2013
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615                                                          
   HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0                                                                
   Hong GB, 2008, BIOMED MICRODEVICES, V10, P693, DOI 10.1007/s10544-008-9180-9
   Hua Z. Xin, 1994, J CONTROL RELEASE, V29, P239
   Jiang GF, 2006, CANCER BIOL THER, V5, P435, DOI 10.4161/cbt.5.4.2542                                                            
   Jiang HC, 2010, CANCER INVEST, V28, P74, DOI 10.3109/07357900902744510
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342
   Kaneto H, 2004, NAT MED, V10, P1128, DOI 10.1038/nm1111
   Kanwar JR, 2008, IMMUNOL CELL BIOL, V86, P277, DOI 10.1038/sj.icb.7100163
   Kanwar JR, 2010, NANOMEDICINE-UK, V5, P1435, DOI [10.2217/nnm.10.115, 10.2217/NNM.10.115]
   Kanwar JR, 2010, EXPERT OPIN THER PAT, V20, P1723, DOI 10.1517/13543776.2010.533657
   Kanwar Jagat R, 2010, Front Biosci (Schol Ed), V2, P1113
   Kanwar JR, 2009, CURR NANOSCI, V5, P441, DOI 10.2174/157341309789378014                                                      
   Kanwar JR, 2003, CANCER GENE THER, V10, P468, DOI 10.1038/sj.cgt.7700590
   Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541                                                         
   Kanwar JR, 2001, CANCER RES, V61, P1948
   Kanwar JR, 1999, GENE THER, V6, P1835, DOI 10.1038/sj.gt.3301016
   Kanwar R.K., NANO MED IN PRESS
   Kawata E, 2010, CANCER LETT, V294, P245, DOI 10.1016/j.canlet.2010.02.008
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33                                                             
   Kim E, 2010, BIOMATERIALS, V31, P4592, DOI 10.1016/j.biomaterials.2010.02.030
   Kim SH, 2008, J CONTROL RELEASE, V129, P107, DOI 10.1016/j.jconrel.2008.03.008
   Kim SH, 2009, MOL PHARMACEUT, V6, P718, DOI 10.1021/mp800161e
   Kim SW, 2010, J CONTROL RELEASE, V143, P335, DOI 10.1016/j.jconrel.2010.01.009
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820                                                           
   Kobayashi N, 2004, J PHARMACOL EXP THER, V308, P688, DOI 10.1124/jpet.103.059931
   Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139
   Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728                                                                
   Krissansen GW, 2006, EUR J IMMUNOL, V36, P2203, DOI 10.1002/eji.200535324
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Kumar P, 2008, CELL, V134, P577, DOI 10.1016/j.cell.2008.06.034
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lameiro MH, 2006, INT J PHARMACEUT, V312, P119, DOI 10.1016/j.ijpharm.2006.01.006
   Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee SH, 2007, BIOCHEM BIOPH RES CO, V357, P511, DOI 10.1016/j.bbrc.2007.03.185
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476
   Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006
   Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634
   Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327
   Li H., 2010, AM J CHINESE MED, V38, P1
   Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com
   Luo LQ, 2006, INT J CANCER, V118, P1823, DOI 10.1002/ijc.21557
   Mahidhara G., INT J NANOT IN PRESS
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Maliyekkel A, 2006, CELL CYCLE, V5, P2390, DOI 10.4161/cc.5.20.3363                                                            
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104                                                         
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004
   Mi J, 2008, MOL THER, V16, P66, DOI 10.1038/sj.mt.6300320
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Mie M, 2003, BIOCHEM BIOPH RES CO, V310, P730, DOI 10.1016/j.bbrc.2003.09.071
   Mok H, 2008, BIOPOLYMERS, V89, P881, DOI 10.1002/bip.21032
   MORIMOTO K, 1991, PHARMACEUT RES, V8, P1175, DOI 10.1023/A:1015862603939                                                         
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Moschos SA, 2007, BIOCONJUGATE CHEM, V18, P1450, DOI 10.1021/bc070077d
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018                                                            
   O'Rourke G.E., 2000, MED J AUSTRALIA, V173, P616
   Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773
   OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002                                                              
   Paduano F, 2006, MOL CANCER THER, V5, P179, DOI 10.1158/1535-7163.MCT-05-0132
   Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556
   Pastor F., 2010, NATURE, V465, P227
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Pooga M, 1998, FASEB J, V12, P67
   Prokop A, 2002, BIOTECHNOL BIOENG, V78, P459, DOI 10.1002/bit.10195
   Rawat M, 2008, DRUG DEV IND PHARM, V34, P181, DOI 10.1080/03639040701539479
   Rawat M, 2006, BIOL PHARM BULL, V29, P1790, DOI 10.1248/bpb.29.1790
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Sarraf-Yazdi S, 2008, J SURG RES, V146, P16, DOI 10.1016/j.jss.2007.04.028
   Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675
   Schaffert D, 2008, GENE THER, V15, P1131, DOI 10.1038/gt.2008.105
   Schneider BH, 2000, BIOSENS BIOELECTRON, V15, P13, DOI 10.1016/S0956-5663(00)00056-7
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Shah MH, 2005, INT J PHARM, V294, P161, DOI 10.1016/j.ijpharm.2005.01.019
   Shangguan DH, 2008, ANAL CHEM, V80, P721, DOI 10.1021/ac701962v
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Sun X, 2003, GENE THER, V10, P1728, DOI 10.1038/sj.gt.3302070
   Sun X, 2003, GENE THER, V10, P2081, DOI 10.1038/sj.gt.3302118
   Sun XY, 2005, CANCER GENE THER, V12, P35, DOI 10.1038/sj.cgt.7700766
   Sun XY, 2001, CANCER GENE THER, V8, P719, DOI 10.1038/sj.cgt.7700370
   Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002
   Tanaka K, 2010, INT J PHARMACEUT, V398, P219, DOI 10.1016/j.ijpharm.2010.07.038
   Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229
   Thiel KW, 2009, OLIGONUCLEOTIDES, V19, P209, DOI 10.1089/oli.2009.0199
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082                                                     
   TORCHILIN VP, 1977, J BIOMED MATER RES, V11, P223, DOI 10.1002/jbm.820110208
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Turner JJ, 2007, BLOOD CELL MOL DIS, V38, P1, DOI 10.1016/j.bcmd.2006.10.003
   Veldhoen S, 2006, NUCLEIC ACIDS RES, V34, P6561, DOI 10.1093/nar/gkl941
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553                                                         
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010
   Wooddell CI, 2005, BIOCHEM BIOPH RES CO, V334, P117, DOI 10.1016/j.bbrc.2005.06.066
   Wullner U, 2008, CURR CANCER DRUG TAR, V8, P554, DOI 10.2174/156800908786241078
   Yagihashi A, 2005, CLIN CHIM ACTA, V362, P125, DOI 10.1016/j.cccn.2005.06.009
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200                                                          
   Zhang L, 2008, CLIN CANCER RES, V14, P559, DOI 10.1158/1078-0432.CCR-07-1176
   Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016
   Zhou Jiehua, 2010, Silence, V1, P4, DOI 10.1186/1758-907X-1-4
   ZHOU XH, 1991, INT J PHARM, V70, P271
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
   Zuhorn IS, 2007, EUR BIOPHYS J BIOPHY, V36, P349, DOI 10.1007/s00249-006-0092-4
NR 190
TC 27
Z9 27
U1 1
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD MAR
PY 2011
VL 16
IS 5-6
BP 188
EP 202
DI 10.1016/j.drudis.2011.01.007
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 740XH
UT WOS:000288827200004
PM 21262383
DA 2018-01-05
ER

PT J
AU Malbec, M
   Roesch, F
   Schwartz, O
AF Malbec, Marine
   Roesch, Ferdinand
   Schwartz, Olivier
TI A New Role for the HTLV-1 p8 Protein: Increasing Intercellular Conduits
   and Viral Cell-to-Cell Transmission
SO VIRUSES-BASEL
LA English
DT Article
DE HTLV-1; HIV-1; cell-to-cell transfer; virological synapses; cellular
   conduits; p8; p12; Nef
ID LYMPHOTROPIC VIRUS TYPE-1; ENHANCES INTERLEUKIN-2 PRODUCTION; CLASS-I
   MOLECULES; P12(I) PROTEIN; PRIMARY LYMPHOCYTES; NEF GENE; ACTIVATION;
   EXPRESSION; INFECTION; SPREAD
AB Retroviruses like HIV-1 and HTLV-1 can be transmitted efficiently by direct contact between infected and target cells. For HIV-1, various modes of cell-to-cell transfer have been reported, including virological synapses, polysynapses, filopodial bridges, and nanotube-like structures. So far, only synapses and biofilms have been described for HTLV-1 transmission. Recently, Van Prooyen et al. [1] identified an additional mode of HTLV-1 transmission through cellular conduits induced by the viral accessory protein p8.
C1 [Malbec, Marine; Roesch, Ferdinand; Schwartz, Olivier] Inst Pasteur, CNRS, Virus & Immun Unit, URA 3015, F-75724 Paris, France.
RP Schwartz, O (reprint author), Inst Pasteur, CNRS, Virus & Immun Unit, URA 3015, 28 Rue Dr Roux, F-75724 Paris, France.
EM olivier.schwartz@pasteur.fr
OI SCHWARTZ, OLIVIER/0000-0002-0729-1475
CR Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000
   Banerjee P, 2007, J VIROL, V81, P9707, DOI 10.1128/JVI.00887-07
   Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0
   Ding W, 2003, J VIROL, V77, P11027, DOI 10.1128/JVI.77.20.11027-11039.2003
   Fukumoto R, 2007, J VIROL, V81, P9088, DOI 10.1128/JVI.02703-06
   Fukumoto R, 2009, BLOOD, V113, P3726, DOI 10.1182/blood-2008-04-146928
   Haller C, 2010, EUR J CELL BIOL
   Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115
   Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001                                                
   KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I                                                    
   Kim SJ, 2006, J IMMUNOL, V176, P5463, DOI 10.4049/jimmunol.176.9.5463                                                     
   MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101
   Nobile C, 2010, J VIROL, V84, P2282, DOI 10.1128/JVI.02230-09
   Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065
   Schibeci SD, 2000, AIDS, V14, P1701, DOI 10.1097/00002030-200008180-00003
   Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338
   SCHWARTZ O, 1993, J VIROL, V67, P3274
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682
   Taylor JM, 2009, J VIROL, V83, P11467, DOI 10.1128/JVI.00952-09
   Thoulouze MI, 2006, IMMUNITY, V24, P547, DOI 10.1016/j.immuni.2006.02.016
   Valeri VW, 2010, BLOOD, V116, P3809, DOI 10.1182/blood-2010-05-284141
   Van Prooyen N, 2010, P NATL ACAD SCI USA, V107, P20738, DOI 10.1073/pnas.1009635107
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753
NR 23
TC 7
Z9 7
U1 0
U2 2
PU MDPI AG
PI BASEL
PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND
SN 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD MAR
PY 2011
VL 3
IS 3
BP 254
EP 259
DI 10.3390/v3030254
PG 6
WC Virology
SC Virology
GA 740JB
UT WOS:000288787800005
PM 21994729
OA gold
DA 2018-01-05
ER

PT J
AU Krebs, MD
   Alsberg, E
AF Krebs, Melissa D.
   Alsberg, Eben
TI Localized, Targeted, and Sustained siRNA Delivery
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE biomaterials; biotechnology; gene silencing; localized delivery; siRNA;
   therapeutics
ID ADULT-MOUSE BRAIN; IN-VIVO; RNA INTERFERENCE; OCULAR NEOVASCULARIZATION;
   ADMINISTERED SIRNA; SYSTEMIC DELIVERY; CATIONIC LIPIDS; GENE-EXPRESSION;
   CELLULAR UPTAKE; CELLS
AB Short interfering RNA (siRNA) functions directly in the cytoplasm, where it is assembled into an RNA-induced silencing complex (RISC). The localized delivery of siRNA to a specific site in vivo is highly challenging. There are many disease states in which a systemic effect of RNAi may be desirable; some examples include non-localized cancers, HIV, neurodegenerative diseases, respiratory viruses, and heart and vascular disease. In this Concept, we will focus on the localized delivery of siRNA to a target site using various delivery modalities. In certain tissues, such as the eye, central nervous system and lung, it has been demonstrated that a simple injection of naked siRNA will silence gene expression specifically in that tissue. To achieve local gene silencing in other tissues, a variety of approaches have been pursued to help stabilize the siRNA and facilitate uptake; they include chemical modification of the siRNA or complexation within liposomes or polymers to form nanoparticles. Recently, the use of macroscopic biomaterial scaffolds for siRNA delivery has been reported, and although there is still significant work to be done in this area to optimize the delivery systems, it is an important area of research that offers the potential for having great impact on the field of siRNA delivery.
C1 [Krebs, Melissa D.; Alsberg, Eben] Case Western Reserve Univ, Cleveland, OH 44106 USA.
RP Alsberg, E (reprint author), Case Western Reserve Univ, 309 Wickenden,10900 Euclid Ave, Cleveland, OH 44106 USA.
EM eben.alsberg@case.edu
RI Krebs, Melissa/L-4878-2015
OI Krebs, Melissa/0000-0002-5170-7116; Alsberg, Eben/0000-0002-3487-4625
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457                                                        
   Aigner A, 2007, APPL MICROBIOL BIOT, V76, P9, DOI 10.1007/s00253-007-0984-y
   Aigner A, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/71659
   Alsberg E, 2001, CRIT REV ORAL BIOL M, V12, P64, DOI 10.1177/10454411010120010501                                                    
   Alshamsan A, 2010, BIOMATERIALS, V31, P1420, DOI 10.1016/j.biomaterials.2009.11.003
   BEDI D, 2011, NANOMEDICIN IN PRESS
   Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110                                                                
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Chen QM, 2010, J CONTROL RELEASE, V144, P227, DOI 10.1016/j.jconrel.2010.02.011
   Chen YC, 2008, EXPERT OPIN DRUG DEL, V5, P1301, DOI [10.1517/17425240802568505, 10.1517/17425240802568505 ]
   Collins RE, 2005, FEBS LETT, V579, P5841, DOI 10.1016/j.febslet.2005.07.072
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   DELEAVEY GF, 2009, CURR PROTOC NUCL ACI, pCH16
   Dickerson EB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-10
   DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104
   Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044
   Driscoll KE, 2000, TOXICOL SCI, V55, P24, DOI 10.1093/toxsci/55.1.24
   Dykxhoorn DM, 2006, CELL, V126, P231, DOI 10.1016/j.cell.2006.07.007
   Dykxhoorn DM, 2006, GENE THER, V13, P541, DOI 10.1038/sj.gt.3302703
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gao ZY, 2006, PLAST RECONSTR SURG, V118, P1328, DOI 10.1097/01.prs.0000239537.77870.2c
   Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021
   Hammond SM, 2000, NATURE, V404, P293
   Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010
   Hoyer D, 2006, J RECEPT SIG TRANSD, V26, P527, DOI 10.1080/10799890600929663
   Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609
   Kim SH, 2008, J CONTROL RELEASE, V129, P107, DOI 10.1016/j.jconrel.2008.03.008
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Krebs MD, 2009, J AM CHEM SOC, V131, P9204, DOI 10.1021/ja9037615
   Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280
   Lomas-Neira JL, 2005, J LEUKOCYTE BIOL, V77, P846, DOI 10.1189/jlb.1004617
   Lorenz C, 2004, BIOORG MED CHEM LETT, V14, P4975, DOI 10.1016/j.bmcl.2004.07.018
   Lu W, 2010, CANCER RES, V70, P3177, DOI 10.1158/0008-5472.CAN-09-3379
   MAKIMURA H, 2002, BMC NEUROSCI, V3, pNIL1
   Merkel OM, 2009, MOL PHARMACEUT, V6, P1246, DOI 10.1021/mp900107v
   Murata N, 2008, J CONTROL RELEASE, V126, P246, DOI 10.1016/j.jconrel.2007.11.017
   Namiki Y, 2009, NAT NANOTECHNOL, V4, P598, DOI [10.1038/nnano.2009.202, 10.1038/NNANO.2009.202]
   Natarajan R, 2006, CIRC RES, V98, P133, DOI 10.1161/01.RES.0000197816.63513.27
   Noh SM, 2010, J CONTROL RELEASE, V145, P159, DOI 10.1016/j.jconrel.2010.04.005
   Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Pardridge WM, 2004, EXPERT OPIN BIOL TH, V4, P1103, DOI 10.1517/14712598.4.7.1103                                                       
   Perkel JM, 2009, SCIENCE, V326, P454, DOI 10.1126/science.opms.p0900039
   Reich S, 2003, MOL VIS, V9, P210
   Rutz S, 2004, ARTHRITIS RES THER, V6, P78, DOI 10.1086/ar1168
   Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Sepp-Lorenzino L, 2008, CLIN PHARMACOL THER, V84, P628, DOI 10.1038/clpt.2008.174
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Singh A, 2009, BIOMATERIALS, V30, P5187, DOI 10.1016/j.biomaterials.2009.06.001
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Spagnou S, 2004, BIOCHEMISTRY-US, V43, P13348, DOI 10.1021/bi048950a
   Suh MS, 2009, J CONTROL RELEASE, V140, P268, DOI 10.1016/j.jconrel.2009.06.017
   Taratula O, 2009, J CONTROL RELEASE, V140, P284, DOI 10.1016/j.jconrel.2009.06.019
   Thakker DR, 2005, MOL PSYCHIATR, V10, P782, DOI 10.1038/sj.mp.4001687
   Thakker DR, 2004, P NATL ACAD SCI USA, V101, P17270, DOI 10.1073/pnas.0406214101
   Vinas-Castells R, 2009, BIOCONJUGATE CHEM, V20, P2262, DOI 10.1021/bc900241w
   Wang Y, 2010, CURR DRUG METAB, V11, P182, DOI 10.2174/138920010791110863                                                      
   Watts JK, 2008, DRUG DISCOV TODAY, V13, P842, DOI 10.1016/j.drudi5.2008.05.007
   Wilson DS, 2010, NAT MATER, V9, P923, DOI [10.1038/NMAT2859, 10.1038/nmat2859]
   Wu YC, 2009, CELL HOST MICROBE, V5, P84, DOI 10.1016/j.chom.2008.12.003
   Yao YC, 2009, PHARM RES-DORD, V26, P263, DOI 10.1007/s11095-008-9772-3
   Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200
   Zhang YJ, 2006, MOL THER, V14, P336, DOI 10.1016/j.ymthe.2006.04.001
   Zhu L, 2010, BIOCONJUGATE CHEM, V21, P2119, DOI 10.1021/bc100346n
NR 68
TC 40
Z9 40
U1 0
U2 36
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0947-6539
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD MAR
PY 2011
VL 17
IS 11
BP 3054
EP 3062
DI 10.1002/chem.201003144
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 731IF
UT WOS:000288098800001
PM 21341332
DA 2018-01-05
ER

PT J
AU Ongkudon, CM
   Ho, JN
   Danquah, MK
AF Ongkudon, Clarence M.
   Ho, Jenny
   Danquah, Michael K.
TI Mitigating the looming vaccine crisis: production and delivery of
   plasmid-based vaccines
SO CRITICAL REVIEWS IN BIOTECHNOLOGY
LA English
DT Review
DE Plasmid DNA; DNA vaccine; vaccine production; vaccine delivery;
   bioprocess
ID ARGININE AFFINITY-CHROMATOGRAPHY; HUMAN-IMMUNODEFICIENCY-VIRUS;
   GROWTH-MEDIUM SELECTION; DNA PRODUCTION PLATFORM; NONVIRAL GENE
   DELIVERY; IN-VIVO; IMMUNE-RESPONSES; GOLD NANOPARTICLES;
   CONTROLLED-RELEASE; ENDOTOXIN REMOVAL
AB The exponentially growing human population and the emergence of new diseases are clear indications that the world can no longer depend solely on conventional vaccine technologies and production schemes. The race to find a new vaccine technology is crucial to help speed up and complement the World Health Organization (WHO) disease elimination program. The ultimate goal is to uncover fast and efficient production schemes in the event of a pandemic, and also to effectively fight deadly diseases such as malaria, bird flu, hepatitis, and human immunodeficiency virus (HIV). Plasmid DNA vaccines, if properly formulated, offer specific priming of the immune system and similar or even better prophylactic effects than conventional vaccines. This article discusses many of the critical issues that need to be considered when developing fast, effective, and reliable plasmid DNA vaccine manufacturing processes. Different modes of plasmid production via bacterial fermentation are compared. Plasmid purification by chromatography is specifically discussed as it is the most commercially viable bioprocess engineering technique for continuous purification of supercoiled plasmid DNA. Current techniques and progress covering the area of plasmid DNA vaccine design, formulation, and delivery are also put forward.
C1 [Ongkudon, Clarence M.; Ho, Jenny; Danquah, Michael K.] Monash Univ, Dept Chem Engn, Bio Engn Lab, Clayton, Vic 3800, Australia.
RP Danquah, MK (reprint author), Monash Univ, Dept Chem Engn, Bio Engn Lab, Clayton Campus,Wellington Rd, Clayton, Vic 3800, Australia.
EM michael.danquah@eng.monash.edu.au
FU Monash University, Australia; University Malaysia Sabah, Malaysia
FX The authors wish to thank Monash University, Australia and University
   Malaysia Sabah, Malaysia for the project funding and research
   scholarship.
CR Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867                                                             
   Alpar HO, 2005, ADV DRUG DELIVER REV, V57, P411, DOI 10.1016/j.addr.2004.09.004
   Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
   Anspach FB, 2001, J BIOCHEM BIOPH METH, V49, P665, DOI 10.1016/S0165-022X(01)00228-7
   Arakawa T, 2007, PROTEIN EXPRES PURIF, V52, P410, DOI 10.1016/j.pep.2006.10.005
   Bailey J. E., 1986, BIOCH ENG FUNDAMENTA
   Bawarski WE, 2008, NANOMED-NANOTECHNOL, V4, P273, DOI 10.1016/j.nano.2008.06.002
   Bhattacharya S, 2009, CHEM COMMUN, P4632, DOI 10.1039/b900666b
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   Bodles-Brakhop AM, 2009, MOL THER, V17, P585, DOI 10.1038/mt.2009.5
   Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3                                                   
   Boyaka PN, 2003, CURR PHARM DESIGN, V9, P1965, DOI 10.2174/1381612033454225
   Buck M. L., 2005, PEDIAT PHARM, V11, P1
   BUNGAY HR, 1963, BIOTECHNOL BIOENG, V5, P1, DOI 10.1002/bit.260050102
   CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378                                                     
   Carnes AE, 2006, BIOTECHNOL APPL BIOC, V45, P155, DOI 10.1042/BA20050223
   CASTAGNOLI L, 1989, EMBO J, V8, P621
   Chen W, 1999, U.S. patent, Patent No. [5,955,323, 5955323]
   Choi JS, 2000, J AM CHEM SOC, V122, P474, DOI 10.1021/ja9931473                                                               
   Chun KW, 2005, BIOMATERIALS, V26, P3319, DOI 10.1016/j.biomaterials.2004.07.055
   COBAN C, 2005, J LEUKOCYTE BIOL, V778, P1
   COREY L, 1999, HIV AIDS, V5, P1
   Danquah MK, 2008, CHEM ENG J, V140, P593, DOI 10.1016/j.cej.2008.02.012
   Danquah MK, 2008, J CHROMATOGR A, V1188, P227, DOI 10.1016/j.chroma.2008.02.045
   Danquah MK, 2007, J BIOSCI BIOENG, V104, P490, DOI 10.1263/jbb.104.490
   Danquah MK, 2007, J SEP SCI, V30, P2843, DOI 10.1002/jssc.200700217
   Danquah MK, 2007, J CHROMATOGR B, V853, P38, DOI 10.1016/j.jchromb.2007.02.050
   DANQUAH MK, 2008, BIOTECHNOL BIOPROC E, V13, P1
   de Lima MCP, 2001, ADV DRUG DELIVER REV, V47, P277
   de Vries RD, 2008, EXPERT REV VACCINES, V7, P1215, DOI 10.1586/14760584.7.8.1215
   Diogo MM, 2005, J CHROMATOGR A, V1069, P3, DOI 10.1016/j.chroma.2004.09.050
   Dufes C, 2005, ADV DRUG DELIVER REV, V57, P2177, DOI 10.1016/j.addr.2005.09.017
   Dupuis M, 2000, J IMMUNOL, V165, P2850, DOI 10.4049/jimmunol.165.5.2850                                                     
   Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791                                                      
   FILOMENA S, 2009, J MICROBIOL BIOTECHN, V19, P1408
   Freitas SS, 2009, SEP PURIF TECHNOL, V65, P95, DOI 10.1016/j.seppur.2008.04.001
   Fukunaka Y, 2002, J CONTROL RELEASE, V80, P333, DOI 10.1016/S0168-3659(02)00026-3
   Furuichi K, 2007, APPL ENVIRON MICROB, V73, P3137, DOI 10.1128/AEM.01307-06
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Garmory H, 2003, GENET VACCINES THER, V1, P1
   Genton B, 2008, EXPERT REV VACCINES, V7, P597, DOI 10.1586/14760584.7.5.597
   Ghosh P, 2008, ADV DRUG DELIVER REV, V60, P1307, DOI 10.1016/j.addr.2008.03.016
   Glenting J, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-26
   Godbey WT, 2001, BIOMATERIALS, V22, P471, DOI 10.1016/S0142-9612(00)00203-9
   Gorman CM, 1997, GENE THER, V4, P983, DOI 10.1038/sj.gt.3300473                                                           
   Goula D, 1998, GENE THER, V5, P1291, DOI 10.1038/sj.gt.3300717
   Goya AK, 2008, EXPERT OPIN THER PAT, V18, P1271, DOI 10.1517/13543770802514618
   Gupta AK, 2005, BIOMATERIALS, V26, P1565, DOI 10.1016/j.biomaterials.2004.05.022
   Han Y, 2008, J CHROMATOGR B, V874, P21, DOI 10.1016/j.jchromb.2008.08.025
   Harrison R. G., 2002, BIOSEPARATIONS SCI E
   Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944                                                      
   Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
   Helson R, 2008, VACCINE, V26, P753, DOI 10.1016/j.vaccine.2007.12.006
   Henke A, 2002, MED MICROBIOL IMMUN, V191, P187, DOI 10.1007/s00430-002-0144-z
   Ho J, 2008, BIOTECHNOL BIOENG, V101, P172, DOI 10.1002/bit.21876
   Hofland HEJ, 1997, PHARMACEUT RES, V14, P742, DOI 10.1023/A:1012146305040
   Hofland HEJ, 1996, P NATL ACAD SCI USA, V93, P7305, DOI 10.1073/pnas.93.14.7305
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Huang YX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003214
   HUBER H, 2008, GENET ENG BIOTECHNOL, V28, P4
   Huth S, 2004, J GENE MED, V6, P923, DOI 10.1002/jgm.577
   Hyde SC, 2008, NAT BIOTECHNOL, V26, P549, DOI 10.1038/nbt1399
   JONES DH, 1996, P INT M NUCL AC VACC
   Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0
   Kang HC, 2005, CRIT REV EUKAR GENE, V15, P317, DOI 10.1615/CritRevEukarGeneExpr.v15.i4.30                                          
   Kendall M, 2006, VACCINE, V24, P4651, DOI 10.1016/j.vaccine.2005.08.066
   Kievit FM, 2009, ADV FUNCT MATER, V19, P2244, DOI 10.1002/adfm.200801844
   Kim A, 2003, J CONTROL RELEASE, V90, P81, DOI 10.1016/S0168-3659(03)00175-5
   Ko HJ, 2005, INFECT IMMUN, V73, P5666, DOI 10.1128/IAI.73.9.5666-5674.2005
   Kong S, 2008, BIOTECHNOL APPL BIOC, V51, P43, DOI 10.1042/BA20070174
   Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566                                                      
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Kushibiki T, 2006, J CONTROL RELEASE, V112, P249, DOI 10.1016/j.jconrel.2006.02.003
   Kushibiki T, 2003, J CONTROL RELEASE, V90, P207, DOI 10.1016/S0168-3659(03)00197-4
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lechmann M, 2000, SEMIN LIVER DIS, V20, P211, DOI 10.1055/s-2000-9947
   Lemmens R, 2003, J CHROMATOGR B, V784, P291, DOI 10.1016/S1570-0232(02)00805-X
   Levy MS, 2000, TRENDS BIOTECHNOL, V18, P296, DOI 10.1016/S0167-7799(00)01446-3                                                   
   LI GP, 2009, CELL MOL IMMUNOL, V6, P45
   Li PC, 2008, BIOMATERIALS, V29, P3617, DOI 10.1016/j.biomaterials.2008.05.020
   Li S, 2000, AM J PHYSIOL-LUNG C, V278, pL504
   Li ZH, 2003, PHARMACEUT RES, V20, P884, DOI 10.1023/A:1023887203111                                                         
   Lindner LH, 2006, J CONTROL RELEASE, V110, P444, DOI 10.1016/j.jconrel.2005.10.009
   Listner K, 2006, BIOTECHNOL PROGR, V22, P1335, DOI 10.1021/bp060046h
   Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424
   Liu L, 2005, IMMUNOLOGY, V115, P223, DOI 10.1111/j.1365-2567.2005.02150.x
   Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x
   Lu DM, 2007, EXPERT REV VACCINES, V6, P213, DOI 10.1586/14760584.6.2.213
   Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07
   Lungwitz U, 2005, EUR J PHARM BIOPHARM, V60, P247, DOI 10.1016/j.ejpb.2004.11.011
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   Ma ZY, 2005, POLYM INT, V54, P1502, DOI 10.1002/pi.1875
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   Magalhaes PO, 2007, J PHARM PHARM SCI, V10, P388
   Manoj S, 2004, CRIT REV CL LAB SCI, V41, P1, DOI 10.1080/10408360490269251
   MANTHORPE M, 1993, HUM GENE THER, V4, P419, DOI 10.1089/hum.1993.4.4-419                                                        
   May S, 2000, BIOPHYS J, V78, P1681, DOI 10.1016/S0006-3495(00)76720-8                                                   
   McNeil SE, 2006, EXPERT OPIN THER PAT, V16, P1371, DOI 10.1517/13543776.16.10.1371
   Meacle FJ, 2007, BIOTECHNOL BIOENG, V97, P1148, DOI 10.1002/bit.21275
   Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415
   Miyata K, 2007, J CONTROL RELEASE, V122, P252, DOI 10.1016/j.jconrel.2007.06.020
   Montgomery DL, 1997, PHARMACOL THERAPEUT, V74, P195, DOI 10.1016/S0163-7258(97)82003-7
   Mutschlechner O, 2000, J MOL MICROB BIOTECH, V2, P101
   NAN XZ, 2005, J ZHEJIANG UNIV-SC B, V6, P396
   Nguyen DN, 2009, ADV MATER, V21, P847, DOI 10.1002/adma.200801478
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   O'Hagan DT, 2006, METHODS, V40, P10, DOI 10.1016/j.ymeth.2006.05.017
   O'Kennedy RD, 2000, J BIOTECHNOL, V76, P175, DOI 10.1016/S0168-1656(99)00187-X                                                   
   Oishi M, 2006, BIOCONJUGATE CHEM, V17, P677, DOI 10.1021/bc050364m
   Olafsdottir G, 2008, ACTA VET SCAND, V50, DOI 10.1186/1751-0147-50-44
   ONGKUDON CM, 2005, P 15 MSMBB SCI M KUA
   Ongkudon C.M., 2006, J TEKNOLOGI F, V45, P19
   Pan CH, 2008, CLIN VACCINE IMMUNOL, V15, P1214, DOI 10.1128/CVI.00120-08
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park YC, 2004, APPL MICROBIOL BIOT, V66, P297, DOI 10.1007/s00253-004-1678-3
   Passarinha LA, 2006, J MICROBIOL BIOTECHN, V16, P20
   Patil SD, 2005, AAPS J, V7, pE61, DOI 10.1208/aapsj070109
   Perrie Y, 2001, VACCINE, V19, P3301, DOI 10.1016/S0264-410X(00)00432-1
   PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D                                                    
   Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z
   Phue JN, 2008, BIOTECHNOL BIOENG, V101, P831, DOI 10.1002/bit.21973
   Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082
   Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169-409X(00)00133-2                                                   
   Prather KJ, 2003, ENZYME MICROB TECH, V33, P865, DOI 10.1016/S0141-0229(03)00205-9
   PRAZERES DMF, 1999, TIBTECH, V17, P168
   Rainczuk A, 2004, INFECT IMMUN, V72, P5565, DOI 10.1128/IAI.72.10.5565-5573.2004
   REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0
   Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5
   Romano G, 2000, STEM CELLS, V18, P19, DOI 10.1634/stemcells.18-1-19                                                       
   Sahloff EG, 2005, PHARMACOTHERAPY, V25, P741, DOI 10.1592/phco.25.5.741.63589
   Saldanha AJ, 2004, MOL BIOL CELL, V15, P4089, DOI 10.1091/mbc.E04-04-0306
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   Schmidt T, 2003, U.S. patent, Patent No. [6,664,078, 6664078]
   Segura T, 2005, BIOMATERIALS, V26, P1575, DOI 10.1016/j.biomaterials.2004.05.007
   Sheets EE, 2003, AM J OBSTET GYNECOL, V188, P916, DOI 10.1067/mob.2003.256
   Shroff KE, 1999, PHARM SCI TECHNOL TO, V2, P205, DOI 10.1016/S1461-5347(99)00150-9                                                   
   Shuler M L, 2002, BIOPROCESS ENG BASIC
   Smith Clara R, 2007, J Chromatogr B Analyt Technol Biomed Life Sci, V854, P121, DOI 10.1016/j.jchromb.2007.04.005
   Smith J, 1997, ADV DRUG DELIVER REV, V26, P135, DOI 10.1016/S0169-409X(97)00031-8
   Smith JM, 2004, AIDS RES HUM RETROV, V20, P654, DOI 10.1089/0889222041217419
   Song MK, 2005, J VIROL, V79, P9854, DOI 10.1128/JVI.79.15.9854-9861.2005
   Sousa F, 2009, BIOMED CHROMATOGR, V23, P160, DOI 10.1002/bmc.1097
   Sousa F, 2008, TRENDS BIOTECHNOL, V26, P518, DOI 10.1016/j.tibtech.2008.05.005
   Sousa F, 2009, J GENE MED, V11, P79, DOI 10.1002/jgm.1272
   Stadler J, 2004, J GENE MED, V6, pS54, DOI 10.1002/jgm.512
   Stephan DJ, 1996, HUM GENE THER, V7, P1803, DOI 10.1089/hum.1996.7.15-1803                                                      
   Stern M, 2003, GENE THER, V10, P1282, DOI 10.1038/sj.gt.3301994
   Tan LH, 2007, CHEM ENG SCI, V62, P5809, DOI 10.1016/j.ces.2007.06.019
   Tan LH, 2007, J CHROMATOGR A, V1141, P226, DOI 10.1016/j.chroma.2006.12.023
   Tanaka N, 2003, ANAL BIOANAL CHEM, V376, P298, DOI 10.1007/s00216-003-1889-y
   TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0
   Thierry AR, 2003, CURR OPIN MOL THER, V5, P133
   Thomas M, 2003, P NATL ACAD SCI USA, V100, P9138, DOI 10.1073/pnas.1233634100
   Cordoba LT, 2008, ELECTRON J BIOTECHN, V11, DOI 10.2225/vol11-issue2-fulltext-1
   Turker S, 2004, PHARM WORLD SCI, V26, P137, DOI 10.1023/B:PHAR.0000026823.82950.ff
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Urthaler J, 2005, ACTA BIOCHIM POL, V52, P703
   Urthaler J, 2005, CHEM ENG TECHNOL, V28, P1408, DOI 10.1002/ceat.200500126
   Urthaler J, 2007, J BIOTECHNOL, V128, P132, DOI 10.1016/j.jbiotec.2006.08.018
   US Food and Drug Administration, 2007, CONS PLASM DNA VACC
   WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255                                                         
   WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156                                                          
   Wang H, 2007, MOL PHARM, V4, P189, DOI 10.1021/mp060045s
   Wang ZJ, 2001, PROCESS BIOCHEM, V36, P1085, DOI 10.1016/S0032-9592(01)00149-2                                                   
   Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454
   *WHO, 2007, GUID ASS QUAL NONCL
   Wieland JA, 2007, J CONTROL RELEASE, V120, P233, DOI 10.1016/j.jconrel.2007.04.015
   Wigglesworth TJ, 2008, ORG BIOMOL CHEM, V6, P1905, DOI 10.1039/b802808g
   Williams JA, 2009, BIOTECHNOL BIOENG, V103, P1129, DOI 10.1002/bit.22347
   Xiang JJ, 2003, J GENE MED, V5, P803, DOI 10.1002/jgm.419
   Yao SY, 2007, J BACTERIOL, V189, P1946, DOI 10.1128/JB.01451-06
   Yoshikawa T, 2006, BIOL PHARM BULL, V29, P105, DOI 10.1248/bpb.29.105
   Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5
   Zhang JP, 2005, BIOTECHNOL PROGR, V21, P1220, DOI 10.1021/bp0500359
   THATCHER DR, 1999, Patent No. 5981735
   CARNES AE, 2008, Patent No. 20080318283
   CARNES AE, 2007, Patent No. 20070254342
   GENE THERAPY CLIN TR
NR 181
TC 5
Z9 5
U1 0
U2 17
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0738-8551
J9 CRIT REV BIOTECHNOL
JI Crit. Rev. Biotechnol.
PD MAR
PY 2011
VL 31
IS 1
BP 32
EP 52
DI 10.3109/07388551.2010.483460
PG 21
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 722RT
UT WOS:000287452700003
PM 20879832
DA 2018-01-05
ER

PT J
AU Giri, S
   Sykes, EA
   Jennings, TL
   Chan, WCW
AF Giri, Supratim
   Sykes, Edward A.
   Jennings, Travis L.
   Chan, Warren C. W.
TI Rapid Screening of Genetic Biomarkers of Infectious Agents Using Quantum
   Dot Barcodes
SO ACS NANO
LA English
DT Article
DE quantum dots; global health; infectious diseases; nanotechnology;
   diagnostics; DNA; multiplexing; barcodes
ID POLYMERASE-CHAIN-REACTION; DNA DETECTION; MULTIPLEXED DETECTION;
   SENSITIVE DETECTION; EXPRESSION ANALYSIS; ASSAY; HYBRIDIZATION; PCR;
   NANOCRYSTALS; TECHNOLOGIES
AB The development of a rapid and sensitive infectious disease diagnostic platform would enable one to select proper treatment and to contain the spread of the disease. Here we examined the feasibility of using quantum dot (QD) barcodes to detect genetic biomarkers of the bloodborne pathogens HIV, malaria, hepatitis B and C, and syphilis. The genetic fragments from these pathogens were detected in less than 10 min at a sample volume of 200 mu L. and with a detection limit in the femtomol range. A next step for the advancement of QD barcode technology to the clinic will require validation of the technology with human samples to assess for matrix effects, head-to-head comparison with existing detection method, development of techniques to automate the assay and detection process; and simplification of analytical device for the read-out of the barcode signal. Our study provides an important intermediate step in the translation of QD barcode technology for screening infectious disease agents in the developed and developing world.
C1 [Giri, Supratim; Sykes, Edward A.; Jennings, Travis L.; Chan, Warren C. W.] Univ Toronto, Terrence Donnelly Ctr Biomol Res Mat Sci & Engn C, Inst Biomat & Biomed Engn, Toronto, ON M5S 3G9, Canada.
RP Chan, WCW (reprint author), Univ Toronto, Terrence Donnelly Ctr Biomol Res Mat Sci & Engn C, Inst Biomat & Biomed Engn, 164 Coll St, Toronto, ON M5S 3G9, Canada.
EM warren.chan@utoronto.ca
RI Sykes, Edward/G-1996-2014
FU Natural Sciences and Engineering Research Council; Canadian Institute of
   Health Research; Canadian Foundation for Innovation; Ontario Innovation
   Trust; Canadian Research Chair's Program
FX We acknowledge the Natural Sciences and Engineering Research Council,
   Canadian Institute of Health Research, Canadian Foundation for
   Innovation, Ontario Innovation Trust, Canadian Research Chair's Program
   for Funding support for the project. We thank D. Li for the preparation
   of the quantum dots.
CR BURSTAIN JM, 1991, J CLIN MICROBIOL, V29, P62
   Cao YC, 2006, ANAL BIOCHEM, V351, P193, DOI 10.1016/j.ab.2006.01.007
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y                                                               
   Defoort JP, 2000, J CLIN MICROBIOL, V38, P1066
   Dejneka MJ, 2003, P NATL ACAD SCI USA, V100, P389, DOI 10.1073/pnas.0236044100
   Diebold R, 2005, J MOL DIAGN, V7, P97, DOI 10.1016/S1525-1578(10)60014-1
   Fenniri H, 2003, J AM CHEM SOC, V125, P10546, DOI 10.1021/ja035665q
   Finkel NH, 2004, ANAL CHEM, V76, p353A
   Fournier-Bidoz S, 2008, ANGEW CHEM INT EDIT, V47, P5577, DOI 10.1002/anie.200800409
   Fulton RJ, 1997, CLIN CHEM, V43, P1749
   Gao YL, 2011, SMALL, V7, P137, DOI 10.1002/smll.201000909
   Gao Y, 2006, NUCLEIC ACIDS RES, V34, P3370, DOI 10.1093/nar/gkl422
   Garcia EP, 2005, J MOL DIAGN, V7, P444, DOI 10.1016/S1525-1578(10)60575-2                                                   
   GODREUIL S, 2007, ENCY INFECT DIS MODE, P1
   Halford WP, 1999, NAT BIOTECHNOL, V17, P835, DOI 10.1038/12783                                                                   
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Harraway JR, 2006, J THROMB HAEMOST, V4, P587, DOI 10.1111/j.1538-7836.2006.01790.x
   Hauck TS, 2010, ADV DRUG DELIVER REV, V62, P438, DOI 10.1016/j.addr.2009.11.015
   He MX, 2008, J VIROL METHODS, V151, P126, DOI 10.1016/j.jviromet.2008.03.005
   Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562                                                               
   Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101
   Jennings TL, 2008, ANAL CHEM, V80, P2849, DOI [10.1021/ac7026035, 10.1021/ac702603]
   Johnson PH, 2002, MOL CANCER THER, V1, P1293
   Kingsmore SF, 2006, NAT REV DRUG DISCOV, V5, P310, DOI 10.1038/nrd2006
   Klostranec JM, 2007, NANO LETT, V7, P2812, DOI 10.1021/nl071415m
   Li H, 2008, ANALYST, V133, P1229, DOI 10.1039/b804096f
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Lutz BR, 2008, ACS NANO, V2, P2306, DOI 10.1021/nn800243g
   Mackay IM, 2004, CLIN MICROBIOL INFEC, V10, P190, DOI 10.1111/j.1198-743X.2004.00722.x
   Moser MJ, 2006, J MOL DIAGN, V8, P89, DOI 10.2353/jmoldx.2006.050049
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m                                                               
   Peterlinz KA, 1997, J AM CHEM SOC, V119, P3401, DOI 10.1021/ja964326c                                                               
   Pregibon DC, 2009, ANAL CHEM, V81, P4873, DOI 10.1021/ac9005292
   Schweitzer B, 2001, CURR OPIN BIOTECH, V12, P21, DOI 10.1016/S0958-1669(00)00172-5                                                   
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Wilson R, 2006, ANGEW CHEM INT EDIT, V45, P6104, DOI 10.1002/anie.200600288
   Wong ELS, 2005, LANGMUIR, V21, P6957, DOI 10.1021/la050725m
   Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119
   Xu HX, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng043
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
NR 45
TC 62
Z9 62
U1 1
U2 71
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
J9 ACS NANO
JI ACS Nano
PD MAR
PY 2011
VL 5
IS 3
BP 1580
EP 1587
DI 10.1021/nn102873w
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 737LP
UT WOS:000288570600004
PM 21355538
DA 2018-01-05
ER

PT J
AU Sato, Y
   Morimoto, K
   Hirayama, M
   Hori, K
AF Sato, Yuichiro
   Morimoto, Kinjiro
   Hirayama, Makoto
   Hori, Kanji
TI High mannose-specific lectin (KAA-2) from the red alga Kappaphycus
   alvarezii potently inhibits influenza virus infection in a
   strain-independent manner
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Lectin; Red algae; High mannose type N-glycan; Anti-influenza activity
ID HIV-INACTIVATING PROTEIN; SWINE-ORIGIN H1N1; CYANOVIRIN-N; IN-VITRO;
   GLYCOPROTEIN; HEMAGGLUTININ; GLYCANS; BINDING; GLYCOSYLATION;
   GRIFFITHSIN
AB The carbohydrate binding profile of the red algal lectin KAA-2 from Kappaphycus alvarezii was evaluated by a centrifugal ultrafiltration-HPLC method using pyridylaminated oligosaccharides. KAA-2 bound exclusively to high mannose type N-glycans, but not to other glycans such as complex type, hybrid type, or the pentasaccharide core of N-glycans. This lectin exhibited a preference for an exposed alpha 1-3 Man on a 02 arm in a similar manner to Eucheuma serra agglutinin (ESA-2), which shows various biological activities, such as anti-HIV and anti-carcinogenic activity. We tested the anti-influenza virus activity of KAA-2 against various strains including the recent pandemic H1N1-2009 influenza virus. KAA-2 inhibited infection of various influenza strains with EC(50)s of low nanomolar levels. Immunofluorescence microscopy using an anti-influenza antibody demonstrated that the antiviral activity of KAA-2 was exerted by interference with virus entry into host cells. This mechanism was further confirmed by the evidence of direct binding of KAA-2 to a viral envelope protein, hemagglutinin (HA), using an ELISA assay. These results indicate that this lectin would be useful as a novel antiviral reagent for the prevention of infection. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Hirayama, Makoto; Hori, Kanji] Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan.
   [Sato, Yuichiro; Morimoto, Kinjiro] Yasuda Womens Univ, Fac Pharm, Asaminami Ku, Hiroshima 7310153, Japan.
RP Hori, K (reprint author), Hiroshima Univ, Grad Sch Biosphere Sci, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.
EM kanhori@hiroshima-u.ac.jp
CR Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088
   Fukuda Y, 2006, ANTI-CANCER DRUG, V17, P943, DOI 10.1097/01.cad.0000224458.13651.b4
   Hartshorn KL, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-65
   Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200
   Hori K, 2007, GLYCOBIOLOGY, V17, P479, DOI 10.1093/glycob/cwm007
   Huskens D, 2010, J BIOL CHEM, V285, P24845, DOI 10.1074/jbc.M110.128546
   Job ER, 2010, J IMMUNOL, V185, P4284, DOI 10.4049/jimmunol.1001613
   Kawakubo A, 1999, J APPL PHYCOL, V11, P149, DOI 10.1023/A:1008062127564
   Li Y, 2008, J VIROL, V82, P638, DOI 10.1128/JVI.01691-07
   MirShekari SY, 1997, J BIOL CHEM, V272, P4027, DOI 10.1074/jbc.272.7.4027                                                          
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Octaviani CP, 2010, J VIROL, V84, P10918, DOI 10.1128/JVI.01140-10
   Ritchie G, 2010, VIROLOGY, V399, P257, DOI 10.1016/j.virol.2009.12.020
   Sato Y, 2007, J BIOL CHEM, V282, P11021, DOI 10.1074/jbc.M701252200
   Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Ziolkowska NE, 2006, ACTA BIOCHIM POL, V53, P617
NR 25
TC 24
Z9 26
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 11
PY 2011
VL 405
IS 2
BP 291
EP 296
DI 10.1016/j.bbrc.2011.01.031
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 725EH
UT WOS:000287627500025
PM 21219864
DA 2018-01-05
ER

PT J
AU Shlyakhtenko, LS
   Lushnikov, AY
   Li, M
   Lackey, L
   Harris, RS
   Lyubchenko, YL
AF Shlyakhtenko, Luda S.
   Lushnikov, Alexander Y.
   Li, Ming
   Lackey, Lela
   Harris, Reuben S.
   Lyubchenko, Yuri L.
TI Atomic Force Microscopy Studies Provide Direct Evidence for Dimerization
   of the HIV Restriction Factor APOBEC3G
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SINGLE-STRANDED-DNA; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; CYTIDINE
   DEAMINASE; PROTEINS; COMPLEXES; INFECTION; CELLS; MODEL; GAG
AB APOBEC3G (A3G) is an antiviral protein that binds RNA and single-stranded DNA (ssDNA). The oligomerization state of A3G is likely to be influenced by these nucleic acid interactions. We applied the power of nanoimaging atomic force microscopy technology to characterize the role of ssDNA in A3G oligomerization. We used recombinant human A3G prepared from HEK-293 cells and specially designed DNA substrates that enable free A3G to be distinguished unambiguously from DNA-bound protein complexes. This DNA substrate can be likened to a molecular ruler because it consists of a 235-bp double-stranded DNA visual tag spliced to a 69-nucleotide ssDNA substrate. This hybrid substrate enabled us to use volume measurements to determine A3G stoichiometry in both free and ssDNA-bound states. We observed that free A3G is primarily monomeric, whereas ssDNA-complexed A3G is mostly dimeric. A3G stoichiometry increased slightly with the addition of Mg2+, but dimers still predominated when Mg2+ was depleted. A His-248/His-250 Zn2+-mediated intermolecular bridge was observed in a catalytic domain crystal structure (Protein Data Bank code 3IR2); however, atomic force microscopy analyses showed that the stoichiometry of the A3G-ssDNA complexes changed insignificantly when these residues were mutated to Ala. We conclude that A3G exchanges between oligomeric forms in solution with monomers predominating and that this equilibrium shifts toward dimerization upon binding ssDNA.
C1 [Lyubchenko, Yuri L.] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   [Li, Ming; Lackey, Lela; Harris, Reuben S.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Inst Mol Virol, Ctr Genome Engn,Masonic Canc Ctr, Minneapolis, MN 55455 USA.
RP Lyubchenko, YL (reprint author), 986025 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM ylyubchenko@unmc.edu
OI Lackey, Lela/0000-0003-2163-4005
FU National Institutes of Health [AI064046, P01 GM091743, SIG 1S10
   SS023400]; National Science Foundation [PHY-0615590]; NATO [SFP-983204];
   Nebraska Research Initiative Grant
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants AI064046 (to R. S. H.) and P01 GM091743 (to R. S. H. and
   Y. L. L.). This work was also supported by National Science Foundation
   Grant PHY-0615590 (to Y. L. L.), NATO Grant SFP-983204 (to Y. L. L.), a
   Nebraska Research Initiative Grant (to Y. L. L.), and a National Science
   Foundation doctoral scholarship (to L. L.). The AFM experiments were
   performed in the University of Nebraska Nanoimaging Core Facility with
   the use of AFM instruments purchased with National Institutes of Health
   Support Grant SIG 1S10 SS023400.
CR Abmayr SM, 2006, CURR PROTOC MOL BIOL, P12, DOI [DOI 10.1002/0471142727.MB1201S75, 10.1002/0471142727.mb1201s75]
   Brar SS, 2008, DNA REPAIR, V7, P77, DOI 10.1016/j.dnarep.2007.08.002
   Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200
   Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086
   Chelico L, 2008, J BIOL CHEM, V283, P13780, DOI 10.1074/jbc.M801004200
   Chelico L, 2010, J BIOL CHEM, V285, P16195, DOI 10.1074/jbc.M110.107987
   Chen KM, 2008, NATURE, V452, P116, DOI 10.1038/nature06638
   Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493
   Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229
   Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005
   Furukawa A, 2009, EMBO J, V28, P440, DOI 10.1038/emboj.2008.290
   Hamon L, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm147
   HANSMA HG, 1995, BIOPHYS J, V68, P1672, DOI 10.1016/S0006-3495(95)80343-7                                                   
   Harjes E, 2009, J MOL BIOL, V389, P819, DOI 10.1016/j.jmb.2009.04.031
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   Holden LG, 2008, NATURE, V456, P121, DOI 10.1038/nature07357
   Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004
   Hultquist JF, 2009, FUTURE VIROL, V4, P605, DOI 10.2217/FVL.09.59
   Huthoff H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000330
   Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05
   Kataoka Naoyuki, 2008, V488, P357, DOI 10.1007/978-1-60327-475-3_23
   Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005
   Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004
   Lushnikov AY, 2006, BIOCHEMISTRY-US, V45, P152, DOI 10.1021/bi051767c
   Lushnikov AY, 2004, NUCLEIC ACIDS RES, V32, P4704, DOI 10.1093/nar/gkh810
   Lyubchenko YL, 2004, CELL BIOCHEM BIOPHYS, V41, P75, DOI 10.1385/CBB:41:1:075
   Lyubchenko YL, 2009, METHODS, V47, P206, DOI 10.1016/j.ymeth.2008.09.002
   Malim MH, 2009, PHILOS T R SOC B, V364, P675, DOI 10.1098/rstb.2008.0185
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Nowarski R, 2008, NAT STRUCT MOL BIOL, V15, P1059, DOI 10.1038/nsmb.1495
   Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200
   Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652                                                         
   Roy R, 2009, NATURE, V461, P1092, DOI 10.1038/nature08442
   Salter JD, 2009, BIOCHEMISTRY-US, V48, P10685, DOI 10.1021/bi901642c
   Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006
   Shandilya SMD, 2010, STRUCTURE, V18, P28, DOI 10.1016/j.str.2009.10.016
   Shlyakhtenko LS, 2003, ULTRAMICROSCOPY, V97, P279, DOI 10.1016/S0304-3991(03)00053-6
   Shlyakhtenko LS, 2007, BIOCHEMISTRY-US, V46, P11128, DOI 10.1021/bi701123u
   Stenglein MD, 2008, J VIROL, V82, P9591, DOI 10.1128/JVI.02471-07
   Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744
   Strebel K, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-48
   Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200
   Wang XJ, 2007, J BIOL CHEM, V282, P1585, DOI 10.1074/jbc.M610150200
   Wedekind JE, 2006, J BIOL CHEM, V281, P38122, DOI 10.1074/jbc.C600253200
   WICHROSKI MJ, 2006, PLOS PATHOG, V2, pNIL40, DOI DOI 10.1371/JOURNAL.PPAT.0020041
   Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758
   Zennou Veronique, 2004, Journal of Virology, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
NR 48
TC 51
Z9 51
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 4
PY 2011
VL 286
IS 5
BP 3387
EP 3395
DI 10.1074/jbc.M110.195685
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 712GE
UT WOS:000286653200025
PM 21123176
OA gold
DA 2018-01-05
ER

PT J
AU Worsdorfer, B
   Woycechowsky, KJ
   Hilvert, D
AF Woersdoerfer, Bigna
   Woycechowsky, Kenneth J.
   Hilvert, Donald
TI Directed Evolution of a Protein Container
SO SCIENCE
LA English
DT Article
ID LUMAZINE SYNTHASE; CONSTRAINED SYNTHESIS; CONTRAST AGENTS; IRON-OXIDE;
   NANOPARTICLES; CAGE; ENCAPSULATION; DELIVERY; INTERIOR; RELEASE
AB Confinement of enzymes in protein nanocompartments represents a potentially powerful strategy for controlling catalytic activity in cells. By using a simple electrostatically based tagging system for protein encapsulation, we successfully sequestered HIV protease, a toxic enzyme when produced cytoplasmically, within an engineered lumazine synthase capsid. The growth advantage resulting from protecting the Escherichia coli host from the protease enabled directed evolution of improved capsids. After four rounds of mutagenesis and selection, we obtained a variant with a 5- to 10-fold higher loading capacity than the starting capsid, which permitted efficient growth even at high intracellular concentrations of HIV protease. The superior properties of the evolved capsid can be ascribed to multiple mutations that increase the net negative charge on its luminal surface and thereby enhance engineered Coulombic interactions between host and guest. Such structures could be used for diverse biotechnological applications in living cells.
C1 [Woersdoerfer, Bigna; Woycechowsky, Kenneth J.; Hilvert, Donald] ETH, Organ Chem Lab, CH-8093 Zurich, Switzerland.
RP Hilvert, D (reprint author), ETH, Organ Chem Lab, CH-8093 Zurich, Switzerland.
EM hilvert@org.chem.ethz.ch
RI Woycechowsky, Kenneth/K-5833-2015
FU Schweizerischer Nationalfond; ETH Zurich
FX We thank B. Roschitzki at the Functional Genomics Center Zurich for
   collection of mass spectrometic data and assistance with data analysis;
   T. Ishikawa and M. Lucas at the Electron Microscopy Center of the ETH
   Zurich (EMEZ) for collecting the EM images and assistance with EM data
   analysis; H.-M. Fischer, F. Narberhaus, M. Neuenschwander, and F.
   Seebeck for contributive discussions; and P. Kast for careful reading of
   the manuscript. This work was supported in part by the Schweizerischer
   Nationalfond and the ETH Zurich. The supercharged GFP described in fig.
   S8 was obtained under a materials transfer agreement (MTA) with D. R.
   Liu at Harvard. An MTA would be required for sharing of materials used
   in the reported research.
CR Abbing A, 2004, J BIOL CHEM, V279, P27410, DOI 10.1074/jbc.M313612200
   Aime S, 2002, ANGEW CHEM INT EDIT, V41, P1017, DOI 10.1002/1521-3773(20020315)41:6<1017::AID-ANIE1017>3.0.CO;2-P                   
   Allen M, 2002, ADV MATER, V14, P1562, DOI 10.1002/1521-4095(20021104)14:21<1562::AID-ADMA1562>3.0.CO;2-D                  
   de la Escosura A, 2009, J MATER CHEM, V19, P2274, DOI 10.1039/b815274h
   DOUGLAS T, 1995, SCIENCE, V269, P54, DOI 10.1126/science.269.5220.54
   Flenniken ML, 2005, CHEM COMMUN, P447, DOI 10.1039/b413435d
   Flint S. J., 2009, PRINCIPLES VIROLOGY
   Hooker JM, 2007, NANO LETT, V7, P2207, DOI 10.1021/nl070512c
   Ishii D, 2003, NATURE, V423, P628, DOI 10.1038/nature01663
   Jenni S, 2007, SCIENCE, V316, P254, DOI 10.1126/science.1138248
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788                                                        
   Klem MT, 2007, J AM CHEM SOC, V129, P197, DOI 10.1021/ja0667561
   Knez M, 2003, NANO LETT, V3, P1079, DOI 10.1021/nl0342545
   Liu XF, 2005, ACCOUNTS CHEM RES, V38, P167, DOI 10.1021/ar0302336
   McMillan RA, 2005, J AM CHEM SOC, V127, P2800, DOI 10.1021/ja043827s
   Neuenschwander M, 2007, NAT BIOTECHNOL, V25, P1145, DOI [10.1038/nbt1341, 10.1038/nbtl341]
   Rebek J, 2005, ANGEW CHEM INT EDIT, V44, P2068, DOI 10.1002/anie.200462839
   Saibil HR, 2008, CURR OPIN STRUC BIOL, V18, P35, DOI 10.1016/j.sbi.2007.11.006
   Schaffer DV, 2008, ANNU REV BIOMED ENG, V10, P169, DOI 10.1146/annurev.bioeng.10.061807.160514
   Seebeck FP, 2006, J AM CHEM SOC, V128, P4516, DOI 10.1021/ja058363s
   Shenton W, 2001, ANGEW CHEM INT EDIT, V40, P442, DOI 10.1002/1521-3773(20010119)40:2<442::AID-ANIE442>3.0.CO;2-2
   Sutter M, 2008, NAT STRUCT MOL BIOL, V15, P939, DOI 10.1038/nsmb.1473
   Tanaka S, 2010, SCIENCE, V327, P81, DOI 10.1126/science.1179513
   Uchida M, 2007, ADV MATER, V19, P1025, DOI 10.1002/adma.200601168
   Uchida M, 2006, J AM CHEM SOC, V128, P16626, DOI 10.1021/ja0655690
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
   Yeates TO, 2008, NAT REV MICROBIOL, V6, P681, DOI 10.1038/nrmicro1913
   Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435
   Zhang XF, 2006, J MOL BIOL, V362, P753, DOI 10.1016/j.jmb.2006.07.037
   Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698
NR 31
TC 122
Z9 122
U1 7
U2 84
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 4
PY 2011
VL 331
IS 6017
BP 589
EP 592
DI 10.1126/science.1199081
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 715ZE
UT WOS:000286933600055
PM 21292977
DA 2018-01-05
ER

PT J
AU Kim, JM
   Han, SH
AF Kim, June Myung
   Han, Sang Hoon
TI Immunotherapeutic restoration in HIV-infected individuals
SO IMMUNOTHERAPY
LA English
DT Review
DE cytokine therapy; HIV; immune-modulating drugs; immunotherapy;
   monoclonal antibodies; nanotechnology-based approaches;
   radioimmunotherapy; therapeutic immunization
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; RANDOMIZED
   CONTROLLED-TRIAL; CCR5 MONOCLONAL-ANTIBODY; CHRONIC VIRAL-INFECTION;
   CD4(+) T-CELLS; INTERMITTENT INTERLEUKIN-2 THERAPY; DOSE SUBCUTANEOUS
   INTERLEUKIN-2; CELLULAR IMMUNE-RESPONSES; DENDRITIC CELLS
AB While the development of combined active antiretroviral therapy (cART) has dramatically improved life expectancies and quality of life in HIV-infected individuals, long-term clinical problems, such as metabolic complications, remain important constraints of life-long cART. Complete immune restoration using only cART is normally unattainable even in cases of sufficient plasma viral suppression. The need for immunologic adjuncts that complement cART remains, because while cART alone may result in the complete recovery of peripheral net CDC(+) T lymphocytes, it may not affect the reservoir of HIV-infected cells. Here, we review current immunotherapies for HIV infection, with a particular emphasis on recent advances in cytokine therapies, therapeutic immunization, monoclonal antibodies, immune-modulating drugs, nanotechnology-based approaches and radioimmunotherapy.
C1 [Kim, June Myung; Han, Sang Hoon] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea.
   [Kim, June Myung; Han, Sang Hoon] Yonsei Univ, Coll Med, AIDS Res Inst, Seoul 120752, South Korea.
RP Kim, JM (reprint author), Yonsei Univ, Coll Med, Dept Internal Med, 250 Seongsanno, Seoul 120752, South Korea.
CR Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175
   Abrams DI, 2002, J ACQ IMMUN DEF SYND, V29, P221
   Ahuja SS, 1999, J IMMUNOL, V163, P3890
   Aiuti F, 2006, AIDS REV, V8, P88
   Albuquerque AS, 2007, CLIN IMMUNOL, V125, P67, DOI 10.1016/j.clim.2007.07.001
   Aline F, 2009, VACCINE, V27, P5284, DOI 10.1016/j.vaccine.2009.05.028
   Arduino RC, 2004, CLIN INFECT DIS, V39, P115, DOI 10.1086/421775
   Arno A, 1999, J INFECT DIS, V180, P56, DOI 10.1086/314831
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Barouch DH, 2001, IMMUNOL LETT, V79, P57, DOI 10.1016/S0165-2478(01)00266-8                                                   
   Beq S, 2006, J IMMUNOL, V176, P914, DOI 10.4049/jimmunol.176.2.914                                                      
   Berger R, 2008, CLIN CANCER RES, V14, P3044, DOI 10.1158/1078-0432.CCR-07-4079
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129
   Boon L, 2002, TOXICOLOGY, V172, P191, DOI 10.1016/S0300-483X(02)00002-1
   Bourinbaiar AS, 2006, CURR PHARM DESIGN, V12, P2017, DOI 10.2174/138161206777442119
   Boyer JD, 2007, P NATL ACAD SCI USA, V104, P18648, DOI 10.1073/pnas.0709198104
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brown BK, 2007, J VIROL, V81, P2087, DOI 10.1128/JVI.02011-06
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   Calarota SA, 2008, VACCINE, V26, P5188, DOI 10.1016/j.vaccine.2008.03.067
   Carr A, 1998, J INFECT DIS, V178, P992, DOI 10.1086/515653
   Cavacini LA, 1998, AIDS RES HUM RETROV, V14, P545, DOI 10.1089/aid.1998.14.545
   Chapuis AG, 2000, NAT MED, V6, P762
   Chong SY, 2007, VACCINE, V25, P4967, DOI 10.1016/j.vaccine.2006.11.070
   Cilliers T, 2003, J VIROL, V77, P4449, DOI 10.1128/JVI.77.7.4449-4456.2003
   Clayton R, 2007, J VIROL METHODS, V139, P17, DOI 10.1016/j.jviromet.2006.08.017
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Coull JJ, 2001, J ACQ IMMUN DEF SYND, V26, P423
   COUTINHO A, 1989, IMMUNOL REV, V110, P63, DOI 10.1111/j.1600-065X.1989.tb00027.x                                              
   Cristillo AD, 2007, VIROLOGY, V366, P197, DOI 10.1016/j.virol.2007.04.012
   Dadachova E, 2009, SEMIN NUCL MED, V39, P146, DOI 10.1053/j.semnuclmed.2008.10.007
   Davey RT, 2000, JAMA-J AM MED ASSOC, V284, P183, DOI 10.1001/jama.284.2.183                                                          
   Davey RT, 1999, J INFECT DIS, V179, P849
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   de Boer AW, 2003, CLIN IMMUNOL, V106, P188, DOI 10.1016/S1521-6616(02)00038-4
   Delaugerre C, 2003, ANTIVIR THER, V8, P233
   Dezube BJ, 2003, J INFECT DIS, V187, P500, DOI 10.1086/367710
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Durier C, 2007, AIDS, V21, P1887, DOI 10.1097/QAD.0b013e3282703825
   Eda Y, 2006, J VIROL, V80, P5563, DOI 10.1128/JVI.02095-05
   Eda Y, 2006, J VIROL, V80, P5552, DOI 10.1128/JVI.02094-05
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Elsaesser H, 2009, SCIENCE, V324, P1569, DOI 10.1126/science.1174182
   Franceschini D, 2009, J CLIN INVEST, V119, P551, DOI 10.1172/JCI36604
   Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815
   Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892                                                       
   Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983
   Fry TJ, 2003, BLOOD, V101, P2294, DOI 10.1182/blood-2002-07-2297
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07
   Goldstein G, 2010, VACCINE, V28, P1008, DOI 10.1016/j.vaccine.2009.10.129
   Gorny MK, 2004, J VIROL, V78, P2394, DOI 10.1128/JVI.78.5.2394-2404.2004
   Gorny MK, 2002, J VIROL, V76, P9035, DOI 10.1128/JVI.76.18.9035-9045.2002
   Hatada M, 2010, J GEN VIROL, V91, P1335, DOI 10.1099/vir.0.017426-0
   Havlir DV, 2001, AIDS, V15, P1379, DOI 10.1097/00002030-200107270-00007
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Henry K, 2006, JAIDS-J ACQ IMM DEF, V42, P140, DOI 10.1097/01.qai.0000225319.59652.1e
   Hossain MM, 2002, ANTIVIR RES, V55, P41, DOI 10.1016/S0166-3542(02)00006-2
   Iannello A, 2008, VIRAL IMMUNOL, V21, P385, DOI 10.1089/vim.2008.0025
   Iannello A, 2010, J IMMUNOL, V184, P114, DOI 10.4049/jimmunol.0901967
   Ide F, 2006, J MED VIROL, V78, P711, DOI 10.1002/jmv.20612
   Jacobson JM, 2008, J INFECT DIS, V198, P1345, DOI 10.1086/592169
   Jacobson JM, 2010, ANTIMICROB AGENTS CH, V54, P4137, DOI 10.1128/AAC.00086-10
   Jacobson JM, 2010, J INFECT DIS, V201, P1481, DOI 10.1086/652190
   Jacobson JM, 2009, ANTIMICROB AGENTS CH, V53, P450, DOI 10.1128/AAC.00942-08
   Jenwitheesuk E, 2007, BIOINFORMATICS, V23, P2797, DOI 10.1093/bioinformatics/btm424
   Ji CH, 2007, ANTIVIR RES, V74, P125, DOI 10.1016/j.antiviral.2006.11.003
   Ji C, 2007, MOL PHARMACOL, V72, P18, DOI 10.1124/mol.107.035055
   Katlama C, 2002, AIDS, V16, P2027, DOI 10.1097/00002030-200210180-00007
   Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803                                                     
   KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904
   Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551
   Kuritzkes DR, 2004, J INFECT DIS, V189, P286, DOI 10.1086/380802                                                                  
   Lalezari J P, 2000, HIV Clin Trials, V1, P1
   Lalezari J, 2008, J INFECT DIS, V197, P721, DOI 10.1086/527327
   Levy Y, 1999, LANCET, V353, P1923, DOI 10.1016/S0140-6736(98)07345-0                                                   
   Levy Y, 2003, AIDS, V17, P343, DOI 10.1097/01.aids.0000050801.28043.04
   LEVY Y, 2009, 49 ICAAC SAN FRANC C
   LIEGLER TJ, 1994, J ACQ IMMUN DEF SYND, V7, P340
   Lin SJ, 1997, CLIN IMMUNOL IMMUNOP, V82, P163, DOI 10.1006/clin.1996.4298                                                          
   Lisziewicz J, 2003, DRUG SAFETY, V26, P605, DOI 10.2165/00002018-200326090-00002
   Lisziewicz J, 2007, EXPERT OPIN BIOL TH, V7, P1563, DOI 10.1517/14712598.7.10.1563
   Lisziewicz Julianna, 2006, Current Drug Delivery, V3, P83, DOI 10.2174/156720106775197574
   Lopez M, 2004, AIDS, V18, P1251, DOI 10.1097/01.aids.0000125984.56410.24
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Lori F, 2005, AIDS, V19, P1173, DOI 10.1097/01.aids.0000176217.02743.d1
   LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634
   Lori Franco, 2002, HIV Clin Trials, V3, P115
   Losso MH, 2000, J INFECT DIS, V181, P1614, DOI 10.1086/315430
   Lova L, 2005, AIDS, V19, P137, DOI 10.1097/00002030-200501280-00005
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806
   Marchetti G, 2002, J INFECT DIS, V186, P606, DOI 10.1086/342479                                                                  
   Margolis DM, 2002, JAIDS, V31, P45, DOI 10.1097/01.QAI.0000026508.98625.05
   Marozsan AJ, 2005, VIROLOGY, V338, P182, DOI 10.1016/j.virol.2005.04.035
   Marziali M, 2006, AIDS, V20, P2033, DOI 10.1097/01.aids.0000247588.69438.fd                                             
   Mason RD, 2009, J VIROL, V83, P1501, DOI 10.1128/JVI.02119-08
   Matsushita Shuzo, 2005, Human Antibodies, V14, P81
   McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648
   Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010
   MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839
   Metlas R, 2007, CURR HIV RES, V5, P261, DOI 10.2174/157016207780077093
   Metlas RM, 2009, CURR HIV RES, V7, P378, DOI 10.2174/157016209788680516                                                      
   Miller KD, 2001, CLIN IMMUNOL, V99, P30, DOI 10.1006/clim.2001.5001
   Mitsuyasu R, 2007, ARCH INTERN MED, V167, P597, DOI 10.1001/archinte.167.6.597                                                      
   Moody MA, 2010, J EXP MED, V207, P763, DOI 10.1084/jem.20091281
   Murakami T, 2009, AIDS, V23, P1485, DOI 10.1097/QAD.0b013e32832e5331
   Murga JD, 2006, ANTIMICROB AGENTS CH, V50, P3289, DOI 10.1128/AAC.00699-06
   Nacsa J, 2005, J IMMUNOL, V174, P1913, DOI 10.4049/jimmunol.174.4.1913                                                     
   Nicolette CA, 2007, VACCINE, V25, pB47, DOI 10.1016/j.vaccine.2007.06.006
   Norris D, 2006, 16 INT AIDS C TOR ON
   Ozawa H, 1999, J INVEST DERMATOL, V113, P999, DOI 10.1046/j.1523-1747.1999.00769.x
   Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16                                              
   Peluso I, 2007, J IMMUNOL, V178, P732, DOI 10.4049/jimmunol.178.2.732                                                      
   Peng GP, 2008, MOL IMMUNOL, V45, P963, DOI 10.1016/j.molimm.2007.07.038
   Pett Sarah L, 2003, Expert Rev Anti Infect Ther, V1, P83, DOI 10.1586/14787210.1.1.83
   Pett SL, 2004, HIV CLIN TRIALS, V5, P91, DOI 10.1310/1FLN-8KFC-5HEQ-K19J                                                     
   Preece AF, 2002, BLOOD, V99, P2477, DOI 10.1182/blood.V99.7.2477
   Pugach P, 2004, VIROLOGY, V321, P8, DOI 10.1016/j.virol.2003.12.012
   Pugach P, 2008, VIROLOGY, V377, P401, DOI 10.1016/j.virol.2008.04.032
   Read SW, 2008, J INFECT DIS, V198, P843, DOI 10.1086/591250
   Read SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011937
   Reddy ST, 2006, J CONTROL RELEASE, V112, P26, DOI 10.1016/j.jconrel.2006.01.006
   Redel L, 2010, J LEUKOCYTE BIOL, V87, P575, DOI 10.1189/jlb.0409264
   Reimann KA, 2002, AIDS RES HUM RETROV, V18, P747, DOI 10.1089/08892220260139486
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x
   Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   Roschke V, 2004, 44 INT C ANT AG CHEM
   Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2
   Rusert P, 2005, J VIROL, V79, P8454, DOI 10.1128/JVI.79.13.8454-8469.2005
   Ruxrungtham K, 2000, AIDS, V14, P2509, DOI 10.1097/00002030-200011100-00013
   SALK J, 1987, NATURE, V327, P473, DOI 10.1038/327473a0                                                                
   Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930
   Sereti I, 2007, J INFECT DIS, V196, P677, DOI 10.1086/520087
   Sester U, 2008, AM J TRANSPLANT, V8, P1486, DOI 10.1111/j.1600-6143.2008.02279.x
   Shapero MH, 2000, CELL TRANSPLANT, V9, P307, DOI 10.1177/096368970000900302
   Shearer WT, 2006, J ALLERGY CLIN IMMUN, V118, P518, DOI 10.1016/j.jaci.2006.03.028
   Shibata J, 2007, J VIROL, V81, P3757, DOI 10.1128/JVI.01544-06
   SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876
   Sodora DL, 2008, AIDS, V22, P439, DOI 10.1097/QAD.0b013e3282f2dbe7
   Sommerfelt MA, 2008, EXPERT OPIN BIOL TH, V8, P745, DOI [10.1517/14712590802083437, 10.1517/14712598.8.6.745 ]
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song RJ, 2010, J VIROL, V84, P6935, DOI 10.1128/JVI.00453-10
   Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681
   Steinberger P, 2000, J BIOL CHEM, V275, P36073, DOI 10.1074/jbc.M002765200
   Stellbrink HJ, 2002, AIDS, V16, P1479, DOI 10.1097/00002030-200207260-00004
   Storek J, 2003, BLOOD, V101, P4209, DOI 10.1182/blood-2002-08-2671
   Suto A, 2008, J EXP MED, V205, P1369, DOI 10.1084/jem.20072057
   Szeto GL, 2010, J INFECT DIS, V201, P1132, DOI 10.1086/651277
   Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173
   Takayama T, 1999, TRANSPLANTATION, V68, P1903, DOI 10.1097/00007890-199912270-00015                                                
   Tambussi G, 2001, J INFECT DIS, V183, P1476, DOI 10.1086/320188                                                                  
   Touzet O, 2010, AIDS, V24, P1437, DOI 10.1097/QAD.0b013e32833a6114
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001
   Tsibris AMN, 2008, J VIROL, V82, P8210, DOI 10.1128/JVI.00444-08
   Velu V, 2009, NATURE, V458, P206, DOI 10.1038/nature07662
   Verity EE, 2006, AIDS, V20, P505, DOI 10.1097/01.aids.0000210604.78385.95
   Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200
   Whitcomb JM, 2007, ANTIMICROB AGENTS CH, V51, P566, DOI 10.1128/AAC.00853-06
   Yamamoto N, 2006, AIDS RES HUM RETROV, V22, P262, DOI 10.1089/aid.2006.22.262
   YAMAMOTO N, 1995, AIDS RES HUM RETROV, V11, P1373, DOI 10.1089/aid.1995.11.1373
   Yamamoto N, 2009, J MED VIROL, V81, P16, DOI 10.1002/jmv.21376
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
   Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194
   Yoshimura K, 2006, AIDS, V20, P2065, DOI 10.1097/01.aids.0000247587.31320.fe                                             
   Zhang HS, 2009, LIFE SCI, V85, P484, DOI 10.1016/j.lfs.2009.07.014
   Zhang XQ, 2006, ANTIMICROB AGENTS CH, V50, P2231, DOI 10.1128/AAC.00761-05
   Zink MC, 1999, J VIROL, V73, P10480
   Zink MC, 2005, JAMA-J AM MED ASSOC, V293, P2003, DOI 10.1001/jama.293.16.2003
   [Anonymous], 2009, AIDS PATIENT CARE ST, V23, P987
NR 175
TC 4
Z9 4
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD FEB
PY 2011
VL 3
IS 2
BP 247
EP 267
DI 10.2217/IMT.10.91
PG 21
WC Immunology
SC Immunology
GA 738GI
UT WOS:000288627900016
PM 21322762
DA 2018-01-05
ER

PT J
AU Sambasivarao, SV
   Acevedo, O
AF Sambasivarao, Somisetti V.
   Acevedo, Orlando
TI Computational Insight into Small Molecule Inhibition of Cyclophilins
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN EXPRESSION PROFILES;
   PEPTIDYL-PROLYL ISOMERASE; CYTOSOLIC BINDING-PROTEIN; CIS-TRANS
   ISOMERASES; CHRONIC HEPATITIS-C; CYCLOSPORINE-A; CRYSTAL-STRUCTURE;
   BIOMOLECULAR SYSTEMS; RNA-POLYMERASE
AB Cyclophilins (Gyp) are a family of cellular enzymes possessing peptidyl-prolyl isomerase activity, which catalyze the cis-trans interconversion of proline-containing peptide bonds. The two most abundant family members, CypA and CypB, have been identified as valid drug targets for a wide range of diseases, including HCV, HIV, and multiple cancers However, the development of small molecule inhibitors that possess nM potency and high specificity for a particular Cyp is difficult given the complete conservation of all active site residues between the enzymes Monte Carlo statistical sampling coupled to free energy perturbation theory (MC/FEP) calculations have been carried out to elucidate the origin of the experimentally observed nM inhibition of CypA, by acylurea-based derivatives and the >200 fold hi vitro selectivity between CypA and CypB from aryl 1-indanylketone-based mu M inhibitors. The computed free energies of binding were in close accord with those derived from experiments. Binding affinity values for the inhibitors were determined to be dependent upon the stabilization strength of the nonbonded interactions provided toward two catalytic residues: Arg55 and Asn102 in CypA and the analogous Arg63 and Asn110 residues in CypB. Fine-tuning of the hydrophobic interactions. allowed for enhanced potency among derivatives The aryl 1-indanylketones are predicted to differentiate between the cyclophilins by using distinct binding motifs that exploit subtle differences in the active site arrangement:. Ideas for the development of new selective compounds with the potential for advancement to low-nanomolar inhibition are presented.
C1 [Sambasivarao, Somisetti V.; Acevedo, Orlando] Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA.
RP Acevedo, O (reprint author), Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA.
EM orlando.acevedo@auburn.edu
FU Auburn University
FX Gratitude is expressed to Auburn University for support of this
   research. This research was stimulated by discussions with Prof. Patrick
   Flaherty.
CR Acevedo O, 2009, J PHYS CHEM B, V113, P15372, DOI 10.1021/jp9069114
   Arora K, 2005, J IMMUNOL, V175, P517, DOI 10.4049/jimmunol.175.1.517                                                      
   Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975                                                           
   CALNE RY, 1989, LANCET, V2, P227
   CUTHBERT JA, 1994, CLIN MICROBIOL REV, V7, P505
   Daum S, 2006, ANGEW CHEM INT EDIT, V45, P7454, DOI 10.1002/anie.200601569
   Daum S, 2009, BIOCHEMISTRY-US, V48, P6268, DOI 10.1021/bi9007287
   Dornan J, 2003, CURR TOP MED CHEM, V3, P1392, DOI 10.2174/1568026033451899
   Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753
   Fischer G, 2003, Rev Physiol Biochem Pharmacol, V148, P105, DOI 10.1007/s10254-003-0011-3
   Flisiak R, 2008, HEPATOLOGY, V47, P817, DOI 10.1002/hep.22131
   Fraser JS, 2009, NATURE, V462, P669, DOI 10.1038/nature08615
   FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G
   Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3                                                   
   Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299
   Hamelberg D, 2009, J AM CHEM SOC, V131, P147, DOI 10.1021/ja806146g
   HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408
   Howard BA, 2004, LUNG CANCER-J IASLC, V46, P313, DOI 10.1016/j.lungcan.2004.05.013
   Inoue K, 2005, TRANSPLANT P, V37, P1233, DOI 10.1016/j.transproceed.2004.11.041
   Inoue K, 2003, J GASTROENTEROL, V38, P567, DOI 10.1007/s00535-002-1104-5
   Jarvis LM, 2010, C EN, V88, P12
   Jorgensen WL, 2008, J CHEM THEORY COMPUT, V4, P869, DOI 10.1021/ct800011m
   Jorgensen WL, 2009, ACCOUNTS CHEM RES, V42, P724, DOI 10.1021/ar800236t
   Jorgensen WL, 2005, J COMPUT CHEM, V26, P1689, DOI 10.1002/jcc.20297
   JORGENSEN WL, 1985, J CHEM PHYS, V83, P3050, DOI 10.1063/1.449208                                                                
   Jorgensen WL, 2005, P NATL ACAD SCI USA, V102, P6665, DOI 10.1073/pnas.0408037102
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kajitani K, 2008, PROTEINS, V70, P1635, DOI 10.1002/prot.21855
   KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0
   KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483
   KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850
   KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007                                                             
   LIANG TJ, 1993, HEPATOLOGY, V18, P1326, DOI 10.1002/hep.1840180607
   Lohmann V, 1997, J VIROL, V71, P8416
   LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6                                                    
   Martinot-Peignoux M, 1998, J HEPATOL, V29, P214, DOI 10.1016/S0168-8278(98)80006-8                                                   
   Michel J, 2009, J AM CHEM SOC, V131, P15403, DOI 10.1021/ja906058w
   MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nakagawa M, 2005, GASTROENTEROLOGY, V129, P1031, DOI 10.1053/j.gastro.2005.06.031
   Nakagawa M, 2004, BIOCHEM BIOPH RES CO, V313, P42, DOI 10.1016/j.bbrc.2003.11.080
   NERI P, 1991, FEBS LETT, V290, P195, DOI 10.1016/0014-5793(91)81258-A
   Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903
   SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007
   SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904                                                         
   Sedrani R, 2003, J AM CHEM SOC, V125, P3849, DOI 10.1021/ja021327y
   Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262                                                   
   SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0
   STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407
   Tang HL, 2010, VIRUSES-BASEL, V2, P1621, DOI 10.3390/v2081621
   Tang HL, 2009, CLIN SCI, V117, P49, DOI 10.1042/CS20080631
   Vajdos FE, 1997, PROTEIN SCI, V6, P2297
   Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449
   Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014
   Watashi K, 2005, HEPATOLOGY, V42, P1455
   Yang F, 2008, J VIROL, V82, P5269, DOI 10.1128/JVI.02614-07
   Yao QZ, 2005, WORLD J SURG, V29, P276, DOI 10.1007/s00268-004-7812-7
   Zeevaart JG, 2008, J AM CHEM SOC, V130, P9492, DOI 10.1021/ja8019214
   Zheng JM, 2008, CANCER RES, V68, P7769, DOI 10.1158/0008-5472.CAN-08-0639
NR 61
TC 8
Z9 8
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549-9596
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD FEB
PY 2011
VL 51
IS 2
BP 475
EP 482
DI 10.1021/ci1004114
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA 725ZP
UT WOS:000287685700027
PM 21194235
DA 2018-01-05
ER

PT J
AU Semlin, L
   Schafer-Korting, M
   Borelli, C
   Korting, HC
AF Semlin, Lydia
   Schaefer-Korting, Monika
   Borelli, Claudia
   Korting, Hans C.
TI In vitro models for human skin disease
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID RECONSTRUCTED HUMAN EPIDERMIS; SECRETED ASPARTYL PROTEINASES; HUMAN
   CUTANEOUS CANDIDOSIS; SOLID LIPID NANOPARTICLES; SQUAMOUS-CELL
   CARCINOMA; HIV-INFECTED PATIENTS; HUMAN ORAL CANDIDOSIS; EQUIVALENT
   MODEL; PSORIATIC SKIN; RHINO MOUSE
AB Modern tissue culture technology has made it possible to generate human skin equivalents that represent either epidermis or epidermis plus dermis (full-thickness skin) in vitro. Commercially available skin equivalents and in-house models are used for safety analysis of cosmetics and toxicity screening of various pharmaceutical compounds. Recently, tissue culture technology has also been used to develop in vitro models of skin disease, in particular to promote cutaneous drug research while sparing experimental animals. The spectrum of model diseases available covers a range from inflammatory disease to cancer. It has, thus, been possible to gain more insight into the role of active pharmaceutical ingredients of various dermatologically relevant drug classes as well as conventional and innovative formulations.
C1 [Semlin, Lydia; Borelli, Claudia; Korting, Hans C.] Ludwig Maximilians Univ Munchen, Dept Dermatol, D-80337 Munich, Germany.
   [Schaefer-Korting, Monika] Free Univ Berlin, Inst Pharm, D-14195 Berlin, Germany.
RP Korting, HC (reprint author), Ludwig Maximilians Univ Munchen, Dept Dermatol, Frauenlobstr 9-11, D-80337 Munich, Germany.
EM HansChristian.Korting@med.uni-muenchen.de
CR Barker CL, 2004, J INVEST DERMATOL, V123, P892, DOI 10.1111/j.0022-202X.2004.23435.x
   Bechetoille N, 2007, TISSUE ENG, V13, P2667, DOI 10.1089/ten.2006.0405
   Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998                                                          
   Bernerd F, 2000, PHOTOCHEM PHOTOBIOL, V71, P314, DOI 10.1562/0031-8655(2000)071<0314:EOTPEO>2.0.CO;2
   Bernerd F, 2008, J AM ACAD DERMATOL, V58, pS155, DOI 10.1016/j.jaad.2007.08.050
   Bernerd Francoise, 2005, Journal de la Societe de Biologie, V199, P313, DOI 10.1051/jbio:2005032
   Bonowitz A, 2001, J DRUG TARGET, V9, P75, DOI 10.3109/10611860108995634                                                       
   Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8
   Borgia SL, 2008, EUR J PHARM BIOPHARM, V68, P380, DOI 10.1016/j.ejpb.2007.05.003
   Bouez C, 2006, CLIN CANCER RES, V12, P1463, DOI 10.1158/1078-0432.CCR-05-1456
   Braye F, 2005, PATHOL BIOL, V53, P613, DOI 10.1016/j.patbio.2004.12.004
   Cario-Andre M, 2007, PIGM CELL RES, V20, P385, DOI 10.1111/j.1600-0749.2007.00396.x
   Cheng T, 2009, BRIT J DERMATOL, V161, P253, DOI 10.1111/j.1365-2133.2009.09156.x
   Commandeur S, 2009, EXP DERMATOL, V18, P849, DOI 10.1111/j.1600-0625.2009.00856.x
   de Brugerolle de F., 1999, CELL BIOL TOXICOL, V15, P121
   Duval C, 2003, EXP DERMATOL, V12, P64, DOI 10.1034/j.1600-0625.12.s2.10.x                                                  
   Ehrlich HP, 2004, AM J SURG, V187, p29S, DOI 10.1016/S0002-9610(03)00301-5
   Engelhart K, 2005, ARCH DERMATOL RES, V297, P1, DOI 10.1007/s00403-005-0575-7
   Eves P, 2000, BRIT J DERMATOL, V142, P210, DOI 10.1046/j.1365-2133.2000.03287.x                                                
   Facy V, 2004, J INVEST DERMATOL, V122, P552, DOI 10.1046/j.0022-202X.2004.22209.x
   Gysler A, 1999, PHARMACEUT RES, V16, P1386, DOI 10.1023/A:1018946924585
   Hakozaki T, 2008, ARCH DERMATOL RES, V300, pS51, DOI 10.1007/s00403-007-0804-3
   Hoegl L, 1998, MYCOSES, V41, P321, DOI 10.1111/j.1439-0507.1998.tb00345.x                                              
   Holland DB, 2008, FEMS MICROBIOL LETT, V279, P110, DOI 10.1111/j.1574-6968.2007.01021.x
   Holland DB, 2009, FEMS MICROBIOL LETT, V290, P149, DOI 10.1111/j.1574-6968.2008.01402.x
   Hsia E, 2008, J INVEST DERMATOL, V128, P125, DOI 10.1038/sj.jid.5700968
   Jean J, 2009, J DERMATOL SCI, V53, P19, DOI 10.1016/j.jdermsci.2008.07.009
   Kemp K, 2010, DRUG DISCOV TODAY, V15, P161, DOI 10.1016/j.drudis.2010.01.005
   KLIGMAN LH, 1979, J INVEST DERMATOL, V73, P354, DOI 10.1111/1523-1747.ep12550409
   Korting HC, 1999, ANTIMICROB AGENTS CH, V43, P2038
   Korting HC, 2003, J MED MICROBIOL, V52, P623, DOI 10.1099/jmm.0.05125-0
   Korting HC, 1998, J INFECTION, V36, P259, DOI 10.1016/S0163-4453(98)94063-4
   KORTING HC, 2009, HDB EXPT PHARM, V197
   KORTING HC, 2007, CLIN DRUG INVEST, V14, P286
   Kuchler S, 2010, J BIOTECHNOL, V148, P24, DOI 10.1016/j.jbiotec.2010.01.001
   Kuchler S, 2009, EUR J PHARM BIOPHARM, V71, P243, DOI 10.1016/j.ejpb.2008.08.019
   Maia CS, 2002, J DRUG TARGET, V10, P489, DOI 10.1080/1061186021000038364
   MEZICK JA, 1984, J INVEST DERMATOL, V83, P110, DOI 10.1111/1523-1747.ep12263280
   MILS V, 1994, DIFFERENTIATION, V58, P77, DOI 10.1046/j.1432-0436.1994.5810077.x
   Netzaff F, 2005, EUR J PHARM BIOPHARM, V60, P167, DOI 10.1016/j.ejpb.2005.03.004
   O'Leary R, 2002, CELL BIOCHEM FUNCT, V20, P129, DOI 10.1002/cbf.965
   Obrigkeit DH, 2009, PHOTOCHEM PHOTOBIOL, V85, P272, DOI 10.1111/j.1751-1097.2008.00432.x
   *OECD, 2004, TEST GUID OECD, V432
   Organisation for Economic Co-operation and Development (OECD), 2008, GUID TEST C IN PRESS
   *OECD, 2004, TEST GUID OECD, V431
   Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005
   Pageon H, 2008, EXP GERONTOL, V43, P584, DOI 10.1016/j.exger.2008.04.004
   Ponec Maria, 1992, International Journal of Cosmetic Science, V14, P245, DOI 10.1111/j.1467-2494.1992.tb00058.x
   Proksch E, 2009, J DTSCH DERMATOL GES, V7, P899, DOI 10.1111/j.1610-0387.2009.07157.x
   RASHID A, 1995, J MED VET MYCOL, V33, P229
   Robinson MK, 2002, FOOD CHEM TOXICOL, V40, P573, DOI 10.1016/S0278-6915(02)00005-4                                                   
   ROUGIER A, 1994, IN VITRO SKIN TOXICO
   Schafer-Korting M, 2008, ATLA-ALTERN LAB ANIM, V36, P161
   Schafer-Korting M, 2007, ADV DRUG DELIVER REV, V59, P427, DOI 10.1016/j.addr.2007.04.006
   Schaller M, 1998, MOL MICROBIOL, V29, P605, DOI 10.1046/j.1365-2958.1998.00957.x
   Schaller M, 2004, SKIN PHARMACOL PHYSI, V17, P31, DOI 10.1159/000074060
   Schaller M, 1999, MOL MICROBIOL, V34, P169, DOI 10.1046/j.1365-2958.1999.01590.x
   Schaller M, 1999, J DRUG TARGET, V6, P361, DOI 10.3109/10611869908996843                                                       
   Schaller M, 2002, J MED MICROBIOL, V51, P672, DOI 10.1099/0022-1317-51-8-672                                                      
   Schaller M, 2002, J INVEST DERMATOL, V118, P652, DOI 10.1046/j.1523-1747.2002.01699.x
   Schaller M, 2003, INFECT IMMUN, V71, P3227, DOI 10.1128/IAI.71.6.3227-3234.2003
   SCHERWITZ C, 1982, J INVEST DERMATOL, V78, P200, DOI 10.1111/1523-1747.ep12506451
   Schwarz A, 2008, PHOTOCHEM PHOTOBIOL, V84, P350, DOI 10.1111/j.1751-1097.2007.00265.x
   Smijs TGM, 2007, J ANTIMICROB CHEMOTH, V59, P433, DOI 10.1093/jac/dkl490
   Spielmann H, 2001, TOXICOL IN VITRO, V15, P585, DOI 10.1016/S0887-2333(01)00070-4                                                   
   Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017
   Tjabringa G, 2008, AM J PATHOL, V173, P815, DOI 10.2353/ajpath.2008.080173
   Vaughan MB, 2004, REJUV RES, V7, P99, DOI 10.1089/1549168041552982
   Weindl G, 2007, J CLIN INVEST, V117, P3664, DOI 10.1172/JCI28115
   Wolf NB, 2009, EUR J PHARM BIOPHARM, V73, P34, DOI 10.1016/j.ejpb.2009.03.009
   Yeh AT, 2004, J BIOMED OPT, V9, P248, DOI [10.1117/1.1648646, 10.1117/1-16486461]
NR 71
TC 19
Z9 19
U1 0
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD FEB
PY 2011
VL 16
IS 3-4
BP 132
EP 139
DI 10.1016/j.drudis.2010.12.001
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 727WW
UT WOS:000287834700006
PM 21146629
DA 2018-01-05
ER

PT J
AU Kobayashi, M
   Yoshinaga, T
   Seki, T
   Wakasa-Morimoto, C
   Brown, KW
   Ferris, R
   Foster, SA
   Hazen, RJ
   Miki, S
   Suyama-Kagitani, A
   Kawauchi-Miki, S
   Taishi, T
   Kawasuji, T
   Johns, BA
   Underwood, MR
   Garvey, EP
   Sato, A
   Fujiwara, T
AF Kobayashi, Masanori
   Yoshinaga, Tomokazu
   Seki, Takahiro
   Wakasa-Morimoto, Chiaki
   Brown, Kevin W.
   Ferris, Robert
   Foster, Scott A.
   Hazen, Richard J.
   Miki, Shigeru
   Suyama-Kagitani, Akemi
   Kawauchi-Miki, Shinobu
   Taishi, Teruhiko
   Kawasuji, Takashi
   Johns, Brian A.
   Underwood, Mark R.
   Garvey, Edward P.
   Sato, Akihiko
   Fujiwara, Tamio
TI In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation
   HIV Integrase Inhibitor
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID TYPE-1 REVERSE-TRANSCRIPTASE; EXPERIENCED PATIENTS; TREATMENT-NAIVE;
   STRAND TRANSFER; VIRUS; RESISTANT; REPLICATION; DRUG; RALTEGRAVIR;
   MUTATIONS
AB S/GSK1349572 is a next-generation HIV integrase (IN) inhibitor designed to deliver potent antiviral activity with a low-milligram once-daily dose requiring no pharmacokinetic (PK) booster. In addition, S/GSK1349572 demonstrates activity against clinically relevant IN mutant viruses and has potential for a high genetic barrier to resistance. S/GSK1349572 is a two-metal-binding HIV integrase strand transfer inhibitor whose mechanism of action was established through in vitro integrase enzyme assays, resistance passage experiments, activity against viral strains resistant to other classes of anti-HIV agents, and mechanistic cellular assays. In a variety of cellular antiviral assays, S/GSK1349572 inhibited HIV replication with low-nanomolar or subnanomolar potency and with a selectivity index of 9,400. The protein-adjusted half-maximal effective concentration (PA-EC(50)) extrapolated to 100% human serum was 38 nM. When virus was passaged in the presence of S/GSK1349572, highly resistant mutants were not selected, but mutations that effected a low fold change (FC) in the EC(50) (up to 4.1 fold) were identified in the vicinity of the integrase active site. S/GSK1349572 demonstrated activity against site-directed molecular clones containing the raltegravir-resistant signature mutations Y143R, Q148K, N155H, and G140S/Q148H (FCs, 1.4, 1.1, 1.2, and 2.6, respectively), while these mutants led to a high FC in the EC(50) of raltegravir (11- to >130-fold). Either additive or synergistic effects were observed when S/GSK1349572 was tested in combination with representative approved antiretroviral agents; no antagonistic effects were seen. These findings demonstrate that S/GSK1349572 would be classified as a next-generation drug in the integrase inhibitor class, with a resistance profile markedly different from that of first-generation integrase inhibitors.
C1 [Kobayashi, Masanori; Yoshinaga, Tomokazu; Seki, Takahiro; Wakasa-Morimoto, Chiaki; Miki, Shigeru; Suyama-Kagitani, Akemi; Kawauchi-Miki, Shinobu; Sato, Akihiko] Shionogi & Co Ltd, Med Res Labs, Virol, Osaka, Japan.
   [Taishi, Teruhiko] Shionogi & Co Ltd, Strateg Dev Dept, Osaka, Japan.
   [Fujiwara, Tamio] Shionogi & Co Ltd, Pharmaceut Dev Div, Osaka, Japan.
   [Brown, Kevin W.; Ferris, Robert; Foster, Scott A.; Hazen, Richard J.; Johns, Brian A.; Underwood, Mark R.; Garvey, Edward P.] GlaxoSmithKline Inc, Res Triangle Pk, NC USA.
RP Sato, A (reprint author), Shionogi & Co Ltd, Shionogi Res Labs, 2-5-1 Mishima, Settsu, Osaka 5660022, Japan.
EM akihiko.sato@shionogi.co.jp
CR ADACHI A, 1986, J VIROL, V59, P284
   Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001
   Bacheler LT, 2000, ANTIMICROB AGENTS CH, V44, P2475, DOI 10.1128/AAC.44.9.2475-2484.2000                                                 
   Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
   Boros EE, 2006, BIOORG MED CHEM LETT, V16, P5668, DOI 10.1016/j.bmcl.2006.08.007
   BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231                                                          
   Caliendo AM, 1996, J VIROL, V70, P2146
   Ceccherini-Silberstein F, 2009, AIDS REV, V11, P17
   Chackerian B, 1997, J VIROL, V71, P3932
   Charpentier C, 2010, AIDS, V24, P2753, DOI 10.1097/QAD.0b013e32833f9e36
   Cooper DA, 2008, NEW ENGL J MED, V359, P355, DOI 10.1056/NEJMoa0708978
   DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590                                                           
   DeJesus E, 2006, JAIDS-J ACQ IMM DEF, V43, P1, DOI 10.1097/01.qai.0000233308.82860.2f
   Egbertson MS, 2007, BIOORG MED CHEM LETT, V17, P1392, DOI 10.1016/j.bmcl.2006.11.080
   Garvey EP, 2008, ANTIMICROB AGENTS CH, V52, P901, DOI 10.1128/AAC.01218-07
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   HAZUDA DJ, 2007, 16 INT HIV DRUG RES
   Hoggard PG, 1997, ANTIMICROB AGENTS CH, V41, P1231
   Isaka Y, 1999, VIROLOGY, V264, P237, DOI 10.1006/viro.1999.0006
   Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040
   Jones GS, 2009, ANTIMICROB AGENTS CH, V53, P1194, DOI 10.1128/AAC.00984-08
   Kempf DJ, 2001, J VIROL, V75, P7462, DOI 10.1128/JVI.75.16.7462-7469.2001                                                
   Kobayashi M, 2008, ANTIVIR RES, V80, P213, DOI 10.1016/j.antiviral.2008.06.012
   Lalezari J, 2009, 5 INT AIDS SOC C HIV
   Lataillade M, 2007, ANTIVIR THER, V12, P563
   Ledford RM, 2007, 4 INT AIDS SOC C HIV
   Malet I, 2009, J ANTIMICROB CHEMOTH, V63, P795, DOI 10.1093/jac/dkp014
   Marinello J, 2008, BIOCHEMISTRY-US, V47, P9345, DOI 10.1021/bi800791q
   MARKOWITZ M, 2007, 4 INT AIDS SOC C HIV
   Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956
   Ledford R, 2007, 16 INT HIV DRUG RES
   Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09
   Nakahara K, 2009, ANTIVIR RES, V81, P141, DOI 10.1016/j.antiviral.2008.10.007
   Palmer S, 1999, AIDS, V13, P661
   PARTALEDIS JA, 1995, J VIROL, V69, P5228
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N                                                    
   Rockstroh Jurgen K, 2009, Eur J Med Res, V14 Suppl 3, P1
   Selleseth DW, 2003, ANTIMICROB AGENTS CH, V47, P1468, DOI 10.1128/AAC.47.4.1468-1471.2003
   TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653
   TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666
   ZOLOPA A, 2007, 14 C RETR OPP INF LO
NR 42
TC 189
Z9 190
U1 1
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2011
VL 55
IS 2
BP 813
EP 821
DI 10.1128/AAC.01209-10
PG 9
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 709FE
UT WOS:000286422500047
PM 21115794
OA gold
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Knepp, AM
   Grunbeck, A
   Banerjee, S
   Sakmar, TP
   Huber, T
AF Knepp, Adam M.
   Grunbeck, Amy
   Banerjee, Sourabh
   Sakmar, Thomas P.
   Huber, Thomas
TI Direct Measurement of Thermal Stability of Expressed CCR5 and
   Stabilization by Small Molecule Ligands
SO BIOCHEMISTRY
LA English
DT Article
ID TIME-RESOLVED FLUORESCENCE; IMMUNODEFICIENCY-VIRUS TYPE-1;
   COUPLED-RECEPTOR RHODOPSIN; G-PROTEIN; ENERGY-TRANSFER; BIOSENSOR
   TECHNOLOGY; MONOCLONAL-ANTIBODY; CHEMOKINE RECEPTORS; HIV-1 ENTRY;
   BINDING
AB The inherent instability of heptahelical G protein-coupled receptors (GPCRs) during purification and reconstitution is a primary impediment to biophysical studies and to obtaining high-resolution crystal structures. New approaches to stabilizing receptors during purification and screening reconstitution procedures are needed. Here we report the development of a novel homogeneous time-resolved fluorescence assay (HTRF) to quantify properly folded CC-chemokine receptor 5 (CCR5). The assay permits high-throughput thermal stability measurements of femtomole quantities of CCR5 in detergent and in engineered nanoscale apolipoprotein-bound bilayer (NABB) particles. We show that recombinantly expressed CCR5 can be incorporated into NABB particles in high yield, resulting in greater thermal stability compared with that of CCR5 in a detergent solution. We also demonstrate that binding of CCR5 to the HIV-1 cellular entry inhibitors maraviroc, AD101, CMPD 167, and vicriviroc dramatically increases receptor stability. The HTRF assay technology reported here is applicable to other membrane proteins and could greatly facilitate structural studies of GPCRs.
C1 [Knepp, Adam M.; Grunbeck, Amy; Banerjee, Sourabh; Sakmar, Thomas P.; Huber, Thomas] Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10065 USA.
RP Huber, T (reprint author), Rockefeller Univ, Biochem & Mol Biol Lab, 1230 York Ave, New York, NY 10065 USA.
EM hubert@rockefeller.edu
RI Huber, Thomas/A-8016-2008; Sakmar, Thomas/D-1833-2015
OI Huber, Thomas/0000-0002-1844-262X; Sakmar, Thomas/0000-0002-2836-8953
FU Tri-Institutional Program in Chemical Biology; National Institutes of
   Health [EY12049]
FX This work was supported by the Tri-Institutional Program in Chemical
   Biology and National Institutes of Health Grant EY12049.
CR Albizu L, 2007, J MED CHEM, V50, P4976, DOI 10.1021/jm061404q
   Albizu L, 2006, MOL PHARMACOL, V70, P1783, DOI 10.1124/mol.106.025684
   Alexandrov AI, 2008, STRUCTURE, V16, P351, DOI 10.1016/j.str.2008.02.004
   Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529
   Banerjee S, 2008, J MOL BIOL, V377, P1067, DOI 10.1016/j.jmb.2008.01.066
   Bartfai T, 2004, NAT REV DRUG DISCOV, V3, P574, DOI 10.1038/nrd1458
   Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k
   Cummings RT, 1999, ANAL BIOCHEM, V269, P79, DOI 10.1006/abio.1999.4021
   Deupi X, 2007, MECH PATHWAYS HETERO, P137
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Ernst OP, 2007, P NATL ACAD SCI USA, V104, P10859, DOI 10.1073/pnas.0701967104
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Goding JW, 1996, MONOCLONAL ANTIBODIE
   Horuk R, 2009, NAT REV DRUG DISCOV, V8, P23, DOI 10.1038/nrd2734
   Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200
   Kane SA, 2000, ANAL BIOCHEM, V278, P29, DOI 10.1006/abio.1999.4413
   Khurana S, 2005, J VIROL, V79, P6791, DOI 10.1128/JVI.79.11.6791-6800.2005
   Kondru R, 2008, MOL PHARMACOL, V73, P789, DOI 10.1124/mol.107.042101
   Kuhmann SE, 2008, ANNU REV PHARMACOL, V48, P425, DOI 10.1146/annurev.pharmtox.48.113006.094847
   Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617
   LOPEZ E, 1993, CLIN CHEM, V39, P196
   Lopez-Crapez E, 2008, ANAL BIOCHEM, V383, P301, DOI 10.1016/j.ab.2008.09.004
   Lusso P, 2006, EMBO J, V25, P447, DOI 10.1038/sj.emboj.7600947
   Mancia F, 2007, P NATL ACAD SCI USA, V104, P4303, DOI 10.1073/pnas.0700301104
   MATHIS G, 1995, CLIN CHEM, V41, P1391
   MATHIS G, 1993, CLIN CHEM, V39, P1953
   Maurel D, 2004, ANAL BIOCHEM, V329, P253, DOI 10.1016/j.ab.2004.02.013
   McKnight A, 1997, J VIROL, V71, P1692
   Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745                                                        
   Navratilova I, 2005, ANAL BIOCHEM, V339, P271, DOI 10.1016/j.ab.2004.12.017
   Navratilova I, 2006, ANAL BIOCHEM, V355, P132, DOI 10.1016/j.ab.2006.04.021
   OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874
   Premont RT, 2007, ANNU REV PHYSIOL, V69, P511, DOI 10.1146/annurev.physiol.69.022405.154731
   Rich RL, 2009, ANAL BIOCHEM, V386, P98, DOI 10.1016/j.ab.2008.12.011
   Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144
   Seibert C, 2006, VIROLOGY, V349, P41, DOI 10.1016/j.virol.2006.01.018
   Serrano-Vega MJ, 2008, P NATL ACAD SCI USA, V105, P877, DOI 10.1073/pnas.0711253105
   Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005
   Trinquet E, 2001, ANAL BIOCHEM, V296, P232, DOI 10.1006/abio.2001.5298
   Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099                                                          
   Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003
   Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266
   Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
   Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100
   Yoshiura C, 2010, J AM CHEM SOC, V132, P6768, DOI 10.1021/ja100830f
NR 47
TC 22
Z9 22
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD FEB 1
PY 2011
VL 50
IS 4
BP 502
EP 511
DI 10.1021/bi101059w
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 710BJ
UT WOS:000286485400009
PM 21155586
OA green_accepted
DA 2018-01-05
ER

PT J
AU Chen, CC
   Kruger, J
   Sramala, I
   Hsu, HJ
   Henklein, P
   Chen, YMA
   Fischer, WB
AF Chen, Cheng-Chang
   Krueger, Jens
   Sramala, Issara
   Hsu, Hao-Jen
   Henklein, Peter
   Chen, Yi-Ming Arthur
   Fischer, Wolfgang B.
TI ORF8a of SARS-CoV forms an ion channel: Experiments and molecular
   dynamics simulations
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE SARS-CoV; ORF8a; Ion channel; Molecular dynamics; Bilayer recording
ID ACUTE RESPIRATORY SYNDROME; TRANSMEMBRANE ALPHA-HELICES;
   MEMBRANE-PROTEIN; ANTIMICROBIAL PEPTIDE; 2-STAGE MODEL; VIRUS RELEASE;
   VPU; HIV-1; CORONAVIRUS; PORE
AB ORF8a protein is 39 residues long and contains a single transmembrane domain. The protein is synthesized using solid phase peptide synthesis and reconstituted into artificial lipid bilayers that forms cation-selective ion channels with a main conductance level of 8.9 +/- 0.8 pS at elevated temperature (38.5 degrees C). Computational modeling studies including multi nanosecond molecular dynamics simulations in a hydrated POPC lipid bilayer are done with a 22 amino acid transmembrane helix to predict a putative homooligomeric helical bundle model. A structural model of a pentameric bundle is proposed with cysteines, serines and threonines facing the pore. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Chen, Cheng-Chang; Krueger, Jens; Hsu, Hao-Jen; Fischer, Wolfgang B.] Natl Yang Ming Univ, Sch Biomed Sci & Engn, Inst Biophoton, Taipei 112, Taiwan.
   [Henklein, Peter] Humboldt Univ, Inst Biochem, Berlin, Germany.
   [Chen, Yi-Ming Arthur] NYMU, AIDS Prevent & Res Ctr, Taipei, Taiwan.
RP Fischer, WB (reprint author), Natl Yang Ming Univ, Sch Biomed Sci & Engn, Inst Biophoton, 155 Li Nong St,Sec 2, Taipei 112, Taiwan.
EM wfischer@ym.edu.tw
RI Sramala, Issara/I-3430-2013
OI Fischer, Wolfgang/0000-0001-7753-1828; Hsu, Hao-Jen/0000-0001-6096-7481
FU National Yang-Ming University; Government of Taiwan; National Science
   Council of Taiwan (NSC); Alexander von Humboldt-Foundation
FX WBF acknowledges the National Yang-Ming University and the Government of
   Taiwan for financial support (Aim of Excellence Program), as well as the
   National Science Council of Taiwan (NSC). JK acknowledges a fellowship
   granted jointly by the Alexander von Humboldt-Foundation and NSC.
CR Bhunia A, 2010, J BIOL CHEM, V285, P3883, DOI 10.1074/jbc.M109.065672
   Bowie JU, 2005, NATURE, V438, P581, DOI 10.1038/nature04395
   Bu LT, 2007, BIOPHYS J, V92, P854, DOI 10.1529/biophysj.106.095216
   Chapman ML, 1997, BIOPHYS J, V72, P708, DOI 10.1016/S0006-3495(97)78707-1                                                   
   Cordes FS, 2002, BIOCHEMISTRY-US, V41, P7359, DOI 10.1021/bi025518p
   Cordes FS, 2001, BBA-BIOMEMBRANES, V1512, P291, DOI 10.1016/S0005-2736(01)00332-7
   Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673                                                        
   Duneau JP, 1999, BIOPHYS CHEM, V76, P35, DOI 10.1016/S0301-4622(98)00216-6
   Engelman DM, 2003, FEBS LETT, V555, P122, DOI 10.1016/S0014-5793(03)01106-2
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47
   Ewart GD, 1996, J VIROL, V70, P7108
   Faham S, 2004, J MOL BIOL, V335, P297, DOI 10.1016/j.jmb.2003.10.041
   Fischer WB, 2002, BBA-BIOMEMBRANES, V1561, P27, DOI 10.1016/S0304-4157(01)00009-0
   Fischer WB, 2009, INT REV CEL MOL BIO, V275, P35, DOI 10.1016/S1937-6448(09)75002-6
   Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hallock KJ, 2002, BIOPHYS J, V83, P1004, DOI 10.1016/S0006-3495(02)75226-0                                                   
   Hilf RJC, 2009, NATURE, V457, P115, DOI 10.1038/nature07461
   Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378
   Stoffel W., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143
   Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s
   Kandasamy SK, 2009, BBA-BIOMEMBRANES, V1788, P686, DOI 10.1016/j.bbamem.2008.11.009
   Kruger J, 2009, J CHEM THEORY COMPUT, V5, P2503, DOI 10.1021/ct900185n
   Kruger J, 2008, J COMPUT CHEM, V29, P2416, DOI 10.1002/jcc.20986
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512
   Kuner T, 2001, J NEUROSCI, V21, P4162
   LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281
   Lu W, 2006, P NATL ACAD SCI USA, V103, P12540, DOI 10.1073/pnas.0605402103
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mehnert T, 2008, PROTEINS, V70, P1488, DOI 10.1002/prot.21642
   Mehnert T, 2007, J BIOMOL STRUCT DYN, V24, P589, DOI 10.1080/07391102.2007.10507148                                                  
   Mei ZZ, 2006, AM J PHYSIOL-CELL PH, V291, pC1022, DOI 10.1152/ajpcell.00606.2005
   Melton JV, 2002, J BIOL CHEM, V277, P46923, DOI 10.1074/jbc.M207847200
   Mereuta L, 2009, J BIOENERG BIOMEMBR, V41, P79, DOI 10.1007/s10863-009-9204-z
   Montal M, 2003, FEBS LETT, V552, P47, DOI 10.1016/S0014-5793(03)00849-4
   Moore PB, 1998, FEBS LETT, V431, P143, DOI 10.1016/S0014-5793(98)00714-5                                                   
   OIKI S, 1990, PROTEINS, V8, P226, DOI 10.1002/prot.340080305
   Pan JJ, 2009, J MEMBRANE BIOL, V231, P11, DOI 10.1007/s00232-009-9199-8
   Park SH, 2005, J MOL BIOL, V350, P310, DOI 10.1016/j.jmb.2005.05.004
   Patargias G., 2009, J BIOMOL STRUCT DYN, V26, P1
   PAWLAK M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P94, DOI 10.1016/0005-2736(91)90339-A
   POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001
   Porcelli F, 2004, J BIOL CHEM, V279, P45815, DOI 10.1074/jbc.M405454200
   Premkumar A, 2004, FEBS LETT, V557, P99, DOI 10.1016/S0014-5793(03)01453-4
   Ramamoorthy A, 2007, BIOCHEMISTRY-US, V46, P965, DOI 10.1021/bi061895g
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.108952
   Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5
   Slugoski MD, 2008, J BIOL CHEM, V283, P8496, DOI 10.1074/jbc.M710433200
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   STRANDBERG E, 2003, FEBS LETT, V544
   Torres J, 2001, BIOPHYS J, V81, P2681, DOI 10.1016/S0006-3495(01)75911-5                                                   
NR 53
TC 16
Z9 16
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD FEB
PY 2011
VL 1808
IS 2
SI SI
BP 572
EP 579
DI 10.1016/j.bbamem.2010.08.004
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 712QQ
UT WOS:000286681700010
PM 20708597
OA gold
DA 2018-01-05
ER

PT J
AU Gurkan, UA
   Moon, S
   Geckil, H
   Xu, F
   Wang, SQ
   Lu, TJ
   Demirci, U
AF Gurkan, Umut Atakan
   Moon, Sangjun
   Geckil, Hikmet
   Xu, Feng
   Wang, Shuqi
   Lu, Tian Jian
   Demirci, Utkan
TI Miniaturized lensless imaging systems for cell and microorganism
   visualization in point-of-care testing
SO BIOTECHNOLOGY JOURNAL
LA English
DT Review
DE Lensless imaging; Microfluidics; Point-of-care; Resource-limited
   settings
ID LINE HOLOGRAPHIC MICROSCOPY; SUBWAVELENGTH HOLE ARRAYS; RESOURCE-LIMITED
   SETTINGS; HIV-INFECTED SUBJECTS; ON-CHIP; GLOBAL HEALTH; DIAGNOSTIC
   TECHNOLOGIES; CAENORHABDITIS-ELEGANS; OPTICAL-TRANSMISSION; MICROFLUIDIC
   SYSTEMS
AB Low-cost, robust, and user-friendly diagnostic capabilities at the point-of-care (POC) are critical for treating infectious diseases and preventing their spread in developing countries. Recent advances in micro- and nanoscale technologies have enabled the merger of optical and fluidic technologies (optofluidics) paving the way for cost-effective lensless imaging and diagnosis for POC testing in resource-limited settings. Applications of the emerging lensless imaging technologies include detecting and counting cells of interest, which allows rapid and affordable diagnostic decisions. This review presents the advances in lensless imaging and diagnostic systems, and their potential clinical applications in developing countries. The emerging technologies are reviewed from a POC perspective considering cost effectiveness, portability, sensitivity, throughput and ease of use for resource-limited settings.
C1 [Demirci, Utkan] Harvard Massachusetts Inst Technol MIT Hlth Sci &, Cambridge, MA 02139 USA.
   [Gurkan, Umut Atakan; Moon, Sangjun; Geckil, Hikmet; Xu, Feng; Wang, Shuqi; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Sch Med, BAMM Lab,Ctr Biomed Engn,Dept Med, Boston, MA 02115 USA.
   [Geckil, Hikmet] Inonu Univ, Dept Biol, Malatya, Turkey.
   [Lu, Tian Jian] Xi An Jiao Tong Univ, Sch Aerosp, Biomed Engn & Biomech Ctr, Xian 710049, Peoples R China.
RP Demirci, U (reprint author), Harvard Massachusetts Inst Technol MIT Hlth Sci &, Cambridge, MA 02139 USA.
EM udemirci@rics.bwh.harvard.edu
RI Wang, Shuqi/F-2861-2011; Xu, Feng/H-4468-2011; Zhou, Feng/E-9510-2011;
   Xu, Feng/C-7430-2011; Geckil, Hikmet/F-7647-2012; Lu, Tian
   Jian/E-6063-2016
OI Xu, Feng/0000-0003-4351-0222; Geckil, Hikmet/0000-0003-0070-0691;
   Gurkan, Umut/0000-0002-0331-9960
FU US Department of the Defense (DOD); Coulter Foundation; NIH
   [R01AI081534, R21AI087107]; Center for Integration of Medicine and
   Innovative Technology (CIMIT) under U.S. Army Medical Research
   Acquisition Activity Cooperative Agreement; National Natural Science
   Foundation [30150110125]; U.S. Army Medical Research & Material Command
   (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC),
   at Fort Detrick, MD
FX This work was performed at the Demirci Bio-Acoustic MEMS in Medicine
   (BAMM) Labs at the HST-BWH Center for Bioengineering, Harvard Medical
   School. This work was partially supported by New Development Grant of
   the US Department of the Defense (DOD). We would like to acknowledge the
   Coulter Foundation Young Investigator Award, NIH (R01AI081534), NIH
   (R21AI087107), the Center for Integration of Medicine and Innovative
   Technology (CIMIT) under U.S. Army Medical Research Acquisition Activity
   Cooperative Agreement..; Dr. Demirci thanks the The China Research Fund
   for International Young Scientists (30150110125) through the National
   Natural Science Foundation Young Scholars Research Fund. This study was
   made possible by a research grant that was awarded and administered by
   the U.S. Army Medical Research & Material Command (USAMRMC) and the
   Telemedicine & Advanced Technology Research Center (TATRC), at Fort
   Detrick, MD.
CR Adiga SP, 2005, NANO LETT, V5, P2509, DOI 10.1021/nl051843x
   Alyassin MA, 2009, LAB CHIP, V9, P3364, DOI 10.1039/b911882a
   Andersson H, 2003, SENSOR ACTUAT B-CHEM, V92, P315, DOI 10.1016/S0925-4005(03)00266-1
   Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937
   Brennan D, 2009, ANAL BIOANAL CHEM, V395, P621, DOI 10.1007/s00216-009-2826-5
   Bub G, 2010, NAT METHODS, V7, P209, DOI [10.1038/NMETH.1429, 10.1038/nmeth.1429]
   Chen L, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/1/013001
   Cheng XH, 2007, JAIDS-J ACQ IMM DEF, V45, P257
   Cheng XH, 2007, LAB CHIP, V7, P170, DOI 10.1039/b612966h
   Chin CD, 2007, LAB CHIP, V7, P41, DOI 10.1039/b611455e
   Choi Jong Young, 2009, Biotechnology Journal, V4, P1530, DOI 10.1002/biot.200900202
   Christodoulides N, 2005, LAB CHIP, V5, P261, DOI 10.1039/b414194f
   Christodoulides N, 2007, ANN NY ACAD SCI, V1098, P411, DOI 10.1196/annals.1384.035
   Coskun AF, 2010, LAB CHIP, V10, P824, DOI 10.1039/b926561a
   Cui XQ, 2008, P NATL ACAD SCI USA, V105, P10670, DOI 10.1073/pnas.0804612105
   Daar AS, 2002, NAT GENET, V32, P229, DOI 10.1038/ng1038-229
   Demirci U, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2170143
   Demirel MC, 2009, BIOINTERPHASES, V4, P35, DOI 10.1116/1.3147962
   Di JL, 2008, APPL OPTICS, V47, P5654, DOI 10.1364/AO.47.005654
   Douville N, 2008, ANAL BIOANAL CHEM, V391, P2395, DOI 10.1007/s00216-008-1995-y
   Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570
   El-Sayed MA, 2001, ACCOUNTS CHEM RES, V34, P257, DOI 10.1021/ar960016n
   GABOR D, 1948, NATURE, V161, P777, DOI 10.1038/161777a0
   Garcia-Sucerquia J, 2006, OPT LETT, V31, P1211, DOI 10.1364/OL.31.001211
   Garcia-Sucerquia J, 2006, APPL OPTICS, V45, P836, DOI 10.1364/AO.45.000836
   Gardeniers H, 2004, INT J ENVIRON AN CH, V84, P809, DOI 10.1080/03067310310001626678
   Ghosh S, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2816219
   Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7
   Gopinathan U, 2008, J OPT SOC AM A, V25, P2459, DOI 10.1364/JOSAA.25.002459
   Haes AJ, 2002, J AM CHEM SOC, V124, P10596, DOI 10.1021/ja020393x
   Hattori K, 2010, BIOTECHNOL J, V5, P463, DOI 10.1002/biot.201000021
   He X, 2006, AICHE J, V52, P3842, DOI 10.1002/aic.10985
   Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395
   Heng X, 2007, OPT EXPRESS, V15, P16367, DOI 10.1364/OE.15.016367
   Heng X, 2006, LAB CHIP, V6, P1274, DOI 10.1039/b604676b
   Huber G, 2010, J OPT SOC AM B, V27, pB93, DOI 10.1364/JOSAB.27.000B93
   Huh D, 2005, PHYSIOL MEAS, V26, pR73, DOI 10.1088/0967-3334/26/3/R02
   Huh D, 2007, NAT MATER, V6, P424, DOI 10.1038/nmat1907
   Jokerst JV, 2010, NANOMEDICINE-UK, V5, P143, DOI 10.2217/NNM.09.94
   Jokerst JV, 2009, BIOSENS BIOELECTRON, V24, P3622, DOI 10.1016/j.bios.2009.05.026
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Kim YG, 2009, BIOSENS BIOELECTRON, V25, P253, DOI 10.1016/j.bios.2009.06.023
   Klapperich CM, 2009, EXPERT REV MED DEVIC, V6, P211, DOI 10.1586/ERD.09.11
   Koo JM, 2003, J MICROMECH MICROENG, V13, P568, DOI 10.1088/0960-1317/13/5/307                                                      
   Kotz KT, 2010, NAT MED, V16, P1042, DOI 10.1038/nm.2205
   Kulmala S, 2003, ANAL CHIM ACTA, V500, P21, DOI 10.1016/j.aca.2003.09.004
   Kuswandi B, 2007, ANAL CHIM ACTA, V601, P141, DOI 10.1016/j.aca.2007.08.046
   LAKSANASOPIN T, 2009, MICROFLUIDIC POINT O
   Lange D, 2005, SENSOR ACTUAT B-CHEM, V107, P904, DOI 10.1016/j.snb.2004.12.039
   LEE LM, 2009, BIOMED MICRODEVICES
   Lee WG, 2010, ADV DRUG DELIVER REV, V62, P449, DOI 10.1016/j.addr.2009.11.016
   Lee WG, 2009, INTEGR BIOL, V1, P242, DOI 10.1039/b819201d
   Lewis A, 2003, NAT BIOTECHNOL, V21, P1377, DOI 10.1038/nbt898
   Lezec HJ, 2004, OPT EXPRESS, V12, P3629, DOI 10.1364/OPEX.12.003629                                                          
   Link S, 1999, J PHYS CHEM B, V103, P8410, DOI 10.1021/jp9917648
   Loubiere S, 2010, CLIN MICROBIOL INFEC, V16, P1070, DOI 10.1111/j.1469-0691.2010.03280.x
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Malvadkar NA, 2010, NAT MATER, V9, P1023, DOI 10.1038/NMAT2864
   Martinez AW, 2010, ANAL CHEM, V82, P3, DOI 10.1021/ac9013989
   Masters BR, 2009, J BIOPHOTONICS, V2, P127, DOI 10.1002/jbio.200810039
   Mills KL, 2010, LAB CHIP, V10, P1627, DOI 10.1039/c000863j
   Moon S, 2009, BIOSENS BIOELECTRON, V24, P3208, DOI 10.1016/j.bios.2009.03.037
   Morlens AS, 2006, OPT LETT, V31, P3095, DOI 10.1364/OL.31.003095
   Mulvaney P, 1996, LANGMUIR, V12, P788, DOI 10.1021/la9502711                                                               
   Neto C, 2005, REP PROG PHYS, V68, P2859, DOI 10.1088/0034-4885/68/12/R05
   Oshikane Y, 2007, SCI TECHNOL ADV MAT, V8, P181, DOI 10.1016/j.stam.2007.02.013
   Ozcan A, 2008, LAB CHIP, V8, P98, DOI 10.1039/b713695a
   Ozcan A, 2007, OPT COMMUN, V270, P225, DOI 10.1016/j.optcom.2006.09.032
   Paguirigan AL, 2008, BIOESSAYS, V30, P811, DOI 10.1002/bies.20804
   Parsa H, 2008, LAB CHIP, V8, P2062, DOI 10.1039/b813350f
   Peeling RW, 2006, SEX TRANSM INFECT, V82, pV1, DOI 10.1136/sti.2006.024265
   Pine J, 2009, IEEE T BIO-MED ENG, V56, P1184, DOI 10.1109/TBME.2008.2005641
   Psaltis D, 2002, SCIENCE, V298, P1359, DOI 10.1126/science.1078823                                                         
   Pursel S, 2005, POLYMER, V46, P9544, DOI 10.1016/j.polymer.2005.07.092
   Repetto L, 2004, OPT LETT, V29, P1132, DOI 10.1364/OL.29.001132
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Roth JM, 2002, OPT LETT, V27, P2076, DOI 10.1364/OL.27.002076                                                            
   Ryvolova M, 2010, TRAC-TREND ANAL CHEM, V29, P339, DOI 10.1016/j.trac.2009.12.010
   Samel B, 2007, BIOMED MICRODEVICES, V9, P61, DOI 10.1007/s10544-006-9015-5
   SCHAWLOW AL, 1958, PHYS REV, V112, P1940, DOI 10.1103/PhysRev.112.1940
   Schubert EF, 2005, SCIENCE, V308, P1274, DOI 10.1126/science.1108712
   Seo S, 2008, CELL MOL BIOENG, V1, P146, DOI 10.1007/s12195-008-0018-6
   Seo S, 2009, LAB CHIP, V9, P777, DOI 10.1039/b813943a
   Sethu P, 2004, SENSOR ACTUAT B-CHEM, V98, P337, DOI 10.1016/j.snb.2003.09.036
   Shui L, 2007, ADV COLLOID INTERFAC, V133, P35, DOI 10.1016/j.cis.2007.03.001
   Sia SK, 2008, LAB CHIP, V8, P1982, DOI 10.1039/b817915h
   Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977                                                       
   Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403
   Su TW, 2009, BIOTECHNOL BIOENG, V102, P856, DOI 10.1002/bit.22116
   Tasoglu S, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3475527
   Tasoglu S, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2912441
   Thio T, 2006, AM SCI, V94, P40, DOI 10.1511/2006.1.40
   Tian Z, 2008, J LASER APPL, V20, P106, DOI 10.2351/1.2831607
   Tulandi T, 2008, OBSTET GYNECOL, V112, P1160, DOI 10.1097/AOG.0b013e31818bba31
   Usdin M, 2010, J INFECT DIS, V201, pS73, DOI 10.1086/650384
   Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769                                                         
   Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   *WHO, 2008, 2007 UNAIDS ANN REP
   Xiong X, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2763967
   Xu W, 2002, APPL OPTICS, V41, P5367, DOI 10.1364/AO.41.005367
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   YANG C, 2007, OPTOFLUIDIC MICROSCO
   Yang CH, 2006, LASER FOCUS WORLD, V42, P85
   Yi CQ, 2006, ANAL CHIM ACTA, V560, P1, DOI 10.1016/j.aca.2005.12.037
   Zhang X, 2002, ANAL BIOANAL CHEM, V373, P332, DOI 10.1007/s00216-002-1288-9
NR 107
TC 47
Z9 47
U1 4
U2 56
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-6768
EI 1860-7314
J9 BIOTECHNOL J
JI Biotechnol. J.
PD FEB
PY 2011
VL 6
IS 2
BP 138
EP 149
DI 10.1002/biot.201000427
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 726JV
UT WOS:000287718500002
PM 21298800
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hosseini-Sarvari, M
AF Hosseini-Sarvari, Mona
TI An Efficient and Eco-Friendly Nanocrystalline Zinc Oxide Catalyst for
   One-Pot, Three Component Synthesis of New Ferrocenyl Aminophosphonic
   Esters Under Solvent-Free Condition
SO CATALYSIS LETTERS
LA English
DT Article
DE Nano ZnO; Ferrocenyl aminophosphonic esters; Three-component reactions;
   Solvent-free condition
ID ALPHA-AMINO PHOSPHONATES; STATE ANALOG INHIBITORS; ASYMMETRIC CATALYSIS;
   CONVENIENT SYNTHESIS; ACID-DERIVATIVES; HIV PROTEASE; LIGANDS;
   CHEMISTRY; ALKENES
AB An eco-friendly catalytic amount (10 mol%) of nanocrystalline ZnO has been explored in the synthesis of new series of ferrocenyl aminophosphonic esters by a three-component reaction of ferrocene carbaldehyde, an amine, and a dialkyl phosphate. The nano ZnO catalyzed the selective synthesis of ferrocenyl aminophosphonates and no intermediate formation of either an imines or alpha-hydroxy phosphonate were observed. This is one of the fundamental aspects in green chemistry for simple experimental and product isolation protocol.
C1 Shiraz Univ, Dept Chem, Shiraz, Iran.
RP Hosseini-Sarvari, M (reprint author), Shiraz Univ, Dept Chem, Shiraz, Iran.
EM hossaini@susc.ac.ir
FU Shiraz University Research Council; Iran National Science Foundation
   [87040564]
FX We thank the Shiraz University Research Council, and the Iran National
   Science Foundation (Grant No. 87040564) for financial support.
CR AKIYAMA T, 2005, SYNTHESIS, V206
   AKIYAMA T, 2003, SYNLETT, V1463
   ALLEN MC, 1989, J MED CHEM, V32, P1652, DOI 10.1021/jm00127a041
   Arrayas RG, 2006, ANGEW CHEM INT EDIT, V45, P7674, DOI 10.1002/anie.200602482
   Astruc D, 1995, ELECT TRANSFER RADIC
   Azizi N, 2004, TETRAHEDRON LETT, V45, P9233, DOI 10.1016/j.tetlet.2004.10.092
   Bhagat S, 2007, J ORG CHEM, V72, P1263, DOI 10.1021/jo062140i
   Biot C, 2000, BIOORG MED CHEM LETT, V10, P839, DOI 10.1016/S0960-894X(00)00120-7
   Biot C, 2000, EUR J MED CHEM, V35, P707, DOI 10.1016/S0223-5234(00)00178-1
   Bucci E, 1999, TETRAHEDRON, V55, P14435, DOI 10.1016/S0040-4020(99)00889-3
   Chandrasekhar S, 2001, TETRAHEDRON LETT, V42, P5561, DOI 10.1016/S0040-4039(01)01053-X                                                   
   CHESNEY A, 1998, SYNTHESIS, V413
   Cullity B. D., 2001, ELEMENTS XRAY DIFFRA
   Emsley J, 1976, CHEM PHOSPHORUS, P494
   Enders D., 2006, EUR J ORG CHEM, V29
   FIROUZABADI H, 2004, SYNTHESIS, V2692
   Ghosh R, 2004, J MOL CATAL A-CHEM, V210, P53, DOI 10.1016/j.molcata.2003.09.020
   Grevels FW, 1999, J ORGANOMET CHEM, V587, P122, DOI 10.1016/S0022-328X(99)00313-7                                                   
   Heydari A, 1998, TETRAHEDRON LETT, V39, P6729, DOI 10.1016/S0040-4039(98)01411-7                                                   
   Hosseini-Sarvari M, 2008, TETRAHEDRON, V64, P5519, DOI 10.1016/j.tet.2008.03.095
   Hosseini-Sarvari M, 2008, TETRAHEDRON, V64, P5459, DOI 10.1016/j.tet.2008.04.016
   HOSSEINISARVARI M, 2011, J IRAN CHEM IN PRESS
   Hosseini-Sarvari M., 2008, J IRAN CHEM SOC, V5, P118
   Howarth J, 2001, TETRAHEDRON LETT, V42, P751, DOI 10.1016/S0040-4039(00)02106-7
   Hu XP, 2005, ADV SYNTH CATAL, V347, P541, DOI 10.1002/adsc.200404240
   Huang JM, 2000, HETEROATOM CHEM, V11, P480, DOI 10.1002/1098-1071(2000)11:7<480::AID-HC6>3.3.CO;2-A
   Itoh T, 2000, BIOORG MED CHEM LETT, V10, P1657, DOI 10.1016/S0960-894X(00)00313-9
   Jaouen G, 2000, J ORGANOMET CHEM, V600, P23, DOI 10.1016/S0022-328X(00)00036-X                                                   
   JAOUEN G, 2001, CHEM BER, V36
   [Anonymous], JCPDS DIFFR DAT ZINC
   Jong SJ, 2001, J ORG CHEM, V66, P3533, DOI 10.1021/jo015557r
   Kaboudin B, 2003, TETRAHEDRON LETT, V44, P1051, DOI 10.1016/S0040-4039(02)02727-2                                                   
   Kaboudin B, 2001, TETRAHEDRON LETT, V42, P8211, DOI 10.1016/S0040-4039(01)01627-6
   KABOUDIN B, 2001, CHEM LETT, V880
   Kaldor A., 1988, ADV CHEM PHYSICS 2, V70, P211, DOI DOI 10.1002/9780470122693.CH6
   KEALY TJ, 1951, NATURE, V168, P1039, DOI 10.1038/1681039b0                                                               
   KNIGHT WD, 1984, PHYS REV LETT, V52, P2141, DOI 10.1103/PhysRevLett.52.2141                                                     
   Kong XY, 2003, NANO LETT, V3, P1625, DOI 10.1021/nl034463p
   LEE SG, 2001, CHEM COMMUN, V1698
   Lewkowski J, 2003, HETEROATOM CHEM, V14, P144, DOI 10.1002/hc.10128
   Lewkowski J, 2001, J ORGANOMET CHEM, V631, P105, DOI 10.1016/S0022-328X(01)01011-7                                                   
   Lu EN, 2008, CHINESE J ORG CHEM, V28, P1735
   Ma HR, 2001, J ORGANOMET CHEM, V637, P742, DOI 10.1016/S0022-328X(01)00900-7                                                   
   Maensiri S, 2006, J CRYST GROWTH, V289, P102, DOI 10.1016/j.jcrysgro.2005.10.145
   MANABE K, 2000, CHEM COMMUN, V669
   Maricic S, 2001, TETRAHEDRON, V57, P6523, DOI 10.1016/S0040-4020(01)00544-0
   MILLER EJ, 1992, J ORGANOMET CHEM, V440, P91, DOI 10.1016/0022-328X(92)83487-3                                                    
   MU XJ, 2006, TETRAHEDRON LETT, V1125
   NATCHEV IA, 1988, LIEBIGS ANN CHEM, V5, P861
   Nettekoven U, 1999, J ORG CHEM, V64, P3996, DOI 10.1021/jo982481z                                                               
   Nishibayashi Y, 1997, J ORGANOMET CHEM, V545, P381, DOI 10.1016/S0022-328X(97)00368-9                                                   
   Nishibayashi Y., 1995, SYNLETT, P79
   Pacchioni G, 2000, SURF REV LETT, V7, P277
   Paitayatat S, 1997, J MED CHEM, V40, P633, DOI 10.1021/jm960767v
   Patel VD, 1995, J MED CHEM, V38, P2906
   Peman A, 1994, BIOORG MED CHEM LETT, V4, P2601
   PEYMAN A, 1992, TETRAHEDRON LETT, V33, P4549, DOI 10.1016/S0040-4039(00)61309-6                                                   
   Richards C. J., 1995, SYNLETT, V74
   RICHARDS CJ, 1996, TETRAHEDRON-ASYMMETR, P7
   SAIDI A, 2002, SYNLETT, V1347
   SAMMAKIA T, 1995, J ORG CHEM, V60, P6002, DOI 10.1021/jo00124a003                                                             
   Sarvari M., 2008, HELV CHIM ACTA, V91, P715
   Stepnicka P., 2008, FERROCENES LIGANDS M
   STOWASSER B, 1992, TETRAHEDRON LETT, V33, P6625, DOI 10.1016/S0040-4039(00)61002-X                                                   
   Sun PP, 2004, SYNTHETIC COMMUN, V34, P4293, DOI 10.1081/SCC-200039361
   Whittall IR, 1998, ADV ORGANOMET CHEM, V42, P291, DOI 10.1016/S0065-3055(08)60545-6
   Wiemer DF, 1997, TETRAHEDRON, V53, P16609, DOI 10.1016/S0040-4020(97)10305-2
   YADAV JS, 2001, SYNTHESIS, V2277
   Zhan ZP, 2005, SYNTHETIC COMMUN, V35, P2501, DOI 10.1080/00397910500212692
   Zhang WB, 1996, TETRAHEDRON-ASYMMETR, V7, P451, DOI 10.1016/0957-4166(96)00028-6                                                    
   Green M, 2005, ORGANOMET CHEM, V32, P1, DOI 10.1039/9781847558497
NR 71
TC 20
Z9 20
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1011-372X
J9 CATAL LETT
JI Catal. Lett.
PD FEB
PY 2011
VL 141
IS 2
BP 347
EP 355
DI 10.1007/s10562-010-0489-7
PG 9
WC Chemistry, Physical
SC Chemistry
GA 723KX
UT WOS:000287506500018
DA 2018-01-05
ER

PT J
AU De Luca, L
   De Grazia, S
   Ferro, S
   Gitto, R
   Christ, F
   Debyser, Z
   Chimirri, A
AF De Luca, Laura
   De Grazia, Sara
   Ferro, Stefania
   Gitto, Rosaria
   Christ, Frauke
   Debyser, Zeger
   Chimirri, Alba
TI HIV-1 integrase strand-transfer inhibitors: Design, synthesis and
   molecular modeling investigation
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV-1 integrase; INSTIs; PFV-IN/DNA; Benzylindoles; Molecular docking
ID FULL-LENGTH INTEGRASE; DNA COMPLEX; BINDING MODE; DOCKING; DERIVATIVES;
   DISCOVERY; DYNAMICS; SITE
AB This study is focused on a new series of benzylindole derivatives with various substituents at the benzene-fused ring, suggested by our 3D pharmacophore model developed for HIV-1 integrase inhibitors (INIs). All synthesized compounds proved to be active in the nanomolar range (6-35 nM) on the strand-transfer step (ST). In particular, derivative 4-[1-(4-fluorobenzyl)-5,7-dimethoxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid (8e), presenting the highest best-fit value on pharmacophore model, showed a potency comparable to that of clinical INSTIs GS 9137 (1) and MK-0518 (2). The binding mode of our molecules has been investigated using the recently published crystal structure of the complex of full-length integrase from the prototype foamy virus in complex with its cognate DNA (PFV-IN/DNA). The results highlighted the ability of derivative Se to assume the same binding mode of MK-0518 and GS 9137. (C) 2010 Elsevier Masson SAS. All rights reserved.
C1 [De Luca, Laura; De Grazia, Sara; Ferro, Stefania; Gitto, Rosaria; Chimirri, Alba] Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   [Christ, Frauke; Debyser, Zeger] Katholieke Univ Leuven, B-3000 Louvain, Flanders, Belgium.
   [Christ, Frauke; Debyser, Zeger] IRC KULAK, B-3000 Louvain, Flanders, Belgium.
RP De Luca, L (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
EM ldeluca@unime.it; sdegrazia@pharma.unime.it; sferro@unime.it;
   rgitto@unime.it; frauke.christ@med.kuleuven.be;
   zeger.debyser@med.kuleuven.be; achimirri@unime.it
RI De Luca, Laura/D-8532-2011
OI De Luca, Laura/0000-0003-0614-5713; debyser, zeger/0000-0002-3982-1565;
   Gitto, Rosaria/0000-0003-0002-2253
FU European Commission [HEALTH-F3-2008-201032]
FX This work was supported by THINC project (European Commission
   HEALTH-F3-2008-201032).
CR Bacchi A, 2008, J MED CHEM, V51, P7253, DOI 10.1021/jm800893q
   Barreca ML, 2007, BIOCHEM BIOPH RES CO, V363, P554, DOI 10.1016/j.bbrc.2007.08.199
   Barreca ML, 2009, CHEMMEDCHEM, V4, P1446, DOI 10.1002/cmdc.200900166
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Barreca ML, 2004, J CHEM INF COMP SCI, V44, P1450, DOI 10.1021/ci034296e
   Busschots K, 2007, J MOL BIOL, V365, P1480, DOI 10.1016/j.jmb.2006.10.094
   *CAMBR CRYST DAT C, GOLD 4 1 2
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   Condie GC, 2005, TETRAHEDRON, V61, P4989, DOI 10.1016/j.tet.2005.03.048
   d'Angelo J, 2001, PATHOL BIOL, V49, P237, DOI 10.1016/S0369-8114(01)00135-3                                                   
   De Luca L, 2005, BIOCHEM BIOPH RES CO, V336, P1010, DOI 10.1016/j.bbrc.2005.08.211
   De Luca L, 2003, BIOCHEM BIOPH RES CO, V310, P1083, DOI 10.1016/j.bbrc.2003.09.120
   De Luca L, 2008, BIOORG MED CHEM LETT, V18, P2891, DOI 10.1016/j.bmcl.2008.03.089
   DeLano Warren, PYMOL MOL GRAPHICS S
   Delelis O, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-114
   Este JA, 2010, ANTIVIR RES, V85, P25, DOI 10.1016/j.antiviral.2009.10.007
   Ferro S, 2010, BIOORGAN MED CHEM, V18, P5510, DOI 10.1016/j.bmc.2010.06.063
   Ferro S, 2009, J MED CHEM, V52, P569, DOI 10.1021/jm8009266
   Fukuyama Y, 1998, TETRAHEDRON, V54, P10007, DOI 10.1016/S0040-4020(98)00593-6
   Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Henry L., 1895, CR HEBD ACAD SCI, V120, P1265
   Hwang Y, 2000, NUCLEIC ACIDS RES, V28, P4884, DOI 10.1093/nar/28.24.4884                                                          
   Johnson AA, 2004, CURR TOP MED CHEM, V4, P1059, DOI 10.2174/1568026043388394                                                        
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760                                                               
   Maurin C, 2004, J MED CHEM, V47, P5583, DOI 10.1021/jm0408464
   Mehellou Y, 2010, J MED CHEM, V53, P521, DOI 10.1021/jm900492g
   Melek M, 2002, P NATL ACAD SCI USA, V99, P134, DOI 10.1073/pnas.012610699
   Nair V, 2006, J MED CHEM, V49, P445, DOI 10.1021/jm0508890
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   RAMACHARAN J, 2006, FUTURE MED, V1, P717
   Rege PD, 2006, ORG LETT, V8, P3117, DOI 10.1021/ol061319c
   [Anonymous], 2007, MAESTR VERS 8 0
   Sechi M, 2009, BIOORGAN MED CHEM, V17, P2925, DOI 10.1016/j.bmc.2008.10.088
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3
NR 36
TC 26
Z9 27
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB
PY 2011
VL 46
IS 2
BP 756
EP 764
DI 10.1016/j.ejmech.2010.12.012
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 725AL
UT WOS:000287617500030
PM 21227550
DA 2018-01-05
ER

PT J
AU Kim, T
   Barchi, JJ
   Marquez, VE
   Shapiro, BA
AF Kim, Taejin
   Barchi, Joseph J., Jr.
   Marquez, Victor E.
   Shapiro, Bruce A.
TI Understanding the effects of carbocyclic sugars constrained to north and
   south conformations on RNA nanodesign
SO JOURNAL OF MOLECULAR GRAPHICS & MODELLING
LA English
DT Article
DE RNA; North constrained sugar; South constrained sugar; Molecular
   dynamics simulations; RNA structure deformations; RNA nanodesign
ID MOLECULAR-DYNAMICS; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE;
   NUCLEIC-ACIDS; NEPLANOCIN-C; RESP MODEL; DNA; NMR; OLIGONUCLEOTIDES;
   NUCLEOSIDES
AB Relatively new types of the modified nucleotides, namely carbocyclic sugars that are constrained to north or south (C2' or C3' exo) conformations, can be used for RNA nanoparticle design to control their structures and stability by rigidifying nucleotides and altering the helical properties of RNA duplexes. Two RNA structures, an RNA dodecamer and an HIV kissing loop complex where several nucleotides were replaced with north or south constrained sugars, were studied by molecular dynamics (MD) simulations. The substituted south constrained nucleotides in the dodecamer widened the major groove and narrowed and deepened the minor groove thus inducing local conformational changes that resemble a B-form DNA helix. In the HIV kissing loop complex, north and south constrained nucleotides were substituted into flanking bases and stems. The modified HIV kissing loop complex showed a lower RMSD value than the normal kissing loop complex. The overall twist angle was also changed and its standard deviation was reduced. In addition, the modified RNA dodecamer and HIV kissing loop complex were characterized by principal component analysis (PCA) and steered molecular dynamics (SMD). PCA results showed that the constrained sugars stabilized the overall motions. The results of the SMD simulations indicated that as the backbone delta angles were increased by elongation, more force was applied to the modified RNA due to the constrained sugar analogues. Published by Elsevier Inc.
C1 [Kim, Taejin; Shapiro, Bruce A.] NCI, CCRNP, Frederick, MD 21701 USA.
   [Barchi, Joseph J., Jr.; Marquez, Victor E.] NCI, Med Chem Lab, Frederick, MD 21701 USA.
RP Shapiro, BA (reprint author), NCI, CCRNP, Frederick, MD 21701 USA.
EM shapirbr@mail.nih.gov
RI Barchi Jr., Joseph/N-3784-2014
FU National Institutes of Health (NIH), National Cancer Institute (NCI)
FX We would like to thank Igor Topol for the valuable discussions regarding
   the ab initio calculations. This research was supported by the
   Intramural Research Program of the National Institutes of Health (NIH),
   National Cancer Institute (NCI), Center for Cancer Research Nanobiology
   Program (CCRNP). The computational support was provided by the National
   Cancer Institute's Advanced Biomedical Computing Center (ABCC).
CR Afonin KA, 2010, NAT NANOTECHNOL, V5, P676, DOI [10.1038/NNANO.2010.160, 10.1038/nnano.2010.160]
   ALTMANN KH, 1994, TETRAHEDRON LETT, V35, P7625, DOI 10.1016/S0040-4039(00)78359-6
   ALTMANN KH, 1994, TETRAHEDRON LETT, V35, P2331, DOI 10.1016/0040-4039(94)85212-X
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Bindewald E, 2008, J MOL GRAPH MODEL, V27, P299, DOI 10.1016/j.jmgm.2008.05.004
   Bindewald E, 2008, NUCLEIC ACIDS RES, V36, pD392, DOI 10.1093/nar/gkm842
   Bondensgaard K, 2000, CHEM-EUR J, V6, P2687, DOI 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.3.CO;2-L
   Case DA, 2008, AMBER 10
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   EZZITOUNI A, 1995, CHEM COMMUN, V13, P1345
   Foloppe N, 2000, J COMPUT CHEM, V21, P86, DOI 10.1002/(SICI)1096-987X(20000130)21:2<86::AID-JCC2>3.0.CO;2-G
   Frisch M. J., 2004, GAUSSIAN 03 REVISION
   Hoeprich S, 2003, GENE THER, V10, P1258, DOI 10.1038/sj.gt.3302002
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483                                                  
   Macias AT, 2007, BIOPOLYMERS, V85, P438, DOI 10.1002/bip.20673
   Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+
   Mongan J, 2004, J COMPUT AID MOL DES, V18, P433, DOI 10.1007/s10822-004-4121-z                                                       
   Nielsen KE, 2004, BIOCONJUGATE CHEM, V15, P449, DOI 10.1021/bc034145h
   Nielsen KE, 2000, BIOCONJUGATE CHEM, V11, P228, DOI 10.1021/bc990121s
   Paliy M, 2009, PHYS BIOL, V6, DOI 10.1088/1478-3975/6/4/046003
   Pande V, 2008, NUCLEIC ACIDS RES, V36, P1508, DOI 10.1093/nar/gkm1182
   Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d
   Reblova K, 2007, BIOPHYS J, V93, P3932, DOI 10.1529/biophysj.107.110056
   RODRIGUEZ JB, 1994, J MED CHEM, V37, P3389, DOI 10.1021/jm00046a024                                                             
   RODRIGUEZ JB, 1993, TETRAHEDRON LETT, V34, P6233, DOI 10.1016/S0040-4039(00)73718-X                                                   
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Santosh M, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/3/034113
   Siddiqui MA, 1996, NUCLEOS NUCLEOT, V15, P235, DOI 10.1080/07328319608002382
   TEETER MM, 1990, J PHYS CHEM-US, V94, P8091, DOI 10.1021/j100384a021
   Wadley LM, 2007, J MOL BIOL, V372, P942, DOI 10.1016/j.jmb.2007.06.058
   Wang B, 2006, J CHEM THEORY COMPUT, V2, P209, DOI 10.1021/ct050212s
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
   Wang PY, 2000, J AM CHEM SOC, V122, P12422, DOI 10.1021/ja001989s                                                               
   WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0
   Wu ZR, 2005, P NATL ACAD SCI USA, V102, P24, DOI 10.1073/pnas.0408498102
   Yingling YG, 2007, NANO LETT, V7, P2328, DOI 10.1021/nl070984r
NR 39
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1093-3263
J9 J MOL GRAPH MODEL
JI J. Mol. Graph.
PD FEB
PY 2011
VL 29
IS 5
BP 624
EP 634
DI 10.1016/j.jmgm.2010.11.007
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Computer
   Science, Interdisciplinary Applications; Crystallography; Mathematical &
   Computational Biology
SC Biochemistry & Molecular Biology; Computer Science; Crystallography;
   Mathematical & Computational Biology
GA 733BW
UT WOS:000288236400005
PM 21159533
OA green_accepted
DA 2018-01-05
ER

PT J
AU Dennison, SM
   Anasti, K
   Scearce, RM
   Sutherland, L
   Parks, R
   Xia, SM
   Liao, HX
   Gorny, MK
   Zolla-Pazner, S
   Haynes, BF
   Alam, SM
AF Dennison, S. Moses
   Anasti, Kara
   Scearce, Richard M.
   Sutherland, Laura
   Parks, Robert
   Xia, Shi-Mao
   Liao, Hua-Xin
   Gorny, Miroslaw K.
   Zolla-Pazner, Susan
   Haynes, Barton F.
   Alam, S. Munir
TI Nonneutralizing HIV-1 gp41 Envelope Cluster II Human Monoclonal
   Antibodies Show Polyreactivity for Binding to Phospholipids and Protein
   Autoantigens
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROXIMAL EXTERNAL REGION; BROADLY
   NEUTRALIZING ANTIBODIES; TYPE-1 GP41; VIRAL MEMBRANE; ANTI-GP41 2F5;
   EPITOPE; GLYCOPROTEIN; GP120; 4E10
AB HIV-1 gp41 envelope antibodies, which are frequently induced in HIV-1-infected individuals, are predominantly nonneutralizing. The rare and difficult-to-induce neutralizing antibodies (2F5 and 4E10) that target gp41 membrane-proximal epitopes (MPER) are polyspecific and require lipid binding for HIV-1 neutralization. These results raise the questions of how prevalent polyreactivity is among gp41 antibodies and how the binding properties of gp41-nonneutralizing antibodies differ from those of antibodies that are broadly neutralizing. In this study, we have characterized a panel of human gp41 antibodies with binding specificities within the immunodominant cluster I (gp41 amino acids [aa] 579 to 613) or cluster II (gp41 aa 644 to 667) for reactivity to autoantigens, to the gp140 protein, and with MPER peptide-lipid conjugates. We report that while none of the gp41 cluster I antibodies studied were polyspecific, all three gp41 cluster II antibodies bound either to lipids or autoantigens, thus showing the propensity of cluster II antibodies to manifest polyreactivity. All cluster II gp41 monoclonal antibodies (MAbs), including those that were lipid reactive, failed to bind to gp41 MPER peptide-lipid complexes. Cluster II antibodies bound strongly with nanomolar binding affinity (dissociation constant [K-d]) to oligomeric gp140 proteins, and thus, they recognize conformational epitopes on gp41 that are distinct from those of neutralizing gp41 antibodies. These results demonstrate that lipid-reactive gp41 cluster II antibodies are nonneutralizing due to their inability to bind to the relevant neutralizing epitopes on gp41.
C1 [Alam, S. Munir] Duke Univ, Med Ctr, Human Vaccine Inst, Dept Med,Sch Med, Durham, NC 27710 USA.
   [Dennison, S. Moses; Anasti, Kara; Scearce, Richard M.; Sutherland, Laura; Parks, Robert; Xia, Shi-Mao; Liao, Hua-Xin; Haynes, Barton F.; Alam, S. Munir] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Dennison, S. Moses; Anasti, Kara; Scearce, Richard M.; Sutherland, Laura; Parks, Robert; Xia, Shi-Mao; Liao, Hua-Xin; Haynes, Barton F.; Alam, S. Munir] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA.
   [Dennison, S. Moses; Anasti, Kara; Scearce, Richard M.; Sutherland, Laura; Parks, Robert; Xia, Shi-Mao; Liao, Hua-Xin; Haynes, Barton F.; Alam, S. Munir] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27710 USA.
   [Gorny, Miroslaw K.; Zolla-Pazner, Susan] NYU, Sch Med, New York, NY 10016 USA.
   [Zolla-Pazner, Susan] Vet Affairs New York Harbor Healthcare Syst, New York, NY 10010 USA.
RP Alam, SM (reprint author), Duke Univ, Med Ctr, Human Vaccine Inst, Dept Med,Sch Med, 2 Genome Court,4004 MSRB 2, Durham, NC 27710 USA.
EM hayne002@mc.duke.edu; alam0004@mc.duke.edu
OI Gorny, Miroslaw/0000-0002-2714-8780
FU Bill & Melinda Gates Foundation [38643, 38631_01]; Center for HIV/AIDS
   Vaccine Immunology (CHAVI); NIAID, NIH [AI067854, HL59725, AI27742];
   Department of Veterans Affairs
FX This research was conducted as part of the Collaboration for AIDS
   Vaccine Discovery (CAVD) with support from the Bill & Melinda Gates
   Foundation to B.F.H. (38643) and S.Z-P. (38631_01), the Center for
   HIV/AIDS Vaccine Immunology (CHAVI), grant AI067854 from the NIAID, NIH
   grants HL59725 (to S.Z.P.) and AI27742 (NYU CFAR), and research funds
   from the Department of Veterans Affairs. We thank Laurent Verkoczy for
   comments and suggestions and Millie McAdams for technical assistance in
   performing SPR assays.
CR Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07
   Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424                                                     
   Alam SM, 2009, P NATL ACAD SCI USA, V106, P20234, DOI 10.1073/pnas.0908713106
   Astronomo RD, 2008, J VIROL, V82, P6359, DOI 10.1128/JVI.00293-08
   Brown BK, 2007, J VIROL, V81, P2087, DOI 10.1128/JVI.02011-06
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102                                                         
   Calarota S, 1996, AIDS RES HUM RETROV, V12, P705, DOI 10.1089/aid.1996.12.705
   Cardoso RMF, 2005, IMMUNITY, V22, P163, DOI 10.1016/j.immuni.2004.12.011
   Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0
   Dennison SM, 2009, J VIROL, V83, P10211, DOI 10.1128/JVI.00571-09
   Diskin R, 2010, NAT STRUCT MOL BIOL, V17, P608, DOI 10.1038/nsmb.1796
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002
   Gorny MK, 2009, MOL IMMUNOL, V46, P917, DOI 10.1016/j.molimm.2008.09.005
   Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000
   Gorny MK, 2004, J VIROL, V78, P2394, DOI 10.1128/JVI.78.5.2394-2404.2004
   GORNY MK, 1989, P NATL ACAD SCI USA, V86, P1624, DOI 10.1073/pnas.86.5.1624
   Haynes Barton F., 2005, Human Antibodies, V14, P59
   Haynes BF, 2006, EXPERT REV VACCINES, V5, P347, DOI 10.1586/14760584.5.3.347
   Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781
   Hioe CE, 1997, INT IMMUNOL, V9, P1281, DOI 10.1093/intimm/9.9.1281
   Jeffs SA, 2001, IMMUNOL LETT, V79, P209, DOI 10.1016/S0165-2478(01)00289-9
   Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908
   Liao HX, 2006, VIROLOGY, V353, P268, DOI 10.1016/j.virol.2006.04.043
   Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159
   McGaughey GB, 2003, BIOCHEMISTRY-US, V42, P3214, DOI 10.1021/bi026952u
   Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385
   MUSTER T, 1993, J VIROL, V67, P6642
   Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06
   Nicely NI, 2010, NAT STRUCT MOL BIOL, V17, P1492, DOI 10.1038/nsmb.1944
   Nyambi PN, 2000, J VIROL, V74, P7096, DOI 10.1128/JVI.74.15.7096-7107.2000                                                
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Roux KH, 2007, CURR OPIN STRUC BIOL, V17, P244, DOI 10.1016/j.sbi.2007.03.008
   Sanchez-Martinez S, 2006, FEBS LETT, V580, P2395, DOI 10.1016/j.febslet.2006.03.067
   Sanchez-Martinez S, 2006, AIDS RES HUM RETROV, V22, P998, DOI 10.1089/aid.2006.22.998
   SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8
   SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Shen XY, 2010, P NATL ACAD SCI USA, V107, P5972, DOI 10.1073/pnas.0912381107
   Song LK, 2009, P NATL ACAD SCI USA, V106, P9057, DOI 10.1073/pnas.0901474106
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018
   Taniguchi Y, 2000, VIROLOGY, V273, P333, DOI 10.1006/viro.2000.0436
   Tomaras GD, 2009, CURR OPIN HIV AIDS, V4, P373, DOI 10.1097/COH.0b013e32832f00c0
   Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08
   Trkola A, 1996, J VIROL, V70, P1100
   TYLER DS, 1990, J IMMUNOL, V145, P3276
   Verkoczy L, 2010, P NATL ACAD SCI USA, V107, P181, DOI 10.1073/pnas.0912914107
   Wang PC, 2010, J VIROL, V84, P7114, DOI 10.1128/JVI.00545-10
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   XU JY, 1991, J VIROL, V65, P4832
   Yuan W, 2009, AIDS RES HUM RETROV, V25, P319, DOI 10.1089/aid.2008.0213
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
   Zolla-Pazner S, 1999, J VIROL, V73, P4042
   ZOLLAPAZNER S, 1995, J VIROL, V69, P3807
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
   Zwick MB, 2007, CURR HIV RES, V5, P608, DOI 10.2174/157016207782418443
NR 60
TC 26
Z9 26
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD FEB
PY 2011
VL 85
IS 3
BP 1340
EP 1347
DI 10.1128/JVI.01680-10
PG 8
WC Virology
SC Virology
GA 705PC
UT WOS:000286147400018
PM 21106741
OA gold
DA 2018-01-05
ER

EF